1	The	the	DT	_	3	det
2	concomitant	concomitant	JJ	_	3	amod
3	intake	intake	NN	_	10	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	does	do	VBZ	_	10	aux
9	not	not	RB	_	10	neg
10	affect	affect	VB	_	0	ROOT
11	the	the	DT	_	12	det
12	pharmacokinetics	pharmacokinetic	NNS	_	10	dobj
13	of	of	IN	_	15	case
14	either	either	CC	_	15	cc:preconj
15	drug3	drug3	NN	_	12	nmod
16	or	or	CC	_	15	cc
17	drug4	drug4	NN	_	15	conj
18	.	.	.	_	10	punct

1	Pharmacokinetic	pharmacokinetic	JJ	_	2	amod
2	studies	study	NNS	_	3	nsubj
3	indicate	indicate	VBP	_	0	ROOT
4	that	that	IN	_	12	mark
5	administration	administration	NN	_	12	nsubj
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	or	or	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	does	do	VBZ	_	12	aux
11	not	not	RB	_	12	neg
12	affect	affect	VB	_	3	ccomp
13	the	the	DT	_	14	det
14	pharmacokinetics	pharmacokinetic	NNS	_	12	dobj
15	of	of	IN	_	16	case
16	drug3	drug3	NN	_	14	nmod
17	.	.	.	_	3	punct

1	Co-administration	co-administration	NN	_	6	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	1	nmod
6	produced	produce	VBD	_	0	ROOT
7	a	a	DT	_	10	det
8	25	25	CD	_	9	compound
9	%	%	NN	_	10	amod
10	increase	increase	NN	_	6	dobj
11	in	in	IN	_	12	case
12	AUC	auc	NN	_	10	nmod
13	and	and	CC	_	10	cc
14	a	a	DT	_	17	det
15	33	33	CD	_	16	compound
16	%	%	NN	_	17	amod
17	increase	increase	NN	_	10	conj
18	in	in	IN	_	20	case
19	the	the	DT	_	20	det
20	Cmax	cmax	NN	_	17	nmod
21	of	of	IN	_	22	case
22	drug3	drug3	NN	_	20	nmod
23	.	.	.	_	6	punct

1	No	no	DT	_	2	neg
2	adjustment	adjustment	NN	_	6	nsubjpass
3	of	of	IN	_	4	case
4	dosage	dosage	NN	_	2	nmod
5	is	be	VBZ	_	6	auxpass
6	recommended	recommend	VBN	_	0	ROOT
7	in	in	IN	_	9	case
8	such	such	JJ	_	9	amod
9	patients	patient	NNS	_	6	nmod
10	.	.	.	_	6	punct

1	The	the	DT	_	2	det
2	pharmacokinetics	pharmacokinetic	NNS	_	11	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	its	its	PRP$	_	9	nmod:poss
7	major	major	JJ	_	9	amod
8	metabolite	metabolite	NN	_	9	compound
9	drug2	drug2	NN	_	4	conj
10	were	be	VBD	_	11	aux
11	unaffected	unaffected	JJ	_	0	ROOT
12	following	follow	VBG	_	13	case
13	co-administration	co-administration	NN	_	11	nmod
14	with	with	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	.	.	.	_	11	punct

1	Other	other	JJ	_	3	amod
2	concomitant	concomitant	JJ	_	3	amod
3	therapies	therapy	NNS	_	32	nsubj
4	:	:	:	_	3	punct
5	In	in	IN	_	7	case
6	clinical	clinical	JJ	_	7	amod
7	trials	trial	NNS	_	3	nmod
8	,	,	,	_	7	punct
9	the	the	DT	_	11	det
10	safety	safety	NN	_	11	compound
11	profile	profile	NN	_	7	appos
12	in	in	IN	_	13	case
13	subjects	subject	NNS	_	11	nmod
14	treated	treat	VBN	_	13	acl
15	with	with	IN	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	concomitantly	concomitantly	RB	_	14	advmod
18	with	with	IN	_	19	case
19	drug2	drug2	NN	_	14	nmod
20	,	,	,	_	19	punct
21	drug3	drug3	NN	_	19	conj
22	and	and	CC	_	19	cc
23	drug4	drug4	NN	_	19	conj
24	-LRB-	-lrb-	-LRB-	_	26	punct
25	including	include	VBG	_	26	case
26	drug5	drug5	NN	_	23	nmod
27	-RRB-	-rrb-	-RRB-	_	26	punct
28	,	,	,	_	19	punct
29	or	or	CC	_	19	cc
30	drug6	drug6	NN	_	19	conj
31	was	be	VBD	_	32	cop
32	similar	similar	JJ	_	0	ROOT
33	to	to	TO	_	34	case
34	that	that	DT	_	32	nmod
35	of	of	IN	_	36	case
36	subjects	subject	NNS	_	34	nmod
37	taking	take	VBG	_	36	acl
38	placebo	placebo	NN	_	37	dobj
39	with	with	IN	_	42	case
40	these	these	DT	_	42	det
41	concomitant	concomitant	JJ	_	42	amod
42	medications	medication	NNS	_	37	nmod
43	.	.	.	_	32	punct

1	Patients	patient	NNS	_	0	ROOT
2	taking	take	VBG	_	1	acl
3	drug1	drug1	NN	_	2	dobj
4	concomitantly	concomitantly	RB	_	2	advmod
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	2	nmod
7	more	more	RBR	_	8	advmod
8	commonly	commonly	RB	_	9	advmod
9	reported	report	VBD	_	2	dep
10	both	both	CC	_	12	cc:preconj
11	weight	weight	NN	_	12	compound
12	gain	gain	NN	_	9	dobj
13	and	and	CC	_	12	cc
14	weight	weight	NN	_	15	compound
15	loss	loss	NN	_	12	conj
16	,	,	,	_	12	punct
17	compared	compare	VBN	_	19	case
18	with	with	IN	_	19	case
19	patients	patient	NNS	_	12	nmod
20	taking	take	VBG	_	19	acl
21	either	either	CC	_	22	det
22	medication	medication	NN	_	20	dobj
23	alone	alone	RB	_	20	advmod
24	.	.	.	_	1	punct

1	Drug	drug	NN	_	2	compound
2	interactions	interaction	NNS	_	12	nsubjpass
3	between	between	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	other	other	JJ	_	7	amod
7	drugs	drug	NNS	_	4	conj
8	have	have	VBP	_	12	aux
9	not	not	RB	_	12	neg
10	been	be	VBN	_	12	auxpass
11	fully	fully	RB	_	12	advmod
12	evaluated	evaluate	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	Drugs	drug	NNS	_	16	nsubjpass
2	which	which	WDT	_	4	nsubj
3	may	may	MD	_	4	aux
4	potentiate	potentiate	VB	_	1	acl:relcl
5	the	the	DT	_	6	det
6	release	release	NN	_	4	dobj
7	of	of	IN	_	8	case
8	neutrophils	neutrophil	NNS	_	6	nmod
9	,	,	,	_	8	punct
10	such	such	JJ	_	12	case
11	as	as	IN	_	10	mwe
12	drug1	drug1	NN	_	8	nmod
13	,	,	,	_	8	punct
14	should	should	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	used	use	VBN	_	0	ROOT
17	with	with	IN	_	18	case
18	caution	caution	NN	_	16	nmod
19	.	.	.	_	16	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	augment	augment	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	activity	activity	NN	_	3	dobj
6	of	of	IN	_	8	case
7	other	other	JJ	_	8	amod
8	drug2	drug2	NN	_	5	nmod
9	.	.	.	_	3	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	use	use	NN	_	8	nsubjpass
3	with	with	IN	_	5	case
4	other	other	JJ	_	5	amod
5	drug1	drug1	NN	_	2	nmod
6	is	be	VBZ	_	8	auxpass
7	not	not	RB	_	8	neg
8	recommended	recommend	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	highly	highly	RB	_	4	advmod
4	bound	bind	VBN	_	0	ROOT
5	to	to	TO	_	8	case
6	human	human	JJ	_	8	amod
7	plasma	plasma	NN	_	8	compound
8	protein	protein	NN	_	4	nmod
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	mean	mean	NN	_	8	dep
11	99.2	99.2	CD	_	12	nummod
12	%	%	NN	_	10	dep
13	-RRB-	-rrb-	-RRB-	_	10	punct
14	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	,	,	,	_	1	punct
5	drug3	drug3	NN	_	1	conj
6	,	,	,	_	1	punct
7	and	and	CC	_	1	cc
8	drug4	drug4	NN	_	1	conj
9	The	the	DT	_	12	det
10	in	in	FW	_	12	amod
11	vitro	vitro	FW	_	10	dep
12	binding	binding	NN	_	21	nsubjpass
13	of	of	IN	_	14	case
14	drug5	drug5	NN	_	12	nmod
15	to	to	TO	_	17	case
16	plasma	plasma	NN	_	17	compound
17	proteins	protein	NNS	_	12	nmod
18	is	be	VBZ	_	21	auxpass
19	only	only	RB	_	20	advmod
20	slightly	slightly	RB	_	21	advmod
21	reduced	reduce	VBN	_	8	ccomp
22	by	by	IN	_	23	case
23	drug6	drug6	NN	_	21	nmod
24	-LRB-	-lrb-	-LRB-	_	27	punct
25	99.5	99.5	CD	_	26	compound
26	%	%	NN	_	27	amod
27	control	control	NN	_	23	dep
28	vs	vs	CC	_	27	cc
29	99.3	99.3	CD	_	30	nummod
30	%	%	NN	_	27	conj
31	-RRB-	-rrb-	-RRB-	_	27	punct
32	when	when	WRB	_	36	advmod
33	drug7	drug7	NN	_	35	compound
34	plasma	plasma	NN	_	35	compound
35	concentrations	concentration	NNS	_	36	nsubj
36	reach	reach	VBP	_	23	acl:relcl
37	5	5	CD	_	40	nummod
38	to10	to10	NN	_	40	compound
39	m	m	NN	_	40	compound
40	g/mL	g/ml	NN	_	36	dobj
41	.	.	.	_	1	punct

1	drug1	drug1	NN	_	4	nsubj
2	does	do	VBZ	_	4	aux
3	not	not	RB	_	4	neg
4	alter	alter	VB	_	0	ROOT
5	drug2	drug2	NN	_	7	compound
6	protein	protein	NN	_	7	compound
7	binding	binding	NN	_	4	dobj
8	.	.	.	_	4	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	4	nsubj
4	indicate	indicate	VBP	_	0	ROOT
5	that	that	IN	_	23	mark
6	,	,	,	_	23	punct
7	at	at	IN	_	9	case
8	therapeutic	therapeutic	JJ	_	9	amod
9	concentrations	concentration	NNS	_	23	nmod
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	-LRB-	-lrb-	-LRB-	_	15	punct
13	300	300	CD	_	15	nummod
14	m	m	NN	_	15	compound
15	g/mL	g/ml	NN	_	11	appos
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	,	,	,	_	23	punct
18	the	the	DT	_	19	det
19	binding	binding	NN	_	23	nsubjpass
20	of	of	IN	_	21	case
21	drug2	drug2	NN	_	19	nmod
22	was	be	VBD	_	23	auxpass
23	reduced	reduce	VBN	_	4	ccomp
24	from	from	IN	_	27	case
25	approximately	approximately	RB	_	26	advmod
26	99.2	99.2	CD	_	27	nummod
27	%	%	NN	_	23	nmod
28	to	to	TO	_	30	case
29	97.5	97.5	CD	_	30	nummod
30	%	%	NN	_	23	nmod
31	,	,	,	_	23	punct
32	representing	represent	VBG	_	23	advcl
33	a	a	DT	_	36	det
34	potential	potential	JJ	_	36	amod
35	twofold	twofold	JJ	_	36	amod
36	increase	increase	NN	_	32	dobj
37	in	in	IN	_	41	case
38	unbound	unbound	JJ	_	41	amod
39	drug3	drug3	NN	_	41	compound
40	plasma	plasma	NN	_	41	compound
41	levels	level	NNS	_	36	nmod
42	.	.	.	_	4	punct

1	Therapeutic	therapeutic	JJ	_	2	amod
2	concentrations	concentration	NNS	_	20	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	,	,	,	_	4	punct
6	drug2	drug2	NN	_	4	conj
7	,	,	,	_	4	punct
8	drug3	drug3	NN	_	4	conj
9	,	,	,	_	4	punct
10	drug4	drug4	NN	_	4	conj
11	,	,	,	_	4	punct
12	drug5	drug5	NN	_	4	conj
13	,	,	,	_	4	punct
14	drug6	drug6	NN	_	4	conj
15	,	,	,	_	4	punct
16	drug7	drug7	NN	_	17	compound
17	andtolbutamide	andtolbutamide	NN	_	4	conj
18	did	do	VBD	_	20	aux
19	not	not	RB	_	20	neg
20	alter	alter	VB	_	0	ROOT
21	drug8	drug8	NN	_	23	compound
22	protein	protein	NN	_	23	compound
23	binding	binding	NN	_	20	dobj
24	.	.	.	_	20	punct

1	In	in	IN	_	3	case
2	a	a	DT	_	3	det
3	study	study	NN	_	11	nmod
4	involving	involve	VBG	_	3	acl
5	12	12	CD	_	7	nummod
6	adult	adult	JJ	_	7	amod
7	volunteers	volunteer	NNS	_	4	dobj
8	,	,	,	_	11	punct
9	TORADOLORAL	toradoloral	NN	_	11	nsubjpass
10	was	be	VBD	_	11	auxpass
11	coadministered	coadminister	VBN	_	0	ROOT
12	with	with	IN	_	15	case
13	a	a	DT	_	15	det
14	single	single	JJ	_	15	amod
15	dose	dose	NN	_	11	nmod
16	of	of	IN	_	19	case
17	25	25	CD	_	19	nummod
18	mg	mg	NN	_	19	compound
19	drug1	drug1	NN	_	15	nmod
20	,	,	,	_	11	punct
21	causing	cause	VBG	_	11	advcl
22	no	no	DT	_	24	neg
23	significant	significant	JJ	_	24	amod
24	changes	change	NNS	_	21	dobj
25	in	in	IN	_	26	case
26	pharmacokinetics	pharmacokinetic	NNS	_	24	nmod
27	or	or	CC	_	26	cc
28	pharmacodynamics	pharmacodynamic	NNS	_	26	conj
29	of	of	IN	_	30	case
30	drug2	drug2	NN	_	26	nmod
31	.	.	.	_	11	punct

1	In	in	IN	_	3	case
2	another	another	DT	_	3	det
3	study	study	NN	_	7	nmod
4	,	,	,	_	7	punct
5	TORADOLIV/IM	toradoliv/im	NN	_	7	nsubjpass
6	was	be	VBD	_	7	auxpass
7	given	give	VBN	_	0	ROOT
8	with	with	IN	_	10	case
9	two	two	CD	_	10	nummod
10	doses	dose	NNS	_	7	nmod
11	of	of	IN	_	13	case
12	5000	5000	CD	_	13	nummod
13	U	u	NN	_	10	nmod
14	of	of	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	to	to	TO	_	19	case
17	11	11	CD	_	19	nummod
18	healthy	healthy	JJ	_	19	amod
19	volunteers	volunteer	NNS	_	13	nmod
20	,	,	,	_	7	punct
21	resulting	result	VBG	_	7	advcl
22	in	in	IN	_	27	case
23	a	a	DT	_	27	det
24	mean	mean	JJ	_	27	amod
25	template	template	NN	_	27	compound
26	bleeding	bleeding	NN	_	27	compound
27	time	time	NN	_	21	nmod
28	of	of	IN	_	30	case
29	6.4	6.4	CD	_	30	nummod
30	minutes	minute	NNS	_	27	nmod
31	-LRB-	-lrb-	-LRB-	_	35	punct
32	3.2	3.2	CD	_	34	compound
33	to	to	TO	_	34	dep
34	11.4	11.4	CD	_	35	nummod
35	min	min	NN	_	30	appos
36	-RRB-	-rrb-	-RRB-	_	35	punct
37	compared	compare	VBN	_	40	case
38	to	to	TO	_	40	case
39	a	a	DT	_	40	det
40	mean	mean	NN	_	21	advcl
41	of	of	IN	_	43	case
42	6.0	6.0	CD	_	43	nummod
43	minutes	minute	NNS	_	40	nmod
44	-LRB-	-lrb-	-LRB-	_	48	punct
45	3.4	3.4	CD	_	47	compound
46	to	to	TO	_	47	dep
47	7.5	7.5	CD	_	48	nummod
48	min	min	NN	_	43	appos
49	-RRB-	-rrb-	-RRB-	_	48	punct
50	for	for	IN	_	51	case
51	drug2	drug2	NN	_	40	nmod
52	alone	alone	RB	_	51	advmod
53	and	and	CC	_	51	cc
54	5.1	5.1	CD	_	55	nummod
55	minutes	minute	NNS	_	51	conj
56	-LRB-	-lrb-	-LRB-	_	60	punct
57	3.5	3.5	CD	_	59	compound
58	to	to	TO	_	59	dep
59	8.5	8.5	CD	_	60	nummod
60	min	min	NN	_	55	appos
61	-RRB-	-rrb-	-RRB-	_	60	punct
62	for	for	IN	_	63	case
63	placebo	placebo	NN	_	51	nmod
64	.	.	.	_	7	punct

1	Although	although	IN	_	6	mark
2	these	these	DT	_	3	det
3	results	result	NNS	_	6	nsubj
4	do	do	VBP	_	6	aux
5	not	not	RB	_	6	neg
6	indicate	indicate	VB	_	27	advcl
7	a	a	DT	_	9	det
8	significant	significant	JJ	_	9	amod
9	interaction	interaction	NN	_	6	dobj
10	between	between	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	drug2	drug2	NN	_	11	conj
14	or	or	CC	_	13	cc
15	drug3	drug3	NN	_	13	conj
16	,	,	,	_	27	punct
17	the	the	DT	_	18	det
18	administration	administration	NN	_	27	nsubjpass
19	of	of	IN	_	20	case
20	drug4	drug4	NN	_	18	nmod
21	to	to	TO	_	22	case
22	patients	patient	NNS	_	18	nmod
23	taking	take	VBG	_	22	acl
24	drug5	drug5	NN	_	23	dobj
25	should	should	MD	_	27	aux
26	be	be	VB	_	27	auxpass
27	done	do	VBN	_	0	ROOT
28	extremely	extremely	RB	_	29	advmod
29	cautiously	cautiously	RB	_	27	advmod
30	,	,	,	_	27	punct
31	and	and	CC	_	27	cc
32	patients	patient	NNS	_	36	nsubjpass
33	should	should	MD	_	36	aux
34	be	be	VB	_	36	auxpass
35	closely	closely	RB	_	36	advmod
36	monitored	monitor	VBN	_	27	conj
37	.	.	.	_	27	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	compound
4	IV/IM	iv/im	NN	_	5	nsubj
5	reduced	reduce	VBD	_	1	dep
6	the	the	DT	_	8	det
7	drug3	drug3	NN	_	8	compound
8	response	response	NN	_	5	dobj
9	to	to	TO	_	10	case
10	drug4	drug4	NN	_	8	nmod
11	in	in	IN	_	14	case
12	normovolemic	normovolemic	JJ	_	14	amod
13	healthy	healthy	JJ	_	14	amod
14	subjects	subject	NNS	_	8	nmod
15	by	by	IN	_	18	case
16	approximately	approximately	RB	_	17	advmod
17	20	20	CD	_	18	nummod
18	%	%	NN	_	5	nmod
19	-LRB-	-lrb-	-LRB-	_	24	punct
20	mean	mean	NN	_	24	compound
21	sodium	sodium	NN	_	24	compound
22	and	and	CC	_	21	cc
23	urinary	urinary	JJ	_	21	conj
24	output	output	NN	_	25	nsubj
25	decreased	decrease	VBD	_	18	acl:relcl
26	17	17	CD	_	27	nummod
27	%	%	NN	_	25	dobj
28	-RRB-	-rrb-	-RRB-	_	5	punct
29	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concomitant	concomitant	JJ	_	4	amod
4	administration	administration	NN	_	10	nsubj
5	of	of	IN	_	7	case
6	drug2	drug2	NN	_	7	compound
7	ORAL	oral	NN	_	4	nmod
8	and	and	CC	_	4	cc
9	drug3	drug3	NN	_	4	conj
10	resulted	result	VBD	_	1	appos
11	in	in	IN	_	13	case
12	decreased	decrease	VBN	_	13	amod
13	clearance	clearance	NN	_	10	nmod
14	of	of	IN	_	15	case
15	drug4	drug4	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	significant	significant	JJ	_	18	amod
18	increases	increase	NNS	_	15	conj
19	in	in	IN	_	22	case
20	drug5	drug5	NN	_	22	compound
21	plasma	plasma	NN	_	22	compound
22	levels	level	NNS	_	13	nmod
23	-LRB-	-lrb-	-LRB-	_	26	punct
24	total	total	JJ	_	25	amod
25	AUC	auc	NN	_	26	nsubj
26	increased	increase	VBD	_	22	dep
27	approximately	approximately	RB	_	28	advmod
28	threefold	threefold	RB	_	26	advmod
29	from	from	IN	_	30	case
30	5.4	5.4	CD	_	26	nmod
31	to	to	TO	_	32	dep
32	17.8	17.8	CD	_	34	nummod
33	m	m	NN	_	34	compound
34	g/h/mL	g/h/ml	NN	_	30	dep
35	-RRB-	-rrb-	-RRB-	_	34	punct
36	and	and	CC	_	34	cc
37	terminal	terminal	JJ	_	38	amod
38	half-life	half-life	NN	_	34	conj
39	increased	increase	VBD	_	26	dep
40	approximately	approximately	RB	_	41	advmod
41	twofold	twofold	RB	_	39	advmod
42	from	from	IN	_	43	case
43	6.6	6.6	CD	_	39	nmod
44	to	to	TO	_	46	case
45	15.1	15.1	CD	_	46	nummod
46	hours	hour	NNS	_	39	nmod
47	.	.	.	_	1	punct

1	Therefore	therefore	RB	_	10	advmod
2	,	,	,	_	10	punct
3	concomitant	concomitant	JJ	_	4	amod
4	use	use	NN	_	10	nsubjpass
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	drug2	drug2	NN	_	6	conj
9	is	be	VBZ	_	10	auxpass
10	contraindicated	contraindicate	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Inhibition	inhibition	NN	_	20	nsubjpass
4	of	of	IN	_	7	case
5	renal	renal	JJ	_	7	amod
6	drug2	drug2	NN	_	7	compound
7	clearance	clearance	NN	_	3	nmod
8	,	,	,	_	3	punct
9	leading	lead	VBG	_	3	acl
10	to	to	TO	_	12	case
11	an	a	DT	_	12	det
12	increase	increase	NN	_	9	nmod
13	in	in	IN	_	16	case
14	plasma	plasma	NN	_	16	compound
15	drug3	drug3	NN	_	16	compound
16	concentration	concentration	NN	_	12	nmod
17	,	,	,	_	3	punct
18	has	have	VBZ	_	20	aux
19	been	be	VBN	_	20	auxpass
20	reported	report	VBN	_	1	appos
21	with	with	IN	_	25	case
22	some	some	DT	_	25	det
23	prostaglandin	prostaglandin	NN	_	25	compound
24	synthesis-inhibiting	synthesis-inhibiting	JJ	_	25	amod
25	drugs	drug	NNS	_	20	nmod
26	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	11	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	on	on	IN	_	7	case
6	plasma	plasma	NN	_	7	compound
7	drug2	drug2	NN	_	2	nmod
8	has	have	VBZ	_	11	aux
9	not	not	RB	_	11	neg
10	been	be	VBN	_	11	auxpass
11	studied	study	VBN	_	0	ROOT
12	,	,	,	_	11	punct
13	but	but	CC	_	11	cc
14	cases	case	NNS	_	25	nsubjpass
15	of	of	IN	_	19	case
16	increased	increase	VBN	_	19	amod
17	drug3	drug3	NN	_	19	compound
18	plasma	plasma	NN	_	19	compound
19	levels	level	NNS	_	14	nmod
20	during	during	IN	_	22	case
21	drug4	drug4	NN	_	22	compound
22	therapy	therapy	NN	_	14	nmod
23	have	have	VBP	_	25	aux
24	been	be	VBN	_	25	auxpass
25	reported	report	VBN	_	11	conj
26	.	.	.	_	11	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concomitant	concomitant	JJ	_	4	amod
4	administration	administration	NN	_	12	nsubjpass
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	and	and	CC	_	4	cc
8	some	some	DT	_	9	det
9	drug3	drug3	NN	_	4	conj
10	has	have	VBZ	_	12	aux
11	been	be	VBN	_	12	auxpass
12	reported	report	VBN	_	1	dep
13	to	to	TO	_	14	mark
14	reduce	reduce	VB	_	12	xcomp
15	the	the	DT	_	16	det
16	clearance	clearance	NN	_	14	dobj
17	of	of	IN	_	18	case
18	drug4	drug4	NN	_	16	nmod
19	,	,	,	_	12	punct
20	enhancing	enhance	VBG	_	12	xcomp
21	the	the	DT	_	22	det
22	toxicity	toxicity	NN	_	20	dobj
23	of	of	IN	_	24	case
24	drug5	drug5	NN	_	22	nmod
25	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	11	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	on	on	IN	_	7	case
6	drug2	drug2	NN	_	7	compound
7	clearance	clearance	NN	_	2	nmod
8	has	have	VBZ	_	11	aux
9	not	not	RB	_	11	neg
10	been	be	VBN	_	11	auxpass
11	studied	study	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	4	mark
4	postmarketing	postmarket	VBG	_	9	advcl
5	experience	experience	NN	_	4	dobj
6	there	there	EX	_	9	expl
7	have	have	VBP	_	9	aux
8	been	be	VBN	_	9	cop
9	reports	report	NNS	_	1	dep
10	of	of	IN	_	13	case
11	a	a	DT	_	13	det
12	possible	possible	JJ	_	13	amod
13	interaction	interaction	NN	_	9	nmod
14	between	between	IN	_	15	case
15	TORADOLIV/IM	toradoliv/im	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	drug2	drug2	NN	_	15	conj
18	that	that	WDT	_	19	nsubj
19	resulted	result	VBD	_	13	acl:relcl
20	in	in	IN	_	21	case
21	apnea	apnea	NN	_	19	nmod
22	.	.	.	_	1	punct

1	The	the	DT	_	3	det
2	concurrent	concurrent	JJ	_	3	amod
3	use	use	NN	_	12	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	with	with	IN	_	7	case
7	drug2	drug2	NN	_	3	nmod
8	has	have	VBZ	_	12	aux
9	not	not	RB	_	12	neg
10	been	be	VBN	_	12	auxpass
11	formally	formally	RB	_	12	advmod
12	studied	study	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concomitant	concomitant	JJ	_	4	amod
4	use	use	NN	_	8	nsubj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	may	may	MD	_	8	aux
8	increase	increase	VB	_	1	dep
9	the	the	DT	_	10	det
10	risk	risk	NN	_	8	dobj
11	of	of	IN	_	13	case
12	renal	renal	JJ	_	13	amod
13	impairment	impairment	NN	_	10	nmod
14	,	,	,	_	13	punct
15	particularly	particularly	RB	_	18	advmod
16	in	in	IN	_	18	case
17	volume-depleted	volume-depleted	JJ	_	18	amod
18	patients	patient	NNS	_	13	nmod
19	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Sporadic	sporadic	JJ	_	4	amod
4	cases	case	NNS	_	9	nsubjpass
5	of	of	IN	_	6	case
6	seizures	seizure	NNS	_	4	nmod
7	have	have	VBP	_	9	aux
8	been	be	VBN	_	9	auxpass
9	reported	report	VBN	_	1	appos
10	during	during	IN	_	12	case
11	concomitant	concomitant	JJ	_	12	amod
12	use	use	NN	_	9	nmod
13	of	of	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	and	and	CC	_	14	cc
16	drug3	drug3	NN	_	14	conj
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	drug4	drug4	NN	_	14	dep
19	,	,	,	_	18	punct
20	drug5	drug5	NN	_	18	appos
21	-RRB-	-rrb-	-RRB-	_	18	punct
22	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Hallucinations	hallucination	NNS	_	6	nsubjpass
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	auxpass
6	reported	report	VBN	_	1	appos
7	when	when	WRB	_	10	advmod
8	drug2	drug2	NN	_	10	nsubjpass
9	was	be	VBD	_	10	auxpass
10	used	use	VBN	_	6	advcl
11	in	in	IN	_	12	case
12	patients	patient	NNS	_	10	nmod
13	taking	take	VBG	_	12	acl
14	drug3	drug3	NN	_	13	dobj
15	-LRB-	-lrb-	-LRB-	_	16	punct
16	drug4	drug4	NN	_	14	dep
17	,	,	,	_	16	punct
18	drug5	drug5	NN	_	16	appos
19	,	,	,	_	16	punct
20	drug6	drug6	NN	_	16	appos
21	-RRB-	-rrb-	-RRB-	_	16	punct
22	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	TORADOLIV/IM	toradoliv/im	NN	_	6	nsubjpass
4	has	have	VBZ	_	6	aux
5	been	be	VBN	_	6	auxpass
6	administered	administer	VBN	_	1	dep
7	concurrently	concurrently	RB	_	6	advmod
8	with	with	IN	_	9	case
9	drug2	drug2	NN	_	6	nmod
10	in	in	IN	_	13	case
11	several	several	JJ	_	13	amod
12	clinical	clinical	JJ	_	13	amod
13	trials	trial	NNS	_	6	nmod
14	of	of	IN	_	16	case
15	postoperative	postoperative	JJ	_	16	amod
16	pain	pain	NN	_	13	nmod
17	without	without	IN	_	18	case
18	evidence	evidence	NN	_	6	nmod
19	of	of	IN	_	21	case
20	adverse	adverse	JJ	_	21	amod
21	interactions	interaction	NNS	_	18	nmod
22	.	.	.	_	6	punct

1	Do	do	VB	_	3	aux
2	not	not	RB	_	3	neg
3	mix	mix	VB	_	0	ROOT
4	drug1	drug1	NN	_	3	dobj
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	in	in	IN	_	10	case
8	the	the	DT	_	10	det
9	same	same	JJ	_	10	amod
10	syringe	syringe	NN	_	3	nmod
11	.	.	.	_	3	punct

1	There	there	EX	_	2	expl
2	is	be	VBZ	_	0	ROOT
3	no	no	DT	_	4	neg
4	evidence	evidence	NN	_	2	nsubj
5	in	in	IN	_	9	case
6	animal	animal	NN	_	9	compound
7	or	or	CC	_	6	cc
8	human	human	JJ	_	6	conj
9	studies	study	NNS	_	4	nmod
10	that	that	WDT	_	12	dobj
11	drug1	drug1	NN	_	12	nsubj
12	induces	induce	VBZ	_	9	acl:relcl
13	or	or	CC	_	12	cc
14	inhibits	inhibit	VBZ	_	12	conj
15	hepatic	hepatic	JJ	_	16	amod
16	enzymes	enzyme	NNS	_	12	dobj
17	capable	capable	JJ	_	16	amod
18	of	of	IN	_	19	mark
19	metabolizing	metabolize	VBG	_	17	advcl
20	itself	itself	PRP	_	19	dobj
21	or	or	CC	_	20	cc
22	other	other	JJ	_	23	amod
23	drugs	drug	NNS	_	20	conj

1	.	.	.	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	Synergism	synergism	NN	_	17	nsubjpass
2	between	between	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	-LRB-	-lrb-	-LRB-	_	7	punct
5	e.g.	e.g.	FW	_	7	dep
6	,	,	,	_	7	punct
7	drug2	drug2	NN	_	3	appos
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	,	,	,	_	3	punct
10	drug3	drug3	NN	_	3	conj
11	,	,	,	_	3	punct
12	and	and	CC	_	3	cc
13	other	other	JJ	_	14	amod
14	drug4	drug4	NN	_	3	conj
15	has	have	VBZ	_	17	aux
16	been	be	VBN	_	17	auxpass
17	reported	report	VBN	_	0	ROOT
18	.	.	.	_	17	punct

1	This	this	DT	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	considered	consider	VBN	_	0	ROOT
5	whenever	whenever	WRB	_	9	advmod
6	these	these	DT	_	7	det
7	agents	agent	NNS	_	9	nsubjpass
8	are	be	VBP	_	9	auxpass
9	prescribed	prescribe	VBN	_	4	advcl
10	concomitantly	concomitantly	RB	_	9	advmod
11	.	.	.	_	4	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	administration	administration	NN	_	16	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	,	,	,	_	2	punct
8	which	which	WDT	_	9	nsubj
9	competes	compete	VBZ	_	2	acl:relcl
10	for	for	IN	_	12	case
11	tubular	tubular	JJ	_	12	amod
12	secretion	secretion	NN	_	9	nmod
13	,	,	,	_	2	punct
14	has	have	VBZ	_	16	aux
15	been	be	VBN	_	16	auxpass
16	shown	show	VBN	_	0	ROOT
17	to	to	TO	_	18	mark
18	increase	increase	VB	_	16	xcomp
19	the	the	DT	_	21	det
20	plasma	plasma	NN	_	21	compound
21	half-life	half-life	NN	_	18	dobj
22	of	of	IN	_	23	case
23	drug3	drug3	NN	_	21	nmod
24	.	.	.	_	16	punct

1	Few	few	JJ	_	3	amod
2	systemic	systemic	JJ	_	3	amod
3	data	datum	NNS	_	6	nsubjpass
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	auxpass
6	collected	collect	VBN	_	0	ROOT
7	on	on	IN	_	9	case
8	the	the	DT	_	9	det
9	metabolism	metabolism	NN	_	6	nmod
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	following	follow	VBG	_	14	case
13	concomitant	concomitant	JJ	_	14	amod
14	administration	administration	NN	_	6	nmod
15	with	with	IN	_	17	case
16	other	other	JJ	_	17	amod
17	drugs	drug	NNS	_	14	nmod
18	or	or	CC	_	14	cc
19	,	,	,	_	14	punct
20	alternatively	alternatively	RB	_	14	advmod
21	,	,	,	_	14	punct
22	the	the	DT	_	23	det
23	effect	effect	NN	_	14	appos
24	of	of	IN	_	26	case
25	concomitant	concomitant	JJ	_	26	amod
26	administration	administration	NN	_	23	nmod
27	of	of	IN	_	28	case
28	drug2	drug2	NN	_	26	nmod
29	on	on	IN	_	31	case
30	the	the	DT	_	31	det
31	metabolism	metabolism	NN	_	23	nmod
32	of	of	IN	_	34	case
33	other	other	JJ	_	34	amod
34	drugs	drug	NNS	_	31	nmod
35	.	.	.	_	6	punct

1	Because	because	IN	_	5	mark
2	drug1	drug1	NN	_	5	nsubjpass
3	is	be	VBZ	_	5	auxpass
4	extensively	extensively	RB	_	5	advmod
5	metabolized	metabolize	VBN	_	13	advcl
6	,	,	,	_	13	punct
7	the	the	DT	_	8	det
8	coadministration	coadministration	NN	_	13	nsubj
9	of	of	IN	_	11	case
10	other	other	JJ	_	11	amod
11	drugs	drug	NNS	_	8	nmod
12	may	may	MD	_	13	aux
13	affect	affect	VB	_	0	ROOT
14	its	its	PRP$	_	16	nmod:poss
15	clinical	clinical	JJ	_	16	amod
16	activity	activity	NN	_	13	dobj
17	.	.	.	_	13	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	4	nsubj
4	indicate	indicate	VBP	_	0	ROOT
5	that	that	IN	_	9	mark
6	drug1	drug1	NN	_	9	nsubjpass
7	is	be	VBZ	_	9	auxpass
8	primarily	primarily	RB	_	9	advmod
9	metabolized	metabolize	VBN	_	4	ccomp
10	to	to	TO	_	11	mark
11	drug2	drug2	VB	_	9	xcomp
12	by	by	IN	_	15	case
13	the	the	DT	_	15	det
14	CYP2B6	cyp2b6	NN	_	15	compound
15	isoenzyme	isoenzyme	NN	_	11	nmod
16	.	.	.	_	4	punct

1	Therefore	therefore	RB	_	5	advmod
2	,	,	,	_	5	punct
3	the	the	DT	_	4	det
4	potential	potential	JJ	_	5	nsubj
5	exists	exist	VBZ	_	0	ROOT
6	for	for	IN	_	9	case
7	a	a	DT	_	9	det
8	drug	drug	NN	_	9	compound
9	interaction	interaction	NN	_	5	nmod
10	between	between	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	drugs	drug	NNS	_	11	conj
14	that	that	WDT	_	15	nsubj
15	affect	affect	VBP	_	9	acl:relcl
16	the	the	DT	_	18	det
17	CYP2B6	cyp2b6	NN	_	18	compound
18	isoenzyme	isoenzyme	NN	_	15	dobj
19	-LRB-	-lrb-	-LRB-	_	22	punct
20	e.g.	e.g.	FW	_	22	dep
21	,	,	,	_	22	punct
22	drug2	drug2	NN	_	18	dep
23	and	and	CC	_	22	cc
24	drug3	drug3	NN	_	22	conj
25	-RRB-	-rrb-	-RRB-	_	22	punct
26	.	.	.	_	5	punct

1	The	the	DT	_	3	det
2	drug1	drug1	NN	_	3	compound
3	metabolite	metabolite	NN	_	8	nsubj
4	of	of	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	does	do	VBZ	_	8	aux
7	not	not	RB	_	8	neg
8	appear	appear	VB	_	0	ROOT
9	to	to	TO	_	11	mark
10	be	be	VB	_	11	auxpass
11	produced	produce	VBN	_	8	xcomp
12	by	by	IN	_	16	case
13	the	the	DT	_	16	det
14	cytochrome	cytochrome	NN	_	16	compound
15	P450	p450	NN	_	16	compound
16	isoenzymes	isoenzyme	NNS	_	11	nmod
17	.	.	.	_	8	punct

1	The	the	DT	_	2	det
2	effects	effect	NNS	_	18	nsubjpass
3	of	of	IN	_	5	case
4	concomitant	concomitant	JJ	_	5	amod
5	administration	administration	NN	_	2	nmod
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	on	on	IN	_	10	case
9	the	the	DT	_	10	det
10	pharmacokinetics	pharmacokinetic	NNS	_	2	nmod
11	of	of	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	and	and	CC	_	12	cc
14	its	its	PRP$	_	16	nmod:poss
15	active	active	JJ	_	16	amod
16	metabolites	metabolite	NNS	_	12	conj
17	were	be	VBD	_	18	auxpass
18	studied	study	VBN	_	0	ROOT
19	in	in	IN	_	24	case
20	24	24	CD	_	24	nummod
21	healthy	healthy	JJ	_	24	amod
22	young	young	JJ	_	24	amod
23	male	male	JJ	_	24	amod
24	volunteers	volunteer	NNS	_	18	nmod
25	.	.	.	_	18	punct

1	Following	follow	VBG	_	3	case
2	oral	oral	JJ	_	3	amod
3	administration	administration	NN	_	0	ROOT
4	of	of	IN	_	8	case
5	two	two	CD	_	8	nummod
6	150-mg	150-mg	JJ	_	8	amod
7	sustained-release	sustained-release	JJ	_	8	amod
8	tablets	tablet	NNS	_	3	nmod
9	with	with	IN	_	24	mark
10	and	and	CC	_	24	cc
11	without	without	IN	_	13	case
12	800	800	CD	_	13	nummod
13	mg	mg	NN	_	24	nmod
14	of	of	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	,	,	,	_	24	punct
17	the	the	DT	_	18	det
18	pharmacokinetics	pharmacokinetic	NNS	_	24	nsubj
19	of	of	IN	_	20	case
20	drug2	drug2	NN	_	18	nmod
21	and	and	CC	_	20	cc
22	drug3	drug3	NN	_	20	conj
23	were	be	VBD	_	24	cop
24	unaffected	unaffected	JJ	_	3	acl
25	.	.	.	_	3	punct

1	However	however	RB	_	4	advmod
2	,	,	,	_	4	punct
3	there	there	EX	_	4	expl
4	were	be	VBD	_	0	ROOT
5	16	16	CD	_	6	nummod
6	%	%	NN	_	4	nsubj
7	and	and	CC	_	6	cc
8	32	32	CD	_	9	compound
9	%	%	NN	_	6	conj
10	increases	increase	NNS	_	6	dep
11	in	in	IN	_	13	case
12	the	the	DT	_	13	det
13	AUC	auc	NN	_	6	nmod
14	and	and	CC	_	13	cc
15	Cmax	cmax	NN	_	13	conj
16	,	,	,	_	6	punct
17	respectively	respectively	RB	_	6	advmod
18	,	,	,	_	6	punct
19	of	of	IN	_	22	case
20	the	the	DT	_	22	det
21	combined	combined	JJ	_	22	amod
22	moieties	moiety	NNS	_	6	nmod
23	of	of	IN	_	24	case
24	drug1	drug1	NN	_	22	nmod
25	and	and	CC	_	24	cc
26	drug2	drug2	NN	_	24	conj
27	.	.	.	_	4	punct

1	While	while	IN	_	4	mark
2	not	not	RB	_	4	neg
3	systematically	systematically	RB	_	4	advmod
4	studied	study	VBN	_	9	advcl
5	,	,	,	_	9	punct
6	certain	certain	JJ	_	7	amod
7	drugs	drug	NNS	_	9	nsubj
8	may	may	MD	_	9	aux
9	induce	induce	VB	_	0	ROOT
10	the	the	DT	_	11	det
11	metabolism	metabolism	NN	_	9	dobj
12	of	of	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	-LRB-	-lrb-	-LRB-	_	17	punct
15	e.g.	e.g.	FW	_	17	dep
16	,	,	,	_	17	punct
17	drug2	drug2	NN	_	11	dep
18	,	,	,	_	17	punct
19	drug3	drug3	NN	_	17	appos
20	,	,	,	_	17	punct
21	drug4	drug4	NN	_	17	appos
22	-RRB-	-rrb-	-RRB-	_	17	punct
23	.	.	.	_	9	punct

1	Animal	animal	NN	_	2	compound
2	data	datum	NNS	_	3	nsubj
3	indicated	indicate	VBD	_	0	ROOT
4	that	that	IN	_	9	mark
5	drug1	drug1	NN	_	9	nsubj
6	may	may	MD	_	9	aux
7	be	be	VB	_	9	cop
8	an	a	DT	_	9	det
9	inducer	inducer	NN	_	3	ccomp
10	of	of	IN	_	12	case
11	drug-metabolizing	drug-metabolizing	JJ	_	12	amod
12	enzymes	enzyme	NNS	_	9	nmod
13	in	in	IN	_	14	case
14	humans	human	NNS	_	12	nmod
15	.	.	.	_	3	punct

1	In	in	IN	_	3	case
2	one	one	CD	_	3	nummod
3	study	study	NN	_	26	nmod
4	,	,	,	_	26	punct
5	following	follow	VBG	_	7	case
6	chronic	chronic	JJ	_	7	amod
7	administration	administration	NN	_	26	nmod
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	,	,	,	_	26	punct
11	100	100	CD	_	12	nummod
12	mg	mg	NN	_	26	dep
13	3	3	CD	_	14	compound
14	times	time	NNS	_	12	nmod:npmod
15	daily	daily	JJ	_	14	advmod
16	to	to	TO	_	20	case
17	8	8	CD	_	20	nummod
18	healthy	healthy	JJ	_	20	amod
19	male	male	JJ	_	20	amod
20	volunteers	volunteer	NNS	_	12	nmod
21	for	for	IN	_	23	case
22	14	14	CD	_	23	nummod
23	days	day	NNS	_	12	nmod
24	,	,	,	_	26	punct
25	there	there	EX	_	26	expl
26	was	be	VBD	_	0	ROOT
27	no	no	DT	_	28	neg
28	evidence	evidence	NN	_	26	nsubj
29	of	of	IN	_	30	case
30	induction	induction	NN	_	28	nmod
31	of	of	IN	_	34	case
32	its	its	PRP$	_	34	nmod:poss
33	own	own	JJ	_	34	amod
34	metabolism	metabolism	NN	_	30	nmod
35	.	.	.	_	26	punct

1	Nevertheless	nevertheless	RB	_	7	advmod
2	,	,	,	_	7	punct
3	there	there	EX	_	7	expl
4	may	may	MD	_	7	aux
5	be	be	VB	_	7	cop
6	the	the	DT	_	7	det
7	potential	potential	NN	_	0	ROOT
8	for	for	IN	_	11	case
9	clinically	clinically	RB	_	10	advmod
10	important	important	JJ	_	11	amod
11	alterations	alteration	NNS	_	7	nmod
12	of	of	IN	_	14	case
13	blood	blood	NN	_	14	compound
14	levels	level	NNS	_	11	nmod
15	of	of	IN	_	17	case
16	coadministered	coadministered	JJ	_	17	amod
17	drugs	drug	NNS	_	14	nmod
18	.	.	.	_	7	punct

1	Drugs	drug	NNS	_	0	ROOT
2	Metabolized	metabolize	VBN	_	1	acl
3	by	by	IN	_	5	case
4	Cytochrome	cytochrome	NN	_	5	compound
5	P450IID6	p450iid6	NN	_	2	nmod
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	CYP2D6	cyp2d6	NN	_	5	appos
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	:	:	:	_	1	punct
10	Many	many	JJ	_	11	amod
11	drugs	drug	NNS	_	30	nsubjpass
12	,	,	,	_	11	punct
13	including	include	VBG	_	17	case
14	most	most	RBS	_	15	advmod
15	drug1	drug1	JJ	_	17	amod
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	SSRIs	ssri	NNS	_	11	nmod
18	,	,	,	_	11	punct
19	many	many	JJ	_	20	amod
20	drug2	drug2	NN	_	11	appos
21	-RRB-	-rrb-	-RRB-	_	11	punct
22	,	,	,	_	11	punct
23	drug3	drug3	NN	_	11	appos
24	,	,	,	_	23	punct
25	drug4	drug4	NN	_	23	conj
26	,	,	,	_	23	punct
27	and	and	CC	_	23	cc
28	drug5	drug5	NN	_	23	conj
29	are	be	VBP	_	30	auxpass
30	metabolized	metabolize	VBN	_	1	dep
31	by	by	IN	_	34	case
32	the	the	DT	_	34	det
33	CYP2D6	cyp2d6	NN	_	34	compound
34	isoenzyme	isoenzyme	NN	_	30	nmod
35	.	.	.	_	1	punct

1	Although	although	IN	_	5	mark
2	drug1	drug1	NN	_	5	nsubjpass
3	is	be	VBZ	_	5	auxpass
4	not	not	RB	_	5	neg
5	metabolized	metabolize	VBN	_	14	advcl
6	by	by	IN	_	8	case
7	this	this	DT	_	8	det
8	isoenzyme	isoenzyme	NN	_	5	nmod
9	,	,	,	_	14	punct
10	drug2	drug2	NN	_	14	nsubj
11	and	and	CC	_	10	cc
12	drug3	drug3	NN	_	10	conj
13	are	be	VBP	_	14	cop
14	inhibitors	inhibitor	NNS	_	0	ROOT
15	of	of	IN	_	18	case
16	the	the	DT	_	18	det
17	CYP2D6	cyp2d6	NN	_	18	compound
18	isoenzyme	isoenzyme	NN	_	14	nmod
19	in	in	FW	_	20	compound
20	vitro	vitro	FW	_	14	advmod
21	.	.	.	_	14	punct

1	In	in	IN	_	3	case
2	a	a	DT	_	3	det
3	study	study	NN	_	43	nmod
4	of	of	IN	_	7	case
5	15	15	CD	_	7	nummod
6	male	male	JJ	_	7	amod
7	subjects	subject	NNS	_	3	nmod
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	ages	age	NNS	_	7	appos
10	19	19	CD	_	12	compound
11	to	to	TO	_	12	dep
12	35	35	CD	_	13	nummod
13	years	year	NNS	_	9	nmod:tmod
14	-RRB-	-rrb-	-RRB-	_	9	punct
15	who	who	WP	_	18	nsubj
16	were	be	VBD	_	18	cop
17	extensive	extensive	JJ	_	18	amod
18	metabolizers	metabolizer	NNS	_	7	acl:relcl
19	of	of	IN	_	22	case
20	the	the	DT	_	22	det
21	CYP2D6	cyp2d6	NN	_	22	compound
22	isoenzyme	isoenzyme	NN	_	18	nmod
23	,	,	,	_	22	punct
24	daily	daily	JJ	_	25	amod
25	doses	dose	NNS	_	22	appos
26	of	of	IN	_	27	case
27	drug1	drug1	NN	_	25	nmod
28	given	give	VBN	_	25	acl
29	as	as	IN	_	31	case
30	150	150	CD	_	31	nummod
31	mg	mg	NN	_	28	nmod
32	twice	twice	RB	_	33	advmod
33	daily	daily	JJ	_	34	advmod
34	followed	follow	VBN	_	28	dep
35	by	by	IN	_	38	case
36	a	a	DT	_	38	det
37	single	single	JJ	_	38	amod
38	dose	dose	NN	_	34	nmod
39	of	of	IN	_	42	case
40	50	50	CD	_	41	compound
41	mg	mg	NN	_	42	amod
42	drug2	drug2	NN	_	38	nmod
43	increased	increase	VBD	_	0	ROOT
44	the	the	DT	_	55	det
45	Cmax	Cmax	NNP	_	55	dep
46	,	,	,	_	45	punct
47	AUC	auc	NN	_	45	conj
48	,	,	,	_	45	punct
49	and	and	CC	_	45	cc
50	t1/2	t1/2	NN	_	45	conj
51	of	of	IN	_	52	case
52	drug3	drug3	NN	_	45	nmod
53	by	by	IN	_	55	case
54	an	a	DT	_	55	det
55	average	average	NN	_	43	dobj
56	of	of	IN	_	58	case
57	approximately	approximately	RB	_	58	advmod
58	2	2	LS	_	55	nmod
59	-	-	:	_	58	punct
60	,	,	,	_	58	punct
61	5	5	LS	_	58	advmod
62	-	-	:	_	61	punct
63	and	and	CC	_	61	cc
64	2-fold	2-fold	RB	_	66	advmod
65	,	,	,	_	66	punct
66	respectively	respectively	RB	_	61	conj
67	.	.	.	_	43	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	4	nsubj
3	was	be	VBD	_	4	cop
4	present	present	JJ	_	0	ROOT
5	for	for	IN	_	9	case
6	at	at	IN	_	7	case
7	least	least	JJS	_	8	nmod:npmod
8	7	7	CD	_	9	nummod
9	days	day	NNS	_	4	nmod
10	after	after	IN	_	13	case
11	the	the	DT	_	13	det
12	last	last	JJ	_	13	amod
13	dose	dose	NN	_	9	nmod
14	of	of	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	.	.	.	_	4	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	use	use	NN	_	15	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	7	case
6	other	other	JJ	_	7	amod
7	drugs	drug	NNS	_	2	nmod
8	metabolized	metabolize	VBN	_	7	acl
9	by	by	IN	_	10	case
10	CYP2D6	cyp2d6	NN	_	8	nmod
11	has	have	VBZ	_	15	aux
12	not	not	RB	_	15	neg
13	been	be	VBN	_	15	auxpass
14	formally	formally	RB	_	15	advmod
15	studied	study	VBN	_	0	ROOT
16	.	.	.	_	15	punct

1	Therefore	therefore	RB	_	63	advmod
2	,	,	,	_	63	punct
3	co-administration	co-administration	NN	_	63	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	with	with	IN	_	7	case
7	drugs	drug	NNS	_	3	nmod
8	that	that	WDT	_	10	nsubjpass
9	are	be	VBP	_	10	auxpass
10	metabolized	metabolize	VBN	_	7	acl:relcl
11	by	by	IN	_	13	case
12	CYP2D6	cyp2d6	NN	_	13	compound
13	isoenzyme	isoenzyme	NN	_	10	nmod
14	including	include	VBG	_	16	case
15	certain	certain	JJ	_	16	amod
16	drug2	drug2	NN	_	13	nmod
17	-LRB-	-lrb-	-LRB-	_	20	punct
18	e.g.	e.g.	FW	_	20	dep
19	,	,	,	_	20	punct
20	drug3	drug3	NN	_	16	dep
21	,	,	,	_	20	punct
22	drug4	drug4	NN	_	20	conj
23	,	,	,	_	20	punct
24	drug5	drug5	NN	_	20	conj
25	,	,	,	_	20	punct
26	drug6	drug6	NN	_	20	conj
27	,	,	,	_	20	punct
28	drug7	drug7	NN	_	20	conj
29	,	,	,	_	20	punct
30	drug8	drug8	NN	_	20	appos
31	-RRB-	-rrb-	-RRB-	_	20	punct
32	,	,	,	_	16	punct
33	drug9	drug9	NN	_	16	conj
34	-LRB-	-lrb-	-LRB-	_	37	punct
35	e.g.	e.g.	FW	_	37	dep
36	,	,	,	_	37	punct
37	drug10	drug10	NN	_	33	dep
38	,	,	,	_	37	punct
39	drug11	drug11	NN	_	37	appos
40	,	,	,	_	37	punct
41	drug12	drug12	NN	_	37	appos
42	-RRB-	-rrb-	-RRB-	_	37	punct
43	,	,	,	_	16	punct
44	drug13	drug13	NN	_	16	conj
45	-LRB-	-lrb-	-LRB-	_	48	punct
46	e.g.	e.g.	FW	_	48	dep
47	,	,	,	_	48	punct
48	drug14	drug14	NN	_	44	appos
49	-RRB-	-rrb-	-RRB-	_	48	punct
50	,	,	,	_	16	punct
51	and	and	CC	_	16	cc
52	drug15	drug15	NN	_	16	conj
53	-LRB-	-lrb-	-LRB-	_	56	punct
54	e.g.	e.g.	FW	_	56	dep
55	,	,	,	_	56	punct
56	drug16	drug16	NN	_	52	dep
57	,	,	,	_	56	punct
58	drug17	drug17	NN	_	56	appos
59	-RRB-	-rrb-	-RRB-	_	56	punct
60	,	,	,	_	3	punct
61	should	should	MD	_	63	aux
62	be	be	VB	_	63	auxpass
63	approached	approach	VBN	_	0	ROOT
64	with	with	IN	_	65	case
65	caution	caution	NN	_	63	nmod
66	and	and	CC	_	63	cc
67	should	should	MD	_	69	aux
68	be	be	VB	_	69	auxpass
69	initiated	initiate	VBN	_	63	conj
70	at	at	IN	_	73	case
71	the	the	DT	_	73	det
72	lower	lower	JJR	_	73	amod
73	end	end	NN	_	69	nmod
74	of	of	IN	_	77	case
75	the	the	DT	_	77	det
76	dose	dose	NN	_	77	compound
77	range	range	NN	_	73	nmod
78	of	of	IN	_	81	case
79	the	the	DT	_	81	det
80	concomitant	concomitant	JJ	_	81	amod
81	medication	medication	NN	_	77	nmod
82	.	.	.	_	63	punct

1	If	if	IN	_	4	mark
2	drug1	drug1	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	added	add	VBN	_	32	advcl
5	to	to	TO	_	8	case
6	the	the	DT	_	8	det
7	treatment	treatment	NN	_	8	compound
8	regimen	regimen	NN	_	4	nmod
9	of	of	IN	_	11	case
10	a	a	DT	_	11	det
11	patient	patient	NN	_	8	nmod
12	already	already	RB	_	13	advmod
13	receiving	receive	VBG	_	11	acl
14	a	a	DT	_	15	det
15	drug	drug	NN	_	13	dobj
16	metabolized	metabolize	VBN	_	15	acl
17	by	by	IN	_	18	case
18	CYP2D6	cyp2d6	NN	_	16	nmod
19	,	,	,	_	32	punct
20	the	the	DT	_	21	det
21	need	need	NN	_	32	nsubjpass
22	to	to	TO	_	23	mark
23	decrease	decrease	VB	_	21	acl
24	the	the	DT	_	25	det
25	dose	dose	NN	_	23	dobj
26	of	of	IN	_	29	case
27	the	the	DT	_	29	det
28	original	original	JJ	_	29	amod
29	medication	medication	NN	_	25	nmod
30	should	should	MD	_	32	aux
31	be	be	VB	_	32	auxpass
32	considered	consider	VBN	_	0	ROOT
33	,	,	,	_	32	punct
34	particularly	particularly	RB	_	38	advmod
35	for	for	IN	_	38	case
36	those	those	DT	_	38	det
37	concomitant	concomitant	JJ	_	38	amod
38	medications	medication	NNS	_	32	nmod
39	with	with	IN	_	43	case
40	a	a	DT	_	43	det
41	narrow	narrow	JJ	_	43	amod
42	therapeutic	therapeutic	JJ	_	43	amod
43	index	index	NN	_	38	nmod
44	.	.	.	_	32	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Studies	study	NNS	_	6	nsubj
4	in	in	IN	_	5	case
5	animals	animal	NNS	_	3	nmod
6	demonstrate	demonstrate	VBP	_	1	appos
7	that	that	IN	_	14	mark
8	the	the	DT	_	10	det
9	acute	acute	JJ	_	10	amod
10	toxicity	toxicity	NN	_	14	nsubjpass
11	of	of	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	is	be	VBZ	_	14	auxpass
14	enhanced	enhance	VBN	_	6	ccomp
15	by	by	IN	_	18	case
16	the	the	DT	_	18	det
17	drug3	drug3	NN	_	18	compound
18	drug4	drug4	NN	_	14	nmod
19	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	:	:	:	_	1	punct
5	Limited	Limited	NNP	_	7	compound
6	clinical	clinical	JJ	_	7	amod
7	data	datum	NNS	_	8	nsubj
8	suggest	suggest	VBP	_	1	dep
9	a	a	DT	_	11	det
10	higher	higher	JJR	_	11	amod
11	incidence	incidence	NN	_	8	dobj
12	of	of	IN	_	14	case
13	adverse	adverse	JJ	_	14	amod
14	experiences	experience	NNS	_	11	nmod
15	in	in	IN	_	16	case
16	patients	patient	NNS	_	14	nmod
17	receiving	receive	VBG	_	16	acl
18	drug3	drug3	NN	_	17	dobj
19	concurrently	concurrently	RB	_	22	advmod
20	with	with	IN	_	22	case
21	either	either	CC	_	22	cc:preconj
22	drug4	drug4	NN	_	11	nmod
23	or	or	CC	_	22	cc
24	drug5	drug5	NN	_	22	conj
25	.	.	.	_	1	punct

1	Administration	administration	NN	_	15	nsubjpass
2	of	of	IN	_	4	case
3	drug1	drug1	NN	_	4	compound
4	Tablets	tablet	NNS	_	1	nmod
5	to	to	TO	_	6	case
6	patients	patient	NNS	_	1	nmod
7	receiving	receive	VBG	_	6	acl
8	either	either	CC	_	9	cc:preconj
9	drug2	drug2	NN	_	7	dobj
10	or	or	CC	_	9	cc
11	drug3	drug3	NN	_	9	conj
12	concurrently	concurrently	RB	_	15	advmod
13	should	should	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	undertaken	undertake	VBN	_	0	ROOT
16	with	with	IN	_	17	case
17	caution	caution	NN	_	15	nmod
18	,	,	,	_	15	punct
19	using	use	VBG	_	15	xcomp
20	small	small	JJ	_	22	amod
21	initial	initial	JJ	_	22	amod
22	doses	dose	NNS	_	19	dobj
23	and	and	CC	_	22	cc
24	small	small	JJ	_	27	amod
25	gradual	gradual	JJ	_	27	amod
26	dose	dose	NN	_	27	compound
27	increases	increase	NNS	_	22	conj
28	.	.	.	_	15	punct

1	Drugs	drug	NNS	_	0	ROOT
2	that	that	WDT	_	1	dep
3	Lower	Lower	NNP	_	5	compound
4	Seizure	Seizure	NNP	_	5	compound
5	Threshold	Threshold	NNP	_	2	dep
6	:	:	:	_	5	punct
7	Concurrent	concurrent	JJ	_	8	amod
8	administration	administration	NN	_	5	dep
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	agents	agent	NNS	_	10	conj
13	-LRB-	-lrb-	-LRB-	_	16	punct
14	e.g.	e.g.	FW	_	16	dep
15	,	,	,	_	16	punct
16	drug2	drug2	NN	_	8	dep
17	,	,	,	_	16	punct
18	other	other	JJ	_	19	amod
19	drug3	drug3	NN	_	16	conj
20	,	,	,	_	16	punct
21	drug4	drug4	NN	_	16	conj
22	,	,	,	_	16	punct
23	systemic	systemic	JJ	_	24	amod
24	drug5	drug5	NN	_	16	conj
25	,	,	,	_	16	punct
26	etc.	etc.	FW	_	16	dep
27	-RRB-	-rrb-	-RRB-	_	16	punct
28	that	that	WDT	_	34	mark
29	lower	lower	JJR	_	31	amod
30	seizure	seizure	NN	_	31	compound
31	threshold	threshold	NN	_	34	nsubjpass
32	should	should	MD	_	34	aux
33	be	be	VB	_	34	auxpass
34	undertaken	undertake	VBN	_	8	dep
35	only	only	RB	_	38	advmod
36	with	with	IN	_	38	case
37	extreme	extreme	JJ	_	38	amod
38	caution	caution	NN	_	34	nmod
39	.	.	.	_	1	punct

1	Low	low	JJ	_	3	amod
2	initial	initial	JJ	_	3	amod
3	dosing	dosing	NN	_	11	nsubjpass
4	and	and	CC	_	3	cc
5	small	small	JJ	_	8	amod
6	gradual	gradual	JJ	_	8	amod
7	dose	dose	NN	_	8	compound
8	increases	increase	NNS	_	3	conj
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	employed	employ	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	drug1	drug1	NN	_	3	compound
2	Transdermal	Transdermal	NNP	_	3	compound
3	System	System	NNP	_	0	ROOT
4	:	:	:	_	3	punct
5	.	.	.	_	3	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	5	case
4	post-marketing	post-marketing	JJ	_	5	amod
5	experience	experience	NN	_	11	nmod
6	,	,	,	_	11	punct
7	there	there	EX	_	11	expl
8	have	have	VBP	_	11	aux
9	been	be	VBN	_	11	cop
10	rare	rare	JJ	_	11	amod
11	reports	report	NNS	_	1	appos
12	of	of	IN	_	15	case
13	adverse	adverse	JJ	_	15	amod
14	neuropsychiatric	neuropsychiatric	JJ	_	15	amod
15	events	event	NNS	_	11	nmod
16	or	or	CC	_	15	cc
17	reduced	reduce	VBN	_	19	amod
18	drug2	drug2	NN	_	19	compound
19	tolerance	tolerance	NN	_	15	conj
20	in	in	IN	_	21	case
21	patients	patient	NNS	_	15	nmod
22	who	who	WP	_	24	nsubj
23	were	be	VBD	_	24	aux
24	drinking	drink	VBG	_	21	acl:relcl
25	drug3	drug3	NN	_	24	dobj
26	during	during	IN	_	27	case
27	treatment	treatment	NN	_	24	nmod
28	with	with	IN	_	29	case
29	drug4	drug4	NN	_	27	nmod
30	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	consumption	consumption	NN	_	11	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	during	during	IN	_	6	case
6	treatment	treatment	NN	_	2	nmod
7	with	with	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	minimized	minimize	VBN	_	0	ROOT
12	or	or	CC	_	11	cc
13	avoided	avoid	VBN	_	11	conj
14	-LRB-	-lrb-	-LRB-	_	16	punct
15	also	also	RB	_	16	advmod
16	see	see	VB	_	11	dep
17	a	a	DT	_	18	det
18	href	href	NN	_	16	dobj
19	=	=	JJ	_	18	amod
20	bupropz_od	bupropz_od	NN	_	19	dep
21	.	.	.	_	16	punct
22	htm	htm	NN	_	24	compound
23	#CI	#ci	NN	_	24	compound
24	CONTRAINDICATIONS	contraindication	NNS	_	16	dep
25	-RRB-	-rrb-	-RRB-	_	16	punct

1	.	.	.	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	The	the	DT	_	2	det
2	action	action	NN	_	7	nsubjpass
3	of	of	IN	_	5	case
4	nondepolarizing	nondepolarizing	JJ	_	5	amod
5	relaxants	relaxant	NNS	_	2	nmod
6	is	be	VBZ	_	7	auxpass
7	augmented	augment	VBN	_	0	ROOT
8	by	by	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	.	.	.	_	7	punct

1	Less	less	RBR	_	11	nsubjpass
2	than	than	IN	_	5	case
3	the	the	DT	_	5	det
4	usual	usual	JJ	_	5	amod
5	amounts	amount	NNS	_	1	nmod
6	of	of	IN	_	8	case
7	these	these	DT	_	8	det
8	medicines	medicine	NNS	_	5	nmod
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	used	use	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	If	if	IN	_	9	mark
2	the	the	DT	_	4	det
3	usual	usual	JJ	_	4	amod
4	amounts	amount	NNS	_	9	nsubjpass
5	of	of	IN	_	7	case
6	nondepolarizing	nondepolarizing	JJ	_	7	amod
7	relaxants	relaxant	NNS	_	4	nmod
8	are	be	VBP	_	9	auxpass
9	given	give	VBN	_	20	advcl
10	,	,	,	_	20	punct
11	the	the	DT	_	12	det
12	time	time	NN	_	20	nsubj
13	for	for	IN	_	14	case
14	recovery	recovery	NN	_	12	nmod
15	from	from	IN	_	17	case
16	neuromuscular	neuromuscular	JJ	_	17	amod
17	blockade	blockade	NN	_	14	nmod
18	will	will	MD	_	20	aux
19	be	be	VB	_	20	cop
20	longer	longer	RBR	_	0	ROOT
21	in	in	IN	_	23	case
22	the	the	DT	_	23	det
23	presence	presence	NN	_	20	nmod
24	of	of	IN	_	25	case
25	drug1	drug1	NN	_	23	nmod
26	than	than	IN	_	36	mark
27	when	when	WRB	_	36	advmod
28	drug2	drug2	NN	_	36	nsubjpass
29	or	or	CC	_	28	cc
30	drug3	drug3	NN	_	28	conj
31	with	with	IN	_	34	case
32	a	a	DT	_	34	det
33	balanced	balanced	JJ	_	34	amod
34	technique	technique	NN	_	28	nmod
35	are	be	VBP	_	36	auxpass
36	used	use	VBN	_	20	advcl
37	.	.	.	_	20	punct

1	The	the	DT	_	2	det
2	rate	rate	NN	_	13	nsubjpass
3	of	of	IN	_	4	case
4	metabolism	metabolism	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	the	the	DT	_	8	det
7	leukopenic	leukopenic	JJ	_	8	amod
8	activity	activity	NN	_	4	conj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	reportedly	reportedly	RB	_	13	advmod
12	are	be	VBP	_	13	auxpass
13	increased	increase	VBN	_	0	ROOT
14	by	by	IN	_	16	case
15	chronic	chronic	JJ	_	16	amod
16	administration	administration	NN	_	13	nmod
17	of	of	IN	_	19	case
18	high	high	JJ	_	19	amod
19	doses	dose	NNS	_	16	nmod
20	of	of	IN	_	21	case
21	drug2	drug2	NN	_	19	nmod
22	.	.	.	_	13	punct

1	The	the	DT	_	2	det
2	physician	physician	NN	_	5	nsubj
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	cop
5	alert	alert	JJ	_	0	ROOT
6	for	for	IN	_	10	case
7	possible	possible	JJ	_	10	amod
8	combined	combine	VBN	_	10	amod
9	drug	drug	NN	_	10	compound
10	actions	action	NNS	_	5	nmod
11	,	,	,	_	10	punct
12	desirable	desirable	JJ	_	10	amod
13	or	or	CC	_	12	cc
14	undesirable	undesirable	JJ	_	12	conj
15	,	,	,	_	10	punct
16	involving	involve	VBG	_	10	acl
17	drug1	drug1	NN	_	16	dobj
18	even	even	RB	_	23	advmod
19	though	though	IN	_	23	mark
20	drug2	drug2	NN	_	23	nsubjpass
21	has	have	VBZ	_	23	aux
22	been	be	VBN	_	23	auxpass
23	used	use	VBN	_	16	advcl
24	successfully	successfully	RB	_	25	advmod
25	concurrently	concurrently	RB	_	23	advmod
26	with	with	IN	_	28	case
27	other	other	JJ	_	28	amod
28	drugs	drug	NNS	_	23	nmod
29	,	,	,	_	28	punct
30	including	include	VBG	_	33	case
31	other	other	JJ	_	33	amod
32	cytotoxic	cytotoxic	JJ	_	33	amod
33	drugs	drug	NNS	_	28	nmod
34	.	.	.	_	5	punct

1	drug1	drug1	NN	_	2	compound
2	treatment	treatment	NN	_	15	nsubj
3	,	,	,	_	2	punct
4	which	which	WDT	_	5	nsubj
5	causes	cause	VBZ	_	2	acl:relcl
6	a	a	DT	_	10	det
7	marked	marked	JJ	_	10	amod
8	and	and	CC	_	7	cc
9	persistent	persistent	JJ	_	7	conj
10	inhibition	inhibition	NN	_	5	dobj
11	of	of	IN	_	13	case
12	cholinesterase	cholinesterase	NN	_	13	compound
13	activity	activity	NN	_	10	nmod
14	,	,	,	_	2	punct
15	potentiates	potentiate	VBZ	_	0	ROOT
16	the	the	DT	_	17	det
17	effect	effect	NN	_	15	dobj
18	of	of	IN	_	19	case
19	drug2	drug2	NN	_	17	nmod
20	.	.	.	_	15	punct

1	If	if	IN	_	6	mark
2	a	a	DT	_	3	det
3	patient	patient	NN	_	6	nsubjpass
4	has	have	VBZ	_	6	aux
5	been	be	VBN	_	6	auxpass
6	treated	treat	VBN	_	20	advcl
7	with	with	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	within	within	IN	_	11	case
10	10	10	CD	_	11	nummod
11	days	day	NNS	_	6	nmod
12	of	of	IN	_	14	case
13	general	general	JJ	_	14	amod
14	anesthesia	anesthesia	NN	_	11	nmod
15	,	,	,	_	20	punct
16	the	the	DT	_	17	det
17	anesthesiologist	anesthesiologist	NN	_	20	nsubjpass
18	should	should	MD	_	20	aux
19	be	be	VB	_	20	auxpass
20	alerted	alert	VBN	_	0	ROOT
21	.	.	.	_	20	punct

1	Both	both	CC	_	3	cc:preconj
2	the	the	DT	_	3	det
3	magnitude	magnitude	NN	_	15	nsubjpass
4	and	and	CC	_	3	cc
5	duration	duration	NN	_	3	conj
6	of	of	IN	_	9	case
7	central	central	JJ	_	9	amod
8	nervous	nervous	JJ	_	9	amod
9	system	system	NN	_	3	nmod
10	and	and	CC	_	3	cc
11	cardiovascular	cardiovascular	JJ	_	12	amod
12	effects	effect	NNS	_	3	conj
13	may	may	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	enhanced	enhance	VBN	_	0	ROOT
16	when	when	WRB	_	19	advmod
17	drug1	drug1	NN	_	19	nsubjpass
18	is	be	VBZ	_	19	auxpass
19	administered	administer	VBN	_	15	advcl
20	in	in	IN	_	21	case
21	combination	combination	NN	_	19	nmod
22	with	with	IN	_	24	case
23	other	other	JJ	_	24	amod
24	drug2	drug2	NN	_	21	nmod
25	such	such	JJ	_	27	case
26	as	as	IN	_	25	mwe
27	drug3	drug3	NN	_	24	nmod
28	,	,	,	_	27	punct
29	drug4	drug4	NN	_	27	conj
30	,	,	,	_	27	punct
31	drug5	drug5	NN	_	27	conj
32	,	,	,	_	27	punct
33	or	or	CC	_	27	cc
34	inhalation	inhalation	NN	_	36	compound
35	general	general	JJ	_	36	amod
36	drug6	drug6	NN	_	27	conj
37	.	.	.	_	15	punct

1	Postoperative	postoperative	JJ	_	3	amod
2	respiratory	respiratory	JJ	_	3	amod
3	depression	depression	NN	_	6	nsubjpass
4	may	may	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	enhanced	enhance	VBN	_	0	ROOT
7	or	or	CC	_	6	cc
8	prolonged	prolong	VBN	_	6	conj
9	by	by	IN	_	11	case
10	these	these	DT	_	11	det
11	agents	agent	NNS	_	6	nmod
12	.	.	.	_	6	punct

1	In	in	IN	_	3	case
2	such	such	JJ	_	3	amod
3	cases	case	NNS	_	17	nmod
4	of	of	IN	_	6	case
5	combined	combined	JJ	_	6	amod
6	treatment	treatment	NN	_	3	nmod
7	,	,	,	_	17	punct
8	the	the	DT	_	9	det
9	dose	dose	NN	_	17	nsubjpass
10	of	of	IN	_	11	case
11	one	one	CD	_	9	nmod
12	or	or	CC	_	11	cc
13	both	both	DT	_	14	det
14	agents	agent	NNS	_	11	conj
15	should	should	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	reduced	reduce	VBN	_	0	ROOT
18	.	.	.	_	17	punct

1	Limited	limited	JJ	_	3	amod
2	clinical	clinical	JJ	_	3	amod
3	experience	experience	NN	_	4	nsubj
4	indicates	indicate	VBZ	_	0	ROOT
5	that	that	IN	_	10	mark
6	requirements	requirement	NNS	_	10	nsubjpass
7	for	for	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	are	be	VBP	_	10	auxpass
10	reduced	reduce	VBN	_	4	ccomp
11	by	by	IN	_	15	case
12	30	30	CD	_	14	compound
13	to	to	TO	_	14	dep
14	50	50	CD	_	15	nummod
15	%	%	NN	_	10	nmod
16	for	for	IN	_	19	case
17	the	the	DT	_	19	det
18	first	first	JJ	_	19	amod
19	sixty	sixty	NN	_	10	nmod
20	-LRB-	-lrb-	-LRB-	_	21	punct
21	60	60	CD	_	19	appos
22	-RRB-	-rrb-	-RRB-	_	21	punct
23	minutes	minute	NNS	_	19	dep
24	following	follow	VBG	_	26	case
25	drug2	drug2	NN	_	26	compound
26	induction	induction	NN	_	10	nmod
27	The	the	DT	_	29	det
28	concomitant	concomitant	JJ	_	29	amod
29	use	use	NN	_	36	nsubj
30	of	of	IN	_	31	case
31	drug3	drug3	NN	_	29	nmod
32	with	with	IN	_	33	case
33	drug4	drug4	NN	_	29	nmod
34	can	can	MD	_	36	aux
35	significantly	significantly	RB	_	36	advmod
36	inhibit	inhibit	VB	_	26	acl:relcl
37	drug5	drug5	NN	_	38	compound
38	clearance	clearance	NN	_	36	dobj
39	and	and	CC	_	10	cc
40	may	may	MD	_	41	aux
41	increase	increase	VB	_	10	conj
42	the	the	DT	_	43	det
43	risk	risk	NN	_	41	dobj
44	of	of	IN	_	49	case
45	prolonged	prolonged	JJ	_	49	amod
46	or	or	CC	_	45	cc
47	delayed	delay	VBN	_	45	conj
48	respiratory	respiratory	JJ	_	49	amod
49	depression	depression	NN	_	43	nmod
50	.	.	.	_	4	punct

1	drug1	drug1	NN	_	2	nsubj
2	reduces	reduce	VBZ	_	0	ROOT
3	the	the	DT	_	4	det
4	clearance	clearance	NN	_	2	dobj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	.	.	.	_	2	punct

1	Therefore	therefore	RB	_	7	advmod
2	smaller	smaller	JJR	_	4	amod
3	drug1	drug1	NN	_	4	compound
4	doses	dose	NNS	_	7	nsubjpass
5	will	will	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	required	require	VBN	_	0	ROOT
8	with	with	IN	_	10	case
9	prolonged	prolonged	JJ	_	10	amod
10	administration	administration	NN	_	7	nmod
11	and	and	CC	_	10	cc
12	the	the	DT	_	13	det
13	duration	duration	NN	_	10	conj
14	of	of	IN	_	15	case
15	action	action	NN	_	13	nmod
16	of	of	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	my	my	PRP$	_	20	nsubjpass
19	be	be	VB	_	20	auxpass
20	extended	extend	VBN	_	13	acl:relcl
21	.	.	.	_	7	punct

1	Perioperative	Perioperative	NNP	_	2	compound
2	administration	administration	NN	_	13	nsubj
3	of	of	IN	_	4	case
4	drugs	drug	NNS	_	2	nmod
5	affecting	affect	VBG	_	4	acl
6	hepatic	hepatic	JJ	_	8	amod
7	blood	blood	NN	_	8	compound
8	flow	flow	NN	_	5	dobj
9	or	or	CC	_	8	cc
10	enzyme	enzyme	NN	_	11	compound
11	function	function	NN	_	8	conj
12	may	may	MD	_	13	aux
13	reduce	reduce	VB	_	0	ROOT
14	plasma	plasma	NN	_	15	compound
15	clearance	clearance	NN	_	13	dobj
16	and	and	CC	_	13	cc
17	prolong	prolong	VB	_	13	conj
18	recovery	recovery	NN	_	17	dobj
19	.	.	.	_	13	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	should	should	MD	_	5	aux
3	not	not	RB	_	5	neg
4	be	be	VB	_	5	auxpass
5	administered	administer	VBN	_	0	ROOT
6	concomitantly	concomitantly	RB	_	5	advmod
7	with	with	IN	_	8	case
8	drug2	drug2	NN	_	5	nmod
9	,	,	,	_	8	punct
10	drug3	drug3	NN	_	8	conj
11	,	,	,	_	8	punct
12	drug4	drug4	NN	_	8	conj
13	,	,	,	_	8	punct
14	drug5	drug5	NN	_	8	conj
15	,	,	,	_	8	punct
16	or	or	CC	_	8	cc
17	drug6	drug6	NN	_	8	conj
18	.	.	.	_	5	punct

1	Interactions	interaction	NNS	_	11	nsubjpass
2	between	between	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	other	other	JJ	_	6	amod
6	drugs	drug	NNS	_	3	conj
7	have	have	VBP	_	11	aux
8	not	not	RB	_	11	neg
9	been	be	VBN	_	11	auxpass
10	fully	fully	RB	_	11	advmod
11	evaluated	evaluate	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	Although	although	IN	_	11	mark
2	studies	study	NNS	_	11	nsubjpass
3	designed	design	VBN	_	2	acl
4	to	to	TO	_	5	mark
5	examine	examine	VB	_	3	xcomp
6	drug	drug	NN	_	7	compound
7	interactions	interaction	NNS	_	5	dobj
8	have	have	VBP	_	11	aux
9	not	not	RB	_	11	neg
10	been	be	VBN	_	11	auxpass
11	done	do	VBN	_	15	advcl
12	,	,	,	_	15	punct
13	it	it	PRP	_	15	nsubjpass
14	was	be	VBD	_	15	auxpass
15	noted	note	VBN	_	0	ROOT
16	that	that	IN	_	32	mark
17	drug1	drug1	NN	_	20	compound
18	or	or	CC	_	17	cc
19	drug2	drug2	NN	_	17	conj
20	treatment	treatment	NN	_	32	nsubjpass
21	of	of	IN	_	22	case
22	relapses	relapse	NNS	_	20	nmod
23	for	for	IN	_	24	case
24	periods	period	NNS	_	20	nmod
25	of	of	IN	_	29	case
26	up	up	RB	_	28	dep
27	to	to	TO	_	26	mwe
28	28	28	CD	_	29	nummod
29	days	day	NNS	_	24	nmod
30	has	have	VBZ	_	32	aux
31	been	be	VBN	_	32	auxpass
32	administered	administer	VBN	_	15	ccomp
33	to	to	TO	_	34	case
34	patients	patient	NNS	_	32	nmod
35	-LRB-	-lrb-	-LRB-	_	37	punct
36	N	n	NN	_	37	nsubj
37	=	=	JJ	_	34	dep
38	180	180	CD	_	37	dobj
39	-RRB-	-rrb-	-RRB-	_	37	punct
40	receiving	receive	VBG	_	34	acl
41	drug3	drug3	NN	_	40	dobj
42	.	.	.	_	15	punct

1	drug1	drug1	NN	_	2	compound
2	administration	administration	NN	_	17	nsubj
3	to	to	TO	_	6	case
4	three	three	CD	_	6	nummod
5	cancer	cancer	NN	_	6	compound
6	patients	patient	NNS	_	2	nmod
7	over	over	IN	_	10	case
8	a	a	DT	_	10	det
9	dose	dose	NN	_	10	compound
10	range	range	NN	_	2	nmod
11	of	of	IN	_	13	case
12	0.025	0.025	CD	_	13	nummod
13	mg	mg	NN	_	10	nmod
14	to	to	TO	_	16	case
15	2.2	2.2	CD	_	16	nummod
16	mg	mg	NN	_	10	nmod
17	led	lead	VBD	_	0	ROOT
18	to	to	TO	_	21	case
19	a	a	DT	_	21	det
20	dose-dependent	dose-dependent	JJ	_	21	amod
21	inhibition	inhibition	NN	_	17	nmod
22	of	of	IN	_	24	case
23	drug2	drug2	NN	_	24	compound
24	elimination	elimination	NN	_	21	nmod
25	.14	.14	CD	_	24	nummod
26	The	the	DT	_	27	det
27	effect	effect	NN	_	43	nsubj
28	of	of	IN	_	30	case
29	alternate-day	alternate-day	JJ	_	30	amod
30	administration	administration	NN	_	27	nmod
31	of	of	IN	_	33	case
32	0.25	0.25	CD	_	33	nummod
33	mg	mg	NN	_	30	nmod
34	of	of	IN	_	35	case
35	drug3	drug3	NN	_	33	nmod
36	on	on	IN	_	38	case
37	drug	drug	NN	_	38	compound
38	metabolism	metabolism	NN	_	27	nmod
39	in	in	IN	_	41	case
40	MS	ms	NN	_	41	compound
41	patients	patient	NNS	_	38	nmod
42	is	be	VBZ	_	43	cop
43	unknown	unknown	JJ	_	21	acl:relcl
44	.	.	.	_	17	punct

1	Drug-Drug	Drug-Drug	NNP	_	3	compound
2	Interactions	interaction	NNS	_	3	compound
3	drug1	drug1	NN	_	0	ROOT
4	-	-	:	_	3	punct
5	drug2	drug2	NN	_	8	nsubjpass
6	should	should	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	administered	administer	VBN	_	3	dep
9	with	with	IN	_	10	case
10	caution	caution	NN	_	8	nmod
11	to	to	TO	_	12	case
12	patients	patient	NNS	_	8	nmod
13	being	be	VBG	_	14	auxpass
14	treated	treat	VBN	_	12	acl
15	with	with	IN	_	16	case
16	systemically-administered	systemically-administered	JJ	_	14	nmod
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	oral	oral	JJ	_	16	dep
19	or	or	CC	_	18	cc
20	intravenous	intravenous	JJ	_	18	conj
21	-RRB-	-rrb-	-RRB-	_	18	punct
22	drug3	drug3	NN	_	16	dep
23	-LRB-	-lrb-	-LRB-	_	26	punct
24	or	or	CC	_	26	cc
25	other	other	JJ	_	26	amod
26	drug4	drug4	NN	_	22	appos
27	-RRB-	-rrb-	-RRB-	_	26	punct
28	because	because	IN	_	39	mark
29	the	the	DT	_	30	det
30	action	action	NN	_	39	nsubj
31	of	of	IN	_	32	case
32	drug5	drug5	NN	_	30	nmod
33	on	on	IN	_	36	case
34	the	the	DT	_	36	det
35	cardiovascular	cardiovascular	JJ	_	36	amod
36	system	system	NN	_	30	nmod
37	can	can	MD	_	39	aux
38	be	be	VB	_	39	cop
39	potentiated	potentiated	JJ	_	8	advcl
40	resulting	result	VBG	_	39	xcomp
41	in	in	IN	_	42	case
42	increases	increase	NNS	_	40	nmod
43	in	in	IN	_	45	case
44	heart	heart	NN	_	45	compound
45	rate	rate	NN	_	42	nmod
46	and	and	CC	_	45	cc
47	blood	blood	NN	_	48	compound
48	pressure	pressure	NN	_	45	conj
49	.	.	.	_	3	punct

1	CYP2D6	cyp2d6	NN	_	2	compound
2	inhibitors	inhibitor	NNS	_	0	ROOT
3	-	-	:	_	2	punct
4	drug1	drug1	NN	_	7	nsubjpass
5	is	be	VBZ	_	7	auxpass
6	primarily	primarily	RB	_	7	advmod
7	metabolized	metabolize	VBN	_	2	dep
8	by	by	IN	_	11	case
9	the	the	DT	_	11	det
10	CYP2D6	cyp2d6	NN	_	11	compound
11	pathway	pathway	NN	_	7	nmod
12	to	to	TO	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	.	.	.	_	2	punct

1	In	in	IN	_	2	case
2	EMs	em	NNS	_	0	ROOT
3	,	,	,	_	2	punct
4	selective	selective	JJ	_	5	amod
5	inhibitors	inhibitor	NNS	_	3	root
6	of	of	IN	_	12	case
7	CYP2D6	cyp2d6	NN	_	12	compound
8	increase	increase	NN	_	12	compound
9	drug1	drug1	NN	_	12	compound
10	steady-state	steady-state	JJ	_	12	amod
11	plasma	plasma	NN	_	12	compound
12	concentrations	concentration	NNS	_	5	nmod
13	to	to	TO	_	14	case
14	exposures	exposure	NNS	_	5	nmod
15	similar	similar	JJ	_	14	amod
16	to	to	TO	_	17	case
17	those	those	DT	_	15	nmod
18	observed	observe	VBN	_	17	acl
19	in	in	IN	_	20	case
20	PMs	pm	NNS	_	18	nmod
21	.	.	.	_	5	punct

1	Dosage	dosage	NN	_	2	compound
2	adjustment	adjustment	NN	_	7	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	may	may	MD	_	7	aux
6	be	be	VB	_	7	cop
7	necessary	necessary	JJ	_	0	ROOT
8	when	when	WRB	_	9	advmod
9	coadministered	coadminister	VBN	_	7	advcl
10	with	with	IN	_	12	case
11	CYP2D6	cyp2d6	NN	_	12	compound
12	inhibitors	inhibitor	NNS	_	9	nmod
13	,	,	,	_	9	punct
14	e.g.	e.g.	FW	_	9	dep
15	,	,	,	_	16	punct
16	drug2	drug2	NN	_	14	dep
17	,	,	,	_	16	punct
18	drug3	drug3	NN	_	16	conj
19	,	,	,	_	16	punct
20	and	and	CC	_	16	cc
21	drug4	drug4	NN	_	16	conj
22	.	.	.	_	7	punct

1	In	in	IN	_	3	case
2	EM	em	NN	_	3	compound
3	individuals	individual	NNS	_	16	nmod
4	treated	treat	VBN	_	3	acl
5	with	with	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	or	or	CC	_	6	cc
8	drug2	drug2	NN	_	6	conj
9	,	,	,	_	16	punct
10	the	the	DT	_	11	det
11	AUC	auc	NN	_	16	nsubj
12	of	of	IN	_	13	case
13	drug3	drug3	NN	_	11	nmod
14	is	be	VBZ	_	16	cop
15	approximately	approximately	RB	_	16	advmod
16	6	6	CD	_	0	ROOT
17	-	-	:	_	16	punct
18	to	to	TO	_	19	dep
19	8-fold	8-fold	JJ	_	16	dep
20	and	and	CC	_	19	cc
21	Css	css	NN	_	19	conj
22	,	,	,	_	16	punct
23	max	max	NN	_	26	nsubj
24	is	be	VBZ	_	26	cop
25	about	about	IN	_	26	advmod
26	3	3	CD	_	16	parataxis
27	-	-	:	_	26	punct
28	to	to	TO	_	30	dep
29	4-fold	4-fold	RB	_	30	advmod
30	greater	greater	JJR	_	26	dep
31	than	than	IN	_	32	case
32	drug4	drug4	NN	_	30	nmod
33	alone	alone	RB	_	32	advmod
34	.	.	.	_	16	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	4	nsubj
4	suggest	suggest	VBP	_	0	ROOT
5	that	that	IN	_	15	mark
6	coadministration	coadministration	NN	_	15	nsubj
7	of	of	IN	_	10	case
8	cytochrome	cytochrome	NN	_	10	compound
9	P450	p450	NN	_	10	compound
10	inhibitors	inhibitor	NNS	_	6	nmod
11	to	to	TO	_	12	case
12	PMs	pm	NNS	_	6	nmod
13	will	will	MD	_	15	aux
14	not	not	RB	_	15	neg
15	increase	increase	VB	_	4	ccomp
16	the	the	DT	_	18	det
17	plasma	plasma	NN	_	18	compound
18	concentrations	concentration	NNS	_	15	dobj
19	of	of	IN	_	20	case
20	drug1	drug1	NN	_	18	nmod
21	.	.	.	_	4	punct

1	Pressor	Pressor	NNP	_	2	compound
2	agents	agent	NNS	_	0	ROOT
3	-	-	:	_	7	punct
4	Because	because	IN	_	7	case
5	of	of	IN	_	4	mwe
6	possible	possible	JJ	_	7	amod
7	effects	effect	NNS	_	2	nmod
8	on	on	IN	_	10	case
9	blood	blood	NN	_	10	compound
10	pressure	pressure	NN	_	7	nmod
11	,	,	,	_	7	punct
12	drug1	drug1	NN	_	15	nsubjpass
13	should	should	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	used	use	VBN	_	7	acl:relcl
16	cautiously	cautiously	RB	_	15	advmod
17	with	with	IN	_	19	case
18	pressor	pressor	NN	_	19	compound
19	agents	agent	NNS	_	15	nmod
20	.	.	.	_	2	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	exercised	exercise	VBN	_	0	ROOT
5	when	when	WRB	_	8	advmod
6	drug1	drug1	NN	_	8	nsubjpass
7	are	be	VBP	_	8	auxpass
8	given	give	VBN	_	4	advcl
9	in	in	IN	_	10	case
10	conjunction	conjunction	NN	_	8	nmod
11	with	with	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	.	.	.	_	4	punct

1	Usually	usually	RB	_	10	advmod
2	,	,	,	_	10	punct
3	the	the	DT	_	4	det
4	dosage	dosage	NN	_	10	nsubjpass
5	of	of	IN	_	7	case
6	the	the	DT	_	7	det
7	drug1	drug1	NN	_	4	nmod
8	should	should	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	reduced	reduce	VBN	_	0	ROOT
11	by	by	IN	_	12	case
12	one-half	one-half	NN	_	10	nmod
13	-LRB-	-lrb-	-LRB-	_	18	punct
14	depending	depend	VBG	_	18	case
15	on	on	IN	_	18	case
16	the	the	DT	_	18	det
17	individual	individual	JJ	_	18	amod
18	case	case	NN	_	10	dep
19	-RRB-	-rrb-	-RRB-	_	18	punct
20	to	to	TO	_	21	mark
21	maintain	maintain	VB	_	10	xcomp
22	the	the	DT	_	24	det
23	prothrombin	prothrombin	NN	_	24	compound
24	time	time	NN	_	21	dobj
25	at	at	IN	_	28	case
26	the	the	DT	_	28	det
27	desired	desire	VBN	_	28	amod
28	level	level	NN	_	24	nmod
29	to	to	TO	_	30	mark
30	prevent	prevent	VB	_	24	acl
31	bleeding	bleeding	JJ	_	32	amod
32	complications	complication	NNS	_	30	dobj
33	.	.	.	_	10	punct

1	Frequent	frequent	JJ	_	3	amod
2	prothrombin	prothrombin	NN	_	3	compound
3	determinations	determination	NNS	_	5	nsubj
4	are	be	VBP	_	5	cop
5	advisable	advisable	JJ	_	0	ROOT
6	until	until	IN	_	10	mark
7	it	it	PRP	_	10	nsubjpass
8	has	have	VBZ	_	10	aux
9	been	be	VBN	_	10	auxpass
10	determined	determine	VBN	_	5	advcl
11	definitely	definitely	RB	_	10	advmod
12	that	that	IN	_	18	mark
13	the	the	DT	_	15	det
14	prothrombin	prothrombin	NN	_	15	compound
15	level	level	NN	_	18	nsubjpass
16	has	have	VBZ	_	18	aux
17	been	be	VBN	_	18	auxpass
18	stabilized	stabilize	VBN	_	10	ccomp
19	.	.	.	_	5	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	displace	displace	VB	_	0	ROOT
4	acidic	acidic	JJ	_	5	amod
5	drugs	drug	NNS	_	3	dobj
6	such	such	JJ	_	8	case
7	as	as	IN	_	6	mwe
8	drug2	drug2	NN	_	5	nmod
9	or	or	CC	_	8	cc
10	drug3	drug3	NN	_	8	conj
11	from	from	IN	_	14	case
12	their	they	PRP$	_	14	nmod:poss
13	binding	binding	NN	_	14	amod
14	sites	site	NNS	_	3	nmod
15	.	.	.	_	3	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	exercised	exercise	VBN	_	0	ROOT
5	when	when	WRB	_	6	advmod
6	treating	treat	VBG	_	4	advcl
7	patients	patient	NNS	_	6	dobj
8	with	with	IN	_	9	case
9	either	either	DT	_	7	nmod
10	of	of	IN	_	12	case
11	these	these	DT	_	12	det
12	drugs	drug	NNS	_	9	nmod
13	or	or	CC	_	12	cc
14	other	other	JJ	_	17	amod
15	highly	highly	RB	_	16	advmod
16	protein-bound	protein-bound	JJ	_	17	amod
17	drugs	drug	NNS	_	12	conj
18	and	and	CC	_	17	cc
19	drug1	drug1	NN	_	17	conj
20	.	.	.	_	4	punct

1	The	the	DT	_	3	det
2	hypoglycemic	hypoglycemic	JJ	_	3	amod
3	effect	effect	NN	_	8	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	has	have	VBZ	_	8	aux
7	been	be	VBN	_	8	auxpass
8	reported	report	VBN	_	0	ROOT
9	to	to	TO	_	10	mark
10	increase	increase	VB	_	8	xcomp
11	when	when	WRB	_	14	advmod
12	drug2	drug2	NN	_	14	nsubjpass
13	is	be	VBZ	_	14	auxpass
14	given	give	VBN	_	10	advcl
15	concurrently	concurrently	RB	_	14	advmod
16	.	.	.	_	8	punct

1	Fulminant	fulminant	JJ	_	2	amod
2	rhabdomyolysis	rhabdomyolysis	NN	_	5	nsubjpass
3	has	have	VBZ	_	5	aux
4	been	be	VBN	_	5	auxpass
5	seen	see	VBN	_	0	ROOT
6	as	as	IN	_	7	advmod
7	early	early	JJ	_	5	advcl
8	as	as	IN	_	10	case
9	three	three	CD	_	10	nummod
10	weeks	week	NNS	_	7	nmod
11	after	after	IN	_	10	case
12	initiation	initiation	NN	_	10	dep
13	of	of	IN	_	15	case
14	combined	combined	JJ	_	15	amod
15	therapy	therapy	NN	_	12	nmod
16	with	with	IN	_	18	case
17	another	another	DT	_	18	det
18	drug1	drug1	NN	_	12	nmod
19	and	and	CC	_	18	cc
20	drug2	drug2	NN	_	18	conj
21	but	but	CC	_	5	cc
22	may	may	MD	_	24	aux
23	be	be	VB	_	24	auxpass
24	seen	see	VBN	_	5	conj
25	after	after	IN	_	27	case
26	several	several	JJ	_	27	amod
27	months	month	NNS	_	24	nmod
28	.	.	.	_	5	punct

1	For	for	IN	_	3	case
2	these	these	DT	_	3	det
3	reasons	reason	NNS	_	7	nmod
4	,	,	,	_	7	punct
5	it	it	PRP	_	7	nsubjpass
6	is	be	VBZ	_	7	auxpass
7	felt	feel	VBN	_	0	ROOT
8	that	that	IN	_	38	mark
9	,	,	,	_	38	punct
10	in	in	IN	_	12	case
11	most	most	JJS	_	12	amod
12	subjects	subject	NNS	_	38	nmod
13	who	who	WP	_	15	nsubj
14	have	have	VBP	_	15	aux
15	had	have	VBD	_	12	acl:relcl
16	an	a	DT	_	19	det
17	unsatisfactory	unsatisfactory	JJ	_	19	amod
18	lipid	lipid	NN	_	19	compound
19	response	response	NN	_	15	dobj
20	to	to	TO	_	22	case
21	either	either	CC	_	22	det
22	drug	drug	NN	_	19	nmod
23	alone	alone	RB	_	22	advmod
24	,	,	,	_	38	punct
25	the	the	DT	_	27	det
26	possible	possible	JJ	_	27	amod
27	benefits	benefit	NNS	_	38	nsubj
28	of	of	IN	_	30	case
29	combined	combined	JJ	_	30	amod
30	therapy	therapy	NN	_	27	nmod
31	with	with	IN	_	32	case
32	drug1	drug1	NN	_	30	nmod
33	and	and	CC	_	32	cc
34	a	a	DT	_	35	det
35	drug2	drug2	NN	_	32	conj
36	do	do	VBP	_	38	aux
37	not	not	RB	_	38	neg
38	outweigh	outweigh	VB	_	7	ccomp
39	the	the	DT	_	40	det
40	risks	risk	NNS	_	38	dobj
41	of	of	IN	_	43	case
42	severe	severe	JJ	_	43	amod
43	myopathy	myopathy	NN	_	40	nmod
44	,	,	,	_	43	punct
45	rhabdomyolysis	rhabdomyolysis	NN	_	43	conj
46	,	,	,	_	43	punct
47	and	and	CC	_	43	cc
48	acute	acute	JJ	_	50	amod
49	renal	renal	JJ	_	50	amod
50	failure	failure	NN	_	43	conj
51	.	.	.	_	7	punct

1	While	while	IN	_	5	mark
2	it	it	PRP	_	5	nsubjpass
3	is	be	VBZ	_	5	auxpass
4	not	not	RB	_	5	neg
5	known	know	VBN	_	22	csubjpass
6	whether	whether	IN	_	9	mark
7	this	this	DT	_	8	det
8	interaction	interaction	NN	_	9	nsubj
9	occurs	occur	VBZ	_	5	ccomp
10	with	with	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	other	other	JJ	_	11	amod
13	than	than	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	,	,	,	_	14	punct
16	myopathy	myopathy	NN	_	14	conj
17	and	and	CC	_	14	cc
18	rhabdomyolysis	rhabdomyolysis	NN	_	14	conj
19	have	have	VBP	_	22	aux
20	occasionally	occasionally	RB	_	22	advmod
21	been	be	VBN	_	22	auxpass
22	associated	associate	VBN	_	0	ROOT
23	with	with	IN	_	25	case
24	the	the	DT	_	25	det
25	use	use	NN	_	22	nmod
26	of	of	IN	_	27	case
27	drug3	drug3	NN	_	25	nmod
28	alone	alone	RB	_	27	advmod
29	,	,	,	_	27	punct
30	including	include	VBG	_	31	case
31	drug4	drug4	NN	_	27	nmod
32	.	.	.	_	22	punct

1	Therefore	therefore	RB	_	13	advmod
2	,	,	,	_	13	punct
3	the	the	DT	_	5	det
4	combined	combine	VBN	_	5	amod
5	use	use	NN	_	13	nsubjpass
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	with	with	IN	_	9	case
9	drug2	drug2	NN	_	5	nmod
10	should	should	MD	_	13	aux
11	generally	generally	RB	_	13	advmod
12	be	be	VB	_	13	auxpass
13	avoided	avoid	VBN	_	0	ROOT
14	.	.	.	_	13	punct

1	Drug	drug	NN	_	2	compound
2	Interactions	interaction	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	drug1	drug1	NN	_	6	nsubj
5	may	may	MD	_	6	aux
6	interact	interact	VB	_	2	dep
7	with	with	IN	_	9	case
8	some	some	DT	_	9	det
9	drugs	drug	NNS	_	6	nmod
10	,	,	,	_	9	punct
11	like	like	IN	_	12	case
12	drug2	drug2	NN	_	9	nmod
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	drug3	drug3	NN	_	12	appos
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	:	:	:	_	6	punct
17	drug4	drug4	NN	_	20	nsubj
18	could	could	MD	_	20	aux
19	theoretically	theoretically	RB	_	20	advmod
20	affect	affect	VB	_	6	parataxis
21	drug5	drug5	NN	_	22	compound
22	pharmacodynamics	pharmacodynamic	NNS	_	20	dobj
23	-	-	:	_	20	punct
24	drug6	drug6	SYM	_	26	dep
25	-	-	:	_	26	punct
26	Eproxindine	eproxindine	NN	_	20	dep
27	-	-	:	_	26	punct
28	drug7	drug7	NN	_	26	dep
29	:	:	:	_	26	punct
30	drug8	drug8	NN	_	33	nsubj
31	and	and	CC	_	30	cc
32	drug9	drug9	NN	_	30	conj
33	cause	cause	VBP	_	26	parataxis
34	additive	additive	JJ	_	36	amod
35	CNS	cns	NN	_	36	compound
36	depression	depression	NN	_	33	dobj
37	-	-	:	_	36	punct
38	drug10	drug10	NN	_	36	dep
39	:	:	:	_	33	punct
40	drug11	drug11	NN	_	41	nsubj
41	increases	increase	VBZ	_	33	parataxis
42	the	the	DT	_	43	det
43	effect	effect	NN	_	41	dobj
44	of	of	IN	_	45	case
45	drug12	drug12	NN	_	43	nmod

1	The	the	DT	_	3	det
2	vasodilating	vasodilating	JJ	_	3	amod
3	effects	effect	NNS	_	8	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	cop
8	additive	additive	JJ	_	0	ROOT
9	with	with	IN	_	10	case
10	those	those	DT	_	8	nmod
11	of	of	IN	_	13	case
12	other	other	JJ	_	13	amod
13	drug2	drug2	NN	_	10	nmod
14	.	.	.	_	8	punct

1	drug1	drug1	NN	_	8	nsubjpass
2	,	,	,	_	8	punct
3	in	in	IN	_	4	case
4	particular	particular	JJ	_	8	nmod
5	,	,	,	_	8	punct
6	has	have	VBZ	_	8	aux
7	been	be	VBN	_	8	auxpass
8	found	find	VBN	_	0	ROOT
9	to	to	TO	_	10	mark
10	exhibit	exhibit	VB	_	8	xcomp
11	additive	additive	JJ	_	12	amod
12	effects	effect	NNS	_	10	dobj
13	of	of	IN	_	15	case
14	this	this	DT	_	15	det
15	variety	variety	NN	_	12	nmod
16	.	.	.	_	8	punct

1	Marked	marked	JJ	_	4	amod
2	symptomatic	symptomatic	JJ	_	4	amod
3	orthostatic	orthostatic	JJ	_	4	amod
4	hypotension	hypotension	NN	_	7	nsubjpass
5	has	have	VBZ	_	7	aux
6	been	be	VBN	_	7	auxpass
7	reported	report	VBN	_	0	ROOT
8	when	when	WRB	_	14	advmod
9	drug1	drug1	NN	_	12	compound
10	and	and	CC	_	9	cc
11	organic	organic	JJ	_	9	conj
12	drug2	drug2	NN	_	14	nsubjpass
13	were	be	VBD	_	14	auxpass
14	used	use	VBN	_	7	advcl
15	in	in	IN	_	16	case
16	combination	combination	NN	_	14	nmod
17	.	.	.	_	7	punct

1	Dose	dose	NN	_	2	compound
2	adjustments	adjustment	NNS	_	10	nsubj
3	of	of	IN	_	5	case
4	either	either	CC	_	5	det
5	class	class	NN	_	2	nmod
6	of	of	IN	_	7	case
7	agents	agent	NNS	_	5	nmod
8	may	may	MD	_	10	aux
9	be	be	VB	_	10	cop
10	necessary	necessary	JJ	_	0	ROOT
11	.	.	.	_	10	punct

1	In	in	IN	_	3	case
2	clinical	clinical	JJ	_	3	amod
3	studies	study	NNS	_	33	nmod
4	performed	perform	VBN	_	3	acl
5	with	with	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	,	,	,	_	33	punct
8	the	the	DT	_	10	det
9	concomitant	concomitant	JJ	_	10	amod
10	use	use	NN	_	33	nsubj
11	of	of	IN	_	13	case
12	oral	oral	JJ	_	13	amod
13	drug2	drug2	NN	_	10	nmod
14	-LRB-	-lrb-	-LRB-	_	15	punct
15	drug3	drug3	NN	_	13	appos
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	,	,	,	_	13	punct
18	drug4	drug4	NN	_	13	conj
19	-LRB-	-lrb-	-LRB-	_	20	punct
20	drug5	drug5	NN	_	18	appos
21	-RRB-	-rrb-	-RRB-	_	20	punct
22	,	,	,	_	13	punct
23	drug6	drug6	NN	_	13	conj
24	-LRB-	-lrb-	-LRB-	_	25	punct
25	drug7	drug7	NN	_	23	appos
26	-RRB-	-rrb-	-RRB-	_	25	punct
27	,	,	,	_	13	punct
28	and	and	CC	_	13	cc
29	drug8	drug8	NN	_	13	conj
30	did	do	VBD	_	33	aux
31	not	not	RB	_	33	neg
32	significantly	significantly	RB	_	33	advmod
33	affect	affect	VB	_	0	ROOT
34	the	the	DT	_	35	det
35	pharmacokinetics/pharmacodynamics	pharmacokinetics/pharmacodynamics	NNS	_	33	dobj
36	of	of	IN	_	37	case
37	drug9	drug9	NN	_	35	nmod
38	.	.	.	_	33	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	6	nmod
3	,	,	,	_	6	punct
4	drug1	drug1	NN	_	6	nsubj
5	neither	neither	CC	_	6	advmod
6	influenced	influence	VBD	_	0	ROOT
7	the	the	DT	_	8	det
8	pharmacodynamics	pharmacodynamic	NNS	_	6	dobj
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	,	,	,	_	10	punct
12	drug3	drug3	NN	_	10	conj
13	,	,	,	_	10	punct
14	drug4	drug4	NN	_	10	conj
15	,	,	,	_	10	punct
16	and	and	CC	_	10	cc
17	drug5	drug5	NN	_	10	conj
18	,	,	,	_	6	punct
19	nor	nor	CC	_	6	cc
20	the	the	DT	_	21	det
21	pharmacokinetics	pharmacokinetic	NNS	_	6	conj
22	of	of	IN	_	23	case
23	drug6	drug6	NN	_	21	nmod
24	at	at	IN	_	26	case
25	steady	steady	JJ	_	26	amod
26	state	state	NN	_	21	nmod
27	.	.	.	_	6	punct

1	Agents	agent	NNS	_	11	nsubjpass
2	that	that	WDT	_	4	nsubj
3	may	may	MD	_	4	aux
4	enhance	enhance	VB	_	1	acl:relcl
5	the	the	DT	_	6	det
6	risk	risk	NN	_	4	dobj
7	of	of	IN	_	8	case
8	hemorrhage	hemorrhage	NN	_	6	nmod
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	discontinued	discontinue	VBN	_	0	ROOT
12	prior	prior	RB	_	11	advmod
13	to	to	TO	_	14	case
14	initiation	initiation	NN	_	12	nmod
15	of	of	IN	_	17	case
16	drug1	drug1	NN	_	17	compound
17	therapy	therapy	NN	_	14	nmod
18	.	.	.	_	11	punct

1	If	if	IN	_	4	mark
2	co-administration	co-administration	NN	_	4	nsubj
3	is	be	VBZ	_	4	cop
4	essential	essential	JJ	_	10	advcl
5	,	,	,	_	10	punct
6	close	close	JJ	_	7	amod
7	monitoring	monitoring	NN	_	10	nsubj
8	may	may	MD	_	10	aux
9	be	be	VB	_	10	cop
10	appropriate	appropriate	JJ	_	0	ROOT
11	.	.	.	_	10	punct

1	In	in	IN	_	5	case
2	an	a	DT	_	5	det
3	in	in	FW	_	5	amod
4	vitro	vitro	FW	_	3	dep
5	study	study	NN	_	31	nmod
6	in	in	IN	_	9	case
7	human	human	JJ	_	9	amod
8	liver	liver	NN	_	9	compound
9	microsomes	microsome	NNS	_	5	nmod
10	,	,	,	_	31	punct
11	inhibition	inhibition	NN	_	31	nsubj
12	of	of	IN	_	14	case
13	CYP2A6	cyp2a6	NN	_	14	compound
14	hydroxylation	hydroxylation	NN	_	11	nmod
15	of	of	IN	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	by	by	IN	_	18	case
18	drug2	drug2	NN	_	11	nmod
19	-LRB-	-lrb-	-LRB-	_	23	punct
20	200	200	CD	_	23	nummod
21	m	m	NN	_	23	compound
22	m	m	NN	_	23	compound
23	M	m	NN	_	18	dep
24	i.e.	i.e.	FW	_	23	dep
25	,	,	,	_	23	punct
26	350	350	CD	_	27	nummod
27	mg/L	mg/l	NN	_	23	appos
28	-RRB-	-rrb-	-RRB-	_	23	punct
29	was	be	VBD	_	31	cop
30	17-28	17-28	CD	_	31	nummod
31	%	%	NN	_	0	ROOT
32	.	.	.	_	31	punct

1	Inhibition	inhibition	NN	_	24	nsubj
2	of	of	IN	_	5	case
3	the	the	DT	_	5	det
4	other	other	JJ	_	5	amod
5	isozymes	isozyme	NNS	_	1	nmod
6	evaluated	evaluate	VBN	_	5	acl
7	-LRB-	-lrb-	-LRB-	_	9	punct
8	CYPs	cyp	NNS	_	9	compound
9	2A1	2a1	NN	_	5	dep
10	,	,	,	_	9	punct
11	2C9	2c9	NN	_	9	conj
12	,	,	,	_	9	punct
13	2C19	2c19	NN	_	9	conj
14	,	,	,	_	9	punct
15	2D6	2d6	NN	_	9	conj
16	,	,	,	_	9	punct
17	3A4	3a4	NN	_	9	conj
18	,	,	,	_	9	punct
19	and	and	CC	_	9	cc
20	3E1	3e1	NN	_	9	conj
21	-RRB-	-rrb-	-RRB-	_	9	punct
22	was	be	VBD	_	24	cop
23	0-16	0-16	CD	_	24	nummod
24	%	%	NN	_	0	ROOT
25	.	.	.	_	24	punct

1	Since	since	IN	_	6	mark
2	drug1	drug1	NN	_	6	nsubj
3	does	do	VBZ	_	6	aux
4	not	not	RB	_	6	neg
5	markedly	markedly	RB	_	6	advmod
6	inhibit	inhibit	VB	_	30	advcl
7	CYP450s	cyp450s	NN	_	6	dobj
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	CYP1A2	cyp1a2	NN	_	7	dep
10	,	,	,	_	9	punct
11	CYP2A6	cyp2a6	NN	_	9	conj
12	,	,	,	_	9	punct
13	CYP2C9	cyp2c9	NN	_	9	conj
14	,	,	,	_	9	punct
15	CYP2C19	cyp2c19	NN	_	9	conj
16	,	,	,	_	9	punct
17	CYP2D6	cyp2d6	NN	_	9	conj
18	,	,	,	_	9	punct
19	CYP2E1	cyp2e1	NN	_	9	conj
20	,	,	,	_	9	punct
21	or	or	CC	_	9	cc
22	CYP3A4	cyp3a4	NN	_	9	conj
23	-RRB-	-rrb-	-RRB-	_	9	punct
24	in	in	FW	_	25	compound
25	vitro	vitro	FW	_	6	advmod
26	,	,	,	_	30	punct
27	drug2	drug2	NN	_	30	nsubjpass
28	is	be	VBZ	_	30	auxpass
29	not	not	RB	_	30	neg
30	expected	expect	VBN	_	0	ROOT
31	to	to	TO	_	33	mark
32	significantly	significantly	RB	_	33	advmod
33	interact	interact	VB	_	30	xcomp
34	with	with	IN	_	36	case
35	other	other	JJ	_	36	amod
36	drugs	drug	NNS	_	33	nmod
37	in	in	FW	_	38	compound
38	vivo	vivo	FW	_	33	advmod
39	by	by	IN	_	40	case
40	inhibition	inhibition	NN	_	33	nmod
41	of	of	IN	_	42	case
42	metabolism	metabolism	NN	_	40	nmod
43	mediated	mediate	VBN	_	42	acl
44	by	by	IN	_	46	case
45	these	these	DT	_	46	det
46	isozymes	isozyme	NNS	_	43	nmod
47	.	.	.	_	30	punct

1	Since	since	IN	_	5	mark
2	drug1	drug1	NN	_	5	nsubj
3	does	do	VBZ	_	5	aux
4	not	not	RB	_	5	neg
5	bind	bind	VB	_	21	advcl
6	significantly	significantly	RB	_	5	advmod
7	to	to	TO	_	9	case
8	plasma	plasma	NN	_	9	compound
9	proteins	protein	NNS	_	5	nmod
10	other	other	JJ	_	9	amod
11	than	than	IN	_	12	case
12	ATIII	atiii	NN	_	10	nmod
13	,	,	,	_	21	punct
14	no	no	DT	_	16	neg
15	drug	drug	NN	_	16	compound
16	interactions	interaction	NNS	_	21	nsubjpass
17	by	by	IN	_	19	case
18	protein-binding	protein-binding	JJ	_	19	amod
19	displacement	displacement	NN	_	16	nmod
20	are	be	VBP	_	21	auxpass
21	expected	expect	VBN	_	0	ROOT
22	.	.	.	_	21	punct

1	Prospective	prospective	JJ	_	2	amod
2	studies	study	NNS	_	16	nsubjpass
3	on	on	IN	_	5	case
4	the	the	DT	_	5	det
5	potential	potential	NN	_	2	nmod
6	for	for	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	to	to	TO	_	9	mark
9	interact	interact	VB	_	5	acl
10	with	with	IN	_	12	case
11	other	other	JJ	_	12	amod
12	drugs	drug	NNS	_	9	nmod
13	have	have	VBP	_	16	aux
14	not	not	RB	_	16	neg
15	been	be	VBN	_	16	auxpass
16	performed	perform	VBN	_	0	ROOT
17	.	.	.	_	16	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	use	use	NN	_	13	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	other	other	JJ	_	8	amod
7	myelosuppressive	myelosuppressive	JJ	_	8	amod
8	agents	agent	NNS	_	4	conj
9	or	or	CC	_	8	cc
10	radiation	radiation	NN	_	11	compound
11	therapy	therapy	NN	_	8	conj
12	may	may	MD	_	13	aux
13	increase	increase	VB	_	0	ROOT
14	the	the	DT	_	15	det
15	likelihood	likelihood	NN	_	13	dobj
16	of	of	IN	_	19	case
17	bone	bone	NN	_	19	compound
18	marrow	marrow	NN	_	19	compound
19	depression	depression	NN	_	15	nmod
20	or	or	CC	_	19	cc
21	other	other	JJ	_	23	amod
22	adverse	adverse	JJ	_	23	amod
23	events	event	NNS	_	19	conj
24	.	.	.	_	13	punct

1	Since	since	IN	_	4	mark
2	drug1	drug1	NN	_	4	nsubj
3	may	may	MD	_	4	aux
4	raise	raise	VB	_	17	advcl
5	the	the	DT	_	9	det
6	serum	serum	NN	_	9	compound
7	uric	uric	JJ	_	9	amod
8	acid	acid	NN	_	9	compound
9	level	level	NN	_	4	dobj
10	,	,	,	_	17	punct
11	dosage	dosage	NN	_	12	compound
12	adjustment	adjustment	NN	_	17	nsubj
13	of	of	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	may	may	MD	_	17	aux
16	be	be	VB	_	17	cop
17	necessary	necessary	JJ	_	0	ROOT

1	.	.	.	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	drug1	drug1	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	oral	oral	JJ	_	1	dep

1	-LRB-	-lrb-	-LRB-	_	5	punct
2	Effects	effect	NNS	_	5	nsubjpass
3	may	may	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	decreased	decrease	VBN	_	0	ROOT
6	when	when	WRB	_	7	advmod
7	used	use	VBN	_	5	advcl
8	concurrently	concurrently	RB	_	7	advmod
9	with	with	IN	_	10	case
10	drug1	drug1	NN	_	7	nmod
11	;	;	:	_	5	punct

1	dosage	dosage	NN	_	2	compound
2	adjustments	adjustment	NNS	_	5	nsubj
3	may	may	MD	_	5	aux
4	be	be	VB	_	5	cop
5	necessary	necessary	JJ	_	0	ROOT
6	.	.	.	_	5	punct
7	-RRB-	-rrb-	-RRB-	_	5	punct

1	drug1	drug1	NN	_	0	ROOT

1	-LRB-	-lrb-	-LRB-	_	4	punct
2	drug1	drug1	NN	_	4	nsubj
3	may	may	MD	_	4	aux
4	raise	raise	VB	_	0	ROOT
5	the	the	DT	_	6	det
6	level	level	NN	_	4	dobj
7	of	of	IN	_	10	case
8	blood	blood	NN	_	10	compound
9	uric	uric	JJ	_	10	amod
10	acid	acid	NN	_	6	nmod
11	;	;	:	_	4	punct

1	dosage	dosage	NN	_	2	compound
2	adjustment	adjustment	NN	_	7	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	may	may	MD	_	7	aux
6	be	be	VB	_	7	cop
7	necessary	necessary	JJ	_	0	ROOT
8	to	to	TO	_	9	mark
9	control	control	VB	_	7	xcomp
10	hyperuricemia	hyperuricemia	NN	_	9	dobj
11	and	and	CC	_	10	cc
12	gout	gout	NN	_	10	conj
13	.	.	.	_	7	punct
14	-RRB-	-rrb-	-RRB-	_	7	punct

1	drug1	drug1	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	other	other	JJ	_	6	amod
4	,	,	,	_	6	punct
5	especially	especially	RB	_	6	advmod
6	drug2	drug2	NN	_	1	conj
7	,	,	,	_	1	punct
8	or	or	CC	_	1	cc
9	preanesthetic	preanesthetic	JJ	_	12	amod
10	and	and	CC	_	9	cc
11	drug3	drug3	NN	_	9	conj
12	agents	agent	NNS	_	1	conj
13	used	use	VBN	_	12	acl
14	in	in	IN	_	15	case
15	surgery	surgery	NN	_	13	nmod
16	or	or	CC	_	15	cc
17	drug4	drug4	NN	_	15	conj
18	,	,	,	_	1	punct
19	nondepolarizing	nondepolarizing	JJ	_	1	amod
20	,	,	,	_	1	punct
21	used	use	VBN	_	1	acl
22	in	in	IN	_	23	case
23	surgery	surgery	NN	_	21	nmod

1	-LRB-	-lrb-	-LRB-	_	5	punct
2	Effects	effect	NNS	_	5	nsubjpass
3	may	may	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	potentiated	potentiate	VBN	_	0	ROOT
6	when	when	WRB	_	7	advmod
7	used	use	VBN	_	5	advcl
8	concurrently	concurrently	RB	_	7	advmod
9	with	with	IN	_	10	case
10	drug1	drug1	NN	_	7	nmod
11	;	;	:	_	5	punct

1	dosage	dosage	NN	_	2	compound
2	adjustments	adjustment	NNS	_	5	nsubj
3	may	may	MD	_	5	aux
4	be	be	VB	_	5	cop
5	necessary	necessary	JJ	_	0	ROOT
6	.	.	.	_	5	punct
7	-RRB-	-rrb-	-RRB-	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	or	or	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	or	or	CC	_	3	cc
5	drug3	drug3	NN	_	3	conj
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	drug4	drug4	NN	_	5	appos
8	-RRB-	-rrb-	-RRB-	_	7	punct

1	-LRB-	-lrb-	-LRB-	_	7	punct
2	Concurrent	concurrent	JJ	_	3	amod
3	use	use	NN	_	7	nsubj
4	with	with	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	may	may	MD	_	7	aux
7	intensify	intensify	VB	_	0	ROOT
8	electrolyte	electrolyte	NN	_	9	compound
9	imbalance	imbalance	NN	_	7	dobj
10	,	,	,	_	9	punct
11	particularly	particularly	RB	_	12	advmod
12	hypokalemia	hypokalemia	NN	_	9	appos
13	.	.	.	_	7	punct
14	-RRB-	-rrb-	-RRB-	_	7	punct

1	drug1	drug1	NN	_	0	ROOT

1	-LRB-	-lrb-	-LRB-	_	7	punct
2	Concurrent	concurrent	JJ	_	3	amod
3	use	use	NN	_	7	nsubj
4	with	with	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	may	may	MD	_	7	aux
7	enhance	enhance	VB	_	0	ROOT
8	the	the	DT	_	9	det
9	possibility	possibility	NN	_	7	dobj
10	of	of	IN	_	12	case
11	drug2	drug2	NN	_	12	compound
12	toxicity	toxicity	NN	_	9	nmod
13	associated	associate	VBN	_	12	acl
14	with	with	IN	_	15	case
15	hypokalemia	hypokalemia	NN	_	13	nmod
16	.	.	.	_	7	punct
17	-RRB-	-rrb-	-RRB-	_	7	punct

1	drug1	drug1	NN	_	0	ROOT

1	-LRB-	-lrb-	-LRB-	_	3	punct
2	May	May	NNP	_	3	nsubj
3	inhibit	inhibit	VBP	_	0	ROOT
4	gastrointestinal	gastrointestinal	JJ	_	5	amod
5	absorption	absorption	NN	_	3	dobj
6	of	of	IN	_	8	case
7	the	the	DT	_	8	det
8	drug1	drug1	NN	_	5	nmod
9	;	;	:	_	3	punct

1	administration	administration	NN	_	3	compound
2	1	1	CD	_	3	nummod
3	hour	hour	NN	_	0	ROOT
4	before	before	IN	_	3	dep
5	or	or	CC	_	4	cc
6	4	4	CD	_	7	nummod
7	hours	hour	NNS	_	11	dep
8	after	after	IN	_	11	mark
9	drug1	drug1	NN	_	11	nsubjpass
10	is	be	VBZ	_	11	auxpass
11	recommended	recommend	VBN	_	4	conj
12	.	.	.	_	3	punct
13	-RRB-	-rrb-	-RRB-	_	3	punct

1	drug1	drug1	NN	_	0	ROOT

1	-LRB-	-lrb-	-LRB-	_	4	punct
2	drug1	drug1	NN	_	4	nsubj
3	may	may	MD	_	4	aux
4	raise	raise	VB	_	0	ROOT
5	blood	blood	NN	_	7	compound
6	glucose	glucose	NN	_	7	compound
7	levels	level	NNS	_	4	dobj
8	;	;	:	_	4	punct

1	for	for	IN	_	3	case
2	adult-onset	adult-onset	JJ	_	3	amod
3	diabetics	diabetic	NNS	_	11	nmod
4	,	,	,	_	11	punct
5	dosage	dosage	NN	_	6	compound
6	adjustment	adjustment	NN	_	11	nsubj
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	may	may	MD	_	11	aux
10	be	be	VB	_	11	cop
11	necessary	necessary	JJ	_	0	ROOT
12	during	during	IN	_	16	case
13	and	and	CC	_	12	cc
14	after	after	IN	_	12	conj
15	drug2	drug2	NN	_	16	compound
16	therapy	therapy	NN	_	11	nmod
17	;	;	:	_	11	punct

1	drug1	drug1	NN	_	2	compound
2	requirements	requirement	NNS	_	5	nsubjpass
3	may	may	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	increased	increase	VBN	_	0	ROOT
6	,	,	,	_	5	punct
7	decreased	decrease	VBN	_	5	conj
8	,	,	,	_	5	punct
9	or	or	CC	_	5	cc
10	unchanged	unchanged	JJ	_	5	conj
11	.	.	.	_	5	punct
12	-RRB-	-rrb-	-RRB-	_	5	punct

1	drug1	drug1	NN	_	2	compound
2	salts	salt	NNS	_	0	ROOT

1	-LRB-	-lrb-	-LRB-	_	8	punct
2	Concurrent	concurrent	JJ	_	3	amod
3	use	use	NN	_	8	nsubjpass
4	with	with	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	is	be	VBZ	_	8	auxpass
7	not	not	RB	_	8	neg
8	recommended	recommend	VBN	_	0	ROOT
9	,	,	,	_	8	punct
10	as	as	IN	_	13	mark
11	they	they	PRP	_	13	nsubj
12	may	may	MD	_	13	aux
13	provoke	provoke	VB	_	8	advcl
14	drug2	drug2	NN	_	15	compound
15	toxicity	toxicity	NN	_	13	dobj
16	because	because	IN	_	20	case
17	of	of	IN	_	16	mwe
18	reduced	reduce	VBN	_	20	amod
19	renal	renal	JJ	_	20	amod
20	clearance	clearance	NN	_	13	nmod
21	.	.	.	_	8	punct
22	-RRB-	-rrb-	-RRB-	_	8	punct

1	drug1	drug1	NN	_	0	ROOT

1	-LRB-	-lrb-	-LRB-	_	5	punct
2	Effectiveness	effectiveness	NN	_	5	nsubjpass
3	may	may	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	decreased	decrease	VBN	_	0	ROOT
6	when	when	WRB	_	7	advmod
7	used	use	VBN	_	5	advcl
8	concurrently	concurrently	RB	_	7	advmod
9	with	with	IN	_	10	case
10	drug1	drug1	NN	_	7	nmod
11	because	because	IN	_	13	case
12	of	of	IN	_	11	mwe
13	alkalinization	alkalinization	NN	_	7	nmod
14	of	of	IN	_	16	case
15	the	the	DT	_	16	det
16	urine	urine	NN	_	13	nmod
17	.	.	.	_	5	punct
18	-RRB-	-rrb-	-RRB-	_	5	punct

1	drug1	drug1	NN	_	0	ROOT

1	-LRB-	-lrb-	-LRB-	_	9	punct
2	In	in	IN	_	4	case
3	some	some	DT	_	4	det
4	patients	patient	NNS	_	9	nmod
5	,	,	,	_	9	punct
6	the	the	DT	_	7	det
7	drug1	drug1	NN	_	9	nsubj
8	can	can	MD	_	9	aux
9	reduce	reduce	VB	_	0	ROOT
10	the	the	DT	_	17	det
11	diuretic	diuretic	JJ	_	17	amod
12	,	,	,	_	11	punct
13	natriuretic	natriuretic	JJ	_	11	conj
14	,	,	,	_	11	punct
15	and	and	CC	_	11	cc
16	antihypertensive	antihypertensive	JJ	_	11	conj
17	effects	effect	NNS	_	9	dobj
18	of	of	IN	_	19	case
19	drug2	drug2	NN	_	17	nmod
20	,	,	,	_	19	punct
21	drug3	drug3	NN	_	19	conj
22	,	,	,	_	19	punct
23	and	and	CC	_	19	cc
24	drug4	drug4	NN	_	19	conj
25	.	.	.	_	9	punct

1	Therefore	therefore	RB	_	15	advmod
2	,	,	,	_	15	punct
3	when	when	WRB	_	8	advmod
4	drug1	drug1	NN	_	8	nsubjpass
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	are	be	VBP	_	8	auxpass
8	used	use	VBN	_	15	advcl
9	concomitantly	concomitantly	RB	_	8	advmod
10	,	,	,	_	15	punct
11	the	the	DT	_	12	det
12	patient	patient	NN	_	15	nsubjpass
13	should	should	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	observed	observe	VBN	_	0	ROOT
16	closely	closely	RB	_	15	advmod
17	to	to	TO	_	18	mark
18	determine	determine	VB	_	15	xcomp
19	if	if	IN	_	27	mark
20	the	the	DT	_	22	det
21	desired	desire	VBN	_	22	amod
22	effect	effect	NN	_	27	nsubjpass
23	of	of	IN	_	25	case
24	the	the	DT	_	25	det
25	drug3	drug3	NN	_	22	nmod
26	is	be	VBZ	_	27	auxpass
27	obtained	obtain	VBN	_	18	advcl
28	.	.	.	_	15	punct
29	-RRB-	-rrb-	-RRB-	_	15	punct

1	drug1	drug1	NN	_	0	ROOT

1	-LRB-	-lrb-	-LRB-	_	4	punct
2	drug1	drug1	NN	_	4	nsubj
3	may	may	MD	_	4	aux
4	decrease	decrease	VB	_	0	ROOT
5	arterial	arterial	JJ	_	6	amod
6	responsiveness	responsiveness	NN	_	4	dobj
7	to	to	TO	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	.	.	.	_	4	punct

1	This	this	DT	_	2	det
2	diminution	diminution	NN	_	5	nsubj
3	is	be	VBZ	_	5	cop
4	not	not	RB	_	5	neg
5	sufficient	sufficient	JJ	_	0	ROOT
6	to	to	TO	_	7	mark
7	preclude	preclude	VB	_	5	xcomp
8	effectiveness	effectiveness	NN	_	7	dobj
9	of	of	IN	_	12	case
10	the	the	DT	_	12	det
11	pressor	pressor	NN	_	12	compound
12	agent	agent	NN	_	8	nmod
13	for	for	IN	_	15	case
14	therapeutic	therapeutic	JJ	_	15	amod
15	use	use	NN	_	7	nmod
16	.	.	.	_	5	punct
17	-RRB-	-rrb-	-RRB-	_	5	punct

1	drug1	drug1	NN	_	0	ROOT

1	-LRB-	-lrb-	-LRB-	_	4	punct
2	drug1	drug1	NN	_	4	nsubj
3	may	may	MD	_	4	aux
4	increase	increase	VB	_	0	ROOT
5	the	the	DT	_	6	det
6	responsiveness	responsiveness	NN	_	4	dobj
7	to	to	TO	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	.	.	.	_	4	punct
10	-RRB-	-rrb-	-RRB-	_	4	punct

1	DIAGNOSTIC	diagnostic	JJ	_	2	amod
2	INTERFERENCE	interference	NN	_	0	ROOT
3	With	with	IN	_	6	case
4	expected	expect	VBN	_	6	amod
5	physiologic	physiologic	JJ	_	6	amod
6	effects	effect	NNS	_	2	nmod
7	:	:	:	_	2	punct
8	Blood	blood	NN	_	12	compound
9	and	and	CC	_	8	cc
10	urine	urine	NN	_	8	conj
11	glucose	glucose	NN	_	12	compound
12	levels	level	NNS	_	2	dep
13	-LRB-	-lrb-	-LRB-	_	17	punct
14	usually	usually	RB	_	17	advmod
15	only	only	RB	_	17	advmod
16	in	in	IN	_	17	case
17	patients	patient	NNS	_	12	dep
18	with	with	IN	_	20	case
19	a	a	DT	_	20	det
20	predisposition	predisposition	NN	_	17	nmod
21	for	for	IN	_	23	case
22	glucose	glucose	NN	_	23	compound
23	intolerance	intolerance	NN	_	20	nmod
24	-RRB-	-rrb-	-RRB-	_	17	punct
25	and	and	CC	_	12	cc
26	Serum	serum	NN	_	28	compound
27	bilirubin	bilirubin	NN	_	28	compound
28	levels	level	NNS	_	12	conj
29	-LRB-	-lrb-	-LRB-	_	31	punct
30	by	by	IN	_	31	case
31	displacement	displacement	NN	_	28	nmod
32	from	from	IN	_	34	case
33	albumin	albumin	NN	_	34	compound
34	binding	binding	NN	_	31	nmod
35	-RRB-	-rrb-	-RRB-	_	31	punct
36	and	and	CC	_	12	cc
37	Serum	serum	NN	_	39	compound
38	calcium	calcium	NN	_	39	compound
39	levels	level	NNS	_	12	conj
40	-LRB-	-lrb-	-LRB-	_	41	punct
41	drug1	drug1	NN	_	44	nsubjpass
42	should	should	MD	_	44	aux
43	be	be	VB	_	44	auxpass
44	discontinued	discontinue	VBN	_	39	acl:relcl
45	before	before	IN	_	49	mark
46	parathyroid-function	parathyroid-function	NN	_	47	compound
47	tests	test	NNS	_	49	nsubjpass
48	are	be	VBP	_	49	auxpass
49	carried	carry	VBN	_	44	advcl
50	out	out	RP	_	49	compound:prt
51	-RRB-	-rrb-	-RRB-	_	12	punct
52	and	and	CC	_	12	cc
53	Serum	serum	NN	_	56	compound
54	uric	uric	JJ	_	56	amod
55	acid	acid	NN	_	56	compound
56	levels	level	NNS	_	12	conj
57	-LRB-	-lrb-	-LRB-	_	60	punct
58	may	may	MD	_	60	aux
59	be	be	VB	_	60	auxpass
60	increased	increase	VBN	_	12	dep
61	-RRB-	-rrb-	-RRB-	_	60	punct
62	Serum	serum	NN	_	63	compound
63	magnesium	magnesium	NN	_	12	dep
64	,	,	,	_	63	punct
65	potassium	potassium	NN	_	63	conj
66	,	,	,	_	63	punct
67	and	and	CC	_	63	cc
68	sodium	sodium	NN	_	69	compound
69	levels	level	NNS	_	63	conj
70	-LRB-	-lrb-	-LRB-	_	73	punct
71	may	may	MD	_	73	aux
72	be	be	VB	_	73	auxpass
73	decreased	decrease	VBN	_	63	dep
74	;	;	:	_	2	punct

1	serum	serum	NN	_	3	compound
2	magnesium	magnesium	NN	_	3	compound
3	levels	level	NNS	_	5	nsubj
4	may	may	MD	_	5	aux
5	increase	increase	VB	_	0	ROOT
6	in	in	IN	_	8	case
7	uremic	uremic	JJ	_	8	amod
8	patients	patient	NNS	_	25	nmod
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	Serum	serum	NN	_	12	compound
11	protein-bound	protein-bound	JJ	_	12	amod
12	iodine	iodine	NN	_	16	compound
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	PBI	pbi	NN	_	12	appos
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	levels	level	NNS	_	25	dep
17	-LRB-	-lrb-	-LRB-	_	20	punct
18	may	may	MD	_	20	aux
19	be	be	VB	_	20	auxpass
20	decreased	decrease	VBN	_	25	dep
21	-RRB-	-rrb-	-RRB-	_	20	punct
22	drug1	drug1	NN	_	25	nsubjpass
23	should	should	MD	_	25	aux
24	be	be	VB	_	25	auxpass
25	discontinued	discontinue	VBN	_	5	xcomp
26	before	before	IN	_	27	mark
27	carrying	carry	VBG	_	25	advcl
28	out	out	RP	_	27	compound:prt
29	tests	test	NNS	_	27	dobj
30	for	for	IN	_	32	case
31	parathyroid	parathyroid	JJ	_	32	amod
32	function	function	NN	_	29	nmod
33	.	.	.	_	5	punct

1	Tablets	tablet	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	drug1	drug1	NN	_	9	nsubj
5	,	,	,	_	4	punct
6	including	include	VBG	_	7	case
7	drug2	drug2	NN	_	4	nmod
8	,	,	,	_	4	punct
9	produce	produce	VBP	_	1	dep
10	CNS-depressant	cns-depressant	JJ	_	11	amod
11	effects	effect	NNS	_	9	dobj
12	when	when	WRB	_	13	advmod
13	administered	administer	VBN	_	9	advcl
14	with	with	IN	_	16	case
15	such	such	JJ	_	16	amod
16	medications	medication	NNS	_	13	nmod
17	as	as	IN	_	18	case
18	drug3	drug3	NN	_	16	nmod
19	or	or	CC	_	18	cc
20	drug4	drug4	NN	_	18	conj
21	.	.	.	_	9	punct

1	Injection	injection	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug1	drug1	NN	_	4	compound
4	injection	injection	NN	_	11	nsubj
5	,	,	,	_	4	punct
6	like	like	IN	_	9	case
7	other	other	JJ	_	9	amod
8	injectable	injectable	JJ	_	9	amod
9	drug2	drug2	NN	_	4	nmod
10	,	,	,	_	4	punct
11	produces	produce	VBZ	_	1	dep
12	depression	depression	NN	_	11	dobj
13	of	of	IN	_	17	case
14	the	the	DT	_	17	det
15	central	central	JJ	_	17	amod
16	nervous	nervous	JJ	_	17	amod
17	system	system	NN	_	12	nmod
18	when	when	WRB	_	19	advmod
19	administered	administer	VBN	_	11	advcl
20	with	with	IN	_	21	case
21	drug3	drug3	NN	_	19	nmod
22	,	,	,	_	21	punct
23	drug4	drug4	NN	_	21	conj
24	,	,	,	_	21	punct
25	drug5	drug5	NN	_	21	conj
26	,	,	,	_	21	punct
27	drug6	drug6	NN	_	21	conj
28	,	,	,	_	21	punct
29	and	and	CC	_	21	cc
30	other	other	JJ	_	31	amod
31	drug7	drug7	NN	_	21	conj
32	.	.	.	_	11	punct
33	When	when	WRB	_	36	advmod
34	drug8	drug8	NN	_	36	nsubjpass
35	is	be	VBZ	_	36	auxpass
36	used	use	VBN	_	55	advcl
37	concomitantly	concomitantly	RB	_	36	advmod
38	with	with	IN	_	40	case
39	injectable	injectable	JJ	_	40	amod
40	drug9	drug9	NN	_	36	nmod
41	,	,	,	_	55	punct
42	an	a	DT	_	44	det
43	increased	increase	VBN	_	44	amod
44	incidence	incidence	NN	_	55	nsubjpass
45	of	of	IN	_	46	case
46	sedation	sedation	NN	_	44	nmod
47	,	,	,	_	46	punct
48	hallucinations	hallucination	NNS	_	46	conj
49	,	,	,	_	46	punct
50	and	and	CC	_	46	cc
51	irrational	irrational	JJ	_	52	amod
52	behavior	behavior	NN	_	46	conj
53	has	have	VBZ	_	55	aux
54	been	be	VBN	_	55	auxpass
55	observed	observe	VBN	_	11	parataxis
56	.	.	.	_	1	punct

1	drug1	drug1	NN	_	2	nsubj
2	appears	appear	VBZ	_	0	ROOT
3	to	to	TO	_	4	mark
4	decrease	decrease	VB	_	2	xcomp
5	the	the	DT	_	6	det
6	rate	rate	NN	_	4	dobj
7	at	at	IN	_	8	case
8	which	which	WDT	_	12	nmod
9	certain	certain	JJ	_	10	amod
10	drugs	drug	NNS	_	12	nsubjpass
11	are	be	VBP	_	12	auxpass
12	metabolized	metabolize	VBN	_	6	acl:relcl
13	and	and	CC	_	12	cc
14	therefore	therefore	RB	_	16	advmod
15	may	may	MD	_	16	aux
16	increase	increase	VB	_	12	conj
17	the	the	DT	_	19	det
18	blood	blood	NN	_	19	compound
19	levels	level	NNS	_	16	dobj
20	and	and	CC	_	4	cc
21	the	the	DT	_	22	det
22	possibility	possibility	NN	_	4	conj
23	of	of	IN	_	25	case
24	clinical	clinical	JJ	_	25	amod
25	toxicity	toxicity	NN	_	22	nmod
26	of	of	IN	_	27	case
27	drugs	drug	NNS	_	25	nmod
28	given	give	VBN	_	27	acl
29	concomitantly	concomitantly	RB	_	28	advmod
30	.	.	.	_	2	punct

1	drug1	drug1	NN	_	3	nsubj
2	SHOULD	should	MD	_	3	aux
3	BE	be	VB	_	0	ROOT
4	USED	used	JJ	_	3	xcomp
5	WITH	with	IN	_	6	case
6	CAUTION	caution	NN	_	4	nmod
7	IN	in	IN	_	3	advmod
8	THOSE	those	DT	_	9	det
9	PATIENTS	patient	NNS	_	7	dobj
10	REVEIVING	reveive	VBG	_	9	acl
11	drug2	drug2	NN	_	14	compound
12	AND	and	CC	_	11	cc
13	ITS	its	NNS	_	11	conj
14	CONGENERS	congener	NNS	_	10	dobj
15	.	.	.	_	3	punct

1	SINCE	since	IN	_	4	case
2	THE	the	DT	_	4	det
3	CONCOMITANT	concomitant	JJ	_	4	amod
4	ADMINISTRATION	administration	NN	_	0	ROOT
5	OF	of	IN	_	8	case
6	THESE	these	NN	_	8	compound
7	TWO	two	CD	_	8	nummod
8	DRUGS	drug	NNS	_	4	nmod
9	CAN	can	JJ	_	10	amod
10	LEAD	lead	NN	_	32	nsubj
11	TO	to	TO	_	13	case
12	drug1	drug1	NN	_	13	compound
13	INTOXICATION	intoxication	NN	_	10	nmod
14	,	,	,	_	10	punct
15	PRIOR	PRIOR	NNP	_	10	appos
16	TO	to	TO	_	18	case
17	ADMINISTERING	ADMINISTERING	NNP	_	18	compound
18	drug2	drug2	NN	_	15	nmod
19	TO	to	TO	_	21	case
20	A	a	DT	_	21	det
21	PATIENT	patient	NN	_	15	nmod
22	ON	on	IN	_	24	case
23	drug3	drug3	NN	_	24	compound
24	THERAPY	therapy	NN	_	21	nmod
25	,	,	,	_	10	punct
26	A	a	DT	_	30	det
27	BASELINE	baseline	NN	_	30	compound
28	drug4	drug4	NN	_	30	compound
29	SERUM	serum	NN	_	30	compound
30	LEVEL	level	NN	_	10	appos
31	SHOULD	should	MD	_	32	aux
32	BE	be	VB	_	8	acl:relcl
33	OBTAINED	OBTAINED	NNP	_	32	dobj
34	.	.	.	_	4	punct

1	SUBSEQUENT	subsequent	JJ	_	0	ROOT
2	TO	to	TO	_	1	dep
3	INITIATION	INITIATION	NNP	_	2	dobj
4	OF	of	IN	_	6	case
5	drug1	drug1	NN	_	6	compound
6	THERAPY	therapy	NN	_	3	nmod
7	.	.	.	_	1	punct

1	SERUM	serum	NN	_	2	compound
2	LEVELS	level	NNS	_	7	nsubjpass
3	OF	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	SHOULD	should	MD	_	7	aux
6	BE	be	VB	_	7	auxpass
7	DETERMINED	determine	VBN	_	0	ROOT
8	ON	on	IN	_	10	case
9	DIFFERENT	different	JJ	_	10	amod
10	DAYS	day	NNS	_	7	nmod
11	FOR	for	IN	_	12	case
12	EVIDENCE	evidence	NNS	_	10	nmod
13	OF	of	IN	_	16	case
14	AN	a	DT	_	16	det
15	INCREASE	increase	NN	_	16	compound
16	OR	or	NN	_	12	nmod
17	FOR	for	IN	_	20	case
18	A	a	DT	_	20	det
19	CONTINUING	CONTINUING	NNP	_	20	compound
20	RISE	RISE	NNP	_	16	nmod
21	IN	in	IN	_	22	case
22	LEVELS	LEVELS	NNP	_	20	nmod
23	.	.	.	_	7	punct

1	INCREASED	increase	VBN	_	3	amod
2	drug1	drug1	NN	_	3	compound
3	LEVELS	level	NNS	_	6	nsubjpass
4	SHOULD	should	MD	_	6	aux
5	BE	be	VB	_	6	auxpass
6	TREATED	treat	VBN	_	0	ROOT
7	WITH	with	IN	_	10	case
8	APPROPRIATE	appropriate	JJ	_	10	amod
9	DOSAGE	dosage	NN	_	10	compound
10	ADJUSTMENT	adjustment	NN	_	6	nmod
11	.	.	.	_	6	punct

1	It	it	PRP	_	4	nsubj
2	may	may	MD	_	4	aux
3	be	be	VB	_	4	cop
4	necessary	necessary	JJ	_	0	ROOT
5	to	to	TO	_	6	mark
6	adjust	adjust	VB	_	4	xcomp
7	the	the	DT	_	8	det
8	dosage	dosage	NN	_	6	dobj
9	of	of	IN	_	11	case
10	oral	oral	JJ	_	11	amod
11	drug1	drug1	NN	_	8	nmod
12	upon	upon	IN	_	13	mark
13	beginning	begin	VBG	_	6	advcl
14	or	or	CC	_	13	cc
15	stopping	stop	VBG	_	13	conj
16	drug2	drug2	NN	_	13	dobj
17	.	.	.	_	4	punct
18	since	since	IN	_	21	mark
19	drug3	drug3	NN	_	21	nsubj
20	may	may	MD	_	21	aux
21	prolong	prolong	VB	_	4	advcl
22	prothrombin	prothrombin	NN	_	23	compound
23	time	time	NN	_	21	dobj
24	.	.	.	_	4	punct

1	Patients	patient	NNS	_	10	nsubjpass
2	taking	take	VBG	_	1	acl
3	drug1	drug1	NN	_	2	dobj
4	when	when	WRB	_	7	advmod
5	drug2	drug2	NN	_	7	nsubjpass
6	is	be	VBZ	_	7	auxpass
7	given	give	VBN	_	2	advcl
8	should	should	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	observed	observe	VBN	_	0	ROOT
11	for	for	IN	_	13	case
12	the	the	DT	_	13	det
13	appearance	appearance	NN	_	10	nmod
14	of	of	IN	_	16	case
15	unsteady	unsteady	JJ	_	16	amod
16	gait	gait	NN	_	13	nmod
17	or	or	CC	_	16	cc
18	marked	marked	JJ	_	19	amod
19	changes	change	NNS	_	16	conj
20	in	in	IN	_	22	case
21	mental	mental	JJ	_	22	amod
22	status	status	NN	_	13	nmod
23	;	;	:	_	10	punct

1	the	the	DT	_	2	det
2	drug1	drug1	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	discontinued	discontinue	VBN	_	0	ROOT
6	if	if	IN	_	9	mark
7	such	such	JJ	_	8	amod
8	signs	sign	NNS	_	9	nsubj
9	appear	appear	VBP	_	5	advcl
10	.	.	.	_	5	punct

1	In	in	IN	_	2	case
2	rats	rat	NNS	_	18	nmod
3	,	,	,	_	18	punct
4	simultaneous	simultaneous	JJ	_	5	amod
5	ingestion	ingestion	NN	_	18	nsubjpass
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	in	in	IN	_	12	case
11	the	the	DT	_	12	det
12	diet	diet	NN	_	5	nmod
13	for	for	IN	_	15	case
14	78	78	CD	_	15	nummod
15	weeks	week	NNS	_	5	nmod
16	has	have	VBZ	_	18	aux
17	been	be	VBN	_	18	auxpass
18	reported	report	VBN	_	0	ROOT
19	to	to	TO	_	20	mark
20	cause	cause	VB	_	18	xcomp
21	tumors	tumor	NNS	_	20	dobj
22	,	,	,	_	18	punct
23	and	and	CC	_	18	cc
24	it	it	PRP	_	27	nsubjpass
25	has	have	VBZ	_	27	aux
26	been	be	VBN	_	27	auxpass
27	suggested	suggest	VBN	_	18	conj
28	that	that	IN	_	31	mark
29	drug3	drug3	NN	_	31	nsubj
30	may	may	MD	_	31	aux
31	react	react	VB	_	27	ccomp
32	with	with	IN	_	33	case
33	drug4	drug4	NN	_	31	nmod
34	in	in	IN	_	37	case
35	the	the	DT	_	37	det
36	rat	rat	NN	_	37	compound
37	stomach	stomach	NN	_	33	nmod
38	to	to	TO	_	39	mark
39	form	form	VB	_	31	xcomp
40	a	a	DT	_	41	det
41	nitrosamine	nitrosamine	NN	_	39	dobj
42	,	,	,	_	41	punct
43	which	which	WDT	_	45	nsubj
44	is	be	VBZ	_	45	cop
45	tumorigenic	tumorigenic	JJ	_	41	acl:relcl
46	.	.	.	_	18	punct

1	drug1	drug1	NN	_	10	nsubj
2	alone	alone	RB	_	1	advmod
3	in	in	IN	_	7	case
4	the	the	DT	_	7	det
5	rat	rat	NN	_	7	compound
6	s	be	VBZ	_	7	compound
7	diet	diet	NN	_	1	nmod
8	did	do	VBD	_	10	aux
9	not	not	RB	_	10	neg
10	lead	lead	VB	_	0	ROOT
11	to	to	TO	_	13	case
12	such	such	JJ	_	13	amod
13	tumors	tumor	NNS	_	10	nmod
14	.	.	.	_	10	punct

1	The	the	DT	_	2	det
2	relevance	relevance	NN	_	10	nsubjpass
3	of	of	IN	_	5	case
4	this	this	DT	_	5	det
5	finding	finding	NN	_	2	nmod
6	to	to	TO	_	7	case
7	humans	human	NNS	_	2	nmod
8	is	be	VBZ	_	10	auxpass
9	not	not	RB	_	10	neg
10	known	know	VBN	_	0	ROOT
11	at	at	IN	_	13	case
12	this	this	DT	_	13	det
13	time	time	NN	_	10	nmod
14	.	.	.	_	10	punct

1	Inhibitors	inhibitor	NNS	_	9	nsubjpass
2	of	of	IN	_	3	case
3	CYP3A4	cyp3a4	NN	_	1	nmod
4	-	-	:	_	3	punct
5	drug1	drug1	NN	_	6	compound
6	metabolism	metabolism	NN	_	3	dep
7	is	be	VBZ	_	9	auxpass
8	predominantly	predominantly	RB	_	9	advmod
9	mediated	mediate	VBN	_	0	ROOT
10	via	via	IN	_	11	case
11	CYP3A4	cyp3a4	NN	_	9	nmod
12	.	.	.	_	9	punct

1	A	a	DT	_	3	det
2	pharmacokinetic	pharmacokinetic	JJ	_	3	amod
3	study	study	NN	_	29	nsubj
4	evaluating	evaluate	VBG	_	3	acl
5	the	the	DT	_	6	det
6	administration	administration	NN	_	4	dobj
7	of	of	IN	_	10	case
8	a	a	DT	_	10	det
9	single	single	JJ	_	10	amod
10	dose	dose	NN	_	6	nmod
11	of	of	IN	_	14	case
12	drug1	drug1	NN	_	14	compound
13	100	100	CD	_	14	nummod
14	mg	mg	NN	_	10	nmod
15	with	with	IN	_	18	case
16	drug2	drug2	NN	_	18	compound
17	200	200	CD	_	18	nummod
18	mg	mg	NN	_	4	nmod
19	BID	BID	NNP	_	18	dep
20	,	,	,	_	19	punct
21	a	a	DT	_	23	det
22	potent	potent	JJ	_	23	amod
23	inhibitor	inhibitor	NN	_	19	appos
24	of	of	IN	_	27	case
25	the	the	DT	_	27	det
26	CYP3A4	cyp3a4	NN	_	27	compound
27	pathway	pathway	NN	_	23	nmod
28	,	,	,	_	19	punct
29	showed	show	VBD	_	0	ROOT
30	a	a	DT	_	32	det
31	1.7-fold	1.7-fold	JJ	_	32	amod
32	increase	increase	NN	_	29	dobj
33	in	in	IN	_	34	case
34	Cmax	cmax	NN	_	32	nmod
35	of	of	IN	_	36	case
36	drug3	drug3	NN	_	34	nmod
37	and	and	CC	_	32	cc
38	a	a	DT	_	40	det
39	5.4-fold	5.4-fold	JJ	_	40	amod
40	increase	increase	NN	_	32	conj
41	in	in	IN	_	42	case
42	AUC	auc	NN	_	40	nmod
43	of	of	IN	_	44	case
44	drug4	drug4	NN	_	42	nmod
45	.	.	.	_	29	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	should	should	MD	_	5	aux
3	not	not	RB	_	5	neg
4	be	be	VB	_	5	auxpass
5	used	use	VBN	_	0	ROOT
6	with	with	IN	_	7	case
7	drugs	drug	NNS	_	5	nmod
8	described	describe	VBN	_	7	acl
9	as	as	IN	_	11	case
10	strong	strong	JJ	_	11	amod
11	inhibitors	inhibitor	NNS	_	8	nmod
12	of	of	IN	_	13	case
13	CYP3A4	cyp3a4	NN	_	11	nmod
14	in	in	IN	_	16	case
15	their	they	PRP$	_	16	nmod:poss
16	labeling	labeling	NN	_	11	nmod
17	.	.	.	_	5	punct

1	Administration	administration	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	7	case
5	other	other	JJ	_	7	amod
6	CYP3A4	cyp3a4	NN	_	7	compound
7	inhibitors	inhibitor	NNS	_	1	nmod
8	-LRB-	-lrb-	-LRB-	_	31	punct
9	e.g.	e.g.	FW	_	31	advmod
10	,	,	,	_	31	punct
11	drug2	drug2	NN	_	31	nsubj
12	500	500	CD	_	13	nummod
13	mg	mg	NN	_	11	dep
14	BID	BID	NNP	_	13	dep
15	,	,	,	_	13	punct
16	drug3	drug3	NN	_	19	compound
17	240	240	CD	_	18	compound
18	mg	mg	NN	_	19	amod
19	QD	qd	NN	_	13	appos
20	,	,	,	_	13	punct
21	drug4	drug4	NN	_	24	compound
22	1200	1200	CD	_	24	nummod
23	mg	mg	NN	_	24	compound
24	TID	tid	NN	_	13	appos
25	,	,	,	_	13	punct
26	drug5	drug5	NN	_	29	compound
27	200	200	CD	_	28	compound
28	mg	mg	NN	_	29	amod
29	QD	qd	NN	_	13	appos
30	-RRB-	-rrb-	-RRB-	_	13	punct
31	resulted	result	VBD	_	7	dep
32	in	in	IN	_	33	case
33	increases	increase	NNS	_	31	nmod
34	in	in	IN	_	35	case
35	Cmax	cmax	NN	_	33	nmod
36	of	of	IN	_	37	case
37	drug6	drug6	NN	_	35	nmod
38	ranging	range	VBG	_	37	acl
39	from	from	IN	_	40	case
40	1.4	1.4	CD	_	38	nmod
41	-	-	:	_	40	punct
42	to	to	TO	_	43	dep
43	1.6	1.6	CD	_	40	dep
44	-	-	:	_	43	punct
45	fold	fold	JJ	_	43	dep
46	and	and	CC	_	45	cc
47	AUC	auc	NN	_	45	conj
48	from	from	IN	_	49	case
49	2.0	2.0	CD	_	45	nmod
50	-	-	:	_	43	punct
51	to	to	TO	_	52	dep
52	2.9	2.9	CD	_	43	dep
53	-	-	:	_	43	punct
54	fold	fold	NN	_	43	dep
55	.	.	.	_	1	punct

1	drug1	drug1	NN	_	28	nsubj
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	-LRB-	-lrb-	-LRB-	_	9	punct
5	Congestive	congestive	JJ	_	9	amod
6	Heart	Heart	NNP	_	9	compound
7	Failure	failure	NN	_	9	compound
8	Post-Myocardial	post-myocardial	JJ	_	9	amod
9	Infarction	infarction	NN	_	1	appos
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	-	-	:	_	1	punct
12	In	in	IN	_	13	case
13	EPHESUS	EPHESUS	NNP	_	28	nmod
14	,	,	,	_	13	punct
15	3020	3020	CD	_	20	nummod
16	-LRB-	-lrb-	-LRB-	_	18	punct
17	91	91	CD	_	18	nummod
18	%	%	NN	_	20	appos
19	-RRB-	-rrb-	-RRB-	_	18	punct
20	patients	patient	NNS	_	13	appos
21	receiving	receive	VBG	_	20	acl
22	drug3	drug3	NN	_	26	compound
23	25	25	CD	_	25	compound
24	to	to	TO	_	25	dep
25	50	50	CD	_	26	nummod
26	mg	mg	NN	_	21	dobj
27	also	also	RB	_	28	advmod
28	received	receive	VBD	_	0	ROOT
29	drug4	drug4	NN	_	28	dobj
30	or	or	CC	_	29	cc
31	drug5	drug5	NN	_	29	conj
32	-LRB-	-lrb-	-LRB-	_	33	punct
33	drug6	drug6	NN	_	31	dep
34	/	/	:	_	33	punct
35	drug7	drug7	NN	_	33	dep
36	-RRB-	-rrb-	-RRB-	_	33	punct
37	.	.	.	_	28	punct

1	Rates	rate	NNS	_	11	nsubj
2	of	of	IN	_	3	case
3	patients	patient	NNS	_	1	nmod
4	with	with	IN	_	7	case
5	maximum	maximum	NN	_	7	compound
6	potassium	potassium	NN	_	7	compound
7	levels	level	NNS	_	3	nmod
8	5.5	5.5	CD	_	9	nummod
9	mEq/L	meq/l	NN	_	7	dep
10	were	be	VBD	_	11	cop
11	similar	similar	JJ	_	0	ROOT
12	regardless	regardless	RB	_	11	advmod
13	of	of	IN	_	15	case
14	the	the	DT	_	15	det
15	use	use	NN	_	12	nmod
16	of	of	IN	_	17	case
17	drug1	drug1	NN	_	15	nmod
18	/	/	:	_	17	punct
19	drug2	drug2	NN	_	17	dep
20	.	.	.	_	11	punct

1	drug1	drug1	NN	_	28	nsubj
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	Hypertension	hypertension	NN	_	3	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	-	-	:	_	1	punct
8	In	in	IN	_	10	case
9	clinical	clinical	JJ	_	10	amod
10	studies	study	NNS	_	1	nmod
11	of	of	IN	_	12	case
12	patients	patient	NNS	_	10	nmod
13	with	with	IN	_	14	case
14	hypertension	hypertension	NN	_	12	nmod
15	,	,	,	_	1	punct
16	the	the	DT	_	17	det
17	addition	addition	NN	_	1	appos
18	of	of	IN	_	19	case
19	drug3	drug3	NN	_	17	nmod
20	50	50	CD	_	19	nummod
21	to	to	TO	_	23	case
22	100	100	CD	_	23	nummod
23	mg	mg	NN	_	17	nmod
24	to	to	TO	_	25	case
25	drug4	drug4	NN	_	23	nmod
26	and	and	CC	_	23	cc
27	drug5	drug5	NN	_	23	conj
28	increased	increase	VBD	_	0	ROOT
29	mean	mean	JJ	_	31	amod
30	serum	serum	NN	_	31	compound
31	potassium	potassium	NN	_	28	dobj
32	slightly	slightly	RB	_	31	advmod
33	-LRB-	-lrb-	-LRB-	_	37	punct
34	about	about	IN	_	36	advmod
35	0.09-0	0.09-0	CD	_	36	compound
36	.13	.13	CD	_	37	nummod
37	mEq/L	meq/l	NN	_	31	appos
38	-RRB-	-rrb-	-RRB-	_	37	punct
39	.	.	.	_	28	punct

1	In	in	IN	_	3	case
2	a	a	DT	_	3	det
3	study	study	NN	_	18	nmod
4	in	in	IN	_	5	case
5	diabetics	diabetic	NNS	_	3	nmod
6	with	with	IN	_	10	case
7	microalbuminuria	microalbuminuria	NN	_	10	compound
8	drug1	drug1	NN	_	10	compound
9	200	200	CD	_	10	nummod
10	mg	mg	NN	_	5	nmod
11	combined	combine	VBN	_	10	acl
12	with	with	IN	_	17	case
13	the	the	DT	_	17	det
14	drug2	drug2	NN	_	17	compound
15	drug3	drug3	NN	_	17	compound
16	10	10	CD	_	17	nummod
17	mg	mg	NN	_	11	nmod
18	increased	increase	VBD	_	0	ROOT
19	the	the	DT	_	20	det
20	frequency	frequency	NN	_	18	dobj
21	of	of	IN	_	22	case
22	hyperkalemia	hyperkalemia	NN	_	20	nmod
23	-LRB-	-lrb-	-LRB-	_	25	punct
24	serum	serum	NN	_	25	compound
25	potassium	potassium	NN	_	22	appos
26	5.5	5.5	CD	_	27	nummod
27	mEq/L	meq/l	NN	_	25	dep
28	-RRB-	-rrb-	-RRB-	_	25	punct
29	from	from	IN	_	31	case
30	17	17	CD	_	31	nummod
31	%	%	NN	_	18	nmod
32	on	on	IN	_	33	case
33	drug4	drug4	NN	_	18	nmod
34	alone	alone	RB	_	33	advmod
35	to	to	TO	_	37	case
36	38	38	CD	_	37	nummod
37	%	%	NN	_	18	nmod
38	.	.	.	_	18	punct

1	drug1	drug1	NN	_	0	ROOT
2	-	-	:	_	1	punct
3	A	a	DT	_	6	det
4	drug	drug	NN	_	6	compound
5	interaction	interaction	NN	_	6	compound
6	study	study	NN	_	14	nsubjpass
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	with	with	IN	_	10	case
10	drug3	drug3	NN	_	8	nmod
11	has	have	VBZ	_	14	aux
12	not	not	RB	_	14	neg
13	been	be	VBN	_	14	auxpass
14	conducted	conduct	VBN	_	1	dep
15	.	.	.	_	1	punct

1	Serum	serum	NN	_	3	compound
2	drug1	drug1	NN	_	3	compound
3	levels	level	NNS	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	monitored	monitor	VBN	_	0	ROOT
7	frequently	frequently	RB	_	6	advmod
8	if	if	IN	_	11	mark
9	drug2	drug2	NN	_	11	nsubjpass
10	is	be	VBZ	_	11	auxpass
11	administered	administer	VBN	_	6	advcl
12	concomitantly	concomitantly	RB	_	11	advmod
13	with	with	IN	_	14	case
14	drug3	drug3	NN	_	11	nmod
15	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	drug2	drug2	NN	_	1	appos
4	-RRB-	-rrb-	-RRB-	_	3	punct
5	-	-	:	_	1	punct
6	A	a	DT	_	9	det
7	drug	drug	NN	_	9	compound
8	interaction	interaction	NN	_	9	compound
9	study	study	NN	_	18	nsubjpass
10	of	of	IN	_	11	case
11	drug3	drug3	NN	_	9	nmod
12	with	with	IN	_	14	case
13	an	a	DT	_	14	det
14	drug4	drug4	NN	_	11	nmod
15	has	have	VBZ	_	18	aux
16	not	not	RB	_	18	neg
17	been	be	VBN	_	18	auxpass
18	conducted	conduct	VBN	_	1	dep
19	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	administration	administration	NN	_	10	nsubjpass
3	of	of	IN	_	5	case
4	other	other	JJ	_	5	amod
5	drug1	drug1	NN	_	2	nmod
6	with	with	IN	_	7	case
7	drug2	drug2	NN	_	2	nmod
8	has	have	VBZ	_	10	aux
9	been	be	VBN	_	10	auxpass
10	shown	show	VBN	_	0	ROOT
11	to	to	TO	_	12	mark
12	reduce	reduce	VB	_	10	xcomp
13	the	the	DT	_	15	det
14	antihypertensive	antihypertensive	JJ	_	15	amod
15	effect	effect	NN	_	12	dobj
16	in	in	IN	_	18	case
17	some	some	DT	_	18	det
18	patients	patient	NNS	_	15	nmod
19	and	and	CC	_	10	cc
20	result	result	VBP	_	10	conj
21	in	in	IN	_	23	case
22	severe	severe	JJ	_	23	amod
23	hyperkalemia	hyperkalemia	NN	_	20	nmod
24	in	in	IN	_	25	case
25	patients	patient	NNS	_	23	nmod
26	with	with	IN	_	29	case
27	impaired	impaired	JJ	_	29	amod
28	renal	renal	JJ	_	29	amod
29	function	function	NN	_	25	nmod
30	.	.	.	_	10	punct

1	Therefore	therefore	RB	_	14	advmod
2	,	,	,	_	14	punct
3	when	when	WRB	_	8	advmod
4	drug1	drug1	NN	_	8	nsubjpass
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	are	be	VBP	_	8	auxpass
8	used	use	VBN	_	14	advcl
9	concomitantly	concomitantly	RB	_	8	advmod
10	,	,	,	_	14	punct
11	patients	patient	NNS	_	14	nsubjpass
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	observed	observe	VBN	_	0	ROOT
15	to	to	TO	_	16	mark
16	determine	determine	VB	_	14	xcomp
17	whether	whether	IN	_	25	mark
18	the	the	DT	_	20	det
19	desired	desire	VBN	_	20	amod
20	effect	effect	NN	_	25	nsubjpass
21	on	on	IN	_	23	case
22	blood	blood	NN	_	23	compound
23	pressure	pressure	NN	_	20	nmod
24	is	be	VBZ	_	25	auxpass
25	obtained	obtain	VBN	_	16	ccomp
26	.	.	.	_	14	punct

1	Tissue	tissue	NN	_	2	compound
2	culture	culture	NN	_	6	nsubj
3	and	and	CC	_	2	cc
4	animal	animal	NN	_	5	compound
5	studies	study	NNS	_	2	conj
6	indicate	indicate	VBP	_	0	ROOT
7	that	that	IN	_	10	mark
8	drug1	drug1	NN	_	10	nsubj
9	can	can	MD	_	10	aux
10	diminish	diminish	VB	_	6	ccomp
11	or	or	CC	_	10	cc
12	abolish	abolish	VB	_	10	conj
13	the	the	DT	_	14	det
14	effect	effect	NN	_	10	dobj
15	of	of	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	on	on	IN	_	19	case
18	malignant	malignant	JJ	_	19	amod
19	cells	cell	NNS	_	14	nmod
20	.14	.14	CD	_	19	nummod
21	This	this	DT	_	22	det
22	effect	effect	NN	_	26	nsubj
23	on	on	IN	_	25	case
24	drug3	drug3	NN	_	25	compound
25	activity	activity	NN	_	22	nmod
26	persists	persist	VBZ	_	10	dep
27	as	as	RB	_	28	advmod
28	long	long	JJ	_	26	advmod
29	as	as	IN	_	34	mark
30	plasma	plasma	NN	_	32	compound
31	asparagine	asparagine	NN	_	32	compound
32	levels	level	NNS	_	34	nsubjpass
33	are	be	VBP	_	34	auxpass
34	suppressed	suppress	VBN	_	28	advcl
35	.	.	.	_	6	punct

1	These	these	DT	_	2	det
2	results	result	NNS	_	4	nsubj
3	would	would	MD	_	4	aux
4	seem	seem	VB	_	0	ROOT
5	to	to	TO	_	6	mark
6	dictate	dictate	VB	_	4	xcomp
7	against	against	IN	_	10	case
8	the	the	DT	_	10	det
9	clinical	clinical	JJ	_	10	amod
10	use	use	NN	_	6	nmod
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	with	with	IN	_	14	case
14	drug2	drug2	NN	_	10	nmod
15	,	,	,	_	14	punct
16	or	or	CC	_	14	cc
17	during	during	IN	_	19	case
18	the	the	DT	_	19	det
19	period	period	NN	_	14	conj
20	following	follow	VBG	_	22	case
21	drug3	drug3	NN	_	22	compound
22	therapy	therapy	NN	_	19	nmod
23	when	when	WRB	_	29	advmod
24	plasma	plasma	NN	_	26	compound
25	asparagine	asparagine	NN	_	26	compound
26	levels	level	NNS	_	29	nsubj
27	are	be	VBP	_	29	cop
28	below	below	IN	_	29	case
29	normal	normal	JJ	_	19	acl:relcl
30	.	.	.	_	4	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	decrease	decrease	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	amount	amount	NN	_	3	dobj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	drug3	drug3	NN	_	7	dep
10	,	,	,	_	9	punct
11	drug4	drug4	NN	_	9	appos
12	-RRB-	-rrb-	-RRB-	_	9	punct
13	that	that	WDT	_	15	nsubjpass
14	gets	get	VBZ	_	15	auxpass
15	absorbed	absorb	VBN	_	7	acl:relcl
16	into	into	IN	_	18	case
17	your	you	PRP$	_	18	nmod:poss
18	body	body	NN	_	15	nmod
19	.	.	.	_	3	punct

1	In	in	IN	_	3	case
2	the	the	DT	_	3	det
3	case	case	NN	_	19	nmod
4	that	that	IN	_	7	mark
5	you	you	PRP	_	7	nsubj
6	are	be	VBP	_	7	aux
7	taking	take	VBG	_	3	ccomp
8	drug1	drug1	NN	_	7	dobj
9	while	while	IN	_	10	mark
10	taking	take	VBG	_	7	advcl
11	drug2	drug2	NN	_	10	dobj
12	,	,	,	_	19	punct
13	higher	higher	JJR	_	14	amod
14	doses	dose	NNS	_	19	nsubjpass
15	of	of	IN	_	16	case
16	drug3	drug3	NN	_	14	nmod
17	may	may	MD	_	19	aux
18	be	be	VB	_	19	auxpass
19	needed	need	VBN	_	0	ROOT
20	.	.	.	_	19	punct

1	drug1	drug1	NN	_	4	nsubj
2	may	may	MD	_	4	aux
3	also	also	RB	_	4	advmod
4	decrease	decrease	VB	_	0	ROOT
5	the	the	DT	_	6	det
6	absorption	absorption	NN	_	4	dobj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	,	,	,	_	6	punct
10	which	which	WDT	_	12	nsubj
11	can	can	MD	_	12	aux
12	lead	lead	VB	_	6	acl:relcl
13	to	to	TO	_	15	case
14	a	a	DT	_	15	det
15	deficiency	deficiency	NN	_	12	nmod
16	.	.	.	_	4	punct

1	Therefore	therefore	RB	_	4	advmod
2	you	you	PRP	_	4	nsubj
3	may	may	MD	_	4	aux
4	need	need	VB	_	0	ROOT
5	to	to	TO	_	6	mark
6	take	take	VB	_	4	xcomp
7	a	a	DT	_	9	det
8	drug1	drug1	NN	_	9	compound
9	supplement	supplement	NN	_	6	dobj
10	while	while	IN	_	11	mark
11	taking	take	VBG	_	6	advcl
12	drug2	drug2	NN	_	11	dobj
13	.	.	.	_	4	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	augment	augment	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	activity	activity	NN	_	3	dobj
6	of	of	IN	_	8	case
7	other	other	JJ	_	8	amod
8	drug2	drug2	NN	_	5	nmod
9	.	.	.	_	3	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	use	use	NN	_	8	nsubjpass
3	with	with	IN	_	5	case
4	other	other	JJ	_	5	amod
5	drug1	drug1	NN	_	2	nmod
6	is	be	VBZ	_	8	auxpass
7	not	not	RB	_	8	neg
8	recommended	recommend	VBN	_	0	ROOT

1	.	.	.	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	No	no	DT	_	2	neg
2	information	information	NN	_	4	nsubj
3	is	be	VBZ	_	4	cop
4	available	available	JJ	_	0	ROOT
5	.	.	.	_	4	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	accentuate	accentuate	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	electrolyte	electrolyte	NN	_	6	compound
6	loss	loss	NN	_	3	dobj
7	associated	associate	VBN	_	6	acl
8	with	with	IN	_	10	case
9	drug2	drug2	NN	_	10	compound
10	therapy	therapy	NN	_	7	nmod
11	.	.	.	_	3	punct

1	Patients	patient	NNS	_	28	nsubj
2	receiving	receive	VBG	_	1	acl
3	other	other	JJ	_	5	amod
4	drug1	drug1	NN	_	5	compound
5	s	s	NNS	_	2	dobj
6	,	,	,	_	5	punct
7	general	general	JJ	_	8	amod
8	drug2	drug2	NN	_	5	conj
9	,	,	,	_	5	punct
10	drug3	drug3	NN	_	5	conj
11	,	,	,	_	5	punct
12	drug4	drug4	NN	_	5	conj
13	,	,	,	_	5	punct
14	drug5	drug5	NN	_	5	conj
15	,	,	,	_	5	punct
16	drug6	drug6	NN	_	5	conj
17	or	or	CC	_	5	cc
18	other	other	JJ	_	19	amod
19	drug7	drug7	NN	_	5	conj
20	-LRB-	-lrb-	-LRB-	_	22	punct
21	including	include	VBG	_	22	case
22	drug8	drug8	NN	_	19	nmod
23	-RRB-	-rrb-	-RRB-	_	22	punct
24	concomitantly	concomitantly	RB	_	28	advmod
25	with	with	IN	_	26	case
26	drug9	drug9	NN	_	24	nmod
27	may	may	MD	_	28	aux
28	exhibit	exhibit	VB	_	0	ROOT
29	an	a	DT	_	32	det
30	additive	additive	JJ	_	32	amod
31	CNS	cns	NN	_	32	compound
32	depression	depression	NN	_	28	dobj
33	.	.	.	_	28	punct

1	When	when	WRB	_	6	advmod
2	such	such	JJ	_	4	amod
3	combined	combined	JJ	_	4	amod
4	therapy	therapy	NN	_	6	nsubjpass
5	is	be	VBZ	_	6	auxpass
6	contemplated	contemplate	VBN	_	17	advcl
7	,	,	,	_	17	punct
8	the	the	DT	_	9	det
9	dose	dose	NN	_	17	nsubjpass
10	of	of	IN	_	11	case
11	one	one	CD	_	9	nmod
12	or	or	CC	_	11	cc
13	both	both	DT	_	14	det
14	agents	agent	NNS	_	11	conj
15	should	should	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	reduced	reduce	VBN	_	0	ROOT
18	.	.	.	_	17	punct

1	No	no	DT	_	4	neg
2	significant	significant	JJ	_	4	amod
3	drug-drug	drug-drug	JJ	_	4	amod
4	pharmacokinetic	pharmacokinetic	JJ	_	9	amod
5	-LRB-	-lrb-	-LRB-	_	7	punct
6	or	or	CC	_	7	cc
7	pharmacodynamic	pharmacodynamic	JJ	_	4	dep
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	interactions	interaction	NNS	_	12	nsubjpass
10	have	have	VBP	_	12	aux
11	been	be	VBN	_	12	auxpass
12	found	find	VBN	_	0	ROOT
13	in	in	IN	_	15	case
14	interaction	interaction	NN	_	15	compound
15	studies	study	NNS	_	12	nmod
16	with	with	IN	_	17	case
17	drug1	drug1	NN	_	15	nmod
18	,	,	,	_	17	punct
19	drug2	drug2	NN	_	17	conj
20	,	,	,	_	17	punct
21	drug3	drug3	NN	_	17	conj
22	,	,	,	_	17	punct
23	and	and	CC	_	17	cc
24	drug4	drug4	NN	_	17	conj
25	.	.	.	_	12	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	4	nsubj
4	show	show	VBP	_	0	ROOT
5	significant	significant	JJ	_	6	amod
6	inhibition	inhibition	NN	_	4	dobj
7	of	of	IN	_	9	case
8	the	the	DT	_	9	det
9	formation	formation	NN	_	6	nmod
10	of	of	IN	_	13	case
11	oxidized	oxidize	VBN	_	13	amod
12	irbesartan	irbesartan	NN	_	13	compound
13	metabolites	metabolite	NNS	_	9	nmod
14	with	with	IN	_	20	case
15	the	the	DT	_	20	det
16	known	known	JJ	_	20	amod
17	cytochrome	cytochrome	NN	_	20	compound
18	CYP	cyp	NN	_	20	compound
19	2C9	2c9	CD	_	20	nummod
20	substrates/inhibitors	substrates/inhibitors	NNS	_	6	nmod
21	drug1	drug1	NN	_	20	dep
22	,	,	,	_	21	punct
23	drug2	drug2	NN	_	21	conj
24	and	and	CC	_	21	cc
25	drug3	drug3	NN	_	21	conj
26	.	.	.	_	4	punct

1	However	however	RB	_	17	advmod
2	,	,	,	_	17	punct
3	in	in	IN	_	5	case
4	clinical	clinical	JJ	_	5	amod
5	studies	study	NNS	_	17	nmod
6	the	the	DT	_	7	det
7	consequences	consequence	NNS	_	17	nsubj
8	of	of	IN	_	10	case
9	concomitant	concomitant	JJ	_	10	amod
10	drug1	drug1	NN	_	7	nmod
11	on	on	IN	_	13	case
12	the	the	DT	_	13	det
13	pharmacodynamics	pharmacodynamic	NNS	_	7	nmod
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	were	be	VBD	_	17	cop
17	negligible	negligible	JJ	_	0	ROOT
18	.	.	.	_	17	punct

1	Based	base	VBN	_	5	case
2	on	on	IN	_	5	case
3	in	in	FW	_	5	amod
4	vitro	vitro	FW	_	3	dep
5	data	datum	NNS	_	11	advcl
6	,	,	,	_	11	punct
7	no	no	DT	_	8	neg
8	interaction	interaction	NN	_	11	nsubjpass
9	would	would	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	expected	expect	VBN	_	0	ROOT
12	with	with	IN	_	13	case
13	drugs	drug	NNS	_	11	nmod
14	whose	whose	WP$	_	15	nmod:poss
15	metabolism	metabolism	NN	_	17	nsubj
16	is	be	VBZ	_	17	cop
17	dependent	dependent	JJ	_	13	acl:relcl
18	upon	upon	IN	_	22	case
19	cytochrome	cytochrome	NN	_	22	compound
20	P450	p450	NN	_	22	compound
21	isozymes	isozyme	NNS	_	22	compound
22	1A1	1a1	NN	_	17	nmod
23	,	,	,	_	22	punct
24	1A2	1a2	NN	_	26	compound
25	,2	,2	CD	_	26	nummod
26	A6	a6	NN	_	22	conj
27	,2	,2	CD	_	28	nummod
28	B6	b6	NN	_	26	dep
29	,2	,2	CD	_	30	nummod
30	D6	d6	NN	_	28	dep
31	,2	,2	CD	_	32	nummod
32	E1	e1	NN	_	30	dep
33	,	,	,	_	22	punct
34	or	or	CC	_	22	cc
35	3A4	3a4	NN	_	22	conj
36	.	.	.	_	11	punct

1	In	in	IN	_	3	case
2	separate	separate	JJ	_	3	amod
3	studies	study	NNS	_	22	nmod
4	of	of	IN	_	5	case
5	patients	patient	NNS	_	3	nmod
6	receiving	receive	VBG	_	5	acl
7	maintenance	maintenance	NN	_	8	compound
8	doses	dose	NNS	_	6	dobj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	,	,	,	_	10	punct
12	drug2	drug2	NN	_	10	conj
13	,	,	,	_	10	punct
14	or	or	CC	_	10	cc
15	drug3	drug3	NN	_	10	conj
16	,	,	,	_	22	punct
17	drug4	drug4	NN	_	18	compound
18	administration	administration	NN	_	22	nsubj
19	for	for	IN	_	21	case
20	7	7	CD	_	21	nummod
21	days	day	NNS	_	18	nmod
22	had	have	VBD	_	0	ROOT
23	no	no	DT	_	24	neg
24	effect	effect	NN	_	22	dobj
25	on	on	IN	_	27	case
26	the	the	DT	_	27	det
27	pharmacodynamics	pharmacodynamic	NNS	_	22	nmod
28	of	of	IN	_	29	case
29	drug5	drug5	NN	_	27	nmod
30	-LRB-	-lrb-	-LRB-	_	32	punct
31	prothrombin	prothrombin	NN	_	32	compound
32	time	time	NN	_	29	appos
33	-RRB-	-rrb-	-RRB-	_	32	punct
34	or	or	CC	_	29	cc
35	pharmacokinetics	pharmacokinetic	NNS	_	29	conj
36	of	of	IN	_	37	case
37	drug6	drug6	NN	_	35	nmod
38	.	.	.	_	22	punct

1	The	the	DT	_	2	det
2	pharmacokinetics	pharmacokinetic	NNS	_	7	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	were	be	VBD	_	7	auxpass
6	not	not	RB	_	7	neg
7	affected	affect	VBN	_	0	ROOT
8	by	by	IN	_	9	case
9	coadministration	coadministration	NN	_	7	nmod
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	or	or	CC	_	11	cc
13	drug3	drug3	NN	_	11	conj

1	.	.	.	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	Interactions	interaction	NNS	_	11	nsubjpass
2	between	between	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	other	other	JJ	_	6	amod
6	drugs	drug	NNS	_	3	conj
7	have	have	VBP	_	11	aux
8	not	not	RB	_	11	neg
9	been	be	VBN	_	11	auxpass
10	fully	fully	RB	_	11	advmod
11	evaluated	evaluate	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	Results	result	NNS	_	6	nsubj
2	from	from	IN	_	5	case
3	existing	exist	VBG	_	5	amod
4	clinical	clinical	JJ	_	5	amod
5	trials	trial	NNS	_	1	nmod
6	suggest	suggest	VBP	_	0	ROOT
7	no	no	DT	_	9	neg
8	significant	significant	JJ	_	9	amod
9	interactions	interaction	NNS	_	6	dobj
10	between	between	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	other	other	JJ	_	14	amod
14	therapies	therapy	NNS	_	11	conj
15	commonly	commonly	RB	_	16	advmod
16	used	use	VBN	_	9	acl
17	in	in	IN	_	19	case
18	MS	ms	NN	_	19	compound
19	patients	patient	NNS	_	16	nmod
20	,	,	,	_	9	punct
21	including	include	VBG	_	24	case
22	the	the	DT	_	24	det
23	concurrent	concurrent	JJ	_	24	amod
24	use	use	NN	_	9	nmod
25	of	of	IN	_	26	case
26	drug2	drug2	NN	_	24	nmod
27	for	for	IN	_	31	case
28	up	up	RB	_	30	dep
29	to	to	TO	_	28	mwe
30	28	28	CD	_	31	nummod
31	days	day	NNS	_	24	nmod
32	.	.	.	_	6	punct

1	drug1	drug1	NN	_	6	nsubjpass
2	has	have	VBZ	_	6	aux
3	not	not	RB	_	6	neg
4	been	be	VBN	_	6	auxpass
5	formally	formally	RB	_	6	advmod
6	evaluated	evaluate	VBN	_	0	ROOT
7	in	in	IN	_	8	case
8	combination	combination	NN	_	6	nmod
9	with	with	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	.	.	.	_	6	punct

1	However	however	RB	_	15	advmod
2	,	,	,	_	15	punct
3	10	10	CD	_	4	nummod
4	patients	patient	NNS	_	15	nsubj
5	who	who	WP	_	6	nsubj
6	switched	switch	VBD	_	4	acl:relcl
7	from	from	IN	_	8	case
8	therapy	therapy	NN	_	6	nmod
9	with	with	IN	_	10	case
10	drug1	drug1	NN	_	6	nmod
11	to	to	TO	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	did	do	VBD	_	15	aux
14	not	not	RB	_	15	neg
15	report	report	VB	_	0	ROOT
16	any	any	DT	_	21	det
17	serious	serious	JJ	_	21	amod
18	and	and	CC	_	17	cc
19	unexpected	unexpected	JJ	_	17	conj
20	adverse	adverse	JJ	_	21	amod
21	reactions	reaction	NNS	_	15	dobj
22	thought	think	VBD	_	21	acl
23	to	to	TO	_	25	mark
24	be	be	VB	_	25	cop
25	related	relate	VBN	_	22	xcomp
26	to	to	TO	_	27	case
27	treatment	treatment	NN	_	25	nmod
28	.	.	.	_	15	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	extensively	extensively	RB	_	4	advmod
4	metabolized	metabolize	VBN	_	0	ROOT
5	in	in	IN	_	7	case
6	the	the	DT	_	7	det
7	liver	liver	NN	_	4	nmod
8	by	by	IN	_	9	case
9	CYP2C19	cyp2c19	NN	_	4	nmod
10	and	and	CC	_	9	cc
11	CYP3A4	cyp3a4	NN	_	9	conj
12	.	.	.	_	4	punct

1	In	in	FW	_	2	compound
2	vitro	vitro	FW	_	3	advmod
3	and	and	CC	_	8	cc
4	in	in	FW	_	6	amod
5	vivo	vivo	FW	_	4	dep
6	studies	study	NNS	_	8	nsubj
7	have	have	VBP	_	8	aux
8	shown	show	VBN	_	0	ROOT
9	that	that	IN	_	13	mark
10	drug1	drug1	NN	_	13	nsubj
11	is	be	VBZ	_	13	cop
12	not	not	RB	_	13	neg
13	likely	likely	JJ	_	8	ccomp
14	to	to	TO	_	15	mark
15	inhibit	inhibit	VB	_	13	xcomp
16	CYPs	cyp	NNS	_	17	compound
17	1A2	1a2	NN	_	15	dobj
18	,	,	,	_	17	punct
19	2A6	2a6	NN	_	17	conj
20	,	,	,	_	17	punct
21	2C9	2c9	NN	_	17	conj
22	,	,	,	_	17	punct
23	2D6	2d6	NN	_	17	conj
24	,	,	,	_	17	punct
25	2E1	2e1	NN	_	17	conj
26	and	and	CC	_	17	cc
27	3A4	3a4	NN	_	17	conj
28	.	.	.	_	8	punct

1	No	no	DT	_	4	neg
2	clinically	clinically	RB	_	3	advmod
3	relevant	relevant	JJ	_	4	amod
4	interactions	interaction	NNS	_	14	nsubjpass
5	with	with	IN	_	6	case
6	drugs	drug	NNS	_	4	nmod
7	metabolized	metabolize	VBN	_	6	acl
8	by	by	IN	_	11	case
9	these	these	DT	_	11	det
10	CYP	cyp	NN	_	11	compound
11	enzymes	enzyme	NNS	_	7	nmod
12	would	would	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	expected	expect	VBN	_	0	ROOT
15	.	.	.	_	14	punct

1	Drug	drug	NN	_	3	compound
2	interaction	interaction	NN	_	3	compound
3	studies	study	NNS	_	5	nsubj
4	have	have	VBP	_	5	aux
5	shown	show	VBN	_	0	ROOT
6	that	that	IN	_	10	mark
7	drug1	drug1	NN	_	10	nsubj
8	does	do	VBZ	_	10	aux
9	not	not	RB	_	10	neg
10	have	have	VB	_	5	ccomp
11	any	any	DT	_	14	det
12	clinically	clinically	RB	_	13	advmod
13	significant	significant	JJ	_	14	amod
14	interactions	interaction	NNS	_	10	dobj
15	with	with	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	,	,	,	_	16	punct
18	drug3	drug3	NN	_	16	conj
19	,	,	,	_	16	punct
20	drug4	drug4	NN	_	16	conj
21	,	,	,	_	16	punct
22	drug5	drug5	NN	_	16	conj
23	or	or	CC	_	16	cc
24	drug6	drug6	NN	_	16	conj
25	.	.	.	_	5	punct

1	Post-marketing	post-marketing	JJ	_	2	amod
2	reports	report	NNS	_	10	nsubjpass
3	of	of	IN	_	4	case
4	changes	change	NNS	_	2	nmod
5	in	in	IN	_	7	case
6	prothrombin	prothrombin	NN	_	7	compound
7	measures	measure	NNS	_	4	nmod
8	have	have	VBP	_	10	aux
9	been	be	VBN	_	10	auxpass
10	received	receive	VBN	_	0	ROOT
11	among	among	IN	_	12	case
12	patients	patient	NNS	_	10	nmod
13	on	on	IN	_	15	case
14	concomitant	concomitant	JJ	_	15	amod
15	drug1	drug1	NN	_	12	nmod
16	and	and	CC	_	15	cc
17	drug2	drug2	NN	_	18	compound
18	therapy	therapy	NN	_	15	conj
19	.	.	.	_	10	punct

1	Increases	increase	NNS	_	0	ROOT
2	in	in	IN	_	3	case
3	INR	inr	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	prothrombin	prothrombin	NN	_	3	conj
6	time	time	NN	_	8	nsubj
7	may	may	MD	_	8	aux
8	lead	lead	VB	_	1	acl:relcl
9	to	to	TO	_	11	case
10	abnormal	abnormal	JJ	_	11	amod
11	bleeding	bleeding	NN	_	8	nmod
12	and	and	CC	_	11	cc
13	even	even	RB	_	14	advmod
14	death	death	NN	_	11	conj
15	.	.	.	_	1	punct

1	Patients	patient	NNS	_	9	nsubj
2	treated	treat	VBN	_	1	acl
3	with	with	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	concomitantly	concomitantly	RB	_	9	advmod
8	may	may	MD	_	9	aux
9	need	need	VB	_	0	ROOT
10	to	to	TO	_	12	mark
11	be	be	VB	_	12	auxpass
12	monitored	monitor	VBN	_	9	xcomp
13	for	for	IN	_	14	case
14	increases	increase	NNS	_	12	nmod
15	in	in	IN	_	16	case
16	INR	inr	NN	_	14	nmod
17	and	and	CC	_	16	cc
18	prothrombin	prothrombin	NN	_	19	compound
19	time	time	NN	_	16	conj
20	.	.	.	_	9	punct

1	drug1	drug1	NN	_	4	nsubj
2	may	may	MD	_	4	aux
3	potentially	potentially	RB	_	4	advmod
4	interfere	interfere	VB	_	0	ROOT
5	with	with	IN	_	6	case
6	CYP2C19	cyp2c19	NN	_	4	nmod
7	,	,	,	_	6	punct
8	the	the	DT	_	12	det
9	major	major	JJ	_	12	amod
10	drug2	drug2	NN	_	12	compound
11	metabolizing	metabolize	VBG	_	12	amod
12	enzyme	enzyme	NN	_	6	appos
13	.	.	.	_	4	punct

1	Coadministration	coadministration	NN	_	13	nsubj
2	of	of	IN	_	5	case
3	drug1	drug1	NN	_	5	compound
4	30	30	CD	_	5	nummod
5	mg	mg	NN	_	1	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	,	,	,	_	5	punct
9	a	a	DT	_	11	det
10	CYP2C19	cyp2c19	NN	_	11	compound
11	substrate	substrate	NN	_	5	appos
12	,	,	,	_	5	punct
13	resulted	result	VBD	_	0	ROOT
14	in	in	IN	_	18	case
15	a	a	DT	_	18	det
16	45	45	CD	_	17	compound
17	%	%	NN	_	18	amod
18	decrease	decrease	NN	_	13	nmod
19	in	in	IN	_	20	case
20	clearance	clearance	NN	_	18	nmod
21	of	of	IN	_	22	case
22	drug3	drug3	NN	_	20	nmod
23	.	.	.	_	13	punct

1	Increased	increase	VBN	_	3	amod
2	plasma	plasma	NN	_	3	compound
3	levels	level	NNS	_	7	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	were	be	VBD	_	7	auxpass
7	observed	observe	VBN	_	0	ROOT
8	12	12	CD	_	9	nummod
9	hours	hour	NNS	_	7	nmod
10	after	after	IN	_	9	case
11	dosing	dosing	NN	_	9	dep
12	and	and	CC	_	11	cc
13	onwards	onward	NNS	_	11	conj
14	.	.	.	_	7	punct

1	However	however	RB	_	16	advmod
2	,	,	,	_	16	punct
3	at	at	IN	_	5	case
4	that	that	DT	_	5	det
5	time	time	NN	_	16	nmod
6	,	,	,	_	16	punct
7	the	the	DT	_	9	det
8	plasma	plasma	NN	_	9	compound
9	levels	level	NNS	_	16	nsubj
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	were	be	VBD	_	16	cop
13	below	below	IN	_	16	case
14	the	the	DT	_	16	det
15	therapeutic	therapeutic	JJ	_	16	amod
16	interval	interval	NN	_	0	ROOT
17	,	,	,	_	16	punct
18	and	and	CC	_	16	cc
19	thus	thus	RB	_	23	advmod
20	this	this	DT	_	21	det
21	interaction	interaction	NN	_	23	nsubj
22	is	be	VBZ	_	23	cop
23	unlikely	unlikely	JJ	_	16	conj
24	to	to	TO	_	28	mark
25	be	be	VB	_	28	cop
26	of	of	IN	_	28	case
27	clinical	clinical	JJ	_	28	amod
28	relevance	relevance	NN	_	23	xcomp
29	.	.	.	_	16	punct

1	drug1	drug1	NN	_	2	nsubj
2	inhibits	inhibit	VBZ	_	0	ROOT
3	gastric	gastric	JJ	_	5	amod
4	acid	acid	NN	_	5	compound
5	secretion	secretion	NN	_	2	dobj
6	.	.	.	_	2	punct

1	Therefore	therefore	RB	_	5	advmod
2	,	,	,	_	5	punct
3	drug1	drug1	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	interfere	interfere	VB	_	0	ROOT
6	with	with	IN	_	8	case
7	the	the	DT	_	8	det
8	absorption	absorption	NN	_	5	nmod
9	of	of	IN	_	10	case
10	drugs	drug	NNS	_	8	nmod
11	where	where	WRB	_	17	advmod
12	gastric	gastric	JJ	_	13	amod
13	pH	ph	NN	_	17	nsubj
14	is	be	VBZ	_	17	cop
15	an	a	DT	_	17	det
16	important	important	JJ	_	17	amod
17	determinant	determinant	NN	_	10	acl:relcl
18	of	of	IN	_	19	case
19	bioavailability	bioavailability	NN	_	17	nmod
20	-LRB-	-lrb-	-LRB-	_	23	punct
21	eg	eg	FW	_	23	compound
22	,	,	,	_	23	punct
23	drug2	drug2	NN	_	8	dep
24	,	,	,	_	23	punct
25	drug3	drug3	NN	_	26	compound
26	salts	salt	NNS	_	23	conj
27	and	and	CC	_	23	cc
28	drug4	drug4	NN	_	23	conj
29	-RRB-	-rrb-	-RRB-	_	23	punct
30	.	.	.	_	5	punct

1	Coadministration	coadministration	NN	_	14	nsubj
2	of	of	IN	_	4	case
3	oral	oral	JJ	_	4	amod
4	drug1	drug1	NN	_	1	nmod
5	,	,	,	_	4	punct
6	drug2	drug2	NN	_	4	conj
7	,	,	,	_	4	punct
8	drug3	drug3	NN	_	4	conj
9	,	,	,	_	4	punct
10	or	or	CC	_	4	cc
11	drug4	drug4	NN	_	4	conj
12	did	do	VBD	_	14	aux
13	not	not	RB	_	14	neg
14	seem	seem	VB	_	0	ROOT
15	to	to	TO	_	16	mark
16	change	change	VB	_	14	xcomp
17	the	the	DT	_	19	det
18	pharmacokinetic	pharmacokinetic	JJ	_	19	amod
19	profile	profile	NN	_	16	dobj
20	of	of	IN	_	21	case
21	drug5	drug5	NN	_	19	nmod
22	.	.	.	_	14	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	8	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	2	nmod
7	is	be	VBZ	_	8	auxpass
8	contraindicated	contraindicate	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	No	no	DT	_	5	neg
2	significant	significant	JJ	_	5	amod
3	drug-drug	drug-drug	JJ	_	5	amod
4	pharmacokinetic	pharmacokinetic	JJ	_	5	amod
5	interactions	interaction	NNS	_	8	nsubjpass
6	have	have	VBP	_	8	aux
7	been	be	VBN	_	8	auxpass
8	found	find	VBN	_	0	ROOT
9	in	in	IN	_	11	case
10	interaction	interaction	NN	_	11	compound
11	studies	study	NNS	_	8	nmod
12	with	with	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	,	,	,	_	13	punct
15	drug2	drug2	NN	_	13	conj
16	,	,	,	_	13	punct
17	drug3	drug3	NN	_	13	conj
18	,	,	,	_	13	punct
19	drug4	drug4	NN	_	13	conj
20	and	and	CC	_	13	cc
21	drug5	drug5	NN	_	13	conj
22	.	.	.	_	8	punct

1	drug1	drug1	NN	_	9	nsubj
2	,	,	,	_	1	punct
3	an	a	DT	_	4	det
4	inducer	inducer	NN	_	1	appos
5	of	of	IN	_	7	case
6	drug	drug	NN	_	7	compound
7	metabolism	metabolism	NN	_	4	nmod
8	,	,	,	_	1	punct
9	decreased	decrease	VBD	_	0	ROOT
10	the	the	DT	_	11	det
11	concentrations	concentration	NNS	_	9	dobj
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	and	and	CC	_	13	cc
15	its	its	PRP$	_	17	nmod:poss
16	active	active	JJ	_	17	amod
17	metabolite	metabolite	NN	_	13	conj
18	.	.	.	_	9	punct

1	In	in	IN	_	2	case
2	humans	human	NNS	_	11	nmod
3	,	,	,	_	11	punct
4	two	two	CD	_	5	nummod
5	inhibitors	inhibitor	NNS	_	11	nsubjpass
6	of	of	IN	_	8	case
7	P450	p450	NN	_	8	compound
8	3A4	3a4	NN	_	5	nmod
9	have	have	VBP	_	11	aux
10	been	be	VBN	_	11	auxpass
11	studied	study	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	drug1	drug1	NN	_	4	nsubj
2	did	do	VBD	_	4	aux
3	not	not	RB	_	4	neg
4	affect	affect	VB	_	0	ROOT
5	the	the	DT	_	6	det
6	conversion	conversion	NN	_	4	dobj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	to	to	TO	_	12	case
10	the	the	DT	_	12	det
11	active	active	JJ	_	12	amod
12	metabolite	metabolite	NN	_	6	nmod
13	after	after	IN	_	15	case
14	intravenous	intravenous	JJ	_	15	amod
15	administration	administration	NN	_	4	nmod
16	of	of	IN	_	17	case
17	drug3	drug3	NN	_	15	nmod
18	,	,	,	_	4	punct
19	and	and	CC	_	4	cc
20	drug4	drug4	NN	_	21	nsubj
21	had	have	VBD	_	4	conj
22	no	no	DT	_	25	neg
23	clinically	clinically	RB	_	24	advmod
24	significant	significant	JJ	_	25	amod
25	effect	effect	NN	_	21	dobj
26	after	after	IN	_	28	case
27	oral	oral	JJ	_	28	amod
28	administration	administration	NN	_	21	nmod
29	.	.	.	_	4	punct

1	drug1	drug1	NN	_	9	nsubj
2	,	,	,	_	1	punct
3	an	a	DT	_	4	det
4	inhibitor	inhibitor	NN	_	1	appos
5	of	of	IN	_	7	case
6	P450	p450	NN	_	7	compound
7	2C9	2c9	NN	_	4	nmod
8	,	,	,	_	1	punct
9	decreased	decrease	VBD	_	0	ROOT
10	active	active	JJ	_	12	amod
11	metabolite	metabolite	NN	_	12	compound
12	concentration	concentration	NN	_	9	dobj
13	and	and	CC	_	9	cc
14	increased	increase	VBD	_	16	amod
15	drug2	drug2	NN	_	16	compound
16	concentration	concentration	NN	_	9	conj
17	.	.	.	_	9	punct

1	The	the	DT	_	3	det
2	pharmacodynamic	pharmacodynamic	JJ	_	3	amod
3	consequences	consequence	NNS	_	17	nsubjpass
4	of	of	IN	_	6	case
5	concomitant	concomitant	JJ	_	6	amod
6	use	use	NN	_	3	nmod
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	inhibitors	inhibitor	NNS	_	8	conj
11	of	of	IN	_	13	case
12	P450	p450	NN	_	13	compound
13	2C9	2c9	NN	_	8	nmod
14	have	have	VBP	_	17	aux
15	not	not	RB	_	17	neg
16	been	be	VBN	_	17	auxpass
17	examined	examine	VBN	_	0	ROOT
18	.	.	.	_	17	punct

1	Subjects	subject	NNS	_	12	nsubjpass
2	who	who	WP	_	5	nsubj
3	do	do	VBP	_	5	aux
4	not	not	RB	_	5	neg
5	metabolize	metabolize	VB	_	1	acl:relcl
6	drug1	drug1	NN	_	5	dobj
7	to	to	TO	_	9	case
8	active	active	JJ	_	9	amod
9	metabolite	metabolite	NN	_	5	nmod
10	have	have	VBP	_	12	aux
11	been	be	VBN	_	12	auxpass
12	shown	show	VBN	_	0	ROOT
13	to	to	TO	_	14	mark
14	have	have	VB	_	12	xcomp
15	a	a	DT	_	19	det
16	specific	specific	JJ	_	19	amod
17	,	,	,	_	19	punct
18	rare	rare	JJ	_	19	amod
19	defect	defect	NN	_	14	dobj
20	in	in	IN	_	23	case
21	cytochrome	cytochrome	NN	_	23	compound
22	P450	p450	NN	_	23	compound
23	2C9	2c9	NN	_	14	nmod
24	.	.	.	_	12	punct

1	These	these	DT	_	2	det
2	data	datum	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	14	mark
5	the	the	DT	_	6	det
6	conversion	conversion	NN	_	14	nsubjpass
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	to	to	TO	_	12	case
10	its	its	PRP$	_	12	nmod:poss
11	active	active	JJ	_	12	amod
12	metabolite	metabolite	NN	_	6	nmod
13	is	be	VBZ	_	14	auxpass
14	mediated	mediate	VBN	_	3	ccomp
15	primarily	primarily	RB	_	14	advmod
16	by	by	IN	_	18	case
17	P450	p450	NN	_	18	compound
18	2C9	2c9	NN	_	14	nmod
19	and	and	CC	_	18	cc
20	not	not	RB	_	22	neg
21	P450	p450	NN	_	22	compound
22	3A4	3a4	NN	_	18	conj
23	.	.	.	_	3	punct

1	As	as	IN	_	4	case
2	with	with	IN	_	4	case
3	other	other	JJ	_	4	amod
4	drugs	drug	NNS	_	36	nmod
5	that	that	WDT	_	6	nsubj
6	block	block	VBP	_	4	acl:relcl
7	angiotensin	angiotensin	NN	_	6	dobj
8	II	ii	CD	_	7	nummod
9	or	or	CC	_	7	cc
10	its	its	PRP$	_	11	nmod:poss
11	effects	effect	NNS	_	7	conj
12	,	,	,	_	36	punct
13	concomitant	concomitant	JJ	_	14	amod
14	use	use	NN	_	36	nsubj
15	of	of	IN	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	-LRB-	-lrb-	-LRB-	_	20	punct
18	e.g.	e.g.	FW	_	20	dep
19	,	,	,	_	20	punct
20	drug2	drug2	NN	_	16	dep
21	,	,	,	_	20	punct
22	drug3	drug3	NN	_	20	appos
23	,	,	,	_	20	punct
24	drug4	drug4	NN	_	20	appos
25	-RRB-	-rrb-	-RRB-	_	20	punct
26	,	,	,	_	16	punct
27	drug5	drug5	NN	_	28	compound
28	supplements	supplement	NNS	_	16	conj
29	,	,	,	_	16	punct
30	or	or	CC	_	16	cc
31	salt	salt	NN	_	32	compound
32	substitutes	substitute	NNS	_	16	conj
33	containing	contain	VBG	_	32	acl
34	potassium	potassium	NN	_	33	dobj
35	may	may	MD	_	36	aux
36	lead	lead	VB	_	0	ROOT
37	to	to	TO	_	38	case
38	increases	increase	NNS	_	36	nmod
39	in	in	IN	_	41	case
40	serum	serum	NN	_	41	compound
41	potassium	potassium	NN	_	38	nmod
42	.	.	.	_	36	punct

1	As	as	IN	_	4	case
2	with	with	IN	_	4	case
3	other	other	JJ	_	4	amod
4	drug1	drug1	NN	_	13	nmod
5	,	,	,	_	13	punct
6	the	the	DT	_	8	det
7	antihypertensive	antihypertensive	JJ	_	8	amod
8	effect	effect	NN	_	13	nsubjpass
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	may	may	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	blunted	blunt	VBN	_	0	ROOT
14	by	by	IN	_	17	case
15	the	the	DT	_	17	det
16	drug3	drug3	NN	_	17	compound
17	drug4	drug4	NN	_	13	nmod

1	.	.	.	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	drug1	drug1	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	with	with	IN	_	6	case
6	caution	caution	NN	_	4	nmod
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	receiving	receive	VBG	_	8	acl
10	drug2	drug2	NN	_	9	dobj
11	.	.	.	_	4	punct

1	When	when	WRB	_	12	advmod
2	other	other	JJ	_	5	amod
3	potent	potent	JJ	_	5	amod
4	parental	parental	JJ	_	5	amod
5	drug1	drug1	NN	_	12	nsubjpass
6	,	,	,	_	5	punct
7	such	such	JJ	_	9	case
8	as	as	IN	_	7	mwe
9	drug2	drug2	NN	_	5	nmod
10	,	,	,	_	5	punct
11	are	be	VBP	_	12	auxpass
12	used	use	VBN	_	22	advcl
13	in	in	IN	_	14	case
14	combination	combination	NN	_	12	nmod
15	with	with	IN	_	16	case
16	drug3	drug3	NN	_	14	nmod
17	,	,	,	_	22	punct
18	patients	patient	NNS	_	22	nsubjpass
19	should	should	MD	_	22	aux
20	be	be	VB	_	22	auxpass
21	continuously	continuously	RB	_	22	advmod
22	observed	observe	VBN	_	0	ROOT
23	for	for	IN	_	25	case
24	several	several	JJ	_	25	amod
25	hours	hour	NNS	_	22	nmod
26	for	for	IN	_	29	case
27	any	any	DT	_	29	det
28	excessive	excessive	JJ	_	29	amod
29	fall	fall	NN	_	22	nmod
30	in	in	IN	_	32	case
31	blood	blood	NN	_	32	compound
32	pressure	pressure	NN	_	29	nmod
33	.	.	.	_	22	punct

1	Profound	profound	JJ	_	3	amod
2	hypotensive	hypotensive	JJ	_	3	amod
3	episodes	episode	NNS	_	5	nsubj
4	may	may	MD	_	5	aux
5	occur	occur	VB	_	0	ROOT
6	when	when	WRB	_	12	advmod
7	drug1	drug1	NN	_	8	compound
8	infection	infection	NN	_	12	nsubjpass
9	and	and	CC	_	8	cc
10	drug2	drug2	NN	_	8	conj
11	are	be	VBP	_	12	auxpass
12	used	use	VBN	_	5	advcl
13	concomitantly	concomitantly	RB	_	12	advmod
14	.	.	.	_	5	punct

1	drug1	drug1	NN	_	8	compound
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	drug2	drug2	NN	_	1	dep
4	,	,	,	_	3	punct
5	drug3	drug3	NN	_	3	appos
6	-RRB-	-rrb-	-RRB-	_	3	punct
7	serum	serum	NN	_	8	compound
8	concentrations	concentration	NNS	_	14	nsubjpass
9	and	and	CC	_	8	cc
10	pharmacologic	pharmacologic	JJ	_	11	amod
11	effects	effect	NNS	_	8	conj
12	may	may	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	increased	increase	VBN	_	0	ROOT
15	.	.	.	_	14	punct

1	Monitor	Monitor	NNP	_	3	compound
2	cardiovascular	cardiovascular	JJ	_	3	amod
3	status	status	NN	_	0	ROOT
4	.	.	.	_	3	punct

1	drug1	drug1	NN	_	2	nsubj
2	increases	increase	VBZ	_	0	ROOT
3	drug2	drug2	NN	_	6	compound
4	s	s	NNS	_	6	compound
5	serum	serum	NN	_	6	compound
6	concentrations	concentration	NNS	_	2	dobj
7	.	.	.	_	2	punct

1	drug1	drug1	NN	_	17	nsubj
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	,	,	,	_	1	punct
5	and	and	CC	_	1	cc
6	drug3	drug3	NN	_	1	conj
7	-LRB-	-lrb-	-LRB-	_	10	punct
8	low	low	JJ	_	10	amod
9	hepatic	hepatic	JJ	_	10	amod
10	clearance	clearance	NN	_	6	dep
11	or	or	CC	_	10	cc
12	no	no	DT	_	14	neg
13	first-pass	first-pass	JJ	_	14	amod
14	metabolism	metabolism	NN	_	10	conj
15	-RRB-	-rrb-	-RRB-	_	10	punct
16	are	be	VBP	_	17	cop
17	unlikely	unlikely	JJ	_	0	ROOT
18	to	to	TO	_	20	mark
19	be	be	VB	_	20	auxpass
20	affected	affect	VBN	_	17	xcomp
21	.	.	.	_	17	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	decrease	decrease	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	hemodynamic	hemodynamic	JJ	_	6	amod
6	effects	effect	NNS	_	3	dobj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	;	;	:	_	3	punct

1	avoid	avoid	VB	_	0	ROOT
2	use	use	NN	_	1	dobj
3	if	if	IN	_	4	mark
4	possible	possible	JJ	_	1	advcl
5	or	or	CC	_	4	cc
6	closely	closely	RB	_	7	advmod
7	monitor	monitor	VB	_	4	conj
8	cardiovascular	cardiovascular	JJ	_	9	amod
9	status	status	NN	_	4	dep
10	at	at	IN	_	12	case
11	the	the	DT	_	12	det
12	end	end	NN	_	4	nmod
13	of	of	IN	_	15	case
14	drug	drug	NN	_	15	compound
15	interactions	interaction	NNS	_	12	nmod

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Twelve	twelve	CD	_	6	nummod
4	healthy	healthy	JJ	_	6	amod
5	male	male	JJ	_	6	amod
6	volunteers	volunteer	NNS	_	8	nsubjpass
7	were	be	VBD	_	8	auxpass
8	administered	administer	VBN	_	1	dep
9	one	one	CD	_	12	nummod
10	200-mg	200-mg	JJ	_	12	amod
11	drug2	drug2	NN	_	12	compound
12	capsule	capsule	NN	_	8	dobj
13	twice	twice	RB	_	14	advmod
14	daily	daily	RB	_	12	advmod
15	for	for	IN	_	17	case
16	6	6	CD	_	17	nummod
17	days	day	NNS	_	8	nmod
18	.	.	.	_	1	punct

1	With	with	IN	_	4	case
2	the	the	DT	_	4	det
3	morning	morning	NN	_	4	compound
4	dose	dose	NN	_	13	nmod
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	on	on	IN	_	8	case
8	day	day	NN	_	4	nmod
9	6	6	CD	_	8	nummod
10	,	,	,	_	13	punct
11	each	each	DT	_	12	det
12	volunteer	volunteer	NN	_	13	nsubj
13	received	receive	VBD	_	0	ROOT
14	a	a	DT	_	17	det
15	single	single	JJ	_	17	amod
16	intravenous	intravenous	JJ	_	17	amod
17	infusion	infusion	NN	_	13	dobj
18	of	of	IN	_	19	case
19	drug2	drug2	NN	_	17	nmod
20	-LRB-	-lrb-	-LRB-	_	22	punct
21	4	4	CD	_	22	nummod
22	mg/kg	mg/kg	NN	_	19	appos
23	-RRB-	-rrb-	-RRB-	_	22	punct
24	.	.	.	_	13	punct

1	The	the	DT	_	2	det
2	pharmacokinetics	pharmacokinetic	NNS	_	7	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	were	be	VBD	_	7	auxpass
6	not	not	RB	_	7	neg
7	altered	alter	VBN	_	0	ROOT
8	.	.	.	_	7	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	15	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	on	on	IN	_	7	case
6	the	the	DT	_	7	det
7	pharmacokinetics	pharmacokinetic	NNS	_	2	nmod
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	administered	administer	VBN	_	9	acl
11	orally	orally	RB	_	10	advmod
12	has	have	VBZ	_	15	aux
13	not	not	RB	_	15	neg
14	been	be	VBN	_	15	auxpass
15	investigated	investigate	VBN	_	0	ROOT
16	.	.	.	_	15	punct

1	drug1	drug1	NN	_	0	ROOT
2	or	or	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	:	:	:	_	1	punct
5	The	the	DT	_	6	det
6	effect	effect	NN	_	17	nsubjpass
7	of	of	IN	_	10	case
8	increased	increase	VBN	_	10	amod
9	gastric	gastric	JJ	_	10	amod
10	pH	ph	NN	_	6	nmod
11	on	on	IN	_	13	case
12	the	the	DT	_	13	det
13	bioavailability	bioavailability	NN	_	6	nmod
14	of	of	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	was	be	VBD	_	17	auxpass
17	evaluated	evaluate	VBN	_	1	dep
18	in	in	IN	_	22	case
19	18	18	CD	_	22	nummod
20	healthy	healthy	JJ	_	22	amod
21	adult	adult	JJ	_	22	amod
22	volunteers	volunteer	NNS	_	17	nmod
23	.	.	.	_	17	punct

1	Each	each	DT	_	2	det
2	volunteer	volunteer	NN	_	4	nsubjpass
3	was	be	VBD	_	4	auxpass
4	administered	administer	VBN	_	0	ROOT
5	one	one	CD	_	8	nummod
6	400-mg	400-mg	JJ	_	8	amod
7	drug1	drug1	NN	_	8	compound
8	capsule	capsule	NN	_	4	dobj
9	.	.	.	_	4	punct

1	A	a	DT	_	3	det
2	single	single	JJ	_	3	amod
3	dose	dose	NN	_	9	nsubj
4	of	of	IN	_	6	case
5	liquid	liquid	JJ	_	6	amod
6	drug1	drug1	NN	_	3	nmod
7	did	do	VBD	_	9	aux
8	not	not	RB	_	9	neg
9	affect	affect	VB	_	0	ROOT
10	the	the	DT	_	12	det
11	C	c	NN	_	12	compound
12	max	max	NN	_	9	dobj
13	or	or	CC	_	12	cc
14	AUC	auc	NN	_	12	conj
15	of	of	IN	_	16	case
16	drug2	drug2	NN	_	12	nmod
17	;	;	:	_	9	punct

1	however	however	RB	_	11	advmod
2	,	,	,	_	11	punct
3	150	150	CD	_	4	nummod
4	mg	mg	NN	_	11	nsubj
5	of	of	IN	_	7	case
6	drug1	drug1	NN	_	7	compound
7	q12h	q12h	NN	_	4	nmod
8	for	for	IN	_	10	case
9	3	3	CD	_	10	nummod
10	days	day	NNS	_	4	nmod
11	increased	increase	VBD	_	0	ROOT
12	the	the	DT	_	15	det
13	drug2	drug2	NN	_	15	compound
14	C	c	NN	_	15	compound
15	max	max	NN	_	11	dobj
16	by	by	IN	_	18	case
17	23	23	CD	_	18	nummod
18	%	%	NN	_	11	nmod
19	and	and	CC	_	11	cc
20	drug3	drug3	NN	_	21	compound
21	AUC	auc	NN	_	11	conj
22	by	by	IN	_	24	case
23	16	16	CD	_	24	nummod
24	%	%	NN	_	21	nmod
25	.	.	.	_	11	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	relevance	relevance	NN	_	9	nsubjpass
4	of	of	IN	_	6	case
5	these	these	DT	_	6	det
6	increases	increase	NNS	_	3	nmod
7	is	be	VBZ	_	9	auxpass
8	not	not	RB	_	9	neg
9	known	know	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	3	amod
2	Test	test	NN	_	3	compound
3	Interactions	interaction	NNS	_	0	ROOT
4	:	:	:	_	3	punct
5	There	there	EX	_	9	expl
6	have	have	VBP	_	9	aux
7	been	be	VBN	_	9	cop
8	no	no	DT	_	9	neg
9	chemical	chemical	NN	_	3	dep
10	or	or	CC	_	9	cc
11	laboratory	laboratory	NN	_	13	compound
12	test	test	NN	_	13	compound
13	interactions	interaction	NNS	_	9	conj
14	with	with	IN	_	15	case
15	drug1	drug1	NN	_	9	nmod
16	noted	note	VBD	_	9	acl
17	to	to	TO	_	18	case
18	date	date	NN	_	16	nmod
19	.	.	.	_	3	punct

1	False-positive	false-positive	JJ	_	4	amod
2	direct	direct	JJ	_	4	amod
3	Coombs	Coombs	NNP	_	4	compound
4	tests	test	NNS	_	7	nsubjpass
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	reported	report	VBN	_	0	ROOT
8	during	during	IN	_	9	case
9	treatment	treatment	NN	_	7	nmod
10	with	with	IN	_	12	case
11	other	other	JJ	_	12	amod
12	drug1	drug1	NN	_	9	nmod
13	.	.	.	_	7	punct

1	Therefore	therefore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	it	it	PRP	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	recognized	recognize	VBN	_	0	ROOT
7	that	that	IN	_	17	mark
8	a	a	DT	_	11	det
9	positive	positive	JJ	_	11	amod
10	Coombs	Coombs	NNP	_	11	compound
11	test	test	NN	_	17	nsubj
12	could	could	MD	_	17	aux
13	be	be	VB	_	17	cop
14	due	due	JJ	_	17	case
15	to	to	TO	_	14	mwe
16	the	the	DT	_	17	det
17	drug	drug	NN	_	6	ccomp
18	.	.	.	_	6	punct

1	The	the	DT	_	2	det
2	results	result	NNS	_	22	nsubj
3	of	of	IN	_	4	case
4	assays	assay	NNS	_	2	nmod
5	using	use	VBG	_	4	acl
6	red	red	JJ	_	7	amod
7	cells	cell	NNS	_	5	dobj
8	from	from	IN	_	10	case
9	healthy	healthy	JJ	_	10	amod
10	subjects	subject	NNS	_	7	nmod
11	to	to	TO	_	12	mark
12	determine	determine	VB	_	5	advcl
13	whether	whether	IN	_	16	mark
14	drug1	drug1	NN	_	16	nsubj
15	would	would	MD	_	16	aux
16	cause	cause	VB	_	12	ccomp
17	direct	direct	JJ	_	19	amod
18	Coombs	Coombs	NNP	_	19	compound
19	reactions	reaction	NNS	_	16	dobj
20	in	in	FW	_	21	compound
21	vitro	vitro	FW	_	16	advmod
22	showed	show	VBD	_	0	ROOT
23	no	no	DT	_	25	neg
24	positive	positive	JJ	_	25	amod
25	reaction	reaction	NN	_	22	dobj
26	at	at	IN	_	28	case
27	drug2	drug2	NN	_	28	compound
28	concentrations	concentration	NNS	_	25	nmod
29	as	as	IN	_	30	advmod
30	high	high	JJ	_	25	amod
31	as	as	IN	_	33	case
32	40	40	CD	_	33	nummod
33	g/mL	g/ml	NN	_	30	nmod
34	.	.	.	_	22	punct

1	Although	although	IN	_	7	mark
2	the	the	DT	_	3	det
3	occurrence	occurrence	NN	_	7	nsubjpass
4	has	have	VBZ	_	7	aux
5	not	not	RB	_	7	neg
6	been	be	VBN	_	7	auxpass
7	reported	report	VBN	_	14	advcl
8	with	with	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	,	,	,	_	14	punct
11	nephrotoxicity	nephrotoxicity	NN	_	14	nsubjpass
12	has	have	VBZ	_	14	aux
13	been	be	VBN	_	14	auxpass
14	reported	report	VBN	_	0	ROOT
15	following	follow	VBG	_	17	case
16	concomitant	concomitant	JJ	_	17	amod
17	administration	administration	NN	_	14	nmod
18	of	of	IN	_	20	case
19	other	other	JJ	_	20	amod
20	drug2	drug2	NN	_	17	nmod
21	and	and	CC	_	20	cc
22	drug3	drug3	NN	_	20	conj
23	.	.	.	_	14	punct

1	Although	although	IN	_	8	mark
2	acid-base	acid-base	NN	_	5	compound
3	and	and	CC	_	2	cc
4	electrolyte	electrolyte	NN	_	2	conj
5	disturbances	disturbance	NNS	_	8	nsubjpass
6	were	be	VBD	_	8	auxpass
7	not	not	RB	_	8	neg
8	reported	report	VBN	_	20	advcl
9	in	in	IN	_	12	case
10	the	the	DT	_	12	det
11	clinical	clinical	JJ	_	12	amod
12	trials	trial	NNS	_	8	nmod
13	with	with	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	,	,	,	_	20	punct
16	these	these	DT	_	17	det
17	disturbances	disturbance	NNS	_	20	nsubjpass
18	have	have	VBP	_	20	aux
19	been	be	VBN	_	20	auxpass
20	reported	report	VBN	_	0	ROOT
21	with	with	IN	_	23	case
22	oral	oral	JJ	_	23	amod
23	drug2	drug2	NN	_	20	nmod
24	and	and	CC	_	20	cc
25	have	have	VBP	_	31	aux
26	,	,	,	_	31	punct
27	in	in	IN	_	29	case
28	some	some	DT	_	29	det
29	instances	instance	NNS	_	31	nmod
30	,	,	,	_	31	punct
31	resulted	result	VBD	_	20	conj
32	in	in	IN	_	34	case
33	drug	drug	NN	_	34	compound
34	interactions	interaction	NNS	_	31	nmod
35	-LRB-	-lrb-	-LRB-	_	34	punct
36	e.g.	e.g.	FW	_	35	root
37	,	,	,	_	36	punct
38	toxicity	toxicity	NN	_	37	root
39	associated	associate	VBN	_	38	acl
40	with	with	IN	_	43	case
41	high-dose	high-dose	JJ	_	43	amod
42	drug3	drug3	NN	_	43	compound
43	therapy	therapy	NN	_	39	nmod
44	-RRB-	-rrb-	-RRB-	_	38	punct
45	.	.	.	_	38	punct

1	Therefore	therefore	RB	_	11	advmod
2	,	,	,	_	11	punct
3	the	the	DT	_	4	det
4	potential	potential	NN	_	11	nsubjpass
5	for	for	IN	_	8	case
6	such	such	JJ	_	8	amod
7	drug	drug	NN	_	8	compound
8	interactions	interaction	NNS	_	4	nmod
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	considered	consider	VBN	_	0	ROOT
12	in	in	IN	_	13	case
13	patients	patient	NNS	_	11	nmod
14	receiving	receive	VBG	_	13	acl
15	drug1	drug1	NN	_	14	dobj
16	.	.	.	_	11	punct

1	Interactions	interaction	NNS	_	3	nsubj
2	may	may	MD	_	3	aux
3	occur	occur	VB	_	0	ROOT
4	between	between	IN	_	6	case
5	drug1	drug1	NN	_	6	compound
6	supplements	supplement	NNS	_	3	nmod
7	and	and	CC	_	6	cc
8	drug2	drug2	NN	_	6	conj
9	and	and	CC	_	8	cc
10	other	other	JJ	_	11	amod
11	drug3	drug3	NN	_	8	conj
12	and	and	CC	_	6	cc
13	herbs	herb	NNS	_	6	conj
14	such	such	JJ	_	16	case
15	as	as	IN	_	14	mwe
16	garlic	garlic	NN	_	13	nmod
17	-LRB-	-lrb-	-LRB-	_	19	punct
18	Allium	allium	NN	_	19	compound
19	sativum	sativum	NN	_	16	appos
20	-RRB-	-rrb-	-RRB-	_	19	punct
21	and	and	CC	_	16	cc
22	drug4	drug4	NN	_	16	conj
23	-LRB-	-lrb-	-LRB-	_	24	punct
24	drug5	drug5	NN	_	22	appos
25	-RRB-	-rrb-	-RRB-	_	24	punct
26	.	.	.	_	3	punct

1	Such	such	JJ	_	2	amod
2	interactions	interaction	NNS	_	5	nsubjpass
3	might	might	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	manifested	manifest	VBN	_	0	ROOT
6	by	by	IN	_	8	case
7	increased	increase	VBN	_	8	amod
8	susceptibility	susceptibility	NN	_	5	nmod
9	to	to	TO	_	10	mark
10	bruising	bruise	VBG	_	8	acl
11	,	,	,	_	10	punct
12	nosebleeds	nosebleed	NNS	_	10	conj
13	,	,	,	_	10	punct
14	hemoptysis	hemoptysis	NN	_	10	conj
15	,	,	,	_	10	punct
16	hematemesis	hematemesis	NN	_	10	conj
17	,	,	,	_	10	punct
18	hematuria	hematuria	NN	_	10	conj
19	and	and	CC	_	10	cc
20	blood	blood	NN	_	10	conj
21	in	in	IN	_	23	case
22	the	the	DT	_	23	det
23	stool	stool	NN	_	20	nmod
24	.	.	.	_	5	punct

1	Most	most	JJS	_	0	ROOT
2	who	who	WP	_	3	nsubj
3	take	take	VBP	_	1	acl:relcl
4	drug1	drug1	NN	_	5	compound
5	supplements	supplement	NNS	_	3	dobj
6	and	and	CC	_	3	cc
7	the	the	DT	_	9	det
8	above	above	JJ	_	9	amod
9	drugs	drug	NNS	_	14	nsubj
10	or	or	CC	_	9	cc
11	herbs	herb	NNS	_	9	conj
12	do	do	VBP	_	14	aux
13	not	not	RB	_	14	neg
14	suffer	suffer	VB	_	3	conj
15	from	from	IN	_	17	case
16	these	these	DT	_	17	det
17	problems	problem	NNS	_	14	nmod
18	and	and	CC	_	14	cc
19	if	if	IN	_	21	mark
20	they	they	PRP	_	21	nsubj
21	occur	occur	VBP	_	25	advcl
22	,	,	,	_	25	punct
23	they	they	PRP	_	25	nsubj
24	are	be	VBP	_	25	cop
25	rare	rare	JJ	_	14	conj
26	.	.	.	_	1	punct

1	If	if	IN	_	4	mark
2	they	they	PRP	_	4	nsubj
3	do	do	VBP	_	4	aux
4	occur	occur	VB	_	11	advcl
5	,	,	,	_	11	punct
6	the	the	DT	_	8	det
7	drug1	drug1	NN	_	8	compound
8	dose	dose	NN	_	11	nsubjpass
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	lowered	lower	VBN	_	0	ROOT
12	or	or	CC	_	11	cc
13	discontinued	discontinue	VBN	_	11	conj
14	.	.	.	_	11	punct

1	Conflicting	conflicting	JJ	_	2	amod
2	results	result	NNS	_	5	nsubjpass
3	have	have	VBP	_	5	aux
4	been	be	VBN	_	5	auxpass
5	reported	report	VBN	_	0	ROOT
6	regarding	regard	VBG	_	8	case
7	the	the	DT	_	8	det
8	effects	effect	NNS	_	5	nmod
9	of	of	IN	_	11	case
10	drug1	drug1	NN	_	11	compound
11	supplements	supplement	NNS	_	8	nmod
12	on	on	IN	_	14	case
13	glycemic	glycemic	JJ	_	14	amod
14	control	control	NN	_	8	nmod
15	in	in	IN	_	16	case
16	non-diabetics	non-diabetic	NNS	_	14	nmod
17	with	with	IN	_	19	case
18	glucose	glucose	NN	_	19	compound
19	intolerance	intolerance	NN	_	16	nmod
20	,	,	,	_	8	punct
21	and	and	CC	_	8	cc
22	those	those	DT	_	8	conj
23	with	with	IN	_	26	case
24	type	type	NN	_	26	compound
25	2	2	CD	_	26	nummod
26	diabetes	diabetes	NN	_	22	nmod
27	.	.	.	_	5	punct

1	Some	some	DT	_	3	det
2	early	early	JJ	_	3	amod
3	studies	study	NNS	_	4	nsubj
4	indicated	indicate	VBD	_	0	ROOT
5	that	that	IN	_	9	mark
6	drug1	drug1	NN	_	7	compound
7	supplements	supplement	NNS	_	9	nsubj
8	might	might	MD	_	9	aux
9	have	have	VB	_	4	ccomp
10	detrimental	detrimental	JJ	_	11	amod
11	effects	effect	NNS	_	9	dobj
12	in	in	IN	_	14	case
13	those	those	DT	_	14	det
14	groups	group	NNS	_	9	nmod
15	.	.	.	_	4	punct

1	Recent	recent	JJ	_	8	advmod
2	,	,	,	_	8	punct
3	better	better	RBR	_	4	advmod
4	designed	design	VBN	_	5	amod
5	studies	study	NNS	_	8	nsubj
6	have	have	VBP	_	8	aux
7	not	not	RB	_	8	neg
8	reported	report	VBN	_	0	ROOT
9	these	these	DT	_	11	det
10	adverse	adverse	JJ	_	11	amod
11	effects	effect	NNS	_	8	dobj
12	.	.	.	_	8	punct

1	There	there	EX	_	2	expl
2	is	be	VBZ	_	0	ROOT
3	no	no	DT	_	4	neg
4	evidence	evidence	NN	_	2	nsubj
5	that	that	IN	_	8	mark
6	drug1	drug1	NN	_	7	compound
7	supplements	supplement	NNS	_	8	nsubj
8	have	have	VBP	_	4	ccomp
9	detrimental	detrimental	JJ	_	10	amod
10	effects	effect	NNS	_	8	dobj
11	on	on	IN	_	13	case
12	glucose	glucose	NN	_	13	compound
13	tolerance	tolerance	NN	_	8	nmod
14	,	,	,	_	13	punct
15	insulin	insulin	NN	_	16	compound
16	secretion	secretion	NN	_	13	conj
17	or	or	CC	_	13	cc
18	insulin	insulin	NN	_	19	compound
19	resistance	resistance	NN	_	13	conj
20	in	in	IN	_	22	case
21	non-diabetic	non-diabetic	JJ	_	22	amod
22	subjects	subject	NNS	_	19	nmod
23	.	.	.	_	2	punct

1	Diabetics	diabetic	NNS	_	3	nsubj
2	should	should	MD	_	3	aux
3	discuss	discuss	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	use	use	NN	_	3	dobj
6	of	of	IN	_	8	case
7	these	these	DT	_	8	det
8	supplements	supplement	NNS	_	5	nmod
9	with	with	IN	_	11	case
10	their	they	PRP$	_	11	nmod:poss
11	physicians	physician	NNS	_	5	nmod
12	and	and	CC	_	11	cc
13	note	note	NN	_	11	conj
14	if	if	IN	_	17	mark
15	the	the	DT	_	16	det
16	supplements	supplement	NNS	_	17	nsubj
17	affect	affect	VBP	_	3	advcl
18	their	they	PRP$	_	20	nmod:poss
19	glycemic	glycemic	JJ	_	20	amod
20	control	control	NN	_	17	dobj
21	.	.	.	_	3	punct

1	Diabetics	diabetic	NNS	_	8	nsubjpass
2	who	who	WP	_	3	nsubj
3	take	take	VBP	_	1	acl:relcl
4	drug1	drug1	NN	_	5	compound
5	supplements	supplement	NNS	_	3	dobj
6	should	should	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	monitored	monitor	VBN	_	0	ROOT
9	by	by	IN	_	11	case
10	their	they	PRP$	_	11	nmod:poss
11	physicians	physician	NNS	_	8	nmod
12	.	.	.	_	8	punct

1	Caution	caution	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	advised	advise	VBN	_	0	ROOT
4	in	in	IN	_	5	case
5	patients	patient	NNS	_	3	nmod
6	receiving	receive	VBG	_	5	acl
7	concomitant	concomitant	JJ	_	9	amod
8	high-dose	high-dose	JJ	_	9	amod
9	drug1	drug1	NN	_	6	dobj
10	and	and	CC	_	9	cc
11	drug2	drug2	NN	_	9	conj
12	,	,	,	_	3	punct
13	as	as	IN	_	14	case
14	anorexia	anorexia	NN	_	3	nmod
15	,	,	,	_	14	punct
16	tachypnea	tachypnea	NN	_	14	conj
17	,	,	,	_	14	punct
18	lethargy	lethargy	NN	_	14	conj
19	and	and	CC	_	14	cc
20	coma	coma	NN	_	14	conj
21	have	have	VBP	_	24	aux
22	been	be	VBN	_	24	auxpass
23	rarely	rarely	RB	_	24	advmod
24	reported	report	VBN	_	3	dep
25	due	due	JJ	_	30	case
26	to	to	TO	_	25	mwe
27	a	a	DT	_	30	det
28	possible	possible	JJ	_	30	amod
29	drug	drug	NN	_	30	compound
30	interaction	interaction	NN	_	24	nmod
31	.	.	.	_	3	punct

1	No	no	DT	_	3	neg
2	specific	specific	JJ	_	3	amod
3	information	information	NN	_	0	ROOT
4	available	available	JJ	_	3	amod

1	.	.	.	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	drug1	drug1	NN	_	4	nsubj
2	does	do	VBZ	_	4	aux
3	not	not	RB	_	4	neg
4	influence	influence	VB	_	0	ROOT
5	the	the	DT	_	6	det
6	pharmacokinetics	pharmacokinetic	NNS	_	4	dobj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	.	.	.	_	4	punct

1	Carcinogenesis	carcinogenesis	NN	_	14	nsubjpass
2	,	,	,	_	1	punct
3	Mutagenesis	mutagenesis	NN	_	1	conj
4	,	,	,	_	1	punct
5	Impairment	impairment	NN	_	1	appos
6	of	of	IN	_	11	case
7	Fertility	Fertility	NNP	_	11	compound
8	No	No	NNP	_	11	compound
9	long-term	long-term	JJ	_	11	amod
10	carcinogenicity	carcinogenicity	NN	_	11	compound
11	studies	study	NNS	_	5	nmod
12	have	have	VBP	_	14	aux
13	been	be	VBN	_	14	auxpass
14	carried	carry	VBN	_	0	ROOT
15	out	out	RP	_	14	compound:prt
16	with	with	IN	_	17	case
17	drug1	drug1	NN	_	14	nmod
18	in	in	IN	_	19	case
19	animals	animal	NNS	_	17	nmod
20	.	.	.	_	14	punct

1	drug1	drug1	NN	_	4	nsubj
2	was	be	VBD	_	4	cop
3	not	not	RB	_	4	neg
4	mutagenic	mutagenic	JJ	_	0	ROOT
5	in	in	IN	_	8	case
6	the	the	DT	_	8	det
7	Ames	Ames	NNP	_	8	compound
8	test	test	NN	_	4	nmod
9	but	but	CC	_	4	cc
10	was	be	VBD	_	11	auxpass
11	found	find	VBN	_	4	conj
12	to	to	TO	_	14	mark
13	be	be	VB	_	14	cop
14	clastogenic	clastogenic	JJ	_	11	xcomp
15	to	to	TO	_	17	case
16	human	human	JJ	_	17	amod
17	lymphocytes	lymphocyte	NNS	_	14	nmod
18	in	in	FW	_	19	compound
19	vitro	vitro	FW	_	14	advmod
20	and	and	CC	_	14	cc
21	to	to	TO	_	25	case
22	mouse	mouse	NN	_	25	compound
23	bone	bone	NN	_	25	compound
24	marrow	marrow	NN	_	25	compound
25	erythrocytes	erythrocyte	NNS	_	14	conj
26	in	in	FW	_	27	compound
27	vivo	vivo	FW	_	25	advmod
28	-LRB-	-lrb-	-LRB-	_	30	punct
29	micronucleus	micronucleus	NN	_	30	compound
30	test	test	NN	_	25	appos
31	-RRB-	-rrb-	-RRB-	_	30	punct
32	.	.	.	_	4	punct

1	The	the	DT	_	4	det
2	possible	possible	JJ	_	4	amod
3	adverse	adverse	JJ	_	4	amod
4	effects	effect	NNS	_	24	nsubjpass
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	on	on	IN	_	9	case
8	the	the	DT	_	9	det
9	fertility	fertility	NN	_	4	nmod
10	of	of	IN	_	11	case
11	humans	human	NNS	_	9	nmod
12	and	and	CC	_	11	cc
13	experimental	experimental	JJ	_	14	amod
14	animals	animal	NNS	_	11	conj
15	,	,	,	_	11	punct
16	male	male	JJ	_	11	amod
17	or	or	CC	_	16	cc
18	female	female	JJ	_	16	conj
19	,	,	,	_	4	punct
20	have	have	VBP	_	24	aux
21	not	not	RB	_	24	neg
22	been	be	VBN	_	24	auxpass
23	adequately	adequately	RB	_	24	advmod
24	studied	study	VBN	_	0	ROOT
25	.	.	.	_	24	punct

1	Testicular	testicular	JJ	_	2	amod
2	atrophy	atrophy	NN	_	4	nsubjpass
3	was	be	VBD	_	4	auxpass
4	seen	see	VBN	_	0	ROOT
5	with	with	IN	_	7	case
6	drug1	drug1	NN	_	7	compound
7	administration	administration	NN	_	4	nmod
8	at	at	IN	_	9	case
9	doses	dose	NNS	_	7	nmod
10	as	as	RB	_	11	advmod
11	low	low	JJ	_	9	amod
12	as	as	IN	_	14	case
13	30	30	CD	_	14	nummod
14	mg/kg	mg/kg	NN	_	11	nmod
15	weekly	weekly	JJ	_	14	amod
16	for	for	IN	_	18	case
17	6	6	CD	_	18	nummod
18	weeks	week	NNS	_	15	nmod
19	in	in	IN	_	20	case
20	rats	rat	NNS	_	18	nmod
21	-LRB-	-lrb-	-LRB-	_	25	punct
22	1/3	1/3	CD	_	25	nummod
23	the	the	DT	_	25	det
24	human	human	JJ	_	25	amod
25	dose	dose	NN	_	18	dep
26	on	on	IN	_	30	case
27	a	a	DT	_	30	det
28	mg/m	mg/m	NN	_	30	compound
29	2	2	CD	_	30	nummod
30	basis	basis	NN	_	25	nmod
31	-RRB-	-rrb-	-RRB-	_	25	punct
32	and	and	CC	_	7	cc
33	as	as	RB	_	34	advmod
34	low	low	JJ	_	7	conj
35	as	as	IN	_	37	case
36	20	20	CD	_	37	nummod
37	mg/kg	mg/kg	NN	_	34	nmod
38	weekly	weekly	JJ	_	37	amod
39	for	for	IN	_	41	case
40	13	13	CD	_	41	nummod
41	weeks	week	NNS	_	38	nmod
42	in	in	IN	_	43	case
43	dogs	dog	NNS	_	41	nmod
44	-LRB-	-lrb-	-LRB-	_	46	punct
45	approximately	approximately	RB	_	46	advmod
46	equal	equal	JJ	_	34	dep
47	to	to	TO	_	50	case
48	the	the	DT	_	50	det
49	human	human	JJ	_	50	amod
50	dose	dose	NN	_	46	nmod
51	on	on	IN	_	55	case
52	a	a	DT	_	55	det
53	mg/m	mg/m	NN	_	55	compound
54	2	2	CD	_	55	nummod
55	basis	basis	NN	_	46	nmod
56	-RRB-	-rrb-	-RRB-	_	46	punct
57	.	.	.	_	4	punct

1	Persons	person	NNS	_	0	ROOT
2	taking	take	VBG	_	1	acl
3	most	most	RBS	_	4	advmod
4	drug1	drug1	RB	_	2	advmod
5	,	,	,	_	2	punct
6	drug2	drug2	NN	_	9	nsubj
7	and	and	CC	_	6	cc
8	drug3	drug3	NN	_	6	conj
9	invalidate	invalidate	VBP	_	2	parataxis
10	drug4	drug4	NN	_	15	compound
11	and	and	CC	_	10	cc
12	drug5	drug5	NN	_	10	conj
13	diagnostic	diagnostic	JJ	_	15	amod
14	blood	blood	NN	_	15	compound
15	assays	assay	NNS	_	9	dobj
16	.	.	.	_	1	punct

1	drug1	drug1	NN	_	2	compound
2	drug2	drug2	NN	_	0	ROOT
3	and	and	CC	_	2	cc
4	heavy	heavy	JJ	_	6	amod
5	drug3	drug3	NN	_	6	compound
6	intake	intake	NN	_	2	conj
7	for	for	IN	_	13	mark
8	longer	longer	JJR	_	13	advmod
9	than	than	IN	_	11	case
10	2	2	CD	_	11	nummod
11	weeks	week	NNS	_	8	nmod
12	may	may	MD	_	13	aux
13	produce	produce	VB	_	2	acl
14	malabsorption	malabsorption	NN	_	13	dobj
15	of	of	IN	_	16	case
16	drug4	drug4	NN	_	14	nmod
17	.	.	.	_	2	punct

1	No	no	DT	_	2	neg
2	drugs	drug	NNS	_	4	nsubjpass
3	are	be	VBP	_	4	auxpass
4	known	know	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	interfere	interfere	VB	_	4	xcomp
7	with	with	IN	_	9	case
8	the	the	DT	_	9	det
9	conversion	conversion	NN	_	6	nmod
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	to	to	TO	_	13	case
13	drug2	drug2	NN	_	9	nmod
14	.	.	.	_	4	punct

1	Conversion	conversion	NN	_	4	nsubjpass
2	could	could	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	affected	affect	VBN	_	0	ROOT
5	by	by	IN	_	6	case
6	alterations	alteration	NNS	_	4	nmod
7	in	in	IN	_	9	case
8	the	the	DT	_	9	det
9	level	level	NN	_	6	nmod
10	of	of	IN	_	12	case
11	phosphatase	phosphatase	NN	_	12	compound
12	activity	activity	NN	_	9	nmod
13	,	,	,	_	4	punct
14	but	but	CC	_	4	cc
15	given	give	VBN	_	17	case
16	the	the	DT	_	17	det
17	abundance	abundance	NN	_	4	conj
18	and	and	CC	_	17	cc
19	wide	wide	JJ	_	20	amod
20	distribution	distribution	NN	_	17	conj
21	of	of	IN	_	22	case
22	phosphatases	phosphatase	NNS	_	17	nmod
23	in	in	IN	_	25	case
24	the	the	DT	_	25	det
25	body	body	NN	_	28	nmod
26	it	it	PRP	_	28	nsubj
27	is	be	VBZ	_	28	cop
28	unlikely	unlikely	JJ	_	17	acl:relcl
29	that	that	IN	_	32	mark
30	drugs	drug	NNS	_	32	nsubj
31	would	would	MD	_	32	aux
32	affect	affect	VB	_	28	ccomp
33	this	this	DT	_	34	det
34	activity	activity	NN	_	32	dobj
35	enough	enough	RB	_	32	advmod
36	to	to	TO	_	37	mark
37	affect	affect	VB	_	35	dep
38	conversion	conversion	NN	_	37	dobj
39	of	of	IN	_	40	case
40	drug1	drug1	NN	_	38	nmod
41	to	to	TO	_	42	case
42	drug2	drug2	NN	_	38	nmod
43	.	.	.	_	4	punct

1	Drugs	drug	NNS	_	3	nsubj
2	highly	highly	RB	_	3	advmod
3	bound	bind	VBD	_	0	ROOT
4	to	to	TO	_	5	case
5	albumin	albumin	NN	_	3	nmod
6	could	could	MD	_	7	aux
7	increase	increase	VB	_	3	ccomp
8	the	the	DT	_	10	det
9	unbound	unbound	JJ	_	10	amod
10	fraction	fraction	NN	_	7	dobj
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	.	.	.	_	3	punct

1	Although	although	IN	_	5	mark
2	,	,	,	_	5	punct
3	it	it	PRP	_	5	nsubj
4	is	be	VBZ	_	5	cop
5	unknown	unknown	JJ	_	17	advcl
6	whether	whether	IN	_	9	mark
7	this	this	DT	_	9	nsubj
8	could	could	MD	_	9	aux
9	result	result	VB	_	5	ccomp
10	in	in	IN	_	13	case
11	clinically	clinically	RB	_	12	advmod
12	significant	significant	JJ	_	13	amod
13	effects	effect	NNS	_	9	nmod
14	,	,	,	_	17	punct
15	caution	caution	NN	_	17	nsubjpass
16	is	be	VBZ	_	17	auxpass
17	advised	advise	VBN	_	0	ROOT
18	when	when	WRB	_	19	advmod
19	administering	administer	VBG	_	17	advcl
20	drug1	drug1	NN	_	19	dobj
21	with	with	IN	_	23	case
22	other	other	JJ	_	23	amod
23	drugs	drug	NNS	_	19	nmod
24	that	that	WDT	_	26	nsubj
25	significantly	significantly	RB	_	26	advmod
26	bind	bind	VBP	_	23	acl:relcl
27	to	to	TO	_	29	case
28	serum	serum	NN	_	29	compound
29	albumin	albumin	NN	_	26	nmod
30	.	.	.	_	17	punct

1	The	the	DT	_	2	dep
2	pharmacokinetics	pharmacokinetic	NNS	_	15	nsubjpass
3	and	and	CC	_	2	cc
4	protein	protein	NN	_	5	compound
5	binding	binding	NN	_	2	conj
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	2	nmod
8	,	,	,	_	7	punct
9	drug2	drug2	NN	_	7	conj
10	,	,	,	_	7	punct
11	and	and	CC	_	7	cc
12	drug3	drug3	NN	_	7	conj
13	were	be	VBD	_	15	auxpass
14	not	not	RB	_	15	neg
15	altered	alter	VBN	_	0	ROOT
16	when	when	WRB	_	22	advmod
17	drug4	drug4	NN	_	22	nsubjpass
18	and	and	CC	_	17	cc
19	drug5	drug5	NN	_	17	conj
20	were	be	VBD	_	22	auxpass
21	concurrently	concurrently	RB	_	22	advmod
22	administered	administer	VBN	_	15	advcl
23	in	in	IN	_	26	case
24	single	single	JJ	_	26	amod
25	submaximal	submaximal	JJ	_	26	amod
26	doses	dose	NNS	_	22	nmod
27	.	.	.	_	15	punct

1	The	the	DT	_	5	det
2	most	most	RBS	_	3	advmod
3	significant	significant	JJ	_	5	amod
4	drug	drug	NN	_	5	compound
5	interactions	interaction	NNS	_	11	nsubjpass
6	following	follow	VBG	_	7	case
7	administration	administration	NN	_	5	nmod
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	are	be	VBP	_	11	auxpass
11	expected	expect	VBN	_	0	ROOT
12	to	to	TO	_	13	mark
13	occur	occur	VB	_	11	xcomp
14	with	with	IN	_	15	case
15	drugs	drug	NNS	_	13	nmod
16	that	that	WDT	_	17	nsubj
17	interact	interact	VBP	_	15	acl:relcl
18	with	with	IN	_	19	case
19	drug2	drug2	NN	_	17	nmod
20	.	.	.	_	11	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	extensively	extensively	RB	_	4	advmod
4	bound	bind	VBN	_	0	ROOT
5	to	to	TO	_	8	case
6	serum	serum	NN	_	8	compound
7	plasma	plasma	NN	_	8	compound
8	proteins	protein	NNS	_	4	nmod
9	and	and	CC	_	4	cc
10	is	be	VBZ	_	11	cop
11	prone	prone	JJ	_	4	conj
12	to	to	TO	_	14	case
13	competitive	competitive	JJ	_	14	amod
14	displacement	displacement	NN	_	11	nmod
15	.	.	.	_	4	punct

1	drug1	drug1	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	metabolized	metabolize	VBN	_	0	ROOT
4	by	by	IN	_	8	case
5	hepatic	hepatic	JJ	_	8	amod
6	cytochrome	cytochrome	NN	_	8	compound
7	P450	p450	NN	_	8	compound
8	enzymes	enzyme	NNS	_	3	nmod
9	and	and	CC	_	3	cc
10	is	be	VBZ	_	12	cop
11	particularly	particularly	RB	_	12	advmod
12	susceptible	susceptible	JJ	_	3	conj
13	to	to	TO	_	16	case
14	inhibitory	inhibitory	JJ	_	16	amod
15	drug	drug	NN	_	16	compound
16	interactions	interaction	NNS	_	12	nmod
17	because	because	IN	_	20	mark
18	it	it	PRP	_	20	nsubj
19	is	be	VBZ	_	20	cop
20	subject	subject	JJ	_	12	advcl
21	to	to	TO	_	23	case
22	saturable	saturable	JJ	_	23	amod
23	metabolism	metabolism	NN	_	20	nmod
24	.	.	.	_	3	punct

1	Inhibition	inhibition	NN	_	5	nsubj
2	of	of	IN	_	3	case
3	metabolism	metabolism	NN	_	1	nmod
4	may	may	MD	_	5	aux
5	produce	produce	VB	_	0	ROOT
6	significant	significant	JJ	_	7	amod
7	increases	increase	NNS	_	5	dobj
8	in	in	IN	_	11	case
9	circulating	circulate	VBG	_	11	amod
10	drug1	drug1	NN	_	11	compound
11	concentrations	concentration	NNS	_	7	nmod
12	and	and	CC	_	5	cc
13	enhance	enhance	VBP	_	5	conj
14	the	the	DT	_	15	det
15	risk	risk	NN	_	13	dobj
16	of	of	IN	_	18	case
17	drug	drug	NN	_	18	compound
18	toxicity	toxicity	NN	_	15	nmod
19	.	.	.	_	5	punct

1	drug1	drug1	NN	_	5	nsubj
2	is	be	VBZ	_	5	cop
3	a	a	DT	_	5	det
4	potent	potent	JJ	_	5	amod
5	inducer	inducer	NN	_	0	ROOT
6	of	of	IN	_	9	case
7	hepatic	hepatic	JJ	_	9	amod
8	drug-metabolizing	drug-metabolizing	JJ	_	9	amod
9	enzymes	enzyme	NNS	_	5	nmod
10	.	.	.	_	5	punct

1	The	the	DT	_	6	det
2	most	most	RBS	_	3	advmod
3	commonly	commonly	RB	_	4	advmod
4	occurring	occur	VBG	_	6	amod
5	drug	drug	NN	_	6	compound
6	interactions	interaction	NNS	_	8	nsubjpass
7	are	be	VBP	_	8	auxpass
8	listed	list	VBN	_	0	ROOT
9	below	below	IN	_	19	case
10	:	:	:	_	19	punct
11	-	-	:	_	19	punct
12	Drugs	drug	NNS	_	19	nsubj
13	that	that	WDT	_	15	nsubj
14	may	may	MD	_	15	aux
15	increase	increase	VB	_	12	acl:relcl
16	plasma	plasma	NN	_	18	compound
17	drug1	drug1	NN	_	18	compound
18	concentrations	concentration	NNS	_	15	dobj
19	include	include	VBP	_	8	advcl
20	:	:	:	_	19	punct
21	acute	acute	JJ	_	23	amod
22	drug2	drug2	NN	_	23	compound
23	intake	intake	NN	_	19	dep
24	,	,	,	_	23	punct
25	drug3	drug3	NN	_	23	conj
26	,	,	,	_	23	punct
27	chboramphenicol	chboramphenicol	NN	_	23	conj
28	,	,	,	_	23	punct
29	drug4	drug4	NN	_	23	conj
30	,	,	,	_	23	punct
31	drug5	drug5	NN	_	23	conj
32	,	,	,	_	23	punct
33	drug6	drug6	NN	_	23	conj
34	,	,	,	_	23	punct
35	drug7	drug7	NN	_	23	conj
36	,	,	,	_	23	punct
37	drug8	drug8	NN	_	23	conj
38	,	,	,	_	23	punct
39	drug9	drug9	NN	_	23	conj
40	,	,	,	_	23	punct
41	drug10	drug10	NN	_	23	conj
42	,	,	,	_	23	punct
43	drug11	drug11	NN	_	23	conj
44	,	,	,	_	23	punct
45	drug12	drug12	NN	_	23	conj
46	,	,	,	_	23	punct
47	drug13	drug13	NN	_	23	conj
48	,	,	,	_	23	punct
49	drug14	drug14	NN	_	23	conj
50	,	,	,	_	23	punct
51	drug15	drug15	NN	_	23	conj
52	,	,	,	_	23	punct
53	drug16	drug16	NN	_	23	conj
54	,	,	,	_	23	punct
55	drug17	drug17	NN	_	23	conj
56	,	,	,	_	23	punct
57	drug18	drug18	NN	_	23	conj
58	,	,	,	_	23	punct
59	drug19	drug19	NN	_	23	conj
60	,	,	,	_	23	punct
61	drug20	drug20	NN	_	23	conj
62	,	,	,	_	23	punct
63	drug21	drug21	NN	_	23	conj
64	,	,	,	_	23	punct
65	drug22	drug22	NN	_	23	appos

1	.	.	.	_	0	ROOT

1	-	-	:	_	9	punct
2	Drugs	drug	NNS	_	9	nsubj
3	that	that	WDT	_	5	nsubj
4	may	may	MD	_	5	aux
5	decrease	decrease	VB	_	2	acl:relcl
6	plasma	plasma	NN	_	8	compound
7	drug1	drug1	NN	_	8	compound
8	concentrations	concentration	NNS	_	5	dobj
9	include	include	VBP	_	0	ROOT
10	:	:	:	_	9	punct
11	drug2	drug2	NN	_	9	dep
12	,	,	,	_	11	punct
13	chronic	chronic	JJ	_	15	amod
14	drug3	drug3	NN	_	15	compound
15	abuse	abuse	NN	_	11	conj
16	,	,	,	_	11	punct
17	drug4	drug4	NN	_	11	conj

1	.	.	.	_	0	ROOT

1	-	-	:	_	12	punct
2	Drugs	drug	NNS	_	12	nsubj
3	that	that	WDT	_	6	nsubj
4	may	may	MD	_	6	aux
5	either	either	RB	_	6	advmod
6	increase	increase	VB	_	2	acl:relcl
7	or	or	CC	_	6	cc
8	decrease	decrease	VB	_	6	conj
9	plasma	plasma	NN	_	11	compound
10	drug1	drug1	NN	_	11	compound
11	concentrations	concentration	NNS	_	6	dobj
12	include	include	VBP	_	0	ROOT
13	:	:	:	_	12	punct
14	drug2	drug2	NN	_	12	dep
15	,	,	,	_	14	punct
16	vaiproic	vaiproic	JJ	_	17	amod
17	acid	acid	NN	_	14	conj
18	,	,	,	_	14	punct
19	and	and	CC	_	14	cc
20	drug3	drug3	NN	_	14	conj
21	.	.	.	_	12	punct

1	Similarly	similarly	RB	_	17	advmod
2	,	,	,	_	17	punct
3	the	the	DT	_	4	det
4	effects	effect	NNS	_	17	nsubj
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	on	on	IN	_	8	case
8	drug2	drug2	NN	_	4	nmod
9	,	,	,	_	8	punct
10	drug3	drug3	NN	_	8	conj
11	and	and	CC	_	8	cc
12	sodium	sodium	NN	_	15	compound
13	plasma	plasma	NN	_	15	compound
14	drug4	drug4	NN	_	15	compound
15	concentrations	concentration	NNS	_	8	conj
16	are	be	VBP	_	17	cop
17	unpredictable	unpredictable	JJ	_	0	ROOT

1	.	.	.	_	0	ROOT

1	-	-	:	_	20	punct
2	Although	although	IN	_	11	dep
3	not	not	RB	_	7	neg
4	a	a	DT	_	7	det
5	true	true	JJ	_	7	amod
6	drug	drug	NN	_	7	compound
7	interaction	interaction	NN	_	11	dep
8	,	,	,	_	11	punct
9	drug1	drug1	NN	_	11	nsubj
10	may	may	MD	_	11	aux
11	precipitate	precipitate	VB	_	12	amod
12	seizures	seizure	NNS	_	20	nsubj
13	in	in	IN	_	15	case
14	susceptible	susceptible	JJ	_	15	amod
15	patients	patient	NNS	_	12	nmod
16	and	and	CC	_	15	cc
17	drug2	drug2	NN	_	18	compound
18	dosage	dosage	NN	_	15	conj
19	may	may	MD	_	20	aux
20	need	need	VB	_	0	ROOT
21	to	to	TO	_	23	mark
22	be	be	VB	_	23	auxpass
23	adjusted	adjust	VBN	_	20	xcomp

1	.	.	.	_	0	ROOT

1	-	-	:	_	9	punct
2	Drugs	drug	NNS	_	9	nsubj
3	whose	whose	WP$	_	4	nmod:poss
4	efficacy	efficacy	NN	_	6	nsubjpass
5	is	be	VBZ	_	6	auxpass
6	impaired	impair	VBN	_	2	acl:relcl
7	by	by	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	include	include	VBP	_	0	ROOT
10	:	:	:	_	9	punct
11	drug2	drug2	NN	_	9	dep
12	,	,	,	_	11	punct
13	drug3	drug3	NN	_	11	conj
14	,	,	,	_	11	punct
15	drug4	drug4	NN	_	11	conj
16	,	,	,	_	11	punct
17	drug5	drug5	NN	_	11	conj
18	,	,	,	_	11	punct
19	drug6	drug6	NN	_	11	conj
20	,	,	,	_	11	punct
21	drug7	drug7	NN	_	11	conj
22	,	,	,	_	11	punct
23	drug8	drug8	NN	_	11	conj
24	,	,	,	_	11	punct
25	oral	oral	JJ	_	26	amod
26	drug9	drug9	NN	_	11	conj
27	,	,	,	_	11	punct
28	drug10	drug10	NN	_	11	conj
29	,	,	,	_	11	punct
30	drug11	drug11	NN	_	11	conj
31	,	,	,	_	11	punct
32	drug12	drug12	NN	_	11	conj
33	,	,	,	_	11	punct
34	drug13	drug13	NN	_	11	conj
35	.	.	.	_	9	punct

1	Monitoring	monitoring	NN	_	8	nsubj
2	of	of	IN	_	5	case
3	plasma	plasma	NN	_	5	compound
4	drug1	drug1	NN	_	5	compound
5	concentrations	concentration	NNS	_	1	nmod
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	cop
8	helpful	helpful	JJ	_	0	ROOT
9	when	when	WRB	_	14	advmod
10	possible	possible	JJ	_	12	amod
11	drug	drug	NN	_	12	compound
12	interactions	interaction	NNS	_	14	nsubjpass
13	are	be	VBP	_	14	auxpass
14	suspected	suspect	VBN	_	8	advcl
15	.	.	.	_	8	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	4	amod
2	Test	test	NN	_	4	compound
3	Interactions	interaction	NNS	_	4	compound
4	drug1	drug1	NN	_	6	nsubj
5	may	may	MD	_	6	aux
6	decrease	decrease	VB	_	0	ROOT
7	serum	serum	NN	_	8	compound
8	concentrations	concentration	NNS	_	6	dobj
9	of	of	IN	_	10	case
10	14	14	CD	_	8	nmod
11	.	.	.	_	6	punct

1	It	it	PRP	_	4	nsubj
2	may	may	MD	_	4	aux
3	also	also	RB	_	4	advmod
4	produce	produce	VB	_	0	ROOT
5	artifactually	artifactually	RB	_	6	advmod
6	low	low	JJ	_	7	amod
7	results	result	NNS	_	4	dobj
8	in	in	IN	_	9	case
9	dexamethasone	dexamethasone	NN	_	7	nmod
10	or	or	CC	_	9	cc
11	metyrapone	metyrapone	NN	_	12	compound
12	tests	test	NNS	_	9	conj
13	.	.	.	_	4	punct

1	drug1	drug1	NN	_	4	nsubj
2	may	may	MD	_	4	aux
3	also	also	RB	_	4	advmod
4	cause	cause	VB	_	0	ROOT
5	increased	increase	VBN	_	7	amod
6	serum	serum	NN	_	7	compound
7	concentrations	concentration	NNS	_	4	dobj
8	of	of	IN	_	9	case
9	glucose	glucose	NN	_	7	nmod
10	,	,	,	_	9	punct
11	alkaline	alkaline	NN	_	12	compound
12	phosphatase	phosphatase	NN	_	9	conj
13	,	,	,	_	9	punct
14	and	and	CC	_	9	cc
15	gamma	gamma	NN	_	17	compound
16	glutamyl	glutamyl	NN	_	17	compound
17	transpeptidase	transpeptidase	NN	_	9	conj
18	-LRB-	-lrb-	-LRB-	_	19	punct
19	GGT	ggt	NN	_	17	appos
20	-RRB-	-rrb-	-RRB-	_	19	punct
21	.	.	.	_	4	punct

1	Care	Care	NNP	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	taken	take	VBN	_	0	ROOT
5	when	when	WRB	_	6	advmod
6	using	use	VBG	_	4	advcl
7	immunoanalytical	immunoanalytical	JJ	_	8	amod
8	methods	method	NNS	_	6	dobj
9	to	to	TO	_	10	mark
10	measure	measure	VB	_	6	advcl
11	plasma	plasma	NN	_	13	compound
12	drug1	drug1	NN	_	13	compound
13	concentrations	concentration	NNS	_	10	dobj
14	following	follow	VBG	_	16	case
15	drug2	drug2	NN	_	16	compound
16	administration	administration	NN	_	10	nmod
17	.	.	.	_	4	punct

1	drug1	drug1	NN	_	4	compound
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	Administration	administration	NN	_	23	nsubj
5	of	of	IN	_	6	case
6	drug3	drug3	NN	_	4	nmod
7	or	or	CC	_	6	cc
8	drug4	drug4	NN	_	6	conj
9	in	in	IN	_	10	case
10	patients	patient	NNS	_	4	nmod
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	n	n	NN	_	10	dep
13	=	=	JJ	_	12	amod
14	13	13	CD	_	13	dep
15	-RRB-	-rrb-	-RRB-	_	12	punct
16	and	and	CC	_	10	cc
17	volunteers	volunteer	NNS	_	10	conj
18	-LRB-	-lrb-	-LRB-	_	19	punct
19	n	n	NN	_	17	dep
20	=	=	JJ	_	19	amod
21	96	96	CD	_	20	dep
22	-RRB-	-rrb-	-RRB-	_	19	punct
23	resulted	result	VBD	_	0	ROOT
24	in	in	IN	_	29	case
25	a	a	DT	_	29	det
26	rapid	rapid	JJ	_	29	amod
27	and	and	CC	_	26	cc
28	significant	significant	JJ	_	26	conj
29	decrease	decrease	NN	_	23	nmod
30	in	in	IN	_	32	case
31	plasma	plasma	NN	_	32	compound
32	M1	m1	NN	_	29	nmod
33	-LRB-	-lrb-	-LRB-	_	36	punct
34	the	the	DT	_	36	det
35	active	active	JJ	_	36	amod
36	metabolite	metabolite	NN	_	29	dep
37	of	of	IN	_	38	case
38	drug5	drug5	NN	_	36	nmod
39	-RRB-	-rrb-	-RRB-	_	36	punct
40	concentration	concentration	NN	_	29	dep
41	.	.	.	_	23	punct

1	Hepatotoxic	hepatotoxic	JJ	_	2	amod
2	Drugs	drug	NNS	_	0	ROOT
3	Increased	increase	VBN	_	5	amod
4	side	side	JJ	_	5	amod
5	effects	effect	NNS	_	7	nsubj
6	may	may	MD	_	7	aux
7	occur	occur	VB	_	2	acl:relcl
8	when	when	WRB	_	11	advmod
9	drug1	drug1	NN	_	11	nsubjpass
10	is	be	VBZ	_	11	auxpass
11	given	give	VBN	_	7	advcl
12	concomitantly	concomitantly	RB	_	11	advmod
13	with	with	IN	_	15	case
14	hepatotoxic	hepatotoxic	JJ	_	15	amod
15	substances	substance	NNS	_	11	nmod
16	.	.	.	_	2	punct

1	This	this	DT	_	6	nsubjpass
2	is	be	VBZ	_	6	auxpass
3	also	also	RB	_	6	advmod
4	to	to	TO	_	6	mark
5	be	be	VB	_	6	auxpass
6	considered	consider	VBN	_	0	ROOT
7	when	when	WRB	_	11	advmod
8	drug1	drug1	NN	_	9	compound
9	treatment	treatment	NN	_	11	nsubjpass
10	is	be	VBZ	_	11	auxpass
11	followed	follow	VBN	_	6	advcl
12	by	by	IN	_	14	case
13	such	such	JJ	_	14	amod
14	drugs	drug	NNS	_	11	nmod
15	without	without	IN	_	19	case
16	a	a	DT	_	19	det
17	drug	drug	NN	_	19	compound
18	elimination	elimination	NN	_	19	compound
19	procedure	procedure	NN	_	14	nmod
20	.	.	.	_	6	punct

1	In	in	IN	_	5	case
2	a	a	DT	_	5	det
3	small	small	JJ	_	5	amod
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	n	n	NN	_	0	ROOT
6	=	=	JJ	_	5	amod
7	30	30	CD	_	6	dep
8	-RRB-	-rrb-	-RRB-	_	5	punct
9	combination	combination	NN	_	10	compound
10	study	study	NN	_	5	dep
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	with	with	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	,	,	,	_	14	punct
16	a	a	DT	_	14	appos
17	2	2	LS	_	26	nsubjpass
18	-	-	:	_	17	punct
19	to	to	TO	_	21	case
20	3-fold	3-fold	JJ	_	21	amod
21	elevation	elevation	NN	_	17	nmod
22	in	in	IN	_	24	case
23	liver	liver	NN	_	24	compound
24	enzymes	enzyme	NNS	_	21	nmod
25	was	be	VBD	_	26	auxpass
26	seen	see	VBN	_	16	acl:relcl
27	in	in	IN	_	26	nmod
28	5	5	CD	_	27	dep
29	of	of	IN	_	31	case
30	30	30	CD	_	31	nummod
31	patients	patient	NNS	_	28	nmod
32	.	.	.	_	5	punct

1	All	all	DT	_	2	det
2	elevations	elevation	NNS	_	3	nsubj
3	resolved	resolve	VBN	_	0	ROOT
4	,	,	,	_	3	punct
5	2	2	CD	_	3	dobj
6	with	with	IN	_	7	case
7	continuation	continuation	NN	_	5	nmod
8	of	of	IN	_	10	case
9	both	both	CC	_	10	cc:preconj
10	drugs	drug	NNS	_	7	nmod
11	and	and	CC	_	10	cc
12	3	3	CD	_	10	conj
13	after	after	IN	_	14	case
14	discontinuation	discontinuation	NN	_	3	nmod
15	of	of	IN	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	.	.	.	_	3	punct

1	A	a	DT	_	3	det
2	3-fold	3-fold	JJ	_	3	amod
3	increase	increase	NN	_	5	nsubjpass
4	was	be	VBD	_	5	auxpass
5	seen	see	VBN	_	0	ROOT
6	in	in	IN	_	9	case
7	another	another	DT	_	9	det
8	5	5	CD	_	9	nummod
9	patients	patient	NNS	_	5	nmod
10	.	.	.	_	5	punct

1	All	all	DT	_	5	nsubj
2	of	of	IN	_	3	case
3	these	these	DT	_	1	nmod
4	also	also	RB	_	5	advmod
5	resolved	resolve	VBN	_	0	ROOT
6	,	,	,	_	5	punct
7	2	2	CD	_	5	dobj
8	with	with	IN	_	9	case
9	continuation	continuation	NN	_	7	nmod
10	of	of	IN	_	12	case
11	both	both	CC	_	12	cc:preconj
12	drugs	drug	NNS	_	9	nmod
13	and	and	CC	_	12	cc
14	3	3	CD	_	12	conj
15	after	after	IN	_	16	case
16	discontinuation	discontinuation	NN	_	5	nmod
17	of	of	IN	_	18	case
18	drug1	drug1	NN	_	16	nmod
19	.	.	.	_	5	punct

1	Three	three	CD	_	2	nummod
2	patients	patient	NNS	_	3	nsubj
3	met	meet	VBD	_	0	ROOT
4	ACR	acr	NN	_	5	compound
5	criteria	criterion	NNS	_	3	dobj
6	for	for	IN	_	8	case
7	liver	liver	NN	_	8	compound
8	biopsy	biopsy	NN	_	5	nmod
9	-LRB-	-lrb-	-LRB-	_	8	punct
10	1	1	CD	_	9	root
11	:	:	:	_	10	punct
12	Roegnik	Roegnik	NNP	_	13	compound
13	Grade	Grade	NNP	_	11	root
14	I	I	PRP	_	13	dep
15	,	,	,	_	14	punct
16	2	2	CD	_	14	nummod
17	:	:	:	_	14	punct
18	Roegnik	Roegnik	NNP	_	20	compound
19	Grade	Grade	NNP	_	20	compound
20	IIIa	iiia	NN	_	14	dep
21	-RRB-	-rrb-	-RRB-	_	13	punct
22	.	.	.	_	13	punct

1	No	no	DT	_	3	neg
2	pharmacokinetic	pharmacokinetic	JJ	_	3	amod
3	interaction	interaction	NN	_	5	nsubjpass
4	was	be	VBD	_	5	auxpass
5	identified	identify	VBN	_	0	ROOT
6	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	6	case
4	in	in	FW	_	6	amod
5	vitro	vitro	FW	_	4	dep
6	studies	study	NNS	_	10	nmod
7	,	,	,	_	10	punct
8	M1	m1	NN	_	10	nsubjpass
9	was	be	VBD	_	10	auxpass
10	shown	show	VBN	_	1	dep
11	to	to	TO	_	12	mark
12	cause	cause	VB	_	10	xcomp
13	increases	increase	NNS	_	12	dobj
14	ranging	range	VBG	_	13	acl
15	from	from	IN	_	16	case
16	13	13	CD	_	14	nmod
17	-	-	:	_	16	punct
18	50	50	CD	_	19	nummod
19	%	%	NN	_	16	dep
20	in	in	IN	_	23	case
21	the	the	DT	_	23	det
22	free	free	JJ	_	23	amod
23	fraction	fraction	NN	_	19	nmod
24	of	of	IN	_	25	case
25	drug2	drug2	NN	_	23	nmod
26	and	and	CC	_	25	cc
27	drug3	drug3	NN	_	25	conj
28	at	at	IN	_	29	case
29	concentrations	concentration	NNS	_	23	nmod
30	in	in	IN	_	33	case
31	the	the	DT	_	33	det
32	clinical	clinical	JJ	_	33	amod
33	range	range	NN	_	29	nmod
34	.	.	.	_	1	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	significance	significance	NN	_	8	nsubj
4	of	of	IN	_	6	case
5	this	this	DT	_	6	det
6	finding	finding	NN	_	3	nmod
7	is	be	VBZ	_	8	cop
8	unknown	unknown	JJ	_	0	ROOT
9	;	;	:	_	8	punct

1	however	however	RB	_	4	advmod
2	,	,	,	_	4	punct
3	there	there	EX	_	4	expl
4	was	be	VBD	_	0	ROOT
5	extensive	extensive	JJ	_	7	amod
6	concomitant	concomitant	JJ	_	7	amod
7	use	use	NN	_	18	nsubjpass
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	in	in	IN	_	12	case
11	clinical	clinical	JJ	_	12	amod
12	studies	study	NNS	_	7	nmod
13	and	and	CC	_	7	cc
14	no	no	DT	_	16	neg
15	differential	differential	JJ	_	16	amod
16	effect	effect	NN	_	7	conj
17	was	be	VBD	_	18	auxpass
18	observed	observe	VBN	_	4	ccomp
19	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	6	case
4	in	in	FW	_	6	amod
5	vitro	vitro	FW	_	4	dep
6	studies	study	NNS	_	10	nmod
7	,	,	,	_	10	punct
8	M1	m1	NN	_	10	nsubjpass
9	was	be	VBD	_	10	auxpass
10	shown	show	VBN	_	1	dep
11	to	to	TO	_	12	mark
12	cause	cause	VB	_	10	xcomp
13	increases	increase	NNS	_	12	dobj
14	ranging	range	VBG	_	13	acl
15	from	from	IN	_	16	case
16	13	13	CD	_	14	nmod
17	-	-	:	_	16	punct
18	50	50	CD	_	19	nummod
19	%	%	NN	_	16	dep
20	in	in	IN	_	23	case
21	the	the	DT	_	23	det
22	free	free	JJ	_	23	amod
23	fraction	fraction	NN	_	19	nmod
24	of	of	IN	_	25	case
25	drug2	drug2	NN	_	23	nmod
26	at	at	IN	_	27	case
27	concentrations	concentration	NNS	_	19	nmod
28	in	in	IN	_	31	case
29	the	the	DT	_	31	det
30	clinical	clinical	JJ	_	31	amod
31	range	range	NN	_	27	nmod
32	.	.	.	_	1	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	significance	significance	NN	_	8	nsubj
4	of	of	IN	_	6	case
5	this	this	DT	_	6	det
6	finding	finding	NN	_	3	nmod
7	is	be	VBZ	_	8	cop
8	unknown	unknown	JJ	_	0	ROOT
9	.	.	.	_	8	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Following	follow	VBG	_	5	case
4	concomitant	concomitant	JJ	_	5	amod
5	administration	administration	NN	_	24	nsubjpass
6	of	of	IN	_	9	case
7	a	a	DT	_	9	det
8	single	single	JJ	_	9	amod
9	dose	dose	NN	_	5	nmod
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	to	to	TO	_	13	case
13	subjects	subject	NNS	_	5	nmod
14	receiving	receive	VBG	_	13	acl
15	multiple	multiple	JJ	_	16	amod
16	doses	dose	NNS	_	14	dobj
17	of	of	IN	_	18	case
18	drug3	drug3	NN	_	16	nmod
19	,	,	,	_	18	punct
20	M1	m1	NN	_	22	compound
21	peak	peak	NN	_	22	compound
22	levels	level	NNS	_	18	conj
23	were	be	VBD	_	24	auxpass
24	increased	increase	VBN	_	1	dep
25	-LRB-	-lrb-	-LRB-	_	28	punct
26	~	~	CD	_	27	compound
27	40	40	CD	_	28	nummod
28	%	%	NN	_	24	dep
29	-RRB-	-rrb-	-RRB-	_	28	punct
30	over	over	IN	_	31	case
31	those	those	DT	_	24	nmod
32	seen	see	VBN	_	31	acl
33	when	when	WRB	_	36	advmod
34	drug4	drug4	NN	_	36	nsubjpass
35	was	be	VBD	_	36	auxpass
36	given	give	VBN	_	32	advcl
37	alone	alone	RB	_	36	advmod
38	.	.	.	_	1	punct

1	Because	because	IN	_	4	case
2	of	of	IN	_	1	mwe
3	the	the	DT	_	4	det
4	potential	potential	NN	_	19	nmod
5	for	for	IN	_	7	case
6	drug1	drug1	NN	_	7	compound
7	levels	level	NNS	_	4	nmod
8	to	to	TO	_	9	mark
9	continue	continue	VB	_	4	acl
10	to	to	TO	_	11	mark
11	increase	increase	VB	_	9	xcomp
12	with	with	IN	_	14	case
13	multiple	multiple	JJ	_	14	amod
14	dosing	dosing	NN	_	11	nmod
15	,	,	,	_	19	punct
16	caution	caution	NN	_	19	nsubjpass
17	should	should	MD	_	19	aux
18	be	be	VB	_	19	auxpass
19	used	use	VBN	_	0	ROOT
20	if	if	IN	_	22	mark
21	patients	patient	NNS	_	22	nsubj
22	are	be	VBP	_	19	advcl
23	to	to	TO	_	25	mark
24	be	be	VB	_	25	aux
25	receiving	receive	VBG	_	22	xcomp
26	both	both	DT	_	27	cc:preconj
27	drug2	drug2	NN	_	25	dobj
28	and	and	CC	_	27	cc
29	drug3	drug3	NN	_	27	conj
30	.	.	.	_	19	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Increased	increase	VBN	_	4	amod
4	INR	inr	NN	_	19	nsubjpass
5	-LRB-	-lrb-	-LRB-	_	8	punct
6	International	International	NNP	_	8	compound
7	Normalized	Normalized	NNP	_	8	compound
8	Ratio	Ratio	NNP	_	4	appos
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	when	when	WRB	_	15	advmod
11	drug2	drug2	NN	_	15	nsubjpass
12	and	and	CC	_	11	cc
13	drug3	drug3	NN	_	11	conj
14	were	be	VBD	_	15	auxpass
15	co-administered	co-administer	VBN	_	4	acl:relcl
16	has	have	VBZ	_	19	aux
17	been	be	VBN	_	19	auxpass
18	rarely	rarely	RB	_	19	advmod
19	reported	report	VBN	_	1	dep
20	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	potential	potential	NN	_	13	nsubj
3	for	for	IN	_	7	case
4	clinically	clinically	RB	_	5	advmod
5	significant	significant	JJ	_	7	amod
6	drug-drug	drug-drug	JJ	_	7	amod
7	interactions	interaction	NNS	_	2	nmod
8	posed	pose	VBN	_	7	acl
9	by	by	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	drug2	drug2	NN	_	10	conj
13	appears	appear	VBZ	_	0	ROOT
14	to	to	TO	_	16	mark
15	be	be	VB	_	16	cop
16	low	low	JJ	_	13	xcomp
17	for	for	IN	_	18	case
18	drugs	drug	NNS	_	16	nmod
19	commonly	commonly	RB	_	20	advmod
20	used	use	VBN	_	18	acl
21	in	in	IN	_	22	case
22	chemotherapy	chemotherapy	NN	_	20	nmod
23	or	or	CC	_	22	cc
24	surgery	surgery	NN	_	22	conj
25	,	,	,	_	13	punct
26	because	because	IN	_	29	mark
27	drug3	drug3	NN	_	29	nsubjpass
28	is	be	VBZ	_	29	auxpass
29	eliminated	eliminate	VBN	_	13	advcl
30	by	by	IN	_	32	case
31	multiple	multiple	JJ	_	32	amod
32	routes	route	NNS	_	29	nmod
33	.	.	.	_	13	punct

1	Blood	blood	NN	_	2	compound
2	levels	level	NNS	_	5	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	increased	increase	VBD	_	0	ROOT
6	24	24	CD	_	7	nummod
7	%	%	NN	_	5	dobj
8	when	when	WRB	_	11	advmod
9	drug2	drug2	NN	_	11	nsubjpass
10	was	be	VBD	_	11	auxpass
11	coadministered	coadminister	VBN	_	5	advcl
12	with	with	IN	_	13	case
13	drug3	drug3	NN	_	11	nmod
14	-LRB-	-lrb-	-LRB-	_	16	punct
15	nonselective	nonselective	JJ	_	16	amod
16	inhibitor	inhibitor	NN	_	13	appos
17	of	of	IN	_	19	case
18	cytochrome	cytochrome	NN	_	19	compound
19	P-450	p-450	NN	_	16	nmod
20	-RRB-	-rrb-	-RRB-	_	16	punct
21	for	for	IN	_	23	case
22	7	7	CD	_	23	nummod
23	days	day	NNS	_	11	nmod
24	,	,	,	_	5	punct
25	and	and	CC	_	5	cc
26	decreased	decrease	VBD	_	5	conj
27	28	28	CD	_	28	nummod
28	%	%	NN	_	26	dobj
29	with	with	IN	_	30	case
30	coadministration	coadministration	NN	_	26	nmod
31	of	of	IN	_	32	case
32	drug4	drug4	NN	_	30	nmod
33	-LRB-	-lrb-	-LRB-	_	35	punct
34	potent	potent	JJ	_	35	amod
35	inducer	inducer	NN	_	32	dep
36	of	of	IN	_	38	case
37	cytochrome	cytochrome	NN	_	38	compound
38	P-450	p-450	NN	_	35	nmod
39	-RRB-	-rrb-	-RRB-	_	35	punct
40	for	for	IN	_	42	case
41	7	7	CD	_	42	nummod
42	days	day	NNS	_	26	nmod
43	.	.	.	_	5	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	has	have	VBZ	_	5	aux
3	been	be	VBN	_	5	auxpass
4	safely	safely	RB	_	5	advmod
5	coadministered	coadminister	VBN	_	0	ROOT
6	with	with	IN	_	7	case
7	drugs	drug	NNS	_	5	nmod
8	used	use	VBN	_	7	acl
9	in	in	IN	_	10	case
10	chemotherapy	chemotherapy	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	surgery	surgery	NN	_	10	conj
13	.	.	.	_	5	punct

1	As	as	IN	_	4	case
2	with	with	IN	_	4	case
3	other	other	JJ	_	4	amod
4	agents	agent	NNS	_	13	nmod
5	which	which	WDT	_	6	nsubj
6	prolong	prolong	VBP	_	4	acl:relcl
7	ECG	ecg	NN	_	8	compound
8	intervals	interval	NNS	_	6	dobj
9	,	,	,	_	13	punct
10	caution	caution	NN	_	13	nsubjpass
11	should	should	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	exercised	exercise	VBN	_	0	ROOT
14	in	in	IN	_	15	case
15	patients	patient	NNS	_	13	nmod
16	taking	take	VBG	_	15	acl
17	drugs	drug	NNS	_	16	dobj
18	which	which	WDT	_	19	nsubj
19	prolong	prolong	VBP	_	17	acl:relcl
20	ECG	ecg	NN	_	21	compound
21	intervals	interval	NNS	_	19	dobj
22	,	,	,	_	13	punct
23	particularly	particularly	RB	_	24	advmod
24	QTc	qtc	NN	_	13	xcomp
25	.	.	.	_	13	punct

1	In	in	IN	_	2	case
2	patients	patient	NNS	_	26	nmod
3	taking	take	VBG	_	2	acl
4	drug1	drug1	NN	_	3	dobj
5	,	,	,	_	4	punct
6	drug2	drug2	NN	_	4	conj
7	,	,	,	_	4	punct
8	drug3	drug3	NN	_	4	conj
9	,	,	,	_	4	punct
10	drug4	drug4	NN	_	4	conj
11	,	,	,	_	4	punct
12	drug5	drug5	NN	_	4	conj
13	,	,	,	_	4	punct
14	drug6	drug6	NN	_	4	conj
15	,	,	,	_	4	punct
16	drug7	drug7	NN	_	4	conj
17	,	,	,	_	4	punct
18	and	and	CC	_	4	cc
19	various	various	JJ	_	21	amod
20	chemotherapy	chemotherapy	NN	_	21	compound
21	agents	agent	NNS	_	4	conj
22	,	,	,	_	26	punct
23	no	no	DT	_	24	neg
24	effect	effect	NN	_	26	nsubjpass
25	was	be	VBD	_	26	auxpass
26	shown	show	VBN	_	0	ROOT
27	on	on	IN	_	29	case
28	the	the	DT	_	29	det
29	clearance	clearance	NN	_	26	nmod
30	of	of	IN	_	31	case
31	drug8	drug8	NN	_	29	nmod
32	.	.	.	_	26	punct

1	Clearance	clearance	NN	_	4	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	decreased	decrease	VBN	_	0	ROOT
5	by	by	IN	_	8	case
6	about	about	IN	_	7	advmod
7	27	27	CD	_	8	nummod
8	%	%	NN	_	4	nmod
9	when	when	WRB	_	12	advmod
10	drug2	drug2	NN	_	12	nsubjpass
11	was	be	VBD	_	12	auxpass
12	administered	administer	VBN	_	4	advcl
13	intravenously	intravenously	RB	_	14	advmod
14	concomitantly	concomitantly	RB	_	12	advmod
15	with	with	IN	_	16	case
16	drug3	drug3	NN	_	12	nmod
17	.	.	.	_	4	punct

1	drug1	drug1	NN	_	4	nsubj
2	does	do	VBZ	_	4	aux
3	not	not	RB	_	4	neg
4	influence	influence	VB	_	0	ROOT
5	anesthesia	anesthesia	NN	_	7	compound
6	recovery	recovery	NN	_	7	compound
7	time	time	NN	_	4	dobj
8	in	in	IN	_	9	case
9	patients	patient	NNS	_	7	nmod
10	.	.	.	_	4	punct

1	drug1	drug1	NN	_	4	nsubj
2	did	do	VBD	_	4	aux
3	not	not	RB	_	4	neg
4	inhibit	inhibit	VB	_	0	ROOT
5	the	the	DT	_	7	det
6	antitumor	antitumor	NN	_	7	compound
7	activity	activity	NN	_	4	dobj
8	of	of	IN	_	10	case
9	four	four	CD	_	10	nummod
10	drug2	drug2	NN	_	7	nmod
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	drug3	drug3	NN	_	10	dep
13	,	,	,	_	12	punct
14	drug4	drug4	NN	_	12	conj
15	,	,	,	_	12	punct
16	drug5	drug5	NN	_	12	conj
17	,	,	,	_	12	punct
18	drug6	drug6	NN	_	12	appos
19	-RRB-	-rrb-	-RRB-	_	12	punct
20	in	in	IN	_	23	case
21	four	four	CD	_	23	nummod
22	murine	murine	JJ	_	23	amod
23	models	model	NNS	_	7	nmod
24	.	.	.	_	4	punct

1	Coadministration	coadministration	NN	_	13	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	5	case
5	drugs	drug	NNS	_	1	nmod
6	that	that	WDT	_	8	nsubjpass
7	are	be	VBP	_	8	auxpass
8	known	know	VBN	_	5	acl:relcl
9	to	to	TO	_	10	mark
10	cause	cause	VB	_	8	xcomp
11	pancreatitis	pancreatitis	NN	_	10	dobj
12	may	may	MD	_	13	aux
13	increase	increase	VB	_	0	ROOT
14	the	the	DT	_	15	det
15	risk	risk	NN	_	13	dobj
16	of	of	IN	_	18	case
17	this	this	DT	_	18	det
18	toxicity	toxicity	NN	_	15	nmod
19	-LRB-	-lrb-	-LRB-	_	20	punct
20	see	see	VB	_	13	parataxis
21	WARNINGS	warning	NNS	_	20	dobj
22	-RRB-	-rrb-	-RRB-	_	20	punct
23	and	and	CC	_	13	cc
24	should	should	MD	_	26	aux
25	be	be	VB	_	26	auxpass
26	done	do	VBN	_	13	conj
27	with	with	IN	_	29	case
28	extreme	extreme	JJ	_	29	amod
29	caution	caution	NN	_	26	nmod
30	,	,	,	_	26	punct
31	only	only	RB	_	37	advmod
32	if	if	IN	_	37	mark
33	other	other	JJ	_	34	amod
34	alternatives	alternative	NNS	_	37	nsubj
35	are	be	VBP	_	37	cop
36	not	not	RB	_	37	neg
37	available	available	JJ	_	26	advcl
38	,	,	,	_	37	punct
39	and	and	CC	_	37	cc
40	only	only	RB	_	43	advmod
41	if	if	IN	_	43	mark
42	clearly	clearly	RB	_	43	advmod
43	indicated	indicate	VBN	_	37	conj
44	.	.	.	_	13	punct

1	Neuropathy	neuropathy	NN	_	3	nsubj
2	has	have	VBZ	_	3	aux
3	occurred	occur	VBN	_	0	ROOT
4	more	more	RBR	_	5	advmod
5	frequently	frequently	RB	_	3	advmod
6	in	in	IN	_	7	case
7	patients	patient	NNS	_	3	nmod
8	with	with	IN	_	10	case
9	a	a	DT	_	10	det
10	history	history	NN	_	7	nmod
11	of	of	IN	_	12	case
12	neuropathy	neuropathy	NN	_	10	nmod
13	or	or	CC	_	12	cc
14	neurotoxic	neurotoxic	JJ	_	16	amod
15	drug	drug	NN	_	16	compound
16	therapy	therapy	NN	_	12	conj
17	,	,	,	_	7	punct
18	including	include	VBG	_	19	case
19	drug1	drug1	NN	_	7	nmod
20	,	,	,	_	3	punct
21	and	and	CC	_	3	cc
22	these	these	DT	_	23	det
23	patients	patient	NNS	_	28	nsubj
24	may	may	MD	_	28	aux
25	be	be	VB	_	28	cop
26	at	at	IN	_	28	case
27	increased	increase	VBN	_	28	amod
28	risk	risk	NN	_	3	conj
29	of	of	IN	_	30	case
30	neuropathy	neuropathy	NN	_	28	nmod
31	during	during	IN	_	33	case
32	drug2	drug2	NN	_	33	compound
33	therapy	therapy	NN	_	28	nmod
34	-LRB-	-lrb-	-LRB-	_	35	punct
35	see	see	VB	_	28	parataxis
36	ADVERSE	adverse	JJ	_	37	amod
37	REACTIONS	reaction	NNS	_	35	dobj
38	-RRB-	-rrb-	-RRB-	_	35	punct
39	.	.	.	_	3	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	AUC	auc	NN	_	8	nsubjpass
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	was	be	VBD	_	8	auxpass
8	increased	increase	VBN	_	1	appos
9	about	about	IN	_	10	advmod
10	4-fold	4-fold	RB	_	8	advmod
11	when	when	WRB	_	17	advmod
12	drug3	drug3	NN	_	17	nsubjpass
13	at	at	IN	_	15	case
14	300	300	CD	_	15	nummod
15	mg/day	mg/day	NN	_	12	nmod
16	was	be	VBD	_	17	auxpass
17	coadministered	coadminister	VBN	_	10	advcl
18	with	with	IN	_	22	case
19	a	a	DT	_	22	det
20	single	single	JJ	_	22	amod
21	200-mg	200-mg	JJ	_	22	amod
22	dose	dose	NN	_	17	nmod
23	of	of	IN	_	24	case
24	drug4	drug4	NN	_	22	nmod
25	to	to	TO	_	27	case
26	two	two	CD	_	27	nummod
27	patients	patient	NNS	_	17	nmod
28	with	with	IN	_	30	case
29	renal	renal	JJ	_	30	amod
30	impairment	impairment	NN	_	27	nmod
31	-LRB-	-lrb-	-LRB-	_	32	punct
32	CLcr	clcr	NN	_	27	dep
33	=	=	JJ	_	32	amod
34	15	15	CD	_	37	nummod
35	and	and	CC	_	34	cc
36	18	18	CD	_	34	conj
37	mL/min	ml/min	NN	_	33	dep
38	-RRB-	-rrb-	-RRB-	_	32	punct
39	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	effects	effect	NNS	_	16	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	on	on	IN	_	7	case
6	drug2	drug2	NN	_	7	compound
7	pharmacokinetics	pharmacokinetic	NNS	_	2	nmod
8	in	in	IN	_	9	case
9	subjects	subject	NNS	_	7	nmod
10	with	with	IN	_	13	case
11	normal	normal	JJ	_	13	amod
12	renal	renal	JJ	_	13	amod
13	function	function	NN	_	9	nmod
14	are	be	VBP	_	16	auxpass
15	not	not	RB	_	16	neg
16	known	know	VBN	_	0	ROOT
17	.	.	.	_	16	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concomitant	concomitant	JJ	_	4	amod
4	administration	administration	NN	_	23	nsubj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	containing	contain	VBG	_	6	acl
8	drug3	drug3	NN	_	7	dobj
9	or	or	CC	_	8	cc
10	drug4	drug4	NN	_	8	conj
11	with	with	IN	_	15	case
12	drug5	drug5	NN	_	15	compound
13	Chewable/Dispersible	chewable/dispersible	NN	_	15	compound
14	Buffered	Buffered	NNP	_	15	compound
15	Tablets	Tablets	NNPS	_	4	nmod
16	or	or	CC	_	15	cc
17	Pediatric	Pediatric	NNP	_	18	compound
18	Powder	Powder	NNP	_	15	conj
19	for	for	IN	_	21	case
20	Oral	Oral	NNP	_	21	compound
21	Solution	solution	NN	_	4	nmod
22	may	may	MD	_	23	aux
23	potentiate	potentiate	VB	_	1	dep
24	adverse	adverse	JJ	_	25	amod
25	events	event	NNS	_	23	dobj
26	associated	associate	VBN	_	25	acl
27	with	with	IN	_	30	case
28	the	the	DT	_	30	det
29	drug6	drug6	NN	_	30	compound
30	components	component	NNS	_	26	nmod
31	.	.	.	_	1	punct

1	Drugs	drug	NNS	_	0	ROOT
2	Whose	whose	WP$	_	3	nmod:poss
3	Absorption	absorption	NN	_	6	nsubjpass
4	Can	can	MD	_	6	aux
5	Be	be	VB	_	6	auxpass
6	Affected	affect	VBN	_	1	acl:relcl
7	by	by	IN	_	9	case
8	the	the	DT	_	9	det
9	Level	level	NN	_	6	nmod
10	of	of	IN	_	11	case
11	Acidity	acidity	NN	_	9	nmod
12	in	in	IN	_	14	case
13	the	the	DT	_	14	det
14	Stomach	Stomach	NNP	_	9	nmod
15	:	:	:	_	1	punct
16	Drugs	drug	NNS	_	24	nsubjpass
17	such	such	JJ	_	19	case
18	as	as	IN	_	17	mwe
19	drug1	drug1	NN	_	16	nmod
20	and	and	CC	_	19	cc
21	drug2	drug2	NN	_	19	conj
22	should	should	MD	_	24	aux
23	be	be	VB	_	24	auxpass
24	administered	administer	VBN	_	1	dep
25	at	at	IN	_	26	case
26	least	least	JJS	_	27	nmod:npmod
27	2	2	CD	_	28	nummod
28	hours	hour	NNS	_	24	dobj
29	prior	prior	RB	_	31	advmod
30	to	to	TO	_	31	case
31	dosing	dosing	NN	_	24	nmod
32	with	with	IN	_	33	case
33	drug3	drug3	NN	_	31	nmod
34	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Administration	administration	NN	_	1	dep
4	of	of	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	2	2	CD	_	7	nummod
7	hours	hour	NNS	_	3	dep
8	prior	prior	RB	_	16	advmod
9	to	to	TO	_	16	mark
10	or	or	CC	_	9	cc
11	concurrent	concurrent	JJ	_	9	conj
12	with	with	IN	_	14	case
13	oral	oral	JJ	_	14	amod
14	drug3	drug3	NN	_	9	nmod
15	was	be	VBD	_	16	auxpass
16	associated	associate	VBN	_	7	acl
17	with	with	IN	_	24	case
18	a	a	DT	_	24	det
19	111	111	CD	_	24	nummod
20	-LRB-	-lrb-	-LRB-	_	24	punct
21	114	114	CD	_	24	nummod
22	-RRB-	-rrb-	-RRB-	_	24	punct
23	%	%	NN	_	24	compound
24	increase	increase	NN	_	16	nmod
25	in	in	IN	_	28	case
26	the	the	DT	_	28	det
27	steady-state	steady-state	JJ	_	28	amod
28	AUC	auc	NN	_	24	nmod
29	of	of	IN	_	30	case
30	drug4	drug4	NN	_	28	nmod
31	-LRB-	-lrb-	-LRB-	_	32	punct
32	n	n	NN	_	7	dep
33	=	=	JJ	_	32	amod
34	12	12	CD	_	33	dep
35	-RRB-	-rrb-	-RRB-	_	32	punct
36	.	.	.	_	1	punct

1	A	a	DT	_	7	det
2	21	21	CD	_	7	nummod
3	-LRB-	-lrb-	-LRB-	_	7	punct
4	17	17	CD	_	7	nummod
5	-RRB-	-rrb-	-RRB-	_	7	punct
6	%	%	NN	_	7	compound
7	decrease	decrease	NN	_	15	nsubjpass
8	in	in	IN	_	11	case
9	the	the	DT	_	11	det
10	steady-state	steady-state	JJ	_	11	amod
11	AUC	auc	NN	_	7	nmod
12	of	of	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	was	be	VBD	_	15	auxpass
15	observed	observe	VBN	_	0	ROOT
16	when	when	WRB	_	19	advmod
17	drug2	drug2	NN	_	19	nsubjpass
18	was	be	VBD	_	19	auxpass
19	administered	administer	VBN	_	15	advcl
20	2	2	CD	_	21	nummod
21	hours	hour	NNS	_	19	dobj
22	prior	prior	RB	_	21	advmod
23	to	to	TO	_	24	case
24	drug3	drug3	NN	_	22	nmod
25	,	,	,	_	19	punct
26	but	but	CC	_	19	cc
27	not	not	RB	_	19	conj
28	when	when	WRB	_	33	advmod
29	the	the	DT	_	31	det
30	two	two	CD	_	31	nummod
31	drugs	drug	NNS	_	33	nsubjpass
32	were	be	VBD	_	33	auxpass
33	administered	administer	VBN	_	27	dep
34	simultaneously	simultaneously	RB	_	33	advmod
35	-LRB-	-lrb-	-LRB-	_	36	punct
36	n	n	NN	_	33	dep
37	=	=	JJ	_	36	amod
38	12	12	CD	_	37	dep
39	-RRB-	-rrb-	-RRB-	_	36	punct
40	.	.	.	_	15	punct

1	drug1	drug1	NN	_	2	compound
2	s	s	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	drug2	drug2	NN	_	7	nsubjpass
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	administered	administer	VBN	_	2	dep
8	at	at	IN	_	9	case
9	least	least	JJS	_	10	nmod:npmod
10	2	2	CD	_	11	nummod
11	hours	hour	NNS	_	7	dobj
12	after	after	IN	_	15	case
13	or	or	CC	_	12	cc
14	6	6	CD	_	12	conj
15	hours	hour	NNS	_	11	nmod
16	before	before	IN	_	17	case
17	dosing	dosing	NN	_	7	nmod
18	with	with	IN	_	19	case
19	drug3	drug3	NN	_	17	nmod
20	because	because	IN	_	26	mark
21	plasma	plasma	NN	_	22	compound
22	concentrations	concentration	NNS	_	26	nsubjpass
23	of	of	IN	_	24	case
24	drug4	drug4	NN	_	22	nmod
25	are	be	VBP	_	26	auxpass
26	decreased	decrease	VBN	_	7	advcl
27	when	when	WRB	_	28	advmod
28	administered	administer	VBN	_	26	advcl
29	with	with	IN	_	30	case
30	drug5	drug5	NN	_	28	nmod
31	containing	contain	VBG	_	30	acl
32	drug6	drug6	NN	_	31	dobj
33	,	,	,	_	32	punct
34	drug7	drug7	NN	_	32	conj
35	,	,	,	_	32	punct
36	or	or	CC	_	32	cc
37	drug8	drug8	NN	_	32	conj
38	.	.	.	_	2	punct

1	In	in	IN	_	4	case
2	eight	eight	CD	_	4	nummod
3	HIV-infected	hiv-infected	JJ	_	4	amod
4	patients	patient	NNS	_	12	nmod
5	,	,	,	_	12	punct
6	the	the	DT	_	8	det
7	steady-state	steady-state	JJ	_	8	amod
8	AUC	auc	NN	_	12	nsubjpass
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	was	be	VBD	_	12	auxpass
12	decreased	decrease	VBN	_	0	ROOT
13	an	a	DT	_	14	det
14	average	average	NN	_	12	dobj
15	of	of	IN	_	17	case
16	26	26	CD	_	17	nummod
17	%	%	NN	_	14	nmod
18	-LRB-	-lrb-	-LRB-	_	21	punct
19	95	95	CD	_	20	compound
20	%	%	NN	_	21	amod
21	CI	ci	NN	_	17	dep
22	=	=	JJ	_	21	amod
23	14	14	CD	_	24	nummod
24	%	%	NN	_	22	dep
25	,	,	,	_	21	punct
26	37	37	CD	_	27	nummod
27	%	%	NN	_	21	appos
28	-RRB-	-rrb-	-RRB-	_	21	punct
29	when	when	WRB	_	32	advmod
30	drug2	drug2	NN	_	32	nsubjpass
31	was	be	VBD	_	32	auxpass
32	administered	administer	VBN	_	12	advcl
33	2	2	CD	_	34	nummod
34	hours	hour	NNS	_	35	nmod:npmod
35	prior	prior	RB	_	32	advmod
36	to	to	TO	_	41	case
37	a	a	DT	_	41	det
38	marketed	market	VBN	_	41	amod
39	chewable/dispersible	chewable/dispersible	JJ	_	41	amod
40	tablet	tablet	NN	_	41	compound
41	formulation	formulation	NN	_	32	nmod
42	of	of	IN	_	43	case
43	drug3	drug3	NN	_	41	nmod
44	.	.	.	_	12	punct

1	The	the	DT	_	2	det
2	AUC	auc	NN	_	6	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	was	be	VBD	_	6	auxpass
6	decreased	decrease	VBN	_	0	ROOT
7	an	a	DT	_	8	det
8	average	average	NN	_	6	dobj
9	of	of	IN	_	10	case
10	15-fold	15-fold	JJ	_	8	nmod
11	in	in	IN	_	14	case
12	12	12	CD	_	14	nummod
13	healthy	healthy	JJ	_	14	amod
14	subjects	subject	NNS	_	8	nmod
15	given	give	VBN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	and	and	CC	_	16	cc
18	drug3	drug3	NN	_	16	conj
19	-	-	:	_	16	punct
20	placebo	placebo	NN	_	21	compound
21	tablets	tablet	NNS	_	16	dep
22	concurrently	concurrently	RB	_	21	advmod
23	.	.	.	_	6	punct

1	In	in	IN	_	4	case
2	a	a	DT	_	4	det
3	single	single	JJ	_	4	amod
4	subject	subject	JJ	_	0	ROOT
5	given	give	VBN	_	7	case
6	one	one	CD	_	7	nummod
7	dose	dose	NN	_	4	nmod
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	2	2	CD	_	11	nummod
11	hours	hour	NNS	_	9	dep
12	after	after	IN	_	14	case
13	a	a	DT	_	14	det
14	dose	dose	NN	_	7	nmod
15	of	of	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	-	-	:	_	19	punct
18	placebo	placebo	NN	_	19	compound
19	tablets	tablet	NNS	_	4	dep
20	,	,	,	_	19	punct
21	a	a	DT	_	26	det
22	greater	greater	JJR	_	24	advmod
23	than	than	IN	_	24	advmod
24	50	50	CD	_	25	dep
25	%	%	NN	_	26	dep
26	reduction	reduction	NN	_	33	nsubjpass
27	in	in	IN	_	29	case
28	the	the	DT	_	29	det
29	AUC	auc	NN	_	26	nmod
30	of	of	IN	_	31	case
31	drug3	drug3	NN	_	29	nmod
32	was	be	VBD	_	33	auxpass
33	observed	observe	VBN	_	19	acl:relcl
34	.	.	.	_	4	punct

1	Plasma	plasma	NN	_	2	compound
2	concentrations	concentration	NNS	_	6	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	are	be	VBP	_	6	auxpass
6	decreased	decrease	VBN	_	0	ROOT
7	when	when	WRB	_	8	advmod
8	administered	administer	VBN	_	6	advcl
9	with	with	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	containing	contain	VBG	_	10	acl
12	drug3	drug3	NN	_	11	dobj
13	,	,	,	_	12	punct
14	drug4	drug4	NN	_	12	conj
15	,	,	,	_	12	punct
16	or	or	CC	_	12	cc
17	drug5	drug5	NN	_	12	conj
18	.	.	.	_	6	punct

1	The	the	DT	_	4	det
2	optimal	optimal	JJ	_	4	amod
3	dosing	dosing	NN	_	4	compound
4	interval	interval	NN	_	11	nsubjpass
5	for	for	IN	_	6	case
6	coadministration	coadministration	NN	_	4	nmod
7	with	with	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	determined	determine	VBN	_	0	ROOT
12	by	by	IN	_	13	mark
13	consulting	consult	VBG	_	11	advcl
14	the	the	DT	_	18	det
15	appropriate	appropriate	JJ	_	18	amod
16	drug2	drug2	NN	_	18	compound
17	package	package	NN	_	18	compound
18	insert	insert	NN	_	13	dobj
19	.	.	.	_	11	punct

1	Interactions	interaction	NNS	_	0	ROOT
2	with	with	IN	_	4	case
3	Other	other	JJ	_	4	amod
4	drug1	drug1	NN	_	1	nmod
5	:	:	:	_	1	punct
6	Significant	significant	JJ	_	7	amod
7	decreases	decrease	NNS	_	23	nsubj
8	in	in	IN	_	10	case
9	the	the	DT	_	10	det
10	AUC	auc	NN	_	7	nmod
11	of	of	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	-LRB-	-lrb-	-LRB-	_	15	punct
14	20	20	CD	_	15	nummod
15	%	%	NN	_	7	appos
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	and	and	CC	_	7	cc
18	drug3	drug3	NN	_	7	conj
19	-LRB-	-lrb-	-LRB-	_	21	punct
20	84	84	CD	_	21	nummod
21	%	%	NN	_	18	appos
22	-RRB-	-rrb-	-RRB-	_	21	punct
23	occurred	occur	VBD	_	1	dep
24	following	follow	VBG	_	26	case
25	simultaneous	simultaneous	JJ	_	26	amod
26	administration	administration	NN	_	23	nmod
27	of	of	IN	_	29	case
28	these	these	DT	_	29	det
29	agents	agent	NNS	_	26	nmod
30	with	with	IN	_	31	case
31	drug4	drug4	NN	_	26	nmod
32	.	.	.	_	1	punct

1	To	to	TO	_	2	mark
2	avoid	avoid	VB	_	0	ROOT
3	this	this	DT	_	4	det
4	interaction	interaction	NN	_	2	dobj
5	,	,	,	_	4	punct
6	drug1	drug1	NN	_	4	conj
7	or	or	CC	_	4	cc
8	drug2	drug2	NN	_	4	conj
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	given	give	VBN	_	2	dep
12	1	1	CD	_	13	nummod
13	hour	hour	NN	_	11	dobj
14	prior	prior	RB	_	16	advmod
15	to	to	TO	_	16	case
16	dosing	dosing	NN	_	13	acl
17	with	with	IN	_	18	case
18	drug3	drug3	NN	_	16	nmod
19	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	pharmacokinetics	pharmacokinetic	NNS	_	7	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	are	be	VBP	_	7	auxpass
6	not	not	RB	_	7	neg
7	altered	alter	VBN	_	0	ROOT
8	to	to	TO	_	12	case
9	a	a	DT	_	12	det
10	clinically	clinically	RB	_	11	advmod
11	significant	significant	JJ	_	12	amod
12	degree	degree	NN	_	7	nmod
13	when	when	WRB	_	16	advmod
14	it	it	PRP	_	16	nsubjpass
15	is	be	VBZ	_	16	auxpass
16	administered	administer	VBN	_	7	advcl
17	with	with	IN	_	20	case
18	a	a	DT	_	20	det
19	light	light	JJ	_	20	amod
20	meal	meal	NN	_	16	nmod
21	1	1	CD	_	22	nummod
22	hour	hour	NN	_	20	nmod
23	after	after	IN	_	22	case
24	drug2	drug2	NN	_	22	dep
25	.	.	.	_	7	punct

1	No	no	DT	_	5	neg
2	formal	formal	JJ	_	5	amod
3	drug	drug	NN	_	5	compound
4	interaction	interaction	NN	_	5	compound
5	studies	study	NNS	_	8	nsubjpass
6	have	have	VBP	_	8	aux
7	been	be	VBN	_	8	auxpass
8	performed	perform	VBN	_	0	ROOT
9	with	with	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	.	.	.	_	8	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	should	should	MD	_	5	aux
3	not	not	RB	_	5	neg
4	be	be	VB	_	5	auxpass
5	used	use	VBN	_	0	ROOT
6	with	with	IN	_	8	case
7	other	other	JJ	_	8	amod
8	drug2	drug2	NN	_	5	nmod
9	.	.	.	_	5	punct

1	drug1	drug1	NN	_	9	nsubjpass
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	and	and	CC	_	1	cc
5	drug3	drug3	NN	_	1	conj
6	should	should	MD	_	9	aux
7	not	not	RB	_	9	neg
8	be	be	VB	_	9	auxpass
9	administered	administer	VBN	_	0	ROOT
10	during	during	IN	_	12	case
11	drug4	drug4	NN	_	12	compound
12	treatment	treatment	NN	_	9	nmod
13	.	.	.	_	9	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	4	amod
2	Test	test	NN	_	4	compound
3	Interactions	interaction	NNS	_	4	compound
4	Increases	increase	NNS	_	7	nsubj
5	in	in	IN	_	6	case
6	lymphocyte	lymphocyte	NN	_	4	nmod
7	counts	count	VBZ	_	17	csubjpass
8	related	related	JJ	_	7	xcomp
9	to	to	TO	_	12	case
10	the	the	DT	_	12	det
11	pharmacologic	pharmacologic	JJ	_	12	amod
12	mechanism	mechanism	NN	_	8	nmod
13	of	of	IN	_	14	case
14	action	action	NN	_	12	nmod
15	are	be	VBP	_	17	auxpass
16	frequently	frequently	RB	_	17	advmod
17	observed	observe	VBN	_	0	ROOT
18	during	during	IN	_	20	case
19	drug1	drug1	NN	_	20	compound
20	treatment	treatment	NN	_	17	nmod
21	.	.	.	_	17	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	administration	administration	NN	_	20	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	-LRB-	-lrb-	-LRB-	_	7	punct
6	another	another	DT	_	7	det
7	TNF	tnf	NN	_	4	dep
8	-	-	:	_	7	punct
9	blocking	block	VBG	_	10	amod
10	agent	agent	NN	_	7	dep
11	-RRB-	-rrb-	-RRB-	_	7	punct
12	and	and	CC	_	4	cc
13	drug2	drug2	NN	_	4	conj
14	-LRB-	-lrb-	-LRB-	_	16	punct
15	an	a	DT	_	16	det
16	drug3	drug3	NN	_	13	appos
17	-RRB-	-rrb-	-RRB-	_	16	punct
18	has	have	VBZ	_	20	aux
19	been	be	VBN	_	20	auxpass
20	associated	associate	VBN	_	0	ROOT
21	with	with	IN	_	24	case
22	an	a	DT	_	24	det
23	increased	increase	VBN	_	24	amod
24	risk	risk	NN	_	20	nmod
25	of	of	IN	_	27	case
26	serious	serious	JJ	_	27	amod
27	infections	infection	NNS	_	24	nmod
28	,	,	,	_	20	punct
29	and	and	CC	_	20	cc
30	increased	increase	VBD	_	31	amod
31	risk	risk	NN	_	20	conj
32	of	of	IN	_	33	case
33	neutropenia	neutropenia	NN	_	31	nmod
34	and	and	CC	_	31	cc
35	no	no	DT	_	37	neg
36	additional	additional	JJ	_	37	amod
37	benefit	benefit	NN	_	31	conj
38	compared	compare	VBN	_	42	case
39	to	to	TO	_	42	case
40	these	these	DT	_	42	det
41	medicinal	medicinal	JJ	_	42	amod
42	products	product	NNS	_	31	acl
43	alone	alone	RB	_	42	advmod
44	.	.	.	_	20	punct

1	Other	other	JJ	_	2	amod
2	drug1	drug1	NN	_	14	nsubj
3	-LRB-	-lrb-	-LRB-	_	5	punct
4	including	include	VBG	_	5	case
5	drug2	drug2	NN	_	2	nmod
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	used	use	VBN	_	2	acl
8	in	in	IN	_	9	case
9	combination	combination	NN	_	7	nmod
10	with	with	IN	_	11	case
11	drug3	drug3	NN	_	9	nmod
12	may	may	MD	_	14	aux
13	also	also	RB	_	14	advmod
14	result	result	VB	_	0	ROOT
15	in	in	IN	_	17	case
16	similar	similar	JJ	_	17	amod
17	toxicities	toxicity	NNS	_	14	nmod
18	.	.	.	_	14	punct

1	Specific	specific	JJ	_	4	amod
2	drug	drug	NN	_	4	compound
3	interaction	interaction	NN	_	4	compound
4	studies	study	NNS	_	14	nsubjpass
5	,	,	,	_	4	punct
6	including	include	VBG	_	7	case
7	interactions	interaction	NNS	_	4	nmod
8	with	with	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	,	,	,	_	4	punct
11	have	have	VBP	_	14	aux
12	not	not	RB	_	14	neg
13	been	be	VBN	_	14	auxpass
14	conducted	conduct	VBN	_	0	ROOT
15	.	.	.	_	14	punct

1	The	the	DT	_	2	det
2	majority	majority	NN	_	14	nsubj
3	of	of	IN	_	4	case
4	patients	patient	NNS	_	2	nmod
5	in	in	IN	_	7	case
6	rheumatoid	rheumatoid	JJ	_	7	amod
7	arthritis	arthritis	NN	_	4	nmod
8	or	or	CC	_	7	cc
9	Crohn	crohn	NN	_	13	compound
10	s	s	NNS	_	13	compound
11	disease	disease	NN	_	13	compound
12	clinical	clinical	JJ	_	13	amod
13	studies	study	NNS	_	7	conj
14	received	receive	VBD	_	0	ROOT
15	one	one	CD	_	19	nummod
16	or	or	CC	_	15	cc
17	more	more	JJR	_	15	conj
18	concomitant	concomitant	JJ	_	19	amod
19	medications	medication	NNS	_	14	dobj
20	.	.	.	_	14	punct

1	In	in	IN	_	3	case
2	rheumatoid	rheumatoid	JJ	_	3	amod
3	arthritis	arthritis	NN	_	10	nmod
4	,	,	,	_	10	punct
5	concomitant	concomitant	JJ	_	6	amod
6	medications	medication	NNS	_	10	nsubj
7	besides	besides	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	were	be	VBD	_	10	cop
10	drug2	drug2	NN	_	0	ROOT
11	,	,	,	_	10	punct
12	drug3	drug3	NN	_	10	conj
13	,	,	,	_	10	punct
14	drug4	drug4	NN	_	10	conj
15	and/or	and/or	CC	_	10	cc
16	drug5	drug5	NN	_	10	conj
17	.	.	.	_	10	punct

1	Concomitant	concomitant	JJ	_	5	amod
2	Crohn	crohn	NN	_	5	compound
3	s	s	NNS	_	5	compound
4	disease	disease	NN	_	5	compound
5	medications	medication	NNS	_	7	nsubj
6	were	be	VBD	_	7	cop
7	drug1	drug1	NN	_	0	ROOT
8	,	,	,	_	7	punct
9	drug2	drug2	NN	_	7	conj
10	,	,	,	_	7	punct
11	drug3	drug3	NN	_	7	conj
12	,	,	,	_	7	punct
13	drug4	drug4	NN	_	15	compound
14	/	/	:	_	15	punct
15	drug5	drug5	NN	_	7	conj
16	and	and	CC	_	7	cc
17	aminosalicylates	aminosalicylate	NNS	_	7	conj
18	.	.	.	_	7	punct

1	In	in	IN	_	5	case
2	psoriatic	psoriatic	JJ	_	5	amod
3	arthritis	arthritis	NN	_	5	compound
4	clinical	clinical	JJ	_	5	amod
5	trials	trial	NNS	_	9	nmod
6	,	,	,	_	9	punct
7	concomitant	concomitant	JJ	_	8	amod
8	medications	medication	NNS	_	9	nsubj
9	included	include	VBD	_	0	ROOT
10	drug1	drug1	NN	_	9	dobj
11	in	in	IN	_	13	case
12	approximately	approximately	RB	_	13	advmod
13	half	half	DT	_	10	nmod
14	of	of	IN	_	16	case
15	the	the	DT	_	16	det
16	patients	patient	NNS	_	13	nmod
17	as	as	RB	_	10	cc
18	well	well	RB	_	17	mwe
19	as	as	IN	_	17	mwe
20	drug2	drug2	NN	_	10	conj
21	,	,	,	_	20	punct
22	drug3	drug3	NN	_	20	conj
23	and	and	CC	_	20	cc
24	drug4	drug4	NN	_	20	conj
25	.	.	.	_	9	punct

1	Patients	patient	NNS	_	9	nsubj
2	with	with	IN	_	5	case
3	Crohn	crohn	NN	_	5	compound
4	s	s	NNS	_	5	compound
5	disease	disease	NN	_	1	nmod
6	who	who	WP	_	7	nsubj
7	received	receive	VBD	_	1	acl:relcl
8	drug1	drug1	NN	_	7	dobj
9	tended	tend	VBD	_	0	ROOT
10	to	to	TO	_	11	mark
11	experience	experience	VB	_	9	xcomp
12	fewer	fewer	JJR	_	14	amod
13	infusion	infusion	NN	_	14	compound
14	reactions	reaction	NNS	_	11	dobj
15	compared	compare	VBN	_	17	case
16	to	to	TO	_	17	case
17	patients	patient	NNS	_	14	acl
18	on	on	IN	_	20	case
19	no	no	DT	_	20	neg
20	drug2	drug2	NN	_	17	nmod
21	.	.	.	_	9	punct

1	Serum	serum	NN	_	3	compound
2	drug1	drug1	NN	_	3	compound
3	concentrations	concentration	NNS	_	4	nsubj
4	appeared	appear	VBD	_	0	ROOT
5	to	to	TO	_	7	mark
6	be	be	VB	_	7	aux
7	unaffected	unaffected	JJ	_	4	xcomp
8	by	by	IN	_	10	case
9	baseline	baseline	NN	_	10	compound
10	use	use	NN	_	7	nmod
11	of	of	IN	_	12	case
12	medications	medication	NNS	_	10	nmod
13	for	for	IN	_	15	case
14	the	the	DT	_	15	det
15	treatment	treatment	NN	_	10	nmod
16	of	of	IN	_	19	case
17	Crohn	crohn	NN	_	19	compound
18	s	s	NNS	_	19	compound
19	disease	disease	NN	_	15	nmod
20	including	include	VBG	_	21	case
21	drug2	drug2	NN	_	19	nmod
22	,	,	,	_	21	punct
23	drug3	drug3	NN	_	21	conj
24	-LRB-	-lrb-	-LRB-	_	25	punct
25	drug4	drug4	NN	_	23	dep
26	or	or	CC	_	25	cc
27	drug5	drug5	NN	_	25	conj
28	-RRB-	-rrb-	-RRB-	_	25	punct
29	and	and	CC	_	21	cc
30	aminosalicylates	aminosalicylate	NNS	_	21	conj
31	.	.	.	_	4	punct

1	When	when	WRB	_	2	advmod
2	given	give	VBN	_	8	advcl
3	concurrently	concurrently	RB	_	2	advmod
4	the	the	DT	_	6	det
5	following	follow	VBG	_	6	amod
6	drugs	drug	NNS	_	8	nsubj
7	may	may	MD	_	8	aux
8	interact	interact	VB	_	0	ROOT
9	with	with	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	.	.	.	_	8	punct

1	-	-	:	_	4	punct
2	drug1	drug1	NN	_	4	compound
3	,	,	,	_	4	punct
4	drug2	drug2	NN	_	0	ROOT
5	,	,	,	_	4	punct
6	or	or	CC	_	4	cc
7	drug3	drug3	NN	_	4	conj
8	:	:	:	_	4	punct
9	Potentiation	potentiation	NN	_	14	nsubj
10	of	of	IN	_	12	case
11	otthostatic	otthostatic	JJ	_	12	amod
12	hypotension	hypotension	NN	_	9	nmod
13	may	may	MD	_	14	aux
14	occur	occur	VB	_	4	parataxis

1	.	.	.	_	0	ROOT

1	-	-	:	_	2	punct
2	drug1	drug1	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	-LRB-	-lrb-	-LRB-	_	6	punct
5	Oral	oral	JJ	_	6	amod
6	agents	agent	NNS	_	17	dep
7	and	and	CC	_	6	cc
8	drug2	drug2	NN	_	6	conj
9	-RRB-	-rrb-	-RRB-	_	6	punct
10	Dosage	dosage	NN	_	11	compound
11	adjustment	adjustment	NN	_	17	nsubjpass
12	of	of	IN	_	14	case
13	the	the	DT	_	14	det
14	drug3	drug3	NN	_	11	nmod
15	may	may	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	required	require	VBN	_	2	parataxis

1	.	.	.	_	0	ROOT

1	-	-	:	_	0	ROOT
2	Other	other	JJ	_	3	amod
3	drug1	drug1	NN	_	1	root
4	:	:	:	_	3	punct
5	Additive	additive	JJ	_	6	amod
6	effect	effect	NN	_	3	dep
7	or	or	CC	_	6	cc
8	potentiation	potentiation	NN	_	6	conj

1	.	.	.	_	0	ROOT

1	-	-	:	_	0	ROOT
2	drug1	drug1	NN	_	5	compound
3	and	and	CC	_	2	cc
4	drug2	drug2	NN	_	2	conj
5	drug3	drug3	NN	_	1	root
6	:	:	:	_	5	punct
7	drug4	drug4	NN	_	10	compound
8	and	and	CC	_	7	cc
9	drug5	drug5	NN	_	7	conj
10	drug6	drug6	NN	_	11	nsubj
11	have	have	VBP	_	5	dep
12	the	the	DT	_	13	det
13	potential	potential	NN	_	11	dobj
14	of	of	IN	_	16	case
15	binding	binding	NN	_	16	compound
16	drug7	drug7	NN	_	13	nmod
17	and	and	CC	_	11	cc
18	reducing	reduce	VBG	_	11	conj
19	drug8	drug8	NN	_	20	compound
20	absorption	absorption	NN	_	18	dobj
21	from	from	IN	_	24	case
22	the	the	DT	_	24	det
23	gastrointestinal	gastrointestinal	JJ	_	24	amod
24	tract	tract	NN	_	18	nmod

1	.	.	.	_	0	ROOT

1	-	-	:	_	0	ROOT
2	drug1	drug1	NN	_	1	root
3	,	,	,	_	2	punct
4	drug2	drug2	NN	_	3	root
5	:	:	:	_	4	punct
6	Intensified	intensify	VBN	_	8	amod
7	electrolyte	electrolyte	NN	_	8	compound
8	depletion	depletion	NN	_	4	dep
9	,	,	,	_	8	punct
10	particularly	particularly	RB	_	11	advmod
11	hypokalemia	hypokalemia	NN	_	8	appos

1	.	.	.	_	0	ROOT

1	-	-	:	_	0	ROOT
2	Pressor	pressor	NN	_	3	compound
3	amines	amine	NNS	_	1	root
4	-LRB-	-lrb-	-LRB-	_	7	punct
5	e.g.	e.g.	FW	_	7	dep
6	,	,	,	_	7	punct
7	drug1	drug1	NN	_	3	appos
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	:	:	:	_	3	punct
10	Possible	possible	JJ	_	12	amod
11	decreased	decrease	VBN	_	12	amod
12	response	response	NN	_	3	dep
13	to	to	TO	_	15	case
14	pressor	pressor	NN	_	15	compound
15	amines	amine	NNS	_	12	nmod
16	but	but	CC	_	17	cc
17	not	not	RB	_	15	cc
18	sufficient	sufficient	JJ	_	15	conj
19	to	to	TO	_	20	mark
20	preclude	preclude	VB	_	18	xcomp
21	their	they	PRP$	_	22	nmod:poss
22	use	use	NN	_	20	dobj

1	.	.	.	_	0	ROOT

1	-	-	:	_	4	punct
2	drug1	drug1	NN	_	4	compound
3	,	,	,	_	4	punct
4	nondepolarizing	nondepolarizing	JJ	_	0	ROOT
5	-LRB-	-lrb-	-LRB-	_	8	punct
6	e.g.	e.g.	FW	_	8	dep
7	,	,	,	_	8	punct
8	drug2	drug2	NN	_	4	dep
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	:	:	:	_	4	punct
11	Possible	possible	JJ	_	13	amod
12	increased	increase	VBN	_	13	amod
13	responsiveness	responsiveness	NN	_	4	dep
14	to	to	TO	_	16	case
15	the	the	DT	_	16	det
16	drug3	drug3	NN	_	13	nmod

1	.	.	.	_	0	ROOT

1	-	-	:	_	8	punct
2	drug1	drug1	NN	_	8	dep
3	:	:	:	_	8	punct
4	Generally	generally	RB	_	8	nsubjpass
5	should	should	MD	_	8	aux
6	not	not	RB	_	8	neg
7	be	be	VB	_	8	auxpass
8	given	give	VBN	_	0	ROOT
9	with	with	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	.	.	.	_	8	punct

1	drug1	drug1	NN	_	2	nsubj
2	reduce	reduce	VB	_	0	ROOT
3	the	the	DT	_	5	det
4	renal	renal	JJ	_	5	amod
5	clearance	clearance	NN	_	2	dobj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	and	and	CC	_	2	cc
9	add	add	VB	_	2	conj
10	a	a	DT	_	12	det
11	high	high	JJ	_	12	amod
12	risk	risk	NN	_	9	dobj
13	of	of	IN	_	15	case
14	drug3	drug3	NN	_	15	compound
15	toxicity	toxicity	NN	_	12	nmod
16	.	.	.	_	2	punct

1	Refer	refer	VB	_	0	ROOT
2	to	to	TO	_	5	case
3	the	the	DT	_	5	det
4	package	package	NN	_	5	compound
5	insert	insert	NN	_	1	nmod
6	for	for	IN	_	8	case
7	drug1	drug1	NN	_	8	compound
8	preparations	preparation	NNS	_	5	nmod
9	before	before	IN	_	10	case
10	use	use	NN	_	1	nmod
11	of	of	IN	_	13	case
12	such	such	JJ	_	13	amod
13	preparations	preparation	NNS	_	10	nmod
14	with	with	IN	_	15	case
15	drug2	drug2	NN	_	10	nmod

1	.	.	.	_	0	ROOT

1	-	-	:	_	0	ROOT
2	drug1	drug1	NN	_	1	root
3	:	:	:	_	2	punct
4	In	in	IN	_	6	case
5	some	some	DT	_	6	det
6	patients	patient	NNS	_	14	nmod
7	,	,	,	_	14	punct
8	the	the	DT	_	9	det
9	administration	administration	NN	_	14	nsubj
10	of	of	IN	_	12	case
11	a	a	DT	_	12	det
12	drug2	drug2	NN	_	9	nmod
13	can	can	MD	_	14	aux
14	reduce	reduce	VB	_	2	appos
15	the	the	DT	_	22	det
16	diuretic	diuretic	JJ	_	22	amod
17	,	,	,	_	16	punct
18	natriuretic	natriuretic	JJ	_	16	conj
19	,	,	,	_	16	punct
20	and	and	CC	_	16	cc
21	antihypertensive	antihypertensive	JJ	_	16	conj
22	effects	effect	NNS	_	14	dobj
23	of	of	IN	_	24	case
24	drug3	drug3	NN	_	22	nmod
25	,	,	,	_	24	punct
26	drug4	drug4	NN	_	24	conj
27	and	and	CC	_	24	cc
28	drug5	drug5	NN	_	24	conj
29	.	.	.	_	2	punct

1	Therefore	therefore	RB	_	15	advmod
2	,	,	,	_	15	punct
3	when	when	WRB	_	8	advmod
4	drug1	drug1	NN	_	8	nsubjpass
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	are	be	VBP	_	8	auxpass
8	used	use	VBN	_	15	advcl
9	concomitantly	concomitantly	RB	_	8	advmod
10	,	,	,	_	15	punct
11	the	the	DT	_	12	det
12	patient	patient	NN	_	15	nsubjpass
13	should	should	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	observed	observe	VBN	_	0	ROOT
16	closely	closely	RB	_	15	advmod
17	to	to	TO	_	18	mark
18	determine	determine	VB	_	15	xcomp
19	if	if	IN	_	27	mark
20	the	the	DT	_	22	det
21	desired	desire	VBN	_	22	amod
22	effect	effect	NN	_	27	nsubjpass
23	of	of	IN	_	25	case
24	the	the	DT	_	25	det
25	drug3	drug3	NN	_	22	nmod
26	is	be	VBZ	_	27	auxpass
27	obtained	obtain	VBN	_	18	advcl

1	.	.	.	_	0	ROOT

1	-	-	:	_	0	ROOT
2	Drug/Laboratory	drug/laboratory	NN	_	4	compound
3	Test	test	NN	_	4	compound
4	Interactions	interaction	NNS	_	1	root
5	:	:	:	_	4	punct
6	drug1	drug1	NN	_	9	nsubjpass
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	discontinued	discontinue	VBN	_	4	dep
10	before	before	IN	_	11	mark
11	carrying	carry	VBG	_	9	advcl
12	out	out	RP	_	11	compound:prt
13	tests	test	NNS	_	11	dobj
14	for	for	IN	_	16	case
15	parathyroid	parathyroid	JJ	_	16	amod
16	function	function	NN	_	13	nmod
17	.	.	.	_	4	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	exercised	exercise	VBN	_	0	ROOT
5	when	when	WRB	_	10	advmod
6	the	the	DT	_	8	det
7	following	follow	VBG	_	8	amod
8	drugs	drug	NNS	_	10	nsubjpass
9	are	be	VBP	_	10	auxpass
10	administered	administer	VBN	_	4	advcl
11	concomitantly	concomitantly	RB	_	10	advmod
12	with	with	IN	_	13	case
13	drug1	drug1	NN	_	10	nmod
14	-LRB-	-lrb-	-LRB-	_	15	punct
15	drug2	drug2	NN	_	13	appos
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	given	give	VBN	_	13	acl
18	with	with	IN	_	19	case
19	drug3	drug3	NN	_	17	nmod
20	or	or	CC	_	19	cc
21	drug4	drug4	NN	_	19	conj
22	-	-	:	_	4	punct
23	drug5	drug5	NN	_	25	compound
24	combination	combination	NN	_	25	compound
25	products	product	NNS	_	4	dep
26	.	.	.	_	4	punct

1	For	for	IN	_	2	case
2	patients	patient	NNS	_	6	nmod
3	receiving	receive	VBG	_	2	acl
4	drug1	drug1	NN	_	3	dobj
5	,	,	,	_	6	punct
6	see	see	VBP	_	0	ROOT
7	CONTRAINDICATIONS	contraindication	NNS	_	6	dobj
8	.	.	.	_	6	punct

1	drug1	drug1	NN	_	14	nsubj
2	-LRB-	-lrb-	-LRB-	_	5	punct
3	e.g.	e.g.	FW	_	5	dep
4	,	,	,	_	5	punct
5	drug2	drug2	NN	_	1	dep
6	,	,	,	_	5	punct
7	drug3	drug3	NN	_	5	appos
8	,	,	,	_	5	punct
9	drug4	drug4	NN	_	5	appos
10	-RRB-	-rrb-	-RRB-	_	5	punct
11	and	and	CC	_	1	cc
12	drug5	drug5	NN	_	1	conj
13	may	may	MD	_	14	aux
14	reduce	reduce	VB	_	0	ROOT
15	the	the	DT	_	17	det
16	therapeutic	therapeutic	JJ	_	17	amod
17	effects	effect	NNS	_	14	dobj
18	of	of	IN	_	19	case
19	drug6	drug6	NN	_	17	nmod
20	.	.	.	_	14	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	14	nmod
3	,	,	,	_	14	punct
4	the	the	DT	_	6	det
5	beneficial	beneficial	JJ	_	6	amod
6	effects	effect	NNS	_	14	nsubjpass
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	in	in	IN	_	11	case
10	Parkinsons	Parkinsons	NNPS	_	11	compound
11	disease	disease	NN	_	6	nmod
12	have	have	VBP	_	14	aux
13	been	be	VBN	_	14	auxpass
14	reported	report	VBN	_	0	ROOT
15	to	to	TO	_	17	mark
16	be	be	VB	_	17	auxpass
17	reversed	reverse	VBN	_	14	xcomp
18	by	by	IN	_	19	case
19	drug2	drug2	NN	_	17	nmod
20	and	and	CC	_	19	cc
21	drug3	drug3	NN	_	19	conj
22	.	.	.	_	14	punct

1	Patients	patient	NNS	_	0	ROOT
2	taking	take	VBG	_	1	acl
3	these	these	DT	_	4	det
4	drugs	drug	NNS	_	2	dobj
5	with	with	IN	_	6	case
6	drug1	drug1	NN	_	2	nmod
7	and	and	CC	_	6	cc
8	drug2	drug2	NN	_	6	conj
9	or	or	CC	_	6	cc
10	drug3	drug3	NN	_	6	conj
11	-	-	:	_	1	punct
12	drug4	drug4	NN	_	14	compound
13	combination	combination	NN	_	14	compound
14	products	product	NNS	_	18	nsubjpass
15	should	should	MD	_	18	aux
16	be	be	VB	_	18	auxpass
17	carefully	carefully	RB	_	18	advmod
18	observed	observe	VBN	_	1	dep
19	for	for	IN	_	20	case
20	loss	loss	NN	_	18	nmod
21	of	of	IN	_	23	case
22	therapeutic	therapeutic	JJ	_	23	amod
23	response	response	NN	_	20	nmod
24	.	.	.	_	1	punct

1	drug1	drug1	NN	_	2	compound
2	salts	salt	NNS	_	4	nsubj
3	may	may	MD	_	4	aux
4	reduce	reduce	VB	_	0	ROOT
5	the	the	DT	_	6	det
6	bioavailability	bioavailability	NN	_	4	dobj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	drug3	drug3	NN	_	8	conj
11	.	.	.	_	4	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	relevance	relevance	NN	_	5	nsubj
4	is	be	VBZ	_	5	cop
5	unclear	unclear	JJ	_	0	ROOT
6	.	.	.	_	5	punct

1	Although	although	IN	_	4	mark
2	drug1	drug1	NN	_	4	nsubj
3	may	may	MD	_	4	aux
4	increase	increase	VB	_	18	advcl
5	the	the	DT	_	6	det
6	bioavailability	bioavailability	NN	_	4	dobj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	by	by	IN	_	10	mark
10	increasing	increase	VBG	_	4	advcl
11	gastric	gastric	JJ	_	12	amod
12	emptying	emptying	NN	_	10	dobj
13	,	,	,	_	18	punct
14	drug3	drug3	NN	_	18	nsubj
15	may	may	MD	_	18	aux
16	also	also	RB	_	18	advmod
17	adversely	adversely	RB	_	18	advmod
18	affect	affect	VB	_	0	ROOT
19	disease	disease	NN	_	20	compound
20	control	control	NN	_	18	dobj
21	by	by	IN	_	26	case
22	its	its	PRP$	_	26	nmod:poss
23	dopamine	dopamine	NN	_	26	compound
24	receptor	receptor	NN	_	26	compound
25	antagonistic	antagonistic	JJ	_	26	amod
26	properties	property	NNS	_	18	nmod
27	.	.	.	_	18	punct

1	Drugs	drug	NNS	_	0	ROOT
2	that	that	WDT	_	4	nsubj
3	may	may	MD	_	4	aux
4	increase	increase	VB	_	1	acl:relcl
5	drug1	drug1	NN	_	7	compound
6	plasma	plasma	NN	_	7	compound
7	concentrations	concentration	NNS	_	4	dobj
8	CYP3A4	cyp3a4	NN	_	9	compound
9	Inhibitors	inhibitor	NNS	_	7	dep
10	:	:	:	_	1	punct
11	drug2	drug2	NN	_	15	nsubj
12	is	be	VBZ	_	15	cop
13	a	a	DT	_	15	det
14	CYP3A4	cyp3a4	NN	_	15	compound
15	substrate	substrate	NN	_	1	dep
16	.	.	.	_	1	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	use	use	NN	_	36	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drugs	drug	NNS	_	4	conj
7	that	that	WDT	_	8	nsubj
8	inhibit	inhibit	VBP	_	2	acl:relcl
9	CYP3A4	cyp3a4	NN	_	8	dobj
10	-LRB-	-lrb-	-LRB-	_	13	punct
11	eg	eg	FW	_	13	compound
12	,	,	,	_	13	punct
13	drug2	drug2	NN	_	9	dep
14	,	,	,	_	13	punct
15	drug3	drug3	NN	_	13	conj
16	,	,	,	_	13	punct
17	drug4	drug4	NN	_	13	conj
18	,	,	,	_	13	punct
19	drug5	drug5	NN	_	13	conj
20	,	,	,	_	13	punct
21	drug6	drug6	NN	_	13	conj
22	,	,	,	_	13	punct
23	drug7	drug7	NN	_	13	conj
24	,	,	,	_	13	punct
25	drug8	drug8	NN	_	13	conj
26	,	,	,	_	13	punct
27	drug9	drug9	NN	_	13	conj
28	,	,	,	_	13	punct
29	drug10	drug10	NN	_	13	conj
30	,	,	,	_	13	punct
31	drug11	drug11	NN	_	13	conj
32	,	,	,	_	13	punct
33	drug12	drug12	NN	_	13	appos
34	-RRB-	-rrb-	-RRB-	_	13	punct
35	may	may	MD	_	36	aux
36	increase	increase	VB	_	0	ROOT
37	exposure	exposure	NN	_	36	dobj
38	to	to	TO	_	39	case
39	drug13	drug13	NN	_	37	nmod
40	and	and	CC	_	36	cc
41	should	should	MD	_	43	aux
42	be	be	VB	_	43	auxpass
43	avoided	avoid	VBN	_	36	conj
44	.	.	.	_	36	punct

1	In	in	IN	_	2	case
2	patients	patient	NNS	_	19	nmod
3	receiving	receive	VBG	_	2	acl
4	treatment	treatment	NN	_	3	dobj
5	with	with	IN	_	6	case
6	drug1	drug1	NN	_	3	nmod
7	,	,	,	_	19	punct
8	close	close	JJ	_	9	amod
9	monitoring	monitoring	NN	_	19	nsubjpass
10	for	for	IN	_	11	case
11	toxicity	toxicity	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	a	a	DT	_	16	det
14	drug2	drug2	NN	_	16	compound
15	dose	dose	NN	_	16	compound
16	reduction	reduction	NN	_	11	conj
17	should	should	MD	_	19	aux
18	be	be	VB	_	19	auxpass
19	considered	consider	VBN	_	0	ROOT
20	if	if	IN	_	31	mark
21	systemic	systemic	JJ	_	22	amod
22	administration	administration	NN	_	31	nsubjpass
23	of	of	IN	_	27	case
24	a	a	DT	_	27	det
25	potent	potent	JJ	_	27	amod
26	CYP3A4	cyp3a4	NN	_	27	compound
27	inhibitor	inhibitor	NN	_	22	nmod
28	can	can	MD	_	31	aux
29	not	not	RB	_	31	neg
30	be	be	VB	_	31	auxpass
31	avoided	avoid	VBN	_	19	advcl
32	.	.	.	_	19	punct

1	Drugs	drug	NNS	_	0	ROOT
2	that	that	WDT	_	4	nsubj
3	may	may	MD	_	4	aux
4	decrease	decrease	VB	_	1	acl:relcl
5	drug1	drug1	NN	_	7	compound
6	plasma	plasma	NN	_	7	compound
7	concentrations	concentration	NNS	_	4	dobj
8	CYP3A4	cyp3a4	NN	_	9	compound
9	Inducers	inducer	NNS	_	7	dep
10	:	:	:	_	1	punct
11	Drugs	drug	NNS	_	17	nsubj
12	that	that	WDT	_	13	nsubj
13	induce	induce	VBP	_	11	acl:relcl
14	CYP3A4	cyp3a4	NN	_	15	compound
15	activity	activity	NN	_	13	dobj
16	may	may	MD	_	17	aux
17	decrease	decrease	VB	_	1	dep
18	drug2	drug2	NN	_	20	compound
19	plasma	plasma	NN	_	20	compound
20	concentrations	concentration	NNS	_	17	dobj
21	.	.	.	_	1	punct

1	In	in	IN	_	2	case
2	patients	patient	NNS	_	32	nmod
3	in	in	IN	_	4	case
4	whom	whom	WP	_	21	nmod
5	CYP3A4	cyp3a4	NN	_	6	compound
6	inducers	inducer	NNS	_	21	nsubjpass
7	-LRB-	-lrb-	-LRB-	_	10	punct
8	eg	eg	FW	_	10	compound
9	,	,	,	_	10	punct
10	drug1	drug1	NN	_	6	dep
11	,	,	,	_	10	punct
12	drug2	drug2	NN	_	10	conj
13	,	,	,	_	10	punct
14	drug3	drug3	NN	_	10	conj
15	,	,	,	_	10	punct
16	drug4	drug4	NN	_	10	conj
17	,	,	,	_	10	punct
18	drug5	drug5	NN	_	10	appos
19	-RRB-	-rrb-	-RRB-	_	10	punct
20	are	be	VBP	_	21	auxpass
21	indicated	indicate	VBN	_	2	acl:relcl
22	,	,	,	_	32	punct
23	alternative	alternative	JJ	_	24	amod
24	agents	agent	NNS	_	32	nsubjpass
25	with	with	IN	_	29	case
26	less	less	JJR	_	29	amod
27	enzyme	enzyme	NN	_	29	compound
28	induction	induction	NN	_	29	compound
29	potential	potential	NN	_	24	nmod
30	should	should	MD	_	32	aux
31	be	be	VB	_	32	auxpass
32	used	use	VBN	_	0	ROOT
33	.	.	.	_	32	punct

1	If	if	IN	_	5	mark
2	drug1	drug1	NN	_	5	nsubjpass
3	must	must	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	administered	administer	VBN	_	18	advcl
6	with	with	IN	_	9	case
7	a	a	DT	_	9	det
8	CYP3A4	cyp3a4	NN	_	9	compound
9	inducer	inducer	NN	_	5	nmod
10	,	,	,	_	18	punct
11	a	a	DT	_	13	det
12	dose	dose	NN	_	13	compound
13	increase	increase	NN	_	18	nsubjpass
14	in	in	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	should	should	MD	_	18	aux
17	be	be	VB	_	18	auxpass
18	considered	consider	VBN	_	0	ROOT
19	.	.	.	_	18	punct

1	St.	St.	NNP	_	3	compound
2	Johns	Johns	NNP	_	3	compound
3	wort	wort	NN	_	9	nsubj
4	-LRB-	-lrb-	-LRB-	_	6	punct
5	Hypericum	hypericum	NN	_	6	compound
6	perforatum	perforatum	NN	_	3	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	may	may	MD	_	9	aux
9	decrease	decrease	VB	_	0	ROOT
10	drug1	drug1	NN	_	12	compound
11	plasma	plasma	NN	_	12	compound
12	concentrations	concentration	NNS	_	9	dobj
13	unpredictably	unpredictably	RB	_	9	advmod
14	.	.	.	_	9	punct

1	Patients	patient	NNS	_	6	nsubj
2	receiving	receive	VBG	_	1	acl
3	drug1	drug1	NN	_	2	dobj
4	should	should	MD	_	6	aux
5	not	not	RB	_	6	neg
6	take	take	VB	_	0	ROOT
7	St.	St.	NNP	_	9	compound
8	Johns	Johns	NNP	_	9	compound
9	wort	wort	NN	_	6	dobj
10	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Nonclinical	nonclinical	JJ	_	4	amod
4	data	datum	NNS	_	5	nsubj
5	demonstrate	demonstrate	VBP	_	1	appos
6	that	that	IN	_	13	mark
7	the	the	DT	_	8	det
8	solubility	solubility	NN	_	13	nsubj
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	is	be	VBZ	_	13	cop
12	pH	ph	NN	_	13	nmod:npmod
13	dependent	dependent	JJ	_	5	ccomp
14	.	.	.	_	1	punct

1	Simultaneous	simultaneous	JJ	_	2	amod
2	administration	administration	NN	_	9	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	2	nmod
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	avoided	avoid	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	If	if	IN	_	5	mark
2	drug1	drug1	NN	_	3	compound
3	therapy	therapy	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	needed	need	VBN	_	12	advcl
6	,	,	,	_	12	punct
7	the	the	DT	_	9	det
8	antacid	antacid	NN	_	9	compound
9	dose	dose	NN	_	12	nsubjpass
10	should	should	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	administered	administer	VBN	_	0	ROOT
13	at	at	IN	_	14	case
14	least	least	JJS	_	15	nmod:npmod
15	2	2	CD	_	16	nummod
16	hours	hour	NNS	_	12	dobj
17	prior	prior	RB	_	21	advmod
18	to	to	TO	_	21	case
19	or	or	CC	_	18	cc
20	2	2	CD	_	18	conj
21	hours	hour	NNS	_	12	nmod
22	after	after	IN	_	24	case
23	the	the	DT	_	24	det
24	dose	dose	NN	_	21	nmod
25	of	of	IN	_	26	case
26	drug2	drug2	NN	_	24	nmod
27	.	.	.	_	12	punct

1	drug1	drug1	NN	_	3	compound
2	/	/	:	_	3	punct
3	drug2	drug2	NN	_	0	ROOT
4	:	:	:	_	3	punct
5	Long-term	long-term	JJ	_	6	amod
6	suppression	suppression	NN	_	23	nsubj
7	of	of	IN	_	10	case
8	gastric	gastric	JJ	_	10	amod
9	acid	acid	NN	_	10	compound
10	secretion	secretion	NN	_	6	nmod
11	by	by	IN	_	12	case
12	drug3	drug3	NN	_	6	nmod
13	or	or	CC	_	12	cc
14	drug4	drug4	NN	_	12	conj
15	-LRB-	-lrb-	-LRB-	_	18	punct
16	eg	eg	FW	_	18	dep
17	,	,	,	_	18	punct
18	drug5	drug5	NN	_	14	dep
19	and	and	CC	_	18	cc
20	drug6	drug6	NN	_	18	conj
21	-RRB-	-rrb-	-RRB-	_	18	punct
22	is	be	VBZ	_	23	cop
23	likely	likely	JJ	_	3	dep
24	to	to	TO	_	25	mark
25	reduce	reduce	VB	_	23	xcomp
26	drug7	drug7	NN	_	27	compound
27	exposure	exposure	NN	_	25	dobj
28	.	.	.	_	3	punct

1	The	the	DT	_	3	det
2	concomitant	concomitant	JJ	_	3	amod
3	use	use	NN	_	12	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	or	or	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	with	with	IN	_	9	case
9	drug3	drug3	NN	_	3	nmod
10	is	be	VBZ	_	12	auxpass
11	not	not	RB	_	12	neg
12	recommended	recommend	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	The	the	DT	_	2	det
2	use	use	NN	_	7	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	considered	consider	VBN	_	0	ROOT
8	in	in	IN	_	9	case
9	place	place	NN	_	7	nmod
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	or	or	CC	_	11	cc
13	drug3	drug3	NN	_	11	conj
14	in	in	IN	_	15	case
15	patients	patient	NNS	_	9	nmod
16	receiving	receive	VBG	_	15	acl
17	drug4	drug4	NN	_	18	compound
18	therapy	therapy	NN	_	16	dobj
19	.	.	.	_	7	punct

1	Drugs	drug	NNS	_	0	ROOT
2	that	that	WDT	_	4	nsubj
3	may	may	MD	_	4	aux
4	have	have	VB	_	1	acl:relcl
5	their	they	PRP$	_	7	nmod:poss
6	plasma	plasma	NN	_	7	compound
7	concentration	concentration	NN	_	4	dobj
8	altered	alter	VBN	_	7	acl
9	by	by	IN	_	12	case
10	drug1	drug1	NN	_	12	compound
11	CYP3A4	cyp3a4	NN	_	12	compound
12	Substrates	substrate	NNS	_	8	nmod
13	:	:	:	_	1	punct
14	drug2	drug2	NN	_	18	nsubj
15	is	be	VBZ	_	18	cop
16	a	a	DT	_	18	det
17	time-dependent	time-dependent	JJ	_	18	amod
18	inhibitor	inhibitor	NN	_	1	dep
19	of	of	IN	_	20	case
20	CYP3A4	cyp3a4	NN	_	18	nmod
21	.	.	.	_	1	punct

1	Therefore	therefore	RB	_	43	advmod
2	,	,	,	_	43	punct
3	CYP3A4	cyp3a4	NN	_	4	compound
4	substrates	substrate	NNS	_	43	nsubjpass
5	known	know	VBN	_	4	acl
6	to	to	TO	_	7	mark
7	have	have	VB	_	5	xcomp
8	a	a	DT	_	11	det
9	narrow	narrow	JJ	_	11	amod
10	therapeutic	therapeutic	JJ	_	11	amod
11	index	index	NN	_	7	dobj
12	such	such	JJ	_	14	case
13	as	as	IN	_	12	mwe
14	drug1	drug1	NN	_	11	nmod
15	,	,	,	_	14	punct
16	drug2	drug2	NN	_	14	conj
17	,	,	,	_	14	punct
18	drug3	drug3	NN	_	14	conj
19	,	,	,	_	14	punct
20	drug4	drug4	NN	_	14	conj
21	,	,	,	_	14	punct
22	drug5	drug5	NN	_	14	conj
23	,	,	,	_	14	punct
24	drug6	drug6	NN	_	14	conj
25	,	,	,	_	14	punct
26	drug7	drug7	NN	_	14	conj
27	,	,	,	_	14	punct
28	drug8	drug8	NN	_	14	conj
29	,	,	,	_	14	punct
30	drug9	drug9	NN	_	14	conj
31	,	,	,	_	14	punct
32	drug10	drug10	NN	_	14	conj
33	,	,	,	_	14	punct
34	or	or	CC	_	14	cc
35	drug11	drug11	NN	_	14	conj
36	-LRB-	-lrb-	-LRB-	_	37	punct
37	drug12	drug12	NN	_	35	dep
38	,	,	,	_	37	punct
39	drug13	drug13	NN	_	37	appos
40	-RRB-	-rrb-	-RRB-	_	37	punct
41	should	should	MD	_	43	aux
42	be	be	VB	_	43	auxpass
43	administered	administer	VBN	_	0	ROOT
44	with	with	IN	_	45	case
45	caution	caution	NN	_	43	nmod
46	in	in	IN	_	47	case
47	patients	patient	NNS	_	45	nmod
48	receiving	receive	VBG	_	47	acl
49	drug14	drug14	NN	_	48	dobj
50	.	.	.	_	43	punct

1	Hepatic	hepatic	JJ	_	2	amod
2	Impairment	impairment	NN	_	0	ROOT
3	There	there	EX	_	4	expl
4	are	be	VBP	_	2	acl:relcl
5	currently	currently	RB	_	4	advmod
6	no	no	DT	_	8	neg
7	clinical	clinical	JJ	_	8	amod
8	studies	study	NNS	_	4	nsubj
9	with	with	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	in	in	IN	_	12	case
12	patients	patient	NNS	_	10	nmod
13	with	with	IN	_	16	case
14	impaired	impaired	JJ	_	16	amod
15	liver	liver	NN	_	16	compound
16	function	function	NN	_	12	nmod
17	-LRB-	-lrb-	-LRB-	_	19	punct
18	clinical	clinical	JJ	_	19	amod
19	studies	study	NNS	_	21	nsubj
20	have	have	VBP	_	21	aux
21	excluded	exclude	VBN	_	8	acl:relcl
22	patients	patient	NNS	_	21	dobj
23	with	with	IN	_	24	case
24	ALT	alt	NN	_	22	nmod
25	and/or	and/or	CC	_	24	cc
26	AST	AST	NNP	_	24	conj
27	2.5	2.5	CD	_	28	compound
28	times	time	NNS	_	31	nummod
29	the	the	DT	_	31	det
30	upper	upper	JJ	_	31	amod
31	limit	limit	NN	_	24	dep
32	of	of	IN	_	35	case
33	the	the	DT	_	35	det
34	normal	normal	JJ	_	35	amod
35	range	range	NN	_	31	nmod
36	and/or	and/or	CC	_	31	cc
37	total	total	JJ	_	38	amod
38	bilirubin	bilirubin	NN	_	31	conj
39	2	2	CD	_	40	compound
40	times	time	NNS	_	43	nummod
41	the	the	DT	_	43	det
42	upper	upper	JJ	_	43	amod
43	limit	limit	NN	_	38	dep
44	of	of	IN	_	47	case
45	the	the	DT	_	47	det
46	normal	normal	JJ	_	47	amod
47	range	range	NN	_	43	nmod
48	-RRB-	-rrb-	-RRB-	_	2	punct
49	.	.	.	_	2	punct

1	Metabolism	metabolism	NN	_	6	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	is	be	VBZ	_	6	cop
5	mainly	mainly	RB	_	6	advmod
6	hepatic	hepatic	JJ	_	0	ROOT
7	.	.	.	_	6	punct

1	Caution	caution	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	recommended	recommend	VBN	_	0	ROOT
4	in	in	IN	_	5	case
5	patients	patient	NNS	_	3	nmod
6	with	with	IN	_	8	case
7	hepatic	hepatic	JJ	_	8	amod
8	impairment	impairment	NN	_	5	nmod
9	.	.	.	_	3	punct

1	Renal	renal	JJ	_	2	amod
2	Impairment	impairment	NN	_	0	ROOT
3	There	there	EX	_	4	expl
4	are	be	VBP	_	2	acl:relcl
5	currently	currently	RB	_	4	advmod
6	no	no	DT	_	8	neg
7	clinical	clinical	JJ	_	8	amod
8	studies	study	NNS	_	4	nsubj
9	with	with	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	in	in	IN	_	12	case
12	patients	patient	NNS	_	10	nmod
13	with	with	IN	_	16	case
14	impaired	impaired	JJ	_	16	amod
15	renal	renal	JJ	_	16	amod
16	function	function	NN	_	12	nmod
17	-LRB-	-lrb-	-LRB-	_	19	punct
18	clinical	clinical	JJ	_	19	amod
19	studies	study	NNS	_	21	nsubj
20	have	have	VBP	_	21	aux
21	excluded	exclude	VBN	_	8	acl:relcl
22	patients	patient	NNS	_	21	dobj
23	with	with	IN	_	26	case
24	serum	serum	NN	_	26	compound
25	creatinine	creatinine	NN	_	26	compound
26	concentration	concentration	NN	_	22	nmod
27	1.5	1.5	CD	_	28	compound
28	times	time	NNS	_	31	nummod
29	the	the	DT	_	31	det
30	upper	upper	JJ	_	31	amod
31	limit	limit	NN	_	26	dep
32	of	of	IN	_	35	case
33	the	the	DT	_	35	det
34	normal	normal	JJ	_	35	amod
35	range	range	NN	_	31	nmod
36	-RRB-	-rrb-	-RRB-	_	2	punct
37	.	.	.	_	2	punct

1	drug1	drug1	NN	_	7	nsubjpass
2	and	and	CC	_	1	cc
3	its	its	PRP$	_	4	nmod:poss
4	metabolites	metabolite	NNS	_	1	conj
5	are	be	VBP	_	7	auxpass
6	minimally	minimally	RB	_	7	advmod
7	excreted	excrete	VBN	_	0	ROOT
8	via	via	IN	_	10	case
9	the	the	DT	_	10	det
10	kidney	kidney	NN	_	7	nmod
11	.	.	.	_	7	punct

1	Since	since	IN	_	13	mark
2	the	the	DT	_	4	det
3	renal	renal	JJ	_	4	amod
4	excretion	excretion	NN	_	13	nsubj
5	of	of	IN	_	7	case
6	unchanged	unchanged	JJ	_	7	amod
7	drug1	drug1	NN	_	4	nmod
8	and	and	CC	_	7	cc
9	its	its	PRP$	_	10	nmod:poss
10	metabolites	metabolite	NNS	_	7	conj
11	is	be	VBZ	_	13	cop
12	4	4	CD	_	13	nummod
13	%	%	NN	_	23	advcl
14	,	,	,	_	23	punct
15	a	a	DT	_	16	det
16	decrease	decrease	NN	_	23	nsubjpass
17	in	in	IN	_	20	case
18	total	total	JJ	_	20	amod
19	body	body	NN	_	20	compound
20	clearance	clearance	NN	_	16	nmod
21	is	be	VBZ	_	23	auxpass
22	not	not	RB	_	23	neg
23	expected	expect	VBN	_	0	ROOT
24	in	in	IN	_	25	case
25	patients	patient	NNS	_	23	nmod
26	with	with	IN	_	28	case
27	renal	renal	JJ	_	28	amod
28	insufficiency	insufficiency	NN	_	25	nmod
29	.	.	.	_	23	punct

1	Drug	drug	NN	_	3	compound
2	interaction	interaction	NN	_	3	compound
3	studies	study	NNS	_	7	nsubjpass
4	have	have	VBP	_	7	aux
5	not	not	RB	_	7	neg
6	been	be	VBN	_	7	auxpass
7	performed	perform	VBN	_	0	ROOT
8	with	with	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	.	.	.	_	7	punct

1	No	no	DT	_	5	neg
2	formal	formal	JJ	_	5	amod
3	drug-drug	drug-drug	JJ	_	5	amod
4	interaction	interaction	NN	_	5	compound
5	studies	study	NNS	_	8	nsubjpass
6	have	have	VBP	_	8	aux
7	been	be	VBN	_	8	auxpass
8	performed	perform	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	No	no	DT	_	3	neg
2	confirmed	confirm	VBD	_	3	amod
3	interactions	interaction	NNS	_	6	nsubjpass
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	auxpass
6	reported	report	VBN	_	0	ROOT
7	between	between	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	other	other	JJ	_	11	amod
11	drugs	drug	NNS	_	8	conj

1	drug1	drug1	NN	_	3	compound
2	Inhalation	Inhalation	NNP	_	3	compound
3	Aerosol	Aerosol	NNP	_	6	nsubjpass
4	has	have	VBZ	_	6	aux
5	been	be	VBN	_	6	auxpass
6	used	use	VBN	_	0	ROOT
7	concomitantly	concomitantly	RB	_	6	advmod
8	with	with	IN	_	10	case
9	other	other	JJ	_	10	amod
10	drugs	drug	NNS	_	6	nmod
11	,	,	,	_	10	punct
12	including	include	VBG	_	13	case
13	drug2	drug2	NN	_	10	nmod
14	,	,	,	_	13	punct
15	drug3	drug3	NN	_	13	conj
16	,	,	,	_	13	punct
17	and	and	CC	_	13	cc
18	drug4	drug4	NN	_	13	conj
19	,	,	,	_	10	punct
20	commonly	commonly	RB	_	21	advmod
21	used	use	VBN	_	10	acl
22	in	in	IN	_	24	case
23	the	the	DT	_	24	det
24	treatment	treatment	NN	_	21	nmod
25	of	of	IN	_	29	case
26	chronic	chronic	JJ	_	29	amod
27	obstructive	obstructive	JJ	_	29	amod
28	pulmonary	pulmonary	JJ	_	29	amod
29	disease	disease	NN	_	24	nmod
30	.	.	.	_	6	punct

1	With	with	IN	_	3	case
2	the	the	DT	_	3	det
3	exception	exception	NN	_	8	nmod
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	,	,	,	_	8	punct
7	there	there	EX	_	8	expl
8	are	be	VBP	_	0	ROOT
9	no	no	DT	_	11	neg
10	formal	formal	JJ	_	11	amod
11	studies	study	NNS	_	8	nsubj
12	fully	fully	RB	_	13	advmod
13	evaluating	evaluate	VBG	_	11	acl
14	the	the	DT	_	16	det
15	interaction	interaction	NN	_	16	compound
16	effects	effect	NNS	_	13	dobj
17	of	of	IN	_	20	case
18	drug2	drug2	NN	_	20	compound
19	Inhalation	Inhalation	NNP	_	20	compound
20	Aerosol	Aerosol	NNP	_	16	nmod
21	and	and	CC	_	20	cc
22	these	these	DT	_	23	det
23	drugs	drug	NNS	_	20	conj
24	with	with	IN	_	25	case
25	respect	respect	NN	_	13	nmod
26	to	to	TO	_	27	case
27	effectiveness	effectiveness	NN	_	25	nmod
28	.	.	.	_	8	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Although	although	IN	_	7	mark
4	drug2	drug2	NN	_	7	nsubjpass
5	is	be	VBZ	_	7	auxpass
6	minimally	minimally	RB	_	7	advmod
7	absorbed	absorb	VBN	_	14	advcl
8	into	into	IN	_	11	case
9	the	the	DT	_	11	det
10	systemic	systemic	JJ	_	11	amod
11	circulation	circulation	NN	_	7	nmod
12	,	,	,	_	14	punct
13	there	there	EX	_	14	expl
14	is	be	VBZ	_	1	dep
15	some	some	DT	_	16	det
16	potential	potential	JJ	_	14	nsubj
17	for	for	IN	_	20	case
18	an	a	DT	_	20	det
19	additive	additive	JJ	_	20	amod
20	interaction	interaction	NN	_	16	nmod
21	with	with	IN	_	24	case
22	concomitantly	concomitantly	RB	_	23	advmod
23	used	use	VBN	_	24	amod
24	drug3	drug3	NN	_	20	nmod
25	.	.	.	_	1	punct

1	Caution	caution	NN	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	therefore	therefore	RB	_	4	advmod
4	advised	advise	VBN	_	0	ROOT
5	in	in	IN	_	7	case
6	the	the	DT	_	7	det
7	coadministration	coadministration	NN	_	4	nmod
8	of	of	IN	_	11	case
9	drug1	drug1	NN	_	11	compound
10	Inhalation	Inhalation	NNP	_	11	compound
11	Aerosol	Aerosol	NNP	_	7	nmod
12	with	with	IN	_	14	case
13	other	other	JJ	_	14	amod
14	drug2	drug2	NN	_	4	nmod
15	-	-	:	_	14	punct
16	containing	contain	VBG	_	14	acl
17	drugs	drug	NNS	_	16	dobj
18	.	.	.	_	4	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	treatment	treatment	NN	_	0	ROOT
3	with	with	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	-LRB-	-lrb-	-LRB-	_	8	punct
6	eg	eg	FW	_	8	dep
7	,	,	,	_	8	punct
8	rt-PA	rt-pa	NN	_	4	dep
9	or	or	CC	_	8	cc
10	drug2	drug2	NN	_	8	conj
11	-RRB-	-rrb-	-RRB-	_	8	punct
12	may	may	MD	_	2	dep
13	:	:	:	_	12	punct
14	-	-	:	_	12	punct
15	increase	increase	VB	_	12	dep
16	the	the	DT	_	17	det
17	risk	risk	NN	_	15	dobj
18	of	of	IN	_	19	mark
19	bleeding	bleed	VBG	_	17	acl
20	complications	complication	NNS	_	19	dobj
21	-	-	:	_	15	punct
22	considerably	considerably	RB	_	23	advmod
23	enhance	enhance	VBP	_	15	dep
24	the	the	DT	_	25	det
25	effect	effect	NN	_	23	dobj
26	of	of	IN	_	27	case
27	drug3	drug3	NN	_	25	nmod
28	on	on	IN	_	30	case
29	aPTT	aptt	NN	_	30	compound
30	prolongation	prolongation	NN	_	25	nmod

1	Concomitant	concomitant	JJ	_	2	amod
2	treatment	treatment	NN	_	16	nsubj
3	with	with	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	-LRB-	-lrb-	-LRB-	_	6	punct
6	drug2	drug2	NN	_	4	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	and	and	CC	_	4	cc
9	drugs	drug	NNS	_	4	conj
10	that	that	WDT	_	11	nsubj
11	affect	affect	VBP	_	2	acl:relcl
12	platelet	platelet	NN	_	13	compound
13	function	function	NN	_	11	dobj
14	may	may	MD	_	16	aux
15	also	also	RB	_	16	advmod
16	increase	increase	VB	_	0	ROOT
17	the	the	DT	_	18	det
18	risk	risk	NN	_	16	dobj
19	of	of	IN	_	20	case
20	bleeding	bleeding	NN	_	18	nmod
21	.	.	.	_	16	punct

1	Co-administration	co-administration	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	at	at	IN	_	5	case
5	steady-state	steady-state	JJ	_	1	nmod
6	with	with	IN	_	9	case
7	a	a	DT	_	9	det
8	single	single	JJ	_	9	amod
9	dose	dose	NN	_	5	nmod
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	.	.	.	_	1	punct

1	Co-administration	co-administration	NN	_	19	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	at	at	IN	_	5	case
5	steady-state	steady-state	JJ	_	1	nmod
6	with	with	IN	_	9	case
7	a	a	DT	_	9	det
8	single	single	JJ	_	9	amod
9	dose	dose	NN	_	5	nmod
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	-LRB-	-lrb-	-LRB-	_	17	punct
13	2	2	CD	_	17	nummod
14	x	x	CC	_	13	cc
15	600	600	CD	_	13	conj
16	mg	mg	NN	_	17	compound
17	tablets	tablet	NNS	_	11	appos
18	-RRB-	-rrb-	-RRB-	_	17	punct
19	results	result	VBZ	_	0	ROOT
20	in	in	IN	_	24	case
21	increased	increase	VBN	_	24	amod
22	drug3	drug3	NN	_	24	compound
23	serum	serum	NN	_	24	compound
24	concentrations	concentration	NNS	_	19	nmod
25	.	.	.	_	19	punct

1	Although	although	IN	_	9	mark
2	a	a	DT	_	4	det
3	dose	dose	NN	_	4	compound
4	adjustment	adjustment	NN	_	9	nsubjpass
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	is	be	VBZ	_	9	auxpass
8	not	not	RB	_	9	neg
9	recommended	recommend	VBN	_	36	advcl
10	when	when	WRB	_	11	advmod
11	administered	administer	VBN	_	9	advcl
12	in	in	IN	_	13	case
13	combination	combination	NN	_	11	nmod
14	with	with	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	,	,	,	_	15	punct
17	close	close	JJ	_	18	amod
18	monitoring	monitoring	NN	_	15	appos
19	for	for	IN	_	22	case
20	known	known	JJ	_	22	amod
21	side	side	JJ	_	22	amod
22	effects	effect	NNS	_	18	nmod
23	of	of	IN	_	24	case
24	drug3	drug3	NN	_	22	nmod
25	,	,	,	_	24	punct
26	such	such	JJ	_	30	case
27	as	as	IN	_	26	mwe
28	liver	liver	NN	_	30	compound
29	enzyme	enzyme	NN	_	30	compound
30	abnormalities	abnormality	NNS	_	24	nmod
31	and	and	CC	_	30	cc
32	hearing	hear	VBG	_	30	conj
33	impairment	impairment	NN	_	32	dobj
34	,	,	,	_	36	punct
35	is	be	VBZ	_	36	auxpass
36	warranted	warrant	VBN	_	0	ROOT
37	.	.	.	_	36	punct

1	drug1	drug1	NN	_	4	nsubj
2	did	do	VBD	_	4	aux
3	not	not	RB	_	4	neg
4	affect	affect	VB	_	0	ROOT
5	the	the	DT	_	8	det
6	prothrombin	prothrombin	NN	_	8	compound
7	time	time	NN	_	8	compound
8	response	response	NN	_	4	dobj
9	to	to	TO	_	12	case
10	a	a	DT	_	12	det
11	single	single	JJ	_	12	amod
12	dose	dose	NN	_	8	nmod
13	of	of	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	.	.	.	_	4	punct

1	However	however	RB	_	6	advmod
2	,	,	,	_	6	punct
3	prudent	prudent	JJ	_	5	amod
4	medical	medical	JJ	_	5	amod
5	practice	practice	NN	_	6	nsubj
6	dictates	dictate	VBZ	_	0	ROOT
7	careful	careful	JJ	_	8	amod
8	monitoring	monitoring	NN	_	6	dobj
9	of	of	IN	_	11	case
10	prothrombin	prothrombin	NN	_	11	compound
11	time	time	NN	_	8	nmod
12	in	in	IN	_	14	case
13	all	all	DT	_	14	det
14	patients	patient	NNS	_	8	nmod
15	treated	treat	VBN	_	14	acl
16	with	with	IN	_	17	case
17	drug1	drug1	NN	_	15	nmod
18	and	and	CC	_	17	cc
19	drug2	drug2	NN	_	17	conj
20	concomitantly	concomitantly	RB	_	6	advmod
21	.	.	.	_	6	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	use	use	NN	_	12	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	in	in	IN	_	9	case
8	clinical	clinical	JJ	_	9	amod
9	practice	practice	NN	_	2	nmod
10	has	have	VBZ	_	12	aux
11	been	be	VBN	_	12	auxpass
12	associated	associate	VBN	_	0	ROOT
13	with	with	IN	_	16	case
14	increased	increase	VBN	_	16	amod
15	anticoagulant	anticoagulant	JJ	_	16	amod
16	effects	effect	NNS	_	12	nmod
17	.	.	.	_	12	punct

1	Drug	drug	NN	_	3	compound
2	interaction	interaction	NN	_	3	compound
3	studies	study	NNS	_	5	nsubjpass
4	were	be	VBD	_	5	auxpass
5	performed	perform	VBN	_	0	ROOT
6	with	with	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	other	other	JJ	_	10	amod
10	drugs	drug	NNS	_	7	conj
11	likely	likely	JJ	_	7	amod
12	to	to	TO	_	14	mark
13	be	be	VB	_	14	auxpass
14	co-administered	co-administer	VBN	_	11	xcomp
15	.	.	.	_	5	punct

1	When	when	WRB	_	2	advmod
2	used	use	VBN	_	8	advcl
3	in	in	IN	_	5	case
4	therapeutic	therapeutic	JJ	_	5	amod
5	doses	dose	NNS	_	2	nmod
6	,	,	,	_	8	punct
7	drug1	drug1	NN	_	8	nsubj
8	had	have	VBD	_	0	ROOT
9	a	a	DT	_	11	det
10	modest	modest	JJ	_	11	amod
11	effect	effect	NN	_	8	dobj
12	on	on	IN	_	14	case
13	the	the	DT	_	14	det
14	pharmacokinetics	pharmacokinetic	NNS	_	8	nmod
15	of	of	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	,	,	,	_	16	punct
18	drug3	drug3	NN	_	16	conj
19	,	,	,	_	16	punct
20	drug4	drug4	NN	_	16	conj
21	,	,	,	_	16	punct
22	drug5	drug5	NN	_	16	conj
23	,	,	,	_	16	punct
24	drug6	drug6	NN	_	16	conj
25	,	,	,	_	16	punct
26	drug7	drug7	NN	_	16	conj
27	,	,	,	_	16	punct
28	drug8	drug8	NN	_	16	conj
29	,	,	,	_	16	punct
30	drug9	drug9	NN	_	16	conj
31	,	,	,	_	16	punct
32	drug10	drug10	NN	_	16	conj
33	,	,	,	_	16	punct
34	drug11	drug11	NN	_	16	conj
35	,	,	,	_	16	punct
36	drug12	drug12	NN	_	16	conj
37	-LRB-	-lrb-	-LRB-	_	38	punct
38	intravenous	intravenous	JJ	_	36	dep
39	and	and	CC	_	38	cc
40	oral	oral	JJ	_	38	conj
41	-RRB-	-rrb-	-RRB-	_	38	punct
42	,	,	,	_	16	punct
43	drug13	drug13	NN	_	16	conj
44	,	,	,	_	16	punct
45	drug14	drug14	NN	_	16	conj
46	/	/	:	_	16	punct
47	drug15	drug15	NN	_	16	dep
48	or	or	CC	_	47	cc
49	drug16	drug16	NN	_	47	conj
50	.	.	.	_	8	punct

1	Co-administration	co-administration	NN	_	6	nsubj
2	with	with	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	or	or	CC	_	3	cc
5	drug2	drug2	NN	_	3	conj
6	had	have	VBD	_	0	ROOT
7	a	a	DT	_	9	det
8	modest	modest	JJ	_	9	amod
9	effect	effect	NN	_	6	dobj
10	on	on	IN	_	12	case
11	the	the	DT	_	12	det
12	pharmacokinetics	pharmacokinetic	NNS	_	6	nmod
13	of	of	IN	_	14	case
14	drug3	drug3	NN	_	12	nmod
15	.	.	.	_	6	punct

1	No	no	DT	_	3	neg
2	dosage	dosage	NN	_	3	compound
3	adjustment	adjustment	NN	_	8	nsubjpass
4	of	of	IN	_	6	case
5	either	either	CC	_	6	det
6	drug	drug	NN	_	3	nmod
7	is	be	VBZ	_	8	auxpass
8	recommended	recommend	VBN	_	0	ROOT
9	when	when	WRB	_	13	advmod
10	drug1	drug1	NN	_	13	nsubjpass
11	is	be	VBZ	_	13	auxpass
12	co	co	NN	_	13	nsubjpass
13	administered	administer	VBN	_	8	advcl
14	with	with	IN	_	15	case
15	any	any	DT	_	13	nmod
16	of	of	IN	_	19	case
17	the	the	DT	_	19	det
18	above	above	JJ	_	19	amod
19	agents	agent	NNS	_	15	nmod
20	.	.	.	_	8	punct

1	Interactions	interaction	NNS	_	10	nsubjpass
2	with	with	IN	_	4	case
3	the	the	DT	_	4	det
4	drugs	drug	NNS	_	1	nmod
5	listed	list	VBN	_	4	acl
6	below	below	RB	_	5	advmod
7	have	have	VBP	_	10	aux
8	not	not	RB	_	10	neg
9	been	be	VBN	_	10	auxpass
10	reported	report	VBN	_	0	ROOT
11	in	in	IN	_	13	case
12	clinical	clinical	JJ	_	13	amod
13	trials	trial	NNS	_	10	nmod
14	with	with	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	;	;	:	_	10	punct

1	however	however	RB	_	10	advmod
2	,	,	,	_	10	punct
3	no	no	DT	_	7	neg
4	specific	specific	JJ	_	7	amod
5	drug	drug	NN	_	7	compound
6	interaction	interaction	NN	_	7	compound
7	studies	study	NNS	_	10	nsubjpass
8	have	have	VBP	_	10	aux
9	been	be	VBN	_	10	auxpass
10	performed	perform	VBN	_	0	ROOT
11	to	to	TO	_	12	mark
12	evaluate	evaluate	VB	_	10	xcomp
13	potential	potential	JJ	_	15	amod
14	drug-drug	drug-drug	JJ	_	15	amod
15	interaction	interaction	NN	_	12	dobj
16	.	.	.	_	10	punct

1	Nonetheless	nonetheless	RB	_	6	advmod
2	,	,	,	_	6	punct
3	they	they	PRP	_	6	nsubjpass
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	auxpass
6	observed	observe	VBN	_	0	ROOT
7	with	with	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	.	.	.	_	6	punct

1	Until	until	IN	_	5	mark
2	further	further	JJ	_	3	amod
3	data	datum	NNS	_	5	nsubjpass
4	are	be	VBP	_	5	auxpass
5	developed	develop	VBN	_	23	advcl
6	regarding	regard	VBG	_	8	case
7	drug	drug	NN	_	8	compound
8	interactions	interaction	NNS	_	5	nmod
9	when	when	WRB	_	15	advmod
10	drug1	drug1	NN	_	15	nsubjpass
11	and	and	CC	_	10	cc
12	these	these	DT	_	13	det
13	drugs	drug	NNS	_	10	conj
14	are	be	VBP	_	15	auxpass
15	used	use	VBN	_	5	advcl
16	concomitantly	concomitantly	RB	_	15	advmod
17	,	,	,	_	23	punct
18	careful	careful	JJ	_	19	amod
19	monitoring	monitoring	NN	_	23	nsubjpass
20	of	of	IN	_	21	case
21	patients	patient	NNS	_	19	nmod
22	is	be	VBZ	_	23	auxpass
23	advised	advise	VBN	_	0	ROOT
24	:	:	:	_	23	punct
25	drug2	drug2	NN	_	28	compound
26	elevated	elevated	JJ	_	28	amod
27	drug3	drug3	NN	_	28	compound
28	concentrations	concentration	NNS	_	23	dep
29	.	.	.	_	23	punct

1	drug1	drug1	NN	_	6	compound
2	or	or	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	acute	acute	JJ	_	6	amod
5	ergot	ergot	NN	_	6	compound
6	toxicity	toxicity	NN	_	0	ROOT
7	characterized	characterize	VBN	_	6	acl
8	by	by	IN	_	11	case
9	severe	severe	JJ	_	11	amod
10	peripheral	peripheral	JJ	_	11	amod
11	vasospasm	vasospasm	NN	_	7	nmod
12	and	and	CC	_	11	cc
13	dysesthesia	dysesthesia	NN	_	11	conj
14	.	.	.	_	6	punct

1	drug1	drug1	NN	_	6	compound
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	and	and	CC	_	1	cc
5	drug3	drug3	NN	_	1	conj
6	concentrations	concentration	NNS	_	0	ROOT
7	.	.	.	_	6	punct

1	Laboratory	Laboratory	NNP	_	3	compound
2	Test	Test	NNP	_	3	compound
3	Interactions	interaction	NNS	_	0	ROOT
4	There	there	EX	_	5	expl
5	are	be	VBP	_	3	acl:relcl
6	no	no	DT	_	10	neg
7	reported	report	VBN	_	10	amod
8	laboratory	laboratory	NN	_	10	compound
9	test	test	NN	_	10	compound
10	interactions	interaction	NNS	_	5	nsubj
11	.	.	.	_	3	punct

1	Repeat	repeat	NN	_	3	compound
2	Treatment	treatment	NN	_	3	compound
3	Studies	study	NNS	_	15	nsubjpass
4	evaluating	evaluate	VBG	_	3	acl
5	the	the	DT	_	6	det
6	use	use	NN	_	4	dobj
7	of	of	IN	_	9	case
8	repeated	repeat	VBN	_	9	amod
9	courses	course	NNS	_	6	nmod
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	have	have	VBP	_	15	aux
13	not	not	RB	_	15	neg
14	been	be	VBN	_	15	auxpass
15	conducted	conduct	VBN	_	0	ROOT
16	.	.	.	_	15	punct

1	Oral	oral	JJ	_	2	amod
2	drug1	drug1	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	drug2	drug2	NN	_	5	nsubj
5	appear	appear	VBP	_	2	dep
6	to	to	TO	_	7	mark
7	increase	increase	VB	_	5	xcomp
8	catabolism	catabolism	NN	_	7	dobj
9	of	of	IN	_	13	case
10	vitamin	vitamin	NN	_	13	compound
11	K-dependent	k-dependent	JJ	_	13	amod
12	clotting	clotting	NN	_	13	compound
13	factors	factor	NNS	_	8	nmod
14	.	.	.	_	2	punct

1	If	if	IN	_	7	mark
2	oral	oral	JJ	_	3	amod
3	drug1	drug1	NN	_	7	nsubjpass
4	are	be	VBP	_	7	aux
5	also	also	RB	_	7	advmod
6	being	be	VBG	_	7	auxpass
7	given	give	VBN	_	16	advcl
8	,	,	,	_	16	punct
9	compensatory	compensatory	JJ	_	10	amod
10	increases	increase	NNS	_	16	nsubj
11	in	in	IN	_	14	case
12	clotting	clotting	NN	_	14	compound
13	factor	factor	NN	_	14	compound
14	synthesis	synthesis	NN	_	10	nmod
15	are	be	VBP	_	16	cop
16	impaired	impaired	JJ	_	0	ROOT
17	.	.	.	_	16	punct

1	Patients	patient	NNS	_	2	nsubj
2	stabilized	stabilize	VBD	_	0	ROOT
3	on	on	IN	_	5	case
4	oral	oral	JJ	_	5	amod
5	drug1	drug1	NN	_	2	nmod
6	who	who	WP	_	8	nsubjpass
7	are	be	VBP	_	8	auxpass
8	found	find	VBN	_	5	acl:relcl
9	to	to	TO	_	10	mark
10	require	require	VB	_	8	xcomp
11	drug2	drug2	NN	_	13	compound
12	replacement	replacement	NN	_	13	compound
13	therapy	therapy	NN	_	10	dobj
14	should	should	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	watched	watch	VBN	_	2	ccomp
17	very	very	RB	_	18	advmod
18	closely	closely	RB	_	16	advmod
19	when	when	WRB	_	22	advmod
20	thyroid	thyroid	NN	_	22	nsubjpass
21	is	be	VBZ	_	22	auxpass
22	started	start	VBN	_	16	advcl
23	.	.	.	_	2	punct

1	If	if	IN	_	6	mark
2	a	a	DT	_	3	det
3	patient	patient	NN	_	6	nsubj
4	is	be	VBZ	_	6	cop
5	truly	truly	RB	_	6	advmod
6	hypothyroid	hypothyroid	JJ	_	10	advcl
7	,	,	,	_	10	punct
8	it	it	PRP	_	10	nsubj
9	is	be	VBZ	_	10	cop
10	likely	likely	JJ	_	0	ROOT
11	that	that	IN	_	19	mark
12	a	a	DT	_	13	det
13	reduction	reduction	NN	_	19	nsubjpass
14	in	in	IN	_	16	case
15	drug1	drug1	NN	_	16	compound
16	dosage	dosage	NN	_	13	nmod
17	will	will	MD	_	19	aux
18	be	be	VB	_	19	auxpass
19	required	require	VBN	_	10	ccomp
20	.	.	.	_	10	punct

1	No	no	DT	_	3	neg
2	special	special	JJ	_	3	amod
3	precautions	precaution	NNS	_	4	nsubj
4	appear	appear	VBP	_	0	ROOT
5	to	to	TO	_	7	mark
6	be	be	VB	_	7	cop
7	necessary	necessary	JJ	_	4	xcomp
8	when	when	WRB	_	13	advmod
9	oral	oral	JJ	_	11	amod
10	anticoagulant	anticoagulant	JJ	_	11	amod
11	therapy	therapy	NN	_	13	nsubjpass
12	is	be	VBZ	_	13	auxpass
13	begun	begin	VBN	_	7	advcl
14	in	in	IN	_	16	case
15	a	a	DT	_	16	det
16	patient	patient	NN	_	13	nmod
17	already	already	RB	_	18	advmod
18	stabilized	stabilize	VBD	_	16	acl
19	on	on	IN	_	23	case
20	maintenance	maintenance	NN	_	23	compound
21	thyroid	thyroid	NN	_	23	compound
22	replacement	replacement	NN	_	23	compound
23	therapy	therapy	NN	_	18	nmod
24	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT
2	or	or	CC	_	1	cc
3	Oral	oral	JJ	_	1	conj
4	drug2	drug2	NN	_	1	dep
5	:	:	:	_	1	punct
6	Initiating	initiate	VBG	_	11	csubj
7	thyroid	thyroid	NN	_	9	compound
8	replacement	replacement	NN	_	9	compound
9	therapy	therapy	NN	_	6	dobj
10	may	may	MD	_	11	aux
11	cause	cause	VB	_	1	dep
12	increases	increase	NNS	_	11	dobj
13	in	in	IN	_	14	case
14	drug3	drug3	NN	_	12	nmod
15	or	or	CC	_	14	cc
16	oral	oral	JJ	_	18	amod
17	drug4	drug4	NN	_	18	compound
18	requirements	requirement	NNS	_	14	conj
19	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	effects	effect	NNS	_	6	nsubjpass
3	seen	see	VBN	_	2	acl
4	are	be	VBP	_	6	auxpass
5	poorly	poorly	RB	_	6	advmod
6	understood	understand	VBN	_	0	ROOT
7	and	and	CC	_	6	cc
8	depend	depend	VB	_	6	conj
9	upon	upon	IN	_	11	case
10	a	a	DT	_	11	det
11	variety	variety	NN	_	8	nmod
12	of	of	IN	_	13	case
13	factors	factor	NNS	_	11	nmod
14	such	such	JJ	_	16	case
15	as	as	IN	_	14	mwe
16	dose	dose	NN	_	13	nmod
17	and	and	CC	_	16	cc
18	type	type	NN	_	16	conj
19	of	of	IN	_	20	case
20	drug1	drug1	NN	_	16	nmod
21	and	and	CC	_	20	cc
22	endocrine	endocrine	JJ	_	23	amod
23	status	status	NN	_	20	conj
24	of	of	IN	_	26	case
25	the	the	DT	_	26	det
26	patient	patient	NN	_	20	nmod
27	.	.	.	_	6	punct

1	Patients	patient	NNS	_	10	nsubjpass
2	receiving	receive	VBG	_	1	acl
3	drug1	drug1	NN	_	2	dobj
4	or	or	CC	_	3	cc
5	oral	oral	JJ	_	6	amod
6	drug2	drug2	NN	_	3	conj
7	should	should	MD	_	10	aux
8	be	be	VB	_	10	auxpass
9	closely	closely	RB	_	10	advmod
10	watched	watch	VBN	_	0	ROOT
11	during	during	IN	_	12	case
12	initiation	initiation	NN	_	10	nmod
13	of	of	IN	_	16	case
14	thyroid	thyroid	NN	_	16	compound
15	replacement	replacement	NN	_	16	compound
16	therapy	therapy	NN	_	12	nmod
17	.	.	.	_	10	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	nsubj
4	binds	bind	VBZ	_	1	appos
5	both	both	CC	_	6	cc:preconj
6	drug3	drug3	NN	_	4	dobj
7	and	and	CC	_	6	cc
8	drug4	drug4	NN	_	6	conj
9	in	in	IN	_	11	case
10	the	the	DT	_	11	det
11	intestine	intestine	NN	_	4	nmod
12	,	,	,	_	4	punct
13	thus	thus	RB	_	14	advmod
14	impairing	impair	VBG	_	4	advcl
15	absorption	absorption	NN	_	14	dobj
16	of	of	IN	_	18	case
17	these	these	DT	_	18	det
18	drug5	drug5	NN	_	15	nmod
19	.	.	.	_	1	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	4	nsubj
4	indicate	indicate	VBP	_	0	ROOT
5	that	that	IN	_	11	mark
6	the	the	DT	_	7	det
7	binding	binding	NN	_	11	nsubjpass
8	is	be	VBZ	_	11	auxpass
9	not	not	RB	_	11	neg
10	easily	easily	RB	_	11	advmod
11	removed	remove	VBN	_	4	ccomp
12	.	.	.	_	4	punct

1	Therefore	therefore	RB	_	8	advmod
2	,	,	,	_	8	punct
3	4	4	CD	_	5	compound
4	to	to	TO	_	5	dep
5	5	5	CD	_	6	nummod
6	hours	hour	NNS	_	8	nsubj
7	should	should	MD	_	8	aux
8	elapse	elapse	VB	_	0	ROOT
9	between	between	IN	_	10	case
10	administration	administration	NN	_	8	nmod
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	and	and	CC	_	12	cc
14	drug2	drug2	NN	_	12	conj
15	.	.	.	_	8	punct

1	drug1	drug1	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	Oral	oral	JJ	_	4	amod
4	drug2	drug2	NN	_	1	appos
5	:	:	:	_	1	punct
6	drug3	drug3	NN	_	7	compound
7	tend	tend	VB	_	1	dep
8	to	to	TO	_	9	mark
9	increase	increase	VB	_	7	xcomp
10	serum	serum	NN	_	12	compound
11	thyroxine-binding	thyroxine-binding	JJ	_	12	amod
12	globulin	globulin	NN	_	9	dobj
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	TBg	tbg	NN	_	12	appos
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	.	.	.	_	1	punct

1	In	in	IN	_	3	case
2	a	a	DT	_	3	det
3	patient	patient	NN	_	20	nmod
4	with	with	IN	_	8	case
5	a	a	DT	_	8	det
6	nonfunctioning	nonfunctioning	JJ	_	8	amod
7	thyroid	thyroid	NN	_	8	compound
8	gland	gland	NN	_	3	nmod
9	who	who	WP	_	11	nsubj
10	is	be	VBZ	_	11	aux
11	receiving	receive	VBG	_	8	acl:relcl
12	thyroid	thyroid	NN	_	14	compound
13	replacement	replacement	NN	_	14	compound
14	therapy	therapy	NN	_	11	dobj
15	,	,	,	_	20	punct
16	free	free	JJ	_	17	amod
17	drug1	drug1	NN	_	20	nsubjpass
18	may	may	MD	_	20	aux
19	be	be	VB	_	20	auxpass
20	decreased	decrease	VBN	_	0	ROOT
21	when	when	WRB	_	24	advmod
22	drug2	drug2	NN	_	24	nsubjpass
23	are	be	VBP	_	24	auxpass
24	started	start	VBN	_	20	advcl
25	thus	thus	RB	_	26	advmod
26	increasing	increase	VBG	_	24	xcomp
27	drug3	drug3	NN	_	28	compound
28	requirements	requirement	NNS	_	26	dobj
29	.	.	.	_	20	punct

1	However	however	RB	_	0	ROOT
2	,	,	,	_	1	punct
3	if	if	IN	_	8	mark
4	the	the	DT	_	5	det
5	patients	patient	NNS	_	8	nsubj
6	thyroid	thyroid	NN	_	7	compound
7	gland	gland	NN	_	5	dep
8	has	have	VBZ	_	2	root
9	sufficient	sufficient	JJ	_	10	amod
10	function	function	NN	_	8	dobj
11	,	,	,	_	8	punct
12	the	the	DT	_	15	det
13	decreased	decrease	VBN	_	15	amod
14	free	free	JJ	_	15	amod
15	drug1	drug1	NN	_	11	root
16	e	e	SYM	_	18	nsubj
17	will	will	MD	_	18	aux
18	result	result	VB	_	15	acl:relcl
19	in	in	IN	_	22	case
20	a	a	DT	_	22	det
21	compensatory	compensatory	JJ	_	22	amod
22	increase	increase	NN	_	18	nmod
23	in	in	IN	_	25	case
24	thyroxine	thyroxine	JJ	_	25	amod
25	output	output	NN	_	22	nmod
26	by	by	IN	_	28	case
27	the	the	DT	_	28	det
28	thyroid	thyroid	NN	_	22	nmod
29	.	.	.	_	15	punct

1	Therefore	therefore	RB	_	16	advmod
2	,	,	,	_	16	punct
3	patients	patient	NNS	_	16	nsubj
4	without	without	IN	_	8	case
5	a	a	DT	_	8	det
6	functioning	function	VBG	_	8	amod
7	drug1	drug1	NN	_	8	compound
8	gland	gland	NN	_	3	nmod
9	who	who	WP	_	14	nsubj
10	are	be	VBP	_	14	cop
11	on	on	IN	_	14	case
12	thyroid	thyroid	NN	_	14	compound
13	replacement	replacement	NN	_	14	compound
14	therapy	therapy	NN	_	8	acl:relcl
15	may	may	MD	_	16	aux
16	need	need	VB	_	0	ROOT
17	to	to	TO	_	18	mark
18	increase	increase	VB	_	16	xcomp
19	their	they	PRP$	_	21	nmod:poss
20	thyroid	thyroid	NN	_	21	compound
21	dose	dose	NN	_	18	dobj
22	if	if	IN	_	31	mark
23	drug2	drug2	NN	_	31	nsubjpass
24	or	or	CC	_	23	cc
25	drug3	drug3	NN	_	23	conj
26	-	-	:	_	23	punct
27	containing	contain	VBG	_	23	acl
28	oral	oral	JJ	_	29	amod
29	drug4	drug4	NN	_	27	dobj
30	are	be	VBP	_	31	auxpass
31	given	give	VBN	_	18	advcl
32	.	.	.	_	16	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Use	use	NN	_	12	nsubj
4	of	of	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	with	with	IN	_	7	case
7	drug3	drug3	NN	_	3	nmod
8	and	and	CC	_	7	cc
9	other	other	JJ	_	10	amod
10	drug4	drug4	NN	_	7	conj
11	may	may	MD	_	12	aux
12	increase	increase	VB	_	1	appos
13	receptor	receptor	NN	_	14	compound
14	sensitivity	sensitivity	NN	_	12	dobj
15	and	and	CC	_	12	cc
16	enhance	enhance	VBP	_	12	conj
17	antidepressant	antidepressant	JJ	_	18	amod
18	activity	activity	NN	_	16	dobj
19	transient	transient	JJ	_	21	amod
20	cardiac	cardiac	JJ	_	21	amod
21	arrhythmias	arrhythmia	NNS	_	24	nsubjpass
22	have	have	VBP	_	24	aux
23	been	be	VBN	_	24	auxpass
24	observed	observe	VBN	_	18	acl:relcl
25	.	.	.	_	1	punct

1	drug1	drug1	NN	_	2	compound
2	activity	activity	NN	_	6	nsubjpass
3	may	may	MD	_	6	aux
4	also	also	RB	_	6	advmod
5	be	be	VB	_	6	auxpass
6	enhanced	enhance	VBN	_	0	ROOT
7	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	potentiate	potentiate	VB	_	1	appos
6	the	the	DT	_	8	det
7	toxic	toxic	JJ	_	8	amod
8	effects	effect	NNS	_	5	dobj
9	of	of	IN	_	10	case
10	drug3	drug3	NN	_	8	nmod
11	.	.	.	_	1	punct

1	Thyroid	thyroid	NN	_	3	compound
2	hormonal	hormonal	JJ	_	3	amod
3	replacement	replacement	NN	_	4	nsubj
4	increases	increase	VBZ	_	0	ROOT
5	metabolic	metabolic	JJ	_	6	amod
6	rate	rate	NN	_	4	dobj
7	,	,	,	_	6	punct
8	which	which	WDT	_	9	nsubj
9	requires	require	VBZ	_	6	acl:relcl
10	an	a	DT	_	11	det
11	increase	increase	NN	_	9	dobj
12	in	in	IN	_	14	case
13	drug1	drug1	NN	_	14	compound
14	dosage	dosage	NN	_	11	nmod
15	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	When	when	WRB	_	4	advmod
4	administered	administer	VBN	_	15	advcl
5	to	to	TO	_	6	case
6	patients	patient	NNS	_	4	nmod
7	on	on	IN	_	9	case
8	a	a	DT	_	9	det
9	drug2	drug2	NN	_	6	nmod
10	,	,	,	_	15	punct
11	this	this	DT	_	13	det
12	parenteral	parenteral	JJ	_	13	amod
13	drug3	drug3	NN	_	15	nsubj
14	may	may	MD	_	15	aux
15	cause	cause	VB	_	1	dep
16	hypertension	hypertension	NN	_	15	dobj
17	and	and	CC	_	16	cc
18	tachycardia	tachycardia	NN	_	16	conj
19	.	.	.	_	1	punct

1	Use	use	NN	_	12	dep
2	with	with	IN	_	3	case
3	caution	caution	NN	_	1	nmod
4	and	and	CC	_	1	cc
5	be	be	VB	_	6	auxpass
6	prepared	prepare	VBN	_	1	conj
7	to	to	TO	_	8	mark
8	treat	treat	VB	_	6	xcomp
9	hypertension	hypertension	NN	_	8	dobj
10	,	,	,	_	12	punct
11	if	if	IN	_	12	mark
12	necessary	necessary	JJ	_	0	ROOT
13	.	.	.	_	12	punct

1	drug1	drug1	NN	_	2	compound
2	s	s	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	drug2	drug2	NN	_	5	nsubj
5	increases	increase	VBZ	_	2	dep
6	the	the	DT	_	8	det
7	adrenergic	adrenergic	JJ	_	8	amod
8	effect	effect	NN	_	5	dobj
9	of	of	IN	_	10	case
10	catecholamines	catecholamine	NNS	_	8	nmod
11	such	such	JJ	_	13	case
12	as	as	IN	_	11	mwe
13	drug3	drug3	NN	_	10	nmod
14	and	and	CC	_	13	cc
15	drug4	drug4	NN	_	13	conj
16	.	.	.	_	5	punct

1	Therefore	therefore	RB	_	11	advmod
2	,	,	,	_	11	punct
3	injection	injection	NN	_	11	nsubj
4	of	of	IN	_	6	case
5	these	these	DT	_	6	det
6	agents	agent	NNS	_	3	nmod
7	into	into	IN	_	8	case
8	patients	patient	NNS	_	3	nmod
9	receiving	receive	VBG	_	8	acl
10	drug1	drug1	NN	_	9	dobj
11	increases	increase	VBZ	_	0	ROOT
12	the	the	DT	_	13	det
13	risk	risk	NN	_	11	dobj
14	of	of	IN	_	15	mark
15	precipitating	precipitate	VBG	_	13	acl
16	coronary	coronary	JJ	_	17	amod
17	insufficiency	insufficiency	NN	_	15	dobj
18	especially	especially	RB	_	20	advmod
19	in	in	IN	_	20	case
20	patients	patient	NNS	_	15	nmod
21	with	with	IN	_	24	case
22	coronary	coronary	JJ	_	24	amod
23	artery	artery	NN	_	24	compound
24	disease	disease	NN	_	20	nmod
25	.	.	.	_	11	punct

1	Careful	careful	JJ	_	2	amod
2	observation	observation	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	required	require	VBN	_	0	ROOT
5	.	.	.	_	4	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	3	amod
2	Test	test	NN	_	3	compound
3	Interactions	interaction	NNS	_	0	ROOT
4	The	the	DT	_	6	det
5	following	following	JJ	_	6	amod
6	drugs	drug	NNS	_	10	nsubjpass
7	or	or	CC	_	6	cc
8	moieties	moiety	NNS	_	6	conj
9	are	be	VBP	_	10	auxpass
10	known	know	VBN	_	3	acl:relcl
11	to	to	TO	_	12	mark
12	interfere	interfere	VB	_	10	xcomp
13	with	with	IN	_	15	case
14	laboratory	laboratory	NN	_	15	compound
15	tests	test	NNS	_	12	nmod
16	performed	perform	VBN	_	15	acl
17	in	in	IN	_	18	case
18	patients	patient	NNS	_	16	nmod
19	on	on	IN	_	21	case
20	drug1	drug1	NN	_	21	compound
21	therapy	therapy	NN	_	18	nmod
22	:	:	:	_	3	punct
23	drug2	drug2	NN	_	3	dep
24	,	,	,	_	23	punct
25	drug3	drug3	NN	_	23	conj
26	,	,	,	_	23	punct
27	drug4	drug4	NN	_	23	conj
28	,	,	,	_	23	punct
29	oral	oral	JJ	_	30	amod
30	drug5	drug5	NN	_	23	appos
31	containing	contain	VBG	_	30	acl
32	drug6	drug6	NN	_	31	dobj
33	,	,	,	_	32	punct
34	drug7	drug7	NN	_	32	appos
35	-	-	:	_	32	punct
36	containing	contain	VBG	_	32	acl
37	preparations	preparation	NNS	_	36	dobj
38	and	and	CC	_	37	cc
39	the	the	DT	_	41	det
40	numerous	numerous	JJ	_	41	amod
41	preparations	preparation	NNS	_	37	conj
42	containing	contain	VBG	_	41	acl
43	drug8	drug8	NN	_	42	dobj
44	.	.	.	_	3	punct

1	-	-	:	_	8	punct
2	Changes	change	NNS	_	8	nsubjpass
3	in	in	IN	_	5	case
4	TBg	tbg	NN	_	5	compound
5	concentration	concentration	NN	_	2	nmod
6	should	should	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	taken	take	VBN	_	0	ROOT
9	into	into	IN	_	10	case
10	consideration	consideration	NN	_	8	nmod
11	in	in	IN	_	13	case
12	the	the	DT	_	13	det
13	interpretation	interpretation	NN	_	8	nmod
14	of	of	IN	_	15	case
15	T4	t4	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	T3	t3	NN	_	15	conj
18	values	value	NNS	_	15	dep
19	.	.	.	_	8	punct

1	In	in	IN	_	3	case
2	such	such	JJ	_	3	amod
3	cases	case	NNS	_	13	nmod
4	,	,	,	_	13	punct
5	the	the	DT	_	10	det
6	unbound	unbound	JJ	_	10	amod
7	-LRB-	-lrb-	-LRB-	_	8	punct
8	free	free	JJ	_	6	dep
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	hormone	hormone	NN	_	13	nsubjpass
11	should	should	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	measured	measure	VBN	_	0	ROOT
14	.	.	.	_	13	punct

1	Pregnancy	pregnancy	NN	_	2	compound
2	drug1	drug1	NN	_	0	ROOT
3	and	and	CC	_	2	cc
4	drug2	drug2	NN	_	2	conj
5	-	-	:	_	2	punct
6	containing	contain	VBG	_	2	acl
7	oral	oral	JJ	_	11	amod
8	drug3	drug3	NN	_	11	compound
9	increase	increase	NN	_	11	compound
10	TBg	tbg	NN	_	11	compound
11	concentrations	concentration	NNS	_	6	dobj
12	.	.	.	_	2	punct

1	TBg	tbg	NN	_	5	nsubjpass
2	may	may	MD	_	5	aux
3	also	also	RB	_	5	advmod
4	be	be	VB	_	5	auxpass
5	increased	increase	VBN	_	0	ROOT
6	during	during	IN	_	8	case
7	infectious	infectious	JJ	_	8	amod
8	hepatitis	hepatitis	NN	_	5	nmod
9	.	.	.	_	5	punct

1	Decreases	decrease	VBZ	_	6	nsubjpass
2	in	in	IN	_	4	case
3	TBg	tbg	NN	_	4	compound
4	concentrations	concentration	NNS	_	1	nmod
5	are	be	VBP	_	6	auxpass
6	observed	observe	VBN	_	0	ROOT
7	in	in	IN	_	8	case
8	nephrosis	nephrosis	NN	_	6	nmod
9	,	,	,	_	8	punct
10	acromegaly	acromegaly	NN	_	8	conj
11	and	and	CC	_	8	cc
12	after	after	IN	_	13	case
13	drug1	drug1	NN	_	8	conj
14	or	or	CC	_	13	cc
15	drug2	drug2	NN	_	16	compound
16	therapy	therapy	NN	_	13	conj
17	.	.	.	_	6	punct

1	Familial	familial	JJ	_	2	amod
2	hyper	hyper	NN	_	8	nsubjpass
3	-	-	:	_	2	punct
4	or	or	CC	_	2	cc
5	hypo-thyroxine-binding-globulinemias	hypo-thyroxine-binding-globulinemia	NNS	_	2	conj
6	have	have	VBP	_	8	aux
7	been	be	VBN	_	8	auxpass
8	described	describe	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	The	the	DT	_	2	det
2	incidence	incidence	NN	_	6	nsubj
3	of	of	IN	_	5	case
4	TBg	tbg	NN	_	5	compound
5	deficiency	deficiency	NN	_	2	nmod
6	approximates	approximate	VBZ	_	0	ROOT
7	1	1	CD	_	6	dobj
8	in	in	IN	_	9	case
9	9000	9000	CD	_	6	nmod
10	.	.	.	_	6	punct

1	The	the	DT	_	2	det
2	binding	binding	NN	_	12	nsubjpass
3	of	of	IN	_	4	case
4	thyroxine	thyroxine	NN	_	2	nmod
5	by	by	IN	_	7	case
6	thyroxine-binding	thyroxine-binding	JJ	_	7	amod
7	prealbumin	prealbumin	NN	_	2	nmod
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	TBPA	tbpa	NN	_	7	appos
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	is	be	VBZ	_	12	auxpass
12	inhibited	inhibit	VBN	_	0	ROOT
13	by	by	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod

1	.	.	.	_	0	ROOT

1	-	-	:	_	6	punct
2	Medicinal	medicinal	JJ	_	5	amod
3	or	or	CC	_	2	cc
4	dietary	dietary	JJ	_	2	conj
5	drug1	drug1	NN	_	6	nsubj
6	interferes	interfere	VBZ	_	0	ROOT
7	with	with	IN	_	11	case
8	all	all	DT	_	11	det
9	in	in	FW	_	11	amod
10	vivo	vivo	FW	_	9	dep
11	tests	test	NNS	_	6	nmod
12	of	of	IN	_	14	case
13	radio-iodine	radio-iodine	NN	_	14	compound
14	uptake	uptake	NN	_	11	nmod
15	producing	produce	VBG	_	14	acl
16	low	low	JJ	_	17	amod
17	uptakes	uptake	NNS	_	15	dobj
18	which	which	WDT	_	22	nsubj
19	may	may	MD	_	22	aux
20	not	not	RB	_	22	neg
21	be	be	VB	_	22	cop
22	reflective	reflective	JJ	_	17	acl:relcl
23	of	of	IN	_	26	case
24	a	a	DT	_	26	det
25	true	true	JJ	_	26	amod
26	decrease	decrease	NN	_	22	nmod
27	in	in	IN	_	29	case
28	hormone	hormone	NN	_	29	compound
29	synthesis	synthesis	NN	_	26	nmod

1	.	.	.	_	0	ROOT

1	-	-	:	_	17	punct
2	The	the	DT	_	3	det
3	persistence	persistence	NN	_	17	nsubj
4	of	of	IN	_	8	case
5	clinical	clinical	JJ	_	8	amod
6	and	and	CC	_	5	cc
7	laboratory	laboratory	JJ	_	5	conj
8	evidence	evidence	NN	_	3	nmod
9	of	of	IN	_	10	case
10	hypothyroidism	hypothyroidism	NN	_	8	nmod
11	in	in	IN	_	12	case
12	spite	spite	NN	_	3	nmod
13	of	of	IN	_	16	case
14	adequate	adequate	JJ	_	16	amod
15	dosage	dosage	NN	_	16	compound
16	replacement	replacement	NN	_	12	nmod
17	indicates	indicate	VBZ	_	0	ROOT
18	either	either	CC	_	21	cc:preconj
19	poor	poor	JJ	_	21	amod
20	patient	patient	NN	_	21	compound
21	compliance	compliance	NN	_	17	dobj
22	,	,	,	_	21	punct
23	poor	poor	JJ	_	24	amod
24	absorption	absorption	NN	_	21	conj
25	,	,	,	_	21	punct
26	excessive	excessive	JJ	_	28	amod
27	fecal	fecal	JJ	_	28	amod
28	loss	loss	NN	_	21	conj
29	,	,	,	_	21	punct
30	or	or	CC	_	21	cc
31	inactivity	inactivity	NN	_	21	conj
32	of	of	IN	_	34	case
33	the	the	DT	_	34	det
34	preparation	preparation	NN	_	31	nmod
35	.	.	.	_	17	punct

1	Intracellular	intracellular	JJ	_	2	amod
2	resistance	resistance	NN	_	7	nsubj
3	to	to	TO	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	is	be	VBZ	_	7	cop
6	quite	quite	RB	_	7	advmod
7	rare	rare	JJ	_	0	ROOT
8	.	.	.	_	7	punct

1	drug1	drug1	NN	_	2	compound
2	injection	injection	NN	_	8	nsubjpass
3	and	and	CC	_	2	cc
4	drug2	drug2	NN	_	2	conj
5	should	should	MD	_	8	aux
6	not	not	RB	_	8	neg
7	be	be	VB	_	8	auxpass
8	administered	administer	VBN	_	0	ROOT
9	simultaneously	simultaneously	RB	_	8	advmod
10	because	because	IN	_	16	mark
11	both	both	DT	_	12	det
12	drugs	drug	NNS	_	16	nsubj
13	are	be	VBP	_	16	cop
14	direct	direct	JJ	_	16	amod
15	cardiac	cardiac	JJ	_	16	amod
16	stimulants	stimulant	NNS	_	8	advcl
17	and	and	CC	_	16	cc
18	their	they	PRP$	_	20	nmod:poss
19	combined	combined	JJ	_	20	amod
20	effects	effect	NNS	_	22	nsubj
21	may	may	MD	_	22	aux
22	induce	induce	VB	_	16	conj
23	serious	serious	JJ	_	24	amod
24	arrhythmias	arrhythmia	NNS	_	22	dobj
25	.	.	.	_	8	punct

1	The	the	DT	_	2	det
2	drugs	drug	NNS	_	8	nsubjpass
3	may	may	MD	_	8	aux
4	,	,	,	_	8	punct
5	however	however	RB	_	8	advmod
6	,	,	,	_	8	punct
7	be	be	VB	_	8	auxpass
8	administered	administer	VBN	_	0	ROOT
9	alternately	alternately	RB	_	10	advmod
10	provided	provide	VBN	_	8	xcomp
11	a	a	DT	_	13	det
12	proper	proper	JJ	_	13	amod
13	interval	interval	NN	_	15	nsubj
14	has	have	VBZ	_	15	aux
15	elapsed	elapse	VBN	_	10	ccomp
16	between	between	IN	_	17	case
17	doses	dose	NNS	_	15	nmod
18	.	.	.	_	8	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	with	with	IN	_	6	case
6	caution	caution	NN	_	4	nmod
7	,	,	,	_	4	punct
8	if	if	IN	_	4	dep
9	at	at	IN	_	10	case
10	all	all	DT	_	8	root
11	,	,	,	_	10	punct
12	when	when	WRB	_	20	advmod
13	potent	potent	JJ	_	15	amod
14	inhalational	inhalational	JJ	_	15	amod
15	drug2	drug2	NN	_	20	nsubjpass
16	such	such	JJ	_	18	case
17	as	as	IN	_	16	mwe
18	drug3	drug3	NN	_	15	nmod
19	are	be	VBP	_	20	auxpass
20	employed	employ	VBN	_	11	root
21	because	because	IN	_	23	case
22	of	of	IN	_	21	mwe
23	potential	potential	JJ	_	20	nmod
24	to	to	TO	_	25	mark
25	sensitize	sensitize	VB	_	23	acl
26	the	the	DT	_	27	det
27	myocardium	myocardium	NN	_	25	dobj
28	to	to	TO	_	29	case
29	effects	effect	NNS	_	25	nmod
30	of	of	IN	_	31	case
31	drug4	drug4	NN	_	29	nmod
32	.	.	.	_	20	punct

1	Taking	take	VBG	_	7	csubj
2	drug1	drug1	NN	_	1	dobj
3	after	after	IN	_	4	mark
4	drinking	drink	VBG	_	1	advcl
5	drug2	drug2	NN	_	4	dobj
6	may	may	MD	_	7	aux
7	worsen	worsen	VB	_	0	ROOT
8	side	side	JJ	_	9	amod
9	effects	effect	NNS	_	7	dobj
10	and	and	CC	_	7	cc
11	may	may	MD	_	12	aux
12	cause	cause	VB	_	7	conj
13	severe	severe	JJ	_	14	amod
14	hypotension	hypotension	NN	_	12	dobj
15	and	and	CC	_	14	cc
16	cardiovascular	cardiovascular	JJ	_	17	amod
17	collapse	collapse	NN	_	14	conj
18	.	.	.	_	7	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	mixing	mix	VBG	_	16	nsubj
4	of	of	IN	_	6	case
5	an	a	DT	_	6	det
6	drug1	drug1	NN	_	3	nmod
7	with	with	IN	_	9	case
8	beta-lactamtype	beta-lactamtype	JJ	_	9	amod
9	drug2	drug2	NN	_	6	nmod
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	drug3	drug3	NN	_	9	dep
12	or	or	CC	_	11	cc
13	drug4	drug4	NN	_	11	conj
14	-RRB-	-rrb-	-RRB-	_	11	punct
15	may	may	MD	_	16	aux
16	result	result	VB	_	0	ROOT
17	in	in	IN	_	21	case
18	a	a	DT	_	21	det
19	significant	significant	JJ	_	21	amod
20	mutual	mutual	JJ	_	21	amod
21	inactivation	inactivation	NN	_	16	nmod
22	.	.	.	_	16	punct

1	Even	even	RB	_	2	advmod
2	when	when	WRB	_	0	ROOT
3	an	a	DT	_	4	det
4	drug1	drug1	NN	_	2	dep
5	and	and	CC	_	4	cc
6	a	a	DT	_	4	conj
7	drug2	drug2	NN	_	12	dep
8	-	-	:	_	12	punct
9	type	type	NN	_	10	compound
10	drug	drug	NN	_	12	nsubjpass
11	are	be	VBP	_	12	auxpass
12	administered	administer	VBN	_	6	root
13	separately	separately	RB	_	12	advmod
14	by	by	IN	_	16	case
15	different	different	JJ	_	16	amod
16	routes	route	NNS	_	12	nmod
17	,	,	,	_	12	punct
18	a	a	DT	_	19	det
19	reduction	reduction	NN	_	29	nsubjpass
20	in	in	IN	_	23	case
21	drug3	drug3	NN	_	23	compound
22	serum	serum	NN	_	23	compound
23	half-life	half-life	NN	_	19	nmod
24	or	or	CC	_	23	cc
25	serum	serum	NN	_	26	compound
26	levels	level	NNS	_	23	conj
27	has	have	VBZ	_	29	aux
28	been	be	VBN	_	29	auxpass
29	reported	report	VBN	_	12	parataxis
30	in	in	IN	_	31	case
31	patients	patient	NNS	_	29	nmod
32	with	with	IN	_	35	case
33	impaired	impaired	JJ	_	35	amod
34	renal	renal	JJ	_	35	amod
35	function	function	NN	_	31	nmod
36	and	and	CC	_	31	cc
37	in	in	IN	_	39	case
38	some	some	DT	_	39	det
39	patients	patient	NNS	_	31	conj
40	with	with	IN	_	43	case
41	normal	normal	JJ	_	43	amod
42	renal	renal	JJ	_	43	amod
43	function	function	NN	_	39	nmod
44	.	.	.	_	12	punct

1	Usually	usually	RB	_	10	advmod
2	,	,	,	_	10	punct
3	such	such	JJ	_	4	amod
4	inactivation	inactivation	NN	_	10	nsubj
5	of	of	IN	_	7	case
6	the	the	DT	_	7	det
7	drug1	drug1	NN	_	4	nmod
8	is	be	VBZ	_	10	cop
9	clinically	clinically	RB	_	10	advmod
10	significant	significant	JJ	_	0	ROOT
11	only	only	RB	_	13	advmod
12	in	in	IN	_	13	case
13	patients	patient	NNS	_	10	nmod
14	with	with	IN	_	18	case
15	severely	severely	RB	_	16	advmod
16	impaired	impaired	JJ	_	18	amod
17	renal	renal	JJ	_	18	amod
18	function	function	NN	_	13	nmod
19	.	.	.	_	10	punct
20	.	.	.	_	10	punct

1	See	see	VB	_	0	ROOT

1	No	no	DT	_	5	neg
2	formal	formal	JJ	_	5	amod
3	drug	drug	NN	_	5	compound
4	interaction	interaction	NN	_	5	compound
5	studies	study	NNS	_	8	nsubjpass
6	have	have	VBP	_	8	aux
7	been	be	VBN	_	8	auxpass
8	conducted	conduct	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	The	the	DT	_	2	det
2	effects	effect	NNS	_	7	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	may	may	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	potentiated	potentiate	VBN	_	0	ROOT
8	by	by	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	which	which	WDT	_	11	nsubj
11	inhibits	inhibit	VBZ	_	9	acl:relcl
12	the	the	DT	_	13	det
13	metabolism	metabolism	NN	_	11	dobj
14	of	of	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	.	.	.	_	7	punct

1	The	the	DT	_	3	det
2	pressor	pressor	JJ	_	3	amod
3	effects	effect	NNS	_	10	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	other	other	JJ	_	8	amod
8	drug2	drug2	NN	_	5	conj
9	can	can	MD	_	10	aux
10	combine	combine	VB	_	0	ROOT
11	to	to	TO	_	12	mark
12	cause	cause	VB	_	10	xcomp
13	dangerous	dangerous	JJ	_	14	amod
14	hypertension	hypertension	NN	_	12	dobj
15	.	.	.	_	10	punct

1	Administration	administration	NN	_	0	ROOT
2	of	of	IN	_	5	case
3	0.1-mg	0.1-mg	JJ	_	5	amod
4	/	/	:	_	5	punct
5	kg	kg	NN	_	1	nmod
6	-LRB-	-lrb-	-LRB-	_	11	punct
7	2	2	CD	_	11	nummod
8	x	x	CC	_	11	compound
9	ED95	ed95	NN	_	11	compound
10	-RRB-	-rrb-	-RRB-	_	11	punct
11	drug1	drug1	NN	_	5	dep
12	at	at	IN	_	14	case
13	10	10	CD	_	14	nummod
14	%	%	NN	_	11	nmod
15	or	or	CC	_	11	cc
16	95	95	CD	_	17	compound
17	%	%	NN	_	18	amod
18	recovery	recovery	NN	_	11	conj
19	following	follow	VBG	_	22	case
20	an	a	DT	_	22	det
21	intubating	intubate	VBG	_	22	amod
22	dose	dose	NN	_	18	nmod
23	of	of	IN	_	24	case
24	drug2	drug2	NN	_	22	nmod
25	-LRB-	-lrb-	-LRB-	_	27	punct
26	1	1	CD	_	27	nummod
27	mg/kg	mg/kg	NN	_	18	appos
28	-RRB-	-rrb-	-RRB-	_	27	punct
29	produced	produce	VBD	_	11	acl
30	95	95	CD	_	31	nummod
31	%	%	NN	_	29	dobj
32	neuromuscular	neuromuscular	JJ	_	33	amod
33	block	block	NN	_	31	dep
34	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	time	time	NN	_	14	nsubj
3	to	to	TO	_	4	case
4	onset	onset	NN	_	2	nmod
5	of	of	IN	_	7	case
6	maximum	maximum	NN	_	7	compound
7	block	block	NN	_	4	nmod
8	following	follow	VBG	_	9	case
9	drug1	drug1	NN	_	4	nmod
10	is	be	VBZ	_	14	cop
11	approximately	approximately	RB	_	12	advmod
12	2	2	CD	_	13	nummod
13	minutes	minute	NNS	_	14	nmod:npmod
14	faster	faster	RBR	_	0	ROOT
15	with	with	IN	_	17	case
16	prior	prior	JJ	_	17	amod
17	administration	administration	NN	_	14	nmod
18	of	of	IN	_	19	case
19	drug2	drug2	NN	_	17	nmod
20	.	.	.	_	14	punct

1	Prior	prior	RB	_	5	advmod
2	administration	administration	NN	_	5	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	had	have	VBD	_	0	ROOT
6	no	no	DT	_	7	neg
7	effect	effect	NN	_	5	dobj
8	on	on	IN	_	10	case
9	the	the	DT	_	10	det
10	duration	duration	NN	_	5	nmod
11	of	of	IN	_	13	case
12	neuromuscular	neuromuscular	JJ	_	13	amod
13	block	block	NN	_	10	nmod
14	following	follow	VBG	_	19	case
15	initial	initial	JJ	_	19	amod
16	or	or	CC	_	15	cc
17	maintenance	maintenance	NN	_	15	conj
18	bolus	bolus	NN	_	19	compound
19	doses	dose	NNS	_	5	nmod
20	of	of	IN	_	21	case
21	drug2	drug2	NN	_	19	nmod
22	.	.	.	_	5	punct

1	Infusion	infusion	NN	_	2	compound
2	requirements	requirement	NNS	_	15	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	in	in	IN	_	6	case
6	patients	patient	NNS	_	2	nmod
7	administered	administer	VBN	_	8	amod
8	drug2	drug2	NN	_	6	dep
9	prior	prior	RB	_	11	advmod
10	to	to	TO	_	11	case
11	infusions	infusion	NNS	_	8	nmod
12	of	of	IN	_	13	case
13	drug3	drug3	NN	_	11	nmod
14	were	be	VBD	_	15	cop
15	comparable	comparable	JJ	_	0	ROOT
16	to	to	TO	_	15	dep
17	or	or	CC	_	16	cc
18	slightly	slightly	RB	_	19	advmod
19	greater	greater	JJR	_	16	conj
20	than	than	IN	_	25	mark
21	when	when	WRB	_	25	advmod
22	drug4	drug4	NN	_	25	nsubjpass
23	was	be	VBD	_	25	auxpass
24	not	not	RB	_	25	neg
25	administered	administer	VBN	_	16	dep
26	.	.	.	_	15	punct

1	The	the	DT	_	2	det
2	use	use	NN	_	19	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	before	before	IN	_	6	case
6	drug2	drug2	NN	_	2	nmod
7	to	to	TO	_	8	mark
8	attenuate	attenuate	VB	_	2	acl
9	some	some	DT	_	8	dobj
10	of	of	IN	_	13	case
11	the	the	DT	_	13	det
12	side	side	JJ	_	13	amod
13	effects	effect	NNS	_	9	nmod
14	of	of	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	has	have	VBZ	_	19	aux
17	not	not	RB	_	19	neg
18	been	be	VBN	_	19	auxpass
19	studied	study	VBN	_	0	ROOT
20	.	.	.	_	19	punct

1	Although	although	IN	_	3	mark
2	not	not	RB	_	3	neg
3	studied	study	VBN	_	13	advcl
4	systematically	systematically	RB	_	3	advmod
5	in	in	IN	_	7	case
6	clinical	clinical	JJ	_	7	amod
7	trials	trial	NNS	_	3	nmod
8	,	,	,	_	13	punct
9	no	no	DT	_	11	neg
10	drug	drug	NN	_	11	compound
11	interactions	interaction	NNS	_	13	nsubjpass
12	were	be	VBD	_	13	auxpass
13	observed	observe	VBN	_	0	ROOT
14	when	when	WRB	_	22	advmod
15	drug1	drug1	NN	_	22	nsubjpass
16	,	,	,	_	15	punct
17	drug2	drug2	NN	_	15	conj
18	,	,	,	_	15	punct
19	or	or	CC	_	15	cc
20	drug3	drug3	NN	_	15	conj
21	were	be	VBD	_	22	auxpass
22	administered	administer	VBN	_	13	advcl
23	following	follow	VBG	_	25	case
24	varying	vary	VBG	_	25	amod
25	degrees	degree	NNS	_	22	nmod
26	of	of	IN	_	27	case
27	recovery	recovery	NN	_	25	nmod
28	from	from	IN	_	30	case
29	single	single	JJ	_	30	amod
30	doses	dose	NNS	_	27	nmod
31	or	or	CC	_	30	cc
32	infusions	infusion	NNS	_	30	conj
33	of	of	IN	_	34	case
34	drug4	drug4	NN	_	32	nmod
35	.	.	.	_	13	punct

1	drug1	drug1	NN	_	0	ROOT
2	or	or	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	administered	administer	VBN	_	1	acl
5	with	with	IN	_	6	case
6	drug3	drug3	NN	_	4	nmod
7	/	/	:	_	1	punct
8	drug4	drug4	NN	_	19	nsubj
9	to	to	TO	_	10	mark
10	achieve	achieve	VB	_	8	acl
11	1.25	1.25	CD	_	12	nummod
12	MAC	MAC	NNP	_	10	dobj
13	-LSB-	-lsb-	-LRB-	_	16	punct
14	Minimum	Minimum	NNP	_	16	compound
15	Alveolar	alveolar	JJ	_	16	amod
16	Concentration	concentration	NN	_	12	appos
17	-RSB-	-rsb-	-RRB-	_	16	punct
18	may	may	MD	_	19	aux
19	prolong	prolong	VB	_	1	parataxis
20	the	the	DT	_	23	det
21	clinically	clinically	RB	_	22	advmod
22	effective	effective	JJ	_	23	amod
23	duration	duration	NN	_	19	dobj
24	of	of	IN	_	25	case
25	action	action	NN	_	23	nmod
26	of	of	IN	_	30	case
27	initial	initial	JJ	_	30	amod
28	and	and	CC	_	27	cc
29	maintenance	maintenance	NN	_	27	conj
30	doses	dose	NNS	_	25	nmod
31	of	of	IN	_	32	case
32	drug5	drug5	NN	_	30	nmod
33	and	and	CC	_	19	cc
34	decrease	decrease	VB	_	19	conj
35	the	the	DT	_	38	det
36	required	require	VBN	_	38	amod
37	infusion	infusion	NN	_	38	compound
38	rate	rate	NN	_	34	dobj
39	of	of	IN	_	40	case
40	drug6	drug6	NN	_	38	nmod
41	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	magnitude	magnitude	NN	_	7	nsubj
3	of	of	IN	_	5	case
4	these	these	DT	_	5	det
5	effects	effect	NNS	_	2	nmod
6	may	may	MD	_	7	aux
7	depend	depend	VB	_	0	ROOT
8	on	on	IN	_	10	case
9	the	the	DT	_	10	det
10	duration	duration	NN	_	7	nmod
11	of	of	IN	_	12	case
12	administration	administration	NN	_	10	nmod
13	of	of	IN	_	16	case
14	the	the	DT	_	16	det
15	volatile	volatile	JJ	_	16	amod
16	agents	agent	NNS	_	12	nmod
17	.	.	.	_	7	punct

1	Fifteen	fifteen	CD	_	3	compound
2	to	to	TO	_	3	dep
3	30	30	CD	_	4	nummod
4	minutes	minute	NNS	_	13	nsubj
5	of	of	IN	_	6	case
6	exposure	exposure	NN	_	4	nmod
7	to	to	TO	_	10	case
8	1.25	1.25	CD	_	10	nummod
9	MAC	MAC	NNP	_	10	compound
10	drug1	drug1	NN	_	6	nmod
11	or	or	CC	_	10	cc
12	drug2	drug2	NN	_	10	conj
13	had	have	VBD	_	0	ROOT
14	minimal	minimal	JJ	_	15	amod
15	effects	effect	NNS	_	13	dobj
16	on	on	IN	_	18	case
17	the	the	DT	_	18	det
18	duration	duration	NN	_	13	nmod
19	of	of	IN	_	20	case
20	action	action	NN	_	18	nmod
21	of	of	IN	_	23	case
22	initial	initial	JJ	_	23	amod
23	doses	dose	NNS	_	20	nmod
24	of	of	IN	_	25	case
25	drug3	drug3	NN	_	23	nmod
26	and	and	CC	_	13	cc
27	therefore	therefore	RB	_	37	advmod
28	,	,	,	_	37	punct
29	no	no	DT	_	30	neg
30	adjustment	adjustment	NN	_	37	nsubj
31	to	to	TO	_	34	case
32	the	the	DT	_	34	det
33	initial	initial	JJ	_	34	amod
34	dose	dose	NN	_	30	nmod
35	should	should	MD	_	37	aux
36	be	be	VB	_	37	cop
37	necessary	necessary	JJ	_	13	conj
38	when	when	WRB	_	41	advmod
39	drug4	drug4	NN	_	41	nsubjpass
40	is	be	VBZ	_	41	auxpass
41	administered	administer	VBN	_	37	advcl
42	shortly	shortly	RB	_	44	advmod
43	after	after	IN	_	44	case
44	initiation	initiation	NN	_	41	nmod
45	of	of	IN	_	47	case
46	volatile	volatile	JJ	_	47	amod
47	agents	agent	NNS	_	44	nmod
48	.	.	.	_	13	punct

1	In	in	IN	_	4	case
2	long	long	JJ	_	4	amod
3	surgical	surgical	JJ	_	4	amod
4	procedures	procedure	NNS	_	28	nmod
5	during	during	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	or	or	CC	_	6	cc
8	drug2	drug2	NN	_	9	compound
9	anesthesia	anesthesia	NN	_	6	conj
10	,	,	,	_	28	punct
11	less	less	JJR	_	12	advmod
12	frequent	frequent	JJ	_	14	amod
13	maintenance	maintenance	NN	_	14	compound
14	dosing	dosing	NN	_	28	nsubj
15	,	,	,	_	14	punct
16	lower	lower	JJR	_	18	amod
17	maintenance	maintenance	NN	_	18	compound
18	doses	dose	NNS	_	14	conj
19	,	,	,	_	14	punct
20	or	or	CC	_	14	cc
21	reduced	reduce	VBN	_	23	amod
22	infusion	infusion	NN	_	23	compound
23	rates	rate	NNS	_	14	conj
24	of	of	IN	_	25	case
25	drug3	drug3	NN	_	23	nmod
26	may	may	MD	_	28	aux
27	be	be	VB	_	28	cop
28	necessary	necessary	JJ	_	0	ROOT
29	.	.	.	_	28	punct

1	The	the	DT	_	5	det
2	average	average	JJ	_	5	amod
3	infusion	infusion	NN	_	5	compound
4	rate	rate	NN	_	5	compound
5	requirement	requirement	NN	_	8	nsubjpass
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	decreased	decrease	VBN	_	0	ROOT
9	by	by	IN	_	14	case
10	as	as	RB	_	13	advmod
11	much	much	JJ	_	13	advmod
12	as	as	IN	_	13	advmod
13	30	30	CD	_	14	nummod
14	%	%	NN	_	8	nmod
15	to	to	TO	_	17	case
16	40	40	CD	_	17	nummod
17	%	%	NN	_	8	nmod
18	.	.	.	_	8	punct

1	In	in	IN	_	3	case
2	clinical	clinical	JJ	_	3	amod
3	studies	study	NNS	_	5	nmod
4	drug1	drug1	NN	_	5	nsubj
5	had	have	VBD	_	0	ROOT
6	no	no	DT	_	7	neg
7	effect	effect	NN	_	5	dobj
8	on	on	IN	_	10	case
9	the	the	DT	_	10	det
10	duration	duration	NN	_	5	nmod
11	of	of	IN	_	12	case
12	action	action	NN	_	10	nmod
13	or	or	CC	_	12	cc
14	dosing	dosing	NN	_	15	compound
15	requirements	requirement	NNS	_	12	conj
16	for	for	IN	_	17	case
17	drug2	drug2	NN	_	12	nmod
18	.	.	.	_	5	punct

1	Other	other	JJ	_	2	amod
2	drugs	drug	NNS	_	15	nsubj
3	which	which	WDT	_	5	nsubj
4	may	may	MD	_	5	aux
5	enhance	enhance	VB	_	2	acl:relcl
6	the	the	DT	_	9	det
7	neuromuscular	neuromuscular	JJ	_	9	amod
8	blocking	block	VBG	_	9	amod
9	action	action	NN	_	5	dobj
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	such	such	JJ	_	14	case
13	as	as	IN	_	12	mwe
14	drug2	drug2	NN	_	11	nmod
15	include	include	VBP	_	0	ROOT
16	certain	certain	JJ	_	17	amod
17	drug3	drug3	NN	_	15	dobj
18	-LRB-	-lrb-	-LRB-	_	20	punct
19	e.	e.	FW	_	20	compound
20	g.	g.	FW	_	17	dep
21	,	,	,	_	20	punct
22	drug4	drug4	NN	_	20	conj
23	,	,	,	_	20	punct
24	drug5	drug5	NN	_	20	conj
25	,	,	,	_	20	punct
26	drug6	drug6	NN	_	20	conj
27	,	,	,	_	20	punct
28	drug7	drug7	NN	_	20	conj
29	,	,	,	_	20	punct
30	drug8	drug8	NN	_	20	conj
31	,	,	,	_	20	punct
32	drug9	drug9	NN	_	20	conj
33	,	,	,	_	20	punct
34	drug10	drug10	NN	_	20	conj
35	,	,	,	_	20	punct
36	and	and	CC	_	20	cc
37	drug11	drug11	NN	_	20	conj
38	-RRB-	-rrb-	-RRB-	_	20	punct
39	,	,	,	_	17	punct
40	drug12	drug12	NN	_	41	compound
41	salts	salt	NNS	_	17	conj
42	,	,	,	_	17	punct
43	drug13	drug13	NN	_	17	conj
44	,	,	,	_	17	punct
45	local	local	JJ	_	46	amod
46	drug14	drug14	NN	_	17	conj
47	,	,	,	_	17	punct
48	drug15	drug15	NN	_	17	conj
49	,	,	,	_	17	punct
50	and	and	CC	_	17	cc
51	drug16	drug16	NN	_	17	conj
52	.	.	.	_	15	punct

1	Resistance	resistance	NN	_	11	nsubjpass
2	to	to	TO	_	6	case
3	the	the	DT	_	6	det
4	neuromuscular	neuromuscular	JJ	_	6	amod
5	blocking	block	VBG	_	6	amod
6	action	action	NN	_	1	nmod
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	has	have	VBZ	_	11	aux
10	been	be	VBN	_	11	auxpass
11	demonstrated	demonstrate	VBN	_	0	ROOT
12	in	in	IN	_	13	case
13	patients	patient	NNS	_	11	nmod
14	chronically	chronically	RB	_	15	advmod
15	administered	administer	VBN	_	13	acl
16	drug2	drug2	NN	_	15	dobj
17	or	or	CC	_	16	cc
18	drug3	drug3	NN	_	16	conj
19	.	.	.	_	11	punct

1	While	while	IN	_	16	mark
2	the	the	DT	_	3	det
3	effects	effect	NNS	_	16	nsubj
4	of	of	IN	_	6	case
5	chronic	chronic	JJ	_	6	amod
6	drug1	drug1	NN	_	3	nmod
7	or	or	CC	_	6	cc
8	drug2	drug2	NN	_	9	compound
9	therapy	therapy	NN	_	6	conj
10	on	on	IN	_	12	case
11	the	the	DT	_	12	det
12	action	action	NN	_	3	nmod
13	of	of	IN	_	14	case
14	drug3	drug3	NN	_	12	nmod
15	are	be	VBP	_	16	cop
16	unknown	unknown	JJ	_	20	advcl
17	,	,	,	_	20	punct
18	slightly	slightly	RB	_	19	advmod
19	shorter	shorter	JJR	_	20	amod
20	durations	duration	NNS	_	33	nmod
21	of	of	IN	_	23	case
22	neuromuscular	neuromuscular	JJ	_	23	amod
23	block	block	NN	_	20	nmod
24	may	may	MD	_	26	aux
25	be	be	VB	_	26	auxpass
26	anticipated	anticipate	VBN	_	33	csubj
27	and	and	CC	_	26	cc
28	infusion	infusion	NN	_	30	compound
29	rate	rate	NN	_	30	compound
30	requirements	requirement	NNS	_	26	conj
31	may	may	MD	_	33	aux
32	be	be	VB	_	33	cop
33	higher	higher	JJR	_	0	ROOT
34	.	.	.	_	33	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	4	amod
2	Test	test	NN	_	4	compound
3	Interactions	interaction	NNS	_	4	compound
4	None	none	NN	_	0	ROOT
5	known	know	VBN	_	4	acl
6	.	.	.	_	4	punct

1	In	in	IN	_	3	case
2	clinical	clinical	JJ	_	3	amod
3	studies	study	NNS	_	8	nmod
4	,	,	,	_	8	punct
5	drug1	drug1	NN	_	8	nsubjpass
6	has	have	VBZ	_	8	aux
7	been	be	VBN	_	8	auxpass
8	co-administered	co-administer	VBN	_	0	ROOT
9	with	with	IN	_	12	case
10	other	other	JJ	_	12	amod
11	anti-asthma	anti-asthma	JJ	_	12	amod
12	medications	medication	NNS	_	8	nmod
13	,	,	,	_	12	punct
14	including	include	VBG	_	18	case
15	inhaled	inhale	VBN	_	18	amod
16	and	and	CC	_	15	cc
17	oral	oral	JJ	_	15	conj
18	drug2	drug2	NN	_	12	nmod
19	,	,	,	_	8	punct
20	and	and	CC	_	8	cc
21	inhaled	inhale	VBD	_	8	conj
22	drug3	drug3	NN	_	21	dobj
23	,	,	,	_	21	punct
24	with	with	IN	_	26	case
25	no	no	DT	_	26	neg
26	evidence	evidence	NN	_	21	nmod
27	of	of	IN	_	29	case
28	increased	increase	VBN	_	29	amod
29	frequency	frequency	NN	_	26	nmod
30	of	of	IN	_	32	case
31	adverse	adverse	JJ	_	32	amod
32	events	event	NNS	_	29	nmod
33	or	or	CC	_	32	cc
34	laboratory	laboratory	NN	_	35	compound
35	abnormalities	abnormality	NNS	_	32	conj
36	.	.	.	_	8	punct

1	No	no	DT	_	5	neg
2	formal	formal	JJ	_	5	amod
3	drug-drug	drug-drug	JJ	_	5	amod
4	interaction	interaction	NN	_	5	compound
5	studies	study	NNS	_	11	nsubjpass
6	,	,	,	_	11	punct
7	however	however	RB	_	11	advmod
8	,	,	,	_	11	punct
9	have	have	VBP	_	11	aux
10	been	be	VBN	_	11	auxpass
11	conducted	conduct	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	drug1	drug1	NN	_	3	nsubj
2	can	can	MD	_	3	aux
3	interact	interact	VB	_	0	ROOT
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	or	or	CC	_	5	cc
7	other	other	JJ	_	8	amod
8	drug3	drug3	NN	_	5	conj
9	-LRB-	-lrb-	-LRB-	_	11	punct
10	may	may	MD	_	11	aux
11	potentiate	potentiate	VB	_	3	dep
12	the	the	DT	_	15	det
13	CNS	cns	NN	_	15	compound
14	depressant	depressant	NN	_	15	compound
15	effects	effect	NNS	_	11	dobj
16	of	of	IN	_	19	case
17	either	either	CC	_	19	cc:preconj
18	these	these	DT	_	19	det
19	medications	medication	NNS	_	15	nmod
20	or	or	CC	_	19	cc
21	drug4	drug4	NN	_	19	conj
22	-RRB-	-rrb-	-RRB-	_	19	punct
23	,	,	,	_	19	punct
24	drug5	drug5	NN	_	19	conj
25	or	or	CC	_	19	cc
26	other	other	JJ	_	27	amod
27	medications	medication	NNS	_	19	conj
28	with	with	IN	_	30	case
29	anticholinergic	anticholinergic	JJ	_	30	amod
30	activity	activity	NN	_	27	nmod
31	-LRB-	-lrb-	-LRB-	_	33	punct
32	anticholinergic	anticholinergic	JJ	_	33	amod
33	effects	effect	NNS	_	36	nsubjpass
34	may	may	MD	_	36	aux
35	be	be	VB	_	36	auxpass
36	potentiated	potentiate	VBN	_	11	ccomp
37	when	when	WRB	_	41	advmod
38	these	these	DT	_	39	det
39	medications	medication	NNS	_	41	nsubjpass
40	are	be	VBP	_	41	auxpass
41	used	use	VBN	_	36	advcl
42	concurrently	concurrently	RB	_	41	advmod
43	with	with	IN	_	44	case
44	drug6	drug6	NN	_	41	nmod
45	-RRB-	-rrb-	-RRB-	_	11	punct
46	,	,	,	_	3	punct
47	and	and	CC	_	3	cc
48	drug7	drug7	NN	_	3	conj
49	-LRB-	-lrb-	-LRB-	_	51	punct
50	concurrent	concurrent	JJ	_	51	amod
51	use	use	NN	_	55	nsubj
52	with	with	IN	_	53	case
53	drug8	drug8	NN	_	51	nmod
54	may	may	MD	_	55	aux
55	prolong	prolong	VB	_	48	acl:relcl
56	and	and	CC	_	55	cc
57	intensify	intensify	VB	_	55	conj
58	the	the	DT	_	63	det
59	anticholinergic	anticholinergic	JJ	_	63	amod
60	and	and	CC	_	59	cc
61	CNS	cns	NN	_	59	conj
62	depressant	depressant	NN	_	63	compound
63	effects	effect	NNS	_	57	dobj
64	of	of	IN	_	65	case
65	drug9	drug9	NN	_	63	nmod
66	-RRB-	-rrb-	-RRB-	_	48	punct
67	.	.	.	_	3	punct

1	drug1	drug1	NN	_	0	ROOT
2	such	such	JJ	_	4	case
3	as	as	IN	_	2	mwe
4	drug2	drug2	NN	_	1	nmod
5	-LRB-	-lrb-	-LRB-	_	8	punct
6	e.g.	e.g.	FW	_	8	dep
7	,	,	,	_	8	punct
8	drug3	drug3	NN	_	4	appos
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	,	,	,	_	4	punct
11	drug4	drug4	NN	_	4	conj
12	-LRB-	-lrb-	-LRB-	_	15	punct
13	e.g.	e.g.	FW	_	15	dep
14	,	,	,	_	15	punct
15	drug5	drug5	NN	_	11	appos
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	,	,	,	_	4	punct
18	drug6	drug6	NN	_	4	conj
19	-LRB-	-lrb-	-LRB-	_	22	punct
20	e.g.	e.g.	FW	_	22	dep
21	,	,	,	_	22	punct
22	drug7	drug7	NN	_	18	appos
23	-RRB-	-rrb-	-RRB-	_	22	punct
24	,	,	,	_	4	punct
25	drug8	drug8	NN	_	4	conj
26	-LRB-	-lrb-	-LRB-	_	29	punct
27	e.g.	e.g.	FW	_	29	dep
28	,	,	,	_	29	punct
29	drug9	drug9	NN	_	25	appos
30	-RRB-	-rrb-	-RRB-	_	29	punct
31	,	,	,	_	4	punct
32	and	and	CC	_	4	cc
33	drug10	drug10	NN	_	4	conj
34	-LRB-	-lrb-	-LRB-	_	37	punct
35	e.g.	e.g.	FW	_	37	dep
36	,	,	,	_	37	punct
37	drug11	drug11	NN	_	33	appos
38	-RRB-	-rrb-	-RRB-	_	37	punct
39	:	:	:	_	1	punct
40	Using	use	VBG	_	46	csubj
41	these	these	DT	_	42	det
42	medicines	medicine	NNS	_	40	dobj
43	with	with	IN	_	44	case
44	drug12	drug12	NN	_	40	nmod
45	may	may	MD	_	46	aux
46	increase	increase	VB	_	1	dep
47	the	the	DT	_	48	det
48	chance	chance	NN	_	46	dobj
49	of	of	IN	_	51	case
50	side	side	JJ	_	51	amod
51	effects	effect	NNS	_	48	nmod
52	.	.	.	_	46	punct

1	Addition	addition	NN	_	17	nsubj
2	or	or	CC	_	1	cc
3	deletion	deletion	NN	_	1	conj
4	of	of	IN	_	6	case
5	any	any	DT	_	6	det
6	drug	drug	NN	_	1	nmod
7	from	from	IN	_	10	case
8	the	the	DT	_	10	det
9	therapeutic	therapeutic	JJ	_	10	amod
10	regimen	regimen	NN	_	6	nmod
11	of	of	IN	_	12	case
12	patients	patient	NNS	_	10	nmod
13	receiving	receive	VBG	_	12	acl
14	oral	oral	JJ	_	15	amod
15	drug1	drug1	NN	_	13	dobj
16	may	may	MD	_	17	aux
17	affect	affect	VB	_	0	ROOT
18	patient	patient	NN	_	19	compound
19	response	response	NN	_	17	dobj
20	to	to	TO	_	22	case
21	the	the	DT	_	22	det
22	drug2	drug2	NN	_	19	nmod
23	.	.	.	_	17	punct

1	Frequent	frequent	JJ	_	2	amod
2	determination	determination	NN	_	13	nsubj
3	of	of	IN	_	5	case
4	prothrombin	prothrombin	NN	_	5	compound
5	time	time	NN	_	2	nmod
6	and	and	CC	_	5	cc
7	close	close	JJ	_	8	amod
8	monitoring	monitoring	NN	_	5	conj
9	of	of	IN	_	11	case
10	the	the	DT	_	11	det
11	patient	patient	NN	_	8	nmod
12	is	be	VBZ	_	13	cop
13	essential	essential	JJ	_	0	ROOT
14	to	to	TO	_	15	mark
15	ascertain	ascertain	VB	_	13	xcomp
16	when	when	WRB	_	24	advmod
17	adjustment	adjustment	NN	_	24	nsubjpass
18	of	of	IN	_	19	case
19	dosage	dosage	NN	_	17	nmod
20	of	of	IN	_	21	case
21	drug1	drug1	NN	_	19	nmod
22	may	may	MD	_	24	aux
23	be	be	VB	_	24	auxpass
24	needed	need	VBN	_	15	advcl
25	.	.	.	_	13	punct

1	Because	because	IN	_	4	case
2	of	of	IN	_	1	mwe
3	the	the	DT	_	4	det
4	variability	variability	NN	_	45	nmod
5	of	of	IN	_	8	case
6	individual	individual	JJ	_	8	amod
7	patient	patient	NN	_	8	compound
8	response	response	NN	_	4	nmod
9	,	,	,	_	45	punct
10	multiple	multiple	JJ	_	12	amod
11	interacting	interact	VBG	_	12	amod
12	mechanisms	mechanism	NNS	_	45	dep
13	with	with	IN	_	15	case
14	some	some	DT	_	15	det
15	drugs	drug	NNS	_	12	nmod
16	,	,	,	_	12	punct
17	the	the	DT	_	18	det
18	dependency	dependency	NN	_	12	conj
19	of	of	IN	_	21	case
20	the	the	DT	_	21	det
21	extent	extent	NN	_	18	nmod
22	of	of	IN	_	24	case
23	the	the	DT	_	24	det
24	interaction	interaction	NN	_	21	nmod
25	on	on	IN	_	27	case
26	the	the	DT	_	27	det
27	dosage	dosage	NN	_	24	nmod
28	and	and	CC	_	27	cc
29	duration	duration	NN	_	27	conj
30	of	of	IN	_	31	case
31	therapy	therapy	NN	_	27	nmod
32	,	,	,	_	12	punct
33	and	and	CC	_	12	cc
34	the	the	DT	_	36	det
35	possible	possible	JJ	_	36	amod
36	administration	administration	NN	_	12	conj
37	of	of	IN	_	40	case
38	several	several	JJ	_	40	amod
39	interacting	interact	VBG	_	40	amod
40	drugs	drug	NNS	_	36	nmod
41	simultaneously	simultaneously	RB	_	36	advmod
42	,	,	,	_	45	punct
43	it	it	PRP	_	45	nsubj
44	is	be	VBZ	_	45	cop
45	difficult	difficult	JJ	_	0	ROOT
46	to	to	TO	_	47	mark
47	predict	predict	VB	_	45	xcomp
48	the	the	DT	_	49	det
49	direction	direction	NN	_	47	dobj
50	and	and	CC	_	49	cc
51	degree	degree	NN	_	49	conj
52	of	of	IN	_	55	case
53	the	the	DT	_	55	det
54	ultimate	ultimate	JJ	_	55	amod
55	effect	effect	NN	_	49	nmod
56	of	of	IN	_	58	case
57	concomitant	concomitant	JJ	_	58	amod
58	medications	medication	NNS	_	55	nmod
59	on	on	IN	_	61	case
60	drug1	drug1	NN	_	61	compound
61	response	response	NN	_	55	nmod
62	.	.	.	_	45	punct

1	For	for	IN	_	2	case
2	example	example	NN	_	23	nmod
3	,	,	,	_	23	punct
4	since	since	IN	_	7	mark
5	drug1	drug1	NN	_	7	nsubj
6	may	may	MD	_	7	aux
7	reduce	reduce	VB	_	23	advcl
8	the	the	DT	_	10	det
9	gastrointestinal	gastrointestinal	JJ	_	10	amod
10	absorption	absorption	NN	_	7	dobj
11	of	of	IN	_	15	case
12	both	both	CC	_	15	cc:preconj
13	the	the	DT	_	15	det
14	oral	oral	JJ	_	15	amod
15	drug2	drug2	NN	_	10	nmod
16	and	and	CC	_	15	cc
17	drug3	drug3	NN	_	15	conj
18	,	,	,	_	23	punct
19	the	the	DT	_	21	det
20	net	net	JJ	_	21	amod
21	effects	effect	NNS	_	23	nsubj
22	are	be	VBP	_	23	cop
23	unpredictable	unpredictable	JJ	_	0	ROOT
24	.	.	.	_	23	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	cause	cause	VB	_	0	ROOT
4	an	a	DT	_	7	det
5	increased	increase	VBN	_	7	amod
6	prothrombin	prothrombin	NN	_	7	compound
7	response	response	NN	_	3	dobj
8	by	by	IN	_	9	mark
9	displacing	displace	VBG	_	3	advcl
10	the	the	DT	_	11	det
11	drug2	drug2	NN	_	9	dobj
12	from	from	IN	_	15	case
13	protein	protein	NN	_	15	compound
14	binding	binding	NN	_	15	compound
15	sites	site	NNS	_	9	nmod
16	or	or	CC	_	9	cc
17	a	a	DT	_	20	det
18	diminished	diminish	VBN	_	20	amod
19	prothrombin	prothrombin	NN	_	20	compound
20	response	response	NN	_	9	conj
21	through	through	IN	_	23	case
22	increased	increase	VBN	_	23	amod
23	metabolism	metabolism	NN	_	20	nmod
24	of	of	IN	_	27	case
25	the	the	DT	_	27	det
26	unbound	unbound	JJ	_	27	amod
27	drug	drug	NN	_	23	nmod
28	by	by	IN	_	31	case
29	hepatic	hepatic	JJ	_	31	amod
30	enzyme	enzyme	NN	_	31	compound
31	induction	induction	NN	_	20	nmod
32	,	,	,	_	3	punct
33	thus	thus	RB	_	34	advmod
34	leading	lead	VBG	_	3	xcomp
35	to	to	TO	_	37	case
36	inter-patient	inter-patient	JJ	_	37	amod
37	variation	variation	NN	_	34	nmod
38	in	in	IN	_	41	case
39	ultimate	ultimate	JJ	_	41	amod
40	prothrombin	prothrombin	NN	_	41	compound
41	effect	effect	NN	_	37	nmod
42	.	.	.	_	3	punct

1	An	a	DT	_	3	det
2	interacting	interact	VBG	_	3	amod
3	drug	drug	NN	_	32	nsubj
4	which	which	WDT	_	5	nsubj
5	leads	lead	VBZ	_	3	acl:relcl
6	to	to	TO	_	8	case
7	a	a	DT	_	8	det
8	decrease	decrease	NN	_	5	nmod
9	in	in	IN	_	11	case
10	prothrombin	prothrombin	NN	_	11	compound
11	time	time	NN	_	8	nmod
12	necessitating	necessitate	VBG	_	8	acl
13	an	a	DT	_	15	det
14	increased	increase	VBN	_	15	amod
15	dose	dose	NN	_	12	dobj
16	of	of	IN	_	18	case
17	oral	oral	JJ	_	18	amod
18	drug1	drug1	NN	_	15	nmod
19	to	to	TO	_	20	mark
20	maintain	maintain	VB	_	12	advcl
21	an	a	DT	_	23	det
22	adequate	adequate	JJ	_	23	amod
23	degree	degree	NN	_	20	dobj
24	of	of	IN	_	25	case
25	anticoagulation	anticoagulation	NN	_	23	nmod
26	may	may	MD	_	32	aux
27	,	,	,	_	30	punct
28	if	if	IN	_	30	mark
29	abruptly	abruptly	RB	_	30	advmod
30	discontinued	discontinue	VBN	_	32	parataxis
31	,	,	,	_	30	punct
32	increase	increase	VB	_	0	ROOT
33	the	the	DT	_	34	det
34	risk	risk	NN	_	32	dobj
35	of	of	IN	_	37	case
36	subsequent	subsequent	JJ	_	37	amod
37	bleeding	bleeding	NN	_	34	nmod
38	.	.	.	_	32	punct

1	Drugs	drug	NNS	_	14	nsubj
2	that	that	WDT	_	5	nsubjpass
3	have	have	VBP	_	5	aux
4	been	be	VBN	_	5	auxpass
5	reported	report	VBN	_	1	acl:relcl
6	to	to	TO	_	7	mark
7	diminish	diminish	VB	_	5	xcomp
8	oral	oral	JJ	_	10	amod
9	drug1	drug1	NN	_	10	compound
10	response	response	NN	_	7	dobj
11	,	,	,	_	14	punct
12	ie	ie	FW	_	14	advmod
13	,	,	,	_	14	punct
14	decreased	decrease	VBD	_	0	ROOT
15	prothrom-bin	prothrom-bin	NN	_	17	compound
16	time	time	NN	_	17	compound
17	response	response	NN	_	14	dobj
18	,	,	,	_	14	punct
19	in	in	IN	_	20	case
20	man	man	NN	_	14	nmod
21	significantly	significantly	RB	_	22	advmod
22	include	include	VBP	_	20	dep
23	:	:	:	_	20	punct
24	drug2	drug2	NN	_	20	dep
25	;	;	:	_	14	punct

1	drug1	drug1	NN	_	0	ROOT
2	*	*	SYM	_	1	dep
3	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	*	*	SYM	_	1	dep
3	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	diet	diet	NN	_	0	ROOT
2	high	high	JJ	_	1	amod
3	in	in	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	*	*	SYM	_	1	dep
3	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	oral	oral	JJ	_	2	amod
2	drug1	drug1	NN	_	0	ROOT
3	;	;	:	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	*	*	SYM	_	1	dep
3	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	unreliable	unreliable	JJ	_	4	amod
2	prothrombin	prothrombin	NN	_	4	compound
3	time	time	NN	_	4	compound
4	determinations	determination	NNS	_	0	ROOT
5	;	;	:	_	4	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	Drugs	drug	NNS	_	14	nsubj
2	that	that	WDT	_	5	nsubjpass
3	have	have	VBP	_	5	aux
4	been	be	VBN	_	5	auxpass
5	reported	report	VBN	_	1	acl:relcl
6	to	to	TO	_	7	mark
7	diminish	diminish	VB	_	5	xcomp
8	oral	oral	JJ	_	10	amod
9	drug1	drug1	NN	_	10	compound
10	response	response	NN	_	7	dobj
11	,	,	,	_	14	punct
12	ie	ie	FW	_	14	advmod
13	,	,	,	_	14	punct
14	decreased	decrease	VBD	_	0	ROOT
15	prothrom-bin	prothrom-bin	NN	_	17	compound
16	time	time	NN	_	17	compound
17	response	response	NN	_	14	dobj
18	,	,	,	_	14	punct
19	in	in	IN	_	20	case
20	man	man	NN	_	14	nmod
21	significantly	significantly	RB	_	22	advmod
22	include	include	VBP	_	20	dep
23	:	:	:	_	20	punct
24	drug2	drug2	NN	_	27	dep
25	;	;	:	_	27	punct
26	drug3	drug3	NN	_	27	dep
27	*	*	SYM	_	20	dep
28	;	;	:	_	27	punct
29	drug4	drug4	NN	_	27	dep
30	;	;	:	_	27	punct
31	drug5	drug5	NN	_	27	dep
32	;	;	:	_	27	punct
33	drug6	drug6	NN	_	27	dep
34	;	;	:	_	27	punct
35	drug7	drug7	NN	_	38	dep
36	;	;	:	_	38	punct
37	drug8	drug8	CD	_	38	nummod
38	*	*	SYM	_	27	dep
39	;	;	:	_	38	punct
40	drug9	drug9	NN	_	38	dep
41	;	;	:	_	27	punct
42	drug10	drug10	NN	_	45	dep
43	;	;	:	_	45	punct
44	diet	diet	NN	_	45	dep
45	high	high	JJ	_	27	parataxis
46	in	in	IN	_	47	case
47	drug11	drug11	NN	_	45	nmod
48	;	;	:	_	27	punct
49	drug12	drug12	NN	_	50	compound
50	*	*	SYM	_	27	dep
51	;	;	:	_	27	punct
52	drug13	drug13	NN	_	27	dep
53	;	;	:	_	27	punct
54	drug14	drug14	NN	_	27	dep
55	;	;	:	_	27	punct
56	drug15	drug15	NN	_	27	dep
57	;	;	:	_	27	punct
58	drug16	drug16	NN	_	27	dep
59	;	;	:	_	27	punct
60	drug17	drug17	NN	_	27	dep
61	;	;	:	_	27	punct
62	oral	oral	JJ	_	63	amod
63	drug18	drug18	NN	_	27	dep
64	;	;	:	_	27	punct
65	drug19	drug19	NN	_	27	dep
66	;	;	:	_	27	punct
67	drug20	drug20	NN	_	70	dep
68	;	;	:	_	70	punct
69	drug21	drug21	NN	_	70	dep
70	*	*	SYM	_	27	dep
71	;	;	:	_	70	punct
72	drug22	drug22	NN	_	70	dep
73	;	;	:	_	72	punct
74	unreliable	unreliable	JJ	_	77	amod
75	prothrombin	prothrombin	NN	_	77	compound
76	time	time	NN	_	77	compound
77	determinations	determination	NNS	_	72	conj
78	;	;	:	_	72	punct
79	drug23	drug23	NN	_	72	conj
80	;	;	:	_	72	punct
81	drug24	drug24	NN	_	82	compound
82	under-dosage	under-dosage	NN	_	72	conj
83	.	.	.	_	14	punct

1	Drugs	drug	NNS	_	12	nsubj
2	that	that	WDT	_	5	nsubj
3	reportedly	reportedly	RB	_	5	advmod
4	may	may	MD	_	5	aux
5	increase	increase	VB	_	1	acl:relcl
6	oral	oral	JJ	_	8	amod
7	drug1	drug1	NN	_	8	compound
8	response	response	NN	_	5	dobj
9	,	,	,	_	12	punct
10	ie	ie	FW	_	12	advmod
11	,	,	,	_	12	punct
12	increased	increase	VBD	_	0	ROOT
13	prothrombin	prothrombin	NN	_	14	compound
14	response	response	NN	_	12	dobj
15	,	,	,	_	12	punct
16	in	in	IN	_	17	case
17	man	man	NN	_	18	nmod
18	include	include	VBP	_	12	parataxis
19	:	:	:	_	18	punct
20	drug2	drug2	NN	_	21	compound
21	*	*	SYM	_	18	dep
22	;	;	:	_	12	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	*	*	SYM	_	1	dep
3	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	dietary	dietary	JJ	_	2	amod
2	deficiencies	deficiency	NNS	_	0	ROOT
3	;	;	:	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	*	*	SYM	_	1	dep
3	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drugs	drug	NNS	_	0	ROOT
2	affecting	affect	VBG	_	1	acl
3	blood	blood	NN	_	4	compound
4	elements	element	NNS	_	2	dobj
5	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	hepatotoxic	hepatotoxic	JJ	_	2	amod
2	drugs	drug	NNS	_	0	ROOT
3	;	;	:	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	inhalation	inhalation	NN	_	2	compound
2	drug1	drug1	NN	_	0	ROOT
3	;	;	:	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	prolonged	prolonged	JJ	_	3	amod
2	hot	hot	JJ	_	3	amod
3	weather	weather	NN	_	0	ROOT
4	;	;	:	_	3	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	*	*	SYM	_	1	dep
3	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct
3	drug2	drug2	NN	_	1	dep
4	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	long	long	RB	_	4	advmod
4	acting	act	VBG	_	1	acl
5	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	3	compound
2	/	/	:	_	3	punct
3	drug2	drug2	NN	_	0	ROOT
4	;	;	:	_	3	punct

1	unreliable	unreliable	JJ	_	4	amod
2	prothrombin	prothrombin	NN	_	4	compound
3	time	time	NN	_	4	compound
4	determinations	determination	NNS	_	0	ROOT
5	;	;	:	_	4	punct

1	Drugs	drug	NNS	_	12	nsubj
2	that	that	WDT	_	5	nsubj
3	reportedly	reportedly	RB	_	5	advmod
4	may	may	MD	_	5	aux
5	increase	increase	VB	_	1	acl:relcl
6	oral	oral	JJ	_	8	amod
7	drug1	drug1	NN	_	8	compound
8	response	response	NN	_	5	dobj
9	,	,	,	_	12	punct
10	ie	ie	FW	_	12	advmod
11	,	,	,	_	12	punct
12	increased	increase	VBD	_	0	ROOT
13	prothrombin	prothrombin	NN	_	14	compound
14	response	response	NN	_	12	dobj
15	,	,	,	_	12	punct
16	in	in	IN	_	17	case
17	man	man	NN	_	18	nmod
18	include	include	VBP	_	12	parataxis
19	:	:	:	_	18	punct
20	drug2	drug2	NN	_	18	dep
21	*	*	SYM	_	20	dep
22	;	;	:	_	20	punct
23	drug3	drug3	NN	_	20	dep
24	;	;	:	_	20	punct
25	drug4	drug4	NN	_	20	dep
26	;	;	:	_	20	punct
27	drug5	drug5	NN	_	20	dep
28	;	;	:	_	20	punct
29	drug6	drug6	NN	_	20	dep
30	;	;	:	_	20	punct
31	drug7	drug7	NN	_	20	dep
32	;	;	:	_	20	punct
33	drug8	drug8	NN	_	20	dep
34	;	;	:	_	20	punct
35	drug9	drug9	NN	_	55	compound
36	*	*	SYM	_	55	dep
37	;	;	:	_	36	punct
38	drug10	drug10	NN	_	36	dep
39	;	;	:	_	36	punct
40	drug11	drug11	NN	_	36	dep
41	;	;	:	_	36	punct
42	drug12	drug12	NN	_	36	dep
43	;	;	:	_	36	punct
44	drug13	drug13	NN	_	36	dep
45	;	;	:	_	36	punct
46	drug14	drug14	NN	_	36	dep
47	;	;	:	_	36	punct
48	drug15	drug15	NN	_	36	dep
49	;	;	:	_	36	punct
50	drug16	drug16	NN	_	36	dep
51	;	;	:	_	36	punct
52	drug17	drug17	NN	_	36	dep
53	;	;	:	_	36	punct
54	dietary	dietary	JJ	_	55	amod
55	deficiencies	deficiency	NNS	_	20	dep
56	;	;	:	_	55	punct
57	drug18	drug18	NN	_	55	dep
58	;	;	:	_	55	punct
59	drug19	drug19	NN	_	55	dep
60	;	;	:	_	20	punct
61	drugs	drug	NNS	_	20	dep
62	affecting	affect	VBG	_	61	acl
63	blood	blood	NN	_	64	compound
64	elements	element	NNS	_	62	dobj
65	;	;	:	_	20	punct
66	drug20	drug20	NN	_	20	dep
67	;	;	:	_	20	punct
68	drug21	drug21	NN	_	20	dep
69	;	;	:	_	20	punct
70	drug22	drug22	NN	_	20	dep
71	;	;	:	_	20	punct
72	hepatotoxic	hepatotoxic	JJ	_	73	amod
73	drugs	drug	NNS	_	20	dep
74	;	;	:	_	20	punct
75	drug23	drug23	NN	_	20	dep
76	;	;	:	_	20	punct
77	drug24	drug24	NN	_	20	dep
78	;	;	:	_	20	punct
79	drug25	drug25	NN	_	20	dep
80	;	;	:	_	20	punct
81	inhalation	inhalation	NN	_	82	compound
82	drug26	drug26	NN	_	20	dep
83	;	;	:	_	20	punct
84	drug27	drug27	NN	_	20	dep
85	;	;	:	_	20	punct
86	drug28	drug28	NN	_	20	dep
87	;	;	:	_	20	punct
88	drug29	drug29	NN	_	20	dep
89	;	;	:	_	20	punct
90	drug30	drug30	NN	_	20	dep
91	;	;	:	_	20	punct
92	drug31	drug31	NN	_	20	dep
93	;	;	:	_	20	punct
94	drug32	drug32	NN	_	20	dep
95	;	;	:	_	20	punct
96	drug33	drug33	NN	_	20	dep
97	;	;	:	_	20	punct
98	drug34	drug34	NN	_	20	dep
99	;	;	:	_	20	punct
100	drug35	drug35	NN	_	20	dep
101	;	;	:	_	20	punct
102	drug36	drug36	NN	_	20	dep
103	;	;	:	_	20	punct
104	drug37	drug37	NN	_	20	dep
105	;	;	:	_	20	punct
106	drug38	drug38	NN	_	20	dep
107	;	;	:	_	20	punct
108	drug39	drug39	NN	_	20	dep
109	;	;	:	_	20	punct
110	drug40	drug40	NN	_	20	dep
111	;	;	:	_	20	punct
112	prolonged	prolonged	JJ	_	114	amod
113	hot	hot	JJ	_	114	amod
114	weather	weather	NN	_	20	dep
115	;	;	:	_	20	punct
116	drug41	drug41	NN	_	20	dep
117	;	;	:	_	20	punct
118	drug42	drug42	NN	_	20	dep
119	;	;	:	_	20	punct
120	drug43	drug43	NN	_	20	dep
121	;	;	:	_	20	punct
122	drug44	drug44	NN	_	20	dep
123	;	;	:	_	20	punct
124	drug45	drug45	NN	_	134	dep
125	*	*	SYM	_	134	dep
126	;	;	:	_	125	punct
127	drug46	drug46	NN	_	125	dep
128	;	;	:	_	125	punct
129	drug47	drug47	NN	_	125	dep
130	;	;	:	_	125	punct
131	drug48	drug48	NN	_	134	nsubj
132	,	,	,	_	134	punct
133	long	long	RB	_	134	advmod
134	acting	act	VBG	_	20	dep
135	;	;	:	_	134	punct
136	drug49	drug49	NN	_	134	conj
137	;	;	:	_	134	punct
138	drug50	drug50	NN	_	134	conj
139	;	;	:	_	134	punct
140	drug51	drug51	NN	_	134	conj
141	;	;	:	_	134	punct
142	drug52	drug52	NN	_	134	conj
143	;	;	:	_	134	punct
144	drug53	drug53	NN	_	146	compound
145	/	/	:	_	146	punct
146	drug54	drug54	NN	_	134	conj
147	;	;	:	_	134	punct
148	unreliable	unreliable	JJ	_	151	amod
149	prothrombin	prothrombin	NN	_	151	compound
150	time	time	NN	_	151	compound
151	determinations	determination	NNS	_	134	conj
152	;	;	:	_	134	punct
153	drug55	drug55	NN	_	154	compound
154	overdosage	overdosage	NN	_	134	conj
155	.	.	.	_	12	punct

1	Oral	oral	JJ	_	2	amod
2	drug1	drug1	NN	_	4	nsubj
3	may	may	MD	_	4	aux
4	potentiate	potentiate	VB	_	0	ROOT
5	the	the	DT	_	7	det
6	hypoglycemic	hypoglycemic	JJ	_	7	amod
7	action	action	NN	_	4	dobj
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	,	,	,	_	9	punct
11	eg	eg	FW	_	9	conj
12	,	,	,	_	9	punct
13	drug3	drug3	NN	_	9	conj
14	and	and	CC	_	9	cc
15	drug4	drug4	NN	_	9	conj
16	,	,	,	_	4	punct
17	by	by	IN	_	18	mark
18	inhibiting	inhibit	VBG	_	4	advcl
19	their	they	PRP$	_	20	nmod:poss
20	metabolism	metabolism	NN	_	18	dobj
21	in	in	IN	_	23	case
22	the	the	DT	_	23	det
23	liver	liver	NN	_	20	nmod
24	.	.	.	_	4	punct

1	Because	because	IN	_	5	mark
2	oral	oral	JJ	_	3	amod
3	drug1	drug1	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	interfere	interfere	VB	_	19	advcl
6	with	with	IN	_	9	case
7	the	the	DT	_	9	det
8	hepatic	hepatic	JJ	_	9	amod
9	metabolism	metabolism	NN	_	5	nmod
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	,	,	,	_	19	punct
13	toxic	toxic	JJ	_	14	amod
14	levels	level	NNS	_	19	nsubj
15	of	of	IN	_	17	case
16	the	the	DT	_	17	det
17	drug3	drug3	NN	_	14	nmod
18	may	may	MD	_	19	aux
19	occur	occur	VB	_	0	ROOT
20	when	when	WRB	_	27	advmod
21	an	a	DT	_	23	det
22	oral	oral	JJ	_	23	amod
23	drug4	drug4	NN	_	27	nsubjpass
24	and	and	CC	_	23	cc
25	drug5	drug5	NN	_	23	conj
26	are	be	VBP	_	27	auxpass
27	administered	administer	VBN	_	19	advcl
28	concurrently	concurrently	RB	_	27	advmod
29	.	.	.	_	19	punct

1	Drugs	drug	NNS	_	42	nsubj
2	that	that	WDT	_	3	nsubj
3	reduce	reduce	VBP	_	1	acl:relcl
4	the	the	DT	_	5	det
5	number	number	NN	_	3	dobj
6	of	of	IN	_	8	case
7	blood	blood	NN	_	8	compound
8	platelets	platelet	NNS	_	5	nmod
9	by	by	IN	_	10	mark
10	causing	cause	VBG	_	3	advcl
11	bone	bone	NN	_	13	compound
12	marrow	marrow	NN	_	13	compound
13	depression	depression	NN	_	10	dobj
14	-LRB-	-lrb-	-LRB-	_	17	punct
15	such	such	JJ	_	17	case
16	as	as	IN	_	15	mwe
17	drug1	drug1	NN	_	13	dep
18	-RRB-	-rrb-	-RRB-	_	17	punct
19	or	or	CC	_	13	cc
20	drugs	drug	NNS	_	13	conj
21	which	which	WDT	_	22	nsubj
22	inhibit	inhibit	VBP	_	20	acl:relcl
23	platelet	platelet	NN	_	24	compound
24	function	function	NN	_	22	dobj
25	-LRB-	-lrb-	-LRB-	_	28	punct
26	eg	eg	FW	_	28	dep
27	,	,	,	_	28	punct
28	drug2	drug2	NN	_	1	dep
29	and	and	CC	_	28	cc
30	other	other	JJ	_	31	amod
31	drug3	drug3	NN	_	28	conj
32	,	,	,	_	28	punct
33	drug4	drug4	NN	_	28	conj
34	,	,	,	_	28	punct
35	drug5	drug5	NN	_	28	conj
36	,	,	,	_	28	punct
37	drug6	drug6	NN	_	28	conj
38	,	,	,	_	28	punct
39	drug7	drug7	NN	_	28	appos
40	-RRB-	-rrb-	-RRB-	_	28	punct
41	may	may	MD	_	42	aux
42	increase	increase	VB	_	0	ROOT
43	the	the	DT	_	45	det
44	bleeding	bleeding	NN	_	45	compound
45	tendency	tendency	NN	_	42	dobj
46	produced	produce	VBN	_	45	acl
47	by	by	IN	_	48	case
48	drug8	drug8	NN	_	46	nmod
49	without	without	IN	_	50	mark
50	altering	alter	VBG	_	42	advcl
51	prothrombin	prothrombin	NN	_	53	compound
52	time	time	NN	_	53	compound
53	determinations	determination	NNS	_	50	dobj
54	.	.	.	_	42	punct

1	The	the	DT	_	3	det
2	beneficial	beneficial	JJ	_	3	amod
3	effects	effect	NNS	_	17	nsubjpass
4	on	on	IN	_	7	case
5	arterial	arterial	JJ	_	7	amod
6	thrombus	thrombus	NN	_	7	compound
7	formation	formation	NN	_	3	nmod
8	from	from	IN	_	10	case
9	combined	combined	JJ	_	10	amod
10	therapy	therapy	NN	_	7	nmod
11	with	with	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	and	and	CC	_	12	cc
14	drug2	drug2	NN	_	12	conj
15	must	must	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	weighed	weigh	VBN	_	0	ROOT
18	against	against	IN	_	21	case
19	an	a	DT	_	21	det
20	increased	increase	VBN	_	21	amod
21	risk	risk	NN	_	17	nmod
22	of	of	IN	_	23	mark
23	inducing	induce	VBG	_	21	acl
24	hemorrhage	hemorrhage	NN	_	23	dobj
25	.	.	.	_	17	punct

1	*	*	SYM	_	7	det
2	Increased	increase	VBN	_	7	amod
3	and	and	CC	_	2	cc
4	decreased	decrease	VBN	_	2	conj
5	prothrombin	prothrombin	NN	_	7	compound
6	time	time	NN	_	7	compound
7	responses	response	NNS	_	10	nsubjpass
8	have	have	VBP	_	10	aux
9	been	be	VBN	_	10	auxpass
10	reported	report	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	3	amod
2	Test	test	NN	_	3	compound
3	Interferences	interference	NNS	_	0	ROOT
4	:	:	:	_	3	punct
5	drug1	drug1	NN	_	16	nsubj
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	,	,	,	_	5	punct
9	including	include	VBG	_	10	case
10	drug3	drug3	NN	_	5	conj
11	,	,	,	_	5	punct
12	or	or	CC	_	5	cc
13	their	they	PRP$	_	14	nmod:poss
14	metabolites	metabolite	NNS	_	5	conj
15	may	may	MD	_	16	aux
16	color	color	VB	_	3	dep
17	alkaline	alkaline	NN	_	19	compound
18	urine	urine	NN	_	19	compound
19	red-orange	red-orange	NN	_	16	dobj
20	,	,	,	_	19	punct
21	which	which	WDT	_	23	nsubj
22	may	may	MD	_	23	aux
23	interfere	interfere	VB	_	19	acl:relcl
24	with	with	IN	_	29	case
25	spectrophotometrically	spectrophotometrically	RB	_	26	advmod
26	determined	determine	VBN	_	29	amod
27	urinary	urinary	JJ	_	29	amod
28	laboratory	laboratory	NN	_	29	compound
29	tests	test	NNS	_	23	nmod
30	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	color	color	NN	_	3	nsubj
3	reverses	reverse	VBZ	_	0	ROOT
4	when	when	WRB	_	9	advmod
5	the	the	DT	_	7	det
6	test	test	NN	_	7	compound
7	sample	sample	NN	_	9	nsubjpass
8	is	be	VBZ	_	9	auxpass
9	acidified	acidify	VBN	_	3	advcl
10	in	in	FW	_	11	compound
11	vitro	vitro	FW	_	9	advmod
12	to	to	TO	_	14	case
13	a	a	DT	_	14	det
14	pH	ph	NN	_	9	nmod
15	below	below	IN	_	16	case
16	4	4	CD	_	14	nmod
17	.	.	.	_	3	punct

1	drug1	drug1	NN	_	2	compound
2	preparations	preparation	NNS	_	4	nsubj
3	are	be	VBP	_	4	cop
4	incompatible	incompatible	JJ	_	0	ROOT
5	with	with	IN	_	7	case
6	drug2	drug2	NN	_	7	compound
7	preparations	preparation	NNS	_	4	nmod
8	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT
2	-	-	:	_	1	punct
3	Concomitant	concomitant	JJ	_	4	amod
4	use	use	NN	_	10	nsubj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	drug3	drug3	NN	_	6	conj
9	may	may	MD	_	10	aux
10	enhance	enhance	VB	_	1	dep
11	nutrient	nutrient	JJ	_	12	amod
12	absorption	absorption	NN	_	10	dobj
13	in	in	IN	_	14	case
14	those	those	DT	_	10	nmod
15	with	with	IN	_	19	case
16	severe	severe	JJ	_	19	amod
17	short	short	JJ	_	19	amod
18	bowel	bowel	NN	_	19	compound
19	syndrome	syndrome	NN	_	14	nmod
20	.	.	.	_	1	punct

1	drug1	drug1	NN	_	2	nsubj
2	has	have	VBZ	_	0	ROOT
3	orphan	orphan	JJ	_	5	amod
4	drug	drug	NN	_	5	compound
5	status	status	NN	_	2	dobj
6	for	for	IN	_	8	case
7	this	this	DT	_	8	det
8	indication	indication	NN	_	5	nmod
9	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	-	-	:	_	1	punct
3	Concomitant	concomitant	JJ	_	4	amod
4	use	use	NN	_	10	nsubj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	drug3	drug3	NN	_	6	conj
9	may	may	MD	_	10	aux
10	ameliorate	ameliorate	VB	_	1	dep
11	increased	increase	VBN	_	13	amod
12	intestinal	intestinal	JJ	_	13	amod
13	permeability	permeability	NN	_	10	dobj
14	caused	cause	VBN	_	13	acl
15	by	by	IN	_	16	case
16	drug4	drug4	NN	_	14	nmod
17	.	.	.	_	1	punct

1	The	the	DT	_	3	det
2	reported	report	VBN	_	3	amod
3	dose	dose	NN	_	9	nsubj
4	used	use	VBN	_	3	acl
5	for	for	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	was	be	VBD	_	9	cop
8	21	21	CD	_	9	nummod
9	grams	gram	NNS	_	0	ROOT
10	daily	daily	JJ	_	11	advmod
11	taken	take	VBN	_	9	acl
12	in	in	IN	_	14	case
13	divided	divide	VBN	_	14	amod
14	doses	dose	NNS	_	11	nmod
15	three	three	CD	_	16	nummod
16	times	time	NNS	_	11	nmod:tmod
17	a	a	DT	_	18	det
18	day	day	NN	_	16	nmod:npmod
19	.	.	.	_	9	punct

1	Further	further	RB	_	5	advmod
2	,	,	,	_	5	punct
3	drug1	drug1	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	reported	report	VBN	_	0	ROOT
6	to	to	TO	_	7	mark
7	have	have	VB	_	5	xcomp
8	a	a	DT	_	10	det
9	synergistic	synergistic	JJ	_	10	amod
10	effect	effect	NN	_	7	dobj
11	with	with	IN	_	13	case
12	this	this	DT	_	13	det
13	combination	combination	NN	_	7	nmod
14	in	in	IN	_	15	mark
15	ameliorating	ameliorate	VBG	_	7	advcl
16	intestinal	intestinal	JJ	_	17	amod
17	permeability	permeability	NN	_	15	dobj
18	.	.	.	_	5	punct

1	drug1	drug1	NN	_	6	nsubj
2	-	-	:	_	1	punct
3	There	there	EX	_	1	dep
4	is	be	VBZ	_	6	cop
5	one	one	CD	_	6	nummod
6	report	report	NN	_	0	ROOT
7	that	that	IN	_	10	mark
8	drug2	drug2	NN	_	10	nsubj
9	may	may	MD	_	10	aux
10	decrease	decrease	VB	_	6	ccomp
11	the	the	DT	_	13	det
12	possible	possible	JJ	_	13	amod
13	effectiveness	effectiveness	NN	_	10	dobj
14	of	of	IN	_	16	case
15	supplemental	supplemental	JJ	_	16	amod
16	drug3	drug3	NN	_	13	nmod
17	for	for	IN	_	19	case
18	chemotherapy-induced	chemotherapy-induced	JJ	_	19	amod
19	mucositis	mucositis	NN	_	13	nmod
20	.	.	.	_	6	punct

1	In	in	IN	_	3	case
2	another	another	DT	_	3	det
3	report	report	NN	_	11	nmod
4	,	,	,	_	11	punct
5	nine	nine	CD	_	6	nummod
6	patients	patient	NNS	_	11	nsubjpass
7	with	with	IN	_	9	case
8	breast	breast	NN	_	9	compound
9	cancer	cancer	NN	_	6	nmod
10	were	be	VBD	_	11	auxpass
11	reported	report	VBN	_	0	ROOT
12	to	to	TO	_	14	mark
13	have	have	VB	_	14	aux
14	decreased	decrease	VBN	_	11	xcomp
15	symptoms	symptom	NNS	_	14	dobj
16	of	of	IN	_	17	case
17	drug1	drug1	NN	_	15	nmod
18	-	-	:	_	15	punct
19	related	related	JJ	_	20	amod
20	toxicity	toxicity	NN	_	15	dep
21	when	when	WRB	_	22	advmod
22	given	give	VBN	_	20	acl:relcl
23	supplemental	supplemental	JJ	_	24	amod
24	drug2	drug2	NN	_	22	dobj
25	at	at	IN	_	27	case
26	a	a	DT	_	27	det
27	dose	dose	NN	_	22	nmod
28	of	of	IN	_	30	case
29	0.5	0.5	CD	_	30	nummod
30	gram/kilogram/day	gram/kilogram/day	NN	_	27	nmod
31	.	.	.	_	11	punct

1	drug1	drug1	NN	_	25	nsubj
2	-	-	:	_	25	punct
3	In	in	IN	_	5	case
4	one	one	CD	_	5	nummod
5	report	report	NN	_	25	nmod
6	,	,	,	_	25	punct
7	drug2	drug2	NN	_	25	nsubj
8	at	at	IN	_	10	case
9	a	a	DT	_	10	det
10	dose	dose	NN	_	7	nmod
11	of	of	IN	_	13	case
12	10	10	CD	_	13	nummod
13	grams	gram	NNS	_	10	nmod
14	three	three	CD	_	15	nummod
15	times	time	NNS	_	7	nmod:tmod
16	daily	daily	RB	_	15	advmod
17	,	,	,	_	7	punct
18	given	give	VBN	_	20	case
19	24	24	CD	_	20	nummod
20	hours	hour	NNS	_	7	nmod
21	after	after	IN	_	22	mark
22	receiving	receive	VBG	_	20	acl
23	drug3	drug3	NN	_	22	dobj
24	,	,	,	_	7	punct
25	appeared	appear	VBD	_	0	ROOT
26	to	to	TO	_	27	mark
27	prevent	prevent	VB	_	25	xcomp
28	the	the	DT	_	29	det
29	development	development	NN	_	27	dobj
30	of	of	IN	_	31	case
31	myalgia	myalgia	NN	_	29	nmod
32	and	and	CC	_	31	cc
33	arthralgia	arthralgia	NN	_	31	conj
34	,	,	,	_	25	punct
35	adverse	adverse	JJ	_	36	amod
36	reactions	reaction	NNS	_	25	dobj
37	of	of	IN	_	38	case
38	drug4	drug4	NN	_	36	nmod
39	.	.	.	_	25	punct

1	In	in	IN	_	7	case
2	two	two	CD	_	7	nummod
3	controlled	controlled	JJ	_	7	amod
4	crossover	crossover	NN	_	7	compound
5	clinical	clinical	JJ	_	7	amod
6	pharmacology	pharmacology	NN	_	7	compound
7	studies	study	NNS	_	45	nmod
8	in	in	IN	_	10	case
9	healthy	healthy	JJ	_	10	amod
10	male	male	NN	_	7	nmod
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	n	n	NN	_	7	dep
13	=	=	JJ	_	12	amod
14	12	12	CD	_	13	dep
15	in	in	IN	_	17	case
16	each	each	DT	_	17	det
17	study	study	NN	_	12	nmod
18	-RRB-	-rrb-	-RRB-	_	12	punct
19	a	a	DT	_	21	det
20	nd	nd	NN	_	21	compound
21	female	female	NN	_	30	compound
22	-LRB-	-lrb-	-LRB-	_	23	punct
23	n	n	NN	_	21	appos
24	=	=	JJ	_	23	amod
25	12	12	CD	_	24	dep
26	in	in	IN	_	28	case
27	each	each	DT	_	28	det
28	study	study	NN	_	23	nmod
29	-RRB-	-rrb-	-RRB-	_	23	punct
30	volunteers	volunteer	NNS	_	45	nsubjpass
31	,	,	,	_	30	punct
32	drug1	drug1	NN	_	34	compound
33	7.5	7.5	CD	_	34	nummod
34	mg	mg	NN	_	30	appos
35	-LRB-	-lrb-	-LRB-	_	40	punct
36	1.5	1.5	CD	_	37	compound
37	times	time	NNS	_	40	nummod
38	the	the	DT	_	40	det
39	daily	daily	JJ	_	40	amod
40	dose	dose	NN	_	34	appos
41	-RRB-	-rrb-	-RRB-	_	40	punct
42	once	once	RB	_	43	advmod
43	daily	daily	RB	_	34	advmod
44	was	be	VBD	_	45	auxpass
45	coadministered	coadminister	VBN	_	0	ROOT
46	with	with	IN	_	49	case
47	drug2	drug2	NN	_	49	compound
48	500	500	CD	_	49	nummod
49	mg	mg	NN	_	45	nmod
50	every	every	DT	_	52	det
51	8	8	CD	_	52	nummod
52	hours	hour	NNS	_	45	dobj
53	or	or	CC	_	52	cc
54	drug3	drug3	NN	_	56	compound
55	200	200	CD	_	56	nummod
56	mg	mg	NN	_	52	conj
57	every	every	DT	_	59	det
58	12	12	CD	_	59	nummod
59	hours	hour	NNS	_	52	nmod:npmod
60	for	for	IN	_	62	case
61	10	10	CD	_	62	nummod
62	days	day	NNS	_	52	nmod
63	.	.	.	_	45	punct

1	In	in	IN	_	4	case
2	three	three	CD	_	4	nummod
3	separate	separate	JJ	_	4	amod
4	controlled	controlled	JJ	_	7	nmod
5	,	,	,	_	7	punct
6	parallel	parallel	JJ	_	7	amod
7	group	group	NN	_	0	ROOT
8	clinical	clinical	JJ	_	10	amod
9	pharmacology	pharmacology	NN	_	10	compound
10	studies	study	NNS	_	22	nsubjpass
11	,	,	,	_	10	punct
12	drug1	drug1	NN	_	10	appos
13	at	at	IN	_	16	case
14	the	the	DT	_	16	det
15	clinical	clinical	JJ	_	16	amod
16	dose	dose	NN	_	12	nmod
17	of	of	IN	_	19	case
18	5	5	CD	_	19	nummod
19	mg	mg	NN	_	16	nmod
20	has	have	VBZ	_	22	aux
21	been	be	VBN	_	22	auxpass
22	coadministered	coadminister	VBN	_	7	ccomp
23	with	with	IN	_	26	case
24	drug2	drug2	NN	_	26	compound
25	500	500	CD	_	26	nummod
26	mg	mg	NN	_	22	nmod
27	followed	follow	VBN	_	26	acl
28	by	by	IN	_	30	case
29	250	250	CD	_	30	nummod
30	mg	mg	NN	_	27	nmod
31	once	once	RB	_	32	advmod
32	daily	daily	RB	_	27	advmod
33	for	for	IN	_	35	case
34	4	4	CD	_	35	nummod
35	days	day	NNS	_	27	nmod
36	-LRB-	-lrb-	-LRB-	_	37	punct
37	n	n	NN	_	35	dep
38	=	=	JJ	_	37	amod
39	18	18	CD	_	38	dep
40	-RRB-	-rrb-	-RRB-	_	37	punct
41	or	or	CC	_	26	cc
42	with	with	IN	_	45	case
43	drug3	drug3	NN	_	45	compound
44	20	20	CD	_	45	nummod
45	mg	mg	NN	_	26	conj
46	once	once	RB	_	47	advmod
47	daily	daily	RB	_	45	advmod
48	for	for	IN	_	50	case
49	7	7	CD	_	50	nummod
50	days	day	NNS	_	45	nmod
51	after	after	IN	_	56	case
52	a	a	DT	_	56	det
53	23	23	CD	_	54	compound
54	day	day	NN	_	56	amod
55	pretreatment	pretreatment	NN	_	56	compound
56	period	period	NN	_	45	nmod
57	with	with	IN	_	58	case
58	drug4	drug4	NN	_	56	nmod
59	-LRB-	-lrb-	-LRB-	_	60	punct
60	n	n	NN	_	45	dep
61	=	=	JJ	_	60	amod
62	18	18	CD	_	61	dep
63	-RRB-	-rrb-	-RRB-	_	60	punct
64	or	or	CC	_	45	cc
65	with	with	IN	_	68	case
66	drug5	drug5	NN	_	68	compound
67	600	600	CD	_	68	nummod
68	mg	mg	NN	_	45	conj
69	every	every	DT	_	71	det
70	12	12	CD	_	71	nummod
71	hours	hour	NNS	_	45	dep
72	for	for	IN	_	74	case
73	14	14	CD	_	74	nummod
74	days	day	NNS	_	71	nmod
75	-LRB-	-lrb-	-LRB-	_	76	punct
76	n	n	NN	_	45	dep
77	=	=	JJ	_	76	amod
78	18	18	CD	_	77	dep
79	-RRB-	-rrb-	-RRB-	_	76	punct
80	under	under	IN	_	83	case
81	steady	steady	JJ	_	83	amod
82	state	state	NN	_	83	compound
83	conditions	condition	NNS	_	22	nmod
84	to	to	TO	_	87	case
85	normal	normal	JJ	_	87	amod
86	healthy	healthy	JJ	_	87	amod
87	male	male	NN	_	83	nmod
88	and	and	CC	_	87	cc
89	female	female	JJ	_	90	amod
90	volunteers	volunteer	NNS	_	87	conj
91	.	.	.	_	7	punct

1	Although	although	IN	_	18	mark
2	increased	increase	VBN	_	4	amod
3	plasma	plasma	NN	_	4	compound
4	concentrations	concentration	NNS	_	18	nsubjpass
5	-LRB-	-lrb-	-LRB-	_	7	punct
6	C	c	NN	_	7	compound
7	max	max	NN	_	4	dep
8	and	and	CC	_	7	cc
9	AUC	auc	NN	_	11	compound
10	0-24	0-24	CD	_	11	nummod
11	hrs	hr	NNS	_	7	conj
12	-RRB-	-rrb-	-RRB-	_	7	punct
13	of	of	IN	_	14	case
14	drug1	drug1	NN	_	4	nmod
15	and	and	CC	_	14	cc
16	drug2	drug2	NN	_	14	conj
17	were	be	VBD	_	18	auxpass
18	observed	observe	VBN	_	21	advcl
19	,	,	,	_	21	punct
20	there	there	EX	_	21	expl
21	were	be	VBD	_	0	ROOT
22	no	no	DT	_	25	neg
23	clinically	clinically	RB	_	24	advmod
24	relevant	relevant	JJ	_	25	amod
25	changes	change	NNS	_	21	nsubj
26	in	in	IN	_	29	case
27	the	the	DT	_	29	det
28	safety	safety	NN	_	29	compound
29	profile	profile	NN	_	25	nmod
30	of	of	IN	_	31	case
31	drug3	drug3	NN	_	29	nmod
32	,	,	,	_	21	punct
33	as	as	IN	_	34	mark
34	assessed	assess	VBN	_	21	advcl
35	by	by	IN	_	37	case
36	electrocardiographic	electrocardiographic	JJ	_	37	amod
37	parameters	parameter	NNS	_	34	nmod
38	-LRB-	-lrb-	-LRB-	_	37	punct
39	including	include	VBG	_	43	case
40	the	the	DT	_	43	det
41	corrected	correct	VBN	_	43	amod
42	QT	qt	NN	_	43	compound
43	interval	interval	NN	_	37	nmod
44	-RRB-	-rrb-	-RRB-	_	37	punct
45	,	,	,	_	37	punct
46	clinical	clinical	JJ	_	48	amod
47	laboratory	laboratory	NN	_	48	compound
48	tests	test	NNS	_	37	conj
49	,	,	,	_	37	punct
50	vital	vital	JJ	_	51	amod
51	signs	sign	NNS	_	37	conj
52	,	,	,	_	37	punct
53	and	and	CC	_	37	cc
54	adverse	adverse	JJ	_	55	amod
55	events	event	NNS	_	37	conj
56	.	.	.	_	21	punct

1	Table	Table	NNP	_	3	compound
2	1	1	CD	_	3	nummod
3	Changes	change	NNS	_	0	ROOT
4	in	in	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	8	compound
8	Pharmacokinetics	pharmacokinetic	NNS	_	5	conj
9	in	in	IN	_	11	case
10	Healthy	healthy	JJ	_	11	amod
11	Male	male	NN	_	3	nmod
12	and	and	CC	_	11	cc
13	Female	female	JJ	_	14	amod
14	Volunteers	volunteer	NNS	_	11	conj

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	drug1	drug1	NN	_	2	compound
2	drug2	drug2	NN	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	C	c	NN	_	8	compound
2	max	max	NN	_	8	compound
3	AUC	auc	NN	_	8	compound
4	0-24	0-24	CD	_	8	nummod
5	hrs	hr	NNS	_	8	compound
6	C	c	NN	_	8	compound
7	max	max	NN	_	8	compound
8	AUC	auc	NN	_	10	nsubj
9	0-24	0-24	CD	_	8	nummod
10	hrs	hr	NNS	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT

1	-LRB-	-lrb-	-LRB-	_	4	punct
2	500	500	CD	_	4	nummod
3	mg	mg	NN	_	4	compound
4	Q8h	q8h	NN	_	0	ROOT
5	-RRB-	-rrb-	-RRB-	_	4	punct

1	+24	+24	CD	_	2	nummod
2	%	%	NN	_	0	ROOT
3	+14	+14	CD	_	4	nummod
4	%	%	NN	_	2	dep
5	+43	+43	CD	_	6	nummod
6	%	%	NN	_	4	dep
7	+40	+40	CD	_	8	nummod
8	%	%	NN	_	2	dep

1	drug1	drug1	NN	_	0	ROOT

1	-LRB-	-lrb-	-LRB-	_	4	punct
2	200	200	CD	_	3	compound
3	mg	mg	NN	_	4	amod
4	Q12h	q12h	NN	_	0	ROOT
5	-RRB-	-rrb-	-RRB-	_	4	punct

1	+45	+45	CD	_	2	nummod
2	%	%	NN	_	0	ROOT
3	+39	+39	CD	_	4	nummod
4	%	%	NN	_	2	dep
5	+43	+43	CD	_	6	nummod
6	%	%	NN	_	4	dep
7	+72	+72	CD	_	8	nummod
8	%	%	NN	_	2	dep

1	drug1	drug1	NN	_	0	ROOT

1	-LRB-	-lrb-	-LRB-	_	9	punct
2	500	500	CD	_	3	nummod
3	mg	mg	NN	_	9	compound
4	day	day	NN	_	9	compound
5	1	1	CD	_	4	nummod
6	,	,	,	_	4	punct
7	250	250	CD	_	4	nummod
8	mg	mg	NN	_	9	compound
9	QD	qd	NN	_	0	ROOT
10	4	4	CD	_	11	nummod
11	days	day	NNS	_	9	nmod:tmod
12	-RRB-	-rrb-	-RRB-	_	9	punct

1	+15	+15	CD	_	2	nummod
2	%	%	NN	_	0	ROOT
3	+5	+5	CD	_	4	nummod
4	%	%	NN	_	2	dep
5	+15	+15	CD	_	6	nummod
6	%	%	NN	_	4	dep
7	+4	+4	CD	_	8	nummod
8	%	%	NN	_	2	dep

1	drug1	drug1	NN	_	0	ROOT

1	-LRB-	-lrb-	-LRB-	_	4	punct
2	20	20	CD	_	3	compound
3	mg	mg	NN	_	4	amod
4	QD	qd	NN	_	0	ROOT
5	-RRB-	-rrb-	-RRB-	_	4	punct

1	+15	+15	CD	_	2	nummod
2	%	%	NN	_	0	ROOT
3	+0	+0	CD	_	4	nummod
4	%	%	NN	_	2	dep
5	+17	+17	CD	_	6	nummod
6	%	%	NN	_	4	dep
7	+13	+13	CD	_	8	nummod
8	%	%	NN	_	2	dep

1	drug1	drug1	NN	_	0	ROOT

1	-LRB-	-lrb-	-LRB-	_	4	punct
2	600	600	CD	_	4	nummod
3	mg	mg	NN	_	4	compound
4	Q12h	q12h	NN	_	0	ROOT
5	-RRB-	-rrb-	-RRB-	_	4	punct

1	+12	+12	CD	_	2	nummod
2	%	%	NN	_	0	ROOT
3	+19	+19	CD	_	4	nummod
4	%	%	NN	_	2	dep
5	-11	-11	CD	_	6	nummod
6	%	%	NN	_	4	dep
7	-3	-3	CD	_	8	nummod
8	%	%	NN	_	2	dep

1	No	no	DT	_	9	neg
2	specific	specific	JJ	_	9	amod
3	pharmacokinetic	pharmacokinetic	JJ	_	9	amod
4	or	or	CC	_	3	cc
5	other	other	JJ	_	3	conj
6	formal	formal	JJ	_	9	amod
7	drug	drug	NN	_	9	compound
8	interaction	interaction	NN	_	9	compound
9	studies	study	NNS	_	11	nsubjpass
10	were	be	VBD	_	11	auxpass
11	conducted	conduct	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Supraventricular	supraventricular	JJ	_	4	amod
4	arrhythmias	arrhythmia	NNS	_	6	nsubj
5	may	may	MD	_	6	aux
6	mask	mask	NN	_	1	dep
7	the	the	DT	_	8	det
8	cardiotoxicity	cardiotoxicity	NN	_	6	dobj
9	associated	associate	VBN	_	8	acl
10	with	with	IN	_	13	case
11	excessive	excessive	JJ	_	13	amod
12	drug2	drug2	NN	_	13	compound
13	levels	level	NNS	_	9	nmod
14	.	.	.	_	1	punct

1	Therefore	therefore	RB	_	5	advmod
2	,	,	,	_	5	punct
3	it	it	PRP	_	5	nsubj
4	is	be	VBZ	_	5	cop
5	advisable	advisable	JJ	_	0	ROOT
6	to	to	TO	_	9	mark
7	be	be	VB	_	9	cop
8	particularly	particularly	RB	_	9	advmod
9	cautious	cautious	JJ	_	5	xcomp
10	in	in	IN	_	11	case
11	patients	patient	NNS	_	9	nmod
12	whose	whose	WP$	_	15	nmod:poss
13	plasma	plasma	NN	_	15	compound
14	drug1	drug1	NN	_	15	compound
15	levels	level	NNS	_	17	nsubj
16	are	be	VBP	_	17	cop
17	above	above	IN	_	11	acl:relcl
18	or	or	CC	_	17	cc
19	suspected	suspect	VBN	_	17	conj
20	to	to	TO	_	26	mark
21	be	be	VB	_	26	cop
22	above	above	IN	_	26	case
23	the	the	DT	_	26	det
24	usual	usual	JJ	_	26	amod
25	therapeutic	therapeutic	JJ	_	26	amod
26	range	range	NN	_	19	xcomp
27	.	.	.	_	5	punct

1	Coadministration	coadministration	NN	_	6	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	did	do	VBD	_	6	aux
5	not	not	RB	_	6	neg
6	have	have	VB	_	0	ROOT
7	effects	effect	NNS	_	6	dobj
8	on	on	IN	_	11	case
9	either	either	CC	_	11	cc:preconj
10	the	the	DT	_	11	det
11	safety	safety	NN	_	7	nmod
12	or	or	CC	_	11	cc
13	efficacy	efficacy	NN	_	11	conj
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	11	nmod
16	in	in	IN	_	19	case
17	the	the	DT	_	19	det
18	clinical	clinical	JJ	_	19	amod
19	trials	trial	NNS	_	6	nmod
20	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Coadministration	coadministration	NN	_	8	nsubj
4	of	of	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	did	do	VBD	_	8	aux
7	not	not	RB	_	8	neg
8	have	have	VB	_	1	dep
9	any	any	DT	_	10	det
10	effect	effect	NN	_	8	dobj
11	on	on	IN	_	14	case
12	either	either	CC	_	14	cc:preconj
13	the	the	DT	_	14	det
14	safety	safety	NN	_	8	nmod
15	or	or	CC	_	14	cc
16	efficacy	efficacy	NN	_	14	conj
17	of	of	IN	_	18	case
18	drug3	drug3	NN	_	14	nmod
19	in	in	IN	_	22	case
20	the	the	DT	_	22	det
21	clinical	clinical	JJ	_	22	amod
22	trials	trial	NNS	_	14	nmod
23	.	.	.	_	8	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Coadministration	coadministration	NN	_	8	nsubj
4	of	of	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	did	do	VBD	_	8	aux
7	not	not	RB	_	8	neg
8	have	have	VB	_	1	dep
9	any	any	DT	_	10	det
10	effect	effect	NN	_	8	dobj
11	on	on	IN	_	14	case
12	either	either	CC	_	14	cc:preconj
13	the	the	DT	_	14	det
14	safety	safety	NN	_	8	nmod
15	or	or	CC	_	14	cc
16	efficacy	efficacy	NN	_	14	conj
17	of	of	IN	_	18	case
18	drug3	drug3	NN	_	14	nmod
19	in	in	IN	_	22	case
20	the	the	DT	_	22	det
21	clinical	clinical	JJ	_	22	amod
22	trials	trial	NNS	_	14	nmod
23	.	.	.	_	8	punct

1	Use	use	NN	_	12	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	in	in	IN	_	6	case
5	a	a	DT	_	6	det
6	patient	patient	NN	_	1	nmod
7	who	who	WP	_	10	nsubj
8	has	have	VBZ	_	10	aux
9	previously	previously	RB	_	10	advmod
10	received	receive	VBN	_	6	acl:relcl
11	drug2	drug2	NN	_	10	dobj
12	increases	increase	VBZ	_	0	ROOT
13	the	the	DT	_	14	det
14	risk	risk	NN	_	12	dobj
15	of	of	IN	_	16	case
16	cardiotoxicity	cardiotoxicity	NN	_	14	nmod
17	.	.	.	_	12	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	should	should	MD	_	5	aux
3	not	not	RB	_	5	neg
4	be	be	VB	_	5	auxpass
5	used	use	VBN	_	0	ROOT
6	in	in	IN	_	7	case
7	patients	patient	NNS	_	5	nmod
8	who	who	WP	_	11	nsubj
9	have	have	VBP	_	11	aux
10	previously	previously	RB	_	11	advmod
11	received	receive	VBN	_	7	acl:relcl
12	the	the	DT	_	16	det
13	recommended	recommend	VBN	_	16	amod
14	maximum	maximum	NN	_	16	compound
15	cumulative	cumulative	JJ	_	16	amod
16	doses	dose	NNS	_	11	dobj
17	of	of	IN	_	18	case
18	drug2	drug2	NN	_	16	nmod
19	or	or	CC	_	18	cc
20	drug3	drug3	NN	_	18	conj
21	.	.	.	_	5	punct

1	drug1	drug1	NN	_	2	nsubj
2	used	use	VBD	_	0	ROOT
3	concurrently	concurrently	RB	_	2	advmod
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	2	nmod
6	may	may	MD	_	8	aux
7	also	also	RB	_	8	advmod
8	result	result	VB	_	2	dep
9	in	in	IN	_	11	case
10	increased	increase	VBN	_	11	amod
11	cardiotoxicity	cardiotoxicity	NN	_	8	nmod
12	.	.	.	_	2	punct

1	Dosage	dosage	NN	_	2	compound
2	reduction	reduction	NN	_	7	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	may	may	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	required	require	VBN	_	0	ROOT
8	when	when	WRB	_	9	advmod
9	used	use	VBN	_	7	advcl
10	concurrently	concurrently	RB	_	9	advmod
11	with	with	IN	_	14	case
12	other	other	JJ	_	14	amod
13	myelosuppressive	myelosuppressive	JJ	_	14	amod
14	agents	agent	NNS	_	9	nmod
15	.	.	.	_	7	punct

1	Hepatotoxic	hepatotoxic	JJ	_	2	amod
2	medications	medication	NNS	_	10	nsubj
3	,	,	,	_	2	punct
4	such	such	JJ	_	7	case
5	as	as	IN	_	4	mwe
6	high-dose	high-dose	JJ	_	7	amod
7	drug1	drug1	NN	_	2	nmod
8	,	,	,	_	2	punct
9	may	may	MD	_	10	aux
10	impair	impair	VB	_	0	ROOT
11	liver	liver	NN	_	12	compound
12	function	function	NN	_	10	dobj
13	and	and	CC	_	10	cc
14	increase	increase	VB	_	10	conj
15	the	the	DT	_	16	det
16	risk	risk	NN	_	14	dobj
17	of	of	IN	_	18	case
18	toxicity	toxicity	NN	_	16	nmod
19	.	.	.	_	10	punct

1	drug1	drug1	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	metabolized	metabolize	VBN	_	0	ROOT
4	by	by	IN	_	6	case
5	CYP	cyp	NN	_	6	compound
6	3A4	3a4	NN	_	3	nmod
7	in	in	FW	_	8	compound
8	vitro	vitro	FW	_	3	advmod
9	.	.	.	_	3	punct

1	Clinical	clinical	JJ	_	2	amod
2	studies	study	NNS	_	19	nsubjpass
3	of	of	IN	_	5	case
4	the	the	DT	_	5	det
5	effect	effect	NN	_	2	nmod
6	of	of	IN	_	10	case
7	strong	strong	JJ	_	10	amod
8	CYP	cyp	NN	_	10	compound
9	3A4	3a4	NN	_	10	compound
10	inhibitors	inhibitor	NNS	_	5	nmod
11	on	on	IN	_	13	case
12	the	the	DT	_	13	det
13	pharmacokinetics	pharmacokinetic	NNS	_	5	nmod
14	of	of	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	have	have	VBP	_	19	aux
17	not	not	RB	_	19	neg
18	been	be	VBN	_	19	auxpass
19	performed	perform	VBN	_	0	ROOT
20	.	.	.	_	19	punct

1	Carcinogenesis	carcinogenesis	NN	_	13	nsubjpass
2	,	,	,	_	1	punct
3	Mutagenesis	mutagenesis	NN	_	1	conj
4	and	and	CC	_	1	cc
5	Impairment	impairment	NN	_	1	conj
6	of	of	IN	_	11	case
7	Fertility	fertility	NN	_	11	compound
8	A	a	NN	_	11	compound
9	two-year	two-year	JJ	_	11	amod
10	carcinogenesis	carcinogenesis	NN	_	11	compound
11	study	study	NN	_	1	nmod
12	was	be	VBD	_	13	auxpass
13	conducted	conduct	VBN	_	0	ROOT
14	in	in	IN	_	18	case
15	female	female	JJ	_	18	amod
16	and	and	CC	_	15	cc
17	male	male	JJ	_	15	conj
18	rats	rat	NNS	_	13	nmod
19	,	,	,	_	18	punct
20	at	at	IN	_	22	case
21	intramuscular	intramuscular	JJ	_	22	amod
22	doses	dose	NNS	_	18	nmod
23	of	of	IN	_	26	case
24	15	15	CD	_	26	nummod
25	mg/kg/30	mg/kg/30	CD	_	26	nummod
26	days	day	NNS	_	22	nmod
27	,	,	,	_	18	punct
28	10	10	CD	_	30	nummod
29	mg/rat/30	mg/rat/30	CD	_	30	nummod
30	days	day	NNS	_	18	appos
31	and	and	CC	_	30	cc
32	10	10	CD	_	34	nummod
33	mg/rat/15	mg/rat/15	CD	_	34	nummod
34	days	day	NNS	_	30	conj
35	.	.	.	_	13	punct

1	These	these	DT	_	2	det
2	doses	dose	NNS	_	3	nsubj
3	correspond	correspond	VBP	_	0	ROOT
4	to	to	TO	_	6	case
5	approximately	approximately	RB	_	6	advmod
6	1	1	CD	_	3	nmod
7	-	-	:	_	3	punct
8	,	,	,	_	3	punct
9	3	3	LS	_	3	dep
10	-	-	:	_	9	punct
11	,	,	,	_	9	punct
12	and	and	CC	_	9	cc
13	5-fold	5-fold	RB	_	39	advmod
14	-LRB-	-lrb-	-LRB-	_	16	punct
15	in	in	IN	_	16	case
16	females	female	NNS	_	13	dep
17	-RRB-	-rrb-	-RRB-	_	16	punct
18	and	and	CC	_	13	cc
19	1.3	1.3	CD	_	13	conj
20	-	-	:	_	19	punct
21	,	,	,	_	19	punct
22	1.3	1.3	CD	_	19	conj
23	-	-	:	_	19	punct
24	,	,	,	_	13	punct
25	and	and	CC	_	13	cc
26	1.6-fold	1.6-fold	RB	_	33	advmod
27	-LRB-	-lrb-	-LRB-	_	29	punct
28	in	in	IN	_	29	case
29	males	male	NNS	_	33	dep
30	-RRB-	-rrb-	-RRB-	_	29	punct
31	the	the	DT	_	33	det
32	systemic	systemic	JJ	_	33	amod
33	exposure	exposure	NN	_	13	conj
34	-LSB-	-lsb-	-LRB-	_	36	punct
35	AUC0-30	auc0-30	CD	_	36	nummod
36	days	day	NNS	_	33	dep
37	-RSB-	-rsb-	-RRB-	_	36	punct
38	-RSB-	-rsb-	-RRB-	_	13	punct
39	achieved	achieve	VBN	_	9	conj
40	in	in	IN	_	41	case
41	women	woman	NNS	_	39	nmod
42	receiving	receive	VBG	_	41	acl
43	the	the	DT	_	45	det
44	recommended	recommend	VBN	_	45	amod
45	dose	dose	NN	_	42	dobj
46	of	of	IN	_	48	case
47	250	250	CD	_	48	nummod
48	mg/month	mg/month	NN	_	45	nmod
49	.	.	.	_	3	punct

1	An	a	DT	_	3	det
2	increased	increase	VBN	_	3	amod
3	incidence	incidence	NN	_	16	nsubj
4	of	of	IN	_	9	case
5	benign	benign	JJ	_	9	amod
6	ovarian	ovarian	JJ	_	9	amod
7	granulosa	granulosa	NN	_	9	compound
8	cell	cell	NN	_	9	compound
9	tumors	tumor	NNS	_	3	nmod
10	and	and	CC	_	9	cc
11	testicular	testicular	JJ	_	14	amod
12	Leydig	leydig	NN	_	14	compound
13	cell	cell	NN	_	14	compound
14	tumors	tumor	NNS	_	9	conj
15	was	be	VBD	_	16	cop
16	evident	evident	JJ	_	0	ROOT
17	,	,	,	_	16	punct
18	in	in	IN	_	19	case
19	females	female	NNS	_	16	nmod
20	dosed	dose	VBN	_	19	acl
21	at	at	IN	_	24	case
22	10	10	CD	_	24	nummod
23	mg/rat/15	mg/rat/15	CD	_	24	nummod
24	days	day	NNS	_	20	nmod
25	and	and	CC	_	19	cc
26	males	male	NNS	_	19	conj
27	dosed	dose	VBN	_	26	acl
28	at	at	IN	_	31	case
29	15	15	CD	_	30	compound
30	mg/rat/30	mg/rat/30	CD	_	31	nummod
31	days	day	NNS	_	27	nmod
32	,	,	,	_	16	punct
33	respectively	respectively	RB	_	16	advmod
34	.	.	.	_	16	punct

1	Induction	induction	NN	_	6	nsubj
2	of	of	IN	_	4	case
3	such	such	JJ	_	4	amod
4	tumors	tumor	NNS	_	1	nmod
5	is	be	VBZ	_	6	cop
6	consistent	consistent	JJ	_	0	ROOT
7	with	with	IN	_	12	case
8	the	the	DT	_	12	det
9	pharmacology-related	pharmacology-related	JJ	_	12	amod
10	endocrine	endocrine	JJ	_	12	amod
11	feedback	feedback	NN	_	12	compound
12	alterations	alteration	NNS	_	6	nmod
13	in	in	IN	_	15	case
14	gonadotropin	gonadotropin	NN	_	15	compound
15	levels	level	NNS	_	12	nmod
16	caused	cause	VBN	_	15	acl
17	by	by	IN	_	19	case
18	an	a	DT	_	19	det
19	drug1	drug1	NN	_	16	nmod
20	.	.	.	_	6	punct

1	drug1	drug1	NN	_	4	nsubj
2	was	be	VBD	_	4	cop
3	not	not	RB	_	4	neg
4	mutagenic	mutagenic	JJ	_	0	ROOT
5	or	or	CC	_	4	cc
6	clastogenic	clastogenic	JJ	_	4	conj
7	in	in	IN	_	11	case
8	multiple	multiple	JJ	_	11	amod
9	in	in	FW	_	11	amod
10	vitro	vitro	FW	_	9	dep
11	tests	test	NNS	_	4	nmod
12	with	with	IN	_	16	nmod
13	and	and	CC	_	12	cc
14	without	without	IN	_	12	conj
15	the	the	DT	_	16	det
16	addition	addition	NN	_	11	nmod
17	of	of	IN	_	23	case
18	a	a	DT	_	23	det
19	mammalian	mammalian	JJ	_	23	amod
20	liver	liver	NN	_	23	compound
21	metabolic	metabolic	JJ	_	23	amod
22	activation	activation	NN	_	23	compound
23	factor	factor	NN	_	16	nmod
24	-LRB-	-lrb-	-LRB-	_	27	punct
25	bacterial	bacterial	JJ	_	27	amod
26	mutation	mutation	NN	_	27	compound
27	assay	assay	NN	_	23	dep
28	in	in	IN	_	29	case
29	strains	strain	NNS	_	27	nmod
30	of	of	IN	_	32	case
31	Salmonella	salmonella	FW	_	32	compound
32	typhimurium	typhimurium	FW	_	29	nmod
33	and	and	CC	_	32	cc
34	Escherichia	escherichia	FW	_	35	compound
35	coli	coli	FW	_	32	conj
36	,	,	,	_	27	punct
37	in	in	FW	_	40	amod
38	vitro	vitro	FW	_	37	dep
39	cytogenetics	cytogenetic	NNS	_	40	compound
40	study	study	NN	_	27	conj
41	in	in	IN	_	43	case
42	human	human	JJ	_	43	amod
43	lymphocytes	lymphocyte	NNS	_	40	nmod
44	,	,	,	_	27	punct
45	mammalian	mammalian	JJ	_	48	amod
46	cell	cell	NN	_	48	compound
47	mutation	mutation	NN	_	48	compound
48	assay	assay	NN	_	27	conj
49	in	in	IN	_	52	case
50	mouse	mouse	NN	_	52	compound
51	lymphoma	lymphoma	NN	_	52	compound
52	cells	cell	NNS	_	48	nmod
53	and	and	CC	_	27	cc
54	in	in	FW	_	57	amod
55	vivo	vivo	FW	_	54	dep
56	micronucleus	micronucleus	FW	_	57	compound
57	test	test	NN	_	27	conj
58	in	in	IN	_	59	case
59	rat	rat	NN	_	57	nmod
60	.	.	.	_	4	punct

1	In	in	IN	_	3	case
2	female	female	JJ	_	3	amod
3	rats	rat	NNS	_	6	nmod
4	,	,	,	_	6	punct
5	drug1	drug1	NN	_	6	nsubj
6	administered	administer	VBN	_	0	ROOT
7	at	at	IN	_	8	case
8	doses	dose	NNS	_	40	nmod
9	0.01	0.01	CD	_	10	nummod
10	mg/kg/day	mg/kg/day	NN	_	40	nsubj
11	-LRB-	-lrb-	-LRB-	_	13	punct
12	approximately	approximately	RB	_	13	advmod
13	one-hundredth	one-hundredth	JJ	_	40	dep
14	of	of	IN	_	18	case
15	the	the	DT	_	18	det
16	human	human	JJ	_	18	amod
17	recommended	recommend	VBN	_	18	amod
18	dose	dose	NN	_	13	nmod
19	based	base	VBN	_	18	acl
20	on	on	IN	_	23	case
21	body	body	NN	_	23	compound
22	surface	surface	NN	_	23	compound
23	area	area	NN	_	19	nmod
24	-LSB-	-lsb-	-LRB-	_	25	punct
25	BSA	bsa	NN	_	23	appos
26	-RSB-	-rsb-	-RRB-	_	25	punct
27	,	,	,	_	13	punct
28	for	for	IN	_	30	case
29	2	2	CD	_	30	nummod
30	weeks	week	NNS	_	13	nmod
31	prior	prior	RB	_	30	advmod
32	to	to	TO	_	36	case
33	and	and	CC	_	32	cc
34	for	for	IN	_	32	conj
35	1	1	CD	_	36	nummod
36	week	week	NN	_	31	nmod
37	following	follow	VBG	_	38	case
38	mating	mating	NN	_	36	nmod
39	,	,	,	_	13	punct
40	caused	cause	VBD	_	6	ccomp
41	a	a	DT	_	42	det
42	reduction	reduction	NN	_	40	dobj
43	in	in	IN	_	44	case
44	fertility	fertility	NN	_	42	nmod
45	and	and	CC	_	44	cc
46	embryonic	embryonic	JJ	_	47	amod
47	survival	survival	NN	_	44	conj
48	.	.	.	_	6	punct

1	No	no	DT	_	3	neg
2	adverse	adverse	JJ	_	3	amod
3	effects	effect	NNS	_	11	nsubj
4	on	on	IN	_	6	case
5	female	female	JJ	_	6	amod
6	fertility	fertility	NN	_	3	nmod
7	and	and	CC	_	6	cc
8	embryonic	embryonic	JJ	_	9	amod
9	survival	survival	NN	_	6	conj
10	were	be	VBD	_	11	cop
11	evident	evident	JJ	_	0	ROOT
12	in	in	IN	_	14	case
13	female	female	JJ	_	14	amod
14	animals	animal	NNS	_	11	nmod
15	dosed	dose	VBN	_	14	acl
16	at	at	IN	_	18	case
17	0.001	0.001	CD	_	18	nummod
18	mg/kg/day	mg/kg/day	NN	_	15	nmod
19	-LRB-	-lrb-	-LRB-	_	21	punct
20	approximately	approximately	RB	_	21	advmod
21	one-thousandth	one-thousandth	JJ	_	18	dep
22	of	of	IN	_	25	case
23	the	the	DT	_	25	det
24	human	human	JJ	_	25	amod
25	dose	dose	NN	_	21	nmod
26	based	base	VBN	_	25	acl
27	on	on	IN	_	28	case
28	BSA	bsa	NN	_	26	nmod
29	-RRB-	-rrb-	-RRB-	_	21	punct
30	.	.	.	_	11	punct

1	Restoration	restoration	NN	_	11	nsubj
2	of	of	IN	_	4	case
3	female	female	JJ	_	4	amod
4	fertility	fertility	NN	_	1	nmod
5	to	to	TO	_	6	case
6	values	value	NNS	_	1	nmod
7	similar	similar	JJ	_	6	amod
8	to	to	TO	_	9	case
9	controls	control	NNS	_	7	nmod
10	was	be	VBD	_	11	cop
11	evident	evident	JJ	_	0	ROOT
12	following	follow	VBG	_	16	case
13	a	a	DT	_	16	det
14	29-day	29-day	JJ	_	16	amod
15	withdrawal	withdrawal	NN	_	16	compound
16	period	period	NN	_	11	nmod
17	after	after	IN	_	18	case
18	dosing	dosing	NN	_	16	nmod
19	at	at	IN	_	21	case
20	2	2	CD	_	21	nummod
21	mg/kg/day	mg/kg/day	NN	_	18	nmod
22	-LRB-	-lrb-	-LRB-	_	26	punct
23	twice	twice	RB	_	26	advmod
24	the	the	DT	_	26	det
25	human	human	JJ	_	26	amod
26	dose	dose	NN	_	21	dep
27	based	base	VBN	_	26	acl
28	on	on	IN	_	29	case
29	BSA	bsa	NN	_	27	nmod
30	-RRB-	-rrb-	-RRB-	_	26	punct
31	.	.	.	_	11	punct

1	The	the	DT	_	2	det
2	effects	effect	NNS	_	11	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	on	on	IN	_	7	case
6	the	the	DT	_	7	det
7	fertility	fertility	NN	_	2	nmod
8	of	of	IN	_	10	case
9	female	female	JJ	_	10	amod
10	rats	rat	NNS	_	7	nmod
11	appear	appear	VBP	_	0	ROOT
12	to	to	TO	_	14	mark
13	be	be	VB	_	14	cop
14	consistent	consistent	JJ	_	11	xcomp
15	with	with	IN	_	18	case
16	its	its	PRP$	_	18	nmod:poss
17	anti-estrogenic	anti-estrogenic	JJ	_	18	amod
18	activity	activity	NN	_	14	nmod
19	.	.	.	_	11	punct

1	The	the	DT	_	3	det
2	potential	potential	JJ	_	3	amod
3	effects	effect	NNS	_	14	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	on	on	IN	_	8	case
7	the	the	DT	_	8	det
8	fertility	fertility	NN	_	3	nmod
9	of	of	IN	_	11	case
10	male	male	JJ	_	11	amod
11	animals	animal	NNS	_	8	nmod
12	were	be	VBD	_	14	auxpass
13	not	not	RB	_	14	neg
14	studied	study	VBN	_	0	ROOT
15	but	but	CC	_	14	cc
16	in	in	IN	_	20	case
17	a	a	DT	_	20	det
18	6-month	6-month	JJ	_	20	amod
19	toxicology	toxicology	NN	_	20	compound
20	study	study	NN	_	14	conj
21	,	,	,	_	20	punct
22	male	male	JJ	_	23	amod
23	rats	rat	NNS	_	20	appos
24	treated	treat	VBN	_	23	acl
25	with	with	IN	_	27	case
26	intramuscular	intramuscular	JJ	_	27	amod
27	doses	dose	NNS	_	24	nmod
28	of	of	IN	_	31	case
29	15	15	CD	_	31	nummod
30	mg/kg/30	mg/kg/30	CD	_	31	nummod
31	days	day	NNS	_	27	nmod
32	,	,	,	_	31	punct
33	10	10	CD	_	34	compound
34	mg/rat/30	mg/rat/30	CD	_	35	nummod
35	days	day	NNS	_	31	conj
36	,	,	,	_	31	punct
37	or	or	CC	_	31	cc
38	10	10	CD	_	39	compound
39	mg/rat/15	mg/rat/15	CD	_	40	nummod
40	days	day	NNS	_	42	nmod:tmod
41	drug2	drug2	NN	_	42	nsubj
42	showed	show	VBD	_	31	conj
43	a	a	DT	_	44	det
44	loss	loss	NN	_	42	dobj
45	of	of	IN	_	46	case
46	spermatozoa	spermatozoa	NN	_	44	nmod
47	from	from	IN	_	50	case
48	the	the	DT	_	50	det
49	seminiferous	seminiferous	JJ	_	50	amod
50	tubules	tubule	NNS	_	44	nmod
51	,	,	,	_	50	punct
52	seminiferous	seminiferous	JJ	_	54	amod
53	tubular	tubular	JJ	_	54	amod
54	atrophy	atrophy	NN	_	50	conj
55	,	,	,	_	50	punct
56	and	and	CC	_	50	cc
57	degenerative	degenerative	JJ	_	58	amod
58	changes	change	NNS	_	50	conj
59	in	in	IN	_	61	case
60	the	the	DT	_	61	det
61	epididymides	epididymide	NNS	_	58	nmod
62	.	.	.	_	14	punct

1	Changes	change	NNS	_	9	nsubj
2	in	in	IN	_	4	case
3	the	the	DT	_	4	det
4	testes	testis	NNS	_	1	nmod
5	and	and	CC	_	4	cc
6	epididymides	epididymide	NNS	_	4	conj
7	had	have	VBD	_	9	aux
8	not	not	RB	_	9	neg
9	recovered	recover	VBN	_	0	ROOT
10	20	20	CD	_	11	nummod
11	weeks	week	NNS	_	9	nmod
12	after	after	IN	_	11	case
13	cessation	cessation	NN	_	11	dep
14	of	of	IN	_	15	case
15	dosing	dosing	NN	_	13	nmod
16	.	.	.	_	9	punct

1	These	these	DT	_	3	det
2	drug1	drug1	NN	_	3	compound
3	doses	dose	NNS	_	4	nsubj
4	correspond	correspond	VBP	_	0	ROOT
5	to	to	TO	_	7	case
6	approximately	approximately	RB	_	7	advmod
7	2	2	CD	_	4	nmod
8	-	-	:	_	4	punct
9	,	,	,	_	4	punct
10	3	3	LS	_	4	dep
11	-	-	:	_	10	punct
12	,	,	,	_	10	punct
13	and	and	CC	_	10	cc
14	3-fold	3-fold	RB	_	17	advmod
15	the	the	DT	_	17	det
16	systemic	systemic	JJ	_	17	amod
17	exposure	exposure	NN	_	10	conj
18	-LSB-	-lsb-	-LRB-	_	20	punct
19	AUC0-30	auc0-30	CD	_	20	nummod
20	days	day	NNS	_	17	appos
21	-RSB-	-rsb-	-RRB-	_	20	punct
22	achieved	achieve	VBN	_	17	acl
23	in	in	IN	_	24	case
24	women	woman	NNS	_	22	nmod
25	.	.	.	_	4	punct

1	Pregnancy	Pregnancy	NNP	_	4	compound
2	Pregnancy	Pregnancy	NNP	_	4	compound
3	Category	Category	NNP	_	4	compound
4	D	D	NNP	_	0	ROOT
5	:	:	:	_	4	punct
6	.	.	.	_	4	punct

1	In	in	IN	_	2	case
2	studies	study	NNS	_	0	ROOT
3	in	in	IN	_	5	case
4	female	female	JJ	_	5	amod
5	rats	rat	NNS	_	2	nmod
6	at	at	IN	_	7	case
7	doses	dose	NNS	_	5	nmod
8	0.01	0.01	CD	_	9	nummod
9	mg/kg/day	mg/kg/day	NN	_	7	dep
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	IM	im	NN	_	9	appos
12	;	;	:	_	11	punct

1	approximately	approximately	RB	_	2	advmod
2	one-hundredth	one-hundredth	NN	_	19	dep
3	of	of	IN	_	7	case
4	the	the	DT	_	7	det
5	human	human	JJ	_	7	amod
6	recommended	recommend	VBN	_	7	amod
7	dose	dose	NN	_	2	nmod
8	based	base	VBN	_	2	acl
9	on	on	IN	_	12	case
10	body	body	NN	_	12	compound
11	surface	surface	NN	_	12	compound
12	area	area	NN	_	8	nmod
13	-LSB-	-lsb-	-LRB-	_	14	punct
14	BSA	bsa	NN	_	12	appos
15	-RSB-	-rsb-	-RRB-	_	14	punct
16	-RRB-	-rrb-	-RRB-	_	2	punct
17	,	,	,	_	19	punct
18	drug1	drug1	NN	_	19	nsubj
19	caused	cause	VBD	_	0	ROOT
20	a	a	DT	_	22	det
21	reversible	reversible	JJ	_	22	amod
22	reduction	reduction	NN	_	19	dobj
23	in	in	IN	_	25	case
24	female	female	JJ	_	25	amod
25	fertility	fertility	NN	_	22	nmod
26	,	,	,	_	22	punct
27	as	as	RB	_	22	cc
28	well	well	RB	_	27	mwe
29	as	as	IN	_	27	mwe
30	effects	effect	NNS	_	22	conj
31	on	on	IN	_	33	case
32	embryo/fetal	embryo/fetal	JJ	_	33	amod
33	development	development	NN	_	30	nmod
34	consistent	consistent	JJ	_	30	amod
35	with	with	IN	_	38	case
36	its	its	PRP$	_	38	nmod:poss
37	anti-estrogenic	anti-estrogenic	JJ	_	38	amod
38	activity	activity	NN	_	34	nmod
39	.	.	.	_	19	punct

1	drug1	drug1	NN	_	2	nsubj
2	caused	cause	VBD	_	0	ROOT
3	an	a	DT	_	5	det
4	increased	increase	VBN	_	5	amod
5	incidence	incidence	NN	_	2	dobj
6	of	of	IN	_	8	case
7	fetal	fetal	JJ	_	8	amod
8	abnormalities	abnormality	NNS	_	5	nmod
9	in	in	IN	_	10	case
10	rats	rat	NNS	_	8	nmod
11	-LRB-	-lrb-	-LRB-	_	13	punct
12	tarsal	tarsal	JJ	_	13	amod
13	flexure	flexure	NN	_	10	dep
14	of	of	IN	_	17	case
15	the	the	DT	_	17	det
16	hind	hind	JJ	_	17	amod
17	paw	paw	NN	_	13	nmod
18	at	at	IN	_	21	case
19	2	2	CD	_	21	nummod
20	mg/kg/day	mg/kg/day	NN	_	21	compound
21	IM	im	NN	_	13	nmod
22	;	;	:	_	13	punct

1	twice	twice	RB	_	4	advmod
2	the	the	DT	_	4	det
3	human	human	JJ	_	4	amod
4	dose	dose	NN	_	0	ROOT
5	on	on	IN	_	6	case
6	BSA	bsa	NN	_	4	nmod
7	-RRB-	-rrb-	-RRB-	_	4	punct
8	and	and	CC	_	4	cc
9	non-ossification	non-ossification	NN	_	4	conj
10	of	of	IN	_	15	case
11	the	the	DT	_	15	det
12	odontoid	odontoid	NN	_	15	amod
13	and	and	CC	_	12	cc
14	ventral	ventral	JJ	_	12	conj
15	tubercle	tubercle	NN	_	9	nmod
16	of	of	IN	_	20	case
17	the	the	DT	_	20	det
18	first	first	JJ	_	20	amod
19	cervical	cervical	JJ	_	20	amod
20	vertebra	vertebra	NN	_	15	nmod
21	at	at	IN	_	22	case
22	doses	dose	NNS	_	9	nmod
23	0.1	0.1	CD	_	25	nummod
24	mg/kg/day	mg/kg/day	NN	_	25	compound
25	IM	im	NN	_	22	dep
26	-LRB-	-lrb-	-LRB-	_	28	punct
27	approximately	approximately	RB	_	28	advmod
28	one-tenth	one-tenth	NN	_	25	dep
29	of	of	IN	_	32	case
30	the	the	DT	_	32	det
31	human	human	JJ	_	32	amod
32	dose	dose	NN	_	28	nmod
33	on	on	IN	_	34	case
34	BSA	bsa	NN	_	28	nmod
35	-RRB-	-rrb-	-RRB-	_	28	punct
36	when	when	WRB	_	37	advmod
37	administered	administer	VBN	_	4	advcl
38	during	during	IN	_	40	case
39	the	the	DT	_	40	det
40	period	period	NN	_	37	nmod
41	of	of	IN	_	42	case
42	organogenesis	organogenesis	NN	_	40	nmod
43	.	.	.	_	4	punct

1	Rabbits	rabbit	NNS	_	2	nsubj
2	failed	fail	VBD	_	0	ROOT
3	to	to	TO	_	4	mark
4	maintain	maintain	VB	_	2	xcomp
5	pregnancy	pregnancy	NN	_	4	dobj
6	when	when	WRB	_	7	advmod
7	dosed	dose	VBN	_	2	advcl
8	with	with	IN	_	12	case
9	1	1	CD	_	12	nummod
10	mg/kg/day	mg/kg/day	NN	_	12	compound
11	drug1	drug1	NN	_	12	compound
12	IM	im	NN	_	7	nmod
13	-LRB-	-lrb-	-LRB-	_	17	punct
14	twice	twice	RB	_	17	advmod
15	the	the	DT	_	17	det
16	human	human	JJ	_	17	amod
17	dose	dose	NN	_	12	dep
18	on	on	IN	_	19	case
19	BSA	bsa	NN	_	17	nmod
20	-RRB-	-rrb-	-RRB-	_	17	punct
21	during	during	IN	_	23	case
22	the	the	DT	_	23	det
23	period	period	NN	_	7	nmod
24	of	of	IN	_	25	case
25	organogenesis	organogenesis	NN	_	23	nmod
26	.	.	.	_	2	punct

1	Further	further	RB	_	19	advmod
2	,	,	,	_	19	punct
3	in	in	IN	_	4	case
4	rabbits	rabbit	NNS	_	19	nmod
5	dosed	dose	VBN	_	4	acl
6	at	at	IN	_	8	case
7	0.25	0.25	CD	_	8	nummod
8	mg/kg/day	mg/kg/day	NN	_	5	nmod
9	-LRB-	-lrb-	-LRB-	_	14	punct
10	about	about	IN	_	11	advmod
11	one-half	one-half	NN	_	14	nummod
12	the	the	DT	_	14	det
13	human	human	JJ	_	14	amod
14	dose	dose	NN	_	8	dep
15	on	on	IN	_	16	case
16	BSA	bsa	NN	_	14	nmod
17	-RRB-	-rrb-	-RRB-	_	14	punct
18	,	,	,	_	19	punct
19	increases	increase	VBZ	_	27	nsubjpass
20	in	in	IN	_	22	case
21	placental	placental	JJ	_	22	amod
22	weight	weight	NN	_	19	nmod
23	and	and	CC	_	22	cc
24	post-implantation	post-implantation	JJ	_	25	amod
25	loss	loss	NN	_	22	conj
26	were	be	VBD	_	27	auxpass
27	observed	observe	VBN	_	0	ROOT
28	but	but	CC	_	27	cc
29	,	,	,	_	27	punct
30	there	there	EX	_	31	expl
31	were	be	VBD	_	27	conj
32	no	no	DT	_	34	neg
33	observed	observe	VBN	_	34	amod
34	effects	effect	NNS	_	31	nsubj
35	on	on	IN	_	37	case
36	fetal	fetal	JJ	_	37	amod
37	development	development	NN	_	34	nmod
38	.	.	.	_	27	punct

1	drug1	drug1	NN	_	3	nsubjpass
2	was	be	VBD	_	3	auxpass
3	associated	associate	VBN	_	0	ROOT
4	with	with	IN	_	7	case
5	an	a	DT	_	7	det
6	increased	increase	VBN	_	7	amod
7	incidence	incidence	NN	_	3	nmod
8	of	of	IN	_	10	case
9	fetal	fetal	JJ	_	10	amod
10	variations	variation	NNS	_	7	nmod
11	in	in	IN	_	12	case
12	rabbits	rabbit	NNS	_	10	nmod
13	-LRB-	-lrb-	-LRB-	_	15	punct
14	backwards	backwards	RB	_	15	advmod
15	displacement	displacement	NN	_	10	dep
16	of	of	IN	_	19	case
17	the	the	DT	_	19	det
18	pelvic	pelvic	JJ	_	19	amod
19	girdle	girdle	NN	_	15	nmod
20	,	,	,	_	15	punct
21	and	and	CC	_	15	cc
22	27	27	CD	_	24	nummod
23	pre-sacral	pre-sacral	JJ	_	24	amod
24	vertebrae	vertebra	NNS	_	15	conj
25	at	at	IN	_	28	case
26	0.25	0.25	CD	_	28	nummod
27	mg/kg/day	mg/kg/day	NN	_	28	compound
28	IM	im	NN	_	24	nmod
29	;	;	:	_	15	punct

1	one-half	one-half	NN	_	0	ROOT
2	the	the	DT	_	4	det
3	human	human	JJ	_	4	amod
4	dose	dose	NN	_	1	dep
5	on	on	IN	_	6	case
6	BSA	bsa	NN	_	4	nmod
7	-RRB-	-rrb-	-RRB-	_	4	punct
8	when	when	WRB	_	9	advmod
9	administered	administer	VBN	_	1	acl:relcl
10	during	during	IN	_	12	case
11	the	the	DT	_	12	det
12	period	period	NN	_	9	nmod
13	of	of	IN	_	14	case
14	organogenesis	organogenesis	NN	_	12	nmod
15	.	.	.	_	1	punct

1	Because	because	IN	_	6	mark
2	pregnancy	pregnancy	NN	_	6	nsubjpass
3	could	could	MD	_	6	aux
4	not	not	RB	_	6	neg
5	be	be	VB	_	6	auxpass
6	maintained	maintain	VBN	_	23	advcl
7	in	in	IN	_	9	case
8	the	the	DT	_	9	det
9	rabbit	rabbit	NN	_	6	nmod
10	following	follow	VBG	_	11	case
11	doses	dose	NNS	_	6	nmod
12	of	of	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	of	of	IN	_	16	case
15	1	1	CD	_	16	nummod
16	mg/kg/day	mg/kg/day	NN	_	13	nmod
17	and	and	CC	_	16	cc
18	above	above	RB	_	16	conj
19	,	,	,	_	23	punct
20	this	this	DT	_	21	det
21	study	study	NN	_	23	nsubj
22	was	be	VBD	_	23	cop
23	inadequate	inadequate	JJ	_	0	ROOT
24	to	to	TO	_	26	mark
25	fully	fully	RB	_	26	advmod
26	define	define	VB	_	23	xcomp
27	the	the	DT	_	30	det
28	possible	possible	JJ	_	30	amod
29	adverse	adverse	JJ	_	30	amod
30	effects	effect	NNS	_	26	dobj
31	on	on	IN	_	33	case
32	fetal	fetal	JJ	_	33	amod
33	development	development	NN	_	30	nmod
34	at	at	IN	_	37	case
35	clinically	clinically	RB	_	36	advmod
36	relevant	relevant	JJ	_	37	amod
37	exposures	exposure	NNS	_	30	nmod
38	.	.	.	_	23	punct

1	Nursing	Nursing	NNP	_	3	compound
2	Mothers	Mothers	NNP	_	3	compound
3	drug1	drug1	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	found	find	VBN	_	0	ROOT
6	in	in	IN	_	8	case
7	rat	rat	NN	_	8	compound
8	milk	milk	NN	_	5	nmod
9	at	at	IN	_	10	case
10	levels	level	NNS	_	5	nmod
11	significantly	significantly	RB	_	12	advmod
12	higher	higher	JJR	_	10	advmod
13	-LRB-	-lrb-	-LRB-	_	15	punct
14	approximately	approximately	RB	_	15	advmod
15	12-fold	12-fold	RB	_	12	dep
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	than	than	IN	_	18	case
18	plasma	plasma	NN	_	12	nmod
19	after	after	IN	_	20	case
20	administration	administration	NN	_	18	nmod
21	of	of	IN	_	23	case
22	2	2	CD	_	23	nummod
23	mg/kg	mg/kg	NN	_	20	nmod
24	.	.	.	_	5	punct

1	Drug	drug	NN	_	2	compound
2	exposure	exposure	NN	_	0	ROOT
3	in	in	IN	_	5	case
4	rodent	rodent	JJ	_	5	amod
5	pups	pup	NNS	_	2	nmod
6	from	from	IN	_	7	case
7	drug1	drug1	NN	_	2	nmod
8	-	-	:	_	2	punct
9	treated	treat	VBN	_	11	amod
10	lactating	lactating	JJ	_	11	amod
11	dams	dam	NNS	_	13	nsubjpass
12	was	be	VBD	_	13	auxpass
13	estimated	estimate	VBN	_	2	dep
14	as	as	IN	_	16	case
15	10	10	CD	_	16	nummod
16	%	%	NN	_	13	nmod
17	of	of	IN	_	20	case
18	the	the	DT	_	20	det
19	administered	administer	VBN	_	20	amod
20	dose	dose	NN	_	16	nmod
21	.	.	.	_	2	punct

1	It	it	PRP	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	not	not	RB	_	4	neg
4	known	know	VBN	_	0	ROOT
5	if	if	IN	_	8	mark
6	drug1	drug1	NN	_	8	nsubjpass
7	is	be	VBZ	_	8	auxpass
8	excreted	excrete	VBN	_	4	advcl
9	in	in	IN	_	11	case
10	human	human	JJ	_	11	amod
11	milk	milk	NN	_	8	nmod
12	.	.	.	_	4	punct

1	Because	because	IN	_	5	mark
2	many	many	JJ	_	3	amod
3	drugs	drug	NNS	_	5	nsubjpass
4	are	be	VBP	_	5	auxpass
5	excreted	excrete	VBN	_	0	ROOT
6	in	in	IN	_	8	case
7	human	human	JJ	_	8	amod
8	milk	milk	NN	_	5	nmod
9	,	,	,	_	5	punct
10	and	and	CC	_	5	cc
11	because	because	IN	_	14	case
12	of	of	IN	_	11	mwe
13	the	the	DT	_	14	det
14	potential	potential	NN	_	5	conj
15	for	for	IN	_	18	case
16	serious	serious	JJ	_	18	amod
17	adverse	adverse	JJ	_	18	amod
18	reactions	reaction	NNS	_	14	nmod
19	from	from	IN	_	20	case
20	drug1	drug1	NN	_	18	nmod
21	in	in	IN	_	23	case
22	nursing	nursing	NN	_	23	compound
23	infants	infant	NNS	_	20	nmod
24	,	,	,	_	14	punct
25	a	a	DT	_	26	det
26	decision	decision	NN	_	29	nsubjpass
27	should	should	MD	_	29	aux
28	be	be	VB	_	29	auxpass
29	made	make	VBN	_	14	acl:relcl
30	whether	whether	IN	_	32	mark
31	to	to	TO	_	32	mark
32	discontinue	discontinue	VB	_	29	ccomp
33	nursing	nursing	NN	_	32	dobj
34	or	or	CC	_	32	cc
35	to	to	TO	_	36	mark
36	discontinue	discontinue	VB	_	32	conj
37	the	the	DT	_	38	det
38	drug	drug	NN	_	36	dobj
39	taking	take	VBG	_	38	acl
40	into	into	IN	_	41	case
41	account	account	NN	_	39	nmod
42	the	the	DT	_	43	det
43	importance	importance	NN	_	39	dobj
44	of	of	IN	_	46	case
45	the	the	DT	_	46	det
46	drug	drug	NN	_	43	nmod
47	to	to	TO	_	49	case
48	the	the	DT	_	49	det
49	mother	mother	NN	_	43	nmod
50	.	.	.	_	5	punct

1	Pediatric	Pediatric	NNP	_	4	compound
2	Use	Use	NNP	_	4	compound
3	The	The	NNP	_	4	compound
4	safety	safety	NN	_	15	nsubjpass
5	and	and	CC	_	4	cc
6	efficacy	efficacy	NN	_	4	conj
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	in	in	IN	_	11	case
10	pediatric	pediatric	JJ	_	11	amod
11	patients	patient	NNS	_	4	nmod
12	have	have	VBP	_	15	aux
13	not	not	RB	_	15	neg
14	been	be	VBN	_	15	auxpass
15	established	establish	VBN	_	0	ROOT
16	.	.	.	_	15	punct

1	Geriatric	Geriatric	NNP	_	2	compound
2	Use	Use	NNP	_	14	nsubjpass
3	When	when	WRB	_	7	advmod
4	tumor	tumor	NN	_	5	compound
5	response	response	NN	_	7	nsubjpass
6	was	be	VBD	_	7	auxpass
7	considered	consider	VBN	_	2	acl:relcl
8	by	by	IN	_	9	case
9	age	age	NN	_	7	nmod
10	,	,	,	_	2	punct
11	objective	objective	JJ	_	12	amod
12	responses	response	NNS	_	14	nsubjpass
13	were	be	VBD	_	14	auxpass
14	seen	see	VBN	_	0	ROOT
15	in	in	IN	_	17	case
16	24	24	CD	_	17	nummod
17	%	%	NN	_	14	nmod
18	and	and	CC	_	17	cc
19	22	22	CD	_	20	nummod
20	%	%	NN	_	17	conj
21	of	of	IN	_	22	case
22	patients	patient	NNS	_	17	nmod
23	under	under	IN	_	25	case
24	65	65	CD	_	25	nummod
25	years	year	NNS	_	22	nmod
26	of	of	IN	_	27	case
27	age	age	NN	_	25	nmod
28	and	and	CC	_	17	cc
29	in	in	IN	_	31	case
30	16	16	CD	_	31	nummod
31	%	%	NN	_	17	conj
32	and	and	CC	_	31	cc
33	11	11	CD	_	34	nummod
34	%	%	NN	_	31	conj
35	of	of	IN	_	36	case
36	patients	patient	NNS	_	31	nmod
37	65	65	CD	_	38	nummod
38	years	year	NNS	_	36	dep
39	of	of	IN	_	40	case
40	age	age	NN	_	38	nmod
41	and	and	CC	_	40	cc
42	older	older	JJR	_	40	conj
43	,	,	,	_	17	punct
44	who	who	WP	_	46	nsubjpass
45	were	be	VBD	_	46	auxpass
46	treated	treat	VBN	_	17	acl:relcl
47	with	with	IN	_	48	case
48	drug1	drug1	NN	_	46	nmod
49	in	in	IN	_	55	case
50	the	the	DT	_	55	det
51	European	european	JJ	_	55	amod
52	and	and	CC	_	51	cc
53	North	north	JJ	_	51	conj
54	American	american	JJ	_	55	amod
55	trials	trial	NNS	_	46	nmod
56	,	,	,	_	17	punct
57	respectively	respectively	RB	_	17	advmod
58	.	.	.	_	14	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	predominantly	predominantly	RB	_	4	advmod
4	eliminated	eliminate	VBN	_	0	ROOT
5	in	in	IN	_	7	case
6	the	the	DT	_	7	det
7	urine	urine	NN	_	4	nmod
8	by	by	IN	_	12	case
9	active	active	JJ	_	12	amod
10	organic	organic	JJ	_	12	amod
11	cationic	cationic	JJ	_	12	amod
12	secretion	secretion	NN	_	4	nmod
13	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	possibility	possibility	NN	_	12	nsubjpass
3	of	of	IN	_	4	case
4	interactions	interaction	NNS	_	2	nmod
5	with	with	IN	_	7	case
6	other	other	JJ	_	7	amod
7	drugs	drug	NNS	_	4	nmod
8	administered	administer	VBN	_	7	acl
9	concurrently	concurrently	RB	_	8	advmod
10	should	should	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	considered	consider	VBN	_	0	ROOT
13	,	,	,	_	12	punct
14	particularly	particularly	RB	_	24	advmod
15	when	when	WRB	_	24	advmod
16	their	they	PRP$	_	18	nmod:poss
17	main	main	JJ	_	18	amod
18	route	route	NN	_	24	nsubj
19	of	of	IN	_	20	case
20	elimination	elimination	NN	_	18	nmod
21	is	be	VBZ	_	24	cop
22	active	active	JJ	_	24	amod
23	renal	renal	JJ	_	24	amod
24	secretion	secretion	NN	_	12	advcl
25	via	via	IN	_	30	case
26	the	the	DT	_	30	det
27	organic	organic	JJ	_	30	amod
28	cationic	cationic	NN	_	30	compound
29	transport	transport	NN	_	30	compound
30	system	system	NN	_	24	nmod
31	-LRB-	-lrb-	-LRB-	_	34	punct
32	e.g.	e.g.	FW	_	34	dep
33	,	,	,	_	34	punct
34	drug1	drug1	NN	_	30	appos
35	-RRB-	-rrb-	-RRB-	_	34	punct
36	.	.	.	_	12	punct

1	No	no	DT	_	2	neg
2	change	change	NN	_	9	nsubjpass
3	in	in	IN	_	4	case
4	dose	dose	NN	_	2	nmod
5	of	of	IN	_	7	case
6	either	either	CC	_	7	det
7	drug	drug	NN	_	4	nmod
8	is	be	VBZ	_	9	auxpass
9	recommended	recommend	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	There	there	EX	_	2	expl
2	is	be	VBZ	_	0	ROOT
3	no	no	DT	_	4	neg
4	information	information	NN	_	2	nsubj
5	regarding	regard	VBG	_	7	case
6	the	the	DT	_	7	det
7	effect	effect	NN	_	4	nmod
8	on	on	IN	_	10	case
9	drug1	drug1	NN	_	10	compound
10	pharmacokinetics	pharmacokinetic	NNS	_	7	nmod
11	of	of	IN	_	13	case
12	higher	higher	JJR	_	13	amod
13	doses	dose	NNS	_	10	nmod
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	/	/	:	_	17	punct
17	drug3	drug3	NN	_	4	dep
18	such	such	JJ	_	20	case
19	as	as	IN	_	18	mwe
20	those	those	DT	_	17	nmod
21	used	use	VBN	_	20	acl
22	to	to	TO	_	23	mark
23	treat	treat	VB	_	21	xcomp
24	Pneumocystis	pneumocystis	NN	_	26	compound
25	carinii	carinii	NN	_	26	compound
26	pneumonia	pneumonia	NN	_	23	dobj
27	.	.	.	_	2	punct

1	No	no	DT	_	2	neg
2	data	datum	NNS	_	4	nsubj
3	are	be	VBP	_	4	cop
4	available	available	JJ	_	0	ROOT
5	regarding	regard	VBG	_	6	case
6	interactions	interaction	NNS	_	4	nmod
7	with	with	IN	_	9	case
8	other	other	JJ	_	9	amod
9	drugs	drug	NNS	_	6	nmod
10	that	that	WDT	_	11	nsubj
11	have	have	VBP	_	9	acl:relcl
12	renal	renal	JJ	_	14	amod
13	clearance	clearance	NN	_	14	compound
14	mechanisms	mechanism	NNS	_	11	dobj
15	similar	similar	JJ	_	14	amod
16	to	to	TO	_	17	case
17	that	that	DT	_	15	nmod
18	of	of	IN	_	19	case
19	drug1	drug1	NN	_	17	nmod
20	.	.	.	_	4	punct

1	drug1	drug1	NN	_	5	nsubj
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	may	may	MD	_	5	aux
5	inhibit	inhibit	VB	_	0	ROOT
6	the	the	DT	_	8	det
7	intracellular	intracellular	JJ	_	8	amod
8	phosphorylation	phosphorylation	NN	_	5	dobj
9	of	of	IN	_	11	case
10	one	one	CD	_	11	nummod
11	another	another	DT	_	8	nmod
12	.	.	.	_	5	punct

1	Therefore	therefore	RB	_	12	advmod
2	,	,	,	_	12	punct
3	use	use	NN	_	12	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	in	in	IN	_	7	case
7	combination	combination	NN	_	3	nmod
8	with	with	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	is	be	VBZ	_	12	auxpass
11	not	not	RB	_	12	neg
12	recommended	recommend	VBN	_	0	ROOT

1	.	.	.	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	drug1	drug1	NN	_	2	nsubj
2	decreases	decrease	VBZ	_	0	ROOT
3	drug2	drug2	NN	_	4	compound
4	clearance	clearance	NN	_	2	dobj
5	by	by	IN	_	9	case
6	up	up	RB	_	8	dep
7	to	to	TO	_	6	mwe
8	25	25	CD	_	9	nummod
9	%	%	NN	_	2	nmod
10	,	,	,	_	2	punct
11	and	and	CC	_	2	cc
12	may	may	MD	_	13	aux
13	produce	produce	VB	_	2	conj
14	AUCs	auc	NNS	_	17	compound
15	1500	1500	CD	_	17	nummod
16	M	m	NN	_	17	compound
17	min	min	NN	_	13	dobj
18	in	in	IN	_	20	case
19	some	some	DT	_	20	det
20	patients	patient	NNS	_	13	nmod
21	.	.	.	_	2	punct

1	drug1	drug1	NN	_	18	nsubjpass
2	,	,	,	_	1	punct
3	and	and	CC	_	1	cc
4	the	the	DT	_	6	det
5	drug2	drug2	NN	_	6	compound
6	drug3	drug3	NN	_	1	conj
7	-LRB-	-lrb-	-LRB-	_	8	punct
8	drug4	drug4	NN	_	6	appos
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	and	and	CC	_	6	cc
11	drug5	drug5	NN	_	6	conj
12	-LRB-	-lrb-	-LRB-	_	13	punct
13	drug6	drug6	NN	_	11	appos
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	have	have	VBP	_	18	aux
16	all	all	DT	_	18	dep
17	been	be	VBN	_	18	auxpass
18	used	use	VBN	_	0	ROOT
19	with	with	IN	_	20	case
20	drug7	drug7	NN	_	18	nmod
21	.	.	.	_	18	punct

1	drug1	drug1	NN	_	2	nsubj
2	increases	increase	VBZ	_	0	ROOT
3	the	the	DT	_	4	det
4	clearance	clearance	NN	_	2	dobj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	by	by	IN	_	9	case
8	15	15	CD	_	9	nummod
9	%	%	NN	_	2	nmod
10	or	or	CC	_	11	cc
11	more	more	JJR	_	9	nummod
12	,	,	,	_	2	punct
13	possibly	possibly	RB	_	17	advmod
14	due	due	JJ	_	17	case
15	to	to	TO	_	14	mwe
16	the	the	DT	_	17	det
17	induction	induction	NN	_	2	nmod
18	of	of	IN	_	19	case
19	glutathione-S-transferase	glutathione-s-transferase	NN	_	17	nmod
20	.	.	.	_	2	punct

1	Since	since	IN	_	7	mark
2	the	the	DT	_	3	det
3	pharmacokinetics	pharmacokinetic	NNS	_	7	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	were	be	VBD	_	7	auxpass
7	studied	study	VBN	_	24	advcl
8	in	in	IN	_	9	case
9	patients	patient	NNS	_	7	nmod
10	treated	treat	VBN	_	9	acl
11	with	with	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	,	,	,	_	24	punct
14	the	the	DT	_	15	det
15	clearance	clearance	NN	_	24	nsubj
16	of	of	IN	_	17	case
17	drug3	drug3	NN	_	15	nmod
18	at	at	IN	_	21	case
19	the	the	DT	_	21	det
20	recommended	recommend	VBN	_	21	amod
21	dose	dose	NN	_	15	nmod
22	may	may	MD	_	24	aux
23	be	be	VB	_	24	cop
24	lower	lower	JJR	_	0	ROOT
25	and	and	CC	_	24	cc
26	exposure	exposure	NN	_	30	nmod:npmod
27	-LRB-	-lrb-	-LRB-	_	28	punct
28	AUC	auc	NN	_	26	appos
29	-RRB-	-rrb-	-RRB-	_	28	punct
30	higher	higher	JJR	_	24	conj
31	in	in	IN	_	32	case
32	patients	patient	NNS	_	30	nmod
33	not	not	RB	_	34	neg
34	treated	treat	VBN	_	32	acl
35	with	with	IN	_	36	case
36	drug4	drug4	NN	_	34	nmod
37	.	.	.	_	24	punct

1	Because	because	IN	_	4	mark
2	drug1	drug1	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	eliminated	eliminate	VBN	_	0	ROOT
5	from	from	IN	_	7	case
6	the	the	DT	_	7	det
7	body	body	NN	_	4	nmod
8	via	via	IN	_	9	case
9	conjugation	conjugation	NN	_	4	nmod
10	with	with	IN	_	11	case
11	glutathione	glutathione	NN	_	9	nmod
12	,	,	,	_	4	punct
13	use	use	NN	_	12	root
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	prior	prior	RB	_	27	advmod
17	to	to	TO	_	27	mark
18	-LRB-	-lrb-	-LRB-	_	20	punct
19	72	72	CD	_	20	nummod
20	hours	hour	NNS	_	17	dep
21	-RRB-	-rrb-	-RRB-	_	20	punct
22	or	or	CC	_	17	cc
23	concurrent	concurrent	JJ	_	17	conj
24	with	with	IN	_	25	case
25	drug3	drug3	NN	_	23	nmod
26	may	may	MD	_	27	aux
27	result	result	VB	_	13	acl
28	in	in	IN	_	31	case
29	reduced	reduce	VBN	_	31	amod
30	drug4	drug4	NN	_	31	compound
31	clearance	clearance	NN	_	27	nmod
32	based	base	VBN	_	31	acl
33	upon	upon	IN	_	36	case
34	the	the	DT	_	36	det
35	known	known	JJ	_	36	amod
36	property	property	NN	_	32	nmod
37	of	of	IN	_	38	case
38	drug5	drug5	NN	_	36	nmod
39	to	to	TO	_	40	mark
40	decrease	decrease	VB	_	27	xcomp
41	glutathione	glutathione	NN	_	42	compound
42	levels	level	NNS	_	40	dobj
43	in	in	IN	_	45	case
44	the	the	DT	_	45	det
45	blood	blood	NN	_	40	nmod
46	and	and	CC	_	45	cc
47	tissues	tissue	NNS	_	45	conj
48	.	.	.	_	13	punct

1	Catecholamine-depleting	catecholamine-depleting	JJ	_	2	amod
2	drugs	drug	NNS	_	9	nsubj
3	-LRB-	-lrb-	-LRB-	_	4	punct
4	eg	eg	FW	_	2	dep
5	,	,	,	_	4	punct
6	drug1	drug1	NN	_	4	appos
7	-RRB-	-rrb-	-RRB-	_	4	punct
8	may	may	MD	_	9	aux
9	have	have	VB	_	0	ROOT
10	an	a	DT	_	12	det
11	additive	additive	JJ	_	12	amod
12	effect	effect	NN	_	9	dobj
13	when	when	WRB	_	14	advmod
14	given	give	VBN	_	9	advcl
15	with	with	IN	_	17	case
16	drug2	drug2	NN	_	17	compound
17	s.	s.	NN	_	14	nmod

1	Patients	patient	NNS	_	13	nsubjpass
2	treated	treat	VBN	_	1	acl
3	with	with	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	plus	plus	CC	_	4	cc
6	a	a	DT	_	8	det
7	catecholamine	catecholamine	NN	_	8	compound
8	depletor	depletor	NN	_	4	conj
9	should	should	MD	_	13	aux
10	therefore	therefore	RB	_	13	advmod
11	be	be	VB	_	13	auxpass
12	closely	closely	RB	_	13	advmod
13	observed	observe	VBN	_	0	ROOT
14	for	for	IN	_	15	case
15	evidence	evidence	NN	_	13	nmod
16	of	of	IN	_	17	case
17	hypotension	hypotension	NN	_	15	nmod
18	and/or	and/or	CC	_	17	cc
19	marked	marked	JJ	_	20	amod
20	bradycardia	bradycardia	NN	_	17	conj
21	which	which	WDT	_	23	nsubj
22	may	may	MD	_	23	aux
23	produce	produce	VB	_	15	acl:relcl
24	vertigo	vertigo	NN	_	23	dobj
25	,	,	,	_	24	punct
26	syncope	syncope	NN	_	24	conj
27	,	,	,	_	24	punct
28	or	or	CC	_	24	cc
29	postural	postural	JJ	_	30	amod
30	hypotension	hypotension	NN	_	24	conj
31	.	.	.	_	13	punct

1	drug1	drug1	NN	_	4	nsubj
2	may	may	MD	_	4	aux
3	also	also	RB	_	4	advmod
4	have	have	VB	_	0	ROOT
5	an	a	DT	_	7	det
6	additive	additive	JJ	_	7	amod
7	effect	effect	NN	_	4	dobj
8	when	when	WRB	_	9	advmod
9	given	give	VBN	_	4	advcl
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	.	.	.	_	4	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	exacerbate	exacerbate	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	rebound	rebound	NN	_	6	compound
6	hypertension	hypertension	NN	_	3	dobj
7	which	which	WDT	_	9	nsubj
8	can	can	MD	_	9	aux
9	follow	follow	VB	_	6	acl:relcl
10	the	the	DT	_	11	det
11	withdrawal	withdrawal	NN	_	9	dobj
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	.	.	.	_	3	punct

1	If	if	IN	_	6	mark
2	the	the	DT	_	4	det
3	two	two	CD	_	4	nummod
4	drugs	drug	NNS	_	6	nsubjpass
5	are	be	VBP	_	6	auxpass
6	coadministered	coadminister	VBN	_	12	advcl
7	,	,	,	_	12	punct
8	the	the	DT	_	9	det
9	drug1	drug1	NN	_	12	nsubjpass
10	should	should	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	withdrawn	withdraw	VBN	_	0	ROOT
13	several	several	JJ	_	14	amod
14	days	day	NNS	_	12	nmod:tmod
15	before	before	IN	_	18	case
16	the	the	DT	_	18	det
17	gradual	gradual	JJ	_	18	amod
18	withdrawal	withdrawal	NN	_	12	nmod
19	of	of	IN	_	20	case
20	drug2	drug2	NN	_	18	nmod
21	.	.	.	_	12	punct

1	If	if	IN	_	2	mark
2	replacing	replace	VBG	_	14	advcl
3	drug1	drug1	NN	_	2	dobj
4	by	by	IN	_	6	case
5	drug2	drug2	NN	_	6	compound
6	therapy	therapy	NN	_	2	nmod
7	,	,	,	_	14	punct
8	the	the	DT	_	9	det
9	introduction	introduction	NN	_	14	nsubjpass
10	of	of	IN	_	11	case
11	drug3	drug3	NN	_	9	nmod
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	delayed	delay	VBN	_	0	ROOT
15	for	for	IN	_	17	case
16	several	several	JJ	_	17	amod
17	days	day	NNS	_	14	nmod
18	after	after	IN	_	22	mark
19	drug4	drug4	NN	_	20	compound
20	administration	administration	NN	_	22	nsubj
21	has	have	VBZ	_	22	aux
22	stopped	stop	VBN	_	14	advcl
23	.	.	.	_	14	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	use	use	NN	_	14	nsubj
3	of	of	IN	_	5	case
4	prostaglandin	prostaglandin	NN	_	5	compound
5	synthase	synthase	NN	_	2	nmod
6	inhibiting	inhibit	VBG	_	5	acl
7	drugs	drug	NNS	_	6	dobj
8	,	,	,	_	2	punct
9	eg	eg	FW	_	11	compound
10	,	,	,	_	11	punct
11	drug1	drug1	NN	_	2	appos
12	,	,	,	_	2	punct
13	may	may	MD	_	14	aux
14	decrease	decrease	VB	_	0	ROOT
15	the	the	DT	_	17	det
16	hypotensive	hypotensive	JJ	_	17	amod
17	effects	effect	NNS	_	14	dobj
18	of	of	IN	_	19	case
19	drug2	drug2	NN	_	17	nmod
20	.	.	.	_	14	punct

1	Information	information	NN	_	10	nsubjpass
2	on	on	IN	_	4	case
3	concurrent	concurrent	JJ	_	4	amod
4	usage	usage	NN	_	1	nmod
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	drug2	drug2	NN	_	6	conj
9	is	be	VBZ	_	10	auxpass
10	limited	limit	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	Data	datum	NNS	_	0	ROOT
2	from	from	IN	_	4	case
3	several	several	JJ	_	4	amod
4	studies	study	NNS	_	1	nmod
5	,	,	,	_	4	punct
6	ie	ie	FW	_	8	dep
7	,	,	,	_	8	punct
8	TIMI-II	timi-ii	NN	_	15	nsubj
9	,	,	,	_	8	punct
10	ISIS-2	isis-2	NN	_	8	appos
11	,	,	,	_	8	punct
12	currently	currently	RB	_	15	advmod
13	do	do	VBP	_	15	aux
14	not	not	RB	_	15	neg
15	suggest	suggest	VB	_	4	acl:relcl
16	any	any	DT	_	18	det
17	clinical	clinical	JJ	_	18	amod
18	interaction	interaction	NN	_	15	dobj
19	between	between	IN	_	20	case
20	drug1	drug1	NN	_	18	nmod
21	and	and	CC	_	20	cc
22	drug2	drug2	NN	_	20	conj
23	in	in	IN	_	28	case
24	the	the	DT	_	28	det
25	acute	acute	JJ	_	28	amod
26	myocardial	myocardial	JJ	_	28	amod
27	infarction	infarction	NN	_	28	compound
28	setting	setting	NN	_	18	nmod
29	.	.	.	_	1	punct

1	While	while	IN	_	2	mark
2	taking	take	VBG	_	18	advcl
3	drug1	drug1	NN	_	2	dobj
4	,	,	,	_	18	punct
5	patients	patient	NNS	_	18	nsubj
6	with	with	IN	_	8	case
7	a	a	DT	_	8	det
8	history	history	NN	_	5	nmod
9	of	of	IN	_	11	case
10	anaphylactic	anaphylactic	JJ	_	11	amod
11	reaction	reaction	NN	_	8	nmod
12	to	to	TO	_	14	case
13	a	a	DT	_	14	det
14	variety	variety	NN	_	11	nmod
15	of	of	IN	_	16	case
16	allergens	allergen	NNS	_	14	nmod
17	may	may	MD	_	18	aux
18	have	have	VB	_	0	ROOT
19	a	a	DT	_	22	det
20	more	more	RBR	_	21	advmod
21	severe	severe	JJ	_	22	amod
22	reaction	reaction	NN	_	18	dobj
23	on	on	IN	_	25	case
24	repeated	repeat	VBN	_	25	amod
25	challenge	challenge	NN	_	22	nmod
26	,	,	,	_	18	punct
27	either	either	CC	_	28	cc:preconj
28	accidental	accidental	JJ	_	18	dep
29	,	,	,	_	28	punct
30	diagnostic	diagnostic	JJ	_	28	conj
31	or	or	CC	_	28	cc
32	therapeutic	therapeutic	JJ	_	28	conj
33	.	.	.	_	18	punct

1	Such	such	JJ	_	2	amod
2	patients	patient	NNS	_	5	nsubj
3	may	may	MD	_	5	aux
4	be	be	VB	_	5	cop
5	unresponsive	unresponsive	JJ	_	0	ROOT
6	to	to	TO	_	9	case
7	the	the	DT	_	9	det
8	usual	usual	JJ	_	9	amod
9	doses	dose	NNS	_	5	nmod
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	used	use	VBN	_	9	acl
13	to	to	TO	_	14	mark
14	treat	treat	VB	_	12	xcomp
15	the	the	DT	_	17	det
16	allergic	allergic	JJ	_	17	amod
17	reaction	reaction	NN	_	14	dobj
18	.	.	.	_	5	punct

1	drug1	drug1	NN	_	2	nsubj
2	augments	augment	VBZ	_	0	ROOT
3	the	the	DT	_	4	det
4	action	action	NN	_	2	dobj
5	of	of	IN	_	7	case
6	drug2	drug2	NN	_	7	compound
7	s	s	NNS	_	4	nmod
8	and	and	CC	_	7	cc
9	the	the	DT	_	12	det
10	muscle	muscle	NN	_	12	compound
11	relaxant	relaxant	NN	_	12	compound
12	effects	effect	NNS	_	7	conj
13	of	of	IN	_	14	case
14	drug3	drug3	NN	_	12	nmod
15	.	.	.	_	2	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	augment	augment	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	hypotension	hypotension	NN	_	3	dobj
6	caused	cause	VBN	_	5	acl
7	by	by	IN	_	10	case
8	the	the	DT	_	10	det
9	ganglionic-blocking	ganglionic-blocking	NN	_	10	compound
10	effect	effect	NN	_	6	nmod
11	of	of	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	.	.	.	_	3	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	exercised	exercise	VBN	_	0	ROOT
5	during	during	IN	_	7	case
6	the	the	DT	_	7	det
7	administration	administration	NN	_	4	nmod
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	to	to	TO	_	11	case
11	patients	patient	NNS	_	4	nmod
12	anaesthetised	anaesthetise	VBN	_	11	acl
13	with	with	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	as	as	IN	_	19	mark
16	arrhythmias	arrhythmia	NNS	_	19	nsubjpass
17	may	may	MD	_	19	aux
18	be	be	VB	_	19	auxpass
19	precipitated	precipitate	VBN	_	12	advcl
20	.	.	.	_	4	punct

1	For	for	IN	_	3	case
2	this	this	DT	_	3	det
3	reason	reason	NN	_	10	nmod
4	the	the	DT	_	5	det
5	dose	dose	NN	_	10	nsubjpass
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	should	should	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	restricted	restricted	JJ	_	0	ROOT
11	and	and	CC	_	10	cc
12	an	a	DT	_	13	det
13	drug2	drug2	NN	_	10	conj
14	administered	administer	VBN	_	13	acl
15	as	as	IN	_	16	case
16	appropriate	appropriate	JJ	_	14	advcl
17	.	.	.	_	10	punct

1	Caution	caution	NN	_	5	nsubjpass
2	should	should	MD	_	5	aux
3	also	also	RB	_	5	advmod
4	be	be	VB	_	5	auxpass
5	applied	apply	VBN	_	0	ROOT
6	for	for	IN	_	8	case
7	other	other	JJ	_	8	amod
8	drug1	drug1	NN	_	5	nmod
9	,	,	,	_	5	punct
10	and	and	CC	_	5	cc
11	for	for	IN	_	12	case
12	drug2	drug2	NN	_	5	conj
13	and	and	CC	_	12	cc
14	drug3	drug3	NN	_	12	conj
15	and	and	CC	_	14	cc
16	drug4	drug4	NN	_	14	conj
17	,	,	,	_	12	punct
18	which	which	WDT	_	21	nsubj
19	may	may	MD	_	21	aux
20	also	also	RB	_	21	advmod
21	precipitate	precipitate	VB	_	12	acl:relcl
22	arrhythmias	arrhythmia	NNS	_	21	dobj
23	.	.	.	_	5	punct

1	Limited	limited	JJ	_	2	amod
2	PK	pk	NN	_	5	compound
3	and/or	and/or	CC	_	2	cc
4	PD	pd	NN	_	2	conj
5	studies	study	NNS	_	17	nsubjpass
6	investigating	investigate	VBG	_	5	acl
7	possible	possible	JJ	_	8	amod
8	interactions	interaction	NNS	_	6	dobj
9	between	between	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	other	other	JJ	_	14	amod
13	medicinal	medicinal	JJ	_	14	amod
14	products	product	NNS	_	10	conj
15	have	have	VBP	_	17	aux
16	been	be	VBN	_	17	auxpass
17	conducted	conduct	VBN	_	0	ROOT
18	.	.	.	_	17	punct

1	In	in	FW	_	4	amod
2	vivo	vivo	FW	_	1	dep
3	interaction	interaction	NN	_	4	compound
4	studies	study	NNS	_	8	nsubj
5	in	in	IN	_	6	case
6	humans	human	NNS	_	4	nmod
7	have	have	VBP	_	8	aux
8	demonstrated	demonstrate	VBN	_	0	ROOT
9	that	that	IN	_	15	mark
10	drug1	drug1	NN	_	15	nsubj
11	and	and	CC	_	10	cc
12	drug2	drug2	NN	_	10	conj
13	do	do	VBP	_	15	aux
14	not	not	RB	_	15	neg
15	affect	affect	VB	_	8	ccomp
16	the	the	DT	_	18	det
17	PK	pk	NN	_	18	compound
18	properties	property	NNS	_	15	dobj
19	of	of	IN	_	20	case
20	drug3	drug3	NN	_	18	nmod
21	,	,	,	_	15	punct
22	nor	nor	CC	_	15	cc
23	does	do	VBZ	_	25	aux
24	drug4	drug4	NN	_	25	nsubj
25	affect	affect	VB	_	15	conj
26	the	the	DT	_	28	det
27	PK	pk	NN	_	28	compound
28	properties	property	NNS	_	25	dobj
29	of	of	IN	_	30	case
30	drug5	drug5	NN	_	28	nmod
31	or	or	CC	_	30	cc
32	drug6	drug6	NN	_	30	conj
33	.	.	.	_	8	punct

1	Although	although	IN	_	9	mark
2	additional	additional	JJ	_	5	amod
3	drug	drug	NN	_	5	compound
4	interaction	interaction	NN	_	5	compound
5	studies	study	NNS	_	9	nsubjpass
6	have	have	VBP	_	9	aux
7	not	not	RB	_	9	neg
8	been	be	VBN	_	9	auxpass
9	conducted	conduct	VBN	_	15	advcl
10	,	,	,	_	15	punct
11	the	the	DT	_	14	det
12	most	most	RBS	_	13	advmod
13	common	common	JJ	_	14	amod
14	medications	medication	NNS	_	15	nsubj
15	used	use	VBN	_	0	ROOT
16	concomitantly	concomitantly	RB	_	15	advmod
17	with	with	IN	_	18	case
18	drug1	drug1	NN	_	15	nmod
19	in	in	IN	_	21	case
20	clinical	clinical	JJ	_	21	amod
21	trials	trial	NNS	_	23	nmod
22	were	be	VBD	_	23	cop
23	drug2	drug2	NN	_	15	nmod
24	,	,	,	_	23	punct
25	drug3	drug3	NN	_	23	conj
26	,	,	,	_	23	punct
27	drug4	drug4	NN	_	23	conj
28	,	,	,	_	23	punct
29	drug5	drug5	NN	_	23	conj
30	,	,	,	_	23	punct
31	drug6	drug6	NN	_	23	conj
32	,	,	,	_	23	punct
33	drug7	drug7	NN	_	23	conj
34	,	,	,	_	23	punct
35	and	and	CC	_	23	cc
36	drug8	drug8	NN	_	23	conj
37	.	.	.	_	15	punct

1	There	there	EX	_	2	expl
2	is	be	VBZ	_	0	ROOT
3	no	no	DT	_	5	neg
4	clinical	clinical	JJ	_	5	amod
5	evidence	evidence	NN	_	2	nsubj
6	to	to	TO	_	7	mark
7	suggest	suggest	VB	_	5	acl
8	that	that	IN	_	10	mark
9	drug1	drug1	NN	_	10	nsubj
10	interacts	interact	VBZ	_	7	ccomp
11	with	with	IN	_	12	case
12	any	any	DT	_	10	nmod
13	of	of	IN	_	15	case
14	these	these	DT	_	15	det
15	compounds	compound	NNS	_	12	nmod
16	.	.	.	_	2	punct

1	An	a	DT	_	5	det
2	in	in	FW	_	5	amod
3	vivo	vivo	FW	_	2	dep
4	interaction	interaction	NN	_	5	compound
5	study	study	NN	_	8	nsubj
6	in	in	IN	_	7	case
7	humans	human	NNS	_	5	nmod
8	demonstrated	demonstrate	VBD	_	29	csubjpass
9	that	that	IN	_	16	mark
10	a	a	DT	_	13	det
11	single	single	JJ	_	13	amod
12	1mg	1mg	JJ	_	13	amod
13	dose	dose	NN	_	16	nsubj
14	of	of	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	administered	administer	VBN	_	8	ccomp
17	concomitantly	concomitantly	RB	_	16	advmod
18	with	with	IN	_	23	case
19	a	a	DT	_	23	det
20	single	single	JJ	_	23	amod
21	900	900	CD	_	22	compound
22	mg	mg	NN	_	23	amod
23	dose	dose	NN	_	16	nmod
24	of	of	IN	_	25	case
25	drug2	drug2	NN	_	23	nmod
26	was	be	VBD	_	29	auxpass
27	generally	generally	RB	_	29	advmod
28	well	well	RB	_	29	advmod
29	tolerated	tolerate	VBN	_	0	ROOT
30	.	.	.	_	29	punct

1	There	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	no	no	DT	_	4	neg
4	effect	effect	NN	_	2	nsubj
5	on	on	IN	_	7	case
6	bleeding	bleeding	JJ	_	7	amod
7	time	time	NN	_	2	nmod
8	,	,	,	_	7	punct
9	PT	pt	NN	_	8	root
10	or	or	CC	_	9	cc
11	aPTT	aptt	NN	_	9	conj
12	.	.	.	_	9	punct

1	No	no	DT	_	5	neg
2	clinically	clinically	RB	_	3	advmod
3	relevant	relevant	JJ	_	5	amod
4	pharmacokinetic	pharmacokinetic	JJ	_	5	amod
5	interactions	interaction	NNS	_	11	nsubjpass
6	between	between	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	were	be	VBD	_	11	auxpass
11	observed	observe	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	In	in	IN	_	4	case
2	that	that	DT	_	4	det
3	same	same	JJ	_	4	amod
4	study	study	NN	_	8	nmod
5	,	,	,	_	8	punct
6	drug1	drug1	NN	_	8	nsubj
7	alone	alone	RB	_	6	advmod
8	produced	produce	VBD	_	0	ROOT
9	a	a	DT	_	11	det
10	marked	marked	JJ	_	11	amod
11	inhibition	inhibition	NN	_	8	dobj
12	in	in	IN	_	14	case
13	platelet	platelet	NN	_	14	compound
14	aggregation	aggregation	NN	_	11	nmod
15	ex	ex	FW	_	16	compound
16	vivo	vivo	FW	_	14	advmod
17	.	.	.	_	8	punct

1	drug1	drug1	NN	_	3	nsubj
2	alone	alone	RB	_	1	advmod
3	had	have	VBD	_	0	ROOT
4	no	no	DT	_	5	neg
5	effect	effect	NN	_	3	dobj
6	on	on	IN	_	8	case
7	platelet	platelet	NN	_	8	compound
8	aggregation	aggregation	NN	_	3	nmod
9	,	,	,	_	3	punct
10	but	but	CC	_	3	cc
11	did	do	VBD	_	13	aux
12	slightly	slightly	RB	_	13	advmod
13	enhance	enhance	VB	_	3	conj
14	the	the	DT	_	15	det
15	inhibition	inhibition	NN	_	13	dobj
16	of	of	IN	_	18	case
17	platelet	platelet	NN	_	18	compound
18	aggregation	aggregation	NN	_	15	nmod
19	by	by	IN	_	20	case
20	drug2	drug2	NN	_	15	nmod
21	.	.	.	_	3	punct

1	drug1	drug1	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	metabolized	metabolize	VBN	_	0	ROOT
4	at	at	IN	_	7	advmod
5	least	least	JJS	_	4	mwe
6	in	in	IN	_	7	case
7	part	part	NN	_	3	nmod
8	by	by	IN	_	9	case
9	CYP1A2	cyp1a2	NN	_	3	nmod
10	.	.	.	_	3	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	known	know	VBN	_	23	csubj
4	that	that	IN	_	7	mark
5	CYP1A2	cyp1a2	NN	_	7	nsubjpass
6	is	be	VBZ	_	7	auxpass
7	inhibited	inhibit	VBN	_	3	ccomp
8	by	by	IN	_	11	case
9	several	several	JJ	_	11	amod
10	medicinal	medicinal	JJ	_	11	amod
11	products	product	NNS	_	7	nmod
12	,	,	,	_	11	punct
13	including	include	VBG	_	14	case
14	drug1	drug1	NN	_	11	nmod
15	,	,	,	_	11	punct
16	and	and	CC	_	11	cc
17	such	such	JJ	_	19	amod
18	medicinal	medicinal	JJ	_	19	amod
19	products	product	NNS	_	11	conj
20	could	could	MD	_	23	aux
21	theoretically	theoretically	RB	_	23	advmod
22	adversely	adversely	RB	_	23	advmod
23	influence	influence	VB	_	0	ROOT
24	the	the	DT	_	25	det
25	clearance	clearance	NN	_	23	dobj
26	of	of	IN	_	27	case
27	drug2	drug2	NN	_	25	nmod
28	.	.	.	_	23	punct

1	drug1	drug1	NN	_	2	nsubj
2	demonstrates	demonstrate	VBZ	_	0	ROOT
3	some	some	DT	_	6	det
4	limited	limited	JJ	_	6	amod
5	inhibitory	inhibitory	JJ	_	6	amod
6	activity	activity	NN	_	2	dobj
7	towards	towards	IN	_	8	case
8	CYP1A2	cyp1a2	NN	_	6	nmod
9	which	which	WDT	_	11	nsubj
10	may	may	MD	_	11	aux
11	present	present	VB	_	6	acl:relcl
12	a	a	DT	_	14	det
13	theoretical	theoretical	JJ	_	14	amod
14	potential	potential	NN	_	11	dobj
15	for	for	IN	_	16	case
16	interaction	interaction	NN	_	14	nmod
17	with	with	IN	_	21	case
18	other	other	JJ	_	21	amod
19	coadministered	coadministered	JJ	_	21	amod
20	medicinal	medicinal	JJ	_	21	amod
21	products	product	NNS	_	16	nmod
22	sharing	share	VBG	_	21	acl
23	that	that	IN	_	25	det
24	clearance	clearance	NN	_	25	compound
25	mechanism	mechanism	NN	_	22	dobj
26	e.g.	e.g.	FW	_	2	dep

1	drug1	drug1	NN	_	2	nsubj
2	demonstrates	demonstrate	VBZ	_	0	ROOT
3	some	some	DT	_	6	det
4	limited	limited	JJ	_	6	amod
5	inhibitory	inhibitory	JJ	_	6	amod
6	activity	activity	NN	_	2	dobj
7	towards	towards	IN	_	8	case
8	CYP1A2	cyp1a2	NN	_	6	nmod
9	which	which	WDT	_	11	nsubj
10	may	may	MD	_	11	aux
11	present	present	VB	_	6	acl:relcl
12	a	a	DT	_	14	det
13	theoretical	theoretical	JJ	_	14	amod
14	potential	potential	NN	_	11	dobj
15	for	for	IN	_	16	case
16	interaction	interaction	NN	_	14	nmod
17	with	with	IN	_	21	case
18	other	other	JJ	_	21	amod
19	coadministered	coadministered	JJ	_	21	amod
20	medicinal	medicinal	JJ	_	21	amod
21	products	product	NNS	_	16	nmod
22	sharing	share	VBG	_	21	acl
23	that	that	IN	_	25	det
24	clearance	clearance	NN	_	25	compound
25	mechanism	mechanism	NN	_	22	dobj
26	e.g.	e.g.	FW	_	27	compound
27	drug2	drug2	FW	_	22	advmod
28	.	.	.	_	2	punct

1	drug1	drug1	NN	_	4	nsubj
2	is	be	VBZ	_	4	cop
3	an	a	DT	_	4	det
4	inhibitor	inhibitor	NN	_	0	ROOT
5	of	of	IN	_	8	case
6	cyclic	cyclic	JJ	_	8	amod
7	AMP	amp	NN	_	8	compound
8	PDE	pde	NN	_	4	nmod
9	III	iii	CD	_	8	nummod
10	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	effects	effect	NNS	_	23	nsubjpass
3	of	of	IN	_	5	case
4	medicinal	medicinal	JJ	_	5	amod
5	products	product	NNS	_	2	nmod
6	with	with	IN	_	8	case
7	similar	similar	JJ	_	8	amod
8	properties	property	NNS	_	2	nmod
9	such	such	JJ	_	12	case
10	as	as	IN	_	9	mwe
11	inotropes	inotrope	NNS	_	12	compound
12	drug1	drug1	NN	_	8	nmod
13	,	,	,	_	12	punct
14	drug2	drug2	NN	_	12	conj
15	,	,	,	_	12	punct
16	drug3	drug3	NN	_	12	conj
17	,	,	,	_	12	punct
18	drug4	drug4	NN	_	12	conj
19	and	and	CC	_	12	cc
20	drug5	drug5	NN	_	12	conj
21	may	may	MD	_	23	aux
22	be	be	VB	_	23	auxpass
23	exacerbated	exacerbate	VBN	_	0	ROOT
24	by	by	IN	_	25	case
25	drug6	drug6	NN	_	23	nmod
26	.	.	.	_	23	punct

1	There	there	EX	_	2	expl
2	is	be	VBZ	_	0	ROOT
3	a	a	DT	_	6	det
4	single	single	JJ	_	6	amod
5	case	case	NN	_	6	compound
6	report	report	NN	_	2	nsubj
7	,	,	,	_	6	punct
8	which	which	WDT	_	9	nsubj
9	suggests	suggest	VBZ	_	6	acl:relcl
10	that	that	IN	_	13	mark
11	drug1	drug1	NN	_	13	nsubj
12	may	may	MD	_	13	aux
13	interfere	interfere	VB	_	9	ccomp
14	with	with	IN	_	16	case
15	drug2	drug2	NN	_	16	compound
16	absorption	absorption	NN	_	13	nmod
17	.	.	.	_	2	punct

1	Food	Food	NNP	_	2	nsubj
2	has	have	VBZ	_	0	ROOT
3	no	no	DT	_	6	neg
4	clinically	clinically	RB	_	5	advmod
5	significant	significant	JJ	_	6	amod
6	effect	effect	NN	_	2	dobj
7	on	on	IN	_	9	case
8	the	the	DT	_	9	det
9	bioavailability	bioavailability	NN	_	2	nmod
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	.	.	.	_	2	punct

1	Potential	potential	JJ	_	0	ROOT
2	for	for	IN	_	3	case
3	Interaction	interaction	NN	_	1	nmod
4	with	with	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod

1	In	in	IN	_	2	case
2	patients	patient	NNS	_	17	nmod
3	receiving	receive	VBG	_	2	acl
4	another	another	DT	_	5	det
5	drug1	drug1	NN	_	3	dobj
6	in	in	IN	_	7	case
7	combination	combination	NN	_	3	nmod
8	with	with	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	drug3	drug3	NN	_	9	appos
12	-RRB-	-rrb-	-RRB-	_	11	punct
13	,	,	,	_	17	punct
14	there	there	EX	_	17	expl
15	have	have	VBP	_	17	aux
16	been	be	VBN	_	17	cop
17	reports	report	NNS	_	0	ROOT
18	of	of	IN	_	17	dep
19	serious	serious	JJ	_	18	root
20	,	,	,	_	19	punct
21	sometimes	sometimes	RB	_	22	advmod
22	fatal	fatal	JJ	_	20	root
23	,	,	,	_	22	punct
24	reactions	reaction	NNS	_	23	root
25	including	include	VBG	_	26	case
26	hyperthermia	hyperthermia	NN	_	24	nmod
27	,	,	,	_	26	punct
28	rigidity	rigidity	NN	_	26	conj
29	,	,	,	_	26	punct
30	myoclonus	myoclonus	NN	_	26	conj
31	,	,	,	_	26	punct
32	autonomic	autonomic	JJ	_	33	amod
33	instability	instability	NN	_	26	conj
34	with	with	IN	_	37	case
35	possible	possible	JJ	_	37	amod
36	rapid	rapid	JJ	_	37	amod
37	fluctuations	fluctuation	NNS	_	33	nmod
38	of	of	IN	_	40	case
39	vital	vital	JJ	_	40	amod
40	signs	sign	NNS	_	37	nmod
41	,	,	,	_	26	punct
42	and	and	CC	_	26	cc
43	mental	mental	JJ	_	45	amod
44	status	status	NN	_	45	compound
45	changes	change	NNS	_	26	conj
46	that	that	WDT	_	47	nsubj
47	include	include	VBP	_	45	acl:relcl
48	extreme	extreme	JJ	_	49	amod
49	agitation	agitation	NN	_	47	dobj
50	progressing	progress	VBG	_	49	acl
51	to	to	TO	_	52	case
52	delirium	delirium	NN	_	50	nmod
53	and	and	CC	_	52	cc
54	coma	coma	NN	_	52	conj
55	.	.	.	_	24	punct

1	These	these	DT	_	2	det
2	reactions	reaction	NNS	_	6	nsubjpass
3	have	have	VBP	_	6	aux
4	also	also	RB	_	6	advmod
5	been	be	VBN	_	6	auxpass
6	reported	report	VBN	_	0	ROOT
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	who	who	WP	_	11	nsubj
10	have	have	VBP	_	11	aux
11	discontinued	discontinue	VBN	_	8	acl:relcl
12	that	that	IN	_	13	det
13	drug	drug	NN	_	11	dobj
14	and	and	CC	_	11	cc
15	have	have	VBP	_	17	aux
16	been	be	VBN	_	17	auxpass
17	started	start	VBN	_	11	conj
18	on	on	IN	_	20	case
19	a	a	DT	_	20	det
20	drug1	drug1	NN	_	17	nmod
21	.	.	.	_	6	punct

1	Some	some	DT	_	2	det
2	cases	case	NNS	_	0	ROOT
3	presented	present	VBN	_	2	acl
4	with	with	IN	_	6	mark
5	features	feature	NNS	_	6	nsubj
6	resembling	resemble	VBG	_	3	advcl
7	neuroleptic	neuroleptic	JJ	_	9	amod
8	malignant	malignant	JJ	_	9	amod
9	syndrome	syndrome	NN	_	6	dobj
10	.	.	.	_	2	punct

1	Therefore	therefore	RB	_	5	advmod
2	,	,	,	_	5	punct
3	it	it	PRP	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	recommended	recommend	VBN	_	0	ROOT
6	that	that	IN	_	11	mark
7	drug1	drug1	NN	_	8	compound
8	Tablets	tablet	NNS	_	11	nsubjpass
9	not	not	RB	_	11	neg
10	be	be	VB	_	11	auxpass
11	used	use	VBN	_	5	ccomp
12	in	in	IN	_	13	case
13	combination	combination	NN	_	11	nmod
14	with	with	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	,	,	,	_	15	punct
17	or	or	CC	_	15	cc
18	within	within	IN	_	20	case
19	14	14	CD	_	20	nummod
20	days	day	NNS	_	15	conj
21	of	of	IN	_	22	mark
22	discontinuing	discontinue	VBG	_	20	acl
23	treatment	treatment	NN	_	22	dobj
24	with	with	IN	_	26	case
25	a	a	DT	_	26	det
26	drug3	drug3	NN	_	23	nmod
27	.	.	.	_	5	punct

1	After	after	IN	_	2	mark
2	stopping	stop	VBG	_	12	advcl
3	drug1	drug1	NN	_	4	compound
4	Tablets	tablet	NNS	_	2	dobj
5	,	,	,	_	12	punct
6	at	at	IN	_	7	case
7	least	least	JJS	_	8	nmod:npmod
8	2	2	CD	_	9	nummod
9	weeks	week	NNS	_	12	nsubjpass
10	should	should	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	allowed	allow	VBN	_	0	ROOT
13	before	before	IN	_	14	mark
14	starting	start	VBG	_	12	advcl
15	a	a	DT	_	16	det
16	drug2	drug2	NN	_	14	dobj
17	.	.	.	_	12	punct

1	Potential	potential	JJ	_	2	amod
2	drug1	drug1	NN	_	0	ROOT
3	,	,	,	_	2	punct
4	drug2	drug2	NN	_	2	conj
5	,	,	,	_	2	punct
6	and	and	CC	_	2	cc
7	drug3	drug3	NN	_	8	compound
8	Interactions	interaction	NNS	_	2	conj

1	drug1	drug1	NN	_	8	nsubjpass
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	and	and	CC	_	1	cc
5	drug3	drug3	NN	_	1	conj
6	are	be	VBP	_	8	auxpass
7	all	all	DT	_	8	advmod
8	metabolized	metabolize	VBN	_	0	ROOT
9	by	by	IN	_	13	case
10	the	the	DT	_	13	det
11	cytochrome	cytochrome	NN	_	13	compound
12	P450IIIA4	p450iiia4	NN	_	13	compound
13	isozyme	isozyme	NN	_	8	nmod
14	,	,	,	_	8	punct
15	and	and	CC	_	8	cc
16	it	it	PRP	_	19	nsubjpass
17	has	have	VBZ	_	19	aux
18	been	be	VBN	_	19	auxpass
19	demonstrated	demonstrate	VBN	_	8	conj
20	that	that	IN	_	29	mark
21	drug4	drug4	NN	_	29	nsubj
22	,	,	,	_	21	punct
23	a	a	DT	_	25	det
24	potent	potent	JJ	_	25	amod
25	inhibitor	inhibitor	NN	_	21	appos
26	of	of	IN	_	27	case
27	IIIA4	iiia4	NN	_	25	nmod
28	,	,	,	_	21	punct
29	blocks	block	VBZ	_	19	ccomp
30	the	the	DT	_	31	det
31	metabolism	metabolism	NN	_	29	dobj
32	of	of	IN	_	34	case
33	these	these	DT	_	34	det
34	drugs	drug	NNS	_	31	nmod
35	,	,	,	_	29	punct
36	resulting	result	VBG	_	29	advcl
37	in	in	IN	_	40	case
38	increased	increase	VBN	_	40	amod
39	plasma	plasma	NN	_	40	compound
40	concentrations	concentration	NNS	_	36	nmod
41	of	of	IN	_	43	case
42	parent	parent	NN	_	43	compound
43	drug	drug	NN	_	40	nmod
44	.	.	.	_	8	punct

1	Increased	increase	VBN	_	3	amod
2	plasma	plasma	NN	_	3	compound
3	concentrations	concentration	NNS	_	11	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	,	,	,	_	5	punct
7	drug2	drug2	NN	_	5	conj
8	,	,	,	_	5	punct
9	and	and	CC	_	5	cc
10	drug3	drug3	NN	_	5	conj
11	cause	cause	VBP	_	0	ROOT
12	QT	QT	NNP	_	13	compound
13	prolongation	prolongation	NN	_	11	dobj
14	and	and	CC	_	11	cc
15	have	have	VBP	_	17	aux
16	been	be	VBN	_	17	auxpass
17	associated	associate	VBN	_	11	conj
18	with	with	IN	_	23	case
19	torsades	torsade	NNS	_	23	compound
20	de	de	IN	_	23	amod
21	pointes-type	pointes-type	JJ	_	23	amod
22	ventricular	ventricular	JJ	_	23	amod
23	tachycardia	tachycardia	NN	_	17	nmod
24	,	,	,	_	23	punct
25	sometimes	sometimes	RB	_	26	advmod
26	fatal	fatal	JJ	_	23	amod
27	.	.	.	_	11	punct

1	As	as	IN	_	2	mark
2	noted	note	VBN	_	0	ROOT
3	below	below	IN	_	2	advmod
4	,	,	,	_	2	punct
5	a	a	DT	_	6	det
6	sub	sub	NN	_	4	root
7	-	-	:	_	9	punct
8	for	for	IN	_	9	case
9	drug1	drug1	NN	_	6	nmod
10	in	in	IN	_	11	case
11	combination	combination	NN	_	9	nmod
12	with	with	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	,	,	,	_	13	punct
15	a	a	DT	_	16	det
16	drug	drug	NN	_	13	appos
17	that	that	WDT	_	19	nsubjpass
18	is	be	VBZ	_	19	auxpass
19	known	know	VBN	_	16	acl:relcl
20	to	to	TO	_	22	mark
21	be	be	VB	_	22	auxpass
22	metabolized	metabolize	VBN	_	19	xcomp
23	by	by	IN	_	26	case
24	the	the	DT	_	26	det
25	IIIA4	iiia4	NN	_	26	compound
26	isozyme	isozyme	NN	_	22	nmod
27	.	.	.	_	6	punct

1	Although	although	IN	_	7	mark
2	it	it	PRP	_	7	nsubjpass
3	has	have	VBZ	_	7	aux
4	not	not	RB	_	7	neg
5	been	be	VBN	_	7	auxpass
6	definitively	definitively	RB	_	7	advmod
7	demonstrated	demonstrate	VBN	_	18	advcl
8	that	that	IN	_	14	mark
9	drug1	drug1	NN	_	14	nsubj
10	is	be	VBZ	_	14	cop
11	a	a	DT	_	14	det
12	potent	potent	JJ	_	14	amod
13	IIIA4	iiia4	NN	_	14	compound
14	inhibitor	inhibitor	NN	_	7	ccomp
15	,	,	,	_	18	punct
16	it	it	PRP	_	18	nsubj
17	is	be	VBZ	_	18	cop
18	likely	likely	JJ	_	0	ROOT
19	to	to	TO	_	22	mark
20	be	be	VB	_	22	auxpass
21	,	,	,	_	22	punct
22	given	give	VBN	_	18	xcomp
23	the	the	DT	_	25	det
24	substantial	substantial	JJ	_	25	amod
25	interaction	interaction	NN	_	22	dobj
26	of	of	IN	_	27	case
27	drug2	drug2	NN	_	25	nmod
28	with	with	IN	_	29	case
29	drug3	drug3	NN	_	25	nmod
30	.	.	.	_	18	punct

1	Consequently	consequently	RB	_	5	advmod
2	,	,	,	_	5	punct
3	it	it	PRP	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	recommended	recommend	VBN	_	0	ROOT
6	that	that	IN	_	10	mark
7	drug1	drug1	NN	_	10	nsubjpass
8	not	not	RB	_	10	neg
9	be	be	VB	_	10	auxpass
10	used	use	VBN	_	5	ccomp
11	in	in	IN	_	12	case
12	combination	combination	NN	_	10	nmod
13	with	with	IN	_	15	case
14	either	either	CC	_	15	cc:preconj
15	drug2	drug2	NN	_	12	nmod
16	,	,	,	_	15	punct
17	drug3	drug3	NN	_	15	conj
18	,	,	,	_	15	punct
19	or	or	CC	_	15	cc
20	drug4	drug4	NN	_	15	conj
21	.	.	.	_	5	punct

1	Other	other	JJ	_	5	amod
2	Potentially	potentially	RB	_	3	advmod
3	Important	important	JJ	_	5	amod
4	Drug	drug	NN	_	5	compound
5	Interactions	interaction	NNS	_	0	ROOT
6	:	:	:	_	5	punct
7	drug1	drug1	NN	_	5	dep
8	:	:	:	_	7	punct
9	drug2	drug2	NN	_	27	nsubjpass
10	metabolized	metabolize	VBN	_	9	acl
11	by	by	IN	_	13	case
12	hepatic	hepatic	JJ	_	13	amod
13	oxidation	oxidation	NN	_	10	nmod
14	-LRB-	-lrb-	-LRB-	_	17	punct
15	e.g.	e.g.	FW	_	17	dep
16	,	,	,	_	17	punct
17	drug3	drug3	NN	_	13	dep
18	,	,	,	_	17	punct
19	drug4	drug4	NN	_	17	conj
20	,	,	,	_	17	punct
21	drug5	drug5	NN	_	22	compound
22	elc	elc	NN	_	17	conj
23	.	.	.	_	17	punct
24	-RRB-	-rrb-	-RRB-	_	17	punct
25	should	should	MD	_	27	aux
26	be	be	VB	_	27	auxpass
27	used	use	VBN	_	7	parataxis
28	with	with	IN	_	29	case
29	caution	caution	NN	_	27	nmod
30	because	because	IN	_	37	mark
31	the	the	DT	_	32	det
32	clearance	clearance	NN	_	37	nsubj
33	of	of	IN	_	35	case
34	these	these	DT	_	35	det
35	drugs	drug	NNS	_	32	nmod
36	is	be	VBZ	_	37	cop
37	likely	likely	JJ	_	27	advcl
38	to	to	TO	_	40	mark
39	be	be	VB	_	40	auxpass
40	reduced	reduce	VBN	_	37	xcomp
41	by	by	IN	_	42	case
42	drug6	drug6	NN	_	40	nmod
43	.	.	.	_	5	punct

1	The	the	DT	_	2	det
2	clearance	clearance	NN	_	19	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	metabolized	metabolize	VBN	_	4	acl
6	by	by	IN	_	7	case
7	glucuronidation	glucuronidation	NN	_	5	nmod
8	-LRB-	-lrb-	-LRB-	_	10	punct
9	e.	e.	FW	_	10	compound
10	g.	g.	FW	_	7	dep
11	,	,	,	_	10	punct
12	drug2	drug2	NN	_	10	conj
13	,	,	,	_	10	punct
14	drug3	drug3	NN	_	10	conj
15	,	,	,	_	10	punct
16	drug4	drug4	NN	_	10	appos
17	-RRB-	-rrb-	-RRB-	_	10	punct
18	is	be	VBZ	_	19	cop
19	unlikely	unlikely	JJ	_	0	ROOT
20	to	to	TO	_	22	mark
21	be	be	VB	_	22	auxpass
22	affected	affect	VBN	_	19	xcomp
23	by	by	IN	_	24	case
24	drug5	drug5	NN	_	22	nmod
25	.	.	.	_	19	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	When	when	WRB	_	17	advmod
4	drug2	drug2	NN	_	17	nsubjpass
5	-LRB-	-lrb-	-LRB-	_	8	punct
6	100	100	CD	_	7	compound
7	mg	mg	NN	_	8	nummod
8	qd	qd	NN	_	4	appos
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	and	and	CC	_	4	cc
11	drug3	drug3	NN	_	15	compound
12	-LRB-	-lrb-	-LRB-	_	15	punct
13	1	1	CD	_	15	nummod
14	mg	mg	NN	_	15	compound
15	q.d.	q.d.	NN	_	4	conj
16	were	be	VBD	_	17	auxpass
17	co-administered	co-administer	VBN	_	41	advcl
18	to	to	TO	_	20	case
19	steady	steady	JJ	_	20	amod
20	state	state	NN	_	17	nmod
21	,	,	,	_	41	punct
22	plasma	plasma	NN	_	23	compound
23	concentration	concentration	NN	_	41	nsubj
24	and	and	CC	_	23	cc
25	other	other	JJ	_	27	amod
26	pharmacokinetics	pharmacokinetic	NNS	_	27	compound
27	parameters	parameter	NNS	_	23	conj
28	-LRB-	-lrb-	-LRB-	_	29	punct
29	AUC	auc	NN	_	27	appos
30	,	,	,	_	29	punct
31	Cmax	cmax	NN	_	29	conj
32	,	,	,	_	29	punct
33	T1/2	t1/2	NN	_	29	conj
34	,	,	,	_	29	punct
35	-RRB-	-rrb-	-RRB-	_	29	punct
36	of	of	IN	_	37	case
37	drug4	drug4	NN	_	23	nmod
38	were	be	VBD	_	41	cop
39	approximately	approximately	RB	_	40	advmod
40	twice	twice	RB	_	41	advmod
41	those	those	DT	_	1	dep
42	observed	observe	VBN	_	41	acl
43	when	when	WRB	_	46	advmod
44	drug5	drug5	NN	_	46	nsubjpass
45	was	be	VBD	_	46	auxpass
46	administered	administer	VBN	_	42	advcl
47	alone	alone	RB	_	46	advmod
48	;	;	:	_	1	punct

1	oral	oral	JJ	_	2	amod
2	clearance	clearance	NN	_	4	nsubjpass
3	was	be	VBD	_	4	auxpass
4	reduced	reduce	VBN	_	0	ROOT
5	by	by	IN	_	8	case
6	about	about	IN	_	7	advmod
7	50	50	CD	_	8	nummod
8	%	%	NN	_	4	nmod
9	.	.	.	_	4	punct

1	The	the	DT	_	5	det
2	elevated	elevated	JJ	_	5	amod
3	plasma	plasma	NN	_	5	compound
4	drug1	drug1	NN	_	5	compound
5	concentrations	concentration	NNS	_	6	nsubj
6	resulted	result	VBD	_	0	ROOT
7	in	in	IN	_	10	case
8	decreased	decrease	VBN	_	10	amod
9	psychomotor	psychomotor	NN	_	10	compound
10	performance	performance	NN	_	6	nmod
11	and	and	CC	_	10	cc
12	memory	memory	NN	_	10	conj
13	.	.	.	_	6	punct

1	This	this	DT	_	2	det
2	interaction	interaction	NN	_	18	nsubj
3	,	,	,	_	2	punct
4	which	which	WDT	_	8	nsubjpass
5	has	have	VBZ	_	8	aux
6	not	not	RB	_	8	neg
7	been	be	VBN	_	8	auxpass
8	investigated	investigate	VBN	_	2	acl:relcl
9	using	use	VBG	_	8	xcomp
10	higher	higher	JJR	_	11	amod
11	doses	dose	NNS	_	9	dobj
12	of	of	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	,	,	,	_	2	punct
15	may	may	MD	_	18	aux
16	be	be	VB	_	18	cop
17	more	more	RBR	_	18	advmod
18	pronounced	pronounced	JJ	_	0	ROOT
19	if	if	IN	_	26	mark
20	a	a	DT	_	24	det
21	300	300	CD	_	24	nummod
22	mg	mg	NN	_	24	compound
23	daily	daily	JJ	_	24	amod
24	dose	dose	NN	_	26	nsubj
25	is	be	VBZ	_	26	cop
26	co-administered	co-administered	JJ	_	18	advcl
27	,	,	,	_	26	punct
28	particularly	particularly	RB	_	31	advmod
29	since	since	IN	_	31	mark
30	drug2	drug2	NN	_	31	nsubj
31	exhibits	exhibit	VBZ	_	26	advcl
32	non-linear	non-linear	JJ	_	33	amod
33	pharmacokinetics	pharmacokinetic	NNS	_	31	dobj
34	over	over	IN	_	37	case
35	the	the	DT	_	37	det
36	dosage	dosage	NN	_	37	compound
37	range	range	NN	_	33	nmod
38	100-300	100-300	CD	_	39	nummod
39	mg	mg	NN	_	37	dep
40	.	.	.	_	18	punct
41	If	if	IN	_	44	mark
42	drug3	drug3	NN	_	44	nsubjpass
43	is	be	VBZ	_	44	auxpass
44	co-administered	co-administer	VBN	_	57	advcl
45	with	with	IN	_	47	case
46	drug4	drug4	NN	_	47	compound
47	Tablets	tablet	NNS	_	44	nmod
48	,	,	,	_	57	punct
49	the	the	DT	_	52	det
50	initial	initial	JJ	_	52	amod
51	drug5	drug5	NN	_	52	compound
52	dosage	dosage	NN	_	57	nsubj
53	should	should	MD	_	57	aux
54	be	be	VB	_	57	cop
55	at	at	IN	_	56	case
56	least	least	JJS	_	57	nmod:npmod
57	halved	halved	JJ	_	18	parataxis
58	and	and	CC	_	57	cc
59	titration	titration	NN	_	66	nsubjpass
60	to	to	TO	_	64	case
61	the	the	DT	_	64	det
62	lowest	lowest	JJS	_	64	amod
63	effective	effective	JJ	_	64	amod
64	dose	dose	NN	_	59	nmod
65	is	be	VBZ	_	66	auxpass
66	recommended	recommend	VBN	_	57	conj
67	.	.	.	_	18	punct

1	No	no	DT	_	3	neg
2	dosage	dosage	NN	_	3	compound
3	adjustment	adjustment	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	required	require	VBN	_	0	ROOT
6	for	for	IN	_	8	case
7	drug1	drug1	NN	_	8	compound
8	Tablets	tablet	NNS	_	5	nmod
9	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	co-administration	co-administration	NN	_	13	nsubj
5	of	of	IN	_	7	case
6	drug2	drug2	NN	_	7	compound
7	Tablets	tablet	NNS	_	4	nmod
8	and	and	CC	_	7	cc
9	drug3	drug3	NN	_	7	conj
10	is	be	VBZ	_	13	cop
11	generally	generally	RB	_	13	advmod
12	not	not	RB	_	13	neg
13	advisable	advisable	JJ	_	1	dep
14	.	.	.	_	1	punct

1	Because	because	IN	_	3	mark
2	drug1	drug1	NN	_	3	nsubj
3	reduces	reduce	VBZ	_	17	advcl
4	the	the	DT	_	5	det
5	clearance	clearance	NN	_	3	dobj
6	of	of	IN	_	8	case
7	both	both	CC	_	8	cc:preconj
8	drug2	drug2	NN	_	5	nmod
9	and	and	CC	_	8	cc
10	its	its	PRP$	_	12	nmod:poss
11	active	active	JJ	_	12	amod
12	metabolite	metabolite	NN	_	8	conj
13	,	,	,	_	12	punct
14	drug3	drug3	NN	_	12	appos
15	,	,	,	_	12	punct
16	there	there	EX	_	17	expl
17	is	be	VBZ	_	0	ROOT
18	a	a	DT	_	20	det
19	strong	strong	JJ	_	20	amod
20	likelihood	likelihood	NN	_	17	nsubj
21	of	of	IN	_	23	case
22	substantial	substantial	JJ	_	23	amod
23	accumulation	accumulation	NN	_	20	nmod
24	of	of	IN	_	26	case
25	both	both	DT	_	26	det
26	species	species	NNS	_	23	nmod
27	during	during	IN	_	29	case
28	chronic	chronic	JJ	_	29	amod
29	co-administration	co-administration	NN	_	20	nmod
30	.	.	.	_	17	punct

1	Evidence	evidence	NN	_	15	nsubjpass
2	supporting	support	VBG	_	1	acl
3	the	the	DT	_	4	det
4	conclusion	conclusion	NN	_	2	dobj
5	that	that	IN	_	8	mark
6	it	it	PRP	_	8	nsubj
7	is	be	VBZ	_	8	cop
8	inadvisable	inadvisable	JJ	_	4	ccomp
9	to	to	TO	_	11	case
10	co-administer	co-administer	NN	_	11	compound
11	drug1	drug1	NN	_	8	nmod
12	and	and	CC	_	11	cc
13	drug2	drug2	NN	_	11	conj
14	is	be	VBZ	_	15	auxpass
15	derived	derive	VBN	_	0	ROOT
16	from	from	IN	_	18	case
17	a	a	DT	_	18	det
18	study	study	NN	_	15	nmod
19	in	in	IN	_	20	case
20	which	which	WDT	_	29	nmod
21	healthy	healthy	JJ	_	22	amod
22	volunteers	volunteer	NNS	_	29	nsubjpass
23	taking	take	VBG	_	22	acl
24	150	150	CD	_	25	nummod
25	mg/day	mg/day	NN	_	23	dobj
26	of	of	IN	_	27	case
27	drug3	drug3	NN	_	25	nmod
28	were	be	VBD	_	29	auxpass
29	administered	administer	VBN	_	18	acl:relcl
30	a	a	DT	_	33	det
31	single	single	JJ	_	33	amod
32	oral	oral	JJ	_	33	amod
33	dose	dose	NN	_	29	dobj
34	of	of	IN	_	36	case
35	10	10	CD	_	36	nummod
36	mg	mg	NN	_	33	nmod
37	of	of	IN	_	38	case
38	drug4	drug4	NN	_	36	nmod
39	.	.	.	_	15	punct

1	In	in	IN	_	3	case
2	these	these	DT	_	3	det
3	subjects	subject	NNS	_	15	nmod
4	-LRB-	-lrb-	-LRB-	_	15	punct
5	R	r	NN	_	15	nsubjpass
6	=	=	JJ	_	5	amod
7	B	b	NN	_	6	dep
8	-RRB-	-rrb-	-RRB-	_	15	punct
9	,	,	,	_	15	punct
10	the	the	DT	_	11	det
11	clearance	clearance	NN	_	15	nsubjpass
12	of	of	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	was	be	VBD	_	15	auxpass
15	reduced	reduce	VBN	_	0	ROOT
16	by	by	IN	_	18	case
17	65	65	CD	_	18	nummod
18	%	%	NN	_	15	nmod
19	and	and	CC	_	15	cc
20	that	that	IN	_	15	conj
21	of	of	IN	_	22	case
22	drug2	drug2	NN	_	20	nmod
23	to	to	TO	_	25	case
24	a	a	DT	_	25	det
25	level	level	NN	_	22	nmod
26	that	that	WDT	_	29	nsubj
27	was	be	VBD	_	29	cop
28	too	too	RB	_	29	advmod
29	low	low	JJ	_	25	acl:relcl
30	to	to	TO	_	31	mark
31	measure	measure	VB	_	29	xcomp
32	over	over	IN	_	34	case
33	the	the	DT	_	34	det
34	course	course	NN	_	31	nmod
35	of	of	IN	_	38	case
36	the	the	DT	_	38	det
37	2	2	CD	_	38	nummod
38	week	week	NN	_	34	nmod
39	long	long	JJ	_	40	amod
40	study	study	NN	_	38	dep
41	.	.	.	_	15	punct

1	It	it	PRP	_	3	nsubj
2	is	be	VBZ	_	3	cop
3	likely	likely	JJ	_	0	ROOT
4	that	that	IN	_	7	mark
5	experience	experience	NN	_	7	nsubj
6	significantly	significantly	RB	_	7	advmod
7	underestimates	underestimate	VBZ	_	3	ccomp
8	the	the	DT	_	9	det
9	degree	degree	NN	_	7	dobj
10	of	of	IN	_	11	case
11	accumulation	accumulation	NN	_	9	nmod
12	that	that	WDT	_	14	nsubj
13	might	might	MD	_	14	aux
14	occur	occur	VB	_	11	acl:relcl
15	with	with	IN	_	18	case
16	repealed	repeal	VBN	_	18	amod
17	drug1	drug1	NN	_	18	compound
18	administration	administration	NN	_	14	nmod
19	.	.	.	_	3	punct

1	Moreover	moreover	RB	_	16	advmod
2	,	,	,	_	16	punct
3	as	as	IN	_	4	mark
4	noted	note	VBN	_	16	advcl
5	with	with	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	,	,	,	_	16	punct
8	the	the	DT	_	9	det
9	effect	effect	NN	_	16	nsubj
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	may	may	MD	_	16	aux
13	even	even	RB	_	16	advmod
14	be	be	VB	_	16	cop
15	more	more	RBR	_	16	advmod
16	pronounced	pronounced	JJ	_	0	ROOT
17	when	when	WRB	_	20	advmod
18	it	it	PRP	_	20	nsubjpass
19	is	be	VBZ	_	20	auxpass
20	administered	administer	VBN	_	16	advcl
21	at	at	IN	_	23	case
22	higher	higher	JJR	_	23	amod
23	doses	dose	NNS	_	20	nmod
24	.	.	.	_	16	punct

1	Accordingly	accordingly	RB	_	10	advmod
2	,	,	,	_	10	punct
3	drug1	drug1	NN	_	10	nsubjpass
4	and	and	CC	_	3	cc
5	drug2	drug2	NN	_	3	conj
6	should	should	MD	_	10	aux
7	not	not	RB	_	10	neg
8	ordinarily	ordinarily	RB	_	10	advmod
9	be	be	VB	_	10	auxpass
10	co-administered	co-administer	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	effect	effect	NN	_	29	nsubjpass
5	of	of	IN	_	10	case
6	steady-state	steady-state	JJ	_	10	amod
7	drug2	drug2	NN	_	10	compound
8	l50	l50	NN	_	10	compound
9	mg	mg	NN	_	10	compound
10	bid	bid	NN	_	4	nmod
11	on	on	IN	_	13	case
12	the	the	DT	_	13	det
13	pharmacokinetics	pharmacokinetic	NNS	_	10	nmod
14	of	of	IN	_	17	case
15	a	a	DT	_	17	det
16	single	single	JJ	_	17	amod
17	dose	dose	NN	_	13	nmod
18	of	of	IN	_	19	case
19	drug3	drug3	NN	_	17	nmod
20	-LRB-	-lrb-	-LRB-	_	22	punct
21	375	375	CD	_	22	nummod
22	mg	mg	NN	_	17	appos
23	-RRB-	-rrb-	-RRB-	_	22	punct
24	as	as	IN	_	27	case
25	442	442	CD	_	26	compound
26	mg	mg	NN	_	27	amod
27	drug4	drug4	NN	_	4	nmod
28	was	be	VBD	_	29	auxpass
29	evaluated	evaluate	VBN	_	1	appos
30	in	in	IN	_	36	case
31	12	12	CD	_	36	nummod
32	healthy	healthy	JJ	_	36	amod
33	non-smoking	non-smoking	JJ	_	36	amod
34	,	,	,	_	36	punct
35	male	male	JJ	_	36	amod
36	volunteers	volunteer	NNS	_	29	nmod
37	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	clearance	clearance	NN	_	6	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	was	be	VBD	_	6	auxpass
6	decreased	decrease	VBN	_	0	ROOT
7	approximately	approximately	RB	_	8	advmod
8	3-fold	3-fold	RB	_	6	advmod
9	.	.	.	_	6	punct

1	Therefore	therefore	RB	_	14	advmod
2	,	,	,	_	14	punct
3	if	if	IN	_	6	mark
4	drug1	drug1	NN	_	6	nsubjpass
5	is	be	VBZ	_	6	auxpass
6	co-administered	co-administer	VBN	_	14	advcl
7	with	with	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	,	,	,	_	14	punct
10	its	its	PRP$	_	11	nmod:poss
11	dose	dose	NN	_	14	nsubjpass
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	reduced	reduce	VBN	_	0	ROOT
15	to	to	TO	_	17	case
16	one	one	CD	_	17	nummod
17	third	third	NN	_	14	nmod
18	of	of	IN	_	23	case
19	the	the	DT	_	23	det
20	usual	usual	JJ	_	23	amod
21	daily	daily	JJ	_	23	amod
22	maintenance	maintenance	NN	_	23	compound
23	dose	dose	NN	_	17	nmod
24	and	and	CC	_	17	cc
25	plasma	plasma	NN	_	26	compound
26	concentrations	concentration	NNS	_	17	conj
27	of	of	IN	_	28	case
28	drug3	drug3	NN	_	26	nmod
29	should	should	MD	_	31	aux
30	to	to	TO	_	31	mark
31	monitored	monitor	VBN	_	14	advcl
32	.	.	.	_	14	punct

1	No	no	DT	_	3	neg
2	dosage	dosage	NN	_	3	compound
3	adjustment	adjustment	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	required	require	VBN	_	0	ROOT
6	for	for	IN	_	8	case
7	drug1	drug1	NN	_	8	compound
8	Tablets	tablet	NNS	_	5	nmod
9	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	When	when	WRB	_	11	advmod
4	drug2	drug2	NN	_	11	nsubjpass
5	-LRB-	-lrb-	-LRB-	_	8	punct
6	50	50	CD	_	8	nummod
7	mg	mg	NN	_	8	compound
8	tid	tid	NN	_	4	appos
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	was	be	VBD	_	11	auxpass
11	administered	administer	VBN	_	22	advcl
12	concomitantly	concomitantly	RB	_	11	advmod
13	with	with	IN	_	14	case
14	drug3	drug3	NN	_	11	nmod
15	for	for	IN	_	17	case
16	two	two	CD	_	17	nummod
17	weeks	week	NNS	_	11	nmod
18	,	,	,	_	22	punct
19	drug4	drug4	NN	_	21	compound
20	plasma	plasma	NN	_	21	compound
21	concentrations	concentration	NNS	_	22	nsubj
22	increased	increase	VBN	_	1	dep
23	by	by	IN	_	25	case
24	98	98	CD	_	25	nummod
25	%	%	NN	_	22	nmod
26	and	and	CC	_	22	cc
27	prothrombin	prothrombin	NN	_	28	compound
28	times	time	NNS	_	30	nsubjpass
29	were	be	VBD	_	30	auxpass
30	prolonged	prolong	VBN	_	22	conj
31	.	.	.	_	1	punct

1	Thus	thus	RB	_	10	advmod
2	patients	patient	NNS	_	10	nsubj
3	receiving	receive	VBG	_	2	acl
4	oral	oral	JJ	_	5	amod
5	drug1	drug1	NN	_	3	dobj
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	8	compound
8	Tablets	tablet	NNS	_	5	conj
9	should	should	MD	_	10	aux
10	have	have	VB	_	0	ROOT
11	their	they	PRP$	_	13	nmod:poss
12	prothrombin	prothrombin	NN	_	13	compound
13	time	time	NN	_	14	nsubj
14	monitored	monitor	VBD	_	10	ccomp
15	and	and	CC	_	14	cc
16	their	they	PRP$	_	18	nmod:poss
17	drug3	drug3	NN	_	18	compound
18	dose	dose	NN	_	19	nsubj
19	adjusted	adjust	VBN	_	14	conj
20	accordingly	accordingly	RB	_	19	advmod
21	.	.	.	_	10	punct

1	No	no	DT	_	3	neg
2	dosage	dosage	NN	_	3	compound
3	adjustment	adjustment	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	required	require	VBN	_	0	ROOT
6	for	for	IN	_	8	case
7	drug1	drug1	NN	_	8	compound
8	Tablets	tablet	NNS	_	5	nmod
9	.	.	.	_	5	punct

1	In	in	IN	_	4	case
2	occasional	occasional	JJ	_	4	amod
3	susceptible	susceptible	JJ	_	4	amod
4	patients	patient	NNS	_	22	nmod
5	or	or	CC	_	4	cc
6	in	in	IN	_	7	case
7	those	those	DT	_	4	conj
8	receiving	receive	VBG	_	7	acl
9	drug1	drug1	NN	_	8	dobj
10	-LRB-	-lrb-	-LRB-	_	13	punct
11	including	include	VBG	_	13	case
12	antiparkinsonism	antiparkinsonism	JJ	_	13	amod
13	agents	agent	NNS	_	9	nmod
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	in	in	IN	_	16	case
16	addition	addition	NN	_	8	nmod
17	,	,	,	_	22	punct
18	the	the	DT	_	20	det
19	atropine-like	atropine-like	JJ	_	20	amod
20	effects	effect	NNS	_	22	nsubj
21	may	may	MD	_	22	aux
22	become	become	VB	_	0	ROOT
23	more	more	RBR	_	24	advmod
24	pronounced	pronounced	JJ	_	22	xcomp
25	-LRB-	-lrb-	-LRB-	_	29	punct
26	e.g.	e.g.	FW	_	29	dep
27	,	,	,	_	29	punct
28	paralytic	paralytic	JJ	_	29	amod
29	ileus	ileus	NN	_	22	dep
30	-RRB-	-rrb-	-RRB-	_	29	punct
31	.	.	.	_	22	punct

1	Close	close	JJ	_	2	amod
2	supervision	supervision	NN	_	9	nsubjpass
3	and	and	CC	_	2	cc
4	careful	careful	JJ	_	5	amod
5	adjustment	adjustment	NN	_	2	conj
6	of	of	IN	_	7	case
7	dosage	dosage	NN	_	2	nmod
8	is	be	VBZ	_	9	auxpass
9	required	require	VBN	_	0	ROOT
10	when	when	WRB	_	14	advmod
11	this	this	DT	_	12	det
12	drug	drug	NN	_	14	nsubjpass
13	is	be	VBZ	_	14	auxpass
14	administered	administer	VBN	_	9	advcl
15	concomitantly	concomitantly	RB	_	14	advmod
16	with	with	IN	_	17	case
17	drug1	drug1	NN	_	14	nmod
18	.	.	.	_	9	punct

1	Avoid	avoid	VB	_	0	ROOT
2	the	the	DT	_	3	det
3	use	use	NN	_	1	dobj
4	of	of	IN	_	5	case
5	preparations	preparation	NNS	_	3	nmod
6	such	such	JJ	_	8	case
7	as	as	IN	_	6	mwe
8	drug1	drug1	NN	_	5	nmod
9	and	and	CC	_	8	cc
10	local	local	JJ	_	11	amod
11	drug2	drug2	NN	_	8	conj
12	which	which	WDT	_	13	nsubj
13	contain	contain	VBP	_	5	acl:relcl
14	any	any	DT	_	15	det
15	drug3	drug3	NN	_	13	dobj
16	-LRB-	-lrb-	-LRB-	_	19	punct
17	e.g.	e.g.	FW	_	19	dep
18	,	,	,	_	19	punct
19	drug4	drug4	NN	_	15	dep
20	,	,	,	_	19	punct
21	drug5	drug5	NN	_	19	appos
22	-RRB-	-rrb-	-RRB-	_	19	punct
23	,	,	,	_	1	punct
24	since	since	IN	_	28	mark
25	it	it	PRP	_	28	nsubjpass
26	has	have	VBZ	_	28	aux
27	been	be	VBN	_	28	auxpass
28	reported	report	VBN	_	1	advcl
29	that	that	IN	_	32	mark
30	drug6	drug6	NN	_	32	nsubj
31	can	can	MD	_	32	aux
32	potentiate	potentiate	VB	_	28	ccomp
33	the	the	DT	_	34	det
34	effects	effect	NNS	_	32	dobj
35	of	of	IN	_	36	case
36	catecholamines	catecholamine	NNS	_	34	nmod
37	.	.	.	_	1	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	exercised	exercise	VBN	_	0	ROOT
5	when	when	WRB	_	8	advmod
6	drug1	drug1	NN	_	8	nsubjpass
7	is	be	VBZ	_	8	auxpass
8	used	use	VBN	_	4	advcl
9	with	with	IN	_	10	case
10	agents	agent	NNS	_	8	nmod
11	that	that	WDT	_	14	det
12	lower	lower	JJR	_	14	amod
13	blood	blood	NN	_	14	compound
14	pressure	pressure	NN	_	10	dep
15	.	.	.	_	4	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	potentiate	potentiate	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	effects	effect	NNS	_	3	dobj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	.	.	.	_	3	punct

1	The	the	DT	_	3	det
2	plasma	plasma	NN	_	3	compound
3	concentration	concentration	NN	_	7	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	may	may	MD	_	7	aux
7	increase	increase	VB	_	0	ROOT
8	when	when	WRB	_	12	advmod
9	the	the	DT	_	10	det
10	drug	drug	NN	_	12	nsubjpass
11	is	be	VBZ	_	12	auxpass
12	given	give	VBN	_	7	advcl
13	concomitantly	concomitantly	RB	_	17	advmod
14	with	with	IN	_	17	case
15	hepatic	hepatic	JJ	_	17	amod
16	enzyme	enzyme	NN	_	17	compound
17	inhibitors	inhibitor	NNS	_	12	nmod
18	-LRB-	-lrb-	-LRB-	_	21	punct
19	e.g.	e.g.	FW	_	21	dep
20	,	,	,	_	21	punct
21	drug2	drug2	NN	_	17	dep
22	,	,	,	_	21	punct
23	drug3	drug3	NN	_	21	appos
24	-RRB-	-rrb-	-RRB-	_	21	punct
25	and	and	CC	_	17	cc
26	decrease	decrease	NN	_	17	conj
27	by	by	IN	_	29	case
28	concomitant	concomitant	JJ	_	29	amod
29	administration	administration	NN	_	26	nmod
30	of	of	IN	_	33	case
31	hepatic	hepatic	JJ	_	33	amod
32	enzyme	enzyme	NN	_	33	compound
33	inducers	inducer	NNS	_	29	nmod
34	-LRB-	-lrb-	-LRB-	_	37	punct
35	e.g.	e.g.	FW	_	37	dep
36	,	,	,	_	37	punct
37	drug4	drug4	NN	_	26	dep
38	,	,	,	_	37	punct
39	drug5	drug5	NN	_	37	appos
40	-RRB-	-rrb-	-RRB-	_	37	punct
41	,	,	,	_	7	punct
42	and	and	CC	_	7	cc
43	adjustment	adjustment	NN	_	52	nsubj
44	of	of	IN	_	46	case
45	the	the	DT	_	46	det
46	dosage	dosage	NN	_	43	nmod
47	of	of	IN	_	48	case
48	drug6	drug6	NN	_	46	nmod
49	may	may	MD	_	52	aux
50	therefore	therefore	RB	_	52	advmod
51	be	be	VB	_	52	cop
52	necessary	necessary	JJ	_	7	conj
53	.	.	.	_	7	punct

1	Drugs	drug	NNS	_	22	nsubjpass
2	Metabolized	metabolize	VBN	_	1	acl
3	by	by	IN	_	5	case
4	P450	p450	NN	_	5	compound
5	2D6	2d6	NN	_	2	nmod
6	The	the	DT	_	8	det
7	biochemical	biochemical	JJ	_	8	amod
8	activity	activity	NN	_	2	dobj
9	of	of	IN	_	11	case
10	the	the	DT	_	11	det
11	drug	drug	NN	_	8	nmod
12	metabolizing	metabolize	VBG	_	11	acl
13	isozyme	isozyme	NN	_	16	compound
14	cytochrome	cytochrome	NN	_	16	compound
15	P450	p450	NN	_	16	compound
16	2D6	2d6	NN	_	12	dobj
17	-LRB-	-lrb-	-LRB-	_	19	punct
18	debrisoquin	debrisoquin	NN	_	19	compound
19	hydroxylase	hydroxylase	NN	_	16	appos
20	-RRB-	-rrb-	-RRB-	_	19	punct
21	is	be	VBZ	_	22	auxpass
22	reduced	reduce	VBN	_	0	ROOT
23	in	in	IN	_	25	case
24	a	a	DT	_	25	det
25	subset	subset	NN	_	22	nmod
26	of	of	IN	_	29	case
27	the	the	DT	_	29	det
28	caucasian	caucasian	JJ	_	29	amod
29	population	population	NN	_	25	nmod
30	-LRB-	-lrb-	-LRB-	_	40	punct
31	about	about	IN	_	34	advmod
32	7	7	CD	_	34	compound
33	to	to	TO	_	34	dep
34	10	10	CD	_	35	nummod
35	%	%	NN	_	40	nsubjpass
36	of	of	IN	_	37	case
37	caucasians	caucasian	NNS	_	35	nmod
38	are	be	VBP	_	40	auxpass
39	so	so	RB	_	40	advmod
40	called	call	VBN	_	25	dep
41	poor	poor	JJ	_	42	amod
42	metabolizers	metabolizer	NNS	_	40	xcomp
43	-RRB-	-rrb-	-RRB-	_	40	punct
44	;	;	:	_	22	punct

1	reliable	reliable	JJ	_	2	amod
2	estimates	estimate	NNS	_	22	nsubj
3	of	of	IN	_	5	case
4	the	the	DT	_	5	det
5	prevalence	prevalence	NN	_	2	nmod
6	of	of	IN	_	11	case
7	reduced	reduce	VBN	_	11	amod
8	P450	p450	NN	_	11	compound
9	2D6	2d6	NN	_	11	compound
10	isozyme	isozyme	NN	_	11	compound
11	activity	activity	NN	_	5	nmod
12	among	among	IN	_	18	case
13	Asian	asian	JJ	_	18	amod
14	,	,	,	_	13	punct
15	African	african	JJ	_	13	conj
16	and	and	CC	_	13	cc
17	other	other	JJ	_	13	conj
18	populations	population	NNS	_	11	nmod
19	are	be	VBP	_	22	cop
20	not	not	RB	_	22	neg
21	yet	yet	RB	_	22	advmod
22	available	available	JJ	_	0	ROOT
23	.	.	.	_	22	punct

1	Poor	Poor	NNP	_	2	compound
2	metabolizers	metabolizer	NNS	_	3	nsubj
3	have	have	VBP	_	0	ROOT
4	higher	higher	JJR	_	8	amod
5	than	than	IN	_	6	dep
6	expected	expect	VBN	_	8	amod
7	plasma	plasma	NN	_	8	compound
8	concentrations	concentration	NNS	_	3	dobj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	drug2	drug2	NN	_	10	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	when	when	WRB	_	15	advmod
15	given	give	VBN	_	3	advcl
16	usual	usual	JJ	_	17	amod
17	doses	dose	NNS	_	15	dobj
18	.	.	.	_	3	punct

1	Depending	depend	VBG	_	4	case
2	on	on	IN	_	4	case
3	the	the	DT	_	4	det
4	fraction	fraction	NN	_	19	nmod
5	of	of	IN	_	6	case
6	drug	drug	NN	_	4	nmod
7	metabolized	metabolize	VBN	_	6	acl
8	by	by	IN	_	10	case
9	P450	p450	NN	_	10	compound
10	2D6	2d6	NN	_	7	nmod
11	,	,	,	_	19	punct
12	the	the	DT	_	13	det
13	increase	increase	NN	_	19	nsubj
14	in	in	IN	_	16	case
15	plasma	plasma	NN	_	16	compound
16	concentration	concentration	NN	_	13	nmod
17	may	may	MD	_	19	aux
18	be	be	VB	_	19	cop
19	small	small	JJ	_	0	ROOT
20	,	,	,	_	19	punct
21	or	or	CC	_	19	cc
22	quite	quite	RB	_	23	advmod
23	large	large	JJ	_	26	amod
24	-LRB-	-lrb-	-LRB-	_	26	punct
25	8-fold	8-fold	JJ	_	26	amod
26	increase	increase	NN	_	19	conj
27	in	in	IN	_	29	case
28	plasma	plasma	NN	_	29	compound
29	AUC	auc	NN	_	26	nmod
30	of	of	IN	_	32	case
31	the	the	DT	_	32	det
32	drug1	drug1	NN	_	29	nmod
33	-RRB-	-rrb-	-RRB-	_	19	punct
34	.	.	.	_	19	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	6	nmod
3	,	,	,	_	6	punct
4	certain	certain	JJ	_	5	amod
5	drugs	drug	NNS	_	6	nsubj
6	inhibit	inhibit	VBP	_	0	ROOT
7	the	the	DT	_	8	det
8	activity	activity	NN	_	6	dobj
9	of	of	IN	_	11	case
10	this	this	DT	_	11	det
11	isozyme	isozyme	NN	_	8	nmod
12	and	and	CC	_	6	cc
13	make	make	VB	_	6	conj
14	normal	normal	JJ	_	15	amod
15	metabolizers	metabolizer	NNS	_	16	nsubj
16	resemble	resemble	VBP	_	13	ccomp
17	p.o.	p.o.	NN	_	16	xcomp

1	metabolizers	metabolizer	NNS	_	0	ROOT
2	.	.	.	_	1	punct

1	An	a	DT	_	2	det
2	individual	individual	NN	_	13	nsubj
3	who	who	WP	_	5	nsubj
4	is	be	VBZ	_	5	cop
5	stable	stable	JJ	_	2	acl:relcl
6	on	on	IN	_	9	case
7	a	a	DT	_	9	det
8	given	give	VBN	_	9	amod
9	dose	dose	NN	_	5	nmod
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	may	may	MD	_	13	aux
13	become	become	VB	_	0	ROOT
14	abruptly	abruptly	RB	_	15	advmod
15	toxic	toxic	JJ	_	13	xcomp
16	when	when	WRB	_	17	advmod
17	given	give	VBN	_	13	advcl
18	one	one	CD	_	17	dobj
19	of	of	IN	_	22	case
20	these	these	DT	_	22	det
21	inhibiting	inhibit	VBG	_	22	amod
22	drugs	drug	NNS	_	18	nmod
23	as	as	IN	_	25	case
24	concomitant	concomitant	JJ	_	25	amod
25	therapy	therapy	NN	_	17	nmod
26	.	.	.	_	13	punct

1	The	the	DT	_	2	det
2	drugs	drug	NNS	_	8	nsubj
3	that	that	WDT	_	4	nsubj
4	inhibit	inhibit	VBP	_	2	acl:relcl
5	cytochrome	cytochrome	NN	_	7	compound
6	P450	p450	NN	_	7	compound
7	2D6	2d6	NN	_	4	dobj
8	include	include	VBP	_	0	ROOT
9	some	some	DT	_	8	dobj
10	that	that	WDT	_	13	nsubjpass
11	are	be	VBP	_	13	auxpass
12	not	not	RB	_	13	neg
13	metabolized	metabolize	VBN	_	9	acl:relcl
14	by	by	IN	_	16	case
15	the	the	DT	_	16	det
16	enzyme	enzyme	NN	_	13	nmod
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	drug1	drug1	NN	_	16	appos
19	;	;	:	_	18	punct

1	drug1	drug1	NN	_	0	ROOT
2	-RRB-	-rrb-	-RRB-	_	1	punct
3	and	and	CC	_	1	cc
4	many	many	JJ	_	1	conj
5	that	that	WDT	_	7	nsubj
6	are	be	VBP	_	7	cop
7	substrates	substrate	NNS	_	4	acl:relcl
8	for	for	IN	_	10	case
9	P450	p450	NN	_	10	compound
10	2D6	2d6	NN	_	7	nmod
11	-LRB-	-lrb-	-LRB-	_	14	punct
12	many	many	JJ	_	14	amod
13	other	other	JJ	_	14	amod
14	drug2	drug2	NN	_	1	dep
15	,	,	,	_	14	punct
16	drug3	drug3	NN	_	14	conj
17	,	,	,	_	14	punct
18	and	and	CC	_	14	cc
19	the	the	DT	_	21	det
20	drug4	drug4	NN	_	21	compound
21	drug5	drug5	NN	_	14	conj
22	and	and	CC	_	21	cc
23	drug6	drug6	NN	_	21	conj
24	-RRB-	-rrb-	-RRB-	_	14	punct
25	.	.	.	_	1	punct

1	While	while	IN	_	19	mark
2	all	all	PDT	_	19	dep
3	the	the	DT	_	19	dep
4	drug1	drug1	NN	_	19	dep
5	-LRB-	-lrb-	-LRB-	_	6	punct
6	drug2	drug2	NN	_	4	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	,	,	,	_	4	punct
9	e.	e.	FW	_	10	compound
10	g.	g.	FW	_	4	dep
11	,	,	,	_	4	punct
12	drug3	drug3	NN	_	4	conj
13	,	,	,	_	4	punct
14	drug4	drug4	NN	_	4	conj
15	,	,	,	_	4	punct
16	and	and	CC	_	4	cc
17	drug5	drug5	NN	_	4	conj
18	,	,	,	_	4	punct
19	inhibit	inhibit	VBP	_	25	advcl
20	P450	p450	NN	_	21	compound
21	2D6	2d6	NN	_	19	dobj
22	,	,	,	_	25	punct
23	they	they	PRP	_	25	nsubj
24	may	may	MD	_	25	aux
25	vary	vary	VB	_	0	ROOT
26	in	in	IN	_	28	case
27	the	the	DT	_	28	det
28	extent	extent	NN	_	25	nmod
29	of	of	IN	_	30	case
30	inhibition	inhibition	NN	_	28	nmod
31	.	.	.	_	25	punct

1	The	the	DT	_	2	det
2	extent	extent	NN	_	0	ROOT
3	to	to	TO	_	4	case
4	which	which	WDT	_	10	nmod
5	drug1	drug1	SYM	_	10	dep
6	-	-	:	_	10	punct
7	drug2	drug2	NN	_	8	compound
8	interactions	interaction	NNS	_	10	nsubj
9	may	may	MD	_	10	aux
10	pose	pose	VB	_	2	acl:relcl
11	clinical	clinical	JJ	_	12	amod
12	problems	problem	NNS	_	14	nsubj
13	will	will	MD	_	14	aux
14	depend	depend	VB	_	10	ccomp
15	on	on	IN	_	17	case
16	the	the	DT	_	17	det
17	degree	degree	NN	_	14	nmod
18	of	of	IN	_	19	case
19	inhibition	inhibition	NN	_	17	nmod
20	,	,	,	_	2	punct
21	and	and	CC	_	2	cc
22	the	the	DT	_	23	det
23	pharmacokinetics	pharmacokinetic	NNS	_	2	conj
24	of	of	IN	_	26	case
25	the	the	DT	_	26	det
26	drug3	drug3	NN	_	23	nmod
27	involved	involve	VBN	_	26	acl
28	.	.	.	_	2	punct

1	Nevertheless	nevertheless	RB	_	5	advmod
2	,	,	,	_	5	punct
3	caution	caution	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	indicated	indicate	VBN	_	0	ROOT
6	in	in	IN	_	8	case
7	the	the	DT	_	8	det
8	co-administration	co-administration	NN	_	5	nmod
9	of	of	IN	_	10	case
10	TCA5	tca5	NN	_	8	nmod
11	with	with	IN	_	12	case
12	any	any	DT	_	5	nmod
13	of	of	IN	_	15	case
14	the	the	DT	_	15	det
15	drug1	drug1	NN	_	12	nmod
16	and	and	CC	_	12	cc
17	also	also	RB	_	19	advmod
18	in	in	IN	_	19	case
19	switching	switching	NN	_	12	conj
20	from	from	IN	_	22	case
21	one	one	CD	_	22	nummod
22	class	class	NN	_	19	nmod
23	to	to	TO	_	25	case
24	the	the	DT	_	25	det
25	other	other	JJ	_	19	nmod
26	.	.	.	_	5	punct

1	Of	of	IN	_	3	case
2	particular	particular	JJ	_	3	amod
3	importance	importance	NN	_	8	nmod
4	,	,	,	_	8	punct
5	sufficient	sufficient	JJ	_	6	amod
6	time	time	NN	_	8	nsubj
7	must	must	MD	_	8	aux
8	elapse	elapse	VB	_	0	ROOT
9	before	before	IN	_	10	mark
10	initiating	initiate	VBG	_	8	advcl
11	TCA	TCA	NNP	_	12	compound
12	treatment	treatment	NN	_	10	dobj
13	in	in	IN	_	15	case
14	a	a	DT	_	15	det
15	patient	patient	NN	_	12	nmod
16	being	be	VBG	_	17	auxpass
17	withdrawn	withdraw	VBN	_	15	acl
18	from	from	IN	_	19	case
19	drug1	drug1	NN	_	17	nmod
20	,	,	,	_	8	punct
21	given	give	VBN	_	24	case
22	the	the	DT	_	24	det
23	long	long	JJ	_	24	amod
24	half-life	half-life	NN	_	8	nmod
25	of	of	IN	_	27	case
26	the	the	DT	_	27	det
27	parent	parent	NN	_	24	nmod
28	and	and	CC	_	27	cc
29	active	active	JJ	_	30	amod
30	metabolite	metabolite	NN	_	27	conj
31	-LRB-	-lrb-	-LRB-	_	38	punct
32	at	at	IN	_	33	case
33	least	least	JJS	_	34	nmod:npmod
34	5	5	CD	_	35	nummod
35	weeks	week	NNS	_	38	nsubj
36	may	may	MD	_	38	aux
37	be	be	VB	_	38	cop
38	necessary	necessary	JJ	_	24	dep
39	-RRB-	-rrb-	-RRB-	_	38	punct
40	.	.	.	_	8	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	use	use	NN	_	14	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	6	case
6	drugs	drug	NNS	_	2	nmod
7	that	that	WDT	_	9	nsubj
8	can	can	MD	_	9	aux
9	inhibit	inhibit	VB	_	6	acl:relcl
10	cytochrome	cytochrome	NN	_	12	compound
11	P450	p450	NN	_	12	compound
12	2D6	2d6	NN	_	9	dobj
13	may	may	MD	_	14	aux
14	require	require	VB	_	0	ROOT
15	lower	lower	JJR	_	16	amod
16	doses	dose	NNS	_	14	dobj
17	than	than	IN	_	19	mark
18	usually	usually	RB	_	19	advmod
19	prescribed	prescribe	VBN	_	16	dep
20	for	for	IN	_	23	case
21	either	either	CC	_	23	cc:preconj
22	the	the	DT	_	23	det
23	drug2	drug2	NN	_	19	nmod
24	or	or	CC	_	23	cc
25	the	the	DT	_	27	det
26	other	other	JJ	_	27	amod
27	drug	drug	NN	_	23	conj
28	.	.	.	_	14	punct

1	Furthermore	furthermore	RB	_	21	advmod
2	,	,	,	_	21	punct
3	whenever	whenever	WRB	_	10	advmod
4	one	one	CD	_	10	nsubjpass
5	of	of	IN	_	8	case
6	these	these	DT	_	8	det
7	other	other	JJ	_	8	amod
8	drugs	drug	NNS	_	4	nmod
9	is	be	VBZ	_	10	auxpass
10	withdrawn	withdraw	VBN	_	21	advcl
11	from	from	IN	_	12	case
12	cotherapy	cotherapy	NN	_	10	nmod
13	,	,	,	_	21	punct
14	an	a	DT	_	16	det
15	increased	increase	VBN	_	16	amod
16	dose	dose	NN	_	21	nsubjpass
17	of	of	IN	_	18	case
18	drug1	drug1	NN	_	16	nmod
19	may	may	MD	_	21	aux
20	be	be	VB	_	21	auxpass
21	required	require	VBN	_	0	ROOT
22	.	.	.	_	21	punct

1	It	it	PRP	_	3	nsubj
2	is	be	VBZ	_	3	cop
3	desirable	desirable	JJ	_	0	ROOT
4	to	to	TO	_	5	mark
5	monitor	monitor	VB	_	3	xcomp
6	drug1	drug1	NN	_	8	compound
7	plasma	plasma	NN	_	8	compound
8	levels	level	NNS	_	5	dobj
9	whenever	whenever	WRB	_	13	advmod
10	a	a	DT	_	11	det
11	drug2	drug2	NN	_	13	nsubj
12	is	be	VBZ	_	13	aux
13	going	go	VBG	_	5	advcl
14	to	to	TO	_	16	mark
15	be	be	VB	_	16	auxpass
16	co-administered	co-administer	VBN	_	13	xcomp
17	with	with	IN	_	19	case
18	another	another	DT	_	19	det
19	drug	drug	NN	_	16	nmod
20	known	know	VBN	_	19	acl
21	to	to	TO	_	24	mark
22	be	be	VB	_	24	cop
23	an	a	DT	_	24	det
24	inhibitor	inhibitor	NN	_	20	xcomp
25	of	of	IN	_	27	case
26	P450	p450	NN	_	27	compound
27	2D6	2d6	NN	_	24	nmod
28	.	.	.	_	3	punct

1	drug1	drug1	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	,	,	,	_	1	punct
5	Metal	metal	NN	_	6	compound
6	Cations	cation	NNS	_	1	conj
7	,	,	,	_	1	punct
8	drug3	drug3	NN	_	10	compound
9	drug4	drug4	NN	_	10	compound
10	form	form	NN	_	11	nsubj
11	chelates	chelate	VBZ	_	1	acl:relcl
12	with	with	IN	_	14	case
13	alkaline	alkaline	NN	_	14	compound
14	earth	earth	NN	_	11	nmod
15	and	and	CC	_	14	cc
16	transition	transition	NN	_	18	compound
17	metal	metal	NN	_	18	compound
18	cations	cation	NNS	_	14	conj
19	.	.	.	_	1	punct

1	Administration	administration	NN	_	46	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	1	nmod
6	containing	contain	VBG	_	5	acl
7	drug3	drug3	NN	_	6	dobj
8	,	,	,	_	7	punct
9	drug4	drug4	NN	_	7	conj
10	,	,	,	_	7	punct
11	or	or	CC	_	7	cc
12	drug5	drug5	NN	_	7	conj
13	,	,	,	_	1	punct
14	with	with	IN	_	15	case
15	drug6	drug6	NN	_	1	nmod
16	,	,	,	_	1	punct
17	with	with	IN	_	19	case
18	metal	metal	NN	_	19	compound
19	cations	cation	NNS	_	1	nmod
20	such	such	JJ	_	22	case
21	as	as	IN	_	20	mwe
22	drug7	drug7	NN	_	19	nmod
23	,	,	,	_	22	punct
24	or	or	CC	_	22	cc
25	with	with	IN	_	26	case
26	drug8	drug8	NN	_	22	conj
27	containing	contain	VBG	_	26	acl
28	drug9	drug9	NN	_	27	dobj
29	or	or	CC	_	28	cc
30	drug10	drug10	NN	_	28	conj
31	,	,	,	_	28	punct
32	or	or	CC	_	28	cc
33	with	with	IN	_	34	case
34	formulations	formulation	NNS	_	28	conj
35	containing	contain	VBG	_	34	acl
36	divalent	divalent	JJ	_	39	amod
37	and	and	CC	_	36	cc
38	trivalent	trivalent	JJ	_	36	conj
39	cations	cation	NNS	_	35	dobj
40	such	such	JJ	_	42	case
41	as	as	IN	_	40	mwe
42	drug11	drug11	NN	_	39	nmod
43	-LRB-	-lrb-	-LRB-	_	44	punct
44	drug12	drug12	NN	_	42	appos
45	-RRB-	-rrb-	-RRB-	_	44	punct
46	chewable/buffered	chewable/buffered	VBD	_	0	ROOT
47	tablets	tablet	NNS	_	46	dobj
48	or	or	CC	_	47	cc
49	the	the	DT	_	51	det
50	pediatric	pediatric	JJ	_	51	amod
51	powder	powder	NN	_	47	conj
52	for	for	IN	_	54	case
53	oral	oral	JJ	_	54	amod
54	solution	solution	NN	_	46	nmod
55	,	,	,	_	46	punct
56	may	may	MD	_	58	aux
57	substantially	substantially	RB	_	58	advmod
58	interfere	interfere	VB	_	46	dep
59	with	with	IN	_	61	case
60	the	the	DT	_	61	det
61	absorption	absorption	NN	_	58	nmod
62	of	of	IN	_	63	case
63	drug13	drug13	NN	_	61	nmod
64	,	,	,	_	58	punct
65	resulting	result	VBG	_	58	advcl
66	in	in	IN	_	68	case
67	systemic	systemic	JJ	_	68	amod
68	concentrations	concentration	NNS	_	65	nmod
69	considerably	considerably	RB	_	70	advmod
70	lower	lower	JJR	_	68	amod
71	than	than	IN	_	72	mark
72	desired	desire	VBN	_	70	advcl
73	.	.	.	_	46	punct

1	These	these	DT	_	2	det
2	agents	agent	NNS	_	6	nsubjpass
3	should	should	MD	_	6	aux
4	not	not	RB	_	6	neg
5	be	be	VB	_	6	auxpass
6	taken	take	VBN	_	0	ROOT
7	within	within	IN	_	9	case
8	4	4	CD	_	9	nummod
9	hours	hour	NNS	_	6	nmod
10	before	before	IN	_	9	advmod
11	or	or	CC	_	10	cc
12	4	4	CD	_	13	nummod
13	hours	hour	NNS	_	10	conj
14	after	after	IN	_	16	case
15	drug1	drug1	NN	_	16	compound
16	administration	administration	NN	_	10	nmod
17	.	.	.	_	6	punct

1	drug1	drug1	NN	_	3	compound
2	drug2	drug2	NN	_	3	compound
3	drug3	drug3	NN	_	10	nsubj
4	,	,	,	_	3	punct
5	like	like	IN	_	7	case
6	other	other	JJ	_	7	amod
7	drug4	drug4	NN	_	3	nmod
8	,	,	,	_	3	punct
9	may	may	MD	_	10	aux
10	inhibit	inhibit	VB	_	0	ROOT
11	the	the	DT	_	12	det
12	metabolism	metabolism	NN	_	10	dobj
13	of	of	IN	_	14	case
14	drug5	drug5	NN	_	12	nmod
15	and	and	CC	_	14	cc
16	drug6	drug6	NN	_	14	conj
17	.	.	.	_	10	punct

1	These	these	DT	_	2	det
2	stimulants	stimulant	NNS	_	5	nsubjpass
3	are	be	VBP	_	5	auxpass
4	commonly	commonly	RB	_	5	advmod
5	found	find	VBN	_	0	ROOT
6	in	in	IN	_	7	case
7	coffee	coffee	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	tea	tea	NN	_	7	conj
10	,	,	,	_	5	punct
11	respectively	respectively	RB	_	5	advmod
12	.	.	.	_	5	punct

1	In	in	IN	_	3	case
2	some	some	DT	_	3	det
3	patients	patient	NNS	_	7	nmod
4	,	,	,	_	7	punct
5	this	this	DT	_	7	nsubj
6	may	may	MD	_	7	aux
7	lead	lead	VB	_	0	ROOT
8	to	to	TO	_	10	case
9	reduced	reduce	VBN	_	10	amod
10	clearance	clearance	NN	_	7	nmod
11	,	,	,	_	10	punct
12	prolongation	prolongation	NN	_	10	conj
13	of	of	IN	_	15	case
14	plasma	plasma	NN	_	15	compound
15	half-life	half-life	NN	_	12	nmod
16	,	,	,	_	10	punct
17	and	and	CC	_	10	cc
18	enhanced	enhance	VBD	_	19	amod
19	effects	effect	NNS	_	10	conj
20	of	of	IN	_	21	case
21	drug1	drug1	NN	_	19	nmod
22	and	and	CC	_	21	cc
23	drug2	drug2	NN	_	21	conj
24	.	.	.	_	7	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	7	nsubj
4	is	be	VBZ	_	7	cop
5	a	a	DT	_	7	det
6	competitive	competitive	JJ	_	7	amod
7	inhibitor	inhibitor	NN	_	1	dep
8	of	of	IN	_	10	case
9	the	the	DT	_	10	det
10	metabolism	metabolism	NN	_	7	nmod
11	of	of	IN	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	.	.	.	_	1	punct

1	Serum	serum	NN	_	3	compound
2	drug1	drug1	NN	_	3	compound
3	concentrations	concentration	NNS	_	4	nsubj
4	increase	increase	VBP	_	0	ROOT
5	when	when	WRB	_	8	advmod
6	drug2	drug2	NN	_	8	nsubjpass
7	is	be	VBZ	_	8	auxpass
8	initiated	initiate	VBN	_	4	advcl
9	in	in	IN	_	11	case
10	a	a	DT	_	11	det
11	patient	patient	NN	_	8	nmod
12	maintained	maintain	VBD	_	11	acl
13	on	on	IN	_	14	case
14	drug3	drug3	NN	_	12	nmod
15	.	.	.	_	4	punct

1	When	when	WRB	_	2	advmod
2	initiating	initiate	VBG	_	21	advcl
3	a	a	DT	_	5	det
4	multi-day	multi-day	JJ	_	5	amod
5	course	course	NN	_	2	dobj
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	in	in	IN	_	10	case
9	a	a	DT	_	10	det
10	patient	patient	NN	_	2	nmod
11	maintained	maintain	VBD	_	10	acl
12	on	on	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	,	,	,	_	21	punct
15	the	the	DT	_	18	det
16	drug3	drug3	NN	_	18	compound
17	maintenance	maintenance	NN	_	18	compound
18	dose	dose	NN	_	21	nsubjpass
19	should	should	MD	_	21	aux
20	be	be	VB	_	21	auxpass
21	halved	halve	VBN	_	0	ROOT
22	for	for	IN	_	24	case
23	the	the	DT	_	24	det
24	period	period	NN	_	21	nmod
25	of	of	IN	_	27	case
26	concurrent	concurrent	JJ	_	27	amod
27	use	use	NN	_	24	nmod
28	of	of	IN	_	29	case
29	drug4	drug4	NN	_	27	nmod
30	and	and	CC	_	29	cc
31	monitoring	monitoring	NN	_	29	conj
32	of	of	IN	_	35	case
33	serum	serum	NN	_	35	compound
34	drug5	drug5	NN	_	35	compound
35	concentrations	concentration	NNS	_	29	nmod
36	should	should	MD	_	38	aux
37	be	be	VB	_	38	auxpass
38	initiated	initiate	VBN	_	21	dep
39	as	as	IN	_	41	case
40	a	a	DT	_	41	det
41	guide	guide	NN	_	38	nmod
42	to	to	TO	_	45	case
43	further	further	JJ	_	45	amod
44	dosage	dosage	NN	_	45	compound
45	adjustments	adjustment	NNS	_	41	nmod
46	.	.	.	_	21	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	4	case
4	subjects	subject	NNS	_	15	nmod
5	receiving	receive	VBG	_	4	acl
6	drug2	drug2	NN	_	5	dobj
7	,	,	,	_	4	punct
8	no	no	DT	_	10	neg
9	significant	significant	JJ	_	10	amod
10	change	change	NN	_	15	nsubjpass
11	in	in	IN	_	13	case
12	clotting	clot	VBG	_	13	amod
13	time	time	NN	_	10	nmod
14	was	be	VBD	_	15	auxpass
15	observed	observe	VBN	_	1	appos
16	when	when	WRB	_	19	advmod
17	drug3	drug3	NN	_	19	nsubjpass
18	was	be	VBD	_	19	auxpass
19	coadministered	coadminister	VBN	_	15	advcl
20	.	.	.	_	1	punct

1	However	however	RB	_	28	advmod
2	,	,	,	_	28	punct
3	because	because	IN	_	8	mark
4	some	some	DT	_	5	det
5	drug1	drug1	NN	_	8	nsubjpass
6	have	have	VBP	_	8	aux
7	been	be	VBN	_	8	auxpass
8	reported	report	VBN	_	28	advcl
9	to	to	TO	_	10	mark
10	enhance	enhance	VB	_	8	xcomp
11	the	the	DT	_	12	det
12	effects	effect	NNS	_	10	dobj
13	of	of	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	or	or	CC	_	14	cc
16	its	its	PRP$	_	17	nmod:poss
17	derivatives	derivative	NNS	_	14	conj
18	,	,	,	_	28	punct
19	prothrombin	prothrombin	NN	_	20	compound
20	time	time	NN	_	28	nsubjpass
21	or	or	CC	_	20	cc
22	other	other	JJ	_	25	amod
23	suitable	suitable	JJ	_	25	amod
24	anticoagulation	anticoagulation	JJ	_	25	amod
25	test	test	NN	_	20	conj
26	should	should	MD	_	28	aux
27	be	be	VB	_	28	auxpass
28	monitored	monitor	VBN	_	0	ROOT
29	closely	closely	RB	_	28	advmod
30	if	if	IN	_	34	mark
31	a	a	DT	_	32	det
32	drug3	drug3	NN	_	34	nsubjpass
33	is	be	VBZ	_	34	auxpass
34	administered	administer	VBN	_	28	advcl
35	with	with	IN	_	36	case
36	drug4	drug4	NN	_	34	nmod
37	or	or	CC	_	36	cc
38	its	its	PRP$	_	39	nmod:poss
39	derivatives	derivative	NNS	_	36	conj
40	.	.	.	_	28	punct

1	Drugs	drug	NNS	_	18	nsubj
2	Metabolized	metabolize	VBN	_	18	dep
3	by	by	IN	_	6	case
4	Cytochrome	cytochrome	NN	_	6	compound
5	P450	p450	NN	_	6	compound
6	Enzymes	enzyme	NNS	_	18	nmod
7	The	the	DT	_	10	det
8	drug	drug	NN	_	10	compound
9	interaction	interaction	NN	_	10	compound
10	study	study	NN	_	18	nsubj
11	evaluating	evaluate	VBG	_	10	acl
12	the	the	DT	_	13	det
13	effect	effect	NN	_	11	dobj
14	of	of	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	on	on	IN	_	17	case
17	drug2	drug2	NN	_	13	nmod
18	indicates	indicate	VBZ	_	0	ROOT
19	that	that	IN	_	21	mark
20	drug3	drug3	NN	_	21	nsubj
21	inhibits	inhibit	VBZ	_	18	ccomp
22	drug4	drug4	NN	_	23	compound
23	metabolism	metabolism	NN	_	21	dobj
24	,	,	,	_	23	punct
25	which	which	WDT	_	27	nsubjpass
26	is	be	VBZ	_	27	auxpass
27	mediated	mediate	VBN	_	23	acl:relcl
28	by	by	IN	_	29	case
29	CYP1A2	cyp1a2	NN	_	27	nmod
30	.	.	.	_	18	punct

1	While	while	IN	_	7	mark
2	no	no	DT	_	4	neg
3	clinical	clinical	JJ	_	4	amod
4	studies	study	NNS	_	7	nsubjpass
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	conducted	conduct	VBN	_	0	ROOT
8	to	to	TO	_	9	mark
9	evaluate	evaluate	VB	_	7	xcomp
10	the	the	DT	_	11	det
11	effect	effect	NN	_	9	dobj
12	of	of	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	on	on	IN	_	16	case
15	the	the	DT	_	16	det
16	metabolism	metabolism	NN	_	11	nmod
17	of	of	IN	_	18	case
18	C.P.A.	C.P.A.	NNP	_	16	nmod

1	substrates	substrate	NNS	_	6	nsubj
2	,	,	,	_	1	punct
3	in	in	FW	_	5	amod
4	vitro	vitro	FW	_	3	dep
5	data	datum	NNS	_	6	nsubj
6	suggest	suggest	VBP	_	0	ROOT
7	similar	similar	JJ	_	8	amod
8	effects	effect	NNS	_	13	nsubj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	in	in	IN	_	12	case
12	CYP3A4	cyp3a4	NN	_	13	nmod
13	mediated	mediate	VBD	_	6	ccomp
14	metabolism	metabolism	NN	_	17	compound
15	and	and	CC	_	14	cc
16	drug2	drug2	NN	_	14	conj
17	metabolism	metabolism	NN	_	13	dobj
18	.	.	.	_	6	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	8	nmod
3	,	,	,	_	8	punct
4	other	other	JJ	_	5	amod
5	drug1	drug1	NN	_	8	nsubjpass
6	have	have	VBP	_	8	aux
7	been	be	VBN	_	8	auxpass
8	reported	report	VBN	_	0	ROOT
9	to	to	TO	_	10	mark
10	decrease	decrease	VB	_	8	xcomp
11	the	the	DT	_	13	det
12	CYP3A4-mediated	cyp3a4-mediated	JJ	_	13	amod
13	metabolism	metabolism	NN	_	10	dobj
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	.	.	.	_	8	punct

1	Other	other	JJ	_	2	amod
2	drugs	drug	NNS	_	0	ROOT
3	metabolized	metabolize	VBN	_	2	acl
4	by	by	IN	_	5	case
5	C.P.A.	C.P.A.	NNP	_	3	nmod

1	include	include	VB	_	0	ROOT
2	drug1	drug1	NN	_	1	dobj
3	,	,	,	_	2	punct
4	drug2	drug2	NN	_	2	conj
5	,	,	,	_	2	punct
6	drug3	drug3	NN	_	2	conj
7	,	,	,	_	2	punct
8	drug4	drug4	NN	_	2	conj
9	,	,	,	_	2	punct
10	and	and	CC	_	2	cc
11	drug5	drug5	NN	_	2	conj
12	.	.	.	_	1	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	relevance	relevance	NN	_	18	nsubjpass
4	of	of	IN	_	7	case
5	the	the	DT	_	7	det
6	potential	potential	JJ	_	7	amod
7	effect	effect	NN	_	3	nmod
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	on	on	IN	_	12	case
11	the	the	DT	_	12	det
12	metabolism	metabolism	NN	_	7	nmod
13	of	of	IN	_	15	case
14	C.P.A.	C.P.A.	NNP	_	15	compound
15	substrates	substrate	NNS	_	12	nmod
16	is	be	VBZ	_	18	auxpass
17	not	not	RB	_	18	neg
18	known	know	VBN	_	0	ROOT
19	.	.	.	_	18	punct

1	Patients	patient	NNS	_	11	nsubjpass
2	receiving	receive	VBG	_	1	acl
3	concurrent	concurrent	JJ	_	4	amod
4	administration	administration	NN	_	2	dobj
5	of	of	IN	_	6	case
6	substrates	substrate	NNS	_	4	nmod
7	of	of	IN	_	8	case
8	C.P.A.	C.P.A.	NNP	_	6	nmod
9	were	be	VBD	_	11	auxpass
10	not	not	RB	_	11	neg
11	excluded	exclude	VBN	_	0	ROOT
12	from	from	IN	_	14	case
13	clinical	clinical	JJ	_	14	amod
14	trials	trial	NNS	_	11	nmod
15	of	of	IN	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	.	.	.	_	11	punct

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	drug2	drug2	NN	_	1	appos
4	-RRB-	-rrb-	-RRB-	_	3	punct
5	:	:	:	_	1	punct
6	The	the	DT	_	8	det
7	concomitant	concomitant	JJ	_	8	amod
8	administration	administration	NN	_	16	nsubj
9	of	of	IN	_	11	case
10	a	a	DT	_	11	det
11	drug3	drug3	NN	_	8	nmod
12	with	with	IN	_	14	case
13	a	a	DT	_	14	det
14	drug4	drug4	NN	_	11	nmod
15	may	may	MD	_	16	aux
16	increase	increase	VB	_	1	dep
17	the	the	DT	_	18	det
18	risks	risk	NNS	_	16	dobj
19	of	of	IN	_	21	case
20	CNS	cns	NN	_	21	compound
21	stimulation	stimulation	NN	_	18	nmod
22	and	and	CC	_	21	cc
23	convulsions	convulsion	NNS	_	21	conj
24	.	.	.	_	16	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Disturbances	disturbance	NNS	_	15	nsubjpass
4	of	of	IN	_	6	case
5	blood	blood	NN	_	6	compound
6	glucose	glucose	NN	_	3	nmod
7	,	,	,	_	3	punct
8	including	include	VBG	_	9	case
9	hyperglycemia	hyperglycemia	NN	_	3	nmod
10	and	and	CC	_	9	cc
11	hypoglycemia	hypoglycemia	NN	_	9	conj
12	,	,	,	_	3	punct
13	have	have	VBP	_	15	aux
14	been	be	VBN	_	15	auxpass
15	reported	report	VBN	_	1	appos
16	in	in	IN	_	17	case
17	patients	patient	NNS	_	15	nmod
18	treated	treat	VBN	_	17	acl
19	concomitantly	concomitantly	RB	_	18	advmod
20	with	with	IN	_	21	case
21	drug2	drug2	NN	_	18	nmod
22	and	and	CC	_	21	cc
23	an	a	DT	_	24	det
24	drug3	drug3	NN	_	21	conj
25	.	.	.	_	1	punct

1	Therefore	therefore	RB	_	9	advmod
2	,	,	,	_	9	punct
3	careful	careful	JJ	_	4	amod
4	monitoring	monitoring	NN	_	9	nsubjpass
5	of	of	IN	_	7	case
6	blood	blood	NN	_	7	compound
7	glucose	glucose	NN	_	4	nmod
8	is	be	VBZ	_	9	auxpass
9	recommended	recommend	VBN	_	0	ROOT
10	when	when	WRB	_	14	advmod
11	these	these	DT	_	12	det
12	agents	agent	NNS	_	14	nsubjpass
13	are	be	VBP	_	14	auxpass
14	coadministered	coadminister	VBN	_	9	advcl
15	.	.	.	_	9	punct

1	The	the	DT	_	2	det
2	absorption	absorption	NN	_	7	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	may	may	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	affected	affect	VBN	_	0	ROOT
8	by	by	IN	_	11	case
9	the	the	DT	_	11	det
10	simultaneous	simultaneous	JJ	_	11	amod
11	administration	administration	NN	_	7	nmod
12	of	of	IN	_	14	case
13	indigestion	indigestion	NN	_	14	compound
14	remedies	remedy	NNS	_	11	nmod
15	,	,	,	_	14	punct
16	drug2	drug2	NN	_	14	conj
17	or	or	CC	_	14	cc
18	drug3	drug3	NN	_	19	compound
19	supplements	supplement	NNS	_	14	conj
20	.	.	.	_	7	punct

1	Oral	oral	JJ	_	2	amod
2	drug1	drug1	NN	_	6	nsubj
3	may	may	MD	_	6	aux
4	be	be	VB	_	6	cop
5	less	less	RBR	_	6	advmod
6	effective	effective	JJ	_	0	ROOT
7	while	while	IN	_	10	mark
8	you	you	PRP	_	10	nsubj
9	are	be	VBP	_	10	aux
10	taking	take	VBG	_	6	advcl
11	drug2	drug2	NN	_	10	dobj
12	.	.	.	_	6	punct

1	Potential	potential	JJ	_	3	amod
2	drug	drug	NN	_	3	compound
3	interactions	interaction	NNS	_	22	nsubjpass
4	between	between	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	-LRB-	-lrb-	-LRB-	_	8	punct
7	drug2	drug2	NN	_	8	compound
8	cream	cream	NN	_	5	appos
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	Cream	cream	NN	_	5	dep
11	,	,	,	_	3	punct
12	1	1	CD	_	13	nummod
13	%	%	NN	_	3	conj
14	,	,	,	_	3	punct
15	and	and	CC	_	3	cc
16	other	other	JJ	_	17	amod
17	drugs	drug	NNS	_	3	conj
18	have	have	VBP	_	22	aux
19	not	not	RB	_	22	neg
20	been	be	VBN	_	22	auxpass
21	systematically	systematically	RB	_	22	advmod
22	evaluated	evaluate	VBN	_	0	ROOT
23	.	.	.	_	22	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	10	nsubjpass
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	drug3	drug3	NN	_	3	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	has	have	VBZ	_	10	aux
8	been	be	VBN	_	10	auxpass
9	safely	safely	RB	_	10	advmod
10	coadministered	coadminister	VBN	_	1	appos
11	with	with	IN	_	12	case
12	drug4	drug4	NN	_	10	nmod
13	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	A	a	DT	_	4	det
4	study	study	NN	_	10	nsubj
5	in	in	IN	_	8	case
6	normal	normal	JJ	_	8	amod
7	healthy	healthy	JJ	_	8	amod
8	volunteers	volunteer	NNS	_	4	nmod
9	has	have	VBZ	_	10	aux
10	shown	show	VBN	_	1	dep
11	that	that	IN	_	23	mark
12	concomitant	concomitant	JJ	_	13	amod
13	administration	administration	NN	_	23	nsubj
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	drug3	drug3	NN	_	15	appos
18	-RRB-	-rrb-	-RRB-	_	17	punct
19	and	and	CC	_	15	cc
20	drug4	drug4	NN	_	15	conj
21	does	do	VBZ	_	23	aux
22	not	not	RB	_	23	neg
23	result	result	VB	_	10	ccomp
24	in	in	IN	_	26	case
25	altered	altered	JJ	_	26	amod
26	pharmacoktnetics	pharmacoktnetic	NNS	_	23	nmod
27	of	of	IN	_	29	case
28	either	either	CC	_	29	det
29	drug	drug	NN	_	26	nmod
30	.	.	.	_	1	punct

1	In	in	IN	_	3	case
2	a	a	DT	_	3	det
3	study	study	NN	_	17	nmod
4	in	in	IN	_	6	case
5	hypertensive	hypertensive	JJ	_	6	amod
6	patients	patient	NNS	_	3	nmod
7	,	,	,	_	17	punct
8	addition	addition	NN	_	17	nsubj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	to	to	TO	_	14	case
12	existing	exist	VBG	_	14	amod
13	drug2	drug2	NN	_	14	compound
14	therapy	therapy	NN	_	8	nmod
15	did	do	VBD	_	17	aux
16	not	not	RB	_	17	neg
17	result	result	VB	_	0	ROOT
18	in	in	IN	_	22	case
19	any	any	DT	_	22	det
20	unexpected	unexpected	JJ	_	22	amod
21	adverse	adverse	JJ	_	22	amod
22	effects	effect	NNS	_	17	nmod
23	,	,	,	_	17	punct
24	and	and	CC	_	17	cc
25	drug3	drug3	NN	_	26	nsubj
26	had	have	VBD	_	17	conj
27	an	a	DT	_	30	det
28	additional	additional	JJ	_	30	amod
29	antihypertensive	antihypertensive	JJ	_	30	amod
30	effect	effect	NN	_	26	dobj
31	.	.	.	_	17	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	7	case
4	a	a	DT	_	7	det
5	single	single	JJ	_	7	amod
6	dose	dose	NN	_	7	compound
7	study	study	NN	_	15	nmod
8	in	in	IN	_	10	case
9	normal	normal	JJ	_	10	amod
10	volunteers	volunteer	NNS	_	7	nmod
11	,	,	,	_	7	punct
12	coadministration	coadministration	NN	_	15	nsubj
13	of	of	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	had	have	VBD	_	1	dep
16	a	a	DT	_	18	det
17	small	small	JJ	_	18	amod
18	effect	effect	NN	_	15	dobj
19	on	on	IN	_	21	case
20	the	the	DT	_	21	det
21	rate	rate	NN	_	15	nmod
22	but	but	CC	_	15	cc
23	no	no	DT	_	24	neg
24	effect	effect	NN	_	15	conj
25	on	on	IN	_	27	case
26	the	the	DT	_	27	det
27	extent	extent	NN	_	24	nmod
28	of	of	IN	_	30	case
29	drug3	drug3	NN	_	30	compound
30	bioavailability	bioavailability	NN	_	27	nmod
31	.	.	.	_	1	punct

1	Significant	significant	JJ	_	2	amod
2	increases	increase	NNS	_	26	nsubjpass
3	In	in	IN	_	4	case
4	AUC	auc	NN	_	2	nmod
5	-LRB-	-lrb-	-LRB-	_	7	punct
6	27	27	CD	_	7	nummod
7	%	%	NN	_	2	appos
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	and	and	CC	_	2	cc
10	Cmax	cmax	NN	_	2	conj
11	-LRB-	-lrb-	-LRB-	_	13	punct
12	58	58	CD	_	13	nummod
13	%	%	NN	_	10	appos
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	and	and	CC	_	2	cc
16	decreases	decrease	VBZ	_	2	conj
17	in	in	IN	_	18	case
18	tmax	tmax	NN	_	16	nmod
19	-LRB-	-lrb-	-LRB-	_	21	punct
20	23	23	CD	_	21	nummod
21	%	%	NN	_	18	appos
22	-RRB-	-rrb-	-RRB-	_	21	punct
23	of	of	IN	_	24	case
24	drug1	drug1	NN	_	18	nmod
25	were	be	VBD	_	26	auxpass
26	noted	note	VBN	_	0	ROOT
27	in	in	IN	_	29	case
28	this	this	DT	_	29	det
29	study	study	NN	_	26	nmod
30	.	.	.	_	26	punct

1	However	however	RB	_	0	ROOT
2	,	,	,	_	1	punct
3	concomitant	concomitant	JJ	_	4	amod
4	administration	administration	NN	_	2	root
5	of	of	IN	_	9	case
6	5	5	CD	_	7	compound
7	mg	mg	NN	_	9	amod
8	b.i.d.	b.i.d.	NN	_	9	compound
9	drug1	drug1	NN	_	4	nmod
10	and	and	CC	_	9	cc
11	40	40	CD	_	12	compound
12	mg	mg	NN	_	13	amod
13	b.i.d.	b.i.d.	NN	_	9	conj

1	drug1	drug1	NN	_	8	nsubj
2	to	to	TO	_	4	case
3	healthy	healthy	JJ	_	4	amod
4	volunteers	volunteer	NNS	_	1	nmod
5	under	under	IN	_	7	case
6	steady-state	steady-state	JJ	_	7	amod
7	conditions	condition	NNS	_	1	nmod
8	had	have	VBD	_	0	ROOT
9	no	no	DT	_	11	neg
10	relevant	relevant	JJ	_	11	amod
11	effect	effect	NN	_	8	dobj
12	on	on	IN	_	16	case
13	either	either	CC	_	16	cc:preconj
14	drug	drug	NN	_	16	compound
15	s	s	NNS	_	16	compound
16	bioavailability	bioavailability	NN	_	8	nmod
17	,	,	,	_	16	punct
18	AUC	auc	NN	_	16	conj
19	and	and	CC	_	16	cc
20	Cmax	cmax	NN	_	16	conj
21	,	,	,	_	8	punct
22	differences	difference	NNS	_	25	nsubj
23	were	be	VBD	_	25	cop
24	20	20	CD	_	25	nummod
25	%	%	NN	_	8	ccomp
26	between	between	IN	_	27	case
27	drug2	drug2	NN	_	25	nmod
28	given	give	VBN	_	27	acl
29	singly	singly	RB	_	30	advmod
30	and	and	CC	_	28	advmod
31	in	in	IN	_	32	case
32	combination	combination	NN	_	30	conj
33	with	with	IN	_	34	case
34	drug3	drug3	NN	_	32	nmod
35	,	,	,	_	8	punct
36	and	and	CC	_	8	cc
37	between	between	IN	_	38	case
38	drug4	drug4	NN	_	8	conj
39	given	give	VBN	_	38	acl
40	singly	singly	RB	_	41	advmod
41	and	and	CC	_	39	advmod
42	in	in	IN	_	43	case
43	combination	combination	NN	_	41	conj
44	with	with	IN	_	45	case
45	drug5	drug5	NN	_	43	nmod
46	.	.	.	_	8	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	5	case
4	a	a	DT	_	5	det
5	study	study	NN	_	31	nmod
6	in	in	IN	_	8	case
7	healthy	healthy	JJ	_	8	amod
8	volunteers	volunteer	NNS	_	5	nmod
9	,	,	,	_	5	punct
10	a	a	DT	_	12	det
11	one-week	one-week	JJ	_	12	amod
12	course	course	NN	_	31	nsubj
13	of	of	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	at	at	IN	_	18	case
16	400	400	CD	_	18	nummod
17	mg	mg	NN	_	18	compound
18	b.i.d.	b.i.d.	NN	_	12	nmod
19	with	with	IN	_	24	case
20	a	a	DT	_	24	det
21	single	single	JJ	_	24	amod
22	5	5	CD	_	23	compound
23	mg	mg	NN	_	24	amod
24	dose	dose	NN	_	18	nmod
25	of	of	IN	_	26	case
26	drug3	drug3	NN	_	24	nmod
27	on	on	IN	_	30	case
28	the	the	DT	_	30	det
29	sixth	sixth	JJ	_	30	amod
30	day	day	NN	_	18	nmod
31	showed	show	VBD	_	1	dep
32	an	a	DT	_	33	det
33	increase	increase	NN	_	31	dobj
34	in	in	IN	_	39	case
35	drug4	drug4	NN	_	39	compound
36	mean	mean	NN	_	39	compound
37	peak	peak	JJ	_	39	amod
38	plasma	plasma	NN	_	39	compound
39	concentrations	concentration	NNS	_	33	nmod
40	-LRB-	-lrb-	-LRB-	_	42	punct
41	36	36	CD	_	42	nummod
42	%	%	NN	_	33	appos
43	-RRB-	-rrb-	-RRB-	_	42	punct
44	and	and	CC	_	33	cc
45	significant	significant	JJ	_	46	amod
46	increase	increase	NN	_	33	conj
47	in	in	IN	_	48	case
48	area	area	NN	_	46	nmod
49	under	under	IN	_	51	case
50	the	the	DT	_	51	det
51	curve	curve	NN	_	33	nmod
52	-LRB-	-lrb-	-LRB-	_	54	punct
53	50	50	CD	_	54	nummod
54	%	%	NN	_	51	appos
55	-RRB-	-rrb-	-RRB-	_	54	punct
56	.	.	.	_	31	punct

1	If	if	IN	_	5	mark
2	drug1	drug1	NN	_	3	compound
3	therapy	therapy	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	initiated	initiate	VBN	_	18	advcl
6	in	in	IN	_	8	case
7	a	a	DT	_	8	det
8	patient	patient	NN	_	5	nmod
9	currently	currently	RB	_	10	advmod
10	receiving	receive	VBG	_	8	acl
11	drug2	drug2	NN	_	13	compound
12	careful	careful	JJ	_	13	amod
13	monitoring	monitoring	NN	_	10	dobj
14	for	for	IN	_	16	case
15	adverse	adverse	JJ	_	16	amod
16	reactions	reaction	NNS	_	10	nmod
17	is	be	VBZ	_	18	auxpass
18	advised	advise	VBN	_	0	ROOT
19	and	and	CC	_	18	cc
20	downward	downward	JJ	_	22	amod
21	dose	dose	NN	_	22	compound
22	adjustment	adjustment	NN	_	25	nsubjpass
23	may	may	MD	_	25	aux
24	be	be	VB	_	25	auxpass
25	required	require	VBN	_	18	conj
26	.	.	.	_	18	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	5	case
4	a	a	DT	_	5	det
5	study	study	NN	_	27	nmod
6	in	in	IN	_	8	case
7	healthy	healthy	JJ	_	8	amod
8	volunteers	volunteer	NNS	_	5	nmod
9	,	,	,	_	5	punct
10	a	a	DT	_	12	det
11	six-day	six-day	JJ	_	12	amod
12	course	course	NN	_	27	nsubj
13	of	of	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	at	at	IN	_	17	case
16	600	600	CD	_	17	nummod
17	mg/day	mg/day	NN	_	12	nmod
18	followed	follow	VBN	_	12	acl
19	by	by	IN	_	24	case
20	a	a	DT	_	24	det
21	single	single	JJ	_	24	amod
22	5	5	CD	_	23	compound
23	mg	mg	NN	_	24	amod
24	dose	dose	NN	_	18	nmod
25	of	of	IN	_	26	case
26	drug3	drug3	NN	_	24	nmod
27	resulted	result	VBD	_	1	appos
28	in	in	IN	_	30	case
29	a	a	DT	_	30	det
30	reduction	reduction	NN	_	27	nmod
31	in	in	IN	_	33	case
32	drug4	drug4	NN	_	33	compound
33	levels	level	NNS	_	30	nmod
34	to	to	TO	_	37	case
35	below	below	IN	_	37	case
36	detectable	detectable	JJ	_	37	amod
37	limits	limit	NNS	_	30	nmod
38	.	.	.	_	1	punct

1	If	if	IN	_	5	mark
2	drug1	drug1	NN	_	3	compound
3	therapy	therapy	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	required	require	VBN	_	13	advcl
6	,	,	,	_	13	punct
7	drug2	drug2	NN	_	8	compound
8	concentrations	concentration	NNS	_	13	nsubj
9	and	and	CC	_	8	cc
10	therapeutic	therapeutic	JJ	_	11	amod
11	effects	effect	NNS	_	8	conj
12	are	be	VBP	_	13	cop
13	likely	likely	JJ	_	0	ROOT
14	to	to	TO	_	17	mark
15	be	be	VB	_	17	auxpass
16	markedly	markedly	RB	_	17	advmod
17	reduced	reduce	VBN	_	13	xcomp
18	or	or	CC	_	17	cc
19	abolished	abolish	VBN	_	17	conj
20	as	as	IN	_	22	case
21	a	a	DT	_	22	det
22	consequence	consequence	NN	_	17	nmod
23	of	of	IN	_	25	case
24	increased	increase	VBN	_	25	amod
25	metabolism	metabolism	NN	_	22	nmod
26	and	and	CC	_	25	cc
27	higher	higher	JJR	_	28	amod
28	clearance	clearance	NN	_	25	conj
29	of	of	IN	_	30	case
30	drug3	drug3	NN	_	28	nmod
31	.	.	.	_	13	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	5	case
4	a	a	DT	_	5	det
5	study	study	NN	_	23	nmod
6	in	in	IN	_	8	case
7	healthy	healthy	JJ	_	8	amod
8	volunteers	volunteer	NNS	_	5	nmod
9	,	,	,	_	5	punct
10	no	no	DT	_	16	neg
11	clinically	clinically	RB	_	12	advmod
12	relevant	relevant	JJ	_	16	amod
13	pharmacokinetic	pharmacokinetic	JJ	_	16	amod
14	or	or	CC	_	13	cc
15	pharmacodynamic	pharmacodynamic	JJ	_	13	conj
16	interaction	interaction	NN	_	23	nsubjpass
17	between	between	IN	_	18	case
18	drug2	drug2	NN	_	16	nmod
19	and	and	CC	_	18	cc
20	racemic	racemic	JJ	_	21	amod
21	drug3	drug3	NN	_	18	conj
22	was	be	VBD	_	23	auxpass
23	seen	see	VBN	_	1	appos
24	when	when	WRB	_	38	advmod
25	two	two	CD	_	28	nummod
26	single	single	JJ	_	28	amod
27	oral	oral	JJ	_	28	amod
28	doses	dose	NNS	_	38	nsubjpass
29	of	of	IN	_	30	case
30	drug4	drug4	NN	_	28	nmod
31	-LRB-	-lrb-	-LRB-	_	35	punct
32	0.7	0.7	CD	_	35	nummod
33	mg/kg	mg/kg	NN	_	35	compound
34	body	body	NN	_	35	compound
35	weight	weight	NN	_	28	appos
36	-RRB-	-rrb-	-RRB-	_	35	punct
37	were	be	VBD	_	38	auxpass
38	administered	administer	VBN	_	23	advcl
39	during	during	IN	_	41	case
40	11	11	CD	_	41	nummod
41	days	day	NNS	_	38	nmod
42	of	of	IN	_	44	case
43	multipledose	multipledose	JJ	_	44	amod
44	treatment	treatment	NN	_	41	nmod
45	with	with	IN	_	49	case
46	5	5	CD	_	47	compound
47	mg	mg	NN	_	49	amod
48	b.i.d.	b.i.d.	NN	_	49	compound
49	drug5	drug5	NN	_	44	nmod
50	.	.	.	_	1	punct

1	Neither	neither	DT	_	3	cc:preconj
2	racemic	racemic	JJ	_	3	amod
3	drug1	drug1	NN	_	13	nsubjpass
4	nor	nor	CC	_	3	cc
5	drug2	drug2	NN	_	6	compound
6	binding	binding	NN	_	3	conj
7	to	to	TO	_	9	case
8	plasma	plasma	NN	_	9	compound
9	proteins	protein	NNS	_	6	nmod
10	in	in	FW	_	11	compound
11	vitro	vitro	FW	_	3	advmod
12	was	be	VBD	_	13	auxpass
13	altered	alter	VBN	_	0	ROOT
14	by	by	IN	_	16	case
15	the	the	DT	_	16	det
16	addition	addition	NN	_	13	nmod
17	of	of	IN	_	20	case
18	the	the	DT	_	20	det
19	other	other	JJ	_	20	amod
20	drug	drug	NN	_	16	nmod
21	.	.	.	_	13	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	5	det
4	concomitant	concomitant	JJ	_	5	amod
5	administration	administration	NN	_	20	nsubj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	drug3	drug3	NN	_	7	appos
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	and	and	CC	_	7	cc
12	drug4	drug4	NN	_	7	conj
13	in	in	IN	_	17	case
14	a	a	DT	_	17	det
15	single-dose	single-dose	JJ	_	17	amod
16	pharmacokinetic	pharmacokinetic	JJ	_	17	amod
17	study	study	NN	_	5	nmod
18	did	do	VBD	_	20	aux
19	not	not	RB	_	20	neg
20	affect	affect	VB	_	1	dep
21	renal	renal	JJ	_	27	amod
22	,	,	,	_	21	punct
23	nonrenal	nonrenal	JJ	_	21	conj
24	and	and	CC	_	21	cc
25	total	total	JJ	_	21	conj
26	body	body	NN	_	27	compound
27	clearance	clearance	NN	_	20	dobj
28	of	of	IN	_	29	case
29	drug5	drug5	NN	_	27	nmod
30	.	.	.	_	20	punct

1	drug1	drug1	NN	_	2	compound
2	Anesthesia	Anesthesia	NNP	_	0	ROOT
3	:	:	:	_	2	punct
4	Severe	severe	JJ	_	5	amod
5	hypotension	hypotension	NN	_	8	nsubjpass
6	has	have	VBZ	_	8	aux
7	been	be	VBN	_	8	auxpass
8	reported	report	VBN	_	2	dep
9	during	during	IN	_	11	case
10	drug2	drug2	NN	_	11	compound
11	anesthesia	anesthesia	NN	_	8	nmod
12	with	with	IN	_	14	case
13	concomitant	concomitant	JJ	_	14	amod
14	use	use	NN	_	11	nmod
15	of	of	IN	_	17	case
16	a	a	DT	_	17	det
17	drug3	drug3	NN	_	14	nmod
18	and	and	CC	_	17	cc
19	a	a	DT	_	20	det
20	drug4	drug4	NN	_	17	conj
21	.	.	.	_	2	punct

1	Even	even	RB	_	8	advmod
2	though	though	IN	_	8	mark
3	such	such	JJ	_	4	amod
4	interactions	interaction	NNS	_	8	nsubjpass
5	have	have	VBP	_	8	aux
6	not	not	RB	_	8	neg
7	been	be	VBN	_	8	auxpass
8	seen	see	VBN	_	0	ROOT
9	in	in	IN	_	11	case
10	clinical	clinical	JJ	_	11	amod
11	studies	study	NNS	_	26	nmod
12	with	with	IN	_	13	case
13	drug1	drug1	NN	_	26	nmod
14	-LRB-	-lrb-	-LRB-	_	15	punct
15	drug2	drug2	NN	_	13	appos
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	,	,	,	_	13	punct
18	an	a	DT	_	20	det
19	increased	increase	VBN	_	20	amod
20	volume	volume	NN	_	26	nsubjpass
21	of	of	IN	_	23	case
22	circulating	circulate	VBG	_	23	amod
23	fluids	fluid	NNS	_	20	nmod
24	might	might	MD	_	26	aux
25	be	be	VB	_	26	auxpass
26	required	require	VBN	_	8	ccomp
27	if	if	IN	_	31	mark
28	such	such	PDT	_	30	det:predet
29	an	a	DT	_	30	det
30	interaction	interaction	NN	_	31	nsubj
31	were	be	VBD	_	26	advcl
32	to	to	TO	_	33	mark
33	occur	occur	VB	_	31	xcomp
34	.	.	.	_	8	punct

1	In	in	IN	_	3	case
2	normal	normal	JJ	_	3	amod
3	volunteers	volunteer	NNS	_	11	nmod
4	receiving	receive	VBG	_	3	acl
5	drug1	drug1	NN	_	4	dobj
6	,	,	,	_	11	punct
7	the	the	DT	_	8	det
8	administration	administration	NN	_	11	nsubj
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	decreased	decrease	VBD	_	0	ROOT
12	the	the	DT	_	14	det
13	renal	renal	JJ	_	14	amod
14	clearance	clearance	NN	_	11	dobj
15	and	and	CC	_	11	cc
16	significantly	significantly	RB	_	17	advmod
17	increased	increase	VBD	_	11	conj
18	the	the	DT	_	20	det
19	plasma	plasma	NN	_	20	compound
20	levels	level	NNS	_	17	dobj
21	of	of	IN	_	22	case
22	drug3	drug3	NN	_	20	nmod
23	.	.	.	_	11	punct

1	In	in	IN	_	3	case
2	some	some	DT	_	3	det
3	patients	patient	NNS	_	13	nmod
4	,	,	,	_	13	punct
5	combined	combine	VBN	_	6	amod
6	use	use	NN	_	13	nsubjpass
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	drug2	drug2	NN	_	8	conj
11	has	have	VBZ	_	13	aux
12	been	be	VBN	_	13	auxpass
13	associated	associate	VBN	_	0	ROOT
14	with	with	IN	_	17	case
15	fatal	fatal	JJ	_	17	amod
16	gastrointestinal	gastrointestinal	JJ	_	17	amod
17	hemorrhage	hemorrhage	NN	_	13	nmod
18	.	.	.	_	13	punct

1	Therefore	therefore	RB	_	9	advmod
2	,	,	,	_	9	punct
3	drug1	drug1	NN	_	9	nsubjpass
4	and	and	CC	_	3	cc
5	drug2	drug2	NN	_	3	conj
6	should	should	MD	_	9	aux
7	not	not	RB	_	9	neg
8	be	be	VB	_	9	auxpass
9	used	use	VBN	_	0	ROOT
10	concomitantly	concomitantly	RB	_	9	advmod
11	.	.	.	_	9	punct

1	In	in	IN	_	3	case
2	a	a	DT	_	3	det
3	study	study	NN	_	10	nmod
4	in	in	IN	_	6	case
5	normal	normal	JJ	_	6	amod
6	volunteers	volunteer	NNS	_	3	nmod
7	,	,	,	_	10	punct
8	it	it	PRP	_	10	nsubjpass
9	was	be	VBD	_	10	auxpass
10	found	find	VBN	_	0	ROOT
11	that	that	IN	_	22	mark
12	chronic	chronic	JJ	_	14	amod
13	concurrent	concurrent	JJ	_	14	amod
14	administration	administration	NN	_	22	nsubj
15	of	of	IN	_	17	case
16	3.6	3.6	CD	_	17	nummod
17	g	g	NN	_	14	nmod
18	of	of	IN	_	19	case
19	drug1	drug1	NN	_	17	nmod
20	per	per	IN	_	21	case
21	day	day	NN	_	14	nmod
22	decreases	decrease	VBZ	_	10	ccomp
23	drug2	drug2	NN	_	25	compound
24	blood	blood	NN	_	25	compound
25	levels	level	NNS	_	22	dobj
26	approximately	approximately	RB	_	27	advmod
27	20	20	CD	_	28	nummod
28	%	%	NN	_	22	nmod:npmod
29	.	.	.	_	10	punct

1	The	the	DT	_	3	det
2	concomitant	concomitant	JJ	_	3	amod
3	use	use	NN	_	11	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	with	with	IN	_	8	case
7	other	other	JJ	_	8	amod
8	drug2	drug2	NN	_	3	nmod
9	is	be	VBZ	_	11	auxpass
10	not	not	RB	_	11	neg
11	recommended	recommend	VBN	_	0	ROOT
12	due	due	JJ	_	16	case
13	to	to	TO	_	12	mwe
14	the	the	DT	_	16	det
15	increased	increase	VBN	_	16	amod
16	possibility	possibility	NN	_	11	nmod
17	of	of	IN	_	19	case
18	gastrointestinal	gastrointestinal	JJ	_	19	amod
19	toxicity	toxicity	NN	_	16	nmod
20	,	,	,	_	11	punct
21	with	with	IN	_	22	case
22	little	little	JJ	_	11	nmod
23	or	or	CC	_	22	cc
24	no	no	DT	_	22	conj
25	increase	increase	NN	_	22	dep
26	in	in	IN	_	27	case
27	efficacy	efficacy	NN	_	22	nmod
28	.	.	.	_	11	punct

1	Clinical	clinical	JJ	_	2	amod
2	studies	study	NNS	_	4	nsubj
3	have	have	VBP	_	4	aux
4	shown	show	VBN	_	0	ROOT
5	that	that	IN	_	9	mark
6	drug1	drug1	NN	_	9	nsubj
7	does	do	VBZ	_	9	aux
8	not	not	RB	_	9	neg
9	influence	influence	VB	_	4	ccomp
10	the	the	DT	_	11	det
11	hypoprothrombinemia	hypoprothrombinemia	NN	_	9	dobj
12	produced	produce	VBN	_	11	acl
13	by	by	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	.	.	.	_	4	punct

1	However	however	RB	_	26	advmod
2	,	,	,	_	26	punct
3	when	when	WRB	_	12	advmod
4	any	any	DT	_	6	det
5	additional	additional	JJ	_	6	amod
6	drug	drug	NN	_	12	nsubjpass
7	,	,	,	_	6	punct
8	including	include	VBG	_	9	case
9	drug1	drug1	NN	_	6	nmod
10	,	,	,	_	6	punct
11	is	be	VBZ	_	12	auxpass
12	added	add	VBN	_	26	advcl
13	to	to	TO	_	15	case
14	the	the	DT	_	15	det
15	treatment	treatment	NN	_	12	nmod
16	of	of	IN	_	17	case
17	patients	patient	NNS	_	15	nmod
18	on	on	IN	_	20	case
19	drug2	drug2	NN	_	20	compound
20	therapy	therapy	NN	_	17	nmod
21	,	,	,	_	26	punct
22	the	the	DT	_	23	det
23	patients	patient	NNS	_	26	nsubjpass
24	should	should	MD	_	26	aux
25	be	be	VB	_	26	auxpass
26	observed	observe	VBN	_	0	ROOT
27	for	for	IN	_	28	case
28	alterations	alteration	NNS	_	26	nmod
29	of	of	IN	_	32	case
30	the	the	DT	_	32	det
31	prothrombin	prothrombin	NN	_	32	compound
32	time	time	NN	_	28	nmod
33	.	.	.	_	26	punct

1	In	in	IN	_	3	case
2	post-marketing	post-marketing	JJ	_	3	amod
3	experience	experience	NN	_	8	nmod
4	,	,	,	_	8	punct
5	bleeding	bleeding	NN	_	8	nsubjpass
6	has	have	VBZ	_	8	aux
7	been	be	VBN	_	8	auxpass
8	reported	report	VBN	_	0	ROOT
9	in	in	IN	_	10	case
10	patients	patient	NNS	_	8	nmod
11	on	on	IN	_	13	case
12	concomitant	concomitant	JJ	_	13	amod
13	treatment	treatment	NN	_	10	nmod
14	with	with	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	drug2	drug2	NN	_	15	conj
18	.	.	.	_	8	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	exercised	exercise	VBN	_	0	ROOT
5	when	when	WRB	_	10	advmod
6	drug1	drug1	NN	_	10	nsubjpass
7	and	and	CC	_	6	cc
8	drug2	drug2	NN	_	6	conj
9	are	be	VBP	_	10	auxpass
10	administered	administer	VBN	_	4	advcl
11	concomitantly	concomitantly	RB	_	10	advmod
12	.	.	.	_	4	punct

1	When	when	WRB	_	4	advmod
2	drug1	drug1	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	given	give	VBN	_	16	advcl
5	to	to	TO	_	6	case
6	patients	patient	NNS	_	4	nmod
7	receiving	receive	VBG	_	6	acl
8	drug2	drug2	NN	_	7	dobj
9	,	,	,	_	16	punct
10	the	the	DT	_	12	det
11	plasma	plasma	NN	_	12	compound
12	levels	level	NNS	_	16	nsubj
13	of	of	IN	_	14	case
14	drug3	drug3	NN	_	12	nmod
15	are	be	VBP	_	16	cop
16	likely	likely	JJ	_	0	ROOT
17	to	to	TO	_	19	mark
18	be	be	VB	_	19	auxpass
19	increased	increase	VBN	_	16	xcomp
20	.	.	.	_	16	punct

1	Therefore	therefore	RB	_	11	advmod
2	,	,	,	_	11	punct
3	a	a	DT	_	5	det
4	lower	lower	JJR	_	5	amod
5	total	total	JJ	_	11	nsubj
6	daily	daily	RB	_	7	advmod
7	dosage	dosage	NN	_	5	dep
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	may	may	MD	_	11	aux
11	produce	produce	VB	_	0	ROOT
12	a	a	DT	_	15	det
13	satisfactory	satisfactory	JJ	_	15	amod
14	therapeutic	therapeutic	JJ	_	15	amod
15	effect	effect	NN	_	11	dobj
16	.	.	.	_	11	punct

1	When	when	WRB	_	9	advmod
2	increases	increase	NNS	_	9	nsubjpass
3	in	in	IN	_	5	case
4	the	the	DT	_	5	det
5	dose	dose	NN	_	2	nmod
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	are	be	VBP	_	9	auxpass
9	made	make	VBN	_	14	advcl
10	,	,	,	_	14	punct
11	they	they	PRP	_	14	nsubjpass
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	made	make	VBN	_	0	ROOT
15	carefully	carefully	RB	_	16	advmod
16	and	and	CC	_	14	advmod
17	in	in	IN	_	19	case
18	small	small	JJ	_	19	amod
19	increments	increment	NNS	_	16	conj
20	.	.	.	_	14	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	if	if	IN	_	8	mark
6	drug1	drug1	NN	_	8	nsubjpass
7	is	be	VBZ	_	8	auxpass
8	administered	administer	VBN	_	4	advcl
9	simultaneously	simultaneously	RB	_	8	advmod
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	8	nmod
12	.	.	.	_	4	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	decrease	decrease	VB	_	4	ccomp
7	the	the	DT	_	9	det
8	tubular	tubular	JJ	_	9	amod
9	secretion	secretion	NN	_	6	dobj
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	and	and	CC	_	6	cc
13	to	to	TO	_	14	mark
14	potentiate	potentiate	VB	_	6	conj
15	its	its	PRP$	_	16	nmod:poss
16	toxicity	toxicity	NN	_	14	dobj
17	.	.	.	_	4	punct

1	Administration	administration	NN	_	9	nsubjpass
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	concomitantly	concomitantly	RB	_	9	nsubjpass
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	has	have	VBZ	_	9	aux
8	been	be	VBN	_	9	auxpass
9	associated	associate	VBN	_	0	ROOT
10	with	with	IN	_	12	case
11	an	a	DT	_	12	det
12	increase	increase	NN	_	9	nmod
13	in	in	IN	_	14	case
14	drug3	drug3	NN	_	12	nmod
15	-	-	:	_	12	punct
16	induced	induce	VBN	_	17	amod
17	toxicity	toxicity	NN	_	12	dep
18	,	,	,	_	17	punct
19	possibly	possibly	RB	_	20	advmod
20	due	due	JJ	_	17	amod
21	to	to	TO	_	23	case
22	decreased	decrease	VBN	_	23	amod
23	synthesis	synthesis	NN	_	20	nmod
24	of	of	IN	_	26	case
25	renal	renal	JJ	_	26	amod
26	prostacyclin	prostacyclin	NN	_	23	nmod
27	.	.	.	_	9	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	with	with	IN	_	6	case
6	caution	caution	NN	_	4	nmod
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	taking	take	VBG	_	8	acl
10	drug2	drug2	NN	_	9	dobj
11	,	,	,	_	4	punct
12	and	and	CC	_	4	cc
13	renal	renal	JJ	_	14	amod
14	function	function	NN	_	18	nsubjpass
15	should	should	MD	_	18	aux
16	be	be	VB	_	18	auxpass
17	carefully	carefully	RB	_	18	advmod
18	monitored	monitor	VBN	_	4	conj
19	.	.	.	_	4	punct

1	Capsules	capsule	NNS	_	2	nsubj
2	drug1	drug1	VBP	_	0	ROOT
3	50	50	CD	_	5	nummod
4	mg	mg	NN	_	5	compound
5	t.i.d.	t.i.d.	NN	_	6	nsubj
6	produced	produce	VBD	_	2	ccomp
7	a	a	DT	_	10	det
8	clinically	clinically	RB	_	9	advmod
9	relevant	relevant	JJ	_	10	amod
10	elevation	elevation	NN	_	6	dobj
11	of	of	IN	_	13	case
12	plasma	plasma	NN	_	13	compound
13	drug2	drug2	NN	_	10	nmod
14	and	and	CC	_	13	cc
15	reduction	reduction	NN	_	13	conj
16	in	in	IN	_	19	case
17	renal	renal	JJ	_	19	amod
18	drug3	drug3	NN	_	19	compound
19	clearance	clearance	NN	_	10	nmod
20	in	in	IN	_	22	case
21	psychiatric	psychiatric	JJ	_	22	amod
22	patients	patient	NNS	_	19	nmod
23	and	and	CC	_	22	cc
24	normal	normal	JJ	_	25	amod
25	subjects	subject	NNS	_	22	conj
26	with	with	IN	_	31	case
27	steady	steady	JJ	_	31	amod
28	state	state	NN	_	31	compound
29	plasma	plasma	NN	_	31	compound
30	drug4	drug4	NN	_	31	compound
31	concentrations	concentration	NNS	_	22	nmod
32	.	.	.	_	2	punct

1	This	this	DT	_	2	det
2	effect	effect	NN	_	5	nsubjpass
3	has	have	VBZ	_	5	aux
4	been	be	VBN	_	5	auxpass
5	attributed	attribute	VBN	_	0	ROOT
6	to	to	TO	_	7	case
7	inhibition	inhibition	NN	_	5	nmod
8	of	of	IN	_	10	case
9	prostaglandin	prostaglandin	NN	_	10	compound
10	synthesis	synthesis	NN	_	7	nmod
11	.	.	.	_	5	punct

1	As	as	IN	_	3	case
2	a	a	DT	_	3	det
3	consequence	consequence	NN	_	18	nmod
4	,	,	,	_	18	punct
5	when	when	WRB	_	10	advmod
6	drug1	drug1	NN	_	10	nsubjpass
7	and	and	CC	_	6	cc
8	drug2	drug2	NN	_	6	conj
9	are	be	VBP	_	10	auxpass
10	given	give	VBN	_	18	advcl
11	concomitantly	concomitantly	RB	_	10	advmod
12	,	,	,	_	18	punct
13	the	the	DT	_	14	det
14	patient	patient	NN	_	18	nsubjpass
15	should	should	MD	_	18	aux
16	be	be	VB	_	18	auxpass
17	carefully	carefully	RB	_	18	advmod
18	observed	observe	VBN	_	0	ROOT
19	for	for	IN	_	20	case
20	signs	sign	NNS	_	18	nmod
21	of	of	IN	_	23	case
22	drug3	drug3	NN	_	23	compound
23	toxicity	toxicity	NN	_	20	nmod
24	.	.	.	_	18	punct

1	-LRB-	-lrb-	-LRB-	_	0	ROOT
2	Read	read	VB	_	1	root
3	circulars	circular	NNS	_	2	dobj
4	for	for	IN	_	6	case
5	drug1	drug1	NN	_	6	compound
6	preparations	preparation	NNS	_	3	nmod
7	before	before	IN	_	8	case
8	use	use	NN	_	2	nmod
9	of	of	IN	_	12	case
10	such	such	JJ	_	12	amod
11	concomitant	concomitant	JJ	_	12	amod
12	therapy	therapy	NN	_	8	nmod
13	.	.	.	_	2	punct
14	-RRB-	-rrb-	-RRB-	_	2	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	13	nmod
3	,	,	,	_	13	punct
4	the	the	DT	_	5	det
5	frequency	frequency	NN	_	13	nsubjpass
6	of	of	IN	_	7	mark
7	monitoring	monitor	VBG	_	5	acl
8	serum	serum	NN	_	10	compound
9	drug1	drug1	NN	_	10	compound
10	concentration	concentration	NN	_	7	dobj
11	should	should	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	increased	increase	VBN	_	0	ROOT
14	at	at	IN	_	16	case
15	the	the	DT	_	16	det
16	outset	outset	NN	_	13	nmod
17	of	of	IN	_	21	case
18	such	such	JJ	_	21	amod
19	combination	combination	NN	_	21	compound
20	drug	drug	NN	_	21	compound
21	treatment	treatment	NN	_	16	nmod
22	.	.	.	_	13	punct

1	drug1	drug1	NN	_	8	nsubjpass
2	given	give	VBN	_	1	acl
3	concomitantly	concomitantly	RB	_	2	advmod
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	2	nmod
6	has	have	VBZ	_	8	aux
7	been	be	VBN	_	8	auxpass
8	reported	report	VBN	_	0	ROOT
9	to	to	TO	_	10	mark
10	increase	increase	VB	_	8	xcomp
11	the	the	DT	_	13	det
12	serum	serum	NN	_	13	compound
13	concentration	concentration	NN	_	10	dobj
14	and	and	CC	_	10	cc
15	prolong	prolong	VB	_	10	conj
16	the	the	DT	_	17	det
17	half-life	half-life	NN	_	15	dobj
18	of	of	IN	_	19	case
19	drug3	drug3	NN	_	17	nmod
20	.	.	.	_	8	punct

1	Therefore	therefore	RB	_	17	advmod
2	,	,	,	_	17	punct
3	when	when	WRB	_	8	advmod
4	drug1	drug1	NN	_	8	nsubjpass
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	are	be	VBP	_	8	auxpass
8	used	use	VBN	_	17	advcl
9	concomitantly	concomitantly	RB	_	8	advmod
10	,	,	,	_	17	punct
11	serum	serum	NN	_	13	compound
12	drug3	drug3	NN	_	13	compound
13	levels	level	NNS	_	17	nsubjpass
14	should	should	MD	_	17	aux
15	be	be	VB	_	17	auxpass
16	closely	closely	RB	_	17	advmod
17	monitored	monitor	VBN	_	0	ROOT
18	.	.	.	_	17	punct

1	In	in	IN	_	3	case
2	some	some	DT	_	3	det
3	patients	patient	NNS	_	10	nmod
4	,	,	,	_	10	punct
5	the	the	DT	_	6	det
6	administration	administration	NN	_	10	nsubj
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	can	can	MD	_	10	aux
10	reduce	reduce	VB	_	0	ROOT
11	the	the	DT	_	18	det
12	diuretic	diuretic	JJ	_	18	amod
13	,	,	,	_	12	punct
14	natriuretic	natriuretic	JJ	_	12	conj
15	,	,	,	_	12	punct
16	and	and	CC	_	12	cc
17	antihypertensive	antihypertensive	JJ	_	12	conj
18	effects	effect	NNS	_	10	dobj
19	of	of	IN	_	20	case
20	drug2	drug2	NN	_	18	nmod
21	,	,	,	_	20	punct
22	drug3	drug3	NN	_	20	conj
23	,	,	,	_	20	punct
24	and	and	CC	_	20	cc
25	drug4	drug4	NN	_	20	conj
26	.	.	.	_	10	punct

1	Therefore	therefore	RB	_	0	ROOT
2	,	,	,	_	1	punct
3	when	when	WRB	_	2	root
4	drug1	drug1	NN	_	3	dep
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	.	.	.	_	3	punct

1	-LRB-	-lrb-	-LRB-	_	4	punct
2	drug1	drug1	NN	_	4	compound
3	-RRB-	-rrb-	-RRB-	_	4	punct
4	drug2	drug2	NN	_	6	nsubjpass
5	are	be	VBP	_	6	auxpass
6	used	use	VBN	_	13	advcl
7	concomitantly	concomitantly	RB	_	6	advmod
8	,	,	,	_	13	punct
9	the	the	DT	_	10	det
10	patient	patient	NN	_	13	nsubjpass
11	should	should	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	observed	observe	VBN	_	0	ROOT
14	closely	closely	RB	_	13	advmod
15	to	to	TO	_	16	mark
16	determine	determine	VB	_	13	xcomp
17	if	if	IN	_	25	mark
18	the	the	DT	_	20	det
19	desired	desire	VBN	_	20	amod
20	effect	effect	NN	_	25	nsubjpass
21	of	of	IN	_	23	case
22	the	the	DT	_	23	det
23	drug3	drug3	NN	_	20	nmod
24	is	be	VBZ	_	25	auxpass
25	obtained	obtain	VBN	_	16	advcl
26	.	.	.	_	13	punct

1	drug1	drug1	NN	_	2	nsubj
2	reduces	reduce	VBZ	_	0	ROOT
3	basal	basal	JJ	_	6	amod
4	plasma	plasma	NN	_	6	compound
5	renin	renin	NN	_	6	compound
6	activity	activity	NN	_	2	dobj
7	-LRB-	-lrb-	-LRB-	_	8	punct
8	PRA	PRA	NNP	_	6	appos
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	,	,	,	_	6	punct
11	as	as	RB	_	6	cc
12	well	well	RB	_	11	mwe
13	as	as	IN	_	11	mwe
14	those	those	DT	_	15	det
15	elevations	elevation	NNS	_	6	conj
16	of	of	IN	_	17	case
17	PRA	PRA	NNP	_	15	nmod
18	induced	induce	VBN	_	15	acl
19	by	by	IN	_	21	case
20	drug2	drug2	NN	_	21	compound
21	administration	administration	NN	_	18	nmod
22	,	,	,	_	15	punct
23	or	or	CC	_	15	cc
24	salt	salt	NN	_	27	compound
25	or	or	CC	_	24	cc
26	volume	volume	NN	_	24	conj
27	depletion	depletion	NN	_	15	conj
28	.	.	.	_	2	punct

1	These	these	DT	_	2	det
2	facts	fact	NNS	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	considered	consider	VBN	_	0	ROOT
6	when	when	WRB	_	7	advmod
7	evaluating	evaluate	VBG	_	5	advcl
8	plasma	plasma	NN	_	10	compound
9	renin	renin	NN	_	10	compound
10	activity	activity	NN	_	7	dobj
11	in	in	IN	_	13	case
12	hypertensive	hypertensive	JJ	_	13	amod
13	patients	patient	NNS	_	10	nmod
14	.	.	.	_	5	punct

1	It	it	PRP	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	that	that	IN	_	16	mark
6	the	the	DT	_	7	det
7	addition	addition	NN	_	16	nsubj
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	to	to	TO	_	13	case
11	a	a	DT	_	13	det
12	maintenance	maintenance	NN	_	13	compound
13	schedule	schedule	NN	_	7	nmod
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	resulted	result	VBD	_	4	ccomp
17	in	in	IN	_	21	case
18	reversible	reversible	JJ	_	21	amod
19	acute	acute	JJ	_	21	amod
20	renal	renal	JJ	_	21	amod
21	failure	failure	NN	_	16	nmod
22	in	in	IN	_	23	case
23	two	two	CD	_	21	nmod
24	of	of	IN	_	25	advmod
25	four	four	CD	_	27	nummod
26	healthy	healthy	JJ	_	27	amod
27	volunteers	volunteer	NNS	_	23	dep
28	.	.	.	_	4	punct

1	drug1	drug1	NN	_	7	nsubjpass
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	should	should	MD	_	7	aux
5	not	not	RB	_	7	neg
6	be	be	VB	_	7	auxpass
7	administered	administer	VBN	_	0	ROOT
8	together	together	RB	_	7	advmod
9	.	.	.	_	7	punct

1	drug1	drug1	NN	_	7	nsubjpass
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	each	each	DT	_	1	dep
5	may	may	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	associated	associate	VBN	_	0	ROOT
8	with	with	IN	_	12	case
9	increased	increase	VBN	_	12	amod
10	serum	serum	NN	_	12	compound
11	potassium	potassium	NN	_	12	compound
12	levels	level	NNS	_	7	nmod
13	.	.	.	_	7	punct

1	The	the	DT	_	3	det
2	potential	potential	JJ	_	3	amod
3	effects	effect	NNS	_	16	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	on	on	IN	_	10	case
9	potassium	potassium	NN	_	10	compound
10	kinetics	kinetics	NNS	_	3	nmod
11	and	and	CC	_	10	cc
12	renal	renal	JJ	_	13	amod
13	function	function	NN	_	10	conj
14	should	should	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	considered	consider	VBN	_	0	ROOT
17	when	when	WRB	_	21	advmod
18	these	these	DT	_	19	det
19	agents	agent	NNS	_	21	nsubjpass
20	are	be	VBP	_	21	auxpass
21	administered	administer	VBN	_	16	advcl
22	concurrently	concurrently	RB	_	21	advmod
23	.	.	.	_	16	punct

1	Most	most	JJS	_	10	nsubjpass
2	of	of	IN	_	5	case
3	the	the	DT	_	5	det
4	above	above	JJ	_	5	amod
5	effects	effect	NNS	_	1	nmod
6	concerning	concern	VBG	_	5	acl
7	drug1	drug1	NN	_	6	dobj
8	have	have	VBP	_	10	aux
9	been	be	VBN	_	10	auxpass
10	attributed	attribute	VBN	_	0	ROOT
11	,	,	,	_	10	punct
12	at	at	IN	_	15	advmod
13	least	least	JJS	_	12	mwe
14	in	in	IN	_	15	case
15	part	part	NN	_	10	nmod
16	,	,	,	_	10	punct
17	to	to	TO	_	18	case
18	mechanisms	mechanism	NNS	_	10	nmod
19	involving	involve	VBG	_	18	acl
20	inhibition	inhibition	NN	_	19	dobj
21	of	of	IN	_	23	case
22	prostaglandin	prostaglandin	NN	_	23	compound
23	synthesis	synthesis	NN	_	20	nmod
24	by	by	IN	_	25	case
25	drug2	drug2	NN	_	20	nmod
26	.	.	.	_	10	punct

1	Blunting	blunt	VBG	_	14	nsubjpass
2	of	of	IN	_	5	case
3	the	the	DT	_	5	det
4	antihypertensive	antihypertensive	JJ	_	5	amod
5	effect	effect	NN	_	1	nmod
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	by	by	IN	_	9	case
9	drug2	drug2	NN	_	5	nmod
10	including	include	VBG	_	11	case
11	drug3	drug3	NN	_	9	nmod
12	has	have	VBZ	_	14	aux
13	been	be	VBN	_	14	auxpass
14	reported	report	VBN	_	0	ROOT
15	.	.	.	_	14	punct

1	Therefore	therefore	RB	_	15	advmod
2	,	,	,	_	15	punct
3	when	when	WRB	_	4	advmod
4	using	use	VBG	_	15	advcl
5	these	these	DT	_	7	det
6	blocking	block	VBG	_	7	amod
7	agents	agent	NNS	_	4	dobj
8	to	to	TO	_	9	mark
9	treat	treat	VB	_	4	advcl
10	hypertension	hypertension	NN	_	9	dobj
11	,	,	,	_	15	punct
12	patients	patient	NNS	_	15	nsubjpass
13	should	should	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	observed	observe	VBN	_	0	ROOT
16	carefully	carefully	RB	_	15	advmod
17	in	in	IN	_	20	mark
18	order	order	NN	_	17	mwe
19	to	to	TO	_	20	mark
20	confirm	confirm	VB	_	15	advcl
21	that	that	IN	_	28	mark
22	the	the	DT	_	25	det
23	desired	desire	VBN	_	25	amod
24	therapeutic	therapeutic	JJ	_	25	amod
25	effect	effect	NN	_	28	nsubjpass
26	has	have	VBZ	_	28	aux
27	been	be	VBN	_	28	auxpass
28	obtained	obtain	VBN	_	20	ccomp
29	.	.	.	_	15	punct

1	drug1	drug1	NN	_	3	nsubj
2	can	can	MD	_	3	aux
3	reduce	reduce	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	antihypertensive	antihypertensive	JJ	_	6	amod
6	effects	effect	NNS	_	3	dobj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	drug3	drug3	NN	_	8	conj
11	.	.	.	_	3	punct

1	False-negative	false-negative	JJ	_	2	amod
2	results	result	NNS	_	19	nsubjpass
3	in	in	IN	_	7	case
4	the	the	DT	_	7	det
5	dexamethasone	dexamethasone	NN	_	7	compound
6	suppression	suppression	NN	_	7	compound
7	test	test	NN	_	2	nmod
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	DST	dst	NN	_	7	appos
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	in	in	IN	_	12	case
12	patients	patient	NNS	_	7	nmod
13	being	be	VBG	_	14	auxpass
14	treated	treat	VBN	_	12	acl
15	with	with	IN	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	have	have	VBP	_	19	aux
18	been	be	VBN	_	19	auxpass
19	reported	report	VBN	_	0	ROOT
20	.	.	.	_	19	punct

1	Thus	thus	RB	_	9	advmod
2	,	,	,	_	9	punct
3	results	result	NNS	_	9	nsubjpass
4	of	of	IN	_	6	case
5	the	the	DT	_	6	det
6	DST	DST	NNP	_	3	nmod
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	interpreted	interpret	VBN	_	0	ROOT
10	with	with	IN	_	11	case
11	caution	caution	NN	_	9	nmod
12	in	in	IN	_	14	case
13	these	these	DT	_	14	det
14	patients	patient	NNS	_	11	nmod
15	.	.	.	_	9	punct

1	Patients	patient	NNS	_	6	nsubj
2	on	on	IN	_	4	case
3	drug1	drug1	NN	_	4	compound
4	therapy	therapy	NN	_	1	nmod
5	may	may	MD	_	6	aux
6	require	require	VB	_	0	ROOT
7	dosage	dosage	NN	_	8	compound
8	adjustment	adjustment	NN	_	6	dobj
9	of	of	IN	_	11	case
10	the	the	DT	_	11	det
11	anticoagulant	anticoagulant	JJ	_	8	nmod
12	during	during	IN	_	16	nmod
13	and	and	CC	_	12	cc
14	after	after	IN	_	12	conj
15	drug2	drug2	NN	_	16	compound
16	therapy	therapy	NN	_	6	nmod
17	.	.	.	_	6	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	use	use	NN	_	6	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	usually	usually	RB	_	6	advmod
6	depresses	depress	VBZ	_	0	ROOT
7	drug2	drug2	NN	_	8	compound
8	activity	activity	NN	_	6	dobj
9	and	and	CC	_	6	cc
10	may	may	MD	_	11	aux
11	necessitate	necessitate	VB	_	6	conj
12	raising	raise	VBG	_	11	xcomp
13	the	the	DT	_	14	det
14	dosage	dosage	NN	_	12	dobj
15	.	.	.	_	6	punct

1	The	the	DT	_	3	det
2	concomitant	concomitant	JJ	_	3	amod
3	administration	administration	NN	_	8	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	has	have	VBZ	_	8	aux
7	been	be	VBN	_	8	auxpass
8	reported	report	VBN	_	0	ROOT
9	to	to	TO	_	10	mark
10	reduce	reduce	VB	_	8	xcomp
11	the	the	DT	_	12	det
12	efficacy	efficacy	NN	_	10	dobj
13	of	of	IN	_	15	case
14	oral	oral	JJ	_	15	amod
15	drug2	drug2	NN	_	12	nmod
16	and	and	CC	_	10	cc
17	to	to	TO	_	18	mark
18	increase	increase	VB	_	10	conj
19	the	the	DT	_	20	det
20	incidence	incidence	NN	_	18	dobj
21	of	of	IN	_	23	case
22	breakthrough	breakthrough	NN	_	23	compound
23	bleeding	bleeding	NN	_	20	nmod
24	.	.	.	_	8	punct

1	The	the	DT	_	3	det
2	concomitant	concomitant	JJ	_	3	amod
3	administration	administration	NN	_	15	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	-	-	:	_	3	punct
9	containing	contain	VBG	_	3	acl
10	drug3	drug3	NN	_	9	dobj
11	has	have	VBZ	_	15	aux
12	not	not	RB	_	15	neg
13	been	be	VBN	_	15	auxpass
14	formally	formally	RB	_	15	advmod
15	studied	study	VBN	_	0	ROOT
16	.	.	.	_	15	punct

1	Although	although	IN	_	3	mark
2	drug1	drug1	NN	_	3	nsubj
3	has	have	VBZ	_	17	advcl
4	a	a	DT	_	6	det
5	lower	lower	JJR	_	6	amod
6	affinity	affinity	NN	_	3	dobj
7	for	for	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	than	than	IN	_	11	case
10	for	for	IN	_	11	case
11	drug3	drug3	NN	_	6	nmod
12	,	,	,	_	17	punct
13	drug4	drug4	NN	_	17	nsubjpass
14	should	should	MD	_	17	aux
15	not	not	RB	_	17	neg
16	be	be	VB	_	17	auxpass
17	taken	take	VBN	_	0	ROOT
18	with	with	IN	_	19	case
19	drug5	drug5	NN	_	17	nmod
20	-	-	:	_	19	punct
21	containing	contain	VBG	_	19	acl
22	drug6	drug6	NN	_	21	dobj
23	.	.	.	_	17	punct

1	In	in	IN	_	3	case
2	healthy	healthy	JJ	_	3	amod
3	volunteers	volunteer	NNS	_	6	nmod
4	,	,	,	_	6	punct
5	drug1	drug1	NN	_	6	nsubj
6	had	have	VBD	_	0	ROOT
7	no	no	DT	_	8	neg
8	effect	effect	NN	_	6	dobj
9	on	on	IN	_	11	case
10	the	the	DT	_	11	det
11	pharmacokinetics	pharmacokinetic	NNS	_	6	nmod
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	.	.	.	_	6	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	11	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	on	on	IN	_	7	case
6	drug2	drug2	NN	_	7	compound
7	pharmacokinetics	pharmacokinetic	NNS	_	2	nmod
8	has	have	VBZ	_	11	aux
9	not	not	RB	_	11	neg
10	been	be	VBN	_	11	auxpass
11	studied	study	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	The	the	DT	_	3	det
2	concomitant	concomitant	JJ	_	3	amod
3	administration	administration	NN	_	12	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	has	have	VBZ	_	12	aux
9	not	not	RB	_	12	neg
10	been	be	VBN	_	12	auxpass
11	formally	formally	RB	_	12	advmod
12	studied	study	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	Doses	dose	NNS	_	0	ROOT
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	up	up	IN	_	6	advmod
5	to	to	TO	_	6	dep
6	200	200	CD	_	7	nummod
7	mg	mg	NN	_	9	nsubjpass
8	were	be	VBD	_	9	auxpass
9	allowed	allow	VBN	_	1	acl:relcl
10	in	in	IN	_	12	case
11	clinical	clinical	JJ	_	12	amod
12	studies	study	NNS	_	9	nmod
13	without	without	IN	_	15	case
14	negative	negative	JJ	_	15	amod
15	consequences	consequence	NNS	_	12	nmod
16	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	interaction	interaction	NN	_	11	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	2	nmod
7	has	have	VBZ	_	11	aux
8	not	not	RB	_	11	neg
9	been	be	VBN	_	11	auxpass
10	formally	formally	RB	_	11	advmod
11	studied	study	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	No	no	DT	_	2	neg
2	inhibition	inhibition	NN	_	9	nsubjpass
3	of	of	IN	_	5	case
4	drug1	drug1	NN	_	5	compound
5	metabolism	metabolism	NN	_	2	nmod
6	by	by	IN	_	7	case
7	drug2	drug2	NN	_	2	nmod
8	is	be	VBZ	_	9	auxpass
9	expected	expect	VBN	_	0	ROOT
10	based	base	VBN	_	13	case
11	on	on	IN	_	13	case
12	the	the	DT	_	13	det
13	results	result	NNS	_	9	advcl
14	of	of	IN	_	18	case
15	an	a	DT	_	18	det
16	in	in	FW	_	18	amod
17	vitro	vitro	FW	_	16	dep
18	study	study	NN	_	13	nmod
19	.	.	.	_	9	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	should	should	MD	_	5	aux
3	not	not	RB	_	5	neg
4	be	be	VB	_	5	auxpass
5	combined	combine	VBN	_	20	csubjpass
6	with	with	IN	_	10	case
7	other	other	JJ	_	10	amod
8	iron	iron	NN	_	10	compound
9	chelator	chelator	NN	_	10	compound
10	therapies	therapy	NNS	_	5	nmod
11	,	,	,	_	10	punct
12	as	as	IN	_	13	case
13	safety	safety	NN	_	10	nmod
14	of	of	IN	_	16	case
15	such	such	JJ	_	16	amod
16	combinations	combination	NNS	_	13	nmod
17	has	have	VBZ	_	20	aux
18	not	not	RB	_	20	neg
19	been	be	VBN	_	20	auxpass
20	established	establish	VBN	_	0	ROOT
21	.	.	.	_	20	punct

1	Drug/Food	Drug/Food	NNP	_	2	compound
2	Interactions	interaction	NNS	_	0	ROOT
3	The	the	DT	_	12	nsubjpass
4	bioavailability	bioavailability	NN	_	3	amod
5	-LRB-	-lrb-	-LRB-	_	6	punct
6	AUC	auc	NN	_	4	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	4	nmod
10	was	be	VBD	_	12	auxpass
11	variably	variably	RB	_	12	advmod
12	increased	increase	VBN	_	2	acl:relcl
13	when	when	WRB	_	14	advmod
14	taken	take	VBN	_	12	advcl
15	with	with	IN	_	17	case
16	a	a	DT	_	17	det
17	meal	meal	NN	_	14	nmod
18	.	.	.	_	2	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	taken	take	VBN	_	0	ROOT
5	on	on	IN	_	8	case
6	an	a	DT	_	8	det
7	empty	empty	JJ	_	8	amod
8	stomach	stomach	NN	_	4	nmod
9	30	30	CD	_	10	nummod
10	minutes	minute	NNS	_	8	nmod
11	before	before	IN	_	10	mark
12	eating	eat	VBG	_	10	dep
13	.	.	.	_	4	punct

1	drug1	drug1	NN	_	2	compound
2	tablets	tablet	NNS	_	8	nsubjpass
3	for	for	IN	_	5	case
4	oral	oral	JJ	_	5	amod
5	suspension	suspension	NN	_	2	nmod
6	can	can	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	dispersed	disperse	VBN	_	0	ROOT
9	in	in	IN	_	10	case
10	water	water	NN	_	8	nmod
11	,	,	,	_	10	punct
12	orange	orange	JJ	_	13	amod
13	juice	juice	NN	_	10	conj
14	,	,	,	_	10	punct
15	or	or	CC	_	10	cc
16	apple	apple	NN	_	17	compound
17	juice	juice	NN	_	10	conj
18	.	.	.	_	8	punct

1	The	the	DT	_	2	det
2	use	use	NN	_	12	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	in	in	IN	_	6	case
6	patients	patient	NNS	_	2	nmod
7	who	who	WP	_	9	nsubj
8	are	be	VBP	_	9	aux
9	receiving	receive	VBG	_	6	acl:relcl
10	drug2	drug2	NN	_	9	dobj
11	may	may	MD	_	12	aux
12	potentiate	potentiate	VB	_	0	ROOT
13	renal	renal	JJ	_	15	amod
14	disease	disease	NN	_	15	compound
15	states	state	NNS	_	12	dobj
16	.	.	.	_	12	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	5	nsubj
4	have	have	VBP	_	5	aux
5	shown	show	VBN	_	0	ROOT
6	that	that	IN	_	18	mark
7	drug1	drug1	NN	_	8	compound
8	anion	anion	NN	_	18	nsubj
9	,	,	,	_	18	punct
10	because	because	IN	_	13	case
11	of	of	IN	_	10	mwe
12	its	its	PRP$	_	13	nmod:poss
13	affinity	affinity	NN	_	18	nmod
14	for	for	IN	_	15	case
15	protein	protein	NN	_	13	nmod
16	,	,	,	_	18	punct
17	may	may	MD	_	18	aux
18	displace	displace	VB	_	5	ccomp
19	from	from	IN	_	22	case
20	their	they	PRP$	_	22	nmod:poss
21	binding	binding	NN	_	22	compound
22	sites	site	NNS	_	18	nmod
23	other	other	JJ	_	24	amod
24	drugs	drug	NNS	_	22	dep
25	which	which	WDT	_	28	nsubj
26	are	be	VBP	_	28	cop
27	also	also	RB	_	28	advmod
28	albumin-bound	albumin-bound	JJ	_	24	acl:relcl
29	.	.	.	_	5	punct

1	Theoretically	theoretically	RB	_	10	advmod
2	,	,	,	_	10	punct
3	the	the	DT	_	5	det
4	drug1	drug1	NN	_	5	compound
5	anion	anion	NN	_	10	nsubjpass
6	itself	itself	PRP	_	5	nmod:npmod
7	could	could	MD	_	10	aux
8	likewise	likewise	RB	_	10	advmod
9	be	be	VB	_	10	auxpass
10	displaced	displace	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	Short-term	short-term	JJ	_	3	amod
2	controlled	controlled	JJ	_	3	amod
3	studies	study	NNS	_	4	nsubj
4	failed	fail	VBD	_	0	ROOT
5	to	to	TO	_	6	mark
6	show	show	VB	_	4	xcomp
7	that	that	IN	_	12	mark
8	taking	take	VBG	_	12	csubj
9	the	the	DT	_	10	det
10	drug	drug	NN	_	8	dobj
11	significantly	significantly	RB	_	12	advmod
12	affects	affect	VBZ	_	6	ccomp
13	prothrombin	prothrombin	NN	_	14	compound
14	times	time	NNS	_	12	dobj
15	when	when	WRB	_	16	advmod
16	administered	administer	VBN	_	12	advcl
17	to	to	TO	_	18	case
18	individuals	individual	NNS	_	16	nmod
19	on	on	IN	_	20	case
20	drug1	drug1	NN	_	18	nmod
21	.	.	.	_	4	punct

1	Caution	caution	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	advised	advise	VBN	_	0	ROOT
4	nonetheless	nonetheless	RB	_	3	advmod
5	,	,	,	_	3	punct
6	since	since	IN	_	10	mark
7	interactions	interaction	NNS	_	10	nsubjpass
8	have	have	VBP	_	10	aux
9	been	be	VBN	_	10	auxpass
10	seen	see	VBN	_	3	advcl
11	with	with	IN	_	14	case
12	other	other	JJ	_	14	amod
13	nonsteroidal	nonsteroidal	JJ	_	14	amod
14	agents	agent	NNS	_	10	nmod
15	of	of	IN	_	17	case
16	this	this	DT	_	17	det
17	class	class	NN	_	14	nmod
18	.	.	.	_	3	punct

1	Similarly	similarly	RB	_	16	advmod
2	,	,	,	_	16	punct
3	patients	patient	NNS	_	16	nsubjpass
4	receiving	receive	VBG	_	3	acl
5	the	the	DT	_	6	det
6	drug	drug	NN	_	4	dobj
7	and	and	CC	_	3	cc
8	a	a	DT	_	9	det
9	drug1	drug1	NN	_	3	conj
10	,	,	,	_	9	punct
11	drug2	drug2	NN	_	9	conj
12	or	or	CC	_	9	cc
13	drug3	drug3	NN	_	9	conj
14	should	should	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	observed	observe	VBN	_	0	ROOT
17	for	for	IN	_	18	case
18	signs	sign	NNS	_	16	nmod
19	of	of	IN	_	20	case
20	toxicity	toxicity	NN	_	18	nmod
21	to	to	TO	_	23	case
22	these	these	DT	_	23	det
23	drugs	drug	NNS	_	18	nmod
24	.	.	.	_	16	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	9	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	is	be	VBZ	_	9	auxpass
8	not	not	RB	_	9	neg
9	recommended	recommend	VBN	_	0	ROOT
10	because	because	IN	_	13	mark
11	drug3	drug3	NN	_	13	nsubjpass
12	is	be	VBZ	_	13	auxpass
13	displaced	displace	VBN	_	9	advcl
14	from	from	IN	_	17	case
15	its	its	PRP$	_	17	nmod:poss
16	binding	binding	NN	_	17	amod
17	sites	site	NNS	_	13	nmod
18	during	during	IN	_	21	case
19	the	the	DT	_	21	det
20	concomitant	concomitant	JJ	_	21	amod
21	administration	administration	NN	_	13	nmod
22	of	of	IN	_	23	case
23	drug4	drug4	NN	_	21	nmod
24	,	,	,	_	13	punct
25	resulting	result	VBG	_	13	advcl
26	in	in	IN	_	29	case
27	lower	lower	JJR	_	29	amod
28	plasma	plasma	NN	_	29	compound
29	concentrations	concentration	NNS	_	25	nmod
30	and	and	CC	_	29	cc
31	peak	peak	JJ	_	33	amod
32	plasma	plasma	NN	_	33	compound
33	levels	level	NNS	_	29	conj
34	.	.	.	_	9	punct

1	The	the	DT	_	3	det
2	natriuretic	natriuretic	JJ	_	3	amod
3	effect	effect	NN	_	8	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	has	have	VBZ	_	8	aux
7	been	be	VBN	_	8	auxpass
8	reported	report	VBN	_	0	ROOT
9	to	to	TO	_	11	mark
10	be	be	VB	_	11	auxpass
11	inhibited	inhibit	VBN	_	8	xcomp
12	by	by	IN	_	14	case
13	some	some	DT	_	14	det
14	drugs	drug	NNS	_	11	nmod
15	of	of	IN	_	17	case
16	this	this	DT	_	17	det
17	class	class	NN	_	14	nmod
18	.	.	.	_	8	punct

1	Inhibition	inhibition	NN	_	16	nsubjpass
2	of	of	IN	_	5	case
3	renal	renal	JJ	_	5	amod
4	drug1	drug1	NN	_	5	compound
5	clearance	clearance	NN	_	1	nmod
6	leading	lead	VBG	_	5	acl
7	to	to	TO	_	8	case
8	increases	increase	NNS	_	6	nmod
9	in	in	IN	_	12	case
10	plasma	plasma	NN	_	12	compound
11	drug2	drug2	NN	_	12	compound
12	concentrations	concentration	NNS	_	8	nmod
13	has	have	VBZ	_	16	aux
14	also	also	RB	_	16	advmod
15	been	be	VBN	_	16	auxpass
16	reported	report	VBN	_	0	ROOT
17	.	.	.	_	16	punct

1	drug1	drug1	NN	_	6	nsubj
2	and	and	CC	_	1	cc
3	other	other	JJ	_	4	amod
4	drug2	drug2	NN	_	1	conj
5	can	can	MD	_	6	aux
6	reduce	reduce	VB	_	0	ROOT
7	the	the	DT	_	9	det
8	antihypertensive	antihypertensive	JJ	_	9	amod
9	effect	effect	NN	_	6	dobj
10	of	of	IN	_	11	case
11	drug3	drug3	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	other	other	JJ	_	14	amod
14	drug4	drug4	NN	_	11	conj
15	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	given	give	VBN	_	1	acl
3	concurrently	concurrently	RB	_	4	advmod
4	increases	increase	VBZ	_	2	dobj
5	drug2	drug2	NN	_	8	compound
6	anion	anion	NN	_	8	compound
7	plasma	plasma	NN	_	8	compound
8	levels	level	NNS	_	4	dobj
9	and	and	CC	_	4	cc
10	extends	extend	VBZ	_	4	conj
11	its	its	PRP$	_	13	nmod:poss
12	plasma	plasma	NN	_	13	compound
13	half-life	half-life	NN	_	10	dobj
14	significantly	significantly	RB	_	10	advmod
15	.	.	.	_	1	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	if	if	IN	_	8	mark
6	drug1	drug1	NN	_	8	nsubjpass
7	is	be	VBZ	_	8	auxpass
8	administered	administer	VBN	_	4	advcl
9	concomitantly	concomitantly	RB	_	8	advmod
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	8	nmod
12	.	.	.	_	4	punct

1	drug1	drug1	NN	_	9	nsubjpass
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	and	and	CC	_	1	cc
5	other	other	JJ	_	6	amod
6	drug3	drug3	NN	_	1	conj
7	have	have	VBP	_	9	aux
8	been	be	VBN	_	9	auxpass
9	reported	report	VBN	_	0	ROOT
10	to	to	TO	_	11	mark
11	reduce	reduce	VB	_	9	xcomp
12	the	the	DT	_	14	det
13	tubular	tubular	JJ	_	14	amod
14	secretion	secretion	NN	_	11	dobj
15	of	of	IN	_	16	case
16	drug4	drug4	NN	_	14	nmod
17	in	in	IN	_	20	case
18	an	a	DT	_	20	det
19	animal	animal	NN	_	20	compound
20	model	model	NN	_	11	nmod
21	,	,	,	_	11	punct
22	possibly	possibly	RB	_	23	advmod
23	increasing	increase	VBG	_	11	advcl
24	the	the	DT	_	25	det
25	toxicity	toxicity	NN	_	23	dobj
26	of	of	IN	_	27	case
27	drug5	drug5	NN	_	25	nmod
28	.	.	.	_	9	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	4	amod
2	Test	test	NN	_	4	compound
3	Interactions	interaction	NNS	_	4	compound
4	drug1	drug1	NN	_	6	nsubj
5	may	may	MD	_	6	aux
6	decrease	decrease	VB	_	0	ROOT
7	platelet	platelet	NN	_	8	compound
8	aggregation	aggregation	NN	_	6	dobj
9	and	and	CC	_	6	cc
10	prolong	prolong	VB	_	6	conj
11	bleeding	bleeding	JJ	_	12	amod
12	time	time	NN	_	10	dobj
13	.	.	.	_	6	punct

1	This	this	DT	_	2	det
2	effect	effect	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	kept	keep	VBN	_	0	ROOT
6	in	in	IN	_	7	case
7	mind	mind	NN	_	5	nmod
8	when	when	WRB	_	12	advmod
9	bleeding	bleed	VBG	_	10	amod
10	times	time	NNS	_	12	nsubjpass
11	are	be	VBP	_	12	auxpass
12	determined	determine	VBN	_	5	advcl
13	.	.	.	_	5	punct

1	The	the	DT	_	2	det
2	administration	administration	NN	_	6	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	may	may	MD	_	6	aux
6	result	result	VB	_	0	ROOT
7	in	in	IN	_	10	case
8	increased	increase	VBN	_	10	amod
9	urinary	urinary	JJ	_	10	amod
10	values	value	NNS	_	6	nmod
11	for	for	IN	_	13	case
12	17-ketogenic	17-ketogenic	JJ	_	13	amod
13	steroids	steroid	NNS	_	10	nmod
14	because	because	IN	_	17	case
15	of	of	IN	_	14	mwe
16	an	a	DT	_	17	det
17	interaction	interaction	NN	_	6	nmod
18	between	between	IN	_	20	case
19	the	the	DT	_	20	det
20	drug	drug	NN	_	17	nmod
21	and/or	and/or	CC	_	20	cc
22	its	its	PRP$	_	23	nmod:poss
23	metabolites	metabolite	NNS	_	20	conj
24	with	with	IN	_	25	case
25	m-dinitrobenzene	m-dinitrobenzene	NN	_	23	nmod
26	used	use	VBN	_	20	acl
27	in	in	IN	_	29	case
28	this	this	DT	_	29	det
29	assay	assay	NN	_	26	nmod
30	.	.	.	_	6	punct

1	Although	although	IN	_	10	mark
2	17-hydroxy-corticosteroid	17-hydroxy-corticosteroid	JJ	_	3	amod
3	measurements	measurement	NNS	_	10	nsubj
4	-LRB-	-lrb-	-LRB-	_	6	punct
5	Porter-Silber	Porter-Silber	NNP	_	6	compound
6	test	test	NN	_	3	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	do	do	VBP	_	10	aux
9	not	not	RB	_	10	neg
10	appear	appear	VB	_	18	advcl
11	to	to	TO	_	14	mark
12	be	be	VB	_	14	auxpass
13	artifactually	artifactually	RB	_	14	advmod
14	altered	alter	VBN	_	10	xcomp
15	,	,	,	_	18	punct
16	it	it	PRP	_	18	nsubjpass
17	is	be	VBZ	_	18	auxpass
18	suggested	suggest	VBN	_	33	csubjpass
19	that	that	IN	_	25	mark
20	therapy	therapy	NN	_	25	nsubjpass
21	with	with	IN	_	22	case
22	drug1	drug1	NN	_	20	nmod
23	be	be	VB	_	25	auxpass
24	temporarily	temporarily	RB	_	25	advmod
25	discontinued	discontinue	VBN	_	18	ccomp
26	72	72	CD	_	27	nummod
27	hours	hour	NNS	_	25	nmod
28	before	before	IN	_	27	case
29	adrenal	adrenal	JJ	_	31	amod
30	function	function	NN	_	31	compound
31	tests	test	NNS	_	27	dep
32	are	be	VBP	_	33	auxpass
33	performed	perform	VBN	_	0	ROOT
34	if	if	IN	_	38	mark
35	the	the	DT	_	37	det
36	Porter-Silber	Porter-Silber	NNP	_	37	compound
37	test	test	NN	_	38	nsubj
38	is	be	VBZ	_	33	advcl
39	to	to	TO	_	41	mark
40	be	be	VB	_	41	auxpass
41	used	use	VBN	_	38	xcomp
42	.	.	.	_	33	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	interfere	interfere	VB	_	0	ROOT
4	with	with	IN	_	7	case
5	some	some	DT	_	7	det
6	urinary	urinary	JJ	_	7	amod
7	assays	assay	NNS	_	3	nmod
8	of	of	IN	_	11	case
9	5-hydroxy	5-hydroxy	JJ	_	11	amod
10	indoleacetic	indoleacetic	JJ	_	11	amod
11	acid	acid	NN	_	7	nmod
12	-LRB-	-lrb-	-LRB-	_	13	punct
13	5HIAA	5hiaa	NN	_	11	appos
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	.	.	.	_	3	punct

1	The	the	DT	_	3	det
2	concurrent	concurrent	JJ	_	3	amod
3	use	use	NN	_	41	nsubj
4	of	of	IN	_	8	case
5	two	two	CD	_	8	nummod
6	or	or	CC	_	5	cc
7	more	more	JJR	_	5	conj
8	drugs	drug	NNS	_	3	nmod
9	with	with	IN	_	11	case
10	anticholinergic	anticholinergic	JJ	_	11	amod
11	activity	activity	NN	_	3	nmod
12	--	--	:	_	11	punct
13	such	such	JJ	_	16	case
14	as	as	IN	_	13	mwe
15	an	a	DT	_	16	det
16	drug1	drug1	NN	_	11	nmod
17	-LRB-	-lrb-	-LRB-	_	20	punct
18	eg	eg	FW	_	20	dep
19	,	,	,	_	20	punct
20	drug2	drug2	NN	_	16	appos
21	-RRB-	-rrb-	-RRB-	_	20	punct
22	,	,	,	_	16	punct
23	an	a	DT	_	24	det
24	drug3	drug3	NN	_	16	conj
25	-LRB-	-lrb-	-LRB-	_	28	punct
26	eg	eg	FW	_	28	dep
27	,	,	,	_	28	punct
28	drug4	drug4	NN	_	24	appos
29	-RRB-	-rrb-	-RRB-	_	28	punct
30	,	,	,	_	16	punct
31	and/or	and/or	CC	_	16	cc
32	a	a	DT	_	33	det
33	drug5	drug5	NN	_	16	conj
34	-LRB-	-lrb-	-LRB-	_	37	punct
35	eg	eg	FW	_	37	dep
36	,	,	,	_	37	punct
37	drug6	drug6	NN	_	33	appos
38	-RRB-	-rrb-	-RRB-	_	37	punct
39	--	--	:	_	11	punct
40	commonly	commonly	RB	_	41	advmod
41	results	result	VBZ	_	0	ROOT
42	in	in	IN	_	45	case
43	excessive	excessive	JJ	_	45	amod
44	anticholinergic	anticholinergic	JJ	_	45	amod
45	effects	effect	NNS	_	41	nmod
46	,	,	,	_	45	punct
47	including	include	VBG	_	49	case
48	dry	dry	JJ	_	49	amod
49	mouth	mouth	NN	_	45	nmod
50	and	and	CC	_	49	cc
51	associated	associate	VBN	_	53	amod
52	dental	dental	JJ	_	53	amod
53	complications	complication	NNS	_	49	conj
54	,	,	,	_	45	punct
55	blurred	blur	VBD	_	45	conj
56	vision	vision	NN	_	55	dobj
57	,	,	,	_	45	punct
58	and	and	CC	_	45	cc
59	,	,	,	_	45	punct
60	in	in	IN	_	61	case
61	patients	patient	NNS	_	45	nmod
62	exposed	expose	VBN	_	61	acl
63	to	to	TO	_	65	case
64	high	high	JJ	_	65	amod
65	temperature	temperature	NN	_	62	nmod
66	and	and	CC	_	65	cc
67	humidity	humidity	NN	_	65	conj
68	,	,	,	_	61	punct
69	hyperpyrexia	hyperpyrexia	NN	_	61	appos
70	.	.	.	_	41	punct

1	Interactions	interaction	NNS	_	4	nsubj
2	may	may	MD	_	4	aux
3	also	also	RB	_	4	advmod
4	occur	occur	VB	_	0	ROOT
5	with	with	IN	_	7	case
6	the	the	DT	_	7	det
7	following	following	NN	_	4	nmod
8	:	:	:	_	4	punct
9	drug1	drug1	NN	_	11	compound
10	/	/	:	_	11	punct
11	drug2	drug2	NN	_	4	parataxis
12	,	,	,	_	11	punct
13	drugs	drug	NNS	_	11	appos
14	used	use	VBN	_	13	acl
15	to	to	TO	_	16	mark
16	treat	treat	VB	_	14	xcomp
17	an	a	DT	_	19	det
18	overactive	overactive	JJ	_	19	amod
19	thyroid	thyroid	NN	_	16	dobj
20	,	,	,	_	19	punct
21	drug3	drug3	NN	_	19	conj
22	-LRB-	-lrb-	-LRB-	_	25	punct
23	e.g.	e.g.	FW	_	25	dep
24	,	,	,	_	25	punct
25	drug4	drug4	NN	_	21	appos
26	-RRB-	-rrb-	-RRB-	_	25	punct
27	,	,	,	_	19	punct
28	drug5	drug5	NN	_	19	conj
29	,	,	,	_	19	punct
30	drug6	drug6	NN	_	19	conj
31	,	,	,	_	19	punct
32	drug7	drug7	NN	_	19	conj
33	,	,	,	_	19	punct
34	drug8	drug8	NN	_	19	conj
35	,	,	,	_	19	punct
36	drug9	drug9	NN	_	19	conj
37	,	,	,	_	19	punct
38	drug10	drug10	NN	_	19	conj
39	,	,	,	_	19	punct
40	drug11	drug11	NN	_	19	conj
41	,	,	,	_	19	punct
42	drug12	drug12	NN	_	44	compound
43	pain	pain	NN	_	44	compound
44	medication	medication	NN	_	19	conj
45	-LRB-	-lrb-	-LRB-	_	48	punct
46	e.g.	e.g.	FW	_	48	dep
47	,	,	,	_	48	punct
48	drug13	drug13	NN	_	44	appos
49	-RRB-	-rrb-	-RRB-	_	48	punct
50	,	,	,	_	19	punct
51	drugs	drug	NNS	_	19	appos
52	used	use	VBN	_	51	acl
53	to	to	TO	_	54	mark
54	aid	aid	VB	_	52	xcomp
55	sleep	sleep	NN	_	54	dobj
56	,	,	,	_	55	punct
57	drowsiness-causing	drowsiness-causing	JJ	_	58	amod
58	drug14	drug14	NN	_	55	conj
59	-LRB-	-lrb-	-LRB-	_	62	punct
60	e.g.	e.g.	FW	_	62	dep
61	,	,	,	_	62	punct
62	drug15	drug15	NN	_	58	dep
63	-RRB-	-rrb-	-RRB-	_	62	punct
64	,	,	,	_	55	punct
65	any	any	DT	_	67	det
66	other	other	JJ	_	67	amod
67	drugs	drug	NNS	_	55	appos
68	that	that	WDT	_	70	nsubj
69	may	may	MD	_	70	aux
70	make	make	VB	_	67	acl:relcl
71	you	you	PRP	_	72	nsubj
72	drowsy	drowsy	JJ	_	70	xcomp
73	.	.	.	_	4	punct

1	Drug	drug	NN	_	2	compound
2	Interactions	interaction	NNS	_	0	ROOT
3	.	.	.	_	2	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	administered	administer	VBN	_	0	ROOT
5	to	to	TO	_	6	case
6	patients	patient	NNS	_	4	nmod
7	receiving	receive	VBG	_	6	acl
8	drug2	drug2	NN	_	7	dobj
9	or	or	CC	_	8	cc
10	drug3	drug3	NN	_	8	conj
11	without	without	IN	_	13	case
12	adverse	adverse	JJ	_	13	amod
13	effects	effect	NNS	_	4	nmod
14	.	.	.	_	4	punct

1	During	during	IN	_	2	case
2	administration	administration	NN	_	12	nmod
3	of	of	IN	_	6	case
4	multiple	multiple	JJ	_	6	amod
5	oral	oral	JJ	_	6	amod
6	doses	dose	NNS	_	2	nmod
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	to	to	TO	_	11	case
10	healthy	healthy	JJ	_	11	amod
11	subjects	subject	NNS	_	2	nmod
12	stabilized	stabilize	VBD	_	0	ROOT
13	on	on	IN	_	16	case
14	a	a	DT	_	16	det
15	maintenance	maintenance	NN	_	16	compound
16	dose	dose	NN	_	12	nmod
17	of	of	IN	_	18	case
18	drug2	drug2	NN	_	16	nmod
19	,	,	,	_	16	punct
20	a	a	DT	_	25	det
21	13	13	CD	_	22	compound
22	%	%	NN	_	24	dep
23	-19	-19	CD	_	24	compound
24	%	%	NN	_	25	dep
25	increase	increase	NN	_	30	nsubj
26	in	in	IN	_	29	case
27	plasma	plasma	NN	_	29	compound
28	drug3	drug3	NN	_	29	compound
29	levels	level	NNS	_	25	nmod
30	occurred	occur	VBD	_	16	acl:relcl
31	at	at	IN	_	33	case
32	six	six	CD	_	33	nummod
33	hours	hour	NNS	_	30	nmod
34	postdose	postdose	NN	_	33	dep
35	.	.	.	_	12	punct

1	In	in	IN	_	3	case
2	a	a	DT	_	3	det
3	study	study	NN	_	17	nmod
4	involving	involve	VBG	_	3	acl
5	healthy	healthy	JJ	_	6	amod
6	subjects	subject	NNS	_	4	dobj
7	receiving	receive	VBG	_	6	acl
8	drug1	drug1	NN	_	7	dobj
9	and	and	CC	_	8	cc
10	drug2	drug2	NN	_	8	conj
11	concurrently	concurrently	RB	_	7	advmod
12	,	,	,	_	17	punct
13	plasma	plasma	NN	_	15	compound
14	drug3	drug3	NN	_	15	compound
15	levels	level	NNS	_	17	nsubjpass
16	were	be	VBD	_	17	auxpass
17	increased	increase	VBN	_	0	ROOT
18	about	about	RB	_	19	advmod
19	20	20	CD	_	20	nummod
20	%	%	NN	_	17	dobj
21	and	and	CC	_	20	cc
22	drug4	drug4	NN	_	23	compound
23	levels	level	NNS	_	20	conj
24	were	be	VBD	_	25	auxpass
25	increased	increase	VBN	_	17	nmod
26	about	about	IN	_	27	advmod
27	30	30	CD	_	28	nummod
28	%	%	NN	_	25	nmod:npmod
29	compared	compare	VBN	_	25	dep
30	to	to	TO	_	31	mark
31	control	control	VB	_	29	xcomp
32	values	value	NNS	_	31	dobj
33	.	.	.	_	17	punct

1	In	in	IN	_	5	case
2	this	this	DT	_	5	det
3	formal	formal	JJ	_	5	amod
4	interaction	interaction	NN	_	5	compound
5	study	study	NN	_	12	nmod
6	,	,	,	_	12	punct
7	drug1	drug1	NN	_	12	nsubjpass
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	were	be	VBD	_	12	auxpass
11	each	each	DT	_	12	dep
12	found	find	VBN	_	0	ROOT
13	to	to	TO	_	14	mark
14	have	have	VB	_	12	xcomp
15	negative	negative	JJ	_	17	amod
16	inotropic	inotropic	JJ	_	17	amod
17	effects	effect	NNS	_	14	dobj
18	;	;	:	_	12	punct

1	when	when	WRB	_	5	advmod
2	the	the	DT	_	3	det
3	drugs	drug	NNS	_	5	nsubjpass
4	were	be	VBD	_	5	auxpass
5	administered	administer	VBN	_	11	advcl
6	together	together	RB	_	5	advmod
7	,	,	,	_	11	punct
8	the	the	DT	_	9	det
9	effects	effect	NNS	_	11	nsubj
10	were	be	VBD	_	11	cop
11	additive	additive	JJ	_	0	ROOT
12	.	.	.	_	11	punct

1	The	the	DT	_	2	det
2	effects	effect	NNS	_	15	nsubj
3	of	of	IN	_	5	case
4	concomitant	concomitant	JJ	_	5	amod
5	administration	administration	NN	_	2	nmod
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	on	on	IN	_	13	case
11	the	the	DT	_	13	det
12	PR	pr	NN	_	13	compound
13	interval	interval	NN	_	2	nmod
14	were	be	VBD	_	15	cop
15	less	less	JJR	_	0	ROOT
16	than	than	IN	_	17	case
17	additive	additive	JJ	_	15	advcl
18	.	.	.	_	15	punct

1	In	in	IN	_	4	case
2	drug1	drug1	NN	_	4	compound
3	clinical	clinical	JJ	_	4	amod
4	trials	trial	NNS	_	14	nmod
5	,	,	,	_	14	punct
6	patients	patient	NNS	_	14	nsubj
7	who	who	WP	_	9	nsubj
8	were	be	VBD	_	9	aux
9	receiving	receive	VBG	_	6	acl:relcl
10	drug2	drug2	NN	_	9	dobj
11	concurrently	concurrently	RB	_	14	advmod
12	did	do	VBD	_	14	aux
13	not	not	RB	_	14	neg
14	experience	experience	VB	_	0	ROOT
15	an	a	DT	_	17	det
16	increased	increase	VBN	_	17	amod
17	incidence	incidence	NN	_	14	dobj
18	of	of	IN	_	20	case
19	side	side	JJ	_	20	amod
20	effects	effect	NNS	_	17	nmod
21	.	.	.	_	14	punct

1	Nevertheless	nevertheless	RB	_	16	advmod
2	,	,	,	_	16	punct
3	the	the	DT	_	4	det
4	possibility	possibility	NN	_	16	nsubjpass
5	of	of	IN	_	9	case
6	additive	additive	JJ	_	9	amod
7	negative	negative	JJ	_	9	amod
8	inotropic	inotropic	JJ	_	9	amod
9	effects	effect	NNS	_	4	nmod
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	drug2	drug2	NN	_	11	conj
14	should	should	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	recognized	recognize	VBN	_	0	ROOT
17	.	.	.	_	16	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	is	be	VBZ	_	5	auxpass
3	not	not	RB	_	5	neg
4	extensively	extensively	RB	_	5	advmod
5	bound	bind	VBN	_	0	ROOT
6	to	to	TO	_	8	case
7	plasma	plasma	NN	_	8	compound
8	proteins	protein	NNS	_	5	nmod
9	.	.	.	_	5	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	12	nsubj
4	with	with	IN	_	6	case
5	several	several	JJ	_	6	amod
6	drugs	drug	NNS	_	3	nmod
7	which	which	WDT	_	10	nsubjpass
8	may	may	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	administered	administer	VBN	_	6	acl:relcl
11	concomitantly	concomitantly	RB	_	10	advmod
12	showed	show	VBD	_	0	ROOT
13	that	that	IN	_	25	mark
14	the	the	DT	_	15	det
15	extent	extent	NN	_	25	nsubj
16	of	of	IN	_	18	case
17	drug1	drug1	NN	_	18	compound
18	binding	binding	NN	_	15	nmod
19	to	to	TO	_	22	case
20	human	human	JJ	_	22	amod
21	plasma	plasma	NN	_	22	compound
22	proteins	protein	NNS	_	18	nmod
23	is	be	VBZ	_	25	cop
24	either	either	CC	_	25	cc:preconj
25	unchanged	unchanged	JJ	_	12	ccomp
26	or	or	CC	_	25	cc
27	only	only	RB	_	29	advmod
28	slightly	slightly	RB	_	29	advmod
29	less	less	RBR	_	25	conj
30	.	.	.	_	12	punct

1	Consequently	consequently	RB	_	20	advmod
2	,	,	,	_	20	punct
3	interactions	interaction	NNS	_	20	nsubjpass
4	with	with	IN	_	6	case
5	other	other	JJ	_	6	amod
6	drugs	drug	NNS	_	3	nmod
7	which	which	WDT	_	11	nsubj
8	are	be	VBP	_	11	cop
9	highly	highly	RB	_	11	advmod
10	protein	protein	NN	_	11	nmod:npmod
11	bound	bind	VBD	_	6	acl:relcl
12	-LRB-	-lrb-	-LRB-	_	15	punct
13	e.g.	e.g.	FW	_	15	dep
14	,	,	,	_	15	punct
15	drug1	drug1	NN	_	11	dep
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	would	would	MD	_	20	aux
18	not	not	RB	_	20	neg
19	be	be	VB	_	20	auxpass
20	expected	expect	VBN	_	0	ROOT
21	.	.	.	_	20	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	in	in	IN	_	8	case
6	a	a	DT	_	8	det
7	large	large	JJ	_	8	amod
8	number	number	NN	_	4	nmod
9	of	of	IN	_	10	case
10	patients	patient	NNS	_	8	nmod
11	receiving	receive	VBG	_	10	acl
12	drug2	drug2	NN	_	11	dobj
13	without	without	IN	_	15	case
14	apparent	apparent	JJ	_	15	amod
15	interaction	interaction	NN	_	11	nmod
16	.	.	.	_	4	punct

1	Limited	limited	JJ	_	2	amod
2	data	datum	NNS	_	16	nsubj
3	in	in	IN	_	4	case
4	patients	patient	NNS	_	2	nmod
5	receiving	receive	VBG	_	4	acl
6	known	known	JJ	_	8	amod
7	enzyme	enzyme	NN	_	8	compound
8	inducers	inducer	NNS	_	5	dobj
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	drug1	drug1	NN	_	8	dep
11	,	,	,	_	10	punct
12	drug2	drug2	NN	_	10	appos
13	,	,	,	_	10	punct
14	drug3	drug3	NN	_	10	appos
15	-RRB-	-rrb-	-RRB-	_	10	punct
16	indicate	indicate	VBP	_	0	ROOT
17	only	only	RB	_	21	advmod
18	a	a	DT	_	21	det
19	30	30	CD	_	20	compound
20	%	%	NN	_	21	amod
21	increase	increase	NN	_	16	dobj
22	in	in	IN	_	24	case
23	the	the	DT	_	24	det
24	rate	rate	NN	_	21	nmod
25	of	of	IN	_	27	case
26	drug4	drug4	NN	_	27	compound
27	elimination	elimination	NN	_	24	nmod
28	.	.	.	_	16	punct

1	In	in	IN	_	3	case
2	healthy	healthy	JJ	_	3	amod
3	subjects	subject	NNS	_	18	nmod
4	receiving	receive	VBG	_	3	acl
5	drug1	drug1	NN	_	4	dobj
6	-LRB-	-lrb-	-LRB-	_	8	punct
7	1	1	CD	_	8	nummod
8	gm	gm	NN	_	5	dep
9	daily	daily	JJ	_	8	amod
10	-RRB-	-rrb-	-RRB-	_	8	punct
11	for	for	IN	_	13	case
12	one	one	CD	_	13	nummod
13	week	week	NN	_	4	nmod
14	,	,	,	_	18	punct
15	plasma	plasma	NN	_	17	compound
16	drug2	drug2	NN	_	17	compound
17	levels	level	NNS	_	18	nsubj
18	increased	increase	VBN	_	0	ROOT
19	by	by	IN	_	22	case
20	about	about	IN	_	21	advmod
21	30	30	CD	_	22	nummod
22	%	%	NN	_	18	nmod
23	and	and	CC	_	18	cc
24	half-life	half-life	NN	_	18	conj
25	increased	increase	VBN	_	24	acl
26	by	by	IN	_	29	case
27	about	about	RB	_	28	advmod
28	10	10	CD	_	29	nummod
29	%	%	NN	_	25	nmod
30	.	.	.	_	18	punct

1	When	when	WRB	_	4	advmod
2	drug1	drug1	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	added	add	VBN	_	13	advcl
5	to	to	TO	_	7	case
6	drug2	drug2	NN	_	7	compound
7	therapy	therapy	NN	_	4	nmod
8	,	,	,	_	13	punct
9	plasma	plasma	NN	_	11	compound
10	drug3	drug3	NN	_	11	compound
11	levels	level	NNS	_	13	nsubj
12	may	may	MD	_	13	aux
13	increase	increase	VB	_	0	ROOT
14	two-fold	two-fold	RB	_	13	advmod
15	or	or	CC	_	14	cc
16	more	more	RBR	_	14	conj
17	in	in	IN	_	19	case
18	some	some	DT	_	19	det
19	patients	patient	NNS	_	13	nmod
20	,	,	,	_	13	punct
21	if	if	IN	_	26	mark
22	drug4	drug4	NN	_	23	compound
23	dosage	dosage	NN	_	26	nsubjpass
24	is	be	VBZ	_	26	auxpass
25	not	not	RB	_	26	neg
26	reduced	reduce	VBN	_	13	advcl
27	.	.	.	_	13	punct

1	Drugs	drug	NNS	_	12	nsubj
2	that	that	WDT	_	3	nsubj
3	inhibit	inhibit	VBP	_	1	acl:relcl
4	cytochrome	cytochrome	NN	_	5	compound
5	P450IID6	p450iid6	NN	_	3	dobj
6	,	,	,	_	5	punct
7	such	such	JJ	_	9	case
8	as	as	IN	_	7	mwe
9	drug1	drug1	NN	_	5	nmod
10	,	,	,	_	12	punct
11	might	might	MD	_	12	aux
12	increase	increase	VB	_	0	ROOT
13	the	the	DT	_	15	det
14	plasma	plasma	NN	_	15	compound
15	concentrations	concentration	NNS	_	12	dobj
16	of	of	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	in	in	IN	_	19	case
19	patients	patient	NNS	_	12	nmod
20	that	that	WDT	_	25	nsubj
21	are	be	VBP	_	25	cop
22	on	on	IN	_	25	case
23	chronic	chronic	JJ	_	25	amod
24	drug3	drug3	NN	_	25	compound
25	therapy	therapy	NN	_	19	acl:relcl
26	;	;	:	_	12	punct

1	especially	especially	RB	_	7	advmod
2	if	if	IN	_	7	mark
3	these	these	DT	_	4	det
4	patients	patient	NNS	_	7	nsubj
5	are	be	VBP	_	7	cop
6	extensive	extensive	JJ	_	7	amod
7	metabolizers	metabolizer	NNS	_	0	ROOT
8	.	.	.	_	7	punct

1	There	there	EX	_	5	expl
2	has	have	VBZ	_	5	aux
3	been	be	VBN	_	5	cop
4	little	little	JJ	_	5	amod
5	experience	experience	NN	_	0	ROOT
6	with	with	IN	_	8	case
7	the	the	DT	_	8	det
8	coadministration	coadministration	NN	_	5	nmod
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	and	and	CC	_	8	cc
12	either	either	CC	_	13	cc:preconj
13	drug2	drug2	NN	_	8	conj
14	or	or	CC	_	13	cc
15	drug3	drug3	NN	_	13	conj
16	.	.	.	_	5	punct

1	Because	because	IN	_	6	mark
2	both	both	DT	_	6	nsubj
3	of	of	IN	_	5	case
4	these	these	DT	_	5	det
5	drugs	drug	NNS	_	2	nmod
6	have	have	VBP	_	26	advcl
7	negative	negative	JJ	_	9	amod
8	inotropic	inotropic	JJ	_	9	amod
9	properties	property	NNS	_	6	dobj
10	and	and	CC	_	6	cc
11	the	the	DT	_	12	det
12	effects	effect	NNS	_	18	nsubj
13	of	of	IN	_	14	case
14	coadministration	coadministration	NN	_	12	nmod
15	with	with	IN	_	16	case
16	drug1	drug1	NN	_	12	nmod
17	are	be	VBP	_	18	cop
18	unknown	unknown	JJ	_	6	conj
19	,	,	,	_	26	punct
20	neither	neither	CC	_	21	cc:preconj
21	drug2	drug2	NN	_	26	nsubjpass
22	nor	nor	CC	_	21	cc
23	drug3	drug3	NN	_	21	conj
24	should	should	MD	_	26	aux
25	be	be	VB	_	26	auxpass
26	administered	administer	VBN	_	0	ROOT
27	concurrently	concurrently	RB	_	26	advmod
28	with	with	IN	_	29	case
29	drug4	drug4	NN	_	26	nmod
30	unless	unless	IN	_	44	mark
31	,	,	,	_	44	punct
32	in	in	IN	_	34	case
33	the	the	DT	_	34	det
34	judgment	judgment	NN	_	44	nmod
35	of	of	IN	_	37	case
36	the	the	DT	_	37	det
37	physician	physician	NN	_	34	nmod
38	,	,	,	_	44	punct
39	the	the	DT	_	40	det
40	benefits	benefit	NNS	_	44	nsubj
41	of	of	IN	_	43	case
42	this	this	DT	_	43	det
43	combination	combination	NN	_	40	nmod
44	outweigh	outweigh	VBP	_	26	advcl
45	the	the	DT	_	46	det
46	risks	risk	NNS	_	44	dobj
47	.	.	.	_	26	punct

1	There	there	EX	_	6	expl
2	has	have	VBZ	_	6	aux
3	been	be	VBN	_	6	cop
4	too	too	RB	_	5	advmod
5	little	little	JJ	_	6	amod
6	experience	experience	NN	_	0	ROOT
7	with	with	IN	_	9	case
8	the	the	DT	_	9	det
9	coadministration	coadministration	NN	_	6	nmod
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	with	with	IN	_	13	case
13	drug2	drug2	NN	_	9	nmod
14	or	or	CC	_	13	cc
15	drug3	drug3	NN	_	13	conj
16	to	to	TO	_	17	mark
17	recommend	recommend	VB	_	6	acl
18	concomitant	concomitant	JJ	_	19	amod
19	use	use	NN	_	17	dobj
20	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	effect	effect	NN	_	24	nsubjpass
5	of	of	IN	_	7	case
6	an	a	DT	_	7	det
7	drug2	drug2	NN	_	4	nmod
8	-	-	:	_	4	punct
9	and	and	CC	_	4	cc
10	drug3	drug3	NN	_	4	conj
11	-	-	:	_	10	punct
12	containing	contain	VBG	_	10	acl
13	drug4	drug4	NN	_	12	dobj
14	-LRB-	-lrb-	-LRB-	_	15	punct
15	drug5	drug5	NN	_	13	appos
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	*	*	SYM	_	13	dep
18	on	on	IN	_	20	case
19	the	the	DT	_	20	det
20	pharmacokinetics	pharmacokinetic	NNS	_	17	nmod
21	of	of	IN	_	22	case
22	drug6	drug6	NN	_	20	nmod
23	was	be	VBD	_	24	auxpass
24	investigated	investigate	VBN	_	1	appos
25	in	in	IN	_	28	case
26	12	12	CD	_	28	nummod
27	cancer	cancer	NN	_	28	compound
28	patients	patient	NNS	_	24	nmod
29	.	.	.	_	1	punct

1	There	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	a	a	DT	_	5	det
4	small	small	JJ	_	5	amod
5	increase	increase	NN	_	2	nsubj
6	in	in	IN	_	8	case
7	plasma	plasma	NN	_	8	compound
8	concentrations	concentration	NNS	_	5	nmod
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	one	one	CD	_	13	nummod
13	metabolite	metabolite	NN	_	10	conj
14	-LRB-	-lrb-	-LRB-	_	15	punct
15	drug2	drug2	NN	_	13	appos
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	;	;	:	_	2	punct

1	there	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	no	no	DT	_	4	neg
4	effect	effect	NN	_	2	nsubj
5	on	on	IN	_	9	case
6	the	the	DT	_	9	det
7	3	3	CD	_	9	nummod
8	major	major	JJ	_	9	amod
9	metabolites	metabolite	NNS	_	2	nmod
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	drug1	drug1	NN	_	9	dep
12	,	,	,	_	11	punct
13	drug2	drug2	NN	_	11	conj
14	and	and	CC	_	11	cc
15	drug3	drug3	NN	_	11	conj
16	-RRB-	-rrb-	-RRB-	_	11	punct
17	.	.	.	_	2	punct

1	drug1	drug1	NN	_	4	compound
2	Altered	altered	JJ	_	4	amod
3	coagulation	coagulation	NN	_	4	compound
4	parameters	parameter	NNS	_	9	nsubjpass
5	and/or	and/or	CC	_	4	cc
6	bleeding	bleed	VBG	_	4	conj
7	have	have	VBP	_	9	aux
8	been	be	VBN	_	9	auxpass
9	reported	report	VBN	_	0	ROOT
10	in	in	IN	_	11	case
11	patients	patient	NNS	_	9	nmod
12	taking	take	VBG	_	11	acl
13	drug2	drug2	NN	_	12	dobj
14	concomitantly	concomitantly	RB	_	12	advmod
15	with	with	IN	_	16	case
16	drug3	drug3	NN	_	12	nmod
17	such	such	JJ	_	19	case
18	as	as	IN	_	17	mwe
19	drug4	drug4	NN	_	16	nmod
20	and	and	CC	_	19	cc
21	drug5	drug5	NN	_	19	conj
22	.	.	.	_	9	punct

1	Patients	patient	NNS	_	9	nsubjpass
2	taking	take	VBG	_	1	acl
3	drug1	drug1	NN	_	2	dobj
4	concomitantly	concomitantly	RB	_	2	advmod
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	2	nmod
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	monitored	monitor	VBN	_	0	ROOT
10	regularly	regularly	RB	_	9	advmod
11	for	for	IN	_	12	case
12	alterations	alteration	NNS	_	9	nmod
13	in	in	IN	_	16	case
14	their	they	PRP$	_	16	nmod:poss
15	coagulation	coagulation	NN	_	16	compound
16	parameters	parameter	NNS	_	12	nmod
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	PT	pt	NN	_	16	dep
19	or	or	CC	_	18	cc
20	INR	inr	NN	_	18	conj
21	-RRB-	-rrb-	-RRB-	_	18	punct
22	.	.	.	_	9	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	concentration	concentration	NN	_	8	nsubjpass
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	is	be	VBZ	_	8	auxpass
8	increased	increase	VBN	_	1	dep
9	and	and	CC	_	8	cc
10	its	its	PRP$	_	11	nmod:poss
11	toxicity	toxicity	NN	_	14	nsubjpass
12	may	may	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	enhanced	enhance	VBN	_	8	conj
15	by	by	IN	_	16	case
16	drug3	drug3	NN	_	14	nmod
17	.	.	.	_	8	punct

1	Deaths	death	NNS	_	12	nsubjpass
2	from	from	IN	_	4	case
3	severe	severe	JJ	_	4	amod
4	enterocolitis	enterocolitis	NN	_	1	nmod
5	,	,	,	_	4	punct
6	diarrhea	diarrhea	NN	_	4	conj
7	,	,	,	_	4	punct
8	and	and	CC	_	4	cc
9	dehydration	dehydration	NN	_	4	conj
10	have	have	VBP	_	12	aux
11	been	be	VBN	_	12	auxpass
12	reported	report	VBN	_	0	ROOT
13	in	in	IN	_	15	case
14	elderly	elderly	JJ	_	15	amod
15	patients	patient	NNS	_	12	nmod
16	receiving	receive	VBG	_	15	acl
17	weekly	weekly	JJ	_	18	amod
18	drug1	drug1	NN	_	16	dobj
19	and	and	CC	_	18	cc
20	drug2	drug2	NN	_	18	conj
21	.	.	.	_	12	punct

1	Cytochrome	cytochrome	NN	_	3	compound
2	P450	p450	NN	_	3	compound
3	1A2	1a2	NN	_	8	nsubjpass
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	CYP1A2	cyp1a2	NN	_	3	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	is	be	VBZ	_	8	auxpass
8	known	know	VBN	_	0	ROOT
9	to	to	TO	_	13	mark
10	be	be	VB	_	13	cop
11	the	the	DT	_	13	det
12	major	major	JJ	_	13	amod
13	enzyme	enzyme	NN	_	8	xcomp
14	involved	involve	VBN	_	13	acl
15	in	in	IN	_	17	case
16	the	the	DT	_	17	det
17	metabolism	metabolism	NN	_	14	nmod
18	of	of	IN	_	19	case
19	drug1	drug1	NN	_	17	nmod
20	.	.	.	_	8	punct

1	Therefore	therefore	RB	_	4	advmod
2	,	,	,	_	4	punct
3	drug1	drug1	NN	_	4	nsubj
4	has	have	VBZ	_	0	ROOT
5	the	the	DT	_	6	det
6	potential	potential	JJ	_	4	dobj
7	to	to	TO	_	8	mark
8	interact	interact	VB	_	6	acl
9	with	with	IN	_	10	case
10	drugs	drug	NNS	_	8	nmod
11	that	that	WDT	_	13	nsubj
12	are	be	VBP	_	13	cop
13	substrates	substrate	NNS	_	10	acl:relcl
14	for	for	IN	_	15	case
15	CYP1A2	cyp1a2	NN	_	13	nmod
16	,	,	,	_	4	punct
17	inhibit	inhibit	VBP	_	4	advcl
18	CYP1A2	cyp1a2	NN	_	17	dobj
19	,	,	,	_	18	punct
20	or	or	CC	_	18	cc
21	induce	induce	VB	_	18	conj
22	CYP1A2	cyp1a2	NN	_	21	dobj
23	.	.	.	_	4	punct

1	Few	few	JJ	_	2	amod
2	data	datum	NNS	_	3	nsubj
3	exist	exist	VBP	_	0	ROOT
4	on	on	IN	_	6	case
5	drug	drug	NN	_	6	compound
6	interactions	interaction	NNS	_	3	nmod
7	with	with	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	in	in	IN	_	11	case
10	preterm	preterm	JJ	_	11	amod
11	neonates	neonate	NNS	_	6	nmod
12	.	.	.	_	3	punct

1	Based	base	VBN	_	4	case
2	on	on	IN	_	4	case
3	adult	adult	JJ	_	4	amod
4	data	datum	NNS	_	12	advcl
5	,	,	,	_	12	punct
6	lower	lower	JJR	_	7	amod
7	doses	dose	NNS	_	12	nsubjpass
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	may	may	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	needed	need	VBN	_	0	ROOT
13	following	follow	VBG	_	14	case
14	coadministration	coadministration	NN	_	12	nmod
15	of	of	IN	_	16	case
16	drugs	drug	NNS	_	14	nmod
17	which	which	WDT	_	19	nsubjpass
18	are	be	VBP	_	19	auxpass
19	reported	report	VBN	_	16	acl:relcl
20	to	to	TO	_	21	mark
21	decrease	decrease	VB	_	19	xcomp
22	drug2	drug2	NN	_	23	compound
23	elimination	elimination	NN	_	21	dobj
24	-LRB-	-lrb-	-LRB-	_	27	punct
25	e.g.	e.g.	FW	_	27	dep
26	,	,	,	_	27	punct
27	drug3	drug3	NN	_	23	dep
28	and	and	CC	_	27	cc
29	drug4	drug4	NN	_	27	conj
30	-RRB-	-rrb-	-RRB-	_	27	punct
31	and	and	CC	_	23	cc
32	higher	higher	JJR	_	34	amod
33	drug5	drug5	NN	_	34	compound
34	doses	dose	NNS	_	23	conj
35	may	may	MD	_	37	aux
36	be	be	VB	_	37	auxpass
37	needed	need	VBN	_	12	xcomp
38	following	follow	VBG	_	39	case
39	coadministration	coadministration	NN	_	37	nmod
40	of	of	IN	_	41	case
41	drugs	drug	NNS	_	39	nmod
42	that	that	WDT	_	43	nsubj
43	increase	increase	VBP	_	41	acl:relcl
44	drug6	drug6	NN	_	45	compound
45	elimination	elimination	NN	_	43	dobj
46	-LRB-	-lrb-	-LRB-	_	49	punct
47	e.g.	e.g.	FW	_	49	dep
48	,	,	,	_	49	punct
49	drug7	drug7	NN	_	37	parataxis
50	and	and	CC	_	49	cc
51	drug8	drug8	NN	_	49	conj
52	-RRB-	-rrb-	-RRB-	_	49	punct
53	.	.	.	_	12	punct

1	drug1	drug1	NN	_	2	nsubj
2	administered	administer	VBN	_	0	ROOT
3	concurrently	concurrently	RB	_	2	advmod
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	2	nmod
6	reduced	reduce	VBD	_	2	dep
7	the	the	DT	_	9	det
8	urine	urine	NN	_	9	compound
9	volume	volume	NN	_	6	dobj
10	in	in	IN	_	13	case
11	4	4	CD	_	13	nummod
12	healthy	healthy	JJ	_	13	amod
13	volunteers	volunteer	NNS	_	6	nmod
14	.	.	.	_	2	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	significance	significance	NN	_	12	nsubjpass
4	of	of	IN	_	6	case
5	this	this	DT	_	6	det
6	interaction	interaction	NN	_	3	nmod
7	in	in	IN	_	9	case
8	preterm	preterm	JJ	_	9	amod
9	neonates	neonate	NNS	_	6	nmod
10	is	be	VBZ	_	12	auxpass
11	not	not	RB	_	12	neg
12	known	know	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	Interconversion	interconversion	NN	_	8	nsubjpass
2	between	between	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	drug2	drug2	NN	_	3	conj
6	has	have	VBZ	_	8	aux
7	been	be	VBN	_	8	auxpass
8	reported	report	VBN	_	0	ROOT
9	in	in	IN	_	11	case
10	preterm	preterm	JJ	_	11	amod
11	neonates	neonate	NNS	_	8	nmod
12	.	.	.	_	8	punct

1	The	the	DT	_	3	det
2	concurrent	concurrent	JJ	_	3	amod
3	use	use	NN	_	9	nsubjpass
4	of	of	IN	_	6	case
5	these	these	DT	_	6	det
6	drugs	drug	NNS	_	3	nmod
7	is	be	VBZ	_	9	auxpass
8	not	not	RB	_	9	neg
9	recommended	recommend	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	No	no	DT	_	4	neg
2	drug	drug	NN	_	4	compound
3	interaction	interaction	NN	_	4	compound
4	studies	study	NNS	_	7	nsubjpass
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	performed	perform	VBN	_	0	ROOT
8	.	.	.	_	7	punct

1	Other	other	JJ	_	2	amod
2	medicines	medicine	NNS	_	0	ROOT
3	-	-	:	_	2	punct
4	Although	although	IN	_	10	mark
5	certain	certain	JJ	_	6	amod
6	medicines	medicine	NNS	_	10	nsubjpass
7	should	should	MD	_	10	aux
8	not	not	RB	_	10	neg
9	be	be	VB	_	10	auxpass
10	used	use	VBN	_	2	dep
11	together	together	RB	_	10	advmod
12	at	at	IN	_	13	case
13	all	all	DT	_	10	nmod
14	,	,	,	_	10	punct
15	in	in	IN	_	17	case
16	other	other	JJ	_	17	amod
17	cases	case	NNS	_	23	nmod
18	two	two	CD	_	20	nummod
19	different	different	JJ	_	20	amod
20	medicines	medicine	NNS	_	23	nsubjpass
21	may	may	MD	_	23	aux
22	be	be	VB	_	23	auxpass
23	used	use	VBN	_	10	parataxis
24	together	together	RB	_	23	advmod
25	even	even	RB	_	30	advmod
26	if	if	IN	_	30	mark
27	an	a	DT	_	28	det
28	interaction	interaction	NN	_	30	nsubj
29	might	might	MD	_	30	aux
30	occur	occur	VB	_	23	advcl
31	.	.	.	_	2	punct

1	In	in	IN	_	3	case
2	these	these	DT	_	3	det
3	cases	case	NNS	_	8	nmod
4	,	,	,	_	8	punct
5	your	you	PRP$	_	6	nmod:poss
6	doctor	doctor	NN	_	8	nsubj
7	may	may	MD	_	8	aux
8	want	want	VB	_	19	csubj
9	to	to	TO	_	10	mark
10	change	change	VB	_	8	xcomp
11	the	the	DT	_	12	det
12	dose	dose	NN	_	10	dobj
13	,	,	,	_	12	punct
14	or	or	CC	_	12	cc
15	other	other	JJ	_	16	amod
16	precautions	precaution	NNS	_	12	conj
17	may	may	MD	_	19	aux
18	be	be	VB	_	19	cop
19	necessary	necessary	JJ	_	0	ROOT
20	.	.	.	_	19	punct

1	When	when	WRB	_	4	advmod
2	you	you	PRP	_	4	nsubj
3	are	be	VBP	_	4	aux
4	using	use	VBG	_	10	advcl
5	drug1	drug1	NN	_	4	dobj
6	,	,	,	_	10	punct
7	it	it	PRP	_	10	nsubj
8	is	be	VBZ	_	10	cop
9	especially	especially	RB	_	10	advmod
10	important	important	JJ	_	0	ROOT
11	that	that	IN	_	16	mark
12	your	you	PRP$	_	14	nmod:poss
13	health	health	NN	_	14	compound
14	care	care	NN	_	16	nsubj
15	professional	professional	JJ	_	14	amod
16	know	know	VBP	_	10	ccomp
17	if	if	IN	_	20	mark
18	you	you	PRP	_	20	nsubj
19	are	be	VBP	_	20	aux
20	using	use	VBG	_	16	advcl
21	the	the	DT	_	22	det
22	following	following	NN	_	20	dobj
23	:	:	:	_	10	punct
24	Eye	Eye	NNP	_	25	compound
25	product	product	NN	_	10	dep
26	containing	contain	VBG	_	25	acl
27	drug2	drug2	NN	_	26	dobj
28	.	.	.	_	10	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	interact	interact	VB	_	0	ROOT
4	with	with	IN	_	7	case
5	the	the	DT	_	7	det
6	drug2	drug2	NN	_	7	compound
7	preparation	preparation	NN	_	3	nmod
8	causing	cause	VBG	_	7	acl
9	a	a	DT	_	11	det
10	gritty	gritty	JJ	_	11	amod
11	substance	substance	NN	_	8	dobj
12	to	to	TO	_	13	mark
13	form	form	VB	_	8	xcomp
14	or	or	CC	_	13	cc
15	may	may	MD	_	16	aux
16	interact	interact	VB	_	13	conj
17	with	with	IN	_	19	case
18	the	the	DT	_	19	det
19	preservative	preservative	NN	_	16	nmod
20	in	in	IN	_	23	case
21	the	the	DT	_	23	det
22	drug3	drug3	NN	_	23	compound
23	preparation	preparation	NN	_	19	nmod
24	causing	cause	VBG	_	13	xcomp
25	a	a	DT	_	27	det
26	toxic	toxic	JJ	_	27	amod
27	effect	effect	NN	_	24	dobj
28	in	in	IN	_	30	case
29	the	the	DT	_	30	det
30	eye	eye	NN	_	27	nmod
31	.	.	.	_	3	punct

1	No	no	DT	_	4	neg
2	well-known	well-known	JJ	_	4	amod
3	drug	drug	NN	_	4	compound
4	interactions	interaction	NNS	_	0	ROOT
5	with	with	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod

1	Clinical	clinical	JJ	_	2	amod
2	trials	trial	NNS	_	4	nsubj
3	have	have	VBP	_	4	aux
4	indicated	indicate	VBN	_	0	ROOT
5	that	that	IN	_	12	mark
6	drug1	drug1	NN	_	12	nsubjpass
7	can	can	MD	_	12	aux
8	be	be	VB	_	12	auxpass
9	effectively	effectively	RB	_	12	advmod
10	and	and	CC	_	9	cc
11	safely	safely	RB	_	9	conj
12	used	use	VBN	_	4	ccomp
13	in	in	IN	_	14	case
14	conjunction	conjunction	NN	_	12	nmod
15	with	with	IN	_	19	case
16	standard	standard	JJ	_	19	amod
17	cystic	cystic	JJ	_	19	amod
18	fibrosis	fibrosis	NN	_	19	compound
19	therapies	therapy	NNS	_	14	nmod
20	including	include	VBG	_	21	case
21	oral	oral	JJ	_	19	nmod
22	,	,	,	_	21	punct
23	inhaled	inhale	VBD	_	21	conj
24	and/or	and/or	CC	_	21	cc
25	parenteral	parenteral	JJ	_	26	amod
26	drug2	drug2	NN	_	21	conj
27	,	,	,	_	21	punct
28	drug3	drug3	NN	_	21	conj
29	,	,	,	_	21	punct
30	enzyme	enzyme	NN	_	31	compound
31	supplements	supplement	NNS	_	21	conj
32	,	,	,	_	21	punct
33	drug4	drug4	NN	_	21	conj
34	,	,	,	_	21	punct
35	oral	oral	JJ	_	21	conj
36	or	or	CC	_	21	cc
37	inhaled	inhale	VBN	_	21	conj
38	drug5	drug5	NN	_	21	dep
39	,	,	,	_	21	punct
40	and	and	CC	_	21	cc
41	drug6	drug6	NN	_	21	conj
42	.	.	.	_	4	punct

1	No	no	DT	_	5	neg
2	formal	formal	JJ	_	5	amod
3	drug	drug	NN	_	5	compound
4	interaction	interaction	NN	_	5	compound
5	studies	study	NNS	_	8	nsubjpass
6	have	have	VBP	_	8	aux
7	been	be	VBN	_	8	auxpass
8	performed	perform	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	Clinically	clinically	RB	_	4	advmod
2	meaningful	meaningful	JJ	_	4	amod
3	drug	drug	NN	_	4	compound
4	interactions	interaction	NNS	_	6	nsubj
5	have	have	VBP	_	6	aux
6	occurred	occur	VBN	_	0	ROOT
7	with	with	IN	_	9	case
8	concomitant	concomitant	JJ	_	9	amod
9	medications	medication	NNS	_	6	nmod
10	and	and	CC	_	6	cc
11	include	include	VBP	_	6	conj
12	,	,	,	_	6	punct
13	but	but	CC	_	6	cc
14	are	be	VBP	_	16	cop
15	not	not	RB	_	16	neg
16	limited	limit	VBN	_	6	conj
17	to	to	TO	_	19	case
18	the	the	DT	_	19	det
19	following	following	NN	_	16	nmod
20	:	:	:	_	6	punct
21	Agents	agent	NNS	_	31	nsubjpass
22	Highly	highly	RB	_	23	advmod
23	Bound	bind	VBN	_	21	acl
24	to	to	TO	_	27	case
25	Plasma	plasma	NN	_	27	compound
26	Protein	protein	NN	_	27	compound
27	drug1	drug1	NN	_	23	nmod
28	is	be	VBZ	_	31	auxpass
29	not	not	RB	_	31	neg
30	highly	highly	RB	_	31	advmod
31	bound	bind	VBN	_	6	parataxis
32	to	to	TO	_	34	case
33	plasma	plasma	NN	_	34	compound
34	proteins	protein	NNS	_	31	nmod
35	;	;	:	_	6	punct

1	therefore	therefore	RB	_	0	ROOT
2	,	,	,	_	1	punct
3	administration	administration	NN	_	2	root
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	to	to	TO	_	8	case
7	a	a	DT	_	8	det
8	patient	patient	NN	_	3	nmod
9	taking	take	VBG	_	8	acl
10	another	another	DT	_	11	det
11	drug	drug	NN	_	9	dobj
12	that	that	WDT	_	19	nsubj
13	is	be	VBZ	_	19	aux
14	highly	highly	RB	_	19	advmod
15	protein	protein	NN	_	19	nsubj
16	bound	bind	VBD	_	15	acl
17	should	should	MD	_	19	aux
18	not	not	RB	_	19	neg
19	cause	cause	VB	_	11	acl:relcl
20	increased	increase	VBN	_	22	amod
21	free	free	JJ	_	22	amod
22	concentrations	concentration	NNS	_	19	dobj
23	of	of	IN	_	26	case
24	the	the	DT	_	26	det
25	other	other	JJ	_	26	amod
26	drug	drug	NN	_	22	nmod
27	.	.	.	_	3	punct

1	Agents	agent	NNS	_	12	nsubjpass
2	that	that	WDT	_	3	nsubj
3	Inhibit	inhibit	VBP	_	1	acl:relcl
4	Cytochrome	cytochrome	NN	_	6	compound
5	P450	p450	NN	_	6	compound
6	Isoenzymes	isoenzyme	NNS	_	3	dobj
7	and/or	and/or	CC	_	6	cc
8	Epoxide	Epoxide	NNP	_	10	compound
9	Hydrolase	Hydrolase	NNP	_	10	compound
10	drug1	drug1	NN	_	6	conj
11	is	be	VBZ	_	12	auxpass
12	metabolized	metabolize	VBN	_	0	ROOT
13	mainly	mainly	RB	_	12	advmod
14	by	by	IN	_	16	case
15	cytochrome	cytochrome	NN	_	16	compound
16	P450	p450	NN	_	12	nmod
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	CYP	cyp	NN	_	16	appos
19	-RRB-	-rrb-	-RRB-	_	18	punct
20	3A4	3a4	NN	_	16	dep
21	to	to	TO	_	24	case
22	the	the	DT	_	24	det
23	active	active	JJ	_	24	amod
24	drug2	drug2	NN	_	12	nmod
25	,	,	,	_	24	punct
26	which	which	WDT	_	29	nsubjpass
27	is	be	VBZ	_	29	auxpass
28	further	further	JJ	_	29	advmod
29	metabolized	metabolize	VBN	_	24	acl:relcl
30	to	to	TO	_	32	case
31	the	the	DT	_	32	det
32	trans-diol	trans-diol	NN	_	29	nmod
33	by	by	IN	_	35	case
34	epoxide	epoxide	NN	_	35	compound
35	hydrolase	hydrolase	NN	_	29	nmod
36	.	.	.	_	12	punct

1	Therefore	therefore	RB	_	5	advmod
2	,	,	,	_	5	punct
3	the	the	DT	_	4	det
4	potential	potential	JJ	_	5	nsubj
5	exists	exist	VBZ	_	0	ROOT
6	for	for	IN	_	7	case
7	interaction	interaction	NN	_	5	nmod
8	between	between	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	any	any	DT	_	12	det
12	agent	agent	NN	_	9	conj
13	that	that	WDT	_	14	nsubj
14	inhibits	inhibit	VBZ	_	12	acl:relcl
15	CYP3A4	cyp3a4	NN	_	18	compound
16	and/or	and/or	CC	_	15	cc
17	epoxide	epoxide	NN	_	15	conj
18	hydrolase	hydrolase	NN	_	14	dobj
19	.	.	.	_	5	punct

1	Agents	agent	NNS	_	23	nsubj
2	that	that	WDT	_	5	nsubj
3	are	be	VBP	_	5	cop
4	CYP3A4	cyp3a4	NN	_	5	compound
5	inhibitors	inhibitor	NNS	_	1	acl:relcl
6	that	that	WDT	_	9	nsubjpass
7	have	have	VBP	_	9	aux
8	been	be	VBN	_	9	auxpass
9	found	find	VBN	_	5	acl:relcl
10	,	,	,	_	1	punct
11	or	or	CC	_	1	cc
12	are	be	VBP	_	13	auxpass
13	expected	expect	VBN	_	1	conj
14	,	,	,	_	1	punct
15	to	to	TO	_	16	mark
16	increase	increase	VB	_	1	acl
17	plasma	plasma	NN	_	18	compound
18	levels	level	NNS	_	16	dobj
19	of	of	IN	_	20	case
20	drug1	drug1	NN	_	18	nmod
21	are	be	VBP	_	23	cop
22	the	the	DT	_	23	det
23	following	following	NN	_	0	ROOT
24	:	:	:	_	23	punct
25	drug2	drug2	NN	_	23	dep
26	,	,	,	_	25	punct
27	drug3	drug3	NN	_	25	conj
28	,	,	,	_	25	punct
29	drug4	drug4	NN	_	25	conj
30	,	,	,	_	25	punct
31	drug5	drug5	NN	_	25	conj
32	-LRB-	-lrb-	-LRB-	_	33	punct
33	1	1	CD	_	31	appos
34	-RRB-	-rrb-	-RRB-	_	33	punct
35	,	,	,	_	25	punct
36	drug6	drug6	NN	_	25	conj
37	,	,	,	_	25	punct
38	drug7	drug7	NN	_	25	conj
39	,	,	,	_	25	punct
40	drug8	drug8	NN	_	25	conj
41	,	,	,	_	25	punct
42	drug9	drug9	NN	_	25	conj
43	,	,	,	_	25	punct
44	drug10	drug10	NN	_	25	conj
45	-LRB-	-lrb-	-LRB-	_	46	punct
46	1	1	CD	_	44	appos
47	-RRB-	-rrb-	-RRB-	_	46	punct
48	,	,	,	_	25	punct
49	drug11	drug11	NN	_	25	conj
50	,	,	,	_	25	punct
51	drug12	drug12	NN	_	25	conj
52	,	,	,	_	25	punct
53	grapefruit	grapefruit	NN	_	54	compound
54	juice	juice	NN	_	25	conj
55	,	,	,	_	25	punct
56	drug13	drug13	NN	_	25	conj
57	,	,	,	_	25	punct
58	drug14	drug14	NN	_	25	conj
59	,	,	,	_	25	punct
60	drug15	drug15	NN	_	25	conj
61	,	,	,	_	25	punct
62	drug16	drug16	NN	_	25	conj
63	,	,	,	_	25	punct
64	drug17	drug17	NN	_	25	conj
65	,	,	,	_	25	punct
66	drug18	drug18	NN	_	25	conj
67	,	,	,	_	25	punct
68	drug19	drug19	NN	_	25	conj
69	,	,	,	_	25	punct
70	drug20	drug20	NN	_	25	conj
71	,	,	,	_	25	punct
72	drug21	drug21	NN	_	25	conj
73	,	,	,	_	25	punct
74	drug22	drug22	NN	_	25	conj
75	,	,	,	_	25	punct
76	drug23	drug23	NN	_	25	conj
77	,	,	,	_	25	punct
78	drug24	drug24	NN	_	25	conj
79	,	,	,	_	25	punct
80	drug25	drug25	NN	_	25	conj
81	-LRB-	-lrb-	-LRB-	_	82	punct
82	1	1	CD	_	80	appos
83	-RRB-	-rrb-	-RRB-	_	82	punct
84	,	,	,	_	25	punct
85	drug26	drug26	NN	_	25	conj
86	,	,	,	_	25	punct
87	drug27	drug27	NN	_	25	conj
88	.	.	.	_	23	punct

1	Thus	thus	RB	_	18	advmod
2	,	,	,	_	18	punct
3	if	if	IN	_	8	mark
4	a	a	DT	_	5	det
5	patient	patient	NN	_	8	nsubjpass
6	has	have	VBZ	_	8	aux
7	been	be	VBN	_	8	auxpass
8	titrated	titrate	VBN	_	18	advcl
9	to	to	TO	_	12	case
10	a	a	DT	_	12	det
11	stable	stable	JJ	_	12	amod
12	dosage	dosage	NN	_	8	nmod
13	of	of	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	,	,	,	_	18	punct
16	and	and	CC	_	18	cc
17	then	then	RB	_	18	advmod
18	begins	begin	VBZ	_	0	ROOT
19	a	a	DT	_	20	det
20	course	course	NN	_	18	dobj
21	of	of	IN	_	22	case
22	treatment	treatment	NN	_	20	nmod
23	with	with	IN	_	24	case
24	one	one	CD	_	22	nmod
25	of	of	IN	_	27	case
26	these	these	DT	_	27	det
27	CYP3A4	cyp3a4	NN	_	24	nmod
28	or	or	CC	_	27	cc
29	epoxide	epoxide	NN	_	31	compound
30	hydrolase	hydrolase	NN	_	31	compound
31	inhibitors	inhibitor	NNS	_	27	conj
32	,	,	,	_	18	punct
33	it	it	PRP	_	35	nsubj
34	is	be	VBZ	_	35	cop
35	reasonable	reasonable	JJ	_	18	parataxis
36	to	to	TO	_	37	mark
37	expect	expect	VB	_	35	xcomp
38	that	that	IN	_	46	mark
39	a	a	DT	_	41	det
40	dose	dose	NN	_	41	compound
41	reduction	reduction	NN	_	46	nsubj
42	for	for	IN	_	43	case
43	drug2	drug2	NN	_	41	nmod
44	may	may	MD	_	46	aux
45	be	be	VB	_	46	cop
46	necessary	necessary	JJ	_	37	ccomp
47	.	.	.	_	18	punct

1	Agents	agent	NNS	_	9	nsubjpass
2	that	that	WDT	_	3	nsubj
3	Induce	induce	VBP	_	1	acl:relcl
4	Cytochrome	cytochrome	NN	_	7	compound
5	P450	p450	NN	_	7	compound
6	Isoenzymes	isoenzyme	NNS	_	7	compound
7	drug1	drug1	NN	_	3	dobj
8	is	be	VBZ	_	9	auxpass
9	metabolized	metabolize	VBN	_	0	ROOT
10	by	by	IN	_	11	case
11	CYP3A4	cyp3a4	NN	_	9	nmod
12	.	.	.	_	9	punct

1	Therefore	therefore	RB	_	5	advmod
2	,	,	,	_	5	punct
3	the	the	DT	_	4	det
4	potential	potential	JJ	_	5	nsubj
5	exists	exist	VBZ	_	0	ROOT
6	for	for	IN	_	7	case
7	interaction	interaction	NN	_	5	nmod
8	between	between	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	any	any	DT	_	12	det
12	agent	agent	NN	_	9	conj
13	that	that	WDT	_	14	nsubj
14	induces	induce	VBZ	_	12	acl:relcl
15	CYP3A4	cyp3a4	NN	_	14	dobj
16	.	.	.	_	5	punct

1	Agents	agent	NNS	_	23	nsubj
2	that	that	WDT	_	5	nsubj
3	are	be	VBP	_	5	cop
4	CYP	CYP	NNP	_	5	compound
5	inducers	inducer	NNS	_	1	acl:relcl
6	that	that	WDT	_	9	nsubjpass
7	have	have	VBP	_	9	aux
8	been	be	VBN	_	9	auxpass
9	found	find	VBN	_	5	acl:relcl
10	,	,	,	_	1	punct
11	or	or	CC	_	1	cc
12	are	be	VBP	_	13	auxpass
13	expected	expect	VBN	_	1	conj
14	,	,	,	_	1	punct
15	to	to	TO	_	16	mark
16	decrease	decrease	VB	_	1	acl
17	plasma	plasma	NN	_	18	compound
18	levels	level	NNS	_	16	dobj
19	of	of	IN	_	20	case
20	drug1	drug1	NN	_	18	nmod
21	are	be	VBP	_	23	cop
22	the	the	DT	_	23	det
23	following	following	NN	_	0	ROOT
24	:	:	:	_	23	punct
25	drug2	drug2	NN	_	77	ccomp
26	,	,	,	_	25	punct
27	drug3	drug3	NN	_	25	conj
28	,	,	,	_	25	punct
29	drug4	drug4	NN	_	25	conj
30	,	,	,	_	25	punct
31	drug5	drug5	NN	_	25	conj
32	,	,	,	_	25	punct
33	drug6	drug6	NN	_	25	conj
34	,	,	,	_	25	punct
35	drug7	drug7	NN	_	25	conj
36	-LRB-	-lrb-	-LRB-	_	37	punct
37	2	2	CD	_	35	appos
38	-RRB-	-rrb-	-RRB-	_	37	punct
39	,	,	,	_	25	punct
40	drug8	drug8	NN	_	25	conj
41	,	,	,	_	25	punct
42	drug9	drug9	NN	_	25	conj
43	,	,	,	_	25	punct
44	and	and	CC	_	25	cc
45	drug10	drug10	NN	_	25	conj
46	Thus	thus	RB	_	25	advmod
47	,	,	,	_	25	punct
48	if	if	IN	_	53	mark
49	a	a	DT	_	50	det
50	patient	patient	NN	_	53	nsubjpass
51	has	have	VBZ	_	53	aux
52	been	be	VBN	_	53	auxpass
53	titrated	titrate	VBN	_	25	advcl
54	to	to	TO	_	57	case
55	a	a	DT	_	57	det
56	stable	stable	JJ	_	57	amod
57	dosage	dosage	NN	_	53	nmod
58	on	on	IN	_	59	case
59	drug11	drug11	NN	_	57	nmod
60	,	,	,	_	25	punct
61	and	and	CC	_	25	cc
62	then	then	RB	_	63	advmod
63	begins	begin	VBZ	_	25	conj
64	a	a	DT	_	65	det
65	course	course	NN	_	63	dobj
66	of	of	IN	_	67	case
67	treatment	treatment	NN	_	65	nmod
68	with	with	IN	_	69	case
69	one	one	CD	_	67	nmod
70	of	of	IN	_	73	case
71	these	these	DT	_	73	det
72	CYP3A4	cyp3a4	NN	_	73	compound
73	inducers	inducer	NNS	_	69	nmod
74	,	,	,	_	77	punct
75	it	it	PRP	_	77	nsubj
76	is	be	VBZ	_	77	cop
77	reasonable	reasonable	JJ	_	23	parataxis
78	to	to	TO	_	79	mark
79	expect	expect	VB	_	77	xcomp
80	that	that	IN	_	88	mark
81	a	a	DT	_	83	det
82	dose	dose	NN	_	83	compound
83	increase	increase	NN	_	88	nsubj
84	for	for	IN	_	85	case
85	drug12	drug12	NN	_	83	nmod
86	may	may	MD	_	88	aux
87	be	be	VB	_	88	cop
88	necessary	necessary	JJ	_	79	ccomp
89	.	.	.	_	23	punct

1	Agents	agent	NNS	_	19	nsubjpass
2	with	with	IN	_	4	case
3	Decreased	decrease	VBN	_	4	amod
4	Levels	level	NNS	_	1	nmod
5	in	in	IN	_	7	case
6	the	the	DT	_	7	det
7	Presence	presence	NN	_	4	nmod
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	due	due	JJ	_	12	case
11	to	to	TO	_	10	mwe
12	Induction	induction	NN	_	1	nmod
13	of	of	IN	_	17	case
14	Cytochrome	cytochrome	NN	_	17	compound
15	P450	p450	NN	_	17	compound
16	Enzymes	enzyme	NNS	_	17	compound
17	drug2	drug2	NN	_	12	nmod
18	is	be	VBZ	_	19	auxpass
19	known	know	VBN	_	0	ROOT
20	to	to	TO	_	21	mark
21	induce	induce	VB	_	19	xcomp
22	CYP1A2	cyp1a2	NN	_	21	dobj
23	and	and	CC	_	22	cc
24	CYP3A4	cyp3a4	NN	_	22	conj
25	.	.	.	_	19	punct

1	Therefore	therefore	RB	_	5	advmod
2	,	,	,	_	5	punct
3	the	the	DT	_	4	det
4	potential	potential	JJ	_	5	nsubj
5	exists	exist	VBZ	_	0	ROOT
6	for	for	IN	_	7	case
7	interaction	interaction	NN	_	5	nmod
8	between	between	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	any	any	DT	_	12	det
12	agent	agent	NN	_	9	conj
13	metabolized	metabolize	VBN	_	12	acl
14	by	by	IN	_	15	case
15	one	one	CD	_	13	nmod
16	-LRB-	-lrb-	-LRB-	_	18	punct
17	or	or	CC	_	18	cc
18	more	more	JJR	_	15	dep
19	-RRB-	-rrb-	-RRB-	_	18	punct
20	of	of	IN	_	22	case
21	these	these	DT	_	22	det
22	enzymes	enzyme	NNS	_	15	nmod
23	.	.	.	_	5	punct

1	Agents	agent	NNS	_	28	nsubj
2	that	that	WDT	_	5	nsubjpass
3	have	have	VBP	_	5	aux
4	been	be	VBN	_	5	auxpass
5	found	find	VBN	_	1	acl:relcl
6	,	,	,	_	5	punct
7	or	or	CC	_	5	cc
8	are	be	VBP	_	9	auxpass
9	expected	expect	VBN	_	5	conj
10	to	to	TO	_	12	mark
11	have	have	VB	_	12	aux
12	decreased	decrease	VBN	_	9	xcomp
13	plasma	plasma	NN	_	14	compound
14	levels	level	NNS	_	12	dobj
15	in	in	IN	_	17	case
16	the	the	DT	_	17	det
17	presence	presence	NN	_	12	nmod
18	of	of	IN	_	19	case
19	drug1	drug1	NN	_	17	nmod
20	due	due	JJ	_	22	case
21	to	to	TO	_	20	mwe
22	induction	induction	NN	_	12	nmod
23	of	of	IN	_	25	case
24	CYP	cyp	NN	_	25	compound
25	enzymes	enzyme	NNS	_	22	nmod
26	are	be	VBP	_	28	cop
27	the	the	DT	_	28	det
28	following	following	NN	_	0	ROOT
29	:	:	:	_	28	punct
30	drug2	drug2	NN	_	28	dep
31	,	,	,	_	30	punct
32	drug3	drug3	NN	_	30	conj
33	,	,	,	_	30	punct
34	drug4	drug4	NN	_	30	conj
35	,	,	,	_	30	punct
36	drug5	drug5	NN	_	30	conj
37	,	,	,	_	30	punct
38	drug6	drug6	NN	_	30	conj
39	,	,	,	_	30	punct
40	drug7	drug7	NN	_	30	conj
41	,	,	,	_	30	punct
42	drug8	drug8	NN	_	30	conj
43	,	,	,	_	30	punct
44	drug9	drug9	NN	_	30	conj
45	,	,	,	_	30	punct
46	drug10	drug10	NN	_	30	conj
47	,	,	,	_	30	punct
48	drug11	drug11	NN	_	30	conj
49	,	,	,	_	30	punct
50	drug12	drug12	NN	_	30	conj
51	,	,	,	_	30	punct
52	drug13	drug13	NN	_	30	conj
53	,	,	,	_	30	punct
54	drug14	drug14	NN	_	30	conj
55	,	,	,	_	30	punct
56	drug15	drug15	NN	_	30	conj
57	,	,	,	_	30	punct
58	drug16	drug16	NN	_	30	conj
59	,	,	,	_	30	punct
60	drug17	drug17	NN	_	30	conj
61	,	,	,	_	30	punct
62	drug18	drug18	NN	_	30	conj
63	,	,	,	_	30	punct
64	drug19	drug19	NN	_	30	conj
65	,	,	,	_	30	punct
66	drug20	drug20	NN	_	30	conj
67	,	,	,	_	30	punct
68	drug21	drug21	NN	_	30	conj
69	,	,	,	_	30	punct
70	drug22	drug22	NN	_	30	conj
71	,	,	,	_	30	punct
72	drug23	drug23	NN	_	30	conj
73	,	,	,	_	30	punct
74	drug24	drug24	NN	_	30	conj
75	,	,	,	_	30	punct
76	drug25	drug25	NN	_	30	conj
77	,	,	,	_	30	punct
78	drug26	drug26	NN	_	30	conj
79	,	,	,	_	30	punct
80	drug27	drug27	NN	_	30	conj
81	,	,	,	_	30	punct
82	drug28	drug28	NN	_	30	conj
83	,	,	,	_	30	punct
84	drug29	drug29	NN	_	30	conj
85	,	,	,	_	30	punct
86	drug30	drug30	NN	_	30	conj
87	,	,	,	_	30	punct
88	oral	oral	JJ	_	89	amod
89	drug31	drug31	NN	_	30	conj
90	-LRB-	-lrb-	-LRB-	_	91	punct
91	3	3	CD	_	89	appos
92	-RRB-	-rrb-	-RRB-	_	91	punct
93	,	,	,	_	30	punct
94	drug32	drug32	NN	_	30	conj
95	,	,	,	_	30	punct
96	drug33	drug33	NN	_	30	conj
97	-LRB-	-lrb-	-LRB-	_	98	punct
98	4	4	CD	_	96	appos
99	-RRB-	-rrb-	-RRB-	_	98	punct
100	,	,	,	_	30	punct
101	drug34	drug34	NN	_	30	conj
102	,	,	,	_	30	punct
103	drug35	drug35	NN	_	30	conj
104	,	,	,	_	30	punct
105	drug36	drug36	NN	_	30	conj
106	,	,	,	_	30	punct
107	drug37	drug37	NN	_	30	conj
108	,	,	,	_	30	punct
109	drug38	drug38	NN	_	30	conj
110	,	,	,	_	30	punct
111	drug39	drug39	NN	_	30	conj
112	,	,	,	_	30	punct
113	drug40	drug40	NN	_	30	conj
114	,	,	,	_	30	punct
115	drug41	drug41	NN	_	30	conj
116	,	,	,	_	30	punct
117	drug42	drug42	NN	_	30	conj
118	,	,	,	_	30	punct
119	drug43	drug43	NN	_	30	conj
120	,	,	,	_	30	punct
121	drug44	drug44	NN	_	30	conj
122	-LRB-	-lrb-	-LRB-	_	123	punct
123	5	5	CD	_	121	appos
124	-RRB-	-rrb-	-RRB-	_	123	punct
125	,	,	,	_	30	punct
126	drug45	drug45	NN	_	30	conj
127	,	,	,	_	30	punct
128	and	and	CC	_	30	cc
129	drug46	drug46	NN	_	30	conj
130	.	.	.	_	28	punct

1	Thus	thus	RB	_	24	advmod
2	,	,	,	_	24	punct
3	if	if	IN	_	8	mark
4	a	a	DT	_	5	det
5	patient	patient	NN	_	8	nsubjpass
6	has	have	VBZ	_	8	aux
7	been	be	VBN	_	8	auxpass
8	titrated	titrate	VBN	_	24	advcl
9	to	to	TO	_	12	case
10	a	a	DT	_	12	det
11	stable	stable	JJ	_	12	amod
12	dosage	dosage	NN	_	8	nmod
13	on	on	IN	_	14	case
14	one	one	CD	_	8	nmod
15	of	of	IN	_	17	case
16	the	the	DT	_	17	det
17	agents	agent	NNS	_	14	nmod
18	in	in	IN	_	20	case
19	this	this	DT	_	20	det
20	category	category	NN	_	17	nmod
21	,	,	,	_	24	punct
22	and	and	CC	_	24	cc
23	then	then	RB	_	24	advmod
24	begins	begin	VBZ	_	0	ROOT
25	a	a	DT	_	26	det
26	course	course	NN	_	24	dobj
27	of	of	IN	_	28	case
28	treatment	treatment	NN	_	26	nmod
29	with	with	IN	_	30	case
30	drug1	drug1	NN	_	28	nmod
31	,	,	,	_	24	punct
32	it	it	PRP	_	34	nsubj
33	is	be	VBZ	_	34	cop
34	reasonable	reasonable	JJ	_	24	parataxis
35	to	to	TO	_	36	mark
36	expect	expect	VB	_	34	xcomp
37	that	that	IN	_	47	mark
38	a	a	DT	_	40	det
39	dose	dose	NN	_	40	compound
40	increase	increase	NN	_	47	nsubj
41	for	for	IN	_	44	case
42	the	the	DT	_	44	det
43	concomitant	concomitant	JJ	_	44	amod
44	agent	agent	NN	_	40	nmod
45	may	may	MD	_	47	aux
46	be	be	VB	_	47	cop
47	necessary	necessary	JJ	_	36	ccomp
48	.	.	.	_	24	punct

1	Agents	agent	NNS	_	0	ROOT
2	with	with	IN	_	4	case
3	Increased	increase	VBN	_	4	amod
4	Levels	level	NNS	_	1	nmod
5	in	in	IN	_	7	case
6	the	the	DT	_	7	det
7	Presence	presence	NN	_	4	nmod
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	:	:	:	_	1	punct
11	drug2	drug2	NN	_	12	nsubj
12	increases	increase	VBZ	_	1	dep
13	the	the	DT	_	15	det
14	plasma	plasma	NN	_	15	compound
15	levels	level	NNS	_	12	dobj
16	of	of	IN	_	19	case
17	the	the	DT	_	19	det
18	following	follow	VBG	_	19	amod
19	agents	agent	NNS	_	15	nmod
20	:	:	:	_	12	punct
21	drug3	drug3	NN	_	12	dep
22	,	,	,	_	21	punct
23	drug4	drug4	NN	_	21	conj
24	-LRB-	-lrb-	-LRB-	_	25	punct
25	6	6	CD	_	23	appos
26	-RRB-	-rrb-	-RRB-	_	25	punct
27	,	,	,	_	21	punct
28	and	and	CC	_	21	cc
29	drug5	drug5	NN	_	21	conj
30	Thus	thus	RB	_	21	advmod
31	,	,	,	_	21	punct
32	if	if	IN	_	37	mark
33	a	a	DT	_	34	det
34	patient	patient	NN	_	37	nsubjpass
35	has	have	VBZ	_	37	aux
36	been	be	VBN	_	37	auxpass
37	titrated	titrate	VBN	_	64	advcl
38	to	to	TO	_	41	case
39	a	a	DT	_	41	det
40	stable	stable	JJ	_	41	amod
41	dosage	dosage	NN	_	37	nmod
42	on	on	IN	_	43	case
43	one	one	CD	_	37	nmod
44	of	of	IN	_	46	case
45	the	the	DT	_	46	det
46	agents	agent	NNS	_	43	nmod
47	in	in	IN	_	49	case
48	this	this	DT	_	49	det
49	category	category	NN	_	46	nmod
50	,	,	,	_	37	punct
51	and	and	CC	_	37	cc
52	then	then	RB	_	53	advmod
53	begins	begin	VBZ	_	37	conj
54	a	a	DT	_	55	det
55	course	course	NN	_	53	dobj
56	of	of	IN	_	58	case
57	the	the	DT	_	58	det
58	treatment	treatment	NN	_	55	nmod
59	with	with	IN	_	60	case
60	drug6	drug6	NN	_	58	nmod
61	,	,	,	_	64	punct
62	it	it	PRP	_	64	nsubj
63	is	be	VBZ	_	64	cop
64	reasonable	reasonable	JJ	_	21	dep
65	to	to	TO	_	66	mark
66	expect	expect	VB	_	64	xcomp
67	that	that	IN	_	77	mark
68	a	a	DT	_	70	det
69	dose	dose	NN	_	70	compound
70	decrease	decrease	NN	_	77	nsubj
71	for	for	IN	_	74	case
72	the	the	DT	_	74	det
73	concomitant	concomitant	JJ	_	74	amod
74	agent	agent	NN	_	70	nmod
75	may	may	MD	_	77	aux
76	be	be	VB	_	77	cop
77	necessary	necessary	JJ	_	66	ccomp
78	.	.	.	_	1	punct

1	Pharmacological/Pharmacodynamic	pharmacological/pharmacodynamic	JJ	_	2	amod
2	Interactions	interaction	NNS	_	12	nsubj
3	with	with	IN	_	6	case
4	drug1	drug1	NN	_	6	compound
5	Concomitant	concomitant	JJ	_	6	amod
6	administration	administration	NN	_	2	nmod
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	drug3	drug3	NN	_	8	conj
11	may	may	MD	_	12	aux
12	increase	increase	VB	_	0	ROOT
13	the	the	DT	_	14	det
14	risk	risk	NN	_	12	dobj
15	of	of	IN	_	18	case
16	neurotoxic	neurotoxic	JJ	_	18	amod
17	side	side	JJ	_	18	amod
18	effects	effect	NNS	_	14	nmod
19	.	.	.	_	12	punct

1	Given	give	VBN	_	4	case
2	the	the	DT	_	4	det
3	anticonvulsant	anticonvulsant	JJ	_	4	amod
4	properties	property	NNS	_	10	nmod
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	,	,	,	_	10	punct
8	drug2	drug2	NN	_	10	nsubj
9	may	may	MD	_	10	aux
10	reduce	reduce	VB	_	0	ROOT
11	the	the	DT	_	13	det
12	thyroid	thyroid	NN	_	13	compound
13	function	function	NN	_	10	dobj
14	as	as	IN	_	17	mark
15	has	have	VBZ	_	17	aux
16	been	be	VBN	_	17	auxpass
17	reported	report	VBN	_	10	advcl
18	with	with	IN	_	20	case
19	other	other	JJ	_	20	amod
20	drug3	drug3	NN	_	17	nmod
21	.	.	.	_	10	punct

1	Additionally	additionally	RB	_	12	advmod
2	,	,	,	_	12	punct
3	drug1	drug1	NN	_	12	nsubj
4	,	,	,	_	3	punct
5	such	such	JJ	_	7	case
6	as	as	IN	_	5	mwe
7	drug2	drug2	NN	_	3	nmod
8	and	and	CC	_	7	cc
9	drug3	drug3	NN	_	7	conj
10	,	,	,	_	3	punct
11	may	may	MD	_	12	aux
12	antagonize	antagonize	VB	_	0	ROOT
13	the	the	DT	_	14	det
14	activity	activity	NN	_	12	dobj
15	of	of	IN	_	16	case
16	drug4	drug4	NN	_	14	nmod
17	.	.	.	_	12	punct

1	Thus	thus	RB	_	33	advmod
2	if	if	IN	_	7	mark
3	a	a	DT	_	4	det
4	patient	patient	NN	_	7	nsubjpass
5	has	have	VBZ	_	7	aux
6	been	be	VBN	_	7	auxpass
7	titrated	titrate	VBN	_	33	advcl
8	to	to	TO	_	11	case
9	a	a	DT	_	11	det
10	stable	stable	JJ	_	11	amod
11	dosage	dosage	NN	_	7	nmod
12	on	on	IN	_	13	case
13	one	one	CD	_	7	nmod
14	of	of	IN	_	16	case
15	the	the	DT	_	16	det
16	agents	agent	NNS	_	13	nmod
17	in	in	IN	_	19	case
18	this	this	DT	_	19	det
19	category	category	NN	_	16	nmod
20	,	,	,	_	7	punct
21	and	and	CC	_	7	cc
22	then	then	RB	_	23	advmod
23	begins	begin	VBZ	_	7	conj
24	a	a	DT	_	25	det
25	course	course	NN	_	23	dobj
26	of	of	IN	_	27	case
27	treatment	treatment	NN	_	25	nmod
28	with	with	IN	_	29	case
29	drug1	drug1	NN	_	27	nmod
30	,	,	,	_	33	punct
31	it	it	PRP	_	33	nsubj
32	is	be	VBZ	_	33	cop
33	reasonable	reasonable	JJ	_	0	ROOT
34	to	to	TO	_	35	mark
35	expect	expect	VB	_	33	xcomp
36	that	that	IN	_	42	mark
37	a	a	DT	_	39	det
38	dose	dose	NN	_	39	compound
39	adjustment	adjustment	NN	_	42	nsubj
40	may	may	MD	_	42	aux
41	be	be	VB	_	42	cop
42	necessary	necessary	JJ	_	35	ccomp
43	.	.	.	_	33	punct

1	Because	because	IN	_	6	case
2	of	of	IN	_	1	mwe
3	its	its	PRP$	_	6	nmod:poss
4	primary	primary	JJ	_	6	amod
5	CNS	cns	NN	_	6	compound
6	effect	effect	NN	_	11	nmod
7	,	,	,	_	11	punct
8	caution	caution	NN	_	11	nsubjpass
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	used	use	VBN	_	0	ROOT
12	when	when	WRB	_	15	advmod
13	drug1	drug1	NN	_	15	nsubjpass
14	is	be	VBZ	_	15	auxpass
15	taken	take	VBN	_	11	advcl
16	with	with	IN	_	18	case
17	other	other	JJ	_	18	amod
18	drug2	drug2	NN	_	15	nmod
19	and	and	CC	_	18	cc
20	drug3	drug3	NN	_	18	conj
21	.	.	.	_	11	punct

1	drug1	drug1	NN	_	3	compound
2	-	-	:	_	3	punct
3	drug2	drug2	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	counteract	counteract	VB	_	0	ROOT
6	the	the	DT	_	8	det
7	antinaturetic	antinaturetic	JJ	_	8	amod
8	effect	effect	NN	_	5	dobj
9	of	of	IN	_	10	case
10	drug3	drug3	NN	_	8	nmod
11	.	.	.	_	5	punct

1	drug1	drug1	NN	_	3	compound
2	-	-	:	_	3	punct
3	drug2	drug2	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	increase	increase	VB	_	0	ROOT
6	the	the	DT	_	7	det
7	absorption	absorption	NN	_	5	dobj
8	of	of	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	if	if	IN	_	11	mark
11	taken	take	VBN	_	5	advcl
12	concomitantly	concomitantly	RB	_	11	advmod
13	.	.	.	_	5	punct

1	Organic	Organic	NNP	_	2	compound
2	drug1	drug1	NN	_	0	ROOT
3	-	-	:	_	2	punct
4	drug2	drug2	NN	_	5	compound
5	supplements	supplement	NNS	_	8	nsubj
6	theoretically	theoretically	RB	_	8	advmod
7	may	may	MD	_	8	aux
8	potentiate	potentiate	VB	_	2	dep
9	the	the	DT	_	10	det
10	effects	effect	NNS	_	8	dobj
11	of	of	IN	_	13	case
12	organic	organic	JJ	_	13	amod
13	drug3	drug3	NN	_	10	nmod
14	if	if	IN	_	15	mark
15	taken	take	VBN	_	8	advcl
16	concomitantly	concomitantly	RB	_	15	advmod
17	.	.	.	_	2	punct

1	drug1	drug1	NN	_	7	nsubjpass
2	-	-	:	_	7	punct
3	Theoretically	theoretically	RB	_	7	advmod
4	,	,	,	_	7	punct
5	drug2	drug2	NN	_	6	compound
6	supplements	supplement	NNS	_	7	nsubj
7	taken	take	VBN	_	0	ROOT
8	concomitantly	concomitantly	RB	_	7	advmod
9	with	with	IN	_	10	case
10	drug3	drug3	NN	_	7	nmod
11	,	,	,	_	7	punct
12	may	may	MD	_	13	aux
13	potentiate	potentiate	VB	_	7	dep
14	the	the	DT	_	15	det
15	effects	effect	NNS	_	13	dobj
16	of	of	IN	_	18	case
17	the	the	DT	_	18	det
18	drug	drug	NN	_	15	nmod
19	.	.	.	_	7	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	decrease	decrease	VB	_	0	ROOT
4	drug2	drug2	NN	_	5	compound
5	response	response	NN	_	3	dobj
6	to	to	TO	_	7	case
7	drug3	drug3	NN	_	5	nmod
8	.	.	.	_	3	punct

1	drug1	drug1	NN	_	4	nsubj
2	is	be	VBZ	_	4	cop
3	an	a	DT	_	4	det
4	inhibitor	inhibitor	NN	_	0	ROOT
5	of	of	IN	_	10	case
6	the	the	DT	_	10	det
7	cytochrome	cytochrome	NN	_	10	compound
8	P450	p450	NN	_	10	compound
9	isoform	isoform	NN	_	10	compound
10	CYP3A4	cyp3a4	NN	_	4	nmod
11	.	.	.	_	4	punct

1	Coadministration	coadministration	NN	_	11	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	drugs	drug	NNS	_	3	conj
6	primarily	primarily	RB	_	7	advmod
7	metabolized	metabolize	VBN	_	1	acl
8	by	by	IN	_	9	case
9	CYP3A4	cyp3a4	NN	_	7	nmod
10	may	may	MD	_	11	aux
11	result	result	VB	_	0	ROOT
12	in	in	IN	_	15	case
13	increased	increase	VBN	_	15	amod
14	plasma	plasma	NN	_	15	compound
15	concentrations	concentration	NNS	_	11	nmod
16	of	of	IN	_	19	case
17	the	the	DT	_	19	det
18	other	other	JJ	_	19	amod
19	drug	drug	NN	_	15	nmod
20	,	,	,	_	19	punct
21	which	which	WDT	_	23	nsubj
22	could	could	MD	_	23	aux
23	increase	increase	VB	_	19	acl:relcl
24	or	or	CC	_	23	cc
25	prolong	prolong	VB	_	23	conj
26	its	its	PRP$	_	30	nmod:poss
27	therapeutic	therapeutic	JJ	_	30	amod
28	and	and	CC	_	27	cc
29	adverse	adverse	JJ	_	27	conj
30	effects	effect	NNS	_	23	dobj
31	.	.	.	_	11	punct

1	drug1	drug1	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	metabolized	metabolize	VBN	_	0	ROOT
4	by	by	IN	_	5	case
5	CYP3A4	cyp3a4	NN	_	3	nmod
6	.	.	.	_	3	punct

1	Drugs	drug	NNS	_	8	nsubjpass
2	that	that	WDT	_	3	nsubj
3	induce	induce	VBP	_	1	acl:relcl
4	CYP3A4	cyp3a4	NN	_	5	compound
5	activity	activity	NN	_	3	dobj
6	would	would	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	expected	expect	VBN	_	0	ROOT
9	to	to	TO	_	10	mark
10	increase	increase	VB	_	8	xcomp
11	the	the	DT	_	12	det
12	clearance	clearance	NN	_	10	dobj
13	of	of	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	,	,	,	_	8	punct
16	resulting	result	VBG	_	8	xcomp
17	in	in	IN	_	20	case
18	lowered	lowered	JJ	_	20	amod
19	plasma	plasma	NN	_	20	compound
20	concentrations	concentration	NNS	_	16	nmod
21	of	of	IN	_	22	case
22	drug2	drug2	NN	_	20	nmod
23	.	.	.	_	8	punct

1	Coadministration	coadministration	NN	_	11	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	other	other	JJ	_	6	amod
6	drugs	drug	NNS	_	3	conj
7	that	that	WDT	_	8	nsubj
8	inhibit	inhibit	VBP	_	1	acl:relcl
9	CYP3A4	cyp3a4	NN	_	8	dobj
10	may	may	MD	_	11	aux
11	decrease	decrease	VB	_	0	ROOT
12	the	the	DT	_	13	det
13	clearance	clearance	NN	_	11	dobj
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	and	and	CC	_	11	cc
17	may	may	MD	_	18	aux
18	result	result	VB	_	11	conj
19	in	in	IN	_	22	case
20	increased	increase	VBN	_	22	amod
21	plasma	plasma	NN	_	22	compound
22	concentrations	concentration	NNS	_	18	nmod
23	of	of	IN	_	24	case
24	drug3	drug3	NN	_	22	nmod
25	.	.	.	_	11	punct

1	Table	Table	NNP	_	0	ROOT
2	8	8	CD	_	1	nummod

1	Drugs	drug	NNS	_	0	ROOT
2	That	that	WDT	_	6	nsubjpass
3	Should	should	MD	_	6	aux
4	Not	not	RB	_	6	neg
5	Be	be	VB	_	6	auxpass
6	Coadministered	coadminister	VBN	_	1	acl:relcl
7	with	with	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod

1	Drug	drug	NN	_	2	compound
2	Class	class	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	Drug	Drug	NNP	_	5	nsubj
5	Name	name	VB	_	2	dep
6	Clinical	clinical	JJ	_	7	amod
7	Comment	comment	NN	_	5	dobj

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	1	dep

1	CONTRAINDICATED	contraindicate	VBN	_	0	ROOT
2	due	due	JJ	_	1	xcomp
3	to	to	TO	_	4	case
4	potential	potential	JJ	_	2	nmod
5	for	for	IN	_	9	case
6	serious	serious	JJ	_	9	amod
7	and/or	and/or	CC	_	6	cc
8	life-threatening	life-threatening	JJ	_	6	conj
9	reactions	reaction	NNS	_	4	nmod
10	such	such	JJ	_	13	case
11	as	as	IN	_	10	mwe
12	cardiac	cardiac	JJ	_	13	amod
13	arrhythmias	arrhythmia	NNS	_	9	nmod
14	.	.	.	_	1	punct

1	Ergot	Ergot	NNP	_	2	compound
2	derivatives	derivative	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	drug1	drug1	NN	_	2	dep
5	,	,	,	_	4	punct
6	drug2	drug2	NN	_	4	conj
7	,	,	,	_	4	punct
8	drug3	drug3	NN	_	4	conj
9	,	,	,	_	4	punct
10	drug4	drug4	NN	_	4	conj

1	CONTRAINDICATED	contraindicate	VBN	_	0	ROOT
2	due	due	JJ	_	1	xcomp
3	to	to	TO	_	4	case
4	potential	potential	JJ	_	2	nmod
5	for	for	IN	_	9	case
6	serious	serious	JJ	_	9	amod
7	and/or	and/or	CC	_	6	cc
8	life-threatening	life-threatening	JJ	_	6	conj
9	reactions	reaction	NNS	_	4	nmod
10	such	such	JJ	_	14	case
11	as	as	IN	_	10	mwe
12	acute	acute	JJ	_	14	amod
13	ergot	ergot	NN	_	14	compound
14	toxicity	toxicity	NN	_	9	nmod
15	characterized	characterize	VBN	_	14	acl
16	by	by	IN	_	18	case
17	peripheral	peripheral	JJ	_	18	amod
18	vasospasm	vasospasm	NN	_	15	nmod
19	and	and	CC	_	18	cc
20	ischemia	ischemia	NN	_	18	conj
21	of	of	IN	_	23	case
22	the	the	DT	_	23	det
23	extremities	extremity	NNS	_	18	nmod
24	and	and	CC	_	23	cc
25	other	other	JJ	_	26	amod
26	tissues	tissue	NNS	_	23	conj
27	.	.	.	_	1	punct

1	drug1	drug1	NN	_	3	compound
2	/	/	:	_	3	punct
3	drug2	drug2	NN	_	0	ROOT
4	:	:	:	_	3	punct
5	drug3	drug3	NN	_	3	dep
6	,	,	,	_	5	punct
7	drug4	drug4	NN	_	5	appos

1	CONTRAINDICATED	contraindicate	VBN	_	0	ROOT
2	due	due	JJ	_	1	xcomp
3	to	to	TO	_	4	case
4	potential	potential	JJ	_	2	nmod
5	for	for	IN	_	9	case
6	serious	serious	JJ	_	9	amod
7	and/or	and/or	CC	_	6	cc
8	life-threatening	life-threatening	JJ	_	6	conj
9	reactions	reaction	NNS	_	4	nmod
10	such	such	JJ	_	12	case
11	as	as	IN	_	10	mwe
12	prolonged	prolonged	JJ	_	9	nmod
13	or	or	CC	_	12	cc
14	increased	increase	VBN	_	12	conj
15	sedation	sedation	NN	_	18	amod
16	or	or	CC	_	15	cc
17	respiratory	respiratory	JJ	_	15	conj
18	depression	depression	NN	_	12	dep
19	.	.	.	_	1	punct

1	GI	gi	NN	_	3	compound
2	motility	motility	NN	_	3	compound
3	agents	agent	NNS	_	0	ROOT
4	:	:	:	_	3	punct
5	drug1	drug1	NN	_	3	dep

1	CONTRAINDICATED	contraindicate	VBN	_	0	ROOT
2	due	due	JJ	_	1	xcomp
3	to	to	TO	_	4	case
4	potential	potential	JJ	_	2	nmod
5	for	for	IN	_	9	case
6	serious	serious	JJ	_	9	amod
7	and/or	and/or	CC	_	6	cc
8	life-threatening	life-threatening	JJ	_	6	conj
9	reactions	reaction	NNS	_	4	nmod
10	such	such	JJ	_	13	case
11	as	as	IN	_	10	mwe
12	cardiac	cardiac	JJ	_	13	amod
13	arrhythmias	arrhythmia	NNS	_	9	nmod
14	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	1	dep

1	CONTRAINDICATED	contraindicate	VBN	_	0	ROOT
2	due	due	JJ	_	1	xcomp
3	to	to	TO	_	4	case
4	potential	potential	JJ	_	2	nmod
5	for	for	IN	_	9	case
6	serious	serious	JJ	_	9	amod
7	and/or	and/or	CC	_	6	cc
8	life-threatening	life-threatening	JJ	_	6	conj
9	reactions	reaction	NNS	_	4	nmod
10	such	such	JJ	_	13	case
11	as	as	IN	_	10	mwe
12	cardiac	cardiac	JJ	_	13	amod
13	arrhythmias	arrhythmia	NNS	_	9	nmod
14	.	.	.	_	1	punct

1	Herbal	herbal	JJ	_	2	amod
2	products	product	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	St.	St.	NNP	_	7	compound
5	John	John	NNP	_	7	compound
6	s	be	VBZ	_	7	compound
7	wort	wort	NN	_	2	dep
8	-LRB-	-lrb-	-LRB-	_	10	punct
9	Hypericum	hypericum	NN	_	10	compound
10	perforatum	perforatum	NN	_	7	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct

1	May	may	MD	_	2	aux
2	lead	lead	VB	_	0	ROOT
3	to	to	TO	_	4	case
4	loss	loss	NN	_	2	nmod
5	of	of	IN	_	7	case
6	virologic	virologic	JJ	_	7	amod
7	response	response	NN	_	4	nmod
8	and	and	CC	_	4	cc
9	possible	possible	JJ	_	10	amod
10	resistance	resistance	NN	_	4	conj
11	to	to	TO	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	or	or	CC	_	12	cc
14	to	to	TO	_	16	case
15	the	the	DT	_	16	det
16	class	class	NN	_	12	conj
17	of	of	IN	_	18	case
18	drug2	drug2	NN	_	16	nmod
19	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	1	dep

1	May	may	MD	_	2	aux
2	lead	lead	VB	_	0	ROOT
3	to	to	TO	_	4	case
4	loss	loss	NN	_	2	nmod
5	of	of	IN	_	7	case
6	virologic	virologic	JJ	_	7	amod
7	response	response	NN	_	4	nmod
8	and	and	CC	_	4	cc
9	possible	possible	JJ	_	10	amod
10	resistance	resistance	NN	_	4	conj
11	to	to	TO	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	or	or	CC	_	12	cc
14	to	to	TO	_	16	case
15	the	the	DT	_	16	det
16	class	class	NN	_	12	conj
17	of	of	IN	_	18	case
18	drug2	drug2	NN	_	16	nmod
19	or	or	CC	_	18	cc
20	other	other	JJ	_	22	amod
21	coadministered	coadministered	JJ	_	22	amod
22	drug3	drug3	NN	_	18	conj
23	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	1	dep
4	,	,	,	_	3	punct
5	drug3	drug3	NN	_	3	appos

1	Potential	potential	JJ	_	0	ROOT
2	for	for	IN	_	4	case
3	serious	serious	JJ	_	4	amod
4	reactions	reaction	NNS	_	1	nmod
5	such	such	JJ	_	7	case
6	as	as	IN	_	5	mwe
7	risk	risk	NN	_	4	nmod
8	of	of	IN	_	9	case
9	myopathy	myopathy	NN	_	7	nmod
10	including	include	VBG	_	11	case
11	rhabdomyolysis	rhabdomyolysis	NN	_	9	nmod
12	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	1	dep

1	Both	both	DT	_	2	cc:preconj
2	drug1	drug1	NN	_	6	nsubjpass
3	and	and	CC	_	2	cc
4	drug2	drug2	NN	_	2	conj
5	are	be	VBP	_	6	auxpass
6	associated	associate	VBN	_	0	ROOT
7	with	with	IN	_	12	case
8	indirect	indirect	JJ	_	12	amod
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	unconjugated	unconjugated	JJ	_	8	dep
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	hyperbilirubinemia	hyperbilirubinemia	NN	_	6	nmod
13	.	.	.	_	6	punct

1	Combinations	combination	NNS	_	8	nsubjpass
2	of	of	IN	_	4	case
3	these	these	DT	_	4	det
4	drugs	drug	NNS	_	1	nmod
5	have	have	VBP	_	8	aux
6	not	not	RB	_	8	neg
7	been	be	VBN	_	8	auxpass
8	studied	study	VBN	_	0	ROOT
9	and	and	CC	_	8	cc
10	coadministration	coadministration	NN	_	17	nsubjpass
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	and	and	CC	_	12	cc
14	drug2	drug2	NN	_	12	conj
15	is	be	VBZ	_	17	auxpass
16	not	not	RB	_	17	neg
17	recommended	recommend	VBN	_	8	conj
18	.	.	.	_	8	punct

1	Table	Table	NNP	_	0	ROOT
2	9	9	CD	_	1	nummod

1	Established	establish	VBN	_	7	amod
2	and	and	CC	_	1	cc
3	Other	other	JJ	_	1	conj
4	Potentially	potentially	RB	_	5	advmod
5	Significant	significant	JJ	_	7	amod
6	Drug	drug	NN	_	7	compound
7	Interactions	interaction	NNS	_	0	ROOT
8	:	:	:	_	7	punct
9	Alteration	alteration	NN	_	16	nsubjpass
10	in	in	IN	_	11	case
11	Dose	dose	NN	_	9	nmod
12	or	or	CC	_	11	cc
13	Regimen	Regimen	NNP	_	14	compound
14	May	May	NNP	_	11	conj
15	Be	be	VB	_	16	auxpass
16	Recommended	recommend	VBN	_	7	dep
17	Based	base	VBN	_	21	case
18	on	on	IN	_	21	case
19	Drug	drug	NN	_	21	compound
20	Interaction	interaction	NN	_	21	compound
21	Studies	study	NNS	_	16	advcl
22	or	or	CC	_	21	cc
23	Predicted	predict	VBN	_	24	amod
24	Interaction	interaction	NN	_	21	conj

1	Drug	drug	NN	_	2	nsubj
2	Name	name	VB	_	0	ROOT

1	Effect	effect	NN	_	0	ROOT

1	Clinical	clinical	JJ	_	2	amod
2	Comment	comment	NN	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	2	compound
2	concentration	concentration	NN	_	0	ROOT

1	Dose	dose	NN	_	2	compound
2	reduction	reduction	NN	_	0	ROOT
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	to	to	TO	_	7	case
6	600	600	CD	_	7	nummod
7	mg	mg	NN	_	2	nmod
8	every	every	DT	_	10	det
9	8	8	CD	_	10	nummod
10	hours	hour	NNS	_	13	nsubjpass
11	should	should	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	considered	consider	VBN	_	2	acl:relcl
14	when	when	WRB	_	15	advmod
15	taking	take	VBG	_	13	advcl
16	drug2	drug2	NN	_	18	compound
17	400	400	CD	_	18	nummod
18	mg	mg	NN	_	15	dobj
19	three	three	CD	_	20	nummod
20	times	time	NNS	_	15	nmod:tmod
21	a	a	DT	_	22	det
22	day	day	NN	_	20	nmod:npmod
23	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	4	compound
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	formulations	formulation	NNS	_	9	nsubjpass
5	containing	contain	VBG	_	4	acl
6	buffer	buffer	NN	_	5	dobj
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	administered	administer	VBN	_	0	ROOT
10	at	at	IN	_	11	case
11	least	least	JJS	_	12	nmod:npmod
12	one	one	CD	_	13	nummod
13	hour	hour	NN	_	14	nmod:npmod
14	apart	apart	RB	_	9	advmod
15	on	on	IN	_	18	case
16	an	a	DT	_	18	det
17	empty	empty	JJ	_	18	amod
18	stomach	stomach	NN	_	9	nmod
19	.	.	.	_	9	punct

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	2	compound
2	concentration	concentration	NN	_	0	ROOT

1	The	the	DT	_	3	det
2	optimal	optimal	JJ	_	3	amod
3	dose	dose	NN	_	16	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	,	,	,	_	3	punct
7	when	when	WRB	_	8	advmod
8	given	give	VBN	_	3	acl:relcl
9	in	in	IN	_	10	case
10	combination	combination	NN	_	8	nmod
11	with	with	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	,	,	,	_	3	punct
14	is	be	VBZ	_	16	auxpass
15	not	not	RB	_	16	neg
16	known	know	VBN	_	0	ROOT
17	.	.	.	_	16	punct

1	Increasing	increase	VBG	_	0	ROOT
2	the	the	DT	_	4	det
3	drug1	drug1	NN	_	4	compound
4	dose	dose	NN	_	1	dobj
5	to	to	TO	_	7	case
6	1000	1000	CD	_	7	nummod
7	mg	mg	NN	_	1	nmod
8	every	every	DT	_	10	det
9	8	8	CD	_	10	nummod
10	hours	hour	NNS	_	13	nsubj
11	does	do	VBZ	_	13	aux
12	not	not	RB	_	13	neg
13	compensate	compensate	VB	_	1	dep
14	for	for	IN	_	18	case
15	the	the	DT	_	18	det
16	increased	increase	VBN	_	18	amod
17	drug2	drug2	NN	_	18	compound
18	metabolism	metabolism	NN	_	13	nmod
19	due	due	JJ	_	21	case
20	to	to	TO	_	19	mwe
21	drug3	drug3	NN	_	18	nmod
22	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	2	compound
2	concentration	concentration	NN	_	0	ROOT

1	The	the	DT	_	3	det
2	appropriate	appropriate	JJ	_	3	amod
3	doses	dose	NNS	_	18	nsubjpass
4	for	for	IN	_	6	case
5	this	this	DT	_	6	det
6	combination	combination	NN	_	3	nmod
7	,	,	,	_	3	punct
8	with	with	IN	_	9	case
9	respect	respect	NN	_	3	nmod
10	to	to	TO	_	11	case
11	efficacy	efficacy	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	safety	safety	NN	_	11	conj
14	,	,	,	_	3	punct
15	have	have	VBP	_	18	aux
16	not	not	RB	_	18	neg
17	been	be	VBN	_	18	auxpass
18	established	establish	VBN	_	0	ROOT
19	.	.	.	_	18	punct

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	2	compound
2	concentration	concentration	NN	_	0	ROOT

1	drug1	drug1	NN	_	2	compound
2	concentrations	concentration	NNS	_	5	nsubjpass
3	may	may	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	decreased	decrease	VBN	_	0	ROOT
6	in	in	IN	_	8	case
7	the	the	DT	_	8	det
8	presence	presence	NN	_	5	nmod
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	.	.	.	_	5	punct

1	The	the	DT	_	3	det
2	appropriate	appropriate	JJ	_	3	amod
3	doses	dose	NNS	_	18	nsubjpass
4	for	for	IN	_	6	case
5	this	this	DT	_	6	det
6	combination	combination	NN	_	3	nmod
7	,	,	,	_	3	punct
8	with	with	IN	_	9	case
9	respect	respect	NN	_	3	nmod
10	to	to	TO	_	11	case
11	efficacy	efficacy	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	safety	safety	NN	_	11	conj
14	,	,	,	_	3	punct
15	have	have	VBP	_	18	aux
16	not	not	RB	_	18	neg
17	been	be	VBN	_	18	auxpass
18	established	establish	VBN	_	0	ROOT
19	.	.	.	_	18	punct

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	4	compound
2	concentration	concentration	NN	_	4	compound
3	drug2	drug2	NN	_	4	compound
4	concentration	concentration	NN	_	0	ROOT

1	The	the	DT	_	3	det
2	appropriate	appropriate	JJ	_	3	amod
3	doses	dose	NNS	_	18	nsubjpass
4	for	for	IN	_	6	case
5	this	this	DT	_	6	det
6	combination	combination	NN	_	3	nmod
7	,	,	,	_	3	punct
8	with	with	IN	_	9	case
9	respect	respect	NN	_	3	nmod
10	to	to	TO	_	11	case
11	efficacy	efficacy	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	safety	safety	NN	_	11	conj
14	,	,	,	_	3	punct
15	have	have	VBP	_	18	aux
16	not	not	RB	_	18	neg
17	been	be	VBN	_	18	auxpass
18	established	establish	VBN	_	0	ROOT
19	.	.	.	_	18	punct

1	Preliminary	preliminary	JJ	_	3	amod
2	clinical	clinical	JJ	_	3	amod
3	data	datum	NNS	_	4	nsubj
4	suggest	suggest	VBP	_	0	ROOT
5	that	that	IN	_	11	mark
6	the	the	DT	_	7	det
7	incidence	incidence	NN	_	11	nsubj
8	of	of	IN	_	9	case
9	nephrolithiasis	nephrolithiasis	NN	_	7	nmod
10	is	be	VBZ	_	11	cop
11	higher	higher	JJR	_	4	ccomp
12	in	in	IN	_	13	case
13	patients	patient	NNS	_	11	nmod
14	receiving	receive	VBG	_	13	acl
15	drug1	drug1	NN	_	14	dobj
16	in	in	IN	_	17	case
17	combination	combination	NN	_	14	nmod
18	with	with	IN	_	19	case
19	drug2	drug2	NN	_	17	nmod
20	than	than	IN	_	21	case
21	those	those	DT	_	11	nmod
22	receiving	receive	VBG	_	21	acl
23	drug3	drug3	NN	_	26	compound
24	800	800	CD	_	25	compound
25	mg	mg	NN	_	26	amod
26	q8h	q8h	NN	_	22	dobj
27	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	2	compound
2	concentration	concentration	NN	_	0	ROOT

1	The	the	DT	_	3	det
2	appropriate	appropriate	JJ	_	3	amod
3	doses	dose	NNS	_	18	nsubjpass
4	for	for	IN	_	6	case
5	this	this	DT	_	6	det
6	combination	combination	NN	_	3	nmod
7	,	,	,	_	3	punct
8	with	with	IN	_	9	case
9	respect	respect	NN	_	3	nmod
10	to	to	TO	_	11	case
11	efficacy	efficacy	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	safety	safety	NN	_	11	conj
14	,	,	,	_	3	punct
15	have	have	VBP	_	18	aux
16	not	not	RB	_	18	neg
17	been	be	VBN	_	18	auxpass
18	established	establish	VBN	_	0	ROOT
19	.	.	.	_	18	punct

1	Other	other	JJ	_	2	amod
2	Agents	agent	NNS	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	1	dep
4	,	,	,	_	3	punct
5	drug3	drug3	NN	_	4	root
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	systemic	systemic	JJ	_	5	dep
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	and	and	CC	_	5	cc
10	drug4	drug4	NN	_	5	conj

1	drug1	drug1	NN	_	2	compound
2	concentration	concentration	NN	_	0	ROOT

1	Caution	caution	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	warranted	warrant	VBN	_	0	ROOT
4	and	and	CC	_	3	cc
5	therapeutic	therapeutic	JJ	_	7	amod
6	concentration	concentration	NN	_	7	compound
7	monitoring	monitoring	NN	_	9	nsubjpass
8	is	be	VBZ	_	9	auxpass
9	recommended	recommend	VBN	_	3	conj
10	for	for	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	when	when	WRB	_	13	advmod
13	coadministered	coadminister	VBN	_	9	advcl
14	with	with	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	.	.	.	_	3	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	1	dep
4	,	,	,	_	3	punct
5	drug3	drug3	NN	_	3	conj
6	,	,	,	_	3	punct
7	drug4	drug4	NN	_	3	conj

1	drug1	drug1	NN	_	2	compound
2	concentration	concentration	NN	_	0	ROOT

1	Use	use	NN	_	0	ROOT
2	with	with	IN	_	3	case
3	caution	caution	NN	_	1	nmod
4	.	.	.	_	1	punct

1	drug1	drug1	NN	_	5	nsubj
2	may	may	MD	_	5	aux
3	not	not	RB	_	5	neg
4	be	be	VB	_	5	cop
5	effective	effective	JJ	_	0	ROOT
6	due	due	JJ	_	10	case
7	to	to	TO	_	10	case
8	decreased	decrease	VBN	_	10	amod
9	drug2	drug2	NN	_	10	compound
10	concentrations	concentration	NNS	_	5	advcl
11	in	in	IN	_	12	case
12	patients	patient	NNS	_	10	nmod
13	taking	take	VBG	_	12	acl
14	these	these	DT	_	15	det
15	agents	agent	NNS	_	13	dobj
16	concomitantly	concomitantly	RB	_	13	advmod
17	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	appos
4	:	:	:	_	1	punct
5	e.g.	e.g.	FW	_	7	dep
6	,	,	,	_	7	punct
7	drug3	drug3	NN	_	1	dep
8	,	,	,	_	7	punct
9	drug4	drug4	NN	_	7	conj
10	,	,	,	_	7	punct
11	drug5	drug5	NN	_	7	conj

1	drug1	drug1	NN	_	2	compound
2	concentration	concentration	NN	_	0	ROOT

1	Caution	caution	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	warranted	warrant	VBN	_	0	ROOT
4	and	and	CC	_	3	cc
5	clinical	clinical	JJ	_	6	amod
6	monitoring	monitoring	NN	_	10	nsubjpass
7	of	of	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	is	be	VBZ	_	10	auxpass
10	recommended	recommend	VBN	_	3	conj
11	.	.	.	_	3	punct

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	4	compound
2	concentration	concentration	NN	_	4	compound
3	drug2	drug2	NN	_	4	compound
4	concentration	concentration	NN	_	0	ROOT

1	The	the	DT	_	3	det
2	appropriate	appropriate	JJ	_	3	amod
3	doses	dose	NNS	_	18	nsubjpass
4	for	for	IN	_	6	case
5	this	this	DT	_	6	det
6	combination	combination	NN	_	3	nmod
7	,	,	,	_	3	punct
8	with	with	IN	_	9	case
9	respect	respect	NN	_	3	nmod
10	to	to	TO	_	11	case
11	efficacy	efficacy	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	safety	safety	NN	_	11	conj
14	,	,	,	_	3	punct
15	have	have	VBP	_	18	aux
16	not	not	RB	_	18	neg
17	been	be	VBN	_	18	auxpass
18	established	establish	VBN	_	0	ROOT
19	.	.	.	_	18	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	1	dep

1	drug1	drug1	NN	_	2	compound
2	concentration	concentration	NN	_	0	ROOT

1	Use	Use	NNP	_	4	compound
2	lowest	lowest	JJS	_	4	amod
3	possible	possible	JJ	_	4	amod
4	dose	dose	NN	_	0	ROOT
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	with	with	IN	_	9	case
8	careful	careful	JJ	_	9	amod
9	monitoring	monitoring	NN	_	4	nmod
10	,	,	,	_	4	punct
11	or	or	CC	_	4	cc
12	consider	consider	VB	_	4	conj
13	drug2	drug2	NN	_	12	dobj
14	that	that	WDT	_	18	nsubjpass
15	are	be	VBP	_	18	auxpass
16	not	not	RB	_	18	neg
17	primarily	primarily	RB	_	18	advmod
18	metabolized	metabolize	VBN	_	13	acl:relcl
19	by	by	IN	_	20	case
20	CYP3A4	cyp3a4	NN	_	18	nmod
21	,	,	,	_	13	punct
22	such	such	JJ	_	24	case
23	as	as	IN	_	22	mwe
24	drug3	drug3	NN	_	13	nmod
25	,	,	,	_	24	punct
26	drug4	drug4	NN	_	24	conj
27	,	,	,	_	24	punct
28	or	or	CC	_	24	cc
29	drug5	drug5	NN	_	24	conj
30	in	in	IN	_	31	case
31	combination	combination	NN	_	24	nmod
32	with	with	IN	_	33	case
33	drug6	drug6	NN	_	31	nmod
34	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	1	dep
4	,	,	,	_	3	punct
5	drug3	drug3	NN	_	3	conj
6	,	,	,	_	3	punct
7	drug4	drug4	NN	_	3	conj

1	drug1	drug1	NN	_	2	compound
2	concentration	concentration	NN	_	0	ROOT

1	Plasma	plasma	NN	_	2	compound
2	concentrations	concentration	NNS	_	5	nsubjpass
3	may	may	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	increased	increase	VBN	_	0	ROOT
6	by	by	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	2	compound
2	concentration	concentration	NN	_	0	ROOT

1	Dose	dose	NN	_	2	compound
2	reduction	reduction	NN	_	0	ROOT
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	to	to	TO	_	7	case
6	600	600	CD	_	7	nummod
7	mg	mg	NN	_	2	nmod
8	every	every	DT	_	10	det
9	8	8	CD	_	10	nummod
10	hours	hour	NNS	_	12	nsubjpass
11	is	be	VBZ	_	12	auxpass
12	recommended	recommend	VBN	_	2	acl:relcl
13	when	when	WRB	_	14	advmod
14	administering	administer	VBG	_	12	advcl
15	drug2	drug2	NN	_	14	dobj
16	concurrently	concurrently	RB	_	14	advmod
17	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	2	compound
2	concentration	concentration	NN	_	0	ROOT

1	Dose	dose	NN	_	2	compound
2	reduction	reduction	NN	_	13	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	to	to	TO	_	7	case
6	600	600	CD	_	7	nummod
7	mg	mg	NN	_	2	nmod
8	every	every	DT	_	10	det
9	8	8	CD	_	10	nummod
10	hours	hour	NNS	_	13	nsubjpass
11	should	should	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	considered	consider	VBN	_	0	ROOT
14	.	.	.	_	13	punct

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	4	compound
2	concentration	concentration	NN	_	4	compound
3	drug2	drug2	NN	_	4	compound
4	concentration	concentration	NN	_	0	ROOT

1	Dose	dose	NN	_	2	compound
2	reduction	reduction	NN	_	28	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	to	to	TO	_	9	case
6	half	half	PDT	_	9	det:predet
7	the	the	DT	_	9	det
8	standard	standard	JJ	_	9	amod
9	dose	dose	NN	_	2	nmod
10	and	and	CC	_	9	cc
11	a	a	DT	_	13	det
12	dose	dose	NN	_	13	compound
13	increase	increase	NN	_	9	conj
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	to	to	TO	_	18	case
17	1000	1000	CD	_	18	nummod
18	mg	mg	NN	_	13	nmod
19	-LRB-	-lrb-	-LRB-	_	22	punct
20	three	three	CD	_	22	nummod
21	333-mg	333-mg	JJ	_	22	amod
22	capsules	capsule	NNS	_	2	appos
23	-RRB-	-rrb-	-RRB-	_	22	punct
24	every	every	DT	_	26	det
25	8	8	CD	_	26	nummod
26	hours	hour	NNS	_	28	nsubjpass
27	are	be	VBP	_	28	auxpass
28	recommended	recommend	VBN	_	0	ROOT
29	when	when	WRB	_	34	advmod
30	drug3	drug3	NN	_	34	nsubjpass
31	and	and	CC	_	30	cc
32	drug4	drug4	NN	_	30	conj
33	are	be	VBP	_	34	auxpass
34	coadministered	coadminister	VBN	_	28	advcl
35	.	.	.	_	28	punct

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	2	compound
2	concentration	concentration	NN	_	0	ROOT

1	drug1	drug1	NN	_	2	compound
2	dose	dose	NN	_	5	nsubj
3	should	should	MD	_	5	aux
4	not	not	RB	_	5	neg
5	exceed	exceed	VB	_	0	ROOT
6	a	a	DT	_	7	det
7	maximum	maximum	NN	_	5	dobj
8	of	of	IN	_	10	case
9	25	25	CD	_	10	nummod
10	mg	mg	NN	_	7	nmod
11	in	in	IN	_	16	case
12	a	a	DT	_	16	det
13	48	48	CD	_	16	nummod
14	-	-	:	_	16	punct
15	hour	hour	NN	_	16	compound
16	period	period	NN	_	5	nmod
17	in	in	IN	_	18	case
18	patients	patient	NNS	_	16	nmod
19	receiving	receive	VBG	_	18	acl
20	concomitant	concomitant	JJ	_	22	amod
21	drug2	drug2	NN	_	22	compound
22	therapy	therapy	NN	_	19	dobj
23	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	2	compound
2	concentration	concentration	NN	_	0	ROOT

1	drug1	drug1	NN	_	2	compound
2	dose	dose	NN	_	5	nsubj
3	should	should	MD	_	5	aux
4	not	not	RB	_	5	neg
5	exceed	exceed	VB	_	0	ROOT
6	a	a	DT	_	7	det
7	maximum	maximum	NN	_	5	dobj
8	of	of	IN	_	10	case
9	10	10	CD	_	10	nummod
10	mg	mg	NN	_	7	nmod
11	in	in	IN	_	16	case
12	a	a	DT	_	16	det
13	72	72	CD	_	16	nummod
14	-	-	:	_	16	punct
15	hour	hour	NN	_	16	compound
16	period	period	NN	_	5	nmod
17	in	in	IN	_	18	case
18	patients	patient	NNS	_	16	nmod
19	receiving	receive	VBG	_	18	acl
20	concomitant	concomitant	JJ	_	22	amod
21	drug2	drug2	NN	_	22	compound
22	therapy	therapy	NN	_	19	dobj
23	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	2	compound
2	concentration	concentration	NN	_	0	ROOT

1	drug1	drug1	NN	_	2	compound
2	dose	dose	NN	_	5	nsubj
3	should	should	MD	_	5	aux
4	not	not	RB	_	5	neg
5	exceed	exceed	VB	_	0	ROOT
6	a	a	DT	_	7	det
7	maximum	maximum	NN	_	5	dobj
8	of	of	IN	_	10	case
9	2.5	2.5	CD	_	10	nummod
10	mg	mg	NN	_	7	nmod
11	in	in	IN	_	14	case
12	a	a	DT	_	14	det
13	24-hour	24-hour	JJ	_	14	amod
14	period	period	NN	_	5	nmod
15	in	in	IN	_	16	case
16	patients	patient	NNS	_	14	nmod
17	receiving	receive	VBG	_	16	acl
18	concomitant	concomitant	JJ	_	20	amod
19	drug2	drug2	NN	_	20	compound
20	therapy	therapy	NN	_	17	dobj
21	.	.	.	_	5	punct

1	Note	note	VB	_	0	ROOT
2	:	:	:	_	1	punct

1	=	=	JJ	_	2	amod
2	increase	increase	NN	_	0	ROOT
3	;	;	:	_	2	punct

1	=	=	JJ	_	0	ROOT
2	decrease	decrease	NN	_	1	dep

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	Interactions	interaction	NNS	_	0	ROOT
2	for	for	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	drug2	drug2	NN	_	3	dep
6	,	,	,	_	5	punct
7	drug3	drug3	NN	_	5	conj
8	,	,	,	_	5	punct
9	drug4	drug4	NN	_	5	conj
10	,	,	,	_	5	punct
11	and	and	CC	_	5	cc
12	drug5	drug5	NN	_	5	conj
13	-RRB-	-rrb-	-RRB-	_	5	punct
14	:	:	:	_	1	punct
15	drug6	drug6	NN	_	1	dep
16	:	:	:	_	15	punct
17	drug7	drug7	NN	_	20	nsubjpass
18	has	have	VBZ	_	20	aux
19	been	be	VBN	_	20	auxpass
20	reported	report	VBN	_	15	appos
21	to	to	TO	_	22	mark
22	reduce	reduce	VB	_	20	xcomp
23	intestinal	intestinal	JJ	_	24	amod
24	absorption	absorption	NN	_	22	dobj
25	of	of	IN	_	26	case
26	drug8	drug8	NN	_	24	nmod
27	;	;	:	_	1	punct

1	as	as	IN	_	5	mark
2	such	such	JJ	_	5	mark
3	it	it	PRP	_	5	nsubj
4	may	may	MD	_	5	aux
5	impair	impair	VB	_	0	ROOT
6	intestinal	intestinal	JJ	_	7	amod
7	absorption	absorption	NN	_	5	dobj
8	of	of	IN	_	9	case
9	any	any	DT	_	7	nmod
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	.	.	.	_	5	punct

1	drug1	drug1	NN	_	3	compound
2	/	/	:	_	3	punct
3	drug2	drug2	NN	_	0	ROOT
4	:	:	:	_	3	punct
5	The	the	DT	_	6	det
6	coadministration	coadministration	NN	_	13	nsubj
7	of	of	IN	_	8	case
8	drug3	drug3	NN	_	6	nmod
9	or	or	CC	_	8	cc
10	drug4	drug4	NN	_	8	conj
11	will	will	MD	_	13	aux
12	not	not	RB	_	13	neg
13	affect	affect	VB	_	3	dep
14	plasma	plasma	NN	_	15	compound
15	concentrations	concentration	NNS	_	13	dobj
16	of	of	IN	_	17	case
17	drug5	drug5	NN	_	15	nmod
18	,	,	,	_	13	punct
19	but	but	CC	_	13	cc
20	may	may	MD	_	21	aux
21	reduce	reduce	VB	_	13	conj
22	endogenous	endogenous	JJ	_	24	amod
23	plasma	plasma	NN	_	24	compound
24	levels	level	NNS	_	21	dobj
25	of	of	IN	_	26	case
26	drug6	drug6	NN	_	24	nmod
27	/	/	:	_	13	punct
28	ergocalcitriol	ergocalcitriol	NN	_	13	conj
29	by	by	IN	_	30	mark
30	accelerating	accelerate	VBG	_	28	acl
31	metabolism	metabolism	NN	_	30	dobj
32	.	.	.	_	3	punct

1	Since	since	IN	_	10	mark
2	blood	blood	NN	_	3	compound
3	level	level	NN	_	10	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	/	/	:	_	7	punct
7	ergocalcitriol	ergocalcitriol	NN	_	10	nsubjpass
8	will	will	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	reduced	reduce	VBN	_	18	advcl
11	,	,	,	_	18	punct
12	higher	higher	JJR	_	13	amod
13	doses	dose	NNS	_	18	nsubj
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	may	may	MD	_	18	aux
17	be	be	VB	_	18	cop
18	necessary	necessary	JJ	_	0	ROOT
19	if	if	IN	_	23	mark
20	these	these	DT	_	21	det
21	drugs	drug	NNS	_	23	nsubjpass
22	are	be	VBP	_	23	auxpass
23	administered	administer	VBN	_	18	advcl
24	simultaneously	simultaneously	RB	_	23	advmod
25	.	.	.	_	18	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubjpass
4	are	be	VBP	_	5	auxpass
5	known	know	VBN	_	1	appos
6	to	to	TO	_	7	mark
7	induce	induce	VB	_	5	xcomp
8	hypercalcemia	hypercalcemia	NN	_	7	dobj
9	by	by	IN	_	11	case
10	the	the	DT	_	11	det
11	reduction	reduction	NN	_	7	nmod
12	of	of	IN	_	14	case
13	calcium	calcium	NN	_	14	compound
14	excretion	excretion	NN	_	11	nmod
15	in	in	IN	_	16	case
16	urine	urine	NN	_	11	nmod
17	.	.	.	_	1	punct

1	Some	some	DT	_	2	det
2	reports	report	NNS	_	4	nsubj
3	have	have	VBP	_	4	aux
4	shown	show	VBN	_	0	ROOT
5	that	that	IN	_	13	mark
6	the	the	DT	_	8	det
7	concomitant	concomitant	JJ	_	8	amod
8	administration	administration	NN	_	13	nsubj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	with	with	IN	_	12	case
12	drug2	drug2	NN	_	8	nmod
13	causes	cause	VBZ	_	4	ccomp
14	hypercalcemia	hypercalcemia	NN	_	13	dobj
15	.	.	.	_	4	punct

1	Therefore	therefore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	precaution	precaution	NN	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	taken	take	VBN	_	0	ROOT
7	when	when	WRB	_	10	advmod
8	coadministration	coadministration	NN	_	10	nsubj
9	is	be	VBZ	_	10	cop
10	necessary	necessary	JJ	_	6	advcl
11	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	compound
4	dosage	dosage	NN	_	7	nsubjpass
5	must	must	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	determined	determine	VBN	_	1	dep
8	with	with	IN	_	9	case
9	care	care	NN	_	7	nmod
10	in	in	IN	_	11	case
11	patients	patient	NNS	_	9	nmod
12	undergoing	undergo	VBG	_	11	acl
13	treatment	treatment	NN	_	12	dobj
14	with	with	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	,	,	,	_	7	punct
17	as	as	IN	_	18	case
18	hypercalcemia	hypercalcemia	NN	_	7	nmod
19	in	in	IN	_	21	case
20	such	such	JJ	_	21	amod
21	patients	patient	NNS	_	18	nmod
22	may	may	MD	_	23	aux
23	precipitate	precipitate	VB	_	7	ccomp
24	cardiac	cardiac	JJ	_	25	amod
25	arrhythmias	arrhythmia	NNS	_	23	dobj
26	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	inhibit	inhibit	VB	_	1	dep
6	both	both	DT	_	7	cc:preconj
7	synthetic	synthetic	JJ	_	5	dobj
8	and	and	CC	_	7	cc
9	catabolic	catabolic	JJ	_	7	conj
10	enzymes	enzyme	NNS	_	7	dep
11	of	of	IN	_	12	case
12	drug3	drug3	NN	_	7	nmod
13	.	.	.	_	5	punct

1	Reductions	reduction	NNS	_	10	nsubjpass
2	in	in	IN	_	7	case
3	serum	serum	NN	_	7	compound
4	endogenous	endogenous	JJ	_	7	amod
5	vitamin	vitamin	NN	_	7	compound
6	D	d	NN	_	7	compound
7	concentrations	concentration	NNS	_	1	nmod
8	have	have	VBP	_	10	aux
9	been	be	VBN	_	10	auxpass
10	observed	observe	VBN	_	0	ROOT
11	following	follow	VBG	_	13	case
12	the	the	DT	_	13	det
13	administration	administration	NN	_	10	nmod
14	of	of	IN	_	16	case
15	300	300	CD	_	16	nummod
16	mg/day	mg/day	NN	_	13	nmod
17	to	to	TO	_	20	case
18	1200	1200	CD	_	20	nummod
19	mg/day	mg/day	NN	_	20	compound
20	drug1	drug1	NN	_	13	nmod
21	for	for	IN	_	23	case
22	a	a	DT	_	23	det
23	week	week	NN	_	13	nmod
24	to	to	TO	_	26	case
25	healthy	healthy	JJ	_	26	amod
26	men	man	NNS	_	23	nmod
27	.	.	.	_	10	punct

1	However	however	RB	_	15	advmod
2	,	,	,	_	15	punct
3	in	in	FW	_	7	amod
4	vivo	vivo	FW	_	3	dep
5	drug	drug	NN	_	7	compound
6	interaction	interaction	NN	_	7	compound
7	studies	study	NNS	_	15	nsubjpass
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	have	have	VBP	_	15	aux
13	not	not	RB	_	15	neg
14	been	be	VBN	_	15	auxpass
15	investigated	investigate	VBN	_	0	ROOT
16	.	.	.	_	15	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	A	a	DT	_	4	det
4	relationship	relationship	NN	_	8	nsubj
5	of	of	IN	_	7	case
6	functional	functional	JJ	_	7	amod
7	antagonism	antagonism	NN	_	4	nmod
8	exists	exist	VBZ	_	1	appos
9	between	between	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	,	,	,	_	10	punct
12	which	which	WDT	_	13	nsubj
13	promote	promote	VBP	_	10	acl:relcl
14	calcium	calcium	NN	_	15	compound
15	absorption	absorption	NN	_	13	dobj
16	,	,	,	_	10	punct
17	and	and	CC	_	10	cc
18	drug3	drug3	NN	_	10	conj
19	,	,	,	_	18	punct
20	which	which	WDT	_	21	nsubj
21	inhibit	inhibit	VBP	_	18	acl:relcl
22	calcium	calcium	NN	_	23	compound
23	absorption	absorption	NN	_	21	dobj
24	.	.	.	_	1	punct

1	Phosphate-Binding	phosphate-binding	JJ	_	2	amod
2	Agents	agent	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	Since	since	IN	_	5	case
5	drug1	drug1	NN	_	7	nmod
6	also	also	RB	_	7	advmod
7	has	have	VBZ	_	2	dep
8	an	a	DT	_	9	det
9	effect	effect	NN	_	7	dobj
10	on	on	IN	_	12	case
11	phosphate	phosphate	NN	_	12	compound
12	transport	transport	NN	_	9	nmod
13	in	in	IN	_	15	case
14	the	the	DT	_	15	det
15	intestine	intestine	NN	_	7	nmod
16	,	,	,	_	15	punct
17	kidneys	kidney	NNS	_	15	conj
18	and	and	CC	_	15	cc
19	bones	bone	NNS	_	15	conj
20	,	,	,	_	7	punct
21	the	the	DT	_	22	det
22	dosage	dosage	NN	_	28	nsubjpass
23	of	of	IN	_	25	case
24	phosphate-binding	phosphate-binding	JJ	_	25	amod
25	agents	agent	NNS	_	22	nmod
26	must	must	MD	_	28	aux
27	be	be	VB	_	28	auxpass
28	adjusted	adjust	VBN	_	7	ccomp
29	in	in	IN	_	30	case
30	accordance	accordance	NN	_	28	nmod
31	with	with	IN	_	35	case
32	the	the	DT	_	35	det
33	serum	serum	NN	_	35	compound
34	phosphate	phosphate	NN	_	35	compound
35	concentration	concentration	NN	_	30	nmod
36	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	coadministration	coadministration	NN	_	12	nsubjpass
5	of	of	IN	_	6	case
6	any	any	DT	_	4	nmod
7	of	of	IN	_	9	case
8	the	the	DT	_	9	det
9	drug2	drug2	NN	_	6	nmod
10	should	should	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	avoided	avoid	VBN	_	1	appos
13	as	as	IN	_	16	mark
14	this	this	DT	_	16	nsubj
15	could	could	MD	_	16	aux
16	create	create	VB	_	12	advcl
17	possible	possible	JJ	_	19	amod
18	additive	additive	JJ	_	19	amod
19	effects	effect	NNS	_	16	dobj
20	and	and	CC	_	19	cc
21	hypercalcemia	hypercalcemia	NN	_	19	conj
22	.	.	.	_	1	punct

1	drug1	drug1	NN	_	2	compound
2	Supplements	supplement	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	Uncontrolled	uncontrolled	JJ	_	5	amod
5	intake	intake	NN	_	14	nsubjpass
6	of	of	IN	_	8	case
7	additional	additional	JJ	_	8	amod
8	drug2	drug2	NN	_	5	nmod
9	-	-	:	_	5	punct
10	containing	contain	VBG	_	5	acl
11	preparations	preparation	NNS	_	10	dobj
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	avoided	avoid	VBN	_	2	dep
15	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	dep
4	-	-	:	_	5	punct
5	containing	contain	VBG	_	1	dep
6	preparations	preparation	NNS	_	5	dobj
7	-LRB-	-lrb-	-LRB-	_	8	punct
8	eg	eg	FW	_	6	dep
9	,	,	,	_	8	punct
10	drug3	drug3	NN	_	8	appos
11	-RRB-	-rrb-	-RRB-	_	8	punct
12	may	may	MD	_	13	aux
13	cause	cause	VB	_	5	dep
14	hypermagnesemia	hypermagnesemia	NN	_	13	dobj
15	and	and	CC	_	13	cc
16	should	should	MD	_	20	aux
17	therefore	therefore	RB	_	20	advmod
18	not	not	RB	_	20	neg
19	be	be	VB	_	20	auxpass
20	taken	take	VBN	_	13	conj
21	during	during	IN	_	22	case
22	therapy	therapy	NN	_	20	nmod
23	with	with	IN	_	24	case
24	drug4	drug4	NN	_	22	nmod
25	by	by	IN	_	26	case
26	patients	patient	NNS	_	20	nmod
27	on	on	IN	_	30	case
28	chronic	chronic	JJ	_	30	amod
29	renal	renal	JJ	_	30	amod
30	dialysis	dialysis	NN	_	26	nmod
31	.	.	.	_	1	punct

1	Drugs	drug	NNS	_	0	ROOT
2	Metabolized	metabolize	VBN	_	1	acl
3	by	by	IN	_	5	case
4	P450	p450	NN	_	5	compound
5	2D6	2d6	NN	_	2	nmod
6	-	-	:	_	1	punct
7	The	the	DT	_	9	det
8	biochemical	biochemical	JJ	_	9	amod
9	activity	activity	NN	_	23	nsubjpass
10	of	of	IN	_	12	case
11	the	the	DT	_	12	det
12	drug	drug	NN	_	9	nmod
13	metabolizing	metabolize	VBG	_	12	acl
14	isozyme	isozyme	NN	_	17	compound
15	cytochrome	cytochrome	NN	_	17	compound
16	P450	p450	NN	_	17	compound
17	2D6	2d6	NN	_	13	dobj
18	-LRB-	-lrb-	-LRB-	_	20	punct
19	debrisoquin	debrisoquin	NN	_	20	compound
20	hydroxylase	hydroxylase	NN	_	17	appos
21	-RRB-	-rrb-	-RRB-	_	20	punct
22	is	be	VBZ	_	23	auxpass
23	reduced	reduce	VBN	_	1	parataxis
24	in	in	IN	_	26	case
25	a	a	DT	_	26	det
26	subset	subset	NN	_	23	nmod
27	of	of	IN	_	30	case
28	the	the	DT	_	30	det
29	caucasian	caucasian	JJ	_	30	amod
30	population	population	NN	_	26	nmod
31	-LRB-	-lrb-	-LRB-	_	39	punct
32	about	about	IN	_	33	advmod
33	7-10	7-10	CD	_	34	nummod
34	%	%	NN	_	39	nsubjpass
35	of	of	IN	_	36	case
36	caucasians	caucasian	NNS	_	34	nmod
37	are	be	VBP	_	39	auxpass
38	so	so	RB	_	39	advmod
39	called	call	VBN	_	26	dep
40	poor	poor	JJ	_	41	amod
41	metabolizers	metabolizer	NNS	_	39	xcomp
42	-RRB-	-rrb-	-RRB-	_	39	punct
43	;	;	:	_	1	punct

1	reliable	reliable	JJ	_	2	amod
2	estimates	estimate	NNS	_	22	nsubj
3	of	of	IN	_	5	case
4	the	the	DT	_	5	det
5	prevalence	prevalence	NN	_	2	nmod
6	of	of	IN	_	11	case
7	reduced	reduce	VBN	_	11	amod
8	P450	p450	NN	_	11	compound
9	2D6	2d6	NN	_	11	compound
10	isozyme	isozyme	NN	_	11	compound
11	activity	activity	NN	_	5	nmod
12	among	among	IN	_	18	case
13	Asian	asian	JJ	_	18	amod
14	,	,	,	_	13	punct
15	African	african	JJ	_	13	conj
16	and	and	CC	_	13	cc
17	other	other	JJ	_	13	conj
18	populations	population	NNS	_	11	nmod
19	are	be	VBP	_	22	cop
20	not	not	RB	_	22	neg
21	yet	yet	RB	_	22	advmod
22	available	available	JJ	_	0	ROOT
23	.	.	.	_	22	punct

1	Poor	Poor	NNP	_	2	compound
2	metabolizers	metabolizer	NNS	_	3	nsubj
3	have	have	VBP	_	0	ROOT
4	higher	higher	JJR	_	8	amod
5	than	than	IN	_	6	dep
6	expected	expect	VBN	_	8	amod
7	plasma	plasma	NN	_	8	compound
8	concentrations	concentration	NNS	_	3	dobj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	drug2	drug2	NN	_	10	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	when	when	WRB	_	15	advmod
15	given	give	VBN	_	3	advcl
16	usual	usual	JJ	_	17	amod
17	doses	dose	NNS	_	15	dobj
18	.	.	.	_	3	punct

1	Depending	depend	VBG	_	4	case
2	on	on	IN	_	4	case
3	the	the	DT	_	4	det
4	fraction	fraction	NN	_	19	nmod
5	of	of	IN	_	6	case
6	drug	drug	NN	_	4	nmod
7	metabolized	metabolize	VBN	_	6	acl
8	by	by	IN	_	10	case
9	P450	p450	NN	_	10	compound
10	2D6	2d6	NN	_	7	nmod
11	,	,	,	_	19	punct
12	the	the	DT	_	13	det
13	increase	increase	NN	_	19	nsubj
14	in	in	IN	_	16	case
15	plasma	plasma	NN	_	16	compound
16	concentration	concentration	NN	_	13	nmod
17	may	may	MD	_	19	aux
18	be	be	VB	_	19	cop
19	small	small	JJ	_	0	ROOT
20	,	,	,	_	19	punct
21	or	or	CC	_	19	cc
22	quite	quite	RB	_	23	advmod
23	large	large	JJ	_	26	amod
24	-LRB-	-lrb-	-LRB-	_	26	punct
25	8-fold	8-fold	JJ	_	26	amod
26	increase	increase	NN	_	19	conj
27	in	in	IN	_	29	case
28	plasma	plasma	NN	_	29	compound
29	AUC	auc	NN	_	26	nmod
30	of	of	IN	_	32	case
31	the	the	DT	_	32	det
32	drug1	drug1	NN	_	29	nmod
33	-RRB-	-rrb-	-RRB-	_	19	punct
34	.	.	.	_	19	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	6	nmod
3	,	,	,	_	6	punct
4	certain	certain	JJ	_	5	amod
5	drugs	drug	NNS	_	6	nsubj
6	inhibit	inhibit	VBP	_	0	ROOT
7	the	the	DT	_	8	det
8	activity	activity	NN	_	6	dobj
9	of	of	IN	_	11	case
10	this	this	DT	_	11	det
11	isozyme	isozyme	NN	_	8	nmod
12	and	and	CC	_	6	cc
13	make	make	VB	_	6	conj
14	normal	normal	JJ	_	15	amod
15	metabolizers	metabolizer	NNS	_	16	nsubj
16	resemble	resemble	VBP	_	13	ccomp
17	poor	poor	JJ	_	18	amod
18	metabolizers	metabolizer	NNS	_	16	xcomp
19	.	.	.	_	6	punct

1	An	a	DT	_	2	det
2	individual	individual	NN	_	13	nsubj
3	who	who	WP	_	5	nsubj
4	is	be	VBZ	_	5	cop
5	stable	stable	JJ	_	2	acl:relcl
6	on	on	IN	_	9	case
7	a	a	DT	_	9	det
8	given	give	VBN	_	9	amod
9	dose	dose	NN	_	5	nmod
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	may	may	MD	_	13	aux
13	become	become	VB	_	0	ROOT
14	abruptly	abruptly	RB	_	15	advmod
15	toxic	toxic	JJ	_	13	xcomp
16	when	when	WRB	_	17	advmod
17	given	give	VBN	_	13	advcl
18	one	one	CD	_	17	dobj
19	of	of	IN	_	22	case
20	these	these	DT	_	22	det
21	inhibiting	inhibit	VBG	_	22	amod
22	drugs	drug	NNS	_	18	nmod
23	as	as	IN	_	25	case
24	concomitant	concomitant	JJ	_	25	amod
25	therapy	therapy	NN	_	17	nmod
26	.	.	.	_	13	punct

1	The	the	DT	_	2	det
2	drugs	drug	NNS	_	8	nsubj
3	that	that	WDT	_	4	nsubj
4	inhibit	inhibit	VBP	_	2	acl:relcl
5	cytochrome	cytochrome	NN	_	7	compound
6	P450	p450	NN	_	7	compound
7	2D6	2d6	NN	_	4	dobj
8	include	include	VBP	_	0	ROOT
9	some	some	DT	_	8	dobj
10	that	that	WDT	_	13	nsubjpass
11	are	be	VBP	_	13	auxpass
12	not	not	RB	_	13	neg
13	metabolized	metabolize	VBN	_	9	acl:relcl
14	by	by	IN	_	16	case
15	the	the	DT	_	16	det
16	enzyme	enzyme	NN	_	13	nmod
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	drug1	drug1	NN	_	16	appos
19	;	;	:	_	18	punct

1	drug1	drug1	NN	_	0	ROOT
2	-RRB-	-rrb-	-RRB-	_	1	punct
3	and	and	CC	_	1	cc
4	many	many	JJ	_	1	conj
5	that	that	WDT	_	7	nsubj
6	are	be	VBP	_	7	cop
7	substrates	substrate	NNS	_	4	acl:relcl
8	for	for	IN	_	10	case
9	P450	p450	NN	_	10	compound
10	2D6	2d6	NN	_	7	nmod
11	-LRB-	-lrb-	-LRB-	_	14	punct
12	many	many	JJ	_	14	amod
13	other	other	JJ	_	14	amod
14	drug2	drug2	NN	_	1	dep
15	,	,	,	_	14	punct
16	drug3	drug3	NN	_	14	conj
17	,	,	,	_	14	punct
18	and	and	CC	_	14	cc
19	the	the	DT	_	21	det
20	drug4	drug4	NN	_	21	compound
21	drug5	drug5	NN	_	14	conj
22	and	and	CC	_	21	cc
23	drug6	drug6	NN	_	21	conj
24	-RRB-	-rrb-	-RRB-	_	14	punct
25	.	.	.	_	1	punct

1	While	while	IN	_	0	ROOT
2	all	all	PDT	_	5	det:predet
3	the	the	DT	_	5	det
4	selective	selective	JJ	_	5	amod
5	drug1	drug1	NN	_	1	dep
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	drug2	drug2	NN	_	5	appos
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	,	,	,	_	5	punct
10	e.g.	e.g.	FW	_	12	dep
11	,	,	,	_	12	punct
12	drug3	drug3	NN	_	5	dep
13	,	,	,	_	12	punct
14	drug4	drug4	NN	_	12	conj
15	,	,	,	_	12	punct
16	and	and	CC	_	12	cc
17	drug5	drug5	NN	_	12	conj
18	,	,	,	_	12	punct
19	inhibit	inhibit	VBP	_	12	conj
20	P450	p450	NN	_	21	compound
21	2D6	2d6	NN	_	19	dobj
22	,	,	,	_	12	punct
23	they	they	PRP	_	25	nsubj
24	may	may	MD	_	25	aux
25	vary	vary	VB	_	12	acl:relcl
26	in	in	IN	_	28	case
27	the	the	DT	_	28	det
28	extent	extent	NN	_	25	nmod
29	of	of	IN	_	30	case
30	inhibition	inhibition	NN	_	28	nmod
31	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	extent	extent	NN	_	0	ROOT
3	to	to	TO	_	4	case
4	which	which	WDT	_	10	nmod
5	drug1	drug1	SYM	_	10	dep
6	-	-	:	_	10	punct
7	drug2	drug2	NN	_	8	compound
8	interactions	interaction	NNS	_	10	nsubj
9	may	may	MD	_	10	aux
10	pose	pose	VB	_	2	acl:relcl
11	clinical	clinical	JJ	_	12	amod
12	problems	problem	NNS	_	14	nsubj
13	will	will	MD	_	14	aux
14	depend	depend	VB	_	10	ccomp
15	on	on	IN	_	17	case
16	the	the	DT	_	17	det
17	degree	degree	NN	_	14	nmod
18	of	of	IN	_	19	case
19	inhibition	inhibition	NN	_	17	nmod
20	and	and	CC	_	19	cc
21	the	the	DT	_	22	det
22	pharmacokinetics	pharmacokinetic	NNS	_	19	conj
23	of	of	IN	_	25	case
24	the	the	DT	_	25	det
25	drug3	drug3	NN	_	22	nmod
26	involved	involve	VBN	_	25	acl
27	.	.	.	_	2	punct

1	Nevertheless	nevertheless	RB	_	5	advmod
2	,	,	,	_	5	punct
3	caution	caution	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	indicated	indicate	VBN	_	0	ROOT
6	in	in	IN	_	8	case
7	the	the	DT	_	8	det
8	coadministration	coadministration	NN	_	5	nmod
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	with	with	IN	_	12	case
12	any	any	DT	_	5	nmod
13	of	of	IN	_	15	case
14	the	the	DT	_	15	det
15	drug2	drug2	NN	_	12	nmod
16	and	and	CC	_	12	cc
17	also	also	RB	_	19	advmod
18	in	in	IN	_	19	case
19	switching	switching	NN	_	12	conj
20	from	from	IN	_	22	case
21	one	one	CD	_	22	nummod
22	class	class	NN	_	19	nmod
23	to	to	TO	_	25	case
24	the	the	DT	_	25	det
25	other	other	JJ	_	19	nmod
26	.	.	.	_	5	punct

1	Of	of	IN	_	3	case
2	particular	particular	JJ	_	3	amod
3	importance	importance	NN	_	8	nmod
4	,	,	,	_	8	punct
5	sufficient	sufficient	JJ	_	6	amod
6	time	time	NN	_	8	nsubj
7	must	must	MD	_	8	aux
8	elapse	elapse	VB	_	0	ROOT
9	before	before	IN	_	10	mark
10	initiating	initiate	VBG	_	8	advcl
11	TCA	TCA	NNP	_	12	compound
12	treatment	treatment	NN	_	10	dobj
13	in	in	IN	_	15	case
14	a	a	DT	_	15	det
15	patient	patient	NN	_	12	nmod
16	being	be	VBG	_	17	auxpass
17	withdrawn	withdraw	VBN	_	15	acl
18	from	from	IN	_	19	case
19	drug1	drug1	NN	_	17	nmod
20	,	,	,	_	8	punct
21	given	give	VBN	_	24	case
22	the	the	DT	_	24	det
23	long	long	JJ	_	24	amod
24	half-life	half-life	NN	_	8	nmod
25	of	of	IN	_	27	case
26	the	the	DT	_	27	det
27	parent	parent	NN	_	24	nmod
28	and	and	CC	_	27	cc
29	active	active	JJ	_	30	amod
30	metabolite	metabolite	NN	_	27	conj
31	-LRB-	-lrb-	-LRB-	_	38	punct
32	at	at	IN	_	33	case
33	least	least	JJS	_	34	nmod:npmod
34	5	5	CD	_	35	nummod
35	weeks	week	NNS	_	38	nsubj
36	may	may	MD	_	38	aux
37	be	be	VB	_	38	cop
38	necessary	necessary	JJ	_	24	dep
39	-RRB-	-rrb-	-RRB-	_	38	punct
40	.	.	.	_	8	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	use	use	NN	_	14	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	6	case
6	drugs	drug	NNS	_	2	nmod
7	that	that	WDT	_	9	nsubj
8	can	can	MD	_	9	aux
9	inhibit	inhibit	VB	_	6	acl:relcl
10	cytochrome	cytochrome	NN	_	12	compound
11	P450	p450	NN	_	12	compound
12	2D6	2d6	NN	_	9	dobj
13	may	may	MD	_	14	aux
14	require	require	VB	_	0	ROOT
15	lower	lower	JJR	_	16	amod
16	doses	dose	NNS	_	14	dobj
17	than	than	IN	_	19	mark
18	usually	usually	RB	_	19	advmod
19	prescribed	prescribe	VBN	_	16	dep
20	for	for	IN	_	23	case
21	either	either	CC	_	23	cc:preconj
22	the	the	DT	_	23	det
23	drug2	drug2	NN	_	19	nmod
24	or	or	CC	_	23	cc
25	the	the	DT	_	27	det
26	other	other	JJ	_	27	amod
27	drug	drug	NN	_	23	conj
28	.	.	.	_	14	punct

1	Furthermore	furthermore	RB	_	21	advmod
2	,	,	,	_	21	punct
3	whenever	whenever	WRB	_	10	advmod
4	one	one	CD	_	10	nsubjpass
5	of	of	IN	_	8	case
6	these	these	DT	_	8	det
7	other	other	JJ	_	8	amod
8	drugs	drug	NNS	_	4	nmod
9	is	be	VBZ	_	10	auxpass
10	withdrawn	withdraw	VBN	_	21	advcl
11	from	from	IN	_	12	case
12	co-therapy	co-therapy	JJ	_	10	nmod
13	,	,	,	_	21	punct
14	an	a	DT	_	16	det
15	increased	increase	VBN	_	16	amod
16	dose	dose	NN	_	21	nsubjpass
17	of	of	IN	_	18	case
18	drug1	drug1	NN	_	16	nmod
19	may	may	MD	_	21	aux
20	be	be	VB	_	21	auxpass
21	required	require	VBN	_	0	ROOT
22	.	.	.	_	21	punct

1	It	it	PRP	_	3	nsubj
2	is	be	VBZ	_	3	cop
3	desirable	desirable	JJ	_	0	ROOT
4	to	to	TO	_	5	mark
5	monitor	monitor	VB	_	3	xcomp
6	drug1	drug1	NN	_	8	compound
7	plasma	plasma	NN	_	8	compound
8	levels	level	NNS	_	5	dobj
9	whenever	whenever	WRB	_	13	advmod
10	a	a	DT	_	11	det
11	drug2	drug2	NN	_	13	nsubj
12	is	be	VBZ	_	13	aux
13	going	go	VBG	_	5	advcl
14	to	to	TO	_	16	mark
15	be	be	VB	_	16	auxpass
16	coadministered	coadminister	VBN	_	13	xcomp
17	with	with	IN	_	19	case
18	another	another	DT	_	19	det
19	drug	drug	NN	_	16	nmod
20	known	know	VBN	_	19	acl
21	to	to	TO	_	24	mark
22	be	be	VB	_	24	cop
23	an	a	DT	_	24	det
24	inhibitor	inhibitor	NN	_	20	xcomp
25	of	of	IN	_	27	case
26	P450	p450	NN	_	27	compound
27	2D6	2d6	NN	_	24	nmod
28	.	.	.	_	3	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	7	compound
4	or	or	CC	_	3	cc
5	similarly	similarly	RB	_	6	advmod
6	acting	act	VBG	_	3	conj
7	compounds	compound	NNS	_	1	dep
8	;	;	:	_	1	punct

1	drug1	drug1	NN	_	2	compound
2	medication	medication	NN	_	0	ROOT
3	;	;	:	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	and	and	CC	_	1	cc
5	other	other	JJ	_	6	amod
6	drug3	drug3	NN	_	1	conj
7	;	;	:	_	1	punct

1	and	and	CC	_	29	cc
2	drug1	drug1	NN	_	29	nsubjpass
3	When	when	WRB	_	6	advmod
4	drug2	drug2	NN	_	6	nsubjpass
5	is	be	VBZ	_	6	auxpass
6	given	give	VBN	_	2	acl:relcl
7	with	with	IN	_	9	case
8	drug3	drug3	NN	_	9	compound
9	agents	agent	NNS	_	6	nmod
10	or	or	CC	_	9	cc
11	drug4	drug4	NN	_	12	compound
12	drugs	drug	NNS	_	9	conj
13	,	,	,	_	9	punct
14	including	include	VBG	_	15	case
15	drug5	drug5	NN	_	9	nmod
16	combined	combine	VBN	_	15	acl
17	with	with	IN	_	19	case
18	local	local	JJ	_	19	amod
19	drug6	drug6	NN	_	16	nmod
20	,	,	,	_	19	punct
21	close	close	JJ	_	22	amod
22	supervision	supervision	NN	_	19	conj
23	and	and	CC	_	19	cc
24	careful	careful	JJ	_	25	amod
25	adjustment	adjustment	NN	_	19	conj
26	of	of	IN	_	27	case
27	dosages	dosage	NNS	_	25	nmod
28	are	be	VBP	_	29	auxpass
29	required	require	VBN	_	0	ROOT
30	.	.	.	_	29	punct

1	Hyperpyrexia	Hyperpyrexia	NNP	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	when	when	WRB	_	8	advmod
6	drug1	drug1	NN	_	8	nsubjpass
7	is	be	VBZ	_	8	auxpass
8	administered	administer	VBN	_	4	advcl
9	with	with	IN	_	11	case
10	drug2	drug2	NN	_	11	compound
11	agents	agent	NNS	_	8	nmod
12	or	or	CC	_	11	cc
13	with	with	IN	_	15	case
14	drug3	drug3	NN	_	15	compound
15	drugs	drug	NNS	_	11	conj
16	,	,	,	_	8	punct
17	particularly	particularly	RB	_	20	advmod
18	during	during	IN	_	20	case
19	hot	hot	JJ	_	20	amod
20	weather	weather	NN	_	8	nmod
21	.	.	.	_	4	punct

1	Paralytic	paralytic	JJ	_	2	amod
2	ileus	ileus	NN	_	4	nsubj
3	may	may	MD	_	4	aux
4	occur	occur	VB	_	0	ROOT
5	in	in	IN	_	6	case
6	patients	patient	NNS	_	4	nmod
7	taking	take	VBG	_	6	acl
8	drug1	drug1	NN	_	7	dobj
9	in	in	IN	_	10	case
10	combination	combination	NN	_	7	nmod
11	with	with	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	-	-	:	_	12	punct
14	type	type	NN	_	15	compound
15	drugs	drug	NNS	_	12	dep
16	.	.	.	_	4	punct

1	drug1	drug1	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	reported	report	VBN	_	0	ROOT
4	to	to	TO	_	5	mark
5	reduce	reduce	VB	_	3	xcomp
6	hepatic	hepatic	JJ	_	7	amod
7	metabolism	metabolism	NN	_	5	dobj
8	of	of	IN	_	10	case
9	certain	certain	JJ	_	10	amod
10	drug2	drug2	NN	_	7	nmod
11	,	,	,	_	5	punct
12	thereby	thereby	RB	_	13	advmod
13	delaying	delay	VBG	_	5	dep
14	elimination	elimination	NN	_	13	dobj
15	and	and	CC	_	13	cc
16	increasing	increase	VBG	_	13	conj
17	steady-state	steady-state	JJ	_	18	amod
18	concentrations	concentration	NNS	_	16	dobj
19	of	of	IN	_	21	case
20	these	these	DT	_	21	det
21	drug3	drug3	NN	_	18	nmod
22	.	.	.	_	3	punct

1	Clinically	clinically	RB	_	3	advmod
2	significant	significant	JJ	_	3	amod
3	effects	effect	NNS	_	6	nsubjpass
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	auxpass
6	reported	report	VBN	_	0	ROOT
7	with	with	IN	_	9	case
8	the	the	DT	_	9	det
9	drug1	drug1	NN	_	6	nmod
10	when	when	WRB	_	11	advmod
11	used	use	VBN	_	6	advcl
12	concomitantly	concomitantly	RB	_	11	advmod
13	with	with	IN	_	14	case
14	drug2	drug2	NN	_	11	nmod
15	.	.	.	_	6	punct

1	Increases	increase	NNS	_	23	nsubjpass
2	in	in	IN	_	4	case
3	plasma	plasma	NN	_	4	compound
4	levels	level	NNS	_	1	nmod
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	,	,	,	_	1	punct
8	and	and	CC	_	1	cc
9	in	in	IN	_	11	case
10	the	the	DT	_	11	det
11	frequency	frequency	NN	_	1	conj
12	and	and	CC	_	11	cc
13	severity	severity	NN	_	11	conj
14	of	of	IN	_	16	case
15	side	side	JJ	_	16	amod
16	effects	effect	NNS	_	11	nmod
17	,	,	,	_	1	punct
18	particularly	particularly	RB	_	19	advmod
19	drug2	drug2	NN	_	1	appos
20	,	,	,	_	1	punct
21	have	have	VBP	_	23	aux
22	been	be	VBN	_	23	auxpass
23	reported	report	VBN	_	0	ROOT
24	when	when	WRB	_	27	advmod
25	drug3	drug3	NN	_	27	nsubjpass
26	was	be	VBD	_	27	auxpass
27	added	add	VBN	_	23	advcl
28	to	to	TO	_	31	case
29	the	the	DT	_	31	det
30	drug4	drug4	NN	_	31	compound
31	regimen	regimen	NN	_	27	nmod
32	.	.	.	_	23	punct

1	Discontinuation	discontinuation	NN	_	12	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	in	in	IN	_	6	case
5	well-controlled	well-controlled	JJ	_	6	amod
6	patients	patient	NNS	_	1	nmod
7	receiving	receive	VBG	_	6	acl
8	drug2	drug2	NN	_	7	dobj
9	and	and	CC	_	8	cc
10	drug3	drug3	NN	_	8	conj
11	may	may	MD	_	12	aux
12	decrease	decrease	VB	_	0	ROOT
13	the	the	DT	_	15	det
14	plasma	plasma	NN	_	15	compound
15	levels	level	NNS	_	12	dobj
16	and	and	CC	_	15	cc
17	efficacy	efficacy	NN	_	15	conj
18	of	of	IN	_	20	case
19	the	the	DT	_	20	det
20	drug4	drug4	NN	_	15	nmod
21	.	.	.	_	12	punct

1	Caution	caution	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	advised	advise	VBN	_	0	ROOT
4	if	if	IN	_	6	mark
5	patients	patient	NNS	_	6	nsubj
6	receive	receive	VBP	_	3	advcl
7	large	large	JJ	_	8	amod
8	doses	dose	NNS	_	6	dobj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	concurrently	concurrently	RB	_	6	advmod
12	.	.	.	_	3	punct

1	Transient	transient	JJ	_	2	amod
2	delirium	delirium	NN	_	5	nsubjpass
3	has	have	VBZ	_	5	aux
4	been	be	VBN	_	5	auxpass
5	reported	report	VBN	_	0	ROOT
6	in	in	IN	_	7	case
7	patients	patient	NNS	_	5	nmod
8	who	who	WP	_	10	nsubjpass
9	were	be	VBD	_	10	auxpass
10	treated	treat	VBN	_	7	acl:relcl
11	with	with	IN	_	13	case
12	one	one	CD	_	13	nummod
13	gram	gram	NN	_	10	nmod
14	of	of	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	and	and	CC	_	13	cc
17	75	75	CD	_	20	nummod
18	-	-	:	_	20	punct
19	150	150	CD	_	20	nummod
20	mg	mg	NN	_	13	conj
21	of	of	IN	_	22	case
22	drug2	drug2	NN	_	20	nmod
23	.	.	.	_	5	punct

1	Increased	increase	VBN	_	2	amod
2	nephrotoxicity	nephrotoxicity	NN	_	5	nsubjpass
3	has	have	VBZ	_	5	aux
4	been	be	VBN	_	5	auxpass
5	reported	report	VBN	_	0	ROOT
6	following	follow	VBG	_	8	case
7	concomitant	concomitant	JJ	_	8	amod
8	administration	administration	NN	_	5	nmod
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	drug2	drug2	NN	_	10	conj
13	.	.	.	_	5	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	4	amod
2	Test	test	NN	_	4	compound
3	Interactions	interaction	NNS	_	4	compound
4	drug1	drug1	NN	_	10	nsubjpass
5	,	,	,	_	4	punct
6	including	include	VBG	_	7	case
7	drug2	drug2	NN	_	4	nmod
8	,	,	,	_	4	punct
9	are	be	VBP	_	10	auxpass
10	known	know	VBN	_	0	ROOT
11	to	to	TO	_	13	mark
12	occasionally	occasionally	RB	_	13	advmod
13	induce	induce	VB	_	10	xcomp
14	a	a	DT	_	18	det
15	positive	positive	JJ	_	18	amod
16	direct	direct	JJ	_	18	amod
17	Coombs	coomb	NNS	_	18	compound
18	test	test	NN	_	13	dobj
19	.	.	.	_	10	punct

1	Steady	steady	JJ	_	5	amod
2	state	state	NN	_	5	compound
3	plasma	plasma	NN	_	5	compound
4	drug1	drug1	NN	_	5	compound
5	concentrations	concentration	NNS	_	8	nsubj
6	did	do	VBD	_	8	aux
7	not	not	RB	_	8	neg
8	appear	appear	VB	_	0	ROOT
9	to	to	TO	_	10	mark
10	change	change	VB	_	8	xcomp
11	.	.	.	_	8	punct

1	Therefore	therefore	RB	_	10	advmod
2	,	,	,	_	10	punct
3	monitoring	monitoring	NN	_	10	nsubjpass
4	of	of	IN	_	7	case
5	plasma	plasma	NN	_	7	compound
6	drug1	drug1	NN	_	7	compound
7	levels	level	NNS	_	3	nmod
8	may	may	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	indicated	indicate	VBN	_	0	ROOT
11	in	in	IN	_	12	case
12	patients	patient	NNS	_	10	nmod
13	receiving	receive	VBG	_	12	acl
14	similar	similar	JJ	_	17	amod
15	combination	combination	NN	_	17	compound
16	chemotherapy	chemotherapy	NN	_	17	compound
17	regimens	regimen	NNS	_	13	dobj
18	.	.	.	_	10	punct

1	The	the	DT	_	2	det
2	utilization	utilization	NN	_	10	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	for	for	IN	_	7	case
6	such	such	JJ	_	7	amod
7	patients	patient	NNS	_	2	nmod
8	may	may	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	considered	consider	VBN	_	0	ROOT
11	as	as	IN	_	13	case
12	an	a	DT	_	13	det
13	alternative	alternative	NN	_	10	nmod
14	.	.	.	_	10	punct

1	Also	also	RB	_	2	advmod
2	drug1	drug1	NN	_	0	ROOT
3	.	.	.	_	2	punct

1	No	no	DT	_	2	neg
2	information	information	NN	_	0	ROOT
3	provided	provide	VBN	_	2	acl

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Aerosol	Aerosol	NNP	_	4	compound
4	drug2	drug2	NN	_	13	nsubjpass
5	of	of	IN	_	10	case
6	the	the	DT	_	10	det
7	short-acting	short-acting	JJ	_	10	amod
8	adrenergic	adrenergic	JJ	_	10	amod
9	stimulant	stimulant	NN	_	10	compound
10	type	type	NN	_	4	nmod
11	may	may	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	used	use	VBN	_	1	dep
14	for	for	IN	_	15	case
15	relief	relief	NN	_	13	nmod
16	of	of	IN	_	18	case
17	breakthrough	breakthrough	NN	_	18	compound
18	symptoms	symptom	NNS	_	15	nmod
19	while	while	IN	_	20	mark
20	using	use	VBG	_	13	advcl
21	drug3	drug3	NN	_	20	dobj
22	.	.	.	_	1	punct

1	However	however	RB	_	11	advmod
2	,	,	,	_	11	punct
3	increasing	increase	VBG	_	4	amod
4	use	use	NN	_	11	nsubj
5	of	of	IN	_	7	case
6	such	such	JJ	_	7	amod
7	preparations	preparation	NNS	_	4	nmod
8	to	to	TO	_	9	mark
9	control	control	VB	_	4	acl
10	symptoms	symptom	NNS	_	9	dobj
11	indicates	indicate	VBZ	_	0	ROOT
12	deterioration	deterioration	NN	_	11	dobj
13	of	of	IN	_	15	case
14	asthma	asthma	NN	_	15	compound
15	control	control	NN	_	12	nmod
16	and	and	CC	_	12	cc
17	the	the	DT	_	18	det
18	need	need	NN	_	12	conj
19	to	to	TO	_	20	mark
20	reassess	reassess	NN	_	18	acl
21	the	the	DT	_	22	det
22	patient	patient	NN	_	20	dobj
23	s	be	VBZ	_	24	compound
24	therapy	therapy	NN	_	22	dep
25	.	.	.	_	11	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	7	nsubj
3	of	of	IN	_	5	case
4	other	other	JJ	_	5	amod
5	drug1	drug1	NN	_	2	nmod
6	may	may	MD	_	7	aux
7	potentiate	potentiate	VB	_	0	ROOT
8	the	the	DT	_	10	det
9	undesirable	undesirable	JJ	_	10	amod
10	effects	effect	NNS	_	7	dobj
11	of	of	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	.	.	.	_	7	punct

1	drug1	drug1	NN	_	0	ROOT
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	:	:	:	_	1	punct
5	drug3	drug3	NN	_	8	nsubjpass
6	should	should	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	administered	administer	VBN	_	1	dep
9	with	with	IN	_	11	case
10	extreme	extreme	JJ	_	11	amod
11	caution	caution	NN	_	8	nmod
12	in	in	IN	_	13	case
13	patients	patient	NNS	_	11	nmod
14	being	be	VBG	_	15	auxpass
15	treated	treat	VBN	_	13	acl
16	with	with	IN	_	17	case
17	drug4	drug4	NN	_	15	nmod
18	or	or	CC	_	17	cc
19	drug5	drug5	NN	_	17	conj
20	because	because	IN	_	31	mark
21	the	the	DT	_	22	det
22	action	action	NN	_	31	nsubjpass
23	of	of	IN	_	24	case
24	drug6	drug6	NN	_	22	nmod
25	on	on	IN	_	28	case
26	the	the	DT	_	28	det
27	cardiovascular	cardiovascular	JJ	_	28	amod
28	system	system	NN	_	22	nmod
29	may	may	MD	_	31	aux
30	be	be	VB	_	31	auxpass
31	potentiated	potentiate	VBN	_	8	advcl
32	by	by	IN	_	34	case
33	these	these	DT	_	34	det
34	agents	agent	NNS	_	31	nmod
35	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	and	and	CC	_	1	cc
5	drug3	drug3	NN	_	1	conj
6	:	:	:	_	1	punct
7	Concomitant	concomitant	JJ	_	8	amod
8	treatment	treatment	NN	_	17	nsubj
9	with	with	IN	_	10	case
10	drug4	drug4	NN	_	8	nmod
11	,	,	,	_	10	punct
12	drug5	drug5	NN	_	10	conj
13	,	,	,	_	10	punct
14	or	or	CC	_	10	cc
15	drug6	drug6	NN	_	10	conj
16	may	may	MD	_	17	aux
17	potentiate	potentiate	VB	_	1	dep
18	a	a	DT	_	21	det
19	possible	possible	JJ	_	21	amod
20	hypokalemic	hypokalemic	JJ	_	21	amod
21	effect	effect	NN	_	17	dobj
22	of	of	IN	_	23	case
23	drug7	drug7	NN	_	21	nmod

1	Hypokalemia	hypokalemia	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	increase	increase	VB	_	0	ROOT
4	susceptibility	susceptibility	NN	_	3	dobj
5	to	to	TO	_	7	case
6	cardiac	cardiac	JJ	_	7	amod
7	arrhythmias	arrhythmia	NNS	_	4	nmod
8	in	in	IN	_	9	case
9	patients	patient	NNS	_	7	nmod
10	treated	treat	VBN	_	9	acl
11	with	with	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	.	.	.	_	3	punct

1	-	-	:	_	3	punct
2	adrenergic	adrenergic	JJ	_	3	amod
3	Blockers	blocker	NNS	_	0	ROOT
4	:	:	:	_	3	punct
5	-	-	:	_	3	punct
6	adrenergic	adrenergic	JJ	_	7	amod
7	blockers	blocker	NNS	_	9	nsubj
8	may	may	MD	_	9	aux
9	weaken	weaken	VB	_	3	dep
10	or	or	CC	_	9	cc
11	antagonise	antagonise	VB	_	9	conj
12	the	the	DT	_	13	det
13	effect	effect	NN	_	9	dobj
14	of	of	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	.	.	.	_	3	punct

1	Therefore	therefore	RB	_	6	advmod
2	drug1	drug1	NN	_	6	nsubjpass
3	should	should	MD	_	6	aux
4	not	not	RB	_	6	neg
5	be	be	VB	_	6	auxpass
6	given	give	VBN	_	0	ROOT
7	together	together	RP	_	6	compound:prt
8	with	with	IN	_	11	case
9	-	-	:	_	11	punct
10	adrenergic	adrenergic	JJ	_	11	amod
11	blockers	blocker	NNS	_	6	nmod
12	-LRB-	-lrb-	-LRB-	_	11	punct
13	including	include	VBG	_	15	case
14	eye	eye	NN	_	15	compound
15	drops	drop	NNS	_	11	nmod
16	-RRB-	-rrb-	-RRB-	_	11	punct
17	unless	unless	IN	_	19	mark
18	there	there	EX	_	19	expl
19	are	be	VBP	_	6	advcl
20	compelling	compelling	JJ	_	21	amod
21	reasons	reason	NNS	_	19	nsubj
22	for	for	IN	_	24	case
23	their	they	PRP$	_	24	nmod:poss
24	use	use	NN	_	21	nmod
25	.	.	.	_	6	punct

1	Other	other	JJ	_	2	amod
2	Drugs	drug	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	Drugs	drug	NNS	_	21	nsubjpass
5	such	such	JJ	_	7	case
6	as	as	IN	_	5	mwe
7	drug1	drug1	NN	_	4	nmod
8	,	,	,	_	7	punct
9	drug2	drug2	NN	_	7	conj
10	,	,	,	_	7	punct
11	drug3	drug3	NN	_	7	conj
12	,	,	,	_	7	punct
13	drug4	drug4	NN	_	7	conj
14	,	,	,	_	7	punct
15	drug5	drug5	NN	_	7	conj
16	,	,	,	_	7	punct
17	and	and	CC	_	7	cc
18	drug6	drug6	NN	_	7	conj
19	may	may	MD	_	21	aux
20	be	be	VB	_	21	auxpass
21	associated	associate	VBN	_	2	appos
22	with	with	IN	_	24	case
23	QT-interval	qt-interval	JJ	_	24	amod
24	prolongation	prolongation	NN	_	21	nmod
25	and	and	CC	_	24	cc
26	an	a	DT	_	28	det
27	increased	increase	VBN	_	28	amod
28	risk	risk	NN	_	24	conj
29	of	of	IN	_	31	case
30	ventricular	ventricular	JJ	_	31	amod
31	arrhythmia	arrhythmia	NN	_	28	nmod
32	.	.	.	_	2	punct

1	INFORMATION	information	NN	_	0	ROOT
2	TO	to	TO	_	4	mark
3	BE	be	VB	_	4	auxpass
4	PROVIDED	provide	VBN	_	1	acl
5	TO	to	TO	_	11	mark
6	THE	the	DT	_	10	det
7	PATIENT	patient	NN	_	10	compound
8	OR	or	NN	_	10	compound
9	GUARDIAN	GUARDIAN	NNP	_	10	compound
10	See	See	NNP	_	11	nsubj
11	illustrated	illustrate	VBD	_	4	advcl
12	Information	information	NN	_	11	dobj
13	For	for	IN	_	15	case
14	The	the	DT	_	15	det
15	Patient	patient	NN	_	11	nmod
16	or	or	CC	_	15	cc
17	Guardian	Guardian	NNP	_	18	compound
18	section	section	NN	_	15	conj
19	.	.	.	_	1	punct

1	It	it	PRP	_	3	nsubj
2	is	be	VBZ	_	3	cop
3	important	important	JJ	_	0	ROOT
4	that	that	IN	_	6	mark
5	patients	patient	NNS	_	6	nsubj
6	understand	understand	VBP	_	3	ccomp
7	how	how	WRB	_	9	advmod
8	to	to	TO	_	9	mark
9	use	use	VB	_	6	ccomp
10	drug1	drug1	NN	_	14	compound
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	drug2	drug2	NN	_	10	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	capsules	capsule	NNS	_	9	dobj
15	with	with	IN	_	20	case
16	the	the	DT	_	20	det
17	supplied	supply	VBN	_	20	amod
18	AerolizerTM	aerolizertm	NN	_	20	compound
19	inhalation	inhalation	NN	_	20	compound
20	device	device	NN	_	9	nmod
21	and	and	CC	_	9	cc
22	how	how	WRB	_	26	advmod
23	it	it	PRP	_	26	nsubjpass
24	should	should	MD	_	26	aux
25	be	be	VB	_	26	auxpass
26	used	use	VBN	_	37	advcl
27	in	in	IN	_	28	case
28	relation	relation	NN	_	26	nmod
29	to	to	TO	_	31	case
30	other	other	JJ	_	31	amod
31	asthma	asthma	NN	_	28	nmod
32	or	or	CC	_	31	cc
33	COPD	copd	NN	_	34	compound
34	medications	medication	NNS	_	31	conj
35	they	they	PRP	_	37	nsubj
36	are	be	VBP	_	37	aux
37	taking	take	VBG	_	9	conj
38	.	.	.	_	3	punct

1	Patients/Guardians	patients/guardians	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	given	give	VBN	_	0	ROOT
5	the	the	DT	_	7	det
6	following	follow	VBG	_	7	amod
7	information	information	NN	_	4	dobj
8	:	:	:	_	7	punct
9	i	i	LS	_	7	dep
10	.	.	.	_	4	punct

1	The	the	DT	_	3	det
2	recommended	recommend	VBN	_	3	amod
3	dosage	dosage	NN	_	19	nsubjpass
4	-LRB-	-lrb-	-LRB-	_	8	punct
5	one	one	CD	_	8	nummod
6	or	or	CC	_	5	cc
7	two	two	CD	_	5	conj
8	capsules	capsule	NNS	_	3	dep
9	twice	twice	RB	_	10	advmod
10	daily	daily	RB	_	8	advmod
11	,	,	,	_	8	punct
12	morning	morning	NN	_	8	appos
13	and	and	CC	_	12	cc
14	evening	evening	NN	_	12	conj
15	-RRB-	-rrb-	-RRB-	_	8	punct
16	should	should	MD	_	19	aux
17	not	not	RB	_	19	neg
18	be	be	VB	_	19	auxpass
19	exceeded	exceed	VBN	_	0	ROOT
20	.	.	.	_	19	punct

1	ii	ii	LS	_	0	ROOT
2	.	.	.	_	1	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	not	not	RB	_	4	neg
4	meant	mean	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	relieve	relieve	VB	_	4	xcomp
7	acute	acute	JJ	_	8	amod
8	asthma	asthma	NN	_	6	dobj
9	or	or	CC	_	8	cc
10	COPD	copd	NN	_	11	compound
11	symptoms	symptom	NNS	_	8	conj
12	and	and	CC	_	8	cc
13	extra	extra	JJ	_	14	amod
14	doses	dose	NNS	_	8	conj
15	should	should	MD	_	18	aux
16	not	not	RB	_	18	neg
17	be	be	VB	_	18	auxpass
18	used	use	VBN	_	4	dep
19	for	for	IN	_	21	case
20	that	that	DT	_	21	det
21	purpose	purpose	NN	_	18	nmod
22	.	.	.	_	4	punct

1	Acute	acute	JJ	_	2	amod
2	symptoms	symptom	NNS	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	treated	treat	VBN	_	0	ROOT
6	with	with	IN	_	8	case
7	a	a	DT	_	8	det
8	short-acting	short-acting	JJ	_	5	nmod
9	,	,	,	_	5	punct
10	inhaled	inhale	VBD	_	5	dep
11	drug1	drug1	NN	_	10	dobj
12	such	such	JJ	_	14	case
13	as	as	IN	_	12	mwe
14	drug2	drug2	NN	_	11	nmod
15	-LRB-	-lrb-	-LRB-	_	19	punct
16	the	the	DT	_	17	det
17	physician	physician	NN	_	19	nsubj
18	should	should	MD	_	19	aux
19	provide	provide	VB	_	14	dep
20	the	the	DT	_	21	det
21	patient	patient	NN	_	19	dobj
22	with	with	IN	_	24	case
23	such	such	JJ	_	24	amod
24	medication	medication	NN	_	21	nmod
25	and	and	CC	_	19	cc
26	instruct	instruct	VB	_	19	conj
27	the	the	DT	_	28	det
28	patient	patient	NN	_	26	dobj
29	in	in	IN	_	34	mark
30	how	how	WRB	_	34	advmod
31	it	it	PRP	_	34	nsubjpass
32	should	should	MD	_	34	aux
33	be	be	VB	_	34	auxpass
34	used	use	VBN	_	26	advcl
35	-RRB-	-rrb-	-RRB-	_	19	punct
36	.	.	.	_	5	punct

1	iii	iii	LS	_	0	ROOT
2	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	physician	physician	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	notified	notify	VBN	_	0	ROOT
6	immediately	immediately	RB	_	5	advmod
7	if	if	IN	_	13	mark
8	any	any	DT	_	13	nsubj
9	of	of	IN	_	12	case
10	the	the	DT	_	12	det
11	following	follow	VBG	_	12	amod
12	situations	situation	NNS	_	8	nmod
13	occur	occur	VBP	_	5	advcl
14	,	,	,	_	13	punct
15	which	which	WDT	_	19	nsubj
16	may	may	MD	_	19	aux
17	be	be	VB	_	19	cop
18	a	a	DT	_	19	det
19	sign	sign	NN	_	13	dep
20	of	of	IN	_	23	case
21	seriously	seriously	RB	_	22	advmod
22	worsening	worsen	VBG	_	23	amod
23	asthma	asthma	NN	_	19	nmod
24	:	:	:	_	19	punct
25	Decreased	decrease	VBN	_	26	amod
26	effectiveness	effectiveness	NN	_	19	dep
27	of	of	IN	_	28	case
28	drug1	drug1	NN	_	26	nmod
29	;	;	:	_	5	punct

1	Need	need	VBN	_	0	ROOT
2	for	for	IN	_	4	case
3	more	more	JJR	_	4	amod
4	inhalations	inhalation	NNS	_	1	nmod
5	than	than	IN	_	6	case
6	usual	usual	JJ	_	4	nmod
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	.	.	.	_	1	punct

1	iv	iv	NN	_	0	ROOT
2	.	.	.	_	1	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	should	should	MD	_	5	aux
3	not	not	RB	_	5	neg
4	be	be	VB	_	5	auxpass
5	used	use	VBN	_	0	ROOT
6	as	as	IN	_	8	case
7	a	a	DT	_	8	det
8	substitute	substitute	NN	_	5	nmod
9	for	for	IN	_	13	case
10	oral	oral	JJ	_	13	amod
11	or	or	CC	_	10	cc
12	inhaled	inhale	VBN	_	10	conj
13	drug2	drug2	NN	_	8	nmod
14	.	.	.	_	5	punct

1	The	the	DT	_	2	det
2	dosage	dosage	NN	_	9	nsubjpass
3	of	of	IN	_	5	case
4	these	these	DT	_	5	det
5	medications	medication	NNS	_	2	nmod
6	should	should	MD	_	9	aux
7	not	not	RB	_	9	neg
8	be	be	VB	_	9	auxpass
9	changed	change	VBN	_	0	ROOT
10	and	and	CC	_	9	cc
11	they	they	PRP	_	15	nsubjpass
12	should	should	MD	_	15	aux
13	not	not	RB	_	15	neg
14	be	be	VB	_	15	auxpass
15	stopped	stop	VBN	_	9	conj
16	without	without	IN	_	17	mark
17	consulting	consult	VBG	_	15	advcl
18	the	the	DT	_	19	det
19	physician	physician	NN	_	17	dobj
20	,	,	,	_	9	punct
21	even	even	RB	_	25	advmod
22	if	if	IN	_	25	mark
23	the	the	DT	_	24	det
24	patient	patient	NN	_	25	nsubj
25	feels	feel	VBZ	_	9	advcl
26	better	better	RB	_	25	advmod
27	after	after	IN	_	28	mark
28	initiating	initiate	VBG	_	25	advcl
29	treatment	treatment	NN	_	28	dobj
30	with	with	IN	_	31	case
31	drug1	drug1	NN	_	29	nmod
32	.	.	.	_	9	punct

1	v.	v.	CC	_	2	case
2	Patients	patient	NNS	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	cautioned	caution	VBN	_	0	ROOT
6	regarding	regard	VBG	_	5	xcomp
7	potential	potential	JJ	_	10	amod
8	adverse	adverse	JJ	_	10	amod
9	cardiovascular	cardiovascular	JJ	_	10	amod
10	effects	effect	NNS	_	6	dobj
11	,	,	,	_	10	punct
12	such	such	JJ	_	14	case
13	as	as	IN	_	12	mwe
14	palpitations	palpitation	NNS	_	10	nmod
15	or	or	CC	_	14	cc
16	chest	chest	NN	_	17	compound
17	pain	pain	NN	_	14	conj
18	.	.	.	_	5	punct

1	vi	vi	LS	_	0	ROOT
2	.	.	.	_	1	punct

1	In	in	IN	_	2	case
2	patients	patient	NNS	_	11	nmod
3	receiving	receive	VBG	_	2	acl
4	drug1	drug1	NN	_	3	dobj
5	,	,	,	_	11	punct
6	other	other	JJ	_	8	amod
7	inhaled	inhale	VBN	_	8	amod
8	medications	medication	NNS	_	11	nsubjpass
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	used	use	VBN	_	0	ROOT
12	only	only	RB	_	14	advmod
13	as	as	IN	_	14	mark
14	directed	direct	VBN	_	11	advcl
15	by	by	IN	_	17	case
16	the	the	DT	_	17	det
17	physician	physician	NN	_	14	nmod
18	.	.	.	_	11	punct

1	vii	vii	LS	_	0	ROOT
2	.	.	.	_	1	punct

1	Guardians	guardian	NNS	_	11	nsubjpass
2	of	of	IN	_	3	case
3	children	child	NNS	_	1	nmod
4	who	who	WP	_	7	nsubjpass
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	prescribed	prescribe	VBN	_	3	acl:relcl
8	drug1	drug1	NN	_	7	dobj
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	alerted	alert	VBN	_	0	ROOT
12	to	to	TO	_	15	case
13	the	the	DT	_	15	det
14	general	general	JJ	_	15	amod
15	concern	concern	NN	_	11	nmod
16	regarding	regard	VBG	_	19	case
17	asthma	asthma	NN	_	19	compound
18	therapy	therapy	NN	_	19	compound
19	compliance	compliance	NN	_	15	nmod
20	,	,	,	_	19	punct
21	especially	especially	RB	_	22	advmod
22	neglect	neglect	NN	_	19	appos
23	of	of	IN	_	25	case
24	anti-inflammatory	anti-inflammatory	JJ	_	25	amod
25	therapy	therapy	NN	_	22	nmod
26	and	and	CC	_	22	cc
27	overuse	overuse	NN	_	22	conj
28	of	of	IN	_	29	case
29	drug2	drug2	NN	_	27	nmod
30	.	.	.	_	11	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	increase	increase	VB	_	0	ROOT
4	slightly	slightly	RB	_	3	advmod
5	the	the	DT	_	6	det
6	effect	effect	NN	_	3	dobj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	,	,	,	_	8	punct
10	e.g.	e.g.	FW	_	12	dep
11	,	,	,	_	12	punct
12	drug3	drug3	NN	_	8	nmod
13	,	,	,	_	12	punct
14	drug4	drug4	NN	_	12	conj
15	,	,	,	_	12	punct
16	drug5	drug5	NN	_	12	conj
17	.	.	.	_	3	punct

1	Other	other	JJ	_	2	amod
2	drug1	drug1	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	used	use	VBN	_	0	ROOT
6	with	with	IN	_	7	case
7	caution	caution	NN	_	5	nmod
8	in	in	IN	_	9	case
9	patients	patient	NNS	_	5	nmod
10	taking	take	VBG	_	9	acl
11	drug2	drug2	NN	_	10	dobj
12	,	,	,	_	5	punct
13	since	since	IN	_	18	mark
14	the	the	DT	_	15	det
15	effects	effect	NNS	_	18	nsubj
16	may	may	MD	_	18	aux
17	be	be	VB	_	18	cop
18	additive	additive	JJ	_	5	advcl
19	.	.	.	_	5	punct

1	drug1	drug1	NN	_	21	nsubj
2	including	include	VBG	_	4	case
3	coumarin	coumarin	NN	_	4	compound
4	derivatives	derivative	NNS	_	1	nmod
5	,	,	,	_	4	punct
6	indandione	indandione	NN	_	7	compound
7	derivatives	derivative	NNS	_	4	conj
8	,	,	,	_	4	punct
9	and	and	CC	_	4	cc
10	drug2	drug2	NN	_	4	conj
11	such	such	JJ	_	13	case
12	as	as	IN	_	11	mwe
13	drug3	drug3	NN	_	10	nmod
14	-LRB-	-lrb-	-LRB-	_	15	punct
15	drug4	drug4	NN	_	13	appos
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	,	,	,	_	1	punct
18	and	and	CC	_	1	cc
19	drug5	drug5	NN	_	1	conj
20	may	may	MD	_	21	aux
21	increase	increase	VB	_	0	ROOT
22	the	the	DT	_	23	det
23	risk	risk	NN	_	21	dobj
24	of	of	IN	_	25	case
25	bleeding	bleed	VBG	_	23	nmod
26	when	when	WRB	_	27	advmod
27	administered	administer	VBN	_	21	advcl
28	concomitantly	concomitantly	RB	_	27	advmod
29	with	with	IN	_	30	case
30	drug6	drug6	NN	_	27	nmod
31	.	.	.	_	21	punct

1	A	a	DT	_	6	det
2	30	30	CD	_	4	compound
3	to	to	TO	_	4	dep
4	45	45	CD	_	5	dep
5	%	%	NN	_	6	dep
6	increase	increase	NN	_	14	nsubjpass
7	in	in	IN	_	8	case
8	AUC	auc	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	Cmax	cmax	NN	_	8	conj
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	8	nmod
13	was	be	VBD	_	14	auxpass
14	observed	observe	VBN	_	0	ROOT
15	with	with	IN	_	17	case
16	concomitant	concomitant	JJ	_	17	amod
17	administration	administration	NN	_	14	nmod
18	of	of	IN	_	19	case
19	drug2	drug2	NN	_	17	nmod
20	twice	twice	RB	_	21	advmod
21	daily	daily	RB	_	14	advmod
22	.	.	.	_	14	punct

1	drug1	drug1	NN	_	3	compound
2	150	150	CD	_	3	nummod
3	mg	mg	NN	_	8	nsubj
4	twice	twice	RB	_	5	advmod
5	daily	daily	RB	_	8	advmod
6	did	do	VBD	_	8	aux
7	not	not	RB	_	8	neg
8	interact	interact	VB	_	0	ROOT
9	significantly	significantly	RB	_	8	advmod
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	15	nmod
12	-LRB-	-lrb-	-LRB-	_	13	punct
13	AUC	auc	NN	_	15	nsubjpass
14	was	be	VBD	_	15	auxpass
15	decreased	decrease	VBN	_	8	ccomp
16	by	by	IN	_	18	case
17	15-20	15-20	CD	_	18	nummod
18	%	%	NN	_	15	nmod
19	-RRB-	-rrb-	-RRB-	_	8	punct
20	.	.	.	_	8	punct

1	No	no	DT	_	3	neg
2	pharmacodynamic	pharmacodynamic	JJ	_	3	amod
3	effects	effect	NNS	_	8	nsubjpass
4	of	of	IN	_	6	case
5	either	either	CC	_	6	det
6	drug1	drug1	NN	_	3	nmod
7	were	be	VBD	_	8	auxpass
8	observed	observe	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	Coadministration	coadministration	NN	_	12	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	8	case
5	40	40	CD	_	8	nummod
6	mg	mg	NN	_	8	compound
7	drug2	drug2	NN	_	8	compound
8	tablets	tablet	NNS	_	1	nmod
9	in	in	IN	_	11	case
10	epileptic	epileptic	JJ	_	11	amod
11	patients	patient	NNS	_	8	nmod
12	lowered	lower	VBD	_	0	ROOT
13	the	the	DT	_	16	det
14	drug3	drug3	NN	_	16	compound
15	plasma	plasma	NN	_	16	compound
16	concentrations	concentration	NNS	_	12	dobj
17	to	to	TO	_	19	case
18	undetectable	undetectable	JJ	_	19	amod
19	levels	level	NNS	_	12	nmod
20	.	.	.	_	12	punct

1	Coadministration	coadministration	NN	_	13	nsubjpass
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	1	nmod
6	or	or	CC	_	5	cc
7	any	any	DT	_	10	det
8	known	known	JJ	_	10	amod
9	CYP3A4	cyp3a4	NN	_	10	compound
10	inducer	inducer	NN	_	5	conj
11	should	should	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	avoided	avoid	VBN	_	0	ROOT
14	and	and	CC	_	13	cc
15	alternative	alternative	JJ	_	17	amod
16	drug3	drug3	NN	_	17	compound
17	therapy	therapy	NN	_	20	nsubjpass
18	should	should	MD	_	20	aux
19	be	be	VB	_	20	auxpass
20	considered	consider	VBN	_	13	conj
21	.	.	.	_	13	punct

1	Pharmacokinetic	pharmacokinetic	JJ	_	2	amod
2	interactions	interaction	NNS	_	13	nsubj
3	between	between	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	-LRB-	-lrb-	-LRB-	_	8	punct
8	drug3	drug3	NN	_	6	dep
9	,	,	,	_	8	punct
10	drug4	drug4	NN	_	8	appos
11	-RRB-	-rrb-	-RRB-	_	8	punct
12	were	be	VBD	_	13	cop
13	variable	variable	JJ	_	0	ROOT
14	and	and	CC	_	13	cc
15	not	not	RB	_	16	neg
16	significant	significant	JJ	_	13	conj
17	.	.	.	_	13	punct

1	drug1	drug1	NN	_	2	nsubj
2	attenuated	attenuate	VBD	_	0	ROOT
3	the	the	DT	_	6	det
4	heart	heart	NN	_	6	compound
5	rate	rate	NN	_	6	compound
6	increase	increase	NN	_	2	dobj
7	following	follow	VBG	_	8	case
8	administration	administration	NN	_	2	nmod
9	of	of	IN	_	12	case
10	immediate	immediate	JJ	_	12	amod
11	release	release	NN	_	12	compound
12	drug2	drug2	NN	_	8	nmod
13	.	.	.	_	2	punct

1	The	the	DT	_	4	det
2	blood	blood	NN	_	4	compound
3	pressure	pressure	NN	_	4	compound
4	effect	effect	NN	_	7	nsubj
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	tended	tend	VBD	_	0	ROOT
8	to	to	TO	_	10	mark
9	be	be	VB	_	10	cop
10	greater	greater	JJR	_	7	xcomp
11	in	in	IN	_	12	case
12	patients	patient	NNS	_	10	nmod
13	on	on	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	than	than	IN	_	17	case
16	in	in	IN	_	17	case
17	patients	patient	NNS	_	10	nmod
18	on	on	IN	_	22	case
19	no	no	DT	_	22	neg
20	other	other	JJ	_	22	amod
21	drug3	drug3	NN	_	22	compound
22	therapy	therapy	NN	_	17	nmod
23	.	.	.	_	7	punct

1	drug1	drug1	NN	_	6	nsubj
2	at	at	IN	_	5	case
3	648	648	CD	_	4	compound
4	mg	mg	NN	_	5	amod
5	bid	bid	NN	_	1	nmod
6	decreased	decrease	VBD	_	0	ROOT
7	the	the	DT	_	6	dobj
8	bioavailability	bioavailability	NN	_	7	amod
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	AUC	auc	NN	_	8	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	8	nmod
14	by	by	IN	_	16	case
15	26	26	CD	_	16	nummod
16	%	%	NN	_	8	nmod
17	,	,	,	_	16	punct
18	but	but	CC	_	16	cc
19	not	not	RB	_	22	neg
20	the	the	DT	_	22	det
21	peak	peak	NN	_	22	compound
22	concentration	concentration	NN	_	16	conj
23	.	.	.	_	6	punct

1	The	the	DT	_	3	det
2	immediate	immediate	JJ	_	3	amod
3	release	release	NN	_	0	ROOT
4	,	,	,	_	3	punct
5	but	but	CC	_	6	cc
6	not	not	RB	_	3	cc
7	the	the	DT	_	9	det
8	coat-core	coat-core	JJ	_	9	amod
9	formulation	formulation	NN	_	3	conj
10	of	of	IN	_	15	case
11	drug1	drug1	NN	_	15	compound
12	increased	increase	VBN	_	15	amod
13	plasma	plasma	NN	_	15	compound
14	drug2	drug2	NN	_	15	compound
15	concentrations	concentration	NNS	_	9	nmod
16	by	by	IN	_	19	case
17	about	about	RB	_	18	advmod
18	20	20	CD	_	19	nummod
19	%	%	NN	_	9	nmod
20	.	.	.	_	3	punct

1	This	this	DT	_	2	det
2	interaction	interaction	NN	_	5	nsubjpass
3	was	be	VBD	_	5	auxpass
4	not	not	RB	_	5	neg
5	accompanied	accompany	VBN	_	15	csubjpass
6	by	by	IN	_	8	case
7	ECG	ecg	NN	_	8	compound
8	changes	change	NNS	_	5	nmod
9	and	and	CC	_	8	cc
10	its	its	PRP$	_	12	nmod:poss
11	clinical	clinical	JJ	_	12	amod
12	significance	significance	NN	_	8	conj
13	is	be	VBZ	_	15	auxpass
14	not	not	RB	_	15	neg
15	known	know	VBN	_	0	ROOT
16	.	.	.	_	15	punct

1	No	no	DT	_	3	neg
2	significant	significant	JJ	_	3	amod
3	interactions	interaction	NNS	_	5	nsubjpass
4	were	be	VBD	_	5	auxpass
5	found	find	VBN	_	0	ROOT
6	between	between	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	or	or	CC	_	9	cc
11	drug3	drug3	NN	_	9	conj
12	.	.	.	_	5	punct

1	Hypotension	hypotension	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Patients	patient	NNS	_	1	dep
4	on	on	IN	_	6	case
5	Diuretic	diuretic	JJ	_	6	amod
6	Therapy	therapy	NN	_	3	nmod
7	:	:	:	_	3	punct
8	Patients	patient	NNS	_	24	nsubj
9	on	on	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	and	and	CC	_	8	cc
12	especially	especially	RB	_	13	advmod
13	those	those	DT	_	8	conj
14	in	in	IN	_	15	case
15	whom	whom	WP	_	20	nmod
16	diuretic	diuretic	JJ	_	17	amod
17	therapy	therapy	NN	_	20	nsubjpass
18	was	be	VBD	_	20	auxpass
19	recently	recently	RB	_	20	advmod
20	instituted	institute	VBN	_	13	acl:relcl
21	,	,	,	_	8	punct
22	may	may	MD	_	24	aux
23	occasionally	occasionally	RB	_	24	advmod
24	experience	experience	VB	_	3	dep
25	an	a	DT	_	27	det
26	excessive	excessive	JJ	_	27	amod
27	reduction	reduction	NN	_	24	dobj
28	of	of	IN	_	30	case
29	blood	blood	NN	_	30	compound
30	pressure	pressure	NN	_	27	nmod
31	after	after	IN	_	32	case
32	initiation	initiation	NN	_	24	nmod
33	of	of	IN	_	34	case
34	therapy	therapy	NN	_	32	nmod
35	with	with	IN	_	36	case
36	drug2	drug2	NN	_	32	nmod
37	or	or	CC	_	36	cc
38	drug3	drug3	NN	_	36	conj
39	.	.	.	_	24	punct

1	The	the	DT	_	2	det
2	possibility	possibility	NN	_	12	nsubjpass
3	of	of	IN	_	5	case
4	hypotensive	hypotensive	JJ	_	5	amod
5	effects	effect	NNS	_	2	nmod
6	with	with	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	or	or	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	can	can	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	minimized	minimize	VBN	_	0	ROOT
13	by	by	IN	_	15	mark
14	either	either	CC	_	15	cc:preconj
15	discontinuing	discontinue	VBG	_	12	advcl
16	the	the	DT	_	17	det
17	drug3	drug3	NN	_	15	dobj
18	or	or	CC	_	15	cc
19	increasing	increase	VBG	_	15	conj
20	the	the	DT	_	22	det
21	salt	salt	NN	_	22	compound
22	intake	intake	NN	_	19	dobj
23	prior	prior	RB	_	19	advmod
24	to	to	TO	_	25	case
25	initiation	initiation	NN	_	23	nmod
26	of	of	IN	_	27	case
27	treatment	treatment	NN	_	25	nmod
28	with	with	IN	_	29	case
29	drug4	drug4	NN	_	27	nmod
30	or	or	CC	_	29	cc
31	drug5	drug5	NN	_	29	conj
32	.	.	.	_	12	punct

1	If	if	IN	_	4	mark
2	it	it	PRP	_	4	nsubj
3	is	be	VBZ	_	4	cop
4	necessary	necessary	JJ	_	10	advcl
5	to	to	TO	_	6	mark
6	continue	continue	VB	_	4	xcomp
7	the	the	DT	_	8	det
8	drug1	drug1	NN	_	6	dobj
9	,	,	,	_	10	punct
10	provide	provide	VBP	_	0	ROOT
11	close	close	JJ	_	13	amod
12	medical	medical	JJ	_	13	amod
13	supervision	supervision	NN	_	10	dobj
14	after	after	IN	_	17	case
15	the	the	DT	_	17	det
16	initial	initial	JJ	_	17	amod
17	dose	dose	NN	_	10	nmod
18	for	for	IN	_	22	case
19	at	at	IN	_	20	case
20	least	least	JJS	_	21	nmod:npmod
21	two	two	CD	_	22	nummod
22	hours	hour	NNS	_	10	nmod
23	and	and	CC	_	10	cc
24	until	until	IN	_	28	mark
25	blood	blood	NN	_	26	compound
26	pressure	pressure	NN	_	28	nsubj
27	has	have	VBZ	_	28	aux
28	stabilized	stabilize	VBN	_	10	conj
29	for	for	IN	_	34	case
30	at	at	IN	_	31	case
31	least	least	JJS	_	34	advmod
32	an	a	DT	_	34	det
33	additional	additional	JJ	_	34	amod
34	hour	hour	NN	_	28	nmod
35	.	.	.	_	10	punct
36	.	.	.	_	10	punct

1	Agents	agent	NNS	_	0	ROOT
2	Causing	cause	VBG	_	1	acl
3	Renin	Renin	NNP	_	4	compound
4	Release	Release	NNP	_	2	dobj
5	:	:	:	_	4	punct
6	The	the	DT	_	8	det
7	antihypertensive	antihypertensive	JJ	_	8	amod
8	effect	effect	NN	_	15	nsubjpass
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	drug2	drug2	NN	_	10	conj
13	IV	iv	CD	_	12	nummod
14	is	be	VBZ	_	15	auxpass
15	augmented	augment	VBN	_	4	dep
16	by	by	IN	_	17	case
17	drug3	drug3	NN	_	15	nmod
18	that	that	WDT	_	19	nsubj
19	cause	cause	VBP	_	17	acl:relcl
20	renin	renin	NN	_	21	compound
21	release	release	NN	_	19	dobj
22	-LRB-	-lrb-	-LRB-	_	25	punct
23	e.g.	e.g.	FW	_	25	dep
24	,	,	,	_	25	punct
25	drug4	drug4	NN	_	15	dep
26	-RRB-	-rrb-	-RRB-	_	25	punct
27	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	5	case
4	some	some	DT	_	5	det
5	patients	patient	NNS	_	22	nmod
6	with	with	IN	_	9	case
7	compromised	compromise	VBN	_	9	amod
8	renal	renal	JJ	_	9	amod
9	function	function	NN	_	5	nmod
10	who	who	WP	_	13	nsubjpass
11	are	be	VBP	_	13	aux
12	being	be	VBG	_	13	auxpass
13	treated	treat	VBN	_	5	acl:relcl
14	with	with	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	,	,	,	_	5	punct
17	the	the	DT	_	18	det
18	co-administration	co-administration	NN	_	22	nsubj
19	of	of	IN	_	20	case
20	drug3	drug3	NN	_	18	nmod
21	may	may	MD	_	22	aux
22	result	result	VB	_	1	dep
23	in	in	IN	_	26	case
24	a	a	DT	_	26	det
25	further	further	JJ	_	26	amod
26	deterioration	deterioration	NN	_	22	nmod
27	of	of	IN	_	29	case
28	renal	renal	JJ	_	29	amod
29	function	function	NN	_	26	nmod
30	.	.	.	_	1	punct

1	These	these	DT	_	2	det
2	effects	effect	NNS	_	5	nsubj
3	are	be	VBP	_	5	cop
4	usually	usually	RB	_	5	advmod
5	reversible	reversible	JJ	_	0	ROOT
6	.	.	.	_	5	punct

1	In	in	IN	_	5	case
2	a	a	DT	_	5	det
3	clinical	clinical	JJ	_	5	amod
4	pharmacology	pharmacology	NN	_	5	compound
5	study	study	NN	_	11	nmod
6	,	,	,	_	11	punct
7	drug1	drug1	NN	_	11	nsubjpass
8	or	or	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	was	be	VBD	_	11	auxpass
11	administered	administer	VBN	_	0	ROOT
12	to	to	TO	_	14	case
13	hypertensive	hypertensive	JJ	_	14	amod
14	patients	patient	NNS	_	11	nmod
15	receiving	receive	VBG	_	14	acl
16	drug3	drug3	NN	_	15	dobj
17	.	.	.	_	11	punct

1	In	in	IN	_	3	case
2	this	this	DT	_	3	det
3	study	study	NN	_	5	nmod
4	there	there	EX	_	5	expl
5	was	be	VBD	_	0	ROOT
6	no	no	DT	_	7	neg
7	evidence	evidence	NN	_	5	nsubj
8	of	of	IN	_	10	case
9	a	a	DT	_	10	det
10	blunting	blunting	NN	_	7	nmod
11	of	of	IN	_	14	case
12	the	the	DT	_	14	det
13	antihypertensive	antihypertensive	JJ	_	14	amod
14	action	action	NN	_	10	nmod
15	of	of	IN	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	.	.	.	_	5	punct

1	However	however	RB	_	4	advmod
2	,	,	,	_	4	punct
3	reports	report	NNS	_	4	nsubj
4	suggest	suggest	VBP	_	0	ROOT
5	that	that	IN	_	8	mark
6	drug1	drug1	NN	_	8	nsubj
7	may	may	MD	_	8	aux
8	diminish	diminish	VB	_	4	ccomp
9	the	the	DT	_	11	det
10	antihypertensive	antihypertensive	JJ	_	11	amod
11	effect	effect	NN	_	8	dobj
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	.	.	.	_	4	punct

1	This	this	DT	_	2	det
2	interaction	interaction	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	given	give	VBN	_	0	ROOT
6	consideration	consideration	NN	_	5	dobj
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	5	nmod
9	taking	take	VBG	_	8	acl
10	drug1	drug1	NN	_	9	dobj
11	concomitantly	concomitantly	RB	_	9	advmod
12	with	with	IN	_	13	case
13	drug2	drug2	NN	_	9	nmod
14	.	.	.	_	5	punct

1	Other	other	JJ	_	3	amod
2	Cardiovascular	Cardiovascular	NNP	_	3	compound
3	Agents	Agents	NNPS	_	0	ROOT
4	:	:	:	_	3	punct
5	drug1	drug1	NN	_	11	nsubjpass
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	IV	iv	CD	_	5	nummod
9	have	have	VBP	_	11	aux
10	been	be	VBN	_	11	auxpass
11	used	use	VBN	_	3	dep
12	concomitantly	concomitantly	RB	_	11	advmod
13	with	with	IN	_	14	case
14	drug3	drug3	NN	_	11	nmod
15	,	,	,	_	14	punct
16	drug4	drug4	NN	_	14	conj
17	,	,	,	_	14	punct
18	drug5	drug5	NN	_	14	conj
19	,	,	,	_	14	punct
20	drug6	drug6	NN	_	14	conj
21	,	,	,	_	14	punct
22	drug7	drug7	NN	_	14	conj
23	,	,	,	_	14	punct
24	drug8	drug8	NN	_	14	conj
25	and	and	CC	_	14	cc
26	drug9	drug9	NN	_	14	conj
27	without	without	IN	_	28	case
28	evidence	evidence	NN	_	11	nmod
29	of	of	IN	_	33	case
30	clinically	clinically	RB	_	31	advmod
31	significant	significant	JJ	_	33	amod
32	adverse	adverse	JJ	_	33	amod
33	interactions	interaction	NNS	_	28	nmod
34	.	.	.	_	3	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	IV	iv	CD	_	1	nummod
3	has	have	VBZ	_	5	aux
4	been	be	VBN	_	5	auxpass
5	used	use	VBN	_	0	ROOT
6	concomitantly	concomitantly	RB	_	5	advmod
7	with	with	IN	_	8	case
8	drug2	drug2	NN	_	5	nmod
9	without	without	IN	_	10	case
10	evidence	evidence	NN	_	5	nmod
11	of	of	IN	_	15	case
12	clinically	clinically	RB	_	13	advmod
13	significant	significant	JJ	_	15	amod
14	adverse	adverse	JJ	_	15	amod
15	reactions	reaction	NNS	_	10	nmod
16	.	.	.	_	5	punct

1	Agents	agent	NNS	_	4	compound
2	Increasing	increase	VBG	_	4	amod
3	Serum	serum	NN	_	4	compound
4	Potassium	potassium	NN	_	0	ROOT
5	:	:	:	_	4	punct
6	drug1	drug1	NN	_	10	nsubj
7	and	and	CC	_	6	cc
8	drug2	drug2	NN	_	6	conj
9	IV	iv	CD	_	8	nummod
10	attenuate	attenuate	VBP	_	4	dep
11	potassium	potassium	NN	_	12	compound
12	loss	loss	NN	_	10	dobj
13	caused	cause	VBN	_	12	acl
14	by	by	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	.	.	.	_	4	punct

1	drug1	drug1	NN	_	23	nsubj
2	-LRB-	-lrb-	-LRB-	_	5	punct
3	e.g.	e.g.	FW	_	5	dep
4	,	,	,	_	5	punct
5	drug2	drug2	NN	_	1	dep
6	,	,	,	_	5	punct
7	drug3	drug3	NN	_	5	conj
8	,	,	,	_	5	punct
9	or	or	CC	_	5	cc
10	drug4	drug4	NN	_	5	conj
11	-RRB-	-rrb-	-RRB-	_	5	punct
12	,	,	,	_	1	punct
13	drug5	drug5	NN	_	14	compound
14	supplements	supplement	NNS	_	1	conj
15	,	,	,	_	1	punct
16	or	or	CC	_	1	cc
17	drug6	drug6	NN	_	1	conj
18	-	-	:	_	1	punct
19	containing	contain	VBG	_	1	acl
20	salt	salt	NN	_	21	compound
21	substitutes	substitute	NNS	_	19	dobj
22	may	may	MD	_	23	aux
23	lead	lead	VB	_	0	ROOT
24	to	to	TO	_	26	case
25	significant	significant	JJ	_	26	amod
26	increases	increase	NNS	_	23	nmod
27	in	in	IN	_	29	case
28	serum	serum	NN	_	29	compound
29	potassium	potassium	NN	_	26	nmod
30	.	.	.	_	23	punct

1	Therefore	therefore	RB	_	19	advmod
2	,	,	,	_	19	punct
3	if	if	IN	_	10	mark
4	concomitant	concomitant	JJ	_	5	amod
5	use	use	NN	_	10	nsubjpass
6	of	of	IN	_	8	case
7	these	these	DT	_	8	det
8	agents	agent	NNS	_	5	nmod
9	is	be	VBZ	_	10	auxpass
10	indicated	indicate	VBN	_	19	advcl
11	because	because	IN	_	14	case
12	of	of	IN	_	11	mwe
13	demonstrated	demonstrate	VBN	_	14	amod
14	hypokalemia	hypokalemia	NN	_	10	nmod
15	,	,	,	_	19	punct
16	they	they	PRP	_	19	nsubjpass
17	should	should	MD	_	19	aux
18	be	be	VB	_	19	auxpass
19	used	use	VBN	_	0	ROOT
20	with	with	IN	_	21	case
21	caution	caution	NN	_	19	nmod
22	and	and	CC	_	21	cc
23	with	with	IN	_	25	case
24	frequent	frequent	JJ	_	25	amod
25	monitoring	monitoring	NN	_	21	conj
26	of	of	IN	_	28	case
27	serum	serum	NN	_	28	compound
28	potassium	potassium	NN	_	25	nmod
29	.	.	.	_	19	punct

1	Potassium	potassium	NN	_	3	compound
2	sparing	sparing	NN	_	3	compound
3	agents	agent	NNS	_	8	nsubjpass
4	should	should	MD	_	8	aux
5	generally	generally	RB	_	8	advmod
6	not	not	RB	_	8	neg
7	be	be	VB	_	8	auxpass
8	used	use	VBN	_	0	ROOT
9	in	in	IN	_	10	case
10	patients	patient	NNS	_	8	nmod
11	with	with	IN	_	13	case
12	heart	heart	NN	_	13	compound
13	failure	failure	NN	_	10	nmod
14	receiving	receive	VBG	_	13	acl
15	drug1	drug1	NN	_	14	dobj
16	.	.	.	_	8	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	compound
4	toxicity	toxicity	NN	_	7	nsubjpass
5	has	have	VBZ	_	7	aux
6	been	be	VBN	_	7	auxpass
7	reported	report	VBN	_	1	appos
8	in	in	IN	_	9	case
9	patients	patient	NNS	_	7	nmod
10	receiving	receive	VBG	_	9	acl
11	drug3	drug3	NN	_	10	dobj
12	concomitantly	concomitantly	RB	_	10	advmod
13	with	with	IN	_	14	case
14	drugs	drug	NNS	_	10	nmod
15	which	which	WDT	_	16	nsubj
16	cause	cause	VBP	_	14	acl:relcl
17	elimination	elimination	NN	_	16	dobj
18	of	of	IN	_	19	case
19	sodium	sodium	NN	_	17	nmod
20	,	,	,	_	14	punct
21	including	include	VBG	_	22	case
22	drug4	drug4	NN	_	14	nmod
23	.	.	.	_	1	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	recommended	recommend	VBN	_	0	ROOT
4	that	that	IN	_	9	mark
5	serum	serum	NN	_	7	compound
6	drug1	drug1	NN	_	7	compound
7	levels	level	NNS	_	9	nsubjpass
8	be	be	VB	_	9	auxpass
9	monitored	monitor	VBN	_	3	ccomp
10	frequently	frequently	RB	_	9	advmod
11	if	if	IN	_	14	mark
12	drug2	drug2	NN	_	14	nsubjpass
13	is	be	VBZ	_	14	auxpass
14	administered	administer	VBN	_	9	advcl
15	concomitantly	concomitantly	RB	_	14	advmod
16	with	with	IN	_	17	case
17	drug3	drug3	NN	_	14	nmod
18	.	.	.	_	3	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	administered	administer	VBN	_	0	ROOT
5	with	with	IN	_	6	case
6	caution	caution	NN	_	4	nmod
7	to	to	TO	_	8	case
8	patients	patient	NNS	_	6	nmod
9	receiving	receive	VBG	_	8	acl
10	drug2	drug2	NN	_	9	dobj
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	drug3	drug3	NN	_	10	dep
13	,	,	,	_	12	punct
14	Wyeth-Ayerst	Wyeth-Ayerst	NNP	_	15	compound
15	Laboratories	Laboratories	NNP	_	12	appos
16	-RRB-	-rrb-	-RRB-	_	12	punct
17	.	.	.	_	4	punct

1	In	in	IN	_	4	case
2	a	a	DT	_	4	det
3	single	single	JJ	_	4	amod
4	study	study	NN	_	16	nmod
5	,	,	,	_	16	punct
6	rats	rat	NNS	_	16	nsubj
7	given	give	VBN	_	10	case
8	high	high	JJ	_	10	amod
9	intraperitoneal	intraperitoneal	JJ	_	10	amod
10	doses	dose	NNS	_	6	nmod
11	of	of	IN	_	13	case
12	an	a	DT	_	13	det
13	drug1	drug1	NN	_	10	nmod
14	plus	plus	CC	_	13	cc
15	drug2	drug2	NN	_	13	conj
16	experienced	experience	VBD	_	0	ROOT
17	severe	severe	JJ	_	18	amod
18	toxicity	toxicity	NN	_	16	dobj
19	,	,	,	_	18	punct
20	including	include	VBG	_	21	case
21	convulsions	convulsion	NNS	_	18	nmod
22	and	and	CC	_	21	cc
23	death	death	NN	_	21	conj
24	.	.	.	_	16	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	use	use	NN	_	11	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	other	other	JJ	_	7	amod
7	drug2	drug2	NN	_	4	conj
8	is	be	VBZ	_	11	auxpass
9	generally	generally	RB	_	11	advmod
10	not	not	RB	_	11	neg
11	recommended	recommend	VBN	_	0	ROOT
12	because	because	IN	_	16	case
13	of	of	IN	_	12	mwe
14	possible	possible	JJ	_	16	amod
15	potentiating	potentiating	NN	_	16	compound
16	effects	effect	NNS	_	11	nmod
17	.	.	.	_	11	punct

1	This	this	DT	_	4	nsubj
2	is	be	VBZ	_	4	cop
3	especially	especially	RB	_	4	advmod
4	true	true	JJ	_	0	ROOT
5	in	in	IN	_	6	case
6	patients	patient	NNS	_	4	nmod
7	who	who	WP	_	9	nsubj
8	may	may	MD	_	9	aux
9	subject	subject	VB	_	6	acl:relcl
10	themselves	themselves	PRP	_	9	dobj
11	to	to	TO	_	13	case
12	an	a	DT	_	13	det
13	overdosage	overdosage	NN	_	9	nmod
14	of	of	IN	_	15	case
15	drugs	drug	NNS	_	13	nmod
16	.	.	.	_	4	punct

1	If	if	IN	_	5	mark
2	combination	combination	NN	_	3	compound
3	therapy	therapy	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	needed	need	VBN	_	11	advcl
6	,	,	,	_	11	punct
7	careful	careful	JJ	_	8	amod
8	consideration	consideration	NN	_	11	nsubjpass
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	given	give	VBN	_	0	ROOT
12	to	to	TO	_	14	case
13	the	the	DT	_	14	det
14	pharmacology	pharmacology	NN	_	11	nmod
15	of	of	IN	_	17	case
16	all	all	DT	_	17	det
17	agents	agent	NNS	_	14	nmod
18	to	to	TO	_	20	mark
19	be	be	VB	_	20	auxpass
20	used	use	VBN	_	11	xcomp
21	.	.	.	_	11	punct

1	The	the	DT	_	5	det
2	monoamine	monoamine	NN	_	5	compound
3	oxidase	oxidase	NN	_	5	compound
4	inhibitory	inhibitory	JJ	_	5	amod
5	effects	effect	NNS	_	9	nsubj
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	may	may	MD	_	9	aux
9	persist	persist	VB	_	0	ROOT
10	for	for	IN	_	13	case
11	a	a	DT	_	13	det
12	substantial	substantial	JJ	_	13	amod
13	period	period	NN	_	9	nmod
14	after	after	IN	_	15	case
15	discontinuation	discontinuation	NN	_	9	nmod
16	of	of	IN	_	18	case
17	the	the	DT	_	18	det
18	drug	drug	NN	_	15	nmod
19	,	,	,	_	9	punct
20	and	and	CC	_	9	cc
21	this	this	DT	_	24	nsubjpass
22	should	should	MD	_	24	aux
23	be	be	VB	_	24	auxpass
24	borne	bear	VBN	_	9	conj
25	in	in	IN	_	26	case
26	mind	mind	NN	_	24	nmod
27	when	when	WRB	_	31	advmod
28	another	another	DT	_	29	det
29	drug	drug	NN	_	31	nsubjpass
30	is	be	VBZ	_	31	auxpass
31	prescribed	prescribe	VBN	_	24	advcl
32	following	follow	VBG	_	33	case
33	drug2	drug2	NN	_	31	nmod
34	.	.	.	_	9	punct

1	To	to	TO	_	2	mark
2	avoid	avoid	VB	_	20	advcl
3	potentiation	potentiation	NN	_	2	dobj
4	,	,	,	_	20	punct
5	the	the	DT	_	6	det
6	physician	physician	NN	_	20	nsubj
7	wishing	wish	VBG	_	6	acl
8	to	to	TO	_	9	mark
9	terminate	terminate	VB	_	7	xcomp
10	treatment	treatment	NN	_	9	dobj
11	with	with	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	and	and	CC	_	9	cc
14	begin	begin	VB	_	9	conj
15	therapy	therapy	NN	_	14	dobj
16	with	with	IN	_	18	case
17	another	another	DT	_	18	det
18	agent	agent	NN	_	14	nmod
19	should	should	MD	_	20	aux
20	allow	allow	VB	_	0	ROOT
21	for	for	IN	_	23	case
22	an	a	DT	_	23	det
23	interval	interval	NN	_	20	nmod
24	of	of	IN	_	26	case
25	10	10	CD	_	26	nummod
26	days	day	NNS	_	23	nmod
27	.	.	.	_	20	punct

1	drug1	drug1	NN	_	0	ROOT
2	/	/	:	_	3	punct
3	drug2	drug2	NN	_	1	dep
4	,	,	,	_	3	punct
5	drug3	drug3	NN	_	3	appos
6	,	,	,	_	3	punct
7	Including	include	VBG	_	3	acl
8	drug4	drug4	NN	_	7	dobj

1	The	the	DT	_	2	det
2	administration	administration	NN	_	19	nsubj
3	of	of	IN	_	5	case
4	local	local	JJ	_	5	amod
5	drug1	drug1	NN	_	2	nmod
6	containing	contain	VBG	_	5	acl
7	drug2	drug2	NN	_	6	dobj
8	or	or	CC	_	7	cc
9	drug3	drug3	NN	_	7	conj
10	to	to	TO	_	11	case
11	patients	patient	NNS	_	6	nmod
12	receiving	receive	VBG	_	11	acl
13	drug4	drug4	NN	_	12	dobj
14	,	,	,	_	13	punct
15	drug5	drug5	NN	_	13	conj
16	or	or	CC	_	13	cc
17	drug6	drug6	NN	_	13	conj
18	may	may	MD	_	19	aux
19	produce	produce	VB	_	0	ROOT
20	severe	severe	JJ	_	19	dobj
21	,	,	,	_	20	punct
22	prolonged	prolonged	JJ	_	23	amod
23	hypotension	hypotension	NN	_	20	conj
24	or	or	CC	_	20	cc
25	hypertension	hypertension	NN	_	20	conj
26	.	.	.	_	19	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	use	use	NN	_	9	nsubjpass
3	of	of	IN	_	5	case
4	these	these	DT	_	5	det
5	agents	agent	NNS	_	2	nmod
6	should	should	MD	_	9	aux
7	generally	generally	RB	_	9	advmod
8	be	be	VB	_	9	auxpass
9	avoided	avoid	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	In	in	IN	_	2	case
2	situations	situation	NNS	_	13	nmod
3	when	when	WRB	_	7	advmod
4	concurrent	concurrent	JJ	_	5	amod
5	therapy	therapy	NN	_	7	nsubj
6	is	be	VBZ	_	7	cop
7	necessary	necessary	JJ	_	2	acl:relcl
8	,	,	,	_	13	punct
9	careful	careful	JJ	_	11	amod
10	patient	patient	NN	_	11	compound
11	monitoring	monitoring	NN	_	13	nsubj
12	is	be	VBZ	_	13	cop
13	essential	essential	JJ	_	0	ROOT
14	.	.	.	_	13	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	administration	administration	NN	_	19	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	-LRB-	-lrb-	-LRB-	_	8	punct
6	for	for	IN	_	8	case
7	the	the	DT	_	8	det
8	treatment	treatment	NN	_	2	nmod
9	of	of	IN	_	10	case
10	hypotension	hypotension	NN	_	8	nmod
11	related	related	JJ	_	10	amod
12	to	to	TO	_	14	case
13	obstetric	obstetric	JJ	_	14	amod
14	blocks	block	NNS	_	11	nmod
15	-RRB-	-rrb-	-RRB-	_	8	punct
16	and	and	CC	_	2	cc
17	drug2	drug2	NN	_	2	conj
18	may	may	MD	_	19	aux
19	cause	cause	VB	_	0	ROOT
20	severe	severe	JJ	_	26	amod
21	,	,	,	_	20	punct
22	persistent	persistent	JJ	_	23	amod
23	hypertension	hypertension	NN	_	20	conj
24	or	or	CC	_	20	cc
25	cerebrovascular	cerebrovascular	JJ	_	20	conj
26	accidents	accident	NNS	_	19	dobj
27	.	.	.	_	19	punct

1	The	the	DT	_	4	det
2	para-aminobenzoic	para-aminobenzoic	JJ	_	4	amod
3	acid	acid	NN	_	4	compound
4	metabolite	metabolite	NN	_	7	nsubj
5	of	of	IN	_	6	case
6	chloroprocaine	chloroprocaine	NN	_	4	nmod
7	inhibits	inhibit	VBZ	_	0	ROOT
8	the	the	DT	_	9	det
9	action	action	NN	_	7	dobj
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	.	.	.	_	7	punct

1	Therefore	therefore	RB	_	7	advmod
2	,	,	,	_	7	punct
3	drug1	drug1	NN	_	7	nsubjpass
4	should	should	MD	_	7	aux
5	not	not	RB	_	7	neg
6	be	be	VB	_	7	auxpass
7	used	use	VBN	_	0	ROOT
8	in	in	IN	_	10	case
9	any	any	DT	_	10	det
10	condition	condition	NN	_	7	nmod
11	in	in	IN	_	12	case
12	which	which	WDT	_	17	nmod
13	a	a	DT	_	14	det
14	drug2	drug2	NN	_	17	nsubjpass
15	is	be	VBZ	_	17	aux
16	being	be	VBG	_	17	auxpass
17	employed	employ	VBN	_	10	acl:relcl
18	.	.	.	_	7	punct

1	drug1	drug1	NN	_	0	ROOT
2	including	include	VBG	_	3	case
3	drug2	drug2	NN	_	1	nmod
4	,	,	,	_	3	punct
5	drug3	drug3	NN	_	3	conj
6	,	,	,	_	3	punct
7	and	and	CC	_	3	cc
8	drug4	drug4	NN	_	9	compound
9	HC1	hc1	NN	_	3	conj
10	:	:	:	_	1	punct
11	Concomitant	concomitant	JJ	_	12	amod
12	use	use	NN	_	19	nsubj
13	of	of	IN	_	14	case
14	drug5	drug5	NN	_	12	nmod
15	and	and	CC	_	14	cc
16	non-selective	non-selective	JJ	_	17	amod
17	drug6	drug6	NN	_	14	conj
18	may	may	MD	_	19	aux
19	cause	cause	VB	_	1	dep
20	hypertension	hypertension	NN	_	19	dobj
21	.	.	.	_	19	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	use	use	NN	_	9	nsubj
3	with	with	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	or	or	CC	_	4	cc
6	other	other	JJ	_	7	amod
7	drugs	drug	NNS	_	4	conj
8	significantly	significantly	RB	_	9	advmod
9	eliminated	eliminate	VBN	_	0	ROOT
10	by	by	IN	_	14	case
11	active	active	JJ	_	14	amod
12	renal	renal	JJ	_	14	amod
13	tubular	tubular	JJ	_	14	amod
14	secretion	secretion	NN	_	9	nmod
15	may	may	MD	_	16	aux
16	result	result	VB	_	9	dep
17	in	in	IN	_	20	case
18	increased	increase	VBN	_	20	amod
19	plasma	plasma	NN	_	20	compound
20	concentrations	concentration	NNS	_	16	nmod
21	of	of	IN	_	22	case
22	drug2	drug2	NN	_	20	nmod
23	.	.	.	_	9	punct

1	The	the	DT	_	2	det
2	conversion	conversion	NN	_	8	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	to	to	TO	_	6	case
6	drug2	drug2	NN	_	2	nmod
7	is	be	VBZ	_	8	auxpass
8	catalyzed	catalyze	VBN	_	0	ROOT
9	by	by	IN	_	11	case
10	aldehyde	aldehyde	NN	_	11	compound
11	oxidase	oxidase	NN	_	8	nmod
12	.	.	.	_	8	punct

1	Interactions	interaction	NNS	_	11	nsubj
2	with	with	IN	_	4	case
3	other	other	JJ	_	4	amod
4	drugs	drug	NNS	_	1	nmod
5	metabolized	metabolize	VBN	_	4	acl
6	by	by	IN	_	8	case
7	this	this	DT	_	8	det
8	enzyme	enzyme	NN	_	5	nmod
9	could	could	MD	_	11	aux
10	potentially	potentially	RB	_	11	advmod
11	occur	occur	VB	_	0	ROOT
12	.	.	.	_	11	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	nsubj
4	enhances	enhance	VBZ	_	1	appos
5	the	the	DT	_	6	det
6	effect	effect	NN	_	4	dobj
7	of	of	IN	_	8	case
8	drug3	drug3	NN	_	6	nmod
9	.	.	.	_	1	punct

1	Therefore	therefore	RB	_	19	advmod
2	,	,	,	_	19	punct
3	when	when	WRB	_	6	advmod
4	drug1	drug1	NN	_	6	nsubjpass
5	is	be	VBZ	_	6	auxpass
6	given	give	VBN	_	19	advcl
7	to	to	TO	_	9	case
8	a	a	DT	_	9	det
9	patient	patient	NN	_	6	nmod
10	receiving	receive	VBG	_	9	acl
11	drug2	drug2	NN	_	10	dobj
12	,	,	,	_	19	punct
13	the	the	DT	_	14	det
14	dosage	dosage	NN	_	19	nsubjpass
15	of	of	IN	_	16	case
16	drug3	drug3	NN	_	14	nmod
17	should	should	MD	_	19	aux
18	be	be	VB	_	19	auxpass
19	reduced	reduce	VBN	_	0	ROOT
20	to	to	TO	_	21	mark
21	prevent	prevent	VB	_	19	xcomp
22	excessive	excessive	JJ	_	23	amod
23	prolongation	prolongation	NN	_	21	dobj
24	of	of	IN	_	27	case
25	the	the	DT	_	27	det
26	prothrombin	prothrombin	NN	_	27	compound
27	time	time	NN	_	23	nmod
28	.	.	.	_	19	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concurrent	concurrent	JJ	_	4	amod
4	administration	administration	NN	_	8	nsubj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	may	may	MD	_	8	aux
8	lower	lower	VB	_	1	dep
9	drug3	drug3	NN	_	11	compound
10	plasma	plasma	NN	_	11	compound
11	levels	level	NNS	_	8	dobj
12	,	,	,	_	8	punct
13	possibly	possibly	RB	_	15	advmod
14	by	by	IN	_	15	mark
15	competing	compete	VBG	_	8	advcl
16	for	for	IN	_	18	case
17	protein-binding	protein-binding	JJ	_	18	amod
18	sites	site	NNS	_	15	nmod
19	.	.	.	_	1	punct

1	The	the	DT	_	3	det
2	urinary	urinary	JJ	_	3	amod
3	excretion	excretion	NN	_	7	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	is	be	VBZ	_	7	aux
7	unaffected	unaffected	JJ	_	0	ROOT
8	by	by	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	,	,	,	_	7	punct
11	indicating	indicate	VBG	_	7	xcomp
12	no	no	DT	_	13	neg
13	change	change	NN	_	11	dobj
14	in	in	IN	_	16	case
15	drug3	drug3	NN	_	16	compound
16	absorption	absorption	NN	_	13	nmod
17	.	.	.	_	7	punct

1	drug1	drug1	NN	_	4	nsubj
2	does	do	VBZ	_	4	aux
3	not	not	RB	_	4	neg
4	affect	affect	VB	_	0	ROOT
5	serum	serum	NN	_	7	compound
6	drug2	drug2	NN	_	7	compound
7	levels	level	NNS	_	4	dobj
8	.	.	.	_	4	punct

1	Greater	Greater	NNP	_	4	compound
2	fecal	fecal	JJ	_	4	amod
3	blood	blood	NN	_	4	compound
4	loss	loss	NN	_	5	nsubj
5	results	result	VBZ	_	0	ROOT
6	from	from	IN	_	8	case
7	concomitant	concomitant	JJ	_	8	amod
8	administration	administration	NN	_	5	nmod
9	of	of	IN	_	11	case
10	both	both	CC	_	11	det
11	drugs	drug	NNS	_	8	nmod
12	than	than	IN	_	15	case
13	from	from	IN	_	15	case
14	either	either	CC	_	15	det
15	drug	drug	NN	_	8	nmod
16	alone	alone	RB	_	15	advmod
17	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	5	det
4	concurrent	concurrent	JJ	_	5	amod
5	administration	administration	NN	_	10	nsubj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	does	do	VBZ	_	10	aux
9	not	not	RB	_	10	neg
10	affect	affect	VB	_	1	dep
11	the	the	DT	_	12	det
12	bioavailability	bioavailability	NN	_	10	dobj
13	of	of	IN	_	14	case
14	drug3	drug3	NN	_	12	nmod
15	.	.	.	_	10	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concomitant	concomitant	JJ	_	4	amod
4	administration	administration	NN	_	12	nsubj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	drug3	drug3	NN	_	9	compound
9	s	s	NNS	_	6	conj
10	does	do	VBZ	_	12	aux
11	not	not	RB	_	12	neg
12	interfere	interfere	VB	_	1	dep
13	with	with	IN	_	14	case
14	absorption	absorption	NN	_	12	nmod
15	of	of	IN	_	16	case
16	drug4	drug4	NN	_	14	nmod
17	.	.	.	_	1	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	affect	affect	VB	_	0	ROOT
4	central	central	JJ	_	6	amod
5	nervous	nervous	JJ	_	6	amod
6	function	function	NN	_	3	dobj
7	.	.	.	_	3	punct

1	Therefore	therefore	RB	_	5	advmod
2	,	,	,	_	5	punct
3	interactions	interaction	NNS	_	5	nsubj
4	could	could	MD	_	5	aux
5	occur	occur	VB	_	0	ROOT
6	following	follow	VBG	_	8	case
7	concomitant	concomitant	JJ	_	8	amod
8	administration	administration	NN	_	5	nmod
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	-LRB-	-lrb-	-LRB-	_	14	punct
12	e.g.	e.g.	FW	_	14	dep
13	,	,	,	_	14	punct
14	drug2	drug2	NN	_	10	dep
15	,	,	,	_	14	punct
16	drug3	drug3	NN	_	14	conj
17	,	,	,	_	14	punct
18	drug4	drug4	NN	_	14	conj
19	,	,	,	_	14	punct
20	drug5	drug5	NN	_	14	conj
21	,	,	,	_	14	punct
22	drug6	drug6	NN	_	14	appos
23	-RRB-	-rrb-	-RRB-	_	14	punct
24	.	.	.	_	5	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	administration	administration	NN	_	42	nsubj
3	of	of	IN	_	4	case
4	drugs	drug	NNS	_	2	nmod
5	possessing	possess	VBG	_	4	acl
6	nephrotoxic	nephrotoxic	JJ	_	38	amod
7	-LRB-	-lrb-	-LRB-	_	10	punct
8	e.g.	e.g.	FW	_	10	dep
9	,	,	,	_	10	punct
10	drug1	drug1	NN	_	6	dep
11	,	,	,	_	10	punct
12	drug2	drug2	NN	_	10	appos
13	-RRB-	-rrb-	-RRB-	_	10	punct
14	,	,	,	_	6	punct
15	myelotoxic	myelotoxic	JJ	_	6	conj
16	-LRB-	-lrb-	-LRB-	_	20	punct
17	e.g.	e.g.	FW	_	20	dep
18	,	,	,	_	20	punct
19	drug3	drug3	NN	_	20	compound
20	chemotherapy	chemotherapy	NN	_	15	dep
21	-RRB-	-rrb-	-RRB-	_	20	punct
22	,	,	,	_	6	punct
23	cardiotoxic	cardiotoxic	JJ	_	6	conj
24	-LRB-	-lrb-	-LRB-	_	27	punct
25	e.g.	e.g.	FW	_	27	dep
26	,	,	,	_	27	punct
27	drug4	drug4	NN	_	23	dep
28	-RRB-	-rrb-	-RRB-	_	27	punct
29	or	or	CC	_	6	cc
30	hepatotoxic	hepatotoxic	JJ	_	6	conj
31	-LRB-	-lrb-	-LRB-	_	34	punct
32	e.g.	e.g.	FW	_	34	dep
33	,	,	,	_	34	punct
34	drug5	drug5	NN	_	38	dep
35	,	,	,	_	34	punct
36	drug6	drug6	NN	_	34	appos
37	-RRB-	-rrb-	-RRB-	_	34	punct
38	effects	effect	NNS	_	5	dobj
39	with	with	IN	_	40	case
40	drug7	drug7	NN	_	5	nmod
41	may	may	MD	_	42	aux
42	increase	increase	VB	_	0	ROOT
43	toxicity	toxicity	NN	_	42	dobj
44	in	in	IN	_	47	case
45	these	these	DT	_	47	det
46	organ	organ	NN	_	47	compound
47	systems	system	NNS	_	42	nmod
48	.	.	.	_	42	punct

1	The	the	DT	_	2	det
2	safety	safety	NN	_	15	nsubjpass
3	and	and	CC	_	2	cc
4	efficacy	efficacy	NN	_	2	conj
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	2	nmod
7	in	in	IN	_	8	case
8	combination	combination	NN	_	2	nmod
9	with	with	IN	_	11	case
10	any	any	DT	_	11	det
11	drug2	drug2	NN	_	8	nmod
12	have	have	VBP	_	15	aux
13	not	not	RB	_	15	neg
14	been	be	VBN	_	15	auxpass
15	established	establish	VBN	_	0	ROOT
16	.	.	.	_	15	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	14	nmod
3	,	,	,	_	14	punct
4	reduced	reduce	VBD	_	8	amod
5	kidney	kidney	NN	_	8	compound
6	and	and	CC	_	5	cc
7	liver	liver	NN	_	5	conj
8	function	function	NN	_	14	nsubj
9	secondary	secondary	JJ	_	8	amod
10	to	to	TO	_	12	case
11	drug1	drug1	NN	_	12	compound
12	treatment	treatment	NN	_	9	nmod
13	may	may	MD	_	14	aux
14	delay	delay	VB	_	0	ROOT
15	elimination	elimination	NN	_	14	dobj
16	of	of	IN	_	18	case
17	concomitant	concomitant	JJ	_	18	amod
18	medications	medication	NNS	_	15	nmod
19	and	and	CC	_	14	cc
20	increase	increase	VB	_	14	conj
21	the	the	DT	_	22	det
22	risk	risk	NN	_	20	dobj
23	of	of	IN	_	25	case
24	adverse	adverse	JJ	_	25	amod
25	events	event	NNS	_	22	nmod
26	from	from	IN	_	28	case
27	those	those	DT	_	28	det
28	drugs	drug	NNS	_	25	nmod
29	.	.	.	_	14	punct

1	Hypersensitivity	hypersensitivity	NN	_	2	compound
2	reactions	reaction	NNS	_	5	nsubjpass
3	have	have	VBP	_	5	aux
4	been	be	VBN	_	5	auxpass
5	reported	report	VBN	_	0	ROOT
6	in	in	IN	_	7	case
7	patients	patient	NNS	_	5	nmod
8	receiving	receive	VBG	_	7	acl
9	combination	combination	NN	_	10	compound
10	regimens	regimen	NNS	_	8	dobj
11	containing	contain	VBG	_	10	acl
12	sequential	sequential	JJ	_	15	amod
13	high	high	JJ	_	15	amod
14	dose	dose	NN	_	15	compound
15	drug1	drug1	NN	_	11	dobj
16	and	and	CC	_	15	cc
17	drug2	drug2	NN	_	15	conj
18	,	,	,	_	7	punct
19	specifically	specifically	RB	_	7	dep
20	,	,	,	_	19	punct
21	drug3	drug3	NN	_	20	root
22	,	,	,	_	21	punct
23	drug4	drug4	NN	_	22	root
24	,	,	,	_	23	punct
25	drug5	drug5	NN	_	23	conj
26	and	and	CC	_	23	cc
27	drug6	drug6	NN	_	23	conj
28	.	.	.	_	23	punct

1	These	these	DT	_	2	det
2	reactions	reaction	NNS	_	3	nsubj
3	consisted	consist	VBD	_	0	ROOT
4	of	of	IN	_	5	case
5	erythema	erythema	NN	_	3	nmod
6	,	,	,	_	5	punct
7	pruritus	pruritus	NN	_	5	conj
8	,	,	,	_	5	punct
9	and	and	CC	_	5	cc
10	hypotension	hypotension	NN	_	5	conj
11	and	and	CC	_	3	cc
12	occurred	occur	VBD	_	3	conj
13	within	within	IN	_	14	case
14	hours	hour	NNS	_	12	nmod
15	of	of	IN	_	16	case
16	administration	administration	NN	_	14	nmod
17	of	of	IN	_	18	case
18	chemotherapy	chemotherapy	NN	_	16	nmod
19	.	.	.	_	3	punct

1	These	these	DT	_	2	det
2	events	event	NNS	_	3	nsubj
3	required	require	VBN	_	0	ROOT
4	medical	medical	JJ	_	5	amod
5	intervention	intervention	NN	_	3	dobj
6	in	in	IN	_	8	case
7	some	some	DT	_	8	det
8	patients	patient	NNS	_	3	nmod
9	.	.	.	_	3	punct

1	Myocardial	myocardial	JJ	_	2	amod
2	injury	injury	NN	_	16	nsubj
3	,	,	,	_	2	punct
4	including	include	VBG	_	6	case
5	myocardial	myocardial	JJ	_	6	amod
6	infarction	infarction	NN	_	2	nmod
7	,	,	,	_	6	punct
8	myocarditis	myocarditis	NN	_	6	conj
9	,	,	,	_	6	punct
10	ventricular	ventricular	JJ	_	11	amod
11	hypokinesia	hypokinesia	NN	_	6	conj
12	,	,	,	_	6	punct
13	and	and	CC	_	6	cc
14	severe	severe	JJ	_	15	amod
15	rhabdomyolysis	rhabdomyolysis	NN	_	6	conj
16	appear	appear	VBP	_	0	ROOT
17	to	to	TO	_	19	mark
18	be	be	VB	_	19	auxpass
19	increased	increase	VBN	_	16	xcomp
20	in	in	IN	_	21	case
21	patients	patient	NNS	_	19	nmod
22	receiving	receive	VBG	_	21	acl
23	drug1	drug1	NN	_	22	dobj
24	and	and	CC	_	23	cc
25	drug2	drug2	NN	_	23	conj
26	concurrently	concurrently	RB	_	19	advmod
27	.	.	.	_	16	punct

1	Exacerbation	exacerbation	NN	_	16	nsubjpass
2	or	or	CC	_	1	cc
3	the	the	DT	_	5	det
4	initial	initial	JJ	_	5	amod
5	presentation	presentation	NN	_	1	conj
6	of	of	IN	_	8	case
7	a	a	DT	_	8	det
8	number	number	NN	_	5	nmod
9	of	of	IN	_	13	case
10	autoimmune	autoimmune	JJ	_	13	amod
11	and	and	CC	_	10	cc
12	inflammatory	inflammatory	JJ	_	10	conj
13	disorders	disorder	NNS	_	8	nmod
14	has	have	VBZ	_	16	aux
15	been	be	VBN	_	16	auxpass
16	observed	observe	VBN	_	0	ROOT
17	following	follow	VBG	_	19	case
18	concurrent	concurrent	JJ	_	19	amod
19	use	use	NN	_	16	nmod
20	of	of	IN	_	21	case
21	drug1	drug1	NN	_	19	nmod
22	and	and	CC	_	21	cc
23	drug2	drug2	NN	_	21	conj
24	,	,	,	_	19	punct
25	including	include	VBG	_	28	case
26	crescentic	crescentic	JJ	_	28	amod
27	IgA	iga	NN	_	28	compound
28	glomerulonephritis	glomerulonephritis	NN	_	19	nmod
29	,	,	,	_	28	punct
30	oculo-bulbar	oculo-bulbar	JJ	_	32	amod
31	myasthenia	myasthenia	NN	_	32	compound
32	gravis	gravis	NN	_	28	conj
33	,	,	,	_	28	punct
34	inflammatory	inflammatory	JJ	_	35	amod
35	arthritis	arthritis	NN	_	28	conj
36	,	,	,	_	28	punct
37	thyroiditis	thyroiditis	NN	_	28	conj
38	,	,	,	_	28	punct
39	bullous	bullous	JJ	_	40	amod
40	pemphigoid	pemphigoid	NN	_	28	conj
41	,	,	,	_	28	punct
42	and	and	CC	_	28	cc
43	Stevens-Johnson	stevens-johnson	NN	_	44	compound
44	syndrome	syndrome	NN	_	28	conj
45	.	.	.	_	16	punct

1	Although	although	IN	_	5	mark
2	drug1	drug1	NN	_	5	nsubjpass
3	have	have	VBP	_	5	aux
4	been	be	VBN	_	5	auxpass
5	shown	show	VBN	_	0	ROOT
6	to	to	TO	_	7	mark
7	reduce	reduce	VB	_	5	xcomp
8	drug2	drug2	NN	_	7	dobj
9	-	-	:	_	8	punct
10	induced	induce	VBN	_	12	amod
11	side	side	JJ	_	12	amod
12	effects	effect	NNS	_	34	nsubj
13	including	include	VBG	_	14	case
14	fever	fever	NN	_	12	nmod
15	,	,	,	_	14	punct
16	renal	renal	JJ	_	17	amod
17	insufficiency	insufficiency	NN	_	14	conj
18	,	,	,	_	14	punct
19	hyperbilirubinemia	hyperbilirubinemia	NN	_	14	conj
20	,	,	,	_	14	punct
21	confusion	confusion	NN	_	14	conj
22	,	,	,	_	14	punct
23	and	and	CC	_	14	cc
24	dyspnea	dyspnea	NN	_	14	conj
25	,	,	,	_	12	punct
26	concomitant	concomitant	JJ	_	27	amod
27	administration	administration	NN	_	12	appos
28	of	of	IN	_	30	case
29	these	these	DT	_	30	det
30	agents	agent	NNS	_	27	nmod
31	with	with	IN	_	32	case
32	drug3	drug3	NN	_	27	nmod
33	may	may	MD	_	34	aux
34	reduce	reduce	VB	_	8	dep
35	the	the	DT	_	37	det
36	antitumor	antitumor	NN	_	37	compound
37	effectiveness	effectiveness	NN	_	34	dobj
38	of	of	IN	_	39	case
39	drug4	drug4	NN	_	37	nmod
40	and	and	CC	_	34	cc
41	thus	thus	RB	_	34	advmod
42	should	should	MD	_	44	aux
43	be	be	VB	_	44	auxpass
44	avoided	avoid	VBN	_	34	dep
45	.	.	.	_	44	punct
46	12	12	CD	_	47	nummod
47	drug5	drug5	NN	_	52	nsubj
48	and	and	CC	_	47	cc
49	other	other	JJ	_	50	amod
50	drug6	drug6	NN	_	47	conj
51	may	may	MD	_	52	aux
52	potentiate	potentiate	VB	_	44	parataxis
53	the	the	DT	_	54	det
54	hypotension	hypotension	NN	_	52	dobj
55	seen	see	VBN	_	54	acl
56	with	with	IN	_	57	case
57	drug7	drug7	NN	_	55	nmod
58	.	.	.	_	5	punct

1	Delayed	delay	VBN	_	3	amod
2	Adverse	adverse	JJ	_	3	amod
3	Reactions	reaction	NNS	_	0	ROOT
4	to	to	TO	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	:	:	:	_	3	punct
7	A	a	DT	_	8	det
8	review	review	NN	_	12	nsubj
9	of	of	IN	_	11	case
10	the	the	DT	_	11	det
11	literature	literature	NN	_	8	nmod
12	revealed	reveal	VBD	_	3	dep
13	that	that	IN	_	35	mark
14	12.6	12.6	CD	_	15	nummod
15	%	%	NN	_	35	nsubj
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	range	range	NN	_	15	dep
18	11-28	11-28	CD	_	19	nummod
19	%	%	NN	_	17	dep
20	-RRB-	-rrb-	-RRB-	_	17	punct
21	of	of	IN	_	23	case
22	501	501	CD	_	23	nummod
23	patients	patient	NNS	_	15	nmod
24	treated	treat	VBN	_	23	acl
25	with	with	IN	_	27	case
26	various	various	JJ	_	27	amod
27	drug2	drug2	NN	_	24	nmod
28	containing	contain	VBG	_	27	acl
29	regimens	regimen	NNS	_	28	dobj
30	who	who	WP	_	33	nsubjpass
31	were	be	VBD	_	33	auxpass
32	subsequently	subsequently	RB	_	33	advmod
33	administered	administer	VBN	_	29	acl:relcl
34	drug3	drug3	NN	_	33	dobj
35	experienced	experience	VBD	_	12	ccomp
36	acute	acute	JJ	_	40	amod
37	,	,	,	_	36	punct
38	atypical	atypical	JJ	_	36	dep
39	adverse	adverse	JJ	_	40	amod
40	reactions	reaction	NNS	_	35	dobj
41	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	onset	onset	NN	_	6	nsubj
3	of	of	IN	_	4	case
4	symptoms	symptom	NNS	_	2	nmod
5	usually	usually	RB	_	6	advmod
6	occurred	occur	VBD	_	0	ROOT
7	within	within	IN	_	8	case
8	hours	hour	NNS	_	6	nmod
9	-LRB-	-lrb-	-LRB-	_	11	punct
10	most	most	RBS	_	11	advmod
11	commonly	commonly	RB	_	8	dep
12	1	1	CD	_	14	compound
13	to	to	TO	_	14	dep
14	4	4	CD	_	15	nummod
15	hours	hour	NNS	_	11	nmod:npmod
16	-RRB-	-rrb-	-RRB-	_	11	punct
17	following	follow	VBG	_	19	case
18	the	the	DT	_	19	det
19	administration	administration	NN	_	6	nmod
20	of	of	IN	_	22	case
21	contrast	contrast	NN	_	22	compound
22	media	media	NNS	_	19	nmod
23	.	.	.	_	6	punct

1	These	these	DT	_	2	det
2	reactions	reaction	NNS	_	3	nsubj
3	include	include	VBP	_	0	ROOT
4	fever	fever	NN	_	3	dobj
5	,	,	,	_	4	punct
6	chills	chill	NNS	_	4	conj
7	,	,	,	_	4	punct
8	nausea	nausea	NN	_	4	conj
9	,	,	,	_	4	punct
10	vomiting	vomit	VBG	_	4	conj
11	,	,	,	_	4	punct
12	pruritus	pruritus	NN	_	4	conj
13	,	,	,	_	4	punct
14	rash	rash	NN	_	4	conj
15	,	,	,	_	4	punct
16	diarrhea	diarrhea	NN	_	4	conj
17	,	,	,	_	4	punct
18	hypotension	hypotension	NN	_	4	conj
19	,	,	,	_	4	punct
20	edema	edema	NN	_	4	conj
21	,	,	,	_	4	punct
22	and	and	CC	_	4	cc
23	oliguria	oliguria	NN	_	4	conj
24	.	.	.	_	3	punct

1	Some	some	DT	_	2	det
2	clinicians	clinician	NNS	_	4	nsubj
3	have	have	VBP	_	4	aux
4	noted	note	VBN	_	0	ROOT
5	that	that	IN	_	8	mark
6	these	these	DT	_	7	det
7	reactions	reaction	NNS	_	8	nsubj
8	resemble	resemble	VBP	_	4	ccomp
9	the	the	DT	_	12	det
10	immediate	immediate	JJ	_	12	amod
11	side	side	JJ	_	12	amod
12	effects	effect	NNS	_	8	dobj
13	caused	cause	VBN	_	12	acl
14	by	by	IN	_	16	case
15	drug1	drug1	NN	_	16	compound
16	administration	administration	NN	_	13	nmod
17	,	,	,	_	8	punct
18	however	however	RB	_	28	advmod
19	the	the	DT	_	20	det
20	cause	cause	NN	_	28	nsubj
21	of	of	IN	_	23	case
22	contrast	contrast	NN	_	23	compound
23	reactions	reaction	NNS	_	20	nmod
24	after	after	IN	_	26	case
25	interleukin-2	interleukin-2	NN	_	26	compound
26	therapy	therapy	NN	_	20	nmod
27	is	be	VBZ	_	28	cop
28	unknown	unknown	JJ	_	8	parataxis
29	.	.	.	_	4	punct

1	Most	most	JJS	_	2	amod
2	events	event	NNS	_	4	nsubjpass
3	were	be	VBD	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	occur	occur	VB	_	4	xcomp
7	when	when	WRB	_	11	advmod
8	contrast	contrast	NN	_	9	compound
9	media	media	NNS	_	11	nsubjpass
10	was	be	VBD	_	11	auxpass
11	given	give	VBN	_	6	advcl
12	within	within	IN	_	14	case
13	4	4	CD	_	14	nummod
14	weeks	week	NNS	_	11	nmod
15	after	after	IN	_	18	case
16	the	the	DT	_	18	det
17	last	last	JJ	_	18	amod
18	dose	dose	NN	_	14	nmod
19	of	of	IN	_	20	case
20	drug1	drug1	NN	_	18	nmod
21	.	.	.	_	4	punct

1	These	these	DT	_	2	det
2	events	event	NNS	_	5	nsubjpass
3	were	be	VBD	_	5	auxpass
4	also	also	RB	_	5	advmod
5	reported	report	VBN	_	0	ROOT
6	to	to	TO	_	7	mark
7	occur	occur	VB	_	5	xcomp
8	when	when	WRB	_	12	advmod
9	contrast	contrast	NN	_	10	compound
10	media	media	NNS	_	12	nsubjpass
11	was	be	VBD	_	12	auxpass
12	given	give	VBN	_	7	advcl
13	several	several	JJ	_	14	amod
14	months	month	NNS	_	12	dobj
15	after	after	IN	_	17	case
16	drug1	drug1	NN	_	17	compound
17	treatment	treatment	NN	_	14	nmod
18	.	.	.	_	5	punct

1	Drugs	drug	NNS	_	0	ROOT
2	that	that	WDT	_	4	nsubj
3	may	may	MD	_	4	aux
4	alter	alter	VB	_	1	acl:relcl
5	drug1	drug1	NN	_	7	compound
6	plasma	plasma	NN	_	7	compound
7	concentrations	concentration	NNS	_	8	compound
8	Drugs	drug	NNS	_	4	dobj
9	that	that	WDT	_	11	nsubj
10	may	may	MD	_	11	aux
11	increase	increase	VB	_	8	acl:relcl
12	drug2	drug2	NN	_	14	compound
13	plasma	plasma	NN	_	14	compound
14	concentrations	concentration	NNS	_	11	dobj
15	:	:	:	_	1	punct
16	Caution	caution	NN	_	18	nsubjpass
17	is	be	VBZ	_	18	auxpass
18	recommended	recommend	VBN	_	1	dep
19	when	when	WRB	_	20	advmod
20	administering	administer	VBG	_	18	advcl
21	drug3	drug3	NN	_	20	dobj
22	with	with	IN	_	23	case
23	inhibitors	inhibitor	NNS	_	20	nmod
24	of	of	IN	_	27	case
25	the	the	DT	_	27	det
26	CYP3A4	cyp3a4	NN	_	27	compound
27	family	family	NN	_	23	nmod
28	-LRB-	-lrb-	-LRB-	_	31	punct
29	e.g.	e.g.	FW	_	31	dep
30	,	,	,	_	31	punct
31	drug4	drug4	NN	_	23	dep
32	,	,	,	_	31	punct
33	drug5	drug5	NN	_	31	conj
34	,	,	,	_	31	punct
35	drug6	drug6	NN	_	31	conj
36	,	,	,	_	31	punct
37	drug7	drug7	NN	_	31	appos
38	-RRB-	-rrb-	-RRB-	_	31	punct
39	.	.	.	_	1	punct

1	Substances	substance	NNS	_	13	nsubj
2	that	that	WDT	_	3	nsubj
3	inhibit	inhibit	VBP	_	1	acl:relcl
4	the	the	DT	_	7	det
5	cytochrome	cytochrome	NN	_	7	compound
6	P450	p450	NN	_	7	compound
7	isoenzyme	isoenzyme	NN	_	11	compound
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	CYP3A4	cyp3a4	NN	_	7	appos
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	activity	activity	NN	_	3	dobj
12	may	may	MD	_	13	aux
13	decrease	decrease	VB	_	0	ROOT
14	metabolism	metabolism	NN	_	18	compound
15	and	and	CC	_	14	cc
16	increase	increase	NN	_	14	conj
17	drug1	drug1	NN	_	18	compound
18	concentrations	concentration	NNS	_	13	dobj
19	.	.	.	_	13	punct

1	There	there	EX	_	2	expl
2	is	be	VBZ	_	0	ROOT
3	a	a	DT	_	5	det
4	significant	significant	JJ	_	5	amod
5	increase	increase	NN	_	2	nsubj
6	in	in	IN	_	7	case
7	exposure	exposure	NN	_	5	nmod
8	to	to	TO	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	when	when	WRB	_	13	advmod
11	drug2	drug2	NN	_	13	nsubjpass
12	is	be	VBZ	_	13	auxpass
13	coadministered	coadminister	VBN	_	2	advcl
14	with	with	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	-LRB-	-lrb-	-LRB-	_	18	punct
17	CYP3A4	cyp3a4	NN	_	18	compound
18	inhibitor	inhibitor	NN	_	15	appos
19	-RRB-	-rrb-	-RRB-	_	18	punct
20	.	.	.	_	2	punct

1	Drugs	drug	NNS	_	0	ROOT
2	that	that	WDT	_	4	nsubj
3	may	may	MD	_	4	aux
4	decrease	decrease	VB	_	1	acl:relcl
5	drug1	drug1	NN	_	7	compound
6	plasma	plasma	NN	_	7	compound
7	concentrations	concentration	NNS	_	4	dobj
8	:	:	:	_	1	punct
9	Substances	substance	NNS	_	17	nsubj
10	that	that	WDT	_	12	nsubj
11	are	be	VBP	_	12	cop
12	inducers	inducer	NNS	_	9	acl:relcl
13	of	of	IN	_	15	case
14	CYP3A4	cyp3a4	NN	_	15	compound
15	activity	activity	NN	_	12	nmod
16	may	may	MD	_	17	aux
17	increase	increase	VB	_	1	dep
18	metabolism	metabolism	NN	_	17	dobj
19	and	and	CC	_	17	cc
20	decrease	decrease	VB	_	17	conj
21	drug2	drug2	NN	_	23	compound
22	plasma	plasma	NN	_	23	compound
23	concentrations	concentration	NNS	_	20	dobj
24	.	.	.	_	1	punct

1	Co-medications	co-medication	NNS	_	0	ROOT
2	that	that	WDT	_	3	nsubj
3	induce	induce	VBP	_	1	acl:relcl
4	CYP3A4	cyp3a4	NN	_	3	dobj
5	-LRB-	-lrb-	-LRB-	_	8	punct
6	e.g.	e.g.	FW	_	8	dep
7	,	,	,	_	8	punct
8	drug1	drug1	NN	_	1	dep
9	,	,	,	_	8	punct
10	drug2	drug2	NN	_	8	conj
11	,	,	,	_	8	punct
12	drug3	drug3	NN	_	8	conj
13	,	,	,	_	8	punct
14	drug4	drug4	NN	_	8	conj
15	,	,	,	_	8	punct
16	drug5	drug5	NN	_	8	conj
17	or	or	CC	_	8	cc
18	St.	St.	NNP	_	8	conj

1	Johns	Johns	NNP	_	2	compound
2	Wort	Wort	NNP	_	6	nsubj
3	-RRB-	-rrb-	-RRB-	_	2	punct
4	may	may	MD	_	6	aux
5	significantly	significantly	RB	_	6	advmod
6	reduce	reduce	VB	_	0	ROOT
7	exposure	exposure	NN	_	6	dobj
8	to	to	TO	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	.	.	.	_	6	punct

1	Pretreatment	pretreatment	NN	_	10	nsubj
2	of	of	IN	_	4	case
3	healthy	healthy	JJ	_	4	amod
4	volunteers	volunteer	NNS	_	1	nmod
5	with	with	IN	_	7	case
6	multiple	multiple	JJ	_	7	amod
7	doses	dose	NNS	_	1	nmod
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	followed	follow	VBN	_	0	ROOT
11	by	by	IN	_	14	case
12	a	a	DT	_	14	det
13	single	single	JJ	_	14	amod
14	dose	dose	NN	_	10	nmod
15	of	of	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	,	,	,	_	10	punct
18	increased	increase	VBD	_	21	amod
19	drug3	drug3	NN	_	21	compound
20	oral-dose	oral-dose	JJ	_	21	amod
21	clearance	clearance	NN	_	17	root
22	by	by	IN	_	23	case
23	3.8-fold	3.8-fold	JJ	_	21	nmod
24	,	,	,	_	23	punct
25	which	which	WDT	_	31	nsubj
26	significantly	significantly	RB	_	31	advmod
27	-LRB-	-lrb-	-LRB-	_	28	punct
28	p	p	NN	_	26	dep
29	0.05	0.05	CD	_	28	nummod
30	-RRB-	-rrb-	-RRB-	_	28	punct
31	decreased	decrease	VBD	_	23	acl:relcl
32	mean	mean	NN	_	31	dobj
33	cmax	cmax	NN	_	32	dep
34	and	and	CC	_	33	cc
35	AUC	auc	NN	_	33	conj
36	-LRB-	-lrb-	-LRB-	_	37	punct
37	0-8	0-8	CD	_	35	appos
38	-RRB-	-rrb-	-RRB-	_	37	punct
39	.	.	.	_	21	punct

1	In	in	IN	_	2	case
2	patients	patient	NNS	_	22	nmod
3	where	where	WRB	_	10	advmod
4	drug1	drug1	NN	_	10	nsubjpass
5	or	or	CC	_	4	cc
6	other	other	JJ	_	8	amod
7	CYP3A4	cyp3a4	NN	_	8	compound
8	inducers	inducer	NNS	_	4	conj
9	are	be	VBP	_	10	auxpass
10	indicated	indicate	VBN	_	2	acl:relcl
11	,	,	,	_	22	punct
12	alternative	alternative	JJ	_	14	amod
13	therapeutic	therapeutic	JJ	_	14	amod
14	agents	agent	NNS	_	22	nsubjpass
15	with	with	IN	_	19	case
16	less	less	JJR	_	19	amod
17	enzyme	enzyme	NN	_	19	compound
18	induction	induction	NN	_	19	compound
19	potential	potential	NN	_	14	nmod
20	should	should	MD	_	22	aux
21	be	be	VB	_	22	auxpass
22	considered	consider	VBN	_	0	ROOT
23	.	.	.	_	22	punct

1	Drugs	drug	NNS	_	12	nsubj
2	that	that	WDT	_	4	nsubj
3	may	may	MD	_	4	aux
4	have	have	VB	_	1	acl:relcl
5	their	they	PRP$	_	7	nmod:poss
6	plasma	plasma	NN	_	7	compound
7	concentration	concentration	NN	_	4	dobj
8	altered	alter	VBN	_	7	acl
9	by	by	IN	_	11	case
10	drug1	drug1	NN	_	11	compound
11	drug2	drug2	NN	_	8	nmod
12	increases	increase	VBZ	_	0	ROOT
13	the	the	DT	_	15	det
14	mean	mean	NN	_	15	compound
15	cmax	cmax	NN	_	12	dobj
16	and	and	CC	_	15	cc
17	AUC	auc	NN	_	15	conj
18	of	of	IN	_	19	case
19	drug3	drug3	NN	_	15	nmod
20	-LRB-	-lrb-	-LRB-	_	22	punct
21	CYP3A4	cyp3a4	NN	_	22	compound
22	substrate	substrate	NN	_	19	appos
23	-RRB-	-rrb-	-RRB-	_	22	punct
24	2	2	LS	_	15	dep
25	-	-	:	_	24	punct
26	and	and	CC	_	24	cc
27	3.5-fold	3.5-fold	RB	_	24	conj
28	,	,	,	_	27	punct
29	respectively	respectively	RB	_	28	root
30	,	,	,	_	29	punct
31	suggesting	suggest	VBG	_	30	root
32	an	a	DT	_	33	det
33	inhibition	inhibition	NN	_	31	dobj
34	of	of	IN	_	36	case
35	the	the	DT	_	36	det
36	CYP3A4	cyp3a4	NN	_	33	nmod
37	by	by	IN	_	38	case
38	drug4	drug4	NN	_	33	nmod
39	.	.	.	_	31	punct

1	Particular	particular	JJ	_	2	amod
2	caution	caution	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	recommended	recommend	VBN	_	0	ROOT
5	when	when	WRB	_	6	advmod
6	administering	administer	VBG	_	4	advcl
7	drug1	drug1	NN	_	6	dobj
8	with	with	IN	_	10	case
9	CYP3A4	cyp3a4	NN	_	10	compound
10	substrates	substrate	NNS	_	6	nmod
11	that	that	WDT	_	12	nsubj
12	have	have	VBP	_	10	acl:relcl
13	a	a	DT	_	16	det
14	narrow	narrow	JJ	_	16	amod
15	therapeutic	therapeutic	JJ	_	16	amod
16	window	window	NN	_	12	dobj
17	-LRB-	-lrb-	-LRB-	_	20	punct
18	e.g.	e.g.	FW	_	20	dep
19	,	,	,	_	20	punct
20	drug2	drug2	NN	_	4	dep
21	or	or	CC	_	20	cc
22	drug3	drug3	NN	_	20	conj
23	-RRB-	-rrb-	-RRB-	_	20	punct
24	.	.	.	_	4	punct

1	drug1	drug1	NN	_	3	nsubj
2	will	will	MD	_	3	aux
3	increase	increase	VB	_	0	ROOT
4	plasmaconcentration	plasmaconcentration	NN	_	3	dobj
5	of	of	IN	_	9	case
6	other	other	JJ	_	9	amod
7	CYP3A4	cyp3a4	NN	_	9	compound
8	metabolized	metabolize	VBN	_	9	amod
9	drugs	drug	NNS	_	4	nmod
10	-LRB-	-lrb-	-LRB-	_	13	punct
11	e.g.	e.g.	FW	_	13	advmod
12	,	,	,	_	13	punct
13	triazolo	triazolo	NN	_	9	dep
14	-	-	:	_	13	punct
15	drug2	drug2	NN	_	13	dep
16	,	,	,	_	13	punct
17	drug3	drug3	NN	_	13	conj
18	,	,	,	_	13	punct
19	certain	certain	JJ	_	20	amod
20	drug4	drug4	NN	_	13	conj
21	,	,	,	_	13	punct
22	etc.	etc.	FW	_	13	dep
23	-RRB-	-rrb-	-RRB-	_	13	punct
24	.	.	.	_	3	punct

1	Because	because	IN	_	4	mark
2	drug1	drug1	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	metabolized	metabolize	VBN	_	15	advcl
5	by	by	IN	_	6	case
6	CYP2C9	cyp2c9	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	CYP3A4	cyp3a4	NN	_	6	conj
9	,	,	,	_	15	punct
10	patients	patient	NNS	_	15	nsubj
11	who	who	WP	_	12	nsubj
12	require	require	VBP	_	10	acl:relcl
13	anticoagulation	anticoagulation	NN	_	12	dobj
14	should	should	MD	_	15	aux
15	receive	receive	VB	_	0	ROOT
16	low-molecular	low-molecular	JJ	_	17	amod
17	weight	weight	NN	_	15	dobj
18	or	or	CC	_	17	cc
19	standard	standard	JJ	_	20	amod
20	drug2	drug2	NN	_	17	conj
21	.	.	.	_	15	punct

1	in	in	FW	_	2	compound
2	vitro	vitro	FW	_	5	advmod
3	,	,	,	_	5	punct
4	drug1	drug1	NN	_	5	nsubj
5	inhibits	inhibit	VBZ	_	0	ROOT
6	the	the	DT	_	11	det
7	cytochrome	cytochrome	NN	_	11	compound
8	P450	p450	NN	_	11	compound
9	isoenzyme	isoenzyme	NN	_	11	compound
10	CYP2D6	cyp2d6	NN	_	11	compound
11	activity	activity	NN	_	5	dobj
12	at	at	IN	_	14	case
13	similar	similar	JJ	_	14	amod
14	concentrations	concentration	NNS	_	5	nmod
15	that	that	WDT	_	16	nsubj
16	affect	affect	VBP	_	14	acl:relcl
17	CYP3A4	cyp3a4	NN	_	18	compound
18	activity	activity	NN	_	16	dobj
19	.	.	.	_	5	punct

1	Systemic	systemic	JJ	_	2	amod
2	exposure	exposure	NN	_	8	nsubjpass
3	to	to	TO	_	4	case
4	substrates	substrate	NNS	_	2	nmod
5	of	of	IN	_	6	case
6	CYP2D6	cyp2d6	NN	_	4	nmod
7	is	be	VBZ	_	8	auxpass
8	expected	expect	VBN	_	0	ROOT
9	to	to	TO	_	11	mark
10	be	be	VB	_	11	auxpass
11	increased	increase	VBN	_	8	xcomp
12	when	when	WRB	_	13	advmod
13	coadministered	coadminister	VBN	_	11	advcl
14	with	with	IN	_	15	case
15	Gleevec	gleevec	NN	_	13	nmod
16	.	.	.	_	8	punct

1	No	no	DT	_	3	neg
2	specific	specific	JJ	_	3	amod
3	studies	study	NNS	_	6	nsubjpass
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	auxpass
6	performed	perform	VBN	_	0	ROOT
7	and	and	CC	_	6	cc
8	caution	caution	NN	_	10	nsubjpass
9	is	be	VBZ	_	10	auxpass
10	recommended	recommend	VBN	_	6	conj
11	.	.	.	_	6	punct

1	in	in	FW	_	2	compound
2	vitro	vitro	FW	_	5	advmod
3	,	,	,	_	5	punct
4	drug1	drug1	NN	_	5	nsubj
5	inhibits	inhibit	VBZ	_	0	ROOT
6	acetaminophen	acetaminophen	NN	_	7	compound
7	O-glucuronidation	o-glucuronidation	NN	_	5	dobj
8	-LRB-	-lrb-	-LRB-	_	10	punct
9	Ki	ki	NN	_	10	compound
10	value	value	NN	_	7	dep
11	of	of	IN	_	13	case
12	58.5	58.5	CD	_	13	nummod
13	M	m	NN	_	10	nmod
14	-RRB-	-rrb-	-RRB-	_	10	punct
15	at	at	IN	_	17	case
16	therapeutic	therapeutic	JJ	_	17	amod
17	levels	level	NNS	_	5	nmod
18	.	.	.	_	5	punct

1	Systemic	systemic	JJ	_	2	amod
2	exposure	exposure	NN	_	6	nsubjpass
3	to	to	TO	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	is	be	VBZ	_	6	auxpass
6	expected	expect	VBN	_	0	ROOT
7	to	to	TO	_	9	mark
8	be	be	VB	_	9	auxpass
9	increased	increase	VBN	_	6	xcomp
10	when	when	WRB	_	11	advmod
11	coadministered	coadminister	VBN	_	9	advcl
12	with	with	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	.	.	.	_	6	punct

1	No	no	DT	_	3	neg
2	specific	specific	JJ	_	3	amod
3	studies	study	NNS	_	8	nsubjpass
4	in	in	IN	_	5	case
5	humans	human	NNS	_	3	nmod
6	have	have	VBP	_	8	aux
7	been	be	VBN	_	8	auxpass
8	performed	perform	VBN	_	0	ROOT
9	and	and	CC	_	8	cc
10	caution	caution	NN	_	12	nsubjpass
11	is	be	VBZ	_	12	auxpass
12	recommended	recommend	VBN	_	8	conj
13	.	.	.	_	8	punct

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	Careful	careful	JJ	_	2	amod
2	observation	observation	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	required	require	VBN	_	0	ROOT
5	when	when	WRB	_	8	advmod
6	drug1	drug1	NN	_	8	nsubjpass
7	is	be	VBZ	_	8	auxpass
8	administered	administer	VBN	_	4	advcl
9	concurrently	concurrently	RB	_	8	advmod
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	8	nmod
12	.	.	.	_	4	punct

1	Coadministration	coadministration	NN	_	6	nsubjpass
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	has	have	VBZ	_	6	aux
5	been	be	VBN	_	6	auxpass
6	reported	report	VBN	_	0	ROOT
7	to	to	TO	_	8	mark
8	worsen	worsen	VB	_	6	xcomp
9	the	the	DT	_	10	det
10	tremor	tremor	NN	_	8	dobj
11	in	in	IN	_	13	case
12	elderly	elderly	JJ	_	13	amod
13	patients	patient	NNS	_	10	nmod
14	with	with	IN	_	16	case
15	Parkinsons	Parkinsons	NNPS	_	16	compound
16	disease	disease	NN	_	13	nmod
17	;	;	:	_	6	punct

1	however	however	RB	_	6	advmod
2	,	,	,	_	6	punct
3	it	it	PRP	_	6	nsubjpass
4	is	be	VBZ	_	6	auxpass
5	not	not	RB	_	6	neg
6	known	know	VBN	_	0	ROOT
7	if	if	IN	_	10	mark
8	other	other	JJ	_	9	amod
9	drug1	drug1	NN	_	10	nsubj
10	produce	produce	VBP	_	6	advcl
11	a	a	DT	_	13	det
12	similar	similar	JJ	_	13	amod
13	response	response	NN	_	10	dobj
14	.	.	.	_	6	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	use	use	NN	_	7	nsubj
3	with	with	IN	_	5	case
4	drug1	drug1	NN	_	5	compound
5	s	s	NNS	_	2	nmod
6	may	may	MD	_	7	aux
7	result	result	VB	_	0	ROOT
8	in	in	IN	_	11	case
9	the	the	DT	_	11	det
10	reduced	reduce	VBN	_	11	amod
11	absorption	absorption	NN	_	7	nmod
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	.	.	.	_	7	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	5	nsubj
4	have	have	VBP	_	5	aux
5	shown	show	VBN	_	0	ROOT
6	that	that	IN	_	8	mark
7	precipitation	precipitation	NN	_	8	nsubj
8	occurs	occur	VBZ	_	5	ccomp
9	when	when	WRB	_	11	advmod
10	eye	eye	NN	_	11	nsubj
11	drops	drop	VBZ	_	8	advcl
12	containing	contain	VBG	_	11	xcomp
13	drug1	drug1	NN	_	12	dobj
14	are	be	VBP	_	15	auxpass
15	mixed	mix	VBN	_	5	dep
16	with	with	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	.	.	.	_	5	punct

1	If	if	IN	_	5	mark
2	such	such	JJ	_	3	amod
3	drugs	drug	NNS	_	5	nsubjpass
4	are	be	VBP	_	5	auxpass
5	used	use	VBN	_	9	advcl
6	they	they	PRP	_	9	nsubjpass
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	administered	administer	VBN	_	0	ROOT
10	with	with	IN	_	12	case
11	an	a	DT	_	12	det
12	interval	interval	NN	_	9	nmod
13	of	of	IN	_	17	case
14	at	at	IN	_	15	case
15	least	least	JJS	_	16	nmod:npmod
16	5	5	CD	_	17	nummod
17	minutes	minute	NNS	_	12	nmod
18	between	between	IN	_	19	case
19	applications	application	NNS	_	17	nmod
20	.	.	.	_	9	punct

1	The	the	DT	_	4	det
2	following	follow	VBG	_	4	amod
3	drug	drug	NN	_	4	compound
4	interactions	interaction	NNS	_	7	nsubjpass
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	reported	report	VBN	_	0	ROOT
8	with	with	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	.	.	.	_	7	punct

1	Drug	drug	NN	_	2	compound
2	Effect	effect	NN	_	0	ROOT

1	drug1	drug1	NN	_	3	compound
2	Prolonged	prolonged	JJ	_	3	amod
3	action	action	NN	_	0	ROOT
4	of	of	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod

1	drug1	drug1	NN	_	2	compound
2	Hypotension	hypotension	NN	_	0	ROOT

1	drug1	drug1	NN	_	3	compound
2	drug2	drug2	NN	_	3	compound
3	antagonism	antagonism	NN	_	0	ROOT

1	drug1	drug1	NN	_	2	nsubj
2	Decreased	decrease	VBD	_	0	ROOT
3	antinociceptive	antinociceptive	JJ	_	4	amod
4	action	action	NN	_	2	dobj

1	drug1	drug1	NN	_	3	compound
2	drug2	drug2	NN	_	3	compound
3	antagonism	antagonism	NN	_	0	ROOT

1	drug1	drug1	NN	_	2	compound
2	Synergism	synergism	NN	_	0	ROOT

1	CNS	cns	NN	_	2	compound
2	depression	depression	NN	_	9	nsubj
3	producing	produce	VBG	_	2	acl
4	medications	medication	NNS	_	7	compound
5	-	-	:	_	7	punct
6	concurrent	concurrent	JJ	_	7	amod
7	use	use	NN	_	3	dobj
8	may	may	MD	_	9	aux
9	potentiate	potentiate	VB	_	0	ROOT
10	the	the	DT	_	11	det
11	effects	effect	NNS	_	9	dobj
12	of	of	IN	_	15	case
13	either	either	CC	_	15	cc:preconj
14	these	these	DT	_	15	det
15	medications	medication	NNS	_	11	nmod
16	or	or	CC	_	15	cc
17	drug1	drug1	NN	_	15	conj
18	;	;	:	_	9	punct

1	drug1	drug1	NN	_	0	ROOT
2	or	or	CC	_	1	cc
3	other	other	JJ	_	4	amod
4	medications	medication	NNS	_	1	conj
5	with	with	IN	_	7	case
6	anticholinergic	anticholinergic	JJ	_	7	amod
7	activity	activity	NN	_	1	nmod
8	-	-	:	_	1	punct
9	anticholinergic	anticholinergic	JJ	_	10	amod
10	effects	effect	NNS	_	13	nsubjpass
11	may	may	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	potentiated	potentiate	VBN	_	1	dep
14	when	when	WRB	_	18	advmod
15	these	these	DT	_	16	det
16	medications	medication	NNS	_	18	nsubjpass
17	are	be	VBP	_	18	auxpass
18	used	use	VBN	_	13	advcl
19	concurrently	concurrently	RB	_	18	advmod
20	with	with	IN	_	21	case
21	drug2	drug2	NN	_	18	nmod
22	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	-	-	:	_	1	punct
3	prior	prior	RB	_	4	advmod
4	ingestion	ingestion	NN	_	8	nsubj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	may	may	MD	_	8	aux
8	decrease	decrease	VB	_	1	dep
9	the	the	DT	_	11	det
10	drug3	drug3	NN	_	11	compound
11	response	response	NN	_	8	dobj
12	to	to	TO	_	13	case
13	drug4	drug4	NN	_	11	nmod
14	in	in	IN	_	16	case
15	the	the	DT	_	16	det
16	treatment	treatment	NN	_	8	nmod
17	of	of	IN	_	18	case
18	poisoning	poisoning	NN	_	16	nmod
19	.	.	.	_	1	punct

1	Nephrotoxicity	nephrotoxicity	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	following	follow	VBG	_	7	case
6	concomitant	concomitant	JJ	_	7	amod
7	administration	administration	NN	_	4	nmod
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	drug2	drug2	NN	_	9	conj
12	.	.	.	_	4	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	5	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	doubled	double	VBD	_	0	ROOT
6	the	the	DT	_	7	det
7	AUC	auc	NN	_	5	dobj
8	for	for	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	.	.	.	_	5	punct

1	The	the	DT	_	2	det
2	bioavailability	bioavailability	NN	_	11	nsubjpass
3	of	of	IN	_	6	case
4	the	the	DT	_	6	det
5	capsule	capsule	NN	_	6	compound
6	formulation	formulation	NN	_	2	nmod
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	was	be	VBD	_	11	auxpass
10	not	not	RB	_	11	neg
11	affected	affect	VBN	_	0	ROOT
12	when	when	WRB	_	13	advmod
13	administered	administer	VBN	_	11	advcl
14	5	5	CD	_	15	nummod
15	minutes	minute	NNS	_	13	dobj
16	following	follow	VBG	_	18	case
17	an	a	DT	_	18	det
18	drug2	drug2	NN	_	13	nmod
19	.	.	.	_	11	punct

1	Nephrotoxicity	nephrotoxicity	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	following	follow	VBG	_	7	case
6	concomitant	concomitant	JJ	_	7	amod
7	administration	administration	NN	_	4	nmod
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	7	nmod
12	or	or	CC	_	11	cc
13	potent	potent	JJ	_	14	amod
14	drug3	drug3	NN	_	11	conj
15	such	such	JJ	_	17	case
16	as	as	IN	_	15	mwe
17	drug4	drug4	NN	_	14	nmod
18	.	.	.	_	4	punct

1	Renal	renal	JJ	_	2	amod
2	function	function	NN	_	6	nsubjpass
3	should	should	MD	_	6	aux
4	be	be	VB	_	6	auxpass
5	carefully	carefully	RB	_	6	advmod
6	monitored	monitor	VBN	_	0	ROOT
7	,	,	,	_	6	punct
8	especially	especially	RB	_	15	advmod
9	if	if	IN	_	15	mark
10	higher	higher	JJR	_	11	amod
11	dosages	dosage	NNS	_	15	nsubj
12	of	of	IN	_	14	case
13	the	the	DT	_	14	det
14	drug1	drug1	NN	_	11	nmod
15	are	be	VBP	_	6	advcl
16	to	to	TO	_	18	mark
17	be	be	VB	_	18	auxpass
18	administered	administer	VBN	_	15	xcomp
19	or	or	CC	_	18	cc
20	if	if	IN	_	23	mark
21	therapy	therapy	NN	_	23	nsubjpass
22	is	be	VBZ	_	23	auxpass
23	prolonged	prolong	VBN	_	18	conj
24	,	,	,	_	18	punct
25	because	because	IN	_	29	case
26	of	of	IN	_	25	mwe
27	the	the	DT	_	29	det
28	potential	potential	JJ	_	29	amod
29	nephrotoxicity	nephrotoxicity	NN	_	18	nmod
30	and	and	CC	_	29	cc
31	ototoxicity	ototoxicity	NN	_	29	conj
32	of	of	IN	_	33	case
33	drug2	drug2	NN	_	29	nmod
34	.	.	.	_	6	punct

1	Nephrotoxicity	nephrotoxicity	NN	_	6	nsubjpass
2	and	and	CC	_	1	cc
3	ototoxicity	ototoxicity	NN	_	1	conj
4	were	be	VBD	_	6	auxpass
5	not	not	RB	_	6	neg
6	noted	note	VBN	_	0	ROOT
7	when	when	WRB	_	10	advmod
8	drug1	drug1	NN	_	10	nsubjpass
9	was	be	VBD	_	10	auxpass
10	given	give	VBN	_	6	advcl
11	alone	alone	RB	_	10	advmod
12	in	in	IN	_	14	case
13	clinical	clinical	JJ	_	14	amod
14	trials	trial	NNS	_	10	nmod
15	.	.	.	_	6	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	shown	show	VBN	_	0	ROOT
5	to	to	TO	_	7	mark
6	be	be	VB	_	7	cop
7	antagonistic	antagonistic	JJ	_	4	xcomp
8	to	to	TO	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	,	,	,	_	9	punct
11	including	include	VBG	_	12	case
12	drug3	drug3	NN	_	9	nmod
13	,	,	,	_	9	punct
14	based	base	VBN	_	18	case
15	on	on	IN	_	18	case
16	in	in	FW	_	18	amod
17	vitro	vitro	FW	_	16	dep
18	studies	study	NNS	_	9	nmod
19	and	and	CC	_	18	cc
20	time	time	NN	_	21	nsubj
21	kill	kill	VBP	_	18	conj
22	curves	curve	NNS	_	21	dobj
23	with	with	IN	_	26	case
24	enteric	enteric	JJ	_	26	amod
25	gram-negative	gram-negative	JJ	_	26	amod
26	bacilli	bacillus	NNS	_	21	nmod
27	.	.	.	_	4	punct

1	Due	due	JJ	_	4	case
2	to	to	TO	_	1	mwe
3	the	the	DT	_	4	det
4	possibility	possibility	NN	_	22	nmod
5	of	of	IN	_	6	case
6	antagonism	antagonism	NN	_	4	nmod
7	in	in	FW	_	8	compound
8	vivo	vivo	FW	_	6	advmod
9	,	,	,	_	22	punct
10	particularly	particularly	RB	_	11	advmod
11	when	when	WRB	_	15	advmod
12	bactericidal	bactericidal	JJ	_	13	amod
13	activity	activity	NN	_	15	nsubjpass
14	is	be	VBZ	_	15	auxpass
15	desired	desire	VBN	_	22	advcl
16	,	,	,	_	22	punct
17	this	this	DT	_	19	det
18	drug	drug	NN	_	19	compound
19	combination	combination	NN	_	22	nsubjpass
20	should	should	MD	_	22	aux
21	be	be	VB	_	22	auxpass
22	avoided	avoid	VBN	_	0	ROOT
23	.	.	.	_	22	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	3	amod
2	Test	test	NN	_	3	compound
3	Interactions	interaction	NNS	_	0	ROOT
4	The	the	DT	_	5	det
5	administration	administration	NN	_	9	nsubj
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	may	may	MD	_	9	aux
9	result	result	VB	_	3	acl:relcl
10	in	in	IN	_	13	case
11	a	a	DT	_	13	det
12	false-positive	false-positive	JJ	_	13	amod
13	reaction	reaction	NN	_	9	nmod
14	for	for	IN	_	15	case
15	glucose	glucose	NN	_	13	nmod
16	in	in	IN	_	18	case
17	the	the	DT	_	18	det
18	urine	urine	NN	_	15	nmod
19	when	when	WRB	_	20	advmod
20	using	use	VBG	_	9	advcl
21	CLINITEST	clinitest	NN	_	22	compound
22	tablets	tablet	NNS	_	20	dobj
23	,	,	,	_	3	punct
24	Benedicts	Benedicts	NNP	_	25	compound
25	solution	solution	NN	_	23	root
26	,	,	,	_	25	punct
27	or	or	CC	_	25	cc
28	Fehlings	Fehlings	NNP	_	29	compound
29	solution	solution	NN	_	25	conj
30	.	.	.	_	25	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	recommended	recommend	VBN	_	0	ROOT
4	that	that	IN	_	21	mark
5	glucose	glucose	NN	_	6	compound
6	tests	test	NNS	_	21	nsubjpass
7	based	base	VBN	_	12	case
8	on	on	IN	_	12	case
9	enzymatic	enzymatic	JJ	_	12	amod
10	glucose	glucose	NN	_	12	compound
11	oxidase	oxidase	NN	_	12	compound
12	reactions	reaction	NNS	_	6	nmod
13	-LRB-	-lrb-	-LRB-	_	16	punct
14	such	such	JJ	_	16	case
15	as	as	IN	_	14	mwe
16	CLINISTIX	clinistix	NN	_	12	nmod
17	or	or	CC	_	16	cc
18	TES-TAPE	tes-tape	NN	_	16	conj
19	-RRB-	-rrb-	-RRB-	_	16	punct
20	be	be	VB	_	21	auxpass
21	used	use	VBN	_	3	ccomp
22	.	.	.	_	3	punct

1	Some	some	DT	_	2	det
2	drug1	drug1	NN	_	10	nsubjpass
3	,	,	,	_	2	punct
4	including	include	VBG	_	5	case
5	drug2	drug2	NN	_	2	nmod
6	,	,	,	_	2	punct
7	have	have	VBP	_	10	aux
8	also	also	RB	_	10	advmod
9	been	be	VBN	_	10	auxpass
10	shown	show	VBN	_	0	ROOT
11	to	to	TO	_	12	mark
12	interfere	interfere	VB	_	10	xcomp
13	with	with	IN	_	15	case
14	the	the	DT	_	15	det
15	metabolism	metabolism	NN	_	12	nmod
16	of	of	IN	_	17	case
17	drug3	drug3	NN	_	15	nmod
18	.	.	.	_	10	punct

1	This	this	DT	_	3	nsubj
2	may	may	MD	_	3	aux
3	lead	lead	VB	_	0	ROOT
4	to	to	TO	_	6	case
5	reduced	reduce	VBN	_	6	amod
6	clearance	clearance	NN	_	3	nmod
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	and	and	CC	_	6	cc
10	a	a	DT	_	11	det
11	prolongation	prolongation	NN	_	6	conj
12	of	of	IN	_	15	case
13	its	its	PRP$	_	15	nmod:poss
14	serum	serum	NN	_	15	compound
15	half-life	half-life	NN	_	11	nmod
16	.	.	.	_	3	punct

1	Some	some	DT	_	2	det
2	drug1	drug1	NN	_	9	nsubjpass
3	,	,	,	_	2	punct
4	including	include	VBG	_	5	case
5	drug2	drug2	NN	_	2	nmod
6	,	,	,	_	2	punct
7	have	have	VBP	_	9	aux
8	been	be	VBN	_	9	auxpass
9	associated	associate	VBN	_	0	ROOT
10	with	with	IN	_	12	case
11	transient	transient	JJ	_	12	amod
12	elevations	elevation	NNS	_	9	nmod
13	in	in	IN	_	15	case
14	serum	serum	NN	_	15	compound
15	creatinine	creatinine	NN	_	12	nmod
16	in	in	IN	_	17	case
17	patients	patient	NNS	_	15	nmod
18	receiving	receive	VBG	_	17	acl
19	drug3	drug3	NN	_	18	dobj
20	concomitantly	concomitantly	RB	_	18	advmod
21	.	.	.	_	9	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	5	det
4	concomitant	concomitant	JJ	_	5	amod
5	administration	administration	NN	_	12	nsubj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	with	with	IN	_	11	case
9	the	the	DT	_	11	det
10	drug3	drug3	NN	_	11	compound
11	drug4	drug4	NN	_	5	nmod
12	has	have	VBZ	_	1	dep
13	,	,	,	_	12	punct
14	on	on	IN	_	16	case
15	rare	rare	JJ	_	16	amod
16	occasions	occasion	NNS	_	12	nmod
17	,	,	,	_	12	punct
18	resulted	result	VBD	_	12	dep
19	in	in	IN	_	21	case
20	severe	severe	JJ	_	21	amod
21	hypoglycemia	hypoglycemia	NN	_	18	nmod
22	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	nsubj
4	appear	appear	VBP	_	1	appos
5	to	to	TO	_	6	mark
6	have	have	VB	_	4	xcomp
7	no	no	DT	_	9	neg
8	significant	significant	JJ	_	9	amod
9	effect	effect	NN	_	6	dobj
10	on	on	IN	_	12	case
11	the	the	DT	_	12	det
12	bioavailability	bioavailability	NN	_	6	nmod
13	of	of	IN	_	14	case
14	drug3	drug3	NN	_	12	nmod
15	.	.	.	_	1	punct

1	drug1	drug1	NN	_	4	compound
2	Renal	renal	JJ	_	4	amod
3	tubular	tubular	JJ	_	4	amod
4	transport	transport	NN	_	9	nsubjpass
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	may	may	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	inhibited	inhibit	VBN	_	0	ROOT
10	by	by	IN	_	12	case
11	concomitant	concomitant	JJ	_	12	amod
12	administration	administration	NN	_	9	nmod
13	of	of	IN	_	14	case
14	drug3	drug3	NN	_	12	nmod
15	,	,	,	_	9	punct
16	potentially	potentially	RB	_	17	advmod
17	leading	lead	VBG	_	9	xcomp
18	to	to	TO	_	21	case
19	increased	increase	VBN	_	21	amod
20	plasma	plasma	NN	_	21	compound
21	levels	level	NNS	_	17	nmod
22	of	of	IN	_	23	case
23	drug4	drug4	NN	_	21	nmod
24	.	.	.	_	9	punct

1	This	this	DT	_	3	nsubj
2	might	might	MD	_	3	aux
3	increase	increase	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	risk	risk	NN	_	3	dobj
6	of	of	IN	_	9	case
7	drug1	drug1	NN	_	9	compound
8	toxic	toxic	JJ	_	9	amod
9	reactions	reaction	NNS	_	5	nmod
10	.	.	.	_	3	punct

1	Therefore	therefore	RB	_	10	advmod
2	,	,	,	_	10	punct
3	patients	patient	NNS	_	10	nsubjpass
4	under	under	IN	_	6	case
5	drug1	drug1	NN	_	6	compound
6	therapy	therapy	NN	_	3	nmod
7	should	should	MD	_	10	aux
8	be	be	VB	_	10	auxpass
9	carefully	carefully	RB	_	10	advmod
10	monitored	monitor	VBN	_	0	ROOT
11	when	when	WRB	_	16	advmod
12	concomitant	concomitant	JJ	_	14	amod
13	drug2	drug2	NN	_	14	compound
14	therapy	therapy	NN	_	16	nsubjpass
15	is	be	VBZ	_	16	auxpass
16	indicated	indicate	VBN	_	10	advcl
17	.	.	.	_	10	punct

1	Multivalent	multivalent	JJ	_	3	amod
2	Cation-Containing	Cation-Containing	NNP	_	3	compound
3	Products	Products	NNPS	_	0	ROOT
4	:	:	:	_	3	punct
5	Concurrent	concurrent	JJ	_	6	amod
6	administration	administration	NN	_	45	nsubj
7	of	of	IN	_	9	case
8	a	a	DT	_	9	det
9	drug1	drug1	NN	_	6	nmod
10	,	,	,	_	9	punct
11	including	include	VBG	_	12	case
12	drug2	drug2	NN	_	9	nmod
13	,	,	,	_	9	punct
14	with	with	IN	_	17	case
15	multivalent	multivalent	JJ	_	17	amod
16	cation-containing	cation-containing	JJ	_	17	amod
17	products	product	NNS	_	9	nmod
18	such	such	JJ	_	20	case
19	as	as	IN	_	18	mwe
20	drug3	drug3	NN	_	17	nmod
21	or	or	CC	_	20	cc
22	drug4	drug4	NN	_	23	compound
23	drug5	drug5	NN	_	20	conj
24	,	,	,	_	20	punct
25	drug6	drug6	NN	_	20	conj
26	,	,	,	_	20	punct
27	drug7	drug7	NN	_	20	conj
28	chewable/buffered	chewable/buffered	VBD	_	20	acl
29	tablets	tablet	NNS	_	28	dobj
30	or	or	CC	_	29	cc
31	pediatric	pediatric	JJ	_	32	amod
32	powder	powder	NN	_	29	conj
33	,	,	,	_	29	punct
34	or	or	CC	_	29	cc
35	products	product	NNS	_	29	conj
36	containing	contain	VBG	_	35	acl
37	drug8	drug8	NN	_	36	dobj
38	,	,	,	_	37	punct
39	drug9	drug9	NN	_	37	conj
40	,	,	,	_	37	punct
41	or	or	CC	_	37	cc
42	drug10	drug10	NN	_	37	conj
43	may	may	MD	_	45	aux
44	substantially	substantially	RB	_	45	advmod
45	decrease	decrease	VB	_	3	dep
46	the	the	DT	_	47	det
47	absorption	absorption	NN	_	45	dobj
48	of	of	IN	_	49	case
49	drug11	drug11	NN	_	47	nmod
50	,	,	,	_	45	punct
51	resulting	result	VBG	_	45	advcl
52	in	in	IN	_	56	case
53	serum	serum	NN	_	56	compound
54	and	and	CC	_	53	cc
55	urine	urine	NN	_	53	conj
56	levels	level	NNS	_	51	nmod
57	considerably	considerably	RB	_	58	advmod
58	lower	lower	JJR	_	56	amod
59	than	than	IN	_	60	mark
60	desired	desire	VBN	_	58	advcl
61	.	.	.	_	3	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	administered	administer	VBN	_	0	ROOT
5	at	at	IN	_	6	case
6	least	least	JJS	_	7	nmod:npmod
7	4	4	CD	_	8	nummod
8	hours	hour	NNS	_	4	dobj
9	before	before	IN	_	8	dep
10	or	or	CC	_	9	cc
11	2	2	CD	_	12	nummod
12	hours	hour	NNS	_	9	conj
13	after	after	IN	_	15	case
14	these	these	DT	_	15	det
15	products	product	NNS	_	4	nmod
16	.	.	.	_	4	punct

1	This	this	DT	_	3	det
2	time	time	NN	_	3	compound
3	window	window	NN	_	5	nsubj
4	is	be	VBZ	_	5	cop
5	different	different	JJ	_	0	ROOT
6	than	than	IN	_	10	case
7	for	for	IN	_	10	case
8	other	other	JJ	_	10	amod
9	oral	oral	JJ	_	10	amod
10	formulations	formulation	NNS	_	5	nmod
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	,	,	,	_	12	punct
14	which	which	WDT	_	17	nsubjpass
15	are	be	VBP	_	17	auxpass
16	usually	usually	RB	_	17	advmod
17	administered	administer	VBN	_	12	acl:relcl
18	2	2	CD	_	19	nummod
19	hours	hour	NNS	_	17	dobj
20	before	before	IN	_	25	nmod
21	or	or	CC	_	20	cc
22	6	6	CD	_	23	nummod
23	hours	hour	NNS	_	20	conj
24	after	after	IN	_	23	case
25	drug2	drug2	NN	_	19	nmod
26	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	4	punct
3	but	but	CC	_	4	cc
4	not	not	RB	_	1	dep
5	drug2	drug2	NN	_	4	dep
6	-RRB-	-rrb-	-RRB-	_	4	punct
7	:	:	:	_	1	punct
8	These	these	DT	_	9	det
9	drugs	drug	NNS	_	20	nsubjpass
10	in	in	IN	_	11	case
11	combination	combination	NN	_	9	nmod
12	with	with	IN	_	15	case
13	very	very	RB	_	14	advmod
14	high	high	JJ	_	15	amod
15	doses	dose	NNS	_	11	nmod
16	of	of	IN	_	17	case
17	drug3	drug3	NN	_	15	nmod
18	have	have	VBP	_	20	aux
19	been	be	VBN	_	20	auxpass
20	shown	show	VBN	_	1	dep
21	to	to	TO	_	22	mark
22	provoke	provoke	VB	_	20	xcomp
23	convulsions	convulsion	NNS	_	22	dobj
24	in	in	IN	_	26	case
25	pre-clinical	pre-clinical	JJ	_	26	amod
26	studies	study	NNS	_	22	nmod
27	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	rate	rate	NN	_	12	nsubj
5	and	and	CC	_	4	cc
6	extent	extent	NN	_	4	conj
7	of	of	IN	_	8	case
8	absorption	absorption	NN	_	4	nmod
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	was	be	VBD	_	12	cop
12	bioequivalent	bioequivalent	JJ	_	1	dep
13	when	when	WRB	_	16	advmod
14	drug3	drug3	NN	_	16	nsubjpass
15	was	be	VBD	_	16	auxpass
16	given	give	VBN	_	12	advcl
17	alone	alone	RB	_	16	advmod
18	or	or	CC	_	16	cc
19	when	when	WRB	_	22	advmod
20	drug4	drug4	NN	_	22	nsubjpass
21	was	be	VBD	_	22	auxpass
22	given	give	VBN	_	16	conj
23	2	2	CD	_	24	nummod
24	hours	hour	NNS	_	22	nmod
25	after	after	IN	_	24	case
26	drug5	drug5	NN	_	24	dep
27	at	at	IN	_	29	case
28	the	the	DT	_	29	det
29	dose	dose	NN	_	26	nmod
30	that	that	WDT	_	32	nsubj
31	maximally	maximally	RB	_	32	advmod
32	suppresses	suppress	VBZ	_	29	acl:relcl
33	gastric	gastric	JJ	_	35	amod
34	acid	acid	NN	_	35	compound
35	secretion	secretion	NN	_	32	dobj
36	.	.	.	_	12	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	taken	take	VBN	_	0	ROOT
5	as	as	IN	_	6	mark
6	directed	direct	VBN	_	4	advcl
7	and	and	CC	_	6	cc
8	drug2	drug2	NN	_	6	conj
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	taken	take	VBN	_	4	xcomp
12	with	with	IN	_	15	case
13	a	a	DT	_	15	det
14	main	main	JJ	_	15	amod
15	meal	meal	NN	_	11	nmod
16	of	of	IN	_	18	case
17	the	the	DT	_	18	det
18	day	day	NN	_	15	nmod
19	,	,	,	_	11	punct
20	preferably	preferably	RB	_	23	advmod
21	the	the	DT	_	23	det
22	evening	evening	NN	_	23	compound
23	meal	meal	NN	_	11	nmod
24	.	.	.	_	4	punct
25	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Altered	altered	JJ	_	5	amod
4	serum	serum	NN	_	5	compound
5	levels	level	NNS	_	15	nsubjpass
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	increased	increase	VBN	_	7	dep
10	and	and	CC	_	9	cc
11	decreased	decrease	VBN	_	9	conj
12	-RRB-	-rrb-	-RRB-	_	9	punct
13	have	have	VBP	_	15	aux
14	been	be	VBN	_	15	auxpass
15	reported	report	VBN	_	1	appos
16	in	in	IN	_	17	case
17	patients	patient	NNS	_	15	nmod
18	receiving	receive	VBG	_	17	acl
19	concomitant	concomitant	JJ	_	20	amod
20	drug3	drug3	NN	_	18	dobj
21	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	nsubj
4	interferes	interfere	VBZ	_	1	dep
5	with	with	IN	_	8	case
6	renal	renal	JJ	_	8	amod
7	tubular	tubular	JJ	_	8	amod
8	secretion	secretion	NN	_	4	nmod
9	of	of	IN	_	10	case
10	drug3	drug3	NN	_	8	nmod
11	and	and	CC	_	4	cc
12	produces	produce	VBZ	_	4	conj
13	an	a	DT	_	14	det
14	increase	increase	NN	_	12	dobj
15	in	in	IN	_	17	case
16	the	the	DT	_	17	det
17	level	level	NN	_	14	nmod
18	of	of	IN	_	19	case
19	drug4	drug4	NN	_	17	nmod
20	in	in	IN	_	21	case
21	serum	serum	NN	_	19	nmod
22	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	As	as	IN	_	7	case
4	with	with	IN	_	7	case
5	some	some	DT	_	7	det
6	other	other	JJ	_	7	amod
7	drug2	drug2	NN	_	16	nmod
8	,	,	,	_	16	punct
9	concurrent	concurrent	JJ	_	10	amod
10	administration	administration	NN	_	16	nsubj
11	of	of	IN	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	with	with	IN	_	14	case
14	drug4	drug4	NN	_	10	nmod
15	may	may	MD	_	16	aux
16	lead	lead	VB	_	1	appos
17	to	to	TO	_	20	case
18	elevated	elevated	JJ	_	20	amod
19	serum	serum	NN	_	20	compound
20	concentrations	concentration	NNS	_	16	nmod
21	of	of	IN	_	22	case
22	drug5	drug5	NN	_	20	nmod
23	and	and	CC	_	20	cc
24	prolongation	prolongation	NN	_	20	conj
25	of	of	IN	_	28	case
26	its	its	PRP$	_	28	nmod:poss
27	elimination	elimination	NN	_	28	compound
28	half-life	half-life	NN	_	24	nmod
29	.	.	.	_	1	punct

1	This	this	DT	_	3	nsubj
2	may	may	MD	_	3	aux
3	result	result	VB	_	0	ROOT
4	in	in	IN	_	6	case
5	increased	increase	VBN	_	6	amod
6	risk	risk	NN	_	3	nmod
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	-	-	:	_	8	punct
10	related	related	JJ	_	12	amod
11	adverse	adverse	JJ	_	12	amod
12	reactions	reaction	NNS	_	8	dep
13	.	.	.	_	3	punct

1	If	if	IN	_	7	mark
2	concomitant	concomitant	JJ	_	3	amod
3	use	use	NN	_	7	nsubjpass
4	can	can	MD	_	7	aux
5	not	not	RB	_	7	neg
6	be	be	VB	_	7	auxpass
7	avoided	avoid	VBN	_	15	advcl
8	,	,	,	_	15	punct
9	serum	serum	NN	_	10	compound
10	levels	level	NNS	_	15	nsubjpass
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	should	should	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	monitored	monitor	VBN	_	0	ROOT
16	and	and	CC	_	15	cc
17	dosage	dosage	NN	_	18	compound
18	adjustments	adjustment	NNS	_	15	conj
19	made	make	VBN	_	18	acl
20	as	as	IN	_	21	case
21	appropriate	appropriate	JJ	_	19	advcl
22	.	.	.	_	15	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	6	nsubjpass
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	auxpass
6	reported	report	VBN	_	1	appos
7	to	to	TO	_	8	mark
8	enhance	enhance	VB	_	6	xcomp
9	the	the	DT	_	10	det
10	effects	effect	NNS	_	8	dobj
11	of	of	IN	_	15	case
12	the	the	DT	_	15	det
13	oral	oral	JJ	_	15	amod
14	drug3	drug3	NN	_	15	compound
15	drug4	drug4	NN	_	10	nmod
16	or	or	CC	_	15	cc
17	its	its	PRP$	_	18	nmod:poss
18	derivatives	derivative	NNS	_	15	conj
19	.	.	.	_	1	punct

1	When	when	WRB	_	5	advmod
2	these	these	DT	_	3	det
3	products	product	NNS	_	5	nsubjpass
4	are	be	VBP	_	5	auxpass
5	administered	administer	VBN	_	17	advcl
6	concomitantly	concomitantly	RB	_	5	advmod
7	,	,	,	_	17	punct
8	prothrombin	prothrombin	NN	_	9	compound
9	time	time	NN	_	17	nsubjpass
10	or	or	CC	_	9	cc
11	other	other	JJ	_	14	amod
12	suitable	suitable	JJ	_	14	amod
13	coagulation	coagulation	NN	_	14	compound
14	tests	test	NNS	_	9	conj
15	should	should	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	monitored	monitor	VBN	_	0	ROOT
18	.	.	.	_	17	punct

1	DRUG	drug	NN	_	2	compound
2	INTERACTIONS	interaction	NNS	_	0	ROOT

1	Several	several	JJ	_	4	amod
2	drug	drug	NN	_	4	compound
3	interaction	interaction	NN	_	4	compound
4	studies	study	NNS	_	7	nsubjpass
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	completed	complete	VBN	_	0	ROOT
8	with	with	IN	_	10	case
9	both	both	CC	_	10	cc:preconj
10	drug1	drug1	NN	_	7	nmod
11	and	and	CC	_	10	cc
12	drug2	drug2	NN	_	10	conj
13	.	.	.	_	7	punct

1	Observations	observation	NNS	_	11	nsubj
2	from	from	IN	_	5	case
3	drug	drug	NN	_	5	compound
4	interaction	interaction	NN	_	5	compound
5	studies	study	NNS	_	1	nmod
6	with	with	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	may	may	MD	_	11	aux
9	not	not	RB	_	11	neg
10	be	be	VB	_	11	cop
11	predictive	predictive	JJ	_	0	ROOT
12	for	for	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	.	.	.	_	11	punct

1	Because	because	IN	_	4	mark
2	drug1	drug1	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	coadministered	coadminister	VBN	_	9	advcl
5	,	,	,	_	9	punct
6	prescribers	prescriber	NNS	_	9	nsubj
7	should	should	MD	_	9	aux
8	also	also	RB	_	9	advmod
9	refer	refer	VB	_	0	ROOT
10	to	to	TO	_	13	case
11	the	the	DT	_	13	det
12	prescribing	prescribe	VBG	_	13	amod
13	information	information	NN	_	9	nmod
14	for	for	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	regarding	regard	VBG	_	18	case
17	drug	drug	NN	_	18	compound
18	interactions	interaction	NNS	_	15	nmod
19	associated	associate	VBN	_	18	acl
20	with	with	IN	_	22	case
21	this	this	DT	_	22	det
22	agent	agent	NN	_	19	nmod
23	.	.	.	_	9	punct

1	The	the	DT	_	2	det
2	metabolism	metabolism	NN	_	6	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	is	be	VBZ	_	6	auxpass
6	mediated	mediate	VBN	_	0	ROOT
7	by	by	IN	_	9	case
8	cytochrome	cytochrome	NN	_	9	compound
9	P450	p450	NN	_	6	nmod
10	,	,	,	_	6	punct
11	with	with	IN	_	15	case
12	the	the	DT	_	15	det
13	specific	specific	JJ	_	15	amod
14	isoenzyme	isoenzyme	NN	_	15	compound
15	CYP3A4	cyp3a4	NN	_	6	nmod
16	responsible	responsible	JJ	_	15	amod
17	for	for	IN	_	19	case
18	90	90	CD	_	19	nummod
19	%	%	NN	_	16	nmod
20	of	of	IN	_	23	case
21	the	the	DT	_	23	det
22	hepatic	hepatic	JJ	_	23	amod
23	metabolism	metabolism	NN	_	19	nmod
24	.	.	.	_	6	punct

1	Additionally	additionally	RB	_	6	advmod
2	,	,	,	_	6	punct
3	drug1	drug1	NN	_	6	nsubj
4	is	be	VBZ	_	6	cop
5	a	a	DT	_	6	det
6	substrate	substrate	NN	_	0	ROOT
7	for	for	IN	_	8	case
8	P-Glycoprotein	p-glycoprotein	NN	_	6	nmod
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	Pgp	pgp	NN	_	8	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	.	.	.	_	6	punct

1	Therefore	therefore	RB	_	11	advmod
2	,	,	,	_	11	punct
3	drugs	drug	NNS	_	11	nsubj
4	that	that	WDT	_	5	nsubj
5	affect	affect	VBP	_	3	acl:relcl
6	CYP3A4	cyp3a4	NN	_	5	dobj
7	and/or	and/or	CC	_	6	cc
8	Pgp	pgp	NN	_	6	conj
9	,	,	,	_	11	punct
10	may	may	MD	_	11	aux
11	modify	modify	VB	_	0	ROOT
12	the	the	DT	_	13	det
13	pharmacokinetics	pharmacokinetic	NNS	_	11	dobj
14	of	of	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	.	.	.	_	11	punct

1	Similarly	similarly	RB	_	6	advmod
2	,	,	,	_	6	punct
3	drug1	drug1	NN	_	6	nsubj
4	might	might	MD	_	6	aux
5	also	also	RB	_	6	advmod
6	modify	modify	VB	_	0	ROOT
7	the	the	DT	_	8	det
8	pharmacokinetics	pharmacokinetic	NNS	_	6	dobj
9	of	of	IN	_	11	case
10	other	other	JJ	_	11	amod
11	drugs	drug	NNS	_	8	nmod
12	that	that	WDT	_	14	nsubj
13	are	be	VBP	_	14	cop
14	substrates	substrate	NNS	_	11	acl:relcl
15	for	for	IN	_	16	case
16	CYP3A4	cyp3a4	NN	_	14	nmod
17	or	or	CC	_	16	cc
18	Pgp	pgp	NN	_	16	conj
19	.	.	.	_	6	punct

1	Drugs	drug	NNS	_	20	nsubjpass
2	that	that	WDT	_	4	nsubjpass
3	are	be	VBP	_	4	auxpass
4	contraindicated	contraindicate	VBN	_	1	acl:relcl
5	specifically	specifically	RB	_	6	advmod
6	due	due	JJ	_	4	xcomp
7	to	to	TO	_	10	case
8	the	the	DT	_	10	det
9	expected	expect	VBN	_	10	amod
10	magnitude	magnitude	NN	_	6	nmod
11	of	of	IN	_	12	case
12	interaction	interaction	NN	_	10	nmod
13	and	and	CC	_	12	cc
14	potential	potential	NN	_	12	conj
15	for	for	IN	_	18	case
16	serious	serious	JJ	_	18	amod
17	adverse	adverse	JJ	_	18	amod
18	events	event	NNS	_	12	nmod
19	are	be	VBP	_	20	auxpass
20	listed	list	VBN	_	0	ROOT
21	CONTRAINDICATIONS	contraindication	NNS	_	20	dobj
22	.	.	.	_	20	punct

1	Additional	additional	JJ	_	2	amod
2	drugs	drug	NNS	_	14	nsubjpass
3	that	that	WDT	_	6	nsubjpass
4	are	be	VBP	_	6	auxpass
5	not	not	RB	_	6	neg
6	recommended	recommend	VBN	_	2	acl:relcl
7	for	for	IN	_	8	case
8	coadministration	coadministration	NN	_	6	nmod
9	with	with	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	drug2	drug2	NN	_	10	conj
13	are	be	VBP	_	14	auxpass
14	included	include	VBN	_	0	ROOT
15	below	below	IN	_	14	advmod
16	.	.	.	_	14	punct

1	These	these	DT	_	2	det
2	recommendations	recommendation	NNS	_	4	nsubjpass
3	are	be	VBP	_	4	auxpass
4	based	base	VBN	_	0	ROOT
5	on	on	IN	_	9	case
6	either	either	CC	_	9	cc:preconj
7	drug	drug	NN	_	9	compound
8	interaction	interaction	NN	_	9	compound
9	studies	study	NNS	_	4	nmod
10	or	or	CC	_	9	cc
11	predicted	predict	VBN	_	12	amod
12	interactions	interaction	NNS	_	9	conj
13	due	due	JJ	_	17	case
14	to	to	TO	_	13	mwe
15	the	the	DT	_	17	det
16	expected	expect	VBN	_	17	amod
17	magnitude	magnitude	NN	_	9	nmod
18	of	of	IN	_	19	case
19	interaction	interaction	NN	_	17	nmod
20	and	and	CC	_	19	cc
21	potential	potential	NN	_	19	conj
22	for	for	IN	_	24	case
23	serious	serious	JJ	_	24	amod
24	events	event	NNS	_	19	nmod
25	or	or	CC	_	24	cc
26	loss	loss	NN	_	24	conj
27	of	of	IN	_	28	case
28	efficacy	efficacy	NN	_	26	nmod
29	.	.	.	_	4	punct

1	With	with	IN	_	3	case
2	some	some	DT	_	3	det
3	agents	agent	NNS	_	9	nmod
4	,	,	,	_	9	punct
5	the	the	DT	_	6	det
6	metabolism	metabolism	NN	_	9	nsubjpass
7	may	may	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	induced	induce	VBN	_	0	ROOT
10	,	,	,	_	9	punct
11	resulting	result	VBG	_	9	xcomp
12	in	in	IN	_	14	case
13	decreased	decrease	VBN	_	14	amod
14	concentrations	concentration	NNS	_	11	nmod
15	.	.	.	_	9	punct

1	Drugs	drug	NNS	_	0	ROOT
2	That	that	WDT	_	6	nsubj
3	Should	should	MD	_	6	aux
4	Not	not	RB	_	6	neg
5	Be	be	VB	_	6	cop
6	Coadministered	coadministered	JJ	_	1	acl:relcl
7	With	with	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	/	/	:	_	1	punct
10	drug2	drug2	NN	_	1	dep

1	Drug	drug	NN	_	2	compound
2	Class	class	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	Drug	Drug	NNP	_	5	nsubj
5	Name	name	VB	_	2	dep
6	Clinical	clinical	JJ	_	7	amod
7	Comment	comment	NN	_	5	dobj

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	1	dep
4	,	,	,	_	3	punct
5	drug3	drug3	NN	_	3	conj
6	,	,	,	_	3	punct
7	drug4	drug4	NN	_	3	conj
8	,	,	,	_	3	punct
9	drug5	drug5	NN	_	3	conj
10	,	,	,	_	3	punct
11	drug6	drug6	NN	_	12	compound
12	CONTRAINDICATED	CONTRAINDICATED	NNP	_	3	appos
13	due	due	JJ	_	12	amod
14	to	to	TO	_	15	case
15	potential	potential	JJ	_	13	nmod
16	for	for	IN	_	20	case
17	serious	serious	JJ	_	20	amod
18	and/or	and/or	CC	_	17	cc
19	life-threatening	life-threatening	JJ	_	17	conj
20	reactions	reaction	NNS	_	15	nmod
21	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	compound
4	*	*	NN	_	1	dep
5	,	,	,	_	4	punct
6	drug3	drug3	NN	_	8	compound
7	*	*	SYM	_	8	dep
8	CONTRAINDICATED	CONTRAINDICATED	NNP	_	4	appos
9	due	due	JJ	_	8	amod
10	to	to	TO	_	11	case
11	potential	potential	JJ	_	9	nmod
12	for	for	IN	_	17	case
13	serious	serious	JJ	_	17	amod
14	and/or	and/or	CC	_	13	cc
15	life-threatening	life-threatening	JJ	_	13	conj
16	cardiac	cardiac	JJ	_	17	amod
17	arrhythmias	arrhythmia	NNS	_	11	nmod
18	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	1	dep
4	,	,	,	_	3	punct
5	drug3	drug3	NN	_	3	conj
6	,	,	,	_	3	punct
7	drug4	drug4	NN	_	3	conj
8	,	,	,	_	3	punct
9	drug5	drug5	NN	_	10	compound
10	CONTRAINDICATED	CONTRAINDICATED	NNP	_	3	appos
11	due	due	JJ	_	10	amod
12	to	to	TO	_	13	case
13	potential	potential	JJ	_	11	nmod
14	for	for	IN	_	18	case
15	serious	serious	JJ	_	18	amod
16	and	and	CC	_	15	cc
17	life-threatening	life-threatening	JJ	_	15	conj
18	reactions	reaction	NNS	_	13	nmod
19	such	such	JJ	_	23	case
20	as	as	IN	_	19	mwe
21	acute	acute	JJ	_	23	amod
22	drug6	drug6	NN	_	23	compound
23	toxicity	toxicity	NN	_	18	nmod
24	characterized	characterize	VBN	_	23	acl
25	by	by	IN	_	27	case
26	peripheral	peripheral	JJ	_	27	amod
27	vasospasm	vasospasm	NN	_	24	nmod
28	and	and	CC	_	27	cc
29	ischemia	ischemia	NN	_	27	conj
30	of	of	IN	_	32	case
31	the	the	DT	_	32	det
32	extremities	extremity	NNS	_	27	nmod
33	and	and	CC	_	32	cc
34	other	other	JJ	_	35	amod
35	tissues	tissue	NNS	_	32	conj
36	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	compound
4	CONTRAINDICATED	CONTRAINDICATED	NNP	_	17	nsubj
5	since	since	IN	_	7	case
6	the	the	DT	_	7	det
7	coadministration	coadministration	NN	_	4	nmod
8	of	of	IN	_	10	case
9	this	this	DT	_	10	det
10	product	product	NN	_	7	nmod
11	with	with	IN	_	12	case
12	drug3	drug3	NN	_	7	nmod
13	in	in	IN	_	16	case
14	an	a	DT	_	16	det
15	drug4	drug4	NN	_	16	compound
16	regimen	regimen	NN	_	12	nmod
17	reduces	reduce	VBZ	_	1	appos
18	the	the	DT	_	20	det
19	plasma	plasma	NN	_	20	compound
20	concentrations	concentration	NNS	_	17	dobj
21	of	of	IN	_	22	case
22	drug5	drug5	NN	_	20	nmod
23	.	.	.	_	1	punct

1	Garlic	Garlic	NNP	_	4	compound
2	Capsules	Capsules	NNPS	_	4	compound
3	Garlic	Garlic	NNP	_	4	compound
4	capsules	capsule	NNS	_	8	nsubjpass
5	should	should	MD	_	8	aux
6	not	not	RB	_	8	neg
7	be	be	VB	_	8	auxpass
8	used	use	VBN	_	0	ROOT
9	while	while	IN	_	10	mark
10	taking	take	VBG	_	8	advcl
11	drug1	drug1	NN	_	10	dobj
12	-LRB-	-lrb-	-LRB-	_	13	punct
13	drug2	drug2	NN	_	11	appos
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	as	as	IN	_	18	case
16	the	the	DT	_	18	det
17	sole	sole	JJ	_	18	amod
18	drug3	drug3	NN	_	10	nmod
19	due	due	JJ	_	22	case
20	to	to	TO	_	19	mwe
21	the	the	DT	_	22	det
22	risk	risk	NN	_	18	nmod
23	of	of	IN	_	27	case
24	decreased	decrease	VBN	_	27	amod
25	drug4	drug4	NN	_	27	compound
26	plasma	plasma	NN	_	27	compound
27	concentrations	concentration	NNS	_	22	nmod
28	.	.	.	_	8	punct

1	No	no	DT	_	2	neg
2	data	datum	NNS	_	4	nsubj
3	are	be	VBP	_	4	cop
4	available	available	JJ	_	0	ROOT
5	for	for	IN	_	7	case
6	the	the	DT	_	7	det
7	coadministration	coadministration	NN	_	4	nmod
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	/	/	:	_	9	punct
11	drug2	drug2	NN	_	9	dep
12	or	or	CC	_	11	cc
13	drug3	drug3	NN	_	11	conj
14	/	/	:	_	9	punct
15	drug4	drug4	NN	_	18	compound
16	and	and	CC	_	15	cc
17	garlic	garlic	JJ	_	15	conj
18	capsules	capsule	NNS	_	9	dep
19	.	.	.	_	4	punct

1	GI	gi	NN	_	3	compound
2	Motility	motility	NN	_	3	compound
3	Agent	Agent	NNP	_	0	ROOT
4	:	:	:	_	3	punct
5	drug1	drug1	NN	_	7	compound
6	*	*	SYM	_	7	dep
7	CONTRAINDICATED	CONTRAINDICATED	NNP	_	3	dep
8	due	due	JJ	_	7	amod
9	to	to	TO	_	10	case
10	potential	potential	JJ	_	8	nmod
11	for	for	IN	_	15	case
12	serious	serious	JJ	_	15	amod
13	and/or	and/or	CC	_	12	cc
14	life-threatening	life-threatening	JJ	_	12	conj
15	reactions	reaction	NNS	_	10	nmod
16	such	such	JJ	_	19	case
17	as	as	IN	_	16	mwe
18	cardiac	cardiac	JJ	_	19	amod
19	arrhythmias	arrhythmia	NNS	_	15	nmod
20	.	.	.	_	3	punct

1	Herbal	Herbal	NNP	_	2	compound
2	Products	Products	NNPS	_	0	ROOT
3	:	:	:	_	2	punct
4	St.	St.	NNP	_	7	compound
5	John	John	NNP	_	7	compound
6	s	be	VBZ	_	7	compound
7	wort	wort	NN	_	13	compound
8	-LRB-	-lrb-	-LRB-	_	10	punct
9	hypericum	hypericum	NN	_	10	compound
10	perforatum	perforatum	NN	_	7	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	WARNING	warning	NN	_	13	compound
13	coadministration	coadministration	NN	_	15	nsubj
14	may	may	MD	_	15	aux
15	lead	lead	VB	_	2	appos
16	to	to	TO	_	17	case
17	loss	loss	NN	_	15	nmod
18	of	of	IN	_	20	case
19	virologic	virologic	JJ	_	20	amod
20	response	response	NN	_	17	nmod
21	and	and	CC	_	17	cc
22	possible	possible	JJ	_	23	amod
23	resistance	resistance	NN	_	17	conj
24	to	to	TO	_	25	case
25	drug1	drug1	NN	_	23	nmod
26	or	or	CC	_	25	cc
27	to	to	TO	_	29	case
28	the	the	DT	_	29	det
29	class	class	NN	_	25	conj
30	of	of	IN	_	32	case
31	protease	protease	NN	_	32	compound
32	inhibitors	inhibitor	NNS	_	29	nmod
33	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	1	dep
4	,	,	,	_	3	punct
5	drug3	drug3	NN	_	7	compound
6	WARNING	warning	NN	_	7	compound
7	potential	potential	NN	_	3	appos
8	for	for	IN	_	10	case
9	serious	serious	JJ	_	10	amod
10	reactions	reaction	NNS	_	7	nmod
11	such	such	JJ	_	13	case
12	as	as	IN	_	11	mwe
13	risk	risk	NN	_	10	nmod
14	of	of	IN	_	15	case
15	myopathy	myopathy	NN	_	13	nmod
16	including	include	VBG	_	17	case
17	rhabdomyolysis	rhabdomyolysis	NN	_	15	nmod
18	.	.	.	_	1	punct

1	drug1	drug1	NN	_	3	compound
2	/	/	:	_	3	punct
3	drug2	drug2	NN	_	0	ROOT
4	:	:	:	_	3	punct
5	drug3	drug3	NN	_	3	dep
6	,	,	,	_	5	punct
7	drug4	drug4	NN	_	8	compound
8	CONTRAINDICATED	CONTRAINDICATED	NNP	_	5	appos
9	due	due	JJ	_	5	amod
10	to	to	TO	_	11	case
11	potential	potential	JJ	_	9	nmod
12	for	for	IN	_	16	case
13	serious	serious	JJ	_	16	amod
14	and/or	and/or	CC	_	13	cc
15	life-threatening	life-threatening	JJ	_	13	conj
16	reactions	reaction	NNS	_	11	nmod
17	such	such	JJ	_	19	case
18	as	as	IN	_	17	mwe
19	prolonged	prolonged	JJ	_	16	nmod
20	or	or	CC	_	19	cc
21	increased	increase	VBN	_	19	conj
22	sedation	sedation	NN	_	25	amod
23	or	or	CC	_	22	cc
24	respiratory	respiratory	JJ	_	22	conj
25	depression	depression	NN	_	19	dep
26	.	.	.	_	3	punct

1	*	*	SYM	_	4	dep
2	No	no	DT	_	3	neg
3	longer	longer	RBR	_	4	advmod
4	marketed	market	VBN	_	0	ROOT
5	in	in	IN	_	7	case
6	the	the	DT	_	7	det
7	US	US	NNP	_	4	nmod
8	.	.	.	_	4	punct

1	Drugs	drug	NNS	_	0	ROOT
2	That	that	WDT	_	5	nsubjpass
3	Are	be	VBP	_	5	auxpass
4	Mainly	mainly	RB	_	5	advmod
5	Metabolized	metabolize	VBN	_	1	acl:relcl
6	by	by	IN	_	7	case
7	CYP3A4	cyp3a4	NN	_	5	nmod

1	Although	although	IN	_	7	mark
2	specific	specific	JJ	_	3	amod
3	studies	study	NNS	_	7	nsubjpass
4	have	have	VBP	_	7	aux
5	not	not	RB	_	7	neg
6	been	be	VBN	_	7	auxpass
7	performed	perform	VBN	_	55	advcl
8	,	,	,	_	55	punct
9	coadministration	coadministration	NN	_	55	nsubj
10	with	with	IN	_	11	case
11	drugs	drug	NNS	_	9	nmod
12	that	that	WDT	_	15	nsubjpass
13	are	be	VBP	_	15	auxpass
14	mainly	mainly	RB	_	15	advmod
15	metabolized	metabolize	VBN	_	11	acl:relcl
16	by	by	IN	_	17	case
17	CYP3A4	cyp3a4	NN	_	15	nmod
18	-LRB-	-lrb-	-LRB-	_	21	punct
19	eg	eg	FW	_	21	compound
20	,	,	,	_	21	punct
21	drug1	drug1	NN	_	17	dep
22	,	,	,	_	21	punct
23	drug2	drug2	NN	_	21	conj
24	,	,	,	_	21	punct
25	drug3	drug3	NN	_	21	conj
26	,	,	,	_	21	punct
27	drug4	drug4	NN	_	21	conj
28	,	,	,	_	21	punct
29	drug5	drug5	NN	_	21	conj
30	,	,	,	_	21	punct
31	drug6	drug6	NN	_	21	conj
32	,	,	,	_	21	punct
33	drug7	drug7	NN	_	21	conj
34	,	,	,	_	21	punct
35	drug8	drug8	NN	_	21	conj
36	,	,	,	_	21	punct
37	drug9	drug9	NN	_	21	conj
38	,	,	,	_	21	punct
39	drug10	drug10	NN	_	21	conj
40	,	,	,	_	21	punct
41	drug11	drug11	NN	_	21	conj
42	,	,	,	_	21	punct
43	drug12	drug12	NN	_	21	conj
44	,	,	,	_	21	punct
45	drug13	drug13	NN	_	21	conj
46	,	,	,	_	21	punct
47	drug14	drug14	NN	_	21	conj
48	,	,	,	_	21	punct
49	drug15	drug15	NN	_	21	conj
50	,	,	,	_	21	punct
51	and	and	CC	_	21	cc
52	drug16	drug16	NN	_	21	conj
53	-RRB-	-rrb-	-RRB-	_	21	punct
54	may	may	MD	_	55	aux
55	have	have	VB	_	0	ROOT
56	elevated	elevated	JJ	_	58	amod
57	plasma	plasma	NN	_	58	compound
58	concentrations	concentration	NNS	_	55	dobj
59	when	when	WRB	_	60	advmod
60	coadministered	coadminister	VBN	_	55	advcl
61	with	with	IN	_	62	case
62	drug17	drug17	NN	_	60	nmod
63	;	;	:	_	55	punct

1	therefore	therefore	RB	_	7	advmod
2	,	,	,	_	7	punct
3	these	these	DT	_	4	det
4	combinations	combination	NNS	_	7	nsubjpass
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	used	use	VBN	_	0	ROOT
8	with	with	IN	_	9	case
9	caution	caution	NN	_	7	nmod
10	.	.	.	_	7	punct

1	Since	since	IN	_	4	mark
2	drug1	drug1	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	coadministered	coadminister	VBN	_	13	advcl
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	,	,	,	_	13	punct
8	the	the	DT	_	10	det
9	drug3	drug3	NN	_	10	compound
10	label	label	NN	_	13	nsubjpass
11	should	should	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	reviewed	review	VBN	_	0	ROOT
14	for	for	IN	_	16	case
15	additional	additional	JJ	_	16	amod
16	drugs	drug	NNS	_	13	nmod
17	that	that	WDT	_	21	nsubjpass
18	should	should	MD	_	21	aux
19	not	not	RB	_	21	neg
20	be	be	VB	_	21	auxpass
21	coadministered	coadminister	VBN	_	16	acl:relcl
22	.	.	.	_	13	punct

1	Inducers	inducer	NNS	_	0	ROOT
2	of	of	IN	_	3	case
3	CYP3A4	cyp3a4	NN	_	1	nmod

1	Coadministration	coadministration	NN	_	22	nsubj
2	with	with	IN	_	3	case
3	compounds	compound	NNS	_	1	nmod
4	that	that	WDT	_	7	nsubj
5	are	be	VBP	_	7	cop
6	potent	potent	JJ	_	7	amod
7	inducers	inducer	NNS	_	3	acl:relcl
8	of	of	IN	_	9	case
9	CYP3A4	cyp3a4	NN	_	7	nmod
10	-LRB-	-lrb-	-LRB-	_	13	punct
11	eg	eg	FW	_	13	compound
12	,	,	,	_	13	punct
13	drug1	drug1	NN	_	1	dep
14	,	,	,	_	13	punct
15	drug2	drug2	NN	_	13	conj
16	,	,	,	_	13	punct
17	drug3	drug3	NN	_	13	conj
18	,	,	,	_	13	punct
19	drug4	drug4	NN	_	13	appos
20	-RRB-	-rrb-	-RRB-	_	13	punct
21	may	may	MD	_	22	aux
22	result	result	VB	_	0	ROOT
23	in	in	IN	_	26	case
24	decreased	decrease	VBN	_	26	amod
25	plasma	plasma	NN	_	26	compound
26	levels	level	NNS	_	22	nmod
27	of	of	IN	_	28	case
28	drug5	drug5	NN	_	26	nmod
29	.	.	.	_	22	punct

1	There	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	no	no	DT	_	4	neg
4	evidence	evidence	NN	_	2	nsubj
5	in	in	IN	_	7	case
6	clinical	clinical	JJ	_	7	amod
7	trials	trial	NNS	_	4	nmod
8	of	of	IN	_	10	case
9	drug	drug	NN	_	10	compound
10	interactions	interaction	NNS	_	7	nmod
11	with	with	IN	_	13	case
12	concurrent	concurrent	JJ	_	13	amod
13	medications	medication	NNS	_	10	nmod
14	.	.	.	_	2	punct

1	Drug	drug	NN	_	3	compound
2	interaction	interaction	NN	_	3	compound
3	studies	study	NNS	_	9	nsubjpass
4	with	with	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	have	have	VBP	_	9	aux
7	not	not	RB	_	9	neg
8	been	be	VBN	_	9	auxpass
9	conducted	conduct	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	8	nsubj
4	in	in	IN	_	7	case
5	human	human	JJ	_	7	amod
6	liver	liver	NN	_	7	compound
7	microsomes	microsome	NNS	_	3	nmod
8	suggest	suggest	VBP	_	0	ROOT
9	that	that	IN	_	12	mark
10	drug1	drug1	NN	_	12	nsubj
11	is	be	VBZ	_	12	cop
12	unlikely	unlikely	JJ	_	8	ccomp
13	to	to	TO	_	14	mark
14	inhibit	inhibit	VB	_	12	xcomp
15	or	or	CC	_	14	cc
16	induce	induce	VB	_	14	conj
17	cytochrome	cytochrome	NN	_	19	compound
18	P450	p450	NN	_	19	compound
19	enzymes	enzyme	NNS	_	14	dobj
20	.	.	.	_	8	punct

1	In	in	FW	_	4	amod
2	vitro	vitro	FW	_	1	dep
3	metabolism	metabolism	NN	_	4	compound
4	studies	study	NNS	_	6	nsubj
5	have	have	VBP	_	6	aux
6	suggested	suggest	VBN	_	0	ROOT
7	that	that	IN	_	12	mark
8	drug1	drug1	NN	_	12	nsubj
9	is	be	VBZ	_	12	cop
10	not	not	RB	_	12	neg
11	a	a	DT	_	12	det
12	substrate	substrate	NN	_	6	ccomp
13	for	for	IN	_	19	case
14	the	the	DT	_	19	det
15	human	human	JJ	_	19	amod
16	liver	liver	NN	_	19	compound
17	cytochrome	cytochrome	NN	_	19	compound
18	P450	p450	NN	_	19	compound
19	enzymes	enzyme	NNS	_	12	nmod
20	.	.	.	_	6	punct

1	As	as	IN	_	8	mark
2	plasma	plasma	NN	_	4	compound
3	protein	protein	NN	_	4	compound
4	binding	binding	NN	_	8	nsubj
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	is	be	VBZ	_	8	cop
8	negligible	negligible	JJ	_	14	advcl
9	-LRB-	-lrb-	-LRB-	_	11	punct
10	1	1	CD	_	11	nummod
11	%	%	NN	_	8	dep
12	-RRB-	-rrb-	-RRB-	_	11	punct
13	,	,	,	_	14	punct
14	interactions	interaction	NNS	_	29	nsubjpass
15	due	due	JJ	_	17	case
16	to	to	TO	_	17	case
17	displacement	displacement	NN	_	14	nmod
18	of	of	IN	_	23	case
19	more	more	RBR	_	20	advmod
20	highly	highly	RB	_	23	amod
21	protein	protein	NN	_	23	compound
22	bound	bind	VBD	_	23	amod
23	drugs	drug	NNS	_	17	nmod
24	from	from	IN	_	26	case
25	plasma	plasma	NN	_	26	compound
26	proteins	protein	NNS	_	23	nmod
27	are	be	VBP	_	29	auxpass
28	not	not	RB	_	29	neg
29	expected	expect	VBN	_	0	ROOT
30	.	.	.	_	29	punct

1	No	no	DT	_	5	neg
2	formal	formal	JJ	_	5	amod
3	drug	drug	NN	_	5	compound
4	interaction	interaction	NN	_	5	compound
5	studies	study	NNS	_	8	nsubjpass
6	have	have	VBP	_	8	aux
7	been	be	VBN	_	8	auxpass
8	conducted	conduct	VBN	_	0	ROOT
9	with	with	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	.	.	.	_	8	punct

1	Until	until	IN	_	6	mark
2	specific	specific	JJ	_	4	amod
3	compatibility	compatibility	NN	_	4	compound
4	data	datum	NNS	_	6	nsubj
5	are	be	VBP	_	6	cop
6	available	available	JJ	_	11	advcl
7	,	,	,	_	11	punct
8	it	it	PRP	_	11	nsubjpass
9	is	be	VBZ	_	11	auxpass
10	not	not	RB	_	11	neg
11	recommended	recommend	VBN	_	0	ROOT
12	that	that	IN	_	15	mark
13	drug1	drug1	NN	_	15	nsubj
14	be	be	VB	_	15	cop
15	mixed	mix	VBN	_	11	ccomp
16	with	with	IN	_	18	case
17	other	other	JJ	_	18	amod
18	drugs	drug	NNS	_	15	nmod
19	.	.	.	_	11	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	interact	interact	VB	_	0	ROOT
4	with	with	IN	_	5	case
5	drugs	drug	NNS	_	3	nmod
6	known	know	VBN	_	5	acl
7	to	to	TO	_	8	mark
8	interact	interact	VB	_	6	xcomp
9	with	with	IN	_	12	case
10	the	the	DT	_	12	det
11	conventional	conventional	JJ	_	12	amod
12	formulation	formulation	NN	_	8	nmod
13	of	of	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	.	.	.	_	3	punct

1	May	May	NNP	_	2	nsubj
2	interact	interact	VBP	_	0	ROOT
3	with	with	IN	_	4	case
4	wthionamide	wthionamide	NN	_	2	nmod
5	-LRB-	-lrb-	-LRB-	_	6	punct
6	drug1	drug1	NN	_	4	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	and	and	CC	_	4	cc
9	drug2	drug2	NN	_	4	conj
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	drug3	drug3	NN	_	9	appos
12	-RRB-	-rrb-	-RRB-	_	11	punct
13	.	.	.	_	2	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	increase	increase	VB	_	0	ROOT
4	sensitivity	sensitivity	NN	_	3	dobj
5	to	to	TO	_	7	case
6	oral	oral	JJ	_	7	amod
7	anticoagulahts	anticoagulaht	NNS	_	4	nmod
8	.	.	.	_	3	punct

1	Dosage	dosage	NN	_	6	nsubj
2	of	of	IN	_	4	case
3	the	the	DT	_	4	det
4	drug1	drug1	NN	_	1	nmod
5	may	may	MD	_	6	aux
6	require	require	VB	_	0	ROOT
7	reduction	reduction	NN	_	6	dobj
8	in	in	IN	_	11	mark
9	order	order	NN	_	8	mwe
10	to	to	TO	_	11	mark
11	maintain	maintain	VB	_	7	acl
12	satisfactory	satisfactory	JJ	_	14	amod
13	therapeutic	therapeutic	JJ	_	14	amod
14	hypoprothrombinemia	hypoprothrombinemia	NN	_	11	dobj
15	.	.	.	_	6	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	administration	administration	NN	_	8	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	may	may	MD	_	8	aux
8	result	result	VB	_	0	ROOT
9	in	in	IN	_	12	case
10	elevated	elevated	JJ	_	12	amod
11	serum	serum	NN	_	12	compound
12	levels	level	NNS	_	8	nmod
13	of	of	IN	_	14	case
14	drug3	drug3	NN	_	12	nmod
15	.	.	.	_	8	punct

1	In	in	IN	_	3	case
2	diabetic	diabetic	JJ	_	3	amod
3	patients	patient	NNS	_	11	nmod
4	,	,	,	_	11	punct
5	the	the	DT	_	7	det
6	metabolic	metabolic	JJ	_	7	amod
7	effects	effect	NNS	_	11	nsubj
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	may	may	MD	_	11	aux
11	decrease	decrease	VB	_	0	ROOT
12	blood	blood	NN	_	13	compound
13	glucose	glucose	NN	_	11	dobj
14	and	and	CC	_	11	cc
15	therefore	therefore	RB	_	18	advmod
16	,	,	,	_	18	punct
17	drug2	drug2	NN	_	18	compound
18	requirements	requirement	NNS	_	11	conj
19	.	.	.	_	11	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	shown	show	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	have	have	VB	_	4	xcomp
7	neuromuscular	neuromuscular	JJ	_	9	amod
8	blocking	block	VBG	_	9	compound
9	properties	property	NNS	_	6	dobj
10	that	that	WDT	_	12	nsubj
11	may	may	MD	_	12	aux
12	enhance	enhance	VB	_	9	acl:relcl
13	the	the	DT	_	14	det
14	action	action	NN	_	12	dobj
15	of	of	IN	_	17	case
16	other	other	JJ	_	17	amod
17	drug2	drug2	NN	_	14	nmod
18	.	.	.	_	4	punct

1	Therefore	therefore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	it	it	PRP	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	used	use	VBN	_	0	ROOT
7	in	in	IN	_	8	case
8	caution	caution	NN	_	6	nmod
9	in	in	IN	_	10	case
10	patients	patient	NNS	_	8	nmod
11	receiving	receive	VBG	_	10	acl
12	such	such	JJ	_	13	amod
13	agents	agent	NNS	_	11	dobj
14	.	.	.	_	6	punct

1	Antagonism	antagonism	NN	_	10	nsubjpass
2	between	between	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	drug2	drug2	NN	_	3	conj
6	in	in	FW	_	7	compound
7	vitro	vitro	FW	_	1	advmod
8	has	have	VBZ	_	10	aux
9	been	be	VBN	_	10	auxpass
10	demonstrated	demonstrate	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	Because	because	IN	_	5	case
2	of	of	IN	_	1	mwe
3	possible	possible	JJ	_	5	amod
4	clinical	clinical	JJ	_	5	amod
5	significance	significance	NN	_	13	nmod
6	,	,	,	_	13	punct
7	the	the	DT	_	9	det
8	two	two	CD	_	9	nummod
9	drugs	drug	NNS	_	13	nsubjpass
10	should	should	MD	_	13	aux
11	not	not	RB	_	13	neg
12	be	be	VB	_	13	auxpass
13	administered	administer	VBN	_	0	ROOT
14	concurrently	concurrently	RB	_	13	advmod
15	.	.	.	_	13	punct

1	The	the	DT	_	2	det
2	drug1	drug1	NN	_	7	nsubj
3	,	,	,	_	2	punct
4	including	include	VBG	_	5	case
5	drug2	drug2	NN	_	2	nmod
6	,	,	,	_	2	punct
7	produce	produce	VBP	_	0	ROOT
8	additive	additive	JJ	_	11	amod
9	CNS	cn	NNS	_	11	compound
10	depressant	depressant	NN	_	11	compound
11	effects	effect	NNS	_	7	dobj
12	when	when	WRB	_	13	advmod
13	co-administered	co-administer	VBN	_	7	advcl
14	with	with	IN	_	16	case
15	other	other	JJ	_	16	amod
16	drug3	drug3	NN	_	13	nmod
17	,	,	,	_	16	punct
18	drug4	drug4	NN	_	16	conj
19	,	,	,	_	16	punct
20	drug5	drug5	NN	_	16	conj
21	,	,	,	_	16	punct
22	drug6	drug6	NN	_	16	conj
23	,	,	,	_	16	punct
24	and	and	CC	_	16	cc
25	other	other	JJ	_	26	amod
26	drugs	drug	NNS	_	16	conj
27	which	which	WDT	_	29	dobj
28	themselves	themselves	PRP	_	29	nsubj
29	produce	produce	VBP	_	26	acl:relcl
30	CNS	cns	NN	_	31	compound
31	depression	depression	NN	_	29	dobj
32	.	.	.	_	7	punct

1	The	the	DT	_	5	det
2	steady	steady	JJ	_	5	amod
3	state	state	NN	_	5	compound
4	plasma	plasma	NN	_	5	compound
5	concentrations	concentration	NNS	_	12	nsubjpass
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	have	have	VBP	_	12	aux
11	been	be	VBN	_	12	auxpass
12	reported	report	VBN	_	0	ROOT
13	to	to	TO	_	15	mark
14	be	be	VB	_	15	auxpass
15	increased	increase	VBN	_	12	xcomp
16	an	a	DT	_	17	det
17	average	average	NN	_	15	dobj
18	of	of	IN	_	20	case
19	31	31	CD	_	20	nummod
20	%	%	NN	_	17	nmod
21	and	and	CC	_	20	cc
22	20	20	CD	_	23	nummod
23	%	%	NN	_	20	conj
24	,	,	,	_	15	punct
25	respectively	respectively	RB	_	15	advmod
26	,	,	,	_	15	punct
27	by	by	IN	_	30	case
28	the	the	DT	_	30	det
29	concomitant	concomitant	JJ	_	30	amod
30	administration	administration	NN	_	15	nmod
31	of	of	IN	_	33	case
32	drug3	drug3	NN	_	33	compound
33	tablets	tablet	NNS	_	30	nmod
34	in	in	IN	_	35	case
35	doses	dose	NNS	_	30	nmod
36	up	up	RB	_	35	advmod
37	to	to	TO	_	39	case
38	4	4	CD	_	39	nummod
39	mg/day	mg/day	NN	_	36	nmod
40	.	.	.	_	12	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	significance	significance	NN	_	8	nsubj
4	of	of	IN	_	6	case
5	these	these	DT	_	6	det
6	changes	change	NNS	_	3	nmod
7	is	be	VBZ	_	8	cop
8	unknown	unknown	JJ	_	0	ROOT
9	.	.	.	_	8	punct

1	Drugs	drug	NNS	_	0	ROOT
2	That	that	WDT	_	3	nsubj
3	Inhibit	inhibit	VBP	_	1	acl:relcl
4	drug1	drug1	NN	_	9	compound
5	Metabolism	metabolism	NN	_	9	compound
6	Via	Via	NNP	_	9	compound
7	Cytochrome	Cytochrome	NNP	_	9	compound
8	P450	p450	NN	_	9	compound
9	3A	3a	NN	_	3	dobj
10	:	:	:	_	1	punct
11	The	the	DT	_	13	det
12	initial	initial	JJ	_	13	amod
13	step	step	NN	_	1	dep
14	in	in	IN	_	16	case
15	drug2	drug2	NN	_	16	compound
16	metabolism	metabolism	NN	_	13	nmod
17	is	be	VBZ	_	13	acl
18	hydroxylation	hydroxylation	NN	_	17	nsubj
19	catalyzed	catalyze	VBN	_	18	acl
20	by	by	IN	_	23	case
21	cytochrome	cytochrome	NN	_	23	compound
22	P450	p450	NN	_	23	compound
23	3A	3a	NN	_	19	nmod
24	-LRB-	-lrb-	-LRB-	_	26	punct
25	CYP	cyp	NN	_	26	compound
26	3A	3a	NN	_	23	appos
27	-RRB-	-rrb-	-RRB-	_	26	punct
28	.	.	.	_	1	punct

1	Drugs	drug	NNS	_	8	nsubj
2	which	which	WDT	_	3	nsubj
3	inhibit	inhibit	VBP	_	1	acl:relcl
4	this	this	DT	_	6	det
5	metabolic	metabolic	JJ	_	6	amod
6	pathway	pathway	NN	_	3	dobj
7	may	may	MD	_	8	aux
8	have	have	VB	_	0	ROOT
9	a	a	DT	_	11	det
10	profound	profound	JJ	_	11	amod
11	effect	effect	NN	_	8	dobj
12	on	on	IN	_	14	case
13	the	the	DT	_	14	det
14	clearance	clearance	NN	_	8	nmod
15	of	of	IN	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	.	.	.	_	8	punct

1	Drugs	drug	NNS	_	2	nsubj
2	Demonstrated	demonstrate	VBN	_	23	csubjpass
3	to	to	TO	_	7	mark
4	be	be	VB	_	7	cop
5	CYP	cyp	NN	_	7	compound
6	3A	3a	NN	_	7	compound
7	Inhibitors	inhibitor	NNS	_	2	xcomp
8	of	of	IN	_	11	case
9	Possible	possible	JJ	_	11	amod
10	Clinical	clinical	JJ	_	11	amod
11	Significance	significance	NN	_	7	nmod
12	on	on	IN	_	14	case
13	the	the	DT	_	14	det
14	Basis	basis	NN	_	7	nmod
15	of	of	IN	_	17	case
16	Clinical	clinical	JJ	_	17	amod
17	Studies	study	NNS	_	14	nmod
18	Involving	involve	VBG	_	17	acl
19	drug1	drug1	NN	_	21	compound
20	-LRB-	-lrb-	-LRB-	_	21	punct
21	caution	caution	NN	_	18	dobj
22	is	be	VBZ	_	23	auxpass
23	recommended	recommend	VBN	_	0	ROOT
24	during	during	IN	_	25	case
25	coadministration	coadministration	NN	_	23	nmod
26	with	with	IN	_	27	case
27	drug2	drug2	NN	_	25	nmod
28	-RRB-	-rrb-	-RRB-	_	23	punct
29	:	:	:	_	23	punct
30	Coadministration	coadministration	NN	_	35	nsubj
31	of	of	IN	_	32	case
32	drug3	drug3	NN	_	30	nmod
33	with	with	IN	_	34	case
34	drug4	drug4	NN	_	30	nmod
35	increased	increase	VBD	_	23	parataxis
36	the	the	DT	_	39	det
37	maximum	maximum	NN	_	39	compound
38	plasma	plasma	NN	_	39	compound
39	concentration	concentration	NN	_	35	dobj
40	of	of	IN	_	41	case
41	drug5	drug5	NN	_	39	nmod
42	by	by	IN	_	44	case
43	46	46	CD	_	44	nummod
44	%	%	NN	_	35	nmod
45	,	,	,	_	35	punct
46	decreased	decrease	VBD	_	35	conj
47	clearance	clearance	NN	_	46	dobj
48	by	by	IN	_	50	case
49	21	21	CD	_	50	nummod
50	%	%	NN	_	46	nmod
51	,	,	,	_	35	punct
52	increased	increase	VBD	_	35	conj
53	half-life	half-life	NN	_	52	dobj
54	by	by	IN	_	56	case
55	17	17	CD	_	56	nummod
56	%	%	NN	_	52	nmod
57	,	,	,	_	35	punct
58	and	and	CC	_	35	cc
59	decreased	decrease	VBD	_	35	conj
60	measured	measure	VBN	_	62	amod
61	psychomotor	psychomotor	NN	_	62	compound
62	performance	performance	NN	_	59	dobj
63	.	.	.	_	23	punct

1	Coadministration	coadministration	NN	_	4	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	decreased	decrease	VBD	_	0	ROOT
5	the	the	DT	_	8	det
6	maximum	maximum	NN	_	8	compound
7	plasma	plasma	NN	_	8	compound
8	concentration	concentration	NN	_	4	dobj
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	by	by	IN	_	13	case
12	6	6	CD	_	13	nummod
13	%	%	NN	_	4	nmod
14	,	,	,	_	4	punct
15	decreased	decrease	VBD	_	16	amod
16	clearance	clearance	NN	_	4	conj
17	by	by	IN	_	19	case
18	38	38	CD	_	19	nummod
19	%	%	NN	_	16	nmod
20	,	,	,	_	4	punct
21	and	and	CC	_	4	cc
22	increased	increase	VBD	_	23	amod
23	half-life	half-life	NN	_	4	conj
24	by	by	IN	_	26	case
25	58	58	CD	_	26	nummod
26	%	%	NN	_	23	nmod
27	.	.	.	_	4	punct

1	Coadministration	coadministration	NN	_	5	nsubj
2	of	of	IN	_	4	case
3	oral	oral	JJ	_	4	amod
4	drug1	drug1	NN	_	1	nmod
5	increased	increase	VBD	_	0	ROOT
6	the	the	DT	_	9	det
7	maximum	maximum	NN	_	9	compound
8	plasma	plasma	NN	_	9	compound
9	concentration	concentration	NN	_	5	dobj
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	by	by	IN	_	14	case
13	18	18	CD	_	14	nummod
14	%	%	NN	_	5	nmod
15	,	,	,	_	5	punct
16	decreased	decrease	VBD	_	5	conj
17	clearance	clearance	NN	_	16	dobj
18	by	by	IN	_	20	case
19	22	22	CD	_	20	nummod
20	%	%	NN	_	16	nmod
21	,	,	,	_	5	punct
22	and	and	CC	_	5	cc
23	increased	increase	VBD	_	5	conj
24	half-life	half-life	NN	_	23	dobj
25	by	by	IN	_	27	case
26	29	29	CD	_	27	nummod
27	%	%	NN	_	23	nmod
28	.	.	.	_	5	punct

1	Drugs	drug	NNS	_	5	nsubj
2	and	and	CC	_	1	cc
3	other	other	JJ	_	4	amod
4	substances	substance	NNS	_	1	conj
5	demonstrated	demonstrate	VBD	_	0	ROOT
6	to	to	TO	_	10	mark
7	be	be	VB	_	10	cop
8	CYP	cyp	NN	_	10	compound
9	3A	3a	NN	_	10	compound
10	inhibitors	inhibitor	NNS	_	5	xcomp
11	on	on	IN	_	13	case
12	the	the	DT	_	13	det
13	basis	basis	NN	_	10	nmod
14	of	of	IN	_	16	case
15	clinical	clinical	JJ	_	16	amod
16	studies	study	NNS	_	13	nmod
17	involving	involve	VBG	_	16	acl
18	drug1	drug1	NN	_	17	dobj
19	metabolized	metabolize	VBN	_	18	acl
20	similarly	similarly	RB	_	19	advmod
21	to	to	TO	_	22	case
22	drug2	drug2	NN	_	19	nmod
23	or	or	CC	_	22	cc
24	on	on	IN	_	26	case
25	the	the	DT	_	26	det
26	basis	basis	NN	_	22	conj
27	of	of	IN	_	30	case
28	in	in	FW	_	30	amod
29	vitro	vitro	FW	_	28	dep
30	studies	study	NNS	_	26	nmod
31	with	with	IN	_	32	case
32	drug3	drug3	NN	_	30	nmod
33	or	or	CC	_	32	cc
34	other	other	JJ	_	35	amod
35	drug4	drug4	NN	_	32	conj
36	-LRB-	-lrb-	-LRB-	_	37	punct
37	caution	caution	NN	_	39	nsubjpass
38	is	be	VBZ	_	39	auxpass
39	recommended	recommend	VBN	_	35	acl:relcl
40	during	during	IN	_	41	case
41	coadministration	coadministration	NN	_	39	nmod
42	with	with	IN	_	43	case
43	drug5	drug5	NN	_	41	nmod
44	-RRB-	-rrb-	-RRB-	_	10	punct
45	:	:	:	_	10	punct
46	Available	available	JJ	_	47	amod
47	data	datum	NNS	_	56	nsubj
48	from	from	IN	_	50	case
49	clinical	clinical	JJ	_	50	amod
50	studies	study	NNS	_	47	nmod
51	of	of	IN	_	52	case
52	drug6	drug6	NN	_	50	nmod
53	other	other	JJ	_	52	amod
54	than	than	IN	_	55	case
55	drug7	drug7	NN	_	53	nmod
56	suggest	suggest	VBP	_	10	parataxis
57	a	a	DT	_	60	det
58	possible	possible	JJ	_	60	amod
59	drug	drug	NN	_	60	compound
60	interaction	interaction	NN	_	56	dobj
61	with	with	IN	_	62	case
62	drug8	drug8	NN	_	60	nmod
63	for	for	IN	_	65	case
64	the	the	DT	_	65	det
65	following	following	NN	_	60	nmod
66	:	:	:	_	56	punct
67	drug9	drug9	NN	_	56	dep
68	,	,	,	_	67	punct
69	drug10	drug10	NN	_	67	conj
70	,	,	,	_	67	punct
71	drug11	drug11	NN	_	67	conj
72	such	such	JJ	_	74	case
73	as	as	IN	_	72	mwe
74	drug12	drug12	NN	_	71	nmod
75	and	and	CC	_	74	cc
76	drug13	drug13	NN	_	74	conj
77	,	,	,	_	67	punct
78	and	and	CC	_	67	cc
79	grapefruit	grapefruit	NN	_	80	compound
80	juice	juice	NN	_	67	conj
81	.	.	.	_	5	punct

1	Data	datum	NNS	_	8	nsubj
2	from	from	IN	_	5	case
3	in	in	FW	_	5	amod
4	vitro	vitro	FW	_	3	dep
5	studies	study	NNS	_	1	nmod
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	suggest	suggest	VBP	_	0	ROOT
9	a	a	DT	_	12	det
10	possible	possible	JJ	_	12	amod
11	drug	drug	NN	_	12	compound
12	interaction	interaction	NN	_	8	dobj
13	with	with	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	for	for	IN	_	17	case
16	the	the	DT	_	17	det
17	following	following	NN	_	12	nmod
18	:	:	:	_	12	punct
19	drug3	drug3	NN	_	12	dep
20	and	and	CC	_	19	cc
21	drug4	drug4	NN	_	19	conj
22	.	.	.	_	8	punct

1	Data	datum	NNS	_	11	nsubj
2	from	from	IN	_	5	case
3	in	in	FW	_	5	amod
4	vitro	vitro	FW	_	3	dep
5	studies	study	NNS	_	1	nmod
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	other	other	JJ	_	7	amod
9	than	than	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	suggest	suggest	VBP	_	0	ROOT
12	a	a	DT	_	15	det
13	possible	possible	JJ	_	15	amod
14	drug	drug	NN	_	15	compound
15	interaction	interaction	NN	_	11	dobj
16	for	for	IN	_	18	case
17	the	the	DT	_	18	det
18	following	following	NN	_	15	nmod
19	:	:	:	_	15	punct
20	drug3	drug3	NN	_	15	dep
21	,	,	,	_	20	punct
22	drug4	drug4	NN	_	20	conj
23	,	,	,	_	20	punct
24	drug5	drug5	NN	_	20	conj
25	,	,	,	_	20	punct
26	drug6	drug6	NN	_	20	conj
27	,	,	,	_	20	punct
28	and	and	CC	_	20	cc
29	drug7	drug7	NN	_	20	conj
30	.	.	.	_	11	punct

1	Caution	caution	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	recommended	recommend	VBN	_	0	ROOT
4	during	during	IN	_	6	case
5	the	the	DT	_	6	det
6	coadministration	coadministration	NN	_	3	nmod
7	of	of	IN	_	8	case
8	any	any	DT	_	6	nmod
9	of	of	IN	_	10	case
10	these	these	DT	_	8	nmod
11	with	with	IN	_	12	case
12	drug1	drug1	NN	_	6	nmod
13	.	.	.	_	3	punct

1	Oral	oral	JJ	_	2	amod
2	drug1	drug1	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	In	in	IN	_	7	case
5	some	some	DT	_	7	det
6	normal	normal	JJ	_	7	amod
7	volunteers	volunteer	NNS	_	21	nmod
8	,	,	,	_	21	punct
9	the	the	DT	_	11	det
10	concomitant	concomitant	JJ	_	11	amod
11	administration	administration	NN	_	21	nsubj
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	and	and	CC	_	13	cc
15	drug3	drug3	NN	_	13	conj
16	,	,	,	_	13	punct
17	drug4	drug4	NN	_	13	conj
18	,	,	,	_	13	punct
19	or	or	CC	_	13	cc
20	drug5	drug5	NN	_	13	conj
21	resulted	result	VBD	_	2	appos
22	in	in	IN	_	23	case
23	prolongation	prolongation	NN	_	21	nmod
24	of	of	IN	_	26	case
25	prothrombin	prothrombin	NN	_	26	compound
26	time	time	NN	_	23	nmod
27	.	.	.	_	2	punct

1	This	this	DT	_	3	nsubj
2	may	may	MD	_	3	aux
3	occur	occur	VB	_	0	ROOT
4	because	because	IN	_	7	mark
5	drug1	drug1	NN	_	7	nsubj
6	competitively	competitively	RB	_	7	advmod
7	displaces	displace	VBZ	_	3	advcl
8	drug2	drug2	NN	_	7	dobj
9	from	from	IN	_	12	case
10	protein	protein	NN	_	12	compound
11	binding	binding	NN	_	12	compound
12	sites	site	NNS	_	7	nmod
13	.	.	.	_	3	punct

1	Accordingly	accordingly	RB	_	17	advmod
2	,	,	,	_	17	punct
3	when	when	WRB	_	6	advmod
4	drug1	drug1	NN	_	6	nsubjpass
5	is	be	VBZ	_	6	auxpass
6	administered	administer	VBN	_	17	advcl
7	with	with	IN	_	9	case
8	oral	oral	JJ	_	9	amod
9	drug2	drug2	NN	_	6	nmod
10	,	,	,	_	17	punct
11	the	the	DT	_	13	det
12	prothrombin	prothrombin	NN	_	13	compound
13	time	time	NN	_	17	nsubjpass
14	should	should	MD	_	17	aux
15	be	be	VB	_	17	auxpass
16	closely	closely	RB	_	17	advmod
17	monitored	monitor	VBN	_	0	ROOT
18	during	during	IN	_	22	case
19	and	and	CC	_	18	cc
20	for	for	IN	_	18	conj
21	several	several	JJ	_	22	amod
22	days	day	NNS	_	17	nmod
23	after	after	IN	_	26	case
24	concomitant	concomitant	JJ	_	26	amod
25	drug	drug	NN	_	26	compound
26	administration	administration	NN	_	17	nmod
27	.	.	.	_	17	punct

1	Adjustment	Adjustment	NNP	_	9	nsubjpass
2	of	of	IN	_	3	case
3	dosage	dosage	NN	_	1	nmod
4	of	of	IN	_	6	case
5	oral	oral	JJ	_	6	amod
6	drug1	drug1	NN	_	3	nmod
7	may	may	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	required	require	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	5	case
4	diabetic	diabetic	JJ	_	5	amod
5	patients	patient	NNS	_	15	nmod
6	receiving	receive	VBG	_	5	acl
7	drug2	drug2	NN	_	6	dobj
8	and	and	CC	_	7	cc
9	drug3	drug3	NN	_	7	conj
10	,	,	,	_	5	punct
11	no	no	DT	_	13	neg
12	significant	significant	JJ	_	13	amod
13	effects	effect	NNS	_	15	nsubjpass
14	were	be	VBD	_	15	auxpass
15	seen	see	VBN	_	1	appos
16	on	on	IN	_	19	case
17	drug4	drug4	NN	_	19	compound
18	plasma	plasma	NN	_	19	compound
19	levels	level	NNS	_	15	nmod
20	or	or	CC	_	19	cc
21	fasting	fasting	JJ	_	23	amod
22	blood	blood	NN	_	23	compound
23	glucose	glucose	NN	_	19	conj
24	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	5	case
4	normal	normal	JJ	_	5	amod
5	volunteers	volunteer	NNS	_	1	nmod
6	,	,	,	_	5	punct
7	concomitant	concomitant	JJ	_	8	amod
8	administration	administration	NN	_	5	appos
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	drug3	drug3	NN	_	10	conj
13	resulted	result	VBD	_	5	acl
14	in	in	IN	_	18	case
15	significantly	significantly	RB	_	16	advmod
16	increased	increase	VBN	_	18	amod
17	plasma	plasma	NN	_	18	compound
18	levels	level	NNS	_	13	nmod
19	of	of	IN	_	20	case
20	drug4	drug4	NN	_	18	nmod
21	.	.	.	_	1	punct

1	drug1	drug1	NN	_	2	nsubj
2	decreased	decrease	VBD	_	0	ROOT
3	the	the	DT	_	5	det
4	hyperuricemic	hyperuricemic	JJ	_	5	amod
5	effect	effect	NN	_	2	dobj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	5	case
4	normal	normal	JJ	_	5	amod
5	volunteers	volunteer	NNS	_	1	nmod
6	,	,	,	_	5	punct
7	the	the	DT	_	9	det
8	concomitant	concomitant	JJ	_	9	amod
9	administration	administration	NN	_	14	nsubj
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	drug3	drug3	NN	_	11	conj
14	had	have	VBD	_	5	acl:relcl
15	no	no	DT	_	16	neg
16	effect	effect	NN	_	14	dobj
17	on	on	IN	_	20	case
18	the	the	DT	_	20	det
19	diuretic	diuretic	JJ	_	20	amod
20	activity	activity	NN	_	14	nmod
21	of	of	IN	_	22	case
22	drug4	drug4	NN	_	20	nmod
23	.	.	.	_	1	punct

1	drug1	drug1	NN	_	2	nsubj
2	decreased	decrease	VBD	_	0	ROOT
3	the	the	DT	_	5	det
4	hyperuricemic	hyperuricemic	JJ	_	5	amod
5	effect	effect	NN	_	2	dobj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concomitant	concomitant	JJ	_	4	amod
4	administration	administration	NN	_	8	nsubj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	may	may	MD	_	8	aux
8	reduce	reduce	VB	_	1	appos
9	plasma	plasma	NN	_	10	compound
10	levels	level	NNS	_	8	dobj
11	of	of	IN	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	.	.	.	_	1	punct

1	This	this	DT	_	2	det
2	effect	effect	NN	_	4	nsubj
3	is	be	VBZ	_	4	cop
4	small	small	JJ	_	0	ROOT
5	with	with	IN	_	7	case
6	occasional	occasional	JJ	_	7	amod
7	doses	dose	NNS	_	4	nmod
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	,	,	,	_	4	punct
11	but	but	CC	_	4	cc
12	may	may	MD	_	15	aux
13	be	be	VB	_	15	cop
14	clinically	clinically	RB	_	15	advmod
15	significant	significant	JJ	_	4	conj
16	when	when	WRB	_	19	advmod
17	drug2	drug2	NN	_	19	nsubjpass
18	are	be	VBP	_	19	auxpass
19	used	use	VBN	_	15	advcl
20	on	on	IN	_	23	case
21	a	a	DT	_	23	det
22	continuous	continuous	JJ	_	23	amod
23	schedule	schedule	NN	_	19	nmod
24	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	5	case
4	normal	normal	JJ	_	5	amod
5	volunteers	volunteer	NNS	_	13	nmod
6	,	,	,	_	5	punct
7	concomitant	concomitant	JJ	_	8	amod
8	administration	administration	NN	_	5	appos
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	drug3	drug3	NN	_	10	conj
13	resulted	result	VBD	_	1	appos
14	in	in	IN	_	19	case
15	an	a	DT	_	19	det
16	approximate	approximate	JJ	_	19	amod
17	50	50	CD	_	18	compound
18	%	%	NN	_	19	amod
19	increase	increase	NN	_	13	nmod
20	in	in	IN	_	22	case
21	plasma	plasma	NN	_	22	compound
22	levels	level	NNS	_	19	nmod
23	of	of	IN	_	24	case
24	drug4	drug4	NN	_	22	nmod
25	.	.	.	_	1	punct

1	drug1	drug1	NN	_	2	nsubj
2	had	have	VBD	_	0	ROOT
3	no	no	DT	_	4	neg
4	effect	effect	NN	_	2	dobj
5	on	on	IN	_	7	case
6	plasma	plasma	NN	_	7	compound
7	levels	level	NNS	_	2	nmod
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	.	.	.	_	2	punct

1	Since	since	IN	_	2	case
2	drug1	drug1	NN	_	8	nmod
3	in	in	IN	_	5	case
4	high	high	JJ	_	5	amod
5	doses	dose	NNS	_	2	nmod
6	has	have	VBZ	_	8	aux
7	been	be	VBN	_	8	auxpass
8	associated	associate	VBN	_	20	nsubjpass
9	with	with	IN	_	10	case
10	hepatotoxicity	hepatotoxicity	NN	_	8	nmod
11	,	,	,	_	10	punct
12	concomitant	concomitant	JJ	_	13	amod
13	administration	administration	NN	_	10	appos
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	drug3	drug3	NN	_	15	conj
18	should	should	MD	_	20	aux
19	be	be	VB	_	20	auxpass
20	used	use	VBN	_	0	ROOT
21	cautiously	cautiously	RB	_	20	advmod
22	,	,	,	_	20	punct
23	with	with	IN	_	25	case
24	careful	careful	JJ	_	25	amod
25	monitoring	monitoring	NN	_	20	nmod
26	of	of	IN	_	27	case
27	patients	patient	NNS	_	25	nmod
28	.	.	.	_	20	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	37	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	in	in	IN	_	8	case
8	dogs	dog	NNS	_	2	nmod
9	,	,	,	_	8	punct
10	but	but	CC	_	8	cc
11	not	not	RB	_	13	neg
12	in	in	IN	_	13	case
13	rats	rat	NNS	_	8	conj
14	,	,	,	_	2	punct
15	at	at	IN	_	18	case
16	approximately	approximately	RB	_	17	advmod
17	2	2	CD	_	18	nummod
18	times	time	NNS	_	37	nmod
19	the	the	DT	_	24	det
20	recommended	recommend	VBN	_	24	amod
21	maximum	maximum	NN	_	24	amod
22	human	human	JJ	_	24	amod
23	therapeutic	therapeutic	JJ	_	24	amod
24	dose	dose	NN	_	37	nsubj
25	of	of	IN	_	26	case
26	each	each	DT	_	24	nmod
27	-LRB-	-lrb-	-LRB-	_	31	punct
28	40	40	CD	_	30	compound
29	to	to	TO	_	30	dep
30	52	52	CD	_	31	nummod
31	mg/kg/day	mg/kg/day	NN	_	26	dep
32	of	of	IN	_	33	case
33	drug3	drug3	NN	_	31	nmod
34	/	/	:	_	31	punct
35	drug4	drug4	NN	_	31	dep
36	-RRB-	-rrb-	-RRB-	_	31	punct
37	resulted	result	VBD	_	0	ROOT
38	in	in	IN	_	41	case
39	greater	greater	JJR	_	41	amod
40	gastrointestinal	gastrointestinal	JJ	_	41	amod
41	toxicity	toxicity	NN	_	37	nmod
42	than	than	IN	_	47	mark
43	when	when	WRB	_	47	advmod
44	either	either	CC	_	45	det
45	drug	drug	NN	_	47	nsubjpass
46	was	be	VBD	_	47	auxpass
47	administered	administer	VBN	_	41	acl
48	alone	alone	RB	_	47	advmod
49	.	.	.	_	37	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	significance	significance	NN	_	10	nsubjpass
4	of	of	IN	_	6	case
5	these	these	DT	_	6	det
6	findings	finding	NNS	_	3	nmod
7	has	have	VBZ	_	10	aux
8	not	not	RB	_	10	neg
9	been	be	VBN	_	10	auxpass
10	established	establish	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Caution	caution	NN	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	used	use	VBN	_	1	appos
7	if	if	IN	_	10	mark
8	drug2	drug2	NN	_	10	nsubjpass
9	is	be	VBZ	_	10	auxpass
10	administered	administer	VBN	_	6	advcl
11	concomitantly	concomitantly	RB	_	10	advmod
12	with	with	IN	_	13	case
13	drug3	drug3	NN	_	10	nmod
14	.	.	.	_	1	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	have	have	VBP	_	4	aux
3	been	be	VBN	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	decrease	decrease	VB	_	4	ccomp
7	the	the	DT	_	9	det
8	tubular	tubular	JJ	_	9	amod
9	secretion	secretion	NN	_	6	dobj
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	and	and	CC	_	6	cc
13	to	to	TO	_	14	mark
14	potentiate	potentiate	VB	_	6	conj
15	its	its	PRP$	_	16	nmod:poss
16	toxicity	toxicity	NN	_	14	dobj
17	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Administration	administration	NN	_	11	nsubjpass
4	of	of	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	concomitantly	concomitantly	RB	_	3	advmod
7	with	with	IN	_	8	case
8	drug3	drug3	NN	_	6	nmod
9	has	have	VBZ	_	11	aux
10	been	be	VBN	_	11	auxpass
11	associated	associate	VBN	_	1	appos
12	with	with	IN	_	14	case
13	an	a	DT	_	14	det
14	increase	increase	NN	_	11	nmod
15	in	in	IN	_	16	case
16	drug4	drug4	NN	_	14	nmod
17	-	-	:	_	14	punct
18	induced	induce	VBN	_	19	amod
19	toxicity	toxicity	NN	_	14	dep
20	,	,	,	_	19	punct
21	possibly	possibly	RB	_	22	advmod
22	due	due	JJ	_	19	amod
23	to	to	TO	_	25	case
24	decreased	decrease	VBN	_	25	amod
25	synthesis	synthesis	NN	_	22	nmod
26	of	of	IN	_	28	case
27	renal	renal	JJ	_	28	amod
28	prostacyclin	prostacyclin	NN	_	25	nmod
29	.	.	.	_	1	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	with	with	IN	_	6	case
6	caution	caution	NN	_	4	nmod
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	taking	take	VBG	_	8	acl
10	drug2	drug2	NN	_	9	dobj
11	,	,	,	_	4	punct
12	and	and	CC	_	4	cc
13	renal	renal	JJ	_	14	amod
14	function	function	NN	_	18	nsubjpass
15	should	should	MD	_	18	aux
16	be	be	VB	_	18	auxpass
17	carefully	carefully	RB	_	18	advmod
18	monitored	monitor	VBN	_	4	conj
19	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	administration	administration	NN	_	12	nsubj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	to	to	TO	_	9	case
8	normal	normal	JJ	_	9	amod
9	volunteers	volunteer	NNS	_	4	nmod
10	receiving	receive	VBG	_	9	acl
11	drug3	drug3	NN	_	10	dobj
12	decreased	decrease	VBD	_	1	appos
13	the	the	DT	_	15	det
14	renal	renal	JJ	_	15	amod
15	clearance	clearance	NN	_	12	dobj
16	and	and	CC	_	12	cc
17	significantly	significantly	RB	_	18	advmod
18	increased	increase	VBD	_	12	conj
19	the	the	DT	_	21	det
20	plasma	plasma	NN	_	21	compound
21	levels	level	NNS	_	18	dobj
22	of	of	IN	_	23	case
23	drug4	drug4	NN	_	21	nmod
24	.	.	.	_	1	punct

1	In	in	IN	_	3	case
2	some	some	DT	_	3	det
3	patients	patient	NNS	_	13	nmod
4	the	the	DT	_	6	det
5	combined	combined	JJ	_	6	amod
6	use	use	NN	_	13	nsubjpass
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	drug2	drug2	NN	_	8	conj
11	has	have	VBZ	_	13	aux
12	been	be	VBN	_	13	auxpass
13	associated	associate	VBN	_	0	ROOT
14	with	with	IN	_	17	case
15	fatal	fatal	JJ	_	17	amod
16	gastrointestinal	gastrointestinal	JJ	_	17	amod
17	hemorrhage	hemorrhage	NN	_	13	nmod
18	.	.	.	_	13	punct

1	Therefore	therefore	RB	_	9	advmod
2	,	,	,	_	9	punct
3	drug1	drug1	NN	_	9	nsubjpass
4	and	and	CC	_	3	cc
5	drug2	drug2	NN	_	3	conj
6	should	should	MD	_	9	aux
7	not	not	RB	_	9	neg
8	be	be	VB	_	9	auxpass
9	used	use	VBN	_	0	ROOT
10	concomitantly	concomitantly	RB	_	9	advmod
11	.	.	.	_	9	punct

1	The	the	DT	_	3	det
2	concomitant	concomitant	JJ	_	3	amod
3	use	use	NN	_	12	nsubjpass
4	of	of	IN	_	6	case
5	drug1	drug1	NN	_	6	compound
6	tablets	tablet	NNS	_	3	nmod
7	and	and	CC	_	6	cc
8	other	other	JJ	_	9	amod
9	drug2	drug2	NN	_	6	conj
10	is	be	VBZ	_	12	auxpass
11	not	not	RB	_	12	neg
12	recommended	recommend	VBN	_	0	ROOT
13	due	due	JJ	_	17	case
14	to	to	TO	_	13	mwe
15	the	the	DT	_	17	det
16	increased	increase	VBN	_	17	amod
17	possibility	possibility	NN	_	12	nmod
18	of	of	IN	_	20	case
19	gastrointestinal	gastrointestinal	JJ	_	20	amod
20	toxicity	toxicity	NN	_	17	nmod
21	,	,	,	_	12	punct
22	with	with	IN	_	23	case
23	little	little	JJ	_	12	nmod
24	or	or	CC	_	23	cc
25	no	no	DT	_	23	conj
26	increase	increase	NN	_	23	dep
27	in	in	IN	_	28	case
28	efficacy	efficacy	NN	_	23	nmod
29	.	.	.	_	12	punct

1	The	the	DT	_	3	det
2	following	follow	VBG	_	3	amod
3	information	information	NN	_	5	nsubjpass
4	was	be	VBD	_	5	auxpass
5	obtained	obtain	VBN	_	0	ROOT
6	from	from	IN	_	7	case
7	studies	study	NNS	_	5	nmod
8	in	in	IN	_	10	case
9	normal	normal	JJ	_	10	amod
10	volunteers	volunteer	NNS	_	7	nmod
11	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	5	case
4	normal	normal	JJ	_	5	amod
5	volunteers	volunteer	NNS	_	14	nmod
6	,	,	,	_	5	punct
7	a	a	DT	_	9	det
8	small	small	JJ	_	9	amod
9	decrease	decrease	NN	_	14	nsubjpass
10	in	in	IN	_	12	case
11	drug2	drug2	NN	_	12	compound
12	levels	level	NNS	_	9	nmod
13	was	be	VBD	_	14	auxpass
14	observed	observe	VBN	_	1	appos
15	when	when	WRB	_	23	advmod
16	multiple	multiple	JJ	_	17	amod
17	doses	dose	NNS	_	23	nsubjpass
18	of	of	IN	_	19	case
19	drug3	drug3	NN	_	17	nmod
20	and	and	CC	_	19	cc
21	drug4	drug4	NN	_	19	conj
22	were	be	VBD	_	23	auxpass
23	administered	administer	VBN	_	14	advcl
24	concomitantly	concomitantly	RB	_	23	advmod
25	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	5	det
4	concomitant	concomitant	JJ	_	5	amod
5	administration	administration	NN	_	13	nsubj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drug3	drug3	NN	_	7	conj
10	in	in	IN	_	12	case
11	normal	normal	JJ	_	12	amod
12	volunteers	volunteer	NNS	_	5	nmod
13	resulted	result	VBD	_	1	dep
14	in	in	IN	_	15	case
15	lowering	lowering	NN	_	13	nmod
16	of	of	IN	_	19	case
17	the	the	DT	_	19	det
18	plasma	plasma	NN	_	19	compound
19	levels	level	NNS	_	15	nmod
20	of	of	IN	_	25	case
21	the	the	DT	_	25	det
22	active	active	JJ	_	25	amod
23	sulindac	sulindac	NN	_	25	compound
24	sulfide	sulfide	NN	_	25	compound
25	metabolite	metabolite	NN	_	19	nmod
26	by	by	IN	_	28	case
27	approximately	approximately	RB	_	28	advmod
28	one-third	one-third	JJ	_	13	nmod
29	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	5	det
4	concomitant	concomitant	JJ	_	5	amod
5	administration	administration	NN	_	13	nsubj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drug3	drug3	NN	_	7	conj
10	in	in	IN	_	12	case
11	normal	normal	JJ	_	12	amod
12	volunteers	volunteer	NNS	_	5	nmod
13	had	have	VBD	_	1	appos
14	no	no	DT	_	15	neg
15	effect	effect	NN	_	13	dobj
16	on	on	IN	_	19	case
17	the	the	DT	_	19	det
18	plasma	plasma	NN	_	19	compound
19	levels	level	NNS	_	13	nmod
20	of	of	IN	_	21	case
21	drug4	drug4	NN	_	19	nmod
22	,	,	,	_	13	punct
23	but	but	CC	_	13	cc
24	significantly	significantly	RB	_	25	advmod
25	decreased	decrease	VBD	_	13	conj
26	the	the	DT	_	28	det
27	urinary	urinary	JJ	_	28	amod
28	excretion	excretion	NN	_	25	dobj
29	of	of	IN	_	30	case
30	drug5	drug5	NN	_	28	nmod
31	and	and	CC	_	30	cc
32	its	its	PRP$	_	34	nmod:poss
33	glucuronide	glucuronide	NN	_	34	compound
34	metabolite	metabolite	NN	_	30	conj
35	.	.	.	_	1	punct

1	drug1	drug1	NN	_	2	nsubj
2	had	have	VBD	_	0	ROOT
3	no	no	DT	_	4	neg
4	effect	effect	NN	_	2	dobj
5	on	on	IN	_	7	case
6	plasma	plasma	NN	_	7	compound
7	levels	level	NNS	_	2	nmod
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	.	.	.	_	2	punct

1	Drug	drug	NN	_	7	compound
2	laboratory	laboratory	NN	_	7	compound
3	Test	test	NN	_	7	compound
4	Interactions	interaction	NNS	_	7	compound
5	Serum	serum	NN	_	7	compound
6	Salicylate	Salicylate	NNP	_	7	compound
7	Assays	assay	NNS	_	0	ROOT
8	:	:	:	_	7	punct
9	Caution	caution	NN	_	12	nsubjpass
10	should	should	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	used	use	VBN	_	7	dep
13	in	in	IN	_	14	mark
14	interpreting	interpret	VBG	_	12	advcl
15	the	the	DT	_	16	det
16	results	result	NNS	_	14	dobj
17	of	of	IN	_	20	case
18	serum	serum	NN	_	20	compound
19	salicylate	salicylate	NN	_	20	compound
20	assays	assay	NNS	_	16	nmod
21	when	when	WRB	_	24	advmod
22	drug1	drug1	NN	_	24	nsubj
23	is	be	VBZ	_	24	cop
24	present	present	JJ	_	12	advcl
25	.	.	.	_	7	punct

1	drug1	drug1	NN	_	2	compound
2	levels	level	NNS	_	5	nsubjpass
3	have	have	VBP	_	5	aux
4	been	be	VBN	_	5	auxpass
5	found	find	VBN	_	0	ROOT
6	to	to	TO	_	9	mark
7	be	be	VB	_	9	cop
8	falsely	falsely	RB	_	9	advmod
9	elevated	elevated	JJ	_	5	xcomp
10	with	with	IN	_	13	case
11	some	some	DT	_	13	det
12	assay	assay	NN	_	13	compound
13	methods	method	NNS	_	9	nmod
14	.	.	.	_	5	punct

1	Co-administration	co-administration	NN	_	21	nsubjpass
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	drug2	drug2	NN	_	3	conj
6	or	or	CC	_	3	cc
7	other	other	JJ	_	8	amod
8	agents	agent	NNS	_	3	conj
9	interfering	interfere	VBG	_	8	acl
10	with	with	IN	_	12	case
11	neuromuscular	neuromuscular	JJ	_	12	amod
12	transmission	transmission	NN	_	9	nmod
13	-LRB-	-lrb-	-LRB-	_	16	punct
14	e.g.	e.g.	FW	_	16	dep
15	,	,	,	_	16	punct
16	drug3	drug3	NN	_	12	appos
17	-RRB-	-rrb-	-RRB-	_	16	punct
18	should	should	MD	_	21	aux
19	only	only	RB	_	21	advmod
20	be	be	VB	_	21	auxpass
21	performed	perform	VBN	_	32	csubjpass
22	with	with	IN	_	23	case
23	caution	caution	NN	_	21	nmod
24	as	as	IN	_	26	case
25	the	the	DT	_	26	det
26	effect	effect	NN	_	21	nmod
27	of	of	IN	_	29	case
28	the	the	DT	_	29	det
29	drug4	drug4	NN	_	26	nmod
30	may	may	MD	_	32	aux
31	be	be	VB	_	32	auxpass
32	potentiated	potentiate	VBN	_	0	ROOT
33	.	.	.	_	32	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	20	nsubj
3	of	of	IN	_	4	mark
4	administering	administer	VBG	_	2	acl
5	different	different	JJ	_	7	amod
6	drug1	drug1	NN	_	7	compound
7	serotypes	serotype	NNS	_	4	dobj
8	at	at	IN	_	11	case
9	the	the	DT	_	11	det
10	same	same	JJ	_	11	amod
11	time	time	NN	_	4	nmod
12	or	or	CC	_	11	cc
13	within	within	IN	_	15	case
14	several	several	JJ	_	15	amod
15	months	month	NNS	_	11	conj
16	of	of	IN	_	18	case
17	each	each	DT	_	18	det
18	other	other	JJ	_	11	nmod
19	is	be	VBZ	_	20	cop
20	unknown	unknown	JJ	_	0	ROOT
21	.	.	.	_	20	punct

1	Excessive	excessive	JJ	_	3	amod
2	neuromuscular	neuromuscular	JJ	_	3	amod
3	weakness	weakness	NN	_	6	nsubjpass
4	may	may	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	exacerbated	exacerbate	VBN	_	0	ROOT
7	by	by	IN	_	8	case
8	administration	administration	NN	_	6	nmod
9	of	of	IN	_	11	case
10	another	another	DT	_	11	det
11	drug1	drug1	NN	_	8	nmod
12	prior	prior	RB	_	6	advmod
13	to	to	TO	_	15	case
14	the	the	DT	_	15	det
15	resolution	resolution	NN	_	12	nmod
16	of	of	IN	_	18	case
17	the	the	DT	_	18	det
18	effects	effect	NNS	_	15	nmod
19	of	of	IN	_	23	case
20	a	a	DT	_	23	det
21	previously	previously	RB	_	22	advmod
22	administered	administer	VBN	_	23	amod
23	drug2	drug2	NN	_	18	nmod
24	.	.	.	_	6	punct

1	There	there	EX	_	2	expl
2	are	be	VBP	_	0	ROOT
3	no	no	RB	_	6	neg
4	known	know	VBN	_	6	amod
5	drug	drug	NN	_	6	compound
6	interactions	interaction	NNS	_	2	nsubj
7	with	with	IN	_	9	case
8	drug1	drug1	NN	_	9	compound
9	Injection	injection	NN	_	6	nmod
10	.	.	.	_	2	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	exercised	exercise	VBN	_	0	ROOT
5	if	if	IN	_	9	mark
6	drug1	drug1	NN	_	7	compound
7	Injection	injection	NN	_	9	nsubjpass
8	is	be	VBZ	_	9	auxpass
9	administered	administer	VBN	_	4	advcl
10	before	before	RB	_	9	advmod
11	,	,	,	_	9	punct
12	after	after	IN	_	9	dep
13	,	,	,	_	12	punct
14	or	or	CC	_	13	root
15	in	in	IN	_	16	case
16	conjunction	conjunction	NN	_	14	conj
17	with	with	IN	_	19	case
18	other	other	JJ	_	19	amod
19	drugs	drug	NNS	_	16	nmod
20	known	know	VBN	_	19	acl
21	to	to	TO	_	22	mark
22	cause	cause	VB	_	20	xcomp
23	immunosuppression	immunosuppression	NN	_	22	dobj
24	or	or	CC	_	23	cc
25	myelosuppression	myelosuppression	NN	_	23	conj
26	.	.	.	_	14	punct

1	Effects	effect	NNS	_	13	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	on	on	IN	_	5	case
5	Drug	drug	NN	_	1	nmod
6	Metabolizing	metabolize	VBG	_	12	amod
7	Enzymes	enzyme	NNS	_	12	compound
8	and	and	CC	_	7	cc
9	Drug	drug	NN	_	7	conj
10	Transport	Transport	NNP	_	12	compound
11	Systems	Systems	NNP	_	12	compound
12	drug2	drug2	NN	_	5	dep
13	inhibits	inhibit	VBZ	_	0	ROOT
14	CYP3A4	cyp3a4	NN	_	13	dobj
15	and	and	CC	_	14	cc
16	CYP2C8	cyp2c8	NN	_	14	conj
17	in	in	FW	_	18	compound
18	vitro	vitro	FW	_	13	advmod
19	at	at	IN	_	22	case
20	clinically	clinically	RB	_	21	advmod
21	relevant	relevant	JJ	_	22	amod
22	concentrations	concentration	NNS	_	13	nmod
23	.	.	.	_	13	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	exercised	exercise	VBN	_	0	ROOT
5	and	and	CC	_	4	cc
6	dose	dose	NN	_	7	compound
7	reduction	reduction	NN	_	15	nsubjpass
8	of	of	IN	_	12	case
9	the	the	DT	_	12	det
10	concomitant	concomitant	JJ	_	12	amod
11	substrate	substrate	NN	_	12	compound
12	drug	drug	NN	_	7	nmod
13	should	should	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	considered	consider	VBN	_	4	conj
16	when	when	WRB	_	15	dep
17	dosing	dosing	NN	_	18	compound
18	drug1	drug1	NN	_	16	dep
19	concurrently	concurrently	RB	_	21	advmod
20	with	with	IN	_	21	case
21	medications	medication	NNS	_	18	nmod
22	with	with	IN	_	25	case
23	narrow	narrow	JJ	_	25	amod
24	therapeutic	therapeutic	JJ	_	25	amod
25	windows	window	NNS	_	21	nmod
26	that	that	WDT	_	28	nsubj
27	are	be	VBP	_	28	cop
28	substrates	substrate	NNS	_	25	acl:relcl
29	of	of	IN	_	30	case
30	CYP3A4	cyp3a4	NN	_	28	nmod
31	or	or	CC	_	30	cc
32	CYP2C8	cyp2c8	NN	_	30	conj
33	.	.	.	_	4	punct

1	drug1	drug1	NN	_	5	nsubj
2	did	do	VBD	_	5	aux
3	not	not	RB	_	5	neg
4	significantly	significantly	RB	_	5	advmod
5	inhibit	inhibit	VB	_	0	ROOT
6	the	the	DT	_	8	det
7	following	follow	VBG	_	8	amod
8	enzymes	enzyme	NNS	_	5	dobj
9	in	in	IN	_	12	case
10	human	human	JJ	_	12	amod
11	liver	liver	NN	_	12	compound
12	microsomes	microsome	NNS	_	8	nmod
13	:	:	:	_	8	punct
14	CYP1A2	cyp1a2	NN	_	8	dep
15	,	,	,	_	14	punct
16	CYP2C9	cyp2c9	NN	_	14	conj
17	,	,	,	_	14	punct
18	CYP2C19	cyp2c19	NN	_	14	conj
19	,	,	,	_	14	punct
20	and	and	CC	_	14	cc
21	CYP2D6	cyp2d6	NN	_	24	compound
22	or	or	CC	_	21	cc
23	UGT	ugt	NN	_	21	conj
24	enzymes	enzyme	NNS	_	14	conj
25	in	in	FW	_	26	compound
26	vitro	vitro	FW	_	14	advmod
27	,	,	,	_	14	punct
28	however	however	RB	_	14	advmod
29	,	,	,	_	14	punct
30	the	the	DT	_	32	det
31	clinical	clinical	JJ	_	32	amod
32	significance	significance	NN	_	34	nsubj
33	is	be	VBZ	_	34	cop
34	unknown	unknown	JJ	_	14	dep
35	.	.	.	_	5	punct

1	drug1	drug1	NN	_	2	nsubj
2	inhibits	inhibit	VBZ	_	0	ROOT
3	human	human	JJ	_	4	amod
4	P-glycoprotein	p-glycoprotein	NN	_	2	dobj
5	.	.	.	_	2	punct

1	If	if	IN	_	4	mark
2	drug1	drug1	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	administered	administer	VBN	_	20	advcl
5	with	with	IN	_	6	case
6	drugs	drug	NNS	_	4	nmod
7	that	that	WDT	_	9	nsubj
8	are	be	VBP	_	9	cop
9	substrates	substrate	NNS	_	6	acl:relcl
10	of	of	IN	_	11	case
11	Pgp	Pgp	NNP	_	9	nmod
12	,	,	,	_	20	punct
13	increased	increase	VBD	_	14	amod
14	concentrations	concentration	NNS	_	20	nsubj
15	of	of	IN	_	18	case
16	the	the	DT	_	18	det
17	substrate	substrate	NN	_	18	compound
18	drug	drug	NN	_	14	nmod
19	are	be	VBP	_	20	cop
20	likely	likely	JJ	_	0	ROOT
21	,	,	,	_	20	punct
22	and	and	CC	_	20	cc
23	caution	caution	NN	_	26	nsubjpass
24	should	should	MD	_	26	aux
25	be	be	VB	_	26	auxpass
26	exercised	exercise	VBN	_	20	conj
27	.	.	.	_	20	punct

1	Drugs	drug	NNS	_	11	nsubj
2	that	that	WDT	_	3	nsubj
3	Inhibit	inhibit	VBP	_	1	acl:relcl
4	or	or	CC	_	3	cc
5	Induce	induce	VBP	_	3	conj
6	Cytochrome	cytochrome	NN	_	10	compound
7	P450	p450	NN	_	10	compound
8	3A4	3a4	NN	_	10	compound
9	Enzymes	enzyme	NNS	_	10	compound
10	drug1	drug1	NN	_	3	dobj
11	undergoes	undergo	VBZ	_	0	ROOT
12	extensive	extensive	JJ	_	13	amod
13	metabolism	metabolism	NN	_	11	dobj
14	by	by	IN	_	15	case
15	CYP3A4	cyp3a4	NN	_	11	nmod
16	,	,	,	_	11	punct
17	and	and	CC	_	11	cc
18	concomitant	concomitant	JJ	_	19	amod
19	administration	administration	NN	_	27	nsubj
20	of	of	IN	_	22	case
21	strong	strong	JJ	_	22	amod
22	inhibitors	inhibitor	NNS	_	19	nmod
23	or	or	CC	_	22	cc
24	inducers	inducer	NNS	_	22	conj
25	of	of	IN	_	26	case
26	CYP3A4	cyp3a4	NN	_	22	nmod
27	alter	alter	VBP	_	11	conj
28	drug2	drug2	NN	_	29	compound
29	concentrations	concentration	NNS	_	27	dobj
30	significantly	significantly	RB	_	27	advmod
31	.	.	.	_	11	punct

1	Dose	dose	NN	_	2	compound
2	adjustment	adjustment	NN	_	7	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	considered	consider	VBN	_	0	ROOT
8	for	for	IN	_	9	case
9	patients	patient	NNS	_	7	nmod
10	who	who	WP	_	12	nsubj
11	must	must	MD	_	12	aux
12	receive	receive	VB	_	9	acl:relcl
13	concomitant	concomitant	JJ	_	15	amod
14	strong	strong	JJ	_	15	amod
15	inhibitors	inhibitor	NNS	_	12	dobj
16	or	or	CC	_	15	cc
17	concomitant	concomitant	JJ	_	19	amod
18	strong	strong	JJ	_	19	amod
19	inducers	inducer	NNS	_	15	conj
20	of	of	IN	_	22	case
21	CYP3A4	cyp3a4	NN	_	22	compound
22	enzymes	enzyme	NNS	_	19	nmod
23	.	.	.	_	7	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	5	case
4	healthy	healthy	JJ	_	5	amod
5	subjects	subject	NNS	_	30	nmod
6	receiving	receive	VBG	_	5	acl
7	drug2	drug2	NN	_	6	dobj
8	,	,	,	_	5	punct
9	a	a	DT	_	11	det
10	CYP3A4	cyp3a4	NN	_	11	compound
11	inhibitor	inhibitor	NN	_	5	appos
12	,	,	,	_	5	punct
13	at	at	IN	_	15	case
14	200	200	CD	_	15	nummod
15	mg	mg	NN	_	5	nmod
16	twice	twice	RB	_	17	advmod
17	daily	daily	RB	_	15	advmod
18	for	for	IN	_	20	case
19	7	7	CD	_	20	nummod
20	days	day	NNS	_	15	nmod
21	,	,	,	_	15	punct
22	systemic	systemic	JJ	_	23	amod
23	exposure	exposure	NN	_	15	conj
24	-LRB-	-lrb-	-LRB-	_	25	punct
25	AUC	auc	NN	_	23	appos
26	-RRB-	-rrb-	-RRB-	_	25	punct
27	to	to	TO	_	28	case
28	drug3	drug3	NN	_	23	nmod
29	was	be	VBD	_	30	auxpass
30	increased	increase	VBN	_	1	dep
31	to	to	TO	_	33	case
32	approximately	approximately	RB	_	33	advmod
33	3.6-fold	3.6-fold	RB	_	30	nmod
34	of	of	IN	_	35	case
35	control	control	NN	_	33	nmod
36	and	and	CC	_	30	cc
37	half-life	half-life	NN	_	38	nsubj
38	increased	increase	VBD	_	30	conj
39	to	to	TO	_	40	case
40	1.7-fold	1.7-fold	RB	_	38	nmod
41	of	of	IN	_	42	case
42	control	control	NN	_	40	nmod
43	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	5	case
4	healthy	healthy	JJ	_	5	amod
5	subjects	subject	NNS	_	38	nmod
6	receiving	receive	VBG	_	5	acl
7	the	the	DT	_	9	det
8	CYP3A4	cyp3a4	NN	_	9	compound
9	inducer	inducer	NN	_	6	dobj
10	,	,	,	_	9	punct
11	drug2	drug2	NN	_	9	appos
12	,	,	,	_	9	punct
13	at	at	IN	_	15	case
14	100	100	CD	_	15	nummod
15	mg	mg	NN	_	6	nmod
16	twice	twice	RB	_	17	advmod
17	daily	daily	RB	_	15	advmod
18	for	for	IN	_	20	case
19	3	3	CD	_	20	nummod
20	days	day	NNS	_	6	nmod
21	and	and	CC	_	20	cc
22	200	200	CD	_	23	nummod
23	mg	mg	NN	_	20	conj
24	twice	twice	RB	_	25	advmod
25	daily	daily	RB	_	20	advmod
26	for	for	IN	_	28	case
27	17	17	CD	_	28	nummod
28	days	day	NNS	_	6	nmod
29	,	,	,	_	38	punct
30	systemic	systemic	JJ	_	31	amod
31	exposure	exposure	NN	_	38	nsubjpass
32	-LRB-	-lrb-	-LRB-	_	33	punct
33	AUC	auc	NN	_	31	appos
34	-RRB-	-rrb-	-RRB-	_	33	punct
35	to	to	TO	_	36	case
36	drug3	drug3	NN	_	31	nmod
37	was	be	VBD	_	38	auxpass
38	decreased	decrease	VBN	_	1	dep
39	approximately	approximately	RB	_	40	advmod
40	72	72	CD	_	41	nummod
41	%	%	NN	_	38	dobj
42	.	.	.	_	1	punct

1	Drugs	drug	NNS	_	10	nsubj
2	that	that	WDT	_	3	nsubj
3	Inhibit	inhibit	VBP	_	1	acl:relcl
4	Drug	drug	NN	_	7	compound
5	Transport	Transport	NNP	_	7	compound
6	Systems	Systems	NNP	_	7	compound
7	drug1	drug1	NN	_	3	dobj
8	is	be	VBZ	_	10	cop
9	a	a	DT	_	10	det
10	substrate	substrate	NN	_	0	ROOT
11	of	of	IN	_	15	case
12	the	the	DT	_	15	det
13	efflux	efflux	NN	_	15	compound
14	transporter	transporter	NN	_	15	compound
15	P-glycoprotein	p-glycoprotein	NN	_	10	nmod
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	Pgp	pgp	NN	_	15	dep
18	,	,	,	_	17	punct
19	ABCB1	abcb1	NN	_	17	appos
20	-RRB-	-rrb-	-RRB-	_	17	punct
21	.	.	.	_	10	punct

1	If	if	IN	_	4	mark
2	drug1	drug1	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	administered	administer	VBN	_	16	advcl
5	with	with	IN	_	6	case
6	drugs	drug	NNS	_	4	nmod
7	that	that	WDT	_	8	nsubj
8	inhibit	inhibit	VBP	_	6	acl:relcl
9	Pgp	Pgp	NNP	_	8	dobj
10	,	,	,	_	16	punct
11	increased	increase	VBD	_	12	amod
12	concentrations	concentration	NNS	_	16	nsubj
13	of	of	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	are	be	VBP	_	16	cop
16	likely	likely	JJ	_	0	ROOT
17	,	,	,	_	16	punct
18	and	and	CC	_	16	cc
19	caution	caution	NN	_	22	nsubjpass
20	should	should	MD	_	22	aux
21	be	be	VB	_	22	auxpass
22	exercised	exercise	VBN	_	16	conj
23	.	.	.	_	16	punct

1	Other	other	JJ	_	3	amod
2	Chemotherapy	Chemotherapy	NNP	_	3	compound
3	Agents	Agents	NNPS	_	18	nsubj
4	In	in	IN	_	7	case
5	a	a	DT	_	7	det
6	separate	separate	JJ	_	7	amod
7	study	study	NN	_	3	nmod
8	,	,	,	_	3	punct
9	concomitant	concomitant	JJ	_	10	amod
10	administration	administration	NN	_	3	appos
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	with	with	IN	_	14	case
14	drug2	drug2	NN	_	10	nmod
15	did	do	VBD	_	18	aux
16	not	not	RB	_	18	neg
17	meaningfully	meaningfully	RB	_	18	advmod
18	alter	alter	VB	_	0	ROOT
19	the	the	DT	_	20	det
20	pharmacokinetics	pharmacokinetic	NNS	_	18	dobj
21	of	of	IN	_	23	case
22	either	either	CC	_	23	cc:preconj
23	agent	agent	NN	_	20	nmod
24	-LRB-	-lrb-	-LRB-	_	27	punct
25	or	or	CC	_	27	cc
26	the	the	DT	_	27	det
27	metabolites	metabolite	NNS	_	23	dep
28	of	of	IN	_	29	case
29	drug3	drug3	NN	_	27	nmod
30	-RRB-	-rrb-	-RRB-	_	27	punct
31	.	.	.	_	18	punct

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	increases	increase	NNS	_	1	dep
4	bioavailability	bioavailability	NN	_	3	dobj
5	by	by	IN	_	7	case
6	50	50	CD	_	7	nummod
7	%	%	NN	_	3	nmod
8	-RRB-	-rrb-	-RRB-	_	3	punct
9	,	,	,	_	1	punct
10	drug2	drug2	NN	_	1	conj
11	,	,	,	_	1	punct
12	and	and	CC	_	1	cc
13	valproates	valproate	NNS	_	1	conj
14	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	5	det
4	concomitant	concomitant	JJ	_	5	amod
5	use	use	NN	_	17	nsubjpass
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	with	with	IN	_	9	case
9	long	long	JJ	_	5	nmod
10	-	-	:	_	9	punct
11	and	and	CC	_	9	cc
12	short-acting	short-acting	JJ	_	9	conj
13	drug3	drug3	NN	_	9	dep
14	has	have	VBZ	_	17	aux
15	been	be	VBN	_	17	auxpass
16	safely	safely	RB	_	17	advmod
17	tolerated	tolerate	VBN	_	1	appos
18	in	in	IN	_	19	case
19	patients	patient	NNS	_	17	nmod
20	with	with	IN	_	23	case
21	stable	stable	JJ	_	23	amod
22	angina	angina	NN	_	23	compound
23	pectoris	pectoris	NN	_	19	nmod
24	.	.	.	_	1	punct

1	Sublingual	sublingual	JJ	_	2	amod
2	drug1	drug1	NN	_	5	nsubjpass
3	may	may	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	taken	take	VBN	_	0	ROOT
6	if	if	IN	_	7	mark
7	necessary	necessary	JJ	_	5	advcl
8	for	for	IN	_	10	case
9	the	the	DT	_	10	det
10	control	control	NN	_	7	nmod
11	of	of	IN	_	14	case
12	acute	acute	JJ	_	14	amod
13	angina	angina	NN	_	14	compound
14	attacks	attack	NNS	_	10	nmod
15	during	during	IN	_	17	case
16	drug2	drug2	NN	_	17	compound
17	therapy	therapy	NN	_	10	nmod
18	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	5	det
4	concomitant	concomitant	JJ	_	5	amod
5	use	use	NN	_	13	nsubjpass
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drug3	drug3	NN	_	7	conj
10	has	have	VBZ	_	13	aux
11	been	be	VBN	_	13	auxpass
12	well	well	RB	_	13	advmod
13	tolerated	tolerate	VBN	_	1	appos
14	in	in	IN	_	15	case
15	patients	patient	NNS	_	13	nmod
16	with	with	IN	_	18	case
17	stable	stable	JJ	_	18	amod
18	angina	angina	NN	_	15	nmod
19	.	.	.	_	1	punct

1	Available	available	JJ	_	2	amod
2	data	datum	NNS	_	5	nsubj
3	are	be	VBP	_	5	cop
4	not	not	RB	_	5	neg
5	sufficient	sufficient	JJ	_	0	ROOT
6	,	,	,	_	5	punct
7	however	however	RB	_	5	advmod
8	,	,	,	_	5	punct
9	to	to	TO	_	10	mark
10	predict	predict	VB	_	5	xcomp
11	the	the	DT	_	12	det
12	effects	effect	NNS	_	10	dobj
13	of	of	IN	_	15	case
14	concomitant	concomitant	JJ	_	15	amod
15	medication	medication	NN	_	12	nmod
16	on	on	IN	_	17	case
17	patients	patient	NNS	_	12	nmod
18	with	with	IN	_	21	case
19	impaired	impaired	JJ	_	21	amod
20	ventricular	ventricular	JJ	_	21	amod
21	function	function	NN	_	17	nmod
22	or	or	CC	_	21	cc
23	cardiac	cardiac	JJ	_	25	amod
24	conduction	conduction	NN	_	25	compound
25	abnormalities	abnormality	NNS	_	21	conj
26	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	5	case
4	controlled	controlled	JJ	_	5	amod
5	studies	study	NNS	_	1	dep
6	in	in	IN	_	8	case
7	healthy	healthy	JJ	_	8	amod
8	volunteers	volunteer	NNS	_	5	nmod
9	,	,	,	_	8	punct
10	drug2	drug2	NN	_	8	conj
11	either	either	CC	_	12	dep
12	had	have	VBD	_	8	dep
13	no	no	DT	_	14	neg
14	effect	effect	NN	_	12	dobj
15	-LRB-	-lrb-	-LRB-	_	17	punct
16	one	one	CD	_	17	nummod
17	study	study	NN	_	5	appos
18	-RRB-	-rrb-	-RRB-	_	17	punct
19	or	or	CC	_	5	cc
20	was	be	VBD	_	21	auxpass
21	associated	associate	VBN	_	5	conj
22	with	with	IN	_	24	case
23	modest	modest	JJ	_	24	amod
24	increases	increase	NNS	_	21	nmod
25	,	,	,	_	24	punct
26	about	about	IN	_	27	advmod
27	30	30	CD	_	28	nummod
28	%	%	NN	_	24	appos
29	-LRB-	-lrb-	-LRB-	_	31	punct
30	two	two	CD	_	31	nummod
31	studies	study	NNS	_	28	appos
32	-RRB-	-rrb-	-RRB-	_	31	punct
33	in	in	IN	_	37	case
34	steady-state	steady-state	JJ	_	37	amod
35	serum	serum	NN	_	37	compound
36	drug3	drug3	NN	_	37	compound
37	concentrations	concentration	NNS	_	28	nmod
38	.	.	.	_	1	punct

1	Limited	limited	JJ	_	3	amod
2	clinical	clinical	JJ	_	3	amod
3	data	datum	NNS	_	13	nsubj
4	in	in	IN	_	6	case
5	angina	angina	NN	_	6	compound
6	patients	patient	NNS	_	3	nmod
7	receiving	receive	VBG	_	6	acl
8	concomitant	concomitant	JJ	_	9	amod
9	drug1	drug1	NN	_	7	dobj
10	and	and	CC	_	9	cc
11	drug2	drug2	NN	_	12	compound
12	therapy	therapy	NN	_	9	conj
13	indicate	indicate	VBP	_	0	ROOT
14	no	no	DT	_	16	neg
15	discernible	discernible	JJ	_	16	amod
16	changes	change	NNS	_	13	dobj
17	in	in	IN	_	20	case
18	serum	serum	NN	_	20	compound
19	digoxin	digoxin	NN	_	20	compound
20	levels	level	NNS	_	16	nmod
21	.	.	.	_	13	punct

1	Available	available	JJ	_	2	amod
2	data	datum	NNS	_	5	nsubj
3	are	be	VBP	_	5	cop
4	neither	neither	DT	_	5	cc:preconj
5	sufficient	sufficient	JJ	_	0	ROOT
6	to	to	TO	_	7	mark
7	rule	rule	VB	_	5	xcomp
8	out	out	RP	_	7	compound:prt
9	possible	possible	JJ	_	10	amod
10	increases	increase	NNS	_	7	dobj
11	in	in	IN	_	13	case
12	serum	serum	NN	_	13	compound
13	drug1	drug1	NN	_	10	nmod
14	with	with	IN	_	16	case
15	concomitant	concomitant	JJ	_	16	amod
16	treatment	treatment	NN	_	10	nmod
17	in	in	IN	_	19	case
18	some	some	DT	_	19	det
19	patients	patient	NNS	_	16	nmod
20	,	,	,	_	5	punct
21	nor	nor	CC	_	5	cc
22	other	other	JJ	_	24	amod
23	possible	possible	JJ	_	24	amod
24	interactions	interaction	NNS	_	5	conj
25	,	,	,	_	24	punct
26	particularly	particularly	RB	_	28	advmod
27	in	in	IN	_	28	case
28	patients	patient	NNS	_	24	nmod
29	with	with	IN	_	32	case
30	cardiac	cardiac	JJ	_	32	amod
31	conduction	conduction	NN	_	32	compound
32	abnormalities	abnormality	NNS	_	28	nmod
33	-LRB-	-lrb-	-LRB-	_	35	punct
34	Also	also	RB	_	35	advmod
35	see	see	VB	_	24	dep
36	WARNINGS	WARNINGS	NNP	_	39	compound
37	Congestive	congestive	JJ	_	39	amod
38	Heart	Heart	NNP	_	39	compound
39	Failure	failure	NN	_	35	dobj
40	-RRB-	-rrb-	-RRB-	_	35	punct
41	.	.	.	_	5	punct

1	Oral	oral	JJ	_	2	amod
2	drug1	drug1	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	drug2	drug2	NN	_	8	nsubjpass
5	has	have	VBZ	_	8	aux
6	been	be	VBN	_	8	auxpass
7	safely	safely	RB	_	8	advmod
8	used	use	VBN	_	2	dep
9	in	in	IN	_	11	case
10	diabetic	diabetic	JJ	_	11	amod
11	patients	patient	NNS	_	8	nmod
12	without	without	IN	_	14	mark
13	significantly	significantly	RB	_	14	advmod
14	lowering	lower	VBG	_	8	advcl
15	their	they	PRP$	_	18	nmod:poss
16	blood	blood	NN	_	18	compound
17	glucose	glucose	NN	_	18	compound
18	levels	level	NNS	_	14	dobj
19	or	or	CC	_	14	cc
20	altering	alter	VBG	_	14	conj
21	their	they	PRP$	_	22	nmod:poss
22	need	need	NN	_	20	dobj
23	for	for	IN	_	24	case
24	drug3	drug3	NN	_	22	nmod
25	or	or	CC	_	24	cc
26	oral	oral	JJ	_	27	amod
27	drug4	drug4	NN	_	24	conj
28	.	.	.	_	2	punct

1	General	General	NNP	_	2	compound
2	Interactions	interaction	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	Certain	certain	JJ	_	5	amod
5	drugs	drug	NNS	_	7	nsubj
6	could	could	MD	_	7	aux
7	increase	increase	VB	_	2	dep
8	the	the	DT	_	9	det
9	likelihood	likelihood	NN	_	7	dobj
10	of	of	IN	_	14	case
11	potentially	potentially	RB	_	12	advmod
12	serious	serious	JJ	_	14	amod
13	adverse	adverse	JJ	_	14	amod
14	effects	effect	NNS	_	9	nmod
15	with	with	IN	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	.	.	.	_	2	punct

1	In	in	IN	_	2	case
2	general	general	JJ	_	6	nmod
3	,	,	,	_	6	punct
4	these	these	DT	_	6	nsubj
5	are	be	VBP	_	6	cop
6	drugs	drug	NNS	_	0	ROOT
7	that	that	WDT	_	8	nsubj
8	have	have	VBP	_	6	acl:relcl
9	one	one	CD	_	13	nummod
10	or	or	CC	_	9	cc
11	more	more	JJR	_	9	conj
12	pharmacologic	pharmacologic	JJ	_	13	amod
13	activities	activity	NNS	_	8	dobj
14	similar	similar	JJ	_	13	amod
15	to	to	TO	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	,	,	,	_	13	punct
18	including	include	VBG	_	19	case
19	drug2	drug2	NN	_	13	nmod
20	such	such	JJ	_	22	case
21	as	as	IN	_	20	mwe
22	drug3	drug3	NN	_	19	nmod
23	and	and	CC	_	22	cc
24	drug4	drug4	NN	_	22	conj
25	,	,	,	_	22	punct
26	drug5	drug5	NN	_	22	conj
27	and	and	CC	_	22	cc
28	drug6	drug6	NN	_	22	conj
29	.	.	.	_	6	punct

1	drug1	drug1	NN	_	5	nsubj
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	could	could	MD	_	5	aux
5	exaggerate	exaggerate	VB	_	0	ROOT
6	the	the	DT	_	7	det
7	prolongation	prolongation	NN	_	5	dobj
8	of	of	IN	_	11	case
9	the	the	DT	_	11	det
10	QT	QT	NNP	_	11	compound
11	interval	interval	NN	_	7	nmod
12	observed	observe	VBN	_	11	acl
13	with	with	IN	_	14	case
14	drug3	drug3	NN	_	12	nmod
15	.	.	.	_	5	punct

1	drug1	drug1	NN	_	3	nsubj
2	could	could	MD	_	3	aux
3	exaggerate	exaggerate	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	depression	depression	NN	_	3	dobj
6	of	of	IN	_	9	case
7	AV	av	NN	_	9	compound
8	nodal	nodal	JJ	_	9	amod
9	conduction	conduction	NN	_	5	nmod
10	observed	observe	VBN	_	5	acl
11	with	with	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	.	.	.	_	3	punct

1	Although	although	IN	_	9	mark
2	specific	specific	JJ	_	5	amod
3	drug	drug	NN	_	5	compound
4	interaction	interaction	NN	_	5	compound
5	studies	study	NNS	_	9	nsubjpass
6	have	have	VBP	_	9	aux
7	not	not	RB	_	9	neg
8	been	be	VBN	_	9	auxpass
9	conducted	conduct	VBN	_	37	advcl
10	with	with	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	,	,	,	_	37	punct
13	the	the	DT	_	14	det
14	possibility	possibility	NN	_	37	nsubjpass
15	of	of	IN	_	20	case
16	an	a	DT	_	20	det
17	additive	additive	JJ	_	20	amod
18	or	or	CC	_	17	cc
19	potentiating	potentiating	NN	_	17	conj
20	effect	effect	NN	_	14	nmod
21	with	with	IN	_	22	case
22	drug2	drug2	NN	_	20	nmod
23	-LRB-	-lrb-	-LRB-	_	24	punct
24	drug3	drug3	NN	_	22	dep
25	,	,	,	_	24	punct
26	drug4	drug4	NN	_	24	conj
27	,	,	,	_	24	punct
28	drug5	drug5	NN	_	24	conj
29	,	,	,	_	24	punct
30	drug6	drug6	NN	_	24	conj
31	,	,	,	_	24	punct
32	or	or	CC	_	24	cc
33	drug7	drug7	NN	_	24	conj
34	-RRB-	-rrb-	-RRB-	_	24	punct
35	should	should	MD	_	37	aux
36	be	be	VB	_	37	auxpass
37	considered	consider	VBN	_	0	ROOT
38	.	.	.	_	37	punct

1	drug1	drug1	NN	_	8	nsubj
2	,	,	,	_	8	punct
3	as	as	IN	_	5	case
4	a	a	DT	_	5	det
5	class	class	NN	_	8	nmod
6	,	,	,	_	8	punct
7	may	may	MD	_	8	aux
8	reduce	reduce	VB	_	0	ROOT
9	pulse	pulse	NN	_	8	dobj
10	and	and	CC	_	9	cc
11	blood	blood	NN	_	12	compound
12	pressure	pressure	NN	_	9	conj
13	.	.	.	_	8	punct

1	Caution	caution	NN	_	19	nsubjpass
2	in	in	IN	_	3	mark
3	using	use	VBG	_	1	acl
4	concomitant	concomitant	JJ	_	5	amod
5	drugs	drug	NNS	_	3	dobj
6	such	such	JJ	_	8	case
7	as	as	IN	_	6	mwe
8	drug1	drug1	NN	_	5	nmod
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	ophthalmic	ophthalmic	JJ	_	8	dep
11	and	and	CC	_	10	cc
12	systemic	systemic	JJ	_	10	conj
13	-RRB-	-rrb-	-RRB-	_	10	punct
14	,	,	,	_	8	punct
15	drug2	drug2	NN	_	8	conj
16	and/or	and/or	CC	_	8	cc
17	drug3	drug3	NN	_	8	conj
18	is	be	VBZ	_	19	auxpass
19	advised	advise	VBN	_	0	ROOT
20	.	.	.	_	19	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	have	have	VBP	_	4	aux
3	been	be	VBN	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	blunt	blunt	VB	_	4	xcomp
7	the	the	DT	_	9	det
8	hypotensive	hypotensive	JJ	_	9	amod
9	effect	effect	NN	_	6	dobj
10	of	of	IN	_	12	case
11	systemic	systemic	JJ	_	12	amod
12	drug2	drug2	NN	_	9	nmod
13	.	.	.	_	4	punct
14	It	it	PRP	_	17	nsubjpass
15	is	be	VBZ	_	17	auxpass
16	not	not	RB	_	17	neg
17	known	know	VBN	_	4	parataxis
18	whether	whether	IN	_	30	mark
19	the	the	DT	_	21	det
20	concurrent	concurrent	JJ	_	21	amod
21	use	use	NN	_	30	nsubj
22	of	of	IN	_	24	case
23	these	these	DT	_	24	det
24	agents	agent	NNS	_	21	nmod
25	with	with	IN	_	26	case
26	drug3	drug3	NN	_	21	nmod
27	in	in	IN	_	28	case
28	humans	human	NNS	_	26	nmod
29	can	can	MD	_	30	aux
30	lead	lead	VB	_	17	ccomp
31	to	to	TO	_	33	case
32	resulting	result	VBG	_	33	amod
33	interference	interference	NN	_	30	nmod
34	with	with	IN	_	38	case
35	the	the	DT	_	38	det
36	IOP	iop	NN	_	38	compound
37	lowering	lowering	NN	_	38	compound
38	effect	effect	NN	_	33	nmod
39	.	.	.	_	4	punct

1	No	no	DT	_	2	neg
2	data	datum	NNS	_	0	ROOT
3	on	on	IN	_	5	case
4	the	the	DT	_	5	det
5	level	level	NN	_	2	nmod
6	of	of	IN	_	8	case
7	circulating	circulate	VBG	_	8	amod
8	catecholamines	catecholamine	NNS	_	5	nmod
9	after	after	IN	_	13	mark
10	drug1	drug1	NN	_	11	compound
11	administration	administration	NN	_	13	nsubj
12	are	be	VBP	_	13	cop
13	available	available	JJ	_	2	advcl
14	.	.	.	_	2	punct

1	Caution	caution	NN	_	6	nsubjpass
2	,	,	,	_	6	punct
3	however	however	RB	_	6	advmod
4	,	,	,	_	6	punct
5	is	be	VBZ	_	6	auxpass
6	advised	advise	VBN	_	0	ROOT
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	taking	take	VBG	_	8	acl
10	drug1	drug1	NN	_	9	dobj
11	which	which	WDT	_	13	nsubj
12	can	can	MD	_	13	aux
13	affect	affect	VB	_	10	acl:relcl
14	the	the	DT	_	15	det
15	metabolism	metabolism	NN	_	13	dobj
16	and	and	CC	_	15	cc
17	uptake	uptake	NN	_	15	conj
18	of	of	IN	_	20	case
19	circulating	circulate	VBG	_	20	amod
20	amines	amine	NNS	_	15	nmod
21	.	.	.	_	6	punct

1	drug1	drug1	NN	_	3	compound
2	-	-	:	_	3	punct
3	drug2	drug2	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	sterilize	sterilize	VB	_	0	ROOT
6	the	the	DT	_	7	det
7	bowel	bowel	NN	_	5	dobj
8	and	and	CC	_	5	cc
9	decrease	decrease	VB	_	5	conj
10	the	the	DT	_	12	det
11	drug3	drug3	NN	_	12	compound
12	contribution	contribution	NN	_	9	dobj
13	to	to	TO	_	15	case
14	the	the	DT	_	15	det
15	body	body	NN	_	12	nmod
16	by	by	IN	_	19	case
17	the	the	DT	_	19	det
18	intestinal	intestinal	JJ	_	19	amod
19	microflora	microflora	NN	_	9	nmod
20	.	.	.	_	5	punct

1	drug1	drug1	NN	_	26	nsubj
2	-	-	:	_	1	punct
3	drug2	drug2	NN	_	1	dep
4	containing	contain	VBG	_	3	acl
5	side	side	NN	_	6	amod
6	chains	chain	NNS	_	4	dobj
7	of	of	IN	_	8	case
8	N-methylthiotetrazole	n-methylthiotetrazole	NN	_	6	nmod
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	drug3	drug3	NN	_	8	dep
11	,	,	,	_	10	punct
12	drug4	drug4	NN	_	10	conj
13	,	,	,	_	10	punct
14	drug5	drug5	NN	_	10	conj
15	,	,	,	_	10	punct
16	drug6	drug6	NN	_	10	conj
17	,	,	,	_	10	punct
18	drug7	drug7	NN	_	10	conj
19	-RRB-	-rrb-	-RRB-	_	10	punct
20	or	or	CC	_	8	cc
21	methylthiadiazole	methylthiadiazole	NN	_	8	conj
22	-LRB-	-lrb-	-LRB-	_	23	punct
23	drug8	drug8	NN	_	21	appos
24	-RRB-	-rrb-	-RRB-	_	23	punct
25	can	can	MD	_	26	aux
26	cause	cause	VB	_	0	ROOT
27	vitamin	vitamin	NN	_	29	compound
28	K	k	NN	_	29	compound
29	deficiency	deficiency	NN	_	26	dobj
30	and	and	CC	_	29	cc
31	hypoprothrombinemia	hypoprothrombinemia	NN	_	29	conj
32	.	.	.	_	26	punct

1	These	these	DT	_	2	det
2	drug1	drug1	NN	_	4	nsubj
3	are	be	VBP	_	4	cop
4	inhibitors	inhibitor	NNS	_	0	ROOT
5	of	of	IN	_	10	case
6	hepatic	hepatic	JJ	_	10	amod
7	vitamin	vitamin	NN	_	10	compound
8	K	k	NN	_	10	compound
9	epoxide	epoxide	NN	_	10	compound
10	reductase	reductase	NN	_	4	nmod
11	.	.	.	_	4	punct

1	drug1	drug1	NN	_	10	nsubj
2	-	-	:	_	1	punct
3	Concomitant	concomitant	JJ	_	4	amod
4	intake	intake	NN	_	1	dep
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	drug3	drug3	NN	_	6	conj
9	may	may	MD	_	10	aux
10	reduce	reduce	VB	_	0	ROOT
11	the	the	DT	_	12	det
12	absorption	absorption	NN	_	10	dobj
13	of	of	IN	_	14	case
14	drug4	drug4	NN	_	12	nmod
15	.	.	.	_	10	punct

1	drug1	drug1	NN	_	10	nsubj
2	-	-	:	_	1	punct
3	Concomitant	concomitant	JJ	_	4	amod
4	intake	intake	NN	_	1	dep
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	drug3	drug3	NN	_	6	conj
9	may	may	MD	_	10	aux
10	reduce	reduce	VB	_	0	ROOT
11	the	the	DT	_	12	det
12	absorption	absorption	NN	_	10	dobj
13	of	of	IN	_	14	case
14	drug4	drug4	NN	_	12	nmod
15	.	.	.	_	10	punct

1	drug1	drug1	NN	_	10	nsubj
2	-	-	:	_	1	punct
3	Concomitant	concomitant	JJ	_	4	amod
4	intake	intake	NN	_	1	dep
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	drug3	drug3	NN	_	6	conj
9	may	may	MD	_	10	aux
10	reduce	reduce	VB	_	0	ROOT
11	the	the	DT	_	12	det
12	absorption	absorption	NN	_	10	dobj
13	of	of	IN	_	14	case
14	drug4	drug4	NN	_	12	nmod
15	.	.	.	_	10	punct

1	drug1	drug1	NN	_	3	compound
2	-	-	:	_	3	punct
3	drug2	drug2	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	decrease	decrease	VB	_	0	ROOT
6	the	the	DT	_	7	det
7	absorption	absorption	NN	_	5	dobj
8	of	of	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	.	.	.	_	5	punct

1	drug1	drug1	NN	_	8	nsubj
2	-	-	:	_	1	punct
3	drug2	drug2	NN	_	1	dep
4	in	in	IN	_	6	case
5	large	large	JJ	_	6	amod
6	doses	dose	NNS	_	3	nmod
7	may	may	MD	_	8	aux
8	inhibit	inhibit	VB	_	0	ROOT
9	vitamin	vitamin	NN	_	12	compound
10	K	k	NN	_	12	compound
11	epoxide	epoxide	NN	_	12	compound
12	reductase	reductase	NN	_	8	dobj
13	resulting	result	VBG	_	12	acl
14	in	in	IN	_	17	case
15	vitamin	vitamin	NN	_	17	compound
16	K	k	NN	_	17	compound
17	deficiency	deficiency	NN	_	13	nmod
18	.	.	.	_	8	punct

1	drug1	drug1	NN	_	5	nsubj
2	-	-	:	_	5	punct
3	drug2	drug2	NN	_	5	nsubj
4	can	can	MD	_	5	aux
5	antagonize	antagonize	VB	_	0	ROOT
6	the	the	DT	_	7	det
7	effect	effect	NN	_	5	dobj
8	of	of	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod

1	The	the	DT	_	2	det
2	risk	risk	NN	_	13	nsubjpass
3	of	of	IN	_	4	case
4	myopathy	myopathy	NN	_	2	nmod
5	during	during	IN	_	6	case
6	treatment	treatment	NN	_	2	nmod
7	with	with	IN	_	8	case
8	drugs	drug	NNS	_	6	nmod
9	of	of	IN	_	11	case
10	this	this	DT	_	11	det
11	class	class	NN	_	8	nmod
12	is	be	VBZ	_	13	auxpass
13	increased	increase	VBN	_	0	ROOT
14	with	with	IN	_	16	case
15	concurrent	concurrent	JJ	_	16	amod
16	administration	administration	NN	_	13	nmod
17	of	of	IN	_	18	case
18	drug1	drug1	NN	_	16	nmod
19	,	,	,	_	18	punct
20	drug2	drug2	NN	_	18	conj
21	,	,	,	_	18	punct
22	drug3	drug3	NN	_	18	conj
23	-LRB-	-lrb-	-LRB-	_	24	punct
24	drug4	drug4	NN	_	22	appos
25	-RRB-	-rrb-	-RRB-	_	24	punct
26	,	,	,	_	18	punct
27	drug5	drug5	NN	_	18	conj
28	,	,	,	_	18	punct
29	drug6	drug6	NN	_	18	appos
30	.	.	.	_	13	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	When	when	WRB	_	9	advmod
4	drug2	drug2	NN	_	7	compound
5	and	and	CC	_	4	cc
6	drug3	drug3	NN	_	4	conj
7	suspension	suspension	NN	_	9	nsubjpass
8	were	be	VBD	_	9	auxpass
9	coadministered	coadminister	VBN	_	15	advcl
10	,	,	,	_	15	punct
11	plasma	plasma	NN	_	12	compound
12	concentrations	concentration	NNS	_	15	nsubj
13	of	of	IN	_	14	case
14	drug4	drug4	NN	_	12	nmod
15	decreased	decrease	VBD	_	1	dep
16	approximately	approximately	RB	_	17	advmod
17	35	35	CD	_	18	nummod
18	%	%	NN	_	15	dobj
19	.	.	.	_	1	punct

1	However	however	RB	_	7	advmod
2	,	,	,	_	7	punct
3	LDL-C	ldl-c	NN	_	4	compound
4	reduction	reduction	NN	_	7	nsubjpass
5	was	be	VBD	_	7	auxpass
6	not	not	RB	_	7	neg
7	altered	alter	VBN	_	0	ROOT
8	.	.	.	_	7	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Because	because	IN	_	7	mark
4	drug2	drug2	NN	_	7	nsubj
5	does	do	VBZ	_	7	aux
6	not	not	RB	_	7	neg
7	affect	affect	VB	_	25	csubjpass
8	the	the	DT	_	9	det
9	pharmacokinetics	pharmacokinetic	NNS	_	7	dobj
10	of	of	IN	_	11	case
11	drug3	drug3	NN	_	9	nmod
12	,	,	,	_	11	punct
13	interactions	interaction	NNS	_	11	appos
14	with	with	IN	_	16	case
15	other	other	JJ	_	16	amod
16	drug4	drug4	NN	_	13	nmod
17	metabolized	metabolize	VBN	_	16	acl
18	via	via	IN	_	22	case
19	the	the	DT	_	22	det
20	same	same	JJ	_	22	amod
21	cytochrome	cytochrome	NN	_	22	compound
22	isozymes	isozyme	NNS	_	17	nmod
23	are	be	VBP	_	25	auxpass
24	not	not	RB	_	25	neg
25	expected	expect	VBN	_	1	appos
26	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Plasma	plasma	NN	_	4	compound
4	concentrations	concentration	NNS	_	7	nsubj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	decreased	decrease	VBD	_	1	appos
8	approximately	approximately	RB	_	9	advmod
9	25	25	CD	_	10	nummod
10	%	%	NN	_	7	dobj
11	when	when	WRB	_	16	advmod
12	drug3	drug3	NN	_	16	nsubjpass
13	and	and	CC	_	12	cc
14	drug4	drug4	NN	_	12	conj
15	were	be	VBD	_	16	auxpass
16	coadministered	coadminister	VBN	_	7	advcl
17	.	.	.	_	1	punct

1	However	however	RB	_	6	advmod
2	,	,	,	_	6	punct
3	LDL-C	ldl-c	NN	_	4	compound
4	reduction	reduction	NN	_	6	nsubj
5	was	be	VBD	_	6	cop
6	greater	greater	JJR	_	0	ROOT
7	when	when	WRB	_	12	advmod
8	drug1	drug1	NN	_	12	nsubjpass
9	and	and	CC	_	8	cc
10	drug2	drug2	NN	_	8	conj
11	were	be	VBD	_	12	auxpass
12	coadministered	coadminister	VBN	_	6	advcl
13	than	than	IN	_	18	mark
14	when	when	WRB	_	18	advmod
15	either	either	CC	_	16	det
16	drug	drug	NN	_	18	nsubjpass
17	was	be	VBD	_	18	auxpass
18	given	give	VBN	_	12	advcl
19	alone	alone	RB	_	18	advmod
20	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	compound
4	plasma	plasma	NN	_	5	compound
5	concentrations	concentration	NNS	_	11	nsubjpass
6	and	and	CC	_	5	cc
7	LDL-C	ldl-c	NN	_	8	compound
8	reduction	reduction	NN	_	5	conj
9	were	be	VBD	_	11	auxpass
10	not	not	RB	_	11	neg
11	altered	alter	VBN	_	1	appos
12	by	by	IN	_	13	case
13	coadministration	coadministration	NN	_	11	nmod
14	of	of	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	When	when	WRB	_	11	advmod
4	multiple	multiple	JJ	_	5	amod
5	doses	dose	NNS	_	11	nsubjpass
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drug3	drug3	NN	_	7	conj
10	were	be	VBD	_	11	auxpass
11	coadministered	coadminister	VBN	_	1	dep
12	,	,	,	_	11	punct
13	steady-state	steady-state	JJ	_	16	amod
14	plasma	plasma	NN	_	16	compound
15	drug4	drug4	NN	_	16	compound
16	concentrations	concentration	NNS	_	12	root
17	increased	increase	VBN	_	16	acl
18	by	by	IN	_	21	case
19	approximately	approximately	RB	_	20	advmod
20	20	20	CD	_	21	nummod
21	%	%	NN	_	17	nmod
22	.	.	.	_	16	punct

1	Patients	patient	NNS	_	6	nsubjpass
2	taking	take	VBG	_	1	acl
3	drug1	drug1	NN	_	2	dobj
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	monitored	monitor	VBN	_	0	ROOT
7	appropriately	appropriately	RB	_	6	advmod
8	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	5	case
4	healthy	healthy	JJ	_	5	amod
5	individuals	individual	NNS	_	11	nmod
6	,	,	,	_	5	punct
7	plasma	plasma	NN	_	8	compound
8	concentrations	concentration	NNS	_	11	nsubj
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	increased	increase	VBD	_	1	appos
12	approximately	approximately	RB	_	13	advmod
13	40	40	CD	_	14	nummod
14	%	%	NN	_	11	dobj
15	with	with	IN	_	16	case
16	coadministration	coadministration	NN	_	11	nmod
17	of	of	IN	_	18	case
18	drug3	drug3	NN	_	16	nmod
19	and	and	CC	_	18	cc
20	drug4	drug4	NN	_	18	conj
21	,	,	,	_	18	punct
22	a	a	DT	_	24	det
23	known	known	JJ	_	24	amod
24	inhibitor	inhibitor	NN	_	18	appos
25	of	of	IN	_	28	case
26	cytochrome	cytochrome	NN	_	28	compound
27	P450	p450	NN	_	28	compound
28	3A4	3a4	NN	_	24	nmod
29	.	.	.	_	1	punct

1	Oral	oral	JJ	_	2	amod
2	drug1	drug1	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	Coadministration	coadministration	NN	_	11	nsubj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	and	and	CC	_	4	cc
8	an	a	DT	_	10	det
9	oral	oral	JJ	_	10	amod
10	drug3	drug3	NN	_	4	conj
11	increased	increase	VBD	_	2	dep
12	AUC	auc	NN	_	13	compound
13	values	value	NNS	_	11	dobj
14	for	for	IN	_	15	case
15	drug4	drug4	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	drug5	drug5	NN	_	15	conj
18	by	by	IN	_	21	case
19	approximately	approximately	RB	_	20	advmod
20	30	30	CD	_	21	nummod
21	%	%	NN	_	11	nmod
22	and	and	CC	_	11	cc
23	20	20	CD	_	24	nummod
24	%	%	NN	_	11	conj
25	.	.	.	_	2	punct

1	These	these	DT	_	2	det
2	increases	increase	NNS	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	considered	consider	VBN	_	0	ROOT
6	when	when	WRB	_	7	advmod
7	selecting	select	VBG	_	5	advcl
8	an	a	DT	_	10	det
9	oral	oral	JJ	_	10	amod
10	drug1	drug1	NN	_	7	dobj
11	for	for	IN	_	13	case
12	a	a	DT	_	13	det
13	woman	woman	NN	_	10	nmod
14	taking	take	VBG	_	13	acl
15	drug2	drug2	NN	_	14	dobj
16	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	nsubj
4	had	have	VBD	_	1	appos
5	no	no	DT	_	8	neg
6	clinically	clinically	RB	_	7	advmod
7	significant	significant	JJ	_	8	amod
8	effect	effect	NN	_	4	dobj
9	on	on	IN	_	11	case
10	prothrombin	prothrombin	NN	_	11	compound
11	time	time	NN	_	4	nmod
12	when	when	WRB	_	13	advmod
13	administered	administer	VBN	_	4	advcl
14	to	to	TO	_	15	case
15	patients	patient	NNS	_	13	nmod
16	receiving	receive	VBG	_	15	acl
17	chronic	chronic	JJ	_	19	amod
18	drug3	drug3	NN	_	19	compound
19	treatment	treatment	NN	_	16	dobj
20	.	.	.	_	1	punct

1	Endocrine	endocrine	JJ	_	3	amod
2	Function	function	NN	_	3	compound
3	drug1	drug1	NN	_	4	nsubj
4	interfere	interfere	VBP	_	0	ROOT
5	with	with	IN	_	7	case
6	cholesterol	cholesterol	NN	_	7	compound
7	synthesis	synthesis	NN	_	4	nmod
8	and	and	CC	_	4	cc
9	theoretically	theoretically	RB	_	11	advmod
10	might	might	MD	_	11	aux
11	blunt	blunt	VB	_	4	conj
12	adrenal	adrenal	JJ	_	16	amod
13	and/or	and/or	CC	_	12	cc
14	gonadal	gonadal	JJ	_	12	conj
15	steroid	steroid	NN	_	16	compound
16	production	production	NN	_	11	dobj
17	.	.	.	_	4	punct

1	Clinical	clinical	JJ	_	2	amod
2	studies	study	NNS	_	4	nsubj
3	have	have	VBP	_	4	aux
4	shown	show	VBN	_	0	ROOT
5	that	that	IN	_	9	mark
6	drug1	drug1	NN	_	9	nsubj
7	does	do	VBZ	_	9	aux
8	not	not	RB	_	9	neg
9	reduce	reduce	VB	_	4	ccomp
10	basal	basal	JJ	_	13	amod
11	plasma	plasma	NN	_	13	compound
12	cortisol	cortisol	NN	_	13	compound
13	concentration	concentration	NN	_	9	dobj
14	or	or	CC	_	9	cc
15	impair	impair	VB	_	9	conj
16	adrenal	adrenal	JJ	_	17	amod
17	reserve	reserve	NN	_	15	dobj
18	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	effects	effect	NNS	_	11	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	on	on	IN	_	7	case
6	male	male	JJ	_	7	amod
7	fertility	fertility	NN	_	2	nmod
8	have	have	VBP	_	11	aux
9	not	not	RB	_	11	neg
10	been	be	VBN	_	11	auxpass
11	studied	study	VBN	_	0	ROOT
12	in	in	IN	_	14	case
13	adequate	adequate	JJ	_	14	amod
14	numbers	number	NNS	_	11	nmod
15	of	of	IN	_	16	case
16	patients	patient	NNS	_	14	nmod
17	.	.	.	_	11	punct

1	The	the	DT	_	2	det
2	effects	effect	NNS	_	15	nsubj
3	,	,	,	_	5	punct
4	if	if	IN	_	5	mark
5	any	any	DT	_	2	dep
6	,	,	,	_	5	punct
7	on	on	IN	_	10	case
8	the	the	DT	_	10	det
9	pituitary-gonadal	pituitary-gonadal	JJ	_	10	amod
10	axis	axis	NN	_	2	nmod
11	in	in	IN	_	13	case
12	premenopausal	premenopausal	JJ	_	13	amod
13	women	woman	NNS	_	10	nmod
14	are	be	VBP	_	15	cop
15	unknown	unknown	JJ	_	0	ROOT
16	.	.	.	_	15	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	exercised	exercise	VBN	_	0	ROOT
5	if	if	IN	_	9	mark
6	an	a	DT	_	7	det
7	drug1	drug1	NN	_	9	nsubjpass
8	is	be	VBZ	_	9	auxpass
9	administered	administer	VBN	_	4	advcl
10	concomitantly	concomitantly	RB	_	9	advmod
11	with	with	IN	_	12	case
12	drugs	drug	NNS	_	9	nmod
13	that	that	WDT	_	15	nsubj
14	may	may	MD	_	15	aux
15	decrease	decrease	VB	_	12	acl:relcl
16	the	the	DT	_	17	det
17	levels	level	NNS	_	15	dobj
18	or	or	CC	_	17	cc
19	activity	activity	NN	_	17	conj
20	of	of	IN	_	23	case
21	endogenous	endogenous	JJ	_	23	amod
22	steroid	steroid	NN	_	23	compound
23	hormones	hormone	NNS	_	17	nmod
24	,	,	,	_	23	punct
25	such	such	JJ	_	27	case
26	as	as	IN	_	25	mwe
27	drug2	drug2	NN	_	23	nmod
28	,	,	,	_	27	punct
29	drug3	drug3	NN	_	27	conj
30	,	,	,	_	27	punct
31	and	and	CC	_	27	cc
32	drug4	drug4	NN	_	27	conj
33	.	.	.	_	4	punct

1	CNS	cns	NN	_	4	compound
2	Toxicity	toxicity	NN	_	4	compound
3	Brain	brain	NN	_	4	compound
4	hemorrhage	hemorrhage	NN	_	6	nsubjpass
5	was	be	VBD	_	6	auxpass
6	seen	see	VBN	_	0	ROOT
7	in	in	IN	_	10	case
8	a	a	DT	_	10	det
9	female	female	JJ	_	10	amod
10	dog	dog	NN	_	6	nmod
11	treated	treat	VBN	_	10	acl
12	for	for	IN	_	14	case
13	3	3	CD	_	14	nummod
14	months	month	NNS	_	11	nmod
15	at	at	IN	_	17	case
16	120	120	CD	_	17	nummod
17	mg/kg/day	mg/kg/day	NN	_	11	nmod
18	.	.	.	_	6	punct

1	Brain	brain	NN	_	2	compound
2	hemorrhage	hemorrhage	NN	_	8	nsubjpass
3	and	and	CC	_	2	cc
4	optic	optic	JJ	_	6	amod
5	nerve	nerve	NN	_	6	compound
6	vacuolation	vacuolation	NN	_	2	conj
7	were	be	VBD	_	8	auxpass
8	seen	see	VBN	_	0	ROOT
9	in	in	IN	_	12	case
10	another	another	DT	_	12	det
11	female	female	JJ	_	12	amod
12	dog	dog	NN	_	8	nmod
13	that	that	WDT	_	15	nsubjpass
14	was	be	VBD	_	15	auxpass
15	sacrificed	sacrifice	VBN	_	12	acl:relcl
16	in	in	IN	_	18	case
17	moribund	moribund	JJ	_	18	amod
18	condition	condition	NN	_	15	nmod
19	after	after	IN	_	21	case
20	11	11	CD	_	21	nummod
21	weeks	week	NNS	_	15	nmod
22	of	of	IN	_	23	mark
23	escalating	escalate	VBG	_	21	acl
24	doses	dose	NNS	_	23	dobj
25	up	up	RB	_	27	advmod
26	to	to	TO	_	27	dep
27	280	280	CD	_	28	nummod
28	mg/kg/day	mg/kg/day	NN	_	23	nmod:tmod
29	.	.	.	_	8	punct

1	The	the	DT	_	4	det
2	120	120	CD	_	4	nummod
3	mg/kg	mg/kg	NN	_	4	compound
4	dose	dose	NN	_	5	nsubj
5	resulted	result	VBD	_	0	ROOT
6	in	in	IN	_	9	case
7	a	a	DT	_	9	det
8	systemic	systemic	JJ	_	9	amod
9	exposure	exposure	NN	_	5	nmod
10	approximately	approximately	RB	_	12	advmod
11	16	16	CD	_	12	compound
12	times	time	NNS	_	16	nummod
13	the	the	DT	_	16	det
14	human	human	JJ	_	16	amod
15	plasma	plasma	NN	_	16	compound
16	area-under-the-curve	area-under-the-curve	NN	_	9	dep
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	AUC	auc	NN	_	16	dep
19	,	,	,	_	18	punct
20	0-24	0-24	CD	_	21	nummod
21	hours	hour	NNS	_	18	appos
22	-RRB-	-rrb-	-RRB-	_	18	punct
23	based	base	VBN	_	28	case
24	on	on	IN	_	28	case
25	the	the	DT	_	28	det
26	maximum	maximum	NN	_	28	compound
27	human	human	JJ	_	28	amod
28	dose	dose	NN	_	16	nmod
29	of	of	IN	_	31	case
30	80	80	CD	_	31	nummod
31	mg/day	mg/day	NN	_	28	nmod
32	.	.	.	_	5	punct

1	A	a	DT	_	4	det
2	single	single	JJ	_	4	amod
3	tonic	tonic	JJ	_	4	amod
4	convulsion	convulsion	NN	_	6	nsubjpass
5	was	be	VBD	_	6	auxpass
6	seen	see	VBN	_	0	ROOT
7	in	in	IN	_	8	case
8	each	each	DT	_	6	nmod
9	of	of	IN	_	12	case
10	2	2	CD	_	12	nummod
11	male	male	JJ	_	12	amod
12	dogs	dog	NNS	_	8	nmod
13	-LRB-	-lrb-	-LRB-	_	15	punct
14	one	one	CD	_	15	nsubj
15	treated	treat	VBN	_	12	dep
16	at	at	IN	_	18	case
17	10	10	CD	_	18	nummod
18	mg/kg/day	mg/kg/day	NN	_	15	nmod
19	and	and	CC	_	15	cc
20	one	one	CD	_	15	conj
21	at	at	IN	_	23	case
22	120	120	CD	_	23	nummod
23	mg/kg/day	mg/kg/day	NN	_	20	nmod
24	-RRB-	-rrb-	-RRB-	_	15	punct
25	in	in	IN	_	28	case
26	a	a	DT	_	28	det
27	2-year	2-year	JJ	_	28	amod
28	study	study	NN	_	6	nmod
29	.	.	.	_	6	punct

1	No	no	DT	_	3	neg
2	CNS	cns	NN	_	3	compound
3	lesions	lesion	NNS	_	6	nsubjpass
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	auxpass
6	observed	observe	VBN	_	0	ROOT
7	in	in	IN	_	8	case
8	mice	mouse	NNS	_	6	nmod
9	after	after	IN	_	11	case
10	chronic	chronic	JJ	_	11	amod
11	treatment	treatment	NN	_	6	nmod
12	for	for	IN	_	16	case
13	up	up	RB	_	15	dep
14	to	to	TO	_	13	mwe
15	2	2	CD	_	16	nummod
16	years	year	NNS	_	11	nmod
17	at	at	IN	_	18	case
18	doses	dose	NNS	_	16	nmod
19	up	up	RB	_	21	advmod
20	to	to	TO	_	21	dep
21	400	400	CD	_	22	nummod
22	mg/kg/day	mg/kg/day	NN	_	18	dep
23	or	or	CC	_	22	cc
24	in	in	IN	_	25	case
25	rats	rat	NNS	_	22	conj
26	at	at	IN	_	27	case
27	doses	dose	NNS	_	22	nmod
28	up	up	RB	_	30	advmod
29	to	to	TO	_	30	dep
30	100	100	CD	_	31	nummod
31	mg/kg/day	mg/kg/day	NN	_	27	dep
32	.	.	.	_	6	punct

1	These	these	DT	_	2	det
2	doses	dose	NNS	_	7	nsubj
3	were	be	VBD	_	7	cop
4	6	6	CD	_	6	compound
5	to	to	TO	_	6	dep
6	11	11	CD	_	7	nummod
7	times	time	NNS	_	0	ROOT
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	mouse	mouse	NN	_	7	appos
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	and	and	CC	_	7	cc
12	8	8	CD	_	14	compound
13	to	to	TO	_	14	dep
14	16	16	CD	_	15	nummod
15	times	time	NNS	_	7	conj
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	rat	rat	NN	_	15	appos
18	-RRB-	-rrb-	-RRB-	_	17	punct
19	the	the	DT	_	21	det
20	human	human	JJ	_	21	amod
21	AUC	auc	NN	_	7	dep
22	-LRB-	-lrb-	-LRB-	_	23	punct
23	0-24	0-24	CD	_	21	appos
24	-RRB-	-rrb-	-RRB-	_	23	punct
25	based	base	VBN	_	28	case
26	on	on	IN	_	28	case
27	the	the	DT	_	28	det
28	maximum	maximum	NN	_	21	nmod
29	recommended	recommend	VBD	_	28	acl
30	human	human	JJ	_	31	amod
31	dose	dose	NN	_	29	dobj
32	of	of	IN	_	34	case
33	80	80	CD	_	34	nummod
34	mg/day	mg/day	NN	_	31	nmod
35	.	.	.	_	7	punct

1	CNS	cns	NN	_	3	compound
2	vascular	vascular	JJ	_	3	amod
3	lesions	lesion	NNS	_	22	nsubjpass
4	,	,	,	_	3	punct
5	characterized	characterize	VBN	_	3	acl
6	by	by	IN	_	8	case
7	perivascular	perivascular	JJ	_	8	amod
8	hemorrhages	hemorrhage	NNS	_	5	nmod
9	,	,	,	_	8	punct
10	edema	edema	NN	_	8	conj
11	,	,	,	_	8	punct
12	and	and	CC	_	8	cc
13	mononuclear	mononuclear	JJ	_	15	amod
14	cell	cell	NN	_	15	compound
15	infiltration	infiltration	NN	_	8	conj
16	of	of	IN	_	18	case
17	perivascular	perivascular	JJ	_	18	amod
18	spaces	space	NNS	_	15	nmod
19	,	,	,	_	3	punct
20	have	have	VBP	_	22	aux
21	been	be	VBN	_	22	auxpass
22	observed	observe	VBN	_	0	ROOT
23	in	in	IN	_	24	case
24	dogs	dog	NNS	_	22	nmod
25	treated	treat	VBN	_	24	acl
26	with	with	IN	_	28	case
27	other	other	JJ	_	28	amod
28	members	member	NNS	_	25	nmod
29	of	of	IN	_	31	case
30	this	this	DT	_	31	det
31	class	class	NN	_	28	nmod
32	.	.	.	_	22	punct

1	A	a	DT	_	4	det
2	chemically	chemically	RB	_	3	advmod
3	similar	similar	JJ	_	4	amod
4	drug	drug	NN	_	8	nsubj
5	in	in	IN	_	7	case
6	this	this	DT	_	7	det
7	class	class	NN	_	4	nmod
8	produced	produce	VBD	_	0	ROOT
9	optic	optic	JJ	_	11	amod
10	nerve	nerve	NN	_	11	compound
11	degeneration	degeneration	NN	_	8	dobj
12	-LRB-	-lrb-	-LRB-	_	14	punct
13	Wallerian	wallerian	JJ	_	14	amod
14	degeneration	degeneration	NN	_	11	appos
15	of	of	IN	_	17	case
16	retinogeniculate	retinogeniculate	NN	_	17	compound
17	fibers	fiber	NNS	_	14	nmod
18	-RRB-	-rrb-	-RRB-	_	14	punct
19	in	in	IN	_	22	case
20	clinically	clinically	RB	_	21	advmod
21	normal	normal	JJ	_	22	amod
22	dogs	dog	NNS	_	8	nmod
23	in	in	IN	_	26	case
24	a	a	DT	_	26	det
25	dose-dependent	dose-dependent	JJ	_	26	amod
26	fashion	fashion	NN	_	8	nmod
27	at	at	IN	_	29	case
28	a	a	DT	_	29	det
29	dose	dose	NN	_	8	nmod
30	that	that	WDT	_	31	nsubj
31	produced	produce	VBD	_	29	acl:relcl
32	plasma	plasma	NN	_	34	compound
33	drug	drug	NN	_	34	compound
34	levels	level	NNS	_	31	dobj
35	about	about	IN	_	37	advmod
36	30	30	CD	_	37	compound
37	times	time	NNS	_	38	nmod:npmod
38	higher	higher	JJR	_	31	advmod
39	than	than	IN	_	43	case
40	the	the	DT	_	43	det
41	mean	mean	NN	_	43	compound
42	drug	drug	NN	_	43	compound
43	level	level	NN	_	38	nmod
44	in	in	IN	_	45	case
45	humans	human	NNS	_	43	nmod
46	taking	take	VBG	_	45	acl
47	the	the	DT	_	50	det
48	highest	highest	JJS	_	50	amod
49	recommended	recommend	VBN	_	50	amod
50	dose	dose	NN	_	46	dobj
51	.	.	.	_	8	punct

1	drug1	drug1	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	,	,	,	_	1	punct
5	drug3	drug3	NN	_	1	appos
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	drug4	drug4	NN	_	5	dep
8	,	,	,	_	7	punct
9	drug5	drug5	NN	_	7	appos
10	,	,	,	_	7	punct
11	drug6	drug6	NN	_	7	appos
12	:	:	:	_	7	punct
13	Skeletal	skeletal	JJ	_	14	amod
14	Muscle	muscle	NN	_	7	dep
15	.	.	.	_	7	punct

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	drug2	drug2	NN	_	1	appos
4	-RRB-	-rrb-	-RRB-	_	3	punct
5	:	:	:	_	1	punct
6	drug3	drug3	NN	_	8	compound
7	plasma	plasma	NN	_	8	compound
8	concentrations	concentration	NNS	_	11	nsubjpass
9	were	be	VBD	_	11	auxpass
10	not	not	RB	_	11	neg
11	affected	affect	VBN	_	1	dep
12	by	by	IN	_	13	case
13	co-administration	co-administration	NN	_	11	nmod
14	of	of	IN	_	15	case
15	drug4	drug4	NN	_	13	nmod
16	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	compound
4	plasma	plasma	NN	_	5	compound
5	concentrations	concentration	NNS	_	8	nsubjpass
6	were	be	VBD	_	8	auxpass
7	not	not	RB	_	8	neg
8	affected	affect	VBN	_	1	appos
9	by	by	IN	_	10	case
10	co-administration	co-administration	NN	_	8	nmod
11	of	of	IN	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	influence	influence	NN	_	16	nsubjpass
5	of	of	IN	_	9	case
6	the	the	DT	_	9	det
7	bile-acidsequestering	bile-acidsequestering	JJ	_	9	amod
8	agent	agent	NN	_	9	compound
9	drug2	drug2	NN	_	4	nmod
10	on	on	IN	_	12	case
11	the	the	DT	_	12	det
12	pharmacokinetits	pharmacokinetit	NNS	_	4	nmod
13	of	of	IN	_	14	case
14	drug3	drug3	NN	_	12	nmod
15	was	be	VBD	_	16	auxpass
16	evaluated	evaluate	VBN	_	1	appos
17	in	in	IN	_	20	case
18	12	12	CD	_	20	nummod
19	healthy	healthy	JJ	_	20	amod
20	males	male	NNS	_	16	nmod
21	in	in	IN	_	26	case
22	2	2	CD	_	26	nummod
23	separate	separate	JJ	_	26	amod
24	randomized	randomized	JJ	_	26	amod
25	crossover	crossover	NN	_	26	compound
26	studies	study	NNS	_	20	nmod
27	.	.	.	_	1	punct

1	In	in	IN	_	4	case
2	the	the	DT	_	4	det
3	first	first	JJ	_	4	amod
4	study	study	NN	_	16	nmod
5	,	,	,	_	16	punct
6	concomitant	concomitant	JJ	_	7	amod
7	administration	administration	NN	_	16	nsubj
8	of	of	IN	_	11	case
9	0.2	0.2	CD	_	10	compound
10	mg	mg	NN	_	11	amod
11	drug1	drug1	NN	_	7	nmod
12	and	and	CC	_	11	cc
13	12	12	CD	_	15	nummod
14	g	g	NN	_	15	compound
15	drug2	drug2	NN	_	11	conj
16	resulted	result	VBD	_	0	ROOT
17	in	in	IN	_	18	case
18	decreases	decrease	NNS	_	16	nmod
19	of	of	IN	_	23	case
20	more	more	JJR	_	22	advmod
21	than	than	IN	_	20	mwe
22	22	22	CD	_	23	nummod
23	%	%	NN	_	18	nmod
24	for	for	IN	_	25	case
25	AUC	auc	NN	_	23	nmod
26	and	and	CC	_	23	cc
27	40	40	CD	_	28	nummod
28	%	%	NN	_	23	conj
29	for	for	IN	_	30	case
30	Cmax	Cmax	NNP	_	28	nmod
31	when	when	WRB	_	32	advmod
32	compared	compare	VBN	_	16	advcl
33	to	to	TO	_	35	case
34	dosing	dosing	NN	_	35	compound
35	drug3	drug3	NN	_	32	nmod
36	alone	alone	RB	_	35	advmod
37	.	.	.	_	16	punct

1	However	however	RB	_	31	advmod
2	,	,	,	_	31	punct
3	in	in	IN	_	6	case
4	the	the	DT	_	6	det
5	second	second	JJ	_	6	amod
6	study	study	NN	_	31	nmod
7	,	,	,	_	31	punct
8	administration	administration	NN	_	31	nsubj
9	of	of	IN	_	12	case
10	12	12	CD	_	12	nummod
11	g	g	NN	_	12	compound
12	drug1	drug1	NN	_	8	nmod
13	1	1	CD	_	14	nummod
14	hour	hour	NN	_	12	dep
15	before	before	IN	_	18	case
16	the	the	DT	_	18	det
17	evening	evening	NN	_	18	compound
18	meal	meal	NN	_	8	nmod
19	and	and	CC	_	18	cc
20	0.3	0.3	CD	_	21	compound
21	mg	mg	NN	_	22	amod
22	drug2	drug2	NN	_	18	conj
23	approximately	approximately	RB	_	24	advmod
24	4	4	CD	_	25	nummod
25	hours	hour	NNS	_	8	nmod
26	after	after	IN	_	25	case
27	the	the	DT	_	30	det
28	same	same	JJ	_	30	amod
29	evening	evening	NN	_	30	compound
30	meal	meal	NN	_	25	dep
31	resulted	result	VBD	_	0	ROOT
32	in	in	IN	_	34	case
33	a	a	DT	_	34	det
34	decrease	decrease	NN	_	31	nmod
35	in	in	IN	_	38	case
36	the	the	DT	_	38	det
37	drug3	drug3	NN	_	38	compound
38	AUC	auc	NN	_	34	nmod
39	of	of	IN	_	43	case
40	less	less	JJR	_	42	advmod
41	than	than	IN	_	40	mwe
42	8	8	CD	_	43	nummod
43	%	%	NN	_	38	nmod
44	,	,	,	_	31	punct
45	and	and	CC	_	31	cc
46	a	a	DT	_	47	det
47	decrease	decrease	NN	_	31	conj
48	in	in	IN	_	49	case
49	Cmax	cmax	NN	_	47	nmod
50	of	of	IN	_	53	case
51	about	about	IN	_	52	advmod
52	30	30	CD	_	53	nummod
53	%	%	NN	_	49	nmod
54	when	when	WRB	_	55	advmod
55	compared	compare	VBN	_	47	dep
56	to	to	TO	_	58	case
57	dosing	dosing	NN	_	58	compound
58	drug4	drug4	NN	_	55	nmod
59	alone	alone	RB	_	58	advmod
60	.	.	.	_	31	punct

1	Therefore	therefore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	it	it	PRP	_	6	nsubjpass
4	would	would	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	expected	expect	VBN	_	0	ROOT
7	that	that	IN	_	6	dobj
8	a	a	DT	_	10	det
9	dosing	dosing	NN	_	10	compound
10	schedule	schedule	NN	_	7	dep
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	given	give	VBN	_	10	acl
14	at	at	IN	_	15	case
15	bedtime	bedtime	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	drug2	drug2	NN	_	15	conj
18	given	give	VBN	_	25	mark
19	before	before	IN	_	25	mark
20	the	the	DT	_	22	det
21	evening	evening	NN	_	22	compound
22	meal	meal	NN	_	25	nsubj
23	would	would	MD	_	25	aux
24	not	not	RB	_	25	neg
25	result	result	VB	_	15	acl
26	in	in	IN	_	29	case
27	a	a	DT	_	29	det
28	significant	significant	JJ	_	29	amod
29	decrease	decrease	NN	_	25	nmod
30	in	in	IN	_	33	case
31	the	the	DT	_	33	det
32	clinical	clinical	JJ	_	33	amod
33	effect	effect	NN	_	29	nmod
34	of	of	IN	_	35	case
35	drug3	drug3	NN	_	33	nmod
36	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Plasma	plasma	NN	_	5	compound
4	drug2	drug2	NN	_	5	compound
5	levels	level	NNS	_	13	nsubjpass
6	and	and	CC	_	5	cc
7	drug3	drug3	NN	_	8	compound
8	clearance	clearance	NN	_	5	conj
9	at	at	IN	_	10	case
10	steady-state	steady-state	JJ	_	5	nmod
11	were	be	VBD	_	13	auxpass
12	not	not	RB	_	13	neg
13	affected	affect	VBN	_	1	appos
14	by	by	IN	_	15	case
15	co-administration	co-administration	NN	_	13	nmod
16	of	of	IN	_	19	case
17	0.2	0.2	CD	_	18	compound
18	mg	mg	NN	_	19	amod
19	drug4	drug4	NN	_	15	nmod
20	.	.	.	_	1	punct

1	drug1	drug1	NN	_	3	compound
2	plasma	plasma	NN	_	3	compound
3	concentrations	concentration	NNS	_	7	nsubjpass
4	were	be	VBD	_	7	auxpass
5	also	also	RB	_	7	advmod
6	not	not	RB	_	7	neg
7	affected	affect	VBN	_	0	ROOT
8	by	by	IN	_	9	case
9	co-administration	co-administration	NN	_	7	nmod
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	.	.	.	_	7	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Co	Co	NNP	_	5	compound
4	-	-	:	_	5	punct
5	administration	administration	NN	_	15	nsubj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drug3	drug3	NN	_	7	conj
10	to	to	TO	_	12	case
11	healthy	healthy	JJ	_	12	amod
12	volunteers	volunteer	NNS	_	5	nmod
13	did	do	VBD	_	15	aux
14	not	not	RB	_	15	neg
15	result	result	VB	_	1	dep
16	in	in	IN	_	18	case
17	any	any	DT	_	18	det
18	changes	change	NNS	_	15	nmod
19	in	in	IN	_	21	case
20	prothrombin	prothrombin	NN	_	21	compound
21	time	time	NN	_	18	nmod
22	or	or	CC	_	21	cc
23	clotting	clotting	NN	_	25	compound
24	factor	factor	NN	_	25	compound
25	VII	vii	NN	_	21	conj
26	when	when	WRB	_	27	advmod
27	compared	compare	VBN	_	15	advcl
28	to	to	TO	_	29	case
29	co-administration	co-administration	NN	_	27	nmod
30	of	of	IN	_	31	case
31	drug4	drug4	NN	_	29	nmod
32	and	and	CC	_	31	cc
33	placebo	placebo	NN	_	31	conj
34	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	AUC	auc	NN	_	19	nsubj
3	and	and	CC	_	2	cc
4	Cmax	cmax	NN	_	2	conj
5	of	of	IN	_	9	case
6	both	both	CC	_	9	cc:preconj
7	the	the	DT	_	9	det
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	R	r	NN	_	2	nmod
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	and	and	CC	_	9	cc
12	-LRB-	-lrb-	-LRB-	_	13	punct
13	S	s	NN	_	9	conj
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	isomers	isomer	NNS	_	9	dep
16	of	of	IN	_	17	case
17	drug1	drug1	NN	_	9	nmod
18	were	be	VBD	_	19	aux
19	unaffected	unaffected	JJ	_	0	ROOT
20	by	by	IN	_	22	case
21	concurrent	concurrent	JJ	_	22	amod
22	dosing	dosing	NN	_	19	nmod
23	of	of	IN	_	26	case
24	0.3	0.3	CD	_	26	nummod
25	mg	mg	NN	_	26	compound
26	drug2	drug2	NN	_	22	nmod
27	.	.	.	_	19	punct

1	Co-administration	co-administration	NN	_	8	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	drug2	drug2	NN	_	3	conj
6	did	do	VBD	_	8	aux
7	not	not	RB	_	8	neg
8	alter	alter	VB	_	0	ROOT
9	the	the	DT	_	10	det
10	pharmacokinetics	pharmacokinetic	NNS	_	8	dobj
11	of	of	IN	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	.	.	.	_	8	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	5	case
4	hypercholesterolemic	hypercholesterolemic	JJ	_	5	amod
5	patients	patient	NNS	_	1	nmod
6	,	,	,	_	5	punct
7	steady-state	steady-state	JJ	_	9	amod
8	drug2	drug2	NN	_	9	compound
9	AUC	auc	NN	_	5	conj
10	and	and	CC	_	5	cc
11	Cmax	cmax	NN	_	5	conj
12	increased	increase	VBD	_	5	acl
13	approximately	approximately	RB	_	14	advmod
14	50	50	CD	_	15	nummod
15	%	%	NN	_	12	dobj
16	and	and	CC	_	15	cc
17	24	24	CD	_	18	nummod
18	%	%	NN	_	15	conj
19	respectively	respectively	RB	_	12	advmod
20	after	after	IN	_	22	case
21	10	10	CD	_	22	nummod
22	days	day	NNS	_	12	nmod
23	with	with	IN	_	24	case
24	co-administration	co-administration	NN	_	22	nmod
25	of	of	IN	_	26	case
26	drug3	drug3	NN	_	24	nmod
27	,	,	,	_	26	punct
28	a	a	DT	_	30	det
29	known	known	JJ	_	30	amod
30	inhibitor	inhibitor	NN	_	26	appos
31	of	of	IN	_	34	case
32	cytochrome	cytochrome	NN	_	34	compound
33	P450	p450	NN	_	34	compound
34	3A4	3a4	NN	_	30	nmod
35	.	.	.	_	1	punct

1	OTHER	other	JJ	_	3	amod
2	CONCOMITANT	concomitant	JJ	_	3	amod
3	THERAPY	therapy	NN	_	0	ROOT
4	:	:	:	_	3	punct
5	Although	although	IN	_	11	mark
6	specific	specific	JJ	_	8	amod
7	interaction	interaction	NN	_	8	compound
8	studies	study	NNS	_	11	nsubjpass
9	were	be	VBD	_	11	auxpass
10	not	not	RB	_	11	neg
11	performed	perform	VBN	_	3	dep
12	,	,	,	_	11	punct
13	in	in	IN	_	15	case
14	clinical	clinical	JJ	_	15	amod
15	studies	study	NNS	_	11	nmod
16	,	,	,	_	11	punct
17	drug1	drug1	NN	_	19	nsubjpass
18	was	be	VBD	_	19	auxpass
19	used	use	VBN	_	11	parataxis
20	concomitantly	concomitantly	RB	_	19	advmod
21	with	with	IN	_	22	case
22	drug2	drug2	NN	_	19	nmod
23	,	,	,	_	22	punct
24	drug3	drug3	NN	_	22	conj
25	,	,	,	_	22	punct
26	drug4	drug4	NN	_	22	conj
27	,	,	,	_	22	punct
28	drug5	drug5	NN	_	22	conj
29	,	,	,	_	22	punct
30	and	and	CC	_	22	cc
31	drug6	drug6	NN	_	22	conj
32	-LRB-	-lrb-	-LRB-	_	33	punct
33	drug7	drug7	NN	_	31	appos
34	-RRB-	-rrb-	-RRB-	_	33	punct
35	without	without	IN	_	36	case
36	evidence	evidence	NN	_	19	nmod
37	of	of	IN	_	41	case
38	clinically	clinically	RB	_	39	advmod
39	significant	significant	JJ	_	41	amod
40	adverse	adverse	JJ	_	41	amod
41	interactions	interaction	NNS	_	36	nmod
42	.	.	.	_	3	punct

1	Additive	additive	JJ	_	3	amod
2	adverse	adverse	JJ	_	3	amod
3	effects	effect	NNS	_	9	nsubj
4	resulting	result	VBG	_	3	acl
5	from	from	IN	_	7	case
6	cholinergic	cholinergic	JJ	_	7	amod
7	blockade	blockade	NN	_	4	nmod
8	may	may	MD	_	9	aux
9	occur	occur	VB	_	0	ROOT
10	when	when	WRB	_	13	advmod
11	drug1	drug1	NN	_	13	nsubjpass
12	is	be	VBZ	_	13	auxpass
13	administered	administer	VBN	_	9	advcl
14	concomitantly	concomitantly	RB	_	13	advmod
15	with	with	IN	_	17	case
16	other	other	JJ	_	17	amod
17	drug2	drug2	NN	_	13	nmod
18	,	,	,	_	17	punct
19	drug3	drug3	NN	_	17	conj
20	,	,	,	_	17	punct
21	drug4	drug4	NN	_	17	conj
22	,	,	,	_	17	punct
23	drug5	drug5	NN	_	17	conj
24	,	,	,	_	17	punct
25	drug6	drug6	NN	_	17	conj
26	,	,	,	_	17	punct
27	drug7	drug7	NN	_	17	conj
28	or	or	CC	_	17	cc
29	some	some	DT	_	30	det
30	drug8	drug8	NN	_	17	conj
31	.	.	.	_	9	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	interfere	interfere	VB	_	0	ROOT
4	with	with	IN	_	6	case
5	the	the	DT	_	6	det
6	absorption	absorption	NN	_	3	nmod
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	.	.	.	_	3	punct

1	Administer	administer	VB	_	0	ROOT
2	drug1	drug1	NN	_	1	dobj
3	before	before	IN	_	4	case
4	meals	meal	NNS	_	1	nmod
5	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	after	after	IN	_	3	case
3	meals	meal	NNS	_	1	nmod
4	.	.	.	_	1	punct

1	drug1	drug1	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	metabolized	metabolize	VBN	_	0	ROOT
4	to	to	TO	_	5	mark
5	drug2	drug2	VB	_	3	xcomp
6	by	by	IN	_	9	case
7	the	the	DT	_	9	det
8	cytochrome	cytochrome	NN	_	9	compound
9	P450	p450	NN	_	5	nmod
10	-LRB-	-lrb-	-LRB-	_	14	punct
11	CYP450	cyp450	NN	_	14	compound
12	-RRB-	-rrb-	-RRB-	_	14	punct
13	enzyme	enzyme	NN	_	14	compound
14	group	group	NN	_	9	dep
15	,	,	,	_	14	punct
16	specifically	specifically	RB	_	17	advmod
17	cytochromes	cytochrome	VBZ	_	14	acl
18	P450	p450	NN	_	19	compound
19	3A4	3a4	NN	_	17	dobj
20	-LRB-	-lrb-	-LRB-	_	21	punct
21	CYP3A4	cyp3a4	NN	_	19	appos
22	-RRB-	-rrb-	-RRB-	_	21	punct
23	and	and	CC	_	19	cc
24	CYP2C8	cyp2c8	NN	_	19	conj
25	.	.	.	_	3	punct

1	The	the	DT	_	3	det
2	CYP3A4	cyp3a4	NN	_	3	compound
3	isoenzyme	isoenzyme	NN	_	5	nsubj
4	is	be	VBZ	_	5	cop
5	present	present	JJ	_	0	ROOT
6	in	in	IN	_	9	case
7	both	both	CC	_	9	cc:preconj
8	the	the	DT	_	9	det
9	liver	liver	NN	_	5	nmod
10	and	and	CC	_	9	cc
11	intestines	intestine	NNS	_	9	conj
12	.	.	.	_	5	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	also	also	RB	_	4	advmod
4	known	know	VBN	_	0	ROOT
5	to	to	TO	_	8	mark
6	be	be	VB	_	8	cop
7	an	a	DT	_	8	det
8	inhibitor	inhibitor	NN	_	4	xcomp
9	of	of	IN	_	10	case
10	CYP3A4	cyp3a4	NN	_	8	nmod
11	.	.	.	_	4	punct

1	Therefore	therefore	RB	_	4	advmod
2	,	,	,	_	4	punct
3	drug1	drug1	NN	_	4	nsubj
4	has	have	VBZ	_	0	ROOT
5	the	the	DT	_	6	det
6	potential	potential	NN	_	4	dobj
7	for	for	IN	_	8	case
8	interactions	interaction	NNS	_	6	nmod
9	with	with	IN	_	10	case
10	drugs	drug	NNS	_	8	nmod
11	or	or	CC	_	10	cc
12	substances	substance	NNS	_	10	conj
13	that	that	WDT	_	16	nsubj
14	may	may	MD	_	16	aux
15	be	be	VB	_	16	cop
16	substrates	substrate	NNS	_	8	acl:relcl
17	,	,	,	_	16	punct
18	inhibitors	inhibitor	NNS	_	16	conj
19	or	or	CC	_	16	cc
20	inducers	inducer	NNS	_	16	conj
21	of	of	IN	_	22	case
22	CYP3A4	cyp3a4	NN	_	20	nmod
23	.	.	.	_	4	punct

1	While	while	IN	_	15	mark
2	only	only	RB	_	5	advmod
3	a	a	DT	_	5	det
4	limited	limited	JJ	_	5	amod
5	number	number	NN	_	15	nsubjpass
6	of	of	IN	_	10	case
7	in	in	FW	_	10	amod
8	vivo	vivo	FW	_	7	dep
9	drug-drug	drug-drug	JJ	_	10	amod
10	interactions	interaction	NNS	_	5	nmod
11	with	with	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	have	have	VBP	_	15	aux
14	been	be	VBN	_	15	auxpass
15	reported	report	VBN	_	30	advcl
16	,	,	,	_	30	punct
17	chiefly	chiefly	RB	_	21	advmod
18	with	with	IN	_	21	case
19	the	the	DT	_	21	det
20	oral	oral	JJ	_	21	amod
21	formulation	formulation	NN	_	30	nmod
22	,	,	,	_	30	punct
23	the	the	DT	_	24	det
24	potential	potential	NN	_	30	nsubjpass
25	for	for	IN	_	27	case
26	other	other	JJ	_	27	amod
27	interactions	interaction	NNS	_	24	nmod
28	should	should	MD	_	30	aux
29	be	be	VB	_	30	auxpass
30	anticipated	anticipate	VBN	_	0	ROOT
31	.	.	.	_	30	punct

1	This	this	DT	_	4	nsubj
2	is	be	VBZ	_	4	cop
3	especially	especially	RB	_	4	advmod
4	important	important	JJ	_	0	ROOT
5	for	for	IN	_	6	case
6	drugs	drug	NNS	_	4	nmod
7	associated	associate	VBN	_	6	acl
8	with	with	IN	_	10	case
9	serious	serious	JJ	_	10	amod
10	toxicity	toxicity	NN	_	7	nmod
11	,	,	,	_	6	punct
12	such	such	JJ	_	15	case
13	as	as	IN	_	12	mwe
14	other	other	JJ	_	15	amod
15	drug1	drug1	NN	_	6	nmod
16	.	.	.	_	4	punct

1	If	if	IN	_	5	mark
2	such	such	JJ	_	3	amod
3	drugs	drug	NNS	_	5	nsubjpass
4	are	be	VBP	_	5	auxpass
5	needed	need	VBN	_	11	advcl
6	,	,	,	_	11	punct
7	their	they	PRP$	_	8	nmod:poss
8	dose	dose	NN	_	11	nsubjpass
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	reassessed	reassess	VBN	_	0	ROOT
12	and	and	CC	_	11	cc
13	,	,	,	_	11	punct
14	where	where	WRB	_	19	advmod
15	appropriate	appropriate	JJ	_	19	advmod
16	,	,	,	_	19	punct
17	plasma	plasma	NN	_	18	compound
18	concentration	concentration	NN	_	19	nsubj
19	measured	measure	VBN	_	11	advcl
20	.	.	.	_	11	punct

1	In	in	IN	_	2	case
2	view	view	NN	_	16	nmod
3	of	of	IN	_	8	case
4	the	the	DT	_	8	det
5	long	long	JJ	_	8	amod
6	and	and	CC	_	5	cc
7	variable	variable	JJ	_	5	conj
8	half-life	half-life	NN	_	2	nmod
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	,	,	,	_	16	punct
12	potential	potential	NN	_	16	nsubj
13	for	for	IN	_	15	case
14	drug	drug	NN	_	15	compound
15	interactions	interaction	NNS	_	12	nmod
16	exists	exist	VBZ	_	0	ROOT
17	not	not	RB	_	18	neg
18	only	only	RB	_	21	cc:preconj
19	with	with	IN	_	21	case
20	concomitant	concomitant	JJ	_	21	amod
21	medication	medication	NN	_	16	nmod
22	but	but	CC	_	21	cc
23	also	also	RB	_	25	advmod
24	with	with	IN	_	25	case
25	drugs	drug	NNS	_	21	conj
26	administered	administer	VBN	_	25	acl
27	after	after	IN	_	28	case
28	discontinuation	discontinuation	NN	_	26	nmod
29	of	of	IN	_	30	case
30	drug2	drug2	NN	_	28	nmod
31	.	.	.	_	16	punct

1	Since	since	IN	_	5	mark
2	drug1	drug1	NN	_	5	nsubj
3	is	be	VBZ	_	5	cop
4	a	a	DT	_	5	det
5	substrate	substrate	NN	_	17	advcl
6	for	for	IN	_	7	case
7	CYP3A4	cyp3a4	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	CYP2C8	cyp2c8	NN	_	7	conj
10	,	,	,	_	17	punct
11	drugs/substances	drugs/substances	NNS	_	17	nsubj
12	that	that	WDT	_	13	nsubj
13	inhibit	inhibit	VBP	_	11	acl:relcl
14	these	these	DT	_	15	det
15	isoenzymes	isoenzyme	NNS	_	13	dobj
16	may	may	MD	_	17	aux
17	decrease	decrease	VB	_	0	ROOT
18	the	the	DT	_	19	det
19	metabolism	metabolism	NN	_	17	dobj
20	and	and	CC	_	19	cc
21	increase	increase	NN	_	23	compound
22	serum	serum	NN	_	23	compound
23	concentration	concentration	NN	_	19	conj
24	of	of	IN	_	25	case
25	drug2	drug2	NN	_	19	nmod
26	.	.	.	_	17	punct

1	Reported	report	VBN	_	2	amod
2	examples	example	NNS	_	3	nsubj
3	include	include	VBP	_	0	ROOT
4	the	the	DT	_	5	det
5	following	following	NN	_	3	dobj
6	:	:	:	_	5	punct
7	drug1	drug1	NN	_	5	dep
8	:	:	:	_	7	punct
9	drug2	drug2	NN	_	11	nsubjpass
10	are	be	VBP	_	11	auxpass
11	known	know	VBN	_	7	dep
12	to	to	TO	_	13	mark
13	inhibit	inhibit	VB	_	11	xcomp
14	CYP3A4	cyp3a4	NN	_	13	dobj
15	to	to	TO	_	17	case
16	varying	vary	VBG	_	17	amod
17	degrees	degree	NNS	_	14	nmod
18	.	.	.	_	3	punct

1	A	a	DT	_	3	det
2	case	case	NN	_	3	compound
3	report	report	NN	_	19	nsubj
4	of	of	IN	_	6	case
5	one	one	CD	_	6	nummod
6	patient	patient	NN	_	3	nmod
7	taking	take	VBG	_	6	acl
8	drug1	drug1	NN	_	10	compound
9	200	200	CD	_	10	nummod
10	mg	mg	NN	_	7	dobj
11	and	and	CC	_	10	cc
12	drug2	drug2	NN	_	14	compound
13	800	800	CD	_	14	nummod
14	mg	mg	NN	_	10	conj
15	three	three	CD	_	16	nummod
16	times	time	NNS	_	7	nmod:tmod
17	a	a	DT	_	18	det
18	day	day	NN	_	16	nmod:npmod
19	resulted	result	VBD	_	0	ROOT
20	in	in	IN	_	21	case
21	increases	increase	NNS	_	19	nmod
22	in	in	IN	_	24	case
23	drug3	drug3	NN	_	24	compound
24	concentrations	concentration	NNS	_	21	nmod
25	from	from	IN	_	27	case
26	0.9	0.9	CD	_	27	nummod
27	mg/L	mg/l	NN	_	24	nmod
28	to	to	TO	_	30	case
29	1.3	1.3	CD	_	30	nummod
30	mg/L	mg/l	NN	_	27	nmod
31	.	.	.	_	19	punct

1	DEA	DEA	NNP	_	2	compound
2	concentrations	concentration	NNS	_	5	nsubjpass
3	were	be	VBD	_	5	auxpass
4	not	not	RB	_	5	neg
5	affected	affect	VBN	_	0	ROOT
6	.	.	.	_	5	punct

1	There	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	no	no	DT	_	4	neg
4	evidence	evidence	NN	_	2	nsubj
5	of	of	IN	_	6	case
6	toxicity	toxicity	NN	_	4	nmod
7	.	.	.	_	2	punct

1	Monitoring	monitor	VBG	_	18	nsubjpass
2	for	for	IN	_	4	case
3	drug1	drug1	NN	_	4	compound
4	toxicity	toxicity	NN	_	1	nmod
5	and	and	CC	_	4	cc
6	serial	serial	NN	_	7	compound
7	measurement	measurement	NN	_	4	conj
8	of	of	IN	_	11	case
9	drug2	drug2	NN	_	11	compound
10	serum	serum	NN	_	11	compound
11	concentration	concentration	NN	_	4	nmod
12	during	during	IN	_	15	case
13	concomitant	concomitant	JJ	_	15	amod
14	drug3	drug3	NN	_	15	compound
15	therapy	therapy	NN	_	1	nmod
16	should	should	MD	_	18	aux
17	be	be	VB	_	18	auxpass
18	considered	consider	VBN	_	0	ROOT
19	.	.	.	_	18	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	nsubj
4	inhibits	inhibit	VBZ	_	1	dep
5	CYP3A4	cyp3a4	NN	_	4	dobj
6	and	and	CC	_	4	cc
7	can	can	MD	_	8	aux
8	increase	increase	VB	_	4	conj
9	serum	serum	NN	_	11	compound
10	drug3	drug3	NN	_	11	compound
11	levels	level	NNS	_	8	dobj
12	.	.	.	_	1	punct

1	Other	other	JJ	_	2	amod
2	substances	substance	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	Grapefruit	grapefruit	NN	_	5	compound
5	juice	juice	NN	_	10	nsubj
6	given	give	VBN	_	5	acl
7	to	to	TO	_	9	case
8	healthy	healthy	JJ	_	9	amod
9	volunteers	volunteer	NNS	_	6	nmod
10	increased	increase	VBD	_	2	dep
11	drug1	drug1	NN	_	12	compound
12	AUC	auc	NN	_	10	dobj
13	by	by	IN	_	15	case
14	50	50	CD	_	15	nummod
15	%	%	NN	_	10	nmod
16	and	and	CC	_	10	cc
17	Cmax	cmax	NN	_	10	conj
18	by	by	IN	_	20	case
19	84	84	CD	_	20	nummod
20	%	%	NN	_	17	nmod
21	,	,	,	_	10	punct
22	resulting	result	VBG	_	10	advcl
23	in	in	IN	_	26	case
24	increased	increase	VBN	_	26	amod
25	plasma	plasma	NN	_	26	compound
26	levels	level	NNS	_	22	nmod
27	of	of	IN	_	28	case
28	drug2	drug2	NN	_	26	nmod
29	.	.	.	_	2	punct

1	Grapefruit	grapefruit	NN	_	2	compound
2	juice	juice	NN	_	6	nsubjpass
3	should	should	MD	_	6	aux
4	not	not	RB	_	6	neg
5	be	be	VB	_	6	auxpass
6	taken	take	VBN	_	0	ROOT
7	during	during	IN	_	8	case
8	treatment	treatment	NN	_	6	nmod
9	with	with	IN	_	11	case
10	oral	oral	JJ	_	11	amod
11	amiodarone	amiodarone	NN	_	8	nmod
12	.	.	.	_	6	punct

1	This	this	DT	_	2	det
2	information	information	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	considered	consider	VBN	_	0	ROOT
6	when	when	WRB	_	7	advmod
7	changing	change	VBG	_	5	advcl
8	from	from	IN	_	10	case
9	intravenous	intravenous	JJ	_	10	amod
10	drug1	drug1	NN	_	7	nmod
11	to	to	TO	_	13	case
12	oral	oral	JJ	_	13	amod
13	drug2	drug2	NN	_	7	nmod
14	.	.	.	_	5	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	suppress	suppress	VB	_	0	ROOT
4	certain	certain	JJ	_	6	amod
5	CYP450	cyp450	NN	_	6	compound
6	enzymes	enzyme	NNS	_	3	dobj
7	,	,	,	_	6	punct
8	including	include	VBG	_	9	case
9	drug2	drug2	NN	_	6	nmod
10	,	,	,	_	9	punct
11	drug3	drug3	NN	_	9	conj
12	,	,	,	_	9	punct
13	drug4	drug4	NN	_	9	conj
14	,	,	,	_	9	punct
15	and	and	CC	_	9	cc
16	drug5	drug5	NN	_	9	conj
17	.	.	.	_	3	punct

1	This	this	DT	_	2	det
2	inhibition	inhibition	NN	_	4	nsubj
3	can	can	MD	_	4	aux
4	result	result	VB	_	0	ROOT
5	in	in	IN	_	9	case
6	unexpectedly	unexpectedly	RB	_	7	advmod
7	high	high	JJ	_	9	amod
8	plasma	plasma	NN	_	9	compound
9	levels	level	NNS	_	4	nmod
10	of	of	IN	_	12	case
11	other	other	JJ	_	12	amod
12	drug1	drug1	NN	_	9	nmod
13	which	which	WDT	_	15	nsubjpass
14	are	be	VBP	_	15	auxpass
15	metabolized	metabolize	VBN	_	12	acl:relcl
16	by	by	IN	_	19	case
17	those	those	DT	_	19	det
18	CYP450	cyp450	NN	_	19	compound
19	enzymes	enzyme	NNS	_	15	nmod
20	.	.	.	_	4	punct

1	Reported	report	VBN	_	2	amod
2	examples	example	NNS	_	6	nsubj
3	of	of	IN	_	5	case
4	this	this	DT	_	5	det
5	interaction	interaction	NN	_	2	nmod
6	include	include	VBP	_	0	ROOT
7	the	the	DT	_	8	det
8	following	following	NN	_	6	dobj
9	:	:	:	_	8	punct
10	drug1	drug1	NN	_	11	compound
11	s	s	NNS	_	8	dep
12	:	:	:	_	11	punct
13	drug2	drug2	NN	_	26	nsubjpass
14	-LRB-	-lrb-	-LRB-	_	16	punct
15	drug3	drug3	NN	_	16	compound
16	substrate	substrate	NN	_	13	appos
17	-RRB-	-rrb-	-RRB-	_	16	punct
18	administered	administer	VBN	_	13	acl
19	in	in	IN	_	20	case
20	combination	combination	NN	_	18	nmod
21	with	with	IN	_	23	case
22	oral	oral	JJ	_	23	amod
23	drug4	drug4	NN	_	20	nmod
24	has	have	VBZ	_	26	aux
25	been	be	VBN	_	26	auxpass
26	reported	report	VBN	_	11	dep
27	to	to	TO	_	28	mark
28	produce	produce	VB	_	26	xcomp
29	persistently	persistently	RB	_	30	advmod
30	elevated	elevated	JJ	_	32	amod
31	plasma	plasma	NN	_	32	compound
32	concentrations	concentration	NNS	_	28	dobj
33	of	of	IN	_	34	case
34	drug5	drug5	NN	_	32	nmod
35	resulting	result	VBG	_	32	acl
36	in	in	IN	_	38	case
37	elevated	elevated	JJ	_	38	amod
38	creatinine	creatinine	NN	_	35	nmod
39	,	,	,	_	26	punct
40	despite	despite	IN	_	41	case
41	reduction	reduction	NN	_	26	nmod
42	in	in	IN	_	43	case
43	dose	dose	NN	_	41	nmod
44	of	of	IN	_	45	case
45	drug6	drug6	NN	_	43	nmod
46	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	14	nsubjpass
4	-LRB-	-lrb-	-LRB-	_	6	punct
5	drug3	drug3	NN	_	6	compound
6	substrate	substrate	NN	_	3	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	in	in	IN	_	9	case
9	combination	combination	NN	_	3	nmod
10	with	with	IN	_	11	case
11	drug4	drug4	NN	_	9	nmod
12	has	have	VBZ	_	14	aux
13	been	be	VBN	_	14	auxpass
14	associated	associate	VBN	_	1	appos
15	with	with	IN	_	16	case
16	reports	report	NNS	_	14	nmod
17	of	of	IN	_	18	case
18	myopathy/rhabdomyolysis	myopathy/rhabdomyolysis	NN	_	16	nmod
19	.	.	.	_	1	punct

1	Cardiovasculars	Cardiovasculars	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	drug1	drug1	NN	_	1	dep
4	:	:	:	_	3	punct
5	In	in	IN	_	6	case
6	patients	patient	NNS	_	16	nmod
7	receiving	receive	VBG	_	6	acl
8	drug2	drug2	NN	_	9	compound
9	therapy	therapy	NN	_	7	dobj
10	,	,	,	_	16	punct
11	administration	administration	NN	_	16	nsubj
12	of	of	IN	_	14	case
13	oral	oral	JJ	_	14	amod
14	drug3	drug3	NN	_	11	nmod
15	regularly	regularly	RB	_	16	advmod
16	results	result	VBZ	_	3	dep
17	in	in	IN	_	19	case
18	an	a	DT	_	19	det
19	increase	increase	NN	_	16	nmod
20	in	in	IN	_	23	case
21	serum	serum	NN	_	23	compound
22	drug4	drug4	NN	_	23	compound
23	concentration	concentration	NN	_	19	nmod
24	that	that	WDT	_	26	nsubj
25	may	may	MD	_	26	aux
26	reach	reach	VB	_	19	acl:relcl
27	toxic	toxic	JJ	_	28	amod
28	levels	level	NNS	_	26	dobj
29	with	with	IN	_	32	case
30	resultant	resultant	JJ	_	32	amod
31	clinical	clinical	JJ	_	32	amod
32	toxicity	toxicity	NN	_	28	nmod
33	.	.	.	_	1	punct

1	drug1	drug1	NN	_	2	nsubj
2	taken	take	VBN	_	0	ROOT
3	concomitantly	concomitantly	RB	_	2	advmod
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	2	nmod
6	increases	increase	VBZ	_	2	dep
7	the	the	DT	_	10	det
8	serum	serum	NN	_	10	compound
9	drug3	drug3	NN	_	10	compound
10	concentration	concentration	NN	_	6	dobj
11	by	by	IN	_	13	case
12	70	70	CD	_	13	nummod
13	%	%	NN	_	6	nmod
14	after	after	IN	_	16	case
15	one	one	CD	_	16	nummod
16	day	day	NN	_	6	nmod
17	.	.	.	_	2	punct

1	On	on	IN	_	2	case
2	administration	administration	NN	_	14	nmod
3	of	of	IN	_	5	case
4	oral	oral	JJ	_	5	amod
5	drug1	drug1	NN	_	2	nmod
6	,	,	,	_	14	punct
7	the	the	DT	_	8	det
8	need	need	NN	_	14	nsubjpass
9	for	for	IN	_	11	case
10	drug2	drug2	NN	_	11	compound
11	therapy	therapy	NN	_	8	nmod
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	reviewed	review	VBN	_	0	ROOT
15	and	and	CC	_	14	cc
16	the	the	DT	_	17	det
17	dose	dose	NN	_	14	conj
18	reduced	reduce	VBN	_	17	acl
19	by	by	IN	_	22	case
20	approximately	approximately	RB	_	21	advmod
21	50	50	CD	_	22	nummod
22	%	%	NN	_	18	nmod
23	or	or	CC	_	17	cc
24	discontinued	discontinue	VBN	_	17	conj
25	.	.	.	_	14	punct

1	If	if	IN	_	5	mark
2	drug1	drug1	NN	_	3	compound
3	treatment	treatment	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	continued	continue	VBN	_	12	advcl
6	,	,	,	_	12	punct
7	serum	serum	NN	_	8	compound
8	levels	level	NNS	_	12	nsubjpass
9	should	should	MD	_	12	aux
10	be	be	VB	_	12	auxpass
11	closely	closely	RB	_	12	advmod
12	monitored	monitor	VBN	_	0	ROOT
13	and	and	CC	_	12	cc
14	patients	patient	NNS	_	12	conj
15	observed	observe	VBN	_	14	acl
16	for	for	IN	_	18	case
17	clinical	clinical	JJ	_	18	amod
18	evidence	evidence	NN	_	15	nmod
19	of	of	IN	_	20	case
20	toxicity	toxicity	NN	_	18	nmod
21	.	.	.	_	12	punct

1	These	these	DT	_	2	det
2	precautions	precaution	NNS	_	5	nsubj
3	probably	probably	RB	_	5	advmod
4	should	should	MD	_	5	aux
5	apply	apply	VB	_	0	ROOT
6	to	to	TO	_	8	case
7	drug1	drug1	NN	_	8	compound
8	administration	administration	NN	_	5	nmod
9	as	as	RB	_	5	advmod
10	well	well	RB	_	9	mwe
11	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Other	other	JJ	_	5	amod
4	drug2	drug2	NN	_	5	compound
5	drugs	drug	NNS	_	20	nsubjpass
6	,	,	,	_	5	punct
7	such	such	JJ	_	9	case
8	as	as	IN	_	7	mwe
9	drug3	drug3	NN	_	5	nmod
10	,	,	,	_	9	punct
11	drug4	drug4	NN	_	9	conj
12	,	,	,	_	9	punct
13	drug5	drug5	NN	_	9	conj
14	,	,	,	_	9	punct
15	and	and	CC	_	9	cc
16	drug6	drug6	NN	_	9	conj
17	,	,	,	_	5	punct
18	have	have	VBP	_	20	aux
19	been	be	VBN	_	20	auxpass
20	used	use	VBN	_	1	dep
21	concurrently	concurrently	RB	_	20	advmod
22	with	with	IN	_	23	case
23	drug7	drug7	NN	_	20	nmod
24	.	.	.	_	1	punct

1	There	there	EX	_	5	expl
2	have	have	VBP	_	5	aux
3	been	be	VBN	_	5	cop
4	case	case	NN	_	5	compound
5	reports	report	NNS	_	0	ROOT
6	of	of	IN	_	9	case
7	increased	increase	VBN	_	9	amod
8	steady-state	steady-state	JJ	_	9	amod
9	levels	level	NNS	_	5	nmod
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	,	,	,	_	11	punct
13	drug2	drug2	NN	_	11	conj
14	,	,	,	_	11	punct
15	and	and	CC	_	11	cc
16	drug3	drug3	NN	_	11	conj
17	during	during	IN	_	19	case
18	concomitant	concomitant	JJ	_	19	amod
19	therapy	therapy	NN	_	9	nmod
20	with	with	IN	_	21	case
21	drug4	drug4	NN	_	19	nmod
22	.	.	.	_	5	punct

1	drug1	drug1	NN	_	2	nsubj
2	decreases	decrease	VBZ	_	0	ROOT
3	serum	serum	NN	_	5	compound
4	amiodarone	amiodarone	NN	_	5	compound
5	levels	level	NNS	_	2	dobj
6	.	.	.	_	2	punct

1	drug1	drug1	NN	_	2	nsubj
2	taken	take	VBN	_	0	ROOT
3	concomitantly	concomitantly	RB	_	2	advmod
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	2	nmod
6	increases	increase	VBZ	_	2	dep
7	drug3	drug3	NN	_	9	compound
8	serum	serum	NN	_	9	compound
9	concentration	concentration	NN	_	6	dobj
10	by	by	IN	_	12	case
11	33	33	CD	_	12	nummod
12	%	%	NN	_	6	nmod
13	after	after	IN	_	15	case
14	two	two	CD	_	15	nummod
15	days	day	NNS	_	6	nmod
16	.	.	.	_	2	punct

1	drug1	drug1	NN	_	2	nsubj
2	taken	take	VBN	_	0	ROOT
3	concomitantly	concomitantly	RB	_	2	advmod
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	2	nmod
6	for	for	IN	_	10	case
7	less	less	JJR	_	9	advmod
8	than	than	IN	_	7	mwe
9	seven	seven	CD	_	10	nummod
10	days	day	NNS	_	2	nmod
11	increases	increase	VBZ	_	2	dep
12	plasma	plasma	NN	_	13	compound
13	concentrations	concentration	NNS	_	11	dobj
14	of	of	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	n-acetyl	n-acetyl	NN	_	18	compound
18	drug4	drug4	NN	_	15	conj
19	by	by	IN	_	21	case
20	55	55	CD	_	21	nummod
21	%	%	NN	_	11	nmod
22	and	and	CC	_	21	cc
23	33	33	CD	_	24	nummod
24	%	%	NN	_	21	conj
25	,	,	,	_	11	punct
26	respectively	respectively	RB	_	11	advmod
27	.	.	.	_	2	punct

1	drug1	drug1	NN	_	4	compound
2	and	and	CC	_	1	cc
3	procainamide	procainamide	NN	_	1	conj
4	doses	dose	NNS	_	7	nsubjpass
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	reduced	reduce	VBN	_	0	ROOT
8	by	by	IN	_	9	case
9	one-third	one-third	NN	_	7	nmod
10	when	when	WRB	_	13	advmod
11	either	either	CC	_	13	nsubjpass
12	is	be	VBZ	_	13	auxpass
13	administered	administer	VBN	_	7	advcl
14	with	with	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	.	.	.	_	7	punct

1	Plasma	plasma	NN	_	2	compound
2	levels	level	NNS	_	7	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	reported	report	VBN	_	0	ROOT
8	to	to	TO	_	9	mark
9	increase	increase	VB	_	7	xcomp
10	in	in	IN	_	15	case
11	the	the	DT	_	15	dep
12	presence	presence	NN	_	15	dep
13	of	of	IN	_	15	case
14	oral	oral	JJ	_	15	amod
15	drug2	drug2	NN	_	9	nmod
16	;	;	:	_	7	punct

1	because	because	IN	_	3	case
2	of	of	IN	_	1	mwe
3	this	this	DT	_	11	nmod
4	,	,	,	_	11	punct
5	the	the	DT	_	6	det
6	dosage	dosage	NN	_	11	nsubjpass
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	adjusted	adjust	VBN	_	0	ROOT
12	when	when	WRB	_	16	advmod
13	these	these	DT	_	14	det
14	drug2	drug2	NN	_	16	nsubjpass
15	are	be	VBP	_	16	auxpass
16	administered	administer	VBN	_	11	advcl
17	concomitantly	concomitantly	RB	_	16	advmod
18	.	.	.	_	11	punct

1	In	in	IN	_	2	case
2	general	general	JJ	_	9	nmod
3	,	,	,	_	9	punct
4	any	any	DT	_	6	det
5	added	add	VBD	_	6	amod
6	drug1	drug1	NN	_	9	nsubjpass
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	initiated	initiate	VBN	_	0	ROOT
10	at	at	IN	_	18	case
11	a	a	DT	_	18	dep
12	lower	lower	JJR	_	18	dep
13	than	than	IN	_	15	case
14	usual	usual	JJ	_	15	amod
15	dose	dose	NN	_	12	nmod
16	with	with	IN	_	18	case
17	careful	careful	JJ	_	18	amod
18	monitoring	monitoring	NN	_	9	nmod
19	.	.	.	_	9	punct

1	Combination	combination	NN	_	10	nsubjpass
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	7	case
5	other	other	JJ	_	7	amod
6	drug2	drug2	NN	_	7	compound
7	therapy	therapy	NN	_	1	nmod
8	should	should	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	reserved	reserve	VBN	_	0	ROOT
11	for	for	IN	_	12	case
12	patients	patient	NNS	_	10	nmod
13	with	with	IN	_	16	case
14	life-threatening	life-threatening	JJ	_	16	amod
15	ventricular	ventricular	JJ	_	16	amod
16	arrhythmias	arrhythmia	NNS	_	12	nmod
17	who	who	WP	_	20	nsubj
18	are	be	VBP	_	20	cop
19	incompletely	incompletely	RB	_	20	advmod
20	responsive	responsive	JJ	_	16	acl:relcl
21	to	to	TO	_	24	case
22	a	a	DT	_	24	det
23	single	single	JJ	_	24	amod
24	agent	agent	NN	_	20	nmod
25	or	or	CC	_	24	cc
26	incompletely	incompletely	RB	_	27	advmod
27	responsive	responsive	JJ	_	24	conj
28	to	to	TO	_	29	case
29	drug3	drug3	NN	_	27	nmod
30	.	.	.	_	10	punct

1	During	during	IN	_	2	case
2	transfer	transfer	NN	_	16	nmod
3	to	to	TO	_	5	case
4	oral	oral	JJ	_	5	amod
5	drug1	drug1	NN	_	2	nmod
6	,	,	,	_	16	punct
7	the	the	DT	_	9	det
8	dose	dose	NN	_	9	compound
9	levels	level	NNS	_	16	nsubjpass
10	of	of	IN	_	13	case
11	previously	previously	RB	_	12	advmod
12	administered	administer	VBN	_	13	amod
13	agents	agent	NNS	_	9	nmod
14	should	should	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	reduced	reduce	VBN	_	0	ROOT
17	by	by	IN	_	21	case
18	30	30	CD	_	20	compound
19	to	to	TO	_	20	dep
20	50	50	CD	_	21	nummod
21	%	%	NN	_	16	nmod
22	several	several	JJ	_	23	amod
23	days	day	NNS	_	16	nmod
24	after	after	IN	_	23	case
25	the	the	DT	_	26	det
26	addition	addition	NN	_	23	dep
27	of	of	IN	_	29	case
28	oral	oral	JJ	_	29	amod
29	drug2	drug2	NN	_	26	nmod
30	.	.	.	_	16	punct

1	The	the	DT	_	3	det
2	continued	continued	JJ	_	3	amod
3	need	need	NN	_	11	nsubjpass
4	for	for	IN	_	8	case
5	the	the	DT	_	8	det
6	other	other	JJ	_	8	amod
7	drug1	drug1	NN	_	8	compound
8	agent	agent	NN	_	3	nmod
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	reviewed	review	VBN	_	19	csubjpass
12	after	after	IN	_	14	case
13	the	the	DT	_	14	det
14	effects	effect	NNS	_	11	nmod
15	of	of	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	have	have	VBP	_	19	aux
18	been	be	VBN	_	19	auxpass
19	established	establish	VBN	_	0	ROOT
20	,	,	,	_	19	punct
21	and	and	CC	_	19	cc
22	discontinuation	discontinuation	NN	_	26	nsubjpass
23	ordinarily	ordinarily	RB	_	26	advmod
24	should	should	MD	_	26	aux
25	be	be	VB	_	26	auxpass
26	attempted	attempt	VBN	_	19	conj
27	.	.	.	_	19	punct

1	If	if	IN	_	5	mark
2	the	the	DT	_	3	det
3	treatment	treatment	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	continued	continue	VBN	_	13	advcl
6	,	,	,	_	13	punct
7	these	these	DT	_	8	det
8	patients	patient	NNS	_	13	nsubjpass
9	should	should	MD	_	13	aux
10	be	be	VB	_	13	auxpass
11	particularly	particularly	RB	_	12	advmod
12	carefully	carefully	RB	_	13	advmod
13	monitored	monitor	VBN	_	0	ROOT
14	for	for	IN	_	16	case
15	adverse	adverse	JJ	_	16	amod
16	effects	effect	NNS	_	13	nmod
17	,	,	,	_	16	punct
18	especially	especially	RB	_	20	advmod
19	conduction	conduction	NN	_	20	compound
20	disturbances	disturbance	NNS	_	16	appos
21	and	and	CC	_	20	cc
22	exacerbation	exacerbation	NN	_	20	conj
23	of	of	IN	_	24	case
24	tachyarrhythmias	tachyarrhythmia	NNS	_	22	nmod
25	,	,	,	_	16	punct
26	as	as	IN	_	29	mark
27	drug1	drug1	NN	_	29	nsubjpass
28	is	be	VBZ	_	29	auxpass
29	continued	continue	VBN	_	16	dep
30	.	.	.	_	13	punct

1	In	in	IN	_	2	case
2	drug1	drug1	NN	_	5	nmod
3	-	-	:	_	5	punct
4	treated	treated	JJ	_	5	amod
5	patients	patient	NNS	_	0	ROOT
6	who	who	WP	_	7	nsubj
7	require	require	VBP	_	5	acl:relcl
8	additional	additional	JJ	_	10	amod
9	drug2	drug2	NN	_	10	compound
10	therapy	therapy	NN	_	7	dobj
11	,	,	,	_	5	punct
12	the	the	DT	_	14	det
13	initial	initial	JJ	_	14	amod
14	dose	dose	NN	_	21	nsubj
15	of	of	IN	_	17	case
16	such	such	JJ	_	17	amod
17	agents	agent	NNS	_	14	nmod
18	should	should	MD	_	21	aux
19	be	be	VB	_	21	cop
20	approximately	approximately	RB	_	21	advmod
21	half	half	NN	_	5	appos
22	of	of	IN	_	26	case
23	the	the	DT	_	26	det
24	usual	usual	JJ	_	26	amod
25	recommended	recommend	VBN	_	26	amod
26	dose	dose	NN	_	21	nmod
27	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	used	use	VBN	_	1	dep
7	with	with	IN	_	8	case
8	caution	caution	NN	_	6	nmod
9	in	in	IN	_	10	case
10	patients	patient	NNS	_	8	nmod
11	receiving	receive	VBG	_	10	acl
12	-	-	:	_	11	punct
13	drug3	drug3	NN	_	15	compound
14	blocking	block	VBG	_	15	compound
15	agents	agent	NNS	_	11	dobj
16	-LRB-	-lrb-	-LRB-	_	19	punct
17	e.g.	e.g.	FW	_	19	dep
18	,	,	,	_	19	punct
19	drug4	drug4	NN	_	15	dep
20	,	,	,	_	19	punct
21	a	a	DT	_	23	det
22	drug5	drug5	NN	_	23	compound
23	inhibitor	inhibitor	NN	_	19	appos
24	-RRB-	-rrb-	-RRB-	_	19	punct
25	or	or	CC	_	15	cc
26	drug6	drug6	NN	_	27	compound
27	antagonists	antagonist	NNS	_	15	conj
28	-LRB-	-lrb-	-LRB-	_	31	punct
29	e.g.	e.g.	FW	_	31	dep
30	,	,	,	_	31	punct
31	drug7	drug7	NN	_	27	dep
32	,	,	,	_	31	punct
33	a	a	DT	_	35	det
34	drug8	drug8	NN	_	35	compound
35	substrate	substrate	NN	_	31	conj
36	,	,	,	_	31	punct
37	and	and	CC	_	31	cc
38	drug9	drug9	NN	_	31	conj
39	,	,	,	_	31	punct
40	a	a	DT	_	42	det
41	drug10	drug10	NN	_	42	compound
42	inhibitor	inhibitor	NN	_	31	appos
43	-RRB-	-rrb-	-RRB-	_	31	punct
44	because	because	IN	_	48	case
45	of	of	IN	_	44	mwe
46	the	the	DT	_	48	det
47	possible	possible	JJ	_	48	amod
48	potentiation	potentiation	NN	_	6	nmod
49	of	of	IN	_	50	case
50	bradycardia	bradycardia	NN	_	48	nmod
51	,	,	,	_	6	punct
52	sinus	sinus	NN	_	53	compound
53	arrest	arrest	NN	_	6	conj
54	,	,	,	_	6	punct
55	and	and	CC	_	6	cc
56	AV	av	NN	_	57	compound
57	block	block	NN	_	6	conj
58	;	;	:	_	1	punct

1	if	if	IN	_	2	mark
2	necessary	necessary	JJ	_	6	advcl
3	,	,	,	_	6	punct
4	drug1	drug1	NN	_	6	nsubj
5	can	can	MD	_	6	aux
6	continue	continue	VB	_	0	ROOT
7	to	to	TO	_	9	mark
8	be	be	VB	_	9	auxpass
9	used	use	VBN	_	6	xcomp
10	after	after	IN	_	11	case
11	insertion	insertion	NN	_	9	nmod
12	of	of	IN	_	14	case
13	a	a	DT	_	14	det
14	pacemaker	pacemaker	NN	_	11	nmod
15	in	in	IN	_	16	case
16	patients	patient	NNS	_	14	nmod
17	with	with	IN	_	19	case
18	severe	severe	JJ	_	19	amod
19	bradycardia	bradycardia	NN	_	16	nmod
20	or	or	CC	_	19	cc
21	sinus	sinus	NN	_	22	compound
22	arrest	arrest	NN	_	19	conj
23	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Potentiation	potentiation	NN	_	19	nsubjpass
4	of	of	IN	_	7	case
5	drug2	drug2	NN	_	7	compound
6	-	-	:	_	7	punct
7	type	type	NN	_	3	nmod
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	drug3	drug3	NN	_	7	dep
10	and	and	CC	_	9	cc
11	drug4	drug4	NN	_	12	compound
12	substrate	substrate	NN	_	9	conj
13	-RRB-	-rrb-	-RRB-	_	9	punct
14	drug5	drug5	NN	_	15	compound
15	response	response	NN	_	7	dep
16	is	be	VBZ	_	19	auxpass
17	almost	almost	RB	_	18	advmod
18	always	always	RB	_	19	advmod
19	seen	see	VBN	_	1	dep
20	in	in	IN	_	21	case
21	patients	patient	NNS	_	19	nmod
22	receiving	receive	VBG	_	21	acl
23	drug6	drug6	NN	_	22	dobj
24	and	and	CC	_	19	cc
25	can	can	MD	_	26	aux
26	result	result	VB	_	19	conj
27	in	in	IN	_	31	case
28	serious	serious	JJ	_	31	amod
29	or	or	CC	_	28	cc
30	fatal	fatal	JJ	_	28	conj
31	bleeding	bleeding	NN	_	26	nmod
32	.	.	.	_	1	punct

1	Since	since	IN	_	9	mark
2	the	the	DT	_	4	det
3	concomitant	concomitant	JJ	_	4	amod
4	administration	administration	NN	_	9	nsubj
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	with	with	IN	_	8	case
8	drug2	drug2	NN	_	4	nmod
9	increases	increase	VBZ	_	29	advcl
10	the	the	DT	_	12	det
11	prothrombin	prothrombin	NN	_	12	compound
12	time	time	NN	_	9	dobj
13	by	by	IN	_	15	case
14	100	100	CD	_	15	nummod
15	%	%	NN	_	9	nmod
16	after	after	IN	_	20	case
17	3	3	CD	_	19	compound
18	to	to	TO	_	19	dep
19	4	4	CD	_	20	nummod
20	days	day	NNS	_	9	nmod
21	,	,	,	_	29	punct
22	the	the	DT	_	23	det
23	dose	dose	NN	_	29	nsubjpass
24	of	of	IN	_	26	case
25	the	the	DT	_	26	det
26	drug3	drug3	NN	_	23	nmod
27	should	should	MD	_	29	aux
28	be	be	VB	_	29	auxpass
29	reduced	reduce	VBN	_	0	ROOT
30	by	by	IN	_	31	case
31	one-third	one-third	NN	_	29	nmod
32	to	to	TO	_	33	case
33	one-half	one-half	NN	_	29	nmod
34	,	,	,	_	29	punct
35	and	and	CC	_	29	cc
36	prothrombin	prothrombin	NN	_	37	compound
37	times	time	NNS	_	40	nsubjpass
38	should	should	MD	_	40	aux
39	be	be	VB	_	40	auxpass
40	monitored	monitor	VBN	_	29	conj
41	closely	closely	RB	_	40	advmod
42	.	.	.	_	29	punct

1	Some	some	DT	_	2	det
2	drug1	drug1	NN	_	0	ROOT
3	/	/	:	_	2	punct
4	substances	substance	NNS	_	6	nsubjpass
5	are	be	VBP	_	6	auxpass
6	known	know	VBN	_	2	dep
7	to	to	TO	_	8	mark
8	accelerate	accelerate	VB	_	6	xcomp
9	the	the	DT	_	10	det
10	metabolism	metabolism	NN	_	8	dobj
11	of	of	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	by	by	IN	_	14	mark
14	stimulating	stimulate	VBG	_	8	advcl
15	the	the	DT	_	16	det
16	synthesis	synthesis	NN	_	14	dobj
17	of	of	IN	_	18	case
18	drug3	drug3	NN	_	16	nmod
19	-LRB-	-lrb-	-LRB-	_	21	punct
20	enzyme	enzyme	NN	_	21	compound
21	induction	induction	NN	_	18	appos
22	-RRB-	-rrb-	-RRB-	_	21	punct
23	.	.	.	_	2	punct

1	This	this	DT	_	3	nsubj
2	may	may	MD	_	3	aux
3	lead	lead	VB	_	0	ROOT
4	to	to	TO	_	8	case
5	low	low	JJ	_	8	amod
6	drug1	drug1	NN	_	8	compound
7	serum	serum	NN	_	8	compound
8	levels	level	NNS	_	3	nmod
9	and	and	CC	_	8	cc
10	potential	potential	JJ	_	11	amod
11	decrease	decrease	NN	_	8	conj
12	in	in	IN	_	13	case
13	efficacy	efficacy	NN	_	11	nmod
14	.	.	.	_	3	punct

1	Reported	report	VBN	_	2	amod
2	examples	example	NNS	_	6	nsubj
3	of	of	IN	_	5	case
4	this	this	DT	_	5	det
5	interaction	interaction	NN	_	2	nmod
6	include	include	VBP	_	0	ROOT
7	the	the	DT	_	8	det
8	following	following	NN	_	6	dobj
9	:	:	:	_	8	punct
10	drug1	drug1	NN	_	8	dep
11	:	:	:	_	10	punct
12	drug2	drug2	NN	_	16	nsubj
13	is	be	VBZ	_	16	cop
14	a	a	DT	_	16	det
15	potent	potent	JJ	_	16	amod
16	inducer	inducer	NN	_	10	dep
17	of	of	IN	_	18	case
18	drug3	drug3	NN	_	16	nmod
19	.	.	.	_	6	punct

1	Administration	administration	NN	_	10	nsubjpass
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	concomitantly	concomitantly	RB	_	10	advmod
5	with	with	IN	_	7	case
6	oral	oral	JJ	_	7	amod
7	drug2	drug2	NN	_	4	nmod
8	has	have	VBZ	_	10	aux
9	been	be	VBN	_	10	auxpass
10	shown	show	VBN	_	0	ROOT
11	to	to	TO	_	12	mark
12	result	result	VB	_	10	xcomp
13	in	in	IN	_	14	case
14	decreases	decrease	NNS	_	12	nmod
15	in	in	IN	_	17	case
16	serum	serum	NN	_	17	compound
17	concentrations	concentration	NNS	_	14	nmod
18	of	of	IN	_	19	case
19	drug3	drug3	NN	_	17	nmod
20	and	and	CC	_	19	cc
21	drug4	drug4	NN	_	19	conj
22	.	.	.	_	10	punct

1	Other	other	JJ	_	2	amod
2	substances	substance	NNS	_	0	ROOT
3	,	,	,	_	2	punct
4	including	include	VBG	_	6	case
5	herbal	herbal	JJ	_	6	amod
6	preparations	preparation	NNS	_	2	nmod
7	:	:	:	_	2	punct
8	St.	St.	NNP	_	11	compound
9	John	John	NNP	_	11	compound
10	s	be	VBZ	_	11	compound
11	Wort	Wort	NNP	_	16	nsubj
12	-LRB-	-lrb-	-LRB-	_	14	punct
13	Hypericum	Hypericum	NNP	_	14	compound
14	perforatum	perforatum	NN	_	11	appos
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	induces	induce	VBZ	_	2	dep
17	CYP3A4	cyp3a4	NN	_	16	dobj
18	.	.	.	_	2	punct

1	Since	since	IN	_	5	mark
2	drug1	drug1	NN	_	5	nsubj
3	is	be	VBZ	_	5	cop
4	a	a	DT	_	5	det
5	substrate	substrate	NN	_	10	advcl
6	for	for	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	,	,	,	_	10	punct
9	there	there	EX	_	10	expl
10	is	be	VBZ	_	0	ROOT
11	the	the	DT	_	12	det
12	potential	potential	NN	_	10	nsubj
13	that	that	IN	_	26	mark
14	the	the	DT	_	15	det
15	use	use	NN	_	26	nsubj
16	of	of	IN	_	20	case
17	St.	St.	NNP	_	20	compound
18	John	John	NNP	_	20	compound
19	s	be	VBZ	_	20	compound
20	Wort	Wort	NNP	_	15	nmod
21	in	in	IN	_	22	case
22	patients	patient	NNS	_	15	nmod
23	receiving	receive	VBG	_	22	acl
24	drug3	drug3	NN	_	23	dobj
25	could	could	MD	_	26	aux
26	result	result	VB	_	12	ccomp
27	in	in	IN	_	30	case
28	reduced	reduce	VBN	_	30	amod
29	drug4	drug4	NN	_	30	compound
30	levels	level	NNS	_	26	nmod
31	.	.	.	_	10	punct

1	Other	other	JJ	_	3	amod
2	reported	report	VBN	_	3	amod
3	interactions	interaction	NNS	_	0	ROOT
4	with	with	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	:	:	:	_	3	punct
7	drug2	drug2	NN	_	17	nsubj
8	-LRB-	-lrb-	-LRB-	_	10	punct
9	drug3	drug3	NN	_	10	compound
10	substrate	substrate	NN	_	7	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	in	in	IN	_	13	case
13	combination	combination	NN	_	7	nmod
14	with	with	IN	_	15	case
15	drug4	drug4	NN	_	13	nmod
16	may	may	MD	_	17	aux
17	cause	cause	VB	_	3	dep
18	hypotension	hypotension	NN	_	17	dobj
19	,	,	,	_	18	punct
20	bradycardia	bradycardia	NN	_	18	conj
21	,	,	,	_	18	punct
22	and	and	CC	_	17	cc
23	decreased	decrease	VBD	_	17	conj
24	cardiac	cardiac	JJ	_	25	amod
25	output	output	NN	_	23	dobj
26	.	.	.	_	3	punct

1	Sinus	sinus	NN	_	2	compound
2	bradycardia	bradycardia	NN	_	5	nsubjpass
3	has	have	VBZ	_	5	aux
4	been	be	VBN	_	5	auxpass
5	reported	report	VBN	_	0	ROOT
6	with	with	IN	_	8	case
7	oral	oral	JJ	_	8	amod
8	drug1	drug1	NN	_	5	nmod
9	in	in	IN	_	10	case
10	combination	combination	NN	_	5	nmod
11	with	with	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	-LRB-	-lrb-	-LRB-	_	15	punct
14	drug3	drug3	NN	_	15	compound
15	substrate	substrate	NN	_	12	appos
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	given	give	VBN	_	12	acl
18	for	for	IN	_	20	case
19	local	local	JJ	_	20	amod
20	drug4	drug4	NN	_	17	nmod
21	.	.	.	_	5	punct

1	Seizure	seizure	NN	_	11	nsubjpass
2	,	,	,	_	1	punct
3	associated	associate	VBN	_	1	acl
4	with	with	IN	_	7	case
5	increased	increase	VBN	_	7	amod
6	drug1	drug1	NN	_	7	compound
7	concentrations	concentration	NNS	_	3	nmod
8	,	,	,	_	1	punct
9	has	have	VBZ	_	11	aux
10	been	be	VBN	_	11	auxpass
11	reported	report	VBN	_	0	ROOT
12	with	with	IN	_	14	case
13	concomitant	concomitant	JJ	_	14	amod
14	administration	administration	NN	_	11	nmod
15	of	of	IN	_	17	case
16	intravenous	intravenous	JJ	_	17	amod
17	drug2	drug2	NN	_	14	nmod
18	.	.	.	_	11	punct

1	drug1	drug1	NN	_	4	nsubj
2	is	be	VBZ	_	4	cop
3	a	a	DT	_	4	det
4	substrate	substrate	NN	_	0	ROOT
5	for	for	IN	_	7	case
6	both	both	DT	_	7	cc:preconj
7	drug2	drug2	NN	_	4	nmod
8	and	and	CC	_	7	cc
9	drug3	drug3	NN	_	7	conj
10	.	.	.	_	4	punct

1	drug1	drug1	NN	_	2	nsubj
2	inhibits	inhibit	VBZ	_	0	ROOT
3	drug2	drug2	NN	_	2	dobj
4	.	.	.	_	2	punct

1	drug1	drug1	NN	_	2	nsubj
2	increases	increase	VBZ	_	0	ROOT
3	enterohepatic	enterohepatic	JJ	_	4	amod
4	elimination	elimination	NN	_	2	dobj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	and	and	CC	_	2	cc
8	may	may	MD	_	9	aux
9	reduce	reduce	VB	_	2	conj
10	its	its	PRP$	_	12	nmod:poss
11	serum	serum	NN	_	12	compound
12	levels	level	NNS	_	9	dobj
13	and	and	CC	_	12	cc
14	drug3	drug3	NN	_	12	conj
15	/	/	:	_	14	punct
16	2	2	CD	_	14	nummod
17	.	.	.	_	2	punct

1	drug1	drug1	NN	_	2	nsubj
2	increases	increase	VBZ	_	0	ROOT
3	QT	QT	NNP	_	4	compound
4	prolongation	prolongation	NN	_	2	dobj
5	which	which	WDT	_	7	nsubj
6	could	could	MD	_	7	aux
7	cause	cause	VB	_	4	acl:relcl
8	arrhythmia	arrhythmia	NN	_	7	dobj
9	.	.	.	_	2	punct

1	drug1	drug1	NN	_	8	nsubjpass
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	,	,	,	_	1	punct
5	and	and	CC	_	1	cc
6	azoles	azole	NNS	_	1	conj
7	are	be	VBP	_	8	auxpass
8	known	know	VBN	_	0	ROOT
9	to	to	TO	_	10	mark
10	cause	cause	VB	_	8	xcomp
11	QTc	qtc	NN	_	12	compound
12	prolongation	prolongation	NN	_	10	dobj
13	.	.	.	_	8	punct

1	There	there	EX	_	4	expl
2	have	have	VBP	_	4	aux
3	been	be	VBN	_	4	cop
4	reports	report	NNS	_	0	ROOT
5	of	of	IN	_	7	case
6	QTc	qtc	NN	_	7	compound
7	prolongation	prolongation	NN	_	4	nmod
8	,	,	,	_	4	punct
9	with	with	IN	_	12	nmod
10	or	or	CC	_	9	cc
11	without	without	IN	_	9	conj
12	TdP	tdp	NN	_	4	nmod
13	,	,	,	_	4	punct
14	in	in	IN	_	15	case
15	patients	patient	NNS	_	4	nmod
16	taking	take	VBG	_	15	acl
17	drug1	drug1	NN	_	16	dobj
18	when	when	WRB	_	26	advmod
19	drug2	drug2	NN	_	26	nsubjpass
20	,	,	,	_	19	punct
21	drug3	drug3	NN	_	19	conj
22	,	,	,	_	19	punct
23	or	or	CC	_	19	cc
24	azoles	azole	NNS	_	19	conj
25	were	be	VBD	_	26	auxpass
26	administered	administer	VBN	_	16	advcl
27	concomitantly	concomitantly	RB	_	26	advmod
28	.	.	.	_	4	punct

1	Hemodynamic	hemodynamic	JJ	_	4	amod
2	and	and	CC	_	1	cc
3	electrophysiologic	electrophysiologic	JJ	_	1	conj
4	interactions	interaction	NNS	_	8	nsubjpass
5	have	have	VBP	_	8	aux
6	also	also	RB	_	8	advmod
7	been	be	VBN	_	8	auxpass
8	observed	observe	VBN	_	0	ROOT
9	after	after	IN	_	11	case
10	concomitant	concomitant	JJ	_	11	amod
11	administration	administration	NN	_	8	nmod
12	with	with	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	,	,	,	_	13	punct
15	drug2	drug2	NN	_	13	conj
16	,	,	,	_	13	punct
17	and	and	CC	_	13	cc
18	drug3	drug3	NN	_	13	conj
19	.	.	.	_	8	punct

1	Volatile	volatile	JJ	_	3	amod
2	drug1	drug1	NN	_	3	compound
3	Agents	agent	NNS	_	0	ROOT
4	:	:	:	_	3	punct
5	.	.	.	_	3	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	17	nmod
3	to	to	TO	_	5	case
4	the	the	DT	_	5	det
5	interactions	interaction	NNS	_	2	nmod
6	noted	note	VBD	_	2	acl
7	above	above	RB	_	6	advmod
8	,	,	,	_	17	punct
9	chronic	chronic	JJ	_	16	amod
10	-LRB-	-lrb-	-LRB-	_	12	punct
11	2	2	CD	_	12	nummod
12	weeks	week	NNS	_	9	dep
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	oral	oral	JJ	_	16	amod
15	drug1	drug1	NN	_	16	compound
16	administration	administration	NN	_	17	nsubj
17	impairs	impair	VBZ	_	0	ROOT
18	metabolism	metabolism	NN	_	17	dobj
19	of	of	IN	_	20	case
20	drug2	drug2	NN	_	18	nmod
21	,	,	,	_	20	punct
22	drug3	drug3	NN	_	20	conj
23	,	,	,	_	20	punct
24	and	and	CC	_	20	cc
25	drug4	drug4	NN	_	20	conj
26	.	.	.	_	17	punct

1	Electrolyte	Electrolyte	NNP	_	3	compound
2	Disturbances	Disturbances	NNPS	_	3	compound
3	Patients	Patients	NNPS	_	9	nsubj
4	with	with	IN	_	5	case
5	hypokalemia	hypokalemia	NN	_	3	nmod
6	or	or	CC	_	5	cc
7	hypomagnesemia	hypomagnesemia	NN	_	5	conj
8	should	should	MD	_	9	aux
9	have	have	VB	_	0	ROOT
10	the	the	DT	_	11	det
11	condition	condition	NN	_	12	nsubj
12	corrected	correct	VBN	_	9	ccomp
13	whenever	whenever	WRB	_	14	advmod
14	possible	possible	JJ	_	12	advcl
15	before	before	IN	_	17	mark
16	being	be	VBG	_	17	auxpass
17	treated	treat	VBN	_	14	advcl
18	with	with	IN	_	19	case
19	drug1	drug1	NN	_	17	nmod
20	,	,	,	_	9	punct
21	as	as	IN	_	25	mark
22	these	these	DT	_	23	det
23	disorders	disorder	NNS	_	25	nsubj
24	can	can	MD	_	25	aux
25	exaggerate	exaggerate	VB	_	9	advcl
26	the	the	DT	_	27	det
27	degree	degree	NN	_	25	dobj
28	of	of	IN	_	30	case
29	QTc	qtc	NN	_	30	compound
30	prolongation	prolongation	NN	_	27	nmod
31	and	and	CC	_	25	cc
32	increase	increase	VB	_	25	conj
33	the	the	DT	_	34	det
34	potential	potential	NN	_	32	dobj
35	for	for	IN	_	36	case
36	TdP	tdp	NN	_	34	nmod
37	.	.	.	_	9	punct

1	Special	special	JJ	_	2	amod
2	attention	attention	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	given	give	VBN	_	0	ROOT
6	to	to	TO	_	7	case
7	electrolyte	electrolyte	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	acid-base	acid-base	NN	_	7	conj
10	balance	balance	NN	_	7	dep
11	in	in	IN	_	12	case
12	patients	patient	NNS	_	7	nmod
13	experiencing	experience	VBG	_	12	acl
14	severe	severe	JJ	_	17	amod
15	or	or	CC	_	14	cc
16	prolonged	prolonged	JJ	_	14	conj
17	diarrhea	diarrhea	NN	_	13	dobj
18	or	or	CC	_	17	cc
19	in	in	IN	_	20	case
20	patients	patient	NNS	_	17	conj
21	receiving	receive	VBG	_	20	acl
22	concomitant	concomitant	JJ	_	23	amod
23	drug1	drug1	NN	_	21	dobj
24	.	.	.	_	5	punct

1	Concomitant	concomitant	JJ	_	3	amod
2	oral	oral	JJ	_	3	amod
3	administration	administration	NN	_	22	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	-LRB-	-lrb-	-LRB-	_	9	punct
7	a	a	DT	_	9	det
8	known	known	JJ	_	9	amod
9	inhibitor	inhibitor	NN	_	5	dep
10	of	of	IN	_	12	case
11	CYP3A4	cyp3a4	NN	_	12	compound
12	activity	activity	NN	_	9	nmod
13	in	in	IN	_	15	case
14	the	the	DT	_	15	det
15	liver	liver	NN	_	9	nmod
16	and	and	CC	_	9	cc
17	in	in	IN	_	20	case
18	the	the	DT	_	20	det
19	intestinal	intestinal	JJ	_	20	amod
20	mucosa	mucosa	NN	_	9	conj
21	-RRB-	-rrb-	-RRB-	_	9	punct
22	caused	cause	VBD	_	0	ROOT
23	an	a	DT	_	25	det
24	eight-fold	eight-fold	JJ	_	25	amod
25	increase	increase	NN	_	22	dobj
26	of	of	IN	_	29	case
27	the	the	DT	_	29	det
28	systemic	systemic	JJ	_	29	amod
29	exposure	exposure	NN	_	25	nmod
30	to	to	TO	_	32	case
31	oral	oral	JJ	_	32	amod
32	drug2	drug2	NN	_	29	nmod
33	.	.	.	_	22	punct

1	If	if	IN	_	26	mark
2	treatment	treatment	NN	_	26	nsubjpass
3	with	with	IN	_	4	case
4	inhibitors	inhibitor	NNS	_	2	nmod
5	of	of	IN	_	7	case
6	CYP3A4	cyp3a4	NN	_	7	compound
7	activity	activity	NN	_	4	nmod
8	-LRB-	-lrb-	-LRB-	_	11	punct
9	such	such	JJ	_	11	case
10	as	as	IN	_	9	mwe
11	drug1	drug1	NN	_	4	nmod
12	,	,	,	_	11	punct
13	drug2	drug2	NN	_	11	conj
14	,	,	,	_	11	punct
15	drug3	drug3	NN	_	11	conj
16	,	,	,	_	11	punct
17	drug4	drug4	NN	_	11	conj
18	,	,	,	_	11	punct
19	drug5	drug5	NN	_	11	conj
20	,	,	,	_	11	punct
21	drug6	drug6	NN	_	11	conj
22	,	,	,	_	11	punct
23	etc.	etc.	FW	_	11	dep
24	-RRB-	-rrb-	-RRB-	_	11	punct
25	is	be	VBZ	_	26	auxpass
26	indicated	indicate	VBN	_	35	advcl
27	,	,	,	_	35	punct
28	reduction	reduction	NN	_	35	nsubjpass
29	of	of	IN	_	32	case
30	the	the	DT	_	32	det
31	drug7	drug7	NN	_	32	compound
32	dose	dose	NN	_	28	nmod
33	should	should	MD	_	35	aux
34	be	be	VB	_	35	auxpass
35	considered	consider	VBN	_	0	ROOT
36	.	.	.	_	35	punct

1	After	after	IN	_	3	case
2	extensive	extensive	JJ	_	3	amod
3	intake	intake	NN	_	25	nmod
4	of	of	IN	_	6	case
5	grapefruit	grapefruit	NN	_	6	compound
6	juice	juice	NN	_	3	nmod
7	-LRB-	-lrb-	-LRB-	_	6	punct
8	which	which	WDT	_	9	nsubj
9	inhibits	inhibit	VBZ	_	6	acl:relcl
10	CYP3A4	cyp3a4	NN	_	11	compound
11	activity	activity	NN	_	9	dobj
12	predominantly	predominantly	RB	_	16	advmod
13	in	in	IN	_	16	case
14	the	the	DT	_	16	det
15	intestinal	intestinal	JJ	_	16	amod
16	mucosa	mucosa	NN	_	9	nmod
17	-RRB-	-rrb-	-RRB-	_	6	punct
18	,	,	,	_	25	punct
19	the	the	DT	_	21	det
20	systemic	systemic	JJ	_	21	amod
21	exposure	exposure	NN	_	25	nsubj
22	for	for	IN	_	24	case
23	oral	oral	JJ	_	24	amod
24	drug1	drug1	NN	_	21	nmod
25	increased	increase	VBD	_	0	ROOT
26	about	about	IN	_	28	advmod
27	two	two	CD	_	28	nummod
28	times	time	NNS	_	25	dobj
29	.	.	.	_	25	punct

1	As	as	IN	_	4	case
2	with	with	IN	_	4	case
3	other	other	JJ	_	4	amod
4	drugs	drug	NNS	_	19	nmod
5	primarily	primarily	RB	_	7	advmod
6	being	be	VBG	_	7	auxpass
7	metabolized	metabolize	VBN	_	4	acl
8	through	through	IN	_	9	case
9	CYP3A4	cyp3a4	NN	_	7	nmod
10	,	,	,	_	19	punct
11	ingestion	ingestion	NN	_	19	nsubjpass
12	of	of	IN	_	13	case
13	grapefruit	grapefruit	NN	_	11	nmod
14	or	or	CC	_	13	cc
15	grapefruit	grapefruit	NN	_	16	compound
16	juice	juice	NN	_	13	conj
17	should	should	MD	_	19	aux
18	be	be	VB	_	19	auxpass
19	avoided	avoid	VBN	_	0	ROOT
20	in	in	IN	_	21	case
21	connection	connection	NN	_	19	nmod
22	with	with	IN	_	24	case
23	drug1	drug1	NN	_	24	compound
24	administration	administration	NN	_	21	nmod
25	.	.	.	_	19	punct

1	Plasma	plasma	NN	_	2	compound
2	levels	level	NNS	_	6	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	may	may	MD	_	6	aux
6	become	become	VB	_	0	ROOT
7	subtherapeutic	subtherapeutic	JJ	_	6	xcomp
8	during	during	IN	_	10	case
9	drug2	drug2	NN	_	10	compound
10	therapy	therapy	NN	_	6	nmod
11	.	.	.	_	6	punct

1	drug1	drug1	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	inhibited	inhibit	VBN	_	0	ROOT
4	by	by	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	action	action	NN	_	6	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	is	be	VBZ	_	6	auxpass
6	potentiated	potentiate	VBN	_	0	ROOT
7	by	by	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	.	.	.	_	6	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	increase	increase	VB	_	0	ROOT
4	sensitivity	sensitivity	NN	_	3	dobj
5	to	to	TO	_	7	case
6	the	the	DT	_	7	det
7	drug2	drug2	NN	_	4	nmod
8	.	.	.	_	3	punct

1	Response	response	NN	_	6	nsubjpass
2	to	to	TO	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	may	may	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	enhanced	enhance	VBN	_	0	ROOT
7	by	by	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	.	.	.	_	6	punct

1	No	no	DT	_	3	neg
2	formal	formal	JJ	_	3	amod
3	assessments	assessment	NNS	_	14	nsubjpass
4	of	of	IN	_	6	case
5	drug-drug	drug-drug	JJ	_	6	amod
6	interactions	interaction	NNS	_	3	nmod
7	between	between	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	other	other	JJ	_	11	amod
11	agents	agent	NNS	_	8	conj
12	have	have	VBP	_	14	aux
13	been	be	VBN	_	14	auxpass
14	conducted	conduct	VBN	_	0	ROOT

1	.	.	.	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Since	since	IN	_	6	mark
4	drug2	drug2	NN	_	6	nsubjpass
5	is	be	VBZ	_	6	auxpass
6	contraindicated	contraindicate	VBN	_	1	dep
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	with	with	IN	_	10	case
10	drug3	drug3	NN	_	8	nmod
11	-	-	:	_	6	punct
12	induced	induce	VBN	_	13	amod
13	thrombocytopenia	thrombocytopenia	NN	_	22	nsubj
14	,	,	,	_	13	punct
15	the	the	DT	_	16	det
16	co-administration	co-administration	NN	_	13	appos
17	of	of	IN	_	18	case
18	drug4	drug4	NN	_	16	nmod
19	and	and	CC	_	18	cc
20	drug5	drug5	NN	_	18	conj
21	is	be	VBZ	_	22	cop
22	unlikely	unlikely	JJ	_	6	parataxis
23	for	for	IN	_	25	case
24	this	this	DT	_	25	det
25	indication	indication	NN	_	22	nmod
26	.	.	.	_	1	punct

1	However	however	RB	_	15	advmod
2	,	,	,	_	15	punct
3	if	if	IN	_	5	mark
4	drug1	drug1	NN	_	5	nsubj
5	is	be	VBZ	_	15	advcl
6	to	to	TO	_	8	mark
7	be	be	VB	_	8	auxpass
8	initiated	initiate	VBN	_	5	xcomp
9	after	after	IN	_	10	case
10	cessation	cessation	NN	_	8	nmod
11	of	of	IN	_	13	case
12	drug2	drug2	NN	_	13	compound
13	therapy	therapy	NN	_	10	nmod
14	,	,	,	_	15	punct
15	allow	allow	VBP	_	0	ROOT
16	sufficient	sufficient	JJ	_	17	amod
17	time	time	NN	_	15	dobj
18	for	for	IN	_	20	case
19	heparins	heparin	NNS	_	20	compound
20	effect	effect	NN	_	17	nmod
21	on	on	IN	_	23	case
22	the	the	DT	_	23	det
23	aPTT	aptt	NN	_	20	nmod
24	to	to	TO	_	25	mark
25	decrease	decrease	VB	_	15	xcomp
26	prior	prior	RB	_	25	advmod
27	to	to	TO	_	28	case
28	initiation	initiation	NN	_	26	nmod
29	of	of	IN	_	31	case
30	drug3	drug3	NN	_	31	compound
31	therapy	therapy	NN	_	28	nmod
32	.	.	.	_	15	punct

1	drug1	drug1	NN	_	3	compound
2	/	/	:	_	3	punct
3	drug2	drug2	NN	_	0	ROOT
4	:	:	:	_	3	punct
5	Pharmacokinetic	pharmacokinetic	JJ	_	9	amod
6	or	or	CC	_	5	cc
7	pharmacodynamic	pharmacodynamic	JJ	_	5	conj
8	drug-drug	drug-drug	NN	_	9	compound
9	interactions	interaction	NNS	_	13	nsubjpass
10	have	have	VBP	_	13	aux
11	not	not	RB	_	13	neg
12	been	be	VBN	_	13	auxpass
13	demonstrated	demonstrate	VBN	_	3	dep
14	between	between	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	concomitantly	concomitantly	RB	_	18	advmod
18	administered	administer	VBN	_	19	amod
19	drug4	drug4	NN	_	15	conj
20	-LRB-	-lrb-	-LRB-	_	22	punct
21	162.5	162.5	CD	_	22	nummod
22	mg	mg	NN	_	19	dep
23	orally	orally	RB	_	24	advmod
24	given	give	VBN	_	22	acl
25	26	26	CD	_	28	nummod
26	and	and	CC	_	25	cc
27	2	2	CD	_	25	conj
28	hours	hour	NNS	_	24	dobj
29	prior	prior	RB	_	31	advmod
30	to	to	TO	_	31	case
31	initiation	initiation	NN	_	28	nmod
32	of	of	IN	_	35	case
33	drug5	drug5	NN	_	35	compound
34	1	1	CD	_	35	nummod
35	g/kg/min	g/kg/min	NN	_	31	nmod
36	.	.	.	_	22	punct
37	over	over	IN	_	39	case
38	4	4	CD	_	39	nummod
39	hours	hour	NNS	_	22	nmod
40	-RRB-	-rrb-	-RRB-	_	22	punct
41	or	or	CC	_	19	cc
42	drug6	drug6	NN	_	19	conj
43	-LRB-	-lrb-	-LRB-	_	45	punct
44	1000	1000	CD	_	45	nummod
45	mg	mg	NN	_	42	dep
46	orally	orally	RB	_	47	advmod
47	given	give	VBN	_	45	acl
48	12	12	CD	_	53	nummod
49	,	,	,	_	48	punct
50	6	6	CD	_	48	conj
51	and	and	CC	_	48	cc
52	0	0	CD	_	48	conj
53	hours	hour	NNS	_	47	dobj
54	prior	prior	RB	_	53	advmod
55	to	to	TO	_	54	mwe
56	,	,	,	_	57	punct
57	and	and	CC	_	55	root
58	6	6	CD	_	61	compound
59	and	and	CC	_	58	cc
60	12	12	CD	_	58	conj
61	hours	hour	NNS	_	57	dep
62	subsequent	subsequent	JJ	_	61	amod
63	to	to	TO	_	62	dep
64	,	,	,	_	61	punct
65	initiation	initiation	NN	_	64	root
66	of	of	IN	_	69	case
67	drug7	drug7	NN	_	69	compound
68	1.5	1.5	CD	_	69	nummod
69	g/kg/min	g/kg/min	NN	_	65	nmod
70	.	.	.	_	65	punct
71	over	over	IN	_	73	case
72	18	18	CD	_	73	nummod
73	hours	hour	NNS	_	65	nmod
74	-RRB-	-rrb-	-RRB-	_	65	punct
75	.	.	.	_	65	punct

1	Oral	oral	JJ	_	2	amod
2	drug1	drug1	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	Pharmacokinetic	pharmacokinetic	JJ	_	6	amod
5	drug-drug	drug-drug	JJ	_	6	amod
6	interactions	interaction	NNS	_	21	nsubjpass
7	between	between	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	drug3	drug3	NN	_	8	conj
11	-LRB-	-lrb-	-LRB-	_	16	punct
12	7.5	7.5	CD	_	13	nummod
13	mg	mg	NN	_	16	dep
14	single	single	JJ	_	16	amod
15	oral	oral	JJ	_	16	amod
16	dose	dose	NN	_	10	appos
17	-RRB-	-rrb-	-RRB-	_	16	punct
18	have	have	VBP	_	21	aux
19	not	not	RB	_	21	neg
20	been	be	VBN	_	21	auxpass
21	demonstrated	demonstrate	VBN	_	2	dep
22	.	.	.	_	2	punct

1	However	however	RB	_	26	advmod
2	,	,	,	_	26	punct
3	the	the	DT	_	5	det
4	concomitant	concomitant	JJ	_	5	amod
5	use	use	NN	_	26	nsubj
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	-LRB-	-lrb-	-LRB-	_	16	punct
11	5-7	5-7	CD	_	13	compound
12	.5	.5	CD	_	13	compound
13	mg	mg	NN	_	16	amod
14	initial	initial	JJ	_	16	amod
15	oral	oral	JJ	_	16	amod
16	dose	dose	NN	_	7	dep
17	followed	follow	VBN	_	16	acl
18	by	by	IN	_	20	case
19	2.5-6	2.5-6	CD	_	20	nummod
20	mg/day	mg/day	NN	_	17	nmod
21	orally	orally	RB	_	20	advmod
22	for	for	IN	_	24	case
23	6-10	6-10	CD	_	24	nummod
24	days	day	NNS	_	20	nmod
25	-RRB-	-rrb-	-RRB-	_	16	punct
26	results	result	VBZ	_	0	ROOT
27	in	in	IN	_	28	case
28	prolongation	prolongation	NN	_	26	nmod
29	of	of	IN	_	32	case
30	the	the	DT	_	32	det
31	prothrombin	prothrombin	NN	_	32	compound
32	time	time	NN	_	28	nmod
33	-LRB-	-lrb-	-LRB-	_	34	punct
34	PT	pt	NN	_	32	appos
35	-RRB-	-rrb-	-RRB-	_	34	punct
36	and	and	CC	_	32	cc
37	International	International	NNP	_	39	compound
38	Normalized	Normalized	NNP	_	39	compound
39	Ratio	Ratio	NNP	_	32	conj
40	-LRB-	-lrb-	-LRB-	_	41	punct
41	INR	INR	NNP	_	39	appos
42	-RRB-	-rrb-	-RRB-	_	41	punct
43	.	.	.	_	26	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	safety	safety	NN	_	14	nsubjpass
5	and	and	CC	_	4	cc
6	effectiveness	effectiveness	NN	_	4	conj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	4	nmod
9	with	with	IN	_	10	case
10	drug3	drug3	NN	_	4	nmod
11	have	have	VBP	_	14	aux
12	not	not	RB	_	14	neg
13	been	be	VBN	_	14	auxpass
14	established	establish	VBN	_	1	appos
15	.	.	.	_	1	punct

1	Co-administration	co-administration	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concomitant	concomitant	JJ	_	4	amod
4	use	use	NN	_	16	nsubj
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	with	with	IN	_	8	case
8	drug2	drug2	NN	_	4	nmod
9	,	,	,	_	8	punct
10	drug3	drug3	NN	_	8	conj
11	,	,	,	_	8	punct
12	and	and	CC	_	8	cc
13	other	other	JJ	_	14	amod
14	drug4	drug4	NN	_	8	conj
15	may	may	MD	_	16	aux
16	increase	increase	VB	_	1	dep
17	the	the	DT	_	18	det
18	risk	risk	NN	_	16	dobj
19	of	of	IN	_	20	case
20	bleeding	bleeding	NN	_	18	nmod
21	.	.	.	_	1	punct

1	Drug-drug	drug-drug	JJ	_	2	amod
2	interactions	interaction	NNS	_	6	nsubjpass
3	have	have	VBP	_	6	aux
4	not	not	RB	_	6	neg
5	been	be	VBN	_	6	auxpass
6	observed	observe	VBN	_	0	ROOT
7	between	between	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	drug2	drug2	NN	_	8	conj
11	or	or	CC	_	10	cc
12	drug3	drug3	NN	_	10	conj
13	.	.	.	_	6	punct

1	Possible	possible	JJ	_	3	amod
2	drug	drug	NN	_	3	compound
3	interactions	interaction	NNS	_	0	ROOT
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	with	with	IN	_	7	case
7	drug2	drug2	NN	_	3	nmod
8	or	or	CC	_	7	cc
9	with	with	IN	_	11	case
10	other	other	JJ	_	11	amod
11	drug3	drug3	NN	_	7	conj
12	.	.	.	_	3	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	have	have	VB	_	0	ROOT
4	life-threatening	life-threatening	JJ	_	5	amod
5	interactions	interaction	NNS	_	3	dobj
6	with	with	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	.	.	.	_	3	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	enhance	enhance	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	effects	effect	NNS	_	3	dobj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	,	,	,	_	7	punct
9	drug3	drug3	NN	_	7	conj
10	,	,	,	_	7	punct
11	and	and	CC	_	7	cc
12	other	other	JJ	_	13	amod
13	drug4	drug4	NN	_	7	conj
14	.	.	.	_	3	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	block	block	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	antihypertensive	antihypertensive	JJ	_	6	amod
6	action	action	NN	_	3	dobj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	and	and	CC	_	3	cc
10	similarly	similarly	RB	_	11	advmod
11	acting	act	VBG	_	12	amod
12	compounds	compound	NNS	_	3	conj
13	.	.	.	_	3	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	enhance	enhance	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	seizure	seizure	NN	_	6	compound
6	risk	risk	NN	_	3	dobj
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	taking	take	VBG	_	8	acl
10	drug2	drug2	NN	_	9	dobj

1	.	.	.	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	drug1	drug1	NN	_	6	nsubj
2	in	in	IN	_	4	case
3	large	large	JJ	_	4	amod
4	amounts	amount	NNS	_	1	nmod
5	may	may	MD	_	6	aux
6	counteract	counteract	VB	_	0	ROOT
7	the	the	DT	_	9	det
8	antiepileptic	antiepileptic	JJ	_	9	amod
9	effect	effect	NN	_	6	dobj
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	,	,	,	_	11	punct
13	drug3	drug3	NN	_	11	conj
14	and	and	CC	_	11	cc
15	drug4	drug4	NN	_	11	conj
16	,	,	,	_	6	punct
17	and	and	CC	_	6	cc
18	increase	increase	VB	_	6	conj
19	the	the	DT	_	20	det
20	frequency	frequency	NN	_	18	dobj
21	of	of	IN	_	22	case
22	seizures	seizure	NNS	_	20	nmod
23	in	in	IN	_	26	case
24	susceptible	susceptible	JJ	_	26	amod
25	pediatric	pediatric	JJ	_	26	amod
26	patients	patient	NNS	_	18	nmod
27	.	.	.	_	6	punct

1	Preliminary	preliminary	JJ	_	2	amod
2	animal	animal	NN	_	7	nsubj
3	and	and	CC	_	2	cc
4	human	human	JJ	_	5	amod
5	studies	study	NNS	_	2	conj
6	have	have	VBP	_	7	aux
7	shown	show	VBN	_	0	ROOT
8	that	that	IN	_	15	mark
9	small	small	JJ	_	10	amod
10	quantities	quantity	NNS	_	15	nsubj
11	of	of	IN	_	14	case
12	systemically	systemically	RB	_	13	advmod
13	administered	administer	VBN	_	14	amod
14	drug1	drug1	NN	_	10	nmod
15	enter	enter	VBP	_	7	ccomp
16	the	the	DT	_	17	det
17	CSF	csf	NN	_	15	dobj
18	primarily	primarily	RB	_	20	advmod
19	as	as	IN	_	20	case
20	5-methyltetrahydro-folate	5-methyltetrahydro-folate	JJ	_	15	nmod
21	and	and	CC	_	20	cc
22	,	,	,	_	26	punct
23	in	in	IN	_	24	case
24	humans	human	NNS	_	26	nmod
25	,	,	,	_	26	punct
26	remain	remain	VBP	_	20	conj
27	1	1	CD	_	29	compound
28	to	to	TO	_	29	dep
29	3	3	CD	_	30	nummod
30	orders	order	NNS	_	33	nmod:npmod
31	of	of	IN	_	32	case
32	magnitude	magnitude	NN	_	30	nmod
33	lower	lower	JJR	_	26	xcomp
34	than	than	IN	_	38	case
35	the	the	DT	_	38	det
36	usual	usual	JJ	_	38	amod
37	drug2	drug2	NN	_	38	compound
38	concentrations	concentration	NNS	_	33	nmod
39	following	follow	VBG	_	41	case
40	intrathecal	intrathecal	JJ	_	41	amod
41	administration	administration	NN	_	38	nmod
42	.	.	.	_	7	punct

1	However	however	RB	_	8	advmod
2	,	,	,	_	8	punct
3	high	high	JJ	_	4	amod
4	doses	dose	NNS	_	8	nsubj
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	may	may	MD	_	8	aux
8	reduce	reduce	VB	_	0	ROOT
9	the	the	DT	_	10	det
10	efficacy	efficacy	NN	_	8	dobj
11	of	of	IN	_	14	case
12	intrathecally	intrathecally	RB	_	13	advmod
13	administered	administer	VBN	_	14	amod
14	drug2	drug2	NN	_	10	nmod
15	.	.	.	_	8	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	enhance	enhance	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	toxicity	toxicity	NN	_	3	dobj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	.	.	.	_	3	punct

1	Certain	certain	JJ	_	2	amod
2	endocrine	endocrine	NN	_	9	nsubjpass
3	and	and	CC	_	2	cc
4	liver	liver	NN	_	6	compound
5	function	function	NN	_	6	compound
6	tests	test	NNS	_	2	conj
7	may	may	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	affected	affect	VBN	_	0	ROOT
10	by	by	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	-	-	:	_	11	punct
13	containing	contain	VBG	_	11	acl
14	oral	oral	JJ	_	15	amod
15	drug2	drug2	NN	_	13	dobj
16	.	.	.	_	9	punct

1	The	the	DT	_	4	det
2	following	follow	VBG	_	4	amod
3	similar	similar	JJ	_	4	amod
4	changes	change	NNS	_	7	nsubjpass
5	may	may	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	expected	expect	VBN	_	0	ROOT
8	with	with	IN	_	10	case
9	larger	larger	JJR	_	10	amod
10	doses	dose	NNS	_	7	nmod
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	:	:	:	_	7	punct
14	Increased	increase	VBN	_	16	amod
15	sulfobromophthalein	sulfobromophthalein	NN	_	16	compound
16	retention	retention	NN	_	7	dep
17	;	;	:	_	16	punct

1	increased	increase	VBN	_	2	amod
2	prothrombin	prothrombin	NN	_	0	ROOT
3	and	and	CC	_	2	cc
4	factors	factor	NNS	_	2	conj
5	VII	VII	NNP	_	4	dep
6	,	,	,	_	5	punct
7	VIII	VIII	NNP	_	5	conj
8	,	,	,	_	5	punct
9	IX	ix	CD	_	5	conj
10	,	,	,	_	5	punct
11	and	and	CC	_	5	cc
12	X	x	NN	_	5	conj
13	;	;	:	_	2	punct

1	decreased	decrease	VBN	_	2	amod
2	antithrombin	antithrombin	NN	_	0	ROOT
3	3	3	CD	_	2	nummod
4	;	;	:	_	2	punct

1	increased	increase	VBN	_	5	amod
2	norepinephrine-induced	norepinephrine-induced	JJ	_	5	amod
3	platel	platel	NN	_	5	compound
4	et	et	FW	_	5	compound
5	aggregation	aggregation	NN	_	0	ROOT
6	;	;	:	_	5	punct

1	increased	increase	VBN	_	4	amod
2	thyroid	thyroid	NN	_	4	compound
3	binding	binding	NN	_	4	compound
4	globulin	globulin	NN	_	0	ROOT
5	-LRB-	-lrb-	-LRB-	_	6	punct
6	TBG	tbg	NN	_	4	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	leading	lead	VBG	_	4	acl
9	to	to	TO	_	14	case
10	increased	increase	VBN	_	14	amod
11	circulating	circulate	VBG	_	14	amod
12	total	total	JJ	_	14	amod
13	thyroid	thyroid	NN	_	14	compound
14	hormone	hormone	NN	_	8	nmod
15	,	,	,	_	4	punct
16	as	as	IN	_	17	mark
17	measured	measure	VBN	_	4	dep
18	by	by	IN	_	19	case
19	PBI	pbi	NN	_	17	nmod
20	,	,	,	_	19	punct
21	T4	t4	NN	_	19	appos
22	by	by	IN	_	23	case
23	column	column	NN	_	21	nmod
24	,	,	,	_	23	punct
25	or	or	CC	_	23	cc
26	T4	t4	NN	_	23	conj
27	by	by	IN	_	28	case
28	radioimmunoassay	radioimmunoassay	NN	_	26	nmod
29	.	.	.	_	4	punct

1	Free	Free	NNP	_	4	compound
2	T3	t3	NN	_	4	compound
3	resin	resin	NN	_	4	compound
4	uptake	uptake	NN	_	6	nsubjpass
5	is	be	VBZ	_	6	auxpass
6	decreased	decrease	VBN	_	0	ROOT
7	,	,	,	_	6	punct
8	reflecting	reflect	VBG	_	6	xcomp
9	the	the	DT	_	11	det
10	elevated	elevated	JJ	_	11	amod
11	TBG	tbg	NN	_	8	dobj
12	;	;	:	_	6	punct

1	free	free	JJ	_	3	amod
2	T4	t4	NN	_	3	compound
3	concentration	concentration	NN	_	5	nsubj
4	is	be	VBZ	_	5	cop
5	unaltered	unaltered	JJ	_	0	ROOT
6	:	:	:	_	5	punct
7	impaired	impaired	JJ	_	9	amod
8	glucose	glucose	NN	_	9	compound
9	tolerance	tolerance	NN	_	5	dep
10	;	;	:	_	5	punct

1	decreased	decrease	VBN	_	3	amod
2	pregnanediol	pregnanediol	NN	_	3	compound
3	excretion	excretion	NN	_	0	ROOT
4	;	;	:	_	3	punct

1	reduced	reduce	VBN	_	2	amod
2	response	response	NN	_	0	ROOT
3	to	to	TO	_	5	case
4	metyrapone	metyrapone	NN	_	5	compound
5	test	test	NN	_	2	nmod
6	;	;	:	_	2	punct

1	reduced	reduce	VBN	_	2	amod
2	serum	serum	NN	_	3	nsubj
3	folate	folate	VBP	_	0	ROOT
4	concentration	concentration	NN	_	3	dobj
5	;	;	:	_	3	punct

1	increased	increase	VBN	_	3	amod
2	serum	serum	NN	_	3	compound
3	triglyceride	triglyceride	NN	_	0	ROOT
4	and	and	CC	_	3	cc
5	phospholipid	phospholipid	JJ	_	6	amod
6	concentration	concentration	NN	_	3	conj
7	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	administration	administration	NN	_	17	nsubj
3	of	of	IN	_	5	case
4	local	local	JJ	_	5	amod
5	drug1	drug1	NN	_	2	nmod
6	containing	contain	VBG	_	5	acl
7	drug2	drug2	NN	_	6	dobj
8	or	or	CC	_	7	cc
9	drug3	drug3	NN	_	7	conj
10	to	to	TO	_	11	case
11	patients	patient	NNS	_	6	nmod
12	receiving	receive	VBG	_	11	acl
13	drug4	drug4	NN	_	12	dobj
14	or	or	CC	_	13	cc
15	drug5	drug5	NN	_	13	conj
16	may	may	MD	_	17	aux
17	produce	produce	VB	_	0	ROOT
18	severe	severe	JJ	_	21	amod
19	,	,	,	_	21	punct
20	prolonged	prolonged	JJ	_	21	amod
21	hypertension	hypertension	NN	_	17	dobj
22	.	.	.	_	17	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	use	use	NN	_	9	nsubjpass
3	of	of	IN	_	5	case
4	these	these	DT	_	5	det
5	agents	agent	NNS	_	2	nmod
6	should	should	MD	_	9	aux
7	generally	generally	RB	_	9	advmod
8	be	be	VB	_	9	auxpass
9	avoided	avoid	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	In	in	IN	_	2	case
2	situations	situation	NNS	_	14	nmod
3	in	in	IN	_	4	case
4	which	which	WDT	_	8	nmod
5	concurrent	concurrent	JJ	_	6	amod
6	therapy	therapy	NN	_	8	nsubj
7	is	be	VBZ	_	8	cop
8	necessary	necessary	JJ	_	2	acl:relcl
9	,	,	,	_	14	punct
10	careful	careful	JJ	_	12	amod
11	patient	patient	NN	_	12	compound
12	monitoring	monitoring	NN	_	14	nsubj
13	is	be	VBZ	_	14	cop
14	essential	essential	JJ	_	0	ROOT
15	.	.	.	_	14	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	administration	administration	NN	_	9	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	4	conj
8	may	may	MD	_	9	aux
9	cause	cause	VB	_	0	ROOT
10	severe	severe	JJ	_	16	amod
11	,	,	,	_	10	punct
12	persistent	persistent	JJ	_	13	amod
13	hypertension	hypertension	NN	_	10	conj
14	or	or	CC	_	10	cc
15	cerebrovascular	cerebrovascular	JJ	_	10	conj
16	accidents	accident	NNS	_	9	dobj
17	.	.	.	_	9	punct

1	drug1	drug1	NN	_	5	nsubj
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	may	may	MD	_	5	aux
5	reduce	reduce	VB	_	0	ROOT
6	or	or	CC	_	5	cc
7	reverse	reverse	VB	_	5	conj
8	the	the	DT	_	10	det
9	pressor	pressor	NN	_	10	compound
10	effect	effect	NN	_	5	dobj
11	of	of	IN	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	.	.	.	_	5	punct

1	The	the	DT	_	2	det
2	coadministration	coadministration	NN	_	5	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	decreases	decrease	VBZ	_	0	ROOT
6	the	the	DT	_	8	det
7	biologic	biologic	JJ	_	8	amod
8	half-life	half-life	NN	_	5	dobj
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	because	because	IN	_	14	case
12	of	of	IN	_	11	mwe
13	an	a	DT	_	14	det
14	increase	increase	NN	_	5	nmod
15	in	in	IN	_	17	case
16	metabolic	metabolic	JJ	_	17	amod
17	clearance	clearance	NN	_	14	nmod
18	that	that	WDT	_	19	nsubj
19	results	result	VBZ	_	14	acl:relcl
20	in	in	IN	_	23	case
21	a	a	DT	_	23	det
22	greater	greater	JJR	_	23	amod
23	amount	amount	NN	_	19	nmod
24	of	of	IN	_	25	case
25	drug3	drug3	NN	_	23	nmod
26	in	in	IN	_	28	case
27	the	the	DT	_	28	det
28	urine	urine	NN	_	23	nmod
29	.	.	.	_	5	punct

1	Although	although	IN	_	13	mark
2	the	the	DT	_	3	det
3	mechanism	mechanism	NN	_	13	nsubjpass
4	of	of	IN	_	5	case
5	interaction	interaction	NN	_	3	nmod
6	between	between	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	is	be	VBZ	_	13	auxpass
11	not	not	RB	_	13	neg
12	totally	totally	RB	_	13	advmod
13	known	know	VBN	_	27	advcl
14	,	,	,	_	27	punct
15	enzyme	enzyme	NN	_	16	compound
16	induction	induction	NN	_	27	nsubj
17	and	and	CC	_	16	cc
18	displacement	displacement	NN	_	16	conj
19	of	of	IN	_	20	case
20	drug3	drug3	NN	_	16	nmod
21	from	from	IN	_	25	case
22	plasma	plasma	NN	_	25	compound
23	albumin	albumin	NN	_	25	compound
24	binding	bind	VBG	_	25	amod
25	sites	site	NNS	_	16	nmod
26	are	be	VBP	_	27	cop
27	possibilities	possibility	NNS	_	0	ROOT
28	.	.	.	_	27	punct

1	Because	because	IN	_	6	mark
2	drug1	drug1	NN	_	6	nsubjpass
3	has	have	VBZ	_	6	aux
4	not	not	RB	_	6	neg
5	been	be	VBN	_	6	auxpass
6	shown	show	VBN	_	38	advcl
7	to	to	TO	_	8	mark
8	produce	produce	VB	_	6	xcomp
9	any	any	DT	_	11	det
10	additional	additional	JJ	_	11	amod
11	effect	effect	NN	_	8	dobj
12	beyond	beyond	IN	_	13	case
13	that	that	DT	_	11	nmod
14	obtained	obtain	VBN	_	13	acl
15	with	with	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	alone	alone	RB	_	16	advmod
18	and	and	CC	_	6	cc
19	because	because	RB	_	21	mark
20	drug3	drug3	NN	_	21	nsubj
21	increases	increase	VBZ	_	6	conj
22	the	the	DT	_	23	det
23	rate	rate	NN	_	21	dobj
24	of	of	IN	_	25	case
25	excretion	excretion	NN	_	23	nmod
26	of	of	IN	_	27	case
27	drug4	drug4	NN	_	25	nmod
28	,	,	,	_	38	punct
29	the	the	DT	_	31	det
30	concomitant	concomitant	JJ	_	31	amod
31	use	use	NN	_	38	nsubjpass
32	of	of	IN	_	33	case
33	drug5	drug5	NN	_	31	nmod
34	and	and	CC	_	33	cc
35	drug6	drug6	NN	_	33	conj
36	is	be	VBZ	_	38	auxpass
37	not	not	RB	_	38	neg
38	recommended	recommend	VBN	_	0	ROOT
39	.	.	.	_	38	punct

1	Chronic	chronic	JJ	_	2	amod
2	administration	administration	NN	_	13	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	,	,	,	_	4	punct
6	a	a	DT	_	9	det
7	known	known	JJ	_	9	amod
8	enzyme	enzyme	NN	_	9	compound
9	inducer	inducer	NN	_	4	appos
10	,	,	,	_	4	punct
11	may	may	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	associated	associate	VBN	_	0	ROOT
14	with	with	IN	_	16	case
15	a	a	DT	_	16	det
16	decrease	decrease	NN	_	13	nmod
17	in	in	IN	_	20	case
18	the	the	DT	_	20	det
19	plasma	plasma	NN	_	20	compound
20	half-life	half-life	NN	_	16	nmod
21	of	of	IN	_	22	case
22	drug2	drug2	NN	_	20	nmod
23	.	.	.	_	13	punct

1	When	when	WRB	_	4	advmod
2	drug1	drug1	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	added	add	VBN	_	17	advcl
5	to	to	TO	_	17	nsubjpass
6	or	or	CC	_	5	cc
7	withdrawn	withdraw	VBN	_	5	conj
8	from	from	IN	_	9	case
9	treatment	treatment	NN	_	5	nmod
10	,	,	,	_	9	punct
11	dosage	dosage	NN	_	12	compound
12	adjustment	adjustment	NN	_	9	appos
13	of	of	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	may	may	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	required	require	VBN	_	0	ROOT
18	.	.	.	_	17	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	5	nsubj
4	have	have	VBP	_	5	aux
5	shown	show	VBN	_	0	ROOT
6	that	that	IN	_	17	mark
7	drug1	drug1	NN	_	17	nsubj
8	,	,	,	_	17	punct
9	because	because	IN	_	12	case
10	of	of	IN	_	9	mwe
11	its	its	PRP$	_	12	nmod:poss
12	affinity	affinity	NN	_	17	nmod
13	for	for	IN	_	14	case
14	albumin	albumin	NN	_	12	nmod
15	,	,	,	_	17	punct
16	may	may	MD	_	17	aux
17	displace	displace	VB	_	5	ccomp
18	from	from	IN	_	21	case
19	their	they	PRP$	_	21	nmod:poss
20	binding	binding	NN	_	21	compound
21	sites	site	NNS	_	17	nmod
22	other	other	JJ	_	23	amod
23	drugs	drug	NNS	_	21	dep
24	that	that	WDT	_	28	nsubjpass
25	are	be	VBP	_	28	auxpass
26	also	also	RB	_	28	advmod
27	albumin	albumin	NN	_	28	advmod
28	bound	bind	VBD	_	23	acl:relcl
29	,	,	,	_	23	punct
30	and	and	CC	_	23	cc
31	this	this	DT	_	33	nsubj
32	may	may	MD	_	33	aux
33	lead	lead	VB	_	23	conj
34	to	to	TO	_	36	case
35	drug	drug	NN	_	36	compound
36	interaction	interaction	NN	_	33	nmod
37	.	.	.	_	5	punct

1	Theoretically	theoretically	RB	_	7	advmod
2	,	,	,	_	7	punct
3	drug1	drug1	NN	_	7	nsubjpass
4	could	could	MD	_	7	aux
5	likewise	likewise	RB	_	7	advmod
6	be	be	VB	_	7	auxpass
7	displaced	displace	VBN	_	0	ROOT
8	.	.	.	_	7	punct

1	Patients	patient	NNS	_	11	nsubjpass
2	receiving	receive	VBG	_	1	acl
3	drug1	drug1	NN	_	2	dobj
4	,	,	,	_	3	punct
5	drug2	drug2	NN	_	3	conj
6	,	,	,	_	3	punct
7	or	or	CC	_	3	cc
8	drug3	drug3	NN	_	3	conj
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	observed	observe	VBN	_	0	ROOT
12	for	for	IN	_	14	case
13	increased	increase	VBN	_	14	amod
14	activity	activity	NN	_	11	nmod
15	of	of	IN	_	17	case
16	these	these	DT	_	17	det
17	drugs	drug	NNS	_	14	nmod
18	and	and	CC	_	14	cc
19	,	,	,	_	14	punct
20	therefore	therefore	RB	_	14	advmod
21	,	,	,	_	14	punct
22	signs	sign	NNS	_	14	conj
23	of	of	IN	_	24	case
24	toxicity	toxicity	NN	_	22	nmod
25	from	from	IN	_	27	case
26	these	these	DT	_	27	det
27	drugs	drug	NNS	_	22	nmod
28	.	.	.	_	11	punct

1	In	in	IN	_	2	case
2	patients	patient	NNS	_	13	nmod
3	receiving	receive	VBG	_	2	acl
4	drug1	drug1	NN	_	3	dobj
5	,	,	,	_	13	punct
6	the	the	DT	_	7	det
7	addition	addition	NN	_	13	nsubj
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	to	to	TO	_	11	case
11	therapy	therapy	NN	_	7	nmod
12	could	could	MD	_	13	aux
13	prolong	prolong	VB	_	0	ROOT
14	the	the	DT	_	16	det
15	prothrombin	prothrombin	NN	_	16	compound
16	time	time	NN	_	13	dobj
17	.	.	.	_	13	punct

1	Patients	patient	NNS	_	9	nsubj
2	receiving	receive	VBG	_	1	acl
3	both	both	CC	_	4	det
4	drugs	drug	NNS	_	2	dobj
5	should	should	MD	_	9	aux
6	be	be	VB	_	9	cop
7	under	under	IN	_	9	case
8	careful	careful	JJ	_	9	amod
9	observation	observation	NN	_	0	ROOT
10	.	.	.	_	9	punct

1	Patients	patient	NNS	_	7	nsubj
2	treated	treat	VBN	_	1	acl
3	with	with	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	may	may	MD	_	7	aux
6	be	be	VB	_	7	cop
7	resistant	resistant	JJ	_	0	ROOT
8	to	to	TO	_	10	case
9	the	the	DT	_	10	det
10	effects	effect	NNS	_	7	nmod
11	of	of	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	.	.	.	_	7	punct

1	In	in	IN	_	2	case
2	patients	patient	NNS	_	17	nmod
3	receiving	receive	VBG	_	2	acl
4	drug1	drug1	NN	_	3	dobj
5	and	and	CC	_	2	cc
6	a	a	DT	_	7	det
7	drug2	drug2	NN	_	2	conj
8	concomitantly	concomitantly	RB	_	7	advmod
9	,	,	,	_	17	punct
10	any	any	DT	_	11	det
11	reduction	reduction	NN	_	17	nsubj
12	in	in	IN	_	14	case
13	drug3	drug3	NN	_	14	compound
14	dosage	dosage	NN	_	11	nmod
15	should	should	MD	_	17	aux
16	be	be	VB	_	17	cop
17	gradual	gradual	JJ	_	0	ROOT
18	in	in	IN	_	21	mark
19	order	order	NN	_	18	mwe
20	to	to	TO	_	21	mark
21	avoid	avoid	VB	_	17	advcl
22	the	the	DT	_	24	det
23	possible	possible	JJ	_	24	amod
24	complications	complication	NNS	_	21	dobj
25	of	of	IN	_	28	case
26	sudden	sudden	JJ	_	28	amod
27	drug4	drug4	NN	_	28	compound
28	withdrawal	withdrawal	NN	_	24	nmod
29	.	.	.	_	17	punct

1	No	no	DT	_	2	neg
2	information	information	NN	_	0	ROOT
3	available	available	JJ	_	2	amod
4	.	.	.	_	2	punct

1	None	none	NN	_	2	nsubj
2	Reported	report	VBN	_	0	ROOT

1	Clinical	clinical	JJ	_	3	amod
2	interaction	interaction	NN	_	3	compound
3	studies	study	NNS	_	8	nsubj
4	with	with	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	indicated	indicate	VBD	_	0	ROOT
9	that	that	IN	_	19	mark
10	the	the	DT	_	11	det
11	coadministration	coadministration	NN	_	19	nsubj
12	of	of	IN	_	13	case
13	drug3	drug3	NN	_	11	nmod
14	with	with	IN	_	16	case
15	these	these	DT	_	16	det
16	drugs	drug	NNS	_	11	nmod
17	does	do	VBZ	_	19	aux
18	not	not	RB	_	19	neg
19	result	result	VB	_	8	ccomp
20	in	in	IN	_	25	case
21	clinically	clinically	RB	_	25	advmod
22	-	-	:	_	25	punct
23	significant	significant	JJ	_	25	amod
24	drug	drug	NN	_	25	compound
25	interactions	interaction	NNS	_	19	nmod
26	.	.	.	_	8	punct

1	-LRB-	-lrb-	-LRB-	_	2	punct
2	See	see	VB	_	0	ROOT
3	CLINICAL	CLINICAL	NNP	_	4	compound
4	PHARMACOLOGY	PHARMACOLOGY	NNP	_	14	nsubj
5	-RRB-	-rrb-	-RRB-	_	4	punct
6	Coadministration	Coadministration	NNP	_	13	compound
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	and	and	CC	_	6	cc
10	drug2	drug2	NN	_	12	compound
11	20	20	CD	_	12	nummod
12	mg	mg	NN	_	6	conj
13	daily	daily	JJ	_	14	advmod
14	resulted	result	VBD	_	2	ccomp
15	in	in	IN	_	17	case
16	a	a	DT	_	17	det
17	reduction	reduction	NN	_	14	nmod
18	of	of	IN	_	21	case
19	drug3	drug3	NN	_	21	compound
20	plasma	plasma	NN	_	21	compound
21	levels	level	NNS	_	17	nmod
22	by	by	IN	_	24	case
23	38	38	CD	_	24	nummod
24	%	%	NN	_	14	nmod
25	on	on	IN	_	26	case
26	average	average	NN	_	24	nmod
27	.	.	.	_	2	punct

1	There	there	EX	_	2	expl
2	is	be	VBZ	_	0	ROOT
3	no	no	DT	_	5	neg
4	clinical	clinical	JJ	_	5	amod
5	experience	experience	NN	_	2	nsubj
6	to	to	TO	_	7	case
7	date	date	NN	_	5	nmod
8	on	on	IN	_	10	case
9	the	the	DT	_	10	det
10	use	use	NN	_	5	nmod
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	in	in	IN	_	14	case
14	combination	combination	NN	_	10	nmod
15	with	with	IN	_	18	case
16	other	other	JJ	_	18	amod
17	anticancer	anticancer	JJ	_	18	amod
18	agents	agent	NNS	_	14	nmod
19	.	.	.	_	2	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	3	amod
2	Test-Interactions	test-interaction	NNS	_	3	compound
3	None	none	NN	_	4	nsubj
4	observed	observe	VBN	_	0	ROOT
5	.	.	.	_	4	punct

1	Urinary	urinary	JJ	_	3	amod
2	acidifying	acidify	VBG	_	3	amod
3	agents	agent	NNS	_	13	nsubj
4	These	these	DT	_	5	det
5	agents	agent	NNS	_	3	dep
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	drug1	drug1	NN	_	5	dep
8	,	,	,	_	7	punct
9	drug2	drug2	NN	_	7	appos
10	,	,	,	_	7	punct
11	etc.	etc.	FW	_	7	appos
12	-RRB-	-rrb-	-RRB-	_	7	punct
13	increase	increase	VBP	_	0	ROOT
14	the	the	DT	_	15	det
15	concentration	concentration	NN	_	13	dobj
16	of	of	IN	_	19	case
17	the	the	DT	_	19	det
18	ionized	ionize	VBN	_	19	amod
19	species	species	NNS	_	15	nmod
20	of	of	IN	_	23	case
21	the	the	DT	_	23	det
22	drug3	drug3	NN	_	23	compound
23	molecule	molecule	NN	_	19	nmod
24	,	,	,	_	13	punct
25	thereby	thereby	RB	_	26	advmod
26	increasing	increase	VBG	_	13	advcl
27	urinary	urinary	JJ	_	28	amod
28	excretion	excretion	NN	_	26	dobj
29	.	.	.	_	13	punct

1	Both	both	DT	_	2	det
2	groups	group	NNS	_	5	nsubj
3	of	of	IN	_	4	case
4	agents	agent	NNS	_	2	nmod
5	lower	lower	JJR	_	0	ROOT
6	blood	blood	NN	_	7	compound
7	levels	level	NNS	_	5	dobj
8	and	and	CC	_	7	cc
9	efficacy	efficacy	NN	_	7	conj
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	7	nmod
12	.	.	.	_	5	punct

1	drug1	drug1	NN	_	2	compound
2	drug2	drug2	NN	_	4	nsubjpass
3	are	be	VBP	_	4	auxpass
4	inhibited	inhibit	VBN	_	0	ROOT
5	by	by	IN	_	6	case
6	drug3	drug3	NN	_	4	nmod
7	.	.	.	_	4	punct

1	drug1	drug1	NN	_	6	nmod:tmod
2	,	,	,	_	6	punct
3	drug2	drug2	NN	_	4	compound
4	drug3	drug3	NN	_	6	nsubj
5	may	may	MD	_	6	aux
6	enhance	enhance	VB	_	0	ROOT
7	the	the	DT	_	8	det
8	activity	activity	NN	_	6	dobj
9	of	of	IN	_	10	case
10	drug4	drug4	NN	_	8	nmod
11	or	or	CC	_	10	cc
12	drug5	drug5	NN	_	10	conj
13	;	;	:	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	with	with	IN	_	3	case
3	drug2	drug2	NN	_	1	nmod
4	or	or	CC	_	3	cc
5	drug3	drug3	NN	_	3	conj
6	and	and	CC	_	3	cc
7	possibly	possibly	RB	_	10	advmod
8	other	other	JJ	_	10	amod
9	drug4	drug4	NN	_	10	compound
10	cause	cause	NN	_	3	conj
11	striking	striking	JJ	_	14	amod
12	and	and	CC	_	11	cc
13	sustained	sustained	JJ	_	11	conj
14	increases	increase	NNS	_	10	dobj
15	in	in	IN	_	17	case
16	the	the	DT	_	17	det
17	concentration	concentration	NN	_	14	nmod
18	of	of	IN	_	19	case
19	drug5	drug5	NN	_	17	nmod
20	in	in	IN	_	22	case
21	the	the	DT	_	22	det
22	brain	brain	NN	_	17	nmod
23	;	;	:	_	1	punct

1	cardiovascular	cardiovascular	JJ	_	2	amod
2	effects	effect	NNS	_	5	nsubjpass
3	can	can	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	potentiated	potentiate	VBN	_	0	ROOT
6	.	.	.	_	5	punct

1	drug1	drug1	NN	_	2	compound
2	drug2	drug2	NN	_	0	ROOT
3	,	,	,	_	2	punct
4	as	as	RB	_	2	cc
5	well	well	RB	_	4	mwe
6	as	as	IN	_	4	mwe
7	a	a	DT	_	8	det
8	metabolite	metabolite	NN	_	2	conj
9	of	of	IN	_	10	case
10	drug3	drug3	NN	_	8	nmod
11	,	,	,	_	2	punct
12	slow	slow	JJ	_	14	amod
13	drug4	drug4	NN	_	14	compound
14	metabolism	metabolism	NN	_	2	appos
15	.	.	.	_	2	punct

1	This	this	DT	_	0	ROOT
2	slowing	slow	VBG	_	1	acl
3	potentiates	potentiate	VBZ	_	2	dobj
4	drug1	drug1	NN	_	3	dobj
5	,	,	,	_	3	punct
6	increasing	increase	VBG	_	3	advcl
7	their	they	PRP$	_	8	nmod:poss
8	effect	effect	NN	_	6	dobj
9	on	on	IN	_	11	case
10	the	the	DT	_	11	det
11	release	release	NN	_	8	nmod
12	of	of	IN	_	13	case
13	norepinephrine	norepinephrine	NN	_	11	nmod
14	and	and	CC	_	13	cc
15	other	other	JJ	_	16	amod
16	monoamines	monoamine	NNS	_	13	conj
17	from	from	IN	_	20	case
18	adrenergic	adrenergic	JJ	_	20	amod
19	nerve	nerve	NN	_	20	compound
20	endings	ending	NNS	_	11	nmod
21	;	;	:	_	1	punct

1	this	this	DT	_	3	nsubj
2	can	can	MD	_	3	aux
3	cause	cause	VB	_	0	ROOT
4	headaches	headache	NNS	_	3	dobj
5	and	and	CC	_	4	cc
6	other	other	JJ	_	7	amod
7	signs	sign	NNS	_	4	conj
8	of	of	IN	_	10	case
9	hypertensive	hypertensive	JJ	_	10	amod
10	crisis	crisis	NN	_	7	nmod
11	.	.	.	_	3	punct

1	A	a	DT	_	2	det
2	variety	variety	NN	_	11	nsubj
3	of	of	IN	_	6	case
4	toxic	toxic	JJ	_	6	amod
5	neurological	neurological	JJ	_	6	amod
6	effects	effect	NNS	_	2	nmod
7	and	and	CC	_	6	cc
8	malignant	malignant	JJ	_	9	amod
9	hyperpyrexia	hyperpyrexia	NN	_	6	conj
10	can	can	MD	_	11	aux
11	occur	occur	VB	_	0	ROOT
12	,	,	,	_	11	punct
13	sometimes	sometimes	RB	_	16	advmod
14	with	with	IN	_	16	case
15	fatal	fatal	JJ	_	16	amod
16	results	result	NNS	_	11	nmod
17	.	.	.	_	11	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	counteract	counteract	VB	_	1	dep
6	the	the	DT	_	8	det
7	sedative	sedative	JJ	_	8	amod
8	effect	effect	NN	_	5	dobj
9	of	of	IN	_	10	case
10	drug3	drug3	NN	_	8	nmod
11	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	antagonize	antagonize	VB	_	1	appos
6	the	the	DT	_	8	det
7	hypotensive	hypotensive	JJ	_	8	amod
8	effects	effect	NNS	_	5	dobj
9	of	of	IN	_	10	case
10	drug3	drug3	NN	_	8	nmod
11	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	nsubj
4	blocks	block	VBZ	_	1	appos
5	dopamine	dopamine	NN	_	8	compound
6	and	and	CC	_	5	cc
7	norepinephrine	norepinephrine	NN	_	5	conj
8	receptors	receptor	NNS	_	4	dobj
9	,	,	,	_	4	punct
10	thus	thus	RB	_	11	advmod
11	inhibiting	inhibit	VBG	_	4	advcl
12	the	the	DT	_	15	det
13	central	central	JJ	_	15	amod
14	stimulant	stimulant	NN	_	15	compound
15	effects	effect	NNS	_	11	dobj
16	of	of	IN	_	17	case
17	drug3	drug3	NN	_	15	nmod
18	and	and	CC	_	4	cc
19	can	can	MD	_	21	aux
20	be	be	VB	_	21	auxpass
21	used	use	VBN	_	4	conj
22	to	to	TO	_	23	mark
23	treat	treat	VB	_	21	xcomp
24	drug4	drug4	NN	_	25	compound
25	poisoning	poisoning	NN	_	23	dobj
26	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	delay	delay	VB	_	1	appos
6	intestinal	intestinal	JJ	_	7	amod
7	absorption	absorption	NN	_	5	dobj
8	of	of	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	nsubj
4	blocks	block	VBZ	_	1	appos
5	dopamine	dopamine	NN	_	6	compound
6	receptors	receptor	NNS	_	4	dobj
7	,	,	,	_	4	punct
8	thus	thus	RB	_	9	advmod
9	inhibiting	inhibit	VBG	_	4	advcl
10	the	the	DT	_	13	det
11	central	central	JJ	_	13	amod
12	stimulant	stimulant	NN	_	13	compound
13	effects	effect	NNS	_	9	dobj
14	of	of	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	anorectic	anorectic	NN	_	12	nsubjpass
5	and	and	CC	_	4	cc
6	stimulatory	stimulatory	JJ	_	7	amod
7	effects	effect	NNS	_	4	conj
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	4	nmod
10	may	may	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	inhibited	inhibit	VBN	_	1	appos
13	by	by	IN	_	14	case
14	drug3	drug3	NN	_	12	nmod
15	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	nsubj
4	potentiate	potentiate	VB	_	1	dep
5	the	the	DT	_	7	det
6	analgesic	analgesic	JJ	_	7	amod
7	effect	effect	NN	_	4	dobj
8	of	of	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	.	.	.	_	1	punct

1	drug1	drug1	NN	_	4	compound
2	therapy	therapy	NN	_	4	compound
3	Urinary	urinary	JJ	_	4	amod
4	excretion	excretion	NN	_	8	nsubjpass
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	is	be	VBZ	_	8	auxpass
8	increased	increase	VBN	_	0	ROOT
9	,	,	,	_	8	punct
10	and	and	CC	_	8	cc
11	efficacy	efficacy	NN	_	13	nsubjpass
12	is	be	VBZ	_	13	auxpass
13	reduced	reduce	VBN	_	8	conj
14	by	by	IN	_	16	case
15	acidifying	acidify	VBG	_	16	amod
16	agents	agent	NNS	_	13	nmod
17	used	use	VBN	_	16	acl
18	in	in	IN	_	20	case
19	drug3	drug3	NN	_	20	compound
20	therapy	therapy	NN	_	17	nmod
21	.	.	.	_	8	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	nsubj
4	enhance	enhance	VBP	_	1	appos
5	the	the	DT	_	7	det
6	adrenergic	adrenergic	JJ	_	7	amod
7	effect	effect	NN	_	4	dobj
8	of	of	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	delay	delay	VB	_	1	appos
6	intestinal	intestinal	JJ	_	7	amod
7	absorption	absorption	NN	_	5	dobj
8	of	of	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	;	;	:	_	1	punct

1	co-administration	co-administration	NN	_	5	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	may	may	MD	_	5	aux
5	produce	produce	VB	_	0	ROOT
6	a	a	DT	_	9	det
7	synergistic	synergistic	JJ	_	9	amod
8	anticonvulsant	anticonvulsant	JJ	_	9	amod
9	action	action	NN	_	5	dobj
10	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	delay	delay	VB	_	1	appos
6	intestinal	intestinal	JJ	_	7	amod
7	absorption	absorption	NN	_	5	dobj
8	of	of	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	;	;	:	_	1	punct

1	co-administration	co-administration	NN	_	5	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	may	may	MD	_	5	aux
5	produce	produce	VB	_	0	ROOT
6	a	a	DT	_	9	det
7	synergistic	synergistic	JJ	_	9	amod
8	anticonvulsant	anticonvulsant	JJ	_	9	amod
9	action	action	NN	_	5	dobj
10	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	4	case
4	cases	case	NNS	_	13	nmod
5	of	of	IN	_	7	case
6	drug2	drug2	NN	_	7	compound
7	overdosage	overdosage	NN	_	4	nmod
8	,	,	,	_	13	punct
9	drug3	drug3	NN	_	11	compound
10	CNS	cns	NN	_	11	compound
11	stimulation	stimulation	NN	_	13	nsubj
12	is	be	VBZ	_	13	cop
13	potentiated	potentiated	JJ	_	1	dep
14	and	and	CC	_	13	cc
15	fatal	fatal	JJ	_	16	amod
16	convulsions	convulsion	NNS	_	18	nsubj
17	can	can	MD	_	18	aux
18	occur	occur	VB	_	13	conj
19	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	nsubj
4	inhibit	inhibit	VBP	_	1	appos
5	the	the	DT	_	7	det
6	hypotensive	hypotensive	JJ	_	7	amod
7	effect	effect	NN	_	4	dobj
8	of	of	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	.	.	.	_	1	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	3	amod
2	Test	test	NN	_	3	compound
3	Interactions	interaction	NNS	_	0	ROOT
4	:	:	:	_	3	punct
5	drug1	drug1	NN	_	7	nsubj
6	can	can	MD	_	7	aux
7	cause	cause	VB	_	3	dep
8	a	a	DT	_	10	det
9	significant	significant	JJ	_	10	amod
10	elevation	elevation	NN	_	7	dobj
11	in	in	IN	_	14	case
12	plasma	plasma	NN	_	14	compound
13	corticosteroid	corticosteroid	NN	_	14	compound
14	levels	level	NNS	_	10	nmod
15	.	.	.	_	3	punct

1	This	this	DT	_	2	det
2	increase	increase	NN	_	4	nsubj
3	is	be	VBZ	_	4	cop
4	greatest	greatest	JJS	_	0	ROOT
5	in	in	IN	_	7	case
6	the	the	DT	_	7	det
7	evening	evening	NN	_	4	nmod
8	.	.	.	_	4	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	interfere	interfere	VB	_	0	ROOT
4	with	with	IN	_	7	case
5	urinary	urinary	JJ	_	7	amod
6	steroid	steroid	NN	_	7	compound
7	determinations	determination	NNS	_	3	nmod
8	.	.	.	_	3	punct

1	No	no	DT	_	3	neg
2	drug	drug	NN	_	3	compound
3	interactions	interaction	NNS	_	6	nsubjpass
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	auxpass
6	observed	observe	VBN	_	0	ROOT
7	with	with	IN	_	10	case
8	the	the	DT	_	10	det
9	drug1	drug1	NN	_	10	compound
10	Implant	implant	NN	_	6	nmod
11	.	.	.	_	6	punct

1	There	there	EX	_	2	expl
2	is	be	VBZ	_	0	ROOT
3	limited	limited	JJ	_	4	amod
4	experience	experience	NN	_	2	nsubj
5	with	with	IN	_	6	case
6	use	use	NN	_	4	nmod
7	of	of	IN	_	9	case
8	retinal	retinal	JJ	_	9	amod
9	tamponades	tamponade	NNS	_	6	nmod
10	in	in	IN	_	11	case
11	conjunction	conjunction	NN	_	2	nmod
12	with	with	IN	_	15	case
13	the	the	DT	_	15	det
14	drug1	drug1	NN	_	15	compound
15	Implant	implant	NN	_	11	nmod
16	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	results	result	NNS	_	24	nsubj
3	of	of	IN	_	5	case
4	a	a	DT	_	5	det
5	study	study	NN	_	2	nmod
6	of	of	IN	_	7	case
7	coadministration	coadministration	NN	_	5	nmod
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	-LRB-	-lrb-	-LRB-	_	12	punct
11	50	50	CD	_	12	nummod
12	mg/kg	mg/kg	NN	_	9	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	with	with	IN	_	16	case
15	an	a	DT	_	16	det
16	drug2	drug2	NN	_	5	nmod
17	containing	contain	VBG	_	16	acl
18	drug3	drug3	NN	_	17	dobj
19	to	to	TO	_	21	case
20	13	13	CD	_	21	nummod
21	patients	patient	NNS	_	17	nmod
22	with	with	IN	_	23	case
23	tuberculosis	tuberculosis	NN	_	21	nmod
24	showed	show	VBD	_	0	ROOT
25	a	a	DT	_	26	det
26	reduction	reduction	NN	_	24	dobj
27	of	of	IN	_	30	case
28	mean	mean	JJ	_	30	amod
29	serum	serum	NN	_	30	compound
30	concentrations	concentration	NNS	_	26	nmod
31	and	and	CC	_	30	cc
32	urinary	urinary	JJ	_	33	amod
33	excretion	excretion	NN	_	30	conj
34	of	of	IN	_	35	case
35	drug4	drug4	NN	_	33	nmod
36	of	of	IN	_	39	case
37	approximately	approximately	RB	_	38	advmod
38	20	20	CD	_	39	nummod
39	%	%	NN	_	35	nmod
40	and	and	CC	_	39	cc
41	13	13	CD	_	42	nummod
42	%	%	NN	_	39	conj
43	,	,	,	_	26	punct
44	respectively	respectively	RB	_	26	advmod
45	,	,	,	_	26	punct
46	suggesting	suggest	VBG	_	26	acl
47	that	that	IN	_	55	mark
48	the	the	DT	_	50	det
49	oral	oral	JJ	_	50	amod
50	absorption	absorption	NN	_	55	nsubjpass
51	of	of	IN	_	52	case
52	drug5	drug5	NN	_	50	nmod
53	may	may	MD	_	55	aux
54	be	be	VB	_	55	auxpass
55	reduced	reduce	VBN	_	46	ccomp
56	by	by	IN	_	58	case
57	these	these	DT	_	58	det
58	drug6	drug6	NN	_	55	nmod
59	.	.	.	_	24	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	recommended	recommend	VBN	_	0	ROOT
4	to	to	TO	_	5	mark
5	avoid	avoid	VB	_	3	xcomp
6	concurrent	concurrent	JJ	_	7	amod
7	administration	administration	NN	_	5	dobj
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	with	with	IN	_	5	dep
11	drug2	drug2	NN	_	10	dobj
12	containing	contain	VBG	_	11	acl
13	drug3	drug3	NN	_	12	dobj
14	for	for	IN	_	18	case
15	at	at	IN	_	16	case
16	least	least	JJS	_	17	nmod:npmod
17	4	4	CD	_	18	nummod
18	hours	hour	NNS	_	12	nmod
19	following	follow	VBG	_	21	case
20	drug4	drug4	NN	_	21	compound
21	administration	administration	NN	_	11	nmod
22	.	.	.	_	3	punct

1	No	no	DT	_	5	neg
2	specific	specific	JJ	_	5	amod
3	drug	drug	NN	_	5	compound
4	interaction	interaction	NN	_	5	compound
5	studies	study	NNS	_	8	nsubjpass
6	have	have	VBP	_	8	aux
7	been	be	VBN	_	8	auxpass
8	conducted	conduct	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	For	for	IN	_	2	case
2	information	information	NN	_	13	nmod
3	on	on	IN	_	5	case
4	the	the	DT	_	5	det
5	pharmacokinetics	pharmacokinetic	NNS	_	2	nmod
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	in	in	IN	_	11	case
11	combination	combination	NN	_	5	nmod
12	,	,	,	_	13	punct
13	see	see	VBP	_	0	ROOT
14	Drug	drug	NN	_	15	compound
15	Interactions	interaction	NNS	_	13	dobj
16	under	under	IN	_	19	case
17	CLINICAL	CLINICAL	NNP	_	19	compound
18	PHARMACOLOGY	PHARMACOLOGY	NNP	_	19	compound
19	section	section	NN	_	15	nmod
20	.	.	.	_	13	punct

1	When	when	WRB	_	2	advmod
2	given	give	VBN	_	8	advcl
3	concurrently	concurrently	RB	_	2	advmod
4	the	the	DT	_	6	det
5	following	follow	VBG	_	6	amod
6	drugs	drug	NNS	_	8	nsubj
7	may	may	MD	_	8	aux
8	interact	interact	VB	_	0	ROOT
9	with	with	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	.	.	.	_	8	punct

1	drug1	drug1	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	,	,	,	_	1	punct
5	or	or	CC	_	1	cc
6	drug3	drug3	NN	_	1	conj
7	:	:	:	_	1	punct
8	potentiation	potentiation	NN	_	13	nsubj
9	of	of	IN	_	11	case
10	orthostatic	orthostatic	JJ	_	11	amod
11	hypotension	hypotension	NN	_	8	nmod
12	may	may	MD	_	13	aux
13	occur	occur	VB	_	1	dep
14	.	.	.	_	13	punct

1	drug1	drug1	NN	_	17	nsubjpass
2	:	:	:	_	1	punct
3	-LRB-	-lrb-	-LRB-	_	5	punct
4	oral	oral	JJ	_	5	amod
5	agents	agent	NNS	_	1	dep
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	-RRB-	-rrb-	-RRB-	_	5	punct
9	-	-	:	_	1	punct
10	dosage	dosage	NN	_	11	compound
11	adjustment	adjustment	NN	_	1	dep
12	of	of	IN	_	14	case
13	the	the	DT	_	14	det
14	drug3	drug3	NN	_	11	nmod
15	may	may	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	required	require	VBN	_	0	ROOT
18	.	.	.	_	17	punct

1	Other	other	JJ	_	2	amod
2	drug1	drug1	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	additive	additive	JJ	_	5	amod
5	effect	effect	NN	_	2	dep
6	or	or	CC	_	5	cc
7	potentiation	potentiation	NN	_	5	conj
8	.	.	.	_	2	punct

1	drug1	drug1	NN	_	4	compound
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	drug3	drug3	NN	_	0	ROOT
5	:	:	:	_	4	punct
6	Absorption	absorption	NN	_	10	nsubj
7	of	of	IN	_	8	case
8	drug4	drug4	NN	_	6	nmod
9	is	be	VBZ	_	10	cop
10	impaired	impaired	JJ	_	4	dep
11	in	in	IN	_	13	case
12	the	the	DT	_	13	det
13	presence	presence	NN	_	10	nmod
14	of	of	IN	_	15	case
15	drug5	drug5	NN	_	13	nmod
16	.	.	.	_	4	punct

1	Single	single	JJ	_	2	amod
2	doses	dose	NNS	_	9	nsubj
3	of	of	IN	_	5	case
4	either	either	CC	_	5	cc:preconj
5	drug1	drug1	NN	_	2	nmod
6	or	or	CC	_	5	cc
7	drug2	drug2	NN	_	8	compound
8	drug3	drug3	NN	_	5	conj
9	bind	bind	VBP	_	0	ROOT
10	the	the	DT	_	11	det
11	drug4	drug4	NN	_	9	dobj
12	and	and	CC	_	9	cc
13	reduce	reduce	VB	_	9	conj
14	its	its	PRP$	_	15	nmod:poss
15	absorption	absorption	NN	_	13	dobj
16	from	from	IN	_	19	case
17	the	the	DT	_	19	det
18	gastrointestinal	gastrointestinal	JJ	_	19	amod
19	tract	tract	NN	_	13	nmod
20	by	by	IN	_	26	case
21	up	up	RB	_	23	dep
22	to	to	TO	_	21	mwe
23	85	85	CD	_	26	nummod
24	and	and	CC	_	23	cc
25	43	43	CD	_	23	conj
26	percent	percent	NN	_	13	nmod
27	,	,	,	_	9	punct
28	respectively	respectively	RB	_	9	advmod
29	.	.	.	_	9	punct

1	drug1	drug1	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	appos
4	:	:	:	_	1	punct
5	intensified	intensify	VBN	_	7	amod
6	electrolyte	electrolyte	NN	_	7	compound
7	depletion	depletion	NN	_	1	dep
8	,	,	,	_	7	punct
9	particularly	particularly	RB	_	10	advmod
10	hypokalemia	hypokalemia	NN	_	7	appos
11	.	.	.	_	1	punct

1	Pressor	Pressor	NNP	_	2	compound
2	amines	amine	NNS	_	0	ROOT
3	-LRB-	-lrb-	-LRB-	_	6	punct
4	e.g.	e.g.	FW	_	6	dep
5	,	,	,	_	6	punct
6	drug1	drug1	NN	_	2	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	:	:	:	_	2	punct
9	possible	possible	JJ	_	11	amod
10	decreased	decrease	VBN	_	11	amod
11	response	response	NN	_	2	dep
12	to	to	TO	_	14	case
13	pressor	pressor	NN	_	14	compound
14	amines	amine	NNS	_	11	nmod
15	but	but	CC	_	16	cc
16	not	not	RB	_	14	cc
17	sufficient	sufficient	JJ	_	14	conj
18	to	to	TO	_	19	mark
19	preclude	preclude	VB	_	17	xcomp
20	their	they	PRP$	_	21	nmod:poss
21	use	use	NN	_	19	dobj
22	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	nondepolarizing	nondepolarizing	JJ	_	1	amod
4	-LRB-	-lrb-	-LRB-	_	7	punct
5	e.g.	e.g.	FW	_	7	dep
6	,	,	,	_	7	punct
7	drug2	drug2	NN	_	3	dep
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	:	:	:	_	1	punct
10	possible	possible	JJ	_	12	amod
11	increased	increase	VBN	_	12	amod
12	responsiveness	responsiveness	NN	_	1	dep
13	to	to	TO	_	15	case
14	the	the	DT	_	15	det
15	drug3	drug3	NN	_	12	nmod
16	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	generally	generally	RB	_	7	advmod
4	should	should	MD	_	7	aux
5	not	not	RB	_	7	neg
6	be	be	VB	_	7	auxpass
7	given	give	VBN	_	1	dep
8	with	with	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	.	.	.	_	1	punct

1	drug1	drug1	NN	_	2	nsubj
2	reduce	reduce	VB	_	0	ROOT
3	the	the	DT	_	5	det
4	renal	renal	JJ	_	5	amod
5	clearance	clearance	NN	_	2	dobj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	and	and	CC	_	2	cc
9	add	add	VB	_	2	conj
10	a	a	DT	_	12	det
11	high	high	JJ	_	12	amod
12	risk	risk	NN	_	9	dobj
13	of	of	IN	_	15	case
14	drug3	drug3	NN	_	15	compound
15	toxicity	toxicity	NN	_	12	nmod
16	.	.	.	_	2	punct

1	Refer	refer	VB	_	0	ROOT
2	to	to	TO	_	5	case
3	the	the	DT	_	5	det
4	package	package	NN	_	5	compound
5	insert	insert	NN	_	1	nmod
6	for	for	IN	_	8	case
7	drug1	drug1	NN	_	8	compound
8	preparations	preparation	NNS	_	5	nmod
9	before	before	IN	_	10	case
10	use	use	NN	_	1	nmod
11	of	of	IN	_	13	case
12	such	such	JJ	_	13	amod
13	preparations	preparation	NNS	_	10	nmod
14	with	with	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	5	case
4	some	some	DT	_	5	det
5	patients	patient	NNS	_	13	nmod
6	,	,	,	_	13	punct
7	the	the	DT	_	8	det
8	administration	administration	NN	_	13	nsubj
9	of	of	IN	_	11	case
10	a	a	DT	_	11	det
11	drug2	drug2	NN	_	8	nmod
12	can	can	MD	_	13	aux
13	reduce	reduce	VB	_	1	appos
14	the	the	DT	_	21	det
15	diuretic	diuretic	JJ	_	21	amod
16	,	,	,	_	15	punct
17	natriuretic	natriuretic	JJ	_	15	conj
18	,	,	,	_	15	punct
19	and	and	CC	_	15	cc
20	antihypertensive	antihypertensive	JJ	_	15	conj
21	effects	effect	NNS	_	13	dobj
22	of	of	IN	_	23	case
23	drug3	drug3	NN	_	21	nmod
24	,	,	,	_	23	punct
25	drug4	drug4	NN	_	23	conj
26	and	and	CC	_	23	cc
27	drug5	drug5	NN	_	23	conj
28	.	.	.	_	1	punct

1	Therefore	therefore	RB	_	15	advmod
2	,	,	,	_	15	punct
3	when	when	WRB	_	8	advmod
4	drug1	drug1	NN	_	8	nsubjpass
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	are	be	VBP	_	8	auxpass
8	used	use	VBN	_	15	advcl
9	concomitantly	concomitantly	RB	_	8	advmod
10	,	,	,	_	15	punct
11	the	the	DT	_	12	det
12	patient	patient	NN	_	15	nsubjpass
13	should	should	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	observed	observe	VBN	_	0	ROOT
16	closely	closely	RB	_	15	advmod
17	to	to	TO	_	18	mark
18	determine	determine	VB	_	15	xcomp
19	if	if	IN	_	27	mark
20	the	the	DT	_	22	det
21	desired	desire	VBN	_	22	amod
22	effect	effect	NN	_	27	nsubjpass
23	of	of	IN	_	25	case
24	the	the	DT	_	25	det
25	drug3	drug3	NN	_	22	nmod
26	is	be	VBZ	_	27	auxpass
27	obtained	obtain	VBN	_	18	advcl
28	.	.	.	_	15	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Because	because	IN	_	6	case
4	of	of	IN	_	3	mwe
5	the	the	DT	_	6	det
6	relationship	relationship	NN	_	15	nmod
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	to	to	TO	_	10	case
10	drug3	drug3	NN	_	6	nmod
11	,	,	,	_	15	punct
12	patients	patient	NNS	_	15	nsubjpass
13	should	should	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	advised	advise	VBN	_	1	dep
16	against	against	IN	_	17	mark
17	taking	take	VBG	_	15	advcl
18	drug4	drug4	NN	_	17	dobj
19	containing	contain	VBG	_	18	acl
20	drug5	drug5	NN	_	19	dobj
21	to	to	TO	_	22	mark
22	avoid	avoid	VB	_	17	advcl
23	additive	additive	JJ	_	25	amod
24	toxic	toxic	JJ	_	25	amod
25	effects	effect	NNS	_	22	dobj

1	.	.	.	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concomitant	concomitant	JJ	_	4	amod
4	treatment	treatment	NN	_	11	nsubjpass
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	drug3	drug3	NN	_	6	conj
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	avoided	avoid	VBN	_	1	appos
12	because	because	IN	_	17	mark
13	drug4	drug4	NN	_	14	compound
14	use	use	NN	_	17	nsubjpass
15	has	have	VBZ	_	17	aux
16	been	be	VBN	_	17	auxpass
17	associated	associate	VBN	_	11	advcl
18	with	with	IN	_	20	case
19	a	a	DT	_	20	det
20	number	number	NN	_	17	nmod
21	of	of	IN	_	22	case
22	cases	case	NNS	_	20	nmod
23	of	of	IN	_	25	case
24	pseudotumor	pseudotumor	NN	_	25	compound
25	cerebri	cerebri	NN	_	22	nmod
26	-LRB-	-lrb-	-LRB-	_	29	punct
27	benign	benign	JJ	_	29	amod
28	intracranial	intracranial	JJ	_	29	amod
29	hypertension	hypertension	NN	_	25	appos
30	-RRB-	-rrb-	-RRB-	_	29	punct
31	,	,	,	_	25	punct
32	some	some	DT	_	35	nsubj
33	of	of	IN	_	34	case
34	which	which	WDT	_	32	nmod
35	involved	involved	JJ	_	25	acl:relcl
36	concomitant	concomitant	JJ	_	37	amod
37	use	use	NN	_	35	dobj
38	of	of	IN	_	39	case
39	drug5	drug5	NN	_	37	nmod

1	.	.	.	_	0	ROOT

1	Micro-dosed	micro-dosed	JJ	_	3	amod
2	drug1	drug1	NN	_	3	compound
3	Preparations	preparation	NNS	_	0	ROOT
4	:	:	:	_	3	punct
5	Micro-dosed	micro-dosed	JJ	_	7	amod
6	drug2	drug2	NN	_	7	compound
7	preparations	preparation	NNS	_	21	nsubj
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	minipills	minipill	NNS	_	7	dep
10	that	that	WDT	_	13	nsubj
11	do	do	VBP	_	13	aux
12	not	not	RB	_	13	neg
13	contain	contain	VB	_	9	acl:relcl
14	an	a	DT	_	15	det
15	drug3	drug3	NN	_	13	dobj
16	-RRB-	-rrb-	-RRB-	_	9	punct
17	may	may	MD	_	21	aux
18	be	be	VB	_	21	cop
19	an	a	DT	_	21	det
20	inadequate	inadequate	JJ	_	21	amod
21	method	method	NN	_	3	dep
22	of	of	IN	_	23	case
23	contraception	contraception	NN	_	21	nmod
24	during	during	IN	_	26	case
25	drug4	drug4	NN	_	26	compound
26	therapy	therapy	NN	_	21	nmod
27	.	.	.	_	3	punct

1	Although	although	IN	_	6	mark
2	other	other	JJ	_	3	amod
3	drug1	drug1	NN	_	6	nsubj
4	are	be	VBP	_	6	cop
5	highly	highly	RB	_	6	advmod
6	effective	effective	JJ	_	11	advcl
7	,	,	,	_	11	punct
8	there	there	EX	_	11	expl
9	have	have	VBP	_	11	aux
10	been	be	VBN	_	11	cop
11	reports	report	NNS	_	0	ROOT
12	of	of	IN	_	13	case
13	pregnancy	pregnancy	NN	_	11	nmod
14	from	from	IN	_	15	case
15	women	woman	NNS	_	13	nmod
16	who	who	WP	_	18	nsubj
17	have	have	VBP	_	18	aux
18	used	use	VBN	_	15	acl:relcl
19	drug2	drug2	NN	_	18	dobj
20	,	,	,	_	19	punct
21	as	as	RB	_	19	cc
22	well	well	RB	_	21	mwe
23	as	as	IN	_	21	mwe
24	topical/injectable/implantable	topical/injectable/implantable	JJ	_	30	amod
25	/	/	:	_	30	punct
26	insertable	insertable	JJ	_	30	amod
27	hormonal	hormonal	JJ	_	30	amod
28	birth	birth	NN	_	30	compound
29	control	control	NN	_	30	compound
30	products	product	NNS	_	19	conj
31	.	.	.	_	11	punct

1	These	these	DT	_	2	det
2	reports	report	NNS	_	5	nsubj
3	are	be	VBP	_	5	cop
4	more	more	RBR	_	5	advmod
5	frequent	frequent	JJ	_	0	ROOT
6	for	for	IN	_	7	case
7	women	woman	NNS	_	5	nmod
8	who	who	WP	_	9	nsubj
9	use	use	VBP	_	7	acl:relcl
10	only	only	RB	_	13	advmod
11	a	a	DT	_	13	det
12	single	single	JJ	_	13	amod
13	method	method	NN	_	9	dobj
14	of	of	IN	_	15	case
15	contraception	contraception	NN	_	13	nmod
16	.	.	.	_	5	punct

1	It	it	PRP	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	not	not	RB	_	4	neg
4	known	know	VBN	_	0	ROOT
5	if	if	IN	_	7	mark
6	drug1	drug1	NN	_	7	nsubj
7	differ	differ	VBP	_	4	advcl
8	in	in	IN	_	10	case
9	their	they	PRP$	_	10	nmod:poss
10	effectiveness	effectiveness	NN	_	7	nmod
11	when	when	WRB	_	12	advmod
12	used	use	VBN	_	7	advcl
13	with	with	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	.	.	.	_	4	punct

1	Therefore	therefore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	it	it	PRP	_	6	nsubj
4	is	be	VBZ	_	6	cop
5	critically	critically	RB	_	6	advmod
6	important	important	JJ	_	0	ROOT
7	for	for	IN	_	8	case
8	women	woman	NNS	_	6	nmod
9	of	of	IN	_	11	case
10	childbearing	childbearing	JJ	_	11	amod
11	potential	potential	NN	_	8	nmod
12	to	to	TO	_	13	mark
13	select	select	VB	_	11	acl
14	and	and	CC	_	13	cc
15	commit	commit	VB	_	13	conj
16	to	to	TO	_	17	mark
17	use	use	VB	_	15	xcomp
18	2	2	CD	_	19	nummod
19	forms	form	NNS	_	17	dobj
20	of	of	IN	_	22	case
21	effective	effective	JJ	_	22	amod
22	contraception	contraception	NN	_	19	nmod
23	simultaneously	simultaneously	RB	_	17	advmod
24	,	,	,	_	17	punct
25	at	at	IN	_	26	case
26	least	least	JJS	_	27	nmod:npmod
27	1	1	CD	_	34	nsubj
28	of	of	IN	_	29	case
29	which	which	WDT	_	27	nmod
30	must	must	MD	_	34	aux
31	be	be	VB	_	34	cop
32	a	a	DT	_	34	det
33	primary	primary	JJ	_	34	amod
34	form	form	NN	_	17	ccomp
35	,	,	,	_	34	punct
36	unless	unless	IN	_	42	mark
37	absolute	absolute	JJ	_	38	amod
38	abstinence	abstinence	NN	_	42	nsubj
39	is	be	VBZ	_	42	cop
40	the	the	DT	_	42	det
41	chosen	choose	VBN	_	42	amod
42	method	method	NN	_	34	advcl
43	,	,	,	_	42	punct
44	or	or	CC	_	42	cc
45	the	the	DT	_	46	det
46	patient	patient	NN	_	48	nsubj
47	has	have	VBZ	_	48	aux
48	undergone	undergo	VBN	_	42	conj
49	a	a	DT	_	50	det
50	hysterectomy	hysterectomy	NN	_	48	dobj

1	.	.	.	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	7	nsubjpass
4	has	have	VBZ	_	7	aux
5	not	not	RB	_	7	neg
6	been	be	VBN	_	7	auxpass
7	shown	show	VBN	_	1	appos
8	to	to	TO	_	9	mark
9	alter	alter	VB	_	7	xcomp
10	the	the	DT	_	11	det
11	pharmacokinetics	pharmacokinetic	NNS	_	9	dobj
12	of	of	IN	_	13	case
13	drug3	drug3	NN	_	11	nmod
14	in	in	IN	_	16	case
15	a	a	DT	_	16	det
16	study	study	NN	_	9	nmod
17	in	in	IN	_	20	case
18	seven	seven	CD	_	20	nummod
19	healthy	healthy	JJ	_	20	amod
20	volunteers	volunteer	NNS	_	16	nmod
21	.	.	.	_	1	punct

1	These	these	DT	_	2	det
2	results	result	NNS	_	4	nsubj
3	are	be	VBP	_	4	cop
4	consistent	consistent	JJ	_	0	ROOT
5	with	with	IN	_	9	case
6	the	the	DT	_	9	det
7	in	in	FW	_	9	amod
8	vitro	vitro	FW	_	7	dep
9	finding	finding	NN	_	4	nmod
10	that	that	IN	_	16	mark
11	neither	neither	CC	_	12	cc:preconj
12	drug1	drug1	NN	_	16	nsubj
13	nor	nor	CC	_	12	cc
14	its	its	PRP$	_	15	nmod:poss
15	metabolites	metabolite	NNS	_	12	conj
16	induce	induce	VBP	_	9	ccomp
17	or	or	CC	_	16	cc
18	inhibit	inhibit	VBP	_	16	conj
19	the	the	DT	_	20	det
20	activity	activity	NN	_	16	dobj
21	of	of	IN	_	28	case
22	the	the	DT	_	28	det
23	CYP	cyp	NN	_	28	compound
24	2C9	2c9	NN	_	28	compound
25	human	human	JJ	_	28	amod
26	hepatic	hepatic	JJ	_	28	amod
27	P450	p450	NN	_	28	compound
28	enzyme	enzyme	NN	_	20	nmod
29	.	.	.	_	4	punct

1	drug1	drug1	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	known	know	VBN	_	0	ROOT
4	to	to	TO	_	5	mark
5	cause	cause	VB	_	3	xcomp
6	osteomalacia	osteomalacia	NN	_	5	dobj
7	.	.	.	_	3	punct

1	No	no	DT	_	4	neg
2	formal	formal	JJ	_	4	amod
3	clinical	clinical	JJ	_	4	amod
4	studies	study	NNS	_	7	nsubjpass
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	conducted	conduct	VBN	_	0	ROOT
8	to	to	TO	_	9	mark
9	assess	assess	VB	_	7	xcomp
10	if	if	IN	_	12	mark
11	there	there	EX	_	12	expl
12	is	be	VBZ	_	9	advcl
13	an	a	DT	_	15	det
14	interactive	interactive	JJ	_	15	amod
15	effect	effect	NN	_	12	nsubj
16	on	on	IN	_	18	case
17	bone	bone	NN	_	18	compound
18	loss	loss	NN	_	15	nmod
19	between	between	IN	_	20	case
20	drug1	drug1	NN	_	18	nmod
21	and	and	CC	_	20	cc
22	drug2	drug2	NN	_	20	conj
23	.	.	.	_	7	punct

1	Therefore	therefore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	caution	caution	NN	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	exercised	exercise	VBN	_	0	ROOT
7	when	when	WRB	_	8	advmod
8	using	use	VBG	_	6	advcl
9	these	these	DT	_	10	det
10	drugs	drug	NNS	_	8	dobj
11	together	together	RB	_	6	advmod

1	.	.	.	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubjpass
4	are	be	VBP	_	5	auxpass
5	known	know	VBN	_	1	appos
6	to	to	TO	_	7	mark
7	cause	cause	VB	_	5	xcomp
8	osteoporosis	osteoporosis	NN	_	7	dobj
9	.	.	.	_	1	punct

1	No	no	DT	_	4	neg
2	formal	formal	JJ	_	4	amod
3	clinical	clinical	JJ	_	4	amod
4	studies	study	NNS	_	7	nsubjpass
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	conducted	conduct	VBN	_	0	ROOT
8	to	to	TO	_	9	mark
9	assess	assess	VB	_	7	xcomp
10	if	if	IN	_	12	mark
11	there	there	EX	_	12	expl
12	is	be	VBZ	_	9	advcl
13	an	a	DT	_	15	det
14	interactive	interactive	JJ	_	15	amod
15	effect	effect	NN	_	12	nsubj
16	on	on	IN	_	18	case
17	bone	bone	NN	_	18	compound
18	loss	loss	NN	_	15	nmod
19	between	between	IN	_	20	case
20	drug1	drug1	NN	_	18	nmod
21	and	and	CC	_	20	cc
22	drug2	drug2	NN	_	20	conj
23	.	.	.	_	7	punct

1	Therefore	therefore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	caution	caution	NN	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	exercised	exercise	VBN	_	0	ROOT
7	when	when	WRB	_	8	advmod
8	using	use	VBG	_	6	advcl
9	these	these	DT	_	10	det
10	drugs	drug	NNS	_	8	dobj
11	together	together	RB	_	8	advmod
12	.	.	.	_	6	punct

1	Prescribers	prescriber	NNS	_	3	nsubjpass
2	are	be	VBP	_	3	auxpass
3	advised	advise	VBN	_	0	ROOT
4	to	to	TO	_	5	mark
5	consult	consult	VB	_	3	xcomp
6	the	the	DT	_	8	det
7	package	package	NN	_	8	compound
8	insert	insert	NN	_	5	dobj
9	of	of	IN	_	10	case
10	medication	medication	NN	_	8	nmod
11	administered	administer	VBN	_	10	acl
12	concomitantly	concomitantly	RB	_	11	advmod
13	with	with	IN	_	14	case
14	drug1	drug1	NN	_	11	nmod
15	,	,	,	_	3	punct
16	since	since	IN	_	20	mark
17	some	some	DT	_	18	det
18	medications	medication	NNS	_	20	nsubj
19	may	may	MD	_	20	aux
20	decrease	decrease	VB	_	3	advcl
21	the	the	DT	_	22	det
22	effectiveness	effectiveness	NN	_	20	dobj
23	of	of	IN	_	27	case
24	these	these	DT	_	27	det
25	birth	birth	NN	_	27	compound
26	control	control	NN	_	27	compound
27	products	product	NNS	_	22	nmod
28	.	.	.	_	3	punct

1	drug1	drug1	NN	_	2	compound
2	use	use	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	associated	associate	VBN	_	0	ROOT
5	with	with	IN	_	6	case
6	depression	depression	NN	_	4	nmod
7	in	in	IN	_	9	case
8	some	some	DT	_	9	det
9	patients	patient	NNS	_	6	nmod
10	.	.	.	_	4	punct

1	Pregnancies	pregnancy	NNS	_	4	nsubjpass
2	have	have	VBP	_	4	aux
3	been	be	VBN	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	by	by	IN	_	6	case
6	users	user	NNS	_	4	nmod
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	who	who	WP	_	11	nsubj
10	also	also	RB	_	11	advmod
11	used	use	VBD	_	8	acl:relcl
12	some	some	DT	_	13	det
13	form	form	NN	_	11	dobj
14	of	of	IN	_	17	case
15	St.	St.	NNP	_	17	compound
16	Johns	Johns	NNP	_	17	compound
17	Wort	Wort	NNP	_	13	nmod
18	.	.	.	_	4	punct

1	Laboratory	Laboratory	NNP	_	6	compound
2	Tests	Tests	NNP	_	6	compound
3	Pregnancy	Pregnancy	NNP	_	6	compound
4	Test	Test	NNP	_	6	compound
5	Female	female	JJ	_	6	amod
6	patients	patient	NNS	_	11	nsubj
7	of	of	IN	_	9	case
8	childbearing	childbearing	JJ	_	9	amod
9	potential	potential	NN	_	6	nmod
10	must	must	MD	_	11	aux
11	have	have	VB	_	0	ROOT
12	negative	negative	JJ	_	13	amod
13	results	result	NNS	_	11	dobj
14	from	from	IN	_	16	case
15	2	2	CD	_	16	nummod
16	urine	urine	NN	_	13	nmod
17	or	or	CC	_	16	cc
18	serum	serum	NN	_	20	compound
19	pregnancy	pregnancy	NN	_	20	compound
20	tests	test	NNS	_	16	conj
21	with	with	IN	_	23	case
22	a	a	DT	_	23	det
23	sensitivity	sensitivity	NN	_	11	nmod
24	of	of	IN	_	28	case
25	at	at	IN	_	26	case
26	least	least	JJS	_	27	nmod:npmod
27	25	25	CD	_	28	nummod
28	mIU/mL	miu/ml	NN	_	23	nmod
29	before	before	IN	_	30	mark
30	receiving	receive	VBG	_	23	acl
31	the	the	DT	_	34	det
32	initial	initial	JJ	_	34	amod
33	drug1	drug1	NN	_	34	compound
34	prescription	prescription	NN	_	30	dobj
35	.	.	.	_	11	punct

1	The	the	DT	_	3	det
2	first	first	JJ	_	3	amod
3	test	test	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	obtained	obtain	VBN	_	0	ROOT
6	by	by	IN	_	8	case
7	the	the	DT	_	8	det
8	prescriber	prescriber	NN	_	5	nmod
9	when	when	WRB	_	13	advmod
10	the	the	DT	_	11	det
11	decision	decision	NN	_	13	nsubjpass
12	is	be	VBZ	_	13	auxpass
13	made	make	VBN	_	5	advcl
14	to	to	TO	_	15	mark
15	pursue	pursue	VB	_	13	xcomp
16	qualification	qualification	NN	_	15	dobj
17	of	of	IN	_	19	case
18	the	the	DT	_	19	det
19	patient	patient	NN	_	16	nmod
20	for	for	IN	_	21	case
21	drug1	drug1	NN	_	19	nmod
22	-LRB-	-lrb-	-LRB-	_	25	punct
23	a	a	DT	_	25	det
24	screening	screening	NN	_	25	compound
25	test	test	NN	_	19	appos
26	-RRB-	-rrb-	-RRB-	_	25	punct
27	.	.	.	_	5	punct

1	The	the	DT	_	4	det
2	second	second	JJ	_	4	amod
3	pregnancy	pregnancy	NN	_	4	compound
4	test	test	NN	_	12	nsubjpass
5	-LRB-	-lrb-	-LRB-	_	8	punct
6	a	a	DT	_	8	det
7	confirmation	confirmation	NN	_	8	compound
8	test	test	NN	_	4	appos
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	should	should	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	done	do	VBN	_	0	ROOT
13	during	during	IN	_	17	case
14	the	the	DT	_	17	det
15	first	first	JJ	_	17	amod
16	5	5	CD	_	17	nummod
17	days	day	NNS	_	12	nmod
18	of	of	IN	_	21	case
19	the	the	DT	_	21	det
20	menstrual	menstrual	JJ	_	21	amod
21	period	period	NN	_	17	nmod
22	immediately	immediately	RB	_	23	advmod
23	preceding	precede	VBG	_	12	xcomp
24	the	the	DT	_	25	det
25	beginning	beginning	NN	_	23	dobj
26	of	of	IN	_	28	case
27	drug1	drug1	NN	_	28	compound
28	therapy	therapy	NN	_	25	nmod
29	.	.	.	_	12	punct

1	For	for	IN	_	2	case
2	patients	patient	NNS	_	11	nmod
3	with	with	IN	_	4	case
4	amenorrhea	amenorrhea	NN	_	2	nmod
5	,	,	,	_	11	punct
6	the	the	DT	_	8	det
7	second	second	JJ	_	8	amod
8	test	test	NN	_	11	nsubjpass
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	done	do	VBN	_	0	ROOT
12	at	at	IN	_	13	case
13	least	least	JJS	_	14	nmod:npmod
14	11	11	CD	_	15	nummod
15	days	day	NNS	_	11	nmod
16	after	after	IN	_	15	case
17	the	the	DT	_	19	det
18	last	last	JJ	_	19	amod
19	act	act	NN	_	15	dep
20	of	of	IN	_	23	case
21	unprotected	unprotected	JJ	_	23	amod
22	sexual	sexual	JJ	_	23	amod
23	intercourse	intercourse	NN	_	19	nmod
24	-LRB-	-lrb-	-LRB-	_	26	punct
25	without	without	IN	_	26	mark
26	using	use	VBG	_	11	parataxis
27	2	2	CD	_	29	nummod
28	effective	effective	JJ	_	29	amod
29	forms	form	NNS	_	26	dobj
30	of	of	IN	_	31	case
31	contraception	contraception	NN	_	29	nmod
32	-RRB-	-rrb-	-RRB-	_	26	punct
33	.	.	.	_	11	punct

1	Each	each	DT	_	2	det
2	month	month	NN	_	9	nmod:tmod
3	of	of	IN	_	4	case
4	therapy	therapy	NN	_	2	nmod
5	,	,	,	_	9	punct
6	the	the	DT	_	7	det
7	patient	patient	NN	_	9	nsubj
8	must	must	MD	_	9	aux
9	have	have	VB	_	0	ROOT
10	a	a	DT	_	12	det
11	negative	negative	JJ	_	12	amod
12	result	result	NN	_	9	dobj
13	from	from	IN	_	15	case
14	a	a	DT	_	15	det
15	urine	urine	NN	_	12	nmod
16	or	or	CC	_	15	cc
17	serum	serum	NN	_	19	compound
18	pregnancy	pregnancy	NN	_	19	compound
19	test	test	NN	_	15	conj
20	.	.	.	_	9	punct

1	A	a	DT	_	3	det
2	pregnancy	pregnancy	NN	_	3	compound
3	test	test	NN	_	6	nsubjpass
4	must	must	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	repeated	repeat	VBN	_	0	ROOT
7	each	each	DT	_	8	det
8	month	month	NN	_	6	nmod:tmod
9	prior	prior	RB	_	6	advmod
10	to	to	TO	_	13	case
11	the	the	DT	_	13	det
12	female	female	JJ	_	13	amod
13	patient	patient	NN	_	9	nmod
14	receiving	receive	VBG	_	13	acl
15	each	each	DT	_	16	det
16	prescription	prescription	NN	_	14	dobj

1	.	.	.	_	0	ROOT

1	Lipids	lipid	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	Pretreatment	pretreatment	NN	_	7	amod
4	and	and	CC	_	3	cc
5	follow-up	follow-up	JJ	_	3	conj
6	blood	blood	NN	_	7	compound
7	lipids	lipid	NNS	_	10	nsubjpass
8	should	should	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	obtained	obtain	VBN	_	1	dep
11	under	under	IN	_	13	case
12	fasting	fasting	NN	_	13	compound
13	conditions	condition	NNS	_	10	nmod
14	.	.	.	_	1	punct

1	After	after	IN	_	2	case
2	consumption	consumption	NN	_	11	nmod
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	,	,	,	_	11	punct
6	at	at	IN	_	7	case
7	least	least	JJS	_	8	nmod:npmod
8	36	36	CD	_	9	nummod
9	hours	hour	NNS	_	11	nsubj
10	should	should	MD	_	11	aux
11	elapse	elapse	VB	_	0	ROOT
12	before	before	IN	_	16	mark
13	these	these	DT	_	14	det
14	determinations	determination	NNS	_	16	nsubjpass
15	are	be	VBP	_	16	auxpass
16	made	make	VBN	_	11	advcl
17	.	.	.	_	11	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	recommended	recommend	VBN	_	0	ROOT
4	that	that	IN	_	8	mark
5	these	these	DT	_	6	det
6	tests	test	NNS	_	8	nsubjpass
7	be	be	VB	_	8	auxpass
8	performed	perform	VBN	_	3	ccomp
9	at	at	IN	_	13	case
10	weekly	weekly	JJ	_	13	amod
11	or	or	CC	_	10	cc
12	biweekly	biweekly	JJ	_	10	conj
13	intervals	interval	NNS	_	8	nmod
14	until	until	IN	_	21	mark
15	the	the	DT	_	17	det
16	lipid	lipid	NN	_	17	compound
17	response	response	NN	_	21	nsubjpass
18	to	to	TO	_	19	case
19	drug1	drug1	NN	_	17	nmod
20	is	be	VBZ	_	21	auxpass
21	established	establish	VBN	_	8	advcl
22	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	incidence	incidence	NN	_	7	nsubj
3	of	of	IN	_	4	case
4	hypertriglyceridemia	hypertriglyceridemia	NN	_	2	nmod
5	is	be	VBZ	_	7	cop
6	1	1	CD	_	7	nummod
7	patient	patient	NN	_	0	ROOT
8	in	in	IN	_	9	case
9	4	4	CD	_	7	nmod
10	on	on	IN	_	12	case
11	drug1	drug1	NN	_	12	compound
12	therapy	therapy	NN	_	7	nmod

1	.	.	.	_	0	ROOT

1	Liver	liver	NN	_	3	compound
2	Function	function	NN	_	3	compound
3	Tests	test	NNS	_	0	ROOT
4	:	:	:	_	3	punct
5	Since	since	IN	_	6	case
6	elevations	elevation	NNS	_	12	nmod
7	of	of	IN	_	9	case
8	liver	liver	NN	_	9	compound
9	enzymes	enzyme	NNS	_	6	nmod
10	have	have	VBP	_	12	aux
11	been	be	VBN	_	12	auxpass
12	observed	observe	VBN	_	3	dep
13	during	during	IN	_	15	case
14	clinical	clinical	JJ	_	15	amod
15	trials	trial	NNS	_	12	nmod
16	,	,	,	_	12	punct
17	and	and	CC	_	12	cc
18	hepatitis	hepatitis	NN	_	21	nsubjpass
19	has	have	VBZ	_	21	aux
20	been	be	VBN	_	21	auxpass
21	reported	report	VBN	_	12	conj
22	,	,	,	_	21	punct
23	pretreatment	pretreatment	NN	_	21	conj
24	and	and	CC	_	21	cc
25	follow-up	follow-up	NN	_	28	compound
26	liver	liver	NN	_	28	compound
27	function	function	NN	_	28	compound
28	tests	test	NNS	_	31	nsubjpass
29	should	should	MD	_	31	aux
30	be	be	VB	_	31	auxpass
31	performed	perform	VBN	_	21	conj
32	at	at	IN	_	36	case
33	weekly	weekly	JJ	_	36	amod
34	or	or	CC	_	33	cc
35	biweekly	biweekly	JJ	_	33	conj
36	intervals	interval	NNS	_	31	nmod
37	until	until	IN	_	44	mark
38	the	the	DT	_	39	det
39	response	response	NN	_	44	nsubjpass
40	to	to	TO	_	41	case
41	drug1	drug1	NN	_	39	nmod
42	has	have	VBZ	_	44	aux
43	been	be	VBN	_	44	auxpass
44	established	establish	VBN	_	31	advcl

1	.	.	.	_	0	ROOT

1	Glucose	glucose	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Some	some	DT	_	4	det
4	patients	patient	NNS	_	8	nsubj
5	receiving	receive	VBG	_	4	acl
6	drug1	drug1	NN	_	5	dobj
7	have	have	VBP	_	8	aux
8	experienced	experience	VBN	_	1	appos
9	problems	problem	NNS	_	8	dobj
10	in	in	IN	_	12	case
11	the	the	DT	_	12	det
12	control	control	NN	_	9	nmod
13	of	of	IN	_	16	case
14	their	they	PRP$	_	16	nmod:poss
15	blood	blood	NN	_	16	compound
16	sugar	sugar	NN	_	12	nmod
17	.	.	.	_	1	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	10	nmod
3	,	,	,	_	10	punct
4	new	new	JJ	_	5	amod
5	cases	case	NNS	_	10	nsubjpass
6	of	of	IN	_	7	case
7	diabetes	diabetes	NNS	_	5	nmod
8	have	have	VBP	_	10	aux
9	been	be	VBN	_	10	auxpass
10	diagnosed	diagnose	VBN	_	0	ROOT
11	during	during	IN	_	13	case
12	drug1	drug1	NN	_	13	compound
13	therapy	therapy	NN	_	10	nmod
14	,	,	,	_	10	punct
15	although	although	IN	_	21	mark
16	no	no	DT	_	18	neg
17	causal	causal	JJ	_	18	amod
18	relationship	relationship	NN	_	21	nsubjpass
19	has	have	VBZ	_	21	aux
20	been	be	VBN	_	21	auxpass
21	established	establish	VBN	_	10	advcl

1	.	.	.	_	0	ROOT

1	CPK	CPK	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	Some	some	DT	_	4	det
4	patients	patient	NNS	_	1	dep
5	undergoing	undergo	VBG	_	4	acl
6	vigorous	vigorous	JJ	_	8	amod
7	physical	physical	JJ	_	8	amod
8	activity	activity	NN	_	5	dobj
9	while	while	IN	_	14	mark
10	on	on	IN	_	12	case
11	drug1	drug1	NN	_	12	compound
12	therapy	therapy	NN	_	14	nmod
13	have	have	VBP	_	14	aux
14	experienced	experience	VBN	_	4	acl
15	elevated	elevated	JJ	_	17	amod
16	CPK	cpk	NN	_	17	compound
17	levels	level	NNS	_	14	dobj
18	;	;	:	_	1	punct

1	however	however	RB	_	7	advmod
2	,	,	,	_	7	punct
3	the	the	DT	_	5	det
4	clinical	clinical	JJ	_	5	amod
5	significance	significance	NN	_	7	nsubj
6	is	be	VBZ	_	7	cop
7	unknown	unknown	JJ	_	0	ROOT
8	.	.	.	_	7	punct

1	There	there	EX	_	4	expl
2	have	have	VBP	_	4	aux
3	been	be	VBN	_	4	cop
4	rare	rare	JJ	_	0	ROOT
5	postmarketing	postmarket	VBG	_	6	amod
6	reports	report	NNS	_	4	dobj
7	of	of	IN	_	8	case
8	rhabdomyolysis	rhabdomyolysis	NN	_	6	nmod
9	,	,	,	_	6	punct
10	some	some	DT	_	6	appos
11	associated	associate	VBN	_	10	acl
12	with	with	IN	_	15	case
13	strenuous	strenuous	JJ	_	15	amod
14	physical	physical	JJ	_	15	amod
15	activity	activity	NN	_	11	nmod
16	.	.	.	_	4	punct

1	In	in	IN	_	4	case
2	a	a	DT	_	4	det
3	clinical	clinical	JJ	_	4	amod
4	trial	trial	NN	_	26	nmod
5	of	of	IN	_	8	case
6	217	217	CD	_	8	nummod
7	pediatric	pediatric	JJ	_	8	amod
8	patients	patient	NNS	_	4	nmod
9	-LRB-	-lrb-	-LRB-	_	13	punct
10	12	12	CD	_	12	compound
11	to	to	TO	_	12	dep
12	17	17	CD	_	13	nummod
13	years	year	NNS	_	8	appos
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	with	with	IN	_	19	case
16	severe	severe	JJ	_	19	amod
17	recalcitrant	recalcitrant	JJ	_	19	amod
18	nodular	nodular	JJ	_	19	amod
19	acne	acne	NN	_	8	nmod
20	,	,	,	_	26	punct
21	transient	transient	JJ	_	22	amod
22	elevations	elevation	NNS	_	26	nsubjpass
23	in	in	IN	_	24	case
24	CPK	CPK	NNP	_	22	nmod
25	were	be	VBD	_	26	auxpass
26	observed	observe	VBN	_	0	ROOT
27	in	in	IN	_	29	case
28	12	12	CD	_	29	nummod
29	%	%	NN	_	26	nmod
30	of	of	IN	_	31	case
31	patients	patient	NNS	_	29	nmod
32	,	,	,	_	29	punct
33	including	include	VBG	_	34	case
34	those	those	DT	_	29	nmod
35	undergoing	undergo	VBG	_	34	acl
36	strenuous	strenuous	JJ	_	38	amod
37	physical	physical	JJ	_	38	amod
38	activity	activity	NN	_	35	dobj
39	in	in	IN	_	40	case
40	association	association	NN	_	35	nmod
41	with	with	IN	_	45	case
42	reported	report	VBN	_	45	amod
43	musculoskeletal	musculoskeletal	JJ	_	45	amod
44	adverse	adverse	JJ	_	45	amod
45	events	event	NNS	_	40	nmod
46	such	such	JJ	_	49	case
47	as	as	IN	_	46	mwe
48	back	back	RB	_	49	advmod
49	pain	pain	NN	_	45	nmod
50	,	,	,	_	49	punct
51	arthralgia	arthralgia	NN	_	49	conj
52	,	,	,	_	49	punct
53	limb	limb	NN	_	54	compound
54	injury	injury	NN	_	49	conj
55	,	,	,	_	49	punct
56	or	or	CC	_	49	cc
57	muscle	muscle	NN	_	58	compound
58	sprain	sprain	NN	_	49	conj
59	.	.	.	_	26	punct

1	In	in	IN	_	3	case
2	these	these	DT	_	3	det
3	patients	patient	NNS	_	11	nmod
4	,	,	,	_	11	punct
5	approximately	approximately	RB	_	6	advmod
6	half	half	NN	_	11	nsubj
7	of	of	IN	_	10	case
8	the	the	DT	_	10	det
9	CPK	cpk	NN	_	10	compound
10	elevations	elevation	NNS	_	6	nmod
11	returned	return	VBD	_	0	ROOT
12	to	to	TO	_	13	case
13	normal	normal	JJ	_	11	nmod
14	within	within	IN	_	16	case
15	2	2	CD	_	16	nummod
16	weeks	week	NNS	_	11	nmod
17	and	and	CC	_	11	cc
18	half	half	NN	_	19	nsubj
19	returned	return	VBD	_	11	conj
20	to	to	TO	_	21	case
21	normal	normal	JJ	_	19	nmod
22	within	within	IN	_	24	case
23	4	4	CD	_	24	nummod
24	weeks	week	NNS	_	19	nmod
25	.	.	.	_	11	punct

1	No	no	DT	_	2	neg
2	cases	case	NNS	_	6	nsubjpass
3	of	of	IN	_	4	case
4	rhabdomyolysis	rhabdomyolysis	NN	_	2	nmod
5	were	be	VBD	_	6	auxpass
6	reported	report	VBN	_	0	ROOT
7	in	in	IN	_	9	case
8	this	this	DT	_	9	det
9	trial	trial	NN	_	6	nmod
10	.	.	.	_	6	punct

1	No	no	DT	_	4	neg
2	drug	drug	NN	_	4	compound
3	interaction	interaction	NN	_	4	compound
4	studies	study	NNS	_	6	nsubjpass
5	were	be	VBD	_	6	auxpass
6	performed	perform	VBN	_	0	ROOT
7	.	.	.	_	6	punct

1	No	no	DT	_	5	neg
2	in	in	FW	_	5	amod
3	vitro	vitro	FW	_	2	dep
4	metabolism	metabolism	NN	_	5	compound
5	studies	study	NNS	_	7	nsubjpass
6	were	be	VBD	_	7	auxpass
7	performed	perform	VBN	_	0	ROOT
8	.	.	.	_	7	punct

1	Both	both	DT	_	2	cc:preconj
2	drug1	drug1	NN	_	11	nsubj
3	and	and	CC	_	2	cc
4	its	its	PRP$	_	6	nmod:poss
5	major	major	JJ	_	6	amod
6	metabolite	metabolite	NN	_	2	conj
7	,	,	,	_	6	punct
8	drug2	drug2	NN	_	6	appos
9	,	,	,	_	6	punct
10	are	be	VBP	_	11	cop
11	inhibitors	inhibitor	NNS	_	0	ROOT
12	of	of	IN	_	18	case
13	the	the	DT	_	18	det
14	cytochrome	cytochrome	NN	_	18	compound
15	P450	p450	NN	_	18	compound
16	3A4	3a4	NN	_	18	compound
17	enzyme	enzyme	NN	_	18	compound
18	system	system	NN	_	11	nmod
19	.	.	.	_	11	punct

1	Coadministration	coadministration	NN	_	16	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	drugs	drug	NNS	_	3	conj
6	primarily	primarily	RB	_	7	advmod
7	metabolized	metabolize	VBN	_	1	acl
8	by	by	IN	_	14	case
9	the	the	DT	_	14	det
10	cytochrome	cytochrome	NN	_	14	compound
11	P450	p450	NN	_	14	compound
12	3A4	3a4	NN	_	14	compound
13	enzyme	enzyme	NN	_	14	compound
14	system	system	NN	_	7	nmod
15	may	may	MD	_	16	aux
16	result	result	VB	_	0	ROOT
17	in	in	IN	_	20	case
18	increased	increase	VBN	_	20	amod
19	plasma	plasma	NN	_	20	compound
20	concentrations	concentration	NNS	_	16	nmod
21	of	of	IN	_	23	case
22	the	the	DT	_	23	det
23	drugs	drug	NNS	_	20	nmod
24	that	that	WDT	_	26	nsubj
25	could	could	MD	_	26	aux
26	increase	increase	VB	_	23	acl:relcl
27	or	or	CC	_	26	cc
28	prolong	prolong	VB	_	26	conj
29	both	both	DT	_	30	cc:preconj
30	therapeutic	therapeutic	JJ	_	33	amod
31	and	and	CC	_	30	cc
32	adverse	adverse	JJ	_	30	conj
33	effects	effect	NNS	_	26	dobj
34	.	.	.	_	16	punct

1	Therefore	therefore	RB	_	12	advmod
2	,	,	,	_	12	punct
3	unless	unless	IN	_	5	mark
4	otherwise	otherwise	RB	_	5	advmod
5	specified	specify	VBN	_	12	advcl
6	,	,	,	_	12	punct
7	appropriate	appropriate	JJ	_	9	amod
8	dosage	dosage	NN	_	9	compound
9	adjustments	adjustment	NNS	_	12	nsubj
10	may	may	MD	_	12	aux
11	be	be	VB	_	12	cop
12	necessary	necessary	JJ	_	0	ROOT
13	.	.	.	_	12	punct

1	Coadministration	coadministration	NN	_	7	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	1	nmod
6	has	have	VBZ	_	7	aux
7	led	lead	VBN	_	0	ROOT
8	to	to	TO	_	11	case
9	elevated	elevated	JJ	_	11	amod
10	plasma	plasma	NN	_	11	compound
11	concentrations	concentration	NNS	_	7	nmod
12	of	of	IN	_	13	case
13	drug3	drug3	NN	_	11	nmod
14	,	,	,	_	7	punct
15	resulting	result	VBG	_	7	advcl
16	in	in	IN	_	18	case
17	rare	rare	JJ	_	18	amod
18	instances	instance	NNS	_	15	nmod
19	of	of	IN	_	20	case
20	life	life	NN	_	18	nmod
21	-	-	:	_	15	punct
22	threatening	threaten	VBG	_	15	dep
23	cardiac	cardiac	JJ	_	24	amod
24	dysrhythmias	dysrhythmia	NNS	_	22	dobj
25	and	and	CC	_	24	cc
26	one	one	CD	_	27	nummod
27	death	death	NN	_	24	conj
28	.	.	.	_	7	punct

1	Another	another	DT	_	3	det
2	oral	oral	JJ	_	3	amod
3	drug1	drug1	NN	_	7	nsubj
4	,	,	,	_	3	punct
5	drug2	drug2	NN	_	3	appos
6	,	,	,	_	3	punct
7	inhibits	inhibit	VBZ	_	0	ROOT
8	the	the	DT	_	9	det
9	metabolism	metabolism	NN	_	7	dobj
10	of	of	IN	_	11	case
11	drug3	drug3	NN	_	9	nmod
12	,	,	,	_	7	punct
13	resulting	result	VBG	_	7	advcl
14	in	in	IN	_	17	case
15	elevated	elevated	JJ	_	17	amod
16	plasma	plasma	NN	_	17	compound
17	concentrations	concentration	NNS	_	13	nmod
18	of	of	IN	_	19	case
19	drug4	drug4	NN	_	17	nmod
20	and	and	CC	_	19	cc
21	its	its	PRP$	_	24	nmod:poss
22	active	active	JJ	_	24	amod
23	metabolite	metabolite	NN	_	24	compound
24	drug5	drug5	NN	_	19	conj
25	which	which	WDT	_	27	nsubj
26	may	may	MD	_	27	aux
27	prolong	prolong	VB	_	24	acl:relcl
28	QT	QT	NNP	_	29	compound
29	intervals	interval	NNS	_	27	dobj
30	.	.	.	_	7	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	data	datum	NNS	_	4	nsubj
4	suggest	suggest	VBP	_	0	ROOT
5	that	that	IN	_	13	mark
6	drug1	drug1	NN	_	13	nsubj
7	,	,	,	_	6	punct
8	when	when	WRB	_	9	advmod
9	compared	compare	VBN	_	13	advcl
10	to	to	TO	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	,	,	,	_	13	punct
13	has	have	VBZ	_	4	ccomp
14	a	a	DT	_	17	det
15	less	less	RBR	_	16	advmod
16	pronounced	pronounced	JJ	_	17	amod
17	effect	effect	NN	_	13	dobj
18	on	on	IN	_	21	case
19	the	the	DT	_	21	det
20	biotransformation	biotransformation	NN	_	21	compound
21	system	system	NN	_	13	nmod
22	responsible	responsible	JJ	_	21	amod
23	for	for	IN	_	25	case
24	the	the	DT	_	25	det
25	metabolism	metabolism	NN	_	22	nmod
26	of	of	IN	_	27	case
27	drug3	drug3	NN	_	25	nmod
28	.	.	.	_	4	punct

1	Based	base	VBN	_	5	case
2	on	on	IN	_	5	case
3	the	the	DT	_	5	det
4	chemical	chemical	NN	_	5	compound
5	resemblance	resemblance	NN	_	17	advcl
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	,	,	,	_	17	punct
11	coadministration	coadministration	NN	_	17	nsubjpass
12	of	of	IN	_	13	case
13	drug3	drug3	NN	_	11	nmod
14	with	with	IN	_	15	case
15	drug4	drug4	NN	_	11	nmod
16	is	be	VBZ	_	17	auxpass
17	contraindicated	contraindicate	VBN	_	0	ROOT
18	.	.	.	_	17	punct

1	Human	human	JJ	_	3	amod
2	pharmacokinetics	pharmacokinetic	NNS	_	3	compound
3	data	datum	NNS	_	4	nsubj
4	indicate	indicate	VBP	_	0	ROOT
5	that	that	IN	_	9	mark
6	oral	oral	JJ	_	7	amod
7	drug1	drug1	NN	_	9	nsubj
8	potently	potently	RB	_	9	advmod
9	inhibits	inhibit	VBZ	_	4	ccomp
10	the	the	DT	_	11	det
11	metabolism	metabolism	NN	_	9	dobj
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	resulting	result	VBG	_	11	acl
15	in	in	IN	_	18	case
16	an	a	DT	_	18	det
17	eight-fold	eight-fold	JJ	_	18	amod
18	increase	increase	NN	_	14	nmod
19	in	in	IN	_	22	case
20	the	the	DT	_	22	det
21	mean	mean	NN	_	22	compound
22	AUC	auc	NN	_	18	nmod
23	of	of	IN	_	24	case
24	drug3	drug3	NN	_	22	nmod
25	.	.	.	_	4	punct

1	Data	datum	NNS	_	2	nsubj
2	suggest	suggest	VBP	_	0	ROOT
3	that	that	IN	_	11	mark
4	coadministration	coadministration	NN	_	11	nsubj
5	of	of	IN	_	7	case
6	oral	oral	JJ	_	7	amod
7	drug1	drug1	NN	_	4	nmod
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	can	can	MD	_	11	aux
11	result	result	VB	_	2	ccomp
12	in	in	IN	_	13	case
13	prolongation	prolongation	NN	_	11	nmod
14	of	of	IN	_	17	case
15	the	the	DT	_	17	det
16	QT	QT	NNP	_	17	compound
17	interval	interval	NN	_	13	nmod
18	on	on	IN	_	20	case
19	the	the	DT	_	20	det
20	ECG	ecg	NN	_	17	nmod
21	.	.	.	_	2	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	data	datum	NNS	_	4	nsubj
4	suggest	suggest	VBP	_	0	ROOT
5	that	that	IN	_	9	mark
6	drug1	drug1	NN	_	9	nsubj
7	also	also	RB	_	9	advmod
8	markedly	markedly	RB	_	9	advmod
9	inhibits	inhibit	VBZ	_	4	ccomp
10	the	the	DT	_	12	det
11	biotransformation	biotransformation	NN	_	12	compound
12	system	system	NN	_	9	dobj
13	mainly	mainly	RB	_	14	advmod
14	responsible	responsible	JJ	_	12	amod
15	for	for	IN	_	17	case
16	the	the	DT	_	17	det
17	metabolism	metabolism	NN	_	14	nmod
18	of	of	IN	_	19	case
19	drug2	drug2	NN	_	17	nmod
20	;	;	:	_	4	punct

1	therefore	therefore	RB	_	3	advmod
2	concomitant	concomitant	JJ	_	3	amod
3	administration	administration	NN	_	9	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	with	with	IN	_	7	case
7	drug2	drug2	NN	_	3	nmod
8	is	be	VBZ	_	9	auxpass
9	contraindicated	contraindicate	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	Coadministration	coadministration	NN	_	10	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	6	case
5	oral	oral	JJ	_	6	amod
6	drug2	drug2	NN	_	1	nmod
7	or	or	CC	_	6	cc
8	drug3	drug3	NN	_	6	conj
9	has	have	VBZ	_	10	aux
10	resulted	result	VBN	_	0	ROOT
11	in	in	IN	_	14	case
12	elevated	elevated	JJ	_	14	amod
13	plasma	plasma	NN	_	14	compound
14	concentrations	concentration	NNS	_	10	nmod
15	of	of	IN	_	19	case
16	the	the	DT	_	19	det
17	latter	latter	JJ	_	19	amod
18	two	two	CD	_	19	nummod
19	drugs	drug	NNS	_	14	nmod
20	.	.	.	_	10	punct

1	This	this	DT	_	3	nsubj
2	may	may	MD	_	3	aux
3	potentiate	potentiate	VB	_	0	ROOT
4	and	and	CC	_	3	cc
5	prolong	prolong	VB	_	3	conj
6	hypnotic	hypnotic	JJ	_	9	amod
7	and	and	CC	_	6	cc
8	sedative	sedative	JJ	_	6	conj
9	effects	effect	NNS	_	3	dobj
10	.	.	.	_	3	punct

1	These	these	DT	_	2	det
2	agents	agent	NNS	_	6	nsubjpass
3	should	should	MD	_	6	aux
4	not	not	RB	_	6	neg
5	be	be	VB	_	6	auxpass
6	used	use	VBN	_	0	ROOT
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	treated	treat	VBN	_	8	acl
10	with	with	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	.	.	.	_	6	punct

1	If	if	IN	_	4	mark
2	drug1	drug1	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	administered	administer	VBN	_	10	advcl
5	parenterally	parenterally	RB	_	4	advmod
6	,	,	,	_	10	punct
7	special	special	JJ	_	8	amod
8	precaution	precaution	NN	_	10	nsubjpass
9	is	be	VBZ	_	10	auxpass
10	required	require	VBN	_	0	ROOT
11	since	since	IN	_	17	mark
12	the	the	DT	_	14	det
13	sedative	sedative	JJ	_	14	amod
14	effect	effect	NN	_	17	nsubjpass
15	may	may	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	prolonged	prolong	VBN	_	10	advcl
18	.	.	.	_	10	punct

1	Coadministration	coadministration	NN	_	11	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	drug2	drug2	NN	_	3	conj
6	,	,	,	_	3	punct
7	drug3	drug3	NN	_	3	conj
8	or	or	CC	_	3	cc
9	drug4	drug4	NN	_	3	conj
10	has	have	VBZ	_	11	aux
11	led	lead	VBN	_	0	ROOT
12	to	to	TO	_	15	case
13	increased	increase	VBN	_	15	amod
14	plasma	plasma	NN	_	15	compound
15	concentrations	concentration	NNS	_	11	nmod
16	of	of	IN	_	20	case
17	the	the	DT	_	20	det
18	latter	latter	JJ	_	20	amod
19	three	three	CD	_	20	nummod
20	drugs	drug	NNS	_	15	nmod
21	.	.	.	_	11	punct

1	drug1	drug1	NN	_	6	compound
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	and	and	CC	_	1	cc
5	drug3	drug3	NN	_	1	conj
6	concentrations	concentration	NNS	_	9	nsubjpass
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	monitored	monitor	VBN	_	0	ROOT
10	at	at	IN	_	12	case
11	the	the	DT	_	12	det
12	initiation	initiation	NN	_	9	nmod
13	of	of	IN	_	15	case
14	drug4	drug4	NN	_	15	compound
15	therapy	therapy	NN	_	12	nmod
16	and	and	CC	_	9	cc
17	frequently	frequently	RB	_	18	advmod
18	thereafter	thereafter	RB	_	9	advmod
19	,	,	,	_	9	punct
20	and	and	CC	_	9	cc
21	the	the	DT	_	22	det
22	dose	dose	NN	_	28	nsubj
23	of	of	IN	_	27	case
24	these	these	DT	_	27	det
25	three	three	CD	_	27	nummod
26	drug	drug	NN	_	27	compound
27	products	product	NNS	_	22	nmod
28	adjusted	adjust	VBN	_	9	conj
29	appropriately	appropriately	RB	_	28	advmod
30	.	.	.	_	9	punct

1	Rhabdomyolysis	Rhabdomyolysis	NNP	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	observed	observe	VBN	_	0	ROOT
5	in	in	IN	_	6	case
6	patients	patient	NNS	_	4	nmod
7	receiving	receive	VBG	_	6	acl
8	drug1	drug1	NN	_	7	dobj
9	administered	administer	VBN	_	8	acl
10	alone	alone	RB	_	9	advmod
11	-LRB-	-lrb-	-LRB-	_	14	punct
12	at	at	IN	_	14	case
13	recommended	recommend	VBN	_	14	amod
14	dosages	dosage	NNS	_	4	dep
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	or	or	CC	_	4	cc
17	concomitantly	concomitantly	RB	_	19	advmod
18	with	with	IN	_	19	case
19	drug2	drug2	NN	_	4	conj
20	including	include	VBG	_	21	case
21	drug3	drug3	NN	_	19	nmod
22	.	.	.	_	4	punct

1	When	when	WRB	_	4	advmod
2	drug1	drug1	NN	_	4	nsubjpass
3	was	be	VBD	_	4	auxpass
4	coadministered	coadminister	VBN	_	19	advcl
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	,	,	,	_	6	punct
8	drug3	drug3	NN	_	6	conj
9	,	,	,	_	6	punct
10	or	or	CC	_	6	cc
11	H2antagonists	h2antagonist	NNS	_	6	conj
12	,	,	,	_	19	punct
13	reduced	reduce	VBN	_	15	amod
14	plasma	plasma	NN	_	15	compound
15	concentrations	concentration	NNS	_	19	nsubjpass
16	of	of	IN	_	17	case
17	drug4	drug4	NN	_	15	nmod
18	were	be	VBD	_	19	auxpass
19	reported	report	VBN	_	0	ROOT
20	.	.	.	_	19	punct

1	The	the	DT	_	2	det
2	physician	physician	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	advised	advise	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	monitor	monitor	VB	_	4	xcomp
7	the	the	DT	_	9	det
8	plasma	plasma	NN	_	9	compound
9	concentrations	concentration	NNS	_	6	dobj
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	when	when	WRB	_	18	advmod
13	any	any	DT	_	18	nsubjpass
14	of	of	IN	_	16	case
15	these	these	DT	_	16	det
16	drugs	drug	NNS	_	13	nmod
17	is	be	VBZ	_	18	auxpass
18	taken	take	VBN	_	6	advcl
19	concurrently	concurrently	RB	_	18	advmod
20	,	,	,	_	4	punct
21	and	and	CC	_	4	cc
22	to	to	TO	_	23	mark
23	increase	increase	VB	_	4	conj
24	the	the	DT	_	25	det
25	dose	dose	NN	_	23	dobj
26	of	of	IN	_	27	case
27	drug2	drug2	NN	_	25	nmod
28	if	if	IN	_	29	mark
29	necessary	necessary	JJ	_	23	advcl
30	.	.	.	_	4	punct

1	Although	although	IN	_	6	mark
2	no	no	DT	_	3	neg
3	studies	study	NNS	_	6	nsubjpass
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	auxpass
6	conducted	conduct	VBN	_	15	advcl
7	,	,	,	_	15	punct
8	concomitant	concomitant	JJ	_	9	amod
9	administration	administration	NN	_	15	nsubj
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	drug2	drug2	NN	_	11	conj
14	may	may	MD	_	15	aux
15	alter	alter	VB	_	0	ROOT
16	the	the	DT	_	17	det
17	metabolism	metabolism	NN	_	15	dobj
18	of	of	IN	_	19	case
19	drug3	drug3	NN	_	17	nmod
20	;	;	:	_	15	punct

1	therefore	therefore	RB	_	10	advmod
2	,	,	,	_	10	punct
3	plasma	plasma	NN	_	4	compound
4	concentrations	concentration	NNS	_	10	nsubjpass
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	should	should	MD	_	10	aux
8	also	also	RB	_	10	advmod
9	be	be	VB	_	10	auxpass
10	monitored	monitor	VBN	_	0	ROOT
11	when	when	WRB	_	14	advmod
12	it	it	PRP	_	14	nsubjpass
13	is	be	VBZ	_	14	auxpass
14	given	give	VBN	_	10	advcl
15	concurrently	concurrently	RB	_	14	advmod
16	with	with	IN	_	17	case
17	drug2	drug2	NN	_	14	nmod
18	.	.	.	_	10	punct

1	It	it	PRP	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	that	that	IN	_	7	mark
6	drug1	drug1	NN	_	7	nsubj
7	enhances	enhance	VBZ	_	4	ccomp
8	the	the	DT	_	10	det
9	anticoagulant	anticoagulant	JJ	_	10	amod
10	effect	effect	NN	_	7	dobj
11	of	of	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	-	-	:	_	7	punct
14	like	like	IN	_	15	case
15	drugs	drug	NNS	_	7	nmod
16	.	.	.	_	4	punct

1	Therefore	therefore	RB	_	8	advmod
2	,	,	,	_	8	punct
3	prothrombin	prothrombin	NN	_	4	compound
4	time	time	NN	_	8	nsubjpass
5	should	should	MD	_	8	aux
6	be	be	VB	_	8	auxpass
7	carefully	carefully	RB	_	8	advmod
8	monitored	monitor	VBN	_	0	ROOT
9	in	in	IN	_	10	case
10	patients	patient	NNS	_	8	nmod
11	receiving	receive	VBG	_	10	acl
12	drug1	drug1	NN	_	11	dobj
13	and	and	CC	_	12	cc
14	drug2	drug2	NN	_	12	conj
15	-	-	:	_	10	punct
16	like	like	IN	_	17	case
17	drugs	drug	NNS	_	10	nmod
18	simultaneously	simultaneously	RB	_	17	advmod
19	.	.	.	_	8	punct

1	Plasma	plasma	NN	_	2	compound
2	concentrations	concentration	NNS	_	6	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	are	be	VBP	_	6	auxpass
6	reduced	reduce	VBN	_	0	ROOT
7	when	when	WRB	_	8	advmod
8	given	give	VBN	_	6	advcl
9	concurrently	concurrently	RB	_	8	advmod
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	8	nmod
12	.	.	.	_	6	punct

1	drug1	drug1	NN	_	3	compound
2	plasma	plasma	NN	_	3	compound
3	concentrations	concentration	NNS	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	monitored	monitor	VBN	_	0	ROOT
7	when	when	WRB	_	12	advmod
8	drug2	drug2	NN	_	12	nsubjpass
9	and	and	CC	_	8	cc
10	drug3	drug3	NN	_	8	conj
11	are	be	VBP	_	12	auxpass
12	coadministered	coadminister	VBN	_	6	advcl
13	.	.	.	_	6	punct

1	Severe	severe	JJ	_	2	amod
2	hypoglycemia	hypoglycemia	NN	_	5	nsubjpass
3	has	have	VBZ	_	5	aux
4	been	be	VBN	_	5	auxpass
5	reported	report	VBN	_	0	ROOT
6	in	in	IN	_	7	case
7	patients	patient	NNS	_	5	nmod
8	concomitantly	concomitantly	RB	_	9	advmod
9	receiving	receive	VBG	_	7	acl
10	drug1	drug1	NN	_	13	compound
11	and	and	CC	_	10	cc
12	oral	oral	JJ	_	10	conj
13	drug2	drug2	NN	_	9	dobj
14	.	.	.	_	5	punct

1	Blood	blood	NN	_	3	compound
2	glucose	glucose	NN	_	3	compound
3	concentrations	concentration	NNS	_	7	nsubjpass
4	should	should	MD	_	7	aux
5	be	be	VB	_	7	auxpass
6	carefully	carefully	RB	_	7	advmod
7	monitored	monitor	VBN	_	0	ROOT
8	when	when	WRB	_	14	advmod
9	drug1	drug1	NN	_	14	nsubjpass
10	and	and	CC	_	9	cc
11	oral	oral	JJ	_	9	conj
12	drug2	drug2	NN	_	9	dep
13	are	be	VBP	_	14	auxpass
14	coadministered	coadminister	VBN	_	7	advcl
15	.	.	.	_	7	punct

1	Tinnitus	Tinnitus	NNP	_	7	nsubjpass
2	and	and	CC	_	1	cc
3	decreased	decrease	VBD	_	4	amod
4	hearing	hearing	NN	_	1	conj
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	reported	report	VBN	_	0	ROOT
8	in	in	IN	_	9	case
9	patients	patient	NNS	_	7	nmod
10	concomitantly	concomitantly	RB	_	11	advmod
11	receiving	receive	VBG	_	9	acl
12	drug1	drug1	NN	_	11	dobj
13	and	and	CC	_	12	cc
14	drug2	drug2	NN	_	12	conj
15	.	.	.	_	7	punct

1	Edema	edema	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	in	in	IN	_	6	case
6	patients	patient	NNS	_	4	nmod
7	concomitantly	concomitantly	RB	_	8	advmod
8	receiving	receive	VBG	_	6	acl
9	drug1	drug1	NN	_	8	dobj
10	and	and	CC	_	9	cc
11	drug2	drug2	NN	_	9	conj
12	.	.	.	_	4	punct

1	Appropriate	appropriate	JJ	_	3	amod
2	dosage	dosage	NN	_	3	compound
3	adjustments	adjustment	NNS	_	6	nsubj
4	may	may	MD	_	6	aux
5	be	be	VB	_	6	cop
6	necessary	necessary	JJ	_	0	ROOT
7	.	.	.	_	6	punct

1	The	the	DT	_	2	det
2	results	result	NNS	_	23	nsubj
3	from	from	IN	_	5	case
4	a	a	DT	_	5	det
5	study	study	NN	_	2	nmod
6	in	in	IN	_	7	case
7	which	which	WDT	_	12	nmod
8	eight	eight	CD	_	10	nummod
9	HIV-infected	hiv-infected	JJ	_	10	amod
10	individuals	individual	NNS	_	12	nsubjpass
11	were	be	VBD	_	12	auxpass
12	treated	treat	VBN	_	5	acl:relcl
13	with	with	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	,	,	,	_	5	punct
16	8	8	CD	_	5	appos
17	+	+	CC	_	16	cc
18	/	/	:	_	21	punct
19	-	-	:	_	21	punct
20	0.4	0.4	CD	_	21	nummod
21	mg/kg/day	mg/kg/day	NN	_	16	conj
22	,	,	,	_	5	punct
23	showed	show	VBD	_	0	ROOT
24	that	that	IN	_	31	mark
25	the	the	DT	_	26	det
26	pharmacokinetics	pharmacokinetic	NNS	_	31	nsubjpass
27	of	of	IN	_	28	case
28	drug2	drug2	NN	_	26	nmod
29	were	be	VBD	_	31	auxpass
30	not	not	RB	_	31	neg
31	affected	affect	VBN	_	23	ccomp
32	during	during	IN	_	34	case
33	concomitant	concomitant	JJ	_	34	amod
34	administration	administration	NN	_	31	nmod
35	of	of	IN	_	36	case
36	drug3	drug3	NN	_	34	nmod
37	,	,	,	_	34	punct
38	100	100	CD	_	39	compound
39	mg	mg	NN	_	40	amod
40	b.i.d.	b.i.d.	NN	_	34	appos

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	found	find	VBN	_	0	ROOT
5	to	to	TO	_	7	mark
6	temporarily	temporarily	RB	_	7	advmod
7	raise	raise	VB	_	4	xcomp
8	serum	serum	NN	_	9	compound
9	concentrations	concentration	NNS	_	7	dobj
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	.	.	.	_	4	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	potentiate	potentiate	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	adverse	adverse	JJ	_	6	amod
6	effects	effect	NNS	_	3	dobj
7	of	of	IN	_	9	case
8	other	other	JJ	_	9	amod
9	drug2	drug2	NN	_	6	nmod
10	administered	administer	VBN	_	9	acl
11	concomitantly	concomitantly	RB	_	10	advmod
12	.	.	.	_	3	punct

1	In	in	IN	_	2	case
2	particular	particular	JJ	_	7	nmod
3	,	,	,	_	7	punct
4	convulsions	convulsion	NNS	_	7	nsubjpass
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	reported	report	VBN	_	0	ROOT
8	when	when	WRB	_	11	advmod
9	drug1	drug1	NN	_	11	nsubjpass
10	is	be	VBZ	_	11	auxpass
11	administered	administer	VBN	_	7	advcl
12	with	with	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	and	and	CC	_	13	cc
15	special	special	JJ	_	16	amod
16	care	care	NN	_	13	conj
17	should	should	MD	_	19	aux
18	be	be	VB	_	19	auxpass
19	taken	take	VBN	_	7	ccomp
20	when	when	WRB	_	24	advmod
21	the	the	DT	_	23	det
22	treatment	treatment	NN	_	23	compound
23	regimen	regimen	NN	_	24	nsubj
24	includes	include	VBZ	_	19	advcl
25	both	both	DT	_	24	dobj
26	of	of	IN	_	28	case
27	these	these	DT	_	28	det
28	drugs	drug	NNS	_	25	nmod
29	.	.	.	_	7	punct

1	Excessive	excessive	JJ	_	3	amod
2	drug1	drug1	NN	_	3	compound
3	ingestion	ingestion	NN	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	avoided	avoid	VBN	_	0	ROOT
7	because	because	IN	_	13	mark
8	a	a	DT	_	10	det
9	psychotic	psychotic	JJ	_	10	amod
10	reaction	reaction	NN	_	13	nsubjpass
11	has	have	VBZ	_	13	aux
12	been	be	VBN	_	13	auxpass
13	reported	report	VBN	_	6	advcl
14	.	.	.	_	6	punct

1	Potentially	potentially	RB	_	4	advmod
2	fatal	fatal	JJ	_	4	amod
3	drug	drug	NN	_	4	compound
4	interactions	interaction	NNS	_	6	nsubj
5	may	may	MD	_	6	aux
6	occur	occur	VB	_	0	ROOT
7	when	when	WRB	_	8	advmod
8	coadministered	coadminister	VBN	_	6	advcl
9	with	with	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	,	,	,	_	6	punct
12	as	as	IN	_	15	mark
13	this	this	DT	_	15	nsubj
14	may	may	MD	_	15	aux
15	enhance	enhance	VB	_	21	csubj
16	cardiovascular	cardiovascular	JJ	_	17	amod
17	depression	depression	NN	_	15	dobj
18	and	and	CC	_	17	cc
19	bradyarrhythmias	bradyarrhythmia	NNS	_	17	conj
20	may	may	MD	_	21	aux
21	occur	occur	VB	_	6	parataxis
22	.	.	.	_	6	punct

1	drug1	drug1	NN	_	14	nsubj
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	neostgmine	neostgmine	NN	_	1	dep
4	,	,	,	_	3	punct
5	drug2	drug2	NN	_	3	appos
6	-RRB-	-rrb-	-RRB-	_	3	punct
7	,	,	,	_	1	punct
8	drug3	drug3	NN	_	1	conj
9	,	,	,	_	1	punct
10	drug4	drug4	NN	_	1	conj
11	,	,	,	_	1	punct
12	drug5	drug5	NN	_	1	conj
13	can	can	MD	_	14	aux
14	enhance	enhance	VB	_	0	ROOT
15	toxicity	toxicity	NN	_	14	dobj
16	and	and	CC	_	14	cc
17	cause	cause	VB	_	14	conj
18	cardio	cardio	NN	_	20	compound
19	respiratory	respiratory	JJ	_	20	amod
20	depression	depression	NN	_	17	dobj
21	.	.	.	_	14	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	8	nmod
3	,	,	,	_	8	punct
4	neuromuscular	neuromuscular	JJ	_	8	nsubjpass
5	blocking	block	VBG	_	4	dep
6	action	action	NN	_	5	dobj
7	is	be	VBZ	_	8	auxpass
8	enhanced	enhance	VBN	_	0	ROOT
9	by	by	IN	_	11	case
10	general	general	JJ	_	11	amod
11	drug1	drug1	NN	_	8	nmod
12	,	,	,	_	11	punct
13	local	local	JJ	_	14	amod
14	drug2	drug2	NN	_	11	appos
15	like	like	IN	_	16	case
16	drug3	drug3	NN	_	14	nmod
17	,	,	,	_	16	punct
18	drug4	drug4	NN	_	16	conj
19	,	,	,	_	16	punct
20	drug5	drug5	NN	_	16	conj
21	,	,	,	_	16	punct
22	drug6	drug6	NN	_	16	conj
23	,	,	,	_	16	punct
24	drug7	drug7	NN	_	16	conj
25	,	,	,	_	16	punct
26	and	and	CC	_	16	cc
27	drug8	drug8	NN	_	16	conj
28	.	.	.	_	8	punct

1	This	this	DT	_	2	det
2	drug	drug	NN	_	4	nsubj
3	may	may	MD	_	4	aux
4	interact	interact	VB	_	0	ROOT
5	with	with	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	or	or	CC	_	6	cc
8	other	other	JJ	_	9	amod
9	drug2	drug2	NN	_	6	conj
10	-LRB-	-lrb-	-LRB-	_	12	punct
11	may	may	MD	_	12	aux
12	potentiate	potentiate	VB	_	4	dep
13	the	the	DT	_	16	det
14	CNS	cns	NN	_	16	compound
15	depressant	depressant	NN	_	16	compound
16	effects	effect	NNS	_	12	dobj
17	of	of	IN	_	20	case
18	either	either	CC	_	20	cc:preconj
19	these	these	DT	_	20	det
20	medications	medication	NNS	_	16	nmod
21	or	or	CC	_	20	cc
22	drug3	drug3	NN	_	20	conj
23	-RRB-	-rrb-	-RRB-	_	20	punct
24	,	,	,	_	20	punct
25	drug4	drug4	NN	_	20	conj
26	or	or	CC	_	20	cc
27	other	other	JJ	_	28	amod
28	medications	medication	NNS	_	20	conj
29	with	with	IN	_	31	case
30	anticholinergic	anticholinergic	JJ	_	31	amod
31	activity	activity	NN	_	28	nmod
32	-LRB-	-lrb-	-LRB-	_	34	punct
33	anticholinergic	anticholinergic	JJ	_	34	amod
34	effects	effect	NNS	_	37	nsubjpass
35	may	may	MD	_	37	aux
36	be	be	VB	_	37	auxpass
37	potentiated	potentiate	VBN	_	12	ccomp
38	when	when	WRB	_	42	advmod
39	these	these	DT	_	40	det
40	medications	medication	NNS	_	42	nsubjpass
41	are	be	VBP	_	42	auxpass
42	used	use	VBN	_	37	advcl
43	concurrently	concurrently	RB	_	42	advmod
44	with	with	IN	_	45	case
45	drug5	drug5	NN	_	42	nmod
46	-RRB-	-rrb-	-RRB-	_	12	punct
47	,	,	,	_	4	punct
48	and	and	CC	_	4	cc
49	drug6	drug6	NN	_	4	conj
50	-LRB-	-lrb-	-LRB-	_	52	punct
51	concurrent	concurrent	JJ	_	52	amod
52	use	use	NN	_	56	nsubj
53	with	with	IN	_	54	case
54	drug7	drug7	NN	_	52	nmod
55	may	may	MD	_	56	aux
56	prolong	prolong	VB	_	49	acl:relcl
57	and	and	CC	_	56	cc
58	intensify	intensify	VB	_	56	conj
59	the	the	DT	_	64	det
60	anticholinergic	anticholinergic	JJ	_	64	amod
61	and	and	CC	_	60	cc
62	CNS	cns	NN	_	60	conj
63	depressant	depressant	NN	_	64	compound
64	effects	effect	NNS	_	58	dobj
65	of	of	IN	_	66	case
66	drug8	drug8	NN	_	64	nmod
67	-RRB-	-rrb-	-RRB-	_	49	punct
68	.	.	.	_	4	punct

1	Results	result	NNS	_	11	nsubj
2	from	from	IN	_	7	case
3	human	human	JJ	_	7	amod
4	in	in	FW	_	7	amod
5	vitro	vitro	FW	_	4	dep
6	metabolism	metabolism	NN	_	7	compound
7	studies	study	NNS	_	1	nmod
8	and	and	CC	_	7	cc
9	nonclinical	nonclinical	JJ	_	10	amod
10	studies	study	NNS	_	7	conj
11	show	show	VBP	_	0	ROOT
12	that	that	IN	_	19	mark
13	drug1	drug1	NN	_	19	nsubjpass
14	-LRB-	-lrb-	-LRB-	_	15	punct
15	drug2	drug2	NN	_	13	appos
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	is	be	VBZ	_	19	auxpass
18	neither	neither	DT	_	19	advmod
19	metabolized	metabolize	VBN	_	11	ccomp
20	by	by	IN	_	19	nmod
21	nor	nor	CC	_	19	cc
22	inhibits	inhibit	VBZ	_	19	conj
23	or	or	CC	_	19	cc
24	induces	induce	VBZ	_	19	conj
25	the	the	DT	_	28	det
26	cytochrome	cytochrome	NN	_	28	compound
27	P450	p450	NN	_	28	compound
28	pathway	pathway	NN	_	24	dobj
29	suggesting	suggest	VBG	_	28	acl
30	that	that	IN	_	34	mark
31	drug3	drug3	NN	_	34	nsubj
32	is	be	VBZ	_	34	cop
33	not	not	RB	_	34	neg
34	likely	likely	JJ	_	29	ccomp
35	to	to	TO	_	36	mark
36	cause	cause	VB	_	34	xcomp
37	or	or	CC	_	36	cc
38	be	be	VB	_	39	cop
39	subject	subject	JJ	_	36	conj
40	to	to	TO	_	44	case
41	P450-based	p450-based	JJ	_	44	amod
42	metabolic	metabolic	JJ	_	44	amod
43	drug	drug	NN	_	44	compound
44	interactions	interaction	NNS	_	39	nmod
45	in	in	IN	_	46	case
46	man	man	NN	_	44	nmod
47	.	.	.	_	11	punct

1	Co-administration	co-administration	NN	_	10	nsubj
2	of	of	IN	_	4	case
3	multiple	multiple	JJ	_	4	amod
4	doses	dose	NNS	_	1	nmod
5	of	of	IN	_	7	case
6	10	10	CD	_	7	nummod
7	mg	mg	NN	_	4	nmod
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	had	have	VBD	_	0	ROOT
11	no	no	DT	_	12	neg
12	effect	effect	NN	_	10	dobj
13	on	on	IN	_	17	case
14	the	the	DT	_	17	det
15	single	single	JJ	_	17	amod
16	dose	dose	NN	_	17	compound
17	pharmacokinetics	pharmacokinetic	NNS	_	10	nmod
18	of	of	IN	_	19	case
19	drug2	drug2	NN	_	17	nmod
20	and	and	CC	_	19	cc
21	drug3	drug3	NN	_	19	conj
22	.	.	.	_	10	punct

1	Co-administration	co-administration	NN	_	7	nsubj
2	of	of	IN	_	6	case
3	single	single	JJ	_	6	amod
4	25-mg	25-mg	JJ	_	6	amod
5	dose	dose	NN	_	6	compound
6	drug1	drug1	NN	_	1	nmod
7	had	have	VBD	_	0	ROOT
8	no	no	DT	_	9	neg
9	effect	effect	NN	_	7	dobj
10	on	on	IN	_	12	case
11	the	the	DT	_	12	det
12	pharmacokinetics	pharmacokinetic	NNS	_	7	nmod
13	of	of	IN	_	15	case
14	total	total	JJ	_	15	amod
15	drug2	drug2	NN	_	12	nmod
16	.	.	.	_	7	punct

1	Expected	expect	VBN	_	2	amod
2	changes	change	NNS	_	11	nsubjpass
3	in	in	IN	_	5	case
4	laboratory	laboratory	NN	_	5	compound
5	assessments	assessment	NNS	_	2	nmod
6	of	of	IN	_	7	case
7	PT	pt	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	INR	inr	NN	_	7	conj
10	were	be	VBD	_	11	auxpass
11	observed	observe	VBN	_	0	ROOT
12	after	after	IN	_	14	case
13	drug1	drug1	NN	_	14	compound
14	administration	administration	NN	_	11	nmod
15	,	,	,	_	11	punct
16	but	but	CC	_	11	cc
17	these	these	DT	_	18	det
18	changes	change	NNS	_	21	nsubjpass
19	were	be	VBD	_	21	auxpass
20	not	not	RB	_	21	neg
21	affected	affect	VBN	_	11	conj
22	by	by	IN	_	25	case
23	concomitant	concomitant	JJ	_	25	amod
24	drug2	drug2	NN	_	25	compound
25	administration	administration	NN	_	21	nmod
26	.	.	.	_	11	punct

1	Agents	agent	NNS	_	10	nsubjpass
2	Affecting	affect	VBG	_	1	acl
3	Cytochrome	cytochrome	NN	_	8	compound
4	P450	p450	NN	_	8	compound
5	3A4	3a4	NN	_	8	compound
6	Isoenzyme	Isoenzyme	NNP	_	8	compound
7	System	System	NNP	_	8	compound
8	drug1	drug1	NN	_	2	dobj
9	is	be	VBZ	_	10	auxpass
10	metabolized	metabolize	VBN	_	0	ROOT
11	mainly	mainly	RB	_	10	advmod
12	via	via	IN	_	19	case
13	the	the	DT	_	19	det
14	human	human	JJ	_	19	amod
15	cytochrome	cytochrome	NN	_	19	compound
16	P450	p450	NN	_	19	compound
17	3A4	3a4	NN	_	19	compound
18	isoenzyme	isoenzyme	NN	_	19	compound
19	system	system	NN	_	10	nmod
20	-LRB-	-lrb-	-LRB-	_	21	punct
21	CYP3A4	cyp3a4	NN	_	19	appos
22	-RRB-	-rrb-	-RRB-	_	21	punct
23	,	,	,	_	10	punct
24	therefore	therefore	RB	_	26	advmod
25	potential	potential	JJ	_	26	amod
26	interactions	interaction	NNS	_	28	nsubj
27	may	may	MD	_	28	aux
28	occur	occur	VB	_	10	parataxis
29	when	when	WRB	_	32	advmod
30	drug2	drug2	NN	_	32	nsubjpass
31	is	be	VBZ	_	32	auxpass
32	given	give	VBN	_	28	advcl
33	concurrently	concurrently	RB	_	32	advmod
34	with	with	IN	_	35	case
35	agents	agent	NNS	_	32	nmod
36	that	that	WDT	_	37	nsubj
37	affect	affect	VBP	_	35	acl:relcl
38	CYP3A4	cyp3a4	NN	_	39	compound
39	activity	activity	NN	_	37	dobj
40	.	.	.	_	10	punct

1	Coadminstration	coadminstration	NN	_	9	nsubj
2	with	with	IN	_	3	case
3	agents	agent	NNS	_	1	nmod
4	that	that	WDT	_	5	nsubj
5	induce	induce	VBP	_	3	acl:relcl
6	3A4	3a4	NN	_	7	compound
7	activity	activity	NN	_	5	dobj
8	may	may	MD	_	9	aux
9	reduce	reduce	VB	_	0	ROOT
10	the	the	DT	_	11	det
11	efficacy	efficacy	NN	_	9	dobj
12	of	of	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	.	.	.	_	9	punct

1	The	the	DT	_	3	det
2	concomitant	concomitant	JJ	_	3	amod
3	use	use	NN	_	29	nsubj
4	of	of	IN	_	6	case
5	transdermal	transdermal	JJ	_	6	amod
6	drug1	drug1	NN	_	3	nmod
7	with	with	IN	_	8	case
8	drug2	drug2	NN	_	3	nmod
9	or	or	CC	_	8	cc
10	other	other	JJ	_	13	amod
11	potent	potent	JJ	_	13	amod
12	3A4	3a4	NN	_	13	compound
13	inhibitors	inhibitor	NNS	_	8	conj
14	such	such	JJ	_	16	case
15	as	as	IN	_	14	mwe
16	drug3	drug3	NN	_	13	nmod
17	,	,	,	_	16	punct
18	drug4	drug4	NN	_	16	conj
19	,	,	,	_	16	punct
20	drug5	drug5	NN	_	16	conj
21	,	,	,	_	16	punct
22	drug6	drug6	NN	_	16	conj
23	,	,	,	_	16	punct
24	drug7	drug7	NN	_	16	conj
25	,	,	,	_	16	punct
26	and	and	CC	_	16	cc
27	nefazadone	nefazadone	NN	_	16	conj
28	may	may	MD	_	29	aux
29	result	result	VB	_	0	ROOT
30	in	in	IN	_	32	case
31	an	a	DT	_	32	det
32	increase	increase	NN	_	29	nmod
33	in	in	IN	_	36	case
34	drug8	drug8	NN	_	36	compound
35	plasma	plasma	NN	_	36	compound
36	concentrations	concentration	NNS	_	32	nmod
37	.	.	.	_	29	punct

1	The	the	DT	_	3	det
2	concomitant	concomitant	JJ	_	3	amod
3	use	use	NN	_	18	nsubj
4	of	of	IN	_	7	case
5	other	other	JJ	_	7	amod
6	CYP3A4	cyp3a4	NN	_	7	compound
7	inhibitors	inhibitor	NNS	_	3	nmod
8	such	such	JJ	_	10	case
9	as	as	IN	_	8	mwe
10	drug1	drug1	NN	_	7	nmod
11	and	and	CC	_	10	cc
12	drug2	drug2	NN	_	10	conj
13	with	with	IN	_	15	case
14	transdermal	transdermal	JJ	_	15	amod
15	drug3	drug3	NN	_	3	nmod
16	may	may	MD	_	18	aux
17	also	also	RB	_	18	advmod
18	result	result	VB	_	0	ROOT
19	in	in	IN	_	21	case
20	an	a	DT	_	21	det
21	increase	increase	NN	_	18	nmod
22	in	in	IN	_	25	case
23	drug4	drug4	NN	_	25	compound
24	plasma	plasma	NN	_	25	compound
25	concentrations	concentration	NNS	_	21	nmod
26	,	,	,	_	21	punct
27	which	which	WDT	_	29	nsubj
28	could	could	MD	_	29	aux
29	increase	increase	VB	_	21	acl:relcl
30	or	or	CC	_	29	cc
31	prolong	prolong	VB	_	29	conj
32	adverse	adverse	JJ	_	34	amod
33	drug	drug	NN	_	34	compound
34	effects	effect	NNS	_	29	dobj
35	and	and	CC	_	29	cc
36	may	may	MD	_	37	aux
37	cause	cause	VB	_	29	conj
38	serious	serious	JJ	_	40	amod
39	respiratory	respiratory	JJ	_	40	amod
40	depression	depression	NN	_	37	dobj
41	.	.	.	_	18	punct

1	In	in	IN	_	3	case
2	this	this	DT	_	3	det
3	situation	situation	NN	_	11	nmod
4	,	,	,	_	11	punct
5	special	special	JJ	_	7	amod
6	patient	patient	NN	_	7	compound
7	care	care	NN	_	11	nsubj
8	and	and	CC	_	7	cc
9	observation	observation	NN	_	7	conj
10	are	be	VBP	_	11	cop
11	appropriate	appropriate	JJ	_	0	ROOT
12	.	.	.	_	11	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	5	det
4	concomitant	concomitant	JJ	_	5	amod
5	use	use	NN	_	47	nsubj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	-LRB-	-lrb-	-LRB-	_	11	punct
9	drug3	drug3	NN	_	11	compound
10	transdermal	transdermal	JJ	_	11	amod
11	system	system	NN	_	7	appos
12	-RRB-	-rrb-	-RRB-	_	11	punct
13	with	with	IN	_	15	case
14	other	other	JJ	_	15	amod
15	drug4	drug4	NN	_	5	nmod
16	,	,	,	_	15	punct
17	including	include	VBG	_	15	acl
18	but	but	CC	_	20	cc
19	not	not	RB	_	20	neg
20	limited	limit	VBN	_	17	dep
21	to	to	TO	_	23	case
22	other	other	JJ	_	23	amod
23	drug5	drug5	NN	_	20	nmod
24	,	,	,	_	23	punct
25	drug6	drug6	NN	_	23	conj
26	,	,	,	_	23	punct
27	drug7	drug7	NN	_	23	conj
28	,	,	,	_	23	punct
29	drug8	drug8	NN	_	23	conj
30	-LRB-	-lrb-	-LRB-	_	33	punct
31	e.g.	e.g.	FW	_	33	dep
32	,	,	,	_	33	punct
33	drug9	drug9	NN	_	29	dep
34	-RRB-	-rrb-	-RRB-	_	33	punct
35	,	,	,	_	23	punct
36	general	general	JJ	_	37	amod
37	drug10	drug10	NN	_	23	conj
38	,	,	,	_	23	punct
39	drug11	drug11	NN	_	23	conj
40	,	,	,	_	23	punct
41	drug12	drug12	NN	_	23	conj
42	,	,	,	_	23	punct
43	and	and	CC	_	23	cc
44	drug13	drug13	NN	_	23	conj
45	,	,	,	_	20	punct
46	may	may	MD	_	47	aux
47	cause	cause	VB	_	1	dep
48	respiratory	respiratory	JJ	_	49	amod
49	depression	depression	NN	_	47	dobj
50	,	,	,	_	49	punct
51	hypotension	hypotension	NN	_	49	conj
52	,	,	,	_	49	punct
53	and	and	CC	_	49	cc
54	profound	profound	JJ	_	55	amod
55	sedation	sedation	NN	_	49	conj
56	,	,	,	_	47	punct
57	or	or	CC	_	47	cc
58	potentially	potentially	RB	_	59	advmod
59	result	result	VBP	_	47	conj
60	in	in	IN	_	61	case
61	coma	coma	NN	_	59	nmod
62	or	or	CC	_	61	cc
63	death	death	NN	_	61	conj
64	.	.	.	_	1	punct

1	When	when	WRB	_	6	advmod
2	such	such	JJ	_	4	amod
3	combined	combined	JJ	_	4	amod
4	therapy	therapy	NN	_	6	nsubjpass
5	is	be	VBZ	_	6	auxpass
6	contemplated	contemplate	VBN	_	18	advcl
7	,	,	,	_	18	punct
8	the	the	DT	_	9	det
9	dose	dose	NN	_	18	nsubjpass
10	of	of	IN	_	11	case
11	one	one	CD	_	9	nmod
12	or	or	CC	_	11	cc
13	both	both	DT	_	14	det
14	agents	agent	NNS	_	11	conj
15	should	should	MD	_	18	aux
16	be	be	VB	_	18	auxpass
17	significantly	significantly	RB	_	18	advmod
18	reduced	reduce	VBN	_	0	ROOT
19	.	.	.	_	18	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	6	nsubjpass
4	is	be	VBZ	_	6	auxpass
5	not	not	RB	_	6	neg
6	recommended	recommend	VBN	_	1	dep
7	for	for	IN	_	8	case
8	use	use	NN	_	6	nmod
9	in	in	IN	_	10	case
10	patients	patient	NNS	_	8	nmod
11	who	who	WP	_	13	nsubj
12	have	have	VBP	_	13	aux
13	received	receive	VBN	_	10	acl:relcl
14	drug3	drug3	NN	_	13	dobj
15	within	within	IN	_	17	case
16	14	14	CD	_	17	nummod
17	days	day	NNS	_	13	nmod
18	because	because	IN	_	27	mark
19	severe	severe	JJ	_	22	amod
20	and	and	CC	_	19	cc
21	unpredictable	unpredictable	JJ	_	19	conj
22	potentiation	potentiation	NN	_	27	nsubjpass
23	by	by	IN	_	24	case
24	drug4	drug4	NN	_	22	nmod
25	has	have	VBZ	_	27	aux
26	been	be	VBN	_	27	auxpass
27	reported	report	VBN	_	13	advcl
28	with	with	IN	_	29	case
29	drug5	drug5	NN	_	27	nmod

1	.	.	.	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	drug1	drug1	NN	_	6	nsubj
2	,	,	,	_	6	punct
3	apparently	apparently	RB	_	6	advmod
4	through	through	IN	_	6	case
5	an	a	DT	_	6	det
6	effect	effect	NN	_	0	ROOT
7	on	on	IN	_	11	case
8	certain	certain	JJ	_	11	amod
9	microsomal	microsomal	JJ	_	11	amod
10	enzyme	enzyme	NN	_	11	compound
11	systems	system	NNS	_	6	nmod
12	,	,	,	_	6	punct
13	has	have	VBZ	_	15	aux
14	been	be	VBN	_	15	auxpass
15	reported	report	VBN	_	6	parataxis
16	to	to	TO	_	17	mark
17	reduce	reduce	VB	_	15	xcomp
18	the	the	DT	_	20	det
19	hepatic	hepatic	JJ	_	20	amod
20	metabolism	metabolism	NN	_	17	dobj
21	of	of	IN	_	22	case
22	drug2	drug2	NN	_	20	nmod
23	,	,	,	_	22	punct
24	drug3	drug3	NN	_	22	conj
25	,	,	,	_	22	punct
26	drug4	drug4	NN	_	22	conj
27	,	,	,	_	22	punct
28	drug5	drug5	NN	_	22	conj
29	,	,	,	_	22	punct
30	drug6	drug6	NN	_	22	conj
31	,	,	,	_	22	punct
32	drug7	drug7	NN	_	22	conj
33	,	,	,	_	22	punct
34	certain	certain	JJ	_	35	amod
35	drug8	drug8	NN	_	22	conj
36	,	,	,	_	22	punct
37	drug9	drug9	NN	_	22	conj
38	,	,	,	_	22	punct
39	drug10	drug10	NN	_	22	conj
40	and	and	CC	_	22	cc
41	drug11	drug11	NN	_	22	conj
42	,	,	,	_	15	punct
43	thereby	thereby	RB	_	44	advmod
44	delaying	delay	VBG	_	15	dep
45	elimination	elimination	NN	_	44	dobj
46	and	and	CC	_	44	cc
47	increasing	increase	VBG	_	49	amod
48	blood	blood	NN	_	49	compound
49	levels	level	NNS	_	44	conj
50	of	of	IN	_	52	case
51	these	these	DT	_	52	det
52	drugs	drug	NNS	_	49	nmod
53	.	.	.	_	6	punct

1	Clinically	clinically	RB	_	3	advmod
2	significant	significant	JJ	_	3	amod
3	effects	effect	NNS	_	6	nsubjpass
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	auxpass
6	reported	report	VBN	_	0	ROOT
7	with	with	IN	_	9	case
8	the	the	DT	_	9	det
9	drug1	drug1	NN	_	6	nmod
10	;	;	:	_	6	punct

1	therefore	therefore	RB	_	9	advmod
2	,	,	,	_	9	punct
3	close	close	JJ	_	4	amod
4	monitoring	monitoring	NN	_	9	nsubjpass
5	of	of	IN	_	7	case
6	prothrombin	prothrombin	NN	_	7	compound
7	time	time	NN	_	4	nmod
8	is	be	VBZ	_	9	auxpass
9	recommended	recommend	VBN	_	0	ROOT
10	,	,	,	_	9	punct
11	and	and	CC	_	9	cc
12	adjustment	adjustment	NN	_	19	nsubj
13	of	of	IN	_	16	case
14	the	the	DT	_	16	det
15	drug1	drug1	NN	_	16	compound
16	dose	dose	NN	_	12	nmod
17	may	may	MD	_	19	aux
18	be	be	VB	_	19	cop
19	necessary	necessary	JJ	_	9	conj
20	when	when	WRB	_	23	advmod
21	drug2	drug2	NN	_	23	nsubjpass
22	is	be	VBZ	_	23	auxpass
23	administered	administer	VBN	_	19	advcl
24	concomitantly	concomitantly	RB	_	23	advmod
25	.	.	.	_	9	punct

1	Interaction	interaction	NN	_	11	nsubjpass
2	with	with	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	,	,	,	_	3	punct
5	drug2	drug2	NN	_	3	conj
6	and	and	CC	_	3	cc
7	drug3	drug3	NN	_	3	conj
8	has	have	VBZ	_	11	aux
9	also	also	RB	_	11	advmod
10	been	be	VBN	_	11	auxpass
11	reported	report	VBN	_	0	ROOT
12	to	to	TO	_	13	mark
13	produce	produce	VB	_	11	xcomp
14	adverse	adverse	JJ	_	16	amod
15	clinical	clinical	JJ	_	16	amod
16	effects	effect	NNS	_	13	dobj
17	.	.	.	_	11	punct

1	However	however	RB	_	36	advmod
2	,	,	,	_	36	punct
3	a	a	DT	_	5	det
4	crossover	crossover	NN	_	5	compound
5	study	study	NN	_	36	nsubj
6	in	in	IN	_	8	case
7	healthy	healthy	JJ	_	8	amod
8	subjects	subject	NNS	_	5	nmod
9	receiving	receive	VBG	_	8	acl
10	either	either	CC	_	14	cc:preconj
11	drug1	drug1	NN	_	14	compound
12	300	300	CD	_	13	compound
13	mg	mg	NN	_	14	amod
14	q.i.d.	q.i.d.	NN	_	9	dobj
15	or	or	CC	_	14	cc
16	800	800	CD	_	17	compound
17	mg	mg	NN	_	18	amod
18	h.s.	h.s.	NN	_	14	conj
19	concomitantly	concomitantly	RB	_	9	advmod
20	with	with	IN	_	25	case
21	a	a	DT	_	25	det
22	300	300	CD	_	23	compound
23	mg	mg	NN	_	25	amod
24	b.i.d.	b.i.d.	NN	_	25	compound
25	dosage	dosage	NN	_	9	nmod
26	of	of	IN	_	27	case
27	drug2	drug2	NN	_	25	nmod
28	-LRB-	-lrb-	-LRB-	_	29	punct
29	drug3	drug3	NN	_	27	dep
30	,	,	,	_	29	punct
31	Key	Key	NNP	_	32	compound
32	Pharmaceuticals	Pharmaceuticals	NNP	_	29	appos
33	,	,	,	_	29	punct
34	Inc.	Inc.	NNP	_	29	appos
35	-RRB-	-rrb-	-RRB-	_	29	punct
36	demonstrated	demonstrate	VBD	_	0	ROOT
37	less	less	JJR	_	38	amod
38	alteration	alteration	NN	_	36	dobj
39	in	in	IN	_	44	case
40	steady-state	steady-state	JJ	_	44	amod
41	drug4	drug4	NN	_	44	compound
42	peak	peak	NN	_	44	compound
43	serum	serum	NN	_	44	compound
44	levels	level	NNS	_	38	nmod
45	with	with	IN	_	50	case
46	the	the	DT	_	50	det
47	800	800	CD	_	50	nummod
48	mg	mg	NN	_	50	compound
49	h.s.	h.s.	NN	_	50	compound
50	regimen	regimen	NN	_	38	nmod
51	,	,	,	_	38	punct
52	particularly	particularly	RB	_	54	advmod
53	in	in	IN	_	54	case
54	subjects	subject	NNS	_	38	nmod
55	aged	aged	JJ	_	54	amod
56	54	54	CD	_	57	nummod
57	years	year	NNS	_	55	dep
58	and	and	CC	_	57	cc
59	older	older	JJR	_	57	conj
60	.	.	.	_	36	punct

1	Data	datum	NNS	_	7	nsubj
2	beyond	beyond	IN	_	4	case
3	10	10	CD	_	4	nummod
4	days	day	NNS	_	1	nmod
5	are	be	VBP	_	7	cop
6	not	not	RB	_	7	neg
7	available	available	JJ	_	0	ROOT
8	.	.	.	_	7	punct

1	-LRB-	-lrb-	-LRB-	_	2	punct
2	Note	note	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	All	all	DT	_	5	det
5	patients	patient	NNS	_	10	nsubjpass
6	receiving	receive	VBG	_	5	acl
7	drug1	drug1	NN	_	6	dobj
8	should	should	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	monitored	monitor	VBN	_	2	dep
11	appropriately	appropriately	RB	_	10	advmod
12	,	,	,	_	10	punct
13	regardless	regardless	RB	_	10	advmod
14	of	of	IN	_	17	case
15	concomitant	concomitant	JJ	_	17	amod
16	drug	drug	NN	_	17	compound
17	therapy	therapy	NN	_	13	nmod
18	.	.	.	_	2	punct
19	-RRB-	-rrb-	-RRB-	_	2	punct

1	Dosage	dosage	NN	_	29	nsubj
2	of	of	IN	_	4	case
3	the	the	DT	_	4	det
4	drugs	drug	NNS	_	1	nmod
5	mentioned	mention	VBN	_	4	acl
6	above	above	IN	_	5	advmod
7	and	and	CC	_	6	cc
8	other	other	JJ	_	11	amod
9	similarly	similarly	RB	_	10	advmod
10	metabolized	metabolize	VBN	_	11	amod
11	drugs	drug	NNS	_	6	conj
12	,	,	,	_	1	punct
13	particularly	particularly	RB	_	14	advmod
14	those	those	DT	_	1	appos
15	of	of	IN	_	18	case
16	low	low	JJ	_	18	amod
17	therapeutic	therapeutic	JJ	_	18	amod
18	ratio	ratio	NN	_	14	nmod
19	or	or	CC	_	18	cc
20	in	in	IN	_	21	case
21	patients	patient	NNS	_	18	conj
22	with	with	IN	_	26	case
23	renal	renal	JJ	_	26	amod
24	and/or	and/or	CC	_	23	cc
25	hepatic	hepatic	JJ	_	23	conj
26	impairment	impairment	NN	_	21	nmod
27	,	,	,	_	1	punct
28	may	may	MD	_	29	aux
29	require	require	VB	_	0	ROOT
30	adjustment	adjustment	NN	_	29	dobj
31	when	when	WRB	_	32	advmod
32	starting	start	VBG	_	29	advcl
33	or	or	CC	_	32	cc
34	stopping	stop	VBG	_	32	conj
35	concomitantly	concomitantly	RB	_	36	advmod
36	administered	administer	VBN	_	37	amod
37	drug1	drug1	NN	_	32	dobj
38	to	to	TO	_	39	mark
39	maintain	maintain	VB	_	37	acl
40	optimum	optimum	JJ	_	43	amod
41	therapeutic	therapeutic	JJ	_	43	amod
42	blood	blood	NN	_	43	compound
43	levels	level	NNS	_	39	dobj
44	.	.	.	_	29	punct

1	Alteration	alteration	NN	_	5	nsubj
2	of	of	IN	_	3	case
3	pH	ph	NN	_	1	nmod
4	may	may	MD	_	5	aux
5	affect	affect	VB	_	0	ROOT
6	absorption	absorption	NN	_	5	dobj
7	of	of	IN	_	9	case
8	certain	certain	JJ	_	9	amod
9	drugs	drug	NNS	_	6	nmod
10	-LRB-	-lrb-	-LRB-	_	13	punct
11	e.g.	e.g.	FW	_	13	dep
12	,	,	,	_	13	punct
13	drug1	drug1	NN	_	5	dep
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	.	.	.	_	5	punct

1	If	if	IN	_	5	mark
2	these	these	DT	_	3	det
3	products	product	NNS	_	5	nsubjpass
4	are	be	VBP	_	5	auxpass
5	needed	need	VBN	_	10	advcl
6	,	,	,	_	10	punct
7	they	they	PRP	_	10	nsubjpass
8	should	should	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	given	give	VBN	_	0	ROOT
11	at	at	IN	_	12	case
12	least	least	JJS	_	13	nmod:npmod
13	2	2	CD	_	14	nummod
14	hours	hour	NNS	_	10	dobj
15	before	before	IN	_	17	case
16	drug1	drug1	NN	_	17	compound
17	administration	administration	NN	_	10	nmod
18	.	.	.	_	10	punct

1	Additional	additional	JJ	_	3	amod
2	clinical	clinical	JJ	_	3	amod
3	experience	experience	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	reveal	reveal	VB	_	0	ROOT
6	other	other	JJ	_	7	amod
7	drugs	drug	NNS	_	5	dobj
8	affected	affect	VBN	_	7	acl
9	by	by	IN	_	12	case
10	the	the	DT	_	12	det
11	concomitant	concomitant	JJ	_	12	amod
12	administration	administration	NN	_	8	nmod
13	of	of	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	.	.	.	_	5	punct

1	General	General	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	Significant	significant	JJ	_	4	amod
4	interactions	interaction	NNS	_	6	nsubj
5	may	may	MD	_	6	aux
6	occur	occur	VB	_	1	appos
7	when	when	WRB	_	10	advmod
8	drug1	drug1	NN	_	10	nsubjpass
9	is	be	VBZ	_	10	auxpass
10	administered	administer	VBN	_	6	advcl
11	together	together	RB	_	10	advmod
12	with	with	IN	_	13	case
13	drugs	drug	NNS	_	10	nmod
14	that	that	WDT	_	15	nsubj
15	inhibit	inhibit	VBP	_	13	acl:relcl
16	P450	p450	NN	_	17	compound
17	2C9	2c9	NN	_	15	dobj
18	.	.	.	_	1	punct

1	drug1	drug1	NN	_	2	compound
2	metabolism	metabolism	NN	_	5	nsubjpass
3	is	be	VBZ	_	5	auxpass
4	predominantly	predominantly	RB	_	5	advmod
5	mediated	mediate	VBN	_	0	ROOT
6	via	via	IN	_	9	case
7	cytochrome	cytochrome	NN	_	9	compound
8	P450	p450	NN	_	9	compound
9	2C9	2c9	NN	_	5	nmod
10	in	in	IN	_	12	case
11	the	the	DT	_	12	det
12	liver	liver	NN	_	9	nmod
13	.	.	.	_	5	punct

1	Co-administration	co-administration	NN	_	14	nsubjpass
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	5	case
5	drugs	drug	NNS	_	1	nmod
6	that	that	WDT	_	8	nsubjpass
7	are	be	VBP	_	8	auxpass
8	known	know	VBN	_	5	acl:relcl
9	to	to	TO	_	10	mark
10	inhibit	inhibit	VB	_	8	xcomp
11	2C9	2c9	NN	_	10	dobj
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	done	do	VBN	_	0	ROOT
15	with	with	IN	_	16	case
16	caution	caution	NN	_	14	nmod
17	.	.	.	_	14	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	4	nsubj
4	indicate	indicate	VBP	_	0	ROOT
5	that	that	IN	_	10	mark
6	drug1	drug1	NN	_	10	nsubj
7	is	be	VBZ	_	10	cop
8	not	not	RB	_	10	neg
9	an	a	DT	_	10	det
10	inhibitor	inhibitor	NN	_	4	ccomp
11	of	of	IN	_	14	case
12	cytochrome	cytochrome	NN	_	14	compound
13	P450	p450	NN	_	14	compound
14	2C9	2c9	NN	_	10	nmod
15	,	,	,	_	14	punct
16	2C19	2c19	NN	_	14	conj
17	or	or	CC	_	14	cc
18	3A4	3a4	NN	_	14	conj
19	.	.	.	_	4	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	5	nsubj
4	also	also	RB	_	5	advmod
5	indicate	indicate	VBP	_	0	ROOT
6	that	that	IN	_	5	dobj
7	drug1	drug1	NN	_	6	dep
8	,	,	,	_	7	punct
9	although	although	IN	_	12	mark
10	not	not	RB	_	12	neg
11	a	a	DT	_	12	det
12	substrate	substrate	NN	_	16	dep
13	,	,	,	_	16	punct
14	is	be	VBZ	_	16	cop
15	an	a	DT	_	16	det
16	inhibitor	inhibitor	NN	_	7	appos
17	of	of	IN	_	20	case
18	cytochrome	cytochrome	NN	_	20	compound
19	P450	p450	NN	_	20	compound
20	2D6	2d6	NN	_	16	nmod
21	.	.	.	_	5	punct

1	Therefore	therefore	RB	_	4	advmod
2	,	,	,	_	4	punct
3	there	there	EX	_	4	expl
4	is	be	VBZ	_	0	ROOT
5	a	a	DT	_	6	det
6	potential	potential	NN	_	4	nsubj
7	for	for	IN	_	12	case
8	an	a	DT	_	12	det
9	in	in	FW	_	12	amod
10	vivo	vivo	FW	_	9	dep
11	drug	drug	NN	_	12	compound
12	interaction	interaction	NN	_	6	nmod
13	with	with	IN	_	14	case
14	drugs	drug	NNS	_	12	nmod
15	that	that	WDT	_	17	nsubjpass
16	are	be	VBP	_	17	auxpass
17	metabolized	metabolize	VBN	_	14	acl:relcl
18	by	by	IN	_	20	case
19	P450	p450	NN	_	20	compound
20	2D6	2d6	NN	_	17	nmod
21	.	.	.	_	4	punct

1	Clinical	clinical	JJ	_	2	amod
2	studies	study	NNS	_	6	nsubj
3	with	with	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	have	have	VBP	_	6	aux
6	identified	identify	VBN	_	0	ROOT
7	potentially	potentially	RB	_	8	advmod
8	significant	significant	JJ	_	9	amod
9	interactions	interaction	NNS	_	6	dobj
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	drug3	drug3	NN	_	11	conj
14	.	.	.	_	6	punct

1	Experience	experience	NN	_	7	nsubj
2	with	with	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	drug2	drug2	NN	_	3	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	suggests	suggest	VBZ	_	0	ROOT
8	the	the	DT	_	9	det
9	potential	potential	NN	_	7	dobj
10	for	for	IN	_	11	case
11	interactions	interaction	NNS	_	9	nmod
12	with	with	IN	_	13	case
13	drug3	drug3	NN	_	11	nmod
14	and	and	CC	_	13	cc
15	drug4	drug4	NN	_	13	conj
16	.	.	.	_	7	punct

1	The	the	DT	_	2	det
2	effects	effect	NNS	_	24	nsubjpass
3	drug1	drug1	NN	_	2	acl
4	on	on	IN	_	6	case
5	the	the	DT	_	6	det
6	pharmacokinetics	pharmacokinetic	NNS	_	3	nmod
7	and/or	and/or	CC	_	6	cc
8	pharmacodynamics	pharmacodynamic	NNS	_	6	conj
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	6	nmod
11	,	,	,	_	10	punct
12	drug3	drug3	NN	_	10	conj
13	,	,	,	_	10	punct
14	drug4	drug4	NN	_	10	conj
15	,	,	,	_	10	punct
16	drug5	drug5	NN	_	10	conj
17	,	,	,	_	10	punct
18	drug6	drug6	NN	_	10	conj
19	,	,	,	_	10	punct
20	and	and	CC	_	10	cc
21	drug7	drug7	NN	_	10	conj
22	have	have	VBP	_	24	aux
23	been	be	VBN	_	24	auxpass
24	studied	study	VBN	_	0	ROOT
25	in	in	FW	_	26	compound
26	vivo	vivo	FW	_	24	advmod
27	and	and	CC	_	24	cc
28	clinically	clinically	RB	_	29	advmod
29	important	important	JJ	_	30	amod
30	interactions	interaction	NNS	_	34	nsubjpass
31	have	have	VBP	_	34	aux
32	not	not	RB	_	34	neg
33	been	be	VBN	_	34	auxpass
34	found	find	VBN	_	24	conj
35	.	.	.	_	24	punct

1	drug1	drug1	NN	_	4	nsubj
2	:	:	:	_	4	punct
3	Reports	report	NNS	_	4	nsubj
4	suggest	suggest	VBP	_	0	ROOT
5	that	that	IN	_	8	mark
6	drug2	drug2	NN	_	8	nsubj
7	may	may	MD	_	8	aux
8	diminish	diminish	VB	_	4	ccomp
9	the	the	DT	_	11	det
10	antihypertensive	antihypertensive	JJ	_	11	amod
11	effect	effect	NN	_	8	dobj
12	of	of	IN	_	13	case
13	drug3	drug3	NN	_	11	nmod
14	.	.	.	_	4	punct

1	This	this	DT	_	2	det
2	interaction	interaction	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	given	give	VBN	_	0	ROOT
6	consideration	consideration	NN	_	5	dobj
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	5	nmod
9	taking	take	VBG	_	8	acl
10	drug1	drug1	NN	_	9	dobj
11	concomitantly	concomitantly	RB	_	9	advmod
12	with	with	IN	_	13	case
13	drug2	drug2	NN	_	9	nmod
14	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Clinical	clinical	JJ	_	4	amod
4	studies	study	NNS	_	14	nsubj
5	,	,	,	_	4	punct
6	as	as	RB	_	4	cc
7	well	well	RB	_	6	mwe
8	as	as	IN	_	6	mwe
9	post	post	NN	_	11	compound
10	marketing	marketing	NN	_	11	compound
11	observations	observation	NNS	_	4	conj
12	,	,	,	_	4	punct
13	have	have	VBP	_	14	aux
14	shown	show	VBN	_	1	appos
15	that	that	IN	_	18	mark
16	drug2	drug2	NN	_	18	nsubj
17	can	can	MD	_	18	aux
18	reduce	reduce	VB	_	14	ccomp
19	the	the	DT	_	21	det
20	natriuretic	natriuretic	JJ	_	21	amod
21	effect	effect	NN	_	18	dobj
22	of	of	IN	_	23	case
23	drug3	drug3	NN	_	21	nmod
24	and	and	CC	_	23	cc
25	drug4	drug4	NN	_	23	conj
26	in	in	IN	_	28	case
27	some	some	DT	_	28	det
28	patients	patient	NNS	_	21	nmod
29	.	.	.	_	1	punct

1	This	this	DT	_	2	det
2	response	response	NN	_	5	nsubjpass
3	has	have	VBZ	_	5	aux
4	been	be	VBN	_	5	auxpass
5	attributed	attribute	VBN	_	0	ROOT
6	to	to	TO	_	7	case
7	inhibition	inhibition	NN	_	5	nmod
8	of	of	IN	_	11	case
9	renal	renal	JJ	_	11	amod
10	prostaglandin	prostaglandin	NN	_	11	compound
11	synthesis	synthesis	NN	_	7	nmod
12	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	6	nsubjpass
4	can	can	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	used	use	VBN	_	1	dep
7	with	with	IN	_	10	case
8	low	low	JJ	_	10	amod
9	dose	dose	NN	_	10	compound
10	drug3	drug3	NN	_	6	nmod
11	.	.	.	_	1	punct

1	However	however	RB	_	10	advmod
2	,	,	,	_	10	punct
3	concomitant	concomitant	JJ	_	4	amod
4	administration	administration	NN	_	10	nsubj
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	with	with	IN	_	8	case
8	drug2	drug2	NN	_	4	nmod
9	may	may	MD	_	10	aux
10	result	result	VB	_	0	ROOT
11	in	in	IN	_	14	case
12	an	a	DT	_	14	det
13	increased	increase	VBN	_	14	amod
14	rate	rate	NN	_	10	nmod
15	of	of	IN	_	17	case
16	GI	gi	NN	_	17	compound
17	ulceration	ulceration	NN	_	14	nmod
18	or	or	CC	_	17	cc
19	other	other	JJ	_	20	amod
20	complications	complication	NNS	_	17	conj
21	,	,	,	_	10	punct
22	compared	compare	VBN	_	24	case
23	to	to	TO	_	24	case
24	use	use	VB	_	10	advcl
25	of	of	IN	_	26	case
26	drug3	drug3	NN	_	24	nmod
27	alone	alone	RB	_	26	advmod
28	.	.	.	_	10	punct

1	Because	because	IN	_	4	case
2	of	of	IN	_	1	mwe
3	its	its	PRP$	_	4	nmod:poss
4	lack	lack	NN	_	13	nmod
5	of	of	IN	_	7	case
6	platelet	platelet	NN	_	7	compound
7	effects	effect	NNS	_	4	nmod
8	,	,	,	_	13	punct
9	drug1	drug1	NN	_	13	nsubj
10	is	be	VBZ	_	13	cop
11	not	not	RB	_	13	neg
12	a	a	DT	_	13	det
13	substitute	substitute	NN	_	0	ROOT
14	for	for	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	for	for	IN	_	18	case
17	cardiovascular	cardiovascular	JJ	_	18	amod
18	prophylaxis	prophylaxis	NN	_	13	nmod
19	.	.	.	_	13	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concomitant	concomitant	JJ	_	4	amod
4	administration	administration	NN	_	11	nsubj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	at	at	IN	_	10	case
8	200	200	CD	_	9	compound
9	mg	mg	NN	_	10	amod
10	QD	qd	NN	_	4	nmod
11	resulted	result	VBD	_	1	dep
12	in	in	IN	_	15	case
13	a	a	DT	_	15	det
14	two-fold	two-fold	JJ	_	15	amod
15	increase	increase	NN	_	11	nmod
16	in	in	IN	_	19	case
17	drug3	drug3	NN	_	19	compound
18	plasma	plasma	NN	_	19	compound
19	concentration	concentration	NN	_	15	nmod
20	.	.	.	_	1	punct

1	This	this	DT	_	2	det
2	increase	increase	NN	_	7	nsubj
3	is	be	VBZ	_	7	cop
4	due	due	JJ	_	7	case
5	to	to	TO	_	4	mwe
6	the	the	DT	_	7	det
7	inhibition	inhibition	NN	_	0	ROOT
8	of	of	IN	_	10	case
9	drug1	drug1	NN	_	10	compound
10	metabolism	metabolism	NN	_	7	nmod
11	via	via	IN	_	13	case
12	P450	p450	NN	_	13	compound
13	2C9	2c9	NN	_	7	nmod
14	by	by	IN	_	15	case
15	drug2	drug2	NN	_	7	nmod
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	see	see	VB	_	7	parataxis
18	CLINICAL	CLINICAL	NNP	_	19	compound
19	PHARMACOLOGY	PHARMACOLOGY	NNP	_	17	dobj
20	-	-	:	_	19	punct
21	Pharmacokinetics	pharmacokinetic	NNS	_	19	dep
22	:	:	:	_	19	punct
23	Metabolism	metabolism	NN	_	19	dep
24	-RRB-	-rrb-	-RRB-	_	17	punct
25	.	.	.	_	7	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	introduced	introduce	VBN	_	0	ROOT
5	at	at	IN	_	9	case
6	the	the	DT	_	9	det
7	lowest	lowest	JJS	_	9	amod
8	recommended	recommend	VBN	_	9	amod
9	dose	dose	NN	_	4	nmod
10	in	in	IN	_	11	case
11	patients	patient	NNS	_	4	nmod
12	receiving	receive	VBG	_	11	acl
13	drug2	drug2	NN	_	12	dobj
14	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	5	case
4	a	a	DT	_	5	det
5	study	study	NN	_	11	nmod
6	conducted	conduct	VBN	_	5	acl
7	in	in	IN	_	9	case
8	healthy	healthy	JJ	_	9	amod
9	subjects	subject	NNS	_	6	nmod
10	,	,	,	_	11	punct
11	mean	mean	VB	_	1	dep
12	steady-state	steady-state	JJ	_	15	amod
13	drug2	drug2	NN	_	15	compound
14	plasma	plasma	NN	_	15	compound
15	levels	level	NNS	_	16	nsubj
16	increased	increase	VBD	_	11	ccomp
17	approximately	approximately	RB	_	18	advmod
18	17	17	CD	_	19	nummod
19	%	%	NN	_	16	dobj
20	in	in	IN	_	21	case
21	subjects	subject	NNS	_	16	nmod
22	receiving	receive	VBG	_	21	acl
23	drug3	drug3	NN	_	22	dobj
24	450	450	CD	_	25	nummod
25	mg	mg	NN	_	23	dobj
26	BID	BID	NNP	_	31	compound
27	with	with	IN	_	30	case
28	drug4	drug4	NN	_	30	compound
29	200	200	CD	_	30	nummod
30	mg	mg	NN	_	26	nmod
31	BID	BID	NNP	_	25	dep
32	as	as	IN	_	33	mark
33	compared	compare	VBN	_	16	advcl
34	to	to	TO	_	35	case
35	subjects	subject	NNS	_	33	nmod
36	receiving	receive	VBG	_	35	acl
37	drug5	drug5	NN	_	36	dobj
38	alone	alone	RB	_	36	advmod
39	.	.	.	_	1	punct

1	Patients	patient	NNS	_	8	nsubjpass
2	on	on	IN	_	4	case
3	drug1	drug1	NN	_	4	compound
4	treatment	treatment	NN	_	1	nmod
5	should	should	MD	_	8	aux
6	be	be	VB	_	8	auxpass
7	closely	closely	RB	_	8	advmod
8	monitored	monitor	VBN	_	0	ROOT
9	when	when	WRB	_	12	advmod
10	drug2	drug2	NN	_	12	nsubjpass
11	is	be	VBZ	_	12	auxpass
12	introduced	introduce	VBN	_	8	advcl
13	or	or	CC	_	12	cc
14	withdrawn	withdraw	VBN	_	12	conj
15	.	.	.	_	8	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	6	case
4	an	a	DT	_	6	det
5	interaction	interaction	NN	_	6	compound
6	study	study	NN	_	17	nmod
7	of	of	IN	_	10	case
8	rheumatoid	rheumatoid	JJ	_	10	amod
9	arthritis	arthritis	NN	_	10	compound
10	patients	patient	NNS	_	6	nmod
11	taking	take	VBG	_	10	acl
12	drug2	drug2	NN	_	11	dobj
13	,	,	,	_	17	punct
14	drug3	drug3	NN	_	17	nsubj
15	did	do	VBD	_	17	aux
16	not	not	RB	_	17	neg
17	have	have	VB	_	1	dep
18	a	a	DT	_	20	det
19	significant	significant	JJ	_	20	amod
20	effect	effect	NN	_	17	dobj
21	on	on	IN	_	23	case
22	the	the	DT	_	23	det
23	pharmacokinetics	pharmacokinetic	NNS	_	17	nmod
24	of	of	IN	_	25	case
25	drug4	drug4	NN	_	23	nmod
26	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	effect	effect	NN	_	14	nsubjpass
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	on	on	IN	_	10	case
8	the	the	DT	_	10	det
9	anti-coagulant	anti-coagulant	JJ	_	10	amod
10	effect	effect	NN	_	4	nmod
11	of	of	IN	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	was	be	VBD	_	14	auxpass
14	studied	study	VBN	_	1	appos
15	in	in	IN	_	17	case
16	a	a	DT	_	17	det
17	group	group	NN	_	14	nmod
18	of	of	IN	_	20	case
19	healthy	healthy	JJ	_	20	amod
20	subjects	subject	NNS	_	17	nmod
21	receiving	receive	VBG	_	20	acl
22	daily	daily	JJ	_	23	amod
23	doses	dose	NNS	_	21	dobj
24	of	of	IN	_	26	case
25	2-5	2-5	CD	_	26	nummod
26	mg	mg	NN	_	23	nmod
27	of	of	IN	_	28	case
28	drug4	drug4	NN	_	26	nmod
29	.	.	.	_	1	punct

1	In	in	IN	_	3	case
2	these	these	DT	_	3	det
3	subjects	subject	NNS	_	8	nmod
4	,	,	,	_	8	punct
5	drug1	drug1	NN	_	8	nsubj
6	did	do	VBD	_	8	aux
7	not	not	RB	_	8	neg
8	alter	alter	VB	_	0	ROOT
9	the	the	DT	_	11	det
10	anticoagulant	anticoagulant	JJ	_	11	amod
11	effect	effect	NN	_	8	dobj
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	as	as	IN	_	15	mark
15	determined	determine	VBN	_	8	advcl
16	by	by	IN	_	18	case
17	prothrombin	prothrombin	NN	_	18	compound
18	time	time	NN	_	15	nmod
19	.	.	.	_	8	punct

1	However	however	RB	_	6	advmod
2	,	,	,	_	6	punct
3	caution	caution	NN	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	used	use	VBN	_	0	ROOT
7	when	when	WRB	_	8	advmod
8	administering	administer	VBG	_	6	advcl
9	drug1	drug1	NN	_	8	dobj
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	8	nmod
12	since	since	IN	_	18	mark
13	these	these	DT	_	14	det
14	patients	patient	NNS	_	18	nsubj
15	are	be	VBP	_	18	cop
16	at	at	IN	_	18	case
17	increased	increase	VBN	_	18	amod
18	risk	risk	NN	_	8	advcl
19	of	of	IN	_	20	mark
20	bleeding	bleed	VBG	_	18	acl
21	complications	complication	NNS	_	20	dobj
22	.	.	.	_	6	punct

1	May	May	NNP	_	2	nsubj
2	interact	interact	VBP	_	0	ROOT
3	with	with	IN	_	5	case
4	other	other	JJ	_	5	amod
5	creams	cream	NNS	_	2	nmod
6	,	,	,	_	5	punct
7	lotions	lotion	NNS	_	5	conj
8	,	,	,	_	5	punct
9	or	or	CC	_	5	cc
10	skin	skin	NN	_	11	compound
11	medicines	medicine	NNS	_	5	conj
12	when	when	WRB	_	13	advmod
13	placed	place	VBN	_	2	advcl
14	on	on	IN	_	17	case
15	the	the	DT	_	17	det
16	same	same	JJ	_	17	amod
17	areas	area	NNS	_	13	nmod
18	of	of	IN	_	20	case
19	your	you	PRP$	_	20	nmod:poss
20	skin	skin	NN	_	17	nmod
21	that	that	IN	_	24	mark
22	you	you	PRP	_	24	nsubj
23	are	be	VBP	_	24	aux
24	using	use	VBG	_	17	dep
25	drug1	drug1	NN	_	24	dobj
26	.	.	.	_	2	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	5	nsubj
4	have	have	VBP	_	5	aux
5	shown	show	VBN	_	0	ROOT
6	that	that	IN	_	17	mark
7	,	,	,	_	17	punct
8	because	because	IN	_	11	case
9	of	of	IN	_	8	mwe
10	its	its	PRP$	_	11	nmod:poss
11	affinity	affinity	NN	_	17	nmod
12	for	for	IN	_	13	case
13	protein	protein	NN	_	11	nmod
14	,	,	,	_	17	punct
15	drug1	drug1	NN	_	17	nsubj
16	may	may	MD	_	17	aux
17	displace	displace	VB	_	5	ccomp
18	other	other	JJ	_	20	amod
19	protein-bound	protein-bound	JJ	_	20	amod
20	drugs	drug	NNS	_	17	dobj
21	from	from	IN	_	24	case
22	their	they	PRP$	_	24	nmod:poss
23	binding	binding	NN	_	24	amod
24	site	site	NN	_	17	nmod
25	.	.	.	_	5	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	exercised	exercise	VBN	_	0	ROOT
5	when	when	WRB	_	6	advmod
6	administering	administer	VBG	_	4	advcl
7	drug1	drug1	NN	_	6	dobj
8	with	with	IN	_	9	case
9	drug2	drug2	NN	_	6	nmod
10	since	since	IN	_	14	mark
11	interactions	interaction	NNS	_	14	nsubjpass
12	have	have	VBP	_	14	aux
13	been	be	VBN	_	14	auxpass
14	seen	see	VBN	_	6	advcl
15	with	with	IN	_	17	case
16	other	other	JJ	_	17	amod
17	drug3	drug3	NN	_	14	nmod
18	.	.	.	_	4	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	9	nsubj
3	of	of	IN	_	5	case
4	an	a	DT	_	5	det
5	drug1	drug1	NN	_	2	nmod
6	-	-	:	_	5	punct
7	containing	contain	VBG	_	5	acl
8	drug2	drug2	NN	_	7	dobj
9	had	have	VBD	_	0	ROOT
10	no	no	DT	_	12	neg
11	significant	significant	JJ	_	12	amod
12	effect	effect	NN	_	9	dobj
13	in	in	IN	_	15	case
14	the	the	DT	_	15	det
15	bioavailability	bioavailability	NN	_	9	nmod
16	of	of	IN	_	17	case
17	drug3	drug3	NN	_	15	nmod
18	.	.	.	_	9	punct

1	When	when	WRB	_	2	advmod
2	administered	administer	VBN	_	9	advcl
3	with	with	IN	_	4	case
4	food	food	NN	_	2	nmod
5	or	or	CC	_	4	cc
6	milk	milk	NN	_	4	conj
7	,	,	,	_	9	punct
8	there	there	EX	_	9	expl
9	is	be	VBZ	_	0	ROOT
10	more	more	RBR	_	11	advmod
11	rapid	rapid	JJ	_	12	amod
12	absorption	absorption	NN	_	9	nsubj
13	;	;	:	_	9	punct

1	however	however	RB	_	12	advmod
2	,	,	,	_	12	punct
3	the	the	DT	_	5	det
4	total	total	JJ	_	5	amod
5	amount	amount	NN	_	12	nsubj
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	in	in	IN	_	10	case
9	the	the	DT	_	10	det
10	plasma	plasma	NN	_	5	nmod
11	is	be	VBZ	_	12	cop
12	unchanged	unchanged	JJ	_	0	ROOT
13	.	.	.	_	12	punct

1	Hypotension	hypotension	NN	_	2	compound
2	Patients	patient	NNS	_	0	ROOT
3	on	on	IN	_	5	case
4	drug1	drug1	NN	_	5	compound
5	Therapy	therapy	NN	_	2	nmod
6	:	:	:	_	2	punct
7	Patients	patient	NNS	_	35	nsubj
8	on	on	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	and	and	CC	_	7	cc
11	especially	especially	RB	_	12	advmod
12	those	those	DT	_	7	conj
13	in	in	IN	_	14	case
14	whom	whom	WP	_	19	nmod
15	drug3	drug3	NN	_	16	compound
16	therapy	therapy	NN	_	19	nsubjpass
17	was	be	VBD	_	19	auxpass
18	recently	recently	RB	_	19	advmod
19	instituted	institute	VBN	_	12	acl:relcl
20	,	,	,	_	7	punct
21	as	as	RB	_	7	cc
22	well	well	RB	_	21	mwe
23	as	as	IN	_	21	mwe
24	those	those	DT	_	7	conj
25	on	on	IN	_	29	case
26	severe	severe	JJ	_	29	amod
27	dietary	dietary	JJ	_	29	amod
28	salt	salt	NN	_	29	compound
29	restriction	restriction	NN	_	24	nmod
30	or	or	CC	_	29	cc
31	dialysis	dialysis	NN	_	29	conj
32	,	,	,	_	7	punct
33	may	may	MD	_	35	aux
34	occasionally	occasionally	RB	_	35	advmod
35	experience	experience	VB	_	2	parataxis
36	a	a	DT	_	38	det
37	precipitous	precipitous	JJ	_	38	amod
38	reduction	reduction	NN	_	35	dobj
39	of	of	IN	_	41	case
40	blood	blood	NN	_	41	compound
41	pressure	pressure	NN	_	38	nmod
42	usually	usually	RB	_	46	advmod
43	within	within	IN	_	46	case
44	the	the	DT	_	46	det
45	first	first	JJ	_	46	amod
46	hour	hour	NN	_	35	nmod
47	after	after	IN	_	48	mark
48	receiving	receive	VBG	_	46	acl
49	the	the	DT	_	51	det
50	initial	initial	JJ	_	51	amod
51	dose	dose	NN	_	48	dobj
52	of	of	IN	_	53	case
53	drug4	drug4	NN	_	51	nmod
54	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	possibility	possibility	NN	_	10	nsubjpass
3	of	of	IN	_	5	case
4	hypotensive	hypotensive	JJ	_	5	amod
5	effects	effect	NNS	_	2	nmod
6	with	with	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	can	can	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	minimized	minimize	VBN	_	0	ROOT
11	by	by	IN	_	13	mark
12	either	either	CC	_	13	cc:preconj
13	discontinuing	discontinue	VBG	_	10	advcl
14	the	the	DT	_	15	det
15	drug2	drug2	NN	_	13	dobj
16	or	or	CC	_	13	cc
17	increasing	increase	VBG	_	13	conj
18	the	the	DT	_	20	det
19	salt	salt	NN	_	20	compound
20	intake	intake	NN	_	17	dobj
21	approximately	approximately	RB	_	23	advmod
22	one	one	CD	_	23	nummod
23	week	week	NN	_	17	nmod:tmod
24	prior	prior	RB	_	17	advmod
25	to	to	TO	_	26	case
26	initiation	initiation	NN	_	24	nmod
27	of	of	IN	_	28	case
28	treatment	treatment	NN	_	26	nmod
29	with	with	IN	_	30	case
30	drug3	drug3	NN	_	28	nmod
31	-LRB-	-lrb-	-LRB-	_	33	punct
32	drug4	drug4	NN	_	33	compound
33	tablets	tablet	NNS	_	30	dep
34	,	,	,	_	33	punct
35	USP	usp	NN	_	33	appos
36	-RRB-	-rrb-	-RRB-	_	33	punct
37	or	or	CC	_	30	cc
38	initiating	initiate	VBG	_	39	amod
39	therapy	therapy	NN	_	30	conj
40	with	with	IN	_	42	case
41	small	small	JJ	_	42	amod
42	doses	dose	NNS	_	39	nmod
43	-LRB-	-lrb-	-LRB-	_	47	punct
44	6.25	6.25	CD	_	47	nummod
45	or	or	CC	_	44	cc
46	12.5	12.5	CD	_	44	conj
47	mg	mg	NN	_	42	appos
48	-RRB-	-rrb-	-RRB-	_	47	punct
49	.	.	.	_	10	punct

1	Alternatively	alternatively	RB	_	3	advmod
2	,	,	,	_	3	punct
3	provide	provide	VBP	_	0	ROOT
4	medical	medical	JJ	_	5	amod
5	supervision	supervision	NN	_	3	dobj
6	for	for	IN	_	10	case
7	at	at	IN	_	8	case
8	least	least	JJS	_	9	nmod:npmod
9	one	one	CD	_	10	nummod
10	hour	hour	NN	_	3	nmod
11	after	after	IN	_	14	case
12	the	the	DT	_	14	det
13	initial	initial	JJ	_	14	amod
14	dose	dose	NN	_	3	nmod
15	.	.	.	_	3	punct

1	If	if	IN	_	3	mark
2	hypotension	hypotension	NN	_	3	nsubj
3	occurs	occur	VBZ	_	9	advcl
4	,	,	,	_	9	punct
5	the	the	DT	_	6	det
6	patient	patient	NN	_	9	nsubjpass
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	placed	place	VBN	_	0	ROOT
10	in	in	IN	_	13	case
11	a	a	DT	_	13	det
12	supine	supine	NN	_	13	compound
13	position	position	NN	_	9	nmod
14	and	and	CC	_	9	cc
15	,	,	,	_	9	punct
16	if	if	IN	_	17	mark
17	necessary	necessary	JJ	_	19	advcl
18	,	,	,	_	19	punct
19	receive	receive	VBP	_	9	conj
20	an	a	DT	_	22	det
21	intravenous	intravenous	JJ	_	22	amod
22	infusion	infusion	NN	_	19	dobj
23	of	of	IN	_	25	case
24	normal	normal	JJ	_	25	amod
25	saline	saline	NN	_	22	nmod
26	.	.	.	_	9	punct

1	This	this	DT	_	4	det
2	transient	transient	JJ	_	4	amod
3	hypotensive	hypotensive	JJ	_	4	amod
4	response	response	NN	_	8	nsubj
5	is	be	VBZ	_	8	cop
6	not	not	RB	_	8	neg
7	a	a	DT	_	8	det
8	contraindication	contraindication	NN	_	0	ROOT
9	to	to	TO	_	11	case
10	further	further	JJ	_	11	amod
11	doses	dose	NNS	_	8	nmod
12	which	which	WDT	_	15	nsubjpass
13	can	can	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	given	give	VBN	_	11	acl:relcl
16	without	without	IN	_	17	case
17	difficulty	difficulty	NN	_	15	nmod
18	once	once	IN	_	23	mark
19	the	the	DT	_	21	det
20	blood	blood	NN	_	21	compound
21	pressure	pressure	NN	_	23	nsubj
22	has	have	VBZ	_	23	aux
23	increased	increase	VBN	_	15	advcl
24	after	after	IN	_	26	case
25	volume	volume	NN	_	26	compound
26	expansion	expansion	NN	_	23	nmod
27	.	.	.	_	8	punct

1	Agents	agent	NNS	_	0	ROOT
2	Having	have	VBG	_	1	acl
3	Vasodilator	vasodilator	NN	_	4	compound
4	Activity	activity	NN	_	2	dobj
5	:	:	:	_	1	punct
6	Data	datum	NNS	_	25	nsubj
7	on	on	IN	_	9	case
8	the	the	DT	_	9	det
9	effect	effect	NN	_	6	nmod
10	of	of	IN	_	12	case
11	concomitant	concomitant	JJ	_	12	amod
12	use	use	NN	_	9	nmod
13	of	of	IN	_	15	case
14	other	other	JJ	_	15	amod
15	drug1	drug1	NN	_	12	nmod
16	in	in	IN	_	17	case
17	patients	patient	NNS	_	12	nmod
18	receiving	receive	VBG	_	17	acl
19	drug2	drug2	NN	_	18	dobj
20	for	for	IN	_	22	case
21	heart	heart	NN	_	22	compound
22	failure	failure	NN	_	18	nmod
23	are	be	VBP	_	25	cop
24	not	not	RB	_	25	neg
25	available	available	JJ	_	1	dep
26	;	;	:	_	25	punct

1	therefore	therefore	RB	_	0	ROOT
2	,	,	,	_	1	punct
3	drug1	drug1	NN	_	2	root
4	or	or	CC	_	3	cc
5	other	other	JJ	_	6	amod
6	drug2	drug2	NN	_	3	conj
7	-LRB-	-lrb-	-LRB-	_	9	punct
8	as	as	IN	_	9	mark
9	used	use	VBN	_	3	dep
10	for	for	IN	_	11	case
11	management	management	NN	_	9	nmod
12	of	of	IN	_	13	case
13	angina	angina	NN	_	11	nmod
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	or	or	CC	_	13	cc
16	other	other	JJ	_	17	amod
17	drugs	drug	NNS	_	13	conj
18	having	have	VBG	_	17	acl
19	vasodilator	vasodilator	NN	_	20	compound
20	activity	activity	NN	_	18	dobj
21	should	should	MD	_	27	aux
22	,	,	,	_	27	punct
23	if	if	IN	_	24	mark
24	possible	possible	JJ	_	27	advcl
25	,	,	,	_	27	punct
26	be	be	VB	_	27	auxpass
27	discontinued	discontinue	VBN	_	9	ccomp
28	before	before	IN	_	29	mark
29	starting	start	VBG	_	27	advcl
30	drug3	drug3	NN	_	29	dobj
31	.	.	.	_	3	punct

1	If	if	IN	_	2	mark
2	resumed	resume	VBN	_	11	advcl
3	during	during	IN	_	5	case
4	drug1	drug1	NN	_	5	compound
5	therapy	therapy	NN	_	2	nmod
6	,	,	,	_	11	punct
7	such	such	JJ	_	8	amod
8	agents	agent	NNS	_	11	nsubjpass
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	administered	administer	VBN	_	0	ROOT
12	cautiously	cautiously	RB	_	11	advmod
13	,	,	,	_	11	punct
14	and	and	CC	_	11	cc
15	perhaps	perhaps	RB	_	18	advmod
16	at	at	IN	_	18	case
17	lower	lower	JJR	_	18	amod
18	dosage	dosage	NN	_	11	conj
19	.	.	.	_	11	punct

1	Agents	agent	NNS	_	10	nsubjpass
2	Causing	cause	VBG	_	1	acl
3	Renin	Renin	NNP	_	5	compound
4	Release	Release	NNP	_	5	compound
5	drug1	drug1	NN	_	7	nmod:poss
6	's	's	POS	_	5	case
7	effect	effect	NN	_	2	dobj
8	will	will	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	augmented	augment	VBN	_	0	ROOT
11	by	by	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	that	that	WDT	_	14	nsubj
14	cause	cause	VBP	_	12	acl:relcl
15	renin	renin	NN	_	16	compound
16	release	release	NN	_	14	dobj
17	.	.	.	_	10	punct

1	For	for	IN	_	2	case
2	example	example	NN	_	11	nmod
3	,	,	,	_	11	punct
4	drug1	drug1	NN	_	11	nsubj
5	-LRB-	-lrb-	-LRB-	_	8	punct
6	e.g.	e.g.	FW	_	8	dep
7	,	,	,	_	8	punct
8	drug2	drug2	NN	_	4	appos
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	may	may	MD	_	11	aux
11	activate	activate	VB	_	0	ROOT
12	the	the	DT	_	14	det
13	renin-angiotensin-aldosterone	renin-angiotensin-aldosterone	NN	_	14	compound
14	system	system	NN	_	11	dobj
15	.	.	.	_	11	punct

1	Agents	agent	NNS	_	0	ROOT
2	Affecting	affect	VBG	_	1	acl
3	Sympathetic	sympathetic	JJ	_	4	amod
4	Activity	activity	NN	_	2	dobj
5	The	the	DT	_	8	det
6	sympathetic	sympathetic	JJ	_	8	amod
7	nervous	nervous	JJ	_	8	amod
8	system	system	NN	_	12	nsubj
9	may	may	MD	_	12	aux
10	be	be	VB	_	12	cop
11	especially	especially	RB	_	12	advmod
12	important	important	JJ	_	4	acl:relcl
13	in	in	IN	_	14	mark
14	supporting	support	VBG	_	12	advcl
15	blood	blood	NN	_	16	compound
16	pressure	pressure	NN	_	14	dobj
17	in	in	IN	_	18	case
18	patients	patient	NNS	_	16	nmod
19	receiving	receive	VBG	_	18	acl
20	drug1	drug1	NN	_	19	dobj
21	alone	alone	RB	_	20	advmod
22	or	or	CC	_	18	cc
23	with	with	IN	_	24	case
24	drug2	drug2	NN	_	18	conj
25	.	.	.	_	1	punct

1	Therefore	therefore	RB	_	16	advmod
2	,	,	,	_	16	punct
3	agents	agent	NNS	_	16	nsubjpass
4	affecting	affect	VBG	_	3	acl
5	sympathetic	sympathetic	JJ	_	6	amod
6	activity	activity	NN	_	4	dobj
7	-LRB-	-lrb-	-LRB-	_	10	punct
8	e.g.	e.g.	FW	_	10	dep
9	,	,	,	_	10	punct
10	drug1	drug1	NN	_	3	dep
11	or	or	CC	_	10	cc
12	drug2	drug2	NN	_	10	conj
13	-RRB-	-rrb-	-RRB-	_	10	punct
14	should	should	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	used	use	VBN	_	0	ROOT
17	with	with	IN	_	18	case
18	caution	caution	NN	_	16	nmod
19	.	.	.	_	16	punct

1	drug1	drug1	NN	_	2	nsubj
2	add	add	VB	_	0	ROOT
3	some	some	DT	_	6	det
4	further	further	JJ	_	6	amod
5	antihypertensive	antihypertensive	JJ	_	6	amod
6	effect	effect	NN	_	2	dobj
7	to	to	TO	_	8	case
8	drug2	drug2	NN	_	2	nmod
9	,	,	,	_	2	punct
10	but	but	CC	_	2	cc
11	the	the	DT	_	13	det
12	overall	overall	JJ	_	13	amod
13	response	response	NN	_	15	nsubj
14	is	be	VBZ	_	15	cop
15	less	less	JJR	_	2	conj
16	than	than	IN	_	17	case
17	additive	additive	JJ	_	15	advcl
18	.	.	.	_	2	punct

1	Agents	agent	NNS	_	16	nsubj
2	Increasing	increase	VBG	_	1	acl
3	Serum	serum	NN	_	4	compound
4	Potassium	potassium	NN	_	2	dobj
5	Since	since	IN	_	7	mark
6	drug1	drug1	NN	_	7	nsubj
7	decreases	decrease	VBZ	_	2	advcl
8	aldosterone	aldosterone	NN	_	9	compound
9	production	production	NN	_	7	dobj
10	,	,	,	_	1	punct
11	elevation	elevation	NN	_	16	nsubj
12	of	of	IN	_	14	case
13	serum	serum	NN	_	14	compound
14	potassium	potassium	NN	_	11	nmod
15	may	may	MD	_	16	aux
16	occur	occur	VB	_	0	ROOT
17	.	.	.	_	16	punct

1	drug1	drug1	NN	_	16	nsubjpass
2	such	such	JJ	_	4	case
3	as	as	IN	_	2	mwe
4	drug2	drug2	NN	_	1	nmod
5	,	,	,	_	4	punct
6	drug3	drug3	NN	_	4	conj
7	,	,	,	_	4	punct
8	or	or	CC	_	4	cc
9	drug4	drug4	NN	_	4	conj
10	,	,	,	_	4	punct
11	or	or	CC	_	4	cc
12	drug5	drug5	NN	_	13	compound
13	supplements	supplement	NNS	_	4	conj
14	should	should	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	given	give	VBN	_	0	ROOT
17	only	only	RB	_	20	advmod
18	for	for	IN	_	20	case
19	documented	document	VBN	_	20	amod
20	hypokalemia	hypokalemia	NN	_	16	nmod
21	,	,	,	_	16	punct
22	and	and	CC	_	16	cc
23	then	then	RB	_	16	conj
24	with	with	IN	_	25	case
25	caution	caution	NN	_	23	nmod
26	,	,	,	_	16	punct
27	since	since	IN	_	30	mark
28	they	they	PRP	_	30	nsubj
29	may	may	MD	_	30	aux
30	lead	lead	VB	_	16	advcl
31	to	to	TO	_	34	case
32	a	a	DT	_	34	det
33	significant	significant	JJ	_	34	amod
34	increase	increase	NN	_	30	nmod
35	of	of	IN	_	37	case
36	serum	serum	NN	_	37	compound
37	potassium	potassium	NN	_	34	nmod
38	.	.	.	_	16	punct

1	Salt	Salt	NNP	_	2	nsubj
2	substitutes	substitute	VBZ	_	0	ROOT
3	containing	contain	VBG	_	2	xcomp
4	drug1	drug1	NN	_	3	dobj
5	should	should	MD	_	8	aux
6	also	also	RB	_	8	advmod
7	be	be	VB	_	8	auxpass
8	used	use	VBN	_	2	dep
9	with	with	IN	_	10	case
10	caution	caution	NN	_	8	nmod
11	.	.	.	_	2	punct

1	Inhibitors	inhibitor	NNS	_	0	ROOT
2	Of	of	IN	_	5	case
3	Endogenous	endogenous	JJ	_	5	amod
4	Prostaglandin	prostaglandin	NN	_	5	compound
5	Synthesis	synthesis	NN	_	1	nmod
6	It	it	PRP	_	9	nsubjpass
7	has	have	VBZ	_	9	aux
8	been	be	VBN	_	9	auxpass
9	reported	report	VBN	_	1	acl:relcl
10	that	that	IN	_	13	mark
11	drug1	drug1	NN	_	13	nsubj
12	may	may	MD	_	13	aux
13	reduce	reduce	VB	_	9	ccomp
14	the	the	DT	_	16	det
15	antihypertensive	antihypertensive	JJ	_	16	amod
16	effect	effect	NN	_	13	dobj
17	of	of	IN	_	18	case
18	drug2	drug2	NN	_	16	nmod
19	,	,	,	_	13	punct
20	especially	especially	RB	_	22	advmod
21	in	in	IN	_	22	case
22	cases	case	NNS	_	13	nmod
23	of	of	IN	_	26	case
24	low	low	JJ	_	26	amod
25	renin	renin	NN	_	26	compound
26	hypertension	hypertension	NN	_	22	nmod
27	.	.	.	_	1	punct

1	Other	other	JJ	_	2	amod
2	drug1	drug1	NN	_	10	nsubj
3	-LRB-	-lrb-	-LRB-	_	6	punct
4	e.g.	e.g.	FW	_	6	dep
5	,	,	,	_	6	punct
6	drug2	drug2	NN	_	2	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	may	may	MD	_	10	aux
9	also	also	RB	_	10	advmod
10	have	have	VB	_	0	ROOT
11	this	this	DT	_	12	det
12	effect	effect	NN	_	10	dobj
13	.	.	.	_	10	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Increased	increase	VBN	_	6	amod
4	serum	serum	NN	_	6	compound
5	drug2	drug2	NN	_	6	compound
6	levels	level	NNS	_	14	nsubjpass
7	and	and	CC	_	6	cc
8	symptoms	symptom	NNS	_	6	conj
9	of	of	IN	_	11	case
10	drug3	drug3	NN	_	11	compound
11	toxicity	toxicity	NN	_	8	nmod
12	have	have	VBP	_	14	aux
13	been	be	VBN	_	14	auxpass
14	reported	report	VBN	_	1	appos
15	in	in	IN	_	16	case
16	patients	patient	NNS	_	14	nmod
17	receiving	receive	VBG	_	16	acl
18	concomitant	concomitant	JJ	_	19	amod
19	drug4	drug4	NN	_	17	dobj
20	and	and	CC	_	19	cc
21	drug5	drug5	NN	_	22	compound
22	therapy	therapy	NN	_	19	conj
23	.	.	.	_	1	punct

1	These	these	DT	_	2	det
2	drugs	drug	NNS	_	5	nsubj
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	cop
5	coad-ministered	coad-ministered	JJ	_	16	csubjpass
6	with	with	IN	_	7	case
7	caution	caution	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	frequent	frequent	JJ	_	10	amod
10	monitoring	monitoring	NN	_	7	conj
11	of	of	IN	_	14	case
12	serum	serum	NN	_	14	compound
13	drug1	drug1	NN	_	14	compound
14	levels	level	NNS	_	10	nmod
15	is	be	VBZ	_	16	auxpass
16	recommended	recommend	VBN	_	0	ROOT
17	.	.	.	_	16	punct

1	If	if	IN	_	6	mark
2	a	a	DT	_	3	det
3	drug1	drug1	NN	_	6	nsubjpass
4	is	be	VBZ	_	6	auxpass
5	also	also	RB	_	6	advmod
6	used	use	VBN	_	10	advcl
7	,	,	,	_	10	punct
8	it	it	PRP	_	10	nsubj
9	may	may	MD	_	10	aux
10	increase	increase	VB	_	0	ROOT
11	the	the	DT	_	12	det
12	risk	risk	NN	_	10	dobj
13	of	of	IN	_	15	case
14	drug2	drug2	NN	_	15	compound
15	toxicity	toxicity	NN	_	12	nmod
16	.	.	.	_	10	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	5	case
4	a	a	DT	_	5	det
5	study	study	NN	_	1	nmod
6	of	of	IN	_	10	case
7	young	young	JJ	_	10	amod
8	healthy	healthy	JJ	_	10	amod
9	male	male	JJ	_	10	amod
10	subjects	subject	NNS	_	5	nmod
11	no	no	DT	_	12	neg
12	evidence	evidence	NN	_	5	dep
13	of	of	IN	_	17	case
14	a	a	DT	_	17	det
15	direct	direct	JJ	_	17	amod
16	pharmacokinetic	pharmacokinetic	JJ	_	17	amod
17	drug2	drug2	NN	_	12	nmod
18	-	-	:	_	17	punct
19	drug3	drug3	NN	_	20	compound
20	interaction	interaction	NN	_	23	nsubjpass
21	could	could	MD	_	23	aux
22	be	be	VB	_	23	auxpass
23	found	find	VBN	_	17	acl:relcl
24	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	10	nsubj
4	administered	administer	VBN	_	3	acl
5	concurrently	concurrently	RB	_	4	advmod
6	with	with	IN	_	7	case
7	drug3	drug3	NN	_	4	nmod
8	does	do	VBZ	_	10	aux
9	not	not	RB	_	10	neg
10	alter	alter	VB	_	1	dep
11	the	the	DT	_	12	det
12	pharmacokinetics	pharmacokinetic	NNS	_	10	dobj
13	of	of	IN	_	14	case
14	drug4	drug4	NN	_	12	nmod
15	in	in	IN	_	19	case
16	renally	renally	RB	_	17	advmod
17	impaired	impaired	JJ	_	19	amod
18	hypertensive	hypertensive	JJ	_	19	amod
19	patients	patient	NNS	_	10	nmod
20	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	5	case
4	a	a	DT	_	5	det
5	study	study	NN	_	1	nmod
6	of	of	IN	_	9	case
7	healthy	healthy	JJ	_	9	amod
8	male	male	JJ	_	9	amod
9	volunteers	volunteer	NNS	_	5	nmod
10	no	no	DT	_	13	neg
11	significant	significant	JJ	_	13	amod
12	pharmacokinetic	pharmacokinetic	JJ	_	13	amod
13	interaction	interaction	NN	_	14	nsubj
14	occurred	occur	VBD	_	9	acl:relcl
15	when	when	WRB	_	20	advmod
16	drug2	drug2	NN	_	20	nsubjpass
17	and	and	CC	_	16	cc
18	drug3	drug3	NN	_	16	conj
19	were	be	VBD	_	20	auxpass
20	administered	administer	VBN	_	14	advcl
21	concomitantly	concomitantly	RB	_	20	advmod
22	for	for	IN	_	24	case
23	6	6	CD	_	24	nummod
24	days	day	NNS	_	20	nmod
25	.	.	.	_	1	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	4	amod
2	Test	test	NN	_	4	compound
3	Interaction	interaction	NN	_	4	compound
4	drug1	drug1	NN	_	6	nsubj
5	may	may	MD	_	6	aux
6	cause	cause	VB	_	0	ROOT
7	a	a	DT	_	10	det
8	false-positive	false-positive	JJ	_	10	amod
9	urine	urine	NN	_	10	compound
10	test	test	NN	_	6	dobj
11	for	for	IN	_	12	case
12	acetone	acetone	NN	_	10	nmod
13	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Patients	patient	NNS	_	16	nsubj
4	on	on	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	,	,	,	_	3	punct
7	especially	especially	RB	_	8	advmod
8	those	those	DT	_	3	appos
9	with	with	IN	_	12	case
10	intravascular	intravascular	JJ	_	12	amod
11	volume	volume	NN	_	12	compound
12	depletion	depletion	NN	_	8	nmod
13	,	,	,	_	3	punct
14	may	may	MD	_	16	aux
15	occasionally	occasionally	RB	_	16	advmod
16	experience	experience	VB	_	1	dep
17	an	a	DT	_	19	det
18	excessive	excessive	JJ	_	19	amod
19	reduction	reduction	NN	_	16	dobj
20	of	of	IN	_	22	case
21	blood	blood	NN	_	22	compound
22	pressure	pressure	NN	_	19	nmod
23	after	after	IN	_	24	case
24	initiation	initiation	NN	_	16	nmod
25	of	of	IN	_	26	case
26	therapy	therapy	NN	_	24	nmod
27	with	with	IN	_	28	case
28	drug3	drug3	NN	_	24	nmod
29	.	.	.	_	16	punct

1	The	the	DT	_	2	det
2	possibility	possibility	NN	_	8	nsubjpass
3	of	of	IN	_	5	case
4	hypotensive	hypotensive	JJ	_	5	amod
5	effects	effect	NNS	_	2	nmod
6	can	can	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	minimized	minimize	VBN	_	0	ROOT
9	by	by	IN	_	11	mark
10	either	either	CC	_	11	cc:preconj
11	discontinuing	discontinue	VBG	_	8	advcl
12	the	the	DT	_	13	det
13	drug1	drug1	NN	_	11	dobj
14	or	or	CC	_	11	cc
15	increasing	increase	VBG	_	11	conj
16	salt	salt	NN	_	17	compound
17	intake	intake	NN	_	15	dobj
18	prior	prior	RB	_	15	advmod
19	to	to	TO	_	20	case
20	initiation	initiation	NN	_	18	nmod
21	of	of	IN	_	22	case
22	treatment	treatment	NN	_	20	nmod
23	with	with	IN	_	24	case
24	drug2	drug2	NN	_	22	nmod
25	.	.	.	_	8	punct

1	If	if	IN	_	5	mark
2	this	this	DT	_	5	nsubj
3	is	be	VBZ	_	5	cop
4	not	not	RB	_	5	neg
5	possible	possible	JJ	_	12	advcl
6	,	,	,	_	12	punct
7	the	the	DT	_	9	det
8	starting	start	VBG	_	9	amod
9	dose	dose	NN	_	12	nsubjpass
10	should	should	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	reduced	reduce	VBN	_	0	ROOT
13	and	and	CC	_	12	cc
14	the	the	DT	_	15	det
15	patient	patient	NN	_	18	nsubjpass
16	should	should	MD	_	18	aux
17	be	be	VB	_	18	auxpass
18	observed	observe	VBN	_	12	conj
19	closely	closely	RB	_	18	advmod
20	for	for	IN	_	22	case
21	several	several	JJ	_	22	amod
22	hours	hour	NNS	_	18	nmod
23	following	follow	VBG	_	26	case
24	an	a	DT	_	26	det
25	initial	initial	JJ	_	26	amod
26	dose	dose	NN	_	18	nmod
27	and	and	CC	_	26	cc
28	until	until	IN	_	32	mark
29	blood	blood	NN	_	30	compound
30	pressure	pressure	NN	_	32	nsubj
31	has	have	VBZ	_	32	aux
32	stabilized	stabilize	VBN	_	26	conj
33	-LRB-	-lrb-	-LRB-	_	34	punct
34	see	see	VB	_	32	dep
35	DOSAGE	DOSAGE	NNP	_	34	dobj
36	AND	and	CC	_	35	cc
37	ADMINISTRATION	ADMINISTRATION	NNP	_	35	conj
38	.	.	.	_	34	punct
39	-RRB-	-rrb-	-RRB-	_	34	punct

1	drug1	drug1	NN	_	2	compound
2	Supplements	supplement	NNS	_	0	ROOT
3	and	and	CC	_	2	cc
4	drug2	drug2	NN	_	2	conj
5	:	:	:	_	2	punct
6	drug3	drug3	NN	_	8	nsubj
7	can	can	MD	_	8	aux
8	attenuate	attenuate	VB	_	2	dep
9	potassium	potassium	NN	_	10	compound
10	loss	loss	NN	_	8	dobj
11	caused	cause	VBN	_	10	acl
12	by	by	IN	_	13	case
13	drug4	drug4	NN	_	11	nmod
14	.	.	.	_	2	punct

1	drug1	drug1	NN	_	14	compound
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	drug2	drug2	NN	_	1	dep
4	,	,	,	_	3	punct
5	drug3	drug3	NN	_	3	conj
6	,	,	,	_	3	punct
7	drug4	drug4	NN	_	3	conj
8	,	,	,	_	3	punct
9	and	and	CC	_	3	cc
10	others	other	NNS	_	3	conj
11	-RRB-	-rrb-	-RRB-	_	3	punct
12	or	or	CC	_	1	cc
13	drug5	drug5	NN	_	1	conj
14	supplements	supplement	NNS	_	16	nsubj
15	can	can	MD	_	16	aux
16	increase	increase	VB	_	0	ROOT
17	the	the	DT	_	18	det
18	risk	risk	NN	_	16	dobj
19	of	of	IN	_	20	case
20	hyperkalemia	hyperkalemia	NN	_	18	nmod
21	.	.	.	_	16	punct

1	Therefore	therefore	RB	_	15	advmod
2	,	,	,	_	15	punct
3	if	if	IN	_	10	mark
4	concomitant	concomitant	JJ	_	5	amod
5	use	use	NN	_	10	nsubjpass
6	of	of	IN	_	8	case
7	such	such	JJ	_	8	amod
8	agents	agent	NNS	_	5	nmod
9	is	be	VBZ	_	10	auxpass
10	indicated	indicate	VBN	_	15	advcl
11	,	,	,	_	15	punct
12	they	they	PRP	_	15	nsubjpass
13	should	should	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	given	give	VBN	_	0	ROOT
16	with	with	IN	_	17	case
17	caution	caution	NN	_	15	nmod
18	,	,	,	_	15	punct
19	and	and	CC	_	15	cc
20	the	the	DT	_	21	det
21	patients	patient	NNS	_	15	conj
22	serum	serum	NN	_	23	compound
23	potassium	potassium	NN	_	26	nsubjpass
24	should	should	MD	_	26	aux
25	be	be	VB	_	26	auxpass
26	monitored	monitor	VBN	_	21	acl:relcl
27	frequently	frequently	RB	_	26	advmod
28	.	.	.	_	15	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Increased	increase	VBN	_	6	amod
4	serum	serum	NN	_	6	compound
5	drug2	drug2	NN	_	6	compound
6	levels	level	NNS	_	14	nsubjpass
7	and	and	CC	_	6	cc
8	symptoms	symptom	NNS	_	6	conj
9	of	of	IN	_	11	case
10	drug3	drug3	NN	_	11	compound
11	toxicity	toxicity	NN	_	8	nmod
12	have	have	VBP	_	14	aux
13	been	be	VBN	_	14	auxpass
14	reported	report	VBN	_	1	appos
15	in	in	IN	_	16	case
16	patients	patient	NNS	_	14	nmod
17	receiving	receive	VBG	_	16	acl
18	drug4	drug4	NN	_	17	dobj
19	during	during	IN	_	20	case
20	therapy	therapy	NN	_	17	nmod
21	with	with	IN	_	22	case
22	drug5	drug5	NN	_	20	nmod
23	.	.	.	_	1	punct

1	These	these	DT	_	2	det
2	drugs	drug	NNS	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	coadministered	coadminister	VBN	_	0	ROOT
6	with	with	IN	_	7	case
7	caution	caution	NN	_	5	nmod
8	,	,	,	_	5	punct
9	and	and	CC	_	5	cc
10	frequent	frequent	JJ	_	11	amod
11	monitoring	monitoring	NN	_	17	nsubjpass
12	of	of	IN	_	15	case
13	serum	serum	NN	_	15	compound
14	drug1	drug1	NN	_	15	compound
15	levels	level	NNS	_	11	nmod
16	is	be	VBZ	_	17	auxpass
17	recommended	recommend	VBN	_	5	conj
18	.	.	.	_	5	punct

1	If	if	IN	_	6	mark
2	a	a	DT	_	3	det
3	drug1	drug1	NN	_	6	nsubjpass
4	is	be	VBZ	_	6	auxpass
5	also	also	RB	_	6	advmod
6	used	use	VBN	_	15	advcl
7	,	,	,	_	15	punct
8	the	the	DT	_	9	det
9	risk	risk	NN	_	15	nsubjpass
10	of	of	IN	_	12	case
11	lithium	lithium	NN	_	12	compound
12	toxicity	toxicity	NN	_	9	nmod
13	may	may	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	increased	increase	VBN	_	0	ROOT
16	.	.	.	_	15	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	7	case
4	a	a	DT	_	7	det
5	clinical	clinical	JJ	_	7	amod
6	pharmacology	pharmacology	NN	_	7	compound
7	study	study	NN	_	23	nmod
8	,	,	,	_	23	punct
9	coadministration	coadministration	NN	_	23	nsubj
10	of	of	IN	_	12	case
11	an	a	DT	_	12	det
12	drug2	drug2	NN	_	9	nmod
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	drug3	drug3	NN	_	12	dep
15	,	,	,	_	14	punct
16	drug4	drug4	NN	_	14	conj
17	,	,	,	_	14	punct
18	and	and	CC	_	14	cc
19	drug5	drug5	NN	_	14	conj
20	-RRB-	-rrb-	-RRB-	_	14	punct
21	with	with	IN	_	22	case
22	drug6	drug6	NN	_	9	nmod
23	reduced	reduce	VBD	_	1	dep
24	serum	serum	NN	_	25	compound
25	levels	level	NNS	_	23	dobj
26	and	and	CC	_	25	cc
27	urinary	urinary	JJ	_	28	amod
28	excretion	excretion	NN	_	25	conj
29	of	of	IN	_	30	case
30	drug7	drug7	NN	_	25	nmod
31	as	as	IN	_	32	mark
32	compared	compare	VBN	_	23	advcl
33	with	with	IN	_	34	case
34	drug8	drug8	NN	_	32	nmod
35	administered	administer	VBN	_	34	acl
36	alone	alone	RB	_	35	advmod
37	,	,	,	_	23	punct
38	suggesting	suggest	VBG	_	23	xcomp
39	that	that	IN	_	42	mark
40	drug9	drug9	NN	_	42	nsubj
41	may	may	MD	_	42	aux
42	impair	impair	VB	_	38	ccomp
43	absorption	absorption	NN	_	42	dobj
44	of	of	IN	_	45	case
45	drug10	drug10	NN	_	43	nmod
46	.	.	.	_	1	punct

1	Therefore	therefore	RB	_	15	advmod
2	,	,	,	_	15	punct
3	if	if	IN	_	10	mark
4	concomitant	concomitant	JJ	_	5	amod
5	administration	administration	NN	_	10	nsubjpass
6	of	of	IN	_	8	case
7	these	these	DT	_	8	det
8	agents	agent	NNS	_	5	nmod
9	is	be	VBZ	_	10	auxpass
10	indicated	indicate	VBN	_	15	advcl
11	,	,	,	_	15	punct
12	dosing	dosing	NN	_	15	nsubjpass
13	should	should	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	separated	separate	VBN	_	0	ROOT
16	by	by	IN	_	18	case
17	2	2	CD	_	18	nummod
18	hours	hour	NNS	_	15	nmod
19	.	.	.	_	15	punct

1	Other	other	JJ	_	0	ROOT
2	:	:	:	_	1	punct
3	Neither	neither	DT	_	4	det
4	drug1	drug1	NN	_	10	nsubjpass
5	nor	nor	CC	_	4	cc
6	its	its	PRP$	_	7	nmod:poss
7	metabolites	metabolite	NNS	_	4	conj
8	have	have	VBP	_	10	aux
9	been	be	VBN	_	10	auxpass
10	found	find	VBN	_	1	parataxis
11	to	to	TO	_	12	mark
12	interact	interact	VB	_	10	xcomp
13	with	with	IN	_	14	case
14	food	food	NN	_	12	nmod
15	.	.	.	_	1	punct

1	In	in	IN	_	9	case
2	separate	separate	JJ	_	9	amod
3	single	single	JJ	_	9	amod
4	or	or	CC	_	3	cc
5	multiple	multiple	JJ	_	3	conj
6	dose	dose	NN	_	9	compound
7	pharmacokinetic	pharmacokinetic	JJ	_	9	amod
8	interaction	interaction	NN	_	9	compound
9	studies	study	NNS	_	36	nmod
10	with	with	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	,	,	,	_	11	punct
13	drug2	drug2	NN	_	11	conj
14	,	,	,	_	11	punct
15	drug3	drug3	NN	_	11	conj
16	,	,	,	_	11	punct
17	drug4	drug4	NN	_	11	conj
18	,	,	,	_	11	punct
19	drug5	drug5	NN	_	11	conj
20	,	,	,	_	11	punct
21	drug6	drug6	NN	_	11	conj
22	,	,	,	_	11	punct
23	drug7	drug7	NN	_	11	conj
24	,	,	,	_	11	punct
25	drug8	drug8	NN	_	11	conj
26	,	,	,	_	11	punct
27	and	and	CC	_	11	cc
28	drug9	drug9	NN	_	11	conj
29	,	,	,	_	36	punct
30	the	the	DT	_	31	det
31	bioavailability	bioavailability	NN	_	36	nsubjpass
32	of	of	IN	_	33	case
33	drug10	drug10	NN	_	31	nmod
34	was	be	VBD	_	36	auxpass
35	not	not	RB	_	36	neg
36	altered	alter	VBN	_	0	ROOT
37	by	by	IN	_	38	case
38	coadministration	coadministration	NN	_	36	nmod
39	of	of	IN	_	40	case
40	drug11	drug11	NN	_	38	nmod
41	with	with	IN	_	43	case
42	any	any	DT	_	43	det
43	one	one	CD	_	36	nmod
44	of	of	IN	_	46	case
45	these	these	DT	_	46	det
46	drugs	drug	NNS	_	43	nmod
47	.	.	.	_	36	punct

1	In	in	IN	_	3	case
2	a	a	DT	_	3	det
3	study	study	NN	_	19	nmod
4	with	with	IN	_	6	case
5	concomitant	concomitant	JJ	_	6	amod
6	administration	administration	NN	_	3	nmod
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	drug2	drug2	NN	_	8	conj
11	,	,	,	_	19	punct
12	the	the	DT	_	13	det
13	bioavailability	bioavailability	NN	_	19	nsubjpass
14	of	of	IN	_	16	case
15	unbound	unbound	JJ	_	16	amod
16	drug3	drug3	NN	_	13	nmod
17	was	be	VBD	_	19	auxpass
18	not	not	RB	_	19	neg
19	altered	alter	VBN	_	0	ROOT
20	.	.	.	_	19	punct

1	In	in	IN	_	5	case
2	a	a	DT	_	5	det
3	pharmacokinetic	pharmacokinetic	JJ	_	5	amod
4	interaction	interaction	NN	_	5	compound
5	study	study	NN	_	33	nmod
6	with	with	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	,	,	,	_	33	punct
9	bioavailability	bioavailability	NN	_	10	compound
10	parameters	parameter	NNS	_	33	nsubjpass
11	,	,	,	_	10	punct
12	the	the	DT	_	13	det
13	degree	degree	NN	_	10	conj
14	of	of	IN	_	16	case
15	protein	protein	NN	_	16	compound
16	binding	binding	NN	_	13	nmod
17	,	,	,	_	10	punct
18	and	and	CC	_	10	cc
19	the	the	DT	_	21	det
20	anticoagulant	anticoagulant	JJ	_	21	amod
21	effect	effect	NN	_	10	conj
22	-LRB-	-lrb-	-LRB-	_	23	punct
23	measured	measure	VBN	_	21	dep
24	by	by	IN	_	26	case
25	prothrombin	prothrombin	NN	_	26	compound
26	time	time	NN	_	23	nmod
27	-RRB-	-rrb-	-RRB-	_	23	punct
28	of	of	IN	_	29	case
29	drug2	drug2	NN	_	21	nmod
30	were	be	VBD	_	33	auxpass
31	not	not	RB	_	33	neg
32	significantly	significantly	RB	_	33	advmod
33	changed	change	VBD	_	0	ROOT
34	.	.	.	_	33	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	4	amod
2	Test	test	NN	_	4	compound
3	Interaction	interaction	NN	_	4	compound
4	drug1	drug1	NN	_	6	nsubj
5	may	may	MD	_	6	aux
6	cause	cause	VB	_	0	ROOT
7	a	a	DT	_	10	det
8	false	false	JJ	_	10	amod
9	low	low	JJ	_	10	amod
10	measurement	measurement	NN	_	6	dobj
11	of	of	IN	_	14	case
12	serum	serum	NN	_	14	compound
13	drug2	drug2	NN	_	14	compound
14	levels	level	NNS	_	10	nmod
15	with	with	IN	_	21	case
16	the	the	DT	_	21	det
17	Digi	Digi	NNP	_	21	compound
18	-	-	:	_	21	punct
19	Tab	Tab	NNP	_	21	compound
20	RIA	ria	NN	_	21	compound
21	Kit	kit	NN	_	6	nmod
22	for	for	IN	_	23	case
23	drug3	drug3	NN	_	21	nmod
24	.	.	.	_	6	punct

1	Other	other	JJ	_	2	amod
2	kits	kit	NNS	_	13	nsubjpass
3	,	,	,	_	2	punct
4	such	such	JJ	_	9	case
5	as	as	IN	_	4	mwe
6	the	the	DT	_	9	det
7	Coat-A-Count	Coat-A-Count	NNP	_	9	compound
8	RIA	ria	NN	_	9	compound
9	Kit	kit	NN	_	2	nmod
10	,	,	,	_	2	punct
11	may	may	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	used	use	VBN	_	0	ROOT
14	.	.	.	_	13	punct

1	In	in	FW	_	2	compound
2	vitro	vitro	FW	_	7	advmod
3	,	,	,	_	7	punct
4	drug1	drug1	NN	_	7	nsubjpass
5	has	have	VBZ	_	7	aux
6	been	be	VBN	_	7	auxpass
7	shown	show	VBN	_	0	ROOT
8	to	to	TO	_	9	mark
9	inhibit	inhibit	VB	_	7	xcomp
10	the	the	DT	_	11	det
11	activity	activity	NN	_	9	dobj
12	of	of	IN	_	16	case
13	liver	liver	NN	_	16	compound
14	cytochrome	cytochrome	NN	_	16	compound
15	P-450	p-450	NN	_	16	compound
16	isoenzymes	isoenzyme	NNS	_	11	nmod
17	and	and	CC	_	9	cc
18	therefore	therefore	RB	_	9	advmod
19	,	,	,	_	9	punct
20	may	may	MD	_	21	aux
21	reduce	reduce	VB	_	9	dep
22	the	the	DT	_	23	det
23	metabolism	metabolism	NN	_	21	dobj
24	of	of	IN	_	25	case
25	compounds	compound	NNS	_	23	nmod
26	requiring	require	VBG	_	25	acl
27	these	these	DT	_	28	det
28	systems	system	NNS	_	26	dobj
29	.	.	.	_	7	punct

1	Consequently	consequently	RB	_	20	advmod
2	,	,	,	_	20	punct
3	drugs	drug	NNS	_	20	nsubj
4	with	with	IN	_	8	case
5	a	a	DT	_	8	det
6	low	low	JJ	_	8	amod
7	therapeutic	therapeutic	JJ	_	8	amod
8	margin	margin	NN	_	3	nmod
9	,	,	,	_	8	punct
10	such	such	JJ	_	12	case
11	as	as	IN	_	10	mwe
12	drug1	drug1	NN	_	8	nmod
13	,	,	,	_	12	punct
14	drug2	drug2	NN	_	12	conj
15	,	,	,	_	12	punct
16	and	and	CC	_	12	cc
17	drug3	drug3	NN	_	12	conj
18	,	,	,	_	8	punct
19	could	could	MD	_	20	aux
20	have	have	VB	_	0	ROOT
21	a	a	DT	_	23	det
22	delayed	delay	VBN	_	23	amod
23	elimination	elimination	NN	_	20	dobj
24	and	and	CC	_	20	cc
25	increases	increase	VBZ	_	20	conj
26	in	in	IN	_	29	case
27	their	they	PRP$	_	29	nmod:poss
28	serum	serum	NN	_	29	compound
29	half-life	half-life	NN	_	25	nmod
30	leading	lead	VBG	_	29	acl
31	to	to	TO	_	34	case
32	a	a	DT	_	34	det
33	toxic	toxic	JJ	_	34	amod
34	level	level	NN	_	30	nmod
35	.	.	.	_	20	punct

1	The	the	DT	_	2	det
2	dosage	dosage	NN	_	13	nsubj
3	of	of	IN	_	5	case
4	these	these	DT	_	5	det
5	drugs	drug	NNS	_	2	nmod
6	or	or	CC	_	5	cc
7	others	other	NNS	_	5	conj
8	with	with	IN	_	11	case
9	a	a	DT	_	11	det
10	similar	similar	JJ	_	11	amod
11	metabolism	metabolism	NN	_	2	nmod
12	may	may	MD	_	13	aux
13	need	need	VB	_	0	ROOT
14	to	to	TO	_	16	mark
15	be	be	VB	_	16	auxpass
16	modified	modify	VBN	_	13	xcomp
17	if	if	IN	_	20	mark
18	they	they	PRP	_	20	nsubjpass
19	are	be	VBP	_	20	auxpass
20	administered	administer	VBN	_	16	advcl
21	concomitantly	concomitantly	RB	_	20	advmod
22	with	with	IN	_	23	case
23	drug1	drug1	NN	_	20	nmod
24	.	.	.	_	13	punct

1	For	for	IN	_	2	case
2	example	example	NN	_	17	nmod
3	,	,	,	_	17	punct
4	when	when	WRB	_	7	advmod
5	drug1	drug1	NN	_	7	nsubjpass
6	are	be	VBP	_	7	auxpass
7	administered	administer	VBN	_	17	advcl
8	concomitantly	concomitantly	RB	_	7	advmod
9	with	with	IN	_	10	case
10	drug2	drug2	NN	_	7	nmod
11	,	,	,	_	17	punct
12	prothrombin	prothrombin	NN	_	13	compound
13	time	time	NN	_	17	nsubjpass
14	should	should	MD	_	17	aux
15	be	be	VB	_	17	auxpass
16	carefully	carefully	RB	_	17	advmod
17	monitored	monitor	VBN	_	0	ROOT
18	and	and	CC	_	17	cc
19	if	if	IN	_	20	mark
20	necessary	necessary	JJ	_	17	conj
21	,	,	,	_	17	punct
22	the	the	DT	_	23	det
23	dosage	dosage	NN	_	28	nsubjpass
24	of	of	IN	_	25	case
25	drug3	drug3	NN	_	23	nmod
26	should	should	MD	_	28	aux
27	be	be	VB	_	28	auxpass
28	reduced	reduce	VBN	_	17	parataxis
29	.	.	.	_	17	punct

1	The	the	DT	_	3	det
2	hypoglycemic	hypoglycemic	JJ	_	3	amod
3	action	action	NN	_	8	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	potentiated	potentiate	VBN	_	0	ROOT
9	by	by	IN	_	11	case
10	certain	certain	JJ	_	11	amod
11	drugs	drug	NNS	_	8	nmod
12	including	include	VBG	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	and	and	CC	_	13	cc
15	other	other	JJ	_	16	amod
16	drugs	drug	NNS	_	13	conj
17	that	that	WDT	_	21	nsubj
18	are	be	VBP	_	21	cop
19	highly	highly	RB	_	21	advmod
20	protein	protein	NN	_	21	nmod:npmod
21	bound	bind	VBD	_	11	acl:relcl
22	,	,	,	_	21	punct
23	drug3	drug3	NN	_	21	dobj
24	,	,	,	_	23	punct
25	drug4	drug4	NN	_	23	conj
26	,	,	,	_	23	punct
27	drug5	drug5	NN	_	23	conj
28	,	,	,	_	23	punct
29	drug6	drug6	NN	_	23	conj
30	,	,	,	_	23	punct
31	drug7	drug7	NN	_	23	conj
32	,	,	,	_	23	punct
33	drug8	drug8	NN	_	23	conj
34	,	,	,	_	23	punct
35	and	and	CC	_	23	cc
36	drug9	drug9	NN	_	23	conj
37	.	.	.	_	8	punct

1	When	when	WRB	_	5	advmod
2	such	such	JJ	_	3	amod
3	drugs	drug	NNS	_	5	nsubjpass
4	are	be	VBP	_	5	auxpass
5	administered	administer	VBN	_	16	advcl
6	to	to	TO	_	8	case
7	a	a	DT	_	8	det
8	patient	patient	NN	_	5	nmod
9	receiving	receive	VBG	_	8	acl
10	drug1	drug1	NN	_	9	dobj
11	,	,	,	_	16	punct
12	the	the	DT	_	13	det
13	patient	patient	NN	_	16	nsubjpass
14	should	should	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	observed	observe	VBN	_	0	ROOT
17	closely	closely	RB	_	16	advmod
18	for	for	IN	_	19	case
19	hypoglycemia	hypoglycemia	NN	_	16	nmod
20	.	.	.	_	16	punct

1	When	when	WRB	_	5	advmod
2	such	such	JJ	_	3	amod
3	drugs	drug	NNS	_	5	nsubjpass
4	are	be	VBP	_	5	auxpass
5	withdrawn	withdraw	VBN	_	16	advcl
6	from	from	IN	_	8	case
7	a	a	DT	_	8	det
8	patient	patient	NN	_	5	nmod
9	receiving	receive	VBG	_	8	acl
10	drug1	drug1	NN	_	9	dobj
11	,	,	,	_	16	punct
12	the	the	DT	_	13	det
13	patient	patient	NN	_	16	nsubjpass
14	should	should	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	observed	observe	VBN	_	0	ROOT
17	closely	closely	RB	_	16	advmod
18	for	for	IN	_	19	case
19	loss	loss	NN	_	16	nmod
20	of	of	IN	_	21	case
21	control	control	NN	_	19	nmod
22	.	.	.	_	16	punct

1	Certain	certain	JJ	_	2	amod
2	drugs	drug	NNS	_	3	nsubj
3	tend	tend	VBP	_	0	ROOT
4	to	to	TO	_	5	mark
5	produce	produce	VB	_	3	xcomp
6	hyperglycemia	hyperglycemia	NN	_	5	dobj
7	and	and	CC	_	3	cc
8	may	may	MD	_	9	aux
9	lead	lead	VB	_	3	conj
10	to	to	TO	_	11	case
11	loss	loss	NN	_	9	nmod
12	of	of	IN	_	13	case
13	control	control	NN	_	11	nmod
14	.	.	.	_	3	punct

1	These	these	DT	_	2	det
2	drugs	drug	NNS	_	3	nsubj
3	include	include	VBP	_	0	ROOT
4	the	the	DT	_	5	det
5	drug1	drug1	NN	_	3	dobj
6	and	and	CC	_	5	cc
7	other	other	JJ	_	8	amod
8	drug2	drug2	NN	_	5	conj
9	,	,	,	_	8	punct
10	drug3	drug3	NN	_	8	conj
11	,	,	,	_	8	punct
12	phe-nothiazines	phe-nothiazine	NNS	_	8	conj
13	,	,	,	_	8	punct
14	drug4	drug4	NN	_	8	conj
15	,	,	,	_	8	punct
16	drug5	drug5	NN	_	8	conj
17	,	,	,	_	8	punct
18	oral	oral	JJ	_	19	amod
19	drug6	drug6	NN	_	8	conj
20	,	,	,	_	8	punct
21	drug7	drug7	NN	_	8	conj
22	,	,	,	_	8	punct
23	drug8	drug8	NN	_	8	conj
24	,	,	,	_	8	punct
25	sympathomimet-ics	sympathomimet-ic	NNS	_	8	conj
26	,	,	,	_	8	punct
27	drug9	drug9	NN	_	8	conj
28	,	,	,	_	8	punct
29	and	and	CC	_	8	cc
30	drug10	drug10	NN	_	8	conj
31	.	.	.	_	3	punct

1	When	when	WRB	_	5	advmod
2	such	such	JJ	_	3	amod
3	drugs	drug	NNS	_	5	nsubjpass
4	are	be	VBP	_	5	auxpass
5	administered	administer	VBN	_	17	advcl
6	to	to	TO	_	8	case
7	a	a	DT	_	8	det
8	patient	patient	NN	_	5	nmod
9	receiving	receive	VBG	_	8	acl
10	drug1	drug1	NN	_	9	dobj
11	,	,	,	_	17	punct
12	the	the	DT	_	13	det
13	patient	patient	NN	_	17	nsubjpass
14	should	should	MD	_	17	aux
15	be	be	VB	_	17	auxpass
16	closely	closely	RB	_	17	advmod
17	observed	observe	VBN	_	0	ROOT
18	for	for	IN	_	19	case
19	loss	loss	NN	_	17	nmod
20	of	of	IN	_	21	case
21	control	control	NN	_	19	nmod
22	.	.	.	_	17	punct

1	When	when	WRB	_	5	advmod
2	such	such	JJ	_	3	amod
3	drugs	drug	NNS	_	5	nsubjpass
4	are	be	VBP	_	5	auxpass
5	withdrawn	withdraw	VBN	_	16	advcl
6	from	from	IN	_	8	case
7	a	a	DT	_	8	det
8	patient	patient	NN	_	5	nmod
9	receiving	receive	VBG	_	8	acl
10	drug1	drug1	NN	_	9	dobj
11	,	,	,	_	16	punct
12	the	the	DT	_	13	det
13	patient	patient	NN	_	16	nsubjpass
14	should	should	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	observed	observe	VBN	_	0	ROOT
17	closely	closely	RB	_	16	advmod
18	for	for	IN	_	19	case
19	hypoglycemia	hypoglycemia	NN	_	16	nmod
20	.	.	.	_	16	punct

1	A	a	DT	_	3	det
2	possible	possible	JJ	_	3	amod
3	interaction	interaction	NN	_	14	nsubjpass
4	between	between	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	,	,	,	_	3	punct
9	a	a	DT	_	10	det
10	drug3	drug3	NN	_	3	appos
11	,	,	,	_	3	punct
12	has	have	VBZ	_	14	aux
13	been	be	VBN	_	14	auxpass
14	reported	report	VBN	_	0	ROOT
15	,	,	,	_	14	punct
16	resulting	result	VBG	_	14	advcl
17	in	in	IN	_	19	case
18	a	a	DT	_	19	det
19	potentiation	potentiation	NN	_	16	nmod
20	of	of	IN	_	23	case
21	the	the	DT	_	23	det
22	hypoglycemic	hypoglycemic	JJ	_	23	amod
23	action	action	NN	_	19	nmod
24	of	of	IN	_	25	case
25	drug4	drug4	NN	_	23	nmod
26	.	.	.	_	14	punct

1	The	the	DT	_	2	det
2	mechanism	mechanism	NN	_	8	nsubjpass
3	for	for	IN	_	5	case
4	this	this	DT	_	5	det
5	interaction	interaction	NN	_	2	nmod
6	is	be	VBZ	_	8	auxpass
7	not	not	RB	_	8	neg
8	known	know	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	A	a	DT	_	3	det
2	potential	potential	JJ	_	3	amod
3	interaction	interaction	NN	_	16	nsubjpass
4	between	between	IN	_	6	case
5	oral	oral	JJ	_	6	amod
6	drug1	drug1	NN	_	3	nmod
7	and	and	CC	_	6	cc
8	oral	oral	JJ	_	9	amod
9	drug2	drug2	NN	_	6	conj
10	leading	lead	VBG	_	3	acl
11	to	to	TO	_	13	case
12	severe	severe	JJ	_	13	amod
13	hypoglycemia	hypoglycemia	NN	_	10	nmod
14	has	have	VBZ	_	16	aux
15	been	be	VBN	_	16	auxpass
16	reported	report	VBN	_	0	ROOT
17	.	.	.	_	16	punct

1	Whether	whether	IN	_	5	mark
2	this	this	DT	_	3	det
3	interaction	interaction	NN	_	5	nsubj
4	also	also	RB	_	5	advmod
5	occurs	occur	VBZ	_	18	csubjpass
6	with	with	IN	_	13	case
7	the	the	DT	_	13	det
8	intravenous	intravenous	JJ	_	13	amod
9	,	,	,	_	8	punct
10	topical	topical	JJ	_	8	conj
11	or	or	CC	_	8	cc
12	vaginal	vaginal	JJ	_	8	conj
13	preparations	preparation	NNS	_	5	nmod
14	of	of	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	is	be	VBZ	_	18	auxpass
17	not	not	RB	_	18	neg
18	known	know	VBN	_	0	ROOT
19	.	.	.	_	18	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	7	case
4	a	a	DT	_	7	det
5	single-dose	single-dose	JJ	_	7	amod
6	interaction	interaction	NN	_	7	compound
7	study	study	NN	_	19	nmod
8	in	in	IN	_	10	case
9	NIDDM	NIDDM	NNP	_	10	compound
10	subjects	subject	NNS	_	7	nmod
11	,	,	,	_	7	punct
12	decreases	decrease	VBZ	_	19	nsubjpass
13	in	in	IN	_	15	case
14	drug2	drug2	NN	_	15	compound
15	AUC	auc	NN	_	12	nmod
16	and	and	CC	_	15	cc
17	Cmax	cmax	NN	_	15	conj
18	were	be	VBD	_	19	auxpass
19	observed	observe	VBN	_	1	dep
20	,	,	,	_	19	punct
21	but	but	CC	_	19	cc
22	were	be	VBD	_	24	cop
23	highly	highly	RB	_	24	advmod
24	variable	variable	JJ	_	19	conj
25	.	.	.	_	1	punct

1	The	the	DT	_	3	det
2	single-dose	single-dose	JJ	_	3	amod
3	nature	nature	NN	_	20	nsubj
4	of	of	IN	_	6	case
5	this	this	DT	_	6	det
6	study	study	NN	_	3	nmod
7	and	and	CC	_	3	cc
8	the	the	DT	_	9	det
9	lack	lack	NN	_	3	conj
10	of	of	IN	_	11	case
11	correlation	correlation	NN	_	9	nmod
12	between	between	IN	_	15	case
13	drug1	drug1	NN	_	15	compound
14	blood	blood	NN	_	15	compound
15	levels	level	NNS	_	11	nmod
16	and	and	CC	_	15	cc
17	pharmaco-dynamic	pharmaco-dynamic	JJ	_	18	amod
18	effects	effect	NNS	_	15	conj
19	,	,	,	_	3	punct
20	makes	make	VBZ	_	0	ROOT
21	the	the	DT	_	23	det
22	clinical	clinical	JJ	_	23	amod
23	significance	significance	NN	_	20	dobj
24	of	of	IN	_	26	case
25	this	this	DT	_	26	det
26	interaction	interaction	NN	_	23	nmod
27	uncertain	uncertain	JJ	_	26	amod
28	.	.	.	_	20	punct

1	Coadministration	coadministration	NN	_	8	nsubj
2	of	of	IN	_	3	case
3	gly-buride	gly-buride	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	drug1	drug1	NN	_	3	conj
6	did	do	VBD	_	8	aux
7	not	not	RB	_	8	neg
8	result	result	VB	_	0	ROOT
9	in	in	IN	_	11	case
10	any	any	DT	_	11	det
11	changes	change	NNS	_	8	nmod
12	in	in	IN	_	15	case
13	either	either	CC	_	15	cc:preconj
14	drug2	drug2	NN	_	15	compound
15	pharmacokinetics	pharmacokinetic	NNS	_	11	nmod
16	or	or	CC	_	15	cc
17	pharmaco-dynamics	pharmaco-dynamics	NNS	_	15	conj
18	.	.	.	_	8	punct

1	Interations	interation	NNS	_	0	ROOT

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	interact	interact	VB	_	0	ROOT
4	with	with	IN	_	5	case
5	any	any	DT	_	3	nmod
6	of	of	IN	_	8	case
7	the	the	DT	_	8	det
8	following	following	NN	_	5	nmod
9	:	:	:	_	3	punct
10	-	-	:	_	3	punct
11	drug2	drug2	NN	_	3	dep
12	-LRB-	-lrb-	-LRB-	_	15	punct
13	e.g.	e.g.	FW	_	15	dep
14	,	,	,	_	15	punct
15	drug3	drug3	NN	_	11	appos
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	-LRB-	-lrb-	-LRB-	_	11	punct
18	with	with	IN	_	22	case
19	long-term	long-term	JJ	_	22	amod
20	,	,	,	_	22	punct
21	high-dose	high-dose	JJ	_	22	amod
22	use	use	NN	_	11	nmod
23	-RRB-	-rrb-	-RRB-	_	11	punct
24	or	or	CC	_	11	cc

1	-	-	:	_	0	ROOT
2	drug1	drug1	NN	_	1	root
3	-LRB-	-lrb-	-LRB-	_	6	punct
4	e.g.	e.g.	FW	_	6	dep
5	,	,	,	_	6	punct
6	drug2	drug2	NN	_	2	dep
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	or	or	CC	_	2	cc

1	-	-	:	_	0	ROOT
2	drug1	drug1	NN	_	4	compound
3	-LRB-	-lrb-	-LRB-	_	4	punct
4	drug2	drug2	NN	_	1	root
5	-LSB-	-lsb-	-LRB-	_	8	punct
6	e.g.	e.g.	FW	_	8	dep
7	,	,	,	_	8	punct
8	drug3	drug3	NN	_	4	dep
9	-RSB-	-rsb-	-RRB-	_	8	punct
10	,	,	,	_	4	punct
11	drug4	drug4	NN	_	4	conj
12	-LSB-	-lsb-	-LRB-	_	15	punct
13	e.g.	e.g.	FW	_	15	dep
14	,	,	,	_	15	punct
15	drug5	drug5	NN	_	11	dep
16	-RSB-	-rsb-	-RRB-	_	15	punct
17	,	,	,	_	4	punct
18	drug6	drug6	NN	_	4	conj
19	-LSB-	-lsb-	-LRB-	_	22	punct
20	e.g.	e.g.	FW	_	22	dep
21	,	,	,	_	22	punct
22	drug7	drug7	NN	_	18	dep
23	-RSB-	-rsb-	-RRB-	_	22	punct
24	,	,	,	_	4	punct
25	drug8	drug8	NN	_	4	conj
26	-LSB-	-lsb-	-LRB-	_	29	punct
27	e.g.	e.g.	FW	_	29	dep
28	,	,	,	_	29	punct
29	drug9	drug9	NN	_	25	dep
30	-RSB-	-rsb-	-RRB-	_	29	punct
31	-RRB-	-rrb-	-RRB-	_	29	punct
32	or	or	CC	_	4	cc

1	-	-	:	_	0	ROOT
2	drug1	drug1	NN	_	1	root
3	-LRB-	-lrb-	-LRB-	_	5	punct
4	male	male	JJ	_	5	amod
5	hormones	hormone	NNS	_	2	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	or	or	CC	_	2	cc

1	-	-	:	_	0	ROOT
2	drug1	drug1	NN	_	4	compound
3	-LRB-	-lrb-	-LRB-	_	4	punct
4	medicine	medicine	NN	_	1	root
5	for	for	IN	_	7	case
6	overactive	overactive	JJ	_	7	amod
7	thyroid	thyroid	NN	_	4	nmod
8	-RRB-	-rrb-	-RRB-	_	4	punct
9	or	or	CC	_	4	cc

1	-	-	:	_	0	ROOT
2	drug1	drug1	NN	_	1	root
3	-LRB-	-lrb-	-LRB-	_	6	punct
4	e.g.	e.g.	FW	_	6	dep
5	,	,	,	_	6	punct
6	drug2	drug2	NN	_	2	dep
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	or	or	CC	_	2	cc

1	-	-	:	_	0	ROOT
2	drug1	drug1	NN	_	1	root
3	-LRB-	-lrb-	-LRB-	_	6	punct
4	e.g.	e.g.	FW	_	6	dep
5	,	,	,	_	6	punct
6	drug2	drug2	NN	_	2	dep
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	or	or	CC	_	2	cc

1	-	-	:	_	0	ROOT
2	drug1	drug1	NN	_	1	root
3	-LRB-	-lrb-	-LRB-	_	6	punct
4	e.g.	e.g.	FW	_	6	dep
5	,	,	,	_	6	punct
6	drug2	drug2	NN	_	2	dep
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	or	or	CC	_	2	cc

1	-	-	:	_	0	ROOT
2	drug1	drug1	NN	_	1	root
3	-LRB-	-lrb-	-LRB-	_	6	punct
4	e.g.	e.g.	FW	_	6	dep
5	,	,	,	_	6	punct
6	drug2	drug2	NN	_	2	dep
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	or	or	CC	_	2	cc

1	-	-	:	_	0	ROOT
2	drug1	drug1	NN	_	1	root
3	-LRB-	-lrb-	-LRB-	_	6	punct
4	e.g.	e.g.	FW	_	6	dep
5	,	,	,	_	6	punct
6	drug2	drug2	NN	_	2	dep
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	or	or	CC	_	2	cc

1	-	-	:	_	0	ROOT
2	drug1	drug1	NN	_	1	root
3	-LRB-	-lrb-	-LRB-	_	6	punct
4	e.g.	e.g.	FW	_	6	dep
5	,	,	,	_	6	punct
6	drug2	drug2	NN	_	2	dep
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	or	or	CC	_	2	cc

1	-	-	:	_	0	ROOT
2	drug1	drug1	NN	_	1	root
3	-LRB-	-lrb-	-LRB-	_	6	punct
4	e.g.	e.g.	FW	_	6	dep
5	,	,	,	_	6	punct
6	drug2	drug2	NN	_	2	dep
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	or	or	CC	_	2	cc

1	-	-	:	_	0	ROOT
2	drug1	drug1	NN	_	1	root
3	-LRB-	-lrb-	-LRB-	_	5	punct
4	female	female	JJ	_	5	amod
5	hormones	hormone	NNS	_	2	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	or	or	CC	_	2	cc

1	-	-	:	_	0	ROOT
2	drug1	drug1	NN	_	1	root
3	-LRB-	-lrb-	-LRB-	_	6	punct
4	e.g.	e.g.	FW	_	6	dep
5	,	,	,	_	6	punct
6	drug2	drug2	NN	_	2	dep
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	or	or	CC	_	2	cc

1	-	-	:	_	0	ROOT
2	drug1	drug1	NN	_	3	compound
3	salts	salt	NNS	_	1	root
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	medicine	medicine	NN	_	3	dep
6	for	for	IN	_	7	case
7	arthritis	arthritis	NN	_	5	nmod
8	-RRB-	-rrb-	-RRB-	_	5	punct
9	or	or	CC	_	3	cc

1	-	-	:	_	0	ROOT
2	drug1	drug1	NN	_	1	root
3	-LRB-	-lrb-	-LRB-	_	6	punct
4	e.g.	e.g.	FW	_	6	dep
5	,	,	,	_	6	punct
6	drug2	drug2	NN	_	2	dep
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	or	or	CC	_	2	cc

1	-	-	:	_	0	ROOT
2	drug1	drug1	NN	_	1	root
3	-LRB-	-lrb-	-LRB-	_	6	punct
4	e.g.	e.g.	FW	_	6	dep
5	,	,	,	_	6	punct
6	drug2	drug2	NN	_	2	dep
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	or	or	CC	_	2	cc

1	-	-	:	_	0	ROOT
2	drug1	drug1	NN	_	1	root
3	-LRB-	-lrb-	-LRB-	_	6	punct
4	e.g.	e.g.	FW	_	6	dep
5	,	,	,	_	6	punct
6	drug2	drug2	NN	_	2	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	-LRB-	-lrb-	-LRB-	_	13	punct
9	with	with	IN	_	13	case
10	long-term	long-term	JJ	_	13	amod
11	,	,	,	_	13	punct
12	high-dose	high-dose	JJ	_	13	amod
13	use	use	NN	_	2	nmod
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	or	or	CC	_	2	cc

1	-	-	:	_	0	ROOT
2	Oral	oral	JJ	_	3	amod
3	drug1	drug1	NN	_	1	root
4	-LRB-	-lrb-	-LRB-	_	7	punct
5	birth	birth	NN	_	7	compound
6	control	control	NN	_	7	compound
7	pills	pill	NNS	_	3	appos
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	containing	contain	VBG	_	3	acl
10	drug2	drug2	NN	_	9	dobj
11	or	or	CC	_	10	cc

1	-	-	:	_	0	ROOT
2	Other	other	JJ	_	3	amod
3	drug1	drug1	NN	_	1	root
4	by	by	IN	_	5	case
5	mouth	mouth	NN	_	3	nmod
6	or	or	CC	_	5	cc
7	by	by	IN	_	8	case
8	injection	injection	NN	_	5	conj
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	medicine	medicine	NN	_	8	dep
11	for	for	IN	_	12	case
12	infection	infection	NN	_	10	nmod
13	-RRB-	-rrb-	-RRB-	_	10	punct
14	or	or	CC	_	3	cc

1	-	-	:	_	0	ROOT
2	drug1	drug1	NN	_	4	compound
3	-LRB-	-lrb-	-LRB-	_	4	punct
4	drug2	drug2	NN	_	1	root
5	-LSB-	-lsb-	-LRB-	_	8	punct
6	e.g.	e.g.	FW	_	8	dep
7	,	,	,	_	8	punct
8	drug3	drug3	NN	_	4	dep
9	-RSB-	-rsb-	-RRB-	_	8	punct
10	,	,	,	_	4	punct
11	drug4	drug4	NN	_	4	conj
12	-LSB-	-lsb-	-LRB-	_	15	punct
13	e.g.	e.g.	FW	_	15	dep
14	,	,	,	_	15	punct
15	drug5	drug5	NN	_	11	dep
16	-RSB-	-rsb-	-RRB-	_	15	punct
17	,	,	,	_	4	punct
18	drug6	drug6	NN	_	4	conj
19	-LSB-	-lsb-	-LRB-	_	22	punct
20	e.g.	e.g.	FW	_	22	dep
21	,	,	,	_	22	punct
22	drug7	drug7	NN	_	18	dep
23	-RSB-	-rsb-	-RRB-	_	22	punct
24	,	,	,	_	4	punct
25	drug8	drug8	NN	_	4	conj
26	-LSB-	-lsb-	-LRB-	_	29	punct
27	e.g.	e.g.	FW	_	29	dep
28	,	,	,	_	29	punct
29	drug9	drug9	NN	_	25	dep
30	-RSB-	-rsb-	-RRB-	_	29	punct
31	,	,	,	_	4	punct
32	drug10	drug10	NN	_	4	conj
33	-LSB-	-lsb-	-LRB-	_	36	punct
34	e.g.	e.g.	FW	_	36	dep
35	,	,	,	_	36	punct
36	drug11	drug11	NN	_	32	dep
37	-RSB-	-rsb-	-RRB-	_	36	punct
38	,	,	,	_	4	punct
39	drug12	drug12	NN	_	4	conj
40	-LSB-	-lsb-	-LRB-	_	43	punct
41	e.g.	e.g.	FW	_	43	dep
42	,	,	,	_	43	punct
43	drug13	drug13	NN	_	39	dep
44	-RSB-	-rsb-	-RRB-	_	43	punct
45	,	,	,	_	4	punct
46	drug14	drug14	NN	_	4	conj
47	-LSB-	-lsb-	-LRB-	_	50	punct
48	e.g.	e.g.	FW	_	50	dep
49	,	,	,	_	50	punct
50	drug15	drug15	NN	_	46	dep
51	-RSB-	-rsb-	-RRB-	_	50	punct
52	,	,	,	_	4	punct
53	drug16	drug16	NN	_	4	conj
54	-LSB-	-lsb-	-LRB-	_	57	punct
55	e.g.	e.g.	FW	_	57	dep
56	,	,	,	_	57	punct
57	drug17	drug17	NN	_	53	dep
58	-RSB-	-rsb-	-RRB-	_	57	punct
59	,	,	,	_	4	punct
60	drug18	drug18	NN	_	4	conj
61	-LSB-	-lsb-	-LRB-	_	64	punct
62	e.g.	e.g.	FW	_	64	dep
63	,	,	,	_	64	punct
64	drug19	drug19	NN	_	60	dep
65	-RSB-	-rsb-	-RRB-	_	64	punct
66	,	,	,	_	4	punct
67	drug20	drug20	NN	_	4	conj
68	-LSB-	-lsb-	-LRB-	_	71	punct
69	e.g.	e.g.	FW	_	71	dep
70	,	,	,	_	71	punct
71	drug21	drug21	NN	_	67	dep
72	-RSB-	-rsb-	-RRB-	_	71	punct
73	,	,	,	_	4	punct
74	drug22	drug22	NN	_	4	conj
75	-LSB-	-lsb-	-LRB-	_	78	punct
76	e.g.	e.g.	FW	_	78	dep
77	,	,	,	_	78	punct
78	drug23	drug23	NN	_	74	dep
79	-RSB-	-rsb-	-RRB-	_	78	punct
80	,	,	,	_	4	punct
81	drug24	drug24	NN	_	4	conj
82	-LSB-	-lsb-	-LRB-	_	85	punct
83	e.g.	e.g.	FW	_	85	dep
84	,	,	,	_	85	punct
85	drug25	drug25	NN	_	81	dep
86	-RSB-	-rsb-	-RRB-	_	85	punct
87	-RRB-	-rrb-	-RRB-	_	85	punct
88	or	or	CC	_	4	cc

1	-	-	:	_	0	ROOT
2	drug1	drug1	NN	_	1	root
3	-LRB-	-lrb-	-LRB-	_	6	punct
4	e.g.	e.g.	FW	_	6	dep
5	,	,	,	_	6	punct
6	drug2	drug2	NN	_	2	dep
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	or	or	CC	_	2	cc

1	-	-	:	_	15	punct
2	drug1	drug1	NN	_	8	compound
3	-LRB-	-lrb-	-LRB-	_	6	punct
4	e.g.	e.g.	FW	_	6	dep
5	,	,	,	_	6	punct
6	drug2	drug2	NN	_	8	dep
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	Use	use	NN	_	15	nsubj
9	of	of	IN	_	10	case
10	drug3	drug3	NN	_	8	nmod
11	with	with	IN	_	13	case
12	these	these	DT	_	13	det
13	medicines	medicine	NNS	_	8	nmod
14	may	may	MD	_	15	aux
15	increase	increase	VB	_	0	ROOT
16	the	the	DT	_	17	det
17	chance	chance	NN	_	15	dobj
18	of	of	IN	_	20	case
19	side	side	JJ	_	20	amod
20	effects	effect	NNS	_	17	nmod
21	affecting	affect	VBG	_	20	acl
22	the	the	DT	_	23	det
23	liver	liver	NN	_	21	dobj

1	-	-	:	_	0	ROOT
2	drug1	drug1	NN	_	1	root
3	-LRB-	-lrb-	-LRB-	_	6	punct
4	e.g.	e.g.	FW	_	6	dep
5	,	,	,	_	6	punct
6	drug2	drug2	NN	_	2	dep
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	or	or	CC	_	2	cc

1	-	-	:	_	0	ROOT
2	drug1	drug1	NN	_	1	root
3	or	or	CC	_	2	cc

1	-	-	:	_	0	ROOT
2	drug1	drug1	NN	_	1	root
3	-LRB-	-lrb-	-LRB-	_	6	punct
4	e.g.	e.g.	FW	_	6	dep
5	,	,	,	_	6	punct
6	drug2	drug2	NN	_	2	dep
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	or	or	CC	_	2	cc

1	-	-	:	_	0	ROOT
2	drug1	drug1	NN	_	1	root
3	-LRB-	-lrb-	-LRB-	_	6	punct
4	e.g.	e.g.	FW	_	6	dep
5	,	,	,	_	6	punct
6	drug2	drug2	NN	_	2	dep
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	or	or	CC	_	2	cc

1	-	-	:	_	0	ROOT
2	drug1	drug1	NN	_	1	root
3	or	or	CC	_	2	cc

1	-	-	:	_	0	ROOT
2	drug1	drug1	NN	_	1	root
3	-LRB-	-lrb-	-LRB-	_	6	punct
4	e.g.	e.g.	FW	_	6	dep
5	,	,	,	_	6	punct
6	drug2	drug2	NN	_	2	dep
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	or	or	CC	_	2	cc

1	-	-	:	_	0	ROOT
2	drug1	drug1	NN	_	1	root
3	-LRB-	-lrb-	-LRB-	_	6	punct
4	e.g.	e.g.	FW	_	6	dep
5	,	,	,	_	6	punct
6	drug2	drug2	NN	_	2	dep
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	or	or	CC	_	2	cc

1	-	-	:	_	0	ROOT
2	drug1	drug1	NN	_	1	root
3	-LRB-	-lrb-	-LRB-	_	6	punct
4	e.g.	e.g.	FW	_	6	dep
5	,	,	,	_	6	punct
6	drug2	drug2	NN	_	2	dep
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	or	or	CC	_	2	cc

1	-	-	:	_	0	ROOT
2	drug1	drug1	NN	_	1	root
3	-LRB-	-lrb-	-LRB-	_	6	punct
4	e.g.	e.g.	FW	_	6	dep
5	,	,	,	_	6	punct
6	drug2	drug2	NN	_	2	dep
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	or	or	CC	_	2	cc

1	-	-	:	_	17	punct
2	drug1	drug1	NN	_	10	compound
3	-LRB-	-lrb-	-LRB-	_	6	punct
4	e.g.	e.g.	FW	_	6	dep
5	,	,	,	_	6	punct
6	drug2	drug2	NN	_	10	dep
7	,	,	,	_	6	punct
8	drug3	drug3	NN	_	6	appos
9	-RRB-	-rrb-	-RRB-	_	6	punct
10	Use	use	NN	_	17	nsubj
11	of	of	IN	_	12	case
12	drug4	drug4	NN	_	10	nmod
13	with	with	IN	_	15	case
14	these	these	DT	_	15	det
15	medicines	medicine	NNS	_	10	nmod
16	may	may	MD	_	17	aux
17	increase	increase	VB	_	0	ROOT
18	the	the	DT	_	19	det
19	chance	chance	NN	_	17	dobj
20	of	of	IN	_	22	case
21	side	side	JJ	_	22	amod
22	effects	effect	NNS	_	19	nmod
23	affecting	affect	VBG	_	22	acl
24	the	the	DT	_	25	det
25	blood	blood	NN	_	23	dobj

1	-	-	:	_	5	punct
2	drug1	drug1	NN	_	5	compound
3	-LRB-	-lrb-	-LRB-	_	5	punct
4	drug2	drug2	NN	_	5	compound
5	s	s	NNS	_	0	ROOT
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	or	or	CC	_	5	cc

1	-	-	:	_	0	ROOT
2	drug1	drug1	NN	_	1	root
3	-LRB-	-lrb-	-LRB-	_	6	punct
4	e.g.	e.g.	FW	_	6	dep
5	,	,	,	_	6	punct
6	drug2	drug2	NN	_	2	dep
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	or	or	CC	_	2	cc

1	-	-	:	_	15	punct
2	drug1	drug1	NN	_	8	compound
3	-LRB-	-lrb-	-LRB-	_	6	punct
4	e.g.	e.g.	FW	_	6	dep
5	,	,	,	_	6	punct
6	drug2	drug2	NN	_	8	dep
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	Use	use	NN	_	15	nsubj
9	of	of	IN	_	10	case
10	drug3	drug3	NN	_	8	nmod
11	with	with	IN	_	13	case
12	these	these	DT	_	13	det
13	medicines	medicine	NNS	_	8	nmod
14	may	may	MD	_	15	aux
15	increase	increase	VB	_	0	ROOT
16	the	the	DT	_	17	det
17	chance	chance	NN	_	15	dobj
18	of	of	IN	_	20	case
19	side	side	JJ	_	20	amod
20	effects	effect	NNS	_	17	nmod
21	of	of	IN	_	23	case
22	these	these	DT	_	23	det
23	medicines	medicine	NNS	_	20	nmod

1	-	-	:	_	20	punct
2	drug1	drug1	NN	_	20	nmod:tmod
3	,	,	,	_	20	punct
4	oral	oral	JJ	_	7	amod
5	-LRB-	-lrb-	-LRB-	_	7	punct
6	diabetes	diabetes	NN	_	7	compound
7	medicine	medicine	NN	_	20	nsubj
8	you	you	PRP	_	9	nsubj
9	take	take	VBP	_	7	acl:relcl
10	by	by	IN	_	11	case
11	mouth	mouth	NN	_	9	nmod
12	-RRB-	-rrb-	-RRB-	_	7	punct
13	Use	use	NN	_	7	dep
14	of	of	IN	_	16	case
15	oral	oral	JJ	_	16	amod
16	drug2	drug2	NN	_	13	nmod
17	with	with	IN	_	18	case
18	drug3	drug3	NN	_	13	nmod
19	may	may	MD	_	20	aux
20	increase	increase	VB	_	0	ROOT
21	the	the	DT	_	22	det
22	chance	chance	NN	_	20	dobj
23	of	of	IN	_	25	case
24	side	side	JJ	_	25	amod
25	effects	effect	NNS	_	22	nmod
26	affecting	affect	VBG	_	25	acl
27	the	the	DT	_	28	det
28	blood	blood	NN	_	26	dobj
29	and/or	and/or	CC	_	28	cc
30	the	the	DT	_	32	det
31	side	side	JJ	_	32	amod
32	effects	effect	NNS	_	28	conj
33	or	or	CC	_	28	cc
34	oral	oral	JJ	_	35	amod
35	drug4	drug4	NN	_	28	conj

1	-	-	:	_	14	punct
2	drug1	drug1	NN	_	8	compound
3	-LRB-	-lrb-	-LRB-	_	6	punct
4	e.g.	e.g.	FW	_	6	dep
5	,	,	,	_	6	punct
6	drug2	drug2	NN	_	8	dep
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	Use	use	NN	_	14	nsubj
9	of	of	IN	_	10	case
10	drug3	drug3	NN	_	8	nmod
11	with	with	IN	_	12	case
12	drug4	drug4	NN	_	8	nmod
13	may	may	MD	_	14	aux
14	increase	increase	VB	_	0	ROOT
15	the	the	DT	_	16	det
16	chance	chance	NN	_	14	dobj
17	of	of	IN	_	19	case
18	side	side	JJ	_	19	amod
19	effects	effect	NNS	_	16	nmod
20	affecting	affect	VBG	_	19	acl
21	the	the	DT	_	22	det
22	liver	liver	NN	_	20	dobj
23	and/or	and/or	CC	_	22	cc
24	the	the	DT	_	26	det
25	side	side	JJ	_	26	amod
26	effects	effect	NNS	_	22	conj
27	of	of	IN	_	28	case
28	drug5	drug5	NN	_	26	nmod

1	-	-	:	_	14	punct
2	drug1	drug1	NN	_	8	compound
3	-LRB-	-lrb-	-LRB-	_	6	punct
4	e.g.	e.g.	FW	_	6	dep
5	,	,	,	_	6	punct
6	drug2	drug2	NN	_	8	dep
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	Use	use	NN	_	14	nsubj
9	of	of	IN	_	10	case
10	drug3	drug3	NN	_	8	nmod
11	with	with	IN	_	12	case
12	drug4	drug4	NN	_	8	nmod
13	may	may	MD	_	14	aux
14	increase	increase	VB	_	0	ROOT
15	the	the	DT	_	16	det
16	chance	chance	NN	_	14	dobj
17	of	of	IN	_	19	case
18	side	side	JJ	_	19	amod
19	effects	effect	NNS	_	16	nmod
20	affecting	affect	VBG	_	19	acl
21	the	the	DT	_	22	det
22	liver	liver	NN	_	20	dobj
23	and/or	and/or	CC	_	22	cc
24	the	the	DT	_	25	det
25	blood	blood	NN	_	22	conj

1	-	-	:	_	14	punct
2	drug1	drug1	NN	_	8	compound
3	-LRB-	-lrb-	-LRB-	_	6	punct
4	e.g.	e.g.	FW	_	6	dep
5	,	,	,	_	6	punct
6	drug2	drug2	NN	_	8	dep
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	Use	use	NN	_	14	nsubj
9	of	of	IN	_	10	case
10	drug3	drug3	NN	_	8	nmod
11	with	with	IN	_	12	case
12	drug4	drug4	NN	_	8	nmod
13	may	may	MD	_	14	aux
14	increase	increase	VB	_	0	ROOT
15	the	the	DT	_	16	det
16	chance	chance	NN	_	14	dobj
17	of	of	IN	_	19	case
18	side	side	JJ	_	19	amod
19	effects	effect	NNS	_	16	nmod
20	affecting	affect	VBG	_	19	acl
21	the	the	DT	_	22	det
22	liver	liver	NN	_	20	dobj
23	and/or	and/or	CC	_	22	cc
24	the	the	DT	_	26	det
25	side	side	JJ	_	26	amod
26	effects	effect	NNS	_	22	conj
27	of	of	IN	_	28	case
28	drug5	drug5	NN	_	26	nmod

1	drug1	drug1	NN	_	2	compound
2	toxicity	toxicity	NN	_	5	nsubjpass
3	may	may	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	aggravated	aggravate	VBN	_	0	ROOT
6	by	by	IN	_	9	case
7	the	the	DT	_	9	det
8	initial	initial	JJ	_	9	amod
9	release	release	NN	_	5	nmod
10	of	of	IN	_	11	case
11	norepinephrine	norepinephrine	NN	_	9	nmod
12	caused	cause	VBN	_	11	acl
13	by	by	IN	_	15	case
14	drug2	drug2	NN	_	15	compound
15	Injection	injection	NN	_	12	nmod
16	.	.	.	_	5	punct

1	The	the	DT	_	3	det
2	pressor	pressor	JJ	_	3	amod
3	effects	effect	NNS	_	12	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	such	such	JJ	_	8	case
7	as	as	IN	_	6	mwe
8	drug2	drug2	NN	_	5	nmod
9	or	or	CC	_	8	cc
10	drug3	drug3	NN	_	8	conj
11	are	be	VBP	_	12	auxpass
12	enhanced	enhance	VBN	_	0	ROOT
13	by	by	IN	_	14	case
14	drug4	drug4	NN	_	12	nmod
15	.	.	.	_	12	punct

1	When	when	WRB	_	4	advmod
2	drug1	drug1	NN	_	4	nsubjpass
3	are	be	VBP	_	4	auxpass
4	administered	administer	VBN	_	10	advcl
5	,	,	,	_	10	punct
6	dilute	dilute	VB	_	7	amod
7	solutions	solution	NNS	_	10	nsubjpass
8	should	should	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	used	use	VBN	_	0	ROOT
11	and	and	CC	_	10	cc
12	blood	blood	NN	_	13	compound
13	pressure	pressure	NN	_	16	nsubjpass
14	should	should	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	monitored	monitor	VBN	_	10	conj
17	closely	closely	RB	_	16	advmod
18	.	.	.	_	10	punct

1	Although	although	IN	_	3	mark
2	there	there	EX	_	3	expl
3	is	be	VBZ	_	19	advcl
4	little	little	JJ	_	6	amod
5	published	publish	VBN	_	6	amod
6	information	information	NN	_	3	nsubj
7	on	on	IN	_	9	case
8	concomitant	concomitant	JJ	_	9	amod
9	administration	administration	NN	_	6	nmod
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	drug2	drug2	NN	_	11	conj
14	,	,	,	_	19	punct
15	these	these	DT	_	16	det
16	drugs	drug	NNS	_	19	nsubjpass
17	are	be	VBP	_	19	auxpass
18	often	often	RB	_	19	advmod
19	administered	administer	VBN	_	0	ROOT
20	concurrently	concurrently	RB	_	19	advmod
21	without	without	IN	_	23	case
22	any	any	DT	_	23	det
23	evidence	evidence	NN	_	19	nmod
24	of	of	IN	_	25	case
25	interactions	interaction	NNS	_	23	nmod
26	resulting	result	VBG	_	25	acl
27	in	in	IN	_	29	case
28	adverse	adverse	JJ	_	29	amod
29	effects	effect	NNS	_	26	nmod
30	or	or	CC	_	29	cc
31	diminished	diminish	VBN	_	32	amod
32	efficacy	efficacy	NN	_	29	conj
33	.	.	.	_	19	punct

1	drug1	drug1	NN	_	0	ROOT
2	or	or	CC	_	1	cc
3	other	other	JJ	_	4	amod
4	drug2	drug2	NN	_	11	dep
5	-LRB-	-lrb-	-LRB-	_	7	punct
6	concurrent	concurrent	JJ	_	7	amod
7	use	use	NN	_	11	nsubj
8	with	with	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	may	may	MD	_	11	aux
11	result	result	VB	_	1	conj
12	in	in	IN	_	14	case
13	uterine	uterine	JJ	_	14	amod
14	hypertonus	hypertonus	NN	_	11	nmod
15	,	,	,	_	1	punct
16	possibly	possibly	RB	_	17	advmod
17	causing	cause	VBG	_	1	acl
18	uterine	uterine	JJ	_	19	amod
19	rupture	rupture	NN	_	17	dobj
20	or	or	CC	_	19	cc
21	cervical	cervical	JJ	_	22	amod
22	laceration	laceration	NN	_	19	conj
23	,	,	,	_	17	punct
24	especially	especially	RB	_	27	advmod
25	in	in	IN	_	27	case
26	the	the	DT	_	27	det
27	absence	absence	NN	_	17	nmod
28	of	of	IN	_	31	case
29	adequate	adequate	JJ	_	31	amod
30	cervical	cervical	JJ	_	31	amod
31	dilatation	dilatation	NN	_	27	nmod
32	;	;	:	_	1	punct

1	although	although	IN	_	5	mark
2	combinations	combination	NNS	_	5	nsubjpass
3	are	be	VBP	_	5	auxpass
4	sometimes	sometimes	RB	_	5	advmod
5	used	use	VBN	_	18	advcl
6	for	for	IN	_	8	case
7	therapeutic	therapeutic	JJ	_	8	amod
8	advantage	advantage	NN	_	5	nmod
9	,	,	,	_	18	punct
10	when	when	WRB	_	11	advmod
11	used	use	VBN	_	18	advcl
12	concurrently	concurrently	RB	_	11	advmod
13	,	,	,	_	18	punct
14	patient	patient	NN	_	18	nsubjpass
15	should	should	MD	_	18	aux
16	be	be	VB	_	18	auxpass
17	closely	closely	RB	_	18	advmod
18	monitored	monitor	VBN	_	0	ROOT
19	.	.	.	_	18	punct

1	No	no	DT	_	5	neg
2	clinical	clinical	JJ	_	5	amod
3	drug	drug	NN	_	5	compound
4	interaction	interaction	NN	_	5	compound
5	studies	study	NNS	_	8	nsubjpass
6	have	have	VBP	_	8	aux
7	been	be	VBN	_	8	auxpass
8	conducted	conduct	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	However	however	RB	_	11	advmod
2	,	,	,	_	11	punct
3	in	in	IN	_	10	case
4	a	a	DT	_	10	det
5	single	single	JJ	_	10	amod
6	in	in	FW	_	10	amod
7	vivo	vivo	FW	_	6	dep
8	rodent	rodent	JJ	_	10	amod
9	study	study	NN	_	10	compound
10	drug1	drug1	NN	_	11	nmod
11	had	have	VBD	_	0	ROOT
12	no	no	DT	_	13	neg
13	effect	effect	NN	_	11	dobj
14	on	on	IN	_	16	case
15	P450	p450	NN	_	16	compound
16	levels	level	NNS	_	11	nmod
17	.	.	.	_	11	punct

1	No	no	DT	_	4	neg
2	formal	formal	JJ	_	4	amod
3	drug-interaction	drug-interaction	NN	_	4	compound
4	studies	study	NNS	_	7	nsubjpass
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	performed	perform	VBN	_	0	ROOT
8	,	,	,	_	7	punct
9	and	and	CC	_	7	cc
10	a	a	DT	_	13	det
11	clinically	clinically	RB	_	12	advmod
12	significant	significant	JJ	_	13	amod
13	interaction	interaction	NN	_	28	nsubjpass
14	with	with	IN	_	16	case
15	other	other	JJ	_	16	amod
16	medications	medication	NNS	_	13	nmod
17	used	use	VBN	_	16	acl
18	in	in	IN	_	20	case
19	the	the	DT	_	20	det
20	treatment	treatment	NN	_	17	nmod
21	of	of	IN	_	24	case
22	hypoxic	hypoxic	JJ	_	24	amod
23	respiratory	respiratory	JJ	_	24	amod
24	failure	failure	NN	_	20	nmod
25	can	can	MD	_	28	aux
26	not	not	RB	_	28	neg
27	be	be	VB	_	28	auxpass
28	excluded	exclude	VBN	_	7	conj
29	based	base	VBN	_	33	case
30	on	on	IN	_	33	case
31	the	the	DT	_	33	det
32	available	available	JJ	_	33	amod
33	data	datum	NNS	_	28	advcl
34	.	.	.	_	7	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	administered	administer	VBN	_	0	ROOT
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	,	,	,	_	6	punct
8	drug3	drug3	NN	_	6	conj
9	,	,	,	_	6	punct
10	drug4	drug4	NN	_	6	conj
11	,	,	,	_	6	punct
12	drug5	drug5	NN	_	6	conj
13	,	,	,	_	6	punct
14	drug6	drug6	NN	_	6	conj
15	,	,	,	_	6	punct
16	and	and	CC	_	6	cc
17	high-frequency	high-frequency	VB	_	6	conj
18	ventilation	ventilation	NN	_	17	dobj
19	.	.	.	_	4	punct

1	Although	although	IN	_	3	mark
2	there	there	EX	_	3	expl
3	are	be	VBP	_	20	advcl
4	no	no	DT	_	6	neg
5	study	study	NN	_	6	compound
6	data	datum	NNS	_	3	nsubj
7	to	to	TO	_	8	mark
8	evaluate	evaluate	VB	_	6	acl
9	the	the	DT	_	10	det
10	possibility	possibility	NN	_	8	dobj
11	,	,	,	_	10	punct
12	drug1	drug1	NN	_	10	appos
13	,	,	,	_	10	punct
14	including	include	VBG	_	15	case
15	drug2	drug2	NN	_	10	nmod
16	and	and	CC	_	15	cc
17	drug3	drug3	NN	_	15	conj
18	,	,	,	_	20	punct
19	may	may	MD	_	20	aux
20	have	have	VB	_	0	ROOT
21	an	a	DT	_	23	det
22	additive	additive	JJ	_	23	amod
23	effect	effect	NN	_	20	dobj
24	with	with	IN	_	25	case
25	drug4	drug4	NN	_	23	nmod
26	on	on	IN	_	28	case
27	the	the	DT	_	28	det
28	risk	risk	NN	_	20	nmod
29	of	of	IN	_	30	mark
30	developing	develop	VBG	_	28	acl
31	methemoglobinemia	methemoglobinemia	NN	_	30	dobj
32	.	.	.	_	20	punct

1	An	a	DT	_	2	det
2	association	association	NN	_	19	nsubjpass
3	between	between	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	an	a	DT	_	8	det
7	increased	increase	VBN	_	8	amod
8	risk	risk	NN	_	4	conj
9	of	of	IN	_	10	case
10	methaemoglobinaemia	methaemoglobinaemia	NN	_	8	nmod
11	,	,	,	_	2	punct
12	particularly	particularly	RB	_	14	advmod
13	in	in	IN	_	14	case
14	infants	infant	NNS	_	2	nmod
15	,	,	,	_	2	punct
16	has	have	VBZ	_	19	aux
17	specifically	specifically	RB	_	19	advmod
18	been	be	VBN	_	19	auxpass
19	described	describe	VBN	_	0	ROOT
20	in	in	IN	_	24	case
21	a	a	DT	_	24	det
22	literature	literature	NN	_	24	compound
23	case	case	NN	_	24	compound
24	report	report	NN	_	19	nmod
25	.	.	.	_	19	punct

1	This	this	DT	_	2	det
2	risk	risk	NN	_	4	nsubj
3	is	be	VBZ	_	4	cop
4	present	present	JJ	_	0	ROOT
5	whether	whether	IN	_	9	mark
6	the	the	DT	_	7	det
7	drugs	drug	NNS	_	9	nsubjpass
8	are	be	VBP	_	9	auxpass
9	administered	administer	VBN	_	4	ccomp
10	as	as	IN	_	11	case
11	oral	oral	JJ	_	9	nmod
12	,	,	,	_	11	punct
13	parenteral	parenteral	JJ	_	11	conj
14	,	,	,	_	11	punct
15	or	or	CC	_	11	cc
16	topical	topical	JJ	_	17	amod
17	formulations	formulation	NNS	_	11	conj
18	.	.	.	_	4	punct

1	Interactions	interaction	NNS	_	3	nsubj
2	may	may	MD	_	3	aux
3	occur	occur	VB	_	0	ROOT
4	with	with	IN	_	6	case
5	the	the	DT	_	6	det
6	following	following	NN	_	3	nmod
7	:	:	:	_	3	punct
8	adrenocorticoids	adrenocorticoid	NNS	_	26	nsubj
9	-LRB-	-lrb-	-LRB-	_	11	punct
10	cortisone-like	cortisone-like	JJ	_	11	amod
11	medicine	medicine	NN	_	8	appos
12	-RRB-	-rrb-	-RRB-	_	11	punct
13	,	,	,	_	8	punct
14	drug1	drug1	NN	_	17	compound
15	-LRB-	-lrb-	-LRB-	_	17	punct
16	drug2	drug2	NN	_	17	compound
17	s	s	NNS	_	8	appos
18	-RRB-	-rrb-	-RRB-	_	17	punct
19	,	,	,	_	8	punct
20	drug3	drug3	NN	_	8	appos
21	,	,	,	_	8	punct
22	drug4	drug4	NN	_	24	compound
23	-LRB-	-lrb-	-LRB-	_	24	punct
24	drug5	drug5	NN	_	8	appos
25	may	may	MD	_	26	aux
26	decrease	decrease	VB	_	3	parataxis
27	the	the	DT	_	28	det
28	effects	effect	NNS	_	26	dobj
29	of	of	IN	_	31	case
30	these	these	DT	_	31	det
31	medicines	medicine	NNS	_	28	nmod
32	-RRB-	-rrb-	-RRB-	_	31	punct
33	,	,	,	_	31	punct
34	drug6	drug6	NN	_	31	appos
35	-LRB-	-lrb-	-LRB-	_	36	punct
36	using	use	VBG	_	42	csubj
37	these	these	DT	_	38	det
38	medicines	medicine	NNS	_	36	dobj
39	with	with	IN	_	40	case
40	drug7	drug7	NN	_	36	nmod
41	may	may	MD	_	42	aux
42	result	result	VB	_	34	acl:relcl
43	in	in	IN	_	47	case
44	increased	increase	VBN	_	47	amod
45	CNS	cns	NN	_	47	compound
46	depressant	depressant	NN	_	47	compound
47	effects	effect	NNS	_	42	nmod
48	-RRB-	-rrb-	-RRB-	_	26	punct
49	,	,	,	_	26	punct
50	drug8	drug8	NN	_	60	nsubj
51	,	,	,	_	50	punct
52	drug9	drug9	NN	_	50	appos
53	-LRB-	-lrb-	-LRB-	_	50	punct
54	using	use	VBG	_	50	acl
55	these	these	DT	_	56	det
56	medicines	medicine	NNS	_	54	dobj
57	with	with	IN	_	58	case
58	drug10	drug10	NN	_	54	nmod
59	may	may	MD	_	60	aux
60	change	change	VB	_	26	parataxis
61	the	the	DT	_	62	det
62	amount	amount	NN	_	60	dobj
63	of	of	IN	_	65	case
64	either	either	CC	_	65	det
65	medicine	medicine	NN	_	62	nmod
66	that	that	IN	_	68	dobj
67	you	you	PRP	_	68	nsubj
68	need	need	VBP	_	62	acl:relcl
69	to	to	TO	_	70	mark
70	take	take	VB	_	68	xcomp
71	-RRB-	-rrb-	-RRB-	_	60	punct
72	,	,	,	_	26	punct
73	and	and	CC	_	26	cc
74	oral	oral	JJ	_	75	amod
75	drug11	drug11	NN	_	81	nsubj
76	containing	contain	VBG	_	75	acl
77	drug12	drug12	NN	_	79	compound
78	-LRB-	-lrb-	-LRB-	_	79	punct
79	drug13	drug13	NN	_	76	dobj
80	may	may	MD	_	81	aux
81	decrease	decrease	VB	_	26	conj
82	the	the	DT	_	83	det
83	effectiveness	effectiveness	NN	_	81	dobj
84	of	of	IN	_	87	case
85	these	these	DT	_	87	det
86	oral	oral	JJ	_	87	amod
87	drug14	drug14	NN	_	83	nmod
88	,	,	,	_	26	punct
89	and	and	CC	_	26	cc
90	you	you	PRP	_	92	nsubj
91	may	may	MD	_	92	aux
92	need	need	VB	_	26	conj
93	to	to	TO	_	94	mark
94	change	change	VB	_	92	xcomp
95	to	to	TO	_	98	case
96	a	a	DT	_	98	det
97	different	different	JJ	_	98	amod
98	type	type	NN	_	94	nmod
99	of	of	IN	_	101	case
100	birth	birth	NN	_	101	compound
101	control	control	NN	_	98	nmod
102	-RRB-	-rrb-	-RRB-	_	26	punct
103	.	.	.	_	3	punct

1	A	a	DT	_	4	det
2	drug-drug	drug-drug	JJ	_	4	amod
3	interaction	interaction	NN	_	4	compound
4	study	study	NN	_	5	nsubj
5	evaluated	evaluate	VBD	_	0	ROOT
6	the	the	DT	_	7	det
7	effect	effect	NN	_	5	dobj
8	of	of	IN	_	10	case
9	the	the	DT	_	10	det
10	use	use	NN	_	7	nmod
11	of	of	IN	_	13	case
12	drug1	drug1	NN	_	13	compound
13	Gel	gel	NN	_	10	nmod
14	,	,	,	_	13	punct
15	5	5	CD	_	16	nummod
16	%	%	NN	_	13	appos
17	,	,	,	_	13	punct
18	in	in	IN	_	19	case
19	combination	combination	NN	_	7	nmod
20	with	with	IN	_	22	case
21	double	double	JJ	_	22	amod
22	strength	strength	NN	_	19	nmod
23	-LRB-	-lrb-	-LRB-	_	26	punct
24	160	160	CD	_	26	nummod
25	mg/800	mg/800	NN	_	26	compound
26	mg	mg	NN	_	22	appos
27	-RRB-	-rrb-	-RRB-	_	26	punct
28	drug2	drug2	NN	_	22	dep
29	/	/	:	_	30	punct
30	drug3	drug3	NN	_	22	dep
31	-LRB-	-lrb-	-LRB-	_	32	punct
32	drug4	drug4	NN	_	30	dep
33	/	/	:	_	32	punct
34	drug5	drug5	NN	_	32	dep
35	-RRB-	-rrb-	-RRB-	_	32	punct
36	.	.	.	_	5	punct

1	During	during	IN	_	2	case
2	co-administration	co-administration	NN	_	12	nmod
3	,	,	,	_	12	punct
4	systemic	systemic	JJ	_	5	amod
5	levels	level	NNS	_	12	nsubj
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	were	be	VBD	_	12	cop
11	essentially	essentially	RB	_	12	advmod
12	unchanged	unchanged	JJ	_	0	ROOT
13	.	.	.	_	12	punct

1	Notably	notably	RB	_	16	advmod
2	,	,	,	_	16	punct
3	systemic	systemic	JJ	_	4	amod
4	exposure	exposure	NN	_	16	nsubjpass
5	-LRB-	-lrb-	-LRB-	_	6	punct
6	AUC0-12	auc0-12	NN	_	4	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	4	nmod
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	drug2	drug2	NN	_	9	appos
12	-RRB-	-rrb-	-RRB-	_	11	punct
13	was	be	VBD	_	16	auxpass
14	more	more	JJR	_	16	advmod
15	than	than	IN	_	14	case
16	doubled	double	VBN	_	0	ROOT
17	in	in	IN	_	21	case
18	the	the	DT	_	21	dep
19	presence	presence	NN	_	21	dep
20	of	of	IN	_	21	case
21	drug3	drug3	NN	_	16	nmod
22	/	/	:	_	21	punct
23	drug4	drug4	NN	_	21	dep
24	.	.	.	_	16	punct

1	Exposure	exposure	NN	_	10	nsubj
2	from	from	IN	_	6	case
3	the	the	DT	_	6	det
4	proposed	propose	VBN	_	6	amod
5	topical	topical	JJ	_	6	amod
6	dose	dose	NN	_	1	nmod
7	is	be	VBZ	_	10	cop
8	about	about	IN	_	9	advmod
9	1	1	CD	_	10	nummod
10	%	%	NN	_	0	ROOT
11	of	of	IN	_	12	case
12	that	that	DT	_	10	nmod
13	from	from	IN	_	18	case
14	the	the	DT	_	18	det
15	100	100	CD	_	18	nummod
16	mg	mg	NN	_	18	compound
17	oral	oral	JJ	_	18	amod
18	dose	dose	NN	_	12	nmod
19	,	,	,	_	10	punct
20	even	even	RB	_	21	advmod
21	when	when	WRB	_	22	advmod
22	co-administered	co-administer	VBN	_	26	dep
23	with	with	IN	_	24	case
24	drug1	drug1	NN	_	22	nmod
25	/	/	:	_	26	punct
26	drug2	drug2	NN	_	10	parataxis
27	.	.	.	_	10	punct

1	Certain	certain	JJ	_	3	amod
2	concomitant	concomitant	JJ	_	3	amod
3	medications	medication	NNS	_	0	ROOT
4	-LRB-	-lrb-	-LRB-	_	7	punct
5	such	such	JJ	_	7	case
6	as	as	IN	_	5	mwe
7	drug1	drug1	NN	_	3	nmod
8	,	,	,	_	7	punct
9	drug2	drug2	NN	_	7	conj
10	,	,	,	_	7	punct
11	St.	St.	NNP	_	7	appos

1	John	John	NNP	_	3	compound
2	s	be	VBZ	_	3	compound
3	wort	wort	NN	_	6	nsubj
4	-RRB-	-rrb-	-RRB-	_	3	punct
5	may	may	MD	_	6	aux
6	increase	increase	VB	_	0	ROOT
7	the	the	DT	_	8	det
8	formation	formation	NN	_	6	dobj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	,	,	,	_	10	punct
12	a	a	DT	_	13	det
13	metabolite	metabolite	NN	_	10	appos
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	associated	associate	VBN	_	13	acl
17	with	with	IN	_	18	case
18	hemolysis	hemolysis	NN	_	16	nmod
19	.	.	.	_	6	punct

1	With	with	IN	_	4	case
2	oral	oral	JJ	_	4	amod
3	drug1	drug1	NN	_	4	compound
4	treatment	treatment	NN	_	12	nmod
5	,	,	,	_	12	punct
6	drug2	drug2	NN	_	12	nsubjpass
7	such	such	JJ	_	9	case
8	as	as	IN	_	7	mwe
9	drug3	drug3	NN	_	6	nmod
10	have	have	VBP	_	12	aux
11	been	be	VBN	_	12	auxpass
12	noted	note	VBN	_	0	ROOT
13	to	to	TO	_	15	mark
14	possibly	possibly	RB	_	15	advmod
15	increase	increase	VB	_	12	xcomp
16	the	the	DT	_	17	det
17	likelihood	likelihood	NN	_	15	dobj
18	of	of	IN	_	20	case
19	hematologic	hematologic	JJ	_	20	amod
20	reactions	reaction	NNS	_	17	nmod

1	.	.	.	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	An	a	DT	_	3	det
2	encephalopathic	encephalopathic	JJ	_	3	amod
3	syndrome	syndrome	NN	_	37	nsubj
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	characterized	characterize	VBN	_	3	dep
6	by	by	IN	_	7	case
7	weakness	weakness	NN	_	5	nmod
8	,	,	,	_	7	punct
9	lethargy	lethargy	NN	_	7	conj
10	,	,	,	_	7	punct
11	fever	fever	NN	_	7	conj
12	,	,	,	_	7	punct
13	tremulousness	tremulousness	NN	_	7	conj
14	and	and	CC	_	7	cc
15	confusion	confusion	NN	_	7	conj
16	,	,	,	_	5	punct
17	extrapyramidal	extrapyramidal	JJ	_	18	amod
18	symptoms	symptom	NNS	_	5	dep
19	,	,	,	_	18	punct
20	leukocytosis	leukocytosis	NN	_	18	conj
21	,	,	,	_	18	punct
22	elevated	elevated	JJ	_	24	amod
23	serum	serum	NN	_	24	compound
24	enzymes	enzyme	NNS	_	18	conj
25	,	,	,	_	18	punct
26	BUN	bun	NN	_	18	conj
27	,	,	,	_	18	punct
28	and	and	CC	_	18	cc
29	FBS	fbs	NN	_	18	conj
30	-RRB-	-rrb-	-RRB-	_	5	punct
31	followed	follow	VBN	_	3	acl
32	by	by	IN	_	35	case
33	irreversible	irreversible	JJ	_	35	amod
34	brain	brain	NN	_	35	compound
35	damage	damage	NN	_	31	nmod
36	has	have	VBZ	_	37	aux
37	occurred	occur	VBN	_	0	ROOT
38	in	in	IN	_	41	case
39	a	a	DT	_	41	det
40	few	few	JJ	_	41	amod
41	patients	patient	NNS	_	37	nmod
42	treated	treat	VBN	_	41	acl
43	with	with	IN	_	44	case
44	drug1	drug1	NN	_	42	nmod
45	plus	plus	CC	_	44	cc
46	drug2	drug2	NN	_	44	conj
47	.	.	.	_	37	punct

1	A	a	DT	_	3	det
2	causal	causal	JJ	_	3	amod
3	relationship	relationship	NN	_	18	nsubjpass
4	between	between	IN	_	6	case
5	these	these	DT	_	6	det
6	events	event	NNS	_	3	nmod
7	and	and	CC	_	6	cc
8	the	the	DT	_	10	det
9	concomitant	concomitant	JJ	_	10	amod
10	administration	administration	NN	_	6	conj
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	and	and	CC	_	12	cc
14	drug2	drug2	NN	_	12	conj
15	has	have	VBZ	_	18	aux
16	not	not	RB	_	18	neg
17	been	be	VBN	_	18	auxpass
18	established	establish	VBN	_	0	ROOT
19	;	;	:	_	18	punct

1	however	however	RB	_	10	advmod
2	,	,	,	_	10	punct
3	patients	patient	NNS	_	10	nsubjpass
4	receiving	receive	VBG	_	3	acl
5	such	such	JJ	_	7	amod
6	combined	combined	JJ	_	7	amod
7	therapy	therapy	NN	_	4	dobj
8	should	should	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	monitored	monitor	VBN	_	0	ROOT
11	closely	closely	RB	_	10	advmod
12	for	for	IN	_	14	case
13	early	early	JJ	_	14	amod
14	evidence	evidence	NN	_	10	nmod
15	of	of	IN	_	17	case
16	neurological	neurological	JJ	_	17	amod
17	toxicity	toxicity	NN	_	14	nmod
18	and	and	CC	_	17	cc
19	treatment	treatment	NN	_	17	conj
20	discontinued	discontinue	VBN	_	14	acl
21	promptly	promptly	RB	_	20	advmod
22	if	if	IN	_	25	mark
23	such	such	JJ	_	24	amod
24	signs	sign	NNS	_	25	nsubj
25	appear	appear	VBP	_	20	advcl
26	.	.	.	_	10	punct

1	As	as	IN	_	4	case
2	with	with	IN	_	4	case
3	other	other	JJ	_	4	amod
4	drug1	drug1	NN	_	9	nmod
5	,	,	,	_	9	punct
6	it	it	PRP	_	9	nsubjpass
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	noted	note	VBN	_	0	ROOT
10	that	that	IN	_	14	mark
11	drug2	drug2	NN	_	14	nsubj
12	may	may	MD	_	14	aux
13	be	be	VB	_	14	cop
14	capable	capable	JJ	_	9	ccomp
15	of	of	IN	_	16	mark
16	potentiating	potentiate	VBG	_	14	advcl
17	drug3	drug3	NN	_	16	dobj
18	such	such	JJ	_	20	case
19	as	as	IN	_	18	mwe
20	drug4	drug4	NN	_	17	nmod
21	,	,	,	_	20	punct
22	drug5	drug5	NN	_	20	conj
23	,	,	,	_	20	punct
24	and	and	CC	_	20	cc
25	drug6	drug6	NN	_	20	conj
26	.	.	.	_	9	punct

1	In	in	IN	_	3	case
2	a	a	DT	_	3	det
3	study	study	NN	_	18	nmod
4	of	of	IN	_	7	case
5	12	12	CD	_	7	nummod
6	schizophrenic	schizophrenic	JJ	_	7	amod
7	patients	patient	NNS	_	3	nmod
8	coadministered	coadminister	VBN	_	7	acl
9	oral	oral	JJ	_	10	amod
10	drug1	drug1	NN	_	8	dobj
11	and	and	CC	_	10	cc
12	drug2	drug2	NN	_	10	conj
13	,	,	,	_	18	punct
14	plasma	plasma	NN	_	16	compound
15	drug3	drug3	NN	_	16	compound
16	levels	level	NNS	_	18	nsubjpass
17	were	be	VBD	_	18	auxpass
18	decreased	decrease	VBN	_	0	ROOT
19	by	by	IN	_	21	case
20	a	a	DT	_	21	det
21	mean	mean	NN	_	18	nmod
22	of	of	IN	_	24	case
23	70	70	CD	_	24	nummod
24	%	%	NN	_	21	nmod
25	and	and	CC	_	18	cc
26	mean	mean	VB	_	18	conj
27	scores	score	NNS	_	35	nsubjpass
28	on	on	IN	_	33	case
29	the	the	DT	_	33	det
30	Brief	brief	JJ	_	33	amod
31	Psychiatric	psychiatric	JJ	_	33	amod
32	Rating	Rating	NNP	_	33	compound
33	Scale	Scale	NNP	_	27	nmod
34	were	be	VBD	_	35	auxpass
35	increased	increase	VBN	_	26	ccomp
36	from	from	IN	_	37	case
37	baseline	baseline	NN	_	35	nmod
38	.	.	.	_	18	punct

1	In	in	IN	_	5	case
2	5	5	CD	_	5	nummod
3	other	other	JJ	_	5	amod
4	schizophrenic	schizophrenic	JJ	_	5	amod
5	patients	patient	NNS	_	16	nmod
6	treated	treat	VBN	_	5	acl
7	with	with	IN	_	9	case
8	oral	oral	JJ	_	9	amod
9	drug1	drug1	NN	_	6	nmod
10	and	and	CC	_	9	cc
11	drug2	drug2	NN	_	9	conj
12	,	,	,	_	16	punct
13	discontinuation	discontinuation	NN	_	16	nsubj
14	of	of	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	produced	produce	VBD	_	0	ROOT
17	a	a	DT	_	20	det
18	mean	mean	JJ	_	20	amod
19	3.3-fold	3.3-fold	RB	_	20	advmod
20	increase	increase	VB	_	16	dobj
21	in	in	IN	_	23	case
22	drug4	drug4	NN	_	23	compound
23	concentrations	concentration	NNS	_	20	nmod
24	.	.	.	_	16	punct

1	Thus	thus	RB	_	9	advmod
2	,	,	,	_	9	punct
3	careful	careful	JJ	_	4	amod
4	monitoring	monitoring	NN	_	9	nsubjpass
5	of	of	IN	_	7	case
6	clinical	clinical	JJ	_	7	amod
7	status	status	NN	_	4	nmod
8	is	be	VBZ	_	9	auxpass
9	warranted	warrant	VBN	_	0	ROOT
10	when	when	WRB	_	13	advmod
11	drug1	drug1	NN	_	13	nsubjpass
12	is	be	VBZ	_	13	auxpass
13	administered	administer	VBN	_	9	advcl
14	or	or	CC	_	13	cc
15	discontinued	discontinue	VBN	_	13	conj
16	in	in	IN	_	17	case
17	drug2	drug2	NN	_	13	nmod
18	-	-	:	_	13	punct
19	treated	treated	JJ	_	20	amod
20	patients	patient	NNS	_	13	dobj
21	.	.	.	_	9	punct

1	Food	Food	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	drug1	drug1	NN	_	7	nsubjpass
4	should	should	MD	_	7	aux
5	not	not	RB	_	7	neg
6	be	be	VB	_	7	auxpass
7	administered	administer	VBN	_	1	appos
8	with	with	IN	_	9	case
9	food	food	NN	_	7	nmod
10	.	.	.	_	1	punct

1	Studies	study	NNS	_	3	nsubj
2	have	have	VBP	_	3	aux
3	shown	show	VBN	_	0	ROOT
4	that	that	IN	_	10	mark
5	the	the	DT	_	6	det
6	bioavailability	bioavailability	NN	_	10	nsubjpass
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	is	be	VBZ	_	10	auxpass
10	reduced	reduce	VBN	_	3	ccomp
11	significantly	significantly	RB	_	10	advmod
12	when	when	WRB	_	13	advmod
13	administered	administer	VBN	_	10	advcl
14	with	with	IN	_	15	case
15	food	food	NN	_	13	nmod
16	.	.	.	_	3	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	A	a	DT	_	4	det
4	report	report	NN	_	10	nsubjpass
5	of	of	IN	_	8	case
6	severe	severe	JJ	_	8	amod
7	drug2	drug2	NN	_	8	compound
8	toxicity	toxicity	NN	_	4	nmod
9	was	be	VBD	_	10	auxpass
10	reported	report	VBN	_	1	appos
11	in	in	IN	_	13	case
12	a	a	DT	_	13	det
13	patient	patient	NN	_	10	nmod
14	receiving	receive	VBG	_	13	acl
15	drug3	drug3	NN	_	14	dobj
16	.	.	.	_	1	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	believed	believe	VBN	_	28	csubjpass
4	that	that	IN	_	9	mark
5	the	the	DT	_	6	det
6	toxicity	toxicity	NN	_	9	nsubj
7	may	may	MD	_	9	aux
8	have	have	VB	_	9	aux
9	resulted	result	VBN	_	3	ccomp
10	from	from	IN	_	14	case
11	a	a	DT	_	14	det
12	previously	previously	RB	_	13	advmod
13	unrecognized	unrecognized	JJ	_	14	amod
14	interaction	interaction	NN	_	9	nmod
15	between	between	IN	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	and	and	CC	_	16	cc
18	drug2	drug2	NN	_	16	conj
19	and	and	CC	_	16	cc
20	a	a	DT	_	22	det
21	molecular	molecular	JJ	_	22	amod
22	basis	basis	NN	_	16	conj
23	for	for	IN	_	25	case
24	this	this	DT	_	25	det
25	interaction	interaction	NN	_	22	nmod
26	has	have	VBZ	_	28	aux
27	been	be	VBN	_	28	auxpass
28	proposed	propose	VBN	_	0	ROOT
29	.	.	.	_	28	punct

1	However	however	RB	_	5	advmod
2	,	,	,	_	5	punct
3	current	current	JJ	_	4	amod
4	evidence	evidence	NN	_	5	nsubj
5	suggests	suggest	VBZ	_	0	ROOT
6	that	that	IN	_	9	mark
7	drug1	drug1	NN	_	9	nsubj
8	does	do	VBZ	_	9	aux
9	induce	induce	VB	_	5	ccomp
10	P-450IIE1	p-450iie1	NN	_	9	dobj
11	,	,	,	_	10	punct
12	a	a	DT	_	15	det
13	mixed-function	mixed-function	NN	_	15	compound
14	oxidase	oxidase	NN	_	15	compound
15	enzyme	enzyme	NN	_	10	appos
16	that	that	WDT	_	17	nsubj
17	appears	appear	VBZ	_	15	acl:relcl
18	to	to	TO	_	19	mark
19	generate	generate	VB	_	17	xcomp
20	the	the	DT	_	22	det
21	toxic	toxic	JJ	_	22	amod
22	metabolites	metabolite	NNS	_	19	dobj
23	,	,	,	_	10	punct
24	in	in	IN	_	26	case
25	the	the	DT	_	26	det
26	liver	liver	NN	_	9	nmod
27	.	.	.	_	5	punct

1	Furthermore	furthermore	RB	_	5	advmod
2	it	it	PRP	_	5	nsubjpass
3	has	have	VBZ	_	5	aux
4	been	be	VBN	_	5	auxpass
5	proposed	propose	VBN	_	0	ROOT
6	that	that	IN	_	8	mark
7	drug1	drug1	NN	_	8	nsubj
8	resulted	result	VBD	_	5	ccomp
9	In	in	IN	_	10	case
10	induction	induction	NN	_	8	nmod
11	of	of	IN	_	12	case
12	P-450IIE1	p-450iie1	NN	_	10	nmod
13	in	in	IN	_	15	case
14	the	the	DT	_	15	det
15	patients	patient	NNS	_	10	nmod
16	liver	liver	NN	_	15	dep
17	which	which	WDT	_	22	nsubj
18	,	,	,	_	22	punct
19	in	in	IN	_	20	case
20	turn	turn	NN	_	22	nmod
21	,	,	,	_	22	punct
22	resulted	result	VBD	_	16	acl:relcl
23	in	in	IN	_	26	case
24	a	a	DT	_	26	det
25	greater	greater	JJR	_	26	amod
26	proportion	proportion	NN	_	22	nmod
27	of	of	IN	_	30	case
28	the	the	DT	_	30	det
29	ingested	ingest	VBN	_	30	amod
30	drug2	drug2	NN	_	26	nmod
31	being	be	VBG	_	32	auxpass
32	converted	convert	VBN	_	30	acl
33	to	to	TO	_	36	case
34	the	the	DT	_	36	det
35	toxic	toxic	JJ	_	36	amod
36	metabolites	metabolite	NNS	_	32	nmod
37	.	.	.	_	5	punct

1	Studies	study	NNS	_	3	nsubj
2	have	have	VBP	_	3	aux
3	demonstrated	demonstrate	VBN	_	0	ROOT
4	that	that	IN	_	8	mark
5	pretreatment	pretreatment	NN	_	8	nsubj
6	with	with	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	potentiates	potentiate	VBZ	_	3	ccomp
9	a	a	DT	_	11	det
10	cetaminophen	cetaminophen	NN	_	11	compound
11	hepatoxicity	hepatoxicity	NN	_	8	dobj
12	in	in	IN	_	13	case
13	rats	rat	NNS	_	11	nmod
14	.	.	.	_	3	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	known	know	VBN	_	1	dep
6	to	to	TO	_	7	mark
7	slow	slow	VB	_	5	xcomp
8	the	the	DT	_	9	det
9	metabolism	metabolism	NN	_	7	dobj
10	of	of	IN	_	11	case
11	drug3	drug3	NN	_	9	nmod
12	and	and	CC	_	7	cc
13	increase	increase	VB	_	7	conj
14	its	its	PRP$	_	16	nmod:poss
15	serum	serum	NN	_	16	compound
16	levels	level	NNS	_	13	dobj
17	drug4	drug4	NN	_	18	compound
18	levels	level	NNS	_	7	dobj
19	should	should	MD	_	21	aux
20	be	be	VB	_	21	auxpass
21	determined	determine	VBN	_	5	xcomp
22	prior	prior	RB	_	21	advmod
23	to	to	TO	_	25	case
24	concurrent	concurrent	JJ	_	25	amod
25	administration	administration	NN	_	22	nmod
26	with	with	IN	_	27	case
27	drug5	drug5	NN	_	25	nmod
28	,	,	,	_	25	punct
29	signs	sign	NNS	_	25	conj
30	and	and	CC	_	25	cc
31	symptoms	symptom	NNS	_	25	conj
32	of	of	IN	_	34	case
33	drug6	drug6	NN	_	34	compound
34	toxicity	toxicity	NN	_	31	nmod
35	should	should	MD	_	37	aux
36	be	be	VB	_	37	auxpass
37	monitored	monitor	VBN	_	21	ccomp
38	closely	closely	RB	_	37	advmod
39	,	,	,	_	37	punct
40	and	and	CC	_	37	cc
41	appropriate	appropriate	JJ	_	43	amod
42	dosage	dosage	NN	_	43	compound
43	adjustment	adjustment	NN	_	49	nsubjpass
44	of	of	IN	_	46	case
45	the	the	DT	_	46	det
46	drug7	drug7	NN	_	43	nmod
47	should	should	MD	_	49	aux
48	be	be	VB	_	49	auxpass
49	made	make	VBN	_	37	conj
50	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Potential	potential	JJ	_	4	amod
4	interaction	interaction	NN	_	10	nsubj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	drug3	drug3	NN	_	6	conj
9	may	may	MD	_	10	aux
10	exist	exist	VB	_	1	dep
11	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	increase	increase	VB	_	1	appos
6	serum	serum	NN	_	7	compound
7	levels	level	NNS	_	5	dobj
8	of	of	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	.	.	.	_	1	punct

1	To	to	TO	_	2	mark
2	avoid	avoid	VB	_	13	csubjpass
3	drug1	drug1	NN	_	4	compound
4	intoxication	intoxication	NN	_	2	dobj
5	,	,	,	_	4	punct
6	appropriate	appropriate	JJ	_	7	amod
7	adjustment	adjustment	NN	_	4	appos
8	of	of	IN	_	10	case
9	the	the	DT	_	10	det
10	drug2	drug2	NN	_	7	nmod
11	should	should	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	made	make	VBN	_	0	ROOT
14	.	.	.	_	13	punct

1	Therophylline	Therophylline	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	A	A	NNP	_	5	compound
4	recent	recent	JJ	_	5	amod
5	study	study	NN	_	7	nsubj
6	has	have	VBZ	_	7	aux
7	shown	show	VBN	_	1	dep
8	that	that	IN	_	16	mark
9	concomitan	concomitan	NN	_	10	compound
10	administration	administration	NN	_	16	nsubj
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	and	and	CC	_	12	cc
14	drug2	drug2	NN	_	12	conj
15	may	may	MD	_	16	aux
16	cause	cause	VB	_	7	ccomp
17	elevated	elevated	JJ	_	19	amod
18	plasma	plasma	NN	_	19	compound
19	levels	level	NNS	_	16	dobj
20	of	of	IN	_	21	case
21	drug3	drug3	NN	_	19	nmod
22	,	,	,	_	16	punct
23	and	and	CC	_	16	cc
24	in	in	IN	_	26	case
25	some	some	DT	_	26	det
26	instances	instance	NNS	_	16	conj
27	a	a	DT	_	29	det
28	slight	slight	JJ	_	29	amod
29	decrease	decrease	NN	_	26	dep
30	in	in	IN	_	32	case
31	the	the	DT	_	32	det
32	elimination	elimination	NN	_	29	nmod
33	of	of	IN	_	34	case
34	drug4	drug4	NN	_	32	nmod
35	.	.	.	_	1	punct

1	Since	since	IN	_	11	mark
2	the	the	DT	_	4	det
3	therapeutic	therapeutic	JJ	_	4	amod
4	range	range	NN	_	11	nsubj
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	is	be	VBZ	_	11	cop
8	narrow	narrow	JJ	_	11	amod
9	drug2	drug2	NN	_	11	compound
10	serum	serum	NN	_	11	compound
11	levels	level	NNS	_	0	ROOT
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	monitored	monitor	VBN	_	11	dep
15	closely	closely	RB	_	14	advmod
16	,	,	,	_	14	punct
17	and	and	CC	_	14	cc
18	appropriate	appropriate	JJ	_	20	amod
19	dosage	dosage	NN	_	20	compound
20	adjustments	adjustment	NNS	_	25	nsubjpass
21	of	of	IN	_	22	case
22	drug3	drug3	NN	_	20	nmod
23	should	should	MD	_	25	aux
24	be	be	VB	_	25	auxpass
25	made	make	VBN	_	14	conj
26	.	.	.	_	11	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	A	a	DT	_	6	det
4	recent	recent	JJ	_	6	amod
5	case	case	NN	_	6	compound
6	study	study	NN	_	8	nsubj
7	has	have	VBZ	_	8	aux
8	shown	show	VBN	_	1	dep
9	a	a	DT	_	11	det
10	possible	possible	JJ	_	11	amod
11	increase	increase	NN	_	8	dobj
12	in	in	IN	_	15	case
13	the	the	DT	_	15	det
14	plasma	plasma	NN	_	15	compound
15	level	level	NN	_	11	nmod
16	of	of	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	when	when	WRB	_	20	advmod
19	co	co	NN	_	20	nsubj
20	administered	administer	VBN	_	11	acl:relcl
21	with	with	IN	_	22	case
22	drug3	drug3	NN	_	20	nmod
23	.	.	.	_	1	punct

1	Plasma	plasma	NN	_	3	compound
2	drug1	drug1	NN	_	3	compound
3	concentration	concentration	NN	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	monitored	monitor	VBN	_	0	ROOT
7	when	when	WRB	_	13	advmod
8	drug2	drug2	NN	_	13	nsubjpass
9	and	and	CC	_	8	cc
10	drug3	drug3	NN	_	8	conj
11	are	be	VBP	_	13	auxpass
12	co	co	NN	_	13	nmod:npmod
13	administered	administer	VBN	_	6	advcl
14	,	,	,	_	6	punct
15	and	and	CC	_	6	cc
16	appropriate	appropriate	JJ	_	18	amod
17	dosage	dosage	NN	_	18	compound
18	adjustments	adjustment	NNS	_	23	nsubjpass
19	of	of	IN	_	20	case
20	drug4	drug4	NN	_	18	nmod
21	should	should	MD	_	23	aux
22	be	be	VB	_	23	auxpass
23	made	make	VBN	_	6	conj
24	.	.	.	_	6	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	administration	administration	NN	_	8	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	may	may	MD	_	8	aux
8	cause	cause	VB	_	0	ROOT
9	severe	severe	JJ	_	11	amod
10	orthostatic	orthostatic	JJ	_	11	amod
11	hypotension	hypotension	NN	_	8	dobj
12	.	.	.	_	8	punct
13	drug3	drug3	NN	_	22	nsubj
14	,	,	,	_	13	punct
15	an	a	DT	_	16	det
16	inhibitor	inhibitor	NN	_	13	appos
17	of	of	IN	_	20	case
18	microsomal	microsomal	JJ	_	20	amod
19	drug	drug	NN	_	20	compound
20	metabolism	metabolism	NN	_	16	nmod
21	,	,	,	_	13	punct
22	increased	increase	VBD	_	8	parataxis
23	drug4	drug4	NN	_	25	compound
24	s	s	NNS	_	25	compound
25	half-life	half-life	NN	_	22	dobj
26	and	and	CC	_	25	cc
27	toxicity	toxicity	NN	_	25	conj
28	in	in	IN	_	31	case
29	a	a	DT	_	31	det
30	rat	rat	NN	_	31	compound
31	model	model	NN	_	22	nmod
32	.	.	.	_	8	punct

1	Data	datum	NNS	_	17	nsubj
2	from	from	IN	_	5	case
3	a	a	DT	_	5	det
4	randomized	randomized	JJ	_	5	amod
5	trial	trial	NN	_	1	nmod
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	plus	plus	CC	_	7	cc
11	or	or	CC	_	7	cc
12	minus	minus	CC	_	13	case
13	drug3	drug3	NN	_	7	conj
14	in	in	IN	_	16	case
15	ovarian	ovarian	JJ	_	16	amod
16	cancer	cancer	NN	_	5	nmod
17	indicated	indicate	VBD	_	0	ROOT
18	that	that	IN	_	21	mark
19	drug4	drug4	NN	_	21	nsubj
20	significantly	significantly	RB	_	21	advmod
21	reduced	reduce	VBD	_	17	ccomp
22	neurotoxicity	neurotoxicity	NN	_	21	dobj
23	;	;	:	_	17	punct

1	however	however	RB	_	5	advmod
2	,	,	,	_	5	punct
3	it	it	PRP	_	5	nsubj
4	adversely	adversely	RB	_	5	advmod
5	affected	affect	VBD	_	0	ROOT
6	response	response	NN	_	7	compound
7	duration	duration	NN	_	5	dobj
8	suggesting	suggest	VBG	_	5	xcomp
9	that	that	IN	_	14	mark
10	drug1	drug1	NN	_	14	nsubjpass
11	should	should	MD	_	14	aux
12	not	not	RB	_	14	neg
13	be	be	VB	_	14	auxpass
14	administered	administer	VBN	_	8	ccomp
15	with	with	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	and/or	and/or	CC	_	16	cc
18	drug3	drug3	NN	_	16	conj
19	.1	.1	CD	_	18	nummod

1	No	no	DT	_	3	neg
2	Important	important	JJ	_	3	amod
3	Interactions	interaction	NNS	_	9	nsubj
4	To	to	TO	_	5	mark
5	Date	date	VB	_	3	acl
6	drug1	drug1	NN	_	5	dobj
7	does	do	VBZ	_	9	aux
8	not	not	RB	_	9	neg
9	have	have	VB	_	0	ROOT
10	clinically	clinically	RB	_	11	advmod
11	important	important	JJ	_	13	amod
12	pharmacokinetic	pharmacokinetic	JJ	_	13	amod
13	interactions	interaction	NNS	_	9	dobj
14	with	with	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	,	,	,	_	15	punct
17	drug3	drug3	NN	_	15	conj
18	,	,	,	_	15	punct
19	drug4	drug4	NN	_	15	conj
20	,	,	,	_	15	punct
21	drug5	drug5	NN	_	15	conj
22	,	,	,	_	15	punct
23	drug6	drug6	NN	_	15	conj
24	,	,	,	_	15	punct
25	drug7	drug7	NN	_	15	conj
26	,	,	,	_	15	punct
27	drug8	drug8	NN	_	15	conj
28	,	,	,	_	15	punct
29	drug9	drug9	NN	_	15	conj
30	or	or	CC	_	15	cc
31	drug10	drug10	NN	_	15	conj
32	.	.	.	_	9	punct

1	Drug	drug	NN	_	3	compound
2	interaction	interaction	NN	_	3	compound
3	studies	study	NNS	_	9	nsubjpass
4	with	with	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	have	have	VBP	_	9	aux
7	not	not	RB	_	9	neg
8	been	be	VBN	_	9	auxpass
9	performed	perform	VBN	_	0	ROOT
10	in	in	IN	_	11	case
11	patients	patient	NNS	_	9	nmod
12	with	with	IN	_	14	case
13	severe	severe	JJ	_	14	amod
14	sepsis	sepsis	NN	_	11	nmod
15	.	.	.	_	9	punct

1	However	however	RB	_	17	advmod
2	,	,	,	_	17	punct
3	since	since	IN	_	5	mark
4	there	there	EX	_	5	expl
5	is	be	VBZ	_	17	advcl
6	an	a	DT	_	8	det
7	increased	increase	VBN	_	8	amod
8	risk	risk	NN	_	5	nsubj
9	of	of	IN	_	10	mark
10	bleeding	bleed	VBG	_	8	acl
11	with	with	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	,	,	,	_	17	punct
14	caution	caution	NN	_	17	nsubjpass
15	should	should	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	employed	employ	VBN	_	0	ROOT
18	when	when	WRB	_	21	advmod
19	drug2	drug2	NN	_	21	nsubjpass
20	is	be	VBZ	_	21	auxpass
21	used	use	VBN	_	17	advcl
22	with	with	IN	_	24	case
23	other	other	JJ	_	24	amod
24	drugs	drug	NNS	_	21	nmod
25	that	that	WDT	_	26	nsubj
26	affect	affect	VBP	_	24	acl:relcl
27	hemostasis	hemostasis	NN	_	26	dobj
28	.	.	.	_	17	punct

1	Approximately	approximately	RB	_	2	advmod
2	2/3	2/3	CD	_	11	nsubj
3	of	of	IN	_	5	case
4	the	the	DT	_	5	det
5	patients	patient	NNS	_	2	nmod
6	in	in	IN	_	10	case
7	the	the	DT	_	10	det
8	Phase	phase	NN	_	10	compound
9	3	3	CD	_	10	nummod
10	study	study	NN	_	5	nmod
11	received	receive	VBD	_	0	ROOT
12	either	either	CC	_	16	cc:preconj
13	prophylactic	prophylactic	NN	_	16	compound
14	low	low	JJ	_	16	amod
15	dose	dose	NN	_	16	compound
16	drug1	drug1	NN	_	11	dobj
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	drug2	drug2	NN	_	16	appos
19	up	up	IN	_	21	advmod
20	to	to	TO	_	21	dep
21	15,000	15,000	CD	_	22	nummod
22	units/day	units/day	NNS	_	18	dep
23	-RRB-	-rrb-	-RRB-	_	18	punct
24	or	or	CC	_	16	cc
25	prophylactic	prophylactic	NN	_	26	compound
26	doses	dose	NNS	_	16	conj
27	of	of	IN	_	28	case
28	drug3	drug3	NN	_	26	nmod
29	as	as	IN	_	30	mark
30	indicated	indicate	VBN	_	11	advcl
31	in	in	IN	_	34	case
32	the	the	DT	_	34	det
33	prescribing	prescribe	VBG	_	34	amod
34	information	information	NN	_	30	nmod
35	for	for	IN	_	38	case
36	the	the	DT	_	38	det
37	specific	specific	JJ	_	38	amod
38	products	product	NNS	_	34	nmod
39	.	.	.	_	11	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	use	use	NN	_	10	nsubj
3	of	of	IN	_	7	case
4	prophylactic	prophylactic	NN	_	7	compound
5	low	low	JJ	_	7	amod
6	dose	dose	NN	_	7	compound
7	drug1	drug1	NN	_	2	nmod
8	did	do	VBD	_	10	aux
9	not	not	RB	_	10	neg
10	appear	appear	VB	_	0	ROOT
11	to	to	TO	_	12	mark
12	affect	affect	VB	_	10	xcomp
13	safety	safety	NN	_	12	dobj
14	,	,	,	_	10	punct
15	however	however	RB	_	10	advmod
16	,	,	,	_	10	punct
17	its	its	PRP$	_	18	nmod:poss
18	effects	effect	NNS	_	27	nsubjpass
19	on	on	IN	_	21	case
20	the	the	DT	_	21	det
21	efficacy	efficacy	NN	_	18	nmod
22	of	of	IN	_	23	case
23	drug2	drug2	NN	_	21	nmod
24	have	have	VBP	_	27	aux
25	not	not	RB	_	27	neg
26	been	be	VBN	_	27	auxpass
27	evaluated	evaluate	VBN	_	10	ccomp
28	in	in	IN	_	34	case
29	an	a	DT	_	34	det
30	adequate	adequate	JJ	_	34	amod
31	and	and	CC	_	30	cc
32	well-controlled	well-controlled	JJ	_	30	conj
33	clinical	clinical	JJ	_	34	amod
34	trial	trial	NN	_	27	nmod
35	.	.	.	_	10	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	3	amod
2	Test	test	NN	_	3	compound
3	Interaction	interaction	NN	_	18	nsubj
4	Because	because	IN	_	7	mark
5	drug1	drug1	NN	_	7	nsubj
6	may	may	MD	_	7	aux
7	affect	affect	VB	_	18	advcl
8	the	the	DT	_	10	det
9	APTT	aptt	NN	_	10	compound
10	assay	assay	NN	_	7	dobj
11	,	,	,	_	18	punct
12	drug2	drug2	NN	_	18	nsubj
13	present	present	JJ	_	12	amod
14	in	in	IN	_	16	case
15	plasma	plasma	NN	_	16	compound
16	samples	sample	NNS	_	13	nmod
17	may	may	MD	_	18	aux
18	interfere	interfere	VB	_	0	ROOT
19	with	with	IN	_	22	case
20	one-stage	one-stage	JJ	_	22	amod
21	coagulation	coagulation	NN	_	22	compound
22	assays	assay	NNS	_	18	nmod
23	based	base	VBN	_	26	case
24	on	on	IN	_	26	case
25	the	the	DT	_	26	det
26	APTT	APTT	NNP	_	22	nmod
27	-LRB-	-lrb-	-LRB-	_	30	punct
28	such	such	JJ	_	30	case
29	as	as	IN	_	28	mwe
30	factor	factor	NN	_	26	nmod
31	VIII	viii	CD	_	30	nummod
32	,	,	,	_	30	punct
33	IX	ix	CD	_	30	nummod
34	,	,	,	_	30	punct
35	and	and	CC	_	30	cc
36	XI	xi	NN	_	37	compound
37	assays	assay	NNS	_	30	conj
38	-RRB-	-rrb-	-RRB-	_	30	punct
39	.	.	.	_	18	punct

1	This	this	DT	_	2	det
2	interference	interference	NN	_	4	nsubj
3	may	may	MD	_	4	aux
4	result	result	VB	_	0	ROOT
5	in	in	IN	_	9	case
6	an	a	DT	_	9	det
7	apparent	apparent	JJ	_	9	amod
8	factor	factor	NN	_	9	compound
9	concentration	concentration	NN	_	4	nmod
10	that	that	WDT	_	12	nsubj
11	is	be	VBZ	_	12	cop
12	lower	lower	JJR	_	9	acl:relcl
13	than	than	IN	_	16	case
14	the	the	DT	_	16	det
15	true	true	JJ	_	16	amod
16	concentration	concentration	NN	_	12	nmod
17	.	.	.	_	4	punct

1	drug1	drug1	NN	_	8	nsubj
2	present	present	JJ	_	1	amod
3	in	in	IN	_	5	case
4	plasma	plasma	NN	_	5	compound
5	samples	sample	NNS	_	2	nmod
6	does	do	VBZ	_	8	aux
7	not	not	RB	_	8	neg
8	interfere	interfere	VB	_	0	ROOT
9	with	with	IN	_	12	case
10	one-stage	one-stage	JJ	_	12	amod
11	factor	factor	NN	_	12	compound
12	assays	assay	NNS	_	8	nmod
13	based	base	VBN	_	16	case
14	on	on	IN	_	16	case
15	the	the	DT	_	16	det
16	PT	pt	NN	_	12	nmod
17	-LRB-	-lrb-	-LRB-	_	20	punct
18	such	such	JJ	_	20	case
19	as	as	IN	_	18	mwe
20	factor	factor	NN	_	16	nmod
21	II	ii	CD	_	20	nummod
22	,	,	,	_	20	punct
23	V	v	NN	_	20	appos
24	,	,	,	_	20	punct
25	VII	vii	NN	_	20	conj
26	,	,	,	_	20	punct
27	and	and	CC	_	20	cc
28	X	x	NN	_	29	compound
29	assays	assay	NNS	_	20	conj
30	-RRB-	-rrb-	-RRB-	_	20	punct
31	.	.	.	_	8	punct

1	There	there	EX	_	2	expl
2	is	be	VBZ	_	0	ROOT
3	no	no	DT	_	6	neg
4	known	known	JJ	_	6	amod
5	drug	drug	NN	_	6	compound
6	interference	interference	NN	_	2	nsubj
7	with	with	IN	_	11	case
8	standard	standard	JJ	_	11	amod
9	clinical	clinical	JJ	_	11	amod
10	laboratory	laboratory	NN	_	11	compound
11	tests	test	NNS	_	6	nmod
12	.	.	.	_	2	punct

1	drug1	drug1	NN	_	2	nsubj
2	enhance	enhance	VBP	_	0	ROOT
3	the	the	DT	_	5	det
4	renal	renal	JJ	_	5	amod
5	toxicity	toxicity	NN	_	2	dobj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	in	in	IN	_	9	case
9	animals	animal	NNS	_	5	nmod
10	.	.	.	_	2	punct
11	7	7	CD	_	12	nummod
12	drug3	drug3	NN	_	13	nsubj
13	interferes	interfere	VBZ	_	2	parataxis
14	with	with	IN	_	16	case
15	the	the	DT	_	16	det
16	action	action	NN	_	13	nmod
17	of	of	IN	_	19	case
18	drug4	drug4	NN	_	19	compound
19	preparations	preparation	NNS	_	16	nmod
20	by	by	IN	_	21	mark
21	chelating	chelate	VBG	_	13	advcl
22	the	the	DT	_	23	det
23	drug5	drug5	NN	_	21	dobj
24	.	.	.	_	2	punct
25	7	7	CD	_	2	parataxis

1	drug1	drug1	NN	_	3	nsubj
2	can	can	MD	_	3	aux
3	interact	interact	VB	_	0	ROOT
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	or	or	CC	_	5	cc
7	other	other	JJ	_	8	amod
8	drug3	drug3	NN	_	5	conj
9	-LRB-	-lrb-	-LRB-	_	11	punct
10	may	may	MD	_	11	aux
11	potentiate	potentiate	VB	_	3	dep
12	the	the	DT	_	15	det
13	CNS	cns	NN	_	15	compound
14	depressant	depressant	NN	_	15	compound
15	effects	effect	NNS	_	11	dobj
16	of	of	IN	_	19	case
17	either	either	CC	_	19	cc:preconj
18	these	these	DT	_	19	det
19	medications	medication	NNS	_	15	nmod
20	or	or	CC	_	19	cc
21	drug4	drug4	NN	_	19	conj
22	-RRB-	-rrb-	-RRB-	_	19	punct
23	,	,	,	_	19	punct
24	drug5	drug5	NN	_	19	conj
25	or	or	CC	_	19	cc
26	other	other	JJ	_	27	amod
27	medications	medication	NNS	_	19	conj
28	with	with	IN	_	30	case
29	anticholinergic	anticholinergic	JJ	_	30	amod
30	activity	activity	NN	_	27	nmod
31	-LRB-	-lrb-	-LRB-	_	33	punct
32	anticholinergic	anticholinergic	JJ	_	33	amod
33	effects	effect	NNS	_	36	nsubjpass
34	may	may	MD	_	36	aux
35	be	be	VB	_	36	auxpass
36	potentiated	potentiate	VBN	_	11	ccomp
37	when	when	WRB	_	41	advmod
38	these	these	DT	_	39	det
39	medications	medication	NNS	_	41	nsubjpass
40	are	be	VBP	_	41	auxpass
41	used	use	VBN	_	36	advcl
42	concurrently	concurrently	RB	_	41	advmod
43	with	with	IN	_	44	case
44	drug6	drug6	NN	_	41	nmod
45	-RRB-	-rrb-	-RRB-	_	11	punct
46	,	,	,	_	3	punct
47	and	and	CC	_	3	cc
48	drug7	drug7	NN	_	3	conj
49	-LRB-	-lrb-	-LRB-	_	51	punct
50	concurrent	concurrent	JJ	_	51	amod
51	use	use	NN	_	55	nsubj
52	with	with	IN	_	53	case
53	drug8	drug8	NN	_	51	nmod
54	may	may	MD	_	55	aux
55	prolong	prolong	VB	_	48	acl:relcl
56	and	and	CC	_	55	cc
57	intensify	intensify	VB	_	55	conj
58	the	the	DT	_	63	det
59	anticholinergic	anticholinergic	JJ	_	63	amod
60	and	and	CC	_	59	cc
61	CNS	cns	NN	_	59	conj
62	depressant	depressant	NN	_	63	compound
63	effects	effect	NNS	_	57	dobj
64	of	of	IN	_	65	case
65	drug9	drug9	NN	_	63	nmod
66	-RRB-	-rrb-	-RRB-	_	48	punct
67	.	.	.	_	3	punct

1	A	a	DT	_	4	det
2	drug	drug	NN	_	4	compound
3	interaction	interaction	NN	_	4	compound
4	study	study	NN	_	6	nsubjpass
5	was	be	VBD	_	6	auxpass
6	performed	perform	VBN	_	0	ROOT
7	in	in	IN	_	8	case
8	which	which	WDT	_	11	nmod
9	drug1	drug1	NN	_	11	nsubjpass
10	was	be	VBD	_	11	auxpass
11	administered	administer	VBN	_	6	ccomp
12	in	in	IN	_	13	case
13	combination	combination	NN	_	11	nmod
14	with	with	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	.	.	.	_	6	punct

1	There	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	no	no	DT	_	4	neg
4	evidence	evidence	NN	_	2	nsubj
5	of	of	IN	_	8	case
6	any	any	DT	_	8	det
7	pharmacokinetic	pharmacokinetic	JJ	_	8	amod
8	interactions	interaction	NNS	_	4	nmod
9	between	between	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	drug2	drug2	NN	_	10	conj
13	.	.	.	_	2	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	exercised	exercise	VBN	_	0	ROOT
5	when	when	WRB	_	6	advmod
6	administering	administer	VBG	_	4	advcl
7	drug1	drug1	NN	_	6	dobj
8	with	with	IN	_	9	case
9	drugs	drug	NNS	_	6	nmod
10	that	that	WDT	_	12	nsubjpass
11	are	be	VBP	_	12	auxpass
12	known	know	VBN	_	9	acl:relcl
13	to	to	TO	_	14	mark
14	inhibit	inhibit	VB	_	12	xcomp
15	phosphatase	phosphatase	NN	_	16	compound
16	activities	activity	NNS	_	14	dobj
17	-LRB-	-lrb-	-LRB-	_	20	punct
18	e.g.	e.g.	FW	_	20	dep
19	,	,	,	_	20	punct
20	drug2	drug2	NN	_	16	dep
21	-RRB-	-rrb-	-RRB-	_	20	punct
22	.	.	.	_	4	punct

1	High-dose	high-dose	JJ	_	2	amod
2	drug1	drug1	NN	_	14	nsubj
3	resulting	result	VBG	_	2	acl
4	in	in	IN	_	5	case
5	concentrations	concentration	NNS	_	3	nmod
6	above	above	IN	_	8	case
7	2000	2000	CD	_	8	nummod
8	ng/mL	ng/ml	NN	_	5	nmod
9	administered	administer	VBN	_	5	acl
10	with	with	IN	_	12	case
11	oral	oral	JJ	_	12	amod
12	drug2	drug2	NN	_	9	nmod
13	has	have	VBZ	_	14	aux
14	led	lead	VBN	_	0	ROOT
15	to	to	TO	_	19	case
16	an	a	DT	_	19	det
17	80	80	CD	_	18	compound
18	%	%	NN	_	19	amod
19	increase	increase	NN	_	14	nmod
20	in	in	IN	_	22	case
21	drug3	drug3	NN	_	22	compound
22	exposure	exposure	NN	_	19	nmod
23	with	with	IN	_	27	case
24	a	a	DT	_	27	det
25	38	38	CD	_	26	compound
26	%	%	NN	_	27	amod
27	decrease	decrease	NN	_	19	nmod
28	in	in	IN	_	31	case
29	total	total	JJ	_	31	amod
30	body	body	NN	_	31	compound
31	clearance	clearance	NN	_	27	nmod
32	of	of	IN	_	33	case
33	drug4	drug4	NN	_	31	nmod
34	compared	compare	VBN	_	27	acl
35	to	to	TO	_	36	case
36	drug5	drug5	NN	_	34	nmod
37	alone	alone	RB	_	36	advmod
38	.	.	.	_	14	punct

1	drug1	drug1	NN	_	2	nsubj
2	inhibited	inhibit	VBD	_	0	ROOT
3	in	in	FW	_	6	amod
4	vitro	vitro	FW	_	3	dep
5	metabolic	metabolic	JJ	_	6	amod
6	reactions	reaction	NNS	_	2	dobj
7	catalyzed	catalyze	VBN	_	6	acl
8	by	by	IN	_	11	case
9	cytochromes	cytochrome	NNS	_	11	compound
10	P450	p450	NN	_	11	compound
11	1A2	1a2	NN	_	7	nmod
12	,	,	,	_	11	punct
13	2C8/9	2c8/9	NN	_	11	conj
14	,	,	,	_	11	punct
15	and	and	CC	_	11	cc
16	3A4	3a4	NN	_	11	conj
17	but	but	CC	_	2	cc
18	only	only	RB	_	22	advmod
19	at	at	IN	_	22	case
20	relatively	relatively	RB	_	21	advmod
21	high	high	JJ	_	22	amod
22	concentrations	concentration	NNS	_	2	conj
23	.	.	.	_	2	punct

1	drug1	drug1	NN	_	4	nsubj
2	did	do	VBD	_	4	aux
3	not	not	RB	_	4	neg
4	inhibit	inhibit	VB	_	0	ROOT
5	P450	p450	NN	_	6	compound
6	2A6	2a6	NN	_	4	dobj
7	or	or	CC	_	6	cc
8	the	the	DT	_	11	det
9	polymorphic	polymorphic	JJ	_	11	amod
10	P450	p450	NN	_	11	compound
11	2D6	2d6	NN	_	6	conj
12	in	in	IN	_	15	case
13	human	human	JJ	_	15	amod
14	liver	liver	NN	_	15	compound
15	microsomes	microsome	NNS	_	6	nmod
16	.	.	.	_	4	punct

1	drug1	drug1	NN	_	4	nsubj
2	did	do	VBD	_	4	aux
3	not	not	RB	_	4	neg
4	alter	alter	VB	_	0	ROOT
5	the	the	DT	_	6	det
6	pharmacokinetics	pharmacokinetic	NNS	_	4	dobj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	.	.	.	_	4	punct

1	Although	although	IN	_	8	mark
2	there	there	EX	_	8	expl
3	have	have	VBP	_	8	aux
4	been	be	VBN	_	8	cop
5	no	no	DT	_	8	neg
6	formal	formal	JJ	_	8	amod
7	interaction	interaction	NN	_	8	compound
8	studies	study	NNS	_	0	ROOT
9	other	other	JJ	_	8	advmod
10	than	than	IN	_	12	case
11	with	with	IN	_	12	case
12	drug1	drug1	NN	_	9	nmod
13	,	,	,	_	9	punct
14	based	base	VBN	_	26	dep
15	on	on	IN	_	16	case
16	these	these	DT	_	14	nmod
17	in	in	FW	_	18	compound
18	vivo	vivo	FW	_	19	advmod
19	and	and	CC	_	26	cc
20	in	in	FW	_	22	amod
21	vitro	vitro	FW	_	20	dep
22	studies	study	NNS	_	26	conj
23	,	,	,	_	26	punct
24	it	it	PRP	_	26	nsubj
25	is	be	VBZ	_	26	cop
26	unlikely	unlikely	JJ	_	9	dep
27	that	that	IN	_	40	mark
28	co-administration	co-administration	NN	_	40	nsubj
29	of	of	IN	_	33	case
30	a	a	DT	_	33	det
31	1	1	CD	_	32	compound
32	mg	mg	NN	_	33	amod
33	dose	dose	NN	_	28	nmod
34	of	of	IN	_	35	case
35	drug2	drug2	NN	_	33	nmod
36	with	with	IN	_	38	case
37	other	other	JJ	_	38	amod
38	drugs	drug	NNS	_	35	nmod
39	will	will	MD	_	40	aux
40	result	result	VB	_	26	ccomp
41	in	in	IN	_	45	case
42	clinically	clinically	RB	_	43	advmod
43	significant	significant	JJ	_	45	amod
44	drug	drug	NN	_	45	compound
45	inhibition	inhibition	NN	_	40	nmod
46	of	of	IN	_	49	case
47	cytochrome	cytochrome	NN	_	49	compound
48	P450-mediated	p450-mediated	JJ	_	49	amod
49	metabolism	metabolism	NN	_	45	nmod
50	of	of	IN	_	53	case
51	the	the	DT	_	53	det
52	other	other	JJ	_	53	amod
53	drugs	drug	NNS	_	49	nmod
54	.	.	.	_	8	punct

1	An	a	DT	_	3	det
2	interaction	interaction	NN	_	3	compound
3	study	study	NN	_	6	nsubj
4	with	with	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	showed	show	VBD	_	0	ROOT
7	no	no	DT	_	10	neg
8	clinically	clinically	RB	_	9	advmod
9	significant	significant	JJ	_	10	amod
10	effect	effect	NN	_	6	dobj
11	of	of	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	on	on	IN	_	15	case
14	drug3	drug3	NN	_	15	compound
15	pharmacokinetics	pharmacokinetic	NNS	_	10	nmod
16	or	or	CC	_	15	cc
17	anticoagulant	anticoagulant	JJ	_	18	amod
18	activity	activity	NN	_	15	conj
19	.	.	.	_	6	punct

1	At	at	IN	_	4	case
2	a	a	DT	_	4	det
3	median	median	JJ	_	4	amod
4	follow-up	follow-up	NN	_	17	nmod
5	of	of	IN	_	7	case
6	33	33	CD	_	7	nummod
7	months	month	NNS	_	4	nmod
8	,	,	,	_	17	punct
9	the	the	DT	_	10	det
10	combination	combination	NN	_	17	nsubj
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	and	and	CC	_	12	cc
14	drug2	drug2	NN	_	12	conj
15	did	do	VBD	_	17	aux
16	not	not	RB	_	17	neg
17	demonstrate	demonstrate	VB	_	0	ROOT
18	any	any	DT	_	20	det
19	efficacy	efficacy	NN	_	20	compound
20	benefit	benefit	NN	_	17	dobj
21	when	when	WRB	_	22	advmod
22	compared	compare	VBN	_	17	advcl
23	with	with	IN	_	24	case
24	drug3	drug3	NN	_	22	nmod
25	in	in	IN	_	27	case
26	all	all	DT	_	27	det
27	patients	patient	NNS	_	24	nmod
28	as	as	RB	_	27	cc
29	well	well	RB	_	28	mwe
30	as	as	IN	_	28	mwe
31	in	in	IN	_	35	case
32	the	the	DT	_	35	det
33	hormone	hormone	NN	_	35	compound
34	receptor-positive	receptor-positive	JJ	_	35	amod
35	subpopulation	subpopulation	NN	_	27	conj
36	.	.	.	_	17	punct

1	This	this	DT	_	3	det
2	treatment	treatment	NN	_	3	compound
3	arm	arm	NN	_	5	nsubjpass
4	was	be	VBD	_	5	auxpass
5	discontinued	discontinue	VBN	_	0	ROOT
6	from	from	IN	_	8	case
7	the	the	DT	_	8	det
8	trial	trial	NN	_	5	nmod
9	.	.	.	_	5	punct

1	Based	base	VBN	_	6	case
2	on	on	IN	_	6	case
3	clinical	clinical	JJ	_	6	amod
4	and	and	CC	_	3	cc
5	pharmacokinetic	pharmacokinetic	JJ	_	3	conj
6	results	result	NNS	_	16	advcl
7	from	from	IN	_	10	case
8	the	the	DT	_	10	det
9	ATAC	atac	NN	_	10	compound
10	trial	trial	NN	_	6	nmod
11	,	,	,	_	16	punct
12	drug1	drug1	NN	_	16	nsubjpass
13	should	should	MD	_	16	aux
14	not	not	RB	_	16	neg
15	be	be	VB	_	16	auxpass
16	administered	administer	VBN	_	0	ROOT
17	with	with	IN	_	18	case
18	drug2	drug2	NN	_	16	nmod
19	-LRB-	-lrb-	-LRB-	_	20	punct
20	see	see	VB	_	16	parataxis
21	CLINICAL	CLINICAL	NNP	_	24	compound
22	PHARMACOLOGY	PHARMACOLOGY	NNP	_	24	compound
23	Drug	Drug	NNP	_	24	compound
24	Interactions	interaction	NNS	_	20	dobj
25	and	and	CC	_	24	cc
26	CLINICAL	clinical	JJ	_	27	amod
27	PHARMACOLOGY	pharmacology	NN	_	24	conj
28	-	-	:	_	27	punct
29	Clinical	clinical	JJ	_	30	amod
30	Studies	study	NNS	_	27	dep
31	-	-	:	_	27	punct
32	Adjuvant	adjuvant	JJ	_	33	amod
33	Treatment	treatment	NN	_	27	dep
34	of	of	IN	_	36	case
35	Breast	breast	NN	_	36	compound
36	Cancer	cancer	NN	_	33	nmod
37	in	in	IN	_	40	case
38	Postmenopausal	Postmenopausal	NNP	_	40	compound
39	Women	Women	NNP	_	40	compound
40	subsections	subsection	NNS	_	33	nmod
41	-RRB-	-rrb-	-RRB-	_	20	punct
42	.	.	.	_	16	punct

1	Co-administration	co-administration	NN	_	6	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	drug2	drug2	NN	_	3	conj
6	resulted	result	VBD	_	0	ROOT
7	in	in	IN	_	9	case
8	a	a	DT	_	9	det
9	reduction	reduction	NN	_	6	nmod
10	of	of	IN	_	13	case
11	drug3	drug3	NN	_	13	compound
12	plasma	plasma	NN	_	13	compound
13	levels	level	NNS	_	9	nmod
14	by	by	IN	_	16	case
15	27	27	CD	_	16	nummod
16	%	%	NN	_	6	nmod
17	compared	compare	VBN	_	19	case
18	with	with	IN	_	19	case
19	those	those	DT	_	6	advcl
20	achieved	achieve	VBN	_	19	acl
21	with	with	IN	_	22	case
22	drug4	drug4	NN	_	20	nmod
23	alone	alone	RB	_	22	advmod
24	.	.	.	_	6	punct

1	drug1	drug1	NN	_	8	nsubjpass
2	-	-	:	_	8	punct
3	containing	contain	VBG	_	8	csubjpass
4	therapies	therapy	NNS	_	3	dobj
5	should	should	MD	_	8	aux
6	not	not	RB	_	8	neg
7	be	be	VB	_	8	auxpass
8	used	use	VBN	_	0	ROOT
9	with	with	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	as	as	IN	_	14	mark
12	they	they	PRP	_	14	nsubj
13	may	may	MD	_	14	aux
14	diminish	diminish	VB	_	8	advcl
15	its	its	PRP$	_	17	nmod:poss
16	pharmacologic	pharmacologic	JJ	_	17	amod
17	action	action	NN	_	14	dobj
18	.	.	.	_	8	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	3	amod
2	Test	test	NN	_	3	compound
3	Interactions	interaction	NNS	_	7	nsubj
4	No	no	DT	_	7	neg
5	clinically	clinically	RB	_	6	advmod
6	significant	significant	JJ	_	7	amod
7	changes	change	NNS	_	17	nsubjpass
8	in	in	IN	_	10	case
9	the	the	DT	_	10	det
10	results	result	NNS	_	7	nmod
11	of	of	IN	_	14	case
12	clinical	clinical	JJ	_	14	amod
13	laboratory	laboratory	NN	_	14	compound
14	tests	test	NNS	_	10	nmod
15	have	have	VBP	_	17	aux
16	been	be	VBN	_	17	auxpass
17	observed	observe	VBN	_	0	ROOT

1	.	.	.	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	Treatment	treatment	NN	_	13	nsubjpass
2	with	with	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	once	once	RB	_	5	advmod
5	weekly	weekly	JJ	_	1	amod
6	for	for	IN	_	8	case
7	4	4	CD	_	8	nummod
8	weeks	week	NNS	_	5	nmod
9	in	in	IN	_	11	case
10	healthy	healthy	JJ	_	11	amod
11	subjects	subject	NNS	_	5	nmod
12	was	be	VBD	_	13	auxpass
13	associated	associate	VBN	_	0	ROOT
14	with	with	IN	_	16	case
15	an	a	DT	_	16	det
16	inhibition	inhibition	NN	_	13	nmod
17	of	of	IN	_	19	case
18	P450	p450	NN	_	19	compound
19	1A2	1a2	NN	_	16	nmod
20	and	and	CC	_	16	cc
21	a	a	DT	_	24	det
22	25	25	CD	_	23	compound
23	%	%	NN	_	24	amod
24	increase	increase	NN	_	16	conj
25	in	in	IN	_	27	case
26	drug2	drug2	NN	_	27	compound
27	AUC	auc	NN	_	24	nmod
28	.	.	.	_	13	punct

1	drug1	drug1	NN	_	3	compound
2	serum	serum	NN	_	3	compound
3	levels	level	NNS	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	monitored	monitor	VBN	_	0	ROOT
7	and	and	CC	_	6	cc
8	appropriate	appropriate	JJ	_	10	amod
9	dose	dose	NN	_	10	compound
10	adjustments	adjustment	NNS	_	6	conj
11	considered	consider	VBN	_	10	acl
12	for	for	IN	_	13	case
13	patients	patient	NNS	_	11	nmod
14	given	give	VBN	_	16	case
15	both	both	CC	_	16	cc:preconj
16	drug2	drug2	NN	_	13	nmod
17	and	and	CC	_	16	cc
18	drug3	drug3	NN	_	16	conj
19	.	.	.	_	6	punct

1	There	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	no	no	DT	_	4	neg
4	effect	effect	NN	_	2	nsubj
5	on	on	IN	_	7	case
6	the	the	DT	_	7	det
7	pharmacokinetics	pharmacokinetic	NNS	_	4	nmod
8	of	of	IN	_	10	case
9	representative	representative	JJ	_	10	amod
10	drugs	drug	NNS	_	7	nmod
11	metabolized	metabolize	VBN	_	10	acl
12	by	by	IN	_	14	case
13	CYP	cyp	NN	_	14	compound
14	2C9	2c9	NN	_	11	nmod
15	,	,	,	_	2	punct
16	CYP	cyp	NN	_	17	compound
17	2C19	2c19	NN	_	2	nsubj
18	,	,	,	_	17	punct
19	CYP	cyp	NN	_	20	compound
20	2D6	2d6	NN	_	17	conj
21	or	or	CC	_	17	cc
22	CYP	cyp	NN	_	23	compound
23	3A4	3a4	NN	_	17	conj
24	.	.	.	_	2	punct

1	In	in	IN	_	2	case
2	patients	patient	NNS	_	19	nmod
3	with	with	IN	_	6	case
4	chronic	chronic	JJ	_	6	amod
5	hepatitis	hepatitis	NN	_	6	compound
6	C	c	NN	_	2	nmod
7	treated	treat	VBN	_	6	acl
8	with	with	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	in	in	IN	_	11	case
11	combination	combination	NN	_	7	nmod
12	with	with	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	,	,	,	_	19	punct
15	drug3	drug3	NN	_	16	compound
16	treatment	treatment	NN	_	19	nsubj
17	did	do	VBD	_	19	aux
18	not	not	RB	_	19	neg
19	affect	affect	VB	_	0	ROOT
20	drug4	drug4	NN	_	21	compound
21	distribution	distribution	NN	_	19	dobj
22	or	or	CC	_	21	cc
23	clearance	clearance	NN	_	21	conj
24	.	.	.	_	19	punct

1	Nucleoside	nucleoside	NN	_	2	compound
2	Analogues	analogue	NNS	_	3	nsubj
3	drug1	drug1	VBP	_	0	ROOT
4	Co-administration	co-administration	NN	_	11	nsubjpass
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	drug3	drug3	NN	_	6	conj
9	is	be	VBZ	_	11	auxpass
10	not	not	RB	_	11	neg
11	recommended	recommend	VBN	_	3	ccomp
12	.	.	.	_	3	punct

1	Reports	report	NNS	_	21	nsubjpass
2	of	of	IN	_	5	case
3	fatal	fatal	JJ	_	5	amod
4	hepatic	hepatic	JJ	_	5	amod
5	failure	failure	NN	_	1	nmod
6	,	,	,	_	1	punct
7	as	as	RB	_	1	cc
8	well	well	RB	_	7	mwe
9	as	as	IN	_	7	mwe
10	peripheral	peripheral	JJ	_	11	amod
11	neuropathy	neuropathy	NN	_	1	conj
12	,	,	,	_	11	punct
13	pancreatitis	pancreatitis	NN	_	11	conj
14	,	,	,	_	11	punct
15	and	and	CC	_	11	cc
16	symptomatic	symptomatic	JJ	_	18	amod
17	hyperlactatemia/lactic	hyperlactatemia/lactic	JJ	_	18	amod
18	acidosis	acidosis	NN	_	11	conj
19	have	have	VBP	_	21	aux
20	been	be	VBN	_	21	auxpass
21	reported	report	VBN	_	0	ROOT
22	in	in	IN	_	24	case
23	clinical	clinical	JJ	_	24	amod
24	trials	trial	NNS	_	21	nmod
25	.	.	.	_	21	punct

1	drug1	drug1	NN	_	4	compound
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	drug3	drug3	NN	_	6	nsubj
5	can	can	MD	_	6	aux
6	antagonize	antagonize	VB	_	0	ROOT
7	the	the	DT	_	11	det
8	in	in	FW	_	11	amod
9	vitro	vitro	FW	_	8	dep
10	antiviral	antiviral	JJ	_	11	amod
11	activity	activity	NN	_	6	dobj
12	of	of	IN	_	13	case
13	drug4	drug4	NN	_	11	nmod
14	and	and	CC	_	13	cc
15	drug5	drug5	NN	_	13	conj
16	against	against	IN	_	17	case
17	HIV	hiv	NN	_	11	nmod
18	.	.	.	_	6	punct

1	Therefore	therefore	RB	_	14	advmod
2	,	,	,	_	14	punct
3	concomitant	concomitant	JJ	_	4	amod
4	use	use	NN	_	14	nsubjpass
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	with	with	IN	_	8	case
8	either	either	DT	_	4	nmod
9	of	of	IN	_	11	case
10	these	these	DT	_	11	det
11	drugs	drug	NNS	_	8	nmod
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	avoided	avoid	VBN	_	0	ROOT
15	.	.	.	_	14	punct

1	Carcinogenesis	carcinogenesis	NN	_	13	nsubjpass
2	,	,	,	_	1	punct
3	Mutagenesis	mutagenesis	NN	_	1	conj
4	,	,	,	_	1	punct
5	Impairment	impairment	NN	_	1	appos
6	of	of	IN	_	9	case
7	Fertility	fertility	NN	_	9	compound
8	Carcinogenesis	carcinogenesis	NN	_	9	compound
9	drug1	drug1	NN	_	5	nmod
10	has	have	VBZ	_	13	aux
11	not	not	RB	_	13	neg
12	been	be	VBN	_	13	auxpass
13	tested	test	VBN	_	0	ROOT
14	for	for	IN	_	17	case
15	its	its	PRP$	_	17	nmod:poss
16	carcinogenic	carcinogenic	JJ	_	17	amod
17	potential	potential	NN	_	13	nmod
18	.	.	.	_	13	punct

1	Mutagenesis	mutagenesis	NN	_	2	compound
2	drug1	drug1	NN	_	5	nsubj
3	did	do	VBD	_	5	aux
4	not	not	RB	_	5	neg
5	cause	cause	VB	_	0	ROOT
6	DNA	dna	NN	_	7	compound
7	damage	damage	NN	_	5	dobj
8	when	when	WRB	_	9	advmod
9	tested	test	VBN	_	5	advcl
10	in	in	IN	_	15	case
11	the	the	DT	_	15	det
12	Ames	Ames	NNP	_	15	compound
13	bacterial	bacterial	JJ	_	15	amod
14	mutagenicity	mutagenicity	NN	_	15	compound
15	assay	assay	NN	_	9	nmod
16	and	and	CC	_	15	cc
17	in	in	IN	_	23	case
18	the	the	DT	_	23	det
19	in	in	FW	_	23	amod
20	vitro	vitro	FW	_	19	dep
21	chromosomal	chromosomal	JJ	_	23	amod
22	aberration	aberration	NN	_	23	compound
23	assay	assay	NN	_	15	conj
24	in	in	IN	_	26	case
25	human	human	JJ	_	26	amod
26	lymphocytes	lymphocyte	NNS	_	23	nmod
27	,	,	,	_	5	punct
28	either	either	CC	_	31	dep
29	in	in	IN	_	31	case
30	the	the	DT	_	31	dep
31	presence	presence	NN	_	5	nmod
32	or	or	CC	_	31	cc
33	absence	absence	NN	_	31	conj
34	of	of	IN	_	36	case
35	metabolic	metabolic	JJ	_	36	amod
36	activation	activation	NN	_	31	nmod
37	.	.	.	_	5	punct

1	Use	Use	NNP	_	6	nsubj
2	With	with	IN	_	4	case
3	drug1	drug1	NN	_	4	compound
4	drug2	drug2	NN	_	1	nmod
5	is	be	VBZ	_	6	cop
6	genotoxic	genotoxic	JJ	_	0	ROOT
7	and	and	CC	_	6	cc
8	mutagenic	mutagenic	JJ	_	6	conj
9	.	.	.	_	6	punct

1	The	the	DT	_	3	det
2	carcinogenic	carcinogenic	JJ	_	3	amod
3	potential	potential	NN	_	10	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	has	have	VBZ	_	10	aux
7	not	not	RB	_	10	neg
8	been	be	VBN	_	10	auxpass
9	fully	fully	RB	_	10	advmod
10	determined	determine	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	In	in	IN	_	3	case
2	a	a	DT	_	3	det
3	p53	p53	NN	_	26	nmod
4	-LRB-	-lrb-	-LRB-	_	11	punct
5	+	+	CC	_	11	cc
6	/	/	:	_	11	punct
7	-	-	:	_	11	punct
8	-RRB-	-rrb-	-RRB-	_	11	punct
9	mouse	mouse	NN	_	11	compound
10	carcinogenicity	carcinogenicity	NN	_	11	compound
11	study	study	NN	_	26	nsubj
12	at	at	IN	_	13	case
13	doses	dose	NNS	_	11	nmod
14	up	up	RB	_	13	advmod
15	to	to	TO	_	17	case
16	the	the	DT	_	17	det
17	maximum	maximum	NN	_	14	nmod
18	tolerated	tolerate	VBD	_	11	acl
19	dose	dose	NN	_	18	dobj
20	of	of	IN	_	23	case
21	100	100	CD	_	23	nummod
22	mg/kg/day	mg/kg/day	NN	_	23	compound
23	drug1	drug1	NN	_	19	nmod
24	was	be	VBD	_	26	cop
25	not	not	RB	_	26	neg
26	oncogenic	oncogenic	JJ	_	0	ROOT
27	.	.	.	_	26	punct

1	However	however	RB	_	19	advmod
2	,	,	,	_	19	punct
3	on	on	IN	_	8	case
4	a	a	DT	_	8	det
5	body	body	NN	_	8	compound
6	surface	surface	NN	_	8	compound
7	area	area	NN	_	8	compound
8	basis	basis	NN	_	19	nmod
9	,	,	,	_	19	punct
10	this	this	DT	_	11	det
11	dose	dose	NN	_	19	nsubj
12	was	be	VBD	_	19	cop
13	0.5	0.5	CD	_	14	compound
14	times	time	NNS	_	19	nummod
15	maximum	maximum	JJ	_	19	amod
16	recommended	recommend	VBN	_	19	amod
17	human	human	JJ	_	19	amod
18	24-hour	24-hour	JJ	_	19	amod
19	dose	dose	NN	_	0	ROOT
20	of	of	IN	_	21	case
21	drug1	drug1	NN	_	19	nmod
22	.	.	.	_	19	punct

1	A	a	DT	_	2	det
2	study	study	NN	_	13	nsubj
3	in	in	IN	_	4	case
4	rats	rat	NNS	_	2	nmod
5	to	to	TO	_	6	mark
6	assess	assess	VB	_	4	acl
7	the	the	DT	_	9	det
8	carcinogenic	carcinogenic	JJ	_	9	amod
9	potential	potential	NN	_	6	dobj
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	is	be	VBZ	_	13	cop
13	ongoing	ongoing	JJ	_	0	ROOT
14	.	.	.	_	13	punct

1	Mutagenesis	mutagenesis	NN	_	2	compound
2	Impairment	impairment	NN	_	7	nsubj
3	of	of	IN	_	5	case
4	Fertility	fertility	NN	_	5	compound
5	drug1	drug1	NN	_	2	nmod
6	may	may	MD	_	7	aux
7	impair	impair	VB	_	0	ROOT
8	fertility	fertility	NN	_	7	dobj
9	in	in	IN	_	10	case
10	women	woman	NNS	_	7	nmod
11	.	.	.	_	7	punct

1	Prolonged	prolonged	JJ	_	3	amod
2	menstrual	menstrual	JJ	_	3	amod
3	cycles	cycle	NNS	_	7	nsubjpass
4	and/or	and/or	CC	_	3	cc
5	amenorrhea	amenorrhea	NN	_	3	conj
6	were	be	VBD	_	7	auxpass
7	observed	observe	VBN	_	0	ROOT
8	in	in	IN	_	11	case
9	female	female	JJ	_	11	amod
10	cynomolgus	cynomolgus	NN	_	11	compound
11	monkeys	monkey	NNS	_	7	nmod
12	given	give	VBN	_	14	case
13	sc	sc	NN	_	14	compound
14	injections	injection	NNS	_	11	nmod
15	of	of	IN	_	18	case
16	600	600	CD	_	18	nummod
17	m	m	NN	_	18	compound
18	g/kg/dose	g/kg/dose	NN	_	14	nmod
19	-LRB-	-lrb-	-LRB-	_	22	punct
20	7200	7200	CD	_	22	nummod
21	m	m	NN	_	22	compound
22	g/m2/dose	g/m2/dose	NN	_	18	appos
23	-RRB-	-rrb-	-RRB-	_	22	punct
24	of	of	IN	_	25	case
25	drug1	drug1	NN	_	18	nmod
26	every	every	DT	_	28	det
27	other	other	JJ	_	28	amod
28	day	day	NN	_	7	nmod:tmod
29	for	for	IN	_	31	case
30	one	one	CD	_	31	nummod
31	month	month	NN	_	7	nmod
32	,	,	,	_	7	punct
33	at	at	IN	_	36	case
34	approximately	approximately	RB	_	35	advmod
35	180	180	CD	_	36	nummod
36	times	time	NNS	_	7	nmod
37	the	the	DT	_	41	det
38	recommended	recommend	VBN	_	41	amod
39	weekly	weekly	JJ	_	41	amod
40	human	human	JJ	_	41	amod
41	dose	dose	NN	_	36	dep
42	for	for	IN	_	46	case
43	a	a	DT	_	46	det
44	60	60	CD	_	46	nummod
45	kg	kg	NN	_	46	compound
46	person	person	NN	_	41	nmod
47	-LRB-	-lrb-	-LRB-	_	48	punct
48	based	base	VBN	_	41	dep
49	on	on	IN	_	52	case
50	body	body	NN	_	52	compound
51	surface	surface	NN	_	52	compound
52	area	area	NN	_	48	nmod
53	-RRB-	-rrb-	-RRB-	_	48	punct
54	.	.	.	_	7	punct

1	Menstrual	menstrual	JJ	_	3	amod
2	cycle	cycle	NN	_	3	compound
3	irregularities	irregularity	NNS	_	5	nsubjpass
4	were	be	VBD	_	5	auxpass
5	accompanied	accompany	VBN	_	0	ROOT
6	by	by	IN	_	9	case
7	both	both	CC	_	9	cc:preconj
8	a	a	DT	_	9	det
9	decrease	decrease	NN	_	5	nmod
10	and	and	CC	_	9	cc
11	delay	delay	NN	_	9	conj
12	in	in	IN	_	15	case
13	the	the	DT	_	15	det
14	peak	peak	JJ	_	15	amod
15	17b	17b	NN	_	9	nmod
16	-	-	:	_	15	punct
17	estradiol	estradiol	NN	_	20	compound
18	and	and	CC	_	17	cc
19	progesterone	progesterone	NN	_	17	conj
20	levels	level	NNS	_	15	dep
21	following	follow	VBG	_	22	case
22	administration	administration	NN	_	20	nmod
23	of	of	IN	_	24	case
24	drug1	drug1	NN	_	22	nmod
25	to	to	TO	_	27	case
26	female	female	JJ	_	27	amod
27	monkeys	monkey	NNS	_	22	nmod
28	.	.	.	_	5	punct

1	A	a	DT	_	2	det
2	return	return	NN	_	7	nsubj
3	to	to	TO	_	6	case
4	normal	normal	JJ	_	6	amod
5	menstrual	menstrual	JJ	_	6	amod
6	rhythm	rhythm	NN	_	2	nmod
7	followed	follow	VBD	_	0	ROOT
8	cessation	cessation	NN	_	7	dobj
9	of	of	IN	_	10	case
10	treatment	treatment	NN	_	8	nmod
11	.	.	.	_	7	punct

1	Every	every	DT	_	4	det
2	other	other	JJ	_	4	amod
3	day	day	NN	_	4	compound
4	dosing	dosing	NN	_	24	nsubj
5	with	with	IN	_	7	case
6	100m	100m	NN	_	7	compound
7	g/kg	g/kg	NN	_	4	nmod
8	-LRB-	-lrb-	-LRB-	_	10	punct
9	1200m	1200m	CD	_	10	nummod
10	g/m2	g/m2	NN	_	7	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	drug1	drug1	NN	_	7	dep
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	equivalent	equivalent	JJ	_	4	dep
15	to	to	TO	_	18	case
16	approximately	approximately	RB	_	17	advmod
17	30	30	CD	_	18	nummod
18	times	time	NNS	_	14	nmod
19	the	the	DT	_	22	det
20	recommended	recommend	VBN	_	22	amod
21	human	human	JJ	_	22	amod
22	dose	dose	NN	_	14	dep
23	-RRB-	-rrb-	-RRB-	_	14	punct
24	had	have	VBD	_	0	ROOT
25	no	no	DT	_	26	neg
26	effects	effect	NNS	_	24	dobj
27	on	on	IN	_	29	case
28	cycle	cycle	NN	_	29	compound
29	duration	duration	NN	_	24	nmod
30	or	or	CC	_	29	cc
31	reproductive	reproductive	JJ	_	33	amod
32	hormone	hormone	NN	_	33	compound
33	status	status	NN	_	29	conj
34	.	.	.	_	24	punct

1	The	the	DT	_	2	det
2	effects	effect	NNS	_	11	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	on	on	IN	_	7	case
6	male	male	JJ	_	7	amod
7	fertility	fertility	NN	_	2	nmod
8	have	have	VBP	_	11	aux
9	not	not	RB	_	11	neg
10	been	be	VBN	_	11	auxpass
11	studied	study	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	However	however	RB	_	9	advmod
2	,	,	,	_	9	punct
3	no	no	DT	_	5	neg
4	adverse	adverse	JJ	_	5	amod
5	effects	effect	NNS	_	9	nsubjpass
6	on	on	IN	_	7	case
7	fertility	fertility	NN	_	5	nmod
8	were	be	VBD	_	9	auxpass
9	observed	observe	VBN	_	0	ROOT
10	in	in	IN	_	13	case
11	male	male	JJ	_	13	amod
12	Rhesus	Rhesus	NNP	_	13	compound
13	monkeys	monkey	NNS	_	9	nmod
14	treated	treat	VBN	_	13	acl
15	with	with	IN	_	18	case
16	non	non	JJ	_	18	amod
17	-	-	:	_	18	punct
18	drug1	drug1	NN	_	14	nmod
19	for	for	IN	_	21	case
20	5	5	CD	_	21	nummod
21	months	month	NNS	_	14	nmod
22	at	at	IN	_	23	case
23	doses	dose	NNS	_	14	nmod
24	up	up	RB	_	23	advmod
25	to	to	TO	_	29	case
26	25	25	CD	_	29	nummod
27	x	x	CC	_	26	cc
28	106	106	CD	_	26	conj
29	IU/kg/day	iu/kg/day	NN	_	24	nmod
30	.	.	.	_	9	punct

1	Pregnancy	Pregnancy	NNP	_	2	compound
2	Pregnancy	Pregnancy	NNP	_	0	ROOT
3	:	:	:	_	2	punct
4	Category	category	NN	_	6	compound
5	C	c	NN	_	6	compound
6	drug1	drug1	NN	_	10	nsubjpass
7	has	have	VBZ	_	10	aux
8	not	not	RB	_	10	neg
9	been	be	VBN	_	10	auxpass
10	studied	study	VBN	_	2	dep
11	for	for	IN	_	14	case
12	its	its	PRP$	_	14	nmod:poss
13	teratogenic	teratogenic	JJ	_	14	amod
14	effect	effect	NN	_	10	nmod
15	.	.	.	_	2	punct

1	drug1	drug1	NN	_	2	compound
2	treatment	treatment	NN	_	17	nsubj
3	of	of	IN	_	6	case
4	pregnant	pregnant	JJ	_	6	amod
5	Rhesus	Rhesus	NNP	_	6	compound
6	monkeys	monkey	NNS	_	2	nmod
7	at	at	IN	_	12	case
8	approximately	approximately	RB	_	11	advmod
9	20	20	CD	_	11	compound
10	to	to	TO	_	11	dep
11	500	500	CD	_	12	nummod
12	times	time	NNS	_	17	nmod
13	the	the	DT	_	16	det
14	human	human	JJ	_	16	amod
15	weekly	weekly	JJ	_	16	amod
16	dose	dose	NN	_	17	nsubj
17	resulted	result	VBD	_	0	ROOT
18	in	in	IN	_	22	case
19	a	a	DT	_	22	det
20	statistically	statistically	RB	_	21	advmod
21	significant	significant	JJ	_	22	amod
22	increase	increase	NN	_	17	nmod
23	in	in	IN	_	24	case
24	abortions	abortion	NNS	_	22	nmod
25	.	.	.	_	17	punct

1	No	no	DT	_	3	neg
2	teratogenic	teratogenic	JJ	_	3	amod
3	effects	effect	NNS	_	5	nsubjpass
4	were	be	VBD	_	5	auxpass
5	seen	see	VBN	_	0	ROOT
6	in	in	IN	_	8	case
7	the	the	DT	_	8	det
8	offspring	offspring	NN	_	5	nmod
9	delivered	deliver	VBN	_	8	acl
10	at	at	IN	_	11	case
11	term	term	NN	_	9	nmod
12	.	.	.	_	5	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	assumed	assume	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	have	have	VB	_	4	xcomp
7	abortifacient	abortifacient	JJ	_	8	amod
8	potential	potential	NN	_	6	dobj
9	.	.	.	_	4	punct

1	There	there	EX	_	2	expl
2	are	be	VBP	_	0	ROOT
3	no	no	DT	_	7	neg
4	adequate	adequate	JJ	_	7	amod
5	and	and	CC	_	4	cc
6	well-controlled	well-controlled	JJ	_	4	conj
7	studies	study	NNS	_	2	nsubj
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	in	in	IN	_	12	case
11	pregnant	pregnant	JJ	_	12	amod
12	women	woman	NNS	_	7	nmod
13	.	.	.	_	2	punct

1	drug1	drug1	NN	_	2	nsubj
2	is	be	VBZ	_	0	ROOT
3	to	to	TO	_	5	mark
4	be	be	VB	_	5	auxpass
5	used	use	VBN	_	2	xcomp
6	during	during	IN	_	7	case
7	pregnancy	pregnancy	NN	_	5	nmod
8	only	only	RB	_	13	advmod
9	if	if	IN	_	13	mark
10	the	the	DT	_	12	det
11	potential	potential	JJ	_	12	amod
12	benefit	benefit	NN	_	13	nsubj
13	justifies	justify	VBZ	_	5	advcl
14	the	the	DT	_	16	det
15	potential	potential	JJ	_	16	amod
16	risk	risk	NN	_	13	dobj
17	to	to	TO	_	19	case
18	the	the	DT	_	19	det
19	fetus	fetus	NN	_	16	nmod
20	.	.	.	_	2	punct

1	drug1	drug1	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	recommended	recommend	VBN	_	0	ROOT
4	for	for	IN	_	5	case
5	use	use	NN	_	3	nmod
6	in	in	IN	_	7	case
7	women	woman	NNS	_	5	nmod
8	of	of	IN	_	10	case
9	childbearing	childbearing	JJ	_	10	amod
10	potential	potential	NN	_	7	nmod
11	only	only	RB	_	12	advmod
12	when	when	WRB	_	15	advmod
13	they	they	PRP	_	15	nsubj
14	are	be	VBP	_	15	aux
15	using	use	VBG	_	3	advcl
16	effective	effective	JJ	_	17	amod
17	contraception	contraception	NN	_	15	dobj
18	during	during	IN	_	19	case
19	therapy	therapy	NN	_	15	nmod
20	.	.	.	_	3	punct

1	Pregnancy	pregnancy	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Category	category	NN	_	4	compound
4	X	x	NN	_	1	dep
5	:	:	:	_	4	punct
6	Use	Use	NNP	_	17	compound
7	With	with	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	see	see	VB	_	6	dep
11	CONTRAINDICATIONS	contraindication	NNS	_	10	dobj
12	-RRB-	-rrb-	-RRB-	_	10	punct
13	Significant	significant	JJ	_	17	amod
14	teratogenic	teratogenic	JJ	_	17	amod
15	and/or	and/or	CC	_	14	cc
16	embryocidal	embryocidal	JJ	_	14	conj
17	effects	effect	NNS	_	20	nsubjpass
18	have	have	VBP	_	20	aux
19	been	be	VBN	_	20	auxpass
20	demonstrated	demonstrate	VBN	_	4	appos
21	in	in	IN	_	24	case
22	all	all	DT	_	24	det
23	animal	animal	JJ	_	24	amod
24	species	species	NNS	_	20	nmod
25	exposed	expose	VBN	_	24	acl
26	to	to	TO	_	27	case
27	drug2	drug2	NN	_	25	nmod
28	.	.	.	_	1	punct

1	drug1	drug1	NN	_	2	compound
2	therapy	therapy	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	contraindicated	contraindicate	VBN	_	0	ROOT
5	in	in	IN	_	6	case
6	women	woman	NNS	_	4	nmod
7	who	who	WP	_	9	nsubj
8	are	be	VBP	_	9	cop
9	pregnant	pregnant	JJ	_	6	acl:relcl
10	and	and	CC	_	9	cc
11	in	in	IN	_	14	case
12	the	the	DT	_	14	det
13	male	male	JJ	_	14	amod
14	partners	partner	NNS	_	9	conj
15	of	of	IN	_	16	case
16	women	woman	NNS	_	14	nmod
17	who	who	WP	_	19	nsubj
18	are	be	VBP	_	19	cop
19	pregnant	pregnant	JJ	_	16	acl:relcl
20	.	.	.	_	4	punct

1	If	if	IN	_	3	mark
2	pregnancy	pregnancy	NN	_	3	nsubj
3	occurs	occur	VBZ	_	27	advcl
4	in	in	IN	_	6	case
5	a	a	DT	_	6	det
6	patient	patient	NN	_	3	nmod
7	or	or	CC	_	6	cc
8	partner	partner	NN	_	6	conj
9	of	of	IN	_	11	case
10	a	a	DT	_	11	det
11	patient	patient	NN	_	6	nmod
12	during	during	IN	_	13	case
13	treatment	treatment	NN	_	3	nmod
14	or	or	CC	_	13	cc
15	during	during	IN	_	18	case
16	the	the	DT	_	18	det
17	6	6	CD	_	18	nummod
18	months	month	NNS	_	13	conj
19	after	after	IN	_	21	case
20	treatment	treatment	NN	_	21	compound
21	cessation	cessation	NN	_	18	nmod
22	,	,	,	_	27	punct
23	such	such	JJ	_	24	amod
24	cases	case	NNS	_	27	nsubjpass
25	should	should	MD	_	27	aux
26	be	be	VB	_	27	auxpass
27	reported	report	VBN	_	0	ROOT
28	to	to	TO	_	32	case
29	the	the	DT	_	32	det
30	drug1	drug1	NN	_	32	compound
31	Pregnancy	pregnancy	NN	_	32	compound
32	Registry	registry	NN	_	27	nmod
33	at	at	IN	_	34	case
34	1-800-526-6367	1-800-526-6367	CD	_	27	nmod
35	.	.	.	_	27	punct

1	Nursing	Nursing	NNP	_	2	compound
2	Mothers	Mothers	NNP	_	0	ROOT
3	It	it	PRP	_	6	nsubjpass
4	is	be	VBZ	_	6	auxpass
5	not	not	RB	_	6	neg
6	known	know	VBN	_	2	acl:relcl
7	whether	whether	IN	_	15	mark
8	drug1	drug1	NN	_	15	nsubjpass
9	or	or	CC	_	8	cc
10	drug2	drug2	NN	_	8	conj
11	or	or	CC	_	8	cc
12	its	its	PRP$	_	13	nmod:poss
13	components	component	NNS	_	8	conj
14	are	be	VBP	_	15	auxpass
15	excreted	excrete	VBN	_	6	ccomp
16	in	in	IN	_	18	case
17	human	human	JJ	_	18	amod
18	milk	milk	NN	_	15	nmod
19	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	19	nsubjpass
3	of	of	IN	_	6	case
4	orally	orally	RB	_	5	advmod
5	ingested	ingest	VBN	_	6	amod
6	drug1	drug1	NN	_	2	nmod
7	or	or	CC	_	6	cc
8	drug2	drug2	NN	_	6	conj
9	from	from	IN	_	11	case
10	breast	breast	NN	_	11	compound
11	milk	milk	NN	_	2	nmod
12	on	on	IN	_	15	case
13	the	the	DT	_	15	det
14	nursing	nursing	NN	_	15	compound
15	infant	infant	NN	_	2	nmod
16	has	have	VBZ	_	19	aux
17	not	not	RB	_	19	neg
18	been	be	VBN	_	19	auxpass
19	evaluated	evaluate	VBN	_	0	ROOT
20	.	.	.	_	19	punct

1	Because	because	IN	_	4	case
2	of	of	IN	_	1	mwe
3	the	the	DT	_	4	det
4	potential	potential	NN	_	19	nmod
5	for	for	IN	_	7	case
6	adverse	adverse	JJ	_	7	amod
7	reactions	reaction	NNS	_	4	nmod
8	from	from	IN	_	10	case
9	the	the	DT	_	10	det
10	drugs	drug	NNS	_	7	nmod
11	in	in	IN	_	13	case
12	nursing	nursing	NN	_	13	compound
13	infants	infant	NNS	_	10	nmod
14	,	,	,	_	19	punct
15	a	a	DT	_	16	det
16	decision	decision	NN	_	19	nsubjpass
17	must	must	MD	_	19	aux
18	be	be	VB	_	19	auxpass
19	made	make	VBN	_	0	ROOT
20	whether	whether	IN	_	22	mark
21	to	to	TO	_	22	mark
22	discontinue	discontinue	VB	_	19	ccomp
23	nursing	nursing	NN	_	22	dobj
24	or	or	CC	_	22	cc
25	discontinue	discontinue	VB	_	22	conj
26	drug1	drug1	NN	_	29	compound
27	and	and	CC	_	26	cc
28	drug2	drug2	NN	_	26	conj
29	treatment	treatment	NN	_	25	dobj
30	.	.	.	_	19	punct

1	Pediatric	Pediatric	NNP	_	4	compound
2	Use	Use	NNP	_	4	compound
3	The	The	NNP	_	4	compound
4	safety	safety	NN	_	27	nsubjpass
5	and	and	CC	_	4	cc
6	effectiveness	effectiveness	NN	_	4	conj
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	,	,	,	_	8	punct
10	alone	alone	RB	_	8	conj
11	or	or	CC	_	8	cc
12	in	in	IN	_	13	case
13	combination	combination	NN	_	8	conj
14	with	with	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	in	in	IN	_	17	case
17	patients	patient	NNS	_	15	nmod
18	below	below	IN	_	20	case
19	the	the	DT	_	20	det
20	age	age	NN	_	17	nmod
21	of	of	IN	_	23	case
22	18	18	CD	_	23	nummod
23	years	year	NNS	_	20	nmod
24	have	have	VBP	_	27	aux
25	not	not	RB	_	27	neg
26	been	be	VBN	_	27	auxpass
27	established	establish	VBN	_	0	ROOT
28	.	.	.	_	27	punct

1	drug1	drug1	NN	_	2	nsubj
2	contains	contain	VBZ	_	0	ROOT
3	drug2	drug2	NN	_	2	dobj
4	.	.	.	_	2	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	to	to	TO	_	7	mark
6	be	be	VB	_	7	auxpass
7	associated	associate	VBN	_	4	xcomp
8	with	with	IN	_	11	case
9	an	a	DT	_	11	det
10	increased	increase	VBN	_	11	amod
11	incidence	incidence	NN	_	7	nmod
12	of	of	IN	_	16	case
13	neurological	neurological	JJ	_	16	amod
14	and	and	CC	_	13	cc
15	other	other	JJ	_	13	conj
16	complications	complication	NNS	_	11	nmod
17	in	in	IN	_	18	case
18	neonates	neonate	NNS	_	16	nmod
19	and	and	CC	_	18	cc
20	infants	infant	NNS	_	18	conj
21	,	,	,	_	16	punct
22	which	which	WDT	_	25	nsubj
23	are	be	VBP	_	25	cop
24	sometimes	sometimes	RB	_	25	advmod
25	fatal	fatal	JJ	_	16	acl:relcl
26	.	.	.	_	4	punct

1	Geriatric	Geriatric	NNP	_	4	compound
2	Use	Use	NNP	_	4	compound
3	Younger	Younger	NNP	_	4	compound
4	patients	patient	NNS	_	5	nsubj
5	have	have	VBP	_	0	ROOT
6	higher	higher	JJR	_	9	amod
7	virologic	virologic	JJ	_	9	amod
8	response	response	NN	_	9	compound
9	rates	rate	NNS	_	5	dobj
10	than	than	IN	_	12	case
11	older	older	JJR	_	12	amod
12	patients	patient	NNS	_	9	nmod
13	.	.	.	_	5	punct

1	Clinical	clinical	JJ	_	2	amod
2	studies	study	NNS	_	13	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	alone	alone	RB	_	4	advmod
6	or	or	CC	_	4	cc
7	in	in	IN	_	8	case
8	combination	combination	NN	_	4	conj
9	with	with	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	did	do	VBD	_	13	aux
12	not	not	RB	_	13	neg
13	include	include	VB	_	0	ROOT
14	sufficient	sufficient	JJ	_	15	amod
15	numbers	number	NNS	_	13	dobj
16	of	of	IN	_	17	case
17	subjects	subject	NNS	_	15	nmod
18	aged	aged	JJ	_	17	amod
19	65	65	CD	_	18	dep
20	or	or	CC	_	19	cc
21	over	over	IN	_	19	conj
22	to	to	TO	_	23	mark
23	determine	determine	VB	_	13	advcl
24	whether	whether	IN	_	26	mark
25	they	they	PRP	_	26	nsubj
26	respond	respond	VBP	_	23	ccomp
27	differently	differently	RB	_	26	advmod
28	from	from	IN	_	30	case
29	younger	younger	JJR	_	30	amod
30	subjects	subject	NNS	_	26	nmod
31	.	.	.	_	13	punct

1	Adverse	adverse	JJ	_	2	amod
2	reactions	reaction	NNS	_	25	nsubj
3	related	relate	VBN	_	2	acl
4	to	to	TO	_	6	case
5	drug1	drug1	NN	_	6	compound
6	s	s	NNS	_	3	nmod
7	,	,	,	_	6	punct
8	such	such	JJ	_	10	case
9	as	as	IN	_	8	mwe
10	CNS	cns	NN	_	6	nmod
11	,	,	,	_	10	punct
12	cardiac	cardiac	JJ	_	10	conj
13	,	,	,	_	10	punct
14	and	and	CC	_	10	cc
15	systemic	systemic	JJ	_	10	conj
16	-LRB-	-lrb-	-LRB-	_	19	punct
17	eg	eg	FW	_	19	advmod
18	,	,	,	_	19	punct
19	flu-like	flu-like	JJ	_	15	dep
20	-RRB-	-rrb-	-RRB-	_	19	punct
21	effects	effect	NNS	_	10	dep
22	may	may	MD	_	25	aux
23	be	be	VB	_	25	cop
24	more	more	RBR	_	25	advmod
25	severe	severe	JJ	_	0	ROOT
26	in	in	IN	_	28	case
27	the	the	DT	_	28	det
28	elderly	elderly	JJ	_	25	nmod
29	and	and	CC	_	28	cc
30	caution	caution	NN	_	28	conj
31	should	should	MD	_	33	aux
32	be	be	VB	_	33	auxpass
33	exercised	exercise	VBN	_	25	ccomp
34	in	in	IN	_	36	case
35	the	the	DT	_	36	det
36	use	use	NN	_	33	nmod
37	of	of	IN	_	38	case
38	drug2	drug2	NN	_	36	nmod
39	in	in	IN	_	41	case
40	this	this	DT	_	41	det
41	population	population	NN	_	36	nmod
42	.	.	.	_	25	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	are	be	VBP	_	5	auxpass
5	excreted	excrete	VBN	_	0	ROOT
6	by	by	IN	_	8	case
7	the	the	DT	_	8	det
8	kidney	kidney	NN	_	5	nmod
9	,	,	,	_	5	punct
10	and	and	CC	_	5	cc
11	the	the	DT	_	12	det
12	risk	risk	NN	_	21	nsubj
13	of	of	IN	_	15	case
14	toxic	toxic	JJ	_	15	amod
15	reactions	reaction	NNS	_	12	nmod
16	to	to	TO	_	18	case
17	this	this	DT	_	18	det
18	therapy	therapy	NN	_	15	nmod
19	may	may	MD	_	21	aux
20	be	be	VB	_	21	cop
21	greater	greater	JJR	_	5	conj
22	in	in	IN	_	23	case
23	patients	patient	NNS	_	21	nmod
24	with	with	IN	_	27	case
25	impaired	impaired	JJ	_	27	amod
26	renal	renal	JJ	_	27	amod
27	function	function	NN	_	23	nmod
28	.	.	.	_	5	punct

1	Because	because	IN	_	6	mark
2	elderly	elderly	JJ	_	3	amod
3	patients	patient	NNS	_	6	nsubj
4	are	be	VBP	_	6	cop
5	more	more	RBR	_	6	advmod
6	likely	likely	JJ	_	16	advcl
7	to	to	TO	_	9	mark
8	have	have	VB	_	9	aux
9	decreased	decrease	VBN	_	6	xcomp
10	renal	renal	JJ	_	11	amod
11	function	function	NN	_	9	dobj
12	,	,	,	_	16	punct
13	care	care	NN	_	16	nsubjpass
14	should	should	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	taken	take	VBN	_	0	ROOT
17	in	in	IN	_	19	case
18	dose	dose	NN	_	19	compound
19	selection	selection	NN	_	16	nmod
20	and	and	CC	_	16	cc
21	it	it	PRP	_	24	nsubj
22	may	may	MD	_	24	aux
23	be	be	VB	_	24	cop
24	useful	useful	JJ	_	16	conj
25	to	to	TO	_	26	mark
26	monitor	monitor	VB	_	24	xcomp
27	renal	renal	JJ	_	28	amod
28	function	function	NN	_	26	dobj
29	.	.	.	_	16	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	with	with	IN	_	6	case
6	caution	caution	NN	_	4	nmod
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	with	with	IN	_	11	case
10	creatinine	creatinine	NN	_	11	compound
11	clearance	clearance	NN	_	8	nmod
12	50	50	CD	_	13	nummod
13	mL/min	ml/min	NN	_	11	dep
14	and	and	CC	_	13	cc
15	drug2	drug2	NN	_	13	conj
16	should	should	MD	_	19	aux
17	not	not	RB	_	19	neg
18	be	be	VB	_	19	auxpass
19	administered	administer	VBN	_	4	dep
20	to	to	TO	_	21	case
21	patients	patient	NNS	_	19	nmod
22	with	with	IN	_	24	case
23	creatinine	creatinine	NN	_	24	compound
24	clearance	clearance	NN	_	21	nmod
25	50	50	CD	_	24	nummod
26	mL/min	ml/min	NN	_	19	dobj

1	.	.	.	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	General	General	NNP	_	4	compound
2	In	in	FW	_	4	amod
3	vitro	vitro	FW	_	2	dep
4	studies	study	NNS	_	9	nsubj
5	in	in	IN	_	8	case
6	human	human	JJ	_	8	amod
7	liver	liver	NN	_	8	compound
8	microsomes	microsome	NNS	_	4	nmod
9	demonstrated	demonstrate	VBD	_	0	ROOT
10	no	no	DT	_	11	neg
11	evidence	evidence	NN	_	9	dobj
12	of	of	IN	_	16	case
13	cytochrome	cytochrome	NN	_	16	compound
14	P450-mediated	p450-mediated	JJ	_	16	amod
15	drug	drug	NN	_	16	compound
16	interactions	interaction	NNS	_	11	nmod
17	that	that	WDT	_	19	nsubj
18	are	be	VBP	_	19	cop
19	likely	likely	JJ	_	16	acl:relcl
20	to	to	TO	_	24	mark
21	be	be	VB	_	24	cop
22	of	of	IN	_	24	case
23	clinical	clinical	JJ	_	24	amod
24	relevance	relevance	NN	_	19	xcomp
25	.	.	.	_	9	punct

1	drug1	drug1	NN	_	0	ROOT
2	/	/	:	_	3	punct
3	drug2	drug2	NN	_	1	dep
4	/	/	:	_	3	punct
5	drug3	drug3	NN	_	3	dep
6	/	/	:	_	3	punct
7	drug4	drug4	NN	_	3	dep
8	:	:	:	_	3	punct
9	Co-administration	co-administration	NN	_	22	nsubj
10	of	of	IN	_	11	case
11	drug5	drug5	NN	_	9	nmod
12	with	with	IN	_	13	case
13	drug6	drug6	NN	_	9	nmod
14	,	,	,	_	13	punct
15	drug7	drug7	NN	_	13	conj
16	,	,	,	_	13	punct
17	drug8	drug8	NN	_	13	conj
18	,	,	,	_	13	punct
19	and	and	CC	_	13	cc
20	drug9	drug9	NN	_	13	conj
21	is	be	VBZ	_	22	cop
22	likely	likely	JJ	_	3	dep
23	to	to	TO	_	24	mark
24	lead	lead	VB	_	22	xcomp
25	to	to	TO	_	27	case
26	an	a	DT	_	27	det
27	enhancement	enhancement	NN	_	24	nmod
28	of	of	IN	_	29	case
29	effects	effect	NNS	_	27	nmod
30	.	.	.	_	1	punct

1	Specific	specific	JJ	_	2	amod
2	studies	study	NNS	_	4	nsubj
3	have	have	VBP	_	4	aux
4	confirmed	confirm	VBN	_	0	ROOT
5	these	these	DT	_	6	det
6	effects	effect	NNS	_	4	dobj
7	with	with	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	,	,	,	_	8	punct
10	drug2	drug2	NN	_	8	conj
11	,	,	,	_	8	punct
12	drug3	drug3	NN	_	8	conj
13	,	,	,	_	8	punct
14	drug4	drug4	NN	_	8	conj
15	,	,	,	_	8	punct
16	and	and	CC	_	8	cc
17	drug5	drug5	NN	_	8	conj
18	.	.	.	_	4	punct

1	No	no	DT	_	3	neg
2	pharmacokinetic	pharmacokinetic	JJ	_	3	amod
3	interactions	interaction	NNS	_	17	nsubjpass
4	between	between	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	,	,	,	_	5	punct
9	drug3	drug3	NN	_	5	conj
10	,	,	,	_	5	punct
11	drug4	drug4	NN	_	5	conj
12	,	,	,	_	5	punct
13	and	and	CC	_	5	cc
14	drug5	drug5	NN	_	5	conj
15	have	have	VBP	_	17	aux
16	been	be	VBN	_	17	auxpass
17	demonstrated	demonstrate	VBN	_	0	ROOT
18	.	.	.	_	17	punct

1	However	however	RB	_	32	advmod
2	,	,	,	_	32	punct
3	due	due	JJ	_	7	case
4	to	to	TO	_	3	mwe
5	possible	possible	JJ	_	7	amod
6	pharmacodynamic	pharmacodynamic	JJ	_	7	amod
7	interactions	interaction	NNS	_	32	nmod
8	,	,	,	_	32	punct
9	when	when	WRB	_	10	advmod
10	co-administered	co-administer	VBN	_	32	advcl
11	with	with	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	,	,	,	_	32	punct
14	a	a	DT	_	15	det
15	reduction	reduction	NN	_	32	nsubjpass
16	in	in	IN	_	17	case
17	dosage	dosage	NN	_	15	nmod
18	of	of	IN	_	19	case
19	drug2	drug2	NN	_	17	nmod
20	on	on	IN	_	23	case
21	the	the	DT	_	23	det
22	concomitant	concomitant	JJ	_	23	amod
23	drug3	drug3	NN	_	15	nmod
24	,	,	,	_	23	punct
25	drug4	drug4	NN	_	23	conj
26	,	,	,	_	23	punct
27	drug5	drug5	NN	_	23	conj
28	or	or	CC	_	23	cc
29	drug6	drug6	NN	_	23	conj
30	may	may	MD	_	32	aux
31	be	be	VB	_	32	auxpass
32	required	require	VBN	_	0	ROOT
33	.	.	.	_	32	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	5	case
4	one	one	CD	_	5	nummod
5	study	study	NN	_	27	nmod
6	of	of	IN	_	9	case
7	10	10	CD	_	9	nummod
8	healthy	healthy	JJ	_	9	amod
9	volunteers	volunteer	NNS	_	5	nmod
10	,	,	,	_	5	punct
11	administration	administration	NN	_	27	nsubj
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	for	for	IN	_	16	case
15	45	45	CD	_	16	nummod
16	minutes	minute	NNS	_	11	nmod
17	at	at	IN	_	20	case
18	a	a	DT	_	20	det
19	plasma	plasma	NN	_	20	compound
20	concentration	concentration	NN	_	11	nmod
21	of	of	IN	_	26	case
22	1	1	CD	_	26	compound
23	-LRB-	-lrb-	-LRB-	_	24	punct
24	one	one	CD	_	22	appos
25	-RRB-	-rrb-	-RRB-	_	24	punct
26	ng/mL	ng/ml	NN	_	20	nmod
27	resulted	result	VBD	_	1	appos
28	in	in	IN	_	32	case
29	no	no	DT	_	32	neg
30	clinically	clinically	RB	_	31	advmod
31	meaningful	meaningful	JJ	_	32	amod
32	increases	increase	NNS	_	27	nmod
33	in	in	IN	_	35	case
34	the	the	DT	_	35	det
35	magnitude	magnitude	NN	_	32	nmod
36	or	or	CC	_	35	cc
37	neuromuscular	neuromuscular	JJ	_	38	amod
38	blockade	blockade	NN	_	35	conj
39	associated	associate	VBN	_	35	acl
40	with	with	IN	_	42	case
41	drug3	drug3	NN	_	42	compound
42	administration	administration	NN	_	39	nmod
43	.	.	.	_	1	punct

1	Effect	effect	NN	_	0	ROOT
2	of	of	IN	_	4	case
3	other	other	JJ	_	4	amod
4	drugs	drug	NNS	_	1	nmod
5	on	on	IN	_	6	case
6	drug1	drug1	NN	_	1	nmod

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	0	ROOT
4	:	:	:	_	3	punct
5	Studies	study	NNS	_	10	nsubj
6	in	in	IN	_	9	case
7	human	human	JJ	_	9	amod
8	liver	liver	NN	_	9	compound
9	microsomes	microsome	NNS	_	5	nmod
10	showed	show	VBD	_	3	appos
11	that	that	IN	_	14	mark
12	drug1	drug1	NN	_	14	nsubjpass
13	is	be	VBZ	_	14	auxpass
14	metabolized	metabolize	VBN	_	10	ccomp
15	primarily	primarily	RB	_	14	advmod
16	by	by	IN	_	18	case
17	cytochrome	cytochrome	NN	_	18	compound
18	P450	p450	NN	_	14	nmod
19	-LRB-	-lrb-	-LRB-	_	20	punct
20	CYP	cyp	NN	_	18	appos
21	-RRB-	-rrb-	-RRB-	_	20	punct
22	isoforms	isoform	NNS	_	23	compound
23	3A4/5	3a4/5	NN	_	18	dep
24	,	,	,	_	14	punct
25	and	and	CC	_	14	cc
26	to	to	TO	_	29	case
27	a	a	DT	_	29	det
28	lesser	lesser	JJR	_	29	amod
29	degree	degree	NN	_	14	conj
30	by	by	IN	_	31	case
31	CYP2C9	cyp2c9	NN	_	29	nmod
32	.	.	.	_	3	punct

1	Therefore	therefore	RB	_	8	advmod
2	,	,	,	_	8	punct
3	inhibitors	inhibitor	NNS	_	8	nsubjpass
4	of	of	IN	_	6	case
5	these	these	DT	_	6	det
6	enzymes	enzyme	NNS	_	3	nmod
7	are	be	VBP	_	8	auxpass
8	expected	expect	VBN	_	0	ROOT
9	to	to	TO	_	10	mark
10	reduce	reduce	VB	_	8	xcomp
11	drug1	drug1	NN	_	12	compound
12	clearance	clearance	NN	_	10	dobj
13	.	.	.	_	8	punct

1	In	in	FW	_	3	amod
2	vivo	vivo	FW	_	1	dep
3	studies	study	NNS	_	0	ROOT
4	:	:	:	_	3	punct
5	Cytochrome	cytochrome	NN	_	7	compound
6	P450	p450	NN	_	7	compound
7	Inhibitors	inhibitor	NNS	_	3	dep

1	drug1	drug1	NN	_	7	nsubj
2	-LRB-	-lrb-	-LRB-	_	5	punct
3	400	400	CD	_	5	nummod
4	mg	mg	NN	_	5	compound
5	b.i.d.	b.i.d.	NN	_	1	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	had	have	VBD	_	0	ROOT
8	no	no	DT	_	9	neg
9	effect	effect	NN	_	7	dobj
10	on	on	IN	_	12	case
11	drug2	drug2	NN	_	12	compound
12	bioavailability	bioavailability	NN	_	7	nmod
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	AUC	auc	NN	_	12	appos
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	and	and	CC	_	12	cc
17	maximum	maximum	NN	_	18	compound
18	concentration	concentration	NN	_	12	conj
19	-LRB-	-lrb-	-LRB-	_	20	punct
20	Cmax	cmax	NN	_	18	appos
21	-RRB-	-rrb-	-RRB-	_	20	punct
22	of	of	IN	_	23	case
23	drug3	drug3	NN	_	12	nmod
24	when	when	WRB	_	25	advmod
25	co-administered	co-administer	VBN	_	7	advcl
26	with	with	IN	_	29	case
27	20	20	CD	_	28	compound
28	mg	mg	NN	_	29	amod
29	drug4	drug4	NN	_	25	nmod
30	in	in	IN	_	32	case
31	healthy	healthy	JJ	_	32	amod
32	volunteers	volunteer	NNS	_	25	nmod
33	.	.	.	_	7	punct

1	drug1	drug1	NN	_	7	nsubj
2	-LRB-	-lrb-	-LRB-	_	5	punct
3	500	500	CD	_	5	nummod
4	mg	mg	NN	_	5	compound
5	t.i.d	t.i.d	NN	_	1	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	produced	produce	VBD	_	0	ROOT
8	a	a	DT	_	10	det
9	4-fold	4-fold	JJ	_	10	amod
10	increase	increase	NN	_	7	dobj
11	in	in	IN	_	13	case
12	drug2	drug2	NN	_	13	compound
13	AUC	auc	NN	_	10	nmod
14	and	and	CC	_	10	cc
15	a	a	DT	_	17	det
16	3-fold	3-fold	JJ	_	17	amod
17	increase	increase	NN	_	10	conj
18	in	in	IN	_	19	case
19	Cmax	Cmax	NNP	_	17	nmod
20	when	when	WRB	_	21	advmod
21	co-administered	co-administer	VBN	_	17	acl:relcl
22	with	with	IN	_	25	case
23	drug3	drug3	NN	_	25	compound
24	5	5	CD	_	25	nummod
25	mg	mg	NN	_	21	nmod
26	in	in	IN	_	28	case
27	healthy	healthy	JJ	_	28	amod
28	volunteers	volunteer	NNS	_	21	nmod
29	.	.	.	_	7	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	recommended	recommend	VBN	_	0	ROOT
4	not	not	RB	_	6	neg
5	to	to	TO	_	6	mark
6	exceed	exceed	VB	_	3	xcomp
7	a	a	DT	_	11	det
8	single	single	JJ	_	11	amod
9	5	5	CD	_	10	compound
10	mg	mg	NN	_	11	amod
11	dose	dose	NN	_	6	dobj
12	of	of	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	in	in	IN	_	17	case
15	a	a	DT	_	17	det
16	24-hour	24-hour	JJ	_	17	amod
17	period	period	NN	_	6	nmod
18	when	when	WRB	_	19	advmod
19	used	use	VBN	_	17	acl:relcl
20	in	in	IN	_	21	case
21	combination	combination	NN	_	19	nmod
22	with	with	IN	_	23	case
23	drug2	drug2	NN	_	21	nmod
24	.	.	.	_	3	punct

1	drug1	drug1	NN	_	8	nsubj
2	-LRB-	-lrb-	-LRB-	_	4	punct
3	200	200	CD	_	4	nummod
4	mg	mg	NN	_	1	dep
5	once	once	RB	_	6	advmod
6	daily	daily	JJ	_	4	amod
7	-RRB-	-rrb-	-RRB-	_	4	punct
8	produced	produce	VBD	_	0	ROOT
9	a	a	DT	_	11	det
10	10-fold	10-fold	JJ	_	11	amod
11	increase	increase	NN	_	8	dobj
12	in	in	IN	_	14	case
13	drug2	drug2	NN	_	14	compound
14	AUC	auc	NN	_	11	nmod
15	and	and	CC	_	11	cc
16	a	a	DT	_	18	det
17	4-fold	4-fold	JJ	_	18	amod
18	increase	increase	NN	_	11	conj
19	in	in	IN	_	20	case
20	Cmax	Cmax	NNP	_	18	nmod
21	when	when	WRB	_	22	advmod
22	co-administered	co-administer	VBN	_	18	acl:relcl
23	with	with	IN	_	24	case
24	drug3	drug3	NN	_	22	nmod
25	-LRB-	-lrb-	-LRB-	_	27	punct
26	5	5	CD	_	27	nummod
27	mg	mg	NN	_	24	appos
28	-RRB-	-rrb-	-RRB-	_	27	punct
29	in	in	IN	_	31	case
30	healthy	healthy	JJ	_	31	amod
31	volunteers	volunteer	NNS	_	22	nmod
32	.	.	.	_	8	punct

1	A	a	DT	_	4	det
2	5-mg	5-mg	JJ	_	4	amod
3	drug1	drug1	NN	_	4	compound
4	dose	dose	NN	_	8	nsubjpass
5	should	should	MD	_	8	aux
6	not	not	RB	_	8	neg
7	be	be	VB	_	8	auxpass
8	exceeded	exceed	VBN	_	0	ROOT
9	when	when	WRB	_	10	advmod
10	used	use	VBN	_	8	advcl
11	in	in	IN	_	12	case
12	combination	combination	NN	_	10	nmod
13	with	with	IN	_	15	case
14	200	200	CD	_	15	nummod
15	mg	mg	NN	_	12	nmod
16	once	once	RB	_	18	advmod
17	daily	daily	JJ	_	18	amod
18	drug2	drug2	NN	_	10	nmod
19	.	.	.	_	8	punct

1	Since	since	IN	_	12	mark
2	higher	higher	JJR	_	3	amod
3	doses	dose	NNS	_	12	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	-LRB-	-lrb-	-LRB-	_	8	punct
7	400	400	CD	_	8	nummod
8	mg	mg	NN	_	5	dep
9	daily	daily	JJ	_	8	amod
10	-RRB-	-rrb-	-RRB-	_	8	punct
11	may	may	MD	_	12	aux
12	result	result	VB	_	31	advcl
13	in	in	IN	_	15	case
14	higher	higher	JJR	_	15	amod
15	increases	increase	NNS	_	12	nmod
16	in	in	IN	_	17	case
17	Cmax	cmax	NN	_	15	nmod
18	and	and	CC	_	17	cc
19	AUC	auc	NN	_	17	conj
20	,	,	,	_	31	punct
21	a	a	DT	_	25	det
22	single	single	JJ	_	25	amod
23	2.5	2.5	CD	_	24	compound
24	mg	mg	NN	_	25	amod
25	dose	dose	NN	_	31	nsubjpass
26	of	of	IN	_	27	case
27	drug2	drug2	NN	_	25	nmod
28	should	should	MD	_	31	aux
29	not	not	RB	_	31	neg
30	be	be	VB	_	31	auxpass
31	exceeded	exceed	VBN	_	0	ROOT
32	in	in	IN	_	35	case
33	a	a	DT	_	35	det
34	24-hour	24-hour	JJ	_	35	amod
35	period	period	NN	_	31	nmod
36	when	when	WRB	_	37	advmod
37	used	use	VBN	_	35	acl:relcl
38	in	in	IN	_	39	case
39	combination	combination	NN	_	37	nmod
40	with	with	IN	_	43	case
41	drug3	drug3	NN	_	43	compound
42	400	400	CD	_	43	nummod
43	mg	mg	NN	_	39	nmod
44	daily	daily	RB	_	43	advmod
45	.	.	.	_	31	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	9	compound
4	-LRB-	-lrb-	-LRB-	_	7	punct
5	800	800	CD	_	7	nummod
6	mg	mg	NN	_	7	compound
7	t.i.d.	t.i.d.	NN	_	3	appos
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	co-administered	co-administered	JJ	_	14	nsubj
10	with	with	IN	_	13	case
11	drug3	drug3	NN	_	13	compound
12	10	10	CD	_	13	nummod
13	mg	mg	NN	_	9	nmod
14	resulted	result	VBD	_	1	dep
15	in	in	IN	_	18	case
16	a	a	DT	_	18	det
17	16-fold	16-fold	JJ	_	18	amod
18	increase	increase	NN	_	14	nmod
19	in	in	IN	_	21	case
20	drug4	drug4	NN	_	21	compound
21	AUC	auc	NN	_	18	nmod
22	,	,	,	_	18	punct
23	a	a	DT	_	25	det
24	7-fold	7-fold	JJ	_	25	amod
25	increase	increase	NN	_	18	conj
26	in	in	IN	_	28	case
27	drug5	drug5	NN	_	28	compound
28	Cmax	cmax	NN	_	25	nmod
29	and	and	CC	_	18	cc
30	a	a	DT	_	32	det
31	2-fold	2-fold	JJ	_	32	amod
32	increase	increase	NN	_	18	conj
33	in	in	IN	_	35	case
34	drug6	drug6	NN	_	35	compound
35	half-life	half-life	NN	_	32	nmod
36	.	.	.	_	1	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	recommended	recommend	VBN	_	0	ROOT
4	not	not	RB	_	6	neg
5	to	to	TO	_	6	mark
6	exceed	exceed	VB	_	3	xcomp
7	a	a	DT	_	12	det
8	single	single	JJ	_	12	amod
9	2.5	2.5	CD	_	10	compound
10	mg	mg	NN	_	12	amod
11	drug1	drug1	NN	_	12	compound
12	dose	dose	NN	_	6	dobj
13	in	in	IN	_	16	case
14	a	a	DT	_	16	det
15	24-hour	24-hour	JJ	_	16	amod
16	period	period	NN	_	6	nmod
17	when	when	WRB	_	18	advmod
18	used	use	VBN	_	16	acl:relcl
19	in	in	IN	_	20	case
20	combination	combination	NN	_	18	nmod
21	with	with	IN	_	22	case
22	drug2	drug2	NN	_	20	nmod
23	.	.	.	_	3	punct

1	drug1	drug1	NN	_	12	nsubj
2	-LRB-	-lrb-	-LRB-	_	5	punct
3	600	600	CD	_	5	nummod
4	mg	mg	NN	_	5	compound
5	b.i.d.	b.i.d.	NN	_	1	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	co-administered	co-administered	JJ	_	1	amod
8	with	with	IN	_	11	case
9	drug2	drug2	NN	_	11	compound
10	5	5	CD	_	11	nummod
11	mg	mg	NN	_	7	nmod
12	resulted	result	VBD	_	0	ROOT
13	in	in	IN	_	16	case
14	a	a	DT	_	16	det
15	49-fold	49-fold	JJ	_	16	amod
16	increase	increase	NN	_	12	nmod
17	in	in	IN	_	19	case
18	drug3	drug3	NN	_	19	compound
19	AUC	auc	NN	_	16	nmod
20	and	and	CC	_	16	cc
21	a	a	DT	_	23	det
22	13-fold	13-fold	RB	_	23	amod
23	increase	increase	NN	_	16	conj
24	in	in	IN	_	26	case
25	drug4	drug4	NN	_	26	compound
26	Cmax	cmax	NN	_	23	nmod
27	.	.	.	_	12	punct

1	The	the	DT	_	2	det
2	interaction	interaction	NN	_	5	nsubj
3	is	be	VBZ	_	5	cop
4	a	a	DT	_	5	det
5	consequence	consequence	NN	_	0	ROOT
6	of	of	IN	_	7	mark
7	blocking	block	VBG	_	5	acl
8	hepatic	hepatic	JJ	_	9	amod
9	metabolism	metabolism	NN	_	7	dobj
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	by	by	IN	_	13	case
13	drug2	drug2	NN	_	7	nmod
14	,	,	,	_	13	punct
15	a	a	DT	_	19	det
16	highly	highly	RB	_	17	advmod
17	potent	potent	JJ	_	19	amod
18	CYP3A4	cyp3a4	NN	_	19	compound
19	inhibitor	inhibitor	NN	_	13	appos
20	,	,	,	_	13	punct
21	which	which	WDT	_	23	nsubj
22	also	also	RB	_	23	advmod
23	inhibits	inhibit	VBZ	_	13	acl:relcl
24	CYP2C9	cyp2c9	NN	_	23	dobj
25	.	.	.	_	5	punct

1	drug1	drug1	NN	_	3	nsubj
2	significantly	significantly	RB	_	3	advmod
3	prolonged	prolong	VBD	_	0	ROOT
4	the	the	DT	_	5	det
5	half-life	half-life	NN	_	3	dobj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	to	to	TO	_	10	case
9	26	26	CD	_	10	nummod
10	hours	hour	NNS	_	3	nmod
11	.	.	.	_	3	punct

1	Consequently	consequently	RB	_	5	advmod
2	,	,	,	_	5	punct
3	it	it	PRP	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	recommended	recommend	VBN	_	0	ROOT
6	not	not	RB	_	8	neg
7	to	to	TO	_	8	mark
8	exceed	exceed	VB	_	5	xcomp
9	a	a	DT	_	14	det
10	single	single	JJ	_	14	amod
11	2.5	2.5	CD	_	12	compound
12	mg	mg	NN	_	14	amod
13	drug1	drug1	NN	_	14	compound
14	dose	dose	NN	_	8	dobj
15	in	in	IN	_	18	case
16	a	a	DT	_	18	det
17	72-hour	72-hour	JJ	_	18	amod
18	period	period	NN	_	8	nmod
19	when	when	WRB	_	20	advmod
20	used	use	VBN	_	18	acl:relcl
21	in	in	IN	_	22	case
22	combination	combination	NN	_	20	nmod
23	with	with	IN	_	24	case
24	drug2	drug2	NN	_	22	nmod
25	.	.	.	_	5	punct

1	Other	other	JJ	_	3	amod
2	Drug	drug	NN	_	3	compound
3	Interactions	interaction	NNS	_	0	ROOT
4	:	:	:	_	3	punct
5	No	no	DT	_	7	neg
6	pharmacokinetic	pharmacokinetic	JJ	_	7	amod
7	interactions	interaction	NNS	_	9	nsubjpass
8	were	be	VBD	_	9	auxpass
9	observed	observe	VBN	_	3	dep
10	between	between	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	the	the	DT	_	15	det
14	following	follow	VBG	_	15	amod
15	drugs	drug	NNS	_	11	conj
16	:	:	:	_	9	punct
17	drug2	drug2	NN	_	9	dep
18	,	,	,	_	17	punct
19	drug3	drug3	NN	_	17	conj
20	,	,	,	_	17	punct
21	drug4	drug4	NN	_	17	conj
22	,	,	,	_	17	punct
23	drug5	drug5	NN	_	17	conj
24	,	,	,	_	17	punct
25	and	and	CC	_	17	cc
26	drug6	drug6	NN	_	17	conj
27	.	.	.	_	3	punct

1	In	in	IN	_	4	case
2	the	the	DT	_	4	det
3	drug1	drug1	NN	_	4	compound
4	study	study	NN	_	7	nmod
5	,	,	,	_	7	punct
6	drug2	drug2	NN	_	7	nsubj
7	had	have	VBD	_	0	ROOT
8	no	no	DT	_	9	neg
9	effect	effect	NN	_	7	dobj
10	on	on	IN	_	13	case
11	the	the	DT	_	13	det
12	prothrombin	prothrombin	NN	_	13	compound
13	time	time	NN	_	7	nmod
14	or	or	CC	_	13	cc
15	other	other	JJ	_	17	amod
16	pharmacodynamic	pharmacodynamic	JJ	_	17	amod
17	parameters	parameter	NNS	_	13	conj
18	.	.	.	_	7	punct

1	Effects	effect	NNS	_	0	ROOT
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	on	on	IN	_	6	case
5	other	other	JJ	_	6	amod
6	drugs	drug	NNS	_	1	nmod

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	0	ROOT
4	:	:	:	_	3	punct
5	drug1	drug1	NN	_	9	nsubj
6	and	and	CC	_	5	cc
7	its	its	PRP$	_	8	nmod:poss
8	metabolites	metabolite	NNS	_	5	conj
9	had	have	VBD	_	3	dep
10	no	no	DT	_	11	neg
11	effect	effect	NN	_	9	dobj
12	on	on	IN	_	13	case
13	CYP1A2	cyp1a2	NN	_	9	nmod
14	,	,	,	_	13	punct
15	2A6	2a6	NN	_	13	conj
16	,	,	,	_	13	punct
17	and	and	CC	_	13	cc
18	2E1	2e1	NN	_	13	conj
19	-LRB-	-lrb-	-LRB-	_	21	punct
20	Ki	ki	NN	_	21	compound
21	100uM	100um	NN	_	18	appos
22	-RRB-	-rrb-	-RRB-	_	21	punct
23	.	.	.	_	9	punct

1	Weak	weak	JJ	_	3	amod
2	inhibitory	inhibitory	JJ	_	3	amod
3	effects	effect	NNS	_	19	nsubjpass
4	toward	toward	IN	_	6	case
5	other	other	JJ	_	6	amod
6	isoforms	isoform	NNS	_	3	nmod
7	-LRB-	-lrb-	-LRB-	_	8	punct
8	CYP2C8	cyp2c8	NN	_	6	dep
9	,	,	,	_	8	punct
10	2C9	2c9	NN	_	8	conj
11	,	,	,	_	8	punct
12	2C19	2c19	NN	_	8	conj
13	,	,	,	_	8	punct
14	2D6	2d6	NN	_	8	conj
15	,	,	,	_	8	punct
16	3A4	3a4	NN	_	8	appos
17	-RRB-	-rrb-	-RRB-	_	8	punct
18	were	be	VBD	_	19	auxpass
19	found	find	VBN	_	0	ROOT
20	,	,	,	_	19	punct
21	but	but	CC	_	19	cc
22	Ki	ki	NN	_	23	compound
23	values	value	NNS	_	26	nsubj
24	were	be	VBD	_	26	cop
25	in	in	IN	_	26	case
26	excess	excess	NN	_	19	conj
27	of	of	IN	_	29	case
28	plasma	plasma	NN	_	29	compound
29	concentrations	concentration	NNS	_	26	nmod
30	achieved	achieve	VBN	_	29	acl
31	following	follow	VBG	_	32	case
32	dosing	dosing	NN	_	30	nmod
33	.	.	.	_	19	punct

1	The	the	DT	_	5	det
2	most	most	RBS	_	3	advmod
3	potent	potent	JJ	_	5	amod
4	inhibitory	inhibitory	JJ	_	5	amod
5	activity	activity	NN	_	7	nsubjpass
6	was	be	VBD	_	7	auxpass
7	observed	observe	VBN	_	0	ROOT
8	for	for	IN	_	11	case
9	vardenafil	vardenafil	NN	_	11	compound
10	metabolite	metabolite	NN	_	11	compound
11	M1	m1	NN	_	7	nmod
12	,	,	,	_	11	punct
13	which	which	WDT	_	14	nsubj
14	had	have	VBD	_	11	acl:relcl
15	a	a	DT	_	16	det
16	Ki	ki	NN	_	14	dobj
17	of	of	IN	_	19	case
18	1.4	1.4	CD	_	19	nummod
19	uM	um	NN	_	16	nmod
20	toward	toward	IN	_	21	case
21	CYP3A4	cyp3a4	NN	_	16	nmod
22	,	,	,	_	11	punct
23	which	which	WDT	_	28	nsubj
24	is	be	VBZ	_	28	cop
25	about	about	IN	_	27	advmod
26	20	20	CD	_	27	compound
27	times	time	NNS	_	28	nmod:npmod
28	higher	higher	JJR	_	11	acl:relcl
29	than	than	IN	_	33	case
30	the	the	DT	_	33	det
31	M1	m1	NN	_	33	compound
32	Cmax	cmax	NN	_	33	compound
33	values	value	NNS	_	28	nmod
34	after	after	IN	_	39	case
35	an	a	DT	_	39	det
36	80	80	CD	_	39	nummod
37	mg	mg	NN	_	39	compound
38	drug1	drug1	NN	_	39	compound
39	dose	dose	NN	_	33	nmod
40	.	.	.	_	7	punct

1	In	in	FW	_	3	amod
2	vivo	vivo	FW	_	1	dep
3	studies	study	NNS	_	0	ROOT
4	:	:	:	_	3	punct
5	drug1	drug1	NN	_	3	dep
6	:	:	:	_	5	punct
7	The	the	DT	_	9	det
8	blood	blood	NN	_	9	compound
9	pressure	pressure	NN	_	41	nsubjpass
10	lowering	lower	VBG	_	9	acl
11	effects	effect	NNS	_	10	dobj
12	of	of	IN	_	14	case
13	sublingual	sublingual	JJ	_	14	amod
14	drug2	drug2	NN	_	11	nmod
15	-LRB-	-lrb-	-LRB-	_	17	punct
16	0.4	0.4	CD	_	17	nummod
17	mg	mg	NN	_	14	appos
18	-RRB-	-rrb-	-RRB-	_	17	punct
19	taken	take	VBN	_	14	acl
20	1	1	CD	_	23	nummod
21	and	and	CC	_	20	cc
22	4	4	CD	_	20	conj
23	hours	hour	NNS	_	19	nmod
24	after	after	IN	_	23	case
25	drug3	drug3	NN	_	23	dep
26	and	and	CC	_	9	cc
27	increases	increase	VBZ	_	9	conj
28	in	in	IN	_	30	case
29	heart	heart	NN	_	30	compound
30	rate	rate	NN	_	27	nmod
31	when	when	WRB	_	32	advmod
32	taken	take	VBN	_	27	advcl
33	at	at	IN	_	39	case
34	1	1	CD	_	39	nummod
35	,	,	,	_	34	punct
36	4	4	CD	_	34	conj
37	and	and	CC	_	34	cc
38	8	8	CD	_	34	conj
39	hours	hour	NNS	_	32	nmod
40	were	be	VBD	_	41	auxpass
41	potentiated	potentiate	VBN	_	5	dep
42	by	by	IN	_	46	case
43	a	a	DT	_	46	det
44	20	20	CD	_	45	compound
45	mg	mg	NN	_	46	amod
46	dose	dose	NN	_	41	nmod
47	of	of	IN	_	48	case
48	drug4	drug4	NN	_	46	nmod
49	in	in	IN	_	52	case
50	healthy	healthy	JJ	_	52	amod
51	middle-aged	middle-aged	JJ	_	52	amod
52	subjects	subject	NNS	_	41	nmod
53	.	.	.	_	3	punct

1	These	these	DT	_	2	det
2	effects	effect	NNS	_	5	nsubjpass
3	were	be	VBD	_	5	auxpass
4	not	not	RB	_	5	neg
5	observed	observe	VBN	_	0	ROOT
6	when	when	WRB	_	11	advmod
7	drug1	drug1	NN	_	9	compound
8	20	20	CD	_	9	nummod
9	mg	mg	NN	_	11	nsubjpass
10	was	be	VBD	_	11	auxpass
11	taken	take	VBN	_	5	advcl
12	24	24	CD	_	13	nummod
13	hours	hour	NNS	_	11	nmod
14	before	before	IN	_	13	case
15	the	the	DT	_	16	det
16	drug2	drug2	NN	_	13	dep
17	.	.	.	_	5	punct

1	Potentiation	potentiation	NN	_	17	nsubjpass
2	of	of	IN	_	5	case
3	the	the	DT	_	5	det
4	hypotensive	hypotensive	JJ	_	5	amod
5	effects	effect	NNS	_	1	nmod
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	for	for	IN	_	9	case
9	patients	patient	NNS	_	5	nmod
10	with	with	IN	_	13	case
11	ischemic	ischemic	JJ	_	13	amod
12	heart	heart	NN	_	13	compound
13	disease	disease	NN	_	9	nmod
14	has	have	VBZ	_	17	aux
15	not	not	RB	_	17	neg
16	been	be	VBN	_	17	auxpass
17	evaluated	evaluate	VBN	_	0	ROOT
18	,	,	,	_	17	punct
19	and	and	CC	_	17	cc
20	concomitant	concomitant	JJ	_	21	amod
21	use	use	NN	_	27	nsubjpass
22	of	of	IN	_	23	case
23	drug2	drug2	NN	_	21	nmod
24	and	and	CC	_	23	cc
25	drug3	drug3	NN	_	23	conj
26	is	be	VBZ	_	27	auxpass
27	contraindicated	contraindicate	VBN	_	17	conj
28	.	.	.	_	17	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	compound
4	20	20	CD	_	5	nummod
5	mg	mg	NN	_	22	nsubj
6	,	,	,	_	5	punct
7	when	when	WRB	_	8	advmod
8	co-administered	co-administer	VBN	_	5	acl:relcl
9	with	with	IN	_	11	case
10	slow-release	slow-release	NN	_	11	compound
11	drug3	drug3	NN	_	8	nmod
12	30	30	CD	_	13	nummod
13	mg	mg	NN	_	11	dep
14	or	or	CC	_	13	cc
15	60	60	CD	_	16	nummod
16	mg	mg	NN	_	13	conj
17	once	once	RB	_	18	advmod
18	daily	daily	RB	_	8	advmod
19	,	,	,	_	5	punct
20	did	do	VBD	_	22	aux
21	not	not	RB	_	22	neg
22	affect	affect	VB	_	1	dep
23	the	the	DT	_	25	det
24	relative	relative	JJ	_	25	amod
25	bioavailability	bioavailability	NN	_	22	dobj
26	-LRB-	-lrb-	-LRB-	_	27	punct
27	AUC	auc	NN	_	25	appos
28	-RRB-	-rrb-	-RRB-	_	27	punct
29	or	or	CC	_	25	cc
30	maximum	maximum	NN	_	31	compound
31	concentration	concentration	NN	_	25	conj
32	-LRB-	-lrb-	-LRB-	_	33	punct
33	Cmax	cmax	NN	_	31	appos
34	-RRB-	-rrb-	-RRB-	_	33	punct
35	of	of	IN	_	36	case
36	drug4	drug4	NN	_	25	nmod
37	,	,	,	_	25	punct
38	a	a	DT	_	39	det
39	drug	drug	NN	_	25	appos
40	that	that	WDT	_	42	nsubjpass
41	is	be	VBZ	_	42	auxpass
42	metabolized	metabolize	VBN	_	39	acl:relcl
43	via	via	IN	_	44	case
44	CYP3A4	cyp3a4	NN	_	42	nmod
45	.	.	.	_	1	punct

1	drug1	drug1	NN	_	4	nsubj
2	did	do	VBD	_	4	aux
3	not	not	RB	_	4	neg
4	alter	alter	VB	_	0	ROOT
5	the	the	DT	_	7	det
6	plasma	plasma	NN	_	7	compound
7	levels	level	NNS	_	4	dobj
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	when	when	WRB	_	11	advmod
11	taken	take	VBN	_	4	advcl
12	in	in	IN	_	13	case
13	combination	combination	NN	_	11	nmod
14	.	.	.	_	4	punct

1	In	in	IN	_	3	case
2	these	these	DT	_	3	det
3	patients	patient	NNS	_	14	nmod
4	whose	whose	WP$	_	5	nmod:poss
5	hypertension	hypertension	NN	_	7	nsubjpass
6	was	be	VBD	_	7	auxpass
7	controlled	control	VBN	_	3	acl:relcl
8	with	with	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	,	,	,	_	14	punct
11	drug2	drug2	NN	_	13	compound
12	20	20	CD	_	13	nummod
13	mg	mg	NN	_	14	nsubj
14	produced	produce	VBD	_	0	ROOT
15	mean	mean	JJ	_	21	amod
16	additional	additional	JJ	_	21	amod
17	supine	supine	NN	_	21	compound
18	systolic/diastolic	systolic/diastolic	JJ	_	21	amod
19	blood	blood	NN	_	21	compound
20	pressure	pressure	NN	_	21	compound
21	reductions	reduction	NNS	_	14	dobj
22	of	of	IN	_	25	case
23	6/5	6/5	CD	_	25	nummod
24	mm	mm	NN	_	25	compound
25	Hg	hg	NN	_	21	nmod
26	compared	compare	VBN	_	28	case
27	to	to	TO	_	28	case
28	placebo	placebo	NN	_	21	acl
29	.	.	.	_	14	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	When	when	WRB	_	10	advmod
4	drug2	drug2	NN	_	10	nsubjpass
5	10	10	CD	_	4	nummod
6	or	or	CC	_	4	cc
7	20	20	CD	_	8	nummod
8	mg	mg	NN	_	4	conj
9	was	be	VBD	_	10	auxpass
10	given	give	VBN	_	29	advcl
11	to	to	TO	_	13	case
12	healthy	healthy	JJ	_	13	amod
13	volunteers	volunteer	NNS	_	10	nmod
14	either	either	CC	_	15	cc:preconj
15	simultaneously	simultaneously	RB	_	10	advmod
16	or	or	CC	_	15	cc
17	6	6	CD	_	15	conj
18	hours	hour	NNS	_	15	dep
19	after	after	IN	_	23	case
20	a	a	DT	_	23	det
21	10	10	CD	_	22	compound
22	mg	mg	NN	_	23	amod
23	dose	dose	NN	_	10	nmod
24	of	of	IN	_	25	case
25	drug3	drug3	NN	_	23	nmod
26	,	,	,	_	29	punct
27	significant	significant	JJ	_	28	amod
28	hypotension	hypotension	NN	_	29	nsubj
29	developed	develop	VBN	_	1	dep
30	in	in	IN	_	33	case
31	a	a	DT	_	33	det
32	substantial	substantial	JJ	_	33	amod
33	number	number	NN	_	29	nmod
34	of	of	IN	_	35	case
35	subjects	subject	NNS	_	33	nmod
36	.	.	.	_	1	punct

1	With	with	IN	_	3	case
2	simultaneous	simultaneous	JJ	_	3	amod
3	dosing	dosing	NN	_	17	nmod
4	of	of	IN	_	7	case
5	drug1	drug1	NN	_	7	compound
6	10	10	CD	_	7	nummod
7	mg	mg	NN	_	3	nmod
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	11	compound
10	10	10	CD	_	11	nummod
11	mg	mg	NN	_	7	conj
12	,	,	,	_	17	punct
13	6	6	CD	_	17	nsubj
14	of	of	IN	_	16	case
15	8	8	CD	_	16	nummod
16	subjects	subject	NNS	_	13	nmod
17	experienced	experience	VBD	_	0	ROOT
18	a	a	DT	_	22	det
19	standing	standing	NN	_	22	amod
20	systolic	systolic	JJ	_	22	amod
21	blood	blood	NN	_	22	compound
22	pressure	pressure	NN	_	17	dobj
23	of	of	IN	_	28	case
24	less	less	JJR	_	26	advmod
25	than	than	IN	_	24	mwe
26	85	85	CD	_	28	nummod
27	mm	mm	NN	_	28	compound
28	Hg	hg	NN	_	22	nmod
29	.	.	.	_	17	punct

1	With	with	IN	_	3	case
2	simultaneous	simultaneous	JJ	_	3	amod
3	dosing	dosing	NN	_	17	nmod
4	of	of	IN	_	7	case
5	drug1	drug1	NN	_	7	compound
6	20	20	CD	_	7	nummod
7	mg	mg	NN	_	3	nmod
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	11	compound
10	10	10	CD	_	11	nummod
11	mg	mg	NN	_	7	conj
12	,	,	,	_	11	punct
13	2	2	CD	_	15	compound
14	of	of	IN	_	15	advmod
15	9	9	CD	_	16	nummod
16	subjects	subject	NNS	_	11	appos
17	experienced	experience	VBD	_	0	ROOT
18	a	a	DT	_	22	det
19	standing	standing	NN	_	22	amod
20	systolic	systolic	JJ	_	22	amod
21	blood	blood	NN	_	22	compound
22	pressure	pressure	NN	_	17	dobj
23	of	of	IN	_	28	case
24	less	less	JJR	_	26	advmod
25	than	than	IN	_	24	mwe
26	85	85	CD	_	28	nummod
27	mm	mm	NN	_	28	compound
28	Hg	hg	NN	_	22	nmod
29	.	.	.	_	17	punct

1	When	when	WRB	_	5	advmod
2	drug1	drug1	NN	_	3	compound
3	dosing	dosing	NN	_	5	nsubjpass
4	was	be	VBD	_	5	auxpass
5	separated	separate	VBN	_	24	advcl
6	from	from	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	10	10	CD	_	9	nummod
9	mg	mg	NN	_	7	dep
10	by	by	IN	_	12	case
11	6	6	CD	_	12	nummod
12	hours	hour	NNS	_	9	nmod
13	,	,	,	_	9	punct
14	7	7	CD	_	16	compound
15	of	of	IN	_	16	advmod
16	28	28	CD	_	17	nummod
17	subjects	subject	NNS	_	9	appos
18	who	who	WP	_	19	nsubj
19	received	receive	VBD	_	17	acl:relcl
20	20	20	CD	_	21	nummod
21	mg	mg	NN	_	19	dobj
22	of	of	IN	_	23	case
23	drug3	drug3	NN	_	21	nmod
24	experienced	experience	VBD	_	0	ROOT
25	a	a	DT	_	26	det
26	decrease	decrease	NN	_	24	dobj
27	in	in	IN	_	28	mark
28	standing	stand	VBG	_	26	acl
29	systolic	systolic	JJ	_	31	amod
30	blood	blood	NN	_	31	compound
31	pressure	pressure	NN	_	28	dobj
32	below	below	IN	_	35	case
33	85	85	CD	_	35	nummod
34	mm	mm	NN	_	35	compound
35	Hg	hg	NN	_	28	nmod
36	.	.	.	_	24	punct

1	In	in	IN	_	4	case
2	a	a	DT	_	4	det
3	similar	similar	JJ	_	4	amod
4	study	study	NN	_	28	nmod
5	with	with	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	in	in	IN	_	9	case
8	healthy	healthy	JJ	_	9	amod
9	volunteers	volunteer	NNS	_	6	nmod
10	,	,	,	_	28	punct
11	1	1	CD	_	28	nsubj
12	of	of	IN	_	14	case
13	24	24	CD	_	14	nummod
14	subjects	subject	NNS	_	11	nmod
15	dosed	dosed	JJ	_	14	amod
16	with	with	IN	_	19	case
17	drug2	drug2	NN	_	19	compound
18	20	20	CD	_	19	nummod
19	mg	mg	NN	_	15	nmod
20	and	and	CC	_	19	cc
21	drug3	drug3	NN	_	23	compound
22	0.4	0.4	CD	_	23	nummod
23	mg	mg	NN	_	19	conj
24	separated	separate	VBN	_	19	acl
25	by	by	IN	_	27	case
26	6	6	CD	_	27	nummod
27	hours	hour	NNS	_	24	nmod
28	experienced	experience	VBD	_	0	ROOT
29	a	a	DT	_	33	det
30	standing	standing	NN	_	33	compound
31	systolic	systolic	JJ	_	33	amod
32	blood	blood	NN	_	33	compound
33	pressure	pressure	NN	_	28	dobj
34	below	below	IN	_	37	case
35	85	85	CD	_	37	nummod
36	mm	mm	NN	_	37	compound
37	Hg	hg	NN	_	33	nmod
38	.	.	.	_	28	punct

1	Two	two	CD	_	3	compound
2	of	of	IN	_	3	advmod
3	16	16	CD	_	4	nummod
4	subjects	subject	NNS	_	15	nsubj
5	dosed	dosed	JJ	_	4	amod
6	simultaneously	simultaneously	RB	_	5	advmod
7	with	with	IN	_	10	case
8	drug1	drug1	NN	_	10	compound
9	10	10	CD	_	10	nummod
10	mg	mg	NN	_	5	nmod
11	and	and	CC	_	10	cc
12	drug2	drug2	NN	_	14	compound
13	0.4	0.4	CD	_	14	nummod
14	mg	mg	NN	_	10	conj
15	experienced	experience	VBD	_	0	ROOT
16	a	a	DT	_	20	det
17	standing	standing	NN	_	20	compound
18	systolic	systolic	JJ	_	20	amod
19	blood	blood	NN	_	20	compound
20	pressure	pressure	NN	_	15	dobj
21	below	below	IN	_	24	case
22	85	85	CD	_	24	nummod
23	mm	mm	NN	_	24	compound
24	Hg	hg	NN	_	20	nmod
25	.	.	.	_	15	punct

1	The	the	DT	_	2	det
2	administration	administration	NN	_	14	nsubjpass
3	of	of	IN	_	5	case
4	lower	lower	JJR	_	5	amod
5	doses	dose	NNS	_	2	nmod
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	with	with	IN	_	9	case
9	drug2	drug2	NN	_	2	nmod
10	has	have	VBZ	_	14	aux
11	not	not	RB	_	14	neg
12	been	be	VBN	_	14	auxpass
13	completely	completely	RB	_	14	advmod
14	evaluated	evaluate	VBN	_	0	ROOT
15	to	to	TO	_	16	mark
16	determine	determine	VB	_	14	xcomp
17	if	if	IN	_	22	mark
18	they	they	PRP	_	22	nsubjpass
19	can	can	MD	_	22	aux
20	be	be	VB	_	22	auxpass
21	safely	safely	RB	_	22	advmod
22	administered	administer	VBN	_	16	advcl
23	together	together	RB	_	22	advmod
24	.	.	.	_	14	punct

1	Based	base	VBN	_	4	case
2	on	on	IN	_	4	case
3	these	these	DT	_	4	det
4	data	datum	NNS	_	10	advcl
5	,	,	,	_	10	punct
6	drug1	drug1	NN	_	10	nsubjpass
7	should	should	MD	_	10	aux
8	not	not	RB	_	10	neg
9	be	be	VB	_	10	auxpass
10	used	use	VBN	_	0	ROOT
11	in	in	IN	_	12	case
12	patients	patient	NNS	_	10	nmod
13	on	on	IN	_	15	case
14	drug2	drug2	NN	_	15	compound
15	therapy	therapy	NN	_	12	nmod
16	.	.	.	_	10	punct

1	drug1	drug1	NN	_	0	ROOT
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	:	:	:	_	1	punct
5	Upon	upon	IN	_	7	case
6	concomitant	concomitant	JJ	_	7	amod
7	administration	administration	NN	_	1	nmod
8	of	of	IN	_	10	case
9	5	5	CD	_	10	nummod
10	mg	mg	NN	_	7	nmod
11	of	of	IN	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	with	with	IN	_	17	case
14	600	600	CD	_	17	nummod
15	mg	mg	NN	_	17	compound
16	BID	BID	NNP	_	17	compound
17	drug4	drug4	NN	_	7	nmod
18	,	,	,	_	7	punct
19	the	the	DT	_	20	det
20	Cmax	Cmax	NNP	_	26	nsubjpass
21	and	and	CC	_	20	cc
22	AUC	auc	NN	_	20	conj
23	of	of	IN	_	24	case
24	drug5	drug5	NN	_	20	nmod
25	were	be	VBD	_	26	auxpass
26	reduced	reduce	VBN	_	7	acl:relcl
27	by	by	IN	_	30	case
28	approximately	approximately	RB	_	29	advmod
29	20	20	CD	_	30	nummod
30	%	%	NN	_	26	nmod
31	.	.	.	_	1	punct

1	Upon	upon	IN	_	2	case
2	administration	administration	NN	_	21	nmod
3	of	of	IN	_	5	case
4	10	10	CD	_	5	nummod
5	mg	mg	NN	_	2	nmod
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	with	with	IN	_	12	case
9	800	800	CD	_	12	nummod
10	mg	mg	NN	_	12	compound
11	TID	tid	NN	_	12	compound
12	drug2	drug2	NN	_	2	nmod
13	,	,	,	_	21	punct
14	the	the	DT	_	15	det
15	Cmax	Cmax	NNP	_	21	nsubjpass
16	and	and	CC	_	15	cc
17	AUC	auc	NN	_	15	conj
18	of	of	IN	_	19	case
19	drug3	drug3	NN	_	15	nmod
20	were	be	VBD	_	21	auxpass
21	reduced	reduce	VBN	_	0	ROOT
22	by	by	IN	_	24	case
23	40	40	CD	_	24	nummod
24	%	%	NN	_	21	nmod
25	and	and	CC	_	24	cc
26	30	30	CD	_	27	nummod
27	%	%	NN	_	24	conj
28	,	,	,	_	24	punct
29	respectively	respectively	RB	_	24	advmod
30	.	.	.	_	21	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	25	compound
4	-LRB-	-lrb-	-LRB-	_	8	punct
5	0.5	0.5	CD	_	8	nummod
6	g/kg	g/kg	NN	_	8	compound
7	body	body	NN	_	8	compound
8	weight	weight	NN	_	3	dep
9	:	:	:	_	8	punct
10	approximately	approximately	RB	_	11	advmod
11	40	40	CD	_	12	nummod
12	mL	ml	NN	_	8	dep
13	of	of	IN	_	15	case
14	absolute	absolute	JJ	_	15	amod
15	alcohol	alcohol	NN	_	12	nmod
16	in	in	IN	_	20	case
17	a	a	DT	_	20	det
18	70	70	CD	_	20	nummod
19	kg	kg	NN	_	20	compound
20	person	person	NN	_	12	nmod
21	-RRB-	-rrb-	-RRB-	_	8	punct
22	and	and	CC	_	3	cc
23	drug3	drug3	NN	_	3	conj
24	plasma	plasma	NN	_	25	compound
25	levels	level	NNS	_	28	nsubjpass
26	were	be	VBD	_	28	auxpass
27	not	not	RB	_	28	neg
28	altered	alter	VBN	_	1	appos
29	when	when	WRB	_	30	advmod
30	dosed	dose	VBN	_	28	advcl
31	simultaneously	simultaneously	RB	_	30	advmod
32	.	.	.	_	1	punct

1	drug1	drug1	NN	_	8	nsubj
2	-LRB-	-lrb-	-LRB-	_	4	punct
3	20	20	CD	_	4	nummod
4	mg	mg	NN	_	1	appos
5	-RRB-	-rrb-	-RRB-	_	4	punct
6	did	do	VBD	_	8	aux
7	not	not	RB	_	8	neg
8	potentiate	potentiate	VB	_	0	ROOT
9	the	the	DT	_	11	det
10	hypotensive	hypotensive	JJ	_	11	amod
11	effects	effect	NNS	_	8	dobj
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	during	during	IN	_	18	case
15	the	the	DT	_	18	det
16	4-hour	4-hour	JJ	_	18	amod
17	observation	observation	NN	_	18	compound
18	period	period	NN	_	11	nmod
19	in	in	IN	_	21	case
20	healthy	healthy	JJ	_	21	amod
21	volunteers	volunteer	NNS	_	18	nmod
22	when	when	WRB	_	23	advmod
23	administered	administer	VBN	_	8	advcl
24	with	with	IN	_	25	case
25	drug3	drug3	NN	_	23	nmod
26	-LRB-	-lrb-	-LRB-	_	30	punct
27	0.5	0.5	CD	_	30	nummod
28	g/kg	g/kg	NN	_	30	compound
29	body	body	NN	_	30	compound
30	weight	weight	NN	_	25	appos
31	-RRB-	-rrb-	-RRB-	_	30	punct
32	.	.	.	_	8	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	13	nsubj
4	-LRB-	-lrb-	-LRB-	_	6	punct
5	10	10	CD	_	6	nummod
6	mg	mg	NN	_	3	dep
7	and	and	CC	_	6	cc
8	20	20	CD	_	9	nummod
9	mg	mg	NN	_	6	conj
10	-RRB-	-rrb-	-RRB-	_	6	punct
11	did	do	VBD	_	13	aux
12	not	not	RB	_	13	neg
13	potentiate	potentiate	VB	_	1	dep
14	the	the	DT	_	15	det
15	increase	increase	NN	_	13	dobj
16	in	in	IN	_	18	case
17	bleeding	bleeding	JJ	_	18	amod
18	time	time	NN	_	15	nmod
19	caused	cause	VBN	_	18	acl
20	by	by	IN	_	21	case
21	drug3	drug3	NN	_	19	nmod
22	-LRB-	-lrb-	-LRB-	_	26	punct
23	two	two	CD	_	26	nummod
24	81	81	CD	_	26	nummod
25	mg	mg	NN	_	26	compound
26	tablets	tablet	NNS	_	21	appos
27	-RRB-	-rrb-	-RRB-	_	26	punct
28	.	.	.	_	1	punct

1	Other	other	JJ	_	2	amod
2	interactions	interaction	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	drug1	drug1	NN	_	5	nsubj
5	had	have	VBD	_	2	dep
6	no	no	DT	_	7	neg
7	effect	effect	NN	_	5	dobj
8	on	on	IN	_	10	case
9	the	the	DT	_	10	det
10	pharmacodynamics	pharmacodynamic	NNS	_	5	nmod
11	of	of	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	glucose	glucose	NN	_	12	dep
15	and	and	CC	_	14	cc
16	insulin	insulin	NN	_	17	compound
17	concentrations	concentration	NNS	_	14	conj
18	-RRB-	-rrb-	-RRB-	_	14	punct
19	and	and	CC	_	12	cc
20	drug3	drug3	NN	_	23	compound
21	-LRB-	-lrb-	-LRB-	_	23	punct
22	prothrombin	prothrombin	NN	_	23	compound
23	time	time	NN	_	12	conj
24	or	or	CC	_	23	cc
25	other	other	JJ	_	27	amod
26	pharmacodynamic	pharmacodynamic	JJ	_	27	amod
27	parameters	parameter	NNS	_	23	conj
28	-RRB-	-rrb-	-RRB-	_	23	punct
29	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	When	when	WRB	_	4	advmod
4	coadministered	coadminister	VBN	_	17	advcl
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	,	,	,	_	6	punct
8	drug3	drug3	NN	_	6	conj
9	,	,	,	_	6	punct
10	a	a	DT	_	11	det
11	drug	drug	NN	_	6	appos
12	which	which	WDT	_	13	nsubj
13	increases	increase	VBZ	_	11	acl:relcl
14	gastrointestinal	gastrointestinal	JJ	_	15	amod
15	motility	motility	NN	_	13	dobj
16	,	,	,	_	17	punct
17	lowers	lower	VBZ	_	1	dep
18	the	the	DT	_	20	det
19	serum	serum	NN	_	20	compound
20	concentration	concentration	NN	_	17	dobj
21	and	and	CC	_	20	cc
22	urinary	urinary	JJ	_	23	amod
23	excretion	excretion	NN	_	20	conj
24	of	of	IN	_	25	case
25	drug4	drug4	NN	_	20	nmod
26	.	.	.	_	1	punct

1	Other	other	JJ	_	2	amod
2	drugs	drug	NNS	_	8	nsubj
3	that	that	WDT	_	4	nsubj
4	increase	increase	VBP	_	2	acl:relcl
5	gastrointestinal	gastrointestinal	JJ	_	6	amod
6	motility	motility	NN	_	4	dobj
7	may	may	MD	_	8	aux
8	produce	produce	VB	_	0	ROOT
9	similar	similar	JJ	_	10	amod
10	effects	effect	NNS	_	8	dobj
11	.	.	.	_	8	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	6	nsubj
4	does	do	VBZ	_	6	aux
5	not	not	RB	_	6	neg
6	affect	affect	VB	_	1	dep
7	the	the	DT	_	8	det
8	pharmacokinetics	pharmacokinetic	NNS	_	6	dobj
9	of	of	IN	_	10	case
10	drug3	drug3	NN	_	8	nmod
11	when	when	WRB	_	12	advmod
12	coadministered	coadminister	VBN	_	6	advcl
13	with	with	IN	_	14	case
14	drug4	drug4	NN	_	12	nmod
15	.	.	.	_	1	punct

1	Co-administration	co-administration	NN	_	8	nsubjpass
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	1	nmod
6	has	have	VBZ	_	8	aux
7	been	be	VBN	_	8	auxpass
8	shown	show	VBN	_	0	ROOT
9	to	to	TO	_	10	mark
10	increase	increase	VB	_	8	xcomp
11	the	the	DT	_	13	det
12	mean	mean	NN	_	13	compound
13	half-life	half-life	NN	_	10	dobj
14	and	and	CC	_	13	cc
15	the	the	DT	_	16	det
16	area	area	NN	_	13	conj
17	under	under	IN	_	20	case
18	the	the	DT	_	20	det
19	concentration-time	concentration-time	JJ	_	20	amod
20	curve	curve	NN	_	10	nmod
21	.	.	.	_	8	punct

1	Urinary	urinary	JJ	_	2	amod
2	excretion	excretion	NN	_	8	nsubjpass
3	and	and	CC	_	2	cc
4	renal	renal	JJ	_	5	amod
5	clearance	clearance	NN	_	2	conj
6	were	be	VBD	_	8	auxpass
7	correspondingly	correspondingly	RB	_	8	advmod
8	reduced	reduce	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	effects	effect	NNS	_	10	nsubjpass
4	of	of	IN	_	6	case
5	this	this	DT	_	6	det
6	combination	combination	NN	_	3	nmod
7	have	have	VBP	_	10	aux
8	not	not	RB	_	10	neg
9	been	be	VBN	_	10	auxpass
10	studied	study	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	No	no	DT	_	3	neg
2	reported	report	VBN	_	3	amod
3	interactions	interaction	NNS	_	0	ROOT
4	.	.	.	_	3	punct

1	Steady-state	steady-state	JJ	_	3	amod
2	serum	serum	NN	_	3	compound
3	concentrations	concentration	NNS	_	7	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	are	be	VBP	_	7	auxpass
7	reported	report	VBN	_	0	ROOT
8	to	to	TO	_	9	mark
9	fluctuate	fluctuate	VB	_	7	xcomp
10	significantly	significantly	RB	_	9	advmod
11	when	when	WRB	_	15	advmod
12	drug2	drug2	NN	_	15	nsubjpass
13	is	be	VBZ	_	15	auxpass
14	either	either	CC	_	15	cc:preconj
15	added	add	VBN	_	9	advcl
16	or	or	CC	_	15	cc
17	deleted	delete	VBN	_	15	conj
18	from	from	IN	_	21	case
19	the	the	DT	_	21	det
20	drug	drug	NN	_	21	compound
21	regimen	regimen	NN	_	15	nmod
22	.	.	.	_	7	punct

1	Serious	serious	JJ	_	3	amod
2	anticholinergic	anticholinergic	JJ	_	3	amod
3	symptoms	symptom	NNS	_	17	nsubjpass
4	-LRB-	-lrb-	-LRB-	_	7	punct
5	severe	severe	JJ	_	7	amod
6	dry	dry	JJ	_	7	amod
7	mouth	mouth	NN	_	3	dep
8	,	,	,	_	7	punct
9	urinary	urinary	JJ	_	10	amod
10	retention	retention	NN	_	7	appos
11	,	,	,	_	7	punct
12	blurred	blur	VBD	_	13	amod
13	vision	vision	NN	_	7	appos
14	-RRB-	-rrb-	-RRB-	_	7	punct
15	have	have	VBP	_	17	aux
16	been	be	VBN	_	17	auxpass
17	associated	associate	VBN	_	0	ROOT
18	with	with	IN	_	19	case
19	elevations	elevation	NNS	_	17	nmod
20	in	in	IN	_	23	case
21	the	the	DT	_	23	det
22	serum	serum	NN	_	23	compound
23	levels	level	NNS	_	19	nmod
24	of	of	IN	_	25	case
25	drug1	drug1	NN	_	23	nmod
26	when	when	WRB	_	29	advmod
27	drug2	drug2	NN	_	29	nsubjpass
28	is	be	VBZ	_	29	auxpass
29	added	add	VBN	_	17	advcl
30	to	to	TO	_	33	case
31	the	the	DT	_	33	det
32	drug	drug	NN	_	33	compound
33	regimen	regimen	NN	_	29	nmod
34	.	.	.	_	17	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	5	nmod
3	,	,	,	_	5	punct
4	higher-than	higher-than	NN	_	5	nsubj
5	expected	expect	VBD	_	0	ROOT
6	steady-state	steady-state	JJ	_	8	amod
7	serum	serum	NN	_	8	compound
8	concentrations	concentration	NNS	_	13	nsubjpass
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	have	have	VBP	_	13	aux
12	been	be	VBN	_	13	auxpass
13	observed	observe	VBN	_	5	ccomp
14	when	when	WRB	_	17	advmod
15	therapy	therapy	NN	_	17	nsubjpass
16	is	be	VBZ	_	17	auxpass
17	initiated	initiate	VBN	_	13	advcl
18	in	in	IN	_	19	case
19	patients	patient	NNS	_	17	nmod
20	already	already	RB	_	21	advmod
21	taking	take	VBG	_	19	acl
22	drug2	drug2	NN	_	21	dobj
23	.	.	.	_	5	punct

1	In	in	IN	_	3	case
2	well-controlled	well-controlled	JJ	_	3	amod
3	patients	patient	NNS	_	20	nmod
4	undergoing	undergo	VBG	_	3	acl
5	concurrent	concurrent	JJ	_	6	amod
6	therapy	therapy	NN	_	4	dobj
7	with	with	IN	_	8	case
8	drug1	drug1	NN	_	4	nmod
9	,	,	,	_	20	punct
10	a	a	DT	_	11	det
11	decrease	decrease	NN	_	20	nsubj
12	in	in	IN	_	16	case
13	the	the	DT	_	16	det
14	steady-state	steady-state	JJ	_	16	amod
15	serum	serum	NN	_	16	compound
16	concentrations	concentration	NNS	_	11	nmod
17	of	of	IN	_	18	case
18	drug2	drug2	NN	_	16	nmod
19	may	may	MD	_	20	aux
20	occur	occur	VB	_	0	ROOT
21	when	when	WRB	_	25	advmod
22	cime-tidine	cime-tidine	NN	_	23	compound
23	therapy	therapy	NN	_	25	nsubjpass
24	is	be	VBZ	_	25	auxpass
25	discontinued	discontinue	VBN	_	20	advcl
26	.	.	.	_	20	punct

1	The	the	DT	_	3	det
2	therapeutic	therapeutic	JJ	_	3	amod
3	efficacy	efficacy	NN	_	8	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	compromised	compromise	VBN	_	0	ROOT
9	in	in	IN	_	11	case
10	these	these	DT	_	11	det
11	patients	patient	NNS	_	8	nmod
12	when	when	WRB	_	15	advmod
13	drug2	drug2	NN	_	15	nsubjpass
14	is	be	VBZ	_	15	auxpass
15	discontinued	discontinue	VBN	_	8	advcl
16	.	.	.	_	8	punct

1	Several	several	JJ	_	7	nsubjpass
2	of	of	IN	_	4	case
3	the	the	DT	_	4	det
4	drug1	drug1	NN	_	1	nmod
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	cited	cite	VBN	_	0	ROOT
8	in	in	IN	_	10	case
9	these	these	DT	_	10	det
10	reports	report	NNS	_	7	nmod
11	.	.	.	_	7	punct

1	There	there	EX	_	4	expl
2	have	have	VBP	_	4	aux
3	been	be	VBN	_	4	cop
4	greater	greater	JJR	_	0	ROOT
5	than	than	IN	_	6	case
6	2-fold	2-fold	JJ	_	4	nmod
7	increases	increase	NNS	_	6	dep
8	in	in	IN	_	12	case
9	previously	previously	RB	_	10	advmod
10	stable	stable	JJ	_	12	amod
11	plasma	plasma	NN	_	12	compound
12	levels	level	NNS	_	6	nmod
13	of	of	IN	_	15	case
14	other	other	JJ	_	15	amod
15	drug1	drug1	NN	_	12	nmod
16	,	,	,	_	15	punct
17	including	include	VBG	_	18	case
18	drug2	drug2	NN	_	15	nmod
19	,	,	,	_	15	punct
20	when	when	WRB	_	24	advmod
21	drug3	drug3	NN	_	24	nsubjpass
22	has	have	VBZ	_	24	aux
23	been	be	VBN	_	24	auxpass
24	administered	administer	VBN	_	15	acl:relcl
25	in	in	IN	_	26	case
26	combination	combination	NN	_	24	nmod
27	with	with	IN	_	29	case
28	these	these	DT	_	29	det
29	agents	agent	NNS	_	26	nmod
30	.	.	.	_	4	punct

1	drug1	drug1	NN	_	9	nsubj
2	and	and	CC	_	1	cc
3	its	its	PRP$	_	5	nmod:poss
4	active	active	JJ	_	5	amod
5	metabolite	metabolite	NN	_	1	conj
6	,	,	,	_	5	punct
7	norfluoxe-tine	norfluoxe-tine	NN	_	5	appos
8	,	,	,	_	5	punct
9	have	have	VBP	_	0	ROOT
10	long	long	JJ	_	11	amod
11	half-lives	half-life	NNS	_	9	dobj
12	-LRB-	-lrb-	-LRB-	_	16	punct
13	4	4	CD	_	15	compound
14	to	to	TO	_	15	dep
15	16	16	CD	_	16	nummod
16	days	day	NNS	_	11	dep
17	for	for	IN	_	18	case
18	drug2	drug2	NN	_	16	nmod
19	-RRB-	-rrb-	-RRB-	_	16	punct
20	,	,	,	_	9	punct
21	that	that	WDT	_	23	nsubj
22	may	may	MD	_	23	aux
23	affect	affect	VB	_	9	dep
24	strategies	strategy	NNS	_	23	dobj
25	during	during	IN	_	26	case
26	conversion	conversion	NN	_	23	nmod
27	from	from	IN	_	29	case
28	one	one	CD	_	29	nummod
29	drug	drug	NN	_	26	nmod
30	to	to	TO	_	32	case
31	the	the	DT	_	32	det
32	other	other	JJ	_	29	nmod
33	.	.	.	_	9	punct

1	Administration	administration	NN	_	11	nsubjpass
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	during	during	IN	_	5	case
5	therapy	therapy	NN	_	1	nmod
6	with	with	IN	_	8	case
7	a	a	DT	_	8	det
8	drug2	drug2	NN	_	5	nmod
9	has	have	VBZ	_	11	aux
10	been	be	VBN	_	11	auxpass
11	shown	show	VBN	_	0	ROOT
12	to	to	TO	_	13	mark
13	produce	produce	VB	_	11	xcomp
14	a	a	DT	_	16	det
15	stimulating	stimulating	JJ	_	16	amod
16	effect	effect	NN	_	13	dobj
17	in	in	IN	_	20	case
18	some	some	DT	_	20	det
19	depressed	depressed	JJ	_	20	amod
20	patients	patient	NNS	_	13	nmod
21	.	.	.	_	11	punct

1	Close	close	JJ	_	2	amod
2	supervision	supervision	NN	_	10	nsubjpass
3	and	and	CC	_	2	cc
4	careful	careful	JJ	_	5	amod
5	adjustment	adjustment	NN	_	2	conj
6	of	of	IN	_	8	case
7	the	the	DT	_	8	det
8	dosage	dosage	NN	_	2	nmod
9	are	be	VBP	_	10	auxpass
10	required	require	VBN	_	0	ROOT
11	when	when	WRB	_	14	advmod
12	drug1	drug1	NN	_	14	nsubjpass
13	is	be	VBZ	_	14	auxpass
14	used	use	VBN	_	10	advcl
15	with	with	IN	_	17	case
16	other	other	JJ	_	17	amod
17	drug2	drug2	NN	_	14	nmod
18	or	or	CC	_	17	cc
19	drug3	drug3	NN	_	17	conj
20	.	.	.	_	10	punct

1	The	the	DT	_	2	det
2	patient	patient	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	informed	inform	VBN	_	0	ROOT
6	that	that	IN	_	13	mark
7	the	the	DT	_	8	det
8	response	response	NN	_	13	nsubjpass
9	to	to	TO	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	may	may	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	exaggerated	exaggerate	VBN	_	5	ccomp
14	.	.	.	_	5	punct

1	Drugs	drug	NNS	_	18	nsubj
2	Metabolized	metabolize	VBN	_	1	acl
3	by	by	IN	_	6	case
4	P450IID6	p450iid6	NN	_	6	compound
5	A	a	NN	_	6	compound
6	subset	subset	NN	_	2	nmod
7	-LRB-	-lrb-	-LRB-	_	12	punct
8	3	3	CD	_	12	compound
9	%	%	NN	_	12	dep
10	to	to	TO	_	12	case
11	10	10	CD	_	12	nummod
12	%	%	NN	_	6	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	of	of	IN	_	16	case
15	the	the	DT	_	16	det
16	population	population	NN	_	6	nmod
17	has	have	VBZ	_	18	aux
18	reduced	reduce	VBN	_	0	ROOT
19	activity	activity	NN	_	18	dobj
20	of	of	IN	_	22	case
21	certain	certain	JJ	_	22	amod
22	drug	drug	NN	_	19	nmod
23	metabolizing	metabolize	VBG	_	24	amod
24	enzymes	enzyme	NNS	_	22	dep
25	such	such	JJ	_	31	case
26	as	as	IN	_	25	mwe
27	the	the	DT	_	31	det
28	cytochrome	cytochrome	NN	_	31	compound
29	P450	p450	NN	_	31	compound
30	isoenzyme	isoenzyme	NN	_	31	compound
31	P450IID6	p450iid6	NN	_	24	nmod
32	.	.	.	_	18	punct

1	Such	such	JJ	_	2	amod
2	individuals	individual	NNS	_	4	nsubjpass
3	are	be	VBP	_	4	auxpass
4	referred	refer	VBN	_	0	ROOT
5	to	to	TO	_	8	case
6	as	as	IN	_	8	case
7	poor	poor	JJ	_	8	amod
8	metabolizers	metabolizer	NNS	_	4	nmod
9	of	of	IN	_	10	case
10	drugs	drug	NNS	_	8	nmod
11	such	such	JJ	_	13	case
12	as	as	IN	_	11	mwe
13	drug1	drug1	NN	_	10	nmod
14	,	,	,	_	13	punct
15	drug2	drug2	NN	_	13	conj
16	,	,	,	_	13	punct
17	and	and	CC	_	13	cc
18	the	the	DT	_	19	det
19	drug3	drug3	NN	_	13	conj
20	.	.	.	_	4	punct

1	These	these	DT	_	2	det
2	individuals	individual	NNS	_	4	nsubj
3	may	may	MD	_	4	aux
4	have	have	VB	_	0	ROOT
5	higher	higher	JJR	_	9	amod
6	than	than	IN	_	7	dep
7	expected	expect	VBN	_	9	amod
8	plasma	plasma	NN	_	9	compound
9	concentrations	concentration	NNS	_	4	dobj
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	when	when	WRB	_	13	advmod
13	given	give	VBN	_	4	advcl
14	usual	usual	JJ	_	15	amod
15	doses	dose	NNS	_	13	dobj
16	.	.	.	_	4	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	26	nmod
3	,	,	,	_	26	punct
4	certain	certain	JJ	_	5	amod
5	drugs	drug	NNS	_	26	nsubj
6	that	that	WDT	_	8	nsubjpass
7	are	be	VBP	_	8	auxpass
8	metabolized	metabolize	VBN	_	5	acl:relcl
9	by	by	IN	_	11	case
10	this	this	DT	_	11	det
11	isoenzyme	isoenzyme	NN	_	8	nmod
12	,	,	,	_	5	punct
13	including	include	VBG	_	15	case
14	many	many	JJ	_	15	amod
15	drug1	drug1	NN	_	5	nmod
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	drug2	drug2	NN	_	15	dep
18	,	,	,	_	17	punct
19	drug3	drug3	NN	_	17	conj
20	,	,	,	_	17	punct
21	and	and	CC	_	17	cc
22	others	other	NNS	_	17	conj
23	-RRB-	-rrb-	-RRB-	_	17	punct
24	,	,	,	_	5	punct
25	may	may	MD	_	26	aux
26	inhibit	inhibit	VB	_	0	ROOT
27	the	the	DT	_	28	det
28	activity	activity	NN	_	26	dobj
29	of	of	IN	_	31	case
30	this	this	DT	_	31	det
31	isoenzyme	isoenzyme	NN	_	28	nmod
32	,	,	,	_	26	punct
33	and	and	CC	_	26	cc
34	thus	thus	RB	_	36	advmod
35	may	may	MD	_	36	aux
36	make	make	VB	_	26	conj
37	normal	normal	JJ	_	38	amod
38	metab-olizers	metab-olizer	NNS	_	39	nsubj
39	resemble	resemble	VBP	_	36	ccomp
40	poor	poor	JJ	_	41	amod
41	metabolizers	metabolizer	NNS	_	39	dobj
42	with	with	IN	_	43	case
43	regard	regard	NN	_	39	nmod
44	to	to	TO	_	46	case
45	concomitant	concomitant	JJ	_	46	amod
46	therapy	therapy	NN	_	43	nmod
47	with	with	IN	_	49	case
48	other	other	JJ	_	49	amod
49	drugs	drug	NNS	_	46	nmod
50	metabolized	metabolize	VBN	_	49	acl
51	by	by	IN	_	54	case
52	this	this	DT	_	54	det
53	enzyme	enzyme	NN	_	54	compound
54	system	system	NN	_	50	nmod
55	,	,	,	_	39	punct
56	leading	lead	VBG	_	39	xcomp
57	to	to	TO	_	59	case
58	drug	drug	NN	_	59	compound
59	interactions	interaction	NNS	_	56	nmod
60	.	.	.	_	26	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	use	use	NN	_	13	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	7	case
6	other	other	JJ	_	7	amod
7	drugs	drug	NNS	_	2	nmod
8	metabolized	metabolize	VBN	_	7	acl
9	by	by	IN	_	11	case
10	cytochrome	cytochrome	NN	_	11	compound
11	P450IID6	p450iid6	NN	_	8	nmod
12	may	may	MD	_	13	aux
13	require	require	VB	_	0	ROOT
14	lower	lower	JJR	_	15	amod
15	doses	dose	NNS	_	13	dobj
16	than	than	IN	_	18	mark
17	usually	usually	RB	_	18	advmod
18	prescribed	prescribe	VBN	_	15	dep
19	for	for	IN	_	22	case
20	either	either	CC	_	22	cc:preconj
21	the	the	DT	_	22	det
22	drug2	drug2	NN	_	18	nmod
23	or	or	CC	_	22	cc
24	the	the	DT	_	26	det
25	other	other	JJ	_	26	amod
26	drug	drug	NN	_	22	conj
27	.	.	.	_	13	punct

1	Therefore	therefore	RB	_	50	advmod
2	,	,	,	_	50	punct
3	co-administration	co-administration	NN	_	50	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	with	with	IN	_	8	case
7	other	other	JJ	_	8	amod
8	drugs	drug	NNS	_	3	nmod
9	that	that	WDT	_	11	nsubjpass
10	are	be	VBP	_	11	auxpass
11	metabolized	metabolize	VBN	_	8	acl:relcl
12	by	by	IN	_	14	case
13	this	this	DT	_	14	det
14	isoenzyme	isoenzyme	NN	_	11	nmod
15	,	,	,	_	8	punct
16	including	include	VBG	_	18	case
17	other	other	JJ	_	18	amod
18	drug2	drug2	NN	_	8	nmod
19	,	,	,	_	18	punct
20	drug3	drug3	NN	_	18	conj
21	,	,	,	_	18	punct
22	drug4	drug4	NN	_	18	conj
23	,	,	,	_	18	punct
24	and	and	CC	_	18	cc
25	drug5	drug5	NN	_	18	conj
26	-LRB-	-lrb-	-LRB-	_	29	punct
27	eg	eg	FW	_	29	compound
28	,	,	,	_	29	punct
29	drug6	drug6	NN	_	25	dep
30	,	,	,	_	29	punct
31	drug7	drug7	NN	_	29	conj
32	,	,	,	_	29	punct
33	and	and	CC	_	29	cc
34	drug8	drug8	NN	_	29	conj
35	-RRB-	-rrb-	-RRB-	_	29	punct
36	,	,	,	_	8	punct
37	or	or	CC	_	8	cc
38	that	that	IN	_	39	nsubj
39	inhibit	inhibit	VBP	_	8	conj
40	this	this	DT	_	41	det
41	enzyme	enzyme	NN	_	39	dobj
42	-LRB-	-lrb-	-LRB-	_	45	punct
43	eg	eg	FW	_	45	compound
44	,	,	,	_	45	punct
45	drug9	drug9	NN	_	39	dep
46	-RRB-	-rrb-	-RRB-	_	45	punct
47	,	,	,	_	3	punct
48	should	should	MD	_	50	aux
49	be	be	VB	_	50	auxpass
50	approached	approach	VBN	_	0	ROOT
51	with	with	IN	_	52	case
52	caution	caution	NN	_	50	nmod
53	.	.	.	_	50	punct

1	No	no	DT	_	3	neg
2	drug	drug	NN	_	3	compound
3	interactions	interaction	NNS	_	6	nsubjpass
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	auxpass
6	identified	identify	VBN	_	0	ROOT
7	.	.	.	_	6	punct

1	Studies	study	NNS	_	15	nsubj
2	with	with	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	in	in	IN	_	5	case
5	man	man	NN	_	3	nmod
6	,	,	,	_	1	punct
7	in	in	IN	_	9	case
8	animal	animal	NN	_	9	compound
9	models	model	NNS	_	1	nmod
10	,	,	,	_	1	punct
11	and	and	CC	_	1	cc
12	in	in	FW	_	13	compound
13	vitro	vitro	FW	_	1	conj
14	have	have	VBP	_	15	aux
15	shown	show	VBN	_	0	ROOT
16	no	no	DT	_	18	neg
17	significant	significant	JJ	_	18	amod
18	interference	interference	NN	_	15	dobj
19	with	with	IN	_	21	case
20	the	the	DT	_	21	det
21	disposition	disposition	NN	_	18	nmod
22	of	of	IN	_	23	case
23	compounds	compound	NNS	_	21	nmod
24	metabolized	metabolize	VBN	_	23	acl
25	by	by	IN	_	29	case
26	the	the	DT	_	29	det
27	hepatic	hepatic	JJ	_	29	amod
28	microsomal	microsomal	JJ	_	29	amod
29	enzymes	enzyme	NNS	_	24	nmod
30	,	,	,	_	18	punct
31	e.g.	e.g.	FW	_	35	dep
32	,	,	,	_	35	punct
33	cytochrome	cytochrome	NN	_	35	compound
34	P450	p450	NN	_	35	compound
35	system	system	NN	_	18	nmod
36	.	.	.	_	15	punct

1	Compounds	compound	NNS	_	5	nsubj
2	tested	test	VBN	_	1	acl
3	in	in	IN	_	4	case
4	man	man	NN	_	2	nmod
5	include	include	VBP	_	0	ROOT
6	drug1	drug1	NN	_	5	dobj
7	,	,	,	_	6	punct
8	drug2	drug2	NN	_	6	conj
9	,	,	,	_	6	punct
10	drug3	drug3	NN	_	6	conj
11	,	,	,	_	6	punct
12	drug4	drug4	NN	_	6	conj
13	,	,	,	_	6	punct
14	drug5	drug5	NN	_	6	conj
15	and	and	CC	_	6	cc
16	drug6	drug6	NN	_	6	conj
17	.	.	.	_	5	punct

1	drug1	drug1	NN	_	11	nsubjpass
2	as	as	IN	_	4	case
3	an	a	DT	_	4	det
4	index	index	NN	_	1	nmod
5	of	of	IN	_	8	case
6	hepatic	hepatic	JJ	_	8	amod
7	drug	drug	NN	_	8	compound
8	extraction	extraction	NN	_	4	nmod
9	has	have	VBZ	_	11	aux
10	been	be	VBN	_	11	auxpass
11	tested	test	VBN	_	0	ROOT
12	and	and	CC	_	11	cc
13	no	no	DT	_	15	neg
14	significant	significant	JJ	_	15	amod
15	effects	effect	NNS	_	18	nsubjpass
16	have	have	VBP	_	18	aux
17	been	be	VBN	_	18	auxpass
18	found	find	VBN	_	11	conj
19	.	.	.	_	11	punct

1	When	when	WRB	_	2	advmod
2	administered	administer	VBN	_	9	advcl
3	concurrently	concurrently	RB	_	2	advmod
4	,	,	,	_	9	punct
5	the	the	DT	_	7	det
6	following	follow	VBG	_	7	amod
7	drugs	drug	NNS	_	9	nsubj
8	may	may	MD	_	9	aux
9	interact	interact	VB	_	0	ROOT
10	with	with	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	:	:	:	_	9	punct
13	drug2	drug2	NN	_	9	dep
14	,	,	,	_	13	punct
15	general	general	JJ	_	13	amod
16	:	:	:	_	13	punct
17	exaggeration	exaggeration	NN	_	13	dep
18	of	of	IN	_	20	case
19	the	the	DT	_	20	det
20	hypotension	hypotension	NN	_	17	nmod
21	induced	induce	VBN	_	20	acl
22	by	by	IN	_	24	case
23	general	general	JJ	_	24	amod
24	drug3	drug3	NN	_	21	nmod
25	.	.	.	_	9	punct

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	4	punct
3	oral	oral	JJ	_	4	amod
4	agents	agent	NNS	_	1	dep
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	-RRB-	-rrb-	-RRB-	_	4	punct
8	:	:	:	_	1	punct
9	hypoglycemia	hypoglycemia	NN	_	1	dep
10	or	or	CC	_	9	cc
11	hyperglycemia	hyperglycemia	NN	_	9	conj
12	;	;	:	_	1	punct

1	adjust	adjust	VBP	_	0	ROOT
2	dosage	dosage	NN	_	1	dobj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	accordingly	accordingly	RB	_	1	advmod
6	.	.	.	_	1	punct

1	Catecholamine-depleting	catecholamine-depleting	JJ	_	2	amod
2	drugs	drug	NNS	_	0	ROOT
3	-LRB-	-lrb-	-LRB-	_	6	punct
4	e.g.	e.g.	FW	_	6	dep
5	,	,	,	_	6	punct
6	drug1	drug1	NN	_	2	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	:	:	:	_	2	punct
9	additive	additive	JJ	_	10	amod
10	effect	effect	NN	_	2	dep
11	;	;	:	_	2	punct

1	monitor	monitor	NN	_	0	ROOT
2	closely	closely	RB	_	1	advmod
3	for	for	IN	_	4	case
4	evidence	evidence	NN	_	1	nmod
5	of	of	IN	_	6	case
6	hypotension	hypotension	NN	_	4	nmod
7	and/or	and/or	CC	_	6	cc
8	excessive	excessive	JJ	_	9	amod
9	bradycardia	bradycardia	NN	_	6	conj
10	-LRB-	-lrb-	-LRB-	_	13	punct
11	e.g.	e.g.	FW	_	13	dep
12	,	,	,	_	13	punct
13	vertigo	vertigo	NN	_	9	dep
14	,	,	,	_	13	punct
15	syncope	syncope	NN	_	13	conj
16	,	,	,	_	13	punct
17	postural	postural	JJ	_	18	amod
18	hypotension	hypotension	NN	_	13	appos
19	-RRB-	-rrb-	-RRB-	_	13	punct
20	.	.	.	_	1	punct

1	Response	response	NN	_	0	ROOT
2	to	to	TO	_	3	case
3	Treatment	treatment	NN	_	1	nmod
4	for	for	IN	_	6	case
5	Anaphylactic	Anaphylactic	NNP	_	6	compound
6	Reaction	Reaction	NNP	_	3	nmod
7	:	:	:	_	1	punct
8	While	while	IN	_	9	mark
9	taking	take	VBG	_	28	advcl
10	drug1	drug1	NN	_	9	dobj
11	,	,	,	_	28	punct
12	patients	patient	NNS	_	28	nsubj
13	with	with	IN	_	15	case
14	a	a	DT	_	15	det
15	history	history	NN	_	12	nmod
16	of	of	IN	_	19	case
17	severe	severe	JJ	_	19	amod
18	anaphylactic	anaphylactic	JJ	_	19	amod
19	reaction	reaction	NN	_	15	nmod
20	to	to	TO	_	22	case
21	a	a	DT	_	22	det
22	variety	variety	NN	_	19	nmod
23	of	of	IN	_	24	case
24	allergens	allergen	NNS	_	22	nmod
25	may	may	MD	_	28	aux
26	be	be	VB	_	28	cop
27	more	more	RBR	_	28	advmod
28	reactive	reactive	JJ	_	1	dep
29	to	to	TO	_	31	case
30	repeated	repeat	VBN	_	31	amod
31	challenge	challenge	NN	_	28	nmod
32	,	,	,	_	28	punct
33	either	either	CC	_	34	cc:preconj
34	accidental	accidental	JJ	_	28	dep
35	,	,	,	_	34	punct
36	diagnostic	diagnostic	JJ	_	34	conj
37	,	,	,	_	34	punct
38	or	or	CC	_	34	cc
39	therapeutic	therapeutic	JJ	_	34	conj
40	.	.	.	_	1	punct

1	Such	such	JJ	_	2	amod
2	patients	patient	NNS	_	5	nsubj
3	may	may	MD	_	5	aux
4	be	be	VB	_	5	cop
5	unresponsive	unresponsive	JJ	_	0	ROOT
6	to	to	TO	_	9	case
7	the	the	DT	_	9	det
8	usual	usual	JJ	_	9	amod
9	doses	dose	NNS	_	5	nmod
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	used	use	VBN	_	9	acl
13	to	to	TO	_	14	mark
14	treat	treat	VB	_	12	xcomp
15	allergic	allergic	JJ	_	16	amod
16	reaction	reaction	NN	_	14	dobj
17	.	.	.	_	5	punct

1	Since	since	IN	_	7	mark
2	drug1	drug1	NN	_	7	nsubj
3	-LRB-	-lrb-	-LRB-	_	4	punct
4	drug2	drug2	NN	_	2	appos
5	-RRB-	-rrb-	-RRB-	_	4	punct
6	may	may	MD	_	7	aux
7	interact	interact	VB	_	22	advcl
8	with	with	IN	_	11	case
9	concurrently	concurrently	RB	_	10	advmod
10	administered	administer	VBN	_	11	amod
11	drug3	drug3	NN	_	7	nmod
12	,	,	,	_	22	punct
13	periodic	periodic	JJ	_	16	amod
14	serum	serum	NN	_	16	compound
15	level	level	NN	_	16	compound
16	determinations	determination	NNS	_	22	nsubj
17	of	of	IN	_	19	case
18	these	these	DT	_	19	det
19	drugs	drug	NNS	_	16	nmod
20	may	may	MD	_	22	aux
21	be	be	VB	_	22	cop
22	necessary	necessary	JJ	_	0	ROOT
23	-LRB-	-lrb-	-LRB-	_	28	punct
24	eg	eg	FW	_	28	advmod
25	,	,	,	_	28	punct
26	drug4	drug4	NN	_	28	nsubj
27	may	may	MD	_	28	aux
28	elevate	elevate	VB	_	22	dep
29	drug5	drug5	NN	_	31	compound
30	serum	serum	NN	_	31	compound
31	levels	level	NNS	_	28	dobj
32	and	and	CC	_	28	cc
33	drug6	drug6	NN	_	36	nsubjpass
34	has	have	VBZ	_	36	aux
35	been	be	VBN	_	36	auxpass
36	reported	report	VBN	_	28	conj
37	to	to	TO	_	39	case
38	both	both	DT	_	39	cc:preconj
39	increase	increase	NN	_	36	nmod
40	and	and	CC	_	39	cc
41	decrease	decrease	VB	_	39	conj
42	drug7	drug7	NN	_	43	compound
43	levels	level	NNS	_	41	dobj
44	-RRB-	-rrb-	-RRB-	_	28	punct
45	.	.	.	_	22	punct

1	Results	result	NNS	_	9	nsubj
2	of	of	IN	_	4	case
3	preliminary	preliminary	JJ	_	4	amod
4	studies	study	NNS	_	1	nmod
5	in	in	IN	_	6	case
6	humans	human	NNS	_	4	nmod
7	and	and	CC	_	6	cc
8	rats	rat	NNS	_	6	conj
9	suggest	suggest	VBP	_	0	ROOT
10	that	that	IN	_	18	mark
11	nonabsorbable	nonabsorbable	JJ	_	12	amod
12	drug1	drug1	NN	_	18	nsubj
13	given	give	VBN	_	12	acl
14	concurrently	concurrently	RB	_	13	advmod
15	with	with	IN	_	16	case
16	drug2	drug2	NN	_	13	nmod
17	may	may	MD	_	18	aux
18	inhibit	inhibit	VB	_	9	ccomp
19	the	the	DT	_	21	det
20	desired	desire	VBN	_	21	amod
21	drug3	drug3	NN	_	18	dobj
22	-	-	:	_	21	punct
23	induced	induce	VBN	_	24	amod
24	drop	drop	NN	_	21	dep
25	in	in	IN	_	27	case
26	colonic	colonic	JJ	_	27	amod
27	pH.	ph.	NN	_	24	nmod

1	Therefore	therefore	RB	_	13	advmod
2	,	,	,	_	13	punct
3	a	a	DT	_	5	det
4	possible	possible	JJ	_	5	amod
5	lack	lack	NN	_	13	nsubjpass
6	of	of	IN	_	8	case
7	desired	desire	VBN	_	8	amod
8	effect	effect	NN	_	5	nmod
9	of	of	IN	_	10	case
10	treatment	treatment	NN	_	8	nmod
11	should	should	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	taken	take	VBN	_	0	ROOT
14	into	into	IN	_	15	case
15	consideration	consideration	NN	_	13	nmod
16	before	before	IN	_	20	mark
17	such	such	JJ	_	18	amod
18	drugs	drug	NNS	_	20	nsubjpass
19	are	be	VBP	_	20	auxpass
20	given	give	VBN	_	13	advcl
21	concomitantly	concomitantly	RB	_	20	advmod
22	with	with	IN	_	23	case
23	drug1	drug1	NN	_	20	nmod
24	.	.	.	_	13	punct

1	Substances	substance	NNS	_	8	nsubj
2	that	that	WDT	_	4	nsubj
3	are	be	VBP	_	4	cop
4	inducers	inducer	NNS	_	1	acl:relcl
5	of	of	IN	_	7	case
6	CYP3A4	cyp3a4	NN	_	7	compound
7	activity	activity	NN	_	4	nmod
8	increase	increase	VBP	_	0	ROOT
9	the	the	DT	_	10	det
10	metabolism	metabolism	NN	_	8	dobj
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	and	and	CC	_	8	cc
14	decrease	decrease	VB	_	8	conj
15	its	its	PRP$	_	17	nmod:poss
16	plasma	plasma	NN	_	17	compound
17	concentrations	concentration	NNS	_	14	dobj
18	.	.	.	_	8	punct

1	In	in	IN	_	2	case
2	patients	patient	NNS	_	23	nmod
3	receiving	receive	VBG	_	2	acl
4	a	a	DT	_	7	det
5	potent	potent	JJ	_	7	amod
6	CYP3A4	cyp3a4	NN	_	7	compound
7	inducer	inducer	NN	_	3	dobj
8	such	such	JJ	_	10	case
9	as	as	IN	_	8	mwe
10	drug1	drug1	NN	_	7	nmod
11	or	or	CC	_	10	cc
12	drug2	drug2	NN	_	10	conj
13	,	,	,	_	23	punct
14	a	a	DT	_	16	det
15	dose	dose	NN	_	16	compound
16	increase	increase	NN	_	23	nsubjpass
17	to	to	TO	_	19	case
18	500	500	CD	_	19	nummod
19	mg	mg	NN	_	16	nmod
20	daily	daily	RB	_	23	advmod
21	should	should	MD	_	23	aux
22	be	be	VB	_	23	auxpass
23	considered	consider	VBN	_	0	ROOT
24	in	in	IN	_	26	case
25	the	the	DT	_	26	det
26	absence	absence	NN	_	23	nmod
27	of	of	IN	_	31	case
28	severe	severe	JJ	_	31	amod
29	adverse	adverse	JJ	_	31	amod
30	drug	drug	NN	_	31	compound
31	reaction	reaction	NN	_	26	nmod
32	,	,	,	_	23	punct
33	and	and	CC	_	23	cc
34	clinical	clinical	JJ	_	35	amod
35	response	response	NN	_	42	nsubjpass
36	and	and	CC	_	35	cc
37	adverse	adverse	JJ	_	38	amod
38	events	event	NNS	_	35	conj
39	should	should	MD	_	42	aux
40	be	be	VB	_	42	auxpass
41	carefully	carefully	RB	_	42	advmod
42	monitored	monitor	VBN	_	23	conj
43	-LRB-	-lrb-	-LRB-	_	44	punct
44	see	see	VB	_	42	dep
45	CLINICAL	CLINICAL	NNP	_	47	compound
46	PHARMACOLOGY-Pharmacokinetics-Drug-Drug	PHARMACOLOGY-Pharmacokinetics-Drug-Drug	NNP	_	47	compound
47	Interactions	interaction	NNS	_	44	dobj
48	and	and	CC	_	47	cc
49	DOSAGE	dosage	NN	_	53	compound
50	AND	and	CC	_	49	cc
51	ADMINISTRATION-Dosage	administration-dosage	NN	_	49	conj
52	Adjustment	Adjustment	NNP	_	53	compound
53	sections	section	NNS	_	47	conj
54	-RRB-	-rrb-	-RRB-	_	44	punct
55	.	.	.	_	23	punct

1	International	International	NNP	_	3	compound
2	Normalized	Normalized	NNP	_	3	compound
3	Ratio	Ratio	NNP	_	7	nsubj
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	INR	INR	NNP	_	3	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	elevations	elevation	NNS	_	13	nsubjpass
8	and/or	and/or	CC	_	7	cc
9	bleeding	bleed	VBG	_	10	amod
10	events	event	NNS	_	7	conj
11	have	have	VBP	_	13	aux
12	been	be	VBN	_	13	auxpass
13	reported	report	VBN	_	0	ROOT
14	in	in	IN	_	16	case
15	some	some	DT	_	16	det
16	patients	patient	NNS	_	13	nmod
17	taking	take	VBG	_	16	acl
18	drug1	drug1	NN	_	17	dobj
19	while	while	IN	_	22	case
20	on	on	IN	_	22	case
21	drug2	drug2	NN	_	22	compound
22	therapy	therapy	NN	_	17	nmod
23	.	.	.	_	13	punct

1	Patients	patient	NNS	_	6	nsubjpass
2	taking	take	VBG	_	1	acl
3	drug1	drug1	NN	_	2	dobj
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	monitored	monitor	VBN	_	0	ROOT
7	regularly	regularly	RB	_	6	advmod
8	for	for	IN	_	9	case
9	changes	change	NNS	_	6	nmod
10	in	in	IN	_	12	case
11	prothrombin	prothrombin	NN	_	12	compound
12	time	time	NN	_	9	nmod
13	or	or	CC	_	12	cc
14	INR	inr	NN	_	12	conj
15	.	.	.	_	6	punct

1	Substances	substance	NNS	_	16	nsubj
2	that	that	WDT	_	5	nsubj
3	are	be	VBP	_	5	cop
4	potent	potent	JJ	_	5	amod
5	inhibitors	inhibitor	NNS	_	1	acl:relcl
6	of	of	IN	_	8	case
7	CYP3A4	cyp3a4	NN	_	8	compound
8	activity	activity	NN	_	5	nmod
9	-LRB-	-lrb-	-LRB-	_	12	punct
10	eg	eg	FW	_	12	dep
11	,	,	,	_	12	punct
12	drug1	drug1	NN	_	1	dep
13	and	and	CC	_	12	cc
14	drug2	drug2	NN	_	12	conj
15	-RRB-	-rrb-	-RRB-	_	12	punct
16	decrease	decrease	NN	_	0	ROOT
17	drug3	drug3	NN	_	18	compound
18	metabolism	metabolism	NN	_	16	dobj
19	and	and	CC	_	18	cc
20	increase	increase	NN	_	23	compound
21	drug4	drug4	NN	_	23	compound
22	plasma	plasma	NN	_	23	compound
23	concentrations	concentration	NNS	_	18	conj
24	.	.	.	_	16	punct

1	This	this	DT	_	2	det
2	increase	increase	NN	_	6	nsubj
3	may	may	MD	_	6	aux
4	be	be	VB	_	6	cop
5	clinically	clinically	RB	_	6	advmod
6	relevant	relevant	JJ	_	0	ROOT
7	as	as	IN	_	11	mark
8	adverse	adverse	JJ	_	9	amod
9	experiences	experience	NNS	_	11	nsubj
10	are	be	VBP	_	11	cop
11	related	related	JJ	_	6	advcl
12	to	to	TO	_	13	case
13	dose	dose	NN	_	11	nmod
14	and	and	CC	_	13	cc
15	exposure	exposure	NN	_	13	conj
16	;	;	:	_	6	punct

1	therefore	therefore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	caution	caution	NN	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	used	use	VBN	_	0	ROOT
7	when	when	WRB	_	8	advmod
8	administering	administer	VBG	_	6	advcl
9	CYP3A4	cyp3a4	NN	_	10	compound
10	inhibitors	inhibitor	NNS	_	8	dobj
11	with	with	IN	_	12	case
12	drug1	drug1	NN	_	8	nmod
13	.	.	.	_	6	punct

1	Drugs	drug	NNS	_	19	nsubj
2	that	that	WDT	_	3	nsubj
3	cause	cause	VBP	_	1	acl:relcl
4	significant	significant	JJ	_	6	amod
5	sustained	sustained	JJ	_	6	amod
6	elevation	elevation	NN	_	3	dobj
7	in	in	IN	_	9	case
8	gastric	gastric	JJ	_	9	amod
9	pH	ph	NN	_	6	nmod
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	drug1	drug1	NN	_	9	dep
12	such	such	JJ	_	14	case
13	as	as	IN	_	12	mwe
14	drug2	drug2	NN	_	11	nmod
15	or	or	CC	_	14	cc
16	drug3	drug3	NN	_	14	conj
17	-RRB-	-rrb-	-RRB-	_	11	punct
18	may	may	MD	_	19	aux
19	reduce	reduce	VB	_	0	ROOT
20	plasma	plasma	NN	_	21	compound
21	concentrations	concentration	NNS	_	19	dobj
22	of	of	IN	_	23	case
23	drug4	drug4	NN	_	21	nmod
24	and	and	CC	_	19	cc
25	therefore	therefore	RB	_	28	advmod
26	potentially	potentially	RB	_	28	advmod
27	may	may	MD	_	28	aux
28	reduce	reduce	VB	_	19	conj
29	efficacy	efficacy	NN	_	28	dobj
30	.	.	.	_	19	punct

1	Phase	phase	NN	_	5	compound
2	II	ii	CD	_	5	nummod
3	clinical	clinical	JJ	_	5	amod
4	trial	trial	NN	_	5	compound
5	data	datum	NNS	_	16	nsubj
6	,	,	,	_	5	punct
7	where	where	WRB	_	13	advmod
8	drug1	drug1	NN	_	13	nsubjpass
9	and	and	CC	_	8	cc
10	drug2	drug2	NN	_	8	conj
11	have	have	VBP	_	13	aux
12	been	be	VBN	_	13	auxpass
13	used	use	VBN	_	5	acl:relcl
14	concomitantly	concomitantly	RB	_	13	advmod
15	,	,	,	_	5	punct
16	indicate	indicate	VBP	_	0	ROOT
17	that	that	IN	_	20	mark
18	drug3	drug3	NN	_	20	nsubj
19	may	may	MD	_	20	aux
20	exacerbate	exacerbate	VB	_	16	ccomp
21	the	the	DT	_	23	det
22	neutropenic	neutropenic	JJ	_	23	amod
23	effect	effect	NN	_	20	dobj
24	of	of	IN	_	25	case
25	drug4	drug4	NN	_	23	nmod
26	.	.	.	_	16	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	interact	interact	VB	_	0	ROOT
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	,	,	,	_	5	punct
7	drug3	drug3	NN	_	8	compound
8	s	s	NNS	_	5	conj
9	,	,	,	_	5	punct
10	drug4	drug4	NN	_	5	conj
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	allergy	allergy	NN	_	10	dep
13	,	,	,	_	12	punct
14	cold	cold	JJ	_	12	conj
15	,	,	,	_	12	punct
16	and	and	CC	_	12	cc
17	sinus	sinus	NN	_	18	compound
18	medicines	medicine	NNS	_	12	conj
19	-RRB-	-rrb-	-RRB-	_	12	punct
20	,	,	,	_	5	punct
21	diabetic	diabetic	JJ	_	22	amod
22	drugs	drug	NNS	_	5	conj
23	,	,	,	_	5	punct
24	drug5	drug5	NN	_	5	conj
25	,	,	,	_	5	punct
26	drug6	drug6	NN	_	5	conj
27	,	,	,	_	5	punct
28	drug7	drug7	NN	_	5	conj
29	like	like	IN	_	30	case
30	drug8	drug8	NN	_	28	nmod
31	or	or	CC	_	30	cc
32	drug9	drug9	NN	_	30	conj
33	,	,	,	_	5	punct
34	and	and	CC	_	5	cc
35	high	high	JJ	_	38	amod
36	blood	blood	NN	_	38	compound
37	pressure	pressure	NN	_	38	compound
38	medications	medication	NNS	_	5	conj
39	.	.	.	_	3	punct

1	No	no	DT	_	3	neg
2	drug	drug	NN	_	3	compound
3	interactions	interaction	NNS	_	9	nsubjpass
4	of	of	IN	_	6	case
5	clinical	clinical	JJ	_	6	amod
6	importance	importance	NN	_	3	nmod
7	have	have	VBP	_	9	aux
8	been	be	VBN	_	9	auxpass
9	identified	identify	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	drug1	drug1	NN	_	4	nsubj
2	does	do	VBZ	_	4	aux
3	not	not	RB	_	4	neg
4	appear	appear	VB	_	0	ROOT
5	to	to	TO	_	6	mark
6	affect	affect	VB	_	4	xcomp
7	the	the	DT	_	12	det
8	cytochrome	cytochrome	NN	_	12	compound
9	P450-linked	p450-linked	JJ	_	12	amod
10	drug-metabolizing	drug-metabolizing	JJ	_	12	amod
11	enzyme	enzyme	NN	_	12	compound
12	system	system	NN	_	6	dobj
13	.	.	.	_	4	punct

1	Compounds	compound	NNS	_	8	nsubj
2	that	that	WDT	_	5	nsubjpass
3	have	have	VBP	_	5	aux
4	been	be	VBN	_	5	auxpass
5	tested	test	VBN	_	1	acl:relcl
6	in	in	IN	_	7	case
7	man	man	NN	_	5	nmod
8	include	include	VBP	_	0	ROOT
9	drug1	drug1	NN	_	25	nsubjpass
10	,	,	,	_	9	punct
11	drug2	drug2	NN	_	9	conj
12	,	,	,	_	9	punct
13	drug3	drug3	NN	_	9	conj
14	,	,	,	_	9	punct
15	drug4	drug4	NN	_	9	conj
16	,	,	,	_	9	punct
17	and	and	CC	_	9	cc
18	drug5	drug5	NN	_	9	conj
19	and	and	CC	_	9	cc
20	no	no	DT	_	23	neg
21	clinically	clinically	RB	_	22	advmod
22	meaningful	meaningful	JJ	_	23	amod
23	interactions	interaction	NNS	_	9	conj
24	were	be	VBD	_	25	auxpass
25	found	find	VBN	_	8	ccomp
26	.	.	.	_	8	punct

1	Other	other	JJ	_	3	amod
2	concomitant	concomitant	JJ	_	3	amod
3	therapy	therapy	NN	_	21	nsubjpass
4	Although	although	IN	_	10	mark
5	specific	specific	JJ	_	7	amod
6	interaction	interaction	NN	_	7	compound
7	studies	study	NNS	_	10	nsubjpass
8	were	be	VBD	_	10	auxpass
9	not	not	RB	_	10	neg
10	performed	perform	VBN	_	21	advcl
11	,	,	,	_	21	punct
12	drug1	drug1	NN	_	13	compound
13	doses	dose	NNS	_	21	nsubjpass
14	of	of	IN	_	16	case
15	1	1	CD	_	16	nummod
16	mg	mg	NN	_	13	nmod
17	or	or	CC	_	18	cc
18	more	more	JJR	_	16	nummod
19	were	be	VBD	_	21	auxpass
20	concomitantly	concomitantly	RB	_	21	advmod
21	used	use	VBN	_	0	ROOT
22	in	in	IN	_	24	case
23	clinical	clinical	JJ	_	24	amod
24	studies	study	NNS	_	21	nmod
25	with	with	IN	_	26	case
26	drug2	drug2	NN	_	24	nmod
27	,	,	,	_	26	punct
28	drug3	drug3	NN	_	26	conj
29	,	,	,	_	26	punct
30	a-blockers	a-blocker	NNS	_	26	conj
31	,	,	,	_	26	punct
32	drug4	drug4	NN	_	26	conj
33	,	,	,	_	26	punct
34	drug5	drug5	NN	_	26	conj
35	,	,	,	_	26	punct
36	drug6	drug6	NN	_	26	conj
37	,	,	,	_	26	punct
38	drug7	drug7	NN	_	26	conj
39	,	,	,	_	26	punct
40	drug8	drug8	NN	_	26	conj
41	,	,	,	_	26	punct
42	drug9	drug9	NN	_	26	conj
43	,	,	,	_	26	punct
44	cardiac	cardiac	JJ	_	45	amod
45	drug10	drug10	NN	_	26	conj
46	,	,	,	_	26	punct
47	drug11	drug11	NN	_	26	conj
48	,	,	,	_	26	punct
49	drug12	drug12	NN	_	26	conj
50	,	,	,	_	26	punct
51	drug13	drug13	NN	_	26	conj
52	,	,	,	_	26	punct
53	drug14	drug14	NN	_	26	conj
54	-LRB-	-lrb-	-LRB-	_	56	punct
55	also	also	RB	_	56	advmod
56	referred	refer	VBN	_	53	dep
57	to	to	TO	_	56	nmod
58	as	as	IN	_	59	case
59	drug15	drug15	NN	_	56	nmod
60	-RRB-	-rrb-	-RRB-	_	56	punct
61	,	,	,	_	26	punct
62	and	and	CC	_	26	cc
63	drug16	drug16	NN	_	26	conj
64	without	without	IN	_	65	case
65	evidence	evidence	NN	_	21	nmod
66	of	of	IN	_	70	case
67	clinically	clinically	RB	_	68	advmod
68	significant	significant	JJ	_	70	amod
69	adverse	adverse	JJ	_	70	amod
70	interactions	interaction	NNS	_	65	nmod
71	.	.	.	_	21	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	4	amod
2	Test	test	NN	_	4	compound
3	Interactions	interaction	NNS	_	4	compound
4	drug1	drug1	NN	_	5	nsubj
5	had	have	VBD	_	0	ROOT
6	no	no	DT	_	7	neg
7	effect	effect	NN	_	5	dobj
8	on	on	IN	_	10	case
9	circulating	circulate	VBG	_	10	amod
10	levels	level	NNS	_	5	nmod
11	of	of	IN	_	12	case
12	cortisol	cortisol	NN	_	10	nmod
13	,	,	,	_	12	punct
14	thyroid-stimulating	thyroid-stimulating	JJ	_	15	amod
15	hormone	hormone	NN	_	12	conj
16	,	,	,	_	12	punct
17	or	or	CC	_	12	cc
18	thyroxine	thyroxine	NN	_	12	conj
19	,	,	,	_	5	punct
20	nor	nor	CC	_	5	cc
21	did	do	VBD	_	23	aux
22	it	it	PRP	_	23	nsubj
23	affect	affect	VB	_	5	conj
24	the	the	DT	_	27	det
25	plasma	plasma	NN	_	27	compound
26	lipid	lipid	NN	_	27	compound
27	profile	profile	NN	_	23	dobj
28	-LRB-	-lrb-	-LRB-	_	32	punct
29	e.g.	e.g.	FW	_	32	dep
30	,	,	,	_	32	punct
31	total	total	JJ	_	32	amod
32	cholesterol	cholesterol	NN	_	27	dep
33	,	,	,	_	32	punct
34	low-density	low-density	JJ	_	35	amod
35	lipoproteins	lipoprotein	NNS	_	32	conj
36	,	,	,	_	32	punct
37	high-density	high-density	JJ	_	38	amod
38	lipoproteins	lipoprotein	NNS	_	32	conj
39	and	and	CC	_	32	cc
40	triglycerides	triglyceride	NNS	_	32	conj
41	-RRB-	-rrb-	-RRB-	_	32	punct
42	or	or	CC	_	27	cc
43	bone	bone	NN	_	45	compound
44	mineral	mineral	NN	_	45	compound
45	density	density	NN	_	27	conj
46	.	.	.	_	5	punct

1	In	in	IN	_	2	case
2	studies	study	NNS	_	25	nmod
3	with	with	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	,	,	,	_	25	punct
6	no	no	DT	_	9	neg
7	clinically	clinically	RB	_	8	advmod
8	meaningful	meaningful	JJ	_	9	amod
9	changes	change	NNS	_	25	nsubjpass
10	in	in	IN	_	12	case
11	luteinizing	luteinize	VBG	_	12	amod
12	hormone	hormone	NN	_	9	nmod
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	LH	lh	NN	_	12	appos
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	,	,	,	_	12	punct
17	follicle-stimulating	follicle-stimulating	JJ	_	18	amod
18	hormone	hormone	NN	_	12	conj
19	-LRB-	-lrb-	-LRB-	_	20	punct
20	FSH	fsh	NN	_	18	appos
21	-RRB-	-rrb-	-RRB-	_	20	punct
22	or	or	CC	_	12	cc
23	prolactin	prolactin	NN	_	12	conj
24	were	be	VBD	_	25	auxpass
25	detected	detect	VBN	_	0	ROOT
26	.	.	.	_	25	punct

1	In	in	IN	_	3	case
2	healthy	healthy	JJ	_	3	amod
3	volunteers	volunteer	NNS	_	10	nmod
4	,	,	,	_	10	punct
5	treatment	treatment	NN	_	10	nsubj
6	with	with	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	did	do	VBD	_	10	aux
9	not	not	RB	_	10	neg
10	alter	alter	VB	_	0	ROOT
11	the	the	DT	_	12	det
12	response	response	NN	_	10	dobj
13	of	of	IN	_	14	case
14	LH	lh	NN	_	12	nmod
15	and	and	CC	_	14	cc
16	FSH	fsh	NN	_	14	conj
17	to	to	TO	_	19	case
18	gonadotropin-releasing	gonadotropin-releasing	NN	_	19	compound
19	hormone	hormone	NN	_	12	nmod
20	indicating	indicate	VBG	_	12	acl
21	that	that	IN	_	27	mark
22	the	the	DT	_	24	det
23	hypothalamic-pituitary-testicular	hypothalamic-pituitary-testicular	JJ	_	24	amod
24	axis	axis	NN	_	27	nsubjpass
25	was	be	VBD	_	27	auxpass
26	not	not	RB	_	27	neg
27	affected	affect	VBN	_	20	ccomp
28	.	.	.	_	10	punct

1	In	in	IN	_	3	case
2	clinical	clinical	JJ	_	3	amod
3	studies	study	NNS	_	29	nmod
4	with	with	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	drug2	drug2	NN	_	5	dep
8	,	,	,	_	7	punct
9	1	1	CD	_	10	nummod
10	mg	mg	NN	_	7	appos
11	-RRB-	-rrb-	-RRB-	_	7	punct
12	in	in	IN	_	13	case
13	men	man	NNS	_	3	nmod
14	18-41	18-41	CD	_	15	nummod
15	years	year	NNS	_	13	dep
16	of	of	IN	_	17	case
17	age	age	NN	_	15	nmod
18	,	,	,	_	29	punct
19	the	the	DT	_	21	det
20	mean	mean	JJ	_	21	amod
21	value	value	NN	_	29	nsubj
22	of	of	IN	_	25	case
23	serum	serum	NN	_	25	compound
24	prostate-specific	prostate-specific	JJ	_	25	amod
25	antigen	antigen	NN	_	21	nmod
26	-LRB-	-lrb-	-LRB-	_	27	punct
27	PSA	psa	NN	_	25	appos
28	-RRB-	-rrb-	-RRB-	_	27	punct
29	decreased	decrease	VBD	_	0	ROOT
30	from	from	IN	_	32	case
31	0.7	0.7	CD	_	32	nummod
32	ng/mL	ng/ml	NN	_	29	nmod
33	at	at	IN	_	34	case
34	baseline	baseline	NN	_	29	nmod
35	to	to	TO	_	37	case
36	0.5	0.5	CD	_	37	nummod
37	ng/mL	ng/ml	NN	_	34	nmod
38	at	at	IN	_	39	case
39	Month	Month	NNP	_	29	nmod
40	12	12	CD	_	39	nummod
41	.	.	.	_	29	punct

1	Further	further	RB	_	31	advmod
2	,	,	,	_	31	punct
3	in	in	IN	_	5	case
4	clinical	clinical	JJ	_	5	amod
5	studies	study	NNS	_	31	nmod
6	with	with	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	drug2	drug2	NN	_	7	dep
10	,	,	,	_	9	punct
11	5	5	CD	_	12	nummod
12	mg	mg	NN	_	9	appos
13	-RRB-	-rrb-	-RRB-	_	9	punct
14	when	when	WRB	_	15	advmod
15	used	use	VBN	_	5	acl:relcl
16	in	in	IN	_	18	case
17	older	older	JJR	_	18	amod
18	men	man	NNS	_	15	nmod
19	who	who	WP	_	20	nsubj
20	have	have	VBP	_	18	acl:relcl
21	benign	benign	JJ	_	23	amod
22	prostatic	prostatic	JJ	_	23	amod
23	hyperplasia	hyperplasia	NN	_	20	dobj
24	-LRB-	-lrb-	-LRB-	_	25	punct
25	BPH	BPH	NNP	_	23	appos
26	-RRB-	-rrb-	-RRB-	_	25	punct
27	,	,	,	_	23	punct
28	PSA	psa	NN	_	29	compound
29	levels	level	NNS	_	23	appos
30	are	be	VBP	_	31	auxpass
31	decreased	decrease	VBN	_	0	ROOT
32	by	by	IN	_	35	case
33	approximately	approximately	RB	_	34	advmod
34	50	50	CD	_	35	nummod
35	%	%	NN	_	31	nmod
36	.	.	.	_	31	punct

1	These	these	DT	_	2	det
2	findings	finding	NNS	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	taken	take	VBN	_	0	ROOT
6	into	into	IN	_	7	case
7	account	account	NN	_	5	nmod
8	for	for	IN	_	10	case
9	proper	proper	JJ	_	10	amod
10	interpretation	interpretation	NN	_	7	nmod
11	of	of	IN	_	13	case
12	serum	serum	NN	_	13	compound
13	PSA	psa	NN	_	10	nmod
14	when	when	WRB	_	5	dep
15	evaluating	evaluate	VBG	_	14	dep
16	men	man	NNS	_	15	dobj
17	treated	treat	VBN	_	16	acl
18	with	with	IN	_	19	case
19	drug1	drug1	NN	_	17	nmod
20	.	.	.	_	5	punct

1	drug1	drug1	NN	_	4	nsubj
2	:	:	:	_	4	punct
3	Reports	report	NNS	_	4	nsubj
4	suggest	suggest	VBP	_	0	ROOT
5	that	that	IN	_	8	mark
6	drug2	drug2	NN	_	8	nsubj
7	may	may	MD	_	8	aux
8	diminish	diminish	VB	_	4	ccomp
9	the	the	DT	_	11	det
10	antihypertensive	antihypertensive	JJ	_	11	amod
11	effect	effect	NN	_	8	dobj
12	of	of	IN	_	13	case
13	drug3	drug3	NN	_	11	nmod
14	.	.	.	_	4	punct

1	In	in	IN	_	2	case
2	patients	patient	NNS	_	30	nmod
3	with	with	IN	_	4	case
4	mild	mild	JJ	_	2	nmod
5	to	to	TO	_	7	case
6	moderate	moderate	JJ	_	7	amod
7	hypertension	hypertension	NN	_	4	nmod
8	,	,	,	_	30	punct
9	administration	administration	NN	_	30	nsubjpass
10	of	of	IN	_	13	case
11	25	25	CD	_	13	nummod
12	mg	mg	NN	_	13	compound
13	daily	daily	NN	_	9	nmod
14	of	of	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	with	with	IN	_	19	case
17	the	the	DT	_	19	det
18	drug2	drug2	NN	_	19	compound
19	drug3	drug3	NN	_	9	nmod
20	,	,	,	_	9	punct
21	10	10	CD	_	23	compound
22	to	to	TO	_	23	dep
23	40	40	CD	_	24	nummod
24	mg	mg	NN	_	9	appos
25	for	for	IN	_	27	case
26	4	4	CD	_	27	nummod
27	weeks	week	NNS	_	24	nmod
28	,	,	,	_	9	punct
29	was	be	VBD	_	30	auxpass
30	associated	associate	VBN	_	0	ROOT
31	with	with	IN	_	34	case
32	an	a	DT	_	34	det
33	average	average	JJ	_	34	amod
34	increase	increase	NN	_	30	nmod
35	in	in	IN	_	38	case
36	mean	mean	JJ	_	38	amod
37	arterial	arterial	JJ	_	38	amod
38	pressure	pressure	NN	_	34	nmod
39	of	of	IN	_	43	case
40	about	about	IN	_	41	advmod
41	3	3	CD	_	43	nummod
42	mm	mm	NN	_	43	compound
43	Hg	hg	NN	_	38	nmod
44	compared	compare	VBN	_	34	acl
45	to	to	TO	_	46	case
46	drug4	drug4	NN	_	44	nmod
47	alone	alone	RB	_	46	advmod
48	.	.	.	_	30	punct

1	This	this	DT	_	2	det
2	interaction	interaction	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	given	give	VBN	_	0	ROOT
6	consideration	consideration	NN	_	5	dobj
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	5	nmod
9	taking	take	VBG	_	8	acl
10	drug1	drug1	NN	_	9	dobj
11	concomitantly	concomitantly	RB	_	9	advmod
12	with	with	IN	_	13	case
13	drug2	drug2	NN	_	9	nmod
14	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concomitant	concomitant	JJ	_	4	amod
4	administration	administration	NN	_	11	nsubj
5	of	of	IN	_	7	case
6	low-dose	low-dose	JJ	_	7	amod
7	drug2	drug2	NN	_	4	nmod
8	with	with	IN	_	9	case
9	drug3	drug3	NN	_	4	nmod
10	may	may	MD	_	11	aux
11	result	result	VB	_	1	dep
12	in	in	IN	_	15	case
13	an	a	DT	_	15	det
14	increased	increase	VBN	_	15	amod
15	rate	rate	NN	_	11	nmod
16	of	of	IN	_	18	case
17	GI	gi	NN	_	18	compound
18	ulceration	ulceration	NN	_	15	nmod
19	or	or	CC	_	18	cc
20	other	other	JJ	_	21	amod
21	complications	complication	NNS	_	18	conj
22	,	,	,	_	11	punct
23	compared	compare	VBN	_	25	case
24	to	to	TO	_	25	case
25	use	use	VB	_	11	advcl
26	of	of	IN	_	27	case
27	drug4	drug4	NN	_	25	nmod
28	alone	alone	RB	_	27	advmod
29	.	.	.	_	1	punct

1	In	in	IN	_	5	case
2	a	a	DT	_	5	det
3	12-week	12-week	JJ	_	5	amod
4	endoscopy	endoscopy	NN	_	5	compound
5	study	study	NN	_	0	ROOT
6	conducted	conduct	VBN	_	5	acl
7	in	in	IN	_	9	case
8	OA	oa	NN	_	9	compound
9	patients	patient	NNS	_	6	nmod
10	there	there	EX	_	11	expl
11	was	be	VBD	_	6	ccomp
12	no	no	DT	_	13	neg
13	difference	difference	NN	_	11	nsubj
14	in	in	IN	_	17	case
15	the	the	DT	_	17	det
16	cumulative	cumulative	JJ	_	17	amod
17	incidence	incidence	NN	_	13	nmod
18	of	of	IN	_	21	case
19	endoscopic	endoscopic	JJ	_	21	amod
20	gastroduodenal	gastroduodenal	JJ	_	21	amod
21	ulcers	ulcer	NNS	_	17	nmod
22	in	in	IN	_	23	case
23	patients	patient	NNS	_	21	nmod
24	taking	take	VBG	_	23	acl
25	low-dose	low-dose	JJ	_	32	amod
26	-LRB-	-lrb-	-LRB-	_	28	punct
27	81	81	CD	_	28	nummod
28	mg	mg	NN	_	25	dep
29	-RRB-	-rrb-	-RRB-	_	28	punct
30	enteric	enteric	JJ	_	32	amod
31	coated	coated	JJ	_	32	amod
32	drug1	drug1	NN	_	24	dobj
33	plus	plus	CC	_	32	cc
34	drug2	drug2	NN	_	36	compound
35	25	25	CD	_	36	nummod
36	mg	mg	NN	_	32	conj
37	daily	daily	RB	_	24	advmod
38	,	,	,	_	11	punct
39	as	as	IN	_	40	mark
40	compared	compare	VBN	_	11	advcl
41	to	to	TO	_	42	case
42	those	those	DT	_	40	nmod
43	taking	take	VBG	_	42	acl
44	drug3	drug3	NN	_	43	dobj
45	2400	2400	CD	_	46	nummod
46	mg	mg	NN	_	44	dep
47	daily	daily	JJ	_	46	advmod
48	alone	alone	RB	_	47	advmod
49	.	.	.	_	5	punct

1	Patients	patient	NNS	_	9	nsubjpass
2	taking	take	VBG	_	1	acl
3	low-dose	low-dose	JJ	_	4	amod
4	drug1	drug1	NN	_	2	dobj
5	plus	plus	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	were	be	VBD	_	9	auxpass
8	not	not	RB	_	9	neg
9	studied	study	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	At	at	IN	_	3	case
2	steady	steady	JJ	_	3	amod
3	state	state	NN	_	10	nmod
4	,	,	,	_	10	punct
5	drug1	drug1	NN	_	7	compound
6	50	50	CD	_	7	nummod
7	mg	mg	NN	_	10	nsubj
8	once	once	RB	_	9	advmod
9	daily	daily	RB	_	10	advmod
10	had	have	VBD	_	0	ROOT
11	no	no	DT	_	12	neg
12	effect	effect	NN	_	10	dobj
13	on	on	IN	_	16	case
14	the	the	DT	_	16	det
15	anti-platelet	anti-platelet	JJ	_	16	amod
16	activity	activity	NN	_	10	nmod
17	of	of	IN	_	25	case
18	low-dose	low-dose	JJ	_	25	amod
19	-LRB-	-lrb-	-LRB-	_	21	punct
20	81	81	CD	_	21	nummod
21	mg	mg	NN	_	18	dep
22	once	once	RB	_	23	advmod
23	daily	daily	JJ	_	21	amod
24	-RRB-	-rrb-	-RRB-	_	21	punct
25	drug2	drug2	NN	_	16	nmod
26	,	,	,	_	10	punct
27	as	as	IN	_	28	mark
28	assessed	assess	VBN	_	10	advcl
29	by	by	IN	_	33	case
30	ex	ex	FW	_	33	amod
31	vivo	vivo	FW	_	30	dep
32	platelet	platelet	NN	_	33	compound
33	aggregation	aggregation	NN	_	28	nmod
34	and	and	CC	_	33	cc
35	serum	serum	NN	_	37	compound
36	TXB2	txb2	NN	_	37	compound
37	generation	generation	NN	_	33	conj
38	in	in	IN	_	39	mark
39	clotting	clot	VBG	_	33	acl
40	blood	blood	NN	_	39	dobj
41	.	.	.	_	10	punct

1	Because	because	IN	_	4	case
2	of	of	IN	_	1	mwe
3	its	its	PRP$	_	4	nmod:poss
4	lack	lack	NN	_	13	nmod
5	of	of	IN	_	7	case
6	platelet	platelet	NN	_	7	compound
7	effects	effect	NNS	_	4	nmod
8	,	,	,	_	13	punct
9	drug1	drug1	NN	_	13	nsubj
10	is	be	VBZ	_	13	cop
11	not	not	RB	_	13	neg
12	a	a	DT	_	13	det
13	substitute	substitute	NN	_	0	ROOT
14	for	for	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	for	for	IN	_	18	case
17	cardiovascular	cardiovascular	JJ	_	18	amod
18	prophylaxis	prophylaxis	NN	_	13	nmod
19	.	.	.	_	13	punct

1	Therefore	therefore	RB	_	13	advmod
2	,	,	,	_	13	punct
3	in	in	IN	_	4	case
4	patients	patient	NNS	_	13	nmod
5	taking	take	VBG	_	4	acl
6	drug1	drug1	NN	_	5	dobj
7	,	,	,	_	13	punct
8	antiplatelet	antiplatelet	JJ	_	9	amod
9	therapies	therapy	NNS	_	13	nsubjpass
10	should	should	MD	_	13	aux
11	not	not	RB	_	13	neg
12	be	be	VB	_	13	auxpass
13	discontinued	discontinue	VBN	_	0	ROOT
14	and	and	CC	_	13	cc
15	should	should	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	considered	consider	VBN	_	13	conj
18	in	in	IN	_	19	case
19	patients	patient	NNS	_	17	nmod
20	with	with	IN	_	22	case
21	an	a	DT	_	22	det
22	indication	indication	NN	_	19	nmod
23	for	for	IN	_	25	case
24	cardiovascular	cardiovascular	JJ	_	25	amod
25	prophylaxis	prophylaxis	NN	_	22	nmod
26	.	.	.	_	13	punct

1	Prospective	prospective	JJ	_	4	amod
2	,	,	,	_	4	punct
3	long-term	long-term	JJ	_	4	amod
4	studies	study	NNS	_	15	nsubjpass
5	on	on	IN	_	7	case
6	concomitant	concomitant	JJ	_	7	amod
7	administration	administration	NN	_	4	nmod
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	drug2	drug2	NN	_	9	conj
12	have	have	VBP	_	15	aux
13	not	not	RB	_	15	neg
14	been	be	VBN	_	15	auxpass
15	conducted	conduct	VBN	_	0	ROOT
16	.	.	.	_	15	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Co-administration	co-administration	NN	_	15	nsubj
4	with	with	IN	_	6	case
5	high	high	JJ	_	6	amod
6	doses	dose	NNS	_	3	nmod
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	-LSB-	-lsb-	-LRB-	_	11	punct
10	800	800	CD	_	11	nummod
11	mg	mg	NN	_	6	dep
12	twice	twice	RB	_	13	advmod
13	daily	daily	JJ	_	11	amod
14	-RSB-	-rsb-	-RRB-	_	11	punct
15	increased	increase	VBD	_	1	dep
16	the	the	DT	_	17	det
17	Cmax	cmax	NN	_	15	dobj
18	of	of	IN	_	19	case
19	drug3	drug3	NN	_	17	nmod
20	by	by	IN	_	22	case
21	21	21	CD	_	22	nummod
22	%	%	NN	_	15	nmod
23	,	,	,	_	15	punct
24	the	the	DT	_	25	det
25	AUC0-120hr	auc0-120hr	NN	_	15	dobj
26	by	by	IN	_	28	case
27	23	23	CD	_	28	nummod
28	%	%	NN	_	25	nmod
29	and	and	CC	_	25	cc
30	the	the	DT	_	31	det
31	t1/2	t1/2	NN	_	25	conj
32	by	by	IN	_	34	case
33	15	15	CD	_	34	nummod
34	%	%	NN	_	31	nmod
35	.	.	.	_	1	punct

1	These	these	DT	_	3	det
2	small	small	JJ	_	3	amod
3	changes	change	NNS	_	7	nsubj
4	are	be	VBP	_	7	cop
5	not	not	RB	_	7	neg
6	clinically	clinically	RB	_	7	advmod
7	significant	significant	JJ	_	0	ROOT
8	and	and	CC	_	7	cc
9	no	no	DT	_	11	neg
10	dose	dose	NN	_	11	compound
11	adjustment	adjustment	NN	_	13	nsubj
12	is	be	VBZ	_	13	cop
13	necessary	necessary	JJ	_	7	conj
14	.	.	.	_	7	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	compound
4	75	75	CD	_	5	nummod
5	mg	mg	NN	_	13	nsubj
6	once	once	RB	_	7	advmod
7	daily	daily	RB	_	5	advmod
8	for	for	IN	_	10	case
9	11	11	CD	_	10	nummod
10	days	day	NNS	_	5	nmod
11	does	do	VBZ	_	13	aux
12	not	not	RB	_	13	neg
13	alter	alter	VB	_	1	dep
14	the	the	DT	_	17	det
15	plasma	plasma	NN	_	17	compound
16	concentration	concentration	NN	_	17	compound
17	profile	profile	NN	_	13	dobj
18	or	or	CC	_	17	cc
19	renal	renal	JJ	_	20	amod
20	elimination	elimination	NN	_	17	conj
21	of	of	IN	_	22	case
22	drug3	drug3	NN	_	17	nmod
23	after	after	IN	_	29	case
24	a	a	DT	_	29	det
25	single	single	JJ	_	29	amod
26	0.5	0.5	CD	_	27	compound
27	mg	mg	NN	_	29	amod
28	oral	oral	JJ	_	29	amod
29	dose	dose	NN	_	13	nmod
30	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Clinical	clinical	JJ	_	4	amod
4	studies	study	NNS	_	13	nsubj
5	,	,	,	_	4	punct
6	as	as	RB	_	4	cc
7	well	well	RB	_	6	mwe
8	as	as	IN	_	6	mwe
9	post-marketing	post-marketing	JJ	_	10	amod
10	observations	observation	NNS	_	4	conj
11	,	,	,	_	4	punct
12	have	have	VBP	_	13	aux
13	shown	show	VBN	_	1	appos
14	that	that	IN	_	17	mark
15	drug2	drug2	NN	_	17	nsubj
16	can	can	MD	_	17	aux
17	reduce	reduce	VB	_	13	ccomp
18	the	the	DT	_	20	det
19	natriuretic	natriuretic	JJ	_	20	amod
20	effect	effect	NN	_	17	dobj
21	of	of	IN	_	22	case
22	drug3	drug3	NN	_	20	nmod
23	and	and	CC	_	22	cc
24	drug4	drug4	NN	_	22	conj
25	in	in	IN	_	27	case
26	some	some	DT	_	27	det
27	patients	patient	NNS	_	20	nmod
28	.	.	.	_	1	punct

1	This	this	DT	_	2	det
2	response	response	NN	_	5	nsubjpass
3	has	have	VBZ	_	5	aux
4	been	be	VBN	_	5	auxpass
5	attributed	attribute	VBN	_	0	ROOT
6	to	to	TO	_	7	case
7	inhibition	inhibition	NN	_	5	nmod
8	of	of	IN	_	11	case
9	renal	renal	JJ	_	11	amod
10	prostaglandin	prostaglandin	NN	_	11	compound
11	synthesis	synthesis	NN	_	7	nmod
12	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	compound
4	400	400	CD	_	5	nummod
5	mg	mg	NN	_	9	nsubj
6	daily	daily	RB	_	5	advmod
7	did	do	VBD	_	9	aux
8	not	not	RB	_	9	neg
9	have	have	VB	_	1	dep
10	any	any	DT	_	13	det
11	clinically	clinically	RB	_	12	advmod
12	important	important	JJ	_	13	amod
13	effect	effect	NN	_	9	dobj
14	on	on	IN	_	16	case
15	the	the	DT	_	16	det
16	pharmacokinetics	pharmacokinetic	NNS	_	9	nmod
17	of	of	IN	_	18	case
18	drug3	drug3	NN	_	16	nmod
19	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubj
4	have	have	VBP	_	5	aux
5	produced	produce	VBN	_	1	appos
6	an	a	DT	_	7	det
7	elevation	elevation	NN	_	5	dobj
8	of	of	IN	_	11	case
9	plasma	plasma	NN	_	11	compound
10	drug3	drug3	NN	_	11	compound
11	levels	level	NNS	_	7	nmod
12	and	and	CC	_	7	cc
13	a	a	DT	_	14	det
14	reduction	reduction	NN	_	7	conj
15	in	in	IN	_	18	case
16	renal	renal	JJ	_	18	amod
17	drug4	drug4	NN	_	18	compound
18	clearance	clearance	NN	_	14	nmod
19	.	.	.	_	1	punct

1	In	in	IN	_	3	case
2	post-marketing	post-marketing	JJ	_	3	amod
3	experience	experience	NN	_	7	nmod
4	there	there	EX	_	7	expl
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	cop
7	reports	report	NNS	_	0	ROOT
8	of	of	IN	_	9	case
9	increases	increase	NNS	_	7	nmod
10	in	in	IN	_	13	case
11	plasma	plasma	NN	_	13	compound
12	drug1	drug1	NN	_	13	compound
13	levels	level	NNS	_	9	nmod
14	.	.	.	_	7	punct

1	Thus	thus	RB	_	14	advmod
2	,	,	,	_	14	punct
3	when	when	WRB	_	8	advmod
4	drug1	drug1	NN	_	8	nsubjpass
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	are	be	VBP	_	8	auxpass
8	administered	administer	VBN	_	14	advcl
9	concurrently	concurrently	RB	_	8	advmod
10	,	,	,	_	14	punct
11	subjects	subject	NNS	_	14	nsubjpass
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	observed	observe	VBN	_	0	ROOT
15	carefully	carefully	RB	_	14	advmod
16	for	for	IN	_	17	case
17	signs	sign	NNS	_	14	nmod
18	of	of	IN	_	20	case
19	drug3	drug3	NN	_	20	compound
20	toxicity	toxicity	NN	_	17	nmod
21	.	.	.	_	14	punct

1	drug1	drug1	NN	_	2	compound
2	drug2	drug2	NN	_	20	nsubj
3	12.5	12.5	CD	_	2	nummod
4	,	,	,	_	2	punct
5	25	25	CD	_	2	nummod
6	,	,	,	_	2	punct
7	and	and	CC	_	2	cc
8	50	50	CD	_	9	nummod
9	mg	mg	NN	_	2	conj
10	,	,	,	_	2	punct
11	each	each	DT	_	12	det
12	dose	dose	NN	_	13	nsubj
13	administered	administer	VBN	_	2	acl:relcl
14	once	once	RB	_	15	advmod
15	daily	daily	RB	_	13	advmod
16	for	for	IN	_	18	case
17	7	7	CD	_	18	nummod
18	days	day	NNS	_	13	nmod
19	,	,	,	_	2	punct
20	had	have	VBD	_	0	ROOT
21	no	no	DT	_	22	neg
22	effect	effect	NN	_	20	dobj
23	on	on	IN	_	26	case
24	the	the	DT	_	26	det
25	plasma	plasma	NN	_	26	compound
26	concentration	concentration	NN	_	20	nmod
27	of	of	IN	_	28	case
28	drug3	drug3	NN	_	26	nmod
29	as	as	IN	_	30	mark
30	measured	measure	VBN	_	20	advcl
31	by	by	IN	_	32	case
32	AUC0-24hr	auc0-24hr	NN	_	30	nmod
33	in	in	IN	_	34	case
34	patients	patient	NNS	_	32	nmod
35	receiving	receive	VBG	_	34	acl
36	single	single	JJ	_	39	amod
37	weekly	weekly	JJ	_	39	amod
38	drug4	drug4	NN	_	39	compound
39	doses	dose	NNS	_	35	dobj
40	of	of	IN	_	44	case
41	7.5	7.5	CD	_	43	compound
42	to	to	TO	_	43	dep
43	20	20	CD	_	44	nummod
44	mg	mg	NN	_	39	nmod
45	for	for	IN	_	47	case
46	rheumatoid	rheumatoid	JJ	_	47	amod
47	arthritis	arthritis	NN	_	35	nmod
48	.	.	.	_	20	punct

1	At	at	IN	_	0	ROOT
2	higher	higher	JJR	_	1	dep
3	than	than	IN	_	5	case
4	recommended	recommend	VBN	_	5	amod
5	doses	dose	NNS	_	2	nmod
6	,	,	,	_	2	punct
7	drug1	drug1	NN	_	9	compound
8	75	75	CD	_	9	nummod
9	mg	mg	NN	_	2	dep
10	administered	administer	VBN	_	9	acl
11	once	once	RB	_	12	advmod
12	daily	daily	RB	_	10	advmod
13	for	for	IN	_	15	case
14	10	10	CD	_	15	nummod
15	days	day	NNS	_	10	nmod
16	increased	increase	VBN	_	18	amod
17	plasma	plasma	NN	_	18	compound
18	concentrations	concentration	NNS	_	15	dep
19	by	by	IN	_	21	case
20	23	23	CD	_	21	nummod
21	%	%	NN	_	18	nmod
22	as	as	IN	_	23	mark
23	measured	measure	VBN	_	18	dep
24	by	by	IN	_	25	case
25	AUC0-24hr	auc0-24hr	NN	_	23	nmod
26	in	in	IN	_	27	case
27	patients	patient	NNS	_	25	nmod
28	receiving	receive	VBG	_	27	acl
29	drug2	drug2	NN	_	33	compound
30	7.5	7.5	CD	_	32	compound
31	to	to	TO	_	32	dep
32	15	15	CD	_	33	nummod
33	mg/week	mg/week	NN	_	28	dobj
34	for	for	IN	_	36	case
35	rheumatoid	rheumatoid	JJ	_	36	amod
36	arthritis	arthritis	NN	_	28	nmod
37	.	.	.	_	1	punct

1	At	at	IN	_	3	case
2	24	24	CD	_	3	nummod
3	hours	hour	NNS	_	34	nmod
4	postdose	postdose	NN	_	3	dep
5	,	,	,	_	34	punct
6	a	a	DT	_	8	det
7	similar	similar	JJ	_	8	amod
8	proportion	proportion	NN	_	34	nsubj
9	of	of	IN	_	10	case
10	patients	patient	NNS	_	8	nmod
11	treated	treat	VBN	_	10	acl
12	with	with	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	alone	alone	RB	_	13	advmod
15	-LRB-	-lrb-	-LRB-	_	17	punct
16	94	94	CD	_	17	nummod
17	%	%	NN	_	8	appos
18	-RRB-	-rrb-	-RRB-	_	17	punct
19	and	and	CC	_	8	cc
20	subsequently	subsequently	RB	_	21	advmod
21	treated	treat	VBN	_	8	conj
22	with	with	IN	_	23	case
23	drug2	drug2	NN	_	21	nmod
24	co-administered	co-administer	VBN	_	23	acl
25	with	with	IN	_	27	case
26	75	75	CD	_	27	nummod
27	mg	mg	NN	_	24	nmod
28	of	of	IN	_	29	case
29	drug3	drug3	NN	_	27	nmod
30	-LRB-	-lrb-	-LRB-	_	32	punct
31	88	88	CD	_	32	nummod
32	%	%	NN	_	27	appos
33	-RRB-	-rrb-	-RRB-	_	32	punct
34	had	have	VBD	_	0	ROOT
35	drug4	drug4	NN	_	37	compound
36	plasma	plasma	NN	_	37	compound
37	concentrations	concentration	NNS	_	34	dobj
38	below	below	IN	_	41	case
39	the	the	DT	_	41	det
40	measurable	measurable	JJ	_	41	amod
41	limit	limit	NN	_	37	nmod
42	-LRB-	-lrb-	-LRB-	_	44	punct
43	5	5	CD	_	44	nummod
44	ng/mL	ng/ml	NN	_	37	appos
45	-RRB-	-rrb-	-RRB-	_	44	punct
46	.	.	.	_	34	punct

1	Standard	Standard	NNP	_	2	amod
2	monitoring	monitoring	NN	_	0	ROOT
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	-	-	:	_	4	punct
6	related	related	JJ	_	7	amod
7	toxicity	toxicity	NN	_	10	nsubjpass
8	should	should	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	continued	continue	VBN	_	4	dep
11	if	if	IN	_	16	mark
12	drug2	drug2	NN	_	16	nsubjpass
13	and	and	CC	_	12	cc
14	drug3	drug3	NN	_	12	conj
15	are	be	VBP	_	16	auxpass
16	administered	administer	VBN	_	10	advcl
17	concomitantly	concomitantly	RB	_	16	advmod
18	.	.	.	_	2	punct

1	Oral	oral	JJ	_	3	amod
2	drug1	drug1	NN	_	3	compound
3	drug2	drug2	NN	_	6	nsubj
4	did	do	VBD	_	6	aux
5	not	not	RB	_	6	neg
6	have	have	VB	_	0	ROOT
7	any	any	DT	_	10	det
8	clinically	clinically	RB	_	9	advmod
9	important	important	JJ	_	10	amod
10	effect	effect	NN	_	6	dobj
11	on	on	IN	_	13	case
12	the	the	DT	_	13	det
13	pharmacokinetics	pharmacokinetic	NNS	_	6	nmod
14	of	of	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	drug4	drug4	NN	_	15	conj
18	.	.	.	_	6	punct

1	drug1	drug1	NN	_	3	compound
2	/	/	:	_	3	punct
3	drug2	drug2	NN	_	0	ROOT
4	:	:	:	_	3	punct
5	drug3	drug3	NN	_	8	nsubj
6	did	do	VBD	_	8	aux
7	not	not	RB	_	8	neg
8	have	have	VB	_	3	dep
9	any	any	DT	_	12	det
10	clinically	clinically	RB	_	11	advmod
11	important	important	JJ	_	12	amod
12	effect	effect	NN	_	8	dobj
13	on	on	IN	_	15	case
14	the	the	DT	_	15	det
15	pharmacokinetics	pharmacokinetic	NNS	_	8	nmod
16	of	of	IN	_	17	case
17	drug4	drug4	NN	_	15	nmod
18	or	or	CC	_	17	cc
19	drug5	drug5	NN	_	17	conj
20	.	.	.	_	8	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Co-administration	co-administration	NN	_	19	nsubj
4	of	of	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	with	with	IN	_	9	case
7	drug3	drug3	NN	_	9	compound
8	600	600	CD	_	9	nummod
9	mg	mg	NN	_	3	nmod
10	daily	daily	RB	_	3	advmod
11	,	,	,	_	3	punct
12	a	a	DT	_	14	det
13	potent	potent	JJ	_	14	amod
14	inducer	inducer	NN	_	3	appos
15	of	of	IN	_	17	case
16	hepatic	hepatic	JJ	_	17	amod
17	metabolism	metabolism	NN	_	14	nmod
18	,	,	,	_	3	punct
19	produced	produce	VBD	_	1	appos
20	an	a	DT	_	24	det
21	approximate	approximate	JJ	_	24	amod
22	50	50	CD	_	23	compound
23	%	%	NN	_	24	amod
24	decrease	decrease	NN	_	19	dobj
25	in	in	IN	_	28	case
26	drug4	drug4	NN	_	28	compound
27	plasma	plasma	NN	_	28	compound
28	concentrations	concentration	NNS	_	24	nmod
29	.	.	.	_	1	punct

1	Therefore	therefore	RB	_	14	advmod
2	,	,	,	_	14	punct
3	a	a	DT	_	6	det
4	starting	start	VBG	_	6	amod
5	daily	daily	JJ	_	6	amod
6	dose	dose	NN	_	14	nsubjpass
7	of	of	IN	_	9	case
8	25	25	CD	_	9	nummod
9	mg	mg	NN	_	6	nmod
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	considered	consider	VBN	_	0	ROOT
15	for	for	IN	_	17	case
16	the	the	DT	_	17	det
17	treatment	treatment	NN	_	14	nmod
18	of	of	IN	_	19	case
19	osteoarthritis	osteoarthritis	NN	_	17	nmod
20	when	when	WRB	_	23	advmod
21	drug2	drug2	NN	_	23	nsubjpass
22	is	be	VBZ	_	23	auxpass
23	co-administered	co-administer	VBN	_	14	advcl
24	with	with	IN	_	26	case
25	potent	potent	JJ	_	26	amod
26	inducers	inducer	NNS	_	23	nmod
27	of	of	IN	_	29	case
28	hepatic	hepatic	JJ	_	29	amod
29	metabolism	metabolism	NN	_	26	nmod
30	.	.	.	_	14	punct

1	drug1	drug1	NN	_	2	compound
2	drug2	drug2	NN	_	0	ROOT
3	12.5	12.5	CD	_	2	nummod
4	,	,	,	_	2	punct
5	25	25	CD	_	2	nummod
6	,	,	,	_	2	punct
7	and	and	CC	_	2	cc
8	50	50	CD	_	9	nummod
9	mg	mg	NN	_	2	conj
10	administered	administer	VBN	_	9	acl
11	once	once	RB	_	12	advmod
12	daily	daily	RB	_	10	advmod
13	for	for	IN	_	15	case
14	7	7	CD	_	15	nummod
15	days	day	NNS	_	10	nmod
16	increased	increase	VBN	_	19	amod
17	plasma	plasma	NN	_	19	compound
18	drug3	drug3	NN	_	19	compound
19	concentrations	concentration	NNS	_	15	dep
20	-LRB-	-lrb-	-LRB-	_	21	punct
21	AUC	auc	NN	_	19	dep
22	-LRB-	-lrb-	-LRB-	_	31	punct
23	0	0	CD	_	31	nummod
24	-	-	:	_	31	punct
25	-RRB-	-rrb-	-RRB-	_	31	punct
26	-RRB-	-rrb-	-RRB-	_	31	punct
27	by	by	IN	_	31	case
28	38	38	CD	_	30	compound
29	to	to	TO	_	30	dep
30	60	60	CD	_	31	nummod
31	%	%	NN	_	21	dep
32	in	in	IN	_	34	case
33	healthy	healthy	JJ	_	34	amod
34	subjects	subject	NNS	_	31	nmod
35	administered	administer	VBN	_	34	acl
36	a	a	DT	_	39	det
37	single	single	JJ	_	39	amod
38	300-mg	300-mg	JJ	_	39	amod
39	dose	dose	NN	_	35	dobj
40	of	of	IN	_	41	case
41	drug4	drug4	NN	_	39	nmod
42	.	.	.	_	2	punct

1	Adequate	adequate	JJ	_	2	amod
2	monitoring	monitoring	NN	_	9	nsubjpass
3	of	of	IN	_	6	case
4	drug1	drug1	NN	_	6	compound
5	plasma	plasma	NN	_	6	compound
6	concentrations	concentration	NNS	_	2	nmod
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	considered	consider	VBN	_	0	ROOT
10	when	when	WRB	_	15	advmod
11	therapy	therapy	NN	_	15	nsubjpass
12	with	with	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	is	be	VBZ	_	15	auxpass
15	initiated	initiate	VBN	_	9	advcl
16	or	or	CC	_	15	cc
17	changed	change	VBN	_	15	conj
18	in	in	IN	_	19	case
19	patients	patient	NNS	_	15	nmod
20	receiving	receive	VBG	_	19	acl
21	drug3	drug3	NN	_	20	dobj
22	.	.	.	_	9	punct

1	These	these	DT	_	2	det
2	data	datum	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	7	mark
5	drug1	drug1	NN	_	7	nsubj
6	may	may	MD	_	7	aux
7	produce	produce	VB	_	3	ccomp
8	a	a	DT	_	10	det
9	modest	modest	JJ	_	10	amod
10	inhibition	inhibition	NN	_	7	dobj
11	of	of	IN	_	13	case
12	cytochrome	cytochrome	NN	_	13	compound
13	P450	p450	NN	_	10	nmod
14	-LRB-	-lrb-	-LRB-	_	15	punct
15	CYP	cyp	NN	_	13	appos
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	1A2	1a2	NN	_	13	dep
18	.	.	.	_	3	punct

1	Therefore	therefore	RB	_	4	advmod
2	,	,	,	_	4	punct
3	there	there	EX	_	4	expl
4	is	be	VBZ	_	0	ROOT
5	a	a	DT	_	6	det
6	potential	potential	NN	_	4	nsubj
7	for	for	IN	_	9	case
8	an	a	DT	_	9	det
9	interaction	interaction	NN	_	6	nmod
10	with	with	IN	_	12	case
11	other	other	JJ	_	12	amod
12	drugs	drug	NNS	_	9	nmod
13	that	that	WDT	_	15	nsubjpass
14	are	be	VBP	_	15	auxpass
15	metabolized	metabolize	VBN	_	12	acl:relcl
16	by	by	IN	_	18	case
17	CYP	cyp	NN	_	18	compound
18	1A2	1a2	NN	_	15	nmod
19	-LRB-	-lrb-	-LRB-	_	22	punct
20	e.g.	e.g.	FW	_	22	dep
21	,	,	,	_	22	punct
22	drug1	drug1	NN	_	18	dep
23	,	,	,	_	22	punct
24	drug2	drug2	NN	_	22	conj
25	,	,	,	_	22	punct
26	and	and	CC	_	22	cc
27	drug3	drug3	NN	_	22	conj
28	-RRB-	-rrb-	-RRB-	_	22	punct
29	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Anticoagulant	anticoagulant	JJ	_	4	amod
4	activity	activity	NN	_	7	nsubjpass
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	monitored	monitor	VBN	_	1	dep
8	,	,	,	_	7	punct
9	particularly	particularly	RB	_	14	advmod
10	in	in	IN	_	14	case
11	the	the	DT	_	14	det
12	first	first	JJ	_	14	amod
13	few	few	JJ	_	14	amod
14	days	day	NNS	_	7	nmod
15	after	after	IN	_	16	mark
16	initiating	initiate	VBG	_	14	acl
17	or	or	CC	_	16	cc
18	changing	change	VBG	_	16	conj
19	drug2	drug2	NN	_	20	compound
20	therapy	therapy	NN	_	16	dobj
21	in	in	IN	_	22	case
22	patients	patient	NNS	_	20	nmod
23	receiving	receive	VBG	_	22	acl
24	drug3	drug3	NN	_	23	dobj
25	or	or	CC	_	24	cc
26	similar	similar	JJ	_	24	conj
27	agents	agent	NNS	_	24	dep
28	,	,	,	_	7	punct
29	since	since	IN	_	36	mark
30	these	these	DT	_	31	det
31	patients	patient	NNS	_	36	nsubj
32	are	be	VBP	_	36	cop
33	at	at	IN	_	36	case
34	an	a	DT	_	36	det
35	increased	increase	VBN	_	36	amod
36	risk	risk	NN	_	7	advcl
37	of	of	IN	_	38	mark
38	bleeding	bleed	VBG	_	36	acl
39	complications	complication	NNS	_	38	dobj
40	.	.	.	_	1	punct

1	In	in	IN	_	6	case
2	single	single	JJ	_	6	amod
3	and	and	CC	_	2	cc
4	multiple	multiple	JJ	_	2	conj
5	dose	dose	NN	_	6	compound
6	studies	study	NNS	_	24	nmod
7	in	in	IN	_	9	case
8	healthy	healthy	JJ	_	9	amod
9	subjects	subject	NNS	_	6	nmod
10	receiving	receive	VBG	_	9	acl
11	both	both	CC	_	12	cc:preconj
12	drug1	drug1	NN	_	10	dobj
13	and	and	CC	_	12	cc
14	drug2	drug2	NN	_	12	conj
15	,	,	,	_	24	punct
16	prothrombin	prothrombin	NN	_	17	compound
17	time	time	NN	_	24	nsubjpass
18	-LRB-	-lrb-	-LRB-	_	19	punct
19	measured	measure	VBN	_	17	dep
20	as	as	IN	_	21	case
21	INR	inr	NN	_	19	nmod
22	-RRB-	-rrb-	-RRB-	_	19	punct
23	was	be	VBD	_	24	auxpass
24	increased	increase	VBN	_	0	ROOT
25	by	by	IN	_	28	case
26	approximately	approximately	RB	_	27	advmod
27	8	8	CD	_	28	nummod
28	%	%	NN	_	24	nmod
29	to	to	TO	_	31	case
30	11	11	CD	_	31	nummod
31	%	%	NN	_	24	nmod
32	.	.	.	_	24	punct

1	In	in	IN	_	3	case
2	post-marketing	post-marketing	JJ	_	3	amod
3	experience	experience	NN	_	9	nmod
4	,	,	,	_	9	punct
5	bleeding	bleed	VBG	_	6	amod
6	events	event	NNS	_	9	nsubjpass
7	have	have	VBP	_	9	aux
8	been	be	VBN	_	9	auxpass
9	reported	report	VBN	_	0	ROOT
10	,	,	,	_	9	punct
11	predominantly	predominantly	RB	_	14	advmod
12	in	in	IN	_	14	case
13	the	the	DT	_	14	det
14	elderly	elderly	JJ	_	9	nmod
15	,	,	,	_	14	punct
16	in	in	IN	_	17	case
17	association	association	NN	_	14	nmod
18	with	with	IN	_	19	case
19	increases	increase	NNS	_	17	nmod
20	in	in	IN	_	22	case
21	prothrombin	prothrombin	NN	_	22	compound
22	time	time	NN	_	19	nmod
23	in	in	IN	_	24	case
24	patients	patient	NNS	_	22	nmod
25	receiving	receive	VBG	_	24	acl
26	drug1	drug1	NN	_	25	dobj
27	concurrently	concurrently	RB	_	25	advmod
28	with	with	IN	_	29	case
29	drug2	drug2	NN	_	25	nmod
30	.	.	.	_	9	punct

1	When	when	WRB	_	2	advmod
2	administered	administer	VBN	_	9	advcl
3	concurrently	concurrently	RB	_	2	advmod
4	,	,	,	_	9	punct
5	the	the	DT	_	7	det
6	following	follow	VBG	_	7	amod
7	drugs	drug	NNS	_	9	nsubj
8	may	may	MD	_	9	aux
9	interact	interact	VB	_	0	ROOT
10	with	with	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	.	.	.	_	9	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Increased	increase	VBN	_	4	amod
4	possibility	possibility	NN	_	14	nsubj
5	of	of	IN	_	7	case
6	skin	skin	NN	_	7	compound
7	rash	rash	NN	_	4	nmod
8	,	,	,	_	4	punct
9	particularly	particularly	RB	_	12	advmod
10	in	in	IN	_	12	case
11	hyperuricemic	hyperuricemic	JJ	_	12	amod
12	patients	patient	NNS	_	4	nmod
13	may	may	MD	_	14	aux
14	occur	occur	VB	_	1	dep
15	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	12	nsubj
4	,	,	,	_	3	punct
5	drug3	drug3	NN	_	3	conj
6	,	,	,	_	3	punct
7	drug4	drug4	NN	_	3	conj
8	,	,	,	_	3	punct
9	or	or	CC	_	3	cc
10	drug5	drug5	NN	_	3	conj
11	may	may	MD	_	12	aux
12	interfere	interfere	VB	_	1	dep
13	with	with	IN	_	16	case
14	the	the	DT	_	16	det
15	bactericidal	bactericidal	JJ	_	16	amod
16	effect	effect	NN	_	12	nmod
17	of	of	IN	_	18	case
18	drug6	drug6	NN	_	16	nmod
19	.	.	.	_	12	punct

1	This	this	DT	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	demonstrated	demonstrate	VBN	_	0	ROOT
5	in	in	IN	_	6	case
6	view	view	NN	_	4	nmod
7	,	,	,	_	4	punct
8	however	however	RB	_	4	advmod
9	,	,	,	_	4	punct
10	the	the	DT	_	12	det
11	clinical	clinical	JJ	_	12	amod
12	significance	significance	NN	_	19	nsubjpass
13	of	of	IN	_	15	case
14	this	this	DT	_	15	det
15	interaction	interaction	NN	_	12	nmod
16	is	be	VBZ	_	19	auxpass
17	not	not	RB	_	19	neg
18	well	well	RB	_	19	advmod
19	documented	document	VBN	_	4	ccomp
20	.	.	.	_	4	punct

1	Oral	oral	JJ	_	2	amod
2	drug1	drug1	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	May	may	MD	_	7	aux
5	be	be	VB	_	7	cop
6	less	less	RBR	_	7	advmod
7	effective	effective	JJ	_	2	dep
8	and	and	CC	_	7	cc
9	increased	increase	VBD	_	11	amod
10	breakthrough	breakthrough	NN	_	11	compound
11	bleeding	bleeding	NN	_	7	conj
12	may	may	MD	_	13	aux
13	occur	occur	VB	_	7	dep
14	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	May	May	NNP	_	4	nsubj
4	decrease	decrease	VB	_	1	dep
5	renal	renal	JJ	_	7	amod
6	tubular	tubular	JJ	_	7	amod
7	secretion	secretion	NN	_	4	dobj
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	resulting	result	VBG	_	4	advcl
11	in	in	IN	_	14	case
12	increased	increase	VBN	_	14	amod
13	blood	blood	NN	_	14	compound
14	levels	level	NNS	_	10	nmod
15	and/or	and/or	CC	_	14	cc
16	drug3	drug3	NN	_	17	compound
17	toxicity	toxicity	NN	_	14	conj
18	.	.	.	_	1	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	3	amod
2	Test	test	NN	_	3	compound
3	Interaction	interaction	NN	_	18	nsubj
4	After	after	IN	_	5	case
5	treatment	treatment	NN	_	3	nmod
6	with	with	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	,	,	,	_	7	punct
9	a	a	DT	_	11	det
10	false-positive	false-positive	JJ	_	11	amod
11	reaction	reaction	NN	_	7	appos
12	for	for	IN	_	13	case
13	glucose	glucose	NN	_	11	nmod
14	in	in	IN	_	16	case
15	the	the	DT	_	16	det
16	urine	urine	NN	_	13	nmod
17	may	may	MD	_	18	aux
18	occur	occur	VB	_	0	ROOT
19	with	with	IN	_	21	case
20	drug2	drug2	NN	_	21	compound
21	tests	test	NNS	_	18	nmod
22	-LRB-	-lrb-	-LRB-	_	24	punct
23	Benedicts	benedict	NNS	_	24	compound
24	solution	solution	NN	_	21	dep
25	,	,	,	_	24	punct
26	Fehlings	Fehlings	NNP	_	27	compound
27	solution	solution	NN	_	24	conj
28	,	,	,	_	24	punct
29	or	or	CC	_	24	cc
30	Clinitest	Clinitest	NNP	_	31	compound
31	tablets	tablet	NNS	_	24	conj
32	-RRB-	-rrb-	-RRB-	_	24	punct
33	but	but	CC	_	21	cc
34	not	not	RB	_	36	neg
35	with	with	IN	_	36	case
36	enzyme	enzyme	NN	_	21	conj
37	based	base	VBN	_	38	amod
38	tests	test	NNS	_	36	dep
39	such	such	JJ	_	41	case
40	as	as	IN	_	39	mwe
41	Clinistix	Clinistix	NNP	_	38	nmod
42	and	and	CC	_	41	cc
43	Glucose	Glucose	NNP	_	47	compound
44	Enzymatic	enzymatic	JJ	_	47	amod
45	Test	test	NN	_	47	compound
46	Strip	Strip	NNP	_	47	compound
47	USP	USP	NNP	_	41	conj
48	.	.	.	_	18	punct

1	in	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	data	datum	NNS	_	7	nsubj
4	on	on	IN	_	6	case
5	metabolic	metabolic	JJ	_	6	amod
6	interactions	interaction	NNS	_	3	nmod
7	indicate	indicate	VBP	_	0	ROOT
8	that	that	IN	_	11	mark
9	drug1	drug1	NN	_	11	nsubj
10	is	be	VBZ	_	11	cop
11	unlikely	unlikely	JJ	_	7	ccomp
12	to	to	TO	_	13	mark
13	produce	produce	VB	_	11	xcomp
14	,	,	,	_	11	punct
15	or	or	CC	_	11	cc
16	be	be	VB	_	17	cop
17	subject	subject	JJ	_	11	conj
18	to	to	TO	_	21	case
19	,	,	,	_	21	punct
20	pharmacokinetic	pharmacokinetic	JJ	_	21	amod
21	interactions	interaction	NNS	_	17	nmod
22	.	.	.	_	7	punct

1	drug1	drug1	NN	_	13	nsubj
2	and	and	CC	_	1	cc
3	its	its	PRP$	_	5	nmod:poss
4	major	major	JJ	_	5	amod
5	metabolite	metabolite	NN	_	1	conj
6	,	,	,	_	1	punct
7	at	at	IN	_	8	case
8	concentrations	concentration	NNS	_	1	nmod
9	well	well	RB	_	12	advmod
10	above	above	IN	_	12	case
11	cmax	cmax	NN	_	12	compound
12	levels	level	NNS	_	8	nmod
13	achieved	achieve	VBD	_	0	ROOT
14	within	within	IN	_	18	case
15	the	the	DT	_	18	det
16	therapeutic	therapeutic	JJ	_	18	amod
17	dose	dose	NN	_	18	compound
18	range	range	NN	_	13	nmod
19	,	,	,	_	13	punct
20	are	be	VBP	_	22	cop
21	neither	neither	DT	_	22	det
22	inhibitors	inhibitor	NNS	_	13	dep
23	of	of	IN	_	27	case
24	nor	nor	CC	_	23	cc
25	high	high	JJ	_	23	conj
26	affinity	affinity	NN	_	27	compound
27	substrates	substrate	NNS	_	22	nmod
28	for	for	IN	_	33	case
29	human	human	JJ	_	33	amod
30	liver	liver	NN	_	33	compound
31	cytochrome	cytochrome	NN	_	33	compound
32	P450	p450	NN	_	33	compound
33	isoforms	isoform	NNS	_	22	nmod
34	,	,	,	_	33	punct
35	epoxide	epoxide	NN	_	36	compound
36	hydrolase	hydrolase	NN	_	33	conj
37	or	or	CC	_	33	cc
38	UDP-glucuronidation	udp-glucuronidation	NN	_	39	compound
39	enzymes	enzyme	NNS	_	33	conj
40	.	.	.	_	13	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	7	nmod
3	,	,	,	_	7	punct
4	drug1	drug1	NN	_	7	nsubj
5	does	do	VBZ	_	7	aux
6	not	not	RB	_	7	neg
7	affect	affect	VB	_	0	ROOT
8	the	the	DT	_	11	det
9	in	in	FW	_	11	amod
10	vitro	vitro	FW	_	9	dep
11	glucuronidation	glucuronidation	NN	_	7	dobj
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	.	.	.	_	7	punct

1	drug1	drug1	NN	_	2	nsubj
2	circulates	circulate	VBZ	_	0	ROOT
3	largely	largely	RB	_	4	advmod
4	unbound	unbound	JJ	_	2	dobj
5	-LRB-	-lrb-	-LRB-	_	8	punct
6	10	10	CD	_	7	nummod
7	%	%	NN	_	8	dep
8	bound	bind	VBN	_	4	dep
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	to	to	TO	_	12	case
11	plasma	plasma	NN	_	12	compound
12	proteins	protein	NNS	_	4	nmod
13	;	;	:	_	2	punct

1	clinically	clinically	RB	_	2	advmod
2	significant	significant	JJ	_	3	amod
3	interactions	interaction	NNS	_	15	nsubj
4	with	with	IN	_	6	case
5	other	other	JJ	_	6	amod
6	drugs	drug	NNS	_	3	nmod
7	through	through	IN	_	8	case
8	competition	competition	NN	_	3	nmod
9	for	for	IN	_	12	case
10	protein	protein	NN	_	12	compound
11	binding	binding	NN	_	12	compound
12	sites	site	NNS	_	8	nmod
13	are	be	VBP	_	15	cop
14	therefore	therefore	RB	_	15	advmod
15	unlikely	unlikely	JJ	_	0	ROOT
16	.	.	.	_	15	punct

1	Potential	potential	JJ	_	3	amod
2	pharmacokinetic	pharmacokinetic	JJ	_	3	amod
3	interactions	interaction	NNS	_	5	nsubjpass
4	were	be	VBD	_	5	auxpass
5	assessed	assess	VBN	_	0	ROOT
6	in	in	IN	_	9	case
7	clinical	clinical	JJ	_	9	amod
8	pharmacokinetic	pharmacokinetic	JJ	_	9	amod
9	studies	study	NNS	_	5	nmod
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	drug1	drug1	NN	_	9	dep
12	,	,	,	_	11	punct
13	drug2	drug2	NN	_	11	conj
14	,	,	,	_	11	punct
15	oral	oral	JJ	_	16	amod
16	drug3	drug3	NN	_	11	conj
17	,	,	,	_	11	punct
18	drug4	drug4	NN	_	11	conj
19	,	,	,	_	11	punct
20	drug5	drug5	NN	_	11	conj
21	,	,	,	_	11	punct
22	drug6	drug6	NN	_	11	appos
23	-RRB-	-rrb-	-RRB-	_	11	punct
24	and	and	CC	_	9	cc
25	through	through	IN	_	27	case
26	pharmacokinetic	pharmacokinetic	JJ	_	27	amod
27	screening	screening	NN	_	9	conj
28	in	in	IN	_	32	case
29	the	the	DT	_	32	det
30	placebo-controlled	placebo-controlled	JJ	_	32	amod
31	clinical	clinical	JJ	_	32	amod
32	studies	study	NNS	_	27	nmod
33	in	in	IN	_	35	case
34	epilepsy	epilepsy	NN	_	35	compound
35	patients	patient	NNS	_	32	nmod
36	.	.	.	_	5	punct

1	Drug-Drug	Drug-Drug	NNP	_	2	compound
2	Interactions	interaction	NNS	_	18	nsubj
3	Between	between	IN	_	12	case
4	drug1	drug1	NN	_	12	compound
5	And	and	CC	_	4	cc
6	Other	other	JJ	_	7	amod
7	drug2	drug2	NN	_	4	conj
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	drug3	drug3	NN	_	7	appos
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	drug4	drug4	NN	_	12	compound
12	drug5	drug5	NN	_	2	nmod
13	-LRB-	-lrb-	-LRB-	_	16	punct
14	3000	3000	CD	_	15	nummod
15	mg	mg	NN	_	16	nmod:npmod
16	daily	daily	JJ	_	12	dep
17	-RRB-	-rrb-	-RRB-	_	16	punct
18	had	have	VBD	_	0	ROOT
19	no	no	DT	_	20	neg
20	effect	effect	NN	_	18	dobj
21	on	on	IN	_	24	case
22	the	the	DT	_	24	det
23	pharmacokinetic	pharmacokinetic	JJ	_	24	amod
24	disposition	disposition	NN	_	18	nmod
25	of	of	IN	_	26	case
26	drug6	drug6	NN	_	24	nmod
27	in	in	IN	_	28	case
28	patients	patient	NNS	_	18	nmod
29	with	with	IN	_	31	case
30	refractory	refractory	JJ	_	31	amod
31	epilepsy	epilepsy	NN	_	28	nmod
32	.	.	.	_	18	punct

1	Pharmacokinetics	pharmacokinetic	NNS	_	7	nsubjpass
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	were	be	VBD	_	7	auxpass
5	also	also	RB	_	7	advmod
6	not	not	RB	_	7	neg
7	affected	affect	VBN	_	0	ROOT
8	by	by	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	.	.	.	_	7	punct

1	drug1	drug1	NN	_	2	compound
2	drug2	drug2	NN	_	11	nsubj
3	-LRB-	-lrb-	-LRB-	_	5	punct
4	1500	1500	CD	_	5	nummod
5	mg	mg	NN	_	2	appos
6	twice	twice	RB	_	7	advmod
7	daily	daily	RB	_	5	advmod
8	-RRB-	-rrb-	-RRB-	_	5	punct
9	did	do	VBD	_	11	aux
10	not	not	RB	_	11	neg
11	alter	alter	VB	_	0	ROOT
12	the	the	DT	_	13	det
13	pharmacokinetics	pharmacokinetic	NNS	_	11	dobj
14	of	of	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	in	in	IN	_	18	case
17	healthy	healthy	JJ	_	18	amod
18	volunteers	volunteer	NNS	_	13	nmod
19	.	.	.	_	11	punct

1	drug1	drug1	NN	_	3	compound
2	500	500	CD	_	3	nummod
3	mg	mg	NN	_	8	nsubj
4	twice	twice	RB	_	5	advmod
5	daily	daily	RB	_	8	advmod
6	did	do	VBD	_	8	aux
7	not	not	RB	_	8	neg
8	modify	modify	VB	_	0	ROOT
9	the	the	DT	_	10	det
10	rate	rate	NN	_	8	dobj
11	or	or	CC	_	10	cc
12	extent	extent	NN	_	10	conj
13	of	of	IN	_	15	case
14	drug2	drug2	NN	_	15	compound
15	absorption	absorption	NN	_	10	nmod
16	or	or	CC	_	15	cc
17	its	its	PRP$	_	19	nmod:poss
18	plasma	plasma	NN	_	19	compound
19	clearance	clearance	NN	_	15	conj
20	or	or	CC	_	19	cc
21	urinary	urinary	JJ	_	22	amod
22	excretion	excretion	NN	_	19	conj
23	.	.	.	_	8	punct

1	There	there	EX	_	3	expl
2	also	also	RB	_	3	advmod
3	was	be	VBD	_	0	ROOT
4	no	no	DT	_	5	neg
5	effect	effect	NN	_	3	nsubj
6	on	on	IN	_	7	case
7	exposure	exposure	NN	_	5	nmod
8	to	to	TO	_	7	dep
9	and	and	CC	_	8	cc
10	the	the	DT	_	11	det
11	excretion	excretion	NN	_	8	conj
12	of	of	IN	_	15	case
13	the	the	DT	_	15	det
14	primary	primary	JJ	_	15	amod
15	metabolite	metabolite	NN	_	11	nmod
16	,	,	,	_	15	punct
17	ucb	ucb	NN	_	18	compound
18	L057	l057	NN	_	15	appos
19	.	.	.	_	3	punct

1	Potential	potential	JJ	_	3	amod
2	drug	drug	NN	_	3	compound
3	interactions	interaction	NNS	_	26	nsubjpass
4	between	between	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	other	other	JJ	_	8	amod
8	drug2	drug2	NN	_	5	conj
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	drug3	drug3	NN	_	8	dep
11	,	,	,	_	10	punct
12	drug4	drug4	NN	_	10	conj
13	,	,	,	_	10	punct
14	drug5	drug5	NN	_	10	conj
15	,	,	,	_	10	punct
16	drug6	drug6	NN	_	10	conj
17	,	,	,	_	10	punct
18	drug7	drug7	NN	_	10	conj
19	,	,	,	_	10	punct
20	drug8	drug8	NN	_	10	conj
21	and	and	CC	_	10	cc
22	drug9	drug9	NN	_	10	conj
23	-RRB-	-rrb-	-RRB-	_	10	punct
24	were	be	VBD	_	26	auxpass
25	also	also	RB	_	26	advmod
26	assessed	assess	VBN	_	0	ROOT
27	by	by	IN	_	28	mark
28	evaluating	evaluate	VBG	_	26	advcl
29	the	the	DT	_	31	det
30	serum	serum	NN	_	31	compound
31	concentrations	concentration	NNS	_	28	dobj
32	of	of	IN	_	33	case
33	drug10	drug10	NN	_	31	nmod
34	and	and	CC	_	33	cc
35	these	these	DT	_	36	det
36	drug11	drug11	NN	_	33	conj
37	during	during	IN	_	40	case
38	placebo-controlled	placebo-controlled	JJ	_	40	amod
39	clinical	clinical	JJ	_	40	amod
40	studies	study	NNS	_	28	nmod
41	.	.	.	_	26	punct

1	These	these	DT	_	2	det
2	data	datum	NNS	_	3	nsubj
3	indicate	indicate	VBP	_	0	ROOT
4	that	that	IN	_	8	mark
5	drug1	drug1	NN	_	8	nsubj
6	does	do	VBZ	_	8	aux
7	not	not	RB	_	8	neg
8	influence	influence	VB	_	3	ccomp
9	the	the	DT	_	11	det
10	plasma	plasma	NN	_	11	compound
11	concentration	concentration	NN	_	8	dobj
12	of	of	IN	_	14	case
13	other	other	JJ	_	14	amod
14	drug2	drug2	NN	_	11	nmod
15	and	and	CC	_	8	cc
16	that	that	IN	_	21	mark
17	these	these	DT	_	18	det
18	drug3	drug3	NN	_	21	nsubj
19	do	do	VBP	_	21	aux
20	not	not	RB	_	21	neg
21	influence	influence	VB	_	8	conj
22	the	the	DT	_	23	det
23	pharmacokinetics	pharmacokinetic	NNS	_	21	dobj
24	of	of	IN	_	25	case
25	drug4	drug4	NN	_	23	nmod
26	.	.	.	_	3	punct

1	Effect	effect	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	in	in	IN	_	6	case
5	Pediatric	Pediatric	NNP	_	6	compound
6	Patients	Patients	NNPS	_	1	nmod
7	There	there	EX	_	8	expl
8	was	be	VBD	_	1	acl:relcl
9	about	about	IN	_	13	amod
10	a	a	DT	_	13	det
11	22	22	CD	_	12	compound
12	%	%	NN	_	13	amod
13	increase	increase	NN	_	8	nsubj
14	of	of	IN	_	18	case
15	apparent	apparent	JJ	_	18	amod
16	total	total	JJ	_	18	amod
17	body	body	NN	_	18	compound
18	clearance	clearance	NN	_	13	nmod
19	of	of	IN	_	20	case
20	drug2	drug2	NN	_	18	nmod
21	when	when	WRB	_	24	advmod
22	it	it	PRP	_	24	nsubjpass
23	was	be	VBD	_	24	auxpass
24	co-administered	co-administer	VBN	_	8	advcl
25	with	with	IN	_	27	case
26	enzyme-inducing	enzyme-inducing	JJ	_	27	amod
27	drug3	drug3	NN	_	24	nmod
28	.	.	.	_	1	punct

1	Dose	dose	NN	_	2	compound
2	adjustment	adjustment	NN	_	5	nsubjpass
3	is	be	VBZ	_	5	auxpass
4	not	not	RB	_	5	neg
5	recommended	recommend	VBN	_	0	ROOT
6	.	.	.	_	5	punct
7	drug1	drug1	NN	_	8	nsubj
8	had	have	VBD	_	5	parataxis
9	no	no	DT	_	10	neg
10	effect	effect	NN	_	8	dobj
11	on	on	IN	_	13	case
12	plasma	plasma	NN	_	13	compound
13	concentrations	concentration	NNS	_	8	nmod
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	,	,	,	_	15	punct
17	drug3	drug3	NN	_	15	conj
18	,	,	,	_	15	punct
19	drug4	drug4	NN	_	15	conj
20	,	,	,	_	15	punct
21	or	or	CC	_	15	cc
22	drug5	drug5	NN	_	15	conj
23	.	.	.	_	5	punct

1	Other	other	JJ	_	3	amod
2	Drug	drug	NN	_	3	compound
3	Interactions	interaction	NNS	_	15	nsubj
4	Oral	oral	JJ	_	6	amod
5	drug1	drug1	NN	_	6	compound
6	drug2	drug2	NN	_	3	dep
7	-LRB-	-lrb-	-LRB-	_	9	punct
8	500	500	CD	_	9	nummod
9	mg	mg	NN	_	6	dep
10	twice	twice	RB	_	11	advmod
11	daily	daily	RB	_	9	advmod
12	-RRB-	-rrb-	-RRB-	_	9	punct
13	did	do	VBD	_	15	aux
14	not	not	RB	_	15	neg
15	influence	influence	VB	_	0	ROOT
16	the	the	DT	_	17	det
17	pharmacokinetics	pharmacokinetic	NNS	_	15	dobj
18	of	of	IN	_	21	case
19	an	a	DT	_	21	det
20	oral	oral	JJ	_	21	amod
21	drug3	drug3	NN	_	17	nmod
22	containing	contain	VBG	_	21	acl
23	0.03	0.03	CD	_	25	nummod
24	mg	mg	NN	_	25	compound
25	drug4	drug4	NN	_	22	dobj
26	and	and	CC	_	25	cc
27	0.15	0.15	CD	_	28	compound
28	mg	mg	NN	_	29	amod
29	drug5	drug5	NN	_	25	conj
30	,	,	,	_	25	punct
31	or	or	CC	_	25	cc
32	of	of	IN	_	35	case
33	the	the	DT	_	35	det
34	luteinizing	luteinize	VBG	_	35	amod
35	hormone	hormone	NN	_	25	conj
36	and	and	CC	_	35	cc
37	progesterone	progesterone	NN	_	35	conj
38	levels	level	NNS	_	35	dep
39	,	,	,	_	15	punct
40	indicating	indicate	VBG	_	15	advcl
41	that	that	IN	_	47	mark
42	impairment	impairment	NN	_	47	nsubj
43	of	of	IN	_	45	case
44	contraceptive	contraceptive	JJ	_	45	amod
45	efficacy	efficacy	NN	_	42	nmod
46	is	be	VBZ	_	47	cop
47	unlikely	unlikely	JJ	_	40	ccomp
48	.	.	.	_	15	punct

1	Coadministration	coadministration	NN	_	8	nsubj
2	of	of	IN	_	5	case
3	this	this	DT	_	5	det
4	oral	oral	JJ	_	5	amod
5	drug1	drug1	NN	_	1	nmod
6	did	do	VBD	_	8	aux
7	not	not	RB	_	8	neg
8	influence	influence	VB	_	0	ROOT
9	the	the	DT	_	10	det
10	pharmacokinetics	pharmacokinetic	NNS	_	8	dobj
11	of	of	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	.	.	.	_	8	punct

1	drug1	drug1	NN	_	2	compound
2	drug2	drug2	NN	_	11	nsubj
3	-LRB-	-lrb-	-LRB-	_	5	punct
4	1000	1000	CD	_	5	nummod
5	mg	mg	NN	_	2	appos
6	twice	twice	RB	_	7	advmod
7	daily	daily	RB	_	5	advmod
8	-RRB-	-rrb-	-RRB-	_	5	punct
9	did	do	VBD	_	11	aux
10	not	not	RB	_	11	neg
11	influence	influence	VB	_	0	ROOT
12	the	the	DT	_	13	det
13	pharmacokinetics	pharmacokinetic	NNS	_	11	dobj
14	and	and	CC	_	13	cc
15	pharmacodynamics	pharmacodynamic	NNS	_	13	conj
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	ECG	ecg	NN	_	15	appos
18	-RRB-	-rrb-	-RRB-	_	17	punct
19	of	of	IN	_	20	case
20	drug3	drug3	NN	_	13	nmod
21	given	give	VBN	_	13	acl
22	as	as	IN	_	26	case
23	a	a	DT	_	26	det
24	0.25	0.25	CD	_	25	compound
25	mg	mg	NN	_	26	amod
26	dose	dose	NN	_	21	nmod
27	every	every	DT	_	28	det
28	day	day	NN	_	21	nmod:tmod
29	.	.	.	_	11	punct

1	Coadministration	coadministration	NN	_	6	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	did	do	VBD	_	6	aux
5	not	not	RB	_	6	neg
6	influence	influence	VB	_	0	ROOT
7	the	the	DT	_	8	det
8	pharmacokinetics	pharmacokinetic	NNS	_	6	dobj
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	.	.	.	_	6	punct

1	drug1	drug1	NN	_	2	compound
2	drug2	drug2	NN	_	11	nsubj
3	-LRB-	-lrb-	-LRB-	_	5	punct
4	1000	1000	CD	_	5	nummod
5	mg	mg	NN	_	2	appos
6	twice	twice	RB	_	7	advmod
7	daily	daily	RB	_	5	advmod
8	-RRB-	-rrb-	-RRB-	_	5	punct
9	did	do	VBD	_	11	aux
10	not	not	RB	_	11	neg
11	influence	influence	VB	_	0	ROOT
12	the	the	DT	_	13	det
13	pharmacokinetics	pharmacokinetic	NNS	_	11	dobj
14	of	of	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	drug4	drug4	NN	_	15	conj
18	.	.	.	_	11	punct

1	Prothrombin	Prothrombin	NNP	_	2	compound
2	time	time	NN	_	5	nsubjpass
3	was	be	VBD	_	5	auxpass
4	not	not	RB	_	5	neg
5	affected	affect	VBN	_	0	ROOT
6	by	by	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	.	.	.	_	5	punct

1	Coadministration	coadministration	NN	_	6	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	did	do	VBD	_	6	aux
5	not	not	RB	_	6	neg
6	affect	affect	VB	_	0	ROOT
7	the	the	DT	_	8	det
8	pharmacokinetics	pharmacokinetic	NNS	_	6	dobj
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	1	dep
4	,	,	,	_	3	punct
5	a	a	DT	_	8	det
6	renal	renal	JJ	_	8	amod
7	tubular	tubular	JJ	_	8	amod
8	secretion	secretion	NN	_	3	appos
9	blocking	block	VBG	_	10	compound
10	agent	agent	NN	_	26	nsubj
11	,	,	,	_	10	punct
12	administered	administer	VBN	_	10	acl
13	at	at	IN	_	15	case
14	a	a	DT	_	15	det
15	dose	dose	NN	_	12	nmod
16	of	of	IN	_	18	case
17	500	500	CD	_	18	nummod
18	mg	mg	NN	_	15	nmod
19	four	four	CD	_	20	nummod
20	times	time	NNS	_	18	nmod:tmod
21	a	a	DT	_	22	det
22	day	day	NN	_	20	nmod:npmod
23	,	,	,	_	10	punct
24	did	do	VBD	_	26	aux
25	not	not	RB	_	26	neg
26	change	change	VB	_	8	acl:relcl
27	the	the	DT	_	28	det
28	pharmacokinetics	pharmacokinetic	NNS	_	26	dobj
29	of	of	IN	_	32	case
30	drug3	drug3	NN	_	32	compound
31	1000	1000	CD	_	32	nummod
32	mg	mg	NN	_	28	nmod
33	twice	twice	RB	_	34	advmod
34	daily	daily	RB	_	26	advmod
35	.	.	.	_	1	punct

1	Cssmax	cssmax	NN	_	11	nsubjpass
2	of	of	IN	_	4	case
3	the	the	DT	_	4	det
4	metabolite	metabolite	NN	_	1	nmod
5	,	,	,	_	4	punct
6	ucb	ucb	NN	_	7	compound
7	L057	l057	NN	_	4	appos
8	,	,	,	_	4	punct
9	was	be	VBD	_	11	auxpass
10	approximately	approximately	RB	_	11	advmod
11	doubled	double	VBN	_	0	ROOT
12	in	in	IN	_	14	case
13	the	the	DT	_	14	det
14	presence	presence	NN	_	11	nmod
15	of	of	IN	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	while	while	IN	_	22	mark
18	the	the	DT	_	19	det
19	fraction	fraction	NN	_	22	nsubj
20	of	of	IN	_	21	case
21	drug	drug	NN	_	19	nmod
22	excreted	excrete	VBD	_	11	advcl
23	unchanged	unchanged	JJ	_	22	xcomp
24	in	in	IN	_	26	case
25	the	the	DT	_	26	det
26	urine	urine	NN	_	22	nmod
27	remained	remain	VBD	_	22	dep
28	the	the	DT	_	29	det
29	same	same	JJ	_	27	xcomp
30	.	.	.	_	11	punct

1	Renal	renal	JJ	_	2	amod
2	clearance	clearance	NN	_	11	nsubj
3	of	of	IN	_	5	case
4	ucb	ucb	NN	_	5	compound
5	L057	l057	NN	_	2	nmod
6	in	in	IN	_	8	case
7	the	the	DT	_	8	det
8	presence	presence	NN	_	2	nmod
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	decreased	decrease	VBD	_	0	ROOT
12	60	60	CD	_	13	nummod
13	%	%	NN	_	11	dobj
14	,	,	,	_	11	punct
15	probably	probably	RB	_	16	advmod
16	related	relate	VBN	_	11	advcl
17	to	to	TO	_	19	case
18	competitive	competitive	JJ	_	19	amod
19	inhibition	inhibition	NN	_	16	nmod
20	of	of	IN	_	22	case
21	tubular	tubular	JJ	_	22	amod
22	secretion	secretion	NN	_	19	nmod
23	of	of	IN	_	25	case
24	ucb	ucb	NN	_	25	compound
25	L057	l057	NN	_	22	nmod
26	.	.	.	_	11	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	9	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	on	on	IN	_	6	case
6	drug2	drug2	NN	_	2	nmod
7	was	be	VBD	_	9	auxpass
8	not	not	RB	_	9	neg
9	studied	study	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	drug1	drug1	NN	_	6	nsubj
2	or	or	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	excess	excess	NN	_	1	dep
5	may	may	MD	_	6	aux
6	decrease	decrease	VB	_	0	ROOT
7	the	the	DT	_	8	det
8	effect	effect	NN	_	6	dobj
9	of	of	IN	_	10	case
10	drug3	drug3	NN	_	8	nmod
11	,	,	,	_	6	punct
12	and	and	CC	_	6	cc
13	an	a	DT	_	15	det
14	drug4	drug4	NN	_	15	compound
15	deficiency	deficiency	NN	_	17	nsubj
16	can	can	MD	_	17	aux
17	increase	increase	VB	_	6	conj
18	the	the	DT	_	19	det
19	effect	effect	NN	_	17	dobj
20	of	of	IN	_	21	case
21	drug5	drug5	NN	_	19	nmod
22	.	.	.	_	6	punct

1	Serum	serum	NN	_	2	compound
2	concentration	concentration	NN	_	8	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	may	may	MD	_	8	aux
8	increase	increase	VB	_	0	ROOT
9	when	when	WRB	_	11	advmod
10	patients	patient	NNS	_	11	nsubj
11	take	take	VBP	_	8	advcl
12	drug3	drug3	NN	_	11	dobj
13	.	.	.	_	8	punct

1	A	a	DT	_	2	det
2	decrease	decrease	NN	_	8	nsubj
3	of	of	IN	_	5	case
4	the	the	DT	_	5	det
5	dosage	dosage	NN	_	2	nmod
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	cop
8	necessary	necessary	JJ	_	0	ROOT
9	when	when	WRB	_	11	advmod
10	patient	patient	NN	_	11	nsubj
11	becomes	become	VBZ	_	8	advcl
12	euthyroid	euthyroid	JJ	_	11	xcomp
13	.	.	.	_	8	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	decrease	decrease	VB	_	14	csubj
4	thyroidal	thyroidal	JJ	_	5	amod
5	uptake	uptake	NN	_	3	dobj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	,	,	,	_	7	punct
9	a	a	DT	_	10	det
10	rebound	rebound	NN	_	7	appos
11	in	in	IN	_	12	case
12	uptake	uptake	NN	_	10	nmod
13	may	may	MD	_	14	aux
14	occur	occur	VB	_	0	ROOT
15	up	up	RP	_	17	dep
16	to	to	TO	_	15	mwe
17	5	5	CD	_	18	nummod
18	days	day	NNS	_	14	nmod
19	after	after	IN	_	18	case
20	sudden	sudden	JJ	_	21	amod
21	withdrawal	withdrawal	NN	_	18	dep
22	of	of	IN	_	23	case
23	drug3	drug3	NN	_	21	nmod
24	.	.	.	_	14	punct

1	Patients	patient	NNS	_	2	compound
2	response	response	NN	_	8	nsubjpass
3	to	to	TO	_	5	case
4	oral	oral	JJ	_	5	amod
5	drug1	drug1	NN	_	2	nmod
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	affected	affect	VBN	_	0	ROOT
9	by	by	IN	_	11	case
10	his/her	his/her	NN	_	11	compound
11	thyroid	thyroid	NN	_	8	nmod
12	and	and	CC	_	11	cc
13	metabolic	metabolic	JJ	_	14	amod
14	status	status	NN	_	11	conj
15	.	.	.	_	8	punct

1	An	a	DT	_	2	det
2	evaluation	evaluation	NN	_	13	nsubjpass
3	of	of	IN	_	5	case
4	prothrombin	prothrombin	NN	_	5	compound
5	time	time	NN	_	2	nmod
6	and	and	CC	_	2	cc
7	an	a	DT	_	8	det
8	adjustment	adjustment	NN	_	2	conj
9	of	of	IN	_	11	case
10	drug1	drug1	NN	_	11	compound
11	dosage	dosage	NN	_	8	nmod
12	are	be	VBP	_	13	auxpass
13	recommended	recommend	VBN	_	0	ROOT

1	No	no	DT	_	2	neg
2	information	information	NN	_	0	ROOT
3	available	available	JJ	_	2	amod
4	.	.	.	_	2	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	observed	observe	VBN	_	0	ROOT
5	when	when	WRB	_	8	advmod
6	drug1	drug1	NN	_	8	nsubjpass
7	is	be	VBZ	_	8	auxpass
8	coadministered	coadminister	VBN	_	4	advcl
9	with	with	IN	_	11	case
10	other	other	JJ	_	11	amod
11	drug2	drug2	NN	_	8	nmod
12	,	,	,	_	11	punct
13	drug3	drug3	NN	_	11	conj
14	,	,	,	_	11	punct
15	drug4	drug4	NN	_	11	conj
16	,	,	,	_	11	punct
17	or	or	CC	_	11	cc
18	drug5	drug5	NN	_	11	conj
19	,	,	,	_	4	punct
20	as	as	IN	_	24	mark
21	these	these	DT	_	22	det
22	agents	agent	NNS	_	24	nsubj
23	may	may	MD	_	24	aux
24	increase	increase	VB	_	4	advcl
25	respiratory	respiratory	JJ	_	28	amod
26	and	and	CC	_	25	cc
27	circulatory	circulatory	JJ	_	25	conj
28	depression	depression	NN	_	24	dobj
29	.	.	.	_	4	punct

1	CNS-Active	cns-active	JJ	_	2	amod
2	Drugs	drug	NNS	_	3	nsubj
3	drug1	drug1	VBP	_	11	csubjpass
4	An	a	DT	_	6	det
5	additive	additive	JJ	_	6	amod
6	effect	effect	NN	_	3	dobj
7	on	on	IN	_	9	case
8	psychomotor	psychomotor	NN	_	9	compound
9	performance	performance	NN	_	6	nmod
10	was	be	VBD	_	11	auxpass
11	seen	see	VBN	_	0	ROOT
12	with	with	IN	_	13	case
13	coadministration	coadministration	NN	_	11	nmod
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	drug3	drug3	NN	_	19	compound
18	0.70	0.70	CD	_	19	nummod
19	g/kg	g/kg	NN	_	15	conj
20	for	for	IN	_	24	case
21	up	up	RB	_	23	dep
22	to	to	TO	_	21	mwe
23	4	4	CD	_	24	nummod
24	hours	hour	NNS	_	11	nmod
25	after	after	IN	_	27	case
26	drug4	drug4	NN	_	27	compound
27	administration	administration	NN	_	24	nmod
28	.	.	.	_	11	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Coadministration	coadministration	NN	_	19	nsubj
4	of	of	IN	_	6	case
5	single	single	JJ	_	6	amod
6	doses	dose	NNS	_	3	nmod
7	of	of	IN	_	10	case
8	drug2	drug2	NN	_	10	compound
9	3	3	CD	_	10	nummod
10	mg	mg	NN	_	6	nmod
11	and	and	CC	_	10	cc
12	drug3	drug3	NN	_	14	compound
13	20	20	CD	_	14	nummod
14	mg	mg	NN	_	10	conj
15	daily	daily	RB	_	3	advmod
16	for	for	IN	_	18	case
17	7	7	CD	_	18	nummod
18	days	day	NNS	_	3	nmod
19	produced	produce	VBD	_	1	appos
20	no	no	DT	_	24	neg
21	pharmacokinetic	pharmacokinetic	JJ	_	24	amod
22	or	or	CC	_	21	cc
23	pharmacodynamic	pharmacodynamic	JJ	_	21	conj
24	interaction	interaction	NN	_	19	dobj
25	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Coadministration	coadministration	NN	_	17	nsubj
4	of	of	IN	_	6	case
5	single	single	JJ	_	6	amod
6	doses	dose	NNS	_	3	nmod
7	of	of	IN	_	10	case
8	drug2	drug2	NN	_	10	compound
9	3	3	CD	_	10	nummod
10	mg	mg	NN	_	6	nmod
11	and	and	CC	_	10	cc
12	drug3	drug3	NN	_	14	compound
13	2	2	CD	_	14	nummod
14	mg	mg	NN	_	10	conj
15	did	do	VBD	_	17	aux
16	not	not	RB	_	17	neg
17	have	have	VB	_	1	dep
18	clinically	clinically	RB	_	19	advmod
19	relevant	relevant	JJ	_	20	amod
20	effects	effect	NNS	_	17	dobj
21	on	on	IN	_	23	case
22	the	the	DT	_	23	det
23	pharmacodynamics	pharmacodynamic	NNS	_	17	nmod
24	or	or	CC	_	23	cc
25	pharmacokinetics	pharmacokinetic	NNS	_	23	conj
26	of	of	IN	_	28	case
27	either	either	CC	_	28	det
28	drug	drug	NN	_	23	nmod
29	.	.	.	_	17	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Coadministration	coadministration	NN	_	12	nsubj
4	of	of	IN	_	7	case
5	drug2	drug2	NN	_	7	compound
6	3	3	CD	_	7	nummod
7	mg	mg	NN	_	3	nmod
8	and	and	CC	_	7	cc
9	drug3	drug3	NN	_	11	compound
10	10	10	CD	_	11	nummod
11	mg	mg	NN	_	7	conj
12	produced	produce	VBD	_	1	appos
13	a	a	DT	_	14	det
14	decrease	decrease	NN	_	12	dobj
15	in	in	IN	_	17	case
16	DSST	dsst	NN	_	17	compound
17	scores	score	NNS	_	14	nmod
18	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	interaction	interaction	NN	_	4	nsubj
3	was	be	VBD	_	4	cop
4	pharmacodynamic	pharmacodynamic	JJ	_	0	ROOT
5	;	;	:	_	4	punct

1	there	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	no	no	DT	_	4	neg
4	alteration	alteration	NN	_	2	nsubj
5	in	in	IN	_	7	case
6	the	the	DT	_	7	det
7	pharmacokinetics	pharmacokinetic	NNS	_	2	nmod
8	of	of	IN	_	10	case
9	either	either	CC	_	10	det
10	drug	drug	NN	_	7	nmod
11	.	.	.	_	2	punct

1	Drugs	drug	NNS	_	13	nsubj
2	That	that	WDT	_	3	nsubj
3	Inhibit	inhibit	VBP	_	1	acl:relcl
4	CYP3A4	cyp3a4	NN	_	8	compound
5	-LRB-	-lrb-	-LRB-	_	6	punct
6	drug1	drug1	NN	_	4	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	CYP3A4	cyp3a4	NN	_	3	dobj
9	is	be	VBZ	_	13	cop
10	a	a	DT	_	13	det
11	major	major	JJ	_	13	amod
12	metabolic	metabolic	JJ	_	13	amod
13	pathway	pathway	NN	_	0	ROOT
14	for	for	IN	_	15	case
15	elimination	elimination	NN	_	13	nmod
16	of	of	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	.	.	.	_	13	punct

1	The	the	DT	_	2	det
2	AUC	auc	NN	_	6	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	was	be	VBD	_	6	auxpass
6	increased	increase	VBN	_	0	ROOT
7	2.2-fold	2.2-fold	RB	_	6	advmod
8	by	by	IN	_	9	case
9	coadministration	coadministration	NN	_	6	nmod
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	,	,	,	_	11	punct
13	a	a	DT	_	15	det
14	potent	potent	JJ	_	15	amod
15	inhibitor	inhibitor	NN	_	11	appos
16	of	of	IN	_	17	case
17	CYP3A4	cyp3a4	NN	_	15	nmod
18	,	,	,	_	11	punct
19	400	400	CD	_	20	nummod
20	mg	mg	NN	_	11	appos
21	daily	daily	RB	_	20	advmod
22	for	for	IN	_	24	case
23	5	5	CD	_	24	nummod
24	days	day	NNS	_	20	nmod
25	.	.	.	_	6	punct

1	Cmax	cmax	NN	_	5	nsubjpass
2	and	and	CC	_	1	cc
3	t1/2	t1/2	NN	_	1	conj
4	were	be	VBD	_	5	auxpass
5	increased	increase	VBN	_	0	ROOT
6	1.4-fold	1.4-fold	RB	_	5	advmod
7	and	and	CC	_	6	cc
8	1.3-fold	1.3-fold	RB	_	6	conj
9	,	,	,	_	5	punct
10	respectively	respectively	RB	_	5	advmod
11	.	.	.	_	5	punct

1	Other	other	JJ	_	3	amod
2	strong	strong	JJ	_	3	amod
3	inhibitors	inhibitor	NNS	_	23	nsubjpass
4	of	of	IN	_	5	case
5	CYP3A4	cyp3a4	NN	_	3	nmod
6	-LRB-	-lrb-	-LRB-	_	9	punct
7	e.g.	e.g.	FW	_	9	dep
8	,	,	,	_	9	punct
9	drug1	drug1	NN	_	5	dep
10	,	,	,	_	9	punct
11	drug2	drug2	NN	_	9	conj
12	,	,	,	_	9	punct
13	drug3	drug3	NN	_	9	conj
14	,	,	,	_	9	punct
15	drug4	drug4	NN	_	9	conj
16	,	,	,	_	9	punct
17	drug5	drug5	NN	_	9	conj
18	,	,	,	_	9	punct
19	drug6	drug6	NN	_	9	appos
20	-RRB-	-rrb-	-RRB-	_	9	punct
21	would	would	MD	_	23	aux
22	be	be	VB	_	23	auxpass
23	expected	expect	VBN	_	0	ROOT
24	to	to	TO	_	25	mark
25	behave	behave	VB	_	23	xcomp
26	similarly	similarly	RB	_	25	advmod
27	.	.	.	_	23	punct

1	Drugs	drug	NNS	_	12	nsubjpass
2	That	that	WDT	_	3	nsubj
3	Induce	induce	VBP	_	1	acl:relcl
4	CYP3A4	cyp3a4	NN	_	10	compound
5	-LRB-	-lrb-	-LRB-	_	6	punct
6	drug1	drug1	NN	_	4	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	Racemic	racemic	JJ	_	10	amod
9	drug2	drug2	NN	_	10	compound
10	exposure	exposure	NN	_	3	dobj
11	was	be	VBD	_	12	auxpass
12	decreased	decrease	VBN	_	0	ROOT
13	80	80	CD	_	14	nummod
14	%	%	NN	_	12	dobj
15	by	by	IN	_	18	case
16	concomitant	concomitant	JJ	_	18	amod
17	useof	useof	JJ	_	18	amod
18	drug3	drug3	NN	_	12	nmod
19	,	,	,	_	18	punct
20	a	a	DT	_	22	det
21	potent	potent	JJ	_	22	amod
22	inducer	inducer	NN	_	18	appos
23	of	of	IN	_	24	case
24	CYP3A4	cyp3a4	NN	_	22	nmod
25	.	.	.	_	12	punct

1	A	a	DT	_	3	det
2	similar	similar	JJ	_	3	amod
3	effect	effect	NN	_	6	nsubjpass
4	would	would	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	expected	expect	VBN	_	0	ROOT
7	with	with	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	.	.	.	_	6	punct

1	Drugs	drug	NNS	_	3	nsubj
2	Highly	highly	RB	_	3	advmod
3	Bound	bind	VBN	_	11	csubjpass
4	To	to	TO	_	7	case
5	Plasma	plasma	NN	_	7	compound
6	Protein	protein	NN	_	7	compound
7	drug1	drug1	NN	_	3	nmod
8	is	be	VBZ	_	11	auxpass
9	not	not	RB	_	11	neg
10	highly	highly	RB	_	11	advmod
11	bound	bind	VBN	_	0	ROOT
12	to	to	TO	_	14	case
13	plasma	plasma	NN	_	14	compound
14	proteins	protein	NNS	_	11	nmod
15	-LRB-	-lrb-	-LRB-	_	18	punct
16	52-59	52-59	CD	_	17	nummod
17	%	%	NN	_	18	nsubj
18	bound	bind	VBN	_	14	dep
19	-RRB-	-rrb-	-RRB-	_	18	punct
20	;	;	:	_	11	punct

1	therefore	therefore	RB	_	9	advmod
2	,	,	,	_	9	punct
3	the	the	DT	_	4	det
4	disposition	disposition	NN	_	9	nsubjpass
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	is	be	VBZ	_	9	auxpass
8	not	not	RB	_	9	neg
9	expected	expect	VBN	_	0	ROOT
10	to	to	TO	_	12	mark
11	be	be	VB	_	12	cop
12	sensitive	sensitive	JJ	_	9	xcomp
13	to	to	TO	_	14	case
14	alterations	alteration	NNS	_	12	nmod
15	in	in	IN	_	17	case
16	protein	protein	NN	_	17	compound
17	binding	binding	NN	_	14	nmod
18	.	.	.	_	9	punct

1	Administration	administration	NN	_	19	nsubjpass
2	of	of	IN	_	5	case
3	drug1	drug1	NN	_	5	compound
4	3	3	CD	_	5	nummod
5	mg	mg	NN	_	1	nmod
6	to	to	TO	_	8	case
7	a	a	DT	_	8	det
8	patient	patient	NN	_	1	nmod
9	taking	take	VBG	_	8	acl
10	another	another	DT	_	11	det
11	drug	drug	NN	_	9	dobj
12	that	that	WDT	_	15	nsubj
13	is	be	VBZ	_	15	cop
14	highly	highly	RB	_	15	advmod
15	protein-bound	protein-bound	JJ	_	11	acl:relcl
16	would	would	MD	_	19	aux
17	not	not	RB	_	19	neg
18	be	be	VB	_	19	auxpass
19	expected	expect	VBN	_	0	ROOT
20	to	to	TO	_	21	mark
21	cause	cause	VB	_	19	xcomp
22	an	a	DT	_	23	det
23	alteration	alteration	NN	_	21	dobj
24	in	in	IN	_	27	case
25	the	the	DT	_	27	det
26	free	free	JJ	_	27	amod
27	concentration	concentration	NN	_	23	nmod
28	of	of	IN	_	30	case
29	either	either	CC	_	30	det
30	drug	drug	NN	_	27	nmod
31	.	.	.	_	19	punct

1	Drugs	drug	NNS	_	0	ROOT
2	With	with	IN	_	10	case
3	A	a	DT	_	10	det
4	Narrow	narrow	JJ	_	10	amod
5	Therapeutic	therapeutic	JJ	_	10	amod
6	Index	index	NN	_	10	compound
7	drug1	drug1	NN	_	10	compound
8	A	a	NN	_	10	compound
9	single	single	JJ	_	10	amod
10	dose	dose	NN	_	17	nmod
11	of	of	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	3	3	CD	_	12	nummod
14	mg	mg	NN	_	17	nsubj
15	did	do	VBD	_	17	aux
16	not	not	RB	_	17	neg
17	affect	affect	VB	_	1	acl:relcl
18	the	the	DT	_	19	det
19	pharmacokinetics	pharmacokinetic	NNS	_	17	dobj
20	of	of	IN	_	21	case
21	drug3	drug3	NN	_	19	nmod
22	measured	measure	VBN	_	19	acl
23	at	at	IN	_	25	case
24	steady	steady	JJ	_	25	amod
25	state	state	NN	_	22	nmod
26	following	follow	VBG	_	27	case
27	dosing	dosing	NN	_	17	nmod
28	of	of	IN	_	30	case
29	0.5	0.5	CD	_	30	nummod
30	mg	mg	NN	_	27	nmod
31	twice	twice	RB	_	32	advmod
32	daily	daily	RB	_	27	advmod
33	for	for	IN	_	35	case
34	one	one	CD	_	35	nummod
35	day	day	NN	_	27	nmod
36	and	and	CC	_	27	cc
37	0.25	0.25	CD	_	38	nummod
38	mg	mg	NN	_	27	conj
39	daily	daily	RB	_	38	advmod
40	for	for	IN	_	44	case
41	the	the	DT	_	44	det
42	next	next	JJ	_	44	amod
43	6	6	CD	_	44	nummod
44	days	day	NNS	_	38	nmod
45	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	compound
4	3	3	CD	_	5	nummod
5	mg	mg	NN	_	13	nsubj
6	administered	administer	VBN	_	5	acl
7	daily	daily	RB	_	6	advmod
8	for	for	IN	_	10	case
9	5	5	CD	_	10	nummod
10	days	day	NNS	_	6	nmod
11	did	do	VBD	_	13	aux
12	not	not	RB	_	13	neg
13	affect	affect	VB	_	1	dep
14	the	the	DT	_	15	det
15	pharmacokinetics	pharmacokinetic	NNS	_	13	dobj
16	of	of	IN	_	17	case
17	drug3	drug3	NN	_	15	nmod
18	-	-	:	_	17	punct
19	or	or	CC	_	17	cc
20	drug4	drug4	NN	_	17	conj
21	,	,	,	_	13	punct
22	nor	nor	CC	_	13	cc
23	were	be	VBD	_	13	conj
24	there	there	EX	_	23	expl
25	any	any	DT	_	26	det
26	changes	change	NNS	_	23	nsubj
27	in	in	IN	_	30	case
28	the	the	DT	_	30	det
29	pharmacodynamic	pharmacodynamic	JJ	_	30	amod
30	profile	profile	NN	_	26	nmod
31	-LRB-	-lrb-	-LRB-	_	33	punct
32	prothrombin	prothrombin	NN	_	33	compound
33	time	time	NN	_	26	appos
34	-RRB-	-rrb-	-RRB-	_	33	punct
35	following	follow	VBG	_	39	case
36	a	a	DT	_	39	det
37	single	single	JJ	_	39	amod
38	25	25	CD	_	39	nummod
39	mg	mg	NN	_	26	nmod
40	oral	oral	JJ	_	41	amod
41	dose	dose	NN	_	39	dep
42	of	of	IN	_	43	case
43	drug5	drug5	NN	_	41	nmod

1	.	.	.	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	Elevated	elevated	JJ	_	3	amod
2	plasma	plasma	NN	_	3	compound
3	levels	level	NNS	_	8	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	have	have	VBP	_	8	aux
7	been	be	VBN	_	8	auxpass
8	reported	report	VBN	_	0	ROOT
9	with	with	IN	_	12	case
10	concomitant	concomitant	JJ	_	12	amod
11	drug2	drug2	NN	_	12	compound
12	use	use	NN	_	8	nmod
13	.	.	.	_	8	punct

1	There	there	EX	_	4	expl
2	have	have	VBP	_	4	aux
3	been	be	VBN	_	4	cop
4	reports	report	NNS	_	0	ROOT
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	-	-	:	_	6	punct
8	related	related	JJ	_	10	amod
9	side	side	JJ	_	10	amod
10	effects	effect	NNS	_	6	dep
11	in	in	IN	_	12	case
12	patients	patient	NNS	_	10	nmod
13	on	on	IN	_	15	case
14	concomitant	concomitant	JJ	_	15	amod
15	therapy	therapy	NN	_	12	nmod
16	with	with	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	and	and	CC	_	17	cc
19	drug3	drug3	NN	_	17	conj
20	.	.	.	_	4	punct

1	Therefore	therefore	RB	_	10	advmod
2	,	,	,	_	10	punct
3	monitoring	monitoring	NN	_	10	nsubjpass
4	of	of	IN	_	7	case
5	drug1	drug1	NN	_	7	compound
6	plasma	plasma	NN	_	7	compound
7	levels	level	NNS	_	3	nmod
8	should	should	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	considered	consider	VBN	_	0	ROOT
11	and	and	CC	_	10	cc
12	dosage	dosage	NN	_	10	conj
13	of	of	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	adjusted	adjust	VBN	_	12	acl
16	as	as	IN	_	17	mark
17	required	require	VBN	_	15	advcl
18	.	.	.	_	10	punct

1	Elevated	elevated	JJ	_	3	amod
2	serum	serum	NN	_	3	compound
3	levels	level	NNS	_	8	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	have	have	VBP	_	8	aux
7	been	be	VBN	_	8	auxpass
8	reported	report	VBN	_	0	ROOT
9	with	with	IN	_	11	case
10	concomitant	concomitant	JJ	_	11	amod
11	use	use	NN	_	8	nmod
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	with	with	IN	_	15	case
15	drug3	drug3	NN	_	11	nmod
16	.	.	.	_	8	punct

1	Therefore	therefore	RB	_	8	advmod
2	,	,	,	_	8	punct
3	drug1	drug1	NN	_	5	compound
4	serum	serum	NN	_	5	compound
5	levels	level	NNS	_	8	nsubjpass
6	should	should	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	monitored	monitor	VBN	_	0	ROOT
9	and	and	CC	_	8	cc
10	appropriate	appropriate	JJ	_	8	conj
11	drug2	drug2	NN	_	13	compound
12	dosage	dosage	NN	_	13	compound
13	adjustments	adjustment	NNS	_	8	dobj
14	made	make	VBN	_	13	acl
15	when	when	WRB	_	19	advmod
16	these	these	DT	_	17	det
17	drugs	drug	NNS	_	19	nsubjpass
18	are	be	VBP	_	19	auxpass
19	used	use	VBN	_	14	advcl
20	concomitantly	concomitantly	RB	_	19	advmod
21	.	.	.	_	8	punct

1	drug1	drug1	NN	_	7	nsubj
2	,	,	,	_	1	punct
3	including	include	VBG	_	4	case
4	drug2	drug2	NN	_	1	nmod
5	,	,	,	_	1	punct
6	may	may	MD	_	7	aux
7	enhance	enhance	VB	_	0	ROOT
8	the	the	DT	_	9	det
9	effects	effect	NNS	_	7	dobj
10	of	of	IN	_	12	case
11	oral	oral	JJ	_	12	amod
12	drug3	drug3	NN	_	9	nmod
13	,	,	,	_	12	punct
14	including	include	VBG	_	15	case
15	drug4	drug4	NN	_	12	nmod
16	or	or	CC	_	15	cc
17	its	its	PRP$	_	18	nmod:poss
18	derivatives	derivative	NNS	_	15	conj
19	or	or	CC	_	15	cc
20	similar	similar	JJ	_	21	amod
21	agents	agent	NNS	_	15	conj
22	.	.	.	_	7	punct

1	When	when	WRB	_	5	advmod
2	these	these	DT	_	3	det
3	products	product	NNS	_	5	nsubjpass
4	are	be	VBP	_	5	auxpass
5	administered	administer	VBN	_	18	advcl
6	concomitantly	concomitantly	RB	_	5	advmod
7	,	,	,	_	18	punct
8	prothrombin	prothrombin	NN	_	9	compound
9	time	time	NN	_	18	nsubjpass
10	or	or	CC	_	9	cc
11	other	other	JJ	_	14	amod
12	suitable	suitable	JJ	_	14	amod
13	coagulation	coagulation	NN	_	14	compound
14	tests	test	NNS	_	9	conj
15	should	should	MD	_	18	aux
16	be	be	VB	_	18	auxpass
17	closely	closely	RB	_	18	advmod
18	monitored	monitor	VBN	_	0	ROOT
19	.	.	.	_	18	punct

1	The	the	DT	_	3	det
2	concomitant	concomitant	JJ	_	3	amod
3	administration	administration	NN	_	14	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	including	include	VBG	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	with	with	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	-LRB-	-lrb-	-LRB-	_	12	punct
11	a	a	DT	_	12	det
12	drug4	drug4	NN	_	9	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	has	have	VBZ	_	0	ROOT
15	,	,	,	_	14	punct
16	on	on	IN	_	18	case
17	rare	rare	JJ	_	18	amod
18	occasions	occasion	NNS	_	14	nmod
19	,	,	,	_	14	punct
20	resulted	result	VBD	_	14	dep
21	in	in	IN	_	23	case
22	severe	severe	JJ	_	23	amod
23	hypoglycemia	hypoglycemia	NN	_	20	nmod
24	.	.	.	_	14	punct

1	Therefore	therefore	RB	_	8	advmod
2	,	,	,	_	8	punct
3	monitoring	monitoring	NN	_	8	nsubjpass
4	of	of	IN	_	6	case
5	blood	blood	NN	_	6	compound
6	glucose	glucose	NN	_	3	nmod
7	is	be	VBZ	_	8	auxpass
8	recommended	recommend	VBN	_	0	ROOT
9	when	when	WRB	_	13	advmod
10	these	these	DT	_	11	det
11	agents	agent	NNS	_	13	nsubj
12	are	be	VBP	_	13	cop
13	co-administered	co-administered	JJ	_	8	advcl
14	.	.	.	_	8	punct

1	Diminished	diminish	VBN	_	3	amod
2	urinary	urinary	JJ	_	3	amod
3	excretion	excretion	NN	_	8	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	has	have	VBZ	_	8	aux
7	been	be	VBN	_	8	auxpass
8	reported	report	VBN	_	0	ROOT
9	during	during	IN	_	12	case
10	the	the	DT	_	12	det
11	concomitant	concomitant	JJ	_	12	amod
12	administration	administration	NN	_	8	nmod
13	of	of	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	and	and	CC	_	14	cc
16	drug3	drug3	NN	_	14	conj
17	.	.	.	_	8	punct

1	The	the	DT	_	3	det
2	concomitant	concomitant	JJ	_	3	amod
3	use	use	NN	_	8	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	is	be	VBZ	_	8	auxpass
7	not	not	RB	_	8	neg
8	recommended	recommend	VBN	_	0	ROOT
9	since	since	IN	_	12	mark
10	drug2	drug2	NN	_	12	nsubj
11	may	may	MD	_	12	aux
12	antagonize	antagonize	VB	_	8	advcl
13	the	the	DT	_	15	det
14	antibacterial	antibacterial	JJ	_	15	amod
15	effect	effect	NN	_	12	dobj
16	of	of	IN	_	17	case
17	drug3	drug3	NN	_	15	nmod
18	in	in	IN	_	21	case
19	the	the	DT	_	21	det
20	urinary	urinary	JJ	_	21	amod
21	tract	tract	NN	_	15	nmod
22	.	.	.	_	8	punct

1	drug1	drug1	NN	_	17	nsubjpass
2	,	,	,	_	1	punct
3	or	or	CC	_	1	cc
4	other	other	JJ	_	5	amod
5	products	product	NNS	_	1	conj
6	containing	contain	VBG	_	5	acl
7	drug2	drug2	NN	_	6	dobj
8	or	or	CC	_	7	cc
9	drug3	drug3	NN	_	7	conj
10	,	,	,	_	7	punct
11	drug4	drug4	NN	_	7	conj
12	or	or	CC	_	7	cc
13	drug5	drug5	NN	_	7	conj
14	should	should	MD	_	17	aux
15	not	not	RB	_	17	neg
16	be	be	VB	_	17	auxpass
17	administered	administer	VBN	_	0	ROOT
18	concomitantly	concomitantly	RB	_	17	advmod
19	with	with	IN	_	17	dep
20	,	,	,	_	19	punct
21	or	or	CC	_	20	root
22	within	within	IN	_	24	case
23	2	2	CD	_	24	nummod
24	hours	hour	NNS	_	21	nmod
25	of	of	IN	_	24	acl
26	,	,	,	_	24	punct
27	the	the	DT	_	28	det
28	administration	administration	NN	_	26	root
29	of	of	IN	_	30	case
30	drug6	drug6	NN	_	28	nmod
31	,	,	,	_	28	punct
32	because	because	IN	_	35	mark
33	they	they	PRP	_	35	nsubj
34	may	may	MD	_	35	aux
35	interfere	interfere	VB	_	31	root
36	with	with	IN	_	37	case
37	absorption	absorption	NN	_	35	nmod
38	resulting	result	VBG	_	37	acl
39	in	in	IN	_	41	case
40	lower	lower	JJR	_	41	amod
41	serum	serum	NN	_	38	nmod
42	and	and	CC	_	41	cc
43	urine	urine	NN	_	44	compound
44	levels	level	NNS	_	41	conj
45	of	of	IN	_	46	case
46	drug7	drug7	NN	_	44	nmod
47	.	.	.	_	35	punct

1	drug1	drug1	NN	_	5	nsubj
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	drug2	drug2	NN	_	1	appos
4	-RRB-	-rrb-	-RRB-	_	3	punct
5	chewable/buffered	chewable/buffered	VBD	_	0	ROOT
6	tablets	tablet	NNS	_	5	dobj
7	or	or	CC	_	6	cc
8	the	the	DT	_	10	det
9	pediatric	pediatric	JJ	_	10	amod
10	powder	powder	NN	_	6	conj
11	for	for	IN	_	13	case
12	oral	oral	JJ	_	13	amod
13	solution	solution	NN	_	5	nmod
14	should	should	MD	_	17	aux
15	not	not	RB	_	17	neg
16	be	be	VB	_	17	auxpass
17	administered	administer	VBN	_	5	cc
18	concomitantly	concomitantly	RB	_	17	advmod
19	with	with	IN	_	17	dep
20	,	,	,	_	19	punct
21	or	or	CC	_	20	root
22	within	within	IN	_	24	case
23	2	2	CD	_	24	nummod
24	hours	hour	NNS	_	21	nmod
25	of	of	IN	_	24	acl
26	,	,	,	_	24	punct
27	the	the	DT	_	28	det
28	administration	administration	NN	_	26	root
29	of	of	IN	_	30	case
30	drug3	drug3	NN	_	28	nmod
31	,	,	,	_	28	punct
32	because	because	IN	_	36	mark
33	these	these	DT	_	34	det
34	products	product	NNS	_	36	nsubj
35	may	may	MD	_	36	aux
36	interfere	interfere	VB	_	31	root
37	with	with	IN	_	38	case
38	absorption	absorption	NN	_	36	nmod
39	resulting	result	VBG	_	38	acl
40	in	in	IN	_	42	case
41	lower	lower	JJR	_	42	amod
42	serum	serum	NN	_	39	nmod
43	and	and	CC	_	42	cc
44	urine	urine	NN	_	45	compound
45	levels	level	NNS	_	42	conj
46	of	of	IN	_	47	case
47	drug4	drug4	NN	_	45	nmod
48	.	.	.	_	36	punct

1	Some	some	DT	_	2	det
2	drug1	drug1	NN	_	6	nsubjpass
3	have	have	VBP	_	6	aux
4	also	also	RB	_	6	advmod
5	been	be	VBN	_	6	auxpass
6	shown	show	VBN	_	0	ROOT
7	to	to	TO	_	8	mark
8	interfere	interfere	VB	_	6	xcomp
9	with	with	IN	_	11	case
10	the	the	DT	_	11	det
11	metabolism	metabolism	NN	_	8	nmod
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	.	.	.	_	6	punct

1	This	this	DT	_	3	nsubj
2	may	may	MD	_	3	aux
3	lead	lead	VB	_	0	ROOT
4	to	to	TO	_	6	case
5	reduced	reduce	VBN	_	6	amod
6	clearance	clearance	NN	_	3	nmod
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	and	and	CC	_	6	cc
10	a	a	DT	_	11	det
11	prolongation	prolongation	NN	_	6	conj
12	of	of	IN	_	15	case
13	its	its	PRP$	_	15	nmod:poss
14	plasma	plasma	NN	_	15	compound
15	half-life	half-life	NN	_	11	nmod
16	.	.	.	_	3	punct

1	No	no	DT	_	5	neg
2	pharmacokinetic-based	pharmacokinetic-based	JJ	_	5	amod
3	drug-drug	drug-drug	NN	_	5	compound
4	interaction	interaction	NN	_	5	compound
5	studies	study	NNS	_	8	nsubjpass
6	have	have	VBP	_	8	aux
7	been	be	VBN	_	8	auxpass
8	conducted	conduct	VBN	_	0	ROOT
9	with	with	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	.	.	.	_	8	punct

1	However	however	RB	_	42	advmod
2	,	,	,	_	42	punct
3	because	because	IN	_	7	mark
4	drug1	drug1	NN	_	7	nsubj
5	is	be	VBZ	_	7	cop
6	a	a	DT	_	7	det
7	peptide	peptide	NN	_	42	advcl
8	that	that	WDT	_	11	nsubjpass
9	is	be	VBZ	_	11	auxpass
10	primarily	primarily	RB	_	11	advmod
11	degraded	degrade	VBN	_	7	acl:relcl
12	by	by	IN	_	13	case
13	peptidase	peptidase	NN	_	11	nmod
14	and	and	CC	_	13	cc
15	not	not	RB	_	19	neg
16	by	by	IN	_	19	case
17	cytochrome	cytochrome	NN	_	19	compound
18	P-450	p-450	NN	_	19	compound
19	enzymes	enzyme	NNS	_	13	conj
20	,	,	,	_	7	punct
21	and	and	CC	_	7	cc
22	the	the	DT	_	23	det
23	drug	drug	NN	_	29	nsubjpass
24	is	be	VBZ	_	29	auxpass
25	only	only	RB	_	27	advmod
26	about	about	RB	_	27	advmod
27	80	80	CD	_	28	nummod
28	%	%	NN	_	29	nsubjpass
29	bound	bind	VBD	_	7	conj
30	to	to	TO	_	32	case
31	plasma	plasma	NN	_	32	compound
32	proteins	protein	NNS	_	29	nmod
33	at	at	IN	_	35	case
34	4	4	CD	_	35	nummod
35	C	c	NN	_	29	nmod
36	,	,	,	_	42	punct
37	drug	drug	NN	_	38	compound
38	interactions	interaction	NNS	_	42	nsubjpass
39	would	would	MD	_	42	aux
40	not	not	RB	_	42	neg
41	be	be	VB	_	42	auxpass
42	expected	expect	VBN	_	0	ROOT
43	to	to	TO	_	44	mark
44	occur	occur	VB	_	42	xcomp
45	.	.	.	_	42	punct

1	drug1	drug1	NN	_	2	compound
2	Reports	report	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	7	mark
5	drug2	drug2	NN	_	7	nsubj
6	may	may	MD	_	7	aux
7	diminish	diminish	VB	_	3	ccomp
8	the	the	DT	_	10	det
9	antihypertensive	antihypertensive	JJ	_	10	amod
10	effect	effect	NN	_	7	dobj
11	of	of	IN	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	.	.	.	_	3	punct

1	This	this	DT	_	2	det
2	interaction	interaction	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	given	give	VBN	_	0	ROOT
6	consideration	consideration	NN	_	5	dobj
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	5	nmod
9	taking	take	VBG	_	8	acl
10	drug1	drug1	NN	_	9	dobj
11	concomitantly	concomitantly	RB	_	9	advmod
12	with	with	IN	_	13	case
13	drug2	drug2	NN	_	9	nmod
14	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	5	det
4	concomitant	concomitant	JJ	_	5	amod
5	administration	administration	NN	_	8	nsubj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	has	have	VBZ	_	1	dep
9	no	no	DT	_	11	neg
10	apparent	apparent	JJ	_	11	amod
11	effect	effect	NN	_	8	dobj
12	on	on	IN	_	14	case
13	the	the	DT	_	14	det
14	extent	extent	NN	_	8	nmod
15	of	of	IN	_	16	case
16	absorption	absorption	NN	_	14	nmod
17	of	of	IN	_	18	case
18	drug3	drug3	NN	_	16	nmod
19	.	.	.	_	8	punct

1	However	however	RB	_	5	advmod
2	,	,	,	_	5	punct
3	drug1	drug1	NN	_	5	nsubj
4	can	can	MD	_	5	aux
5	decrease	decrease	VB	_	0	ROOT
6	the	the	DT	_	8	det
7	peak	peak	NN	_	8	compound
8	concentration	concentration	NN	_	5	dobj
9	reached	reach	VBN	_	8	acl
10	by	by	IN	_	20	case
11	15	15	CD	_	20	dep
12	%	%	NN	_	11	advmod
13	to	to	TO	_	15	case
14	20	20	CD	_	15	nummod
15	%	%	NN	_	12	nmod
16	but	but	CC	_	11	cc
17	have	have	VBP	_	20	aux
18	no	no	DT	_	20	neg
19	detectable	detectable	JJ	_	20	amod
20	effect	effect	NN	_	9	nmod
21	on	on	IN	_	23	case
22	the	the	DT	_	23	det
23	time-to-peak	time-to-peak	NN	_	20	nmod
24	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	When	when	WRB	_	6	advmod
4	drug2	drug2	NN	_	6	nsubjpass
5	is	be	VBZ	_	6	auxpass
6	administered	administer	VBN	_	14	advcl
7	with	with	IN	_	8	case
8	drug3	drug3	NN	_	6	nmod
9	,	,	,	_	14	punct
10	its	its	PRP$	_	12	nmod:poss
11	protein	protein	NN	_	12	compound
12	binding	binding	NN	_	14	nsubjpass
13	is	be	VBZ	_	14	auxpass
14	reduced	reduce	VBN	_	1	dep
15	,	,	,	_	14	punct
16	although	although	IN	_	24	mark
17	the	the	DT	_	18	det
18	clearance	clearance	NN	_	24	nsubjpass
19	of	of	IN	_	21	case
20	free	free	JJ	_	21	amod
21	drug4	drug4	NN	_	18	nmod
22	is	be	VBZ	_	24	auxpass
23	not	not	RB	_	24	neg
24	altered	alter	VBN	_	14	advcl
25	.	.	.	_	1	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	significance	significance	NN	_	9	nsubjpass
4	of	of	IN	_	6	case
5	this	this	DT	_	6	det
6	interaction	interaction	NN	_	3	nmod
7	is	be	VBZ	_	9	auxpass
8	not	not	RB	_	9	neg
9	known	know	VBN	_	0	ROOT
10	;	;	:	_	9	punct

1	however	however	RB	_	17	advmod
2	,	,	,	_	17	punct
3	as	as	IN	_	6	case
4	with	with	IN	_	6	case
5	other	other	JJ	_	6	amod
6	drug1	drug1	NN	_	17	nmod
7	,	,	,	_	17	punct
8	concomitant	concomitant	JJ	_	9	amod
9	administration	administration	NN	_	17	nsubjpass
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	drug3	drug3	NN	_	11	conj
14	is	be	VBZ	_	17	auxpass
15	not	not	RB	_	17	neg
16	generally	generally	RB	_	17	advmod
17	recommended	recommend	VBN	_	0	ROOT
18	because	because	IN	_	21	case
19	of	of	IN	_	18	mwe
20	the	the	DT	_	21	det
21	potential	potential	NN	_	17	nmod
22	of	of	IN	_	25	case
23	increased	increase	VBN	_	25	amod
24	adverse	adverse	JJ	_	25	amod
25	effects	effect	NNS	_	21	nmod
26	.	.	.	_	17	punct

1	Cyclosporine	cyclosporine	NN	_	19	nsubj
2	,	,	,	_	1	punct
3	Digoxin	Digoxin	NNP	_	1	conj
4	,	,	,	_	1	punct
5	Methotrexate	Methotrexate	NNP	_	6	compound
6	drug1	drug1	NN	_	1	conj
7	,	,	,	_	1	punct
8	like	like	IN	_	10	case
9	other	other	JJ	_	10	amod
10	drug2	drug2	NN	_	1	nmod
11	,	,	,	_	1	punct
12	through	through	IN	_	13	case
13	effects	effect	NNS	_	1	nmod
14	on	on	IN	_	16	case
15	renal	renal	JJ	_	16	amod
16	prostaglandins	prostaglandin	NNS	_	13	nmod
17	,	,	,	_	1	punct
18	may	may	MD	_	19	aux
19	cause	cause	VB	_	0	ROOT
20	changes	change	NNS	_	19	dobj
21	in	in	IN	_	23	case
22	the	the	DT	_	23	det
23	elimination	elimination	NN	_	20	nmod
24	of	of	IN	_	26	case
25	these	these	DT	_	26	det
26	drugs	drug	NNS	_	23	nmod
27	leading	lead	VBG	_	20	acl
28	to	to	TO	_	31	case
29	elevated	elevated	JJ	_	31	amod
30	serum	serum	NN	_	31	compound
31	levels	level	NNS	_	27	nmod
32	of	of	IN	_	33	case
33	drug3	drug3	NN	_	31	nmod
34	,	,	,	_	33	punct
35	drug4	drug4	NN	_	33	conj
36	,	,	,	_	33	punct
37	drug5	drug5	NN	_	33	conj
38	,	,	,	_	33	punct
39	and	and	CC	_	33	cc
40	increased	increase	VBD	_	41	amod
41	toxicity	toxicity	NN	_	33	conj
42	.	.	.	_	19	punct

1	Nephrotoxicity	nephrotoxicity	NN	_	8	nsubjpass
2	associated	associate	VBN	_	1	acl
3	with	with	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	may	may	MD	_	8	aux
6	also	also	RB	_	8	advmod
7	be	be	VB	_	8	auxpass
8	enhanced	enhance	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	Patients	patient	NNS	_	26	nsubjpass
2	receiving	receive	VBG	_	1	acl
3	these	these	DT	_	4	det
4	drugs	drug	NNS	_	2	dobj
5	who	who	WP	_	7	nsubjpass
6	are	be	VBP	_	7	auxpass
7	given	give	VBN	_	4	acl:relcl
8	drug1	drug1	NN	_	7	dobj
9	,	,	,	_	8	punct
10	or	or	CC	_	8	cc
11	any	any	DT	_	13	det
12	other	other	JJ	_	13	amod
13	drug2	drug2	NN	_	8	conj
14	,	,	,	_	8	punct
15	and	and	CC	_	8	cc
16	particularly	particularly	RB	_	18	advmod
17	those	those	DT	_	18	det
18	patients	patient	NNS	_	8	conj
19	with	with	IN	_	22	case
20	altered	altered	JJ	_	22	amod
21	renal	renal	JJ	_	22	amod
22	function	function	NN	_	18	nmod
23	,	,	,	_	26	punct
24	should	should	MD	_	26	aux
25	be	be	VB	_	26	auxpass
26	observed	observe	VBN	_	0	ROOT
27	for	for	IN	_	29	case
28	the	the	DT	_	29	det
29	development	development	NN	_	26	nmod
30	of	of	IN	_	33	case
31	the	the	DT	_	33	det
32	specific	specific	JJ	_	33	amod
33	toxicities	toxicity	NNS	_	29	nmod
34	of	of	IN	_	36	case
35	these	these	DT	_	36	det
36	drugs	drug	NNS	_	33	nmod
37	.	.	.	_	26	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Etodolac	Etodolac	NNP	_	4	nsubj
4	has	have	VBZ	_	1	dep
5	no	no	DT	_	8	neg
6	apparent	apparent	JJ	_	8	amod
7	pharmacokinetic	pharmacokinetic	JJ	_	8	amod
8	interaction	interaction	NN	_	4	dobj
9	when	when	WRB	_	10	advmod
10	administered	administer	VBN	_	4	advcl
11	with	with	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	or	or	CC	_	12	cc
14	drug3	drug3	NN	_	12	conj
15	.	.	.	_	1	punct

1	Nevertheless	nevertheless	RB	_	12	advmod
2	,	,	,	_	12	punct
3	clinical	clinical	JJ	_	4	amod
4	studies	study	NNS	_	12	nsubj
5	,	,	,	_	4	punct
6	as	as	RB	_	4	cc
7	well	well	RB	_	6	mwe
8	as	as	IN	_	6	mwe
9	postmarketing	postmarket	VBG	_	10	amod
10	observations	observation	NNS	_	4	conj
11	have	have	VBP	_	12	aux
12	shown	show	VBN	_	0	ROOT
13	that	that	IN	_	16	mark
14	drug1	drug1	NN	_	16	nsubj
15	can	can	MD	_	16	aux
16	reduce	reduce	VB	_	12	ccomp
17	the	the	DT	_	19	det
18	natriuretic	natriuretic	JJ	_	19	amod
19	effect	effect	NN	_	16	dobj
20	of	of	IN	_	21	case
21	drug2	drug2	NN	_	19	nmod
22	and	and	CC	_	21	cc
23	drug3	drug3	NN	_	21	conj
24	in	in	IN	_	26	case
25	some	some	DT	_	26	det
26	patients	patient	NNS	_	19	nmod
27	.	.	.	_	12	punct

1	This	this	DT	_	2	det
2	response	response	NN	_	5	nsubjpass
3	has	have	VBZ	_	5	aux
4	been	be	VBN	_	5	auxpass
5	attributed	attribute	VBN	_	0	ROOT
6	to	to	TO	_	7	case
7	inhibition	inhibition	NN	_	5	nmod
8	of	of	IN	_	11	case
9	renal	renal	JJ	_	11	amod
10	prostaglandin	prostaglandin	NN	_	11	compound
11	synthesis	synthesis	NN	_	7	nmod
12	.	.	.	_	5	punct

1	During	during	IN	_	3	case
2	concomitant	concomitant	JJ	_	3	amod
3	therapy	therapy	NN	_	11	nmod
4	with	with	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	,	,	,	_	11	punct
7	the	the	DT	_	8	det
8	patient	patient	NN	_	11	nsubjpass
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	observed	observe	VBN	_	0	ROOT
12	closely	closely	RB	_	11	advmod
13	for	for	IN	_	14	case
14	signs	sign	NNS	_	11	nmod
15	of	of	IN	_	17	case
16	renal	renal	JJ	_	17	amod
17	failure	failure	NN	_	14	nmod
18	,	,	,	_	14	punct
19	as	as	RB	_	14	cc
20	well	well	RB	_	19	mwe
21	as	as	IN	_	19	mwe
22	to	to	TO	_	23	mark
23	assure	assure	VB	_	14	conj
24	diuretic	diuretic	JJ	_	25	amod
25	efficacy	efficacy	NN	_	23	dobj
26	.	.	.	_	11	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	nsubj
4	has	have	VBZ	_	1	dep
5	no	no	DT	_	8	neg
6	apparent	apparent	JJ	_	8	amod
7	pharmacokinetic	pharmacokinetic	JJ	_	8	amod
8	interaction	interaction	NN	_	4	dobj
9	when	when	WRB	_	10	advmod
10	administered	administer	VBN	_	4	advcl
11	with	with	IN	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubj
4	have	have	VBP	_	5	aux
5	produced	produce	VBN	_	1	appos
6	an	a	DT	_	7	det
7	elevation	elevation	NN	_	5	dobj
8	of	of	IN	_	11	case
9	plasma	plasma	NN	_	11	compound
10	drug3	drug3	NN	_	11	compound
11	levels	level	NNS	_	7	nmod
12	and	and	CC	_	7	cc
13	a	a	DT	_	14	det
14	reduction	reduction	NN	_	7	conj
15	in	in	IN	_	18	case
16	renal	renal	JJ	_	18	amod
17	drug4	drug4	NN	_	18	compound
18	clearance	clearance	NN	_	14	nmod
19	.	.	.	_	1	punct

1	The	the	DT	_	5	det
2	mean	mean	NN	_	5	compound
3	minimum	minimum	JJ	_	5	amod
4	drug1	drug1	NN	_	5	compound
5	concentration	concentration	NN	_	6	nsubj
6	increased	increase	VBD	_	0	ROOT
7	15	15	CD	_	8	nummod
8	%	%	NN	_	6	dobj
9	and	and	CC	_	6	cc
10	the	the	DT	_	12	det
11	renal	renal	JJ	_	12	amod
12	clearance	clearance	NN	_	14	nsubjpass
13	was	be	VBD	_	14	auxpass
14	decreased	decrease	VBN	_	6	conj
15	by	by	IN	_	18	case
16	approximately	approximately	RB	_	17	advmod
17	20	20	CD	_	18	nummod
18	%	%	NN	_	14	nmod
19	.	.	.	_	6	punct

1	These	these	DT	_	2	det
2	effects	effect	NNS	_	5	nsubjpass
3	have	have	VBP	_	5	aux
4	been	be	VBN	_	5	auxpass
5	attributed	attribute	VBN	_	0	ROOT
6	to	to	TO	_	7	case
7	inhibition	inhibition	NN	_	5	nmod
8	of	of	IN	_	11	case
9	renal	renal	JJ	_	11	amod
10	prostaglandin	prostaglandin	NN	_	11	compound
11	synthesis	synthesis	NN	_	7	nmod
12	by	by	IN	_	14	case
13	the	the	DT	_	14	det
14	drug1	drug1	NN	_	7	nmod
15	.	.	.	_	5	punct

1	Thus	thus	RB	_	14	advmod
2	,	,	,	_	14	punct
3	when	when	WRB	_	8	advmod
4	drug1	drug1	NN	_	8	nsubjpass
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	are	be	VBP	_	8	auxpass
8	administered	administer	VBN	_	14	advcl
9	concurrently	concurrently	RB	_	8	advmod
10	,	,	,	_	14	punct
11	subjects	subject	NNS	_	14	nsubjpass
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	observed	observe	VBN	_	0	ROOT
15	carefully	carefully	RB	_	14	advmod
16	for	for	IN	_	17	case
17	signs	sign	NNS	_	14	nmod
18	of	of	IN	_	20	case
19	drug3	drug3	NN	_	20	compound
20	toxicity	toxicity	NN	_	17	nmod
21	.	.	.	_	14	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	nsubj
4	causes	cause	VBZ	_	1	dep
5	increase	increase	NN	_	4	dobj
6	-LRB-	-lrb-	-LRB-	_	10	punct
7	by	by	IN	_	10	case
8	about	about	IN	_	9	advmod
9	80	80	CD	_	10	nummod
10	%	%	NN	_	4	dep
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	in	in	IN	_	15	case
13	the	the	DT	_	15	det
14	free	free	JJ	_	15	amod
15	fraction	fraction	NN	_	4	nmod
16	of	of	IN	_	17	case
17	drug3	drug3	NN	_	15	nmod
18	.	.	.	_	1	punct

1	Although	although	IN	_	8	mark
2	in	in	FW	_	4	amod
3	vivo	vivo	FW	_	2	dep
4	studies	study	NNS	_	8	nsubjpass
5	have	have	VBP	_	8	aux
6	not	not	RB	_	8	neg
7	been	be	VBN	_	8	auxpass
8	done	do	VBN	_	24	advcl
9	to	to	TO	_	10	mark
10	see	see	VB	_	8	xcomp
11	if	if	IN	_	15	mark
12	drug1	drug1	NN	_	13	compound
13	clearance	clearance	NN	_	15	nsubjpass
14	is	be	VBZ	_	15	auxpass
15	changed	change	VBN	_	10	advcl
16	by	by	IN	_	17	case
17	coadministration	coadministration	NN	_	15	nmod
18	of	of	IN	_	19	case
19	drug2	drug2	NN	_	17	nmod
20	,	,	,	_	24	punct
21	it	it	PRP	_	24	nsubjpass
22	is	be	VBZ	_	24	auxpass
23	not	not	RB	_	24	neg
24	recommended	recommend	VBN	_	0	ROOT
25	that	that	IN	_	28	mark
26	they	they	PRP	_	28	nsubjpass
27	be	be	VB	_	28	auxpass
28	coadministered	coadminister	VBN	_	24	ccomp
29	.	.	.	_	24	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	nsubj
4	has	have	VBZ	_	1	dep
5	no	no	DT	_	8	neg
6	apparent	apparent	JJ	_	8	amod
7	pharmacokinetic	pharmacokinetic	JJ	_	8	amod
8	interaction	interaction	NN	_	4	dobj
9	when	when	WRB	_	10	advmod
10	administered	administer	VBN	_	4	advcl
11	with	with	IN	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	effects	effect	NNS	_	13	nsubj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	drug3	drug3	NN	_	6	conj
9	on	on	IN	_	11	case
10	GI	gi	NN	_	11	compound
11	bleeding	bleeding	NN	_	4	nmod
12	are	be	VBP	_	13	cop
13	synergistic	synergistic	JJ	_	1	dep
14	,	,	,	_	13	punct
15	such	such	JJ	_	22	dep
16	that	that	IN	_	22	mark
17	users	user	NNS	_	22	nsubj
18	of	of	IN	_	20	case
19	both	both	DT	_	20	det
20	drugs	drug	NNS	_	17	nmod
21	together	together	RB	_	22	advmod
22	have	have	VBP	_	13	advcl
23	a	a	DT	_	24	det
24	risk	risk	NN	_	22	dobj
25	of	of	IN	_	27	case
26	serious	serious	JJ	_	27	amod
27	GI	gi	NN	_	24	nmod
28	bleeding	bleed	VBG	_	24	acl
29	higher	higher	JJR	_	28	advmod
30	than	than	IN	_	31	case
31	that	that	DT	_	29	nmod
32	of	of	IN	_	33	case
33	users	user	NNS	_	31	nmod
34	of	of	IN	_	36	case
35	either	either	CC	_	36	det
36	drug	drug	NN	_	33	nmod
37	alone	alone	RB	_	36	advmod
38	.	.	.	_	1	punct

1	Short-term	short-term	JJ	_	3	amod
2	pharmacokinetic	pharmacokinetic	JJ	_	3	amod
3	studies	study	NNS	_	5	nsubj
4	have	have	VBP	_	5	aux
5	demonstrated	demonstrate	VBN	_	0	ROOT
6	that	that	IN	_	19	mark
7	concomitant	concomitant	JJ	_	8	amod
8	administration	administration	NN	_	19	nsubj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	drug2	drug2	NN	_	10	conj
13	-LRB-	-lrb-	-LRB-	_	15	punct
14	drug3	drug3	NN	_	15	compound
15	capsules	capsule	NNS	_	10	dep
16	and	and	CC	_	15	cc
17	tablets	tablet	NNS	_	15	conj
18	-RRB-	-rrb-	-RRB-	_	15	punct
19	results	result	VBZ	_	5	ccomp
20	in	in	IN	_	23	case
21	reduced	reduce	VBN	_	23	amod
22	protein	protein	NN	_	23	compound
23	binding	binding	NN	_	19	nmod
24	of	of	IN	_	25	case
25	drug4	drug4	NN	_	23	nmod
26	,	,	,	_	5	punct
27	but	but	CC	_	5	cc
28	there	there	EX	_	29	expl
29	was	be	VBD	_	5	conj
30	no	no	DT	_	31	neg
31	change	change	NN	_	29	nsubj
32	in	in	IN	_	34	case
33	the	the	DT	_	34	det
34	clearance	clearance	NN	_	29	nmod
35	of	of	IN	_	37	case
36	free	free	JJ	_	37	amod
37	drug5	drug5	NN	_	34	nmod
38	.	.	.	_	5	punct

1	There	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	no	no	DT	_	5	neg
4	significant	significant	JJ	_	5	amod
5	difference	difference	NN	_	2	nsubj
6	in	in	IN	_	9	case
7	the	the	DT	_	9	det
8	pharmacodynamic	pharmacodynamic	JJ	_	9	amod
9	effect	effect	NN	_	2	nmod
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	administered	administer	VBN	_	11	acl
13	alone	alone	RB	_	12	advmod
14	and	and	CC	_	11	cc
15	drug2	drug2	NN	_	11	conj
16	administered	administer	VBN	_	15	acl
17	with	with	IN	_	18	case
18	drug3	drug3	NN	_	16	nmod
19	as	as	IN	_	20	mark
20	measured	measure	VBN	_	16	advcl
21	by	by	IN	_	23	case
22	prothrombin	prothrombin	NN	_	23	compound
23	time	time	NN	_	20	nmod
24	.	.	.	_	2	punct

1	Thus	thus	RB	_	11	advmod
2	,	,	,	_	11	punct
3	concomitant	concomitant	JJ	_	4	amod
4	therapy	therapy	NN	_	11	nsubj
5	with	with	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	drug2	drug2	NN	_	6	conj
9	should	should	MD	_	11	aux
10	not	not	RB	_	11	neg
11	require	require	VB	_	0	ROOT
12	dosage	dosage	NN	_	13	compound
13	adjustment	adjustment	NN	_	11	dobj
14	of	of	IN	_	16	case
15	either	either	CC	_	16	det
16	drug	drug	NN	_	13	nmod
17	.	.	.	_	11	punct

1	However	however	RB	_	6	advmod
2	,	,	,	_	6	punct
3	caution	caution	NN	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	exercised	exercise	VBN	_	0	ROOT
7	because	because	IN	_	14	mark
8	there	there	EX	_	14	expl
9	have	have	VBP	_	14	aux
10	been	be	VBN	_	14	cop
11	a	a	DT	_	14	det
12	few	few	JJ	_	14	amod
13	spontaneous	spontaneous	JJ	_	14	amod
14	reports	report	NNS	_	6	advcl
15	of	of	IN	_	18	case
16	prolonged	prolonged	JJ	_	18	amod
17	prothrombin	prothrombin	NN	_	18	compound
18	times	time	NNS	_	14	nmod
19	,	,	,	_	14	punct
20	with	with	IN	_	23	nmod
21	or	or	CC	_	20	cc
22	without	without	IN	_	20	conj
23	bleeding	bleeding	NN	_	14	nmod
24	,	,	,	_	14	punct
25	in	in	IN	_	26	case
26	drug1	drug1	NN	_	14	nmod
27	-	-	:	_	14	punct
28	treated	treated	JJ	_	29	amod
29	patients	patient	NNS	_	14	dep
30	receiving	receive	VBG	_	29	acl
31	concomitant	concomitant	JJ	_	33	amod
32	drug2	drug2	NN	_	33	compound
33	therapy	therapy	NN	_	30	dobj
34	.	.	.	_	6	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	3	amod
2	Test	test	NN	_	3	compound
3	Interactions	interaction	NNS	_	0	ROOT
4	The	the	DT	_	5	det
5	urine	urine	NN	_	12	nsubj
6	of	of	IN	_	7	case
7	patients	patient	NNS	_	5	nmod
8	who	who	WP	_	9	nsubj
9	take	take	VBP	_	7	acl:relcl
10	drug1	drug1	NN	_	9	dobj
11	can	can	MD	_	12	aux
12	give	give	VB	_	3	acl:relcl
13	a	a	DT	_	15	det
14	false-positive	false-positive	JJ	_	15	amod
15	reaction	reaction	NN	_	12	dobj
16	for	for	IN	_	18	case
17	urinary	urinary	JJ	_	18	amod
18	bilirubin	bilirubin	NN	_	15	nmod
19	-LRB-	-lrb-	-LRB-	_	20	punct
20	urobilin	urobilin	NN	_	18	appos
21	-RRB-	-rrb-	-RRB-	_	20	punct
22	due	due	JJ	_	25	case
23	to	to	TO	_	22	mwe
24	the	the	DT	_	25	det
25	presence	presence	NN	_	12	nmod
26	of	of	IN	_	28	case
27	phenolic	phenolic	JJ	_	28	amod
28	metabolites	metabolite	NNS	_	25	nmod
29	of	of	IN	_	30	case
30	drug2	drug2	NN	_	28	nmod
31	.	.	.	_	3	punct

1	Diagnostic	diagnostic	JJ	_	3	amod
2	dip-stick	dip-stick	NN	_	3	compound
3	methodology	methodology	NN	_	14	nsubj
4	,	,	,	_	3	punct
5	used	use	VBN	_	3	acl
6	to	to	TO	_	7	mark
7	detect	detect	VB	_	5	xcomp
8	ketone	ketone	NN	_	9	compound
9	bodies	body	NNS	_	7	dobj
10	in	in	IN	_	11	case
11	urine	urine	NN	_	7	nmod
12	,	,	,	_	3	punct
13	has	have	VBZ	_	14	aux
14	resulted	result	VBN	_	0	ROOT
15	in	in	IN	_	17	case
16	false-positive	false-positive	JJ	_	17	amod
17	findings	finding	NNS	_	14	nmod
18	in	in	IN	_	20	case
19	some	some	DT	_	20	det
20	patients	patient	NNS	_	17	nmod
21	treated	treat	VBN	_	20	acl
22	with	with	IN	_	23	case
23	drug1	drug1	NN	_	21	nmod
24	.	.	.	_	14	punct

1	Generally	generally	RB	_	8	advmod
2	,	,	,	_	8	punct
3	this	this	DT	_	4	det
4	phenomenon	phenomenon	NN	_	8	nsubjpass
5	has	have	VBZ	_	8	aux
6	not	not	RB	_	8	neg
7	been	be	VBN	_	8	auxpass
8	associated	associate	VBN	_	0	ROOT
9	with	with	IN	_	13	case
10	other	other	JJ	_	13	amod
11	clinically	clinically	RB	_	12	advmod
12	significant	significant	JJ	_	13	amod
13	events	event	NNS	_	8	nmod
14	.	.	.	_	8	punct

1	No	no	DT	_	3	neg
2	dose	dose	NN	_	3	compound
3	relationship	relationship	NN	_	6	nsubjpass
4	has	have	VBZ	_	6	aux
5	been	be	VBN	_	6	auxpass
6	observed	observe	VBN	_	0	ROOT
7	.	.	.	_	6	punct

1	drug1	drug1	NN	_	2	compound
2	treatment	treatment	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	associated	associate	VBN	_	0	ROOT
5	with	with	IN	_	8	case
6	a	a	DT	_	8	det
7	small	small	JJ	_	8	amod
8	decrease	decrease	NN	_	4	nmod
9	in	in	IN	_	13	case
10	serum	serum	NN	_	13	compound
11	uric	uric	JJ	_	13	amod
12	acid	acid	NN	_	13	compound
13	levels	level	NNS	_	8	nmod
14	.	.	.	_	4	punct

1	In	in	IN	_	3	case
2	clinical	clinical	JJ	_	3	amod
3	trials	trial	NNS	_	5	nmod
4	,	,	,	_	5	punct
5	mean	mean	VB	_	0	ROOT
6	decreases	decrease	NNS	_	13	nsubjpass
7	of	of	IN	_	11	case
8	1	1	CD	_	10	compound
9	to	to	TO	_	10	dep
10	2	2	CD	_	11	nummod
11	mg/dL	mg/dl	NN	_	6	nmod
12	were	be	VBD	_	13	auxpass
13	observed	observe	VBN	_	5	ccomp
14	in	in	IN	_	16	case
15	arthritic	arthritic	JJ	_	16	amod
16	patients	patient	NNS	_	13	nmod
17	receiving	receive	VBG	_	16	acl
18	drug1	drug1	NN	_	17	dobj
19	-LRB-	-lrb-	-LRB-	_	21	punct
20	600	600	CD	_	21	nummod
21	mg	mg	NN	_	18	dep
22	to	to	TO	_	21	dep
23	1000	1000	CD	_	24	nummod
24	mg/day	mg/day	NN	_	21	dep
25	-RRB-	-rrb-	-RRB-	_	21	punct
26	after	after	IN	_	28	case
27	4	4	CD	_	28	nummod
28	weeks	week	NNS	_	13	nmod
29	of	of	IN	_	30	case
30	therapy	therapy	NN	_	28	nmod
31	.	.	.	_	5	punct

1	These	these	DT	_	2	det
2	levels	level	NNS	_	4	nsubj
3	then	then	RB	_	4	advmod
4	remained	remain	VBD	_	0	ROOT
5	stable	stable	JJ	_	4	xcomp
6	for	for	IN	_	10	case
7	up	up	RB	_	9	dep
8	to	to	TO	_	7	mwe
9	1	1	CD	_	10	nummod
10	year	year	NN	_	5	nmod
11	of	of	IN	_	12	case
12	therapy	therapy	NN	_	10	nmod
13	.	.	.	_	4	punct

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	Drug-drug	drug-drug	JJ	_	2	amod
2	interactions	interaction	NNS	_	8	nsubjpass
3	with	with	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	have	have	VBP	_	8	aux
6	not	not	RB	_	8	neg
7	been	be	VBN	_	8	auxpass
8	explored	explore	VBN	_	0	ROOT
9	in	in	IN	_	10	case
10	detail	detail	NN	_	8	nmod
11	.	.	.	_	8	punct

1	There	there	EX	_	2	expl
2	is	be	VBZ	_	0	ROOT
3	one	one	CD	_	4	nummod
4	report	report	NN	_	2	nsubj
5	of	of	IN	_	7	case
6	cardiopulmonary	cardiopulmonary	JJ	_	7	amod
7	arrest	arrest	NN	_	4	nmod
8	,	,	,	_	4	punct
9	with	with	IN	_	11	case
10	full	full	JJ	_	11	amod
11	recovery	recovery	NN	_	4	nmod
12	,	,	,	_	4	punct
13	in	in	IN	_	15	case
14	a	a	DT	_	15	det
15	patient	patient	NN	_	4	nmod
16	who	who	WP	_	18	nsubj
17	was	be	VBD	_	18	aux
18	taking	take	VBG	_	15	acl:relcl
19	a	a	DT	_	18	dobj
20	drug1	drug1	NN	_	19	dep
21	-LRB-	-lrb-	-LRB-	_	22	punct
22	drug2	drug2	NN	_	20	appos
23	-RRB-	-rrb-	-RRB-	_	22	punct
24	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	effects	effect	NNS	_	13	nsubjpass
3	of	of	IN	_	4	case
4	Mefloquineuine	mefloquineuine	NN	_	2	nmod
5	on	on	IN	_	9	case
6	the	the	DT	_	9	det
7	compromised	compromise	VBN	_	9	amod
8	cardiovascular	cardiovascular	JJ	_	9	amod
9	system	system	NN	_	2	nmod
10	have	have	VBP	_	13	aux
11	not	not	RB	_	13	neg
12	been	be	VBN	_	13	auxpass
13	evaluated	evaluate	VBN	_	0	ROOT
14	.	.	.	_	13	punct

1	The	the	DT	_	2	det
2	benefits	benefit	NNS	_	8	nsubjpass
3	of	of	IN	_	5	case
4	drug1	drug1	NN	_	5	compound
5	therapy	therapy	NN	_	2	nmod
6	should	should	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	weighed	weigh	VBN	_	0	ROOT
9	against	against	IN	_	11	case
10	the	the	DT	_	11	det
11	possibility	possibility	NN	_	8	nmod
12	of	of	IN	_	14	case
13	adverse	adverse	JJ	_	14	amod
14	effects	effect	NNS	_	11	nmod
15	in	in	IN	_	16	case
16	patients	patient	NNS	_	14	nmod
17	with	with	IN	_	19	case
18	cardiac	cardiac	JJ	_	19	amod
19	disease	disease	NN	_	16	nmod
20	.	.	.	_	8	punct

1	Because	because	IN	_	4	case
2	of	of	IN	_	1	mwe
3	the	the	DT	_	4	det
4	danger	danger	NN	_	19	nmod
5	of	of	IN	_	9	case
6	a	a	DT	_	9	det
7	potentially	potentially	RB	_	8	advmod
8	fatal	fatal	JJ	_	9	amod
9	prolongation	prolongation	NN	_	4	nmod
10	of	of	IN	_	13	case
11	the	the	DT	_	13	det
12	QTc	qtc	NN	_	13	compound
13	interval	interval	NN	_	9	nmod
14	,	,	,	_	19	punct
15	drug1	drug1	NN	_	19	nsubjpass
16	must	must	MD	_	19	aux
17	not	not	RB	_	19	neg
18	be	be	VB	_	19	auxpass
19	given	give	VBN	_	0	ROOT
20	simultaneously	simultaneously	RB	_	19	advmod
21	with	with	IN	_	19	dep
22	or	or	CC	_	21	cc
23	subsequent	subsequent	JJ	_	21	conj
24	to	to	TO	_	25	case
25	drug2	drug2	NN	_	23	nmod
26	.	.	.	_	19	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	19	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	other	other	JJ	_	8	amod
7	related	related	JJ	_	8	amod
8	compounds	compound	NNS	_	4	conj
9	-LRB-	-lrb-	-LRB-	_	12	punct
10	eg	eg	FW	_	12	compound
11	,	,	,	_	12	punct
12	drug2	drug2	NN	_	8	dep
13	,	,	,	_	12	punct
14	drug3	drug3	NN	_	12	conj
15	and	and	CC	_	12	cc
16	drug4	drug4	NN	_	12	conj
17	-RRB-	-rrb-	-RRB-	_	12	punct
18	may	may	MD	_	19	aux
19	produce	produce	VB	_	0	ROOT
20	electrocardiographic	electrocardiographic	JJ	_	21	amod
21	abnormalities	abnormality	NNS	_	19	dobj
22	and	and	CC	_	19	cc
23	increase	increase	VB	_	19	conj
24	the	the	DT	_	25	det
25	risk	risk	NN	_	23	dobj
26	of	of	IN	_	27	case
27	convulsions	convulsion	NNS	_	25	nmod
28	.	.	.	_	19	punct

1	If	if	IN	_	4	mark
2	these	these	DT	_	3	det
3	drugs	drug	NNS	_	4	nsubj
4	are	be	VBP	_	20	advcl
5	to	to	TO	_	7	mark
6	be	be	VB	_	7	auxpass
7	used	use	VBN	_	4	xcomp
8	in	in	IN	_	11	case
9	the	the	DT	_	11	det
10	initial	initial	JJ	_	11	amod
11	treatment	treatment	NN	_	7	nmod
12	of	of	IN	_	14	case
13	severe	severe	JJ	_	14	amod
14	malaria	malaria	NN	_	11	nmod
15	,	,	,	_	14	punct
16	drug1	drug1	NN	_	17	compound
17	administration	administration	NN	_	14	appos
18	should	should	MD	_	20	aux
19	be	be	VB	_	20	auxpass
20	delayed	delay	VBN	_	0	ROOT
21	at	at	IN	_	22	case
22	least	least	JJS	_	23	nmod:npmod
23	12	12	CD	_	24	nummod
24	hours	hour	NNS	_	20	dobj
25	after	after	IN	_	28	case
26	the	the	DT	_	28	det
27	last	last	JJ	_	28	amod
28	dose	dose	NN	_	20	nmod
29	.	.	.	_	20	punct

1	There	there	EX	_	2	expl
2	is	be	VBZ	_	0	ROOT
3	evidence	evidence	NN	_	2	nsubj
4	that	that	IN	_	3	dep
5	the	the	DT	_	6	det
6	use	use	NN	_	4	dep
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	after	after	IN	_	11	mark
10	Mefloquineuine	Mefloquineuine	NNP	_	11	nsubj
11	causes	cause	VBZ	_	6	acl
12	a	a	DT	_	14	det
13	significant	significant	JJ	_	14	amod
14	lengthening	lengthening	NN	_	11	dobj
15	of	of	IN	_	18	case
16	the	the	DT	_	18	det
17	QTc	qtc	NN	_	18	compound
18	interval	interval	NN	_	14	nmod
19	.	.	.	_	2	punct

1	Clinically	clinically	RB	_	2	advmod
2	significant	significant	JJ	_	4	amod
3	QTc	qtc	NN	_	4	compound
4	prolongation	prolongation	NN	_	8	nsubjpass
5	has	have	VBZ	_	8	aux
6	not	not	RB	_	8	neg
7	been	be	VBN	_	8	auxpass
8	found	find	VBN	_	0	ROOT
9	with	with	IN	_	10	case
10	Mefloquineuine	mefloquineuine	NN	_	8	nmod
11	alone	alone	RB	_	10	advmod
12	.	.	.	_	8	punct

1	This	this	DT	_	2	nsubj
2	appears	appear	VBZ	_	0	ROOT
3	to	to	TO	_	9	mark
4	be	be	VB	_	9	cop
5	the	the	DT	_	9	det
6	only	only	JJ	_	9	amod
7	clinically	clinically	RB	_	8	advmod
8	relevant	relevant	JJ	_	9	amod
9	interaction	interaction	NN	_	2	xcomp
10	of	of	IN	_	12	case
11	this	this	DT	_	12	det
12	kind	kind	NN	_	9	nmod
13	with	with	IN	_	14	case
14	drug1	drug1	NN	_	9	nmod
15	,	,	,	_	9	punct
16	although	although	IN	_	17	case
17	theoretically	theoretically	RB	_	47	nmod
18	,	,	,	_	47	punct
19	coadministration	coadministration	NN	_	47	nsubj
20	of	of	IN	_	22	case
21	other	other	JJ	_	22	amod
22	drugs	drug	NNS	_	19	nmod
23	known	know	VBN	_	22	acl
24	to	to	TO	_	25	mark
25	alter	alter	VB	_	23	xcomp
26	cardiac	cardiac	JJ	_	27	amod
27	conduction	conduction	NN	_	25	dobj
28	-LRB-	-lrb-	-LRB-	_	31	punct
29	eg	eg	FW	_	31	dep
30	,	,	,	_	31	punct
31	drug2	drug2	NN	_	27	dep
32	or	or	CC	_	31	cc
33	drug3	drug3	NN	_	31	conj
34	,	,	,	_	31	punct
35	drug4	drug4	NN	_	31	conj
36	,	,	,	_	31	punct
37	drug5	drug5	NN	_	31	conj
38	or	or	CC	_	31	cc
39	drug6	drug6	NN	_	31	conj
40	,	,	,	_	31	punct
41	drug7	drug7	NN	_	31	conj
42	and	and	CC	_	31	cc
43	drug8	drug8	NN	_	31	conj
44	-RRB-	-rrb-	-RRB-	_	31	punct
45	might	might	MD	_	47	aux
46	also	also	RB	_	47	advmod
47	contribute	contribute	VB	_	9	acl:relcl
48	to	to	TO	_	50	case
49	a	a	DT	_	50	det
50	prolongation	prolongation	NN	_	47	nmod
51	of	of	IN	_	54	case
52	the	the	DT	_	54	det
53	QTc	qtc	NN	_	54	compound
54	interval	interval	NN	_	50	nmod
55	.	.	.	_	2	punct

1	There	there	EX	_	2	expl
2	are	be	VBP	_	0	ROOT
3	no	no	DT	_	4	neg
4	data	datum	NNS	_	2	nsubj
5	that	that	WDT	_	7	nsubj
6	conclusively	conclusively	RB	_	7	advmod
7	establish	establish	VBP	_	4	acl:relcl
8	whether	whether	IN	_	19	mark
9	the	the	DT	_	11	det
10	concomitant	concomitant	JJ	_	11	amod
11	administration	administration	NN	_	19	nsubj
12	of	of	IN	_	13	case
13	Mefloquineuine	mefloquineuine	NN	_	11	nmod
14	and	and	CC	_	13	cc
15	the	the	DT	_	18	det
16	above	above	JJ	_	18	amod
17	listed	list	VBN	_	18	amod
18	agents	agent	NNS	_	13	conj
19	has	have	VBZ	_	7	ccomp
20	an	a	DT	_	21	det
21	effect	effect	NN	_	19	dobj
22	on	on	IN	_	24	case
23	cardiac	cardiac	JJ	_	24	amod
24	function	function	NN	_	21	nmod
25	.	.	.	_	2	punct

1	In	in	IN	_	2	case
2	patients	patient	NNS	_	24	nmod
3	taking	take	VBG	_	2	acl
4	an	a	DT	_	5	det
5	drug1	drug1	NN	_	3	dobj
6	-LRB-	-lrb-	-LRB-	_	9	punct
7	eg	eg	FW	_	9	compound
8	,	,	,	_	9	punct
9	drug2	drug2	NN	_	5	dep
10	,	,	,	_	9	punct
11	drug3	drug3	NN	_	9	conj
12	,	,	,	_	9	punct
13	drug4	drug4	NN	_	9	conj
14	or	or	CC	_	9	cc
15	drug5	drug5	NN	_	9	conj
16	-RRB-	-rrb-	-RRB-	_	9	punct
17	,	,	,	_	24	punct
18	the	the	DT	_	20	det
19	concomitant	concomitant	JJ	_	20	amod
20	use	use	NN	_	24	nsubj
21	of	of	IN	_	22	case
22	drug6	drug6	NN	_	20	nmod
23	may	may	MD	_	24	aux
24	reduce	reduce	VB	_	0	ROOT
25	seizure	seizure	NN	_	26	compound
26	control	control	NN	_	24	dobj
27	by	by	IN	_	28	mark
28	lowering	lower	VBG	_	24	advcl
29	the	the	DT	_	31	det
30	plasma	plasma	NN	_	31	compound
31	levels	level	NNS	_	28	dobj
32	of	of	IN	_	34	case
33	the	the	DT	_	34	det
34	drug7	drug7	NN	_	31	nmod
35	.	.	.	_	24	punct

1	Therefore	therefore	RB	_	11	advmod
2	,	,	,	_	11	punct
3	patients	patient	NNS	_	11	nsubj
4	concurrently	concurrently	RB	_	5	advmod
5	taking	take	VBG	_	3	acl
6	antiseizure	antiseizure	JJ	_	7	amod
7	medication	medication	NN	_	5	dobj
8	and	and	CC	_	7	cc
9	drug1	drug1	NN	_	7	conj
10	should	should	MD	_	11	aux
11	have	have	VB	_	0	ROOT
12	the	the	DT	_	14	det
13	blood	blood	NN	_	14	compound
14	level	level	NN	_	19	nsubj
15	of	of	IN	_	18	case
16	their	they	PRP$	_	18	nmod:poss
17	antiseizure	antiseizure	JJ	_	18	amod
18	medication	medication	NN	_	14	nmod
19	monitored	monitor	VBD	_	11	ccomp
20	and	and	CC	_	19	cc
21	the	the	DT	_	22	det
22	dosage	dosage	NN	_	23	nsubj
23	adjusted	adjust	VBN	_	19	conj
24	appropriately	appropriately	RB	_	23	advmod
25	.	.	.	_	11	punct

1	When	when	WRB	_	4	advmod
2	drug1	drug1	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	taken	take	VBN	_	16	advcl
5	concurrently	concurrently	RB	_	4	advmod
6	with	with	IN	_	8	case
7	oral	oral	JJ	_	8	amod
8	drug2	drug2	NN	_	4	nmod
9	,	,	,	_	16	punct
10	attenuation	attenuation	NN	_	16	nsubjpass
11	of	of	IN	_	12	case
12	immunization	immunization	NN	_	10	nmod
13	can	can	MD	_	16	aux
14	not	not	RB	_	16	neg
15	be	be	VB	_	16	auxpass
16	excluded	exclude	VBN	_	0	ROOT
17	.	.	.	_	16	punct

1	Vaccinations	vaccination	NNS	_	9	nsubjpass
2	with	with	IN	_	5	case
3	attenuated	attenuate	VBN	_	5	amod
4	live	live	JJ	_	5	amod
5	bacteria	bacterium	NNS	_	1	nmod
6	should	should	MD	_	9	aux
7	therefore	therefore	RB	_	9	advmod
8	be	be	VB	_	9	auxpass
9	completed	complete	VBN	_	0	ROOT
10	at	at	IN	_	11	case
11	least	least	JJS	_	12	nmod:npmod
12	3	3	CD	_	13	nummod
13	days	day	NNS	_	9	nmod
14	before	before	IN	_	13	case
15	the	the	DT	_	17	det
16	first	first	JJ	_	17	amod
17	dose	dose	NN	_	13	dep
18	of	of	IN	_	19	case
19	drug1	drug1	NN	_	17	nmod
20	.	.	.	_	9	punct

1	No	no	DT	_	4	neg
2	other	other	JJ	_	4	amod
3	drug	drug	NN	_	4	compound
4	interactions	interaction	NNS	_	6	nsubjpass
5	are	be	VBP	_	6	auxpass
6	known	know	VBN	_	0	ROOT
7	.	.	.	_	6	punct

1	Nevertheless	nevertheless	RB	_	21	advmod
2	,	,	,	_	21	punct
3	the	the	DT	_	4	det
4	effects	effect	NNS	_	21	nsubjpass
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	on	on	IN	_	8	case
8	travelers	traveler	NNS	_	4	nmod
9	receiving	receive	VBG	_	8	acl
10	comedication	comedication	NN	_	9	dobj
11	,	,	,	_	8	punct
12	particularly	particularly	RB	_	13	advmod
13	diabetics	diabetic	NNS	_	8	appos
14	or	or	CC	_	13	cc
15	patients	patient	NNS	_	13	conj
16	using	use	VBG	_	13	acl
17	drug2	drug2	NN	_	16	dobj
18	,	,	,	_	4	punct
19	should	should	MD	_	21	aux
20	be	be	VB	_	21	auxpass
21	checked	check	VBN	_	0	ROOT
22	before	before	IN	_	23	case
23	departure	departure	NN	_	21	nmod
24	.	.	.	_	21	punct

1	In	in	IN	_	3	case
2	clinical	clinical	JJ	_	3	amod
3	trials	trial	NNS	_	14	nmod
4	,	,	,	_	14	punct
5	the	the	DT	_	7	det
6	concomitant	concomitant	JJ	_	7	amod
7	administration	administration	NN	_	14	nsubj
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	drug2	drug2	NN	_	9	conj
12	did	do	VBD	_	14	aux
13	not	not	RB	_	14	neg
14	alter	alter	VB	_	0	ROOT
15	the	the	DT	_	18	det
16	adverse	adverse	JJ	_	18	amod
17	reaction	reaction	NN	_	18	compound
18	profile	profile	NN	_	14	dobj
19	.	.	.	_	14	punct

1	The	the	DT	_	2	det
2	risk	risk	NN	_	11	nsubj
3	of	of	IN	_	6	case
4	a	a	DT	_	6	det
5	potential	potential	JJ	_	6	amod
6	interaction	interaction	NN	_	2	nmod
7	between	between	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	drug2	drug2	NN	_	8	conj
11	concentrates	concentrate	VBZ	_	0	ROOT
12	has	have	VBZ	_	16	aux
13	not	not	RB	_	16	neg
14	been	be	VBN	_	16	auxpass
15	adequately	adequately	RB	_	16	advmod
16	evaluated	evaluate	VBN	_	11	ccomp
17	in	in	IN	_	21	case
18	preclinical	preclinical	JJ	_	21	amod
19	or	or	CC	_	18	cc
20	clinical	clinical	JJ	_	18	conj
21	studies	study	NNS	_	16	nmod
22	.	.	.	_	11	punct

1	Simultaneous	simultaneous	JJ	_	2	amod
2	use	use	NN	_	9	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	or	or	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	avoided	avoid	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	Although	although	IN	_	8	mark
2	the	the	DT	_	5	det
3	specific	specific	JJ	_	5	amod
4	drug	drug	NN	_	5	compound
5	interaction	interaction	NN	_	8	nsubjpass
6	was	be	VBD	_	8	auxpass
7	not	not	RB	_	8	neg
8	studied	study	VBN	_	20	advcl
9	in	in	IN	_	12	case
10	a	a	DT	_	12	det
11	clinical	clinical	JJ	_	12	amod
12	trial	trial	NN	_	8	nmod
13	,	,	,	_	20	punct
14	there	there	EX	_	20	expl
15	have	have	VBP	_	20	aux
16	been	be	VBN	_	20	cop
17	more	more	JJR	_	19	advmod
18	than	than	IN	_	17	mwe
19	50	50	CD	_	20	nummod
20	episodes	episode	NNS	_	0	ROOT
21	of	of	IN	_	23	case
22	concomitant	concomitant	JJ	_	23	amod
23	use	use	NN	_	20	nmod
24	of	of	IN	_	26	case
25	antifibrinolytic	antifibrinolytic	JJ	_	26	amod
26	therapies	therapy	NNS	_	23	nmod
27	-LRB-	-lrb-	-LRB-	_	30	punct
28	i.e.	i.e.	FW	_	30	dep
29	,	,	,	_	30	punct
30	drug1	drug1	NN	_	26	dep
31	,	,	,	_	30	punct
32	drug2	drug2	NN	_	30	appos
33	-RRB-	-rrb-	-RRB-	_	30	punct
34	and	and	CC	_	26	cc
35	drug3	drug3	NN	_	26	conj
36	.	.	.	_	20	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	should	should	MD	_	5	aux
3	not	not	RB	_	5	neg
4	be	be	VB	_	5	auxpass
5	mixed	mix	VBN	_	0	ROOT
6	with	with	IN	_	8	case
7	infusion	infusion	NN	_	8	compound
8	solutions	solution	NNS	_	5	nmod
9	until	until	IN	_	13	mark
10	clinical	clinical	JJ	_	11	amod
11	data	datum	NNS	_	13	nsubj
12	are	be	VBP	_	13	cop
13	available	available	JJ	_	5	advcl
14	to	to	TO	_	15	mark
15	direct	direct	VB	_	13	xcomp
16	this	this	DT	_	17	det
17	use	use	NN	_	15	dobj
18	.	.	.	_	5	punct

1	When	when	WRB	_	6	advmod
2	drug1	drug1	NN	_	6	nsubjpass
3	and	and	CC	_	2	cc
4	drug2	drug2	NN	_	2	conj
5	are	be	VBP	_	6	auxpass
6	used	use	VBN	_	28	advcl
7	together	together	RB	_	6	advmod
8	,	,	,	_	28	punct
9	the	the	DT	_	10	det
10	signs	sign	NNS	_	28	nsubj
11	of	of	IN	_	12	case
12	atropinization	atropinization	NN	_	10	nmod
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	flushing	flushing	NN	_	12	dep
15	,	,	,	_	14	punct
16	mydriasis	mydriasis	NN	_	14	conj
17	,	,	,	_	14	punct
18	tachycardia	tachycardia	NN	_	14	conj
19	,	,	,	_	14	punct
20	dryness	dryness	NN	_	14	appos
21	of	of	IN	_	23	case
22	the	the	DT	_	23	det
23	mouth	mouth	NN	_	20	nmod
24	and	and	CC	_	23	cc
25	nose	nose	NN	_	23	conj
26	-RRB-	-rrb-	-RRB-	_	14	punct
27	may	may	MD	_	28	aux
28	occur	occur	VB	_	0	ROOT
29	earlier	earlier	JJR	_	28	advmod
30	than	than	IN	_	33	mark
31	might	might	MD	_	33	aux
32	be	be	VB	_	33	auxpass
33	expected	expect	VBN	_	29	advcl
34	than	than	IN	_	38	mark
35	when	when	WRB	_	38	advmod
36	drug3	drug3	NN	_	38	nsubjpass
37	is	be	VBZ	_	38	auxpass
38	used	use	VBN	_	29	advcl
39	alone	alone	RB	_	38	advmod
40	because	because	IN	_	43	mark
41	drug4	drug4	NN	_	43	nsubj
42	may	may	MD	_	43	aux
43	potentiate	potentiate	VB	_	28	advcl
44	the	the	DT	_	45	det
45	effect	effect	NN	_	43	dobj
46	of	of	IN	_	47	case
47	drug5	drug5	NN	_	45	nmod
48	.	.	.	_	28	punct

1	The	the	DT	_	3	det
2	following	follow	VBG	_	3	amod
3	precautions	precaution	NNS	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	kept	keep	VBN	_	0	ROOT
7	in	in	IN	_	8	case
8	mind	mind	NN	_	6	nmod
9	in	in	IN	_	11	case
10	the	the	DT	_	11	det
11	treatment	treatment	NN	_	6	nmod
12	of	of	IN	_	14	case
13	anticholinesterase	anticholinesterase	JJ	_	14	amod
14	poisoning	poisoning	NN	_	11	nmod
15	although	although	IN	_	19	mark
16	they	they	PRP	_	19	nsubj
17	do	do	VBP	_	19	aux
18	not	not	RB	_	19	neg
19	bear	bear	VB	_	6	advcl
20	directly	directly	RB	_	19	advmod
21	on	on	IN	_	23	case
22	the	the	DT	_	23	det
23	use	use	NN	_	19	nmod
24	of	of	IN	_	25	case
25	drug1	drug1	NN	_	23	nmod
26	and	and	CC	_	25	cc
27	drug2	drug2	NN	_	25	conj
28	.	.	.	_	6	punct

1	Since	since	IN	_	4	mark
2	drug1	drug1	NN	_	4	nsubjpass
3	are	be	VBP	_	4	auxpass
4	potentiated	potentiate	VBN	_	12	advcl
5	by	by	IN	_	7	case
6	the	the	DT	_	7	det
7	drug2	drug2	NN	_	4	nmod
8	,	,	,	_	12	punct
9	they	they	PRP	_	12	nsubjpass
10	should	should	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	used	use	VBN	_	0	ROOT
13	cautiously	cautiously	RB	_	12	advmod
14	in	in	IN	_	16	case
15	the	the	DT	_	16	det
16	treatment	treatment	NN	_	12	nmod
17	of	of	IN	_	18	case
18	convulsions	convulsion	NNS	_	16	nmod
19	.	.	.	_	12	punct

1	Drugs	drug	NNS	_	0	ROOT
2	Metabolized	metabolize	VBN	_	1	acl
3	by	by	IN	_	5	case
4	P450	p450	NN	_	5	compound
5	2D6	2d6	NN	_	2	nmod
6	:	:	:	_	1	punct
7	The	the	DT	_	9	det
8	biochemical	biochemical	JJ	_	9	amod
9	activity	activity	NN	_	23	nsubjpass
10	of	of	IN	_	12	case
11	the	the	DT	_	12	det
12	drug	drug	NN	_	9	nmod
13	metabolizing	metabolize	VBG	_	12	acl
14	isozyme	isozyme	NN	_	17	compound
15	cytochrome	cytochrome	NN	_	17	compound
16	P450	p450	NN	_	17	compound
17	2D6	2d6	NN	_	13	dobj
18	-LRB-	-lrb-	-LRB-	_	20	punct
19	debrisoquin	debrisoquin	NN	_	20	compound
20	hydroxylase	hydroxylase	NN	_	17	appos
21	-RRB-	-rrb-	-RRB-	_	20	punct
22	is	be	VBZ	_	23	auxpass
23	reduced	reduce	VBN	_	1	dep
24	in	in	IN	_	26	case
25	a	a	DT	_	26	det
26	subset	subset	NN	_	23	nmod
27	of	of	IN	_	30	case
28	the	the	DT	_	30	det
29	Caucasian	caucasian	JJ	_	30	amod
30	population	population	NN	_	26	nmod
31	-LRB-	-lrb-	-LRB-	_	40	punct
32	about	about	IN	_	33	advmod
33	7-10	7-10	CD	_	34	nummod
34	%	%	NN	_	40	nsubj
35	of	of	IN	_	36	case
36	Caucasians	Caucasians	NNPS	_	34	nmod
37	are	be	VBP	_	40	cop
38	so-called	so-called	JJ	_	40	amod
39	poor	poor	JJ	_	40	amod
40	metabolizers	metabolizer	NNS	_	26	appos
41	-RRB-	-rrb-	-RRB-	_	40	punct
42	;	;	:	_	1	punct

1	reliable	reliable	JJ	_	2	amod
2	estimates	estimate	NNS	_	22	nsubj
3	of	of	IN	_	5	case
4	the	the	DT	_	5	det
5	prevalence	prevalence	NN	_	2	nmod
6	of	of	IN	_	11	case
7	reduced	reduce	VBN	_	11	amod
8	P450	p450	NN	_	11	compound
9	2D6	2d6	NN	_	11	compound
10	isozyme	isozyme	NN	_	11	compound
11	activity	activity	NN	_	5	nmod
12	among	among	IN	_	18	case
13	Asian	asian	JJ	_	18	amod
14	,	,	,	_	13	punct
15	African	african	JJ	_	13	conj
16	and	and	CC	_	13	cc
17	other	other	JJ	_	13	conj
18	populations	population	NNS	_	11	nmod
19	are	be	VBP	_	22	cop
20	not	not	RB	_	22	neg
21	yet	yet	RB	_	22	advmod
22	available	available	JJ	_	0	ROOT
23	.	.	.	_	22	punct

1	Poor	Poor	NNP	_	2	compound
2	metabolizers	metabolizer	NNS	_	3	nsubj
3	have	have	VBP	_	0	ROOT
4	higher	higher	JJR	_	8	amod
5	than	than	IN	_	6	dep
6	expected	expect	VBN	_	8	amod
7	plasma	plasma	NN	_	8	compound
8	concentrations	concentration	NNS	_	3	dobj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	drug2	drug2	NN	_	10	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	when	when	WRB	_	15	advmod
15	given	give	VBN	_	3	advcl
16	usual	usual	JJ	_	17	amod
17	doses	dose	NNS	_	15	dobj
18	.	.	.	_	3	punct

1	Depending	depend	VBG	_	4	case
2	on	on	IN	_	4	case
3	the	the	DT	_	4	det
4	fraction	fraction	NN	_	19	nmod
5	of	of	IN	_	6	case
6	drug	drug	NN	_	4	nmod
7	metabolized	metabolize	VBN	_	6	acl
8	by	by	IN	_	10	case
9	P450	p450	NN	_	10	compound
10	2D6	2d6	NN	_	7	nmod
11	,	,	,	_	19	punct
12	the	the	DT	_	13	det
13	increase	increase	NN	_	19	nsubj
14	in	in	IN	_	16	case
15	plasma	plasma	NN	_	16	compound
16	concentration	concentration	NN	_	13	nmod
17	may	may	MD	_	19	aux
18	be	be	VB	_	19	cop
19	small	small	JJ	_	0	ROOT
20	,	,	,	_	19	punct
21	or	or	CC	_	19	cc
22	quite	quite	RB	_	23	advmod
23	large	large	JJ	_	26	amod
24	-LRB-	-lrb-	-LRB-	_	26	punct
25	8-fold	8-fold	JJ	_	26	amod
26	increase	increase	NN	_	19	conj
27	in	in	IN	_	29	case
28	plasma	plasma	NN	_	29	compound
29	AUC	auc	NN	_	26	nmod
30	of	of	IN	_	32	case
31	the	the	DT	_	32	det
32	TCA	TCA	NNP	_	29	nmod
33	-RRB-	-rrb-	-RRB-	_	26	punct
34	.	.	.	_	19	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	6	nmod
3	,	,	,	_	6	punct
4	certain	certain	JJ	_	5	amod
5	drugs	drug	NNS	_	6	nsubj
6	inhibit	inhibit	VBP	_	0	ROOT
7	the	the	DT	_	8	det
8	activity	activity	NN	_	6	dobj
9	of	of	IN	_	11	case
10	this	this	DT	_	11	det
11	isozyme	isozyme	NN	_	8	nmod
12	and	and	CC	_	6	cc
13	make	make	VB	_	6	conj
14	normal	normal	JJ	_	15	amod
15	metabolizers	metabolizer	NNS	_	16	nsubj
16	resemble	resemble	VBP	_	13	ccomp
17	poor	poor	JJ	_	18	amod
18	metabolizers	metabolizer	NNS	_	16	xcomp
19	.	.	.	_	6	punct

1	An	a	DT	_	2	det
2	individual	individual	NN	_	13	nsubj
3	who	who	WP	_	5	nsubj
4	is	be	VBZ	_	5	cop
5	stable	stable	JJ	_	2	acl:relcl
6	on	on	IN	_	9	case
7	a	a	DT	_	9	det
8	given	give	VBN	_	9	amod
9	dose	dose	NN	_	5	nmod
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	may	may	MD	_	13	aux
13	become	become	VB	_	0	ROOT
14	abruptly	abruptly	RB	_	15	advmod
15	toxic	toxic	JJ	_	13	xcomp
16	when	when	WRB	_	17	advmod
17	given	give	VBN	_	13	advcl
18	one	one	CD	_	17	dobj
19	of	of	IN	_	22	case
20	these	these	DT	_	22	det
21	inhibiting	inhibit	VBG	_	22	amod
22	drugs	drug	NNS	_	18	nmod
23	as	as	IN	_	25	case
24	concomitant	concomitant	JJ	_	25	amod
25	therapy	therapy	NN	_	17	nmod
26	.	.	.	_	13	punct

1	The	the	DT	_	2	det
2	drugs	drug	NNS	_	8	nsubj
3	that	that	WDT	_	4	nsubj
4	inhibit	inhibit	VBP	_	2	acl:relcl
5	cytochrome	cytochrome	NN	_	7	compound
6	P450	p450	NN	_	7	compound
7	2D6	2d6	NN	_	4	dobj
8	include	include	VBP	_	0	ROOT
9	some	some	DT	_	8	dobj
10	that	that	WDT	_	13	nsubjpass
11	are	be	VBP	_	13	auxpass
12	not	not	RB	_	13	neg
13	metabolized	metabolize	VBN	_	9	acl:relcl
14	by	by	IN	_	16	case
15	the	the	DT	_	16	det
16	enzyme	enzyme	NN	_	13	nmod
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	drug1	drug1	NN	_	16	appos
19	;	;	:	_	18	punct

1	drug1	drug1	NN	_	0	ROOT
2	-RRB-	-rrb-	-RRB-	_	1	punct
3	and	and	CC	_	1	cc
4	many	many	JJ	_	1	conj
5	that	that	WDT	_	7	nsubj
6	are	be	VBP	_	7	cop
7	substrates	substrate	NNS	_	4	acl:relcl
8	for	for	IN	_	10	case
9	P450	p450	NN	_	10	compound
10	2D6	2d6	NN	_	7	nmod
11	-LRB-	-lrb-	-LRB-	_	14	punct
12	many	many	JJ	_	14	amod
13	other	other	JJ	_	14	amod
14	drug2	drug2	NN	_	1	dep
15	,	,	,	_	14	punct
16	drug3	drug3	NN	_	14	conj
17	,	,	,	_	14	punct
18	and	and	CC	_	14	cc
19	the	the	DT	_	21	det
20	drug4	drug4	NN	_	21	compound
21	drug5	drug5	NN	_	14	conj
22	and	and	CC	_	21	cc
23	drug6	drug6	NN	_	21	conj
24	-RRB-	-rrb-	-RRB-	_	14	punct
25	.	.	.	_	1	punct

1	While	while	IN	_	22	mark
2	all	all	PDT	_	22	dep
3	the	the	DT	_	22	dep
4	drug1	drug1	NN	_	22	dep
5	-LRB-	-lrb-	-LRB-	_	6	punct
6	drug2	drug2	NN	_	4	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	,	,	,	_	4	punct
9	e.g.	e.g.	FW	_	4	dep
10	,	,	,	_	4	punct
11	drug3	drug3	NN	_	4	conj
12	,	,	,	_	4	punct
13	drug4	drug4	NN	_	4	conj
14	,	,	,	_	4	punct
15	drug5	drug5	NN	_	4	conj
16	,	,	,	_	4	punct
17	drug6	drug6	NN	_	4	conj
18	,	,	,	_	4	punct
19	and	and	CC	_	4	cc
20	drug7	drug7	NN	_	4	conj
21	,	,	,	_	4	punct
22	inhibit	inhibit	VBP	_	28	advcl
23	P450	p450	NN	_	24	compound
24	2D6	2d6	NN	_	22	dobj
25	,	,	,	_	28	punct
26	they	they	PRP	_	28	nsubj
27	may	may	MD	_	28	aux
28	vary	vary	VB	_	0	ROOT
29	in	in	IN	_	31	case
30	the	the	DT	_	31	det
31	extent	extent	NN	_	28	nmod
32	of	of	IN	_	33	case
33	inhibition	inhibition	NN	_	31	nmod
34	.	.	.	_	28	punct

1	The	the	DT	_	2	det
2	extent	extent	NN	_	0	ROOT
3	to	to	TO	_	4	case
4	which	which	WDT	_	10	nmod
5	drug1	drug1	SYM	_	10	dep
6	-	-	:	_	10	punct
7	drug2	drug2	NN	_	8	compound
8	interactions	interaction	NNS	_	10	nsubj
9	may	may	MD	_	10	aux
10	pose	pose	VB	_	2	acl:relcl
11	clinical	clinical	JJ	_	12	amod
12	problems	problem	NNS	_	14	nsubj
13	will	will	MD	_	14	aux
14	depend	depend	VB	_	10	ccomp
15	on	on	IN	_	17	case
16	the	the	DT	_	17	det
17	degree	degree	NN	_	14	nmod
18	of	of	IN	_	19	case
19	inhibition	inhibition	NN	_	17	nmod
20	and	and	CC	_	19	cc
21	the	the	DT	_	22	det
22	pharmacokinetics	pharmacokinetic	NNS	_	19	conj
23	of	of	IN	_	25	case
24	the	the	DT	_	25	det
25	drug3	drug3	NN	_	22	nmod
26	involved	involve	VBN	_	25	acl
27	.	.	.	_	2	punct

1	Nevertheless	nevertheless	RB	_	5	advmod
2	,	,	,	_	5	punct
3	caution	caution	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	indicated	indicate	VBN	_	0	ROOT
6	in	in	IN	_	8	case
7	the	the	DT	_	8	det
8	co-administration	co-administration	NN	_	5	nmod
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	with	with	IN	_	12	case
12	any	any	DT	_	5	nmod
13	of	of	IN	_	15	case
14	the	the	DT	_	15	det
15	drug2	drug2	NN	_	12	nmod
16	and	and	CC	_	12	cc
17	also	also	RB	_	19	advmod
18	in	in	IN	_	19	case
19	switching	switching	NN	_	12	conj
20	from	from	IN	_	22	case
21	one	one	CD	_	22	nummod
22	class	class	NN	_	19	nmod
23	to	to	TO	_	25	case
24	the	the	DT	_	25	det
25	other	other	JJ	_	19	nmod
26	.	.	.	_	5	punct

1	Of	of	IN	_	3	case
2	particular	particular	JJ	_	3	amod
3	importance	importance	NN	_	8	nmod
4	,	,	,	_	8	punct
5	sufficient	sufficient	JJ	_	6	amod
6	time	time	NN	_	8	nsubj
7	must	must	MD	_	8	aux
8	elapse	elapse	VB	_	0	ROOT
9	before	before	IN	_	10	mark
10	initiating	initiate	VBG	_	8	advcl
11	TCA	TCA	NNP	_	12	compound
12	treatment	treatment	NN	_	10	dobj
13	in	in	IN	_	15	case
14	a	a	DT	_	15	det
15	patient	patient	NN	_	12	nmod
16	being	be	VBG	_	17	auxpass
17	withdrawn	withdraw	VBN	_	15	acl
18	from	from	IN	_	19	case
19	drug1	drug1	NN	_	17	nmod
20	,	,	,	_	8	punct
21	given	give	VBN	_	24	case
22	the	the	DT	_	24	det
23	long	long	JJ	_	24	amod
24	half-life	half-life	NN	_	8	nmod
25	of	of	IN	_	27	case
26	the	the	DT	_	27	det
27	parent	parent	NN	_	24	nmod
28	and	and	CC	_	27	cc
29	active	active	JJ	_	30	amod
30	metabolite	metabolite	NN	_	27	conj
31	-LRB-	-lrb-	-LRB-	_	38	punct
32	at	at	IN	_	33	case
33	least	least	JJS	_	34	nmod:npmod
34	5	5	CD	_	35	nummod
35	weeks	week	NNS	_	38	nsubj
36	may	may	MD	_	38	aux
37	be	be	VB	_	38	cop
38	necessary	necessary	JJ	_	24	dep
39	-RRB-	-rrb-	-RRB-	_	38	punct
40	.	.	.	_	8	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	use	use	NN	_	14	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	6	case
6	drugs	drug	NNS	_	2	nmod
7	that	that	WDT	_	9	nsubj
8	can	can	MD	_	9	aux
9	inhibit	inhibit	VB	_	6	acl:relcl
10	cytochrome	cytochrome	NN	_	12	compound
11	P450	p450	NN	_	12	compound
12	2D6	2d6	NN	_	9	dobj
13	may	may	MD	_	14	aux
14	require	require	VB	_	0	ROOT
15	lower	lower	JJR	_	16	amod
16	doses	dose	NNS	_	14	dobj
17	than	than	IN	_	19	mark
18	usually	usually	RB	_	19	advmod
19	prescribed	prescribe	VBN	_	16	dep
20	for	for	IN	_	23	case
21	either	either	CC	_	23	cc:preconj
22	the	the	DT	_	23	det
23	drug2	drug2	NN	_	19	nmod
24	or	or	CC	_	23	cc
25	the	the	DT	_	27	det
26	other	other	JJ	_	27	amod
27	drug	drug	NN	_	23	conj
28	.	.	.	_	14	punct

1	Furthermore	furthermore	RB	_	21	advmod
2	,	,	,	_	21	punct
3	whenever	whenever	WRB	_	10	advmod
4	one	one	CD	_	10	nsubjpass
5	of	of	IN	_	8	case
6	these	these	DT	_	8	det
7	other	other	JJ	_	8	amod
8	drugs	drug	NNS	_	4	nmod
9	is	be	VBZ	_	10	auxpass
10	withdrawn	withdraw	VBN	_	21	advcl
11	from	from	IN	_	12	case
12	co-therapy	co-therapy	JJ	_	10	nmod
13	,	,	,	_	21	punct
14	an	a	DT	_	16	det
15	increased	increase	VBN	_	16	amod
16	dose	dose	NN	_	21	nsubjpass
17	of	of	IN	_	18	case
18	drug1	drug1	NN	_	16	nmod
19	may	may	MD	_	21	aux
20	be	be	VB	_	21	auxpass
21	required	require	VBN	_	0	ROOT
22	.	.	.	_	21	punct

1	It	it	PRP	_	3	nsubj
2	is	be	VBZ	_	3	cop
3	desirable	desirable	JJ	_	0	ROOT
4	to	to	TO	_	5	mark
5	monitor	monitor	VB	_	3	xcomp
6	drug1	drug1	NN	_	8	compound
7	plasma	plasma	NN	_	8	compound
8	levels	level	NNS	_	5	dobj
9	whenever	whenever	WRB	_	13	advmod
10	a	a	DT	_	11	det
11	drug2	drug2	NN	_	13	nsubj
12	is	be	VBZ	_	13	aux
13	going	go	VBG	_	5	advcl
14	to	to	TO	_	16	mark
15	be	be	VB	_	16	auxpass
16	co-administered	co-administer	VBN	_	13	xcomp
17	with	with	IN	_	19	case
18	another	another	DT	_	19	det
19	drug	drug	NN	_	16	nmod
20	known	know	VBN	_	19	acl
21	to	to	TO	_	24	mark
22	be	be	VB	_	24	cop
23	an	a	DT	_	24	det
24	inhibitor	inhibitor	NN	_	20	xcomp
25	of	of	IN	_	27	case
26	P450	p450	NN	_	27	compound
27	2D6	2d6	NN	_	24	nmod
28	.	.	.	_	3	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	primarily	primarily	RB	_	4	advmod
4	metabolized	metabolize	VBN	_	0	ROOT
5	by	by	IN	_	6	case
6	CYP2D6	cyp2d6	NN	_	4	nmod
7	-LRB-	-lrb-	-LRB-	_	6	punct
8	with	with	IN	_	9	case
9	CYP1A2	cyp1a2	NN	_	6	nmod
10	and	and	CC	_	9	cc
11	CYP3A4	cyp3a4	NN	_	9	conj
12	as	as	IN	_	14	case
13	minor	minor	JJ	_	14	amod
14	pathways	pathway	NNS	_	6	nmod
15	-RRB-	-rrb-	-RRB-	_	4	punct
16	.	.	.	_	4	punct

1	Inhibitors	inhibitor	NNS	_	17	nsubj
2	or	or	CC	_	1	cc
3	substrates	substrate	NNS	_	1	conj
4	of	of	IN	_	5	case
5	CYP2D6	cyp2d6	NN	_	1	nmod
6	-LRB-	-lrb-	-LRB-	_	9	punct
7	i.e.	i.e.	FW	_	9	dep
8	,	,	,	_	9	punct
9	drug1	drug1	NN	_	5	dep
10	,	,	,	_	9	punct
11	drug2	drug2	NN	_	9	appos
12	-LSB-	-lsb-	-LRB-	_	13	punct
13	drug3	drug3	NN	_	11	appos
14	-RSB-	-rsb-	-RRB-	_	13	punct
15	-RRB-	-rrb-	-RRB-	_	9	punct
16	may	may	MD	_	17	aux
17	increase	increase	VB	_	0	ROOT
18	the	the	DT	_	20	det
19	plasma	plasma	NN	_	20	compound
20	concentration	concentration	NN	_	17	dobj
21	of	of	IN	_	22	case
22	drug4	drug4	NN	_	20	nmod
23	when	when	WRB	_	24	advmod
24	administered	administer	VBN	_	17	advcl
25	concomitantly	concomitantly	RB	_	24	advmod
26	.	.	.	_	17	punct

1	The	the	DT	_	2	det
2	extent	extent	NN	_	5	nsubj
3	of	of	IN	_	4	case
4	interaction	interaction	NN	_	2	nmod
5	depends	depend	VBZ	_	0	ROOT
6	on	on	IN	_	8	case
7	the	the	DT	_	8	det
8	variability	variability	NN	_	5	nmod
9	of	of	IN	_	10	case
10	effect	effect	NN	_	8	nmod
11	on	on	IN	_	12	case
12	CYP2D6	cyp2d6	NN	_	10	nmod
13	.	.	.	_	5	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	significance	significance	NN	_	13	nsubjpass
4	of	of	IN	_	6	case
5	this	this	DT	_	6	det
6	interaction	interaction	NN	_	3	nmod
7	with	with	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	has	have	VBZ	_	13	aux
10	not	not	RB	_	13	neg
11	been	be	VBN	_	13	auxpass
12	systematically	systematically	RB	_	13	advmod
13	evaluated	evaluate	VBN	_	0	ROOT
14	.	.	.	_	13	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Serious	serious	JJ	_	5	amod
4	side	side	JJ	_	5	amod
5	effects	effect	NNS	_	11	nsubjpass
6	and	and	CC	_	5	cc
7	even	even	RB	_	8	advmod
8	death	death	NN	_	5	conj
9	have	have	VBP	_	11	aux
10	been	be	VBN	_	11	auxpass
11	reported	report	VBN	_	1	appos
12	following	follow	VBG	_	15	case
13	the	the	DT	_	15	det
14	concomitant	concomitant	JJ	_	15	amod
15	use	use	NN	_	11	nmod
16	of	of	IN	_	18	case
17	certain	certain	JJ	_	18	amod
18	drugs	drug	NNS	_	15	nmod
19	with	with	IN	_	20	case
20	drug2	drug2	NN	_	15	nmod
21	.	.	.	_	1	punct

1	Therefore	therefore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	drug1	drug1	NN	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	discontinued	discontinue	VBN	_	0	ROOT
7	at	at	IN	_	8	case
8	least	least	JJS	_	9	nmod:npmod
9	two	two	CD	_	10	nummod
10	weeks	week	NNS	_	11	nmod:npmod
11	prior	prior	RB	_	6	advmod
12	to	to	TO	_	15	case
13	the	the	DT	_	15	det
14	cautious	cautious	JJ	_	15	amod
15	initiation	initiation	NN	_	11	nmod
16	of	of	IN	_	17	case
17	therapy	therapy	NN	_	15	nmod
18	with	with	IN	_	19	case
19	drug2	drug2	NN	_	15	nmod
20	.	.	.	_	6	punct

1	The	the	DT	_	3	det
2	exact	exact	JJ	_	3	amod
3	length	length	NN	_	7	nsubj
4	of	of	IN	_	5	case
5	time	time	NN	_	3	nmod
6	may	may	MD	_	7	aux
7	vary	vary	VB	_	0	ROOT
8	and	and	CC	_	7	cc
9	is	be	VBZ	_	10	cop
10	dependent	dependent	JJ	_	7	conj
11	upon	upon	IN	_	14	case
12	the	the	DT	_	14	det
13	particular	particular	JJ	_	14	amod
14	drug1	drug1	NN	_	10	nmod
15	being	be	VBG	_	16	auxpass
16	used	use	VBN	_	14	acl
17	,	,	,	_	7	punct
18	the	the	DT	_	19	det
19	length	length	NN	_	7	conj
20	of	of	IN	_	21	case
21	time	time	NN	_	19	nmod
22	it	it	PRP	_	25	nsubjpass
23	has	have	VBZ	_	25	aux
24	been	be	VBN	_	25	auxpass
25	administered	administer	VBN	_	21	acl:relcl
26	,	,	,	_	7	punct
27	and	and	CC	_	7	cc
28	the	the	DT	_	29	det
29	dosage	dosage	NN	_	7	conj
30	involved	involve	VBN	_	29	acl
31	.	.	.	_	7	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	6	nsubjpass
4	has	have	VBZ	_	6	aux
5	been	be	VBN	_	6	auxpass
6	reported	report	VBN	_	1	appos
7	to	to	TO	_	8	mark
8	produce	produce	VB	_	6	xcomp
9	clinically	clinically	RB	_	10	advmod
10	significant	significant	JJ	_	11	amod
11	fluctuations	fluctuation	NNS	_	8	dobj
12	in	in	IN	_	15	case
13	steady-state	steady-state	JJ	_	15	amod
14	serum	serum	NN	_	15	compound
15	concentrations	concentration	NNS	_	8	nmod
16	of	of	IN	_	18	case
17	various	various	JJ	_	18	amod
18	drug3	drug3	NN	_	15	nmod
19	.	.	.	_	1	punct

1	Serious	serious	JJ	_	3	amod
2	anticholinergic	anticholinergic	JJ	_	3	amod
3	symptoms	symptom	NNS	_	19	nsubjpass
4	-LRB-	-lrb-	-LRB-	_	9	punct
5	i.e.	i.e.	FW	_	9	dep
6	,	,	,	_	9	punct
7	severe	severe	JJ	_	9	amod
8	dry	dry	JJ	_	9	amod
9	mouth	mouth	NN	_	3	dep
10	,	,	,	_	9	punct
11	urinary	urinary	JJ	_	12	amod
12	retention	retention	NN	_	9	conj
13	and	and	CC	_	9	cc
14	blurred	blur	VBD	_	15	amod
15	vision	vision	NN	_	9	conj
16	-RRB-	-rrb-	-RRB-	_	9	punct
17	have	have	VBP	_	19	aux
18	been	be	VBN	_	19	auxpass
19	associated	associate	VBN	_	0	ROOT
20	with	with	IN	_	21	case
21	elevations	elevation	NNS	_	19	nmod
22	in	in	IN	_	25	case
23	the	the	DT	_	25	det
24	serum	serum	NN	_	25	compound
25	levels	level	NNS	_	21	nmod
26	of	of	IN	_	27	case
27	drug1	drug1	NN	_	25	nmod
28	when	when	WRB	_	32	advmod
29	drug2	drug2	NN	_	30	compound
30	therapy	therapy	NN	_	32	nsubjpass
31	is	be	VBZ	_	32	auxpass
32	initiated	initiate	VBN	_	19	advcl
33	.	.	.	_	19	punct

1	Additionally	additionally	RB	_	0	ROOT
2	,	,	,	_	1	punct
3	higher	higher	JJR	_	2	root
4	than	than	IN	_	10	mark
5	expected	expect	VBN	_	7	amod
6	drug1	drug1	NN	_	7	compound
7	levels	level	NNS	_	10	nsubjpass
8	have	have	VBP	_	10	aux
9	been	be	VBN	_	10	auxpass
10	observed	observe	VBN	_	3	advcl
11	when	when	WRB	_	14	advmod
12	they	they	PRP	_	14	nsubjpass
13	are	be	VBP	_	14	auxpass
14	begun	begin	VBN	_	10	advcl
15	in	in	IN	_	16	case
16	patients	patient	NNS	_	14	nmod
17	already	already	RB	_	18	advmod
18	taking	take	VBG	_	16	acl
19	drug2	drug2	NN	_	18	dobj
20	.	.	.	_	3	punct

1	In	in	IN	_	2	case
2	patients	patient	NNS	_	23	nmod
3	who	who	WP	_	6	nsubjpass
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	auxpass
6	reported	report	VBN	_	2	acl:relcl
7	to	to	TO	_	10	mark
8	be	be	VB	_	10	auxpass
9	well	well	RB	_	10	advmod
10	controlled	control	VBN	_	6	xcomp
11	on	on	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	receiving	receive	VBG	_	12	acl
14	concurrent	concurrent	JJ	_	16	amod
15	drug2	drug2	NN	_	16	compound
16	therapy	therapy	NN	_	13	dobj
17	,	,	,	_	23	punct
18	discontinuation	discontinuation	NN	_	23	nsubjpass
19	of	of	IN	_	20	case
20	drug3	drug3	NN	_	18	nmod
21	has	have	VBZ	_	23	aux
22	been	be	VBN	_	23	auxpass
23	reported	report	VBN	_	0	ROOT
24	to	to	TO	_	25	mark
25	decrease	decrease	VB	_	23	xcomp
26	established	established	JJ	_	30	amod
27	steady-state	steady-state	JJ	_	30	amod
28	serum	serum	NN	_	30	compound
29	drug4	drug4	NN	_	30	compound
30	levels	level	NNS	_	25	dobj
31	and	and	CC	_	25	cc
32	compromise	compromise	VB	_	25	conj
33	their	they	PRP$	_	35	nmod:poss
34	therapeutic	therapeutic	JJ	_	35	amod
35	effects	effect	NNS	_	32	dobj
36	.	.	.	_	23	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	It	it	PRP	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	borne	bear	VBN	_	1	dep
7	in	in	IN	_	8	case
8	mind	mind	NN	_	6	nmod
9	that	that	IN	_	13	mark
10	drug2	drug2	NN	_	11	compound
11	ingestion	ingestion	NN	_	13	nsubj
12	may	may	MD	_	13	aux
13	increase	increase	VB	_	6	ccomp
14	the	the	DT	_	15	det
15	danger	danger	NN	_	13	dobj
16	inherent	inherent	JJ	_	15	amod
17	in	in	IN	_	23	case
18	any	any	DT	_	23	det
19	intentional	intentional	JJ	_	23	amod
20	or	or	CC	_	19	cc
21	unintentional	unintentional	JJ	_	19	conj
22	drug3	drug3	NN	_	23	compound
23	overdosage	overdosage	NN	_	16	nmod
24	.	.	.	_	1	punct

1	This	this	DT	_	4	nsubj
2	is	be	VBZ	_	4	cop
3	especially	especially	RB	_	4	advmod
4	important	important	JJ	_	0	ROOT
5	in	in	IN	_	6	case
6	patients	patient	NNS	_	4	nmod
7	who	who	WP	_	9	nsubj
8	may	may	MD	_	9	aux
9	use	use	VB	_	6	acl:relcl
10	drug1	drug1	NN	_	9	dobj
11	excessively	excessively	RB	_	9	advmod
12	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	A	a	DT	_	4	det
4	case	case	NN	_	10	nsubjpass
5	of	of	IN	_	7	case
6	severe	severe	JJ	_	7	amod
7	hypoglycemia	hypoglycemia	NN	_	4	nmod
8	has	have	VBZ	_	10	aux
9	been	be	VBN	_	10	auxpass
10	reported	report	VBN	_	1	appos
11	in	in	IN	_	16	case
12	a	a	DT	_	16	det
13	type	type	NN	_	16	compound
14	II	ii	CD	_	16	nummod
15	diabetic	diabetic	JJ	_	16	amod
16	patient	patient	NN	_	10	nmod
17	maintained	maintain	VBD	_	16	acl
18	on	on	IN	_	19	case
19	drug2	drug2	NN	_	17	nmod
20	-LRB-	-lrb-	-LRB-	_	22	punct
21	1	1	CD	_	22	nummod
22	gm/day	gm/day	NN	_	19	appos
23	-RRB-	-rrb-	-RRB-	_	22	punct
24	11	11	CD	_	25	nummod
25	days	day	NNS	_	17	nmod
26	after	after	IN	_	25	case
27	the	the	DT	_	28	det
28	addition	addition	NN	_	25	dep
29	of	of	IN	_	30	case
30	drug3	drug3	NN	_	28	nmod
31	-LRB-	-lrb-	-LRB-	_	33	punct
32	75	75	CD	_	33	nummod
33	mg/day	mg/day	NN	_	30	appos
34	-RRB-	-rrb-	-RRB-	_	33	punct
35	.	.	.	_	1	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	should	should	MD	_	5	aux
3	not	not	RB	_	5	neg
4	be	be	VB	_	5	auxpass
5	used	use	VBN	_	0	ROOT
6	in	in	IN	_	7	case
7	patients	patient	NNS	_	5	nmod
8	receiving	receive	VBG	_	7	acl
9	drug2	drug2	NN	_	8	dobj
10	.	.	.	_	5	punct
11	.	.	.	_	5	punct

1	Although	although	IN	_	14	mark
2	no	no	DT	_	5	neg
3	specific	specific	JJ	_	5	amod
4	drug	drug	NN	_	5	compound
5	interactions	interaction	NNS	_	14	nsubjpass
6	with	with	IN	_	9	case
7	topical	topical	JJ	_	9	amod
8	glaucoma	glaucoma	NN	_	9	compound
9	drugs	drug	NNS	_	5	nmod
10	or	or	CC	_	9	cc
11	systemic	systemic	JJ	_	12	amod
12	medications	medication	NNS	_	9	conj
13	were	be	VBD	_	14	auxpass
14	identified	identify	VBN	_	48	advcl
15	in	in	IN	_	17	case
16	clinical	clinical	JJ	_	17	amod
17	studies	study	NNS	_	14	nmod
18	of	of	IN	_	23	case
19	drug1	drug1	NN	_	23	compound
20	0.5	0.5	CD	_	21	compound
21	%	%	NN	_	23	amod
22	Ophthalmic	ophthalmic	JJ	_	23	amod
23	Solution	solution	NN	_	17	nmod
24	,	,	,	_	48	punct
25	the	the	DT	_	26	det
26	possibility	possibility	NN	_	48	nsubjpass
27	of	of	IN	_	32	case
28	an	a	DT	_	32	det
29	additive	additive	JJ	_	32	amod
30	or	or	CC	_	29	cc
31	potentiating	potentiating	NN	_	29	conj
32	effect	effect	NN	_	26	nmod
33	with	with	IN	_	34	case
34	drug2	drug2	NN	_	32	nmod
35	-LRB-	-lrb-	-LRB-	_	36	punct
36	drug3	drug3	NN	_	34	dep
37	,	,	,	_	36	punct
38	drug4	drug4	NN	_	36	conj
39	,	,	,	_	36	punct
40	drug5	drug5	NN	_	36	conj
41	,	,	,	_	36	punct
42	drug6	drug6	NN	_	36	conj
43	,	,	,	_	36	punct
44	drug7	drug7	NN	_	36	appos
45	-RRB-	-rrb-	-RRB-	_	36	punct
46	should	should	MD	_	48	aux
47	be	be	VB	_	48	auxpass
48	considered	consider	VBN	_	0	ROOT
49	.	.	.	_	48	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	have	have	VBP	_	4	aux
3	been	be	VBN	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	blunt	blunt	VB	_	4	xcomp
7	the	the	DT	_	9	det
8	hypotensive	hypotensive	JJ	_	9	amod
9	effect	effect	NN	_	6	dobj
10	of	of	IN	_	12	case
11	systemic	systemic	JJ	_	12	amod
12	drug2	drug2	NN	_	9	nmod
13	.	.	.	_	4	punct

1	It	it	PRP	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	not	not	RB	_	4	neg
4	known	know	VBN	_	0	ROOT
5	whether	whether	IN	_	15	mark
6	the	the	DT	_	8	det
7	concurrent	concurrent	JJ	_	8	amod
8	use	use	NN	_	15	nsubj
9	of	of	IN	_	11	case
10	these	these	DT	_	11	det
11	agents	agent	NNS	_	8	nmod
12	with	with	IN	_	13	case
13	drug1	drug1	NN	_	8	nmod
14	can	can	MD	_	15	aux
15	lead	lead	VB	_	4	ccomp
16	to	to	TO	_	18	case
17	a	a	DT	_	18	det
18	reduction	reduction	NN	_	15	nmod
19	in	in	IN	_	22	case
20	IOP	IOP	NNP	_	22	compound
21	lowering	lower	VBG	_	22	amod
22	effect	effect	NN	_	18	nmod
23	.	.	.	_	4	punct

1	No	no	DT	_	2	neg
2	data	datum	NNS	_	13	nsubj
3	on	on	IN	_	5	case
4	the	the	DT	_	5	det
5	level	level	NN	_	2	nmod
6	of	of	IN	_	8	case
7	circulating	circulate	VBG	_	8	amod
8	catecholamines	catecholamine	NNS	_	5	nmod
9	after	after	IN	_	11	case
10	drug1	drug1	NN	_	11	compound
11	withdrawal	withdrawal	NN	_	2	nmod
12	are	be	VBP	_	13	cop
13	available	available	JJ	_	0	ROOT
14	.	.	.	_	13	punct

1	Caution	caution	NN	_	6	nsubjpass
2	,	,	,	_	6	punct
3	however	however	RB	_	6	advmod
4	,	,	,	_	6	punct
5	is	be	VBZ	_	6	auxpass
6	advised	advise	VBN	_	0	ROOT
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	taking	take	VBG	_	8	acl
10	drug1	drug1	NN	_	9	dobj
11	which	which	WDT	_	13	nsubj
12	can	can	MD	_	13	aux
13	affect	affect	VB	_	10	acl:relcl
14	the	the	DT	_	15	det
15	metabolism	metabolism	NN	_	13	dobj
16	and	and	CC	_	15	cc
17	uptake	uptake	NN	_	15	conj
18	of	of	IN	_	20	case
19	circulating	circulate	VBG	_	20	amod
20	amines	amine	NNS	_	15	nmod
21	.	.	.	_	6	punct

1	An	a	DT	_	4	det
2	additive	additive	JJ	_	4	amod
3	hypotensive	hypotensive	JJ	_	4	amod
4	effect	effect	NN	_	7	nsubjpass
5	has	have	VBZ	_	7	aux
6	been	be	VBN	_	7	auxpass
7	reported	report	VBN	_	0	ROOT
8	with	with	IN	_	10	case
9	the	the	DT	_	10	det
10	combination	combination	NN	_	7	nmod
11	of	of	IN	_	13	case
12	systemic	systemic	JJ	_	13	amod
13	drug1	drug1	NN	_	10	nmod
14	and	and	CC	_	13	cc
15	drug2	drug2	NN	_	16	compound
16	therapy	therapy	NN	_	13	conj
17	.	.	.	_	7	punct

1	Systemic	systemic	JJ	_	2	amod
2	drug1	drug1	NN	_	4	nsubj
3	may	may	MD	_	4	aux
4	inhibit	inhibit	VB	_	0	ROOT
5	the	the	DT	_	6	det
6	production	production	NN	_	4	dobj
7	of	of	IN	_	8	case
8	catecholamines	catecholamine	NNS	_	6	nmod
9	in	in	IN	_	10	case
10	response	response	NN	_	6	nmod
11	to	to	TO	_	13	case
12	insulin-induced	insulin-induced	JJ	_	13	amod
13	hypoglycemia	hypoglycemia	NN	_	10	nmod
14	and	and	CC	_	13	cc
15	mask	mask	NN	_	13	conj
16	the	the	DT	_	17	det
17	signs	sign	NNS	_	10	dep
18	and	and	CC	_	17	cc
19	symptoms	symptom	NNS	_	17	conj
20	of	of	IN	_	21	case
21	hypoglycemia	hypoglycemia	NN	_	17	nmod
22	.	.	.	_	4	punct

1	Since	since	IN	_	4	mark
2	drug1	drug1	NN	_	4	nsubj
3	may	may	MD	_	4	aux
4	reduce	reduce	VB	_	28	advcl
5	pulse	pulse	NN	_	4	dobj
6	and	and	CC	_	5	cc
7	blood	blood	NN	_	8	compound
8	pressure	pressure	NN	_	5	conj
9	,	,	,	_	28	punct
10	caution	caution	NN	_	28	nsubjpass
11	in	in	IN	_	12	mark
12	using	use	VBG	_	10	acl
13	drugs	drug	NNS	_	12	dobj
14	such	such	JJ	_	16	case
15	as	as	IN	_	14	mwe
16	drug2	drug2	NN	_	13	nmod
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	ophthalmic	ophthalmic	JJ	_	16	dep
19	and	and	CC	_	18	cc
20	systemic	systemic	JJ	_	18	conj
21	-RRB-	-rrb-	-RRB-	_	18	punct
22	,	,	,	_	16	punct
23	drug3	drug3	NN	_	16	conj
24	,	,	,	_	16	punct
25	and	and	CC	_	16	cc
26	drug4	drug4	NN	_	16	conj
27	is	be	VBZ	_	28	auxpass
28	advised	advise	VBN	_	0	ROOT
29	.	.	.	_	28	punct

1	Patients	patient	NNS	_	13	nsubj
2	using	use	VBG	_	1	acl
3	cardiovascular	cardiovascular	JJ	_	4	amod
4	drugs	drug	NNS	_	2	dobj
5	concurrently	concurrently	RB	_	2	advmod
6	with	with	IN	_	11	case
7	drug1	drug1	NN	_	11	compound
8	0.5	0.5	CD	_	9	compound
9	%	%	NN	_	11	amod
10	Ophthalmic	ophthalmic	JJ	_	11	amod
11	Solution	solution	NN	_	5	nmod
12	should	should	MD	_	13	aux
13	have	have	VB	_	0	ROOT
14	pulse	pulse	NN	_	17	compound
15	and	and	CC	_	14	cc
16	blood	blood	NN	_	14	conj
17	pressures	pressure	NNS	_	13	dobj
18	frequently	frequently	RB	_	19	advmod
19	monitored	monitor	VBD	_	13	dep
20	.	.	.	_	13	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	exercised	exercise	VBN	_	0	ROOT
5	with	with	IN	_	7	case
6	simultaneous	simultaneous	JJ	_	7	amod
7	use	use	NN	_	4	nmod
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	other	other	JJ	_	14	amod
12	similar	similar	JJ	_	14	amod
13	pharmacologic	pharmacologic	JJ	_	14	amod
14	agents	agent	NNS	_	9	conj

1	.	.	.	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	Immediate	Immediate	NNP	_	5	compound
2	and	and	CC	_	1	cc
3	Extended	Extended	NNP	_	1	conj
4	Release	Release	NNP	_	5	compound
5	Tablets	Tablets	NNPS	_	0	ROOT
6	The	the	DT	_	8	det
7	hypoglycemic	hypoglycemic	JJ	_	8	amod
8	action	action	NN	_	13	nsubjpass
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	may	may	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	potentiated	potentiate	VBN	_	5	acl:relcl
14	by	by	IN	_	16	case
15	certain	certain	JJ	_	16	amod
16	drugs	drug	NNS	_	13	nmod
17	including	include	VBG	_	18	case
18	drug2	drug2	NN	_	16	nmod
19	,	,	,	_	18	punct
20	some	some	DT	_	21	det
21	drug3	drug3	NN	_	18	conj
22	and	and	CC	_	18	cc
23	other	other	JJ	_	24	amod
24	drugs	drug	NNS	_	18	conj
25	that	that	WDT	_	29	nsubj
26	are	be	VBP	_	29	cop
27	highly	highly	RB	_	29	advmod
28	protein	protein	NN	_	29	nmod:npmod
29	bound	bind	VBD	_	24	acl:relcl
30	,	,	,	_	29	punct
31	drug4	drug4	NN	_	29	dobj
32	,	,	,	_	31	punct
33	drug5	drug5	NN	_	31	conj
34	,	,	,	_	31	punct
35	drug6	drug6	NN	_	31	conj
36	,	,	,	_	31	punct
37	drug7	drug7	NN	_	31	conj
38	,	,	,	_	31	punct
39	drug8	drug8	NN	_	31	conj
40	,	,	,	_	31	punct
41	drug9	drug9	NN	_	31	conj
42	,	,	,	_	31	punct
43	and	and	CC	_	31	cc
44	drug10	drug10	NN	_	31	conj
45	.	.	.	_	5	punct

1	When	when	WRB	_	5	advmod
2	such	such	JJ	_	3	amod
3	drugs	drug	NNS	_	5	nsubjpass
4	are	be	VBP	_	5	auxpass
5	administered	administer	VBN	_	16	advcl
6	to	to	TO	_	8	case
7	a	a	DT	_	8	det
8	patient	patient	NN	_	5	nmod
9	receiving	receive	VBG	_	8	acl
10	drug1	drug1	NN	_	9	dobj
11	,	,	,	_	16	punct
12	the	the	DT	_	13	det
13	patient	patient	NN	_	16	nsubjpass
14	should	should	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	observed	observe	VBN	_	0	ROOT
17	closely	closely	RB	_	16	advmod
18	for	for	IN	_	19	case
19	hypoglycemia	hypoglycemia	NN	_	16	nmod
20	.	.	.	_	16	punct

1	When	when	WRB	_	5	advmod
2	such	such	JJ	_	3	amod
3	drugs	drug	NNS	_	5	nsubjpass
4	are	be	VBP	_	5	auxpass
5	withdrawn	withdraw	VBN	_	16	advcl
6	from	from	IN	_	8	case
7	a	a	DT	_	8	det
8	patient	patient	NN	_	5	nmod
9	receiving	receive	VBG	_	8	acl
10	drug1	drug1	NN	_	9	dobj
11	,	,	,	_	16	punct
12	the	the	DT	_	13	det
13	patient	patient	NN	_	16	nsubjpass
14	should	should	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	observed	observe	VBN	_	0	ROOT
17	closely	closely	RB	_	16	advmod
18	for	for	IN	_	19	case
19	loss	loss	NN	_	16	nmod
20	of	of	IN	_	21	case
21	control	control	NN	_	19	nmod
22	.	.	.	_	16	punct

1	In	in	FW	_	4	amod
2	vitro	vitro	FW	_	1	dep
3	binding	binding	NN	_	4	compound
4	studies	study	NNS	_	9	nsubj
5	with	with	IN	_	8	case
6	human	human	JJ	_	8	amod
7	serum	serum	NN	_	8	compound
8	proteins	protein	NNS	_	4	nmod
9	indicate	indicate	VBP	_	0	ROOT
10	that	that	IN	_	12	mark
11	drug1	drug1	NN	_	12	nsubj
12	binds	bind	VBZ	_	9	ccomp
13	differently	differently	RB	_	12	advmod
14	than	than	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	and	and	CC	_	12	cc
17	does	do	VBZ	_	19	aux
18	not	not	RB	_	19	neg
19	interact	interact	VB	_	12	conj
20	with	with	IN	_	21	case
21	drug3	drug3	NN	_	19	nmod
22	or	or	CC	_	21	cc
23	drug4	drug4	NN	_	21	conj
24	.	.	.	_	9	punct

1	However	however	RB	_	6	advmod
2	,	,	,	_	6	punct
3	caution	caution	NN	_	6	nsubjpass
4	must	must	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	exercised	exercise	VBN	_	0	ROOT
7	in	in	IN	_	8	mark
8	extrapolating	extrapolate	VBG	_	6	advcl
9	these	these	DT	_	10	det
10	findings	finding	NNS	_	8	dobj
11	to	to	TO	_	14	case
12	the	the	DT	_	14	det
13	clinical	clinical	JJ	_	14	amod
14	situation	situation	NN	_	8	nmod
15	and	and	CC	_	14	cc
16	in	in	IN	_	18	case
17	the	the	DT	_	18	det
18	use	use	NN	_	14	conj
19	of	of	IN	_	20	case
20	drug1	drug1	NN	_	18	nmod
21	with	with	IN	_	23	case
22	these	these	DT	_	23	det
23	drugs	drug	NNS	_	18	nmod
24	.	.	.	_	6	punct

1	Certain	certain	JJ	_	2	amod
2	drugs	drug	NNS	_	3	nsubj
3	tend	tend	VBP	_	0	ROOT
4	to	to	TO	_	5	mark
5	produce	produce	VB	_	3	xcomp
6	hyperglycemia	hyperglycemia	NN	_	5	dobj
7	and	and	CC	_	3	cc
8	may	may	MD	_	9	aux
9	lead	lead	VB	_	3	conj
10	to	to	TO	_	11	case
11	loss	loss	NN	_	9	nmod
12	of	of	IN	_	13	case
13	control	control	NN	_	11	nmod
14	.	.	.	_	3	punct

1	These	these	DT	_	2	det
2	drugs	drug	NNS	_	3	nsubj
3	include	include	VBP	_	0	ROOT
4	the	the	DT	_	5	det
5	drug1	drug1	NN	_	3	dobj
6	and	and	CC	_	5	cc
7	other	other	JJ	_	8	amod
8	drug2	drug2	NN	_	5	conj
9	,	,	,	_	8	punct
10	drug3	drug3	NN	_	8	conj
11	,	,	,	_	8	punct
12	drug4	drug4	NN	_	8	conj
13	,	,	,	_	8	punct
14	drug5	drug5	NN	_	8	conj
15	,	,	,	_	8	punct
16	drug6	drug6	NN	_	8	conj
17	,	,	,	_	8	punct
18	oral	oral	JJ	_	19	amod
19	drug7	drug7	NN	_	8	conj
20	,	,	,	_	8	punct
21	drug8	drug8	NN	_	8	conj
22	,	,	,	_	8	punct
23	drug9	drug9	NN	_	8	conj
24	,	,	,	_	8	punct
25	drug10	drug10	NN	_	8	conj
26	,	,	,	_	8	punct
27	drug11	drug11	NN	_	8	conj
28	,	,	,	_	8	punct
29	and	and	CC	_	8	cc
30	drug12	drug12	NN	_	8	conj
31	.	.	.	_	3	punct

1	When	when	WRB	_	5	advmod
2	such	such	JJ	_	3	amod
3	drugs	drug	NNS	_	5	nsubjpass
4	are	be	VBP	_	5	auxpass
5	administered	administer	VBN	_	17	advcl
6	to	to	TO	_	8	case
7	a	a	DT	_	8	det
8	patient	patient	NN	_	5	nmod
9	receiving	receive	VBG	_	8	acl
10	drug1	drug1	NN	_	9	dobj
11	,	,	,	_	17	punct
12	the	the	DT	_	13	det
13	patient	patient	NN	_	17	nsubjpass
14	should	should	MD	_	17	aux
15	be	be	VB	_	17	auxpass
16	closely	closely	RB	_	17	advmod
17	observed	observe	VBN	_	0	ROOT
18	for	for	IN	_	19	case
19	loss	loss	NN	_	17	nmod
20	of	of	IN	_	21	case
21	control	control	NN	_	19	nmod
22	.	.	.	_	17	punct

1	When	when	WRB	_	5	advmod
2	such	such	JJ	_	3	amod
3	drugs	drug	NNS	_	5	nsubjpass
4	are	be	VBP	_	5	auxpass
5	withdrawn	withdraw	VBN	_	16	advcl
6	from	from	IN	_	8	case
7	a	a	DT	_	8	det
8	patient	patient	NN	_	5	nmod
9	receiving	receive	VBG	_	8	acl
10	drug1	drug1	NN	_	9	dobj
11	,	,	,	_	16	punct
12	the	the	DT	_	13	det
13	patient	patient	NN	_	16	nsubjpass
14	should	should	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	observed	observe	VBN	_	0	ROOT
17	closely	closely	RB	_	16	advmod
18	for	for	IN	_	19	case
19	hypoglycemia	hypoglycemia	NN	_	16	nmod
20	.	.	.	_	16	punct

1	A	a	DT	_	3	det
2	potential	potential	JJ	_	3	amod
3	interaction	interaction	NN	_	16	nsubjpass
4	between	between	IN	_	6	case
5	oral	oral	JJ	_	6	amod
6	drug1	drug1	NN	_	3	nmod
7	and	and	CC	_	6	cc
8	oral	oral	JJ	_	9	amod
9	drug2	drug2	NN	_	6	conj
10	leading	lead	VBG	_	3	acl
11	to	to	TO	_	13	case
12	severe	severe	JJ	_	13	amod
13	hypoglycemia	hypoglycemia	NN	_	10	nmod
14	has	have	VBZ	_	16	aux
15	been	be	VBN	_	16	auxpass
16	reported	report	VBN	_	0	ROOT
17	.	.	.	_	16	punct

1	Whether	whether	IN	_	5	mark
2	this	this	DT	_	3	det
3	interaction	interaction	NN	_	5	nsubj
4	also	also	RB	_	5	advmod
5	occurs	occur	VBZ	_	19	csubjpass
6	with	with	IN	_	14	case
7	the	the	DT	_	14	det
8	intravenous	intravenous	JJ	_	14	amod
9	,	,	,	_	8	punct
10	topical	topical	JJ	_	8	conj
11	,	,	,	_	8	punct
12	or	or	CC	_	8	cc
13	vaginal	vaginal	JJ	_	8	conj
14	preparations	preparation	NNS	_	5	nmod
15	of	of	IN	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	is	be	VBZ	_	19	auxpass
18	not	not	RB	_	19	neg
19	known	know	VBN	_	0	ROOT
20	.	.	.	_	19	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	12	nsubjpass
3	of	of	IN	_	5	case
4	concomitant	concomitant	JJ	_	5	amod
5	administration	administration	NN	_	2	nmod
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	and	and	CC	_	5	cc
9	drug2	drug2	NN	_	5	conj
10	has	have	VBZ	_	12	aux
11	been	be	VBN	_	12	auxpass
12	demonstrated	demonstrate	VBN	_	0	ROOT
13	in	in	IN	_	17	case
14	a	a	DT	_	17	det
15	placebo-controlled	placebo-controlled	JJ	_	17	amod
16	crossover	crossover	NN	_	17	compound
17	study	study	NN	_	12	nmod
18	in	in	IN	_	20	case
19	normal	normal	JJ	_	20	amod
20	volunteers	volunteer	NNS	_	17	nmod
21	.	.	.	_	12	punct

1	All	all	DT	_	2	det
2	subjects	subject	NNS	_	3	nsubj
3	received	receive	VBD	_	0	ROOT
4	drug1	drug1	NN	_	3	dobj
5	alone	alone	RB	_	3	advmod
6	and	and	CC	_	3	cc
7	following	follow	VBG	_	8	case
8	treatment	treatment	NN	_	3	conj
9	with	with	IN	_	11	case
10	100	100	CD	_	11	nummod
11	mg	mg	NN	_	8	nmod
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	as	as	IN	_	19	case
15	a	a	DT	_	19	det
16	single	single	JJ	_	19	amod
17	daily	daily	JJ	_	19	amod
18	oral	oral	JJ	_	19	amod
19	dose	dose	NN	_	8	nmod
20	for	for	IN	_	22	case
21	seven	seven	CD	_	22	nummod
22	days	day	NNS	_	8	nmod
23	.	.	.	_	3	punct

1	The	the	DT	_	4	det
2	mean	mean	JJ	_	4	amod
3	percentage	percentage	NN	_	4	compound
4	increase	increase	NN	_	14	nsubj
5	in	in	IN	_	8	case
6	the	the	DT	_	8	det
7	drug1	drug1	NN	_	8	compound
8	AUC	auc	NN	_	4	nmod
9	after	after	IN	_	11	case
10	drug2	drug2	NN	_	11	compound
11	administration	administration	NN	_	4	nmod
12	was	be	VBD	_	14	cop
13	56.9	56.9	CD	_	14	nummod
14	%	%	NN	_	0	ROOT
15	-LRB-	-lrb-	-LRB-	_	16	punct
16	range	range	NN	_	14	dep
17	:	:	:	_	16	punct
18	35	35	CD	_	20	compound
19	to	to	TO	_	20	dep
20	81	81	CD	_	16	dep
21	-RRB-	-rrb-	-RRB-	_	16	punct
22	.	.	.	_	14	punct

1	Intravenous	intravenous	JJ	_	2	amod
2	drug1	drug1	NN	_	9	nsubjpass
3	-LRB-	-lrb-	-LRB-	_	4	punct
4	drug2	drug2	NN	_	2	appos
5	-RRB-	-rrb-	-RRB-	_	4	punct
6	has	have	VBZ	_	9	aux
7	been	be	VBN	_	9	auxpass
8	effectively	effectively	RB	_	9	advmod
9	administered	administer	VBN	_	0	ROOT
10	in	in	IN	_	16	case
11	the	the	DT	_	16	dep
12	presence	presence	NN	_	16	dep
13	of	of	IN	_	16	case
14	other	other	JJ	_	16	amod
15	cardioactive	cardioactive	JJ	_	16	amod
16	drugs	drug	NNS	_	9	nmod
17	,	,	,	_	16	punct
18	such	such	JJ	_	20	case
19	as	as	IN	_	18	mwe
20	drug3	drug3	NN	_	16	nmod
21	,	,	,	_	20	punct
22	drug4	drug4	NN	_	20	conj
23	,	,	,	_	20	punct
24	drug5	drug5	NN	_	20	conj
25	,	,	,	_	20	punct
26	and	and	CC	_	20	cc
27	drug6	drug6	NN	_	20	conj
28	,	,	,	_	16	punct
29	without	without	IN	_	31	case
30	any	any	DT	_	31	det
31	change	change	NN	_	9	nmod
32	in	in	IN	_	36	case
33	the	the	DT	_	36	det
34	adverse	adverse	JJ	_	36	amod
35	reaction	reaction	NN	_	36	compound
36	profile	profile	NN	_	31	nmod
37	.	.	.	_	9	punct

1	drug1	drug1	NN	_	4	compound
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	use	use	NN	_	8	nsubjpass
5	may	may	MD	_	8	aux
6	be	be	VB	_	8	auxpass
7	rarely	rarely	RB	_	8	advmod
8	associated	associate	VBN	_	0	ROOT
9	with	with	IN	_	11	case
10	ventricular	ventricular	JJ	_	11	amod
11	fibrillation	fibrillation	NN	_	8	nmod
12	when	when	WRB	_	13	advmod
13	combined	combine	VBN	_	8	advcl
14	with	with	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	.	.	.	_	8	punct

1	Because	because	IN	_	4	case
2	of	of	IN	_	1	mwe
3	the	the	DT	_	4	det
4	potential	potential	NN	_	23	nmod
5	for	for	IN	_	10	case
6	additive	additive	JJ	_	10	amod
7	or	or	CC	_	6	cc
8	synergistic	synergistic	JJ	_	6	conj
9	depressant	depressant	NN	_	10	compound
10	effects	effect	NNS	_	4	nmod
11	on	on	IN	_	16	case
12	the	the	DT	_	16	det
13	SA	SA	NNP	_	16	compound
14	and	and	CC	_	13	cc
15	AV	AV	NNP	_	13	conj
16	nodes	node	NNS	_	10	nmod
17	,	,	,	_	23	punct
18	however	however	RB	_	23	advmod
19	,	,	,	_	23	punct
20	drug1	drug1	NN	_	23	nsubjpass
21	should	should	MD	_	23	aux
22	be	be	VB	_	23	auxpass
23	used	use	VBN	_	0	ROOT
24	with	with	IN	_	25	case
25	caution	caution	NN	_	23	nmod
26	in	in	IN	_	28	case
27	the	the	DT	_	28	det
28	presence	presence	NN	_	23	nmod
29	of	of	IN	_	31	case
30	these	these	DT	_	31	det
31	agents	agent	NNS	_	28	nmod
32	.	.	.	_	23	punct

1	The	the	DT	_	2	det
2	use	use	NN	_	12	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	in	in	IN	_	6	case
6	patients	patient	NNS	_	2	nmod
7	receiving	receive	VBG	_	6	acl
8	drug2	drug2	NN	_	7	dobj
9	may	may	MD	_	12	aux
10	be	be	VB	_	12	auxpass
11	rarely	rarely	RB	_	12	advmod
12	associated	associate	VBN	_	0	ROOT
13	with	with	IN	_	15	case
14	ventricular	ventricular	JJ	_	15	amod
15	fibrillation	fibrillation	NN	_	12	nmod
16	.	.	.	_	12	punct

1	The	the	DT	_	2	det
2	effects	effect	NNS	_	6	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	are	be	VBP	_	6	auxpass
6	antagonized	antagonize	VBN	_	0	ROOT
7	by	by	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	such	such	JJ	_	11	case
10	as	as	IN	_	9	mwe
11	drug3	drug3	NN	_	8	nmod
12	and	and	CC	_	11	cc
13	drug4	drug4	NN	_	11	conj
14	.	.	.	_	6	punct

1	In	in	IN	_	3	case
2	the	the	DT	_	3	det
3	presence	presence	NN	_	14	nmod
4	of	of	IN	_	6	case
5	these	these	DT	_	6	det
6	drug1	drug1	NN	_	3	nmod
7	,	,	,	_	14	punct
8	larger	larger	JJR	_	9	amod
9	doses	dose	NNS	_	14	nsubjpass
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	may	may	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	required	require	VBN	_	0	ROOT
15	or	or	CC	_	14	cc
16	drug3	drug3	NN	_	20	nsubj
17	may	may	MD	_	20	aux
18	not	not	RB	_	20	neg
19	be	be	VB	_	20	cop
20	effective	effective	JJ	_	14	conj
21	.	.	.	_	14	punct

1	drug1	drug1	NN	_	2	compound
2	effects	effect	NNS	_	4	nsubjpass
3	are	be	VBP	_	4	auxpass
4	potentiated	potentiate	VBN	_	0	ROOT
5	by	by	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	.	.	.	_	4	punct

1	Thus	thus	RB	_	9	advmod
2	,	,	,	_	9	punct
3	smaller	smaller	JJR	_	4	amod
4	doses	dose	NNS	_	9	nsubj
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	may	may	MD	_	9	aux
8	be	be	VB	_	9	cop
9	effective	effective	JJ	_	0	ROOT
10	in	in	IN	_	12	case
11	the	the	DT	_	12	det
12	presence	presence	NN	_	9	nmod
13	of	of	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	.	.	.	_	9	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	increase	increase	VB	_	4	xcomp
7	the	the	DT	_	8	det
8	degree	degree	NN	_	6	dobj
9	of	of	IN	_	11	case
10	heart	heart	NN	_	11	compound
11	block	block	NN	_	8	nmod
12	produced	produce	VBN	_	11	acl
13	by	by	IN	_	15	case
14	other	other	JJ	_	15	amod
15	agents	agent	NNS	_	12	nmod
16	.	.	.	_	4	punct

1	As	as	IN	_	7	mark
2	the	the	DT	_	4	det
3	primary	primary	JJ	_	4	amod
4	effect	effect	NN	_	7	nsubj
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	is	be	VBZ	_	23	advcl
8	to	to	TO	_	9	mark
9	decrease	decrease	VB	_	7	xcomp
10	conduction	conduction	NN	_	9	dobj
11	through	through	IN	_	14	case
12	the	the	DT	_	14	det
13	A-V	a-v	NN	_	14	compound
14	node	node	NN	_	9	nmod
15	,	,	,	_	23	punct
16	higher	higher	JJR	_	17	amod
17	degrees	degree	NNS	_	23	nsubjpass
18	of	of	IN	_	20	case
19	heart	heart	NN	_	20	compound
20	block	block	NN	_	17	nmod
21	may	may	MD	_	23	aux
22	be	be	VB	_	23	auxpass
23	produced	produce	VBN	_	0	ROOT
24	in	in	IN	_	26	case
25	the	the	DT	_	26	det
26	presence	presence	NN	_	23	nmod
27	of	of	IN	_	28	case
28	drug2	drug2	NN	_	26	nmod
29	.	.	.	_	23	punct

1	drug1	drug1	NN	_	2	nsubj
2	potentiates	potentiate	VBZ	_	0	ROOT
3	the	the	DT	_	6	det
4	muscle	muscle	NN	_	6	compound
5	relaxant	relaxant	NN	_	6	compound
6	effect	effect	NN	_	23	nsubjpass
7	of	of	IN	_	9	case
8	all	all	DT	_	9	det
9	drug2	drug2	NN	_	6	nmod
10	,	,	,	_	9	punct
11	most	most	RBS	_	12	advmod
12	notably	notably	RB	_	13	advmod
13	drug3	drug3	NN	_	9	appos
14	,	,	,	_	9	punct
15	and	and	CC	_	9	cc
16	MAC	MAC	NNP	_	9	conj
17	-LRB-	-lrb-	-LRB-	_	20	punct
18	minimum	minimum	JJ	_	20	amod
19	alveolar	alveolar	JJ	_	20	amod
20	concentration	concentration	NN	_	16	appos
21	-RRB-	-rrb-	-RRB-	_	20	punct
22	is	be	VBZ	_	23	auxpass
23	reduced	reduce	VBN	_	2	ccomp
24	by	by	IN	_	26	case
25	concomitant	concomitant	JJ	_	26	amod
26	administration	administration	NN	_	23	nmod
27	of	of	IN	_	29	case
28	N	n	NN	_	29	compound
29	2O	2o	NN	_	26	nmod
30	.	.	.	_	2	punct

1	See	see	VB	_	0	ROOT
2	CLINICAL	CLINICAL	NNP	_	3	compound
3	PHARMACOLOGY	PHARMACOLOGY	NNP	_	1	dobj
4	.	.	.	_	1	punct

1	Oral	oral	JJ	_	2	amod
2	doses	dose	NNS	_	16	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	-LRB-	-lrb-	-LRB-	_	7	punct
6	10-20	10-20	CD	_	7	nummod
7	mg/kg	mg/kg	NN	_	4	appos
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	,	,	,	_	2	punct
10	via	via	IN	_	13	case
11	alcohol	alcohol	NN	_	13	compound
12	dehydrogenase	dehydrogenase	NN	_	13	compound
13	inhibition	inhibition	NN	_	2	nmod
14	,	,	,	_	2	punct
15	significantly	significantly	RB	_	16	advmod
16	reduced	reduce	VBD	_	0	ROOT
17	the	the	DT	_	18	det
18	rate	rate	NN	_	16	dobj
19	of	of	IN	_	20	case
20	elimination	elimination	NN	_	18	nmod
21	of	of	IN	_	22	case
22	drug2	drug2	NN	_	20	nmod
23	-LRB-	-lrb-	-LRB-	_	27	punct
24	by	by	IN	_	27	case
25	approximately	approximately	RB	_	26	advmod
26	40	40	CD	_	27	nummod
27	%	%	NN	_	16	dep
28	-RRB-	-rrb-	-RRB-	_	27	punct
29	given	give	VBN	_	32	case
30	to	to	TO	_	32	case
31	healthy	healthy	JJ	_	32	amod
32	volunteers	volunteer	NNS	_	16	advcl
33	in	in	IN	_	35	case
34	moderate	moderate	JJ	_	35	amod
35	doses	dose	NNS	_	32	nmod
36	.	.	.	_	16	punct

1	Similarly	similarly	RB	_	4	advmod
2	,	,	,	_	4	punct
3	drug1	drug1	NN	_	4	nsubj
4	decreased	decrease	VBD	_	0	ROOT
5	the	the	DT	_	6	det
6	rate	rate	NN	_	4	dobj
7	of	of	IN	_	8	case
8	elimination	elimination	NN	_	6	nmod
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	-LRB-	-lrb-	-LRB-	_	15	punct
12	by	by	IN	_	15	case
13	approximately	approximately	RB	_	14	advmod
14	50	50	CD	_	15	nummod
15	%	%	NN	_	4	nmod
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	by	by	IN	_	20	case
18	the	the	DT	_	20	det
19	same	same	JJ	_	20	amod
20	mechanism	mechanism	NN	_	4	nmod
21	.	.	.	_	4	punct

1	Reciprocal	reciprocal	JJ	_	2	amod
2	interactions	interaction	NNS	_	4	nsubj
3	may	may	MD	_	4	aux
4	occur	occur	VB	_	0	ROOT
5	with	with	IN	_	7	case
6	concomitant	concomitant	JJ	_	7	amod
7	use	use	NN	_	4	nmod
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	drugs	drug	NNS	_	9	conj
12	that	that	WDT	_	13	nsubj
13	increase	increase	VBP	_	9	acl:relcl
14	or	or	CC	_	13	cc
15	inhibit	inhibit	VBP	_	13	conj
16	the	the	DT	_	19	det
17	cytochrome	cytochrome	NN	_	19	compound
18	P450	p450	NN	_	19	compound
19	system	system	NN	_	13	dobj
20	-LRB-	-lrb-	-LRB-	_	23	punct
21	e.g.	e.g.	FW	_	23	dep
22	,	,	,	_	23	punct
23	drug2	drug2	NN	_	4	dep
24	,	,	,	_	23	punct
25	drug3	drug3	NN	_	23	conj
26	,	,	,	_	23	punct
27	drug4	drug4	NN	_	23	conj
28	,	,	,	_	23	punct
29	drug5	drug5	NN	_	23	appos
30	-RRB-	-rrb-	-RRB-	_	23	punct
31	,	,	,	_	4	punct
32	though	though	IN	_	37	mark
33	this	this	DT	_	37	nsubjpass
34	has	have	VBZ	_	37	aux
35	not	not	RB	_	37	neg
36	been	be	VBN	_	37	auxpass
37	studied	study	VBN	_	4	advcl

1	.	.	.	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	Drug	drug	NN	_	2	compound
2	Interaction	interaction	NN	_	0	ROOT
3	During	during	IN	_	4	case
4	Pregnancy	Pregnancy	NNP	_	2	nmod
5	:	:	:	_	2	punct
6	drug1	drug1	NN	_	10	nsubjpass
7	and	and	CC	_	6	cc
8	drug2	drug2	NN	_	6	conj
9	were	be	VBD	_	10	auxpass
10	studied	study	VBN	_	2	dep
11	following	follow	VBG	_	13	case
12	subcutaneous	subcutaneous	JJ	_	13	amod
13	injections	injection	NNS	_	10	nmod
14	in	in	IN	_	16	case
15	pregnant	pregnant	JJ	_	16	amod
16	mice	mouse	NNS	_	13	nmod
17	.	.	.	_	10	punct

1	drug1	drug1	NN	_	28	nsubj
2	alone	alone	RB	_	1	advmod
3	in	in	IN	_	4	case
4	doses	dose	NNS	_	1	nmod
5	up	up	RB	_	7	advmod
6	to	to	TO	_	7	dep
7	540	540	CD	_	8	nummod
8	mg/kg/day	mg/kg/day	NN	_	4	dep
9	-LRB-	-lrb-	-LRB-	_	14	punct
10	approximately	approximately	RB	_	12	advmod
11	340	340	CD	_	12	compound
12	times	time	NNS	_	14	nummod
13	the	the	DT	_	14	det
14	maximum	maximum	NN	_	8	appos
15	recommended	recommend	VBD	_	14	acl
16	daily	daily	JJ	_	18	amod
17	inhalation	inhalation	NN	_	18	compound
18	dose	dose	NN	_	15	dobj
19	in	in	IN	_	20	case
20	adults	adult	NNS	_	18	nmod
21	on	on	IN	_	24	case
22	a	a	DT	_	24	det
23	mg/m2	mg/m2	NN	_	24	compound
24	basis	basis	NN	_	15	nmod
25	-RRB-	-rrb-	-RRB-	_	14	punct
26	did	do	VBD	_	28	aux
27	not	not	RB	_	28	neg
28	cause	cause	VB	_	0	ROOT
29	significant	significant	JJ	_	30	amod
30	increases	increase	NNS	_	28	dobj
31	in	in	IN	_	32	case
32	resorptions	resorption	NNS	_	30	nmod
33	or	or	CC	_	32	cc
34	major	major	JJ	_	35	amod
35	malformations	malformation	NNS	_	32	conj
36	.	.	.	_	28	punct

1	drug1	drug1	NN	_	26	nsubj
2	alone	alone	RB	_	1	advmod
3	at	at	IN	_	5	case
4	a	a	DT	_	5	det
5	dose	dose	NN	_	1	nmod
6	of	of	IN	_	8	case
7	2.7	2.7	CD	_	8	nummod
8	mg/kg/day	mg/kg/day	NN	_	5	nmod
9	-LRB-	-lrb-	-LRB-	_	14	punct
10	approximately	approximately	RB	_	12	advmod
11	7	7	CD	_	12	compound
12	times	time	NNS	_	14	nummod
13	the	the	DT	_	14	det
14	maximum	maximum	NN	_	5	appos
15	recommended	recommend	VBD	_	14	acl
16	daily	daily	JJ	_	18	amod
17	inhalation	inhalation	NN	_	18	compound
18	dose	dose	NN	_	15	dobj
19	in	in	IN	_	20	case
20	adults	adult	NNS	_	18	nmod
21	on	on	IN	_	24	case
22	a	a	DT	_	24	det
23	mg/m2	mg/m2	NN	_	24	compound
24	basis	basis	NN	_	15	nmod
25	-RRB-	-rrb-	-RRB-	_	14	punct
26	increased	increase	VBD	_	0	ROOT
27	both	both	DT	_	28	cc:preconj
28	resorptions	resorption	NNS	_	26	dobj
29	and	and	CC	_	28	cc
30	malformations	malformation	NNS	_	28	conj
31	.	.	.	_	26	punct

1	The	the	DT	_	2	det
2	addition	addition	NN	_	47	nsubj
3	of	of	IN	_	5	case
4	540	540	CD	_	5	nummod
5	mg/kg/day	mg/kg/day	NN	_	2	nmod
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	-LRB-	-lrb-	-LRB-	_	13	punct
9	approximately	approximately	RB	_	11	advmod
10	340	340	CD	_	11	compound
11	times	time	NNS	_	13	nummod
12	the	the	DT	_	13	det
13	maximum	maximum	NN	_	5	dep
14	recommended	recommend	VBD	_	13	acl
15	daily	daily	JJ	_	17	amod
16	inhalation	inhalation	NN	_	17	compound
17	dose	dose	NN	_	14	dobj
18	in	in	IN	_	19	case
19	adults	adult	NNS	_	17	nmod
20	on	on	IN	_	23	case
21	a	a	DT	_	23	det
22	mg/m2	mg/m2	NN	_	23	compound
23	basis	basis	NN	_	14	nmod
24	-RRB-	-rrb-	-RRB-	_	13	punct
25	to	to	TO	_	27	case
26	2.7	2.7	CD	_	27	nummod
27	mg/kg/day	mg/kg/day	NN	_	2	nmod
28	of	of	IN	_	29	case
29	drug2	drug2	NN	_	27	nmod
30	-LRB-	-lrb-	-LRB-	_	35	punct
31	approximately	approximately	RB	_	33	advmod
32	7	7	CD	_	33	compound
33	times	time	NNS	_	35	nummod
34	the	the	DT	_	35	det
35	maximum	maximum	NN	_	27	appos
36	recommended	recommend	VBD	_	35	acl
37	daily	daily	JJ	_	39	amod
38	inhalation	inhalation	NN	_	39	compound
39	dose	dose	NN	_	36	dobj
40	in	in	IN	_	41	case
41	adults	adult	NNS	_	39	nmod
42	on	on	IN	_	45	case
43	a	a	DT	_	45	det
44	mg/m2	mg/m2	NN	_	45	compound
45	basis	basis	NN	_	36	nmod
46	-RRB-	-rrb-	-RRB-	_	35	punct
47	appears	appear	VBZ	_	0	ROOT
48	to	to	TO	_	50	mark
49	have	have	VB	_	50	aux
50	increased	increase	VBN	_	47	xcomp
51	the	the	DT	_	52	det
52	incidence	incidence	NN	_	50	dobj
53	of	of	IN	_	55	case
54	both	both	DT	_	55	cc:preconj
55	resorptions	resorption	NNS	_	52	nmod
56	and	and	CC	_	55	cc
57	malformations	malformation	NNS	_	55	conj
58	.	.	.	_	47	punct

1	LABORATORY	laboratory	NN	_	2	compound
2	TEST	test	NN	_	3	nsubj
3	FINDINGS	finding	VBZ	_	0	ROOT
4	Asymptomatic	asymptomatic	JJ	_	7	amod
5	,	,	,	_	7	punct
6	transitory	transitory	JJ	_	7	amod
7	changes	change	NNS	_	13	nsubjpass
8	in	in	IN	_	10	case
9	serum	serum	NN	_	10	compound
10	iron	iron	NN	_	7	nmod
11	have	have	VBP	_	13	aux
12	been	be	VBN	_	13	auxpass
13	observed	observe	VBN	_	3	ccomp
14	.	.	.	_	3	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	significance	significance	NN	_	5	nsubj
4	is	be	VBZ	_	5	cop
5	unknown	unknown	JJ	_	0	ROOT
6	.	.	.	_	5	punct

1	drug1	drug1	NN	_	2	nsubj
2	interferes	interfere	VBZ	_	0	ROOT
3	with	with	IN	_	6	case
4	serum	serum	NN	_	6	compound
5	calcium	calcium	NN	_	6	compound
6	measurements	measurement	NNS	_	2	nmod
7	with	with	IN	_	13	case
8	some	some	DT	_	13	det
9	colorimetric	colorimetric	JJ	_	13	amod
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	complexometric	complexometric	JJ	_	9	dep
12	-RRB-	-rrb-	-RRB-	_	11	punct
13	methods	method	NNS	_	6	nmod
14	commonly	commonly	RB	_	15	advmod
15	used	use	VBN	_	13	acl
16	in	in	IN	_	17	case
17	hospitals	hospital	NNS	_	15	nmod
18	,	,	,	_	2	punct
19	resulting	result	VBG	_	2	advcl
20	in	in	IN	_	23	case
21	serum	serum	NN	_	23	compound
22	calcium	calcium	NN	_	23	compound
23	concentrations	concentration	NNS	_	19	nmod
24	lower	lower	JJR	_	23	amod
25	than	than	IN	_	28	case
26	the	the	DT	_	28	det
27	true	true	JJ	_	28	amod
28	values	value	NNS	_	24	nmod
29	.	.	.	_	2	punct

1	Thus	thus	RB	_	5	advmod
2	,	,	,	_	5	punct
3	it	it	PRP	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	recommended	recommend	VBN	_	0	ROOT
6	not	not	RB	_	8	neg
7	to	to	TO	_	8	mark
8	use	use	VB	_	5	xcomp
9	such	such	JJ	_	10	amod
10	methods	method	NNS	_	8	dobj
11	for	for	IN	_	13	case
12	12-24	12-24	CD	_	13	nummod
13	hours	hour	NNS	_	8	nmod
14	after	after	IN	_	15	case
15	administration	administration	NN	_	8	nmod
16	of	of	IN	_	17	case
17	drug1	drug1	NN	_	15	nmod
18	.	.	.	_	5	punct

1	If	if	IN	_	5	mark
2	such	such	JJ	_	3	amod
3	measurements	measurement	NNS	_	5	nsubj
4	are	be	VBP	_	5	cop
5	necessary	necessary	JJ	_	13	advcl
6	,	,	,	_	13	punct
7	the	the	DT	_	8	det
8	use	use	NN	_	13	nsubjpass
9	of	of	IN	_	11	case
10	other	other	JJ	_	11	amod
11	methods	method	NNS	_	8	nmod
12	is	be	VBZ	_	13	auxpass
13	recommended	recommend	VBN	_	0	ROOT
14	.	.	.	_	13	punct

1	All	all	DT	_	2	det
2	patients	patient	NNS	_	9	nsubj
3	in	in	IN	_	4	case
4	whom	whom	WP	_	8	nmod
5	this	this	DT	_	6	det
6	effect	effect	NN	_	8	nsubjpass
7	was	be	VBD	_	8	auxpass
8	observed	observe	VBN	_	2	acl:relcl
9	remained	remain	VBD	_	0	ROOT
10	asymptomatic	asymptomatic	JJ	_	9	xcomp
11	.	.	.	_	9	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	increase	increase	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	ototoxic	ototoxic	JJ	_	6	amod
6	potential	potential	NN	_	3	dobj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	,	,	,	_	6	punct
10	especially	especially	RB	_	13	advmod
11	in	in	IN	_	13	case
12	the	the	DT	_	13	det
13	presence	presence	NN	_	6	nmod
14	of	of	IN	_	17	case
15	impaired	impaired	JJ	_	17	amod
16	renal	renal	JJ	_	17	amod
17	function	function	NN	_	13	nmod
18	.	.	.	_	3	punct

1	Except	except	IN	_	4	case
2	in	in	IN	_	4	case
3	life-threatening	life-threatening	JJ	_	4	amod
4	situations	situation	NNS	_	6	nmod
5	,	,	,	_	6	punct
6	avoid	avoid	VB	_	0	ROOT
7	this	this	DT	_	8	det
8	combination	combination	NN	_	6	dobj
9	.	.	.	_	6	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	should	should	MD	_	5	aux
3	not	not	RB	_	5	neg
4	be	be	VB	_	5	auxpass
5	used	use	VBN	_	0	ROOT
6	concomitantly	concomitantly	RB	_	5	advmod
7	with	with	IN	_	8	case
8	drug2	drug2	NN	_	5	nmod
9	because	because	IN	_	12	case
10	of	of	IN	_	9	mwe
11	the	the	DT	_	12	det
12	possibility	possibility	NN	_	5	nmod
13	of	of	IN	_	14	case
14	ototoxicity	ototoxicity	NN	_	12	nmod
15	.	.	.	_	5	punct

1	Patients	patient	NNS	_	17	nsubj
2	receiving	receive	VBG	_	1	acl
3	high	high	JJ	_	4	amod
4	doses	dose	NNS	_	2	dobj
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	concomitantly	concomitantly	RB	_	9	advmod
8	with	with	IN	_	9	case
9	drug2	drug2	NN	_	1	nmod
10	,	,	,	_	9	punct
11	as	as	IN	_	14	case
12	in	in	IN	_	14	case
13	rheumatic	rheumatic	JJ	_	14	amod
14	disease	disease	NN	_	9	nmod
15	,	,	,	_	9	punct
16	may	may	MD	_	17	aux
17	experience	experience	VB	_	0	ROOT
18	drug3	drug3	NN	_	19	compound
19	toxicity	toxicity	NN	_	17	dobj
20	at	at	IN	_	22	case
21	lower	lower	JJR	_	22	amod
22	doses	dose	NNS	_	17	nmod
23	because	because	IN	_	28	case
24	of	of	IN	_	23	mwe
25	competitive	competitive	JJ	_	28	amod
26	renal	renal	JJ	_	28	amod
27	excretory	excretory	NN	_	28	compound
28	sites	site	NNS	_	17	nmod
29	.	.	.	_	17	punct

1	drug1	drug1	NN	_	2	nsubj
2	has	have	VBZ	_	0	ROOT
3	a	a	DT	_	4	det
4	tendency	tendency	NN	_	2	dobj
5	to	to	TO	_	6	mark
6	antagonize	antagonize	VB	_	4	acl
7	the	the	DT	_	11	det
8	skeletal	skeletal	JJ	_	11	amod
9	muscle	muscle	NN	_	11	compound
10	relaxing	relaxing	NN	_	11	compound
11	effect	effect	NN	_	6	dobj
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	and	and	CC	_	2	cc
15	may	may	MD	_	16	aux
16	potentiate	potentiate	VB	_	2	conj
17	the	the	DT	_	18	det
18	action	action	NN	_	16	dobj
19	of	of	IN	_	20	case
20	drug3	drug3	NN	_	18	nmod
21	.	.	.	_	2	punct

1	drug1	drug1	NN	_	6	nsubjpass
2	generally	generally	RB	_	6	advmod
3	should	should	MD	_	6	aux
4	not	not	RB	_	6	neg
5	be	be	VB	_	6	auxpass
6	given	give	VBN	_	0	ROOT
7	with	with	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	because	because	IN	_	11	mark
10	they	they	PRP	_	11	nsubj
11	reduce	reduce	VBP	_	6	advcl
12	drug3	drug3	NN	_	15	compound
13	s	s	NNS	_	15	compound
14	renal	renal	JJ	_	15	amod
15	clearance	clearance	NN	_	11	dobj
16	and	and	CC	_	11	cc
17	add	add	VB	_	11	conj
18	a	a	DT	_	20	det
19	high	high	JJ	_	20	amod
20	risk	risk	NN	_	17	dobj
21	of	of	IN	_	23	case
22	drug4	drug4	NN	_	23	compound
23	toxicity	toxicity	NN	_	20	nmod
24	.	.	.	_	6	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	add	add	VB	_	0	ROOT
4	to	to	TO	_	9	case
5	or	or	CC	_	4	cc
6	potentiate	potentiate	VB	_	4	conj
7	the	the	DT	_	9	det
8	therapeutic	therapeutic	JJ	_	9	amod
9	effect	effect	NN	_	3	nmod
10	of	of	IN	_	12	case
11	other	other	JJ	_	12	amod
12	drug2	drug2	NN	_	9	nmod
13	.	.	.	_	3	punct

1	Potentiation	potentiation	NN	_	2	nsubj
2	occurs	occur	VBZ	_	0	ROOT
3	with	with	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	or	or	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	.	.	.	_	2	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	decrease	decrease	VB	_	0	ROOT
4	arterial	arterial	JJ	_	5	amod
5	responsiveness	responsiveness	NN	_	3	dobj
6	to	to	TO	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	.	.	.	_	3	punct

1	However	however	RB	_	7	advmod
2	,	,	,	_	7	punct
3	drug1	drug1	NN	_	7	nsubjpass
4	may	may	MD	_	7	aux
5	still	still	RB	_	7	advmod
6	be	be	VB	_	7	auxpass
7	used	use	VBN	_	0	ROOT
8	effectively	effectively	RB	_	7	advmod
9	.	.	.	_	7	punct

1	Tablets	tablet	NNS	_	3	compound
2	Simultaneous	simultaneous	JJ	_	3	amod
3	administration	administration	NN	_	10	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	8	compound
8	tablets	tablet	NNS	_	5	conj
9	may	may	MD	_	10	aux
10	reduce	reduce	VB	_	0	ROOT
11	the	the	DT	_	15	det
12	natriuretic	natriuretic	JJ	_	15	amod
13	and	and	CC	_	12	cc
14	antihypertensive	antihypertensive	JJ	_	12	conj
15	effects	effect	NNS	_	10	dobj
16	of	of	IN	_	17	case
17	drug3	drug3	NN	_	15	nmod
18	.	.	.	_	10	punct

1	Patients	patient	NNS	_	7	nsubjpass
2	receiving	receive	VBG	_	1	acl
3	both	both	CC	_	4	det
4	drugs	drug	NNS	_	2	dobj
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	observed	observe	VBN	_	0	ROOT
8	closely	closely	RB	_	7	advmod
9	to	to	TO	_	10	mark
10	determine	determine	VB	_	7	xcomp
11	if	if	IN	_	21	mark
12	the	the	DT	_	17	det
13	desired	desire	VBN	_	17	amod
14	diuretic	diuretic	JJ	_	17	amod
15	and/or	and/or	CC	_	14	cc
16	antihypertensive	antihypertensive	JJ	_	14	conj
17	effect	effect	NN	_	21	nsubjpass
18	of	of	IN	_	19	case
19	drug1	drug1	NN	_	17	nmod
20	is	be	VBZ	_	21	auxpass
21	achieved	achieve	VBN	_	10	advcl
22	.	.	.	_	7	punct

1	The	the	DT	_	2	det
2	intake	intake	NN	_	9	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	separated	separate	VBN	_	0	ROOT
10	by	by	IN	_	14	case
11	at	at	IN	_	12	case
12	least	least	JJS	_	13	nmod:npmod
13	two	two	CD	_	14	nummod
14	hours	hour	NNS	_	9	nmod
15	.	.	.	_	9	punct

1	Tablets	tablet	NNS	_	13	nsubj
2	,	,	,	_	1	punct
3	Injection	injection	NN	_	1	conj
4	,	,	,	_	1	punct
5	and	and	CC	_	1	cc
6	Oral	Oral	NNP	_	9	compound
7	Solution	solution	NN	_	9	compound
8	One	one	CD	_	9	nummod
9	study	study	NN	_	1	conj
10	in	in	IN	_	12	case
11	six	six	CD	_	12	nummod
12	subjects	subject	NNS	_	9	nmod
13	demonstrated	demonstrate	VBD	_	0	ROOT
14	that	that	IN	_	22	mark
15	the	the	DT	_	16	det
16	combination	combination	NN	_	22	nsubj
17	of	of	IN	_	18	case
18	drug1	drug1	NN	_	16	nmod
19	and	and	CC	_	18	cc
20	drug2	drug2	NN	_	18	conj
21	temporarily	temporarily	RB	_	22	advmod
22	reduced	reduce	VBD	_	13	ccomp
23	creatinine	creatinine	NN	_	24	compound
24	clearance	clearance	NN	_	22	dobj
25	in	in	IN	_	26	case
26	patients	patient	NNS	_	22	nmod
27	with	with	IN	_	30	case
28	chronic	chronic	JJ	_	30	amod
29	renal	renal	JJ	_	30	amod
30	insufficiency	insufficiency	NN	_	26	nmod
31	.	.	.	_	13	punct

1	There	there	EX	_	2	expl
2	are	be	VBP	_	0	ROOT
3	case	case	NN	_	4	compound
4	reports	report	NNS	_	2	nsubj
5	of	of	IN	_	6	case
6	patients	patient	NNS	_	4	nmod
7	who	who	WP	_	8	nsubj
8	developed	develop	VBD	_	6	acl:relcl
9	increased	increase	VBN	_	10	amod
10	BUN	bun	NN	_	8	dobj
11	,	,	,	_	10	punct
12	serum	serum	NN	_	13	compound
13	creatinine	creatinine	NN	_	10	conj
14	and	and	CC	_	10	cc
15	serum	serum	NN	_	17	compound
16	potassium	potassium	NN	_	17	compound
17	levels	level	NNS	_	10	conj
18	,	,	,	_	4	punct
19	and	and	CC	_	4	cc
20	weight	weight	NN	_	21	compound
21	gain	gain	NN	_	4	conj
22	when	when	WRB	_	25	advmod
23	drug1	drug1	NN	_	25	nsubjpass
24	was	be	VBD	_	25	auxpass
25	used	use	VBN	_	21	acl:relcl
26	in	in	IN	_	27	case
27	conjunction	conjunction	NN	_	25	nmod
28	with	with	IN	_	29	case
29	drug2	drug2	NN	_	27	nmod
30	.	.	.	_	2	punct

1	Literature	literature	NN	_	2	compound
2	reports	report	NNS	_	3	nsubj
3	indicate	indicate	VBP	_	0	ROOT
4	that	that	IN	_	9	mark
5	coadministration	coadministration	NN	_	9	nsubj
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	may	may	MD	_	9	aux
9	reduce	reduce	VB	_	3	ccomp
10	the	the	DT	_	14	det
11	natriuretic	natriuretic	JJ	_	14	amod
12	and	and	CC	_	11	cc
13	antihypertensive	antihypertensive	JJ	_	11	conj
14	effects	effect	NNS	_	9	dobj
15	of	of	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	in	in	IN	_	19	case
18	some	some	DT	_	19	det
19	patients	patient	NNS	_	14	nmod
20	by	by	IN	_	21	mark
21	inhibiting	inhibit	VBG	_	9	advcl
22	prostaglandin	prostaglandin	NN	_	23	compound
23	synthesis	synthesis	NN	_	21	dobj
24	.	.	.	_	3	punct

1	drug1	drug1	NN	_	4	nsubj
2	may	may	MD	_	4	aux
3	also	also	RB	_	4	advmod
4	affect	affect	VB	_	0	ROOT
5	plasma	plasma	NN	_	7	compound
6	renin	renin	NN	_	7	compound
7	levels	level	NNS	_	4	dobj
8	,	,	,	_	7	punct
9	aldosterone	aldosterone	NN	_	10	compound
10	excretion	excretion	NN	_	7	conj
11	,	,	,	_	7	punct
12	and	and	CC	_	7	cc
13	renin	renin	NN	_	15	compound
14	profile	profile	NN	_	15	compound
15	evaluation	evaluation	NN	_	7	conj
16	.	.	.	_	4	punct

1	Patients	patient	NNS	_	9	nsubjpass
2	receiving	receive	VBG	_	1	acl
3	both	both	CC	_	4	cc:preconj
4	drug1	drug1	NN	_	2	dobj
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	observed	observe	VBN	_	0	ROOT
10	closely	closely	RB	_	9	advmod
11	to	to	TO	_	12	mark
12	determine	determine	VB	_	9	xcomp
13	if	if	IN	_	23	mark
14	the	the	DT	_	19	det
15	desired	desire	VBN	_	19	amod
16	diuretic	diuretic	JJ	_	19	amod
17	and/or	and/or	CC	_	16	cc
18	antihypertensive	antihypertensive	JJ	_	16	conj
19	effect	effect	NN	_	23	nsubjpass
20	of	of	IN	_	21	case
21	drug3	drug3	NN	_	19	nmod
22	is	be	VBZ	_	23	auxpass
23	achieved	achieve	VBN	_	12	advcl
24	.	.	.	_	9	punct

1	After	after	IN	_	3	case
2	multiple	multiple	JJ	_	3	amod
3	dosing	dosing	NN	_	0	ROOT
4	,	,	,	_	3	punct
5	drug1	drug1	NN	_	16	compound
6	-LRB-	-lrb-	-LRB-	_	10	punct
7	drug2	drug2	NN	_	10	compound
8	30	30	CD	_	10	nummod
9	mcg	mcg	NN	_	10	compound
10	IM	im	NN	_	5	dep
11	once	once	RB	_	12	advmod
12	weekly	weekly	JJ	_	10	amod
13	-RRB-	-rrb-	-RRB-	_	10	punct
14	reduced	reduce	VBN	_	16	amod
15	drug3	drug3	NN	_	16	compound
16	clearance	clearance	NN	_	4	root
17	by	by	IN	_	20	case
18	approximately	approximately	RB	_	19	advmod
19	30	30	CD	_	20	nummod
20	%	%	NN	_	16	nmod
21	.	.	.	_	16	punct

1	The	the	DT	_	2	det
2	similarity	similarity	NN	_	27	nsubj
3	of	of	IN	_	5	case
4	the	the	DT	_	5	det
5	drug1	drug1	NN	_	2	nmod
6	-	-	:	_	5	punct
7	associated	associate	VBN	_	10	amod
8	adverse	adverse	JJ	_	10	amod
9	event	event	NN	_	10	compound
10	profile	profile	NN	_	5	dep
11	between	between	IN	_	12	case
12	Study	Study	NNP	_	10	nmod
13	1	1	CD	_	12	nummod
14	-LRB-	-lrb-	-LRB-	_	17	punct
15	without	without	IN	_	17	case
16	co-administered	co-administered	JJ	_	17	amod
17	drug2	drug2	NN	_	12	nmod
18	-RRB-	-rrb-	-RRB-	_	17	punct
19	and	and	CC	_	12	cc
20	Study	study	NN	_	12	conj
21	2	2	CD	_	20	nummod
22	-LRB-	-lrb-	-LRB-	_	20	punct
23	with	with	IN	_	25	case
24	co-administered	co-administered	JJ	_	25	amod
25	drug3	drug3	NN	_	20	nmod
26	-RRB-	-rrb-	-RRB-	_	20	punct
27	indicates	indicate	VBZ	_	0	ROOT
28	that	that	IN	_	35	mark
29	this	this	DT	_	30	det
30	alteration	alteration	NN	_	35	nsubj
31	in	in	IN	_	32	case
32	clearance	clearance	NN	_	30	nmod
33	does	do	VBZ	_	35	aux
34	not	not	RB	_	35	neg
35	necessitate	necessitate	VB	_	27	ccomp
36	reduction	reduction	NN	_	35	dobj
37	of	of	IN	_	40	case
38	the	the	DT	_	40	det
39	drug4	drug4	NN	_	40	compound
40	dose	dose	NN	_	36	nmod
41	to	to	TO	_	42	mark
42	maintain	maintain	VB	_	35	advcl
43	safety	safety	NN	_	42	dobj
44	,	,	,	_	43	punct
45	General	General	NNP	_	43	appos
46	-RRB-	-rrb-	-RRB-	_	35	punct
47	.	.	.	_	27	punct

1	Results	result	NNS	_	24	nsubj
2	of	of	IN	_	3	case
3	studies	study	NNS	_	1	nmod
4	in	in	IN	_	7	case
5	multiple	multiple	JJ	_	7	amod
6	sclerosis	sclerosis	NN	_	7	compound
7	patients	patient	NNS	_	3	nmod
8	taking	take	VBG	_	7	acl
9	drug1	drug1	NN	_	8	dobj
10	and	and	CC	_	9	cc
11	concomitant	concomitant	JJ	_	12	amod
12	drug2	drug2	NN	_	9	conj
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	drug3	drug3	NN	_	7	dep
15	30	30	CD	_	14	nummod
16	mcg	mcg	NN	_	17	compound
17	IM	im	NN	_	14	dep
18	once	once	RB	_	19	advmod
19	weekly	weekly	JJ	_	14	amod
20	-RRB-	-rrb-	-RRB-	_	14	punct
21	or	or	CC	_	7	cc
22	drug4	drug4	NN	_	7	conj
23	were	be	VBD	_	24	cop
24	inconclusive	inconclusive	JJ	_	0	ROOT
25	with	with	IN	_	26	case
26	regard	regard	NN	_	24	nmod
27	to	to	TO	_	29	case
28	the	the	DT	_	29	det
29	need	need	NN	_	26	nmod
30	for	for	IN	_	32	case
31	dose	dose	NN	_	32	compound
32	adjustment	adjustment	NN	_	29	nmod
33	of	of	IN	_	35	case
34	the	the	DT	_	35	det
35	drug5	drug5	NN	_	32	nmod
36	or	or	CC	_	35	cc
37	drug6	drug6	NN	_	35	conj
38	.	.	.	_	24	punct

1	Use	use	NN	_	0	ROOT
2	with	with	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	:	:	:	_	1	punct
5	The	the	DT	_	7	det
6	principal	principal	JJ	_	7	amod
7	pathway	pathway	NN	_	13	nsubjpass
8	for	for	IN	_	9	case
9	detoxification	detoxification	NN	_	7	nmod
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	is	be	VBZ	_	13	auxpass
13	inhibited	inhibit	VBN	_	1	dep
14	by	by	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	.	.	.	_	13	punct

1	Patients	patient	NNS	_	8	nsubj
2	receiving	receive	VBG	_	1	acl
3	drug1	drug1	NN	_	2	dobj
4	and	and	CC	_	3	cc
5	drug2	drug2	NN	_	3	conj
6	concomitantly	concomitantly	RB	_	8	advmod
7	should	should	MD	_	8	aux
8	have	have	VB	_	0	ROOT
9	a	a	DT	_	11	det
10	dose	dose	NN	_	11	compound
11	reduction	reduction	NN	_	8	dobj
12	of	of	IN	_	13	case
13	drug3	drug3	NN	_	11	nmod
14	,	,	,	_	8	punct
15	to	to	TO	_	19	case
16	approximately	approximately	RB	_	19	advmod
17	1/3	1/3	CD	_	19	compound
18	to	to	TO	_	19	dep
19	1/4	1/4	CD	_	8	nmod
20	the	the	DT	_	22	det
21	usual	usual	JJ	_	22	amod
22	dose	dose	NN	_	19	dep
23	.	.	.	_	8	punct

1	Use	use	NN	_	19	nsubj
2	with	with	IN	_	4	case
3	Other	other	JJ	_	4	amod
4	Agents	agent	NNS	_	1	nmod
5	Affecting	affect	VBG	_	4	acl
6	Myelopoesis	Myelopoesis	NNP	_	5	dobj
7	:	:	:	_	6	punct
8	Drugs	drug	NNS	_	6	dep
9	which	which	WDT	_	11	nsubj
10	may	may	MD	_	11	aux
11	affect	affect	VB	_	8	acl:relcl
12	leukocyte	leukocyte	NN	_	13	compound
13	production	production	NN	_	11	dobj
14	,	,	,	_	11	punct
15	including	include	VBG	_	16	case
16	drug1	drug1	NN	_	11	nmod
17	,	,	,	_	6	punct
18	may	may	MD	_	19	aux
19	lead	lead	VB	_	0	ROOT
20	to	to	TO	_	22	case
21	exaggerated	exaggerated	JJ	_	22	amod
22	leukopenia	leukopenia	NN	_	19	nmod
23	,	,	,	_	22	punct
24	especially	especially	RB	_	28	advmod
25	in	in	IN	_	28	case
26	renal	renal	JJ	_	28	amod
27	transplant	transplant	NN	_	28	compound
28	recipients	recipient	NNS	_	22	nmod
29	.	.	.	_	19	punct

1	Use	use	NN	_	0	ROOT
2	with	with	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	:	:	:	_	1	punct
5	The	the	DT	_	6	det
6	use	use	NN	_	18	nsubjpass
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	to	to	TO	_	10	mark
10	control	control	VB	_	6	acl
11	hypertension	hypertension	NN	_	10	dobj
12	in	in	IN	_	13	case
13	patients	patient	NNS	_	11	nmod
14	on	on	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	has	have	VBZ	_	18	aux
17	been	be	VBN	_	18	auxpass
18	reported	report	VBN	_	1	dep
19	to	to	TO	_	20	mark
20	induce	induce	VB	_	18	xcomp
21	severe	severe	JJ	_	22	amod
22	leukopenia	leukopenia	NN	_	20	dobj
23	.	.	.	_	18	punct

1	Interaction	interaction	NN	_	11	nsubjpass
2	with	with	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	other	other	JJ	_	3	amod
5	than	than	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	has	have	VBZ	_	11	aux
8	not	not	RB	_	11	neg
9	been	be	VBN	_	11	auxpass
10	specifically	specifically	RB	_	11	advmod
11	studied	study	VBN	_	0	ROOT
12	;	;	:	_	11	punct

1	however	however	RB	_	7	advmod
2	,	,	,	_	7	punct
3	no	no	DT	_	5	neg
4	deleterious	deleterious	JJ	_	5	amod
5	interactions	interaction	NNS	_	7	nsubjpass
6	were	be	VBD	_	7	auxpass
7	seen	see	VBN	_	0	ROOT
8	when	when	WRB	_	11	advmod
9	drug1	drug1	NN	_	11	nsubjpass
10	was	be	VBD	_	11	auxpass
11	administered	administer	VBN	_	7	advcl
12	after	after	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	,	,	,	_	7	punct
15	inhalational	inhalational	JJ	_	16	amod
16	drug3	drug3	NN	_	14	root
17	,	,	,	_	16	punct
18	drug4	drug4	NN	_	16	conj
19	and	and	CC	_	16	cc
20	muscle	muscle	NN	_	22	compound
21	relaxant	relaxant	NN	_	22	compound
22	antagonists	antagonist	NNS	_	16	conj
23	administered	administer	VBN	_	16	acl
24	in	in	IN	_	25	case
25	conjunction	conjunction	NN	_	23	nmod
26	with	with	IN	_	27	case
27	sedation	sedation	NN	_	25	nmod
28	or	or	CC	_	27	cc
29	anesthesia	anesthesia	NN	_	27	conj
30	.	.	.	_	16	punct

1	Particular	particular	JJ	_	2	amod
2	caution	caution	NN	_	4	nsubj
3	is	be	VBZ	_	4	cop
4	necessary	necessary	JJ	_	0	ROOT
5	when	when	WRB	_	6	advmod
6	using	use	VBG	_	4	advcl
7	drug1	drug1	NN	_	6	dobj
8	in	in	IN	_	9	case
9	cases	case	NNS	_	6	nmod
10	of	of	IN	_	13	case
11	mixed	mixed	JJ	_	13	amod
12	drug	drug	NN	_	13	compound
13	overdosage	overdosage	NN	_	9	nmod
14	since	since	IN	_	37	mark
15	the	the	DT	_	17	det
16	toxic	toxic	JJ	_	17	amod
17	effects	effect	NNS	_	37	nsubj
18	-LRB-	-lrb-	-LRB-	_	21	punct
19	such	such	JJ	_	21	case
20	as	as	IN	_	19	mwe
21	convulsions	convulsion	NNS	_	17	nmod
22	and	and	CC	_	21	cc
23	cardiac	cardiac	JJ	_	24	amod
24	dysrhythmias	dysrhythmia	NNS	_	21	conj
25	-RRB-	-rrb-	-RRB-	_	21	punct
26	of	of	IN	_	28	case
27	other	other	JJ	_	28	amod
28	drugs	drug	NNS	_	21	nmod
29	taken	take	VBN	_	28	acl
30	in	in	IN	_	31	case
31	overdose	overdose	NN	_	29	nmod
32	-LRB-	-lrb-	-LRB-	_	34	punct
33	especially	especially	RB	_	34	advmod
34	drug2	drug2	NN	_	31	appos
35	-RRB-	-rrb-	-RRB-	_	34	punct
36	may	may	MD	_	37	aux
37	emerge	emerge	VB	_	6	advcl
38	with	with	IN	_	40	case
39	the	the	DT	_	40	det
40	reversal	reversal	NN	_	37	nmod
41	of	of	IN	_	44	case
42	the	the	DT	_	44	det
43	drug3	drug3	NN	_	44	compound
44	effect	effect	NN	_	40	nmod
45	by	by	IN	_	46	case
46	drug4	drug4	NN	_	44	nmod
47	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	use	use	NN	_	7	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	is	be	VBZ	_	7	auxpass
6	not	not	RB	_	7	neg
7	recommended	recommend	VBN	_	0	ROOT
8	in	in	IN	_	10	case
9	epileptic	epileptic	JJ	_	10	amod
10	patients	patient	NNS	_	7	nmod
11	who	who	WP	_	14	nsubj
12	have	have	VBP	_	14	aux
13	been	be	VBN	_	14	aux
14	receiving	receive	VBG	_	10	acl:relcl
15	benzodiazepine	benzodiazepine	NN	_	16	compound
16	treatment	treatment	NN	_	14	dobj
17	for	for	IN	_	20	case
18	a	a	DT	_	20	det
19	prolonged	prolonged	JJ	_	20	amod
20	period	period	NN	_	14	nmod
21	.	.	.	_	7	punct

1	Although	although	IN	_	3	mark
2	drug1	drug1	NN	_	3	nsubj
3	exerts	exert	VBZ	_	22	advcl
4	a	a	DT	_	8	det
5	slight	slight	JJ	_	8	amod
6	intrinsic	intrinsic	JJ	_	8	amod
7	anticonvulsant	anticonvulsant	JJ	_	8	amod
8	effect	effect	NN	_	3	dobj
9	,	,	,	_	22	punct
10	its	its	PRP$	_	12	nmod:poss
11	abrupt	abrupt	JJ	_	12	amod
12	suppression	suppression	NN	_	22	nsubj
13	of	of	IN	_	16	case
14	the	the	DT	_	16	det
15	protective	protective	JJ	_	16	amod
16	effect	effect	NN	_	12	nmod
17	of	of	IN	_	20	case
18	a	a	DT	_	20	det
19	drug2	drug2	NN	_	20	compound
20	agonist	agonist	NN	_	16	nmod
21	can	can	MD	_	22	aux
22	give	give	VB	_	0	ROOT
23	rise	rise	VB	_	22	dobj
24	to	to	TO	_	25	case
25	convulsions	convulsion	NNS	_	23	nmod
26	in	in	IN	_	28	case
27	epileptic	epileptic	JJ	_	28	amod
28	patients	patient	NNS	_	23	nmod
29	.	.	.	_	22	punct

1	drug1	drug1	NN	_	2	nsubj
2	blocks	block	VBZ	_	0	ROOT
3	the	the	DT	_	5	det
4	central	central	JJ	_	5	amod
5	effects	effect	NNS	_	2	dobj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	by	by	IN	_	10	case
9	competitive	competitive	JJ	_	10	amod
10	interaction	interaction	NN	_	2	nmod
11	at	at	IN	_	14	case
12	the	the	DT	_	14	det
13	receptor	receptor	NN	_	14	compound
14	level	level	NN	_	10	nmod
15	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	effects	effect	NNS	_	20	nsubjpass
3	of	of	IN	_	5	case
4	nonbenzodiazepine	nonbenzodiazepine	JJ	_	5	amod
5	agonists	agonist	NNS	_	2	nmod
6	at	at	IN	_	8	case
7	benzodiazepine	benzodiazepine	NN	_	8	compound
8	receptors	receptor	NNS	_	2	nmod
9	,	,	,	_	8	punct
10	such	such	JJ	_	12	case
11	as	as	IN	_	10	mwe
12	drug1	drug1	NN	_	8	nmod
13	,	,	,	_	12	punct
14	triazolopyridazines	triazolopyridazine	NNS	_	12	conj
15	and	and	CC	_	12	cc
16	others	other	NNS	_	12	conj
17	,	,	,	_	8	punct
18	are	be	VBP	_	20	auxpass
19	also	also	RB	_	20	advmod
20	blocked	block	VBN	_	0	ROOT
21	by	by	IN	_	22	case
22	drug2	drug2	NN	_	20	nmod
23	.	.	.	_	20	punct

1	The	the	DT	_	2	det
2	pharmacokinetics	pharmacokinetic	NNS	_	6	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	are	be	VBP	_	6	cop
6	unaltered	unaltered	JJ	_	0	ROOT
7	in	in	IN	_	9	case
8	the	the	DT	_	9	det
9	presence	presence	NN	_	6	nmod
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	vice	vice	NN	_	11	conj
14	versa	versa	RB	_	11	advmod
15	.	.	.	_	6	punct

1	There	there	EX	_	2	expl
2	is	be	VBZ	_	0	ROOT
3	no	no	DT	_	5	neg
4	pharmacokinetic	pharmacokinetic	JJ	_	5	amod
5	interaction	interaction	NN	_	2	nsubj
6	between	between	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	.	.	.	_	2	punct

1	Use	use	NN	_	0	ROOT
2	in	in	IN	_	4	case
3	Ambulatory	ambulatory	JJ	_	4	amod
4	Patients	patient	NNS	_	1	nmod
5	The	the	DT	_	6	det
6	effects	effect	NNS	_	10	nsubj
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	may	may	MD	_	10	aux
10	wear	wear	VB	_	1	acl:relcl
11	off	off	RP	_	10	compound:prt
12	before	before	IN	_	17	mark
13	a	a	DT	_	14	det
14	drug2	drug2	NN	_	17	nsubjpass
15	is	be	VBZ	_	17	auxpass
16	completely	completely	RB	_	17	advmod
17	cleared	clear	VBN	_	10	advcl
18	from	from	IN	_	20	case
19	the	the	DT	_	20	det
20	body	body	NN	_	17	nmod
21	.	.	.	_	1	punct

1	In	in	IN	_	2	case
2	general	general	JJ	_	29	nmod
3	,	,	,	_	29	punct
4	if	if	IN	_	7	mark
5	a	a	DT	_	6	det
6	patient	patient	NN	_	7	nsubj
7	shows	show	VBZ	_	29	advcl
8	no	no	DT	_	9	neg
9	signs	sign	NNS	_	7	dobj
10	of	of	IN	_	11	case
11	sedation	sedation	NN	_	9	nmod
12	within	within	IN	_	14	case
13	2	2	CD	_	14	nummod
14	hours	hour	NNS	_	7	nmod
15	after	after	IN	_	18	case
16	a	a	DT	_	18	det
17	1-mg	1-mg	JJ	_	18	amod
18	dose	dose	NN	_	7	nmod
19	of	of	IN	_	20	case
20	drug1	drug1	NN	_	18	nmod
21	,	,	,	_	29	punct
22	serious	serious	JJ	_	23	amod
23	resedation	resedation	NN	_	29	nsubj
24	at	at	IN	_	27	case
25	a	a	DT	_	27	det
26	later	later	JJ	_	27	amod
27	time	time	NN	_	23	nmod
28	is	be	VBZ	_	29	cop
29	unlikely	unlikely	JJ	_	0	ROOT
30	.	.	.	_	29	punct

1	An	a	DT	_	3	det
2	adequate	adequate	JJ	_	3	amod
3	period	period	NN	_	8	nsubjpass
4	of	of	IN	_	5	case
5	observation	observation	NN	_	3	nmod
6	must	must	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	provided	provide	VBN	_	0	ROOT
9	for	for	IN	_	11	case
10	any	any	DT	_	11	det
11	patient	patient	NN	_	8	nmod
12	in	in	IN	_	13	case
13	whom	whom	WP	_	36	nmod
14	either	either	CC	_	15	cc:preconj
15	drug1	drug1	NN	_	36	nsubjpass
16	-LRB-	-lrb-	-LRB-	_	19	punct
17	such	such	JJ	_	19	case
18	as	as	IN	_	17	mwe
19	drug2	drug2	NN	_	15	nmod
20	-RRB-	-rrb-	-RRB-	_	19	punct
21	or	or	CC	_	15	cc
22	large	large	JJ	_	23	amod
23	doses	dose	NNS	_	15	conj
24	of	of	IN	_	25	case
25	drug3	drug3	NN	_	23	nmod
26	-LRB-	-lrb-	-LRB-	_	30	punct
27	such	such	JJ	_	30	case
28	as	as	IN	_	27	mwe
29	10	10	CD	_	30	nummod
30	mg	mg	NN	_	23	nmod
31	of	of	IN	_	32	case
32	drug4	drug4	NN	_	30	nmod
33	-RRB-	-rrb-	-RRB-	_	30	punct
34	have	have	VBP	_	36	aux
35	been	be	VBN	_	36	auxpass
36	used	use	VBN	_	11	acl:relcl
37	.	.	.	_	8	punct

1	Because	because	IN	_	5	case
2	of	of	IN	_	1	mwe
3	the	the	DT	_	5	det
4	increased	increase	VBN	_	5	amod
5	risk	risk	NN	_	24	nmod
6	of	of	IN	_	8	case
7	adverse	adverse	JJ	_	8	amod
8	reactions	reaction	NNS	_	5	nmod
9	in	in	IN	_	10	case
10	patients	patient	NNS	_	8	nmod
11	who	who	WP	_	14	nsubj
12	have	have	VBP	_	14	aux
13	been	be	VBN	_	14	aux
14	taking	take	VBG	_	10	acl:relcl
15	drug1	drug1	NN	_	14	dobj
16	on	on	IN	_	19	case
17	a	a	DT	_	19	det
18	regular	regular	JJ	_	19	amod
19	basis	basis	NN	_	14	nmod
20	,	,	,	_	24	punct
21	it	it	PRP	_	24	nsubj
22	is	be	VBZ	_	24	cop
23	particularly	particularly	RB	_	24	advmod
24	important	important	JJ	_	0	ROOT
25	that	that	IN	_	39	mark
26	physicians	physician	NNS	_	28	compound
27	query	query	NN	_	28	compound
28	patients	patient	NNS	_	39	nsubj
29	or	or	CC	_	28	cc
30	their	they	PRP$	_	31	nmod:poss
31	guardians	guardian	NNS	_	28	conj
32	carefully	carefully	RB	_	34	advmod
33	about	about	IN	_	34	case
34	drug2	drug2	NN	_	28	nmod
35	,	,	,	_	34	punct
36	drug3	drug3	NN	_	34	conj
37	and	and	CC	_	34	cc
38	drug4	drug4	NN	_	34	conj
39	use	use	VBP	_	24	ccomp
40	as	as	IN	_	41	case
41	part	part	NN	_	39	nmod
42	of	of	IN	_	44	case
43	the	the	DT	_	44	det
44	history	history	NN	_	41	nmod
45	prior	prior	RB	_	41	advmod
46	to	to	TO	_	48	case
47	any	any	DT	_	48	det
48	procedure	procedure	NN	_	45	nmod
49	in	in	IN	_	50	case
50	which	which	WDT	_	56	nmod
51	the	the	DT	_	52	det
52	use	use	NN	_	56	nsubjpass
53	of	of	IN	_	54	case
54	drug5	drug5	NN	_	52	nmod
55	is	be	VBZ	_	56	auxpass
56	planned	plan	VBN	_	48	acl:relcl
57	.	.	.	_	24	punct

1	Substrate	substrate	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	CYP2D6	cyp2d6	NN	_	1	nmod
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	minor	minor	JJ	_	3	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	,	,	,	_	3	punct
8	3A4	3a4	NN	_	3	appos
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	major	major	JJ	_	8	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	;	;	:	_	1	punct

1	Inhibits	inhibit	VBZ	_	0	ROOT
2	CYP2D6	cyp2d6	NN	_	1	dobj
3	-LRB-	-lrb-	-LRB-	_	4	punct
4	weak	weak	JJ	_	2	dep
5	-RRB-	-rrb-	-RRB-	_	4	punct
6	.	.	.	_	1	punct

1	Increased	increase	VBN	_	2	amod
2	toxicity	toxicity	NN	_	0	ROOT
3	-LRB-	-lrb-	-LRB-	_	5	punct
4	CNS	cns	NN	_	5	compound
5	depression	depression	NN	_	2	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	:	:	:	_	2	punct
8	drug1	drug1	NN	_	2	dep
9	,	,	,	_	8	punct
10	drug2	drug2	NN	_	8	conj
11	,	,	,	_	8	punct
12	drug3	drug3	NN	_	8	conj
13	,	,	,	_	8	punct
14	drug4	drug4	NN	_	8	conj
15	.	.	.	_	2	punct

1	CYP3A4	cyp3a4	NN	_	2	compound
2	inhibitors	inhibitor	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	May	May	NNP	_	5	nsubj
5	increase	increase	VB	_	2	dep
6	the	the	DT	_	7	det
7	levels/effects	levels/effects	NNS	_	5	dobj
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	.	.	.	_	2	punct

1	Example	example	NN	_	2	compound
2	inhibitors	inhibitor	NNS	_	3	nsubj
3	include	include	VBP	_	0	ROOT
4	drug1	drug1	NN	_	3	dobj
5	,	,	,	_	4	punct
6	drug2	drug2	NN	_	4	conj
7	,	,	,	_	4	punct
8	drug3	drug3	NN	_	4	conj
9	,	,	,	_	4	punct
10	drug4	drug4	NN	_	4	conj
11	,	,	,	_	4	punct
12	drug5	drug5	NN	_	4	conj
13	,	,	,	_	4	punct
14	drug6	drug6	NN	_	4	conj
15	,	,	,	_	4	punct
16	drug7	drug7	NN	_	4	conj
17	,	,	,	_	4	punct
18	drug8	drug8	NN	_	4	conj
19	,	,	,	_	4	punct
20	drug9	drug9	NN	_	4	conj
21	,	,	,	_	4	punct
22	drug10	drug10	NN	_	4	conj
23	,	,	,	_	4	punct
24	drug11	drug11	NN	_	4	conj
25	,	,	,	_	4	punct
26	drug12	drug12	NN	_	4	conj
27	,	,	,	_	4	punct
28	drug13	drug13	NN	_	4	conj
29	,	,	,	_	4	punct
30	and	and	CC	_	4	cc
31	drug14	drug14	NN	_	4	conj
32	.	.	.	_	3	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	19	compound
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	drug3	drug3	NN	_	3	appos
6	,	,	,	_	5	punct
7	drug4	drug4	NN	_	5	conj
8	,	,	,	_	5	punct
9	drug5	drug5	NN	_	5	conj
10	,	,	,	_	5	punct
11	drug6	drug6	NN	_	5	conj
12	,	,	,	_	5	punct
13	fruit	fruit	NN	_	14	compound
14	juices	juice	NNS	_	5	conj
15	,	,	,	_	5	punct
16	etc.	etc.	FW	_	5	dep
17	-RRB-	-rrb-	-RRB-	_	5	punct
18	lower	lower	JJR	_	19	amod
19	absorption	absorption	NN	_	1	dep
20	of	of	IN	_	21	case
21	drug7	drug7	NN	_	19	nmod
22	.	.	.	_	1	punct

1	drug1	drug1	NN	_	9	nsubj
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	drug2	drug2	NN	_	1	appos
4	,	,	,	_	3	punct
5	drug3	drug3	NN	_	3	appos
6	,	,	,	_	3	punct
7	etc.	etc.	FW	_	3	dep
8	-RRB-	-rrb-	-RRB-	_	3	punct
9	increase	increase	VBP	_	0	ROOT
10	the	the	DT	_	11	det
11	concentration	concentration	NN	_	9	dobj
12	of	of	IN	_	15	case
13	the	the	DT	_	15	det
14	ionized	ionize	VBN	_	15	amod
15	species	species	NNS	_	11	nmod
16	of	of	IN	_	19	case
17	the	the	DT	_	19	det
18	drug4	drug4	NN	_	19	compound
19	molecule	molecule	NN	_	15	nmod
20	,	,	,	_	9	punct
21	thereby	thereby	RB	_	22	advmod
22	increasing	increase	VBG	_	9	advcl
23	urinary	urinary	JJ	_	24	amod
24	excretion	excretion	NN	_	22	dobj
25	.	.	.	_	9	punct

1	Both	both	DT	_	2	det
2	groups	group	NNS	_	5	nsubj
3	of	of	IN	_	4	case
4	agents	agent	NNS	_	2	nmod
5	lower	lower	JJR	_	0	ROOT
6	blood	blood	NN	_	7	compound
7	levels	level	NNS	_	5	dobj
8	and	and	CC	_	7	cc
9	efficacy	efficacy	NN	_	7	conj
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	7	nmod
12	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubjpass
4	are	be	VBP	_	5	auxpass
5	inhibited	inhibit	VBN	_	1	appos
6	by	by	IN	_	7	case
7	drug3	drug3	NN	_	5	nmod
8	.	.	.	_	1	punct

1	Alkalinizing	alkalinizing	JJ	_	2	amod
2	agents	agent	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	Gastrointestinal	gastrointestinal	JJ	_	6	amod
5	alkalinizing	alkalinizing	JJ	_	6	amod
6	agents	agent	NNS	_	12	nsubj
7	-LRB-	-lrb-	-LRB-	_	8	punct
8	drug1	drug1	NN	_	6	appos
9	,	,	,	_	8	punct
10	etc.	etc.	FW	_	8	dep
11	-RRB-	-rrb-	-RRB-	_	8	punct
12	increase	increase	NN	_	2	dep
13	absorption	absorption	NN	_	12	dobj
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	.	.	.	_	2	punct

1	Urinary	urinary	JJ	_	3	amod
2	alkalinizing	alkalinizing	JJ	_	3	amod
3	agents	agent	NNS	_	10	nsubj
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	drug1	drug1	NN	_	3	dep
6	,	,	,	_	5	punct
7	some	some	DT	_	8	det
8	drug2	drug2	NN	_	5	appos
9	-RRB-	-rrb-	-RRB-	_	5	punct
10	increase	increase	VBP	_	0	ROOT
11	the	the	DT	_	12	det
12	concentration	concentration	NN	_	10	dobj
13	of	of	IN	_	16	case
14	the	the	DT	_	16	det
15	non-ionized	non-ionized	JJ	_	16	amod
16	species	species	NNS	_	12	nmod
17	of	of	IN	_	20	case
18	the	the	DT	_	20	det
19	drug3	drug3	NN	_	20	compound
20	molecule	molecule	NN	_	16	nmod
21	,	,	,	_	10	punct
22	thereby	thereby	RB	_	23	advmod
23	decreasing	decrease	VBG	_	10	advcl
24	urinary	urinary	JJ	_	25	amod
25	excretion	excretion	NN	_	23	dobj
26	.	.	.	_	10	punct

1	Both	both	DT	_	2	det
2	groups	group	NNS	_	5	nsubj
3	of	of	IN	_	4	case
4	agents	agent	NNS	_	2	nmod
5	increase	increase	VBP	_	0	ROOT
6	blood	blood	NN	_	7	compound
7	levels	level	NNS	_	5	dobj
8	and	and	CC	_	5	cc
9	therefore	therefore	RB	_	10	advmod
10	potentiate	potentiate	VB	_	5	conj
11	the	the	DT	_	12	det
12	actions	action	NNS	_	10	dobj
13	of	of	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	appos
4	:	:	:	_	1	punct
5	drug3	drug3	NN	_	7	nsubj
6	may	may	MD	_	7	aux
7	enhance	enhance	VB	_	1	dep
8	the	the	DT	_	9	det
9	activity	activity	NN	_	7	dobj
10	of	of	IN	_	11	case
11	drug4	drug4	NN	_	9	nmod
12	or	or	CC	_	11	cc
13	drug5	drug5	NN	_	11	conj
14	;	;	:	_	7	punct

1	drug1	drug1	NN	_	0	ROOT
2	with	with	IN	_	3	case
3	drug2	drug2	NN	_	1	nmod
4	or	or	CC	_	3	cc
5	drug3	drug3	NN	_	3	conj
6	and	and	CC	_	3	cc
7	possibly	possibly	RB	_	10	advmod
8	other	other	JJ	_	10	amod
9	drug4	drug4	NN	_	10	compound
10	cause	cause	NN	_	3	conj
11	striking	striking	JJ	_	14	amod
12	and	and	CC	_	11	cc
13	sustained	sustained	JJ	_	11	conj
14	increases	increase	NNS	_	10	dobj
15	in	in	IN	_	17	case
16	the	the	DT	_	17	det
17	concentration	concentration	NN	_	14	nmod
18	of	of	IN	_	19	case
19	drug5	drug5	NN	_	17	nmod
20	in	in	IN	_	22	case
21	the	the	DT	_	22	det
22	brain	brain	NN	_	17	nmod
23	;	;	:	_	1	punct

1	cardiovascular	cardiovascular	JJ	_	2	amod
2	effects	effect	NNS	_	5	nsubjpass
3	can	can	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	potentiated	potentiate	VBN	_	0	ROOT
6	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	1	dep
4	,	,	,	_	3	punct
5	as	as	RB	_	3	cc
6	well	well	RB	_	5	mwe
7	as	as	IN	_	5	mwe
8	a	a	DT	_	9	det
9	metabolite	metabolite	NN	_	3	conj
10	of	of	IN	_	11	case
11	drug3	drug3	NN	_	9	nmod
12	,	,	,	_	3	punct
13	slow	slow	JJ	_	15	amod
14	drug4	drug4	NN	_	15	compound
15	metabolism	metabolism	NN	_	3	appos
16	.	.	.	_	1	punct

1	This	this	DT	_	0	ROOT
2	slowing	slow	VBG	_	1	acl
3	potentiates	potentiate	VBZ	_	2	dobj
4	drug1	drug1	NN	_	3	dobj
5	,	,	,	_	3	punct
6	increasing	increase	VBG	_	3	advcl
7	their	they	PRP$	_	8	nmod:poss
8	effect	effect	NN	_	6	dobj
9	on	on	IN	_	11	case
10	the	the	DT	_	11	det
11	release	release	NN	_	8	nmod
12	of	of	IN	_	13	case
13	norepinephrine	norepinephrine	NN	_	11	nmod
14	and	and	CC	_	13	cc
15	other	other	JJ	_	16	amod
16	monoamines	monoamine	NNS	_	13	conj
17	from	from	IN	_	20	case
18	adrenergic	adrenergic	JJ	_	20	amod
19	nerve	nerve	NN	_	20	compound
20	endings	ending	NNS	_	11	nmod
21	;	;	:	_	1	punct

1	this	this	DT	_	3	nsubj
2	can	can	MD	_	3	aux
3	cause	cause	VB	_	0	ROOT
4	headaches	headache	NNS	_	3	dobj
5	and	and	CC	_	4	cc
6	other	other	JJ	_	7	amod
7	signs	sign	NNS	_	4	conj
8	of	of	IN	_	10	case
9	hypertensive	hypertensive	JJ	_	10	amod
10	crisis	crisis	NN	_	7	nmod
11	.	.	.	_	3	punct

1	A	a	DT	_	2	det
2	variety	variety	NN	_	11	nsubj
3	of	of	IN	_	6	case
4	neurological	neurological	JJ	_	6	amod
5	toxic	toxic	JJ	_	6	amod
6	effects	effect	NNS	_	2	nmod
7	and	and	CC	_	6	cc
8	malignant	malignant	JJ	_	9	amod
9	hyperpyrexia	hyperpyrexia	NN	_	6	conj
10	can	can	MD	_	11	aux
11	occur	occur	VB	_	0	ROOT
12	,	,	,	_	11	punct
13	sometimes	sometimes	RB	_	16	advmod
14	with	with	IN	_	16	case
15	fatal	fatal	JJ	_	16	amod
16	results	result	NNS	_	11	nmod
17	.	.	.	_	11	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	counteract	counteract	VB	_	1	dep
6	the	the	DT	_	8	det
7	sedative	sedative	JJ	_	8	amod
8	effect	effect	NN	_	5	dobj
9	of	of	IN	_	10	case
10	drug3	drug3	NN	_	8	nmod
11	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	antagonize	antagonize	VB	_	1	appos
6	the	the	DT	_	8	det
7	hypotensive	hypotensive	JJ	_	8	amod
8	effects	effect	NNS	_	5	dobj
9	of	of	IN	_	10	case
10	drug3	drug3	NN	_	8	nmod
11	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	nsubj
4	blocks	block	VBZ	_	1	appos
5	dopamine	dopamine	NN	_	8	compound
6	and	and	CC	_	5	cc
7	norepinephrine	norepinephrine	NN	_	5	conj
8	reuptake	reuptake	NN	_	4	dobj
9	,	,	,	_	4	punct
10	thus	thus	RB	_	11	advmod
11	inhibiting	inhibit	VBG	_	4	conj
12	the	the	DT	_	15	det
13	central	central	JJ	_	15	amod
14	stimulant	stimulant	NN	_	15	compound
15	effects	effect	NNS	_	11	dobj
16	of	of	IN	_	17	case
17	drug3	drug3	NN	_	15	nmod
18	,	,	,	_	4	punct
19	and	and	CC	_	4	cc
20	can	can	MD	_	22	aux
21	be	be	VB	_	22	auxpass
22	used	use	VBN	_	4	conj
23	to	to	TO	_	24	mark
24	treat	treat	VB	_	22	xcomp
25	drug4	drug4	NN	_	26	compound
26	poisoning	poisoning	NN	_	24	dobj
27	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	delay	delay	VB	_	1	appos
6	intestinal	intestinal	JJ	_	7	amod
7	absorption	absorption	NN	_	5	dobj
8	of	of	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	nsubj
4	blocks	block	VBZ	_	1	appos
5	dopamine	dopamine	NN	_	8	compound
6	and	and	CC	_	5	cc
7	norepinephrine	norepinephrine	NN	_	5	conj
8	reuptake	reuptake	NN	_	4	dobj
9	,	,	,	_	4	punct
10	thus	thus	RB	_	11	advmod
11	inhibiting	inhibit	VBG	_	4	advcl
12	the	the	DT	_	15	det
13	central	central	JJ	_	15	amod
14	stimulant	stimulant	NN	_	15	compound
15	effects	effect	NNS	_	11	dobj
16	of	of	IN	_	17	case
17	drug3	drug3	NN	_	15	nmod
18	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	5	det
4	stimulatory	stimulatory	JJ	_	5	amod
5	effects	effect	NNS	_	10	nsubjpass
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	may	may	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	inhibited	inhibit	VBN	_	1	appos
11	by	by	IN	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	nsubj
4	potentiate	potentiate	VB	_	1	dep
5	the	the	DT	_	7	det
6	analgesic	analgesic	JJ	_	7	amod
7	effect	effect	NN	_	4	dobj
8	of	of	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	.	.	.	_	1	punct

1	drug1	drug1	NN	_	2	compound
2	therapy	therapy	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	Urinary	urinary	JJ	_	5	amod
5	excretion	excretion	NN	_	9	nsubjpass
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	is	be	VBZ	_	9	auxpass
9	increased	increase	VBN	_	2	dep
10	,	,	,	_	9	punct
11	and	and	CC	_	9	cc
12	efficacy	efficacy	NN	_	14	nsubjpass
13	is	be	VBZ	_	14	auxpass
14	reduced	reduce	VBN	_	9	conj
15	,	,	,	_	9	punct
16	by	by	IN	_	17	case
17	drug3	drug3	NN	_	9	nmod
18	used	use	VBN	_	17	acl
19	in	in	IN	_	21	case
20	drug4	drug4	NN	_	21	compound
21	therapy	therapy	NN	_	18	nmod
22	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	nsubj
4	enhance	enhance	VBP	_	1	appos
5	the	the	DT	_	7	det
6	adrenergic	adrenergic	JJ	_	7	amod
7	effect	effect	NN	_	4	dobj
8	of	of	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	delay	delay	VB	_	1	appos
6	intestinal	intestinal	JJ	_	7	amod
7	absorption	absorption	NN	_	5	dobj
8	of	of	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	;	;	:	_	1	punct

1	co-administration	co-administration	NN	_	5	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	may	may	MD	_	5	aux
5	produce	produce	VB	_	0	ROOT
6	a	a	DT	_	9	det
7	synergistic	synergistic	JJ	_	9	amod
8	anticonvulsant	anticonvulsant	JJ	_	9	amod
9	action	action	NN	_	5	dobj
10	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	delay	delay	VB	_	1	appos
6	intestinal	intestinal	JJ	_	7	amod
7	absorption	absorption	NN	_	5	dobj
8	of	of	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	;	;	:	_	1	punct

1	co-administration	co-administration	NN	_	5	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	may	may	MD	_	5	aux
5	produce	produce	VB	_	0	ROOT
6	a	a	DT	_	9	det
7	synergistic	synergistic	JJ	_	9	amod
8	anticonvulsant	anticonvulsant	JJ	_	9	amod
9	action	action	NN	_	5	dobj
10	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	4	case
4	cases	case	NNS	_	13	nmod
5	of	of	IN	_	7	case
6	drug2	drug2	NN	_	7	compound
7	overdosage	overdosage	NN	_	4	nmod
8	,	,	,	_	13	punct
9	drug3	drug3	NN	_	11	compound
10	CNS	cns	NN	_	11	compound
11	stimulation	stimulation	NN	_	13	nsubj
12	is	be	VBZ	_	13	cop
13	potentiated	potentiated	JJ	_	1	dep
14	and	and	CC	_	13	cc
15	fatal	fatal	JJ	_	16	amod
16	convulsions	convulsion	NNS	_	18	nsubj
17	can	can	MD	_	18	aux
18	occur	occur	VB	_	13	conj
19	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	nsubj
4	inhibit	inhibit	VBP	_	1	appos
5	the	the	DT	_	7	det
6	hypotensive	hypotensive	JJ	_	7	amod
7	effect	effect	NN	_	4	dobj
8	of	of	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	.	.	.	_	1	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	3	amod
2	Test	test	NN	_	3	compound
3	Interactions	interaction	NNS	_	0	ROOT
4	:	:	:	_	3	punct
5	drug1	drug1	NN	_	7	nsubj
6	can	can	MD	_	7	aux
7	cause	cause	VB	_	3	dep
8	a	a	DT	_	10	det
9	significant	significant	JJ	_	10	amod
10	elevation	elevation	NN	_	7	dobj
11	in	in	IN	_	14	case
12	plasma	plasma	NN	_	14	compound
13	drug2	drug2	NN	_	14	compound
14	levels	level	NNS	_	10	nmod
15	.	.	.	_	3	punct

1	This	this	DT	_	2	det
2	increase	increase	NN	_	4	nsubj
3	is	be	VBZ	_	4	cop
4	greatest	greatest	JJS	_	0	ROOT
5	in	in	IN	_	7	case
6	the	the	DT	_	7	det
7	evening	evening	NN	_	4	nmod
8	.	.	.	_	4	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	interfere	interfere	VB	_	0	ROOT
4	with	with	IN	_	7	case
5	urinary	urinary	JJ	_	7	amod
6	steroid	steroid	NN	_	7	compound
7	determinations	determination	NNS	_	3	nmod
8	.	.	.	_	3	punct

1	drug1	drug1	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	metabolized	metabolize	VBN	_	0	ROOT
4	mainly	mainly	RB	_	3	advmod
5	via	via	IN	_	10	case
6	the	the	DT	_	10	det
7	cytochrome	cytochrome	NN	_	10	compound
8	P450	p450	NN	_	10	compound
9	3A4	3a4	NN	_	10	compound
10	enzyme	enzyme	NN	_	3	nmod
11	.	.	.	_	3	punct

1	In	in	IN	_	3	case
2	some	some	DT	_	3	det
3	cases	case	NNS	_	0	ROOT
4	where	where	WRB	_	17	advmod
5	serious	serious	JJ	_	7	amod
6	ventricular	ventricular	JJ	_	7	amod
7	arrhythmias	arrhythmia	NNS	_	17	nsubj
8	,	,	,	_	7	punct
9	QT	qt	NN	_	10	compound
10	prolongation	prolongation	NN	_	7	conj
11	,	,	,	_	7	punct
12	and	and	CC	_	7	cc
13	torsades	torsade	NNS	_	15	compound
14	de	de	IN	_	15	amod
15	pointes	pointe	NNS	_	7	conj
16	have	have	VBP	_	17	aux
17	occurred	occur	VBN	_	3	acl:relcl
18	when	when	WRB	_	21	advmod
19	drug1	drug1	NN	_	21	nsubjpass
20	was	be	VBD	_	21	auxpass
21	taken	take	VBN	_	17	advcl
22	in	in	IN	_	23	case
23	conjunction	conjunction	NN	_	21	nmod
24	with	with	IN	_	25	case
25	one	one	CD	_	23	nmod
26	of	of	IN	_	31	case
27	the	the	DT	_	31	det
28	cytochrome	cytochrome	NN	_	31	compound
29	P450	p450	NN	_	31	compound
30	3A4	3a4	NN	_	31	compound
31	inhibitors	inhibitor	NNS	_	25	nmod
32	,	,	,	_	25	punct
33	elevated	elevated	JJ	_	36	amod
34	blood	blood	NN	_	36	compound
35	drug2	drug2	NN	_	36	compound
36	levels	level	NNS	_	38	nsubjpass
37	were	be	VBD	_	38	auxpass
38	noted	note	VBN	_	25	acl:relcl
39	at	at	IN	_	41	case
40	the	the	DT	_	41	det
41	time	time	NN	_	38	nmod
42	of	of	IN	_	45	case
43	the	the	DT	_	45	det
44	QT	QT	NNP	_	45	compound
45	prolongation	prolongation	NN	_	41	nmod
46	.	.	.	_	3	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	FW	_	4	compound
4	vitro	vitro	FW	_	5	advmod
5	and/or	and/or	CC	_	9	cc
6	in	in	FW	_	8	amod
7	vivo	vivo	FW	_	6	dep
8	data	datum	NNS	_	9	nsubj
9	show	show	VBP	_	1	appos
10	that	that	IN	_	18	mark
11	drug2	drug2	NN	_	18	nsubj
12	,	,	,	_	11	punct
13	drug3	drug3	NN	_	11	conj
14	,	,	,	_	11	punct
15	and	and	CC	_	11	cc
16	drug4	drug4	NN	_	11	conj
17	markedly	markedly	RB	_	18	advmod
18	inhibit	inhibit	VBP	_	9	ccomp
19	the	the	DT	_	20	det
20	metabolism	metabolism	NN	_	18	dobj
21	of	of	IN	_	22	case
22	drug5	drug5	NN	_	20	nmod
23	,	,	,	_	20	punct
24	which	which	WDT	_	26	nsubj
25	can	can	MD	_	26	aux
26	result	result	VB	_	20	acl:relcl
27	in	in	IN	_	29	case
28	an	a	DT	_	29	det
29	increase	increase	NN	_	26	nmod
30	in	in	IN	_	33	case
31	plasma	plasma	NN	_	33	compound
32	drug6	drug6	NN	_	33	compound
33	levels	level	NNS	_	29	nmod
34	and	and	CC	_	29	cc
35	prolongation	prolongation	NN	_	29	conj
36	of	of	IN	_	39	case
37	the	the	DT	_	39	det
38	QT	QT	NNP	_	39	compound
39	interval	interval	NN	_	35	nmod
40	on	on	IN	_	42	case
41	the	the	DT	_	42	det
42	ECG	ecg	NN	_	39	nmod
43	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concurrent	concurrent	JJ	_	4	amod
4	administration	administration	NN	_	17	nsubjpass
5	of	of	IN	_	7	case
6	certain	certain	JJ	_	7	amod
7	drug2	drug2	NN	_	4	nmod
8	,	,	,	_	4	punct
9	such	such	JJ	_	11	case
10	as	as	IN	_	9	mwe
11	drug3	drug3	NN	_	4	nmod
12	and	and	CC	_	11	cc
13	drug4	drug4	NN	_	11	conj
14	,	,	,	_	4	punct
15	would	would	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	expected	expect	VBN	_	1	appos
18	to	to	TO	_	19	mark
19	compromise	compromise	VB	_	17	xcomp
20	the	the	DT	_	22	det
21	beneficial	beneficial	JJ	_	22	amod
22	effects	effect	NNS	_	19	dobj
23	of	of	IN	_	24	case
24	drug5	drug5	NN	_	22	nmod
25	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	Oral	oral	JJ	_	1	appos
4	-RRB-	-rrb-	-RRB-	_	3	punct
5	:	:	:	_	1	punct
6	In	in	IN	_	7	case
7	patients	patient	NNS	_	16	nmod
8	receiving	receive	VBG	_	7	acl
9	oral	oral	JJ	_	10	amod
10	drug2	drug2	NN	_	8	dobj
11	,	,	,	_	7	punct
12	the	the	DT	_	14	det
13	coagulation	coagulation	NN	_	14	compound
14	times	time	NNS	_	16	nsubjpass
15	were	be	VBD	_	16	auxpass
16	increased	increase	VBN	_	1	dep
17	in	in	IN	_	19	case
18	some	some	DT	_	19	det
19	cases	case	NNS	_	16	nmod
20	.	.	.	_	1	punct

1	It	it	PRP	_	3	nsubj
2	is	be	VBZ	_	3	cop
3	advisable	advisable	JJ	_	0	ROOT
4	to	to	TO	_	5	mark
5	check	check	VB	_	3	xcomp
6	coagulation	coagulation	NN	_	7	compound
7	time	time	NN	_	5	dobj
8	within	within	IN	_	12	case
9	the	the	DT	_	12	det
10	first	first	JJ	_	12	amod
11	few	few	JJ	_	12	amod
12	days	day	NNS	_	5	nmod
13	after	after	IN	_	15	case
14	the	the	DT	_	15	det
15	start	start	NN	_	5	nmod
16	and	and	CC	_	15	cc
17	discontinuation	discontinuation	NN	_	15	conj
18	of	of	IN	_	20	case
19	drug1	drug1	NN	_	20	compound
20	therapy	therapy	NN	_	15	nmod
21	,	,	,	_	5	punct
22	with	with	IN	_	25	case
23	an	a	DT	_	25	det
24	appropriate	appropriate	JJ	_	25	amod
25	adjustment	adjustment	NN	_	5	nmod
26	of	of	IN	_	29	case
27	the	the	DT	_	29	det
28	drug2	drug2	NN	_	29	compound
29	dose	dose	NN	_	25	nmod
30	,	,	,	_	5	punct
31	if	if	IN	_	32	mark
32	necessary	necessary	JJ	_	5	advcl
33	.	.	.	_	3	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	FW	_	5	amod
4	vitro	vitro	FW	_	3	dep
5	data	datum	NNS	_	6	nsubj
6	indicate	indicate	VBP	_	1	appos
7	that	that	IN	_	9	mark
8	drug2	drug2	NN	_	9	nsubj
9	inhibits	inhibit	VBZ	_	6	ccomp
10	the	the	DT	_	11	det
11	metabolism	metabolism	NN	_	9	dobj
12	of	of	IN	_	13	case
13	drug3	drug3	NN	_	11	nmod
14	,	,	,	_	11	punct
15	which	which	WDT	_	17	nsubj
16	can	can	MD	_	17	aux
17	result	result	VB	_	11	acl:relcl
18	in	in	IN	_	20	case
19	an	a	DT	_	20	det
20	increase	increase	NN	_	17	nmod
21	in	in	IN	_	24	case
22	plasma	plasma	NN	_	24	compound
23	drug4	drug4	NN	_	24	compound
24	levels	level	NNS	_	20	nmod
25	and	and	CC	_	20	cc
26	prolongation	prolongation	NN	_	20	conj
27	of	of	IN	_	30	case
28	the	the	DT	_	30	det
29	QT	QT	NNP	_	30	compound
30	interval	interval	NN	_	26	nmod
31	on	on	IN	_	33	case
32	the	the	DT	_	33	det
33	ECG	ecg	NN	_	30	nmod
34	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	FW	_	4	compound
4	vitro	vitro	FW	_	5	advmod
5	and/or	and/or	CC	_	9	advmod
6	in	in	FW	_	8	amod
7	vivo	vivo	FW	_	6	dep
8	data	datum	NNS	_	9	nsubj
9	indicate	indicate	VBP	_	1	appos
10	that	that	IN	_	19	mark
11	drug2	drug2	NN	_	19	nsubj
12	,	,	,	_	11	punct
13	drug3	drug3	NN	_	11	conj
14	,	,	,	_	11	punct
15	and	and	CC	_	11	cc
16	oral	oral	JJ	_	17	amod
17	drug4	drug4	NN	_	11	conj
18	markedly	markedly	RB	_	19	advmod
19	inhibit	inhibit	VBP	_	9	ccomp
20	the	the	DT	_	21	det
21	metabolism	metabolism	NN	_	19	dobj
22	of	of	IN	_	23	case
23	drug5	drug5	NN	_	21	nmod
24	,	,	,	_	21	punct
25	which	which	WDT	_	27	nsubj
26	can	can	MD	_	27	aux
27	result	result	VB	_	21	acl:relcl
28	in	in	IN	_	30	case
29	an	a	DT	_	30	det
30	increase	increase	NN	_	27	nmod
31	in	in	IN	_	34	case
32	plasma	plasma	NN	_	34	compound
33	drug6	drug6	NN	_	34	compound
34	levels	level	NNS	_	30	nmod
35	and	and	CC	_	30	cc
36	prolongation	prolongation	NN	_	30	conj
37	of	of	IN	_	40	case
38	the	the	DT	_	40	det
39	QT	QT	NNP	_	40	compound
40	interval	interval	NN	_	36	nmod
41	on	on	IN	_	43	case
42	the	the	DT	_	43	det
43	ECG	ecg	NN	_	40	nmod
44	.	.	.	_	1	punct

1	Human	human	JJ	_	3	amod
2	pharmacokinetic	pharmacokinetic	JJ	_	3	amod
3	data	datum	NNS	_	4	nsubj
4	indicate	indicate	VBP	_	0	ROOT
5	that	that	IN	_	9	mark
6	oral	oral	JJ	_	7	amod
7	drug1	drug1	NN	_	9	nsubj
8	markedly	markedly	RB	_	9	advmod
9	inhibits	inhibit	VBZ	_	4	ccomp
10	the	the	DT	_	11	det
11	metabolism	metabolism	NN	_	9	dobj
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	,	,	,	_	9	punct
15	resulting	result	VBG	_	9	advcl
16	in	in	IN	_	20	case
17	a	a	DT	_	20	det
18	mean	mean	NN	_	20	compound
19	eight-fold	eight-fold	JJ	_	20	amod
20	increase	increase	NN	_	15	nmod
21	in	in	IN	_	22	case
22	AUC	auc	NN	_	20	nmod
23	of	of	IN	_	24	case
24	drug3	drug3	NN	_	22	nmod
25	.	.	.	_	4	punct

1	A	a	DT	_	2	det
2	study	study	NN	_	10	nsubj
3	in	in	IN	_	6	case
4	14	14	CD	_	6	nummod
5	normal	normal	JJ	_	6	amod
6	male	male	NN	_	2	nmod
7	and	and	CC	_	6	cc
8	female	female	JJ	_	9	amod
9	volunteers	volunteer	NNS	_	6	conj
10	suggests	suggest	VBZ	_	0	ROOT
11	that	that	IN	_	18	mark
12	coadministration	coadministration	NN	_	18	nsubj
13	of	of	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	and	and	CC	_	14	cc
16	drug2	drug2	NN	_	14	conj
17	can	can	MD	_	18	aux
18	result	result	VB	_	10	ccomp
19	in	in	IN	_	20	case
20	prolongation	prolongation	NN	_	18	nmod
21	of	of	IN	_	24	case
22	the	the	DT	_	24	det
23	QT	QT	NNP	_	24	compound
24	interval	interval	NN	_	20	nmod
25	on	on	IN	_	27	case
26	the	the	DT	_	27	det
27	ECG	ecg	NN	_	24	nmod
28	.	.	.	_	10	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	compound
4	coadministration	coadministration	NN	_	5	nsubj
5	leads	lead	VBZ	_	1	appos
6	to	to	TO	_	11	case
7	an	a	DT	_	11	det
8	increased	increase	VBN	_	11	amod
9	peak	peak	NN	_	11	compound
10	plasma	plasma	NN	_	11	compound
11	concentration	concentration	NN	_	5	nmod
12	and	and	CC	_	11	cc
13	AUC	auc	NN	_	11	conj
14	of	of	IN	_	15	case
15	drug3	drug3	NN	_	11	nmod
16	,	,	,	_	5	punct
17	there	there	EX	_	18	expl
18	is	be	VBZ	_	5	ccomp
19	no	no	DT	_	20	neg
20	effect	effect	NN	_	18	nsubj
21	on	on	IN	_	23	case
22	drug4	drug4	NN	_	23	compound
23	absorption	absorption	NN	_	20	nmod
24	when	when	WRB	_	27	advmod
25	it	it	PRP	_	27	nsubjpass
26	is	be	VBZ	_	27	auxpass
27	coadministered	coadminister	VBN	_	18	advcl
28	with	with	IN	_	29	case
29	drug5	drug5	NN	_	27	nmod
30	.	.	.	_	1	punct

1	The	the	DT	_	3	det
2	gastrointestinal	gastrointestinal	JJ	_	3	amod
3	absorption	absorption	NN	_	9	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	is	be	VBZ	_	9	auxpass
9	accelerated	accelerate	VBN	_	0	ROOT
10	when	when	WRB	_	13	advmod
11	they	they	PRP	_	13	nsubjpass
12	are	be	VBP	_	13	auxpass
13	coadministered	coadminister	VBN	_	9	advcl
14	with	with	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	.	.	.	_	9	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	FW	_	5	amod
4	vitro	vitro	FW	_	3	dep
5	data	datum	NNS	_	6	nsubj
6	indicate	indicate	VBP	_	1	appos
7	that	that	IN	_	12	mark
8	drug2	drug2	NN	_	12	nsubj
9	and	and	CC	_	8	cc
10	drug3	drug3	NN	_	8	conj
11	markedly	markedly	RB	_	12	advmod
12	inhibit	inhibit	VBP	_	6	ccomp
13	the	the	DT	_	14	det
14	metabolism	metabolism	NN	_	12	dobj
15	of	of	IN	_	16	case
16	drug4	drug4	NN	_	14	nmod
17	which	which	WDT	_	19	nsubj
18	can	can	MD	_	19	aux
19	result	result	VB	_	14	acl:relcl
20	in	in	IN	_	22	case
21	an	a	DT	_	22	det
22	increase	increase	NN	_	19	nmod
23	in	in	IN	_	26	case
24	plasma	plasma	NN	_	26	compound
25	drug5	drug5	NN	_	26	compound
26	levels	level	NNS	_	22	nmod
27	and	and	CC	_	22	cc
28	prolongation	prolongation	NN	_	22	conj
29	of	of	IN	_	32	case
30	the	the	DT	_	32	det
31	QT	QT	NNP	_	32	compound
32	interval	interval	NN	_	28	nmod
33	on	on	IN	_	35	case
34	the	the	DT	_	35	det
35	ECG	ecg	NN	_	32	nmod
36	.	.	.	_	1	punct

1	Other	other	JJ	_	0	ROOT
2	:	:	:	_	1	punct
3	Coadministration	coadministration	NN	_	9	nsubj
4	of	of	IN	_	6	case
5	grapefruit	grapefruit	NN	_	6	compound
6	juice	juice	NN	_	3	nmod
7	with	with	IN	_	8	case
8	drug1	drug1	NN	_	3	nmod
9	increases	increase	VBZ	_	19	csubjpass
10	the	the	DT	_	11	det
11	bioavailability	bioavailability	NN	_	9	dobj
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	and	and	CC	_	11	cc
15	concomitant	concomitant	JJ	_	16	amod
16	use	use	NN	_	11	conj
17	should	should	MD	_	19	aux
18	be	be	VB	_	19	auxpass
19	avoided	avoid	VBN	_	1	dep
20	.	.	.	_	1	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	should	should	MD	_	5	aux
3	not	not	RB	_	5	neg
4	be	be	VB	_	5	auxpass
5	used	use	VBN	_	0	ROOT
6	concomitantly	concomitantly	RB	_	5	advmod
7	with	with	IN	_	9	case
8	other	other	JJ	_	9	amod
9	drugs	drug	NNS	_	5	nmod
10	known	know	VBN	_	9	acl
11	to	to	TO	_	12	mark
12	prolong	prolong	VB	_	10	xcomp
13	the	the	DT	_	15	det
14	QT	QT	NNP	_	15	compound
15	interval	interval	NN	_	12	dobj
16	:	:	:	_	15	punct
17	certain	certain	JJ	_	18	amod
18	drug2	drug2	NN	_	15	dep
19	,	,	,	_	18	punct
20	including	include	VBG	_	21	case
21	those	those	DT	_	18	nmod
22	of	of	IN	_	24	case
23	Class	Class	NNP	_	24	compound
24	IA	IA	NNP	_	21	nmod
25	-LRB-	-lrb-	-LRB-	_	28	punct
26	such	such	JJ	_	28	case
27	as	as	IN	_	26	mwe
28	drug3	drug3	NN	_	24	dep
29	and	and	CC	_	28	cc
30	drug4	drug4	NN	_	28	conj
31	-RRB-	-rrb-	-RRB-	_	28	punct
32	and	and	CC	_	24	cc
33	Class	class	NN	_	24	conj
34	III	iii	CD	_	33	nummod
35	-LRB-	-lrb-	-LRB-	_	38	punct
36	such	such	JJ	_	38	case
37	as	as	IN	_	36	mwe
38	drug5	drug5	NN	_	33	nmod
39	-RRB-	-rrb-	-RRB-	_	38	punct
40	;	;	:	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	5	punct
3	such	such	JJ	_	5	case
4	as	as	IN	_	3	mwe
5	drug2	drug2	NN	_	1	nmod
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	;	;	:	_	1	punct

1	certain	certain	JJ	_	2	amod
2	drug1	drug1	NN	_	0	ROOT
3	-LRB-	-lrb-	-LRB-	_	6	punct
4	such	such	JJ	_	6	case
5	as	as	IN	_	4	mwe
6	drug2	drug2	NN	_	2	nmod
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	;	;	:	_	2	punct

1	certain	certain	JJ	_	2	amod
2	drug1	drug1	NN	_	0	ROOT
3	-LRB-	-lrb-	-LRB-	_	6	punct
4	such	such	JJ	_	6	case
5	as	as	IN	_	4	mwe
6	drug2	drug2	NN	_	2	nmod
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	;	;	:	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	,	,	,	_	1	punct
5	drug3	drug3	NN	_	1	conj
6	,	,	,	_	1	punct
7	and	and	CC	_	1	cc
8	drug4	drug4	NN	_	1	conj
9	.	.	.	_	1	punct

1	The	the	DT	_	3	det
2	preceding	precede	VBG	_	3	amod
3	lists	list	NNS	_	8	nsubj
4	of	of	IN	_	5	case
5	drugs	drug	NNS	_	3	nmod
6	are	be	VBP	_	8	cop
7	not	not	RB	_	8	neg
8	comprehensive	comprehensive	JJ	_	0	ROOT
9	.	.	.	_	8	punct

1	The	the	DT	_	2	det
2	acceleration	acceleration	NN	_	9	nsubj
3	of	of	IN	_	5	case
4	gastric	gastric	JJ	_	5	amod
5	emptying	emptying	NN	_	2	nmod
6	by	by	IN	_	7	case
7	drug1	drug1	NN	_	2	nmod
8	could	could	MD	_	9	aux
9	affect	affect	VB	_	0	ROOT
10	the	the	DT	_	11	det
11	rate	rate	NN	_	9	dobj
12	of	of	IN	_	13	case
13	absorption	absorption	NN	_	11	nmod
14	of	of	IN	_	16	case
15	other	other	JJ	_	16	amod
16	drugs	drug	NNS	_	13	nmod
17	.	.	.	_	9	punct

1	Patients	patient	NNS	_	16	nsubjpass
2	receiving	receive	VBG	_	1	acl
3	narrow	narrow	JJ	_	6	amod
4	therapeutic	therapeutic	JJ	_	6	amod
5	ratio	ratio	NN	_	6	compound
6	drugs	drug	NNS	_	2	dobj
7	or	or	CC	_	6	cc
8	other	other	JJ	_	9	amod
9	drugs	drug	NNS	_	6	conj
10	that	that	WDT	_	11	nsubj
11	require	require	VBP	_	6	acl:relcl
12	careful	careful	JJ	_	13	amod
13	titration	titration	NN	_	11	dobj
14	should	should	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	followed	follow	VBN	_	0	ROOT
17	closely	closely	RB	_	16	advmod
18	;	;	:	_	16	punct

1	if	if	IN	_	6	mark
2	plasma	plasma	NN	_	3	compound
3	levels	level	NNS	_	6	nsubjpass
4	are	be	VBP	_	6	aux
5	being	be	VBG	_	6	auxpass
6	monitored	monitor	VBN	_	11	advcl
7	,	,	,	_	11	punct
8	they	they	PRP	_	11	nsubjpass
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	reassessed	reassess	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	The	the	DT	_	2	det
2	risks	risk	NNS	_	15	nsubjpass
3	of	of	IN	_	4	mark
4	using	use	VBG	_	2	acl
5	drug1	drug1	NN	_	4	dobj
6	in	in	IN	_	7	case
7	combination	combination	NN	_	4	nmod
8	with	with	IN	_	10	case
9	other	other	JJ	_	10	amod
10	drugs	drug	NNS	_	7	nmod
11	have	have	VBP	_	15	aux
12	not	not	RB	_	15	neg
13	been	be	VBN	_	15	auxpass
14	systematically	systematically	RB	_	15	advmod
15	evaluated	evaluate	VBN	_	0	ROOT
16	.	.	.	_	15	punct

1	Given	give	VBN	_	5	case
2	the	the	DT	_	5	det
3	primary	primary	JJ	_	5	amod
4	CNS	cns	NN	_	5	compound
5	effects	effect	NNS	_	11	nmod
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	,	,	,	_	11	punct
9	caution	caution	NN	_	11	nsubjpass
10	is	be	VBZ	_	11	auxpass
11	advised	advise	VBN	_	0	ROOT
12	in	in	IN	_	13	mark
13	using	use	VBG	_	11	advcl
14	it	it	PRP	_	13	dobj
15	concomitantly	concomitantly	RB	_	13	advmod
16	with	with	IN	_	19	case
17	other	other	JJ	_	19	amod
18	CNS-active	cns-active	JJ	_	19	amod
19	drugs	drug	NNS	_	13	nmod
20	.	.	.	_	11	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	should	should	MD	_	5	aux
3	not	not	RB	_	5	neg
4	be	be	VB	_	5	auxpass
5	used	use	VBN	_	0	ROOT
6	with	with	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	.	.	.	_	5	punct

1	Close	close	JJ	_	2	amod
2	supervision	supervision	NN	_	9	nsubjpass
3	and	and	CC	_	2	cc
4	careful	careful	JJ	_	5	amod
5	adjustment	adjustment	NN	_	2	conj
6	of	of	IN	_	7	case
7	dosage	dosage	NN	_	2	nmod
8	are	be	VBP	_	9	auxpass
9	required	require	VBN	_	0	ROOT
10	when	when	WRB	_	13	advmod
11	drug1	drug1	NN	_	13	nsubjpass
12	is	be	VBZ	_	13	auxpass
13	administered	administer	VBN	_	9	advcl
14	with	with	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	or	or	CC	_	15	cc
17	drug3	drug3	NN	_	15	conj
18	.	.	.	_	9	punct

1	Several	several	JJ	_	2	amod
2	drug1	drug1	NN	_	5	nsubjpass
3	have	have	VBP	_	5	aux
4	been	be	VBN	_	5	auxpass
5	reported	report	VBN	_	0	ROOT
6	to	to	TO	_	7	mark
7	block	block	VB	_	5	xcomp
8	the	the	DT	_	10	det
9	pharmacologic	pharmacologic	JJ	_	10	amod
10	effects	effect	NNS	_	7	dobj
11	of	of	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	,	,	,	_	12	punct
14	drug3	drug3	NN	_	12	conj
15	,	,	,	_	12	punct
16	or	or	CC	_	12	cc
17	similar	similar	JJ	_	18	amod
18	agents	agent	NNS	_	12	conj
19	,	,	,	_	5	punct
20	and	and	CC	_	5	cc
21	such	such	PDT	_	23	det:predet
22	an	a	DT	_	23	det
23	effect	effect	NN	_	26	nsubjpass
24	may	may	MD	_	26	aux
25	be	be	VB	_	26	auxpass
26	anticipated	anticipate	VBN	_	5	conj
27	with	with	IN	_	28	case
28	drug4	drug4	NN	_	26	nmod
29	because	because	IN	_	33	case
30	of	of	IN	_	29	mwe
31	its	its	PRP$	_	33	nmod:poss
32	structural	structural	JJ	_	33	amod
33	similarity	similarity	NN	_	26	nmod
34	to	to	TO	_	36	case
35	other	other	JJ	_	36	amod
36	drug5	drug5	NN	_	33	nmod
37	.	.	.	_	5	punct

1	The	the	DT	_	3	det
2	plasma	plasma	NN	_	3	compound
3	concentration	concentration	NN	_	8	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	has	have	VBZ	_	8	aux
7	been	be	VBN	_	8	auxpass
8	reported	report	VBN	_	0	ROOT
9	to	to	TO	_	11	mark
10	be	be	VB	_	11	auxpass
11	increased	increase	VBN	_	8	xcomp
12	by	by	IN	_	15	case
13	the	the	DT	_	15	det
14	concomitant	concomitant	JJ	_	15	amod
15	administration	administration	NN	_	11	nmod
16	of	of	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	;	;	:	_	8	punct

1	plasma	plasma	NN	_	2	compound
2	levels	level	NNS	_	10	nsubjpass
3	of	of	IN	_	7	case
4	several	several	JJ	_	7	amod
5	closely	closely	RB	_	6	advmod
6	related	related	JJ	_	7	amod
7	drug1	drug1	NN	_	2	nmod
8	have	have	VBP	_	10	aux
9	been	be	VBN	_	10	auxpass
10	reported	report	VBN	_	0	ROOT
11	to	to	TO	_	13	mark
12	be	be	VB	_	13	auxpass
13	increased	increase	VBN	_	10	xcomp
14	by	by	IN	_	17	case
15	the	the	DT	_	17	det
16	concomitant	concomitant	JJ	_	17	amod
17	administration	administration	NN	_	13	nmod
18	of	of	IN	_	19	case
19	drug2	drug2	NN	_	17	nmod
20	or	or	CC	_	19	cc
21	hepatic	hepatic	JJ	_	23	amod
22	enzyme	enzyme	NN	_	23	compound
23	inhibitors	inhibitor	NNS	_	19	conj
24	-LRB-	-lrb-	-LRB-	_	27	punct
25	e.g.	e.g.	FW	_	27	dep
26	,	,	,	_	27	punct
27	drug3	drug3	NN	_	17	dep
28	,	,	,	_	27	punct
29	drug4	drug4	NN	_	27	appos
30	-RRB-	-rrb-	-RRB-	_	27	punct
31	and	and	CC	_	13	cc
32	decreased	decrease	VBN	_	13	conj
33	by	by	IN	_	36	case
34	the	the	DT	_	36	det
35	concomitant	concomitant	JJ	_	36	amod
36	administration	administration	NN	_	32	nmod
37	of	of	IN	_	40	case
38	hepatic	hepatic	JJ	_	40	amod
39	enzyme	enzyme	NN	_	40	compound
40	inducers	inducer	NNS	_	36	nmod
41	-LRB-	-lrb-	-LRB-	_	44	punct
42	e.g.	e.g.	FW	_	44	dep
43	,	,	,	_	44	punct
44	drug5	drug5	NN	_	40	dep
45	,	,	,	_	44	punct
46	drug6	drug6	NN	_	44	appos
47	-RRB-	-rrb-	-RRB-	_	44	punct
48	,	,	,	_	13	punct
49	and	and	CC	_	13	cc
50	such	such	PDT	_	52	det:predet
51	an	a	DT	_	52	det
52	effect	effect	NN	_	55	nsubjpass
53	may	may	MD	_	55	aux
54	be	be	VB	_	55	auxpass
55	anticipated	anticipate	VBN	_	13	conj
56	with	with	IN	_	57	case
57	drug7	drug7	NN	_	55	nmod
58	as	as	RB	_	55	advmod
59	well	well	RB	_	58	mwe
60	.	.	.	_	10	punct

1	Administration	administration	NN	_	6	nsubjpass
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	has	have	VBZ	_	6	aux
5	been	be	VBN	_	6	auxpass
6	reported	report	VBN	_	0	ROOT
7	to	to	TO	_	8	mark
8	increase	increase	VB	_	6	xcomp
9	the	the	DT	_	11	det
10	plasma	plasma	NN	_	11	compound
11	levels	level	NNS	_	8	dobj
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	,	,	,	_	8	punct
15	if	if	IN	_	16	mark
16	given	give	VBN	_	8	advcl
17	concomitantly	concomitantly	RB	_	16	advmod
18	.	.	.	_	6	punct

1	Drugs	drug	NNS	_	0	ROOT
2	Metabolized	metabolize	VBN	_	1	acl
3	by	by	IN	_	5	case
4	P450	p450	NN	_	5	compound
5	2D6	2d6	NN	_	2	nmod
6	:	:	:	_	1	punct
7	The	the	DT	_	9	det
8	biochemical	biochemical	JJ	_	9	amod
9	activity	activity	NN	_	23	nsubjpass
10	of	of	IN	_	12	case
11	the	the	DT	_	12	det
12	drug	drug	NN	_	9	nmod
13	metabolizing	metabolize	VBG	_	12	acl
14	isozyme	isozyme	NN	_	17	compound
15	cytochrome	cytochrome	NN	_	17	compound
16	P450	p450	NN	_	17	compound
17	2D6	2d6	NN	_	13	dobj
18	-LRB-	-lrb-	-LRB-	_	20	punct
19	debrisoquin	debrisoquin	NN	_	20	compound
20	hydroxylase	hydroxylase	NN	_	17	appos
21	-RRB-	-rrb-	-RRB-	_	20	punct
22	is	be	VBZ	_	23	auxpass
23	reduced	reduce	VBN	_	1	dep
24	in	in	IN	_	26	case
25	a	a	DT	_	26	det
26	subset	subset	NN	_	23	nmod
27	of	of	IN	_	30	case
28	the	the	DT	_	30	det
29	aucasian	aucasian	JJ	_	30	amod
30	population	population	NN	_	26	nmod
31	-LRB-	-lrb-	-LRB-	_	34	punct
32	about	about	IN	_	33	advmod
33	7	7	CD	_	34	nummod
34	%	%	NN	_	42	nsubj
35	-10	-10	CD	_	36	nummod
36	%	%	NN	_	34	dep
37	of	of	IN	_	38	case
38	Caucasians	Caucasians	NNPS	_	36	nmod
39	are	be	VBP	_	42	cop
40	so-called	so-called	JJ	_	42	amod
41	poor	poor	JJ	_	42	amod
42	metabolizers	metabolizer	NNS	_	26	acl:relcl
43	-RRB-	-rrb-	-RRB-	_	23	punct
44	;	;	:	_	1	punct

1	reliable	reliable	JJ	_	2	amod
2	estimates	estimate	NNS	_	22	nsubj
3	of	of	IN	_	5	case
4	the	the	DT	_	5	det
5	prevalence	prevalence	NN	_	2	nmod
6	of	of	IN	_	11	case
7	reduced	reduce	VBN	_	11	amod
8	P450	p450	NN	_	11	compound
9	2D6	2d6	NN	_	11	compound
10	isozyme	isozyme	NN	_	11	compound
11	activity	activity	NN	_	5	nmod
12	among	among	IN	_	18	case
13	Asian	asian	JJ	_	18	amod
14	,	,	,	_	13	punct
15	African	african	JJ	_	13	conj
16	and	and	CC	_	13	cc
17	other	other	JJ	_	13	conj
18	populations	population	NNS	_	11	nmod
19	are	be	VBP	_	22	cop
20	not	not	RB	_	22	neg
21	yet	yet	RB	_	22	advmod
22	available	available	JJ	_	0	ROOT
23	.	.	.	_	22	punct

1	Poor	Poor	NNP	_	2	compound
2	metabolizers	metabolizer	NNS	_	3	nsubj
3	have	have	VBP	_	0	ROOT
4	higher	higher	JJR	_	3	advmod
5	than	than	IN	_	6	dep
6	expected	expect	VBN	_	4	advcl
7	lasma	lasma	NN	_	8	compound
8	concentrations	concentration	NNS	_	6	dobj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	drug2	drug2	NN	_	10	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	when	when	WRB	_	15	advmod
15	given	give	VBN	_	3	advcl
16	usual	usual	JJ	_	17	amod
17	doses	dose	NNS	_	15	dobj
18	.	.	.	_	3	punct

1	Depending	depend	VBG	_	4	case
2	on	on	IN	_	4	case
3	the	the	DT	_	4	det
4	fraction	fraction	NN	_	19	nmod
5	of	of	IN	_	6	case
6	drug	drug	NN	_	4	nmod
7	metabolized	metabolize	VBN	_	6	acl
8	by	by	IN	_	10	case
9	P450	p450	NN	_	10	compound
10	2D6	2d6	NN	_	7	nmod
11	,	,	,	_	19	punct
12	the	the	DT	_	13	det
13	increase	increase	NN	_	19	nsubj
14	in	in	IN	_	16	case
15	plasma	plasma	NN	_	16	compound
16	concentration	concentration	NN	_	13	nmod
17	may	may	MD	_	19	aux
18	be	be	VB	_	19	cop
19	small	small	JJ	_	0	ROOT
20	,	,	,	_	19	punct
21	or	or	CC	_	19	cc
22	quite	quite	RB	_	23	advmod
23	large	large	JJ	_	19	conj
24	-LRB-	-lrb-	-LRB-	_	27	punct
25	8	8	CD	_	27	nummod
26	fold	fold	JJ	_	27	amod
27	increase	increase	NN	_	23	dep
28	in	in	IN	_	30	case
29	plasma	plasma	NN	_	30	compound
30	AUC	auc	NN	_	27	nmod
31	of	of	IN	_	33	case
32	the	the	DT	_	33	det
33	drug1	drug1	NN	_	30	nmod
34	-RRB-	-rrb-	-RRB-	_	27	punct
35	.	.	.	_	19	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	6	nmod
3	,	,	,	_	6	punct
4	certain	certain	JJ	_	5	amod
5	drugs	drug	NNS	_	6	nsubj
6	inhibit	inhibit	VBP	_	0	ROOT
7	the	the	DT	_	8	det
8	activity	activity	NN	_	6	dobj
9	of	of	IN	_	11	case
10	this	this	DT	_	11	det
11	isozyme	isozyme	NN	_	8	nmod
12	and	and	CC	_	6	cc
13	make	make	VB	_	6	conj
14	normal	normal	JJ	_	15	amod
15	metabolizers	metabolizer	NNS	_	16	nsubj
16	resemble	resemble	VBP	_	13	ccomp
17	poor	poor	JJ	_	18	amod
18	metabolizers	metabolizer	NNS	_	16	xcomp
19	.	.	.	_	6	punct

1	An	a	DT	_	2	det
2	individual	individual	NN	_	13	nsubj
3	who	who	WP	_	5	nsubj
4	is	be	VBZ	_	5	cop
5	stable	stable	JJ	_	2	acl:relcl
6	on	on	IN	_	9	case
7	a	a	DT	_	9	det
8	given	give	VBN	_	9	amod
9	dose	dose	NN	_	5	nmod
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	may	may	MD	_	13	aux
13	become	become	VB	_	0	ROOT
14	abruptly	abruptly	RB	_	15	advmod
15	toxic	toxic	JJ	_	13	xcomp
16	when	when	WRB	_	17	advmod
17	given	give	VBN	_	13	advcl
18	one	one	CD	_	17	dobj
19	of	of	IN	_	22	case
20	these	these	DT	_	22	det
21	inhibiting	inhibit	VBG	_	22	amod
22	drugs	drug	NNS	_	18	nmod
23	as	as	IN	_	25	case
24	concomitant	concomitant	JJ	_	25	amod
25	therapy	therapy	NN	_	17	nmod
26	.	.	.	_	13	punct

1	The	the	DT	_	2	det
2	drugs	drug	NNS	_	8	nsubj
3	that	that	WDT	_	4	nsubj
4	inhibit	inhibit	VBP	_	2	acl:relcl
5	cytochrome	cytochrome	NN	_	7	compound
6	P450	p450	NN	_	7	compound
7	2D6	2d6	NN	_	4	dobj
8	include	include	VBP	_	0	ROOT
9	some	some	DT	_	8	dobj
10	that	that	WDT	_	13	nsubjpass
11	are	be	VBP	_	13	auxpass
12	not	not	RB	_	13	neg
13	metabolized	metabolize	VBN	_	9	acl:relcl
14	by	by	IN	_	16	case
15	the	the	DT	_	16	det
16	enzyme	enzyme	NN	_	13	nmod
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	drug1	drug1	NN	_	16	appos
19	;	;	:	_	18	punct

1	drug1	drug1	NN	_	0	ROOT
2	-RRB-	-rrb-	-RRB-	_	1	punct
3	and	and	CC	_	1	cc
4	many	many	JJ	_	1	conj
5	that	that	WDT	_	7	nsubj
6	are	be	VBP	_	7	cop
7	substrates	substrate	NNS	_	4	acl:relcl
8	for	for	IN	_	10	case
9	P450	p450	NN	_	10	compound
10	2D6	2d6	NN	_	7	nmod
11	-LRB-	-lrb-	-LRB-	_	14	punct
12	many	many	JJ	_	14	amod
13	other	other	JJ	_	14	amod
14	drug2	drug2	NN	_	1	dep
15	,	,	,	_	14	punct
16	drug3	drug3	NN	_	14	conj
17	,	,	,	_	14	punct
18	and	and	CC	_	14	cc
19	the	the	DT	_	21	det
20	drug4	drug4	NN	_	21	compound
21	drug5	drug5	NN	_	14	conj
22	and	and	CC	_	21	cc
23	drug6	drug6	NN	_	21	conj
24	-RRB-	-rrb-	-RRB-	_	14	punct
25	.	.	.	_	1	punct

1	While	while	IN	_	20	mark
2	all	all	PDT	_	20	dep
3	the	the	DT	_	20	dep
4	drug1	drug1	NN	_	20	dep
5	-LRB-	-lrb-	-LRB-	_	6	punct
6	drug2	drug2	NN	_	4	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	,	,	,	_	4	punct
9	e.g.	e.g.	FW	_	4	dep
10	,	,	,	_	4	punct
11	drug3	drug3	NN	_	4	conj
12	,	,	,	_	4	punct
13	drug4	drug4	NN	_	4	conj
14	,	,	,	_	4	punct
15	drug5	drug5	NN	_	4	conj
16	,	,	,	_	4	punct
17	and	and	CC	_	4	cc
18	drug6	drug6	NN	_	4	conj
19	,	,	,	_	4	punct
20	inhibit	inhibit	VBP	_	26	advcl
21	P450	p450	NN	_	22	compound
22	2D6	2d6	NN	_	20	dobj
23	,	,	,	_	26	punct
24	they	they	PRP	_	26	nsubj
25	may	may	MD	_	26	aux
26	vary	vary	VB	_	0	ROOT
27	in	in	IN	_	29	case
28	the	the	DT	_	29	det
29	extent	extent	NN	_	26	nmod
30	of	of	IN	_	31	case
31	inhibition	inhibition	NN	_	29	nmod
32	.	.	.	_	26	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	has	have	VBZ	_	5	aux
3	also	also	RB	_	5	advmod
4	been	be	VBN	_	5	auxpass
5	shown	show	VBN	_	0	ROOT
6	to	to	TO	_	7	mark
7	inhibit	inhibit	VB	_	5	xcomp
8	P450	p450	NN	_	9	compound
9	1A2	1a2	NN	_	7	dobj
10	,	,	,	_	9	punct
11	an	a	DT	_	12	det
12	isoform	isoform	NN	_	9	appos
13	also	also	RB	_	14	advmod
14	involved	involve	VBN	_	12	acl
15	in	in	IN	_	17	case
16	drug2	drug2	NN	_	17	compound
17	metabolism	metabolism	NN	_	14	nmod
18	.	.	.	_	5	punct

1	The	the	DT	_	2	det
2	extent	extent	NN	_	0	ROOT
3	to	to	TO	_	4	case
4	which	which	WDT	_	10	nmod
5	drug1	drug1	SYM	_	10	dep
6	-	-	:	_	10	punct
7	drug2	drug2	NN	_	8	compound
8	interactions	interaction	NNS	_	10	nsubj
9	may	may	MD	_	10	aux
10	pose	pose	VB	_	2	acl:relcl
11	clinical	clinical	JJ	_	12	amod
12	problems	problem	NNS	_	14	nsubj
13	will	will	MD	_	14	aux
14	depend	depend	VB	_	10	ccomp
15	on	on	IN	_	17	case
16	the	the	DT	_	17	det
17	degree	degree	NN	_	14	nmod
18	of	of	IN	_	19	case
19	inhibition	inhibition	NN	_	17	nmod
20	and	and	CC	_	19	cc
21	the	the	DT	_	22	det
22	pharmacokinetics	pharmacokinetic	NNS	_	19	conj
23	of	of	IN	_	25	case
24	the	the	DT	_	25	det
25	drug3	drug3	NN	_	22	nmod
26	involved	involve	VBN	_	25	acl
27	.	.	.	_	2	punct

1	Nevertheless	nevertheless	RB	_	5	advmod
2	,	,	,	_	5	punct
3	caution	caution	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	indicated	indicate	VBN	_	0	ROOT
6	in	in	IN	_	8	case
7	the	the	DT	_	8	det
8	co-administration	co-administration	NN	_	5	nmod
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	with	with	IN	_	12	case
12	any	any	DT	_	5	nmod
13	of	of	IN	_	15	case
14	the	the	DT	_	15	det
15	drug2	drug2	NN	_	12	nmod
16	and	and	CC	_	12	cc
17	also	also	RB	_	19	advmod
18	in	in	IN	_	19	case
19	switching	switching	NN	_	12	conj
20	from	from	IN	_	22	case
21	one	one	CD	_	22	nummod
22	class	class	NN	_	19	nmod
23	to	to	TO	_	25	case
24	the	the	DT	_	25	det
25	other	other	JJ	_	19	nmod
26	.	.	.	_	5	punct

1	Of	of	IN	_	3	case
2	particular	particular	JJ	_	3	amod
3	importance	importance	NN	_	8	nmod
4	,	,	,	_	8	punct
5	sufficient	sufficient	JJ	_	6	amod
6	time	time	NN	_	8	nsubj
7	must	must	MD	_	8	aux
8	elapse	elapse	VB	_	0	ROOT
9	before	before	IN	_	10	mark
10	initiating	initiate	VBG	_	8	advcl
11	drug1	drug1	NN	_	12	compound
12	treatment	treatment	NN	_	10	dobj
13	in	in	IN	_	15	case
14	a	a	DT	_	15	det
15	patient	patient	NN	_	12	nmod
16	being	be	VBG	_	17	auxpass
17	withdrawn	withdraw	VBN	_	15	acl
18	from	from	IN	_	19	case
19	drug2	drug2	NN	_	17	nmod
20	,	,	,	_	8	punct
21	given	give	VBN	_	24	case
22	the	the	DT	_	24	det
23	long	long	JJ	_	24	amod
24	half-life	half-life	NN	_	8	nmod
25	of	of	IN	_	27	case
26	the	the	DT	_	27	det
27	parent	parent	NN	_	24	nmod
28	and	and	CC	_	27	cc
29	active	active	JJ	_	30	amod
30	metabolite	metabolite	NN	_	27	conj
31	-LRB-	-lrb-	-LRB-	_	38	punct
32	at	at	IN	_	33	case
33	least	least	JJS	_	34	nmod:npmod
34	5	5	CD	_	35	nummod
35	weeks	week	NNS	_	38	nsubj
36	may	may	MD	_	38	aux
37	be	be	VB	_	38	cop
38	necessary	necessary	JJ	_	24	dep
39	-RRB-	-rrb-	-RRB-	_	38	punct
40	.	.	.	_	8	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	use	use	NN	_	22	nsubj
3	of	of	IN	_	4	case
4	agents	agent	NNS	_	2	nmod
5	in	in	IN	_	7	case
6	the	the	DT	_	7	det
7	drug1	drug1	NN	_	2	nmod
8	-LRB-	-lrb-	-LRB-	_	10	punct
9	which	which	WDT	_	10	nsubj
10	includes	include	VBZ	_	7	dep
11	drug2	drug2	NN	_	10	dobj
12	-RRB-	-rrb-	-RRB-	_	10	punct
13	with	with	IN	_	14	case
14	drugs	drug	NNS	_	2	nmod
15	that	that	WDT	_	17	nsubj
16	can	can	MD	_	17	aux
17	inhibit	inhibit	VB	_	14	acl:relcl
18	cytochrome	cytochrome	NN	_	20	compound
19	P450	p450	NN	_	20	compound
20	2D6	2d6	NN	_	17	dobj
21	may	may	MD	_	22	aux
22	require	require	VB	_	0	ROOT
23	lower	lower	JJR	_	24	amod
24	doses	dose	NNS	_	22	dobj
25	than	than	IN	_	27	mark
26	usually	usually	RB	_	27	advmod
27	prescribed	prescribe	VBN	_	24	dep
28	for	for	IN	_	31	case
29	either	either	CC	_	31	cc:preconj
30	the	the	DT	_	31	det
31	drug3	drug3	NN	_	27	nmod
32	or	or	CC	_	31	cc
33	the	the	DT	_	35	det
34	other	other	JJ	_	35	amod
35	drug	drug	NN	_	31	conj
36	.	.	.	_	22	punct

1	Furthermore	furthermore	RB	_	20	advmod
2	,	,	,	_	20	punct
3	whenever	whenever	WRB	_	9	advmod
4	one	one	CD	_	9	nsubjpass
5	of	of	IN	_	7	case
6	these	these	DT	_	7	det
7	drugs	drug	NNS	_	4	nmod
8	is	be	VBZ	_	9	auxpass
9	withdrawn	withdraw	VBN	_	20	advcl
10	from	from	IN	_	11	case
11	co-therapy	co-therapy	JJ	_	9	nmod
12	,	,	,	_	20	punct
13	an	a	DT	_	15	det
14	increased	increase	VBN	_	15	amod
15	dose	dose	NN	_	20	nsubjpass
16	of	of	IN	_	17	case
17	drug1	drug1	NN	_	15	nmod
18	may	may	MD	_	20	aux
19	be	be	VB	_	20	auxpass
20	required	require	VBN	_	0	ROOT
21	.	.	.	_	20	punct

1	It	it	PRP	_	3	nsubj
2	is	be	VBZ	_	3	cop
3	desirable	desirable	JJ	_	0	ROOT
4	to	to	TO	_	5	mark
5	monitor	monitor	VB	_	3	xcomp
6	drug1	drug1	NN	_	8	compound
7	plasma	plasma	NN	_	8	compound
8	levels	level	NNS	_	5	dobj
9	whenever	whenever	WRB	_	18	advmod
10	an	a	DT	_	11	det
11	agent	agent	NN	_	18	nsubj
12	of	of	IN	_	14	case
13	the	the	DT	_	14	det
14	drug2	drug2	NN	_	11	nmod
15	including	include	VBG	_	16	case
16	drug3	drug3	NN	_	14	nmod
17	is	be	VBZ	_	18	aux
18	going	go	VBG	_	5	advcl
19	to	to	TO	_	21	mark
20	be	be	VB	_	21	auxpass
21	co-administered	co-administer	VBN	_	18	xcomp
22	with	with	IN	_	24	case
23	another	another	DT	_	24	det
24	drug	drug	NN	_	21	nmod
25	known	know	VBN	_	24	acl
26	to	to	TO	_	29	mark
27	be	be	VB	_	29	cop
28	an	a	DT	_	29	det
29	inhibitor	inhibitor	NN	_	25	xcomp
30	of	of	IN	_	32	case
31	P450	p450	NN	_	32	compound
32	2D6	2d6	NN	_	29	nmod
33	-LRB-	-lrb-	-LRB-	_	36	punct
34	and/or	and/or	CC	_	36	cc
35	P450	p450	NN	_	36	compound
36	1A2	1a2	NN	_	32	appos
37	-RRB-	-rrb-	-RRB-	_	36	punct
38	.	.	.	_	3	punct

1	Because	because	IN	_	5	mark
2	drug1	drug1	NN	_	5	nsubjpass
3	is	be	VBZ	_	5	auxpass
4	highly	highly	RB	_	5	advmod
5	bound	bind	VBN	_	33	advcl
6	to	to	TO	_	8	case
7	serum	serum	NN	_	8	compound
8	protein	protein	NN	_	5	nmod
9	,	,	,	_	33	punct
10	the	the	DT	_	11	det
11	administration	administration	NN	_	33	nsubj
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	to	to	TO	_	15	case
15	patients	patient	NNS	_	11	nmod
16	taking	take	VBG	_	15	acl
17	other	other	JJ	_	18	amod
18	drugs	drug	NNS	_	16	dobj
19	that	that	WDT	_	22	nsubjpass
20	are	be	VBP	_	22	auxpass
21	highly	highly	RB	_	22	advmod
22	bound	bind	VBN	_	18	acl:relcl
23	to	to	TO	_	24	case
24	protein	protein	NN	_	22	nmod
25	-LRB-	-lrb-	-LRB-	_	28	punct
26	e.g.	e.g.	FW	_	28	dep
27	,	,	,	_	28	punct
28	drug3	drug3	NN	_	24	dep
29	,	,	,	_	28	punct
30	drug4	drug4	NN	_	28	appos
31	-RRB-	-rrb-	-RRB-	_	28	punct
32	may	may	MD	_	33	aux
33	cause	cause	VB	_	0	ROOT
34	an	a	DT	_	35	det
35	increase	increase	NN	_	33	dobj
36	in	in	IN	_	38	case
37	plasma	plasma	NN	_	38	compound
38	concentrations	concentration	NNS	_	35	nmod
39	of	of	IN	_	41	case
40	these	these	DT	_	41	det
41	drugs	drug	NNS	_	38	nmod
42	,	,	,	_	33	punct
43	potentially	potentially	RB	_	44	advmod
44	resulting	result	VBG	_	33	advcl
45	in	in	IN	_	47	case
46	adverse	adverse	JJ	_	47	amod
47	effects	effect	NNS	_	44	nmod
48	.	.	.	_	33	punct

1	Conversely	conversely	RB	_	6	advmod
2	,	,	,	_	6	punct
3	adverse	adverse	JJ	_	4	amod
4	effects	effect	NNS	_	6	nsubj
5	may	may	MD	_	6	aux
6	result	result	VB	_	0	ROOT
7	from	from	IN	_	8	case
8	displacement	displacement	NN	_	6	nmod
9	of	of	IN	_	11	case
10	protein-bound	protein-bound	JJ	_	11	amod
11	drug1	drug1	NN	_	8	nmod
12	by	by	IN	_	16	case
13	other	other	JJ	_	16	amod
14	highly	highly	RB	_	15	advmod
15	bound	bind	VBN	_	16	amod
16	drugs	drug	NNS	_	8	nmod
17	.	.	.	_	6	punct

1	No	no	DT	_	2	neg
2	trials	trial	NNS	_	11	nsubjpass
3	specifically	specifically	RB	_	4	advmod
4	examining	examine	VBG	_	2	acl
5	potential	potential	JJ	_	7	amod
6	drug	drug	NN	_	7	compound
7	interactions	interaction	NNS	_	4	dobj
8	with	with	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	were	be	VBD	_	11	auxpass
11	conducted	conduct	VBN	_	0	ROOT
12	,	,	,	_	11	punct
13	although	although	IN	_	18	mark
14	many	many	JJ	_	16	amod
15	concomitant	concomitant	JJ	_	16	amod
16	drugs	drug	NNS	_	18	nsubjpass
17	were	be	VBD	_	18	auxpass
18	used	use	VBN	_	11	advcl
19	in	in	IN	_	21	case
20	clinical	clinical	JJ	_	21	amod
21	trials	trial	NNS	_	18	nmod
22	.	.	.	_	11	punct

1	No	no	DT	_	3	neg
2	drug	drug	NN	_	3	compound
3	interactions	interaction	NNS	_	5	nsubjpass
4	were	be	VBD	_	5	auxpass
5	detected	detect	VBN	_	0	ROOT
6	except	except	IN	_	9	case
7	for	for	IN	_	9	case
8	an	a	DT	_	9	det
9	increase	increase	NN	_	5	nmod
10	in	in	IN	_	12	case
11	symptomatic	symptomatic	JJ	_	12	amod
12	hypotension	hypotension	NN	_	9	nmod
13	in	in	IN	_	14	case
14	patients	patient	NNS	_	12	nmod
15	receiving	receive	VBG	_	14	acl
16	oral	oral	JJ	_	17	amod
17	drug1	drug1	NN	_	15	dobj
18	.	.	.	_	5	punct

1	The	the	DT	_	2	det
2	co-administration	co-administration	NN	_	22	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	7	case
6	IV	iv	CD	_	7	nummod
7	drug2	drug2	NN	_	2	nmod
8	such	such	JJ	_	10	case
9	as	as	IN	_	8	mwe
10	drug3	drug3	NN	_	7	nmod
11	,	,	,	_	10	punct
12	drug4	drug4	NN	_	10	conj
13	,	,	,	_	10	punct
14	drug5	drug5	NN	_	10	conj
15	,	,	,	_	10	punct
16	or	or	CC	_	10	cc
17	IV	iv	CD	_	18	nummod
18	drug6	drug6	NN	_	10	conj
19	has	have	VBZ	_	22	aux
20	not	not	RB	_	22	neg
21	been	be	VBN	_	22	auxpass
22	evaluated	evaluate	VBN	_	0	ROOT
23	-LRB-	-lrb-	-LRB-	_	28	punct
24	these	these	DT	_	25	det
25	drugs	drug	NNS	_	28	nsubjpass
26	were	be	VBD	_	28	auxpass
27	not	not	RB	_	28	neg
28	co-administered	co-administer	VBN	_	22	dep
29	with	with	IN	_	30	case
30	drug7	drug7	NN	_	28	nmod
31	in	in	IN	_	33	case
32	clinical	clinical	JJ	_	33	amod
33	trials	trial	NNS	_	28	nmod
34	-RRB-	-rrb-	-RRB-	_	28	punct
35	.	.	.	_	22	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	interact	interact	VB	_	0	ROOT
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	or	or	CC	_	5	cc
7	other	other	JJ	_	8	amod
8	drug3	drug3	NN	_	5	conj
9	,	,	,	_	3	punct
10	causing	cause	VBG	_	3	xcomp
11	increased	increase	VBN	_	13	amod
12	sedative	sedative	JJ	_	13	amod
13	effects	effect	NNS	_	10	dobj
14	.	.	.	_	3	punct

1	It	it	PRP	_	4	nsubj
2	may	may	MD	_	4	aux
3	also	also	RB	_	4	advmod
4	interact	interact	VB	_	0	ROOT
5	with	with	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	or	or	CC	_	6	cc
8	other	other	JJ	_	9	amod
9	drug2	drug2	NN	_	6	conj
10	or	or	CC	_	9	cc
11	drug3	drug3	NN	_	9	conj
12	,	,	,	_	6	punct
13	which	which	WDT	_	15	nsubj
14	may	may	MD	_	15	aux
15	intensify	intensify	VB	_	6	acl:relcl
16	the	the	DT	_	18	det
17	anticholinergic	anticholinergic	JJ	_	18	amod
18	action	action	NN	_	15	dobj
19	.	.	.	_	4	punct

1	drug1	drug1	NN	_	3	nsubj
2	can	can	MD	_	3	aux
3	interact	interact	VB	_	0	ROOT
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	,	,	,	_	3	punct
7	increasing	increase	VBG	_	3	xcomp
8	the	the	DT	_	9	det
9	metabolism	metabolism	NN	_	7	dobj
10	of	of	IN	_	11	case
11	drug3	drug3	NN	_	9	nmod
12	.	.	.	_	3	punct

1	Additional	additional	JJ	_	2	amod
2	reductions	reduction	NNS	_	7	nsubj
3	in	in	IN	_	5	case
4	blood	blood	NN	_	5	compound
5	pressure	pressure	NN	_	2	nmod
6	may	may	MD	_	7	aux
7	occur	occur	VB	_	0	ROOT
8	when	when	WRB	_	11	advmod
9	drug1	drug1	NN	_	11	nsubjpass
10	is	be	VBZ	_	11	auxpass
11	administered	administer	VBN	_	7	advcl
12	with	with	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	,	,	,	_	13	punct
15	drug3	drug3	NN	_	13	conj
16	,	,	,	_	13	punct
17	or	or	CC	_	13	cc
18	other	other	JJ	_	19	amod
19	drug4	drug4	NN	_	13	conj
20	.	.	.	_	7	punct

1	When	when	WRB	_	7	advmod
2	other	other	JJ	_	3	amod
3	drug1	drug1	NN	_	7	nsubjpass
4	or	or	CC	_	3	cc
5	drug2	drug2	NN	_	3	conj
6	are	be	VBP	_	7	auxpass
7	used	use	VBN	_	11	advcl
8	concomitantly	concomitantly	RB	_	7	advmod
9	,	,	,	_	11	punct
10	there	there	EX	_	11	expl
11	is	be	VBZ	_	0	ROOT
12	the	the	DT	_	13	det
13	potential	potential	NN	_	11	nsubj
14	for	for	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	to	to	TO	_	17	mark
17	increase	increase	VB	_	13	acl
18	the	the	DT	_	19	det
19	risk	risk	NN	_	17	dobj
20	of	of	IN	_	21	case
21	bleeding	bleeding	NN	_	19	nmod
22	.	.	.	_	11	punct

1	However	however	RB	_	12	advmod
2	,	,	,	_	12	punct
3	patients	patient	NNS	_	12	nsubjpass
4	receiving	receive	VBG	_	3	acl
5	infusions	infusion	NNS	_	4	dobj
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	in	in	IN	_	10	case
9	clinical	clinical	JJ	_	10	amod
10	trials	trial	NNS	_	4	nmod
11	were	be	VBD	_	12	auxpass
12	maintained	maintain	VBN	_	0	ROOT
13	on	on	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	without	without	IN	_	16	case
16	evidence	evidence	NN	_	12	nmod
17	of	of	IN	_	19	case
18	increased	increase	VBN	_	19	amod
19	bleeding	bleeding	NN	_	16	nmod
20	.	.	.	_	12	punct

1	In	in	IN	_	3	case
2	clinical	clinical	JJ	_	3	amod
3	trials	trial	NNS	_	7	nmod
4	,	,	,	_	7	punct
5	drug1	drug1	NN	_	7	nsubjpass
6	was	be	VBD	_	7	auxpass
7	used	use	VBN	_	0	ROOT
8	with	with	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	,	,	,	_	9	punct
11	drug3	drug3	NN	_	9	conj
12	,	,	,	_	9	punct
13	drug4	drug4	NN	_	9	conj
14	,	,	,	_	9	punct
15	oral	oral	JJ	_	16	amod
16	drug5	drug5	NN	_	9	conj
17	,	,	,	_	9	punct
18	and	and	CC	_	9	cc
19	supplemental	supplemental	JJ	_	20	amod
20	drug6	drug6	NN	_	9	conj
21	.	.	.	_	7	punct
22	In	in	IN	_	25	case
23	a	a	DT	_	25	det
24	pharmacokinetic	pharmacokinetic	JJ	_	25	amod
25	substudy	substudy	NN	_	63	nmod
26	in	in	IN	_	27	case
27	patients	patient	NNS	_	25	nmod
28	with	with	IN	_	31	case
29	congestive	congestive	JJ	_	31	amod
30	heart	heart	NN	_	31	compound
31	failure	failure	NN	_	27	nmod
32	receiving	receive	VBG	_	31	acl
33	drug7	drug7	NN	_	32	dobj
34	or	or	CC	_	33	cc
35	drug8	drug8	NN	_	33	conj
36	in	in	IN	_	42	mark
37	whom	whom	WP	_	42	dobj
38	therapy	therapy	NN	_	42	nsubjpass
39	with	with	IN	_	40	case
40	drug9	drug9	NN	_	38	nmod
41	was	be	VBD	_	42	auxpass
42	initiated	initiate	VBN	_	32	advcl
43	,	,	,	_	25	punct
44	apparent	apparent	JJ	_	47	amod
45	oral	oral	JJ	_	47	amod
46	clearance	clearance	NN	_	47	compound
47	values	value	NNS	_	25	conj
48	for	for	IN	_	49	case
49	drug10	drug10	NN	_	47	nmod
50	-LRB-	-lrb-	-LRB-	_	51	punct
51	n	n	NN	_	47	dep
52	=	=	JJ	_	51	amod
53	23	23	CD	_	52	dep
54	-RRB-	-rrb-	-RRB-	_	51	punct
55	and	and	CC	_	25	cc
56	drug11	drug11	NN	_	25	conj
57	-LRB-	-lrb-	-LRB-	_	58	punct
58	n	n	NN	_	56	dep
59	=	=	JJ	_	58	amod
60	30	30	CD	_	59	dep
61	-RRB-	-rrb-	-RRB-	_	58	punct
62	were	be	VBD	_	63	auxpass
63	decreased	decrease	VBN	_	7	parataxis
64	by	by	IN	_	66	case
65	13	13	CD	_	66	nummod
66	%	%	NN	_	63	nmod
67	and	and	CC	_	66	cc
68	15	15	CD	_	69	nummod
69	%	%	NN	_	66	conj
70	,	,	,	_	63	punct
71	respectively	respectively	RB	_	63	advmod
72	,	,	,	_	63	punct
73	on	on	IN	_	76	case
74	the	the	DT	_	76	det
75	second	second	JJ	_	76	amod
76	day	day	NN	_	63	nmod
77	of	of	IN	_	78	case
78	therapy	therapy	NN	_	76	nmod
79	and	and	CC	_	63	cc
80	had	have	VBD	_	81	aux
81	returned	return	VBN	_	63	conj
82	to	to	TO	_	84	case
83	baseline	baseline	NN	_	84	compound
84	values	value	NNS	_	81	nmod
85	by	by	IN	_	86	case
86	day	day	NN	_	81	nmod
87	87	87	CD	_	86	nummod
88	.	.	.	_	7	punct

1	The	the	DT	_	2	det
2	change	change	NN	_	9	nsubj
3	in	in	IN	_	6	case
4	drug1	drug1	NN	_	6	compound
5	clearance	clearance	NN	_	6	compound
6	value	value	NN	_	2	nmod
7	is	be	VBZ	_	9	cop
8	not	not	RB	_	9	neg
9	likely	likely	JJ	_	0	ROOT
10	to	to	TO	_	13	mark
11	be	be	VB	_	13	cop
12	clinically	clinically	RB	_	13	advmod
13	significant	significant	JJ	_	9	xcomp
14	.	.	.	_	9	punct

1	However	however	RB	_	7	advmod
2	,	,	,	_	7	punct
3	patients	patient	NNS	_	7	nsubj
4	on	on	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	may	may	MD	_	7	aux
7	show	show	VB	_	0	ROOT
8	elevations	elevation	NNS	_	7	dobj
9	of	of	IN	_	11	case
10	drug2	drug2	NN	_	11	compound
11	concentrations	concentration	NNS	_	8	nmod
12	after	after	IN	_	13	case
13	initiation	initiation	NN	_	7	nmod
14	of	of	IN	_	15	case
15	therapy	therapy	NN	_	13	nmod
16	with	with	IN	_	17	case
17	drug3	drug3	NN	_	13	nmod
18	,	,	,	_	13	punct
19	which	which	WDT	_	23	nsubj
20	may	may	MD	_	23	aux
21	be	be	VB	_	23	cop
22	clinically	clinically	RB	_	23	advmod
23	significant	significant	JJ	_	13	acl:relcl
24	in	in	IN	_	25	case
25	patients	patient	NNS	_	23	nmod
26	prone	prone	JJ	_	25	amod
27	to	to	TO	_	29	case
28	drug4	drug4	NN	_	29	compound
29	toxicity	toxicity	NN	_	26	nmod
30	.	.	.	_	7	punct

1	Specific	specific	JJ	_	4	amod
2	drug	drug	NN	_	4	compound
3	interaction	interaction	NN	_	4	compound
4	studies	study	NNS	_	8	nsubjpass
5	have	have	VBP	_	8	aux
6	not	not	RB	_	8	neg
7	been	be	VBN	_	8	auxpass
8	conducted	conduct	VBN	_	0	ROOT
9	with	with	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	.	.	.	_	8	punct

1	However	however	RB	_	11	advmod
2	,	,	,	_	11	punct
3	the	the	DT	_	5	det
4	systemic	systemic	JJ	_	5	amod
5	administration	administration	NN	_	11	nsubjpass
6	of	of	IN	_	8	case
7	some	some	DT	_	8	det
8	drug1	drug1	NN	_	5	nmod
9	has	have	VBZ	_	11	aux
10	been	be	VBN	_	11	auxpass
11	shown	show	VBN	_	0	ROOT
12	to	to	TO	_	13	mark
13	elevate	elevate	VB	_	11	xcomp
14	plasma	plasma	NN	_	15	compound
15	concentrations	concentration	NNS	_	13	dobj
16	of	of	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	,	,	,	_	11	punct
19	interfere	interfere	VBP	_	11	conj
20	with	with	IN	_	22	case
21	the	the	DT	_	22	det
22	metabolism	metabolism	NN	_	19	nmod
23	of	of	IN	_	24	case
24	drug3	drug3	NN	_	22	nmod
25	,	,	,	_	11	punct
26	and	and	CC	_	11	cc
27	enhance	enhance	VBP	_	11	conj
28	the	the	DT	_	29	det
29	effects	effect	NNS	_	27	dobj
30	of	of	IN	_	34	case
31	the	the	DT	_	34	det
32	oral	oral	JJ	_	34	amod
33	drug4	drug4	NN	_	34	compound
34	drug5	drug5	NN	_	29	nmod
35	and	and	CC	_	34	cc
36	its	its	PRP$	_	37	nmod:poss
37	derivatives	derivative	NNS	_	34	conj
38	,	,	,	_	11	punct
39	and	and	CC	_	11	cc
40	has	have	VBZ	_	42	aux
41	been	be	VBN	_	42	auxpass
42	associated	associate	VBN	_	11	conj
43	with	with	IN	_	45	case
44	transient	transient	JJ	_	45	amod
45	elevations	elevation	NNS	_	42	nmod
46	in	in	IN	_	48	case
47	serum	serum	NN	_	48	compound
48	creatinine	creatinine	NN	_	45	nmod
49	in	in	IN	_	50	case
50	patients	patient	NNS	_	48	nmod
51	receiving	receive	VBG	_	50	acl
52	systemic	systemic	JJ	_	53	amod
53	drug6	drug6	NN	_	51	dobj
54	concomitantly	concomitantly	RB	_	51	advmod
55	.	.	.	_	11	punct

1	No	no	DT	_	2	neg
2	drug	drug	NN	_	12	nsubjpass
3	,	,	,	_	2	punct
4	nutritional	nutritional	JJ	_	5	amod
5	supplement	supplement	NN	_	2	conj
6	,	,	,	_	2	punct
7	food	food	NN	_	2	conj
8	or	or	CC	_	2	cc
9	herb	herb	NN	_	2	conj
10	interactions	interaction	NNS	_	2	dep
11	are	be	VBP	_	12	auxpass
12	known	know	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	Before	before	IN	_	2	mark
2	using	use	VBG	_	6	advcl
3	this	this	DT	_	4	det
4	medication	medication	NN	_	2	dobj
5	,	,	,	_	6	punct
6	tell	tell	VB	_	0	ROOT
7	your	you	PRP$	_	8	nmod:poss
8	doctor	doctor	NN	_	6	dobj
9	or	or	CC	_	8	cc
10	pharmacist	pharmacist	NN	_	8	conj
11	of	of	IN	_	16	case
12	all	all	DT	_	16	det
13	prescription	prescription	NN	_	16	compound
14	and	and	CC	_	13	cc
15	nonprescription	nonprescription	NN	_	13	conj
16	products	product	NNS	_	6	nmod
17	you	you	PRP	_	19	nsubj
18	may	may	MD	_	19	aux
19	use	use	VB	_	16	acl:relcl
20	,	,	,	_	16	punct
21	especially	especially	RB	_	24	advmod
22	of	of	IN	_	24	case
23	:	:	:	_	24	punct
24	drug1	drug1	NN	_	16	nmod
25	-LRB-	-lrb-	-LRB-	_	28	punct
26	e.g.	e.g.	FW	_	28	dep
27	,	,	,	_	28	punct
28	drug2	drug2	NN	_	24	dep
29	,	,	,	_	28	punct
30	drug3	drug3	NN	_	28	appos
31	-RRB-	-rrb-	-RRB-	_	28	punct
32	,	,	,	_	24	punct
33	drug4	drug4	NN	_	24	conj
34	,	,	,	_	24	punct
35	drug5	drug5	NN	_	24	conj
36	,	,	,	_	24	punct
37	drug6	drug6	NN	_	38	compound
38	drugs	drug	NNS	_	24	conj
39	-LRB-	-lrb-	-LRB-	_	42	punct
40	e.g.	e.g.	FW	_	42	dep
41	,	,	,	_	42	punct
42	drug7	drug7	NN	_	38	dep
43	-RRB-	-rrb-	-RRB-	_	42	punct
44	,	,	,	_	24	punct
45	drug8	drug8	NN	_	24	conj
46	,	,	,	_	24	punct
47	drug9	drug9	NN	_	24	conj
48	.	.	.	_	6	punct

1	Do	do	VB	_	3	aux
2	not	not	RB	_	3	neg
3	start	start	VB	_	0	ROOT
4	or	or	CC	_	3	cc
5	stop	stop	VB	_	3	conj
6	any	any	DT	_	7	det
7	medicine	medicine	NN	_	3	dobj
8	without	without	IN	_	12	case
9	doctor	doctor	NN	_	12	compound
10	or	or	CC	_	9	cc
11	pharmacist	pharmacist	NN	_	9	conj
12	approval	approval	NN	_	3	nmod
13	.	.	.	_	3	punct

1	The	the	DT	_	3	det
2	hypoglycemic	hypoglycemic	JJ	_	3	amod
3	action	action	NN	_	8	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	potentiated	potentiate	VBN	_	0	ROOT
9	by	by	IN	_	11	case
10	certain	certain	JJ	_	11	amod
11	drugs	drug	NNS	_	8	nmod
12	including	include	VBG	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	and	and	CC	_	13	cc
15	other	other	JJ	_	16	amod
16	drugs	drug	NNS	_	13	conj
17	that	that	WDT	_	21	nsubj
18	are	be	VBP	_	21	cop
19	highly	highly	RB	_	21	advmod
20	protein	protein	NN	_	21	nmod:npmod
21	bound	bind	VBD	_	11	acl:relcl
22	,	,	,	_	21	punct
23	drug3	drug3	NN	_	21	dobj
24	,	,	,	_	23	punct
25	drug4	drug4	NN	_	23	conj
26	,	,	,	_	23	punct
27	drug5	drug5	NN	_	23	conj
28	,	,	,	_	23	punct
29	drug6	drug6	NN	_	23	conj
30	,	,	,	_	23	punct
31	drug7	drug7	NN	_	23	conj
32	,	,	,	_	23	punct
33	drug8	drug8	NN	_	23	conj
34	,	,	,	_	23	punct
35	and	and	CC	_	23	cc
36	drug9	drug9	NN	_	23	conj
37	.	.	.	_	8	punct

1	When	when	WRB	_	5	advmod
2	such	such	JJ	_	3	amod
3	drugs	drug	NNS	_	5	nsubjpass
4	are	be	VBP	_	5	auxpass
5	administered	administer	VBN	_	16	advcl
6	to	to	TO	_	8	case
7	a	a	DT	_	8	det
8	patient	patient	NN	_	5	nmod
9	receiving	receive	VBG	_	8	acl
10	drug1	drug1	NN	_	9	dobj
11	,	,	,	_	16	punct
12	the	the	DT	_	13	det
13	patient	patient	NN	_	16	nsubjpass
14	should	should	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	observed	observe	VBN	_	0	ROOT
17	closely	closely	RB	_	16	advmod
18	for	for	IN	_	19	case
19	hypoglycemia	hypoglycemia	NN	_	16	nmod
20	.	.	.	_	16	punct

1	When	when	WRB	_	5	advmod
2	such	such	JJ	_	3	amod
3	drugs	drug	NNS	_	5	nsubjpass
4	are	be	VBP	_	5	auxpass
5	withdrawn	withdraw	VBN	_	16	advcl
6	from	from	IN	_	8	case
7	a	a	DT	_	8	det
8	patient	patient	NN	_	5	nmod
9	receiving	receive	VBG	_	8	acl
10	drug1	drug1	NN	_	9	dobj
11	,	,	,	_	16	punct
12	the	the	DT	_	13	det
13	patient	patient	NN	_	16	nsubjpass
14	should	should	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	observed	observe	VBN	_	0	ROOT
17	closely	closely	RB	_	16	advmod
18	for	for	IN	_	19	case
19	loss	loss	NN	_	16	nmod
20	of	of	IN	_	21	case
21	control	control	NN	_	19	nmod
22	.	.	.	_	16	punct

1	Certain	certain	JJ	_	2	amod
2	drugs	drug	NNS	_	3	nsubj
3	tend	tend	VBP	_	0	ROOT
4	to	to	TO	_	5	mark
5	produce	produce	VB	_	3	xcomp
6	hyperglycemia	hyperglycemia	NN	_	5	dobj
7	and	and	CC	_	3	cc
8	may	may	MD	_	9	aux
9	lead	lead	VB	_	3	conj
10	to	to	TO	_	11	case
11	loss	loss	NN	_	9	nmod
12	of	of	IN	_	13	case
13	control	control	NN	_	11	nmod
14	.	.	.	_	3	punct

1	These	these	DT	_	2	det
2	drugs	drug	NNS	_	3	nsubj
3	include	include	VBP	_	0	ROOT
4	the	the	DT	_	5	det
5	drug1	drug1	NN	_	3	dobj
6	and	and	CC	_	5	cc
7	other	other	JJ	_	8	amod
8	drug2	drug2	NN	_	5	conj
9	,	,	,	_	8	punct
10	drug3	drug3	NN	_	8	conj
11	,	,	,	_	8	punct
12	drug4	drug4	NN	_	8	conj
13	,	,	,	_	8	punct
14	thyroid	thyroid	NN	_	15	compound
15	products	product	NNS	_	8	conj
16	,	,	,	_	8	punct
17	drug5	drug5	NN	_	8	conj
18	,	,	,	_	8	punct
19	oral	oral	JJ	_	20	amod
20	drug6	drug6	NN	_	8	conj
21	,	,	,	_	8	punct
22	drug7	drug7	NN	_	8	conj
23	,	,	,	_	8	punct
24	drug8	drug8	NN	_	8	conj
25	,	,	,	_	8	punct
26	drug9	drug9	NN	_	8	conj
27	,	,	,	_	8	punct
28	drug10	drug10	NN	_	8	conj
29	,	,	,	_	8	punct
30	and	and	CC	_	8	cc
31	drug11	drug11	NN	_	8	conj
32	.	.	.	_	3	punct

1	When	when	WRB	_	5	advmod
2	such	such	JJ	_	3	amod
3	drugs	drug	NNS	_	5	nsubjpass
4	are	be	VBP	_	5	auxpass
5	administered	administer	VBN	_	17	advcl
6	to	to	TO	_	8	case
7	a	a	DT	_	8	det
8	patient	patient	NN	_	5	nmod
9	receiving	receive	VBG	_	8	acl
10	drug1	drug1	NN	_	9	dobj
11	,	,	,	_	17	punct
12	the	the	DT	_	13	det
13	patient	patient	NN	_	17	nsubjpass
14	should	should	MD	_	17	aux
15	be	be	VB	_	17	auxpass
16	closely	closely	RB	_	17	advmod
17	observed	observe	VBN	_	0	ROOT
18	for	for	IN	_	19	case
19	loss	loss	NN	_	17	nmod
20	of	of	IN	_	21	case
21	control	control	NN	_	19	nmod
22	.	.	.	_	17	punct

1	When	when	WRB	_	5	advmod
2	such	such	JJ	_	3	amod
3	drugs	drug	NNS	_	5	nsubjpass
4	are	be	VBP	_	5	auxpass
5	withdrawn	withdraw	VBN	_	16	advcl
6	from	from	IN	_	8	case
7	a	a	DT	_	8	det
8	patient	patient	NN	_	5	nmod
9	receiving	receive	VBG	_	8	acl
10	drug1	drug1	NN	_	9	dobj
11	,	,	,	_	16	punct
12	the	the	DT	_	13	det
13	patient	patient	NN	_	16	nsubjpass
14	should	should	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	observed	observe	VBN	_	0	ROOT
17	closely	closely	RB	_	16	advmod
18	for	for	IN	_	19	case
19	hypoglycemia	hypoglycemia	NN	_	16	nmod
20	.	.	.	_	16	punct

1	Since	since	IN	_	4	mark
2	animal	animal	NN	_	3	compound
3	studies	study	NNS	_	4	nsubj
4	suggest	suggest	VBP	_	21	advcl
5	that	that	IN	_	12	mark
6	the	the	DT	_	7	det
7	action	action	NN	_	12	nsubjpass
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	may	may	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	prolonged	prolong	VBN	_	4	ccomp
13	by	by	IN	_	14	case
14	therapy	therapy	NN	_	12	nmod
15	with	with	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	,	,	,	_	21	punct
18	drug3	drug3	NN	_	21	nsubjpass
19	should	should	MD	_	21	aux
20	be	be	VB	_	21	auxpass
21	employed	employ	VBN	_	0	ROOT
22	with	with	IN	_	23	case
23	caution	caution	NN	_	21	nmod
24	.	.	.	_	21	punct

1	In	in	IN	_	3	case
2	some	some	DT	_	3	det
3	patients	patient	NNS	_	12	nmod
4	,	,	,	_	12	punct
5	a	a	DT	_	6	det
6	drug1	drug1	NN	_	12	nsubjpass
7	-	-	:	_	12	punct
8	like	like	IN	_	9	case
9	reaction	reaction	NN	_	12	nmod
10	may	may	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	produced	produce	VBN	_	0	ROOT
13	by	by	IN	_	15	case
14	the	the	DT	_	15	det
15	ingestion	ingestion	NN	_	12	nmod
16	of	of	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	.	.	.	_	12	punct

1	A	a	DT	_	3	det
2	potential	potential	JJ	_	3	amod
3	interaction	interaction	NN	_	16	nsubjpass
4	between	between	IN	_	6	case
5	oral	oral	JJ	_	6	amod
6	drug1	drug1	NN	_	3	nmod
7	and	and	CC	_	6	cc
8	oral	oral	JJ	_	9	amod
9	drug2	drug2	NN	_	6	conj
10	leading	lead	VBG	_	3	acl
11	to	to	TO	_	13	case
12	severe	severe	JJ	_	13	amod
13	hypoglycemia	hypoglycemia	NN	_	10	nmod
14	has	have	VBZ	_	16	aux
15	been	be	VBN	_	16	auxpass
16	reported	report	VBN	_	0	ROOT
17	.	.	.	_	16	punct

1	Whether	whether	IN	_	5	mark
2	this	this	DT	_	3	det
3	interaction	interaction	NN	_	5	nsubj
4	also	also	RB	_	5	advmod
5	occurs	occur	VBZ	_	19	csubjpass
6	with	with	IN	_	14	case
7	the	the	DT	_	14	det
8	intravenous	intravenous	JJ	_	14	amod
9	,	,	,	_	8	punct
10	topical	topical	JJ	_	8	conj
11	,	,	,	_	8	punct
12	or	or	CC	_	8	cc
13	vaginal	vaginal	JJ	_	8	conj
14	preparations	preparation	NNS	_	5	nmod
15	of	of	IN	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	is	be	VBZ	_	19	auxpass
18	not	not	RB	_	19	neg
19	known	know	VBN	_	0	ROOT
20	.	.	.	_	19	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	use	use	NN	_	20	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	2	nmod
7	-LRB-	-lrb-	-LRB-	_	10	punct
8	e.g.	e.g.	FW	_	10	dep
9	,	,	,	_	10	punct
10	drug3	drug3	NN	_	6	dep
11	,	,	,	_	10	punct
12	drug4	drug4	NN	_	10	conj
13	,	,	,	_	10	punct
14	drug5	drug5	NN	_	10	conj
15	,	,	,	_	10	punct
16	and	and	CC	_	10	cc
17	drug6	drug6	NN	_	10	conj
18	-RRB-	-rrb-	-RRB-	_	10	punct
19	may	may	MD	_	20	aux
20	result	result	VB	_	0	ROOT
21	in	in	IN	_	24	case
22	increased	increase	VBN	_	24	amod
23	drug7	drug7	NN	_	24	compound
24	effects	effect	NNS	_	20	nmod
25	.	.	.	_	20	punct

1	When	when	WRB	_	2	advmod
2	used	use	VBN	_	17	advcl
3	concurrently	concurrently	RB	_	2	advmod
4	with	with	IN	_	6	case
5	such	such	JJ	_	6	amod
6	drugs	drug	NNS	_	2	nmod
7	,	,	,	_	17	punct
8	the	the	DT	_	9	det
9	dose	dose	NN	_	17	nsubj
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	should	should	MD	_	17	aux
13	be	be	VB	_	17	cop
14	the	the	DT	_	17	det
15	smallest	smallest	JJS	_	17	amod
16	effective	effective	JJ	_	17	amod
17	dose	dose	NN	_	0	ROOT
18	and	and	CC	_	17	cc
19	the	the	DT	_	20	det
20	frequency	frequency	NN	_	23	nsubj
21	of	of	IN	_	22	case
22	dosing	dosing	NN	_	20	nmod
23	reduced	reduce	VBD	_	17	conj
24	as	as	RB	_	25	advmod
25	much	much	JJ	_	23	dobj
26	as	as	IN	_	27	case
27	possible	possible	JJ	_	25	advcl
28	when	when	WRB	_	29	advmod
29	administered	administer	VBN	_	23	advcl
30	concomitantly	concomitantly	RB	_	29	advmod
31	with	with	IN	_	32	case
32	drugs	drug	NNS	_	29	nmod
33	that	that	WDT	_	34	nsubj
34	potentiate	potentiate	VBP	_	32	acl:relcl
35	the	the	DT	_	36	det
36	action	action	NN	_	34	dobj
37	of	of	IN	_	38	case
38	drug2	drug2	NN	_	36	nmod
39	.	.	.	_	17	punct

1	In	in	IN	_	3	case
2	healthy	healthy	JJ	_	3	amod
3	volunteers	volunteer	NNS	_	0	ROOT
4	,	,	,	_	3	punct
5	the	the	DT	_	6	det
6	pharmacokinetics	pharmacokinetic	NNS	_	4	root
7	of	of	IN	_	10	case
8	a	a	DT	_	10	det
9	1-mg	1-mg	JJ	_	10	amod
10	dose	dose	NN	_	6	nmod
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	administered	administer	VBN	_	10	acl
14	as	as	IN	_	18	mark
15	drug2	drug2	NN	_	18	nsubjpass
16	were	be	VBD	_	18	auxpass
17	not	not	RB	_	18	neg
18	affected	affect	VBN	_	13	advcl
19	by	by	IN	_	21	case
20	the	the	DT	_	21	det
21	coadministration	coadministration	NN	_	18	nmod
22	of	of	IN	_	27	case
23	a	a	DT	_	27	det
24	single	single	JJ	_	27	amod
25	6-mg	6-mg	JJ	_	27	amod
26	subcutaneous	subcutaneous	JJ	_	27	amod
27	dose	dose	NN	_	21	nmod
28	of	of	IN	_	29	case
29	drug3	drug3	NN	_	27	nmod
30	.	.	.	_	6	punct

1	However	however	RB	_	16	advmod
2	,	,	,	_	16	punct
3	in	in	IN	_	5	case
4	another	another	DT	_	5	det
5	study	study	NN	_	16	nmod
6	in	in	IN	_	8	case
7	healthy	healthy	JJ	_	8	amod
8	volunteers	volunteer	NNS	_	5	nmod
9	,	,	,	_	16	punct
10	the	the	DT	_	11	det
11	pharmacokinetics	pharmacokinetic	NNS	_	16	nsubj
12	of	of	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	were	be	VBD	_	16	aux
15	significantly	significantly	RB	_	16	advmod
16	altered	altered	JJ	_	0	ROOT
17	-LRB-	-lrb-	-LRB-	_	20	punct
18	29	29	CD	_	19	compound
19	%	%	NN	_	20	amod
20	decrease	decrease	NN	_	16	dep
21	in	in	IN	_	22	case
22	AUC	auc	NN	_	20	nmod
23	and	and	CC	_	20	cc
24	38	38	CD	_	25	compound
25	%	%	NN	_	26	amod
26	decrease	decrease	NN	_	20	conj
27	in	in	IN	_	28	case
28	Cmax	cmax	NN	_	26	nmod
29	-RRB-	-rrb-	-RRB-	_	20	punct
30	when	when	WRB	_	37	advmod
31	a	a	DT	_	33	det
32	1-mg	1-mg	JJ	_	33	amod
33	dose	dose	NN	_	37	nsubjpass
34	of	of	IN	_	35	case
35	drug2	drug2	NN	_	33	nmod
36	was	be	VBD	_	37	auxpass
37	administered	administer	VBN	_	16	advcl
38	1	1	CD	_	39	nummod
39	minute	minute	NN	_	37	dobj
40	after	after	IN	_	43	case
41	a	a	DT	_	43	det
42	20-mg	20-mg	JJ	_	43	amod
43	dose	dose	NN	_	37	nmod
44	of	of	IN	_	47	case
45	drug3	drug3	NN	_	47	compound
46	nasal	nasal	JJ	_	47	amod
47	spray	spray	NN	_	43	nmod
48	.	.	.	_	16	punct

1	-LRB-	-lrb-	-LRB-	_	6	punct
2	The	the	DT	_	4	det
3	two	two	CD	_	4	nummod
4	drugs	drug	NNS	_	6	nsubjpass
5	were	be	VBD	_	6	auxpass
6	administered	administer	VBN	_	0	ROOT
7	in	in	IN	_	9	case
8	opposite	opposite	JJ	_	9	amod
9	nostrils	nostril	NNS	_	6	nmod
10	.	.	.	_	6	punct
11	-RRB-	-rrb-	-RRB-	_	6	punct

1	When	when	WRB	_	5	advmod
2	the	the	DT	_	3	det
3	drug1	drug1	NN	_	5	nsubjpass
4	was	be	VBD	_	5	auxpass
5	administered	administer	VBN	_	18	advcl
6	30	30	CD	_	7	nummod
7	minutes	minute	NNS	_	5	nmod
8	after	after	IN	_	7	case
9	the	the	DT	_	12	det
10	drug2	drug2	NN	_	12	compound
11	nasal	nasal	JJ	_	12	amod
12	spray	spray	NN	_	7	dep
13	,	,	,	_	18	punct
14	the	the	DT	_	15	det
15	AUC	auc	NN	_	18	nsubj
16	of	of	IN	_	17	case
17	drug3	drug3	NN	_	15	nmod
18	increased	increase	VBD	_	0	ROOT
19	11	11	CD	_	20	nummod
20	%	%	NN	_	18	dobj
21	and	and	CC	_	18	cc
22	Cmax	cmax	NN	_	23	nsubj
23	decreased	decrease	VBD	_	18	conj
24	18	18	CD	_	25	nummod
25	%	%	NN	_	23	dobj
26	.	.	.	_	18	punct

1	In	in	IN	_	3	case
2	neither	neither	DT	_	3	det
3	case	case	NN	_	4	nmod
4	were	be	VBD	_	0	ROOT
5	the	the	DT	_	6	det
6	pharmacokinetics	pharmacokinetic	NNS	_	4	nsubj
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	affected	affect	VBN	_	8	acl
10	by	by	IN	_	11	case
11	coadministration	coadministration	NN	_	9	nmod
12	with	with	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	.	.	.	_	4	punct

1	These	these	DT	_	2	det
2	results	result	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	12	mark
5	the	the	DT	_	7	det
6	analgesic	analgesic	JJ	_	7	amod
7	effect	effect	NN	_	12	nsubjpass
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	may	may	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	diminished	diminish	VBN	_	3	ccomp
13	when	when	WRB	_	16	advmod
14	it	it	PRP	_	16	nsubjpass
15	is	be	VBZ	_	16	auxpass
16	administered	administer	VBN	_	12	advcl
17	shortly	shortly	RB	_	21	advmod
18	after	after	IN	_	21	case
19	drug2	drug2	NN	_	21	compound
20	nasal	nasal	JJ	_	21	amod
21	spray	spray	NN	_	16	nmod
22	,	,	,	_	12	punct
23	but	but	CC	_	12	cc
24	by	by	IN	_	26	case
25	30	30	CD	_	26	nummod
26	minutes	minute	NNS	_	34	nmod
27	any	any	DT	_	29	det
28	such	such	JJ	_	29	amod
29	reduction	reduction	NN	_	34	nsubj
30	in	in	IN	_	31	case
31	effect	effect	NN	_	29	nmod
32	should	should	MD	_	34	aux
33	be	be	VB	_	34	cop
34	minimal	minimal	JJ	_	12	conj
35	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	safety	safety	NN	_	22	nsubjpass
3	of	of	IN	_	4	mark
4	using	use	VBG	_	2	acl
5	drug1	drug1	NN	_	12	compound
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	drug3	drug3	NN	_	7	appos
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	Nasal	nasal	JJ	_	12	amod
12	Spray	spray	NN	_	4	dobj
13	during	during	IN	_	16	case
14	the	the	DT	_	16	det
15	same	same	JJ	_	16	amod
16	episode	episode	NN	_	4	nmod
17	of	of	IN	_	18	case
18	migraine	migraine	NN	_	16	nmod
19	has	have	VBZ	_	22	aux
20	not	not	RB	_	22	neg
21	been	be	VBN	_	22	auxpass
22	established	establish	VBN	_	0	ROOT
23	.	.	.	_	22	punct

1	However	however	RB	_	6	advmod
2	,	,	,	_	6	punct
3	it	it	PRP	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	noted	note	VBN	_	0	ROOT
7	that	that	IN	_	11	mark
8	both	both	CC	_	9	det
9	products	product	NNS	_	11	nsubj
10	are	be	VBP	_	11	cop
11	capable	capable	JJ	_	6	ccomp
12	of	of	IN	_	13	mark
13	producing	produce	VBG	_	11	advcl
14	transient	transient	JJ	_	15	amod
15	increases	increase	NNS	_	13	dobj
16	in	in	IN	_	18	case
17	blood	blood	NN	_	18	compound
18	pressure	pressure	NN	_	15	nmod
19	.	.	.	_	6	punct

1	The	the	DT	_	2	det
2	pharmacokinetics	pharmacokinetic	NNS	_	0	ROOT
3	of	of	IN	_	6	case
4	a	a	DT	_	6	det
5	1-mg	1-mg	JJ	_	6	amod
6	dose	dose	NN	_	2	nmod
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	administered	administer	VBN	_	6	acl
10	as	as	IN	_	14	mark
11	drug2	drug2	NN	_	14	nsubjpass
12	were	be	VBD	_	14	auxpass
13	not	not	RB	_	14	neg
14	affected	affect	VBN	_	9	advcl
15	by	by	IN	_	17	case
16	the	the	DT	_	17	det
17	coadministration	coadministration	NN	_	14	nmod
18	of	of	IN	_	19	case
19	drug3	drug3	NN	_	17	nmod
20	-LRB-	-lrb-	-LRB-	_	23	punct
21	300	300	CD	_	22	compound
22	mg	mg	NN	_	23	nummod
23	QID	qid	NN	_	19	appos
24	-RRB-	-rrb-	-RRB-	_	23	punct
25	.	.	.	_	2	punct

1	Conversely	conversely	RB	_	15	advmod
2	,	,	,	_	15	punct
3	the	the	DT	_	4	det
4	administration	administration	NN	_	15	nsubj
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	-LRB-	-lrb-	-LRB-	_	11	punct
8	1	1	CD	_	9	compound
9	mg	mg	NN	_	11	amod
10	drug2	drug2	NN	_	11	compound
11	QID	qid	NN	_	6	appos
12	-RRB-	-rrb-	-RRB-	_	11	punct
13	did	do	VBD	_	15	aux
14	not	not	RB	_	15	neg
15	alter	alter	VB	_	0	ROOT
16	the	the	DT	_	17	det
17	pharmacokinetics	pharmacokinetic	NNS	_	15	dobj
18	of	of	IN	_	21	case
19	a	a	DT	_	21	det
20	300-mg	300-mg	JJ	_	21	amod
21	dose	dose	NN	_	17	nmod
22	of	of	IN	_	23	case
23	drug3	drug3	NN	_	21	nmod
24	.	.	.	_	15	punct

1	It	it	PRP	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	not	not	RB	_	4	neg
4	known	know	VBN	_	0	ROOT
5	if	if	IN	_	11	mark
6	the	the	DT	_	7	det
7	effects	effect	NNS	_	11	nsubjpass
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	are	be	VBP	_	11	auxpass
11	altered	alter	VBN	_	4	advcl
12	by	by	IN	_	14	case
13	concomitant	concomitant	JJ	_	14	amod
14	medications	medication	NNS	_	11	nmod
15	that	that	WDT	_	16	nsubj
16	affect	affect	VBP	_	14	acl:relcl
17	hepatic	hepatic	JJ	_	18	amod
18	metabolism	metabolism	NN	_	16	dobj
19	of	of	IN	_	20	case
20	drugs	drug	NNS	_	18	nmod
21	-LRB-	-lrb-	-LRB-	_	22	punct
22	drug2	drug2	NN	_	20	dep
23	,	,	,	_	22	punct
24	etc.	etc.	FW	_	22	dep
25	-RRB-	-rrb-	-RRB-	_	22	punct
26	,	,	,	_	4	punct
27	but	but	CC	_	4	cc
28	physicians	physician	NNS	_	31	nsubj
29	should	should	MD	_	31	aux
30	be	be	VB	_	31	cop
31	alert	alert	JJ	_	4	conj
32	to	to	TO	_	34	case
33	the	the	DT	_	34	det
34	possibility	possibility	NN	_	31	nmod
35	that	that	IN	_	47	mark
36	a	a	DT	_	39	det
37	smaller	smaller	JJR	_	39	amod
38	initial	initial	JJ	_	39	amod
39	dose	dose	NN	_	47	nsubjpass
40	and	and	CC	_	39	cc
41	longer	longer	JJR	_	42	amod
42	intervals	interval	NNS	_	39	conj
43	between	between	IN	_	44	case
44	doses	dose	NNS	_	42	nmod
45	may	may	MD	_	47	aux
46	be	be	VB	_	47	auxpass
47	needed	need	VBN	_	34	ccomp
48	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	fraction	fraction	NN	_	7	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	absorbed	absorb	VBN	_	2	acl
6	is	be	VBZ	_	7	aux
7	unaffected	unaffected	JJ	_	0	ROOT
8	by	by	IN	_	11	case
9	the	the	DT	_	11	det
10	concomitant	concomitant	JJ	_	11	amod
11	administration	administration	NN	_	7	nmod
12	of	of	IN	_	11	amod
13	a	a	DT	_	12	dep
14	drug2	drug2	NN	_	13	dep
15	-LRB-	-lrb-	-LRB-	_	16	punct
16	drug3	drug3	NN	_	14	appos
17	-RRB-	-rrb-	-RRB-	_	16	punct
18	,	,	,	_	14	punct
19	but	but	CC	_	14	cc
20	the	the	DT	_	21	det
21	rate	rate	NN	_	25	nsubjpass
22	of	of	IN	_	23	case
23	absorption	absorption	NN	_	21	nmod
24	is	be	VBZ	_	25	auxpass
25	decreased	decrease	VBN	_	14	conj
26	.	.	.	_	7	punct

1	Therefore	therefore	RB	_	8	advmod
2	,	,	,	_	8	punct
3	a	a	DT	_	5	det
4	slower	slower	JJR	_	5	amod
5	onset	onset	NN	_	8	nsubjpass
6	can	can	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	anticipated	anticipate	VBN	_	0	ROOT
9	if	if	IN	_	12	mark
10	drug1	drug1	NN	_	12	nsubjpass
11	is	be	VBZ	_	12	auxpass
12	administered	administer	VBN	_	8	advcl
13	concomitantly	concomitantly	RB	_	12	advmod
14	with	with	IN	_	21	case
15	,	,	,	_	18	punct
16	or	or	CC	_	18	cc
17	immediately	immediately	RB	_	18	advmod
18	following	follow	VBG	_	21	dep
19	,	,	,	_	18	punct
20	a	a	DT	_	21	det
21	drug2	drug2	NN	_	12	nmod
22	.	.	.	_	8	punct

1	No	no	DT	_	2	neg
2	information	information	NN	_	4	nsubj
3	is	be	VBZ	_	4	cop
4	available	available	JJ	_	0	ROOT
5	about	about	IN	_	7	case
6	the	the	DT	_	7	det
7	use	use	NN	_	4	nmod
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	concurrently	concurrently	RB	_	12	advmod
11	with	with	IN	_	12	case
12	drug2	drug2	NN	_	7	nmod
13	.	.	.	_	4	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	cautiously	cautiously	RB	_	4	advmod
6	in	in	IN	_	7	case
7	patients	patient	NNS	_	4	nmod
8	with	with	IN	_	9	case
9	hyperthyroidism	hyperthyroidism	NN	_	7	nmod
10	,	,	,	_	9	punct
11	hypertension	hypertension	NN	_	9	conj
12	and	and	CC	_	9	cc
13	cardiac	cardiac	JJ	_	14	amod
14	arrhythmias	arrhythmia	NNS	_	9	conj
15	.	.	.	_	4	punct

1	All	all	DT	_	2	det
2	drug1	drug1	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	used	use	VBN	_	0	ROOT
6	cautiously	cautiously	RB	_	5	advmod
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	5	nmod
9	taking	take	VBG	_	8	acl
10	drug2	drug2	NN	_	9	dobj
11	.	.	.	_	5	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	should	should	MD	_	5	aux
3	not	not	RB	_	5	neg
4	be	be	VB	_	5	auxpass
5	administered	administer	VBN	_	0	ROOT
6	concomitantly	concomitantly	RB	_	5	advmod
7	with	with	IN	_	9	case
8	other	other	JJ	_	9	amod
9	drug2	drug2	NN	_	5	nmod
10	-LRB-	-lrb-	-LRB-	_	13	punct
11	such	such	JJ	_	13	case
12	as	as	IN	_	11	mwe
13	drug3	drug3	NN	_	9	nmod
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	because	because	IN	_	19	case
16	of	of	IN	_	15	mwe
17	possible	possible	JJ	_	19	amod
18	additive	additive	JJ	_	19	amod
19	effects	effect	NNS	_	5	nmod
20	and	and	CC	_	19	cc
21	increased	increase	VBD	_	22	amod
22	toxicity	toxicity	NN	_	19	conj
23	.	.	.	_	5	punct

1	Combined	combined	JJ	_	2	amod
2	effects	effect	NNS	_	4	nsubj
3	may	may	MD	_	4	aux
4	induce	induce	VB	_	0	ROOT
5	serious	serious	JJ	_	7	amod
6	cardiac	cardiac	JJ	_	7	amod
7	arrhythmias	arrhythmia	NNS	_	4	dobj
8	.	.	.	_	4	punct

1	They	they	PRP	_	4	nsubjpass
2	may	may	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	administered	administer	VBN	_	0	ROOT
5	alternately	alternately	RB	_	4	advmod
6	when	when	WRB	_	15	advmod
7	the	the	DT	_	9	det
8	preceding	preceding	JJ	_	9	amod
9	effect	effect	NN	_	15	nsubj
10	of	of	IN	_	13	case
11	other	other	JJ	_	13	amod
12	such	such	JJ	_	13	amod
13	drug	drug	NN	_	9	nmod
14	has	have	VBZ	_	15	aux
15	subsided	subside	VBN	_	4	advcl
16	.	.	.	_	4	punct

1	Administration	administration	NN	_	19	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	to	to	TO	_	5	case
5	patients	patient	NNS	_	1	nmod
6	receiving	receive	VBG	_	5	acl
7	drug2	drug2	NN	_	6	dobj
8	or	or	CC	_	7	cc
9	drug3	drug3	NN	_	7	conj
10	such	such	JJ	_	12	case
11	as	as	IN	_	10	mwe
12	drug4	drug4	NN	_	5	nmod
13	which	which	WDT	_	14	nsubj
14	sensitize	sensitize	VBP	_	12	acl:relcl
15	the	the	DT	_	16	det
16	myocardium	myocardium	NN	_	14	dobj
17	,	,	,	_	19	punct
18	may	may	MD	_	19	aux
19	induce	induce	VB	_	0	ROOT
20	cardiac	cardiac	JJ	_	21	amod
21	arrhythmia	arrhythmia	NN	_	19	dobj
22	.	.	.	_	19	punct
23	.	.	.	_	19	punct

1	When	when	WRB	_	2	advmod
2	encountered	encounter	VBN	_	7	advcl
3	,	,	,	_	7	punct
4	such	such	JJ	_	5	amod
5	arrhythmias	arrhythmia	NNS	_	7	nsubj
6	may	may	MD	_	7	aux
7	respond	respond	VB	_	0	ROOT
8	to	to	TO	_	9	case
9	administration	administration	NN	_	7	nmod
10	of	of	IN	_	12	case
11	a	a	DT	_	12	det
12	drug1	drug1	NN	_	9	nmod
13	.	.	.	_	7	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	also	also	RB	_	5	advmod
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	used	use	VBN	_	0	ROOT
6	cautiously	cautiously	RB	_	5	advmod
7	with	with	IN	_	9	case
8	other	other	JJ	_	9	amod
9	drugs	drug	NNS	_	5	nmod
10	-LRB-	-lrb-	-LRB-	_	13	punct
11	e.g.	e.g.	FW	_	13	dep
12	,	,	,	_	13	punct
13	drug2	drug2	NN	_	9	dep
14	,	,	,	_	13	punct
15	drug3	drug3	NN	_	13	appos
16	-RRB-	-rrb-	-RRB-	_	13	punct
17	that	that	WDT	_	18	nsubj
18	sensitize	sensitize	VBP	_	9	acl:relcl
19	the	the	DT	_	20	det
20	myocardium	myocardium	NN	_	18	dobj
21	to	to	TO	_	23	case
22	the	the	DT	_	23	det
23	actions	action	NNS	_	18	nmod
24	of	of	IN	_	25	case
25	drug4	drug4	NN	_	23	nmod
26	.	.	.	_	5	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	decrease	decrease	VB	_	0	ROOT
4	vascular	vascular	JJ	_	5	amod
5	response	response	NN	_	3	dobj
6	to	to	TO	_	8	case
7	pressor	pressor	NN	_	8	compound
8	drugs	drug	NNS	_	5	nmod
9	such	such	JJ	_	11	case
10	as	as	IN	_	9	mwe
11	drug2	drug2	NN	_	8	nmod
12	.	.	.	_	3	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	antagonize	antagonize	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	neuron	neuron	NN	_	6	compound
6	blockade	blockade	NN	_	3	dobj
7	produced	produce	VBN	_	6	acl
8	by	by	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	resulting	result	VBG	_	9	acl
11	in	in	IN	_	14	case
12	decreased	decrease	VBN	_	14	amod
13	antihypertensive	antihypertensive	JJ	_	14	amod
14	effect	effect	NN	_	10	nmod
15	and	and	CC	_	3	cc
16	requiring	require	VBG	_	3	conj
17	increased	increase	VBN	_	18	amod
18	dosage	dosage	NN	_	16	dobj
19	of	of	IN	_	21	case
20	the	the	DT	_	21	det
21	latter	latter	JJ	_	18	nmod
22	.	.	.	_	3	punct

1	May	May	NNP	_	2	nsubj
2	interact	interact	VBP	_	0	ROOT
3	drug1	drug1	NN	_	2	dobj
4	-LRB-	-lrb-	-LRB-	_	7	punct
5	altered	altered	JJ	_	7	amod
6	hypo-prothrombinemic	hypo-prothrombinemic	JJ	_	7	amod
7	effect	effect	NN	_	3	appos
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	,	,	,	_	3	punct
10	drug2	drug2	NN	_	3	conj
11	,	,	,	_	3	punct
12	drug3	drug3	NN	_	3	conj
13	and	and	CC	_	3	cc
14	other	other	JJ	_	15	amod
15	inducers	inducer	NNS	_	3	conj
16	of	of	IN	_	21	case
17	hepatic	hepatic	JJ	_	21	amod
18	microsomal	microsomal	JJ	_	21	amod
19	enzyme	enzyme	NN	_	21	compound
20	oxidation	oxidation	NN	_	21	compound
21	system	system	NN	_	15	nmod
22	-LRB-	-lrb-	-LRB-	_	24	punct
23	decreased	decrease	VBN	_	24	amod
24	effect	effect	NN	_	2	dep
25	of	of	IN	_	26	case
26	drug4	drug4	NN	_	24	nmod
27	-RRB-	-rrb-	-RRB-	_	24	punct
28	,	,	,	_	2	punct
29	drug5	drug5	NN	_	2	xcomp
30	-LRB-	-lrb-	-LRB-	_	32	punct
31	increased	increase	VBN	_	32	amod
32	effect	effect	NN	_	29	dep
33	of	of	IN	_	34	case
34	drug6	drug6	NN	_	32	nmod
35	-RRB-	-rrb-	-RRB-	_	32	punct
36	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concomitant	concomitant	JJ	_	4	amod
4	administration	administration	NN	_	11	nsubjpass
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	drug3	drug3	NN	_	6	conj
9	is	be	VBZ	_	11	auxpass
10	not	not	RB	_	11	neg
11	recommended	recommend	VBN	_	1	dep
12	because	because	IN	_	15	mark
13	drug4	drug4	NN	_	15	nsubjpass
14	is	be	VBZ	_	15	auxpass
15	displaced	displace	VBN	_	11	advcl
16	from	from	IN	_	19	case
17	its	its	PRP$	_	19	nmod:poss
18	binding	binding	NN	_	19	amod
19	sites	site	NNS	_	15	nmod
20	during	during	IN	_	23	case
21	the	the	DT	_	23	det
22	concomitant	concomitant	JJ	_	23	amod
23	administration	administration	NN	_	15	nmod
24	of	of	IN	_	25	case
25	drug5	drug5	NN	_	23	nmod
26	,	,	,	_	15	punct
27	resulting	result	VBG	_	15	advcl
28	in	in	IN	_	31	case
29	lower	lower	JJR	_	31	amod
30	plasma	plasma	NN	_	31	compound
31	concentrations	concentration	NNS	_	27	nmod
32	,	,	,	_	31	punct
33	peak	peak	JJ	_	35	amod
34	plasma	plasma	NN	_	35	compound
35	levels	level	NNS	_	31	conj
36	,	,	,	_	31	punct
37	and	and	CC	_	31	cc
38	AUC	auc	NN	_	39	compound
39	values	value	NNS	_	31	conj
40	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	While	while	IN	_	7	mark
4	studies	study	NNS	_	7	nsubj
5	have	have	VBP	_	7	aux
6	not	not	RB	_	7	neg
7	shown	show	VBN	_	17	advcl
8	drug2	drug2	NN	_	7	dobj
9	to	to	TO	_	10	mark
10	interact	interact	VB	_	7	xcomp
11	with	with	IN	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	,	,	,	_	17	punct
14	caution	caution	NN	_	17	nsubjpass
15	should	should	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	exercised	exercise	VBN	_	1	dep
18	,	,	,	_	17	punct
19	nonetheless	nonetheless	RB	_	17	advmod
20	,	,	,	_	17	punct
21	since	since	IN	_	25	mark
22	interactions	interaction	NNS	_	25	nsubjpass
23	have	have	VBP	_	25	aux
24	been	be	VBN	_	25	auxpass
25	seen	see	VBN	_	17	advcl
26	with	with	IN	_	28	case
27	other	other	JJ	_	28	amod
28	drug4	drug4	NN	_	25	nmod
29	.	.	.	_	1	punct

1	Because	because	IN	_	3	mark
2	prostaglandins	prostaglandin	NNS	_	3	nsubj
3	play	play	VBP	_	29	advcl
4	an	a	DT	_	6	det
5	important	important	JJ	_	6	amod
6	role	role	NN	_	3	dobj
7	in	in	IN	_	8	case
8	hemostasis	hemostasis	NN	_	3	nmod
9	,	,	,	_	3	punct
10	and	and	CC	_	3	cc
11	drug1	drug1	NN	_	12	nsubj
12	affect	affect	VBP	_	3	conj
13	platelet	platelet	NN	_	14	compound
14	function	function	NN	_	12	dobj
15	as	as	RB	_	12	advmod
16	well	well	RB	_	15	mwe
17	,	,	,	_	29	punct
18	concurrent	concurrent	JJ	_	19	amod
19	therapy	therapy	NN	_	29	nsubj
20	with	with	IN	_	22	case
21	all	all	DT	_	22	det
22	drug2	drug2	NN	_	19	nmod
23	,	,	,	_	22	punct
24	including	include	VBG	_	25	case
25	drug3	drug3	NN	_	22	nmod
26	,	,	,	_	22	punct
27	and	and	CC	_	22	cc
28	drug4	drug4	NN	_	22	conj
29	requires	require	VBZ	_	0	ROOT
30	close	close	JJ	_	31	amod
31	monitoring	monitoring	NN	_	29	dobj
32	of	of	IN	_	33	case
33	patients	patient	NNS	_	31	nmod
34	to	to	TO	_	36	mark
35	be	be	VB	_	36	cop
36	certain	certain	JJ	_	29	xcomp
37	that	that	IN	_	45	mark
38	no	no	DT	_	39	neg
39	change	change	NN	_	45	nsubjpass
40	in	in	IN	_	43	case
41	their	they	PRP$	_	43	nmod:poss
42	drug5	drug5	NN	_	43	compound
43	dosage	dosage	NN	_	39	nmod
44	is	be	VBZ	_	45	auxpass
45	required	require	VBN	_	36	ccomp
46	.	.	.	_	29	punct

1	drug1	drug1	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	,	,	,	_	1	punct
5	drug3	drug3	NN	_	1	conj
6	:	:	:	_	1	punct
7	drug4	drug4	NN	_	14	nsubj
8	,	,	,	_	7	punct
9	like	like	IN	_	11	case
10	other	other	JJ	_	11	amod
11	drug5	drug5	NN	_	7	nmod
12	,	,	,	_	7	punct
13	may	may	MD	_	14	aux
14	affect	affect	VB	_	1	dep
15	renal	renal	JJ	_	16	amod
16	prostaglandins	prostaglandin	NNS	_	14	dobj
17	and	and	CC	_	14	cc
18	increase	increase	VB	_	14	conj
19	the	the	DT	_	20	det
20	toxicity	toxicity	NN	_	18	dobj
21	of	of	IN	_	23	case
22	certain	certain	JJ	_	23	amod
23	drugs	drug	NNS	_	20	nmod
24	.	.	.	_	1	punct

1	Ingestion	ingestion	NN	_	5	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	may	may	MD	_	5	aux
5	increase	increase	VB	_	0	ROOT
6	serum	serum	NN	_	7	compound
7	concentrations	concentration	NNS	_	5	dobj
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	drug3	drug3	NN	_	9	conj
12	and	and	CC	_	5	cc
13	increase	increase	NN	_	5	conj
14	drug4	drug4	NN	_	16	compound
15	s	be	VBZ	_	16	compound
16	nephrotoxicity	nephrotoxicity	NN	_	13	dobj
17	.	.	.	_	5	punct

1	Patients	patient	NNS	_	25	nsubj
2	who	who	WP	_	3	nsubj
3	begin	begin	VBP	_	1	acl:relcl
4	taking	take	VBG	_	3	xcomp
5	drug1	drug1	NN	_	4	dobj
6	or	or	CC	_	5	cc
7	who	who	WP	_	8	nsubj
8	increase	increase	VBP	_	5	conj
9	their	they	PRP$	_	11	nmod:poss
10	drug2	drug2	NN	_	11	compound
11	dose	dose	NN	_	8	dobj
12	or	or	CC	_	11	cc
13	any	any	DT	_	15	det
14	other	other	JJ	_	15	amod
15	drug3	drug3	NN	_	11	conj
16	while	while	IN	_	17	mark
17	taking	take	VBG	_	3	advcl
18	drug4	drug4	NN	_	17	dobj
19	,	,	,	_	18	punct
20	drug5	drug5	NN	_	18	conj
21	,	,	,	_	18	punct
22	or	or	CC	_	18	cc
23	drug6	drug6	NN	_	18	conj
24	may	may	MD	_	25	aux
25	develop	develop	VB	_	0	ROOT
26	toxicity	toxicity	NN	_	27	compound
27	characteristics	characteristic	NNS	_	25	dobj
28	for	for	IN	_	30	case
29	these	these	DT	_	30	det
30	drugs	drug	NNS	_	27	nmod
31	.	.	.	_	25	punct

1	They	they	PRP	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	observed	observe	VBN	_	0	ROOT
5	closely	closely	RB	_	4	advmod
6	,	,	,	_	4	punct
7	particularly	particularly	RB	_	12	advmod
8	if	if	IN	_	12	mark
9	renal	renal	JJ	_	10	amod
10	function	function	NN	_	12	nsubj
11	is	be	VBZ	_	12	cop
12	impaired	impaired	JJ	_	4	advcl
13	.	.	.	_	4	punct

1	In	in	IN	_	3	case
2	the	the	DT	_	3	det
3	case	case	NN	_	11	nmod
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	,	,	,	_	11	punct
7	serum	serum	NN	_	8	compound
8	levels	level	NNS	_	11	nsubjpass
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	monitored	monitor	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	nsubj
4	decreases	decrease	VBZ	_	1	appos
5	drug3	drug3	NN	_	7	compound
6	renal	renal	JJ	_	7	amod
7	clearance	clearance	NN	_	4	dobj
8	and	and	CC	_	4	cc
9	increases	increase	VBZ	_	4	conj
10	drug4	drug4	NN	_	12	compound
11	plasma	plasma	NN	_	12	compound
12	levels	level	NNS	_	9	dobj
13	.	.	.	_	1	punct

1	In	in	IN	_	2	case
2	patients	patient	NNS	_	12	nmod
3	taking	take	VBG	_	2	acl
4	drug1	drug1	NN	_	3	dobj
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	concomitantly	concomitantly	RB	_	3	advmod
8	,	,	,	_	12	punct
9	drug3	drug3	NN	_	10	compound
10	toxicity	toxicity	NN	_	12	nsubj
11	may	may	MD	_	12	aux
12	develop	develop	VB	_	0	ROOT
13	.	.	.	_	12	punct

1	Oral	oral	JJ	_	2	amod
2	drug1	drug1	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	drug2	drug2	NN	_	7	nsubj
5	does	do	VBZ	_	7	aux
6	not	not	RB	_	7	neg
7	alter	alter	VB	_	2	dep
8	glucose	glucose	NN	_	9	compound
9	metabolism	metabolism	NN	_	7	dobj
10	in	in	IN	_	12	case
11	normal	normal	JJ	_	12	amod
12	subjects	subject	NNS	_	7	nmod
13	nor	nor	CC	_	7	cc
14	does	do	VBZ	_	16	aux
15	it	it	PRP	_	16	nsubj
16	alter	alter	VB	_	7	conj
17	the	the	DT	_	18	det
18	effects	effect	NNS	_	16	dobj
19	of	of	IN	_	21	case
20	oral	oral	JJ	_	21	amod
21	drug3	drug3	NN	_	18	nmod
22	.	.	.	_	2	punct

1	There	there	EX	_	2	expl
2	are	be	VBP	_	0	ROOT
3	rare	rare	JJ	_	4	amod
4	reports	report	NNS	_	2	nsubj
5	,	,	,	_	2	punct
6	however	however	RB	_	2	advmod
7	,	,	,	_	2	punct
8	from	from	IN	_	10	case
9	marketing	marketing	NN	_	10	compound
10	experiences	experience	NNS	_	2	nmod
11	,	,	,	_	10	punct
12	of	of	IN	_	13	case
13	changes	change	NNS	_	10	nmod
14	in	in	IN	_	15	case
15	effects	effect	NNS	_	13	nmod
16	of	of	IN	_	17	case
17	drug1	drug1	NN	_	15	nmod
18	or	or	CC	_	17	cc
19	oral	oral	JJ	_	20	amod
20	drug2	drug2	NN	_	17	conj
21	in	in	IN	_	23	case
22	the	the	DT	_	23	det
23	presence	presence	NN	_	13	nmod
24	of	of	IN	_	25	case
25	drug3	drug3	NN	_	23	nmod
26	that	that	WDT	_	27	nsubj
27	necessitated	necessitate	VBD	_	13	acl:relcl
28	changes	change	NNS	_	27	dobj
29	in	in	IN	_	31	case
30	the	the	DT	_	31	det
31	doses	dose	NNS	_	28	nmod
32	of	of	IN	_	34	case
33	such	such	JJ	_	34	amod
34	agents	agent	NNS	_	31	nmod
35	.	.	.	_	2	punct

1	Both	both	DT	_	2	cc:preconj
2	hypo	hypo	NN	_	9	nsubjpass
3	-	-	:	_	2	punct
4	and	and	CC	_	2	cc
5	hyperglycemic	hyperglycemic	JJ	_	2	conj
6	effects	effect	NNS	_	2	dep
7	have	have	VBP	_	9	aux
8	been	be	VBN	_	9	auxpass
9	reported	report	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	A	a	DT	_	4	det
2	direct	direct	JJ	_	4	amod
3	causal	causal	JJ	_	4	amod
4	relationship	relationship	NN	_	8	nsubjpass
5	has	have	VBZ	_	8	aux
6	not	not	RB	_	8	neg
7	been	be	VBN	_	8	auxpass
8	established	establish	VBN	_	0	ROOT
9	,	,	,	_	8	punct
10	but	but	CC	_	8	cc
11	physicians	physician	NNS	_	13	nsubj
12	should	should	MD	_	13	aux
13	consider	consider	VB	_	8	conj
14	the	the	DT	_	15	det
15	possibility	possibility	NN	_	13	dobj
16	that	that	IN	_	19	mark
17	drug1	drug1	NN	_	19	nsubj
18	may	may	MD	_	19	aux
19	alter	alter	VB	_	15	ccomp
20	a	a	DT	_	24	det
21	diabetic	diabetic	JJ	_	24	amod
22	patient	patient	NN	_	24	compound
23	s	s	NNS	_	24	compound
24	response	response	NN	_	19	dobj
25	to	to	TO	_	26	case
26	drug2	drug2	NN	_	24	nmod
27	or	or	CC	_	26	cc
28	oral	oral	JJ	_	29	amod
29	drug3	drug3	NN	_	26	conj
30	.	.	.	_	8	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	8	nsubj
4	and	and	CC	_	3	cc
5	other	other	JJ	_	6	amod
6	drug3	drug3	NN	_	3	conj
7	can	can	MD	_	8	aux
8	inhibit	inhibit	VB	_	1	dep
9	the	the	DT	_	10	det
10	activity	activity	NN	_	8	dobj
11	of	of	IN	_	12	case
12	drug4	drug4	NN	_	10	nmod
13	.	.	.	_	1	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	treatment	treatment	NN	_	7	nsubjpass
3	with	with	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	may	may	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	associated	associate	VBN	_	0	ROOT
8	with	with	IN	_	12	case
9	increased	increase	VBN	_	12	amod
10	serum	serum	NN	_	12	compound
11	potassium	potassium	NN	_	12	compound
12	levels	level	NNS	_	7	nmod
13	.	.	.	_	7	punct

1	Other	other	JJ	_	2	amod
2	Drugs	drug	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	In	in	IN	_	6	case
5	small	small	JJ	_	6	amod
6	groups	group	NNS	_	37	nmod
7	of	of	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	-LRB-	-lrb-	-LRB-	_	13	punct
10	7-10	7-10	CD	_	13	nummod
11	/	/	:	_	13	punct
12	interaction	interaction	NN	_	13	compound
13	study	study	NN	_	8	appos
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	,	,	,	_	37	punct
16	the	the	DT	_	18	det
17	concomitant	concomitant	JJ	_	18	amod
18	administration	administration	NN	_	37	nsubj
19	of	of	IN	_	20	case
20	drug1	drug1	NN	_	18	nmod
21	,	,	,	_	20	punct
22	drug2	drug2	NN	_	20	conj
23	,	,	,	_	20	punct
24	drug3	drug3	NN	_	20	conj
25	,	,	,	_	20	punct
26	drug4	drug4	NN	_	20	conj
27	,	,	,	_	20	punct
28	drug5	drug5	NN	_	20	conj
29	,	,	,	_	20	punct
30	drug6	drug6	NN	_	20	conj
31	,	,	,	_	20	punct
32	or	or	CC	_	20	cc
33	drug7	drug7	NN	_	20	conj
34	did	do	VBD	_	37	aux
35	not	not	RB	_	37	neg
36	significantly	significantly	RB	_	37	advmod
37	affect	affect	VB	_	2	dep
38	the	the	DT	_	40	det
39	peak	peak	NN	_	40	compound
40	levels	level	NNS	_	37	dobj
41	and	and	CC	_	40	cc
42	AUC	auc	NN	_	43	compound
43	values	value	NNS	_	40	conj
44	of	of	IN	_	45	case
45	drug8	drug8	NN	_	40	nmod
46	.	.	.	_	2	punct

1	drug1	drug1	NN	_	2	compound
2	toxicity	toxicity	NN	_	5	nsubjpass
3	has	have	VBZ	_	5	aux
4	been	be	VBN	_	5	auxpass
5	reported	report	VBN	_	0	ROOT
6	to	to	TO	_	8	mark
7	have	have	VB	_	8	aux
8	occurred	occur	VBN	_	5	xcomp
9	in	in	IN	_	11	case
10	a	a	DT	_	11	det
11	patient	patient	NN	_	8	nmod
12	on	on	IN	_	15	case
13	chronic	chronic	JJ	_	15	amod
14	drug2	drug2	NN	_	15	compound
15	treatment	treatment	NN	_	11	nmod
16	following	follow	VBG	_	18	case
17	the	the	DT	_	18	det
18	initiation	initiation	NN	_	8	nmod
19	of	of	IN	_	21	case
20	drug3	drug3	NN	_	21	compound
21	therapy	therapy	NN	_	18	nmod
22	.	.	.	_	5	punct

1	Protein	protein	NN	_	2	compound
2	Binding	binding	NN	_	0	ROOT
3	In	in	FW	_	4	compound
4	vitro	vitro	FW	_	2	advmod
5	,	,	,	_	2	punct
6	drug1	drug1	NN	_	7	nsubj
7	interferes	interfere	VBZ	_	2	appos
8	minimally	minimally	RB	_	9	advmod
9	or	or	CC	_	7	advmod
10	not	not	RB	_	12	neg
11	at	at	IN	_	12	case
12	all	all	DT	_	9	conj
13	with	with	IN	_	16	case
14	the	the	DT	_	16	det
15	protein	protein	NN	_	16	compound
16	binding	binding	NN	_	12	nmod
17	of	of	IN	_	18	case
18	drug2	drug2	NN	_	16	nmod
19	-LRB-	-lrb-	-LRB-	_	22	punct
20	20	20	CD	_	21	compound
21	%	%	NN	_	22	amod
22	decrease	decrease	NN	_	16	dep
23	in	in	IN	_	24	case
24	binding	binding	NN	_	22	nmod
25	-RRB-	-rrb-	-RRB-	_	22	punct
26	,	,	,	_	16	punct
27	drug3	drug3	NN	_	16	conj
28	,	,	,	_	16	punct
29	drug4	drug4	NN	_	16	conj
30	-LRB-	-lrb-	-LRB-	_	33	punct
31	10	10	CD	_	32	compound
32	%	%	NN	_	33	amod
33	decrease	decrease	NN	_	29	dep
34	in	in	IN	_	35	case
35	binding	binding	NN	_	33	nmod
36	-RRB-	-rrb-	-RRB-	_	33	punct
37	,	,	,	_	16	punct
38	or	or	CC	_	16	cc
39	drug5	drug5	NN	_	16	conj
40	.	.	.	_	2	punct

1	drug1	drug1	NN	_	17	nsubj
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	,	,	,	_	1	punct
5	drug3	drug3	NN	_	1	conj
6	,	,	,	_	1	punct
7	drug4	drug4	NN	_	1	conj
8	,	,	,	_	1	punct
9	drug5	drug5	NN	_	1	conj
10	,	,	,	_	1	punct
11	drug6	drug6	NN	_	1	conj
12	,	,	,	_	1	punct
13	drug7	drug7	NN	_	1	conj
14	,	,	,	_	1	punct
15	and	and	CC	_	1	cc
16	drug8	drug8	NN	_	1	conj
17	have	have	VBP	_	0	ROOT
18	no	no	DT	_	19	neg
19	influence	influence	NN	_	17	dobj
20	in	in	FW	_	21	compound
21	vitro	vitro	FW	_	17	advmod
22	on	on	IN	_	25	case
23	the	the	DT	_	25	det
24	protein	protein	NN	_	25	compound
25	binding	binding	NN	_	17	nmod
26	of	of	IN	_	27	case
27	drug9	drug9	NN	_	25	nmod
28	in	in	IN	_	30	case
29	human	human	JJ	_	30	amod
30	serum	serum	NN	_	25	nmod
31	.	.	.	_	17	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	4	amod
2	Test	test	NN	_	4	compound
3	Interactions	interaction	NNS	_	4	compound
4	Effect	effect	NN	_	0	ROOT
5	on	on	IN	_	7	case
6	Blood	blood	NN	_	7	compound
7	Coagulation	coagulation	NN	_	4	nmod
8	:	:	:	_	4	punct
9	drug1	drug1	NN	_	10	nsubj
10	increases	increase	VBZ	_	4	dep
11	platelet	platelet	NN	_	13	compound
12	aggregation	aggregation	NN	_	13	compound
13	time	time	NN	_	10	dobj
14	but	but	CC	_	10	cc
15	does	do	VBZ	_	17	aux
16	not	not	RB	_	17	neg
17	affect	affect	VB	_	10	conj
18	bleeding	bleeding	JJ	_	19	amod
19	time	time	NN	_	17	dobj
20	,	,	,	_	19	punct
21	plasma	plasma	NN	_	24	compound
22	thrombin	thrombin	NN	_	24	compound
23	clotting	clotting	NN	_	24	compound
24	time	time	NN	_	19	conj
25	,	,	,	_	19	punct
26	plasma	plasma	NN	_	27	compound
27	fibrinogen	fibrinogen	NN	_	19	conj
28	,	,	,	_	19	punct
29	or	or	CC	_	19	cc
30	factors	factor	NNS	_	31	compound
31	V	v	NN	_	19	conj
32	and	and	CC	_	31	cc
33	VII	vii	NN	_	31	conj
34	to	to	TO	_	35	case
35	XII	XII	NNP	_	17	nmod
36	.	.	.	_	4	punct

1	Statistically	statistically	RB	_	2	advmod
2	significant	significant	JJ	_	3	amod
3	changes	change	NNS	_	12	nsubjpass
4	in	in	IN	_	5	case
5	prothrombin	prothrombin	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	partial	partial	JJ	_	9	amod
8	thromboplastin	thromboplastin	NN	_	9	compound
9	times	time	NNS	_	5	conj
10	have	have	VBP	_	12	aux
11	been	be	VBN	_	12	auxpass
12	reported	report	VBN	_	0	ROOT
13	in	in	IN	_	15	case
14	normal	normal	JJ	_	15	amod
15	volunteers	volunteer	NNS	_	12	nmod
16	.	.	.	_	12	punct

1	The	the	DT	_	3	det
2	mean	mean	JJ	_	3	amod
3	changes	change	NNS	_	5	nsubjpass
4	were	be	VBD	_	5	auxpass
5	observed	observe	VBN	_	0	ROOT
6	to	to	TO	_	11	mark
7	be	be	VB	_	11	cop
8	less	less	JJR	_	10	advmod
9	than	than	IN	_	8	mwe
10	1	1	CD	_	11	nummod
11	second	second	JJ	_	5	xcomp
12	in	in	IN	_	14	case
13	both	both	CC	_	14	det
14	instances	instance	NNS	_	11	nmod
15	,	,	,	_	11	punct
16	however	however	RB	_	11	advmod
17	,	,	,	_	11	punct
18	and	and	CC	_	11	cc
19	are	be	VBP	_	20	cop
20	unlikely	unlikely	JJ	_	11	conj
21	to	to	TO	_	24	mark
22	be	be	VB	_	24	cop
23	clinically	clinically	RB	_	24	advmod
24	important	important	JJ	_	20	xcomp
25	.	.	.	_	5	punct

1	drug1	drug1	NN	_	6	nsubj
2	is	be	VBZ	_	6	cop
3	a	a	DT	_	6	det
4	prostaglandin	prostaglandin	NN	_	6	compound
5	synthetase	synthetase	NN	_	6	compound
6	inhibitor	inhibitor	NN	_	0	ROOT
7	,	,	,	_	6	punct
8	however	however	RB	_	6	advmod
9	,	,	,	_	6	punct
10	and	and	CC	_	6	cc
11	all	all	DT	_	12	det
12	drugs	drug	NNS	_	17	nsubj
13	that	that	WDT	_	14	nsubj
14	inhibit	inhibit	VBP	_	12	acl:relcl
15	prostaglandin	prostaglandin	NN	_	16	compound
16	synthesis	synthesis	NN	_	14	dobj
17	interfere	interfere	VBP	_	6	conj
18	with	with	IN	_	20	case
19	platelet	platelet	NN	_	20	compound
20	function	function	NN	_	17	nmod
21	to	to	TO	_	23	case
22	some	some	DT	_	23	det
23	degree	degree	NN	_	20	nmod
24	;	;	:	_	6	punct

1	therefore	therefore	RB	_	16	advmod
2	,	,	,	_	16	punct
3	patients	patient	NNS	_	16	nsubjpass
4	who	who	WP	_	8	nsubjpass
5	may	may	MD	_	8	aux
6	be	be	VB	_	8	auxpass
7	adversely	adversely	RB	_	8	advmod
8	affected	affect	VBN	_	3	acl:relcl
9	by	by	IN	_	12	case
10	such	such	PDT	_	12	det:predet
11	an	a	DT	_	12	det
12	action	action	NN	_	8	nmod
13	should	should	MD	_	16	aux
14	be	be	VB	_	16	auxpass
15	carefully	carefully	RB	_	16	advmod
16	observed	observe	VBN	_	0	ROOT
17	.	.	.	_	16	punct

1	Certain	certain	JJ	_	3	amod
2	other	other	JJ	_	3	amod
3	drug1	drug1	NN	_	12	nsubjpass
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	drug2	drug2	NN	_	3	dep
6	and	and	CC	_	5	cc
7	drug3	drug3	NN	_	5	conj
8	-RRB-	-rrb-	-RRB-	_	5	punct
9	have	have	VBP	_	12	aux
10	also	also	RB	_	12	advmod
11	been	be	VBN	_	12	auxpass
12	reported	report	VBN	_	0	ROOT
13	to	to	TO	_	14	mark
14	interfere	interfere	VB	_	12	xcomp
15	with	with	IN	_	18	case
16	the	the	DT	_	18	det
17	nerve	nerve	NN	_	18	compound
18	transmission	transmission	NN	_	14	nmod
19	at	at	IN	_	22	case
20	the	the	DT	_	22	det
21	neuromuscular	neuromuscular	JJ	_	22	amod
22	junction	junction	NN	_	18	nmod
23	.	.	.	_	12	punct

1	Based	base	VBN	_	5	case
2	on	on	IN	_	5	case
3	this	this	DT	_	5	det
4	reported	report	VBN	_	5	amod
5	activity	activity	NN	_	11	advcl
6	,	,	,	_	11	punct
7	they	they	PRP	_	11	nsubjpass
8	should	should	MD	_	11	aux
9	not	not	RB	_	11	neg
10	be	be	VB	_	11	auxpass
11	given	give	VBN	_	0	ROOT
12	concomitantly	concomitantly	RB	_	15	advmod
13	with	with	IN	_	15	case
14	drug1	drug1	NN	_	15	compound
15	Parenteral	parenteral	JJ	_	11	nmod
16	except	except	IN	_	20	case
17	with	with	IN	_	20	case
18	the	the	DT	_	20	det
19	greatest	greatest	JJS	_	20	amod
20	caution	caution	NN	_	15	nmod
21	.	.	.	_	11	punct

1	drug1	drug1	NN	_	22	nsubj
2	-LRB-	-lrb-	-LRB-	_	5	punct
3	eg	eg	FW	_	5	dep
4	,	,	,	_	5	punct
5	drug2	drug2	NN	_	1	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	and	and	CC	_	1	cc
8	other	other	JJ	_	9	amod
9	drugs	drug	NNS	_	1	conj
10	,	,	,	_	9	punct
11	including	include	VBG	_	12	case
12	ether	ether	NN	_	9	nmod
13	,	,	,	_	12	punct
14	drug3	drug3	NN	_	12	conj
15	,	,	,	_	12	punct
16	drug4	drug4	NN	_	12	conj
17	,	,	,	_	12	punct
18	drug5	drug5	NN	_	12	conj
19	and	and	CC	_	12	cc
20	drug6	drug6	NN	_	12	conj
21	,	,	,	_	1	punct
22	potentiate	potentiate	VB	_	0	ROOT
23	the	the	DT	_	26	det
24	neuromuscular	neuromuscular	JJ	_	26	amod
25	blocking	blocking	NN	_	26	compound
26	effect	effect	NN	_	22	dobj
27	and	and	CC	_	22	cc
28	should	should	MD	_	30	aux
29	be	be	VB	_	30	auxpass
30	used	use	VBN	_	22	conj
31	with	with	IN	_	33	case
32	extreme	extreme	JJ	_	33	amod
33	caution	caution	NN	_	30	nmod
34	in	in	IN	_	35	case
35	patients	patient	NNS	_	33	nmod
36	being	be	VBG	_	37	auxpass
37	treated	treat	VBN	_	35	acl
38	with	with	IN	_	40	case
39	drug7	drug7	NN	_	40	compound
40	Parenteral	parenteral	NN	_	37	nmod
41	.	.	.	_	22	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	enhance	enhance	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	nephrotoxicity	nephrotoxicity	NN	_	3	dobj
6	of	of	IN	_	8	case
7	drug2	drug2	NN	_	8	compound
8	Parenteral	parenteral	NN	_	5	nmod
9	.	.	.	_	3	punct

1	The	the	DT	_	3	det
2	concomitant	concomitant	JJ	_	3	amod
3	use	use	NN	_	11	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	8	compound
8	Parenteral	parenteral	NN	_	5	conj
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	avoided	avoid	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	Antiacid	Antiacid	NNP	_	0	ROOT
2	,	,	,	_	1	punct
3	drug1	drug1	NN	_	1	conj
4	,	,	,	_	1	punct
5	drug2	drug2	NN	_	1	conj
6	,	,	,	_	1	punct
7	drug3	drug3	NN	_	1	conj
8	,	,	,	_	1	punct
9	drug4	drug4	NN	_	1	conj
10	,	,	,	_	1	punct
11	Indanavir	Indanavir	NNP	_	1	conj
12	,	,	,	_	1	punct
13	drug5	drug5	NN	_	1	conj
14	,	,	,	_	1	punct
15	drug6	drug6	NN	_	1	conj
16	,	,	,	_	1	punct
17	Phenobarbitol	Phenobarbitol	NNP	_	1	conj
18	,	,	,	_	1	punct
19	drug7	drug7	NN	_	1	conj
20	,	,	,	_	1	punct
21	drug8	drug8	NN	_	1	conj
22	,	,	,	_	1	punct
23	drug9	drug9	NN	_	1	conj
24	,	,	,	_	1	punct
25	Ritanovir	Ritanovir	NNP	_	1	conj
26	,	,	,	_	1	punct
27	drug10	drug10	NN	_	1	appos
28	.	.	.	_	1	punct

1	Although	although	IN	_	3	mark
2	drug1	drug1	NN	_	3	nsubj
3	used	use	VBN	_	24	advcl
4	alone	alone	RB	_	3	advmod
5	has	have	VBZ	_	3	dep
6	little	little	JJ	_	5	dobj
7	or	or	CC	_	6	cc
8	no	no	DT	_	6	conj
9	effect	effect	NN	_	6	dep
10	on	on	IN	_	12	case
11	pupil	pupil	NN	_	12	compound
12	size	size	NN	_	5	nmod
13	,	,	,	_	24	punct
14	mydriasis	mydriasis	NN	_	24	nsubj
15	resulting	result	VBG	_	14	acl
16	from	from	IN	_	18	case
17	concomitant	concomitant	JJ	_	18	amod
18	therapy	therapy	NN	_	15	nmod
19	with	with	IN	_	20	case
20	drug2	drug2	NN	_	18	nmod
21	and	and	CC	_	20	cc
22	drug3	drug3	NN	_	20	conj
23	may	may	MD	_	24	aux
24	occur	occur	VB	_	0	ROOT
25	.	.	.	_	24	punct

1	Close	close	JJ	_	2	amod
2	observation	observation	NN	_	7	nsubjpass
3	of	of	IN	_	5	case
4	the	the	DT	_	5	det
5	patient	patient	NN	_	2	nmod
6	is	be	VBZ	_	7	auxpass
7	recommended	recommend	VBN	_	0	ROOT
8	when	when	WRB	_	12	advmod
9	a	a	DT	_	10	det
10	drug1	drug1	NN	_	12	nsubjpass
11	is	be	VBZ	_	12	auxpass
12	administered	administer	VBN	_	7	advcl
13	to	to	TO	_	14	case
14	patients	patient	NNS	_	12	nmod
15	receiving	receive	VBG	_	14	acl
16	catecholamine-depleting	catecholamine-depleting	JJ	_	17	amod
17	drugs	drug	NNS	_	15	dobj
18	such	such	JJ	_	20	case
19	as	as	IN	_	18	mwe
20	drug2	drug2	NN	_	17	nmod
21	,	,	,	_	7	punct
22	because	because	IN	_	26	case
23	of	of	IN	_	22	mwe
24	possible	possible	JJ	_	26	amod
25	additive	additive	JJ	_	26	amod
26	effects	effect	NNS	_	7	nmod
27	and	and	CC	_	26	cc
28	the	the	DT	_	29	det
29	production	production	NN	_	26	conj
30	of	of	IN	_	31	case
31	hypotension	hypotension	NN	_	29	nmod
32	and/or	and/or	CC	_	31	cc
33	marked	marked	JJ	_	34	amod
34	bradycardia	bradycardia	NN	_	31	conj
35	,	,	,	_	29	punct
36	which	which	WDT	_	38	nsubj
37	may	may	MD	_	38	aux
38	produce	produce	VB	_	29	acl:relcl
39	vertigo	vertigo	NN	_	38	dobj
40	,	,	,	_	39	punct
41	syncope	syncope	NN	_	39	conj
42	or	or	CC	_	39	cc
43	postural	postural	JJ	_	44	amod
44	hypotension	hypotension	NN	_	39	conj
45	.	.	.	_	7	punct

1	Patients	patient	NNS	_	13	nsubjpass
2	receiving	receive	VBG	_	1	acl
3	drug1	drug1	NN	_	2	dobj
4	along	along	IN	_	2	advmod
5	with	with	IN	_	7	case
6	either	either	CC	_	7	cc:preconj
7	oral	oral	JJ	_	4	nmod
8	or	or	CC	_	7	cc
9	intravenous	intravenous	JJ	_	7	conj
10	drug2	drug2	NN	_	7	dep
11	should	should	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	monitored	monitor	VBN	_	0	ROOT
14	for	for	IN	_	18	case
15	possible	possible	JJ	_	18	amod
16	atrioventricular	atrioventricular	JJ	_	18	amod
17	conduction	conduction	NN	_	18	compound
18	disturbances	disturbance	NNS	_	13	nmod
19	,	,	,	_	13	punct
20	left	leave	VBD	_	13	dep
21	ventricular	ventricular	JJ	_	22	amod
22	failure	failure	NN	_	20	dobj
23	and	and	CC	_	22	cc
24	hypotension	hypotension	NN	_	22	conj
25	.	.	.	_	13	punct

1	In	in	IN	_	2	case
2	patients	patient	NNS	_	12	nmod
3	with	with	IN	_	6	case
4	impaired	impaired	JJ	_	6	amod
5	cardiac	cardiac	JJ	_	6	amod
6	function	function	NN	_	2	nmod
7	,	,	,	_	12	punct
8	simultaneous	simultaneous	JJ	_	9	amod
9	use	use	NN	_	12	nsubjpass
10	should	should	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	avoided	avoid	VBN	_	0	ROOT
13	altogether	altogether	RB	_	12	advmod
14	.	.	.	_	12	punct

1	The	the	DT	_	3	det
2	concomitant	concomitant	JJ	_	3	amod
3	use	use	NN	_	12	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	with	with	IN	_	7	case
7	drug2	drug2	NN	_	3	nmod
8	and	and	CC	_	7	cc
9	drug3	drug3	NN	_	10	compound
10	s	s	NNS	_	7	conj
11	may	may	MD	_	12	aux
12	have	have	VB	_	0	ROOT
13	additive	additive	JJ	_	14	amod
14	effects	effect	NNS	_	12	dobj
15	on	on	IN	_	16	mark
16	prolonging	prolong	VBG	_	12	advcl
17	atrioventricular	atrioventricular	JJ	_	19	amod
18	conduction	conduction	NN	_	19	compound
19	time	time	NN	_	16	dobj
20	.	.	.	_	12	punct

1	drug1	drug1	NN	_	5	nsubj
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	may	may	MD	_	5	aux
5	have	have	VB	_	0	ROOT
6	additive	additive	JJ	_	8	amod
7	hypotensite	hypotensite	JJ	_	8	amod
8	effects	effect	NNS	_	5	dobj
9	due	due	JJ	_	12	case
10	to	to	TO	_	9	mwe
11	the	the	DT	_	12	det
12	inhibition	inhibition	NN	_	8	nmod
13	of	of	IN	_	17	case
14	each	each	DT	_	17	det
15	other	other	JJ	_	17	amod
16	s	s	NNS	_	17	compound
17	metabolism	metabolism	NN	_	12	nmod
18	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	concurrent	concurrent	JJ	_	4	amod
4	use	use	NN	_	6	nsubj
5	may	may	MD	_	6	aux
6	blunt	blunt	VB	_	1	dep
7	the	the	DT	_	8	det
8	response	response	NN	_	6	dobj
9	to	to	TO	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	.	.	.	_	6	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	withdrawn	withdraw	VBN	_	0	ROOT
5	at	at	IN	_	6	case
6	least	least	JJS	_	7	nmod:npmod
7	48	48	CD	_	8	nummod
8	hours	hour	NNS	_	4	dobj
9	before	before	IN	_	10	mark
10	conducting	conduct	VBG	_	4	advcl
11	an	a	DT	_	16	det
12	drug2	drug2	NN	_	16	compound
13	-	-	:	_	16	punct
14	mediated	mediated	JJ	_	16	amod
15	stress	stress	NN	_	16	compound
16	test	test	NN	_	10	dobj
17	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	5	punct
3	such	such	JJ	_	5	case
4	as	as	IN	_	3	mwe
5	drug2	drug2	NN	_	1	nmod
6	,	,	,	_	5	punct
7	drug3	drug3	NN	_	5	conj
8	,	,	,	_	5	punct
9	or	or	CC	_	5	cc
10	drug4	drug4	NN	_	5	conj
11	-RRB-	-rrb-	-RRB-	_	5	punct
12	:	:	:	_	1	punct
13	concurrent	concurrent	JJ	_	14	amod
14	use	use	NN	_	18	nsubj
15	with	with	IN	_	16	case
16	drug5	drug5	NN	_	14	nmod
17	may	may	MD	_	18	aux
18	have	have	VB	_	1	dep
19	a	a	DT	_	21	det
20	proarrhythmic	proarrhythmic	JJ	_	21	amod
21	effect	effect	NN	_	18	dobj
22	.	.	.	_	18	punct

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	drug2	drug2	NN	_	1	appos
4	-RRB-	-rrb-	-RRB-	_	3	punct
5	,	,	,	_	1	punct
6	drug3	drug3	NN	_	1	conj
7	or	or	CC	_	1	cc
8	other	other	JJ	_	9	amod
9	drug4	drug4	NN	_	1	conj
10	,	,	,	_	1	punct
11	or	or	CC	_	1	cc
12	drug5	drug5	NN	_	1	conj
13	:	:	:	_	1	punct
14	concurrent	concurrent	JJ	_	15	amod
15	use	use	NN	_	19	nsubj
16	with	with	IN	_	17	case
17	drug6	drug6	NN	_	15	nmod
18	may	may	MD	_	19	aux
19	produce	produce	VB	_	1	dep
20	additive	additive	JJ	_	24	amod
21	inotropic	inotropic	JJ	_	24	amod
22	and/or	and/or	CC	_	21	cc
23	chronotropic	chronotropic	JJ	_	21	conj
24	effects	effect	NNS	_	19	dobj
25	.	.	.	_	1	punct

1	Other	other	JJ	_	2	amod
2	drug1	drug1	NN	_	14	nsubj
3	-LRB-	-lrb-	-LRB-	_	12	punct
4	e.g.	e.g.	FW	_	12	dep
5	drug2	drug2	FW	_	12	compound
6	,	,	,	_	5	punct
7	drug3	drug3	NN	_	5	conj
8	,	,	,	_	5	punct
9	drug4	drug4	NN	_	5	conj
10	and	and	CC	_	5	cc
11	general	general	JJ	_	5	conj
12	drug5	drug5	NN	_	2	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	have	have	VBP	_	0	ROOT
15	additive	additive	JJ	_	18	amod
16	or	or	CC	_	15	cc
17	potentiating	potentiating	NN	_	15	conj
18	effects	effect	NNS	_	14	dobj
19	with	with	IN	_	20	case
20	drug6	drug6	NN	_	14	nmod
21	.	.	.	_	14	punct

1	When	when	WRB	_	4	advmod
2	patients	patient	NNS	_	4	nsubj
3	have	have	VBP	_	4	aux
4	received	receive	VBN	_	15	advcl
5	such	such	JJ	_	6	amod
6	drugs	drug	NNS	_	4	dobj
7	,	,	,	_	15	punct
8	the	the	DT	_	9	det
9	dose	dose	NN	_	15	nsubj
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	required	require	VBN	_	9	acl
13	will	will	MD	_	15	aux
14	be	be	VB	_	15	cop
15	less	less	JJR	_	0	ROOT
16	than	than	IN	_	17	case
17	usual	usual	JJ	_	15	advcl
18	.	.	.	_	15	punct

1	Following	follow	VBG	_	3	case
2	the	the	DT	_	3	det
3	administration	administration	NN	_	14	nmod
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	,	,	,	_	14	punct
7	the	the	DT	_	8	det
8	dose	dose	NN	_	14	nsubjpass
9	of	of	IN	_	11	case
10	other	other	JJ	_	11	amod
11	drug2	drug2	NN	_	8	nmod
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	reduced	reduce	VBN	_	0	ROOT
15	.	.	.	_	14	punct

1	There	there	EX	_	2	expl
2	are	be	VBP	_	0	ROOT
3	no	no	DT	_	6	neg
4	known	known	JJ	_	6	amod
5	drug/drug	drug/drug	NN	_	6	compound
6	interactions	interaction	NNS	_	2	nsubj
7	with	with	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	.	.	.	_	2	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	shown	show	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	have	have	VB	_	4	xcomp
7	neuromuscular	neuromuscular	JJ	_	9	amod
8	blocking	block	VBG	_	9	compound
9	properties	property	NNS	_	6	dobj
10	that	that	WDT	_	12	nsubj
11	may	may	MD	_	12	aux
12	enhance	enhance	VB	_	9	acl:relcl
13	the	the	DT	_	14	det
14	action	action	NN	_	12	dobj
15	of	of	IN	_	17	case
16	other	other	JJ	_	17	amod
17	drug2	drug2	NN	_	14	nmod
18	.	.	.	_	4	punct

1	Therefore	therefore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	it	it	PRP	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	used	use	VBN	_	0	ROOT
7	with	with	IN	_	8	case
8	caution	caution	NN	_	6	nmod
9	in	in	IN	_	10	case
10	patients	patient	NNS	_	8	nmod
11	receiving	receive	VBG	_	10	acl
12	such	such	JJ	_	13	amod
13	agents	agent	NNS	_	11	dobj
14	.	.	.	_	6	punct

1	Antagonism	antagonism	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	demonstrated	demonstrate	VBN	_	0	ROOT
5	between	between	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	drug2	drug2	NN	_	6	conj
9	in	in	FW	_	10	compound
10	vitro	vitro	FW	_	4	advmod
11	.	.	.	_	4	punct

1	Because	because	IN	_	5	case
2	of	of	IN	_	1	mwe
3	possible	possible	JJ	_	5	amod
4	clinical	clinical	JJ	_	5	amod
5	significance	significance	NN	_	13	nmod
6	,	,	,	_	13	punct
7	these	these	DT	_	9	det
8	two	two	CD	_	9	nummod
9	drugs	drug	NNS	_	13	nsubjpass
10	should	should	MD	_	13	aux
11	not	not	RB	_	13	neg
12	be	be	VB	_	13	auxpass
13	administered	administer	VBN	_	0	ROOT
14	concurrently	concurrently	RB	_	13	advmod
15	.	.	.	_	13	punct

1	Interactions	interaction	NNS	_	0	ROOT
2	with	with	IN	_	5	case
3	Other	other	JJ	_	5	amod
4	CNS	cn	NNS	_	5	compound
5	Agents	agent	NNS	_	1	nmod
6	:	:	:	_	1	punct
7	Concurrent	concurrent	JJ	_	8	amod
8	use	use	NN	_	42	nsubj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	with	with	IN	_	13	case
12	all	all	DT	_	13	det
13	drug2	drug2	NN	_	8	nmod
14	-LRB-	-lrb-	-LRB-	_	17	punct
15	eg	eg	FW	_	17	compound
16	,	,	,	_	17	punct
17	drug3	drug3	NN	_	13	dep
18	,	,	,	_	17	punct
19	drug4	drug4	NN	_	17	conj
20	,	,	,	_	17	punct
21	drug5	drug5	NN	_	17	conj
22	,	,	,	_	17	punct
23	other	other	JJ	_	24	amod
24	drug6	drug6	NN	_	17	conj
25	,	,	,	_	17	punct
26	general	general	JJ	_	27	amod
27	drug7	drug7	NN	_	17	conj
28	,	,	,	_	17	punct
29	drug8	drug8	NN	_	17	conj
30	,	,	,	_	17	punct
31	drug9	drug9	NN	_	17	conj
32	,	,	,	_	17	punct
33	drug10	drug10	NN	_	17	conj
34	,	,	,	_	17	punct
35	drug11	drug11	NN	_	17	conj
36	,	,	,	_	17	punct
37	drug12	drug12	NN	_	17	conj
38	and	and	CC	_	17	cc
39	drug13	drug13	NN	_	17	conj
40	-RRB-	-rrb-	-RRB-	_	17	punct
41	may	may	MD	_	42	aux
42	result	result	VB	_	1	dep
43	in	in	IN	_	49	case
44	additive	additive	JJ	_	49	amod
45	central	central	JJ	_	49	amod
46	nervous	nervous	JJ	_	49	amod
47	system	system	NN	_	49	compound
48	depressant	depressant	NN	_	49	compound
49	effects	effect	NNS	_	42	nmod
50	.	.	.	_	1	punct

1	Respiratory	respiratory	JJ	_	2	amod
2	depression	depression	NN	_	12	nsubj
3	,	,	,	_	2	punct
4	hypotension	hypotension	NN	_	2	conj
5	,	,	,	_	2	punct
6	and	and	CC	_	2	cc
7	profound	profound	JJ	_	8	amod
8	sedation	sedation	NN	_	2	conj
9	or	or	CC	_	8	cc
10	coma	coma	NN	_	8	conj
11	may	may	MD	_	12	aux
12	occur	occur	VB	_	0	ROOT
13	.	.	.	_	12	punct

1	When	when	WRB	_	6	advmod
2	such	such	JJ	_	4	amod
3	combined	combined	JJ	_	4	amod
4	therapy	therapy	NN	_	6	nsubjpass
5	is	be	VBZ	_	6	auxpass
6	contemplated	contemplate	VBN	_	17	advcl
7	,	,	,	_	17	punct
8	the	the	DT	_	9	det
9	dose	dose	NN	_	17	nsubjpass
10	of	of	IN	_	11	case
11	one	one	CD	_	9	nmod
12	or	or	CC	_	11	cc
13	both	both	DT	_	14	det
14	agents	agent	NNS	_	11	conj
15	should	should	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	reduced	reduce	VBN	_	0	ROOT
18	.	.	.	_	17	punct

1	Although	although	IN	_	10	mark
2	no	no	DT	_	3	neg
3	interaction	interaction	NN	_	10	nsubjpass
4	between	between	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	has	have	VBZ	_	10	aux
9	been	be	VBN	_	10	auxpass
10	observed	observe	VBN	_	15	advcl
11	,	,	,	_	15	punct
12	it	it	PRP	_	15	nsubjpass
13	is	be	VBZ	_	15	auxpass
14	not	not	RB	_	15	neg
15	recommended	recommend	VBN	_	0	ROOT
16	for	for	IN	_	17	case
17	use	use	NN	_	15	nmod
18	with	with	IN	_	19	case
19	drug3	drug3	NN	_	17	nmod
20	.	.	.	_	15	punct

1	Most	most	JJS	_	2	amod
2	cases	case	NNS	_	11	nsubj
3	of	of	IN	_	8	case
4	serious	serious	JJ	_	8	amod
5	or	or	CC	_	4	cc
6	fatal	fatal	JJ	_	4	conj
7	adverse	adverse	JJ	_	8	amod
8	events	event	NNS	_	2	nmod
9	involving	involve	VBG	_	8	acl
10	drug1	drug1	NN	_	9	dobj
11	reported	report	VBD	_	0	ROOT
12	to	to	TO	_	14	case
13	the	the	DT	_	14	det
14	manufacturer	manufacturer	NN	_	11	nmod
15	or	or	CC	_	14	cc
16	the	the	DT	_	17	det
17	FDA	FDA	NNP	_	14	conj
18	have	have	VBP	_	19	aux
19	involved	involve	VBN	_	11	dep
20	either	either	CC	_	22	cc:preconj
21	the	the	DT	_	22	det
22	administration	administration	NN	_	19	dobj
23	of	of	IN	_	26	case
24	large	large	JJ	_	26	amod
25	initial	initial	JJ	_	26	amod
26	doses	dose	NNS	_	22	nmod
27	or	or	CC	_	22	cc
28	too	too	RB	_	29	advmod
29	frequent	frequent	JJ	_	30	amod
30	doses	dose	NNS	_	22	conj
31	of	of	IN	_	33	case
32	the	the	DT	_	33	det
33	drug	drug	NN	_	30	nmod
34	to	to	TO	_	37	case
35	nonopioid	nonopioid	JJ	_	37	amod
36	tolerant	tolerant	JJ	_	37	amod
37	patients	patient	NNS	_	30	nmod
38	,	,	,	_	22	punct
39	or	or	CC	_	22	cc
40	the	the	DT	_	42	det
41	simultaneous	simultaneous	JJ	_	42	amod
42	administration	administration	NN	_	22	conj
43	of	of	IN	_	44	case
44	drug2	drug2	NN	_	42	nmod
45	with	with	IN	_	47	case
46	other	other	JJ	_	47	amod
47	drugs	drug	NNS	_	42	nmod
48	affecting	affect	VBG	_	47	acl
49	respiration	respiration	NN	_	48	dobj
50	.	.	.	_	11	punct

1	The	the	DT	_	3	det
2	initial	initial	JJ	_	3	amod
3	dose	dose	NN	_	8	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	should	should	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	reduced	reduce	VBN	_	0	ROOT
9	by	by	IN	_	12	case
10	approximately	approximately	RB	_	11	advmod
11	50	50	CD	_	12	nummod
12	%	%	NN	_	8	nmod
13	or	or	CC	_	14	cc
14	more	more	JJR	_	12	nummod
15	when	when	WRB	_	18	advmod
16	it	it	PRP	_	18	nsubjpass
17	is	be	VBZ	_	18	auxpass
18	given	give	VBN	_	8	advcl
19	to	to	TO	_	20	case
20	patients	patient	NNS	_	18	nmod
21	along	along	IN	_	18	advmod
22	with	with	IN	_	24	case
23	another	another	DT	_	24	det
24	drug	drug	NN	_	21	nmod
25	affecting	affect	VBG	_	24	acl
26	respiration	respiration	NN	_	25	dobj
27	.	.	.	_	8	punct

1	Interactions	interaction	NNS	_	0	ROOT
2	with	with	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	:	:	:	_	1	punct
5	drug2	drug2	NN	_	22	nsubjpass
6	-LRB-	-lrb-	-LRB-	_	9	punct
7	eg	eg	FW	_	9	compound
8	,	,	,	_	9	punct
9	drug3	drug3	NN	_	5	dep
10	,	,	,	_	9	punct
11	drug4	drug4	NN	_	9	conj
12	,	,	,	_	9	punct
13	drug5	drug5	NN	_	9	conj
14	,	,	,	_	9	punct
15	drug6	drug6	NN	_	9	conj
16	and	and	CC	_	9	cc
17	drug7	drug7	NN	_	9	conj
18	-RRB-	-rrb-	-RRB-	_	9	punct
19	should	should	MD	_	22	aux
20	NOT	not	RB	_	22	advmod
21	be	be	VB	_	22	auxpass
22	administered	administer	VBN	_	1	dep
23	to	to	TO	_	25	case
24	a	a	DT	_	25	det
25	patient	patient	NN	_	22	nmod
26	who	who	WP	_	28	nsubj
27	has	have	VBZ	_	28	aux
28	received	receive	VBN	_	25	acl:relcl
29	or	or	CC	_	28	cc
30	is	be	VBZ	_	31	aux
31	receiving	receive	VBG	_	28	conj
32	a	a	DT	_	33	det
33	course	course	NN	_	28	dobj
34	of	of	IN	_	35	case
35	therapy	therapy	NN	_	33	nmod
36	with	with	IN	_	38	case
37	a	a	DT	_	38	det
38	drug8	drug8	NN	_	35	nmod
39	such	such	JJ	_	41	case
40	as	as	IN	_	39	mwe
41	drug9	drug9	NN	_	38	nmod
42	.	.	.	_	1	punct

1	In	in	IN	_	2	case
2	drug1	drug1	NN	_	9	nmod
3	-	-	:	_	5	punct
4	dependent	dependent	JJ	_	5	amod
5	patients	patient	NNS	_	9	nsubj
6	,	,	,	_	5	punct
7	drug2	drug2	NN	_	5	appos
8	may	may	MD	_	9	aux
9	precipitate	precipitate	VB	_	0	ROOT
10	withdrawal	withdrawal	NN	_	11	compound
11	symptoms	symptom	NNS	_	9	dobj
12	.	.	.	_	9	punct

1	drug1	drug1	NN	_	10	nsubjpass
2	-LRB-	-lrb-	-LRB-	_	4	punct
3	10	10	CD	_	4	nummod
4	mg	mg	NN	_	1	dep
5	once	once	RB	_	6	advmod
6	daily	daily	JJ	_	4	amod
7	-RRB-	-rrb-	-RRB-	_	4	punct
8	has	have	VBZ	_	10	aux
9	been	be	VBN	_	10	auxpass
10	coadministered	coadminister	VBN	_	0	ROOT
11	with	with	IN	_	13	case
12	therapeutic	therapeutic	JJ	_	13	amod
13	doses	dose	NNS	_	10	nmod
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	,	,	,	_	15	punct
17	drug3	drug3	NN	_	15	conj
18	,	,	,	_	15	punct
19	and	and	CC	_	15	cc
20	drug4	drug4	NN	_	15	conj
21	in	in	IN	_	25	case
22	controlled	controlled	JJ	_	25	amod
23	clinical	clinical	JJ	_	25	amod
24	pharmacology	pharmacology	NN	_	25	compound
25	studies	study	NNS	_	10	nmod
26	in	in	IN	_	28	case
27	adult	adult	JJ	_	28	amod
28	volunteers	volunteer	NNS	_	25	nmod
29	.	.	.	_	10	punct

1	Although	although	IN	_	15	mark
2	increased	increase	VBN	_	4	amod
3	plasma	plasma	NN	_	4	compound
4	concentrations	concentration	NNS	_	15	nsubjpass
5	-LRB-	-lrb-	-LRB-	_	6	punct
6	AUC	auc	NN	_	4	dep
7	0-24	0-24	CD	_	8	nummod
8	hrs	hr	NNS	_	6	dep
9	-RRB-	-rrb-	-RRB-	_	6	punct
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	4	nmod
12	and/or	and/or	CC	_	11	cc
13	drug2	drug2	NN	_	11	conj
14	were	be	VBD	_	15	auxpass
15	observed	observe	VBN	_	38	advcl
16	following	follow	VBG	_	17	case
17	coadministration	coadministration	NN	_	15	nmod
18	of	of	IN	_	19	case
19	drug3	drug3	NN	_	17	nmod
20	with	with	IN	_	21	case
21	each	each	DT	_	17	nmod
22	of	of	IN	_	24	case
23	these	these	DT	_	24	det
24	drugs	drug	NNS	_	21	nmod
25	in	in	IN	_	27	case
26	normal	normal	JJ	_	27	amod
27	volunteers	volunteer	NNS	_	21	nmod
28	-LRB-	-lrb-	-LRB-	_	29	punct
29	n	n	NN	_	15	dep
30	=	=	JJ	_	29	amod
31	24	24	CD	_	30	dep
32	in	in	IN	_	34	case
33	each	each	DT	_	34	det
34	study	study	NN	_	29	nmod
35	-RRB-	-rrb-	-RRB-	_	29	punct
36	,	,	,	_	38	punct
37	there	there	EX	_	38	expl
38	were	be	VBD	_	0	ROOT
39	no	no	DT	_	42	neg
40	clinically	clinically	RB	_	41	advmod
41	relevant	relevant	JJ	_	42	amod
42	changes	change	NNS	_	38	nsubj
43	in	in	IN	_	46	case
44	the	the	DT	_	46	det
45	safety	safety	NN	_	46	compound
46	profile	profile	NN	_	42	nmod
47	of	of	IN	_	48	case
48	drug4	drug4	NN	_	46	nmod
49	,	,	,	_	38	punct
50	as	as	IN	_	51	mark
51	assessed	assess	VBN	_	38	advcl
52	by	by	IN	_	54	case
53	electrocardiographic	electrocardiographic	JJ	_	54	amod
54	parameters	parameter	NNS	_	51	nmod
55	,	,	,	_	54	punct
56	clinical	clinical	JJ	_	58	amod
57	laboratory	laboratory	NN	_	58	compound
58	tests	test	NNS	_	54	conj
59	,	,	,	_	54	punct
60	vital	vital	JJ	_	61	amod
61	signs	sign	NNS	_	54	conj
62	,	,	,	_	54	punct
63	and	and	CC	_	54	cc
64	adverse	adverse	JJ	_	65	amod
65	events	event	NNS	_	54	conj
66	.	.	.	_	38	punct

1	There	there	EX	_	2	expl
2	were	be	VBD	_	0	ROOT
3	no	no	DT	_	5	neg
4	significant	significant	JJ	_	5	amod
5	effects	effect	NNS	_	2	nsubj
6	on	on	IN	_	8	case
7	QTc	qtc	NN	_	8	compound
8	intervals	interval	NNS	_	5	nmod
9	,	,	,	_	2	punct
10	and	and	CC	_	2	cc
11	no	no	DT	_	12	neg
12	reports	report	NNS	_	2	conj
13	of	of	IN	_	14	case
14	sedation	sedation	NN	_	12	nmod
15	or	or	CC	_	14	cc
16	syncope	syncope	NN	_	14	conj
17	.	.	.	_	2	punct

1	No	no	DT	_	2	neg
2	effects	effect	NNS	_	11	nsubjpass
3	on	on	IN	_	5	case
4	plasma	plasma	NN	_	5	compound
5	concentrations	concentration	NNS	_	2	nmod
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	or	or	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	were	be	VBD	_	11	auxpass
11	observed	observe	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	Plasma	plasma	NN	_	2	compound
2	concentrations	concentration	NNS	_	10	nsubj
3	-LRB-	-lrb-	-LRB-	_	4	punct
4	AUC	auc	NN	_	2	dep
5	0-24	0-24	CD	_	6	nummod
6	hrs	hr	NNS	_	4	dep
7	-RRB-	-rrb-	-RRB-	_	4	punct
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	2	nmod
10	decreased	decrease	VBD	_	0	ROOT
11	15	15	CD	_	12	nummod
12	%	%	NN	_	10	dobj
13	with	with	IN	_	14	case
14	coadministration	coadministration	NN	_	10	nmod
15	of	of	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	relative	relative	JJ	_	14	amod
18	to	to	TO	_	19	case
19	that	that	DT	_	17	nmod
20	observed	observe	VBN	_	19	acl
21	with	with	IN	_	22	case
22	drug3	drug3	NN	_	20	nmod
23	alone	alone	RB	_	22	advmod
24	.	.	.	_	10	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	relevance	relevance	NN	_	8	nsubj
4	of	of	IN	_	6	case
5	this	this	DT	_	6	det
6	difference	difference	NN	_	3	nmod
7	is	be	VBZ	_	8	cop
8	unknown	unknown	JJ	_	0	ROOT
9	.	.	.	_	8	punct

1	These	these	DT	_	5	nsubjpass
2	above	above	IN	_	3	case
3	findings	finding	NNS	_	1	nmod
4	are	be	VBP	_	5	auxpass
5	summarized	summarize	VBN	_	0	ROOT
6	in	in	IN	_	7	case
7	TABLE	table	NN	_	5	nmod
8	1	1	CD	_	7	nummod
9	.	.	.	_	5	punct

1	TABLE	table	NN	_	3	compound
2	1	1	CD	_	3	nummod
3	Effects	effect	NNS	_	0	ROOT
4	on	on	IN	_	6	case
5	Plasma	plasma	NN	_	6	compound
6	Concentrations	concentration	NNS	_	3	nmod
7	-LRB-	-lrb-	-LRB-	_	8	punct
8	AUC	auc	NN	_	6	dep
9	0-24	0-24	CD	_	10	nummod
10	hrs	hr	NNS	_	8	dep
11	-RRB-	-rrb-	-RRB-	_	8	punct
12	of	of	IN	_	13	case
13	drug1	drug1	NN	_	6	nmod
14	and	and	CC	_	13	cc
15	drug2	drug2	NN	_	13	conj
16	After	after	IN	_	18	case
17	10	10	CD	_	18	nummod
18	Days	day	NNS	_	3	nmod
19	of	of	IN	_	20	case
20	Coadministration	coadministration	NN	_	18	nmod
21	-LRB-	-lrb-	-LRB-	_	22	punct
22	drug3	drug3	NN	_	18	dep
23	10	10	CD	_	24	nummod
24	mg	mg	NN	_	22	dep
25	-RRB-	-rrb-	-RRB-	_	22	punct
26	in	in	IN	_	28	case
27	Normal	normal	JJ	_	28	amod
28	Volunteers	volunteer	NNS	_	18	nmod

1	drug1	drug1	NN	_	2	compound
2	drug2	drug2	NN	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	5	punct
3	500	500	CD	_	4	compound
4	mg	mg	NN	_	5	amod
5	q8h	q8h	NN	_	1	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	+	+	CC	_	1	cc
8	40	40	CD	_	9	nummod
9	%	%	NN	_	1	conj
10	+46	+46	CD	_	11	nummod
11	%	%	NN	_	9	dep

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	5	punct
3	300	300	CD	_	5	nummod
4	mg	mg	NN	_	5	compound
5	qid	qid	NN	_	1	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	+103	+103	CD	_	8	nummod
8	%	%	NN	_	1	dep
9	+	+	CC	_	8	cc
10	6	6	CD	_	11	nummod
11	%	%	NN	_	8	conj

1	drug1	drug1	NN	_	8	compound
2	-LRB-	-lrb-	-LRB-	_	5	punct
3	200	200	CD	_	4	compound
4	mg	mg	NN	_	5	amod
5	q12h	q12h	NN	_	1	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	+307	+307	CD	_	8	nummod
8	%	%	NN	_	0	ROOT
9	+73	+73	CD	_	10	nummod
10	%	%	NN	_	8	dep

1	There	there	EX	_	4	expl
2	does	do	VBZ	_	4	aux
3	not	not	RB	_	4	neg
4	appear	appear	VB	_	0	ROOT
5	to	to	TO	_	8	mark
6	be	be	VB	_	8	cop
7	an	a	DT	_	8	det
8	increase	increase	NN	_	4	xcomp
9	in	in	IN	_	11	case
10	adverse	adverse	JJ	_	11	amod
11	events	event	NNS	_	8	nmod
12	in	in	IN	_	13	case
13	subjects	subject	NNS	_	11	nmod
14	who	who	WP	_	15	nsubj
15	received	receive	VBD	_	13	acl:relcl
16	oral	oral	JJ	_	17	amod
17	drug1	drug1	NN	_	15	dobj
18	and	and	CC	_	17	cc
19	drug2	drug2	NN	_	17	conj
20	.	.	.	_	4	punct

1	No	no	DT	_	3	neg
2	drug	drug	NN	_	3	compound
3	interactions	interaction	NNS	_	6	nsubjpass
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	auxpass
6	reported	report	VBN	_	0	ROOT
7	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	known	know	VBN	_	1	appos
6	to	to	TO	_	7	mark
7	interact	interact	VB	_	5	xcomp
8	with	with	IN	_	10	case
9	the	the	DT	_	10	det
10	metabolism	metabolism	NN	_	7	nmod
11	or	or	CC	_	10	cc
12	renal	renal	JJ	_	14	amod
13	tubular	tubular	JJ	_	14	amod
14	excretion	excretion	NN	_	10	conj
15	of	of	IN	_	17	case
16	many	many	JJ	_	17	amod
17	drugs	drug	NNS	_	10	nmod
18	-LRB-	-lrb-	-LRB-	_	21	punct
19	e.g.	e.g.	FW	_	21	dep
20	,	,	,	_	21	punct
21	drug3	drug3	NN	_	17	dep
22	,	,	,	_	21	punct
23	drug4	drug4	NN	_	21	conj
24	,	,	,	_	21	punct
25	drug5	drug5	NN	_	21	conj
26	,	,	,	_	21	punct
27	drug6	drug6	NN	_	21	conj
28	,	,	,	_	21	punct
29	drug7	drug7	NN	_	21	conj
30	,	,	,	_	21	punct
31	drug8	drug8	NN	_	21	conj
32	,	,	,	_	21	punct
33	drug9	drug9	NN	_	21	conj
34	,	,	,	_	21	punct
35	drug10	drug10	NN	_	21	conj
36	,	,	,	_	21	punct
37	drug11	drug11	NN	_	21	conj
38	,	,	,	_	21	punct
39	drug12	drug12	NN	_	21	conj
40	,	,	,	_	21	punct
41	drug13	drug13	NN	_	21	conj
42	,	,	,	_	21	punct
43	drug14	drug14	NN	_	44	compound
44	agents	agent	NNS	_	21	conj
45	,	,	,	_	21	punct
46	drug15	drug15	NN	_	21	conj
47	,	,	,	_	21	punct
48	and	and	CC	_	21	cc
49	drug16	drug16	NN	_	21	conj
50	-RRB-	-rrb-	-RRB-	_	21	punct
51	.	.	.	_	1	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	medications	medication	NNS	_	6	nsubjpass
3	should	should	MD	_	6	aux
4	be	be	VB	_	6	auxpass
5	carefully	carefully	RB	_	6	advmod
6	assessed	assess	VBN	_	0	ROOT
7	.	.	.	_	6	punct

1	drug1	drug1	NN	_	6	nsubjpass
2	should	should	MD	_	6	aux
3	either	either	RB	_	6	advmod
4	be	be	VB	_	6	auxpass
5	temporarily	temporarily	RB	_	6	advmod
6	discontinued	discontinue	VBN	_	0	ROOT
7	or	or	CC	_	6	cc
8	decreased	decrease	VBN	_	6	conj
9	by	by	IN	_	11	case
10	50	50	CD	_	11	nummod
11	%	%	NN	_	6	nmod
12	when	when	WRB	_	13	advmod
13	coadministered	coadminister	VBN	_	6	advcl
14	with	with	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	on	on	IN	_	18	case
17	the	the	DT	_	18	det
18	day	day	NN	_	13	nmod
19	of	of	IN	_	21	case
20	drug3	drug3	NN	_	21	compound
21	infusion	infusion	NN	_	18	nmod
22	.	.	.	_	6	punct

1	Nephrotoxic	nephrotoxic	JJ	_	2	amod
2	agents	agent	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	Concomitant	concomitant	JJ	_	5	amod
5	administration	administration	NN	_	42	nsubjpass
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	agents	agent	NNS	_	7	conj
10	with	with	IN	_	12	case
11	nephrotoxic	nephrotoxic	JJ	_	12	amod
12	potential	potential	JJ	_	5	nmod
13	-LSB-	-lsb-	-LRB-	_	17	punct
14	e.g.	e.g.	FW	_	17	advmod
15	,	,	,	_	17	punct
16	intravenous	intravenous	JJ	_	17	amod
17	drug2	drug2	NN	_	5	dep
18	-LRB-	-lrb-	-LRB-	_	21	punct
19	e.g.	e.g.	FW	_	21	dep
20	,	,	,	_	21	punct
21	drug3	drug3	NN	_	17	dep
22	,	,	,	_	21	punct
23	drug4	drug4	NN	_	21	conj
24	,	,	,	_	21	punct
25	and	and	CC	_	21	cc
26	drug5	drug5	NN	_	21	conj
27	-RRB-	-rrb-	-RRB-	_	21	punct
28	,	,	,	_	17	punct
29	drug6	drug6	NN	_	17	conj
30	,	,	,	_	17	punct
31	drug7	drug7	NN	_	17	conj
32	,	,	,	_	17	punct
33	intravenous	intravenous	JJ	_	34	amod
34	drug8	drug8	NN	_	17	conj
35	,	,	,	_	17	punct
36	drug9	drug9	NN	_	17	conj
37	,	,	,	_	17	punct
38	and	and	CC	_	17	cc
39	drug10	drug10	NN	_	17	conj
40	-RSB-	-rsb-	-RRB-	_	17	punct
41	is	be	VBZ	_	42	auxpass
42	contraindicated	contraindicate	VBN	_	2	dep
43	.	.	.	_	2	punct

1	Such	such	JJ	_	2	amod
2	agents	agent	NNS	_	5	nsubjpass
3	must	must	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	discontinued	discontinue	VBN	_	0	ROOT
6	at	at	IN	_	7	case
7	least	least	JJS	_	8	nmod:npmod
8	seven	seven	CD	_	9	nummod
9	days	day	NNS	_	5	nmod:tmod
10	prior	prior	RB	_	5	advmod
11	to	to	TO	_	12	mark
12	starting	start	VBG	_	10	advcl
13	therapy	therapy	NN	_	12	dobj
14	with	with	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	.	.	.	_	5	punct

1	drug1	drug1	NN	_	7	nsubj
2	,	,	,	_	1	punct
3	a	a	DT	_	4	det
4	drug2	drug2	NN	_	1	appos
5	,	,	,	_	1	punct
6	may	may	MD	_	7	aux
7	antagonize	antagonize	VB	_	21	csubjpass
8	the	the	DT	_	10	det
9	bactericidal	bactericidal	JJ	_	10	amod
10	effect	effect	NN	_	7	dobj
11	of	of	IN	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	and	and	CC	_	12	cc
14	concurrent	concurrent	JJ	_	15	amod
15	use	use	NN	_	12	conj
16	of	of	IN	_	18	case
17	these	these	DT	_	18	det
18	drugs	drug	NNS	_	12	nmod
19	should	should	MD	_	21	aux
20	be	be	VB	_	21	auxpass
21	avoided	avoid	VBN	_	0	ROOT
22	.	.	.	_	21	punct

1	The	the	DT	_	3	det
2	concomitant	concomitant	JJ	_	3	amod
3	use	use	NN	_	10	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	or	or	CC	_	5	cc
7	other	other	JJ	_	8	amod
8	drug2	drug2	NN	_	5	conj
9	may	may	MD	_	10	aux
10	have	have	VB	_	0	ROOT
11	an	a	DT	_	13	det
12	additive	additive	JJ	_	13	amod
13	effect	effect	NN	_	10	dobj
14	.	.	.	_	10	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	There	there	EX	_	4	expl
4	is	be	VBZ	_	1	dep
5	no	no	DT	_	8	neg
6	significant	significant	JJ	_	8	amod
7	pharmacokinetic	pharmacokinetic	JJ	_	8	amod
8	interaction	interaction	NN	_	4	nsubj
9	between	between	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	drug3	drug3	NN	_	10	conj
13	which	which	WDT	_	16	nsubjpass
14	has	have	VBZ	_	16	aux
15	been	be	VBN	_	16	auxpass
16	confirmed	confirm	VBN	_	8	acl:relcl
17	clinically	clinically	RB	_	16	advmod
18	.	.	.	_	1	punct

1	drug1	drug1	NN	_	3	nsubj
2	also	also	RB	_	3	advmod
3	has	have	VBZ	_	0	ROOT
4	no	no	DT	_	6	neg
5	significant	significant	JJ	_	6	amod
6	effect	effect	NN	_	3	dobj
7	on	on	IN	_	10	case
8	the	the	DT	_	10	det
9	intracellular	intracellular	JJ	_	10	amod
10	phosphorylation	phosphorylation	NN	_	3	nmod
11	of	of	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	,	,	,	_	3	punct
14	as	as	IN	_	15	mark
15	shown	show	VBN	_	3	advcl
16	in	in	FW	_	17	compound
17	vitro	vitro	FW	_	15	advmod
18	in	in	IN	_	22	case
19	peripheral	peripheral	JJ	_	22	amod
20	blood	blood	NN	_	22	compound
21	mononuclear	mononuclear	JJ	_	22	amod
22	cells	cell	NNS	_	15	nmod
23	or	or	CC	_	22	cc
24	in	in	IN	_	28	case
25	two	two	CD	_	28	nummod
26	other	other	JJ	_	28	amod
27	cell	cell	NN	_	28	compound
28	lines	line	NNS	_	22	conj
29	-LRB-	-lrb-	-LRB-	_	30	punct
30	U937	u937	NN	_	28	dep
31	and	and	CC	_	30	cc
32	Molt-4	molt-4	NN	_	30	conj
33	-RRB-	-rrb-	-RRB-	_	30	punct
34	.	.	.	_	3	punct

1	In	in	IN	_	4	case
2	the	the	DT	_	4	det
3	same	same	JJ	_	4	amod
4	study	study	NN	_	7	nmod
5	it	it	PRP	_	7	nsubjpass
6	was	be	VBD	_	7	auxpass
7	shown	show	VBN	_	0	ROOT
8	that	that	IN	_	12	mark
9	drug1	drug1	NN	_	12	nsubj
10	and	and	CC	_	9	cc
11	drug2	drug2	NN	_	9	conj
12	had	have	VBD	_	7	ccomp
13	no	no	DT	_	15	neg
14	significant	significant	JJ	_	15	amod
15	effect	effect	NN	_	12	dobj
16	on	on	IN	_	19	case
17	the	the	DT	_	19	det
18	intracellular	intracellular	JJ	_	19	amod
19	phosphorylation	phosphorylation	NN	_	12	nmod
20	of	of	IN	_	21	case
21	drug3	drug3	NN	_	19	nmod
22	in	in	IN	_	26	case
23	peripheral	peripheral	JJ	_	26	amod
24	blood	blood	NN	_	26	compound
25	mononuclear	mononuclear	JJ	_	26	amod
26	cells	cell	NNS	_	19	nmod
27	.	.	.	_	7	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	FW	_	5	amod
4	vitro	vitro	FW	_	3	dep
5	studies	study	NNS	_	16	nsubj
6	in	in	IN	_	10	case
7	peripheral	peripheral	JJ	_	10	amod
8	blood	blood	NN	_	10	compound
9	mononuclear	mononuclear	JJ	_	10	amod
10	cells	cell	NNS	_	5	nmod
11	,	,	,	_	10	punct
12	U937	u937	NN	_	10	conj
13	and	and	CC	_	10	cc
14	Molt-4	molt-4	NN	_	15	compound
15	cells	cell	NNS	_	10	conj
16	revealed	reveal	VBD	_	1	appos
17	that	that	IN	_	20	mark
18	drug2	drug2	NN	_	20	nsubj
19	significantly	significantly	RB	_	20	advmod
20	inhibited	inhibit	VBD	_	16	ccomp
21	drug3	drug3	NN	_	22	compound
22	phosphorylation	phosphorylation	NN	_	20	dobj
23	in	in	IN	_	27	case
24	a	a	DT	_	27	det
25	dose	dose	NN	_	26	nmod:npmod
26	dependent	dependent	JJ	_	27	amod
27	manner	manner	NN	_	20	nmod
28	.	.	.	_	1	punct

1	Effects	effect	NNS	_	4	nsubjpass
2	were	be	VBD	_	4	auxpass
3	already	already	RB	_	4	advmod
4	seen	see	VBN	_	0	ROOT
5	with	with	IN	_	6	case
6	doses	dose	NNS	_	4	nmod
7	corresponding	correspond	VBG	_	6	acl
8	to	to	TO	_	11	case
9	relevant	relevant	JJ	_	11	amod
10	plasma	plasma	NN	_	11	compound
11	levels	level	NNS	_	7	nmod
12	in	in	IN	_	13	case
13	humans	human	NNS	_	11	nmod
14	,	,	,	_	4	punct
15	and	and	CC	_	4	cc
16	the	the	DT	_	18	det
17	intracellular	intracellular	JJ	_	18	amod
18	phosphorylation	phosphorylation	NN	_	35	nsubjpass
19	of	of	IN	_	20	case
20	drug1	drug1	NN	_	18	nmod
21	to	to	TO	_	24	case
22	its	its	PRP$	_	24	nmod:poss
23	three	three	CD	_	24	nummod
24	metabolites	metabolite	NNS	_	18	nmod
25	-LRB-	-lrb-	-LRB-	_	31	punct
26	including	include	VBG	_	31	case
27	the	the	DT	_	31	det
28	active	active	JJ	_	31	amod
29	zalcitabine	zalcitabine	NN	_	31	compound
30	triphosphate	triphosphate	NN	_	31	compound
31	metabolite	metabolite	NN	_	24	nmod
32	-RRB-	-rrb-	-RRB-	_	31	punct
33	was	be	VBD	_	35	auxpass
34	significantly	significantly	RB	_	35	advmod
35	inhibited	inhibit	VBN	_	4	conj
36	.	.	.	_	4	punct

1	drug1	drug1	NN	_	2	nsubj
2	inhibited	inhibit	VBD	_	0	ROOT
3	drug2	drug2	NN	_	4	compound
4	phosphorylation	phosphorylation	NN	_	2	dobj
5	at	at	IN	_	8	case
6	high	high	JJ	_	8	amod
7	concentration	concentration	NN	_	8	compound
8	ratios	ratio	NNS	_	2	nmod
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	10	10	CD	_	8	dep
11	and	and	CC	_	10	cc
12	100	100	CD	_	10	conj
13	-RRB-	-rrb-	-RRB-	_	10	punct
14	;	;	:	_	2	punct

1	however	however	RB	_	5	advmod
2	,	,	,	_	5	punct
3	it	it	PRP	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	considered	consider	VBN	_	0	ROOT
6	to	to	TO	_	8	mark
7	be	be	VB	_	8	cop
8	unlikely	unlikely	JJ	_	5	xcomp
9	that	that	IN	_	19	mark
10	this	this	DT	_	11	det
11	decrease	decrease	NN	_	19	nsubj
12	of	of	IN	_	15	case
13	phosphorylated	phosphorylate	VBN	_	15	amod
14	drug1	drug1	NN	_	15	compound
15	concentration	concentration	NN	_	11	nmod
16	is	be	VBZ	_	19	cop
17	of	of	IN	_	19	case
18	clinical	clinical	JJ	_	19	amod
19	significance	significance	NN	_	8	ccomp
20	,	,	,	_	5	punct
21	as	as	IN	_	27	mark
22	drug2	drug2	NN	_	27	nsubj
23	is	be	VBZ	_	27	cop
24	a	a	DT	_	27	det
25	more	more	RBR	_	26	advmod
26	efficient	efficient	JJ	_	27	amod
27	substrate	substrate	NN	_	5	advcl
28	for	for	IN	_	30	case
29	deoxycytidine	deoxycytidine	NN	_	30	compound
30	kinase	kinase	NN	_	27	nmod
31	than	than	IN	_	32	case
32	drug3	drug3	NN	_	27	nmod
33	.	.	.	_	5	punct

1	These	these	DT	_	4	det
2	in	in	FW	_	4	amod
3	vitro	vitro	FW	_	2	dep
4	studies	study	NNS	_	5	nsubj
5	suggest	suggest	VBP	_	0	ROOT
6	that	that	IN	_	16	mark
7	concomitant	concomitant	JJ	_	8	amod
8	administration	administration	NN	_	16	nsubj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	drug2	drug2	NN	_	10	conj
13	in	in	IN	_	14	case
14	humans	human	NNS	_	8	nmod
15	may	may	MD	_	16	aux
16	result	result	VB	_	5	ccomp
17	in	in	IN	_	19	case
18	sub-therapeutic	sub-therapeutic	JJ	_	19	amod
19	concentrations	concentration	NNS	_	16	nmod
20	of	of	IN	_	23	case
21	active	active	JJ	_	23	amod
22	phosphorylated	phosphorylate	VBN	_	23	amod
23	drug3	drug3	NN	_	19	nmod
24	,	,	,	_	19	punct
25	which	which	WDT	_	27	nsubj
26	may	may	MD	_	27	aux
27	lead	lead	VB	_	19	acl:relcl
28	to	to	TO	_	32	case
29	a	a	DT	_	32	det
30	decreased	decrease	VBN	_	32	amod
31	drug4	drug4	NN	_	32	compound
32	effect	effect	NN	_	27	nmod
33	of	of	IN	_	34	case
34	drug5	drug5	NN	_	32	nmod
35	.	.	.	_	5	punct

1	It	it	PRP	_	3	nsubj
2	is	be	VBZ	_	3	cop
3	unknown	unknown	JJ	_	0	ROOT
4	how	how	WRB	_	13	advmod
5	the	the	DT	_	6	det
6	effect	effect	NN	_	13	nsubj
7	seen	see	VBN	_	6	acl
8	in	in	IN	_	12	case
9	these	these	DT	_	12	det
10	in	in	FW	_	12	amod
11	vitro	vitro	FW	_	10	dep
12	studies	study	NNS	_	7	nmod
13	translates	translate	VBZ	_	3	ccomp
14	into	into	IN	_	16	case
15	clinical	clinical	JJ	_	16	amod
16	consequences	consequence	NNS	_	13	nmod
17	.	.	.	_	3	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	use	use	NN	_	9	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	is	be	VBZ	_	9	auxpass
8	not	not	RB	_	9	neg
9	recommended	recommend	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	combination	combination	NN	_	14	nsubjpass
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	,	,	,	_	6	punct
8	drug3	drug3	NN	_	6	conj
9	,	,	,	_	6	punct
10	and	and	CC	_	6	cc
11	drug4	drug4	NN	_	6	conj
12	has	have	VBZ	_	14	aux
13	been	be	VBN	_	14	auxpass
14	studied	study	VBN	_	1	appos
15	-LRB-	-lrb-	-LRB-	_	14	punct
16	as	as	IN	_	18	case
17	triple	triple	JJ	_	18	amod
18	combination	combination	NN	_	14	nmod
19	-RRB-	-rrb-	-RRB-	_	14	punct
20	in	in	IN	_	21	case
21	adults	adult	NNS	_	14	nmod
22	.	.	.	_	1	punct

1	Pharmacokinetic	pharmacokinetic	JJ	_	2	amod
2	data	datum	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	17	mark
5	absorption	absorption	NN	_	17	nsubj
6	,	,	,	_	5	punct
7	metabolism	metabolism	NN	_	5	conj
8	,	,	,	_	5	punct
9	and	and	CC	_	5	cc
10	elimination	elimination	NN	_	5	conj
11	of	of	IN	_	12	case
12	each	each	DT	_	10	nmod
13	of	of	IN	_	15	case
14	these	these	DT	_	15	det
15	drugs	drug	NNS	_	12	nmod
16	are	be	VBP	_	17	cop
17	unchanged	unchanged	JJ	_	3	ccomp
18	when	when	WRB	_	21	advmod
19	they	they	PRP	_	21	nsubjpass
20	are	be	VBP	_	21	auxpass
21	used	use	VBN	_	17	advcl
22	together	together	RB	_	21	advmod
23	.	.	.	_	3	punct

1	Drugs	drug	NNS	_	2	nsubj
2	Associated	associate	VBD	_	0	ROOT
3	With	with	IN	_	5	case
4	Peripheral	peripheral	JJ	_	5	amod
5	Neuropathy	neuropathy	NN	_	2	nmod
6	:	:	:	_	2	punct
7	The	the	DT	_	9	det
8	concomitant	concomitant	JJ	_	9	amod
9	use	use	NN	_	24	nsubjpass
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	with	with	IN	_	13	case
13	drugs	drug	NNS	_	9	nmod
14	that	that	WDT	_	15	nsubj
15	have	have	VBP	_	13	acl:relcl
16	the	the	DT	_	17	det
17	potential	potential	JJ	_	15	dobj
18	to	to	TO	_	19	mark
19	cause	cause	VB	_	17	acl
20	peripheral	peripheral	JJ	_	21	amod
21	neuropathy	neuropathy	NN	_	19	dobj
22	should	should	MD	_	24	aux
23	be	be	VB	_	24	auxpass
24	avoided	avoid	VBN	_	2	parataxis
25	where	where	WRB	_	26	advmod
26	possible	possible	JJ	_	24	advcl
27	.	.	.	_	2	punct

1	Drugs	drug	NNS	_	9	nsubj
2	that	that	WDT	_	5	nsubjpass
3	have	have	VBP	_	5	aux
4	been	be	VBN	_	5	auxpass
5	associated	associate	VBN	_	1	acl:relcl
6	with	with	IN	_	8	case
7	peripheral	peripheral	JJ	_	8	amod
8	neuropathy	neuropathy	NN	_	5	nmod
9	include	include	VBP	_	0	ROOT
10	drug1	drug1	NN	_	9	dobj
11	,	,	,	_	10	punct
12	drug2	drug2	NN	_	10	conj
13	,	,	,	_	10	punct
14	drug3	drug3	NN	_	10	conj
15	,	,	,	_	10	punct
16	drug4	drug4	NN	_	10	conj
17	,	,	,	_	10	punct
18	drug5	drug5	NN	_	10	conj
19	,	,	,	_	10	punct
20	drug6	drug6	NN	_	10	conj
21	,	,	,	_	10	punct
22	drug7	drug7	NN	_	10	conj
23	,	,	,	_	10	punct
24	drug8	drug8	NN	_	10	conj
25	,	,	,	_	10	punct
26	drug9	drug9	NN	_	10	conj
27	,	,	,	_	10	punct
28	drug10	drug10	NN	_	10	conj
29	,	,	,	_	10	punct
30	drug11	drug11	NN	_	10	conj
31	,	,	,	_	10	punct
32	drug12	drug12	NN	_	10	conj
33	,	,	,	_	10	punct
34	drug13	drug13	NN	_	10	conj
35	,	,	,	_	10	punct
36	drug14	drug14	NN	_	10	conj
37	,	,	,	_	10	punct
38	drug15	drug15	NN	_	10	conj
39	,	,	,	_	10	punct
40	and	and	CC	_	10	cc
41	drug16	drug16	NN	_	10	conj
42	.	.	.	_	9	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	use	use	NN	_	9	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	2	nmod
7	is	be	VBZ	_	9	auxpass
8	not	not	RB	_	9	neg
9	recommended	recommend	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	Intravenous	intravenous	JJ	_	2	amod
2	drug1	drug1	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	Treatment	treatment	NN	_	9	nsubjpass
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	interrupted	interrupt	VBN	_	2	appos
10	when	when	WRB	_	24	advmod
11	the	the	DT	_	12	det
12	use	use	NN	_	24	nsubjpass
13	of	of	IN	_	15	case
14	a	a	DT	_	15	det
15	drug	drug	NN	_	12	nmod
16	that	that	WDT	_	17	nsubj
17	has	have	VBZ	_	15	acl:relcl
18	the	the	DT	_	19	det
19	potential	potential	JJ	_	17	dobj
20	to	to	TO	_	21	mark
21	cause	cause	VB	_	19	acl
22	pancreatitis	pancreatitis	NN	_	21	dobj
23	is	be	VBZ	_	24	auxpass
24	required	require	VBN	_	9	advcl
25	.	.	.	_	2	punct

1	Death	death	NN	_	15	nsubjpass
2	due	due	JJ	_	5	case
3	to	to	TO	_	2	mwe
4	fulminant	fulminant	JJ	_	5	amod
5	pancreatitis	pancreatitis	NN	_	1	nmod
6	possibly	possibly	RB	_	7	advmod
7	related	related	JJ	_	1	amod
8	to	to	TO	_	10	case
9	intravenous	intravenous	JJ	_	10	amod
10	drug1	drug1	NN	_	7	nmod
11	and	and	CC	_	10	cc
12	drug2	drug2	NN	_	10	conj
13	has	have	VBZ	_	15	aux
14	been	be	VBN	_	15	auxpass
15	reported	report	VBN	_	0	ROOT
16	.	.	.	_	15	punct

1	If	if	IN	_	5	mark
2	intravenous	intravenous	JJ	_	3	amod
3	drug1	drug1	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	required	require	VBN	_	17	advcl
6	to	to	TO	_	7	mark
7	treat	treat	VB	_	5	xcomp
8	Pneumocystis	pneumocystis	NN	_	10	compound
9	carinii	carinii	NN	_	10	compound
10	pneumonia	pneumonia	NN	_	7	dobj
11	,	,	,	_	17	punct
12	treatment	treatment	NN	_	17	nsubjpass
13	with	with	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	should	should	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	interrupted	interrupt	VBN	_	0	ROOT
18	.	.	.	_	17	punct

1	drug1	drug1	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	,	,	,	_	1	punct
5	and	and	CC	_	1	cc
6	drug3	drug3	NN	_	1	conj
7	:	:	:	_	1	punct
8	Drugs	drug	NNS	_	18	nsubj
9	such	such	JJ	_	11	case
10	as	as	IN	_	9	mwe
11	drug4	drug4	NN	_	8	nmod
12	,	,	,	_	11	punct
13	drug5	drug5	NN	_	11	conj
14	,	,	,	_	11	punct
15	and	and	CC	_	11	cc
16	drug6	drug6	NN	_	11	conj
17	may	may	MD	_	18	aux
18	increase	increase	VB	_	1	parataxis
19	the	the	DT	_	20	det
20	risk	risk	NN	_	18	dobj
21	of	of	IN	_	22	mark
22	developing	develop	VBG	_	20	acl
23	peripheral	peripheral	JJ	_	24	amod
24	neuropathy	neuropathy	NN	_	22	dobj
25	or	or	CC	_	24	cc
26	other	other	JJ	_	27	amod
27	drug7	drug7	NN	_	24	conj
28	-	-	:	_	18	punct
29	associated	associate	VBN	_	31	amod
30	adverse	adverse	JJ	_	31	amod
31	events	event	NNS	_	18	dobj
32	by	by	IN	_	33	mark
33	interfering	interfere	VBG	_	31	acl
34	with	with	IN	_	37	case
35	the	the	DT	_	37	det
36	renal	renal	JJ	_	37	amod
37	clearance	clearance	NN	_	33	nmod
38	of	of	IN	_	39	case
39	drug8	drug8	NN	_	37	nmod
40	-LRB-	-lrb-	-LRB-	_	42	punct
41	thereby	thereby	RB	_	42	advmod
42	raising	raise	VBG	_	33	dep
43	systemic	systemic	JJ	_	44	amod
44	exposure	exposure	NN	_	42	dobj
45	-RRB-	-rrb-	-RRB-	_	42	punct
46	.	.	.	_	1	punct

1	Patients	patient	NNS	_	14	nsubj
2	who	who	WP	_	3	nsubj
3	require	require	VBP	_	1	acl:relcl
4	the	the	DT	_	5	det
5	use	use	NN	_	3	dobj
6	of	of	IN	_	7	case
7	one	one	CD	_	5	nmod
8	of	of	IN	_	10	case
9	these	these	DT	_	10	det
10	drugs	drug	NNS	_	7	nmod
11	with	with	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	should	should	MD	_	14	aux
14	have	have	VB	_	0	ROOT
15	frequent	frequent	JJ	_	19	amod
16	clinical	clinical	JJ	_	19	amod
17	and	and	CC	_	16	cc
18	laboratory	laboratory	JJ	_	16	conj
19	monitoring	monitoring	NN	_	14	dobj
20	with	with	IN	_	22	case
21	dosage	dosage	NN	_	22	compound
22	adjustment	adjustment	NN	_	19	nmod
23	for	for	IN	_	26	case
24	any	any	DT	_	26	det
25	significant	significant	JJ	_	26	amod
26	change	change	NN	_	19	nmod
27	in	in	IN	_	29	case
28	renal	renal	JJ	_	29	amod
29	function	function	NN	_	26	nmod
30	.	.	.	_	14	punct

1	drug1	drug1	NN	_	0	ROOT
2	or	or	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	:	:	:	_	1	punct
5	Concomitant	concomitant	JJ	_	6	amod
6	administration	administration	NN	_	11	nsubj
7	of	of	IN	_	8	case
8	drug3	drug3	NN	_	6	nmod
9	or	or	CC	_	8	cc
10	drug4	drug4	NN	_	8	conj
11	decreases	decrease	VBZ	_	1	dep
12	the	the	DT	_	13	det
13	elimination	elimination	NN	_	11	dobj
14	of	of	IN	_	15	case
15	drug5	drug5	NN	_	13	nmod
16	,	,	,	_	11	punct
17	most	most	RBS	_	18	advmod
18	likely	likely	RB	_	20	advmod
19	by	by	IN	_	20	case
20	inhibition	inhibition	NN	_	11	nmod
21	of	of	IN	_	24	case
22	renal	renal	JJ	_	24	amod
23	tubular	tubular	JJ	_	24	amod
24	secretion	secretion	NN	_	20	nmod
25	of	of	IN	_	26	case
26	drug6	drug6	NN	_	24	nmod
27	.	.	.	_	1	punct

1	Patients	patient	NNS	_	11	nsubjpass
2	receiving	receive	VBG	_	1	acl
3	these	these	DT	_	4	det
4	drugs	drug	NNS	_	2	dobj
5	in	in	IN	_	6	case
6	combination	combination	NN	_	2	nmod
7	with	with	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	monitored	monitor	VBN	_	0	ROOT
12	for	for	IN	_	13	case
13	signs	sign	NNS	_	11	nmod
14	of	of	IN	_	15	case
15	toxicity	toxicity	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	the	the	DT	_	18	det
18	dose	dose	NN	_	15	conj
19	of	of	IN	_	20	case
20	drug2	drug2	NN	_	18	nmod
21	reduced	reduce	VBN	_	13	acl
22	if	if	IN	_	23	mark
23	warranted	warrant	VBN	_	21	advcl
24	.	.	.	_	11	punct

1	drug1	drug1	NN	_	0	ROOT
2	/	/	:	_	3	punct
3	drug2	drug2	NN	_	1	dep
4	-	-	:	_	3	punct
5	containing	contain	VBG	_	3	acl
6	drug3	drug3	NN	_	5	dobj
7	:	:	:	_	3	punct
8	Absorption	absorption	NN	_	13	nsubjpass
9	of	of	IN	_	10	case
10	drug4	drug4	NN	_	8	nmod
11	is	be	VBZ	_	13	auxpass
12	moderately	moderately	RB	_	13	advmod
13	reduced	reduce	VBN	_	3	parataxis
14	-LRB-	-lrb-	-LRB-	_	17	punct
15	approximately	approximately	RB	_	16	advmod
16	25	25	CD	_	17	nummod
17	%	%	NN	_	13	dep
18	-RRB-	-rrb-	-RRB-	_	17	punct
19	when	when	WRB	_	20	advmod
20	coadministered	coadminister	VBN	_	13	advcl
21	with	with	IN	_	22	case
22	drug5	drug5	NN	_	20	nmod
23	/	/	:	_	13	punct
24	drug6	drug6	NN	_	13	dobj
25	-	-	:	_	24	punct
26	containing	contain	VBG	_	24	acl
27	drug7	drug7	NN	_	26	dobj
28	.	.	.	_	1	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	significance	significance	NN	_	9	nsubjpass
4	of	of	IN	_	6	case
5	this	this	DT	_	6	det
6	reduction	reduction	NN	_	3	nmod
7	is	be	VBZ	_	9	auxpass
8	not	not	RB	_	9	neg
9	known	know	VBN	_	0	ROOT
10	,	,	,	_	9	punct
11	hence	hence	RB	_	15	advmod
12	drug1	drug1	NN	_	15	nsubjpass
13	is	be	VBZ	_	15	auxpass
14	not	not	RB	_	15	neg
15	recommended	recommend	VBN	_	9	ccomp
16	to	to	TO	_	18	mark
17	be	be	VB	_	18	auxpass
18	ingested	ingest	VBN	_	15	xcomp
19	simultaneously	simultaneously	RB	_	18	advmod
20	with	with	IN	_	21	case
21	drug2	drug2	NN	_	18	nmod
22	/	/	:	_	21	punct
23	drug3	drug3	NN	_	21	dep
24	-	-	:	_	21	punct
25	containing	contain	VBG	_	21	acl
26	drug4	drug4	NN	_	25	dobj
27	.	.	.	_	9	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Bioavailability	bioavailability	NN	_	6	nsubjpass
4	is	be	VBZ	_	6	auxpass
5	mildly	mildly	RB	_	6	advmod
6	reduced	reduce	VBN	_	1	dep
7	-LRB-	-lrb-	-LRB-	_	10	punct
8	approximately	approximately	RB	_	9	advmod
9	10	10	CD	_	10	nummod
10	%	%	NN	_	6	dep
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	when	when	WRB	_	17	advmod
13	drug2	drug2	NN	_	17	nsubjpass
14	and	and	CC	_	13	cc
15	drug3	drug3	NN	_	13	conj
16	are	be	VBP	_	17	auxpass
17	coadministered	coadminister	VBN	_	6	advcl
18	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	nsubj
4	caused	cause	VBD	_	1	appos
5	a	a	DT	_	6	det
6	decrease	decrease	NN	_	4	dobj
7	in	in	IN	_	9	case
8	drug3	drug3	NN	_	9	compound
9	phosphorylation	phosphorylation	NN	_	6	nmod
10	-LRB-	-lrb-	-LRB-	_	13	punct
11	50	50	CD	_	12	compound
12	%	%	NN	_	13	amod
13	inhibition	inhibition	NN	_	6	dep
14	of	of	IN	_	17	case
15	total	total	JJ	_	17	amod
16	phosphate	phosphate	NN	_	17	compound
17	formation	formation	NN	_	13	nmod
18	-RRB-	-rrb-	-RRB-	_	13	punct
19	in	in	IN	_	22	case
20	U937/Molt	u937/molt	NN	_	22	compound
21	4	4	CD	_	22	nummod
22	cells	cell	NNS	_	6	nmod
23	.	.	.	_	1	punct

1	Although	although	IN	_	5	mark
2	there	there	EX	_	5	expl
3	may	may	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	decreased	decrease	VBN	_	25	advcl
6	drug1	drug1	NN	_	7	compound
7	activity	activity	NN	_	5	dobj
8	because	because	IN	_	13	case
9	of	of	IN	_	8	mwe
10	lessened	lessen	VBN	_	13	amod
11	active	active	JJ	_	13	amod
12	metabolite	metabolite	NN	_	13	compound
13	formation	formation	NN	_	5	nmod
14	,	,	,	_	25	punct
15	the	the	DT	_	17	det
16	clinical	clinical	JJ	_	17	amod
17	relevance	relevance	NN	_	25	nsubjpass
18	of	of	IN	_	22	case
19	these	these	DT	_	22	det
20	in	in	FW	_	22	amod
21	vitro	vitro	FW	_	20	dep
22	results	result	NNS	_	17	nmod
23	are	be	VBP	_	25	auxpass
24	not	not	RB	_	25	neg
25	known	know	VBN	_	0	ROOT
26	.	.	.	_	25	punct

1	No	no	DT	_	2	neg
2	Information	information	NN	_	0	ROOT
3	Provided	provide	VBN	_	2	acl

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	add	add	VB	_	0	ROOT
4	to	to	TO	_	8	case
5	or	or	CC	_	4	cc
6	potentiate	potentiate	VB	_	4	conj
7	the	the	DT	_	8	det
8	action	action	NN	_	3	nmod
9	of	of	IN	_	11	case
10	other	other	JJ	_	11	amod
11	drug2	drug2	NN	_	8	nmod
12	.	.	.	_	3	punct

1	Potentiation	potentiation	NN	_	2	nsubj
2	occurs	occur	VBZ	_	0	ROOT
3	with	with	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	.	.	.	_	2	punct

1	Medication	medication	NN	_	7	nsubj
2	such	such	JJ	_	4	case
3	as	as	IN	_	2	mwe
4	drug1	drug1	NN	_	1	nmod
5	may	may	MD	_	7	aux
6	also	also	RB	_	7	advmod
7	influence	influence	VB	_	0	ROOT
8	serum	serum	NN	_	9	compound
9	electrolytes	electrolyte	NNS	_	7	dobj
10	.	.	.	_	7	punct

1	Warning	warning	NN	_	2	compound
2	signs	sign	NNS	_	10	nsubj
3	,	,	,	_	2	punct
4	irrespective	irrespective	RB	_	2	amod
5	of	of	IN	_	6	case
6	cause	cause	NN	_	4	nmod
7	,	,	,	_	2	punct
8	are	be	VBP	_	10	cop
9	:	:	:	_	10	punct
10	dryness	dryness	NN	_	0	ROOT
11	of	of	IN	_	12	case
12	mouth	mouth	NN	_	10	nmod
13	,	,	,	_	12	punct
14	thirst	thirst	NN	_	12	conj
15	,	,	,	_	12	punct
16	weakness	weakness	NN	_	12	conj
17	,	,	,	_	12	punct
18	lethargy	lethargy	NN	_	12	conj
19	,	,	,	_	12	punct
20	drowsiness	drowsiness	NN	_	12	conj
21	,	,	,	_	12	punct
22	restlessness	restlessness	NN	_	12	conj
23	,	,	,	_	12	punct
24	muscle	muscle	NN	_	25	compound
25	pains	pain	NNS	_	12	conj
26	or	or	CC	_	12	cc
27	cramps	cramp	NNS	_	12	conj
28	,	,	,	_	10	punct
29	muscular	muscular	JJ	_	30	amod
30	fatigue	fatigue	NN	_	10	appos
31	,	,	,	_	30	punct
32	hypotension	hypotension	NN	_	30	conj
33	,	,	,	_	30	punct
34	oliguria	oliguria	NN	_	30	conj
35	,	,	,	_	30	punct
36	tachycardia	tachycardia	NN	_	30	conj
37	,	,	,	_	30	punct
38	and	and	CC	_	30	cc
39	gastrointestinal	gastrointestinal	JJ	_	40	amod
40	disturbances	disturbance	NNS	_	30	conj
41	such	such	JJ	_	43	case
42	as	as	IN	_	41	mwe
43	nausea	nausea	NN	_	40	nmod
44	and	and	CC	_	43	cc
45	vomiting	vomiting	NN	_	43	conj
46	.	.	.	_	10	punct

1	drug1	drug1	NN	_	2	compound
2	requirements	requirement	NNS	_	8	nsubjpass
3	in	in	IN	_	5	case
4	diabetic	diabetic	JJ	_	5	amod
5	patients	patient	NNS	_	2	nmod
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	increased	increase	VBN	_	0	ROOT
9	,	,	,	_	8	punct
10	decreased	decrease	VBN	_	8	conj
11	,	,	,	_	8	punct
12	or	or	CC	_	8	cc
13	unchanged	unchanged	JJ	_	8	conj
14	.	.	.	_	8	punct

1	Higher	higher	JJR	_	2	amod
2	dosage	dosage	NN	_	8	nsubjpass
3	of	of	IN	_	5	case
4	oral	oral	JJ	_	5	amod
5	drug1	drug1	NN	_	2	nmod
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	required	require	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	Latent	latent	JJ	_	3	amod
2	diabetes	diabetes	NN	_	3	compound
3	mellitus	mellitus	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	become	become	VB	_	0	ROOT
6	manifest	manifest	JJ	_	5	xcomp
7	during	during	IN	_	9	case
8	drug1	drug1	NN	_	9	compound
9	administration	administration	NN	_	5	nmod
10	.	.	.	_	5	punct

1	drug1	drug1	NN	_	6	nsubj
2	and	and	CC	_	1	cc
3	related	related	JJ	_	4	amod
4	drugs	drug	NNS	_	1	conj
5	may	may	MD	_	6	aux
6	increase	increase	VB	_	0	ROOT
7	the	the	DT	_	8	det
8	responsiveness	responsiveness	NN	_	6	dobj
9	to	to	TO	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	.	.	.	_	6	punct

1	drug1	drug1	NN	_	6	nsubj
2	and	and	CC	_	1	cc
3	related	related	JJ	_	4	amod
4	drugs	drug	NNS	_	1	conj
5	may	may	MD	_	6	aux
6	decrease	decrease	VB	_	0	ROOT
7	arterial	arterial	JJ	_	8	amod
8	responsiveness	responsiveness	NN	_	6	dobj
9	to	to	TO	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	.	.	.	_	6	punct

1	This	this	DT	_	2	det
2	diminution	diminution	NN	_	5	nsubj
3	is	be	VBZ	_	5	cop
4	not	not	RB	_	5	neg
5	sufficient	sufficient	JJ	_	0	ROOT
6	to	to	TO	_	7	mark
7	preclude	preclude	VB	_	5	xcomp
8	effectiveness	effectiveness	NN	_	7	dobj
9	of	of	IN	_	12	case
10	the	the	DT	_	12	det
11	pressor	pressor	NN	_	12	compound
12	agent	agent	NN	_	8	nmod
13	for	for	IN	_	15	case
14	therapeutic	therapeutic	JJ	_	15	amod
15	use	use	NN	_	7	nmod
16	.	.	.	_	5	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	5	nsubj
4	have	have	VBP	_	5	aux
5	shown	show	VBN	_	0	ROOT
6	drug1	drug1	NN	_	8	nsubj
7	can	can	MD	_	8	aux
8	displace	displace	VB	_	5	ccomp
9	drug2	drug2	NN	_	10	compound
10	s	s	NNS	_	8	dobj
11	,	,	,	_	10	punct
12	such	such	JJ	_	14	case
13	as	as	IN	_	12	mwe
14	drug3	drug3	NN	_	10	nmod
15	,	,	,	_	10	punct
16	from	from	IN	_	19	case
17	their	they	PRP$	_	19	nmod:poss
18	protein-binding	protein-binding	JJ	_	19	amod
19	sites	site	NNS	_	10	nmod
20	.	.	.	_	5	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	recommended	recommend	VBN	_	0	ROOT
4	that	that	IN	_	20	mark
5	if	if	IN	_	8	mark
6	drug1	drug1	NN	_	8	nsubjpass
7	is	be	VBZ	_	8	auxpass
8	started	start	VBN	_	20	advcl
9	in	in	IN	_	10	case
10	patients	patient	NNS	_	8	nmod
11	already	already	RB	_	12	advmod
12	receiving	receive	VBG	_	10	acl
13	drug2	drug2	NN	_	12	dobj
14	,	,	,	_	20	punct
15	prothrombin	prothrombin	NN	_	16	compound
16	times	time	NNS	_	20	nsubjpass
17	should	should	MD	_	20	aux
18	be	be	VB	_	20	auxpass
19	closely	closely	RB	_	20	advmod
20	monitored	monitor	VBN	_	3	ccomp
21	and	and	CC	_	20	cc
22	adjustment	adjustment	NN	_	29	nsubj
23	of	of	IN	_	26	case
24	the	the	DT	_	26	det
25	drug3	drug3	NN	_	26	compound
26	dose	dose	NN	_	22	nmod
27	may	may	MD	_	29	aux
28	be	be	VB	_	29	cop
29	necessary	necessary	JJ	_	20	conj
30	.	.	.	_	3	punct

1	Prior	prior	RB	_	5	advmod
2	administration	administration	NN	_	5	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	has	have	VBZ	_	0	ROOT
6	no	no	DT	_	9	neg
7	clinically	clinically	RB	_	8	advmod
8	important	important	JJ	_	9	amod
9	effect	effect	NN	_	5	dobj
10	on	on	IN	_	14	case
11	the	the	DT	_	14	det
12	neuromuscular	neuromuscular	JJ	_	14	amod
13	blocking	block	VBG	_	14	amod
14	action	action	NN	_	5	nmod
15	of	of	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	.	.	.	_	5	punct

1	The	the	DT	_	2	det
2	use	use	NN	_	19	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	before	before	IN	_	6	case
6	drug2	drug2	NN	_	2	nmod
7	to	to	TO	_	8	mark
8	attenuate	attenuate	VB	_	2	acl
9	some	some	DT	_	8	dobj
10	of	of	IN	_	13	case
11	the	the	DT	_	13	det
12	side	side	JJ	_	13	amod
13	effects	effect	NNS	_	9	nmod
14	of	of	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	has	have	VBZ	_	19	aux
17	not	not	RB	_	19	neg
18	been	be	VBN	_	19	auxpass
19	studied	study	VBN	_	0	ROOT
20	.	.	.	_	19	punct

1	There	there	EX	_	2	expl
2	are	be	VBP	_	0	ROOT
3	no	no	DT	_	5	neg
4	clinical	clinical	JJ	_	5	amod
5	data	datum	NNS	_	2	nsubj
6	on	on	IN	_	8	case
7	concomitant	concomitant	JJ	_	8	amod
8	use	use	NN	_	5	nmod
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	other	other	JJ	_	14	amod
13	nondepolarizing	nondepolarizing	JJ	_	14	amod
14	drug2	drug2	NN	_	10	conj
15	.	.	.	_	2	punct

1	drug1	drug1	NN	_	7	nsubj
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	,	,	,	_	1	punct
5	and	and	CC	_	1	cc
6	drug3	drug3	NN	_	1	conj
7	decrease	decrease	VBP	_	0	ROOT
8	the	the	DT	_	9	det
9	ED50	ed50	NN	_	7	dobj
10	of	of	IN	_	11	case
11	drug4	drug4	NN	_	9	nmod
12	by	by	IN	_	7	advcl
13	30	30	CD	_	12	dobj
14	%	%	NN	_	13	advmod
15	to	to	TO	_	17	case
16	45	45	CD	_	17	nummod
17	%	%	NN	_	14	nmod
18	.	.	.	_	7	punct

1	These	these	DT	_	2	det
2	agents	agent	NNS	_	5	nsubj
3	may	may	MD	_	5	aux
4	also	also	RB	_	5	advmod
5	prolong	prolong	VB	_	0	ROOT
6	the	the	DT	_	9	det
7	clinically	clinically	RB	_	8	advmod
8	effective	effective	JJ	_	9	amod
9	duration	duration	NN	_	5	dobj
10	of	of	IN	_	11	case
11	action	action	NN	_	9	nmod
12	by	by	IN	_	16	case
13	up	up	RB	_	15	dep
14	to	to	TO	_	13	mwe
15	25	25	CD	_	16	nummod
16	%	%	NN	_	5	nmod
17	.	.	.	_	5	punct

1	Other	other	JJ	_	2	amod
2	drugs	drug	NNS	_	16	nsubj
3	which	which	WDT	_	5	nsubj
4	may	may	MD	_	5	aux
5	enhance	enhance	VB	_	2	acl:relcl
6	the	the	DT	_	9	det
7	neuromuscular	neuromuscular	JJ	_	9	amod
8	blocking	block	VBG	_	9	amod
9	action	action	NN	_	5	dobj
10	of	of	IN	_	12	case
11	nondepolarizing	nondepolarizing	JJ	_	12	amod
12	agents	agent	NNS	_	9	nmod
13	such	such	JJ	_	15	case
14	as	as	IN	_	13	mwe
15	drug1	drug1	NN	_	12	nmod
16	include	include	VBP	_	0	ROOT
17	certain	certain	JJ	_	18	amod
18	drug2	drug2	NN	_	16	dobj
19	-LRB-	-lrb-	-LRB-	_	21	punct
20	e.	e.	FW	_	21	compound
21	g.	g.	FW	_	18	dep
22	,	,	,	_	21	punct
23	drug3	drug3	NN	_	21	conj
24	,	,	,	_	21	punct
25	drug4	drug4	NN	_	21	conj
26	,	,	,	_	21	punct
27	drug5	drug5	NN	_	21	conj
28	,	,	,	_	21	punct
29	drug6	drug6	NN	_	21	conj
30	,	,	,	_	21	punct
31	drug7	drug7	NN	_	21	conj
32	,	,	,	_	21	punct
33	drug8	drug8	NN	_	21	conj
34	,	,	,	_	21	punct
35	drug9	drug9	NN	_	21	conj
36	,	,	,	_	21	punct
37	and	and	CC	_	21	cc
38	drug10	drug10	NN	_	21	conj
39	-RRB-	-rrb-	-RRB-	_	21	punct
40	,	,	,	_	18	punct
41	drug11	drug11	NN	_	42	compound
42	salts	salt	NNS	_	18	conj
43	,	,	,	_	18	punct
44	drug12	drug12	NN	_	18	conj
45	,	,	,	_	18	punct
46	local	local	JJ	_	47	amod
47	drug13	drug13	NN	_	18	conj
48	,	,	,	_	18	punct
49	drug14	drug14	NN	_	18	conj
50	,	,	,	_	18	punct
51	and	and	CC	_	18	cc
52	drug15	drug15	NN	_	18	conj
53	.	.	.	_	16	punct

1	As	as	IN	_	5	case
2	with	with	IN	_	5	case
3	some	some	DT	_	5	det
4	other	other	JJ	_	5	amod
5	drug1	drug1	NN	_	18	nmod
6	,	,	,	_	18	punct
7	the	the	DT	_	8	det
8	time	time	NN	_	18	nsubjpass
9	of	of	IN	_	10	case
10	onset	onset	NN	_	8	nmod
11	of	of	IN	_	13	case
12	neuromuscular	neuromuscular	JJ	_	13	amod
13	block	block	NN	_	10	nmod
14	induced	induce	VBN	_	13	acl
15	by	by	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	is	be	VBZ	_	18	auxpass
18	lengthened	lengthen	VBN	_	0	ROOT
19	and	and	CC	_	18	cc
20	the	the	DT	_	21	det
21	duration	duration	NN	_	25	nsubjpass
22	of	of	IN	_	23	case
23	block	block	NN	_	21	nmod
24	is	be	VBZ	_	25	auxpass
25	shortened	shorten	VBN	_	18	conj
26	in	in	IN	_	27	case
27	patients	patient	NNS	_	25	nmod
28	receiving	receive	VBG	_	27	acl
29	drug3	drug3	NN	_	28	dobj
30	or	or	CC	_	29	cc
31	drug4	drug4	NN	_	29	conj
32	.	.	.	_	18	punct

1	Oils	oils	NNS	_	3	nsubj
2	may	may	MD	_	3	aux
3	enhance	enhance	VB	_	0	ROOT
4	absorption	absorption	NN	_	3	dobj
5	.	.	.	_	3	punct

1	Therefore	therefore	RB	_	13	advmod
2	,	,	,	_	13	punct
3	simultaneous	simultaneous	JJ	_	4	amod
4	use	use	NN	_	13	nsubjpass
5	of	of	IN	_	6	case
6	creams	cream	NNS	_	4	nmod
7	,	,	,	_	6	punct
8	ointments	ointment	NNS	_	6	conj
9	or	or	CC	_	6	cc
10	oils	oils	NNS	_	6	conj
11	should	should	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	avoided	avoid	VBN	_	0	ROOT
14	.	.	.	_	13	punct

1	Inhibitors	inhibitor	NNS	_	0	ROOT
2	of	of	IN	_	3	case
3	CYP2D6	cyp2d6	NN	_	1	nmod
4	;	;	:	_	1	punct

1	poor	poor	JJ	_	2	amod
2	metabolizers	metabolizer	NNS	_	0	ROOT
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	:	:	:	_	2	punct
6	Interactions	interaction	NNS	_	29	nsubjpass
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	with	with	IN	_	11	case
10	strong	strong	JJ	_	11	amod
11	inhibitors	inhibitor	NNS	_	6	nmod
12	of	of	IN	_	13	case
13	CYP2D6	cyp2d6	NN	_	11	nmod
14	-LRB-	-lrb-	-LRB-	_	17	punct
15	such	such	JJ	_	17	case
16	as	as	IN	_	15	mwe
17	drug3	drug3	NN	_	11	nmod
18	,	,	,	_	17	punct
19	drug4	drug4	NN	_	17	conj
20	,	,	,	_	17	punct
21	drug5	drug5	NN	_	17	conj
22	,	,	,	_	17	punct
23	and	and	CC	_	17	cc
24	drug6	drug6	NN	_	17	conj
25	-RRB-	-rrb-	-RRB-	_	17	punct
26	have	have	VBP	_	29	aux
27	not	not	RB	_	29	neg
28	been	be	VBN	_	29	auxpass
29	studied	study	VBN	_	2	dep
30	,	,	,	_	29	punct
31	but	but	CC	_	29	cc
32	these	these	DT	_	33	det
33	drugs	drug	NNS	_	36	nsubjpass
34	would	would	MD	_	36	aux
35	be	be	VB	_	36	auxpass
36	expected	expect	VBN	_	29	conj
37	to	to	TO	_	38	mark
38	increase	increase	VB	_	36	xcomp
39	blood	blood	NN	_	40	compound
40	levels	level	NNS	_	38	dobj
41	of	of	IN	_	43	case
42	the	the	DT	_	43	det
43	R	r	NN	_	40	nmod
44	-LRB-	-lrb-	-LRB-	_	47	punct
45	+	+	CC	_	47	cc
46	-RRB-	-rrb-	-RRB-	_	47	punct
47	enantiomer	enantiomer	NN	_	43	dep
48	of	of	IN	_	49	case
49	drug7	drug7	NN	_	47	nmod
50	.	.	.	_	2	punct

1	Retrospective	retrospective	JJ	_	2	amod
2	analysis	analysis	NN	_	9	nsubj
3	of	of	IN	_	5	case
4	side	side	JJ	_	5	amod
5	effects	effect	NNS	_	2	nmod
6	in	in	IN	_	8	case
7	clinical	clinical	JJ	_	8	amod
8	trials	trial	NNS	_	5	nmod
9	showed	show	VBD	_	0	ROOT
10	that	that	IN	_	14	mark
11	poor	poor	JJ	_	13	amod
12	2D6	2d6	NN	_	13	compound
13	metabolizers	metabolizer	NNS	_	14	nsubj
14	had	have	VBD	_	9	ccomp
15	a	a	DT	_	17	det
16	higher	higher	JJR	_	17	amod
17	rate	rate	NN	_	14	dobj
18	of	of	IN	_	19	case
19	dizziness	dizziness	NN	_	17	nmod
20	during	during	IN	_	21	case
21	up-titration	up-titration	NN	_	14	nmod
22	,	,	,	_	14	punct
23	presumably	presumably	RB	_	24	advmod
24	resulting	result	VBG	_	14	advcl
25	from	from	IN	_	26	mark
26	vasodilating	vasodilate	VBG	_	24	advcl
27	effects	effect	NNS	_	26	dobj
28	of	of	IN	_	31	case
29	the	the	DT	_	31	det
30	higher	higher	JJR	_	31	amod
31	concentrations	concentration	NNS	_	27	nmod
32	of	of	IN	_	35	case
33	the	the	DT	_	35	det
34	a-blocking	a-blocking	NN	_	35	compound
35	R	r	NN	_	31	nmod
36	-LRB-	-lrb-	-LRB-	_	39	punct
37	+	+	CC	_	39	cc
38	-RRB-	-rrb-	-RRB-	_	39	punct
39	enantiomer	enantiomer	NN	_	35	appos
40	.	.	.	_	39	punct

1	Catecholamine-depleting	catecholamine-depleting	JJ	_	2	amod
2	Agents	agent	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	Patients	patient	NNS	_	24	nsubjpass
5	taking	take	VBG	_	4	acl
6	both	both	CC	_	7	cc:preconj
7	drug1	drug1	NN	_	5	dobj
8	and	and	CC	_	7	cc
9	a	a	DT	_	10	det
10	drug	drug	NN	_	7	conj
11	that	that	WDT	_	13	nsubj
12	can	can	MD	_	13	aux
13	deplete	deplete	VB	_	10	acl:relcl
14	catecholamines	catecholamine	NNS	_	13	dobj
15	-LRB-	-lrb-	-LRB-	_	18	punct
16	e.g.	e.g.	FW	_	18	dep
17	,	,	,	_	18	punct
18	drug2	drug2	NN	_	13	dep
19	and	and	CC	_	18	cc
20	drug3	drug3	NN	_	18	conj
21	-RRB-	-rrb-	-RRB-	_	18	punct
22	should	should	MD	_	24	aux
23	be	be	VB	_	24	auxpass
24	observed	observe	VBN	_	2	dep
25	closely	closely	RB	_	24	advmod
26	for	for	IN	_	27	case
27	signs	sign	NNS	_	24	nmod
28	of	of	IN	_	29	case
29	hypotension	hypotension	NN	_	27	nmod
30	and/or	and/or	CC	_	29	cc
31	severe	severe	JJ	_	32	amod
32	bradycardia	bradycardia	NN	_	29	conj
33	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concomitant	concomitant	JJ	_	4	amod
4	administration	administration	NN	_	10	nsubj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	with	with	IN	_	8	case
8	drug3	drug3	NN	_	4	nmod
9	may	may	MD	_	10	aux
10	potentiate	potentiate	VB	_	1	dep
11	blood-pressure	blood-pressure	NN	_	10	dobj
12	-	-	:	_	10	punct
13	and	and	CC	_	10	cc
14	heart-rate-lowering	heart-rate-lowering	JJ	_	15	amod
15	effects	effect	NNS	_	10	conj
16	.	.	.	_	1	punct

1	When	when	WRB	_	8	advmod
2	concomitant	concomitant	JJ	_	3	amod
3	treatment	treatment	NN	_	8	nsubj
4	with	with	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	is	be	VBZ	_	17	advcl
9	to	to	TO	_	11	mark
10	be	be	VB	_	11	auxpass
11	terminated	terminate	VBN	_	8	xcomp
12	,	,	,	_	17	punct
13	the	the	DT	_	14	det
14	drug3	drug3	NN	_	17	nsubjpass
15	should	should	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	discontinued	discontinue	VBN	_	0	ROOT
18	first	first	RB	_	17	advmod
19	.	.	.	_	17	punct

1	drug1	drug1	NN	_	2	compound
2	therapy	therapy	NN	_	6	nsubjpass
3	can	can	MD	_	6	aux
4	then	then	RB	_	6	advmod
5	be	be	VB	_	6	auxpass
6	discontinued	discontinue	VBN	_	0	ROOT
7	several	several	JJ	_	8	amod
8	days	day	NNS	_	9	nmod:npmod
9	later	later	RB	_	6	advmod
10	by	by	IN	_	12	mark
11	gradually	gradually	RB	_	12	advmod
12	decreasing	decrease	VBG	_	6	advcl
13	the	the	DT	_	14	det
14	dosage	dosage	NN	_	12	dobj
15	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Modest	modest	JJ	_	4	amod
4	increases	increase	NNS	_	11	nsubjpass
5	in	in	IN	_	9	case
6	mean	mean	JJ	_	9	amod
7	trough	trough	NN	_	9	compound
8	drug2	drug2	NN	_	9	compound
9	concentrations	concentration	NNS	_	4	nmod
10	were	be	VBD	_	11	auxpass
11	observed	observe	VBN	_	1	appos
12	following	follow	VBG	_	13	case
13	initiation	initiation	NN	_	11	nmod
14	of	of	IN	_	16	case
15	drug3	drug3	NN	_	16	compound
16	treatment	treatment	NN	_	13	nmod
17	in	in	IN	_	21	case
18	21	21	CD	_	21	nummod
19	renal	renal	JJ	_	21	amod
20	transplant	transplant	NN	_	21	compound
21	patients	patient	NNS	_	13	nmod
22	suffering	suffer	VBG	_	21	acl
23	from	from	IN	_	26	case
24	chronic	chronic	JJ	_	26	amod
25	vascular	vascular	JJ	_	26	amod
26	rejection	rejection	NN	_	22	nmod
27	.	.	.	_	1	punct

1	In	in	IN	_	4	case
2	about	about	RB	_	3	advmod
3	30	30	CD	_	4	nummod
4	%	%	NN	_	12	nmod
5	of	of	IN	_	6	case
6	patients	patient	NNS	_	4	nmod
7	,	,	,	_	12	punct
8	the	the	DT	_	9	det
9	dose	dose	NN	_	12	nsubj
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	had	have	VBD	_	0	ROOT
13	to	to	TO	_	15	mark
14	be	be	VB	_	15	auxpass
15	reduced	reduce	VBN	_	12	xcomp
16	in	in	IN	_	19	mark
17	order	order	NN	_	16	mwe
18	to	to	TO	_	19	mark
19	maintain	maintain	VB	_	15	advcl
20	drug2	drug2	NN	_	21	compound
21	concentrations	concentration	NNS	_	19	dobj
22	within	within	IN	_	25	case
23	the	the	DT	_	25	det
24	therapeutic	therapeutic	JJ	_	25	amod
25	range	range	NN	_	21	nmod
26	,	,	,	_	12	punct
27	while	while	IN	_	34	mark
28	in	in	IN	_	30	case
29	the	the	DT	_	30	det
30	remainder	remainder	NN	_	34	nmod
31	no	no	DT	_	32	neg
32	adjustment	adjustment	NN	_	34	nsubjpass
33	was	be	VBD	_	34	auxpass
34	needed	need	VBN	_	12	advcl
35	.	.	.	_	12	punct

1	On	on	IN	_	3	case
2	the	the	DT	_	3	det
3	average	average	NN	_	13	nmod
4	for	for	IN	_	6	case
5	the	the	DT	_	6	det
6	group	group	NN	_	3	nmod
7	,	,	,	_	13	punct
8	the	the	DT	_	9	det
9	dose	dose	NN	_	13	nsubjpass
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	was	be	VBD	_	13	auxpass
13	reduced	reduce	VBN	_	0	ROOT
14	about	about	IN	_	15	advmod
15	20	20	CD	_	16	nummod
16	%	%	NN	_	13	dobj
17	in	in	IN	_	19	case
18	these	these	DT	_	19	det
19	patients	patient	NNS	_	13	nmod
20	.	.	.	_	13	punct

1	Due	due	JJ	_	14	advmod
2	to	to	TO	_	5	case
3	wide	wide	JJ	_	5	amod
4	interindividual	interindividual	JJ	_	5	amod
5	variability	variability	NN	_	1	nmod
6	in	in	IN	_	9	case
7	the	the	DT	_	9	det
8	dose	dose	NN	_	9	compound
9	adjustment	adjustment	NN	_	5	nmod
10	required	require	VBN	_	9	acl
11	,	,	,	_	14	punct
12	it	it	PRP	_	14	nsubjpass
13	is	be	VBZ	_	14	auxpass
14	recommended	recommend	VBN	_	0	ROOT
15	that	that	IN	_	19	mark
16	drug1	drug1	NN	_	17	compound
17	concentrations	concentration	NNS	_	19	nsubjpass
18	be	be	VB	_	19	auxpass
19	monitored	monitor	VBN	_	14	ccomp
20	closely	closely	RB	_	19	advmod
21	after	after	IN	_	22	case
22	initiation	initiation	NN	_	19	nmod
23	of	of	IN	_	25	case
24	drug2	drug2	NN	_	25	compound
25	therapy	therapy	NN	_	22	nmod
26	and	and	CC	_	19	cc
27	that	that	IN	_	33	mark
28	the	the	DT	_	29	det
29	dose	dose	NN	_	33	nsubjpass
30	of	of	IN	_	31	case
31	drug3	drug3	NN	_	29	nmod
32	be	be	VB	_	33	auxpass
33	adjusted	adjust	VBN	_	19	conj
34	as	as	IN	_	35	case
35	appropriate	appropriate	JJ	_	33	advcl
36	.	.	.	_	14	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	compound
4	concentrations	concentration	NNS	_	6	nsubjpass
5	are	be	VBP	_	6	auxpass
6	increased	increase	VBN	_	1	dep
7	by	by	IN	_	10	case
8	about	about	RB	_	9	advmod
9	15	15	CD	_	10	nummod
10	%	%	NN	_	6	nmod
11	when	when	WRB	_	16	advmod
12	drug3	drug3	NN	_	16	nsubjpass
13	and	and	CC	_	12	cc
14	drug4	drug4	NN	_	12	conj
15	are	be	VBP	_	16	auxpass
16	administered	administer	VBN	_	6	advcl
17	concomitantly	concomitantly	RB	_	16	advmod
18	.	.	.	_	6	punct

1	Both	both	DT	_	2	cc:preconj
2	drug1	drug1	NN	_	5	nsubj
3	and	and	CC	_	2	cc
4	drug2	drug2	NN	_	2	conj
5	slow	slow	JJ	_	0	ROOT
6	AV	av	NN	_	7	compound
7	conduction	conduction	NN	_	5	dobj
8	.	.	.	_	5	punct

1	Therefore	therefore	RB	_	3	advmod
2	,	,	,	_	3	punct
3	increased	increase	VBD	_	0	ROOT
4	monitoring	monitoring	NN	_	3	dobj
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	is	be	VBZ	_	8	auxpass
8	recommended	recommend	VBN	_	3	dep
9	when	when	WRB	_	10	advmod
10	initiating	initiate	VBG	_	8	advcl
11	,	,	,	_	10	punct
12	adjusting	adjust	VBG	_	10	conj
13	,	,	,	_	10	punct
14	or	or	CC	_	10	cc
15	discontinuing	discontinue	VBG	_	10	conj
16	drug2	drug2	NN	_	15	dobj
17	.	.	.	_	3	punct

1	Inducers	inducer	NNS	_	0	ROOT
2	and	and	CC	_	1	cc
3	Inhibitors	inhibitor	NNS	_	1	conj
4	of	of	IN	_	6	case
5	Hepatic	hepatic	JJ	_	6	amod
6	Metabolism	metabolism	NN	_	1	nmod
7	:	:	:	_	1	punct
8	drug1	drug1	NN	_	11	compound
9	reduced	reduce	VBN	_	11	amod
10	plasma	plasma	NN	_	11	compound
11	concentrations	concentration	NNS	_	1	dep
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	by	by	IN	_	17	case
15	about	about	RB	_	16	advmod
16	70	70	CD	_	17	nummod
17	%	%	NN	_	11	nmod
18	.	.	.	_	1	punct

1	drug1	drug1	NN	_	2	nsubj
2	increased	increase	VBD	_	0	ROOT
3	AUC	auc	NN	_	2	dobj
4	by	by	IN	_	7	case
5	about	about	IN	_	6	advmod
6	30	30	CD	_	7	nummod
7	%	%	NN	_	2	nmod
8	but	but	CC	_	2	cc
9	caused	cause	VBD	_	2	conj
10	no	no	DT	_	11	neg
11	change	change	NN	_	9	dobj
12	in	in	IN	_	13	case
13	Cmax	Cmax	NNP	_	11	nmod
14	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Isolated	isolate	VBN	_	4	amod
4	cases	case	NNS	_	16	nsubjpass
5	of	of	IN	_	7	case
6	conduction	conduction	NN	_	7	compound
7	disturbance	disturbance	NN	_	4	nmod
8	-LRB-	-lrb-	-LRB-	_	12	punct
9	rarely	rarely	RB	_	12	advmod
10	with	with	IN	_	12	case
11	hemodynamic	hemodynamic	JJ	_	12	amod
12	compromise	compromise	NN	_	4	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	have	have	VBP	_	16	aux
15	been	be	VBN	_	16	auxpass
16	observed	observe	VBN	_	1	dep
17	when	when	WRB	_	20	advmod
18	drug2	drug2	NN	_	20	nsubjpass
19	is	be	VBZ	_	20	auxpass
20	co-administered	co-administer	VBN	_	16	advcl
21	with	with	IN	_	22	case
22	drug3	drug3	NN	_	20	nmod
23	.	.	.	_	1	punct

1	As	as	IN	_	4	case
2	with	with	IN	_	4	case
3	other	other	JJ	_	4	amod
4	drug1	drug1	NN	_	24	nmod
5	,	,	,	_	24	punct
6	if	if	IN	_	8	mark
7	drug2	drug2	NN	_	8	nsubj
8	is	be	VBZ	_	24	advcl
9	to	to	TO	_	11	mark
10	be	be	VB	_	11	auxpass
11	administered	administer	VBN	_	8	xcomp
12	orally	orally	RB	_	11	advmod
13	with	with	IN	_	14	case
14	drug3	drug3	NN	_	11	nmod
15	of	of	IN	_	20	case
16	the	the	DT	_	20	det
17	drug4	drug4	NN	_	20	compound
18	or	or	CC	_	17	cc
19	drug5	drug5	NN	_	17	conj
20	type	type	NN	_	14	nmod
21	,	,	,	_	24	punct
22	it	it	PRP	_	24	nsubjpass
23	is	be	VBZ	_	24	auxpass
24	recommended	recommend	VBN	_	0	ROOT
25	that	that	IN	_	31	mark
26	ECG	ecg	NN	_	31	nsubjpass
27	and	and	CC	_	26	cc
28	blood	blood	NN	_	29	compound
29	pressure	pressure	NN	_	26	conj
30	be	be	VB	_	31	auxpass
31	monitored	monitor	VBN	_	24	ccomp
32	.	.	.	_	24	punct

1	drug1	drug1	NN	_	0	ROOT
2	or	or	CC	_	1	cc
3	Oral	oral	JJ	_	1	conj
4	drug2	drug2	NN	_	1	dep
5	:	:	:	_	1	punct
6	drug3	drug3	NN	_	8	nsubj
7	may	may	MD	_	8	aux
8	enhance	enhance	VB	_	1	dep
9	the	the	DT	_	11	det
10	blood-sugar-reducing	blood-sugar-reducing	JJ	_	11	amod
11	effect	effect	NN	_	8	dobj
12	of	of	IN	_	13	case
13	drug4	drug4	NN	_	11	nmod
14	and	and	CC	_	13	cc
15	oral	oral	JJ	_	16	amod
16	drug5	drug5	NN	_	13	conj
17	.	.	.	_	1	punct

1	Therefore	therefore	RB	_	17	advmod
2	,	,	,	_	17	punct
3	in	in	IN	_	4	case
4	patients	patient	NNS	_	17	nmod
5	taking	take	VBG	_	4	acl
6	drug1	drug1	NN	_	5	dobj
7	or	or	CC	_	6	cc
8	oral	oral	JJ	_	6	conj
9	drug2	drug2	NN	_	6	dep
10	,	,	,	_	17	punct
11	regular	regular	JJ	_	12	amod
12	monitoring	monitoring	NN	_	17	nsubjpass
13	of	of	IN	_	15	case
14	blood	blood	NN	_	15	compound
15	glucose	glucose	NN	_	12	nmod
16	is	be	VBZ	_	17	auxpass
17	recommended	recommend	VBN	_	0	ROOT
18	.	.	.	_	17	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	principally	principally	RB	_	4	advmod
4	metabolized	metabolize	VBN	_	0	ROOT
5	by	by	IN	_	7	case
6	the	the	DT	_	7	det
7	liver	liver	NN	_	4	nmod
8	via	via	IN	_	12	case
9	the	the	DT	_	12	det
10	cytochrome	cytochrome	NN	_	12	compound
11	P450	p450	NN	_	12	compound
12	isoenzymes	isoenzyme	NNS	_	4	nmod
13	,	,	,	_	12	punct
14	3A4	3a4	NN	_	12	appos
15	and	and	CC	_	14	cc
16	2B6	2b6	NN	_	14	conj
17	.	.	.	_	4	punct

1	drug1	drug1	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	known	know	VBN	_	0	ROOT
4	to	to	TO	_	7	mark
5	be	be	VB	_	7	cop
6	an	a	DT	_	7	det
7	inducer	inducer	NN	_	3	xcomp
8	of	of	IN	_	10	case
9	these	these	DT	_	10	det
10	enzymes	enzyme	NNS	_	7	nmod
11	.	.	.	_	3	punct

1	As	as	IN	_	3	case
2	a	a	DT	_	3	det
3	result	result	NN	_	14	nmod
4	,	,	,	_	14	punct
5	drugs	drug	NNS	_	14	nsubj
6	that	that	WDT	_	8	nsubjpass
7	are	be	VBP	_	8	auxpass
8	metabolized	metabolize	VBN	_	5	acl:relcl
9	by	by	IN	_	12	case
10	these	these	DT	_	12	det
11	enzyme	enzyme	NN	_	12	compound
12	systems	system	NNS	_	8	nmod
13	may	may	MD	_	14	aux
14	have	have	VB	_	0	ROOT
15	lower	lower	JJR	_	17	dep
16	than	than	IN	_	17	dep
17	expected	expect	VBN	_	19	amod
18	plasma	plasma	NN	_	19	compound
19	levels	level	NNS	_	14	dobj
20	when	when	WRB	_	21	advmod
21	coadministered	coadminister	VBN	_	14	advcl
22	with	with	IN	_	23	case
23	drug1	drug1	NN	_	21	nmod
24	.	.	.	_	14	punct

1	The	the	DT	_	4	det
2	specific	specific	JJ	_	4	amod
3	pharmacokinetic	pharmacokinetic	JJ	_	4	amod
4	changes	change	NNS	_	15	nsubjpass
5	that	that	WDT	_	6	nsubj
6	occur	occur	VBP	_	4	acl:relcl
7	with	with	IN	_	8	case
8	co-administration	co-administration	NN	_	6	nmod
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	other	other	JJ	_	13	amod
13	drugs	drug	NNS	_	10	conj
14	are	be	VBP	_	15	auxpass
15	listed	list	VBN	_	0	ROOT
16	in	in	IN	_	18	case
17	CLINICAL	CLINICAL	NNP	_	18	compound
18	PHARMACOLOGY	PHARMACOLOGY	NNP	_	15	nmod
19	,	,	,	_	18	punct
20	Table	Table	NNP	_	18	appos
21	1	1	CD	_	20	nummod
22	.	.	.	_	15	punct

1	Clinical	clinical	JJ	_	2	amod
2	comments	comment	NNS	_	13	nsubjpass
3	about	about	IN	_	6	case
4	possible	possible	JJ	_	6	amod
5	dosage	dosage	NN	_	6	compound
6	modifications	modification	NNS	_	2	nmod
7	based	base	VBN	_	11	case
8	on	on	IN	_	11	case
9	these	these	DT	_	11	det
10	pharmacokinetic	pharmacokinetic	JJ	_	11	amod
11	changes	change	NNS	_	6	nmod
12	are	be	VBP	_	13	auxpass
13	listed	list	VBN	_	0	ROOT
14	in	in	IN	_	15	case
15	Table	Table	NNP	_	13	nmod
16	3	3	CD	_	15	nummod
17	.	.	.	_	13	punct

1	The	the	DT	_	2	det
2	data	datum	NNS	_	3	nsubj
3	inTables	intable	NNS	_	0	ROOT
4	1	1	CD	_	3	dep
5	and	and	CC	_	4	cc
6	3	3	CD	_	4	conj
7	are	be	VBP	_	8	auxpass
8	based	base	VBN	_	3	dep
9	on	on	IN	_	11	case
10	the	the	DT	_	11	det
11	results	result	NNS	_	8	nmod
12	of	of	IN	_	15	case
13	drug	drug	NN	_	15	compound
14	interaction	interaction	NN	_	15	compound
15	studies	study	NNS	_	11	nmod
16	conducted	conduct	VBN	_	15	acl
17	in	in	IN	_	20	case
18	HIV-1	hiv-1	NN	_	20	compound
19	seropositive	seropositive	JJ	_	20	amod
20	subjects	subject	NNS	_	16	nmod
21	unless	unless	IN	_	23	mark
22	otherwise	otherwise	RB	_	23	advmod
23	indicated	indicate	VBN	_	16	advcl
24	.	.	.	_	3	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	13	nmod
3	to	to	TO	_	6	case
4	established	establish	VBN	_	6	amod
5	drug	drug	NN	_	6	compound
6	interactions	interaction	NNS	_	2	nmod
7	,	,	,	_	13	punct
8	there	there	EX	_	13	expl
9	may	may	MD	_	13	aux
10	be	be	VB	_	13	cop
11	potential	potential	JJ	_	13	amod
12	pharmacokinetic	pharmacokinetic	JJ	_	13	amod
13	interactions	interaction	NNS	_	0	ROOT
14	between	between	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	other	other	JJ	_	19	amod
18	drug	drug	NN	_	19	compound
19	classes	class	NNS	_	15	conj
20	that	that	WDT	_	22	nsubjpass
21	are	be	VBP	_	22	auxpass
22	metabolized	metabolize	VBN	_	13	acl:relcl
23	by	by	IN	_	27	case
24	the	the	DT	_	27	det
25	cytochrome	cytochrome	NN	_	27	compound
26	P450	p450	NN	_	27	compound
27	system	system	NN	_	22	nmod
28	.	.	.	_	13	punct

1	These	these	DT	_	4	det
2	potential	potential	JJ	_	4	amod
3	drug	drug	NN	_	4	compound
4	interactions	interaction	NNS	_	6	nsubjpass
5	are	be	VBP	_	6	auxpass
6	listed	list	VBN	_	0	ROOT
7	in	in	IN	_	8	case
8	Table	Table	NNP	_	6	nmod
9	4	4	CD	_	8	nummod
10	.	.	.	_	6	punct

1	Although	although	IN	_	13	mark
2	specific	specific	JJ	_	5	amod
3	drug	drug	NN	_	5	compound
4	interaction	interaction	NN	_	5	compound
5	studies	study	NNS	_	13	nsubjpass
6	in	in	IN	_	9	case
7	HIV-1	hiv-1	NN	_	9	compound
8	seropositive	seropositive	JJ	_	9	amod
9	subjects	subject	NNS	_	5	nmod
10	have	have	VBP	_	13	aux
11	not	not	RB	_	13	neg
12	been	be	VBN	_	13	auxpass
13	conducted	conduct	VBN	_	29	advcl
14	for	for	IN	_	16	case
15	the	the	DT	_	16	det
16	classes	class	NNS	_	13	nmod
17	of	of	IN	_	18	case
18	drugs	drug	NNS	_	16	nmod
19	listed	list	VBN	_	18	acl
20	in	in	IN	_	21	case
21	Table	Table	NNP	_	19	nmod
22	4	4	CD	_	21	nummod
23	,	,	,	_	29	punct
24	additional	additional	JJ	_	26	amod
25	clinical	clinical	JJ	_	26	amod
26	monitoring	monitoring	NN	_	29	nsubjpass
27	may	may	MD	_	29	aux
28	be	be	VB	_	29	auxpass
29	warranted	warrant	VBN	_	0	ROOT
30	when	when	WRB	_	31	advmod
31	co-administering	co-administer	VBG	_	29	advcl
32	these	these	DT	_	33	det
33	drugs	drug	NNS	_	31	dobj
34	.	.	.	_	29	punct

1	The	the	DT	_	4	det
2	in	in	FW	_	4	amod
3	vitro	vitro	FW	_	2	dep
4	interaction	interaction	NN	_	12	nsubj
5	between	between	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	the	the	DT	_	10	det
9	drug2	drug2	NN	_	10	compound
10	drug3	drug3	NN	_	6	conj
11	is	be	VBZ	_	12	cop
12	complex	complex	NN	_	0	ROOT
13	.	.	.	_	12	punct

1	As	as	IN	_	3	case
2	a	a	DT	_	3	det
3	result	result	NN	_	15	nmod
4	,	,	,	_	15	punct
5	when	when	WRB	_	6	advmod
6	giving	give	VBG	_	15	advcl
7	these	these	DT	_	8	det
8	drugs	drug	NNS	_	6	dobj
9	concomitantly	concomitantly	RB	_	6	advmod
10	,	,	,	_	15	punct
11	plasma	plasma	NN	_	13	compound
12	drug1	drug1	NN	_	13	compound
13	levels	level	NNS	_	15	nsubj
14	may	may	MD	_	15	aux
15	change	change	VB	_	0	ROOT
16	with	with	IN	_	18	case
17	the	the	DT	_	18	det
18	potential	potential	NN	_	15	nmod
19	for	for	IN	_	20	case
20	increases	increase	NNS	_	18	nmod
21	in	in	IN	_	23	case
22	coagulation	coagulation	NN	_	23	compound
23	time	time	NN	_	20	nmod
24	.	.	.	_	15	punct

1	When	when	WRB	_	4	advmod
2	drug1	drug1	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	co-administered	co-administer	VBN	_	12	advcl
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	,	,	,	_	12	punct
8	anticoagulation	anticoagulation	NN	_	9	compound
9	levels	level	NNS	_	12	nsubjpass
10	should	should	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	monitored	monitor	VBN	_	0	ROOT
13	frequently	frequently	RB	_	12	advmod
14	.	.	.	_	12	punct

1	Table	Table	NNP	_	5	compound
2	3	3	CD	_	5	nummod
3	Established	Established	NNP	_	5	compound
4	Drug	Drug	NNP	_	5	compound
5	Interactions	interaction	NNS	_	0	ROOT
6	:	:	:	_	5	punct
7	Alteration	alteration	NN	_	14	nsubjpass
8	in	in	IN	_	9	case
9	Dose	dose	NN	_	7	nmod
10	or	or	CC	_	9	cc
11	Regimen	Regimen	NNP	_	12	compound
12	May	May	NNP	_	9	conj
13	Be	be	VB	_	14	auxpass
14	Recommended	recommend	VBN	_	5	dep
15	Based	base	VBN	_	19	case
16	on	on	IN	_	19	case
17	Drug	drug	NN	_	19	compound
18	Interaction	interaction	NN	_	19	compound
19	Studies	study	NNS	_	14	advcl

1	Drug	drug	NN	_	2	nsubj
2	Name	name	VB	_	0	ROOT

1	Effect	effect	NN	_	0	ROOT
2	on	on	IN	_	3	case
3	Concentration	concentration	NN	_	1	nmod
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	or	or	CC	_	5	cc
7	Concomitant	concomitant	JJ	_	8	amod
8	Drug	drug	NN	_	5	conj

1	Clinical	clinical	JJ	_	2	amod
2	Comment	comment	NN	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	2	compound
2	14OH	14oh	NN	_	0	ROOT
3	-	-	:	_	2	punct
4	clarithromycin	clarithromycin	NN	_	2	dep

1	drug1	drug1	NN	_	2	compound
2	exposure	exposure	NN	_	5	nsubjpass
3	was	be	VBD	_	5	auxpass
4	significantly	significantly	RB	_	5	advmod
5	decreased	decrease	VBN	_	0	ROOT
6	by	by	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	;	;	:	_	5	punct

1	however	however	RB	_	10	advmod
2	,	,	,	_	10	punct
3	14-OH	14-oh	NN	_	5	compound
4	metabolite	metabolite	NN	_	5	compound
5	concentrations	concentration	NNS	_	10	nsubj
6	were	be	VBD	_	10	cop
7	increased.Because	increased.because	NN	_	10	compound
8	drug1	drug1	NN	_	10	compound
9	active	active	JJ	_	10	amod
10	metabolite	metabolite	NN	_	12	nsubj
11	has	have	VBZ	_	12	aux
12	reduced	reduce	VBN	_	0	ROOT
13	activity	activity	NN	_	12	dobj
14	against	against	IN	_	16	case
15	Mycobacteriumavium-intracellulare	mycobacteriumavium-intracellulare	JJ	_	16	amod
16	complex	complex	NN	_	13	nmod
17	,	,	,	_	12	punct
18	overallactivity	overallactivity	NN	_	23	nsubj
19	against	against	IN	_	21	case
20	this	this	DT	_	21	det
21	pathogen	pathogen	NN	_	18	nmod
22	may	may	MD	_	23	aux
23	bealtered	bealter	VB	_	12	parataxis
24	.	.	.	_	12	punct

1	Alternatives	Alternatives	NNP	_	11	nsubjpass
2	to	to	TO	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	,	,	,	_	1	punct
5	such	such	JJ	_	7	case
6	as	as	IN	_	5	mwe
7	drug2	drug2	NN	_	1	nmod
8	,	,	,	_	1	punct
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	considered	consider	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT

1	Appropriate	appropriate	JJ	_	2	amod
2	doses	dose	NNS	_	8	nsubjpass
3	for	for	IN	_	5	case
4	this	this	DT	_	5	det
5	combination	combination	NN	_	2	nmod
6	are	be	VBP	_	8	auxpass
7	not	not	RB	_	8	neg
8	established	establish	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	drug1	drug1	NN	_	0	ROOT
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj

1	drug1	drug1	NN	_	2	compound
2	drug2	drug2	NN	_	0	ROOT

1	Oral	oral	JJ	_	2	amod
2	drug1	drug1	NN	_	12	nsubj
3	and	and	CC	_	2	cc
4	other	other	JJ	_	5	amod
5	hormonalmethods	hormonalmethod	NNS	_	2	conj
6	of	of	IN	_	8	case
7	birth	birth	NN	_	8	compound
8	control	control	NN	_	5	nmod
9	should	should	MD	_	12	aux
10	not	not	RB	_	12	neg
11	be	be	VB	_	12	cop
12	usedas	usedas	JJ	_	0	ROOT
13	the	the	DT	_	15	det
14	sole	sole	JJ	_	15	amod
15	method	method	NN	_	12	dobj
16	of	of	IN	_	18	case
17	contraception	contraception	NN	_	18	compound
18	inwomen	inwomen	NN	_	15	nmod
19	taking	take	VBG	_	18	acl
20	drug2	drug2	NN	_	19	dobj
21	,	,	,	_	12	punct
22	since	since	IN	_	27	case
23	nevirapinemay	nevirapinemay	NN	_	24	nmod:npmod
24	lower	lower	JJR	_	27	amod
25	the	the	DT	_	27	det
26	plasma	plasma	NN	_	27	compound
27	levels	level	NNS	_	12	nmod
28	of	of	IN	_	29	case
29	thesemedications	thesemedication	NNS	_	27	nmod
30	.	.	.	_	12	punct

1	An	a	DT	_	5	det
2	alternative	alternative	JJ	_	5	amod
3	or	or	CC	_	2	cc
4	additional	additional	JJ	_	2	conj
5	method	method	NN	_	9	nsubjpass
6	of	of	IN	_	7	case
7	contraception	contraception	NN	_	5	nmod
8	is	be	VBZ	_	9	auxpass
9	recommended	recommend	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT

1	Because	because	IN	_	4	case
2	of	of	IN	_	1	mwe
3	the	the	DT	_	4	det
4	risk	risk	NN	_	14	nmod
5	of	of	IN	_	7	case
6	increased	increase	VBN	_	7	amod
7	exposure	exposure	NN	_	4	nmod
8	to	to	TO	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	,	,	,	_	14	punct
11	caution	caution	NN	_	14	nsubjpass
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	used	use	VBN	_	0	ROOT
15	inconcomitant	inconcomitant	JJ	_	16	amod
16	administration	administration	NN	_	14	dobj
17	,	,	,	_	14	punct
18	and	and	CC	_	14	cc
19	patients	patient	NNS	_	22	nsubjpass
20	should	should	MD	_	22	aux
21	be	be	VB	_	22	auxpass
22	monitored	monitor	VBN	_	14	conj
23	closely	closely	RB	_	22	advmod
24	for	for	IN	_	27	case
25	nevirapine-associated	nevirapine-associated	JJ	_	27	amod
26	adverse	adverse	JJ	_	27	amod
27	events	event	NNS	_	22	nmod
28	.	.	.	_	14	punct

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT

1	Appropriate	appropriate	JJ	_	2	amod
2	doses	dose	NNS	_	18	nsubjpass
3	for	for	IN	_	6	case
4	this	this	DT	_	6	det
5	combination	combination	NN	_	6	compound
6	arenot	arenot	NN	_	2	nmod
7	established	establish	VBN	_	6	acl
8	,	,	,	_	2	punct
9	but	but	CC	_	2	cc
10	an	a	DT	_	11	det
11	increase	increase	NN	_	2	conj
12	in	in	IN	_	13	case
13	thedosage	thedosage	NN	_	11	nmod
14	of	of	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	may	may	MD	_	18	aux
17	be	be	VB	_	18	auxpass
18	required	require	VBN	_	0	ROOT
19	.	.	.	_	18	punct

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	6	nsubjpass
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	should	should	MD	_	6	aux
5	not	not	RB	_	6	neg
6	beadministered	beadminister	VBN	_	0	ROOT
7	concomitantly	concomitantly	RB	_	8	advmod
8	becausedecreases	becausedecrease	NNS	_	13	nsubj
9	in	in	IN	_	11	case
10	drug3	drug3	NN	_	11	compound
11	plasmaconcentrations	plasmaconcentration	NNS	_	8	nmod
12	may	may	MD	_	13	aux
13	reduce	reduce	VB	_	6	ccomp
14	the	the	DT	_	15	det
15	efficacy	efficacy	NN	_	13	dobj
16	of	of	IN	_	18	case
17	the	the	DT	_	18	det
18	drug	drug	NN	_	15	nmod
19	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	/	/	:	_	1	punct
3	drug2	drug2	NN	_	1	dep

1	drug1	drug1	NN	_	0	ROOT

1	A	a	DT	_	3	det
2	dose	dose	NN	_	3	compound
3	increase	increase	NN	_	0	ROOT
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	/	/	:	_	3	punct
7	drug2	drug2	NN	_	3	dep
8	to	to	TO	_	10	case
9	533/133	533/133	CD	_	10	nummod
10	mg	mg	NN	_	7	nmod
11	twice	twice	RB	_	12	advmod
12	daily	daily	RB	_	7	advmod
13	with	with	IN	_	14	case
14	food	food	NN	_	7	nmod
15	isrecommended	isrecommend	VBN	_	14	acl
16	in	in	IN	_	17	case
17	combination	combination	NN	_	15	nmod
18	with	with	IN	_	19	case
19	drug3	drug3	NN	_	17	nmod
20	.	.	.	_	3	punct

1	drug1	drug1	NN	_	0	ROOT

1	Methadonea	Methadonea	NNP	_	0	ROOT

1	drug1	drug1	NN	_	2	compound
2	levels	level	NNS	_	5	nsubjpass
3	may	may	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	decreased	decrease	VBN	_	0	ROOT
6	;	;	:	_	5	punct
7	increased	increase	VBN	_	8	amod
8	dosages	dosage	NNS	_	11	nsubjpass
9	may	may	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	required	require	VBN	_	5	parataxis
12	to	to	TO	_	13	mark
13	prevent	prevent	VB	_	11	xcomp
14	symptoms	symptom	NNS	_	13	dobj
15	of	of	IN	_	17	case
16	drug2	drug2	NN	_	17	compound
17	withdrawal	withdrawal	NN	_	14	nmod
18	.	.	.	_	5	punct
19	drug3	drug3	NN	_	21	compound
20	maintained	maintain	VBD	_	21	amod
21	patients	patient	NNS	_	27	nsubjpass
22	beginning	begin	VBG	_	21	acl
23	drug4	drug4	NN	_	24	compound
24	therapy	therapy	NN	_	22	dobj
25	should	should	MD	_	27	aux
26	be	be	VB	_	27	auxpass
27	monitored	monitor	VBN	_	5	parataxis
28	forevidence	forevidence	NN	_	27	xcomp
29	of	of	IN	_	30	case
30	withdrawal	withdrawal	NN	_	28	nmod
31	and	and	CC	_	30	cc
32	drug5	drug5	NN	_	33	compound
33	dose	dose	NN	_	30	conj
34	should	should	MD	_	36	aux
35	be	be	VB	_	36	auxpass
36	adjusted	adjust	VBN	_	27	dep
37	accordingly	accordingly	RB	_	36	advmod
38	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	2	compound
2	M8	m8	NN	_	0	ROOT

1	The	the	DT	_	3	det
2	appropriate	appropriate	JJ	_	3	amod
3	dose	dose	NN	_	19	nsubjpass
4	for	for	IN	_	6	case
5	drug1	drug1	NN	_	6	compound
6	incombination	incombination	NN	_	3	nmod
7	with	with	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	,	,	,	_	3	punct
10	with	with	IN	_	12	case
11	respectto	respectto	NN	_	12	compound
12	safety	safety	NN	_	3	nmod
13	and	and	CC	_	12	cc
14	efficacy	efficacy	NN	_	12	conj
15	,	,	,	_	3	punct
16	has	have	VBZ	_	19	aux
17	not	not	RB	_	19	neg
18	been	be	VBN	_	19	auxpass
19	established	establish	VBN	_	0	ROOT
20	.	.	.	_	19	punct

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	7	nsubj
2	and	and	CC	_	1	cc
3	its	its	PRP$	_	5	nmod:poss
4	metabolite	metabolite	NN	_	5	compound
5	concentrationswere	concentrationswere	NN	_	1	conj
6	moderately	moderately	RB	_	7	advmod
7	increased	increase	VBD	_	0	ROOT
8	.	.	.	_	7	punct

1	Due	due	JJ	_	10	dep
2	to	to	TO	_	4	case
3	highintersubject	highintersubject	JJ	_	4	amod
4	variability	variability	NN	_	1	nmod
5	,	,	,	_	10	punct
6	however	however	RB	_	10	advmod
7	,	,	,	_	10	punct
8	somepatients	somepatient	NNS	_	10	nsubj
9	may	may	MD	_	10	aux
10	experience	experience	VB	_	0	ROOT
11	large	large	JJ	_	12	amod
12	increases	increase	NNS	_	10	dobj
13	in	in	IN	_	15	case
14	drug1	drug1	NN	_	15	compound
15	exposure	exposure	NN	_	12	nmod
16	and	and	CC	_	10	cc
17	may	may	MD	_	23	aux
18	be	be	VB	_	23	cop
19	at	at	IN	_	23	case
20	higher	higher	JJR	_	23	amod
21	riskfor	riskfor	NN	_	23	compound
22	rifabutin	rifabutin	NN	_	23	compound
23	toxicity	toxicity	NN	_	10	conj
24	.	.	.	_	10	punct

1	Therefore	therefore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	caution	caution	NN	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	used	use	VBN	_	0	ROOT
7	in	in	IN	_	9	case
8	concomitant	concomitant	JJ	_	9	amod
9	administration	administration	NN	_	6	nmod
10	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	6	nsubjpass
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	should	should	MD	_	6	aux
5	not	not	RB	_	6	neg
6	beadministered	beadminister	VBN	_	0	ROOT
7	concomitantly	concomitantly	RB	_	8	advmod
8	becausedecreases	becausedecrease	NNS	_	13	nsubj
9	in	in	IN	_	11	case
10	drug3	drug3	NN	_	11	compound
11	plasmaconcentrations	plasmaconcentration	NNS	_	8	nmod
12	may	may	MD	_	13	aux
13	reduce	reduce	VB	_	6	ccomp
14	the	the	DT	_	17	det
15	efficacy	efficacy	NN	_	17	compound
16	ofthe	ofthe	NN	_	17	compound
17	drug	drug	NN	_	13	dobj
18	.	.	.	_	6	punct

1	Physicians	Physicians	NNP	_	0	ROOT
2	needing	need	VBG	_	1	acl
3	to	to	TO	_	4	case
4	treatpatients	treatpatient	NNS	_	2	nmod
5	co-infected	co-infect	VBN	_	4	acl
6	with	with	IN	_	8	case
7	tuberculosis	tuberculosis	NN	_	8	compound
8	andusing	andusing	NN	_	5	nmod
9	a	a	DT	_	10	det
10	drug1	drug1	NN	_	8	dep
11	containing	contain	VBG	_	10	acl
12	regimen	regimen	NN	_	14	compound
13	mayuse	mayuse	NN	_	14	compound
14	drug2	drug2	NN	_	11	dobj
15	instead	instead	RB	_	10	advmod
16	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT

1	Appropriate	appropriate	JJ	_	2	amod
2	doses	dose	NNS	_	18	nsubjpass
3	for	for	IN	_	6	case
4	this	this	DT	_	6	det
5	combination	combination	NN	_	6	compound
6	arenot	arenot	NN	_	2	nmod
7	established	establish	VBN	_	6	acl
8	,	,	,	_	2	punct
9	but	but	CC	_	2	cc
10	an	a	DT	_	11	det
11	increase	increase	NN	_	2	conj
12	in	in	IN	_	13	case
13	thedosage	thedosage	NN	_	11	nmod
14	of	of	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	may	may	MD	_	18	aux
17	be	be	VB	_	18	auxpass
18	required	require	VBN	_	0	ROOT
19	.	.	.	_	18	punct

1	aBased	abase	VBN	_	0	ROOT
2	on	on	IN	_	3	case
3	reports	report	NNS	_	1	nmod
4	of	of	IN	_	7	case
5	narcotic	narcotic	JJ	_	7	amod
6	withdrawal	withdrawal	NN	_	7	compound
7	syndrome	syndrome	NN	_	3	nmod
8	in	in	IN	_	9	case
9	patients	patient	NNS	_	7	nmod
10	treated	treat	VBN	_	9	acl
11	with	with	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	and	and	CC	_	12	cc
14	drug2	drug2	NN	_	12	conj
15	concurrently	concurrently	RB	_	1	advmod
16	,	,	,	_	1	punct
17	and	and	CC	_	1	cc
18	evidence	evidence	NN	_	1	conj
19	of	of	IN	_	22	case
20	decreased	decrease	VBN	_	22	amod
21	plasma	plasma	NN	_	22	compound
22	concentrations	concentration	NNS	_	18	nmod
23	of	of	IN	_	24	case
24	drug3	drug3	NN	_	22	nmod
25	.	.	.	_	1	punct

1	Table	Table	NNP	_	5	compound
2	4	4	CD	_	5	nummod
3	Potential	potential	JJ	_	5	amod
4	Drug	drug	NN	_	5	compound
5	Interactions	interaction	NNS	_	0	ROOT
6	:	:	:	_	5	punct
7	Use	Use	NNP	_	5	dep
8	With	with	IN	_	9	case
9	Caution	caution	NN	_	7	nmod
10	,	,	,	_	7	punct
11	Dose	Dose	NNP	_	12	compound
12	Adjustment	Adjustment	NNP	_	18	nsubjpass
13	of	of	IN	_	16	case
14	Co-administered	Co-administered	NNP	_	16	compound
15	Drug	Drug	NNP	_	16	compound
16	May	May	NNP	_	12	nmod
17	Be	be	VB	_	18	auxpass
18	Needed	need	VBN	_	7	appos
19	due	due	JJ	_	22	case
20	to	to	TO	_	22	case
21	Possible	possible	JJ	_	22	amod
22	Decrease	decrease	NN	_	18	advcl
23	in	in	IN	_	25	case
24	Clinical	clinical	JJ	_	25	amod
25	Effect	effect	NN	_	22	nmod

1	Examples	example	NNS	_	10	nsubjpass
2	of	of	IN	_	3	case
3	Drugs	drug	NNS	_	1	nmod
4	in	in	IN	_	7	case
5	Which	which	WDT	_	7	det
6	Plasma	plasma	NN	_	7	compound
7	Concentrations	concentration	NNS	_	1	nmod
8	May	may	MD	_	10	aux
9	Be	be	VB	_	10	auxpass
10	Decreased	decrease	VBN	_	0	ROOT
11	By	by	IN	_	12	case
12	Co-administration	co-administration	NN	_	10	nmod
13	With	with	IN	_	14	case
14	drug1	drug1	NN	_	10	nmod

1	Drug	Drug	NNP	_	3	compound
2	Class	Class	NNP	_	3	compound
3	Examples	example	NNS	_	0	ROOT
4	of	of	IN	_	5	case
5	Drugs	drug	NNS	_	3	nmod

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	,	,	,	_	1	punct
5	drug3	drug3	NN	_	1	appos

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	,	,	,	_	1	punct
5	drug3	drug3	NN	_	1	appos

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	,	,	,	_	1	punct
5	drug3	drug3	NN	_	1	appos

1	Cancer	cancer	NN	_	2	compound
2	chemotherapy	chemotherapy	NN	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	,	,	,	_	1	punct
5	drug3	drug3	NN	_	1	appos

1	Motility	motility	NN	_	2	compound
2	agents	agent	NNS	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT

1	Examples	example	NNS	_	10	nsubjpass
2	of	of	IN	_	3	case
3	Drugs	drug	NNS	_	1	nmod
4	in	in	IN	_	7	case
5	Which	which	WDT	_	7	det
6	Plasma	plasma	NN	_	7	compound
7	Concentrations	concentration	NNS	_	1	nmod
8	May	may	MD	_	10	aux
9	Be	be	VB	_	10	auxpass
10	Increased	increase	VBN	_	0	ROOT
11	By	by	IN	_	12	case
12	Co-administration	co-administration	NN	_	10	nmod
13	With	with	IN	_	14	case
14	drug1	drug1	NN	_	10	nmod

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT

1	Potential	potential	JJ	_	2	amod
2	effect	effect	NN	_	0	ROOT
3	on	on	IN	_	4	case
4	anticoagulation	anticoagulation	NN	_	2	nmod
5	.	.	.	_	2	punct

1	Monitoring	monitoring	NN	_	6	nsubjpass
2	of	of	IN	_	4	case
3	anticoagulation	anticoagulation	NN	_	4	compound
4	levels	level	NNS	_	1	nmod
5	is	be	VBZ	_	6	auxpass
6	recommended	recommend	VBN	_	0	ROOT
7	.	.	.	_	6	punct

1	Fat	Fat	NNP	_	2	compound
2	redistribution	redistribution	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	Redistribution/accumulation	redistribution/accumulation	NN	_	34	nsubjpass
5	of	of	IN	_	6	case
6	body	body	NN	_	4	nmod
7	fat	fat	JJ	_	6	amod
8	including	include	VBG	_	10	case
9	central	central	JJ	_	10	amod
10	obesity	obesity	NN	_	7	nmod
11	,	,	,	_	10	punct
12	dorsocervical	dorsocervical	JJ	_	14	amod
13	fat	fat	JJ	_	14	amod
14	enlargement	enlargement	NN	_	10	conj
15	-LRB-	-lrb-	-LRB-	_	17	punct
16	buffalo	buffalo	NN	_	17	compound
17	hump	hump	NN	_	14	appos
18	-RRB-	-rrb-	-RRB-	_	17	punct
19	,	,	,	_	10	punct
20	peripheral	peripheral	JJ	_	21	amod
21	wasting	wasting	NN	_	10	conj
22	,	,	,	_	10	punct
23	facial	facial	JJ	_	24	amod
24	wasting	wasting	NN	_	10	conj
25	,	,	,	_	10	punct
26	breast	breast	NN	_	27	compound
27	enlargement	enlargement	NN	_	10	conj
28	,	,	,	_	10	punct
29	and	and	CC	_	10	cc
30	cushingoid	cushingoid	JJ	_	31	amod
31	appearance	appearance	NN	_	10	conj
32	have	have	VBP	_	34	aux
33	been	be	VBN	_	34	auxpass
34	observed	observe	VBN	_	2	dep
35	in	in	IN	_	36	case
36	patients	patient	NNS	_	34	nmod
37	receiving	receive	VBG	_	36	acl
38	drug1	drug1	NN	_	39	compound
39	therapy	therapy	NN	_	37	dobj
40	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	mechanism	mechanism	NN	_	11	nsubj
3	and	and	CC	_	2	cc
4	long-term	long-term	JJ	_	5	amod
5	consequences	consequence	NNS	_	2	conj
6	of	of	IN	_	8	case
7	these	these	DT	_	8	det
8	events	event	NNS	_	2	nmod
9	are	be	VBP	_	11	cop
10	currently	currently	RB	_	11	advmod
11	unknown	unknown	JJ	_	0	ROOT
12	.	.	.	_	11	punct

1	A	a	DT	_	3	det
2	causal	causal	JJ	_	3	amod
3	relationship	relationship	NN	_	7	nsubjpass
4	has	have	VBZ	_	7	aux
5	not	not	RB	_	7	neg
6	been	be	VBN	_	7	auxpass
7	established	establish	VBN	_	0	ROOT

1	.	.	.	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	Physiological	physiological	JJ	_	2	amod
2	changes	change	NNS	_	15	nsubj
3	resulting	result	VBG	_	2	acl
4	from	from	IN	_	6	case
5	smoking	smoking	NN	_	6	compound
6	cessation	cessation	NN	_	3	nmod
7	,	,	,	_	2	punct
8	with	with	IN	_	12	nmod
9	or	or	CC	_	8	cc
10	without	without	IN	_	8	conj
11	drug1	drug1	NN	_	12	compound
12	replacement	replacement	NN	_	2	nmod
13	,	,	,	_	2	punct
14	may	may	MD	_	15	aux
15	alter	alter	VB	_	0	ROOT
16	the	the	DT	_	17	det
17	pharmacokinetics	pharmacokinetic	NNS	_	15	dobj
18	of	of	IN	_	21	case
19	certain	certain	JJ	_	21	amod
20	concomitant	concomitant	JJ	_	21	amod
21	medications	medication	NNS	_	17	nmod
22	,	,	,	_	21	punct
23	such	such	JJ	_	25	case
24	as	as	IN	_	23	mwe
25	drug2	drug2	NN	_	21	nmod
26	and	and	CC	_	25	cc
27	drug3	drug3	NN	_	25	conj
28	.	.	.	_	15	punct

1	Doses	dose	NNS	_	9	nsubj
2	of	of	IN	_	3	case
3	these	these	DT	_	1	nmod
4	and	and	CC	_	3	cc
5	perhaps	perhaps	RB	_	7	advmod
6	other	other	JJ	_	7	amod
7	medications	medication	NNS	_	3	conj
8	may	may	MD	_	9	aux
9	need	need	VB	_	0	ROOT
10	to	to	TO	_	12	mark
11	be	be	VB	_	12	auxpass
12	adjusted	adjust	VBN	_	9	xcomp
13	in	in	IN	_	14	case
14	patients	patient	NNS	_	12	nmod
15	who	who	WP	_	17	nsubj
16	successfully	successfully	RB	_	17	advmod
17	quit	quit	VBD	_	14	acl:relcl
18	smoking	smoking	NN	_	17	dobj
19	.	.	.	_	9	punct

1	The	the	DT	_	2	det
2	risk	risk	NN	_	15	nsubjpass
3	of	of	IN	_	4	mark
4	using	use	VBG	_	2	acl
5	drug1	drug1	NN	_	4	dobj
6	in	in	IN	_	7	case
7	combination	combination	NN	_	4	nmod
8	with	with	IN	_	10	case
9	other	other	JJ	_	10	amod
10	drugs	drug	NNS	_	7	nmod
11	has	have	VBZ	_	15	aux
12	not	not	RB	_	15	neg
13	been	be	VBN	_	15	auxpass
14	systematically	systematically	RB	_	15	advmod
15	evaluated	evaluate	VBN	_	0	ROOT
16	,	,	,	_	15	punct
17	but	but	CC	_	15	cc
18	drug2	drug2	NN	_	20	nsubj
19	may	may	MD	_	20	aux
20	potentiate	potentiate	VB	_	15	conj
21	the	the	DT	_	23	det
22	side	side	JJ	_	23	amod
23	effects	effect	NNS	_	20	dobj
24	of	of	IN	_	25	case
25	drug3	drug3	NN	_	23	nmod
26	.	.	.	_	15	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	interact	interact	VB	_	0	ROOT
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	,	,	,	_	5	punct
7	drug3	drug3	NN	_	5	conj
8	,	,	,	_	5	punct
9	and	and	CC	_	5	cc
10	certain	certain	JJ	_	12	amod
11	other	other	JJ	_	12	amod
12	agents	agent	NNS	_	5	conj
13	.	.	.	_	3	punct

1	Compounds	compound	NNS	_	5	nsubj
2	in	in	IN	_	4	case
3	these	these	DT	_	4	det
4	categories	category	NNS	_	1	nmod
5	result	result	VBP	_	0	ROOT
6	in	in	IN	_	9	case
7	a	a	DT	_	9	det
8	decreased	decrease	VBN	_	9	amod
9	efficacy	efficacy	NN	_	5	nmod
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	:	:	:	_	5	punct
13	drug2	drug2	NN	_	5	dep
14	,	,	,	_	13	punct
15	drug3	drug3	NN	_	13	conj
16	,	,	,	_	13	punct
17	drug4	drug4	NN	_	13	conj
18	,	,	,	_	13	punct
19	drug5	drug5	NN	_	13	conj
20	.	.	.	_	5	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	use	use	NN	_	10	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	7	case
6	other	other	JJ	_	7	amod
7	drug2	drug2	NN	_	2	nmod
8	is	be	VBZ	_	10	auxpass
9	not	not	RB	_	10	neg
10	recommended	recommend	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	Drug-Drug	Drug-Drug	NNP	_	2	compound
2	Interactions	interaction	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	The	the	DT	_	8	det
5	pharmacokinetic	pharmacokinetic	JJ	_	8	amod
6	and	and	CC	_	5	cc
7	pharmacodynamic	pharmacodynamic	JJ	_	5	conj
8	interactions	interaction	NNS	_	17	nsubjpass
9	between	between	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	other	other	JJ	_	13	amod
13	drug2	drug2	NN	_	10	conj
14	have	have	VBP	_	17	aux
15	not	not	RB	_	17	neg
16	been	be	VBN	_	17	auxpass
17	determined	determine	VBN	_	2	dep
18	.	.	.	_	2	punct

1	However	however	RB	_	6	advmod
2	,	,	,	_	6	punct
3	interactions	interaction	NNS	_	6	nsubjpass
4	may	may	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	expected	expect	VBN	_	0	ROOT
7	,	,	,	_	6	punct
8	and	and	CC	_	6	cc
9	drug1	drug1	NN	_	13	nsubjpass
10	should	should	MD	_	13	aux
11	NOT	not	RB	_	13	advmod
12	be	be	VB	_	13	auxpass
13	used	use	VBN	_	6	conj
14	in	in	IN	_	15	case
15	combination	combination	NN	_	13	nmod
16	with	with	IN	_	18	case
17	other	other	JJ	_	18	amod
18	drug2	drug2	NN	_	15	nmod
19	.	.	.	_	6	punct

1	Animal	animal	NN	_	2	compound
2	studies	study	NNS	_	3	nsubj
3	indicate	indicate	VBP	_	0	ROOT
4	that	that	IN	_	8	mark
5	drug1	drug1	NN	_	8	nsubj
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	cop
8	ineffective	ineffective	JJ	_	3	ccomp
9	if	if	IN	_	14	mark
10	the	the	DT	_	11	det
11	patient	patient	NN	_	14	nsubj
12	has	have	VBZ	_	14	aux
13	recently	recently	RB	_	14	advmod
14	received	receive	VBN	_	8	advcl
15	a	a	DT	_	16	det
16	drug2	drug2	NN	_	14	dobj
17	.	.	.	_	3	punct

1	In	in	IN	_	4	case
2	such	such	PDT	_	4	det:predet
3	a	a	DT	_	4	det
4	case	case	NN	_	11	nmod
5	,	,	,	_	11	punct
6	the	the	DT	_	9	det
7	peripheral	peripheral	JJ	_	9	amod
8	vascular	vascular	JJ	_	9	amod
9	resistance	resistance	NN	_	11	nsubj
10	may	may	MD	_	11	aux
11	increase	increase	VB	_	0	ROOT
12	.	.	.	_	11	punct

1	Preliminary	preliminary	JJ	_	2	amod
2	studies	study	NNS	_	3	nsubj
3	indicate	indicate	VBP	_	0	ROOT
4	that	that	IN	_	3	dep
5	the	the	DT	_	7	det
6	concomitant	concomitant	JJ	_	7	amod
7	use	use	NN	_	4	dobj
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	drug2	drug2	NN	_	9	conj
12	results	result	NNS	_	9	dep
13	in	in	IN	_	17	case
14	a	a	DT	_	17	det
15	higher	higher	JJR	_	17	amod
16	cardiac	cardiac	JJ	_	17	amod
17	output	output	NN	_	7	nmod
18	and	and	CC	_	17	cc
19	,	,	,	_	17	punct
20	usually	usually	RB	_	19	root
21	,	,	,	_	20	punct
22	a	a	DT	_	26	det
23	lower	lower	JJR	_	26	amod
24	pulmonary	pulmonary	JJ	_	26	amod
25	wedge	wedge	NN	_	26	compound
26	pressure	pressure	NN	_	21	root
27	than	than	IN	_	32	mark
28	when	when	WRB	_	32	advmod
29	either	either	CC	_	30	det
30	drug	drug	NN	_	32	nsubjpass
31	is	be	VBZ	_	32	auxpass
32	used	use	VBN	_	26	acl
33	alone	alone	RB	_	32	advmod
34	.	.	.	_	26	punct

1	There	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	no	no	DT	_	4	neg
4	evidence	evidence	NN	_	2	nsubj
5	of	of	IN	_	7	case
6	drug	drug	NN	_	7	compound
7	interactions	interaction	NNS	_	4	nmod
8	in	in	IN	_	10	case
9	clinical	clinical	JJ	_	10	amod
10	studies	study	NNS	_	7	nmod
11	in	in	IN	_	12	case
12	which	which	WDT	_	15	nmod
13	drug1	drug1	NN	_	15	nsubjpass
14	was	be	VBD	_	15	auxpass
15	administered	administer	VBN	_	10	acl:relcl
16	concurrently	concurrently	RB	_	15	advmod
17	with	with	IN	_	19	case
18	other	other	JJ	_	19	amod
19	drugs	drug	NNS	_	15	nmod
20	,	,	,	_	19	punct
21	including	include	VBG	_	22	case
22	drug2	drug2	NN	_	19	nmod
23	,	,	,	_	22	punct
24	drug3	drug3	NN	_	22	conj
25	,	,	,	_	22	punct
26	drug4	drug4	NN	_	22	conj
27	,	,	,	_	22	punct
28	drug5	drug5	NN	_	22	conj
29	,	,	,	_	22	punct
30	drug6	drug6	NN	_	22	conj
31	,	,	,	_	22	punct
32	drug7	drug7	NN	_	22	conj
33	,	,	,	_	22	punct
34	drug8	drug8	NN	_	22	conj
35	,	,	,	_	22	punct
36	drug9	drug9	NN	_	22	conj
37	,	,	,	_	22	punct
38	drug10	drug10	NN	_	22	conj
39	,	,	,	_	22	punct
40	drug11	drug11	NN	_	22	conj
41	,	,	,	_	22	punct
42	drug12	drug12	NN	_	22	conj
43	,	,	,	_	22	punct
44	drug13	drug13	NN	_	22	conj
45	,	,	,	_	22	punct
46	and	and	CC	_	22	cc
47	drug14	drug14	NN	_	22	conj
48	.	.	.	_	2	punct

1	No	no	DT	_	4	neg
2	drug-drug	drug-drug	NN	_	4	compound
3	interaction	interaction	NN	_	4	compound
4	studies	study	NNS	_	10	nsubjpass
5	in	in	IN	_	7	case
6	human	human	JJ	_	7	amod
7	subjects	subject	NNS	_	4	nmod
8	have	have	VBP	_	10	aux
9	been	be	VBN	_	10	auxpass
10	conducted	conduct	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	Toxicologic	toxicologic	JJ	_	4	amod
2	and	and	CC	_	1	cc
3	toxicokinetic	toxicokinetic	JJ	_	1	conj
4	studies	study	NNS	_	9	nsubj
5	in	in	IN	_	6	case
6	rats	rat	NNS	_	4	nmod
7	did	do	VBD	_	9	aux
8	not	not	RB	_	9	neg
9	demonstrate	demonstrate	VB	_	0	ROOT
10	any	any	DT	_	11	det
11	alterations	alteration	NNS	_	9	dobj
12	in	in	IN	_	14	case
13	the	the	DT	_	14	det
14	clearance	clearance	NN	_	11	nmod
15	or	or	CC	_	14	cc
16	toxicologic	toxicologic	JJ	_	17	amod
17	profile	profile	NN	_	14	conj
18	of	of	IN	_	20	case
19	either	either	CC	_	20	cc:preconj
20	drug1	drug1	NN	_	14	nmod
21	or	or	CC	_	20	cc
22	drug2	drug2	NN	_	20	conj
23	when	when	WRB	_	28	advmod
24	the	the	DT	_	26	det
25	two	two	CD	_	26	nummod
26	agents	agent	NNS	_	28	nsubjpass
27	were	be	VBD	_	28	auxpass
28	administered	administer	VBN	_	9	advcl
29	together	together	RB	_	28	advmod
30	.	.	.	_	9	punct

1	In	in	IN	_	3	case
2	a	a	DT	_	3	det
3	study	study	NN	_	32	nmod
4	in	in	IN	_	5	case
5	which	which	WDT	_	11	nmod
6	patients	patient	NNS	_	11	nsubjpass
7	with	with	IN	_	9	case
8	active	active	JJ	_	9	amod
9	RA	ra	NN	_	6	nmod
10	were	be	VBD	_	11	auxpass
11	treated	treat	VBN	_	3	acl:relcl
12	for	for	IN	_	16	case
13	up	up	RB	_	15	dep
14	to	to	TO	_	13	mwe
15	24	24	CD	_	16	nummod
16	weeks	week	NNS	_	11	nmod
17	with	with	IN	_	19	case
18	concurrent	concurrent	JJ	_	19	amod
19	drug1	drug1	NN	_	16	nmod
20	and	and	CC	_	19	cc
21	drug2	drug2	NN	_	22	compound
22	therapy	therapy	NN	_	19	conj
23	,	,	,	_	32	punct
24	a	a	DT	_	27	det
25	7	7	CD	_	26	compound
26	%	%	NN	_	27	amod
27	rate	rate	NN	_	32	nsubjpass
28	of	of	IN	_	30	case
29	serious	serious	JJ	_	30	amod
30	infections	infection	NNS	_	27	nmod
31	was	be	VBD	_	32	auxpass
32	observed	observe	VBN	_	0	ROOT
33	,	,	,	_	32	punct
34	which	which	WDT	_	36	nsubj
35	was	be	VBD	_	36	cop
36	higher	higher	JJR	_	32	ccomp
37	than	than	IN	_	38	case
38	that	that	DT	_	36	nmod
39	observed	observe	VBN	_	38	acl
40	with	with	IN	_	41	case
41	drug3	drug3	NN	_	39	nmod
42	alone	alone	RB	_	41	advmod
43	-LRB-	-lrb-	-LRB-	_	45	punct
44	0	0	CD	_	45	nummod
45	%	%	NN	_	41	appos
46	-RRB-	-rrb-	-RRB-	_	45	punct
47	.	.	.	_	32	punct

1	Two	two	CD	_	2	nummod
2	percent	percent	NN	_	11	nsubj
3	of	of	IN	_	4	case
4	patients	patient	NNS	_	2	nmod
5	treated	treat	VBN	_	4	acl
6	concurrently	concurrently	RB	_	5	advmod
7	with	with	IN	_	8	case
8	drug1	drug1	NN	_	5	nmod
9	and	and	CC	_	8	cc
10	drug2	drug2	NN	_	8	conj
11	developed	develop	VBD	_	0	ROOT
12	neutropenia	neutropenia	NN	_	11	dobj
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	ANC	ANC	NNP	_	12	appos
15	1	1	CD	_	14	nummod
16	x	x	CC	_	14	cc
17	109/L	109/l	CD	_	14	nummod
18	-RRB-	-rrb-	-RRB-	_	14	punct
19	.	.	.	_	11	punct

1	drug1	drug1	NN	_	0	ROOT
2	containing	contain	VBG	_	1	acl
3	drug2	drug2	NN	_	2	dobj
4	,	,	,	_	1	punct
5	when	when	WRB	_	6	advmod
6	administered	administer	VBN	_	1	acl:relcl
7	concomitantly	concomitantly	RB	_	6	advmod
8	with	with	IN	_	9	case
9	drug3	drug3	NN	_	6	nmod
10	,	,	,	_	6	punct
11	reduce	reduce	VB	_	6	dep
12	both	both	CC	_	14	cc:preconj
13	the	the	DT	_	14	det
14	rate	rate	NN	_	11	dobj
15	and	and	CC	_	14	cc
16	extent	extent	NN	_	14	conj
17	of	of	IN	_	18	case
18	absorption	absorption	NN	_	14	nmod
19	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	mechanism	mechanism	NN	_	8	nsubj
3	for	for	IN	_	5	case
4	this	this	DT	_	5	det
5	interaction	interaction	NN	_	2	nmod
6	probably	probably	RB	_	8	advmod
7	is	be	VBZ	_	8	cop
8	adsorption	adsorption	NN	_	0	ROOT
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	onto	onto	IN	_	13	case
12	the	the	DT	_	13	det
13	surface	surface	NN	_	8	nmod
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	.	.	.	_	8	punct

1	drug1	drug1	NN	_	10	nsubj
2	,	,	,	_	1	punct
3	such	such	JJ	_	5	case
4	as	as	IN	_	3	mwe
5	drug2	drug2	NN	_	1	nmod
6	and	and	CC	_	5	cc
7	drug3	drug3	NN	_	5	conj
8	,	,	,	_	1	punct
9	can	can	MD	_	10	aux
10	inhibit	inhibit	VB	_	0	ROOT
11	renal	renal	JJ	_	13	amod
12	tubular	tubular	JJ	_	13	amod
13	secretion	secretion	NN	_	10	dobj
14	of	of	IN	_	15	case
15	drug4	drug4	NN	_	13	nmod
16	.	.	.	_	10	punct

1	The	the	DT	_	3	det
2	resulting	result	VBG	_	3	amod
3	increase	increase	NN	_	9	nsubj
4	in	in	IN	_	7	case
5	drug1	drug1	NN	_	7	compound
6	serum	serum	NN	_	7	compound
7	levels	level	NNS	_	3	nmod
8	may	may	MD	_	9	aux
9	increase	increase	VB	_	0	ROOT
10	toxicity	toxicity	NN	_	9	dobj
11	,	,	,	_	9	punct
12	and	and	CC	_	9	cc
13	the	the	DT	_	16	det
14	decreased	decrease	VBN	_	16	amod
15	urinary	urinary	JJ	_	16	amod
16	levels	level	NNS	_	18	nsubj
17	could	could	MD	_	18	aux
18	lessen	lessen	VB	_	9	conj
19	its	its	PRP$	_	20	nmod:poss
20	efficacy	efficacy	NN	_	18	dobj
21	as	as	IN	_	25	case
22	a	a	DT	_	25	det
23	urinary	urinary	JJ	_	25	amod
24	tract	tract	NN	_	25	compound
25	drug2	drug2	NN	_	18	nmod
26	.	.	.	_	9	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	3	amod
2	Test	test	NN	_	3	compound
3	Interactions	interaction	NNS	_	22	nsubj
4	As	as	IN	_	6	case
5	a	a	DT	_	6	det
6	result	result	NN	_	3	nmod
7	of	of	IN	_	9	case
8	the	the	DT	_	9	det
9	presence	presence	NN	_	6	nmod
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	,	,	,	_	11	punct
13	a	a	DT	_	15	det
14	false-positive	false-positive	JJ	_	15	amod
15	reaction	reaction	NN	_	11	appos
16	for	for	IN	_	17	case
17	glucose	glucose	NN	_	15	nmod
18	in	in	IN	_	20	case
19	the	the	DT	_	20	det
20	urine	urine	NN	_	17	nmod
21	may	may	MD	_	22	aux
22	occur	occur	VB	_	0	ROOT
23	.	.	.	_	22	punct

1	This	this	DT	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	observed	observe	VBN	_	0	ROOT
5	with	with	IN	_	7	case
6	Benedict	Benedict	NNP	_	7	compound
7	s	s	NNS	_	4	nmod
8	and	and	CC	_	7	cc
9	Fehling	fehling	NN	_	11	compound
10	s	s	NNS	_	11	compound
11	solutions	solution	NNS	_	7	conj
12	but	but	CC	_	7	cc
13	not	not	RB	_	18	neg
14	with	with	IN	_	18	case
15	the	the	DT	_	18	det
16	glucose	glucose	NN	_	18	compound
17	enzymatic	enzymatic	JJ	_	18	amod
18	test	test	NN	_	7	conj
19	.	.	.	_	4	punct

1	In	in	IN	_	2	mark
2	evaluating	evaluate	VBG	_	30	advcl
3	the	the	DT	_	4	det
4	potential	potential	NN	_	2	dobj
5	for	for	IN	_	6	case
6	interactions	interaction	NNS	_	4	nmod
7	among	among	IN	_	10	case
8	co-administered	co-administered	JJ	_	10	amod
9	antiepilepsy	antiepilepsy	JJ	_	10	amod
10	drugs	drug	NNS	_	6	nmod
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	drug1	drug1	NN	_	10	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	,	,	,	_	30	punct
15	whether	whether	IN	_	20	mark
16	or	or	CC	_	15	cc
17	not	not	RB	_	15	mwe
18	an	a	DT	_	19	det
19	drug2	drug2	NN	_	20	nsubj
20	induces	induce	VBZ	_	30	csubj
21	or	or	CC	_	20	cc
22	does	do	VBZ	_	24	aux
23	not	not	RB	_	24	neg
24	induce	induce	VB	_	20	conj
25	metabolic	metabolic	JJ	_	26	amod
26	enzymes	enzyme	NNS	_	24	dobj
27	is	be	VBZ	_	30	cop
28	an	a	DT	_	30	det
29	important	important	JJ	_	30	amod
30	consideration	consideration	NN	_	0	ROOT
31	.	.	.	_	30	punct

1	drug1	drug1	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	and	and	CC	_	1	cc
5	drug3	drug3	NN	_	1	conj
6	are	be	VBP	_	1	dep
7	ge	ge	NN	_	6	nsubj
8	nerally	nerally	RB	_	9	advmod
9	classified	classify	VBN	_	7	acl
10	as	as	IN	_	12	case
11	enzyme	enzyme	NN	_	12	compound
12	inducers	inducer	NNS	_	9	nmod
13	;	;	:	_	1	punct

1	drug1	drug1	NN	_	4	nsubj
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	are	be	VBP	_	0	ROOT
5	not	not	RB	_	4	neg
6	.	.	.	_	4	punct

1	drug1	drug1	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	considered	consider	VBN	_	0	ROOT
4	to	to	TO	_	3	xcomp
5	be	be	VB	_	4	dep
6	a	a	DT	_	5	nsubj
7	non-enzyme	non-enzyme	JJ	_	6	dep
8	inducing	induce	VBG	_	7	dep
9	drug2	drug2	NN	_	8	dobj
10	.	.	.	_	3	punct

1	The	the	DT	_	4	det
2	drug	drug	NN	_	4	compound
3	interaction	interaction	NN	_	4	compound
4	data	datum	NNS	_	10	nsubjpass
5	described	describe	VBN	_	4	acl
6	in	in	IN	_	8	case
7	this	this	DT	_	8	det
8	section	section	NN	_	5	nmod
9	were	be	VBD	_	10	auxpass
10	obtained	obtain	VBN	_	0	ROOT
11	from	from	IN	_	12	case
12	studies	study	NNS	_	10	nmod
13	involving	involve	VBG	_	12	acl
14	either	either	CC	_	16	cc:preconj
15	healthy	healthy	JJ	_	16	amod
16	subjects	subject	NNS	_	13	dobj
17	or	or	CC	_	16	cc
18	patients	patient	NNS	_	16	conj
19	with	with	IN	_	20	case
20	epilepsy	epilepsy	NN	_	18	nmod
21	.	.	.	_	10	punct

1	Effects	effect	NNS	_	0	ROOT
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	on	on	IN	_	7	case
5	other	other	JJ	_	7	amod
6	Antiepilepsy	Antiepilepsy	NNP	_	7	compound
7	Drugs	drug	NNS	_	1	nmod
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	drug2	drug2	NN	_	7	appos
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	:	:	:	_	1	punct
12	drug3	drug3	NN	_	1	dep
13	:	:	:	_	12	punct
14	drug4	drug4	NN	_	15	nsubj
15	had	have	VBD	_	12	appos
16	no	no	DT	_	17	neg
17	effect	effect	NN	_	15	dobj
18	on	on	IN	_	22	case
19	the	the	DT	_	22	det
20	steady-state	steady-state	JJ	_	22	amod
21	plasma	plasma	NN	_	22	compound
22	concentrations	concentration	NNS	_	15	nmod
23	of	of	IN	_	24	case
24	drug5	drug5	NN	_	22	nmod
25	in	in	IN	_	26	case
26	patients	patient	NNS	_	22	nmod
27	with	with	IN	_	28	case
28	epilepsy	epilepsy	NN	_	26	nmod
29	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	nsubj
4	had	have	VBD	_	1	appos
5	no	no	DT	_	6	neg
6	effect	effect	NN	_	4	dobj
7	on	on	IN	_	11	case
8	the	the	DT	_	11	det
9	steady-state	steady-state	JJ	_	11	amod
10	plasma	plasma	NN	_	11	compound
11	concentrations	concentration	NNS	_	4	nmod
12	of	of	IN	_	13	case
13	drug3	drug3	NN	_	11	nmod
14	or	or	CC	_	13	cc
15	its	its	PRP$	_	17	nmod:poss
16	epoxide	epoxide	NN	_	17	compound
17	metabolite	metabolite	NN	_	13	conj
18	in	in	IN	_	19	case
19	patients	patient	NNS	_	11	nmod
20	with	with	IN	_	21	case
21	epilepsy	epilepsy	NN	_	19	nmod
22	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	nsubj
4	causes	cause	VBZ	_	1	appos
5	a	a	DT	_	7	det
6	slight	slight	JJ	_	7	amod
7	decrease	decrease	NN	_	4	dobj
8	-LRB-	-lrb-	-LRB-	_	11	punct
9	about	about	IN	_	10	advmod
10	10	10	CD	_	11	nummod
11	%	%	NN	_	7	appos
12	-RRB-	-rrb-	-RRB-	_	11	punct
13	in	in	IN	_	16	case
14	steady-state	steady-state	JJ	_	16	amod
15	drug3	drug3	NN	_	16	compound
16	concentrations	concentration	NNS	_	7	nmod
17	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	or	or	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	:	:	:	_	1	punct
5	No	no	DT	_	8	neg
6	formal	formal	JJ	_	8	amod
7	pharmacokinetic	pharmacokinetic	JJ	_	8	amod
8	studies	study	NNS	_	11	nsubjpass
9	have	have	VBP	_	11	aux
10	been	be	VBN	_	11	auxpass
11	performed	perform	VBN	_	1	dep
12	examining	examine	VBG	_	11	xcomp
13	the	the	DT	_	14	det
14	addition	addition	NN	_	12	dobj
15	of	of	IN	_	16	case
16	drug3	drug3	NN	_	14	nmod
17	to	to	TO	_	18	case
18	regimens	regimen	NNS	_	14	nmod
19	containing	contain	VBG	_	18	acl
20	drug4	drug4	NN	_	19	dobj
21	or	or	CC	_	20	cc
22	drug5	drug5	NN	_	20	conj
23	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	addition	addition	NN	_	15	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	in	in	IN	_	8	case
6	a	a	DT	_	8	det
7	limited	limited	JJ	_	8	amod
8	number	number	NN	_	2	nmod
9	of	of	IN	_	10	case
10	patients	patient	NNS	_	8	nmod
11	in	in	IN	_	14	case
12	three	three	CD	_	14	nummod
13	well-controlled	well-controlled	JJ	_	14	amod
14	studies	study	NNS	_	10	nmod
15	caused	cause	VBD	_	0	ROOT
16	no	no	DT	_	18	neg
17	systematic	systematic	JJ	_	18	amod
18	changes	change	NNS	_	15	dobj
19	in	in	IN	_	23	case
20	drug2	drug2	NN	_	23	compound
21	or	or	CC	_	20	cc
22	drug3	drug3	NN	_	20	conj
23	concentrations	concentration	NNS	_	18	nmod
24	when	when	WRB	_	25	advmod
25	compared	compare	VBN	_	15	advcl
26	to	to	TO	_	27	case
27	placebo	placebo	NN	_	25	nmod
28	.	.	.	_	15	punct

1	Effects	effect	NNS	_	0	ROOT
2	of	of	IN	_	5	case
3	other	other	JJ	_	5	amod
4	Antiepilepsy	Antiepilepsy	NNP	_	5	compound
5	Drugs	drug	NNS	_	1	nmod
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	drug1	drug1	NN	_	5	appos
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	on	on	IN	_	10	case
10	drug2	drug2	NN	_	1	nmod
11	:	:	:	_	1	punct
12	drug3	drug3	NN	_	1	dep
13	:	:	:	_	12	punct
14	Population	Population	NNP	_	16	compound
15	pharmacokinetic	pharmacokinetic	JJ	_	16	amod
16	analyses	analysis	NNS	_	17	nsubj
17	indicate	indicate	VBP	_	12	appos
18	that	that	IN	_	24	mark
19	drug4	drug4	NN	_	20	compound
20	clearance	clearance	NN	_	24	nsubj
21	is	be	VBZ	_	24	cop
22	60	60	CD	_	23	nummod
23	%	%	NN	_	24	nmod:npmod
24	greater	greater	JJR	_	17	ccomp
25	in	in	IN	_	26	case
26	patients	patient	NNS	_	24	nmod
27	taking	take	VBG	_	26	acl
28	drug5	drug5	NN	_	27	dobj
29	with	with	IN	_	33	case
30	or	or	CC	_	33	cc
31	without	without	IN	_	33	case
32	other	other	JJ	_	33	amod
33	enzyme	enzyme	NN	_	27	nmod
34	-	-	:	_	24	punct
35	inducing	induce	VBG	_	24	dep
36	drug6	drug6	NN	_	35	dobj
37	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Population	Population	NNP	_	5	compound
4	pharmacokinetic	pharmacokinetic	JJ	_	5	amod
5	analyses	analysis	NNS	_	6	nsubj
6	indicate	indicate	VBP	_	1	appos
7	that	that	IN	_	13	mark
8	drug2	drug2	NN	_	9	compound
9	clearance	clearance	NN	_	13	nsubj
10	is	be	VBZ	_	13	cop
11	60	60	CD	_	12	nummod
12	%	%	NN	_	13	nmod:npmod
13	greater	greater	JJR	_	6	ccomp
14	in	in	IN	_	15	case
15	patients	patient	NNS	_	13	nmod
16	taking	take	VBG	_	15	acl
17	drug3	drug3	NN	_	16	dobj
18	with	with	IN	_	22	case
19	or	or	CC	_	22	cc
20	without	without	IN	_	22	case
21	other	other	JJ	_	22	amod
22	enzyme	enzyme	NN	_	16	nmod
23	-	-	:	_	13	punct
24	inducing	induce	VBG	_	13	dep
25	drug4	drug4	NN	_	24	dobj
26	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	drug2	drug2	NN	_	1	appos
4	-RRB-	-rrb-	-RRB-	_	3	punct
5	:	:	:	_	1	punct
6	Population	Population	NNP	_	8	compound
7	pharmacokinetic	pharmacokinetic	JJ	_	8	amod
8	analyses	analysis	NNS	_	9	nsubj
9	indicate	indicate	VBP	_	1	appos
10	that	that	IN	_	16	mark
11	drug3	drug3	NN	_	12	compound
12	clearance	clearance	NN	_	16	nsubj
13	is	be	VBZ	_	16	cop
14	60	60	CD	_	15	nummod
15	%	%	NN	_	16	nmod:npmod
16	greater	greater	JJR	_	9	ccomp
17	in	in	IN	_	18	case
18	patients	patient	NNS	_	16	nmod
19	taking	take	VBG	_	18	acl
20	drug4	drug4	NN	_	19	dobj
21	-LRB-	-lrb-	-LRB-	_	22	punct
22	drug5	drug5	NN	_	20	appos
23	-RRB-	-rrb-	-RRB-	_	22	punct
24	with	with	IN	_	29	nmod
25	or	or	CC	_	29	cc
26	without	without	IN	_	29	conj
27	other	other	JJ	_	29	amod
28	enzyme-inducing	enzyme-inducing	JJ	_	29	amod
29	drug6	drug6	NN	_	19	nmod
30	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	addition	addition	NN	_	12	nsubj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	to	to	TO	_	8	case
8	patients	patient	NNS	_	4	nmod
9	taking	take	VBG	_	8	acl
10	drug3	drug3	NN	_	9	dobj
11	chronically	chronically	RB	_	12	advmod
12	had	have	VBD	_	1	appos
13	no	no	DT	_	14	neg
14	effect	effect	NN	_	12	dobj
15	on	on	IN	_	17	case
16	drug4	drug4	NN	_	17	compound
17	pharmacokinetics	pharmacokinetic	NNS	_	12	nmod
18	,	,	,	_	12	punct
19	but	but	CC	_	12	cc
20	drug5	drug5	NN	_	22	nsubj
21	significantly	significantly	RB	_	22	advmod
22	decreased	decrease	VBD	_	12	conj
23	drug6	drug6	NN	_	24	compound
24	binding	binding	NN	_	22	dobj
25	in	in	FW	_	26	compound
26	vitro	vitro	FW	_	22	advmod
27	from	from	IN	_	28	case
28	96.3	96.3	CD	_	22	nmod
29	to	to	TO	_	31	case
30	94.8	94.8	CD	_	31	nummod
31	%	%	NN	_	22	nmod
32	,	,	,	_	31	punct
33	which	which	WDT	_	34	nsubj
34	resulted	result	VBD	_	31	acl:relcl
35	in	in	IN	_	37	case
36	an	a	DT	_	37	det
37	increase	increase	NN	_	34	nmod
38	of	of	IN	_	41	case
39	approximately	approximately	RB	_	40	advmod
40	40	40	CD	_	41	nummod
41	%	%	NN	_	37	nmod
42	in	in	IN	_	46	case
43	the	the	DT	_	46	det
44	free	free	JJ	_	46	amod
45	tiagabine	tiagabine	NN	_	46	compound
46	concentration	concentration	NN	_	37	nmod
47	.	.	.	_	1	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	relevance	relevance	NN	_	10	nsubj
4	of	of	IN	_	8	case
5	this	this	DT	_	8	det
6	in	in	FW	_	8	amod
7	vitro	vitro	FW	_	6	dep
8	finding	finding	NN	_	3	nmod
9	is	be	VBZ	_	10	cop
10	unknown	unknown	JJ	_	0	ROOT
11	.	.	.	_	10	punct

1	Interaction	interaction	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	6	case
5	Other	other	JJ	_	6	amod
6	Drugs	drug	NNS	_	1	nmod
7	:	:	:	_	1	punct
8	drug2	drug2	NN	_	1	dep
9	:	:	:	_	8	punct
10	Co-administration	co-administration	NN	_	22	nsubj
11	of	of	IN	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	-LRB-	-lrb-	-LRB-	_	15	punct
14	800	800	CD	_	15	nummod
15	mg/day	mg/day	NN	_	12	appos
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	to	to	TO	_	18	case
18	patients	patient	NNS	_	10	nmod
19	taking	take	VBG	_	18	acl
20	drug4	drug4	NN	_	19	dobj
21	chronically	chronically	RB	_	22	advmod
22	had	have	VBD	_	8	appos
23	no	no	DT	_	24	neg
24	effect	effect	NN	_	22	dobj
25	on	on	IN	_	27	case
26	drug5	drug5	NN	_	27	compound
27	pharmacokinetics	pharmacokinetic	NNS	_	22	nmod
28	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	A	a	DT	_	7	det
4	single	single	JJ	_	7	amod
5	10	10	CD	_	6	compound
6	mg	mg	NN	_	7	amod
7	dose	dose	NN	_	12	nsubj
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	did	do	VBD	_	12	aux
11	not	not	RB	_	12	neg
12	affect	affect	VB	_	1	dep
13	the	the	DT	_	14	det
14	pharmacokinetics	pharmacokinetic	NNS	_	12	dobj
15	of	of	IN	_	16	case
16	drug3	drug3	NN	_	14	nmod
17	at	at	IN	_	19	case
18	steady	steady	JJ	_	19	amod
19	state	state	NN	_	14	nmod
20	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	No	no	DT	_	5	neg
4	significant	significant	JJ	_	5	amod
5	differences	difference	NNS	_	7	nsubjpass
6	were	be	VBD	_	7	auxpass
7	observed	observe	VBN	_	1	dep
8	in	in	IN	_	11	case
9	the	the	DT	_	11	det
10	steady-state	steady-state	JJ	_	11	amod
11	pharmacokinetics	pharmacokinetic	NNS	_	7	nmod
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	or	or	CC	_	13	cc
15	drug3	drug3	NN	_	13	conj
16	with	with	IN	_	18	case
17	the	the	DT	_	18	det
18	addition	addition	NN	_	7	nmod
19	of	of	IN	_	20	case
20	drug4	drug4	NN	_	18	nmod
21	given	give	VBN	_	18	acl
22	as	as	IN	_	25	case
23	a	a	DT	_	25	det
24	single	single	JJ	_	25	amod
25	dose	dose	NN	_	21	nmod
26	.	.	.	_	1	punct

1	Prothrombin	Prothrombin	NNP	_	2	compound
2	times	time	NNS	_	5	nsubjpass
3	were	be	VBD	_	5	auxpass
4	not	not	RB	_	5	neg
5	affected	affect	VBN	_	0	ROOT
6	by	by	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concomitant	concomitant	JJ	_	4	amod
4	administration	administration	NN	_	9	nsubj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	did	do	VBD	_	9	aux
8	not	not	RB	_	9	neg
9	affect	affect	VB	_	1	dep
10	the	the	DT	_	12	det
11	steady-state	steady-state	JJ	_	12	amod
12	pharmacokinetics	pharmacokinetic	NNS	_	9	dobj
13	of	of	IN	_	14	case
14	drug3	drug3	NN	_	12	nmod
15	or	or	CC	_	12	cc
16	the	the	DT	_	21	det
17	mean	mean	JJ	_	21	amod
18	daily	daily	JJ	_	21	amod
19	trough	trough	NN	_	21	compound
20	serum	serum	NN	_	21	compound
21	level	level	NN	_	12	conj
22	of	of	IN	_	23	case
23	drug4	drug4	NN	_	21	nmod
24	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	or	or	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	:	:	:	_	1	punct
5	No	no	DT	_	7	neg
6	significant	significant	JJ	_	7	amod
7	differences	difference	NNS	_	9	nsubjpass
8	were	be	VBD	_	9	auxpass
9	observed	observe	VBN	_	1	dep
10	in	in	IN	_	12	case
11	the	the	DT	_	12	det
12	pharmacokinetics	pharmacokinetic	NNS	_	9	nmod
13	of	of	IN	_	14	case
14	drug3	drug3	NN	_	12	nmod
15	-LRB-	-lrb-	-LRB-	_	17	punct
16	0.125	0.125	CD	_	17	nummod
17	mg	mg	NN	_	14	appos
18	-RRB-	-rrb-	-RRB-	_	17	punct
19	and	and	CC	_	14	cc
20	drug4	drug4	NN	_	14	conj
21	-LRB-	-lrb-	-LRB-	_	23	punct
22	10	10	CD	_	23	nummod
23	mg	mg	NN	_	20	appos
24	-RRB-	-rrb-	-RRB-	_	23	punct
25	when	when	WRB	_	26	advmod
26	given	give	VBN	_	9	advcl
27	together	together	RB	_	26	advmod
28	as	as	IN	_	31	case
29	a	a	DT	_	31	det
30	single	single	JJ	_	31	amod
31	dose	dose	NN	_	26	nmod
32	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	pharmacokinetics	pharmacokinetic	NNS	_	7	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	were	be	VBD	_	7	auxpass
6	not	not	RB	_	7	neg
7	affected	affect	VBN	_	0	ROOT
8	by	by	IN	_	10	case
9	multiple-dose	multiple-dose	JJ	_	10	amod
10	administration	administration	NN	_	7	nmod
11	of	of	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	.	.	.	_	7	punct

1	drug1	drug1	NN	_	3	nsubj
2	has	have	VBZ	_	3	aux
3	shown	show	VBN	_	0	ROOT
4	no	no	DT	_	7	neg
5	clinically	clinically	RB	_	6	advmod
6	important	important	JJ	_	7	amod
7	potentiation	potentiation	NN	_	3	dobj
8	of	of	IN	_	11	case
9	the	the	DT	_	11	det
10	pharmacodynamic	pharmacodynamic	JJ	_	11	amod
11	effects	effect	NNS	_	7	nmod
12	of	of	IN	_	14	case
13	triazo	triazo	NN	_	14	compound
14	lam	lam	NN	_	11	nmod
15	or	or	CC	_	14	cc
16	drug2	drug2	NN	_	14	conj
17	.	.	.	_	3	punct

1	Because	because	IN	_	6	case
2	of	of	IN	_	1	mwe
3	the	the	DT	_	6	det
4	possible	possible	JJ	_	6	amod
5	additive	additive	JJ	_	6	amod
6	effects	effect	NNS	_	21	nmod
7	of	of	IN	_	8	case
8	drugs	drug	NNS	_	6	nmod
9	that	that	WDT	_	11	nsubj
10	may	may	MD	_	11	aux
11	depress	depress	VB	_	6	acl:relcl
12	the	the	DT	_	14	det
13	nervous	nervous	JJ	_	14	amod
14	system	system	NN	_	11	dobj
15	,	,	,	_	14	punct
16	drug1	drug1	NN	_	14	conj
17	or	or	CC	_	14	cc
18	drug2	drug2	NN	_	14	conj
19	should	should	MD	_	21	aux
20	be	be	VB	_	21	auxpass
21	used	use	VBN	_	0	ROOT
22	cautiously	cautiously	RB	_	21	advmod
23	in	in	IN	_	24	case
24	combination	combination	NN	_	21	nmod
25	with	with	IN	_	26	case
26	drug3	drug3	NN	_	24	nmod
27	.	.	.	_	21	punct

1	Oral	oral	JJ	_	2	amod
2	drug1	drug1	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	Multiple	multiple	JJ	_	6	amod
5	dose	dose	NN	_	6	compound
6	administration	administration	NN	_	16	nsubj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	-LRB-	-lrb-	-LRB-	_	12	punct
10	8	8	CD	_	12	nummod
11	mg/day	mg/day	NN	_	12	compound
12	monotherapy	monotherapy	NN	_	6	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	did	do	VBD	_	16	aux
15	not	not	RB	_	16	neg
16	alter	alter	VB	_	2	dep
17	the	the	DT	_	18	det
18	pharmacokinetics	pharmacokinetic	NNS	_	16	dobj
19	of	of	IN	_	21	case
20	oral	oral	JJ	_	21	amod
21	drug3	drug3	NN	_	18	nmod
22	in	in	IN	_	24	case
23	healthy	healthy	JJ	_	24	amod
24	women	woman	NNS	_	18	nmod
25	of	of	IN	_	27	case
26	childbearing	childbearing	JJ	_	27	amod
27	age	age	NN	_	24	nmod
28	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	compound
4	pharmacokinetics	pharmacokinetic	NNS	_	8	nsubj
5	were	be	VBD	_	8	cop
6	not	not	RB	_	8	neg
7	significantly	significantly	RB	_	8	advmod
8	different	different	JJ	_	1	dep
9	before	before	IN	_	14	nmod
10	and	and	CC	_	9	cc
11	after	after	IN	_	9	conj
12	drug3	drug3	NN	_	14	compound
13	multiple-dose	multiple-dose	JJ	_	14	amod
14	regimens	regimen	NNS	_	8	nmod
15	.	.	.	_	1	punct

1	This	this	DT	_	2	nsubj
2	indicates	indicate	VBZ	_	0	ROOT
3	that	that	IN	_	7	mark
4	drug1	drug1	NN	_	7	nsubj
5	does	do	VBZ	_	7	aux
6	not	not	RB	_	7	neg
7	cause	cause	VB	_	2	ccomp
8	induction	induction	NN	_	7	dobj
9	or	or	CC	_	8	cc
10	inhibition	inhibition	NN	_	8	conj
11	of	of	IN	_	16	case
12	the	the	DT	_	16	det
13	hepatic	hepatic	JJ	_	16	amod
14	microsomal	microsomal	JJ	_	16	amod
15	enzyme	enzyme	NN	_	16	compound
16	systems	system	NNS	_	8	nmod
17	responsible	responsible	JJ	_	16	amod
18	for	for	IN	_	20	case
19	the	the	DT	_	20	det
20	metabolism	metabolism	NN	_	17	nmod
21	of	of	IN	_	22	case
22	drug2	drug2	NN	_	20	nmod
23	.	.	.	_	2	punct

1	Interaction	interaction	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	8	case
5	Highly	highly	RB	_	8	amod
6	Protein	protein	NN	_	8	compound
7	Bound	bind	VBN	_	8	amod
8	Drugs	drug	NNS	_	1	nmod
9	:	:	:	_	1	punct
10	In	in	FW	_	12	amod
11	vitro	vitro	FW	_	10	dep
12	data	datum	NNS	_	13	nsubj
13	showed	show	VBD	_	1	dep
14	that	that	IN	_	19	mark
15	drug2	drug2	NN	_	19	nsubjpass
16	is	be	VBZ	_	19	auxpass
17	96	96	CD	_	18	nummod
18	%	%	NN	_	19	dep
19	bound	bind	VBD	_	13	ccomp
20	to	to	TO	_	23	case
21	human	human	JJ	_	23	amod
22	plasma	plasma	NN	_	23	compound
23	protein	protein	NN	_	19	nmod
24	and	and	CC	_	19	cc
25	therefore	therefore	RB	_	26	advmod
26	has	have	VBZ	_	19	conj
27	the	the	DT	_	28	det
28	potential	potential	JJ	_	26	dobj
29	to	to	TO	_	30	mark
30	interact	interact	VB	_	28	acl
31	with	with	IN	_	36	case
32	other	other	JJ	_	36	amod
33	highly	highly	RB	_	35	advmod
34	protein	protein	NN	_	35	nmod:npmod
35	bound	bind	VBD	_	36	amod
36	compounds	compound	NNS	_	30	nmod
37	.	.	.	_	1	punct

1	Such	such	PDT	_	3	amod
2	an	a	DT	_	3	det
3	interaction	interaction	NN	_	6	nsubj
4	can	can	MD	_	6	aux
5	potentially	potentially	RB	_	6	advmod
6	lead	lead	VB	_	0	ROOT
7	to	to	TO	_	10	case
8	higher	higher	JJR	_	10	amod
9	free	free	JJ	_	10	amod
10	fractions	fraction	NNS	_	6	nmod
11	of	of	IN	_	13	case
12	either	either	CC	_	13	cc:preconj
13	drug1	drug1	NN	_	10	nmod
14	or	or	CC	_	13	cc
15	the	the	DT	_	17	det
16	competing	compete	VBG	_	17	amod
17	drug	drug	NN	_	13	conj
18	.	.	.	_	6	punct

1	drug1	drug1	NN	_	2	nsubj
2	dosed	dose	VBD	_	15	csubj
3	as	as	IN	_	9	case
4	a	a	DT	_	9	det
5	1.0	1.0	CD	_	9	nummod
6	mg/kg	mg/kg	NN	_	9	compound
7	subcutaneous	subcutaneous	JJ	_	9	amod
8	injection	injection	NN	_	9	compound
9	q12h	q12h	NN	_	2	nmod
10	for	for	IN	_	12	case
11	four	four	CD	_	12	nummod
12	doses	dose	NNS	_	9	nmod
13	did	do	VBD	_	15	aux
14	not	not	RB	_	15	neg
15	alter	alter	VB	_	0	ROOT
16	the	the	DT	_	17	det
17	pharmacokinetics	pharmacokinetic	NNS	_	15	dobj
18	of	of	IN	_	19	case
19	drug2	drug2	NN	_	17	nmod
20	or	or	CC	_	19	cc
21	the	the	DT	_	22	det
22	level	level	NN	_	19	conj
23	of	of	IN	_	25	case
24	platelet	platelet	NN	_	25	compound
25	aggregation	aggregation	NN	_	22	nmod
26	in	in	IN	_	28	case
27	healthy	healthy	JJ	_	28	amod
28	adults	adult	NNS	_	17	nmod
29	.	.	.	_	15	punct

1	The	the	DT	_	3	det
2	adverse	adverse	JJ	_	3	amod
3	effects	effect	NNS	_	15	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	,	,	,	_	5	punct
7	such	such	JJ	_	9	case
8	as	as	IN	_	7	mwe
9	myelosuppression	myelosuppression	NN	_	5	nmod
10	and	and	CC	_	9	cc
11	diarrhea	diarrhea	NN	_	9	conj
12	,	,	,	_	5	punct
13	would	would	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	expected	expect	VBN	_	0	ROOT
16	to	to	TO	_	18	mark
17	be	be	VB	_	18	auxpass
18	exacerbated	exacerbate	VBN	_	15	xcomp
19	by	by	IN	_	21	case
20	other	other	JJ	_	21	amod
21	drug2	drug2	NN	_	18	nmod
22	having	have	VBG	_	21	acl
23	similar	similar	JJ	_	25	amod
24	adverse	adverse	JJ	_	25	amod
25	effects	effect	NNS	_	22	dobj
26	.	.	.	_	15	punct

1	Patients	patient	NNS	_	13	nsubj
2	who	who	WP	_	5	nsubj
3	have	have	VBP	_	5	aux
4	previously	previously	RB	_	5	advmod
5	received	receive	VBN	_	1	acl:relcl
6	pelvic	pelvic	JJ	_	9	amod
7	/	/	:	_	9	punct
8	abdominal	abdominal	JJ	_	9	amod
9	irradiation	irradiation	NN	_	5	dobj
10	are	be	VBP	_	13	cop
11	at	at	IN	_	13	case
12	increased	increase	VBN	_	13	amod
13	risk	risk	NN	_	0	ROOT
14	of	of	IN	_	16	case
15	severe	severe	JJ	_	16	amod
16	myelosuppression	myelosuppression	NN	_	13	nmod
17	following	follow	VBG	_	19	case
18	the	the	DT	_	19	det
19	administration	administration	NN	_	13	nmod
20	of	of	IN	_	21	case
21	drug1	drug1	NN	_	19	nmod
22	.	.	.	_	13	punct

1	The	the	DT	_	3	det
2	concurrent	concurrent	JJ	_	3	amod
3	administration	administration	NN	_	12	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	with	with	IN	_	7	case
7	irradiation	irradiation	NN	_	3	nmod
8	has	have	VBZ	_	12	aux
9	not	not	RB	_	12	neg
10	been	be	VBN	_	12	auxpass
11	adequately	adequately	RB	_	12	advmod
12	studied	study	VBN	_	0	ROOT
13	and	and	CC	_	12	cc
14	is	be	VBZ	_	16	auxpass
15	not	not	RB	_	16	neg
16	recommended	recommend	VBN	_	12	conj
17	.	.	.	_	12	punct

1	Lymphocytopenia	Lymphocytopenia	NNP	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	in	in	IN	_	6	case
6	patients	patient	NNS	_	4	nmod
7	receiving	receive	VBG	_	6	acl
8	drug1	drug1	NN	_	7	dobj
9	,	,	,	_	4	punct
10	and	and	CC	_	4	cc
11	it	it	PRP	_	13	nsubj
12	is	be	VBZ	_	13	cop
13	possible	possible	JJ	_	4	conj
14	that	that	IN	_	24	mark
15	the	the	DT	_	16	det
16	administration	administration	NN	_	24	nsubj
17	of	of	IN	_	18	case
18	drug2	drug2	NN	_	16	nmod
19	as	as	IN	_	21	case
20	antiemetic	antiemetic	JJ	_	21	amod
21	prophylaxis	prophylaxis	NN	_	16	nmod
22	may	may	MD	_	24	aux
23	have	have	VB	_	24	aux
24	enhanced	enhance	VBN	_	13	ccomp
25	the	the	DT	_	26	det
26	likelihood	likelihood	NN	_	24	dobj
27	of	of	IN	_	29	case
28	this	this	DT	_	29	det
29	effect	effect	NN	_	26	nmod
30	.	.	.	_	4	punct

1	However	however	RB	_	9	advmod
2	,	,	,	_	9	punct
3	serious	serious	JJ	_	5	amod
4	opportunistic	opportunistic	JJ	_	5	amod
5	infections	infection	NNS	_	9	nsubjpass
6	have	have	VBP	_	9	aux
7	not	not	RB	_	9	neg
8	been	be	VBN	_	9	auxpass
9	observed	observe	VBN	_	0	ROOT
10	,	,	,	_	9	punct
11	and	and	CC	_	9	cc
12	no	no	DT	_	13	neg
13	complications	complication	NNS	_	17	nsubjpass
14	have	have	VBP	_	17	aux
15	specifically	specifically	RB	_	17	advmod
16	been	be	VBN	_	17	auxpass
17	attributed	attribute	VBN	_	9	conj
18	to	to	TO	_	19	case
19	lymphocytopenia	lymphocytopenia	NN	_	17	nmod
20	.	.	.	_	9	punct

1	Hyperglycemia	hyperglycemia	NN	_	5	nsubjpass
2	has	have	VBZ	_	5	aux
3	also	also	RB	_	5	advmod
4	been	be	VBN	_	5	auxpass
5	reported	report	VBN	_	0	ROOT
6	in	in	IN	_	7	case
7	patients	patient	NNS	_	5	nmod
8	receiving	receive	VBG	_	7	acl
9	drug1	drug1	NN	_	8	dobj
10	.	.	.	_	5	punct

1	Usually	usually	RB	_	6	advmod
2	,	,	,	_	6	punct
3	this	this	DT	_	6	nsubjpass
4	has	have	VBZ	_	6	aux
5	been	be	VBN	_	6	auxpass
6	observed	observe	VBN	_	0	ROOT
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	with	with	IN	_	11	case
10	a	a	DT	_	11	det
11	history	history	NN	_	8	nmod
12	of	of	IN	_	14	case
13	diabetes	diabetes	NN	_	14	compound
14	mellitus	mellitus	NN	_	11	nmod
15	or	or	CC	_	8	cc
16	evidence	evidence	NN	_	8	conj
17	of	of	IN	_	19	case
18	glucose	glucose	NN	_	19	compound
19	intolerance	intolerance	NN	_	16	nmod
20	prior	prior	RB	_	6	advmod
21	to	to	TO	_	22	case
22	administration	administration	NN	_	20	nmod
23	of	of	IN	_	24	case
24	drug1	drug1	NN	_	22	nmod
25	.	.	.	_	6	punct

1	It	it	PRP	_	3	nsubj
2	is	be	VBZ	_	3	cop
3	probable	probable	JJ	_	0	ROOT
4	that	that	IN	_	12	mark
5	drug1	drug1	NN	_	12	nsubj
6	,	,	,	_	5	punct
7	given	give	VBN	_	5	acl
8	as	as	IN	_	10	case
9	antiemetic	antiemetic	JJ	_	10	amod
10	prophylaxis	prophylaxis	NN	_	7	nmod
11	,	,	,	_	5	punct
12	contributed	contribute	VBD	_	3	ccomp
13	to	to	TO	_	14	case
14	hyperglycemia	hyperglycemia	NN	_	12	nmod
15	in	in	IN	_	17	case
16	some	some	DT	_	17	det
17	patients	patient	NNS	_	14	nmod
18	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	incidence	incidence	NN	_	14	nsubj
3	of	of	IN	_	4	case
4	akathisia	akathisia	NN	_	2	nmod
5	in	in	IN	_	7	case
6	clinical	clinical	JJ	_	7	amod
7	trials	trial	NNS	_	2	nmod
8	of	of	IN	_	12	case
9	the	the	DT	_	12	det
10	weekly	weekly	JJ	_	12	amod
11	dosage	dosage	NN	_	12	compound
12	schedule	schedule	NN	_	7	nmod
13	was	be	VBD	_	14	cop
14	greater	greater	JJR	_	0	ROOT
15	-LRB-	-lrb-	-LRB-	_	17	punct
16	8.5	8.5	CD	_	17	nummod
17	%	%	NN	_	14	dep
18	,	,	,	_	17	punct
19	4/47	4/47	CD	_	20	nummod
20	patients	patient	NNS	_	17	appos
21	-RRB-	-rrb-	-RRB-	_	17	punct
22	when	when	WRB	_	25	advmod
23	drug1	drug1	NN	_	25	nsubjpass
24	was	be	VBD	_	25	auxpass
25	administered	administer	VBN	_	14	advcl
26	on	on	IN	_	29	case
27	the	the	DT	_	29	det
28	same	same	JJ	_	29	amod
29	day	day	NN	_	25	nmod
30	as	as	IN	_	31	case
31	drug2	drug2	NN	_	25	nmod
32	than	than	IN	_	37	mark
33	when	when	WRB	_	37	advmod
34	these	these	DT	_	35	det
35	drugs	drug	NNS	_	37	nsubjpass
36	were	be	VBD	_	37	auxpass
37	given	give	VBN	_	25	advcl
38	on	on	IN	_	40	case
39	separate	separate	JJ	_	40	amod
40	days	day	NNS	_	37	nmod
41	-LRB-	-lrb-	-LRB-	_	43	punct
42	1.3	1.3	CD	_	43	nummod
43	%	%	NN	_	25	dep
44	,	,	,	_	43	punct
45	1/80	1/80	CD	_	46	nummod
46	patients	patient	NNS	_	43	appos
47	-RRB-	-rrb-	-RRB-	_	43	punct
48	.	.	.	_	14	punct

1	The	the	DT	_	4	det
2	8.5	8.5	CD	_	3	compound
3	%	%	NN	_	4	amod
4	incidence	incidence	NN	_	13	nsubj
5	of	of	IN	_	6	case
6	akathisia	akathisia	NN	_	4	nmod
7	,	,	,	_	13	punct
8	however	however	RB	_	13	advmod
9	,	,	,	_	13	punct
10	is	be	VBZ	_	13	cop
11	within	within	IN	_	13	case
12	the	the	DT	_	13	det
13	range	range	NN	_	0	ROOT
14	reported	report	VBD	_	13	acl
15	for	for	IN	_	16	case
16	use	use	NN	_	14	nmod
17	of	of	IN	_	18	case
18	drug1	drug1	NN	_	16	nmod
19	when	when	WRB	_	20	advmod
20	given	give	VBN	_	14	advcl
21	as	as	IN	_	23	case
22	a	a	DT	_	23	det
23	premedication	premedication	NN	_	20	nmod
24	for	for	IN	_	26	case
25	other	other	JJ	_	26	amod
26	chemotherapies	chemotherapy	NNS	_	23	nmod
27	.	.	.	_	13	punct

1	It	it	PRP	_	4	nsubjpass
2	would	would	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	expected	expect	VBN	_	0	ROOT
5	that	that	IN	_	13	mark
6	drug1	drug1	NN	_	7	compound
7	use	use	NN	_	13	nsubj
8	during	during	IN	_	9	case
9	therapy	therapy	NN	_	7	nmod
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	would	would	MD	_	13	aux
13	worsen	worsen	VB	_	4	ccomp
14	the	the	DT	_	15	det
15	incidence	incidence	NN	_	13	dobj
16	or	or	CC	_	15	cc
17	severity	severity	NN	_	15	conj
18	of	of	IN	_	19	case
19	diarrhea	diarrhea	NN	_	15	nmod
20	,	,	,	_	4	punct
21	but	but	CC	_	4	cc
22	this	this	DT	_	26	nsubjpass
23	has	have	VBZ	_	26	aux
24	not	not	RB	_	26	neg
25	been	be	VBN	_	26	auxpass
26	studied	study	VBN	_	4	conj
27	.	.	.	_	4	punct

1	In	in	IN	_	2	case
2	view	view	NN	_	21	nmod
3	of	of	IN	_	6	case
4	the	the	DT	_	6	det
5	potential	potential	JJ	_	6	amod
6	risk	risk	NN	_	2	nmod
7	of	of	IN	_	8	case
8	dehydration	dehydration	NN	_	6	nmod
9	secondary	secondary	JJ	_	8	amod
10	to	to	TO	_	11	mark
11	vomiting	vomit	VBG	_	9	advcl
12	and/or	and/or	CC	_	11	cc
13	diarrhea	diarrhea	NN	_	11	conj
14	induced	induce	VBN	_	11	dep
15	by	by	IN	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	,	,	,	_	21	punct
18	the	the	DT	_	19	det
19	physician	physician	NN	_	21	nsubj
20	may	may	MD	_	21	aux
21	wish	wish	VB	_	0	ROOT
22	to	to	TO	_	23	mark
23	withhold	withhold	VB	_	21	xcomp
24	drug2	drug2	NN	_	23	dobj
25	during	during	IN	_	26	case
26	dosing	dosing	NN	_	23	nmod
27	with	with	IN	_	28	case
28	drug3	drug3	NN	_	26	nmod
29	and	and	CC	_	23	cc
30	,	,	,	_	23	punct
31	certainly	certainly	RB	_	23	dep
32	,	,	,	_	31	punct
33	during	during	IN	_	34	case
34	periods	period	NNS	_	32	root
35	of	of	IN	_	37	case
36	active	active	JJ	_	37	amod
37	vomiting	vomit	VBG	_	34	nmod
38	or	or	CC	_	37	cc
39	diarrhea	diarrhea	NN	_	37	conj
40	.	.	.	_	34	punct

1	Drug-Laboratory	drug-laboratory	JJ	_	3	amod
2	Test	test	NN	_	3	compound
3	Interactions	interaction	NNS	_	0	ROOT
4	There	there	EX	_	5	expl
5	are	be	VBP	_	3	acl:relcl
6	no	no	DT	_	8	neg
7	known	known	JJ	_	8	amod
8	interactions	interaction	NNS	_	5	nsubj
9	between	between	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	laboratory	laboratory	NN	_	13	compound
13	tests	test	NNS	_	10	conj
14	.	.	.	_	3	punct

1	No	no	DT	_	3	neg
2	specific	specific	JJ	_	3	amod
3	information	information	NN	_	0	ROOT
4	available	available	JJ	_	3	amod

1	.	.	.	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	decrease	decrease	VB	_	0	ROOT
4	renal	renal	JJ	_	6	amod
5	tubular	tubular	JJ	_	6	amod
6	secretion	secretion	NN	_	3	dobj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	when	when	WRB	_	10	advmod
10	used	use	VBN	_	3	advcl
11	concurrently	concurrently	RB	_	10	advmod
12	,	,	,	_	3	punct
13	resulting	result	VBG	_	3	advcl
14	in	in	IN	_	21	case
15	increased	increase	VBN	_	21	amod
16	and	and	CC	_	15	cc
17	more	more	JJR	_	18	advmod
18	prolonged	prolonged	JJ	_	15	conj
19	drug3	drug3	NN	_	21	compound
20	blood	blood	NN	_	21	compound
21	levels	level	NNS	_	13	nmod
22	.	.	.	_	3	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	3	amod
2	Test	test	NN	_	3	compound
3	Interactions	interaction	NNS	_	0	ROOT
4	A	a	DT	_	7	det
5	false	false	JJ	_	7	amod
6	positive	positive	JJ	_	7	amod
7	reaction	reaction	NN	_	14	nsubj
8	for	for	IN	_	9	case
9	glucose	glucose	NN	_	7	nmod
10	in	in	IN	_	12	case
11	the	the	DT	_	12	det
12	urine	urine	NN	_	9	nmod
13	may	may	MD	_	14	aux
14	occur	occur	VB	_	3	acl:relcl
15	with	with	IN	_	17	case
16	Benedicts	benedict	NNS	_	17	compound
17	solution	solution	NN	_	14	nmod
18	,	,	,	_	3	punct
19	Fehlings	Fehlings	NNP	_	20	compound
20	solution	solution	NN	_	3	appos
21	or	or	CC	_	20	cc
22	with	with	IN	_	24	case
23	CLINITEST	clinitest	NN	_	24	compound
24	tablets	tablet	NNS	_	20	conj
25	,	,	,	_	3	punct
26	but	but	CC	_	27	cc
27	not	not	RB	_	3	cc
28	with	with	IN	_	30	case
29	enzyme-based	enzyme-based	JJ	_	30	amod
30	tests	test	NNS	_	3	conj
31	such	such	JJ	_	33	case
32	as	as	IN	_	31	mwe
33	CLINISTIX	clinistix	NN	_	30	nmod
34	.	.	.	_	3	punct

1	Positive	positive	JJ	_	5	amod
2	direct	direct	JJ	_	5	amod
3	and	and	CC	_	2	cc
4	indirect	indirect	JJ	_	2	conj
5	antiglobulin	antiglobulin	NN	_	9	compound
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	Coombs	coomb	NNS	_	5	appos
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	tests	test	NNS	_	11	nsubj
10	have	have	VBP	_	11	aux
11	occurred	occur	VBN	_	0	ROOT
12	;	;	:	_	11	punct

1	these	these	DT	_	4	nsubj
2	may	may	MD	_	4	aux
3	also	also	RB	_	4	advmod
4	occur	occur	VB	_	0	ROOT
5	in	in	IN	_	6	case
6	neonates	neonate	NNS	_	4	nmod
7	whose	whose	WP$	_	8	nmod:poss
8	mothers	mother	NNS	_	9	nsubj
9	received	receive	VBD	_	6	acl:relcl
10	drug1	drug1	NN	_	9	dobj
11	before	before	IN	_	12	case
12	delivery	delivery	NN	_	9	nmod
13	.	.	.	_	4	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	should	should	MD	_	5	aux
3	not	not	RB	_	5	neg
4	be	be	VB	_	5	auxpass
5	administered	administer	VBN	_	0	ROOT
6	concurrently	concurrently	RB	_	5	advmod
7	with	with	IN	_	8	case
8	D2-antagonists	d2-antagonist	NNS	_	5	nmod
9	,	,	,	_	8	punct
10	such	such	JJ	_	12	case
11	as	as	IN	_	10	mwe
12	drug2	drug2	NN	_	8	nmod
13	,	,	,	_	12	punct
14	drug3	drug3	NN	_	12	conj
15	,	,	,	_	12	punct
16	drug4	drug4	NN	_	12	conj
17	,	,	,	_	12	punct
18	or	or	CC	_	12	cc
19	drug5	drug5	NN	_	12	conj
20	.	.	.	_	5	punct

1	Oral	oral	JJ	_	3	amod
2	drug1	drug1	NN	_	3	compound
3	CAUTION	caution	NN	_	6	nsubjpass
4	SHOULD	should	MD	_	6	aux
5	BE	be	VB	_	6	auxpass
6	EXERCISED	exercise	VBN	_	0	ROOT
7	WHEN	when	WRB	_	9	advmod
8	drug2	drug2	NN	_	9	nsubj
9	ARE	be	VBP	_	6	advcl
10	GIVEN	GIVEN	NNP	_	9	dobj
11	IN	in	IN	_	12	case
12	CONJUNCTION	CONJUNCTION	NNP	_	10	nmod
13	WITH	with	IN	_	14	case
14	drug3	drug3	NN	_	9	nmod
15	.	.	.	_	6	punct

1	THE	the	DT	_	2	det
2	DOSAGE	dosage	NN	_	7	nsubj
3	OF	of	IN	_	5	case
4	THE	the	DT	_	5	det
5	drug1	drug1	NN	_	2	nmod
6	SHOULD	should	MD	_	7	aux
7	BE	be	VB	_	0	ROOT
8	REDUCED	REDUCED	NNP	_	7	dobj
9	TO	to	TO	_	10	mark
10	MAINTAIN	maintain	VB	_	8	acl
11	THE	the	DT	_	13	det
12	PROTHROMBIN	prothrombin	NN	_	13	compound
13	TIME/INR	time/inr	NN	_	10	dobj
14	AT	at	IN	_	17	case
15	THE	the	DT	_	17	det
16	DESIRED	desired	JJ	_	17	amod
17	LEVEL	level	NN	_	13	nmod
18	TO	to	TO	_	19	mark
19	PREVENT	prevent	VB	_	10	advcl
20	BLEEDING	bleed	VBG	_	19	xcomp
21	COMPLICATIONS	complication	NNS	_	20	dobj
22	.	.	.	_	7	punct

1	FREQUENT	frequent	JJ	_	4	amod
2	PROTHROMBIN	prothrombin	NN	_	4	compound
3	TIME/INR	time/inr	NN	_	4	compound
4	DETERMINATIONS	determination	NNS	_	5	nsubj
5	ARE	be	VBP	_	0	ROOT
6	ADVISABLE	advisable	JJ	_	5	xcomp
7	UNTIL	until	IN	_	9	mark
8	IT	it	PRP	_	9	nsubj
9	HAS	have	VBZ	_	6	advcl
10	BEEN	BEEN	NNP	_	12	compound
11	DEFINITELY	DEFINITELY	NNP	_	12	compound
12	DETERMINED	DETERMINED	NNP	_	9	dobj
13	THAT	that	WDT	_	18	dobj
14	THE	the	DT	_	16	det
15	PROTHROMBIN	prothrombin	NN	_	16	compound
16	TIME/INR	time/inr	NN	_	18	nsubj
17	HAS	have	VBZ	_	18	aux
18	STABILIZED	stabilize	VBN	_	12	acl:relcl
19	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	5	det
4	combined	combine	VBN	_	5	amod
5	use	use	NN	_	12	nsubjpass
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drug3	drug3	NN	_	7	conj
10	should	should	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	avoided	avoid	VBN	_	1	dep
13	unless	unless	IN	_	23	mark
14	the	the	DT	_	15	det
15	benefit	benefit	NN	_	23	nsubj
16	of	of	IN	_	18	case
17	further	further	JJ	_	18	amod
18	alterations	alteration	NNS	_	15	nmod
19	in	in	IN	_	21	case
20	lipid	lipid	NN	_	21	compound
21	levels	level	NNS	_	18	nmod
22	is	be	VBZ	_	23	cop
23	likely	likely	JJ	_	12	advcl
24	to	to	TO	_	25	mark
25	outweigh	outweigh	VB	_	23	xcomp
26	the	the	DT	_	28	det
27	increased	increase	VBN	_	28	amod
28	risk	risk	NN	_	25	dobj
29	of	of	IN	_	32	case
30	this	this	DT	_	32	det
31	drug	drug	NN	_	32	compound
32	combination	combination	NN	_	28	nmod
33	.	.	.	_	12	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Since	since	IN	_	6	mark
4	drug2	drug2	NN	_	6	nsubj
5	may	may	MD	_	6	aux
6	bind	bind	VB	_	14	advcl
7	other	other	JJ	_	8	amod
8	drugs	drug	NNS	_	6	dobj
9	given	give	VBN	_	8	acl
10	concurrently	concurrently	RB	_	9	advmod
11	,	,	,	_	14	punct
12	patients	patient	NNS	_	14	nsubj
13	should	should	MD	_	14	aux
14	take	take	VB	_	1	appos
15	drug3	drug3	NN	_	14	dobj
16	at	at	IN	_	17	case
17	least	least	JJS	_	18	nmod:npmod
18	1	1	CD	_	19	nummod
19	hour	hour	NN	_	14	nmod:tmod
20	before	before	IN	_	19	dep
21	or	or	CC	_	20	cc
22	4-6	4-6	CD	_	23	nummod
23	hours	hour	NNS	_	20	conj
24	after	after	IN	_	28	mark
25	a	a	DT	_	26	det
26	drug4	drug4	CD	_	28	nsubj
27	to	to	TO	_	28	mark
28	avoid	avoid	VB	_	20	dep
29	impeding	impede	VBG	_	28	xcomp
30	its	its	PRP$	_	31	nmod:poss
31	absorption	absorption	NN	_	29	dobj
32	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Because	because	IN	_	6	mark
4	drug2	drug2	NN	_	6	nsubj
5	can	can	MD	_	6	aux
6	produce	produce	VB	_	34	advcl
7	nephrotoxicity	nephrotoxicity	NN	_	6	dobj
8	with	with	IN	_	9	case
9	decreases	decrease	NNS	_	6	nmod
10	in	in	IN	_	12	case
11	creatinine	creatinine	NN	_	12	compound
12	clearance	clearance	NN	_	9	nmod
13	and	and	CC	_	6	cc
14	rises	rise	VBZ	_	6	conj
15	in	in	IN	_	17	case
16	serum	serum	NN	_	17	compound
17	creatinine	creatinine	NN	_	14	nmod
18	,	,	,	_	6	punct
19	and	and	CC	_	6	cc
20	because	because	IN	_	27	mark
21	renal	renal	JJ	_	22	amod
22	excretion	excretion	NN	_	27	nsubj
23	is	be	VBZ	_	27	cop
24	the	the	DT	_	27	det
25	primary	primary	JJ	_	27	amod
26	elimination	elimination	NN	_	27	compound
27	route	route	NN	_	6	conj
28	of	of	IN	_	29	case
29	drug3	drug3	NN	_	27	nmod
30	including	include	VBG	_	31	case
31	drug4	drug4	NN	_	29	nmod
32	,	,	,	_	34	punct
33	there	there	EX	_	34	expl
34	is	be	VBZ	_	1	dep
35	a	a	DT	_	36	det
36	risk	risk	NN	_	34	nsubj
37	that	that	IN	_	41	mark
38	an	a	DT	_	39	det
39	interaction	interaction	NN	_	41	nsubj
40	will	will	MD	_	41	aux
41	lead	lead	VB	_	36	ccomp
42	to	to	TO	_	43	case
43	deterioration	deterioration	NN	_	41	nmod
44	.	.	.	_	34	punct

1	The	the	DT	_	2	det
2	benefits	benefit	NNS	_	18	nsubjpass
3	and	and	CC	_	2	cc
4	risks	risk	NNS	_	2	conj
5	of	of	IN	_	6	mark
6	using	use	VBG	_	2	acl
7	drug1	drug1	NN	_	6	dobj
8	with	with	IN	_	9	case
9	drug2	drug2	NN	_	6	nmod
10	and	and	CC	_	9	cc
11	other	other	JJ	_	14	amod
12	potentially	potentially	RB	_	13	advmod
13	nephrotoxic	nephrotoxic	JJ	_	14	amod
14	agents	agent	NNS	_	9	conj
15	should	should	MD	_	18	aux
16	be	be	VB	_	18	auxpass
17	carefully	carefully	RB	_	18	advmod
18	considered	consider	VBN	_	0	ROOT
19	,	,	,	_	18	punct
20	and	and	CC	_	18	cc
21	the	the	DT	_	24	det
22	lowest	lowest	JJS	_	24	amod
23	effective	effective	JJ	_	24	amod
24	dose	dose	NN	_	18	conj
25	employed	employ	VBN	_	24	acl

1	.	.	.	_	0	ROOT

1	Drug-drug	drug-drug	JJ	_	2	amod
2	interactions	interaction	NNS	_	10	nsubj
3	In	in	FW	_	5	amod
4	vitro	vitro	FW	_	3	dep
5	studies	study	NNS	_	10	nsubj
6	using	use	VBG	_	5	acl
7	human	human	JJ	_	9	amod
8	liver	liver	NN	_	9	compound
9	microsomes	microsome	NNS	_	6	dobj
10	indicate	indicate	VBP	_	0	ROOT
11	that	that	IN	_	17	mark
12	drug1	drug1	NN	_	17	nsubj
13	and	and	CC	_	12	cc
14	drug2	drug2	NN	_	12	conj
15	are	be	VBP	_	17	cop
16	not	not	RB	_	17	neg
17	inhibitors	inhibitor	NNS	_	10	ccomp
18	of	of	IN	_	19	case
19	cytochrome	cytochrome	NN	_	17	nmod
20	-LRB-	-lrb-	-LRB-	_	21	punct
21	CYP	cyp	NN	_	19	appos
22	-RRB-	-rrb-	-RRB-	_	21	punct
23	P450	p450	NN	_	24	compound
24	isoforms	isoform	NNS	_	19	dep
25	CYP3A4	cyp3a4	NN	_	24	dep
26	,	,	,	_	25	punct
27	CYP2D6	cyp2d6	NN	_	25	conj
28	,	,	,	_	25	punct
29	CYP2E1	cyp2e1	NN	_	25	conj
30	,	,	,	_	25	punct
31	or	or	CC	_	25	cc
32	CYP1A2	cyp1a2	NN	_	25	conj
33	.	.	.	_	10	punct

1	They	they	PRP	_	4	nsubj
2	are	be	VBP	_	4	cop
3	weak	weak	JJ	_	4	amod
4	inhibitors	inhibitor	NNS	_	0	ROOT
5	of	of	IN	_	6	case
6	CYP2C19	cyp2c19	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	CYP2A6	cyp2a6	NN	_	6	conj
9	,	,	,	_	4	punct
10	and	and	CC	_	4	cc
11	mild-to-moderate	mild-to-moderate	JJ	_	12	amod
12	inhibitors	inhibitor	NNS	_	4	conj
13	of	of	IN	_	14	case
14	CYP2C9	cyp2c9	NN	_	12	nmod
15	at	at	IN	_	17	case
16	therapeutic	therapeutic	JJ	_	17	amod
17	concentrations	concentration	NNS	_	12	nmod
18	.	.	.	_	4	punct

1	Potentiation	potentiation	NN	_	6	nsubjpass
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	has	have	VBZ	_	6	aux
5	been	be	VBN	_	6	auxpass
6	observed	observe	VBN	_	0	ROOT
7	with	with	IN	_	8	case
8	prolongation	prolongation	NN	_	6	nmod
9	of	of	IN	_	12	case
10	the	the	DT	_	12	det
11	prothrombin	prothrombin	NN	_	12	compound
12	time/INR	time/inr	NN	_	8	nmod
13	.	.	.	_	6	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	have	have	VBP	_	4	aux
3	been	be	VBN	_	4	auxpass
4	shown	show	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	bind	bind	VB	_	4	xcomp
7	other	other	JJ	_	8	amod
8	drugs	drug	NNS	_	6	dobj
9	given	give	VBN	_	8	acl
10	concurrently	concurrently	RB	_	9	advmod
11	.	.	.	_	4	punct

1	Therefore	therefore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	drug1	drug1	NN	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	taken	take	VBN	_	0	ROOT
7	at	at	IN	_	8	case
8	least	least	JJS	_	9	nmod:npmod
9	1	1	CD	_	10	nummod
10	hour	hour	NN	_	6	dobj
11	before	before	IN	_	10	dep
12	or	or	CC	_	11	cc
13	4-6	4-6	CD	_	14	nummod
14	hours	hour	NNS	_	11	conj
15	after	after	IN	_	19	mark
16	a	a	DT	_	17	det
17	drug2	drug2	CD	_	19	nsubj
18	to	to	TO	_	19	mark
19	avoid	avoid	VB	_	11	dep
20	impeding	impede	VBG	_	19	xcomp
21	its	its	PRP$	_	22	nmod:poss
22	absorption	absorption	NN	_	20	dobj
23	.	.	.	_	6	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	24	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	-LRB-	-lrb-	-LRB-	_	6	punct
6	equivalent	equivalent	JJ	_	2	dep
7	to	to	TO	_	8	mark
8	145mg	145mg	VB	_	6	xcomp
9	drug2	drug2	NN	_	8	dobj
10	-RRB-	-rrb-	-RRB-	_	6	punct
11	with	with	IN	_	12	case
12	drug3	drug3	NN	_	2	nmod
13	-LRB-	-lrb-	-LRB-	_	15	punct
14	40	40	CD	_	15	nummod
15	mg	mg	NN	_	12	appos
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	once	once	RB	_	18	advmod
18	daily	daily	RB	_	24	advmod
19	for	for	IN	_	21	case
20	10	10	CD	_	21	nummod
21	days	day	NNS	_	18	nmod
22	has	have	VBZ	_	24	aux
23	been	be	VBN	_	24	auxpass
24	shown	show	VBN	_	0	ROOT
25	to	to	TO	_	26	mark
26	increase	increase	VB	_	24	xcomp
27	the	the	DT	_	29	det
28	mean	mean	NN	_	29	compound
29	Cmax	cmax	NN	_	26	dobj
30	and	and	CC	_	29	cc
31	AUC	auc	NN	_	32	compound
32	values	value	NNS	_	29	conj
33	for	for	IN	_	34	case
34	drug4	drug4	NN	_	29	nmod
35	by	by	IN	_	37	case
36	36	36	CD	_	37	nummod
37	%	%	NN	_	26	nmod
38	-LRB-	-lrb-	-LRB-	_	39	punct
39	range	range	NN	_	37	dep
40	from	from	IN	_	42	case
41	69	69	CD	_	42	nummod
42	%	%	NN	_	39	nmod
43	decrease	decrease	NN	_	46	dep
44	to	to	TO	_	46	dep
45	321	321	CD	_	46	compound
46	%	%	NN	_	47	dep
47	increase	increase	NN	_	42	dep
48	-RRB-	-rrb-	-RRB-	_	39	punct
49	and	and	CC	_	37	cc
50	28	28	CD	_	51	nummod
51	%	%	NN	_	37	conj
52	-LRB-	-lrb-	-LRB-	_	53	punct
53	range	range	NN	_	51	dep
54	from	from	IN	_	57	case
55	54	54	CD	_	56	compound
56	%	%	NN	_	57	amod
57	decrease	decrease	NN	_	53	nmod
58	to	to	TO	_	60	dep
59	128	128	CD	_	60	compound
60	%	%	NN	_	57	dep
61	increase	increase	NN	_	60	dep
62	-RRB-	-rrb-	-RRB-	_	60	punct
63	,	,	,	_	53	punct
64	respectively	respectively	RB	_	53	advmod
65	,	,	,	_	53	punct
66	and	and	CC	_	53	cc
67	for	for	IN	_	68	case
68	3	3	LS	_	53	conj
69	-	-	:	_	68	punct
70	hydroxy-iso-pravastatin	hydroxy-iso-pravastatin	NN	_	68	dep
71	by	by	IN	_	73	case
72	55	55	CD	_	73	nummod
73	%	%	NN	_	70	nmod
74	-LRB-	-lrb-	-LRB-	_	75	punct
75	range	range	NN	_	73	dep
76	from	from	IN	_	79	case
77	32	32	CD	_	78	compound
78	%	%	NN	_	79	amod
79	decrease	decrease	NN	_	83	nmod
80	to	to	TO	_	82	dep
81	314	314	CD	_	82	compound
82	%	%	NN	_	83	dep
83	increase	increase	NN	_	75	nmod
84	-RRB-	-rrb-	-RRB-	_	75	punct
85	and	and	CC	_	73	cc
86	39	39	CD	_	87	nummod
87	%	%	NN	_	73	conj
88	-LRB-	-lrb-	-LRB-	_	89	punct
89	range	range	NN	_	87	dep
90	from	from	IN	_	93	case
91	24	24	CD	_	92	compound
92	%	%	NN	_	93	amod
93	decrease	decrease	NN	_	89	nmod
94	to	to	TO	_	96	dep
95	261	261	CD	_	96	compound
96	%	%	NN	_	93	dep
97	increase	increase	NN	_	96	dep
98	-RRB-	-rrb-	-RRB-	_	96	punct
99	,	,	,	_	89	punct
100	respectively	respectively	RB	_	104	advmod
101	in	in	IN	_	104	case
102	23	23	CD	_	104	nummod
103	healthy	healthy	JJ	_	104	amod
104	adults	adult	NNS	_	89	nmod
105	.	.	.	_	24	punct

1	A	a	DT	_	3	det
2	single	single	JJ	_	3	amod
3	dose	dose	NN	_	6	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	had	have	VBD	_	0	ROOT
7	no	no	DT	_	10	neg
8	clinically	clinically	RB	_	9	advmod
9	important	important	JJ	_	10	amod
10	effect	effect	NN	_	6	dobj
11	on	on	IN	_	13	case
12	the	the	DT	_	13	det
13	pharmacokinetics	pharmacokinetic	NNS	_	6	nmod
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	.	.	.	_	6	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	23	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	-LRB-	-lrb-	-LRB-	_	9	punct
6	equivalent	equivalent	JJ	_	9	dep
7	to	to	TO	_	9	dep
8	145	145	CD	_	9	compound
9	mg	mg	NN	_	2	dep
10	drug2	drug2	NN	_	9	dep
11	-RRB-	-rrb-	-RRB-	_	9	punct
12	with	with	IN	_	13	case
13	drug3	drug3	NN	_	2	nmod
14	-LRB-	-lrb-	-LRB-	_	16	punct
15	20	20	CD	_	16	nummod
16	mg	mg	NN	_	13	appos
17	-RRB-	-rrb-	-RRB-	_	16	punct
18	once	once	RB	_	19	advmod
19	daily	daily	RB	_	23	advmod
20	for	for	IN	_	22	case
21	10	10	CD	_	22	nummod
22	days	day	NNS	_	19	nmod
23	resulted	result	VBD	_	0	ROOT
24	in	in	IN	_	28	case
25	approximately	approximately	RB	_	26	advmod
26	17	17	CD	_	27	dep
27	%	%	NN	_	28	dep
28	decrease	decrease	NN	_	23	nmod
29	-LRB-	-lrb-	-LRB-	_	30	punct
30	range	range	NN	_	28	dep
31	from	from	IN	_	33	case
32	67	67	CD	_	33	nummod
33	%	%	NN	_	30	nmod
34	decrease	decrease	NN	_	37	dep
35	to	to	TO	_	37	dep
36	44	44	CD	_	37	compound
37	%	%	NN	_	38	dep
38	increase	increase	NN	_	33	dep
39	-RRB-	-rrb-	-RRB-	_	30	punct
40	in	in	IN	_	43	case
41	drug4	drug4	NN	_	43	compound
42	AUC	auc	NN	_	43	compound
43	values	value	NNS	_	28	nmod
44	in	in	IN	_	47	case
45	22	22	CD	_	47	nummod
46	healthy	healthy	JJ	_	47	amod
47	males	male	NNS	_	28	nmod
48	.	.	.	_	23	punct

1	The	the	DT	_	4	det
2	drug1	drug1	NN	_	4	compound
3	Cmax	cmax	NN	_	4	compound
4	values	value	NNS	_	8	nsubjpass
5	were	be	VBD	_	8	auxpass
6	not	not	RB	_	8	neg
7	significantly	significantly	RB	_	8	advmod
8	affected	affect	VBN	_	0	ROOT
9	by	by	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	.	.	.	_	8	punct

1	The	the	DT	_	2	det
2	pharmacokinetics	pharmacokinetic	NNS	_	8	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	were	be	VBD	_	8	auxpass
6	not	not	RB	_	8	neg
7	significantly	significantly	RB	_	8	advmod
8	affected	affect	VBN	_	0	ROOT
9	by	by	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod

1	.	.	.	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	If	if	IN	_	4	mark
2	additional	additional	JJ	_	3	amod
3	drug1	drug1	NN	_	4	nsubj
4	are	be	VBP	_	15	advcl
5	to	to	TO	_	7	mark
6	be	be	VB	_	7	auxpass
7	administered	administer	VBN	_	4	xcomp
8	by	by	IN	_	10	case
9	any	any	DT	_	10	det
10	route	route	NN	_	7	nmod
11	,	,	,	_	15	punct
12	they	they	PRP	_	15	nsubjpass
13	should	should	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	used	use	VBN	_	0	ROOT
16	with	with	IN	_	17	case
17	caution	caution	NN	_	15	nmod
18	because	because	IN	_	28	mark
19	the	the	DT	_	23	det
20	pharmacologically	pharmacologically	RB	_	21	advmod
21	predictable	predictable	JJ	_	23	amod
22	sympathetic	sympathetic	JJ	_	23	amod
23	effects	effect	NNS	_	28	nsubjpass
24	of	of	IN	_	25	case
25	drug2	drug2	NN	_	23	nmod
26	may	may	MD	_	28	aux
27	be	be	VB	_	28	auxpass
28	potentiated	potentiate	VBN	_	15	advcl
29	.	.	.	_	15	punct

1	When	when	WRB	_	11	advmod
2	drug1	drug1	NN	_	11	nsubjpass
3	,	,	,	_	2	punct
4	a	a	DT	_	6	det
5	potent	potent	JJ	_	6	amod
6	inhibitor	inhibitor	NN	_	2	appos
7	of	of	IN	_	8	case
8	CYP2D6	cyp2d6	NN	_	6	nmod
9	,	,	,	_	2	punct
10	was	be	VBD	_	11	auxpass
11	co-administered	co-administer	VBN	_	23	advcl
12	with	with	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	at	at	IN	_	15	case
15	steady-state	steady-state	JJ	_	11	nmod
16	,	,	,	_	23	punct
17	exposure	exposure	NN	_	23	nsubjpass
18	to	to	TO	_	20	case
19	either	either	CC	_	20	det
20	drug	drug	NN	_	17	nmod
21	was	be	VBD	_	23	auxpass
22	not	not	RB	_	23	neg
23	altered	alter	VBN	_	0	ROOT
24	.	.	.	_	23	punct

1	Dosage	dosage	NN	_	2	compound
2	adjustments	adjustment	NNS	_	7	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	are	be	VBP	_	7	cop
6	not	not	RB	_	7	neg
7	necessary	necessary	JJ	_	0	ROOT
8	when	when	WRB	_	12	advmod
9	the	the	DT	_	10	det
10	drug	drug	NN	_	12	nsubjpass
11	is	be	VBZ	_	12	auxpass
12	given	give	VBN	_	7	advcl
13	concomitantly	concomitantly	RB	_	12	advmod
14	with	with	IN	_	17	case
15	potent	potent	JJ	_	17	amod
16	CYP2D6	cyp2d6	NN	_	17	compound
17	inhibitors	inhibitor	NNS	_	12	nmod
18	.	.	.	_	7	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	treatment	treatment	NN	_	16	nsubj
3	with	with	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	-LRB-	-lrb-	-LRB-	_	6	punct
6	drug2	drug2	NN	_	4	dep
7	,	,	,	_	6	punct
8	drug3	drug3	NN	_	6	appos
9	-RRB-	-rrb-	-RRB-	_	6	punct
10	,	,	,	_	4	punct
11	drug4	drug4	NN	_	4	conj
12	,	,	,	_	4	punct
13	or	or	CC	_	4	cc
14	drug5	drug5	NN	_	4	conj
15	may	may	MD	_	16	aux
16	potentiate	potentiate	VB	_	0	ROOT
17	any	any	DT	_	19	det
18	hypokalemic	hypokalemic	JJ	_	19	amod
19	effect	effect	NN	_	16	dobj
20	of	of	IN	_	21	case
21	drug6	drug6	NN	_	19	nmod
22	.	.	.	_	16	punct

1	The	the	DT	_	3	det
2	ECG	ecg	NN	_	3	compound
3	changes	change	NNS	_	24	nsubjpass
4	and/or	and/or	CC	_	3	cc
5	hypokalemia	hypokalemia	NN	_	3	conj
6	that	that	WDT	_	8	nsubj
7	may	may	MD	_	8	aux
8	result	result	VB	_	3	acl:relcl
9	from	from	IN	_	11	case
10	the	the	DT	_	11	det
11	administration	administration	NN	_	8	nmod
12	of	of	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	-LRB-	-lrb-	-LRB-	_	17	punct
15	such	such	JJ	_	17	case
16	as	as	IN	_	15	mwe
17	drug2	drug2	NN	_	13	nmod
18	or	or	CC	_	17	cc
19	drug3	drug3	NN	_	17	conj
20	-RRB-	-rrb-	-RRB-	_	17	punct
21	can	can	MD	_	24	aux
22	be	be	VB	_	24	auxpass
23	acutely	acutely	RB	_	24	advmod
24	worsened	worsen	VBN	_	0	ROOT
25	by	by	IN	_	26	case
26	drug4	drug4	NN	_	24	nmod
27	,	,	,	_	26	punct
28	especially	especially	RB	_	37	advmod
29	when	when	WRB	_	37	advmod
30	the	the	DT	_	32	det
31	recommended	recommend	VBN	_	32	amod
32	dose	dose	NN	_	37	nsubjpass
33	of	of	IN	_	35	case
34	the	the	DT	_	35	det
35	drug5	drug5	NN	_	32	nmod
36	is	be	VBZ	_	37	auxpass
37	exceeded	exceed	VBN	_	26	acl
38	.	.	.	_	24	punct

1	Although	although	IN	_	10	mark
2	the	the	DT	_	4	det
3	clinical	clinical	JJ	_	4	amod
4	significance	significance	NN	_	10	nsubjpass
5	of	of	IN	_	7	case
6	these	these	DT	_	7	det
7	effects	effect	NNS	_	4	nmod
8	is	be	VBZ	_	10	auxpass
9	not	not	RB	_	10	neg
10	known	know	VBN	_	14	advcl
11	,	,	,	_	14	punct
12	caution	caution	NN	_	14	nsubjpass
13	is	be	VBZ	_	14	auxpass
14	advised	advise	VBN	_	0	ROOT
15	in	in	IN	_	17	case
16	the	the	DT	_	17	det
17	co-administration	co-administration	NN	_	14	nmod
18	of	of	IN	_	19	case
19	drug1	drug1	NN	_	17	nmod
20	with	with	IN	_	21	case
21	drug2	drug2	NN	_	14	nmod
22	.	.	.	_	14	punct

1	drug1	drug1	NN	_	10	nsubjpass
2	,	,	,	_	10	punct
3	as	as	IN	_	6	case
4	with	with	IN	_	6	case
5	other	other	JJ	_	6	amod
6	drug2	drug2	NN	_	10	nmod
7	,	,	,	_	10	punct
8	should	should	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	administered	administer	VBN	_	0	ROOT
11	with	with	IN	_	13	case
12	extreme	extreme	JJ	_	13	amod
13	caution	caution	NN	_	10	nmod
14	to	to	TO	_	15	case
15	patients	patient	NNS	_	10	nmod
16	being	be	VBG	_	17	auxpass
17	treated	treat	VBN	_	15	acl
18	with	with	IN	_	19	case
19	drug3	drug3	NN	_	17	nmod
20	,	,	,	_	19	punct
21	drug4	drug4	NN	_	19	conj
22	,	,	,	_	19	punct
23	or	or	CC	_	19	cc
24	drugs	drug	NNS	_	19	conj
25	known	know	VBN	_	24	acl
26	to	to	TO	_	27	mark
27	prolong	prolong	VB	_	25	xcomp
28	the	the	DT	_	30	det
29	QTc	qtc	NN	_	30	compound
30	interval	interval	NN	_	27	dobj
31	because	because	IN	_	42	mark
32	the	the	DT	_	33	det
33	action	action	NN	_	42	nsubjpass
34	of	of	IN	_	35	case
35	drug5	drug5	NN	_	33	nmod
36	on	on	IN	_	39	case
37	the	the	DT	_	39	det
38	cardiovascular	cardiovascular	JJ	_	39	amod
39	system	system	NN	_	33	nmod
40	may	may	MD	_	42	aux
41	be	be	VB	_	42	auxpass
42	potentiated	potentiate	VBN	_	10	advcl
43	by	by	IN	_	45	case
44	these	these	DT	_	45	det
45	agents	agent	NNS	_	42	nmod
46	.	.	.	_	10	punct

1	Drugs	drug	NNS	_	10	nsubj
2	that	that	WDT	_	4	nsubjpass
3	are	be	VBP	_	4	auxpass
4	known	know	VBN	_	1	acl:relcl
5	to	to	TO	_	6	mark
6	prolong	prolong	VB	_	4	xcomp
7	the	the	DT	_	9	det
8	QTc	qtc	NN	_	9	compound
9	interval	interval	NN	_	6	dobj
10	have	have	VBP	_	0	ROOT
11	an	a	DT	_	13	det
12	increased	increase	VBN	_	13	amod
13	risk	risk	NN	_	10	dobj
14	of	of	IN	_	16	case
15	ventricular	ventricular	JJ	_	16	amod
16	arrhythmias	arrhythmia	NNS	_	13	nmod
17	.	.	.	_	10	punct

1	The	the	DT	_	3	det
2	concurrent	concurrent	JJ	_	3	amod
3	use	use	NN	_	25	nsubjpass
4	of	of	IN	_	9	case
5	intravenously	intravenously	RB	_	8	advmod
6	or	or	CC	_	5	cc
7	orally	orally	RB	_	5	conj
8	administered	administer	VBN	_	9	amod
9	drug1	drug1	NN	_	3	nmod
10	-LRB-	-lrb-	-LRB-	_	13	punct
11	e.g.	e.g.	FW	_	13	dep
12	,	,	,	_	13	punct
13	drug2	drug2	NN	_	9	dep
14	,	,	,	_	13	punct
15	drug3	drug3	NN	_	13	appos
16	-RRB-	-rrb-	-RRB-	_	13	punct
17	by	by	IN	_	18	case
18	patients	patient	NNS	_	3	nmod
19	receiving	receive	VBG	_	18	acl
20	drug4	drug4	NN	_	19	dobj
21	has	have	VBZ	_	25	aux
22	not	not	RB	_	25	neg
23	been	be	VBN	_	25	auxpass
24	completely	completely	RB	_	25	advmod
25	evaluated	evaluate	VBN	_	0	ROOT
26	.	.	.	_	25	punct

1	In	in	IN	_	5	case
2	two	two	CD	_	5	nummod
3	combined	combined	JJ	_	5	amod
4	12-week	12-week	JJ	_	5	amod
5	placebo	placebo	NN	_	0	ROOT
6	controlled	control	VBN	_	7	amod
7	trials	trial	NNS	_	5	dep
8	that	that	WDT	_	9	nsubj
9	included	include	VBD	_	7	acl:relcl
10	drug1	drug1	NN	_	11	compound
11	doses	dose	NNS	_	9	dobj
12	of	of	IN	_	14	case
13	15	15	CD	_	14	nummod
14	mcg	mcg	NN	_	11	nmod
15	twice	twice	RB	_	16	advmod
16	daily	daily	RB	_	9	advmod
17	,	,	,	_	7	punct
18	25	25	CD	_	19	nummod
19	mcg	mcg	NN	_	7	conj
20	twice	twice	RB	_	21	advmod
21	daily	daily	RB	_	19	advmod
22	,	,	,	_	7	punct
23	and	and	CC	_	7	cc
24	50	50	CD	_	25	nummod
25	mcg	mcg	NN	_	7	conj
26	once	once	RB	_	27	advmod
27	daily	daily	RB	_	7	advmod
28	,	,	,	_	7	punct
29	54	54	CD	_	31	compound
30	of	of	IN	_	31	advmod
31	873	873	CD	_	32	nummod
32	drug2	drug2	NN	_	7	appos
33	-	-	:	_	32	punct
34	treated	treated	JJ	_	35	amod
35	subjects	subject	NNS	_	36	nsubj
36	received	receive	VBD	_	32	dep
37	concomitant	concomitant	JJ	_	38	amod
38	drug3	drug3	NN	_	36	dobj
39	at	at	IN	_	41	case
40	study	study	NN	_	41	compound
41	entry	entry	NN	_	36	nmod
42	.	.	.	_	5	punct

1	In	in	IN	_	5	case
2	a	a	DT	_	5	det
3	12-month	12-month	JJ	_	5	amod
4	controlled	controlled	JJ	_	5	amod
5	trial	trial	NN	_	0	ROOT
6	that	that	WDT	_	7	nsubj
7	included	include	VBD	_	5	acl:relcl
8	a	a	DT	_	10	det
9	50	50	CD	_	10	nummod
10	mcg	mcg	NN	_	7	dobj
11	once	once	RB	_	14	advmod
12	daily	daily	JJ	_	14	amod
13	drug1	drug1	NN	_	14	compound
14	dose	dose	NN	_	10	dep
15	,	,	,	_	14	punct
16	30	30	CD	_	14	appos
17	of	of	IN	_	20	case
18	the	the	DT	_	20	det
19	528	528	CD	_	20	nummod
20	drug2	drug2	NN	_	16	nmod
21	-	-	:	_	14	punct
22	treated	treated	JJ	_	23	amod
23	subjects	subject	NNS	_	24	nsubj
24	received	receive	VBD	_	14	dep
25	concomitant	concomitant	JJ	_	26	amod
26	drug3	drug3	NN	_	24	dobj
27	at	at	IN	_	29	case
28	study	study	NN	_	29	compound
29	entry	entry	NN	_	24	nmod
30	.	.	.	_	5	punct

1	In	in	IN	_	3	case
2	these	these	DT	_	3	det
3	trials	trial	NNS	_	14	nmod
4	,	,	,	_	14	punct
5	heart	heart	NN	_	6	compound
6	rate	rate	NN	_	14	nsubj
7	and	and	CC	_	6	cc
8	systolic	systolic	JJ	_	10	amod
9	blood	blood	NN	_	10	compound
10	pressure	pressure	NN	_	6	conj
11	were	be	VBD	_	14	cop
12	approximately	approximately	RB	_	13	advmod
13	2-3	2-3	CD	_	14	nummod
14	bpm	bpm	NN	_	0	ROOT
15	and	and	CC	_	14	cc
16	6-8	6-8	CD	_	18	nummod
17	mm	mm	NN	_	18	compound
18	Hg	hg	NN	_	14	conj
19	higher	higher	JJR	_	14	advmod
20	,	,	,	_	19	punct
21	respectively	respectively	RB	_	19	advmod
22	,	,	,	_	19	punct
23	in	in	IN	_	24	case
24	subjects	subject	NNS	_	19	nmod
25	on	on	IN	_	27	case
26	concomitant	concomitant	JJ	_	27	amod
27	drug1	drug1	NN	_	24	nmod
28	compared	compare	VBN	_	32	case
29	with	with	IN	_	32	case
30	the	the	DT	_	32	det
31	overall	overall	JJ	_	32	amod
32	population	population	NN	_	24	nmod
33	.	.	.	_	14	punct

1	drug1	drug1	NN	_	8	nsubj
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	drug2	drug2	NN	_	1	appos
4	-RRB-	-rrb-	-RRB-	_	3	punct
5	and	and	CC	_	1	cc
6	drug3	drug3	NN	_	1	conj
7	may	may	MD	_	8	aux
8	interfere	interfere	VB	_	0	ROOT
9	with	with	IN	_	11	case
10	the	the	DT	_	11	det
11	effect	effect	NN	_	8	nmod
12	of	of	IN	_	14	case
13	each	each	DT	_	14	det
14	other	other	JJ	_	11	nmod
15	when	when	WRB	_	16	advmod
16	administered	administer	VBN	_	8	advcl
17	concurrently	concurrently	RB	_	16	advmod
18	.	.	.	_	8	punct

1	drug1	drug1	NN	_	4	nsubj
2	not	not	RB	_	3	neg
3	only	only	RB	_	4	cc:preconj
4	block	block	VB	_	0	ROOT
5	the	the	DT	_	7	det
6	therapeutic	therapeutic	JJ	_	7	amod
7	effects	effect	NNS	_	4	dobj
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	,	,	,	_	4	punct
11	but	but	CC	_	4	cc
12	may	may	MD	_	13	aux
13	produce	produce	VB	_	4	conj
14	severe	severe	JJ	_	15	amod
15	bronchospasm	bronchospasm	NN	_	13	dobj
16	in	in	IN	_	18	case
17	COPD	copd	NN	_	18	compound
18	patients	patient	NNS	_	13	nmod
19	.	.	.	_	4	punct

1	Therefore	therefore	RB	_	10	advmod
2	,	,	,	_	10	punct
3	patients	patient	NNS	_	10	nsubjpass
4	with	with	IN	_	5	case
5	COPD	copd	NN	_	3	nmod
6	should	should	MD	_	10	aux
7	not	not	RB	_	10	neg
8	normally	normally	RB	_	10	advmod
9	be	be	VB	_	10	auxpass
10	treated	treat	VBN	_	0	ROOT
11	with	with	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	.	.	.	_	10	punct

1	However	however	RB	_	20	advmod
2	,	,	,	_	20	punct
3	under	under	IN	_	5	case
4	certain	certain	JJ	_	5	amod
5	circumstances	circumstance	NNS	_	20	nmod
6	,	,	,	_	20	punct
7	e.g.	e.g.	FW	_	20	advmod
8	,	,	,	_	20	punct
9	as	as	IN	_	10	case
10	prophylaxis	prophylaxis	NN	_	20	nmod
11	after	after	IN	_	13	case
12	myocardial	myocardial	JJ	_	13	amod
13	infarction	infarction	NN	_	10	nmod
14	,	,	,	_	20	punct
15	there	there	EX	_	20	expl
16	may	may	MD	_	20	aux
17	be	be	VB	_	20	cop
18	no	no	DT	_	20	neg
19	acceptable	acceptable	JJ	_	20	amod
20	alternatives	alternative	NNS	_	0	ROOT
21	to	to	TO	_	23	case
22	the	the	DT	_	23	det
23	use	use	NN	_	20	nmod
24	of	of	IN	_	25	case
25	drug1	drug1	NN	_	23	nmod
26	in	in	IN	_	27	case
27	patients	patient	NNS	_	23	nmod
28	with	with	IN	_	29	case
29	COPD	copd	NN	_	27	nmod
30	.	.	.	_	20	punct

1	In	in	IN	_	3	case
2	this	this	DT	_	3	det
3	setting	setting	NN	_	8	nmod
4	,	,	,	_	8	punct
5	drug1	drug1	NN	_	8	nsubjpass
6	could	could	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	considered	consider	VBN	_	0	ROOT
9	,	,	,	_	8	punct
10	although	although	IN	_	14	mark
11	they	they	PRP	_	14	nsubjpass
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	administered	administer	VBN	_	8	advcl
15	with	with	IN	_	16	case
16	caution	caution	NN	_	14	nmod
17	.	.	.	_	8	punct

1	Reduced	reduce	VBN	_	2	amod
2	efficacy	efficacy	NN	_	14	nsubjpass
3	and	and	CC	_	2	cc
4	increased	increase	VBD	_	5	amod
5	incidence	incidence	NN	_	2	conj
6	of	of	IN	_	8	case
7	breakthrough	breakthrough	NN	_	8	compound
8	bleeding	bleeding	NN	_	5	nmod
9	and	and	CC	_	8	cc
10	menstrual	menstrual	JJ	_	11	amod
11	irregularities	irregularity	NNS	_	8	conj
12	have	have	VBP	_	14	aux
13	been	be	VBN	_	14	auxpass
14	associated	associate	VBN	_	0	ROOT
15	with	with	IN	_	17	case
16	concomitant	concomitant	JJ	_	17	amod
17	use	use	NN	_	14	nmod
18	of	of	IN	_	19	case
19	drug1	drug1	NN	_	17	nmod
20	.	.	.	_	14	punct

1	A	a	DT	_	3	det
2	similar	similar	JJ	_	3	amod
3	association	association	NN	_	11	nsubjpass
4	,	,	,	_	11	punct
5	though	though	IN	_	7	mark
6	less	less	JJR	_	7	advmod
7	marked	marked	JJ	_	11	dep
8	,	,	,	_	11	punct
9	has	have	VBZ	_	11	aux
10	been	be	VBN	_	11	auxpass
11	suggested	suggest	VBN	_	0	ROOT
12	with	with	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	,	,	,	_	13	punct
15	phenyl-butazone	phenyl-butazone	NN	_	13	conj
16	,	,	,	_	13	punct
17	drug2	drug2	NN	_	13	conj
18	,	,	,	_	13	punct
19	drug3	drug3	NN	_	13	conj
20	and	and	CC	_	13	cc
21	possibly	possibly	RB	_	23	advmod
22	with	with	IN	_	23	case
23	drug4	drug4	NN	_	13	conj
24	,	,	,	_	23	punct
25	drug5	drug5	NN	_	23	conj
26	,	,	,	_	23	punct
27	and	and	CC	_	23	cc
28	drug6	drug6	NN	_	23	conj
29	-LRB-	-lrb-	-LRB-	_	30	punct
30	72	72	CD	_	28	appos
31	-RRB-	-rrb-	-RRB-	_	30	punct

1	.	.	.	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	increase	increase	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	action	action	NN	_	3	dobj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	,	,	,	_	7	punct
9	drug3	drug3	NN	_	7	conj
10	,	,	,	_	7	punct
11	drug4	drug4	NN	_	7	conj
12	,	,	,	_	7	punct
13	and	and	CC	_	7	cc
14	drug5	drug5	NN	_	7	conj
15	.	.	.	_	3	punct

1	It	it	PRP	_	3	nsubj
2	may	may	MD	_	3	aux
3	increase	increase	VB	_	0	ROOT
4	excretion	excretion	NN	_	3	dobj
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	,	,	,	_	6	punct
8	drug2	drug2	NN	_	6	conj
9	,	,	,	_	6	punct
10	and	and	CC	_	6	cc
11	drug3	drug3	NN	_	6	conj
12	and	and	CC	_	3	cc
13	may	may	MD	_	15	aux
14	also	also	RB	_	15	advmod
15	increase	increase	VB	_	3	conj
16	the	the	DT	_	17	det
17	toxicity	toxicity	NN	_	15	dobj
18	of	of	IN	_	19	case
19	drug4	drug4	NN	_	17	nmod
20	.	.	.	_	3	punct

1	Coadministration	coadministration	NN	_	13	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	6	case
5	other	other	JJ	_	6	amod
6	drug2	drug2	NN	_	1	nmod
7	,	,	,	_	6	punct
8	drug3	drug3	NN	_	6	conj
9	,	,	,	_	6	punct
10	and	and	CC	_	6	cc
11	drug4	drug4	NN	_	6	conj
12	may	may	MD	_	13	aux
13	cause	cause	VB	_	0	ROOT
14	hypokalemia	hypokalemia	NN	_	13	dobj
15	.	.	.	_	13	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	administered	administer	VBN	_	0	ROOT
5	with	with	IN	_	6	case
6	caution	caution	NN	_	4	nmod
7	to	to	TO	_	8	case
8	patients	patient	NNS	_	4	nmod
9	taking	take	VBG	_	8	acl
10	drug2	drug2	NN	_	9	dobj
11	,	,	,	_	4	punct
12	because	because	IN	_	15	case
13	of	of	IN	_	12	mwe
14	the	the	DT	_	15	det
15	possibility	possibility	NN	_	4	nmod
16	of	of	IN	_	18	case
17	conduction	conduction	NN	_	18	compound
18	disturbances	disturbance	NNS	_	15	nmod
19	.	.	.	_	4	punct

1	Drugs	drug	NNS	_	11	nsubjpass
2	with	with	IN	_	4	case
3	parasympathomimetic	parasympathomimetic	JJ	_	4	amod
4	effects	effect	NNS	_	1	nmod
5	administered	administer	VBN	_	4	acl
6	concurrently	concurrently	RB	_	5	advmod
7	with	with	IN	_	8	case
8	drug1	drug1	NN	_	5	nmod
9	can	can	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	expected	expect	VBN	_	0	ROOT
12	to	to	TO	_	13	mark
13	have	have	VB	_	11	xcomp
14	additive	additive	JJ	_	15	amod
15	effects	effect	NNS	_	13	dobj
16	.	.	.	_	11	punct

1	drug1	drug1	NN	_	3	nsubj
2	might	might	MD	_	3	aux
3	interfere	interfere	VB	_	0	ROOT
4	with	with	IN	_	7	case
5	desirable	desirable	JJ	_	7	amod
6	antimuscarinic	antimuscarinic	JJ	_	7	amod
7	effects	effect	NNS	_	3	nmod
8	of	of	IN	_	9	case
9	drugs	drug	NNS	_	7	nmod
10	used	use	VBN	_	9	acl
11	concomitantly	concomitantly	RB	_	10	advmod
12	.	.	.	_	3	punct

1	Drugs	drug	NNS	_	8	nsubj
2	which	which	WDT	_	3	nsubj
3	inhibit	inhibit	VBP	_	1	acl:relcl
4	CYP2D6	cyp2d6	NN	_	3	dobj
5	and	and	CC	_	4	cc
6	CYP3A3/4	cyp3a3/4	NN	_	4	conj
7	also	also	RB	_	8	advmod
8	inhibit	inhibit	VBP	_	0	ROOT
9	the	the	DT	_	10	det
10	metabolism	metabolism	NN	_	8	dobj
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	.	.	.	_	8	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	with	with	IN	_	6	case
6	caution	caution	NN	_	4	nmod
7	in	in	IN	_	8	case
8	individuals	individual	NNS	_	6	nmod
9	known	know	VBN	_	8	acl
10	or	or	CC	_	9	cc
11	suspected	suspect	VBN	_	9	conj
12	to	to	TO	_	14	mark
13	be	be	VB	_	14	cop
14	deficient	deficient	JJ	_	9	xcomp
15	in	in	IN	_	17	case
16	CYP2D6	cyp2d6	NN	_	17	compound
17	activity	activity	NN	_	14	nmod
18	,	,	,	_	4	punct
19	based	base	VBN	_	22	case
20	on	on	IN	_	22	case
21	previous	previous	JJ	_	22	amod
22	experience	experience	NN	_	4	advcl
23	,	,	,	_	4	punct
24	as	as	IN	_	31	mark
25	they	they	PRP	_	31	nsubj
26	may	may	MD	_	31	aux
27	be	be	VB	_	31	cop
28	at	at	IN	_	31	case
29	a	a	DT	_	31	det
30	higher	higher	JJR	_	31	amod
31	risk	risk	NN	_	4	advcl
32	of	of	IN	_	34	case
33	adverse	adverse	JJ	_	34	amod
34	events	event	NNS	_	31	nmod
35	.	.	.	_	4	punct

1	In	in	IN	_	5	case
2	an	a	DT	_	5	det
3	in	in	FW	_	5	amod
4	vitro	vitro	FW	_	3	dep
5	study	study	NN	_	26	nmod
6	,	,	,	_	26	punct
7	cytochrome	cytochrome	NN	_	10	compound
8	P450	p450	NN	_	10	compound
9	isozymes	isozyme	NNS	_	10	compound
10	1A2	1a2	NN	_	26	nsubjpass
11	,	,	,	_	10	punct
12	2A6	2a6	NN	_	10	conj
13	,	,	,	_	10	punct
14	2C9	2c9	NN	_	10	conj
15	,	,	,	_	10	punct
16	2C19	2c19	NN	_	10	conj
17	,	,	,	_	10	punct
18	2D6	2d6	NN	_	10	conj
19	,	,	,	_	10	punct
20	2E1	2e1	NN	_	10	conj
21	,	,	,	_	10	punct
22	and	and	CC	_	10	cc
23	3A4	3a4	NN	_	10	conj
24	were	be	VBD	_	26	auxpass
25	not	not	RB	_	26	neg
26	inhibited	inhibit	VBN	_	0	ROOT
27	by	by	IN	_	28	case
28	exposure	exposure	NN	_	26	nmod
29	to	to	TO	_	30	case
30	drug1	drug1	NN	_	28	nmod
31	.	.	.	_	26	punct

1	In	in	IN	_	5	case
2	a	a	DT	_	5	det
3	Phase	phase	NN	_	5	compound
4	I	I	PRP	_	5	compound
5	trial	trial	NN	_	31	nmod
6	using	use	VBG	_	5	acl
7	escalating	escalate	VBG	_	6	advcl
8	doses	dose	NNS	_	7	dobj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	-LRB-	-lrb-	-LRB-	_	13	punct
12	110-200	110-200	CD	_	13	nummod
13	mg/m2	mg/m2	NN	_	10	appos
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	and	and	CC	_	10	cc
16	drug2	drug2	NN	_	10	conj
17	-LRB-	-lrb-	-LRB-	_	21	punct
18	50	50	CD	_	21	nummod
19	or	or	CC	_	18	cc
20	75	75	CD	_	18	conj
21	mg/m2	mg/m2	NN	_	16	appos
22	-RRB-	-rrb-	-RRB-	_	21	punct
23	given	give	VBN	_	8	acl
24	as	as	IN	_	26	case
25	sequential	sequential	JJ	_	26	amod
26	infusions	infusion	NNS	_	23	nmod
27	,	,	,	_	31	punct
28	myelosuppression	myelosuppression	NN	_	31	nsubj
29	was	be	VBD	_	31	cop
30	more	more	RBR	_	31	advmod
31	profound	profound	JJ	_	0	ROOT
32	when	when	WRB	_	35	advmod
33	drug3	drug3	NN	_	35	nsubjpass
34	was	be	VBD	_	35	auxpass
35	given	give	VBN	_	31	advcl
36	after	after	IN	_	37	case
37	drug4	drug4	NN	_	35	nmod
38	than	than	IN	_	42	case
39	with	with	IN	_	42	case
40	the	the	DT	_	42	det
41	alternate	alternate	JJ	_	42	amod
42	sequence	sequence	NN	_	35	nmod
43	-LRB-	-lrb-	-LRB-	_	46	punct
44	ie	ie	FW	_	46	advmod
45	,	,	,	_	46	punct
46	drug5	drug5	NN	_	42	dep
47	before	before	IN	_	48	case
48	drug6	drug6	NN	_	46	nmod
49	-RRB-	-rrb-	-RRB-	_	46	punct
50	.	.	.	_	31	punct

1	Pharmacokinetic	pharmacokinetic	JJ	_	2	amod
2	data	datum	NNS	_	6	nsubj
3	from	from	IN	_	5	case
4	these	these	DT	_	5	det
5	patients	patient	NNS	_	2	nmod
6	demonstrated	demonstrate	VBD	_	0	ROOT
7	a	a	DT	_	8	det
8	decrease	decrease	NN	_	6	dobj
9	in	in	IN	_	11	case
10	drug1	drug1	NN	_	11	compound
11	clearance	clearance	NN	_	8	nmod
12	of	of	IN	_	15	case
13	approximately	approximately	RB	_	14	advmod
14	33	33	CD	_	15	nummod
15	%	%	NN	_	11	nmod
16	when	when	WRB	_	19	advmod
17	drug2	drug2	NN	_	19	nsubjpass
18	was	be	VBD	_	19	auxpass
19	administered	administer	VBN	_	6	advcl
20	following	follow	VBG	_	21	case
21	drug3	drug3	NN	_	19	nmod
22	.	.	.	_	6	punct

1	The	the	DT	_	2	det
2	metabolism	metabolism	NN	_	6	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	is	be	VBZ	_	6	auxpass
6	catalyzed	catalyze	VBN	_	0	ROOT
7	by	by	IN	_	11	case
8	cytochrome	cytochrome	NN	_	11	compound
9	P450	p450	NN	_	11	compound
10	isoen-zymes	isoen-zyme	NNS	_	11	compound
11	CYP2C8	cyp2c8	NN	_	6	nmod
12	and	and	CC	_	11	cc
13	CYP3A4	cyp3a4	NN	_	11	conj
14	.	.	.	_	6	punct

1	In	in	IN	_	9	case
2	the	the	DT	_	9	dep
3	absence	absence	NN	_	9	dep
4	of	of	IN	_	9	case
5	formal	formal	JJ	_	9	amod
6	clinical	clinical	JJ	_	9	amod
7	drug	drug	NN	_	9	compound
8	interaction	interaction	NN	_	9	compound
9	studies	study	NNS	_	14	nmod
10	,	,	,	_	14	punct
11	caution	caution	NN	_	14	nsubjpass
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	exercised	exercise	VBN	_	0	ROOT
15	when	when	WRB	_	16	advmod
16	administering	administer	VBG	_	14	advcl
17	drug1	drug1	NN	_	16	dobj
18	concomitantly	concomitantly	RB	_	17	advmod
19	with	with	IN	_	21	case
20	known	known	JJ	_	21	amod
21	substrates	substrate	NNS	_	17	nmod
22	or	or	CC	_	21	cc
23	inhibitors	inhibitor	NNS	_	21	conj
24	of	of	IN	_	28	case
25	the	the	DT	_	28	det
26	cytochrome	cytochrome	NN	_	28	compound
27	P450	p450	NN	_	28	compound
28	isoenzymes	isoenzyme	NNS	_	23	nmod
29	CYP2C8	cyp2c8	NN	_	28	dep
30	and	and	CC	_	29	cc
31	CYP3A4	cyp3a4	NN	_	29	conj
32	.	.	.	_	14	punct

1	Potential	potential	JJ	_	2	amod
2	interactions	interaction	NNS	_	35	nsubjpass
3	between	between	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	,	,	,	_	4	punct
6	a	a	DT	_	7	det
7	substrate	substrate	NN	_	4	appos
8	of	of	IN	_	9	case
9	CYP3A4	cyp3a4	NN	_	7	nmod
10	,	,	,	_	4	punct
11	and	and	CC	_	4	cc
12	drug2	drug2	NN	_	4	conj
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	drug3	drug3	NN	_	12	dep
15	,	,	,	_	14	punct
16	drug4	drug4	NN	_	14	conj
17	,	,	,	_	14	punct
18	drug5	drug5	NN	_	14	conj
19	,	,	,	_	14	punct
20	and	and	CC	_	14	cc
21	drug6	drug6	NN	_	14	conj
22	-RRB-	-rrb-	-RRB-	_	14	punct
23	,	,	,	_	2	punct
24	which	which	WDT	_	26	nsubj
25	are	be	VBP	_	26	cop
26	substrates	substrate	NNS	_	2	acl:relcl
27	and/or	and/or	CC	_	26	cc
28	inhibitors	inhibitor	NNS	_	26	conj
29	of	of	IN	_	30	case
30	CYP3A4	cyp3a4	NN	_	26	nmod
31	,	,	,	_	2	punct
32	have	have	VBP	_	35	aux
33	not	not	RB	_	35	neg
34	been	be	VBN	_	35	auxpass
35	evaluated	evaluate	VBN	_	0	ROOT
36	in	in	IN	_	38	case
37	clinical	clinical	JJ	_	38	amod
38	trials	trial	NNS	_	35	nmod
39	.	.	.	_	35	punct

1	Reports	report	NNS	_	5	nsubj
2	in	in	IN	_	4	case
3	the	the	DT	_	4	det
4	literature	literature	NN	_	1	nmod
5	suggest	suggest	VBP	_	0	ROOT
6	that	that	IN	_	20	mark
7	plasma	plasma	NN	_	8	compound
8	levels	level	NNS	_	20	nsubjpass
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	-LRB-	-lrb-	-LRB-	_	10	punct
12	and	and	CC	_	10	cc
13	its	its	PRP$	_	16	nmod:poss
14	active	active	JJ	_	16	amod
15	metabolite	metabolite	NN	_	16	compound
16	drug2	drug2	NN	_	10	conj
17	-RRB-	-rrb-	-RRB-	_	10	punct
18	may	may	MD	_	20	aux
19	be	be	VB	_	20	auxpass
20	increased	increase	VBN	_	5	ccomp
21	when	when	WRB	_	26	advmod
22	drug3	drug3	NN	_	26	nsubjpass
23	and	and	CC	_	22	cc
24	drug4	drug4	NN	_	22	conj
25	are	be	VBP	_	26	auxpass
26	used	use	VBN	_	20	advcl
27	in	in	IN	_	28	case
28	combination	combination	NN	_	26	nmod
29	.	.	.	_	5	punct

1	Hematology	Hematology	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	drug1	drug1	NN	_	4	compound
4	therapy	therapy	NN	_	8	nsubjpass
5	should	should	MD	_	8	aux
6	not	not	RB	_	8	neg
7	be	be	VB	_	8	auxpass
8	administered	administer	VBN	_	1	appos
9	to	to	TO	_	10	case
10	patients	patient	NNS	_	8	nmod
11	with	with	IN	_	14	case
12	baseline	baseline	NN	_	14	compound
13	neutrophil	neutrophil	NN	_	14	compound
14	counts	count	NNS	_	10	nmod
15	of	of	IN	_	19	case
16	less	less	JJR	_	18	advmod
17	than	than	IN	_	16	mwe
18	1,500	1,500	CD	_	19	nummod
19	cells/mm3	cells/mm3	NNS	_	14	nmod
20	.	.	.	_	1	punct

1	In	in	IN	_	4	mark
2	order	order	NN	_	1	mwe
3	to	to	TO	_	4	mark
4	monitor	monitor	VB	_	12	advcl
5	the	the	DT	_	6	det
6	occurrence	occurrence	NN	_	4	dobj
7	of	of	IN	_	8	case
8	myelotoxicity	myelotoxicity	NN	_	6	nmod
9	,	,	,	_	12	punct
10	it	it	PRP	_	12	nsubjpass
11	is	be	VBZ	_	12	auxpass
12	recommended	recommend	VBN	_	0	ROOT
13	that	that	IN	_	20	mark
14	frequent	frequent	JJ	_	18	amod
15	peripheral	peripheral	JJ	_	18	amod
16	blood	blood	NN	_	18	compound
17	cell	cell	NN	_	18	compound
18	counts	count	NNS	_	20	nsubjpass
19	be	be	VB	_	20	auxpass
20	performed	perform	VBN	_	12	ccomp
21	on	on	IN	_	23	case
22	all	all	DT	_	23	det
23	patients	patient	NNS	_	20	nmod
24	receiving	receive	VBG	_	23	acl
25	drug1	drug1	NN	_	24	dobj
26	.	.	.	_	12	punct

1	Patients	patient	NNS	_	5	nsubj
2	should	should	MD	_	5	aux
3	not	not	RB	_	5	neg
4	be	be	VB	_	5	cop
5	re-treated	re-treated	JJ	_	0	ROOT
6	with	with	IN	_	8	case
7	subsequent	subsequent	JJ	_	8	amod
8	cycles	cycle	NNS	_	5	nmod
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	until	until	IN	_	13	mark
12	neutrophils	neutrophil	NNS	_	13	nsubj
13	recover	recover	VBP	_	5	advcl
14	to	to	TO	_	18	case
15	a	a	DT	_	18	det
16	level	level	NN	_	18	compound
17	1500	1500	CD	_	18	nummod
18	cells/mm3	cells/mm3	NNS	_	13	nmod
19	and	and	CC	_	18	cc
20	platelets	platelet	NNS	_	18	conj
21	recover	recover	VBP	_	13	dep
22	to	to	TO	_	26	case
23	a	a	DT	_	26	det
24	level	level	NN	_	26	compound
25	100,000	100,000	CD	_	26	nummod
26	cells/mm3	cells/mm3	NNS	_	21	nmod
27	.	.	.	_	5	punct

1	In	in	IN	_	3	case
2	the	the	DT	_	3	det
3	case	case	NN	_	35	nmod
4	of	of	IN	_	6	case
5	severe	severe	JJ	_	6	amod
6	neutropenia	neutropenia	NN	_	3	nmod
7	-LRB-	-lrb-	-LRB-	_	9	punct
8	500	500	CD	_	9	nummod
9	cells/mm3	cells/mm3	NN	_	6	dep
10	for	for	IN	_	12	case
11	seven	seven	CD	_	12	nummod
12	days	day	NNS	_	9	nmod
13	or	or	CC	_	14	cc
14	more	more	JJR	_	12	nummod
15	-RRB-	-rrb-	-RRB-	_	9	punct
16	during	during	IN	_	18	case
17	a	a	DT	_	18	det
18	course	course	NN	_	3	nmod
19	of	of	IN	_	21	case
20	drug1	drug1	NN	_	21	compound
21	therapy	therapy	NN	_	18	nmod
22	,	,	,	_	35	punct
23	a	a	DT	_	26	det
24	20	20	CD	_	25	compound
25	%	%	NN	_	26	amod
26	reduction	reduction	NN	_	35	nsubjpass
27	in	in	IN	_	28	case
28	dose	dose	NN	_	26	nmod
29	for	for	IN	_	31	case
30	subsequent	subsequent	JJ	_	31	amod
31	courses	course	NNS	_	26	nmod
32	of	of	IN	_	33	case
33	therapy	therapy	NN	_	31	nmod
34	is	be	VBZ	_	35	auxpass
35	recommended	recommend	VBN	_	0	ROOT
36	.	.	.	_	35	punct

1	For	for	IN	_	2	case
2	patients	patient	NNS	_	26	nmod
3	with	with	IN	_	6	case
4	advanced	advanced	JJ	_	6	amod
5	HIV	hiv	NN	_	6	compound
6	disease	disease	NN	_	2	nmod
7	and	and	CC	_	6	cc
8	poor-risk	poor-risk	JJ	_	12	amod
9	AIDS-related	aids-related	JJ	_	12	amod
10	Kaposi	kaposi	NN	_	12	compound
11	s	s	NNS	_	12	compound
12	sarcoma	sarcoma	NN	_	6	conj
13	,	,	,	_	26	punct
14	drug1	drug1	NN	_	26	nsubjpass
15	,	,	,	_	26	punct
16	at	at	IN	_	19	case
17	the	the	DT	_	19	det
18	recommended	recommend	VBN	_	19	amod
19	dose	dose	NN	_	26	nmod
20	for	for	IN	_	22	case
21	this	this	DT	_	22	det
22	disease	disease	NN	_	19	nmod
23	,	,	,	_	26	punct
24	can	can	MD	_	26	aux
25	be	be	VB	_	26	auxpass
26	initiated	initiate	VBN	_	0	ROOT
27	and	and	CC	_	26	cc
28	repeated	repeat	VBN	_	26	conj
29	if	if	IN	_	37	mark
30	the	the	DT	_	32	det
31	neutrophil	neutrophil	NN	_	32	compound
32	count	count	NN	_	37	nsubj
33	is	be	VBZ	_	37	cop
34	at	at	IN	_	35	case
35	least	least	JJS	_	36	nmod:npmod
36	1000	1000	CD	_	37	nummod
37	cells/mm3	cells/mm3	NNS	_	26	advcl
38	.	.	.	_	26	punct

1	Hypersensitivity	hypersensitivity	NN	_	2	compound
2	Reactions	reaction	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	Patients	patient	NNS	_	33	nsubjpass
5	with	with	IN	_	7	case
6	a	a	DT	_	7	det
7	history	history	NN	_	4	nmod
8	of	of	IN	_	11	case
9	severe	severe	JJ	_	11	amod
10	hypersensitivity	hypersensitivity	NN	_	11	compound
11	reactions	reaction	NNS	_	7	nmod
12	to	to	TO	_	13	case
13	products	product	NNS	_	11	nmod
14	containing	contain	VBG	_	13	acl
15	Cremophor	Cremophor	NNP	_	16	compound
16	EL	EL	NNP	_	14	dobj
17	-LRB-	-lrb-	-LRB-	_	20	punct
18	eg	eg	FW	_	20	dep
19	,	,	,	_	20	punct
20	drug1	drug1	NN	_	16	dep
21	for	for	IN	_	23	case
22	injection	injection	NN	_	23	compound
23	concentrate	concentrate	NN	_	20	nmod
24	and	and	CC	_	23	cc
25	drug2	drug2	NN	_	23	conj
26	for	for	IN	_	28	case
27	injection	injection	NN	_	28	compound
28	concentrate	concentrate	NN	_	20	nmod
29	-RRB-	-rrb-	-RRB-	_	20	punct
30	should	should	MD	_	33	aux
31	not	not	RB	_	33	neg
32	be	be	VB	_	33	auxpass
33	treated	treat	VBN	_	2	dep
34	with	with	IN	_	35	case
35	drug3	drug3	NN	_	33	nmod
36	.	.	.	_	2	punct

1	In	in	IN	_	4	mark
2	order	order	NN	_	1	mwe
3	to	to	TO	_	4	mark
4	avoid	avoid	VB	_	19	advcl
5	the	the	DT	_	6	det
6	occurrence	occurrence	NN	_	4	dobj
7	of	of	IN	_	10	case
8	severe	severe	JJ	_	10	amod
9	hypersensitivity	hypersensitivity	NN	_	10	compound
10	reactions	reaction	NNS	_	6	nmod
11	,	,	,	_	19	punct
12	all	all	DT	_	13	det
13	patients	patient	NNS	_	19	nsubjpass
14	treated	treat	VBN	_	13	acl
15	with	with	IN	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	should	should	MD	_	19	aux
18	be	be	VB	_	19	auxpass
19	premedicated	premedicate	VBN	_	0	ROOT
20	with	with	IN	_	21	case
21	drug2	drug2	NN	_	19	nmod
22	-LRB-	-lrb-	-LRB-	_	25	punct
23	such	such	JJ	_	25	case
24	as	as	IN	_	23	mwe
25	drug3	drug3	NN	_	21	nmod
26	-RRB-	-rrb-	-RRB-	_	25	punct
27	,	,	,	_	21	punct
28	diphen-hydramine	diphen-hydramine	NN	_	21	conj
29	and	and	CC	_	21	cc
30	drug4	drug4	NN	_	21	conj
31	-LRB-	-lrb-	-LRB-	_	34	punct
32	such	such	JJ	_	34	case
33	as	as	IN	_	32	mwe
34	drug5	drug5	NN	_	30	nmod
35	or	or	CC	_	34	cc
36	drug6	drug6	NN	_	34	conj
37	-RRB-	-rrb-	-RRB-	_	34	punct
38	.	.	.	_	19	punct

1	Minor	minor	JJ	_	2	amod
2	symptoms	symptom	NNS	_	18	nsubj
3	such	such	JJ	_	5	case
4	as	as	IN	_	3	mwe
5	flushing	flushing	NN	_	2	nmod
6	,	,	,	_	5	punct
7	skin	skin	NN	_	8	compound
8	reactions	reaction	NNS	_	5	conj
9	,	,	,	_	5	punct
10	dyspnea	dyspnea	NN	_	5	conj
11	,	,	,	_	5	punct
12	hypotension	hypotension	NN	_	5	conj
13	,	,	,	_	5	punct
14	or	or	CC	_	5	cc
15	tachycardia	tachycardia	NN	_	5	conj
16	do	do	VBP	_	18	aux
17	not	not	RB	_	18	neg
18	require	require	VB	_	0	ROOT
19	interruption	interruption	NN	_	18	dobj
20	of	of	IN	_	21	case
21	therapy	therapy	NN	_	19	nmod
22	.	.	.	_	18	punct

1	However	however	RB	_	21	advmod
2	,	,	,	_	21	punct
3	severe	severe	JJ	_	4	amod
4	reactions	reaction	NNS	_	21	nsubj
5	,	,	,	_	4	punct
6	such	such	JJ	_	8	case
7	as	as	IN	_	6	mwe
8	hypotension	hypotension	NN	_	4	nmod
9	requiring	require	VBG	_	8	acl
10	treatment	treatment	NN	_	9	dobj
11	,	,	,	_	4	punct
12	dyspnea	dyspnea	NN	_	4	appos
13	requiring	require	VBG	_	12	acl
14	drug1	drug1	NN	_	13	dobj
15	,	,	,	_	14	punct
16	angioedema	angioedema	NN	_	14	conj
17	,	,	,	_	14	punct
18	or	or	CC	_	14	cc
19	generalized	generalize	VBN	_	20	amod
20	urticaria	urticaria	NN	_	14	conj
21	require	require	VBP	_	0	ROOT
22	immediate	immediate	JJ	_	23	amod
23	discontinuation	discontinuation	NN	_	21	dobj
24	of	of	IN	_	25	case
25	drug2	drug2	NN	_	23	nmod
26	and	and	CC	_	25	cc
27	aggressive	aggressive	JJ	_	29	amod
28	symptomatic	symptomatic	JJ	_	29	amod
29	therapy	therapy	NN	_	25	conj
30	.	.	.	_	21	punct

1	Patients	patient	NNS	_	11	nsubjpass
2	who	who	WP	_	4	nsubj
3	have	have	VBP	_	4	aux
4	developed	develop	VBN	_	1	acl:relcl
5	severe	severe	JJ	_	7	amod
6	hypersensitivity	hypersensitivity	NN	_	7	compound
7	reactions	reaction	NNS	_	4	dobj
8	should	should	MD	_	11	aux
9	not	not	RB	_	11	neg
10	be	be	VB	_	11	auxpass
11	rechallenged	rechallenge	VBN	_	0	ROOT
12	with	with	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	.	.	.	_	11	punct

1	Cardiovascular	Cardiovascular	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	Hypotension	hypotension	NN	_	11	nsubjpass
4	,	,	,	_	3	punct
5	bradycardia	bradycardia	NN	_	3	conj
6	,	,	,	_	3	punct
7	and	and	CC	_	3	cc
8	hypertension	hypertension	NN	_	3	conj
9	have	have	VBP	_	11	aux
10	been	be	VBN	_	11	auxpass
11	observed	observe	VBN	_	1	dep
12	during	during	IN	_	13	case
13	administration	administration	NN	_	11	nmod
14	of	of	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	,	,	,	_	11	punct
17	but	but	CC	_	11	cc
18	generally	generally	RB	_	21	advmod
19	do	do	VBP	_	21	aux
20	not	not	RB	_	21	neg
21	require	require	VB	_	11	conj
22	treatment	treatment	NN	_	21	dobj
23	.	.	.	_	1	punct

1	Occasionally	occasionally	RB	_	6	advmod
2	drug1	drug1	NN	_	3	compound
3	infusions	infusion	NNS	_	6	nsubjpass
4	must	must	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	interrupted	interrupted	JJ	_	0	ROOT
7	or	or	CC	_	6	cc
8	discontinued	discontinue	VBN	_	6	conj
9	because	because	IN	_	14	case
10	of	of	IN	_	9	mwe
11	initial	initial	JJ	_	14	amod
12	or	or	CC	_	11	cc
13	recurrent	recurrent	JJ	_	11	conj
14	hypertension	hypertension	NN	_	6	nmod
15	.	.	.	_	6	punct

1	Frequent	frequent	JJ	_	3	amod
2	vital	vital	JJ	_	3	amod
3	sign	sign	NN	_	16	nsubjpass
4	monitoring	monitoring	NN	_	3	dep
5	,	,	,	_	3	punct
6	particularly	particularly	RB	_	10	advmod
7	during	during	IN	_	10	case
8	the	the	DT	_	10	det
9	first	first	JJ	_	10	amod
10	hour	hour	NN	_	3	nmod
11	of	of	IN	_	13	case
12	drug1	drug1	NN	_	13	compound
13	infusion	infusion	NN	_	10	nmod
14	,	,	,	_	3	punct
15	is	be	VBZ	_	16	auxpass
16	recommended	recommend	VBN	_	0	ROOT
17	.	.	.	_	16	punct

1	Continuous	continuous	JJ	_	3	amod
2	cardiac	cardiac	JJ	_	3	amod
3	monitoring	monitoring	NN	_	6	nsubjpass
4	is	be	VBZ	_	6	auxpass
5	not	not	RB	_	6	neg
6	required	require	VBN	_	0	ROOT
7	except	except	IN	_	9	case
8	for	for	IN	_	9	case
9	patients	patient	NNS	_	6	nmod
10	with	with	IN	_	13	case
11	serious	serious	JJ	_	13	amod
12	conduction	conduction	NN	_	13	compound
13	abnormalities	abnormality	NNS	_	9	nmod
14	.	.	.	_	6	punct

1	Nervous	nervous	JJ	_	2	amod
2	System	system	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	Although	although	IN	_	11	mark
5	the	the	DT	_	6	det
6	occurrence	occurrence	NN	_	11	nsubj
7	of	of	IN	_	9	case
8	peripheral	peripheral	JJ	_	9	amod
9	neuropathy	neuropathy	NN	_	6	nmod
10	is	be	VBZ	_	11	cop
11	frequent	frequent	JJ	_	19	advcl
12	,	,	,	_	19	punct
13	the	the	DT	_	14	det
14	development	development	NN	_	19	nsubj
15	of	of	IN	_	17	case
16	severe	severe	JJ	_	17	amod
17	symptomatology	symptomatology	NN	_	14	nmod
18	is	be	VBZ	_	19	cop
19	unusual	unusual	JJ	_	2	dep
20	and	and	CC	_	19	cc
21	requires	require	VBZ	_	19	conj
22	a	a	DT	_	24	det
23	dose	dose	NN	_	24	compound
24	reduction	reduction	NN	_	21	dobj
25	of	of	IN	_	27	case
26	20	20	CD	_	27	nummod
27	%	%	NN	_	24	nmod
28	for	for	IN	_	30	case
29	all	all	DT	_	30	det
30	subsequentcourses	subsequentcourse	NNS	_	24	nmod
31	of	of	IN	_	32	case
32	drug1	drug1	NN	_	30	nmod
33	.	.	.	_	2	punct

1	drug1	drug1	NN	_	2	nsubj
2	contains	contain	VBZ	_	0	ROOT
3	dehydrated	dehydrated	JJ	_	5	amod
4	alcohol	alcohol	NN	_	5	compound
5	USP	usp	NN	_	2	dobj
6	,	,	,	_	5	punct
7	396	396	CD	_	8	nummod
8	mg/mL	mg/ml	NN	_	5	appos
9	;	;	:	_	2	punct

1	consideration	consideration	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	given	give	VBN	_	0	ROOT
5	to	to	TO	_	7	case
6	possible	possible	JJ	_	7	amod
7	CNS	cns	NN	_	4	nmod
8	and	and	CC	_	7	cc
9	other	other	JJ	_	10	amod
10	effects	effect	NNS	_	7	conj
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	.	.	.	_	4	punct

1	Hepatic	hepatic	JJ	_	0	ROOT
2	:	:	:	_	1	punct
3	There	there	EX	_	4	expl
4	is	be	VBZ	_	1	parataxis
5	limited	limited	JJ	_	6	amod
6	evidence	evidence	NN	_	4	nsubj
7	that	that	IN	_	14	mark
8	the	the	DT	_	9	det
9	myelotoxicity	myelotoxicity	NN	_	14	nsubjpass
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	may	may	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	exacerbated	exacerbate	VBN	_	6	ccomp
15	in	in	IN	_	16	case
16	patients	patient	NNS	_	14	nmod
17	with	with	IN	_	20	case
18	serum	serum	NN	_	20	compound
19	total	total	JJ	_	20	amod
20	bilirubin	bilirubin	NN	_	16	nmod
21	2	2	CD	_	22	compound
22	times	time	NNS	_	23	nummod
23	ULN	ULN	NNP	_	20	dep
24	.	.	.	_	1	punct

1	Extreme	extreme	JJ	_	2	amod
2	caution	caution	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	exercised	exercise	VBN	_	0	ROOT
6	when	when	WRB	_	7	advmod
7	administering	administer	VBG	_	5	advcl
8	drug1	drug1	NN	_	7	dobj
9	to	to	TO	_	11	case
10	such	such	JJ	_	11	amod
11	patients	patient	NNS	_	7	nmod
12	,	,	,	_	5	punct
13	with	with	IN	_	15	case
14	dose	dose	NN	_	15	compound
15	reduction	reduction	NN	_	5	nmod
16	as	as	IN	_	17	mark
17	recommended	recommend	VBN	_	15	dep
18	in	in	IN	_	19	case
19	DOSAGE	DOSAGE	NNP	_	17	nmod
20	AND	and	CC	_	19	cc
21	ADMINISTRATION	ADMINISTRATION	NNP	_	19	conj
22	,	,	,	_	19	punct
23	Table	Table	NNP	_	19	appos
24	17	17	CD	_	23	nummod
25	.	.	.	_	5	punct

1	InjectionSite	InjectionSite	NNP	_	2	compound
2	Reaction	Reaction	NNP	_	0	ROOT
3	:	:	:	_	2	punct
4	Injection	injection	NN	_	6	compound
5	site	site	NN	_	6	compound
6	reactions	reaction	NNS	_	16	nsubj
7	,	,	,	_	6	punct
8	including	include	VBG	_	9	case
9	reactions	reaction	NNS	_	6	nmod
10	secondary	secondary	JJ	_	9	amod
11	to	to	TO	_	12	case
12	extravasation	extravasation	NN	_	10	nmod
13	,	,	,	_	6	punct
14	were	be	VBD	_	16	cop
15	usually	usually	RB	_	16	advmod
16	mild	mild	JJ	_	2	dep
17	and	and	CC	_	16	cc
18	consisted	consist	VBD	_	16	conj
19	of	of	IN	_	20	case
20	erythema	erythema	NN	_	18	nmod
21	,	,	,	_	20	punct
22	tenderness	tenderness	NN	_	20	conj
23	,	,	,	_	20	punct
24	skin	skin	NN	_	25	compound
25	discoloration	discoloration	NN	_	20	conj
26	,	,	,	_	20	punct
27	or	or	CC	_	20	cc
28	swelling	swell	VBG	_	20	conj
29	at	at	IN	_	32	case
30	the	the	DT	_	32	det
31	injection	injection	NN	_	32	compound
32	site	site	NN	_	28	nmod
33	.	.	.	_	2	punct

1	These	these	DT	_	2	det
2	reactions	reaction	NNS	_	5	nsubjpass
3	have	have	VBP	_	5	aux
4	been	be	VBN	_	5	auxpass
5	observed	observe	VBN	_	0	ROOT
6	more	more	RBR	_	7	advmod
7	frequently	frequently	RB	_	5	advmod
8	with	with	IN	_	11	case
9	the	the	DT	_	11	det
10	24-hour	24-hour	JJ	_	11	amod
11	infusion	infusion	NN	_	5	nmod
12	than	than	IN	_	16	case
13	with	with	IN	_	16	case
14	the	the	DT	_	16	det
15	3-hour	3-hour	JJ	_	16	amod
16	infusion	infusion	NN	_	5	nmod
17	.	.	.	_	5	punct

1	Recurrence	recurrence	NN	_	26	nsubjpass
2	of	of	IN	_	4	case
3	skin	skin	NN	_	4	compound
4	reactions	reaction	NNS	_	1	nmod
5	at	at	IN	_	7	case
6	a	a	DT	_	7	det
7	site	site	NN	_	1	nmod
8	of	of	IN	_	10	case
9	previous	previous	JJ	_	10	amod
10	extravasation	extravasation	NN	_	7	nmod
11	following	follow	VBG	_	12	case
12	administration	administration	NN	_	1	nmod
13	of	of	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	at	at	IN	_	18	case
16	a	a	DT	_	18	det
17	different	different	JJ	_	18	amod
18	site	site	NN	_	12	nmod
19	,	,	,	_	1	punct
20	ie	ie	FW	_	22	dep
21	,	,	,	_	22	punct
22	recall	recall	NN	_	1	appos
23	,	,	,	_	1	punct
24	has	have	VBZ	_	26	aux
25	been	be	VBN	_	26	auxpass
26	reported	report	VBN	_	0	ROOT
27	rarely	rarely	RB	_	26	advmod
28	.	.	.	_	26	punct

1	Rare	rare	JJ	_	2	amod
2	reports	report	NNS	_	24	nsubjpass
3	of	of	IN	_	6	case
4	more	more	RBR	_	5	advmod
5	severe	severe	JJ	_	6	amod
6	events	event	NNS	_	2	nmod
7	such	such	JJ	_	9	case
8	as	as	IN	_	7	mwe
9	phlebitis	phlebitis	NN	_	6	nmod
10	,	,	,	_	9	punct
11	cellulitis	cellulitis	NN	_	9	conj
12	,	,	,	_	9	punct
13	induration	induration	NN	_	9	conj
14	,	,	,	_	9	punct
15	skin	skin	NN	_	16	compound
16	exfoliation	exfoliation	NN	_	9	conj
17	,	,	,	_	9	punct
18	necrosis	necrosis	NN	_	9	conj
19	,	,	,	_	9	punct
20	and	and	CC	_	9	cc
21	fibrosis	fibrosis	NN	_	9	conj
22	have	have	VBP	_	24	aux
23	been	be	VBN	_	24	auxpass
24	received	receive	VBN	_	0	ROOT
25	as	as	IN	_	26	case
26	part	part	NN	_	24	nmod
27	of	of	IN	_	30	case
28	the	the	DT	_	30	det
29	continuing	continue	VBG	_	30	amod
30	surveillance	surveillance	NN	_	26	nmod
31	of	of	IN	_	33	case
32	drug1	drug1	NN	_	33	compound
33	safety	safety	NN	_	30	nmod
34	.	.	.	_	24	punct

1	In	in	IN	_	3	case
2	some	some	DT	_	3	det
3	cases	case	NNS	_	12	nmod
4	the	the	DT	_	5	det
5	onset	onset	NN	_	12	nsubj
6	of	of	IN	_	10	case
7	the	the	DT	_	10	det
8	injection	injection	NN	_	10	compound
9	site	site	NN	_	10	compound
10	reaction	reaction	NN	_	5	nmod
11	either	either	CC	_	12	dep
12	occurred	occur	VBD	_	0	ROOT
13	during	during	IN	_	16	case
14	a	a	DT	_	16	det
15	prolonged	prolonged	JJ	_	16	amod
16	infusion	infusion	NN	_	12	nmod
17	or	or	CC	_	12	cc
18	was	be	VBD	_	19	auxpass
19	delayed	delay	VBN	_	12	conj
20	by	by	IN	_	22	case
21	a	a	DT	_	22	det
22	week	week	NN	_	19	nmod
23	to	to	TO	_	25	case
24	ten	ten	CD	_	25	nummod
25	days	day	NNS	_	19	nmod
26	.	.	.	_	12	punct

1	A	a	DT	_	3	det
2	specific	specific	JJ	_	3	amod
3	treatment	treatment	NN	_	8	nsubj
4	for	for	IN	_	6	case
5	extravasation	extravasation	NN	_	6	compound
6	reactions	reaction	NNS	_	3	nmod
7	is	be	VBZ	_	8	cop
8	unknown	unknown	JJ	_	0	ROOT
9	at	at	IN	_	11	case
10	this	this	DT	_	11	det
11	time	time	NN	_	8	nmod
12	.	.	.	_	8	punct

1	Given	give	VBN	_	3	case
2	the	the	DT	_	3	det
3	possibility	possibility	NN	_	9	nmod
4	of	of	IN	_	5	case
5	extravasation	extravasation	NN	_	3	nmod
6	,	,	,	_	9	punct
7	it	it	PRP	_	9	nsubj
8	is	be	VBZ	_	9	cop
9	advisable	advisable	JJ	_	0	ROOT
10	to	to	TO	_	12	mark
11	closely	closely	RB	_	12	advmod
12	monitor	monitor	VB	_	9	xcomp
13	the	the	DT	_	15	det
14	infusion	infusion	NN	_	15	compound
15	site	site	NN	_	12	dobj
16	for	for	IN	_	18	case
17	possible	possible	JJ	_	18	amod
18	infiltration	infiltration	NN	_	15	nmod
19	during	during	IN	_	21	case
20	drug	drug	NN	_	21	compound
21	administration	administration	NN	_	18	nmod
22	.	.	.	_	9	punct

1	drug1	drug1	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	metabolized	metabolize	VBN	_	0	ROOT
4	by	by	IN	_	5	case
5	CYP2C9	cyp2c9	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	CYP3A4	cyp3a4	NN	_	5	conj
8	.	.	.	_	3	punct

1	Inhibition	inhibition	NN	_	6	nsubj
2	of	of	IN	_	4	case
3	these	these	DT	_	4	det
4	isoenzymes	isoenzyme	NNS	_	1	nmod
5	may	may	MD	_	6	aux
6	increase	increase	VB	_	0	ROOT
7	the	the	DT	_	9	det
8	plasma	plasma	NN	_	9	compound
9	concentration	concentration	NN	_	6	dobj
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	.	.	.	_	6	punct

1	drug1	drug1	NN	_	4	nsubj
2	is	be	VBZ	_	4	cop
3	an	a	DT	_	4	det
4	inducer	inducer	NN	_	0	ROOT
5	of	of	IN	_	6	case
6	CYP3A4	cyp3a4	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	CYP2C9	cyp2c9	NN	_	6	conj
9	.	.	.	_	4	punct

1	Consequently	consequently	RB	_	14	advmod
2	,	,	,	_	14	punct
3	plasma	plasma	NN	_	4	compound
4	concentrations	concentration	NNS	_	14	nsubjpass
5	of	of	IN	_	6	case
6	drugs	drug	NNS	_	4	nmod
7	metabolized	metabolize	VBN	_	6	acl
8	by	by	IN	_	11	case
9	these	these	DT	_	11	det
10	two	two	CD	_	11	nummod
11	isoenzymes	isoenzyme	NNS	_	7	nmod
12	will	will	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	decreased	decrease	VBN	_	0	ROOT
15	when	when	WRB	_	18	advmod
16	drug1	drug1	NN	_	18	nsubj
17	is	be	VBZ	_	18	cop
18	co-administered	co-administered	JJ	_	14	advcl
19	.	.	.	_	14	punct

1	drug1	drug1	NN	_	2	nsubj
2	had	have	VBD	_	0	ROOT
3	no	no	DT	_	6	neg
4	relevant	relevant	JJ	_	6	amod
5	inhibitory	inhibitory	JJ	_	6	amod
6	effect	effect	NN	_	2	dobj
7	on	on	IN	_	10	case
8	any	any	DT	_	10	det
9	CYP	cyp	NN	_	10	compound
10	isoenzymes	isoenzyme	NNS	_	2	nmod
11	tested	test	VBN	_	10	acl
12	-LRB-	-lrb-	-LRB-	_	13	punct
13	CYP1A2	cyp1a2	NN	_	2	dep
14	,	,	,	_	13	punct
15	CYP2C9	cyp2c9	NN	_	13	conj
16	,	,	,	_	13	punct
17	CYP2C19	cyp2c19	NN	_	13	conj
18	,	,	,	_	13	punct
19	CYP2D6	cyp2d6	NN	_	13	conj
20	,	,	,	_	13	punct
21	CYP3A4	cyp3a4	NN	_	13	appos
22	-RRB-	-rrb-	-RRB-	_	13	punct
23	.	.	.	_	2	punct

1	Consequently	consequently	RB	_	6	advmod
2	,	,	,	_	6	punct
3	drug1	drug1	NN	_	6	nsubjpass
4	is	be	VBZ	_	6	auxpass
5	not	not	RB	_	6	neg
6	expected	expect	VBN	_	0	ROOT
7	to	to	TO	_	8	mark
8	increase	increase	VB	_	6	xcomp
9	the	the	DT	_	11	det
10	plasma	plasma	NN	_	11	compound
11	concentrations	concentration	NNS	_	8	dobj
12	of	of	IN	_	13	case
13	drugs	drug	NNS	_	11	nmod
14	metabolized	metabolize	VBN	_	13	acl
15	by	by	IN	_	17	case
16	these	these	DT	_	17	det
17	enzymes	enzyme	NNS	_	14	nmod
18	.	.	.	_	6	punct

1	drug1	drug1	NN	_	17	nsubj
2	,	,	,	_	17	punct
3	Including	include	VBG	_	12	case
4	Oral	oral	JJ	_	12	amod
5	,	,	,	_	4	punct
6	Injectable	injectable	JJ	_	4	conj
7	,	,	,	_	4	punct
8	Transdermal	transdermal	JJ	_	4	conj
9	,	,	,	_	4	punct
10	and	and	CC	_	4	cc
11	Implantable	implantable	JJ	_	4	conj
12	drug2	drug2	NN	_	17	nmod
13	:	:	:	_	17	punct
14	An	a	DT	_	16	det
15	interaction	interaction	NN	_	16	compound
16	study	study	NN	_	17	nsubj
17	demonstrated	demonstrate	VBD	_	0	ROOT
18	that	that	IN	_	17	dobj
19	co-administration	co-administration	NN	_	18	root
20	of	of	IN	_	21	case
21	drug3	drug3	NN	_	19	nmod
22	and	and	CC	_	21	cc
23	the	the	DT	_	26	det
24	oral	oral	JJ	_	26	amod
25	drug4	drug4	NN	_	26	compound
26	drug5	drug5	NN	_	21	conj
27	produced	produce	VBN	_	29	amod
28	average	average	JJ	_	29	amod
29	decreases	decrease	NNS	_	26	dep
30	of	of	IN	_	31	case
31	drug6	drug6	NN	_	29	nmod
32	and	and	CC	_	31	cc
33	drug7	drug7	NN	_	31	conj
34	levels	level	NNS	_	31	dep
35	of	of	IN	_	37	case
36	14	14	CD	_	37	nummod
37	%	%	NN	_	31	nmod
38	and	and	CC	_	37	cc
39	31	31	CD	_	40	nummod
40	%	%	NN	_	37	conj
41	,	,	,	_	29	punct
42	respectively	respectively	RB	_	29	advmod
43	.	.	.	_	19	punct

1	However	however	RB	_	3	advmod
2	,	,	,	_	3	punct
3	decreases	decrease	VBZ	_	0	ROOT
4	in	in	IN	_	5	case
5	exposure	exposure	NN	_	3	nmod
6	were	be	VBD	_	11	cop
7	as	as	RB	_	10	advmod
8	much	much	JJ	_	10	advmod
9	as	as	IN	_	10	advmod
10	56	56	CD	_	11	nummod
11	%	%	NN	_	3	ccomp
12	and	and	CC	_	11	cc
13	66	66	CD	_	14	nummod
14	%	%	NN	_	11	conj
15	,	,	,	_	11	punct
16	respectively	respectively	RB	_	11	advmod
17	,	,	,	_	11	punct
18	in	in	IN	_	20	case
19	individual	individual	JJ	_	20	amod
20	subjects	subject	NNS	_	11	nmod
21	.	.	.	_	3	punct

1	Therefore	therefore	RB	_	19	advmod
2	,	,	,	_	19	punct
3	drug1	drug1	NN	_	19	nsubj
4	,	,	,	_	3	punct
5	including	include	VBG	_	14	case
6	oral	oral	JJ	_	14	amod
7	,	,	,	_	6	punct
8	injectable	injectable	JJ	_	6	conj
9	,	,	,	_	6	punct
10	transdermal	transdermal	JJ	_	6	conj
11	,	,	,	_	6	punct
12	and	and	CC	_	6	cc
13	implantable	implantable	JJ	_	6	conj
14	forms	form	NNS	_	3	nmod
15	,	,	,	_	3	punct
16	may	may	MD	_	19	aux
17	not	not	RB	_	19	neg
18	be	be	VB	_	19	cop
19	reliable	reliable	JJ	_	0	ROOT
20	when	when	WRB	_	23	advmod
21	drug2	drug2	NN	_	23	nsubj
22	is	be	VBZ	_	23	cop
23	co-administered	co-administered	JJ	_	19	advcl
24	.	.	.	_	19	punct

1	Women	woman	NNS	_	3	nsubj
2	should	should	MD	_	3	aux
3	practice	practice	VB	_	0	ROOT
4	additional	additional	JJ	_	5	amod
5	methods	method	NNS	_	3	dobj
6	of	of	IN	_	7	case
7	contraception	contraception	NN	_	5	nmod
8	and	and	CC	_	3	cc
9	not	not	RB	_	10	neg
10	rely	rely	VB	_	3	conj
11	on	on	IN	_	13	case
12	hormonal	hormonal	JJ	_	13	amod
13	contraception	contraception	NN	_	10	nmod
14	alone	alone	RB	_	13	advmod
15	when	when	WRB	_	16	advmod
16	taking	take	VBG	_	10	advcl
17	drug1	drug1	NN	_	16	dobj
18	.	.	.	_	3	punct

1	Specific	specific	JJ	_	3	amod
2	interaction	interaction	NN	_	3	compound
3	studies	study	NNS	_	5	nsubj
4	have	have	VBP	_	5	aux
5	demonstrated	demonstrate	VBN	_	0	ROOT
6	the	the	DT	_	7	det
7	following	following	NN	_	5	dobj
8	:	:	:	_	7	punct
9	drug1	drug1	NN	_	7	dep
10	:	:	:	_	9	punct
11	During	during	IN	_	14	case
12	the	the	DT	_	14	det
13	first	first	JJ	_	14	amod
14	day	day	NN	_	24	nmod
15	of	of	IN	_	17	case
16	concomitant	concomitant	JJ	_	17	amod
17	administration	administration	NN	_	14	nmod
18	,	,	,	_	24	punct
19	trough	trough	NN	_	20	compound
20	concentrations	concentration	NNS	_	24	nsubjpass
21	of	of	IN	_	22	case
22	drug2	drug2	NN	_	20	nmod
23	were	be	VBD	_	24	auxpass
24	increased	increase	VBN	_	9	dep
25	by	by	IN	_	27	case
26	about	about	IN	_	27	advmod
27	30-fold	30-fold	RB	_	24	nmod
28	.	.	.	_	5	punct

1	Steady-state	steady-state	JJ	_	4	amod
2	drug1	drug1	NN	_	4	compound
3	plasma	plasma	NN	_	4	compound
4	concentrations	concentration	NNS	_	6	nsubj
5	were	be	VBD	_	6	cop
6	3	3	LS	_	0	ROOT
7	-	-	:	_	6	punct
8	to	to	TO	_	10	case
9	4-fold	4-fold	RB	_	10	advmod
10	higher	higher	JJR	_	6	nmod
11	than	than	IN	_	14	case
12	in	in	IN	_	14	case
13	the	the	DT	_	14	det
14	absence	absence	NN	_	10	nmod
15	of	of	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	.	.	.	_	6	punct

1	The	the	DT	_	3	det
2	concomitant	concomitant	JJ	_	3	amod
3	administration	administration	NN	_	9	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	is	be	VBZ	_	9	auxpass
9	contraindicated	contraindicate	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	Co-administration	co-administration	NN	_	4	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	decreased	decrease	VBD	_	0	ROOT
5	the	the	DT	_	7	det
6	plasma	plasma	NN	_	7	compound
7	concentrations	concentration	NNS	_	4	dobj
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	-LRB-	-lrb-	-LRB-	_	13	punct
11	a	a	DT	_	13	det
12	CYP3A4	cyp3a4	NN	_	13	compound
13	substrate	substrate	NN	_	9	appos
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	by	by	IN	_	18	case
16	approximately	approximately	RB	_	17	advmod
17	50	50	CD	_	18	nummod
18	%	%	NN	_	4	nmod
19	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Co-administration	co-administration	NN	_	11	nsubjpass
4	of	of	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug3	drug3	NN	_	5	conj
8	has	have	VBZ	_	11	aux
9	not	not	RB	_	11	neg
10	been	be	VBN	_	11	auxpass
11	studied	study	VBN	_	1	appos
12	in	in	IN	_	13	case
13	man	man	NN	_	11	nmod
14	.	.	.	_	1	punct

1	Co-administration	co-administration	NN	_	6	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	drug2	drug2	NN	_	3	conj
6	resulted	result	VBD	_	0	ROOT
7	in	in	IN	_	11	case
8	markedly	markedly	RB	_	9	advmod
9	increased	increase	VBN	_	11	amod
10	plasma	plasma	NN	_	11	compound
11	concentrations	concentration	NNS	_	6	nmod
12	of	of	IN	_	13	case
13	drug3	drug3	NN	_	11	nmod
14	in	in	IN	_	15	case
15	animals	animal	NNS	_	13	nmod
16	.	.	.	_	6	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	exercised	exercise	VBN	_	0	ROOT
5	if	if	IN	_	10	mark
6	drug1	drug1	NN	_	10	nsubjpass
7	and	and	CC	_	6	cc
8	drug2	drug2	NN	_	6	conj
9	are	be	VBP	_	10	auxpass
10	used	use	VBN	_	4	advcl
11	together	together	RB	_	10	advmod
12	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	An	a	DT	_	5	det
4	increased	increase	VBN	_	5	amod
5	risk	risk	NN	_	11	nsubjpass
6	of	of	IN	_	9	case
7	elevated	elevated	JJ	_	9	amod
8	liver	liver	NN	_	9	compound
9	aminotransferases	aminotransferase	NNS	_	5	nmod
10	was	be	VBD	_	11	auxpass
11	observed	observe	VBN	_	1	appos
12	in	in	IN	_	13	case
13	patients	patient	NNS	_	11	nmod
14	receiving	receive	VBG	_	13	acl
15	concomitant	concomitant	JJ	_	16	amod
16	therapy	therapy	NN	_	14	dobj
17	with	with	IN	_	18	case
18	drug2	drug2	NN	_	14	nmod
19	.	.	.	_	1	punct

1	Therefore	therefore	RB	_	11	advmod
2	,	,	,	_	11	punct
3	the	the	DT	_	5	det
4	concomitant	concomitant	JJ	_	5	amod
5	administration	administration	NN	_	11	nsubjpass
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	is	be	VBZ	_	11	auxpass
11	contraindicated	contraindicate	VBN	_	0	ROOT
12	,	,	,	_	11	punct
13	and	and	CC	_	11	cc
14	alternative	alternative	JJ	_	15	amod
15	drug3	drug3	NN	_	18	nsubjpass
16	should	should	MD	_	18	aux
17	be	be	VB	_	18	auxpass
18	considered	consider	VBN	_	11	conj
19	.	.	.	_	11	punct

1	Co-administration	co-administration	NN	_	4	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	decreased	decrease	VBD	_	0	ROOT
5	the	the	DT	_	7	det
6	plasma	plasma	NN	_	7	compound
7	concentrations	concentration	NNS	_	4	dobj
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	by	by	IN	_	13	case
11	approximately	approximately	RB	_	12	advmod
12	40	40	CD	_	13	nummod
13	%	%	NN	_	4	nmod
14	.	.	.	_	4	punct

1	The	the	DT	_	3	det
2	plasma	plasma	NN	_	3	compound
3	concentrations	concentration	NNS	_	8	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	were	be	VBD	_	8	auxpass
7	also	also	RB	_	8	advmod
8	decreased	decrease	VBN	_	0	ROOT
9	by	by	IN	_	12	case
10	approximately	approximately	RB	_	11	advmod
11	30	30	CD	_	12	nummod
12	%	%	NN	_	8	nmod
13	.	.	.	_	8	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	also	also	RB	_	4	advmod
4	expected	expect	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	reduce	reduce	VB	_	4	xcomp
7	plasma	plasma	NN	_	8	compound
8	concentrations	concentration	NNS	_	6	dobj
9	of	of	IN	_	12	case
10	other	other	JJ	_	12	amod
11	oral	oral	JJ	_	12	amod
12	drug2	drug2	NN	_	8	nmod
13	that	that	WDT	_	16	nsubjpass
14	are	be	VBP	_	16	auxpass
15	predominantly	predominantly	RB	_	16	advmod
16	metabolized	metabolize	VBN	_	12	acl:relcl
17	by	by	IN	_	18	case
18	CYP2C9	cyp2c9	NN	_	16	nmod
19	or	or	CC	_	18	cc
20	CYP3A4	cyp3a4	NN	_	18	conj
21	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	possibility	possibility	NN	_	14	nsubjpass
3	of	of	IN	_	6	case
4	worsened	worsen	VBN	_	6	amod
5	glucose	glucose	NN	_	6	compound
6	control	control	NN	_	2	nmod
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	using	use	VBG	_	8	acl
10	these	these	DT	_	11	det
11	agents	agent	NNS	_	9	dobj
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	considered	consider	VBN	_	0	ROOT
15	.	.	.	_	14	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Co-administration	co-administration	NN	_	17	nsubj
4	of	of	IN	_	7	case
5	drug2	drug2	NN	_	7	compound
6	125	125	CD	_	7	compound
7	mg	mg	NN	_	3	nmod
8	b.i.d.	b.i.d.	NN	_	7	dep
9	and	and	CC	_	8	cc
10	drug3	drug3	NN	_	8	conj
11	,	,	,	_	7	punct
12	a	a	DT	_	15	det
13	potent	potent	JJ	_	15	amod
14	CYP3A4	cyp3a4	NN	_	15	compound
15	inhibitor	inhibitor	NN	_	7	appos
16	,	,	,	_	7	punct
17	increased	increase	VBD	_	1	dep
18	the	the	DT	_	20	det
19	plasma	plasma	NN	_	20	compound
20	concentrations	concentration	NNS	_	17	dobj
21	of	of	IN	_	22	case
22	drug4	drug4	NN	_	20	nmod
23	by	by	IN	_	25	case
24	approximately	approximately	RB	_	25	advmod
25	2-fold	2-fold	RB	_	17	nmod
26	.	.	.	_	1	punct

1	No	no	DT	_	3	neg
2	dose	dose	NN	_	3	compound
3	adjustment	adjustment	NN	_	7	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	is	be	VBZ	_	7	cop
7	necessary	necessary	JJ	_	0	ROOT
8	,	,	,	_	7	punct
9	but	but	CC	_	7	cc
10	increased	increase	VBD	_	11	amod
11	effects	effect	NNS	_	16	nsubjpass
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	should	should	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	considered	consider	VBN	_	7	conj
17	.	.	.	_	7	punct

1	drug1	drug1	NN	_	0	ROOT
2	and	and	CC	_	1	cc
3	Other	other	JJ	_	4	amod
4	drug2	drug2	NN	_	1	conj
5	:	:	:	_	1	punct
6	Co-administration	co-administration	NN	_	9	nsubj
7	of	of	IN	_	8	case
8	drug3	drug3	NN	_	6	nmod
9	decreased	decrease	VBD	_	1	dep
10	the	the	DT	_	12	det
11	plasma	plasma	NN	_	12	compound
12	concentrations	concentration	NNS	_	9	dobj
13	of	of	IN	_	14	case
14	drug4	drug4	NN	_	12	nmod
15	-LRB-	-lrb-	-LRB-	_	18	punct
16	a	a	DT	_	18	det
17	CYP3A4	cyp3a4	NN	_	18	compound
18	substrate	substrate	NN	_	14	appos
19	-RRB-	-rrb-	-RRB-	_	18	punct
20	,	,	,	_	9	punct
21	and	and	CC	_	9	cc
22	its	its	PRP$	_	27	nmod:poss
23	active	active	JJ	_	27	amod
24	-	-	:	_	27	punct
25	hydroxy	hydroxy	NN	_	27	compound
26	acid	acid	NN	_	27	compound
27	metabolite	metabolite	NN	_	9	conj
28	,	,	,	_	27	punct
29	by	by	IN	_	32	case
30	approximately	approximately	RB	_	31	advmod
31	50	50	CD	_	32	nummod
32	%	%	NN	_	27	nmod
33	.	.	.	_	1	punct

1	The	the	DT	_	3	det
2	plasma	plasma	NN	_	3	compound
3	concentrations	concentration	NNS	_	8	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	were	be	VBD	_	8	auxpass
7	not	not	RB	_	8	neg
8	affected	affect	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	also	also	RB	_	4	advmod
4	expected	expect	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	reduce	reduce	VB	_	4	xcomp
7	plasma	plasma	NN	_	8	compound
8	concentrations	concentration	NNS	_	6	dobj
9	of	of	IN	_	11	case
10	other	other	JJ	_	11	amod
11	drug2	drug2	NN	_	8	nmod
12	that	that	WDT	_	13	nsubj
13	have	have	VBP	_	11	acl:relcl
14	significant	significant	JJ	_	15	amod
15	metabolism	metabolism	NN	_	13	dobj
16	by	by	IN	_	17	case
17	CYP3A4	cyp3a4	NN	_	15	nmod
18	,	,	,	_	11	punct
19	such	such	JJ	_	21	case
20	as	as	IN	_	19	mwe
21	drug3	drug3	NN	_	11	nmod
22	and	and	CC	_	21	cc
23	drug4	drug4	NN	_	21	conj
24	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	possibility	possibility	NN	_	9	nsubjpass
3	of	of	IN	_	6	case
4	reduced	reduce	VBN	_	6	amod
5	drug1	drug1	NN	_	6	compound
6	efficacy	efficacy	NN	_	2	nmod
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	considered	consider	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	Patients	patient	NNS	_	7	nsubj
2	using	use	VBG	_	1	acl
3	CYP3A4	cyp3a4	NN	_	5	compound
4	metabolized	metabolize	VBN	_	5	amod
5	drug1	drug1	NN	_	2	dobj
6	should	should	MD	_	7	aux
7	have	have	VB	_	0	ROOT
8	cholesterol	cholesterol	NN	_	9	compound
9	levels	level	NNS	_	10	nsubj
10	monitored	monitor	VBD	_	7	ccomp
11	after	after	IN	_	14	mark
12	drug2	drug2	NN	_	14	nsubjpass
13	is	be	VBZ	_	14	auxpass
14	initiated	initiate	VBN	_	10	advcl
15	to	to	TO	_	16	mark
16	see	see	VB	_	14	xcomp
17	whether	whether	IN	_	21	mark
18	the	the	DT	_	20	det
19	drug3	drug3	NN	_	20	compound
20	dose	dose	NN	_	21	nsubj
21	needs	need	VBZ	_	16	ccomp
22	adjustment	adjustment	NN	_	21	dobj
23	.	.	.	_	7	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Co-administration	co-administration	NN	_	12	nsubj
4	of	of	IN	_	8	case
5	drug2	drug2	NN	_	8	compound
6	500	500	CD	_	7	compound
7	mg	mg	NN	_	8	amod
8	b.i.d.	b.i.d.	NN	_	3	nmod
9	for	for	IN	_	11	case
10	6	6	CD	_	11	nummod
11	days	day	NNS	_	3	nmod
12	decreased	decrease	VBD	_	1	appos
13	the	the	DT	_	15	det
14	plasma	plasma	NN	_	15	compound
15	concentrations	concentration	NNS	_	12	dobj
16	of	of	IN	_	18	case
17	both	both	DT	_	18	det
18	drug3	drug3	NN	_	15	nmod
19	-LRB-	-lrb-	-LRB-	_	22	punct
20	a	a	DT	_	22	det
21	CYP2C9	cyp2c9	NN	_	22	compound
22	substrate	substrate	NN	_	18	appos
23	-RRB-	-rrb-	-RRB-	_	22	punct
24	and	and	CC	_	18	cc
25	drug4	drug4	NN	_	18	conj
26	-LRB-	-lrb-	-LRB-	_	29	punct
27	a	a	DT	_	29	det
28	CYP3A4	cyp3a4	NN	_	29	compound
29	substrate	substrate	NN	_	25	appos
30	-RRB-	-rrb-	-RRB-	_	29	punct
31	by	by	IN	_	32	case
32	29	29	CD	_	12	nmod
33	and	and	CC	_	32	cc
34	38	38	CD	_	32	conj
35	%	%	NN	_	32	dep
36	,	,	,	_	12	punct
37	respectively	respectively	RB	_	12	advmod
38	.	.	.	_	1	punct

1	Clinical	clinical	JJ	_	2	amod
2	experience	experience	NN	_	18	nsubj
3	with	with	IN	_	5	case
4	concomitant	concomitant	JJ	_	5	amod
5	administration	administration	NN	_	2	nmod
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	in	in	IN	_	11	case
11	patients	patient	NNS	_	2	nmod
12	with	with	IN	_	15	case
13	pulmonary	pulmonary	JJ	_	15	amod
14	arterial	arterial	JJ	_	15	amod
15	hypertension	hypertension	NN	_	11	nmod
16	did	do	VBD	_	18	aux
17	not	not	RB	_	18	neg
18	show	show	VB	_	0	ROOT
19	clinically	clinically	RB	_	20	advmod
20	relevant	relevant	JJ	_	21	amod
21	changes	change	NNS	_	18	dobj
22	in	in	IN	_	23	case
23	INR	inr	NN	_	21	nmod
24	or	or	CC	_	23	cc
25	drug3	drug3	NN	_	26	compound
26	dose	dose	NN	_	23	conj
27	-LRB-	-lrb-	-LRB-	_	28	punct
28	baseline	baseline	NN	_	26	appos
29	vs.	vs.	CC	_	28	cc
30	end	end	NN	_	28	conj
31	of	of	IN	_	34	case
32	the	the	DT	_	34	det
33	clinical	clinical	JJ	_	34	amod
34	studies	study	NNS	_	28	nmod
35	-RRB-	-rrb-	-RRB-	_	28	punct
36	,	,	,	_	18	punct
37	and	and	CC	_	18	cc
38	the	the	DT	_	39	det
39	need	need	NN	_	59	nsubj
40	to	to	TO	_	41	mark
41	change	change	VB	_	39	acl
42	the	the	DT	_	44	det
43	drug4	drug4	NN	_	44	compound
44	dose	dose	NN	_	41	dobj
45	during	during	IN	_	47	case
46	the	the	DT	_	47	det
47	trials	trial	NNS	_	41	nmod
48	due	due	JJ	_	50	case
49	to	to	TO	_	48	mwe
50	changes	change	NNS	_	47	nmod
51	in	in	IN	_	52	case
52	INR	inr	NN	_	50	nmod
53	or	or	CC	_	52	cc
54	due	due	JJ	_	57	case
55	to	to	TO	_	54	mwe
56	adverse	adverse	JJ	_	57	amod
57	events	event	NNS	_	52	conj
58	was	be	VBD	_	59	cop
59	similar	similar	JJ	_	18	conj
60	among	among	IN	_	61	case
61	drug5	drug5	NN	_	59	nmod
62	-	-	:	_	59	punct
63	and	and	CC	_	59	cc
64	placebo-treated	placebo-treated	JJ	_	65	amod
65	patients	patient	NNS	_	59	conj
66	.	.	.	_	18	punct

1	drug1	drug1	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	and	and	CC	_	1	cc
5	drug3	drug3	NN	_	1	conj
6	:	:	:	_	1	punct
7	drug4	drug4	NN	_	8	nsubj
8	has	have	VBZ	_	1	dep
9	no	no	DT	_	12	neg
10	significant	significant	JJ	_	12	amod
11	pharmacokinetic	pharmacokinetic	JJ	_	12	amod
12	interactions	interaction	NNS	_	8	dobj
13	with	with	IN	_	14	case
14	drug5	drug5	NN	_	12	nmod
15	and	and	CC	_	14	cc
16	drug6	drug6	NN	_	14	conj
17	,	,	,	_	8	punct
18	and	and	CC	_	8	cc
19	drug7	drug7	NN	_	20	nsubj
20	has	have	VBZ	_	8	conj
21	no	no	DT	_	23	neg
22	significant	significant	JJ	_	23	amod
23	effect	effect	NN	_	20	dobj
24	on	on	IN	_	26	case
25	plasma	plasma	NN	_	26	compound
26	levels	level	NNS	_	20	nmod
27	of	of	IN	_	28	case
28	drug8	drug8	NN	_	26	nmod
29	.	.	.	_	1	punct

1	No	no	DT	_	3	neg
2	drug	drug	NN	_	3	compound
3	interactions	interaction	NNS	_	6	nsubjpass
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	auxpass
6	reported	report	VBN	_	0	ROOT
7	between	between	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	the	the	DT	_	12	det
11	therapy	therapy	NN	_	12	compound
12	standard	standard	NN	_	8	conj
13	in	in	IN	_	14	case
14	neonates	neonate	NNS	_	8	nmod
15	with	with	IN	_	17	case
16	restricted	restricted	JJ	_	17	amod
17	pulmonary	pulmonary	JJ	_	14	nmod
18	or	or	CC	_	17	cc
19	systemic	systemic	JJ	_	17	conj
20	blood	blood	NN	_	21	compound
21	flow	flow	NN	_	17	dep
22	.	.	.	_	6	punct

1	Standard	standard	JJ	_	2	amod
2	therapy	therapy	NN	_	3	nsubj
3	includes	include	VBZ	_	0	ROOT
4	drug1	drug1	NN	_	3	dobj
5	,	,	,	_	4	punct
6	such	such	JJ	_	8	case
7	as	as	IN	_	6	mwe
8	drug2	drug2	NN	_	4	nmod
9	and	and	CC	_	8	cc
10	drug3	drug3	NN	_	8	conj
11	;	;	:	_	3	punct

1	drug1	drug1	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	such	such	JJ	_	5	case
4	as	as	IN	_	3	mwe
5	drug2	drug2	NN	_	1	nmod
6	and	and	CC	_	5	cc
7	drug3	drug3	NN	_	5	conj
8	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	and	and	CC	_	0	ROOT
2	drug1	drug1	NN	_	1	dep
3	,	,	,	_	2	punct
4	such	such	JJ	_	6	case
5	as	as	IN	_	4	mwe
6	drug2	drug2	NN	_	2	nmod
7	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	potential	potential	NN	_	18	nsubjpass
5	for	for	IN	_	8	case
6	pharmacokinetic	pharmacokinetic	JJ	_	8	amod
7	drug-drug	drug-drug	NN	_	8	compound
8	interactions	interaction	NNS	_	4	nmod
9	between	between	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	other	other	JJ	_	13	amod
13	agents	agent	NNS	_	10	conj
14	has	have	VBZ	_	18	aux
15	not	not	RB	_	18	neg
16	been	be	VBN	_	18	auxpass
17	formally	formally	RB	_	18	advmod
18	studied	study	VBN	_	1	dep
19	.	.	.	_	18	punct

1	When	when	WRB	_	6	advmod
2	drug1	drug1	NN	_	6	nsubjpass
3	or	or	CC	_	2	cc
4	drug2	drug2	NN	_	2	conj
5	is	be	VBZ	_	6	auxpass
6	used	use	VBN	_	0	ROOT
7	at	at	IN	_	10	case
8	the	the	DT	_	10	det
9	same	same	JJ	_	10	amod
10	time	time	NN	_	6	nmod
11	as	as	IN	_	21	mark
12	other	other	JJ	_	13	amod
13	medicines	medicine	NNS	_	21	nsubjpass
14	or	or	CC	_	13	cc
15	substances	substance	NNS	_	13	conj
16	the	the	DT	_	18	det
17	following	following	JJ	_	18	amod
18	interactions	interaction	NNS	_	13	dep
19	must	must	MD	_	21	aux
20	be	be	VB	_	21	auxpass
21	taken	take	VBN	_	10	dep
22	into	into	IN	_	23	case
23	account	account	NN	_	21	nmod
24	:	:	:	_	6	punct
25	-	-	:	_	26	punct
26	drug3	drug3	NN	_	30	nsubj
27	and	and	CC	_	26	cc
28	drug4	drug4	NN	_	26	conj
29	may	may	MD	_	30	aux
30	enhance	enhance	VB	_	6	parataxis
31	the	the	DT	_	32	det
32	action	action	NN	_	30	dobj
33	of	of	IN	_	34	case
34	drug5	drug5	NN	_	32	nmod
35	.	.	.	_	6	punct

1	For	for	IN	_	3	case
2	this	this	DT	_	3	det
3	reason	reason	NN	_	12	nmod
4	,	,	,	_	12	punct
5	the	the	DT	_	6	det
6	dose	dose	NN	_	12	nsubjpass
7	of	of	IN	_	9	case
8	the	the	DT	_	9	det
9	drug1	drug1	NN	_	6	nmod
10	should	should	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	reduced	reduce	VBN	_	0	ROOT
13	by	by	IN	_	14	case
14	30	30	CD	_	12	nmod
15	-	-	:	_	14	punct
16	50	50	CD	_	17	nummod
17	%	%	NN	_	14	dep
18	at	at	IN	_	20	case
19	the	the	DT	_	20	det
20	start	start	NN	_	17	nmod
21	of	of	IN	_	22	case
22	treatment	treatment	NN	_	20	nmod
23	with	with	IN	_	24	case
24	drug2	drug2	NN	_	22	nmod
25	or	or	CC	_	24	cc
26	drug3	drug3	NN	_	24	conj
27	retard	retard	VBP	_	14	dep
28	and	and	CC	_	12	cc
29	then	then	RB	_	30	advmod
30	titrated	titrate	VBD	_	12	conj
31	according	accord	VBG	_	36	case
32	to	to	TO	_	31	mwe
33	the	the	DT	_	36	det
34	blood	blood	NN	_	36	compound
35	clotting	clotting	NN	_	36	compound
36	parameters	parameter	NNS	_	30	nmod

1	.	.	.	_	0	ROOT

1	-	-	:	_	10	punct
2	The	the	DT	_	3	det
3	action	action	NN	_	10	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	may	may	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	enhanced	enhance	VBN	_	0	ROOT
11	by	by	IN	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	or	or	CC	_	12	cc
14	drug4	drug4	NN	_	12	conj
15	.	.	.	_	10	punct

1	This	this	DT	_	9	nsubj
2	may	may	MD	_	9	aux
3	be	be	VB	_	9	cop
4	due	due	JJ	_	9	case
5	to	to	TO	_	4	mwe
6	an	a	DT	_	9	det
7	improved	improve	VBN	_	9	amod
8	glucose	glucose	NN	_	9	compound
9	utilization	utilization	NN	_	0	ROOT
10	with	with	IN	_	12	case
11	simultaneous	simultaneous	JJ	_	12	amod
12	reduction	reduction	NN	_	9	nmod
13	in	in	IN	_	15	case
14	drug1	drug1	NN	_	15	compound
15	requirement	requirement	NN	_	12	nmod

1	.	.	.	_	0	ROOT

1	-	-	:	_	0	ROOT
2	In	in	IN	_	4	case
3	isolated	isolate	VBN	_	4	amod
4	cases	case	NNS	_	1	root
5	,	,	,	_	4	punct
6	a	a	DT	_	5	root
7	pronounced	pronounced	JJ	_	6	amod
8	though	though	IN	_	29	mark
9	reversible	reversible	JJ	_	29	advmod
10	,	,	,	_	29	punct
11	impairment	impairment	NN	_	29	nsubjpass
12	of	of	IN	_	14	case
13	renal	renal	JJ	_	14	amod
14	function	function	NN	_	11	nmod
15	-LRB-	-lrb-	-LRB-	_	16	punct
16	accompanied	accompany	VBN	_	11	dep
17	by	by	IN	_	20	case
18	a	a	DT	_	20	det
19	corresponding	corresponding	JJ	_	20	amod
20	increase	increase	NN	_	16	nmod
21	in	in	IN	_	25	case
22	the	the	DT	_	25	det
23	serum	serum	NN	_	25	compound
24	creatinine	creatinine	NN	_	25	compound
25	level	level	NN	_	20	nmod
26	-RRB-	-rrb-	-RRB-	_	16	punct
27	has	have	VBZ	_	29	aux
28	been	be	VBN	_	29	auxpass
29	reported	report	VBN	_	7	advcl
30	in	in	IN	_	33	case
31	organ	organ	NN	_	33	compound
32	transplant	transplant	NN	_	33	compound
33	patients	patient	NNS	_	29	nmod
34	receiving	receive	VBG	_	33	acl
35	drug1	drug1	NN	_	36	compound
36	therapy	therapy	NN	_	34	dobj
37	and	and	CC	_	36	cc
38	concomitant	concomitant	JJ	_	39	amod
39	drug2	drug2	NN	_	36	conj
40	.	.	.	_	6	punct

1	Accordingly	accordingly	RB	_	8	advmod
2	,	,	,	_	8	punct
3	renal	renal	JJ	_	4	amod
4	function	function	NN	_	8	nsubjpass
5	should	should	MD	_	8	aux
6	be	be	VB	_	8	auxpass
7	closely	closely	RB	_	8	advmod
8	monitored	monitor	VBN	_	0	ROOT
9	in	in	IN	_	11	case
10	these	these	DT	_	11	det
11	patients	patient	NNS	_	8	nmod
12	and	and	CC	_	8	cc
13	,	,	,	_	32	punct
14	in	in	IN	_	16	case
15	the	the	DT	_	16	det
16	event	event	NN	_	32	nmod
17	of	of	IN	_	20	case
18	relevant	relevant	JJ	_	20	amod
19	significant	significant	JJ	_	20	amod
20	changes	change	NNS	_	16	nmod
21	in	in	IN	_	23	case
22	laboratory	laboratory	NN	_	23	compound
23	parameters	parameter	NNS	_	20	nmod
24	,	,	,	_	32	punct
25	drug1	drug1	NN	_	32	nsubjpass
26	should	should	MD	_	32	aux
27	,	,	,	_	32	punct
28	if	if	IN	_	29	mark
29	necessary	necessary	JJ	_	32	advcl
30	,	,	,	_	32	punct
31	be	be	VB	_	32	auxpass
32	discontinued	discontinue	VBN	_	8	conj

1	.	.	.	_	0	ROOT

1	-	-	:	_	25	punct
2	When	when	WRB	_	7	advmod
3	drug1	drug1	NN	_	7	nsubjpass
4	or	or	CC	_	3	cc
5	drug2	drug2	NN	_	3	conj
6	is	be	VBZ	_	7	auxpass
7	used	use	VBN	_	25	advcl
8	concurrently	concurrently	RB	_	7	advmod
9	with	with	IN	_	10	case
10	drug3	drug3	NN	_	7	nmod
11	-LRB-	-lrb-	-LRB-	_	13	punct
12	e.g.	e.g.	FW	_	13	dep
13	drug4	drug4	NN	_	10	appos
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	,	,	,	_	25	punct
16	an	a	DT	_	17	det
17	interval	interval	NN	_	25	nsubjpass
18	of	of	IN	_	22	case
19	at	at	IN	_	20	case
20	least	least	JJS	_	21	nmod:npmod
21	2	2	CD	_	22	nummod
22	hours	hour	NNS	_	17	nmod
23	should	should	MD	_	25	aux
24	be	be	VB	_	25	auxpass
25	maintained	maintain	VBN	_	39	csubj
26	between	between	IN	_	29	case
27	the	the	DT	_	29	det
28	two	two	CD	_	29	nummod
29	medicines	medicine	NNS	_	25	nmod
30	,	,	,	_	25	punct
31	since	since	IN	_	33	case
32	the	the	DT	_	33	det
33	absorption	absorption	NN	_	25	nmod
34	of	of	IN	_	35	case
35	drug5	drug5	NN	_	33	nmod
36	or	or	CC	_	35	cc
37	drug6	drug6	NN	_	35	conj
38	is	be	VBZ	_	39	cop
39	impaired	impaired	JJ	_	0	ROOT

1	.	.	.	_	0	ROOT

1	-	-	:	_	13	punct
2	drug1	drug1	NN	_	13	nsubjpass
3	or	or	CC	_	2	cc
4	drug2	drug2	NN	_	2	conj
5	-LRB-	-lrb-	-LRB-	_	8	punct
6	with	with	IN	_	8	case
7	hepatotoxic	hepatotoxic	JJ	_	8	amod
8	potential	potential	NN	_	2	nmod
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	must	must	MD	_	13	aux
11	not	not	RB	_	13	neg
12	be	be	VB	_	13	auxpass
13	administered	administer	VBN	_	0	ROOT
14	together	together	RB	_	13	advmod
15	with	with	IN	_	16	case
16	drug3	drug3	NN	_	13	nmod
17	or	or	CC	_	16	cc
18	drug4	drug4	NN	_	16	conj
19	.	.	.	_	13	punct

1	Care	Care	NNP	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	given	give	VBN	_	0	ROOT
5	when	when	WRB	_	6	advmod
6	administering	administer	VBG	_	4	advcl
7	this	this	DT	_	8	det
8	drug	drug	NN	_	6	dobj
9	to	to	TO	_	10	case
10	patients	patient	NNS	_	6	nmod
11	with	with	IN	_	12	case
12	symptoms	symptom	NNS	_	10	nmod
13	of	of	IN	_	15	case
14	myasthenic	myasthenic	JJ	_	15	amod
15	weakness	weakness	NN	_	12	nmod
16	who	who	WP	_	20	nsubj
17	are	be	VBP	_	20	cop
18	also	also	RB	_	20	advmod
19	on	on	IN	_	20	case
20	drug1	drug1	NN	_	15	acl:relcl
21	.	.	.	_	4	punct

1	Since	since	IN	_	11	mark
2	symptoms	symptom	NNS	_	11	nsubj
3	of	of	IN	_	5	case
4	anticholinesterase	anticholinesterase	NN	_	5	compound
5	overdose	overdose	NN	_	2	nmod
6	-LRB-	-lrb-	-LRB-	_	8	punct
7	cholinergic	cholinergic	JJ	_	8	amod
8	crisis	crisis	NN	_	5	appos
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	may	may	MD	_	11	aux
11	mimic	mimic	VB	_	22	advcl
12	underdosage	underdosage	NN	_	11	dobj
13	-LRB-	-lrb-	-LRB-	_	15	punct
14	myasthenic	myasthenic	JJ	_	15	amod
15	weakness	weakness	NN	_	12	appos
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	,	,	,	_	22	punct
18	their	they	PRP$	_	19	nmod:poss
19	condition	condition	NN	_	22	nsubjpass
20	may	may	MD	_	22	aux
21	be	be	VB	_	22	auxpass
22	worsened	worsen	VBN	_	0	ROOT
23	by	by	IN	_	25	case
24	the	the	DT	_	25	det
25	use	use	NN	_	22	nmod
26	of	of	IN	_	28	case
27	this	this	DT	_	28	det
28	drug	drug	NN	_	25	nmod
29	.	.	.	_	22	punct

1	May	May	NNP	_	2	nsubj
2	interact	interact	VBP	_	0	ROOT
3	with	with	IN	_	5	case
4	thyroid	thyroid	NN	_	5	compound
5	medication	medication	NN	_	2	nmod
6	-LRB-	-lrb-	-LRB-	_	9	punct
7	e.g.	e.g.	FW	_	9	dep
8	,	,	,	_	9	punct
9	drug1	drug1	NN	_	5	appos
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	,	,	,	_	5	punct
12	drug2	drug2	NN	_	14	dep
13	-	-	:	_	14	punct
14	containing	contain	VBG	_	5	acl
15	products	product	NNS	_	14	dobj
16	,	,	,	_	15	punct
17	drug3	drug3	NN	_	15	conj
18	,	,	,	_	15	punct
19	drug4	drug4	NN	_	15	conj
20	-LRB-	-lrb-	-LRB-	_	23	punct
21	e.g.	e.g.	FW	_	23	dep
22	,	,	,	_	23	punct
23	drug5	drug5	NN	_	19	dep
24	,	,	,	_	23	punct
25	drug6	drug6	NN	_	23	appos
26	-RRB-	-rrb-	-RRB-	_	23	punct
27	,	,	,	_	15	punct
28	and	and	CC	_	15	cc
29	drug7	drug7	NN	_	15	conj
30	-LRB-	-lrb-	-LRB-	_	33	punct
31	e.g.	e.g.	FW	_	33	dep
32	,	,	,	_	33	punct
33	drug8	drug8	NN	_	29	dep
34	,	,	,	_	33	punct
35	drug9	drug9	NN	_	33	appos
36	-RRB-	-rrb-	-RRB-	_	33	punct
37	.	.	.	_	2	punct

1	This	this	DT	_	2	det
2	product	product	NN	_	4	nsubj
3	can	can	MD	_	4	aux
4	affect	affect	VB	_	0	ROOT
5	the	the	DT	_	6	det
6	results	result	NNS	_	4	dobj
7	of	of	IN	_	10	case
8	certain	certain	JJ	_	10	amod
9	lab	lab	NN	_	10	compound
10	tests	test	NNS	_	6	nmod
11	.	.	.	_	4	punct

1	Drug/LaboratoryTest	Drug/LaboratoryTest	NNP	_	3	compound
2	Interactions	interaction	NNS	_	3	compound
3	drug1	drug1	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	interfere	interfere	VB	_	0	ROOT
6	with	with	IN	_	8	case
7	bioassay	bioassay	NN	_	8	compound
8	procedures	procedure	NNS	_	5	nmod
9	for	for	IN	_	11	case
10	the	the	DT	_	11	det
11	determination	determination	NN	_	8	nmod
12	of	of	IN	_	14	case
13	drug2	drug2	NN	_	14	compound
14	levels	level	NNS	_	11	nmod
15	.	.	.	_	5	punct

1	Since	since	IN	_	5	mark
2	drug1	drug1	NN	_	5	nsubjpass
3	is	be	VBZ	_	5	auxpass
4	primarily	primarily	RB	_	5	advmod
5	eliminated	eliminate	VBN	_	26	advcl
6	by	by	IN	_	8	case
7	the	the	DT	_	8	det
8	kidneys	kidney	NNS	_	5	nmod
9	,	,	,	_	26	punct
10	coadministration	coadministration	NN	_	26	nsubj
11	of	of	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	with	with	IN	_	14	case
14	drugs	drug	NNS	_	10	nmod
15	that	that	WDT	_	16	nsubj
16	reduce	reduce	VBP	_	14	acl:relcl
17	renal	renal	JJ	_	18	amod
18	function	function	NN	_	16	dobj
19	or	or	CC	_	16	cc
20	compete	compete	VB	_	16	conj
21	for	for	IN	_	24	case
22	active	active	JJ	_	24	amod
23	tubular	tubular	JJ	_	24	amod
24	secretion	secretion	NN	_	20	nmod
25	may	may	MD	_	26	aux
26	increase	increase	VB	_	0	ROOT
27	serum	serum	NN	_	28	compound
28	concentrations	concentration	NNS	_	26	dobj
29	of	of	IN	_	31	case
30	either	either	CC	_	31	cc:preconj
31	drug3	drug3	NN	_	28	nmod
32	or	or	CC	_	31	cc
33	the	the	DT	_	35	det
34	coadministered	coadminister	VBN	_	35	amod
35	drug	drug	NN	_	31	conj
36	.	.	.	_	26	punct

1	Coadministration	coadministration	NN	_	13	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	1	nmod
6	,	,	,	_	5	punct
7	drug3	drug3	NN	_	5	conj
8	,	,	,	_	5	punct
9	or	or	CC	_	5	cc
10	drug4	drug4	NN	_	5	conj
11	did	do	VBD	_	13	aux
12	not	not	RB	_	13	neg
13	result	result	VB	_	0	ROOT
14	in	in	IN	_	17	case
15	significant	significant	JJ	_	17	amod
16	drug	drug	NN	_	17	compound
17	interactions	interaction	NNS	_	13	nmod
18	.	.	.	_	13	punct

1	The	the	DT	_	2	det
2	effects	effect	NNS	_	24	nsubjpass
3	of	of	IN	_	4	case
4	coadministration	coadministration	NN	_	2	nmod
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	with	with	IN	_	9	case
8	other	other	JJ	_	9	amod
9	drugs	drug	NNS	_	2	nmod
10	that	that	WDT	_	13	nsubjpass
11	are	be	VBP	_	13	auxpass
12	renally	renally	RB	_	13	advmod
13	eliminated	eliminate	VBN	_	9	acl:relcl
14	or	or	CC	_	13	cc
15	are	be	VBP	_	16	auxpass
16	known	know	VBN	_	13	conj
17	to	to	TO	_	18	mark
18	affect	affect	VB	_	16	xcomp
19	renal	renal	JJ	_	20	amod
20	function	function	NN	_	18	dobj
21	have	have	VBP	_	24	aux
22	not	not	RB	_	24	neg
23	been	be	VBN	_	24	auxpass
24	evaluated	evaluate	VBN	_	0	ROOT
25	,	,	,	_	24	punct
26	and	and	CC	_	24	cc
27	patients	patient	NNS	_	30	nsubjpass
28	should	should	MD	_	30	aux
29	be	be	VB	_	30	auxpass
30	monitored	monitor	VBN	_	24	conj
31	closely	closely	RB	_	30	advmod
32	for	for	IN	_	34	case
33	adverse	adverse	JJ	_	34	amod
34	events	event	NNS	_	30	nmod
35	when	when	WRB	_	38	advmod
36	drug2	drug2	NN	_	38	nsubjpass
37	is	be	VBZ	_	38	auxpass
38	coadministered	coadminister	VBN	_	30	advcl
39	with	with	IN	_	41	case
40	such	such	JJ	_	41	amod
41	drugs	drug	NNS	_	38	nmod
42	.	.	.	_	24	punct

1	drug1	drug1	NN	_	2	nsubj
2	has	have	VBZ	_	0	ROOT
3	additive	additive	JJ	_	4	amod
4	effects	effect	NNS	_	2	dobj
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	other	other	JJ	_	9	amod
9	drug3	drug3	NN	_	6	conj
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	drug4	drug4	NN	_	9	dep
12	,	,	,	_	11	punct
13	drug5	drug5	NN	_	11	conj
14	,	,	,	_	11	punct
15	drug6	drug6	NN	_	11	conj
16	,	,	,	_	11	punct
17	etc	etc	NN	_	11	appos
18	-RRB-	-rrb-	-RRB-	_	11	punct
19	.	.	.	_	2	punct

1	drug1	drug1	NN	_	2	nsubj
2	prolong	prolong	VB	_	0	ROOT
3	and	and	CC	_	2	cc
4	intensify	intensify	VB	_	2	conj
5	the	the	DT	_	10	det
6	anticholinergic	anticholinergic	JJ	_	10	amod
7	-LRB-	-lrb-	-LRB-	_	8	punct
8	drying	dry	VBG	_	6	dep
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	effects	effect	NNS	_	2	dobj
11	of	of	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	.	.	.	_	2	punct

1	Formal	formal	JJ	_	4	amod
2	drug	drug	NN	_	4	compound
3	interaction	interaction	NN	_	4	compound
4	studies	study	NNS	_	8	nsubjpass
5	have	have	VBP	_	8	aux
6	not	not	RB	_	8	neg
7	been	be	VBN	_	8	auxpass
8	conducted	conduct	VBN	_	0	ROOT
9	with	with	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	.	.	.	_	8	punct

1	Population	Population	NNP	_	3	compound
2	pharmacokinetic	pharmacokinetic	JJ	_	3	amod
3	analyses	analysis	NNS	_	4	nsubj
4	revealed	reveal	VBD	_	0	ROOT
5	that	that	IN	_	16	mark
6	drug1	drug1	NN	_	16	nsubj
7	,	,	,	_	6	punct
8	drug2	drug2	NN	_	6	conj
9	,	,	,	_	6	punct
10	drug3	drug3	NN	_	6	conj
11	,	,	,	_	6	punct
12	and	and	CC	_	6	cc
13	drug4	drug4	NN	_	6	conj
14	did	do	VBD	_	16	aux
15	not	not	RB	_	16	neg
16	influence	influence	VB	_	4	ccomp
17	drug5	drug5	NN	_	18	compound
18	clearance	clearance	NN	_	16	dobj
19	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	majority	majority	NN	_	9	nsubj
3	of	of	IN	_	4	case
4	patients	patient	NNS	_	2	nmod
5	in	in	IN	_	8	case
6	RA	ra	NN	_	8	compound
7	clinical	clinical	JJ	_	8	amod
8	studies	study	NNS	_	4	nmod
9	received	receive	VBD	_	0	ROOT
10	one	one	CD	_	9	dobj
11	or	or	CC	_	10	cc
12	more	more	JJR	_	10	conj
13	of	of	IN	_	17	case
14	the	the	DT	_	17	det
15	following	follow	VBG	_	17	amod
16	concomitant	concomitant	JJ	_	17	amod
17	medications	medication	NNS	_	10	nmod
18	with	with	IN	_	19	case
19	drug1	drug1	NN	_	17	nmod
20	:	:	:	_	9	punct
21	drug2	drug2	NN	_	9	dep
22	,	,	,	_	21	punct
23	drug3	drug3	NN	_	21	conj
24	,	,	,	_	21	punct
25	drug4	drug4	NN	_	21	conj
26	,	,	,	_	21	punct
27	drug5	drug5	NN	_	21	conj
28	,	,	,	_	21	punct
29	drug6	drug6	NN	_	21	conj
30	,	,	,	_	21	punct
31	drug7	drug7	NN	_	21	conj
32	,	,	,	_	21	punct
33	drug8	drug8	NN	_	21	conj
34	,	,	,	_	21	punct
35	drug9	drug9	NN	_	21	conj
36	,	,	,	_	21	punct
37	drug10	drug10	NN	_	21	conj
38	,	,	,	_	21	punct
39	drug11	drug11	NN	_	21	conj
40	,	,	,	_	21	punct
41	and	and	CC	_	21	cc
42	drug12	drug12	NN	_	21	conj
43	.	.	.	_	9	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	administration	administration	NN	_	10	nsubjpass
3	of	of	IN	_	5	case
4	a	a	DT	_	5	det
5	drug1	drug1	NN	_	2	nmod
6	with	with	IN	_	7	case
7	drug2	drug2	NN	_	2	nmod
8	has	have	VBZ	_	10	aux
9	been	be	VBN	_	10	auxpass
10	associated	associate	VBN	_	0	ROOT
11	with	with	IN	_	14	case
12	an	a	DT	_	14	det
13	increased	increase	VBN	_	14	amod
14	risk	risk	NN	_	10	nmod
15	of	of	IN	_	17	case
16	serious	serious	JJ	_	17	amod
17	infections	infection	NNS	_	14	nmod
18	and	and	CC	_	14	cc
19	no	no	DT	_	22	neg
20	significant	significant	JJ	_	22	amod
21	additional	additional	JJ	_	22	amod
22	efficacy	efficacy	NN	_	14	conj
23	over	over	IN	_	24	case
24	use	use	NN	_	22	nmod
25	of	of	IN	_	27	case
26	the	the	DT	_	27	det
27	drug3	drug3	NN	_	24	nmod
28	alone	alone	RB	_	27	advmod
29	.	.	.	_	10	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	therapy	therapy	NN	_	9	nsubjpass
3	with	with	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	is	be	VBZ	_	9	auxpass
8	not	not	RB	_	9	neg
9	recommended	recommend	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	There	there	EX	_	2	expl
2	is	be	VBZ	_	0	ROOT
3	insufficient	insufficient	JJ	_	4	amod
4	experience	experience	NN	_	2	nsubj
5	to	to	TO	_	6	mark
6	assess	assess	VB	_	4	acl
7	the	the	DT	_	8	det
8	safety	safety	NN	_	6	dobj
9	and	and	CC	_	8	cc
10	efficacy	efficacy	NN	_	8	conj
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	8	nmod
13	administered	administer	VBN	_	12	acl
14	concurrently	concurrently	RB	_	13	advmod
15	with	with	IN	_	16	case
16	drug2	drug2	NN	_	13	nmod
17	,	,	,	_	2	punct
18	and	and	CC	_	2	cc
19	therefore	therefore	RB	_	24	advmod
20	such	such	JJ	_	21	amod
21	use	use	NN	_	24	nsubjpass
22	is	be	VBZ	_	24	auxpass
23	not	not	RB	_	24	neg
24	recommended	recommend	VBN	_	2	conj
25	.	.	.	_	2	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	interfere	interfere	VB	_	0	ROOT
4	with	with	IN	_	7	case
5	the	the	DT	_	7	det
6	anti-glaucoma	anti-glaucoma	JJ	_	7	amod
7	action	action	NN	_	3	nmod
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	or	or	CC	_	9	cc
11	drug3	drug3	NN	_	9	conj
12	;	;	:	_	3	punct

1	also	also	RB	_	9	advmod
2	,	,	,	_	9	punct
3	concurrent	concurrent	JJ	_	4	amod
4	use	use	NN	_	9	nsubj
5	of	of	IN	_	7	case
6	this	this	DT	_	7	det
7	medication	medication	NN	_	4	nmod
8	may	may	MD	_	9	aux
9	antagonise	antagonise	VB	_	0	ROOT
10	the	the	DT	_	14	det
11	anti-glaucoma	anti-glaucoma	JJ	_	14	amod
12	and	and	CC	_	11	cc
13	miotic	miotic	JJ	_	11	conj
14	actions	action	NNS	_	9	dobj
15	of	of	IN	_	17	case
16	ophthalmic	ophthalmic	JJ	_	17	amod
17	drug1	drug1	NN	_	14	nmod
18	.	.	.	_	9	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	These	these	DT	_	4	det
4	drugs	drug	NNS	_	7	nsubjpass
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	reported	report	VBN	_	1	dep
8	to	to	TO	_	9	mark
9	cause	cause	VB	_	7	xcomp
10	prolonged	prolonged	JJ	_	12	amod
11	vasospastic	vasospastic	JJ	_	12	amod
12	reactions	reaction	NNS	_	9	dobj
13	.	.	.	_	7	punct

1	Because	because	IN	_	3	mark
2	there	there	EX	_	3	expl
3	is	be	VBZ	_	0	ROOT
4	a	a	DT	_	6	det
5	theoretical	theoretical	JJ	_	6	amod
6	basis	basis	NN	_	3	nsubj
7	that	that	IN	_	12	mark
8	these	these	DT	_	9	det
9	effects	effect	NNS	_	12	nsubj
10	may	may	MD	_	12	aux
11	be	be	VB	_	12	cop
12	additive	additive	JJ	_	6	ccomp
13	,	,	,	_	12	punct
14	use	use	NN	_	37	nsubjpass
15	of	of	IN	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	-	-	:	_	14	punct
18	containing	contain	VBG	_	14	dep
19	or	or	CC	_	18	cc
20	drug2	drug2	NN	_	18	conj
21	-LRB-	-lrb-	-LRB-	_	23	punct
22	like	like	IN	_	23	case
23	drug3	drug3	NN	_	18	nmod
24	or	or	CC	_	23	cc
25	drug4	drug4	NN	_	23	conj
26	-RRB-	-rrb-	-RRB-	_	23	punct
27	and	and	CC	_	18	cc
28	drug5	drug5	NN	_	18	conj
29	within	within	IN	_	31	case
30	24	24	CD	_	31	nummod
31	hours	hour	NNS	_	28	nmod
32	of	of	IN	_	34	case
33	each	each	DT	_	34	det
34	other	other	JJ	_	31	nmod
35	should	should	MD	_	37	aux
36	be	be	VB	_	37	auxpass
37	avoided	avoid	VBN	_	12	parataxis
38	.	.	.	_	3	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Coadministration	coadministration	NN	_	6	nsubj
4	of	of	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	resulted	result	VBD	_	1	appos
7	in	in	IN	_	11	case
8	a	a	DT	_	11	det
9	27	27	CD	_	10	compound
10	%	%	NN	_	11	amod
11	decrease	decrease	NN	_	6	nmod
12	in	in	IN	_	14	case
13	drug3	drug3	NN	_	14	compound
14	clearance	clearance	NN	_	11	nmod
15	and	and	CC	_	11	cc
16	an	a	DT	_	17	det
17	increase	increase	NN	_	11	conj
18	in	in	IN	_	19	case
19	Cmax	cmax	NN	_	17	nmod
20	of	of	IN	_	23	case
21	approximately	approximately	RB	_	22	advmod
22	6	6	CD	_	23	nummod
23	%	%	NN	_	19	nmod
24	.	.	.	_	1	punct

1	No	no	DT	_	3	neg
2	dose	dose	NN	_	3	compound
3	adjustment	adjustment	NN	_	5	nsubj
4	is	be	VBZ	_	5	cop
5	necessary	necessary	JJ	_	0	ROOT
6	.	.	.	_	5	punct

1	Other	other	JJ	_	4	amod
2	drug1	drug1	NN	_	4	compound
3	Concomitant	concomitant	JJ	_	4	amod
4	use	use	NN	_	16	nsubjpass
5	of	of	IN	_	7	case
6	other	other	JJ	_	7	amod
7	drug2	drug2	NN	_	4	nmod
8	within	within	IN	_	10	case
9	24	24	CD	_	10	nummod
10	hours	hour	NNS	_	4	nmod
11	of	of	IN	_	12	case
12	treatment	treatment	NN	_	10	nmod
13	with	with	IN	_	14	case
14	drug3	drug3	NN	_	12	nmod
15	is	be	VBZ	_	16	auxpass
16	contraindicated	contraindicate	VBN	_	0	ROOT
17	.	.	.	_	16	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	pharmacokinetics	pharmacokinetic	NNS	_	9	nsubjpass
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	were	be	VBD	_	9	auxpass
8	not	not	RB	_	9	neg
9	affected	affect	VBN	_	1	appos
10	by	by	IN	_	11	case
11	coadministration	coadministration	NN	_	9	nmod
12	of	of	IN	_	13	case
13	drug3	drug3	NN	_	11	nmod
14	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	drug2	drug2	NN	_	1	appos
4	-RRB-	-rrb-	-RRB-	_	3	punct
5	:	:	:	_	1	punct
6	drug3	drug3	NN	_	21	nsubjpass
7	-LRB-	-lrb-	-LRB-	_	10	punct
8	e.g.	e.g.	FW	_	10	dep
9	,	,	,	_	10	punct
10	drug4	drug4	NN	_	6	dep
11	,	,	,	_	10	punct
12	drug5	drug5	NN	_	10	conj
13	,	,	,	_	10	punct
14	drug6	drug6	NN	_	10	conj
15	,	,	,	_	10	punct
16	drug7	drug7	NN	_	10	appos
17	-RRB-	-rrb-	-RRB-	_	10	punct
18	have	have	VBP	_	21	aux
19	been	be	VBN	_	21	auxpass
20	rarely	rarely	RB	_	21	advmod
21	reported	report	VBN	_	1	dep
22	to	to	TO	_	23	mark
23	cause	cause	VB	_	21	xcomp
24	weakness	weakness	NN	_	23	dobj
25	,	,	,	_	24	punct
26	hyperreflexia	hyperreflexia	NN	_	24	conj
27	,	,	,	_	24	punct
28	and	and	CC	_	24	cc
29	incoordination	incoordination	NN	_	24	conj
30	when	when	WRB	_	31	advmod
31	coadministered	coadminister	VBN	_	23	advcl
32	with	with	IN	_	33	case
33	drug8	drug8	NN	_	31	nmod
34	.	.	.	_	1	punct

1	If	if	IN	_	11	mark
2	concomitant	concomitant	JJ	_	3	amod
3	treatment	treatment	NN	_	11	nsubjpass
4	with	with	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	an	a	DT	_	8	det
8	drug2	drug2	NN	_	5	conj
9	is	be	VBZ	_	11	auxpass
10	clinically	clinically	RB	_	11	advmod
11	warranted	warrant	VBN	_	19	advcl
12	,	,	,	_	19	punct
13	appropriate	appropriate	JJ	_	14	amod
14	observation	observation	NN	_	19	nsubjpass
15	of	of	IN	_	17	case
16	the	the	DT	_	17	det
17	patient	patient	NN	_	14	nmod
18	is	be	VBZ	_	19	auxpass
19	advised	advise	VBN	_	0	ROOT
20	.	.	.	_	19	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Coadministration	coadministration	NN	_	8	nsubj
4	of	of	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug3	drug3	NN	_	5	conj
8	resulted	result	VBD	_	1	appos
9	in	in	IN	_	13	case
10	a	a	DT	_	13	det
11	24	24	CD	_	12	compound
12	%	%	NN	_	13	amod
13	increase	increase	NN	_	8	nmod
14	in	in	IN	_	16	case
15	plasma	plasma	NN	_	16	compound
16	concentrations	concentration	NNS	_	13	nmod
17	of	of	IN	_	18	case
18	drug4	drug4	NN	_	16	nmod
19	.	.	.	_	1	punct

1	No	no	DT	_	3	neg
2	dose	dose	NN	_	3	compound
3	adjustment	adjustment	NN	_	5	nsubj
4	is	be	VBZ	_	5	cop
5	necessary	necessary	JJ	_	0	ROOT
6	.	.	.	_	5	punct

1	Coadministration	coadministration	NN	_	18	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	the	the	DT	_	9	det
6	potent	potent	JJ	_	9	amod
7	CYP3A4	cyp3a4	NN	_	9	compound
8	inhibitor	inhibitor	NN	_	9	compound
9	drug2	drug2	NN	_	3	conj
10	-LRB-	-lrb-	-LRB-	_	13	punct
11	400	400	CD	_	13	nummod
12	mg	mg	NN	_	13	compound
13	q.d.	q.d.	NN	_	9	dep
14	for	for	IN	_	16	case
15	3	3	CD	_	16	nummod
16	days	day	NNS	_	13	nmod
17	-RRB-	-rrb-	-RRB-	_	13	punct
18	resulted	result	VBD	_	0	ROOT
19	in	in	IN	_	24	case
20	an	a	DT	_	24	det
21	approximately	approximately	RB	_	22	advmod
22	60	60	CD	_	23	dep
23	%	%	NN	_	24	dep
24	increase	increase	NN	_	18	nmod
25	in	in	IN	_	27	case
26	the	the	DT	_	27	det
27	area	area	NN	_	24	nmod
28	under	under	IN	_	32	case
29	the	the	DT	_	32	det
30	plasma	plasma	NN	_	32	compound
31	concentration-time	concentration-time	NN	_	32	compound
32	curve	curve	NN	_	24	nmod
33	and	and	CC	_	32	cc
34	maximal	maximal	JJ	_	36	amod
35	plasma	plasma	NN	_	36	compound
36	concentrations	concentration	NNS	_	32	conj
37	of	of	IN	_	38	case
38	drug3	drug3	NN	_	32	nmod
39	.	.	.	_	18	punct

1	Although	although	IN	_	24	mark
2	the	the	DT	_	3	det
3	interaction	interaction	NN	_	24	nsubjpass
4	between	between	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	other	other	JJ	_	10	amod
8	potent	potent	JJ	_	10	amod
9	CYP3A4	cyp3a4	NN	_	10	compound
10	inhibitors	inhibitor	NNS	_	5	conj
11	-LRB-	-lrb-	-LRB-	_	14	punct
12	e.g.	e.g.	FW	_	14	dep
13	,	,	,	_	14	punct
14	drug2	drug2	NN	_	10	dep
15	,	,	,	_	14	punct
16	drug3	drug3	NN	_	14	conj
17	,	,	,	_	14	punct
18	and	and	CC	_	14	cc
19	drug4	drug4	NN	_	14	conj
20	-RRB-	-rrb-	-RRB-	_	14	punct
21	has	have	VBZ	_	24	aux
22	not	not	RB	_	24	neg
23	been	be	VBN	_	24	auxpass
24	studied	study	VBN	_	26	advcl
25	,	,	,	_	26	punct
26	increased	increase	VBD	_	0	ROOT
27	exposures	exposure	NNS	_	26	dobj
28	to	to	TO	_	29	case
29	drug5	drug5	NN	_	27	nmod
30	may	may	MD	_	32	aux
31	be	be	VB	_	32	auxpass
32	expected	expect	VBN	_	26	dep
33	when	when	WRB	_	36	advmod
34	drug6	drug6	NN	_	36	nsubjpass
35	is	be	VBZ	_	36	auxpass
36	used	use	VBN	_	32	advcl
37	concomitantly	concomitantly	RB	_	36	advmod
38	with	with	IN	_	40	case
39	these	these	DT	_	40	det
40	medications	medication	NNS	_	36	nmod
41	.	.	.	_	26	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	not	not	RB	_	4	neg
4	known	know	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	interfere	interfere	VB	_	4	xcomp
7	with	with	IN	_	12	case
8	commonly	commonly	RB	_	9	advmod
9	employed	employ	VBN	_	12	amod
10	clinical	clinical	JJ	_	12	amod
11	laboratory	laboratory	NN	_	12	compound
12	tests	test	NNS	_	6	nmod
13	.	.	.	_	4	punct

1	No	no	DT	_	5	neg
2	formal	formal	JJ	_	5	amod
3	drug	drug	NN	_	5	compound
4	interaction	interaction	NN	_	5	compound
5	studies	study	NNS	_	8	nsubjpass
6	have	have	VBP	_	8	aux
7	been	be	VBN	_	8	auxpass
8	conducted	conduct	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	D.	D.	NNP	_	0	ROOT

1	Drug	drug	NN	_	5	compound
2	and	and	CC	_	1	cc
3	Laboratory	laboratory	NN	_	1	conj
4	Test	test	NN	_	5	compound
5	Interactions	interaction	NNS	_	0	ROOT
6	1	1	CD	_	5	nummod
7	.	.	.	_	5	punct

1	Accelerated	accelerate	VBN	_	3	amod
2	prothrombin	prothrombin	NN	_	3	compound
3	time	time	NN	_	0	ROOT
4	,	,	,	_	3	punct
5	partial	partial	JJ	_	7	amod
6	thromboplastin	thromboplastin	NN	_	7	compound
7	time	time	NN	_	3	conj
8	,	,	,	_	3	punct
9	and	and	CC	_	3	cc
10	platelet	platelet	NN	_	12	compound
11	aggregation	aggregation	NN	_	12	compound
12	time	time	NN	_	3	conj
13	;	;	:	_	3	punct

1	increased	increase	VBN	_	3	amod
2	platelet	platelet	NN	_	3	compound
3	count	count	NN	_	0	ROOT
4	;	;	:	_	3	punct

1	increased	increase	VBN	_	2	amod
2	factors	factor	NNS	_	0	ROOT
3	II	ii	CD	_	2	nummod
4	,	,	,	_	2	punct
5	VII	vii	NN	_	6	compound
6	antigen	antigen	NN	_	2	appos
7	,	,	,	_	6	punct
8	VIII	viii	CD	_	9	nummod
9	antigen	antigen	NN	_	6	conj
10	,	,	,	_	6	punct
11	VIII	viii	CD	_	13	nummod
12	coagulant	coagulant	NN	_	13	compound
13	activity	activity	NN	_	6	conj
14	,	,	,	_	6	punct
15	IX	ix	CD	_	6	conj
16	,	,	,	_	6	punct
17	X	x	NN	_	6	conj
18	,	,	,	_	6	punct
19	XII	XII	NNP	_	6	conj
20	,	,	,	_	6	punct
21	VII-X	vii-x	NN	_	22	compound
22	complex	complex	NN	_	6	conj
23	,	,	,	_	6	punct
24	II-VII-X	ii-vii-x	NN	_	25	compound
25	complex	complex	NN	_	6	conj
26	,	,	,	_	6	punct
27	and	and	CC	_	6	cc
28	beta-thromboglobulin	beta-thromboglobulin	NN	_	6	conj
29	;	;	:	_	2	punct

1	decreased	decrease	VBN	_	2	amod
2	levels	level	NNS	_	10	nsubj
3	of	of	IN	_	5	case
4	anti-factor	anti-factor	JJ	_	5	amod
5	Xa	xa	NN	_	2	nmod
6	and	and	CC	_	5	cc
7	antithrombin	antithrombin	NN	_	5	conj
8	III	iii	CD	_	7	nummod
9	,	,	,	_	2	punct
10	decreased	decrease	VBD	_	0	ROOT
11	antithrombin	antithrombin	NN	_	13	compound
12	III	iii	CD	_	13	nummod
13	activity	activity	NN	_	10	dobj
14	;	;	:	_	10	punct

1	increased	increase	VBN	_	2	amod
2	levels	level	NNS	_	0	ROOT
3	of	of	IN	_	4	case
4	fibrinogen	fibrinogen	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	fibrinogen	fibrinogen	NN	_	7	compound
7	activity	activity	NN	_	4	conj
8	;	;	:	_	2	punct

1	increased	increase	VBN	_	3	amod
2	plasminogen	plasminogen	NN	_	3	compound
3	antigen	antigen	NN	_	0	ROOT
4	and	and	CC	_	3	cc
5	activity	activity	NN	_	3	conj
6	.	.	.	_	3	punct

1	2	2	LS	_	0	ROOT
2	.	.	.	_	1	punct

1	Increased	increase	VBN	_	3	amod
2	thyroid-binding	thyroid-binding	JJ	_	3	amod
3	globulin	globulin	NN	_	0	ROOT
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	TBG	tbg	NN	_	3	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	leading	lead	VBG	_	3	acl
8	to	to	TO	_	14	case
9	increased	increase	VBN	_	14	amod
10	circulating	circulate	VBG	_	14	amod
11	total	total	JJ	_	14	amod
12	thyroid	thyroid	NN	_	14	compound
13	hormone	hormone	NN	_	14	compound
14	levels	level	NNS	_	7	nmod
15	,	,	,	_	3	punct
16	as	as	IN	_	17	mark
17	measured	measure	VBN	_	3	dep
18	by	by	IN	_	20	case
19	protein-bound	protein-bound	JJ	_	20	amod
20	iodine	iodine	NN	_	17	nmod
21	-LRB-	-lrb-	-LRB-	_	22	punct
22	PBI	pbi	NN	_	20	appos
23	-RRB-	-rrb-	-RRB-	_	22	punct
24	,	,	,	_	20	punct
25	T4	t4	NN	_	26	compound
26	levels	level	NNS	_	20	conj
27	-LRB-	-lrb-	-LRB-	_	29	punct
28	by	by	IN	_	29	case
29	column	column	NN	_	26	nmod
30	or	or	CC	_	29	cc
31	by	by	IN	_	32	case
32	radioimmunoassay	radioimmunoassay	NN	_	29	conj
33	-RRB-	-rrb-	-RRB-	_	29	punct
34	or	or	CC	_	20	cc
35	T3	t3	NN	_	36	compound
36	levels	level	NNS	_	20	conj
37	by	by	IN	_	38	case
38	radioimmunoassay	radioimmunoassay	NN	_	36	nmod
39	.	.	.	_	3	punct

1	T3	t3	NN	_	3	compound
2	resin	resin	NN	_	3	compound
3	uptake	uptake	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	decreased	decrease	VBN	_	0	ROOT
6	,	,	,	_	5	punct
7	reflecting	reflect	VBG	_	5	xcomp
8	the	the	DT	_	10	det
9	elevated	elevated	JJ	_	10	amod
10	TBG	tbg	NN	_	7	dobj
11	.	.	.	_	5	punct

1	Free	Free	NNP	_	2	compound
2	T4	t4	NN	_	7	nsubj
3	and	and	CC	_	2	cc
4	T3	t3	NN	_	5	compound
5	concentrations	concentration	NNS	_	2	conj
6	are	be	VBP	_	7	cop
7	unaltered	unaltered	JJ	_	0	ROOT
8	.	.	.	_	7	punct

1	Patients	patient	NNS	_	7	nsubj
2	on	on	IN	_	5	case
3	thyroid	thyroid	NN	_	5	compound
4	replacement	replacement	NN	_	5	compound
5	therapy	therapy	NN	_	1	nmod
6	may	may	MD	_	7	aux
7	require	require	VB	_	0	ROOT
8	higher	higher	JJR	_	9	amod
9	doses	dose	NNS	_	7	dobj
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	.	.	.	_	7	punct

1	3	3	LS	_	0	ROOT
2	.	.	.	_	1	punct

1	Other	other	JJ	_	3	amod
2	binding	binding	NN	_	3	compound
3	proteins	protein	NNS	_	6	nsubj
4	may	may	MD	_	6	aux
5	be	be	VB	_	6	aux
6	elevated	elevated	JJ	_	0	ROOT
7	in	in	IN	_	8	case
8	serum	serum	NN	_	6	nmod
9	,	,	,	_	8	punct
10	i.e.	i.e.	FW	_	8	conj
11	,	,	,	_	8	punct
12	corticosteroid	corticosteroid	NN	_	14	compound
13	binding	binding	NN	_	14	compound
14	globulin	globulin	NN	_	8	conj
15	-LRB-	-lrb-	-LRB-	_	16	punct
16	CBG	cbg	NN	_	14	appos
17	-RRB-	-rrb-	-RRB-	_	16	punct
18	,	,	,	_	8	punct
19	sex	sex	NN	_	21	compound
20	hormone-binding	hormone-binding	JJ	_	21	amod
21	globulin	globulin	NN	_	8	conj
22	-LRB-	-lrb-	-LRB-	_	23	punct
23	SHBG	shbg	NN	_	21	appos
24	-RRB-	-rrb-	-RRB-	_	23	punct
25	,	,	,	_	8	punct
26	leading	lead	VBG	_	8	acl
27	to	to	TO	_	31	case
28	increased	increase	VBN	_	31	amod
29	total	total	JJ	_	31	amod
30	circulating	circulate	VBG	_	31	amod
31	drug1	drug1	NN	_	26	nmod
32	and	and	CC	_	31	cc
33	drug2	drug2	NN	_	31	conj
34	,	,	,	_	8	punct
35	respectively	respectively	RB	_	8	advmod
36	.	.	.	_	6	punct

1	Free	Free	NNP	_	3	compound
2	hormone	hormone	NN	_	3	compound
3	concentrations	concentration	NNS	_	6	nsubjpass
4	may	may	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	decreased	decrease	VBN	_	0	ROOT
7	.	.	.	_	6	punct

1	Other	other	JJ	_	3	amod
2	plasma	plasma	NN	_	3	compound
3	proteins	protein	NNS	_	6	nsubjpass
4	may	may	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	increased	increase	VBN	_	0	ROOT
7	-LRB-	-lrb-	-LRB-	_	9	punct
8	angiotensinogen/renin	angiotensinogen/renin	NN	_	9	compound
9	substrate	substrate	NN	_	6	dep
10	,	,	,	_	9	punct
11	alpha-1-antitrypsin	alpha-1-antitrypsin	NN	_	9	appos
12	,	,	,	_	9	punct
13	ceruloplasmin	ceruloplasmin	NN	_	9	appos
14	-RRB-	-rrb-	-RRB-	_	9	punct
15	.	.	.	_	6	punct

1	4	4	LS	_	0	ROOT
2	.	.	.	_	1	punct

1	Increased	increase	VBN	_	3	amod
2	plasma	plasma	NN	_	3	compound
3	HDL	hdl	NN	_	10	nsubj
4	and	and	CC	_	3	cc
5	HDL2	hdl2	NN	_	8	compound
6	cholesterol	cholesterol	NN	_	8	compound
7	subfraction	subfraction	NN	_	8	compound
8	concentrations	concentration	NNS	_	3	conj
9	,	,	,	_	3	punct
10	reduced	reduce	VBD	_	0	ROOT
11	LDL	ldl	NN	_	13	compound
12	cholesterol	cholesterol	NN	_	13	compound
13	concentration	concentration	NN	_	10	dobj
14	,	,	,	_	10	punct
15	increased	increase	VBD	_	17	amod
16	triglyceride	triglyceride	NN	_	17	compound
17	levels	level	NNS	_	10	dobj
18	.	.	.	_	10	punct

1	5	5	CD	_	0	ROOT
2	.	.	.	_	1	punct

1	Impaired	impaired	JJ	_	3	amod
2	glucose	glucose	NN	_	3	compound
3	tolerance	tolerance	NN	_	0	ROOT
4	.	.	.	_	3	punct

1	6	6	CD	_	0	ROOT
2	.	.	.	_	1	punct

1	Reduced	reduce	VBN	_	2	amod
2	response	response	NN	_	0	ROOT
3	to	to	TO	_	5	case
4	metyrapone	metyrapone	NN	_	5	compound
5	test	test	NN	_	2	nmod
6	.	.	.	_	2	punct

1	http://www.rxlist.com/cgi/generic3/guanethidine_od.htm	http://www.rxlist.com/cgi/generic3/guanethidine_od.htm	NN	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	5	case
4	healthy	healthy	JJ	_	5	amod
5	subjects	subject	NNS	_	18	nmod
6	given	give	VBN	_	10	case
7	single	single	JJ	_	10	amod
8	500	500	CD	_	9	compound
9	mg	mg	NN	_	10	amod
10	doses	dose	NNS	_	5	nmod
11	of	of	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	and	and	CC	_	12	cc
14	drug3	drug3	NN	_	12	conj
15	,	,	,	_	18	punct
16	plasma	plasma	NN	_	17	compound
17	drug4	drug4	NN	_	18	nsubj
18	mean	mean	VB	_	1	dep
19	cmax	cmax	NN	_	18	dobj
20	and	and	CC	_	19	cc
21	AUC	auc	NN	_	19	conj
22	increased	increase	VBN	_	19	acl
23	by	by	IN	_	25	case
24	an	a	DT	_	25	det
25	average	average	NN	_	22	nmod
26	of	of	IN	_	28	case
27	34	34	CD	_	28	nummod
28	%	%	NN	_	25	nmod
29	and	and	CC	_	28	cc
30	24	24	CD	_	31	nummod
31	%	%	NN	_	28	conj
32	,	,	,	_	25	punct
33	respectively	respectively	RB	_	25	advmod
34	,	,	,	_	25	punct
35	and	and	CC	_	25	cc
36	drug5	drug5	NN	_	37	nsubj
37	mean	mean	VBP	_	25	conj
38	renal	renal	JJ	_	39	amod
39	clearance	clearance	NN	_	37	dobj
40	decreased	decrease	VBN	_	39	acl
41	by	by	IN	_	43	case
42	14	14	CD	_	43	nummod
43	%	%	NN	_	40	nmod
44	.	.	.	_	1	punct

1	No	no	DT	_	2	neg
2	information	information	NN	_	4	nsubj
3	is	be	VBZ	_	4	cop
4	available	available	JJ	_	0	ROOT
5	about	about	IN	_	7	case
6	the	the	DT	_	7	det
7	interaction	interaction	NN	_	4	nmod
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	drug2	drug2	NN	_	9	conj
12	following	follow	VBG	_	14	case
13	multiple	multiple	JJ	_	14	amod
14	doses	dose	NNS	_	7	nmod
15	of	of	IN	_	17	case
16	either	either	CC	_	17	det
17	drug	drug	NN	_	14	nmod
18	.	.	.	_	4	punct

1	Although	although	IN	_	3	mark
2	not	not	RB	_	3	neg
3	observed	observe	VBN	_	12	advcl
4	in	in	IN	_	6	case
5	this	this	DT	_	6	det
6	study	study	NN	_	3	nmod
7	,	,	,	_	12	punct
8	adverse	adverse	JJ	_	9	amod
9	effects	effect	NNS	_	12	nsubj
10	could	could	MD	_	12	aux
11	potentially	potentially	RB	_	12	advmod
12	arise	arise	VB	_	0	ROOT
13	from	from	IN	_	14	case
14	co-administration	co-administration	NN	_	12	nmod
15	of	of	IN	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	and	and	CC	_	16	cc
18	drug2	drug2	NN	_	16	conj
19	by	by	IN	_	20	case
20	inhibition	inhibition	NN	_	12	nmod
21	of	of	IN	_	23	case
22	tubular	tubular	JJ	_	23	amod
23	secretion	secretion	NN	_	20	nmod
24	via	via	IN	_	28	case
25	organic	organic	JJ	_	28	amod
26	cationic	cationic	JJ	_	28	amod
27	transporter	transporter	NN	_	28	compound
28	systems	system	NNS	_	20	nmod
29	.	.	.	_	12	punct

1	Accordingly	accordingly	RB	_	12	advmod
2	,	,	,	_	12	punct
3	careful	careful	JJ	_	5	amod
4	patient	patient	NN	_	5	compound
5	monitoring	monitoring	NN	_	12	nsubjpass
6	and	and	CC	_	5	cc
7	dose	dose	NN	_	8	compound
8	adjustment	adjustment	NN	_	5	conj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	5	nmod
11	is	be	VBZ	_	12	auxpass
12	recommended	recommend	VBN	_	0	ROOT
13	in	in	IN	_	14	case
14	patients	patient	NNS	_	12	nmod
15	concomitantly	concomitantly	RB	_	16	advmod
16	taking	take	VBG	_	14	acl
17	drug2	drug2	NN	_	16	dobj
18	and	and	CC	_	17	cc
19	drug3	drug3	NN	_	17	conj
20	.	.	.	_	12	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	As	as	IN	_	6	case
4	with	with	IN	_	6	case
5	other	other	JJ	_	6	amod
6	drug2	drug2	NN	_	14	nmod
7	,	,	,	_	6	punct
8	the	the	DT	_	10	det
9	renal	renal	JJ	_	10	amod
10	excretion	excretion	NN	_	14	nsubjpass
11	of	of	IN	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	is	be	VBZ	_	14	auxpass
14	inhibited	inhibit	VBN	_	1	appos
15	by	by	IN	_	16	case
16	drug4	drug4	NN	_	14	nmod
17	.	.	.	_	1	punct

1	Drug	drug	NN	_	5	compound
2	/	/	:	_	5	punct
3	Laboratory	Laboratory	NNP	_	5	compound
4	Test	Test	NNP	_	5	compound
5	Interactions	interaction	NNS	_	23	nsubj
6	As	as	IN	_	8	case
7	a	a	DT	_	8	det
8	result	result	NN	_	5	nmod
9	of	of	IN	_	10	case
10	administration	administration	NN	_	8	nmod
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	,	,	,	_	12	punct
14	a	a	DT	_	16	det
15	false-positive	false-positive	JJ	_	16	amod
16	reaction	reaction	NN	_	12	appos
17	for	for	IN	_	18	case
18	glucose	glucose	NN	_	16	nmod
19	in	in	IN	_	21	case
20	the	the	DT	_	21	det
21	urine	urine	NN	_	18	nmod
22	may	may	MD	_	23	aux
23	occur	occur	VB	_	0	ROOT
24	.	.	.	_	23	punct

1	This	this	DT	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	observed	observe	VBN	_	0	ROOT
5	with	with	IN	_	7	case
6	Benedict	Benedict	NNP	_	7	compound
7	s	s	NNS	_	4	nmod
8	and	and	CC	_	7	cc
9	Fehling	fehling	NN	_	11	compound
10	s	s	NNS	_	11	compound
11	solutions	solution	NNS	_	7	conj
12	and	and	CC	_	7	cc
13	also	also	RB	_	16	advmod
14	with	with	IN	_	16	case
15	Clinitest	Clinitest	NNP	_	16	compound
16	tablets	tablet	NNS	_	7	conj
17	.	.	.	_	4	punct

1	May	May	NNP	_	2	nsubj
2	interact	interact	VBP	_	0	ROOT
3	with	with	IN	_	5	case
4	the	the	DT	_	5	det
5	following	following	NN	_	2	nmod
6	:	:	:	_	2	punct
7	drug1	drug1	NN	_	15	nsubj
8	,	,	,	_	7	punct
9	drug2	drug2	NN	_	11	compound
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	use	use	NN	_	7	appos
12	with	with	IN	_	13	case
13	drug3	drug3	NN	_	11	nmod
14	may	may	MD	_	15	aux
15	prevent	prevent	VB	_	2	parataxis
16	the	the	DT	_	17	det
17	drug4	drug4	NN	_	15	dobj
18	from	from	IN	_	19	mark
19	working	work	VBG	_	15	advcl
20	properly	properly	RB	_	19	advmod
21	;	;	:	_	2	punct

1	drug1	drug1	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	metabolized	metabolize	VBN	_	0	ROOT
4	by	by	IN	_	6	case
5	the	the	DT	_	6	det
6	liver	liver	NN	_	3	nmod
7	,	,	,	_	3	punct
8	and	and	CC	_	3	cc
9	it	it	PRP	_	12	nsubj
10	is	be	VBZ	_	12	cop
11	theoretically	theoretically	RB	_	12	advmod
12	possible	possible	JJ	_	3	conj
13	that	that	IN	_	18	mark
14	its	its	PRP$	_	15	nmod:poss
15	metabolism	metabolism	NN	_	18	nsubjpass
16	may	may	MD	_	18	aux
17	be	be	VB	_	18	auxpass
18	enhanced	enhance	VBN	_	12	ccomp
19	by	by	IN	_	20	case
20	drugs	drug	NNS	_	18	nmod
21	known	know	VBN	_	20	acl
22	to	to	TO	_	23	mark
23	induce	induce	VB	_	21	xcomp
24	hepatic	hepatic	JJ	_	26	amod
25	microsomal	microsomal	JJ	_	26	amod
26	enzymes	enzyme	NNS	_	23	dobj
27	.	.	.	_	3	punct

1	However	however	RB	_	7	advmod
2	,	,	,	_	7	punct
3	neither	neither	CC	_	4	cc:preconj
4	drug1	drug1	NN	_	7	nsubj
5	nor	nor	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	appears	appear	VBZ	_	0	ROOT
8	to	to	TO	_	9	mark
9	affect	affect	VB	_	7	xcomp
10	drug3	drug3	NN	_	11	compound
11	metabolism	metabolism	NN	_	9	dobj
12	.	.	.	_	7	punct

1	Binding	binding	NN	_	8	nsubjpass
2	to	to	TO	_	4	case
3	plasma	plasma	NN	_	4	compound
4	protein	protein	NN	_	1	nmod
5	is	be	VBZ	_	8	auxpass
6	not	not	RB	_	8	neg
7	significantly	significantly	RB	_	8	advmod
8	altered	alter	VBN	_	0	ROOT
9	by	by	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	,	,	,	_	10	punct
12	drug2	drug2	NN	_	10	conj
13	,	,	,	_	10	punct
14	or	or	CC	_	10	cc
15	drug3	drug3	NN	_	10	conj
16	.	.	.	_	8	punct

1	Binding	binding	NN	_	6	nsubjpass
2	to	to	TO	_	4	case
3	plasma	plasma	NN	_	4	compound
4	proteins	protein	NNS	_	1	nmod
5	is	be	VBZ	_	6	auxpass
6	reduced	reduce	VBN	_	0	ROOT
7	by	by	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	clotibrate	clotibrate	NN	_	8	conj
11	and	and	CC	_	6	cc
12	increased	increase	VBN	_	6	conj
13	by	by	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	.	.	.	_	6	punct

1	Cardiovascular	Cardiovascular	NNP	_	2	compound
2	collapse	collapse	NN	_	12	nsubj
3	in	in	IN	_	4	case
4	patients	patient	NNS	_	2	nmod
5	treated	treat	VBN	_	4	acl
6	simultaneously	simultaneously	RB	_	5	advmod
7	with	with	IN	_	8	case
8	varapamil	varapamil	NN	_	5	nmod
9	and	and	CC	_	8	cc
10	drug1	drug1	NN	_	8	conj
11	is	be	VBZ	_	12	cop
12	rare	rare	JJ	_	0	ROOT
13	.	.	.	_	12	punct

1	The	the	DT	_	2	det
2	combination	combination	NN	_	17	nsubj
3	of	of	IN	_	5	case
4	therapeutic	therapeutic	JJ	_	5	amod
5	doses	dose	NNS	_	2	nmod
6	of	of	IN	_	8	case
7	intravenous	intravenous	JJ	_	8	amod
8	drug1	drug1	NN	_	5	nmod
9	and	and	CC	_	8	cc
10	drug2	drug2	NN	_	8	conj
11	in	in	IN	_	15	case
12	drug3	drug3	NN	_	15	compound
13	a-chloralose	a-chloralose	NN	_	15	compound
14	anesthetized	anesthetized	JJ	_	15	amod
15	swine	swine	NNS	_	2	nmod
16	has	have	VBZ	_	17	aux
17	resulted	result	VBN	_	0	ROOT
18	in	in	IN	_	20	case
19	ventricular	ventricular	JJ	_	20	amod
20	fibrillation	fibrillation	NN	_	17	nmod
21	and	and	CC	_	20	cc
22	cardiovascular	cardiovascular	JJ	_	23	amod
23	collapse	collapse	NN	_	20	conj
24	in	in	IN	_	25	case
25	association	association	NN	_	20	nmod
26	with	with	IN	_	28	case
27	marked	marked	JJ	_	28	amod
28	hyperkalemia	hyperkalemia	NN	_	25	nmod
29	.	.	.	_	17	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	recommended	recommend	VBN	_	0	ROOT
4	that	that	IN	_	37	mark
5	the	the	DT	_	6	det
6	combination	combination	NN	_	37	nsubjpass
7	of	of	IN	_	9	case
8	intravenous	intravenous	JJ	_	9	amod
9	drug1	drug1	NN	_	6	nmod
10	and	and	CC	_	9	cc
11	drug2	drug2	NN	_	9	conj
12	,	,	,	_	9	punct
13	such	such	JJ	_	15	case
14	as	as	IN	_	13	mwe
15	drug3	drug3	NN	_	9	nmod
16	,	,	,	_	9	punct
17	not	not	RB	_	19	neg
18	be	be	VB	_	19	auxpass
19	used	use	VBN	_	9	acl
20	together	together	RB	_	19	advmod
21	during	during	IN	_	23	case
22	the	the	DT	_	23	det
23	management	management	NN	_	19	nmod
24	of	of	IN	_	27	case
25	malignant	malignant	JJ	_	27	amod
26	hyperthermia	hyperthermia	NN	_	27	compound
27	crisis	crisis	NN	_	23	nmod
28	until	until	IN	_	30	case
29	the	the	DT	_	30	det
30	relevance	relevance	NN	_	19	nmod
31	of	of	IN	_	33	case
32	these	these	DT	_	33	det
33	findings	finding	NNS	_	30	nmod
34	to	to	TO	_	35	case
35	humans	human	NNS	_	30	nmod
36	is	be	VBZ	_	37	auxpass
37	established	establish	VBN	_	3	ccomp
38	.	.	.	_	3	punct

1	Administration	administration	NN	_	5	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	may	may	MD	_	5	aux
5	potentiate	potentiate	VB	_	0	ROOT
6	drug2	drug2	NN	_	5	dobj
7	-	-	:	_	6	punct
8	induced	induce	VBN	_	10	amod
9	neuromuscular	neuromuscular	JJ	_	10	amod
10	block	block	NN	_	6	dep
11	.	.	.	_	5	punct

1	The	the	DT	_	2	det
2	effectiveness	effectiveness	NN	_	0	ROOT
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	-	-	:	_	9	punct
6	only	only	RB	_	7	advmod
7	pills	pill	NNS	_	9	nsubjpass
8	is	be	VBZ	_	9	auxpass
9	reduced	reduce	VBN	_	2	dep
10	by	by	IN	_	13	case
11	hepatic	hepatic	JJ	_	13	amod
12	enzyme-inducing	enzyme-inducing	JJ	_	13	amod
13	drugs	drug	NNS	_	9	nmod
14	such	such	JJ	_	18	case
15	as	as	IN	_	14	mwe
16	the	the	DT	_	18	det
17	drug2	drug2	NN	_	18	compound
18	drug3	drug3	NN	_	13	nmod
19	,	,	,	_	18	punct
20	drug4	drug4	NN	_	18	conj
21	,	,	,	_	18	punct
22	and	and	CC	_	18	cc
23	drug5	drug5	NN	_	18	conj
24	,	,	,	_	9	punct
25	and	and	CC	_	9	cc
26	the	the	DT	_	28	det
27	drug6	drug6	NN	_	28	compound
28	drug7	drug7	NN	_	9	conj
29	.	.	.	_	2	punct

1	No	no	DT	_	3	neg
2	significant	significant	JJ	_	3	amod
3	interaction	interaction	NN	_	6	nsubjpass
4	has	have	VBZ	_	6	aux
5	been	be	VBN	_	6	auxpass
6	found	find	VBN	_	0	ROOT
7	with	with	IN	_	9	case
8	broad-spectrum	broad-spectrum	JJ	_	9	amod
9	drug1	drug1	NN	_	6	nmod
10	.	.	.	_	6	punct

1	drug1	drug1	NN	_	3	nsubj
2	can	can	MD	_	3	aux
3	inhibit	inhibit	VB	_	0	ROOT
4	CYP2C19	cyp2c19	NN	_	3	dobj
5	and	and	CC	_	3	cc
6	induce	induce	VB	_	3	conj
7	CYP3A4/5	cyp3a4/5	NN	_	6	dobj
8	with	with	IN	_	11	case
9	potentially	potentially	RB	_	10	advmod
10	important	important	JJ	_	11	amod
11	effects	effect	NNS	_	6	nmod
12	on	on	IN	_	14	case
13	plasma	plasma	NN	_	14	compound
14	concentrations	concentration	NNS	_	11	nmod
15	of	of	IN	_	17	case
16	other	other	JJ	_	17	amod
17	drugs	drug	NNS	_	14	nmod
18	.	.	.	_	3	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	13	nmod
3	,	,	,	_	13	punct
4	several	several	JJ	_	6	amod
5	drug1	drug1	NN	_	6	compound
6	s	s	NNS	_	13	nsubj
7	that	that	WDT	_	11	nsubj
8	are	be	VBP	_	11	cop
9	cytochrome	cytochrome	NN	_	11	compound
10	P450	p450	NN	_	11	compound
11	inducers	inducer	NNS	_	6	acl:relcl
12	can	can	MD	_	13	aux
13	decrease	decrease	VB	_	0	ROOT
14	plasma	plasma	NN	_	15	compound
15	concentrations	concentration	NNS	_	13	dobj
16	of	of	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	and	and	CC	_	17	cc
19	drug3	drug3	NN	_	17	conj
20	.	.	.	_	13	punct

1	drug1	drug1	NN	_	3	nsubjpass
2	was	be	VBD	_	3	auxpass
3	evaluated	evaluate	VBN	_	0	ROOT
4	in	in	IN	_	7	case
5	human	human	JJ	_	7	amod
6	liver	liver	NN	_	7	compound
7	microsomes	microsome	NNS	_	3	nmod
8	to	to	TO	_	9	mark
9	determine	determine	VB	_	3	xcomp
10	its	its	PRP$	_	11	nmod:poss
11	capacity	capacity	NN	_	9	dobj
12	to	to	TO	_	13	mark
13	inhibit	inhibit	VB	_	11	acl
14	the	the	DT	_	18	det
15	major	major	JJ	_	18	amod
16	cytochrome	cytochrome	NN	_	18	compound
17	P450	p450	NN	_	18	compound
18	enzymes	enzyme	NNS	_	13	dobj
19	responsible	responsible	JJ	_	18	amod
20	for	for	IN	_	22	case
21	the	the	DT	_	22	det
22	metabolism	metabolism	NN	_	19	nmod
23	of	of	IN	_	25	case
24	other	other	JJ	_	25	amod
25	drugs	drug	NNS	_	22	nmod
26	.	.	.	_	3	punct

1	Results	result	NNS	_	2	nsubj
2	demonstrate	demonstrate	VBP	_	0	ROOT
3	that	that	IN	_	14	mark
4	drug1	drug1	NN	_	14	nsubj
5	and	and	CC	_	4	cc
6	its	its	PRP$	_	10	nmod:poss
7	pharmacologically	pharmacologically	RB	_	8	advmod
8	active	active	JJ	_	10	amod
9	10-monohydroxy	10-monohydroxy	JJ	_	10	amod
10	metabolite	metabolite	NN	_	4	conj
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	drug2	drug2	NN	_	10	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	have	have	VBP	_	2	ccomp
15	little	little	JJ	_	14	dobj
16	or	or	CC	_	15	cc
17	no	no	DT	_	15	conj
18	capacity	capacity	NN	_	15	dep
19	to	to	TO	_	20	mark
20	function	function	VB	_	14	advcl
21	as	as	IN	_	22	case
22	inhibitors	inhibitor	NNS	_	20	nmod
23	for	for	IN	_	24	case
24	most	most	JJS	_	22	nmod
25	of	of	IN	_	30	case
26	the	the	DT	_	30	det
27	human	human	JJ	_	30	amod
28	cytochrome	cytochrome	NN	_	30	compound
29	P450	p450	NN	_	30	compound
30	enzymes	enzyme	NNS	_	24	nmod
31	evaluated	evaluate	VBN	_	30	acl
32	-LRB-	-lrb-	-LRB-	_	33	punct
33	CYP1A2	cyp1a2	NN	_	30	dep
34	,	,	,	_	33	punct
35	CYP2A6	cyp2a6	NN	_	33	conj
36	,	,	,	_	33	punct
37	CYP2C9	cyp2c9	NN	_	33	conj
38	,	,	,	_	33	punct
39	CYP2D6	cyp2d6	NN	_	33	conj
40	,	,	,	_	33	punct
41	CYP2E1	cyp2e1	NN	_	33	conj
42	,	,	,	_	33	punct
43	CYP4A9	cyp4a9	NN	_	33	conj
44	and	and	CC	_	33	cc
45	CYP4A11	cyp4a11	NN	_	33	conj
46	-RRB-	-rrb-	-RRB-	_	33	punct
47	with	with	IN	_	49	case
48	the	the	DT	_	49	det
49	exception	exception	NN	_	22	nmod
50	of	of	IN	_	51	case
51	CYP2C19	cyp2c19	NN	_	49	nmod
52	and	and	CC	_	51	cc
53	CYP3A4/5	cyp3a4/5	NN	_	51	conj
54	.	.	.	_	2	punct

1	Although	although	IN	_	11	mark
2	inhibition	inhibition	NN	_	11	nsubj
3	of	of	IN	_	5	case
4	CYP	cyp	NN	_	5	compound
5	3A4/5	3a4/5	NN	_	2	nmod
6	by	by	IN	_	7	case
7	drug1	drug1	NN	_	2	nmod
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	did	do	VBD	_	11	aux
11	occur	occur	VB	_	19	advcl
12	at	at	IN	_	14	case
13	high	high	JJ	_	14	amod
14	concentrations	concentration	NNS	_	11	nmod
15	,	,	,	_	19	punct
16	it	it	PRP	_	19	nsubj
17	is	be	VBZ	_	19	cop
18	not	not	RB	_	19	neg
19	likely	likely	JJ	_	0	ROOT
20	to	to	TO	_	24	mark
21	be	be	VB	_	24	cop
22	of	of	IN	_	24	case
23	clinical	clinical	JJ	_	24	amod
24	significance	significance	NN	_	19	xcomp
25	.	.	.	_	19	punct

1	The	the	DT	_	2	det
2	inhibition	inhibition	NN	_	14	nsubj
3	of	of	IN	_	4	case
4	CYP-2C19	cyp-2c19	NN	_	2	nmod
5	by	by	IN	_	6	case
6	drug1	drug1	NN	_	2	nmod
7	and	and	CC	_	6	cc
8	drug2	drug2	NN	_	6	conj
9	,	,	,	_	2	punct
10	however	however	RB	_	14	advmod
11	,	,	,	_	14	punct
12	is	be	VBZ	_	14	cop
13	clinically	clinically	RB	_	14	advmod
14	relevant	relevant	JJ	_	0	ROOT
15	.	.	.	_	14	punct

1	In	in	FW	_	2	compound
2	vitro	vitro	FW	_	9	advmod
3	,	,	,	_	9	punct
4	the	the	DT	_	7	det
5	UDP-glucuronyl	udp-glucuronyl	JJ	_	7	amod
6	transferase	transferase	NN	_	7	compound
7	level	level	NN	_	9	nsubjpass
8	was	be	VBD	_	9	auxpass
9	increased	increase	VBN	_	0	ROOT
10	,	,	,	_	9	punct
11	indicating	indicate	VBG	_	9	advcl
12	induction	induction	NN	_	11	dobj
13	of	of	IN	_	15	case
14	this	this	DT	_	15	det
15	enzyme	enzyme	NN	_	12	nmod
16	.	.	.	_	9	punct

1	Increases	increase	NNS	_	13	nsubjpass
2	of	of	IN	_	4	case
3	22	22	CD	_	4	nummod
4	%	%	NN	_	1	nmod
5	with	with	IN	_	6	case
6	drug1	drug1	NN	_	1	nmod
7	and	and	CC	_	6	cc
8	47	47	CD	_	9	nummod
9	%	%	NN	_	6	conj
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	were	be	VBD	_	13	auxpass
13	observed	observe	VBN	_	0	ROOT
14	.	.	.	_	13	punct

1	As	as	IN	_	2	case
2	drug1	drug1	NN	_	13	nmod
3	,	,	,	_	13	punct
4	the	the	DT	_	7	det
5	predominant	predominant	JJ	_	7	amod
6	plasma	plasma	NN	_	7	compound
7	substrate	substrate	NN	_	13	nsubj
8	,	,	,	_	13	punct
9	is	be	VBZ	_	13	cop
10	only	only	RB	_	13	advmod
11	a	a	DT	_	13	det
12	weak	weak	JJ	_	13	amod
13	inducer	inducer	NN	_	0	ROOT
14	of	of	IN	_	16	case
15	UDP-glucuronyl	udp-glucuronyl	JJ	_	16	amod
16	transferase	transferase	NN	_	13	nmod
17	,	,	,	_	13	punct
18	it	it	PRP	_	20	nsubj
19	is	be	VBZ	_	20	cop
20	unlikely	unlikely	JJ	_	13	ccomp
21	to	to	TO	_	22	mark
22	have	have	VB	_	20	xcomp
23	an	a	DT	_	24	det
24	effect	effect	NN	_	22	dobj
25	on	on	IN	_	26	case
26	drugs	drug	NNS	_	22	nmod
27	that	that	WDT	_	30	nsubjpass
28	are	be	VBP	_	30	auxpass
29	mainly	mainly	RB	_	30	advmod
30	eliminated	eliminate	VBN	_	26	acl:relcl
31	by	by	IN	_	32	case
32	conjugation	conjugation	NN	_	30	nmod
33	through	through	IN	_	35	case
34	UDP-glucuronyl	udp-glucuronyl	JJ	_	35	amod
35	transferase	transferase	NN	_	30	nmod
36	-LRB-	-lrb-	-LRB-	_	39	punct
37	e.g.	e.g.	FW	_	39	dep
38	,	,	,	_	39	punct
39	drug2	drug2	NN	_	35	dep
40	,	,	,	_	39	punct
41	drug3	drug3	NN	_	39	appos
42	-RRB-	-rrb-	-RRB-	_	39	punct
43	.	.	.	_	13	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	7	nmod
3	,	,	,	_	7	punct
4	drug1	drug1	NN	_	7	nsubj
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	induce	induce	VBP	_	0	ROOT
8	a	a	DT	_	9	det
9	subgroup	subgroup	NN	_	7	dobj
10	of	of	IN	_	15	case
11	the	the	DT	_	15	det
12	cytochrome	cytochrome	NN	_	15	compound
13	P450	p450	NN	_	15	compound
14	3A	3a	NN	_	15	compound
15	family	family	NN	_	9	nmod
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	CYP3A4	cyp3a4	NN	_	15	dep
18	and	and	CC	_	17	cc
19	CYP3A5	cyp3a5	NN	_	17	conj
20	-RRB-	-rrb-	-RRB-	_	17	punct
21	responsible	responsible	JJ	_	15	amod
22	for	for	IN	_	24	case
23	the	the	DT	_	24	det
24	metabolism	metabolism	NN	_	21	nmod
25	of	of	IN	_	26	case
26	drug3	drug3	NN	_	24	nmod
27	and	and	CC	_	26	cc
28	oral	oral	JJ	_	29	amod
29	drug4	drug4	NN	_	26	conj
30	,	,	,	_	7	punct
31	resulting	result	VBG	_	7	advcl
32	in	in	IN	_	36	case
33	a	a	DT	_	36	det
34	lower	lower	JJR	_	36	amod
35	plasma	plasma	NN	_	36	compound
36	concentration	concentration	NN	_	31	nmod
37	of	of	IN	_	39	case
38	these	these	DT	_	39	det
39	drugs	drug	NNS	_	36	nmod
40	.	.	.	_	7	punct

1	As	as	IN	_	2	case
2	binding	binding	NN	_	9	nmod
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	to	to	TO	_	7	case
6	plasma	plasma	NN	_	7	compound
7	proteins	protein	NNS	_	2	nmod
8	is	be	VBZ	_	9	cop
9	low	low	JJ	_	0	ROOT
10	-LRB-	-lrb-	-LRB-	_	12	punct
11	40	40	CD	_	12	nummod
12	%	%	NN	_	9	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	,	,	,	_	9	punct
15	clinically	clinically	RB	_	16	advmod
16	significant	significant	JJ	_	17	amod
17	interactions	interaction	NNS	_	28	nsubj
18	with	with	IN	_	20	case
19	other	other	JJ	_	20	amod
20	drugs	drug	NNS	_	17	nmod
21	through	through	IN	_	22	case
22	competition	competition	NN	_	17	nmod
23	for	for	IN	_	26	case
24	protein	protein	NN	_	26	compound
25	binding	binding	NN	_	26	compound
26	sites	site	NNS	_	22	nmod
27	are	be	VBP	_	28	cop
28	unlikely	unlikely	JJ	_	9	ccomp
29	.	.	.	_	9	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Potential	potential	JJ	_	4	amod
4	interactions	interaction	NNS	_	11	nsubjpass
5	between	between	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	other	other	JJ	_	9	amod
9	drug3	drug3	NN	_	6	conj
10	were	be	VBD	_	11	auxpass
11	assessed	assess	VBN	_	1	dep
12	in	in	IN	_	14	case
13	clinical	clinical	JJ	_	14	amod
14	studies	study	NNS	_	11	nmod
15	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	12	nsubjpass
3	of	of	IN	_	5	case
4	these	these	DT	_	5	det
5	interactions	interaction	NNS	_	2	nmod
6	on	on	IN	_	8	case
7	mean	mean	NN	_	8	compound
8	AUCs	auc	NNS	_	2	nmod
9	and	and	CC	_	8	cc
10	Cmin	cmin	NN	_	8	conj
11	are	be	VBP	_	12	auxpass
12	summarized	summarize	VBN	_	0	ROOT
13	in	in	IN	_	14	case
14	Table	Table	NNP	_	12	nmod
15	2	2	CD	_	14	nummod
16	:	:	:	_	12	punct
17	Table	Table	NNP	_	12	dep
18	2	2	CD	_	17	nummod
19	:	:	:	_	17	punct
20	Summary	Summary	NNP	_	17	dep
21	of	of	IN	_	23	case
22	AED	AED	NNP	_	23	compound
23	interactions	interaction	NNS	_	20	nmod
24	with	with	IN	_	25	case
25	drug1	drug1	NN	_	20	nmod

1	drug1	drug1	NN	_	2	nmod:npmod
2	Co-administered	co-administered	JJ	_	0	ROOT

1	Dose	dose	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	mg/day	mg/day	NN	_	3	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct

1	drug1	drug1	NN	_	2	compound
2	dose	dose	NN	_	0	ROOT
3	-LRB-	-lrb-	-LRB-	_	4	punct
4	mg/day	mg/day	NN	_	2	appos
5	-RRB-	-rrb-	-RRB-	_	4	punct

1	Influence	influence	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	on	on	IN	_	6	case
5	drug2	drug2	NN	_	6	compound
6	Concentration	concentration	NN	_	1	nmod
7	-LRB-	-lrb-	-LRB-	_	9	punct
8	Mean	mean	NN	_	9	compound
9	change	change	NN	_	6	dep
10	,	,	,	_	9	punct
11	90	90	CD	_	12	compound
12	%	%	NN	_	14	amod
13	Confidence	confidence	NN	_	14	compound
14	Interval	interval	NN	_	9	appos
15	-RRB-	-rrb-	-RRB-	_	9	punct

1	Influence	influence	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	On	on	IN	_	6	case
5	drug2	drug2	NN	_	6	compound
6	Concentration	concentration	NN	_	1	nmod
7	-LRB-	-lrb-	-LRB-	_	9	punct
8	Mean	mean	NN	_	9	compound
9	change	change	NN	_	6	dep
10	,	,	,	_	9	punct
11	90	90	CD	_	12	compound
12	%	%	NN	_	14	amod
13	Confidence	confidence	NN	_	14	compound
14	Interval	interval	NN	_	9	appos
15	-RRB-	-rrb-	-RRB-	_	9	punct

1	drug1	drug1	NN	_	0	ROOT

1	400-2000	400-2000	CD	_	0	ROOT

1	900	900	CD	_	0	ROOT

1	nc1	nc1	NN	_	4	compound
2	40	40	CD	_	3	compound
3	%	%	NN	_	4	amod
4	decrease	decrease	NN	_	0	ROOT
5	-LSB-	-lsb-	-LRB-	_	6	punct
6	CI	ci	NN	_	4	dep
7	:	:	:	_	6	punct
8	17	17	CD	_	9	compound
9	%	%	NN	_	10	amod
10	decrease	decrease	NN	_	6	dep
11	,	,	,	_	10	punct
12	57	57	CD	_	13	compound
13	%	%	NN	_	14	amod
14	decrease	decrease	NN	_	10	appos
15	-RSB-	-rsb-	-RRB-	_	6	punct

1	drug1	drug1	NN	_	0	ROOT

1	100-150	100-150	CD	_	0	ROOT

1	600-1800	600-1800	CD	_	0	ROOT

1	14	14	CD	_	2	compound
2	%	%	NN	_	3	amod
3	increase	increase	NN	_	0	ROOT
4	-LSB-	-lsb-	-LRB-	_	5	punct
5	CI	ci	NN	_	3	dep
6	:	:	:	_	5	punct
7	2	2	CD	_	8	compound
8	%	%	NN	_	9	amod
9	increase	increase	NN	_	5	dep
10	,	,	,	_	9	punct
11	24	24	CD	_	12	compound
12	%	%	NN	_	13	amod
13	increase	increase	NN	_	9	appos
14	-RSB-	-rsb-	-RRB-	_	9	punct
15	25	25	CD	_	16	compound
16	%	%	NN	_	17	amod
17	decrease	decrease	NN	_	9	dep
18	-LSB-	-lsb-	-LRB-	_	19	punct
19	CI	ci	NN	_	17	dep
20	:	:	:	_	19	punct
21	12	12	CD	_	22	compound
22	%	%	NN	_	23	amod
23	decrease	decrease	NN	_	19	dep
24	,	,	,	_	23	punct
25	51	51	CD	_	26	compound
26	%	%	NN	_	27	amod
27	decrease	decrease	NN	_	23	appos
28	-RSB-	-rsb-	-RRB-	_	19	punct

1	drug1	drug1	NN	_	0	ROOT

1	250-500	250-500	CD	_	0	ROOT

1	600-1800	600-1800	CD	_	0	ROOT

1	nc1	nc1	NN	_	5	compound
2	,2	,2	CD	_	3	compound
3	30	30	CD	_	4	dep
4	%	%	NN	_	5	dep
5	decrease	decrease	NN	_	0	ROOT
6	-LSB-	-lsb-	-LRB-	_	7	punct
7	CI	ci	NN	_	5	dep
8	:	:	:	_	7	punct
9	3	3	CD	_	10	compound
10	%	%	NN	_	11	amod
11	decrease	decrease	NN	_	7	dep
12	,	,	,	_	11	punct
13	48	48	CD	_	14	compound
14	%	%	NN	_	15	amod
15	decrease	decrease	NN	_	11	appos
16	-RSB-	-rsb-	-RRB-	_	7	punct

1	1200-2400	1200-2400	CD	_	4	compound
2	up	up	IN	_	4	advmod
3	to	to	TO	_	4	dep
4	40	40	CD	_	5	dep
5	%	%	NN	_	6	dep
6	increase3	increase3	NN	_	0	ROOT
7	-LSB-	-lsb-	-LRB-	_	8	punct
8	CI	ci	NN	_	6	dep
9	:	:	:	_	8	punct
10	12	12	CD	_	11	compound
11	%	%	NN	_	12	amod
12	increase	increase	NN	_	8	dep
13	,	,	,	_	12	punct
14	60	60	CD	_	15	compound
15	%	%	NN	_	16	amod
16	increase	increase	NN	_	12	appos
17	-RSB-	-rsb-	-RRB-	_	8	punct

1	drug1	drug1	NN	_	0	ROOT

1	400-2800	400-2800	CD	_	0	ROOT

1	600-1800	600-1800	CD	_	0	ROOT

1	nc1	nc1	NN	_	4	compound
2	18	18	CD	_	3	compound
3	%	%	NN	_	4	amod
4	decrease	decrease	NN	_	0	ROOT
5	-LSB-	-lsb-	-LRB-	_	6	punct
6	CI	ci	NN	_	4	dep
7	:	:	:	_	6	punct
8	13	13	CD	_	9	compound
9	%	%	NN	_	10	amod
10	decrease	decrease	NN	_	6	dep
11	,	,	,	_	10	punct
12	40	40	CD	_	13	compound
13	%	%	NN	_	14	amod
14	decrease	decrease	NN	_	10	appos
15	-RSB-	-rsb-	-RRB-	_	6	punct

1	1	1	LS	_	0	ROOT
2	-	-	:	_	1	punct
3	nc	nc	NN	_	4	nsubj
4	denotes	denote	VBZ	_	1	dep
5	a	a	DT	_	7	det
6	mean	mean	JJ	_	7	amod
7	change	change	NN	_	4	dobj
8	of	of	IN	_	12	case
9	less	less	JJR	_	11	advmod
10	than	than	IN	_	9	mwe
11	10	10	CD	_	12	nummod
12	%	%	NN	_	7	nmod
13	2	2	CD	_	12	nummod
14	-	-	:	_	7	punct
15	Pediatrics	pediatrics	NNS	_	7	dep
16	3	3	LS	_	15	dep
17	-	-	:	_	16	punct
18	Mean	mean	NN	_	19	compound
19	increase	increase	NN	_	16	dep
20	in	in	IN	_	21	case
21	adults	adult	NNS	_	19	nmod
22	at	at	IN	_	25	case
23	high	high	JJ	_	25	amod
24	drug1	drug1	NN	_	25	compound
25	doses	dose	NNS	_	19	nmod
26	In	in	FW	_	27	compound
27	vivo	vivo	FW	_	19	advmod
28	,	,	,	_	19	punct
29	the	the	DT	_	31	det
30	plasma	plasma	NN	_	31	compound
31	levels	level	NNS	_	19	appos
32	of	of	IN	_	33	case
33	drug2	drug2	NN	_	31	nmod
34	increased	increase	VBN	_	33	acl
35	by	by	IN	_	39	case
36	up	up	RB	_	38	dep
37	to	to	TO	_	36	mwe
38	40	40	CD	_	39	nummod
39	%	%	NN	_	34	nmod
40	,	,	,	_	19	punct
41	when	when	WRB	_	44	advmod
42	drug3	drug3	NN	_	44	nsubjpass
43	was	be	VBD	_	44	auxpass
44	given	give	VBN	_	19	acl:relcl
45	at	at	IN	_	46	case
46	doses	dose	NNS	_	44	nmod
47	above	above	IN	_	49	case
48	1200	1200	CD	_	49	nummod
49	mg/day	mg/day	NN	_	46	nmod
50	.	.	.	_	4	punct

1	Therefore	therefore	RB	_	25	advmod
2	,	,	,	_	25	punct
3	when	when	WRB	_	4	advmod
4	using	use	VBG	_	25	advcl
5	doses	dose	NNS	_	4	dobj
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	greater	greater	JJR	_	5	amod
9	than	than	IN	_	11	case
10	1200	1200	CD	_	11	nummod
11	mg/day	mg/day	NN	_	8	nmod
12	during	during	IN	_	14	case
13	adjunctive	adjunctive	JJ	_	14	amod
14	therapy	therapy	NN	_	4	nmod
15	,	,	,	_	25	punct
16	a	a	DT	_	17	det
17	decrease	decrease	NN	_	25	nsubjpass
18	in	in	IN	_	20	case
19	the	the	DT	_	20	det
20	dose	dose	NN	_	17	nmod
21	of	of	IN	_	22	case
22	drug2	drug2	NN	_	20	nmod
23	may	may	MD	_	25	aux
24	be	be	VB	_	25	auxpass
25	required	require	VBN	_	0	ROOT
26	.	.	.	_	25	punct

1	The	the	DT	_	2	det
2	increase	increase	NN	_	10	nsubj
3	of	of	IN	_	5	case
4	drug1	drug1	NN	_	5	compound
5	level	level	NN	_	2	nmod
6	,	,	,	_	10	punct
7	however	however	RB	_	10	advmod
8	,	,	,	_	10	punct
9	is	be	VBZ	_	10	cop
10	small	small	JJ	_	0	ROOT
11	-LRB-	-lrb-	-LRB-	_	13	punct
12	15	15	CD	_	13	nummod
13	%	%	NN	_	10	dep
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	when	when	WRB	_	16	advmod
16	given	give	VBN	_	10	advcl
17	with	with	IN	_	18	case
18	drug2	drug2	NN	_	16	nmod
19	.	.	.	_	10	punct

1	Strong	strong	JJ	_	2	amod
2	inducers	inducer	NNS	_	0	ROOT
3	of	of	IN	_	6	case
4	cytochrome	cytochrome	NN	_	6	compound
5	P450	p450	NN	_	6	compound
6	enzymes	enzyme	NNS	_	2	nmod
7	-LRB-	-lrb-	-LRB-	_	17	punct
8	i.e.	i.e.	FW	_	17	advmod
9	drug1	drug1	FW	_	8	dep
10	,	,	,	_	9	punct
11	drug2	drug2	NN	_	9	conj
12	and	and	CC	_	9	cc
13	drug3	drug3	NN	_	9	conj
14	-RRB-	-rrb-	-RRB-	_	17	punct
15	have	have	VBP	_	17	aux
16	been	be	VBN	_	17	auxpass
17	shown	show	VBN	_	6	acl
18	to	to	TO	_	19	mark
19	decrease	decrease	VB	_	17	xcomp
20	the	the	DT	_	22	det
21	plasma	plasma	NN	_	22	compound
22	levels	level	NNS	_	19	dobj
23	of	of	IN	_	24	case
24	drug4	drug4	NN	_	22	nmod
25	-LRB-	-lrb-	-LRB-	_	27	punct
26	29-40	29-40	CD	_	27	nummod
27	%	%	NN	_	24	appos
28	-RRB-	-rrb-	-RRB-	_	27	punct
29	.	.	.	_	2	punct

1	No	no	DT	_	2	neg
2	autoinduction	autoinduction	NN	_	5	nsubjpass
3	has	have	VBZ	_	5	aux
4	been	be	VBN	_	5	auxpass
5	observed	observe	VBN	_	0	ROOT
6	with	with	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	.	.	.	_	5	punct

1	Hormonal	hormonal	JJ	_	3	amod
2	drug1	drug1	NN	_	3	compound
3	Co-administration	co-administration	NN	_	12	nsubjpass
4	of	of	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	with	with	IN	_	9	case
7	an	a	DT	_	9	det
8	oral	oral	JJ	_	9	amod
9	drug3	drug3	NN	_	3	nmod
10	has	have	VBZ	_	12	aux
11	been	be	VBN	_	12	auxpass
12	shown	show	VBN	_	0	ROOT
13	to	to	TO	_	14	mark
14	influence	influence	VB	_	12	xcomp
15	the	the	DT	_	17	det
16	plasma	plasma	NN	_	17	compound
17	concentrations	concentration	NNS	_	14	dobj
18	of	of	IN	_	22	case
19	the	the	DT	_	22	det
20	two	two	CD	_	22	nummod
21	hormonal	hormonal	JJ	_	22	amod
22	components	component	NNS	_	17	nmod
23	,	,	,	_	22	punct
24	drug4	drug4	NN	_	22	appos
25	-LRB-	-lrb-	-LRB-	_	26	punct
26	EE	ee	NN	_	24	appos
27	-RRB-	-rrb-	-RRB-	_	26	punct
28	and	and	CC	_	24	cc
29	drug5	drug5	NN	_	24	conj
30	-LRB-	-lrb-	-LRB-	_	31	punct
31	LNG	lng	NN	_	29	appos
32	-RRB-	-rrb-	-RRB-	_	31	punct
33	.	.	.	_	12	punct

1	The	the	DT	_	4	det
2	mean	mean	NN	_	4	compound
3	AUC	auc	NN	_	4	compound
4	values	value	NNS	_	8	nsubjpass
5	of	of	IN	_	6	case
6	EE	ee	NN	_	4	nmod
7	were	be	VBD	_	8	auxpass
8	decreased	decrease	VBN	_	0	ROOT
9	by	by	IN	_	11	case
10	48	48	CD	_	11	nummod
11	%	%	NN	_	8	nmod
12	-LSB-	-lsb-	-LRB-	_	15	punct
13	90	90	CD	_	14	compound
14	%	%	NN	_	15	amod
15	CI	ci	NN	_	11	dep
16	:	:	:	_	15	punct
17	22-65	22-65	CD	_	15	dep
18	-RSB-	-rsb-	-RRB-	_	15	punct
19	in	in	IN	_	21	case
20	one	one	CD	_	21	nummod
21	study	study	NN	_	8	nmod
22	and	and	CC	_	21	cc
23	52	52	CD	_	24	nummod
24	%	%	NN	_	21	conj
25	-LSB-	-lsb-	-LRB-	_	28	punct
26	90	90	CD	_	27	compound
27	%	%	NN	_	28	amod
28	CI	ci	NN	_	24	appos
29	:	:	:	_	28	punct
30	38-52	38-52	CD	_	28	dep
31	-RSB-	-rsb-	-RRB-	_	28	punct
32	in	in	IN	_	34	case
33	another	another	DT	_	34	det
34	study	study	NN	_	21	nmod
35	-LSB-	-lsb-	-LRB-	_	36	punct
36	1,2	1,2	CD	_	21	appos
37	-RSB-	-rsb-	-RRB-	_	36	punct
38	.	.	.	_	8	punct

1	The	the	DT	_	4	det
2	mean	mean	NN	_	4	compound
3	AUC	auc	NN	_	4	compound
4	values	value	NNS	_	8	nsubjpass
5	of	of	IN	_	6	case
6	LNG	lng	NN	_	4	nmod
7	were	be	VBD	_	8	auxpass
8	decreased	decrease	VBN	_	0	ROOT
9	by	by	IN	_	11	case
10	32	32	CD	_	11	nummod
11	%	%	NN	_	8	nmod
12	-LSB-	-lsb-	-LRB-	_	15	punct
13	90	90	CD	_	14	compound
14	%	%	NN	_	15	amod
15	CI	ci	NN	_	11	dep
16	:	:	:	_	15	punct
17	20-45	20-45	CD	_	15	dep
18	-RSB-	-rsb-	-RRB-	_	15	punct
19	in	in	IN	_	21	case
20	one	one	CD	_	21	nummod
21	study	study	NN	_	8	nmod
22	and	and	CC	_	21	cc
23	52	52	CD	_	24	nummod
24	%	%	NN	_	21	conj
25	-LSB-	-lsb-	-LRB-	_	28	punct
26	90	90	CD	_	27	compound
27	%	%	NN	_	28	amod
28	CI	ci	NN	_	24	appos
29	:	:	:	_	28	punct
30	42-52	42-52	CD	_	28	dep
31	-RSB-	-rsb-	-RRB-	_	28	punct
32	in	in	IN	_	34	case
33	another	another	DT	_	34	det
34	study	study	NN	_	21	nmod
35	.	.	.	_	8	punct

1	Therefore	therefore	RB	_	10	advmod
2	,	,	,	_	10	punct
3	concurrent	concurrent	JJ	_	4	amod
4	use	use	NN	_	10	nsubj
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	with	with	IN	_	8	case
8	drug2	drug2	NN	_	4	nmod
9	may	may	MD	_	10	aux
10	render	render	VB	_	0	ROOT
11	these	these	DT	_	12	det
12	drug3	drug3	NN	_	14	nsubj
13	less	less	RBR	_	14	advmod
14	effective	effective	JJ	_	10	xcomp
15	.	.	.	_	10	punct

1	Studies	study	NNS	_	11	nsubjpass
2	with	with	IN	_	4	case
3	other	other	JJ	_	4	amod
4	oral	oral	JJ	_	1	nmod
5	or	or	CC	_	4	cc
6	implant	implant	VB	_	4	conj
7	drug1	drug1	NN	_	4	dep
8	have	have	VBP	_	11	aux
9	not	not	RB	_	11	neg
10	been	be	VBN	_	11	auxpass
11	conducted	conduct	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	drug1	drug1	NN	_	2	compound
2	s	s	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	After	after	IN	_	6	case
5	repeated	repeat	VBN	_	6	amod
6	co-administration	co-administration	NN	_	15	nmod
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	,	,	,	_	15	punct
10	the	the	DT	_	11	det
11	AUC	auc	NN	_	15	nsubjpass
12	of	of	IN	_	13	case
13	drug3	drug3	NN	_	11	nmod
14	was	be	VBD	_	15	auxpass
15	lowered	lower	VBN	_	2	dep
16	by	by	IN	_	18	case
17	28	28	CD	_	18	nummod
18	%	%	NN	_	15	nmod
19	-LSB-	-lsb-	-LRB-	_	22	punct
20	90	90	CD	_	21	compound
21	%	%	NN	_	22	amod
22	CI	ci	NN	_	18	dep
23	:	:	:	_	22	punct
24	20-33	20-33	CD	_	22	dep
25	-RSB-	-rsb-	-RRB-	_	22	punct
26	.	.	.	_	2	punct

1	drug1	drug1	NN	_	2	nsubj
2	produced	produce	VBD	_	0	ROOT
3	a	a	DT	_	4	det
4	decrease	decrease	NN	_	2	dobj
5	of	of	IN	_	7	case
6	20	20	CD	_	7	nummod
7	%	%	NN	_	4	nmod
8	-LSB-	-lsb-	-LRB-	_	11	punct
9	90	90	CD	_	10	compound
10	%	%	NN	_	11	amod
11	CI	ci	NN	_	7	dep
12	:	:	:	_	11	punct
13	18-27	18-27	CD	_	11	dep
14	-RSB-	-rsb-	-RRB-	_	11	punct
15	of	of	IN	_	18	case
16	the	the	DT	_	18	det
17	plasma	plasma	NN	_	18	compound
18	levels	level	NNS	_	7	nmod
19	of	of	IN	_	20	case
20	drug2	drug2	NN	_	18	nmod
21	.	.	.	_	2	punct

1	Other	other	JJ	_	3	amod
2	drug	drug	NN	_	3	compound
3	interactions	interaction	NNS	_	9	nsubj
4	drug1	drug1	NN	_	3	dep
5	,	,	,	_	4	punct
6	drug2	drug2	NN	_	4	conj
7	and	and	CC	_	4	cc
8	drug3	drug3	NN	_	4	conj
9	had	have	VBD	_	0	ROOT
10	no	no	DT	_	11	neg
11	effect	effect	NN	_	9	dobj
12	on	on	IN	_	14	case
13	the	the	DT	_	14	det
14	pharmacokinetics	pharmacokinetic	NNS	_	9	nmod
15	of	of	IN	_	16	case
16	drug4	drug4	NN	_	14	nmod
17	.	.	.	_	9	punct

1	Results	result	NNS	_	0	ROOT
2	with	with	IN	_	4	case
3	drug1	drug1	NN	_	4	compound
4	wshow	wshow	NN	_	1	nmod
5	no	no	DT	_	6	neg
6	evidence	evidence	NN	_	1	dep
7	of	of	IN	_	8	case
8	interaction	interaction	NN	_	6	nmod
9	with	with	IN	_	11	case
10	either	either	CC	_	11	cc:preconj
11	single	single	JJ	_	8	nmod
12	or	or	CC	_	11	cc
13	repeated	repeated	JJ	_	11	conj
14	doses	dose	NNS	_	11	dep
15	of	of	IN	_	16	case
16	drug2	drug2	NN	_	11	nmod
17	.	.	.	_	1	punct

1	THE	the	DT	_	3	det
2	POTENTIATING	potentiate	VBG	_	3	amod
3	ACTION	action	NN	_	8	nsubjpass
4	OF	of	IN	_	6	case
5	drug1	drug1	NN	_	6	compound
6	MUST	must	NN	_	3	nmod
7	BE	be	VBP	_	8	auxpass
8	CONSIDERED	consider	VBN	_	0	ROOT
9	WHEN	when	WRB	_	12	advmod
10	THE	the	DT	_	11	det
11	DRUG	drug	NN	_	12	nsubj
12	IS	be	VBZ	_	8	advcl
13	USED	USED	NNP	_	12	dobj
14	IN	in	IN	_	15	case
15	CONJUNCTION	CONJUNCTION	NNP	_	13	nmod
16	WITH	with	IN	_	20	case
17	drug2	drug2	NN	_	20	compound
18	SUCH	such	NN	_	20	compound
19	AS	as	JJ	_	20	amod
20	drug3	drug3	NN	_	12	nmod
21	,	,	,	_	20	punct
22	drug4	drug4	NN	_	20	appos
23	AND	and	CC	_	22	cc
24	drug5	drug5	NN	_	22	conj
25	.	.	.	_	8	punct

1	Therefore	therefore	RB	_	0	ROOT
2	when	when	WRB	_	5	advmod
3	drug1	drug1	NN	_	5	nsubjpass
4	are	be	VBP	_	5	auxpass
5	administered	administer	VBN	_	1	dep
6	concomitantly	concomitantly	RB	_	5	advmod
7	with	with	IN	_	8	case
8	drug2	drug2	NN	_	5	nmod
9	their	they	PRP$	_	10	nmod:poss
10	dosage	dosage	NN	_	13	nsubjpass
11	should	should	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	reduced	reduce	VBN	_	8	acl:relcl
14	.	.	.	_	1	punct

1	Since	since	IN	_	4	mark
2	drowsiness	drowsiness	NN	_	4	nsubj
3	may	may	MD	_	4	aux
4	occur	occur	VB	_	14	advcl
5	with	with	IN	_	6	case
6	use	use	NN	_	4	nmod
7	of	of	IN	_	9	case
8	this	this	DT	_	9	det
9	drug	drug	NN	_	6	nmod
10	,	,	,	_	14	punct
11	patients	patient	NNS	_	14	nsubjpass
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	warned	warn	VBN	_	0	ROOT
15	of	of	IN	_	17	case
16	this	this	DT	_	17	det
17	possibility	possibility	NN	_	14	nmod
18	and	and	CC	_	14	cc
19	cautioned	caution	VBD	_	14	conj
20	against	against	IN	_	21	mark
21	driving	drive	VBG	_	19	advcl
22	a	a	DT	_	23	det
23	car	car	NN	_	21	dobj
24	or	or	CC	_	21	cc
25	operating	operate	VBG	_	21	conj
26	dangerous	dangerous	JJ	_	27	amod
27	machinery	machinery	NN	_	25	dobj
28	while	while	IN	_	29	mark
29	taking	take	VBG	_	21	advcl
30	drug1	drug1	NN	_	29	dobj
31	.	.	.	_	14	punct

1	Patients	patient	NNS	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	advised	advise	VBN	_	0	ROOT
5	against	against	IN	_	8	case
6	the	the	DT	_	8	det
7	simultaneous	simultaneous	JJ	_	8	amod
8	use	use	NN	_	4	nmod
9	of	of	IN	_	11	case
10	other	other	JJ	_	11	amod
11	drug1	drug1	NN	_	8	nmod
12	,	,	,	_	4	punct
13	and	and	CC	_	4	cc
14	cautioned	caution	VBD	_	4	conj
15	that	that	IN	_	22	mark
16	the	the	DT	_	17	det
17	effect	effect	NN	_	22	nsubjpass
18	of	of	IN	_	19	case
19	drug2	drug2	NN	_	17	nmod
20	may	may	MD	_	22	aux
21	be	be	VB	_	22	auxpass
22	increased	increase	VBN	_	14	ccomp
23	.	.	.	_	4	punct

1	Additive	additive	JJ	_	3	amod
2	CNS	cns	NN	_	3	compound
3	depression	depression	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	occur	occur	VB	_	0	ROOT
6	when	when	WRB	_	9	advmod
7	drug1	drug1	NN	_	9	nsubjpass
8	are	be	VBP	_	9	auxpass
9	administered	administer	VBN	_	5	advcl
10	concomitantly	concomitantly	RB	_	9	advmod
11	with	with	IN	_	13	case
12	other	other	JJ	_	13	amod
13	drug2	drug2	NN	_	9	nmod
14	including	include	VBG	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	,	,	,	_	15	punct
17	drug4	drug4	NN	_	15	conj
18	,	,	,	_	15	punct
19	and	and	CC	_	15	cc
20	drug5	drug5	NN	_	15	conj
21	.	.	.	_	5	punct

1	Patients	patient	NNS	_	6	nsubjpass
2	receiving	receive	VBG	_	1	acl
3	drug1	drug1	NN	_	2	dobj
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	advised	advise	VBN	_	0	ROOT
7	against	against	IN	_	10	case
8	the	the	DT	_	10	det
9	concurrent	concurrent	JJ	_	10	amod
10	use	use	NN	_	6	nmod
11	of	of	IN	_	13	case
12	other	other	JJ	_	13	amod
13	drug2	drug2	NN	_	10	nmod
14	.	.	.	_	6	punct

1	drug1	drug1	NN	_	2	nsubj
2	prolong	prolong	VB	_	0	ROOT
3	and	and	CC	_	2	cc
4	intensify	intensify	VB	_	2	conj
5	the	the	DT	_	7	det
6	anticholinergic	anticholinergic	JJ	_	7	amod
7	effects	effect	NNS	_	2	dobj
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	.	.	.	_	2	punct

1	It	it	PRP	_	3	nsubj
2	is	be	VBZ	_	3	cop
3	possible	possible	JJ	_	0	ROOT
4	that	that	IN	_	13	mark
5	the	the	DT	_	7	det
6	cardiovascular	cardiovascular	JJ	_	7	amod
7	action	action	NN	_	13	nsubjpass
8	of	of	IN	_	10	case
9	other	other	JJ	_	10	amod
10	drug1	drug1	NN	_	7	nmod
11	could	could	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	enhanced	enhance	VBN	_	3	ccomp
14	by	by	IN	_	16	case
15	the	the	DT	_	16	det
16	addition	addition	NN	_	13	nmod
17	of	of	IN	_	18	case
18	drug2	drug2	NN	_	16	nmod
19	.	.	.	_	3	punct

1	In	in	IN	_	2	case
2	Europe	Europe	NNP	_	6	nmod
3	,	,	,	_	6	punct
4	drug1	drug1	NN	_	6	nsubjpass
5	was	be	VBD	_	6	auxpass
6	observed	observe	VBN	_	0	ROOT
7	to	to	TO	_	9	mark
8	occasionally	occasionally	RB	_	9	advmod
9	intensify	intensify	VB	_	6	xcomp
10	the	the	DT	_	11	det
11	effect	effect	NN	_	9	dobj
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	taken	take	VBN	_	13	acl
15	concomitantly	concomitantly	RB	_	14	advmod
16	by	by	IN	_	17	case
17	patients	patient	NNS	_	14	nmod
18	suffering	suffer	VBG	_	17	acl
19	from	from	IN	_	20	case
20	hypertension	hypertension	NN	_	18	nmod
21	;	;	:	_	6	punct

1	this	this	DT	_	2	det
2	phenomenon	phenomenon	NN	_	5	nsubjpass
3	was	be	VBD	_	5	auxpass
4	not	not	RB	_	5	neg
5	observed	observe	VBN	_	0	ROOT
6	in	in	IN	_	10	case
7	North	north	JJ	_	8	amod
8	American	american	JJ	_	10	amod
9	clinical	clinical	JJ	_	10	amod
10	trials	trial	NNS	_	5	nmod
11	.	.	.	_	5	punct

1	A	a	DT	_	2	det
2	study	study	NN	_	8	nsubj
3	in	in	IN	_	6	case
4	eight	eight	CD	_	6	nummod
5	healthy	healthy	JJ	_	6	amod
6	volunteers	volunteer	NNS	_	2	nmod
7	has	have	VBZ	_	8	aux
8	shown	show	VBN	_	0	ROOT
9	a	a	DT	_	12	det
10	50	50	CD	_	11	compound
11	%	%	NN	_	12	amod
12	increase	increase	NN	_	8	dobj
13	in	in	IN	_	18	case
14	mean	mean	JJ	_	18	amod
15	peak	peak	JJ	_	18	amod
16	drug1	drug1	NN	_	18	compound
17	plasma	plasma	NN	_	18	compound
18	concentrations	concentration	NNS	_	12	nmod
19	and	and	CC	_	12	cc
20	a	a	DT	_	23	det
21	90	90	CD	_	22	compound
22	%	%	NN	_	23	amod
23	increase	increase	NN	_	12	conj
24	in	in	IN	_	26	case
25	mean	mean	JJ	_	26	amod
26	area	area	NN	_	23	nmod
27	under	under	IN	_	29	case
28	the	the	DT	_	29	det
29	curve	curve	NN	_	23	nmod
30	,	,	,	_	12	punct
31	after	after	IN	_	35	case
32	a	a	DT	_	35	det
33	one	one	CD	_	35	nummod
34	week	week	NN	_	35	compound
35	course	course	NN	_	12	nmod
36	of	of	IN	_	37	case
37	drug2	drug2	NN	_	35	nmod
38	at	at	IN	_	40	case
39	1,000	1,000	CD	_	40	nummod
40	mg/day	mg/day	NN	_	35	nmod
41	and	and	CC	_	40	cc
42	drug3	drug3	NN	_	40	conj
43	at	at	IN	_	45	case
44	90	90	CD	_	45	nummod
45	mg/day	mg/day	NN	_	35	nmod
46	.	.	.	_	8	punct

1	This	this	DT	_	2	det
2	effect	effect	NN	_	5	nsubjpass
3	may	may	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	mediated	mediate	VBN	_	0	ROOT
6	by	by	IN	_	9	case
7	the	the	DT	_	9	det
8	known	known	JJ	_	9	amod
9	inhibition	inhibition	NN	_	5	nmod
10	of	of	IN	_	13	case
11	hepatic	hepatic	JJ	_	13	amod
12	cytochrome	cytochrome	NN	_	13	compound
13	P	p	NN	_	9	nmod
14	-	-	:	_	13	punct
15	450	450	CD	_	13	nummod
16	by	by	IN	_	17	case
17	drug1	drug1	NN	_	9	nmod
18	,	,	,	_	9	punct
19	which	which	WDT	_	21	nsubj
20	could	could	MD	_	21	aux
21	decrease	decrease	VB	_	9	acl:relcl
22	first	first	JJ	_	24	amod
23	pass	pass	NN	_	24	compound
24	metabolism	metabolism	NN	_	21	dobj
25	of	of	IN	_	26	case
26	drug2	drug2	NN	_	24	nmod
27	.	.	.	_	5	punct

1	Taking	take	VBG	_	16	csubj
2	a	a	DT	_	3	det
3	drug1	drug1	NN	_	1	dobj
4	while	while	IN	_	7	mark
5	you	you	PRP	_	7	nsubj
6	are	be	VBP	_	7	aux
7	taking	take	VBG	_	1	advcl
8	or	or	CC	_	7	cc
9	within	within	IN	_	11	case
10	2	2	CD	_	11	nummod
11	weeks	week	NNS	_	7	conj
12	of	of	IN	_	13	mark
13	taking	take	VBG	_	11	acl
14	drug2	drug2	NN	_	13	dobj
15	may	may	MD	_	16	aux
16	increase	increase	VB	_	0	ROOT
17	the	the	DT	_	18	det
18	risk	risk	NN	_	16	dobj
19	of	of	IN	_	23	case
20	central	central	JJ	_	23	amod
21	nervous	nervous	JJ	_	23	amod
22	system	system	NN	_	23	compound
23	depression	depression	NN	_	18	nmod
24	or	or	CC	_	16	cc
25	may	may	MD	_	26	aux
26	cause	cause	VB	_	16	conj
27	a	a	DT	_	32	det
28	severe	severe	JJ	_	32	amod
29	high	high	JJ	_	32	amod
30	blood	blood	NN	_	32	compound
31	pressure	pressure	NN	_	32	compound
32	reaction	reaction	NN	_	26	dobj
33	.	.	.	_	16	punct

1	No	no	DT	_	5	neg
2	formal	formal	JJ	_	5	amod
3	drug	drug	NN	_	5	compound
4	interaction	interaction	NN	_	5	compound
5	studies	study	NNS	_	10	nsubjpass
6	with	with	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	have	have	VBP	_	10	aux
9	been	be	VBN	_	10	auxpass
10	conducted	conduct	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	In	in	IN	_	2	case
2	Study	Study	NNP	_	10	nmod
3	1	1	CD	_	2	nummod
4	,	,	,	_	10	punct
5	patients	patient	NNS	_	10	nsubjpass
6	with	with	IN	_	8	case
7	colorectal	colorectal	JJ	_	8	amod
8	cancer	cancer	NN	_	5	nmod
9	were	be	VBD	_	10	auxpass
10	given	give	VBN	_	0	ROOT
11	drug1	drug1	NN	_	13	compound
12	/	/	:	_	13	punct
13	drug2	drug2	NN	_	10	dobj
14	/	/	:	_	13	punct
15	drug3	drug3	NN	_	22	compound
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	bolus-IFL	bolus-ifl	NN	_	15	appos
18	-RRB-	-rrb-	-RRB-	_	17	punct
19	with	with	IN	_	22	nmod
20	or	or	CC	_	19	cc
21	without	without	IN	_	19	conj
22	drug4	drug4	NN	_	13	dep
23	.	.	.	_	10	punct

1	drug1	drug1	NN	_	2	compound
2	concentrations	concentration	NNS	_	4	nsubj
3	were	be	VBD	_	4	cop
4	similar	similar	JJ	_	0	ROOT
5	in	in	IN	_	6	case
6	patients	patient	NNS	_	4	nmod
7	receiving	receive	VBG	_	6	acl
8	bolus-IFL	bolus-ifl	NN	_	7	dobj
9	alone	alone	RB	_	8	advmod
10	and	and	CC	_	6	cc
11	in	in	IN	_	12	case
12	combination	combination	NN	_	6	conj
13	with	with	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	concentrations	concentration	NNS	_	0	ROOT
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	,	,	,	_	4	punct
6	the	the	DT	_	8	det
7	active	active	JJ	_	8	amod
8	metabolite	metabolite	NN	_	4	appos
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	,	,	,	_	4	punct
12	were	be	VBD	_	2	acl
13	on	on	IN	_	16	case
14	average	average	JJ	_	16	amod
15	33	33	CD	_	16	nummod
16	%	%	NN	_	12	nmod
17	higher	higher	JJR	_	16	advmod
18	in	in	IN	_	19	case
19	patients	patient	NNS	_	16	nmod
20	receiving	receive	VBG	_	19	acl
21	bolus-IFL	bolus-ifl	NN	_	20	dobj
22	in	in	IN	_	23	case
23	combination	combination	NN	_	20	nmod
24	with	with	IN	_	25	case
25	drug3	drug3	NN	_	23	nmod
26	when	when	WRB	_	27	advmod
27	compared	compare	VBN	_	12	advcl
28	with	with	IN	_	29	case
29	bolus-IFL	bolus-ifl	NN	_	27	nmod
30	alone	alone	RB	_	29	advmod
31	.	.	.	_	2	punct

1	In	in	IN	_	2	case
2	Study	Study	NNP	_	10	nmod
3	1	1	CD	_	2	nummod
4	,	,	,	_	10	punct
5	patients	patient	NNS	_	10	nsubj
6	receiving	receive	VBG	_	5	acl
7	bolus-IFL	bolus-ifl	NN	_	6	dobj
8	plus	plus	CC	_	7	cc
9	drug1	drug1	NN	_	7	conj
10	had	have	VBD	_	0	ROOT
11	a	a	DT	_	13	det
12	higher	higher	JJR	_	13	amod
13	incidence	incidence	NN	_	10	dobj
14	of	of	IN	_	17	case
15	Grade	Grade	NNP	_	17	compound
16	3-4	3-4	CD	_	17	nummod
17	diarrhea	diarrhea	NN	_	13	nmod
18	and	and	CC	_	17	cc
19	neutropenia	neutropenia	NN	_	17	conj
20	.	.	.	_	10	punct

1	Due	due	JJ	_	5	case
2	to	to	TO	_	1	mwe
3	high	high	JJ	_	5	amod
4	inter-patient	inter-patient	JJ	_	5	amod
5	variability	variability	NN	_	26	nmod
6	and	and	CC	_	5	cc
7	limited	limited	JJ	_	8	amod
8	sampling	sampling	NN	_	5	conj
9	,	,	,	_	26	punct
10	the	the	DT	_	11	det
11	extent	extent	NN	_	26	nsubj
12	of	of	IN	_	14	case
13	the	the	DT	_	14	det
14	increase	increase	NN	_	11	nmod
15	in	in	IN	_	17	case
16	drug1	drug1	NN	_	17	compound
17	levels	level	NNS	_	14	nmod
18	in	in	IN	_	19	case
19	patients	patient	NNS	_	17	nmod
20	receiving	receive	VBG	_	19	acl
21	concurrent	concurrent	JJ	_	22	amod
22	drug2	drug2	NN	_	20	dobj
23	and	and	CC	_	22	cc
24	drug3	drug3	NN	_	22	conj
25	is	be	VBZ	_	26	cop
26	uncertain	uncertain	JJ	_	0	ROOT
27	.	.	.	_	26	punct

1	A	a	DT	_	2	det
2	number	number	NN	_	5	nsubj
3	of	of	IN	_	4	case
4	substances	substance	NNS	_	2	nmod
5	affect	affect	VBP	_	0	ROOT
6	glucose	glucose	NN	_	7	compound
7	metabolism	metabolism	NN	_	5	dobj
8	and	and	CC	_	5	cc
9	may	may	MD	_	10	aux
10	require	require	VB	_	5	conj
11	drug1	drug1	NN	_	13	compound
12	dose	dose	NN	_	13	compound
13	adjustment	adjustment	NN	_	10	dobj
14	and	and	CC	_	13	cc
15	particularly	particularly	RB	_	16	advmod
16	close	close	JJ	_	17	amod
17	monitoring	monitoring	NN	_	13	conj
18	.	.	.	_	5	punct

1	The	the	DT	_	2	det
2	following	follow	VBG	_	4	nsubj
3	are	be	VBP	_	4	cop
4	examples	example	NNS	_	0	ROOT
5	of	of	IN	_	6	case
6	substances	substance	NNS	_	4	nmod
7	that	that	WDT	_	9	nsubj
8	may	may	MD	_	9	aux
9	increase	increase	VB	_	4	acl:relcl
10	the	the	DT	_	12	det
11	blood-glucose-lowering	blood-glucose-lowering	NN	_	12	compound
12	effect	effect	NN	_	9	dobj
13	and	and	CC	_	12	cc
14	susceptibility	susceptibility	NN	_	12	conj
15	to	to	TO	_	16	case
16	hypoglycemia	hypoglycemia	NN	_	14	nmod
17	:	:	:	_	4	punct
18	oral	oral	JJ	_	19	amod
19	drug1	drug1	NN	_	4	dep
20	,	,	,	_	19	punct
21	drug2	drug2	NN	_	19	conj
22	,	,	,	_	19	punct
23	drug3	drug3	NN	_	19	conj
24	,	,	,	_	19	punct
25	drug4	drug4	NN	_	19	conj
26	,	,	,	_	19	punct
27	drug5	drug5	NN	_	19	conj
28	,	,	,	_	19	punct
29	drug6	drug6	NN	_	19	conj
30	,	,	,	_	19	punct
31	drug7	drug7	NN	_	19	conj
32	,	,	,	_	19	punct
33	drug8	drug8	NN	_	19	conj
34	,	,	,	_	19	punct
35	drug9	drug9	NN	_	19	conj
36	-LRB-	-lrb-	-LRB-	_	39	punct
37	e.g.	e.g.	FW	_	39	dep
38	,	,	,	_	39	punct
39	drug10	drug10	NN	_	35	appos
40	-RRB-	-rrb-	-RRB-	_	39	punct
41	,	,	,	_	19	punct
42	drug11	drug11	NN	_	19	conj
43	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	following	follow	VBG	_	4	nsubj
3	are	be	VBP	_	4	cop
4	examples	example	NNS	_	0	ROOT
5	of	of	IN	_	6	case
6	substances	substance	NNS	_	4	nmod
7	that	that	WDT	_	9	nsubj
8	may	may	MD	_	9	aux
9	reduce	reduce	VB	_	6	acl:relcl
10	the	the	DT	_	12	det
11	blood-glucose-lowering	blood-glucose-lowering	NN	_	12	compound
12	effect	effect	NN	_	9	dobj
13	:	:	:	_	4	punct
14	drug1	drug1	NN	_	4	dep
15	,	,	,	_	14	punct
16	drug2	drug2	NN	_	14	conj
17	,	,	,	_	14	punct
18	drug3	drug3	NN	_	14	conj
19	,	,	,	_	14	punct
20	drug4	drug4	NN	_	14	conj
21	,	,	,	_	14	punct
22	drug5	drug5	NN	_	14	conj
23	-LRB-	-lrb-	-LRB-	_	26	punct
24	e.g.	e.g.	FW	_	26	dep
25	,	,	,	_	26	punct
26	drug6	drug6	NN	_	22	dep
27	,	,	,	_	26	punct
28	drug7	drug7	NN	_	26	appos
29	,	,	,	_	26	punct
30	drug8	drug8	NN	_	26	appos
31	-RRB-	-rrb-	-RRB-	_	26	punct
32	,	,	,	_	14	punct
33	drug9	drug9	NN	_	14	conj
34	,	,	,	_	14	punct
35	drug10	drug10	NN	_	14	conj
36	,	,	,	_	14	punct
37	drug11	drug11	NN	_	14	conj
38	,	,	,	_	14	punct
39	drug12	drug12	NN	_	14	conj
40	,	,	,	_	14	punct
41	drug13	drug13	NN	_	14	conj
42	,	,	,	_	14	punct
43	drug14	drug14	NN	_	14	conj
44	-LRB-	-lrb-	-LRB-	_	49	punct
45	e.g.	e.g.	FW	_	49	advmod
46	,	,	,	_	49	punct
47	in	in	IN	_	49	case
48	oral	oral	JJ	_	49	amod
49	drug15	drug15	NN	_	43	appos
50	-RRB-	-rrb-	-RRB-	_	49	punct
51	.	.	.	_	4	punct

1	drug1	drug1	NN	_	12	nsubj
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	,	,	,	_	1	punct
5	drug3	drug3	NN	_	6	compound
6	salts	salt	NNS	_	1	conj
7	,	,	,	_	1	punct
8	and	and	CC	_	1	cc
9	drug4	drug4	NN	_	1	conj
10	may	may	MD	_	12	aux
11	either	either	RB	_	12	advmod
12	potentiate	potentiate	VB	_	0	ROOT
13	or	or	CC	_	12	cc
14	weaken	weaken	VB	_	12	conj
15	the	the	DT	_	17	det
16	blood-glucose-lowering	blood-glucose-lowering	NN	_	17	compound
17	effect	effect	NN	_	12	dobj
18	of	of	IN	_	19	case
19	drug5	drug5	NN	_	17	nmod
20	.	.	.	_	12	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	cause	cause	VB	_	0	ROOT
4	hypoglycemia	hypoglycemia	NN	_	3	dobj
5	,	,	,	_	4	punct
6	which	which	WDT	_	10	nsubjpass
7	may	may	MD	_	10	aux
8	sometimes	sometimes	RB	_	10	advmod
9	be	be	VB	_	10	auxpass
10	followed	follow	VBN	_	4	acl:relcl
11	by	by	IN	_	12	case
12	hyperglycemia	hyperglycemia	NN	_	10	nmod
13	.	.	.	_	3	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	28	nmod
3	,	,	,	_	28	punct
4	under	under	IN	_	6	case
5	the	the	DT	_	6	det
6	influence	influence	NN	_	28	nmod
7	of	of	IN	_	10	case
8	sympatholytic	sympatholytic	JJ	_	10	amod
9	medicinal	medicinal	JJ	_	10	amod
10	products	product	NNS	_	6	nmod
11	such	such	JJ	_	13	case
12	as	as	IN	_	11	mwe
13	drug1	drug1	NN	_	10	nmod
14	,	,	,	_	13	punct
15	drug2	drug2	NN	_	13	conj
16	,	,	,	_	13	punct
17	drug3	drug3	NN	_	13	conj
18	,	,	,	_	13	punct
19	and	and	CC	_	13	cc
20	drug4	drug4	NN	_	13	conj
21	,	,	,	_	28	punct
22	the	the	DT	_	23	det
23	signs	sign	NNS	_	28	nsubjpass
24	of	of	IN	_	25	case
25	hypoglycemia	hypoglycemia	NN	_	23	nmod
26	may	may	MD	_	28	aux
27	be	be	VB	_	28	auxpass
28	reduced	reduce	VBN	_	0	ROOT
29	or	or	CC	_	28	cc
30	absent	absent	JJ	_	28	conj
31	.	.	.	_	28	punct

1	Mixing	mixing	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod

1	A	a	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	study	study	NN	_	13	nsubj
4	in	in	IN	_	7	case
5	healthy	healthy	JJ	_	7	amod
6	male	male	JJ	_	7	amod
7	volunteers	volunteer	NNS	_	3	nmod
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	n	n	NN	_	7	dep
10	=	=	JJ	_	9	amod
11	24	24	CD	_	10	dep
12	-RRB-	-rrb-	-RRB-	_	9	punct
13	demonstrated	demonstrate	VBD	_	0	ROOT
14	that	that	IN	_	13	dobj
15	mixing	mix	VBG	_	14	dep
16	drug1	drug1	NN	_	15	dobj
17	with	with	IN	_	18	case
18	drug2	drug2	NN	_	15	nmod
19	immediately	immediately	RB	_	22	advmod
20	before	before	IN	_	22	mark
21	injection	injection	NN	_	22	nsubj
22	produced	produce	VBD	_	15	advcl
23	some	some	DT	_	24	det
24	attenuation	attenuation	NN	_	22	dobj
25	in	in	IN	_	28	case
26	the	the	DT	_	28	det
27	peak	peak	NN	_	28	compound
28	concentration	concentration	NN	_	22	nmod
29	of	of	IN	_	30	case
30	drug3	drug3	NN	_	28	nmod
31	,	,	,	_	15	punct
32	but	but	CC	_	15	cc
33	that	that	IN	_	47	mark
34	the	the	DT	_	35	det
35	time	time	NN	_	47	nsubjpass
36	to	to	TO	_	37	case
37	peak	peak	NN	_	35	nmod
38	and	and	CC	_	37	cc
39	the	the	DT	_	41	det
40	total	total	JJ	_	41	amod
41	bioavailability	bioavailability	NN	_	37	conj
42	of	of	IN	_	43	case
43	drug4	drug4	NN	_	41	nmod
44	were	be	VBD	_	47	auxpass
45	not	not	RB	_	47	neg
46	significantly	significantly	RB	_	47	advmod
47	affected	affect	VBN	_	15	conj
48	.	.	.	_	13	punct

1	If	if	IN	_	4	mark
2	drug1	drug1	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	mixed	mix	VBN	_	11	advcl
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	,	,	,	_	11	punct
8	drug3	drug3	NN	_	11	nsubjpass
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	drawn	draw	VBN	_	0	ROOT
12	into	into	IN	_	14	case
13	the	the	DT	_	14	det
14	syringe	syringe	NN	_	11	nmod
15	first	first	RB	_	11	advmod
16	.	.	.	_	11	punct

1	The	the	DT	_	2	det
2	injection	injection	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	made	make	VBN	_	0	ROOT
6	immediately	immediately	RB	_	5	advmod
7	after	after	IN	_	8	mark
8	mixing	mix	VBG	_	5	advcl
9	.	.	.	_	5	punct

1	Because	because	IN	_	3	mark
2	there	there	EX	_	3	expl
3	are	be	VBP	_	20	advcl
4	no	no	DT	_	5	neg
5	data	datum	NNS	_	3	nsubj
6	on	on	IN	_	8	case
7	the	the	DT	_	8	det
8	compatibility	compatibility	NN	_	5	nmod
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	crystalline	crystalline	JJ	_	14	amod
13	drug2	drug2	NN	_	14	compound
14	preparations	preparation	NNS	_	10	conj
15	,	,	,	_	20	punct
16	drug3	drug3	NN	_	20	nsubjpass
17	should	should	MD	_	20	aux
18	not	not	RB	_	20	neg
19	be	be	VB	_	20	auxpass
20	mixed	mix	VBN	_	0	ROOT
21	with	with	IN	_	23	case
22	these	these	DT	_	23	det
23	preparations	preparation	NNS	_	20	nmod
24	.	.	.	_	20	punct

1	The	the	DT	_	2	det
2	effects	effect	NNS	_	21	nsubjpass
3	of	of	IN	_	4	mark
4	mixing	mix	VBG	_	2	acl
5	drug1	drug1	NN	_	4	dobj
6	with	with	IN	_	7	case
7	drug2	drug2	NN	_	4	nmod
8	of	of	IN	_	10	case
9	animal	animal	NN	_	10	compound
10	source	source	NN	_	7	nmod
11	or	or	CC	_	10	cc
12	drug3	drug3	NN	_	13	compound
13	preparations	preparation	NNS	_	10	conj
14	produced	produce	VBN	_	7	acl
15	by	by	IN	_	17	case
16	other	other	JJ	_	17	amod
17	manufacturers	manufacturer	NNS	_	14	nmod
18	have	have	VBP	_	21	aux
19	not	not	RB	_	21	neg
20	been	be	VBN	_	21	auxpass
21	studied	study	VBN	_	0	ROOT
22	.	.	.	_	21	punct

1	Mixtures	mixture	NNS	_	5	nsubjpass
2	should	should	MD	_	5	aux
3	not	not	RB	_	5	neg
4	be	be	VB	_	5	auxpass
5	administered	administer	VBN	_	0	ROOT
6	intravenously	intravenously	RB	_	5	advmod
7	.	.	.	_	5	punct

1	When	when	WRB	_	2	advmod
2	used	use	VBN	_	15	advcl
3	in	in	IN	_	7	case
4	external	external	JJ	_	7	amod
5	subcutaneous	subcutaneous	JJ	_	7	amod
6	infusion	infusion	NN	_	7	compound
7	pumps	pump	NNS	_	2	nmod
8	for	for	IN	_	9	case
9	drug1	drug1	NN	_	2	nmod
10	,	,	,	_	15	punct
11	drug2	drug2	NN	_	15	nsubjpass
12	should	should	MD	_	15	aux
13	not	not	RB	_	15	neg
14	be	be	VB	_	15	auxpass
15	mixed	mix	VBN	_	0	ROOT
16	with	with	IN	_	19	case
17	any	any	DT	_	19	det
18	other	other	JJ	_	19	amod
19	drug3	drug3	NN	_	15	nmod
20	or	or	CC	_	19	cc
21	diluent	diluent	NN	_	19	conj
22	.	.	.	_	15	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	diminish	diminish	VB	_	1	appos
6	adrenal	adrenal	JJ	_	7	amod
7	suppression	suppression	NN	_	5	dobj
8	by	by	IN	_	9	case
9	drug3	drug3	NN	_	5	nmod
10	.	.	.	_	1	punct

1	drug1	drug1	NN	_	2	compound
2	injection	injection	NN	_	0	ROOT
3	and	and	CC	_	2	cc
4	potassium-depleting	potassium-depleting	JJ	_	5	amod
5	agents	agent	NNS	_	2	conj
6	:	:	:	_	2	punct
7	When	when	WRB	_	10	advmod
8	drug2	drug2	NN	_	10	nsubjpass
9	are	be	VBP	_	10	auxpass
10	administered	administer	VBN	_	26	advcl
11	concomitantly	concomitantly	RB	_	10	advmod
12	with	with	IN	_	14	case
13	potassium-depleting	potassium-depleting	JJ	_	14	amod
14	agents	agent	NNS	_	10	nmod
15	-LRB-	-lrb-	-LRB-	_	18	punct
16	e.g.	e.g.	FW	_	18	dep
17	,	,	,	_	18	punct
18	drug3	drug3	NN	_	14	dep
19	,	,	,	_	18	punct
20	drug4	drug4	NN	_	18	appos
21	-RRB-	-rrb-	-RRB-	_	18	punct
22	,	,	,	_	26	punct
23	patients	patient	NNS	_	26	nsubjpass
24	should	should	MD	_	26	aux
25	be	be	VB	_	26	auxpass
26	observed	observe	VBN	_	2	dep
27	closely	closely	RB	_	26	advmod
28	for	for	IN	_	29	case
29	development	development	NN	_	26	nmod
30	of	of	IN	_	31	case
31	hypokalemia	hypokalemia	NN	_	29	nmod
32	.	.	.	_	2	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	7	nmod
3	,	,	,	_	7	punct
4	there	there	EX	_	7	expl
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	cop
7	cases	case	NNS	_	0	ROOT
8	reported	report	VBD	_	7	acl
9	in	in	IN	_	10	case
10	which	which	WDT	_	18	nmod
11	concomitant	concomitant	JJ	_	12	amod
12	use	use	NN	_	18	nsubjpass
13	of	of	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	and	and	CC	_	14	cc
16	drug2	drug2	NN	_	14	conj
17	was	be	VBD	_	18	auxpass
18	followed	follow	VBN	_	8	ccomp
19	by	by	IN	_	21	case
20	cardiac	cardiac	JJ	_	21	amod
21	enlargement	enlargement	NN	_	18	nmod
22	and	and	CC	_	21	cc
23	congestive	congestive	JJ	_	25	amod
24	heart	heart	NN	_	25	compound
25	failure	failure	NN	_	21	conj
26	.	.	.	_	7	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	6	nsubjpass
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	auxpass
6	reported	report	VBN	_	1	appos
7	to	to	TO	_	8	mark
8	cause	cause	VB	_	6	xcomp
9	a	a	DT	_	11	det
10	significant	significant	JJ	_	11	amod
11	decrease	decrease	NN	_	8	dobj
12	in	in	IN	_	14	case
13	drug3	drug3	NN	_	14	compound
14	clearance	clearance	NN	_	11	nmod
15	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concomitant	concomitant	JJ	_	4	amod
4	use	use	NN	_	10	nsubj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	drug3	drug3	NN	_	6	conj
9	may	may	MD	_	10	aux
10	produce	produce	VB	_	1	appos
11	severe	severe	JJ	_	12	amod
12	weakness	weakness	NN	_	10	dobj
13	in	in	IN	_	14	case
14	patients	patient	NNS	_	12	nmod
15	with	with	IN	_	17	case
16	myasthenia	myasthenia	NN	_	17	compound
17	gravis	gravis	NN	_	14	nmod
18	.	.	.	_	1	punct

1	If	if	IN	_	2	mark
2	possible	possible	JJ	_	7	advcl
3	,	,	,	_	7	punct
4	drug1	drug1	NN	_	7	nsubjpass
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	withdrawn	withdraw	VBN	_	0	ROOT
8	at	at	IN	_	9	case
9	least	least	JJS	_	10	nmod:npmod
10	24	24	CD	_	11	nummod
11	hours	hour	NNS	_	7	dobj
12	before	before	IN	_	13	mark
13	initiating	initiate	VBG	_	7	advcl
14	drug2	drug2	NN	_	15	compound
15	therapy	therapy	NN	_	13	dobj
16	.	.	.	_	7	punct

1	drug1	drug1	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	oral	oral	JJ	_	1	amod
4	:	:	:	_	1	punct
5	Co-administration	co-administration	NN	_	11	nsubj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drug3	drug3	NN	_	7	conj
10	usually	usually	RB	_	11	advmod
11	results	result	VBZ	_	1	dep
12	in	in	IN	_	13	case
13	inhibition	inhibition	NN	_	11	nmod
14	of	of	IN	_	15	case
15	response	response	NN	_	13	nmod
16	to	to	TO	_	17	case
17	drug4	drug4	NN	_	15	nmod
18	,	,	,	_	11	punct
19	although	although	IN	_	25	mark
20	there	there	EX	_	25	expl
21	have	have	VBP	_	25	aux
22	been	be	VBN	_	25	cop
23	some	some	DT	_	25	det
24	conflicting	conflict	VBG	_	25	amod
25	reports	report	NNS	_	11	advcl
26	.	.	.	_	1	punct

1	Therefore	therefore	RB	_	7	advmod
2	,	,	,	_	7	punct
3	coagulation	coagulation	NN	_	4	compound
4	indices	index	NNS	_	7	nsubjpass
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	monitored	monitor	VBN	_	0	ROOT
8	frequently	frequently	RB	_	7	advmod
9	to	to	TO	_	10	mark
10	maintain	maintain	VB	_	7	xcomp
11	the	the	DT	_	14	det
12	desired	desire	VBN	_	14	amod
13	anticoagulant	anticoagulant	JJ	_	14	amod
14	effect	effect	NN	_	10	dobj
15	.	.	.	_	7	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Because	because	IN	_	6	mark
4	drug2	drug2	NN	_	6	nsubj
5	may	may	MD	_	6	aux
6	increase	increase	VB	_	17	advcl
7	blood	blood	NN	_	9	compound
8	glucose	glucose	NN	_	9	compound
9	concentrations	concentration	NNS	_	6	dobj
10	,	,	,	_	17	punct
11	dosage	dosage	NN	_	12	compound
12	adjustments	adjustment	NNS	_	17	nsubjpass
13	of	of	IN	_	14	case
14	drug3	drug3	NN	_	12	nmod
15	may	may	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	required	require	VBN	_	1	dep
18	.	.	.	_	1	punct

1	Antitubercular	antitubercular	JJ	_	2	amod
2	drugs	drug	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	Serum	serum	NN	_	5	compound
5	concentrations	concentration	NNS	_	10	nsubjpass
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	may	may	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	decreased	decrease	VBN	_	2	dep
11	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	increase	increase	VB	_	1	dep
6	the	the	DT	_	7	det
7	clearance	clearance	NN	_	5	dobj
8	of	of	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Increased	increase	VBN	_	4	amod
4	activity	activity	NN	_	11	nsubj
5	of	of	IN	_	7	case
6	both	both	CC	_	7	cc:preconj
7	drug2	drug2	NN	_	4	nmod
8	and	and	CC	_	7	cc
9	drug3	drug3	NN	_	7	conj
10	may	may	MD	_	11	aux
11	occur	occur	VB	_	1	appos
12	when	when	WRB	_	16	advmod
13	the	the	DT	_	14	det
14	two	two	CD	_	16	nsubjpass
15	are	be	VBP	_	16	auxpass
16	used	use	VBN	_	11	advcl
17	concurrently	concurrently	RB	_	16	advmod
18	.	.	.	_	1	punct

1	Convulsions	convulsion	NNS	_	4	nsubjpass
2	have	have	VBP	_	4	aux
3	been	be	VBN	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	with	with	IN	_	8	case
6	this	this	DT	_	8	det
7	concurrent	concurrent	JJ	_	8	amod
8	use	use	NN	_	4	nmod
9	.	.	.	_	4	punct

1	Dexamethasone	dexamethasone	NN	_	3	compound
2	suppression	suppression	NN	_	3	compound
3	test	test	NN	_	0	ROOT
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	DST	dst	NN	_	3	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	:	:	:	_	3	punct
8	False-negative	false-negative	JJ	_	9	amod
9	results	result	NNS	_	26	nsubjpass
10	in	in	IN	_	14	case
11	the	the	DT	_	14	det
12	dexamethasone	dexamethasone	NN	_	14	compound
13	suppression	suppression	NN	_	14	compound
14	test	test	NN	_	9	nmod
15	-LRB-	-lrb-	-LRB-	_	16	punct
16	DST	dst	NN	_	14	appos
17	-RRB-	-rrb-	-RRB-	_	16	punct
18	in	in	IN	_	19	case
19	patients	patient	NNS	_	14	nmod
20	being	be	VBG	_	21	auxpass
21	treated	treat	VBN	_	19	acl
22	with	with	IN	_	23	case
23	drug1	drug1	NN	_	21	nmod
24	have	have	VBP	_	26	aux
25	been	be	VBN	_	26	auxpass
26	reported	report	VBN	_	3	dep
27	.	.	.	_	3	punct

1	Thus	thus	RB	_	9	advmod
2	,	,	,	_	9	punct
3	results	result	NNS	_	9	nsubjpass
4	of	of	IN	_	6	case
5	the	the	DT	_	6	det
6	DST	DST	NNP	_	3	nmod
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	interpreted	interpret	VBN	_	0	ROOT
10	with	with	IN	_	11	case
11	caution	caution	NN	_	9	nmod
12	in	in	IN	_	14	case
13	these	these	DT	_	14	det
14	patients	patient	NNS	_	11	nmod
15	.	.	.	_	9	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Patients	patient	NNS	_	10	nsubj
4	on	on	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	may	may	MD	_	10	aux
7	be	be	VB	_	10	cop
8	at	at	IN	_	10	case
9	increased	increase	VBN	_	10	amod
10	risk	risk	NN	_	1	appos
11	of	of	IN	_	12	case
12	arrhythmias	arrhythmia	NNS	_	10	nmod
13	due	due	JJ	_	15	case
14	to	to	TO	_	13	mwe
15	hypokalemia	hypokalemia	NN	_	12	nmod
16	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	enhance	enhance	VB	_	1	dep
6	the	the	DT	_	8	det
7	metabolic	metabolic	JJ	_	8	amod
8	clearance	clearance	NN	_	5	dobj
9	of	of	IN	_	10	case
10	drug3	drug3	NN	_	8	nmod
11	,	,	,	_	5	punct
12	resulting	result	VBG	_	5	conj
13	in	in	IN	_	16	case
14	decreased	decrease	VBN	_	16	amod
15	blood	blood	NN	_	16	compound
16	levels	level	NNS	_	12	nmod
17	and	and	CC	_	5	cc
18	lessened	lessen	VBD	_	5	conj
19	physiologic	physiologic	JJ	_	20	amod
20	activity	activity	NN	_	18	dobj
21	,	,	,	_	5	punct
22	thus	thus	RB	_	23	advmod
23	requiring	require	VBG	_	5	advcl
24	an	a	DT	_	25	det
25	increase	increase	NN	_	23	dobj
26	in	in	IN	_	28	case
27	drug4	drug4	NN	_	28	compound
28	dosage	dosage	NN	_	25	nmod
29	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	including	include	VBG	_	5	case
4	oral	oral	JJ	_	5	amod
5	drug2	drug2	NN	_	1	nmod
6	:	:	:	_	1	punct
7	drug3	drug3	NN	_	9	nsubj
8	may	may	MD	_	9	aux
9	decrease	decrease	VB	_	1	dep
10	the	the	DT	_	12	det
11	hepatic	hepatic	JJ	_	12	amod
12	metabolism	metabolism	NN	_	9	dobj
13	of	of	IN	_	15	case
14	certain	certain	JJ	_	15	amod
15	drug4	drug4	NN	_	12	nmod
16	,	,	,	_	9	punct
17	thereby	thereby	RB	_	18	advmod
18	increasing	increase	VBG	_	9	advcl
19	their	they	PRP$	_	20	nmod:poss
20	effect	effect	NN	_	18	dobj
21	.	.	.	_	1	punct

1	Hepatic	hepatic	JJ	_	3	amod
2	Enzyme	enzyme	NN	_	3	compound
3	Inducers	inducer	NNS	_	0	ROOT
4	,	,	,	_	3	punct
5	Inhibitors	inhibitor	NNS	_	3	conj
6	and	and	CC	_	3	cc
7	Substrates	substrate	NNS	_	3	conj
8	:	:	:	_	3	punct
9	Drugs	drug	NNS	_	33	nsubj
10	which	which	WDT	_	11	nsubj
11	induce	induce	VBP	_	9	acl:relcl
12	cytochrome	cytochrome	NN	_	14	compound
13	P450	p450	NN	_	14	compound
14	3A4	3a4	NN	_	20	compound
15	-LRB-	-lrb-	-LRB-	_	17	punct
16	CYP	cyp	NN	_	17	compound
17	3A4	3a4	NN	_	14	appos
18	-RRB-	-rrb-	-RRB-	_	17	punct
19	enzyme	enzyme	NN	_	20	compound
20	activity	activity	NN	_	11	dobj
21	-LRB-	-lrb-	-LRB-	_	24	punct
22	e.g.	e.g.	FW	_	24	dep
23	,	,	,	_	24	punct
24	drug1	drug1	NN	_	9	dep
25	,	,	,	_	24	punct
26	drug2	drug2	NN	_	24	conj
27	,	,	,	_	24	punct
28	drug3	drug3	NN	_	24	conj
29	,	,	,	_	24	punct
30	drug4	drug4	NN	_	24	appos
31	-RRB-	-rrb-	-RRB-	_	24	punct
32	may	may	MD	_	33	aux
33	enhance	enhance	VB	_	3	dep
34	the	the	DT	_	35	det
35	metabolism	metabolism	NN	_	33	dobj
36	of	of	IN	_	37	case
37	drug5	drug5	NN	_	35	nmod
38	and	and	CC	_	33	cc
39	require	require	VB	_	33	conj
40	that	that	IN	_	47	mark
41	the	the	DT	_	42	det
42	dosage	dosage	NN	_	47	nsubjpass
43	of	of	IN	_	45	case
44	the	the	DT	_	45	det
45	drug6	drug6	NN	_	42	nmod
46	be	be	VB	_	47	auxpass
47	increased	increase	VBN	_	39	ccomp
48	.	.	.	_	3	punct

1	Drugs	drug	NNS	_	16	nsubj
2	which	which	WDT	_	3	nsubj
3	inhibit	inhibit	VBP	_	1	acl:relcl
4	CYP	cyp	NN	_	5	compound
5	3A4	3a4	NN	_	3	dobj
6	-LRB-	-lrb-	-LRB-	_	9	punct
7	e.g.	e.g.	FW	_	9	dep
8	,	,	,	_	9	punct
9	drug1	drug1	NN	_	5	dep
10	,	,	,	_	9	punct
11	drug2	drug2	NN	_	9	appos
12	such	such	JJ	_	14	case
13	as	as	IN	_	12	mwe
14	drug3	drug3	NN	_	11	nmod
15	-RRB-	-rrb-	-RRB-	_	9	punct
16	have	have	VBP	_	0	ROOT
17	the	the	DT	_	18	det
18	potential	potential	JJ	_	16	dobj
19	to	to	TO	_	20	mark
20	result	result	VB	_	18	acl
21	in	in	IN	_	24	case
22	increased	increase	VBN	_	24	amod
23	plasma	plasma	NN	_	24	compound
24	concentrations	concentration	NNS	_	20	nmod
25	of	of	IN	_	26	case
26	drug4	drug4	NN	_	24	nmod
27	.	.	.	_	16	punct

1	drug1	drug1	NN	_	5	nsubj
2	is	be	VBZ	_	5	cop
3	a	a	DT	_	5	det
4	moderate	moderate	JJ	_	5	amod
5	inducer	inducer	NN	_	0	ROOT
6	of	of	IN	_	8	case
7	CYP	cyp	NN	_	8	compound
8	3A4	3a4	NN	_	5	nmod
9	.	.	.	_	5	punct

1	Co-administration	co-administration	NN	_	19	nsubj
2	with	with	IN	_	4	case
3	other	other	JJ	_	4	amod
4	drugs	drug	NNS	_	1	nmod
5	that	that	WDT	_	7	nsubjpass
6	are	be	VBP	_	7	auxpass
7	metabolized	metabolize	VBN	_	4	acl:relcl
8	by	by	IN	_	10	case
9	CYP	cyp	NN	_	10	compound
10	3A4	3a4	NN	_	7	nmod
11	-LRB-	-lrb-	-LRB-	_	14	punct
12	e.g.	e.g.	FW	_	14	dep
13	,	,	,	_	14	punct
14	drug1	drug1	NN	_	10	dep
15	,	,	,	_	14	punct
16	drug2	drug2	NN	_	14	appos
17	-RRB-	-rrb-	-RRB-	_	14	punct
18	may	may	MD	_	19	aux
19	increase	increase	VB	_	0	ROOT
20	their	they	PRP$	_	21	nmod:poss
21	clearance	clearance	NN	_	19	dobj
22	,	,	,	_	19	punct
23	resulting	result	VBG	_	19	advcl
24	in	in	IN	_	27	case
25	decreased	decrease	VBN	_	27	amod
26	plasma	plasma	NN	_	27	compound
27	concentration	concentration	NN	_	23	nmod
28	.	.	.	_	19	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	6	nsubjpass
4	has	have	VBZ	_	6	aux
5	been	be	VBN	_	6	auxpass
6	reported	report	VBN	_	1	dep
7	to	to	TO	_	8	mark
8	decrease	decrease	VB	_	6	xcomp
9	the	the	DT	_	10	det
10	metabolism	metabolism	NN	_	8	dobj
11	of	of	IN	_	13	case
12	certain	certain	JJ	_	13	amod
13	drug3	drug3	NN	_	10	nmod
14	by	by	IN	_	18	case
15	up	up	RB	_	17	dep
16	to	to	TO	_	15	mwe
17	60	60	CD	_	18	nummod
18	%	%	NN	_	8	nmod
19	,	,	,	_	6	punct
20	leading	lead	VBG	_	6	advcl
21	to	to	TO	_	23	case
22	increased	increase	VBN	_	23	amod
23	risk	risk	NN	_	20	nmod
24	of	of	IN	_	27	case
25	drug4	drug4	NN	_	27	compound
26	side	side	NN	_	27	compound
27	effects	effect	NNS	_	23	nmod
28	.	.	.	_	1	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	7	nmod
3	,	,	,	_	7	punct
4	drug1	drug1	NN	_	7	nsubj
5	alone	alone	RB	_	4	advmod
6	can	can	MD	_	7	aux
7	inhibit	inhibit	VB	_	0	ROOT
8	adrenal	adrenal	JJ	_	10	amod
9	drug2	drug2	NN	_	10	compound
10	synthesis	synthesis	NN	_	7	dobj
11	and	and	CC	_	7	cc
12	may	may	MD	_	13	aux
13	cause	cause	VB	_	7	conj
14	adrenal	adrenal	JJ	_	15	amod
15	insufficiency	insufficiency	NN	_	13	dobj
16	during	during	IN	_	18	case
17	corticosteroid	corticosteroid	NN	_	18	compound
18	withdrawal	withdrawal	NN	_	13	nmod
19	.	.	.	_	7	punct

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	drug2	drug2	NN	_	1	appos
4	-RRB-	-rrb-	-RRB-	_	3	punct
5	:	:	:	_	1	punct
6	Concomitant	concomitant	JJ	_	7	amod
7	use	use	NN	_	17	nsubj
8	of	of	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	-LRB-	-lrb-	-LRB-	_	13	punct
11	or	or	CC	_	13	cc
12	other	other	JJ	_	13	amod
13	drug4	drug4	NN	_	9	appos
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	and	and	CC	_	9	cc
16	drug5	drug5	NN	_	9	conj
17	increases	increase	VBZ	_	1	dep
18	the	the	DT	_	19	det
19	risk	risk	NN	_	17	dobj
20	of	of	IN	_	23	case
21	gastrointestinal	gastrointestinal	JJ	_	23	amod
22	side	side	JJ	_	23	amod
23	effects	effect	NNS	_	19	nmod
24	.	.	.	_	1	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	cautiously	cautiously	RB	_	4	advmod
6	in	in	IN	_	7	case
7	conjunction	conjunction	NN	_	4	nmod
8	with	with	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	in	in	IN	_	11	case
11	hypoprothrombinemia	hypoprothrombinemia	NN	_	9	nmod
12	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	clearance	clearance	NN	_	7	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	may	may	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	increased	increase	VBN	_	0	ROOT
8	with	with	IN	_	10	case
9	concurrent	concurrent	JJ	_	10	amod
10	use	use	NN	_	7	nmod
11	of	of	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	.	.	.	_	7	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	5	case
4	post-marketing	post-marketing	JJ	_	5	amod
5	experience	experience	NN	_	10	nmod
6	,	,	,	_	10	punct
7	there	there	EX	_	10	expl
8	have	have	VBP	_	10	aux
9	been	be	VBN	_	10	cop
10	reports	report	NNS	_	1	appos
11	of	of	IN	_	13	case
12	both	both	DT	_	13	cc:preconj
13	increases	increase	NNS	_	10	nmod
14	and	and	CC	_	13	cc
15	decreases	decrease	VBZ	_	13	conj
16	in	in	IN	_	18	case
17	drug2	drug2	NN	_	18	compound
18	levels	level	NNS	_	15	nmod
19	with	with	IN	_	21	case
20	drug3	drug3	NN	_	21	compound
21	co-administration	co-administration	NN	_	18	nmod
22	,	,	,	_	10	punct
23	leading	lead	VBG	_	10	acl
24	to	to	TO	_	25	case
25	alterations	alteration	NNS	_	23	nmod
26	in	in	IN	_	28	case
27	seizure	seizure	NN	_	28	compound
28	control	control	NN	_	25	nmod
29	.	.	.	_	1	punct

1	Skin	skin	NN	_	2	compound
2	tests	test	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	drug1	drug1	NN	_	6	nsubj
5	may	may	MD	_	6	aux
6	suppress	suppress	VB	_	2	appos
7	reactions	reaction	NNS	_	6	dobj
8	to	to	TO	_	10	case
9	skin	skin	NN	_	10	compound
10	tests	test	NNS	_	7	nmod
11	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Co-administration	co-administration	NN	_	8	nsubjpass
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	should	should	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	employed	employ	VBN	_	1	dep
9	cautiously	cautiously	RB	_	8	advmod
10	,	,	,	_	8	punct
11	as	as	IN	_	14	case
12	toxic	toxic	JJ	_	14	amod
13	epidermal	epidermal	JJ	_	14	amod
14	necrolysis	necrolysis	NN	_	8	nmod
15	has	have	VBZ	_	17	aux
16	been	be	VBN	_	17	auxpass
17	reported	report	VBN	_	8	dep
18	with	with	IN	_	20	case
19	concomitant	concomitant	JJ	_	20	amod
20	use	use	NN	_	17	nmod
21	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Patients	patient	NNS	_	8	nsubj
4	on	on	IN	_	6	case
5	drug2	drug2	NN	_	6	compound
6	therapy	therapy	NN	_	3	nmod
7	may	may	MD	_	8	aux
8	exhibit	exhibit	VB	_	1	appos
9	a	a	DT	_	11	det
10	diminished	diminished	JJ	_	11	amod
11	response	response	NN	_	8	dobj
12	to	to	TO	_	13	case
13	toxoids	toxoid	NNS	_	11	nmod
14	and	and	CC	_	13	cc
15	drug3	drug3	NN	_	13	conj
16	or	or	CC	_	15	cc
17	drug4	drug4	NN	_	15	conj
18	due	due	JJ	_	20	case
19	to	to	TO	_	18	mwe
20	inhibition	inhibition	NN	_	11	nmod
21	of	of	IN	_	23	case
22	antibody	antibody	NN	_	23	compound
23	response	response	NN	_	20	nmod
24	.	.	.	_	1	punct

1	drug1	drug1	NN	_	4	nsubj
2	may	may	MD	_	4	aux
3	also	also	RB	_	4	advmod
4	potentiate	potentiate	VB	_	0	ROOT
5	the	the	DT	_	6	det
6	replication	replication	NN	_	10	nsubj
7	of	of	IN	_	9	case
8	some	some	DT	_	9	det
9	organisms	organism	NNS	_	6	nmod
10	contained	contain	VBD	_	4	ccomp
11	in	in	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	.	.	.	_	4	punct

1	Routine	routine	JJ	_	2	amod
2	administration	administration	NN	_	9	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	or	or	CC	_	4	cc
6	toxoids	toxoid	NNS	_	4	conj
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	deferred	defer	VBN	_	0	ROOT
10	until	until	IN	_	14	mark
11	drug2	drug2	NN	_	12	compound
12	therapy	therapy	NN	_	14	nsubjpass
13	is	be	VBZ	_	14	auxpass
14	discontinued	discontinue	VBN	_	9	advcl
15	if	if	IN	_	16	mark
16	possible	possible	JJ	_	14	advcl
17	.	.	.	_	9	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Coadministration	coadministration	NN	_	14	nsubj
4	of	of	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	,	,	,	_	5	punct
7	a	a	DT	_	9	det
8	P-glycoprotein	p-glycoprotein	NN	_	9	compound
9	substrate	substrate	NN	_	5	appos
10	,	,	,	_	5	punct
11	with	with	IN	_	13	case
12	oral	oral	JJ	_	13	amod
13	drug3	drug3	NN	_	3	nmod
14	resulted	result	VBD	_	1	appos
15	in	in	IN	_	17	case
16	a	a	DT	_	17	det
17	reduction	reduction	NN	_	14	nmod
18	in	in	IN	_	19	case
19	clearance	clearance	NN	_	17	nmod
20	and	and	CC	_	17	cc
21	an	a	DT	_	22	det
22	increase	increase	NN	_	17	conj
23	in	in	IN	_	25	case
24	drug4	drug4	NN	_	25	compound
25	Cmax	cmax	NN	_	22	nmod
26	and	and	CC	_	25	cc
27	AUC	auc	NN	_	28	compound
28	values	value	NNS	_	25	conj
29	.	.	.	_	1	punct

1	Therefore	therefore	RB	_	14	advmod
2	,	,	,	_	14	punct
3	if	if	IN	_	6	mark
4	drug1	drug1	NN	_	6	nsubjpass
5	is	be	VBZ	_	6	auxpass
6	administered	administer	VBN	_	14	advcl
7	with	with	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	,	,	,	_	14	punct
10	the	the	DT	_	11	det
11	clinician	clinician	NN	_	14	nsubj
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	cop
14	alert	alert	JJ	_	0	ROOT
15	to	to	TO	_	17	case
16	the	the	DT	_	17	det
17	possibility	possibility	NN	_	14	nmod
18	of	of	IN	_	19	case
19	increases	increase	NNS	_	17	nmod
20	in	in	IN	_	22	case
21	drug3	drug3	NN	_	22	compound
22	levels	level	NNS	_	19	nmod
23	.	.	.	_	14	punct

1	drug1	drug1	NN	_	3	compound
2	Inhibitors	inhibitor	NNS	_	3	compound
3	Felodipine	felodipine	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	metabolized	metabolize	VBN	_	0	ROOT
6	by	by	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	.	.	.	_	5	punct

1	Co-administration	co-administration	NN	_	22	nsubj
2	of	of	IN	_	4	case
3	CYP3A4	cyp3a4	NN	_	4	compound
4	inhibitors	inhibitor	NNS	_	1	nmod
5	-LRB-	-lrb-	-LRB-	_	8	punct
6	eg	eg	FW	_	8	compound
7	,	,	,	_	8	punct
8	drug1	drug1	NN	_	4	dep
9	,	,	,	_	8	punct
10	drug2	drug2	NN	_	8	conj
11	,	,	,	_	8	punct
12	drug3	drug3	NN	_	8	conj
13	,	,	,	_	8	punct
14	grapefruit	grapefruit	NN	_	15	compound
15	juice	juice	NN	_	8	conj
16	,	,	,	_	8	punct
17	drug4	drug4	NN	_	8	appos
18	-RRB-	-rrb-	-RRB-	_	8	punct
19	with	with	IN	_	20	case
20	drug5	drug5	NN	_	1	nmod
21	may	may	MD	_	22	aux
22	lead	lead	VB	_	0	ROOT
23	to	to	TO	_	27	case
24	several	several	JJ	_	27	amod
25	-	-	:	_	27	punct
26	fold	fold	JJ	_	27	amod
27	increases	increase	NNS	_	22	nmod
28	in	in	IN	_	31	case
29	the	the	DT	_	31	det
30	plasma	plasma	NN	_	31	compound
31	levels	level	NNS	_	27	nmod
32	of	of	IN	_	33	case
33	drug6	drug6	NN	_	31	nmod
34	,	,	,	_	27	punct
35	either	either	CC	_	39	cc:preconj
36	due	due	JJ	_	39	case
37	to	to	TO	_	36	mwe
38	an	a	DT	_	39	det
39	increase	increase	NN	_	27	nmod
40	in	in	IN	_	41	case
41	bioavailability	bioavailability	NN	_	39	nmod
42	or	or	CC	_	39	cc
43	due	due	JJ	_	46	case
44	to	to	TO	_	43	mwe
45	a	a	DT	_	46	det
46	decrease	decrease	NN	_	39	conj
47	in	in	IN	_	48	case
48	metabolism	metabolism	NN	_	46	nmod
49	.	.	.	_	22	punct

1	These	these	DT	_	2	det
2	increases	increase	NNS	_	6	nsubj
3	in	in	IN	_	4	case
4	concentration	concentration	NN	_	2	nmod
5	may	may	MD	_	6	aux
6	lead	lead	VB	_	0	ROOT
7	to	to	TO	_	9	case
8	increased	increase	VBN	_	9	amod
9	effects	effect	NNS	_	6	nmod
10	,	,	,	_	9	punct
11	-LRB-	-lrb-	-LRB-	_	14	punct
12	lower	lower	JJR	_	14	amod
13	blood	blood	NN	_	14	compound
14	pressure	pressure	NN	_	9	appos
15	and	and	CC	_	14	cc
16	increased	increase	VBD	_	18	amod
17	heart	heart	NN	_	18	compound
18	rate	rate	NN	_	14	conj
19	-RRB-	-rrb-	-RRB-	_	14	punct
20	.	.	.	_	6	punct

1	These	these	DT	_	2	det
2	effects	effect	NNS	_	5	nsubjpass
3	have	have	VBP	_	5	aux
4	been	be	VBN	_	5	auxpass
5	observed	observe	VBN	_	0	ROOT
6	with	with	IN	_	7	case
7	co-administration	co-administration	NN	_	5	nmod
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	-LRB-	-lrb-	-LRB-	_	14	punct
11	a	a	DT	_	14	det
12	potent	potent	JJ	_	14	amod
13	drug2	drug2	NN	_	14	compound
14	inhibitor	inhibitor	NN	_	9	appos
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	.	.	.	_	5	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	when	when	WRB	_	9	advmod
6	drug1	drug1	NN	_	7	compound
7	inhibitors	inhibitor	NNS	_	9	nsubjpass
8	are	be	VBP	_	9	auxpass
9	co-administered	co-administer	VBN	_	4	advcl
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	.	.	.	_	4	punct

1	A	a	DT	_	3	det
2	conservative	conservative	JJ	_	3	amod
3	approach	approach	NN	_	9	nsubjpass
4	to	to	TO	_	6	case
5	dosing	dosing	NN	_	6	compound
6	drug1	drug1	NN	_	3	nmod
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	taken	take	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	The	the	DT	_	4	det
2	following	follow	VBG	_	4	amod
3	specific	specific	JJ	_	4	amod
4	interactions	interaction	NNS	_	7	nsubjpass
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	reported	report	VBN	_	0	ROOT
8	:	:	:	_	7	punct
9	Itraconazole	Itraconazole	NNP	_	10	compound
10	Co-administration	co-administration	NN	_	20	nsubj
11	of	of	IN	_	15	case
12	another	another	DT	_	15	det
13	extended	extend	VBN	_	15	amod
14	release	release	NN	_	15	compound
15	formulation	formulation	NN	_	10	nmod
16	of	of	IN	_	17	case
17	drug1	drug1	NN	_	15	nmod
18	with	with	IN	_	19	case
19	drug2	drug2	NN	_	10	nmod
20	resulted	result	VBD	_	7	parataxis
21	in	in	IN	_	24	case
22	approximately	approximately	RB	_	23	advmod
23	8-fold	8-fold	JJ	_	24	amod
24	increase	increase	NN	_	20	nmod
25	in	in	IN	_	27	case
26	the	the	DT	_	27	det
27	AUC	auc	NN	_	24	nmod
28	,	,	,	_	24	punct
29	more	more	JJR	_	31	advmod
30	than	than	IN	_	29	mwe
31	6	6	CD	_	24	appos
32	-	-	:	_	31	punct
33	fold	fold	JJ	_	34	amod
34	increase	increase	NN	_	31	conj
35	in	in	IN	_	37	case
36	the	the	DT	_	37	det
37	Cmax	Cmax	NNP	_	34	nmod
38	,	,	,	_	31	punct
39	and	and	CC	_	31	cc
40	2-fold	2-fold	JJ	_	41	amod
41	prolongation	prolongation	NN	_	31	conj
42	in	in	IN	_	44	case
43	the	the	DT	_	44	det
44	half	half	NN	_	31	nmod
45	-	-	:	_	31	punct
46	life	life	NN	_	31	dep
47	of	of	IN	_	48	case
48	drug3	drug3	NN	_	46	nmod
49	.	.	.	_	7	punct

1	Erythromycin	erythromycin	NN	_	2	compound
2	Co-administration	co-administration	NN	_	10	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	-LRB-	-lrb-	-LRB-	_	6	punct
6	drug2	drug2	NN	_	4	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	with	with	IN	_	9	case
9	drug3	drug3	NN	_	2	nmod
10	resulted	result	VBD	_	0	ROOT
11	in	in	IN	_	16	case
12	approximately	approximately	RB	_	13	advmod
13	2.5	2.5	CD	_	16	nummod
14	-	-	:	_	16	punct
15	fold	fold	JJ	_	16	amod
16	increase	increase	NN	_	10	nmod
17	in	in	IN	_	19	case
18	the	the	DT	_	19	det
19	AUC	auc	NN	_	16	nmod
20	and	and	CC	_	19	cc
21	Cmax	cmax	NN	_	19	conj
22	,	,	,	_	10	punct
23	and	and	CC	_	10	cc
24	about	about	IN	_	25	advmod
25	2	2	CD	_	10	conj
26	-	-	:	_	25	punct
27	fold	fold	JJ	_	28	amod
28	prolongation	prolongation	NN	_	25	dep
29	in	in	IN	_	31	case
30	the	the	DT	_	31	det
31	half	half	NN	_	28	nmod
32	-	-	:	_	25	punct
33	life	life	NN	_	25	dep
34	of	of	IN	_	35	case
35	drug4	drug4	NN	_	33	nmod
36	.	.	.	_	10	punct

1	Grapefruit	grapefruit	NN	_	3	compound
2	juice	juice	NN	_	3	compound
3	Co-administration	co-administration	NN	_	9	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	with	with	IN	_	8	case
7	grapefruit	grapefruit	NN	_	8	compound
8	juice	juice	NN	_	3	nmod
9	resulted	result	VBD	_	0	ROOT
10	in	in	IN	_	14	case
11	more	more	JJR	_	13	advmod
12	than	than	IN	_	11	mwe
13	2-fold	2-fold	JJ	_	14	amod
14	increase	increase	NN	_	9	nmod
15	in	in	IN	_	17	case
16	the	the	DT	_	17	det
17	AUC	auc	NN	_	14	nmod
18	and	and	CC	_	17	cc
19	Cmax	cmax	NN	_	17	conj
20	,	,	,	_	9	punct
21	but	but	CC	_	9	cc
22	no	no	DT	_	23	neg
23	prolongation	prolongation	NN	_	9	conj
24	in	in	IN	_	26	case
25	the	the	DT	_	26	det
26	half	half	NN	_	23	nmod
27	-	-	:	_	23	punct
28	life	life	NN	_	23	dep
29	of	of	IN	_	30	case
30	drug2	drug2	NN	_	28	nmod
31	.	.	.	_	9	punct

1	Cimetidine	cimetidine	NN	_	2	compound
2	Co-administration	co-administration	NN	_	13	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	2	nmod
7	-LRB-	-lrb-	-LRB-	_	11	punct
8	a	a	DT	_	11	det
9	non-specific	non-specific	JJ	_	11	amod
10	CYP-450	cyp-450	NN	_	11	compound
11	inhibitor	inhibitor	NN	_	6	appos
12	-RRB-	-rrb-	-RRB-	_	11	punct
13	resulted	result	VBD	_	0	ROOT
14	in	in	IN	_	16	case
15	an	a	DT	_	16	det
16	increase	increase	NN	_	13	nmod
17	of	of	IN	_	20	case
18	approximately	approximately	RB	_	19	advmod
19	50	50	CD	_	20	nummod
20	%	%	NN	_	16	nmod
21	in	in	IN	_	23	case
22	the	the	DT	_	23	det
23	AUC	auc	NN	_	16	nmod
24	and	and	CC	_	16	cc
25	the	the	DT	_	26	det
26	Cmax	Cmax	NNP	_	16	conj
27	,	,	,	_	26	punct
28	of	of	IN	_	29	case
29	drug3	drug3	NN	_	26	nmod
30	.	.	.	_	13	punct

1	Beta-Blocking	beta-blocking	JJ	_	5	amod
2	Agents	Agents	NNPS	_	5	compound
3	A	a	DT	_	5	det
4	pharmacokinetic	pharmacokinetic	JJ	_	5	amod
5	study	study	NN	_	12	nsubj
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	in	in	IN	_	9	case
9	conjunction	conjunction	NN	_	5	nmod
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	demonstrated	demonstrate	VBD	_	0	ROOT
13	no	no	DT	_	15	neg
14	significant	significant	JJ	_	15	amod
15	effects	effect	NNS	_	12	dobj
16	on	on	IN	_	18	case
17	the	the	DT	_	18	det
18	pharmacokinetics	pharmacokinetic	NNS	_	15	nmod
19	of	of	IN	_	20	case
20	drug3	drug3	NN	_	18	nmod
21	.	.	.	_	12	punct

1	The	the	DT	_	2	det
2	AUC	auc	NN	_	11	nsubjpass
3	and	and	CC	_	2	cc
4	Cmax	cmax	NN	_	2	conj
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	2	nmod
7	,	,	,	_	11	punct
8	however	however	RB	_	11	advmod
9	,	,	,	_	11	punct
10	were	be	VBD	_	11	auxpass
11	increased	increase	VBN	_	0	ROOT
12	approximately	approximately	RB	_	13	advmod
13	31	31	CD	_	16	nummod
14	and	and	CC	_	13	cc
15	38	38	CD	_	13	conj
16	%	%	NN	_	11	dobj
17	,	,	,	_	11	punct
18	respectively	respectively	RB	_	11	advmod
19	.	.	.	_	11	punct

1	In	in	IN	_	4	case
2	controlled	controlled	JJ	_	4	amod
3	clinical	clinical	JJ	_	4	amod
4	trials	trial	NNS	_	13	nmod
5	,	,	,	_	13	punct
6	however	however	RB	_	13	advmod
7	,	,	,	_	13	punct
8	drug1	drug1	NN	_	13	nsubjpass
9	including	include	VBG	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	were	be	VBD	_	13	auxpass
12	concurrently	concurrently	RB	_	13	advmod
13	administered	administer	VBN	_	0	ROOT
14	with	with	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	and	and	CC	_	13	cc
17	were	be	VBD	_	19	auxpass
18	well	well	RB	_	19	advmod
19	tolerated	tolerate	VBN	_	13	conj
20	.	.	.	_	13	punct

1	Digoxin	Digoxin	NNP	_	0	ROOT
2	When	when	WRB	_	3	advmod
3	given	give	VBN	_	1	acl:relcl
4	concomitantly	concomitantly	RB	_	3	advmod
5	with	with	IN	_	6	case
6	drug1	drug1	NN	_	3	nmod
7	the	the	DT	_	8	det
8	pharmacokinetics	pharmacokinetic	NNS	_	19	nsubjpass
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	in	in	IN	_	12	case
12	patients	patient	NNS	_	8	nmod
13	with	with	IN	_	15	case
14	heart	heart	NN	_	15	compound
15	failure	failure	NN	_	12	nmod
16	were	be	VBD	_	19	auxpass
17	not	not	RB	_	19	neg
18	significantly	significantly	RB	_	19	advmod
19	altered	alter	VBN	_	6	acl:relcl
20	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	6	case
4	a	a	DT	_	6	det
5	pharmacokinetic	pharmacokinetic	JJ	_	6	amod
6	study	study	NN	_	15	nmod
7	,	,	,	_	15	punct
8	maximum	maximum	NN	_	10	compound
9	plasma	plasma	NN	_	10	compound
10	concentrations	concentration	NNS	_	15	nsubj
11	of	of	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	were	be	VBD	_	15	cop
14	considerably	considerably	RB	_	15	advmod
15	lower	lower	JJR	_	1	dep
16	in	in	IN	_	18	case
17	epileptic	epileptic	JJ	_	18	amod
18	patients	patient	NNS	_	15	nmod
19	on	on	IN	_	22	case
20	long-term	long-term	JJ	_	22	amod
21	drug3	drug3	NN	_	22	compound
22	therapy	therapy	NN	_	18	nmod
23	-LRB-	-lrb-	-LRB-	_	26	punct
24	eg	eg	FW	_	26	compound
25	,	,	,	_	26	punct
26	drug4	drug4	NN	_	15	dep
27	,	,	,	_	26	punct
28	drug5	drug5	NN	_	26	conj
29	,	,	,	_	26	punct
30	or	or	CC	_	26	cc
31	drug6	drug6	NN	_	26	conj
32	-RRB-	-rrb-	-RRB-	_	26	punct
33	than	than	IN	_	36	case
34	in	in	IN	_	36	case
35	healthy	healthy	JJ	_	36	amod
36	volunteers	volunteer	NNS	_	15	nmod
37	.	.	.	_	1	punct

1	In	in	IN	_	3	case
2	such	such	JJ	_	3	amod
3	patients	patient	NNS	_	16	nmod
4	,	,	,	_	16	punct
5	the	the	DT	_	7	det
6	mean	mean	JJ	_	7	amod
7	area	area	NN	_	16	nsubjpass
8	under	under	IN	_	13	case
9	the	the	DT	_	13	det
10	drug1	drug1	NN	_	13	compound
11	plasma	plasma	NN	_	13	compound
12	concentration-time	concentration-time	NN	_	13	compound
13	curve	curve	NN	_	7	nmod
14	was	be	VBD	_	16	auxpass
15	also	also	RB	_	16	advmod
16	reduced	reduce	VBN	_	0	ROOT
17	to	to	TO	_	20	case
18	approximately	approximately	RB	_	19	advmod
19	6	6	CD	_	20	nummod
20	%	%	NN	_	16	nmod
21	of	of	IN	_	22	case
22	that	that	DT	_	20	nmod
23	observed	observe	VBN	_	22	acl
24	in	in	IN	_	26	case
25	healthy	healthy	JJ	_	26	amod
26	volunteers	volunteer	NNS	_	23	nmod
27	.	.	.	_	16	punct

1	Since	since	IN	_	8	mark
2	a	a	DT	_	5	det
3	clinically	clinically	RB	_	4	advmod
4	significant	significant	JJ	_	5	amod
5	interaction	interaction	NN	_	8	nsubjpass
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	anticipated	anticipate	VBN	_	15	advcl
9	,	,	,	_	15	punct
10	alternative	alternative	JJ	_	12	amod
11	drug1	drug1	NN	_	12	compound
12	therapy	therapy	NN	_	15	nsubjpass
13	should	should	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	considered	consider	VBN	_	0	ROOT
16	in	in	IN	_	18	case
17	these	these	DT	_	18	det
18	patients	patient	NNS	_	15	nmod
19	.	.	.	_	15	punct

1	Tacrolimus	tacrolimus	NN	_	2	compound
2	drug1	drug1	NN	_	4	nsubj
3	may	may	MD	_	4	aux
4	increase	increase	VB	_	0	ROOT
5	the	the	DT	_	7	det
6	blood	blood	NN	_	7	compound
7	concentration	concentration	NN	_	4	dobj
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	.	.	.	_	4	punct

1	When	when	WRB	_	2	advmod
2	given	give	VBN	_	13	advcl
3	concomitantly	concomitantly	RB	_	2	advmod
4	with	with	IN	_	5	case
5	drug1	drug1	NN	_	2	nmod
6	,	,	,	_	13	punct
7	the	the	DT	_	10	det
8	drug2	drug2	NN	_	10	compound
9	blood	blood	NN	_	10	compound
10	concentration	concentration	NN	_	13	nsubjpass
11	should	should	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	followed	follow	VBN	_	0	ROOT
14	and	and	CC	_	13	cc
15	the	the	DT	_	17	det
16	tacrolimus	tacrolimus	NN	_	17	compound
17	dose	dose	NN	_	19	nsubj
18	may	may	MD	_	19	aux
19	need	need	VB	_	13	conj
20	to	to	TO	_	22	mark
21	be	be	VB	_	22	auxpass
22	adjusted	adjust	VBN	_	19	xcomp
23	.	.	.	_	13	punct

1	Other	other	JJ	_	3	amod
2	Concomitant	concomitant	JJ	_	3	amod
3	Therapy	therapy	NN	_	0	ROOT
4	In	in	IN	_	6	case
5	healthy	healthy	JJ	_	6	amod
6	subjects	subject	NNS	_	3	nmod
7	there	there	EX	_	8	expl
8	were	be	VBD	_	3	acl:relcl
9	no	no	DT	_	12	neg
10	clinically	clinically	RB	_	11	advmod
11	significant	significant	JJ	_	12	amod
12	interactions	interaction	NNS	_	8	nsubj
13	when	when	WRB	_	16	advmod
14	drug1	drug1	NN	_	16	nsubjpass
15	was	be	VBD	_	16	auxpass
16	given	give	VBN	_	8	advcl
17	concomitantly	concomitantly	RB	_	16	advmod
18	with	with	IN	_	19	case
19	drug2	drug2	NN	_	16	nmod
20	or	or	CC	_	19	cc
21	drug3	drug3	NN	_	19	conj
22	.	.	.	_	3	punct

1	Interaction	interaction	NN	_	0	ROOT
2	with	with	IN	_	4	mark
3	Food	Food	NNP	_	4	nsubj
4	See	see	VB	_	1	acl
5	CLINICAL	CLINICAL	NNP	_	6	compound
6	PHARMACOLOGY	PHARMACOLOGY	NNP	_	4	dobj
7	,	,	,	_	6	punct
8	Pharmacokinetics	Pharmacokinetics	NNP	_	6	conj
9	and	and	CC	_	6	cc
10	Metabolism	Metabolism	NNP	_	6	conj
11	.	.	.	_	1	punct

1	DRUG/LABORATORY	drug/laboratory	NN	_	3	compound
2	TEST	test	NN	_	3	compound
3	INTERACTIONS	interaction	NNS	_	0	ROOT
4	1	1	CD	_	3	nummod
5	.	.	.	_	3	punct

1	Accelerated	accelerate	VBN	_	3	amod
2	prothrombin	prothrombin	NN	_	3	compound
3	time	time	NN	_	0	ROOT
4	,	,	,	_	3	punct
5	partial	partial	JJ	_	7	amod
6	thromboplastin	thromboplastin	NN	_	7	compound
7	time	time	NN	_	3	conj
8	,	,	,	_	3	punct
9	and	and	CC	_	3	cc
10	platelet	platelet	NN	_	12	compound
11	aggregation	aggregation	NN	_	12	compound
12	time	time	NN	_	3	conj
13	;	;	:	_	3	punct

1	increased	increase	VBN	_	3	amod
2	platelet	platelet	NN	_	3	compound
3	count	count	NN	_	0	ROOT
4	;	;	:	_	3	punct

1	increased	increase	VBN	_	2	amod
2	factors	factor	NNS	_	0	ROOT
3	II	ii	CD	_	2	nummod
4	,	,	,	_	2	punct
5	VII	vii	NN	_	6	compound
6	antigen	antigen	NN	_	2	appos
7	,	,	,	_	6	punct
8	VIII	viii	CD	_	9	nummod
9	antigen	antigen	NN	_	6	conj
10	,	,	,	_	6	punct
11	VIII	viii	CD	_	13	nummod
12	coagulant	coagulant	NN	_	13	compound
13	activity	activity	NN	_	6	conj
14	,	,	,	_	6	punct
15	IX	ix	CD	_	6	conj
16	,	,	,	_	6	punct
17	X	x	NN	_	6	conj
18	,	,	,	_	6	punct
19	XII	XII	NNP	_	6	conj
20	,	,	,	_	6	punct
21	VII-X	vii-x	NN	_	22	compound
22	complex	complex	NN	_	6	conj
23	,	,	,	_	6	punct
24	II-VII-X	ii-vii-x	NN	_	25	compound
25	complex	complex	NN	_	6	conj
26	,	,	,	_	6	punct
27	and	and	CC	_	6	cc
28	beta-thromboglobulin	beta-thromboglobulin	NN	_	6	conj
29	;	;	:	_	2	punct

1	decreased	decrease	VBN	_	2	amod
2	levels	level	NNS	_	9	nsubj
3	of	of	IN	_	5	case
4	anti-factor	anti-factor	JJ	_	5	amod
5	Xa	xa	NN	_	2	nmod
6	and	and	CC	_	5	cc
7	drug1	drug1	NN	_	5	conj
8	,	,	,	_	2	punct
9	decreased	decrease	VBD	_	0	ROOT
10	drug2	drug2	NN	_	11	compound
11	activity	activity	NN	_	9	dobj
12	;	;	:	_	9	punct

1	increased	increase	VBN	_	2	amod
2	levels	level	NNS	_	0	ROOT
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	7	compound
7	activity	activity	NN	_	4	conj
8	;	;	:	_	2	punct

1	increased	increase	VBN	_	3	amod
2	plasminogen	plasminogen	NN	_	3	compound
3	antigen	antigen	NN	_	0	ROOT
4	and	and	CC	_	3	cc
5	activity	activity	NN	_	3	conj
6	.	.	.	_	3	punct

1	2	2	LS	_	0	ROOT
2	.	.	.	_	1	punct

1	Increased	increase	VBN	_	3	amod
2	thyroid-binding	thyroid-binding	JJ	_	3	amod
3	globulin	globulin	NN	_	7	compound
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	TBG	tbg	NN	_	3	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	levels	level	NNS	_	0	ROOT
8	leading	lead	VBG	_	7	acl
9	to	to	TO	_	15	case
10	increased	increase	VBN	_	15	amod
11	circulating	circulate	VBG	_	15	amod
12	total	total	JJ	_	15	amod
13	thyroid	thyroid	NN	_	15	compound
14	hormone	hormone	NN	_	15	compound
15	levels	level	NNS	_	8	nmod
16	as	as	IN	_	17	mark
17	measured	measure	VBN	_	8	advcl
18	by	by	IN	_	20	case
19	protein-bound	protein-bound	JJ	_	20	amod
20	drug1	drug1	NN	_	17	nmod
21	-LRB-	-lrb-	-LRB-	_	22	punct
22	PBI	pbi	NN	_	20	appos
23	-RRB-	-rrb-	-RRB-	_	22	punct
24	,	,	,	_	7	punct
25	T4	t4	NN	_	26	compound
26	levels	level	NNS	_	7	conj
27	-LRB-	-lrb-	-LRB-	_	29	punct
28	by	by	IN	_	29	case
29	column	column	NN	_	26	nmod
30	or	or	CC	_	29	cc
31	by	by	IN	_	32	case
32	radioimmunoassay	radioimmunoassay	NN	_	29	conj
33	-RRB-	-rrb-	-RRB-	_	29	punct
34	or	or	CC	_	7	cc
35	T3	t3	NN	_	36	compound
36	levels	level	NNS	_	7	conj
37	by	by	IN	_	38	case
38	radioimmunoassay	radioimmunoassay	NN	_	36	nmod
39	.	.	.	_	7	punct

1	T3	t3	NN	_	3	compound
2	resin	resin	NN	_	3	compound
3	uptake	uptake	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	decreased	decrease	VBN	_	0	ROOT
6	,	,	,	_	5	punct
7	reflecting	reflect	VBG	_	5	xcomp
8	the	the	DT	_	10	det
9	elevated	elevated	JJ	_	10	amod
10	TBG	tbg	NN	_	7	dobj
11	.	.	.	_	5	punct

1	Free	Free	NNP	_	2	compound
2	T4	t4	NN	_	8	nsubj
3	and	and	CC	_	2	cc
4	free	free	JJ	_	6	amod
5	T3	t3	NN	_	6	compound
6	concentrations	concentration	NNS	_	2	conj
7	are	be	VBP	_	8	cop
8	unaltered	unaltered	JJ	_	0	ROOT
9	.	.	.	_	8	punct

1	Patients	patient	NNS	_	7	nsubj
2	on	on	IN	_	5	case
3	thyroid	thyroid	NN	_	5	compound
4	replacement	replacement	NN	_	5	compound
5	therapy	therapy	NN	_	1	nmod
6	may	may	MD	_	7	aux
7	require	require	VB	_	0	ROOT
8	higher	higher	JJR	_	9	amod
9	doses	dose	NNS	_	7	dobj
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	.	.	.	_	7	punct

1	3	3	LS	_	0	ROOT
2	.	.	.	_	1	punct

1	Other	other	JJ	_	3	amod
2	binding	binding	NN	_	3	compound
3	proteins	protein	NNS	_	6	nsubj
4	may	may	MD	_	6	aux
5	be	be	VB	_	6	aux
6	elevated	elevated	JJ	_	0	ROOT
7	in	in	IN	_	8	case
8	serum	serum	NN	_	6	nmod
9	,	,	,	_	6	punct
10	-LRB-	-lrb-	-LRB-	_	6	punct
11	i.e.	i.e.	FW	_	10	root
12	,	,	,	_	11	punct
13	corticosteroid	corticosteroid	NN	_	15	compound
14	binding	binding	NN	_	15	compound
15	globulin	globulin	NN	_	12	root
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	CBG	cbg	NN	_	15	appos
18	-RRB-	-rrb-	-RRB-	_	17	punct
19	,	,	,	_	15	punct
20	sex	sex	NN	_	23	compound
21	hormone	hormone	NN	_	23	compound
22	binding	binding	NN	_	23	compound
23	globulin	globulin	NN	_	15	appos
24	-LRB-	-lrb-	-LRB-	_	25	punct
25	SHBG	shbg	NN	_	23	appos
26	-RRB-	-rrb-	-RRB-	_	25	punct
27	-RRB-	-rrb-	-RRB-	_	15	punct
28	leading	lead	VBG	_	15	acl
29	to	to	TO	_	33	case
30	increased	increase	VBN	_	33	amod
31	total	total	JJ	_	33	amod
32	circulating	circulate	VBG	_	33	amod
33	drug1	drug1	NN	_	28	nmod
34	and	and	CC	_	33	cc
35	drug2	drug2	NN	_	33	conj
36	,	,	,	_	28	punct
37	respectively	respectively	RB	_	28	advmod
38	.	.	.	_	15	punct

1	Free	Free	NNP	_	3	compound
2	hormone	hormone	NN	_	3	compound
3	concentrations	concentration	NNS	_	6	nsubjpass
4	may	may	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	decreased	decrease	VBN	_	0	ROOT
7	.	.	.	_	6	punct

1	Other	other	JJ	_	3	amod
2	plasma	plasma	NN	_	3	compound
3	proteins	protein	NNS	_	6	nsubjpass
4	may	may	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	increased	increase	VBN	_	0	ROOT
7	-LRB-	-lrb-	-LRB-	_	9	punct
8	angiotensinogen/renin	angiotensinogen/renin	NN	_	9	compound
9	substrate	substrate	NN	_	6	dep
10	,	,	,	_	9	punct
11	alpha-1-antitrypsin	alpha-1-antitrypsin	NN	_	9	appos
12	,	,	,	_	9	punct
13	ceruloplasmin	ceruloplasmin	NN	_	9	appos
14	-RRB-	-rrb-	-RRB-	_	9	punct
15	.	.	.	_	6	punct

1	4	4	LS	_	0	ROOT
2	.	.	.	_	1	punct

1	Increased	increase	VBN	_	3	amod
2	plasma	plasma	NN	_	3	compound
3	HDL	hdl	NN	_	10	nsubj
4	and	and	CC	_	3	cc
5	HDL2	hdl2	NN	_	8	compound
6	cholesterol	cholesterol	NN	_	8	compound
7	subfraction	subfraction	NN	_	8	compound
8	concentrations	concentration	NNS	_	3	conj
9	,	,	,	_	3	punct
10	reduced	reduce	VBD	_	0	ROOT
11	LDL	ldl	NN	_	13	compound
12	cholesterol	cholesterol	NN	_	13	compound
13	concentration	concentration	NN	_	10	dobj
14	,	,	,	_	10	punct
15	increased	increase	VBD	_	17	amod
16	triglyceride	triglyceride	NN	_	17	compound
17	levels	level	NNS	_	10	dobj
18	.	.	.	_	10	punct

1	5	5	CD	_	0	ROOT
2	.	.	.	_	1	punct

1	Impaired	impaired	JJ	_	3	amod
2	glucose	glucose	NN	_	3	compound
3	tolerance	tolerance	NN	_	0	ROOT
4	.	.	.	_	3	punct

1	6	6	CD	_	0	ROOT
2	.	.	.	_	1	punct

1	Reduced	reduce	VBN	_	2	amod
2	response	response	NN	_	0	ROOT
3	to	to	TO	_	5	case
4	metyrapone	metyrapone	NN	_	5	compound
5	test	test	NN	_	2	nmod
6	.	.	.	_	2	punct

1	When	when	WRB	_	2	advmod
2	administered	administer	VBN	_	9	advcl
3	concurrently	concurrently	RB	_	2	advmod
4	,	,	,	_	9	punct
5	the	the	DT	_	7	det
6	following	follow	VBG	_	7	amod
7	drugs	drug	NNS	_	9	nsubj
8	may	may	MD	_	9	aux
9	interact	interact	VB	_	0	ROOT
10	with	with	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	:	:	:	_	9	punct
13	drug2	drug2	NN	_	9	dep
14	:	:	:	_	13	punct
15	may	may	MD	_	16	aux
16	enhance	enhance	VB	_	13	dep
17	the	the	DT	_	18	det
18	potential	potential	NN	_	16	dobj
19	for	for	IN	_	21	case
20	renal	renal	JJ	_	21	amod
21	toxicity	toxicity	NN	_	18	nmod
22	,	,	,	_	21	punct
23	bronchospasm	bronchospasm	NN	_	21	conj
24	and	and	CC	_	21	cc
25	hypotension	hypotension	NN	_	21	conj
26	.	.	.	_	9	punct

1	drug1	drug1	NN	_	12	nsubjpass
2	-LRB-	-lrb-	-LRB-	_	4	punct
3	e.	e.	FW	_	4	compound
4	g.	g.	FW	_	1	dep
5	,	,	,	_	4	punct
6	drug2	drug2	NN	_	4	appos
7	,	,	,	_	4	punct
8	etc.	etc.	FW	_	4	dep
9	-RRB-	-rrb-	-RRB-	_	4	punct
10	should	should	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	given	give	VBN	_	0	ROOT
13	concomitantly	concomitantly	RB	_	12	advmod
14	only	only	RB	_	17	advmod
15	with	with	IN	_	17	case
16	great	great	JJ	_	17	amod
17	caution	caution	NN	_	13	nmod
18	.	.	.	_	12	punct

1	drug1	drug1	NN	_	0	ROOT
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	drug3	drug3	NN	_	3	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	:	:	:	_	1	punct
8	may	may	MD	_	9	aux
9	potentiate	potentiate	VB	_	1	dep
10	drug4	drug4	NN	_	13	compound
11	-	-	:	_	13	punct
12	induced	induce	VBN	_	13	amod
13	hypokalemia	hypokalemia	NN	_	9	dobj
14	which	which	WDT	_	16	nsubj
15	may	may	MD	_	16	aux
16	predispose	predispose	VB	_	13	acl:relcl
17	the	the	DT	_	18	det
18	patient	patient	NN	_	16	dobj
19	to	to	TO	_	21	case
20	cardiac	cardiac	JJ	_	21	amod
21	dysfunction	dysfunction	NN	_	16	nmod
22	.	.	.	_	1	punct

1	Avoid	avoid	VB	_	0	ROOT
2	concomitant	concomitant	JJ	_	3	amod
3	use	use	NN	_	1	dobj
4	unless	unless	IN	_	5	mark
5	necessary	necessary	JJ	_	1	advcl
6	to	to	TO	_	7	mark
7	control	control	VB	_	5	xcomp
8	side	side	JJ	_	9	amod
9	effects	effect	NNS	_	7	dobj
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	.	.	.	_	1	punct

1	If	if	IN	_	2	mark
2	used	use	VBN	_	6	advcl
3	concomitantly	concomitantly	RB	_	2	advmod
4	,	,	,	_	6	punct
5	closely	closely	RB	_	6	advmod
6	monitor	monitor	VB	_	0	ROOT
7	serum	serum	NN	_	8	compound
8	electrolytes	electrolyte	NNS	_	6	dobj
9	and	and	CC	_	8	cc
10	cardiac	cardiac	JJ	_	11	amod
11	function	function	NN	_	8	conj
12	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	6	compound
4	-	-	:	_	6	punct
5	induced	induce	VBN	_	6	amod
6	hypokalemia	hypokalemia	NN	_	8	nsubj
7	may	may	MD	_	8	aux
8	potentiate	potentiate	VB	_	1	appos
9	drug3	drug3	NN	_	10	compound
10	toxicity	toxicity	NN	_	8	dobj
11	.	.	.	_	1	punct

1	Serum	serum	NN	_	3	compound
2	potassium	potassium	NN	_	3	compound
3	levels	level	NNS	_	10	nsubjpass
4	and	and	CC	_	3	cc
5	cardiac	cardiac	JJ	_	6	amod
6	function	function	NN	_	3	conj
7	should	should	MD	_	10	aux
8	be	be	VB	_	10	auxpass
9	closely	closely	RB	_	10	advmod
10	monitored	monitor	VBN	_	0	ROOT
11	and	and	CC	_	10	cc
12	any	any	DT	_	13	det
13	deficit	deficit	NN	_	15	nsubj
14	promptly	promptly	RB	_	15	advmod
15	corrected	correct	VBN	_	10	conj
16	.	.	.	_	10	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	while	while	IN	_	11	mark
4	a	a	DT	_	6	det
5	synergistic	synergistic	JJ	_	6	amod
6	relationship	relationship	NN	_	11	nsubjpass
7	with	with	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	has	have	VBZ	_	11	aux
10	been	be	VBN	_	11	auxpass
11	reported	report	VBN	_	16	advcl
12	,	,	,	_	16	punct
13	concomitant	concomitant	JJ	_	14	amod
14	use	use	NN	_	16	nsubj
15	may	may	MD	_	16	aux
16	increase	increase	VB	_	1	dep
17	the	the	DT	_	18	det
18	toxicity	toxicity	NN	_	16	dobj
19	of	of	IN	_	20	case
20	drug3	drug3	NN	_	18	nmod
21	by	by	IN	_	23	mark
22	possibly	possibly	RB	_	23	advmod
23	increasing	increase	VBG	_	16	advcl
24	its	its	PRP$	_	26	nmod:poss
25	cellular	cellular	JJ	_	26	amod
26	uptake	uptake	NN	_	23	dobj
27	and/or	and/or	CC	_	23	cc
28	impairing	impair	VBG	_	23	conj
29	its	its	PRP$	_	31	nmod:poss
30	renal	renal	JJ	_	31	amod
31	excretion	excretion	NN	_	28	dobj
32	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	4	punct
3	e.	e.	FW	_	4	compound
4	g.	g.	FW	_	1	dep
5	,	,	,	_	4	punct
6	drug2	drug2	NN	_	4	conj
7	,	,	,	_	4	punct
8	drug3	drug3	NN	_	4	conj
9	,	,	,	_	4	punct
10	drug4	drug4	NN	_	4	conj
11	,	,	,	_	4	punct
12	drug5	drug5	NN	_	4	conj
13	,	,	,	_	4	punct
14	etc.	etc.	FW	_	4	dep
15	-RRB-	-rrb-	-RRB-	_	4	punct
16	:	:	:	_	1	punct
17	in	in	FW	_	18	compound
18	vitro	vitro	FW	_	29	nsubj
19	and	and	CC	_	18	cc
20	animal	animal	JJ	_	18	conj
21	studies	study	NNS	_	18	dep
22	with	with	IN	_	24	case
23	the	the	DT	_	24	det
24	combination	combination	NN	_	18	nmod
25	of	of	IN	_	26	case
26	drug6	drug6	NN	_	24	nmod
27	and	and	CC	_	26	cc
28	drug7	drug7	NN	_	26	conj
29	suggest	suggest	VBP	_	1	appos
30	that	that	IN	_	33	mark
31	drug8	drug8	NN	_	33	nsubj
32	may	may	MD	_	33	aux
33	induce	induce	VB	_	29	ccomp
34	fungal	fungal	JJ	_	35	amod
35	resistance	resistance	NN	_	33	dobj
36	to	to	TO	_	37	case
37	drug9	drug9	NN	_	35	nmod
38	.	.	.	_	1	punct

1	Combination	combination	NN	_	2	compound
2	therapy	therapy	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	administered	administer	VBN	_	0	ROOT
6	with	with	IN	_	7	case
7	caution	caution	NN	_	5	nmod
8	,	,	,	_	5	punct
9	especially	especially	RB	_	12	advmod
10	in	in	IN	_	12	case
11	immunocompromised	immunocompromised	JJ	_	12	amod
12	patients	patient	NNS	_	5	nmod
13	.	.	.	_	5	punct

1	Other	other	JJ	_	3	amod
2	nephrotoxic	nephrotoxic	JJ	_	3	amod
3	medications	medication	NNS	_	0	ROOT
4	:	:	:	_	3	punct
5	agents	agent	NNS	_	15	nsubj
6	such	such	JJ	_	8	case
7	as	as	IN	_	6	mwe
8	drug1	drug1	NN	_	5	nmod
9	,	,	,	_	8	punct
10	drug2	drug2	NN	_	8	conj
11	,	,	,	_	8	punct
12	and	and	CC	_	8	cc
13	drug3	drug3	NN	_	8	conj
14	may	may	MD	_	15	aux
15	enhance	enhance	VB	_	3	dep
16	the	the	DT	_	17	det
17	potential	potential	NN	_	15	dobj
18	for	for	IN	_	21	case
19	drug-induced	drug-induced	JJ	_	21	amod
20	renal	renal	JJ	_	21	amod
21	toxicity	toxicity	NN	_	17	nmod
22	,	,	,	_	15	punct
23	and	and	CC	_	15	cc
24	should	should	MD	_	26	aux
25	be	be	VB	_	26	auxpass
26	used	use	VBN	_	15	conj
27	concomitantly	concomitantly	RB	_	28	advmod
28	only	only	RB	_	31	advmod
29	with	with	IN	_	31	case
30	great	great	JJ	_	31	amod
31	caution	caution	NN	_	26	nmod
32	.	.	.	_	3	punct

1	Intensive	intensive	JJ	_	2	amod
2	monitoring	monitoring	NN	_	7	nsubjpass
3	of	of	IN	_	5	case
4	renal	renal	JJ	_	5	amod
5	function	function	NN	_	2	nmod
6	is	be	VBZ	_	7	auxpass
7	recommended	recommend	VBN	_	0	ROOT
8	in	in	IN	_	9	case
9	patients	patient	NNS	_	7	nmod
10	requiring	require	VBG	_	9	acl
11	any	any	DT	_	12	det
12	combination	combination	NN	_	10	dobj
13	of	of	IN	_	15	case
14	nephrotoxic	nephrotoxic	JJ	_	15	amod
15	medications	medication	NNS	_	12	nmod
16	.	.	.	_	7	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	6	compound
4	-	-	:	_	6	punct
5	induced	induce	VBN	_	6	amod
6	hypokalemia	hypokalemia	NN	_	8	nsubj
7	may	may	MD	_	8	aux
8	enhance	enhance	VB	_	1	dep
9	the	the	DT	_	11	det
10	curariform	curariform	NN	_	11	compound
11	effect	effect	NN	_	8	dobj
12	of	of	IN	_	13	case
13	drug3	drug3	NN	_	11	nmod
14	-LRB-	-lrb-	-LRB-	_	17	punct
15	e.g.	e.g.	FW	_	17	dep
16	,	,	,	_	17	punct
17	drug4	drug4	NN	_	13	appos
18	-RRB-	-rrb-	-RRB-	_	17	punct
19	.	.	.	_	1	punct

1	Serum	serum	NN	_	3	compound
2	potassium	potassium	NN	_	3	compound
3	levels	level	NNS	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	monitored	monitor	VBN	_	0	ROOT
7	and	and	CC	_	6	cc
8	deficiencies	deficiency	NNS	_	9	nsubj
9	corrected	correct	VBN	_	6	conj
10	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	acute	acute	JJ	_	5	amod
4	pulmonary	pulmonary	JJ	_	5	amod
5	toxicity	toxicity	NN	_	8	nsubjpass
6	has	have	VBZ	_	8	aux
7	been	be	VBN	_	8	auxpass
8	reported	report	VBN	_	1	dep
9	in	in	IN	_	10	case
10	patients	patient	NNS	_	8	nmod
11	receiving	receive	VBG	_	10	acl
12	intravenous	intravenous	JJ	_	13	amod
13	drug2	drug2	NN	_	11	dobj
14	and	and	CC	_	13	cc
15	drug3	drug3	NN	_	13	conj
16	.	.	.	_	1	punct

1	Drugs	drug	NNS	_	12	nsubj
2	that	that	WDT	_	3	nsubj
3	inhibit	inhibit	VBP	_	1	acl:relcl
4	or	or	CC	_	3	cc
5	Induce	induce	VBP	_	3	conj
6	CYP	cyp	NN	_	7	compound
7	2D6	2d6	NN	_	3	dobj
8	and	and	CC	_	7	cc
9	CYP	cyp	NN	_	10	compound
10	3A4	3a4	NN	_	7	conj
11	may	may	MD	_	12	aux
12	affect	affect	VB	_	0	ROOT
13	the	the	DT	_	14	det
14	concentration	concentration	NN	_	12	dobj
15	on	on	IN	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	.	.	.	_	12	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	with	with	IN	_	6	case
6	caution	caution	NN	_	4	nmod
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	receiving	receive	VBG	_	8	acl
10	other	other	JJ	_	12	amod
11	local	local	JJ	_	12	amod
12	drug2	drug2	NN	_	9	dobj
13	or	or	CC	_	12	cc
14	agents	agent	NNS	_	12	conj
15	structurally	structurally	RB	_	16	advmod
16	related	related	JJ	_	8	amod
17	to	to	TO	_	20	case
18	amide-type	amide-type	JJ	_	20	amod
19	local	local	JJ	_	20	amod
20	anesthetics	anesthetic	NNS	_	16	nmod
21	since	since	IN	_	30	mark
22	the	the	DT	_	24	det
23	toxic	toxic	JJ	_	24	amod
24	effects	effect	NNS	_	30	nsubj
25	of	of	IN	_	27	case
26	these	these	DT	_	27	det
27	drugs	drug	NNS	_	24	nmod
28	could	could	MD	_	30	aux
29	be	be	VB	_	30	cop
30	additive	additive	JJ	_	4	advcl
31	.	.	.	_	4	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	4	nsubj
4	indicate	indicate	VBP	_	0	ROOT
5	CYP3A4	cyp3a4	NN	_	6	compound
6	isoform	isoform	NN	_	10	nsubj
7	and	and	CC	_	6	cc
8	CYP1A2	cyp1a2	NN	_	9	compound
9	isoform	isoform	NN	_	6	conj
10	mediate	mediate	VBP	_	4	ccomp
11	the	the	DT	_	12	det
12	metabolism	metabolism	NN	_	10	dobj
13	of	of	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	to	to	TO	_	16	case
16	drug2	drug2	NN	_	10	nmod
17	and	and	CC	_	16	cc
18	drug3	drug3	NN	_	16	conj
19	,	,	,	_	10	punct
20	respectively	respectively	RB	_	10	advmod
21	.	.	.	_	4	punct

1	Thus	thus	RB	_	19	advmod
2	agents	agent	NNS	_	19	nsubj
3	likely	likely	JJ	_	2	amod
4	to	to	TO	_	7	mark
5	be	be	VB	_	7	auxpass
6	concomitantly	concomitantly	RB	_	7	advmod
7	administered	administer	VBN	_	3	xcomp
8	with	with	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	that	that	WDT	_	12	nsubjpass
11	are	be	VBP	_	12	auxpass
12	metabolized	metabolize	VBN	_	9	acl:relcl
13	by	by	IN	_	16	case
14	this	this	DT	_	16	det
15	isoenzyme	isoenzyme	NN	_	16	compound
16	family	family	NN	_	12	nmod
17	may	may	MD	_	19	aux
18	potentially	potentially	RB	_	19	advmod
19	interact	interact	VB	_	0	ROOT
20	with	with	IN	_	21	case
21	drug2	drug2	NN	_	19	nmod
22	.	.	.	_	19	punct

1	Although	although	IN	_	7	mark
2	no	no	DT	_	4	neg
3	clinical	clinical	JJ	_	4	amod
4	studies	study	NNS	_	7	nsubjpass
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	conducted	conduct	VBN	_	11	advcl
8	,	,	,	_	11	punct
9	it	it	PRP	_	11	nsubj
10	is	be	VBZ	_	11	cop
11	likely	likely	JJ	_	0	ROOT
12	that	that	IN	_	19	mark
13	the	the	DT	_	14	det
14	metabolism	metabolism	NN	_	19	nsubjpass
15	of	of	IN	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	may	may	MD	_	19	aux
18	be	be	VB	_	19	auxpass
19	affected	affect	VBN	_	11	ccomp
20	by	by	IN	_	24	case
21	the	the	DT	_	24	det
22	known	known	JJ	_	24	amod
23	CYP3A4	cyp3a4	NN	_	24	compound
24	inducers	inducer	NNS	_	19	nmod
25	-LRB-	-lrb-	-LRB-	_	28	punct
26	such	such	JJ	_	28	case
27	as	as	IN	_	26	mwe
28	drug2	drug2	NN	_	24	nmod
29	,	,	,	_	28	punct
30	drug3	drug3	NN	_	28	appos
31	,	,	,	_	28	punct
32	drug4	drug4	NN	_	28	appos
33	-RRB-	-rrb-	-RRB-	_	28	punct
34	,	,	,	_	24	punct
35	CYP3A4	cyp3a4	NN	_	36	compound
36	inhibitors	inhibitor	NNS	_	24	appos
37	-LRB-	-lrb-	-LRB-	_	39	punct
38	azole	azole	NN	_	39	compound
39	antimycotics	antimycotic	NNS	_	36	dep
40	e.g.	e.g.	FW	_	42	dep
41	,	,	,	_	42	punct
42	drug5	drug5	NN	_	39	dep
43	;	;	:	_	39	punct

1	certain	certain	JJ	_	2	amod
2	drug1	drug1	NN	_	5	nsubj
3	e.g.	e.g.	FW	_	5	dep
4	,	,	,	_	5	punct
5	ritanovir	ritanovir	NN	_	0	ROOT
6	;	;	:	_	5	punct

1	drug1	drug1	NN	_	4	dep
2	e.g.	e.g.	FW	_	4	dep
3	,	,	,	_	4	punct
4	drug2	drug2	NN	_	0	ROOT
5	;	;	:	_	4	punct

1	and	and	CC	_	5	cc
2	drug1	drug1	NN	_	3	compound
3	e.g.	e.g.	FW	_	5	dep
4	,	,	,	_	5	punct
5	drug2	drug2	NN	_	0	ROOT
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	,	,	,	_	5	punct
8	CYP1A2	cyp1a2	NN	_	9	compound
9	inducers	inducer	NNS	_	5	conj
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	drug3	drug3	NN	_	9	appos
12	-RRB-	-rrb-	-RRB-	_	11	punct
13	and	and	CC	_	5	cc
14	CYP1A2	cyp1a2	NN	_	15	compound
15	inhibitors	inhibitor	NNS	_	5	conj
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	drug4	drug4	NN	_	15	dep
18	and	and	CC	_	17	cc
19	drug5	drug5	NN	_	17	conj
20	-RRB-	-rrb-	-RRB-	_	17	punct
21	.	.	.	_	5	punct

1	Dosage	dosage	NN	_	2	compound
2	adjustment	adjustment	NN	_	5	nsubjpass
3	may	may	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	warranted	warrant	VBN	_	0	ROOT
6	when	when	WRB	_	10	advmod
7	drug1	drug1	NN	_	10	nsubjpass
8	is	be	VBZ	_	10	auxpass
9	concurrently	concurrently	RB	_	10	advmod
10	administered	administer	VBN	_	5	advcl
11	with	with	IN	_	13	case
12	CYP3A4	cyp3a4	NN	_	13	compound
13	inhibitors	inhibitor	NNS	_	10	nmod
14	and	and	CC	_	13	cc
15	CYP1A2	cyp1a2	NN	_	16	compound
16	inhibitors	inhibitor	NNS	_	13	conj
17	as	as	IN	_	22	mark
18	systemic	systemic	JJ	_	20	amod
19	drug2	drug2	NN	_	20	compound
20	levels	level	NNS	_	22	nsubj
21	may	may	MD	_	22	aux
22	rise	rise	VB	_	10	advcl
23	resulting	result	VBG	_	22	xcomp
24	in	in	IN	_	25	case
25	toxicity	toxicity	NN	_	23	nmod
26	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Steady-state	steady-state	JJ	_	5	amod
4	trough	trough	NN	_	5	compound
5	concentrations	concentration	NNS	_	12	nsubj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	were	be	VBD	_	12	cop
9	about	about	IN	_	10	advmod
10	56	56	CD	_	11	nummod
11	%	%	NN	_	12	nmod:npmod
12	higher	higher	JJR	_	1	dep
13	when	when	WRB	_	18	advmod
14	8	8	CD	_	16	nummod
15	mg	mg	NN	_	16	compound
16	drug3	drug3	NN	_	18	nsubjpass
17	was	be	VBD	_	18	auxpass
18	coadministered	coadminister	VBN	_	12	advcl
19	with	with	IN	_	21	case
20	each	each	DT	_	21	det
21	dose	dose	NN	_	18	nmod
22	of	of	IN	_	23	case
23	drug4	drug4	NN	_	21	nmod
24	-LRB-	-lrb-	-LRB-	_	26	punct
25	15	15	CD	_	26	nummod
26	mg/kg/day	mg/kg/day	NN	_	12	dep
27	-RRB-	-rrb-	-RRB-	_	26	punct
28	in	in	IN	_	31	case
29	eight	eight	CD	_	31	nummod
30	neurocysticercosis	neurocysticercosis	NN	_	31	compound
31	patients	patient	NNS	_	12	nmod
32	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	6	case
4	the	the	DT	_	6	det
5	fed	fed	NN	_	6	compound
6	state	state	NN	_	1	nmod
7	,	,	,	_	6	punct
8	drug2	drug2	NN	_	13	nsubj
9	-LRB-	-lrb-	-LRB-	_	11	punct
10	40	40	CD	_	11	nummod
11	mg/kg	mg/kg	NN	_	8	appos
12	-RRB-	-rrb-	-RRB-	_	11	punct
13	increased	increase	VBD	_	6	acl:relcl
14	mean	mean	JJ	_	17	amod
15	maximum	maximum	NN	_	17	compound
16	plasma	plasma	NN	_	17	compound
17	concentration	concentration	NN	_	13	dobj
18	and	and	CC	_	17	cc
19	area	area	NN	_	17	conj
20	under	under	IN	_	22	case
21	the	the	DT	_	22	det
22	curve	curve	NN	_	13	nmod
23	of	of	IN	_	24	case
24	drug3	drug3	NN	_	22	nmod
25	by	by	IN	_	28	case
26	about	about	IN	_	27	advmod
27	50	50	CD	_	28	nummod
28	%	%	NN	_	13	nmod
29	in	in	IN	_	31	case
30	healthy	healthy	JJ	_	31	amod
31	subjects	subject	NNS	_	13	nmod
32	-LRB-	-lrb-	-LRB-	_	34	punct
33	n	n	NN	_	34	nsubj
34	=	=	JJ	_	13	parataxis
35	10	10	CD	_	34	dobj
36	-RRB-	-rrb-	-RRB-	_	34	punct
37	compared	compare	VBN	_	41	case
38	with	with	IN	_	41	case
39	a	a	DT	_	41	det
40	separate	separate	JJ	_	41	amod
41	group	group	NN	_	13	advcl
42	of	of	IN	_	43	case
43	subjects	subject	NNS	_	41	nmod
44	-LRB-	-lrb-	-LRB-	_	45	punct
45	n	n	NN	_	41	dep
46	=	=	JJ	_	45	amod
47	6	6	CD	_	46	dep
48	-RRB-	-rrb-	-RRB-	_	45	punct
49	given	give	VBN	_	50	case
50	drug4	drug4	NN	_	41	nmod
51	alone	alone	RB	_	50	advmod
52	.	.	.	_	1	punct

1	Mean	mean	NN	_	3	compound
2	T	t	NN	_	3	compound
3	max	max	NN	_	12	nsubj
4	and	and	CC	_	3	cc
5	mean	mean	VB	_	3	conj
6	plasma	plasma	NN	_	8	compound
7	elimination	elimination	NN	_	8	compound
8	half-life	half-life	NN	_	5	dobj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	were	be	VBD	_	12	cop
12	unchanged	unchanged	JJ	_	0	ROOT
13	.	.	.	_	12	punct

1	The	the	DT	_	2	det
2	pharmacokinetics	pharmacokinetic	NNS	_	6	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	were	be	VBD	_	6	cop
6	unchanged	unchanged	JJ	_	0	ROOT
7	following	follow	VBG	_	8	case
8	coadministration	coadministration	NN	_	6	nmod
9	with	with	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	-LRB-	-lrb-	-LRB-	_	13	punct
12	400	400	CD	_	13	nummod
13	mg	mg	NN	_	10	appos
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	compound
4	concentrations	concentration	NNS	_	11	nsubjpass
5	in	in	IN	_	6	case
6	bile	bile	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	cystic	cystic	JJ	_	9	amod
9	fluid	fluid	NN	_	6	conj
10	were	be	VBD	_	11	auxpass
11	increased	increase	VBN	_	1	dep
12	-LRB-	-lrb-	-LRB-	_	14	punct
13	about	about	IN	_	14	case
14	2-fold	2-fold	JJ	_	11	dep
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	in	in	IN	_	19	case
17	hydatid	hydatid	NN	_	19	compound
18	cyst	cyst	NN	_	19	compound
19	patients	patient	NNS	_	11	nmod
20	treated	treat	VBN	_	19	acl
21	with	with	IN	_	22	case
22	drug3	drug3	NN	_	20	nmod
23	-LRB-	-lrb-	-LRB-	_	25	punct
24	10	10	CD	_	25	nummod
25	mg/kg/day	mg/kg/day	NN	_	22	appos
26	-RRB-	-rrb-	-RRB-	_	25	punct
27	-LRB-	-lrb-	-LRB-	_	28	punct
28	n	n	NN	_	22	dep
29	=	=	JJ	_	28	amod
30	7	7	CD	_	29	dep
31	-RRB-	-rrb-	-RRB-	_	28	punct
32	compared	compare	VBN	_	34	case
33	with	with	IN	_	34	case
34	drug4	drug4	NN	_	11	advcl
35	-LRB-	-lrb-	-LRB-	_	37	punct
36	20	20	CD	_	37	nummod
37	mg/kg/day	mg/kg/day	NN	_	34	appos
38	-RRB-	-rrb-	-RRB-	_	37	punct
39	alone	alone	RB	_	34	advmod
40	-LRB-	-lrb-	-LRB-	_	41	punct
41	n	n	NN	_	34	dep
42	=	=	JJ	_	41	amod
43	12	12	CD	_	42	dep
44	-RRB-	-rrb-	-RRB-	_	41	punct
45	.	.	.	_	11	punct

1	drug1	drug1	NN	_	3	compound
2	plasma	plasma	NN	_	3	compound
3	concentrations	concentration	NNS	_	5	nsubj
4	were	be	VBD	_	5	cop
5	unchanged	unchanged	JJ	_	0	ROOT
6	4	4	CD	_	7	nummod
7	hours	hour	NNS	_	5	nmod
8	after	after	IN	_	7	case
9	dosing	dosing	NN	_	7	dep
10	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	pharmacokinetics	pharmacokinetic	NNS	_	17	nsubj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	-LRB-	-lrb-	-LRB-	_	10	punct
8	drug3	drug3	NN	_	10	compound
9	5.8	5.8	CD	_	10	nummod
10	mg/kg	mg/kg	NN	_	6	dep
11	infused	infuse	VBD	_	10	acl
12	over	over	IN	_	14	case
13	20	20	CD	_	14	nummod
14	minutes	minute	NNS	_	11	nmod
15	-RRB-	-rrb-	-RRB-	_	10	punct
16	were	be	VBD	_	17	cop
17	unchanged	unchanged	JJ	_	1	dep
18	following	follow	VBG	_	22	case
19	a	a	DT	_	22	det
20	single	single	JJ	_	22	amod
21	oral	oral	JJ	_	22	amod
22	dose	dose	NN	_	17	nmod
23	of	of	IN	_	24	case
24	drug4	drug4	NN	_	22	nmod
25	-LRB-	-lrb-	-LRB-	_	27	punct
26	400	400	CD	_	27	nummod
27	mg	mg	NN	_	24	appos
28	-RRB-	-rrb-	-RRB-	_	27	punct
29	in	in	IN	_	32	case
30	6	6	CD	_	32	nummod
31	healthy	healthy	JJ	_	32	amod
32	subjects	subject	NNS	_	17	nmod
33	.	.	.	_	1	punct

1	drug1	drug1	NN	_	8	nsubj
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	,	,	,	_	1	punct
5	and	and	CC	_	1	cc
6	drug3	drug3	NN	_	1	conj
7	may	may	MD	_	8	aux
8	increase	increase	VB	_	0	ROOT
9	anticholinergic	anticholinergic	JJ	_	10	amod
10	effect	effect	NN	_	8	dobj
11	of	of	IN	_	12	case
12	drug4	drug4	NN	_	10	nmod
13	.	.	.	_	8	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	decrease	decrease	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	effect	effect	NN	_	3	dobj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	,	,	,	_	7	punct
9	drug3	drug3	NN	_	7	conj
10	,	,	,	_	7	punct
11	and	and	CC	_	7	cc
12	drug4	drug4	NN	_	7	conj
13	.	.	.	_	3	punct

1	Co-administration	co-administration	NN	_	21	nsubjpass
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	drug2	drug2	NN	_	3	conj
6	or	or	CC	_	3	cc
7	other	other	JJ	_	8	amod
8	agents	agent	NNS	_	3	conj
9	interfering	interfere	VBG	_	8	acl
10	with	with	IN	_	12	case
11	neuromuscular	neuromuscular	JJ	_	12	amod
12	transmission	transmission	NN	_	9	nmod
13	-LRB-	-lrb-	-LRB-	_	16	punct
14	e.g.	e.g.	FW	_	16	dep
15	,	,	,	_	16	punct
16	drug3	drug3	NN	_	12	appos
17	-RRB-	-rrb-	-RRB-	_	16	punct
18	should	should	MD	_	21	aux
19	only	only	RB	_	21	advmod
20	be	be	VB	_	21	auxpass
21	performed	perform	VBN	_	32	csubjpass
22	with	with	IN	_	23	case
23	caution	caution	NN	_	21	nmod
24	as	as	IN	_	26	case
25	the	the	DT	_	26	det
26	effect	effect	NN	_	21	nmod
27	of	of	IN	_	29	case
28	the	the	DT	_	29	det
29	drug4	drug4	NN	_	26	nmod
30	may	may	MD	_	32	aux
31	be	be	VB	_	32	auxpass
32	potentiated	potentiate	VBN	_	0	ROOT
33	.	.	.	_	32	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	22	nsubj
3	of	of	IN	_	4	mark
4	administering	administer	VBG	_	2	acl
5	different	different	JJ	_	7	amod
6	drug1	drug1	NN	_	7	compound
7	serotypes	serotype	NNS	_	4	dobj
8	at	at	IN	_	11	case
9	the	the	DT	_	11	det
10	same	same	JJ	_	11	amod
11	time	time	NN	_	4	nmod
12	or	or	CC	_	11	cc
13	within	within	IN	_	17	case
14	less	less	JJR	_	16	advmod
15	than	than	IN	_	14	mwe
16	4	4	CD	_	17	nummod
17	months	month	NNS	_	11	conj
18	of	of	IN	_	20	case
19	each	each	DT	_	20	det
20	other	other	JJ	_	11	nmod
21	is	be	VBZ	_	22	cop
22	unknown	unknown	JJ	_	0	ROOT
23	.	.	.	_	22	punct

1	However	however	RB	_	7	advmod
2	,	,	,	_	7	punct
3	neuromuscular	neuromuscular	JJ	_	4	amod
4	paralysis	paralysis	NN	_	7	nsubjpass
5	may	may	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	potentiated	potentiate	VBN	_	0	ROOT
8	by	by	IN	_	9	case
9	co-administration	co-administration	NN	_	7	nmod
10	or	or	CC	_	9	cc
11	overlapping	overlap	VBG	_	12	amod
12	administration	administration	NN	_	9	conj
13	of	of	IN	_	16	case
14	different	different	JJ	_	16	amod
15	drug1	drug1	NN	_	16	compound
16	serotypes	serotype	NNS	_	9	nmod
17	.	.	.	_	7	punct

1	As	as	IN	_	4	case
2	with	with	IN	_	4	case
3	all	all	DT	_	4	det
4	drugs	drug	NNS	_	8	nmod
5	,	,	,	_	8	punct
6	the	the	DT	_	7	det
7	potential	potential	JJ	_	8	nsubj
8	exists	exist	VBZ	_	0	ROOT
9	for	for	IN	_	10	case
10	interaction	interaction	NN	_	8	nmod
11	with	with	IN	_	13	case
12	other	other	JJ	_	13	amod
13	drugs	drug	NNS	_	10	nmod
14	by	by	IN	_	16	case
15	a	a	DT	_	16	det
16	variety	variety	NN	_	10	nmod
17	of	of	IN	_	18	case
18	mechanisms	mechanism	NNS	_	16	nmod
19	.	.	.	_	8	punct

1	CNS-Active	cns-active	JJ	_	3	amod
2	Drugs	drug	NNS	_	3	compound
3	drug1	drug1	NN	_	0	ROOT
4	:	:	:	_	3	punct
5	drug2	drug2	NN	_	7	compound
6	10	10	CD	_	7	nummod
7	mg	mg	NN	_	8	nsubj
8	potentiated	potentiate	VBD	_	3	dep
9	the	the	DT	_	11	det
10	CNS-impairing	cns-impairing	JJ	_	11	amod
11	effects	effect	NNS	_	8	dobj
12	of	of	IN	_	15	case
13	drug3	drug3	NN	_	15	compound
14	0.75	0.75	CD	_	15	nummod
15	g/kg	g/kg	NN	_	11	nmod
16	on	on	IN	_	18	case
17	balance	balance	NN	_	18	compound
18	testing	testing	NN	_	11	nmod
19	and	and	CC	_	18	cc
20	reaction	reaction	NN	_	21	compound
21	time	time	NN	_	18	conj
22	for	for	IN	_	24	case
23	1	1	CD	_	24	nummod
24	hour	hour	NN	_	8	nmod
25	after	after	IN	_	27	case
26	drug4	drug4	NN	_	27	compound
27	administration	administration	NN	_	8	nmod
28	and	and	CC	_	8	cc
29	on	on	IN	_	34	case
30	the	the	DT	_	34	det
31	digit	digit	NN	_	34	compound
32	symbol	symbol	NN	_	34	compound
33	substitution	substitution	NN	_	34	compound
34	test	test	NN	_	8	conj
35	-LRB-	-lrb-	-LRB-	_	36	punct
36	DSST	dsst	NN	_	34	appos
37	-RRB-	-rrb-	-RRB-	_	36	punct
38	,	,	,	_	34	punct
39	symbol	symbol	NN	_	41	compound
40	copying	copying	NN	_	41	compound
41	test	test	NN	_	34	conj
42	,	,	,	_	34	punct
43	and	and	CC	_	34	cc
44	the	the	DT	_	46	det
45	variability	variability	NN	_	46	compound
46	component	component	NN	_	34	conj
47	of	of	IN	_	51	case
48	the	the	DT	_	51	det
49	divided	divide	VBN	_	51	amod
50	attention	attention	NN	_	51	compound
51	test	test	NN	_	46	nmod
52	for	for	IN	_	54	case
53	2.5	2.5	CD	_	54	nummod
54	hours	hour	NNS	_	46	nmod
55	after	after	IN	_	57	case
56	drug5	drug5	NN	_	57	compound
57	administration	administration	NN	_	46	nmod
58	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	potentiation	potentiation	NN	_	3	nsubj
3	resulted	result	VBD	_	0	ROOT
4	from	from	IN	_	8	case
5	a	a	DT	_	8	det
6	CNS	cns	NN	_	8	compound
7	pharmacodynamic	pharmacodynamic	JJ	_	8	amod
8	interaction	interaction	NN	_	3	nmod
9	;	;	:	_	3	punct

1	drug1	drug1	NN	_	4	nsubj
2	did	do	VBD	_	4	aux
3	not	not	RB	_	4	neg
4	affect	affect	VB	_	0	ROOT
5	the	the	DT	_	6	det
6	pharmacokinetics	pharmacokinetic	NNS	_	4	dobj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Coadministration	coadministration	NN	_	15	nsubj
4	of	of	IN	_	6	case
5	single	single	JJ	_	6	amod
6	doses	dose	NNS	_	3	nmod
7	of	of	IN	_	10	case
8	drug2	drug2	NN	_	10	compound
9	20	20	CD	_	10	nummod
10	mg	mg	NN	_	6	nmod
11	and	and	CC	_	10	cc
12	drug3	drug3	NN	_	14	compound
13	75	75	CD	_	14	nummod
14	mg	mg	NN	_	10	conj
15	produced	produce	VBD	_	1	dep
16	additive	additive	JJ	_	17	amod
17	effects	effect	NNS	_	15	dobj
18	on	on	IN	_	20	case
19	decreased	decrease	VBN	_	20	amod
20	alertness	alertness	NN	_	15	nmod
21	and	and	CC	_	20	cc
22	impaired	impaired	JJ	_	24	amod
23	psychomotor	psychomotor	NN	_	24	compound
24	performance	performance	NN	_	20	conj
25	for	for	IN	_	29	case
26	2	2	CD	_	28	compound
27	to	to	TO	_	28	dep
28	4	4	CD	_	29	nummod
29	hours	hour	NNS	_	20	nmod
30	after	after	IN	_	31	case
31	administration	administration	NN	_	15	nmod
32	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	interaction	interaction	NN	_	4	nsubj
3	was	be	VBD	_	4	cop
4	pharmacodynamic	pharmacodynamic	JJ	_	0	ROOT
5	with	with	IN	_	7	case
6	no	no	DT	_	7	neg
7	alteration	alteration	NN	_	4	nmod
8	of	of	IN	_	10	case
9	the	the	DT	_	10	det
10	pharmacokinetics	pharmacokinetic	NNS	_	7	nmod
11	of	of	IN	_	13	case
12	either	either	CC	_	13	det
13	drug	drug	NN	_	10	nmod
14	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Coadministration	coadministration	NN	_	22	nsubj
4	of	of	IN	_	7	case
5	a	a	DT	_	7	det
6	single	single	JJ	_	7	amod
7	dose	dose	NN	_	3	nmod
8	of	of	IN	_	11	case
9	drug2	drug2	NN	_	11	compound
10	20	20	CD	_	11	nummod
11	mg	mg	NN	_	7	nmod
12	and	and	CC	_	11	cc
13	drug3	drug3	NN	_	15	compound
14	20	20	CD	_	15	nummod
15	mg	mg	NN	_	11	conj
16	daily	daily	RB	_	3	advmod
17	for	for	IN	_	19	case
18	7	7	CD	_	19	nummod
19	days	day	NNS	_	3	nmod
20	did	do	VBD	_	22	aux
21	not	not	RB	_	22	neg
22	produce	produce	VB	_	1	dep
23	any	any	DT	_	24	det
24	interaction	interaction	NN	_	22	dobj
25	on	on	IN	_	27	case
26	psychomotor	psychomotor	NN	_	27	compound
27	performance	performance	NN	_	24	nmod
28	.	.	.	_	22	punct

1	Additionally	additionally	RB	_	6	advmod
2	,	,	,	_	6	punct
3	drug1	drug1	NN	_	6	nsubj
4	did	do	VBD	_	6	aux
5	not	not	RB	_	6	neg
6	alter	alter	VB	_	0	ROOT
7	the	the	DT	_	8	det
8	pharmacokinetics	pharmacokinetic	NNS	_	6	dobj
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	,	,	,	_	6	punct
12	reflecting	reflect	VBG	_	6	advcl
13	the	the	DT	_	14	det
14	absence	absence	NN	_	12	dobj
15	of	of	IN	_	17	case
16	a	a	DT	_	17	det
17	role	role	NN	_	14	nmod
18	of	of	IN	_	19	case
19	CYP2D6	cyp2d6	NN	_	17	nmod
20	in	in	IN	_	23	case
21	drug3	drug3	NN	_	23	compound
22	s	s	NNS	_	23	compound
23	metabolism	metabolism	NN	_	17	nmod
24	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Coadministration	coadministration	NN	_	15	nsubj
4	of	of	IN	_	6	case
5	single	single	JJ	_	6	amod
6	doses	dose	NNS	_	3	nmod
7	of	of	IN	_	10	case
8	drug2	drug2	NN	_	10	compound
9	20	20	CD	_	10	nummod
10	mg	mg	NN	_	6	nmod
11	and	and	CC	_	10	cc
12	drug3	drug3	NN	_	14	compound
13	50	50	CD	_	14	nummod
14	mg	mg	NN	_	10	conj
15	produced	produce	VBD	_	1	dep
16	additive	additive	JJ	_	17	amod
17	effects	effect	NNS	_	15	dobj
18	on	on	IN	_	20	case
19	decreased	decrease	VBN	_	20	amod
20	alertness	alertness	NN	_	15	nmod
21	and	and	CC	_	20	cc
22	impaired	impaired	JJ	_	24	amod
23	psychomotor	psychomotor	NN	_	24	compound
24	performance	performance	NN	_	20	conj
25	for	for	IN	_	29	case
26	2	2	CD	_	28	compound
27	to	to	TO	_	28	dep
28	4	4	CD	_	29	nummod
29	hours	hour	NNS	_	20	nmod
30	after	after	IN	_	31	case
31	administration	administration	NN	_	15	nmod
32	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	interaction	interaction	NN	_	4	nsubj
3	was	be	VBD	_	4	cop
4	pharmacodynamic	pharmacodynamic	JJ	_	0	ROOT
5	with	with	IN	_	7	case
6	no	no	DT	_	7	neg
7	alteration	alteration	NN	_	4	nmod
8	of	of	IN	_	10	case
9	the	the	DT	_	10	det
10	pharmacokinetics	pharmacokinetic	NNS	_	7	nmod
11	of	of	IN	_	13	case
12	either	either	CC	_	13	det
13	drug	drug	NN	_	10	nmod
14	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Coadministration	coadministration	NN	_	23	compound
4	of	of	IN	_	7	case
5	a	a	DT	_	7	det
6	single	single	JJ	_	7	amod
7	dose	dose	NN	_	3	nmod
8	of	of	IN	_	11	case
9	drug2	drug2	NN	_	11	compound
10	10	10	CD	_	11	nummod
11	mg	mg	NN	_	7	nmod
12	and	and	CC	_	11	cc
13	multiple	multiple	JJ	_	14	amod
14	doses	dose	NNS	_	11	conj
15	of	of	IN	_	17	case
16	drug3	drug3	NN	_	17	compound
17	ER	er	NN	_	14	nmod
18	-LRB-	-lrb-	-LRB-	_	20	punct
19	extended	extended	JJ	_	20	amod
20	release	release	NN	_	3	appos
21	-RRB-	-rrb-	-RRB-	_	20	punct
22	150	150	CD	_	23	nummod
23	mg	mg	NN	_	26	nsubj
24	did	do	VBD	_	26	aux
25	not	not	RB	_	26	neg
26	result	result	VB	_	1	dep
27	in	in	IN	_	30	case
28	any	any	DT	_	30	det
29	significant	significant	JJ	_	30	amod
30	changes	change	NNS	_	26	nmod
31	in	in	IN	_	33	case
32	the	the	DT	_	33	det
33	pharmacokinetics	pharmacokinetic	NNS	_	30	nmod
34	of	of	IN	_	36	case
35	either	either	CC	_	36	cc:preconj
36	drug4	drug4	NN	_	33	nmod
37	or	or	CC	_	36	cc
38	drug5	drug5	NN	_	36	conj
39	.	.	.	_	1	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	5	nmod
3	,	,	,	_	5	punct
4	there	there	EX	_	5	expl
5	was	be	VBD	_	0	ROOT
6	no	no	DT	_	8	neg
7	pharmacodynamic	pharmacodynamic	JJ	_	8	amod
8	interaction	interaction	NN	_	5	nsubj
9	as	as	IN	_	11	case
10	a	a	DT	_	11	det
11	result	result	NN	_	5	nmod
12	of	of	IN	_	13	case
13	coadministration	coadministration	NN	_	11	nmod
14	of	of	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	drug2	drug2	NN	_	18	compound
18	ER	er	NN	_	15	conj
19	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Coadministration	coadministration	NN	_	20	nsubj
4	of	of	IN	_	7	case
5	a	a	DT	_	7	det
6	single	single	JJ	_	7	amod
7	dose	dose	NN	_	3	nmod
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	drug3	drug3	NN	_	9	conj
12	-LRB-	-lrb-	-LRB-	_	16	punct
13	10	10	CD	_	16	nummod
14	and	and	CC	_	13	cc
15	25	25	CD	_	13	conj
16	mg	mg	NN	_	7	dep
17	,	,	,	_	16	punct
18	respectively	respectively	RB	_	16	advmod
19	-RRB-	-rrb-	-RRB-	_	16	punct
20	resulted	result	VBD	_	1	appos
21	in	in	IN	_	25	case
22	a	a	DT	_	25	det
23	15	15	CD	_	24	compound
24	%	%	NN	_	25	amod
25	decrease	decrease	NN	_	20	nmod
26	in	in	IN	_	29	case
27	maximal	maximal	JJ	_	29	amod
28	plasma	plasma	NN	_	29	compound
29	concentrations	concentration	NNS	_	25	nmod
30	of	of	IN	_	31	case
31	drug4	drug4	NN	_	29	nmod
32	,	,	,	_	20	punct
33	but	but	CC	_	20	cc
34	no	no	DT	_	35	neg
35	change	change	NN	_	20	conj
36	in	in	IN	_	38	case
37	the	the	DT	_	38	det
38	area	area	NN	_	35	nmod
39	under	under	IN	_	43	case
40	the	the	DT	_	43	det
41	plasma	plasma	NN	_	43	compound
42	concentration-time	concentration-time	NN	_	43	compound
43	curve	curve	NN	_	35	nmod
44	.	.	.	_	1	punct

1	However	however	RB	_	14	advmod
2	,	,	,	_	14	punct
3	the	the	DT	_	4	det
4	pharmacodynamics	pharmacodynamic	NNS	_	14	nsubjpass
5	of	of	IN	_	6	case
6	coadministration	coadministration	NN	_	4	nmod
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	drug2	drug2	NN	_	8	conj
11	have	have	VBP	_	14	aux
12	not	not	RB	_	14	neg
13	been	be	VBN	_	14	auxpass
14	evaluated	evaluate	VBN	_	0	ROOT
15	.	.	.	_	14	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	exercised	exercise	VBN	_	0	ROOT
5	when	when	WRB	_	10	advmod
6	these	these	DT	_	8	det
7	2	2	CD	_	8	nummod
8	agents	agent	NNS	_	10	nsubjpass
9	are	be	VBP	_	10	auxpass
10	coadministered	coadminister	VBN	_	4	advcl
11	.	.	.	_	4	punct

1	Drugs	drug	NNS	_	0	ROOT
2	That	that	WDT	_	3	nsubj
3	Induce	induce	VBP	_	1	acl:relcl
4	CYP3A4	cyp3a4	NN	_	5	compound
5	drug1	drug1	NN	_	3	dobj
6	:	:	:	_	1	punct
7	CYP3A4	cyp3a4	NN	_	13	nsubj
8	is	be	VBZ	_	13	cop
9	ordinarily	ordinarily	RB	_	13	advmod
10	a	a	DT	_	13	det
11	minor	minor	JJ	_	13	amod
12	metabolizing	metabolize	VBG	_	13	amod
13	enzyme	enzyme	NN	_	1	dep
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	.	.	.	_	1	punct

1	Multiple-dose	multiple-dose	JJ	_	2	amod
2	administration	administration	NN	_	25	nsubj
3	of	of	IN	_	8	case
4	the	the	DT	_	8	det
5	potent	potent	JJ	_	8	amod
6	CYP3A4	cyp3a4	NN	_	8	compound
7	inducer	inducer	NN	_	8	compound
8	drug1	drug1	NN	_	2	nmod
9	-LRB-	-lrb-	-LRB-	_	11	punct
10	600	600	CD	_	11	nummod
11	mg	mg	NN	_	8	dep
12	every	every	DT	_	14	det
13	24	24	CD	_	14	nummod
14	hours	hour	NNS	_	11	dep
15	,	,	,	_	11	punct
16	q24h	q24h	NN	_	11	appos
17	,	,	,	_	11	punct
18	for	for	IN	_	20	case
19	14	14	CD	_	20	nummod
20	days	day	NNS	_	11	nmod
21	-RRB-	-rrb-	-RRB-	_	11	punct
22	,	,	,	_	25	punct
23	however	however	RB	_	25	advmod
24	,	,	,	_	25	punct
25	reduced	reduce	VBD	_	0	ROOT
26	drug2	drug2	NN	_	27	compound
27	Cmax	cmax	NN	_	25	dobj
28	and	and	CC	_	27	cc
29	AUC	auc	NN	_	27	conj
30	by	by	IN	_	33	case
31	approximately	approximately	RB	_	32	advmod
32	80	80	CD	_	33	nummod
33	%	%	NN	_	25	nmod
34	.	.	.	_	25	punct

1	The	the	DT	_	2	det
2	coadministration	coadministration	NN	_	19	nsubj
3	of	of	IN	_	8	case
4	a	a	DT	_	8	det
5	potent	potent	JJ	_	8	amod
6	CYP3A4	cyp3a4	NN	_	8	compound
7	enzyme	enzyme	NN	_	8	compound
8	inducer	inducer	NN	_	2	nmod
9	,	,	,	_	19	punct
10	although	although	IN	_	12	mark
11	not	not	RB	_	12	neg
12	posing	pose	VBG	_	19	dep
13	a	a	DT	_	15	det
14	safety	safety	NN	_	15	compound
15	concern	concern	NN	_	12	dobj
16	,	,	,	_	19	punct
17	thus	thus	RB	_	19	advmod
18	could	could	MD	_	19	aux
19	lead	lead	VB	_	0	ROOT
20	to	to	TO	_	21	case
21	ineffectiveness	ineffectiveness	NN	_	19	nmod
22	of	of	IN	_	23	case
23	drug1	drug1	NN	_	21	nmod
24	.	.	.	_	19	punct

1	An	a	DT	_	5	det
2	alternative	alternative	JJ	_	5	amod
3	non-CYP3A4	non-cyp3a4	NN	_	5	compound
4	substrate	substrate	NN	_	5	compound
5	drug1	drug1	NN	_	8	nsubjpass
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	considered	consider	VBN	_	0	ROOT
9	in	in	IN	_	10	case
10	patients	patient	NNS	_	8	nmod
11	taking	take	VBG	_	10	acl
12	CYP3A4	cyp3a4	NN	_	13	compound
13	inducers	inducer	NNS	_	11	dobj
14	such	such	JJ	_	16	case
15	as	as	IN	_	14	mwe
16	drug2	drug2	NN	_	13	nmod
17	,	,	,	_	16	punct
18	drug3	drug3	NN	_	16	conj
19	,	,	,	_	16	punct
20	drug4	drug4	NN	_	16	conj
21	,	,	,	_	16	punct
22	and	and	CC	_	16	cc
23	drug5	drug5	NN	_	16	conj
24	.	.	.	_	8	punct

1	Drugs	drug	NNS	_	10	nsubj
2	That	that	WDT	_	3	nsubj
3	Inhibit	inhibit	VBP	_	1	acl:relcl
4	CYP3A4	cyp3a4	NN	_	5	compound
5	CYP3A4	cyp3a4	NN	_	3	dobj
6	is	be	VBZ	_	10	cop
7	a	a	DT	_	10	det
8	minor	minor	JJ	_	10	amod
9	metabolic	metabolic	JJ	_	10	amod
10	pathway	pathway	NN	_	0	ROOT
11	for	for	IN	_	13	case
12	the	the	DT	_	13	det
13	elimination	elimination	NN	_	10	nmod
14	of	of	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	because	because	IN	_	10	dep
17	the	the	DT	_	18	det
18	sum	sum	NN	_	16	root
19	of	of	IN	_	20	case
20	desethylzaleplon	desethylzaleplon	NN	_	18	nmod
21	-LRB-	-lrb-	-LRB-	_	22	punct
22	formed	form	VBN	_	20	dep
23	via	via	IN	_	24	case
24	CYP3A4	cyp3a4	NN	_	22	nmod
25	in	in	FW	_	26	compound
26	vitro	vitro	FW	_	24	advmod
27	-RRB-	-rrb-	-RRB-	_	22	punct
28	and	and	CC	_	20	cc
29	its	its	PRP$	_	30	nmod:poss
30	metabolites	metabolite	NNS	_	36	nsubj
31	,	,	,	_	30	punct
32	drug2	drug2	NN	_	30	appos
33	and	and	CC	_	32	cc
34	drug3	drug3	NN	_	32	conj
35	,	,	,	_	30	punct
36	account	account	NN	_	20	conj
37	for	for	IN	_	40	case
38	only	only	RB	_	39	advmod
39	9	9	CD	_	40	nummod
40	%	%	NN	_	36	nmod
41	of	of	IN	_	44	case
42	the	the	DT	_	44	det
43	urinary	urinary	JJ	_	44	amod
44	recovery	recovery	NN	_	40	nmod
45	of	of	IN	_	48	case
46	a	a	DT	_	48	det
47	drug4	drug4	NN	_	48	compound
48	dose	dose	NN	_	44	nmod
49	.	.	.	_	18	punct

1	Coadministration	coadministration	NN	_	0	ROOT
2	of	of	IN	_	6	case
3	single	single	JJ	_	6	amod
4	,	,	,	_	6	punct
5	oral	oral	JJ	_	6	amod
6	doses	dose	NNS	_	1	nmod
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	with	with	IN	_	10	case
10	drug2	drug2	NN	_	1	nmod
11	-LRB-	-lrb-	-LRB-	_	13	punct
12	10	10	CD	_	13	nummod
13	mg	mg	NN	_	10	dep
14	and	and	CC	_	13	cc
15	800	800	CD	_	16	nummod
16	mg	mg	NN	_	13	conj
17	,	,	,	_	13	punct
18	respectively	respectively	RB	_	13	advmod
19	-RRB-	-rrb-	-RRB-	_	13	punct
20	,	,	,	_	10	punct
21	a	a	DT	_	26	det
22	strong	strong	JJ	_	26	amod
23	,	,	,	_	26	punct
24	selective	selective	JJ	_	26	amod
25	CYP3A4	cyp3a4	NN	_	26	compound
26	inhibitor	inhibitor	NN	_	27	nsubj
27	produced	produce	VBD	_	10	acl:relcl
28	a	a	DT	_	31	det
29	34	34	CD	_	30	compound
30	%	%	NN	_	31	amod
31	increase	increase	NN	_	27	dobj
32	in	in	IN	_	37	case
33	drug3	drug3	NN	_	34	compound
34	s	s	NNS	_	37	compound
35	maximal	maximal	JJ	_	37	amod
36	plasma	plasma	NN	_	37	compound
37	concentrations	concentration	NNS	_	31	nmod
38	and	and	CC	_	31	cc
39	a	a	DT	_	42	det
40	20	20	CD	_	41	compound
41	%	%	NN	_	42	amod
42	increase	increase	NN	_	31	conj
43	in	in	IN	_	45	case
44	the	the	DT	_	45	det
45	area	area	NN	_	42	nmod
46	under	under	IN	_	50	case
47	the	the	DT	_	50	det
48	plasma	plasma	NN	_	50	compound
49	concentration-time	concentration-time	NN	_	50	compound
50	curve	curve	NN	_	42	nmod
51	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	magnitude	magnitude	NN	_	11	nsubj
3	of	of	IN	_	4	case
4	interaction	interaction	NN	_	2	nmod
5	with	with	IN	_	7	case
6	multiple	multiple	JJ	_	7	amod
7	doses	dose	NNS	_	4	nmod
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	is	be	VBZ	_	11	cop
11	unknown	unknown	JJ	_	0	ROOT
12	.	.	.	_	11	punct

1	Other	other	JJ	_	5	amod
2	strong	strong	JJ	_	5	amod
3	selective	selective	JJ	_	5	amod
4	CYP3A4	cyp3a4	NN	_	5	compound
5	inhibitors	inhibitor	NNS	_	12	nsubjpass
6	such	such	JJ	_	8	case
7	as	as	IN	_	6	mwe
8	drug1	drug1	NN	_	5	nmod
9	can	can	MD	_	12	aux
10	also	also	RB	_	12	advmod
11	be	be	VB	_	12	auxpass
12	expected	expect	VBN	_	0	ROOT
13	to	to	TO	_	14	mark
14	increase	increase	VB	_	12	xcomp
15	the	the	DT	_	16	det
16	exposure	exposure	NN	_	14	dobj
17	of	of	IN	_	18	case
18	drug2	drug2	NN	_	16	nmod
19	.	.	.	_	12	punct

1	A	a	DT	_	4	det
2	routine	routine	JJ	_	4	amod
3	dosage	dosage	NN	_	4	compound
4	adjustment	adjustment	NN	_	9	nsubjpass
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	is	be	VBZ	_	9	auxpass
8	not	not	RB	_	9	neg
9	considered	consider	VBN	_	0	ROOT
10	necessary	necessary	JJ	_	9	xcomp
11	.	.	.	_	9	punct

1	Drugs	drug	NNS	_	14	nsubjpass
2	That	that	WDT	_	3	nsubj
3	Inhibit	inhibit	VBP	_	1	acl:relcl
4	Aldehyde	Aldehyde	NNP	_	10	compound
5	Oxidase	Oxidase	NNP	_	10	compound
6	The	The	NNP	_	10	compound
7	aldehyde	aldehyde	NN	_	10	compound
8	oxidase	oxidase	NN	_	10	compound
9	enzyme	enzyme	NN	_	10	compound
10	system	system	NN	_	3	dobj
11	is	be	VBZ	_	14	auxpass
12	less	less	RBR	_	13	advmod
13	well	well	RB	_	14	advmod
14	studied	study	VBN	_	0	ROOT
15	than	than	IN	_	20	case
16	the	the	DT	_	20	det
17	cytochrome	cytochrome	NN	_	20	compound
18	P450	p450	NN	_	20	compound
19	enzyme	enzyme	NN	_	20	compound
20	system	system	NN	_	14	nmod
21	.	.	.	_	14	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	reported	report	VBN	_	1	dep
6	to	to	TO	_	10	mark
7	be	be	VB	_	10	cop
8	a	a	DT	_	10	det
9	weak	weak	JJ	_	10	amod
10	inhibitor	inhibitor	NN	_	5	xcomp
11	of	of	IN	_	13	case
12	aldehyde	aldehyde	NN	_	13	compound
13	oxidase	oxidase	NN	_	10	nmod
14	in	in	IN	_	16	case
15	rat	rat	NN	_	16	compound
16	liver	liver	NN	_	10	nmod
17	,	,	,	_	5	punct
18	but	but	CC	_	5	cc
19	its	its	PRP$	_	21	nmod:poss
20	inhibitory	inhibitory	JJ	_	21	amod
21	effects	effect	NNS	_	27	nsubjpass
22	in	in	IN	_	24	case
23	human	human	JJ	_	24	amod
24	liver	liver	NN	_	21	nmod
25	are	be	VBP	_	27	auxpass
26	not	not	RB	_	27	neg
27	known	know	VBN	_	5	conj
28	.	.	.	_	1	punct

1	There	there	EX	_	2	expl
2	is	be	VBZ	_	0	ROOT
3	no	no	DT	_	5	neg
4	pharmacokinetic	pharmacokinetic	JJ	_	5	amod
5	interaction	interaction	NN	_	2	nsubj
6	between	between	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	following	follow	VBG	_	12	case
11	the	the	DT	_	12	det
12	administration	administration	NN	_	5	nmod
13	of	of	IN	_	16	case
14	a	a	DT	_	16	det
15	single	single	JJ	_	16	amod
16	dose	dose	NN	_	12	nmod
17	-LRB-	-lrb-	-LRB-	_	19	punct
18	10	10	CD	_	19	nummod
19	mg	mg	NN	_	16	dep
20	and	and	CC	_	19	cc
21	50	50	CD	_	22	nummod
22	mg	mg	NN	_	19	conj
23	,	,	,	_	19	punct
24	respectively	respectively	RB	_	19	advmod
25	-RRB-	-rrb-	-RRB-	_	19	punct
26	of	of	IN	_	28	case
27	each	each	DT	_	28	det
28	drug	drug	NN	_	16	nmod
29	.	.	.	_	2	punct

1	However	however	RB	_	17	advmod
2	,	,	,	_	17	punct
3	because	because	IN	_	8	mark
4	both	both	DT	_	8	nsubj
5	of	of	IN	_	7	case
6	these	these	DT	_	7	det
7	compounds	compound	NNS	_	4	nmod
8	have	have	VBP	_	17	advcl
9	CNS	cns	NN	_	10	compound
10	effects	effect	NNS	_	8	dobj
11	,	,	,	_	17	punct
12	an	a	DT	_	15	det
13	additive	additive	JJ	_	15	amod
14	pharmacodynamic	pharmacodynamic	JJ	_	15	amod
15	effect	effect	NN	_	17	nsubj
16	is	be	VBZ	_	17	cop
17	possible	possible	JJ	_	0	ROOT
18	.	.	.	_	17	punct

1	Drugs	drug	NNS	_	0	ROOT
2	That	that	WDT	_	3	nsubj
3	Inhibit	inhibit	VBP	_	1	acl:relcl
4	Both	both	CC	_	5	cc:preconj
5	Aldehyde	aldehyde	VBP	_	3	ccomp
6	Oxidase	oxidase	NN	_	9	compound
7	and	and	CC	_	6	cc
8	CYP3A4	cyp3a4	NN	_	6	conj
9	drug1	drug1	NN	_	5	dobj
10	:	:	:	_	1	punct
11	drug2	drug2	NN	_	12	nsubj
12	inhibits	inhibit	VBZ	_	1	dep
13	both	both	CC	_	15	cc:preconj
14	aldehyde	aldehyde	NN	_	15	compound
15	oxidase	oxidase	NN	_	12	dobj
16	-LRB-	-lrb-	-LRB-	_	18	punct
17	in	in	FW	_	18	compound
18	vitro	vitro	FW	_	15	dep
19	-RRB-	-rrb-	-RRB-	_	18	punct
20	and	and	CC	_	15	cc
21	CYP3A4	cyp3a4	NN	_	15	conj
22	-LRB-	-lrb-	-LRB-	_	25	punct
23	in	in	FW	_	24	compound
24	vitro	vitro	FW	_	25	advmod
25	and	and	CC	_	21	dep
26	in	in	FW	_	27	compound
27	vivo	vivo	FW	_	25	advmod
28	-RRB-	-rrb-	-RRB-	_	25	punct
29	,	,	,	_	21	punct
30	the	the	DT	_	34	det
31	primary	primary	JJ	_	34	amod
32	and	and	CC	_	31	cc
33	secondary	secondary	JJ	_	31	conj
34	enzymes	enzyme	NNS	_	21	appos
35	,	,	,	_	12	punct
36	respectively	respectively	RB	_	12	advmod
37	,	,	,	_	12	punct
38	responsible	responsible	JJ	_	12	dep
39	for	for	IN	_	41	case
40	drug3	drug3	NN	_	41	compound
41	metabolism	metabolism	NN	_	38	nmod
42	.	.	.	_	1	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	15	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	-LRB-	-lrb-	-LRB-	_	7	punct
6	10	10	CD	_	7	nummod
7	mg	mg	NN	_	4	appos
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	and	and	CC	_	4	cc
10	drug2	drug2	NN	_	4	conj
11	-LRB-	-lrb-	-LRB-	_	13	punct
12	800	800	CD	_	13	nummod
13	mg	mg	NN	_	10	appos
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	produced	produce	VBD	_	0	ROOT
16	an	a	DT	_	19	det
17	85	85	CD	_	18	compound
18	%	%	NN	_	19	amod
19	increase	increase	NN	_	15	dobj
20	in	in	IN	_	23	case
21	the	the	DT	_	23	det
22	mean	mean	NN	_	23	compound
23	Cmax	cmax	NN	_	19	nmod
24	and	and	CC	_	23	cc
25	AUC	auc	NN	_	23	conj
26	of	of	IN	_	27	case
27	drug3	drug3	NN	_	23	nmod
28	.	.	.	_	15	punct

1	An	a	DT	_	3	det
2	initial	initial	JJ	_	3	amod
3	dose	dose	NN	_	9	nsubjpass
4	of	of	IN	_	6	case
5	5	5	CD	_	6	nummod
6	mg	mg	NN	_	3	nmod
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	given	give	VBN	_	0	ROOT
10	to	to	TO	_	11	case
11	patients	patient	NNS	_	9	nmod
12	who	who	WP	_	16	nsubjpass
13	are	be	VBP	_	16	aux
14	concomitantly	concomitantly	RB	_	16	advmod
15	being	be	VBG	_	16	auxpass
16	treated	treat	VBN	_	11	acl:relcl
17	with	with	IN	_	18	case
18	drug1	drug1	NN	_	16	nmod
19	.	.	.	_	9	punct

1	Drugs	drug	NNS	_	11	nsubjpass
2	Highly	highly	RB	_	3	advmod
3	Bound	bind	VBN	_	1	acl
4	to	to	TO	_	7	case
5	Plasma	plasma	NN	_	7	compound
6	Protein	protein	NN	_	7	compound
7	drug1	drug1	NN	_	3	nmod
8	is	be	VBZ	_	11	auxpass
9	not	not	RB	_	11	neg
10	highly	highly	RB	_	11	advmod
11	bound	bind	VBN	_	0	ROOT
12	to	to	TO	_	14	case
13	plasma	plasma	NN	_	14	compound
14	proteins	protein	NNS	_	11	nmod
15	-LRB-	-lrb-	-LRB-	_	16	punct
16	fraction	fraction	NN	_	14	dep
17	bound	bind	VBN	_	16	acl
18	60	60	CD	_	19	nummod
19	%	%	NN	_	17	dobj
20	15	15	CD	_	21	nummod
21	%	%	NN	_	19	dep
22	-RRB-	-rrb-	-RRB-	_	16	punct
23	;	;	:	_	11	punct

1	therefore	therefore	RB	_	9	advmod
2	,	,	,	_	9	punct
3	the	the	DT	_	4	det
4	disposition	disposition	NN	_	9	nsubjpass
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	is	be	VBZ	_	9	auxpass
8	not	not	RB	_	9	neg
9	expected	expect	VBN	_	0	ROOT
10	to	to	TO	_	12	mark
11	be	be	VB	_	12	cop
12	sensitive	sensitive	JJ	_	9	xcomp
13	to	to	TO	_	14	case
14	alterations	alteration	NNS	_	12	nmod
15	in	in	IN	_	17	case
16	protein	protein	NN	_	17	compound
17	binding	binding	NN	_	14	nmod
18	.	.	.	_	9	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	0	ROOT
3	,	,	,	_	2	punct
4	administration	administration	NN	_	3	root
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	to	to	TO	_	9	case
8	a	a	DT	_	9	det
9	patient	patient	NN	_	4	nmod
10	taking	take	VBG	_	9	acl
11	another	another	DT	_	12	det
12	drug	drug	NN	_	10	dobj
13	that	that	WDT	_	20	nsubj
14	is	be	VBZ	_	20	aux
15	highly	highly	RB	_	20	advmod
16	protein	protein	NN	_	20	nsubj
17	bound	bind	VBD	_	16	acl
18	should	should	MD	_	20	aux
19	not	not	RB	_	20	neg
20	cause	cause	VB	_	12	acl:relcl
21	transient	transient	JJ	_	22	amod
22	increase	increase	NN	_	20	dobj
23	in	in	IN	_	25	case
24	free	free	JJ	_	25	amod
25	concentrations	concentration	NNS	_	22	nmod
26	of	of	IN	_	29	case
27	the	the	DT	_	29	det
28	other	other	JJ	_	29	amod
29	drug	drug	NN	_	25	nmod
30	.	.	.	_	4	punct

1	Drugs	drug	NNS	_	0	ROOT
2	with	with	IN	_	7	case
3	a	a	DT	_	7	det
4	Narrow	Narrow	NNP	_	7	compound
5	Therapeutic	therapeutic	JJ	_	7	amod
6	Index	index	NN	_	7	compound
7	drug1	drug1	NN	_	1	nmod
8	:	:	:	_	7	punct
9	drug2	drug2	NN	_	16	nsubj
10	-LRB-	-lrb-	-LRB-	_	12	punct
11	10	10	CD	_	12	nummod
12	mg	mg	NN	_	9	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	did	do	VBD	_	16	aux
15	not	not	RB	_	16	neg
16	affect	affect	VB	_	7	dep
17	the	the	DT	_	21	det
18	pharmacokinetic	pharmacokinetic	JJ	_	21	amod
19	or	or	CC	_	18	cc
20	pharmacodynamic	pharmacodynamic	JJ	_	18	conj
21	profile	profile	NN	_	16	dobj
22	of	of	IN	_	23	case
23	drug3	drug3	NN	_	21	nmod
24	-LRB-	-lrb-	-LRB-	_	27	punct
25	0.375	0.375	CD	_	26	compound
26	mg	mg	NN	_	27	amod
27	q24h	q24h	NN	_	23	dep
28	for	for	IN	_	30	case
29	8	8	CD	_	30	nummod
30	days	day	NNS	_	27	nmod
31	-RRB-	-rrb-	-RRB-	_	27	punct
32	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Multiple	multiple	JJ	_	5	amod
4	oral	oral	JJ	_	5	amod
5	doses	dose	NNS	_	18	nsubj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	-LRB-	-lrb-	-LRB-	_	11	punct
9	20	20	CD	_	10	compound
10	mg	mg	NN	_	11	amod
11	q24h	q24h	NN	_	7	dep
12	for	for	IN	_	14	case
13	13	13	CD	_	14	nummod
14	days	day	NNS	_	11	nmod
15	-RRB-	-rrb-	-RRB-	_	11	punct
16	did	do	VBD	_	18	aux
17	not	not	RB	_	18	neg
18	affect	affect	VB	_	1	dep
19	the	the	DT	_	20	det
20	pharmacokinetics	pharmacokinetic	NNS	_	18	dobj
21	of	of	IN	_	22	case
22	drug3	drug3	NN	_	20	nmod
23	-LRB-	-lrb-	-LRB-	_	24	punct
24	R	r	NN	_	22	appos
25	+	+	CC	_	24	cc
26	-RRB-	-rrb-	-RRB-	_	24	punct
27	-	-	:	_	22	punct
28	or	or	CC	_	22	cc
29	-LRB-	-lrb-	-LRB-	_	30	punct
30	S	s	NN	_	22	conj
31	-	-	:	_	30	punct
32	-RRB-	-rrb-	-RRB-	_	30	punct
33	-	-	:	_	20	punct
34	enantiomers	enantiomer	NNS	_	20	dep
35	or	or	CC	_	34	cc
36	the	the	DT	_	37	det
37	pharmacodynamics	pharmacodynamic	NNS	_	34	conj
38	-LRB-	-lrb-	-LRB-	_	40	punct
39	prothrombin	prothrombin	NN	_	40	compound
40	time	time	NN	_	37	appos
41	-RRB-	-rrb-	-RRB-	_	40	punct
42	following	follow	VBG	_	47	case
43	a	a	DT	_	47	det
44	single	single	JJ	_	47	amod
45	25-mg	25-mg	JJ	_	47	amod
46	oral	oral	JJ	_	47	amod
47	dose	dose	NN	_	18	nmod
48	of	of	IN	_	49	case
49	drug4	drug4	NN	_	47	nmod
50	.	.	.	_	1	punct

1	Drugs	drug	NNS	_	0	ROOT
2	That	that	WDT	_	3	nsubj
3	Alter	alter	VBP	_	1	acl:relcl
4	Renal	renal	JJ	_	6	amod
5	Excretion	excretion	NN	_	6	compound
6	drug1	drug1	NN	_	3	dobj
7	:	:	:	_	1	punct
8	drug2	drug2	NN	_	10	nsubjpass
9	is	be	VBZ	_	10	auxpass
10	known	know	VBN	_	1	dep
11	to	to	TO	_	12	mark
12	affect	affect	VB	_	10	xcomp
13	renal	renal	JJ	_	14	amod
14	function	function	NN	_	12	dobj
15	and	and	CC	_	10	cc
16	,	,	,	_	10	punct
17	consequently	consequently	RB	_	10	advmod
18	,	,	,	_	10	punct
19	alter	alter	VBP	_	10	conj
20	the	the	DT	_	22	det
21	renal	renal	JJ	_	22	amod
22	excretion	excretion	NN	_	19	dobj
23	of	of	IN	_	25	case
24	other	other	JJ	_	25	amod
25	drugs	drug	NNS	_	22	nmod
26	.	.	.	_	1	punct

1	There	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	no	no	DT	_	6	neg
4	apparent	apparent	JJ	_	6	amod
5	pharmacokinetic	pharmacokinetic	JJ	_	6	amod
6	interaction	interaction	NN	_	2	nsubj
7	between	between	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	drug2	drug2	NN	_	8	conj
11	following	follow	VBG	_	14	case
12	single	single	JJ	_	14	amod
13	dose	dose	NN	_	14	compound
14	administration	administration	NN	_	6	nmod
15	-LRB-	-lrb-	-LRB-	_	17	punct
16	10	10	CD	_	17	nummod
17	mg	mg	NN	_	14	dep
18	and	and	CC	_	17	cc
19	600	600	CD	_	20	nummod
20	mg	mg	NN	_	17	conj
21	,	,	,	_	17	punct
22	respectively	respectively	RB	_	17	advmod
23	-RRB-	-rrb-	-RRB-	_	17	punct
24	of	of	IN	_	26	case
25	each	each	DT	_	26	det
26	drug	drug	NN	_	14	nmod
27	.	.	.	_	2	punct

1	This	this	DT	_	3	nsubjpass
2	was	be	VBD	_	3	auxpass
3	expected	expect	VBN	_	0	ROOT
4	because	because	IN	_	8	mark
5	drug1	drug1	NN	_	8	nsubjpass
6	is	be	VBZ	_	8	auxpass
7	primarily	primarily	RB	_	8	advmod
8	metabolized	metabolize	VBN	_	3	advcl
9	and	and	CC	_	8	cc
10	renal	renal	JJ	_	11	amod
11	excretion	excretion	NN	_	8	conj
12	of	of	IN	_	15	case
13	unchanged	unchanged	JJ	_	15	amod
14	drug2	drug2	NN	_	15	compound
15	accounts	account	NNS	_	11	nmod
16	for	for	IN	_	20	case
17	less	less	JJR	_	19	advmod
18	than	than	IN	_	17	mwe
19	1	1	CD	_	20	nummod
20	%	%	NN	_	11	nmod
21	of	of	IN	_	24	case
22	the	the	DT	_	24	det
23	administered	administer	VBN	_	24	amod
24	dose	dose	NN	_	20	nmod
25	.	.	.	_	3	punct

1	Because	because	IN	_	4	mark
2	drug1	drug1	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	metabolized	metabolize	VBN	_	16	advcl
5	by	by	IN	_	7	case
6	monoamine	monoamine	NN	_	7	compound
7	oxidase	oxidase	NN	_	4	nmod
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	MAO	mao	NN	_	7	appos
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	,	,	,	_	16	punct
12	inhibition	inhibition	NN	_	16	nsubj
13	of	of	IN	_	15	case
14	this	this	DT	_	15	det
15	enzyme	enzyme	NN	_	12	nmod
16	prolongs	prolong	VBZ	_	0	ROOT
17	and	and	CC	_	16	cc
18	potentiates	potentiate	VBZ	_	16	conj
19	the	the	DT	_	20	det
20	effect	effect	NN	_	16	dobj
21	of	of	IN	_	22	case
22	drug2	drug2	NN	_	20	nmod
23	.	.	.	_	16	punct

1	Patients	patient	NNS	_	20	nsubj
2	who	who	WP	_	5	nsubjpass
3	have	have	VBP	_	5	aux
4	been	be	VBN	_	5	auxpass
5	treated	treat	VBN	_	1	acl:relcl
6	with	with	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	within	within	IN	_	12	case
9	two	two	CD	_	11	compound
10	to	to	TO	_	11	dep
11	three	three	CD	_	12	nummod
12	weeks	week	NNS	_	5	nmod
13	prior	prior	RB	_	5	advmod
14	to	to	TO	_	16	case
15	the	the	DT	_	16	det
16	administration	administration	NN	_	13	nmod
17	of	of	IN	_	18	case
18	drug2	drug2	NN	_	16	nmod
19	should	should	MD	_	20	aux
20	receive	receive	VB	_	0	ROOT
21	initial	initial	JJ	_	22	amod
22	doses	dose	NNS	_	20	dobj
23	of	of	IN	_	24	case
24	drug3	drug3	NN	_	22	nmod
25	no	no	RB	_	26	neg
26	greater	greater	JJR	_	22	amod
27	than	than	IN	_	28	case
28	one-tenth	one-tenth	JJ	_	26	nmod
29	-LRB-	-lrb-	-LRB-	_	30	punct
30	1/10	1/10	CD	_	28	appos
31	-RRB-	-rrb-	-RRB-	_	30	punct
32	of	of	IN	_	35	case
33	the	the	DT	_	35	det
34	usual	usual	JJ	_	35	amod
35	dose	dose	NN	_	28	nmod
36	.	.	.	_	20	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	administration	administration	NN	_	9	nsubj
3	of	of	IN	_	5	case
4	low-dose	low-dose	JJ	_	5	amod
5	drug1	drug1	NN	_	2	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	may	may	MD	_	9	aux
9	produce	produce	VB	_	0	ROOT
10	an	a	DT	_	14	det
11	additive	additive	JJ	_	14	amod
12	or	or	CC	_	11	cc
13	potentiating	potentiating	NN	_	11	conj
14	effect	effect	NN	_	9	dobj
15	on	on	IN	_	17	case
16	urine	urine	NN	_	17	compound
17	flow	flow	NN	_	14	nmod
18	.	.	.	_	9	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	potentiate	potentiate	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	cardiovascular	cardiovascular	JJ	_	6	amod
6	effects	effect	NNS	_	3	dobj
7	of	of	IN	_	9	case
8	adreneric	adreneric	JJ	_	9	amod
9	agents	agent	NNS	_	6	nmod
10	.	.	.	_	3	punct

1	Cardiac	cardiac	JJ	_	2	amod
2	effects	effect	NNS	_	6	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	are	be	VBP	_	6	auxpass
6	antagonized	antagonize	VBN	_	0	ROOT
7	by	by	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	,	,	,	_	8	punct
10	such	such	JJ	_	12	case
11	as	as	IN	_	10	mwe
12	drug3	drug3	NN	_	8	nmod
13	and	and	CC	_	12	cc
14	drug4	drug4	NN	_	12	conj
15	.	.	.	_	6	punct

1	The	the	DT	_	3	det
2	peripheral	peripheral	JJ	_	3	amod
3	vasoconstriction	vasoconstriction	NN	_	11	nsubjpass
4	caused	cause	VBN	_	3	acl
5	by	by	IN	_	7	case
6	high	high	JJ	_	7	amod
7	doses	dose	NNS	_	4	nmod
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	is	be	VBZ	_	11	auxpass
11	antagonized	antagonize	VBN	_	0	ROOT
12	by	by	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	.	.	.	_	11	punct

1	drug1	drug1	NN	_	10	dep
2	-	-	:	_	1	punct
3	induced	induce	VBN	_	7	amod
4	renal	renal	JJ	_	7	amod
5	and	and	CC	_	4	cc
6	mesenteric	mesenteric	JJ	_	4	conj
7	vasodilation	vasodilation	NN	_	10	nsubjpass
8	is	be	VBZ	_	10	auxpass
9	not	not	RB	_	10	neg
10	antagonized	antagonize	VBN	_	0	ROOT
11	by	by	IN	_	13	case
12	either	either	CC	_	13	cc:preconj
13	drug2	drug2	NN	_	10	nmod
14	or	or	CC	_	13	cc
15	drug3	drug3	NN	_	13	conj
16	.	.	.	_	10	punct

1	drug1	drug1	NN	_	10	nsubj
2	-LRB-	-lrb-	-LRB-	_	5	punct
3	such	such	JJ	_	5	case
4	as	as	IN	_	3	mwe
5	drug2	drug2	NN	_	1	nmod
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	and	and	CC	_	1	cc
8	drug3	drug3	NN	_	1	conj
9	can	can	MD	_	10	aux
10	suppress	suppress	VB	_	0	ROOT
11	the	the	DT	_	17	det
12	drug4	drug4	NN	_	17	compound
13	rgic	rgic	JJ	_	17	amod
14	renal	renal	JJ	_	17	amod
15	and	and	CC	_	14	cc
16	mesenteric	mesenteric	JJ	_	14	conj
17	vasodilation	vasodilation	NN	_	10	dobj
18	induced	induce	VBN	_	17	acl
19	with	with	IN	_	23	case
20	low	low	JJ	_	23	amod
21	dose	dose	NN	_	23	compound
22	dopamine	dopamine	NN	_	23	compound
23	infusion	infusion	NN	_	18	nmod
24	.	.	.	_	10	punct

1	drug1	drug1	NN	_	4	nsubj
2	or	or	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	increase	increase	NN	_	0	ROOT
5	cardiac	cardiac	JJ	_	7	amod
6	autonomic	autonomic	JJ	_	7	amod
7	irritability	irritability	NN	_	4	dobj
8	and	and	CC	_	4	cc
9	may	may	MD	_	10	aux
10	sensitize	sensitize	VB	_	4	conj
11	the	the	DT	_	12	det
12	myocardium	myocardium	NN	_	10	dobj
13	to	to	TO	_	15	case
14	the	the	DT	_	15	det
15	action	action	NN	_	10	nmod
16	of	of	IN	_	20	case
17	certain	certain	JJ	_	20	amod
18	intravenously	intravenously	RB	_	19	advmod
19	administered	administer	VBN	_	20	amod
20	drug3	drug3	NN	_	15	nmod
21	,	,	,	_	20	punct
22	such	such	JJ	_	24	case
23	as	as	IN	_	22	mwe
24	drug4	drug4	NN	_	20	nmod
25	.	.	.	_	4	punct

1	This	this	DT	_	2	det
2	interaction	interaction	NN	_	3	nsubj
3	appears	appear	VBZ	_	0	ROOT
4	to	to	TO	_	6	mark
5	be	be	VB	_	6	auxpass
6	related	relate	VBN	_	3	xcomp
7	both	both	DT	_	10	cc:preconj
8	to	to	TO	_	10	case
9	pressor	pressor	NN	_	10	compound
10	activity	activity	NN	_	6	nmod
11	and	and	CC	_	10	cc
12	to	to	TO	_	15	case
13	beta-adrenergic	beta-adrenergic	JJ	_	15	amod
14	stimulating	stimulating	NN	_	15	compound
15	properties	property	NNS	_	10	conj
16	of	of	IN	_	18	case
17	these	these	DT	_	18	det
18	drug1	drug1	NN	_	15	nmod
19	and	and	CC	_	10	cc
20	may	may	MD	_	21	aux
21	produce	produce	VB	_	10	conj
22	ventricular	ventricular	JJ	_	23	amod
23	arrhythmias	arrhythmia	NNS	_	21	dobj
24	and	and	CC	_	23	cc
25	hypertension	hypertension	NN	_	23	conj
26	.	.	.	_	3	punct

1	Therefore	therefore	RB	_	7	advmod
2	,	,	,	_	7	punct
3	EXTREME	extreme	JJ	_	4	amod
4	CAUTION	caution	NN	_	7	nsubjpass
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	exercised	exercise	VBN	_	0	ROOT
8	when	when	WRB	_	9	advmod
9	administering	administer	VBG	_	7	advcl
10	drug1	drug1	NN	_	9	dobj
11	to	to	TO	_	12	case
12	patients	patient	NNS	_	9	nmod
13	receiving	receive	VBG	_	12	acl
14	drug2	drug2	NN	_	13	dobj
15	or	or	CC	_	14	cc
16	drug3	drug3	NN	_	14	conj
17	.	.	.	_	7	punct

1	It	it	PRP	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	that	that	IN	_	11	mark
6	results	result	NNS	_	11	nsubj
7	of	of	IN	_	8	case
8	studies	study	NNS	_	6	nmod
9	in	in	IN	_	10	case
10	animals	animal	NNS	_	8	nmod
11	indicate	indicate	VBP	_	4	ccomp
12	that	that	IN	_	11	dobj
13	drug1	drug1	NN	_	12	dep
14	-	-	:	_	13	punct
15	induced	induce	VBN	_	17	amod
16	ventricular	ventricular	JJ	_	17	amod
17	arrhythmias	arrhythmia	NNS	_	22	nsubjpass
18	during	during	IN	_	19	case
19	anesthesia	anesthesia	NN	_	17	nmod
20	can	can	MD	_	22	aux
21	be	be	VB	_	22	auxpass
22	reversed	reverse	VBN	_	13	dep
23	by	by	IN	_	24	case
24	drug2	drug2	NN	_	22	nmod
25	.	.	.	_	4	punct

1	The	the	DT	_	3	det
2	concomitant	concomitant	JJ	_	3	amod
3	use	use	NN	_	19	nsubj
4	of	of	IN	_	6	case
5	drug1	drug1	NN	_	6	compound
6	s	s	NNS	_	3	nmod
7	,	,	,	_	6	punct
8	vasoconstricting	vasoconstrict	VBG	_	9	amod
9	agents	agent	NNS	_	6	conj
10	-LRB-	-lrb-	-LRB-	_	13	punct
11	such	such	JJ	_	13	case
12	as	as	IN	_	11	mwe
13	drug2	drug2	NN	_	9	nmod
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	and	and	CC	_	6	cc
16	some	some	DT	_	17	det
17	drug3	drug3	NN	_	6	conj
18	may	may	MD	_	19	aux
19	result	result	VB	_	0	ROOT
20	in	in	IN	_	22	case
21	severe	severe	JJ	_	22	amod
22	hypertension	hypertension	NN	_	19	nmod
23	.	.	.	_	19	punct

1	Administration	administration	NN	_	10	nsubjpass
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	to	to	TO	_	5	case
5	patients	patient	NNS	_	1	nmod
6	receiving	receive	VBG	_	5	acl
7	drug2	drug2	NN	_	6	dobj
8	has	have	VBZ	_	10	aux
9	been	be	VBN	_	10	auxpass
10	reported	report	VBN	_	0	ROOT
11	to	to	TO	_	12	mark
12	lead	lead	VB	_	10	xcomp
13	to	to	TO	_	14	case
14	hypotension	hypotension	NN	_	12	nmod
15	and	and	CC	_	14	cc
16	bradycardia	bradycardia	NN	_	14	conj
17	.	.	.	_	10	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	suggested	suggest	VBN	_	0	ROOT
4	that	that	IN	_	15	mark
5	in	in	IN	_	6	case
6	patients	patient	NNS	_	15	nmod
7	receiving	receive	VBG	_	6	acl
8	drug1	drug1	NN	_	7	dobj
9	,	,	,	_	15	punct
10	alternatives	alternative	NNS	_	15	nsubjpass
11	to	to	TO	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	should	should	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	used	use	VBN	_	3	ccomp
16	if	if	IN	_	20	mark
17	drug3	drug3	NN	_	18	compound
18	therapy	therapy	NN	_	20	nsubjpass
19	is	be	VBZ	_	20	auxpass
20	needed	need	VBN	_	15	advcl
21	.	.	.	_	3	punct

1	drug1	drug1	NN	_	4	compound
2	-	-	:	_	4	punct
3	Taking	take	VBG	_	4	amod
4	drug2	drug2	NN	_	10	nsubj
5	and	and	CC	_	4	cc
6	a	a	DT	_	7	det
7	drug3	drug3	NN	_	4	conj
8	together	together	RB	_	4	advmod
9	may	may	MD	_	10	aux
10	increase	increase	VB	_	0	ROOT
11	the	the	DT	_	12	det
12	risk	risk	NN	_	10	dobj
13	of	of	IN	_	14	case
14	convulsions	convulsion	NNS	_	12	nmod
15	-LRB-	-lrb-	-LRB-	_	16	punct
16	seizures	seizure	NNS	_	14	appos
17	-RRB-	-rrb-	-RRB-	_	16	punct
18	.	.	.	_	10	punct

1	drug1	drug1	NN	_	14	nsubj
2	-LRB-	-lrb-	-LRB-	_	5	punct
3	e.g.	e.g.	FW	_	5	dep
4	,	,	,	_	5	punct
5	drug2	drug2	NN	_	1	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	-	-	:	_	1	punct
8	Taking	take	VBG	_	14	csubj
9	drug3	drug3	NN	_	8	dobj
10	and	and	CC	_	9	cc
11	drug4	drug4	NN	_	9	conj
12	together	together	RB	_	8	advmod
13	may	may	MD	_	14	aux
14	decrease	decrease	VB	_	0	ROOT
15	the	the	DT	_	16	det
16	effects	effect	NNS	_	14	dobj
17	of	of	IN	_	18	case
18	drug5	drug5	NN	_	16	nmod
19	.	.	.	_	14	punct

1	There	there	EX	_	4	expl
2	have	have	VBP	_	4	aux
3	been	be	VBN	_	4	auxpass
4	isolated	isolate	VBN	_	0	ROOT
5	reports	report	NNS	_	4	dobj
6	of	of	IN	_	7	case
7	patients	patient	NNS	_	5	nmod
8	experiencing	experience	VBG	_	7	acl
9	increases	increase	NNS	_	8	dobj
10	in	in	IN	_	13	case
11	their	they	PRP$	_	13	nmod:poss
12	prothrombin	prothrombin	NN	_	13	compound
13	times	time	NNS	_	9	nmod
14	when	when	WRB	_	17	advmod
15	drug1	drug1	NN	_	17	nsubjpass
16	was	be	VBD	_	17	auxpass
17	added	add	VBN	_	4	advcl
18	to	to	TO	_	20	case
19	drug2	drug2	NN	_	20	compound
20	therapy	therapy	NN	_	17	nmod
21	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	majority	majority	NN	_	6	nsubj
3	of	of	IN	_	5	case
4	these	these	DT	_	5	det
5	reports	report	NNS	_	2	nmod
6	concerned	concern	VBN	_	0	ROOT
7	variable	variable	JJ	_	8	amod
8	elevations	elevation	NNS	_	6	dobj
9	in	in	IN	_	11	case
10	prothrombin	prothrombin	NN	_	11	compound
11	times	time	NNS	_	8	nmod
12	without	without	IN	_	15	case
13	clinically	clinically	RB	_	14	advmod
14	significant	significant	JJ	_	15	amod
15	sequelae	sequelae	NN	_	6	nmod
16	.	.	.	_	6	punct

1	Although	although	IN	_	14	mark
2	the	the	DT	_	3	det
3	relevance	relevance	NN	_	14	nsubj
4	of	of	IN	_	6	case
5	these	these	DT	_	6	det
6	reports	report	NNS	_	3	nmod
7	and	and	CC	_	3	cc
8	any	any	DT	_	9	det
9	mechanism	mechanism	NN	_	3	conj
10	of	of	IN	_	12	case
11	coagulation	coagulation	NN	_	12	compound
12	alterations	alteration	NNS	_	9	nmod
13	is	be	VBZ	_	14	cop
14	unclear	unclear	JJ	_	20	advcl
15	,	,	,	_	20	punct
16	patients	patient	NNS	_	20	nsubj
17	on	on	IN	_	18	case
18	drug1	drug1	NN	_	16	nmod
19	should	should	MD	_	20	aux
20	have	have	VB	_	0	ROOT
21	their	they	PRP$	_	23	nmod:poss
22	prothrombin	prothrombin	NN	_	23	compound
23	time	time	NN	_	24	nsubj
24	monitored	monitor	VBD	_	20	ccomp
25	.	.	.	_	20	punct

1	The	the	DT	_	4	det
2	drug	drug	NN	_	4	compound
3	interaction	interaction	NN	_	4	compound
4	studies	study	NNS	_	8	nsubjpass
5	with	with	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	were	be	VBD	_	8	auxpass
8	performed	perform	VBN	_	0	ROOT
9	both	both	CC	_	11	cc:preconj
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	8	nmod
12	and	and	CC	_	11	cc
13	a	a	DT	_	18	det
14	rapidly	rapidly	RB	_	15	advmod
15	hydrolyzed	hydrolyze	VBN	_	18	amod
16	intravenous	intravenous	JJ	_	18	amod
17	prodrug	prodrug	NN	_	18	compound
18	form	form	NN	_	11	conj
19	.	.	.	_	8	punct

1	The	the	DT	_	2	det
2	results	result	NNS	_	10	nsubjpass
3	from	from	IN	_	4	case
4	trials	trial	NNS	_	2	nmod
5	using	use	VBG	_	4	acl
6	the	the	DT	_	8	det
7	intravenous	intravenous	JJ	_	8	amod
8	prodrug	prodrug	NN	_	5	dobj
9	are	be	VBP	_	10	auxpass
10	reported	report	VBN	_	0	ROOT
11	in	in	IN	_	13	case
12	this	this	DT	_	13	det
13	section	section	NN	_	10	nmod
14	as	as	IN	_	16	mark
15	they	they	PRP	_	16	nsubj
16	relate	relate	VBP	_	10	advcl
17	to	to	TO	_	19	case
18	the	the	DT	_	19	det
19	role	role	NN	_	16	nmod
20	of	of	IN	_	21	case
21	drug1	drug1	NN	_	19	nmod
22	in	in	IN	_	24	case
23	drug	drug	NN	_	24	compound
24	interactions	interaction	NNS	_	19	nmod
25	.	.	.	_	10	punct

1	General	General	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	4	case
4	humans	human	NNS	_	10	nmod
5	,	,	,	_	10	punct
6	drug1	drug1	NN	_	7	compound
7	metabolism	metabolism	NN	_	10	nsubjpass
8	is	be	VBZ	_	10	auxpass
9	predominantly	predominantly	RB	_	10	advmod
10	mediated	mediate	VBN	_	1	dep
11	via	via	IN	_	13	case
12	CYP	cyp	NN	_	13	compound
13	3A4	3a4	NN	_	10	nmod
14	and	and	CC	_	13	cc
15	2C9	2c9	NN	_	13	conj
16	with	with	IN	_	25	mark
17	glucuronidation	glucuronidation	NN	_	25	nsubj
18	being	be	VBG	_	25	cop
19	a	a	DT	_	25	det
20	further	further	JJ	_	25	amod
21	-LRB-	-lrb-	-LRB-	_	23	punct
22	20	20	CD	_	23	nummod
23	%	%	NN	_	20	dep
24	-RRB-	-rrb-	-RRB-	_	23	punct
25	route	route	NN	_	10	advcl
26	of	of	IN	_	27	case
27	metabolism	metabolism	NN	_	25	nmod
28	.	.	.	_	1	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	4	nsubj
4	indicate	indicate	VBP	_	0	ROOT
5	that	that	IN	_	10	mark
6	drug1	drug1	NN	_	10	nsubj
7	is	be	VBZ	_	10	cop
8	a	a	DT	_	10	det
9	moderate	moderate	JJ	_	10	amod
10	inhibitor	inhibitor	NN	_	4	ccomp
11	of	of	IN	_	13	case
12	CYP	cyp	NN	_	13	compound
13	2C19	2c19	NN	_	10	nmod
14	-LRB-	-lrb-	-LRB-	_	16	punct
15	IC50	ic50	NN	_	16	nsubj
16	=	=	JJ	_	10	dep
17	6	6	CD	_	18	nummod
18	g/mL	g/ml	NN	_	16	dobj
19	or	or	CC	_	18	cc
20	19	19	CD	_	21	nummod
21	M	m	NN	_	18	conj
22	-RRB-	-rrb-	-RRB-	_	16	punct
23	and	and	CC	_	10	cc
24	2C9	2c9	NN	_	10	conj
25	-LRB-	-lrb-	-LRB-	_	26	punct
26	IC50	ic50	NN	_	24	dep
27	=	=	JJ	_	26	amod
28	13	13	CD	_	29	nummod
29	g/mL	g/ml	NN	_	27	dep
30	or	or	CC	_	29	cc
31	41	41	CD	_	32	nummod
32	M	m	NN	_	29	conj
33	-RRB-	-rrb-	-RRB-	_	26	punct
34	,	,	,	_	10	punct
35	and	and	CC	_	10	cc
36	a	a	DT	_	38	det
37	weak	weak	JJ	_	38	amod
38	inhibitor	inhibitor	NN	_	10	conj
39	of	of	IN	_	41	case
40	CYP	cyp	NN	_	41	compound
41	2D6	2d6	NN	_	38	nmod
42	-LRB-	-lrb-	-LRB-	_	43	punct
43	IC50	ic50	NN	_	38	dep
44	=	=	JJ	_	43	amod
45	31	31	CD	_	46	nummod
46	g/mL	g/ml	NN	_	44	dep
47	or	or	CC	_	46	cc
48	100	100	CD	_	49	nummod
49	M	m	NN	_	46	conj
50	-RRB-	-rrb-	-RRB-	_	43	punct
51	and	and	CC	_	38	cc
52	3A4	3a4	NN	_	38	conj
53	-LRB-	-lrb-	-LRB-	_	55	punct
54	IC50	ic50	NN	_	55	nsubj
55	=	=	JJ	_	52	dep
56	44	44	CD	_	57	nummod
57	g/mL	g/ml	NN	_	55	dobj
58	or	or	CC	_	57	cc
59	141	141	CD	_	60	nummod
60	M	m	NN	_	57	conj
61	-RRB-	-rrb-	-RRB-	_	55	punct
62	.	.	.	_	4	punct
63	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concomitant	concomitant	JJ	_	4	amod
4	administration	administration	NN	_	10	nsubj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	with	with	IN	_	8	case
8	drug3	drug3	NN	_	4	nmod
9	may	may	MD	_	10	aux
10	result	result	VB	_	1	dep
11	in	in	IN	_	14	case
12	an	a	DT	_	14	det
13	increased	increase	VBN	_	14	amod
14	risk	risk	NN	_	10	nmod
15	of	of	IN	_	17	case
16	GI	gi	NN	_	17	compound
17	ulceration	ulceration	NN	_	14	nmod
18	and	and	CC	_	17	cc
19	complications	complication	NNS	_	17	conj
20	compared	compare	VBN	_	14	acl
21	to	to	TO	_	22	case
22	drug4	drug4	NN	_	20	nmod
23	alone	alone	RB	_	22	advmod
24	.	.	.	_	1	punct

1	Because	because	IN	_	4	case
2	of	of	IN	_	1	mwe
3	its	its	PRP$	_	4	nmod:poss
4	lack	lack	NN	_	12	nmod
5	of	of	IN	_	8	case
6	anti-platelet	anti-platelet	JJ	_	8	amod
7	effect	effect	NN	_	8	compound
8	drug1	drug1	NN	_	4	nmod
9	is	be	VBZ	_	12	cop
10	not	not	RB	_	12	neg
11	a	a	DT	_	12	det
12	substitute	substitute	NN	_	0	ROOT
13	for	for	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	for	for	IN	_	17	case
16	cardiovascular	cardiovascular	JJ	_	17	amod
17	prophylaxis	prophylaxis	NN	_	14	nmod
18	.	.	.	_	12	punct

1	In	in	IN	_	7	case
2	a	a	DT	_	7	det
3	parallel	parallel	JJ	_	7	amod
4	group	group	NN	_	7	compound
5	drug	drug	NN	_	7	compound
6	interaction	interaction	NN	_	7	compound
7	study	study	NN	_	33	nmod
8	comparing	compare	VBG	_	7	acl
9	the	the	DT	_	12	det
10	intravenous	intravenous	JJ	_	12	amod
11	prodrug	prodrug	NN	_	12	compound
12	form	form	NN	_	8	dobj
13	of	of	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	at	at	IN	_	17	case
16	40	40	CD	_	17	nummod
17	mg	mg	NN	_	8	nmod
18	BID	BID	NNP	_	17	dep
19	-LRB-	-lrb-	-LRB-	_	20	punct
20	n	n	NN	_	18	dep
21	=	=	JJ	_	20	amod
22	10	10	CD	_	21	dep
23	-RRB-	-rrb-	-RRB-	_	20	punct
24	vs	vs	CC	_	18	cc
25	placebo	placebo	NN	_	18	conj
26	-LRB-	-lrb-	-LRB-	_	27	punct
27	n	n	NN	_	25	dep
28	=	=	JJ	_	27	amod
29	9	9	CD	_	28	dep
30	-RRB-	-rrb-	-RRB-	_	27	punct
31	,	,	,	_	33	punct
32	drug2	drug2	NN	_	33	nsubj
33	had	have	VBD	_	0	ROOT
34	no	no	DT	_	35	neg
35	effect	effect	NN	_	33	dobj
36	on	on	IN	_	39	case
37	in	in	FW	_	39	amod
38	vitro	vitro	FW	_	37	dep
39	drug3	drug3	NN	_	33	nmod
40	-	-	:	_	39	punct
41	mediated	mediate	VBN	_	42	amod
42	inhibition	inhibition	NN	_	39	dep
43	of	of	IN	_	44	case
44	arachidonate	arachidonate	NN	_	42	nmod
45	-	-	:	_	44	punct
46	or	or	CC	_	44	cc
47	collagen-stimulated	collagen-stimulated	JJ	_	49	amod
48	platelet	platelet	NN	_	49	compound
49	aggregation	aggregation	NN	_	44	conj
50	.	.	.	_	33	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	compound
4	BID	BID	NNP	_	7	nsubj
5	did	do	VBD	_	7	aux
6	not	not	RB	_	7	neg
7	show	show	VB	_	1	dep
8	a	a	DT	_	10	det
9	significant	significant	JJ	_	10	amod
10	effect	effect	NN	_	7	dobj
11	on	on	IN	_	14	case
12	the	the	DT	_	14	det
13	plasma	plasma	NN	_	14	compound
14	exposure	exposure	NN	_	10	nmod
15	or	or	CC	_	14	cc
16	renal	renal	JJ	_	17	amod
17	clearance	clearance	NN	_	14	conj
18	of	of	IN	_	19	case
19	drug3	drug3	NN	_	14	nmod
20	.	.	.	_	1	punct

1	drug1	drug1	NN	_	4	nsubj
2	:	:	:	_	4	punct
3	Reports	report	NNS	_	4	nsubj
4	suggest	suggest	VBP	_	0	ROOT
5	that	that	IN	_	8	mark
6	drug2	drug2	NN	_	8	nsubj
7	may	may	MD	_	8	aux
8	diminish	diminish	VB	_	4	ccomp
9	the	the	DT	_	11	det
10	antihypertensive	antihypertensive	JJ	_	11	amod
11	effect	effect	NN	_	8	dobj
12	of	of	IN	_	13	case
13	drug3	drug3	NN	_	11	nmod
14	.	.	.	_	4	punct

1	This	this	DT	_	2	det
2	interaction	interaction	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	given	give	VBN	_	0	ROOT
6	consideration	consideration	NN	_	5	dobj
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	5	nmod
9	taking	take	VBG	_	8	acl
10	drug1	drug1	NN	_	9	dobj
11	concomitantly	concomitantly	RB	_	9	advmod
12	with	with	IN	_	13	case
13	drug2	drug2	NN	_	9	nmod
14	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Clinical	clinical	JJ	_	4	amod
4	studies	study	NNS	_	13	nsubj
5	,	,	,	_	4	punct
6	as	as	RB	_	4	cc
7	well	well	RB	_	6	mwe
8	as	as	IN	_	6	mwe
9	post-marketing	post-marketing	JJ	_	10	amod
10	observations	observation	NNS	_	4	conj
11	,	,	,	_	4	punct
12	have	have	VBP	_	13	aux
13	shown	show	VBN	_	1	appos
14	that	that	IN	_	17	mark
15	drug2	drug2	NN	_	17	nsubj
16	can	can	MD	_	17	aux
17	reduce	reduce	VB	_	13	ccomp
18	the	the	DT	_	20	det
19	natriuretic	natriuretic	JJ	_	20	amod
20	effect	effect	NN	_	17	dobj
21	of	of	IN	_	22	case
22	drug3	drug3	NN	_	20	nmod
23	and	and	CC	_	22	cc
24	drug4	drug4	NN	_	22	conj
25	in	in	IN	_	27	case
26	some	some	DT	_	27	det
27	patients	patient	NNS	_	20	nmod
28	.	.	.	_	1	punct

1	This	this	DT	_	2	det
2	response	response	NN	_	5	nsubjpass
3	has	have	VBZ	_	5	aux
4	been	be	VBN	_	5	auxpass
5	attributed	attribute	VBN	_	0	ROOT
6	to	to	TO	_	7	case
7	inhibition	inhibition	NN	_	5	nmod
8	of	of	IN	_	11	case
9	renal	renal	JJ	_	11	amod
10	prostaglandin	prostaglandin	NN	_	11	compound
11	synthesis	synthesis	NN	_	7	nmod
12	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	drug2	drug2	NN	_	1	appos
4	-RRB-	-rrb-	-RRB-	_	3	punct
5	:	:	:	_	1	punct
6	Steady	steady	JJ	_	9	amod
7	state	state	NN	_	9	compound
8	plasma	plasma	NN	_	9	compound
9	exposure	exposure	NN	_	24	nsubjpass
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	AUC	auc	NN	_	9	appos
12	-RRB-	-rrb-	-RRB-	_	11	punct
13	of	of	IN	_	14	case
14	drug3	drug3	NN	_	9	nmod
15	-LRB-	-lrb-	-LRB-	_	17	punct
16	40	40	CD	_	17	nummod
17	mg	mg	NN	_	14	appos
18	BID	BID	NNP	_	17	dep
19	for	for	IN	_	21	case
20	12	12	CD	_	21	nummod
21	days	day	NNS	_	18	nmod
22	-RRB-	-rrb-	-RRB-	_	17	punct
23	was	be	VBD	_	24	auxpass
24	decreased	decrease	VBN	_	1	dep
25	by	by	IN	_	27	case
26	27	27	CD	_	27	nummod
27	%	%	NN	_	24	nmod
28	when	when	WRB	_	29	advmod
29	co-administered	co-administer	VBN	_	24	advcl
30	with	with	IN	_	32	case
31	multiple	multiple	JJ	_	32	amod
32	doses	dose	NNS	_	29	nmod
33	-LRB-	-lrb-	-LRB-	_	36	punct
34	300	300	CD	_	35	compound
35	mg	mg	NN	_	36	amod
36	QD	qd	NN	_	32	dep
37	for	for	IN	_	39	case
38	12	12	CD	_	39	nummod
39	days	day	NNS	_	36	nmod
40	-RRB-	-rrb-	-RRB-	_	36	punct
41	of	of	IN	_	42	case
42	drug4	drug4	NN	_	32	nmod
43	-LRB-	-lrb-	-LRB-	_	47	punct
44	a	a	DT	_	47	det
45	CYP	cyp	NN	_	47	compound
46	3A4	3a4	NN	_	47	compound
47	inducer	inducer	NN	_	32	appos
48	-RRB-	-rrb-	-RRB-	_	47	punct
49	.	.	.	_	24	punct

1	Patients	patient	NNS	_	3	nsubj
2	already	already	RB	_	3	advmod
3	stabilized	stabilize	VBD	_	0	ROOT
4	on	on	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	should	should	MD	_	9	aux
7	be	be	VB	_	9	auxpass
8	closely	closely	RB	_	9	advmod
9	monitored	monitor	VBN	_	3	ccomp
10	for	for	IN	_	11	case
11	loss	loss	NN	_	9	nmod
12	of	of	IN	_	14	case
13	symptom	symptom	NN	_	14	compound
14	control	control	NN	_	11	nmod
15	with	with	IN	_	17	case
16	drug2	drug2	NN	_	17	compound
17	coadministration	coadministration	NN	_	11	nmod
18	.	.	.	_	3	punct

1	drug1	drug1	NN	_	4	nsubj
2	did	do	VBD	_	4	aux
3	not	not	RB	_	4	neg
4	have	have	VB	_	0	ROOT
5	a	a	DT	_	8	det
6	statistically	statistically	RB	_	7	advmod
7	significant	significant	JJ	_	8	amod
8	effect	effect	NN	_	4	dobj
9	on	on	IN	_	11	case
10	the	the	DT	_	11	det
11	pharmacokinetics	pharmacokinetic	NNS	_	8	nmod
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	-LRB-	-lrb-	-LRB-	_	17	punct
15	a	a	DT	_	17	det
16	CYP	cyp	NN	_	17	compound
17	2C9	2c9	NN	_	13	dep
18	and	and	CC	_	17	cc
19	CYP	cyp	NN	_	21	compound
20	2C19	2c19	NN	_	21	compound
21	substrate	substrate	NN	_	17	conj
22	-RRB-	-rrb-	-RRB-	_	17	punct
23	.	.	.	_	4	punct

1	Drug	drug	NN	_	3	compound
2	interaction	interaction	NN	_	3	compound
3	studies	study	NNS	_	10	nsubjpass
4	with	with	IN	_	6	case
5	other	other	JJ	_	6	amod
6	drug1	drug1	NN	_	3	nmod
7	have	have	VBP	_	10	aux
8	not	not	RB	_	10	neg
9	been	be	VBN	_	10	auxpass
10	conducted	conduct	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	Routine	routine	JJ	_	2	amod
2	monitoring	monitoring	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	performed	perform	VBN	_	0	ROOT
6	when	when	WRB	_	12	advmod
7	therapy	therapy	NN	_	12	nsubjpass
8	with	with	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	is	be	VBZ	_	12	auxpass
11	either	either	CC	_	12	cc:preconj
12	initiated	initiate	VBN	_	5	advcl
13	or	or	CC	_	12	cc
14	discontinued	discontinue	VBN	_	12	conj
15	in	in	IN	_	16	case
16	patients	patient	NNS	_	12	nmod
17	on	on	IN	_	19	case
18	anticonvulsant	anticonvulsant	JJ	_	19	amod
19	therapy	therapy	NN	_	16	nmod
20	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	6	nsubjpass
4	is	be	VBZ	_	6	auxpass
5	primarily	primarily	RB	_	6	advmod
6	metabolized	metabolize	VBN	_	1	dep
7	by	by	IN	_	9	case
8	CYP	cyp	NN	_	9	compound
9	2D6	2d6	NN	_	6	nmod
10	and	and	CC	_	6	cc
11	to	to	TO	_	14	case
12	a	a	DT	_	14	det
13	lesser	lesser	JJR	_	14	amod
14	extent	extent	NN	_	6	conj
15	by	by	IN	_	16	case
16	3A4	3a4	NN	_	14	nmod
17	.	.	.	_	1	punct

1	Coadministration	coadministration	NN	_	12	nsubj
2	with	with	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	-LRB-	-lrb-	-LRB-	_	6	punct
5	40	40	CD	_	6	nummod
6	mg	mg	NN	_	3	dep
7	BID	BID	NNP	_	6	dep
8	for	for	IN	_	10	case
9	7	7	CD	_	10	nummod
10	days	day	NNS	_	7	nmod
11	-RRB-	-rrb-	-RRB-	_	6	punct
12	resulted	result	VBD	_	0	ROOT
13	in	in	IN	_	16	case
14	a	a	DT	_	16	det
15	significant	significant	JJ	_	16	amod
16	increase	increase	NN	_	12	nmod
17	in	in	IN	_	20	case
18	drug2	drug2	NN	_	20	compound
19	plasma	plasma	NN	_	20	compound
20	levels	level	NNS	_	16	nmod
21	suggesting	suggest	VBG	_	12	xcomp
22	that	that	IN	_	32	mark
23	,	,	,	_	32	punct
24	at	at	IN	_	26	case
25	these	these	DT	_	26	det
26	doses	dose	NNS	_	32	nmod
27	,	,	,	_	32	punct
28	drug3	drug3	NN	_	32	nsubj
29	is	be	VBZ	_	32	cop
30	a	a	DT	_	32	det
31	weak	weak	JJ	_	32	amod
32	inhibitor	inhibitor	NN	_	21	ccomp
33	of	of	IN	_	34	case
34	2D6	2d6	NN	_	32	nmod
35	.	.	.	_	12	punct

1	Even	even	RB	_	3	advmod
2	so	so	RB	_	3	advmod
3	drug1	drug1	JJ	_	5	amod
4	plasma	plasma	NN	_	5	compound
5	concentrations	concentration	NNS	_	17	nsubj
6	in	in	IN	_	8	case
7	the	the	DT	_	8	det
8	presence	presence	NN	_	5	nmod
9	of	of	IN	_	11	case
10	high	high	JJ	_	11	amod
11	doses	dose	NNS	_	8	nmod
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	were	be	VBD	_	17	cop
15	almost	almost	RB	_	16	advmod
16	5-fold	5-fold	RB	_	17	advmod
17	lower	lower	JJR	_	0	ROOT
18	than	than	IN	_	19	case
19	those	those	DT	_	17	nmod
20	seen	see	VBN	_	19	acl
21	in	in	IN	_	25	case
22	CYP	cyp	NN	_	25	compound
23	2D6	2d6	NN	_	25	compound
24	poor	poor	JJ	_	25	amod
25	metabolizers	metabolizer	NNS	_	20	nmod
26	suggesting	suggest	VBG	_	17	xcomp
27	that	that	IN	_	32	mark
28	dose	dose	NN	_	29	compound
29	adjustment	adjustment	NN	_	32	nsubj
30	is	be	VBZ	_	32	cop
31	not	not	RB	_	32	neg
32	necessary	necessary	JJ	_	26	ccomp
33	.	.	.	_	17	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	6	compound
4	40	40	CD	_	5	nummod
5	mg	mg	NN	_	6	compound
6	BID	BID	NNP	_	10	nsubj
7	for	for	IN	_	9	case
8	7	7	CD	_	9	nummod
9	days	day	NNS	_	6	nmod
10	produced	produce	VBD	_	1	dep
11	significant	significant	JJ	_	12	amod
12	decreases	decrease	NNS	_	10	dobj
13	in	in	IN	_	16	case
14	drug3	drug3	NN	_	16	compound
15	serum	serum	NN	_	16	compound
16	clearance	clearance	NN	_	12	nmod
17	-LRB-	-lrb-	-LRB-	_	19	punct
18	25	25	CD	_	19	nummod
19	%	%	NN	_	10	dep
20	-RRB-	-rrb-	-RRB-	_	19	punct
21	and	and	CC	_	10	cc
22	renal	renal	JJ	_	23	amod
23	clearance	clearance	NN	_	10	conj
24	-LRB-	-lrb-	-LRB-	_	26	punct
25	30	30	CD	_	26	nummod
26	%	%	NN	_	23	appos
27	-RRB-	-rrb-	-RRB-	_	26	punct
28	with	with	IN	_	34	case
29	a	a	DT	_	34	det
30	34	34	CD	_	31	compound
31	%	%	NN	_	34	amod
32	higher	higher	JJR	_	34	amod
33	serum	serum	NN	_	34	compound
34	exposure	exposure	NN	_	23	nmod
35	compared	compare	VBN	_	34	acl
36	to	to	TO	_	37	case
37	drug4	drug4	NN	_	35	nmod
38	alone	alone	RB	_	37	advmod
39	.	.	.	_	1	punct

1	drug1	drug1	NN	_	3	compound
2	serum	serum	NN	_	3	compound
3	concentrations	concentration	NNS	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	monitored	monitor	VBN	_	0	ROOT
7	closely	closely	RB	_	6	advmod
8	when	when	WRB	_	9	advmod
9	initiating	initiate	VBG	_	6	advcl
10	or	or	CC	_	9	cc
11	changing	change	VBG	_	9	conj
12	therapy	therapy	NN	_	9	dobj
13	with	with	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	in	in	IN	_	16	case
16	patients	patient	NNS	_	12	nmod
17	receiving	receive	VBG	_	16	acl
18	drug3	drug3	NN	_	17	dobj
19	.	.	.	_	6	punct

1	drug1	drug1	NN	_	10	nsubj
2	-LRB-	-lrb-	-LRB-	_	5	punct
3	450	450	CD	_	5	nummod
4	mg	mg	NN	_	5	compound
5	BID	BID	NNP	_	1	dep
6	for	for	IN	_	8	case
7	7	7	CD	_	8	nummod
8	days	day	NNS	_	5	nmod
9	-RRB-	-rrb-	-RRB-	_	5	punct
10	had	have	VBD	_	0	ROOT
11	no	no	DT	_	12	neg
12	effect	effect	NN	_	10	dobj
13	on	on	IN	_	15	case
14	drug2	drug2	NN	_	15	compound
15	pharmacokinetics	pharmacokinetic	NNS	_	10	nmod
16	.	.	.	_	10	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	effect	effect	NN	_	20	nsubjpass
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	on	on	IN	_	10	case
8	the	the	DT	_	10	det
9	anticoagulant	anticoagulant	JJ	_	10	amod
10	effect	effect	NN	_	4	nmod
11	of	of	IN	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	-LRB-	-lrb-	-LRB-	_	17	punct
14	1	1	CD	_	17	nummod
15	-	-	:	_	17	punct
16	8	8	CD	_	17	nummod
17	mg/day	mg/day	NN	_	12	appos
18	-RRB-	-rrb-	-RRB-	_	17	punct
19	was	be	VBD	_	20	auxpass
20	studied	study	VBN	_	1	dep
21	in	in	IN	_	23	case
22	healthy	healthy	JJ	_	23	amod
23	subjects	subject	NNS	_	20	nmod
24	by	by	IN	_	25	case
25	coadministration	coadministration	NN	_	20	nmod
26	of	of	IN	_	29	case
27	drug4	drug4	NN	_	29	compound
28	40	40	CD	_	29	nummod
29	mg	mg	NN	_	25	nmod
30	BID	BID	NNP	_	29	dep
31	for	for	IN	_	33	case
32	7	7	CD	_	33	nummod
33	days	day	NNS	_	20	nmod
34	.	.	.	_	1	punct

1	drug1	drug1	NN	_	2	nsubj
2	caused	cause	VBD	_	0	ROOT
3	a	a	DT	_	6	det
4	statistically	statistically	RB	_	5	advmod
5	significant	significant	JJ	_	6	amod
6	increase	increase	NN	_	2	dobj
7	in	in	IN	_	9	case
8	plasma	plasma	NN	_	9	compound
9	exposures	exposure	NNS	_	6	nmod
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	drug3	drug3	NN	_	11	conj
14	-LRB-	-lrb-	-LRB-	_	16	punct
15	12	12	CD	_	16	nummod
16	%	%	NN	_	6	dep
17	and	and	CC	_	16	cc
18	15	15	CD	_	19	nummod
19	%	%	NN	_	16	conj
20	,	,	,	_	16	punct
21	respectively	respectively	RB	_	16	advmod
22	-RRB-	-rrb-	-RRB-	_	16	punct
23	,	,	,	_	6	punct
24	and	and	CC	_	6	cc
25	in	in	IN	_	28	case
26	the	the	DT	_	28	det
27	pharmacodynamic	pharmacodynamic	JJ	_	28	amod
28	effects	effect	NNS	_	6	conj
29	-LRB-	-lrb-	-LRB-	_	31	punct
30	prothrombin	prothrombin	NN	_	31	compound
31	time	time	NN	_	28	dep
32	,	,	,	_	31	punct
33	measured	measure	VBN	_	31	acl
34	as	as	IN	_	35	case
35	INR	inr	NN	_	33	nmod
36	-RRB-	-rrb-	-RRB-	_	31	punct
37	of	of	IN	_	38	case
38	drug4	drug4	NN	_	28	nmod
39	.	.	.	_	2	punct

1	While	while	IN	_	8	mark
2	mean	mean	NN	_	4	compound
3	INR	inr	NN	_	4	compound
4	values	value	NNS	_	8	nsubjpass
5	were	be	VBD	_	8	auxpass
6	only	only	RB	_	7	advmod
7	slightly	slightly	RB	_	8	advmod
8	increased	increase	VBN	_	22	advcl
9	with	with	IN	_	10	case
10	coadministration	coadministration	NN	_	8	nmod
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	,	,	,	_	22	punct
14	the	the	DT	_	16	det
15	day-to-day	day-to-day	JJ	_	16	amod
16	variability	variability	NN	_	22	nsubjpass
17	in	in	IN	_	20	case
18	individual	individual	JJ	_	20	amod
19	INR	inr	NN	_	20	compound
20	values	value	NNS	_	16	nmod
21	was	be	VBD	_	22	auxpass
22	increased	increase	VBN	_	0	ROOT
23	.	.	.	_	22	punct

1	drug1	drug1	NN	_	2	compound
2	therapy	therapy	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	monitored	monitor	VBN	_	0	ROOT
6	,	,	,	_	5	punct
7	particularly	particularly	RB	_	12	advmod
8	during	during	IN	_	12	case
9	the	the	DT	_	12	det
10	first	first	JJ	_	12	amod
11	few	few	JJ	_	12	amod
12	weeks	week	NNS	_	5	nmod
13	,	,	,	_	5	punct
14	after	after	IN	_	15	mark
15	initiating	initiate	VBG	_	5	advcl
16	therapy	therapy	NN	_	15	dobj
17	with	with	IN	_	18	case
18	drug2	drug2	NN	_	16	nmod
19	in	in	IN	_	20	case
20	patients	patient	NNS	_	16	nmod
21	receiving	receive	VBG	_	20	acl
22	drug3	drug3	NN	_	25	compound
23	or	or	CC	_	22	cc
24	similar	similar	JJ	_	22	conj
25	agents	agent	NNS	_	21	dobj
26	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	:	:	:	_	1	punct
5	drug3	drug3	NN	_	11	nsubj
6	and	and	CC	_	5	cc
7	drug4	drug4	NN	_	5	conj
8	are	be	VBP	_	11	cop
9	predominantly	predominantly	RB	_	11	advmod
10	CYP	CYP	NNP	_	11	compound
11	3A4	3a4	NN	_	1	dep
12	and	and	CC	_	11	cc
13	2C9	2c9	NN	_	14	compound
14	inhibitors	inhibitor	NNS	_	11	conj
15	,	,	,	_	11	punct
16	respectively	respectively	RB	_	11	advmod
17	.	.	.	_	1	punct

1	Concomitant	concomitant	JJ	_	4	amod
2	single	single	JJ	_	4	amod
3	dose	dose	NN	_	4	compound
4	administration	administration	NN	_	16	nsubj
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	20	20	CD	_	8	nummod
8	mg	mg	NN	_	6	dep
9	with	with	IN	_	11	case
10	multiple	multiple	JJ	_	11	amod
11	doses	dose	NNS	_	4	nmod
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	and	and	CC	_	13	cc
15	drug3	drug3	NN	_	13	conj
16	produced	produce	VBD	_	0	ROOT
17	a	a	DT	_	19	det
18	significant	significant	JJ	_	19	amod
19	increase	increase	NN	_	16	dobj
20	in	in	IN	_	21	case
21	exposure	exposure	NN	_	19	nmod
22	of	of	IN	_	23	case
23	drug4	drug4	NN	_	21	nmod
24	.	.	.	_	16	punct

1	Plasma	plasma	NN	_	2	compound
2	exposure	exposure	NN	_	9	nsubjpass
3	-LRB-	-lrb-	-LRB-	_	4	punct
4	AUC	auc	NN	_	2	appos
5	-RRB-	-rrb-	-RRB-	_	4	punct
6	to	to	TO	_	7	case
7	drug1	drug1	NN	_	2	nmod
8	was	be	VBD	_	9	auxpass
9	increased	increase	VBN	_	0	ROOT
10	62	62	CD	_	11	nummod
11	%	%	NN	_	9	dobj
12	when	when	WRB	_	13	advmod
13	coadministered	coadminister	VBN	_	9	advcl
14	with	with	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	38	38	CD	_	18	nummod
18	%	%	NN	_	15	conj
19	when	when	WRB	_	20	advmod
20	coadministered	coadminister	VBN	_	13	advcl
21	with	with	IN	_	22	case
22	drug3	drug3	NN	_	20	nmod
23	.	.	.	_	9	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	8	nsubj
4	is	be	VBZ	_	8	cop
5	a	a	DT	_	8	det
6	CYP	cyp	NN	_	8	compound
7	2C9	2c9	NN	_	8	compound
8	substrate	substrate	NN	_	1	dep
9	.	.	.	_	1	punct

1	Coadministration	coadministration	NN	_	25	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	-LRB-	-lrb-	-LRB-	_	7	punct
5	10	10	CD	_	6	compound
6	mg	mg	NN	_	7	amod
7	BID	BID	NNP	_	3	appos
8	for	for	IN	_	10	case
9	7	7	CD	_	10	nummod
10	days	day	NNS	_	7	nmod
11	-RRB-	-rrb-	-RRB-	_	7	punct
12	with	with	IN	_	13	case
13	drug2	drug2	NN	_	1	nmod
14	-LRB-	-lrb-	-LRB-	_	17	punct
15	5	5	CD	_	16	compound
16	mg	mg	NN	_	17	amod
17	QD	qd	NN	_	13	dep
18	or	or	CC	_	17	cc
19	10	10	CD	_	20	compound
20	mg	mg	NN	_	21	amod
21	BID	BID	NNP	_	17	conj
22	-RRB-	-rrb-	-RRB-	_	17	punct
23	did	do	VBD	_	25	aux
24	not	not	RB	_	25	neg
25	affect	affect	VB	_	0	ROOT
26	the	the	DT	_	27	det
27	pharmacokinetics	pharmacokinetic	NNS	_	25	dobj
28	-LRB-	-lrb-	-LRB-	_	29	punct
29	exposure	exposure	NN	_	27	appos
30	-RRB-	-rrb-	-RRB-	_	29	punct
31	of	of	IN	_	32	case
32	drug3	drug3	NN	_	27	nmod
33	.	.	.	_	25	punct

1	Coadministration	coadministration	NN	_	30	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	-LRB-	-lrb-	-LRB-	_	6	punct
5	40	40	CD	_	6	nummod
6	mg	mg	NN	_	3	dep
7	BID	BID	NNP	_	6	dep
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	day	day	NN	_	6	dep
10	1	1	CD	_	9	nummod
11	-RRB-	-rrb-	-RRB-	_	9	punct
12	and	and	CC	_	6	cc
13	40	40	CD	_	15	nummod
14	mg	mg	NN	_	15	compound
15	QD	qd	NN	_	6	conj
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	days	day	NNS	_	15	dep
18	2-7	2-7	CD	_	17	nummod
19	-RRB-	-rrb-	-RRB-	_	17	punct
20	-RRB-	-rrb-	-RRB-	_	6	punct
21	with	with	IN	_	22	case
22	drug2	drug2	NN	_	1	nmod
23	-LRB-	-lrb-	-LRB-	_	26	punct
24	5	5	CD	_	25	compound
25	mg	mg	NN	_	26	amod
26	QD	qd	NN	_	22	appos
27	-RRB-	-rrb-	-RRB-	_	26	punct
28	did	do	VBD	_	30	aux
29	not	not	RB	_	30	neg
30	affect	affect	VB	_	0	ROOT
31	either	either	CC	_	33	cc:preconj
32	the	the	DT	_	33	det
33	pharmacokinetics	pharmacokinetic	NNS	_	30	dobj
34	-LRB-	-lrb-	-LRB-	_	35	punct
35	exposure	exposure	NN	_	33	appos
36	-RRB-	-rrb-	-RRB-	_	35	punct
37	or	or	CC	_	33	cc
38	the	the	DT	_	39	det
39	pharmacodynamics	pharmacodynamic	NNS	_	33	conj
40	-LRB-	-lrb-	-LRB-	_	42	punct
41	blood	blood	NN	_	42	compound
42	glucose	glucose	NN	_	39	dep
43	and	and	CC	_	42	cc
44	insulin	insulin	NN	_	45	compound
45	levels	level	NNS	_	42	conj
46	-RRB-	-rrb-	-RRB-	_	42	punct
47	of	of	IN	_	48	case
48	drug3	drug3	NN	_	39	nmod
49	.	.	.	_	30	punct

1	Coadministration	coadministration	NN	_	29	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	-LRB-	-lrb-	-LRB-	_	6	punct
5	40	40	CD	_	6	nummod
6	mg	mg	NN	_	3	dep
7	BID	BID	NNP	_	6	dep
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	day	day	NN	_	6	dep
10	1	1	CD	_	9	nummod
11	-RRB-	-rrb-	-RRB-	_	9	punct
12	and	and	CC	_	6	cc
13	40	40	CD	_	15	nummod
14	mg	mg	NN	_	15	compound
15	QD	qd	NN	_	6	conj
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	days	day	NNS	_	15	dep
18	2-7	2-7	CD	_	17	nummod
19	-RRB-	-rrb-	-RRB-	_	17	punct
20	-RRB-	-rrb-	-RRB-	_	6	punct
21	with	with	IN	_	22	case
22	drug2	drug2	NN	_	1	nmod
23	-LRB-	-lrb-	-LRB-	_	27	punct
24	10	10	CD	_	25	compound
25	mg	mg	NN	_	27	amod
26	drug3	drug3	NN	_	27	compound
27	BID	BID	NNP	_	22	appos
28	-RRB-	-rrb-	-RRB-	_	27	punct
29	resulted	result	VBD	_	0	ROOT
30	in	in	IN	_	33	case
31	21	21	CD	_	32	compound
32	%	%	NN	_	33	amod
33	increase	increase	NN	_	29	nmod
34	in	in	IN	_	36	case
35	drug4	drug4	NN	_	36	compound
36	AUC0-12	auc0-12	NN	_	33	nmod
37	and	and	CC	_	33	cc
38	a	a	DT	_	41	det
39	16	16	CD	_	40	compound
40	%	%	NN	_	41	amod
41	increase	increase	NN	_	33	conj
42	in	in	IN	_	44	case
43	drug5	drug5	NN	_	44	compound
44	Cmax	cmax	NN	_	41	nmod
45	leading	lead	VBG	_	41	acl
46	to	to	TO	_	50	case
47	a	a	DT	_	50	det
48	16	16	CD	_	49	compound
49	%	%	NN	_	50	amod
50	decrease	decrease	NN	_	45	nmod
51	in	in	IN	_	53	case
52	glucose	glucose	NN	_	53	compound
53	AUC0-24	auc0-24	NN	_	50	nmod
54	.	.	.	_	29	punct

1	Insulin	insulin	NN	_	2	compound
2	parameters	parameter	NNS	_	5	nsubjpass
3	were	be	VBD	_	5	auxpass
4	not	not	RB	_	5	neg
5	affected	affect	VBN	_	0	ROOT
6	.	.	.	_	5	punct

1	Because	because	IN	_	13	mark
2	changes	change	NNS	_	13	nsubj
3	in	in	IN	_	5	case
4	glucose	glucose	NN	_	5	compound
5	concentrations	concentration	NNS	_	2	nmod
6	with	with	IN	_	8	case
7	drug1	drug1	NN	_	8	compound
8	coadministration	coadministration	NN	_	5	nmod
9	were	be	VBD	_	13	cop
10	within	within	IN	_	13	case
11	the	the	DT	_	13	det
12	normal	normal	JJ	_	13	amod
13	variability	variability	NN	_	50	advcl
14	and	and	CC	_	13	cc
15	individual	individual	JJ	_	17	amod
16	glucose	glucose	NN	_	17	compound
17	concentrations	concentration	NNS	_	19	nsubj
18	were	be	VBD	_	19	cop
19	above	above	IN	_	13	conj
20	or	or	CC	_	19	cc
21	near	near	IN	_	23	case
22	70	70	CD	_	23	nummod
23	mg/dL	mg/dl	NN	_	19	conj
24	,	,	,	_	50	punct
25	dose	dose	NN	_	26	compound
26	adjustment	adjustment	NN	_	50	nsubjpass
27	for	for	IN	_	28	case
28	drug2	drug2	NN	_	26	nmod
29	-LRB-	-lrb-	-LRB-	_	32	punct
30	5	5	CD	_	31	compound
31	mg	mg	NN	_	32	amod
32	QD	qd	NN	_	28	dep
33	and	and	CC	_	32	cc
34	10	10	CD	_	35	compound
35	mg	mg	NN	_	36	amod
36	BID	BID	NNP	_	32	conj
37	-RRB-	-rrb-	-RRB-	_	32	punct
38	with	with	IN	_	40	case
39	drug3	drug3	NN	_	40	compound
40	coadministration	coadministration	NN	_	26	nmod
41	-LRB-	-lrb-	-LRB-	_	46	punct
42	up	up	RB	_	44	advmod
43	to	to	TO	_	44	dep
44	40	40	CD	_	46	nummod
45	mg	mg	NN	_	46	compound
46	QD	qd	NN	_	40	appos
47	-RRB-	-rrb-	-RRB-	_	46	punct
48	is	be	VBZ	_	50	auxpass
49	not	not	RB	_	50	neg
50	indicated	indicate	VBN	_	0	ROOT
51	.	.	.	_	50	punct

1	Coadministration	coadministration	NN	_	21	nsubjpass
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	5	case
5	doses	dose	NNS	_	1	nmod
6	higher	higher	JJR	_	5	amod
7	than	than	IN	_	10	case
8	40	40	CD	_	10	nummod
9	mg	mg	NN	_	10	compound
10	drug2	drug2	NN	_	6	nmod
11	-LRB-	-lrb-	-LRB-	_	16	punct
12	e.g.	e.g.	FW	_	16	dep
13	,	,	,	_	16	punct
14	40	40	CD	_	16	nummod
15	mg	mg	NN	_	16	compound
16	BID	BID	NNP	_	10	appos
17	-RRB-	-rrb-	-RRB-	_	16	punct
18	have	have	VBP	_	21	aux
19	not	not	RB	_	21	neg
20	been	be	VBN	_	21	auxpass
21	studied	study	VBN	_	0	ROOT
22	.	.	.	_	21	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	8	nsubj
4	is	be	VBZ	_	8	cop
5	a	a	DT	_	8	det
6	CYP	cyp	NN	_	8	compound
7	3A4	3a4	NN	_	8	compound
8	substrate	substrate	NN	_	1	dep
9	and	and	CC	_	8	cc
10	CYP	cyp	NN	_	12	compound
11	2C19	2c19	NN	_	12	compound
12	substrate	substrate	NN	_	8	conj
13	and	and	CC	_	8	cc
14	inhibitor	inhibitor	NN	_	8	conj
15	.	.	.	_	1	punct

1	drug1	drug1	NN	_	5	compound
2	steady	steady	JJ	_	5	amod
3	state	state	NN	_	5	compound
4	plasma	plasma	NN	_	5	compound
5	concentrations	concentration	NNS	_	13	nsubjpass
6	-LRB-	-lrb-	-LRB-	_	9	punct
7	40	40	CD	_	9	nummod
8	mg	mg	NN	_	9	compound
9	BID	BID	NNP	_	5	appos
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	were	be	VBD	_	13	auxpass
12	not	not	RB	_	13	neg
13	affected	affect	VBN	_	0	ROOT
14	significantly	significantly	RB	_	13	advmod
15	with	with	IN	_	17	case
16	multiple	multiple	JJ	_	17	amod
17	doses	dose	NNS	_	13	nmod
18	of	of	IN	_	19	case
19	drug2	drug2	NN	_	17	nmod
20	-LRB-	-lrb-	-LRB-	_	23	punct
21	40	40	CD	_	22	compound
22	mg	mg	NN	_	23	nummod
23	QD	qd	NN	_	19	appos
24	-RRB-	-rrb-	-RRB-	_	23	punct
25	.	.	.	_	13	punct

1	Coadministration	coadministration	NN	_	4	nsubj
2	with	with	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	increased	increase	VBD	_	0	ROOT
5	exposure	exposure	NN	_	4	dobj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	AUC	auc	NN	_	7	appos
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	by	by	IN	_	13	case
12	46	46	CD	_	13	nummod
13	%	%	NN	_	4	nmod
14	.	.	.	_	4	punct

1	Drugs	drug	NNS	_	11	nsubjpass
2	whose	whose	WP$	_	3	nmod:poss
3	absorption	absorption	NN	_	5	nsubj
4	is	be	VBZ	_	5	cop
5	sensitive	sensitive	JJ	_	1	acl:relcl
6	to	to	TO	_	7	case
7	pH	ph	NN	_	5	nmod
8	may	may	MD	_	11	aux
9	be	be	VB	_	11	auxpass
10	negatively	negatively	RB	_	11	advmod
11	impacted	impact	VBN	_	0	ROOT
12	by	by	IN	_	14	case
13	concomitant	concomitant	JJ	_	14	amod
14	administration	administration	NN	_	11	nmod
15	of	of	IN	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	and	and	CC	_	16	cc
18	drug2	drug2	NN	_	16	conj
19	.	.	.	_	11	punct

1	However	however	RB	_	30	advmod
2	,	,	,	_	30	punct
3	because	because	IN	_	16	mark
4	higher	higher	JJR	_	5	amod
5	doses	dose	NNS	_	16	nsubjpass
6	-LRB-	-lrb-	-LRB-	_	11	punct
7	up	up	RB	_	9	advmod
8	to	to	TO	_	9	dep
9	360	360	CD	_	11	nummod
10	mg	mg	NN	_	11	compound
11	QD	qd	NN	_	5	appos
12	-RRB-	-rrb-	-RRB-	_	11	punct
13	of	of	IN	_	14	case
14	drug1	drug1	NN	_	5	nmod
15	are	be	VBP	_	16	auxpass
16	tolerated	tolerate	VBN	_	30	advcl
17	in	in	IN	_	18	case
18	Zollinger-Ellison	zollinger-ellison	NN	_	16	nmod
19	-LRB-	-lrb-	-LRB-	_	20	punct
20	ZE	ze	NN	_	18	appos
21	-RRB-	-rrb-	-RRB-	_	20	punct
22	patients	patient	NNS	_	18	dep
23	,	,	,	_	30	punct
24	no	no	DT	_	26	neg
25	dose	dose	NN	_	26	compound
26	adjustment	adjustment	NN	_	30	nsubjpass
27	for	for	IN	_	28	case
28	drug2	drug2	NN	_	26	nmod
29	is	be	VBZ	_	30	auxpass
30	recommended	recommend	VBN	_	0	ROOT
31	at	at	IN	_	33	case
32	current	current	JJ	_	33	amod
33	doses	dose	NNS	_	30	nmod
34	.	.	.	_	30	punct

1	Coadministration	coadministration	NN	_	15	nsubjpass
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	5	case
5	doses	dose	NNS	_	1	nmod
6	higher	higher	JJR	_	5	amod
7	than	than	IN	_	11	case
8	40	40	CD	_	9	compound
9	mg	mg	NN	_	11	amod
10	QD	qd	NN	_	11	compound
11	drug2	drug2	NN	_	6	nmod
12	has	have	VBZ	_	15	aux
13	not	not	RB	_	15	neg
14	been	be	VBN	_	15	auxpass
15	studied	study	VBN	_	0	ROOT
16	.	.	.	_	15	punct

1	Oral	oral	JJ	_	2	amod
2	drug1	drug1	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	drug2	drug2	NN	_	12	nsubj
5	-LRB-	-lrb-	-LRB-	_	8	punct
6	40	40	CD	_	7	nummod
7	mg	mg	NN	_	8	compound
8	BID	BID	NNP	_	4	appos
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	did	do	VBD	_	12	aux
11	not	not	RB	_	12	neg
12	induce	induce	VB	_	2	dep
13	the	the	DT	_	14	det
14	metabolism	metabolism	NN	_	12	dobj
15	of	of	IN	_	20	case
16	the	the	DT	_	20	det
17	combination	combination	NN	_	20	compound
18	oral	oral	JJ	_	20	amod
19	drug3	drug3	NN	_	20	compound
20	drug4	drug4	NN	_	14	nmod
21	/	/	:	_	20	punct
22	drug5	drug5	NN	_	20	dep
23	-LRB-	-lrb-	-LRB-	_	25	punct
24	1	1	CD	_	25	nummod
25	mg	mg	NN	_	22	dep
26	/	/	:	_	25	punct
27	35	35	CD	_	29	nummod
28	mcg	mcg	NN	_	29	compound
29	combination	combination	NN	_	25	dep
30	,	,	,	_	25	punct
31	drug6	drug6	NN	_	25	appos
32	1/35	1/35	CD	_	31	nummod
33	-RRB-	-rrb-	-RRB-	_	25	punct
34	.	.	.	_	2	punct

1	Coadministration	coadministration	NN	_	7	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	drug2	drug2	NN	_	3	conj
6	1/35	1/35	CD	_	3	nummod
7	increased	increase	VBD	_	0	ROOT
8	the	the	DT	_	9	det
9	exposure	exposure	NN	_	7	dobj
10	of	of	IN	_	11	case
11	drug3	drug3	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	drug4	drug4	NN	_	11	conj
14	by	by	IN	_	16	case
15	20	20	CD	_	16	nummod
16	%	%	NN	_	7	nmod
17	and	and	CC	_	16	cc
18	34	34	CD	_	19	nummod
19	%	%	NN	_	16	conj
20	,	,	,	_	7	punct
21	respectively	respectively	RB	_	7	advmod
22	.	.	.	_	7	punct

1	Although	although	IN	_	3	mark
2	there	there	EX	_	3	expl
3	is	be	VBZ	_	25	advcl
4	little	little	JJ	_	5	amod
5	risk	risk	NN	_	3	nsubj
6	for	for	IN	_	7	case
7	loss	loss	NN	_	5	nmod
8	of	of	IN	_	10	case
9	contraceptive	contraceptive	JJ	_	10	amod
10	efficacy	efficacy	NN	_	7	nmod
11	,	,	,	_	25	punct
12	the	the	DT	_	14	det
13	clinical	clinical	JJ	_	14	amod
14	significance	significance	NN	_	25	nsubjpass
15	of	of	IN	_	18	case
16	these	these	DT	_	18	det
17	increased	increase	VBN	_	18	amod
18	exposures	exposure	NNS	_	14	nmod
19	in	in	IN	_	20	case
20	terms	term	NNS	_	14	nmod
21	of	of	IN	_	22	case
22	safety	safety	NN	_	20	nmod
23	is	be	VBZ	_	25	auxpass
24	not	not	RB	_	25	neg
25	known	know	VBN	_	0	ROOT
26	.	.	.	_	25	punct

1	These	these	DT	_	2	nsubj
2	increased	increase	VBD	_	0	ROOT
3	exposures	exposure	NNS	_	2	dobj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	should	should	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	taken	take	VBN	_	2	xcomp
11	into	into	IN	_	12	case
12	consideration	consideration	NN	_	10	nmod
13	when	when	WRB	_	14	advmod
14	selecting	select	VBG	_	10	advcl
15	an	a	DT	_	17	det
16	oral	oral	JJ	_	17	amod
17	drug3	drug3	NN	_	14	dobj
18	for	for	IN	_	19	case
19	women	woman	NNS	_	17	nmod
20	taking	take	VBG	_	19	acl
21	drug4	drug4	NN	_	20	dobj
22	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	10	nsubj
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	drug3	drug3	NN	_	3	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	is	be	VBZ	_	10	cop
8	a	a	DT	_	10	det
9	CYP	cyp	NN	_	10	compound
10	3A4	3a4	NN	_	1	dep
11	and	and	CC	_	10	cc
12	CYP	cyp	NN	_	14	compound
13	2C19	2c19	NN	_	14	compound
14	substrate	substrate	NN	_	10	conj
15	.	.	.	_	1	punct

1	Plasma	plasma	NN	_	2	compound
2	exposure	exposure	NN	_	11	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	-LRB-	-lrb-	-LRB-	_	8	punct
6	10	10	CD	_	7	compound
7	mg	mg	NN	_	8	amod
8	BID	BID	NNP	_	4	appos
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	was	be	VBD	_	11	auxpass
11	increased	increase	VBN	_	0	ROOT
12	by	by	IN	_	14	case
13	28	28	CD	_	14	nummod
14	%	%	NN	_	11	nmod
15	following	follow	VBG	_	16	case
16	administration	administration	NN	_	11	nmod
17	of	of	IN	_	18	case
18	drug2	drug2	NN	_	16	nmod
19	-LRB-	-lrb-	-LRB-	_	21	punct
20	40	40	CD	_	21	nummod
21	mg	mg	NN	_	18	appos
22	BID	BID	NNP	_	21	dep
23	-RRB-	-rrb-	-RRB-	_	21	punct
24	for	for	IN	_	26	case
25	12	12	CD	_	26	nummod
26	days	day	NNS	_	16	nmod
27	,	,	,	_	11	punct
28	while	while	IN	_	11	dep
29	plasma	plasma	NN	_	30	compound
30	exposure	exposure	NN	_	28	dep
31	of	of	IN	_	32	case
32	drug3	drug3	NN	_	30	nmod
33	-LRB-	-lrb-	-LRB-	_	41	punct
34	40	40	CD	_	35	nummod
35	mg	mg	NN	_	41	nsubjpass
36	BID	BID	NNP	_	35	appos
37	-RRB-	-rrb-	-RRB-	_	36	punct
38	was	be	VBD	_	41	auxpass
39	not	not	RB	_	41	neg
40	substantially	substantially	RB	_	41	advmod
41	increased	increase	VBN	_	32	dep
42	following	follow	VBG	_	43	case
43	administration	administration	NN	_	41	nmod
44	of	of	IN	_	45	case
45	drug4	drug4	NN	_	43	nmod
46	-LRB-	-lrb-	-LRB-	_	49	punct
47	10	10	CD	_	48	compound
48	mg	mg	NN	_	49	amod
49	BID	BID	NNP	_	45	appos
50	-RRB-	-rrb-	-RRB-	_	49	punct
51	for	for	IN	_	53	case
52	12	12	CD	_	53	nummod
53	days	day	NNS	_	41	nmod
54	.	.	.	_	11	punct

1	Although	although	IN	_	16	mark
2	the	the	DT	_	3	det
3	magnitude	magnitude	NN	_	16	nsubj
4	of	of	IN	_	5	case
5	changes	change	NNS	_	3	nmod
6	in	in	IN	_	9	case
7	drug1	drug1	NN	_	9	compound
8	plasma	plasma	NN	_	9	compound
9	exposure	exposure	NN	_	5	nmod
10	when	when	WRB	_	11	advmod
11	coadministered	coadminister	VBN	_	3	acl:relcl
12	with	with	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	were	be	VBD	_	16	cop
15	not	not	RB	_	16	neg
16	sufficient	sufficient	JJ	_	24	advcl
17	to	to	TO	_	18	mark
18	warrant	warrant	VB	_	16	xcomp
19	dosage	dosage	NN	_	20	compound
20	adjustments	adjustment	NNS	_	18	dobj
21	,	,	,	_	24	punct
22	patients	patient	NNS	_	24	nsubj
23	may	may	MD	_	24	aux
24	experience	experience	VB	_	0	ROOT
25	enhanced	enhance	VBN	_	28	amod
26	sedative	sedative	JJ	_	28	amod
27	side	side	JJ	_	28	amod
28	effects	effect	NNS	_	24	dobj
29	caused	cause	VBN	_	28	acl
30	by	by	IN	_	32	case
31	increased	increase	VBN	_	32	amod
32	exposure	exposure	NN	_	29	nmod
33	of	of	IN	_	34	case
34	drug3	drug3	NN	_	32	nmod
35	under	under	IN	_	37	case
36	this	this	DT	_	37	det
37	circumstance	circumstance	NN	_	32	nmod
38	.	.	.	_	24	punct

1	Patients	patient	NNS	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	cautioned	caution	VBN	_	0	ROOT
5	against	against	IN	_	6	mark
6	engaging	engage	VBG	_	4	advcl
7	in	in	IN	_	9	case
8	hazardous	hazardous	JJ	_	9	amod
9	activities	activity	NNS	_	6	nmod
10	requiring	require	VBG	_	9	acl
11	complete	complete	JJ	_	13	amod
12	mental	mental	JJ	_	13	amod
13	alertness	alertness	NN	_	10	dobj
14	such	such	JJ	_	17	case
15	as	as	IN	_	14	mwe
16	operating	operate	VBG	_	17	amod
17	machinery	machinery	NN	_	13	nmod
18	or	or	CC	_	17	cc
19	driving	drive	VBG	_	17	conj
20	a	a	DT	_	22	det
21	motor	motor	NN	_	22	compound
22	vehicle	vehicle	NN	_	19	dobj
23	.	.	.	_	4	punct

1	When	when	WRB	_	4	advmod
2	drug1	drug1	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	co-administered	co-administer	VBN	_	17	advcl
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	-LRB-	-lrb-	-LRB-	_	10	punct
8	500	500	CD	_	10	nummod
9	mg	mg	NN	_	10	compound
10	p.o.	p.o.	NN	_	6	dep
11	every	every	DT	_	13	det
12	6	6	CD	_	13	nummod
13	hours	hour	NNS	_	10	dep
14	-RRB-	-rrb-	-RRB-	_	10	punct
15	,	,	,	_	17	punct
16	drug3	drug3	NN	_	17	nsubj
17	competes	compete	VBZ	_	0	ROOT
18	for	for	IN	_	21	case
19	active	active	JJ	_	21	amod
20	tubular	tubular	JJ	_	21	amod
21	secretion	secretion	NN	_	17	nmod
22	and	and	CC	_	17	cc
23	reduces	reduce	VBZ	_	17	conj
24	the	the	DT	_	26	det
25	renal	renal	JJ	_	26	amod
26	clearance	clearance	NN	_	23	dobj
27	of	of	IN	_	28	case
28	drug4	drug4	NN	_	26	nmod
29	.	.	.	_	17	punct

1	Based	base	VBN	_	5	case
2	on	on	IN	_	5	case
3	total	total	JJ	_	5	amod
4	drug1	drug1	NN	_	5	compound
5	concentrations	concentration	NNS	_	8	advcl
6	,	,	,	_	8	punct
7	drug2	drug2	NN	_	8	nsubj
8	increased	increase	VBD	_	0	ROOT
9	the	the	DT	_	10	det
10	AUC	auc	NN	_	8	dobj
11	by	by	IN	_	13	case
12	25	25	CD	_	13	nummod
13	%	%	NN	_	8	nmod
14	and	and	CC	_	8	cc
15	reduced	reduce	VBD	_	8	conj
16	the	the	DT	_	20	det
17	plasma	plasma	NN	_	20	compound
18	and	and	CC	_	17	cc
19	renal	renal	JJ	_	17	conj
20	clearances	clearance	NNS	_	15	dobj
21	by	by	IN	_	23	case
22	20	20	CD	_	23	nummod
23	%	%	NN	_	15	nmod
24	and	and	CC	_	23	cc
25	35	35	CD	_	26	nummod
26	%	%	NN	_	23	conj
27	,	,	,	_	8	punct
28	respectively	respectively	RB	_	8	advmod
29	.	.	.	_	8	punct

1	The	the	DT	_	2	det
2	half-life	half-life	NN	_	3	nsubj
3	increased	increase	VBN	_	0	ROOT
4	from	from	IN	_	8	case
5	4.0	4.0	CD	_	7	compound
6	to	to	TO	_	7	dep
7	4.8	4.8	CD	_	8	nummod
8	hours	hour	NNS	_	3	nmod
9	.	.	.	_	3	punct

1	Because	because	IN	_	5	case
2	of	of	IN	_	1	mwe
3	the	the	DT	_	5	det
4	small	small	JJ	_	5	amod
5	effect	effect	NN	_	21	nmod
6	on	on	IN	_	7	case
7	half-life	half-life	NN	_	5	nmod
8	,	,	,	_	21	punct
9	the	the	DT	_	10	det
10	coadministration	coadministration	NN	_	21	nsubjpass
11	with	with	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	to	to	TO	_	14	mark
14	extend	extend	VB	_	10	acl
15	the	the	DT	_	16	det
16	half-life	half-life	NN	_	14	dobj
17	of	of	IN	_	18	case
18	drug2	drug2	NN	_	16	nmod
19	is	be	VBZ	_	21	auxpass
20	not	not	RB	_	21	neg
21	recommended	recommend	VBN	_	0	ROOT
22	.	.	.	_	21	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	4	nsubj
4	indicate	indicate	VBP	_	0	ROOT
5	that	that	IN	_	9	mark
6	drug1	drug1	NN	_	9	nsubj
7	does	do	VBZ	_	9	aux
8	not	not	RB	_	9	neg
9	inhibit	inhibit	VB	_	4	ccomp
10	P-glycoprotein-mediated	p-glycoprotein-mediated	JJ	_	11	amod
11	transport	transport	NN	_	9	dobj
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	or	or	CC	_	13	cc
15	drug3	drug3	NN	_	13	conj
16	and	and	CC	_	9	cc
17	that	that	IN	_	22	mark
18	drug4	drug4	NN	_	22	nsubj
19	is	be	VBZ	_	22	cop
20	not	not	RB	_	22	neg
21	a	a	DT	_	22	det
22	substrate	substrate	NN	_	9	conj
23	for	for	IN	_	25	case
24	P-glycoprotein-mediated	p-glycoprotein-mediated	JJ	_	25	amod
25	transport	transport	NN	_	22	nmod
26	.	.	.	_	4	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	8	nsubj
4	in	in	IN	_	7	case
5	human	human	JJ	_	7	amod
6	liver	liver	NN	_	7	compound
7	microsomes	microsome	NNS	_	3	nmod
8	indicate	indicate	VBP	_	0	ROOT
9	that	that	IN	_	13	mark
10	drug1	drug1	NN	_	13	nsubj
11	does	do	VBZ	_	13	aux
12	not	not	RB	_	13	neg
13	inhibit	inhibit	VB	_	8	ccomp
14	metabolism	metabolism	NN	_	13	dobj
15	mediated	mediate	VBN	_	14	acl
16	by	by	IN	_	17	case
17	any	any	DT	_	15	nmod
18	of	of	IN	_	17	amod
19	the	the	DT	_	18	dep
20	following	follow	VBG	_	23	case
21	six	six	CD	_	23	nummod
22	cytochrome	cytochrome	NN	_	23	compound
23	p450	p450	NN	_	19	nmod
24	-LRB-	-lrb-	-LRB-	_	25	punct
25	CYP	cyp	NN	_	23	appos
26	-RRB-	-rrb-	-RRB-	_	25	punct
27	isoforms	isoform	NNS	_	23	dep
28	:	:	:	_	27	punct
29	1A2	1a2	NN	_	27	dep
30	,	,	,	_	29	punct
31	2C9	2c9	NN	_	29	conj
32	,	,	,	_	29	punct
33	2C19	2c19	NN	_	29	conj
34	,	,	,	_	29	punct
35	2D6	2d6	NN	_	29	conj
36	,	,	,	_	29	punct
37	2E1	2e1	NN	_	29	conj
38	and	and	CC	_	29	cc
39	3A4	3a4	NN	_	29	conj
40	.	.	.	_	8	punct

1	Drug	drug	NN	_	2	compound
2	interactions	interaction	NNS	_	19	nsubj
3	caused	cause	VBN	_	2	acl
4	by	by	IN	_	5	case
5	inhibition	inhibition	NN	_	3	nmod
6	of	of	IN	_	9	case
7	P-glycoprotein-mediated	p-glycoprotein-mediated	JJ	_	9	amod
8	drug	drug	NN	_	9	compound
9	clearance	clearance	NN	_	5	nmod
10	or	or	CC	_	9	cc
11	CYP-mediated	cyp-mediated	JJ	_	13	amod
12	drug	drug	NN	_	13	compound
13	clearance	clearance	NN	_	9	conj
14	with	with	IN	_	17	case
15	the	the	DT	_	17	det
16	listed	list	VBN	_	17	amod
17	isoforms	isoform	NNS	_	5	nmod
18	are	be	VBP	_	19	cop
19	unlikely	unlikely	JJ	_	0	ROOT
20	.	.	.	_	19	punct

1	Other	other	JJ	_	14	ccomp
2	than	than	IN	_	4	case
3	with	with	IN	_	4	case
4	drug1	drug1	NN	_	1	nmod
5	,	,	,	_	14	punct
6	no	no	DT	_	11	neg
7	specific	specific	JJ	_	11	amod
8	clinical	clinical	JJ	_	11	amod
9	drug	drug	NN	_	11	compound
10	interaction	interaction	NN	_	11	compound
11	studies	study	NNS	_	14	nsubjpass
12	have	have	VBP	_	14	aux
13	been	be	VBN	_	14	auxpass
14	conducted	conduct	VBN	_	0	ROOT

1	.	.	.	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	taken	take	VBN	_	0	ROOT
5	in	in	IN	_	9	case
6	concurrent	concurrent	JJ	_	9	amod
7	or	or	CC	_	6	cc
8	serial	serial	JJ	_	6	conj
9	use	use	NN	_	4	nmod
10	of	of	IN	_	12	case
11	other	other	JJ	_	12	amod
12	neurotoxic	neurotoxic	JJ	_	9	nmod
13	and	and	CC	_	12	cc
14	/	/	:	_	17	punct
15	or	or	CC	_	17	cc
16	nephrotoxic	nephrotoxic	JJ	_	17	amod
17	drugs	drug	NNS	_	12	conj
18	because	because	IN	_	21	case
19	of	of	IN	_	18	mwe
20	possible	possible	JJ	_	21	amod
21	enhancement	enhancement	NN	_	4	nmod
22	of	of	IN	_	24	case
23	the	the	DT	_	24	det
24	nephrotoxicity	nephrotoxicity	NN	_	21	nmod
25	and/or	and/or	CC	_	24	cc
26	ototoxicity	ototoxicity	NN	_	24	conj
27	of	of	IN	_	28	case
28	drug1	drug1	NN	_	24	nmod
29	.	.	.	_	4	punct

1	Caution	caution	NN	_	5	nsubjpass
2	should	should	MD	_	5	aux
3	also	also	RB	_	5	advmod
4	be	be	VB	_	5	auxpass
5	taken	take	VBN	_	0	ROOT
6	in	in	IN	_	10	case
7	concurrent	concurrent	JJ	_	10	amod
8	or	or	CC	_	7	cc
9	serial	serial	JJ	_	7	conj
10	use	use	NN	_	5	nmod
11	of	of	IN	_	13	case
12	other	other	JJ	_	13	amod
13	drug1	drug1	NN	_	10	nmod
14	and	and	CC	_	13	cc
15	drug2	drug2	NN	_	13	conj
16	because	because	IN	_	19	mark
17	they	they	PRP	_	19	nsubj
18	may	may	MD	_	19	aux
19	enhance	enhance	VB	_	5	advcl
20	neomycin	neomycin	NN	_	22	compound
21	s	s	NNS	_	22	compound
22	nephrotoxicity	nephrotoxicity	NN	_	19	dobj
23	and/or	and/or	CC	_	22	cc
24	ototoxicity	ototoxicity	NN	_	22	conj
25	and	and	CC	_	19	cc
26	potentiate	potentiate	VB	_	19	conj
27	drug3	drug3	NN	_	30	compound
28	neuromuscular	neuromuscular	JJ	_	30	amod
29	blocking	blocking	NN	_	30	compound
30	effects	effect	NNS	_	26	dobj
31	.	.	.	_	5	punct

1	Oral	oral	JJ	_	2	amod
2	drug1	drug1	NN	_	3	nsubj
3	inhibits	inhibit	VBZ	_	0	ROOT
4	the	the	DT	_	6	det
5	gastrointestinal	gastrointestinal	JJ	_	6	amod
6	absorption	absorption	NN	_	3	dobj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	,	,	,	_	8	punct
10	oral	oral	JJ	_	11	amod
11	drug3	drug3	NN	_	8	conj
12	,	,	,	_	8	punct
13	drug4	drug4	NN	_	8	conj
14	and	and	CC	_	8	cc
15	drug5	drug5	NN	_	8	conj
16	.	.	.	_	3	punct

1	The	the	DT	_	3	det
2	gastrointestinal	gastrointestinal	JJ	_	3	amod
3	absorption	absorption	NN	_	7	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	also	also	RB	_	7	advmod
7	appears	appear	VBZ	_	0	ROOT
8	to	to	TO	_	10	mark
9	be	be	VB	_	10	auxpass
10	inhibited	inhibit	VBN	_	7	xcomp
11	.	.	.	_	7	punct

1	Therefore	therefore	RB	_	8	advmod
2	,	,	,	_	8	punct
3	drug1	drug1	NN	_	5	compound
4	serum	serum	NN	_	5	compound
5	levels	level	NNS	_	8	nsubjpass
6	should	should	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	monitored	monitor	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	Oral	oral	JJ	_	2	amod
2	drug1	drug1	NN	_	4	nsubj
3	may	may	MD	_	4	aux
4	enhance	enhance	VB	_	0	ROOT
5	the	the	DT	_	6	det
6	effect	effect	NN	_	4	dobj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	in	in	IN	_	10	case
10	drug3	drug3	NN	_	6	nmod
11	by	by	IN	_	12	mark
12	decreasing	decrease	VBG	_	4	advcl
13	vitamin	vitamin	NN	_	15	compound
14	K	k	NN	_	15	compound
15	availability	availability	NN	_	12	dobj
16	.	.	.	_	4	punct

1	-	-	:	_	0	ROOT
2	Drugs	drug	NNS	_	1	root
3	with	with	IN	_	5	case
4	ototoxic	ototoxic	JJ	_	5	amod
5	potential	potential	NN	_	2	nmod
6	:	:	:	_	2	punct
7	Especially	especially	RB	_	33	advmod
8	in	in	IN	_	10	case
9	the	the	DT	_	10	det
10	presence	presence	NN	_	7	nmod
11	of	of	IN	_	14	case
12	impaired	impaired	JJ	_	14	amod
13	renal	renal	JJ	_	14	amod
14	function	function	NN	_	10	nmod
15	,	,	,	_	33	punct
16	the	the	DT	_	17	det
17	use	use	NN	_	33	nsubjpass
18	of	of	IN	_	21	case
19	parenterally	parenterally	RB	_	20	advmod
20	administered	administer	VBN	_	21	amod
21	drug1	drug1	NN	_	17	nmod
22	in	in	IN	_	23	case
23	patients	patient	NNS	_	17	nmod
24	to	to	TO	_	25	case
25	whom	whom	WP	_	30	nmod
26	drug2	drug2	NN	_	30	nsubjpass
27	are	be	VBP	_	30	aux
28	also	also	RB	_	30	advmod
29	being	be	VBG	_	30	auxpass
30	given	give	VBN	_	23	acl:relcl
31	should	should	MD	_	33	aux
32	be	be	VB	_	33	auxpass
33	avoided	avoid	VBN	_	2	dep
34	,	,	,	_	33	punct
35	except	except	IN	_	38	case
36	in	in	IN	_	38	case
37	life-threatening	life-threatening	JJ	_	38	amod
38	conditions	condition	NNS	_	33	nmod
39	.	.	.	_	2	punct

1	-	-	:	_	0	ROOT
2	Drugs	drug	NNS	_	1	root
3	with	with	IN	_	5	case
4	nephrotoxic	nephrotoxic	JJ	_	5	amod
5	potential	potential	NN	_	2	nmod
6	:	:	:	_	2	punct
7	There	there	EX	_	11	expl
8	has	have	VBZ	_	11	aux
9	been	be	VBN	_	11	cop
10	no	no	DT	_	11	neg
11	experience	experience	NN	_	2	dep
12	on	on	IN	_	15	case
13	the	the	DT	_	15	det
14	concurrent	concurrent	JJ	_	15	amod
15	use	use	NN	_	11	nmod
16	of	of	IN	_	17	case
17	drug1	drug1	NN	_	15	nmod
18	with	with	IN	_	19	case
19	drugs	drug	NNS	_	15	nmod
20	known	know	VBN	_	19	acl
21	to	to	TO	_	22	mark
22	have	have	VB	_	20	xcomp
23	a	a	DT	_	25	det
24	nephrotoxic	nephrotoxic	JJ	_	25	amod
25	potential	potential	NN	_	22	dobj
26	.	.	.	_	2	punct

1	Therefore	therefore	RB	_	11	advmod
2	,	,	,	_	11	punct
3	the	the	DT	_	5	det
4	simultaneous	simultaneous	JJ	_	5	amod
5	administration	administration	NN	_	11	nsubjpass
6	of	of	IN	_	8	case
7	these	these	DT	_	8	det
8	drugs	drug	NNS	_	5	nmod
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	avoided	avoid	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	-	-	:	_	9	punct
2	drug1	drug1	NN	_	9	dep
3	:	:	:	_	9	punct
4	drug2	drug2	NN	_	9	nsubjpass
5	should	should	MD	_	9	aux
6	generally	generally	RB	_	9	advmod
7	not	not	RB	_	9	neg
8	be	be	VB	_	9	auxpass
9	given	give	VBN	_	0	ROOT
10	with	with	IN	_	11	case
11	drug3	drug3	NN	_	9	nmod
12	-LRB-	-lrb-	-LRB-	_	15	punct
13	such	such	JJ	_	15	case
14	as	as	IN	_	13	mwe
15	drug4	drug4	NN	_	11	nmod
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	because	because	IN	_	19	mark
18	they	they	PRP	_	19	nsubj
19	reduce	reduce	VBP	_	9	advcl
20	its	its	PRP$	_	22	nmod:poss
21	renal	renal	JJ	_	22	amod
22	clearance	clearance	NN	_	19	dobj
23	and	and	CC	_	19	cc
24	add	add	VB	_	19	conj
25	a	a	DT	_	27	det
26	high	high	JJ	_	27	amod
27	risk	risk	NN	_	24	dobj
28	of	of	IN	_	30	case
29	drug5	drug5	NN	_	30	compound
30	toxicity	toxicity	NN	_	27	nmod
31	.	.	.	_	9	punct

1	-	-	:	_	7	punct
2	drug1	drug1	NN	_	7	dep
3	:	:	:	_	7	punct
4	Pretreatment	pretreatment	NN	_	7	nsubj
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	reduces	reduce	VBZ	_	0	ROOT
8	both	both	CC	_	10	cc:preconj
9	the	the	DT	_	10	det
10	natriuresis	natriuresis	NN	_	7	dobj
11	and	and	CC	_	10	cc
12	hyperreninemia	hyperreninemia	NN	_	10	conj
13	produced	produce	VBN	_	10	acl
14	by	by	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	.	.	.	_	7	punct

1	This	this	DT	_	3	det
2	antagonistic	antagonistic	JJ	_	3	amod
3	effect	effect	NN	_	11	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	on	on	IN	_	8	case
7	drug2	drug2	NN	_	8	compound
8	natriuresis	natriuresis	NN	_	3	nmod
9	is	be	VBZ	_	11	cop
10	not	not	RB	_	11	neg
11	due	due	JJ	_	0	ROOT
12	to	to	TO	_	15	case
13	a	a	DT	_	15	det
14	direct	direct	JJ	_	15	amod
15	action	action	NN	_	11	nmod
16	on	on	IN	_	18	case
17	sodium	sodium	NN	_	18	compound
18	excretion	excretion	NN	_	15	nmod
19	but	but	CC	_	11	cc
20	is	be	VBZ	_	22	cop
21	probably	probably	RB	_	22	advmod
22	secondary	secondary	JJ	_	11	conj
23	to	to	TO	_	26	case
24	its	its	PRP$	_	26	nmod:poss
25	inhibitory	inhibitory	JJ	_	26	amod
26	effect	effect	NN	_	22	nmod
27	on	on	IN	_	30	case
28	renal	renal	JJ	_	30	amod
29	tubular	tubular	JJ	_	30	amod
30	secretion	secretion	NN	_	26	nmod
31	of	of	IN	_	32	case
32	drug3	drug3	NN	_	30	nmod
33	.	.	.	_	11	punct

1	Thus	thus	RB	_	7	advmod
2	,	,	,	_	7	punct
3	drug1	drug1	NN	_	7	nsubjpass
4	should	should	MD	_	7	aux
5	not	not	RB	_	7	neg
6	be	be	VB	_	7	auxpass
7	administered	administer	VBN	_	0	ROOT
8	concurrently	concurrently	RB	_	7	advmod
9	with	with	IN	_	10	case
10	drug2	drug2	NN	_	7	nmod
11	.	.	.	_	7	punct

1	-	-	:	_	5	punct
2	drug1	drug1	NN	_	5	dep
3	:	:	:	_	5	punct
4	drug2	drug2	NN	_	5	nsubj
5	blunts	blunt	VBZ	_	0	ROOT
6	the	the	DT	_	7	det
7	increases	increase	NNS	_	5	dobj
8	in	in	IN	_	10	case
9	urine	urine	NN	_	10	compound
10	volume	volume	NN	_	7	nmod
11	and	and	CC	_	10	cc
12	sodium	sodium	NN	_	13	compound
13	excretion	excretion	NN	_	10	conj
14	seen	see	VBN	_	7	acl
15	during	during	IN	_	17	case
16	drug3	drug3	NN	_	17	compound
17	treatment	treatment	NN	_	14	nmod
18	and	and	CC	_	5	cc
19	inhibits	inhibit	VBZ	_	5	conj
20	the	the	DT	_	21	det
21	drug4	drug4	NN	_	19	dobj
22	-	-	:	_	21	punct
23	induced	induced	JJ	_	24	amod
24	increase	increase	NN	_	21	dep
25	in	in	IN	_	28	case
26	plasma	plasma	NN	_	28	compound
27	renin	renin	NN	_	28	compound
28	activity	activity	NN	_	24	nmod
29	.	.	.	_	5	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	therapy	therapy	NN	_	8	nsubjpass
3	with	with	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	is	be	VBZ	_	8	auxpass
6	thus	thus	RB	_	8	advmod
7	not	not	RB	_	8	neg
8	recommended	recommend	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	-	-	:	_	6	punct
2	drug1	drug1	NN	_	6	dep
3	:	:	:	_	6	punct
4	drug2	drug2	NN	_	6	nsubj
5	may	may	MD	_	6	aux
6	potentiate	potentiate	VB	_	0	ROOT
7	the	the	DT	_	8	det
8	effect	effect	NN	_	6	dobj
9	of	of	IN	_	11	case
10	various	various	JJ	_	11	amod
11	drug3	drug3	NN	_	8	nmod
12	,	,	,	_	6	punct
13	necessitating	necessitate	VBG	_	6	advcl
14	a	a	DT	_	15	det
15	reduction	reduction	NN	_	13	dobj
16	in	in	IN	_	18	case
17	the	the	DT	_	18	det
18	dosage	dosage	NN	_	15	nmod
19	of	of	IN	_	21	case
20	these	these	DT	_	21	det
21	drugs	drug	NNS	_	18	nmod
22	.	.	.	_	6	punct

1	-	-	:	_	9	punct
2	drug1	drug1	NN	_	9	dep
3	:	:	:	_	9	punct
4	Interaction	interaction	NN	_	5	compound
5	studies	study	NNS	_	9	nsubj
6	in	in	IN	_	7	case
7	humans	human	NNS	_	5	nmod
8	have	have	VBP	_	9	aux
9	shown	show	VBN	_	0	ROOT
10	no	no	DT	_	11	neg
11	effect	effect	NN	_	9	dobj
12	on	on	IN	_	15	case
13	drug2	drug2	NN	_	15	compound
14	blood	blood	NN	_	15	compound
15	levels	level	NNS	_	11	nmod
16	.	.	.	_	9	punct

1	-	-	:	_	9	punct
2	drug1	drug1	NN	_	9	dep
3	:	:	:	_	9	punct
4	Interaction	interaction	NN	_	5	compound
5	studies	study	NNS	_	9	nsubj
6	in	in	IN	_	7	case
7	humans	human	NNS	_	5	nmod
8	have	have	VBP	_	9	aux
9	shown	show	VBN	_	0	ROOT
10	drug2	drug2	NN	_	9	dobj
11	to	to	TO	_	12	mark
12	have	have	VB	_	9	advcl
13	no	no	DT	_	14	neg
14	effect	effect	NN	_	12	dobj
15	on	on	IN	_	17	case
16	drug3	drug3	NN	_	17	compound
17	metabolism	metabolism	NN	_	12	nmod
18	or	or	CC	_	17	cc
19	on	on	IN	_	22	case
20	plasma	plasma	NN	_	22	compound
21	prothrombin	prothrombin	NN	_	22	compound
22	activity	activity	NN	_	17	conj
23	.	.	.	_	9	punct

1	Administration	administration	NN	_	13	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	to	to	TO	_	5	case
5	patients	patient	NNS	_	1	nmod
6	who	who	WP	_	8	nsubj
7	are	be	VBP	_	8	aux
8	receiving	receive	VBG	_	5	acl:relcl
9	drug2	drug2	NN	_	8	dobj
10	or	or	CC	_	9	cc
11	drug3	drug3	NN	_	9	conj
12	may	may	MD	_	13	aux
13	result	result	VB	_	0	ROOT
14	in	in	IN	_	18	case
15	an	a	DT	_	18	det
16	additive	additive	JJ	_	18	amod
17	pressor	pressor	NN	_	18	compound
18	effect	effect	NN	_	13	nmod
19	.	.	.	_	13	punct

1	In	in	IN	_	2	case
2	patients	patient	NNS	_	11	nmod
3	who	who	WP	_	5	nsubj
4	have	have	VBP	_	5	aux
5	received	receive	VBN	_	2	acl:relcl
6	drug1	drug1	NN	_	5	dobj
7	,	,	,	_	11	punct
8	drug2	drug2	NN	_	11	nsubj
9	may	may	MD	_	11	aux
10	temporarily	temporarily	RB	_	11	advmod
11	mask	mask	NN	_	0	ROOT
12	the	the	DT	_	14	det
13	residual	residual	JJ	_	14	amod
14	effects	effect	NNS	_	11	dobj
15	of	of	IN	_	16	case
16	drug3	drug3	NN	_	14	nmod
17	.	.	.	_	11	punct

1	In	in	IN	_	2	case
2	patients	patient	NNS	_	25	nmod
3	who	who	WP	_	5	nsubj
4	have	have	VBP	_	5	aux
5	received	receive	VBN	_	2	acl:relcl
6	general	general	JJ	_	7	amod
7	anesthesia	anesthesia	NN	_	5	dobj
8	utilizing	utilize	VBG	_	7	acl
9	a	a	DT	_	11	det
10	volatile	volatile	JJ	_	11	amod
11	agent	agent	NN	_	8	dobj
12	known	know	VBN	_	11	acl
13	to	to	TO	_	14	mark
14	sensitize	sensitize	VB	_	12	xcomp
15	the	the	DT	_	16	det
16	myocardium	myocardium	NN	_	14	dobj
17	to	to	TO	_	18	case
18	catecholamines	catecholamine	NNS	_	14	nmod
19	,	,	,	_	18	punct
20	administration	administration	NN	_	18	appos
21	of	of	IN	_	22	case
22	drug1	drug1	NN	_	20	nmod
23	should	should	MD	_	25	aux
24	be	be	VB	_	25	auxpass
25	delayed	delay	VBN	_	0	ROOT
26	until	until	IN	_	32	mark
27	the	the	DT	_	29	det
28	volatile	volatile	JJ	_	29	amod
29	agent	agent	NN	_	32	nsubjpass
30	has	have	VBZ	_	32	aux
31	been	be	VBN	_	32	auxpass
32	excreted	excrete	VBN	_	25	advcl
33	in	in	IN	_	36	mark
34	order	order	NN	_	33	mwe
35	to	to	TO	_	36	mark
36	lessen	lessen	VB	_	32	advcl
37	the	the	DT	_	38	det
38	potential	potential	NN	_	36	dobj
39	for	for	IN	_	40	case
40	arrhythmias	arrhythmia	NNS	_	38	nmod
41	,	,	,	_	40	punct
42	including	include	VBG	_	44	case
43	ventricular	ventricular	JJ	_	44	amod
44	tachycardia	tachycardia	NN	_	40	nmod
45	and	and	CC	_	44	cc
46	ventricular	ventricular	JJ	_	47	amod
47	fibrillation	fibrillation	NN	_	44	conj
48	.	.	.	_	25	punct

1	Effect	effect	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	on	on	IN	_	6	case
5	the	the	DT	_	6	det
6	Pharmacokinetics	pharmacokinetic	NNS	_	1	nmod
7	of	of	IN	_	9	case
8	Other	other	JJ	_	9	amod
9	Drugs	drug	NNS	_	6	nmod
10	:	:	:	_	1	punct
11	drug2	drug2	NN	_	14	nsubj
12	does	do	VBZ	_	14	aux
13	not	not	RB	_	14	neg
14	appear	appear	VB	_	1	dep
15	to	to	TO	_	16	mark
16	alter	alter	VB	_	14	xcomp
17	the	the	DT	_	18	det
18	pharmacokinetics	pharmacokinetic	NNS	_	16	dobj
19	of	of	IN	_	20	case
20	drug3	drug3	NN	_	18	nmod
21	,	,	,	_	20	punct
22	drug4	drug4	NN	_	20	conj
23	,	,	,	_	20	punct
24	or	or	CC	_	20	cc
25	drug5	drug5	NN	_	20	conj
26	.	.	.	_	14	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	14	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	on	on	IN	_	7	case
6	the	the	DT	_	7	det
7	metabolism	metabolism	NN	_	2	nmod
8	of	of	IN	_	10	case
9	other	other	JJ	_	10	amod
10	drugs	drug	NNS	_	7	nmod
11	has	have	VBZ	_	14	aux
12	not	not	RB	_	14	neg
13	been	be	VBN	_	14	auxpass
14	investigated	investigate	VBN	_	0	ROOT
15	.	.	.	_	14	punct

1	Effect	effect	NN	_	0	ROOT
2	of	of	IN	_	4	case
3	Other	other	JJ	_	4	amod
4	Drugs	drug	NNS	_	1	nmod
5	on	on	IN	_	7	case
6	the	the	DT	_	7	det
7	Pharmacokinetics	pharmacokinetic	NNS	_	1	nmod
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	:	:	:	_	1	punct
11	Literature	literature	NN	_	12	compound
12	reports	report	NNS	_	13	nsubj
13	suggest	suggest	VBP	_	1	dep
14	that	that	IN	_	27	mark
15	drug2	drug2	NN	_	27	nsubj
16	,	,	,	_	15	punct
17	an	a	DT	_	18	det
18	agent	agent	NN	_	15	appos
19	that	that	WDT	_	20	nsubj
20	decreases	decrease	VBZ	_	18	acl:relcl
21	stomach	stomach	NN	_	22	compound
22	acidity	acidity	NN	_	20	dobj
23	,	,	,	_	15	punct
24	does	do	VBZ	_	27	aux
25	not	not	RB	_	27	neg
26	greatly	greatly	RB	_	27	advmod
27	alter	alter	VB	_	13	ccomp
28	drug3	drug3	NN	_	29	compound
29	pharmacokinetics	pharmacokinetic	NNS	_	27	dobj
30	.	.	.	_	1	punct

1	In	in	IN	_	3	case
2	a	a	DT	_	3	det
3	study	study	NN	_	0	ROOT
4	in	in	IN	_	5	case
5	which	which	WDT	_	14	nmod
6	the	the	DT	_	9	det
7	2	2	CD	_	8	compound
8	mg	mg	NN	_	9	amod
9	drug1	drug1	NN	_	14	nsubjpass
10	orally	orally	RB	_	11	advmod
11	disintegrating	disintegrate	VBG	_	12	amod
12	tablet	tablet	NN	_	9	dep
13	was	be	VBD	_	14	auxpass
14	administered	administer	VBN	_	3	acl:relcl
15	with	with	IN	_	41	mark
16	and	and	CC	_	41	cc
17	without	without	IN	_	18	case
18	drug2	drug2	NN	_	41	nmod
19	-LRB-	-lrb-	-LRB-	_	21	punct
20	an	a	DT	_	21	det
21	drug3	drug3	NN	_	18	dep
22	with	with	IN	_	24	case
23	multiple	multiple	JJ	_	24	amod
24	effects	effect	NNS	_	21	nmod
25	on	on	IN	_	28	case
26	the	the	DT	_	28	det
27	GI	gi	NN	_	28	compound
28	tract	tract	NN	_	24	nmod
29	-RRB-	-rrb-	-RRB-	_	21	punct
30	to	to	TO	_	32	case
31	healthy	healthy	JJ	_	32	amod
32	volunteers	volunteer	NNS	_	18	nmod
33	,	,	,	_	41	punct
34	the	the	DT	_	35	det
35	AUC	auc	NN	_	41	nsubj
36	of	of	IN	_	37	case
37	drug4	drug4	NN	_	35	nmod
38	was	be	VBD	_	41	cop
39	10	10	CD	_	40	nummod
40	%	%	NN	_	41	nmod:npmod
41	lower	lower	JJR	_	14	advcl
42	and	and	CC	_	41	cc
43	the	the	DT	_	44	det
44	Cmax	cmax	NN	_	50	nsubj
45	of	of	IN	_	46	case
46	drug5	drug5	NN	_	44	nmod
47	was	be	VBD	_	50	cop
48	20	20	CD	_	49	nummod
49	%	%	NN	_	50	nmod:npmod
50	lower	lower	JJR	_	41	conj
51	when	when	WRB	_	57	advmod
52	the	the	DT	_	55	det
53	orally	orally	RB	_	54	advmod
54	disintegrating	disintegrate	VBG	_	55	amod
55	tablet	tablet	NN	_	57	nsubjpass
56	was	be	VBD	_	57	auxpass
57	given	give	VBN	_	50	advcl
58	with	with	IN	_	59	case
59	drug6	drug6	NN	_	57	nmod
60	compared	compare	VBN	_	57	dep
61	to	to	TO	_	60	dep
62	when	when	WRB	_	65	advmod
63	it	it	PRP	_	65	nsubjpass
64	was	be	VBD	_	65	auxpass
65	given	give	VBN	_	61	advcl
66	alone	alone	RB	_	65	advmod
67	.	.	.	_	3	punct

1	drug1	drug1	NN	_	4	nsubj
2	does	do	VBZ	_	4	aux
3	not	not	RB	_	4	neg
4	affect	affect	VB	_	0	ROOT
5	the	the	DT	_	6	det
6	pharmacokinetics	pharmacokinetic	NNS	_	4	dobj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	.	.	.	_	4	punct

1	Cytochrome	cytochrome	NN	_	3	compound
2	P-450	p-450	NN	_	3	compound
3	inducers	inducer	NNS	_	13	nsubj
4	,	,	,	_	3	punct
5	such	such	JJ	_	7	case
6	as	as	IN	_	5	mwe
7	drug1	drug1	NN	_	3	nmod
8	,	,	,	_	7	punct
9	drug2	drug2	NN	_	7	conj
10	and	and	CC	_	7	cc
11	drug3	drug3	NN	_	7	conj
12	,	,	,	_	3	punct
13	induce	induce	VBP	_	0	ROOT
14	drug4	drug4	NN	_	15	compound
15	metabolism	metabolism	NN	_	13	dobj
16	,	,	,	_	13	punct
17	causing	cause	VBG	_	13	advcl
18	an	a	DT	_	22	det
19	approximately	approximately	RB	_	20	advmod
20	30	30	CD	_	21	dep
21	%	%	NN	_	22	dep
22	decrease	decrease	NN	_	17	dobj
23	in	in	IN	_	26	case
24	plasma	plasma	NN	_	26	compound
25	drug5	drug5	NN	_	26	compound
26	levels	level	NNS	_	22	nmod
27	.	.	.	_	13	punct

1	Although	although	IN	_	7	mark
2	clinical	clinical	JJ	_	3	amod
3	studies	study	NNS	_	7	nsubjpass
4	have	have	VBP	_	7	aux
5	not	not	RB	_	7	neg
6	been	be	VBN	_	7	auxpass
7	performed	perform	VBN	_	35	advcl
8	,	,	,	_	7	punct
9	based	base	VBN	_	12	case
10	on	on	IN	_	12	case
11	the	the	DT	_	12	det
12	involvement	involvement	NN	_	7	advcl
13	of	of	IN	_	18	case
14	the	the	DT	_	18	det
15	cytochrome	cytochrome	NN	_	18	compound
16	P-450	p-450	NN	_	18	compound
17	3A	3a	NN	_	18	compound
18	family	family	NN	_	12	nmod
19	in	in	IN	_	21	case
20	drug1	drug1	NN	_	21	compound
21	metabolism	metabolism	NN	_	12	nmod
22	,	,	,	_	35	punct
23	inhibitors	inhibitor	NNS	_	35	nsubjpass
24	of	of	IN	_	27	case
25	this	this	DT	_	27	det
26	enzyme	enzyme	NN	_	27	compound
27	system	system	NN	_	23	nmod
28	,	,	,	_	23	punct
29	notably	notably	RB	_	30	advmod
30	oral	oral	JJ	_	31	amod
31	drug2	drug2	NN	_	23	appos
32	,	,	,	_	23	punct
33	should	should	MD	_	35	aux
34	be	be	VB	_	35	auxpass
35	used	use	VBN	_	0	ROOT
36	cautiously	cautiously	RB	_	35	advmod
37	in	in	IN	_	38	case
38	patients	patient	NNS	_	35	nmod
39	receiving	receive	VBG	_	38	acl
40	drug3	drug3	NN	_	39	dobj
41	.	.	.	_	35	punct

1	Pharmacodynamic	pharmacodynamic	JJ	_	2	amod
2	Interactions	interaction	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	The	the	DT	_	6	det
5	CNS-depressant	cns-depressant	JJ	_	6	amod
6	action	action	NN	_	14	nsubjpass
7	of	of	IN	_	9	case
8	the	the	DT	_	9	det
9	drug1	drug1	NN	_	6	nmod
10	of	of	IN	_	11	case
11	drugs	drug	NNS	_	9	nmod
12	may	may	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	potentiated	potentiate	VBN	_	2	dep
15	by	by	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	,	,	,	_	16	punct
18	drug3	drug3	NN	_	16	conj
19	,	,	,	_	16	punct
20	drug4	drug4	NN	_	16	conj
21	,	,	,	_	16	punct
22	drug5	drug5	NN	_	16	conj
23	,	,	,	_	16	punct
24	drug6	drug6	NN	_	16	conj
25	,	,	,	_	16	punct
26	the	the	DT	_	27	det
27	drug7	drug7	NN	_	16	conj
28	,	,	,	_	16	punct
29	drug8	drug8	NN	_	16	conj
30	and	and	CC	_	16	cc
31	drug9	drug9	NN	_	16	conj
32	,	,	,	_	16	punct
33	drug10	drug10	NN	_	16	conj
34	and	and	CC	_	16	cc
35	the	the	DT	_	36	det
36	drug11	drug11	NN	_	16	conj
37	,	,	,	_	14	punct
38	and	and	CC	_	14	cc
39	by	by	IN	_	41	case
40	other	other	JJ	_	41	amod
41	drug12	drug12	NN	_	14	conj
42	.	.	.	_	2	punct

1	Hypotension	hypotension	NN	_	3	compound
2	-	-	:	_	3	punct
3	Patients	patient	NNS	_	0	ROOT
4	on	on	IN	_	6	case
5	Diuretic	diuretic	JJ	_	6	amod
6	Therapy	therapy	NN	_	3	nmod
7	:	:	:	_	3	punct
8	Patients	patient	NNS	_	25	nsubj
9	on	on	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	,	,	,	_	8	punct
12	and	and	CC	_	8	cc
13	especially	especially	RB	_	14	advmod
14	those	those	DT	_	8	conj
15	in	in	IN	_	16	case
16	whom	whom	WP	_	21	nmod
17	diuretic	diuretic	JJ	_	18	amod
18	therapy	therapy	NN	_	21	nsubjpass
19	was	be	VBD	_	21	auxpass
20	recently	recently	RB	_	21	advmod
21	instituted	institute	VBN	_	14	acl:relcl
22	,	,	,	_	8	punct
23	may	may	MD	_	25	aux
24	occasionally	occasionally	RB	_	25	advmod
25	experience	experience	VB	_	3	dep
26	an	a	DT	_	28	det
27	excessive	excessive	JJ	_	28	amod
28	reduction	reduction	NN	_	25	dobj
29	of	of	IN	_	31	case
30	blood	blood	NN	_	31	compound
31	pressure	pressure	NN	_	28	nmod
32	after	after	IN	_	33	case
33	initiation	initiation	NN	_	25	nmod
34	of	of	IN	_	35	case
35	therapy	therapy	NN	_	33	nmod
36	with	with	IN	_	37	case
37	drug2	drug2	NN	_	33	nmod
38	.	.	.	_	25	punct

1	The	the	DT	_	2	det
2	possibility	possibility	NN	_	10	nsubjpass
3	of	of	IN	_	5	case
4	hypotensive	hypotensive	JJ	_	5	amod
5	effects	effect	NNS	_	2	nmod
6	with	with	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	can	can	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	minimized	minimize	VBN	_	0	ROOT
11	by	by	IN	_	13	mark
12	either	either	CC	_	13	cc:preconj
13	discontinuing	discontinue	VBG	_	10	advcl
14	the	the	DT	_	15	det
15	drug2	drug2	NN	_	13	dobj
16	or	or	CC	_	13	cc
17	increasing	increase	VBG	_	13	conj
18	the	the	DT	_	20	det
19	salt	salt	NN	_	20	compound
20	intake	intake	NN	_	17	dobj
21	prior	prior	RB	_	17	advmod
22	to	to	TO	_	23	case
23	initiation	initiation	NN	_	21	nmod
24	of	of	IN	_	25	case
25	treatment	treatment	NN	_	23	nmod
26	with	with	IN	_	27	case
27	drug3	drug3	NN	_	25	nmod
28	.	.	.	_	10	punct

1	If	if	IN	_	4	mark
2	it	it	PRP	_	4	nsubj
3	is	be	VBZ	_	4	cop
4	necessary	necessary	JJ	_	11	advcl
5	to	to	TO	_	6	mark
6	continue	continue	VB	_	4	xcomp
7	the	the	DT	_	8	det
8	drug1	drug1	NN	_	6	dobj
9	,	,	,	_	11	punct
10	initiate	initiate	NN	_	11	compound
11	therapy	therapy	NN	_	0	ROOT
12	with	with	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	at	at	IN	_	16	case
15	a	a	DT	_	16	det
16	dose	dose	NN	_	11	nmod
17	of	of	IN	_	19	case
18	5	5	CD	_	19	nummod
19	mg	mg	NN	_	16	nmod
20	daily	daily	RB	_	16	advmod
21	,	,	,	_	11	punct
22	and	and	CC	_	11	cc
23	provide	provide	VBP	_	11	conj
24	close	close	JJ	_	26	amod
25	medical	medical	JJ	_	26	amod
26	supervision	supervision	NN	_	23	dobj
27	after	after	IN	_	30	case
28	the	the	DT	_	30	det
29	initial	initial	JJ	_	30	amod
30	dose	dose	NN	_	23	nmod
31	until	until	IN	_	35	mark
32	blood	blood	NN	_	33	compound
33	pressure	pressure	NN	_	35	nsubj
34	has	have	VBZ	_	35	aux
35	stabilized	stabilize	VBN	_	23	advcl
36	.	.	.	_	11	punct

1	When	when	WRB	_	5	advmod
2	a	a	DT	_	3	det
3	drug1	drug1	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	added	add	VBN	_	21	advcl
6	to	to	TO	_	8	case
7	the	the	DT	_	8	det
8	therapy	therapy	NN	_	5	nmod
9	of	of	IN	_	11	case
10	a	a	DT	_	11	det
11	patient	patient	NN	_	8	nmod
12	receiving	receive	VBG	_	11	acl
13	drug2	drug2	NN	_	12	dobj
14	,	,	,	_	21	punct
15	an	a	DT	_	18	det
16	additional	additional	JJ	_	18	amod
17	antihypertensive	antihypertensive	JJ	_	18	amod
18	effect	effect	NN	_	21	nsubjpass
19	is	be	VBZ	_	21	auxpass
20	usually	usually	RB	_	21	advmod
21	observed	observe	VBN	_	0	ROOT
22	.	.	.	_	21	punct

1	Studies	study	NNS	_	8	nsubj
2	with	with	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	in	in	IN	_	5	case
5	combination	combination	NN	_	1	nmod
6	with	with	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	indicate	indicate	VBP	_	0	ROOT
9	that	that	IN	_	17	mark
10	the	the	DT	_	11	det
11	dose	dose	NN	_	17	nsubjpass
12	of	of	IN	_	14	case
13	the	the	DT	_	14	det
14	drug3	drug3	NN	_	11	nmod
15	can	can	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	reduced	reduce	VBN	_	8	ccomp
18	when	when	WRB	_	21	advmod
19	it	it	PRP	_	21	nsubjpass
20	is	be	VBZ	_	21	auxpass
21	given	give	VBN	_	17	advcl
22	with	with	IN	_	24	case
23	a	a	DT	_	24	det
24	drug4	drug4	NN	_	21	nmod
25	.	.	.	_	8	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	5	case
4	some	some	DT	_	5	det
5	patients	patient	NNS	_	22	nmod
6	with	with	IN	_	9	case
7	compromised	compromise	VBN	_	9	amod
8	renal	renal	JJ	_	9	amod
9	function	function	NN	_	5	nmod
10	who	who	WP	_	13	nsubjpass
11	are	be	VBP	_	13	aux
12	being	be	VBG	_	13	auxpass
13	treated	treat	VBN	_	5	acl:relcl
14	with	with	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	,	,	,	_	5	punct
17	the	the	DT	_	18	det
18	co-administration	co-administration	NN	_	22	nsubj
19	of	of	IN	_	20	case
20	drug3	drug3	NN	_	18	nmod
21	may	may	MD	_	22	aux
22	result	result	VB	_	1	dep
23	in	in	IN	_	26	case
24	a	a	DT	_	26	det
25	further	further	JJ	_	26	amod
26	deterioration	deterioration	NN	_	22	nmod
27	of	of	IN	_	29	case
28	renal	renal	JJ	_	29	amod
29	function	function	NN	_	26	nmod
30	.	.	.	_	1	punct

1	These	these	DT	_	2	det
2	effects	effect	NNS	_	5	nsubj
3	are	be	VBP	_	5	cop
4	usually	usually	RB	_	5	advmod
5	reversible	reversible	JJ	_	0	ROOT
6	.	.	.	_	5	punct

1	Reports	report	NNS	_	2	nsubj
2	suggest	suggest	VBP	_	0	ROOT
3	that	that	IN	_	6	mark
4	drug1	drug1	NN	_	6	nsubj
5	may	may	MD	_	6	aux
6	diminish	diminish	VB	_	2	ccomp
7	the	the	DT	_	9	det
8	antihypertensive	antihypertensive	JJ	_	9	amod
9	effect	effect	NN	_	6	dobj
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	,	,	,	_	11	punct
13	including	include	VBG	_	14	case
14	drug3	drug3	NN	_	11	nmod
15	.	.	.	_	2	punct

1	This	this	DT	_	2	det
2	interaction	interaction	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	given	give	VBN	_	0	ROOT
6	consideration	consideration	NN	_	5	dobj
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	5	nmod
9	taking	take	VBG	_	8	acl
10	drug1	drug1	NN	_	9	dobj
11	concomitantly	concomitantly	RB	_	9	advmod
12	with	with	IN	_	13	case
13	drug2	drug2	NN	_	9	nmod
14	.	.	.	_	5	punct

1	In	in	IN	_	3	case
2	a	a	DT	_	3	det
3	study	study	NN	_	33	nmod
4	in	in	IN	_	6	case
5	36	36	CD	_	6	nummod
6	patients	patient	NNS	_	3	nmod
7	with	with	IN	_	8	case
8	mild	mild	JJ	_	6	nmod
9	to	to	TO	_	11	case
10	moderate	moderate	JJ	_	11	amod
11	hypertension	hypertension	NN	_	8	nmod
12	where	where	WRB	_	20	advmod
13	the	the	DT	_	15	det
14	antihypertensive	antihypertensive	JJ	_	15	amod
15	effects	effect	NNS	_	20	nsubjpass
16	of	of	IN	_	17	case
17	drug1	drug1	NN	_	15	nmod
18	alone	alone	RB	_	15	advmod
19	were	be	VBD	_	20	auxpass
20	compared	compare	VBN	_	11	acl:relcl
21	to	to	TO	_	22	case
22	drug2	drug2	VB	_	20	nmod
23	given	give	VBN	_	22	acl
24	concomitantly	concomitantly	RB	_	23	advmod
25	with	with	IN	_	26	case
26	drug3	drug3	NN	_	23	nmod
27	,	,	,	_	33	punct
28	the	the	DT	_	29	det
29	use	use	NN	_	33	nsubjpass
30	of	of	IN	_	31	case
31	drug4	drug4	NN	_	29	nmod
32	was	be	VBD	_	33	auxpass
33	associated	associate	VBN	_	0	ROOT
34	with	with	IN	_	38	case
35	a	a	DT	_	38	det
36	reduced	reduce	VBN	_	38	amod
37	antihypertensive	antihypertensive	JJ	_	38	amod
38	effect	effect	NN	_	33	nmod
39	,	,	,	_	33	punct
40	although	although	IN	_	49	mark
41	the	the	DT	_	42	det
42	difference	difference	NN	_	49	nsubj
43	between	between	IN	_	46	case
44	the	the	DT	_	46	det
45	two	two	CD	_	46	nummod
46	regimens	regimen	NNS	_	42	nmod
47	was	be	VBD	_	49	cop
48	not	not	RB	_	49	neg
49	significant	significant	JJ	_	33	advcl
50	.	.	.	_	33	punct

1	Other	other	JJ	_	2	amod
2	Agents	agent	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	drug1	drug1	NN	_	7	nsubjpass
5	has	have	VBZ	_	7	aux
6	been	be	VBN	_	7	auxpass
7	used	use	VBN	_	2	dep
8	concomitantly	concomitantly	RB	_	7	advmod
9	with	with	IN	_	10	case
10	drug2	drug2	NN	_	7	nmod
11	and/or	and/or	CC	_	10	cc
12	drug3	drug3	NN	_	10	conj
13	without	without	IN	_	14	case
14	evidence	evidence	NN	_	7	nmod
15	of	of	IN	_	19	case
16	clinically	clinically	RB	_	17	advmod
17	significant	significant	JJ	_	19	amod
18	adverse	adverse	JJ	_	19	amod
19	interactions	interaction	NNS	_	14	nmod
20	.	.	.	_	2	punct

1	This	this	DT	_	2	nsubj
2	included	include	VBD	_	0	ROOT
3	post	post	NN	_	6	compound
4	myocardial	myocardial	JJ	_	6	amod
5	infarction	infarction	NN	_	6	compound
6	patients	patient	NNS	_	2	dobj
7	who	who	WP	_	9	nsubj
8	were	be	VBD	_	9	aux
9	receiving	receive	VBG	_	6	acl:relcl
10	intravenous	intravenous	JJ	_	13	amod
11	or	or	CC	_	10	cc
12	transdermal	transdermal	JJ	_	10	conj
13	drug1	drug1	NN	_	9	dobj
14	.	.	.	_	2	punct

1	No	no	DT	_	5	neg
2	clinically	clinically	RB	_	3	advmod
3	important	important	JJ	_	5	amod
4	pharmacokinetic	pharmacokinetic	JJ	_	5	amod
5	interactions	interaction	NNS	_	6	nsubj
6	occurred	occur	VBD	_	0	ROOT
7	when	when	WRB	_	10	advmod
8	drug1	drug1	NN	_	10	nsubjpass
9	was	be	VBD	_	10	auxpass
10	used	use	VBN	_	6	advcl
11	concomitantly	concomitantly	RB	_	10	advmod
12	with	with	IN	_	13	case
13	drug2	drug2	NN	_	10	nmod
14	or	or	CC	_	13	cc
15	drug3	drug3	NN	_	13	conj
16	.	.	.	_	6	punct

1	The	the	DT	_	2	det
2	presence	presence	NN	_	10	nsubj
3	of	of	IN	_	4	case
4	food	food	NN	_	2	nmod
5	in	in	IN	_	7	case
6	the	the	DT	_	7	det
7	stomach	stomach	NN	_	2	nmod
8	does	do	VBZ	_	10	aux
9	not	not	RB	_	10	neg
10	alter	alter	VB	_	0	ROOT
11	the	the	DT	_	12	det
12	bioavailability	bioavailability	NN	_	10	dobj
13	of	of	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	.	.	.	_	10	punct

1	Agents	agent	NNS	_	4	compound
2	Increasing	increase	VBG	_	4	amod
3	Serum	serum	NN	_	4	compound
4	Potassium	potassium	NN	_	0	ROOT
5	:	:	:	_	4	punct
6	drug1	drug1	NN	_	7	nsubj
7	attenuates	attenuate	VBZ	_	4	dep
8	potassium	potassium	NN	_	9	compound
9	loss	loss	NN	_	7	dobj
10	caused	cause	VBN	_	9	acl
11	by	by	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	.	.	.	_	4	punct

1	Use	use	NN	_	25	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	1	nmod
6	-LRB-	-lrb-	-LRB-	_	9	punct
7	e.g.	e.g.	FW	_	9	dep
8	,	,	,	_	9	punct
9	drug3	drug3	NN	_	5	dep
10	,	,	,	_	9	punct
11	drug4	drug4	NN	_	9	conj
12	,	,	,	_	9	punct
13	or	or	CC	_	9	cc
14	drug5	drug5	NN	_	9	conj
15	-RRB-	-rrb-	-RRB-	_	9	punct
16	,	,	,	_	5	punct
17	drug6	drug6	NN	_	18	compound
18	supplements	supplement	NNS	_	5	conj
19	,	,	,	_	5	punct
20	or	or	CC	_	5	cc
21	potassium-containing	potassium-containing	JJ	_	23	amod
22	salt	salt	NN	_	23	compound
23	substitutes	substitute	NNS	_	5	conj
24	may	may	MD	_	25	aux
25	lead	lead	VB	_	0	ROOT
26	to	to	TO	_	28	case
27	significant	significant	JJ	_	28	amod
28	increases	increase	NNS	_	25	nmod
29	in	in	IN	_	31	case
30	serum	serum	NN	_	31	compound
31	potassium	potassium	NN	_	28	nmod
32	.	.	.	_	25	punct

1	Therefore	therefore	RB	_	19	advmod
2	,	,	,	_	19	punct
3	if	if	IN	_	10	mark
4	concomitant	concomitant	JJ	_	5	amod
5	use	use	NN	_	10	nsubjpass
6	of	of	IN	_	8	case
7	these	these	DT	_	8	det
8	agents	agent	NNS	_	5	nmod
9	is	be	VBZ	_	10	auxpass
10	indicated	indicate	VBN	_	19	advcl
11	because	because	IN	_	14	case
12	of	of	IN	_	11	mwe
13	demonstrated	demonstrate	VBN	_	14	amod
14	hypokalemia	hypokalemia	NN	_	10	nmod
15	,	,	,	_	19	punct
16	they	they	PRP	_	19	nsubjpass
17	should	should	MD	_	19	aux
18	be	be	VB	_	19	auxpass
19	used	use	VBN	_	0	ROOT
20	with	with	IN	_	21	case
21	caution	caution	NN	_	19	nmod
22	and	and	CC	_	21	cc
23	with	with	IN	_	25	case
24	frequent	frequent	JJ	_	25	amod
25	monitoring	monitoring	NN	_	21	conj
26	of	of	IN	_	28	case
27	serum	serum	NN	_	28	compound
28	potassium	potassium	NN	_	25	nmod
29	.	.	.	_	19	punct

1	Potassium	potassium	NN	_	3	compound
2	sparing	sparing	NN	_	3	compound
3	agents	agent	NNS	_	8	nsubjpass
4	should	should	MD	_	8	aux
5	generally	generally	RB	_	8	advmod
6	not	not	RB	_	8	neg
7	be	be	VB	_	8	auxpass
8	used	use	VBN	_	0	ROOT
9	in	in	IN	_	10	case
10	patients	patient	NNS	_	8	nmod
11	with	with	IN	_	13	case
12	heart	heart	NN	_	13	compound
13	failure	failure	NN	_	10	nmod
14	who	who	WP	_	16	nsubj
15	are	be	VBP	_	16	aux
16	receiving	receive	VBG	_	10	acl:relcl
17	drug1	drug1	NN	_	16	dobj
18	.	.	.	_	8	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	compound
4	toxicity	toxicity	NN	_	7	nsubjpass
5	has	have	VBZ	_	7	aux
6	been	be	VBN	_	7	auxpass
7	reported	report	VBN	_	1	appos
8	in	in	IN	_	9	case
9	patients	patient	NNS	_	7	nmod
10	receiving	receive	VBG	_	9	acl
11	drug3	drug3	NN	_	10	dobj
12	concomitantly	concomitantly	RB	_	10	advmod
13	with	with	IN	_	14	case
14	drugs	drug	NNS	_	10	nmod
15	which	which	WDT	_	16	nsubj
16	cause	cause	VBP	_	14	acl:relcl
17	elimination	elimination	NN	_	16	dobj
18	of	of	IN	_	19	case
19	sodium	sodium	NN	_	17	nmod
20	,	,	,	_	14	punct
21	including	include	VBG	_	22	case
22	drug4	drug4	NN	_	14	nmod
23	.	.	.	_	1	punct

1	drug1	drug1	NN	_	2	compound
2	toxicity	toxicity	NN	_	5	nsubj
3	was	be	VBD	_	5	cop
4	usually	usually	RB	_	5	advmod
5	reversible	reversible	JJ	_	0	ROOT
6	upon	upon	IN	_	7	case
7	discontinuation	discontinuation	NN	_	5	nmod
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	and	and	CC	_	7	cc
11	the	the	DT	_	12	det
12	drug3	drug3	NN	_	7	conj
13	.	.	.	_	5	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	recommended	recommend	VBN	_	0	ROOT
4	that	that	IN	_	9	mark
5	serum	serum	NN	_	7	compound
6	drug1	drug1	NN	_	7	compound
7	levels	level	NNS	_	9	nsubjpass
8	be	be	VB	_	9	auxpass
9	monitored	monitor	VBN	_	3	ccomp
10	frequently	frequently	RB	_	9	advmod
11	if	if	IN	_	14	mark
12	drug2	drug2	NN	_	14	nsubjpass
13	is	be	VBZ	_	14	auxpass
14	administered	administer	VBN	_	9	advcl
15	concomitantly	concomitantly	RB	_	14	advmod
16	with	with	IN	_	17	case
17	drug3	drug3	NN	_	14	nmod
18	.	.	.	_	3	punct

1	If	if	IN	_	3	mark
2	drug1	drug1	NN	_	3	nsubj
3	is	be	VBZ	_	21	advcl
4	to	to	TO	_	6	mark
5	be	be	VB	_	6	auxpass
6	combined	combine	VBN	_	3	xcomp
7	with	with	IN	_	10	mark
8	other	other	JJ	_	9	amod
9	drugs	drug	NNS	_	10	nsubj
10	acting	act	VBG	_	6	advcl
11	on	on	IN	_	15	case
12	the	the	DT	_	15	det
13	central	central	JJ	_	15	amod
14	nervous	nervous	JJ	_	15	amod
15	system	system	NN	_	10	nmod
16	,	,	,	_	21	punct
17	careful	careful	JJ	_	18	amod
18	consideration	consideration	NN	_	21	nsubjpass
19	should	should	MD	_	21	aux
20	be	be	VB	_	21	auxpass
21	given	give	VBN	_	0	ROOT
22	to	to	TO	_	24	case
23	the	the	DT	_	24	det
24	pharmacology	pharmacology	NN	_	21	nmod
25	of	of	IN	_	27	case
26	the	the	DT	_	27	det
27	agents	agent	NNS	_	24	nmod
28	to	to	TO	_	30	mark
29	be	be	VB	_	30	auxpass
30	employed	employ	VBN	_	24	acl
31	.	.	.	_	21	punct

1	Animal	animal	NN	_	2	compound
2	experience	experience	NN	_	3	nsubj
3	indicates	indicate	VBZ	_	0	ROOT
4	that	that	IN	_	6	mark
5	drug1	drug1	NN	_	6	nsubj
6	prolongs	prolong	VBZ	_	3	ccomp
7	the	the	DT	_	9	det
8	sleeping	sleep	VBG	_	9	amod
9	time	time	NN	_	6	dobj
10	after	after	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	or	or	CC	_	11	cc
13	after	after	IN	_	14	case
14	drug3	drug3	NN	_	11	conj
15	,	,	,	_	6	punct
16	increases	increase	VBZ	_	6	conj
17	the	the	DT	_	19	det
18	inhibitory	inhibitory	JJ	_	19	amod
19	effects	effect	NNS	_	16	dobj
20	of	of	IN	_	21	case
21	drug4	drug4	NN	_	19	nmod
22	,	,	,	_	6	punct
23	but	but	CC	_	6	cc
24	does	do	VBZ	_	26	aux
25	not	not	RB	_	26	neg
26	exhibit	exhibit	VB	_	6	conj
27	monoamine	monoamine	NN	_	29	compound
28	oxidase	oxidase	NN	_	29	compound
29	inhibition	inhibition	NN	_	26	dobj
30	.	.	.	_	3	punct

1	Clinical	clinical	JJ	_	2	amod
2	studies	study	NNS	_	4	nsubj
3	have	have	VBP	_	4	aux
4	shown	show	VBN	_	0	ROOT
5	increased	increase	VBN	_	6	amod
6	sedation	sedation	NN	_	4	dobj
7	with	with	IN	_	9	case
8	concurrent	concurrent	JJ	_	9	amod
9	drug1	drug1	NN	_	6	nmod
10	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	actions	action	NNS	_	8	nsubjpass
3	of	of	IN	_	5	case
4	the	the	DT	_	5	det
5	drug1	drug1	NN	_	2	nmod
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	potentiated	potentiate	VBN	_	0	ROOT
9	by	by	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	,	,	,	_	10	punct
12	drug3	drug3	NN	_	10	conj
13	,	,	,	_	10	punct
14	drug4	drug4	NN	_	10	conj
15	,	,	,	_	10	punct
16	drug5	drug5	NN	_	10	conj
17	or	or	CC	_	10	cc
18	other	other	JJ	_	19	amod
19	drug6	drug6	NN	_	10	conj
20	.	.	.	_	8	punct

1	If	if	IN	_	5	mark
2	drug1	drug1	NN	_	3	compound
3	tablets	tablet	NNS	_	5	nsubjpass
4	are	be	VBP	_	5	auxpass
5	used	use	VBN	_	19	advcl
6	to	to	TO	_	7	mark
7	treat	treat	VB	_	5	xcomp
8	anxiety	anxiety	NN	_	7	dobj
9	associated	associate	VBN	_	8	acl
10	with	with	IN	_	13	case
11	somatic	somatic	JJ	_	13	amod
12	disease	disease	NN	_	13	compound
13	states	state	NNS	_	9	nmod
14	,	,	,	_	19	punct
15	careful	careful	JJ	_	16	amod
16	attention	attention	NN	_	19	nsubjpass
17	must	must	MD	_	19	aux
18	be	be	VB	_	19	auxpass
19	paid	pay	VBN	_	0	ROOT
20	to	to	TO	_	23	case
21	possible	possible	JJ	_	23	amod
22	drug	drug	NN	_	23	compound
23	interaction	interaction	NN	_	19	nmod
24	with	with	IN	_	26	case
25	concomitant	concomitant	JJ	_	26	amod
26	medication	medication	NN	_	23	nmod
27	.	.	.	_	19	punct

1	In	in	IN	_	3	case
2	bioavailability	bioavailability	NN	_	3	compound
3	studies	study	NNS	_	19	nmod
4	with	with	IN	_	6	case
5	normal	normal	JJ	_	6	amod
6	subjects	subject	NNS	_	3	nmod
7	,	,	,	_	19	punct
8	the	the	DT	_	10	det
9	concurrent	concurrent	JJ	_	10	amod
10	administration	administration	NN	_	19	nsubj
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	at	at	IN	_	15	case
14	therapeutic	therapeutic	JJ	_	15	amod
15	levels	level	NNS	_	10	nmod
16	did	do	VBD	_	19	aux
17	not	not	RB	_	19	neg
18	significantly	significantly	RB	_	19	advmod
19	influence	influence	VB	_	0	ROOT
20	the	the	DT	_	21	det
21	bioavailability	bioavailability	NN	_	19	dobj
22	of	of	IN	_	24	case
23	drug2	drug2	NN	_	24	compound
24	tablets	tablet	NNS	_	21	nmod
25	.	.	.	_	19	punct

1	Although	although	IN	_	6	mark
2	clinical	clinical	JJ	_	3	amod
3	studies	study	NNS	_	6	nsubj
4	have	have	VBP	_	6	aux
5	not	not	RB	_	6	neg
6	established	establish	VBN	_	16	advcl
7	a	a	DT	_	8	det
8	cause	cause	NN	_	6	dobj
9	and	and	CC	_	8	cc
10	effect	effect	NN	_	11	compound
11	relationship	relationship	NN	_	8	conj
12	,	,	,	_	16	punct
13	physicians	physician	NNS	_	16	nsubj
14	should	should	MD	_	16	aux
15	be	be	VB	_	16	cop
16	aware	aware	JJ	_	0	ROOT
17	that	that	IN	_	16	dep
18	variable	variable	JJ	_	19	amod
19	effects	effect	NNS	_	17	dep
20	an	a	DT	_	22	det
21	blood	blood	NN	_	22	compound
22	coagulation	coagulation	NN	_	25	nsubjpass
23	have	have	VBP	_	25	aux
24	been	be	VBN	_	25	auxpass
25	reported	report	VBN	_	19	acl:relcl
26	very	very	RB	_	27	advmod
27	rarely	rarely	RB	_	25	advmod
28	in	in	IN	_	29	case
29	patients	patient	NNS	_	25	nmod
30	receiving	receive	VBG	_	29	acl
31	oral	oral	JJ	_	32	amod
32	drug1	drug1	NN	_	30	dobj
33	and	and	CC	_	32	cc
34	drug2	drug2	NN	_	32	conj
35	.	.	.	_	16	punct

1	The	the	DT	_	3	det
2	concomitant	concomitant	JJ	_	3	amod
3	use	use	NN	_	10	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	or	or	CC	_	5	cc
7	other	other	JJ	_	8	amod
8	drug2	drug2	NN	_	5	conj
9	may	may	MD	_	10	aux
10	have	have	VB	_	0	ROOT
11	an	a	DT	_	13	det
12	additive	additive	JJ	_	13	amod
13	effect	effect	NN	_	10	dobj
14	.	.	.	_	10	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concomitant	concomitant	JJ	_	4	amod
4	administration	administration	NN	_	27	nsubj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	-LRB-	-lrb-	-LRB-	_	9	punct
8	6	6	CD	_	9	nummod
9	mg/kg	mg/kg	NN	_	6	dep
10	once	once	RB	_	13	advmod
11	every	every	DT	_	13	det
12	24	24	CD	_	13	nummod
13	hours	hour	NNS	_	9	dep
14	for	for	IN	_	16	case
15	5	5	CD	_	16	nummod
16	days	day	NNS	_	13	nmod
17	-RRB-	-rrb-	-RRB-	_	9	punct
18	and	and	CC	_	6	cc
19	drug3	drug3	NN	_	6	conj
20	-LRB-	-lrb-	-LRB-	_	25	punct
21	25	25	CD	_	22	nummod
22	mg	mg	NN	_	25	dep
23	single	single	JJ	_	25	amod
24	oral	oral	JJ	_	25	amod
25	dose	dose	NN	_	19	appos
26	-RRB-	-rrb-	-RRB-	_	25	punct
27	had	have	VBD	_	1	dep
28	no	no	DT	_	30	neg
29	significant	significant	JJ	_	30	amod
30	effect	effect	NN	_	27	dobj
31	on	on	IN	_	33	case
32	the	the	DT	_	33	det
33	pharmacokinetics	pharmacokinetic	NNS	_	27	nmod
34	of	of	IN	_	36	case
35	either	either	CC	_	36	det
36	drug	drug	NN	_	33	nmod
37	,	,	,	_	27	punct
38	and	and	CC	_	27	cc
39	the	the	DT	_	40	det
40	INR	inr	NN	_	44	nsubjpass
41	was	be	VBD	_	44	auxpass
42	not	not	RB	_	44	neg
43	significantly	significantly	RB	_	44	advmod
44	altered	alter	VBN	_	27	conj
45	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	cause	cause	VB	_	1	dep
6	myopathy	myopathy	NN	_	5	dobj
7	,	,	,	_	6	punct
8	which	which	WDT	_	10	nsubjpass
9	is	be	VBZ	_	10	auxpass
10	manifested	manifest	VBN	_	6	acl:relcl
11	as	as	IN	_	13	case
12	muscle	muscle	NN	_	13	compound
13	pain	pain	NN	_	10	nmod
14	or	or	CC	_	13	cc
15	weakness	weakness	NN	_	13	conj
16	associated	associate	VBN	_	13	acl
17	with	with	IN	_	19	case
18	elevated	elevated	JJ	_	19	amod
19	levels	level	NNS	_	16	nmod
20	of	of	IN	_	21	case
21	CPK	CPK	NNP	_	19	nmod
22	.	.	.	_	5	punct

1	There	there	EX	_	2	expl
2	were	be	VBD	_	0	ROOT
3	no	no	DT	_	4	neg
4	reports	report	NNS	_	2	nsubj
5	of	of	IN	_	7	case
6	skeletal	skeletal	JJ	_	7	amod
7	myopathy	myopathy	NN	_	4	nmod
8	in	in	IN	_	13	case
9	a	a	DT	_	13	det
10	placebo-controlled	placebo-controlled	JJ	_	13	amod
11	Phase	phase	NN	_	13	compound
12	I	I	PRP	_	13	compound
13	trial	trial	NN	_	2	nmod
14	in	in	IN	_	15	case
15	which	which	WDT	_	24	nmod
16	10	10	CD	_	18	nummod
17	healthy	healthy	JJ	_	18	amod
18	subjects	subject	NNS	_	24	nsubjpass
19	on	on	IN	_	22	case
20	stable	stable	JJ	_	22	amod
21	drug1	drug1	NN	_	22	compound
22	therapy	therapy	NN	_	18	nmod
23	were	be	VBD	_	24	auxpass
24	treated	treat	VBN	_	13	acl:relcl
25	concurrently	concurrently	RB	_	24	advmod
26	with	with	IN	_	27	case
27	drug2	drug2	NN	_	24	nmod
28	-LRB-	-lrb-	-LRB-	_	30	punct
29	4	4	CD	_	30	nummod
30	mg/kg	mg/kg	NN	_	27	appos
31	once	once	RB	_	34	advmod
32	every	every	DT	_	34	det
33	24	24	CD	_	34	nummod
34	hours	hour	NNS	_	30	dep
35	-RRB-	-rrb-	-RRB-	_	30	punct
36	for	for	IN	_	38	case
37	14	14	CD	_	38	nummod
38	days	day	NNS	_	24	nmod
39	.	.	.	_	2	punct

1	Experience	experience	NN	_	11	nsubjpass
2	with	with	IN	_	3	case
3	co-administration	co-administration	NN	_	1	nmod
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	in	in	IN	_	9	case
9	patients	patient	NNS	_	5	nmod
10	is	be	VBZ	_	11	auxpass
11	limited	limit	VBN	_	0	ROOT
12	,	,	,	_	11	punct
13	therefore	therefore	RB	_	11	advmod
14	,	,	,	_	11	punct
15	consideration	consideration	NN	_	18	nsubjpass
16	should	should	MD	_	18	aux
17	be	be	VB	_	18	auxpass
18	given	give	VBN	_	11	ccomp
19	to	to	TO	_	21	mark
20	temporarily	temporarily	RB	_	21	advmod
21	suspending	suspend	VBG	_	18	advcl
22	use	use	NN	_	21	dobj
23	of	of	IN	_	24	case
24	drug3	drug3	NN	_	22	nmod
25	in	in	IN	_	26	case
26	patients	patient	NNS	_	22	nmod
27	receiving	receive	VBG	_	26	acl
28	drug4	drug4	NN	_	27	dobj
29	.	.	.	_	11	punct

1	Drug-Laboratory	drug-laboratory	JJ	_	3	amod
2	Test	test	NN	_	3	compound
3	Interactions	interaction	NNS	_	0	ROOT
4	:	:	:	_	3	punct
5	There	there	EX	_	6	expl
6	are	be	VBP	_	3	dep
7	no	no	DT	_	11	neg
8	reported	report	VBN	_	11	amod
9	drug-laboratory	drug-laboratory	JJ	_	11	amod
10	test	test	NN	_	11	compound
11	interactions	interaction	NNS	_	6	nsubj
12	.	.	.	_	3	punct

1	If	if	IN	_	4	mark
2	drug1	drug1	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	given	give	VBN	_	20	advcl
5	concomitantly	concomitantly	RB	_	4	advmod
6	with	with	IN	_	9	mark
7	other	other	JJ	_	8	amod
8	drugs	drug	NNS	_	9	nsubj
9	acting	act	VBG	_	4	advcl
10	on	on	IN	_	14	case
11	the	the	DT	_	14	det
12	central	central	JJ	_	14	amod
13	nervous	nervous	JJ	_	14	amod
14	system	system	NN	_	9	nmod
15	,	,	,	_	20	punct
16	careful	careful	JJ	_	17	amod
17	consideration	consideration	NN	_	20	nsubjpass
18	should	should	MD	_	20	aux
19	be	be	VB	_	20	auxpass
20	given	give	VBN	_	0	ROOT
21	to	to	TO	_	23	case
22	the	the	DT	_	23	det
23	pharmacology	pharmacology	NN	_	20	nmod
24	of	of	IN	_	26	case
25	all	all	DT	_	26	det
26	agents	agent	NNS	_	23	nmod
27	.	.	.	_	20	punct

1	The	the	DT	_	2	det
2	action	action	NN	_	8	nsubjpass
3	of	of	IN	_	5	case
4	the	the	DT	_	5	det
5	drug1	drug1	NN	_	2	nmod
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	potentiated	potentiate	VBN	_	0	ROOT
9	by	by	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	,	,	,	_	10	punct
12	drug3	drug3	NN	_	10	conj
13	,	,	,	_	10	punct
14	drug4	drug4	NN	_	10	conj
15	,	,	,	_	10	punct
16	drug5	drug5	NN	_	10	conj
17	,	,	,	_	10	punct
18	drug6	drug6	NN	_	10	conj
19	,	,	,	_	10	punct
20	drug7	drug7	NN	_	10	conj
21	,	,	,	_	10	punct
22	drug8	drug8	NN	_	10	conj
23	,	,	,	_	10	punct
24	drug9	drug9	NN	_	10	conj
25	,	,	,	_	10	punct
26	or	or	CC	_	10	cc
27	other	other	JJ	_	28	amod
28	drugs	drug	NNS	_	10	conj
29	that	that	WDT	_	30	nsubj
30	produce	produce	VBP	_	28	acl:relcl
31	CNS	cns	NN	_	32	compound
32	depression	depression	NN	_	30	dobj
33	.	.	.	_	8	punct

1	Smokers	smoker	NNS	_	2	nsubj
2	have	have	VBP	_	0	ROOT
3	an	a	DT	_	5	det
4	increased	increase	VBN	_	5	amod
5	clearance	clearance	NN	_	2	dobj
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	as	as	IN	_	9	mark
9	compared	compare	VBN	_	2	advcl
10	to	to	TO	_	11	case
11	nonsmokers	nonsmoker	NNS	_	9	nmod
12	;	;	:	_	2	punct

1	this	this	DT	_	3	nsubjpass
2	was	be	VBD	_	3	auxpass
3	seen	see	VBN	_	0	ROOT
4	in	in	IN	_	5	case
5	studies	study	NNS	_	3	nmod
6	with	with	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	.	.	.	_	3	punct

1	While	while	IN	_	9	mark
2	no	no	DT	_	7	neg
3	in	in	FW	_	7	amod
4	vivo	vivo	FW	_	3	dep
5	drug-drug	drug-drug	JJ	_	7	amod
6	interaction	interaction	NN	_	7	compound
7	studies	study	NNS	_	9	nsubjpass
8	were	be	VBD	_	9	auxpass
9	conducted	conduct	VBN	_	37	advcl
10	between	between	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	inducers	inducer	NNS	_	11	conj
14	of	of	IN	_	15	case
15	CYP3A	cyp3a	NN	_	11	nmod
16	,	,	,	_	15	punct
17	compounds	compound	NNS	_	15	appos
18	that	that	WDT	_	22	nsubj
19	are	be	VBP	_	22	cop
20	potent	potent	JJ	_	22	amod
21	CYP3A	cyp3a	NN	_	22	compound
22	inducers	inducer	NNS	_	17	acl:relcl
23	-LRB-	-lrb-	-LRB-	_	26	punct
24	such	such	JJ	_	26	case
25	as	as	IN	_	24	mwe
26	drug2	drug2	NN	_	22	nmod
27	,	,	,	_	26	punct
28	drug3	drug3	NN	_	26	conj
29	,	,	,	_	26	punct
30	drug4	drug4	NN	_	26	conj
31	,	,	,	_	26	punct
32	and	and	CC	_	26	cc
33	drug5	drug5	NN	_	26	conj
34	-RRB-	-rrb-	-RRB-	_	26	punct
35	would	would	MD	_	37	aux
36	be	be	VB	_	37	auxpass
37	expected	expect	VBN	_	0	ROOT
38	to	to	TO	_	39	mark
39	decrease	decrease	VB	_	37	xcomp
40	drug6	drug6	NN	_	41	compound
41	concentrations	concentration	NNS	_	39	dobj
42	.	.	.	_	37	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Interaction	interaction	NN	_	1	dep
4	with	with	IN	_	5	case
5	Drugs	drug	NNS	_	3	nmod
6	that	that	WDT	_	7	nsubj
7	Inhibit	inhibit	VBP	_	5	acl:relcl
8	Metabolism	metabolism	NN	_	7	dobj
9	via	via	IN	_	12	case
10	Cytochrome	Cytochrome	NNP	_	12	compound
11	P450	p450	NN	_	12	compound
12	3A	3a	NN	_	7	nmod
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	CYP3A	cyp3a	NN	_	12	appos
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	:	:	:	_	3	punct
17	The	the	DT	_	18	det
18	metabolism	metabolism	NN	_	34	nsubjpass
19	of	of	IN	_	20	case
20	drug2	drug2	NN	_	18	nmod
21	to	to	TO	_	26	case
22	the	the	DT	_	26	det
23	major	major	JJ	_	26	amod
24	circulating	circulate	VBG	_	26	amod
25	metabolite	metabolite	NN	_	26	compound
26	drug3	drug3	NN	_	18	nmod
27	and	and	CC	_	26	cc
28	the	the	DT	_	29	det
29	metabolism	metabolism	NN	_	26	conj
30	of	of	IN	_	32	case
31	other	other	JJ	_	32	amod
32	drug4	drug4	NN	_	29	nmod
33	is	be	VBZ	_	34	auxpass
34	catalyzed	catalyze	VBN	_	3	dep
35	by	by	IN	_	36	case
36	CYP3A	cyp3a	NN	_	34	nmod
37	.	.	.	_	1	punct

1	Consequently	consequently	RB	_	6	advmod
2	,	,	,	_	6	punct
3	drug1	drug1	NN	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	avoided	avoid	VBN	_	0	ROOT
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	receiving	receive	VBG	_	8	acl
10	drug2	drug2	NN	_	9	dobj
11	and	and	CC	_	10	cc
12	drug3	drug3	NN	_	10	conj
13	,	,	,	_	8	punct
14	which	which	WDT	_	18	nsubj
15	are	be	VBP	_	18	cop
16	very	very	RB	_	17	advmod
17	potent	potent	JJ	_	18	amod
18	inhibitors	inhibitor	NNS	_	8	acl:relcl
19	of	of	IN	_	20	case
20	CYP3A	cyp3a	NN	_	18	nmod
21	.	.	.	_	6	punct

1	With	with	IN	_	3	mark
2	drugs	drug	NNS	_	3	nsubj
3	inhibiting	inhibit	VBG	_	17	advcl
4	CYP3A	cyp3a	NN	_	3	dobj
5	to	to	TO	_	12	case
6	a	a	DT	_	12	det
7	lesser	lesser	JJR	_	12	amod
8	,	,	,	_	7	punct
9	but	but	CC	_	7	cc
10	still	still	RB	_	11	advmod
11	significant	significant	JJ	_	7	conj
12	degree	degree	NN	_	3	nmod
13	,	,	,	_	17	punct
14	drug1	drug1	NN	_	17	nsubjpass
15	should	should	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	used	use	VBN	_	0	ROOT
18	only	only	RB	_	20	advmod
19	with	with	IN	_	20	case
20	caution	caution	NN	_	17	nmod
21	and	and	CC	_	20	cc
22	consideration	consideration	NN	_	20	conj
23	of	of	IN	_	26	case
24	appropriate	appropriate	JJ	_	26	amod
25	dosage	dosage	NN	_	26	compound
26	reduction	reduction	NN	_	20	nmod
27	.	.	.	_	17	punct

1	The	the	DT	_	2	det
2	following	follow	VBG	_	4	nsubj
3	are	be	VBP	_	4	cop
4	examples	example	NNS	_	0	ROOT
5	of	of	IN	_	6	case
6	drugs	drug	NNS	_	4	nmod
7	known	know	VBN	_	6	acl
8	to	to	TO	_	9	mark
9	inhibit	inhibit	VB	_	7	xcomp
10	the	the	DT	_	11	det
11	metabolism	metabolism	NN	_	9	dobj
12	of	of	IN	_	15	case
13	other	other	JJ	_	15	amod
14	related	related	JJ	_	15	amod
15	drug1	drug1	NN	_	11	nmod
16	,	,	,	_	4	punct
17	presumably	presumably	RB	_	19	advmod
18	through	through	IN	_	19	case
19	inhibition	inhibition	NN	_	4	nmod
20	of	of	IN	_	21	case
21	CYP3A	cyp3a	NN	_	19	nmod
22	:	:	:	_	19	punct
23	drug2	drug2	NN	_	19	dep
24	,	,	,	_	23	punct
25	drug3	drug3	NN	_	23	conj
26	,	,	,	_	23	punct
27	drug4	drug4	NN	_	23	conj
28	,	,	,	_	23	punct
29	drug5	drug5	NN	_	23	conj
30	,	,	,	_	23	punct
31	drug6	drug6	NN	_	23	conj
32	,	,	,	_	23	punct
33	and	and	CC	_	23	cc
34	some	some	DT	_	35	det
35	drug7	drug7	NN	_	23	conj
36	.	.	.	_	4	punct

1	Drug	drug	NN	_	2	compound
2	Interaction	interaction	NN	_	0	ROOT
3	with	with	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	:	:	:	_	2	punct
6	A	a	DT	_	8	det
7	multiple-dose	multiple-dose	JJ	_	8	amod
8	study	study	NN	_	10	nsubjpass
9	was	be	VBD	_	10	auxpass
10	conducted	conduct	VBN	_	2	dep
11	to	to	TO	_	12	mark
12	assess	assess	VB	_	10	xcomp
13	the	the	DT	_	14	det
14	effect	effect	NN	_	12	dobj
15	of	of	IN	_	19	case
16	drug2	drug2	NN	_	19	compound
17	20	20	CD	_	18	compound
18	mg	mg	NN	_	19	amod
19	BID	BID	NNP	_	14	nmod
20	on	on	IN	_	22	case
21	the	the	DT	_	22	det
22	pharmacokinetics	pharmacokinetic	NNS	_	14	nmod
23	of	of	IN	_	26	case
24	drug3	drug3	NN	_	26	compound
25	2	2	CD	_	26	compound
26	mg	mg	NN	_	22	nmod
27	QHS	qhs	NN	_	26	amod
28	after	after	IN	_	30	case
29	seven	seven	CD	_	30	nummod
30	days	day	NNS	_	12	nmod
31	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	pharmacokinetics	pharmacokinetic	NNS	_	12	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	-LRB-	-lrb-	-LRB-	_	6	punct
6	Cmax	cmax	NN	_	4	dep
7	and	and	CC	_	6	cc
8	AUC	auc	NN	_	6	conj
9	-RRB-	-rrb-	-RRB-	_	6	punct
10	were	be	VBD	_	12	auxpass
11	not	not	RB	_	12	neg
12	affected	affect	VBN	_	0	ROOT
13	during	during	IN	_	15	case
14	multiple-dose	multiple-dose	JJ	_	15	amod
15	drug2	drug2	NN	_	12	nmod
16	,	,	,	_	12	punct
17	suggesting	suggest	VBG	_	12	xcomp
18	no	no	DT	_	22	neg
19	clinically	clinically	RB	_	20	advmod
20	significant	significant	JJ	_	22	amod
21	pharmacokinetic	pharmacokinetic	JJ	_	22	amod
22	interaction	interaction	NN	_	17	dobj
23	.	.	.	_	12	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Interaction	interaction	NN	_	1	dep
4	with	with	IN	_	6	case
5	Other	other	JJ	_	6	amod
6	Drugs	drug	NNS	_	3	nmod
7	that	that	WDT	_	9	nsubjpass
8	are	be	VBP	_	9	auxpass
9	Metabolized	metabolize	VBN	_	6	acl:relcl
10	by	by	IN	_	12	case
11	Cytochrome	cytochrome	NN	_	12	compound
12	P450	p450	NN	_	9	nmod
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	CYP	cyp	NN	_	12	appos
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	:	:	:	_	3	punct
17	At	at	IN	_	20	case
18	clinically	clinically	RB	_	19	advmod
19	relevant	relevant	JJ	_	20	amod
20	concentrations	concentration	NNS	_	25	nmod
21	,	,	,	_	20	punct
22	in	in	FW	_	24	amod
23	vitro	vitro	FW	_	22	dep
24	studies	study	NNS	_	25	nsubj
25	indicate	indicate	VBP	_	3	dep
26	that	that	IN	_	34	mark
27	drug2	drug2	NN	_	34	nsubj
28	-LRB-	-lrb-	-LRB-	_	30	punct
29	0.6	0.6	CD	_	30	nummod
30	M	m	NN	_	27	appos
31	-RRB-	-rrb-	-RRB-	_	30	punct
32	was	be	VBD	_	34	cop
33	not	not	RB	_	34	neg
34	inhibitory	inhibitory	JJ	_	25	ccomp
35	towards	towards	IN	_	40	case
36	the	the	DT	_	40	det
37	major	major	JJ	_	40	amod
38	cytochrome	cytochrome	NN	_	40	compound
39	P450	p450	NN	_	40	compound
40	isoforms	isoform	NNS	_	34	nmod
41	CYP1A2	cyp1a2	NN	_	40	dep
42	,	,	,	_	41	punct
43	CYP2A6	cyp2a6	NN	_	41	conj
44	,	,	,	_	41	punct
45	CYP2C9	cyp2c9	NN	_	41	conj
46	,	,	,	_	41	punct
47	CYP2C19	cyp2c19	NN	_	41	conj
48	,	,	,	_	41	punct
49	CYP2D6	cyp2d6	NN	_	41	conj
50	,	,	,	_	41	punct
51	CYP2E1	cyp2e1	NN	_	41	conj
52	,	,	,	_	41	punct
53	and	and	CC	_	41	cc
54	CYP3A	cyp3a	NN	_	41	conj
55	.	.	.	_	1	punct

1	Therefore	therefore	RB	_	13	advmod
2	,	,	,	_	13	punct
3	based	base	VBN	_	8	case
4	on	on	IN	_	8	case
5	these	these	DT	_	8	det
6	in	in	FW	_	8	amod
7	vitro	vitro	FW	_	6	dep
8	data	datum	NNS	_	13	advcl
9	,	,	,	_	13	punct
10	drug1	drug1	NN	_	13	nsubj
11	is	be	VBZ	_	13	cop
12	very	very	RB	_	13	advmod
13	unlikely	unlikely	JJ	_	0	ROOT
14	to	to	TO	_	15	mark
15	inhibit	inhibit	VB	_	13	xcomp
16	the	the	DT	_	17	det
17	biotransformation	biotransformation	NN	_	15	dobj
18	of	of	IN	_	20	case
19	other	other	JJ	_	20	amod
20	drugs	drug	NNS	_	17	nmod
21	metabolized	metabolize	VBN	_	20	acl
22	by	by	IN	_	25	case
23	these	these	DT	_	25	det
24	CYP	cyp	NN	_	25	compound
25	isoforms	isoform	NNS	_	21	nmod

1	.	.	.	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Elevated	elevated	JJ	_	5	amod
4	drug2	drug2	NN	_	5	compound
5	levels	level	NNS	_	8	nsubjpass
6	have	have	VBP	_	8	aux
7	been	be	VBN	_	8	auxpass
8	reported	report	VBN	_	1	appos
9	in	in	IN	_	10	mark
10	postmarketing	postmarket	VBG	_	8	advcl
11	experience	experience	NN	_	10	dobj
12	when	when	WRB	_	15	advmod
13	drug3	drug3	NN	_	15	nsubjpass
14	is	be	VBZ	_	15	auxpass
15	administered	administer	VBN	_	10	advcl
16	concomitantly	concomitantly	RB	_	15	advmod
17	.	.	.	_	1	punct

1	Drug	drug	NN	_	2	compound
2	monitoring	monitoring	NN	_	6	nsubj
3	may	may	MD	_	6	aux
4	be	be	VB	_	6	cop
5	of	of	IN	_	6	case
6	assistance	assistance	NN	_	0	ROOT
7	in	in	IN	_	8	mark
8	detecting	detect	VBG	_	6	acl
9	alterations	alteration	NNS	_	8	dobj
10	in	in	IN	_	13	case
11	drug1	drug1	NN	_	13	compound
12	plasma	plasma	NN	_	13	compound
13	concentrations	concentration	NNS	_	9	nmod
14	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	:	:	:	_	1	punct
5	Increased	increase	VBN	_	7	amod
6	prothrombin	prothrombin	NN	_	7	compound
7	time	time	NN	_	17	nsubjpass
8	,	,	,	_	7	punct
9	with	with	IN	_	13	nmod
10	or	or	CC	_	9	cc
11	without	without	IN	_	9	conj
12	clinical	clinical	JJ	_	13	amod
13	bleeding	bleeding	NN	_	7	nmod
14	,	,	,	_	7	punct
15	has	have	VBZ	_	17	aux
16	been	be	VBN	_	17	auxpass
17	reported	report	VBN	_	1	dep
18	when	when	WRB	_	21	advmod
19	drug3	drug3	NN	_	21	nsubjpass
20	is	be	VBZ	_	21	auxpass
21	administered	administer	VBN	_	17	advcl
22	concomitantly	concomitantly	RB	_	21	advmod
23	.	.	.	_	1	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	3	amod
2	Test	test	NN	_	3	compound
3	Interactions	interaction	NNS	_	0	ROOT
4	A	a	DT	_	6	det
5	false-positive	false-positive	JJ	_	6	amod
6	reaction	reaction	NN	_	13	nsubj
7	for	for	IN	_	8	case
8	ketones	ketone	NNS	_	6	nmod
9	in	in	IN	_	11	case
10	the	the	DT	_	11	det
11	urine	urine	NN	_	8	nmod
12	may	may	MD	_	13	aux
13	occur	occur	VB	_	3	acl:relcl
14	with	with	IN	_	15	case
15	tests	test	NNS	_	13	nmod
16	using	use	VBG	_	15	acl
17	drug1	drug1	NN	_	16	dobj
18	but	but	CC	_	17	cc
19	not	not	RB	_	21	neg
20	with	with	IN	_	21	case
21	those	those	DT	_	17	conj
22	using	use	VBG	_	21	acl
23	drug2	drug2	NN	_	22	dobj
24	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	administration	administration	NN	_	6	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	may	may	MD	_	6	aux
6	result	result	VB	_	0	ROOT
7	in	in	IN	_	10	case
8	a	a	DT	_	10	det
9	false-positive	false-positive	JJ	_	10	amod
10	reaction	reaction	NN	_	6	nmod
11	for	for	IN	_	12	case
12	glucose	glucose	NN	_	10	nmod
13	in	in	IN	_	15	case
14	the	the	DT	_	15	det
15	urine	urine	NN	_	12	nmod
16	using	use	VBG	_	10	acl
17	Clinitest	Clinitest	NNP	_	18	compound
18	**	**	SYM	_	16	dobj
19	,	,	,	_	6	punct
20	Benedict	Benedict	NNP	_	22	compound
21	s	be	VBZ	_	22	compound
22	solution	solution	NN	_	19	root
23	,	,	,	_	22	punct
24	or	or	CC	_	22	cc
25	Fehling	fehling	NN	_	27	compound
26	s	s	NNS	_	27	compound
27	solution	solution	NN	_	22	conj
28	.	.	.	_	22	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	recommended	recommend	VBN	_	0	ROOT
4	that	that	IN	_	23	mark
5	glucose	glucose	NN	_	6	compound
6	tests	test	NNS	_	23	nsubjpass
7	based	base	VBN	_	12	case
8	on	on	IN	_	12	case
9	enzymatic	enzymatic	JJ	_	12	amod
10	glucose	glucose	NN	_	12	compound
11	oxidase	oxidase	NN	_	12	compound
12	reactions	reaction	NNS	_	6	nmod
13	-LRB-	-lrb-	-LRB-	_	16	punct
14	such	such	JJ	_	16	case
15	as	as	IN	_	14	mwe
16	Clinistix	Clinistix	NNP	_	12	nmod
17	**	**	SYM	_	16	dep
18	or	or	CC	_	17	cc
19	Tes-Tape	tes-tape	JJ	_	17	conj
20	**	**	SYM	_	17	dep
21	-RRB-	-rrb-	-RRB-	_	16	punct
22	be	be	VB	_	23	auxpass
23	used	use	VBN	_	3	ccomp
24	.	.	.	_	3	punct

1	A	a	DT	_	5	det
2	false-positive	false-positive	JJ	_	5	amod
3	direct	direct	JJ	_	5	amod
4	Coombs	coomb	NNS	_	5	compound
5	test	test	NN	_	8	nsubjpass
6	has	have	VBZ	_	8	aux
7	been	be	VBN	_	8	auxpass
8	reported	report	VBN	_	0	ROOT
9	during	during	IN	_	10	case
10	treatment	treatment	NN	_	8	nmod
11	with	with	IN	_	13	case
12	other	other	JJ	_	13	amod
13	drug1	drug1	NN	_	10	nmod
14	;	;	:	_	8	punct

1	therefore	therefore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	it	it	PRP	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	recognized	recognize	VBN	_	0	ROOT
7	that	that	IN	_	17	mark
8	a	a	DT	_	11	det
9	positive	positive	JJ	_	11	amod
10	Coombs	Coombs	NNP	_	11	compound
11	test	test	NN	_	17	nsubj
12	may	may	MD	_	17	aux
13	be	be	VB	_	17	cop
14	due	due	JJ	_	17	case
15	to	to	TO	_	14	mwe
16	the	the	DT	_	17	det
17	drug	drug	NN	_	6	ccomp
18	.	.	.	_	6	punct

1	drug1	drug1	NN	_	4	nsubj
2	is	be	VBZ	_	4	cop
3	an	a	DT	_	4	det
4	inhibitor	inhibitor	NN	_	0	ROOT
5	of	of	IN	_	6	case
6	CYP3A	cyp3a	NN	_	4	nmod
7	-LRB-	-lrb-	-LRB-	_	10	punct
8	cytochrome	cytochrome	NN	_	10	compound
9	P450	p450	NN	_	10	compound
10	3A	3a	NN	_	6	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	.	.	.	_	4	punct

1	Coadministration	coadministration	NN	_	16	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	drugs	drug	NNS	_	3	conj
6	primarily	primarily	RB	_	7	advmod
7	metabolized	metabolize	VBN	_	1	acl
8	by	by	IN	_	9	case
9	CYP3A	cyp3a	NN	_	7	nmod
10	-LRB-	-lrb-	-LRB-	_	13	punct
11	e.g.	e.g.	FW	_	13	dep
12	,	,	,	_	13	punct
13	drug2	drug2	NN	_	9	appos
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	may	may	MD	_	16	aux
16	result	result	VB	_	0	ROOT
17	in	in	IN	_	20	case
18	increased	increase	VBN	_	20	amod
19	plasma	plasma	NN	_	20	compound
20	concentrations	concentration	NNS	_	16	nmod
21	of	of	IN	_	24	case
22	the	the	DT	_	24	det
23	other	other	JJ	_	24	amod
24	drug	drug	NN	_	20	nmod
25	that	that	WDT	_	27	nsubj
26	could	could	MD	_	27	aux
27	increase	increase	VB	_	24	acl:relcl
28	or	or	CC	_	27	cc
29	prolong	prolong	VB	_	27	conj
30	both	both	DT	_	35	det:predet
31	its	its	PRP$	_	35	nmod:poss
32	therapeutic	therapeutic	JJ	_	35	amod
33	and	and	CC	_	32	cc
34	adverse	adverse	JJ	_	32	conj
35	effects	effect	NNS	_	27	dobj
36	.	.	.	_	16	punct

1	drug1	drug1	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	metabolized	metabolize	VBN	_	0	ROOT
4	in	in	IN	_	5	case
5	proof	proof	NN	_	3	nmod
6	by	by	IN	_	7	case
7	C.P.A.	C.P.A.	NNP	_	5	nmod

1	Coadministration	coadministration	NN	_	10	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	drugs	drug	NNS	_	3	conj
6	that	that	WDT	_	7	nsubj
7	induce	induce	VBP	_	1	acl:relcl
8	CYP3A	cyp3a	NN	_	7	dobj
9	may	may	MD	_	10	aux
10	decrease	decrease	VB	_	0	ROOT
11	drug2	drug2	NN	_	13	compound
12	plasma	plasma	NN	_	13	compound
13	concentrations	concentration	NNS	_	10	dobj
14	and	and	CC	_	10	cc
15	reduce	reduce	VB	_	10	conj
16	its	its	PRP$	_	18	nmod:poss
17	therapeutic	therapeutic	JJ	_	18	amod
18	effect	effect	NN	_	15	dobj
19	.	.	.	_	10	punct

1	Coadministration	coadministration	NN	_	10	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	drugs	drug	NNS	_	3	conj
6	that	that	WDT	_	7	nsubj
7	inhibit	inhibit	VBP	_	1	acl:relcl
8	CYP3A	cyp3a	NN	_	7	dobj
9	may	may	MD	_	10	aux
10	increase	increase	VB	_	0	ROOT
11	drug2	drug2	NN	_	13	compound
12	plasma	plasma	NN	_	13	compound
13	concentrations	concentration	NNS	_	10	dobj
14	.	.	.	_	10	punct

1	Based	base	VBN	_	5	case
2	on	on	IN	_	5	case
3	known	known	JJ	_	5	amod
4	metabolic	metabolic	JJ	_	5	amod
5	profiles	profile	NNS	_	13	advcl
6	,	,	,	_	13	punct
7	clinically	clinically	RB	_	8	advmod
8	significant	significant	JJ	_	10	amod
9	drug	drug	NN	_	10	compound
10	interactions	interaction	NNS	_	13	nsubjpass
11	are	be	VBP	_	13	auxpass
12	not	not	RB	_	13	neg
13	expected	expect	VBN	_	0	ROOT
14	between	between	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	drug2	drug2	NN	_	15	conj
18	,	,	,	_	15	punct
19	drug3	drug3	NN	_	21	compound
20	/	/	:	_	21	punct
21	drug4	drug4	NN	_	15	conj
22	,	,	,	_	15	punct
23	drug5	drug5	NN	_	15	conj
24	,	,	,	_	15	punct
25	drug6	drug6	NN	_	15	conj
26	,	,	,	_	15	punct
27	drug7	drug7	NN	_	15	conj
28	or	or	CC	_	15	cc
29	drug8	drug8	NN	_	15	conj
30	.	.	.	_	13	punct

1	Drugs	drug	NNS	_	0	ROOT
2	That	that	WDT	_	6	nsubj
3	Should	should	MD	_	6	aux
4	Not	not	RB	_	6	neg
5	Be	be	VB	_	6	cop
6	Coadministered	coadministered	JJ	_	1	acl:relcl
7	With	with	IN	_	9	case
8	drug1	drug1	NN	_	9	compound
9	drug2	drug2	NN	_	6	nmod
10	:	:	:	_	1	punct
11	drug3	drug3	NN	_	1	dep
12	,	,	,	_	11	punct
13	drug4	drug4	NN	_	14	compound
14	drug5	drug5	NN	_	11	appos
15	:	:	:	_	11	punct
16	drug6	drug6	NN	_	11	dep
17	,	,	,	_	16	punct
18	drug7	drug7	NN	_	19	compound
19	Antimigraine	antimigraine	NN	_	16	appos
20	:	:	:	_	16	punct
21	drug8	drug8	NN	_	22	compound
22	drug9	drug9	NN	_	16	dep
23	:	:	:	_	22	punct
24	drug10	drug10	NN	_	26	compound
25	drug11	drug11	NN	_	26	compound
26	drug12	drug12	NN	_	22	dep
27	,	,	,	_	26	punct
28	drug13	drug13	NN	_	31	compound
29	GI	gi	NN	_	31	compound
30	motility	motility	NN	_	31	compound
31	agents	agent	NNS	_	26	appos
32	:	:	:	_	1	punct
33	drug14	drug14	NN	_	1	dep

1	Drugs	drug	NNS	_	0	ROOT
2	Which	which	WDT	_	3	nsubj
3	Require	require	VBP	_	1	acl:relcl
4	a	a	DT	_	6	det
5	Dose	Dose	NNP	_	6	compound
6	Reduction	Reduction	NNP	_	3	dobj
7	When	when	WRB	_	8	advmod
8	Coadminstered	coadminstered	JJ	_	3	advcl
9	With	with	IN	_	11	case
10	drug1	drug1	NN	_	11	compound
11	drug2	drug2	NN	_	8	nmod
12	:	:	:	_	1	punct
13	drug3	drug3	NN	_	1	dep

1	*	*	SYM	_	3	dep
2	This	this	DT	_	3	det
3	table	table	NN	_	7	nsubj
4	is	be	VBZ	_	7	cop
5	not	not	RB	_	7	neg
6	all	all	DT	_	7	advmod
7	inclusive	inclusive	JJ	_	0	ROOT
8	**	**	SYM	_	9	dep
9	drug1	drug1	NN	_	13	nsubj
10	may	may	MD	_	13	aux
11	not	not	RB	_	13	neg
12	be	be	VB	_	13	cop
13	effective	effective	JJ	_	7	acl:relcl
14	due	due	JJ	_	19	case
15	to	to	TO	_	19	case
16	decreased	decrease	VBN	_	19	amod
17	drug2	drug2	NN	_	19	compound
18	plasma	plasma	NN	_	19	compound
19	concentrations	concentration	NNS	_	13	advcl
20	in	in	IN	_	21	case
21	patients	patient	NNS	_	19	nmod
22	taking	take	VBG	_	21	acl
23	these	these	DT	_	24	det
24	agents	agent	NNS	_	22	dobj
25	concomitantly	concomitantly	RB	_	13	advmod

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Administration	administration	NN	_	8	nsubj
4	of	of	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	with	with	IN	_	7	case
7	drug3	drug3	NN	_	3	nmod
8	resulted	result	VBD	_	1	appos
9	in	in	IN	_	11	case
10	the	the	DT	_	11	det
11	appearance	appearance	NN	_	8	nmod
12	of	of	IN	_	14	case
13	unchanged	unchanged	JJ	_	14	amod
14	drug4	drug4	NN	_	11	nmod
15	in	in	IN	_	16	case
16	plasma	plasma	NN	_	11	nmod
17	;	;	:	_	1	punct

1	therefore	therefore	RB	_	7	advmod
2	,	,	,	_	7	punct
3	drug1	drug1	NN	_	7	nsubjpass
4	should	should	MD	_	7	aux
5	not	not	RB	_	7	neg
6	be	be	VB	_	7	auxpass
7	administered	administer	VBN	_	0	ROOT
8	concurrently	concurrently	RB	_	7	advmod
9	with	with	IN	_	10	case
10	drug2	drug2	NN	_	7	nmod
11	because	because	IN	_	14	case
12	of	of	IN	_	11	mwe
13	the	the	DT	_	14	det
14	potential	potential	NN	_	7	nmod
15	for	for	IN	_	20	case
16	serious	serious	JJ	_	20	amod
17	and/or	and/or	CC	_	16	cc
18	life-threatening	life-threatening	JJ	_	16	conj
19	cardiac	cardiac	JJ	_	20	amod
20	arrhythmias	arrhythmia	NNS	_	14	nmod
21	.	.	.	_	7	punct

1	Because	because	IN	_	6	mark
2	a	a	DT	_	4	det
3	similar	similar	JJ	_	4	amod
4	interaction	interaction	NN	_	6	nsubj
5	is	be	VBZ	_	6	cop
6	likely	likely	RB	_	13	advcl
7	,	,	,	_	13	punct
8	drug1	drug1	NN	_	13	nsubjpass
9	should	should	MD	_	13	aux
10	also	also	RB	_	13	advmod
11	not	not	RB	_	13	neg
12	be	be	VB	_	13	auxpass
13	administered	administer	VBN	_	0	ROOT
14	concurrently	concurrently	RB	_	13	advmod
15	with	with	IN	_	16	case
16	drug2	drug2	NN	_	13	nmod
17	.	.	.	_	13	punct

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Coadministration	coadministration	NN	_	8	nsubj
4	of	of	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	with	with	IN	_	7	case
7	drug3	drug3	NN	_	3	nmod
8	resulted	result	VBD	_	1	dep
9	in	in	IN	_	13	case
10	an	a	DT	_	13	det
11	83	83	CD	_	12	compound
12	%	%	NN	_	13	amod
13	increase	increase	NN	_	8	nmod
14	in	in	IN	_	17	case
15	drug4	drug4	NN	_	17	compound
16	plasma	plasma	NN	_	17	compound
17	AUC	auc	NN	_	13	nmod
18	and	and	CC	_	13	cc
19	a	a	DT	_	22	det
20	51	51	CD	_	21	compound
21	%	%	NN	_	22	amod
22	increase	increase	NN	_	13	conj
23	in	in	IN	_	26	case
24	drug5	drug5	NN	_	26	compound
25	plasma	plasma	NN	_	26	compound
26	A.C.	A.C.	NNP	_	22	nmod

1	Currently	currently	RB	_	4	advmod
2	,	,	,	_	4	punct
3	there	there	EX	_	4	expl
4	are	be	VBP	_	0	ROOT
5	no	no	DT	_	6	neg
6	safety	safety	NN	_	4	nsubj
7	and	and	CC	_	6	cc
8	efficacy	efficacy	NN	_	9	compound
9	data	datum	NNS	_	6	conj
10	available	available	JJ	_	6	amod
11	from	from	IN	_	13	case
12	the	the	DT	_	13	det
13	use	use	NN	_	10	nmod
14	of	of	IN	_	16	case
15	this	this	DT	_	16	det
16	combination	combination	NN	_	13	nmod
17	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Coadministration	coadministration	NN	_	8	nsubj
4	of	of	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	with	with	IN	_	7	case
7	drug3	drug3	NN	_	3	nmod
8	resulted	result	VBD	_	1	dep
9	in	in	IN	_	13	case
10	a	a	DT	_	13	det
11	152	152	CD	_	12	compound
12	%	%	NN	_	13	amod
13	increase	increase	NN	_	8	nmod
14	in	in	IN	_	17	case
15	drug4	drug4	NN	_	17	compound
16	plasma	plasma	NN	_	17	compound
17	AUC	auc	NN	_	13	nmod
18	and	and	CC	_	8	cc
19	very	very	RB	_	20	advmod
20	little	little	JJ	_	21	amod
21	change	change	NN	_	8	conj
22	in	in	IN	_	25	case
23	drug5	drug5	NN	_	25	compound
24	plasma	plasma	NN	_	25	compound
25	A.C.	A.C.	NNP	_	21	nmod

1	Currently	currently	RB	_	4	advmod
2	,	,	,	_	4	punct
3	there	there	EX	_	4	expl
4	are	be	VBP	_	0	ROOT
5	no	no	DT	_	6	neg
6	safety	safety	NN	_	4	nsubj
7	and	and	CC	_	6	cc
8	efficacy	efficacy	NN	_	9	compound
9	data	datum	NNS	_	6	conj
10	available	available	JJ	_	6	amod
11	from	from	IN	_	13	case
12	the	the	DT	_	13	det
13	use	use	NN	_	10	nmod
14	of	of	IN	_	16	case
15	this	this	DT	_	16	det
16	combination	combination	NN	_	13	nmod
17	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Coadministration	coadministration	NN	_	19	nsubj
4	of	of	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	using	use	VBG	_	3	dep
8	an	a	DT	_	12	det
9	experimental	experimental	JJ	_	12	amod
10	soft-gelatin	soft-gelatin	JJ	_	12	amod
11	capsule	capsule	NN	_	12	compound
12	formulation	formulation	NN	_	7	dobj
13	of	of	IN	_	15	case
14	drug3	drug3	NN	_	15	compound
15	1200mg	1200mg	NN	_	12	nmod
16	-RRB-	-rrb-	-RRB-	_	7	punct
17	with	with	IN	_	18	case
18	drug4	drug4	NN	_	3	nmod
19	resulted	result	VBD	_	1	appos
20	in	in	IN	_	24	case
21	an	a	DT	_	24	det
22	18	18	CD	_	23	compound
23	%	%	NN	_	24	amod
24	increase	increase	NN	_	19	nmod
25	in	in	IN	_	28	case
26	drug5	drug5	NN	_	28	compound
27	plasma	plasma	NN	_	28	compound
28	AUC	auc	NN	_	24	nmod
29	and	and	CC	_	24	cc
30	a	a	DT	_	32	det
31	4-fold	4-fold	JJ	_	32	amod
32	increase	increase	NN	_	24	conj
33	in	in	IN	_	36	case
34	drug6	drug6	NN	_	36	compound
35	plasma	plasma	NN	_	36	compound
36	A.C.	A.C.	NNP	_	32	nmod
37	.	.	.	_	1	punct

1	If	if	IN	_	2	mark
2	used	use	VBN	_	23	advcl
3	in	in	IN	_	4	case
4	combination	combination	NN	_	2	nmod
5	with	with	IN	_	9	case
6	drug1	drug1	NN	_	9	compound
7	hard	hard	JJ	_	9	amod
8	gelatin	gelatin	NN	_	9	compound
9	capsules	capsule	NNS	_	4	nmod
10	at	at	IN	_	13	case
11	the	the	DT	_	13	det
12	recommended	recommend	VBN	_	13	amod
13	dose	dose	NN	_	9	nmod
14	of	of	IN	_	17	case
15	600	600	CD	_	17	nummod
16	mg	mg	NN	_	17	compound
17	tid	tid	NN	_	13	nmod
18	,	,	,	_	23	punct
19	no	no	DT	_	21	neg
20	dose	dose	NN	_	21	compound
21	adjustments	adjustment	NNS	_	23	nsubjpass
22	are	be	VBP	_	23	auxpass
23	needed	need	VBN	_	0	ROOT
24	.	.	.	_	23	punct

1	Currently	currently	RB	_	4	advmod
2	,	,	,	_	4	punct
3	there	there	EX	_	4	expl
4	are	be	VBP	_	0	ROOT
5	no	no	DT	_	6	neg
6	safety	safety	NN	_	4	nsubj
7	and	and	CC	_	6	cc
8	efficacy	efficacy	NN	_	9	compound
9	data	datum	NNS	_	6	conj
10	available	available	JJ	_	6	amod
11	from	from	IN	_	13	case
12	the	the	DT	_	13	det
13	use	use	NN	_	10	nmod
14	of	of	IN	_	16	case
15	this	this	DT	_	16	det
16	combination	combination	NN	_	13	nmod
17	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Coadministration	coadministration	NN	_	8	nsubj
4	of	of	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	with	with	IN	_	7	case
7	drug3	drug3	NN	_	3	nmod
8	resulted	result	VBD	_	1	appos
9	in	in	IN	_	13	case
10	a	a	DT	_	13	det
11	35	35	CD	_	12	compound
12	%	%	NN	_	13	amod
13	increase	increase	NN	_	8	nmod
14	in	in	IN	_	17	case
15	drug4	drug4	NN	_	17	compound
16	plasma	plasma	NN	_	17	compound
17	A.C.	A.C.	NNP	_	13	nmod
18	.	.	.	_	1	punct

1	This	this	DT	_	2	det
2	change	change	NN	_	5	nsubjpass
3	was	be	VBD	_	5	auxpass
4	not	not	RB	_	5	neg
5	considered	consider	VBN	_	0	ROOT
6	clinically	clinically	RB	_	7	advmod
7	significant	significant	JJ	_	5	xcomp
8	and	and	CC	_	7	cc
9	no	no	DT	_	11	neg
10	dose	dose	NN	_	11	compound
11	adjustment	adjustment	NN	_	7	conj
12	is	be	VBZ	_	13	auxpass
13	needed	need	VBN	_	5	xcomp
14	when	when	WRB	_	19	advmod
15	drug1	drug1	NN	_	19	nsubjpass
16	and	and	CC	_	15	cc
17	drug2	drug2	NN	_	15	conj
18	are	be	VBP	_	19	auxpass
19	coadministered	coadminister	VBN	_	13	advcl
20	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	It	it	PRP	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	recommended	recommend	VBN	_	1	appos
6	that	that	IN	_	9	mark
7	drug2	drug2	NN	_	9	nsubjpass
8	be	be	VB	_	9	auxpass
9	administered	administer	VBN	_	5	ccomp
10	on	on	IN	_	13	case
11	an	a	DT	_	13	det
12	empty	empty	JJ	_	13	amod
13	stomach	stomach	NN	_	9	nmod
14	;	;	:	_	1	punct

1	therefore	therefore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	drug1	drug1	NN	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	administered	administer	VBN	_	0	ROOT
7	-LRB-	-lrb-	-LRB-	_	9	punct
8	with	with	IN	_	9	case
9	food	food	NN	_	6	dep
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	one	one	CD	_	12	nummod
12	hour	hour	NN	_	6	dobj
13	after	after	IN	_	18	case
14	or	or	CC	_	18	cc
15	more	more	JJR	_	17	advmod
16	than	than	IN	_	15	mwe
17	two	two	CD	_	18	nummod
18	hours	hour	NNS	_	12	nmod
19	before	before	IN	_	20	case
20	drug2	drug2	NN	_	6	nmod
21	.	.	.	_	6	punct

1	A	a	DT	_	3	det
2	dose	dose	NN	_	3	compound
3	adjustment	adjustment	NN	_	6	nsubjpass
4	is	be	VBZ	_	6	auxpass
5	not	not	RB	_	6	neg
6	needed	need	VBN	_	0	ROOT
7	when	when	WRB	_	10	advmod
8	drug1	drug1	NN	_	10	nsubjpass
9	is	be	VBZ	_	10	auxpass
10	administered	administer	VBN	_	6	advcl
11	with	with	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	.	.	.	_	6	punct

1	Little	little	JJ	_	12	nsubjpass
2	or	or	CC	_	1	cc
3	no	no	DT	_	1	conj
4	change	change	NN	_	1	dep
5	in	in	IN	_	7	case
6	the	the	DT	_	7	det
7	pharmacokinetics	pharmacokinetic	NNS	_	1	nmod
8	of	of	IN	_	10	case
9	either	either	CC	_	10	det
10	drug	drug	NN	_	7	nmod
11	was	be	VBD	_	12	auxpass
12	observed	observe	VBN	_	0	ROOT
13	when	when	WRB	_	16	advmod
14	drug1	drug1	NN	_	16	nsubjpass
15	was	be	VBD	_	16	auxpass
16	coadministered	coadminister	VBN	_	12	advcl
17	with	with	IN	_	18	case
18	drug2	drug2	NN	_	16	nmod
19	or	or	CC	_	18	cc
20	drug3	drug3	NN	_	18	conj
21	.	.	.	_	12	punct

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Coadministration	coadministration	NN	_	8	nsubj
4	of	of	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug3	drug3	NN	_	5	conj
8	resulted	result	VBD	_	1	appos
9	in	in	IN	_	13	case
10	a	a	DT	_	13	det
11	32	32	CD	_	12	compound
12	%	%	NN	_	13	amod
13	decrease	decrease	NN	_	8	nmod
14	in	in	IN	_	17	case
15	drug4	drug4	NN	_	17	compound
16	plasma	plasma	NN	_	17	compound
17	AUC	auc	NN	_	13	nmod
18	and	and	CC	_	13	cc
19	a	a	DT	_	22	det
20	207	207	CD	_	21	compound
21	%	%	NN	_	22	amod
22	increase	increase	NN	_	13	conj
23	in	in	IN	_	26	case
24	drug5	drug5	NN	_	26	compound
25	plasma	plasma	NN	_	26	compound
26	A.C.	A.C.	NNP	_	22	nmod
27	.	.	.	_	1	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	recommended	recommend	VBN	_	0	ROOT
4	that	that	IN	_	10	mark
5	the	the	DT	_	6	det
6	dose	dose	NN	_	10	nsubjpass
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	be	be	VB	_	10	auxpass
10	reduced	reduce	VBN	_	3	ccomp
11	to	to	TO	_	12	case
12	one-half	one-half	NN	_	10	nmod
13	the	the	DT	_	15	det
14	usual	usual	JJ	_	15	amod
15	dose	dose	NN	_	10	dobj
16	when	when	WRB	_	17	advmod
17	administered	administer	VBN	_	10	advcl
18	with	with	IN	_	19	case
19	drug2	drug2	NN	_	17	nmod
20	.	.	.	_	3	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Coadministration	coadministration	NN	_	8	nsubj
4	of	of	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug3	drug3	NN	_	5	conj
8	resulted	result	VBD	_	1	appos
9	in	in	IN	_	13	case
10	an	a	DT	_	13	det
11	82	82	CD	_	12	compound
12	%	%	NN	_	13	amod
13	decrease	decrease	NN	_	8	nmod
14	in	in	IN	_	17	case
15	drug4	drug4	NN	_	17	compound
16	plasma	plasma	NN	_	17	compound
17	A.C.	A.C.	NNP	_	13	nmod

1	drug1	drug1	NN	_	7	nsubjpass
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	should	should	MD	_	7	aux
5	not	not	RB	_	7	neg
6	be	be	VB	_	7	auxpass
7	coadministered	coadminister	VBN	_	0	ROOT
8	.	.	.	_	7	punct

1	Oral	oral	JJ	_	2	amod
2	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	:	:	:	_	1	punct
5	Coadministration	coadministration	NN	_	10	nsubj
6	of	of	IN	_	7	case
7	drug3	drug3	NN	_	5	nmod
8	with	with	IN	_	9	case
9	drug4	drug4	NN	_	5	nmod
10	resulted	result	VBD	_	1	dep
11	in	in	IN	_	15	case
12	a	a	DT	_	15	det
13	47	47	CD	_	14	compound
14	%	%	NN	_	15	amod
15	decrease	decrease	NN	_	10	nmod
16	in	in	IN	_	17	case
17	drug5	drug5	NN	_	15	nmod
18	and	and	CC	_	15	cc
19	an	a	DT	_	22	det
20	18	18	CD	_	21	compound
21	%	%	NN	_	22	amod
22	decrease	decrease	NN	_	15	conj
23	in	in	IN	_	26	case
24	drug6	drug6	NN	_	26	compound
25	plasma	plasma	NN	_	26	compound
26	concentrations	concentration	NNS	_	22	nmod
27	.	.	.	_	1	punct

1	Alternate	alternate	JJ	_	5	amod
2	or	or	CC	_	1	cc
3	additional	additional	JJ	_	1	conj
4	contraceptive	contraceptive	JJ	_	5	amod
5	measures	measure	NNS	_	8	nsubjpass
6	should	should	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	used	use	VBN	_	0	ROOT
9	during	during	IN	_	10	case
10	therapy	therapy	NN	_	8	nmod
11	with	with	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod

1	Specific	specific	JJ	_	4	amod
2	drug	drug	NN	_	4	compound
3	interaction	interaction	NN	_	4	compound
4	studies	study	NNS	_	8	nsubjpass
5	have	have	VBP	_	8	aux
6	not	not	RB	_	8	neg
7	been	be	VBN	_	8	auxpass
8	conducted	conduct	VBN	_	0	ROOT
9	with	with	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	.	.	.	_	8	punct

1	However	however	RB	_	5	advmod
2	,	,	,	_	5	punct
3	it	it	PRP	_	5	nsubjpass
4	was	be	VBD	_	5	auxpass
5	observed	observe	VBN	_	0	ROOT
6	that	that	IN	_	12	mark
7	the	the	DT	_	8	det
8	pharmacokinetics	pharmacokinetic	NNS	_	12	nsubj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	was	be	VBD	_	12	cop
12	unaltered	unaltered	JJ	_	5	ccomp
13	by	by	IN	_	15	case
14	concomitant	concomitant	JJ	_	15	amod
15	drug2	drug2	NN	_	12	nmod
16	in	in	IN	_	19	case
17	rheumatoid	rheumatoid	JJ	_	19	amod
18	arthritis	arthritis	NN	_	19	compound
19	patients	patient	NNS	_	12	nmod
20	.	.	.	_	5	punct

1	In	in	IN	_	3	case
2	a	a	DT	_	3	det
3	study	study	NN	_	32	nmod
4	in	in	IN	_	5	case
5	which	which	WDT	_	11	nmod
6	patients	patient	NNS	_	11	nsubjpass
7	with	with	IN	_	9	case
8	active	active	JJ	_	9	amod
9	RA	ra	NN	_	6	nmod
10	were	be	VBD	_	11	auxpass
11	treated	treat	VBN	_	3	acl:relcl
12	for	for	IN	_	16	case
13	up	up	RB	_	15	dep
14	to	to	TO	_	13	mwe
15	24	24	CD	_	16	nummod
16	weeks	week	NNS	_	11	nmod
17	with	with	IN	_	19	case
18	concurrent	concurrent	JJ	_	19	amod
19	drug1	drug1	NN	_	16	nmod
20	and	and	CC	_	19	cc
21	drug2	drug2	NN	_	22	compound
22	therapy	therapy	NN	_	19	conj
23	,	,	,	_	32	punct
24	a	a	DT	_	27	det
25	7	7	CD	_	26	compound
26	%	%	NN	_	27	amod
27	rate	rate	NN	_	32	nsubjpass
28	of	of	IN	_	30	case
29	serious	serious	JJ	_	30	amod
30	infections	infection	NNS	_	27	nmod
31	was	be	VBD	_	32	auxpass
32	observed	observe	VBN	_	0	ROOT
33	,	,	,	_	32	punct
34	which	which	WDT	_	36	nsubj
35	was	be	VBD	_	36	cop
36	higher	higher	JJR	_	32	ccomp
37	than	than	IN	_	38	case
38	that	that	DT	_	36	nmod
39	observed	observe	VBN	_	38	acl
40	with	with	IN	_	41	case
41	drug3	drug3	NN	_	39	nmod
42	alone	alone	RB	_	41	advmod
43	-LRB-	-lrb-	-LRB-	_	45	punct
44	0	0	CD	_	45	nummod
45	%	%	NN	_	41	appos
46	-RRB-	-rrb-	-RRB-	_	45	punct
47	.	.	.	_	32	punct

1	Two	two	CD	_	2	nummod
2	percent	percent	NN	_	11	nsubj
3	of	of	IN	_	4	case
4	patients	patient	NNS	_	2	nmod
5	treated	treat	VBN	_	4	acl
6	concurrently	concurrently	RB	_	5	advmod
7	with	with	IN	_	8	case
8	drug1	drug1	NN	_	5	nmod
9	and	and	CC	_	8	cc
10	drug2	drug2	NN	_	8	conj
11	developed	develop	VBD	_	0	ROOT
12	neutropenia	neutropenia	NN	_	11	dobj
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	ANC	ANC	NNP	_	12	appos
15	1	1	CD	_	14	nummod
16	x	x	CC	_	14	cc
17	109/L	109/l	CD	_	14	nummod
18	-RRB-	-rrb-	-RRB-	_	14	punct
19	.	.	.	_	11	punct

1	Patients	patient	NNS	_	21	nsubjpass
2	in	in	IN	_	5	case
3	a	a	DT	_	5	det
4	clinical	clinical	JJ	_	5	amod
5	study	study	NN	_	1	nmod
6	who	who	WP	_	10	nsubj
7	were	be	VBD	_	10	cop
8	on	on	IN	_	10	case
9	established	established	JJ	_	10	amod
10	therapy	therapy	NN	_	5	acl:relcl
11	with	with	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	,	,	,	_	12	punct
14	to	to	TO	_	15	case
15	which	which	WDT	_	18	nmod
16	drug2	drug2	NN	_	18	nsubjpass
17	was	be	VBD	_	18	auxpass
18	added	add	VBN	_	12	acl:relcl
19	,	,	,	_	1	punct
20	were	be	VBD	_	21	auxpass
21	noted	note	VBN	_	0	ROOT
22	to	to	TO	_	23	mark
23	develop	develop	VB	_	21	xcomp
24	a	a	DT	_	26	det
25	mild	mild	JJ	_	26	amod
26	decrease	decrease	NN	_	23	dobj
27	in	in	IN	_	30	case
28	mean	mean	JJ	_	30	amod
29	neutrophil	neutrophil	NN	_	30	compound
30	counts	count	NNS	_	26	nmod
31	in	in	IN	_	32	case
32	comparison	comparison	NN	_	23	nmod
33	to	to	TO	_	34	case
34	groups	group	NNS	_	32	nmod
35	treated	treat	VBN	_	34	acl
36	with	with	IN	_	39	case
37	either	either	CC	_	39	cc:preconj
38	drug3	drug3	NN	_	39	compound
39	CI	ci	NN	_	35	nmod
40	or	or	CC	_	39	cc
41	drug4	drug4	NN	_	39	conj
42	alone	alone	RB	_	39	advmod
43	.	.	.	_	21	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	significance	significance	NN	_	8	nsubj
4	of	of	IN	_	6	case
5	this	this	DT	_	6	det
6	observation	observation	NN	_	3	nmod
7	is	be	VBZ	_	8	cop
8	unknown	unknown	JJ	_	0	ROOT
9	.	.	.	_	8	punct

1	This	this	DT	_	2	det
2	drug	drug	NN	_	4	nsubj
3	may	may	MD	_	4	aux
4	interact	interact	VB	_	0	ROOT
5	with	with	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	or	or	CC	_	6	cc
8	other	other	JJ	_	9	amod
9	drug2	drug2	NN	_	6	conj
10	-LRB-	-lrb-	-LRB-	_	12	punct
11	may	may	MD	_	12	aux
12	potentiate	potentiate	VB	_	4	dep
13	the	the	DT	_	16	det
14	CNS	cns	NN	_	16	compound
15	depressant	depressant	NN	_	16	compound
16	effects	effect	NNS	_	12	dobj
17	of	of	IN	_	20	case
18	either	either	CC	_	20	cc:preconj
19	these	these	DT	_	20	det
20	medications	medication	NNS	_	16	nmod
21	or	or	CC	_	20	cc
22	drug3	drug3	NN	_	20	conj
23	-RRB-	-rrb-	-RRB-	_	20	punct
24	,	,	,	_	20	punct
25	drug4	drug4	NN	_	20	conj
26	or	or	CC	_	20	cc
27	other	other	JJ	_	28	amod
28	medications	medication	NNS	_	20	conj
29	with	with	IN	_	31	case
30	anticholinergic	anticholinergic	JJ	_	31	amod
31	activity	activity	NN	_	28	nmod
32	-LRB-	-lrb-	-LRB-	_	34	punct
33	anticholinergic	anticholinergic	JJ	_	34	amod
34	effects	effect	NNS	_	37	nsubjpass
35	may	may	MD	_	37	aux
36	be	be	VB	_	37	auxpass
37	potentiated	potentiate	VBN	_	12	ccomp
38	when	when	WRB	_	42	advmod
39	these	these	DT	_	40	det
40	medications	medication	NNS	_	42	nsubjpass
41	are	be	VBP	_	42	auxpass
42	used	use	VBN	_	37	advcl
43	concurrently	concurrently	RB	_	42	advmod
44	with	with	IN	_	45	case
45	drug5	drug5	NN	_	42	nmod
46	-RRB-	-rrb-	-RRB-	_	12	punct
47	,	,	,	_	4	punct
48	and	and	CC	_	4	cc
49	drug6	drug6	NN	_	4	conj
50	-LRB-	-lrb-	-LRB-	_	52	punct
51	concurrent	concurrent	JJ	_	52	amod
52	use	use	NN	_	56	nsubj
53	with	with	IN	_	54	case
54	drug7	drug7	NN	_	52	nmod
55	may	may	MD	_	56	aux
56	prolong	prolong	VB	_	49	acl:relcl
57	and	and	CC	_	56	cc
58	intensify	intensify	VB	_	56	conj
59	the	the	DT	_	64	det
60	anticholinergic	anticholinergic	JJ	_	64	amod
61	and	and	CC	_	60	cc
62	CNS	cns	NN	_	60	conj
63	depressant	depressant	NN	_	64	compound
64	effects	effect	NNS	_	58	dobj
65	of	of	IN	_	66	case
66	drug8	drug8	NN	_	64	nmod
67	-RRB-	-rrb-	-RRB-	_	49	punct
68	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	,	,	,	_	1	punct
5	drug3	drug3	NN	_	1	conj
6	,	,	,	_	1	punct
7	drug4	drug4	NN	_	1	appos

1	Concomitant	concomitant	JJ	_	2	amod
2	use	use	NN	_	9	nsubj
3	of	of	IN	_	5	case
4	drug1	drug1	NN	_	5	compound
5	supplements	supplement	NNS	_	2	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	may	may	MD	_	9	aux
9	increase	increase	VB	_	0	ROOT
10	drug3	drug3	NN	_	11	compound
11	absorption	absorption	NN	_	9	dobj

1	Since	since	IN	_	5	mark
2	drug1	drug1	NN	_	5	nsubj
3	is	be	VBZ	_	5	cop
4	an	a	DT	_	5	det
5	drug2	drug2	NN	_	9	advcl
6	,	,	,	_	9	punct
7	it	it	PRP	_	9	nsubj
8	may	may	MD	_	9	aux
9	have	have	VB	_	0	ROOT
10	a	a	DT	_	12	det
11	strong	strong	JJ	_	12	amod
12	affinity	affinity	NN	_	9	dobj
13	for	for	IN	_	14	case
14	anions	anion	NNS	_	12	nmod
15	other	other	JJ	_	14	amod
16	than	than	IN	_	19	case
17	the	the	DT	_	19	det
18	bile	bile	NN	_	19	compound
19	acids	acid	NNS	_	15	nmod
20	.	.	.	_	9	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	5	nsubj
4	have	have	VBP	_	5	aux
5	indicated	indicate	VBN	_	0	ROOT
6	that	that	IN	_	8	mark
7	drug1	drug1	NN	_	8	nsubj
8	binds	bind	VBZ	_	5	ccomp
9	a	a	DT	_	10	det
10	number	number	NN	_	8	dobj
11	of	of	IN	_	12	case
12	drugs	drug	NNS	_	10	nmod
13	.	.	.	_	5	punct

1	Therefore	therefore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	drug1	drug1	NN	_	4	compound
4	Tablets	tablet	NNS	_	6	nsubj
5	may	may	MD	_	6	aux
6	delay	delay	VB	_	0	ROOT
7	or	or	CC	_	6	cc
8	reduce	reduce	VB	_	6	conj
9	the	the	DT	_	10	det
10	absorption	absorption	NN	_	6	dobj
11	of	of	IN	_	14	case
12	concomitant	concomitant	JJ	_	14	amod
13	oral	oral	JJ	_	14	amod
14	medication	medication	NN	_	10	nmod
15	.	.	.	_	6	punct

1	The	the	DT	_	2	det
2	interval	interval	NN	_	16	nsubj
3	between	between	IN	_	5	case
4	the	the	DT	_	5	det
5	administration	administration	NN	_	2	nmod
6	of	of	IN	_	8	case
7	drug1	drug1	NN	_	8	compound
8	Tablets	tablet	NNS	_	5	nmod
9	and	and	CC	_	5	cc
10	any	any	DT	_	12	det
11	other	other	JJ	_	12	amod
12	medication	medication	NN	_	5	conj
13	should	should	MD	_	16	aux
14	be	be	VB	_	16	cop
15	as	as	RB	_	16	advmod
16	long	long	RB	_	0	ROOT
17	as	as	IN	_	18	case
18	possible	possible	JJ	_	16	advcl
19	.	.	.	_	16	punct

1	Patients	patient	NNS	_	3	nsubj
2	should	should	MD	_	3	aux
3	take	take	VB	_	0	ROOT
4	other	other	JJ	_	5	amod
5	drugs	drug	NNS	_	3	dobj
6	at	at	IN	_	7	case
7	least	least	JJS	_	8	nmod:npmod
8	one	one	CD	_	9	nummod
9	hour	hour	NN	_	18	dep
10	before	before	IN	_	18	mark
11	or	or	CC	_	10	cc
12	four	four	CD	_	13	nummod
13	hours	hour	NNS	_	10	conj
14	after	after	IN	_	13	case
15	drug1	drug1	NN	_	16	compound
16	Tablets	tablet	NNS	_	18	nsubj
17	to	to	TO	_	18	mark
18	avoid	avoid	VB	_	3	advcl
19	impeding	impede	VBG	_	18	xcomp
20	their	they	PRP$	_	21	nmod:poss
21	absorption	absorption	NN	_	19	dobj
22	.	.	.	_	3	punct

1	Repeated	repeated	JJ	_	2	amod
2	doses	dose	NNS	_	18	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	given	give	VBN	_	10	case
6	prior	prior	RB	_	10	advmod
7	to	to	TO	_	10	case
8	a	a	DT	_	10	det
9	single	single	JJ	_	10	amod
10	dose	dose	NN	_	2	nmod
11	of	of	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	in	in	IN	_	15	case
14	human	human	JJ	_	15	amod
15	trials	trial	NNS	_	10	nmod
16	have	have	VBP	_	18	aux
17	been	be	VBN	_	18	auxpass
18	reported	report	VBN	_	0	ROOT
19	to	to	TO	_	20	mark
20	decrease	decrease	VB	_	18	xcomp
21	drug3	drug3	NN	_	22	compound
22	absorption	absorption	NN	_	20	dobj
23	.	.	.	_	18	punct

1	However	however	RB	_	28	advmod
2	,	,	,	_	28	punct
3	in	in	IN	_	6	case
4	a	a	DT	_	6	det
5	follow-up	follow-up	JJ	_	6	amod
6	study	study	NN	_	28	nmod
7	in	in	IN	_	9	case
8	normal	normal	JJ	_	9	amod
9	subjects	subject	NNS	_	6	nmod
10	,	,	,	_	28	punct
11	single-dose	single-dose	JJ	_	12	amod
12	administration	administration	NN	_	28	nsubj
13	of	of	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	and	and	CC	_	14	cc
16	drug2	drug2	NN	_	14	conj
17	and	and	CC	_	14	cc
18	twice-a-day	twice-a-day	JJ	_	19	amod
19	administration	administration	NN	_	14	conj
20	for	for	IN	_	22	case
21	5	5	CD	_	22	nummod
22	days	day	NNS	_	12	nmod
23	of	of	IN	_	25	case
24	both	both	DT	_	25	det
25	agents	agent	NNS	_	22	nmod
26	did	do	VBD	_	28	aux
27	not	not	RB	_	28	neg
28	affect	affect	VB	_	0	ROOT
29	the	the	DT	_	30	det
30	extent	extent	NN	_	28	dobj
31	of	of	IN	_	33	case
32	drug3	drug3	NN	_	33	compound
33	absorption	absorption	NN	_	30	nmod
34	,	,	,	_	28	punct
35	but	but	CC	_	28	cc
36	had	have	VBD	_	28	conj
37	a	a	DT	_	42	det
38	small	small	JJ	_	42	amod
39	yet	yet	RB	_	41	advmod
40	statistically	statistically	RB	_	41	advmod
41	significant	significant	JJ	_	42	amod
42	effect	effect	NN	_	36	dobj
43	on	on	IN	_	45	case
44	its	its	PRP$	_	45	nmod:poss
45	rate	rate	NN	_	36	nmod
46	of	of	IN	_	47	case
47	absorption	absorption	NN	_	45	nmod
48	;	;	:	_	28	punct

1	the	the	DT	_	2	det
2	time	time	NN	_	8	nsubjpass
3	to	to	TO	_	4	mark
4	reach	reach	VB	_	2	acl
5	maximum	maximum	NN	_	6	compound
6	concentration	concentration	NN	_	4	dobj
7	was	be	VBD	_	8	auxpass
8	delayed	delay	VBN	_	0	ROOT
9	approximately	approximately	RB	_	10	advmod
10	30	30	CD	_	11	nummod
11	minutes	minute	NNS	_	8	nmod:tmod
12	.	.	.	_	8	punct

1	Effects	effect	NNS	_	11	nsubjpass
2	on	on	IN	_	4	case
3	the	the	DT	_	4	det
4	absorption	absorption	NN	_	1	nmod
5	of	of	IN	_	7	case
6	other	other	JJ	_	7	amod
7	drug1	drug1	NN	_	4	nmod
8	have	have	VBP	_	11	aux
9	not	not	RB	_	11	neg
10	been	be	VBN	_	11	auxpass
11	determined	determine	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	Therefore	therefore	RB	_	8	advmod
2	,	,	,	_	8	punct
3	patients	patient	NNS	_	8	nsubjpass
4	on	on	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	should	should	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	observed	observe	VBN	_	0	ROOT
9	when	when	WRB	_	14	advmod
10	drug2	drug2	NN	_	11	compound
11	Tablets	tablet	NNS	_	14	nsubjpass
12	are	be	VBP	_	14	auxpass
13	either	either	RB	_	14	advmod
14	added	add	VBN	_	8	advcl
15	or	or	CC	_	14	cc
16	deleted	delete	VBN	_	14	conj
17	from	from	IN	_	20	case
18	a	a	DT	_	20	det
19	therapeutic	therapeutic	JJ	_	20	amod
20	regimen	regimen	NN	_	14	nmod
21	.	.	.	_	8	punct

1	Studies	study	NNS	_	4	nsubj
2	in	in	IN	_	3	case
3	humans	human	NNS	_	1	nmod
4	show	show	VBP	_	0	ROOT
5	that	that	IN	_	17	mark
6	the	the	DT	_	7	det
7	absorption	absorption	NN	_	17	nsubjpass
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	as	as	IN	_	11	mark
11	reflected	reflect	VBN	_	7	dep
12	in	in	IN	_	14	case
13	urinary	urinary	JJ	_	14	amod
14	excretion	excretion	NN	_	11	nmod
15	is	be	VBZ	_	17	auxpass
16	markedly	markedly	RB	_	17	advmod
17	decreased	decrease	VBN	_	4	ccomp
18	even	even	RB	_	19	advmod
19	when	when	WRB	_	20	advmod
20	administered	administer	VBN	_	17	advcl
21	one	one	CD	_	22	nummod
22	hour	hour	NN	_	20	nmod
23	before	before	IN	_	22	case
24	drug2	drug2	NN	_	22	dep
25	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	absorption	absorption	NN	_	16	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	,	,	,	_	4	punct
6	drug2	drug2	NN	_	4	conj
7	,	,	,	_	4	punct
8	drug3	drug3	NN	_	4	conj
9	,	,	,	_	4	punct
10	drug4	drug4	NN	_	4	conj
11	,	,	,	_	4	punct
12	and	and	CC	_	4	cc
13	drug5	drug5	NN	_	4	conj
14	was	be	VBD	_	16	auxpass
15	significantly	significantly	RB	_	16	advmod
16	decreased	decrease	VBN	_	0	ROOT
17	when	when	WRB	_	18	advmod
18	given	give	VBN	_	16	advcl
19	simultaneously	simultaneously	RB	_	18	advmod
20	with	with	IN	_	21	case
21	drug6	drug6	NN	_	18	nmod
22	;	;	:	_	16	punct

1	these	these	DT	_	2	det
2	drugs	drug	NNS	_	5	nsubjpass
3	were	be	VBD	_	5	auxpass
4	not	not	RB	_	5	neg
5	tested	test	VBN	_	0	ROOT
6	to	to	TO	_	7	mark
7	determine	determine	VB	_	5	xcomp
8	the	the	DT	_	9	det
9	effect	effect	NN	_	7	dobj
10	of	of	IN	_	11	case
11	administration	administration	NN	_	9	nmod
12	one	one	CD	_	13	nummod
13	hour	hour	NN	_	9	nmod
14	before	before	IN	_	13	case
15	drug1	drug1	NN	_	13	dep
16	.	.	.	_	5	punct

1	No	no	DT	_	3	neg
2	depressant	depressant	NN	_	3	compound
3	effect	effect	NN	_	10	nsubjpass
4	on	on	IN	_	6	case
5	blood	blood	NN	_	6	compound
6	levels	level	NNS	_	3	nmod
7	in	in	IN	_	8	case
8	humans	human	NNS	_	6	nmod
9	was	be	VBD	_	10	auxpass
10	noted	note	VBN	_	0	ROOT
11	when	when	WRB	_	14	advmod
12	drug1	drug1	NN	_	14	nsubjpass
13	was	be	VBD	_	14	auxpass
14	administered	administer	VBN	_	10	advcl
15	with	with	IN	_	16	case
16	any	any	DT	_	14	nmod
17	of	of	IN	_	20	case
18	the	the	DT	_	20	det
19	following	follow	VBG	_	20	amod
20	drugs	drug	NNS	_	16	nmod
21	:	:	:	_	10	punct
22	drug2	drug2	NN	_	10	dep
23	,	,	,	_	22	punct
24	drug3	drug3	NN	_	22	conj
25	,	,	,	_	22	punct
26	drug4	drug4	NN	_	22	conj
27	,	,	,	_	22	punct
28	drug5	drug5	NN	_	22	conj
29	,	,	,	_	22	punct
30	drug6	drug6	NN	_	22	conj
31	-LRB-	-lrb-	-LRB-	_	32	punct
32	drug7	drug7	NN	_	30	appos
33	-RRB-	-rrb-	-RRB-	_	32	punct
34	,	,	,	_	22	punct
35	drug8	drug8	NN	_	22	conj
36	,	,	,	_	22	punct
37	drug9	drug9	NN	_	22	conj
38	or	or	CC	_	22	cc
39	drug10	drug10	NN	_	22	conj
40	.	.	.	_	10	punct

1	Particular	particular	JJ	_	2	amod
2	caution	caution	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	observed	observe	VBN	_	0	ROOT
6	with	with	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	since	since	IN	_	10	mark
9	there	there	EX	_	10	expl
10	are	be	VBP	_	5	advcl
11	conflicting	conflict	VBG	_	12	amod
12	results	result	NNS	_	10	nsubj
13	for	for	IN	_	15	case
14	the	the	DT	_	15	det
15	effect	effect	NN	_	12	nmod
16	of	of	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	on	on	IN	_	20	case
19	the	the	DT	_	20	det
20	availability	availability	NN	_	15	nmod
21	of	of	IN	_	22	case
22	drug3	drug3	NN	_	20	nmod
23	and	and	CC	_	22	cc
24	drug4	drug4	NN	_	22	conj
25	.	.	.	_	5	punct

1	The	the	DT	_	2	det
2	potential	potential	NN	_	12	nsubj
3	for	for	IN	_	4	case
4	binding	binding	NN	_	2	nmod
5	of	of	IN	_	7	case
6	these	these	DT	_	7	det
7	drugs	drug	NNS	_	4	nmod
8	if	if	IN	_	9	mark
9	given	give	VBN	_	2	dep
10	concomitantly	concomitantly	RB	_	9	advmod
11	is	be	VBZ	_	12	cop
12	present	present	JJ	_	0	ROOT
13	.	.	.	_	12	punct

1	Discontinuing	discontinue	VBG	_	2	amod
2	drug1	drug1	NN	_	4	nsubj
3	could	could	MD	_	4	aux
4	pose	pose	VB	_	0	ROOT
5	a	a	DT	_	6	det
6	hazard	hazard	NN	_	4	dobj
7	to	to	TO	_	8	case
8	health	health	NN	_	4	nmod
9	if	if	IN	_	23	mark
10	a	a	DT	_	13	det
11	potentially	potentially	RB	_	12	advmod
12	toxic	toxic	JJ	_	13	amod
13	drug	drug	NN	_	23	nsubjpass
14	that	that	WDT	_	17	nsubjpass
15	is	be	VBZ	_	17	auxpass
16	significantly	significantly	RB	_	17	advmod
17	bound	bind	VBN	_	13	acl:relcl
18	to	to	TO	_	20	case
19	the	the	DT	_	20	det
20	drug2	drug2	NN	_	17	nmod
21	has	have	VBZ	_	23	aux
22	been	be	VBN	_	23	auxpass
23	titrated	titrate	VBN	_	4	advcl
24	to	to	TO	_	27	case
25	a	a	DT	_	27	det
26	maintenance	maintenance	NN	_	27	compound
27	level	level	NN	_	23	nmod
28	while	while	IN	_	32	mark
29	the	the	DT	_	30	det
30	patient	patient	NN	_	32	nsubj
31	was	be	VBD	_	32	aux
32	taking	take	VBG	_	23	advcl
33	drug3	drug3	NN	_	32	dobj
34	.	.	.	_	4	punct

1	drug1	drug1	NN	_	4	nsubj
2	may	may	MD	_	4	aux
3	also	also	RB	_	4	advmod
4	interfere	interfere	VB	_	0	ROOT
5	with	with	IN	_	7	case
6	the	the	DT	_	7	det
7	absorption	absorption	NN	_	4	nmod
8	of	of	IN	_	11	case
9	oral	oral	JJ	_	11	amod
10	drug2	drug2	NN	_	11	compound
11	supplements	supplement	NNS	_	7	nmod
12	and	and	CC	_	11	cc
13	drug3	drug3	NN	_	11	conj
14	.	.	.	_	4	punct

1	Studies	study	NNS	_	16	nsubjpass
2	to	to	TO	_	3	mark
3	evaluate	evaluate	VB	_	1	acl
4	possible	possible	JJ	_	5	amod
5	interactions	interaction	NNS	_	3	dobj
6	between	between	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drugs	drug	NNS	_	7	conj
10	other	other	JJ	_	5	amod
11	than	than	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	have	have	VBP	_	16	aux
14	not	not	RB	_	16	neg
15	been	be	VBN	_	16	auxpass
16	performed	perform	VBN	_	0	ROOT
17	.	.	.	_	16	punct

1	Consequently	consequently	RB	_	5	advmod
2	,	,	,	_	5	punct
3	caution	caution	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	advised	advise	VBN	_	0	ROOT
6	if	if	IN	_	16	mark
7	the	the	DT	_	9	det
8	concomitant	concomitant	JJ	_	9	amod
9	administration	administration	NN	_	16	nsubjpass
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	other	other	JJ	_	14	amod
14	drugs	drug	NNS	_	11	conj
15	is	be	VBZ	_	16	auxpass
16	required	require	VBN	_	5	advcl
17	.	.	.	_	5	punct

1	The	the	DT	_	2	det
2	safety	safety	NN	_	13	nsubj
3	and	and	CC	_	2	cc
4	efficacy	efficacy	NN	_	2	conj
5	of	of	IN	_	7	case
6	concomitant	concomitant	JJ	_	7	amod
7	use	use	NN	_	2	nmod
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	drug2	drug2	NN	_	9	conj
12	is	be	VBZ	_	13	cop
13	unknown	unknown	JJ	_	0	ROOT
14	,	,	,	_	13	punct
15	and	and	CC	_	13	cc
16	the	the	DT	_	18	det
17	concomitant	concomitant	JJ	_	18	amod
18	use	use	NN	_	27	nsubjpass
19	of	of	IN	_	23	case
20	two	two	CD	_	23	nummod
21	potentially	potentially	RB	_	22	advmod
22	hepatotoxic	hepatotoxic	JJ	_	23	amod
23	medications	medication	NNS	_	18	nmod
24	is	be	VBZ	_	27	auxpass
25	not	not	RB	_	27	neg
26	ordinarily	ordinarily	RB	_	27	advmod
27	recommended	recommend	VBN	_	13	conj
28	unless	unless	IN	_	32	mark
29	the	the	DT	_	31	det
30	probable	probable	JJ	_	31	amod
31	benefits	benefit	NNS	_	32	nsubj
32	outweigh	outweigh	VBP	_	27	advcl
33	the	the	DT	_	35	det
34	known	known	JJ	_	35	amod
35	risks	risk	NNS	_	32	dobj
36	.	.	.	_	13	punct

1	Lethargy	lethargy	NN	_	6	nsubjpass
2	and	and	CC	_	1	cc
3	somnolence	somnolence	NN	_	1	conj
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	auxpass
6	reported	report	VBN	_	0	ROOT
7	following	follow	VBG	_	8	case
8	doses	dose	NNS	_	6	nmod
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	drug2	drug2	NN	_	10	conj
13	.	.	.	_	6	punct

1	Patients	patient	NNS	_	6	nsubj
2	taking	take	VBG	_	1	acl
3	drug1	drug1	NN	_	2	dobj
4	may	may	MD	_	6	aux
5	not	not	RB	_	6	neg
6	benefit	benefit	VB	_	0	ROOT
7	from	from	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	containing	contain	VBG	_	8	acl
10	medicines	medicine	NNS	_	9	dobj
11	,	,	,	_	10	punct
12	such	such	JJ	_	14	case
13	as	as	IN	_	12	mwe
14	cough	cough	NN	_	10	nmod
15	and	and	CC	_	14	cc
16	cold	cold	JJ	_	17	amod
17	preparations	preparation	NNS	_	14	conj
18	,	,	,	_	10	punct
19	antidiarrheal	antidiarrheal	JJ	_	20	amod
20	preparations	preparation	NNS	_	10	conj
21	,	,	,	_	10	punct
22	and	and	CC	_	10	cc
23	drug3	drug3	NN	_	10	conj
24	.	.	.	_	6	punct

1	In	in	IN	_	4	case
2	an	a	DT	_	4	det
3	emergency	emergency	NN	_	4	compound
4	situation	situation	NN	_	24	nmod
5	when	when	WRB	_	10	advmod
6	opioid	opioid	JJ	_	7	amod
7	analgesia	analgesia	NN	_	10	nsubjpass
8	must	must	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	administered	administer	VBN	_	4	acl:relcl
11	to	to	TO	_	13	case
12	a	a	DT	_	13	det
13	patient	patient	NN	_	10	nmod
14	receiving	receive	VBG	_	13	acl
15	drug1	drug1	NN	_	14	dobj
16	,	,	,	_	24	punct
17	the	the	DT	_	18	det
18	amount	amount	NN	_	24	nsubj
19	of	of	IN	_	20	case
20	drug2	drug2	NN	_	18	nmod
21	required	require	VBN	_	18	acl
22	may	may	MD	_	24	aux
23	be	be	VB	_	24	cop
24	greater	greater	JJR	_	0	ROOT
25	than	than	IN	_	26	case
26	usual	usual	JJ	_	24	advcl
27	,	,	,	_	24	punct
28	and	and	CC	_	24	cc
29	the	the	DT	_	32	det
30	resulting	result	VBG	_	32	amod
31	respiratory	respiratory	JJ	_	32	amod
32	depression	depression	NN	_	35	nsubj
33	may	may	MD	_	35	aux
34	be	be	VB	_	35	cop
35	deeper	deeper	JJR	_	24	conj
36	and	and	CC	_	35	cc
37	more	more	RBR	_	38	advmod
38	prolonged	prolonged	JJ	_	35	conj
39	.	.	.	_	24	punct

1	Administration	administration	NN	_	7	nsubj
2	of	of	IN	_	4	case
3	repeat	repeat	NN	_	4	compound
4	doses	dose	NNS	_	1	nmod
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	had	have	VBD	_	0	ROOT
8	no	no	DT	_	9	neg
9	effect	effect	NN	_	7	dobj
10	on	on	IN	_	14	case
11	the	the	DT	_	14	det
12	repeat	repeat	NN	_	14	compound
13	dose	dose	NN	_	14	compound
14	pharmacokinetics	pharmacokinetic	NNS	_	7	nmod
15	of	of	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	,	,	,	_	16	punct
18	drug3	drug3	NN	_	16	conj
19	or	or	CC	_	16	cc
20	an	a	DT	_	21	det
21	drug4	drug4	NN	_	16	conj
22	/	/	:	_	7	punct
23	levonorgestrol	levonorgestrol	NN	_	25	compound
24	oral	oral	JJ	_	25	amod
25	drug5	drug5	NN	_	7	dobj
26	in	in	IN	_	28	case
27	healthy	healthy	JJ	_	28	amod
28	subjects	subject	NNS	_	25	nmod
29	.	.	.	_	7	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	0	ROOT
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	,	,	,	_	4	punct
8	drug3	drug3	NN	_	4	conj
9	,	,	,	_	4	punct
10	drug4	drug4	NN	_	4	conj
11	,	,	,	_	4	punct
12	or	or	CC	_	4	cc
13	an	a	DT	_	14	det
14	drug5	drug5	NN	_	4	conj
15	/	/	:	_	2	punct
16	drug6	drug6	NN	_	18	compound
17	oral	oral	JJ	_	18	amod
18	drug7	drug7	NN	_	19	nsubj
19	produced	produce	VBD	_	2	dep
20	minor	minor	JJ	_	21	amod
21	changes	change	NNS	_	19	dobj
22	in	in	IN	_	24	case
23	the	the	DT	_	24	det
24	pharmacokinetics	pharmacokinetic	NNS	_	19	nmod
25	of	of	IN	_	26	case
26	drug8	drug8	NN	_	24	nmod
27	,	,	,	_	26	punct
28	which	which	WDT	_	30	nsubjpass
29	were	be	VBD	_	30	auxpass
30	considered	consider	VBN	_	26	acl:relcl
31	to	to	TO	_	35	mark
32	be	be	VB	_	35	cop
33	without	without	IN	_	35	case
34	clinical	clinical	JJ	_	35	amod
35	significance	significance	NN	_	30	xcomp
36	.	.	.	_	2	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	7	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	2	nmod
7	resulted	result	VBD	_	0	ROOT
8	in	in	IN	_	12	case
9	a	a	DT	_	12	det
10	45	45	CD	_	11	compound
11	%	%	NN	_	12	amod
12	increase	increase	NN	_	7	nmod
13	in	in	IN	_	15	case
14	systemic	systemic	JJ	_	15	amod
15	exposure	exposure	NN	_	12	nmod
16	to	to	TO	_	17	case
17	drug3	drug3	NN	_	15	nmod
18	.	.	.	_	7	punct

1	drug1	drug1	NN	_	2	nsubj
2	had	have	VBD	_	0	ROOT
3	no	no	DT	_	5	neg
4	significant	significant	JJ	_	5	amod
5	effect	effect	NN	_	2	dobj
6	on	on	IN	_	9	case
7	the	the	DT	_	9	det
8	anticoagulant	anticoagulant	JJ	_	9	amod
9	effect	effect	NN	_	2	nmod
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	in	in	IN	_	14	case
13	healthy	healthy	JJ	_	14	amod
14	subjects	subject	NNS	_	9	nmod
15	on	on	IN	_	18	case
16	stable	stable	JJ	_	18	amod
17	drug3	drug3	NN	_	18	compound
18	therapy	therapy	NN	_	14	nmod
19	.	.	.	_	2	punct

1	However	however	RB	_	33	advmod
2	,	,	,	_	33	punct
3	because	because	IN	_	8	mark
4	some	some	DT	_	5	det
5	drug1	drug1	NN	_	8	nsubjpass
6	have	have	VBP	_	8	aux
7	been	be	VBN	_	8	auxpass
8	reported	report	VBN	_	33	advcl
9	to	to	TO	_	10	mark
10	enhance	enhance	VB	_	8	xcomp
11	the	the	DT	_	13	det
12	anticoagulant	anticoagulant	JJ	_	13	amod
13	effects	effect	NNS	_	10	dobj
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	or	or	CC	_	15	cc
17	its	its	PRP$	_	18	nmod:poss
18	derivatives	derivative	NNS	_	15	conj
19	in	in	IN	_	20	case
20	patients	patient	NNS	_	13	nmod
21	,	,	,	_	33	punct
22	the	the	DT	_	24	det
23	prothrombin	prothrombin	NN	_	24	compound
24	time	time	NN	_	33	nsubjpass
25	or	or	CC	_	24	cc
26	other	other	JJ	_	29	amod
27	suitable	suitable	JJ	_	29	amod
28	coagulation	coagulation	NN	_	29	compound
29	test	test	NN	_	24	conj
30	should	should	MD	_	33	aux
31	be	be	VB	_	33	auxpass
32	closely	closely	RB	_	33	advmod
33	monitored	monitor	VBN	_	0	ROOT
34	if	if	IN	_	38	mark
35	a	a	DT	_	36	det
36	drug3	drug3	NN	_	38	nsubjpass
37	is	be	VBZ	_	38	auxpass
38	administered	administer	VBN	_	33	advcl
39	concomitantly	concomitantly	RB	_	38	advmod
40	with	with	IN	_	41	case
41	drug4	drug4	NN	_	38	nmod
42	or	or	CC	_	41	cc
43	its	its	PRP$	_	44	nmod:poss
44	derivatives	derivative	NNS	_	41	conj
45	.	.	.	_	33	punct

1	drug1	drug1	NN	_	2	compound
2	form	form	NN	_	3	nsubj
3	chelates	chelate	VBZ	_	0	ROOT
4	with	with	IN	_	6	case
5	alkaline	alkaline	NN	_	6	compound
6	earth	earth	NN	_	3	nmod
7	and	and	CC	_	6	cc
8	transition	transition	NN	_	9	compound
9	metals	metal	NNS	_	6	conj
10	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	absorption	absorption	NN	_	8	nsubjpass
3	of	of	IN	_	5	case
4	oral	oral	JJ	_	5	amod
5	drug1	drug1	NN	_	2	nmod
6	is	be	VBZ	_	8	auxpass
7	significantly	significantly	RB	_	8	advmod
8	reduced	reduce	VBN	_	0	ROOT
9	by	by	IN	_	12	case
10	the	the	DT	_	12	det
11	concomitant	concomitant	JJ	_	12	amod
12	administration	administration	NN	_	8	nmod
13	of	of	IN	_	15	case
14	an	a	DT	_	15	det
15	drug2	drug2	NN	_	12	nmod
16	containing	contain	VBG	_	15	acl
17	drug3	drug3	NN	_	16	dobj
18	and	and	CC	_	17	cc
19	drug4	drug4	NN	_	17	conj
20	.	.	.	_	8	punct

1	drug1	drug1	NN	_	41	nsubjpass
2	-	-	:	_	1	punct
3	and/or	and/or	CC	_	1	cc
4	drug2	drug2	NN	_	1	conj
5	-	-	:	_	1	punct
6	containing	contain	VBG	_	1	acl
7	drug3	drug3	NN	_	29	nsubj
8	,	,	,	_	7	punct
9	products	product	NNS	_	7	conj
10	containing	contain	VBG	_	9	acl
11	drug4	drug4	NN	_	10	dobj
12	-LRB-	-lrb-	-LRB-	_	13	punct
13	drug5	drug5	NN	_	11	appos
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	,	,	,	_	11	punct
16	drug6	drug6	NN	_	11	appos
17	containing	contain	VBG	_	16	acl
18	drug7	drug7	NN	_	17	dobj
19	or	or	CC	_	18	cc
20	other	other	JJ	_	22	amod
21	metal	metal	NN	_	22	compound
22	cations	cation	NNS	_	18	conj
23	,	,	,	_	18	punct
24	or	or	CC	_	18	cc
25	drug8	drug8	NN	_	18	conj
26	-LRB-	-lrb-	-LRB-	_	27	punct
27	drug9	drug9	NN	_	25	appos
28	-RRB-	-rrb-	-RRB-	_	27	punct
29	chewable/buffered	chewable/buffered	VBD	_	6	ccomp
30	tablets	tablet	NNS	_	29	dobj
31	or	or	CC	_	30	cc
32	the	the	DT	_	34	det
33	pediatric	pediatric	JJ	_	34	amod
34	powder	powder	NN	_	30	conj
35	for	for	IN	_	37	case
36	oral	oral	JJ	_	37	amod
37	solution	solution	NN	_	29	nmod
38	should	should	MD	_	41	aux
39	not	not	RB	_	41	neg
40	be	be	VB	_	41	auxpass
41	taken	take	VBN	_	0	ROOT
42	within	within	IN	_	44	case
43	3	3	CD	_	44	nummod
44	hours	hour	NNS	_	41	nmod
45	before	before	IN	_	50	nmod
46	or	or	CC	_	45	cc
47	2	2	CD	_	48	nummod
48	hours	hour	NNS	_	45	conj
49	after	after	IN	_	48	case
50	drug10	drug10	NN	_	44	nmod
51	.	.	.	_	41	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	should	should	MD	_	5	aux
3	not	not	RB	_	5	neg
4	be	be	VB	_	5	auxpass
5	taken	take	VBN	_	0	ROOT
6	within	within	IN	_	8	case
7	2	2	CD	_	8	nummod
8	hours	hour	NNS	_	5	nmod
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	.	.	.	_	5	punct

1	Although	although	IN	_	9	mark
2	the	the	DT	_	4	det
3	pressor	pressor	NN	_	4	compound
4	activity	activity	NN	_	9	nsubj
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	is	be	VBZ	_	9	cop
8	very	very	RB	_	9	advmod
9	low	low	JJ	_	23	advcl
10	compared	compare	VBN	_	14	case
11	to	to	TO	_	14	case
12	its	its	PRP$	_	14	nmod:poss
13	antidiuretic	antidiuretic	JJ	_	14	amod
14	activity	activity	NN	_	9	advcl
15	,	,	,	_	23	punct
16	large	large	JJ	_	17	amod
17	doses	dose	NNS	_	23	nsubjpass
18	of	of	IN	_	20	case
19	drug2	drug2	NN	_	20	compound
20	Tablets	tablet	NNS	_	17	nmod
21	should	should	MD	_	23	aux
22	be	be	VB	_	23	auxpass
23	used	use	VBN	_	0	ROOT
24	with	with	IN	_	27	case
25	other	other	JJ	_	27	amod
26	pressor	pressor	NN	_	27	compound
27	agents	agent	NNS	_	23	nmod
28	only	only	RB	_	32	advmod
29	with	with	IN	_	32	case
30	careful	careful	JJ	_	32	amod
31	patient	patient	NN	_	32	compound
32	monitoring	monitoring	NN	_	23	nmod
33	.	.	.	_	23	punct

1	None	none	NN	_	0	ROOT
2	known	know	VBN	_	1	acl
3	.	.	.	_	1	punct

1	Studies	study	NNS	_	4	nsubj
2	in	in	FW	_	3	compound
3	vitro	vitro	FW	_	1	advmod
4	show	show	VBP	_	0	ROOT
5	that	that	IN	_	10	mark
6	drug1	drug1	NN	_	10	nsubj
7	is	be	VBZ	_	10	cop
8	not	not	RB	_	10	neg
9	an	a	DT	_	10	det
10	inhibitor	inhibitor	NN	_	4	ccomp
11	of	of	IN	_	13	case
12	any	any	DT	_	13	det
13	enzyme	enzyme	NN	_	10	nmod
14	in	in	IN	_	21	case
15	the	the	DT	_	21	det
16	cytochrome	cytochrome	NN	_	17	compound
17	P450	p450	NN	_	21	compound
18	-LRB-	-lrb-	-LRB-	_	19	punct
19	CYP	cyp	NN	_	17	appos
20	-RRB-	-rrb-	-RRB-	_	19	punct
21	system	system	NN	_	13	nmod
22	.	.	.	_	4	punct

1	In	in	IN	_	3	case
2	clinical	clinical	JJ	_	3	amod
3	studies	study	NNS	_	8	nmod
4	,	,	,	_	8	punct
5	drug1	drug1	NN	_	8	nsubj
6	did	do	VBD	_	8	aux
7	not	not	RB	_	8	neg
8	induce	induce	VB	_	0	ROOT
9	the	the	DT	_	11	det
10	CYP3A4	cyp3a4	NN	_	11	compound
11	metabolism	metabolism	NN	_	8	dobj
12	of	of	IN	_	14	case
13	other	other	JJ	_	14	amod
14	drugs	drug	NNS	_	11	nmod
15	.	.	.	_	8	punct

1	drug1	drug1	NN	_	5	nsubj
2	is	be	VBZ	_	5	cop
3	not	not	RB	_	5	neg
4	a	a	DT	_	5	det
5	substrate	substrate	NN	_	0	ROOT
6	for	for	IN	_	7	case
7	P-glycoprotein	p-glycoprotein	NN	_	5	nmod
8	and	and	CC	_	5	cc
9	is	be	VBZ	_	12	cop
10	a	a	DT	_	12	det
11	poor	poor	JJ	_	12	amod
12	substrate	substrate	NN	_	5	conj
13	for	for	IN	_	16	case
14	cytochrome	cytochrome	NN	_	16	compound
15	P450	p450	NN	_	16	compound
16	enzymes	enzyme	NNS	_	12	nmod
17	.	.	.	_	5	punct

1	Clinical	clinical	JJ	_	2	amod
2	studies	study	NNS	_	6	nsubj
3	in	in	IN	_	5	case
4	healthy	healthy	JJ	_	5	amod
5	volunteers	volunteer	NNS	_	2	nmod
6	show	show	VBP	_	0	ROOT
7	that	that	IN	_	14	mark
8	the	the	DT	_	9	det
9	pharmacokinetics	pharmacokinetic	NNS	_	14	nsubjpass
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	are	be	VBP	_	14	auxpass
13	not	not	RB	_	14	neg
14	altered	alter	VBN	_	6	ccomp
15	by	by	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	,	,	,	_	16	punct
18	drug3	drug3	NN	_	16	conj
19	,	,	,	_	16	punct
20	drug4	drug4	NN	_	16	conj
21	,	,	,	_	16	punct
22	drug5	drug5	NN	_	16	conj
23	,	,	,	_	16	punct
24	or	or	CC	_	16	cc
25	drug6	drug6	NN	_	16	conj
26	.	.	.	_	6	punct

1	drug1	drug1	NN	_	2	nsubj
2	has	have	VBZ	_	0	ROOT
3	no	no	DT	_	4	neg
4	effect	effect	NN	_	2	dobj
5	on	on	IN	_	7	case
6	the	the	DT	_	7	det
7	pharmacokinetics	pharmacokinetic	NNS	_	2	nmod
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	,	,	,	_	9	punct
11	drug3	drug3	NN	_	9	conj
12	,	,	,	_	9	punct
13	or	or	CC	_	9	cc
14	the	the	DT	_	16	det
15	active	active	JJ	_	16	amod
16	metabolite	metabolite	NN	_	9	conj
17	of	of	IN	_	18	case
18	mycophenolate	mycophenolate	NN	_	16	nmod
19	.	.	.	_	2	punct

1	drug1	drug1	NN	_	2	nsubj
2	reduced	reduce	VBD	_	0	ROOT
3	the	the	DT	_	5	det
4	blood	blood	NN	_	5	compound
5	AUC0-12	auc0-12	NN	_	2	dobj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	by	by	IN	_	11	case
9	approximately	approximately	RB	_	10	advmod
10	20	20	CD	_	11	nummod
11	%	%	NN	_	2	nmod
12	,	,	,	_	2	punct
13	peak	peak	JJ	_	15	amod
14	blood	blood	NN	_	15	compound
15	concentration	concentration	NN	_	2	dobj
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	Cmax	cmax	NN	_	15	appos
18	-RRB-	-rrb-	-RRB-	_	17	punct
19	by	by	IN	_	21	case
20	16	16	CD	_	21	nummod
21	%	%	NN	_	15	nmod
22	,	,	,	_	15	punct
23	and	and	CC	_	15	cc
24	12-hour	12-hour	JJ	_	26	amod
25	blood	blood	NN	_	26	compound
26	concentration	concentration	NN	_	15	conj
27	-LRB-	-lrb-	-LRB-	_	28	punct
28	C12hr	c12hr	NN	_	26	appos
29	-RRB-	-rrb-	-RRB-	_	28	punct
30	by	by	IN	_	32	case
31	26	26	CD	_	32	nummod
32	%	%	NN	_	15	nmod
33	in	in	IN	_	35	case
34	healthy	healthy	JJ	_	35	amod
35	subjects	subject	NNS	_	15	nmod
36	when	when	WRB	_	49	advmod
37	drug3	drug3	NN	_	49	nsubjpass
38	-LRB-	-lrb-	-LRB-	_	40	punct
39	2	2	CD	_	40	nummod
40	doses	dose	NNS	_	37	dep
41	of	of	IN	_	43	case
42	0.1	0.1	CD	_	43	nummod
43	mg/kg	mg/kg	NN	_	40	nmod
44	12	12	CD	_	45	nummod
45	hours	hour	NNS	_	46	nmod:npmod
46	apart	apart	RB	_	43	advmod
47	-RRB-	-rrb-	-RRB-	_	40	punct
48	was	be	VBD	_	49	auxpass
49	administered	administer	VBN	_	15	acl:relcl
50	on	on	IN	_	53	case
51	the	the	DT	_	53	det
52	10th	10th	JJ	_	53	amod
53	day	day	NN	_	49	nmod
54	of	of	IN	_	57	case
55	drug4	drug4	NN	_	57	compound
56	70	70	CD	_	57	nummod
57	mg	mg	NN	_	53	nmod
58	daily	daily	RB	_	53	advmod
59	,	,	,	_	49	punct
60	as	as	IN	_	61	mark
61	compared	compare	VBN	_	49	advcl
62	to	to	TO	_	63	case
63	results	result	NNS	_	61	nmod
64	from	from	IN	_	67	case
65	a	a	DT	_	67	det
66	control	control	NN	_	67	compound
67	period	period	NN	_	63	nmod
68	in	in	IN	_	69	case
69	which	which	WDT	_	72	nmod
70	drug5	drug5	NN	_	72	nsubjpass
71	was	be	VBD	_	72	auxpass
72	administered	administer	VBN	_	67	acl:relcl
73	alone	alone	RB	_	72	advmod
74	.	.	.	_	2	punct

1	For	for	IN	_	2	case
2	patients	patient	NNS	_	19	nmod
3	receiving	receive	VBG	_	2	acl
4	both	both	CC	_	5	cc:preconj
5	therapies	therapy	NNS	_	3	dobj
6	,	,	,	_	19	punct
7	standard	standard	JJ	_	8	amod
8	monitoring	monitoring	NN	_	19	nsubjpass
9	of	of	IN	_	12	case
10	drug1	drug1	NN	_	12	compound
11	blood	blood	NN	_	12	compound
12	concentrations	concentration	NNS	_	8	nmod
13	and	and	CC	_	12	cc
14	appropriate	appropriate	JJ	_	17	amod
15	drug2	drug2	NN	_	17	compound
16	dosage	dosage	NN	_	17	compound
17	adjustments	adjustment	NNS	_	12	conj
18	are	be	VBP	_	19	auxpass
19	recommended	recommend	VBN	_	0	ROOT
20	.	.	.	_	19	punct

1	In	in	IN	_	4	case
2	two	two	CD	_	4	nummod
3	clinical	clinical	JJ	_	4	amod
4	studies	study	NNS	_	18	nmod
5	,	,	,	_	18	punct
6	drug1	drug1	NN	_	18	nsubj
7	-LRB-	-lrb-	-LRB-	_	11	punct
8	one	one	CD	_	11	nummod
9	4	4	CD	_	11	nummod
10	mg/kg	mg/kg	NN	_	11	compound
11	dose	dose	NN	_	6	dep
12	or	or	CC	_	11	cc
13	two	two	CD	_	16	nummod
14	3	3	CD	_	16	nummod
15	mg/kg	mg/kg	NN	_	16	compound
16	doses	dose	NNS	_	11	conj
17	-RRB-	-rrb-	-RRB-	_	11	punct
18	increased	increase	VBD	_	0	ROOT
19	the	the	DT	_	20	det
20	AUC	auc	NN	_	18	dobj
21	of	of	IN	_	22	case
22	drug2	drug2	NN	_	20	nmod
23	by	by	IN	_	26	case
24	approximately	approximately	RB	_	25	advmod
25	35	35	CD	_	26	nummod
26	%	%	NN	_	18	nmod
27	.	.	.	_	18	punct

1	drug1	drug1	NN	_	4	nsubj
2	did	do	VBD	_	4	aux
3	not	not	RB	_	4	neg
4	increase	increase	VB	_	0	ROOT
5	the	the	DT	_	7	det
6	plasma	plasma	NN	_	7	compound
7	levels	level	NNS	_	4	dobj
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	.	.	.	_	4	punct

1	There	there	EX	_	2	expl
2	were	be	VBD	_	0	ROOT
3	transient	transient	JJ	_	4	amod
4	increases	increase	NNS	_	2	nsubj
5	in	in	IN	_	7	case
6	liver	liver	NN	_	7	compound
7	ALT	alt	NN	_	4	nmod
8	and	and	CC	_	7	cc
9	AST	AST	NNP	_	7	conj
10	when	when	WRB	_	15	advmod
11	drug1	drug1	NN	_	15	nsubjpass
12	and	and	CC	_	11	cc
13	drug2	drug2	NN	_	11	conj
14	were	be	VBD	_	15	auxpass
15	co-administered	co-administer	VBN	_	4	acl:relcl
16	.	.	.	_	2	punct

1	A	a	DT	_	4	det
2	drug-drug	drug-drug	JJ	_	4	amod
3	interaction	interaction	NN	_	4	compound
4	study	study	NN	_	11	nsubj
5	with	with	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	in	in	IN	_	9	case
8	healthy	healthy	JJ	_	9	amod
9	volunteers	volunteer	NNS	_	6	nmod
10	has	have	VBZ	_	11	aux
11	shown	show	VBN	_	0	ROOT
12	a	a	DT	_	15	det
13	30	30	CD	_	14	compound
14	%	%	NN	_	15	amod
15	decrease	decrease	NN	_	11	dobj
16	in	in	IN	_	19	case
17	drug2	drug2	NN	_	19	compound
18	trough	trough	NN	_	19	compound
19	concentrations	concentration	NNS	_	15	nmod
20	.	.	.	_	11	punct

1	Patients	patient	NNS	_	5	nsubj
2	on	on	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	should	should	MD	_	5	aux
5	receive	receive	VB	_	0	ROOT
6	70	70	CD	_	7	nummod
7	mg	mg	NN	_	5	dobj
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	daily	daily	RB	_	5	advmod
11	.	.	.	_	5	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	12	nmod
3	,	,	,	_	12	punct
4	results	result	VBZ	_	12	nsubj
5	from	from	IN	_	7	case
6	regression	regression	NN	_	7	compound
7	analyses	analysis	NNS	_	4	nmod
8	of	of	IN	_	11	case
9	patient	patient	NN	_	11	compound
10	pharmacokinetic	pharmacokinetic	JJ	_	11	amod
11	data	datum	NNS	_	7	nmod
12	suggest	suggest	VBP	_	0	ROOT
13	that	that	IN	_	36	mark
14	co-administration	co-administration	NN	_	36	nsubj
15	of	of	IN	_	17	case
16	other	other	JJ	_	17	amod
17	inducers	inducer	NNS	_	14	nmod
18	of	of	IN	_	20	case
19	drug	drug	NN	_	20	compound
20	clearance	clearance	NN	_	17	nmod
21	-LRB-	-lrb-	-LRB-	_	22	punct
22	drug1	drug1	NN	_	17	dep
23	,	,	,	_	22	punct
24	drug2	drug2	NN	_	22	conj
25	,	,	,	_	22	punct
26	drug3	drug3	NN	_	22	conj
27	,	,	,	_	22	punct
28	drug4	drug4	NN	_	22	conj
29	,	,	,	_	22	punct
30	or	or	CC	_	22	cc
31	drug5	drug5	NN	_	22	conj
32	-RRB-	-rrb-	-RRB-	_	22	punct
33	with	with	IN	_	34	case
34	drug6	drug6	NN	_	14	nmod
35	may	may	MD	_	36	aux
36	result	result	VB	_	12	ccomp
37	in	in	IN	_	40	case
38	clinically	clinically	RB	_	39	advmod
39	meaningful	meaningful	JJ	_	40	amod
40	reductions	reduction	NNS	_	36	nmod
41	in	in	IN	_	43	case
42	drug7	drug7	NN	_	43	compound
43	concentrations	concentration	NNS	_	40	nmod
44	.	.	.	_	12	punct

1	It	it	PRP	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	not	not	RB	_	4	neg
4	known	know	VBN	_	0	ROOT
5	which	which	WDT	_	8	det
6	drug	drug	NN	_	8	compound
7	clearance	clearance	NN	_	8	compound
8	mechanism	mechanism	NN	_	15	nsubj
9	involved	involve	VBN	_	8	acl
10	in	in	IN	_	12	case
11	drug1	drug1	NN	_	12	compound
12	disposition	disposition	NN	_	9	nmod
13	may	may	MD	_	15	aux
14	be	be	VB	_	15	cop
15	inducible	inducible	JJ	_	4	ccomp
16	.	.	.	_	4	punct

1	When	when	WRB	_	4	advmod
2	drug1	drug1	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	co-administered	co-administer	VBN	_	36	advcl
5	with	with	IN	_	6	case
6	inducers	inducer	NNS	_	4	nmod
7	of	of	IN	_	9	case
8	drug	drug	NN	_	9	compound
9	clearance	clearance	NN	_	6	nmod
10	,	,	,	_	36	punct
11	such	such	JJ	_	13	case
12	as	as	IN	_	11	mwe
13	drug2	drug2	NN	_	36	nsubjpass
14	,	,	,	_	13	punct
15	drug3	drug3	NN	_	13	conj
16	,	,	,	_	13	punct
17	drug4	drug4	NN	_	13	conj
18	,	,	,	_	13	punct
19	drug5	drug5	NN	_	13	conj
20	,	,	,	_	13	punct
21	or	or	CC	_	13	cc
22	drug6	drug6	NN	_	13	conj
23	,	,	,	_	13	punct
24	use	use	NN	_	13	conj
25	of	of	IN	_	28	case
26	a	a	DT	_	28	det
27	daily	daily	JJ	_	28	amod
28	dose	dose	NN	_	24	nmod
29	of	of	IN	_	31	case
30	70	70	CD	_	31	nummod
31	mg	mg	NN	_	28	nmod
32	of	of	IN	_	33	case
33	drug7	drug7	NN	_	31	nmod
34	should	should	MD	_	36	aux
35	be	be	VB	_	36	auxpass
36	considered	consider	VBN	_	0	ROOT

1	.	.	.	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	As	as	IN	_	6	case
4	with	with	IN	_	6	case
5	other	other	JJ	_	6	amod
6	drug2	drug2	NN	_	13	nmod
7	,	,	,	_	13	punct
8	renal	renal	JJ	_	9	amod
9	excretion	excretion	NN	_	13	nsubjpass
10	of	of	IN	_	11	case
11	drug3	drug3	NN	_	9	nmod
12	is	be	VBZ	_	13	auxpass
13	inhibited	inhibit	VBN	_	1	dep
14	by	by	IN	_	15	case
15	drug4	drug4	NN	_	13	nmod
16	and	and	CC	_	13	cc
17	resulted	result	VBD	_	13	conj
18	in	in	IN	_	23	case
19	an	a	DT	_	23	det
20	approximate	approximate	JJ	_	23	amod
21	80	80	CD	_	22	compound
22	%	%	NN	_	23	amod
23	increase	increase	NN	_	17	nmod
24	in	in	IN	_	26	case
25	the	the	DT	_	26	det
26	AUC	auc	NN	_	23	nmod
27	for	for	IN	_	28	case
28	drug5	drug5	NN	_	26	nmod
29	.	.	.	_	1	punct

1	drug1	drug1	NN	_	2	compound
2	requirements	requirement	NNS	_	10	nsubjpass
3	-LRB-	-lrb-	-LRB-	_	6	punct
4	i.e.	i.e.	FW	_	6	dep
5	,	,	,	_	6	punct
6	drug2	drug2	NN	_	2	dep
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	may	may	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	altered	alter	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	use	use	NN	_	7	nsubj
3	with	with	IN	_	5	case
4	general	general	JJ	_	5	amod
5	drug1	drug1	NN	_	2	nmod
6	may	may	MD	_	7	aux
7	result	result	VB	_	0	ROOT
8	in	in	IN	_	9	case
9	arrhythmias	arrhythmia	NNS	_	7	nmod
10	.	.	.	_	7	punct

1	The	the	DT	_	3	det
2	pressor	pressor	JJ	_	3	amod
3	effects	effect	NNS	_	13	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	those	those	DT	_	5	conj
8	of	of	IN	_	10	case
9	other	other	JJ	_	10	amod
10	drugs	drug	NNS	_	7	nmod
11	may	may	MD	_	13	aux
12	be	be	VB	_	13	cop
13	additive	additive	JJ	_	0	ROOT
14	when	when	WRB	_	18	advmod
15	the	the	DT	_	16	det
16	drugs	drug	NNS	_	18	nsubjpass
17	are	be	VBP	_	18	auxpass
18	used	use	VBN	_	13	advcl
19	concomitantly	concomitantly	RB	_	18	advmod
20	;	;	:	_	13	punct

1	conversely	conversely	RB	_	5	advmod
2	,	,	,	_	5	punct
3	drug1	drug1	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	interfere	interfere	VB	_	0	ROOT
6	with	with	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	-LRB-	-lrb-	-LRB-	_	11	punct
9	i.e.	i.e.	FW	_	11	dep
10	,	,	,	_	11	punct
11	drug3	drug3	NN	_	7	dep
12	,	,	,	_	11	punct
13	drug4	drug4	NN	_	11	appos
14	-RRB-	-rrb-	-RRB-	_	11	punct
15	.	.	.	_	5	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	use	use	NN	_	6	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	may	may	MD	_	6	aux
6	antagonize	antagonize	VB	_	0	ROOT
7	the	the	DT	_	9	det
8	anorectic	anorectic	NN	_	9	compound
9	effect	effect	NN	_	6	dobj
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Clinical	clinical	JJ	_	4	amod
4	evidence	evidence	NN	_	6	nsubj
5	has	have	VBZ	_	6	aux
6	shown	show	VBN	_	1	appos
7	that	that	IN	_	11	mark
8	drug2	drug2	NN	_	11	nsubjpass
9	can	can	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	formed	form	VBN	_	6	ccomp
12	with	with	IN	_	14	case
13	concurrent	concurrent	JJ	_	14	amod
14	ingestion	ingestion	NN	_	11	nmod
15	of	of	IN	_	16	case
16	drug3	drug3	NN	_	14	nmod
17	and	and	CC	_	16	cc
18	drug4	drug4	NN	_	16	conj
19	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	5	case
4	a	a	DT	_	5	det
5	study	study	NN	_	14	nmod
6	of	of	IN	_	10	case
7	7	7	CD	_	10	nummod
8	healthy	healthy	JJ	_	10	amod
9	male	male	JJ	_	10	amod
10	volunteers	volunteer	NNS	_	5	nmod
11	,	,	,	_	14	punct
12	drug2	drug2	NN	_	13	compound
13	treatment	treatment	NN	_	14	nsubj
14	potentiated	potentiate	VBD	_	1	appos
15	the	the	DT	_	17	det
16	blood	blood	NN	_	17	compound
17	glucose	glucose	NN	_	14	dobj
18	lowering	lower	VBG	_	19	amod
19	effect	effect	NN	_	17	dep
20	of	of	IN	_	21	case
21	drug3	drug3	NN	_	19	nmod
22	-LRB-	-lrb-	-LRB-	_	24	punct
23	a	a	DT	_	24	det
24	drug4	drug4	NN	_	21	dep
25	similar	similar	JJ	_	24	amod
26	to	to	TO	_	27	case
27	drug5	drug5	NN	_	25	nmod
28	-RRB-	-rrb-	-RRB-	_	24	punct
29	in	in	IN	_	30	case
30	3	3	CD	_	19	nmod
31	of	of	IN	_	34	case
32	the	the	DT	_	34	det
33	7	7	CD	_	34	nummod
34	subjects	subject	NNS	_	30	nmod
35	.	.	.	_	1	punct

1	Repeating	repeat	VBG	_	16	csubj
2	the	the	DT	_	3	det
3	study	study	NN	_	1	dobj
4	with	with	IN	_	8	case
5	6	6	CD	_	8	nummod
6	healthy	healthy	JJ	_	8	amod
7	male	male	JJ	_	8	amod
8	volunteers	volunteer	NNS	_	1	nmod
9	in	in	IN	_	11	case
10	the	the	DT	_	11	det
11	absence	absence	NN	_	1	nmod
12	of	of	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	did	do	VBD	_	16	aux
15	not	not	RB	_	16	neg
16	detect	detect	VB	_	0	ROOT
17	an	a	DT	_	18	det
18	effect	effect	NN	_	16	dobj
19	of	of	IN	_	20	case
20	drug2	drug2	NN	_	18	nmod
21	on	on	IN	_	23	case
22	glucose	glucose	NN	_	23	compound
23	tolerance	tolerance	NN	_	18	nmod
24	.	.	.	_	16	punct

1	Careful	careful	JJ	_	2	amod
2	supervision	supervision	NN	_	11	nsubjpass
3	of	of	IN	_	5	case
4	diabetic	diabetic	JJ	_	5	amod
5	patients	patient	NNS	_	2	nmod
6	under	under	IN	_	7	case
7	treatment	treatment	NN	_	2	nmod
8	with	with	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	is	be	VBZ	_	11	auxpass
11	recommended	recommend	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	It	it	PRP	_	7	nsubjpass
4	has	have	VBZ	_	7	aux
5	not	not	RB	_	7	neg
6	been	be	VBN	_	7	auxpass
7	established	establish	VBN	_	1	dep
8	if	if	IN	_	10	mark
9	there	there	EX	_	10	expl
10	is	be	VBZ	_	7	advcl
11	a	a	DT	_	13	det
12	pharmacokinetic	pharmacokinetic	JJ	_	13	amod
13	interaction	interaction	NN	_	10	nsubj
14	between	between	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	drug3	drug3	NN	_	15	conj
18	.	.	.	_	1	punct

1	However	however	RB	_	6	advmod
2	,	,	,	_	6	punct
3	it	it	PRP	_	6	nsubjpass
4	has	have	VBZ	_	6	aux
5	been	be	VBN	_	6	auxpass
6	established	establish	VBN	_	0	ROOT
7	that	that	IN	_	9	mark
8	drug1	drug1	NN	_	9	nsubj
9	interferes	interfere	VBZ	_	6	ccomp
10	with	with	IN	_	13	case
11	the	the	DT	_	13	det
12	contraceptive	contraceptive	JJ	_	13	amod
13	effect	effect	NN	_	9	nmod
14	of	of	IN	_	18	case
15	microdosed	microdosed	JJ	_	18	amod
16	drug2	drug2	NN	_	18	compound
17	minipill	minipill	NN	_	18	compound
18	preparations	preparation	NNS	_	13	nmod
19	.	.	.	_	6	punct

1	Microdosed	microdosed	JJ	_	4	amod
2	minipill	minipill	NN	_	4	compound
3	drug1	drug1	NN	_	4	compound
4	preparations	preparation	NNS	_	7	nsubjpass
5	are	be	VBP	_	7	auxpass
6	not	not	RB	_	7	neg
7	recommended	recommend	VBN	_	0	ROOT
8	for	for	IN	_	9	case
9	use	use	NN	_	7	nmod
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	.	.	.	_	7	punct

1	It	it	PRP	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	not	not	RB	_	4	neg
4	known	know	VBN	_	0	ROOT
5	whether	whether	IN	_	17	mark
6	other	other	JJ	_	7	amod
7	drug1	drug1	NN	_	17	nsubj
8	,	,	,	_	7	punct
9	such	such	JJ	_	11	case
10	as	as	IN	_	9	mwe
11	implants	implant	NNS	_	7	nmod
12	and	and	CC	_	11	cc
13	injectables	injectable	NNS	_	11	conj
14	,	,	,	_	7	punct
15	are	be	VBP	_	17	cop
16	adequate	adequate	JJ	_	17	amod
17	methods	method	NNS	_	4	ccomp
18	of	of	IN	_	19	case
19	contraception	contraception	NN	_	17	nmod
20	during	during	IN	_	22	case
21	drug2	drug2	NN	_	22	compound
22	therapy	therapy	NN	_	17	nmod
23	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	An	a	DT	_	5	det
4	increased	increase	VBN	_	5	amod
5	risk	risk	NN	_	10	nsubjpass
6	of	of	IN	_	7	case
7	hepatitis	hepatitis	NN	_	5	nmod
8	has	have	VBZ	_	10	aux
9	been	be	VBN	_	10	auxpass
10	reported	report	VBN	_	1	appos
11	to	to	TO	_	12	mark
12	result	result	VB	_	10	xcomp
13	from	from	IN	_	15	case
14	combined	combine	VBN	_	15	amod
15	use	use	NN	_	12	nmod
16	of	of	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	and	and	CC	_	17	cc
19	drug3	drug3	NN	_	17	conj
20	.	.	.	_	1	punct

1	Consequently	consequently	RB	_	11	advmod
2	,	,	,	_	11	punct
3	the	the	DT	_	4	det
4	combination	combination	NN	_	11	nsubjpass
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	with	with	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	is	be	VBZ	_	11	auxpass
10	also	also	RB	_	11	advmod
11	contraindicated	contraindicate	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	If	if	IN	_	6	mark
4	drug2	drug2	NN	_	6	nsubjpass
5	is	be	VBZ	_	6	auxpass
6	given	give	VBN	_	18	advcl
7	concurrently	concurrently	RB	_	6	advmod
8	with	with	IN	_	9	case
9	drug3	drug3	NN	_	6	nmod
10	,	,	,	_	18	punct
11	the	the	DT	_	13	det
12	protein	protein	NN	_	13	compound
13	binding	binding	NN	_	18	nsubjpass
14	of	of	IN	_	15	case
15	drug4	drug4	NN	_	13	nmod
16	may	may	MD	_	18	aux
17	be	be	VB	_	18	auxpass
18	reduced	reduce	VBN	_	1	dep
19	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Since	since	IN	_	9	mark
4	both	both	DT	_	5	cc:preconj
5	drug2	drug2	NN	_	9	nsubj
6	and	and	CC	_	5	cc
7	drug3	drug3	NN	_	5	conj
8	can	can	MD	_	9	aux
9	cause	cause	VB	_	18	advcl
10	increased	increase	VBN	_	12	amod
11	intracranial	intracranial	JJ	_	12	amod
12	pressure	pressure	NN	_	9	dobj
13	,	,	,	_	18	punct
14	their	they	PRP$	_	16	nmod:poss
15	combined	combine	VBN	_	16	amod
16	use	use	NN	_	18	nsubjpass
17	is	be	VBZ	_	18	auxpass
18	contraindicated	contraindicate	VBN	_	1	dep
19	.	.	.	_	1	punct

1	drug1	drug1	NN	_	4	compound
2	and	and	CC	_	1	cc
3	oral	oral	JJ	_	1	conj
4	drug2	drug2	NN	_	0	ROOT
5	:	:	:	_	4	punct
6	Concomitant	concomitant	JJ	_	7	amod
7	administration	administration	NN	_	18	nsubjpass
8	of	of	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	and/or	and/or	CC	_	9	cc
11	other	other	JJ	_	13	amod
12	oral	oral	JJ	_	13	amod
13	drug4	drug4	NN	_	9	conj
14	with	with	IN	_	15	case
15	drug5	drug5	NN	_	7	nmod
16	must	must	MD	_	18	aux
17	be	be	VB	_	18	auxpass
18	avoided	avoid	VBN	_	4	dep
19	because	because	IN	_	22	case
20	of	of	IN	_	19	mwe
21	the	the	DT	_	22	det
22	risk	risk	NN	_	18	nmod
23	of	of	IN	_	25	case
24	hypervitaminosis	hypervitaminosis	NN	_	25	compound
25	A.	a.	NN	_	22	nmod

1	Other	other	JJ	_	0	ROOT
2	:	:	:	_	1	punct
3	There	there	EX	_	4	expl
4	appears	appear	VBZ	_	1	appos
5	to	to	TO	_	9	mark
6	be	be	VB	_	9	cop
7	no	no	DT	_	9	neg
8	pharmacokinetic	pharmacokinetic	JJ	_	9	amod
9	interaction	interaction	NN	_	4	xcomp
10	between	between	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	drug2	drug2	NN	_	11	conj
14	,	,	,	_	11	punct
15	drug3	drug3	NN	_	11	conj
16	,	,	,	_	11	punct
17	or	or	CC	_	11	cc
18	drug4	drug4	NN	_	11	conj
19	.	.	.	_	1	punct

1	Investigations	investigation	NNS	_	16	nsubj
2	into	into	IN	_	4	case
3	the	the	DT	_	4	det
4	effect	effect	NN	_	1	nmod
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	on	on	IN	_	10	case
8	the	the	DT	_	10	det
9	protein	protein	NN	_	10	compound
10	binding	binding	NN	_	4	nmod
11	of	of	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	drug3	drug3	NN	_	12	appos
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	revealed	reveal	VBD	_	0	ROOT
17	no	no	DT	_	18	neg
18	interaction	interaction	NN	_	16	dobj
19	.	.	.	_	16	punct

1	Laboratory	laboratory	NN	_	2	compound
2	Tests	test	NNS	_	21	nsubjpass
3	If	if	IN	_	9	mark
4	significant	significant	JJ	_	7	amod
5	abnormal	abnormal	JJ	_	7	amod
6	laboratory	laboratory	NN	_	7	compound
7	results	result	NNS	_	9	nsubjpass
8	are	be	VBP	_	9	auxpass
9	obtained	obtain	VBN	_	21	advcl
10	,	,	,	_	21	punct
11	either	either	CC	_	13	cc:preconj
12	dosage	dosage	NN	_	13	compound
13	reduction	reduction	NN	_	21	nsubjpass
14	with	with	IN	_	16	case
15	careful	careful	JJ	_	16	amod
16	monitoring	monitoring	NN	_	13	nmod
17	or	or	CC	_	16	cc
18	treatment	treatment	NN	_	19	compound
19	discontinuation	discontinuation	NN	_	16	conj
20	is	be	VBZ	_	21	auxpass
21	recommended	recommend	VBN	_	0	ROOT
22	,	,	,	_	21	punct
23	depending	depend	VBG	_	26	case
24	on	on	IN	_	26	case
25	clinical	clinical	JJ	_	26	amod
26	judgement	judgement	NN	_	21	advcl
27	.	.	.	_	21	punct

1	Blood	blood	NN	_	2	compound
2	Sugar	Sugar	NNP	_	0	ROOT
3	:	:	:	_	2	punct
4	Some	some	DT	_	5	det
5	patients	patient	NNS	_	9	nsubj
6	receiving	receive	VBG	_	5	acl
7	drug1	drug1	NN	_	6	dobj
8	have	have	VBP	_	9	aux
9	experienced	experience	VBN	_	2	appos
10	problems	problem	NNS	_	9	dobj
11	with	with	IN	_	14	case
12	blood	blood	NN	_	14	compound
13	sugar	sugar	NN	_	14	compound
14	control	control	NN	_	10	nmod
15	.	.	.	_	2	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	10	nmod
3	,	,	,	_	10	punct
4	new	new	JJ	_	5	amod
5	cases	case	NNS	_	10	nsubjpass
6	of	of	IN	_	7	case
7	diabetes	diabetes	NNS	_	5	nmod
8	have	have	VBP	_	10	aux
9	been	be	VBN	_	10	auxpass
10	diagnosed	diagnose	VBN	_	0	ROOT
11	during	during	IN	_	13	case
12	drug1	drug1	NN	_	13	compound
13	therapy	therapy	NN	_	10	nmod
14	,	,	,	_	13	punct
15	including	include	VBG	_	17	case
16	diabetic	diabetic	JJ	_	17	amod
17	ketoacidosis	ketoacidosis	NN	_	13	nmod
18	.	.	.	_	10	punct

1	In	in	IN	_	2	case
2	diabetics	diabetic	NNS	_	8	nmod
3	,	,	,	_	8	punct
4	blood-sugar	blood-sugar	JJ	_	5	amod
5	levels	level	NNS	_	8	nsubjpass
6	should	should	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	monitored	monitor	VBN	_	0	ROOT
9	very	very	RB	_	10	advmod
10	carefully	carefully	RB	_	8	advmod
11	.	.	.	_	8	punct

1	Lipids	lipid	NNS	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	5	case
4	clinical	clinical	JJ	_	5	amod
5	studies	study	NNS	_	13	nmod
6	,	,	,	_	13	punct
7	the	the	DT	_	8	det
8	incidence	incidence	NN	_	13	nsubj
9	of	of	IN	_	10	case
10	hypertriglyceridemia	hypertriglyceridemia	NN	_	8	nmod
11	was	be	VBD	_	13	cop
12	66	66	CD	_	13	nummod
13	%	%	NN	_	1	dep
14	,	,	,	_	13	punct
15	hypercholesterolemia	hypercholesterolemia	NN	_	18	nsubj
16	was	be	VBD	_	18	cop
17	33	33	CD	_	18	nummod
18	%	%	NN	_	13	dep
19	and	and	CC	_	18	cc
20	that	that	IN	_	26	nsubj
21	of	of	IN	_	23	case
22	decreased	decrease	VBN	_	23	amod
23	HDL	hdl	NN	_	20	nmod
24	was	be	VBD	_	26	cop
25	40	40	CD	_	26	nummod
26	%	%	NN	_	18	conj
27	.	.	.	_	1	punct

1	Pretreatment	pretreatment	NN	_	4	compound
2	and	and	CC	_	1	cc
3	follow-up	follow-up	NN	_	1	conj
4	measurements	measurement	NNS	_	7	nsubjpass
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	obtained	obtain	VBN	_	0	ROOT
8	under	under	IN	_	10	case
9	fasting	fasting	NN	_	10	compound
10	conditions	condition	NNS	_	7	nmod
11	.	.	.	_	7	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	recommended	recommend	VBN	_	0	ROOT
4	that	that	IN	_	8	mark
5	these	these	DT	_	6	det
6	tests	test	NNS	_	8	nsubjpass
7	be	be	VB	_	8	auxpass
8	performed	perform	VBN	_	3	ccomp
9	weekly	weekly	JJ	_	8	xcomp
10	or	or	CC	_	9	cc
11	every	every	DT	_	13	det
12	other	other	JJ	_	13	amod
13	week	week	NN	_	9	conj
14	until	until	IN	_	21	mark
15	the	the	DT	_	17	det
16	lipid	lipid	NN	_	17	compound
17	response	response	NN	_	21	nsubj
18	to	to	TO	_	19	case
19	drug1	drug1	NN	_	17	nmod
20	has	have	VBZ	_	21	aux
21	stabilized	stabilize	VBN	_	8	advcl
22	.	.	.	_	3	punct

1	Liver	liver	NN	_	3	compound
2	Function	function	NN	_	3	compound
3	Tests	test	NNS	_	0	ROOT
4	:	:	:	_	3	punct
5	Elevations	elevation	NNS	_	19	nsubjpass
6	of	of	IN	_	7	case
7	AST	AST	NNP	_	5	nmod
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	SGOT	SGOT	NNP	_	7	appos
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	,	,	,	_	7	punct
12	ALT	alt	NN	_	7	conj
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	SGPT	sgpt	NN	_	12	appos
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	or	or	CC	_	7	cc
17	LDH	ldh	NN	_	7	conj
18	were	be	VBD	_	19	auxpass
19	experienced	experience	VBN	_	3	appos
20	by	by	IN	_	22	case
21	approximately	approximately	RB	_	22	advmod
22	1	1	CD	_	19	nmod
23	in	in	IN	_	25	case
24	3	3	CD	_	25	nummod
25	patients	patient	NNS	_	22	nmod
26	treated	treat	VBN	_	25	acl
27	with	with	IN	_	28	case
28	drug1	drug1	NN	_	26	nmod
29	.	.	.	_	3	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	recommended	recommend	VBN	_	0	ROOT
4	that	that	IN	_	8	mark
5	these	these	DT	_	6	det
6	tests	test	NNS	_	8	nsubjpass
7	be	be	VB	_	8	auxpass
8	performed	perform	VBN	_	3	ccomp
9	prior	prior	RB	_	8	advmod
10	to	to	TO	_	11	case
11	initiation	initiation	NN	_	9	nmod
12	of	of	IN	_	14	case
13	drug1	drug1	NN	_	14	compound
14	therapy	therapy	NN	_	11	nmod
15	,	,	,	_	8	punct
16	at	at	IN	_	21	case
17	1	1	LS	_	21	dep
18	-	-	:	_	17	punct
19	to	to	TO	_	21	case
20	2-week	2-week	JJ	_	21	amod
21	intervals	interval	NNS	_	8	nmod
22	until	until	IN	_	23	case
23	stable	stable	JJ	_	21	nmod
24	and	and	CC	_	23	cc
25	thereafter	thereafter	RB	_	23	conj
26	at	at	IN	_	27	case
27	intervals	interval	NNS	_	23	nmod
28	as	as	IN	_	30	mark
29	clinically	clinically	RB	_	30	advmod
30	indicated	indicate	VBN	_	23	dep
31	.	.	.	_	3	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	highly	highly	RB	_	4	advmod
4	bound	bind	VBN	_	0	ROOT
5	to	to	TO	_	7	case
6	plasma	plasma	NN	_	7	compound
7	protein	protein	NN	_	4	nmod
8	-LRB-	-lrb-	-LRB-	_	10	punct
9	99.9	99.9	CD	_	10	nummod
10	%	%	NN	_	7	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	.	.	.	_	4	punct

1	Therefore	therefore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	caution	caution	NN	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	used	use	VBN	_	28	csubj
7	when	when	WRB	_	8	advmod
8	administering	administer	VBG	_	6	advcl
9	drug1	drug1	NN	_	8	dobj
10	concurrently	concurrently	RB	_	9	advmod
11	with	with	IN	_	16	case
12	other	other	JJ	_	16	amod
13	highly	highly	RB	_	16	advmod
14	plasma	plasma	NN	_	16	compound
15	protein-bound	protein-bound	JJ	_	16	amod
16	drugs	drug	NNS	_	8	nmod
17	with	with	IN	_	20	case
18	narrow	narrow	JJ	_	20	amod
19	therapeutic	therapeutic	JJ	_	20	amod
20	indices	index	NNS	_	16	nmod
21	,	,	,	_	6	punct
22	as	as	IN	_	23	case
23	competition	competition	NN	_	6	nmod
24	for	for	IN	_	26	case
25	binding	bind	VBG	_	26	amod
26	sites	site	NNS	_	23	nmod
27	may	may	MD	_	28	aux
28	occur	occur	VB	_	0	ROOT
29	-LRB-	-lrb-	-LRB-	_	32	punct
30	e.g.	e.g.	FW	_	32	dep
31	,	,	,	_	32	punct
32	drug2	drug2	NN	_	28	dep
33	-RRB-	-rrb-	-RRB-	_	32	punct
34	.	.	.	_	28	punct

1	In	in	FW	_	4	amod
2	vitro	vitro	FW	_	1	dep
3	metabolism	metabolism	NN	_	4	compound
4	studies	study	NNS	_	6	nsubj
5	have	have	VBP	_	6	aux
6	demonstrated	demonstrate	VBN	_	0	ROOT
7	that	that	IN	_	9	mark
8	drug1	drug1	NN	_	9	nsubj
9	has	have	VBZ	_	6	ccomp
10	no	no	DT	_	13	neg
11	significant	significant	JJ	_	13	amod
12	inhibitory	inhibitory	JJ	_	13	amod
13	effect	effect	NN	_	9	dobj
14	on	on	IN	_	17	case
15	cytochrome	cytochrome	NN	_	17	compound
16	P450	p450	NN	_	17	compound
17	enzymes	enzyme	NNS	_	9	nmod
18	.	.	.	_	6	punct

1	Although	although	IN	_	8	mark
2	no	no	DT	_	5	neg
3	drug-drug	drug-drug	JJ	_	5	amod
4	interaction	interaction	NN	_	5	compound
5	studies	study	NNS	_	8	nsubjpass
6	have	have	VBP	_	8	aux
7	been	be	VBN	_	8	auxpass
8	conducted	conduct	VBN	_	14	advcl
9	in	in	FW	_	10	compound
10	vivo	vivo	FW	_	8	advmod
11	,	,	,	_	14	punct
12	it	it	PRP	_	14	nsubjpass
13	is	be	VBZ	_	14	auxpass
14	expected	expect	VBN	_	0	ROOT
15	that	that	IN	_	20	mark
16	no	no	DT	_	18	neg
17	significant	significant	JJ	_	18	amod
18	interaction	interaction	NN	_	20	nsubj
19	would	would	MD	_	20	aux
20	occur	occur	VB	_	14	ccomp
21	when	when	WRB	_	24	advmod
22	drug1	drug1	NN	_	24	nsubjpass
23	is	be	VBZ	_	24	auxpass
24	co-administered	co-administer	VBN	_	20	advcl
25	with	with	IN	_	26	case
26	drugs	drug	NNS	_	24	nmod
27	that	that	WDT	_	30	nsubjpass
28	either	either	RB	_	30	advmod
29	are	be	VBP	_	30	auxpass
30	metabolized	metabolize	VBN	_	26	acl:relcl
31	by	by	IN	_	30	nmod
32	or	or	CC	_	30	cc
33	inhibit	inhibit	VB	_	30	conj
34	cytochrome	cytochrome	NN	_	36	compound
35	P450	p450	NN	_	36	compound
36	enzymes	enzyme	NNS	_	33	dobj
37	.	.	.	_	14	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	increase	increase	VB	_	0	ROOT
4	sensitivity	sensitivity	NN	_	3	dobj
5	to	to	TO	_	7	case
6	oral	oral	JJ	_	7	amod
7	anticoagulahts	anticoagulaht	NNS	_	4	nmod
8	.	.	.	_	3	punct

1	Dosage	dosage	NN	_	6	nsubj
2	of	of	IN	_	4	case
3	the	the	DT	_	4	det
4	drug1	drug1	NN	_	1	nmod
5	may	may	MD	_	6	aux
6	require	require	VB	_	0	ROOT
7	reduction	reduction	NN	_	6	dobj
8	in	in	IN	_	11	mark
9	order	order	NN	_	8	mwe
10	to	to	TO	_	11	mark
11	maintain	maintain	VB	_	7	acl
12	satisfactory	satisfactory	JJ	_	14	amod
13	therapeutic	therapeutic	JJ	_	14	amod
14	hypoprothrombinemia	hypoprothrombinemia	NN	_	11	dobj
15	.	.	.	_	6	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	administration	administration	NN	_	8	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	may	may	MD	_	8	aux
8	result	result	VB	_	0	ROOT
9	in	in	IN	_	12	case
10	elevated	elevated	JJ	_	12	amod
11	serum	serum	NN	_	12	compound
12	levels	level	NNS	_	8	nmod
13	of	of	IN	_	14	case
14	drug3	drug3	NN	_	12	nmod
15	.	.	.	_	8	punct

1	In	in	IN	_	3	case
2	diabetic	diabetic	JJ	_	3	amod
3	patients	patient	NNS	_	11	nmod
4	,	,	,	_	11	punct
5	the	the	DT	_	7	det
6	metabolic	metabolic	JJ	_	7	amod
7	effects	effect	NNS	_	11	nsubj
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	may	may	MD	_	11	aux
11	decrease	decrease	VB	_	0	ROOT
12	blood	blood	NN	_	13	compound
13	glucose	glucose	NN	_	11	dobj
14	and	and	CC	_	11	cc
15	therefore	therefore	RB	_	18	advmod
16	,	,	,	_	18	punct
17	drug2	drug2	NN	_	18	compound
18	requirements	requirement	NNS	_	11	conj
19	.	.	.	_	11	punct

1	When	when	WRB	_	5	advmod
2	drug1	drug1	NN	_	3	compound
3	HCl	hcl	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	administered	administer	VBN	_	17	advcl
6	concomitantly	concomitantly	RB	_	5	advmod
7	with	with	IN	_	9	case
8	an	a	DT	_	9	det
9	drug2	drug2	NN	_	5	nmod
10	,	,	,	_	17	punct
11	the	the	DT	_	12	det
12	risk	risk	NN	_	17	nsubjpass
13	of	of	IN	_	14	case
14	hyperkalemia	hyperkalemia	NN	_	12	nmod
15	may	may	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	increased	increase	VBN	_	0	ROOT
18	.	.	.	_	17	punct

1	Therefore	therefore	RB	_	19	advmod
2	,	,	,	_	19	punct
3	if	if	IN	_	10	mark
4	concomitant	concomitant	JJ	_	5	amod
5	use	use	NN	_	10	nsubjpass
6	of	of	IN	_	8	case
7	these	these	DT	_	8	det
8	agents	agent	NNS	_	5	nmod
9	is	be	VBZ	_	10	auxpass
10	indicated	indicate	VBN	_	19	advcl
11	because	because	IN	_	14	case
12	of	of	IN	_	11	mwe
13	demonstrated	demonstrate	VBN	_	14	amod
14	hypokalemia	hypokalemia	NN	_	10	nmod
15	,	,	,	_	19	punct
16	they	they	PRP	_	19	nsubjpass
17	should	should	MD	_	19	aux
18	be	be	VB	_	19	auxpass
19	used	use	VBN	_	0	ROOT
20	with	with	IN	_	21	case
21	caution	caution	NN	_	19	nmod
22	and	and	CC	_	21	cc
23	with	with	IN	_	25	case
24	frequent	frequent	JJ	_	25	amod
25	monitoring	monitoring	NN	_	21	conj
26	of	of	IN	_	28	case
27	serum	serum	NN	_	28	compound
28	potassium	potassium	NN	_	25	nmod
29	.	.	.	_	19	punct

1	drug1	drug1	NN	_	6	nsubjpass
2	generally	generally	RB	_	6	advmod
3	should	should	MD	_	6	aux
4	not	not	RB	_	6	neg
5	be	be	VB	_	6	auxpass
6	given	give	VBN	_	0	ROOT
7	with	with	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	because	because	IN	_	11	mark
10	they	they	PRP	_	11	nsubj
11	reduce	reduce	VBP	_	6	advcl
12	its	its	PRP$	_	14	nmod:poss
13	renal	renal	JJ	_	14	amod
14	clearance	clearance	NN	_	11	dobj
15	and	and	CC	_	11	cc
16	add	add	VB	_	11	conj
17	a	a	DT	_	19	det
18	high	high	JJ	_	19	amod
19	risk	risk	NN	_	16	dobj
20	of	of	IN	_	22	case
21	lithium	lithium	NN	_	22	compound
22	toxicity	toxicity	NN	_	19	nmod
23	.	.	.	_	6	punct

1	Read	read	VB	_	0	ROOT
2	circulars	circular	NNS	_	1	dobj
3	for	for	IN	_	5	case
4	drug1	drug1	NN	_	5	compound
5	preparations	preparation	NNS	_	1	nmod
6	before	before	IN	_	7	case
7	use	use	NN	_	1	nmod
8	of	of	IN	_	11	case
9	such	such	JJ	_	11	amod
10	concomitant	concomitant	JJ	_	11	amod
11	therapy	therapy	NN	_	7	nmod
12	.	.	.	_	1	punct

1	In	in	IN	_	3	case
2	some	some	DT	_	3	det
3	patients	patient	NNS	_	11	nmod
4	,	,	,	_	11	punct
5	the	the	DT	_	6	det
6	administration	administration	NN	_	11	nsubj
7	of	of	IN	_	9	case
8	a	a	DT	_	9	det
9	drug1	drug1	NN	_	6	nmod
10	can	can	MD	_	11	aux
11	reduce	reduce	VB	_	0	ROOT
12	the	the	DT	_	19	det
13	diuretic	diuretic	JJ	_	19	amod
14	,	,	,	_	13	punct
15	natriuretic	natriuretic	JJ	_	13	conj
16	,	,	,	_	13	punct
17	and	and	CC	_	13	cc
18	antihypertensive	antihypertensive	JJ	_	13	conj
19	effects	effect	NNS	_	11	dobj
20	of	of	IN	_	21	case
21	drug2	drug2	NN	_	19	nmod
22	,	,	,	_	21	punct
23	drug3	drug3	NN	_	21	conj
24	and	and	CC	_	21	cc
25	drug4	drug4	NN	_	21	conj
26	.	.	.	_	11	punct

1	Therefore	therefore	RB	_	15	advmod
2	,	,	,	_	15	punct
3	when	when	WRB	_	8	advmod
4	drug1	drug1	NN	_	8	nsubjpass
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	are	be	VBP	_	8	auxpass
8	used	use	VBN	_	15	advcl
9	concomitantly	concomitantly	RB	_	8	advmod
10	,	,	,	_	15	punct
11	the	the	DT	_	12	det
12	patient	patient	NN	_	15	nsubjpass
13	should	should	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	observed	observe	VBN	_	0	ROOT
16	closely	closely	RB	_	15	advmod
17	to	to	TO	_	18	mark
18	determine	determine	VB	_	15	xcomp
19	if	if	IN	_	27	mark
20	the	the	DT	_	22	det
21	desired	desire	VBN	_	22	amod
22	effect	effect	NN	_	27	nsubjpass
23	of	of	IN	_	25	case
24	the	the	DT	_	25	det
25	drug3	drug3	NN	_	22	nmod
26	is	be	VBZ	_	27	auxpass
27	obtained	obtain	VBN	_	18	advcl
28	.	.	.	_	15	punct

1	Since	since	IN	_	0	ROOT
2	drug1	drug1	NN	_	1	dep
3	and	and	CC	_	2	cc
4	drug2	drug2	NN	_	2	conj
5	,	,	,	_	2	punct
6	including	include	VBG	_	7	case
7	drug3	drug3	NN	_	2	nmod
8	,	,	,	_	2	punct
9	may	may	MD	_	12	aux
10	each	each	DT	_	12	nsubjpass
11	be	be	VB	_	12	auxpass
12	associated	associate	VBN	_	2	acl:relcl
13	with	with	IN	_	17	case
14	increased	increase	VBN	_	17	amod
15	serum	serum	NN	_	17	compound
16	potassium	potassium	NN	_	17	compound
17	levels	level	NNS	_	12	nmod
18	,	,	,	_	2	punct
19	the	the	DT	_	21	det
20	potential	potential	JJ	_	21	amod
21	effects	effect	NNS	_	30	nsubjpass
22	on	on	IN	_	24	case
23	potassium	potassium	NN	_	24	compound
24	kinetics	kinetics	NNS	_	21	nmod
25	and	and	CC	_	24	cc
26	renal	renal	JJ	_	27	amod
27	function	function	NN	_	24	conj
28	should	should	MD	_	30	aux
29	be	be	VB	_	30	auxpass
30	considered	consider	VBN	_	2	acl:relcl
31	when	when	WRB	_	35	advmod
32	these	these	DT	_	33	det
33	agents	agent	NNS	_	35	nsubjpass
34	are	be	VBP	_	35	auxpass
35	administered	administer	VBN	_	30	advcl
36	concurrently	concurrently	RB	_	35	advmod
37	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Based	base	VBN	_	5	case
4	on	on	IN	_	5	case
5	reports	report	NNS	_	1	nmod
6	of	of	IN	_	8	case
7	profound	profound	JJ	_	8	amod
8	hypotension	hypotension	NN	_	5	nmod
9	and	and	CC	_	8	cc
10	loss	loss	NN	_	8	conj
11	of	of	IN	_	12	case
12	consciousness	consciousness	NN	_	10	nmod
13	when	when	WRB	_	16	advmod
14	drug2	drug2	NN	_	16	nsubjpass
15	was	be	VBD	_	16	auxpass
16	administered	administer	VBN	_	5	acl:relcl
17	with	with	IN	_	18	case
18	drug3	drug3	NN	_	16	nmod
19	,	,	,	_	5	punct
20	the	the	DT	_	22	det
21	concomitant	concomitant	JJ	_	22	amod
22	use	use	NN	_	5	appos
23	of	of	IN	_	24	case
24	drug4	drug4	NN	_	22	nmod
25	with	with	IN	_	26	case
26	drugs	drug	NNS	_	22	nmod
27	of	of	IN	_	29	case
28	the	the	DT	_	29	det
29	drug5	drug5	NN	_	26	nmod
30	-LRB-	-lrb-	-LRB-	_	48	punct
31	including	include	VBG	_	48	dep
32	,	,	,	_	48	punct
33	for	for	IN	_	34	case
34	example	example	NN	_	48	nmod
35	,	,	,	_	48	punct
36	drug6	drug6	NN	_	48	dep
37	,	,	,	_	48	punct
38	drug7	drug7	NN	_	48	dep
39	,	,	,	_	48	punct
40	drug8	drug8	NN	_	48	nsubjpass
41	,	,	,	_	40	punct
42	drug9	drug9	NN	_	40	conj
43	,	,	,	_	40	punct
44	and	and	CC	_	40	cc
45	drug10	drug10	NN	_	40	conj
46	-RRB-	-rrb-	-RRB-	_	40	punct
47	is	be	VBZ	_	48	auxpass
48	contraindicated	contraindicate	VBN	_	29	acl
49	.	.	.	_	1	punct

1	drug1	drug1	NN	_	2	compound
2	s	s	NNS	_	0	ROOT
3	and	and	CC	_	2	cc
4	drug2	drug2	NN	_	2	conj
5	:	:	:	_	2	punct
6	The	the	DT	_	9	det
7	following	follow	VBG	_	9	amod
8	adverse	adverse	JJ	_	9	amod
9	events	event	NNS	_	11	nsubjpass
10	were	be	VBD	_	11	auxpass
11	experienced	experience	VBN	_	2	dep
12	more	more	RBR	_	13	advmod
13	commonly	commonly	RB	_	11	advmod
14	in	in	IN	_	15	case
15	patients	patient	NNS	_	13	nmod
16	receiving	receive	VBG	_	15	acl
17	concomitant	concomitant	JJ	_	18	amod
18	drug3	drug3	NN	_	16	dobj
19	or	or	CC	_	18	cc
20	drug4	drug4	NN	_	18	conj
21	-LRB-	-lrb-	-LRB-	_	22	punct
22	n	n	NN	_	20	dep
23	=	=	JJ	_	22	amod
24	94	94	CD	_	23	dep
25	-RRB-	-rrb-	-RRB-	_	22	punct
26	compared	compare	VBN	_	28	case
27	to	to	TO	_	28	case
28	patients	patient	NNS	_	15	nmod
29	not	not	RB	_	30	neg
30	receiving	receive	VBG	_	28	acl
31	these	these	DT	_	33	det
32	concomitant	concomitant	JJ	_	33	amod
33	drugs	drug	NNS	_	30	dobj
34	-LRB-	-lrb-	-LRB-	_	35	punct
35	n	n	NN	_	11	dep
36	=	=	JJ	_	35	amod
37	456	456	CD	_	36	dep
38	-RRB-	-rrb-	-RRB-	_	35	punct
39	:	:	:	_	11	punct
40	hypotension	hypotension	NN	_	11	dep
41	10	10	CD	_	42	nummod
42	%	%	NN	_	40	dep
43	vs	vs	CC	_	42	cc
44	4	4	CD	_	45	nummod
45	%	%	NN	_	42	conj
46	,	,	,	_	42	punct
47	myocardial	myocardial	JJ	_	48	amod
48	infarction	infarction	NN	_	42	conj
49	3	3	CD	_	50	nummod
50	%	%	NN	_	48	dep
51	vs	vs	CC	_	50	cc
52	1	1	CD	_	53	nummod
53	%	%	NN	_	50	conj
54	,	,	,	_	42	punct
55	serious	serious	JJ	_	56	amod
56	pneumonia	pneumonia	NN	_	42	appos
57	5	5	CD	_	58	nummod
58	%	%	NN	_	56	dep
59	vs	vs	CC	_	58	cc
60	3	3	CD	_	61	nummod
61	%	%	NN	_	58	conj
62	,	,	,	_	42	punct
63	serious	serious	JJ	_	64	nsubj
64	falls	fall	VBZ	_	42	acl:relcl
65	9	9	CD	_	66	nummod
66	%	%	NN	_	64	dobj
67	vs	vs	CC	_	66	cc
68	3	3	CD	_	69	nummod
69	%	%	NN	_	66	conj
70	,	,	,	_	66	punct
71	and	and	CC	_	66	cc
72	bone	bone	NN	_	75	compound
73	and	and	CC	_	72	cc
74	joint	joint	JJ	_	72	conj
75	injuries	injury	NNS	_	66	conj
76	6	6	CD	_	77	nummod
77	%	%	NN	_	75	dep
78	vs	vs	CC	_	77	cc
79	2	2	CD	_	80	nummod
80	%	%	NN	_	77	conj
81	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	mechanism	mechanism	NN	_	9	nsubj
3	underlying	underlie	VBG	_	2	acl
4	many	many	JJ	_	3	dobj
5	of	of	IN	_	7	case
6	these	these	DT	_	7	det
7	events	event	NNS	_	4	nmod
8	is	be	VBZ	_	9	cop
9	unknown	unknown	JJ	_	0	ROOT
10	,	,	,	_	9	punct
11	but	but	CC	_	9	cc
12	may	may	MD	_	13	aux
13	represent	represent	VB	_	9	conj
14	increased	increase	VBN	_	15	amod
15	hypotension	hypotension	NN	_	13	dobj
16	.	.	.	_	9	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Since	since	IN	_	7	mark
4	drug2	drug2	NN	_	7	nsubj
5	is	be	VBZ	_	7	cop
6	a	a	DT	_	7	det
7	drug3	drug3	NN	_	11	advcl
8	,	,	,	_	11	punct
9	it	it	PRP	_	11	nsubj
10	is	be	VBZ	_	11	cop
11	possible	possible	JJ	_	1	dep
12	that	that	IN	_	30	mark
13	drug4	drug4	NN	_	30	nsubj
14	,	,	,	_	13	punct
15	such	such	JJ	_	18	case
16	as	as	IN	_	15	mwe
17	the	the	DT	_	18	det
18	drug5	drug5	NN	_	13	nmod
19	-LRB-	-lrb-	-LRB-	_	20	punct
20	drug6	drug6	NN	_	18	dep
21	,	,	,	_	20	punct
22	drug7	drug7	NN	_	20	appos
23	,	,	,	_	20	punct
24	drug8	drug8	NN	_	20	appos
25	-RRB-	-rrb-	-RRB-	_	20	punct
26	or	or	CC	_	18	cc
27	drug9	drug9	NN	_	18	conj
28	,	,	,	_	13	punct
29	may	may	MD	_	30	aux
30	diminish	diminish	VB	_	11	ccomp
31	the	the	DT	_	32	det
32	effectiveness	effectiveness	NN	_	30	dobj
33	of	of	IN	_	34	case
34	drug10	drug10	NN	_	32	nmod
35	.	.	.	_	1	punct

1	Patients	patient	NNS	_	13	nsubjpass
2	with	with	IN	_	5	case
3	major	major	JJ	_	5	amod
4	psychotic	psychotic	JJ	_	5	amod
5	disorders	disorder	NNS	_	1	nmod
6	,	,	,	_	1	punct
7	treated	treat	VBN	_	1	acl
8	with	with	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	,	,	,	_	1	punct
11	should	should	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	treated	treat	VBN	_	0	ROOT
14	with	with	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	only	only	RB	_	21	advmod
17	if	if	IN	_	21	mark
18	the	the	DT	_	20	det
19	potential	potential	JJ	_	20	amod
20	benefits	benefit	NNS	_	21	nsubj
21	outweigh	outweigh	VBP	_	13	advcl
22	the	the	DT	_	23	det
23	risks	risk	NNS	_	21	dobj
24	.	.	.	_	13	punct

1	Drugs	drug	NNS	_	9	nsubjpass
2	Prolonging	prolong	VBG	_	1	acl
3	the	the	DT	_	6	det
4	QT/QTc	QT/QTc	NNP	_	6	compound
5	Interval	Interval	NNP	_	6	compound
6	Caution	caution	NN	_	2	dobj
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	exercised	exercise	VBN	_	0	ROOT
10	when	when	WRB	_	11	advmod
11	prescribing	prescribe	VBG	_	9	advcl
12	drug1	drug1	NN	_	11	dobj
13	concomitantly	concomitantly	RB	_	12	advmod
14	with	with	IN	_	15	case
15	drugs	drug	NNS	_	12	nmod
16	that	that	WDT	_	17	nsubj
17	prolong	prolong	VBP	_	15	acl:relcl
18	the	the	DT	_	20	det
19	QT/QTc	qt/qtc	JJ	_	20	amod
20	interval	interval	NN	_	17	dobj
21	.	.	.	_	9	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	3	amod
2	Test	test	NN	_	3	compound
3	Interactions	interaction	NNS	_	0	ROOT
4	There	there	EX	_	5	expl
5	are	be	VBP	_	3	acl:relcl
6	no	no	DT	_	8	neg
7	known	known	JJ	_	8	amod
8	interactions	interaction	NNS	_	5	nsubj
9	between	between	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	laboratory	laboratory	NN	_	13	compound
13	tests	test	NNS	_	10	conj
14	.	.	.	_	3	punct

1	Since	since	IN	_	5	mark
2	drug1	drug1	NN	_	5	nsubjpass
3	is	be	VBZ	_	5	auxpass
4	extensively	extensively	RB	_	5	advmod
5	metabolized	metabolize	VBN	_	14	advcl
6	by	by	IN	_	9	case
7	cytochrome	cytochrome	NN	_	9	compound
8	P-450	p-450	NN	_	9	compound
9	isoenzymes	isoenzyme	NNS	_	5	nmod
10	,	,	,	_	14	punct
11	caution	caution	NN	_	14	nsubjpass
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	exercised	exercise	VBN	_	0	ROOT
15	when	when	WRB	_	18	advmod
16	drug2	drug2	NN	_	18	nsubjpass
17	is	be	VBZ	_	18	auxpass
18	coadministered	coadminister	VBN	_	14	advcl
19	with	with	IN	_	20	case
20	inhibitors	inhibitor	NNS	_	18	nmod
21	of	of	IN	_	22	case
22	C.P.A.	C.P.A.	NNP	_	20	nmod
23	such	such	JJ	_	25	case
24	as	as	IN	_	23	mwe
25	drug3	drug3	NN	_	22	nmod
26	and	and	CC	_	25	cc
27	drug4	drug4	NN	_	25	conj
28	or	or	CC	_	25	cc
29	inhibitors	inhibitor	NNS	_	25	conj
30	of	of	IN	_	31	case
31	CYP2C19	cyp2c19	NN	_	29	nmod
32	such	such	JJ	_	34	case
33	as	as	IN	_	32	mwe
34	drug5	drug5	NN	_	31	nmod
35	.	.	.	_	14	punct

1	Pharmacokinetic	pharmacokinetic	JJ	_	2	amod
2	studies	study	NNS	_	4	nsubj
3	have	have	VBP	_	4	aux
4	demonstrated	demonstrate	VBN	_	0	ROOT
5	that	that	IN	_	10	mark
6	drug1	drug1	NN	_	10	nsubj
7	and	and	CC	_	6	cc
8	drug2	drug2	NN	_	6	conj
9	significantly	significantly	RB	_	10	advmod
10	increased	increase	VBD	_	4	ccomp
11	the	the	DT	_	13	det
12	systemic	systemic	JJ	_	13	amod
13	exposure	exposure	NN	_	10	dobj
14	of	of	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	and/or	and/or	CC	_	15	cc
17	its	its	PRP$	_	19	nmod:poss
18	major	major	JJ	_	19	amod
19	metabolites	metabolite	NNS	_	15	conj
20	.	.	.	_	4	punct

1	Population	Population	NNP	_	3	compound
2	pharmacokinetic	pharmacokinetic	JJ	_	3	amod
3	studies	study	NNS	_	4	nsubj
4	showed	show	VBD	_	0	ROOT
5	higher	higher	JJR	_	6	amod
6	concentrations	concentration	NNS	_	4	dobj
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	among	among	IN	_	10	case
10	patients	patient	NNS	_	6	nmod
11	concurrently	concurrently	RB	_	12	advmod
12	treated	treat	VBN	_	10	acl
13	with	with	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	,	,	,	_	14	punct
16	an	a	DT	_	17	det
17	inhibitor	inhibitor	NN	_	14	appos
18	of	of	IN	_	19	case
19	C.P.A.	C.P.A.	NNP	_	17	nmod
20	.	.	.	_	4	punct

1	drug1	drug1	NN	_	7	nsubj
2	does	do	VBZ	_	7	aux
3	not	not	RB	_	7	neg
4	,	,	,	_	7	punct
5	however	however	RB	_	7	advmod
6	,	,	,	_	7	punct
7	appear	appear	VBP	_	0	ROOT
8	to	to	TO	_	9	mark
9	cause	cause	VB	_	7	xcomp
10	increased	increase	VBN	_	12	amod
11	blood	blood	NN	_	12	compound
12	levels	level	NNS	_	9	dobj
13	of	of	IN	_	14	case
14	drugs	drug	NNS	_	12	nmod
15	metabolized	metabolize	VBN	_	14	acl
16	by	by	IN	_	17	case
17	CYP3A4	cyp3a4	NN	_	15	nmod
18	,	,	,	_	7	punct
19	as	as	IN	_	21	mark
20	it	it	PRP	_	21	nsubj
21	had	have	VBD	_	7	advcl
22	no	no	DT	_	23	neg
23	effect	effect	NN	_	21	dobj
24	on	on	IN	_	25	case
25	drug2	drug2	NN	_	21	nmod
26	,	,	,	_	21	punct
27	a	a	DT	_	28	det
28	drug	drug	NN	_	26	root
29	with	with	IN	_	30	case
30	metabolism	metabolism	NN	_	28	nmod
31	very	very	RB	_	32	advmod
32	sensitive	sensitive	JJ	_	28	amod
33	to	to	TO	_	35	case
34	C.P.A.	C.P.A.	NNP	_	35	compound
35	inhibition	inhibition	NN	_	32	nmod
36	.	.	.	_	28	punct

1	drug1	drug1	NN	_	17	nsubjpass
2	used	use	VBN	_	1	acl
3	in	in	IN	_	4	case
4	combination	combination	NN	_	2	nmod
5	with	with	IN	_	7	case
6	other	other	JJ	_	7	amod
7	drugs	drug	NNS	_	4	nmod
8	known	know	VBN	_	7	acl
9	to	to	TO	_	11	mark
10	adversely	adversely	RB	_	11	advmod
11	affect	affect	VB	_	8	xcomp
12	the	the	DT	_	14	det
13	hematopoietic	hematopoietic	JJ	_	14	amod
14	system	system	NN	_	11	dobj
15	should	should	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	avoided	avoid	VBN	_	0	ROOT
18	if	if	IN	_	19	mark
19	possible	possible	JJ	_	17	advcl
20	.	.	.	_	17	punct

1	Considerable	considerable	JJ	_	2	amod
2	caution	caution	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	exercised	exercise	VBN	_	0	ROOT
6	if	if	IN	_	9	mark
7	drug1	drug1	NN	_	9	nsubjpass
8	is	be	VBZ	_	9	auxpass
9	administered	administer	VBN	_	5	advcl
10	concurrently	concurrently	RB	_	9	advmod
11	with	with	IN	_	12	case
12	drug2	drug2	NN	_	9	nmod
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	drug3	drug3	NN	_	12	appos
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	since	since	IN	_	21	mark
17	paranoid	paranoid	JJ	_	18	amod
18	symptoms	symptom	NNS	_	21	nsubjpass
19	have	have	VBP	_	21	aux
20	been	be	VBN	_	21	auxpass
21	reported	report	VBN	_	9	advcl
22	during	during	IN	_	23	case
23	therapy	therapy	NN	_	21	nmod
24	with	with	IN	_	26	case
25	this	this	DT	_	26	det
26	combination	combination	NN	_	23	nmod
27	.	.	.	_	5	punct

1	A	a	DT	_	3	det
2	two-way	two-way	JJ	_	3	amod
3	interaction	interaction	NN	_	16	nsubjpass
4	between	between	IN	_	6	case
5	the	the	DT	_	6	det
6	drug1	drug1	NN	_	3	nmod
7	,	,	,	_	6	punct
8	drug2	drug2	NN	_	6	appos
9	,	,	,	_	6	punct
10	and	and	CC	_	6	cc
11	the	the	DT	_	13	det
12	drug3	drug3	NN	_	13	compound
13	s	s	NNS	_	6	conj
14	has	have	VBZ	_	16	aux
15	been	be	VBN	_	16	auxpass
16	suggested	suggest	VBN	_	0	ROOT
17	.	.	.	_	16	punct

1	Presumably	presumably	RB	_	4	advmod
2	,	,	,	_	4	punct
3	drug1	drug1	NN	_	4	nsubj
4	acts	act	VBZ	_	0	ROOT
5	as	as	IN	_	7	case
6	a	a	DT	_	7	det
7	stimulator	stimulator	NN	_	4	nmod
8	of	of	IN	_	10	case
9	drug2	drug2	NN	_	10	compound
10	metabolism	metabolism	NN	_	7	nmod
11	and	and	CC	_	4	cc
12	has	have	VBZ	_	14	aux
13	been	be	VBN	_	14	auxpass
14	reported	report	VBN	_	4	conj
15	to	to	TO	_	16	mark
16	cause	cause	VB	_	14	xcomp
17	decreased	decrease	VBN	_	19	amod
18	serum	serum	NN	_	19	compound
19	levels	level	NNS	_	16	dobj
20	of	of	IN	_	22	case
21	the	the	DT	_	22	det
22	drug3	drug3	NN	_	19	nmod
23	and	and	CC	_	16	cc
24	increased	increase	VBD	_	26	amod
25	prothrombin-proconvertin	prothrombin-proconvertin	JJ	_	26	amod
26	concentrations	concentration	NNS	_	16	conj
27	.	.	.	_	4	punct

1	Conversely	conversely	RB	_	7	advmod
2	,	,	,	_	7	punct
3	the	the	DT	_	4	det
4	drug1	drug1	NN	_	7	nsubjpass
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	reported	report	VBN	_	0	ROOT
8	to	to	TO	_	9	mark
9	increase	increase	VB	_	7	xcomp
10	the	the	DT	_	12	det
11	serum	serum	NN	_	12	compound
12	levels	level	NNS	_	9	dobj
13	and	and	CC	_	9	cc
14	prolong	prolong	VB	_	9	conj
15	the	the	DT	_	17	det
16	serum	serum	NN	_	17	compound
17	half-life	half-life	NN	_	14	dobj
18	of	of	IN	_	19	case
19	drug2	drug2	NN	_	17	nmod
20	by	by	IN	_	21	mark
21	inhibiting	inhibit	VBG	_	9	advcl
22	its	its	PRP$	_	23	nmod:poss
23	metabolism	metabolism	NN	_	21	dobj
24	.	.	.	_	7	punct

1	Although	although	IN	_	3	mark
2	there	there	EX	_	3	expl
3	is	be	VBZ	_	0	ROOT
4	no	no	DT	_	5	neg
5	documentation	documentation	NN	_	3	nsubj
6	of	of	IN	_	18	mark
7	such	such	JJ	_	18	advmod
8	,	,	,	_	18	punct
9	a	a	DT	_	11	det
10	similar	similar	JJ	_	11	amod
11	interaction	interaction	NN	_	18	nsubj
12	between	between	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	and	and	CC	_	13	cc
15	the	the	DT	_	16	det
16	drug2	drug2	NN	_	13	conj
17	may	may	MD	_	18	aux
18	occur	occur	VB	_	5	acl
19	.	.	.	_	3	punct

1	Caution	caution	NN	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	therefore	therefore	RB	_	4	advmod
4	advised	advise	VBN	_	0	ROOT
5	when	when	WRB	_	6	advmod
6	administering	administer	VBG	_	4	advcl
7	drug1	drug1	NN	_	6	dobj
8	to	to	TO	_	9	case
9	patients	patient	NNS	_	6	nmod
10	receiving	receive	VBG	_	9	acl
11	drug2	drug2	NN	_	10	dobj
12	.	.	.	_	4	punct

1	Reduced	reduce	VBN	_	2	amod
2	efficacy	efficacy	NN	_	14	nsubjpass
3	and	and	CC	_	2	cc
4	increased	increase	VBD	_	5	amod
5	incidence	incidence	NN	_	2	conj
6	of	of	IN	_	8	case
7	breakthrough	breakthrough	NN	_	8	compound
8	bleeding	bleeding	NN	_	5	nmod
9	and	and	CC	_	8	cc
10	menstrual	menstrual	JJ	_	11	amod
11	irregularities	irregularity	NNS	_	8	conj
12	have	have	VBP	_	14	aux
13	been	be	VBN	_	14	auxpass
14	associated	associate	VBN	_	0	ROOT
15	with	with	IN	_	17	case
16	concomitant	concomitant	JJ	_	17	amod
17	use	use	NN	_	14	nmod
18	of	of	IN	_	19	case
19	drug1	drug1	NN	_	17	nmod
20	.	.	.	_	14	punct

1	A	a	DT	_	3	det
2	similar	similar	JJ	_	3	amod
3	association	association	NN	_	11	nsubjpass
4	,	,	,	_	11	punct
5	though	though	IN	_	7	mark
6	less	less	JJR	_	7	advmod
7	marked	marked	JJ	_	11	dep
8	,	,	,	_	11	punct
9	has	have	VBZ	_	11	aux
10	been	be	VBN	_	11	auxpass
11	suggested	suggest	VBN	_	0	ROOT
12	with	with	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	,	,	,	_	13	punct
15	drug2	drug2	NN	_	13	conj
16	,	,	,	_	13	punct
17	drug3	drug3	NN	_	13	conj
18	,	,	,	_	13	punct
19	drug4	drug4	NN	_	13	conj
20	,	,	,	_	13	punct
21	drug5	drug5	NN	_	13	conj
22	,	,	,	_	13	punct
23	drug6	drug6	NN	_	13	conj
24	,	,	,	_	13	punct
25	and	and	CC	_	13	cc
26	possibly	possibly	RB	_	28	advmod
27	with	with	IN	_	28	case
28	drug7	drug7	NN	_	13	conj
29	and	and	CC	_	28	cc
30	drug8	drug8	NN	_	28	conj
31	72	72	CD	_	30	nummod
32	.	.	.	_	11	punct

1	A	a	DT	_	3	det
2	possible	possible	JJ	_	3	amod
3	interaction	interaction	NN	_	6	nsubjpass
4	has	have	VBZ	_	6	aux
5	been	be	VBN	_	6	auxpass
6	suggested	suggest	VBN	_	0	ROOT
7	with	with	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	the	the	DT	_	15	det
11	herbal	herbal	JJ	_	15	amod
12	supplement	supplement	NN	_	15	compound
13	St.	St.	NNP	_	15	compound
14	Johns	Johns	NNP	_	15	compound
15	Wort	Wort	NNP	_	8	conj
16	based	base	VBN	_	19	case
17	on	on	IN	_	19	case
18	some	some	DT	_	19	det
19	reports	report	NNS	_	8	nmod
20	of	of	IN	_	23	case
21	oral	oral	JJ	_	23	amod
22	drug2	drug2	NN	_	23	compound
23	users	user	NNS	_	19	nmod
24	experiencing	experience	VBG	_	23	acl
25	breakthrough	breakthrough	NN	_	26	compound
26	bleeding	bleeding	NN	_	24	dobj
27	shortly	shortly	RB	_	29	advmod
28	after	after	IN	_	29	mark
29	starting	start	VBG	_	24	advcl
30	St.	St.	NNP	_	32	compound
31	Johns	Johns	NNP	_	32	compound
32	Wort	Wort	NNP	_	29	dobj
33	.	.	.	_	6	punct

1	Pregnancies	pregnancy	NNS	_	4	nsubjpass
2	have	have	VBP	_	4	aux
3	been	be	VBN	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	by	by	IN	_	6	case
6	users	user	NNS	_	4	nmod
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	who	who	WP	_	11	nsubj
10	also	also	RB	_	11	advmod
11	used	use	VBD	_	8	acl:relcl
12	some	some	DT	_	13	det
13	form	form	NN	_	11	dobj
14	of	of	IN	_	17	case
15	St.	St.	NNP	_	17	compound
16	Johns	Johns	NNP	_	17	compound
17	Wort	Wort	NNP	_	13	nmod
18	.	.	.	_	4	punct

1	Healthcare	Healthcare	NNP	_	2	compound
2	prescribers	prescriber	NNS	_	4	nsubjpass
3	are	be	VBP	_	4	auxpass
4	advised	advise	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	consult	consult	VB	_	4	xcomp
7	the	the	DT	_	9	det
8	package	package	NN	_	9	compound
9	inserts	insert	NNS	_	6	dobj
10	of	of	IN	_	11	case
11	medication	medication	NN	_	9	nmod
12	administered	administer	VBN	_	11	acl
13	concomitantly	concomitantly	RB	_	12	advmod
14	with	with	IN	_	16	case
15	oral	oral	JJ	_	16	amod
16	drug1	drug1	NN	_	12	nmod
17	.	.	.	_	4	punct

1	Combination	combination	NN	_	2	compound
2	Therapy	therapy	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	Any	any	DT	_	5	det
5	form	form	NN	_	17	nsubj
6	of	of	IN	_	7	case
7	therapy	therapy	NN	_	5	nmod
8	which	which	WDT	_	9	nsubj
9	adds	add	VBZ	_	5	acl:relcl
10	to	to	TO	_	12	case
11	the	the	DT	_	12	det
12	stress	stress	NN	_	9	nmod
13	of	of	IN	_	15	case
14	the	the	DT	_	15	det
15	patient	patient	NN	_	12	nmod
16	,	,	,	_	5	punct
17	interferes	interfere	VBZ	_	2	dep
18	with	with	IN	_	19	case
19	nutrition	nutrition	NN	_	17	nmod
20	or	or	CC	_	17	cc
21	depresses	depress	VBZ	_	17	conj
22	bone	bone	NN	_	24	compound
23	marrow	marrow	NN	_	24	compound
24	function	function	NN	_	21	dobj
25	will	will	MD	_	26	aux
26	increase	increase	VB	_	17	ccomp
27	the	the	DT	_	28	det
28	toxicity	toxicity	NN	_	26	dobj
29	of	of	IN	_	30	case
30	drug1	drug1	NN	_	28	nmod
31	.	.	.	_	2	punct

1	Based	base	VBN	_	5	case
2	on	on	IN	_	5	case
3	in	in	FW	_	5	amod
4	vitro	vitro	FW	_	3	dep
5	studies	study	NNS	_	12	advcl
6	in	in	IN	_	9	case
7	human	human	JJ	_	9	amod
8	liver	liver	NN	_	9	compound
9	microsomes	microsome	NNS	_	5	nmod
10	,	,	,	_	12	punct
11	drug1	drug1	NN	_	12	nsubj
12	appears	appear	VBZ	_	0	ROOT
13	to	to	TO	_	14	mark
14	have	have	VB	_	12	xcomp
15	no	no	DT	_	19	neg
16	inhibitory	inhibitory	JJ	_	19	amod
17	or	or	CC	_	16	cc
18	induction	induction	NN	_	16	conj
19	potential	potential	NN	_	14	dobj
20	on	on	IN	_	22	case
21	the	the	DT	_	22	det
22	metabolism	metabolism	NN	_	19	nmod
23	of	of	IN	_	25	case
24	other	other	JJ	_	25	amod
25	drugs	drug	NNS	_	22	nmod
26	metabolized	metabolize	VBN	_	25	acl
27	by	by	IN	_	30	case
28	CYP	cyp	NN	_	30	compound
29	450	450	CD	_	30	nummod
30	enzymes	enzyme	NNS	_	26	nmod
31	.	.	.	_	12	punct

1	The	the	DT	_	3	det
2	inhibitory	inhibitory	JJ	_	3	amod
3	potential	potential	NN	_	12	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	on	on	IN	_	8	case
7	CYP450	cyp450	NN	_	8	compound
8	isoenzymes	isoenzyme	NNS	_	3	nmod
9	has	have	VBZ	_	12	aux
10	not	not	RB	_	12	neg
11	been	be	VBN	_	12	auxpass
12	studied	study	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	4	nsubj
4	demonstrated	demonstrate	VBD	_	0	ROOT
5	that	that	IN	_	14	mark
6	the	the	DT	_	9	det
7	plasma	plasma	NN	_	9	compound
8	protein	protein	NN	_	9	compound
9	binding	binding	NN	_	14	nsubjpass
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	was	be	VBD	_	14	auxpass
13	not	not	RB	_	14	neg
14	affected	affect	VBN	_	4	ccomp
15	by	by	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	or	or	CC	_	16	cc
18	drug3	drug3	NN	_	16	conj
19	,	,	,	_	14	punct
20	indicating	indicate	VBG	_	14	xcomp
21	no	no	DT	_	22	neg
22	potential	potential	NN	_	20	dobj
23	for	for	IN	_	27	case
24	protein	protein	NN	_	27	compound
25	binding-based	binding-based	JJ	_	27	amod
26	drug	drug	NN	_	27	compound
27	interactions	interaction	NNS	_	22	nmod
28	.	.	.	_	4	punct

1	In	in	IN	_	5	case
2	a	a	DT	_	5	det
3	drug	drug	NN	_	5	compound
4	interaction	interaction	NN	_	5	compound
5	study	study	NN	_	23	nmod
6	,	,	,	_	23	punct
7	co-administration	co-administration	NN	_	23	nsubj
8	of	of	IN	_	11	case
9	orally	orally	RB	_	10	advmod
10	inhaled	inhale	VBN	_	11	amod
11	drug1	drug1	NN	_	7	nmod
12	and	and	CC	_	11	cc
13	oral	oral	JJ	_	14	amod
14	drug2	drug2	NN	_	11	conj
15	,	,	,	_	11	punct
16	an	a	DT	_	17	det
17	inhibitor	inhibitor	NN	_	11	appos
18	of	of	IN	_	21	case
19	cytochrome	cytochrome	NN	_	21	compound
20	P450	p450	NN	_	21	compound
21	3A4	3a4	NN	_	17	nmod
22	,	,	,	_	11	punct
23	had	have	VBD	_	0	ROOT
24	no	no	DT	_	25	neg
25	effect	effect	NN	_	23	dobj
26	on	on	IN	_	28	case
27	the	the	DT	_	28	det
28	pharmacokinetics	pharmacokinetic	NNS	_	23	nmod
29	of	of	IN	_	31	case
30	either	either	CC	_	31	cc:preconj
31	drug3	drug3	NN	_	28	nmod
32	or	or	CC	_	31	cc
33	drug4	drug4	NN	_	31	conj
34	.	.	.	_	23	punct

1	In	in	IN	_	5	case
2	another	another	DT	_	5	det
3	drug	drug	NN	_	5	compound
4	interaction	interaction	NN	_	5	compound
5	study	study	NN	_	24	nmod
6	,	,	,	_	24	punct
7	co-administration	co-administration	NN	_	24	nsubj
8	of	of	IN	_	11	case
9	orally	orally	RB	_	10	advmod
10	inhaled	inhale	VBN	_	11	amod
11	drug1	drug1	NN	_	7	nmod
12	and	and	CC	_	11	cc
13	oral	oral	JJ	_	14	amod
14	drug2	drug2	NN	_	11	conj
15	,	,	,	_	11	punct
16	a	a	DT	_	18	det
17	potent	potent	JJ	_	18	amod
18	inhibitor	inhibitor	NN	_	11	appos
19	of	of	IN	_	22	case
20	cytochrome	cytochrome	NN	_	22	compound
21	P450	p450	NN	_	22	compound
22	3A4	3a4	NN	_	18	nmod
23	,	,	,	_	11	punct
24	increased	increase	VBD	_	0	ROOT
25	the	the	DT	_	26	det
26	exposure	exposure	NN	_	24	dobj
27	-LRB-	-lrb-	-LRB-	_	28	punct
28	AUC	auc	NN	_	26	appos
29	-RRB-	-rrb-	-RRB-	_	28	punct
30	of	of	IN	_	31	case
31	drug3	drug3	NN	_	26	nmod
32	by	by	IN	_	34	case
33	approximately	approximately	RB	_	34	advmod
34	3.6-fold	3.6-fold	RB	_	24	nmod
35	at	at	IN	_	37	case
36	steady	steady	JJ	_	37	amod
37	state	state	NN	_	34	nmod
38	,	,	,	_	24	punct
39	while	while	IN	_	43	mark
40	levels	level	NNS	_	43	nsubj
41	of	of	IN	_	42	case
42	drug4	drug4	NN	_	40	nmod
43	remained	remain	VBD	_	24	advcl
44	unchanged	unchanged	JJ	_	43	xcomp
45	.	.	.	_	24	punct

1	Therefore	therefore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	drug1	drug1	NN	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	administered	administer	VBN	_	0	ROOT
7	with	with	IN	_	8	case
8	caution	caution	NN	_	6	nmod
9	with	with	IN	_	11	case
10	intranasal	intranasal	JJ	_	11	amod
11	drug2	drug2	NN	_	8	nmod
12	.	.	.	_	6	punct

1	No	no	DT	_	5	neg
2	clinically	clinically	RB	_	3	advmod
3	significant	significant	JJ	_	5	amod
4	adverse	adverse	JJ	_	5	amod
5	interactions	interaction	NNS	_	28	nsubjpass
6	with	with	IN	_	10	case
7	commonly	commonly	RB	_	8	advmod
8	used	use	VBN	_	10	amod
9	preanesthetic	preanesthetic	JJ	_	10	amod
10	drugs	drug	NNS	_	5	nmod
11	,	,	,	_	10	punct
12	or	or	CC	_	10	cc
13	drugs	drug	NNS	_	10	conj
14	used	use	VBN	_	13	acl
15	during	during	IN	_	16	case
16	anesthesia	anesthesia	NN	_	14	nmod
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	drug1	drug1	NN	_	16	dep
19	,	,	,	_	18	punct
20	intravenous	intravenous	JJ	_	21	amod
21	agents	agent	NNS	_	18	conj
22	,	,	,	_	18	punct
23	and	and	CC	_	18	cc
24	local	local	JJ	_	25	amod
25	drug2	drug2	NN	_	18	conj
26	-RRB-	-rrb-	-RRB-	_	18	punct
27	were	be	VBD	_	28	auxpass
28	reported	report	VBN	_	0	ROOT
29	in	in	IN	_	31	case
30	clinical	clinical	JJ	_	31	amod
31	trials	trial	NNS	_	28	nmod
32	.	.	.	_	28	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	14	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	on	on	IN	_	7	case
6	the	the	DT	_	7	det
7	disposition	disposition	NN	_	2	nmod
8	of	of	IN	_	10	case
9	other	other	JJ	_	10	amod
10	drugs	drug	NNS	_	7	nmod
11	has	have	VBZ	_	14	aux
12	not	not	RB	_	14	neg
13	been	be	VBN	_	14	auxpass
14	determined	determine	VBN	_	0	ROOT
15	.	.	.	_	14	punct

1	Like	like	IN	_	2	case
2	drug1	drug1	NN	_	7	nmod
3	,	,	,	_	7	punct
4	drug2	drug2	NN	_	7	nsubj
5	does	do	VBZ	_	7	aux
6	not	not	RB	_	7	neg
7	predispose	predispose	VB	_	0	ROOT
8	to	to	TO	_	11	case
9	premature	premature	JJ	_	11	amod
10	ventricular	ventricular	JJ	_	11	amod
11	arrhythmias	arrhythmia	NNS	_	7	nmod
12	in	in	IN	_	14	case
13	the	the	DT	_	14	det
14	presence	presence	NN	_	7	nmod
15	of	of	IN	_	18	case
16	exogenously	exogenously	RB	_	17	advmod
17	infused	infuse	VBN	_	18	amod
18	drug3	drug3	NN	_	14	nmod
19	in	in	IN	_	20	case
20	swine	swine	NNS	_	18	nmod
21	.	.	.	_	7	punct

1	Because	because	IN	_	4	mark
2	drug1	drug1	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	metabolized	metabolize	VBN	_	21	csubj
5	by	by	IN	_	7	case
6	a	a	DT	_	7	det
7	variety	variety	NN	_	4	nmod
8	of	of	IN	_	12	case
9	hepatic	hepatic	JJ	_	12	amod
10	CYP	cyp	NN	_	12	compound
11	drug-metabolizing	drug-metabolizing	JJ	_	12	amod
12	enzymes	enzyme	NNS	_	7	nmod
13	,	,	,	_	12	punct
14	inducers	inducer	NNS	_	12	conj
15	or	or	CC	_	12	cc
16	inhibitors	inhibitor	NNS	_	12	conj
17	of	of	IN	_	19	case
18	these	these	DT	_	19	det
19	enzymes	enzyme	NNS	_	16	nmod
20	may	may	MD	_	21	aux
21	change	change	VB	_	0	ROOT
22	the	the	DT	_	23	det
23	clearance	clearance	NN	_	21	dobj
24	of	of	IN	_	25	case
25	drug2	drug2	NN	_	23	nmod
26	.	.	.	_	21	punct

1	drug1	drug1	NN	_	6	nsubj
2	is	be	VBZ	_	6	cop
3	a	a	DT	_	6	det
4	known	known	JJ	_	6	amod
5	strong	strong	JJ	_	6	amod
6	inhibitor	inhibitor	NN	_	0	ROOT
7	of	of	IN	_	8	case
8	CYP1A2	cyp1a2	NN	_	6	nmod
9	and	and	CC	_	6	cc
10	also	also	RB	_	11	advmod
11	inhibits	inhibit	VBZ	_	6	conj
12	CYP3A4	cyp3a4	NN	_	11	dobj
13	,	,	,	_	12	punct
14	CYP2C9	cyp2c9	NN	_	12	conj
15	,	,	,	_	12	punct
16	and	and	CC	_	12	cc
17	CYP2C19	cyp2c19	NN	_	12	conj
18	.	.	.	_	6	punct

1	In	in	IN	_	4	case
2	a	a	DT	_	4	det
3	pharmacokinetic	pharmacokinetic	JJ	_	4	amod
4	study	study	NN	_	10	nmod
5	,	,	,	_	10	punct
6	40	40	CD	_	9	nummod
7	healthy	healthy	JJ	_	9	amod
8	female	female	JJ	_	9	amod
9	subjects	subject	NNS	_	10	nsubj
10	received	receive	VBD	_	0	ROOT
11	drug1	drug1	NN	_	10	dobj
12	in	in	IN	_	13	mark
13	escalating	escalate	VBG	_	10	advcl
14	doses	dose	NNS	_	13	dobj
15	from	from	IN	_	19	case
16	50	50	CD	_	18	compound
17	to	to	TO	_	18	dep
18	200	200	CD	_	19	nummod
19	mg	mg	NN	_	13	nmod
20	per	per	IN	_	21	case
21	day	day	NN	_	19	nmod
22	for	for	IN	_	24	case
23	16	16	CD	_	24	nummod
24	days	day	NNS	_	13	nmod
25	,	,	,	_	10	punct
26	with	with	IN	_	27	case
27	coadministration	coadministration	NN	_	10	nmod
28	of	of	IN	_	31	case
29	drug2	drug2	NN	_	31	compound
30	1	1	CD	_	31	nummod
31	mg	mg	NN	_	27	nmod
32	on	on	IN	_	35	case
33	the	the	DT	_	35	det
34	last	last	JJ	_	35	amod
35	day	day	NN	_	27	nmod
36	.	.	.	_	10	punct

1	drug1	drug1	NN	_	2	nsubj
2	increased	increase	VBD	_	0	ROOT
3	mean	mean	JJ	_	6	amod
4	drug2	drug2	NN	_	6	compound
5	plasma	plasma	NN	_	6	compound
6	concentrations	concentration	NNS	_	2	dobj
7	-LRB-	-lrb-	-LRB-	_	8	punct
8	AUC	auc	NN	_	6	appos
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	approximately	approximately	RB	_	11	advmod
11	6-fold	6-fold	RB	_	2	advmod
12	and	and	CC	_	2	cc
13	prolonged	prolong	VBD	_	2	conj
14	the	the	DT	_	15	det
15	half-life	half-life	NN	_	13	dobj
16	by	by	IN	_	18	case
17	approximately	approximately	RB	_	18	advmod
18	3-fold	3-fold	RB	_	13	nmod
19	.	.	.	_	2	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	8	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	is	be	VBZ	_	8	auxpass
8	contraindicated	contraindicate	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	18	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	moderate	moderate	JJ	_	8	amod
7	CYP1A2	cyp1a2	NN	_	8	compound
8	inhibitors	inhibitor	NNS	_	4	conj
9	,	,	,	_	2	punct
10	including	include	VBG	_	11	case
11	drug2	drug2	NN	_	2	nmod
12	and	and	CC	_	11	cc
13	drug3	drug3	NN	_	11	conj
14	,	,	,	_	2	punct
15	has	have	VBZ	_	18	aux
16	not	not	RB	_	18	neg
17	been	be	VBN	_	18	auxpass
18	evaluated	evaluate	VBN	_	0	ROOT
19	,	,	,	_	18	punct
20	but	but	CC	_	18	cc
21	should	should	MD	_	23	aux
22	be	be	VB	_	23	auxpass
23	avoided	avoid	VBN	_	18	conj
24	unless	unless	IN	_	26	mark
25	clinically	clinically	RB	_	26	advmod
26	necessary	necessary	JJ	_	23	advcl
27	because	because	IN	_	32	case
28	of	of	IN	_	27	mwe
29	similar	similar	JJ	_	32	amod
30	potential	potential	JJ	_	32	amod
31	drug	drug	NN	_	32	compound
32	interactions	interaction	NNS	_	26	nmod
33	.	.	.	_	18	punct

1	drug1	drug1	NN	_	6	nsubj
2	is	be	VBZ	_	6	cop
3	a	a	DT	_	6	det
4	known	known	JJ	_	6	amod
5	strong	strong	JJ	_	6	amod
6	inhibitor	inhibitor	NN	_	0	ROOT
7	of	of	IN	_	8	case
8	CYP3A4	cyp3a4	NN	_	6	nmod
9	.	.	.	_	6	punct

1	In	in	IN	_	4	case
2	a	a	DT	_	4	det
3	pharmacokinetic	pharmacokinetic	JJ	_	4	amod
4	study	study	NN	_	10	nmod
5	,	,	,	_	10	punct
6	38	38	CD	_	9	nummod
7	healthy	healthy	JJ	_	9	amod
8	female	female	JJ	_	9	amod
9	subjects	subject	NNS	_	10	nsubj
10	received	receive	VBD	_	0	ROOT
11	drug1	drug1	NN	_	13	compound
12	200	200	CD	_	13	nummod
13	mg	mg	NN	_	10	dobj
14	twice	twice	RB	_	15	advmod
15	daily	daily	RB	_	10	advmod
16	for	for	IN	_	18	case
17	7	7	CD	_	18	nummod
18	days	day	NNS	_	10	nmod
19	,	,	,	_	10	punct
20	with	with	IN	_	21	case
21	coadministration	coadministration	NN	_	10	nmod
22	of	of	IN	_	25	case
23	drug2	drug2	NN	_	25	compound
24	1	1	CD	_	25	nummod
25	mg	mg	NN	_	21	nmod
26	on	on	IN	_	29	case
27	the	the	DT	_	29	det
28	last	last	JJ	_	29	amod
29	day	day	NN	_	21	nmod
30	.	.	.	_	10	punct

1	drug1	drug1	NN	_	2	nsubj
2	increased	increase	VBD	_	0	ROOT
3	mean	mean	JJ	_	6	amod
4	drug2	drug2	NN	_	6	compound
5	plasma	plasma	NN	_	6	compound
6	concentrations	concentration	NNS	_	2	dobj
7	-LRB-	-lrb-	-LRB-	_	8	punct
8	AUC	auc	NN	_	6	appos
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	by	by	IN	_	12	case
11	29	29	CD	_	12	nummod
12	%	%	NN	_	2	nmod
13	.	.	.	_	2	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	when	when	WRB	_	10	advmod
6	drug1	drug1	NN	_	10	nsubjpass
7	and	and	CC	_	6	cc
8	drug2	drug2	NN	_	6	conj
9	are	be	VBP	_	10	auxpass
10	administered	administer	VBN	_	4	advcl
11	concomitantly	concomitantly	RB	_	10	advmod
12	.	.	.	_	4	punct

1	Coadministration	coadministration	NN	_	24	nsubjpass
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	strong	strong	JJ	_	7	amod
6	CYP3A4	cyp3a4	NN	_	7	compound
7	inhibitors	inhibitor	NNS	_	3	conj
8	,	,	,	_	1	punct
9	such	such	JJ	_	11	case
10	as	as	IN	_	9	mwe
11	drug2	drug2	NN	_	1	nmod
12	,	,	,	_	11	punct
13	drug3	drug3	NN	_	11	conj
14	,	,	,	_	11	punct
15	drug4	drug4	NN	_	11	conj
16	,	,	,	_	11	punct
17	drug5	drug5	NN	_	11	conj
18	,	,	,	_	11	punct
19	and	and	CC	_	11	cc
20	drug6	drug6	NN	_	11	conj
21	has	have	VBZ	_	24	aux
22	not	not	RB	_	24	neg
23	been	be	VBN	_	24	auxpass
24	evaluated	evaluate	VBN	_	0	ROOT
25	but	but	CC	_	24	cc
26	should	should	MD	_	28	aux
27	be	be	VB	_	28	auxpass
28	undertaken	undertake	VBN	_	24	conj
29	with	with	IN	_	30	case
30	caution	caution	NN	_	28	nmod
31	because	because	IN	_	36	case
32	of	of	IN	_	31	mwe
33	similar	similar	JJ	_	36	amod
34	potential	potential	JJ	_	36	amod
35	drug	drug	NN	_	36	compound
36	interactions	interaction	NNS	_	28	nmod
37	.	.	.	_	24	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	19	nsubjpass
3	of	of	IN	_	4	case
4	induction	induction	NN	_	2	nmod
5	or	or	CC	_	4	cc
6	inhibition	inhibition	NN	_	4	conj
7	of	of	IN	_	9	case
8	other	other	JJ	_	9	amod
9	pathways	pathway	NNS	_	4	nmod
10	on	on	IN	_	11	case
11	exposure	exposure	NN	_	2	nmod
12	to	to	TO	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	and	and	CC	_	13	cc
15	its	its	PRP$	_	16	nmod:poss
16	metabolites	metabolite	NNS	_	13	conj
17	is	be	VBZ	_	19	auxpass
18	not	not	RB	_	19	neg
19	known	know	VBN	_	0	ROOT
20	.	.	.	_	19	punct

1	In	in	FW	_	6	amod
2	vitro	vitro	FW	_	1	dep
3	human	human	JJ	_	6	amod
4	liver	liver	NN	_	6	compound
5	microsome	microsome	NN	_	6	compound
6	studies	study	NNS	_	14	nsubj
7	and	and	CC	_	6	cc
8	an	a	DT	_	13	det
9	in	in	FW	_	13	amod
10	vivo	vivo	FW	_	9	dep
11	metabolic	metabolic	JJ	_	13	amod
12	probe	probe	NN	_	13	compound
13	study	study	NN	_	6	conj
14	demonstrated	demonstrate	VBD	_	0	ROOT
15	that	that	IN	_	19	mark
16	drug1	drug1	NN	_	19	nsubj
17	did	do	VBD	_	19	aux
18	not	not	RB	_	19	neg
19	inhibit	inhibit	VB	_	14	ccomp
20	CYP	cyp	NN	_	22	compound
21	enzymes	enzyme	NNS	_	22	compound
22	2D6	2d6	NN	_	19	dobj
23	,	,	,	_	22	punct
24	3A4	3a4	NN	_	22	conj
25	,	,	,	_	22	punct
26	2C9	2c9	NN	_	22	conj
27	,	,	,	_	22	punct
28	or	or	CC	_	22	cc
29	2C19	2c19	NN	_	22	conj
30	.	.	.	_	14	punct

1	In	in	FW	_	2	compound
2	vitro	vitro	FW	_	21	advmod
3	,	,	,	_	21	punct
4	at	at	IN	_	7	case
5	total	total	JJ	_	7	amod
6	drug	drug	NN	_	7	compound
7	concentrations	concentration	NNS	_	21	nmod
8	27-fold	27-fold	RB	_	9	advmod
9	higher	higher	JJR	_	7	amod
10	than	than	IN	_	13	case
11	peak	peak	JJ	_	13	amod
12	plasma	plasma	NN	_	13	compound
13	concentrations	concentration	NNS	_	9	nmod
14	observed	observe	VBN	_	13	acl
15	with	with	IN	_	18	case
16	the	the	DT	_	18	det
17	1-mg	1-mg	JJ	_	18	amod
18	dosage	dosage	NN	_	14	nmod
19	,	,	,	_	21	punct
20	drug1	drug1	NN	_	21	nsubj
21	inhibited	inhibit	VBD	_	0	ROOT
22	CYP	cyp	NN	_	24	compound
23	enzymes	enzyme	NNS	_	24	compound
24	1A2	1a2	NN	_	21	dobj
25	-LRB-	-lrb-	-LRB-	_	27	punct
26	60	60	CD	_	27	nummod
27	%	%	NN	_	24	appos
28	-RRB-	-rrb-	-RRB-	_	27	punct
29	and	and	CC	_	24	cc
30	2E1	2e1	NN	_	24	conj
31	-LRB-	-lrb-	-LRB-	_	33	punct
32	50	50	CD	_	33	nummod
33	%	%	NN	_	30	appos
34	-RRB-	-rrb-	-RRB-	_	33	punct
35	.	.	.	_	21	punct

1	In	in	IN	_	7	case
2	an	a	DT	_	7	det
3	in	in	FW	_	7	amod
4	vivo	vivo	FW	_	3	dep
5	metabolic	metabolic	JJ	_	7	amod
6	probe	probe	NN	_	7	compound
7	study	study	NN	_	12	nmod
8	,	,	,	_	12	punct
9	drug1	drug1	NN	_	12	nsubj
10	did	do	VBD	_	12	aux
11	not	not	RB	_	12	neg
12	inhibit	inhibit	VB	_	0	ROOT
13	CYP2E1	cyp2e1	NN	_	12	dobj
14	but	but	CC	_	12	cc
15	did	do	VBD	_	16	aux
16	produce	produce	VB	_	12	conj
17	30	30	CD	_	18	compound
18	%	%	NN	_	19	amod
19	inhibition	inhibition	NN	_	16	dobj
20	of	of	IN	_	22	case
21	both	both	CC	_	22	cc:preconj
22	CYP1A2	cyp1a2	NN	_	19	nmod
23	and	and	CC	_	22	cc
24	N-acetyltransferase	n-acetyltransferase	NN	_	22	conj
25	.	.	.	_	12	punct

1	Although	although	IN	_	3	mark
2	not	not	RB	_	3	neg
3	studied	study	VBN	_	11	advcl
4	with	with	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	,	,	,	_	11	punct
7	inhibition	inhibition	NN	_	11	nsubj
8	of	of	IN	_	9	case
9	N-acetyltransferase	n-acetyltransferase	NN	_	7	nmod
10	may	may	MD	_	11	aux
11	have	have	VB	_	0	ROOT
12	clinically	clinically	RB	_	13	advmod
13	relevant	relevant	JJ	_	14	amod
14	consequences	consequence	NNS	_	11	dobj
15	for	for	IN	_	16	case
16	drugs	drug	NNS	_	14	nmod
17	such	such	JJ	_	19	case
18	as	as	IN	_	17	mwe
19	drug2	drug2	NN	_	16	nmod
20	,	,	,	_	19	punct
21	drug3	drug3	NN	_	19	conj
22	,	,	,	_	19	punct
23	and	and	CC	_	19	cc
24	drug4	drug4	NN	_	19	conj
25	.	.	.	_	11	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	6	nsubjpass
3	on	on	IN	_	4	case
4	CYP1A2	cyp1a2	NN	_	2	nmod
5	was	be	VBD	_	6	auxpass
6	explored	explore	VBN	_	0	ROOT
7	further	further	RB	_	6	advmod
8	in	in	IN	_	12	case
9	a	a	DT	_	12	det
10	clinical	clinical	JJ	_	12	amod
11	interaction	interaction	NN	_	12	compound
12	study	study	NN	_	6	nmod
13	with	with	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	and	and	CC	_	6	cc
16	no	no	DT	_	17	neg
17	effect	effect	NN	_	21	nsubjpass
18	on	on	IN	_	19	case
19	metabolism	metabolism	NN	_	17	nmod
20	was	be	VBD	_	21	auxpass
21	observed	observe	VBN	_	6	conj
22	.	.	.	_	6	punct

1	Another	another	DT	_	2	det
2	study	study	NN	_	3	nsubj
3	showed	show	VBD	_	0	ROOT
4	that	that	IN	_	6	mark
5	drug1	drug1	NN	_	6	nsubj
6	had	have	VBD	_	3	ccomp
7	no	no	DT	_	10	neg
8	clinically	clinically	RB	_	9	advmod
9	significant	significant	JJ	_	10	amod
10	effect	effect	NN	_	6	dobj
11	on	on	IN	_	13	case
12	plasma	plasma	NN	_	13	compound
13	concentrations	concentration	NNS	_	6	nmod
14	of	of	IN	_	18	case
15	the	the	DT	_	18	det
16	oral	oral	JJ	_	18	amod
17	drug2	drug2	NN	_	18	compound
18	drug3	drug3	NN	_	13	nmod
19	and	and	CC	_	18	cc
20	drug4	drug4	NN	_	18	conj
21	-LRB-	-lrb-	-LRB-	_	23	punct
22	CYP3A4	cyp3a4	NN	_	23	compound
23	substrates	substrate	NNS	_	18	appos
24	-RRB-	-rrb-	-RRB-	_	23	punct
25	.	.	.	_	3	punct

1	A	a	DT	_	4	det
2	clinical	clinical	JJ	_	4	amod
3	interaction	interaction	NN	_	4	compound
4	study	study	NN	_	7	nsubjpass
5	was	be	VBD	_	7	auxpass
6	also	also	RB	_	7	advmod
7	conducted	conduct	VBN	_	0	ROOT
8	with	with	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	the	the	DT	_	14	det
12	CYP3A4	cyp3a4	NN	_	14	compound
13	substrate	substrate	NN	_	14	compound
14	drug2	drug2	NN	_	9	conj
15	.	.	.	_	7	punct

1	No	no	DT	_	3	neg
2	significant	significant	JJ	_	3	amod
3	effects	effect	NNS	_	11	nsubjpass
4	on	on	IN	_	6	case
5	drug1	drug1	NN	_	6	compound
6	metabolism	metabolism	NN	_	3	nmod
7	or	or	CC	_	6	cc
8	QT	qt	NN	_	9	compound
9	interval	interval	NN	_	6	conj
10	were	be	VBD	_	11	auxpass
11	noted	note	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	21	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	on	on	IN	_	7	case
6	monoamine	monoamine	NN	_	7	compound
7	oxidases	oxidase	NNS	_	2	nmod
8	and	and	CC	_	7	cc
9	on	on	IN	_	12	case
10	intestinal	intestinal	JJ	_	12	amod
11	first	first	JJ	_	12	amod
12	pass	pass	NN	_	7	conj
13	secondary	secondary	JJ	_	12	amod
14	to	to	TO	_	17	case
15	high	high	JJ	_	17	amod
16	intraluminal	intraluminal	JJ	_	17	amod
17	concentrations	concentration	NNS	_	13	nmod
18	have	have	VBP	_	21	aux
19	not	not	RB	_	21	neg
20	been	be	VBN	_	21	auxpass
21	examined	examine	VBN	_	0	ROOT
22	.	.	.	_	21	punct

1	Based	base	VBN	_	5	case
2	on	on	IN	_	5	case
3	the	the	DT	_	5	det
4	above	above	JJ	_	5	amod
5	data	datum	NNS	_	16	advcl
6	from	from	IN	_	8	case
7	in	in	FW	_	8	compound
8	vitro	vitro	FW	_	5	nmod
9	and	and	CC	_	8	cc
10	in	in	FW	_	8	conj
11	vivo	vivo	FW	_	10	dep
12	studies	study	NNS	_	8	dep
13	,	,	,	_	16	punct
14	it	it	PRP	_	16	nsubj
15	is	be	VBZ	_	16	cop
16	unlikely	unlikely	JJ	_	0	ROOT
17	that	that	IN	_	20	mark
18	drug1	drug1	NN	_	20	nsubj
19	will	will	MD	_	20	aux
20	inhibit	inhibit	VB	_	16	ccomp
21	the	the	DT	_	24	det
22	hepatic	hepatic	JJ	_	24	amod
23	metabolic	metabolic	JJ	_	24	amod
24	clearance	clearance	NN	_	20	dobj
25	of	of	IN	_	26	case
26	drugs	drug	NNS	_	24	nmod
27	metabolized	metabolize	VBN	_	26	acl
28	by	by	IN	_	33	case
29	the	the	DT	_	33	det
30	major	major	JJ	_	33	amod
31	CYP	cyp	NN	_	33	compound
32	enzyme	enzyme	NN	_	33	compound
33	3A4	3a4	NN	_	27	nmod
34	,	,	,	_	24	punct
35	as	as	RB	_	24	cc
36	well	well	RB	_	35	mwe
37	as	as	IN	_	35	mwe
38	the	the	DT	_	41	det
39	CYP	cyp	NN	_	41	compound
40	enzymes	enzyme	NNS	_	41	compound
41	2D6	2d6	NN	_	24	conj
42	,	,	,	_	41	punct
43	2C9	2c9	NN	_	41	conj
44	,	,	,	_	41	punct
45	2C19	2c19	NN	_	41	conj
46	,	,	,	_	41	punct
47	2E1	2e1	NN	_	41	conj
48	,	,	,	_	41	punct
49	or	or	CC	_	41	cc
50	1A2	1a2	NN	_	41	conj
51	.	.	.	_	16	punct

1	drug1	drug1	NN	_	4	nsubj
2	does	do	VBZ	_	4	aux
3	not	not	RB	_	4	neg
4	appear	appear	VB	_	0	ROOT
5	to	to	TO	_	6	mark
6	induce	induce	VB	_	4	xcomp
7	the	the	DT	_	10	det
8	major	major	JJ	_	10	amod
9	cytochrome	cytochrome	NN	_	10	compound
10	P450	p450	NN	_	6	dobj
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	CYP	cyp	NN	_	10	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	drug	drug	NN	_	10	dep
15	metabolizing	metabolize	VBG	_	14	acl
16	enzyme	enzyme	NN	_	17	compound
17	3A	3a	NN	_	15	dobj
18	.	.	.	_	4	punct

1	drug1	drug1	NN	_	5	nsubj
2	also	also	RB	_	5	advmod
3	does	do	VBZ	_	5	aux
4	not	not	RB	_	5	neg
5	appear	appear	VB	_	0	ROOT
6	to	to	TO	_	7	mark
7	induce	induce	VB	_	5	xcomp
8	CYP	cyp	NN	_	9	compound
9	enzymes	enzyme	NNS	_	7	dobj
10	2E1	2e1	NN	_	9	dep
11	or	or	CC	_	10	cc
12	2C19	2c19	NN	_	10	conj
13	.	.	.	_	5	punct

1	It	it	PRP	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	not	not	RB	_	4	neg
4	known	know	VBN	_	0	ROOT
5	whether	whether	IN	_	8	mark
6	drug1	drug1	NN	_	8	nsubj
7	might	might	MD	_	8	aux
8	induce	induce	VB	_	4	ccomp
9	other	other	JJ	_	10	amod
10	enzymes	enzyme	NNS	_	8	dobj
11	.	.	.	_	4	punct

1	drug1	drug1	NN	_	3	compound
2	-	-	:	_	3	punct
3	drug2	drug2	NN	_	5	nsubjpass
4	was	be	VBD	_	5	auxpass
5	observed	observe	VBN	_	0	ROOT
6	to	to	TO	_	7	mark
7	enhance	enhance	VB	_	5	xcomp
8	-LRB-	-lrb-	-LRB-	_	11	punct
9	in	in	IN	_	11	case
10	tissue	tissue	NN	_	11	compound
11	culture	culture	NN	_	7	nmod
12	-RRB-	-rrb-	-RRB-	_	11	punct
13	the	the	DT	_	14	det
14	effect	effect	NN	_	7	dobj
15	of	of	IN	_	16	case
16	drug3	drug3	NN	_	14	nmod
17	in	in	IN	_	18	mark
18	reducing	reduce	VBG	_	14	acl
19	the	the	DT	_	20	det
20	number	number	NN	_	18	dobj
21	of	of	IN	_	25	case
22	human	human	JJ	_	25	amod
23	breast	breast	NN	_	25	compound
24	cancer	cancer	NN	_	25	compound
25	cells	cell	NNS	_	20	nmod
26	that	that	WDT	_	31	nsubj
27	were	be	VBD	_	31	cop
28	in	in	IN	_	31	case
29	the	the	DT	_	31	det
30	S	s	NN	_	31	compound
31	phase	phase	NN	_	25	acl:relcl
32	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	-	-	:	_	1	punct
5	Although	although	IN	_	7	mark
6	not	not	RB	_	7	neg
7	reported	report	VBN	_	18	advcl
8	,	,	,	_	18	punct
9	drug3	drug3	NN	_	18	nsubj
10	,	,	,	_	18	punct
11	via	via	IN	_	13	case
12	its	its	PRP$	_	13	nmod:poss
13	metabolism	metabolism	NN	_	18	nmod
14	to	to	TO	_	15	case
15	histamine	histamine	NN	_	13	nmod
16	,	,	,	_	18	punct
17	might	might	MD	_	18	aux
18	decrease	decrease	VB	_	1	dep
19	the	the	DT	_	20	det
20	efficacy	efficacy	NN	_	18	dobj
21	of	of	IN	_	22	case
22	drug4	drug4	NN	_	20	nmod
23	and	and	CC	_	22	cc
24	drug5	drug5	NN	_	22	conj
25	.	.	.	_	1	punct

1	May	May	NNP	_	2	nsubj
2	interact	interact	VBP	_	0	ROOT
3	with	with	IN	_	5	case
4	skin	skin	NN	_	5	compound
5	products	product	NNS	_	2	nmod
6	or	or	CC	_	5	cc
7	shampoos	shampoo	NNS	_	5	conj
8	for	for	IN	_	9	case
9	dandruff	dandruff	NN	_	2	nmod
10	or	or	CC	_	9	cc
11	psoriasis	psoriasis	NN	_	9	conj
12	.	.	.	_	2	punct

1	Most	most	JJS	_	11	nsubjpass
2	-LRB-	-lrb-	-LRB-	_	4	punct
3	98	98	CD	_	4	nummod
4	%	%	NN	_	1	dep
5	-RRB-	-rrb-	-RRB-	_	4	punct
6	of	of	IN	_	8	case
7	plasma	plasma	NN	_	8	compound
8	drug1	drug1	NN	_	1	nmod
9	is	be	VBZ	_	11	auxpass
10	protein	protein	NN	_	11	nsubjpass
11	bound	bind	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	data	datum	NNS	_	7	nsubj
4	in	in	IN	_	6	case
5	human	human	JJ	_	6	amod
6	plasma	plasma	NN	_	3	nmod
7	indicate	indicate	VBP	_	0	ROOT
8	that	that	IN	_	10	mark
9	drug1	drug1	NN	_	10	nsubj
10	has	have	VBZ	_	7	ccomp
11	no	no	DT	_	12	neg
12	effect	effect	NN	_	10	dobj
13	on	on	IN	_	15	case
14	protein	protein	NN	_	15	compound
15	binding	binding	NN	_	10	nmod
16	of	of	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	,	,	,	_	17	punct
19	drug3	drug3	NN	_	17	conj
20	,	,	,	_	17	punct
21	drug4	drug4	NN	_	17	conj
22	or	or	CC	_	17	cc
23	drug5	drug5	NN	_	17	conj
24	.	.	.	_	7	punct

1	There	there	EX	_	2	expl
2	is	be	VBZ	_	0	ROOT
3	no	no	DT	_	4	neg
4	information	information	NN	_	13	nsubj
5	on	on	IN	_	7	case
6	the	the	DT	_	7	det
7	effect	effect	NN	_	4	nmod
8	of	of	IN	_	12	case
9	other	other	JJ	_	12	amod
10	highly	highly	RB	_	12	advmod
11	plasma	plasma	NN	_	12	compound
12	protein	protein	NN	_	7	nmod
13	bound	bind	VBD	_	2	ccomp
14	drugs	drug	NNS	_	13	dobj
15	on	on	IN	_	17	case
16	drug1	drug1	NN	_	17	compound
17	binding	binding	NN	_	13	nmod
18	.	.	.	_	2	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	administered	administer	VBN	_	0	ROOT
5	without	without	IN	_	7	case
6	any	any	DT	_	7	det
7	evidence	evidence	NN	_	4	nmod
8	of	of	IN	_	12	case
9	an	a	DT	_	12	det
10	adverse	adverse	JJ	_	12	amod
11	drug	drug	NN	_	12	compound
12	interaction	interaction	NN	_	7	nmod
13	to	to	TO	_	14	case
14	patients	patient	NNS	_	12	nmod
15	receiving	receive	VBG	_	14	acl
16	drug2	drug2	NN	_	15	dobj
17	,	,	,	_	19	punct
18	drug3	drug3	NN	_	19	compound
19	s	s	NNS	_	4	dep
20	,	,	,	_	19	punct
21	and	and	CC	_	19	cc
22	drug4	drug4	NN	_	19	conj
23	.	.	.	_	4	punct

1	In	in	IN	_	4	case
2	a	a	DT	_	4	det
3	placebo-controlled	placebo-controlled	JJ	_	4	amod
4	trial	trial	NN	_	35	nmod
5	in	in	IN	_	7	case
6	normal	normal	JJ	_	7	amod
7	volunteers	volunteer	NNS	_	4	nmod
8	,	,	,	_	35	punct
9	the	the	DT	_	10	det
10	administration	administration	NN	_	35	nsubj
11	of	of	IN	_	16	case
12	a	a	DT	_	16	det
13	single	single	JJ	_	16	amod
14	1	1	CD	_	15	compound
15	mg	mg	NN	_	16	amod
16	dose	dose	NN	_	10	nmod
17	of	of	IN	_	18	case
18	drug1	drug1	NN	_	16	nmod
19	on	on	IN	_	20	case
20	day	day	NN	_	10	nmod
21	1	1	CD	_	20	nummod
22	of	of	IN	_	25	case
23	a	a	DT	_	25	det
24	four-day	four-day	JJ	_	25	amod
25	regimen	regimen	NN	_	20	nmod
26	of	of	IN	_	28	case
27	oral	oral	JJ	_	28	amod
28	drug2	drug2	NN	_	25	nmod
29	-LRB-	-lrb-	-LRB-	_	31	punct
30	400	400	CD	_	31	nummod
31	mg	mg	NN	_	28	dep
32	twice	twice	RB	_	33	advmod
33	daily	daily	RB	_	31	advmod
34	-RRB-	-rrb-	-RRB-	_	31	punct
35	resulted	result	VBD	_	0	ROOT
36	in	in	IN	_	40	case
37	a	a	DT	_	40	det
38	10	10	CD	_	39	compound
39	%	%	NN	_	40	amod
40	increase	increase	NN	_	35	nmod
41	in	in	IN	_	43	case
42	mean	mean	JJ	_	43	amod
43	AUC	auc	NN	_	40	nmod
44	of	of	IN	_	45	case
45	drug3	drug3	NN	_	43	nmod
46	-LRB-	-lrb-	-LRB-	_	48	punct
47	p	p	NN	_	48	nsubj
48	=	=	JJ	_	35	parataxis
49	0.006	0.006	CD	_	48	dobj
50	-RRB-	-rrb-	-RRB-	_	48	punct
51	,	,	,	_	35	punct
52	and	and	CC	_	35	cc
53	a	a	DT	_	59	det
54	slight	slight	JJ	_	59	amod
55	but	but	CC	_	54	cc
56	not	not	RB	_	58	neg
57	statistically	statistically	RB	_	58	advmod
58	significant	significant	JJ	_	54	conj
59	increase	increase	NN	_	35	conj
60	in	in	IN	_	62	case
61	mean	mean	JJ	_	62	amod
62	Cmax	cmax	NN	_	59	nmod
63	and	and	CC	_	59	cc
64	mean	mean	VB	_	59	conj
65	half-life	half-life	NN	_	64	dobj
66	of	of	IN	_	67	case
67	drug4	drug4	NN	_	65	nmod
68	.	.	.	_	35	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	significance	significance	NN	_	11	nsubj
4	of	of	IN	_	6	case
5	this	this	DT	_	6	det
6	increase	increase	NN	_	3	nmod
7	in	in	IN	_	9	case
8	drug1	drug1	NN	_	9	compound
9	AUC	auc	NN	_	6	nmod
10	is	be	VBZ	_	11	cop
11	unknown	unknown	JJ	_	0	ROOT
12	.	.	.	_	11	punct

1	In	in	IN	_	3	case
2	clinical	clinical	JJ	_	3	amod
3	trials	trial	NNS	_	9	nmod
4	,	,	,	_	9	punct
5	drug1	drug1	NN	_	6	compound
6	tablets	tablet	NNS	_	9	nsubjpass
7	have	have	VBP	_	9	aux
8	been	be	VBN	_	9	auxpass
9	administered	administer	VBN	_	0	ROOT
10	to	to	TO	_	11	case
11	patients	patient	NNS	_	9	nmod
12	on	on	IN	_	14	case
13	a	a	DT	_	14	det
14	variety	variety	NN	_	11	nmod
15	of	of	IN	_	17	case
16	concomitant	concomitant	JJ	_	17	amod
17	medications	medication	NNS	_	14	nmod
18	;	;	:	_	9	punct

1	while	while	IN	_	8	mark
2	no	no	DT	_	5	neg
3	formal	formal	JJ	_	5	amod
4	interaction	interaction	NN	_	5	compound
5	studies	study	NNS	_	8	nsubjpass
6	have	have	VBP	_	8	aux
7	been	be	VBN	_	8	auxpass
8	conducted	conduct	VBN	_	13	advcl
9	,	,	,	_	13	punct
10	no	no	DT	_	11	neg
11	interactions	interaction	NNS	_	13	nsubjpass
12	were	be	VBD	_	13	auxpass
13	observed	observe	VBN	_	0	ROOT
14	.	.	.	_	13	punct

1	drug1	drug1	NN	_	2	compound
2	tablets	tablet	NNS	_	5	nsubjpass
3	have	have	VBP	_	5	aux
4	been	be	VBN	_	5	auxpass
5	used	use	VBN	_	0	ROOT
6	with	with	IN	_	9	case
7	the	the	DT	_	9	det
8	following	follow	VBG	_	9	amod
9	drugs	drug	NNS	_	5	nmod
10	or	or	CC	_	9	cc
11	drug	drug	NN	_	12	compound
12	classes	class	NNS	_	9	conj
13	:	:	:	_	5	punct
14	1	1	CD	_	5	dep
15	.	.	.	_	5	punct

1	drug1	drug1	NN	_	3	compound
2	/	/	:	_	3	punct
3	drug2	drug2	NN	_	0	ROOT
4	-LRB-	-lrb-	-LRB-	_	7	punct
5	e.g.	e.g.	FW	_	7	dep
6	,	,	,	_	7	punct
7	drug3	drug3	NN	_	3	dep
8	,	,	,	_	7	punct
9	drug4	drug4	NN	_	7	conj
10	,	,	,	_	7	punct
11	drug5	drug5	NN	_	7	conj
12	and	and	CC	_	7	cc
13	drug6	drug6	NN	_	14	compound
14	combinations	combination	NNS	_	7	conj
15	,	,	,	_	7	punct
16	drug7	drug7	NN	_	7	conj
17	,	,	,	_	7	punct
18	drug8	drug8	NN	_	7	appos
19	-RRB-	-rrb-	-RRB-	_	7	punct
20	.	.	.	_	3	punct

1	2	2	LS	_	0	ROOT
2	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	5	punct
3	e.g.	e.g.	FW	_	5	dep
4	,	,	,	_	5	punct
5	drug2	drug2	NN	_	1	dep
6	,	,	,	_	5	punct
7	drug3	drug3	NN	_	5	conj
8	and	and	CC	_	5	cc
9	drug4	drug4	NN	_	5	conj
10	,	,	,	_	5	punct
11	drug5	drug5	NN	_	5	appos
12	-RRB-	-rrb-	-RRB-	_	5	punct
13	.	.	.	_	1	punct

1	3	3	LS	_	0	ROOT
2	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	5	punct
3	e.g.	e.g.	FW	_	5	dep
4	,	,	,	_	5	punct
5	drug2	drug2	NN	_	1	dep
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	.	.	.	_	1	punct

1	4	4	LS	_	0	ROOT
2	.	.	.	_	1	punct

1	Cardiovascular	Cardiovascular	NNP	_	2	compound
2	agents	agent	NNS	_	0	ROOT
3	-LRB-	-lrb-	-LRB-	_	6	punct
4	e.g.	e.g.	FW	_	6	dep
5	,	,	,	_	6	punct
6	drug1	drug1	NN	_	2	dep
7	,	,	,	_	6	punct
8	drug2	drug2	NN	_	6	appos
9	,	,	,	_	6	punct
10	drug3	drug3	NN	_	6	appos
11	-RRB-	-rrb-	-RRB-	_	6	punct
12	.	.	.	_	2	punct

1	5	5	CD	_	0	ROOT
2	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	.	.	.	_	1	punct

1	6	6	CD	_	0	ROOT
2	.	.	.	_	1	punct

1	Gastrointestinal	gastrointestinal	JJ	_	2	amod
2	agents	agent	NNS	_	0	ROOT
3	-LRB-	-lrb-	-LRB-	_	6	punct
4	e.g.	e.g.	FW	_	6	dep
5	,	,	,	_	6	punct
6	drug1	drug1	NN	_	2	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	.	.	.	_	2	punct

1	7	7	CD	_	0	ROOT
2	.	.	.	_	1	punct

1	drug1	drug1	NN	_	4	amod
2	and	and	CC	_	1	cc
3	endocrine	endocrine	JJ	_	1	conj
4	drugs	drug	NNS	_	0	ROOT
5	.	.	.	_	4	punct

1	8	8	CD	_	0	ROOT
2	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	-LRB-	-lrb-	-LRB-	_	7	punct
5	e.g.	e.g.	FW	_	7	dep
6	,	,	,	_	7	punct
7	drug3	drug3	NN	_	1	dep
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	.	.	.	_	1	punct

1	9	9	CD	_	0	ROOT
2	.	.	.	_	1	punct

1	Cold	Cold	NNP	_	4	compound
2	and	and	CC	_	1	cc
3	flu	flu	NN	_	1	conj
4	remedies	remedy	NNS	_	0	ROOT
5	.	.	.	_	4	punct

1	drug1	drug1	NN	_	2	nsubj
2	modifies	modify	VBZ	_	0	ROOT
3	drug2	drug2	NN	_	4	compound
4	metabolism	metabolism	NN	_	2	dobj
5	with	with	IN	_	8	case
6	increased	increase	VBN	_	8	amod
7	serum	serum	NN	_	8	compound
8	levels	level	NNS	_	2	nmod
9	of	of	IN	_	10	case
10	drug3	drug3	NN	_	8	nmod
11	.	.	.	_	2	punct

1	This	this	DT	_	3	nsubj
2	may	may	MD	_	3	aux
3	increase	increase	VB	_	0	ROOT
4	or	or	CC	_	3	cc
5	enhance	enhance	VB	_	3	conj
6	the	the	DT	_	7	det
7	occurrence	occurrence	NN	_	3	dobj
8	of	of	IN	_	9	case
9	osteomalacia	osteomalacia	NN	_	7	nmod
10	in	in	IN	_	12	case
11	some	some	DT	_	12	det
12	patients	patient	NNS	_	3	nmod
13	receiving	receive	VBG	_	12	acl
14	chronic	chronic	JJ	_	16	amod
15	drug1	drug1	NN	_	16	compound
16	therapy	therapy	NN	_	13	dobj
17	.	.	.	_	3	punct

1	Caution	caution	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	advised	advise	VBN	_	0	ROOT
4	in	in	IN	_	5	case
5	patients	patient	NNS	_	3	nmod
6	receiving	receive	VBG	_	5	acl
7	chronic	chronic	JJ	_	9	amod
8	concomitant	concomitant	JJ	_	9	amod
9	therapy	therapy	NN	_	6	dobj
10	.	.	.	_	3	punct

1	By	by	IN	_	2	mark
2	decreasing	decrease	VBG	_	11	advcl
3	the	the	DT	_	5	det
4	gastrointestinal	gastrointestinal	JJ	_	5	amod
5	absorption	absorption	NN	_	2	dobj
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	,	,	,	_	11	punct
9	drug2	drug2	NN	_	11	nsubj
10	may	may	MD	_	11	aux
11	decrease	decrease	VB	_	0	ROOT
12	serum	serum	NN	_	13	compound
13	concentrations	concentration	NNS	_	11	dobj
14	of	of	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	its	its	PRP$	_	18	nmod:poss
18	metabolites	metabolite	NNS	_	15	conj
19	,	,	,	_	11	punct
20	with	with	IN	_	24	case
21	a	a	DT	_	24	det
22	consequent	consequent	JJ	_	24	amod
23	possible	possible	JJ	_	24	amod
24	decrease	decrease	NN	_	11	nmod
25	in	in	IN	_	27	case
26	anticonvulsant	anticonvulsant	JJ	_	27	amod
27	effect	effect	NN	_	24	nmod
28	.	.	.	_	11	punct

1	Caution	caution	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	advised	advise	VBN	_	0	ROOT
4	when	when	WRB	_	5	advmod
5	beginning	begin	VBG	_	3	advcl
6	,	,	,	_	5	punct
7	discontinuing	discontinue	VBG	_	5	conj
8	,	,	,	_	5	punct
9	or	or	CC	_	5	cc
10	changing	change	VBG	_	5	conj
11	the	the	DT	_	12	det
12	dose	dose	NN	_	10	dobj
13	of	of	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	in	in	IN	_	16	case
16	patients	patient	NNS	_	10	nmod
17	receiving	receive	VBG	_	16	acl
18	drug2	drug2	NN	_	17	dobj
19	.	.	.	_	3	punct

1	Because	because	IN	_	5	case
2	of	of	IN	_	1	mwe
3	possible	possible	JJ	_	5	amod
4	additive	additive	JJ	_	5	amod
5	effects	effect	NNS	_	14	nmod
6	with	with	IN	_	8	case
7	other	other	JJ	_	8	amod
8	drug1	drug1	NN	_	5	nmod
9	,	,	,	_	14	punct
10	concomitant	concomitant	JJ	_	11	amod
11	use	use	NN	_	14	nsubj
12	is	be	VBZ	_	14	cop
13	not	not	RB	_	14	neg
14	advisable	advisable	JJ	_	0	ROOT
15	.	.	.	_	14	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	increase	increase	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	effects	effect	NNS	_	3	dobj
6	of	of	IN	_	8	case
7	other	other	JJ	_	8	amod
8	drug2	drug2	NN	_	5	nmod
9	.	.	.	_	3	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	increase	increase	VB	_	0	ROOT
4	or	or	CC	_	3	cc
5	decrease	decrease	VB	_	3	conj
6	blood	blood	NN	_	8	compound
7	glucose	glucose	NN	_	8	compound
8	levels	level	NNS	_	3	dobj
9	.	.	.	_	3	punct

1	Consideration	consideration	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	taken	take	VBN	_	0	ROOT
5	in	in	IN	_	6	case
6	patients	patient	NNS	_	4	nmod
7	being	be	VBG	_	8	auxpass
8	treated	treat	VBN	_	6	acl
9	with	with	IN	_	11	case
10	drug1	drug1	NN	_	11	compound
11	agents	agent	NNS	_	8	nmod
12	.	.	.	_	4	punct

1	drug1	drug1	NN	_	2	nsubj
2	decreases	decrease	VBZ	_	0	ROOT
3	urinary	urinary	JJ	_	4	amod
4	excretion	excretion	NN	_	2	dobj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	and	and	CC	_	2	cc
8	may	may	MD	_	9	aux
9	enhance	enhance	VB	_	2	conj
10	the	the	DT	_	11	det
11	magnitude	magnitude	NN	_	9	dobj
12	and	and	CC	_	11	cc
13	duration	duration	NN	_	11	conj
14	of	of	IN	_	16	case
15	their	they	PRP$	_	16	nmod:poss
16	effect	effect	NN	_	11	nmod
17	.	.	.	_	2	punct

1	drug1	drug1	NN	_	2	nsubj
2	reduces	reduce	VBZ	_	0	ROOT
3	urinary	urinary	JJ	_	4	amod
4	excretion	excretion	NN	_	2	dobj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	and	and	CC	_	2	cc
8	may	may	MD	_	9	aux
9	enhance	enhance	VB	_	2	conj
10	its	its	PRP$	_	11	nmod:poss
11	effect	effect	NN	_	9	dobj
12	.	.	.	_	2	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	prevent	prevent	VB	_	0	ROOT
4	the	the	DT	_	7	det
5	urinary	urinary	JJ	_	7	amod
6	antiseptic	antiseptic	JJ	_	7	amod
7	effect	effect	NN	_	3	dobj
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	.	.	.	_	3	punct

1	drug1	drug1	NN	_	2	nsubj
2	increases	increase	VBZ	_	10	csubjpass
3	drug2	drug2	NN	_	4	compound
4	excretion	excretion	NN	_	2	dobj
5	and	and	CC	_	4	cc
6	the	the	DT	_	7	det
7	drug3	drug3	NN	_	4	conj
8	may	may	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	decreased	decrease	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	drug1	drug1	NN	_	4	nsubj
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	used	use	VBD	_	0	ROOT
5	concurrently	concurrently	RB	_	6	advmod
6	increases	increase	VBZ	_	4	ccomp
7	the	the	DT	_	8	det
8	risk	risk	NN	_	6	dobj
9	of	of	IN	_	12	case
10	renal	renal	JJ	_	12	amod
11	calculus	calculus	NN	_	12	compound
12	formation	formation	NN	_	8	nmod
13	.	.	.	_	4	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	elevate	elevate	VB	_	0	ROOT
4	drug2	drug2	NN	_	5	compound
5	levels	level	NNS	_	3	dobj
6	.	.	.	_	3	punct

1	The	the	DT	_	3	det
2	drug1	drug1	NN	_	3	compound
3	test	test	NN	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	conducted	conduct	VBN	_	0	ROOT
7	in	in	IN	_	9	case
8	the	the	DT	_	9	det
9	absence	absence	NN	_	6	nmod
10	of	of	IN	_	12	case
11	other	other	JJ	_	12	amod
12	drugs	drug	NNS	_	9	nmod
13	which	which	WDT	_	15	nsubj
14	directly	directly	RB	_	15	advmod
15	affect	affect	VBP	_	12	acl:relcl
16	the	the	DT	_	18	det
17	pituitary	pituitary	JJ	_	18	amod
18	secretion	secretion	NN	_	15	dobj
19	of	of	IN	_	21	case
20	the	the	DT	_	21	det
21	gonadotropins	gonadotropin	NNS	_	18	nmod
22	.	.	.	_	6	punct

1	These	these	DT	_	3	nsubj
2	would	would	MD	_	3	aux
3	include	include	VB	_	0	ROOT
4	a	a	DT	_	5	det
5	variety	variety	NN	_	3	dobj
6	of	of	IN	_	7	case
7	preparations	preparation	NNS	_	5	nmod
8	which	which	WDT	_	9	nsubj
9	contain	contain	VBP	_	7	acl:relcl
10	drug1	drug1	NN	_	9	dobj
11	,	,	,	_	10	punct
12	drug2	drug2	NN	_	10	conj
13	,	,	,	_	10	punct
14	drug3	drug3	NN	_	10	conj
15	,	,	,	_	10	punct
16	or	or	CC	_	10	cc
17	drug4	drug4	NN	_	10	conj
18	.	.	.	_	3	punct

1	The	the	DT	_	3	det
2	gonadotropin	gonadotropin	NN	_	3	compound
3	levels	level	NNS	_	7	nsubj
4	may	may	MD	_	7	aux
5	be	be	VB	_	7	aux
6	transiently	transiently	RB	_	7	advmod
7	elevated	elevated	JJ	_	0	ROOT
8	by	by	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	,	,	,	_	7	punct
11	minimally	minimally	RB	_	12	advmod
12	elevated	elevated	JJ	_	7	xcomp
13	by	by	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	,	,	,	_	7	punct
16	and	and	CC	_	7	cc
17	suppressed	suppress	VBN	_	7	conj
18	by	by	IN	_	20	case
19	oral	oral	JJ	_	20	amod
20	drug3	drug3	NN	_	17	nmod
21	and	and	CC	_	20	cc
22	drug4	drug4	NN	_	20	conj
23	.	.	.	_	7	punct

1	The	the	DT	_	2	det
2	response	response	NN	_	7	nsubjpass
3	to	to	TO	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	may	may	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	blunted	blunt	VBN	_	0	ROOT
8	by	by	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	drug3	drug3	NN	_	9	conj
12	which	which	WDT	_	13	nsubj
13	cause	cause	VBP	_	9	acl:relcl
14	a	a	DT	_	15	det
15	rise	rise	NN	_	13	dobj
16	in	in	IN	_	17	case
17	prolactin	prolactin	NN	_	15	nmod
18	.	.	.	_	7	punct

1	As	as	IN	_	4	mark
2	drug1	drug1	NN	_	3	compound
3	Gel	gel	NN	_	4	nsubj
4	has	have	VBZ	_	57	advcl
5	the	the	DT	_	6	det
6	potential	potential	JJ	_	4	dobj
7	to	to	TO	_	8	mark
8	produce	produce	VB	_	6	acl
9	local	local	JJ	_	10	amod
10	irritation	irritation	NN	_	8	dobj
11	in	in	IN	_	13	case
12	some	some	DT	_	13	det
13	patients	patient	NNS	_	8	nmod
14	,	,	,	_	57	punct
15	concomitant	concomitant	JJ	_	16	amod
16	use	use	NN	_	57	nsubjpass
17	of	of	IN	_	22	case
18	other	other	JJ	_	22	amod
19	potentially	potentially	RB	_	20	advmod
20	irritating	irritating	JJ	_	22	amod
21	topical	topical	JJ	_	22	amod
22	products	product	NNS	_	16	nmod
23	-LRB-	-lrb-	-LRB-	_	24	punct
24	medicated	medicate	VBN	_	22	dep
25	or	or	CC	_	24	cc
26	abrasive	abrasive	JJ	_	24	conj
27	soaps	soap	NNS	_	24	dep
28	and	and	CC	_	27	cc
29	cleansers	cleanser	NNS	_	27	conj
30	,	,	,	_	24	punct
31	soaps	soap	NNS	_	24	conj
32	and	and	CC	_	24	cc
33	cosmetics	cosmetic	NNS	_	24	conj
34	that	that	WDT	_	35	nsubj
35	have	have	VBP	_	24	acl:relcl
36	a	a	DT	_	39	det
37	strong	strong	JJ	_	39	amod
38	drying	dry	VBG	_	39	amod
39	effect	effect	NN	_	35	dobj
40	,	,	,	_	24	punct
41	and	and	CC	_	24	cc
42	products	product	NNS	_	24	conj
43	with	with	IN	_	45	case
44	high	high	JJ	_	45	amod
45	concentrations	concentration	NNS	_	42	nmod
46	of	of	IN	_	47	case
47	alcohol	alcohol	NN	_	45	nmod
48	,	,	,	_	47	punct
49	astringents	astringent	NNS	_	47	conj
50	,	,	,	_	47	punct
51	spices	spice	NNS	_	47	conj
52	or	or	CC	_	47	cc
53	lime	lime	NN	_	47	conj
54	-RRB-	-rrb-	-RRB-	_	24	punct
55	should	should	MD	_	57	aux
56	be	be	VB	_	57	auxpass
57	approached	approach	VBN	_	0	ROOT
58	with	with	IN	_	59	case
59	caution	caution	NN	_	57	nmod
60	.	.	.	_	57	punct

1	Particular	particular	JJ	_	2	amod
2	caution	caution	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	exercised	exercise	VBN	_	0	ROOT
6	in	in	IN	_	7	mark
7	using	use	VBG	_	5	advcl
8	preparations	preparation	NNS	_	7	dobj
9	containing	contain	VBG	_	8	acl
10	drug1	drug1	NN	_	9	dobj
11	,	,	,	_	10	punct
12	drug2	drug2	NN	_	10	conj
13	,	,	,	_	10	punct
14	or	or	CC	_	10	cc
15	drug3	drug3	NN	_	10	conj
16	in	in	IN	_	17	case
17	combination	combination	NN	_	7	nmod
18	with	with	IN	_	20	case
19	drug4	drug4	NN	_	20	compound
20	Gel	gel	NN	_	17	nmod
21	.	.	.	_	5	punct

1	If	if	IN	_	6	mark
2	these	these	DT	_	3	det
3	preparations	preparation	NNS	_	6	nsubjpass
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	auxpass
6	used	use	VBN	_	9	advcl
7	it	it	PRP	_	9	nsubj
8	is	be	VBZ	_	9	cop
9	advisable	advisable	JJ	_	0	ROOT
10	not	not	RB	_	12	neg
11	to	to	TO	_	12	mark
12	start	start	VB	_	9	xcomp
13	therapy	therapy	NN	_	12	dobj
14	with	with	IN	_	16	case
15	drug1	drug1	NN	_	16	compound
16	Gel	gel	NN	_	13	nmod
17	until	until	IN	_	27	mark
18	the	the	DT	_	19	det
19	effects	effect	NNS	_	27	nsubj
20	of	of	IN	_	22	case
21	such	such	JJ	_	22	amod
22	preparations	preparation	NNS	_	19	nmod
23	in	in	IN	_	25	case
24	the	the	DT	_	25	det
25	skin	skin	NN	_	19	nmod
26	have	have	VBP	_	27	aux
27	subsided	subside	VBN	_	12	advcl
28	.	.	.	_	9	punct

1	There	there	EX	_	7	expl
2	have	have	VBP	_	7	aux
3	been	be	VBN	_	7	cop
4	no	no	DT	_	7	neg
5	formal	formal	JJ	_	7	amod
6	clinical	clinical	JJ	_	7	amod
7	studies	study	NNS	_	0	ROOT
8	to	to	TO	_	9	mark
9	evaluate	evaluate	VB	_	7	acl
10	the	the	DT	_	12	det
11	drug	drug	NN	_	12	compound
12	interactions	interaction	NNS	_	9	dobj
13	of	of	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	with	with	IN	_	17	case
16	other	other	JJ	_	17	amod
17	medications	medication	NNS	_	12	nmod
18	.	.	.	_	7	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	5	nsubj
4	have	have	VBP	_	5	aux
5	shown	show	VBN	_	0	ROOT
6	that	that	IN	_	13	mark
7	the	the	DT	_	8	det
8	metabolism	metabolism	NN	_	13	nsubjpass
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	may	may	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	modified	modify	VBN	_	5	ccomp
14	by	by	IN	_	17	case
15	the	the	DT	_	17	det
16	concomitant	concomitant	JJ	_	17	amod
17	administration	administration	NN	_	13	nmod
18	of	of	IN	_	19	case
19	compounds	compound	NNS	_	17	nmod
20	that	that	WDT	_	21	nsubj
21	induce	induce	VBP	_	19	acl:relcl
22	,	,	,	_	21	punct
23	inhibit	inhibit	VBP	_	21	conj
24	,	,	,	_	21	punct
25	or	or	CC	_	21	cc
26	are	be	VBP	_	27	auxpass
27	metabolized	metabolize	VBN	_	21	conj
28	by	by	IN	_	31	case
29	cytochrome	cytochrome	NN	_	31	compound
30	P450	p450	NN	_	31	compound
31	3A4	3a4	NN	_	27	nmod
32	,	,	,	_	31	punct
33	such	such	JJ	_	35	case
34	as	as	IN	_	33	mwe
35	drug2	drug2	NN	_	31	nmod
36	,	,	,	_	35	punct
37	drug3	drug3	NN	_	35	conj
38	,	,	,	_	35	punct
39	drug4	drug4	NN	_	35	conj
40	,	,	,	_	35	punct
41	drug5	drug5	NN	_	35	conj
42	,	,	,	_	35	punct
43	and	and	CC	_	35	cc
44	drug6	drug6	NN	_	35	conj
45	.	.	.	_	5	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	exercised	exercise	VBN	_	0	ROOT
5	with	with	IN	_	7	case
6	these	these	DT	_	7	det
7	drugs	drug	NNS	_	4	nmod
8	when	when	WRB	_	9	advmod
9	treating	treat	VBG	_	4	advcl
10	patients	patient	NNS	_	9	dobj
11	receiving	receive	VBG	_	10	acl
12	drug1	drug1	NN	_	11	dobj
13	as	as	IN	_	15	mark
14	there	there	EX	_	15	expl
15	is	be	VBZ	_	9	advcl
16	a	a	DT	_	17	det
17	potential	potential	NN	_	15	nsubj
18	for	for	IN	_	21	case
19	a	a	DT	_	21	det
20	significant	significant	JJ	_	21	amod
21	interaction	interaction	NN	_	17	nmod
22	.	.	.	_	4	punct

1	drug1	drug1	NN	_	2	nsubj
2	accelerates	accelerate	VBZ	_	0	ROOT
3	the	the	DT	_	4	det
4	metabolism	metabolism	NN	_	2	dobj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	;	;	:	_	2	punct

1	therefore	therefore	RB	_	12	advmod
2	,	,	,	_	12	punct
3	if	if	IN	_	7	mark
4	drug1	drug1	NN	_	5	compound
5	replacement	replacement	NN	_	7	nsubjpass
6	is	be	VBZ	_	7	auxpass
7	needed	need	VBN	_	12	advcl
8	,	,	,	_	12	punct
9	drug2	drug2	NN	_	12	nsubjpass
10	should	should	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	prescribed	prescribe	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	drug1	drug1	NN	_	2	nsubj
2	diminishes	diminish	VBZ	_	0	ROOT
3	the	the	DT	_	4	det
4	effect	effect	NN	_	2	dobj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	drug3	drug3	NN	_	6	conj
9	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Experience	experience	NN	_	14	nsubj
4	in	in	IN	_	7	case
5	over	over	IN	_	6	advmod
6	1400	1400	CD	_	7	nummod
7	patients	patient	NNS	_	3	nmod
8	in	in	IN	_	12	case
9	a	a	DT	_	12	det
10	non-comparative	non-comparative	JJ	_	12	amod
11	clinical	clinical	JJ	_	12	amod
12	trial	trial	NN	_	7	nmod
13	has	have	VBZ	_	14	aux
14	shown	show	VBN	_	1	appos
15	that	that	IN	_	25	mark
16	concomitant	concomitant	JJ	_	17	amod
17	administration	administration	NN	_	25	nsubjpass
18	of	of	IN	_	19	case
19	drug2	drug2	NN	_	17	nmod
20	and	and	CC	_	19	cc
21	drug3	drug3	NN	_	19	conj
22	is	be	VBZ	_	25	auxpass
23	usually	usually	RB	_	25	advmod
24	well	well	RB	_	25	advmod
25	tolerated	tolerate	VBD	_	14	ccomp
26	,	,	,	_	14	punct
27	but	but	CC	_	14	cc
28	there	there	EX	_	33	expl
29	have	have	VBP	_	33	aux
30	been	be	VBN	_	33	cop
31	occasional	occasional	JJ	_	33	amod
32	literature	literature	NN	_	33	compound
33	reports	report	NNS	_	14	conj
34	suggesting	suggest	VBG	_	33	acl
35	that	that	IN	_	39	mark
36	the	the	DT	_	37	det
37	combination	combination	NN	_	39	nsubj
38	may	may	MD	_	39	aux
39	increase	increase	VB	_	34	ccomp
40	the	the	DT	_	41	det
41	likelihood	likelihood	NN	_	39	dobj
42	of	of	IN	_	45	case
43	congestive	congestive	JJ	_	45	amod
44	heart	heart	NN	_	45	compound
45	failure	failure	NN	_	41	nmod
46	,	,	,	_	45	punct
47	severe	severe	JJ	_	48	amod
48	hypotension	hypotension	NN	_	45	conj
49	or	or	CC	_	45	cc
50	exacerbation	exacerbation	NN	_	45	conj
51	of	of	IN	_	52	case
52	angina	angina	NN	_	50	nmod
53	.	.	.	_	1	punct

1	Long	long	JJ	_	3	amod
2	Acting	acting	NN	_	3	compound
3	drug1	drug1	NN	_	0	ROOT
4	:	:	:	_	3	punct
5	drug2	drug2	NN	_	9	nsubjpass
6	may	may	MD	_	9	aux
7	be	be	VB	_	9	auxpass
8	safely	safely	RB	_	9	advmod
9	co-administered	co-administer	VBN	_	3	dep
10	with	with	IN	_	11	case
11	drug3	drug3	NN	_	9	nmod
12	,	,	,	_	9	punct
13	but	but	CC	_	9	cc
14	there	there	EX	_	19	expl
15	have	have	VBP	_	19	aux
16	been	be	VBN	_	19	cop
17	no	no	DT	_	19	neg
18	controlled	controlled	JJ	_	19	amod
19	studies	study	NNS	_	9	conj
20	to	to	TO	_	21	mark
21	evaluate	evaluate	VB	_	19	acl
22	the	the	DT	_	24	det
23	antianginal	antianginal	JJ	_	24	amod
24	effectiveness	effectiveness	NN	_	21	dobj
25	of	of	IN	_	27	case
26	this	this	DT	_	27	det
27	combination	combination	NN	_	24	nmod
28	.	.	.	_	3	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Immediate	Immediate	NNP	_	5	compound
4	Release	Release	NNP	_	5	compound
5	Capsules	Capsules	NNPS	_	1	dep
6	:	:	:	_	5	punct
7	Since	since	IN	_	11	mark
8	there	there	EX	_	11	expl
9	have	have	VBP	_	11	aux
10	been	be	VBN	_	11	auxpass
11	isolated	isolate	VBN	_	33	advcl
12	reports	report	NNS	_	11	dobj
13	of	of	IN	_	14	case
14	patients	patient	NNS	_	12	nmod
15	with	with	IN	_	18	case
16	elevated	elevated	JJ	_	18	amod
17	drug2	drug2	NN	_	18	compound
18	levels	level	NNS	_	14	nmod
19	,	,	,	_	11	punct
20	and	and	CC	_	11	cc
21	there	there	EX	_	22	expl
22	is	be	VBZ	_	11	conj
23	a	a	DT	_	25	det
24	possible	possible	JJ	_	25	amod
25	interaction	interaction	NN	_	22	nsubj
26	between	between	IN	_	27	case
27	drug3	drug3	NN	_	25	nmod
28	and	and	CC	_	27	cc
29	drug4	drug4	NN	_	27	conj
30	,	,	,	_	33	punct
31	it	it	PRP	_	33	nsubjpass
32	is	be	VBZ	_	33	auxpass
33	recommended	recommend	VBN	_	5	dep
34	that	that	IN	_	38	mark
35	drug5	drug5	NN	_	36	compound
36	levels	level	NNS	_	38	nsubjpass
37	be	be	VB	_	38	auxpass
38	monitored	monitor	VBN	_	33	ccomp
39	when	when	WRB	_	40	advmod
40	initiating	initiate	VBG	_	38	advcl
41	,	,	,	_	40	punct
42	adjusting	adjust	VBG	_	40	conj
43	,	,	,	_	40	punct
44	and	and	CC	_	40	cc
45	discontinuing	discontinue	VBG	_	40	conj
46	drug6	drug6	NN	_	45	dobj
47	to	to	TO	_	48	mark
48	avoid	avoid	VB	_	45	xcomp
49	possible	possible	JJ	_	48	xcomp
50	over	over	IN	_	53	case
51	-	-	:	_	53	punct
52	or	or	CC	_	53	cc
53	under-digitalization	under-digitalization	NN	_	49	nmod
54	.	.	.	_	1	punct

1	Extended	Extended	NNP	_	3	compound
2	Release	Release	NNP	_	3	compound
3	Tablets	Tablets	NNPS	_	0	ROOT
4	:	:	:	_	3	punct
5	Administration	administration	NN	_	10	nsubj
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	with	with	IN	_	9	case
9	drug2	drug2	NN	_	5	nmod
10	increased	increase	VBD	_	3	dep
11	drug3	drug3	NN	_	12	compound
12	levels	level	NNS	_	10	dobj
13	in	in	IN	_	14	case
14	9	9	CD	_	10	nmod
15	of	of	IN	_	18	case
16	12	12	CD	_	18	nummod
17	normal	normal	JJ	_	18	amod
18	volunteers	volunteer	NNS	_	14	nmod
19	.	.	.	_	3	punct

1	The	the	DT	_	3	det
2	average	average	JJ	_	3	amod
3	increase	increase	NN	_	6	nsubj
4	was	be	VBD	_	6	cop
5	45	45	CD	_	6	nummod
6	%	%	NN	_	0	ROOT
7	.	.	.	_	6	punct

1	Another	another	DT	_	2	det
2	investigator	investigator	NN	_	3	nsubj
3	found	find	VBD	_	0	ROOT
4	no	no	DT	_	5	neg
5	increase	increase	NN	_	3	dobj
6	in	in	IN	_	8	case
7	drug1	drug1	NN	_	8	compound
8	levels	level	NNS	_	5	nmod
9	in	in	IN	_	11	case
10	13	13	CD	_	11	nummod
11	patients	patient	NNS	_	3	nmod
12	with	with	IN	_	15	case
13	coronary	coronary	JJ	_	15	amod
14	artery	artery	NN	_	15	compound
15	disease	disease	NN	_	11	nmod
16	.	.	.	_	3	punct

1	In	in	IN	_	4	case
2	an	a	DT	_	4	det
3	uncontrolled	uncontrolled	JJ	_	4	amod
4	study	study	NN	_	26	nmod
5	of	of	IN	_	8	case
6	over	over	IN	_	7	advmod
7	200	200	CD	_	8	nummod
8	patients	patient	NNS	_	4	nmod
9	with	with	IN	_	12	case
10	congestive	congestive	JJ	_	12	amod
11	heart	heart	NN	_	12	compound
12	failure	failure	NN	_	8	nmod
13	during	during	IN	_	14	case
14	which	which	WDT	_	20	nmod
15	drug1	drug1	NN	_	17	compound
16	blood	blood	NN	_	17	compound
17	levels	level	NNS	_	20	nsubjpass
18	were	be	VBD	_	20	auxpass
19	not	not	RB	_	20	neg
20	measured	measure	VBN	_	8	acl:relcl
21	,	,	,	_	26	punct
22	digitalis	digitalis	NN	_	23	compound
23	toxicity	toxicity	NN	_	26	nsubjpass
24	was	be	VBD	_	26	auxpass
25	not	not	RB	_	26	neg
26	observed	observe	VBN	_	0	ROOT
27	.	.	.	_	26	punct

1	Since	since	IN	_	5	mark
2	there	there	EX	_	5	expl
3	have	have	VBP	_	5	aux
4	been	be	VBN	_	5	auxpass
5	isolated	isolate	VBN	_	16	advcl
6	reports	report	NNS	_	5	dobj
7	of	of	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	with	with	IN	_	12	case
10	elevated	elevated	JJ	_	12	amod
11	drug1	drug1	NN	_	12	compound
12	levels	level	NNS	_	8	nmod
13	,	,	,	_	16	punct
14	it	it	PRP	_	16	nsubjpass
15	is	be	VBZ	_	16	auxpass
16	recommended	recommend	VBN	_	0	ROOT
17	that	that	IN	_	21	mark
18	drug2	drug2	NN	_	19	compound
19	levels	level	NNS	_	21	nsubjpass
20	be	be	VB	_	21	auxpass
21	monitored	monitor	VBN	_	16	ccomp
22	when	when	WRB	_	23	advmod
23	initiating	initiate	VBG	_	21	advcl
24	,	,	,	_	23	punct
25	adjusting	adjust	VBG	_	23	conj
26	,	,	,	_	23	punct
27	and	and	CC	_	23	cc
28	discontinuing	discontinue	VBG	_	23	conj
29	drug3	drug3	NN	_	28	dobj
30	to	to	TO	_	31	mark
31	avoid	avoid	VB	_	28	xcomp
32	possible	possible	JJ	_	31	xcomp
33	over	over	IN	_	36	case
34	-	-	:	_	36	punct
35	or	or	CC	_	36	cc
36	under-digitalization	under-digitalization	NN	_	32	nmod
37	.	.	.	_	16	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Immediate	Immediate	NNP	_	5	compound
4	Release	Release	NNP	_	5	compound
5	Capsules	Capsules	NNPS	_	1	dep
6	:	:	:	_	5	punct
7	There	there	EX	_	11	expl
8	have	have	VBP	_	11	aux
9	been	be	VBN	_	11	cop
10	rare	rare	JJ	_	11	amod
11	reports	report	NNS	_	5	appos
12	of	of	IN	_	14	case
13	an	a	DT	_	14	det
14	interaction	interaction	NN	_	11	nmod
15	between	between	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	and	and	CC	_	16	cc
18	drug3	drug3	NN	_	16	conj
19	-LRB-	-lrb-	-LRB-	_	11	punct
20	with	with	IN	_	24	case
21	a	a	DT	_	24	det
22	decreased	decrease	VBN	_	24	amod
23	plasma	plasma	NN	_	24	compound
24	level	level	NN	_	11	nmod
25	of	of	IN	_	26	case
26	drug4	drug4	NN	_	24	nmod
27	-RRB-	-rrb-	-RRB-	_	11	punct
28	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	There	there	EX	_	7	expl
4	have	have	VBP	_	7	aux
5	been	be	VBN	_	7	cop
6	rare	rare	JJ	_	7	amod
7	reports	report	NNS	_	1	appos
8	of	of	IN	_	11	case
9	increased	increase	VBN	_	11	amod
10	prothrombin	prothrombin	NN	_	11	compound
11	time	time	NN	_	7	nmod
12	in	in	IN	_	13	case
13	patients	patient	NNS	_	7	nmod
14	taking	take	VBG	_	13	acl
15	drug2	drug2	NN	_	14	dobj
16	to	to	TO	_	20	mark
17	whom	whom	WP	_	20	dobj
18	drug3	drug3	NN	_	20	nsubjpass
19	was	be	VBD	_	20	auxpass
20	administered	administer	VBN	_	14	advcl
21	.	.	.	_	1	punct

1	However	however	RB	_	9	advmod
2	,	,	,	_	9	punct
3	the	the	DT	_	4	det
4	relationship	relationship	NN	_	9	nsubj
5	to	to	TO	_	7	case
6	drug1	drug1	NN	_	7	compound
7	therapy	therapy	NN	_	4	nmod
8	is	be	VBZ	_	9	cop
9	uncertain	uncertain	JJ	_	0	ROOT
10	.	.	.	_	9	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	A	a	DT	_	4	det
4	study	study	NN	_	10	nsubj
5	in	in	IN	_	8	case
6	6	6	CD	_	8	nummod
7	healthy	healthy	JJ	_	8	amod
8	volunteers	volunteer	NNS	_	4	nmod
9	has	have	VBZ	_	10	aux
10	shown	show	VBN	_	1	dep
11	a	a	DT	_	13	det
12	significant	significant	JJ	_	13	amod
13	increase	increase	NN	_	10	dobj
14	in	in	IN	_	18	case
15	peak	peak	JJ	_	18	amod
16	drug2	drug2	NN	_	18	compound
17	plasma	plasma	NN	_	18	compound
18	levels	level	NNS	_	13	nmod
19	-LRB-	-lrb-	-LRB-	_	21	punct
20	80	80	CD	_	21	nummod
21	%	%	NN	_	13	dep
22	-RRB-	-rrb-	-RRB-	_	21	punct
23	and	and	CC	_	13	cc
24	area-under-the-curve	area-under-the-curve	NN	_	13	conj
25	-LRB-	-lrb-	-LRB-	_	27	punct
26	74	74	CD	_	27	nummod
27	%	%	NN	_	24	appos
28	-RRB-	-rrb-	-RRB-	_	27	punct
29	after	after	IN	_	33	case
30	a	a	DT	_	33	det
31	1	1	CD	_	32	compound
32	week	week	NN	_	33	amod
33	course	course	NN	_	13	nmod
34	of	of	IN	_	35	case
35	drug3	drug3	NN	_	33	nmod
36	at	at	IN	_	38	case
37	1000	1000	CD	_	38	nummod
38	mg	mg	NN	_	13	nmod
39	per	per	IN	_	40	case
40	day	day	NN	_	38	nmod
41	and	and	CC	_	38	cc
42	drug4	drug4	NN	_	38	conj
43	at	at	IN	_	45	case
44	40	40	CD	_	45	nummod
45	mg	mg	NN	_	42	nmod
46	per	per	IN	_	47	case
47	day	day	NN	_	45	nmod
48	.	.	.	_	1	punct

1	drug1	drug1	NN	_	2	nsubj
2	produced	produce	VBD	_	0	ROOT
3	smaller	smaller	JJR	_	6	amod
4	,	,	,	_	6	punct
5	non-significant	non-significant	JJ	_	6	amod
6	increases	increase	NNS	_	2	dobj
7	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	5	nsubjpass
3	may	may	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	mediated	mediate	VBN	_	0	ROOT
6	by	by	IN	_	9	case
7	the	the	DT	_	9	det
8	known	known	JJ	_	9	amod
9	inhibition	inhibition	NN	_	5	nmod
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	on	on	IN	_	15	case
13	hepatic	hepatic	JJ	_	15	amod
14	cytochrome	cytochrome	NN	_	15	compound
15	P-450	p-450	NN	_	9	nmod
16	,	,	,	_	5	punct
17	the	the	DT	_	19	det
18	enzyme	enzyme	NN	_	19	compound
19	system	system	NN	_	16	root
20	probably	probably	RB	_	21	advmod
21	responsible	responsible	JJ	_	19	amod
22	for	for	IN	_	25	case
23	the	the	DT	_	25	det
24	first-pass	first-pass	JJ	_	25	amod
25	metabolism	metabolism	NN	_	21	nmod
26	of	of	IN	_	27	case
27	drug2	drug2	NN	_	25	nmod
28	.	.	.	_	19	punct

1	If	if	IN	_	5	mark
2	drug1	drug1	NN	_	3	compound
3	therapy	therapy	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	initiated	initiate	VBN	_	16	advcl
6	in	in	IN	_	8	case
7	a	a	DT	_	8	det
8	patient	patient	NN	_	5	nmod
9	currently	currently	RB	_	10	advmod
10	receiving	receive	VBG	_	8	acl
11	drug2	drug2	NN	_	10	dobj
12	,	,	,	_	16	punct
13	cautious	cautious	JJ	_	14	amod
14	titration	titration	NN	_	16	nsubjpass
15	is	be	VBZ	_	16	auxpass
16	advised	advise	VBN	_	0	ROOT
17	.	.	.	_	16	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	avoided	avoid	VBN	_	0	ROOT
5	by	by	IN	_	6	case
6	patients	patient	NNS	_	4	nmod
7	with	with	IN	_	9	case
8	a	a	DT	_	9	det
9	history	history	NN	_	6	nmod
10	of	of	IN	_	12	case
11	serious	serious	JJ	_	12	amod
12	reaction	reaction	NN	_	9	nmod
13	to	to	TO	_	15	case
14	any	any	DT	_	15	det
15	drug2	drug2	NN	_	12	nmod
16	,	,	,	_	12	punct
17	including	include	VBG	_	18	case
18	drug3	drug3	NN	_	12	nmod
19	and	and	CC	_	18	cc
20	drug4	drug4	NN	_	18	conj
21	.	.	.	_	4	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	should	should	MD	_	5	aux
3	not	not	RB	_	5	neg
4	be	be	VB	_	5	auxpass
5	used	use	VBN	_	0	ROOT
6	together	together	RP	_	5	advmod
7	with	with	IN	_	8	case
8	drug2	drug2	NN	_	5	nmod
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	drug3	drug3	NN	_	8	dep
11	,	,	,	_	10	punct
12	drug4	drug4	NN	_	10	appos
13	-RRB-	-rrb-	-RRB-	_	10	punct
14	,	,	,	_	8	punct
15	another	another	DT	_	17	det
16	arthritis	arthritis	NN	_	17	compound
17	medication	medication	NN	_	8	appos
18	.	.	.	_	5	punct

1	It	it	PRP	_	5	nsubjpass
2	should	should	MD	_	5	aux
3	also	also	RB	_	5	advmod
4	be	be	VB	_	5	auxpass
5	avoided	avoid	VBN	_	0	ROOT
6	in	in	IN	_	7	case
7	patients	patient	NNS	_	5	nmod
8	with	with	IN	_	9	case
9	blood	blood	NN	_	7	nmod
10	,	,	,	_	9	punct
11	liver	liver	NN	_	9	conj
12	or	or	CC	_	9	cc
13	kidney	kidney	NN	_	14	compound
14	diseases	disease	NNS	_	9	conj
15	,	,	,	_	5	punct
16	recent	recent	JJ	_	18	amod
17	radiation	radiation	NN	_	18	compound
18	treatment	treatment	NN	_	15	root
19	,	,	,	_	18	punct
20	or	or	CC	_	18	cc
21	uncontrolled	uncontrolled	JJ	_	22	amod
22	diabetes	diabetes	NN	_	18	conj
23	.	.	.	_	18	punct

1	Patients	patient	NNS	_	3	nsubj
2	should	should	MD	_	3	aux
3	report	report	VB	_	0	ROOT
4	to	to	TO	_	6	case
5	their	they	PRP$	_	6	nmod:poss
6	practitioners	practitioner	NNS	_	3	nmod
7	any	any	DT	_	9	det
8	new	new	JJ	_	9	amod
9	rashes	rash	NNS	_	3	dobj
10	,	,	,	_	9	punct
11	itching	itch	VBG	_	9	acl
12	,	,	,	_	11	punct
13	mouth	mouth	NN	_	14	compound
14	sores	sore	NNS	_	11	conj
15	,	,	,	_	11	punct
16	or	or	CC	_	11	cc
17	unusual	unusual	JJ	_	18	amod
18	taste	taste	NN	_	11	conj
19	while	while	IN	_	20	mark
20	taking	take	VBG	_	11	advcl
21	drug1	drug1	NN	_	20	dobj
22	.	.	.	_	3	punct

1	drug1	drug1	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	excreted	excrete	VBN	_	0	ROOT
4	slowly	slowly	RB	_	3	advmod
5	from	from	IN	_	7	case
6	the	the	DT	_	7	det
7	body	body	NN	_	3	nmod
8	.	.	.	_	3	punct

1	Safety	safety	NN	_	9	nsubjpass
2	and	and	CC	_	1	cc
3	effectiveness	effectiveness	NN	_	1	conj
4	in	in	IN	_	5	case
5	children	child	NNS	_	1	nmod
6	has	have	VBZ	_	9	aux
7	not	not	RB	_	9	neg
8	been	be	VBN	_	9	auxpass
9	established	establish	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	The	the	DT	_	2	det
2	potential	potential	NN	_	10	nsubjpass
3	for	for	IN	_	5	case
4	drug	drug	NN	_	5	compound
5	interactions	interaction	NNS	_	2	nmod
6	with	with	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	has	have	VBZ	_	10	aux
9	been	be	VBN	_	10	auxpass
10	studied	study	VBN	_	0	ROOT
11	in	in	IN	_	12	case
12	combination	combination	NN	_	10	nmod
13	with	with	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	,	,	,	_	14	punct
16	drug3	drug3	NN	_	14	conj
17	,	,	,	_	14	punct
18	drug4	drug4	NN	_	14	conj
19	,	,	,	_	14	punct
20	and	and	CC	_	14	cc
21	drug5	drug5	NN	_	14	conj
22	.	.	.	_	10	punct

1	There	there	EX	_	2	expl
2	were	be	VBD	_	0	ROOT
3	no	no	DT	_	7	neg
4	clinically	clinically	RB	_	5	advmod
5	significant	significant	JJ	_	7	amod
6	drug	drug	NN	_	7	compound
7	interactions	interaction	NNS	_	2	nsubj
8	for	for	IN	_	9	case
9	any	any	DT	_	7	nmod
10	of	of	IN	_	12	case
11	these	these	DT	_	12	det
12	drugs	drug	NNS	_	9	nmod

1	.	.	.	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	May	May	NNP	_	2	nsubj
2	interact	interact	VBP	_	0	ROOT
3	with	with	IN	_	5	case
4	addictive	addictive	JJ	_	5	amod
5	medications	medication	NNS	_	2	nmod
6	,	,	,	_	5	punct
7	especially	especially	RB	_	8	advmod
8	drug1	drug1	NN	_	5	appos
9	with	with	IN	_	11	case
10	habituating	habituate	VBG	_	11	amod
11	potential	potential	JJ	_	17	nmod
12	-LRB-	-lrb-	-LRB-	_	15	punct
13	prolonged	prolonged	JJ	_	15	amod
14	concurrent	concurrent	JJ	_	15	amod
15	use	use	NN	_	17	nsubj
16	may	may	MD	_	17	aux
17	increase	increase	VB	_	8	acl:relcl
18	the	the	DT	_	19	det
19	risk	risk	NN	_	17	dobj
20	of	of	IN	_	21	case
21	habituation	habituation	NN	_	19	nmod
22	-RRB-	-rrb-	-RRB-	_	2	punct
23	,	,	,	_	2	punct
24	drug2	drug2	NN	_	27	compound
25	or	or	CC	_	24	cc
26	CNS	cns	NN	_	24	conj
27	depression	depression	NN	_	34	nsubj
28	producing	produce	VBG	_	27	acl
29	medications	medication	NNS	_	32	compound
30	-LRB-	-lrb-	-LRB-	_	32	punct
31	concurrent	concurrent	JJ	_	32	amod
32	use	use	NN	_	28	dobj
33	may	may	MD	_	34	aux
34	increase	increase	VB	_	2	parataxis
35	the	the	DT	_	38	det
36	CNS	cns	NN	_	38	compound
37	depressant	depressant	NN	_	38	compound
38	effects	effect	NNS	_	34	dobj
39	of	of	IN	_	42	case
40	either	either	CC	_	42	cc:preconj
41	these	these	DT	_	42	det
42	medications	medication	NNS	_	38	nmod
43	or	or	CC	_	42	cc
44	drug3	drug3	NN	_	42	conj
45	-RRB-	-rrb-	-RRB-	_	34	punct
46	.	.	.	_	2	punct

1	drug1	drug1	NN	_	2	nsubj
2	potentiates	potentiate	VBZ	_	0	ROOT
3	other	other	JJ	_	4	amod
4	drug2	drug2	NN	_	2	dobj
5	such	such	JJ	_	7	case
6	as	as	IN	_	5	mwe
7	drug3	drug3	NN	_	4	nmod
8	or	or	CC	_	7	cc
9	drug4	drug4	NN	_	7	conj
10	and	and	CC	_	7	cc
11	drug5	drug5	NN	_	7	conj
12	s.	s.	VBP	_	2	dep

1	Patients	patient	NNS	_	8	nsubjpass
2	undergoing	undergo	VBG	_	1	acl
3	systemic	systemic	JJ	_	5	amod
4	anticholinesterase	anticholinesterase	NN	_	5	compound
5	treatment	treatment	NN	_	2	dobj
6	should	should	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	warned	warn	VBN	_	0	ROOT
9	of	of	IN	_	13	case
10	the	the	DT	_	13	det
11	possible	possible	JJ	_	13	amod
12	additive	additive	JJ	_	13	amod
13	effects	effect	NNS	_	8	nmod
14	of	of	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	.	.	.	_	8	punct

1	Renal	renal	JJ	_	2	amod
2	function	function	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	monitored	monitor	VBN	_	0	ROOT
6	carefully	carefully	RB	_	5	advmod
7	if	if	IN	_	12	mark
8	high	high	JJ	_	9	amod
9	doses	dose	NNS	_	12	nsubj
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	are	be	VBP	_	5	advcl
13	to	to	TO	_	15	mark
14	be	be	VB	_	15	auxpass
15	administered	administer	VBN	_	12	xcomp
16	with	with	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	because	because	IN	_	22	case
19	of	of	IN	_	18	mwe
20	the	the	DT	_	22	det
21	increased	increase	VBN	_	22	amod
22	potential	potential	NN	_	15	nmod
23	of	of	IN	_	24	case
24	nephrotoxicity	nephrotoxicity	NN	_	22	nmod
25	and	and	CC	_	24	cc
26	ototoxicity	ototoxicity	NN	_	24	conj
27	of	of	IN	_	28	case
28	drug3	drug3	NN	_	24	nmod
29	.	.	.	_	5	punct

1	Nephrotoxicity	nephrotoxicity	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	following	follow	VBG	_	7	case
6	concomitant	concomitant	JJ	_	7	amod
7	administration	administration	NN	_	4	nmod
8	of	of	IN	_	10	case
9	other	other	JJ	_	10	amod
10	drug1	drug1	NN	_	7	nmod
11	with	with	IN	_	13	case
12	potent	potent	JJ	_	13	amod
13	drug2	drug2	NN	_	7	nmod
14	such	such	JJ	_	16	case
15	as	as	IN	_	14	mwe
16	drug3	drug3	NN	_	13	nmod
17	.	.	.	_	4	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	3	amod
2	Test	test	NN	_	3	compound
3	Interactions	interaction	NNS	_	0	ROOT
4	The	the	DT	_	5	det
5	administration	administration	NN	_	9	nsubj
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	may	may	MD	_	9	aux
9	result	result	VB	_	3	acl:relcl
10	in	in	IN	_	13	case
11	a	a	DT	_	13	det
12	false-positive	false-positive	JJ	_	13	amod
13	reaction	reaction	NN	_	9	nmod
14	for	for	IN	_	15	case
15	glucose	glucose	NN	_	13	nmod
16	in	in	IN	_	18	case
17	the	the	DT	_	18	det
18	urine	urine	NN	_	15	nmod
19	when	when	WRB	_	20	advmod
20	using	use	VBG	_	9	advcl
21	Clinitest	Clinitest	NNP	_	22	compound
22	tablets	tablet	NNS	_	20	dobj
23	.	.	.	_	3	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	recommended	recommend	VBN	_	0	ROOT
4	that	that	IN	_	21	mark
5	glucose	glucose	NN	_	6	compound
6	tests	test	NNS	_	21	nsubjpass
7	based	base	VBN	_	12	case
8	on	on	IN	_	12	case
9	enzymatic	enzymatic	JJ	_	12	amod
10	glucose	glucose	NN	_	12	compound
11	oxidase	oxidase	NN	_	12	compound
12	reactions	reaction	NNS	_	6	nmod
13	-LRB-	-lrb-	-LRB-	_	16	punct
14	such	such	JJ	_	16	case
15	as	as	IN	_	14	mwe
16	Clinistix	Clinistix	NNP	_	12	nmod
17	or	or	CC	_	16	cc
18	Tes-Tape	Tes-Tape	NNP	_	16	conj
19	-RRB-	-rrb-	-RRB-	_	16	punct
20	be	be	VB	_	21	auxpass
21	used	use	VBN	_	3	ccomp
22	.	.	.	_	3	punct

1	There	there	EX	_	6	expl
2	have	have	VBP	_	6	aux
3	been	be	VBN	_	6	cop
4	no	no	DT	_	6	neg
5	formal	formal	JJ	_	6	amod
6	studies	study	NNS	_	0	ROOT
7	of	of	IN	_	9	case
8	the	the	DT	_	9	det
9	interaction	interaction	NN	_	6	nmod
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	for	for	IN	_	14	case
13	Topical	topical	JJ	_	14	amod
14	Solution	solution	NN	_	9	nmod
15	with	with	IN	_	18	case
16	any	any	DT	_	18	det
17	other	other	JJ	_	18	amod
18	drugs	drug	NNS	_	9	nmod
19	,	,	,	_	6	punct
20	and	and	CC	_	6	cc
21	no	no	DT	_	23	neg
22	drug-specific	drug-specific	JJ	_	23	amod
23	interactions	interaction	NNS	_	25	nsubjpass
24	were	be	VBD	_	25	auxpass
25	noted	note	VBN	_	6	conj
26	during	during	IN	_	27	case
27	any	any	DT	_	25	nmod
28	of	of	IN	_	32	case
29	the	the	DT	_	32	det
30	controlled	controlled	JJ	_	32	amod
31	clinical	clinical	JJ	_	32	amod
32	trials	trial	NNS	_	27	nmod
33	.	.	.	_	6	punct

1	It	it	PRP	_	0	ROOT
2	is	be	VBZ	_	1	dep
3	,	,	,	_	2	punct
4	however	however	RB	_	3	root
5	,	,	,	_	4	punct
6	possible	possible	JJ	_	28	dep
7	that	that	IN	_	28	mark
8	concomitant	concomitant	JJ	_	9	amod
9	use	use	NN	_	28	nsubj
10	of	of	IN	_	13	case
11	other	other	JJ	_	13	amod
12	known	known	JJ	_	13	amod
13	drug1	drug1	NN	_	9	nmod
14	such	such	JJ	_	16	case
15	as	as	IN	_	14	mwe
16	drug2	drug2	NN	_	13	nmod
17	,	,	,	_	16	punct
18	drug3	drug3	NN	_	16	conj
19	,	,	,	_	16	punct
20	drug4	drug4	NN	_	16	conj
21	,	,	,	_	16	punct
22	drug5	drug5	NN	_	16	conj
23	,	,	,	_	16	punct
24	drug6	drug6	NN	_	16	conj
25	and	and	CC	_	16	cc
26	drug7	drug7	NN	_	16	conj
27	might	might	MD	_	28	aux
28	increase	increase	VB	_	5	root
29	the	the	DT	_	31	det
30	photosensitivity	photosensitivity	NN	_	31	compound
31	reaction	reaction	NN	_	28	dobj
32	of	of	IN	_	34	case
33	actinic	actinic	JJ	_	34	amod
34	keratoses	keratose	NNS	_	31	nmod
35	treated	treat	VBN	_	34	acl
36	with	with	IN	_	38	case
37	the	the	DT	_	38	det
38	drug8	drug8	NN	_	35	nmod
39	for	for	IN	_	41	case
40	Topical	topical	JJ	_	41	amod
41	Solution	solution	NN	_	38	nmod
42	.	.	.	_	28	punct

1	drug1	drug1	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	metabolized	metabolize	VBN	_	0	ROOT
4	to	to	TO	_	5	mark
5	drug2	drug2	VB	_	3	xcomp
6	by	by	IN	_	9	case
7	cytochrome	cytochrome	NN	_	9	compound
8	CYP	cyp	NN	_	9	compound
9	3A4	3a4	NN	_	5	nmod
10	.	.	.	_	3	punct

1	Because	because	IN	_	6	mark
2	CYP	cyp	NN	_	4	compound
3	3A4	3a4	NN	_	4	compound
4	inhibitors	inhibitor	NNS	_	6	nsubj
5	may	may	MD	_	6	aux
6	increase	increase	VB	_	0	ROOT
7	plasma	plasma	NN	_	8	compound
8	concentrations	concentration	NNS	_	6	dobj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	,	,	,	_	10	punct
12	patients	patient	NNS	_	10	appos
13	already	already	RB	_	17	advmod
14	on	on	IN	_	17	case
15	CYP	cyp	NN	_	17	compound
16	3A4	3a4	NN	_	17	compound
17	inhibitors	inhibitor	NNS	_	12	nmod
18	such	such	JJ	_	20	case
19	as	as	IN	_	18	mwe
20	drug2	drug2	NN	_	17	nmod
21	-LRB-	-lrb-	-LRB-	_	22	punct
22	e.g.	e.g.	FW	_	20	dep

1	drug1	drug1	NN	_	0	ROOT
2	-RRB-	-rrb-	-RRB-	_	1	punct
3	,	,	,	_	1	punct
4	drug2	drug2	NN	_	3	root
5	-LRB-	-lrb-	-LRB-	_	7	punct
6	e.g.	e.g.	FW	_	7	dep
7	drug3	drug3	FW	_	4	dep
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	,	,	,	_	4	punct
10	and	and	CC	_	4	cc
11	drug4	drug4	NN	_	4	conj
12	-LRB-	-lrb-	-LRB-	_	21	punct
13	e.g.	e.g.	FW	_	21	advmod
14	drug5	drug5	FW	_	13	dep
15	,	,	,	_	14	punct
16	drug6	drug6	NN	_	14	conj
17	and	and	CC	_	14	cc
18	drug7	drug7	NN	_	14	conj
19	-RRB-	-rrb-	-RRB-	_	21	punct
20	should	should	MD	_	21	aux
21	have	have	VB	_	11	root
22	their	they	PRP$	_	23	nmod:poss
23	dose	dose	NN	_	28	nsubj
24	of	of	IN	_	25	case
25	drug8	drug8	NN	_	23	nmod
26	or	or	CC	_	25	cc
27	drug9	drug9	NN	_	25	conj
28	adjusted	adjust	VBN	_	21	ccomp
29	.	.	.	_	21	punct

1	Based	base	VBN	_	4	case
2	on	on	IN	_	4	case
3	anecdotal	anecdotal	JJ	_	4	amod
4	reports	report	NNS	_	10	advcl
5	,	,	,	_	10	punct
6	there	there	EX	_	10	expl
7	may	may	MD	_	10	aux
8	be	be	VB	_	10	cop
9	an	a	DT	_	10	det
10	interaction	interaction	NN	_	0	ROOT
11	between	between	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	and	and	CC	_	12	cc
14	drug2	drug2	NN	_	12	conj
15	.	.	.	_	10	punct

1	There	there	EX	_	5	expl
2	have	have	VBP	_	5	aux
3	been	be	VBN	_	5	cop
4	a	a	DT	_	5	det
5	number	number	NN	_	0	ROOT
6	of	of	IN	_	7	case
7	reports	report	NNS	_	5	nmod
8	in	in	IN	_	11	case
9	the	the	DT	_	11	det
10	post-marketing	post-marketing	JJ	_	11	amod
11	experience	experience	NN	_	7	nmod
12	of	of	IN	_	13	case
13	coma	coma	NN	_	11	nmod
14	and	and	CC	_	13	cc
15	death	death	NN	_	13	conj
16	associated	associate	VBN	_	13	acl
17	with	with	IN	_	21	case
18	the	the	DT	_	21	det
19	concomitant	concomitant	JJ	_	21	amod
20	intravenous	intravenous	JJ	_	21	amod
21	misuse	misuse	NN	_	16	nmod
22	of	of	IN	_	23	case
23	drug1	drug1	NN	_	21	nmod
24	and	and	CC	_	23	cc
25	drug2	drug2	NN	_	23	conj
26	by	by	IN	_	27	case
27	addicts	addict	NNS	_	21	nmod
28	.	.	.	_	5	punct

1	In	in	IN	_	2	case
2	many	many	JJ	_	9	nmod
3	of	of	IN	_	5	case
4	these	these	DT	_	5	det
5	cases	case	NNS	_	2	nmod
6	,	,	,	_	9	punct
7	drug1	drug1	NN	_	9	nsubjpass
8	was	be	VBD	_	9	auxpass
9	misused	misuse	VBN	_	0	ROOT
10	by	by	IN	_	11	case
11	self-injection	self-injection	NN	_	9	nmod
12	of	of	IN	_	15	case
13	crushed	crushed	JJ	_	15	amod
14	drug2	drug2	NN	_	15	compound
15	tablets	tablet	NNS	_	11	nmod
16	.	.	.	_	9	punct

1	drug1	drug1	NN	_	6	nsubjpass
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	prescribed	prescribe	VBN	_	0	ROOT
7	with	with	IN	_	8	case
8	caution	caution	NN	_	6	nmod
9	to	to	TO	_	10	case
10	patients	patient	NNS	_	8	nmod
11	on	on	IN	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	or	or	CC	_	12	cc
14	other	other	JJ	_	15	amod
15	drugs	drug	NNS	_	12	conj
16	that	that	WDT	_	17	nsubj
17	act	act	VBP	_	10	acl:relcl
18	on	on	IN	_	22	case
19	the	the	DT	_	22	det
20	central	central	JJ	_	22	amod
21	nervous	nervous	JJ	_	22	amod
22	system	system	NN	_	17	nmod
23	,	,	,	_	6	punct
24	regardless	regardless	RB	_	6	advmod
25	of	of	IN	_	30	mark
26	whether	whether	IN	_	30	mark
27	these	these	DT	_	28	det
28	drugs	drug	NNS	_	30	nsubjpass
29	are	be	VBP	_	30	auxpass
30	taken	take	VBN	_	24	advcl
31	on	on	IN	_	33	case
32	the	the	DT	_	33	det
33	advice	advice	NN	_	30	nmod
34	of	of	IN	_	36	case
35	a	a	DT	_	36	det
36	physician	physician	NN	_	33	nmod
37	or	or	CC	_	30	cc
38	are	be	VBP	_	39	auxpass
39	taken	take	VBN	_	30	conj
40	as	as	IN	_	41	case
41	drugs	drug	NNS	_	39	nmod
42	of	of	IN	_	43	case
43	abuse	abuse	NN	_	41	nmod
44	.	.	.	_	6	punct

1	Patients	patient	NNS	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	warned	warn	VBN	_	0	ROOT
5	of	of	IN	_	8	case
6	the	the	DT	_	8	det
7	potential	potential	JJ	_	8	amod
8	danger	danger	NN	_	4	nmod
9	of	of	IN	_	12	case
10	the	the	DT	_	12	det
11	intravenous	intravenous	JJ	_	12	amod
12	self-administration	self-administration	NN	_	8	nmod
13	of	of	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	while	while	IN	_	4	advcl
16	under	under	IN	_	17	case
17	treatment	treatment	NN	_	15	nmod
18	with	with	IN	_	19	case
19	drug2	drug2	NN	_	17	nmod
20	or	or	CC	_	19	cc
21	drug3	drug3	NN	_	19	conj
22	.	.	.	_	4	punct

1	drug1	drug1	NN	_	7	nsubjpass
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	drug2	drug2	NN	_	1	appos
4	-RRB-	-rrb-	-RRB-	_	3	punct
5	has	have	VBZ	_	7	aux
6	been	be	VBN	_	7	auxpass
7	reported	report	VBN	_	0	ROOT
8	to	to	TO	_	9	mark
9	produce	produce	VB	_	7	xcomp
10	ANTABUSE-like	antabuse-like	JJ	_	12	amod
11	side	side	JJ	_	12	amod
12	effects	effect	NNS	_	9	dobj
13	when	when	WRB	_	14	advmod
14	given	give	VBN	_	9	advcl
15	concomitantly	concomitantly	RB	_	14	advmod
16	with	with	IN	_	17	case
17	drug3	drug3	NN	_	14	nmod
18	.	.	.	_	7	punct

1	The	the	DT	_	2	det
2	physician	physician	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	advised	advise	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	monitor	monitor	VB	_	4	xcomp
7	plasma	plasma	NN	_	8	compound
8	levels	level	NNS	_	6	dobj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	and	and	CC	_	6	cc
12	to	to	TO	_	13	mark
13	decrease	decrease	VB	_	6	conj
14	the	the	DT	_	15	det
15	dose	dose	NN	_	13	dobj
16	if	if	IN	_	17	mark
17	necessary	necessary	JJ	_	13	advcl
18	.	.	.	_	4	punct

1	Because	because	IN	_	3	case
2	of	of	IN	_	1	mwe
3	reports	report	NNS	_	24	nmod
4	of	of	IN	_	5	case
5	prolongation	prolongation	NN	_	3	nmod
6	of	of	IN	_	9	case
7	the	the	DT	_	9	det
8	prothrombin	prothrombin	NN	_	9	compound
9	time	time	NN	_	5	nmod
10	beyond	beyond	IN	_	13	case
11	the	the	DT	_	13	det
12	therapeutic	therapeutic	JJ	_	13	amod
13	range	range	NN	_	9	nmod
14	in	in	IN	_	15	case
15	patients	patient	NNS	_	13	nmod
16	taking	take	VBG	_	15	acl
17	concurrent	concurrent	JJ	_	18	amod
18	drug1	drug1	NN	_	16	dobj
19	and	and	CC	_	18	cc
20	drug2	drug2	NN	_	18	conj
21	,	,	,	_	24	punct
22	it	it	PRP	_	24	nsubjpass
23	is	be	VBZ	_	24	auxpass
24	suggested	suggest	VBN	_	0	ROOT
25	that	that	IN	_	30	mark
26	the	the	DT	_	28	det
27	prothrombin	prothrombin	NN	_	28	compound
28	time	time	NN	_	30	nsubjpass
29	be	be	VB	_	30	auxpass
30	monitored	monitor	VBN	_	24	ccomp
31	carefully	carefully	RB	_	30	advmod
32	,	,	,	_	24	punct
33	and	and	CC	_	24	cc
34	the	the	DT	_	35	det
35	dose	dose	NN	_	46	nsubjpass
36	of	of	IN	_	37	case
37	drug3	drug3	NN	_	35	nmod
38	or	or	CC	_	37	cc
39	other	other	JJ	_	40	amod
40	drug4	drug4	NN	_	37	conj
41	-	-	:	_	35	punct
42	like	like	IN	_	43	case
43	drugs	drug	NNS	_	35	nmod
44	should	should	MD	_	46	aux
45	be	be	VB	_	46	auxpass
46	adjusted	adjust	VBN	_	24	conj
47	accordingly	accordingly	RB	_	46	advmod
48	,	,	,	_	46	punct
49	in	in	IN	_	50	case
50	patients	patient	NNS	_	46	nmod
51	taking	take	VBG	_	50	acl
52	both	both	CC	_	53	det
53	drugs	drug	NNS	_	51	dobj
54	.	.	.	_	24	punct

1	drug1	drug1	NN	_	4	nsubj
2	is	be	VBZ	_	4	cop
3	a	a	DT	_	4	det
4	substrate	substrate	NN	_	0	ROOT
5	,	,	,	_	4	punct
6	a	a	DT	_	8	det
7	moderate	moderate	JJ	_	8	amod
8	inhibitor	inhibitor	NN	_	4	conj
9	,	,	,	_	4	punct
10	and	and	CC	_	4	cc
11	an	a	DT	_	12	det
12	inducer	inducer	NN	_	4	conj
13	of	of	IN	_	14	case
14	CYP3A4	cyp3a4	NN	_	12	nmod
15	.	.	.	_	4	punct

1	drug1	drug1	NN	_	5	nsubj
2	is	be	VBZ	_	5	cop
3	also	also	RB	_	5	advmod
4	an	a	DT	_	5	det
5	inducer	inducer	NN	_	0	ROOT
6	of	of	IN	_	7	case
7	CYP2C9	cyp2c9	NN	_	5	nmod
8	.	.	.	_	5	punct

1	Effect	effect	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	on	on	IN	_	6	case
5	the	the	DT	_	6	det
6	pharmacokinetics	pharmacokinetic	NNS	_	1	nmod
7	of	of	IN	_	9	case
8	other	other	JJ	_	9	amod
9	agents	agent	NNS	_	6	nmod

1	As	as	IN	_	4	case
2	a	a	DT	_	4	det
3	moderate	moderate	JJ	_	4	amod
4	inhibitor	inhibitor	NN	_	10	nmod
5	of	of	IN	_	6	case
6	CYP3A4	cyp3a4	NN	_	4	nmod
7	,	,	,	_	10	punct
8	drug1	drug1	NN	_	10	nsubj
9	can	can	MD	_	10	aux
10	increase	increase	VB	_	0	ROOT
11	plasma	plasma	NN	_	12	compound
12	concentrations	concentration	NNS	_	10	dobj
13	of	of	IN	_	16	case
14	coadministered	coadministered	JJ	_	16	amod
15	medicinal	medicinal	JJ	_	16	amod
16	products	product	NNS	_	12	nmod
17	that	that	WDT	_	19	nsubjpass
18	are	be	VBP	_	19	auxpass
19	metabolized	metabolize	VBN	_	16	acl:relcl
20	through	through	IN	_	21	case
21	CYP3A4	cyp3a4	NN	_	19	nmod
22	.	.	.	_	10	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	shown	show	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	induce	induce	VB	_	4	xcomp
7	the	the	DT	_	8	det
8	metabolism	metabolism	NN	_	6	dobj
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	drug3	drug3	NN	_	10	conj
13	,	,	,	_	8	punct
14	which	which	WDT	_	16	nsubjpass
15	are	be	VBP	_	16	auxpass
16	metabolized	metabolize	VBN	_	8	acl:relcl
17	through	through	IN	_	18	case
18	CYP2C9	cyp2c9	NN	_	16	nmod
19	.	.	.	_	4	punct

1	Coadministration	coadministration	NN	_	24	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	6	case
5	these	these	DT	_	6	det
6	drugs	drug	NNS	_	1	nmod
7	or	or	CC	_	6	cc
8	other	other	JJ	_	9	amod
9	drugs	drug	NNS	_	6	conj
10	that	that	WDT	_	12	nsubjpass
11	are	be	VBP	_	12	auxpass
12	known	know	VBN	_	9	acl:relcl
13	to	to	TO	_	15	mark
14	be	be	VB	_	15	auxpass
15	metabolized	metabolize	VBN	_	12	xcomp
16	by	by	IN	_	17	case
17	CYP2C9	cyp2c9	NN	_	15	nmod
18	,	,	,	_	17	punct
19	such	such	JJ	_	21	case
20	as	as	IN	_	19	mwe
21	drug2	drug2	NN	_	17	nmod
22	,	,	,	_	24	punct
23	may	may	MD	_	24	aux
24	result	result	VB	_	0	ROOT
25	in	in	IN	_	28	case
26	lower	lower	JJR	_	28	amod
27	plasma	plasma	NN	_	28	compound
28	concentrations	concentration	NNS	_	24	nmod
29	of	of	IN	_	31	case
30	these	these	DT	_	31	det
31	drugs	drug	NNS	_	28	nmod
32	.	.	.	_	24	punct

1	drug1	drug1	NN	_	3	nsubj
2	is	be	VBZ	_	3	cop
3	unlikely	unlikely	JJ	_	0	ROOT
4	to	to	TO	_	5	mark
5	interact	interact	VB	_	3	xcomp
6	with	with	IN	_	7	case
7	drugs	drug	NNS	_	5	nmod
8	that	that	WDT	_	10	nsubj
9	are	be	VBP	_	10	cop
10	substrates	substrate	NNS	_	7	acl:relcl
11	for	for	IN	_	14	case
12	the	the	DT	_	14	det
13	P-glycoprotein	p-glycoprotein	NN	_	14	compound
14	transporter	transporter	NN	_	10	nmod
15	,	,	,	_	3	punct
16	as	as	IN	_	17	mark
17	demonstrated	demonstrate	VBN	_	3	advcl
18	by	by	IN	_	20	case
19	the	the	DT	_	20	det
20	lack	lack	NN	_	17	nmod
21	of	of	IN	_	22	case
22	interaction	interaction	NN	_	20	nmod
23	of	of	IN	_	24	case
24	drug2	drug2	NN	_	22	nmod
25	with	with	IN	_	26	case
26	drug3	drug3	NN	_	22	nmod
27	in	in	IN	_	32	case
28	a	a	DT	_	32	det
29	clinical	clinical	JJ	_	32	amod
30	drug	drug	NN	_	32	compound
31	interaction	interaction	NN	_	32	compound
32	study	study	NN	_	22	nmod
33	.	.	.	_	3	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	7	case
4	clinical	clinical	JJ	_	7	amod
5	drug	drug	NN	_	7	compound
6	interaction	interaction	NN	_	7	compound
7	studies	study	NNS	_	12	nmod
8	,	,	,	_	12	punct
9	drug2	drug2	NN	_	12	nsubj
10	did	do	VBD	_	12	aux
11	not	not	RB	_	12	neg
12	have	have	VB	_	1	dep
13	clinically	clinically	RB	_	14	advmod
14	important	important	JJ	_	15	amod
15	effects	effect	NNS	_	12	dobj
16	on	on	IN	_	18	case
17	the	the	DT	_	18	det
18	pharmacokinetics	pharmacokinetic	NNS	_	12	nmod
19	of	of	IN	_	20	case
20	drug3	drug3	NN	_	18	nmod
21	or	or	CC	_	20	cc
22	drug4	drug4	NN	_	20	conj
23	.	.	.	_	1	punct

1	No	no	DT	_	6	neg
2	clinical	clinical	JJ	_	6	amod
3	or	or	CC	_	2	cc
4	drug	drug	NN	_	2	conj
5	interaction	interaction	NN	_	6	compound
6	study	study	NN	_	8	nsubjpass
7	was	be	VBD	_	8	auxpass
8	conducted	conduct	VBN	_	0	ROOT
9	with	with	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	.	.	.	_	8	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	1	dep
4	:	:	:	_	3	punct
5	drug3	drug3	NN	_	45	nsubj
6	,	,	,	_	5	punct
7	when	when	WRB	_	8	advmod
8	given	give	VBN	_	5	acl:relcl
9	as	as	IN	_	11	case
10	a	a	DT	_	11	det
11	regimen	regimen	NN	_	8	nmod
12	of	of	IN	_	13	case
13	125mg	125mg	NN	_	11	nmod
14	with	with	IN	_	15	case
15	drug4	drug4	NN	_	11	nmod
16	coadministered	coadminister	VBN	_	15	acl
17	orally	orally	RB	_	16	advmod
18	as	as	IN	_	20	case
19	20	20	CD	_	20	nummod
20	mg	mg	NN	_	16	nmod
21	on	on	IN	_	22	case
22	Day	day	NN	_	16	nmod
23	1	1	CD	_	22	nummod
24	,	,	,	_	5	punct
25	and	and	CC	_	5	cc
26	drug5	drug5	NN	_	5	conj
27	when	when	WRB	_	28	advmod
28	given	give	VBN	_	5	advcl
29	as	as	IN	_	31	case
30	80	80	CD	_	31	nummod
31	mg/day	mg/day	NN	_	28	nmod
32	with	with	IN	_	33	case
33	drug6	drug6	NN	_	31	nmod
34	coadministered	coadminister	VBN	_	33	acl
35	orally	orally	RB	_	34	advmod
36	as	as	IN	_	38	case
37	8	8	CD	_	38	nummod
38	mg	mg	NN	_	34	nmod
39	on	on	IN	_	40	case
40	Days	day	NNS	_	34	nmod
41	2	2	CD	_	40	nummod
42	through	through	IN	_	43	case
43	5	5	CD	_	34	nmod
44	,	,	,	_	5	punct
45	increased	increase	VBD	_	3	appos
46	the	the	DT	_	47	det
47	AUC	auc	NN	_	45	dobj
48	of	of	IN	_	49	case
49	drug7	drug7	NN	_	47	nmod
50	,	,	,	_	49	punct
51	a	a	DT	_	53	det
52	CYP3A4	cyp3a4	NN	_	53	compound
53	substrate	substrate	NN	_	49	appos
54	by	by	IN	_	55	case
55	2.2-fold	2.2-fold	JJ	_	53	nmod
56	,	,	,	_	49	punct
57	on	on	IN	_	58	case
58	Days	day	NNS	_	47	nmod
59	1	1	CD	_	58	dep
60	and	and	CC	_	59	cc
61	5	5	CD	_	59	conj
62	.	.	.	_	1	punct

1	The	the	DT	_	4	det
2	oral	oral	JJ	_	4	amod
3	drug1	drug1	NN	_	4	compound
4	doses	dose	NNS	_	7	nsubjpass
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	reduced	reduce	VBN	_	0	ROOT
8	by	by	IN	_	11	case
9	approximately	approximately	RB	_	10	advmod
10	50	50	CD	_	11	nummod
11	%	%	NN	_	7	nmod
12	when	when	WRB	_	13	advmod
13	coadministered	coadminister	VBN	_	7	advcl
14	with	with	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	,	,	,	_	7	punct
17	to	to	TO	_	18	mark
18	achieve	achieve	VB	_	7	xcomp
19	exposures	exposure	NNS	_	18	dobj
20	of	of	IN	_	21	case
21	drug3	drug3	NN	_	19	nmod
22	similar	similar	JJ	_	21	amod
23	to	to	TO	_	24	case
24	those	those	DT	_	22	nmod
25	obtained	obtain	VBN	_	24	acl
26	when	when	WRB	_	29	advmod
27	it	it	PRP	_	29	nsubjpass
28	is	be	VBZ	_	29	auxpass
29	given	give	VBN	_	25	advcl
30	without	without	IN	_	31	case
31	drug4	drug4	NN	_	29	nmod
32	.	.	.	_	7	punct

1	The	the	DT	_	3	det
2	daily	daily	JJ	_	3	amod
3	dose	dose	NN	_	12	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	administered	administer	VBN	_	3	acl
7	in	in	IN	_	9	case
8	clinical	clinical	JJ	_	9	amod
9	studies	study	NNS	_	6	nmod
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	reflects	reflect	VBZ	_	0	ROOT
13	an	a	DT	_	17	det
14	approximate	approximate	JJ	_	17	amod
15	50	50	CD	_	16	compound
16	%	%	NN	_	17	amod
17	reduction	reduction	NN	_	12	dobj
18	of	of	IN	_	20	case
19	the	the	DT	_	20	det
20	dose	dose	NN	_	17	nmod
21	of	of	IN	_	22	case
22	drug3	drug3	NN	_	20	nmod
23	.	.	.	_	12	punct

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	23	nsubj
2	,	,	,	_	1	punct
3	when	when	WRB	_	4	advmod
4	given	give	VBN	_	1	acl:relcl
5	as	as	IN	_	7	case
6	a	a	DT	_	7	det
7	regimen	regimen	NN	_	4	nmod
8	of	of	IN	_	10	case
9	125	125	CD	_	10	nummod
10	mg	mg	NN	_	7	nmod
11	on	on	IN	_	12	case
12	Day	day	NN	_	4	nmod
13	1	1	CD	_	12	nummod
14	and	and	CC	_	12	cc
15	80	80	CD	_	16	nummod
16	mg/day	mg/day	NN	_	12	conj
17	on	on	IN	_	18	case
18	Days	day	NNS	_	4	nmod
19	2	2	CD	_	18	dep
20	and	and	CC	_	19	cc
21	3	3	CD	_	19	conj
22	,	,	,	_	1	punct
23	increased	increase	VBD	_	0	ROOT
24	the	the	DT	_	25	det
25	AUC	auc	NN	_	23	dobj
26	of	of	IN	_	27	case
27	drug2	drug2	NN	_	25	nmod
28	,	,	,	_	27	punct
29	a	a	DT	_	31	det
30	CYP3A4	cyp3a4	NN	_	31	compound
31	substrate	substrate	NN	_	27	appos
32	,	,	,	_	27	punct
33	by	by	IN	_	34	case
34	1.34-fold	1.34-fold	JJ	_	23	nmod
35	on	on	IN	_	36	case
36	Day	day	NN	_	23	nmod
37	1	1	CD	_	36	nummod
38	and	and	CC	_	23	cc
39	by	by	IN	_	40	case
40	2.5-fold	2.5-fold	RB	_	23	conj
41	on	on	IN	_	42	case
42	Day	day	NN	_	40	nmod
43	3	3	CD	_	42	nummod
44	,	,	,	_	42	punct
45	when	when	WRB	_	48	advmod
46	drug3	drug3	NN	_	48	nsubjpass
47	was	be	VBD	_	48	auxpass
48	coadministered	coadminister	VBN	_	42	acl:relcl
49	intravenously	intravenously	RB	_	52	advmod
50	as	as	IN	_	52	case
51	125	125	CD	_	52	nummod
52	mg	mg	NN	_	48	nmod
53	on	on	IN	_	54	case
54	Day	day	NN	_	52	nmod
55	1	1	CD	_	54	nummod
56	and	and	CC	_	52	cc
57	orally	orally	RB	_	60	advmod
58	as	as	IN	_	60	case
59	40	40	CD	_	60	nummod
60	mg	mg	NN	_	52	conj
61	on	on	IN	_	62	case
62	Days	day	NNS	_	60	nmod
63	2	2	CD	_	62	dep
64	and	and	CC	_	63	cc
65	3	3	CD	_	63	conj
66	.	.	.	_	23	punct

1	The	the	DT	_	4	det
2	IV	iv	CD	_	4	nummod
3	drug1	drug1	NN	_	4	compound
4	dose	dose	NN	_	7	nsubjpass
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	reduced	reduce	VBN	_	0	ROOT
8	by	by	IN	_	11	case
9	approximately	approximately	RB	_	10	advmod
10	25	25	CD	_	11	nummod
11	%	%	NN	_	7	nmod
12	,	,	,	_	7	punct
13	and	and	CC	_	7	cc
14	the	the	DT	_	17	det
15	oral	oral	JJ	_	17	amod
16	drug2	drug2	NN	_	17	compound
17	dose	dose	NN	_	20	nsubjpass
18	should	should	MD	_	20	aux
19	be	be	VB	_	20	auxpass
20	reduced	reduce	VBN	_	7	conj
21	by	by	IN	_	24	case
22	approximately	approximately	RB	_	23	advmod
23	50	50	CD	_	24	nummod
24	%	%	NN	_	20	nmod
25	when	when	WRB	_	26	advmod
26	coadministered	coadminister	VBN	_	20	advcl
27	with	with	IN	_	28	case
28	drug3	drug3	NN	_	26	nmod
29	to	to	TO	_	30	mark
30	achieve	achieve	VB	_	26	xcomp
31	exposures	exposure	NNS	_	30	dobj
32	of	of	IN	_	33	case
33	drug4	drug4	NN	_	31	nmod
34	similar	similar	JJ	_	33	amod
35	to	to	TO	_	36	case
36	those	those	DT	_	34	nmod
37	obtained	obtain	VBN	_	36	acl
38	when	when	WRB	_	41	advmod
39	it	it	PRP	_	41	nsubjpass
40	is	be	VBZ	_	41	auxpass
41	given	give	VBN	_	37	advcl
42	without	without	IN	_	43	case
43	drug5	drug5	NN	_	41	nmod
44	.	.	.	_	7	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	A	a	DT	_	6	det
4	single	single	JJ	_	6	amod
5	125-mg	125-mg	JJ	_	6	amod
6	dose	dose	NN	_	10	nsubjpass
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	was	be	VBD	_	10	auxpass
10	administered	administer	VBN	_	1	appos
11	on	on	IN	_	12	case
12	Day	day	NN	_	10	nmod
13	1	1	CD	_	12	nummod
14	and	and	CC	_	10	cc
15	80	80	CD	_	16	nummod
16	mg/day	mg/day	NN	_	10	conj
17	on	on	IN	_	18	case
18	Days	day	NNS	_	16	nmod
19	2	2	CD	_	18	nummod
20	and	and	CC	_	18	cc
21	3	3	CD	_	18	conj
22	to	to	TO	_	24	case
23	healthy	healthy	JJ	_	24	amod
24	subjects	subject	NNS	_	16	nmod
25	who	who	WP	_	27	nsubjpass
26	were	be	VBD	_	27	auxpass
27	stabilized	stabilize	VBN	_	24	acl:relcl
28	on	on	IN	_	31	case
29	chronic	chronic	JJ	_	31	amod
30	drug3	drug3	NN	_	31	compound
31	therapy	therapy	NN	_	27	nmod
32	.	.	.	_	1	punct

1	Although	although	IN	_	3	mark
2	there	there	EX	_	3	expl
3	was	be	VBD	_	22	advcl
4	no	no	DT	_	5	neg
5	effect	effect	NN	_	3	nsubj
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	on	on	IN	_	11	case
9	the	the	DT	_	11	det
10	plasma	plasma	NN	_	11	compound
11	AUC	auc	NN	_	5	nmod
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	or	or	CC	_	13	cc
15	drug3	drug3	NN	_	13	conj
16	determined	determine	VBN	_	11	acl
17	on	on	IN	_	18	case
18	Day	day	NN	_	16	nmod
19	3	3	CD	_	18	nummod
20	,	,	,	_	22	punct
21	there	there	EX	_	22	expl
22	was	be	VBD	_	0	ROOT
23	a	a	DT	_	26	det
24	34	34	CD	_	25	compound
25	%	%	NN	_	26	amod
26	decrease	decrease	NN	_	22	nsubj
27	in	in	IN	_	28	case
28	drug4	drug4	NN	_	26	nmod
29	-LRB-	-lrb-	-LRB-	_	32	punct
30	a	a	DT	_	32	det
31	CYP2C9	cyp2c9	NN	_	32	compound
32	substrate	substrate	NN	_	26	appos
33	-RRB-	-rrb-	-RRB-	_	32	punct
34	trough	trough	NN	_	35	compound
35	concentration	concentration	NN	_	26	dep
36	accompanied	accompany	VBN	_	35	acl
37	by	by	IN	_	41	case
38	a	a	DT	_	41	det
39	14	14	CD	_	40	compound
40	%	%	NN	_	41	amod
41	decrease	decrease	NN	_	36	nmod
42	in	in	IN	_	45	case
43	the	the	DT	_	45	det
44	prothrombin	prothrombin	NN	_	45	compound
45	time	time	NN	_	41	nmod
46	-LRB-	-lrb-	-LRB-	_	47	punct
47	reported	report	VBN	_	26	dep
48	as	as	IN	_	51	case
49	International	International	NNP	_	51	compound
50	Normalized	Normalized	NNP	_	51	compound
51	Ratio	Ratio	NNP	_	47	nmod
52	or	or	CC	_	51	cc
53	INR	INR	NNP	_	51	conj
54	-RRB-	-rrb-	-RRB-	_	47	punct
55	5	5	CD	_	56	nummod
56	days	day	NNS	_	26	nmod
57	after	after	IN	_	56	case
58	completion	completion	NN	_	56	dep
59	of	of	IN	_	60	case
60	dosing	dosing	NN	_	58	nmod
61	with	with	IN	_	62	case
62	drug5	drug5	NN	_	58	nmod
63	.	.	.	_	22	punct

1	In	in	IN	_	2	case
2	patients	patient	NNS	_	17	nmod
3	on	on	IN	_	6	case
4	chronic	chronic	JJ	_	6	amod
5	drug1	drug1	NN	_	6	compound
6	therapy	therapy	NN	_	2	nmod
7	,	,	,	_	17	punct
8	the	the	DT	_	10	det
9	prothrombin	prothrombin	NN	_	10	compound
10	time	time	NN	_	17	nsubjpass
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	INR	inr	NN	_	10	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	should	should	MD	_	17	aux
15	be	be	VB	_	17	auxpass
16	closely	closely	RB	_	17	advmod
17	monitored	monitor	VBN	_	0	ROOT
18	in	in	IN	_	21	case
19	the	the	DT	_	21	det
20	2-week	2-week	JJ	_	21	amod
21	period	period	NN	_	17	nmod
22	,	,	,	_	17	punct
23	particularly	particularly	RB	_	28	advmod
24	at	at	IN	_	28	case
25	7	7	CD	_	27	compound
26	to	to	TO	_	27	dep
27	10	10	CD	_	28	nummod
28	days	day	NNS	_	17	nmod
29	,	,	,	_	28	punct
30	following	follow	VBG	_	31	case
31	initiation	initiation	NN	_	28	nmod
32	of	of	IN	_	35	case
33	the	the	DT	_	35	det
34	3-day	3-day	JJ	_	35	amod
35	regimen	regimen	NN	_	31	nmod
36	of	of	IN	_	37	case
37	drug2	drug2	NN	_	35	nmod
38	with	with	IN	_	41	case
39	each	each	DT	_	41	det
40	chemotherapy	chemotherapy	NN	_	41	compound
41	cycle	cycle	NN	_	31	nmod
42	.	.	.	_	17	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	22	nsubj
4	,	,	,	_	3	punct
5	when	when	WRB	_	6	advmod
6	given	give	VBN	_	3	acl:relcl
7	as	as	IN	_	9	case
8	125	125	CD	_	9	nummod
9	mg	mg	NN	_	6	nmod
10	on	on	IN	_	11	case
11	Day	day	NN	_	6	nmod
12	1	1	CD	_	11	nummod
13	and	and	CC	_	11	cc
14	80	80	CD	_	15	nummod
15	mg/day	mg/day	NN	_	11	conj
16	on	on	IN	_	17	case
17	Days	day	NNS	_	6	nmod
18	2	2	CD	_	17	dep
19	and	and	CC	_	18	cc
20	3	3	CD	_	18	conj
21	,	,	,	_	3	punct
22	decreased	decrease	VBD	_	1	dep
23	the	the	DT	_	24	det
24	AUC	auc	NN	_	22	dobj
25	of	of	IN	_	26	case
26	drug3	drug3	NN	_	24	nmod
27	-LRB-	-lrb-	-LRB-	_	30	punct
28	a	a	DT	_	30	det
29	CYP2C9	cyp2c9	NN	_	30	compound
30	substrate	substrate	NN	_	26	appos
31	-RRB-	-rrb-	-RRB-	_	30	punct
32	by	by	IN	_	34	case
33	23	23	CD	_	34	nummod
34	%	%	NN	_	22	nmod
35	on	on	IN	_	36	case
36	Day	day	NN	_	22	nmod
37	4	4	CD	_	36	nummod
38	,	,	,	_	22	punct
39	28	28	CD	_	40	nummod
40	%	%	NN	_	22	conj
41	on	on	IN	_	42	case
42	Day	day	NN	_	40	nmod
43	8	8	CD	_	42	nummod
44	,	,	,	_	22	punct
45	and	and	CC	_	22	cc
46	15	15	CD	_	47	nummod
47	%	%	NN	_	22	conj
48	on	on	IN	_	49	case
49	Day	day	NN	_	47	nmod
50	15	15	CD	_	49	nummod
51	,	,	,	_	22	punct
52	when	when	WRB	_	61	advmod
53	a	a	DT	_	55	det
54	single	single	JJ	_	55	amod
55	dose	dose	NN	_	61	nsubj
56	of	of	IN	_	59	case
57	drug4	drug4	NN	_	59	compound
58	500	500	CD	_	59	nummod
59	mg	mg	NN	_	55	nmod
60	was	be	VBD	_	61	cop
61	admini	admini	JJ	_	22	advcl
62	,	,	,	_	61	punct
63	stered	stered	JJ	_	62	root
64	orally	orally	RB	_	65	advmod
65	prior	prior	RB	_	63	advmod
66	to	to	TO	_	68	case
67	the	the	DT	_	68	det
68	administration	administration	NN	_	65	nmod
69	of	of	IN	_	72	case
70	the	the	DT	_	72	det
71	3-day	3-day	JJ	_	72	amod
72	regimen	regimen	NN	_	68	nmod
73	of	of	IN	_	74	case
74	drug5	drug5	NN	_	72	nmod
75	and	and	CC	_	65	cc
76	on	on	IN	_	77	case
77	Days	day	NNS	_	65	conj
78	4,8	4,8	CD	_	77	nummod
79	,	,	,	_	65	punct
80	and	and	CC	_	65	cc
81	15	15	CD	_	65	conj
82	.	.	.	_	63	punct

1	Oral	oral	JJ	_	2	amod
2	drug1	drug1	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	drug2	drug2	NN	_	32	nsubj
5	,	,	,	_	4	punct
6	when	when	WRB	_	7	advmod
7	given	give	VBN	_	4	acl:relcl
8	once	once	RB	_	9	advmod
9	daily	daily	RB	_	7	advmod
10	for	for	IN	_	12	case
11	14	14	CD	_	12	nummod
12	days	day	NNS	_	7	nmod
13	as	as	IN	_	16	case
14	a	a	DT	_	16	det
15	100-mg	100-mg	JJ	_	16	amod
16	capsule	capsule	NN	_	7	nmod
17	with	with	IN	_	20	case
18	an	a	DT	_	20	det
19	oral	oral	JJ	_	20	amod
20	drug3	drug3	NN	_	16	nmod
21	containing	contain	VBG	_	20	acl
22	35	35	CD	_	23	nummod
23	mcg	mcg	NN	_	21	dobj
24	of	of	IN	_	25	case
25	drug4	drug4	NN	_	23	nmod
26	and	and	CC	_	23	cc
27	1	1	CD	_	28	nummod
28	mg	mg	NN	_	23	conj
29	of	of	IN	_	30	case
30	drug5	drug5	NN	_	28	nmod
31	,	,	,	_	4	punct
32	decreased	decrease	VBD	_	2	appos
33	the	the	DT	_	34	det
34	AUC	auc	NN	_	32	dobj
35	of	of	IN	_	36	case
36	drug6	drug6	NN	_	34	nmod
37	by	by	IN	_	39	case
38	43	43	CD	_	39	nummod
39	%	%	NN	_	32	nmod
40	,	,	,	_	32	punct
41	and	and	CC	_	32	cc
42	decreased	decrease	VBD	_	32	conj
43	the	the	DT	_	44	det
44	AUC	auc	NN	_	42	dobj
45	of	of	IN	_	46	case
46	drug7	drug7	NN	_	44	nmod
47	by	by	IN	_	49	case
48	8	8	CD	_	49	nummod
49	%	%	NN	_	42	nmod
50	;	;	:	_	2	punct

1	therefore	therefore	RB	_	14	advmod
2	,	,	,	_	14	punct
3	the	the	DT	_	4	det
4	efficacy	efficacy	NN	_	14	nsubjpass
5	of	of	IN	_	7	case
6	oral	oral	JJ	_	7	amod
7	drug1	drug1	NN	_	4	nmod
8	during	during	IN	_	9	case
9	administration	administration	NN	_	4	nmod
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	may	may	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	reduced	reduce	VBN	_	0	ROOT
15	.	.	.	_	14	punct

1	Although	although	IN	_	15	mark
2	a	a	DT	_	4	det
3	3-day	3-day	JJ	_	4	amod
4	regimen	regimen	NN	_	15	nsubjpass
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	given	give	VBN	_	4	acl
8	concomitantly	concomitantly	RB	_	7	advmod
9	with	with	IN	_	11	case
10	oral	oral	JJ	_	11	amod
11	drug2	drug2	NN	_	7	nmod
12	has	have	VBZ	_	15	aux
13	not	not	RB	_	15	neg
14	been	be	VBN	_	15	auxpass
15	studied	study	VBN	_	25	advcl
16	,	,	,	_	25	punct
17	alternative	alternative	JJ	_	20	amod
18	or	or	CC	_	17	cc
19	back-up	back-up	JJ	_	17	conj
20	methods	method	NNS	_	25	nsubjpass
21	of	of	IN	_	22	case
22	contraception	contraception	NN	_	20	nmod
23	should	should	MD	_	25	aux
24	be	be	VB	_	25	auxpass
25	used	use	VBN	_	0	ROOT
26	.	.	.	_	25	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	nsubj
4	increased	increase	VBD	_	1	dep
5	the	the	DT	_	6	det
6	AUC	auc	NN	_	4	dobj
7	of	of	IN	_	8	case
8	drug3	drug3	NN	_	6	nmod
9	,	,	,	_	8	punct
10	a	a	DT	_	13	det
11	sensitive	sensitive	JJ	_	13	amod
12	CYP3A4	cyp3a4	NN	_	13	compound
13	substrate	substrate	NN	_	8	appos
14	,	,	,	_	8	punct
15	by	by	IN	_	16	case
16	2.3-fold	2.3-fold	JJ	_	4	nmod
17	on	on	IN	_	18	case
18	Day	day	NN	_	4	nmod
19	1	1	CD	_	18	nummod
20	and	and	CC	_	4	cc
21	3.3-fold	3.3-fold	RB	_	4	conj
22	on	on	IN	_	23	case
23	Day	day	NN	_	21	nmod
24	5	5	CD	_	23	nummod
25	,	,	,	_	23	punct
26	when	when	WRB	_	36	advmod
27	a	a	DT	_	30	det
28	single	single	JJ	_	30	amod
29	oral	oral	JJ	_	30	amod
30	dose	dose	NN	_	36	nsubjpass
31	of	of	IN	_	34	case
32	drug4	drug4	NN	_	34	compound
33	2	2	CD	_	34	nummod
34	mg	mg	NN	_	30	nmod
35	was	be	VBD	_	36	auxpass
36	coadministered	coadminister	VBN	_	23	acl:relcl
37	on	on	IN	_	38	case
38	Day	day	NN	_	36	nmod
39	1	1	CD	_	38	nummod
40	and	and	CC	_	36	cc
41	Day	Day	NNP	_	36	conj
42	5	5	CD	_	41	nummod
43	of	of	IN	_	45	case
44	a	a	DT	_	45	det
45	regimen	regimen	NN	_	41	nmod
46	of	of	IN	_	49	case
47	drug5	drug5	NN	_	49	compound
48	125	125	CD	_	49	nummod
49	mg	mg	NN	_	45	nmod
50	on	on	IN	_	51	case
51	Day	day	NN	_	41	nmod
52	1	1	CD	_	51	nummod
53	and	and	CC	_	51	cc
54	80	80	CD	_	55	nummod
55	mg/day	mg/day	NN	_	51	conj
56	on	on	IN	_	57	case
57	Days	day	NNS	_	41	nmod
58	2	2	CD	_	57	nummod
59	through	through	IN	_	60	case
60	5	5	CD	_	57	nmod
61	.	.	.	_	1	punct

1	The	the	DT	_	3	det
2	potential	potential	JJ	_	3	amod
3	effects	effect	NNS	_	23	nsubjpass
4	of	of	IN	_	7	case
5	increased	increase	VBN	_	7	amod
6	plasma	plasma	NN	_	7	compound
7	concentrations	concentration	NNS	_	3	nmod
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	or	or	CC	_	9	cc
11	other	other	JJ	_	12	amod
12	drug2	drug2	NN	_	9	conj
13	metabolized	metabolize	VBN	_	3	acl
14	via	via	IN	_	15	case
15	CYP3A4	cyp3a4	NN	_	13	nmod
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	drug3	drug3	NN	_	15	dep
18	,	,	,	_	17	punct
19	drug4	drug4	NN	_	17	appos
20	-RRB-	-rrb-	-RRB-	_	17	punct
21	should	should	MD	_	23	aux
22	be	be	VB	_	23	auxpass
23	considered	consider	VBN	_	0	ROOT
24	when	when	WRB	_	25	advmod
25	coadministering	coadminister	VBG	_	23	advcl
26	these	these	DT	_	27	det
27	agents	agent	NNS	_	25	dobj
28	with	with	IN	_	29	case
29	drug5	drug5	NN	_	25	nmod
30	.	.	.	_	23	punct

1	In	in	IN	_	3	case
2	another	another	DT	_	3	det
3	study	study	NN	_	12	nmod
4	with	with	IN	_	6	case
5	intravenous	intravenous	JJ	_	6	amod
6	administration	administration	NN	_	3	nmod
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	,	,	,	_	12	punct
10	drug2	drug2	NN	_	12	nsubjpass
11	was	be	VBD	_	12	auxpass
12	given	give	VBN	_	0	ROOT
13	as	as	IN	_	15	case
14	125	125	CD	_	15	nummod
15	mg	mg	NN	_	12	nmod
16	on	on	IN	_	17	case
17	Day	day	NN	_	15	nmod
18	1	1	CD	_	17	nummod
19	and	and	CC	_	17	cc
20	80	80	CD	_	21	nummod
21	mg/day	mg/day	NN	_	17	conj
22	on	on	IN	_	23	case
23	Days	day	NNS	_	15	nmod
24	2	2	CD	_	23	dep
25	and	and	CC	_	24	cc
26	3	3	CD	_	24	conj
27	,	,	,	_	12	punct
28	and	and	CC	_	12	cc
29	drug3	drug3	NN	_	31	compound
30	2	2	CD	_	31	nummod
31	mg	mg	NN	_	34	nsubjpass
32	IV	iv	CD	_	31	nummod
33	was	be	VBD	_	34	auxpass
34	given	give	VBN	_	12	conj
35	prior	prior	RB	_	34	advmod
36	to	to	TO	_	38	case
37	the	the	DT	_	38	det
38	administration	administration	NN	_	35	nmod
39	of	of	IN	_	42	case
40	the	the	DT	_	42	det
41	3-day	3-day	JJ	_	42	amod
42	regimen	regimen	NN	_	38	nmod
43	of	of	IN	_	44	case
44	drug4	drug4	NN	_	42	nmod
45	and	and	CC	_	35	cc
46	on	on	IN	_	47	case
47	Days	day	NNS	_	35	conj
48	4	4	CD	_	47	nummod
49	,	,	,	_	47	punct
50	8	8	CD	_	47	nummod
51	,	,	,	_	34	punct
52	and	and	CC	_	34	cc
53	15	15	CD	_	34	conj
54	.	.	.	_	12	punct

1	drug1	drug1	NN	_	2	nsubj
2	increased	increase	VBD	_	0	ROOT
3	the	the	DT	_	4	det
4	AUC	auc	NN	_	2	dobj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	by	by	IN	_	9	case
8	25	25	CD	_	9	nummod
9	%	%	NN	_	2	nmod
10	on	on	IN	_	11	case
11	Day	day	NN	_	2	nmod
12	4	4	CD	_	11	nummod
13	and	and	CC	_	2	cc
14	decreased	decrease	VBD	_	2	conj
15	the	the	DT	_	16	det
16	AUC	auc	NN	_	14	dobj
17	of	of	IN	_	18	case
18	drug3	drug3	NN	_	16	nmod
19	by	by	IN	_	21	case
20	19	19	CD	_	21	nummod
21	%	%	NN	_	14	nmod
22	on	on	IN	_	23	case
23	Day	day	NN	_	14	nmod
24	8	8	CD	_	23	nummod
25	relative	relative	JJ	_	28	case
26	to	to	TO	_	28	case
27	the	the	DT	_	28	det
28	dosing	dosing	NN	_	14	nmod
29	of	of	IN	_	30	case
30	drug4	drug4	NN	_	28	nmod
31	on	on	IN	_	32	case
32	Days	day	NNS	_	28	nmod
33	1	1	CD	_	32	nummod
34	through	through	IN	_	35	case
35	3	3	CD	_	32	nmod
36	.	.	.	_	2	punct

1	These	these	DT	_	2	det
2	effects	effect	NNS	_	5	nsubjpass
3	were	be	VBD	_	5	auxpass
4	not	not	RB	_	5	neg
5	considered	consider	VBN	_	0	ROOT
6	clinically	clinically	RB	_	7	advmod
7	important	important	JJ	_	5	xcomp
8	.	.	.	_	5	punct

1	The	the	DT	_	2	det
2	AUC	auc	NN	_	9	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	on	on	IN	_	6	case
6	Day	day	NN	_	2	nmod
7	15	15	CD	_	6	nummod
8	was	be	VBD	_	9	cop
9	similar	similar	JJ	_	0	ROOT
10	to	to	TO	_	11	case
11	that	that	DT	_	9	nmod
12	observed	observe	VBN	_	11	acl
13	at	at	IN	_	14	case
14	baseline	baseline	NN	_	12	nmod
15	.	.	.	_	9	punct

1	Effect	effect	NN	_	0	ROOT
2	of	of	IN	_	4	case
3	other	other	JJ	_	4	amod
4	agents	agent	NNS	_	1	nmod
5	on	on	IN	_	7	case
6	the	the	DT	_	7	det
7	pharmacokinefics	pharmacokinefic	NNS	_	1	nmod
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod

1	drug1	drug1	NN	_	4	nsubj
2	is	be	VBZ	_	4	cop
3	a	a	DT	_	4	det
4	substrate	substrate	NN	_	0	ROOT
5	for	for	IN	_	6	case
6	CYP3A4	cyp3a4	NN	_	4	nmod
7	;	;	:	_	4	punct

1	therefore	therefore	RB	_	13	advmod
2	,	,	,	_	13	punct
3	coadministration	coadministration	NN	_	13	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	with	with	IN	_	7	case
7	drugs	drug	NNS	_	3	nmod
8	that	that	WDT	_	9	nsubj
9	inhibit	inhibit	VBP	_	7	acl:relcl
10	CYP3A4	cyp3a4	NN	_	11	compound
11	activity	activity	NN	_	9	dobj
12	may	may	MD	_	13	aux
13	result	result	VB	_	0	ROOT
14	in	in	IN	_	17	case
15	increased	increase	VBN	_	17	amod
16	plasma	plasma	NN	_	17	compound
17	concentrations	concentration	NNS	_	13	nmod
18	of	of	IN	_	19	case
19	drug2	drug2	NN	_	17	nmod
20	.	.	.	_	13	punct

1	Consequently	consequently	RB	_	30	advmod
2	,	,	,	_	30	punct
3	concomitant	concomitant	JJ	_	4	amod
4	administration	administration	NN	_	30	nsubjpass
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	with	with	IN	_	10	case
8	strong	strong	JJ	_	10	amod
9	CYP3A4	cyp3a4	NN	_	10	compound
10	inhibitors	inhibitor	NNS	_	4	nmod
11	-LRB-	-lrb-	-LRB-	_	14	punct
12	e.g.	e.g.	FW	_	14	dep
13	,	,	,	_	14	punct
14	drug2	drug2	NN	_	10	dep
15	,	,	,	_	14	punct
16	drug3	drug3	NN	_	14	conj
17	,	,	,	_	14	punct
18	drug4	drug4	NN	_	14	conj
19	,	,	,	_	14	punct
20	drug5	drug5	NN	_	14	conj
21	,	,	,	_	14	punct
22	drug6	drug6	NN	_	14	conj
23	,	,	,	_	14	punct
24	drug7	drug7	NN	_	14	conj
25	,	,	,	_	14	punct
26	drug8	drug8	NN	_	14	appos
27	-RRB-	-rrb-	-RRB-	_	14	punct
28	should	should	MD	_	30	aux
29	be	be	VB	_	30	auxpass
30	approached	approach	VBN	_	0	ROOT
31	with	with	IN	_	32	case
32	caution	caution	NN	_	30	nmod
33	.	.	.	_	30	punct

1	Because	because	IN	_	10	mark
2	moderate	moderate	JJ	_	4	amod
3	CYP3A4	cyp3a4	NN	_	4	compound
4	inhibitors	inhibitor	NNS	_	10	nsubj
5	-LRB-	-lrb-	-LRB-	_	8	punct
6	e.g.	e.g.	FW	_	8	dep
7	,	,	,	_	8	punct
8	drug1	drug1	NN	_	4	appos
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	result	result	VBP	_	25	advcl
11	in	in	IN	_	13	case
12	2-fold	2-fold	JJ	_	13	amod
13	increase	increase	NN	_	10	nmod
14	in	in	IN	_	16	case
15	plasma	plasma	NN	_	16	compound
16	concentrations	concentration	NNS	_	13	nmod
17	of	of	IN	_	18	case
18	drug2	drug2	NN	_	16	nmod
19	,	,	,	_	25	punct
20	concomitant	concomitant	JJ	_	21	amod
21	administration	administration	NN	_	25	nsubjpass
22	should	should	MD	_	25	aux
23	also	also	RB	_	25	advmod
24	be	be	VB	_	25	auxpass
25	approached	approach	VBN	_	0	ROOT
26	with	with	IN	_	27	case
27	caution	caution	NN	_	25	nmod
28	.	.	.	_	25	punct

1	drug1	drug1	NN	_	4	nsubj
2	is	be	VBZ	_	4	cop
3	a	a	DT	_	4	det
4	substrate	substrate	NN	_	0	ROOT
5	for	for	IN	_	6	case
6	CYP3A4	cyp3a4	NN	_	4	nmod
7	;	;	:	_	4	punct

1	therefore	therefore	RB	_	23	advmod
2	,	,	,	_	23	punct
3	coadministration	coadministration	NN	_	23	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	with	with	IN	_	7	case
7	drugs	drug	NNS	_	3	nmod
8	that	that	WDT	_	10	nsubj
9	strongly	strongly	RB	_	10	advmod
10	induce	induce	VBP	_	7	acl:relcl
11	CYP3A4	cyp3a4	NN	_	12	compound
12	activity	activity	NN	_	10	dobj
13	-LRB-	-lrb-	-LRB-	_	16	punct
14	e.g.	e.g.	FW	_	16	dep
15	,	,	,	_	16	punct
16	drug2	drug2	NN	_	3	dep
17	,	,	,	_	16	punct
18	drug3	drug3	NN	_	16	appos
19	,	,	,	_	16	punct
20	drug4	drug4	NN	_	16	appos
21	-RRB-	-rrb-	-RRB-	_	16	punct
22	may	may	MD	_	23	aux
23	result	result	VB	_	0	ROOT
24	in	in	IN	_	27	case
25	reduced	reduce	VBN	_	27	amod
26	plasma	plasma	NN	_	27	compound
27	concentrations	concentration	NNS	_	23	nmod
28	of	of	IN	_	29	case
29	drug5	drug5	NN	_	27	nmod
30	that	that	WDT	_	32	nsubj
31	may	may	MD	_	32	aux
32	result	result	VB	_	27	acl:relcl
33	in	in	IN	_	35	case
34	decreased	decrease	VBN	_	35	amod
35	efficacy	efficacy	NN	_	32	nmod
36	of	of	IN	_	37	case
37	drug6	drug6	NN	_	35	nmod
38	.	.	.	_	23	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	When	when	WRB	_	11	advmod
4	a	a	DT	_	7	det
5	single	single	JJ	_	7	amod
6	125-mg	125-mg	JJ	_	7	amod
7	dose	dose	NN	_	11	nsubjpass
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	was	be	VBD	_	11	auxpass
11	administered	administer	VBN	_	1	dep
12	on	on	IN	_	13	case
13	Day5	day5	NN	_	11	nmod
14	of	of	IN	_	15	case
15	a	a	DT	_	13	nmod

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	When	when	WRB	_	11	advmod
4	a	a	DT	_	7	det
5	single	single	JJ	_	7	amod
6	125-mg	125-mg	JJ	_	7	amod
7	dose	dose	NN	_	11	nsubjpass
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	was	be	VBD	_	11	auxpass
11	administered	administer	VBN	_	1	dep
12	on	on	IN	_	13	case
13	Day5	day5	NN	_	11	nmod
14	of	of	IN	_	17	case
15	a	a	DT	_	17	det
16	10-day	10-day	JJ	_	17	amod
17	regimen	regimen	NN	_	13	nmod
18	of	of	IN	_	20	case
19	400	400	CD	_	20	nummod
20	mg/day	mg/day	NN	_	17	nmod
21	of	of	IN	_	22	case
22	drug3	drug3	NN	_	20	nmod
23	,	,	,	_	20	punct
24	a	a	DT	_	27	det
25	strong	strong	JJ	_	27	amod
26	CYP3A4	cyp3a4	NN	_	27	compound
27	inhibitor	inhibitor	NN	_	20	appos
28	,	,	,	_	20	punct
29	the	the	DT	_	30	det
30	AUC	auc	NN	_	33	nsubj
31	of	of	IN	_	32	case
32	drug4	drug4	NN	_	30	nmod
33	increased	increase	VBD	_	20	acl:relcl
34	approximately	approximately	RB	_	35	advmod
35	5-fold	5-fold	RB	_	33	advmod
36	and	and	CC	_	33	cc
37	the	the	DT	_	40	det
38	mean	mean	JJ	_	40	amod
39	terminal	terminal	JJ	_	40	amod
40	half-life	half-life	NN	_	43	nsubj
41	of	of	IN	_	42	case
42	drug5	drug5	NN	_	40	nmod
43	increased	increase	VBD	_	33	conj
44	approximately	approximately	RB	_	45	advmod
45	3-fold	3-fold	RB	_	43	advmod
46	.	.	.	_	1	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	11	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	8	case
6	strong	strong	JJ	_	8	amod
7	CYP3A4	cyp3a4	NN	_	8	compound
8	inhibitors	inhibitor	NNS	_	2	nmod
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	approached	approach	VBN	_	0	ROOT
12	cautiously	cautiously	RB	_	11	advmod
13	.	.	.	_	11	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	When	when	WRB	_	11	advmod
4	a	a	DT	_	7	det
5	single	single	JJ	_	7	amod
6	375-mg	375-mg	JJ	_	7	amod
7	dose	dose	NN	_	11	nsubjpass
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	was	be	VBD	_	11	auxpass
11	administered	administer	VBN	_	1	dep
12	on	on	IN	_	13	case
13	Day9	day9	NN	_	11	nmod
14	of	of	IN	_	17	case
15	a	a	DT	_	17	det
16	14-day	14-day	JJ	_	17	amod
17	regimen	regimen	NN	_	13	nmod
18	of	of	IN	_	20	case
19	600	600	CD	_	20	nummod
20	mg/day	mg/day	NN	_	17	nmod
21	of	of	IN	_	22	case
22	drug3	drug3	NN	_	20	nmod
23	,	,	,	_	20	punct
24	a	a	DT	_	27	det
25	strong	strong	JJ	_	27	amod
26	CYP3A4	cyp3a4	NN	_	27	compound
27	inducer	inducer	NN	_	20	appos
28	,	,	,	_	20	punct
29	the	the	DT	_	30	det
30	AUC	auc	NN	_	33	nsubj
31	of	of	IN	_	32	case
32	drug4	drug4	NN	_	30	nmod
33	decreased	decrease	VBD	_	20	acl:relcl
34	approximately	approximately	RB	_	35	advmod
35	11-fold	11-fold	JJ	_	33	dobj
36	and	and	CC	_	35	cc
37	the	the	DT	_	40	det
38	mean	mean	JJ	_	40	amod
39	terminal	terminal	JJ	_	40	amod
40	half-life	half-life	NN	_	41	nsubj
41	decreased	decrease	VBD	_	35	conj
42	approximately	approximately	RB	_	43	advmod
43	3-fold	3-fold	RB	_	41	advmod
44	.	.	.	_	1	punct

1	Coadministration	coadministration	NN	_	11	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	5	case
5	drugs	drug	NNS	_	1	nmod
6	that	that	WDT	_	7	nsubj
7	induce	induce	VBP	_	5	acl:relcl
8	CYP3A4	cyp3a4	NN	_	9	compound
9	activity	activity	NN	_	7	dobj
10	may	may	MD	_	11	aux
11	result	result	VB	_	0	ROOT
12	in	in	IN	_	15	case
13	reduced	reduce	VBN	_	15	amod
14	plasma	plasma	NN	_	15	compound
15	concentrations	concentration	NNS	_	11	nmod
16	and	and	CC	_	11	cc
17	decreased	decrease	VBD	_	11	conj
18	efficacy	efficacy	NN	_	17	dobj
19	of	of	IN	_	20	case
20	drug2	drug2	NN	_	18	nmod
21	.	.	.	_	11	punct

1	Additional	additional	JJ	_	2	amod
2	interactions	interaction	NNS	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	4	case
4	patients	patient	NNS	_	41	nmod
5	with	with	IN	_	6	case
6	mild	mild	JJ	_	4	nmod
7	to	to	TO	_	9	case
8	moderate	moderate	JJ	_	9	amod
9	hypertension	hypertension	NN	_	6	nmod
10	,	,	,	_	41	punct
11	administration	administration	NN	_	41	nsubj
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	once	once	RB	_	15	advmod
15	daily	daily	RB	_	11	advmod
16	,	,	,	_	41	punct
17	as	as	IN	_	20	case
18	a	a	DT	_	20	det
19	tablet	tablet	JJ	_	20	amod
20	formulation	formulation	NN	_	41	nmod
21	comparable	comparable	JJ	_	20	amod
22	to	to	TO	_	24	case
23	230	230	CD	_	24	nummod
24	mg	mg	NN	_	21	nmod
25	of	of	IN	_	28	case
26	the	the	DT	_	28	det
27	capsule	capsule	NN	_	28	compound
28	formulation	formulation	NN	_	24	nmod
29	,	,	,	_	41	punct
30	with	with	IN	_	33	case
31	drug3	drug3	NN	_	33	compound
32	120	120	CD	_	33	nummod
33	mg	mg	NN	_	41	nmod
34	3	3	CD	_	35	compound
35	times	time	NNS	_	33	dep
36	daily	daily	RB	_	35	advmod
37	for	for	IN	_	39	case
38	5	5	CD	_	39	nummod
39	days	day	NNS	_	35	nmod
40	,	,	,	_	41	punct
41	resulted	result	VBD	_	1	dep
42	in	in	IN	_	45	case
43	a	a	DT	_	45	det
44	2-fold	2-fold	JJ	_	45	amod
45	increase	increase	NN	_	41	nmod
46	of	of	IN	_	48	case
47	drug4	drug4	NN	_	48	compound
48	AUC	auc	NN	_	45	nmod
49	and	and	CC	_	45	cc
50	a	a	DT	_	53	det
51	simultaneous	simultaneous	JJ	_	53	amod
52	1.7-fold	1.7-fold	JJ	_	53	amod
53	increase	increase	NN	_	45	conj
54	of	of	IN	_	56	case
55	drug5	drug5	NN	_	56	compound
56	AUC	auc	NN	_	53	nmod
57	.	.	.	_	1	punct

1	These	these	DT	_	3	det
2	pharmacokinetic	pharmacokinetic	JJ	_	3	amod
3	effects	effect	NNS	_	6	nsubj
4	did	do	VBD	_	6	aux
5	not	not	RB	_	6	neg
6	result	result	VB	_	0	ROOT
7	in	in	IN	_	10	case
8	clinically	clinically	RB	_	9	advmod
9	meaningful	meaningful	JJ	_	10	amod
10	changes	change	NNS	_	6	nmod
11	in	in	IN	_	12	case
12	ECG	ecg	NN	_	10	nmod
13	,	,	,	_	10	punct
14	heart	heart	NN	_	15	compound
15	rate	rate	NN	_	10	appos
16	or	or	CC	_	15	cc
17	blood	blood	NN	_	18	compound
18	pressure	pressure	NN	_	15	conj
19	beyond	beyond	IN	_	21	case
20	those	those	DT	_	21	det
21	changes	change	NNS	_	15	nmod
22	induced	induce	VBN	_	21	acl
23	by	by	IN	_	24	case
24	drug1	drug1	NN	_	22	nmod
25	alone	alone	RB	_	24	advmod
26	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Coadministration	coadministration	NN	_	34	nsubj
4	of	of	IN	_	7	case
5	once	once	RB	_	7	advmod
6	daily	daily	JJ	_	7	amod
7	doses	dose	NNS	_	3	nmod
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	,	,	,	_	3	punct
11	as	as	IN	_	14	case
12	a	a	DT	_	14	det
13	tablet	tablet	JJ	_	14	amod
14	formulation	formulation	NN	_	3	nmod
15	comparable	comparable	JJ	_	14	amod
16	to	to	TO	_	18	case
17	85	85	CD	_	18	nummod
18	mg	mg	NN	_	15	nmod
19	or	or	CC	_	18	cc
20	170	170	CD	_	21	nummod
21	mg	mg	NN	_	18	conj
22	of	of	IN	_	25	case
23	the	the	DT	_	25	det
24	capsule	capsule	NN	_	25	compound
25	formulation	formulation	NN	_	18	nmod
26	,	,	,	_	3	punct
27	with	with	IN	_	30	case
28	drug3	drug3	NN	_	30	compound
29	20	20	CD	_	30	nummod
30	mg	mg	NN	_	3	nmod
31	once	once	RB	_	32	advmod
32	daily	daily	RB	_	30	advmod
33	,	,	,	_	3	punct
34	resulted	result	VBD	_	1	appos
35	in	in	IN	_	37	case
36	a	a	DT	_	37	det
37	decrease	decrease	NN	_	34	nmod
38	in	in	IN	_	39	case
39	AUC	auc	NN	_	37	nmod
40	by	by	IN	_	43	case
41	approximately	approximately	RB	_	42	advmod
42	25	25	CD	_	43	nummod
43	%	%	NN	_	37	nmod
44	and	and	CC	_	43	cc
45	Cmax	cmax	NN	_	43	conj
46	,	,	,	_	37	punct
47	by	by	IN	_	50	case
48	approximately	approximately	RB	_	49	advmod
49	20	20	CD	_	50	nummod
50	%	%	NN	_	37	nmod
51	of	of	IN	_	53	case
52	both	both	CC	_	53	cc:preconj
53	drug4	drug4	NN	_	50	nmod
54	and	and	CC	_	53	cc
55	drug5	drug5	NN	_	53	conj
56	.	.	.	_	1	punct

1	No	no	DT	_	2	neg
2	information	information	NN	_	0	ROOT
3	provided	provide	VBN	_	2	acl

1	Interactions	interaction	NNS	_	0	ROOT
2	for	for	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	drug2	drug2	NN	_	3	dep
6	,	,	,	_	5	punct
7	drug3	drug3	NN	_	5	conj
8	,	,	,	_	5	punct
9	drug4	drug4	NN	_	5	conj
10	,	,	,	_	5	punct
11	and	and	CC	_	5	cc
12	drug5	drug5	NN	_	5	conj
13	-RRB-	-rrb-	-RRB-	_	5	punct
14	:	:	:	_	1	punct
15	drug6	drug6	NN	_	1	dep
16	:	:	:	_	15	punct
17	drug7	drug7	NN	_	20	nsubjpass
18	has	have	VBZ	_	20	aux
19	been	be	VBN	_	20	auxpass
20	reported	report	VBN	_	15	appos
21	to	to	TO	_	22	mark
22	reduce	reduce	VB	_	20	xcomp
23	intestinal	intestinal	JJ	_	24	amod
24	absorption	absorption	NN	_	22	dobj
25	of	of	IN	_	26	case
26	drug8	drug8	NN	_	24	nmod
27	;	;	:	_	1	punct

1	as	as	IN	_	5	mark
2	such	such	JJ	_	5	mark
3	it	it	PRP	_	5	nsubj
4	may	may	MD	_	5	aux
5	impair	impair	VB	_	0	ROOT
6	intestinal	intestinal	JJ	_	7	amod
7	absorption	absorption	NN	_	5	dobj
8	of	of	IN	_	9	case
9	any	any	DT	_	7	nmod
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	.	.	.	_	5	punct

1	drug1	drug1	NN	_	3	compound
2	/	/	:	_	3	punct
3	drug2	drug2	NN	_	0	ROOT
4	:	:	:	_	3	punct
5	The	the	DT	_	6	det
6	coadministration	coadministration	NN	_	13	nsubj
7	of	of	IN	_	8	case
8	drug3	drug3	NN	_	6	nmod
9	or	or	CC	_	8	cc
10	drug4	drug4	NN	_	8	conj
11	will	will	MD	_	13	aux
12	not	not	RB	_	13	neg
13	affect	affect	VB	_	3	dep
14	plasma	plasma	NN	_	15	compound
15	concentrations	concentration	NNS	_	13	dobj
16	of	of	IN	_	17	case
17	drug5	drug5	NN	_	15	nmod
18	,	,	,	_	13	punct
19	but	but	CC	_	13	cc
20	may	may	MD	_	21	aux
21	reduce	reduce	VB	_	13	conj
22	endogenous	endogenous	JJ	_	24	amod
23	plasma	plasma	NN	_	24	compound
24	levels	level	NNS	_	21	dobj
25	of	of	IN	_	26	case
26	drug6	drug6	NN	_	24	nmod
27	/	/	:	_	13	punct
28	ergocalcitriol	ergocalcitriol	NN	_	13	conj
29	by	by	IN	_	30	mark
30	accelerating	accelerate	VBG	_	28	acl
31	metabolism	metabolism	NN	_	30	dobj
32	.	.	.	_	3	punct

1	Since	since	IN	_	10	mark
2	blood	blood	NN	_	3	compound
3	level	level	NN	_	10	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	/	/	:	_	7	punct
7	ergocalcitriol	ergocalcitriol	NN	_	10	nsubjpass
8	will	will	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	reduced	reduce	VBN	_	18	advcl
11	,	,	,	_	18	punct
12	higher	higher	JJR	_	13	amod
13	doses	dose	NNS	_	18	nsubj
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	may	may	MD	_	18	aux
17	be	be	VB	_	18	cop
18	necessary	necessary	JJ	_	0	ROOT
19	if	if	IN	_	23	mark
20	these	these	DT	_	21	det
21	drugs	drug	NNS	_	23	nsubjpass
22	are	be	VBP	_	23	auxpass
23	administered	administer	VBN	_	18	advcl
24	simultaneously	simultaneously	RB	_	23	advmod
25	.	.	.	_	18	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubjpass
4	are	be	VBP	_	5	auxpass
5	known	know	VBN	_	1	appos
6	to	to	TO	_	7	mark
7	induce	induce	VB	_	5	xcomp
8	hypercalcemia	hypercalcemia	NN	_	7	dobj
9	by	by	IN	_	11	case
10	the	the	DT	_	11	det
11	reduction	reduction	NN	_	7	nmod
12	of	of	IN	_	14	case
13	drug3	drug3	NN	_	14	compound
14	excretion	excretion	NN	_	11	nmod
15	in	in	IN	_	16	case
16	urine	urine	NN	_	11	nmod
17	.	.	.	_	1	punct

1	Some	some	DT	_	2	det
2	reports	report	NNS	_	4	nsubj
3	have	have	VBP	_	4	aux
4	shown	show	VBN	_	0	ROOT
5	that	that	IN	_	13	mark
6	the	the	DT	_	8	det
7	concomitant	concomitant	JJ	_	8	amod
8	administration	administration	NN	_	13	nsubj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	with	with	IN	_	12	case
12	drug2	drug2	NN	_	8	nmod
13	causes	cause	VBZ	_	4	ccomp
14	hypercalcemia	hypercalcemia	NN	_	13	dobj
15	.	.	.	_	4	punct

1	Therefore	therefore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	precaution	precaution	NN	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	taken	take	VBN	_	0	ROOT
7	when	when	WRB	_	10	advmod
8	coadministration	coadministration	NN	_	10	nsubj
9	is	be	VBZ	_	10	cop
10	necessary	necessary	JJ	_	6	advcl
11	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	compound
4	dosage	dosage	NN	_	7	nsubjpass
5	must	must	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	determined	determine	VBN	_	1	dep
8	with	with	IN	_	9	case
9	care	care	NN	_	7	nmod
10	in	in	IN	_	11	case
11	patients	patient	NNS	_	9	nmod
12	undergoing	undergo	VBG	_	11	acl
13	treatment	treatment	NN	_	12	dobj
14	with	with	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	,	,	,	_	7	punct
17	as	as	IN	_	18	case
18	hypercalcemia	hypercalcemia	NN	_	7	nmod
19	in	in	IN	_	21	case
20	such	such	JJ	_	21	amod
21	patients	patient	NNS	_	18	nmod
22	may	may	MD	_	23	aux
23	precipitate	precipitate	VB	_	7	ccomp
24	cardiac	cardiac	JJ	_	25	amod
25	arrhythmias	arrhythmia	NNS	_	23	dobj
26	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	inhibit	inhibit	VB	_	1	dep
6	both	both	DT	_	7	cc:preconj
7	synthetic	synthetic	JJ	_	5	dobj
8	and	and	CC	_	7	cc
9	catabolic	catabolic	JJ	_	7	conj
10	enzymes	enzyme	NNS	_	7	dep
11	of	of	IN	_	12	case
12	drug3	drug3	NN	_	7	nmod
13	.	.	.	_	5	punct

1	Reductions	reduction	NNS	_	10	nsubjpass
2	in	in	IN	_	7	case
3	serum	serum	NN	_	7	compound
4	endogenous	endogenous	JJ	_	7	amod
5	vitamin	vitamin	NN	_	7	compound
6	D	d	NN	_	7	compound
7	concentrations	concentration	NNS	_	1	nmod
8	have	have	VBP	_	10	aux
9	been	be	VBN	_	10	auxpass
10	observed	observe	VBN	_	0	ROOT
11	following	follow	VBG	_	13	case
12	the	the	DT	_	13	det
13	administration	administration	NN	_	10	nmod
14	of	of	IN	_	16	case
15	300	300	CD	_	16	nummod
16	mg/day	mg/day	NN	_	13	nmod
17	to	to	TO	_	20	case
18	1200	1200	CD	_	20	nummod
19	mg/day	mg/day	NN	_	20	compound
20	drug1	drug1	NN	_	13	nmod
21	for	for	IN	_	23	case
22	a	a	DT	_	23	det
23	week	week	NN	_	13	nmod
24	to	to	TO	_	26	case
25	healthy	healthy	JJ	_	26	amod
26	men	man	NNS	_	23	nmod
27	.	.	.	_	10	punct

1	However	however	RB	_	15	advmod
2	,	,	,	_	15	punct
3	in	in	FW	_	7	amod
4	vivo	vivo	FW	_	3	dep
5	drug	drug	NN	_	7	compound
6	interaction	interaction	NN	_	7	compound
7	studies	study	NNS	_	15	nsubjpass
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	have	have	VBP	_	15	aux
13	not	not	RB	_	15	neg
14	been	be	VBN	_	15	auxpass
15	investigated	investigate	VBN	_	0	ROOT
16	.	.	.	_	15	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	A	a	DT	_	4	det
4	relationship	relationship	NN	_	8	nsubj
5	of	of	IN	_	7	case
6	functional	functional	JJ	_	7	amod
7	antagonism	antagonism	NN	_	4	nmod
8	exists	exist	VBZ	_	1	appos
9	between	between	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	,	,	,	_	10	punct
12	which	which	WDT	_	13	nsubj
13	promote	promote	VBP	_	10	acl:relcl
14	calcium	calcium	NN	_	15	compound
15	absorption	absorption	NN	_	13	dobj
16	,	,	,	_	10	punct
17	and	and	CC	_	10	cc
18	drug3	drug3	NN	_	10	conj
19	,	,	,	_	18	punct
20	which	which	WDT	_	21	nsubj
21	inhibit	inhibit	VBP	_	18	acl:relcl
22	calcium	calcium	NN	_	23	compound
23	absorption	absorption	NN	_	21	dobj
24	.	.	.	_	1	punct

1	Phosphate-Binding	phosphate-binding	JJ	_	2	amod
2	Agents	agent	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	Since	since	IN	_	5	case
5	drug1	drug1	NN	_	7	nmod
6	also	also	RB	_	7	advmod
7	has	have	VBZ	_	2	dep
8	an	a	DT	_	9	det
9	effect	effect	NN	_	7	dobj
10	on	on	IN	_	12	case
11	phosphate	phosphate	NN	_	12	compound
12	transport	transport	NN	_	9	nmod
13	in	in	IN	_	15	case
14	the	the	DT	_	15	det
15	intestine	intestine	NN	_	7	nmod
16	,	,	,	_	15	punct
17	kidneys	kidney	NNS	_	15	conj
18	and	and	CC	_	15	cc
19	bones	bone	NNS	_	15	conj
20	,	,	,	_	7	punct
21	the	the	DT	_	22	det
22	dosage	dosage	NN	_	28	nsubjpass
23	of	of	IN	_	25	case
24	phosphate-binding	phosphate-binding	JJ	_	25	amod
25	agents	agent	NNS	_	22	nmod
26	must	must	MD	_	28	aux
27	be	be	VB	_	28	auxpass
28	adjusted	adjust	VBN	_	7	ccomp
29	in	in	IN	_	30	case
30	accordance	accordance	NN	_	28	nmod
31	with	with	IN	_	35	case
32	the	the	DT	_	35	det
33	serum	serum	NN	_	35	compound
34	phosphate	phosphate	NN	_	35	compound
35	concentration	concentration	NN	_	30	nmod
36	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	coadministration	coadministration	NN	_	12	nsubjpass
5	of	of	IN	_	6	case
6	any	any	DT	_	4	nmod
7	of	of	IN	_	9	case
8	the	the	DT	_	9	det
9	drug2	drug2	NN	_	6	nmod
10	should	should	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	avoided	avoid	VBN	_	1	appos
13	as	as	IN	_	16	mark
14	this	this	DT	_	16	nsubj
15	could	could	MD	_	16	aux
16	create	create	VB	_	12	advcl
17	possible	possible	JJ	_	19	amod
18	additive	additive	JJ	_	19	amod
19	effects	effect	NNS	_	16	dobj
20	and	and	CC	_	19	cc
21	hypercalcemia	hypercalcemia	NN	_	19	conj
22	.	.	.	_	1	punct

1	drug1	drug1	NN	_	2	compound
2	Supplements	supplement	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	Uncontrolled	uncontrolled	JJ	_	5	amod
5	intake	intake	NN	_	14	nsubjpass
6	of	of	IN	_	8	case
7	additional	additional	JJ	_	8	amod
8	drug2	drug2	NN	_	5	nmod
9	-	-	:	_	5	punct
10	containing	contain	VBG	_	5	acl
11	preparations	preparation	NNS	_	10	dobj
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	avoided	avoid	VBN	_	2	dep
15	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	dep
4	-	-	:	_	5	punct
5	containing	contain	VBG	_	1	dep
6	preparations	preparation	NNS	_	5	dobj
7	-LRB-	-lrb-	-LRB-	_	8	punct
8	eg	eg	FW	_	6	dep
9	,	,	,	_	8	punct
10	drug3	drug3	NN	_	8	appos
11	-RRB-	-rrb-	-RRB-	_	8	punct
12	may	may	MD	_	13	aux
13	cause	cause	VB	_	5	dep
14	hypermagnesemia	hypermagnesemia	NN	_	13	dobj
15	and	and	CC	_	13	cc
16	should	should	MD	_	20	aux
17	therefore	therefore	RB	_	20	advmod
18	not	not	RB	_	20	neg
19	be	be	VB	_	20	auxpass
20	taken	take	VBN	_	13	conj
21	during	during	IN	_	22	case
22	therapy	therapy	NN	_	20	nmod
23	with	with	IN	_	24	case
24	drug4	drug4	NN	_	22	nmod
25	by	by	IN	_	26	case
26	patients	patient	NNS	_	20	nmod
27	on	on	IN	_	30	case
28	chronic	chronic	JJ	_	30	amod
29	renal	renal	JJ	_	30	amod
30	dialysis	dialysis	NN	_	26	nmod
31	.	.	.	_	1	punct

1	It	it	PRP	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	not	not	RB	_	4	neg
4	known	know	VBN	_	0	ROOT
5	if	if	IN	_	8	mark
6	drug1	drug1	NN	_	7	compound
7	Gel	gel	NN	_	8	nsubj
8	interacts	interact	VBZ	_	4	advcl
9	with	with	IN	_	12	case
10	other	other	JJ	_	12	amod
11	topical	topical	JJ	_	12	amod
12	medications	medication	NNS	_	8	nmod
13	applied	apply	VBD	_	12	acl
14	to	to	TO	_	17	case
15	the	the	DT	_	17	det
16	ulcer	ulcer	NN	_	17	compound
17	site	site	NN	_	13	nmod
18	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	use	use	NN	_	13	nsubjpass
3	of	of	IN	_	5	case
4	drug1	drug1	NN	_	5	compound
5	Gel	gel	NN	_	2	nmod
6	with	with	IN	_	9	case
7	other	other	JJ	_	9	amod
8	topical	topical	JJ	_	9	amod
9	drugs	drug	NNS	_	2	nmod
10	has	have	VBZ	_	13	aux
11	not	not	RB	_	13	neg
12	been	be	VBN	_	13	auxpass
13	studied	study	VBN	_	0	ROOT
14	.	.	.	_	13	punct

1	1	1	LS	_	0	ROOT
2	.	.	.	_	1	punct

1	Drugs	drug	NNS	_	0	ROOT
2	Metabolized	metabolize	VBN	_	1	acl
3	by	by	IN	_	5	case
4	P450	p450	NN	_	5	compound
5	2D6	2d6	NN	_	2	nmod
6	:	:	:	_	1	punct
7	The	the	DT	_	9	det
8	biochemical	biochemical	JJ	_	9	amod
9	activity	activity	NN	_	23	nsubjpass
10	of	of	IN	_	12	case
11	the	the	DT	_	12	det
12	drug	drug	NN	_	9	nmod
13	metabolizing	metabolize	VBG	_	12	acl
14	isozyme	isozyme	NN	_	17	compound
15	cytochrome	cytochrome	NN	_	17	compound
16	P450	p450	NN	_	17	compound
17	2D6	2d6	NN	_	13	dobj
18	-LRB-	-lrb-	-LRB-	_	20	punct
19	debrisoquin	debrisoquin	NN	_	20	compound
20	hydroxylase	hydroxylase	NN	_	17	appos
21	-RRB-	-rrb-	-RRB-	_	20	punct
22	is	be	VBZ	_	23	auxpass
23	reduced	reduce	VBN	_	1	dep
24	in	in	IN	_	26	case
25	a	a	DT	_	26	det
26	subset	subset	NN	_	23	nmod
27	of	of	IN	_	30	case
28	the	the	DT	_	30	det
29	caucasian	caucasian	JJ	_	30	amod
30	population	population	NN	_	26	nmod
31	-LRB-	-lrb-	-LRB-	_	41	punct
32	about	about	IN	_	35	advmod
33	7	7	CD	_	35	compound
34	to	to	TO	_	35	dep
35	10	10	CD	_	36	nummod
36	%	%	NN	_	41	nsubjpass
37	of	of	IN	_	38	case
38	caucasians	caucasian	NNS	_	36	nmod
39	are	be	VBP	_	41	auxpass
40	so	so	RB	_	41	advmod
41	called	call	VBN	_	26	dep
42	poor	poor	JJ	_	43	amod
43	metabolizers	metabolizer	NNS	_	41	xcomp
44	-RRB-	-rrb-	-RRB-	_	41	punct
45	;	;	:	_	23	punct

1	reliable	reliable	JJ	_	2	amod
2	estimates	estimate	NNS	_	22	nsubj
3	of	of	IN	_	5	case
4	the	the	DT	_	5	det
5	prevalence	prevalence	NN	_	2	nmod
6	of	of	IN	_	11	case
7	reduced	reduce	VBN	_	11	amod
8	P450	p450	NN	_	11	compound
9	2D6	2d6	NN	_	11	compound
10	isozyme	isozyme	NN	_	11	compound
11	activity	activity	NN	_	5	nmod
12	among	among	IN	_	18	case
13	Asian	asian	JJ	_	18	amod
14	,	,	,	_	13	punct
15	African	african	JJ	_	13	conj
16	and	and	CC	_	13	cc
17	other	other	JJ	_	13	conj
18	populations	population	NNS	_	11	nmod
19	are	be	VBP	_	22	cop
20	not	not	RB	_	22	neg
21	yet	yet	RB	_	22	advmod
22	available	available	JJ	_	0	ROOT
23	.	.	.	_	22	punct

1	Poor	Poor	NNP	_	2	compound
2	metabolizers	metabolizer	NNS	_	3	nsubj
3	have	have	VBP	_	0	ROOT
4	higher	higher	JJR	_	8	amod
5	than	than	IN	_	6	dep
6	expected	expect	VBN	_	8	amod
7	plasma	plasma	NN	_	8	compound
8	concentrations	concentration	NNS	_	3	dobj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	drug2	drug2	NN	_	10	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	when	when	WRB	_	15	advmod
15	given	give	VBN	_	3	advcl
16	usual	usual	JJ	_	17	amod
17	doses	dose	NNS	_	15	dobj
18	.	.	.	_	3	punct

1	Depending	depend	VBG	_	4	case
2	on	on	IN	_	4	case
3	the	the	DT	_	4	det
4	traction	traction	NN	_	19	nmod
5	of	of	IN	_	6	case
6	drug	drug	NN	_	4	nmod
7	metabolized	metabolize	VBN	_	6	acl
8	by	by	IN	_	10	case
9	P450	p450	NN	_	10	compound
10	2D6	2d6	NN	_	7	nmod
11	,	,	,	_	19	punct
12	the	the	DT	_	13	det
13	increase	increase	NN	_	19	nsubj
14	in	in	IN	_	16	case
15	plasma	plasma	NN	_	16	compound
16	concentration	concentration	NN	_	13	nmod
17	may	may	MD	_	19	aux
18	be	be	VB	_	19	cop
19	small	small	JJ	_	0	ROOT
20	,	,	,	_	19	punct
21	or	or	CC	_	19	cc
22	quite	quite	RB	_	23	advmod
23	large	large	JJ	_	19	conj
24	-LRB-	-lrb-	-LRB-	_	27	punct
25	8	8	CD	_	27	nummod
26	fold	fold	JJ	_	27	amod
27	increase	increase	NN	_	23	dep
28	in	in	IN	_	30	case
29	plasma	plasma	NN	_	30	compound
30	AUC	auc	NN	_	27	nmod
31	of	of	IN	_	33	case
32	the	the	DT	_	33	det
33	drug1	drug1	NN	_	30	nmod
34	-RRB-	-rrb-	-RRB-	_	27	punct
35	.	.	.	_	19	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	6	nmod
3	,	,	,	_	6	punct
4	certain	certain	JJ	_	5	amod
5	drugs	drug	NNS	_	6	nsubj
6	inhibit	inhibit	VBP	_	0	ROOT
7	the	the	DT	_	8	det
8	activity	activity	NN	_	6	dobj
9	of	of	IN	_	11	case
10	this	this	DT	_	11	det
11	isozyme	isozyme	NN	_	8	nmod
12	and	and	CC	_	6	cc
13	make	make	VB	_	6	conj
14	normal	normal	JJ	_	15	amod
15	metabolizers	metabolizer	NNS	_	16	nsubj
16	resemble	resemble	VBP	_	13	ccomp
17	p.o.	p.o.	NN	_	16	xcomp

1	metabolizers	metabolizer	NNS	_	0	ROOT
2	.	.	.	_	1	punct

1	An	a	DT	_	2	det
2	individual	individual	NN	_	13	nsubj
3	who	who	WP	_	5	nsubj
4	is	be	VBZ	_	5	cop
5	stable	stable	JJ	_	2	acl:relcl
6	on	on	IN	_	9	case
7	a	a	DT	_	9	det
8	given	give	VBN	_	9	amod
9	dose	dose	NN	_	5	nmod
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	may	may	MD	_	13	aux
13	become	become	VB	_	0	ROOT
14	abruptly	abruptly	RB	_	15	advmod
15	toxic	toxic	JJ	_	13	xcomp
16	when	when	WRB	_	17	advmod
17	given	give	VBN	_	13	advcl
18	one	one	CD	_	17	dobj
19	of	of	IN	_	22	case
20	these	these	DT	_	22	det
21	inhibiting	inhibit	VBG	_	22	amod
22	drugs	drug	NNS	_	18	nmod
23	as	as	IN	_	25	case
24	concomitant	concomitant	JJ	_	25	amod
25	therapy	therapy	NN	_	17	nmod
26	.	.	.	_	13	punct

1	The	the	DT	_	2	det
2	drugs	drug	NNS	_	8	nsubj
3	that	that	WDT	_	4	nsubj
4	inhibit	inhibit	VBP	_	2	acl:relcl
5	cytochrome	cytochrome	NN	_	7	compound
6	P450	p450	NN	_	7	compound
7	2D6	2d6	NN	_	4	dobj
8	include	include	VBP	_	0	ROOT
9	some	some	DT	_	8	dobj
10	that	that	WDT	_	13	nsubjpass
11	are	be	VBP	_	13	auxpass
12	not	not	RB	_	13	neg
13	metabolized	metabolize	VBN	_	9	acl:relcl
14	by	by	IN	_	16	case
15	the	the	DT	_	16	det
16	enzyme	enzyme	NN	_	13	nmod
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	drug1	drug1	NN	_	16	appos
19	;	;	:	_	18	punct

1	drug1	drug1	NN	_	0	ROOT
2	-RRB-	-rrb-	-RRB-	_	1	punct
3	and	and	CC	_	1	cc
4	many	many	JJ	_	1	conj
5	that	that	WDT	_	7	nsubj
6	are	be	VBP	_	7	cop
7	substrates	substrate	NNS	_	4	acl:relcl
8	for	for	IN	_	10	case
9	P450	p450	NN	_	10	compound
10	2D6	2d6	NN	_	7	nmod
11	-LRB-	-lrb-	-LRB-	_	14	punct
12	many	many	JJ	_	14	amod
13	other	other	JJ	_	14	amod
14	drug2	drug2	NN	_	1	dep
15	,	,	,	_	14	punct
16	drug3	drug3	NN	_	14	conj
17	,	,	,	_	14	punct
18	and	and	CC	_	14	cc
19	the	the	DT	_	23	det
20	Type	type	NN	_	23	compound
21	1C	1c	NN	_	23	compound
22	antiarrhythrnics	antiarrhythrnic	NNS	_	23	compound
23	propatenone	propatenone	NN	_	14	conj
24	and	and	CC	_	23	cc
25	drug4	drug4	NN	_	23	conj
26	-RRB-	-rrb-	-RRB-	_	14	punct
27	.	.	.	_	1	punct

1	While	while	IN	_	18	mark
2	all	all	PDT	_	18	dep
3	the	the	DT	_	18	dep
4	drug1	drug1	NN	_	18	dep
5	-LRB-	-lrb-	-LRB-	_	6	punct
6	drug2	drug2	NN	_	4	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	,	,	,	_	4	punct
9	e.g.	e.g.	FW	_	4	dep
10	,	,	,	_	4	punct
11	drug3	drug3	NN	_	4	conj
12	,	,	,	_	4	punct
13	seriraline	seriraline	NN	_	4	conj
14	,	,	,	_	4	punct
15	and	and	CC	_	4	cc
16	drug4	drug4	NN	_	4	conj
17	,	,	,	_	4	punct
18	inhibit	inhibit	VBP	_	24	advcl
19	P450	p450	NN	_	20	compound
20	2D6	2d6	NN	_	18	dobj
21	,	,	,	_	24	punct
22	they	they	PRP	_	24	nsubj
23	may	may	MD	_	24	aux
24	vary	vary	VB	_	0	ROOT
25	in	in	IN	_	27	case
26	the	the	DT	_	27	det
27	extent	extent	NN	_	24	nmod
28	of	of	IN	_	29	case
29	inhibition	inhibition	NN	_	27	nmod
30	.	.	.	_	24	punct

1	The	the	DT	_	2	det
2	extent	extent	NN	_	0	ROOT
3	to	to	TO	_	4	case
4	which	which	WDT	_	10	nmod
5	drug1	drug1	SYM	_	10	dep
6	-	-	:	_	10	punct
7	drug2	drug2	NN	_	8	compound
8	interactions	interaction	NNS	_	10	nsubj
9	may	may	MD	_	10	aux
10	pose	pose	VB	_	2	acl:relcl
11	clinical	clinical	JJ	_	12	amod
12	problems	problem	NNS	_	14	nsubj
13	will	will	MD	_	14	aux
14	depend	depend	VB	_	10	ccomp
15	on	on	IN	_	17	case
16	the	the	DT	_	17	det
17	degree	degree	NN	_	14	nmod
18	of	of	IN	_	19	case
19	inhibition	inhibition	NN	_	17	nmod
20	and	and	CC	_	19	cc
21	the	the	DT	_	22	det
22	pharmacokinetics	pharmacokinetic	NNS	_	19	conj
23	of	of	IN	_	25	case
24	the	the	DT	_	25	det
25	drug3	drug3	NN	_	22	nmod
26	involved	involve	VBN	_	25	acl
27	.	.	.	_	2	punct

1	Nevertheless	nevertheless	RB	_	5	advmod
2	,	,	,	_	5	punct
3	caution	caution	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	indicated	indicate	VBN	_	0	ROOT
6	in	in	IN	_	8	case
7	the	the	DT	_	8	det
8	co-administration	co-administration	NN	_	5	nmod
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	with	with	IN	_	12	case
12	any	any	DT	_	5	nmod
13	of	of	IN	_	15	case
14	the	the	DT	_	15	det
15	drug2	drug2	NN	_	12	nmod
16	and	and	CC	_	12	cc
17	also	also	RB	_	19	advmod
18	in	in	IN	_	19	case
19	switching	switching	NN	_	12	conj
20	from	from	IN	_	22	case
21	one	one	CD	_	22	nummod
22	class	class	NN	_	19	nmod
23	to	to	TO	_	25	case
24	the	the	DT	_	25	det
25	other	other	JJ	_	19	nmod
26	.	.	.	_	5	punct

1	Of	of	IN	_	3	case
2	particular	particular	JJ	_	3	amod
3	importance	importance	NN	_	8	nmod
4	,	,	,	_	8	punct
5	sufficient	sufficient	JJ	_	6	amod
6	time	time	NN	_	8	nsubj
7	must	must	MD	_	8	aux
8	elapse	elapse	VB	_	0	ROOT
9	before	before	IN	_	10	mark
10	initiating	initiate	VBG	_	8	advcl
11	TCA	TCA	NNP	_	12	compound
12	treatment	treatment	NN	_	10	dobj
13	in	in	IN	_	15	case
14	a	a	DT	_	15	det
15	patient	patient	NN	_	12	nmod
16	being	be	VBG	_	17	auxpass
17	withdrawn	withdraw	VBN	_	15	acl
18	from	from	IN	_	19	case
19	drug1	drug1	NN	_	17	nmod
20	,	,	,	_	8	punct
21	given	give	VBN	_	24	case
22	the	the	DT	_	24	det
23	long	long	JJ	_	24	amod
24	half-life	half-life	NN	_	8	nmod
25	of	of	IN	_	27	case
26	the	the	DT	_	27	det
27	parent	parent	NN	_	24	nmod
28	and	and	CC	_	27	cc
29	active	active	JJ	_	30	amod
30	metabolite	metabolite	NN	_	27	conj
31	-LRB-	-lrb-	-LRB-	_	38	punct
32	at	at	IN	_	33	case
33	least	least	JJS	_	34	nmod:npmod
34	5	5	CD	_	35	nummod
35	weeks	week	NNS	_	38	nsubj
36	may	may	MD	_	38	aux
37	be	be	VB	_	38	cop
38	necessary	necessary	JJ	_	24	dep
39	-RRB-	-rrb-	-RRB-	_	38	punct
40	.	.	.	_	8	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	use	use	NN	_	14	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	6	case
6	drugs	drug	NNS	_	2	nmod
7	that	that	WDT	_	9	nsubj
8	can	can	MD	_	9	aux
9	inhibit	inhibit	VB	_	6	acl:relcl
10	cytochrome	cytochrome	NN	_	12	compound
11	P450	p450	NN	_	12	compound
12	2D6	2d6	NN	_	9	dobj
13	may	may	MD	_	14	aux
14	require	require	VB	_	0	ROOT
15	lower	lower	JJR	_	16	amod
16	doses	dose	NNS	_	14	dobj
17	than	than	IN	_	19	mark
18	usually	usually	RB	_	19	advmod
19	prescribed	prescribe	VBN	_	16	dep
20	for	for	IN	_	23	case
21	either	either	CC	_	23	cc:preconj
22	the	the	DT	_	23	det
23	drug2	drug2	NN	_	19	nmod
24	or	or	CC	_	23	cc
25	the	the	DT	_	27	det
26	other	other	JJ	_	27	amod
27	drug	drug	NN	_	23	conj
28	.	.	.	_	14	punct

1	Furthermore	furthermore	RB	_	21	advmod
2	,	,	,	_	21	punct
3	whenever	whenever	WRB	_	10	advmod
4	one	one	CD	_	10	nsubjpass
5	of	of	IN	_	8	case
6	these	these	DT	_	8	det
7	other	other	JJ	_	8	amod
8	drugs	drug	NNS	_	4	nmod
9	is	be	VBZ	_	10	auxpass
10	withdrawn	withdraw	VBN	_	21	advcl
11	from	from	IN	_	12	case
12	co-therapy	co-therapy	JJ	_	10	nmod
13	,	,	,	_	21	punct
14	an	a	DT	_	16	det
15	increased	increase	VBN	_	16	amod
16	dose	dose	NN	_	21	nsubjpass
17	of	of	IN	_	18	case
18	drug1	drug1	NN	_	16	nmod
19	may	may	MD	_	21	aux
20	be	be	VB	_	21	auxpass
21	required	require	VBN	_	0	ROOT
22	.	.	.	_	21	punct

1	It	it	PRP	_	3	nsubj
2	is	be	VBZ	_	3	cop
3	desirable	desirable	JJ	_	0	ROOT
4	to	to	TO	_	5	mark
5	monitor	monitor	VB	_	3	xcomp
6	drug1	drug1	NN	_	8	compound
7	plasma	plasma	NN	_	8	compound
8	levels	level	NNS	_	5	dobj
9	whenever	whenever	WRB	_	13	advmod
10	a	a	DT	_	11	det
11	drug2	drug2	NN	_	13	nsubj
12	is	be	VBZ	_	13	aux
13	going	go	VBG	_	5	advcl
14	to	to	TO	_	16	mark
15	be	be	VB	_	16	auxpass
16	co-administered	co-administer	VBN	_	13	xcomp
17	with	with	IN	_	19	case
18	another	another	DT	_	19	det
19	drug	drug	NN	_	16	nmod
20	known	know	VBN	_	19	acl
21	to	to	TO	_	24	mark
22	be	be	VB	_	24	cop
23	an	a	DT	_	24	det
24	inhibitor	inhibitor	NN	_	20	xcomp
25	of	of	IN	_	27	case
26	P450	p450	NN	_	27	compound
27	2D6	2d6	NN	_	24	nmod
28	.	.	.	_	3	punct

1	2	2	LS	_	0	ROOT
2	.	.	.	_	1	punct

1	Close	close	JJ	_	2	amod
2	supervision	supervision	NN	_	9	nsubjpass
3	and	and	CC	_	2	cc
4	careful	careful	JJ	_	5	amod
5	adjustment	adjustment	NN	_	2	conj
6	of	of	IN	_	7	case
7	dosage	dosage	NN	_	2	nmod
8	are	be	VBP	_	9	auxpass
9	required	require	VBN	_	0	ROOT
10	when	when	WRB	_	14	advmod
11	this	this	DT	_	12	det
12	drug	drug	NN	_	14	nsubjpass
13	is	be	VBZ	_	14	auxpass
14	given	give	VBN	_	9	advcl
15	concomitantly	concomitantly	RB	_	17	advmod
16	with	with	IN	_	17	case
17	drug1	drug1	NN	_	14	nmod
18	or	or	CC	_	17	cc
19	drug2	drug2	NN	_	17	conj
20	.	.	.	_	9	punct

1	3	3	LS	_	0	ROOT
2	.	.	.	_	1	punct

1	Clinical	clinical	JJ	_	2	amod
2	experience	experience	NN	_	12	nsubjpass
3	in	in	IN	_	6	case
4	the	the	DT	_	6	det
5	concurrent	concurrent	JJ	_	6	amod
6	administration	administration	NN	_	2	nmod
7	of	of	IN	_	8	case
8	ECT	ECT	NNP	_	6	nmod
9	and	and	CC	_	8	cc
10	drug1	drug1	NN	_	8	conj
11	is	be	VBZ	_	12	auxpass
12	limited	limit	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	Thus	thus	RB	_	19	advmod
2	,	,	,	_	19	punct
3	if	if	IN	_	7	mark
4	such	such	JJ	_	5	amod
5	treatment	treatment	NN	_	7	nsubj
6	is	be	VBZ	_	7	cop
7	essential	essential	JJ	_	19	advcl
8	,	,	,	_	19	punct
9	the	the	DT	_	10	det
10	possibility	possibility	NN	_	19	nsubjpass
11	of	of	IN	_	13	case
12	increased	increase	VBN	_	13	amod
13	risk	risk	NN	_	10	nmod
14	relative	relative	JJ	_	13	amod
15	to	to	TO	_	16	case
16	benefits	benefit	NNS	_	14	nmod
17	should	should	MD	_	19	aux
18	be	be	VB	_	19	auxpass
19	considered	consider	VBN	_	0	ROOT
20	.	.	.	_	19	punct

1	4	4	LS	_	0	ROOT
2	.	.	.	_	1	punct

1	If	if	IN	_	3	mark
2	drug1	drug1	NN	_	3	nsubj
3	is	be	VBZ	_	22	advcl
4	to	to	TO	_	6	mark
5	be	be	VB	_	6	auxpass
6	combined	combine	VBN	_	3	xcomp
7	with	with	IN	_	9	case
8	other	other	JJ	_	9	amod
9	drug2	drug2	NN	_	6	nmod
10	such	such	JJ	_	12	case
11	as	as	IN	_	10	mwe
12	drug3	drug3	NN	_	9	nmod
13	or	or	CC	_	12	cc
14	drug4	drug4	NN	_	12	conj
15	/	/	:	_	16	punct
16	drug5	drug5	NN	_	22	nsubjpass
17	,	,	,	_	16	punct
18	careful	careful	JJ	_	19	amod
19	consideration	consideration	NN	_	16	appos
20	should	should	MD	_	22	aux
21	be	be	VB	_	22	auxpass
22	given	give	VBN	_	0	ROOT
23	to	to	TO	_	25	case
24	the	the	DT	_	25	det
25	pharmacology	pharmacology	NN	_	22	nmod
26	of	of	IN	_	28	case
27	the	the	DT	_	28	det
28	agents	agent	NNS	_	25	nmod
29	employed	employ	VBN	_	28	acl
30	since	since	IN	_	46	mark
31	the	the	DT	_	33	det
32	sedative	sedative	JJ	_	33	amod
33	effects	effect	NNS	_	46	nsubj
34	of	of	IN	_	35	case
35	drug6	drug6	NN	_	33	nmod
36	and	and	CC	_	35	cc
37	drug7	drug7	NN	_	35	conj
38	-LRB-	-lrb-	-LRB-	_	41	punct
39	e.g.	e.g.	FW	_	41	dep
40	,	,	,	_	41	punct
41	drug8	drug8	NN	_	35	dep
42	or	or	CC	_	41	cc
43	drug9	drug9	NN	_	41	conj
44	-RRB-	-rrb-	-RRB-	_	41	punct
45	are	be	VBP	_	46	cop
46	additive	additive	JJ	_	29	advcl
47	.	.	.	_	22	punct

1	Both	both	CC	_	3	cc:preconj
2	the	the	DT	_	3	dep
3	sedative	sedative	NN	_	12	nsubj
4	and	and	CC	_	3	cc
5	anticholinergic	anticholinergic	JJ	_	3	conj
6	effects	effect	NNS	_	3	dep
7	of	of	IN	_	9	case
8	the	the	DT	_	9	det
9	drug1	drug1	NN	_	3	nmod
10	are	be	VBP	_	12	cop
11	also	also	RB	_	12	advmod
12	additive	additive	JJ	_	0	ROOT
13	to	to	TO	_	14	case
14	those	those	DT	_	12	nmod
15	of	of	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	.	.	.	_	12	punct

1	5	5	CD	_	0	ROOT
2	.	.	.	_	1	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	administration	administration	NN	_	8	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	can	can	MD	_	8	aux
8	produce	produce	VB	_	0	ROOT
9	clinically	clinically	RB	_	10	advmod
10	significant	significant	JJ	_	11	amod
11	increases	increase	NNS	_	8	dobj
12	in	in	IN	_	15	case
13	the	the	DT	_	15	det
14	plasma	plasma	NN	_	15	compound
15	levels	level	NNS	_	11	nmod
16	of	of	IN	_	18	case
17	the	the	DT	_	18	det
18	drug3	drug3	NN	_	15	nmod
19	.	.	.	_	8	punct

1	Conversely	conversely	RB	_	3	advmod
2	,	,	,	_	3	punct
3	decreases	decrease	VBZ	_	12	nsubjpass
4	in	in	IN	_	6	case
5	plasma	plasma	NN	_	6	compound
6	levels	level	NNS	_	3	nmod
7	of	of	IN	_	9	case
8	the	the	DT	_	9	det
9	drug1	drug1	NN	_	6	nmod
10	have	have	VBP	_	12	aux
11	been	be	VBN	_	12	auxpass
12	reported	report	VBN	_	0	ROOT
13	upon	upon	IN	_	14	case
14	discontinuation	discontinuation	NN	_	12	nmod
15	of	of	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	which	which	WDT	_	19	nsubj
18	may	may	MD	_	19	aux
19	result	result	VB	_	14	acl:relcl
20	in	in	IN	_	22	case
21	the	the	DT	_	22	det
22	loss	loss	NN	_	19	nmod
23	of	of	IN	_	26	case
24	the	the	DT	_	26	det
25	therapeutic	therapeutic	JJ	_	26	amod
26	efficacy	efficacy	NN	_	22	nmod
27	of	of	IN	_	29	case
28	the	the	DT	_	29	det
29	drug3	drug3	NN	_	26	nmod
30	6	6	CD	_	29	nummod
31	.	.	.	_	12	punct

1	There	there	EX	_	4	expl
2	have	have	VBP	_	4	aux
3	been	be	VBN	_	4	cop
4	greater	greater	JJR	_	0	ROOT
5	than	than	IN	_	7	case
6	two-fold	two-fold	JJ	_	7	amod
7	increases	increase	NNS	_	4	nmod
8	of	of	IN	_	12	case
9	previously	previously	RB	_	10	advmod
10	stable	stable	JJ	_	12	amod
11	plasma	plasma	NN	_	12	compound
12	levels	level	NNS	_	7	nmod
13	of	of	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	when	when	WRB	_	19	advmod
16	drug2	drug2	NN	_	19	nsubjpass
17	has	have	VBZ	_	19	aux
18	been	be	VBN	_	19	auxpass
19	administered	administer	VBN	_	4	advcl
20	in	in	IN	_	21	case
21	combination	combination	NN	_	19	nmod
22	with	with	IN	_	24	case
23	these	these	DT	_	24	det
24	agents	agent	NNS	_	21	nmod
25	.	.	.	_	4	punct

1	Potential	potential	JJ	_	3	amod
2	drug	drug	NN	_	3	compound
3	interactions	interaction	NNS	_	6	nsubj
4	for	for	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	include	include	VBP	_	0	ROOT
7	,	,	,	_	6	punct
8	increased	increase	VBD	_	9	amod
9	sedation	sedation	NN	_	6	dobj
10	if	if	IN	_	13	mark
11	drug2	drug2	NN	_	13	nsubjpass
12	is	be	VBZ	_	13	auxpass
13	combined	combine	VBN	_	9	advcl
14	with	with	IN	_	16	case
15	other	other	JJ	_	16	amod
16	drug3	drug3	NN	_	13	nmod
17	.	.	.	_	6	punct

1	drug1	drug1	NN	_	4	nsubj
2	may	may	MD	_	4	aux
3	partially	partially	RB	_	4	advmod
4	counteract	counteract	VB	_	0	ROOT
5	the	the	DT	_	7	det
6	anticoagulation	anticoagulation	JJ	_	7	amod
7	effects	effect	NNS	_	4	dobj
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	or	or	CC	_	9	cc
11	drug3	drug3	NN	_	9	conj
12	.	.	.	_	4	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	enhance	enhance	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	effects	effect	NNS	_	3	dobj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	.	.	.	_	3	punct

1	drug1	drug1	NN	_	8	nsubj
2	,	,	,	_	1	punct
3	such	such	JJ	_	5	case
4	as	as	IN	_	3	mwe
5	drug2	drug2	NN	_	1	nmod
6	,	,	,	_	1	punct
7	may	may	MD	_	8	aux
8	have	have	VB	_	0	ROOT
9	an	a	DT	_	11	det
10	additive	additive	JJ	_	11	amod
11	effect	effect	NN	_	8	dobj
12	when	when	WRB	_	13	advmod
13	given	give	VBN	_	8	advcl
14	with	with	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	.	.	.	_	8	punct

1	Patients	patient	NNS	_	12	nsubjpass
2	treated	treat	VBN	_	1	acl
3	with	with	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	plus	plus	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	should	should	MD	_	12	aux
8	,	,	,	_	12	punct
9	therefore	therefore	RB	_	12	advmod
10	,	,	,	_	12	punct
11	be	be	VB	_	12	auxpass
12	observed	observe	VBN	_	0	ROOT
13	closely	closely	RB	_	12	advmod
14	for	for	IN	_	15	case
15	evidence	evidence	NN	_	12	nmod
16	of	of	IN	_	18	case
17	marked	marked	JJ	_	18	amod
18	bradycardia	bradycardia	NN	_	15	nmod
19	or	or	CC	_	18	cc
20	hypotension	hypotension	NN	_	18	conj
21	which	which	WDT	_	23	nsubj
22	may	may	MD	_	23	aux
23	present	present	VB	_	15	acl:relcl
24	as	as	IN	_	25	case
25	vertigo	vertigo	NN	_	23	nmod
26	,	,	,	_	25	punct
27	syncope/presyncope	syncope/presyncope	NN	_	25	conj
28	,	,	,	_	25	punct
29	or	or	CC	_	25	cc
30	orthostatic	orthostatic	JJ	_	31	amod
31	changes	change	NNS	_	25	conj
32	in	in	IN	_	34	case
33	blood	blood	NN	_	34	compound
34	pressure	pressure	NN	_	31	nmod
35	without	without	IN	_	37	case
36	compensatory	compensatory	JJ	_	37	amod
37	tachycardia	tachycardia	NN	_	31	nmod
38	.	.	.	_	12	punct

1	Exaggerated	exaggerated	JJ	_	3	amod
2	hypertensive	hypertensive	JJ	_	3	amod
3	responses	response	NNS	_	6	nsubjpass
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	auxpass
6	reported	report	VBN	_	0	ROOT
7	from	from	IN	_	10	case
8	the	the	DT	_	10	det
9	combined	combine	VBN	_	10	amod
10	use	use	NN	_	6	nmod
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	and	and	CC	_	12	cc
14	drug2	drug2	NN	_	12	conj
15	,	,	,	_	12	punct
16	including	include	VBG	_	17	case
17	those	those	DT	_	12	nmod
18	contained	contain	VBN	_	17	acl
19	in	in	IN	_	22	case
20	proprietary	proprietary	JJ	_	22	amod
21	cold	cold	JJ	_	22	amod
22	remedies	remedy	NNS	_	18	nmod
23	and	and	CC	_	22	cc
24	vasoconstrictive	vasoconstrictive	JJ	_	26	amod
25	nasal	nasal	JJ	_	26	amod
26	drops	drop	NNS	_	22	conj
27	.	.	.	_	6	punct

1	Patients	patient	NNS	_	6	nsubjpass
2	receiving	receive	VBG	_	1	acl
3	drug1	drug1	NN	_	2	dobj
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	warned	warn	VBN	_	0	ROOT
7	of	of	IN	_	10	case
8	this	this	DT	_	10	det
9	potential	potential	JJ	_	10	amod
10	hazard	hazard	NN	_	6	nmod
11	.	.	.	_	6	punct

1	Blunting	blunt	VBG	_	12	nsubjpass
2	of	of	IN	_	5	case
3	the	the	DT	_	5	det
4	antihypertensive	antihypertensive	JJ	_	5	amod
5	effect	effect	NN	_	1	nmod
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	by	by	IN	_	9	case
9	drug2	drug2	NN	_	5	nmod
10	has	have	VBZ	_	12	aux
11	been	be	VBN	_	12	auxpass
12	reported	report	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	No	no	DT	_	3	neg
2	significant	significant	JJ	_	3	amod
3	interactions	interaction	NNS	_	22	nsubjpass
4	with	with	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	,	,	,	_	5	punct
7	drug2	drug2	NN	_	5	conj
8	,	,	,	_	5	punct
9	drug3	drug3	NN	_	5	conj
10	,	,	,	_	5	punct
11	drug4	drug4	NN	_	5	conj
12	,	,	,	_	5	punct
13	oral	oral	JJ	_	14	amod
14	drug5	drug5	NN	_	5	conj
15	,	,	,	_	5	punct
16	drug6	drug6	NN	_	5	conj
17	,	,	,	_	5	punct
18	or	or	CC	_	5	cc
19	drug7	drug7	NN	_	5	conj
20	have	have	VBP	_	22	aux
21	been	be	VBN	_	22	auxpass
22	observed	observe	VBN	_	0	ROOT
23	.	.	.	_	22	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	enhance	enhance	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	effects	effect	NNS	_	3	dobj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	,	,	,	_	7	punct
9	drug3	drug3	NN	_	7	conj
10	,	,	,	_	7	punct
11	drug4	drug4	NN	_	7	conj
12	,	,	,	_	7	punct
13	and	and	CC	_	7	cc
14	other	other	JJ	_	15	amod
15	drug5	drug5	NN	_	7	conj
16	.	.	.	_	3	punct

1	drug1	drug1	NN	_	2	nsubj
2	prolong	prolong	VB	_	0	ROOT
3	and	and	CC	_	2	cc
4	intensify	intensify	VB	_	2	conj
5	the	the	DT	_	7	det
6	anticholinergic	anticholinergic	JJ	_	7	amod
7	effects	effect	NNS	_	2	dobj
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	.	.	.	_	2	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	reduce	reduce	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	antihypertensive	antihypertensive	JJ	_	6	amod
6	effects	effect	NNS	_	3	dobj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	,	,	,	_	8	punct
10	drug3	drug3	NN	_	8	conj
11	,	,	,	_	8	punct
12	drug4	drug4	NN	_	8	conj
13	and	and	CC	_	8	cc
14	drug5	drug5	NN	_	8	conj
15	.	.	.	_	3	punct

1	Effects	effect	NNS	_	5	nsubjpass
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	are	be	VBP	_	5	auxpass
5	increased	increase	VBN	_	0	ROOT
6	with	with	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drug3	drug3	NN	_	7	conj
10	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	such	such	JJ	_	4	case
3	as	as	IN	_	2	mwe
4	drug2	drug2	NN	_	1	nmod
5	or	or	CC	_	4	cc
6	drug3	drug3	NN	_	4	conj
7	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	.	.	.	_	1	punct

1	No	no	DT	_	3	neg
2	separate	separate	JJ	_	3	amod
3	information	information	NN	_	0	ROOT
4	available	available	JJ	_	3	amod

1	Patients	patient	NNS	_	10	nsubj
2	who	who	WP	_	4	nsubj
3	are	be	VBP	_	4	aux
4	applying	apply	VBG	_	1	acl:relcl
5	drug1	drug1	NN	_	6	compound
6	gel	gel	NN	_	4	dobj
7	should	should	MD	_	10	aux
8	not	not	RB	_	10	neg
9	concurrently	concurrently	RB	_	10	advmod
10	use	use	VB	_	0	ROOT
11	products	product	NNS	_	10	dobj
12	that	that	WDT	_	13	nsubj
13	contain	contain	VBP	_	11	acl:relcl
14	drug2	drug2	NN	_	13	dobj
15	-LRB-	-lrb-	-LRB-	_	16	punct
16	N	n	NN	_	14	dep
17	,	,	,	_	16	punct
18	drug3	drug3	NN	_	16	appos
19	-RRB-	-rrb-	-RRB-	_	16	punct
20	,	,	,	_	14	punct
21	a	a	DT	_	23	det
22	common	common	JJ	_	23	amod
23	component	component	NN	_	14	appos
24	of	of	IN	_	27	case
25	insect	insect	JJ	_	27	amod
26	repellent	repellent	NN	_	27	compound
27	products	product	NNS	_	23	nmod
28	.	.	.	_	10	punct

1	Animal	animal	NN	_	3	compound
2	toxicology	toxicology	NN	_	3	compound
3	studies	study	NNS	_	4	nsubj
4	showed	show	VBD	_	0	ROOT
5	increased	increase	VBN	_	7	amod
6	drug1	drug1	NN	_	7	compound
7	toxicity	toxicity	NN	_	4	dobj
8	when	when	WRB	_	11	advmod
9	drug2	drug2	NN	_	11	nsubjpass
10	was	be	VBD	_	11	auxpass
11	included	include	VBN	_	4	advcl
12	as	as	IN	_	13	case
13	proof	proof	NN	_	11	nmod
14	of	of	IN	_	16	case
15	the	the	DT	_	16	det
16	formulation	formulation	NN	_	13	nmod
17	.	.	.	_	4	punct

1	Although	although	IN	_	3	mark
2	there	there	EX	_	3	expl
3	was	be	VBD	_	40	advcl
4	no	no	DT	_	6	neg
5	clinical	clinical	JJ	_	6	amod
6	evidence	evidence	NN	_	3	nsubj
7	in	in	IN	_	10	case
8	the	the	DT	_	10	det
9	vehicle-controlled	vehicle-controlled	JJ	_	10	amod
10	studies	study	NNS	_	3	nmod
11	of	of	IN	_	13	case
12	drug	drug	NN	_	13	compound
13	interactions	interaction	NNS	_	10	nmod
14	with	with	IN	_	16	case
15	systemic	systemic	JJ	_	16	amod
16	drug1	drug1	NN	_	13	nmod
17	,	,	,	_	16	punct
18	including	include	VBG	_	19	case
19	drug2	drug2	NN	_	16	nmod
20	,	,	,	_	19	punct
21	drug3	drug3	NN	_	19	conj
22	,	,	,	_	19	punct
23	and	and	CC	_	19	cc
24	drug4	drug4	NN	_	19	conj
25	,	,	,	_	40	punct
26	the	the	DT	_	27	det
27	effect	effect	NN	_	40	nsubjpass
28	of	of	IN	_	30	case
29	drug5	drug5	NN	_	30	compound
30	gel	gel	NN	_	27	nmod
31	on	on	IN	_	34	case
32	the	the	DT	_	34	det
33	steady-state	steady-state	JJ	_	34	amod
34	concentrations	concentration	NNS	_	27	nmod
35	of	of	IN	_	37	case
36	these	these	DT	_	37	det
37	drugs	drug	NNS	_	34	nmod
38	is	be	VBZ	_	40	auxpass
39	not	not	RB	_	40	neg
40	known	know	VBN	_	0	ROOT
41	.	.	.	_	40	punct

1	No	no	DT	_	4	neg
2	drug	drug	NN	_	4	compound
3	interaction	interaction	NN	_	4	compound
4	data	datum	NNS	_	6	nsubj
5	are	be	VBP	_	6	cop
6	available	available	JJ	_	0	ROOT
7	on	on	IN	_	9	case
8	concomitant	concomitant	JJ	_	9	amod
9	administration	administration	NN	_	6	nmod
10	of	of	IN	_	12	case
11	drug1	drug1	NN	_	12	compound
12	gel	gel	NN	_	9	nmod
13	and	and	CC	_	12	cc
14	systemic	systemic	JJ	_	16	amod
15	anti-KS	anti-ks	JJ	_	16	amod
16	agents	agent	NNS	_	12	conj
17	.	.	.	_	6	punct

1	Pharmacokinetic	pharmacokinetic	JJ	_	3	amod
2	interaction	interaction	NN	_	3	compound
3	studies	study	NNS	_	9	nsubjpass
4	with	with	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	in	in	IN	_	7	case
7	adults	adult	NNS	_	5	nmod
8	were	be	VBD	_	9	auxpass
9	conducted	conduct	VBN	_	0	ROOT
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	,	,	,	_	11	punct
13	drug3	drug3	NN	_	11	conj
14	,	,	,	_	11	punct
15	drug4	drug4	NN	_	11	conj
16	,	,	,	_	11	punct
17	drug5	drug5	NN	_	11	conj
18	and	and	CC	_	11	cc
19	drug6	drug6	NN	_	11	conj
20	.	.	.	_	9	punct

1	No	no	DT	_	2	neg
2	interactions	interaction	NNS	_	4	nsubjpass
3	were	be	VBD	_	4	auxpass
4	observed	observe	VBN	_	0	ROOT
5	.	.	.	_	4	punct

1	In	in	IN	_	5	case
2	a	a	DT	_	5	det
3	multiple	multiple	JJ	_	5	amod
4	dose	dose	NN	_	5	compound
5	study	study	NN	_	39	nmod
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	-LRB-	-lrb-	-LRB-	_	10	punct
9	400	400	CD	_	10	nummod
10	mg	mg	NN	_	7	dep
11	once	once	RB	_	12	advmod
12	daily	daily	RB	_	10	advmod
13	for	for	IN	_	15	case
14	3	3	CD	_	15	nummod
15	days	day	NNS	_	10	nmod
16	-RRB-	-rrb-	-RRB-	_	10	punct
17	and	and	CC	_	7	cc
18	drug2	drug2	NN	_	7	conj
19	-LRB-	-lrb-	-LRB-	_	21	punct
20	20	20	CD	_	21	nummod
21	mg	mg	NN	_	18	dep
22	once	once	RB	_	23	advmod
23	daily	daily	RB	_	21	advmod
24	for	for	IN	_	26	case
25	3	3	CD	_	26	nummod
26	days	day	NNS	_	21	nmod
27	-RRB-	-rrb-	-RRB-	_	21	punct
28	,	,	,	_	39	punct
29	a	a	DT	_	32	det
30	16	16	CD	_	31	compound
31	%	%	NN	_	32	amod
32	decrease	decrease	NN	_	39	nsubjpass
33	in	in	IN	_	35	case
34	the	the	DT	_	35	det
35	clearance	clearance	NN	_	32	nmod
36	of	of	IN	_	37	case
37	drug3	drug3	NN	_	35	nmod
38	was	be	VBD	_	39	auxpass
39	observed	observe	VBN	_	0	ROOT
40	.	.	.	_	39	punct

1	The	the	DT	_	2	det
2	disposition	disposition	NN	_	7	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	was	be	VBD	_	7	auxpass
6	not	not	RB	_	7	neg
7	altered	alter	VBN	_	0	ROOT
8	by	by	IN	_	11	case
9	concomitant	concomitant	JJ	_	11	amod
10	drug2	drug2	NN	_	11	compound
11	administration	administration	NN	_	7	nmod
12	.	.	.	_	7	punct

1	Drug-Drug	Drug-Drug	NNP	_	2	compound
2	Interactions	interaction	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	No	no	DT	_	8	neg
5	clinically	clinically	RB	_	6	advmod
6	significant	significant	JJ	_	8	amod
7	drug	drug	NN	_	8	compound
8	interactions	interaction	NNS	_	11	nsubjpass
9	have	have	VBP	_	11	aux
10	been	be	VBN	_	11	auxpass
11	found	find	VBN	_	2	dep
12	with	with	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	at	at	IN	_	17	case
15	a	a	DT	_	17	det
16	low	low	JJ	_	17	amod
17	dose	dose	NN	_	11	nmod
18	,	,	,	_	17	punct
19	drug2	drug2	NN	_	17	conj
20	,	,	,	_	17	punct
21	drug3	drug3	NN	_	17	conj
22	,	,	,	_	17	punct
23	drug4	drug4	NN	_	17	conj
24	,	,	,	_	17	punct
25	or	or	CC	_	17	cc
26	drug5	drug5	NN	_	17	conj
27	.	.	.	_	2	punct

1	There	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	a	a	DT	_	5	det
4	small	small	JJ	_	5	amod
5	decrease	decrease	NN	_	2	nsubj
6	in	in	IN	_	8	case
7	the	the	DT	_	8	det
8	clearance	clearance	NN	_	5	nmod
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	caused	cause	VBN	_	10	acl
12	by	by	IN	_	15	case
13	a	a	DT	_	15	det
14	400-mg	400-mg	JJ	_	15	amod
15	dose	dose	NN	_	11	nmod
16	of	of	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	;	;	:	_	2	punct

1	it	it	PRP	_	3	nsubj
2	is	be	VBZ	_	3	cop
3	possible	possible	JJ	_	0	ROOT
4	that	that	IN	_	9	mark
5	larger	larger	JJR	_	7	amod
6	drug1	drug1	NN	_	7	compound
7	doses	dose	NNS	_	9	nsubj
8	could	could	MD	_	9	aux
9	have	have	VB	_	3	ccomp
10	a	a	DT	_	12	det
11	greater	greater	JJR	_	12	amod
12	effect	effect	NN	_	9	dobj
13	.	.	.	_	3	punct

1	The	the	DT	_	3	det
2	hypotensive	hypotensive	JJ	_	3	amod
3	effect	effect	NN	_	7	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	is	be	VBZ	_	7	auxpass
7	augmented	augment	VBN	_	0	ROOT
8	by	by	IN	_	9	case
9	that	that	DT	_	7	nmod
10	of	of	IN	_	13	case
11	most	most	RBS	_	13	advmod
12	other	other	JJ	_	13	amod
13	drug2	drug2	NN	_	9	nmod
14	,	,	,	_	13	punct
15	including	include	VBG	_	16	case
16	drug3	drug3	NN	_	13	nmod
17	,	,	,	_	16	punct
18	negative	negative	JJ	_	20	amod
19	inotropic	inotropic	JJ	_	20	amod
20	agents	agent	NNS	_	16	conj
21	,	,	,	_	16	punct
22	and	and	CC	_	16	cc
23	inhaled	inhale	VBD	_	24	amod
24	drug4	drug4	NN	_	16	conj
25	.	.	.	_	7	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	16	nsubj
4	,	,	,	_	3	punct
5	given	give	VBN	_	3	acl
6	concomitantly	concomitantly	RB	_	5	advmod
7	with	with	IN	_	8	case
8	drug3	drug3	NN	_	5	nmod
9	or	or	CC	_	8	cc
10	60	60	CD	_	11	nummod
11	minutes	minute	NNS	_	8	conj
12	following	follow	VBG	_	14	case
13	drug4	drug4	NN	_	14	compound
14	administration	administration	NN	_	5	nmod
15	,	,	,	_	3	punct
16	decreased	decrease	VBD	_	1	dep
17	drug5	drug5	NN	_	18	compound
18	bioavailability	bioavailability	NN	_	16	dobj
19	by	by	IN	_	22	case
20	approximately	approximately	RB	_	21	advmod
21	25	25	CD	_	22	nummod
22	%	%	NN	_	16	nmod
23	.	.	.	_	1	punct

1	Thus	thus	RB	_	11	advmod
2	,	,	,	_	11	punct
3	concomitant	concomitant	JJ	_	4	amod
4	administration	administration	NN	_	11	nsubjpass
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	drug2	drug2	NN	_	6	conj
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	avoided	avoid	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	7	nsubj
4	is	be	VBZ	_	7	cop
5	a	a	DT	_	7	det
6	potent	potent	JJ	_	7	amod
7	inhibitor	inhibitor	NN	_	1	dep
8	of	of	IN	_	12	case
9	the	the	DT	_	12	det
10	cytochrome	cytochrome	NN	_	12	compound
11	P-450	p-450	NN	_	12	compound
12	isozymes	isozyme	NNS	_	7	nmod
13	responsible	responsible	JJ	_	12	amod
14	for	for	IN	_	16	case
15	the	the	DT	_	16	det
16	metabolism	metabolism	NN	_	13	nmod
17	of	of	IN	_	18	case
18	drug3	drug3	NN	_	16	nmod
19	.	.	.	_	1	punct

1	In	in	IN	_	4	case
2	a	a	DT	_	4	det
3	multiple-dose	multiple-dose	JJ	_	4	amod
4	study	study	NN	_	7	nmod
5	,	,	,	_	7	punct
6	drug1	drug1	NN	_	7	nsubj
7	caused	cause	VBD	_	0	ROOT
8	a	a	DT	_	10	det
9	dose-related	dose-related	JJ	_	10	amod
10	increase	increase	NN	_	7	dobj
11	in	in	IN	_	15	case
12	the	the	DT	_	15	det
13	mean	mean	NN	_	15	compound
14	elimination	elimination	NN	_	15	compound
15	half-life	half-life	NN	_	10	nmod
16	of	of	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	,	,	,	_	7	punct
19	thereby	thereby	RB	_	20	advmod
20	decreasing	decrease	VBG	_	7	dep
21	the	the	DT	_	22	det
22	clearance	clearance	NN	_	20	dobj
23	of	of	IN	_	24	case
24	drug3	drug3	NN	_	22	nmod
25	by	by	IN	_	29	case
26	up	up	RB	_	28	dep
27	to	to	TO	_	26	mwe
28	80	80	CD	_	29	nummod
29	%	%	NN	_	20	nmod
30	and	and	CC	_	20	cc
31	leading	lead	VBG	_	20	conj
32	to	to	TO	_	35	case
33	a	a	DT	_	35	det
34	five-fold	five-fold	JJ	_	35	amod
35	increase	increase	NN	_	31	nmod
36	in	in	IN	_	38	case
37	the	the	DT	_	38	det
38	AUC	auc	NN	_	35	nmod
39	and	and	CC	_	35	cc
40	the	the	DT	_	41	det
41	half-life	half-life	NN	_	35	conj
42	of	of	IN	_	43	case
43	drug4	drug4	NN	_	41	nmod
44	.	.	.	_	7	punct

1	Trough	trough	NN	_	4	compound
2	plasma	plasma	NN	_	4	compound
3	drug1	drug1	NN	_	4	compound
4	levels	level	NNS	_	9	nsubj
5	were	be	VBD	_	9	cop
6	also	also	RB	_	9	advmod
7	20	20	CD	_	8	nummod
8	%	%	NN	_	9	nmod:npmod
9	higher	higher	JJR	_	0	ROOT
10	when	when	WRB	_	15	advmod
11	drug2	drug2	NN	_	15	nsubjpass
12	and	and	CC	_	11	cc
13	drug3	drug3	NN	_	11	conj
14	were	be	VBD	_	15	auxpass
15	administered	administer	VBN	_	9	advcl
16	concomitantly	concomitantly	RB	_	15	advmod
17	.	.	.	_	9	punct

1	drug1	drug1	NN	_	0	ROOT
2	-	-	:	_	1	punct
3	related	related	JJ	_	5	amod
4	adverse	adverse	JJ	_	5	amod
5	effects	effect	NNS	_	7	nsubj
6	have	have	VBP	_	7	aux
7	occurred	occur	VBN	_	1	dep
8	in	in	IN	_	9	case
9	patients	patient	NNS	_	7	nmod
10	consuming	consume	VBG	_	9	acl
11	drug2	drug2	NN	_	10	dobj
12	while	while	IN	_	7	xcomp
13	on	on	IN	_	14	case
14	therapy	therapy	NN	_	12	nmod
15	with	with	IN	_	16	case
16	drug3	drug3	NN	_	14	nmod
17	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Elevated	elevated	JJ	_	5	amod
4	serum	serum	NN	_	5	compound
5	levels	level	NNS	_	10	nsubjpass
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	have	have	VBP	_	10	aux
9	been	be	VBN	_	10	auxpass
10	reported	report	VBN	_	1	appos
11	with	with	IN	_	13	case
12	concomitant	concomitant	JJ	_	13	amod
13	use	use	NN	_	10	nmod
14	of	of	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	with	with	IN	_	18	case
17	other	other	JJ	_	18	amod
18	members	member	NNS	_	13	nmod
19	of	of	IN	_	21	case
20	the	the	DT	_	21	det
21	drug4	drug4	NN	_	18	nmod
22	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	raise	raise	VB	_	1	appos
6	serum	serum	NN	_	8	compound
7	drug3	drug3	NN	_	8	compound
8	levels	level	NNS	_	5	dobj
9	in	in	IN	_	11	case
10	some	some	DT	_	11	det
11	individuals	individual	NNS	_	5	nmod
12	.	.	.	_	1	punct

1	If	if	IN	_	9	mark
2	signs	sign	NNS	_	9	nsubj
3	and	and	CC	_	2	cc
4	symptoms	symptom	NNS	_	2	conj
5	suggestive	suggestive	JJ	_	2	amod
6	of	of	IN	_	8	case
7	drug1	drug1	NN	_	8	compound
8	toxicity	toxicity	NN	_	5	nmod
9	occur	occur	VBP	_	20	advcl
10	when	when	WRB	_	15	advmod
11	drug2	drug2	NN	_	15	nsubjpass
12	and	and	CC	_	11	cc
13	drug3	drug3	NN	_	11	conj
14	are	be	VBP	_	15	auxpass
15	given	give	VBN	_	9	advcl
16	concomitantly	concomitantly	RB	_	15	advmod
17	,	,	,	_	20	punct
18	physicians	physician	NNS	_	20	nsubjpass
19	are	be	VBP	_	20	auxpass
20	advised	advise	VBN	_	0	ROOT
21	to	to	TO	_	22	mark
22	obtain	obtain	VB	_	20	xcomp
23	serum	serum	NN	_	25	compound
24	drug4	drug4	NN	_	25	compound
25	levels	level	NNS	_	22	dobj
26	and	and	CC	_	22	cc
27	adjust	adjust	VBP	_	22	conj
28	drug5	drug5	NN	_	29	compound
29	doses	dose	NNS	_	27	dobj
30	appropriately	appropriately	RB	_	27	advmod
31	.	.	.	_	20	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Seizures	seizure	NNS	_	6	nsubjpass
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	auxpass
6	reported	report	VBN	_	1	appos
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	taking	take	VBG	_	8	acl
10	drug2	drug2	NN	_	9	dobj
11	concomitantly	concomitantly	RB	_	9	advmod
12	with	with	IN	_	15	case
13	the	the	DT	_	15	det
14	drug3	drug3	NN	_	15	compound
15	drug4	drug4	NN	_	9	nmod
16	.	.	.	_	1	punct

1	Animal	animal	NN	_	2	compound
2	studies	study	NNS	_	4	nsubj
3	also	also	RB	_	4	advmod
4	suggest	suggest	VBP	_	0	ROOT
5	an	a	DT	_	7	det
6	increased	increase	VBN	_	7	amod
7	potential	potential	NN	_	4	dobj
8	for	for	IN	_	9	case
9	seizures	seizure	NNS	_	7	nmod
10	when	when	WRB	_	15	advmod
11	these	these	DT	_	13	det
12	two	two	CD	_	13	nummod
13	drugs	drug	NNS	_	15	nsubjpass
14	are	be	VBP	_	15	auxpass
15	given	give	VBN	_	4	advcl
16	concomitantly	concomitantly	RB	_	15	advmod
17	.	.	.	_	4	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	not	not	RB	_	4	neg
4	approved	approve	VBN	_	0	ROOT
5	in	in	IN	_	8	case
6	the	the	DT	_	8	det
7	United	United	NNP	_	8	compound
8	States	States	NNPS	_	4	nmod
9	at	at	IN	_	11	case
10	this	this	DT	_	11	det
11	time	time	NN	_	4	nmod
12	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	:	:	:	_	1	punct
5	drug3	drug3	NN	_	6	compound
6	form	form	NN	_	7	nsubj
7	chelates	chelate	VBZ	_	1	dep
8	with	with	IN	_	10	case
9	metal	metal	NN	_	10	compound
10	cations	cation	NNS	_	7	nmod
11	.	.	.	_	1	punct

1	Therefore	therefore	RB	_	0	ROOT
2	,	,	,	_	1	punct
3	administration	administration	NN	_	2	root
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	with	with	IN	_	7	case
7	drug2	drug2	NN	_	3	nmod
8	containing	contain	VBG	_	7	acl
9	drug3	drug3	NN	_	8	dobj
10	,	,	,	_	9	punct
11	drug4	drug4	NN	_	9	conj
12	,	,	,	_	9	punct
13	or	or	CC	_	9	cc
14	drug5	drug5	NN	_	9	conj
15	;	;	:	_	3	punct

1	with	with	IN	_	2	case
2	drug1	drug1	NN	_	0	ROOT
3	;	;	:	_	2	punct

1	with	with	IN	_	5	case
2	divalent	divalent	JJ	_	5	amod
3	or	or	CC	_	2	cc
4	trivalent	trivalent	JJ	_	2	conj
5	cations	cation	NNS	_	0	ROOT
6	such	such	JJ	_	8	case
7	as	as	IN	_	6	mwe
8	drug1	drug1	NN	_	5	nmod
9	;	;	:	_	5	punct

1	or	or	CC	_	8	cc
2	with	with	IN	_	3	case
3	drug1	drug1	NN	_	8	nmod
4	containing	contain	VBG	_	3	acl
5	drug2	drug2	NN	_	4	dobj
6	may	may	MD	_	8	aux
7	substantially	substantially	RB	_	8	advmod
8	interfere	interfere	VB	_	0	ROOT
9	with	with	IN	_	11	case
10	drug	drug	NN	_	11	compound
11	absorption	absorption	NN	_	8	nmod
12	and	and	CC	_	11	cc
13	result	result	NN	_	11	conj
14	in	in	IN	_	16	case
15	insufficient	insufficient	JJ	_	16	amod
16	plasma	plasma	NN	_	8	nmod
17	and	and	CC	_	16	cc
18	tissue	tissue	NN	_	20	compound
19	drug3	drug3	NN	_	20	compound
20	concentrations	concentration	NNS	_	16	conj
21	.	.	.	_	8	punct

1	drug1	drug1	NN	_	6	nsubj
2	containing	contain	VBG	_	1	acl
3	drug2	drug2	NN	_	2	dobj
4	and	and	CC	_	3	cc
5	drug3	drug3	NN	_	3	conj
6	reduce	reduce	VB	_	0	ROOT
7	the	the	DT	_	9	det
8	oral	oral	JJ	_	9	amod
9	absorption	absorption	NN	_	6	dobj
10	of	of	IN	_	11	case
11	drug4	drug4	NN	_	9	nmod
12	by	by	IN	_	14	case
13	75	75	CD	_	14	nummod
14	%	%	NN	_	6	nmod
15	.	.	.	_	6	punct

1	The	the	DT	_	3	det
2	oral	oral	JJ	_	3	amod
3	bioavailability	bioavailability	NN	_	7	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	is	be	VBZ	_	7	auxpass
7	reduced	reduce	VBN	_	0	ROOT
8	by	by	IN	_	10	case
9	60	60	CD	_	10	nummod
10	%	%	NN	_	7	nmod
11	with	with	IN	_	12	case
12	coadministration	coadministration	NN	_	7	nmod
13	of	of	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	.	.	.	_	7	punct

1	These	these	DT	_	2	det
2	agents	agent	NNS	_	6	nsubjpass
3	should	should	MD	_	6	aux
4	not	not	RB	_	6	neg
5	be	be	VB	_	6	auxpass
6	taken	take	VBN	_	0	ROOT
7	for	for	IN	_	9	case
8	8	8	CD	_	9	nummod
9	hours	hour	NNS	_	6	nmod
10	before	before	IN	_	14	case
11	or	or	CC	_	10	cc
12	for	for	IN	_	10	conj
13	2	2	CD	_	14	nummod
14	hours	hour	NNS	_	9	nmod
15	after	after	IN	_	17	case
16	drug1	drug1	NN	_	17	compound
17	administration	administration	NN	_	6	nmod
18	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	7	nsubj
4	is	be	VBZ	_	7	cop
5	a	a	DT	_	7	det
6	potent	potent	JJ	_	7	amod
7	inhibitor	inhibitor	NN	_	1	dep
8	of	of	IN	_	12	case
9	the	the	DT	_	12	det
10	cytochrome	cytochrome	NN	_	12	compound
11	P-450	p-450	NN	_	12	compound
12	isozymes	isozyme	NNS	_	7	nmod
13	responsible	responsible	JJ	_	12	amod
14	for	for	IN	_	16	case
15	the	the	DT	_	16	det
16	metabolism	metabolism	NN	_	13	nmod
17	of	of	IN	_	18	case
18	drug3	drug3	NN	_	16	nmod
19	.	.	.	_	1	punct

1	drug1	drug1	NN	_	2	nsubj
2	interferes	interfere	VBZ	_	0	ROOT
3	with	with	IN	_	5	case
4	the	the	DT	_	5	det
5	metabolism	metabolism	NN	_	2	nmod
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	resulting	result	VBG	_	5	acl
9	in	in	IN	_	17	case
10	a	a	DT	_	17	det
11	42	42	CD	_	15	compound
12	%	%	NN	_	15	dep
13	to	to	TO	_	15	dep
14	74	74	CD	_	15	compound
15	%	%	NN	_	17	nummod
16	dose-related	dose-related	JJ	_	17	amod
17	decrease	decrease	NN	_	8	nmod
18	in	in	IN	_	20	case
19	drug3	drug3	NN	_	20	compound
20	clearance	clearance	NN	_	17	nmod
21	and	and	CC	_	17	cc
22	a	a	DT	_	29	det
23	subsequent	subsequent	JJ	_	29	amod
24	260	260	CD	_	28	compound
25	%	%	NN	_	28	dep
26	to	to	TO	_	28	dep
27	350	350	CD	_	28	compound
28	%	%	NN	_	29	nummod
29	increase	increase	NN	_	17	conj
30	in	in	IN	_	33	case
31	serum	serum	NN	_	33	compound
32	theophylline	theophylline	NN	_	33	compound
33	levels	level	NNS	_	29	nmod
34	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	-	-	:	_	1	punct
3	related	related	JJ	_	5	amod
4	adverse	adverse	JJ	_	5	amod
5	effects	effect	NNS	_	7	nsubj
6	have	have	VBP	_	7	aux
7	occurred	occur	VBN	_	1	dep
8	in	in	IN	_	9	case
9	patients	patient	NNS	_	7	nmod
10	when	when	WRB	_	15	advmod
11	drug2	drug2	NN	_	15	nsubjpass
12	and	and	CC	_	11	cc
13	drug3	drug3	NN	_	11	conj
14	were	be	VBD	_	15	auxpass
15	coadministered	coadminister	VBN	_	9	acl:relcl
16	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	8	nsubj
4	,	,	,	_	3	punct
5	including	include	VBG	_	6	case
6	drug3	drug3	NN	_	3	nmod
7	,	,	,	_	3	punct
8	decrease	decrease	VB	_	1	dep
9	the	the	DT	_	10	det
10	clearance	clearance	NN	_	8	dobj
11	of	of	IN	_	12	case
12	drug4	drug4	NN	_	10	nmod
13	,	,	,	_	8	punct
14	the	the	DT	_	17	det
15	less	less	RBR	_	16	advmod
16	active	active	JJ	_	17	amod
17	isomer	isomer	NN	_	8	dobj
18	of	of	IN	_	20	case
19	racemic	racemic	JJ	_	20	amod
20	drug5	drug5	NN	_	17	nmod
21	.	.	.	_	1	punct

1	drug1	drug1	NN	_	4	nsubj
2	does	do	VBZ	_	4	aux
3	not	not	RB	_	4	neg
4	affect	affect	VB	_	0	ROOT
5	the	the	DT	_	6	det
6	clearance	clearance	NN	_	4	dobj
7	of	of	IN	_	10	case
8	the	the	DT	_	10	det
9	active	active	JJ	_	10	amod
10	S-isomer	s-isomer	NN	_	6	nmod
11	,	,	,	_	4	punct
12	and	and	CC	_	4	cc
13	changes	change	NNS	_	20	nsubjpass
14	in	in	IN	_	16	case
15	clotting	clot	VBG	_	16	amod
16	time	time	NN	_	13	nmod
17	have	have	VBP	_	20	aux
18	not	not	RB	_	20	neg
19	been	be	VBN	_	20	auxpass
20	observed	observe	VBN	_	4	conj
21	when	when	WRB	_	26	advmod
22	drug2	drug2	NN	_	26	nsubjpass
23	and	and	CC	_	22	cc
24	drug3	drug3	NN	_	22	conj
25	were	be	VBD	_	26	auxpass
26	coadministered	coadminister	VBN	_	20	advcl
27	.	.	.	_	4	punct

1	Nevertheless	nevertheless	RB	_	13	advmod
2	,	,	,	_	13	punct
3	the	the	DT	_	5	det
4	prothrombin	prothrombin	NN	_	5	compound
5	time	time	NN	_	13	nsubjpass
6	or	or	CC	_	5	cc
7	other	other	JJ	_	10	amod
8	suitable	suitable	JJ	_	10	amod
9	coagulation	coagulation	NN	_	10	compound
10	test	test	NN	_	5	conj
11	should	should	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	monitored	monitor	VBN	_	0	ROOT
14	when	when	WRB	_	22	advmod
15	drug1	drug1	NN	_	22	nsubjpass
16	or	or	CC	_	15	cc
17	its	its	PRP$	_	18	nmod:poss
18	derivatives	derivative	NNS	_	15	conj
19	and	and	CC	_	15	cc
20	drug2	drug2	NN	_	15	conj
21	are	be	VBP	_	22	auxpass
22	given	give	VBN	_	13	advcl
23	concomitantly	concomitantly	RB	_	22	advmod
24	.	.	.	_	13	punct

1	Patients	patient	NNS	_	24	nsubj
2	receiving	receive	VBG	_	1	acl
3	other	other	JJ	_	4	amod
4	drug1	drug1	NN	_	2	dobj
5	,	,	,	_	4	punct
6	drug2	drug2	NN	_	4	conj
7	,	,	,	_	4	punct
8	drug3	drug3	NN	_	4	conj
9	,	,	,	_	4	punct
10	or	or	CC	_	4	cc
11	other	other	JJ	_	12	amod
12	drug4	drug4	NN	_	4	conj
13	-LRB-	-lrb-	-LRB-	_	15	punct
14	including	include	VBG	_	15	case
15	drug5	drug5	NN	_	12	nmod
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	concomitantly	concomitantly	RB	_	2	advmod
18	with	with	IN	_	19	case
19	drug6	drug6	NN	_	2	nmod
20	and	and	CC	_	19	cc
21	drug7	drug7	NN	_	22	compound
22	tablets	tablet	NNS	_	19	conj
23	may	may	MD	_	24	aux
24	exhibit	exhibit	VB	_	0	ROOT
25	an	a	DT	_	28	det
26	additive	additive	JJ	_	28	amod
27	CNS	cns	NN	_	28	compound
28	depression	depression	NN	_	24	dobj
29	.	.	.	_	24	punct

1	When	when	WRB	_	5	advmod
2	combined	combine	VBN	_	3	amod
3	therapy	therapy	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	contemplated	contemplate	VBN	_	16	advcl
6	,	,	,	_	16	punct
7	the	the	DT	_	8	det
8	dose	dose	NN	_	16	nsubjpass
9	of	of	IN	_	10	case
10	one	one	CD	_	8	nmod
11	or	or	CC	_	10	cc
12	both	both	DT	_	13	det
13	agents	agent	NNS	_	10	conj
14	should	should	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	reduced	reduce	VBN	_	0	ROOT
17	.	.	.	_	16	punct

1	The	the	DT	_	2	det
2	use	use	NN	_	11	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	or	or	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	with	with	IN	_	9	case
8	drug3	drug3	NN	_	9	compound
9	preparations	preparation	NNS	_	2	nmod
10	may	may	MD	_	11	aux
11	increase	increase	VB	_	0	ROOT
12	the	the	DT	_	13	det
13	effect	effect	NN	_	11	dobj
14	of	of	IN	_	17	case
15	either	either	CC	_	17	cc:preconj
16	the	the	DT	_	17	det
17	drug4	drug4	NN	_	13	nmod
18	or	or	CC	_	17	cc
19	drug5	drug5	NN	_	17	conj
20	.	.	.	_	11	punct

1	The	the	DT	_	3	det
2	concurrent	concurrent	JJ	_	3	amod
3	use	use	NN	_	9	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	with	with	IN	_	7	case
7	drug2	drug2	NN	_	3	nmod
8	may	may	MD	_	9	aux
9	produce	produce	VB	_	0	ROOT
10	paralytic	paralytic	JJ	_	11	amod
11	ileus	ileus	NN	_	9	dobj
12	.	.	.	_	9	punct

1	drug1	drug1	NN	_	2	compound
2	use	use	NN	_	14	nsubjpass
3	in	in	IN	_	4	case
4	patients	patient	NNS	_	2	nmod
5	who	who	WP	_	7	nsubj
6	are	be	VBP	_	7	aux
7	receiving	receive	VBG	_	4	acl:relcl
8	high	high	JJ	_	9	amod
9	doses	dose	NNS	_	7	dobj
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	may	may	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	associated	associate	VBN	_	0	ROOT
15	with	with	IN	_	17	case
16	an	a	DT	_	17	det
17	increase	increase	NN	_	14	nmod
18	in	in	IN	_	21	case
19	serum	serum	NN	_	21	compound
20	drug3	drug3	NN	_	21	compound
21	levels	level	NNS	_	17	nmod
22	and	and	CC	_	17	cc
23	potential	potential	JJ	_	25	amod
24	drug4	drug4	NN	_	25	compound
25	toxicity	toxicity	NN	_	17	conj
26	.	.	.	_	14	punct

1	In	in	IN	_	2	case
2	case	case	NN	_	18	nmod
3	of	of	IN	_	5	case
4	drug1	drug1	NN	_	5	compound
5	toxicity	toxicity	NN	_	2	nmod
6	and/or	and/or	CC	_	5	cc
7	elevated	elevated	JJ	_	10	amod
8	serum	serum	NN	_	10	compound
9	drug2	drug2	NN	_	10	compound
10	levels	level	NNS	_	5	conj
11	,	,	,	_	18	punct
12	the	the	DT	_	13	det
13	dose	dose	NN	_	18	nsubjpass
14	of	of	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	should	should	MD	_	18	aux
17	be	be	VB	_	18	auxpass
18	reduced	reduce	VBN	_	0	ROOT
19	while	while	IN	_	23	mark
20	the	the	DT	_	21	det
21	patient	patient	NN	_	23	nsubj
22	is	be	VBZ	_	23	aux
23	receiving	receive	VBG	_	18	advcl
24	concomitant	concomitant	JJ	_	26	amod
25	drug4	drug4	NN	_	26	compound
26	therapy	therapy	NN	_	23	dobj
27	.	.	.	_	18	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	9	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	has	have	VBZ	_	9	aux
8	been	be	VBN	_	9	auxpass
9	reported	report	VBN	_	0	ROOT
10	to	to	TO	_	11	mark
11	result	result	VB	_	9	xcomp
12	in	in	IN	_	16	case
13	elevated	elevated	JJ	_	16	amod
14	drug3	drug3	NN	_	16	compound
15	serum	serum	NN	_	16	compound
16	levels	level	NNS	_	11	nmod
17	.	.	.	_	9	punct

1	There	there	EX	_	4	expl
2	have	have	VBP	_	4	aux
3	been	be	VBN	_	4	cop
4	reports	report	NNS	_	0	ROOT
5	of	of	IN	_	8	case
6	increased	increase	VBN	_	8	amod
7	anticoagulant	anticoagulant	JJ	_	8	amod
8	effects	effect	NNS	_	4	nmod
9	when	when	WRB	_	15	advmod
10	drug1	drug1	NN	_	15	nsubjpass
11	and	and	CC	_	10	cc
12	oral	oral	JJ	_	10	conj
13	drug2	drug2	NN	_	10	dep
14	were	be	VBD	_	15	auxpass
15	used	use	VBN	_	8	acl:relcl
16	concomitantly	concomitantly	RB	_	15	advmod
17	.	.	.	_	4	punct

1	Increased	increase	VBN	_	3	amod
2	anticoagulation	anticoagulation	JJ	_	3	amod
3	effects	effect	NNS	_	16	nsubj
4	due	due	JJ	_	6	case
5	to	to	TO	_	4	mwe
6	interactions	interaction	NNS	_	3	nmod
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	with	with	IN	_	12	case
10	various	various	JJ	_	12	amod
11	oral	oral	JJ	_	12	amod
12	anticoagulents	anticoagulent	NNS	_	6	nmod
13	may	may	MD	_	16	aux
14	be	be	VB	_	16	cop
15	more	more	RBR	_	16	advmod
16	pronounced	pronounced	JJ	_	0	ROOT
17	in	in	IN	_	19	case
18	the	the	DT	_	19	det
19	elderly	elderly	JJ	_	16	nmod
20	.	.	.	_	16	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	use	use	NN	_	11	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	or	or	CC	_	4	cc
8	drug3	drug3	NN	_	4	conj
9	has	have	VBZ	_	11	aux
10	been	be	VBN	_	11	auxpass
11	associated	associate	VBN	_	0	ROOT
12	in	in	IN	_	14	case
13	some	some	DT	_	14	det
14	patients	patient	NNS	_	11	nmod
15	with	with	IN	_	18	case
16	acute	acute	JJ	_	18	amod
17	ergot	ergot	NN	_	18	compound
18	toxicity	toxicity	NN	_	14	nmod
19	characterized	characterize	VBN	_	18	acl
20	by	by	IN	_	23	case
21	severe	severe	JJ	_	23	amod
22	peripheral	peripheral	JJ	_	23	amod
23	vasospasm	vasospasm	NN	_	19	nmod
24	and	and	CC	_	23	cc
25	dysesthesia	dysesthesia	NN	_	23	conj
26	.	.	.	_	11	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	decrease	decrease	VB	_	4	xcomp
7	the	the	DT	_	8	det
8	clearance	clearance	NN	_	6	dobj
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	drug3	drug3	NN	_	10	conj
13	and	and	CC	_	4	cc
14	thus	thus	RB	_	16	advmod
15	may	may	MD	_	16	aux
16	increase	increase	VB	_	4	conj
17	the	the	DT	_	19	det
18	pharmacologic	pharmacologic	JJ	_	19	amod
19	effect	effect	NN	_	16	dobj
20	of	of	IN	_	22	case
21	these	these	DT	_	22	det
22	drug4	drug4	NN	_	19	nmod
23	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	use	use	NN	_	18	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	in	in	IN	_	6	case
6	patients	patient	NNS	_	2	nmod
7	concurrently	concurrently	RB	_	8	advmod
8	taking	take	VBG	_	6	acl
9	drugs	drug	NNS	_	8	dobj
10	metabolized	metabolize	VBN	_	9	acl
11	by	by	IN	_	15	case
12	the	the	DT	_	15	det
13	cytochrome	cytochrome	NN	_	15	compound
14	P450	p450	NN	_	15	compound
15	system	system	NN	_	10	nmod
16	may	may	MD	_	18	aux
17	be	be	VB	_	18	auxpass
18	associated	associate	VBN	_	0	ROOT
19	with	with	IN	_	20	case
20	elevations	elevation	NNS	_	18	nmod
21	in	in	IN	_	23	case
22	serum	serum	NN	_	23	compound
23	levels	level	NNS	_	20	nmod
24	of	of	IN	_	27	case
25	these	these	DT	_	27	det
26	other	other	JJ	_	27	amod
27	drugs	drug	NNS	_	23	nmod
28	.	.	.	_	18	punct

1	There	there	EX	_	4	expl
2	have	have	VBP	_	4	aux
3	been	be	VBN	_	4	cop
4	reports	report	NNS	_	0	ROOT
5	of	of	IN	_	6	case
6	interactions	interaction	NNS	_	4	nmod
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	with	with	IN	_	10	case
10	drug2	drug2	NN	_	6	nmod
11	,	,	,	_	10	punct
12	drug3	drug3	NN	_	10	conj
13	,	,	,	_	10	punct
14	drug4	drug4	NN	_	10	conj
15	,	,	,	_	10	punct
16	drug5	drug5	NN	_	10	conj
17	,	,	,	_	10	punct
18	drug6	drug6	NN	_	10	conj
19	,	,	,	_	10	punct
20	drug7	drug7	NN	_	10	conj
21	,	,	,	_	10	punct
22	drug8	drug8	NN	_	10	conj
23	,	,	,	_	10	punct
24	drug9	drug9	NN	_	10	conj
25	,	,	,	_	10	punct
26	drug10	drug10	NN	_	10	conj
27	,	,	,	_	10	punct
28	drug11	drug11	NN	_	10	conj
29	,	,	,	_	10	punct
30	drug12	drug12	NN	_	10	conj
31	,	,	,	_	10	punct
32	drug13	drug13	NN	_	10	conj
33	,	,	,	_	10	punct
34	and	and	CC	_	10	cc
35	drug14	drug14	NN	_	10	conj
36	.	.	.	_	4	punct

1	Serum	serum	NN	_	2	compound
2	concentrations	concentration	NNS	_	13	nsubjpass
3	of	of	IN	_	4	case
4	drugs	drug	NNS	_	2	nmod
5	metabolized	metabolize	VBN	_	4	acl
6	by	by	IN	_	10	case
7	the	the	DT	_	10	det
8	cytochrome	cytochrome	NN	_	10	compound
9	P450	p450	NN	_	10	compound
10	system	system	NN	_	5	nmod
11	should	should	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	monitored	monitor	VBN	_	0	ROOT
14	closely	closely	RB	_	13	advmod
15	in	in	IN	_	16	case
16	patients	patient	NNS	_	13	nmod
17	concurrently	concurrently	RB	_	18	advmod
18	receiving	receive	VBG	_	16	acl
19	drug1	drug1	NN	_	18	dobj
20	.	.	.	_	13	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	to	to	TO	_	7	mark
6	significantly	significantly	RB	_	7	advmod
7	alter	alter	VB	_	4	xcomp
8	the	the	DT	_	9	det
9	metabolism	metabolism	NN	_	7	dobj
10	of	of	IN	_	13	case
11	nonsedating	nonsedating	JJ	_	13	amod
12	drug2	drug2	NN	_	13	compound
13	drug3	drug3	NN	_	9	nmod
14	and	and	CC	_	13	cc
15	drug4	drug4	NN	_	13	conj
16	when	when	WRB	_	17	advmod
17	taken	take	VBN	_	7	advcl
18	concomitantly	concomitantly	RB	_	17	advmod
19	.	.	.	_	4	punct

1	Rare	rare	JJ	_	2	amod
2	cases	case	NNS	_	28	nsubjpass
3	of	of	IN	_	7	case
4	serious	serious	JJ	_	7	amod
5	cardiovascular	cardiovascular	JJ	_	7	amod
6	adverse	adverse	JJ	_	7	amod
7	events	event	NNS	_	2	nmod
8	,	,	,	_	7	punct
9	including	include	VBG	_	13	case
10	electrocardiographic	electrocardiographic	JJ	_	13	amod
11	QT/QTc	qt/qtc	NN	_	13	compound
12	interval	interval	NN	_	13	compound
13	prolongation	prolongation	NN	_	7	nmod
14	,	,	,	_	13	punct
15	cardiac	cardiac	JJ	_	16	amod
16	arrest	arrest	NN	_	13	conj
17	,	,	,	_	13	punct
18	torsades	torsade	NNS	_	20	compound
19	de	de	IN	_	20	amod
20	pointes	pointe	NNS	_	13	conj
21	,	,	,	_	13	punct
22	and	and	CC	_	13	cc
23	other	other	JJ	_	25	amod
24	ventricular	ventricular	JJ	_	25	amod
25	arrhythmias	arrhythmia	NNS	_	13	conj
26	have	have	VBP	_	28	aux
27	been	be	VBN	_	28	auxpass
28	observed	observe	VBN	_	0	ROOT
29	.	.	.	_	28	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	7	nmod
3	,	,	,	_	7	punct
4	deaths	death	NNS	_	7	nsubjpass
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	reported	report	VBN	_	0	ROOT
8	rarely	rarely	RB	_	7	advmod
9	with	with	IN	_	11	case
10	concomitant	concomitant	JJ	_	11	amod
11	administration	administration	NN	_	7	nmod
12	of	of	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	and	and	CC	_	13	cc
15	drug2	drug2	NN	_	13	conj
16	.	.	.	_	7	punct

1	There	there	EX	_	4	expl
2	have	have	VBP	_	4	aux
3	been	be	VBN	_	4	aux
4	postmarketing	postmarket	VBG	_	0	ROOT
5	reports	report	NNS	_	4	dobj
6	of	of	IN	_	8	case
7	drug	drug	NN	_	8	compound
8	interactions	interaction	NNS	_	5	nmod
9	when	when	WRB	_	12	advmod
10	drug1	drug1	NN	_	12	nsubjpass
11	is	be	VBZ	_	12	auxpass
12	coadministered	coadminister	VBN	_	4	advcl
13	with	with	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	,	,	,	_	4	punct
16	resulting	result	VBG	_	4	advcl
17	in	in	IN	_	19	case
18	QT	QT	NNP	_	19	compound
19	prolongation	prolongation	NN	_	16	nmod
20	,	,	,	_	19	punct
21	cardiac	cardiac	JJ	_	22	amod
22	arrythmias	arrythmia	NNS	_	19	conj
23	,	,	,	_	19	punct
24	ventricular	ventricular	JJ	_	25	amod
25	tachycardia	tachycardia	NN	_	19	conj
26	,	,	,	_	19	punct
27	ventricular	ventricular	JJ	_	28	amod
28	fibrulation	fibrulation	NN	_	19	conj
29	,	,	,	_	19	punct
30	and	and	CC	_	19	cc
31	torsades	torsade	NNS	_	33	compound
32	de	de	IN	_	33	amod
33	pointes	pointe	NNS	_	19	conj
34	,	,	,	_	4	punct
35	most	most	JJS	_	4	dobj
36	like	like	IN	_	39	case
37	due	due	JJ	_	39	case
38	to	to	TO	_	37	mwe
39	inhibition	inhibition	NN	_	35	nmod
40	of	of	IN	_	42	case
41	hepatic	hepatic	JJ	_	42	amod
42	metabolism	metabolism	NN	_	39	nmod
43	of	of	IN	_	44	case
44	drug3	drug3	NN	_	42	nmod
45	by	by	IN	_	46	case
46	drug4	drug4	NN	_	39	nmod
47	.	.	.	_	4	punct

1	Fatalities	fatality	NNS	_	4	nsubjpass
2	have	have	VBP	_	4	aux
3	been	be	VBN	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	.	.	.	_	4	punct

1	Patients	patient	NNS	_	10	nsubjpass
2	receiving	receive	VBG	_	1	acl
3	concomitant	concomitant	JJ	_	4	amod
4	drug1	drug1	NN	_	2	dobj
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	should	should	MD	_	10	aux
8	be	be	VB	_	10	auxpass
9	carefully	carefully	RB	_	10	advmod
10	monitored	monitor	VBN	_	0	ROOT
11	;	;	:	_	10	punct

1	cases	case	NNS	_	6	nsubjpass
2	of	of	IN	_	3	case
3	rhabdomyolysis	rhabdomyolysis	NN	_	1	nmod
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	auxpass
6	reported	report	VBN	_	0	ROOT
7	in	in	IN	_	10	case
8	seriously	seriously	RB	_	9	advmod
9	ill	ill	JJ	_	10	amod
10	patients	patient	NNS	_	6	nmod
11	.	.	.	_	6	punct

1	The	the	DT	_	2	det
2	use	use	NN	_	6	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	may	may	MD	_	6	aux
6	result	result	VB	_	0	ROOT
7	in	in	IN	_	11	case
8	additive	additive	JJ	_	11	amod
9	CNS	cns	NN	_	11	compound
10	depressant	depressant	NN	_	11	compound
11	effects	effect	NNS	_	6	nmod
12	when	when	WRB	_	13	advmod
13	coadministered	coadminister	VBN	_	6	advcl
14	with	with	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	,	,	,	_	15	punct
17	drug3	drug3	NN	_	15	conj
18	,	,	,	_	15	punct
19	drug4	drug4	NN	_	15	conj
20	or	or	CC	_	15	cc
21	other	other	JJ	_	22	amod
22	drugs	drug	NNS	_	15	conj
23	that	that	WDT	_	24	nsubj
24	produce	produce	VBP	_	22	acl:relcl
25	CNS	cns	NN	_	26	compound
26	depression	depression	NN	_	24	dobj
27	.	.	.	_	6	punct

1	Serious	serious	JJ	_	2	amod
2	toxicity	toxicity	NN	_	4	nsubj
3	may	may	MD	_	4	aux
4	result	result	VB	_	0	ROOT
5	if	if	IN	_	8	mark
6	drug1	drug1	NN	_	8	nsubjpass
7	is	be	VBZ	_	8	auxpass
8	coadministered	coadminister	VBN	_	4	advcl
9	with	with	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	drug3	drug3	NN	_	10	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	use	use	NN	_	6	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	may	may	MD	_	6	aux
6	result	result	VB	_	0	ROOT
7	in	in	IN	_	11	case
8	additive	additive	JJ	_	11	amod
9	CNS	cns	NN	_	11	compound
10	depressant	depressant	NN	_	11	compound
11	effects	effect	NNS	_	6	nmod
12	when	when	WRB	_	13	advmod
13	coadministered	coadminister	VBN	_	6	advcl
14	with	with	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	,	,	,	_	15	punct
17	drug3	drug3	NN	_	15	conj
18	,	,	,	_	15	punct
19	drug4	drug4	NN	_	15	conj
20	or	or	CC	_	15	cc
21	other	other	JJ	_	22	amod
22	drugs	drug	NNS	_	15	conj
23	that	that	WDT	_	24	nsubj
24	produce	produce	VBP	_	22	acl:relcl
25	CNS	cns	NN	_	26	compound
26	depression	depression	NN	_	24	dobj
27	.	.	.	_	6	punct

1	Preliminary	preliminary	JJ	_	2	amod
2	data	datum	NNS	_	0	ROOT
3	which	which	WDT	_	4	nsubj
4	suggest	suggest	VBP	_	2	acl:relcl
5	that	that	IN	_	8	mark
6	drug1	drug1	NN	_	8	nsubj
7	may	may	MD	_	8	aux
8	inhibit	inhibit	VB	_	4	ccomp
9	the	the	DT	_	11	det
10	anti-inflammatory	anti-inflammatory	JJ	_	11	amod
11	activity	activity	NN	_	17	nsubjpass
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	have	have	VBP	_	17	aux
15	not	not	RB	_	17	neg
16	been	be	VBN	_	17	auxpass
17	confirmed	confirm	VBN	_	8	ccomp
18	.	.	.	_	2	punct

1	If	if	IN	_	5	mark
2	leprosy-associated	leprosy-associated	JJ	_	4	amod
3	inflammatory	inflammatory	JJ	_	4	amod
4	reactions	reaction	NNS	_	5	nsubj
5	develop	develop	VBP	_	18	advcl
6	in	in	IN	_	7	case
7	patients	patient	NNS	_	5	nmod
8	being	be	VBG	_	9	auxpass
9	treated	treat	VBN	_	7	acl
10	with	with	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	drug2	drug2	NN	_	11	conj
14	,	,	,	_	18	punct
15	it	it	PRP	_	18	nsubj
16	is	be	VBZ	_	18	cop
17	still	still	RB	_	18	advmod
18	advisable	advisable	JJ	_	0	ROOT
19	to	to	TO	_	20	mark
20	continue	continue	VB	_	18	xcomp
21	treatment	treatment	NN	_	20	dobj
22	with	with	IN	_	24	case
23	both	both	CC	_	24	det
24	drugs	drug	NNS	_	21	nmod
25	.	.	.	_	18	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	As	as	IN	_	6	case
4	with	with	IN	_	6	case
5	other	other	JJ	_	6	amod
6	drug2	drug2	NN	_	17	nmod
7	,	,	,	_	17	punct
8	concomitant	concomitant	JJ	_	9	amod
9	administration	administration	NN	_	17	nsubjpass
10	of	of	IN	_	11	case
11	drug3	drug3	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	drug4	drug4	NN	_	11	conj
14	is	be	VBZ	_	17	auxpass
15	not	not	RB	_	17	neg
16	generally	generally	RB	_	17	advmod
17	recommended	recommend	VBN	_	1	appos
18	because	because	IN	_	21	case
19	of	of	IN	_	18	mwe
20	the	the	DT	_	21	det
21	potential	potential	NN	_	17	nmod
22	of	of	IN	_	25	case
23	increased	increase	VBN	_	25	amod
24	adverse	adverse	JJ	_	25	amod
25	effects	effect	NNS	_	21	nmod
26	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	6	nsubjpass
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	auxpass
6	reported	report	VBN	_	1	appos
7	to	to	TO	_	9	mark
8	competitively	competitively	RB	_	9	advmod
9	inhibit	inhibit	VB	_	6	xcomp
10	drug3	drug3	NN	_	11	compound
11	accumulation	accumulation	NN	_	9	dobj
12	in	in	IN	_	15	case
13	rabbit	rabbit	NN	_	15	compound
14	kidney	kidney	NN	_	15	compound
15	slices	slice	NNS	_	11	nmod
16	.	.	.	_	1	punct

1	This	this	DT	_	3	nsubj
2	may	may	MD	_	3	aux
3	indicate	indicate	VB	_	0	ROOT
4	that	that	IN	_	7	mark
5	they	they	PRP	_	7	nsubj
6	could	could	MD	_	7	aux
7	enhance	enhance	VB	_	3	ccomp
8	the	the	DT	_	9	det
9	toxicity	toxicity	NN	_	7	dobj
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	.	.	.	_	3	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	when	when	WRB	_	8	advmod
6	drug1	drug1	NN	_	8	nsubjpass
7	are	be	VBP	_	8	auxpass
8	administered	administer	VBN	_	4	advcl
9	concomitantly	concomitantly	RB	_	8	advmod
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	8	nmod
12	.	.	.	_	4	punct

1	drug1	drug1	NN	_	4	nsubj
2	:	:	:	_	4	punct
3	Reports	report	NNS	_	4	nsubj
4	suggest	suggest	VBP	_	0	ROOT
5	that	that	IN	_	8	mark
6	drug2	drug2	NN	_	8	nsubj
7	may	may	MD	_	8	aux
8	diminish	diminish	VB	_	4	ccomp
9	the	the	DT	_	11	det
10	antihypertensive	antihypertensive	JJ	_	11	amod
11	effect	effect	NN	_	8	dobj
12	of	of	IN	_	13	case
13	drug3	drug3	NN	_	11	nmod
14	.	.	.	_	4	punct

1	This	this	DT	_	2	det
2	interaction	interaction	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	given	give	VBN	_	0	ROOT
6	consideration	consideration	NN	_	5	dobj
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	5	nmod
9	taking	take	VBG	_	8	acl
10	drug1	drug1	NN	_	9	dobj
11	concomitantly	concomitantly	RB	_	9	advmod
12	with	with	IN	_	13	case
13	drug2	drug2	NN	_	9	nmod
14	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Clinical	clinical	JJ	_	4	amod
4	studies	study	NNS	_	13	nsubj
5	,	,	,	_	4	punct
6	as	as	RB	_	4	cc
7	well	well	RB	_	6	mwe
8	as	as	IN	_	6	mwe
9	post-marketing	post-marketing	JJ	_	10	amod
10	observations	observation	NNS	_	4	conj
11	,	,	,	_	4	punct
12	have	have	VBP	_	13	aux
13	shown	show	VBN	_	1	appos
14	that	that	IN	_	17	mark
15	drug2	drug2	NN	_	17	nsubj
16	can	can	MD	_	17	aux
17	reduce	reduce	VB	_	13	ccomp
18	the	the	DT	_	20	det
19	natriuretic	natriuretic	JJ	_	20	amod
20	effect	effect	NN	_	17	dobj
21	of	of	IN	_	22	case
22	drug3	drug3	NN	_	20	nmod
23	and	and	CC	_	22	cc
24	drug4	drug4	NN	_	22	conj
25	in	in	IN	_	27	case
26	some	some	DT	_	27	det
27	patients	patient	NNS	_	20	nmod
28	.	.	.	_	1	punct

1	This	this	DT	_	2	det
2	response	response	NN	_	5	nsubjpass
3	has	have	VBZ	_	5	aux
4	been	be	VBN	_	5	auxpass
5	attributed	attribute	VBN	_	0	ROOT
6	to	to	TO	_	7	case
7	inhibition	inhibition	NN	_	5	nmod
8	of	of	IN	_	11	case
9	renal	renal	JJ	_	11	amod
10	prostaglandin	prostaglandin	NN	_	11	compound
11	synthesis	synthesis	NN	_	7	nmod
12	.	.	.	_	5	punct

1	During	during	IN	_	3	case
2	concomitant	concomitant	JJ	_	3	amod
3	therapy	therapy	NN	_	13	nmod
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	with	with	IN	_	7	case
7	drug2	drug2	NN	_	3	nmod
8	,	,	,	_	13	punct
9	the	the	DT	_	10	det
10	patient	patient	NN	_	13	nsubjpass
11	should	should	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	observed	observe	VBN	_	0	ROOT
14	closely	closely	RB	_	13	advmod
15	for	for	IN	_	16	case
16	signs	sign	NNS	_	13	nmod
17	of	of	IN	_	19	case
18	renal	renal	JJ	_	19	amod
19	failure	failure	NN	_	16	nmod
20	,	,	,	_	16	punct
21	as	as	RB	_	16	cc
22	well	well	RB	_	21	mwe
23	as	as	IN	_	21	mwe
24	to	to	TO	_	25	mark
25	assure	assure	VB	_	16	conj
26	diuretic	diuretic	JJ	_	27	amod
27	efficacy	efficacy	NN	_	25	dobj
28	.	.	.	_	13	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubj
4	have	have	VBP	_	5	aux
5	produced	produce	VBN	_	1	appos
6	an	a	DT	_	7	det
7	elevation	elevation	NN	_	5	dobj
8	of	of	IN	_	11	case
9	plasma	plasma	NN	_	11	compound
10	drug3	drug3	NN	_	11	compound
11	levels	level	NNS	_	7	nmod
12	and	and	CC	_	7	cc
13	a	a	DT	_	14	det
14	reduction	reduction	NN	_	7	conj
15	in	in	IN	_	18	case
16	renal	renal	JJ	_	18	amod
17	drug4	drug4	NN	_	18	compound
18	clearance	clearance	NN	_	14	nmod
19	.	.	.	_	1	punct

1	The	the	DT	_	5	det
2	mean	mean	NN	_	5	compound
3	minimum	minimum	JJ	_	5	amod
4	drug1	drug1	NN	_	5	compound
5	concentration	concentration	NN	_	6	nsubj
6	increased	increase	VBD	_	0	ROOT
7	15	15	CD	_	8	nummod
8	%	%	NN	_	6	dobj
9	and	and	CC	_	6	cc
10	the	the	DT	_	12	det
11	renal	renal	JJ	_	12	amod
12	clearance	clearance	NN	_	14	nsubjpass
13	was	be	VBD	_	14	auxpass
14	decreased	decrease	VBN	_	6	conj
15	by	by	IN	_	18	case
16	approximately	approximately	RB	_	17	advmod
17	20	20	CD	_	18	nummod
18	%	%	NN	_	14	nmod
19	.	.	.	_	6	punct

1	These	these	DT	_	2	det
2	effects	effect	NNS	_	5	nsubjpass
3	have	have	VBP	_	5	aux
4	been	be	VBN	_	5	auxpass
5	attributed	attribute	VBN	_	0	ROOT
6	to	to	TO	_	7	case
7	inhibition	inhibition	NN	_	5	nmod
8	of	of	IN	_	11	case
9	renal	renal	JJ	_	11	amod
10	prostaglandin	prostaglandin	NN	_	11	compound
11	synthesis	synthesis	NN	_	7	nmod
12	by	by	IN	_	14	case
13	the	the	DT	_	14	det
14	drug1	drug1	NN	_	7	nmod
15	.	.	.	_	5	punct

1	Thus	thus	RB	_	14	advmod
2	,	,	,	_	14	punct
3	when	when	WRB	_	8	advmod
4	drug1	drug1	NN	_	8	nsubjpass
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	are	be	VBP	_	8	auxpass
8	administered	administer	VBN	_	14	advcl
9	concurrently	concurrently	RB	_	8	advmod
10	,	,	,	_	14	punct
11	subjects	subject	NNS	_	14	nsubjpass
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	observed	observe	VBN	_	0	ROOT
15	carefully	carefully	RB	_	14	advmod
16	for	for	IN	_	17	case
17	signs	sign	NNS	_	14	nmod
18	of	of	IN	_	20	case
19	drug3	drug3	NN	_	20	compound
20	toxicity	toxicity	NN	_	17	nmod
21	.	.	.	_	14	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	effects	effect	NNS	_	13	nsubj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	drug3	drug3	NN	_	6	conj
9	on	on	IN	_	11	case
10	GI	gi	NN	_	11	compound
11	bleeding	bleeding	NN	_	4	nmod
12	are	be	VBP	_	13	cop
13	synergistic	synergistic	JJ	_	1	dep
14	,	,	,	_	13	punct
15	such	such	JJ	_	22	dep
16	that	that	IN	_	22	mark
17	users	user	NNS	_	22	nsubj
18	of	of	IN	_	20	case
19	both	both	DT	_	20	det
20	drugs	drug	NNS	_	17	nmod
21	together	together	RB	_	22	advmod
22	have	have	VBP	_	13	advcl
23	a	a	DT	_	24	det
24	risk	risk	NN	_	22	dobj
25	of	of	IN	_	27	case
26	serious	serious	JJ	_	27	amod
27	GI	gi	NN	_	24	nmod
28	bleeding	bleed	VBG	_	24	acl
29	higher	higher	JJR	_	28	advmod
30	than	than	IN	_	31	case
31	users	user	NNS	_	29	nmod
32	of	of	IN	_	34	case
33	either	either	CC	_	34	det
34	drug	drug	NN	_	31	nmod
35	alone	alone	RB	_	34	advmod
36	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	7	case
4	a	a	DT	_	7	det
5	single	single	JJ	_	7	amod
6	dose	dose	NN	_	7	compound
7	study	study	NN	_	1	nmod
8	-LRB-	-lrb-	-LRB-	_	10	punct
9	n	n	NN	_	10	nsubj
10	=	=	JJ	_	7	dep
11	6	6	CD	_	10	dobj
12	-RRB-	-rrb-	-RRB-	_	10	punct
13	,	,	,	_	7	punct
14	ingestion	ingestion	NN	_	26	nsubj
15	of	of	IN	_	17	case
16	an	a	DT	_	17	det
17	drug2	drug2	NN	_	14	nmod
18	containing	contain	VBG	_	17	acl
19	1.7-gram	1.7-gram	NN	_	18	dobj
20	of	of	IN	_	21	case
21	drug3	drug3	NN	_	19	nmod
22	with	with	IN	_	23	case
23	500-mg	500-mg	NN	_	14	nmod
24	of	of	IN	_	25	case
25	drug4	drug4	NN	_	23	nmod
26	increased	increase	VBD	_	7	acl:relcl
27	the	the	DT	_	28	det
28	Cmax	cmax	NN	_	26	dobj
29	and	and	CC	_	28	cc
30	AUC	auc	NN	_	28	conj
31	of	of	IN	_	32	case
32	drug5	drug5	NN	_	28	nmod
33	by	by	IN	_	35	case
34	125	125	CD	_	35	nummod
35	%	%	NN	_	26	nmod
36	and	and	CC	_	26	cc
37	36	36	CD	_	38	nummod
38	%	%	NN	_	26	conj
39	,	,	,	_	26	punct
40	respectively	respectively	RB	_	26	advmod
41	.	.	.	_	1	punct
42	A	a	DT	_	43	det
43	number	number	NN	_	47	nsubj
44	of	of	IN	_	45	case
45	compounds	compound	NNS	_	43	nmod
46	are	be	VBP	_	47	cop
47	inhibitors	inhibitor	NNS	_	1	parataxis
48	of	of	IN	_	49	case
49	CYP2C9	cyp2c9	NN	_	47	nmod
50	including	include	VBG	_	51	case
51	drug6	drug6	NN	_	49	nmod
52	,	,	,	_	51	punct
53	drug7	drug7	NN	_	51	conj
54	and	and	CC	_	51	cc
55	drug8	drug8	NN	_	51	conj
56	.	.	.	_	1	punct

1	Drug	drug	NN	_	3	compound
2	interaction	interaction	NN	_	3	compound
3	studies	study	NNS	_	12	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	these	these	DT	_	8	det
8	compounds	compound	NNS	_	5	conj
9	have	have	VBP	_	12	aux
10	not	not	RB	_	12	neg
11	been	be	VBN	_	12	auxpass
12	conducted	conduct	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	The	the	DT	_	2	det
2	possibility	possibility	NN	_	10	nsubjpass
3	of	of	IN	_	5	case
4	altered	altered	JJ	_	5	amod
5	safety	safety	NN	_	2	nmod
6	and	and	CC	_	5	cc
7	efficacy	efficacy	NN	_	5	conj
8	should	should	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	considered	consider	VBN	_	0	ROOT
11	when	when	WRB	_	14	advmod
12	drug1	drug1	NN	_	14	nsubjpass
13	is	be	VBZ	_	14	auxpass
14	used	use	VBN	_	10	advcl
15	concomitantly	concomitantly	RB	_	14	advmod
16	with	with	IN	_	18	case
17	these	these	DT	_	18	det
18	drugs	drug	NNS	_	14	nmod
19	.	.	.	_	10	punct

1	Drug	drug	NN	_	2	compound
2	Interactions	interaction	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	The	the	DT	_	7	det
5	central	central	JJ	_	7	amod
6	drug1	drug1	NN	_	7	compound
7	syndrome	syndrome	NN	_	9	nsubj
8	can	can	MD	_	9	aux
9	occur	occur	VB	_	2	dep
10	when	when	WRB	_	17	advmod
11	anticholinergic	anticholinergic	JJ	_	12	amod
12	agents	agent	NNS	_	17	nsubjpass
13	such	such	JJ	_	15	case
14	as	as	IN	_	13	mwe
15	drug2	drug2	NN	_	12	nmod
16	are	be	VBP	_	17	auxpass
17	administered	administer	VBN	_	9	advcl
18	concomitantly	concomitantly	RB	_	17	advmod
19	with	with	IN	_	20	case
20	drugs	drug	NNS	_	17	nmod
21	that	that	WDT	_	22	nsubj
22	have	have	VBP	_	20	acl:relcl
23	secondary	secondary	JJ	_	25	amod
24	anticholinergic	anticholinergic	JJ	_	25	amod
25	actions	action	NNS	_	22	dobj
26	,	,	,	_	9	punct
27	e.g.	e.g.	FW	_	9	advmod
28	,	,	,	_	9	punct
29	certain	certain	JJ	_	30	amod
30	drug3	drug3	NN	_	9	dobj
31	such	such	JJ	_	33	case
32	as	as	IN	_	31	mwe
33	drug4	drug4	NN	_	30	nmod
34	,	,	,	_	9	punct
35	the	the	DT	_	36	det
36	drug5	drug5	NN	_	9	dobj
37	and	and	CC	_	36	cc
38	other	other	JJ	_	39	amod
39	drug6	drug6	NN	_	36	conj
40	,	,	,	_	39	punct
41	drug7	drug7	NN	_	39	conj
42	,	,	,	_	39	punct
43	certain	certain	JJ	_	44	amod
44	drug8	drug8	NN	_	39	conj
45	such	such	JJ	_	49	case
46	as	as	IN	_	45	mwe
47	the	the	DT	_	49	det
48	drug9	drug9	NN	_	49	compound
49	salts	salt	NNS	_	44	nmod
50	,	,	,	_	39	punct
51	and	and	CC	_	39	cc
52	drug10	drug10	NN	_	39	conj
53	.	.	.	_	2	punct

1	No	no	DT	_	4	neg
2	drug/drug	drug/drug	NN	_	4	compound
3	interaction	interaction	NN	_	4	compound
4	studies	study	NNS	_	7	nsubjpass
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	performed	perform	VBN	_	0	ROOT
8	.	.	.	_	7	punct

1	There	there	EX	_	7	expl
2	have	have	VBP	_	7	aux
3	been	be	VBN	_	7	cop
4	no	no	DT	_	7	neg
5	formal	formal	JJ	_	7	amod
6	drug-interaction	drug-interaction	NN	_	7	compound
7	studies	study	NNS	_	0	ROOT
8	performed	perform	VBN	_	7	acl
9	with	with	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	.	.	.	_	7	punct

1	The	the	DT	_	2	det
2	potential	potential	NN	_	16	nsubjpass
3	for	for	IN	_	5	case
4	drug-drug	drug-drug	JJ	_	5	amod
5	interaction	interaction	NN	_	2	nmod
6	with	with	IN	_	7	case
7	drugs	drug	NNS	_	5	nmod
8	affected	affect	VBN	_	7	acl
9	by	by	IN	_	12	case
10	cytochrome	cytochrome	NN	_	12	compound
11	P450	p450	NN	_	12	compound
12	enzymes	enzyme	NNS	_	8	nmod
13	may	may	MD	_	16	aux
14	not	not	RB	_	16	neg
15	be	be	VB	_	16	auxpass
16	ruled	rule	VBN	_	0	ROOT
17	out	out	RP	_	16	compound:prt
18	.	.	.	_	16	punct

1	Laboratory	Laboratory	NNP	_	3	compound
2	Test	Test	NNP	_	3	compound
3	Interactions	interaction	NNS	_	0	ROOT

1	drug1	drug1	NN	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	not	not	RB	_	4	neg
4	known	know	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	interfere	interfere	VB	_	4	xcomp
7	with	with	IN	_	11	case
8	any	any	DT	_	11	det
9	routine	routine	JJ	_	11	amod
10	diagnostic	diagnostic	JJ	_	11	amod
11	tests	test	NNS	_	6	nmod
12	.	.	.	_	4	punct

1	Interactions	interaction	NNS	_	0	ROOT
2	for	for	IN	_	4	case
3	drug1	drug1	NN	_	4	compound
4	analogues	analogue	NNS	_	1	nmod
5	-LRB-	-lrb-	-LRB-	_	6	punct
6	drug2	drug2	NN	_	4	dep
7	,	,	,	_	6	punct
8	drug3	drug3	NN	_	6	conj
9	,	,	,	_	6	punct
10	drug4	drug4	NN	_	6	conj
11	,	,	,	_	6	punct
12	and	and	CC	_	6	cc
13	drug5	drug5	NN	_	6	conj
14	-RRB-	-rrb-	-RRB-	_	6	punct
15	:	:	:	_	1	punct
16	drug6	drug6	NN	_	1	dep
17	:	:	:	_	16	punct
18	drug7	drug7	NN	_	21	nsubjpass
19	has	have	VBZ	_	21	aux
20	been	be	VBN	_	21	auxpass
21	reported	report	VBN	_	16	appos
22	to	to	TO	_	23	mark
23	reduce	reduce	VB	_	21	xcomp
24	intestinal	intestinal	JJ	_	25	amod
25	absorption	absorption	NN	_	23	dobj
26	of	of	IN	_	27	case
27	drug8	drug8	NN	_	25	nmod
28	;	;	:	_	1	punct

1	as	as	IN	_	5	mark
2	such	such	JJ	_	5	mark
3	it	it	PRP	_	5	nsubj
4	may	may	MD	_	5	aux
5	impair	impair	VB	_	0	ROOT
6	intestinal	intestinal	JJ	_	7	amod
7	absorption	absorption	NN	_	5	dobj
8	of	of	IN	_	9	case
9	any	any	DT	_	7	nmod
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	.	.	.	_	5	punct

1	drug1	drug1	NN	_	3	compound
2	/	/	:	_	3	punct
3	drug2	drug2	NN	_	0	ROOT
4	:	:	:	_	3	punct
5	The	the	DT	_	6	det
6	coadministration	coadministration	NN	_	13	nsubj
7	of	of	IN	_	8	case
8	drug3	drug3	NN	_	6	nmod
9	or	or	CC	_	8	cc
10	drug4	drug4	NN	_	8	conj
11	will	will	MD	_	13	aux
12	not	not	RB	_	13	neg
13	affect	affect	VB	_	3	dep
14	plasma	plasma	NN	_	15	compound
15	concentrations	concentration	NNS	_	13	dobj
16	of	of	IN	_	17	case
17	drug5	drug5	NN	_	15	nmod
18	,	,	,	_	13	punct
19	but	but	CC	_	13	cc
20	may	may	MD	_	21	aux
21	reduce	reduce	VB	_	13	conj
22	endogenous	endogenous	JJ	_	24	amod
23	plasma	plasma	NN	_	24	compound
24	levels	level	NNS	_	21	dobj
25	of	of	IN	_	26	case
26	drug6	drug6	NN	_	24	nmod
27	/	/	:	_	13	punct
28	ergocalcitriol	ergocalcitriol	NN	_	13	conj
29	by	by	IN	_	30	mark
30	accelerating	accelerate	VBG	_	28	acl
31	metabolism	metabolism	NN	_	30	dobj
32	.	.	.	_	3	punct

1	Since	since	IN	_	10	mark
2	blood	blood	NN	_	3	compound
3	level	level	NN	_	10	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	/	/	:	_	7	punct
7	ergocalcitriol	ergocalcitriol	NN	_	10	nsubjpass
8	will	will	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	reduced	reduce	VBN	_	18	advcl
11	,	,	,	_	18	punct
12	higher	higher	JJR	_	13	amod
13	doses	dose	NNS	_	18	nsubj
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	may	may	MD	_	18	aux
17	be	be	VB	_	18	cop
18	necessary	necessary	JJ	_	0	ROOT
19	if	if	IN	_	23	mark
20	these	these	DT	_	21	det
21	drugs	drug	NNS	_	23	nsubjpass
22	are	be	VBP	_	23	auxpass
23	administered	administer	VBN	_	18	advcl
24	simultaneously	simultaneously	RB	_	23	advmod
25	.	.	.	_	18	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubjpass
4	are	be	VBP	_	5	auxpass
5	known	know	VBN	_	1	appos
6	to	to	TO	_	7	mark
7	induce	induce	VB	_	5	xcomp
8	hypercalcemia	hypercalcemia	NN	_	7	dobj
9	by	by	IN	_	11	case
10	the	the	DT	_	11	det
11	reduction	reduction	NN	_	7	nmod
12	of	of	IN	_	14	case
13	calcium	calcium	NN	_	14	compound
14	excretion	excretion	NN	_	11	nmod
15	in	in	IN	_	16	case
16	urine	urine	NN	_	11	nmod
17	.	.	.	_	1	punct

1	Some	some	DT	_	2	det
2	reports	report	NNS	_	4	nsubj
3	have	have	VBP	_	4	aux
4	shown	show	VBN	_	0	ROOT
5	that	that	IN	_	13	mark
6	the	the	DT	_	8	det
7	concomitant	concomitant	JJ	_	8	amod
8	administration	administration	NN	_	13	nsubj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	with	with	IN	_	12	case
12	drug2	drug2	NN	_	8	nmod
13	causes	cause	VBZ	_	4	ccomp
14	hypercalcemia	hypercalcemia	NN	_	13	dobj
15	.	.	.	_	4	punct

1	Therefore	therefore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	precaution	precaution	NN	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	taken	take	VBN	_	0	ROOT
7	when	when	WRB	_	10	advmod
8	coadministration	coadministration	NN	_	10	nsubj
9	is	be	VBZ	_	10	cop
10	necessary	necessary	JJ	_	6	advcl
11	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	compound
4	dosage	dosage	NN	_	7	nsubjpass
5	must	must	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	determined	determine	VBN	_	1	dep
8	with	with	IN	_	9	case
9	care	care	NN	_	7	nmod
10	in	in	IN	_	11	case
11	patients	patient	NNS	_	9	nmod
12	undergoing	undergo	VBG	_	11	acl
13	treatment	treatment	NN	_	12	dobj
14	with	with	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	,	,	,	_	7	punct
17	as	as	IN	_	18	case
18	hypercalcemia	hypercalcemia	NN	_	7	nmod
19	in	in	IN	_	21	case
20	such	such	JJ	_	21	amod
21	patients	patient	NNS	_	18	nmod
22	may	may	MD	_	23	aux
23	precipitate	precipitate	VB	_	7	ccomp
24	cardiac	cardiac	JJ	_	25	amod
25	arrhythmias	arrhythmia	NNS	_	23	dobj
26	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	inhibit	inhibit	VB	_	1	dep
6	both	both	DT	_	7	cc:preconj
7	synthetic	synthetic	JJ	_	5	dobj
8	and	and	CC	_	7	cc
9	catabolic	catabolic	JJ	_	7	conj
10	enzymes	enzyme	NNS	_	7	dep
11	of	of	IN	_	12	case
12	drug3	drug3	NN	_	7	nmod
13	.	.	.	_	5	punct

1	Reductions	reduction	NNS	_	10	nsubjpass
2	in	in	IN	_	7	case
3	serum	serum	NN	_	7	compound
4	endogenous	endogenous	JJ	_	7	amod
5	vitamin	vitamin	NN	_	7	compound
6	D	d	NN	_	7	compound
7	concentrations	concentration	NNS	_	1	nmod
8	have	have	VBP	_	10	aux
9	been	be	VBN	_	10	auxpass
10	observed	observe	VBN	_	0	ROOT
11	following	follow	VBG	_	13	case
12	the	the	DT	_	13	det
13	administration	administration	NN	_	10	nmod
14	of	of	IN	_	16	case
15	300	300	CD	_	16	nummod
16	mg/day	mg/day	NN	_	13	nmod
17	to	to	TO	_	20	case
18	1200	1200	CD	_	20	nummod
19	mg/day	mg/day	NN	_	20	compound
20	drug1	drug1	NN	_	13	nmod
21	for	for	IN	_	23	case
22	a	a	DT	_	23	det
23	week	week	NN	_	13	nmod
24	to	to	TO	_	26	case
25	healthy	healthy	JJ	_	26	amod
26	men	man	NNS	_	23	nmod
27	.	.	.	_	10	punct

1	However	however	RB	_	15	advmod
2	,	,	,	_	15	punct
3	in	in	FW	_	7	amod
4	vivo	vivo	FW	_	3	dep
5	drug	drug	NN	_	7	compound
6	interaction	interaction	NN	_	7	compound
7	studies	study	NNS	_	15	nsubjpass
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	have	have	VBP	_	15	aux
13	not	not	RB	_	15	neg
14	been	be	VBN	_	15	auxpass
15	investigated	investigate	VBN	_	0	ROOT
16	.	.	.	_	15	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	A	a	DT	_	4	det
4	relationship	relationship	NN	_	8	nsubj
5	of	of	IN	_	7	case
6	functional	functional	JJ	_	7	amod
7	antagonism	antagonism	NN	_	4	nmod
8	exists	exist	VBZ	_	1	appos
9	between	between	IN	_	11	case
10	drug2	drug2	NN	_	11	compound
11	analogues	analogue	NNS	_	8	nmod
12	,	,	,	_	11	punct
13	which	which	WDT	_	14	nsubj
14	promote	promote	VBP	_	11	acl:relcl
15	calcium	calcium	NN	_	16	compound
16	absorption	absorption	NN	_	14	dobj
17	,	,	,	_	11	punct
18	and	and	CC	_	11	cc
19	drug3	drug3	NN	_	11	conj
20	,	,	,	_	19	punct
21	which	which	WDT	_	22	nsubj
22	inhibit	inhibit	VBP	_	19	acl:relcl
23	calcium	calcium	NN	_	24	compound
24	absorption	absorption	NN	_	22	dobj
25	.	.	.	_	1	punct

1	Phosphate-Binding	phosphate-binding	JJ	_	2	amod
2	Agents	agent	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	Since	since	IN	_	5	case
5	drug1	drug1	NN	_	7	nmod
6	also	also	RB	_	7	advmod
7	has	have	VBZ	_	2	dep
8	an	a	DT	_	9	det
9	effect	effect	NN	_	7	dobj
10	on	on	IN	_	12	case
11	phosphate	phosphate	NN	_	12	compound
12	transport	transport	NN	_	9	nmod
13	in	in	IN	_	15	case
14	the	the	DT	_	15	det
15	intestine	intestine	NN	_	7	nmod
16	,	,	,	_	15	punct
17	kidneys	kidney	NNS	_	15	conj
18	and	and	CC	_	15	cc
19	bones	bone	NNS	_	15	conj
20	,	,	,	_	7	punct
21	the	the	DT	_	22	det
22	dosage	dosage	NN	_	28	nsubjpass
23	of	of	IN	_	25	case
24	phosphate-binding	phosphate-binding	JJ	_	25	amod
25	agents	agent	NNS	_	22	nmod
26	must	must	MD	_	28	aux
27	be	be	VB	_	28	auxpass
28	adjusted	adjust	VBN	_	7	ccomp
29	in	in	IN	_	30	case
30	accordance	accordance	NN	_	28	nmod
31	with	with	IN	_	35	case
32	the	the	DT	_	35	det
33	serum	serum	NN	_	35	compound
34	phosphate	phosphate	NN	_	35	compound
35	concentration	concentration	NN	_	30	nmod
36	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	coadministration	coadministration	NN	_	13	nsubjpass
5	of	of	IN	_	6	case
6	any	any	DT	_	4	nmod
7	of	of	IN	_	10	case
8	the	the	DT	_	10	det
9	drug2	drug2	NN	_	10	compound
10	analogues	analogue	NNS	_	6	nmod
11	should	should	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	avoided	avoid	VBN	_	1	appos
14	as	as	IN	_	17	mark
15	this	this	DT	_	17	nsubj
16	could	could	MD	_	17	aux
17	create	create	VB	_	13	advcl
18	possible	possible	JJ	_	20	amod
19	additive	additive	JJ	_	20	amod
20	effects	effect	NNS	_	17	dobj
21	and	and	CC	_	20	cc
22	hypercalcemia	hypercalcemia	NN	_	20	conj
23	.	.	.	_	1	punct

1	drug1	drug1	NN	_	2	compound
2	Supplements	supplement	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	Uncontrolled	uncontrolled	JJ	_	5	amod
5	intake	intake	NN	_	14	nsubjpass
6	of	of	IN	_	8	case
7	additional	additional	JJ	_	8	amod
8	drug2	drug2	NN	_	5	nmod
9	-	-	:	_	5	punct
10	containing	contain	VBG	_	5	acl
11	preparations	preparation	NNS	_	10	dobj
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	avoided	avoid	VBN	_	2	dep
15	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	dep
4	-	-	:	_	5	punct
5	containing	contain	VBG	_	1	dep
6	preparations	preparation	NNS	_	5	dobj
7	-LRB-	-lrb-	-LRB-	_	8	punct
8	eg	eg	FW	_	6	dep
9	,	,	,	_	8	punct
10	drug3	drug3	NN	_	8	appos
11	-RRB-	-rrb-	-RRB-	_	8	punct
12	may	may	MD	_	13	aux
13	cause	cause	VB	_	5	dep
14	hypermagnesemia	hypermagnesemia	NN	_	13	dobj
15	and	and	CC	_	13	cc
16	should	should	MD	_	20	aux
17	therefore	therefore	RB	_	20	advmod
18	not	not	RB	_	20	neg
19	be	be	VB	_	20	auxpass
20	taken	take	VBN	_	13	conj
21	during	during	IN	_	22	case
22	therapy	therapy	NN	_	20	nmod
23	with	with	IN	_	24	case
24	drug4	drug4	NN	_	22	nmod
25	by	by	IN	_	26	case
26	patients	patient	NNS	_	20	nmod
27	on	on	IN	_	30	case
28	chronic	chronic	JJ	_	30	amod
29	renal	renal	JJ	_	30	amod
30	dialysis	dialysis	NN	_	26	nmod
31	.	.	.	_	1	punct

1	drug1	drug1	NN	_	5	nsubj
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	may	may	MD	_	5	aux
5	decrease	decrease	VB	_	0	ROOT
6	hypoprothrombinemic	hypoprothrombinemic	JJ	_	7	amod
7	effect	effect	NN	_	5	dobj
8	.	.	.	_	5	punct

1	Other	other	JJ	_	2	amod
2	depressasnts	depressasnt	NNS	_	12	nsubj
3	such	such	JJ	_	5	case
4	as	as	IN	_	3	mwe
5	drug1	drug1	NN	_	2	nmod
6	,	,	,	_	5	punct
7	drug2	drug2	NN	_	5	conj
8	,	,	,	_	5	punct
9	and	and	CC	_	5	cc
10	drug3	drug3	NN	_	5	conj
11	may	may	MD	_	12	aux
12	enhance	enhance	VB	_	0	ROOT
13	CNS	cns	NN	_	14	compound
14	depression	depression	NN	_	12	dobj
15	when	when	WRB	_	16	advmod
16	administered	administer	VBN	_	12	advcl
17	with	with	IN	_	18	case
18	drug4	drug4	NN	_	16	nmod
19	.	.	.	_	12	punct

1	May	May	NNP	_	2	nsubj
2	interact	interact	VBP	_	0	ROOT
3	with	with	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	,	,	,	_	4	punct
6	drug2	drug2	NN	_	4	conj
7	,	,	,	_	4	punct
8	drug3	drug3	NN	_	4	conj
9	,	,	,	_	4	punct
10	drug4	drug4	NN	_	4	conj
11	,	,	,	_	4	punct
12	and	and	CC	_	4	cc
13	drug5	drug5	NN	_	4	conj
14	.	.	.	_	2	punct

1	Drug/Laboratory	Drug/Laboratory	NNP	_	2	compound
2	Interactions	interaction	NNS	_	0	ROOT
3	No	no	DT	_	7	neg
4	formal	formal	JJ	_	7	amod
5	drug	drug	NN	_	7	compound
6	interaction	interaction	NN	_	7	compound
7	studies	study	NNS	_	10	nsubjpass
8	have	have	VBP	_	10	aux
9	been	be	VBN	_	10	auxpass
10	performed	perform	VBN	_	2	acl:relcl
11	with	with	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	.	.	.	_	2	punct

1	An	a	DT	_	3	det
2	immune	immune	JJ	_	3	amod
3	response	response	NN	_	7	nsubj
4	to	to	TO	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	may	may	MD	_	7	aux
7	interfere	interfere	VB	_	0	ROOT
8	with	with	IN	_	12	case
9	subsequent	subsequent	JJ	_	12	amod
10	diagnostic	diagnostic	JJ	_	12	amod
11	serum	serum	NN	_	12	compound
12	tests	test	NNS	_	7	nmod
13	that	that	WDT	_	14	nsubj
14	utilize	utilize	VBP	_	12	acl:relcl
15	drug2	drug2	NN	_	14	dobj

1	.	.	.	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	No	no	DT	_	5	neg
2	formal	formal	JJ	_	5	amod
3	drug	drug	NN	_	5	compound
4	interaction	interaction	NN	_	5	compound
5	studies	study	NNS	_	8	nsubjpass
6	have	have	VBP	_	8	aux
7	been	be	VBN	_	8	auxpass
8	performed	perform	VBN	_	0	ROOT
9	with	with	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	.	.	.	_	8	punct

1	Due	due	JJ	_	5	case
2	to	to	TO	_	1	mwe
3	the	the	DT	_	5	det
4	frequent	frequent	JJ	_	5	amod
5	occurrence	occurrence	NN	_	26	nmod
6	of	of	IN	_	10	case
7	severe	severe	JJ	_	10	amod
8	and	and	CC	_	7	cc
9	prolonged	prolonged	JJ	_	7	conj
10	thrombocytopenia	thrombocytopenia	NN	_	5	nmod
11	,	,	,	_	26	punct
12	the	the	DT	_	14	det
13	potential	potential	JJ	_	14	amod
14	benefits	benefit	NNS	_	26	nsubjpass
15	of	of	IN	_	16	case
16	medications	medication	NNS	_	14	nmod
17	which	which	WDT	_	18	nsubj
18	interfere	interfere	VBP	_	16	acl:relcl
19	with	with	IN	_	21	case
20	platelet	platelet	NN	_	21	compound
21	function	function	NN	_	18	nmod
22	and/or	and/or	CC	_	21	cc
23	anticoagulation	anticoagulation	NN	_	21	conj
24	should	should	MD	_	26	aux
25	be	be	VB	_	26	auxpass
26	weighed	weigh	VBN	_	0	ROOT
27	against	against	IN	_	29	case
28	the	the	DT	_	29	det
29	potential	potential	NN	_	26	nmod
30	increased	increase	VBD	_	31	amod
31	risks	risk	NNS	_	26	dobj
32	of	of	IN	_	33	case
33	bleeding	bleeding	NN	_	31	nmod
34	and	and	CC	_	33	cc
35	hemorrhage	hemorrhage	NN	_	33	conj
36	.	.	.	_	26	punct

1	Patients	patient	NNS	_	12	nsubj
2	receiving	receive	VBG	_	1	acl
3	medications	medication	NNS	_	2	dobj
4	that	that	WDT	_	5	nsubj
5	interfere	interfere	VBP	_	3	acl:relcl
6	with	with	IN	_	8	case
7	platelet	platelet	NN	_	8	compound
8	function	function	NN	_	5	nmod
9	or	or	CC	_	8	cc
10	coagulation	coagulation	NN	_	8	conj
11	should	should	MD	_	12	aux
12	have	have	VB	_	0	ROOT
13	more	more	RBR	_	14	advmod
14	frequent	frequent	JJ	_	16	amod
15	laboratory	laboratory	NN	_	16	compound
16	monitoring	monitoring	NN	_	12	dobj
17	for	for	IN	_	18	case
18	thrombocytopenia	thrombocytopenia	NN	_	16	nmod
19	.	.	.	_	12	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	11	nmod
3	,	,	,	_	11	punct
4	the	the	DT	_	6	det
5	transfusion	transfusion	NN	_	6	compound
6	practices	practice	NNS	_	11	nsubj
7	for	for	IN	_	9	case
8	such	such	JJ	_	9	amod
9	patients	patient	NNS	_	6	nmod
10	may	may	MD	_	11	aux
11	need	need	VB	_	0	ROOT
12	to	to	TO	_	14	mark
13	be	be	VB	_	14	auxpass
14	modified	modify	VBN	_	11	xcomp
15	given	give	VBN	_	18	case
16	the	the	DT	_	18	det
17	increased	increase	VBN	_	18	amod
18	risk	risk	NN	_	14	nmod
19	of	of	IN	_	20	case
20	bleeding	bleeding	NN	_	18	nmod
21	.	.	.	_	11	punct

1	Patients	patient	NNS	_	6	nsubjpass
2	in	in	IN	_	4	case
3	clinical	clinical	JJ	_	4	amod
4	studies	study	NNS	_	1	nmod
5	were	be	VBD	_	6	auxpass
6	prohibited	prohibit	VBN	_	0	ROOT
7	from	from	IN	_	8	mark
8	receiving	receive	VBG	_	6	advcl
9	growth	growth	NN	_	11	compound
10	factor	factor	NN	_	11	compound
11	treatment	treatment	NN	_	8	dobj
12	for	for	IN	_	14	case
13	2	2	CD	_	14	nummod
14	weeks	week	NNS	_	8	nmod
15	prior	prior	RB	_	8	advmod
16	to	to	TO	_	20	case
17	the	the	DT	_	20	det
18	drug1	drug1	NN	_	20	compound
19	therapeutic	therapeutic	JJ	_	20	amod
20	regimen	regimen	NN	_	15	nmod
21	as	as	RB	_	20	cc
22	well	well	RB	_	21	mwe
23	as	as	IN	_	21	mwe
24	for	for	IN	_	26	case
25	2	2	CD	_	26	nummod
26	weeks	week	NNS	_	20	conj
27	following	follow	VBG	_	28	case
28	completion	completion	NN	_	26	nmod
29	of	of	IN	_	31	case
30	the	the	DT	_	31	det
31	regimen	regimen	NN	_	28	nmod
32	.	.	.	_	6	punct

1	Because	because	IN	_	6	mark
2	the	the	DT	_	3	det
3	drug1	drug1	NN	_	6	nsubjpass
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	auxpass
6	shown	show	VBN	_	20	advcl
7	to	to	TO	_	8	mark
8	depress	depress	VB	_	6	xcomp
9	plasma	plasma	NN	_	11	compound
10	prothrombin	prothrombin	NN	_	11	compound
11	activity	activity	NN	_	8	dobj
12	,	,	,	_	20	punct
13	patients	patient	NNS	_	20	nsubj
14	who	who	WP	_	18	nsubj
15	are	be	VBP	_	18	cop
16	on	on	IN	_	18	case
17	drug2	drug2	NN	_	18	compound
18	therapy	therapy	NN	_	13	acl:relcl
19	may	may	MD	_	20	aux
20	require	require	VB	_	0	ROOT
21	downward	downward	JJ	_	22	amod
22	adjustment	adjustment	NN	_	20	dobj
23	of	of	IN	_	26	case
24	their	they	PRP$	_	26	nmod:poss
25	drug3	drug3	NN	_	26	compound
26	dosage	dosage	NN	_	22	nmod
27	.	.	.	_	20	punct

1	Since	since	IN	_	13	mark
2	bacteriostatic	bacteriostatic	JJ	_	3	amod
3	drugs	drug	NNS	_	13	nsubj
4	,	,	,	_	3	punct
5	such	such	JJ	_	8	case
6	as	as	IN	_	5	mwe
7	the	the	DT	_	8	det
8	drug1	drug1	NN	_	3	nmod
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	,	,	,	_	3	punct
12	may	may	MD	_	13	aux
13	interfere	interfere	VB	_	24	advcl
14	with	with	IN	_	17	case
15	the	the	DT	_	17	det
16	bactericidal	bactericidal	JJ	_	17	amod
17	action	action	NN	_	13	nmod
18	of	of	IN	_	19	case
19	drug3	drug3	NN	_	17	nmod
20	,	,	,	_	24	punct
21	it	it	PRP	_	24	nsubj
22	is	be	VBZ	_	24	cop
23	not	not	RB	_	24	neg
24	advisable	advisable	JJ	_	0	ROOT
25	to	to	TO	_	26	mark
26	administer	administer	VB	_	24	xcomp
27	these	these	DT	_	28	det
28	drugs	drug	NNS	_	26	dobj
29	concomitantly	concomitantly	RB	_	26	advmod
30	.	.	.	_	24	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	use	use	NN	_	9	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	7	case
6	oral	oral	JJ	_	7	amod
7	drug2	drug2	NN	_	2	nmod
8	may	may	MD	_	9	aux
9	render	render	VB	_	0	ROOT
10	oral	oral	JJ	_	11	amod
11	drug3	drug3	NN	_	13	nsubj
12	less	less	RBR	_	13	advmod
13	effective	effective	JJ	_	9	xcomp
14	.	.	.	_	9	punct

1	Breakthrough	breakthrough	NN	_	2	compound
2	bleeding	bleeding	NN	_	5	nsubjpass
3	has	have	VBZ	_	5	aux
4	been	be	VBN	_	5	auxpass
5	reported	report	VBN	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	7	compound
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	drug3	drug3	NN	_	3	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	Injection	injection	NN	_	13	nsubjpass
8	,	,	,	_	7	punct
9	USP	usp	NN	_	7	appos
10	should	should	MD	_	13	aux
11	not	not	RB	_	13	neg
12	be	be	VB	_	13	auxpass
13	used	use	VBN	_	1	dep
14	with	with	IN	_	15	case
15	drug4	drug4	NN	_	13	nmod
16	because	because	IN	_	20	mark
17	the	the	DT	_	18	det
18	combination	combination	NN	_	20	nsubj
19	may	may	MD	_	20	aux
20	cause	cause	VB	_	13	advcl
21	synergistic	synergistic	JJ	_	22	amod
22	elevation	elevation	NN	_	20	dobj
23	of	of	IN	_	25	case
24	blood	blood	NN	_	25	compound
25	pressure	pressure	NN	_	22	nmod
26	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	6	nsubjpass
4	has	have	VBZ	_	6	aux
5	been	be	VBN	_	6	auxpass
6	reported	report	VBN	_	1	dep
7	to	to	TO	_	8	mark
8	cause	cause	VB	_	6	xcomp
9	coronary	coronary	JJ	_	11	amod
10	artery	artery	NN	_	11	compound
11	vasospasm	vasospasm	NN	_	8	dobj
12	,	,	,	_	6	punct
13	and	and	CC	_	6	cc
14	its	its	PRP$	_	15	nmod:poss
15	effect	effect	NN	_	18	nsubj
16	could	could	MD	_	18	aux
17	be	be	VB	_	18	cop
18	additive	additive	JJ	_	6	conj
19	with	with	IN	_	20	case
20	drug3	drug3	NN	_	18	nmod
21	-LRB-	-lrb-	-LRB-	_	22	punct
22	drug4	drug4	NN	_	20	appos
23	-RRB-	-rrb-	-RRB-	_	22	punct
24	Injection	injection	NN	_	20	dep
25	,	,	,	_	20	punct
26	USP	usp	NN	_	20	appos
27	.	.	.	_	1	punct

1	drug1	drug1	NN	_	13	dep
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	drug3	drug3	NN	_	3	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	Injection	injection	NN	_	1	dep
8	,	,	,	_	13	punct
9	USP	usp	NN	_	13	nsubjpass
10	should	should	MD	_	13	aux
11	not	not	RB	_	13	neg
12	be	be	VB	_	13	auxpass
13	taken	take	VBN	_	0	ROOT
14	within	within	IN	_	16	case
15	24	24	CD	_	16	nummod
16	hours	hour	NNS	_	13	nmod
17	of	of	IN	_	19	case
18	each	each	DT	_	19	det
19	other	other	JJ	_	16	nmod
20	.	.	.	_	13	punct
21	.	.	.	_	13	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Although	although	IN	_	12	mark
4	the	the	DT	_	5	det
5	results	result	NNS	_	12	nsubj
6	of	of	IN	_	9	case
7	a	a	DT	_	9	det
8	clinical	clinical	JJ	_	9	amod
9	study	study	NN	_	5	nmod
10	did	do	VBD	_	12	aux
11	not	not	RB	_	12	neg
12	indicate	indicate	VB	_	31	advcl
13	a	a	DT	_	15	det
14	safe	safe	JJ	_	15	amod
15	problem	problem	NN	_	12	dobj
16	associated	associate	VBN	_	15	acl
17	with	with	IN	_	19	case
18	the	the	DT	_	19	det
19	administration	administration	NN	_	16	nmod
20	of	of	IN	_	21	case
21	drug2	drug2	NN	_	19	nmod
22	-LRB-	-lrb-	-LRB-	_	23	punct
23	drug3	drug3	NN	_	21	appos
24	-RRB-	-rrb-	-RRB-	_	23	punct
25	Injection	injection	NN	_	21	dep
26	,	,	,	_	31	punct
27	USP	usp	NN	_	31	nsubj
28	to	to	TO	_	29	case
29	subjects	subject	NNS	_	27	nmod
30	already	already	RB	_	31	advmod
31	receiving	receive	VBG	_	1	dep
32	drug4	drug4	NN	_	31	dobj
33	,	,	,	_	31	punct
34	there	there	EX	_	37	expl
35	have	have	VBP	_	37	aux
36	been	be	VBN	_	37	cop
37	reports	report	NNS	_	31	parataxis
38	that	that	IN	_	41	mark
39	drug5	drug5	NN	_	41	nsubj
40	may	may	MD	_	41	aux
41	potentiate	potentiate	VB	_	37	ccomp
42	the	the	DT	_	44	det
43	vasoconstrictive	vasoconstrictive	JJ	_	44	amod
44	action	action	NN	_	41	dobj
45	of	of	IN	_	46	case
46	drug6	drug6	NN	_	44	nmod
47	by	by	IN	_	48	mark
48	blocking	block	VBG	_	41	advcl
49	the	the	DT	_	51	det
50	vasodilating	vasodilate	VBG	_	51	amod
51	property	property	NN	_	48	dobj
52	of	of	IN	_	53	case
53	epinephrine	epinephrine	NN	_	51	nmod
54	.	.	.	_	31	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	provoke	provoke	VB	_	1	appos
6	vasoconstriction	vasoconstriction	NN	_	5	dobj
7	in	in	IN	_	9	case
8	some	some	DT	_	9	det
9	patients	patient	NNS	_	5	nmod
10	,	,	,	_	5	punct
11	predisposing	predispose	VBG	_	5	advcl
12	to	to	TO	_	16	case
13	a	a	DT	_	16	det
14	greater	greater	JJR	_	16	amod
15	ischemic	ischemic	JJ	_	16	amod
16	response	response	NN	_	11	nmod
17	to	to	TO	_	19	case
18	drug3	drug3	NN	_	19	compound
19	therapy	therapy	NN	_	16	nmod
20	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	5	punct
3	e.	e.	FW	_	5	compound
4	g.	g.	FW	_	5	compound
5	drug2	drug2	NN	_	1	dep
6	and	and	CC	_	5	cc
7	drug3	drug3	NN	_	5	conj
8	-RRB-	-rrb-	-RRB-	_	5	punct
9	:	:	:	_	1	punct
10	Agents	agent	NNS	_	30	nsubjpass
11	of	of	IN	_	13	case
12	the	the	DT	_	13	det
13	drug4	drug4	NN	_	10	nmod
14	,	,	,	_	13	punct
15	of	of	IN	_	16	case
16	which	which	WDT	_	26	nmod
17	drug5	drug5	NN	_	21	compound
18	-LRB-	-lrb-	-LRB-	_	19	punct
19	drug6	drug6	NN	_	17	appos
20	-RRB-	-rrb-	-RRB-	_	19	punct
21	Injection	injection	NN	_	26	nsubj
22	,	,	,	_	21	punct
23	USP	usp	NN	_	21	appos
24	is	be	VBZ	_	26	cop
25	a	a	DT	_	26	det
26	member	member	NN	_	13	acl:relcl
27	,	,	,	_	13	punct
28	have	have	VBP	_	30	aux
29	been	be	VBN	_	30	auxpass
30	shown	show	VBN	_	1	dep
31	to	to	TO	_	32	mark
32	interact	interact	VB	_	30	xcomp
33	with	with	IN	_	34	case
34	drug7	drug7	NN	_	32	nmod
35	of	of	IN	_	37	case
36	the	the	DT	_	37	det
37	drug8	drug8	NN	_	34	nmod
38	,	,	,	_	30	punct
39	resulting	result	VBG	_	30	advcl
40	in	in	IN	_	43	case
41	increased	increase	VBN	_	43	amod
42	plasma	plasma	NN	_	43	compound
43	levels	level	NNS	_	39	nmod
44	of	of	IN	_	46	case
45	unchanged	unchanged	JJ	_	46	amod
46	alkaloids	alkaloid	NNS	_	43	nmod
47	and	and	CC	_	46	cc
48	peripheral	peripheral	JJ	_	49	amod
49	vasoconstriction	vasoconstriction	NN	_	46	conj
50	.	.	.	_	1	punct

1	Vasospastic	vasospastic	JJ	_	2	amod
2	reactions	reaction	NNS	_	5	nsubjpass
3	have	have	VBP	_	5	aux
4	been	be	VBN	_	5	auxpass
5	reported	report	VBN	_	0	ROOT
6	with	with	IN	_	8	case
7	therapeutic	therapeutic	JJ	_	8	amod
8	doses	dose	NNS	_	5	nmod
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	-	-	:	_	8	punct
12	containing	contain	VBG	_	8	acl
13	drugs	drug	NNS	_	12	dobj
14	when	when	WRB	_	15	advmod
15	co-administered	co-administer	VBN	_	12	advcl
16	with	with	IN	_	18	case
17	these	these	DT	_	18	det
18	drug2	drug2	NN	_	15	nmod
19	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Weakness	weakness	NN	_	4	compound
4	hyperreflexia	hyperreflexia	NN	_	10	nsubjpass
5	,	,	,	_	4	punct
6	and	and	CC	_	4	cc
7	incoordination	incoordination	NN	_	4	conj
8	have	have	VBP	_	10	aux
9	been	be	VBN	_	10	auxpass
10	reported	report	VBN	_	1	appos
11	rarely	rarely	RB	_	10	advmod
12	when	when	WRB	_	16	advmod
13	drug2	drug2	NN	_	16	nsubjpass
14	have	have	VBP	_	16	aux
15	been	be	VBN	_	16	auxpass
16	co-administered	co-administer	VBN	_	11	dep
17	with	with	IN	_	18	case
18	drug3	drug3	NN	_	16	nmod
19	-LRB-	-lrb-	-LRB-	_	21	punct
20	e.	e.	FW	_	21	compound
21	g.	g.	FW	_	16	dep

1	drug1	drug1	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	,	,	,	_	1	punct
5	drug3	drug3	NN	_	1	conj
6	,	,	,	_	1	punct
7	drug4	drug4	NN	_	1	appos
8	-RRB-	-rrb-	-RRB-	_	1	punct
9	.	.	.	_	1	punct

1	There	there	EX	_	6	expl
2	have	have	VBP	_	6	aux
3	been	be	VBN	_	6	cop
4	no	no	DT	_	6	neg
5	reported	report	VBN	_	6	amod
6	cases	case	NNS	_	0	ROOT
7	from	from	IN	_	9	case
8	spontaneous	spontaneous	JJ	_	9	amod
9	reports	report	NNS	_	6	nmod
10	of	of	IN	_	12	case
11	drug	drug	NN	_	12	compound
12	interaction	interaction	NN	_	9	nmod
13	between	between	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	and	and	CC	_	14	cc
16	drug2	drug2	NN	_	20	compound
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	drug3	drug3	NN	_	16	appos
19	-RRB-	-rrb-	-RRB-	_	18	punct
20	Injection	injection	NN	_	14	conj
21	,	,	,	_	14	punct
22	USP	usp	NN	_	14	appos
23	.	.	.	_	6	punct

1	Oral	oral	JJ	_	2	amod
2	drug1	drug1	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	The	the	DT	_	5	det
5	effect	effect	NN	_	23	nsubjpass
6	of	of	IN	_	8	case
7	oral	oral	JJ	_	8	amod
8	drug2	drug2	NN	_	5	nmod
9	on	on	IN	_	11	case
10	the	the	DT	_	11	det
11	pharmacokinetics	pharmacokinetic	NNS	_	5	nmod
12	of	of	IN	_	13	case
13	drug3	drug3	NN	_	11	nmod
14	-LRB-	-lrb-	-LRB-	_	15	punct
15	drug4	drug4	NN	_	13	appos
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	Injection	injection	NN	_	13	dep
18	,	,	,	_	5	punct
19	USP	USP	NNP	_	5	appos
20	has	have	VBZ	_	23	aux
21	not	not	RB	_	23	neg
22	been	be	VBN	_	23	auxpass
23	studied	study	VBN	_	2	dep
24	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	magnitude	magnitude	NN	_	9	nsubj
3	and	and	CC	_	2	cc
4	relative	relative	JJ	_	5	amod
5	importance	importance	NN	_	2	conj
6	of	of	IN	_	8	case
7	the	the	DT	_	8	det
8	effects	effect	NNS	_	2	nmod
9	noted	note	VBD	_	0	ROOT
10	below	below	RB	_	9	advmod
11	are	be	VBP	_	12	cop
12	likely	likely	JJ	_	9	ccomp
13	to	to	TO	_	15	mark
14	be	be	VB	_	15	cop
15	patient	patient	NN	_	12	xcomp
16	specific	specific	JJ	_	15	amod
17	and	and	CC	_	9	cc
18	may	may	MD	_	19	aux
19	vary	vary	VB	_	9	conj
20	by	by	IN	_	22	case
21	such	such	JJ	_	22	amod
22	factors	factor	NNS	_	19	nmod
23	as	as	IN	_	24	case
24	age	age	NN	_	22	nmod
25	,	,	,	_	24	punct
26	gender	gender	NN	_	24	conj
27	,	,	,	_	24	punct
28	race	race	NN	_	24	conj
29	,	,	,	_	24	punct
30	intercurrent	intercurrent	JJ	_	31	amod
31	illnesses	illness	NNS	_	24	conj
32	,	,	,	_	24	punct
33	dose	dose	NN	_	24	conj
34	of	of	IN	_	36	case
35	either	either	CC	_	36	det
36	agent	agent	NN	_	33	nmod
37	,	,	,	_	24	punct
38	additional	additional	JJ	_	40	amod
39	concomitant	concomitant	JJ	_	40	amod
40	medications	medication	NNS	_	24	conj
41	,	,	,	_	24	punct
42	and	and	CC	_	24	cc
43	timing	timing	NN	_	24	conj
44	of	of	IN	_	46	case
45	drug	drug	NN	_	46	compound
46	administration	administration	NN	_	43	nmod
47	.	.	.	_	9	punct

1	Any	any	DT	_	2	det
2	agent	agent	NN	_	23	nsubj
3	that	that	WDT	_	4	nsubj
4	alters	alter	VBZ	_	2	acl:relcl
5	thyroid	thyroid	NN	_	7	compound
6	hormone	hormone	NN	_	7	compound
7	synthesis	synthesis	NN	_	4	dobj
8	,	,	,	_	7	punct
9	secretion	secretion	NN	_	7	conj
10	,	,	,	_	7	punct
11	distribution	distribution	NN	_	7	conj
12	,	,	,	_	7	punct
13	effect	effect	NN	_	7	appos
14	on	on	IN	_	16	case
15	target	target	NN	_	16	compound
16	tissues	tissue	NNS	_	13	nmod
17	,	,	,	_	16	punct
18	metabolism	metabolism	NN	_	16	conj
19	,	,	,	_	16	punct
20	or	or	CC	_	16	cc
21	elimination	elimination	NN	_	16	conj
22	may	may	MD	_	23	aux
23	alter	alter	VB	_	0	ROOT
24	the	the	DT	_	27	det
25	optimal	optimal	JJ	_	27	amod
26	therapeutic	therapeutic	JJ	_	27	amod
27	dose	dose	NN	_	23	dobj
28	of	of	IN	_	30	case
29	drug1	drug1	NN	_	30	compound
30	sodium	sodium	NN	_	27	nmod
31	.	.	.	_	23	punct

1	drug1	drug1	NN	_	2	compound
2	Absorption	absorption	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	The	the	DT	_	6	det
5	following	follow	VBG	_	6	amod
6	agents	agent	NNS	_	8	nsubj
7	may	may	MD	_	8	aux
8	bind	bind	VB	_	2	dep
9	and	and	CC	_	8	cc
10	decrease	decrease	VB	_	8	conj
11	absorption	absorption	NN	_	8	dobj
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	from	from	IN	_	17	case
15	the	the	DT	_	17	det
16	gastrointestinal	gastrointestinal	JJ	_	17	amod
17	tract	tract	NN	_	8	nmod
18	:	:	:	_	8	punct
19	drug3	drug3	NN	_	8	dep
20	,	,	,	_	19	punct
21	drug4	drug4	NN	_	22	compound
22	resin	resin	NN	_	19	conj
23	,	,	,	_	19	punct
24	drug5	drug5	NN	_	19	conj
25	,	,	,	_	19	punct
26	drug6	drug6	NN	_	19	conj
27	,	,	,	_	19	punct
28	drug7	drug7	NN	_	19	conj
29	,	,	,	_	19	punct
30	soybean	soybean	NN	_	31	compound
31	flour	flour	NN	_	19	conj
32	-LRB-	-lrb-	-LRB-	_	36	punct
33	e.g.	e.g.	FW	_	36	dep
34	,	,	,	_	36	punct
35	infant	infant	JJ	_	36	amod
36	formula	formula	NN	_	31	dep
37	-RRB-	-rrb-	-RRB-	_	36	punct
38	,	,	,	_	19	punct
39	drug8	drug8	NN	_	19	appos
40	.	.	.	_	2	punct

1	Binding	binding	NN	_	0	ROOT
2	to	to	TO	_	4	case
3	Serum	serum	NN	_	4	compound
4	Proteins	protein	NNS	_	1	nmod
5	:	:	:	_	1	punct
6	The	the	DT	_	8	det
7	following	follow	VBG	_	8	amod
8	agents	agent	NNS	_	11	nsubj
9	may	may	MD	_	11	aux
10	either	either	RB	_	11	advmod
11	inhibit	inhibit	VB	_	1	dep
12	drug1	drug1	NN	_	13	compound
13	binding	binding	NN	_	11	dobj
14	to	to	TO	_	16	case
15	serum	serum	NN	_	16	compound
16	proteins	protein	NNS	_	13	nmod
17	or	or	CC	_	11	cc
18	alter	alter	VB	_	11	conj
19	the	the	DT	_	20	det
20	concentrations	concentration	NNS	_	18	dobj
21	of	of	IN	_	24	case
22	serum	serum	NN	_	24	compound
23	binding	binding	NN	_	24	compound
24	proteins	protein	NNS	_	20	nmod
25	:	:	:	_	11	punct
26	drug2	drug2	NN	_	11	dep
27	and	and	CC	_	26	cc
28	related	related	JJ	_	29	amod
29	drug3	drug3	NN	_	26	conj
30	,	,	,	_	26	punct
31	drug4	drug4	NN	_	26	conj
32	,	,	,	_	26	punct
33	drug5	drug5	NN	_	26	conj
34	,	,	,	_	26	punct
35	drug6	drug6	NN	_	26	conj
36	and	and	CC	_	26	cc
37	drug7	drug7	NN	_	26	conj
38	,	,	,	_	26	punct
39	drug8	drug8	NN	_	26	conj
40	,	,	,	_	26	punct
41	drug9	drug9	NN	_	26	conj
42	,	,	,	_	26	punct
43	drug10	drug10	NN	_	26	conj
44	,	,	,	_	26	punct
45	drug11	drug11	NN	_	26	conj
46	,	,	,	_	26	punct
47	drug12	drug12	NN	_	26	conj
48	,	,	,	_	26	punct
49	drug13	drug13	NN	_	26	conj
50	,	,	,	_	26	punct
51	drug14	drug14	NN	_	26	conj
52	,	,	,	_	26	punct
53	drug15	drug15	NN	_	26	conj
54	,	,	,	_	26	punct
55	drug16	drug16	NN	_	26	conj
56	,	,	,	_	26	punct
57	drug17	drug17	NN	_	26	conj
58	,	,	,	_	26	punct
59	drug18	drug18	NN	_	26	conj
60	.	.	.	_	26	punct

1	Thyroid	thyroid	NN	_	2	compound
2	Physiology	Physiology	NNP	_	0	ROOT
3	:	:	:	_	2	punct
4	The	the	DT	_	6	det
5	following	follow	VBG	_	6	amod
6	agents	agent	NNS	_	8	nsubj
7	may	may	MD	_	8	aux
8	alter	alter	VB	_	2	dep
9	thyroid	thyroid	NN	_	10	compound
10	hormone	hormone	NN	_	13	compound
11	or	or	CC	_	10	cc
12	TSH	tsh	NN	_	10	conj
13	levels	level	NNS	_	8	dobj
14	,	,	,	_	8	punct
15	generally	generally	RB	_	17	advmod
16	by	by	IN	_	17	case
17	effects	effect	NNS	_	8	nmod
18	on	on	IN	_	21	case
19	thyroid	thyroid	NN	_	21	compound
20	hormone	hormone	NN	_	21	compound
21	synthesis	synthesis	NN	_	17	nmod
22	,	,	,	_	21	punct
23	secretion	secretion	NN	_	21	conj
24	,	,	,	_	21	punct
25	distribution	distribution	NN	_	21	conj
26	,	,	,	_	21	punct
27	metabolism	metabolism	NN	_	21	conj
28	,	,	,	_	21	punct
29	hormone	hormone	NN	_	30	compound
30	action	action	NN	_	21	conj
31	,	,	,	_	21	punct
32	or	or	CC	_	21	cc
33	elimination	elimination	NN	_	21	conj
34	,	,	,	_	21	punct
35	or	or	CC	_	21	cc
36	altered	altered	JJ	_	38	amod
37	TSH	tsh	NN	_	38	compound
38	secretion	secretion	NN	_	21	conj
39	:	:	:	_	8	punct
40	drug1	drug1	NN	_	8	dep
41	,	,	,	_	40	punct
42	drug2	drug2	NN	_	40	conj
43	,	,	,	_	40	punct
44	drug3	drug3	NN	_	40	conj
45	,	,	,	_	40	punct
46	drug4	drug4	NN	_	40	conj
47	and	and	CC	_	40	cc
48	related	related	JJ	_	50	amod
49	anabolic	anabolic	JJ	_	50	amod
50	hormones	hormone	NNS	_	40	conj
51	,	,	,	_	40	punct
52	complex	complex	JJ	_	53	amod
53	anions	anion	NNS	_	40	conj
54	-LRB-	-lrb-	-LRB-	_	55	punct
55	drug5	drug5	NN	_	53	dep
56	,	,	,	_	55	punct
57	drug6	drug6	NN	_	55	appos
58	,	,	,	_	55	punct
59	drug7	drug7	NN	_	55	appos
60	-RRB-	-rrb-	-RRB-	_	55	punct
61	,	,	,	_	40	punct
62	drug8	drug8	NN	_	40	conj
63	,	,	,	_	40	punct
64	drug9	drug9	NN	_	40	conj
65	,	,	,	_	40	punct
66	drug10	drug10	NN	_	40	conj
67	,	,	,	_	40	punct
68	drug11	drug11	NN	_	40	conj
69	,	,	,	_	40	punct
70	drug12	drug12	NN	_	40	conj
71	,	,	,	_	40	punct
72	drug13	drug13	NN	_	40	conj
73	and	and	CC	_	40	cc
74	drug14	drug14	NN	_	40	conj
75	,	,	,	_	40	punct
76	drug15	drug15	NN	_	40	conj
77	,	,	,	_	40	punct
78	drug16	drug16	NN	_	40	conj
79	,	,	,	_	40	punct
80	drug17	drug17	NN	_	40	conj
81	,	,	,	_	40	punct
82	hepatic	hepatic	JJ	_	84	amod
83	enzyme	enzyme	NN	_	84	compound
84	inducers	inducer	NNS	_	40	conj
85	,	,	,	_	40	punct
86	drug18	drug18	NN	_	40	conj
87	,	,	,	_	40	punct
88	iodinated	iodinate	VBN	_	90	amod
89	cholestographic	cholestographic	JJ	_	90	amod
90	agents	agent	NNS	_	40	conj
91	,	,	,	_	40	punct
92	drug19	drug19	NN	_	40	conj
93	,	,	,	_	40	punct
94	drug20	drug20	NN	_	40	conj
95	,	,	,	_	40	punct
96	drug21	drug21	NN	_	40	conj
97	,	,	,	_	40	punct
98	drug22	drug22	NN	_	40	conj
99	,	,	,	_	40	punct
100	drug23	drug23	NN	_	40	conj
101	,	,	,	_	40	punct
102	drug24	drug24	NN	_	40	conj
103	,	,	,	_	40	punct
104	drug25	drug25	NN	_	40	conj
105	,	,	,	_	40	punct
106	drug26	drug26	NN	_	40	conj
107	,	,	,	_	40	punct
108	drug27	drug27	NN	_	40	conj
109	,	,	,	_	40	punct
110	drug28	drug28	NN	_	40	conj
111	,	,	,	_	40	punct
112	drug29	drug29	NN	_	40	conj
113	,	,	,	_	40	punct
114	drug30	drug30	NN	_	40	conj
115	,	,	,	_	40	punct
116	drug31	drug31	NN	_	40	conj
117	,	,	,	_	40	punct
118	drug32	drug32	NN	_	40	conj
119	,	,	,	_	40	punct
120	drug33	drug33	NN	_	40	conj
121	,	,	,	_	40	punct
122	drug34	drug34	NN	_	40	conj
123	.	.	.	_	40	punct

1	Adrenocorticoids	Adrenocorticoids	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	Metabolic	metabolic	JJ	_	4	amod
4	clearance	clearance	NN	_	8	nsubjpass
5	of	of	IN	_	6	case
6	adrenocorticoids	adrenocorticoid	NNS	_	4	nmod
7	is	be	VBZ	_	8	auxpass
8	decreased	decrease	VBN	_	1	dep
9	in	in	IN	_	11	case
10	hypothyroid	hypothyroid	JJ	_	11	amod
11	patients	patient	NNS	_	8	nmod
12	and	and	CC	_	8	cc
13	increased	increase	VBN	_	8	conj
14	in	in	IN	_	16	case
15	hyperthyroid	hyperthyroid	JJ	_	16	amod
16	patients	patient	NNS	_	13	nmod
17	,	,	,	_	8	punct
18	and	and	CC	_	8	cc
19	may	may	MD	_	21	aux
20	therefore	therefore	RB	_	21	advmod
21	change	change	VB	_	8	conj
22	with	with	IN	_	25	case
23	changing	change	VBG	_	25	amod
24	thyroid	thyroid	NN	_	25	compound
25	status	status	NN	_	21	nmod
26	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	compound
4	therapy	therapy	NN	_	7	nsubj
5	alone	alone	RB	_	4	advmod
6	can	can	MD	_	7	aux
7	cause	cause	VB	_	1	appos
8	hypothyroidism	hypothyroidism	NN	_	7	dobj
9	or	or	CC	_	8	cc
10	hyperthyroidism	hyperthyroidism	NN	_	8	conj
11	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	Oral	oral	JJ	_	1	appos
4	-RRB-	-rrb-	-RRB-	_	3	punct
5	:	:	:	_	1	punct
6	The	the	DT	_	8	det
7	hypoprothrombinemic	hypoprothrombinemic	JJ	_	8	amod
8	effect	effect	NN	_	13	nsubj
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	may	may	MD	_	13	aux
12	be	be	VB	_	13	cop
13	potentiated	potentiated	JJ	_	1	dep
14	,	,	,	_	13	punct
15	apparently	apparently	RB	_	18	advmod
16	by	by	IN	_	18	case
17	increased	increase	VBN	_	18	amod
18	catabloism	catabloism	NN	_	13	nmod
19	of	of	IN	_	23	case
20	vitamin	vitamin	NN	_	23	compound
21	K-dependent	k-dependent	JJ	_	23	amod
22	clotting	clotting	NN	_	23	compound
23	factors	factor	NNS	_	18	nmod
24	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	drug2	drug2	NN	_	1	dep
4	,	,	,	_	3	punct
5	drug3	drug3	NN	_	3	appos
6	-RRB-	-rrb-	-RRB-	_	3	punct
7	:	:	:	_	1	punct
8	Requirements	requirement	NNS	_	16	nsubjpass
9	for	for	IN	_	10	case
10	drug4	drug4	NN	_	8	nmod
11	or	or	CC	_	10	cc
12	oral	oral	JJ	_	13	amod
13	drug5	drug5	NN	_	10	conj
14	may	may	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	reduced	reduce	VBN	_	1	dep
17	in	in	IN	_	19	case
18	hypothyroid	hypothyroid	JJ	_	19	amod
19	patients	patient	NNS	_	16	nmod
20	with	with	IN	_	22	case
21	diabetes	diabetes	NN	_	22	compound
22	mellitus	mellitus	NN	_	19	nmod
23	and	and	CC	_	16	cc
24	may	may	MD	_	26	aux
25	subsequently	subsequently	RB	_	26	advmod
26	increase	increase	VB	_	16	conj
27	with	with	IN	_	29	case
28	the	the	DT	_	29	det
29	initiation	initiation	NN	_	26	nmod
30	of	of	IN	_	34	case
31	thyroid	thyroid	NN	_	34	compound
32	hormone	hormone	NN	_	34	compound
33	replacement	replacement	NN	_	34	compound
34	therapy	therapy	NN	_	29	nmod
35	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Actions	action	NNS	_	10	nsubj
4	of	of	IN	_	5	case
5	some	some	DT	_	3	nmod
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	may	may	MD	_	10	aux
9	be	be	VB	_	10	aux
10	impaired	impaired	JJ	_	1	appos
11	when	when	WRB	_	14	advmod
12	hypothyroid	hypothyroid	JJ	_	13	amod
13	patients	patient	NNS	_	14	nsubj
14	become	become	VBP	_	10	advcl
15	euthyroid	euthyroid	JJ	_	14	xcomp
16	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	drug2	drug2	NN	_	1	dep
4	,	,	,	_	3	punct
5	drug3	drug3	NN	_	3	appos
6	-RRB-	-rrb-	-RRB-	_	3	punct
7	:	:	:	_	1	punct
8	drug4	drug4	NN	_	11	nsubjpass
9	have	have	VBP	_	11	aux
10	been	be	VBN	_	11	auxpass
11	reported	report	VBN	_	1	dep
12	to	to	TO	_	13	mark
13	induce	induce	VB	_	11	xcomp
14	both	both	CC	_	15	cc:preconj
15	hyperthyroidism	hyperthyroidism	NN	_	13	dobj
16	and	and	CC	_	15	cc
17	hypothyroidism	hypothyroidism	NN	_	15	conj
18	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Therapeutic	therapeutic	JJ	_	4	amod
4	effects	effect	NNS	_	9	nsubjpass
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	may	may	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	reduced	reduce	VBN	_	1	dep
10	.	.	.	_	1	punct

1	Serum	serum	NN	_	3	compound
2	drug1	drug1	NN	_	3	compound
3	levels	level	NNS	_	6	nsubjpass
4	may	may	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	decreased	decrease	VBN	_	0	ROOT
7	in	in	IN	_	8	case
8	hyperthyroidism	hyperthyroidism	NN	_	6	nmod
9	or	or	CC	_	8	cc
10	when	when	WRB	_	14	advmod
11	a	a	DT	_	13	det
12	hypothyroid	hypothyroid	JJ	_	13	amod
13	patient	patient	NN	_	14	nsubj
14	becomes	become	VBZ	_	8	conj
15	euthyroid	euthyroid	JJ	_	14	xcomp
16	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Marked	marked	JJ	_	4	amod
4	hypertension	hypertension	NN	_	9	nsubjpass
5	and	and	CC	_	4	cc
6	tachycardia	tachycardia	NN	_	4	conj
7	have	have	VBP	_	9	aux
8	been	be	VBN	_	9	auxpass
9	reported	report	VBN	_	1	appos
10	in	in	IN	_	11	case
11	association	association	NN	_	9	nmod
12	with	with	IN	_	14	case
13	concomitant	concomitant	JJ	_	14	amod
14	administration	administration	NN	_	11	nmod
15	of	of	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	and	and	CC	_	16	cc
18	drug3	drug3	NN	_	16	conj
19	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Risk	risk	NN	_	8	nsubj
4	of	of	IN	_	6	case
5	cardiac	cardiac	JJ	_	6	amod
6	arrhythmias	arrhythmia	NNS	_	3	nmod
7	may	may	MD	_	8	aux
8	increase	increase	VB	_	1	parataxis
9	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	123I	123i	NN	_	1	dep
4	and	and	CC	_	3	cc
5	131I	131i	NN	_	3	conj
6	-RRB-	-rrb-	-RRB-	_	3	punct
7	,	,	,	_	1	punct
8	drug2	drug2	NN	_	1	appos
9	:	:	:	_	1	punct
10	Uptake	Uptake	NNP	_	16	nsubjpass
11	of	of	IN	_	13	case
12	radiolabeled	radiolabele	VBN	_	13	amod
13	ions	ion	NNS	_	10	nmod
14	may	may	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	decreased	decrease	VBN	_	1	dep
17	.	.	.	_	1	punct

1	drug1	drug1	NN	_	3	compound
2	/	/	:	_	3	punct
3	drug2	drug2	NN	_	0	ROOT
4	:	:	:	_	3	punct
5	Excessive	excessive	JJ	_	7	amod
6	concurrent	concurrent	JJ	_	7	amod
7	use	use	NN	_	11	nsubj
8	of	of	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	may	may	MD	_	11	aux
11	accelerate	accelerate	VB	_	3	dep
12	epiphyseal	epiphyseal	NN	_	13	compound
13	closure	closure	NN	_	11	dobj
14	.	.	.	_	3	punct

1	Untreated	untreated	JJ	_	2	amod
2	hypothyroidism	hypothyroidism	NN	_	4	nsubj
3	may	may	MD	_	4	aux
4	interfere	interfere	VB	_	0	ROOT
5	with	with	IN	_	8	case
6	the	the	DT	_	8	det
7	growth	growth	NN	_	8	compound
8	response	response	NN	_	4	nmod
9	to	to	TO	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	or	or	CC	_	10	cc
12	drug2	drug2	NN	_	10	conj
13	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	compound
4	clearance	clearance	NN	_	6	nsubj
5	may	may	MD	_	6	aux
6	decrease	decrease	VB	_	1	dep
7	in	in	IN	_	9	case
8	hypothyroid	hypothyroid	JJ	_	9	amod
9	patients	patient	NNS	_	6	nmod
10	and	and	CC	_	9	cc
11	return	return	NN	_	9	conj
12	toward	toward	IN	_	13	case
13	normal	normal	JJ	_	9	nmod
14	when	when	WRB	_	19	advmod
15	a	a	DT	_	17	det
16	euthyroid	euthyroid	JJ	_	17	amod
17	state	state	NN	_	19	nsubjpass
18	is	be	VBZ	_	19	auxpass
19	achieved	achieve	VBN	_	6	advcl
20	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concurrent	concurrent	JJ	_	4	amod
4	use	use	NN	_	6	nsubj
5	may	may	MD	_	6	aux
6	increase	increase	VB	_	1	dep
7	the	the	DT	_	11	det
8	therapeutic	therapeutic	JJ	_	11	amod
9	and	and	CC	_	8	cc
10	toxic	toxic	JJ	_	8	conj
11	effects	effect	NNS	_	6	dobj
12	of	of	IN	_	14	case
13	both	both	DT	_	14	det
14	drugs	drug	NNS	_	11	nmod
15	,	,	,	_	6	punct
16	possibly	possibly	RB	_	17	advmod
17	due	due	JJ	_	6	advmod
18	to	to	TO	_	21	case
19	increased	increase	VBN	_	21	amod
20	catecholamine	catecholamine	NN	_	21	compound
21	sensitivity	sensitivity	NN	_	17	nmod
22	.	.	.	_	1	punct

1	Onset	onset	NN	_	8	nsubjpass
2	of	of	IN	_	3	case
3	action	action	NN	_	1	nmod
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	accelerated	accelerate	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Possible	possible	JJ	_	5	amod
4	increased	increase	VBN	_	5	amod
5	risk	risk	NN	_	1	dep
6	of	of	IN	_	8	case
7	coronary	coronary	JJ	_	8	amod
8	insufficiency	insufficiency	NN	_	5	nmod
9	in	in	IN	_	10	case
10	patients	patient	NNS	_	5	nmod
11	with	with	IN	_	14	case
12	coronary	coronary	JJ	_	14	amod
13	artery	artery	NN	_	14	compound
14	disease	disease	NN	_	10	nmod
15	.	.	.	_	1	punct

1	In	in	IN	_	3	case
2	one	one	CD	_	3	nummod
3	survey	survey	NN	_	15	nmod
4	,	,	,	_	15	punct
5	2.3	2.3	CD	_	6	nummod
6	%	%	NN	_	15	nsubj
7	of	of	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	taking	take	VBG	_	8	acl
10	drug1	drug1	NN	_	9	dobj
11	in	in	IN	_	12	case
12	combination	combination	NN	_	9	nmod
13	with	with	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	experienced	experience	VBD	_	0	ROOT
16	tremor	tremor	NN	_	15	dobj
17	,	,	,	_	15	punct
18	as	as	IN	_	19	mark
19	compared	compare	VBN	_	15	advcl
20	to	to	TO	_	22	case
21	0.7	0.7	CD	_	22	nummod
22	%	%	NN	_	19	nmod
23	reported	report	VBD	_	22	acl
24	to	to	TO	_	25	mark
25	occur	occur	VB	_	23	xcomp
26	with	with	IN	_	27	case
27	drug3	drug3	NN	_	25	nmod
28	alone	alone	RB	_	27	advmod
29	.	.	.	_	15	punct

1	The	the	DT	_	2	det
2	contribution	contribution	NN	_	13	nsubj
3	of	of	IN	_	4	case
4	each	each	DT	_	2	nmod
5	of	of	IN	_	7	case
6	the	the	DT	_	7	det
7	treatments	treatment	NNS	_	4	nmod
8	to	to	TO	_	11	case
9	this	this	DT	_	11	det
10	adverse	adverse	JJ	_	11	amod
11	reaction	reaction	NN	_	2	nmod
12	is	be	VBZ	_	13	cop
13	unknown	unknown	JJ	_	0	ROOT
14	but	but	CC	_	13	cc
15	the	the	DT	_	16	det
16	possibility	possibility	NN	_	24	nsubjpass
17	of	of	IN	_	20	case
18	a	a	DT	_	20	det
19	drug	drug	NN	_	20	compound
20	interaction	interaction	NN	_	16	nmod
21	can	can	MD	_	24	aux
22	not	not	RB	_	24	neg
23	be	be	VB	_	24	auxpass
24	excluded	exclude	VBN	_	13	conj
25	.	.	.	_	13	punct

1	Drugs	drug	NNS	_	6	nsubj
2	possessing	possess	VBG	_	1	acl
3	beta-blocking	beta-blocking	JJ	_	4	amod
4	properties	property	NNS	_	2	dobj
5	can	can	MD	_	6	aux
6	blunt	blunt	VB	_	0	ROOT
7	the	the	DT	_	9	det
8	bronchodilator	bronchodilator	NN	_	9	compound
9	effect	effect	NN	_	6	dobj
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	in	in	IN	_	13	case
13	patients	patient	NNS	_	6	nmod
14	with	with	IN	_	15	case
15	bronchospasm	bronchospasm	NN	_	13	nmod
16	;	;	:	_	6	punct

1	therefore	therefore	RB	_	14	advmod
2	,	,	,	_	14	punct
3	doses	dose	NNS	_	14	nsubjpass
4	greater	greater	JJR	_	3	amod
5	than	than	IN	_	9	case
6	the	the	DT	_	9	det
7	normal	normal	JJ	_	9	amod
8	antiasthmatic	antiasthmatic	JJ	_	9	amod
9	dose	dose	NN	_	4	nmod
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	may	may	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	required	require	VBN	_	0	ROOT
15	.	.	.	_	14	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	shown	show	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	increase	increase	VB	_	4	xcomp
7	the	the	DT	_	8	det
8	bioavailability	bioavailability	NN	_	6	dobj
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	.	.	.	_	4	punct

1	Since	since	IN	_	5	mark
2	this	this	DT	_	5	nsubjpass
3	could	could	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	explained	explain	VBN	_	24	advcl
6	either	either	CC	_	9	cc:preconj
7	by	by	IN	_	9	case
8	enhanced	enhance	VBN	_	9	amod
9	absorption	absorption	NN	_	5	nmod
10	or	or	CC	_	9	cc
11	by	by	IN	_	13	case
12	an	a	DT	_	13	det
13	alteration	alteration	NN	_	9	conj
14	of	of	IN	_	16	case
15	hepatic	hepatic	JJ	_	16	amod
16	metabolism	metabolism	NN	_	13	nmod
17	of	of	IN	_	18	case
18	drug1	drug1	NN	_	16	nmod
19	,	,	,	_	24	punct
20	special	special	JJ	_	21	amod
21	care	care	NN	_	24	nsubjpass
22	should	should	MD	_	24	aux
23	be	be	VB	_	24	auxpass
24	used	use	VBN	_	0	ROOT
25	in	in	IN	_	26	mark
26	establishing	establish	VBG	_	24	advcl
27	the	the	DT	_	28	det
28	dose	dose	NN	_	26	dobj
29	required	require	VBN	_	28	acl
30	for	for	IN	_	33	case
31	blood	blood	NN	_	33	compound
32	pressure	pressure	NN	_	33	compound
33	control	control	NN	_	29	nmod
34	in	in	IN	_	36	case
35	such	such	JJ	_	36	amod
36	patients	patient	NNS	_	33	nmod
37	.	.	.	_	24	punct

1	Synergism	synergism	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	shown	show	VBN	_	0	ROOT
5	between	between	IN	_	7	case
6	drug1	drug1	NN	_	7	compound
7	anesthesia	anesthesia	NN	_	4	nmod
8	and	and	CC	_	7	cc
9	intravenously	intravenously	RB	_	10	advmod
10	administered	administer	VBN	_	11	amod
11	drug2	drug2	NN	_	7	conj
12	.	.	.	_	4	punct

1	During	during	IN	_	4	case
2	controlled	controlled	JJ	_	4	amod
3	hypotensive	hypotensive	JJ	_	4	amod
4	anesthesia	anesthesia	NN	_	25	nmod
5	using	use	VBG	_	4	acl
6	drug1	drug1	NN	_	5	dobj
7	in	in	IN	_	8	case
8	association	association	NN	_	5	nmod
9	with	with	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	,	,	,	_	25	punct
12	high	high	JJ	_	13	amod
13	concentrations	concentration	NNS	_	25	nsubjpass
14	-LRB-	-lrb-	-LRB-	_	16	punct
15	3	3	CD	_	16	nummod
16	%	%	NN	_	13	dep
17	or	or	CC	_	16	cc
18	above	above	IN	_	16	conj
19	-RRB-	-rrb-	-RRB-	_	16	punct
20	of	of	IN	_	21	case
21	drug3	drug3	NN	_	13	nmod
22	should	should	MD	_	25	aux
23	not	not	RB	_	25	neg
24	be	be	VB	_	25	auxpass
25	used	use	VBN	_	0	ROOT
26	because	because	IN	_	33	mark
27	the	the	DT	_	28	det
28	degree	degree	NN	_	33	nsubjpass
29	of	of	IN	_	30	case
30	hypotension	hypotension	NN	_	28	nmod
31	will	will	MD	_	33	aux
32	be	be	VB	_	33	auxpass
33	increased	increase	VBN	_	25	advcl
34	and	and	CC	_	33	cc
35	because	because	IN	_	38	case
36	of	of	IN	_	35	mwe
37	the	the	DT	_	38	det
38	possibility	possibility	NN	_	33	conj
39	of	of	IN	_	42	case
40	a	a	DT	_	42	det
41	large	large	JJ	_	42	amod
42	reduction	reduction	NN	_	38	nmod
43	in	in	IN	_	45	case
44	cardiac	cardiac	JJ	_	45	amod
45	output	output	NN	_	42	nmod
46	and	and	CC	_	38	cc
47	an	a	DT	_	48	det
48	increase	increase	NN	_	38	conj
49	in	in	IN	_	52	case
50	central	central	JJ	_	52	amod
51	venous	venous	JJ	_	52	amod
52	pressure	pressure	NN	_	48	nmod
53	.	.	.	_	25	punct

1	The	the	DT	_	2	det
2	anesthesiologist	anesthesiologist	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	informed	inform	VBN	_	0	ROOT
6	when	when	WRB	_	10	advmod
7	a	a	DT	_	8	det
8	patient	patient	NN	_	10	nsubj
9	is	be	VBZ	_	10	aux
10	receiving	receive	VBG	_	5	advcl
11	drug1	drug1	NN	_	10	dobj
12	.	.	.	_	5	punct

1	drug1	drug1	NN	_	2	nsubj
2	blunts	blunt	VBZ	_	0	ROOT
3	the	the	DT	_	5	det
4	reflex	reflex	JJ	_	5	amod
5	tachycardia	tachycardia	NN	_	2	dobj
6	produced	produce	VBN	_	5	acl
7	by	by	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	without	without	IN	_	10	mark
10	preventing	prevent	VBG	_	2	advcl
11	its	its	PRP$	_	13	nmod:poss
12	hypotensive	hypotensive	JJ	_	13	amod
13	effect	effect	NN	_	10	dobj
14	.	.	.	_	2	punct

1	If	if	IN	_	4	mark
2	drug1	drug1	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	used	use	VBN	_	17	advcl
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	with	with	IN	_	11	case
10	angina	angina	NN	_	11	compound
11	pectoris	pectoris	NN	_	8	nmod
12	,	,	,	_	17	punct
13	additional	additional	JJ	_	15	amod
14	antihypertensive	antihypertensive	JJ	_	15	amod
15	effects	effect	NNS	_	17	nsubj
16	may	may	MD	_	17	aux
17	occur	occur	VB	_	0	ROOT
18	.	.	.	_	17	punct

1	Care	Care	NNP	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	taken	take	VBN	_	0	ROOT
5	if	if	IN	_	8	mark
6	drug1	drug1	NN	_	8	nsubjpass
7	is	be	VBZ	_	8	auxpass
8	used	use	VBN	_	4	advcl
9	concomitantly	concomitantly	RB	_	8	advmod
10	with	with	IN	_	12	case
11	drug2	drug2	NN	_	12	compound
12	s	s	NNS	_	8	nmod
13	of	of	IN	_	16	case
14	the	the	DT	_	16	det
15	drug3	drug3	NN	_	16	compound
16	type	type	NN	_	12	nmod
17	.	.	.	_	4	punct

1	Risk	risk	NN	_	0	ROOT
2	of	of	IN	_	4	case
3	Anaphylactic	Anaphylactic	NNP	_	4	compound
4	Reaction	Reaction	NNP	_	1	nmod
5	While	while	IN	_	6	mark
6	taking	take	VBG	_	1	acl
7	drug1	drug1	NN	_	6	dobj
8	,	,	,	_	1	punct
9	patients	patient	NNS	_	25	nsubj
10	with	with	IN	_	12	case
11	a	a	DT	_	12	det
12	history	history	NN	_	9	nmod
13	of	of	IN	_	16	case
14	severe	severe	JJ	_	16	amod
15	anaphylactic	anaphylactic	JJ	_	16	amod
16	reaction	reaction	NN	_	12	nmod
17	to	to	TO	_	19	case
18	a	a	DT	_	19	det
19	variety	variety	NN	_	16	nmod
20	of	of	IN	_	21	case
21	allergens	allergen	NNS	_	19	nmod
22	may	may	MD	_	25	aux
23	be	be	VB	_	25	cop
24	more	more	RBR	_	25	advmod
25	reactive	reactive	JJ	_	1	acl:relcl
26	to	to	TO	_	28	case
27	repeated	repeat	VBN	_	28	amod
28	challenge	challenge	NN	_	25	nmod
29	,	,	,	_	1	punct
30	either	either	CC	_	31	cc:preconj
31	accidental	accidental	JJ	_	1	dep
32	,	,	,	_	31	punct
33	diagnostic	diagnostic	JJ	_	31	conj
34	,	,	,	_	31	punct
35	or	or	CC	_	31	cc
36	therapeutic	therapeutic	JJ	_	31	conj
37	.	.	.	_	1	punct

1	Such	such	JJ	_	2	amod
2	patients	patient	NNS	_	5	nsubj
3	may	may	MD	_	5	aux
4	be	be	VB	_	5	cop
5	unresponsive	unresponsive	JJ	_	0	ROOT
6	to	to	TO	_	9	case
7	the	the	DT	_	9	det
8	usual	usual	JJ	_	9	amod
9	doses	dose	NNS	_	5	nmod
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	used	use	VBN	_	9	acl
13	to	to	TO	_	14	mark
14	treat	treat	VB	_	12	xcomp
15	allergic	allergic	JJ	_	16	amod
16	reaction	reaction	NN	_	14	dobj
17	.	.	.	_	5	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	3	amod
2	Test	test	NN	_	3	compound
3	Interactions	interaction	NNS	_	0	ROOT
4	The	the	DT	_	5	det
5	presence	presence	NN	_	13	nsubj
6	of	of	IN	_	8	case
7	labetalol	labetalol	NN	_	8	compound
8	metabolites	metabolite	NNS	_	5	nmod
9	in	in	IN	_	11	case
10	the	the	DT	_	11	det
11	urine	urine	NN	_	5	nmod
12	may	may	MD	_	13	aux
13	result	result	VB	_	3	acl:relcl
14	in	in	IN	_	17	case
15	falsely	falsely	RB	_	16	advmod
16	elevated	elevated	JJ	_	17	amod
17	levels	level	NNS	_	13	nmod
18	of	of	IN	_	20	case
19	urinary	urinary	JJ	_	20	amod
20	catecholamines	catecholamine	NNS	_	17	nmod
21	,	,	,	_	20	punct
22	metanephrine	metanephrine	NN	_	20	conj
23	,	,	,	_	20	punct
24	normetanephrine	normetanephrine	NN	_	20	conj
25	and	and	CC	_	20	cc
26	vanillylmandelic	vanillylmandelic	JJ	_	27	amod
27	acid	acid	NN	_	20	conj
28	when	when	WRB	_	29	advmod
29	measured	measure	VBN	_	17	acl:relcl
30	by	by	IN	_	34	case
31	fluorimetric	fluorimetric	JJ	_	34	amod
32	or	or	CC	_	31	cc
33	photometric	photometric	JJ	_	31	conj
34	methods	method	NNS	_	29	nmod
35	.	.	.	_	3	punct

1	In	in	IN	_	3	case
2	screening	screening	NN	_	3	compound
3	patients	patient	NNS	_	0	ROOT
4	suspected	suspect	VBN	_	3	acl
5	of	of	IN	_	6	mark
6	having	have	VBG	_	4	advcl
7	a	a	DT	_	8	det
8	pheochromocytoma	pheochromocytoma	NN	_	6	dobj
9	and	and	CC	_	6	cc
10	being	be	VBG	_	11	auxpass
11	treated	treat	VBN	_	6	conj
12	with	with	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	,	,	,	_	13	punct
15	a	a	DT	_	17	det
16	specific	specific	JJ	_	17	amod
17	method	method	NN	_	13	appos
18	,	,	,	_	13	punct
19	such	such	JJ	_	26	case
20	as	as	IN	_	19	mwe
21	a	a	DT	_	26	det
22	high	high	JJ	_	26	amod
23	performance	performance	NN	_	26	compound
24	liquid	liquid	NN	_	26	compound
25	chromatographic	chromatographic	JJ	_	26	amod
26	assay	assay	NN	_	13	nmod
27	with	with	IN	_	30	case
28	solid	solid	JJ	_	30	amod
29	phase	phase	NN	_	30	compound
30	extraction	extraction	NN	_	26	nmod
31	-LRB-	-lrb-	-LRB-	_	40	punct
32	e.g.	e.g.	FW	_	40	advmod
33	,	,	,	_	40	punct
34	J	J	NNP	_	35	compound
35	Chromatogr	Chromatogr	NNP	_	40	nsubjpass
36	385:241,1987	385:241,1987	CD	_	35	nummod
37	-RRB-	-rrb-	-RRB-	_	35	punct
38	should	should	MD	_	40	aux
39	be	be	VB	_	40	auxpass
40	employed	employ	VBN	_	30	acl
41	in	in	IN	_	42	mark
42	determining	determine	VBG	_	40	advcl
43	levels	level	NNS	_	42	dobj
44	of	of	IN	_	45	case
45	catecholamines	catecholamine	NNS	_	43	nmod
46	.	.	.	_	3	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	has	have	VBZ	_	5	aux
3	also	also	RB	_	5	advmod
4	been	be	VBN	_	5	auxpass
5	reported	report	VBN	_	0	ROOT
6	to	to	TO	_	7	mark
7	produce	produce	VB	_	5	xcomp
8	a	a	DT	_	11	det
9	false	false	JJ	_	11	amod
10	positive	positive	JJ	_	11	amod
11	test	test	NN	_	7	dobj
12	for	for	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	when	when	WRB	_	15	advmod
15	screening	screen	VBG	_	7	advcl
16	urine	urine	NN	_	15	dobj
17	for	for	IN	_	19	case
18	the	the	DT	_	19	det
19	presence	presence	NN	_	15	nmod
20	of	of	IN	_	21	case
21	drugs	drug	NNS	_	19	nmod
22	using	use	VBG	_	15	advcl
23	the	the	DT	_	29	det
24	commercially	commercially	RB	_	25	advmod
25	available	available	JJ	_	29	amod
26	assay	assay	NN	_	29	compound
27	methods	method	NNS	_	29	compound
28	Toxi-Lab	Toxi-Lab	NNP	_	29	compound
29	A	A	NNP	_	22	dobj
30	-LRB-	-lrb-	-LRB-	_	33	punct
31	thin-layer	thin-layer	JJ	_	33	amod
32	chromatographic	chromatographic	JJ	_	33	amod
33	assay	assay	NN	_	29	appos
34	-RRB-	-rrb-	-RRB-	_	33	punct
35	and	and	CC	_	29	cc
36	Emit-d.a.u.	emit-d.a.u.	NN	_	29	conj
37	-LRB-	-lrb-	-LRB-	_	39	punct
38	radioenzymatic	radioenzymatic	JJ	_	39	amod
39	assay	assay	NN	_	36	appos
40	-RRB-	-rrb-	-RRB-	_	39	punct
41	.	.	.	_	5	punct

1	When	when	WRB	_	4	advmod
2	patients	patient	NNS	_	4	nsubjpass
3	being	be	VBG	_	4	auxpass
4	treated	treat	VBN	_	20	advcl
5	with	with	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	have	have	VBP	_	20	aux
8	a	a	DT	_	11	det
9	positive	positive	JJ	_	11	amod
10	urine	urine	NN	_	11	compound
11	test	test	NN	_	20	nsubjpass
12	for	for	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	using	use	VBG	_	11	acl
15	these	these	DT	_	17	det
16	techniques	technique	NNS	_	17	compound
17	confirmation	confirmation	NN	_	14	dobj
18	should	should	MD	_	20	aux
19	be	be	VB	_	20	auxpass
20	made	make	VBN	_	0	ROOT
21	by	by	IN	_	22	mark
22	using	use	VBG	_	20	advcl
23	more	more	RBR	_	24	advmod
24	specific	specific	JJ	_	25	amod
25	methods	method	NNS	_	22	dobj
26	such	such	JJ	_	32	case
27	as	as	IN	_	26	mwe
28	a	a	DT	_	32	det
29	gas	gas	NN	_	32	compound
30	chromatographic-mass	chromatographic-mass	NN	_	32	compound
31	spectrometer	spectrometer	NN	_	32	compound
32	technique	technique	NN	_	25	nmod
33	.	.	.	_	20	punct

1	The	the	DT	_	4	det
2	following	follow	VBG	_	4	amod
3	drug	drug	NN	_	4	compound
4	interactions	interaction	NNS	_	6	nsubjpass
5	were	be	VBD	_	6	auxpass
6	observed	observe	VBN	_	0	ROOT
7	in	in	IN	_	9	case
8	some	some	DT	_	9	det
9	patients	patient	NNS	_	6	nmod
10	undergoing	undergo	VBG	_	9	acl
11	treatment	treatment	NN	_	10	dobj
12	with	with	IN	_	14	case
13	oral	oral	JJ	_	14	amod
14	drug1	drug1	NN	_	11	nmod
15	.	.	.	_	6	punct

1	Although	although	IN	_	9	mark
2	the	the	DT	_	3	det
3	pattern	pattern	NN	_	9	nsubj
4	of	of	IN	_	5	case
5	use	use	NN	_	3	nmod
6	for	for	IN	_	8	case
7	oral	oral	JJ	_	8	amod
8	drug1	drug1	NN	_	5	nmod
9	includes	include	VBZ	_	23	advcl
10	longer	longer	JJR	_	12	amod
11	term	term	NN	_	12	compound
12	therapy	therapy	NN	_	9	dobj
13	,	,	,	_	23	punct
14	particularly	particularly	RB	_	16	advmod
15	for	for	IN	_	16	case
16	gout	gout	NN	_	23	nmod
17	and	and	CC	_	16	cc
18	renal	renal	JJ	_	19	amod
19	calculi	calculus	NNS	_	16	conj
20	,	,	,	_	23	punct
21	the	the	DT	_	22	det
22	experience	experience	NN	_	23	nsubj
23	gained	gain	VBD	_	0	ROOT
24	may	may	MD	_	26	aux
25	be	be	VB	_	26	cop
26	relevant	relevant	JJ	_	23	ccomp
27	.	.	.	_	23	punct

1	drug1	drug1	NN	_	3	compound
2	/	/	:	_	3	punct
3	drug2	drug2	NN	_	0	ROOT
4	:	:	:	_	3	punct
5	drug3	drug3	NN	_	6	nsubj
6	inhibits	inhibit	VBZ	_	3	dep
7	the	the	DT	_	9	det
8	enzymatic	enzymatic	JJ	_	9	amod
9	oxidation	oxidation	NN	_	6	dobj
10	of	of	IN	_	11	case
11	drug4	drug4	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	drug5	drug5	NN	_	11	conj
14	to	to	TO	_	15	case
15	drug6	drug6	NN	_	6	nmod
16	.	.	.	_	3	punct

1	This	this	DT	_	2	det
2	oxidation	oxidation	NN	_	11	nsubj
3	,	,	,	_	2	punct
4	which	which	WDT	_	6	nsubjpass
5	is	be	VBZ	_	6	auxpass
6	catalyzed	catalyze	VBN	_	2	acl:relcl
7	by	by	IN	_	9	case
8	xanthine	xanthine	NN	_	9	compound
9	oxidase	oxidase	NN	_	6	nmod
10	,	,	,	_	2	punct
11	inactivates	inactivate	VBZ	_	0	ROOT
12	drug1	drug1	NN	_	11	dobj
13	.	.	.	_	11	punct

1	In	in	IN	_	2	case
2	patients	patient	NNS	_	25	nmod
3	receiving	receive	VBG	_	2	acl
4	drug1	drug1	NN	_	3	dobj
5	-LRB-	-lrb-	-LRB-	_	6	punct
6	drug2	drug2	NN	_	4	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	or	or	CC	_	4	cc
9	drug3	drug3	NN	_	4	conj
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	drug4	drug4	NN	_	9	appos
12	-RRB-	-rrb-	-RRB-	_	11	punct
13	,	,	,	_	25	punct
14	the	the	DT	_	16	det
15	concomitant	concomitant	JJ	_	16	amod
16	administration	administration	NN	_	25	nsubj
17	of	of	IN	_	19	case
18	300-600	300-600	CD	_	19	nummod
19	mg	mg	NN	_	16	nmod
20	of	of	IN	_	21	case
21	drug5	drug5	NN	_	19	nmod
22	per	per	IN	_	23	case
23	day	day	NN	_	16	nmod
24	will	will	MD	_	25	aux
25	require	require	VB	_	0	ROOT
26	a	a	DT	_	27	det
27	reduction	reduction	NN	_	25	dobj
28	in	in	IN	_	29	case
29	dose	dose	NN	_	27	nmod
30	to	to	TO	_	32	case
31	approximately	approximately	RB	_	32	advmod
32	one-third	one-third	JJ	_	27	nmod
33	to	to	TO	_	34	case
34	one-fourth	one-fourth	NN	_	27	nmod
35	of	of	IN	_	38	case
36	the	the	DT	_	38	det
37	usual	usual	JJ	_	38	amod
38	dose	dose	NN	_	34	nmod
39	of	of	IN	_	40	case
40	drug6	drug6	NN	_	38	nmod
41	or	or	CC	_	40	cc
42	drug7	drug7	NN	_	40	conj
43	.	.	.	_	25	punct

1	Subsequent	subsequent	JJ	_	2	amod
2	adjustment	adjustment	NN	_	11	nsubjpass
3	of	of	IN	_	4	case
4	doses	dose	NNS	_	2	nmod
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	or	or	CC	_	6	cc
8	drug2	drug2	NN	_	6	conj
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	made	make	VBN	_	0	ROOT
12	on	on	IN	_	14	case
13	the	the	DT	_	14	det
14	basis	basis	NN	_	11	nmod
15	of	of	IN	_	17	case
16	therapeutic	therapeutic	JJ	_	17	amod
17	response	response	NN	_	14	nmod
18	and	and	CC	_	17	cc
19	the	the	DT	_	20	det
20	appearance	appearance	NN	_	17	conj
21	of	of	IN	_	23	case
22	toxic	toxic	JJ	_	23	amod
23	effects	effect	NNS	_	20	nmod
24	.	.	.	_	11	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	It	it	PRP	_	6	nsubjpass
4	has	have	VBZ	_	6	aux
5	been	be	VBN	_	6	auxpass
6	reported	report	VBN	_	1	appos
7	that	that	IN	_	9	mark
8	drug2	drug2	NN	_	9	nsubj
9	prolongs	prolong	VBZ	_	6	ccomp
10	the	the	DT	_	11	det
11	half-life	half-life	NN	_	9	dobj
12	of	of	IN	_	14	case
13	the	the	DT	_	14	det
14	drug3	drug3	NN	_	11	nmod
15	,	,	,	_	14	punct
16	drug4	drug4	NN	_	14	appos
17	.	.	.	_	1	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	basis	basis	NN	_	11	nsubjpass
4	of	of	IN	_	7	case
5	this	this	DT	_	7	det
6	drug	drug	NN	_	7	compound
7	interaction	interaction	NN	_	3	nmod
8	has	have	VBZ	_	11	aux
9	not	not	RB	_	11	neg
10	been	be	VBN	_	11	auxpass
11	established	establish	VBN	_	0	ROOT
12	but	but	CC	_	11	cc
13	should	should	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	noted	note	VBN	_	11	conj
16	when	when	WRB	_	19	advmod
17	drug1	drug1	NN	_	19	nsubjpass
18	is	be	VBZ	_	19	auxpass
19	given	give	VBN	_	15	advcl
20	to	to	TO	_	21	case
21	patients	patient	NNS	_	19	nmod
22	already	already	RB	_	25	advmod
23	on	on	IN	_	25	case
24	drug2	drug2	NN	_	25	compound
25	therapy	therapy	NN	_	19	nmod
26	.	.	.	_	11	punct

1	Consequently	consequently	RB	_	7	advmod
2	,	,	,	_	7	punct
3	prothrombin	prothrombin	NN	_	4	compound
4	time	time	NN	_	7	nsubjpass
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	reassessed	reassess	VBN	_	0	ROOT
8	periodically	periodically	RB	_	7	advmod
9	in	in	IN	_	10	case
10	patients	patient	NNS	_	7	nmod
11	receiving	receive	VBG	_	10	acl
12	both	both	CC	_	13	det
13	drugs	drug	NNS	_	11	dobj
14	.	.	.	_	7	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Since	since	IN	_	9	mark
4	the	the	DT	_	5	det
5	excretion	excretion	NN	_	9	nsubj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	is	be	VBZ	_	9	cop
9	similar	similar	JJ	_	26	advcl
10	to	to	TO	_	11	case
11	that	that	DT	_	9	nmod
12	of	of	IN	_	13	case
13	urate	urate	NN	_	11	nmod
14	,	,	,	_	13	punct
15	drug3	drug3	NN	_	13	appos
16	,	,	,	_	13	punct
17	which	which	WDT	_	18	nsubj
18	increase	increase	VBP	_	13	acl:relcl
19	the	the	DT	_	20	det
20	excretion	excretion	NN	_	18	dobj
21	of	of	IN	_	22	case
22	urate	urate	NN	_	20	nmod
23	,	,	,	_	26	punct
24	are	be	VBP	_	26	cop
25	also	also	RB	_	26	advmod
26	likely	likely	JJ	_	1	dep
27	to	to	TO	_	28	mark
28	increase	increase	VB	_	26	xcomp
29	the	the	DT	_	30	det
30	excretion	excretion	NN	_	28	dobj
31	of	of	IN	_	32	case
32	drug4	drug4	NN	_	30	nmod
33	and	and	CC	_	28	cc
34	thus	thus	RB	_	35	advmod
35	lower	lower	JJR	_	28	conj
36	the	the	DT	_	37	det
37	degree	degree	NN	_	35	dobj
38	of	of	IN	_	39	case
39	inhibition	inhibition	NN	_	37	nmod
40	of	of	IN	_	42	case
41	xanthine	xanthine	NN	_	42	compound
42	oxidase	oxidase	NN	_	39	nmod
43	.	.	.	_	1	punct

1	The	the	DT	_	3	det
2	concomitant	concomitant	JJ	_	3	amod
3	administration	administration	NN	_	10	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	has	have	VBZ	_	10	aux
9	been	be	VBN	_	10	auxpass
10	associated	associate	VBN	_	0	ROOT
11	with	with	IN	_	13	case
12	a	a	DT	_	13	det
13	decrease	decrease	NN	_	10	nmod
14	in	in	IN	_	16	case
15	the	the	DT	_	16	det
16	excretion	excretion	NN	_	13	nmod
17	of	of	IN	_	18	case
18	oxypurines	oxypurine	NNS	_	16	nmod
19	-LRB-	-lrb-	-LRB-	_	20	punct
20	hypoxanthine	hypoxanthine	NN	_	18	dep
21	and	and	CC	_	20	cc
22	xanthine	xanthine	NN	_	20	conj
23	-RRB-	-rrb-	-RRB-	_	20	punct
24	and	and	CC	_	13	cc
25	an	a	DT	_	26	det
26	increase	increase	NN	_	13	conj
27	in	in	IN	_	31	case
28	urinary	urinary	JJ	_	31	amod
29	uric	uric	JJ	_	31	amod
30	acid	acid	NN	_	31	compound
31	excretion	excretion	NN	_	26	nmod
32	compared	compare	VBN	_	34	case
33	with	with	IN	_	34	case
34	that	that	DT	_	10	advcl
35	observed	observe	VBN	_	34	acl
36	with	with	IN	_	37	case
37	drug3	drug3	NN	_	35	nmod
38	alone	alone	RB	_	37	advmod
39	.	.	.	_	10	punct

1	Although	although	IN	_	8	mark
2	clinical	clinical	JJ	_	3	amod
3	evidence	evidence	NN	_	8	nsubj
4	to	to	TO	_	5	case
5	date	date	NN	_	3	nmod
6	has	have	VBZ	_	8	aux
7	not	not	RB	_	8	neg
8	demonstrated	demonstrate	VBN	_	29	advcl
9	renal	renal	JJ	_	10	amod
10	precipitation	precipitation	NN	_	8	dobj
11	of	of	IN	_	12	case
12	oxypurines	oxypurine	NNS	_	10	nmod
13	in	in	IN	_	14	case
14	patients	patient	NNS	_	10	nmod
15	either	either	CC	_	17	cc:preconj
16	on	on	IN	_	17	case
17	drug1	drug1	NN	_	14	nmod
18	alone	alone	RB	_	17	advmod
19	or	or	CC	_	17	cc
20	in	in	IN	_	21	case
21	combination	combination	NN	_	17	conj
22	with	with	IN	_	23	case
23	drug2	drug2	NN	_	21	nmod
24	,	,	,	_	29	punct
25	the	the	DT	_	26	det
26	possibility	possibility	NN	_	29	nsubjpass
27	should	should	MD	_	29	aux
28	be	be	VB	_	29	auxpass
29	kept	keep	VBN	_	0	ROOT
30	in	in	IN	_	31	case
31	mind	mind	NN	_	29	nmod
32	.	.	.	_	29	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	reports	report	NNS	_	26	nsubjpass
5	that	that	IN	_	14	mark
6	the	the	DT	_	8	det
7	concomitant	concomitant	JJ	_	8	amod
8	use	use	NN	_	14	nsubj
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	drug3	drug3	NN	_	10	conj
13	may	may	MD	_	14	aux
14	contribute	contribute	VB	_	4	ccomp
15	to	to	TO	_	17	case
16	the	the	DT	_	17	det
17	enhancement	enhancement	NN	_	14	nmod
18	of	of	IN	_	20	case
19	drug4	drug4	NN	_	20	compound
20	toxicity	toxicity	NN	_	17	nmod
21	in	in	IN	_	23	case
22	some	some	DT	_	23	det
23	patients	patient	NNS	_	17	nmod
24	have	have	VBP	_	26	aux
25	been	be	VBN	_	26	auxpass
26	reviewed	review	VBN	_	1	dep
27	in	in	IN	_	29	case
28	an	a	DT	_	29	det
29	attempt	attempt	NN	_	26	nmod
30	to	to	TO	_	31	mark
31	establish	establish	VB	_	29	acl
32	a	a	DT	_	34	det
33	cause-and-effect	cause-and-effect	JJ	_	34	amod
34	relationship	relationship	NN	_	31	dobj
35	and	and	CC	_	34	cc
36	a	a	DT	_	37	det
37	mechanism	mechanism	NN	_	34	conj
38	of	of	IN	_	39	case
39	causation	causation	NN	_	37	nmod
40	.	.	.	_	26	punct

1	Review	review	NN	_	5	nsubj
2	of	of	IN	_	4	case
3	these	these	DT	_	4	det
4	case	case	NN	_	1	nmod
5	reports	report	VBZ	_	0	ROOT
6	indicates	indicate	VBZ	_	5	ccomp
7	that	that	IN	_	12	mark
8	the	the	DT	_	9	det
9	patients	patient	NNS	_	12	nsubj
10	were	be	VBD	_	12	aux
11	mainly	mainly	RB	_	12	advmod
12	receiving	receive	VBG	_	6	ccomp
13	drug1	drug1	NN	_	12	dobj
14	for	for	IN	_	15	case
15	hypertension	hypertension	NN	_	12	nmod
16	and	and	CC	_	12	cc
17	that	that	IN	_	32	mark
18	tests	test	NNS	_	32	nsubjpass
19	to	to	TO	_	20	mark
20	rule	rule	VB	_	18	acl
21	out	out	RP	_	20	compound:prt
22	decreased	decrease	VBN	_	24	amod
23	renal	renal	JJ	_	24	amod
24	function	function	NN	_	20	dobj
25	secondary	secondary	JJ	_	24	amod
26	to	to	TO	_	28	case
27	hypertensive	hypertensive	JJ	_	28	amod
28	nephropathy	nephropathy	NN	_	25	nmod
29	were	be	VBD	_	32	auxpass
30	not	not	RB	_	32	neg
31	often	often	RB	_	32	advmod
32	performed	perform	VBN	_	12	conj
33	.	.	.	_	5	punct

1	In	in	IN	_	3	case
2	those	those	DT	_	3	det
3	patients	patient	NNS	_	23	nmod
4	in	in	IN	_	5	case
5	whom	whom	WP	_	9	nmod
6	renal	renal	JJ	_	7	amod
7	insufficiency	insufficiency	NN	_	9	nsubjpass
8	was	be	VBD	_	9	auxpass
9	documented	document	VBN	_	3	acl:relcl
10	,	,	,	_	23	punct
11	however	however	RB	_	23	advmod
12	,	,	,	_	23	punct
13	the	the	DT	_	14	det
14	recommendation	recommendation	NN	_	23	nsubjpass
15	to	to	TO	_	16	mark
16	lower	lower	VB	_	14	acl
17	the	the	DT	_	18	det
18	dose	dose	NN	_	16	dobj
19	of	of	IN	_	20	case
20	drug1	drug1	NN	_	18	nmod
21	was	be	VBD	_	23	auxpass
22	not	not	RB	_	23	neg
23	followed	follow	VBN	_	0	ROOT
24	.	.	.	_	23	punct

1	Although	although	IN	_	12	mark
2	a	a	DT	_	4	det
3	causal	causal	JJ	_	4	amod
4	mechanism	mechanism	NN	_	12	nsubjpass
5	and	and	CC	_	4	cc
6	a	a	DT	_	8	det
7	cause-and-effect	cause-and-effect	JJ	_	8	amod
8	relationship	relationship	NN	_	4	conj
9	have	have	VBP	_	12	aux
10	not	not	RB	_	12	neg
11	been	be	VBN	_	12	auxpass
12	established	establish	VBN	_	16	advcl
13	,	,	,	_	16	punct
14	current	current	JJ	_	15	amod
15	evidence	evidence	NN	_	16	nsubj
16	suggests	suggest	VBZ	_	0	ROOT
17	that	that	IN	_	22	mark
18	renal	renal	JJ	_	19	amod
19	function	function	NN	_	22	nsubjpass
20	should	should	MD	_	22	aux
21	be	be	VB	_	22	auxpass
22	monitored	monitor	VBN	_	16	ccomp
23	in	in	IN	_	24	case
24	patients	patient	NNS	_	22	nmod
25	on	on	IN	_	26	case
26	drug1	drug1	NN	_	24	nmod
27	and	and	CC	_	26	cc
28	drug2	drug2	NN	_	26	conj
29	even	even	RB	_	32	advmod
30	in	in	IN	_	32	case
31	the	the	DT	_	32	det
32	absence	absence	NN	_	22	nmod
33	of	of	IN	_	35	case
34	renal	renal	JJ	_	35	amod
35	failure	failure	NN	_	32	nmod
36	,	,	,	_	22	punct
37	and	and	CC	_	22	cc
38	dosage	dosage	NN	_	39	compound
39	levels	level	NNS	_	45	nsubjpass
40	should	should	MD	_	45	aux
41	be	be	VB	_	45	auxpass
42	even	even	RB	_	43	advmod
43	more	more	RBR	_	44	advmod
44	conservatively	conservatively	RB	_	45	advmod
45	adjusted	adjust	VBN	_	22	conj
46	in	in	IN	_	48	case
47	those	those	DT	_	48	det
48	patients	patient	NNS	_	45	nmod
49	on	on	IN	_	52	case
50	such	such	JJ	_	52	amod
51	combined	combined	JJ	_	52	amod
52	therapy	therapy	NN	_	48	nmod
53	if	if	IN	_	58	mark
54	diminished	diminish	VBN	_	56	amod
55	renal	renal	JJ	_	56	amod
56	function	function	NN	_	58	nsubjpass
57	is	be	VBZ	_	58	auxpass
58	detected	detect	VBN	_	45	advcl
59	.	.	.	_	16	punct
60	.	.	.	_	16	punct

1	drug1	drug1	NN	_	3	compound
2	/	/	:	_	3	punct
3	drug2	drug2	NN	_	0	ROOT
4	:	:	:	_	3	punct
5	An	a	DT	_	6	det
6	increase	increase	NN	_	15	nsubjpass
7	in	in	IN	_	9	case
8	the	the	DT	_	9	det
9	frequency	frequency	NN	_	6	nmod
10	of	of	IN	_	12	case
11	skin	skin	NN	_	12	compound
12	rash	rash	NN	_	9	nmod
13	has	have	VBZ	_	15	aux
14	been	be	VBN	_	15	auxpass
15	reported	report	VBN	_	3	appos
16	among	among	IN	_	17	case
17	patients	patient	NNS	_	15	nmod
18	receiving	receive	VBG	_	17	acl
19	drug3	drug3	NN	_	18	dobj
20	or	or	CC	_	19	cc
21	drug4	drug4	NN	_	19	conj
22	concurrently	concurrently	RB	_	24	advmod
23	with	with	IN	_	24	case
24	drug5	drug5	NN	_	17	nmod
25	compared	compare	VBN	_	27	case
26	to	to	TO	_	27	case
27	patients	patient	NNS	_	17	nmod
28	who	who	WP	_	31	nsubj
29	are	be	VBP	_	31	aux
30	not	not	RB	_	31	neg
31	receiving	receive	VBG	_	27	acl:relcl
32	both	both	CC	_	33	det
33	drugs	drug	NNS	_	31	dobj
34	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	cause	cause	NN	_	10	nsubjpass
3	of	of	IN	_	6	case
4	the	the	DT	_	6	det
5	reported	report	VBN	_	6	amod
6	association	association	NN	_	2	nmod
7	has	have	VBZ	_	10	aux
8	not	not	RB	_	10	neg
9	been	be	VBN	_	10	auxpass
10	established	establish	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Enhanced	enhance	VBN	_	6	amod
4	bone	bone	NN	_	6	compound
5	marrow	marrow	NN	_	6	compound
6	suppression	suppression	NN	_	14	nsubjpass
7	by	by	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	other	other	JJ	_	11	amod
11	drug3	drug3	NN	_	8	conj
12	has	have	VBZ	_	14	aux
13	been	be	VBN	_	14	auxpass
14	reported	report	VBN	_	1	dep
15	among	among	IN	_	16	case
16	patients	patient	NNS	_	14	nmod
17	with	with	IN	_	19	case
18	neoplastic	neoplastic	JJ	_	19	amod
19	disease	disease	NN	_	16	nmod
20	,	,	,	_	14	punct
21	except	except	IN	_	22	case
22	leukemia	leukemia	NN	_	14	nmod
23	,	,	,	_	14	punct
24	in	in	IN	_	26	case
25	the	the	DT	_	26	det
26	presence	presence	NN	_	14	nmod
27	of	of	IN	_	28	case
28	drug4	drug4	NN	_	26	nmod
29	.	.	.	_	1	punct

1	However	however	RB	_	18	advmod
2	,	,	,	_	18	punct
3	in	in	IN	_	6	case
4	a	a	DT	_	6	det
5	well-controlled	well-controlled	JJ	_	6	amod
6	study	study	NN	_	18	nmod
7	of	of	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	with	with	IN	_	10	case
10	lymphoma	lymphoma	NN	_	8	nmod
11	on	on	IN	_	13	case
12	combination	combination	NN	_	13	compound
13	therapy	therapy	NN	_	8	nmod
14	,	,	,	_	18	punct
15	drug1	drug1	NN	_	18	nsubj
16	did	do	VBD	_	18	aux
17	not	not	RB	_	18	neg
18	increase	increase	VB	_	0	ROOT
19	the	the	DT	_	21	det
20	marrow	marrow	NN	_	21	compound
21	toxicity	toxicity	NN	_	18	dobj
22	of	of	IN	_	23	case
23	patients	patient	NNS	_	21	nmod
24	treated	treat	VBN	_	23	acl
25	with	with	IN	_	26	case
26	drug2	drug2	NN	_	24	nmod
27	,	,	,	_	26	punct
28	drug3	drug3	NN	_	26	conj
29	,	,	,	_	26	punct
30	drug4	drug4	NN	_	26	conj
31	,	,	,	_	26	punct
32	drug5	drug5	NN	_	26	conj
33	and/or	and/or	CC	_	26	cc
34	drug6	drug6	NN	_	26	conj
35	.	.	.	_	18	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	6	compound
4	s	s	NNS	_	6	compound
5	plasma	plasma	NN	_	6	compound
6	half-life	half-life	NN	_	9	nsubjpass
7	may	may	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	prolonged	prolong	VBN	_	1	dep
10	by	by	IN	_	11	case
11	drug3	drug3	NN	_	9	nmod
12	,	,	,	_	9	punct
13	since	since	IN	_	14	case
14	drug4	drug4	NN	_	9	nmod
15	and	and	CC	_	14	cc
16	drug5	drug5	NN	_	14	conj
17	may	may	MD	_	18	aux
18	compete	compete	VB	_	9	dep
19	for	for	IN	_	20	case
20	excretion	excretion	NN	_	18	nmod
21	in	in	IN	_	24	case
22	the	the	DT	_	24	det
23	renal	renal	JJ	_	24	amod
24	tubule	tubule	NN	_	18	nmod
25	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	risk	risk	NN	_	11	nsubjpass
3	of	of	IN	_	4	case
4	hypoglycemia	hypoglycemia	NN	_	2	nmod
5	secondary	secondary	JJ	_	4	amod
6	to	to	TO	_	8	case
7	this	this	DT	_	8	det
8	mechanism	mechanism	NN	_	5	nmod
9	may	may	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	increased	increase	VBN	_	0	ROOT
12	if	if	IN	_	17	mark
13	drug1	drug1	NN	_	17	nsubjpass
14	and	and	CC	_	13	cc
15	drug2	drug2	NN	_	13	conj
16	are	be	VBP	_	17	auxpass
17	given	give	VBN	_	11	advcl
18	concomitantly	concomitantly	RB	_	17	advmod
19	in	in	IN	_	24	case
20	the	the	DT	_	24	dep
21	presence	presence	NN	_	24	dep
22	of	of	IN	_	24	case
23	renal	renal	JJ	_	24	amod
24	insufficiency	insufficiency	NN	_	17	nmod
25	.	.	.	_	11	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Reports	report	NNS	_	4	nsubj
4	indicate	indicate	VBP	_	1	appos
5	that	that	IN	_	10	mark
6	drug2	drug2	NN	_	7	compound
7	levels	level	NNS	_	10	nsubjpass
8	may	may	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	increased	increase	VBN	_	4	ccomp
11	during	during	IN	_	13	case
12	concomitant	concomitant	JJ	_	13	amod
13	treatment	treatment	NN	_	10	nmod
14	with	with	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	for	for	IN	_	17	case
17	injection	injection	NN	_	13	nmod
18	.	.	.	_	1	punct

1	Monitoring	monitoring	NN	_	13	nsubjpass
2	of	of	IN	_	4	case
3	drug1	drug1	NN	_	4	compound
4	levels	level	NNS	_	1	nmod
5	and	and	CC	_	1	cc
6	possible	possible	JJ	_	7	amod
7	adjustment	adjustment	NN	_	1	conj
8	of	of	IN	_	10	case
9	drug2	drug2	NN	_	10	compound
10	dosage	dosage	NN	_	7	nmod
11	should	should	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	considered	consider	VBN	_	0	ROOT
14	when	when	WRB	_	18	advmod
15	these	these	DT	_	16	det
16	drugs	drug	NNS	_	18	nsubj
17	are	be	VBP	_	18	cop
18	co-administered	co-administered	JJ	_	13	advcl
19	.	.	.	_	13	punct

1	drug1	drug1	NN	_	3	compound
2	s	s	NNS	_	3	compound
3	conversion	conversion	NN	_	9	nsubjpass
4	to	to	TO	_	6	case
5	inactive	inactive	JJ	_	6	amod
6	metabolites	metabolite	NNS	_	3	nmod
7	has	have	VBZ	_	9	aux
8	been	be	VBN	_	9	auxpass
9	shown	show	VBN	_	0	ROOT
10	to	to	TO	_	12	mark
11	be	be	VB	_	12	auxpass
12	catalyzed	catalyze	VBN	_	9	xcomp
13	by	by	IN	_	15	case
14	xanthine	xanthine	NN	_	15	compound
15	oxidase	oxidase	NN	_	12	nmod
16	from	from	IN	_	18	case
17	rat	rat	NN	_	18	compound
18	liver	liver	NN	_	15	nmod
19	.	.	.	_	9	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	significance	significance	NN	_	12	nsubj
4	,	,	,	_	6	punct
5	if	if	IN	_	6	mark
6	any	any	DT	_	3	dep
7	,	,	,	_	6	punct
8	of	of	IN	_	10	case
9	these	these	DT	_	10	det
10	observations	observation	NNS	_	3	nmod
11	is	be	VBZ	_	12	cop
12	unknown	unknown	JJ	_	0	ROOT
13	.	.	.	_	12	punct

1	drug1	drug1	NN	_	6	nsubjpass
2	generally	generally	RB	_	6	advmod
3	should	should	MD	_	6	aux
4	not	not	RB	_	6	neg
5	be	be	VB	_	6	auxpass
6	given	give	VBN	_	0	ROOT
7	with	with	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	because	because	IN	_	11	mark
10	they	they	PRP	_	11	nsubj
11	reduce	reduce	VBP	_	6	advcl
12	its	its	PRP$	_	14	nmod:poss
13	renal	renal	JJ	_	14	amod
14	clearance	clearance	NN	_	11	dobj
15	and	and	CC	_	11	cc
16	add	add	VB	_	11	conj
17	a	a	DT	_	19	det
18	high	high	JJ	_	19	amod
19	risk	risk	NN	_	16	dobj
20	of	of	IN	_	22	case
21	drug3	drug3	NN	_	22	compound
22	toxicity	toxicity	NN	_	19	nmod
23	.	.	.	_	6	punct

1	Read	read	VB	_	0	ROOT
2	circulars	circular	NNS	_	1	dobj
3	for	for	IN	_	5	case
4	drug1	drug1	NN	_	5	compound
5	preparations	preparation	NNS	_	1	nmod
6	before	before	IN	_	7	case
7	use	use	NN	_	1	nmod
8	of	of	IN	_	11	case
9	such	such	JJ	_	11	amod
10	concomitant	concomitant	JJ	_	11	amod
11	therapy	therapy	NN	_	7	nmod
12	.	.	.	_	1	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	increase	increase	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	ototoxic	ototoxic	JJ	_	6	amod
6	potential	potential	NN	_	3	dobj
7	of	of	IN	_	9	case
8	other	other	JJ	_	9	amod
9	drugs	drug	NNS	_	6	nmod
10	such	such	JJ	_	12	case
11	as	as	IN	_	10	mwe
12	drug2	drug2	NN	_	9	nmod
13	and	and	CC	_	12	cc
14	some	some	DT	_	15	det
15	drug3	drug3	NN	_	12	conj
16	.	.	.	_	3	punct

1	Their	they	PRP$	_	3	nmod:poss
2	concurrent	concurrent	JJ	_	3	amod
3	use	use	NN	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	avoided	avoid	VBN	_	0	ROOT
7	.	.	.	_	6	punct

1	A	a	DT	_	2	det
2	number	number	NN	_	11	nsubjpass
3	of	of	IN	_	4	case
4	drugs	drug	NNS	_	2	nmod
5	,	,	,	_	4	punct
6	including	include	VBG	_	7	case
7	drug1	drug1	NN	_	4	nmod
8	,	,	,	_	4	punct
9	have	have	VBP	_	11	aux
10	been	be	VBN	_	11	auxpass
11	shown	show	VBN	_	0	ROOT
12	to	to	TO	_	13	mark
13	displace	displace	VB	_	11	xcomp
14	drug2	drug2	NN	_	13	dobj
15	from	from	IN	_	17	case
16	plasma	plasma	NN	_	17	compound
17	protein	protein	NN	_	13	nmod
18	;	;	:	_	11	punct

1	a	a	DT	_	2	det
2	reduction	reduction	NN	_	10	nsubjpass
3	in	in	IN	_	7	case
4	the	the	DT	_	7	det
5	usual	usual	JJ	_	7	amod
6	drug1	drug1	NN	_	7	compound
7	dosage	dosage	NN	_	2	nmod
8	may	may	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	required	require	VBN	_	0	ROOT
11	in	in	IN	_	12	case
12	patients	patient	NNS	_	10	nmod
13	receiving	receive	VBG	_	12	acl
14	both	both	CC	_	15	det
15	drugs	drug	NNS	_	13	dobj
16	.	.	.	_	10	punct

1	In	in	IN	_	3	case
2	some	some	DT	_	3	det
3	patients	patient	NNS	_	11	nmod
4	,	,	,	_	11	punct
5	the	the	DT	_	6	det
6	administration	administration	NN	_	11	nsubj
7	of	of	IN	_	9	case
8	a	a	DT	_	9	det
9	drug1	drug1	NN	_	6	nmod
10	can	can	MD	_	11	aux
11	reduce	reduce	VB	_	0	ROOT
12	the	the	DT	_	19	det
13	diuretic	diuretic	JJ	_	19	amod
14	,	,	,	_	13	punct
15	natriuretic	natriuretic	JJ	_	13	conj
16	,	,	,	_	13	punct
17	and	and	CC	_	13	cc
18	antihypertensive	antihypertensive	JJ	_	13	conj
19	effects	effect	NNS	_	11	dobj
20	of	of	IN	_	21	case
21	drug2	drug2	NN	_	19	nmod
22	,	,	,	_	21	punct
23	drug3	drug3	NN	_	21	conj
24	and	and	CC	_	21	cc
25	drug4	drug4	NN	_	21	conj
26	.	.	.	_	11	punct

1	Therefore	therefore	RB	_	15	advmod
2	,	,	,	_	15	punct
3	when	when	WRB	_	8	advmod
4	drug1	drug1	NN	_	8	nsubjpass
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	are	be	VBP	_	8	auxpass
8	used	use	VBN	_	15	advcl
9	concomitantly	concomitantly	RB	_	8	advmod
10	,	,	,	_	15	punct
11	the	the	DT	_	12	det
12	patient	patient	NN	_	15	nsubjpass
13	should	should	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	observed	observe	VBN	_	0	ROOT
16	closely	closely	RB	_	15	advmod
17	to	to	TO	_	18	mark
18	determine	determine	VB	_	15	xcomp
19	if	if	IN	_	27	mark
20	the	the	DT	_	22	det
21	desired	desire	VBN	_	22	amod
22	effect	effect	NN	_	27	nsubjpass
23	of	of	IN	_	25	case
24	the	the	DT	_	25	det
25	drug3	drug3	NN	_	22	nmod
26	is	be	VBZ	_	27	auxpass
27	obtained	obtain	VBN	_	18	advcl
28	.	.	.	_	15	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Several	several	JJ	_	6	amod
4	short-term	short-term	JJ	_	6	amod
5	controlled	controlled	JJ	_	6	amod
6	studies	study	NNS	_	7	nsubj
7	failed	fail	VBD	_	1	appos
8	to	to	TO	_	9	mark
9	wshow	wshow	VB	_	7	xcomp
10	that	that	DT	_	11	det
11	drug2	drug2	NN	_	9	dobj
12	significantly	significantly	RB	_	13	advmod
13	affected	affect	VBD	_	9	dep
14	prothrombin	prothrombin	NN	_	15	compound
15	times	time	NNS	_	13	dobj
16	or	or	CC	_	15	cc
17	a	a	DT	_	18	det
18	variety	variety	NN	_	15	conj
19	of	of	IN	_	22	case
20	other	other	JJ	_	22	amod
21	clotting	clotting	NN	_	22	compound
22	factors	factor	NNS	_	15	nmod
23	when	when	WRB	_	24	advmod
24	administered	administer	VBN	_	13	advcl
25	to	to	TO	_	26	case
26	individuals	individual	NNS	_	24	nmod
27	on	on	IN	_	28	case
28	drug3	drug3	NN	_	26	nmod
29	.	.	.	_	1	punct

1	However	however	RB	_	25	advmod
2	,	,	,	_	25	punct
3	because	because	IN	_	7	mark
4	bleeding	bleeding	NN	_	7	nsubjpass
5	has	have	VBZ	_	7	aux
6	been	be	VBN	_	7	auxpass
7	reported	report	VBN	_	25	advcl
8	when	when	WRB	_	15	advmod
9	drug1	drug1	NN	_	15	nsubjpass
10	and	and	CC	_	9	cc
11	other	other	JJ	_	12	amod
12	drug2	drug2	NN	_	9	conj
13	have	have	VBP	_	15	aux
14	been	be	VBN	_	15	auxpass
15	administered	administer	VBN	_	7	advcl
16	to	to	TO	_	17	case
17	patients	patient	NNS	_	15	nmod
18	on	on	IN	_	19	case
19	drug3	drug3	NN	_	17	nmod
20	,	,	,	_	25	punct
21	the	the	DT	_	22	det
22	physician	physician	NN	_	25	nsubj
23	should	should	MD	_	25	aux
24	be	be	VB	_	25	cop
25	cautious	cautious	JJ	_	0	ROOT
26	when	when	WRB	_	27	advmod
27	administering	administer	VBG	_	25	advcl
28	drug4	drug4	NN	_	27	dobj
29	to	to	TO	_	30	case
30	patients	patient	NNS	_	27	nmod
31	on	on	IN	_	32	case
32	drug5	drug5	NN	_	30	nmod
33	.	.	.	_	25	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Animal	animal	NN	_	4	compound
4	studies	study	NNS	_	5	nsubj
5	wshow	wshow	VBP	_	1	appos
6	that	that	IN	_	15	mark
7	drug2	drug2	NN	_	15	nsubj
8	given	give	VBN	_	10	case
9	with	with	IN	_	10	case
10	drug3	drug3	NN	_	7	nmod
11	,	,	,	_	10	punct
12	including	include	VBG	_	13	case
13	drug4	drug4	NN	_	10	nmod
14	,	,	,	_	10	punct
15	yields	yield	VBZ	_	5	ccomp
16	a	a	DT	_	18	det
17	net	net	JJ	_	18	amod
18	decrease	decrease	NN	_	15	dobj
19	in	in	IN	_	21	case
20	anti-inflammatory	anti-inflammatory	JJ	_	21	amod
21	activity	activity	NN	_	18	nmod
22	with	with	IN	_	25	case
23	lowered	lowered	JJ	_	25	amod
24	blood	blood	NN	_	25	compound
25	levels	level	NNS	_	21	nmod
26	of	of	IN	_	29	case
27	the	the	DT	_	29	det
28	non-aspirin	non-aspirin	JJ	_	29	amod
29	drug	drug	NN	_	25	nmod
30	.	.	.	_	1	punct

1	Single	single	JJ	_	4	amod
2	dose	dose	NN	_	4	compound
3	bioavailability	bioavailability	NN	_	4	compound
4	studies	study	NNS	_	9	nsubj
5	in	in	IN	_	7	case
6	normal	normal	JJ	_	7	amod
7	volunteers	volunteer	NNS	_	4	nmod
8	have	have	VBP	_	9	aux
9	failed	fail	VBN	_	0	ROOT
10	to	to	TO	_	11	mark
11	wshow	wshow	VB	_	9	xcomp
12	an	a	DT	_	13	det
13	effect	effect	NN	_	11	dobj
14	of	of	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	on	on	IN	_	19	case
17	drug2	drug2	NN	_	19	compound
18	blood	blood	NN	_	19	compound
19	levels	level	NNS	_	13	nmod
20	.	.	.	_	9	punct

1	Correlative	correlative	JJ	_	3	amod
2	clinical	clinical	JJ	_	3	amod
3	studies	study	NNS	_	7	nsubjpass
4	have	have	VBP	_	7	aux
5	not	not	RB	_	7	neg
6	been	be	VBN	_	7	auxpass
7	performed	perform	VBN	_	0	ROOT
8	.	.	.	_	7	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	12	nsubj
4	,	,	,	_	3	punct
5	as	as	RB	_	3	cc
6	well	well	RB	_	5	mwe
7	as	as	IN	_	5	mwe
8	other	other	JJ	_	9	amod
9	drug3	drug3	NN	_	3	conj
10	,	,	,	_	3	punct
11	probably	probably	RB	_	12	advmod
12	reduces	reduce	VBZ	_	1	appos
13	the	the	DT	_	15	det
14	tubular	tubular	JJ	_	15	amod
15	secretion	secretion	NN	_	12	dobj
16	of	of	IN	_	17	case
17	drug4	drug4	NN	_	15	nmod
18	based	base	VBN	_	22	case
19	on	on	IN	_	22	case
20	in	in	FW	_	22	amod
21	vitro	vitro	FW	_	20	dep
22	studies	study	NNS	_	12	advcl
23	in	in	IN	_	26	case
24	rabbit	rabbit	NN	_	26	compound
25	kidney	kidney	NN	_	26	compound
26	slices	slice	NNS	_	22	nmod
27	.	.	.	_	1	punct

1	This	this	DT	_	3	nsubj
2	may	may	MD	_	3	aux
3	indicate	indicate	VB	_	0	ROOT
4	that	that	IN	_	7	mark
5	drug1	drug1	NN	_	7	nsubj
6	could	could	MD	_	7	aux
7	enhance	enhance	VB	_	3	ccomp
8	the	the	DT	_	9	det
9	toxicity	toxicity	NN	_	7	dobj
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	.	.	.	_	3	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	if	if	IN	_	8	mark
6	drug1	drug1	NN	_	8	nsubjpass
7	is	be	VBZ	_	8	auxpass
8	administered	administer	VBN	_	4	advcl
9	concomitantly	concomitantly	RB	_	8	advmod
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	8	nmod
12	.	.	.	_	4	punct

1	H-2	h-2	NN	_	2	compound
2	Antagonists	antagonist	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	In	in	IN	_	5	case
5	studies	study	NNS	_	2	nmod
6	with	with	IN	_	8	case
7	human	human	JJ	_	8	amod
8	volunteers	volunteer	NNS	_	5	nmod
9	,	,	,	_	5	punct
10	co-administration	co-administration	NN	_	17	nsubj
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	or	or	CC	_	12	cc
14	drug2	drug2	NN	_	12	conj
15	with	with	IN	_	16	case
16	drug3	drug3	NN	_	10	nmod
17	had	have	VBD	_	5	acl:relcl
18	no	no	DT	_	20	neg
19	substantive	substantive	JJ	_	20	amod
20	effect	effect	NN	_	17	dobj
21	on	on	IN	_	24	case
22	drug4	drug4	NN	_	24	compound
23	serum	serum	NN	_	24	compound
24	concentrations	concentration	NNS	_	17	nmod
25	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Clinical	clinical	JJ	_	4	amod
4	studies	study	NNS	_	13	nsubj
5	,	,	,	_	4	punct
6	as	as	RB	_	4	cc
7	well	well	RB	_	6	mwe
8	as	as	IN	_	6	mwe
9	random	random	JJ	_	10	amod
10	observations	observation	NNS	_	4	conj
11	,	,	,	_	4	punct
12	have	have	VBP	_	13	aux
13	shown	show	VBN	_	1	appos
14	that	that	IN	_	17	mark
15	drug2	drug2	NN	_	17	nsubj
16	can	can	MD	_	17	aux
17	reduce	reduce	VB	_	13	ccomp
18	the	the	DT	_	20	det
19	natriuretic	natriuretic	JJ	_	20	amod
20	effect	effect	NN	_	17	dobj
21	of	of	IN	_	22	case
22	drug3	drug3	NN	_	20	nmod
23	and	and	CC	_	22	cc
24	drug4	drug4	NN	_	22	conj
25	in	in	IN	_	27	case
26	some	some	DT	_	27	det
27	patients	patient	NNS	_	20	nmod
28	.	.	.	_	1	punct

1	This	this	DT	_	2	det
2	response	response	NN	_	5	nsubjpass
3	has	have	VBZ	_	5	aux
4	been	be	VBN	_	5	auxpass
5	attributed	attribute	VBN	_	0	ROOT
6	to	to	TO	_	7	case
7	inhibition	inhibition	NN	_	5	nmod
8	of	of	IN	_	11	case
9	renal	renal	JJ	_	11	amod
10	prostaglandin	prostaglandin	NN	_	11	compound
11	synthesis	synthesis	NN	_	7	nmod
12	.	.	.	_	5	punct

1	During	during	IN	_	3	case
2	concomitant	concomitant	JJ	_	3	amod
3	therapy	therapy	NN	_	11	nmod
4	with	with	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	,	,	,	_	11	punct
7	the	the	DT	_	8	det
8	patient	patient	NN	_	11	nsubjpass
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	observed	observe	VBN	_	0	ROOT
12	closely	closely	RB	_	11	advmod
13	for	for	IN	_	14	case
14	signs	sign	NNS	_	11	nmod
15	of	of	IN	_	17	case
16	renal	renal	JJ	_	17	amod
17	failure	failure	NN	_	14	nmod
18	,	,	,	_	14	punct
19	as	as	RB	_	14	cc
20	well	well	RB	_	19	mwe
21	as	as	IN	_	19	mwe
22	to	to	TO	_	23	mark
23	assure	assure	VB	_	14	conj
24	drug2	drug2	NN	_	25	compound
25	efficacy	efficacy	NN	_	23	dobj
26	.	.	.	_	11	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	nsubj
4	produced	produce	VBD	_	1	appos
5	an	a	DT	_	6	det
6	elevation	elevation	NN	_	4	dobj
7	of	of	IN	_	10	case
8	plasma	plasma	NN	_	10	compound
9	drug3	drug3	NN	_	10	compound
10	levels	level	NNS	_	6	nmod
11	and	and	CC	_	6	cc
12	a	a	DT	_	13	det
13	reduction	reduction	NN	_	6	conj
14	in	in	IN	_	17	case
15	renal	renal	JJ	_	17	amod
16	drug4	drug4	NN	_	17	compound
17	clearance	clearance	NN	_	13	nmod
18	in	in	IN	_	20	case
19	a	a	DT	_	20	det
20	study	study	NN	_	13	nmod
21	of	of	IN	_	24	case
22	eleven	eleven	NNS	_	24	compound
23	normal	normal	JJ	_	24	amod
24	volunteers	volunteer	NNS	_	20	nmod
25	.	.	.	_	1	punct

1	The	the	DT	_	5	det
2	mean	mean	NN	_	5	compound
3	minimum	minimum	JJ	_	5	amod
4	drug1	drug1	NN	_	5	compound
5	concentration	concentration	NN	_	6	nsubj
6	increased	increase	VBD	_	0	ROOT
7	15	15	CD	_	8	nummod
8	%	%	NN	_	6	dobj
9	and	and	CC	_	6	cc
10	the	the	DT	_	12	det
11	renal	renal	JJ	_	12	amod
12	clearance	clearance	NN	_	16	nsubjpass
13	of	of	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	was	be	VBD	_	16	auxpass
16	decreased	decrease	VBN	_	6	conj
17	by	by	IN	_	19	case
18	19	19	CD	_	19	nummod
19	%	%	NN	_	16	nmod
20	during	during	IN	_	22	case
21	this	this	DT	_	22	det
22	period	period	NN	_	16	nmod
23	of	of	IN	_	26	case
24	concomitant	concomitant	JJ	_	26	amod
25	drug	drug	NN	_	26	compound
26	administration	administration	NN	_	22	nmod
27	.	.	.	_	6	punct

1	This	this	DT	_	2	det
2	effect	effect	NN	_	5	nsubjpass
3	has	have	VBZ	_	5	aux
4	been	be	VBN	_	5	auxpass
5	attributed	attribute	VBN	_	0	ROOT
6	to	to	TO	_	7	case
7	inhibition	inhibition	NN	_	5	nmod
8	of	of	IN	_	11	case
9	renal	renal	JJ	_	11	amod
10	prostaglandin	prostaglandin	NN	_	11	compound
11	synthesis	synthesis	NN	_	7	nmod
12	by	by	IN	_	13	case
13	drug1	drug1	NN	_	7	nmod
14	.	.	.	_	5	punct

1	Thus	thus	RB	_	14	advmod
2	,	,	,	_	14	punct
3	when	when	WRB	_	8	advmod
4	drug1	drug1	NN	_	8	nsubjpass
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	are	be	VBP	_	8	auxpass
8	administered	administer	VBN	_	14	advcl
9	concurrently	concurrently	RB	_	8	advmod
10	,	,	,	_	14	punct
11	subjects	subject	NNS	_	14	nsubjpass
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	observed	observe	VBN	_	0	ROOT
15	carefully	carefully	RB	_	14	advmod
16	for	for	IN	_	17	case
17	signs	sign	NNS	_	14	nmod
18	of	of	IN	_	20	case
19	drug3	drug3	NN	_	20	compound
20	toxicity	toxicity	NN	_	17	nmod
21	.	.	.	_	14	punct

1	-LRB-	-lrb-	-LRB-	_	0	ROOT
2	Read	read	VB	_	1	root
3	circulars	circular	NNS	_	2	dobj
4	for	for	IN	_	6	case
5	drug1	drug1	NN	_	6	compound
6	preparation	preparation	NN	_	2	nmod
7	before	before	IN	_	8	case
8	use	use	NN	_	2	nmod
9	of	of	IN	_	12	case
10	such	such	JJ	_	12	amod
11	concurrent	concurrent	JJ	_	12	amod
12	therapy	therapy	NN	_	8	nmod
13	-RRB-	-rrb-	-RRB-	_	2	punct
14	.	.	.	_	2	punct

1	Renal	renal	JJ	_	3	amod
2	clearance	clearance	NN	_	3	compound
3	measurements	measurement	NNS	_	9	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	can	can	MD	_	9	aux
7	not	not	RB	_	9	neg
8	be	be	VB	_	9	auxpass
9	made	make	VBN	_	0	ROOT
10	with	with	IN	_	13	case
11	any	any	DT	_	13	det
12	significant	significant	JJ	_	13	amod
13	accuracy	accuracy	NN	_	9	nmod
14	in	in	IN	_	15	case
15	patients	patient	NNS	_	13	nmod
16	receiving	receive	VBG	_	15	acl
17	drug2	drug2	NN	_	16	dobj
18	,	,	,	_	17	punct
19	drug3	drug3	NN	_	17	conj
20	,	,	,	_	17	punct
21	or	or	CC	_	17	cc
22	drug4	drug4	NN	_	17	conj
23	.	.	.	_	9	punct

1	These	these	DT	_	2	det
2	compounds	compound	NNS	_	3	nsubj
3	interfere	interfere	VBP	_	0	ROOT
4	with	with	IN	_	7	case
5	chemical	chemical	NN	_	7	compound
6	color	color	NN	_	7	compound
7	development	development	NN	_	3	nmod
8	essential	essential	JJ	_	7	amod
9	to	to	TO	_	12	case
10	the	the	DT	_	12	det
11	analytical	analytical	JJ	_	12	amod
12	procedures	procedure	NNS	_	8	nmod
13	.	.	.	_	3	punct

1	drug1	drug1	NN	_	2	nsubj
2	depresses	depress	VBZ	_	0	ROOT
3	tubular	tubular	JJ	_	4	amod
4	secretion	secretion	NN	_	2	dobj
5	of	of	IN	_	8	case
6	certain	certain	JJ	_	8	amod
7	weak	weak	JJ	_	8	amod
8	acids	acid	NNS	_	4	nmod
9	such	such	JJ	_	11	case
10	as	as	IN	_	9	mwe
11	drug2	drug2	NN	_	8	nmod
12	.	.	.	_	2	punct

1	Therefore	therefore	RB	_	7	advmod
2	,	,	,	_	7	punct
3	patients	patient	NNS	_	7	nsubj
4	receiving	receive	VBG	_	3	acl
5	drug1	drug1	NN	_	4	dobj
6	will	will	MD	_	7	aux
7	have	have	VB	_	0	ROOT
8	erroneously	erroneously	RB	_	9	advmod
9	low	low	JJ	_	10	amod
10	ERPF	erpf	NN	_	7	dobj
11	and	and	CC	_	10	cc
12	Tm	tm	NN	_	14	compound
13	drug2	drug2	NN	_	14	compound
14	values	value	NNS	_	10	conj
15	.	.	.	_	7	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	should	should	MD	_	5	aux
3	not	not	RB	_	5	neg
4	be	be	VB	_	5	auxpass
5	administered	administer	VBN	_	0	ROOT
6	concomitantly	concomitantly	RB	_	5	advmod
7	with	with	IN	_	9	case
8	potent	potent	JJ	_	9	amod
9	drug2	drug2	NN	_	5	nmod
10	such	such	JJ	_	12	case
11	as	as	IN	_	10	mwe
12	drug3	drug3	NN	_	9	nmod
13	and	and	CC	_	12	cc
14	drug4	drug4	NN	_	12	conj
15	as	as	IN	_	21	mark
16	the	the	DT	_	17	det
17	potential	potential	NN	_	21	nsubjpass
18	for	for	IN	_	19	case
19	ototoxicity	ototoxicity	NN	_	17	nmod
20	is	be	VBZ	_	21	auxpass
21	enhanced	enhance	VBN	_	5	advcl
22	by	by	IN	_	24	case
23	the	the	DT	_	24	det
24	combination	combination	NN	_	21	nmod
25	.	.	.	_	5	punct

1	No	no	DT	_	5	neg
2	formal	formal	JJ	_	5	amod
3	drug	drug	NN	_	5	compound
4	interaction	interaction	NN	_	5	compound
5	studies	study	NNS	_	8	nsubjpass
6	have	have	VBP	_	8	aux
7	been	be	VBN	_	8	auxpass
8	conducted	conduct	VBN	_	0	ROOT
9	with	with	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	.	.	.	_	8	punct

1	The	the	DT	_	3	det
2	concurrent	concurrent	JJ	_	3	amod
3	administration	administration	NN	_	8	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	increases	increase	NNS	_	0	ROOT
9	substantially	substantially	RB	_	11	advmod
10	the	the	DT	_	11	det
11	incidence	incidence	NN	_	8	dobj
12	of	of	IN	_	13	case
13	rashes	rash	NNS	_	11	nmod
14	in	in	IN	_	15	case
15	patients	patient	NNS	_	13	nmod
16	receiving	receive	VBG	_	15	acl
17	both	both	CC	_	18	det
18	drugs	drug	NNS	_	16	dobj
19	as	as	IN	_	20	mark
20	compared	compare	VBN	_	8	advcl
21	to	to	TO	_	22	case
22	patients	patient	NNS	_	20	nmod
23	receiving	receive	VBG	_	22	acl
24	drug3	drug3	NN	_	23	dobj
25	alone	alone	RB	_	23	advmod
26	.	.	.	_	8	punct

1	It	it	PRP	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	not	not	RB	_	4	neg
4	known	know	VBN	_	0	ROOT
5	whether	whether	IN	_	12	mark
6	this	this	DT	_	7	det
7	potentiation	potentiation	NN	_	12	nsubj
8	of	of	IN	_	10	case
9	drug1	drug1	NN	_	10	compound
10	rashes	rash	NNS	_	7	nmod
11	is	be	VBZ	_	12	cop
12	due	due	JJ	_	4	ccomp
13	to	to	TO	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	or	or	CC	_	14	cc
16	the	the	DT	_	17	det
17	hyperuricemia	hyperuricemia	NN	_	14	conj
18	present	present	JJ	_	17	amod
19	in	in	IN	_	21	case
20	these	these	DT	_	21	det
21	patients	patient	NNS	_	18	nmod
22	.	.	.	_	4	punct

1	In	in	IN	_	4	case
2	controlled	controlled	JJ	_	4	amod
3	clinical	clinical	JJ	_	4	amod
4	trials	trial	NNS	_	10	nmod
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	,	,	,	_	10	punct
8	22	22	CD	_	9	nummod
9	patients	patient	NNS	_	10	nsubj
10	received	receive	VBD	_	0	ROOT
11	concomitant	concomitant	JJ	_	12	amod
12	drug2	drug2	NN	_	10	dobj
13	and	and	CC	_	12	cc
14	drug3	drug3	NN	_	12	conj
15	.	.	.	_	10	punct

1	No	no	DT	_	2	neg
2	rashes	rash	NNS	_	4	nsubjpass
3	were	be	VBD	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	in	in	IN	_	7	case
6	these	these	DT	_	7	det
7	patients	patient	NNS	_	4	nmod
8	.	.	.	_	4	punct

1	However	however	RB	_	8	advmod
2	,	,	,	_	8	punct
3	this	this	DT	_	5	det
4	sample	sample	NN	_	5	compound
5	size	size	NN	_	8	nsubj
6	is	be	VBZ	_	8	cop
7	too	too	RB	_	8	advmod
8	small	small	JJ	_	0	ROOT
9	to	to	TO	_	10	mark
10	allow	allow	VB	_	8	xcomp
11	for	for	IN	_	16	mark
12	any	any	DT	_	13	det
13	conclusions	conclusion	NNS	_	16	nsubjpass
14	to	to	TO	_	16	mark
15	be	be	VB	_	16	auxpass
16	drawn	draw	VBN	_	10	advcl
17	regarding	regard	VBG	_	19	case
18	the	the	DT	_	19	det
19	risk	risk	NN	_	16	nmod
20	of	of	IN	_	21	case
21	rashes	rash	NNS	_	19	nmod
22	with	with	IN	_	24	case
23	concomitant	concomitant	JJ	_	24	amod
24	drug1	drug1	NN	_	21	nmod
25	and	and	CC	_	24	cc
26	drug2	drug2	NN	_	27	compound
27	use	use	NN	_	24	conj
28	.	.	.	_	8	punct

1	In	in	IN	_	2	case
2	common	common	JJ	_	9	nmod
3	with	with	IN	_	5	case
4	other	other	JJ	_	5	amod
5	drug1	drug1	NN	_	2	nmod
6	,	,	,	_	9	punct
7	drug2	drug2	NN	_	9	nsubj
8	may	may	MD	_	9	aux
9	reduce	reduce	VB	_	0	ROOT
10	the	the	DT	_	11	det
11	efficacy	efficacy	NN	_	9	dobj
12	of	of	IN	_	14	case
13	oral	oral	JJ	_	14	amod
14	drug3	drug3	NN	_	11	nmod

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	drug2	drug2	NN	_	1	appos
4	-	-	:	_	3	punct
5	or	or	CC	_	3	cc
6	drug3	drug3	NN	_	3	conj
7	-	-	:	_	3	punct
8	containing	contain	VBG	_	3	dep
9	-RRB-	-rrb-	-RRB-	_	3	punct
10	:	:	:	_	1	punct
11	Concomitant	concomitant	JJ	_	12	amod
12	administration	administration	NN	_	22	nsubj
13	of	of	IN	_	16	case
14	300-mg	300-mg	JJ	_	16	amod
15	drug4	drug4	NN	_	16	compound
16	capsules	capsule	NNS	_	12	nmod
17	with	with	IN	_	21	case
18	30	30	CD	_	21	nummod
19	mL	ml	NN	_	21	compound
20	drug5	drug5	NN	_	21	compound
21	suspension	suspension	NN	_	12	nmod
22	reduces	reduce	VBZ	_	1	dep
23	the	the	DT	_	24	det
24	rate	rate	NN	_	22	dobj
25	-LRB-	-lrb-	-LRB-	_	26	punct
26	Cmax	cmax	NN	_	24	appos
27	-RRB-	-rrb-	-RRB-	_	26	punct
28	and	and	CC	_	24	cc
29	extent	extent	NN	_	24	conj
30	-LRB-	-lrb-	-LRB-	_	31	punct
31	AUC	auc	NN	_	29	appos
32	-RRB-	-rrb-	-RRB-	_	31	punct
33	of	of	IN	_	34	case
34	absorption	absorption	NN	_	24	nmod
35	by	by	IN	_	38	case
36	approximately	approximately	RB	_	37	advmod
37	40	40	CD	_	38	nummod
38	%	%	NN	_	22	nmod
39	.	.	.	_	1	punct

1	Time	Time	NNP	_	7	nsubjpass
2	to	to	TO	_	3	mark
3	reach	reach	VB	_	1	acl
4	Cmax	Cmax	NNP	_	3	dobj
5	is	be	VBZ	_	7	auxpass
6	also	also	RB	_	7	advmod
7	prolonged	prolong	VBN	_	0	ROOT
8	by	by	IN	_	10	case
9	1	1	CD	_	10	nummod
10	hour	hour	NN	_	7	nmod
11	.	.	.	_	7	punct

1	There	there	EX	_	2	expl
2	are	be	VBP	_	0	ROOT
3	no	no	DT	_	5	neg
4	significant	significant	JJ	_	5	amod
5	effects	effect	NNS	_	2	nsubj
6	on	on	IN	_	8	case
7	drug1	drug1	NN	_	8	compound
8	pharmacokinetics	pharmacokinetic	NNS	_	5	nmod
9	if	if	IN	_	13	mark
10	the	the	DT	_	11	det
11	drug2	drug2	NN	_	13	nsubjpass
12	is	be	VBZ	_	13	auxpass
13	administered	administer	VBN	_	2	advcl
14	2	2	CD	_	15	nummod
15	hours	hour	NNS	_	13	dobj
16	before	before	IN	_	21	nmod
17	or	or	CC	_	16	cc
18	2	2	CD	_	19	nummod
19	hours	hour	NNS	_	16	conj
20	after	after	IN	_	19	case
21	drug3	drug3	NN	_	15	nmod
22	.	.	.	_	2	punct

1	If	if	IN	_	4	mark
2	drug1	drug1	NN	_	4	nsubjpass
3	are	be	VBP	_	4	auxpass
4	required	require	VBN	_	12	advcl
5	during	during	IN	_	7	case
6	drug2	drug2	NN	_	7	compound
7	therapy	therapy	NN	_	4	nmod
8	,	,	,	_	12	punct
9	drug3	drug3	NN	_	12	nsubjpass
10	should	should	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	taken	take	VBN	_	0	ROOT
13	at	at	IN	_	14	case
14	least	least	JJS	_	15	nmod:npmod
15	2	2	CD	_	16	nummod
16	hours	hour	NNS	_	12	dobj
17	before	before	IN	_	21	nmod
18	or	or	CC	_	17	cc
19	after	after	IN	_	17	conj
20	the	the	DT	_	21	det
21	drug4	drug4	NN	_	16	nmod
22	.	.	.	_	12	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	As	as	IN	_	6	case
4	with	with	IN	_	6	case
5	other	other	JJ	_	6	amod
6	drug2	drug2	NN	_	9	nmod
7	,	,	,	_	9	punct
8	drug3	drug3	NN	_	9	nsubj
9	inhibits	inhibit	VBZ	_	1	appos
10	the	the	DT	_	12	det
11	renal	renal	JJ	_	12	amod
12	excretion	excretion	NN	_	9	dobj
13	of	of	IN	_	14	case
14	drug4	drug4	NN	_	12	nmod
15	,	,	,	_	9	punct
16	resulting	result	VBG	_	9	advcl
17	in	in	IN	_	20	case
18	an	a	DT	_	20	det
19	approximate	approximate	JJ	_	20	amod
20	doubling	doubling	NN	_	16	nmod
21	in	in	IN	_	22	case
22	A.C.	A.C.	NNP	_	20	nmod
23	a	a	DT	_	26	det
24	54	54	CD	_	25	compound
25	%	%	NN	_	26	amod
26	increase	increase	NN	_	20	dep
27	in	in	IN	_	31	case
28	peak	peak	JJ	_	31	amod
29	drug5	drug5	NN	_	31	compound
30	plasma	plasma	NN	_	31	compound
31	levels	level	NNS	_	26	nmod
32	,	,	,	_	26	punct
33	and	and	CC	_	26	cc
34	a	a	DT	_	37	det
35	50	50	CD	_	36	compound
36	%	%	NN	_	37	amod
37	prolongation	prolongation	NN	_	26	conj
38	in	in	IN	_	42	case
39	the	the	DT	_	42	det
40	apparent	apparent	JJ	_	42	amod
41	elimination	elimination	NN	_	42	compound
42	half-life	half-life	NN	_	37	nmod
43	.	.	.	_	1	punct

1	drug1	drug1	NN	_	4	nsubj
2	and	and	CC	_	1	cc
3	Foods	Foods	NNP	_	1	conj
4	Fortified	fortify	VBD	_	0	ROOT
5	With	with	IN	_	8	case
6	drug2	drug2	NN	_	8	compound
7	Concomitant	concomitant	JJ	_	8	amod
8	administration	administration	NN	_	4	nmod
9	of	of	IN	_	10	case
10	drug3	drug3	NN	_	8	nmod
11	with	with	IN	_	14	case
12	a	a	DT	_	14	det
13	therapeutic	therapeutic	JJ	_	14	amod
14	drug4	drug4	NN	_	4	nmod
15	containing	contain	VBG	_	14	acl
16	60	60	CD	_	17	nummod
17	mg	mg	NN	_	15	dobj
18	of	of	IN	_	20	case
19	elemental	elemental	JJ	_	20	amod
20	drug5	drug5	NN	_	17	nmod
21	-LRB-	-lrb-	-LRB-	_	23	punct
22	as	as	IN	_	23	case
23	FeSO4	feso4	NN	_	14	dep
24	-RRB-	-rrb-	-RRB-	_	23	punct
25	or	or	CC	_	14	cc
26	drug6	drug6	NN	_	14	conj
27	supplemented	supplement	VBN	_	26	acl
28	with	with	IN	_	30	case
29	10	10	CD	_	30	nummod
30	mg	mg	NN	_	27	nmod
31	of	of	IN	_	33	case
32	elemental	elemental	JJ	_	33	amod
33	drug7	drug7	NN	_	30	nmod
34	reduced	reduce	VBD	_	35	amod
35	extent	extent	NN	_	4	dobj
36	of	of	IN	_	37	case
37	absorption	absorption	NN	_	35	nmod
38	by	by	IN	_	40	case
39	80	80	CD	_	40	nummod
40	%	%	NN	_	35	nmod
41	and	and	CC	_	40	cc
42	31	31	CD	_	43	nummod
43	%	%	NN	_	40	conj
44	,	,	,	_	35	punct
45	respectively	respectively	RB	_	35	advmod
46	.	.	.	_	4	punct

1	If	if	IN	_	4	mark
2	drug1	drug1	NN	_	4	nsubjpass
3	are	be	VBP	_	4	auxpass
4	required	require	VBN	_	12	advcl
5	during	during	IN	_	7	case
6	drug2	drug2	NN	_	7	compound
7	therapy	therapy	NN	_	4	nmod
8	,	,	,	_	12	punct
9	drug3	drug3	NN	_	12	nsubjpass
10	should	should	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	taken	take	VBN	_	0	ROOT
13	at	at	IN	_	14	case
14	least	least	JJS	_	15	nmod:npmod
15	2	2	CD	_	16	nummod
16	hours	hour	NNS	_	12	dobj
17	before	before	IN	_	21	nmod
18	or	or	CC	_	17	cc
19	after	after	IN	_	17	conj
20	the	the	DT	_	21	det
21	supplement	supplement	NN	_	16	nmod
22	.	.	.	_	12	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	6	nsubj
3	of	of	IN	_	4	case
4	foods	food	NNS	_	2	nmod
5	highly	highly	RB	_	6	advmod
6	fortified	fortify	VBD	_	24	csubjpass
7	with	with	IN	_	9	case
8	elemental	elemental	JJ	_	9	amod
9	drug1	drug1	NN	_	6	nmod
10	-LRB-	-lrb-	-LRB-	_	12	punct
11	primarily	primarily	RB	_	12	advmod
12	drug2	drug2	NN	_	9	dep
13	-	-	:	_	12	punct
14	fortified	fortify	VBN	_	16	amod
15	breakfast	breakfast	NN	_	16	compound
16	cereals	cereal	NNS	_	12	dep
17	-RRB-	-rrb-	-RRB-	_	12	punct
18	on	on	IN	_	20	case
19	drug3	drug3	NN	_	20	compound
20	absorption	absorption	NN	_	6	nmod
21	has	have	VBZ	_	24	aux
22	not	not	RB	_	24	neg
23	been	be	VBN	_	24	auxpass
24	studied	study	VBN	_	0	ROOT
25	.	.	.	_	24	punct

1	Concomitantly	concomitantly	RB	_	2	advmod
2	administered	administer	VBN	_	3	amod
3	drug1	drug1	NN	_	17	nsubj
4	-	-	:	_	3	punct
5	fortified	fortified	JJ	_	7	amod
6	infant	infant	JJ	_	7	amod
7	formula	formula	NN	_	3	dep
8	-LRB-	-lrb-	-LRB-	_	12	punct
9	2.2	2.2	CD	_	12	nummod
10	mg	mg	NN	_	12	compound
11	elemental	elemental	JJ	_	12	amod
12	drug2	drug2	NN	_	7	dep
13	/	/	:	_	12	punct
14	6	6	CD	_	15	nummod
15	oz	oz	NN	_	12	dep
16	-RRB-	-rrb-	-RRB-	_	12	punct
17	has	have	VBZ	_	0	ROOT
18	no	no	DT	_	20	neg
19	significant	significant	JJ	_	20	amod
20	effect	effect	NN	_	17	dobj
21	on	on	IN	_	23	case
22	drug3	drug3	NN	_	23	compound
23	pharmacokinetics	pharmacokinetic	NNS	_	17	nmod
24	.	.	.	_	17	punct

1	Therefore	therefore	RB	_	9	advmod
2	,	,	,	_	9	punct
3	drug1	drug1	NN	_	9	nsubjpass
4	for	for	IN	_	6	case
5	Oral	Oral	NNP	_	6	compound
6	Suspension	Suspension	NNP	_	3	nmod
7	can	can	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	administered	administer	VBN	_	0	ROOT
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	-	-	:	_	11	punct
13	fortified	fortified	JJ	_	15	amod
14	infant	infant	JJ	_	15	amod
15	formula	formula	NN	_	11	dep
16	.	.	.	_	9	punct

1	There	there	EX	_	5	expl
2	have	have	VBP	_	5	aux
3	been	be	VBN	_	5	cop
4	rare	rare	JJ	_	5	amod
5	reports	report	NNS	_	0	ROOT
6	of	of	IN	_	8	case
7	reddish	reddish	JJ	_	8	amod
8	stools	stool	NNS	_	5	nmod
9	in	in	IN	_	10	case
10	patients	patient	NNS	_	8	nmod
11	who	who	WP	_	13	nsubj
12	have	have	VBP	_	13	aux
13	received	receive	VBN	_	10	acl:relcl
14	drug1	drug1	NN	_	13	dobj
15	in	in	IN	_	16	case
16	Japan	Japan	NNP	_	13	nmod
17	.	.	.	_	5	punct

1	The	the	DT	_	3	det
2	reddish	reddish	JJ	_	3	amod
3	color	color	NN	_	8	nsubj
4	is	be	VBZ	_	8	cop
5	due	due	JJ	_	8	case
6	to	to	TO	_	5	mwe
7	the	the	DT	_	8	det
8	formation	formation	NN	_	0	ROOT
9	of	of	IN	_	12	case
10	a	a	DT	_	12	det
11	nonabsorbable	nonabsorbable	JJ	_	12	amod
12	complex	complex	NN	_	8	nmod
13	between	between	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	or	or	CC	_	14	cc
16	its	its	PRP$	_	18	nmod:poss
17	breakdown	breakdown	NN	_	18	compound
18	products	product	NNS	_	14	conj
19	and	and	CC	_	14	cc
20	drug2	drug2	NN	_	14	conj
21	in	in	IN	_	24	case
22	the	the	DT	_	24	det
23	gastrointestinal	gastrointestinal	JJ	_	24	amod
24	tract	tract	NN	_	12	nmod
25	.	.	.	_	8	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	3	amod
2	Test	test	NN	_	3	compound
3	Interactions	interaction	NNS	_	0	ROOT
4	A	a	DT	_	6	det
5	false-positive	false-positive	JJ	_	6	amod
6	reaction	reaction	NN	_	13	nsubj
7	for	for	IN	_	8	case
8	ketones	ketone	NNS	_	6	nmod
9	in	in	IN	_	11	case
10	the	the	DT	_	11	det
11	urine	urine	NN	_	8	nmod
12	may	may	MD	_	13	aux
13	occur	occur	VB	_	3	acl:relcl
14	with	with	IN	_	15	case
15	tests	test	NNS	_	13	nmod
16	using	use	VBG	_	15	acl
17	drug1	drug1	NN	_	16	dobj
18	,	,	,	_	13	punct
19	but	but	CC	_	13	cc
20	not	not	RB	_	22	neg
21	with	with	IN	_	22	case
22	those	those	DT	_	13	conj
23	using	use	VBG	_	22	acl
24	drug2	drug2	NN	_	23	dobj
25	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	administration	administration	NN	_	6	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	may	may	MD	_	6	aux
6	result	result	VB	_	0	ROOT
7	in	in	IN	_	10	case
8	a	a	DT	_	10	det
9	false-positive	false-positive	JJ	_	10	amod
10	reaction	reaction	NN	_	6	nmod
11	for	for	IN	_	12	case
12	glucose	glucose	NN	_	10	nmod
13	in	in	IN	_	14	case
14	urine	urine	NN	_	12	nmod
15	using	use	VBG	_	10	acl
16	Clinitest	Clinitest	NNP	_	15	dobj
17	,	,	,	_	16	punct
18	Benedict	Benedict	NNP	_	20	compound
19	s	be	VBZ	_	20	compound
20	solution	solution	NN	_	16	conj
21	,	,	,	_	16	punct
22	or	or	CC	_	16	cc
23	Fehlings	Fehlings	NNP	_	24	compound
24	solution	solution	NN	_	16	conj
25	.	.	.	_	6	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	recommended	recommend	VBN	_	0	ROOT
4	that	that	IN	_	21	mark
5	glucose	glucose	NN	_	6	compound
6	tests	test	NNS	_	21	nsubjpass
7	based	base	VBN	_	12	case
8	on	on	IN	_	12	case
9	enzymatic	enzymatic	JJ	_	12	amod
10	glucose	glucose	NN	_	12	compound
11	oxidase	oxidase	NN	_	12	compound
12	reactions	reaction	NNS	_	6	nmod
13	-LRB-	-lrb-	-LRB-	_	16	punct
14	such	such	JJ	_	16	case
15	as	as	IN	_	14	mwe
16	Clinistix	Clinistix	NNP	_	12	nmod
17	or	or	CC	_	16	cc
18	Tes-Tape	Tes-Tape	NNP	_	16	conj
19	-RRB-	-rrb-	-RRB-	_	16	punct
20	be	be	VB	_	21	auxpass
21	used	use	VBN	_	3	ccomp
22	.	.	.	_	3	punct

1	drug1	drug1	NN	_	3	nsubjpass
2	are	be	VBP	_	3	auxpass
3	known	know	VBN	_	0	ROOT
4	to	to	TO	_	6	mark
5	occasionally	occasionally	RB	_	6	advmod
6	induce	induce	VB	_	3	xcomp
7	a	a	DT	_	11	det
8	positive	positive	JJ	_	11	amod
9	direct	direct	JJ	_	11	amod
10	Coombs	coomb	NNS	_	11	compound
11	test	test	NN	_	6	dobj
12	.	.	.	_	3	punct

1	No	no	DT	_	2	neg
2	information	information	NN	_	0	ROOT
3	available	available	JJ	_	2	amod
4	.	.	.	_	2	punct

1	Catecholamine-depleting	catecholamine-depleting	JJ	_	2	amod
2	drugs	drug	NNS	_	9	nsubj
3	,	,	,	_	2	punct
4	e.g.	e.g.	FW	_	6	dep
5	,	,	,	_	6	punct
6	drug1	drug1	NN	_	2	nmod
7	,	,	,	_	2	punct
8	may	may	MD	_	9	aux
9	have	have	VB	_	0	ROOT
10	an	a	DT	_	12	det
11	additive	additive	JJ	_	12	amod
12	effect	effect	NN	_	9	dobj
13	when	when	WRB	_	14	advmod
14	given	give	VBN	_	9	advcl
15	with	with	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	.	.	.	_	9	punct

1	Patients	patient	NNS	_	17	nsubjpass
2	treated	treat	VBN	_	1	acl
3	concurrently	concurrently	RB	_	2	advmod
4	with	with	IN	_	5	case
5	drug1	drug1	NN	_	2	nmod
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	drug2	drug2	NN	_	5	appos
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	and	and	CC	_	5	cc
10	a	a	DT	_	12	det
11	catecholamine	catecholamine	NN	_	12	compound
12	depletor	depletor	NN	_	5	conj
13	should	should	MD	_	17	aux
14	therefore	therefore	RB	_	17	advmod
15	be	be	VB	_	17	auxpass
16	closely	closely	RB	_	17	advmod
17	observed	observe	VBN	_	0	ROOT
18	for	for	IN	_	19	case
19	evidence	evidence	NN	_	17	nmod
20	of	of	IN	_	21	case
21	hypotension	hypotension	NN	_	19	nmod
22	or	or	CC	_	21	cc
23	marked	marked	JJ	_	24	amod
24	bradycardia	bradycardia	NN	_	21	conj
25	,	,	,	_	19	punct
26	which	which	WDT	_	28	nsubj
27	may	may	MD	_	28	aux
28	result	result	VB	_	19	acl:relcl
29	in	in	IN	_	30	case
30	vertigo	vertigo	NN	_	28	nmod
31	,	,	,	_	30	punct
32	syncope	syncope	NN	_	30	conj
33	,	,	,	_	30	punct
34	or	or	CC	_	30	cc
35	postural	postural	JJ	_	36	amod
36	hypotension	hypotension	NN	_	30	conj
37	.	.	.	_	17	punct

1	A	a	DT	_	2	det
2	study	study	NN	_	9	nsubj
3	of	of	IN	_	4	case
4	interaction	interaction	NN	_	2	nmod
5	between	between	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	drug2	drug2	NN	_	6	conj
9	showed	show	VBD	_	0	ROOT
10	that	that	IN	_	19	mark
11	concomitant	concomitant	JJ	_	12	amod
12	administration	administration	NN	_	19	nsubj
13	of	of	IN	_	14	case
14	drug3	drug3	NN	_	12	nmod
15	and	and	CC	_	14	cc
16	drug4	drug4	NN	_	14	conj
17	does	do	VBZ	_	19	aux
18	not	not	RB	_	19	neg
19	alter	alter	VB	_	9	ccomp
20	drug5	drug5	NN	_	22	compound
21	plasma	plasma	NN	_	22	compound
22	levels	level	NNS	_	19	dobj
23	.	.	.	_	9	punct

1	drug1	drug1	NN	_	2	compound
2	concentrations	concentration	NNS	_	5	nsubj
3	were	be	VBD	_	5	cop
4	equivocally	equivocally	RB	_	5	advmod
5	higher	higher	JJR	_	0	ROOT
6	when	when	WRB	_	7	advmod
7	given	give	VBN	_	5	advcl
8	with	with	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	,	,	,	_	5	punct
11	but	but	CC	_	5	cc
12	this	this	DT	_	15	nsubj
13	is	be	VBZ	_	15	cop
14	not	not	RB	_	15	neg
15	likely	likely	JJ	_	5	conj
16	to	to	TO	_	19	mark
17	be	be	VB	_	19	cop
18	clinically	clinically	RB	_	19	advmod
19	important	important	JJ	_	15	xcomp
20	.	.	.	_	5	punct

1	When	when	WRB	_	7	advmod
2	drug1	drug1	NN	_	7	nsubjpass
3	and	and	CC	_	2	cc
4	drug2	drug2	NN	_	2	conj
5	were	be	VBD	_	7	auxpass
6	concomitantly	concomitantly	RB	_	7	advmod
7	administered	administer	VBN	_	14	advcl
8	intravenously	intravenously	RB	_	7	advmod
9	to	to	TO	_	11	case
10	normal	normal	JJ	_	11	amod
11	volunteers	volunteer	NNS	_	7	nmod
12	,	,	,	_	14	punct
13	there	there	EX	_	14	expl
14	was	be	VBD	_	0	ROOT
15	a	a	DT	_	18	det
16	10-20	10-20	CD	_	17	compound
17	%	%	NN	_	18	amod
18	increase	increase	NN	_	14	nsubj
19	in	in	IN	_	22	case
20	drug3	drug3	NN	_	22	compound
21	blood	blood	NN	_	22	compound
22	levels	level	NNS	_	18	nmod
23	at	at	IN	_	26	case
24	some	some	DT	_	26	det
25	time	time	NN	_	26	compound
26	points	point	NNS	_	18	nmod
27	.	.	.	_	14	punct

1	drug1	drug1	NN	_	4	nsubj
2	did	do	VBD	_	4	aux
3	not	not	RB	_	4	neg
4	affect	affect	VB	_	0	ROOT
5	drug2	drug2	NN	_	6	compound
6	pharmacokinetics	pharmacokinetic	NNS	_	4	dobj
7	.	.	.	_	4	punct

1	When	when	WRB	_	8	advmod
2	intravenous	intravenous	JJ	_	3	amod
3	drug1	drug1	NN	_	8	nsubjpass
4	and	and	CC	_	3	cc
5	drug2	drug2	NN	_	3	conj
6	were	be	VBD	_	8	auxpass
7	concomitantly	concomitantly	RB	_	8	advmod
8	administered	administer	VBN	_	20	advcl
9	in	in	IN	_	11	case
10	normal	normal	JJ	_	11	amod
11	subjects	subject	NNS	_	8	nmod
12	,	,	,	_	20	punct
13	no	no	DT	_	14	neg
14	effect	effect	NN	_	20	nsubjpass
15	on	on	IN	_	18	case
16	drug3	drug3	NN	_	18	compound
17	blood	blood	NN	_	18	compound
18	levels	level	NNS	_	14	nmod
19	was	be	VBD	_	20	auxpass
20	seen	see	VBN	_	0	ROOT
21	,	,	,	_	20	punct
22	but	but	CC	_	20	cc
23	drug4	drug4	NN	_	26	compound
24	steady-state	steady-state	JJ	_	26	amod
25	blood	blood	NN	_	26	compound
26	levels	level	NNS	_	28	nsubjpass
27	were	be	VBD	_	28	auxpass
28	increased	increase	VBN	_	20	conj
29	by	by	IN	_	31	case
30	46	46	CD	_	31	nummod
31	%	%	NN	_	28	nmod
32	in	in	IN	_	34	case
33	the	the	DT	_	34	det
34	presence	presence	NN	_	28	nmod
35	of	of	IN	_	36	case
36	drug5	drug5	NN	_	34	nmod
37	.	.	.	_	20	punct

1	No	no	DT	_	4	neg
2	other	other	JJ	_	4	amod
3	pharmacokinetic	pharmacokinetic	JJ	_	4	amod
4	parameters	parameter	NNS	_	6	nsubjpass
5	were	be	VBD	_	6	auxpass
6	changed	change	VBN	_	0	ROOT
7	.	.	.	_	6	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	0	ROOT
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	on	on	IN	_	7	case
6	the	the	DT	_	7	det
7	duration	duration	NN	_	2	nmod
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	-	-	:	_	2	punct
11	induced	induce	VBN	_	13	amod
12	neuromuscular	neuromuscular	JJ	_	13	amod
13	blockade	blockade	NN	_	15	nsubjpass
14	was	be	VBD	_	15	auxpass
15	studied	study	VBN	_	2	dep
16	in	in	IN	_	17	case
17	patients	patient	NNS	_	15	nmod
18	undergoing	undergo	VBG	_	17	acl
19	surgery	surgery	NN	_	18	dobj
20	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	onset	onset	NN	_	9	nsubj
3	of	of	IN	_	5	case
4	neuromuscular	neuromuscular	JJ	_	5	amod
5	blockade	blockade	NN	_	2	nmod
6	by	by	IN	_	7	case
7	drug1	drug1	NN	_	2	nmod
8	was	be	VBD	_	9	aux
9	unaffected	unaffected	JJ	_	0	ROOT
10	by	by	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	,	,	,	_	9	punct
13	but	but	CC	_	9	cc
14	the	the	DT	_	15	det
15	duration	duration	NN	_	20	nsubjpass
16	of	of	IN	_	18	case
17	neuromuscular	neuromuscular	JJ	_	18	amod
18	blockade	blockade	NN	_	15	nmod
19	was	be	VBD	_	20	auxpass
20	prolonged	prolong	VBN	_	9	conj
21	from	from	IN	_	23	case
22	5	5	CD	_	23	nummod
23	minutes	minute	NNS	_	20	nmod
24	to	to	TO	_	26	case
25	8	8	CD	_	26	nummod
26	minutes	minute	NNS	_	23	nmod
27	.	.	.	_	9	punct

1	Although	although	IN	_	10	mark
2	the	the	DT	_	3	det
3	interactions	interaction	NNS	_	10	nsubj
4	observed	observe	VBN	_	3	acl
5	in	in	IN	_	7	case
6	these	these	DT	_	7	det
7	studies	study	NNS	_	4	nmod
8	do	do	VBP	_	10	aux
9	not	not	RB	_	10	neg
10	appear	appear	VB	_	21	advcl
11	to	to	TO	_	16	mark
12	be	be	VB	_	16	cop
13	of	of	IN	_	16	case
14	major	major	JJ	_	16	amod
15	clinical	clinical	JJ	_	16	amod
16	importance	importance	NN	_	10	xcomp
17	,	,	,	_	21	punct
18	drug1	drug1	NN	_	21	nsubjpass
19	should	should	MD	_	21	aux
20	be	be	VB	_	21	auxpass
21	titrated	titrate	VBN	_	0	ROOT
22	with	with	IN	_	23	case
23	caution	caution	NN	_	21	nmod
24	in	in	IN	_	25	case
25	patients	patient	NNS	_	21	nmod
26	being	be	VBG	_	27	auxpass
27	treated	treat	VBN	_	25	acl
28	concurrently	concurrently	RB	_	27	advmod
29	with	with	IN	_	30	case
30	drug2	drug2	NN	_	27	nmod
31	,	,	,	_	30	punct
32	drug3	drug3	NN	_	30	conj
33	,	,	,	_	30	punct
34	drug4	drug4	NN	_	30	conj
35	or	or	CC	_	30	cc
36	drug5	drug5	NN	_	30	conj
37	.	.	.	_	21	punct

1	While	while	IN	_	2	mark
2	taking	take	VBG	_	21	advcl
3	drug1	drug1	NN	_	2	dobj
4	,	,	,	_	21	punct
5	patients	patient	NNS	_	21	nsubj
6	with	with	IN	_	8	case
7	a	a	DT	_	8	det
8	history	history	NN	_	5	nmod
9	of	of	IN	_	12	case
10	severe	severe	JJ	_	12	amod
11	anaphylactic	anaphylactic	JJ	_	12	amod
12	reaction	reaction	NN	_	8	nmod
13	to	to	TO	_	15	case
14	a	a	DT	_	15	det
15	variety	variety	NN	_	12	nmod
16	of	of	IN	_	17	case
17	allergens	allergen	NNS	_	15	nmod
18	may	may	MD	_	21	aux
19	be	be	VB	_	21	cop
20	more	more	RBR	_	21	advmod
21	reactive	reactive	JJ	_	0	ROOT
22	to	to	TO	_	24	case
23	repeated	repeat	VBN	_	24	amod
24	challenge	challenge	NN	_	21	nmod
25	,	,	,	_	24	punct
26	either	either	CC	_	27	cc:preconj
27	accidental	accidental	JJ	_	24	amod
28	,	,	,	_	27	punct
29	diagnostic	diagnostic	JJ	_	27	conj
30	,	,	,	_	27	punct
31	or	or	CC	_	27	cc
32	therapeutic	therapeutic	JJ	_	27	conj
33	.	.	.	_	21	punct

1	Such	such	JJ	_	2	amod
2	patients	patient	NNS	_	5	nsubj
3	may	may	MD	_	5	aux
4	be	be	VB	_	5	cop
5	unresponsive	unresponsive	JJ	_	0	ROOT
6	to	to	TO	_	9	case
7	the	the	DT	_	9	det
8	usual	usual	JJ	_	9	amod
9	doses	dose	NNS	_	5	nmod
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	used	use	VBN	_	9	acl
13	to	to	TO	_	14	mark
14	treat	treat	VB	_	12	xcomp
15	allergic	allergic	JJ	_	16	amod
16	reaction	reaction	NN	_	14	dobj
17	.	.	.	_	5	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	exercised	exercise	VBN	_	0	ROOT
5	when	when	WRB	_	6	advmod
6	considering	consider	VBG	_	4	advcl
7	the	the	DT	_	8	det
8	use	use	NN	_	6	dobj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	drug2	drug2	NN	_	10	conj
13	in	in	IN	_	14	case
14	patients	patient	NNS	_	8	nmod
15	with	with	IN	_	18	case
16	depressed	depressed	JJ	_	18	amod
17	myocardial	myocardial	JJ	_	18	amod
18	function	function	NN	_	14	nmod
19	.	.	.	_	4	punct

1	Fatal	fatal	JJ	_	3	amod
2	cardiac	cardiac	JJ	_	3	amod
3	arrests	arrest	NNS	_	5	nsubj
4	have	have	VBP	_	5	aux
5	occurred	occur	VBN	_	0	ROOT
6	in	in	IN	_	7	case
7	patients	patient	NNS	_	5	nmod
8	receiving	receive	VBG	_	7	acl
9	both	both	CC	_	10	det
10	drugs	drug	NNS	_	8	dobj
11	.	.	.	_	5	punct

1	Additionally	additionally	RB	_	7	advmod
2	,	,	,	_	7	punct
3	drug1	drug1	NN	_	7	nsubjpass
4	should	should	MD	_	7	aux
5	not	not	RB	_	7	neg
6	be	be	VB	_	7	auxpass
7	used	use	VBN	_	0	ROOT
8	to	to	TO	_	9	mark
9	control	control	VB	_	7	xcomp
10	supraventricular	supraventricular	JJ	_	11	amod
11	tachycardia	tachycardia	NN	_	9	dobj
12	in	in	IN	_	14	case
13	the	the	DT	_	14	det
14	presence	presence	NN	_	9	nmod
15	of	of	IN	_	16	case
16	agents	agent	NNS	_	14	nmod
17	which	which	WDT	_	19	nsubj
18	are	be	VBP	_	19	cop
19	vasoconstrictive	vasoconstrictive	JJ	_	16	acl:relcl
20	and	and	CC	_	19	cc
21	inotropic	inotropic	JJ	_	19	conj
22	such	such	JJ	_	24	case
23	as	as	IN	_	22	mwe
24	drug2	drug2	NN	_	19	nmod
25	,	,	,	_	24	punct
26	drug3	drug3	NN	_	24	conj
27	,	,	,	_	24	punct
28	and	and	CC	_	24	cc
29	drug4	drug4	NN	_	24	conj
30	because	because	IN	_	33	case
31	of	of	IN	_	30	mwe
32	the	the	DT	_	33	det
33	danger	danger	NN	_	19	nmod
34	of	of	IN	_	35	mark
35	blocking	block	VBG	_	33	acl
36	cardiac	cardiac	JJ	_	37	amod
37	contractility	contractility	NN	_	35	dobj
38	when	when	WRB	_	43	advmod
39	systemic	systemic	JJ	_	41	amod
40	vascular	vascular	JJ	_	41	amod
41	resistance	resistance	NN	_	43	nsubj
42	is	be	VBZ	_	43	cop
43	high	high	JJ	_	35	advcl
44	.	.	.	_	7	punct

1	In	in	IN	_	2	case
2	patients	patient	NNS	_	35	nmod
3	receiving	receive	VBG	_	2	acl
4	nonselective	nonselective	JJ	_	5	amod
5	drug1	drug1	NN	_	3	dobj
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	drug2	drug2	NN	_	5	appos
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	-LRB-	-lrb-	-LRB-	_	12	punct
10	e.g.	e.g.	FW	_	12	dep
11	,	,	,	_	12	punct
12	drug3	drug3	NN	_	2	dep
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	in	in	IN	_	15	case
15	combination	combination	NN	_	2	nmod
16	with	with	IN	_	17	case
17	drug4	drug4	NN	_	15	nmod
18	-LRB-	-lrb-	-LRB-	_	21	punct
19	e.g.	e.g.	FW	_	21	dep
20	,	,	,	_	21	punct
21	drug5	drug5	NN	_	17	dep
22	,	,	,	_	21	punct
23	drug6	drug6	NN	_	21	conj
24	,	,	,	_	21	punct
25	drug7	drug7	NN	_	21	conj
26	,	,	,	_	21	punct
27	drug8	drug8	NN	_	21	conj
28	,	,	,	_	21	punct
29	drug9	drug9	NN	_	21	appos
30	-RRB-	-rrb-	-RRB-	_	21	punct
31	,	,	,	_	35	punct
32	there	there	EX	_	35	expl
33	have	have	VBP	_	35	aux
34	been	be	VBN	_	35	cop
35	reports	report	NNS	_	0	ROOT
36	of	of	IN	_	42	case
37	serious	serious	JJ	_	40	amod
38	,	,	,	_	40	punct
39	sometimes	sometimes	RB	_	40	advmod
40	fatal	fatal	JJ	_	42	amod
41	,	,	,	_	40	punct
42	reactions	reaction	NNS	_	35	nmod
43	.	.	.	_	35	punct

1	Because	because	IN	_	6	mark
2	drug1	drug1	NN	_	6	nsubj
3	is	be	VBZ	_	6	cop
4	a	a	DT	_	6	det
5	serotonin	serotonin	NN	_	6	compound
6	releaser	releaser	NN	_	15	advcl
7	and	and	CC	_	6	cc
8	reuptake	reuptake	NN	_	9	compound
9	inhibitor	inhibitor	NN	_	6	conj
10	,	,	,	_	15	punct
11	drug2	drug2	NN	_	15	nsubjpass
12	should	should	MD	_	15	aux
13	not	not	RB	_	15	neg
14	be	be	VB	_	15	auxpass
15	used	use	VBN	_	0	ROOT
16	concomitantly	concomitantly	RB	_	15	advmod
17	with	with	IN	_	19	case
18	a	a	DT	_	19	det
19	drug3	drug3	NN	_	15	nmod
20	.	.	.	_	15	punct

1	At	at	IN	_	2	case
2	least	least	JJS	_	3	nmod:npmod
3	14	14	CD	_	4	nummod
4	days	day	NNS	_	6	nsubj
5	should	should	MD	_	6	aux
6	elapse	elapse	VB	_	0	ROOT
7	between	between	IN	_	8	case
8	discontinuation	discontinuation	NN	_	6	nmod
9	of	of	IN	_	11	case
10	a	a	DT	_	11	det
11	drug1	drug1	NN	_	8	nmod
12	and	and	CC	_	8	cc
13	initiation	initiation	NN	_	8	conj
14	of	of	IN	_	15	case
15	treatment	treatment	NN	_	13	nmod
16	with	with	IN	_	17	case
17	drug2	drug2	NN	_	13	nmod
18	.	.	.	_	6	punct

1	At	at	IN	_	2	case
2	least	least	JJS	_	3	nmod:npmod
3	3	3	CD	_	4	nummod
4	weeks	week	NNS	_	6	nsubj
5	should	should	MD	_	6	aux
6	elapse	elapse	VB	_	0	ROOT
7	between	between	IN	_	8	case
8	discontinuation	discontinuation	NN	_	6	nmod
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	and	and	CC	_	8	cc
12	initiation	initiation	NN	_	8	conj
13	of	of	IN	_	14	case
14	treatment	treatment	NN	_	12	nmod
15	with	with	IN	_	17	case
16	a	a	DT	_	17	det
17	drug2	drug2	NN	_	14	nmod
18	.	.	.	_	6	punct

1	A	a	DT	_	7	det
2	rare	rare	JJ	_	7	amod
3	,	,	,	_	2	punct
4	but	but	CC	_	2	cc
5	serious	serious	JJ	_	2	conj
6	,	,	,	_	7	punct
7	constellation	constellation	NN	_	17	nsubjpass
8	of	of	IN	_	9	case
9	symptoms	symptom	NNS	_	7	nmod
10	,	,	,	_	7	punct
11	termed	term	VBN	_	7	acl
12	serotonin	serotonin	NN	_	13	compound
13	syndrome	syndrome	NN	_	11	xcomp
14	,	,	,	_	7	punct
15	has	have	VBZ	_	17	aux
16	been	be	VBN	_	17	auxpass
17	reported	report	VBN	_	0	ROOT
18	with	with	IN	_	21	case
19	the	the	DT	_	21	det
20	concomitant	concomitant	JJ	_	21	amod
21	use	use	NN	_	17	nmod
22	of	of	IN	_	23	case
23	drug1	drug1	NN	_	21	nmod
24	-LRB-	-lrb-	-LRB-	_	25	punct
25	drug2	drug2	NN	_	23	appos
26	-RRB-	-rrb-	-RRB-	_	25	punct
27	and	and	CC	_	23	cc
28	agents	agent	NNS	_	23	conj
29	for	for	IN	_	31	case
30	migraine	migraine	NN	_	31	compound
31	therapy	therapy	NN	_	21	nmod
32	,	,	,	_	31	punct
33	such	such	JJ	_	35	case
34	as	as	IN	_	33	mwe
35	drug3	drug3	NN	_	31	nmod
36	-LRB-	-lrb-	-LRB-	_	37	punct
37	drug4	drug4	NN	_	35	appos
38	-RRB-	-rrb-	-RRB-	_	37	punct
39	and	and	CC	_	35	cc
40	drug5	drug5	NN	_	35	conj
41	.	.	.	_	17	punct

1	The	the	DT	_	2	det
2	syndrome	syndrome	NN	_	3	nsubj
3	requires	require	VBZ	_	0	ROOT
4	immediate	immediate	JJ	_	6	amod
5	medical	medical	JJ	_	6	amod
6	attention	attention	NN	_	3	dobj
7	and	and	CC	_	3	cc
8	may	may	MD	_	9	aux
9	include	include	VB	_	3	conj
10	one	one	CD	_	9	dobj
11	or	or	CC	_	10	cc
12	more	more	JJR	_	10	conj
13	of	of	IN	_	16	case
14	the	the	DT	_	16	det
15	following	follow	VBG	_	16	amod
16	symptoms	symptom	NNS	_	10	nmod
17	:	:	:	_	3	punct
18	excitement	excitement	NN	_	3	dep
19	,	,	,	_	18	punct
20	hypomania	hypomania	NN	_	18	conj
21	,	,	,	_	18	punct
22	restlessness	restlessness	NN	_	18	conj
23	,	,	,	_	18	punct
24	loss	loss	NN	_	18	appos
25	of	of	IN	_	26	case
26	consciousness	consciousness	NN	_	24	nmod
27	,	,	,	_	26	punct
28	confusion	confusion	NN	_	26	conj
29	,	,	,	_	26	punct
30	disorientation	disorientation	NN	_	26	conj
31	,	,	,	_	26	punct
32	anxiety	anxiety	NN	_	26	conj
33	,	,	,	_	26	punct
34	agitation	agitation	NN	_	26	conj
35	,	,	,	_	26	punct
36	motor	motor	NN	_	37	compound
37	weakness	weakness	NN	_	26	conj
38	,	,	,	_	26	punct
39	myoclonus	myoclonus	NN	_	26	conj
40	,	,	,	_	26	punct
41	tremor	tremor	NN	_	26	conj
42	,	,	,	_	26	punct
43	hemiballismus	hemiballismus	NN	_	26	conj
44	,	,	,	_	26	punct
45	hyperreflexia	hyperreflexia	NN	_	26	conj
46	,	,	,	_	26	punct
47	ataxia	ataxia	NN	_	26	conj
48	,	,	,	_	26	punct
49	dysarthria	dysarthria	NN	_	26	conj
50	,	,	,	_	26	punct
51	incoordination	incoordination	NN	_	26	conj
52	,	,	,	_	26	punct
53	hyperthermia	hyperthermia	NN	_	26	conj
54	,	,	,	_	26	punct
55	shivering	shiver	VBG	_	26	conj
56	,	,	,	_	26	punct
57	pupillary	pupillary	JJ	_	58	amod
58	dilation	dilation	NN	_	26	conj
59	,	,	,	_	26	punct
60	diaphoresis	diaphoresis	NN	_	26	conj
61	,	,	,	_	26	punct
62	emesis	emesis	NN	_	26	conj
63	,	,	,	_	26	punct
64	and	and	CC	_	26	cc
65	tachycardia	tachycardia	NN	_	26	conj
66	.	.	.	_	3	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	should	should	MD	_	5	aux
3	not	not	RB	_	5	neg
4	be	be	VB	_	5	auxpass
5	administered	administer	VBN	_	0	ROOT
6	with	with	IN	_	8	case
7	other	other	JJ	_	8	amod
8	drug2	drug2	NN	_	5	nmod
9	.	.	.	_	5	punct

1	The	the	DT	_	3	det
2	appropriate	appropriate	JJ	_	3	amod
3	interval	interval	NN	_	14	nsubjpass
4	between	between	IN	_	5	case
5	administration	administration	NN	_	3	nmod
6	of	of	IN	_	8	case
7	these	these	DT	_	8	det
8	agents	agent	NNS	_	5	nmod
9	and	and	CC	_	5	cc
10	drug1	drug1	NN	_	5	conj
11	has	have	VBZ	_	14	aux
12	not	not	RB	_	14	neg
13	been	be	VBN	_	14	auxpass
14	established	establish	VBN	_	0	ROOT
15	.	.	.	_	14	punct

1	The	the	DT	_	2	det
2	use	use	NN	_	13	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	8	case
6	other	other	JJ	_	8	amod
7	CNS-active	cns-active	JJ	_	8	amod
8	drugs	drug	NNS	_	2	nmod
9	has	have	VBZ	_	13	aux
10	not	not	RB	_	13	neg
11	been	be	VBN	_	13	auxpass
12	systematically	systematically	RB	_	13	advmod
13	evaluated	evaluate	VBN	_	0	ROOT
14	;	;	:	_	13	punct

1	consequently	consequently	RB	_	5	advmod
2	,	,	,	_	5	punct
3	caution	caution	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	advised	advise	VBN	_	0	ROOT
6	if	if	IN	_	12	mark
7	drug1	drug1	NN	_	12	nsubjpass
8	and	and	CC	_	7	cc
9	such	such	JJ	_	10	amod
10	drugs	drug	NNS	_	7	conj
11	are	be	VBP	_	12	auxpass
12	prescribed	prescribe	VBN	_	5	advcl
13	concurrently	concurrently	RB	_	12	advmod
14	.	.	.	_	5	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	highly	highly	RB	_	4	advmod
4	bound	bind	VBN	_	0	ROOT
5	to	to	TO	_	7	case
6	plasma	plasma	NN	_	7	compound
7	protein	protein	NN	_	4	nmod
8	-LRB-	-lrb-	-LRB-	_	10	punct
9	99.9	99.9	CD	_	10	nummod
10	%	%	NN	_	7	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	.	.	.	_	4	punct

1	Therefore	therefore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	caution	caution	NN	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	used	use	VBN	_	0	ROOT
7	when	when	WRB	_	8	advmod
8	administering	administer	VBG	_	6	advcl
9	drug1	drug1	NN	_	8	dobj
10	concurrently	concurrently	RB	_	9	advmod
11	with	with	IN	_	15	case
12	other	other	JJ	_	15	amod
13	highly	highly	RB	_	15	advmod
14	plasma	plasma	NN	_	15	compound
15	protein	protein	NN	_	8	nmod
16	-	-	:	_	15	punct
17	bound	bind	VBN	_	18	amod
18	drugs	drug	NNS	_	15	dep
19	with	with	IN	_	22	case
20	narrow	narrow	JJ	_	22	amod
21	therapeutic	therapeutic	JJ	_	22	amod
22	indices	index	NNS	_	18	nmod
23	,	,	,	_	6	punct
24	as	as	IN	_	25	case
25	competition	competition	NN	_	30	nmod
26	for	for	IN	_	28	case
27	binding	bind	VBG	_	28	amod
28	sites	site	NNS	_	25	nmod
29	may	may	MD	_	30	aux
30	occur	occur	VB	_	6	parataxis
31	.	.	.	_	6	punct

1	The	the	DT	_	2	det
2	extent	extent	NN	_	14	nsubjpass
3	of	of	IN	_	6	case
4	plasma	plasma	NN	_	6	compound
5	protein	protein	NN	_	6	compound
6	binding	binding	NN	_	2	nmod
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	in	in	IN	_	11	case
10	human	human	JJ	_	11	amod
11	plasma	plasma	NN	_	6	nmod
12	is	be	VBZ	_	14	auxpass
13	not	not	RB	_	14	neg
14	affected	affect	VBN	_	0	ROOT
15	by	by	IN	_	17	case
16	the	the	DT	_	17	det
17	presence	presence	NN	_	14	nmod
18	of	of	IN	_	20	case
19	therapeutic	therapeutic	JJ	_	20	amod
20	concentrations	concentration	NNS	_	17	nmod
21	of	of	IN	_	22	case
22	drug2	drug2	NN	_	20	nmod
23	-LRB-	-lrb-	-LRB-	_	25	punct
24	15	15	CD	_	25	nummod
25	mcg	mcg	NN	_	22	dep
26	/	/	:	_	25	punct
27	mL	ml	NN	_	25	dep
28	-RRB-	-rrb-	-RRB-	_	25	punct
29	,	,	,	_	14	punct
30	nor	nor	CC	_	14	cc
31	is	be	VBZ	_	33	cop
32	the	the	DT	_	33	det
33	binding	binding	NN	_	14	conj
34	of	of	IN	_	35	case
35	drug3	drug3	NN	_	33	nmod
36	affected	affect	VBN	_	35	acl
37	by	by	IN	_	39	case
38	the	the	DT	_	39	det
39	presence	presence	NN	_	36	nmod
40	of	of	IN	_	41	case
41	drug4	drug4	NN	_	39	nmod
42	.	.	.	_	14	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Coadministration	coadministration	NN	_	9	nsubj
4	of	of	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug3	drug3	NN	_	8	compound
8	Suspension	suspension	NN	_	5	conj
9	results	result	VBZ	_	1	appos
10	in	in	IN	_	13	case
11	a	a	DT	_	13	det
12	significant	significant	JJ	_	13	amod
13	decrease	decrease	NN	_	9	nmod
14	in	in	IN	_	21	case
15	average	average	JJ	_	21	amod
16	steady	steady	JJ	_	21	amod
17	-	-	:	_	21	punct
18	state	state	NN	_	21	compound
19	plasma	plasma	NN	_	21	compound
20	drug4	drug4	NN	_	21	compound
21	concentrations	concentration	NNS	_	13	nmod
22	.	.	.	_	1	punct

1	Alternatives	Alternatives	NNP	_	6	nsubjpass
2	to	to	TO	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	considered	consider	VBN	_	0	ROOT
7	during	during	IN	_	9	case
8	the	the	DT	_	9	det
9	course	course	NN	_	6	nmod
10	of	of	IN	_	12	case
11	PCP	pcp	NN	_	12	compound
12	treatment	treatment	NN	_	9	nmod
13	with	with	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	.	.	.	_	6	punct

1	drug1	drug1	NN	_	8	nsubj
2	,	,	,	_	1	punct
3	another	another	DT	_	4	det
4	drug2	drug2	NN	_	1	appos
5	,	,	,	_	1	punct
6	is	be	VBZ	_	8	cop
7	structurally	structurally	RB	_	8	advmod
8	similar	similar	JJ	_	0	ROOT
9	to	to	TO	_	10	case
10	drug3	drug3	NN	_	8	nmod
11	and	and	CC	_	8	cc
12	may	may	MD	_	14	aux
13	possibly	possibly	RB	_	14	advmod
14	have	have	VB	_	8	conj
15	some	some	DT	_	14	dobj
16	of	of	IN	_	20	case
17	the	the	DT	_	20	det
18	same	same	JJ	_	20	amod
19	drug	drug	NN	_	20	compound
20	interactions	interaction	NNS	_	15	nmod
21	as	as	IN	_	22	case
22	drug4	drug4	NN	_	20	nmod
23	.	.	.	_	8	punct

1	No	no	DT	_	3	neg
2	interaction	interaction	NN	_	3	compound
3	trials	trial	NNS	_	6	nsubjpass
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	auxpass
6	conducted	conduct	VBN	_	0	ROOT
7	with	with	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	drug2	drug2	NN	_	8	conj
11	.	.	.	_	6	punct

1	Drug	drug	NN	_	5	compound
2	/	/	:	_	5	punct
3	Laboratory	Laboratory	NNP	_	5	compound
4	Test	Test	NNP	_	5	compound
5	Interactions	interaction	NNS	_	0	ROOT
6	:	:	:	_	5	punct
7	It	it	PRP	_	10	nsubjpass
8	is	be	VBZ	_	10	auxpass
9	not	not	RB	_	10	neg
10	known	know	VBN	_	5	dep
11	if	if	IN	_	13	mark
12	drug1	drug1	NN	_	13	nsubj
13	interferes	interfere	VBZ	_	10	advcl
14	with	with	IN	_	17	case
15	clinical	clinical	JJ	_	17	amod
16	laboratory	laboratory	NN	_	17	compound
17	test	test	NN	_	13	nmod
18	or	or	CC	_	17	cc
19	assay	assay	NN	_	20	compound
20	results	result	NNS	_	17	conj
21	.	.	.	_	5	punct

1	Medications	medication	NNS	_	13	nsubj
2	that	that	WDT	_	3	nsubj
3	interfere	interfere	VBP	_	1	acl:relcl
4	with	with	IN	_	7	case
5	your	you	PRP$	_	7	nmod:poss
6	bodys	body	NNS	_	7	compound
7	ability	ability	NN	_	3	nmod
8	to	to	TO	_	9	mark
9	use	use	VB	_	7	acl
10	folate	folate	NN	_	9	dobj
11	may	may	MD	_	13	aux
12	also	also	RB	_	13	advmod
13	increase	increase	VB	_	0	ROOT
14	the	the	DT	_	15	det
15	need	need	NN	_	13	dobj
16	for	for	IN	_	18	case
17	this	this	DT	_	18	det
18	drug1	drug1	NN	_	15	nmod
19	.	.	.	_	13	punct

1	Medications	medication	NNS	_	3	nsubj
2	can	can	MD	_	3	aux
3	interfere	interfere	VB	_	0	ROOT
4	with	with	IN	_	6	case
5	folate	folate	NN	_	6	compound
6	utilization	utilization	NN	_	3	nmod
7	,	,	,	_	6	punct
8	including	include	VBG	_	10	case
9	:	:	:	_	10	punct
10	drug1	drug1	NN	_	6	nmod
11	-LRB-	-lrb-	-LRB-	_	14	punct
12	such	such	JJ	_	14	case
13	as	as	IN	_	12	mwe
14	drug2	drug2	NN	_	10	nmod
15	,	,	,	_	14	punct
16	and	and	CC	_	14	cc
17	drug3	drug3	NN	_	14	conj
18	-RRB-	-rrb-	-RRB-	_	14	punct
19	drug4	drug4	NN	_	10	amod
20	-LRB-	-lrb-	-LRB-	_	22	punct
21	sometimes	sometimes	RB	_	22	advmod
22	prescribed	prescribe	VBN	_	19	dep
23	to	to	TO	_	24	mark
24	control	control	VB	_	22	xcomp
25	blood	blood	NN	_	26	compound
26	sugar	sugar	NN	_	24	dobj
27	in	in	IN	_	30	case
28	type	type	NN	_	30	compound
29	2	2	CD	_	30	nummod
30	diabetes	diabetes	NN	_	24	nmod
31	-RRB-	-rrb-	-RRB-	_	30	punct
32	drug5	drug5	NN	_	55	compound
33	-LRB-	-lrb-	-LRB-	_	34	punct
34	used	use	VBN	_	55	dep
35	to	to	TO	_	36	mark
36	control	control	VB	_	34	xcomp
37	inflammation	inflammation	NN	_	36	dobj
38	associated	associate	VBN	_	37	acl
39	with	with	IN	_	41	case
40	Crohns	crohns	NN	_	41	compound
41	disease	disease	NN	_	38	nmod
42	and	and	CC	_	41	cc
43	ulcerative	ulcerative	JJ	_	44	amod
44	colitis	colitis	NN	_	46	dep
45	-RRB-	-rrb-	-RRB-	_	44	punct
46	drug6	drug6	NN	_	51	compound
47	-LRB-	-lrb-	-LRB-	_	49	punct
48	a	a	DT	_	49	det
49	drug7	drug7	NN	_	46	appos
50	-RRB-	-rrb-	-RRB-	_	49	punct
51	drug8	drug8	NN	_	41	conj
52	There	there	EX	_	55	expl
53	has	have	VBZ	_	55	aux
54	been	be	VBN	_	55	cop
55	concern	concern	NN	_	30	dep
56	about	about	IN	_	58	case
57	the	the	DT	_	58	det
58	interaction	interaction	NN	_	55	nmod
59	between	between	IN	_	60	case
60	drug9	drug9	NN	_	58	nmod
61	and	and	CC	_	60	cc
62	drug10	drug10	NN	_	60	conj
63	.	.	.	_	3	punct

1	drug1	drug1	NN	_	2	compound
2	supplements	supplement	NNS	_	4	nsubj
3	can	can	MD	_	4	aux
4	correct	correct	VB	_	0	ROOT
5	the	the	DT	_	6	det
6	anemia	anemia	NN	_	4	dobj
7	associated	associate	VBN	_	6	acl
8	with	with	IN	_	11	case
9	vitamin	vitamin	NN	_	11	compound
10	B12	b12	NN	_	11	compound
11	deficiency	deficiency	NN	_	7	nmod
12	.	.	.	_	4	punct

1	Unfortunately	unfortunately	RB	_	6	advmod
2	,	,	,	_	6	punct
3	drug1	drug1	NN	_	6	nsubj
4	will	will	MD	_	6	aux
5	not	not	RB	_	6	neg
6	correct	correct	VB	_	0	ROOT
7	changes	change	NNS	_	6	dobj
8	in	in	IN	_	11	case
9	the	the	DT	_	11	det
10	nervous	nervous	JJ	_	11	amod
11	system	system	NN	_	7	nmod
12	that	that	WDT	_	13	nsubj
13	result	result	VBP	_	7	acl:relcl
14	from	from	IN	_	17	case
15	vitamin	vitamin	NN	_	17	compound
16	B12	b12	NN	_	17	compound
17	deficiency	deficiency	NN	_	13	nmod
18	.	.	.	_	6	punct

1	Permanent	permanent	JJ	_	3	amod
2	nerve	nerve	NN	_	3	compound
3	damage	damage	NN	_	6	nsubj
4	could	could	MD	_	6	aux
5	theoretically	theoretically	RB	_	6	advmod
6	occur	occur	VB	_	0	ROOT
7	if	if	IN	_	13	mark
8	vitamin	vitamin	NN	_	10	compound
9	B12	b12	NN	_	10	compound
10	deficiency	deficiency	NN	_	13	nsubjpass
11	is	be	VBZ	_	13	auxpass
12	not	not	RB	_	13	neg
13	treated	treat	VBN	_	6	advcl
14	.	.	.	_	6	punct

1	Therefore	therefore	RB	_	9	advmod
2	,	,	,	_	9	punct
3	intake	intake	NN	_	9	nsubj
4	of	of	IN	_	6	case
5	supplemental	supplemental	JJ	_	6	amod
6	drug1	drug1	NN	_	3	nmod
7	should	should	MD	_	9	aux
8	not	not	RB	_	9	neg
9	exceed	exceed	VB	_	0	ROOT
10	1000	1000	CD	_	11	nummod
11	micrograms	microgram	NNS	_	9	dobj
12	-LRB-	-lrb-	-LRB-	_	13	punct
13	g	g	NN	_	11	dep
14	,	,	,	_	13	punct
15	sometimes	sometimes	RB	_	16	advmod
16	mcg	mcg	NN	_	13	appos
17	-RRB-	-rrb-	-RRB-	_	13	punct
18	per	per	IN	_	19	case
19	day	day	NN	_	9	nmod
20	to	to	TO	_	21	mark
21	prevent	prevent	VB	_	9	advcl
22	drug2	drug2	NN	_	21	dobj
23	from	from	IN	_	24	mark
24	masking	mask	VBG	_	21	advcl
25	symptoms	symptom	NNS	_	24	dobj
26	of	of	IN	_	29	case
27	vitamin	vitamin	NN	_	29	compound
28	B12	b12	NN	_	29	compound
29	deficiency	deficiency	NN	_	25	nmod
30	.	.	.	_	9	punct

1	It	it	PRP	_	3	nsubj
2	is	be	VBZ	_	3	cop
3	important	important	JJ	_	0	ROOT
4	for	for	IN	_	9	mark
5	older	older	JJR	_	6	amod
6	adults	adult	NNS	_	9	nsubj
7	to	to	TO	_	9	mark
8	be	be	VB	_	9	cop
9	aware	aware	JJ	_	3	advcl
10	of	of	IN	_	12	case
11	the	the	DT	_	12	det
12	relationship	relationship	NN	_	9	nmod
13	between	between	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	and	and	CC	_	14	cc
16	drug2	drug2	NN	_	14	conj
17	because	because	IN	_	22	mark
18	they	they	PRP	_	22	nsubj
19	are	be	VBP	_	22	cop
20	at	at	IN	_	22	case
21	greater	greater	JJR	_	22	amod
22	risk	risk	NN	_	9	advcl
23	of	of	IN	_	24	mark
24	having	have	VBG	_	22	acl
25	a	a	DT	_	28	det
26	vitamin	vitamin	NN	_	28	compound
27	B12	b12	NN	_	28	compound
28	deficiency	deficiency	NN	_	24	dobj
29	.	.	.	_	3	punct

1	If	if	IN	_	5	mark
2	you	you	PRP	_	5	nsubj
3	are	be	VBP	_	5	cop
4	50	50	CD	_	5	nummod
5	years	year	NNS	_	11	advcl
6	of	of	IN	_	7	case
7	age	age	NN	_	5	nmod
8	or	or	CC	_	7	cc
9	older	older	JJR	_	7	conj
10	,	,	,	_	11	punct
11	ask	ask	VB	_	0	ROOT
12	your	you	PRP$	_	13	nmod:poss
13	physician	physician	NN	_	11	dobj
14	to	to	TO	_	15	mark
15	check	check	VB	_	11	xcomp
16	your	you	PRP$	_	18	nmod:poss
17	B12	b12	NN	_	18	compound
18	status	status	NN	_	15	dobj
19	before	before	IN	_	21	mark
20	you	you	PRP	_	21	nsubj
21	take	take	VBP	_	15	advcl
22	a	a	DT	_	23	det
23	supplement	supplement	NN	_	21	dobj
24	that	that	WDT	_	25	nsubj
25	contains	contain	VBZ	_	23	acl:relcl
26	drug1	drug1	NN	_	25	dobj
27	.	.	.	_	11	punct

1	Ergot-containing	ergot-containing	JJ	_	2	amod
2	drugs	drug	NNS	_	5	nsubjpass
3	have	have	VBP	_	5	aux
4	been	be	VBN	_	5	auxpass
5	reported	report	VBN	_	0	ROOT
6	to	to	TO	_	7	mark
7	cause	cause	VB	_	5	xcomp
8	prolonged	prolonged	JJ	_	10	amod
9	vasospastic	vasospastic	JJ	_	10	amod
10	reactions	reaction	NNS	_	7	dobj
11	.	.	.	_	5	punct

1	Due	due	JJ	_	5	case
2	to	to	TO	_	1	mwe
3	a	a	DT	_	5	det
4	theoretical	theoretical	JJ	_	5	amod
5	risk	risk	NN	_	34	nmod
6	of	of	IN	_	9	case
7	a	a	DT	_	9	det
8	pharmacodynamic	pharmacodynamic	JJ	_	9	amod
9	interaction	interaction	NN	_	5	nmod
10	,	,	,	_	34	punct
11	use	use	NN	_	34	nsubjpass
12	of	of	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	-	-	:	_	13	punct
15	containing	contain	VBG	_	13	dep
16	or	or	CC	_	15	cc
17	drug2	drug2	NN	_	15	conj
18	-LRB-	-lrb-	-LRB-	_	20	punct
19	like	like	IN	_	20	case
20	drug3	drug3	NN	_	15	nmod
21	or	or	CC	_	20	cc
22	drug4	drug4	NN	_	20	conj
23	-RRB-	-rrb-	-RRB-	_	20	punct
24	and	and	CC	_	15	cc
25	drug5	drug5	NN	_	15	conj
26	within	within	IN	_	28	case
27	24	24	CD	_	28	nummod
28	hours	hour	NNS	_	25	nmod
29	of	of	IN	_	31	case
30	each	each	DT	_	31	det
31	other	other	JJ	_	28	nmod
32	should	should	MD	_	34	aux
33	be	be	VB	_	34	auxpass
34	avoided	avoid	VBN	_	0	ROOT
35	-LRB-	-lrb-	-LRB-	_	36	punct
36	see	see	VB	_	34	dep
37	a	a	DT	_	38	det
38	href	href	NN	_	36	dobj
39	=	=	JJ	_	38	amod
40	frova_od	frova_od	NN	_	39	dep
41	.	.	.	_	36	punct
42	htm	htm	NN	_	44	compound
43	#CI	#ci	NN	_	44	compound
44	CONTRAINDICATIONS	contraindication	NNS	_	36	dep
45	-RRB-	-rrb-	-RRB-	_	36	punct
46	.	.	.	_	34	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	use	use	NN	_	17	nsubjpass
3	of	of	IN	_	5	case
4	other	other	JJ	_	5	amod
5	5-HT1B	5-ht1b	NN	_	2	nmod
6	/	/	:	_	5	punct
7	1D	1d	NN	_	8	compound
8	agonists	agonist	NNS	_	5	dep
9	within	within	IN	_	11	case
10	24	24	CD	_	11	nummod
11	hours	hour	NNS	_	2	nmod
12	of	of	IN	_	14	case
13	drug1	drug1	NN	_	14	compound
14	treatment	treatment	NN	_	11	nmod
15	is	be	VBZ	_	17	auxpass
16	not	not	RB	_	17	neg
17	recommended	recommend	VBN	_	0	ROOT
18	.	.	.	_	17	punct

1	drug1	drug1	NN	_	18	nsubjpass
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	drug2	drug2	NN	_	1	appos
4	-RRB-	-rrb-	-RRB-	_	3	punct
5	-LRB-	-lrb-	-LRB-	_	8	punct
6	e.g.	e.g.	FW	_	8	dep
7	,	,	,	_	8	punct
8	drug3	drug3	NN	_	1	dep
9	,	,	,	_	8	punct
10	drug4	drug4	NN	_	8	conj
11	,	,	,	_	8	punct
12	drug5	drug5	NN	_	8	conj
13	,	,	,	_	8	punct
14	drug6	drug6	NN	_	8	appos
15	-RRB-	-rrb-	-RRB-	_	8	punct
16	have	have	VBP	_	18	aux
17	been	be	VBN	_	18	auxpass
18	reported	report	VBN	_	0	ROOT
19	,	,	,	_	18	punct
20	rarely	rarely	RB	_	18	advmod
21	,	,	,	_	18	punct
22	to	to	TO	_	23	mark
23	cause	cause	VB	_	18	xcomp
24	weakness	weakness	NN	_	23	dobj
25	,	,	,	_	24	punct
26	hyperreflexia	hyperreflexia	NN	_	24	conj
27	,	,	,	_	24	punct
28	and	and	CC	_	24	cc
29	incoordination	incoordination	NN	_	24	conj
30	when	when	WRB	_	31	advmod
31	coadministered	coadminister	VBN	_	23	advcl
32	with	with	IN	_	33	case
33	drug7	drug7	NN	_	31	nmod
34	.	.	.	_	18	punct

1	If	if	IN	_	11	mark
2	concomitant	concomitant	JJ	_	3	amod
3	treatment	treatment	NN	_	11	nsubjpass
4	with	with	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	an	a	DT	_	8	det
8	drug2	drug2	NN	_	5	conj
9	is	be	VBZ	_	11	auxpass
10	clinically	clinically	RB	_	11	advmod
11	warranted	warrant	VBN	_	19	advcl
12	,	,	,	_	19	punct
13	appropriate	appropriate	JJ	_	14	amod
14	observation	observation	NN	_	19	nsubjpass
15	of	of	IN	_	17	case
16	the	the	DT	_	17	det
17	patient	patient	NN	_	14	nmod
18	is	be	VBZ	_	19	auxpass
19	advised	advise	VBN	_	0	ROOT
20	.	.	.	_	19	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	4	amod
2	Test	test	NN	_	4	compound
3	Interactions	interaction	NNS	_	4	compound
4	drug1	drug1	NN	_	7	nsubjpass
5	is	be	VBZ	_	7	auxpass
6	not	not	RB	_	7	neg
7	known	know	VBN	_	0	ROOT
8	to	to	TO	_	9	mark
9	interfere	interfere	VB	_	7	xcomp
10	with	with	IN	_	15	case
11	commonly	commonly	RB	_	12	advmod
12	employed	employ	VBN	_	15	amod
13	clinical	clinical	JJ	_	15	amod
14	laboratory	laboratory	NN	_	15	compound
15	tests	test	NNS	_	9	nmod
16	.	.	.	_	7	punct

1	Elevated	elevated	JJ	_	3	amod
2	plasma	plasma	NN	_	3	compound
3	levels	level	NNS	_	8	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	have	have	VBP	_	8	aux
7	been	be	VBN	_	8	auxpass
8	reported	report	VBN	_	0	ROOT
9	with	with	IN	_	12	case
10	concomitant	concomitant	JJ	_	12	amod
11	drug2	drug2	NN	_	12	compound
12	use	use	NN	_	8	nmod
13	.	.	.	_	8	punct

1	There	there	EX	_	4	expl
2	have	have	VBP	_	4	aux
3	been	be	VBN	_	4	cop
4	reports	report	NNS	_	0	ROOT
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	-	-	:	_	6	punct
8	related	related	JJ	_	10	amod
9	side	side	JJ	_	10	amod
10	effects	effect	NNS	_	6	dep
11	in	in	IN	_	12	case
12	patients	patient	NNS	_	10	nmod
13	on	on	IN	_	15	case
14	concomitant	concomitant	JJ	_	15	amod
15	therapy	therapy	NN	_	12	nmod
16	with	with	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	and	and	CC	_	17	cc
19	drug3	drug3	NN	_	17	conj
20	.	.	.	_	4	punct

1	Therefore	therefore	RB	_	10	advmod
2	,	,	,	_	10	punct
3	monitoring	monitoring	NN	_	10	nsubjpass
4	of	of	IN	_	7	case
5	drug1	drug1	NN	_	7	compound
6	plasma	plasma	NN	_	7	compound
7	levels	level	NNS	_	3	nmod
8	should	should	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	considered	consider	VBN	_	0	ROOT
11	and	and	CC	_	10	cc
12	dosage	dosage	NN	_	15	nsubj
13	of	of	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	adjusted	adjust	VBN	_	10	conj
16	,	,	,	_	10	punct
17	as	as	IN	_	18	mark
18	required	require	VBN	_	10	advcl
19	.	.	.	_	10	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	have	have	VBP	_	4	aux
3	been	be	VBN	_	4	auxpass
4	shown	show	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	interfere	interfere	VB	_	4	xcomp
7	with	with	IN	_	9	case
8	the	the	DT	_	9	det
9	metabolism	metabolism	NN	_	6	nmod
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	.	.	.	_	4	punct

1	This	this	DT	_	3	nsubj
2	may	may	MD	_	3	aux
3	lead	lead	VB	_	0	ROOT
4	to	to	TO	_	6	case
5	reduced	reduce	VBN	_	6	amod
6	clearance	clearance	NN	_	3	nmod
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	and	and	CC	_	6	cc
10	the	the	DT	_	11	det
11	prolongation	prolongation	NN	_	6	conj
12	of	of	IN	_	15	case
13	its	its	PRP$	_	15	nmod:poss
14	plasma	plasma	NN	_	15	compound
15	half-life	half-life	NN	_	11	nmod
16	.	.	.	_	3	punct

1	drug1	drug1	NN	_	7	nsubj
2	,	,	,	_	1	punct
3	including	include	VBG	_	4	case
4	drug2	drug2	NN	_	1	nmod
5	,	,	,	_	1	punct
6	may	may	MD	_	7	aux
7	enhance	enhance	VB	_	0	ROOT
8	the	the	DT	_	9	det
9	effects	effect	NNS	_	7	dobj
10	of	of	IN	_	14	case
11	the	the	DT	_	14	det
12	oral	oral	JJ	_	14	amod
13	drug3	drug3	NN	_	14	compound
14	drug4	drug4	NN	_	9	nmod
15	or	or	CC	_	14	cc
16	its	its	PRP$	_	17	nmod:poss
17	derivatives	derivative	NNS	_	14	conj
18	.	.	.	_	7	punct

1	When	when	WRB	_	5	advmod
2	these	these	DT	_	3	det
3	products	product	NNS	_	5	nsubjpass
4	are	be	VBP	_	5	auxpass
5	administered	administer	VBN	_	18	advcl
6	concomitantly	concomitantly	RB	_	5	advmod
7	,	,	,	_	18	punct
8	prothrombin	prothrombin	NN	_	9	compound
9	time	time	NN	_	18	nsubjpass
10	or	or	CC	_	9	cc
11	other	other	JJ	_	14	amod
12	suitable	suitable	JJ	_	14	amod
13	coagulation	coagulation	NN	_	14	compound
14	test	test	NN	_	9	conj
15	should	should	MD	_	18	aux
16	be	be	VB	_	18	auxpass
17	closely	closely	RB	_	18	advmod
18	monitored	monitor	VBN	_	0	ROOT
19	.	.	.	_	18	punct

1	drug1	drug1	NN	_	2	nsubj
2	interferes	interfere	VBZ	_	0	ROOT
3	with	with	IN	_	6	case
4	the	the	DT	_	6	det
5	therapeutic	therapeutic	JJ	_	6	amod
6	action	action	NN	_	2	nmod
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	containing	contain	VBG	_	1	acl
3	drug2	drug2	NN	_	2	dobj
4	,	,	,	_	3	punct
5	drug3	drug3	NN	_	3	conj
6	,	,	,	_	3	punct
7	or	or	CC	_	3	cc
8	drug4	drug4	NN	_	3	conj
9	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	or	or	CC	_	1	cc
3	divalent	divalent	JJ	_	1	conj
4	or	or	CC	_	3	cc
5	trivalent	trivalent	JJ	_	3	conj
6	cations	cation	NNS	_	1	dep
7	such	such	JJ	_	9	case
8	as	as	IN	_	7	mwe
9	drug2	drug2	NN	_	1	nmod
10	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	containing	contain	VBG	_	1	acl
3	drug2	drug2	NN	_	2	dobj
4	;	;	:	_	1	punct

1	and	and	CC	_	19	cc
2	drug1	drug1	NN	_	19	conj
3	,	,	,	_	19	punct
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	drug2	drug2	NN	_	19	dep
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	,	,	,	_	19	punct
8	chewable/buffered	chewable/buffered	JJ	_	9	amod
9	tablets	tablet	NNS	_	19	nsubj
10	or	or	CC	_	9	cc
11	the	the	DT	_	13	det
12	pediatric	pediatric	JJ	_	13	amod
13	powder	powder	NN	_	9	conj
14	for	for	IN	_	16	case
15	oral	oral	JJ	_	16	amod
16	solution	solution	NN	_	13	nmod
17	may	may	MD	_	19	aux
18	substantially	substantially	RB	_	19	advmod
19	interfere	interfere	VB	_	0	ROOT
20	with	with	IN	_	22	case
21	the	the	DT	_	22	det
22	absorption	absorption	NN	_	19	nmod
23	of	of	IN	_	24	case
24	drug3	drug3	NN	_	22	nmod
25	,	,	,	_	19	punct
26	resulting	result	VBG	_	19	advcl
27	in	in	IN	_	29	case
28	systemic	systemic	JJ	_	29	amod
29	levels	level	NNS	_	26	nmod
30	considerably	considerably	RB	_	31	advmod
31	lower	lower	JJR	_	29	amod
32	than	than	IN	_	33	mark
33	desired	desire	VBN	_	31	advcl
34	.	.	.	_	19	punct

1	These	these	DT	_	2	det
2	agents	agent	NNS	_	6	nsubjpass
3	should	should	MD	_	6	aux
4	not	not	RB	_	6	neg
5	be	be	VB	_	6	auxpass
6	taken	take	VBN	_	0	ROOT
7	within	within	IN	_	11	case
8	the	the	DT	_	11	det
9	two	two	CD	_	11	nummod
10	hour	hour	NN	_	11	compound
11	period	period	NN	_	6	nmod
12	before	before	IN	_	17	case
13	or	or	CC	_	12	cc
14	within	within	IN	_	12	conj
15	the	the	DT	_	17	det
16	two-hour	two-hour	JJ	_	17	amod
17	period	period	NN	_	11	nmod
18	after	after	IN	_	20	case
19	drug1	drug1	NN	_	20	compound
20	administration	administration	NN	_	17	nmod
21	.	.	.	_	6	punct

1	Elevated	elevated	JJ	_	3	amod
2	serum	serum	NN	_	3	compound
3	levels	level	NNS	_	8	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	have	have	VBP	_	8	aux
7	been	be	VBN	_	8	auxpass
8	reported	report	VBN	_	0	ROOT
9	with	with	IN	_	12	case
10	the	the	DT	_	12	det
11	concomitant	concomitant	JJ	_	12	amod
12	use	use	NN	_	8	nmod
13	of	of	IN	_	15	case
14	some	some	DT	_	15	det
15	drug2	drug2	NN	_	12	nmod
16	and	and	CC	_	15	cc
17	drug3	drug3	NN	_	15	conj
18	.	.	.	_	8	punct

1	Therefore	therefore	RB	_	8	advmod
2	,	,	,	_	8	punct
3	drug1	drug1	NN	_	5	compound
4	serum	serum	NN	_	5	compound
5	levels	level	NNS	_	8	nsubjpass
6	should	should	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	monitored	monitor	VBN	_	0	ROOT
9	and	and	CC	_	8	cc
10	appropriate	appropriate	JJ	_	8	conj
11	drug2	drug2	NN	_	13	compound
12	dosage	dosage	NN	_	13	compound
13	adjustments	adjustment	NNS	_	8	dobj
14	made	make	VBN	_	13	acl
15	when	when	WRB	_	19	advmod
16	these	these	DT	_	17	det
17	drugs	drug	NNS	_	19	nsubjpass
18	are	be	VBP	_	19	auxpass
19	used	use	VBN	_	14	advcl
20	concomitantly	concomitantly	RB	_	19	advmod
21	.	.	.	_	8	punct

1	drug1	drug1	NN	_	11	nsubj
2	when	when	WRB	_	3	advmod
3	used	use	VBN	_	1	acl:relcl
4	in	in	IN	_	5	case
5	combination	combination	NN	_	3	nmod
6	with	with	IN	_	9	case
7	other	other	JJ	_	9	amod
8	cytotoxic	cytotoxic	JJ	_	9	amod
9	drugs	drug	NNS	_	5	nmod
10	may	may	MD	_	11	aux
11	show	show	VB	_	0	ROOT
12	on-treatment	on-treatment	JJ	_	14	amod
13	additive	additive	JJ	_	14	amod
14	toxicity	toxicity	NN	_	11	dobj
15	,	,	,	_	14	punct
16	especially	especially	RB	_	17	advmod
17	hematologic	hematologic	JJ	_	20	amod
18	and	and	CC	_	17	cc
19	gastrointestinal	gastrointestinal	JJ	_	17	conj
20	effects	effect	NNS	_	14	appos
21	.	.	.	_	11	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	use	use	NN	_	20	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	8	case
6	other	other	JJ	_	8	amod
7	cardioactive	cardioactive	JJ	_	8	amod
8	compounds	compound	NNS	_	2	nmod
9	that	that	WDT	_	11	nsubj
10	could	could	MD	_	11	aux
11	cause	cause	VB	_	8	acl:relcl
12	heart	heart	NN	_	13	compound
13	failure	failure	NN	_	11	dobj
14	-LRB-	-lrb-	-LRB-	_	17	punct
15	e.g.	e.g.	FW	_	17	dep
16	,	,	,	_	17	punct
17	drug2	drug2	NN	_	8	dep
18	-RRB-	-rrb-	-RRB-	_	17	punct
19	,	,	,	_	2	punct
20	requires	require	VBZ	_	0	ROOT
21	close	close	JJ	_	22	amod
22	monitoring	monitoring	NN	_	20	dobj
23	of	of	IN	_	25	case
24	cardiac	cardiac	JJ	_	25	amod
25	function	function	NN	_	22	nmod
26	throughout	throughout	IN	_	27	case
27	treatment	treatment	NN	_	22	nmod
28	.	.	.	_	20	punct

1	There	there	EX	_	2	expl
2	are	be	VBP	_	0	ROOT
3	few	few	JJ	_	4	amod
4	data	datum	NNS	_	2	nsubj
5	regarding	regard	VBG	_	7	case
6	the	the	DT	_	7	det
7	coadministration	coadministration	NN	_	4	nmod
8	of	of	IN	_	10	case
9	radiation	radiation	NN	_	10	compound
10	therapy	therapy	NN	_	7	nmod
11	and	and	CC	_	10	cc
12	drug1	drug1	NN	_	10	conj
13	.	.	.	_	2	punct

1	In	in	IN	_	3	case
2	adjuvant	adjuvant	JJ	_	3	amod
3	trials	trial	NNS	_	16	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	-	-	:	_	3	punct
7	containing	contain	VBG	_	3	acl
8	CEF-120	cef-120	NN	_	11	compound
9	or	or	CC	_	8	cc
10	FEC-100	fec-100	NN	_	8	conj
11	chemotherapies	chemotherapy	NNS	_	7	dobj
12	,	,	,	_	11	punct
13	breast	breast	NN	_	14	compound
14	irradiation	irradiation	NN	_	11	appos
15	was	be	VBD	_	16	auxpass
16	delayed	delay	VBN	_	0	ROOT
17	until	until	IN	_	21	mark
18	after	after	IN	_	21	mark
19	chemotherapy	chemotherapy	NN	_	21	nsubjpass
20	was	be	VBD	_	21	auxpass
21	completed	complete	VBN	_	16	advcl
22	.	.	.	_	16	punct

1	This	this	DT	_	2	det
2	practice	practice	NN	_	3	nsubj
3	resulted	result	VBD	_	0	ROOT
4	in	in	IN	_	7	case
5	no	no	DT	_	7	neg
6	apparent	apparent	JJ	_	7	amod
7	increase	increase	NN	_	3	nmod
8	in	in	IN	_	12	case
9	local	local	JJ	_	12	amod
10	breast	breast	NN	_	12	compound
11	cancer	cancer	NN	_	12	compound
12	recurrence	recurrence	NN	_	7	nmod
13	relative	relative	JJ	_	7	amod
14	to	to	TO	_	16	case
15	published	publish	VBN	_	16	amod
16	accounts	account	NNS	_	13	nmod
17	in	in	IN	_	19	case
18	the	the	DT	_	19	det
19	literature	literature	NN	_	16	nmod
20	.	.	.	_	3	punct

1	A	a	DT	_	3	det
2	small	small	JJ	_	3	amod
3	number	number	NN	_	6	nsubj
4	of	of	IN	_	5	case
5	patients	patient	NNS	_	3	nmod
6	received	receive	VBD	_	0	ROOT
7	drug1	drug1	NN	_	6	dobj
8	-	-	:	_	7	punct
9	based	base	VBN	_	10	amod
10	chemotherapy	chemotherapy	NN	_	7	dep
11	concomitantly	concomitantly	RB	_	14	advmod
12	with	with	IN	_	14	case
13	radiation	radiation	NN	_	14	compound
14	therapy	therapy	NN	_	10	nmod
15	but	but	CC	_	6	cc
16	had	have	VBD	_	18	aux
17	chemotherapy	chemotherapy	NN	_	18	nmod:npmod
18	interrupted	interrupted	JJ	_	6	conj
19	in	in	IN	_	22	mark
20	order	order	NN	_	19	mwe
21	to	to	TO	_	22	mark
22	avoid	avoid	VB	_	18	advcl
23	potential	potential	JJ	_	25	amod
24	overlapping	overlap	VBG	_	25	amod
25	toxicities	toxicity	NNS	_	22	dobj
26	.	.	.	_	6	punct

1	It	it	PRP	_	3	nsubj
2	is	be	VBZ	_	3	cop
3	likely	likely	JJ	_	0	ROOT
4	that	that	IN	_	11	mark
5	use	use	NN	_	11	nsubj
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	with	with	IN	_	9	case
9	radiotherapy	radiotherapy	NN	_	5	nmod
10	may	may	MD	_	11	aux
11	sensitize	sensitize	VB	_	3	ccomp
12	tissues	tissue	NNS	_	11	dobj
13	to	to	TO	_	16	case
14	the	the	DT	_	16	det
15	cytotoxic	cytotoxic	JJ	_	16	amod
16	actions	action	NNS	_	11	nmod
17	of	of	IN	_	18	case
18	irradiation	irradiation	NN	_	16	nmod
19	.	.	.	_	3	punct

1	Administration	administration	NN	_	9	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	after	after	IN	_	7	case
5	previous	previous	JJ	_	7	amod
6	radiation	radiation	NN	_	7	compound
7	therapy	therapy	NN	_	1	nmod
8	may	may	MD	_	9	aux
9	induce	induce	VB	_	0	ROOT
10	an	a	DT	_	13	det
11	inflammatory	inflammatory	JJ	_	13	amod
12	recall	recall	NN	_	13	compound
13	reaction	reaction	NN	_	9	dobj
14	at	at	IN	_	16	case
15	the	the	DT	_	16	det
16	site	site	NN	_	9	nmod
17	of	of	IN	_	19	case
18	the	the	DT	_	19	det
19	irradiation	irradiation	NN	_	16	nmod
20	.	.	.	_	9	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	extensively	extensively	RB	_	4	advmod
4	metabolized	metabolize	VBN	_	0	ROOT
5	by	by	IN	_	7	case
6	the	the	DT	_	7	det
7	liver	liver	NN	_	4	nmod
8	.	.	.	_	4	punct

1	Changes	change	NNS	_	10	nsubj
2	in	in	IN	_	4	case
3	hepatic	hepatic	JJ	_	4	amod
4	function	function	NN	_	1	nmod
5	induced	induce	VBN	_	4	acl
6	by	by	IN	_	8	case
7	concomitant	concomitant	JJ	_	8	amod
8	therapies	therapy	NNS	_	5	nmod
9	may	may	MD	_	10	aux
10	affect	affect	VB	_	0	ROOT
11	drug1	drug1	NN	_	12	compound
12	metabolism	metabolism	NN	_	10	dobj
13	,	,	,	_	12	punct
14	pharmacokinetics	pharmacokinetic	NNS	_	12	conj
15	,	,	,	_	12	punct
16	therapeutic	therapeutic	JJ	_	17	amod
17	efficacy	efficacy	NN	_	12	conj
18	,	,	,	_	12	punct
19	and/or	and/or	CC	_	12	cc
20	toxicity	toxicity	NN	_	12	conj
21	.	.	.	_	10	punct

1	drug1	drug1	NN	_	2	nsubj
2	increased	increase	VBD	_	0	ROOT
3	the	the	DT	_	4	det
4	AUC	auc	NN	_	2	dobj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	by	by	IN	_	9	case
8	50	50	CD	_	9	nummod
9	%	%	NN	_	2	nmod
10	.	.	.	_	2	punct

1	drug1	drug1	NN	_	2	compound
2	treatment	treatment	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	stopped	stop	VBN	_	0	ROOT
6	during	during	IN	_	7	case
7	treatment	treatment	NN	_	5	nmod
8	with	with	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	.	.	.	_	5	punct

1	Drug-Laboratory	drug-laboratory	JJ	_	3	amod
2	Test	test	NN	_	3	compound
3	Interactions	interaction	NNS	_	0	ROOT
4	There	there	EX	_	5	expl
5	are	be	VBP	_	3	acl:relcl
6	no	no	DT	_	8	neg
7	known	known	JJ	_	8	amod
8	interactions	interaction	NNS	_	5	nsubj
9	between	between	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	laboratory	laboratory	NN	_	13	compound
13	tests	test	NNS	_	10	conj
14	.	.	.	_	3	punct

1	drug1	drug1	NN	_	0	ROOT
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	:	:	:	_	1	punct
5	drug3	drug3	NN	_	9	nsubj
6	and	and	CC	_	5	cc
7	drug4	drug4	NN	_	5	conj
8	can	can	MD	_	9	aux
9	reduce	reduce	VB	_	1	dep
10	absorption	absorption	NN	_	9	dobj
11	of	of	IN	_	12	case
12	drug5	drug5	NN	_	10	nmod
13	;	;	:	_	9	punct

1	an	a	DT	_	2	det
2	interval	interval	NN	_	17	nsubjpass
3	of	of	IN	_	7	case
4	at	at	IN	_	5	case
5	least	least	JJS	_	6	nmod:npmod
6	4	4	CD	_	7	nummod
7	hours	hour	NNS	_	2	nmod
8	between	between	IN	_	9	case
9	intake	intake	NN	_	2	nmod
10	of	of	IN	_	12	case
11	these	these	DT	_	12	det
12	agents	agent	NNS	_	9	nmod
13	and	and	CC	_	9	cc
14	drug1	drug1	NN	_	9	conj
15	should	should	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	observed	observe	VBN	_	0	ROOT
18	.	.	.	_	17	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubj
4	can	can	MD	_	5	aux
5	inhibit	inhibit	VB	_	1	dep
6	the	the	DT	_	7	det
7	metabolism	metabolism	NN	_	5	dobj
8	of	of	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	,	,	,	_	5	punct
11	increasing	increase	VBG	_	5	advcl
12	its	its	PRP$	_	14	nmod:poss
13	plasma	plasma	NN	_	14	compound
14	level	level	NN	_	11	dobj
15	.	.	.	_	1	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	use	use	NN	_	7	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	avoided	avoid	VBN	_	0	ROOT
8	.	.	.	_	7	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	5	case
4	a	a	DT	_	5	det
5	study	study	NN	_	12	nmod
6	of	of	IN	_	8	case
7	healthy	healthy	JJ	_	8	amod
8	volunteers	volunteer	NNS	_	5	nmod
9	,	,	,	_	12	punct
10	drug2	drug2	NN	_	12	nsubj
11	significantly	significantly	RB	_	12	advmod
12	reduced	reduce	VBD	_	1	appos
13	the	the	DT	_	14	det
14	bioavailability	bioavailability	NN	_	12	dobj
15	of	of	IN	_	16	case
16	drug3	drug3	NN	_	14	nmod
17	.	.	.	_	1	punct

1	An	a	DT	_	2	det
2	interval	interval	NN	_	17	nsubjpass
3	of	of	IN	_	7	case
4	at	at	IN	_	5	case
5	least	least	JJS	_	6	nmod:npmod
6	two	two	CD	_	7	nummod
7	hours	hour	NNS	_	2	nmod
8	between	between	IN	_	9	case
9	intake	intake	NN	_	2	nmod
10	of	of	IN	_	12	case
11	this	this	DT	_	12	det
12	agent	agent	NN	_	9	nmod
13	and	and	CC	_	9	cc
14	drug1	drug1	NN	_	9	conj
15	should	should	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	observed	observe	VBN	_	0	ROOT
18	.	.	.	_	17	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	After	after	IN	_	4	case
4	introduction	introduction	NN	_	21	nmod
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	-LRB-	-lrb-	-LRB-	_	9	punct
8	oral	oral	JJ	_	9	amod
9	form	form	NN	_	4	appos
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	,	,	,	_	4	punct
12	a	a	DT	_	14	det
13	sudden	sudden	JJ	_	14	amod
14	increase	increase	NN	_	21	nsubjpass
15	in	in	IN	_	18	case
16	serum	serum	NN	_	18	compound
17	drug3	drug3	NN	_	18	compound
18	level	level	NN	_	14	nmod
19	has	have	VBZ	_	21	aux
20	been	be	VBN	_	21	auxpass
21	reported	report	VBN	_	1	appos
22	.	.	.	_	1	punct

1	Therefore	therefore	RB	_	10	advmod
2	,	,	,	_	10	punct
3	close	close	JJ	_	4	amod
4	monitoring	monitoring	NN	_	10	nsubjpass
5	of	of	IN	_	8	case
6	serum	serum	NN	_	8	compound
7	drug1	drug1	NN	_	8	compound
8	level	level	NN	_	4	nmod
9	is	be	VBZ	_	10	auxpass
10	recommended	recommend	VBN	_	0	ROOT
11	and	and	CC	_	10	cc
12	,	,	,	_	10	punct
13	if	if	IN	_	14	mark
14	necessary	necessary	JJ	_	19	advcl
15	,	,	,	_	19	punct
16	drug2	drug2	NN	_	19	nsubjpass
17	should	should	MD	_	19	aux
18	be	be	VB	_	19	auxpass
19	discontinued	discontinue	VBN	_	10	conj
20	.	.	.	_	10	punct

1	Intravenous	intravenous	JJ	_	2	amod
2	drug1	drug1	NN	_	4	nsubjpass
3	was	be	VBD	_	4	auxpass
4	shown	show	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	double	double	VB	_	4	xcomp
7	the	the	DT	_	8	det
8	bioavailability	bioavailability	NN	_	6	dobj
9	of	of	IN	_	11	case
10	oral	oral	JJ	_	11	amod
11	drug2	drug2	NN	_	8	nmod
12	.	.	.	_	4	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	significance	significance	NN	_	20	nsubj
4	of	of	IN	_	7	case
5	this	this	DT	_	7	det
6	increased	increase	VBN	_	7	amod
7	bioavailability	bioavailability	NN	_	3	nmod
8	and	and	CC	_	3	cc
9	whether	whether	IN	_	13	mark
10	similar	similar	JJ	_	11	amod
11	increases	increase	NNS	_	13	nsubj
12	will	will	MD	_	13	aux
13	occur	occur	VB	_	3	conj
14	in	in	IN	_	15	case
15	patients	patient	NNS	_	13	nmod
16	given	give	VBN	_	15	acl
17	oral	oral	JJ	_	18	amod
18	drug1	drug1	NN	_	16	dobj
19	is	be	VBZ	_	20	cop
20	unknown	unknown	JJ	_	0	ROOT
21	;	;	:	_	20	punct

1	no	no	DT	_	6	neg
2	other	other	JJ	_	6	amod
3	specific	specific	JJ	_	6	amod
4	drug	drug	NN	_	6	compound
5	interaction	interaction	NN	_	6	compound
6	studies	study	NNS	_	8	nsubjpass
7	were	be	VBD	_	8	auxpass
8	performed	perform	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	Products	Products	NNPS	_	9	nsubj
2	containing	contain	VBG	_	1	acl
3	drug1	drug1	NN	_	2	dobj
4	and	and	CC	_	3	cc
5	other	other	JJ	_	6	amod
6	drug2	drug2	NN	_	3	conj
7	likely	likely	RB	_	9	advmod
8	will	will	MD	_	9	aux
9	interfere	interfere	VB	_	0	ROOT
10	with	with	IN	_	11	case
11	absorption	absorption	NN	_	9	nmod
12	of	of	IN	_	13	case
13	drug3	drug3	NN	_	11	nmod
14	.	.	.	_	9	punct

1	drug1	drug1	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	metabolized	metabolize	VBN	_	0	ROOT
4	through	through	IN	_	8	case
5	the	the	DT	_	8	det
6	cytochrome	cytochrome	NN	_	8	compound
7	P450	p450	NN	_	8	compound
8	system	system	NN	_	3	nmod
9	,	,	,	_	3	punct
10	specifically	specifically	RB	_	16	advmod
11	through	through	IN	_	16	case
12	the	the	DT	_	16	det
13	CYP3A	cyp3a	NN	_	16	compound
14	and	and	CC	_	13	cc
15	CYP2C19	cyp2c19	NN	_	13	conj
16	isozymes	isozyme	NNS	_	3	nmod
17	.	.	.	_	3	punct

1	Studies	study	NNS	_	3	nsubj
2	have	have	VBP	_	3	aux
3	shown	show	VBN	_	0	ROOT
4	that	that	IN	_	8	mark
5	drug1	drug1	NN	_	8	nsubj
6	does	do	VBZ	_	8	aux
7	not	not	RB	_	8	neg
8	have	have	VB	_	3	ccomp
9	clinically	clinically	RB	_	10	advmod
10	significant	significant	JJ	_	11	amod
11	interactions	interaction	NNS	_	8	dobj
12	with	with	IN	_	14	case
13	other	other	JJ	_	14	amod
14	drugs	drug	NNS	_	11	nmod
15	metabolized	metabolize	VBN	_	14	acl
16	by	by	IN	_	20	case
17	the	the	DT	_	20	det
18	cytochrome	cytochrome	NN	_	20	compound
19	P450	p450	NN	_	20	compound
20	system	system	NN	_	15	nmod
21	,	,	,	_	14	punct
22	such	such	JJ	_	24	case
23	as	as	IN	_	22	mwe
24	drug2	drug2	NN	_	14	nmod
25	,	,	,	_	24	punct
26	drug3	drug3	NN	_	24	conj
27	,	,	,	_	24	punct
28	drug4	drug4	NN	_	24	conj
29	,	,	,	_	24	punct
30	drug5	drug5	NN	_	24	conj
31	,	,	,	_	24	punct
32	drug6	drug6	NN	_	24	conj
33	,	,	,	_	24	punct
34	drug7	drug7	NN	_	24	conj
35	,	,	,	_	24	punct
36	drug8	drug8	NN	_	24	conj
37	,	,	,	_	24	punct
38	drug9	drug9	NN	_	24	conj
39	,	,	,	_	24	punct
40	drug10	drug10	NN	_	24	conj
41	,	,	,	_	24	punct
42	or	or	CC	_	24	cc
43	drug11	drug11	NN	_	24	conj
44	in	in	IN	_	46	case
45	healthy	healthy	JJ	_	46	amod
46	subjects	subject	NNS	_	24	nmod
47	.	.	.	_	3	punct

1	These	these	DT	_	2	det
2	compounds	compound	NNS	_	4	nsubjpass
3	are	be	VBP	_	4	auxpass
4	metabolized	metabolize	VBN	_	0	ROOT
5	through	through	IN	_	9	case
6	various	various	JJ	_	9	amod
7	cytochrome	cytochrome	NN	_	9	compound
8	P450	p450	NN	_	9	compound
9	isozymes	isozyme	NNS	_	4	nmod
10	including	include	VBG	_	11	case
11	CYP1A2	cyp1a2	NN	_	9	nmod
12	,	,	,	_	11	punct
13	CYP2C9	cyp2c9	NN	_	11	conj
14	,	,	,	_	11	punct
15	CYP2C19	cyp2c19	NN	_	11	conj
16	,	,	,	_	11	punct
17	CYP2D6	cyp2d6	NN	_	11	conj
18	,	,	,	_	11	punct
19	and	and	CC	_	11	cc
20	CYP3A	cyp3a	NN	_	11	conj
21	.	.	.	_	4	punct

1	When	when	WRB	_	4	advmod
2	drug1	drug1	NN	_	4	nsubjpass
3	was	be	VBD	_	4	auxpass
4	administered	administer	VBN	_	27	advcl
5	concomitantly	concomitantly	RB	_	4	advmod
6	with	with	IN	_	7	case
7	drug2	drug2	NN	_	4	nmod
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	CYP1A2	cyp1a2	NN	_	7	dep
10	,	,	,	_	9	punct
11	CYP3A	cyp3a	NN	_	9	appos
12	-RRB-	-rrb-	-RRB-	_	9	punct
13	,	,	,	_	27	punct
14	a	a	DT	_	16	det
15	minor	minor	JJ	_	16	amod
16	increase	increase	NN	_	27	nsubjpass
17	-LRB-	-lrb-	-LRB-	_	19	punct
18	10	10	CD	_	19	nummod
19	%	%	NN	_	16	appos
20	-RRB-	-rrb-	-RRB-	_	19	punct
21	in	in	IN	_	23	case
22	the	the	DT	_	23	det
23	clearance	clearance	NN	_	16	nmod
24	of	of	IN	_	25	case
25	drug3	drug3	NN	_	23	nmod
26	was	be	VBD	_	27	auxpass
27	seen	see	VBN	_	0	ROOT
28	.	.	.	_	27	punct

1	Because	because	IN	_	18	mark
2	the	the	DT	_	4	det
3	small	small	JJ	_	4	amod
4	magnitude	magnitude	NN	_	18	nsubj
5	and	and	CC	_	4	cc
6	the	the	DT	_	7	det
7	direction	direction	NN	_	4	conj
8	of	of	IN	_	10	case
9	the	the	DT	_	10	det
10	effect	effect	NN	_	7	nmod
11	on	on	IN	_	13	case
12	drug1	drug1	NN	_	13	compound
13	clearance	clearance	NN	_	10	nmod
14	,	,	,	_	18	punct
15	this	this	DT	_	16	det
16	interaction	interaction	NN	_	18	nsubj
17	is	be	VBZ	_	18	cop
18	unlikely	unlikely	JJ	_	0	ROOT
19	to	to	TO	_	22	mark
20	be	be	VB	_	22	cop
21	clinical	clinical	JJ	_	22	amod
22	concern	concern	NN	_	18	xcomp
23	.	.	.	_	18	punct

1	Nonetheless	nonetheless	RB	_	6	advmod
2	,	,	,	_	6	punct
3	individual	individual	JJ	_	4	amod
4	patients	patient	NNS	_	6	nsubj
5	may	may	MD	_	6	aux
6	require	require	VB	_	0	ROOT
7	additional	additional	JJ	_	8	amod
8	titration	titration	NN	_	6	dobj
9	of	of	IN	_	12	case
10	their	they	PRP$	_	12	nmod:poss
11	drug1	drug1	NN	_	12	compound
12	dosage	dosage	NN	_	8	nmod
13	when	when	WRB	_	16	advmod
14	drug2	drug2	NN	_	16	nsubjpass
15	is	be	VBZ	_	16	auxpass
16	started	start	VBN	_	6	advcl
17	or	or	CC	_	16	cc
18	stopped	stop	VBN	_	16	conj
19	to	to	TO	_	20	mark
20	ensure	ensure	VB	_	18	xcomp
21	clinically	clinically	RB	_	22	advmod
22	effective	effective	JJ	_	24	amod
23	blood	blood	NN	_	24	compound
24	levels	level	NNS	_	20	dobj
25	.	.	.	_	6	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	has	have	VBZ	_	5	aux
3	also	also	RB	_	5	advmod
4	been	be	VBN	_	5	auxpass
5	shown	show	VBN	_	0	ROOT
6	to	to	TO	_	7	mark
7	have	have	VB	_	5	xcomp
8	no	no	DT	_	11	neg
9	clinically	clinically	RB	_	10	advmod
10	significant	significant	JJ	_	11	amod
11	interaction	interaction	NN	_	7	dobj
12	with	with	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	.	.	.	_	5	punct

1	In	in	IN	_	5	case
2	a	a	DT	_	5	det
3	single-dose	single-dose	JJ	_	5	amod
4	crossover	crossover	NN	_	5	compound
5	study	study	NN	_	0	ROOT
6	examining	examine	VBG	_	5	acl
7	drug1	drug1	NN	_	9	compound
8	30	30	CD	_	9	nummod
9	mg	mg	NN	_	6	dobj
10	and	and	CC	_	9	cc
11	drug2	drug2	NN	_	13	compound
12	20	20	CD	_	13	nummod
13	mg	mg	NN	_	9	conj
14	each	each	DT	_	9	dep
15	administered	administer	VBN	_	14	acl
16	alone	alone	RB	_	15	advmod
17	and	and	CC	_	5	cc
18	concomitantly	concomitantly	RB	_	22	advmod
19	with	with	IN	_	22	case
20	drug3	drug3	NN	_	22	compound
21	1	1	CD	_	22	nummod
22	gram	gram	NN	_	29	nmod
23	,	,	,	_	22	punct
24	absorption	absorption	NN	_	22	appos
25	of	of	IN	_	27	case
26	the	the	DT	_	27	det
27	drug4	drug4	NN	_	24	nmod
28	was	be	VBD	_	29	auxpass
29	delayed	delay	VBN	_	5	conj
30	and	and	CC	_	29	cc
31	their	they	PRP$	_	32	nmod:poss
32	bioavailability	bioavailability	NN	_	34	nsubjpass
33	was	be	VBD	_	34	auxpass
34	reduced	reduce	VBN	_	29	conj
35	by	by	IN	_	37	case
36	17	17	CD	_	37	nummod
37	%	%	NN	_	34	nmod
38	and	and	CC	_	34	cc
39	16	16	CD	_	40	nummod
40	%	%	NN	_	34	conj
41	,	,	,	_	40	punct
42	respectively	respectively	RB	_	40	advmod
43	,	,	,	_	40	punct
44	when	when	WRB	_	45	advmod
45	administered	administer	VBN	_	40	acl:relcl
46	concomitantly	concomitantly	RB	_	45	advmod
47	with	with	IN	_	48	case
48	drug5	drug5	NN	_	45	nmod
49	.	.	.	_	5	punct

1	Therefore	therefore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	drug1	drug1	NN	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	taken	take	VBN	_	0	ROOT
7	at	at	IN	_	8	case
8	least	least	JJS	_	9	nmod:npmod
9	30	30	CD	_	10	nummod
10	minutes	minute	NNS	_	6	dobj
11	prior	prior	RB	_	6	advmod
12	to	to	TO	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	.	.	.	_	6	punct

1	In	in	IN	_	3	case
2	clinical	clinical	JJ	_	3	amod
3	trials	trial	NNS	_	7	nmod
4	,	,	,	_	7	punct
5	drug1	drug1	NN	_	7	nsubjpass
6	were	be	VBD	_	7	auxpass
7	administered	administer	VBN	_	0	ROOT
8	concomitantly	concomitantly	RB	_	7	advmod
9	with	with	IN	_	12	case
10	drug2	drug2	NN	_	12	compound
11	delayed-release	delayed-release	NN	_	12	compound
12	capsules	capsule	NNS	_	7	nmod
13	;	;	:	_	7	punct

1	this	this	DT	_	4	nsubj
2	did	do	VBD	_	4	aux
3	not	not	RB	_	4	neg
4	interfere	interfere	VB	_	0	ROOT
5	with	with	IN	_	7	case
6	its	its	PRP$	_	7	nmod:poss
7	effect	effect	NN	_	4	nmod
8	.	.	.	_	4	punct

1	drug1	drug1	NN	_	2	nsubj
2	causes	cause	VBZ	_	0	ROOT
3	a	a	DT	_	8	det
4	profound	profound	JJ	_	8	amod
5	and	and	CC	_	4	cc
6	long	long	JJ	_	4	conj
7	lasting	lasting	JJ	_	8	amod
8	inhibition	inhibition	NN	_	2	dobj
9	of	of	IN	_	12	case
10	gastric	gastric	JJ	_	12	amod
11	acid	acid	NN	_	12	compound
12	secretion	secretion	NN	_	8	nmod
13	;	;	:	_	2	punct

1	therefore	therefore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	it	it	PRP	_	6	nsubj
4	is	be	VBZ	_	6	cop
5	theoretically	theoretically	RB	_	6	advmod
6	possible	possible	JJ	_	0	ROOT
7	that	that	IN	_	10	mark
8	drug1	drug1	NN	_	10	nsubj
9	may	may	MD	_	10	aux
10	interfere	interfere	VB	_	6	ccomp
11	with	with	IN	_	13	case
12	the	the	DT	_	13	det
13	absorption	absorption	NN	_	10	nmod
14	of	of	IN	_	15	case
15	drugs	drug	NNS	_	13	nmod
16	where	where	WRB	_	22	advmod
17	gastric	gastric	JJ	_	18	amod
18	pH	ph	NN	_	22	nsubj
19	is	be	VBZ	_	22	cop
20	an	a	DT	_	22	det
21	important	important	JJ	_	22	amod
22	determinant	determinant	NN	_	15	acl:relcl
23	of	of	IN	_	24	case
24	bioavailability	bioavailability	NN	_	22	nmod
25	-LRB-	-lrb-	-LRB-	_	10	punct
26	e.g.	e.g.	FW	_	25	root
27	drug2	drug2	FW	_	26	dep
28	,	,	,	_	27	punct
29	drug3	drug3	NN	_	30	compound
30	esters	ester	NNS	_	28	root
31	,	,	,	_	30	punct
32	drug4	drug4	NN	_	33	compound
33	salts	salt	NNS	_	30	appos
34	,	,	,	_	30	punct
35	drug5	drug5	NN	_	30	appos
36	-RRB-	-rrb-	-RRB-	_	30	punct
37	.	.	.	_	30	punct

1	APRD00513_IN	aprd00513_in	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	txt	txt	NN	_	1	appos

1	No	no	DT	_	5	neg
2	formal	formal	JJ	_	5	amod
3	drug	drug	NN	_	5	compound
4	interaction	interaction	NN	_	5	compound
5	studies	study	NNS	_	8	nsubjpass
6	have	have	VBP	_	8	aux
7	been	be	VBN	_	8	auxpass
8	conducted	conduct	VBN	_	0	ROOT
9	with	with	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	.	.	.	_	8	punct

1	Due	due	JJ	_	16	advmod
2	to	to	TO	_	4	case
3	its	its	PRP$	_	4	nmod:poss
4	potential	potential	JJ	_	1	nmod
5	to	to	TO	_	6	mark
6	cause	cause	VB	_	4	acl
7	neutropenia	neutropenia	NN	_	6	dobj
8	and	and	CC	_	7	cc
9	lymphopenia	lymphopenia	NN	_	7	conj
10	,	,	,	_	16	punct
11	proper	proper	JJ	_	12	amod
12	monitoring	monitoring	NN	_	16	nsubjpass
13	of	of	IN	_	14	case
14	patients	patient	NNS	_	12	nmod
15	is	be	VBZ	_	16	auxpass
16	required	require	VBN	_	0	ROOT
17	if	if	IN	_	20	mark
18	drug1	drug1	NN	_	20	nsubjpass
19	is	be	VBZ	_	20	auxpass
20	given	give	VBN	_	16	advcl
21	in	in	IN	_	22	case
22	combination	combination	NN	_	20	nmod
23	with	with	IN	_	25	case
24	myelosuppressive	myelosuppressive	JJ	_	25	amod
25	agents	agent	NNS	_	22	nmod
26	.	.	.	_	16	punct

1	Also	also	RB	_	10	advmod
2	,	,	,	_	10	punct
3	the	the	DT	_	4	det
4	potential	potential	NN	_	10	nsubjpass
5	for	for	IN	_	7	case
6	hepatic	hepatic	JJ	_	7	amod
7	injury	injury	NN	_	4	nmod
8	should	should	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	considered	consider	VBN	_	0	ROOT
11	when	when	WRB	_	14	advmod
12	drug1	drug1	NN	_	14	nsubjpass
13	is	be	VBZ	_	14	auxpass
14	used	use	VBN	_	10	advcl
15	in	in	IN	_	16	case
16	combination	combination	NN	_	14	nmod
17	with	with	IN	_	19	case
18	other	other	JJ	_	19	amod
19	products	product	NNS	_	16	nmod
20	associated	associate	VBN	_	19	acl
21	with	with	IN	_	23	case
22	hepatic	hepatic	JJ	_	23	amod
23	injury	injury	NN	_	20	nmod
24	,	,	,	_	14	punct
25	or	or	CC	_	14	cc
26	when	when	WRB	_	30	advmod
27	new	new	JJ	_	28	amod
28	agents	agent	NNS	_	30	nsubjpass
29	are	be	VBP	_	30	auxpass
30	added	add	VBN	_	14	conj
31	to	to	TO	_	33	case
32	the	the	DT	_	33	det
33	regimen	regimen	NN	_	30	nmod
34	of	of	IN	_	35	case
35	patients	patient	NNS	_	33	nmod
36	already	already	RB	_	38	advmod
37	on	on	IN	_	38	case
38	drug2	drug2	NN	_	35	nmod
39	.	.	.	_	10	punct

1	The	the	DT	_	4	det
2	drug	drug	NN	_	4	compound
3	interaction	interaction	NN	_	4	compound
4	data	datum	NNS	_	10	nsubjpass
5	described	describe	VBN	_	4	acl
6	in	in	IN	_	8	case
7	this	this	DT	_	8	det
8	section	section	NN	_	5	nmod
9	were	be	VBD	_	10	auxpass
10	obtained	obtain	VBN	_	0	ROOT
11	from	from	IN	_	14	case
12	controlled	controlled	JJ	_	14	amod
13	clinical	clinical	JJ	_	14	amod
14	trials	trial	NNS	_	10	nmod
15	and	and	CC	_	14	cc
16	studies	study	NNS	_	14	conj
17	involving	involve	VBG	_	14	acl
18	otherwise	otherwise	RB	_	19	advmod
19	healthy	healthy	JJ	_	20	amod
20	adults	adult	NNS	_	17	dobj
21	with	with	IN	_	22	case
22	epilepsy	epilepsy	NN	_	20	nmod
23	.	.	.	_	10	punct

1	Use	use	NN	_	0	ROOT
2	in	in	IN	_	3	case
3	Conjunction	conjunction	NN	_	1	nmod
4	with	with	IN	_	6	case
5	Other	other	JJ	_	6	amod
6	drug1	drug1	NN	_	3	nmod
7	:	:	:	_	1	punct
8	The	the	DT	_	9	det
9	addition	addition	NN	_	17	nsubj
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	to	to	TO	_	13	case
13	drug3	drug3	NN	_	9	nmod
14	-LRB-	-lrb-	-LRB-	_	15	punct
15	drug4	drug4	NN	_	13	appos
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	affects	affect	VBZ	_	1	dep
18	the	the	DT	_	21	det
19	steady-state	steady-state	JJ	_	21	amod
20	plasma	plasma	NN	_	21	compound
21	concentrations	concentration	NNS	_	17	dobj
22	of	of	IN	_	23	case
23	drug5	drug5	NN	_	21	nmod
24	.	.	.	_	17	punct

1	The	the	DT	_	3	det
2	net	net	JJ	_	3	amod
3	effect	effect	NN	_	8	nsubjpass
4	of	of	IN	_	6	case
5	these	these	DT	_	6	det
6	interactions	interaction	NNS	_	3	nmod
7	is	be	VBZ	_	8	auxpass
8	summarized	summarize	VBN	_	0	ROOT
9	in	in	IN	_	12	case
10	the	the	DT	_	12	det
11	following	follow	VBG	_	12	amod
12	table	table	NN	_	8	nmod
13	:	:	:	_	8	punct
14	drug1	drug1	NN	_	16	compound
15	drug2	drug2	NN	_	16	compound
16	drug3	drug3	NN	_	8	dep

1	Coadministered	coadministered	JJ	_	3	amod
2	Concentration	concentration	NN	_	3	compound
3	Concentration	concentration	NN	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT
2	**	**	SYM	_	1	dep

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	drug2	drug2	NN	_	1	appos
4	-RRB-	-rrb-	-RRB-	_	3	punct

1	*	*	SYM	_	3	dep
2	CBZ	cbz	NN	_	3	compound
3	epoxide	epoxide	NN	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT

1	*	*	SYM	_	3	dep
2	Not	not	RB	_	3	neg
3	administered	administer	VBN	_	0	ROOT
4	,	,	,	_	3	punct
5	but	but	CC	_	3	cc
6	an	a	DT	_	8	det
7	active	active	JJ	_	8	amod
8	metabolite	metabolite	NN	_	3	conj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	.	.	.	_	3	punct

1	**	**	SYM	_	4	dep
2	No	no	DT	_	4	neg
3	significant	significant	JJ	_	4	amod
4	effect	effect	NN	_	0	ROOT
5	.	.	.	_	4	punct

1	Specific	specific	JJ	_	2	amod
2	Effects	effect	NNS	_	0	ROOT
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	on	on	IN	_	8	case
6	Other	other	JJ	_	8	amod
7	drug2	drug2	NN	_	8	compound
8	drug3	drug3	NN	_	2	nmod
9	:	:	:	_	2	punct
10	drug4	drug4	NN	_	11	nsubj
11	causes	cause	VBZ	_	2	dep
12	an	a	DT	_	13	det
13	increase	increase	NN	_	11	dobj
14	in	in	IN	_	18	case
15	steady-state	steady-state	JJ	_	18	amod
16	drug5	drug5	NN	_	18	compound
17	plasma	plasma	NN	_	18	compound
18	concentrations	concentration	NNS	_	13	nmod
19	.	.	.	_	2	punct

1	In	in	IN	_	5	case
2	10	10	CD	_	5	nummod
3	otherwise	otherwise	RB	_	4	advmod
4	healthy	healthy	JJ	_	5	amod
5	subjects	subject	NNS	_	23	nmod
6	with	with	IN	_	9	case
7	epilepsy	epilepsy	NN	_	9	compound
8	ingesting	ingest	VBG	_	9	amod
9	drug1	drug1	NN	_	5	nmod
10	,	,	,	_	23	punct
11	the	the	DT	_	13	det
12	steadystate	steadystate	NN	_	13	compound
13	trough	trough	NN	_	19	compound
14	-LRB-	-lrb-	-LRB-	_	15	punct
15	Cmin	cmin	NN	_	13	appos
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	drug2	drug2	NN	_	19	compound
18	plasma	plasma	NN	_	19	compound
19	concentration	concentration	NN	_	23	nsubj
20	was	be	VBD	_	23	cop
21	17	17	CD	_	22	compound
22	5	5	CD	_	23	nummod
23	micrograms/mL	micrograms/ml	NNS	_	0	ROOT
24	.	.	.	_	23	punct

1	The	the	DT	_	3	det
2	steady-state	steady-state	JJ	_	3	amod
3	Cmin	cmin	NN	_	4	nsubj
4	increased	increase	VBD	_	0	ROOT
5	to	to	TO	_	8	case
6	21	21	CD	_	8	nummod
7	5	5	CD	_	8	nummod
8	micrograms/mL	micrograms/ml	NNS	_	4	nmod
9	when	when	WRB	_	15	advmod
10	1200	1200	CD	_	11	nummod
11	mg/day	mg/day	NN	_	15	nsubjpass
12	of	of	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	was	be	VBD	_	15	auxpass
15	coadministered	coadminister	VBN	_	4	advcl
16	.	.	.	_	4	punct

1	Increasing	increase	VBG	_	13	csubj
2	the	the	DT	_	4	det
3	drug1	drug1	NN	_	4	compound
4	dose	dose	NN	_	1	dobj
5	to	to	TO	_	7	case
6	1800	1800	CD	_	7	nummod
7	mg/day	mg/day	NN	_	1	nmod
8	in	in	IN	_	9	case
9	six	six	CD	_	1	nmod
10	of	of	IN	_	12	case
11	these	these	DT	_	12	det
12	subjects	subject	NNS	_	9	nmod
13	increased	increase	VBD	_	0	ROOT
14	the	the	DT	_	17	det
15	steady-state	steady-state	JJ	_	17	amod
16	drug2	drug2	NN	_	17	compound
17	Cmin	cmin	NN	_	13	dobj
18	to	to	TO	_	21	case
19	25	25	CD	_	21	nummod
20	7	7	CD	_	21	nummod
21	micrograms/mL	micrograms/ml	NNS	_	13	nmod
22	.	.	.	_	13	punct

1	In	in	IN	_	4	mark
2	order	order	NN	_	1	mwe
3	to	to	TO	_	4	mark
4	maintain	maintain	VB	_	0	ROOT
5	drug1	drug1	NN	_	6	compound
6	levels	level	NNS	_	4	dobj
7	,	,	,	_	4	punct
8	limit	limit	NN	_	10	compound
9	adverse	adverse	JJ	_	10	amod
10	experiences	experience	NNS	_	7	root
11	,	,	,	_	10	punct
12	and	and	CC	_	10	cc
13	achieve	achieve	VB	_	10	conj
14	the	the	DT	_	16	det
15	drug2	drug2	NN	_	16	compound
16	dose	dose	NN	_	13	dobj
17	of	of	IN	_	19	case
18	3600	3600	CD	_	19	nummod
19	mg/day	mg/day	NN	_	16	nmod
20	,	,	,	_	19	punct
21	a	a	DT	_	24	det
22	drug3	drug3	NN	_	24	compound
23	dose	dose	NN	_	24	compound
24	reduction	reduction	NN	_	30	nsubj
25	of	of	IN	_	28	case
26	approximately	approximately	RB	_	27	advmod
27	40	40	CD	_	28	nummod
28	%	%	NN	_	24	nmod
29	was	be	VBD	_	30	cop
30	necessary	necessary	JJ	_	19	acl:relcl
31	for	for	IN	_	32	case
32	eight	eight	CD	_	30	nmod
33	of	of	IN	_	36	case
34	these	these	DT	_	36	det
35	10	10	CD	_	36	nummod
36	subjects	subject	NNS	_	32	nmod
37	.	.	.	_	10	punct

1	In	in	IN	_	5	case
2	a	a	DT	_	5	det
3	controlled	controlled	JJ	_	5	amod
4	clinical	clinical	JJ	_	5	amod
5	trial	trial	NN	_	21	nmod
6	,	,	,	_	21	punct
7	a	a	DT	_	10	det
8	20	20	CD	_	9	compound
9	%	%	NN	_	10	amod
10	reduction	reduction	NN	_	21	nsubj
11	of	of	IN	_	14	case
12	the	the	DT	_	14	det
13	drug1	drug1	NN	_	14	compound
14	dose	dose	NN	_	10	nmod
15	at	at	IN	_	17	case
16	the	the	DT	_	17	det
17	initiation	initiation	NN	_	10	nmod
18	of	of	IN	_	20	case
19	drug2	drug2	NN	_	20	compound
20	therapy	therapy	NN	_	17	nmod
21	resulted	result	VBD	_	0	ROOT
22	in	in	IN	_	24	case
23	drug3	drug3	NN	_	24	compound
24	levels	level	NNS	_	21	nmod
25	comparable	comparable	JJ	_	24	amod
26	to	to	TO	_	27	case
27	those	those	DT	_	25	nmod
28	prior	prior	JJ	_	27	amod
29	to	to	TO	_	30	mark
30	drug4	drug4	VB	_	28	xcomp
31	administration	administration	NN	_	30	dobj
32	.	.	.	_	21	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	nsubj
4	causes	cause	VBZ	_	1	appos
5	a	a	DT	_	6	det
6	decrease	decrease	NN	_	4	dobj
7	in	in	IN	_	12	case
8	the	the	DT	_	12	det
9	steady-state	steady-state	JJ	_	12	amod
10	drug3	drug3	NN	_	12	compound
11	plasma	plasma	NN	_	12	compound
12	concentrations	concentration	NNS	_	6	nmod
13	and	and	CC	_	6	cc
14	an	a	DT	_	15	det
15	increase	increase	NN	_	6	conj
16	in	in	IN	_	21	case
17	the	the	DT	_	21	det
18	steady-state	steady-state	JJ	_	21	amod
19	drug4	drug4	NN	_	21	compound
20	plasma	plasma	NN	_	21	compound
21	concentration	concentration	NN	_	15	nmod
22	.	.	.	_	1	punct

1	In	in	IN	_	5	case
2	nine	nine	CD	_	5	nummod
3	otherwise	otherwise	RB	_	4	advmod
4	healthy	healthy	JJ	_	5	amod
5	subjects	subject	NNS	_	22	nmod
6	with	with	IN	_	9	case
7	epilepsy	epilepsy	NN	_	9	compound
8	ingesting	ingest	VBG	_	9	amod
9	drug1	drug1	NN	_	5	nmod
10	,	,	,	_	22	punct
11	the	the	DT	_	13	det
12	steady-state	steady-state	JJ	_	13	amod
13	trough	trough	NN	_	18	compound
14	-LRB-	-lrb-	-LRB-	_	15	punct
15	Cmin	cmin	NN	_	13	appos
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	drug2	drug2	NN	_	18	compound
18	concentration	concentration	NN	_	22	nsubj
19	was	be	VBD	_	22	cop
20	8	8	CD	_	22	nummod
21	2	2	CD	_	22	nummod
22	micrograms/mL	micrograms/ml	NNS	_	0	ROOT
23	.	.	.	_	22	punct

1	The	the	DT	_	4	det
2	drug1	drug1	NN	_	4	compound
3	steady-state	steady-state	JJ	_	4	amod
4	Cmin	cmin	NN	_	5	nsubj
5	decreased	decrease	VBD	_	0	ROOT
6	31	31	CD	_	7	nummod
7	%	%	NN	_	5	dobj
8	to	to	TO	_	11	case
9	5	5	CD	_	11	nummod
10	1	1	CD	_	11	nummod
11	micrograms/mL	micrograms/ml	NNS	_	5	nmod
12	when	when	WRB	_	24	advmod
13	drug2	drug2	NN	_	24	nsubjpass
14	-LRB-	-lrb-	-LRB-	_	16	punct
15	3000	3000	CD	_	16	nummod
16	mg/day	mg/day	NN	_	13	dep
17	,	,	,	_	16	punct
18	divided	divide	VBN	_	16	acl
19	into	into	IN	_	21	case
20	three	three	CD	_	21	nummod
21	doses	dose	NNS	_	18	nmod
22	-RRB-	-rrb-	-RRB-	_	16	punct
23	was	be	VBD	_	24	auxpass
24	coadministered	coadminister	VBN	_	5	advcl
25	.	.	.	_	5	punct

1	drug1	drug1	NN	_	4	compound
2	steady-state	steady-state	JJ	_	4	amod
3	Cmin	cmin	JJ	_	4	amod
4	concentrations	concentration	NNS	_	5	nsubj
5	increased	increase	VBD	_	0	ROOT
6	57	57	CD	_	7	nummod
7	%	%	NN	_	5	dobj
8	from	from	IN	_	10	case
9	1.0	1.0	CD	_	10	compound
10	0.3	0.3	CD	_	5	nmod
11	to	to	TO	_	14	case
12	1.6	1.6	CD	_	13	compound
13	0.4	0.4	CD	_	14	nummod
14	micrograms/mL	micrograms/ml	NNS	_	5	nmod
15	with	with	IN	_	17	case
16	the	the	DT	_	17	det
17	addition	addition	NN	_	5	nmod
18	of	of	IN	_	19	case
19	drug2	drug2	NN	_	17	nmod
20	.	.	.	_	5	punct

1	In	in	IN	_	3	case
2	clinical	clinical	JJ	_	3	amod
3	trials	trial	NNS	_	12	nmod
4	,	,	,	_	12	punct
5	similar	similar	JJ	_	6	amod
6	changes	change	NNS	_	12	nsubjpass
7	in	in	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	drug2	drug2	NN	_	8	conj
11	were	be	VBD	_	12	auxpass
12	seen	see	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	nsubj
4	causes	cause	VBZ	_	1	appos
5	an	a	DT	_	6	det
6	increase	increase	NN	_	4	dobj
7	in	in	IN	_	10	case
8	steady-state	steady-state	JJ	_	10	amod
9	drug3	drug3	NN	_	10	compound
10	concentrations	concentration	NNS	_	6	nmod
11	.	.	.	_	1	punct

1	In	in	IN	_	3	case
2	four	four	CD	_	3	nummod
3	subjects	subject	NNS	_	21	nmod
4	with	with	IN	_	7	case
5	epilepsy	epilepsy	NN	_	7	compound
6	ingesting	ingest	VBG	_	7	amod
7	drug1	drug1	NN	_	3	nmod
8	,	,	,	_	21	punct
9	the	the	DT	_	11	det
10	steady-state	steady-state	JJ	_	11	amod
11	trough	trough	NN	_	17	compound
12	-LRB-	-lrb-	-LRB-	_	13	punct
13	Cmin	cmin	NN	_	11	appos
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	drug2	drug2	NN	_	17	compound
16	plasma	plasma	NN	_	17	compound
17	concentration	concentration	NN	_	21	nsubj
18	was	be	VBD	_	21	cop
19	63	63	CD	_	21	nummod
20	16	16	CD	_	21	nummod
21	micrograms/mL	micrograms/ml	NNS	_	0	ROOT
22	.	.	.	_	21	punct

1	The	the	DT	_	3	det
2	steady-state	steady-state	JJ	_	3	amod
3	Cmin	cmin	NN	_	4	nsubj
4	increased	increase	VBD	_	0	ROOT
5	to	to	TO	_	8	case
6	78	78	CD	_	8	nummod
7	14	14	CD	_	8	nummod
8	micrograms/mL	micrograms/ml	NNS	_	4	nmod
9	when	when	WRB	_	15	advmod
10	1200	1200	CD	_	11	nummod
11	mg/day	mg/day	NN	_	15	nsubjpass
12	of	of	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	was	be	VBD	_	15	auxpass
15	coadministered	coadminister	VBN	_	4	advcl
16	.	.	.	_	4	punct

1	Increasing	increase	VBG	_	8	csubj
2	the	the	DT	_	4	det
3	drug1	drug1	NN	_	4	compound
4	dose	dose	NN	_	1	dobj
5	to	to	TO	_	7	case
6	2400	2400	CD	_	7	nummod
7	mg/day	mg/day	NN	_	1	nmod
8	increased	increase	VBD	_	0	ROOT
9	the	the	DT	_	12	det
10	steadystate	steadystate	NN	_	12	compound
11	drug2	drug2	NN	_	12	compound
12	Cmin	cmin	NN	_	8	dobj
13	to	to	TO	_	16	case
14	96	96	CD	_	15	compound
15	25	25	CD	_	16	nummod
16	micrograms/mL	micrograms/ml	NNS	_	8	nmod
17	.	.	.	_	8	punct

1	Corresponding	correspond	VBG	_	2	amod
2	values	value	NNS	_	10	nsubj
3	for	for	IN	_	7	case
4	free	free	JJ	_	7	amod
5	drug1	drug1	NN	_	7	compound
6	Cmin	cmin	NN	_	7	compound
7	concentrations	concentration	NNS	_	2	nmod
8	were	be	VBD	_	10	cop
9	7	7	CD	_	10	compound
10	3	3	CD	_	0	ROOT
11	,	,	,	_	10	punct
12	9	9	CD	_	13	compound
13	4	4	CD	_	10	conj
14	,	,	,	_	10	punct
15	and	and	CC	_	10	cc
16	11	11	CD	_	17	compound
17	6	6	CD	_	18	nummod
18	micrograms/mL	micrograms/ml	NNS	_	10	conj
19	for	for	IN	_	20	case
20	0	0	CD	_	18	nmod
21	,	,	,	_	20	punct
22	1200	1200	CD	_	20	conj
23	,	,	,	_	20	punct
24	and	and	CC	_	20	cc
25	2400	2400	CD	_	20	conj
26	mg/day	mg/day	NN	_	27	compound
27	drug2	drug2	NN	_	20	dep
28	,	,	,	_	10	punct
29	respectively	respectively	RB	_	10	advmod
30	.	.	.	_	10	punct

1	The	the	DT	_	2	det
2	ratios	ratio	NNS	_	18	nsubj
3	of	of	IN	_	5	case
4	the	the	DT	_	5	det
5	AUCs	auc	NNS	_	2	nmod
6	of	of	IN	_	8	case
7	unbound	unbound	JJ	_	8	amod
8	drug1	drug1	NN	_	5	nmod
9	to	to	TO	_	11	case
10	the	the	DT	_	11	det
11	AUCs	auc	NNS	_	2	nmod
12	of	of	IN	_	15	case
13	the	the	DT	_	15	det
14	total	total	JJ	_	15	amod
15	drug2	drug2	NN	_	11	nmod
16	were	be	VBD	_	18	cop
17	11.1	11.1	CD	_	18	nummod
18	%	%	NN	_	0	ROOT
19	,	,	,	_	18	punct
20	13.0	13.0	CD	_	21	nummod
21	%	%	NN	_	18	conj
22	,	,	,	_	18	punct
23	and	and	CC	_	18	cc
24	11.5	11.5	CD	_	25	nummod
25	%	%	NN	_	18	conj
26	,	,	,	_	18	punct
27	with	with	IN	_	28	case
28	coadministration	coadministration	NN	_	18	nmod
29	of	of	IN	_	30	case
30	0	0	CD	_	28	nmod
31	,	,	,	_	30	punct
32	1200	1200	CD	_	30	conj
33	,	,	,	_	30	punct
34	and	and	CC	_	30	cc
35	2400	2400	CD	_	30	conj
36	mg/day	mg/day	NN	_	30	dep
37	of	of	IN	_	38	case
38	drug3	drug3	NN	_	30	nmod
39	,	,	,	_	18	punct
40	respectively	respectively	RB	_	18	advmod
41	.	.	.	_	18	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Coadministration	coadministration	NN	_	8	nsubj
4	of	of	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	with	with	IN	_	7	case
7	drug3	drug3	NN	_	3	nmod
8	causes	cause	VBZ	_	1	appos
9	an	a	DT	_	10	det
10	increase	increase	NN	_	8	dobj
11	in	in	IN	_	14	case
12	drug4	drug4	NN	_	14	compound
13	plasma	plasma	NN	_	14	compound
14	concentrations	concentration	NNS	_	10	nmod
15	,	,	,	_	8	punct
16	In	in	IN	_	21	case
17	12	12	CD	_	21	nummod
18	otherwise	otherwise	RB	_	19	advmod
19	healthy	healthy	JJ	_	21	amod
20	male	male	JJ	_	21	amod
21	volunteers	volunteer	NNS	_	35	nmod
22	ingesting	ingest	VBG	_	23	amod
23	drug5	drug5	NN	_	35	nsubj
24	,	,	,	_	23	punct
25	the	the	DT	_	27	det
26	steady-state	steady-state	JJ	_	27	amod
27	trough	trough	NN	_	32	compound
28	-LRB-	-lrb-	-LRB-	_	29	punct
29	Cmin	cmin	NN	_	27	appos
30	-RRB-	-rrb-	-RRB-	_	29	punct
31	drug6	drug6	NN	_	32	compound
32	concentration	concentration	NN	_	23	appos
33	was	be	VBD	_	35	cop
34	14.2	14.2	CD	_	35	nummod
35	micrograms/mL	micrograms/ml	NNS	_	8	parataxis
36	.	.	.	_	1	punct

1	The	the	DT	_	4	det
2	steady-state	steady-state	JJ	_	4	amod
3	Cmin	cmin	JJ	_	4	amod
4	concentration	concentration	NN	_	5	nsubj
5	increased	increase	VBD	_	0	ROOT
6	to	to	TO	_	8	case
7	17.8	17.8	CD	_	8	nummod
8	micrograms/mL	micrograms/ml	NNS	_	5	nmod
9	when	when	WRB	_	15	advmod
10	2400	2400	CD	_	11	nummod
11	mg/day	mg/day	NN	_	15	nsubjpass
12	of	of	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	was	be	VBD	_	15	auxpass
15	coadministered	coadminister	VBN	_	5	advcl
16	for	for	IN	_	18	case
17	one	one	CD	_	18	nummod
18	week	week	NN	_	15	nmod
19	.	.	.	_	5	punct

1	Effects	effect	NNS	_	0	ROOT
2	of	of	IN	_	4	case
3	Other	other	JJ	_	4	amod
4	drug1	drug1	NN	_	1	nmod
5	on	on	IN	_	7	case
6	drug2	drug2	NN	_	7	compound
7	drug3	drug3	NN	_	1	nmod
8	:	:	:	_	1	punct
9	drug4	drug4	NN	_	10	nsubj
10	causes	cause	VBZ	_	1	dep
11	an	a	DT	_	13	det
12	approximate	approximate	JJ	_	13	amod
13	doubling	doubling	NN	_	10	dobj
14	of	of	IN	_	16	case
15	the	the	DT	_	16	det
16	clearance	clearance	NN	_	13	nmod
17	of	of	IN	_	18	case
18	drug5	drug5	NN	_	16	nmod
19	-LRB-	-lrb-	-LRB-	_	20	punct
20	drug6	drug6	NN	_	18	appos
21	-RRB-	-rrb-	-RRB-	_	20	punct
22	at	at	IN	_	24	case
23	steady	steady	JJ	_	24	amod
24	state	state	NN	_	10	nmod
25	and	and	CC	_	10	cc
26	,	,	,	_	10	punct
27	therefore	therefore	RB	_	10	advmod
28	,	,	,	_	10	punct
29	the	the	DT	_	30	det
30	addition	addition	NN	_	33	nsubj
31	of	of	IN	_	32	case
32	drug7	drug7	NN	_	30	nmod
33	causes	cause	VBZ	_	10	ccomp
34	an	a	DT	_	38	det
35	approximate	approximate	JJ	_	38	amod
36	45	45	CD	_	37	compound
37	%	%	NN	_	38	amod
38	decrease	decrease	NN	_	33	dobj
39	in	in	IN	_	43	case
40	the	the	DT	_	43	det
41	steady-state	steady-state	JJ	_	43	amod
42	trough	trough	NN	_	43	compound
43	concentrations	concentration	NNS	_	38	nmod
44	of	of	IN	_	45	case
45	drug8	drug8	NN	_	43	nmod
46	as	as	IN	_	47	mark
47	compared	compare	VBN	_	33	advcl
48	to	to	TO	_	51	case
49	the	the	DT	_	51	det
50	same	same	JJ	_	51	amod
51	dose	dose	NN	_	47	nmod
52	of	of	IN	_	53	case
53	drug9	drug9	NN	_	51	nmod
54	given	give	VBN	_	51	acl
55	as	as	IN	_	56	case
56	monotherapy	monotherapy	NN	_	54	nmod
57	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	nsubj
4	causes	cause	VBZ	_	1	appos
5	an	a	DT	_	9	det
6	approximate	approximate	JJ	_	9	amod
7	50	50	CD	_	8	compound
8	%	%	NN	_	9	amod
9	increase	increase	NN	_	4	dobj
10	in	in	IN	_	12	case
11	the	the	DT	_	12	det
12	clearance	clearance	NN	_	9	nmod
13	of	of	IN	_	14	case
14	drug3	drug3	NN	_	12	nmod
15	at	at	IN	_	17	case
16	steady	steady	JJ	_	17	amod
17	state	state	NN	_	12	nmod
18	and	and	CC	_	4	cc
19	,	,	,	_	4	punct
20	therefore	therefore	RB	_	4	advmod
21	,	,	,	_	4	punct
22	the	the	DT	_	23	det
23	addition	addition	NN	_	26	nsubj
24	of	of	IN	_	25	case
25	drug4	drug4	NN	_	23	nmod
26	results	result	VBZ	_	4	ccomp
27	in	in	IN	_	32	case
28	an	a	DT	_	32	det
29	approximate	approximate	JJ	_	32	amod
30	40	40	CD	_	31	compound
31	%	%	NN	_	32	amod
32	decrease	decrease	NN	_	26	nmod
33	in	in	IN	_	37	case
34	the	the	DT	_	37	det
35	steady-state	steady-state	JJ	_	37	amod
36	trough	trough	NN	_	37	compound
37	concentrations	concentration	NNS	_	32	nmod
38	of	of	IN	_	39	case
39	drug5	drug5	NN	_	37	nmod
40	as	as	IN	_	41	mark
41	compared	compare	VBN	_	26	advcl
42	to	to	TO	_	45	case
43	the	the	DT	_	45	det
44	same	same	JJ	_	45	amod
45	dose	dose	NN	_	41	nmod
46	of	of	IN	_	47	case
47	drug6	drug6	NN	_	45	nmod
48	given	give	VBN	_	45	acl
49	as	as	IN	_	50	case
50	monotherapy	monotherapy	NN	_	48	nmod
51	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Available	available	JJ	_	4	amod
4	data	datum	NNS	_	5	nsubj
5	suggest	suggest	VBP	_	1	appos
6	that	that	IN	_	8	mark
7	there	there	EX	_	8	expl
8	is	be	VBZ	_	5	ccomp
9	no	no	DT	_	11	neg
10	significant	significant	JJ	_	11	amod
11	effect	effect	NN	_	8	nsubj
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	on	on	IN	_	16	case
15	the	the	DT	_	16	det
16	clearance	clearance	NN	_	11	nmod
17	of	of	IN	_	18	case
18	drug3	drug3	NN	_	16	nmod
19	at	at	IN	_	21	case
20	steady	steady	JJ	_	21	amod
21	state	state	NN	_	16	nmod
22	,	,	,	_	8	punct
23	Therefore	therefore	RB	_	8	advmod
24	,	,	,	_	8	punct
25	the	the	DT	_	26	det
26	addition	addition	NN	_	31	nsubjpass
27	of	of	IN	_	28	case
28	drug4	drug4	NN	_	26	nmod
29	is	be	VBZ	_	31	auxpass
30	not	not	RB	_	31	neg
31	expected	expect	VBN	_	8	parataxis
32	to	to	TO	_	33	mark
33	cause	cause	VB	_	31	xcomp
34	a	a	DT	_	37	det
35	clinically	clinically	RB	_	36	advmod
36	important	important	JJ	_	37	amod
37	effect	effect	NN	_	33	dobj
38	on	on	IN	_	44	case
39	drug5	drug5	NN	_	44	compound
40	-LRB-	-lrb-	-LRB-	_	41	punct
41	drug6	drug6	NN	_	39	appos
42	-RRB-	-rrb-	-RRB-	_	41	punct
43	plasma	plasma	NN	_	44	compound
44	concentrations	concentration	NNS	_	37	nmod
45	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	It	it	PRP	_	4	nsubj
4	appears	appear	VBZ	_	1	appos
5	that	that	IN	_	8	mark
6	drug2	drug2	NN	_	8	nsubj
7	may	may	MD	_	8	aux
8	reduce	reduce	VB	_	4	ccomp
9	plasma	plasma	NN	_	11	compound
10	drug3	drug3	NN	_	11	compound
11	concentrations	concentration	NNS	_	8	dobj
12	.	.	.	_	1	punct

1	Steady-state	steady-state	JJ	_	4	amod
2	plasma	plasma	NN	_	4	compound
3	drug1	drug1	NN	_	4	compound
4	concentrations	concentration	NNS	_	6	nsubjpass
5	were	be	VBD	_	6	auxpass
6	found	find	VBN	_	0	ROOT
7	to	to	TO	_	11	mark
8	be	be	VB	_	11	cop
9	29	29	CD	_	10	nummod
10	%	%	NN	_	11	nmod:npmod
11	lower	lower	JJR	_	6	xcomp
12	than	than	IN	_	15	case
13	the	the	DT	_	15	det
14	mean	mean	JJ	_	15	amod
15	concentrations	concentration	NNS	_	11	nmod
16	of	of	IN	_	18	case
17	a	a	DT	_	18	det
18	group	group	NN	_	15	nmod
19	of	of	IN	_	22	case
20	newly	newly	RB	_	21	advmod
21	diagnosed	diagnose	VBN	_	22	amod
22	subjects	subject	NNS	_	18	nmod
23	with	with	IN	_	24	case
24	epilepsy	epilepsy	NN	_	22	nmod
25	also	also	RB	_	26	advmod
26	receiving	receive	VBG	_	15	acl
27	2400	2400	CD	_	28	nummod
28	mg	mg	NN	_	26	dobj
29	of	of	IN	_	30	case
30	drug2	drug2	NN	_	28	nmod
31	a	a	DT	_	32	det
32	day	day	NN	_	28	nmod:npmod
33	.	.	.	_	6	punct

1	Effects	effect	NNS	_	0	ROOT
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	on	on	IN	_	5	case
5	drug2	drug2	NN	_	1	nmod
6	The	the	DT	_	7	det
7	rate	rate	NN	_	5	dep
8	and	and	CC	_	7	cc
9	extent	extent	NN	_	7	conj
10	of	of	IN	_	11	case
11	absorption	absorption	NN	_	7	nmod
12	of	of	IN	_	16	case
13	a	a	DT	_	16	det
14	2400	2400	CD	_	15	compound
15	mg	mg	NN	_	16	amod
16	dose	dose	NN	_	11	nmod
17	of	of	IN	_	18	case
18	drug3	drug3	NN	_	16	nmod
19	as	as	IN	_	20	case
20	monotherapy	monotherapy	NN	_	7	nmod
21	given	give	VBN	_	20	acl
22	as	as	IN	_	26	mark
23	tablets	tablet	NNS	_	26	nsubjpass
24	was	be	VBD	_	26	auxpass
25	not	not	RB	_	26	neg
26	affected	affect	VBN	_	21	advcl
27	when	when	WRB	_	28	advmod
28	coadministered	coadminister	VBN	_	26	advcl
29	with	with	IN	_	30	case
30	drug4	drug4	NN	_	28	nmod
31	.	.	.	_	1	punct

1	Effects	effect	NNS	_	19	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	on	on	IN	_	5	case
5	drug2	drug2	NN	_	19	nmod
6	The	the	DT	_	7	det
7	coadministration	coadministration	NN	_	19	nsubj
8	of	of	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	-LRB-	-lrb-	-LRB-	_	12	punct
11	1000	1000	CD	_	12	nummod
12	mg/day	mg/day	NN	_	9	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	for	for	IN	_	16	case
15	10	10	CD	_	16	nummod
16	days	day	NNS	_	7	nmod
17	did	do	VBD	_	19	aux
18	not	not	RB	_	19	neg
19	alter	alter	VB	_	0	ROOT
20	the	the	DT	_	22	det
21	pharmacokinetic	pharmacokinetic	JJ	_	22	amod
22	parameters	parameter	NNS	_	19	dobj
23	of	of	IN	_	24	case
24	Cmax	Cmax	NNP	_	22	nmod
25	,	,	,	_	24	punct
26	Cmin	Cmin	NNP	_	24	conj
27	,	,	,	_	24	punct
28	AUC	auc	NN	_	24	conj
29	,	,	,	_	24	punct
30	CI/kg	ci/kg	NN	_	24	conj
31	or	or	CC	_	24	cc
32	tmax	tmax	NN	_	24	conj
33	at	at	IN	_	36	case
34	drug4	drug4	NN	_	36	compound
35	daily	daily	JJ	_	36	amod
36	doses	dose	NNS	_	19	nmod
37	of	of	IN	_	41	case
38	3000	3000	CD	_	41	nummod
39	or	or	CC	_	38	cc
40	3600	3600	CD	_	38	conj
41	mg/day	mg/day	NN	_	36	nmod
42	in	in	IN	_	46	case
43	10	10	CD	_	46	nummod
44	otherwise	otherwise	RB	_	45	advmod
45	healthy	healthy	JJ	_	46	amod
46	subjects	subject	NNS	_	19	nmod
47	with	with	IN	_	48	case
48	epilepsy	epilepsy	NN	_	46	nmod
49	.	.	.	_	19	punct

1	Effects	effect	NNS	_	0	ROOT
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	on	on	IN	_	8	case
5	Low-Dose	low-dose	JJ	_	8	amod
6	drug2	drug2	NN	_	8	compound
7	A	a	DT	_	8	det
8	group	group	NN	_	1	nmod
9	of	of	IN	_	11	case
10	24	24	CD	_	11	nummod
11	nonsmoking	nonsmoking	JJ	_	8	nmod
12	,	,	,	_	11	punct
13	healthy	healthy	JJ	_	16	amod
14	white	white	JJ	_	16	amod
15	female	female	JJ	_	16	amod
16	volunteers	volunteer	NNS	_	36	nsubj
17	established	establish	VBN	_	16	acl
18	on	on	IN	_	22	case
19	an	a	DT	_	22	det
20	oral	oral	JJ	_	22	amod
21	drug3	drug3	NN	_	22	compound
22	regimen	regimen	NN	_	17	nmod
23	containing	contain	VBG	_	22	acl
24	30	30	CD	_	26	nummod
25	mg	mg	NN	_	26	compound
26	drug4	drug4	NN	_	23	dobj
27	and	and	CC	_	26	cc
28	75	75	CD	_	29	compound
29	mg	mg	NN	_	30	amod
30	drug5	drug5	NN	_	26	conj
31	for	for	IN	_	35	case
32	at	at	IN	_	33	case
33	least	least	JJS	_	34	nmod:npmod
34	3	3	CD	_	35	nummod
35	months	month	NNS	_	23	nmod
36	received	receive	VBD	_	11	dep
37	2400	2400	CD	_	38	nummod
38	mg/day	mg/day	NN	_	36	dobj
39	of	of	IN	_	40	case
40	drug6	drug6	NN	_	38	nmod
41	from	from	IN	_	42	case
42	midcycle	midcycle	NN	_	36	nmod
43	-LRB-	-lrb-	-LRB-	_	44	punct
44	day	day	NN	_	42	appos
45	15	15	CD	_	44	nummod
46	-RRB-	-rrb-	-RRB-	_	44	punct
47	to	to	TO	_	48	case
48	midcycle	midcycle	NN	_	42	nmod
49	-LRB-	-lrb-	-LRB-	_	50	punct
50	day	day	NN	_	48	appos
51	14	14	CD	_	50	nummod
52	-RRB-	-rrb-	-RRB-	_	50	punct
53	of	of	IN	_	58	case
54	two	two	CD	_	58	nummod
55	consecutive	consecutive	JJ	_	58	amod
56	oral	oral	JJ	_	58	amod
57	drug7	drug7	NN	_	58	compound
58	cycles	cycle	NNS	_	48	nmod
59	.	.	.	_	1	punct

1	drug1	drug1	NN	_	2	compound
2	treatment	treatment	NN	_	3	nsubj
3	resulted	result	VBD	_	0	ROOT
4	in	in	IN	_	8	case
5	a	a	DT	_	8	det
6	42	42	CD	_	7	compound
7	%	%	NN	_	8	amod
8	decrease	decrease	NN	_	3	nmod
9	in	in	IN	_	12	case
10	the	the	DT	_	12	det
11	drug2	drug2	NN	_	12	compound
12	AUC	auc	NN	_	8	nmod
13	0-24	0-24	CD	_	12	nummod
14	,	,	,	_	3	punct
15	but	but	CC	_	3	cc
16	no	no	DT	_	19	neg
17	clinically	clinically	RB	_	18	advmod
18	relevant	relevant	JJ	_	19	amod
19	effect	effect	NN	_	21	nsubjpass
20	was	be	VBD	_	21	auxpass
21	observed	observe	VBN	_	3	conj
22	on	on	IN	_	25	case
23	the	the	DT	_	25	det
24	pharmacokinetic	pharmacokinetic	JJ	_	25	amod
25	parameters	parameter	NNS	_	21	nmod
26	of	of	IN	_	27	case
27	drug3	drug3	NN	_	25	nmod
28	.	.	.	_	3	punct

1	No	no	DT	_	2	neg
2	volunteer	volunteer	NN	_	3	nsubj
3	showed	show	VBD	_	0	ROOT
4	hormonal	hormonal	JJ	_	5	amod
5	evidence	evidence	NN	_	3	dobj
6	of	of	IN	_	7	case
7	ovulation	ovulation	NN	_	5	nmod
8	,	,	,	_	3	punct
9	but	but	CC	_	3	cc
10	one	one	CD	_	11	nummod
11	volunteer	volunteer	NN	_	12	nsubj
12	reported	report	VBD	_	3	conj
13	intermenstrual	intermenstrual	JJ	_	14	amod
14	bleeding	bleeding	NN	_	12	dobj
15	during	during	IN	_	17	case
16	drug1	drug1	NN	_	17	compound
17	treatment	treatment	NN	_	14	nmod
18	.	.	.	_	3	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	extensively	extensively	RB	_	4	advmod
4	metabolized	metabolize	VBN	_	0	ROOT
5	by	by	IN	_	7	case
6	CYP	cyp	NN	_	7	compound
7	3A4	3a4	NN	_	4	nmod
8	,	,	,	_	4	punct
9	but	but	CC	_	4	cc
10	coadministration	coadministration	NN	_	21	nsubj
11	of	of	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	,	,	,	_	12	punct
14	a	a	DT	_	16	det
15	potent	potent	JJ	_	16	amod
16	inhibitor	inhibitor	NN	_	12	appos
17	of	of	IN	_	19	case
18	CYP	cyp	NN	_	19	compound
19	3A4	3a4	NN	_	16	nmod
20	,	,	,	_	10	punct
21	has	have	VBZ	_	4	conj
22	no	no	DT	_	24	neg
23	significant	significant	JJ	_	24	amod
24	effect	effect	NN	_	21	dobj
25	on	on	IN	_	27	case
26	drug3	drug3	NN	_	27	compound
27	pharmacokinetics	pharmacokinetic	NNS	_	21	nmod
28	.	.	.	_	4	punct

1	Significant	significant	JJ	_	3	amod
2	pharmacokinetic	pharmacokinetic	JJ	_	3	amod
3	interactions	interaction	NNS	_	11	nsubj
4	mediated	mediate	VBN	_	3	acl
5	by	by	IN	_	6	case
6	inhibition	inhibition	NN	_	4	nmod
7	of	of	IN	_	9	case
8	CYP	cyp	NN	_	9	compound
9	isoenzymes	isoenzyme	NNS	_	6	nmod
10	therefore	therefore	RB	_	11	advmod
11	appear	appear	VBP	_	0	ROOT
12	unlikely	unlikely	JJ	_	11	xcomp
13	.	.	.	_	11	punct

1	Co-medications	co-medication	NNS	_	25	nsubj
2	that	that	WDT	_	3	nsubj
3	induce	induce	VBP	_	1	acl:relcl
4	CYP	cyp	NN	_	5	compound
5	3A4	3a4	NN	_	3	dobj
6	-LRB-	-lrb-	-LRB-	_	9	punct
7	e.g.	e.g.	FW	_	9	dep
8	,	,	,	_	9	punct
9	drug1	drug1	NN	_	1	dep
10	,	,	,	_	9	punct
11	drug2	drug2	NN	_	9	conj
12	,	,	,	_	9	punct
13	drug3	drug3	NN	_	9	conj
14	,	,	,	_	9	punct
15	drug4	drug4	NN	_	9	conj
16	,	,	,	_	9	punct
17	or	or	CC	_	9	cc
18	St.	St.	NNP	_	19	compound
19	John	John	NNP	_	21	compound
20	s	be	VBZ	_	21	compound
21	wort	wort	NN	_	9	conj
22	-RRB-	-rrb-	-RRB-	_	9	punct
23	may	may	MD	_	25	aux
24	significantly	significantly	RB	_	25	advmod
25	decrease	decrease	VB	_	0	ROOT
26	exposure	exposure	NN	_	25	dobj
27	to	to	TO	_	28	case
28	drug5	drug5	NN	_	26	nmod
29	.	.	.	_	25	punct

1	Dose	dose	NN	_	2	compound
2	modification	modification	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	recommended	recommend	VBN	_	0	ROOT
5	for	for	IN	_	6	case
6	patients	patient	NNS	_	4	nmod
7	who	who	WP	_	10	nsubj
8	are	be	VBP	_	10	aux
9	also	also	RB	_	10	advmod
10	receiving	receive	VBG	_	6	acl:relcl
11	a	a	DT	_	15	det
12	potent	potent	JJ	_	15	amod
13	CYP	cyp	NN	_	15	compound
14	3A4	3a4	NN	_	15	compound
15	inducer	inducer	NN	_	10	dobj
16	.	.	.	_	4	punct

1	Drug/Laboratory	Drug/Laboratory	NNP	_	3	compound
2	Tests	Tests	NNP	_	3	compound
3	Interactions	interaction	NNS	_	7	nsubj
4	No	no	DT	_	7	neg
5	clinically	clinically	RB	_	6	advmod
6	relevant	relevant	JJ	_	7	amod
7	changes	change	NNS	_	17	nsubjpass
8	in	in	IN	_	10	case
9	the	the	DT	_	10	det
10	results	result	NNS	_	7	nmod
11	of	of	IN	_	14	case
12	clinical	clinical	JJ	_	14	amod
13	laboratory	laboratory	NN	_	14	compound
14	tests	test	NNS	_	10	nmod
15	have	have	VBP	_	17	aux
16	been	be	VBN	_	17	auxpass
17	observed	observe	VBN	_	0	ROOT
18	.	.	.	_	17	punct

1	No	no	DT	_	2	neg
2	drug	drug	NN	_	14	nsubjpass
3	,	,	,	_	2	punct
4	nutritional	nutritional	JJ	_	5	amod
5	supplement	supplement	NN	_	2	conj
6	,	,	,	_	2	punct
7	food	food	NN	_	2	conj
8	or	or	CC	_	2	cc
9	herb	herb	NN	_	2	conj
10	interactions	interaction	NNS	_	2	dep
11	have	have	VBP	_	14	aux
12	yet	yet	RB	_	14	advmod
13	been	be	VBN	_	14	auxpass
14	reported	report	VBN	_	0	ROOT
15	.	.	.	_	14	punct

1	drug1	drug1	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	metabolized	metabolize	VBN	_	0	ROOT
4	in	in	IN	_	6	case
5	the	the	DT	_	6	det
6	liver	liver	NN	_	3	nmod
7	by	by	IN	_	12	case
8	the	the	DT	_	12	det
9	cytochrome	cytochrome	NN	_	12	compound
10	P450	p450	NN	_	12	compound
11	enzyme	enzyme	NN	_	12	compound
12	system	system	NN	_	3	nmod
13	.	.	.	_	3	punct

1	drug1	drug1	NN	_	2	nsubj
2	inhibits	inhibit	VBZ	_	0	ROOT
3	CYP3A4	cyp3a4	NN	_	2	dobj
4	.	.	.	_	2	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	when	when	WRB	_	4	dep
6	coadministering	coadminister	VBG	_	7	amod
7	medications	medication	NNS	_	5	root
8	that	that	WDT	_	10	nsubj
9	are	be	VBP	_	10	cop
10	substrates	substrate	NNS	_	7	acl:relcl
11	,	,	,	_	7	punct
12	inhibitors	inhibitor	NNS	_	7	conj
13	,	,	,	_	7	punct
14	or	or	CC	_	7	cc
15	inducers	inducer	NNS	_	7	conj
16	of	of	IN	_	17	case
17	CYP3A4	cyp3a4	NN	_	15	nmod
18	,	,	,	_	7	punct
19	or	or	CC	_	7	cc
20	potentially	potentially	RB	_	21	advmod
21	toxic	toxic	JJ	_	22	amod
22	medications	medication	NNS	_	7	conj
23	that	that	WDT	_	25	nsubjpass
24	are	be	VBP	_	25	auxpass
25	metabolized	metabolize	VBN	_	22	acl:relcl
26	by	by	IN	_	27	case
27	CYP3A4	cyp3a4	NN	_	25	nmod
28	.	.	.	_	7	punct

1	drug1	drug1	NN	_	4	nsubj
2	does	do	VBZ	_	4	aux
3	not	not	RB	_	4	neg
4	inhibit	inhibit	VB	_	0	ROOT
5	CYP2D6	cyp2d6	NN	_	4	dobj
6	,	,	,	_	5	punct
7	CYP1A2	cyp1a2	NN	_	5	conj
8	,	,	,	_	5	punct
9	CYP2C9	cyp2c9	NN	_	5	conj
10	,	,	,	_	5	punct
11	CYP2C19	cyp2c19	NN	_	5	conj
12	,	,	,	_	5	punct
13	CYP2E1	cyp2e1	NN	_	5	conj
14	,	,	,	_	5	punct
15	or	or	CC	_	5	cc
16	uridine	uridine	NN	_	17	compound
17	glucuronosyltransferase	glucuronosyltransferase	NN	_	5	conj
18	-LRB-	-lrb-	-LRB-	_	19	punct
19	UDPGT	udpgt	NN	_	17	appos
20	-RRB-	-rrb-	-RRB-	_	19	punct
21	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	effect	effect	NN	_	20	nsubjpass
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	on	on	IN	_	10	case
8	total	total	JJ	_	10	amod
9	drug	drug	NN	_	10	compound
10	concentrations	concentration	NNS	_	4	nmod
11	of	of	IN	_	13	case
12	other	other	JJ	_	13	amod
13	drug3	drug3	NN	_	10	nmod
14	in	in	IN	_	15	case
15	subjects	subject	NNS	_	10	nmod
16	receiving	receive	VBG	_	15	acl
17	both	both	CC	_	18	det
18	agents	agent	NNS	_	16	dobj
19	was	be	VBD	_	20	auxpass
20	evaluated	evaluate	VBN	_	1	dep
21	using	use	VBG	_	20	xcomp
22	comparisons	comparison	NNS	_	21	dobj
23	to	to	TO	_	25	case
24	historical	historical	JJ	_	25	amod
25	data	datum	NNS	_	21	nmod
26	.	.	.	_	20	punct

1	drug1	drug1	NN	_	3	compound
2	steady-state	steady-state	JJ	_	3	amod
3	Cmax	cmax	NN	_	9	nsubjpass
4	,	,	,	_	3	punct
5	A.C.	A.C.	NNP	_	3	conj
6	and	and	CC	_	3	cc
7	Cmin	Cmin	NNP	_	3	conj
8	were	be	VBD	_	9	auxpass
9	decreased	decrease	VBN	_	0	ROOT
10	by	by	IN	_	12	case
11	22	22	CD	_	12	nummod
12	%	%	NN	_	9	nmod
13	,	,	,	_	12	punct
14	38	38	CD	_	15	nummod
15	%	%	NN	_	12	conj
16	,	,	,	_	12	punct
17	and	and	CC	_	12	cc
18	27	27	CD	_	19	nummod
19	%	%	NN	_	12	conj
20	,	,	,	_	9	punct
21	respectively	respectively	RB	_	9	advmod
22	,	,	,	_	9	punct
23	by	by	IN	_	25	case
24	concomitant	concomitant	JJ	_	25	amod
25	drug2	drug2	NN	_	9	nmod
26	.	.	.	_	9	punct

1	Similar	similar	JJ	_	2	amod
2	decreases	decrease	NNS	_	8	nsubjpass
3	in	in	IN	_	4	case
4	Cmax	cmax	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	AUC	auc	NN	_	4	conj
7	were	be	VBD	_	8	auxpass
8	seen	see	VBN	_	0	ROOT
9	after	after	IN	_	12	case
10	the	the	DT	_	12	det
11	first	first	JJ	_	12	amod
12	dose	dose	NN	_	8	nmod
13	.	.	.	_	8	punct

1	drug1	drug1	NN	_	3	compound
2	steady-state	steady-state	JJ	_	3	amod
3	Cmax	cmax	NN	_	9	nsubjpass
4	,	,	,	_	3	punct
5	A.C.	A.C.	NNP	_	3	conj
6	and	and	CC	_	3	cc
7	Cmin	Cmin	NNP	_	3	conj
8	were	be	VBD	_	9	auxpass
9	increased	increase	VBN	_	0	ROOT
10	21	21	CD	_	11	nummod
11	%	%	NN	_	9	dobj
12	,	,	,	_	9	punct
13	decreased	decrease	VBD	_	9	conj
14	19	19	CD	_	15	nummod
15	%	%	NN	_	13	dobj
16	,	,	,	_	9	punct
17	and	and	CC	_	9	cc
18	decreased	decrease	VBD	_	9	conj
19	48	48	CD	_	20	nummod
20	%	%	NN	_	18	dobj
21	,	,	,	_	9	punct
22	respectively	respectively	RB	_	9	advmod
23	,	,	,	_	9	punct
24	by	by	IN	_	26	case
25	concomitant	concomitant	JJ	_	26	amod
26	drug2	drug2	NN	_	9	nmod
27	.	.	.	_	9	punct

1	drug1	drug1	NN	_	3	compound
2	steady-state	steady-state	JJ	_	3	amod
3	Cmax	cmax	NN	_	9	nsubjpass
4	,	,	,	_	3	punct
5	A.C.	A.C.	NNP	_	3	conj
6	and	and	CC	_	3	cc
7	Cmin	Cmin	NNP	_	3	conj
8	were	be	VBD	_	9	auxpass
9	increased	increase	VBN	_	0	ROOT
10	by	by	IN	_	12	case
11	12	12	CD	_	12	nummod
12	%	%	NN	_	9	nmod
13	,	,	,	_	9	punct
14	15	15	CD	_	15	nummod
15	%	%	NN	_	9	conj
16	,	,	,	_	9	punct
17	and	and	CC	_	9	cc
18	14	14	CD	_	19	nummod
19	%	%	NN	_	9	conj
20	,	,	,	_	19	punct
21	respectively	respectively	RB	_	19	advmod
22	,	,	,	_	19	punct
23	by	by	IN	_	25	case
24	concomitant	concomitant	JJ	_	25	amod
25	drug2	drug2	NN	_	19	nmod
26	.	.	.	_	9	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Coadministration	coadministration	NN	_	9	nsubj
4	of	of	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug3	drug3	NN	_	5	conj
8	can	can	MD	_	9	aux
9	decrease	decrease	VB	_	1	dep
10	plasma	plasma	NN	_	11	compound
11	levels	level	NNS	_	9	dobj
12	of	of	IN	_	13	case
13	drug4	drug4	NN	_	11	nmod
14	.	.	.	_	1	punct

1	Coadministration	coadministration	NN	_	13	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	drug2	drug2	NN	_	3	conj
6	as	as	IN	_	7	mark
7	compared	compare	VBN	_	1	dep
8	to	to	TO	_	12	case
9	a	a	DT	_	12	det
10	non-matched	non-matched	JJ	_	12	amod
11	historicalcontrol	historicalcontrol	NN	_	12	compound
12	group	group	NN	_	7	nmod
13	resulted	result	VBD	_	0	ROOT
14	in	in	IN	_	17	case
15	a	a	DT	_	17	det
16	30	30	CD	_	17	nummod
17	%	%	NN	_	13	nmod
18	,	,	,	_	17	punct
19	27	27	CD	_	20	nummod
20	%	%	NN	_	17	conj
21	,	,	,	_	17	punct
22	and	and	CC	_	17	cc
23	25	25	CD	_	24	compound
24	%	%	NN	_	25	amod
25	decrease	decrease	NN	_	17	conj
26	in	in	IN	_	29	case
27	serum	serum	NN	_	29	compound
28	drug3	drug3	NN	_	29	compound
29	AUC	auc	NN	_	25	nmod
30	,	,	,	_	29	punct
31	Cmax	cmax	NN	_	29	conj
32	,	,	,	_	29	punct
33	andCmin	andcmin	NN	_	29	conj
34	,	,	,	_	29	punct
35	respectively	respectively	RB	_	29	advmod
36	.	.	.	_	13	punct

1	drug1	drug1	NN	_	4	nsubj
2	is	be	VBZ	_	4	cop
3	an	a	DT	_	4	det
4	inhibitor	inhibitor	NN	_	0	ROOT
5	of	of	IN	_	9	case
6	cytochrome	cytochrome	NN	_	9	compound
7	P450	p450	NN	_	9	compound
8	C.P.A.	c.p.a.	NN	_	9	compound
9	metabolism	metabolism	NN	_	4	nmod
10	and	and	CC	_	4	cc
11	therefore	therefore	RB	_	15	advmod
12	should	should	MD	_	15	aux
13	not	not	RB	_	15	neg
14	be	be	VB	_	15	auxpass
15	administered	administer	VBN	_	4	conj
16	concurrently	concurrently	RB	_	15	advmod
17	with	with	IN	_	18	case
18	medications	medication	NNS	_	15	nmod
19	with	with	IN	_	22	case
20	narrow	narrow	JJ	_	22	amod
21	therapeutic	therapeutic	JJ	_	22	amod
22	windows	window	NNS	_	18	nmod
23	that	that	WDT	_	25	nsubj
24	are	be	VBP	_	25	cop
25	substrates	substrate	NNS	_	22	acl:relcl
26	of	of	IN	_	27	case
27	CYP3A4	cyp3a4	NN	_	25	nmod
28	.	.	.	_	4	punct

1	There	there	EX	_	2	expl
2	are	be	VBP	_	0	ROOT
3	other	other	JJ	_	4	amod
4	agents	agent	NNS	_	2	nsubj
5	that	that	WDT	_	7	nsubj
6	may	may	MD	_	7	aux
7	result	result	VB	_	4	acl:relcl
8	in	in	IN	_	13	case
9	serious	serious	JJ	_	13	amod
10	and/or	and/or	CC	_	9	cc
11	life-threatening	life-threatening	JJ	_	9	conj
12	drug	drug	NN	_	13	compound
13	interactions	interaction	NNS	_	7	nmod
14	.	.	.	_	2	punct

1	Laboratory	laboratory	NN	_	2	compound
2	Tests	test	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	The	the	DT	_	5	det
5	combination	combination	NN	_	13	nsubjpass
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	low-dose	low-dose	JJ	_	10	amod
10	drug2	drug2	NN	_	7	conj
11	has	have	VBZ	_	13	aux
12	been	be	VBN	_	13	auxpass
13	associated	associate	VBN	_	2	appos
14	with	with	IN	_	15	case
15	elevations	elevation	NNS	_	13	nmod
16	of	of	IN	_	17	case
17	cholesterol	cholesterol	NN	_	15	nmod
18	and	and	CC	_	17	cc
19	triglycerides	triglyceride	NNS	_	17	conj
20	,	,	,	_	17	punct
21	SGOT	sgot	NN	_	17	conj
22	-LRB-	-lrb-	-LRB-	_	23	punct
23	AST	AST	NNP	_	21	appos
24	-RRB-	-rrb-	-RRB-	_	23	punct
25	,	,	,	_	17	punct
26	and	and	CC	_	17	cc
27	SGPT	sgpt	NN	_	17	conj
28	-LRB-	-lrb-	-LRB-	_	29	punct
29	ALT	alt	NN	_	27	appos
30	-RRB-	-rrb-	-RRB-	_	29	punct
31	in	in	IN	_	33	case
32	some	some	DT	_	33	det
33	patients	patient	NNS	_	15	nmod
34	.	.	.	_	2	punct

1	Appropriate	appropriate	JJ	_	3	amod
2	laboratory	laboratory	NN	_	3	compound
3	testing	testing	NN	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	considered	consider	VBN	_	0	ROOT
7	prior	prior	RB	_	9	advmod
8	to	to	TO	_	9	mark
9	initiating	initiate	VBG	_	6	xcomp
10	combination	combination	NN	_	11	compound
11	therapy	therapy	NN	_	9	dobj
12	with	with	IN	_	13	case
13	drug1	drug1	NN	_	9	nmod
14	and	and	CC	_	13	cc
15	drug2	drug2	NN	_	13	conj
16	and	and	CC	_	9	cc
17	at	at	IN	_	19	case
18	periodic	periodic	JJ	_	19	amod
19	intervals	interval	NNS	_	9	conj
20	or	or	CC	_	19	cc
21	if	if	IN	_	34	mark
22	any	any	DT	_	24	det
23	clinical	clinical	JJ	_	24	amod
24	signs	sign	NNS	_	34	nsubj
25	or	or	CC	_	24	cc
26	symptoms	symptom	NNS	_	24	conj
27	of	of	IN	_	28	case
28	hyperlipidemia	hyperlipidemia	NN	_	26	nmod
29	or	or	CC	_	28	cc
30	elevated	elevated	JJ	_	33	amod
31	liver	liver	NN	_	33	compound
32	function	function	NN	_	33	compound
33	tests	test	NNS	_	28	conj
34	occur	occur	VBP	_	19	conj
35	during	during	IN	_	36	case
36	therapy	therapy	NN	_	34	nmod
37	.	.	.	_	6	punct

1	For	for	IN	_	3	case
2	comprehensive	comprehensive	JJ	_	3	amod
3	information	information	NN	_	14	nmod
4	concerning	concern	VBG	_	7	case
5	laboratory	laboratory	NN	_	7	compound
6	test	test	NN	_	7	compound
7	alterations	alteration	NNS	_	3	nmod
8	associated	associate	VBN	_	7	acl
9	with	with	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	,	,	,	_	14	punct
12	physicians	physician	NNS	_	14	nsubj
13	should	should	MD	_	14	aux
14	refer	refer	VB	_	0	ROOT
15	to	to	TO	_	19	case
16	the	the	DT	_	19	det
17	complete	complete	JJ	_	19	amod
18	prescribing	prescribe	VBG	_	19	amod
19	information	information	NN	_	14	nmod
20	for	for	IN	_	21	case
21	drug2	drug2	NN	_	19	nmod
22	-LRB-	-lrb-	-LRB-	_	23	punct
23	drug3	drug3	NN	_	21	appos
24	-RRB-	-rrb-	-RRB-	_	23	punct
25	.	.	.	_	14	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	5	nsubjpass
4	were	be	VBD	_	5	auxpass
5	conducted	conduct	VBN	_	0	ROOT
6	to	to	TO	_	7	mark
7	investigate	investigate	VB	_	5	xcomp
8	the	the	DT	_	9	det
9	potential	potential	NN	_	7	dobj
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	to	to	TO	_	13	mark
13	inhibit	inhibit	VB	_	9	acl
14	the	the	DT	_	18	det
15	major	major	JJ	_	18	amod
16	cytochrome	cytochrome	NN	_	18	compound
17	P450	p450	NN	_	18	compound
18	enzymes	enzyme	NNS	_	13	dobj
19	-LRB-	-lrb-	-LRB-	_	20	punct
20	CYP1A2	cyp1a2	NN	_	18	dep
21	,	,	,	_	20	punct
22	CYP2A6	cyp2a6	NN	_	20	conj
23	,	,	,	_	20	punct
24	CYP2C9	cyp2c9	NN	_	20	conj
25	,	,	,	_	20	punct
26	CYP2C19	cyp2c19	NN	_	20	conj
27	,	,	,	_	20	punct
28	CYP2D6	cyp2d6	NN	_	20	conj
29	,	,	,	_	20	punct
30	CYP2E1	cyp2e1	NN	_	20	conj
31	,	,	,	_	20	punct
32	and	and	CC	_	20	cc
33	CYP3A4	cyp3a4	NN	_	20	conj
34	-RRB-	-rrb-	-RRB-	_	20	punct
35	that	that	WDT	_	36	nsubj
36	mediate	mediate	VBP	_	18	acl:relcl
37	drug	drug	NN	_	40	compound
38	and	and	CC	_	37	cc
39	xenobiotic	xenobiotic	JJ	_	37	conj
40	metabolism	metabolism	NN	_	36	dobj
41	using	use	VBG	_	36	xcomp
42	isoform	isoform	NN	_	45	compound
43	selective	selective	JJ	_	45	amod
44	marker	marker	NN	_	45	compound
45	substrates	substrate	NNS	_	41	dobj
46	and	and	CC	_	45	cc
47	human	human	JJ	_	50	amod
48	liver	liver	NN	_	50	compound
49	microsomal	microsomal	JJ	_	50	amod
50	preparations	preparation	NNS	_	45	conj
51	.	.	.	_	5	punct

1	Only	only	RB	_	5	advmod
2	at	at	IN	_	5	case
3	the	the	DT	_	5	det
4	highest	highest	JJS	_	5	amod
5	concentration	concentration	NN	_	0	ROOT
6	tested	test	VBN	_	5	acl
7	-LRB-	-lrb-	-LRB-	_	8	punct
8	171	171	CD	_	5	nummod

1	g/mL	g/ml	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	1	1	CD	_	2	nummod
2	mM	mm	NN	_	7	nsubj
3	-RRB-	-rrb-	-RRB-	_	2	punct
4	was	be	VBD	_	7	cop
5	a	a	DT	_	7	det
6	slight	slight	JJ	_	7	amod
7	degree	degree	NN	_	0	ROOT
8	of	of	IN	_	9	case
9	inhibition	inhibition	NN	_	7	nmod
10	-LRB-	-lrb-	-LRB-	_	12	punct
11	14	14	CD	_	12	nummod
12	%	%	NN	_	7	dep
13	-30	-30	CD	_	14	nummod
14	%	%	NN	_	12	dep
15	-RRB-	-rrb-	-RRB-	_	12	punct
16	of	of	IN	_	18	case
17	isoform	isoform	NN	_	18	compound
18	CYP2A6	cyp2a6	NN	_	7	nmod
19	observed	observe	VBN	_	18	acl
20	.	.	.	_	7	punct

1	No	no	DT	_	2	neg
2	inhibition	inhibition	NN	_	11	nsubjpass
3	of	of	IN	_	4	case
4	any	any	DT	_	2	nmod
5	of	of	IN	_	8	case
6	the	the	DT	_	8	det
7	other	other	JJ	_	8	amod
8	isoforms	isoform	NNS	_	4	nmod
9	tested	test	VBN	_	8	acl
10	was	be	VBD	_	11	auxpass
11	observed	observe	VBN	_	0	ROOT
12	at	at	IN	_	14	case
13	drug1	drug1	NN	_	14	compound
14	concentrations	concentration	NNS	_	11	nmod
15	up	up	IN	_	17	advmod
16	to	to	TO	_	17	dep
17	171	171	CD	_	18	nummod
18	mg/mL	mg/ml	NN	_	11	dep
19	-LRB-	-lrb-	-LRB-	_	24	punct
20	approximately	approximately	RB	_	22	advmod
21	15	15	CD	_	22	compound
22	times	time	NNS	_	24	nummod
23	the	the	DT	_	24	det
24	Cmax	cmax	NN	_	18	dep
25	at	at	IN	_	27	case
26	3600	3600	CD	_	27	nummod
27	mg/day	mg/day	NN	_	24	nmod
28	-RRB-	-rrb-	-RRB-	_	24	punct
29	.	.	.	_	11	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	is	be	VBZ	_	5	auxpass
3	not	not	RB	_	5	neg
4	appreciably	appreciably	RB	_	5	advmod
5	metabolized	metabolize	VBN	_	0	ROOT
6	nor	nor	CC	_	5	cc
7	does	do	VBZ	_	9	aux
8	it	it	PRP	_	9	nsubj
9	interfere	interfere	VB	_	5	conj
10	with	with	IN	_	12	case
11	the	the	DT	_	12	det
12	metabolism	metabolism	NN	_	9	nmod
13	of	of	IN	_	16	case
14	commonly	commonly	RB	_	15	advmod
15	coadministered	coadminister	VBN	_	16	amod
16	drug2	drug2	NN	_	12	nmod
17	.	.	.	_	5	punct

1	The	the	DT	_	4	det
2	drug	drug	NN	_	4	compound
3	interaction	interaction	NN	_	4	compound
4	data	datum	NNS	_	10	nsubjpass
5	described	describe	VBN	_	4	acl
6	in	in	IN	_	8	case
7	this	this	DT	_	8	det
8	section	section	NN	_	5	nmod
9	were	be	VBD	_	10	auxpass
10	obtained	obtain	VBN	_	0	ROOT
11	from	from	IN	_	12	case
12	studies	study	NNS	_	10	nmod
13	involving	involve	VBG	_	12	acl
14	healthy	healthy	JJ	_	15	amod
15	adults	adult	NNS	_	13	dobj
16	and	and	CC	_	15	cc
17	adult	adult	JJ	_	18	amod
18	patients	patient	NNS	_	15	conj
19	with	with	IN	_	20	case
20	epilepsy	epilepsy	NN	_	18	nmod
21	.	.	.	_	10	punct

1	drug1	drug1	NN	_	53	nsubj
2	:	:	:	_	1	punct
3	In	in	IN	_	12	case
4	a	a	DT	_	12	det
5	single	single	JJ	_	12	amod
6	-LRB-	-lrb-	-LRB-	_	8	punct
7	400	400	CD	_	8	nummod
8	mg	mg	NN	_	5	dep
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	and	and	CC	_	5	cc
11	multiple	multiple	JJ	_	5	conj
12	dose	dose	NN	_	1	nmod
13	-LRB-	-lrb-	-LRB-	_	16	punct
14	400	400	CD	_	16	nummod
15	mg	mg	NN	_	16	compound
16	TID	tid	NN	_	12	appos
17	-RRB-	-rrb-	-RRB-	_	16	punct
18	study	study	NN	_	12	amod
19	of	of	IN	_	20	case
20	drug2	drug2	NN	_	18	nmod
21	in	in	IN	_	23	case
22	epileptic	epileptic	JJ	_	23	amod
23	patients	patient	NNS	_	18	nmod
24	-LRB-	-lrb-	-LRB-	_	26	punct
25	N	n	NN	_	26	nsubj
26	=	=	JJ	_	23	dep
27	8	8	CD	_	26	dobj
28	-RRB-	-rrb-	-RRB-	_	26	punct
29	maintained	maintain	VBN	_	23	acl
30	on	on	IN	_	32	case
31	drug3	drug3	NN	_	32	compound
32	monotherapy	monotherapy	NN	_	29	nmod
33	for	for	IN	_	37	case
34	at	at	IN	_	35	case
35	least	least	JJS	_	36	nmod:npmod
36	2	2	CD	_	37	nummod
37	months	month	NNS	_	29	nmod
38	,	,	,	_	1	punct
39	drug4	drug4	NN	_	40	nsubj
40	had	have	VBD	_	1	acl:relcl
41	no	no	DT	_	42	neg
42	effect	effect	NN	_	40	dobj
43	on	on	IN	_	48	case
44	the	the	DT	_	48	det
45	steady-state	steady-state	JJ	_	48	amod
46	trough	trough	NN	_	48	compound
47	plasma	plasma	NN	_	48	compound
48	concentrations	concentration	NNS	_	40	nmod
49	of	of	IN	_	50	case
50	drug5	drug5	NN	_	48	nmod
51	and	and	CC	_	50	cc
52	drug6	drug6	NN	_	50	conj
53	had	have	VBD	_	0	ROOT
54	no	no	DT	_	55	neg
55	effect	effect	NN	_	53	dobj
56	on	on	IN	_	58	case
57	drug7	drug7	NN	_	58	compound
58	pharmacokinetics	pharmacokinetic	NNS	_	53	nmod
59	.	.	.	_	53	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Steady-state	steady-state	JJ	_	6	amod
4	trough	trough	NN	_	6	compound
5	plasma	plasma	NN	_	6	compound
6	drug2	drug2	NN	_	12	nsubjpass
7	and	and	CC	_	6	cc
8	drug3	drug3	NN	_	9	compound
9	concentrations	concentration	NNS	_	6	conj
10	were	be	VBD	_	12	auxpass
11	not	not	RB	_	12	neg
12	affected	affect	VBN	_	1	dep
13	by	by	IN	_	15	case
14	concomitant	concomitant	JJ	_	15	amod
15	drug4	drug4	NN	_	12	nmod
16	-LRB-	-lrb-	-LRB-	_	19	punct
17	400	400	CD	_	19	nummod
18	mg	mg	NN	_	19	compound
19	TID	tid	NN	_	15	appos
20	;	;	:	_	19	punct

1	N	n	NN	_	2	nsubj
2	=	=	JJ	_	0	ROOT
3	12	12	CD	_	2	dobj
4	-RRB-	-rrb-	-RRB-	_	2	punct
5	administration	administration	NN	_	2	dep
6	.	.	.	_	2	punct

1	Likewise	likewise	RB	_	6	advmod
2	,	,	,	_	6	punct
3	drug1	drug1	NN	_	4	compound
4	pharmacokinetics	pharmacokinetic	NNS	_	6	nsubj
5	were	be	VBD	_	6	cop
6	unaltered	unaltered	JJ	_	0	ROOT
7	by	by	IN	_	9	case
8	drug2	drug2	NN	_	9	compound
9	administration	administration	NN	_	6	nmod
10	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	9	det
4	mean	mean	NN	_	9	compound
5	steady-state	steady-state	JJ	_	9	amod
6	trough	trough	NN	_	9	compound
7	serum	serum	NN	_	9	compound
8	drug2	drug2	NN	_	9	compound
9	concentrations	concentration	NNS	_	1	dep
10	prior	prior	RB	_	9	advmod
11	to	to	TO	_	16	case
12	and	and	CC	_	11	cc
13	during	during	IN	_	11	conj
14	concomitant	concomitant	JJ	_	16	amod
15	drug3	drug3	NN	_	16	compound
16	administration	administration	NN	_	10	nmod
17	-LRB-	-lrb-	-LRB-	_	20	punct
18	400	400	CD	_	20	nummod
19	mg	mg	NN	_	20	compound
20	TID	tid	NN	_	16	appos
21	;	;	:	_	20	punct

1	N	n	NN	_	7	nsubj
2	=	=	JJ	_	1	amod
3	17	17	CD	_	2	dep
4	-RRB-	-rrb-	-RRB-	_	1	punct
5	were	be	VBD	_	7	cop
6	not	not	RB	_	7	neg
7	different	different	JJ	_	0	ROOT
8	and	and	CC	_	7	cc
9	neither	neither	CC	_	13	nsubj
10	were	be	VBD	_	13	cop
11	drug1	drug1	CD	_	13	nummod
12	pharmacokinetic	pharmacokinetic	JJ	_	13	amod
13	parameters	parameter	NNS	_	7	conj
14	affected	affect	VBN	_	13	acl
15	by	by	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	.	.	.	_	7	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Estimates	estimate	NNS	_	1	dep
4	of	of	IN	_	7	case
5	steady-state	steady-state	JJ	_	7	amod
6	pharmacokinetic	pharmacokinetic	JJ	_	7	amod
7	parameters	parameter	NNS	_	3	nmod
8	for	for	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	or	or	CC	_	9	cc
11	drug3	drug3	NN	_	15	compound
12	-LRB-	-lrb-	-LRB-	_	15	punct
13	300	300	CD	_	15	nummod
14	mg	mg	NN	_	15	compound
15	TID	tid	NN	_	9	conj
16	;	;	:	_	1	punct

1	N	n	NN	_	6	nsubj
2	=	=	JJ	_	1	amod
3	12	12	CD	_	2	dep
4	-RRB-	-rrb-	-RRB-	_	1	punct
5	are	be	VBP	_	6	cop
6	identical	identical	JJ	_	0	ROOT
7	whether	whether	IN	_	11	mark
8	the	the	DT	_	9	det
9	drugs	drug	NNS	_	11	nsubjpass
10	are	be	VBP	_	11	auxpass
11	administered	administer	VBN	_	6	ccomp
12	alone	alone	RB	_	11	advmod
13	or	or	CC	_	11	cc
14	together	together	RB	_	11	conj
15	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Coadministration	coadministration	NN	_	22	nsubj
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	N	n	NN	_	3	dep
6	=	=	JJ	_	5	amod
7	18	18	CD	_	6	dep
8	-RRB-	-rrb-	-RRB-	_	5	punct
9	of	of	IN	_	11	case
10	drug2	drug2	NN	_	11	compound
11	capsules	capsule	NNS	_	3	nmod
12	-LRB-	-lrb-	-LRB-	_	14	punct
13	250	250	CD	_	14	nummod
14	mg	mg	NN	_	11	appos
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	with	with	IN	_	17	case
17	drug3	drug3	NN	_	3	nmod
18	-LRB-	-lrb-	-LRB-	_	20	punct
19	125	125	CD	_	20	nummod
20	mg	mg	NN	_	17	appos
21	-RRB-	-rrb-	-RRB-	_	20	punct
22	appears	appear	VBZ	_	1	appos
23	to	to	TO	_	24	mark
24	increase	increase	VB	_	22	xcomp
25	the	the	DT	_	26	det
26	amount	amount	NN	_	24	dobj
27	of	of	IN	_	28	case
28	drug4	drug4	NN	_	26	nmod
29	absorbed	absorb	VBN	_	26	acl
30	by	by	IN	_	29	advmod
31	12	12	CD	_	30	dobj
32	%	%	NN	_	31	advmod
33	to	to	TO	_	35	case
34	15	15	CD	_	35	nummod
35	%	%	NN	_	32	nmod
36	.	.	.	_	1	punct

1	drug1	drug1	NN	_	2	nsubj
2	had	have	VBD	_	0	ROOT
3	no	no	DT	_	4	neg
4	effect	effect	NN	_	2	dobj
5	on	on	IN	_	8	case
6	drug2	drug2	NN	_	8	compound
7	pharmacokinetic	pharmacokinetic	JJ	_	8	amod
8	parameters	parameter	NNS	_	2	nmod
9	.	.	.	_	2	punct

1	These	these	DT	_	2	det
2	doses	dose	NNS	_	4	nsubj
3	are	be	VBP	_	4	cop
4	lower	lower	JJR	_	0	ROOT
5	than	than	IN	_	8	case
6	the	the	DT	_	8	det
7	therapeutic	therapeutic	JJ	_	8	amod
8	doses	dose	NNS	_	4	nmod
9	for	for	IN	_	11	case
10	both	both	DT	_	11	det
11	drugs	drug	NNS	_	8	nmod
12	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	magnitude	magnitude	NN	_	15	nsubjpass
3	of	of	IN	_	4	case
4	interaction	interaction	NN	_	2	nmod
5	within	within	IN	_	9	case
6	the	the	DT	_	9	det
7	recommended	recommend	VBN	_	9	amod
8	dose	dose	NN	_	9	compound
9	ranges	range	NNS	_	4	nmod
10	of	of	IN	_	12	case
11	either	either	CC	_	12	det
12	drug	drug	NN	_	9	nmod
13	is	be	VBZ	_	15	auxpass
14	not	not	RB	_	15	neg
15	known	know	VBN	_	0	ROOT
16	.	.	.	_	15	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Coadministration	coadministration	NN	_	1	dep
4	of	of	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	-LRB-	-lrb-	-LRB-	_	10	punct
7	125	125	CD	_	9	compound
8	to	to	TO	_	9	dep
9	500	500	CD	_	10	nummod
10	mg	mg	NN	_	5	appos
11	;	;	:	_	10	punct

1	N	n	NN	_	5	nsubj
2	=	=	JJ	_	1	amod
3	48	48	CD	_	2	dep
4	-RRB-	-rrb-	-RRB-	_	1	punct
5	decreases	decrease	VBZ	_	0	ROOT
6	drug1	drug1	NN	_	9	compound
7	-LRB-	-lrb-	-LRB-	_	9	punct
8	10	10	CD	_	9	nummod
9	mg	mg	NN	_	5	dobj
10	;	;	:	_	5	punct

1	N	n	NN	_	2	nsubj
2	=	=	JJ	_	0	ROOT
3	50	50	CD	_	2	dobj
4	-RRB-	-rrb-	-RRB-	_	2	punct
5	Cmax	cmax	NN	_	8	compound
6	and	and	CC	_	5	cc
7	AUC	auc	NN	_	5	conj
8	values	value	NNS	_	2	dep
9	in	in	IN	_	12	case
10	a	a	DT	_	12	det
11	dose-dependent	dose-dependent	JJ	_	12	amod
12	manner	manner	NN	_	2	nmod
13	relative	relative	JJ	_	2	dep
14	to	to	TO	_	15	case
15	administration	administration	NN	_	13	nmod
16	of	of	IN	_	17	case
17	drug1	drug1	NN	_	15	nmod
18	alone	alone	RB	_	15	advmod
19	;	;	:	_	2	punct

1	Cmax	cmax	NN	_	4	compound
2	and	and	CC	_	1	cc
3	AUC	auc	NN	_	1	conj
4	values	value	NNS	_	11	nsubj
5	are	be	VBP	_	11	cop
6	3	3	CD	_	10	compound
7	%	%	NN	_	10	dep
8	to	to	TO	_	10	dep
9	4	4	CD	_	10	compound
10	%	%	NN	_	11	nmod:npmod
11	lower	lower	JJR	_	0	ROOT
12	,	,	,	_	11	punct
13	respectively	respectively	RB	_	11	advmod
14	,	,	,	_	11	punct
15	after	after	IN	_	16	case
16	administration	administration	NN	_	11	nmod
17	of	of	IN	_	20	case
18	125	125	CD	_	19	compound
19	mg	mg	NN	_	20	amod
20	drug1	drug1	NN	_	16	nmod
21	and	and	CC	_	16	cc
22	21	21	CD	_	26	compound
23	%	%	NN	_	26	dep
24	to	to	TO	_	26	dep
25	22	22	CD	_	26	compound
26	%	%	NN	_	27	nmod:npmod
27	lower	lower	JJR	_	16	conj
28	,	,	,	_	11	punct
29	respectively	respectively	RB	_	11	advmod
30	,	,	,	_	11	punct
31	after	after	IN	_	32	case
32	administration	administration	NN	_	11	nmod
33	of	of	IN	_	36	case
34	500	500	CD	_	36	nummod
35	mg	mg	NN	_	36	compound
36	drug2	drug2	NN	_	32	nmod
37	.	.	.	_	11	punct

1	The	the	DT	_	2	det
2	mechanism	mechanism	NN	_	7	nsubj
3	for	for	IN	_	5	case
4	this	this	DT	_	5	det
5	interaction	interaction	NN	_	2	nmod
6	is	be	VBZ	_	7	cop
7	unknown	unknown	JJ	_	0	ROOT
8	.	.	.	_	7	punct

1	drug1	drug1	NN	_	2	nsubj
2	increases	increase	VBZ	_	0	ROOT
3	drug2	drug2	NN	_	5	compound
4	AUC	auc	NN	_	5	compound
5	values	value	NNS	_	2	dobj
6	by	by	IN	_	8	case
7	14	14	CD	_	8	nummod
8	%	%	NN	_	2	nmod
9	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	magnitude	magnitude	NN	_	10	nsubjpass
3	of	of	IN	_	4	case
4	interaction	interaction	NN	_	2	nmod
5	at	at	IN	_	7	case
6	other	other	JJ	_	7	amod
7	doses	dose	NNS	_	4	nmod
8	is	be	VBZ	_	10	auxpass
9	not	not	RB	_	10	neg
10	known	know	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	A	a	DT	_	5	det
4	literature	literature	NN	_	5	compound
5	article	article	NN	_	1	dep
6	reported	report	VBD	_	5	acl
7	that	that	IN	_	30	mark
8	when	when	WRB	_	15	advmod
9	a	a	DT	_	13	det
10	60-mg	60-mg	JJ	_	13	amod
11	controlled-release	controlled-release	NN	_	13	compound
12	drug2	drug2	NN	_	13	compound
13	capsule	capsule	NN	_	15	nsubjpass
14	was	be	VBD	_	15	auxpass
15	administered	administer	VBN	_	30	advcl
16	2	2	CD	_	17	nummod
17	hours	hour	NNS	_	15	dobj
18	prior	prior	RB	_	23	advmod
19	to	to	TO	_	23	case
20	a	a	DT	_	23	det
21	600-mg	600-mg	JJ	_	23	amod
22	drug3	drug3	NN	_	23	compound
23	capsule	capsule	NN	_	17	nmod
24	-LRB-	-lrb-	-LRB-	_	26	punct
25	N	n	NN	_	26	nsubj
26	=	=	JJ	_	23	dep
27	12	12	CD	_	26	dobj
28	-RRB-	-rrb-	-RRB-	_	26	punct
29	,	,	,	_	30	punct
30	mean	mean	VB	_	6	ccomp
31	drug4	drug4	NN	_	32	compound
32	AUC	auc	NN	_	33	nsubj
33	increased	increase	VBN	_	30	ccomp
34	by	by	IN	_	36	case
35	44	44	CD	_	36	nummod
36	%	%	NN	_	33	nmod
37	compared	compare	VBN	_	33	dep
38	to	to	TO	_	40	mark
39	drug5	drug5	VB	_	40	auxpass
40	administered	administer	VBN	_	37	xcomp
41	without	without	IN	_	42	case
42	drug6	drug6	NN	_	40	nmod
43	.	.	.	_	1	punct

1	drug1	drug1	NN	_	4	compound
2	pharmacokinetic	pharmacokinetic	JJ	_	4	amod
3	parameter	parameter	NN	_	4	compound
4	values	value	NNS	_	7	nsubjpass
5	were	be	VBD	_	7	auxpass
6	not	not	RB	_	7	neg
7	affected	affect	VBN	_	0	ROOT
8	by	by	IN	_	9	case
9	administration	administration	NN	_	7	nmod
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	2	2	CD	_	13	nummod
13	hours	hour	NNS	_	11	nmod
14	after	after	IN	_	13	case
15	drug3	drug3	NN	_	13	dep
16	.	.	.	_	7	punct

1	The	the	DT	_	2	det
2	magnitude	magnitude	NN	_	10	nsubjpass
3	of	of	IN	_	4	case
4	interaction	interaction	NN	_	2	nmod
5	at	at	IN	_	7	case
6	other	other	JJ	_	7	amod
7	doses	dose	NNS	_	4	nmod
8	is	be	VBZ	_	10	auxpass
9	not	not	RB	_	10	neg
10	known	know	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	5	case
4	the	the	DT	_	5	det
5	presence	presence	NN	_	24	nmod
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	at	at	IN	_	11	case
9	300	300	CD	_	11	nummod
10	mg	mg	NN	_	11	compound
11	QID	qid	NN	_	24	nmod
12	-LRB-	-lrb-	-LRB-	_	14	punct
13	N	n	NN	_	14	nsubj
14	=	=	JJ	_	11	dep
15	12	12	CD	_	14	dobj
16	-RRB-	-rrb-	-RRB-	_	14	punct
17	the	the	DT	_	21	det
18	mean	mean	NN	_	21	compound
19	apparent	apparent	JJ	_	21	amod
20	oral	oral	JJ	_	21	amod
21	clearance	clearance	NN	_	24	nsubj
22	of	of	IN	_	23	case
23	drug3	drug3	NN	_	21	nmod
24	fell	fall	VBD	_	1	dep
25	by	by	IN	_	27	case
26	14	14	CD	_	27	nummod
27	%	%	NN	_	24	nmod
28	and	and	CC	_	24	cc
29	creatinine	creatinine	NN	_	30	compound
30	clearance	clearance	NN	_	31	nsubj
31	fell	fall	VBD	_	24	conj
32	by	by	IN	_	34	case
33	10	10	CD	_	34	nummod
34	%	%	NN	_	31	nmod
35	.	.	.	_	1	punct

1	Thus	thus	RB	_	3	advmod
2	drug1	drug1	NN	_	3	nsubj
3	appeared	appear	VBD	_	0	ROOT
4	to	to	TO	_	5	mark
5	alter	alter	VB	_	3	xcomp
6	the	the	DT	_	8	det
7	renal	renal	JJ	_	8	amod
8	excretion	excretion	NN	_	5	dobj
9	of	of	IN	_	11	case
10	both	both	CC	_	11	cc:preconj
11	drug2	drug2	NN	_	8	nmod
12	and	and	CC	_	11	cc
13	creatinine	creatinine	NN	_	11	conj
14	,	,	,	_	8	punct
15	an	a	DT	_	17	det
16	endogenous	endogenous	JJ	_	17	amod
17	marker	marker	NN	_	8	appos
18	of	of	IN	_	20	case
19	renal	renal	JJ	_	20	amod
20	function	function	NN	_	17	nmod
21	.	.	.	_	3	punct

1	This	this	DT	_	3	det
2	small	small	JJ	_	3	amod
3	decrease	decrease	NN	_	12	nsubjpass
4	in	in	IN	_	5	case
5	excretion	excretion	NN	_	3	nmod
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	by	by	IN	_	9	case
9	drug2	drug2	NN	_	3	nmod
10	is	be	VBZ	_	12	auxpass
11	not	not	RB	_	12	neg
12	expected	expect	VBN	_	0	ROOT
13	to	to	TO	_	17	mark
14	be	be	VB	_	17	cop
15	of	of	IN	_	17	case
16	clinical	clinical	JJ	_	17	amod
17	importance	importance	NN	_	12	xcomp
18	.	.	.	_	12	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	9	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	on	on	IN	_	6	case
6	drug2	drug2	NN	_	2	nmod
7	was	be	VBD	_	9	auxpass
8	not	not	RB	_	9	neg
9	evaluated	evaluate	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	Oral	oral	JJ	_	2	amod
2	drug1	drug1	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	Based	base	VBN	_	6	case
5	on	on	IN	_	6	case
6	AUC	auc	NN	_	32	nmod
7	and	and	CC	_	6	cc
8	half-life	half-life	NN	_	6	conj
9	,	,	,	_	6	punct
10	multiple-dose	multiple-dose	JJ	_	12	amod
11	pharmacokinetic	pharmacokinetic	JJ	_	12	amod
12	profiles	profile	NNS	_	6	conj
13	of	of	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	and	and	CC	_	14	cc
16	drug3	drug3	NN	_	14	conj
17	following	follow	VBG	_	18	case
18	administration	administration	NN	_	12	nmod
19	of	of	IN	_	20	case
20	tablets	tablet	NNS	_	18	nmod
21	containing	contain	VBG	_	20	acl
22	2.5	2.5	CD	_	23	nummod
23	mg	mg	NN	_	21	dobj
24	of	of	IN	_	25	case
25	drug4	drug4	NN	_	23	nmod
26	and	and	CC	_	23	cc
27	50	50	CD	_	28	nummod
28	mcg	mcg	NN	_	23	conj
29	of	of	IN	_	30	case
30	drug5	drug5	NN	_	28	nmod
31	were	be	VBD	_	32	cop
32	similar	similar	JJ	_	2	dep
33	with	with	IN	_	32	dep
34	and	and	CC	_	33	cc
35	without	without	IN	_	36	case
36	coadministration	coadministration	NN	_	34	nmod
37	of	of	IN	_	38	case
38	drug6	drug6	NN	_	36	nmod
39	-LRB-	-lrb-	-LRB-	_	42	punct
40	400	400	CD	_	42	nummod
41	mg	mg	NN	_	42	compound
42	TID	tid	NN	_	36	appos
43	;	;	:	_	42	punct

1	N	n	NN	_	2	nsubj
2	=	=	JJ	_	0	ROOT
3	13	13	CD	_	2	dobj
4	-RRB-	-rrb-	-RRB-	_	2	punct
5	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	Cmax	cmax	NN	_	8	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	was	be	VBD	_	8	cop
6	13	13	CD	_	7	nummod
7	%	%	NN	_	8	nmod:npmod
8	higher	higher	JJR	_	0	ROOT
9	when	when	WRB	_	12	advmod
10	it	it	PRP	_	12	nsubjpass
11	was	be	VBD	_	12	auxpass
12	coadministered	coadminister	VBN	_	8	advcl
13	with	with	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	;	;	:	_	8	punct

1	this	this	DT	_	2	det
2	interaction	interaction	NN	_	5	nsubjpass
3	is	be	VBZ	_	5	auxpass
4	not	not	RB	_	5	neg
5	expected	expect	VBN	_	0	ROOT
6	to	to	TO	_	10	mark
7	be	be	VB	_	10	cop
8	of	of	IN	_	10	case
9	clinical	clinical	JJ	_	10	amod
10	importance	importance	NN	_	5	xcomp
11	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	drug2	drug2	NN	_	1	appos
4	-RRB-	-rrb-	-RRB-	_	3	punct
5	:	:	:	_	1	punct
6	drug3	drug3	NN	_	7	nsubj
7	reduced	reduce	VBD	_	1	dep
8	the	the	DT	_	9	det
9	bioavailability	bioavailability	NN	_	7	dobj
10	of	of	IN	_	11	case
11	drug4	drug4	NN	_	9	nmod
12	-LRB-	-lrb-	-LRB-	_	14	punct
13	N	n	NN	_	14	nsubj
14	=	=	JJ	_	11	dep
15	16	16	CD	_	14	dobj
16	-RRB-	-rrb-	-RRB-	_	14	punct
17	by	by	IN	_	20	case
18	about	about	RB	_	19	advmod
19	20	20	CD	_	20	nummod
20	%	%	NN	_	7	nmod
21	.	.	.	_	1	punct

1	This	this	DT	_	2	det
2	decrease	decrease	NN	_	8	nsubj
3	in	in	IN	_	4	case
4	bioavailability	bioavailability	NN	_	2	nmod
5	was	be	VBD	_	8	cop
6	about	about	IN	_	7	advmod
7	5	5	CD	_	8	nummod
8	%	%	NN	_	0	ROOT
9	when	when	WRB	_	12	advmod
10	drug1	drug1	NN	_	12	nsubjpass
11	was	be	VBD	_	12	auxpass
12	administered	administer	VBN	_	8	advcl
13	2	2	CD	_	14	nummod
14	hours	hour	NNS	_	12	nmod
15	after	after	IN	_	14	case
16	drug2	drug2	NN	_	14	dep
17	.	.	.	_	8	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	recommended	recommend	VBN	_	0	ROOT
4	that	that	IN	_	7	mark
5	drug1	drug1	NN	_	7	nsubjpass
6	be	be	VB	_	7	auxpass
7	taken	take	VBN	_	3	ccomp
8	at	at	IN	_	9	case
9	least	least	JJS	_	10	nmod:npmod
10	2	2	CD	_	11	nummod
11	hours	hour	NNS	_	7	dobj
12	following	follow	VBG	_	14	case
13	drug2	drug2	NN	_	14	compound
14	administration	administration	NN	_	7	nmod
15	.	.	.	_	3	punct

1	Effect	effect	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	:	:	:	_	1	punct
5	drug2	drug2	NN	_	8	nsubj
6	is	be	VBZ	_	8	cop
7	a	a	DT	_	8	det
8	blocker	blocker	NN	_	1	dep
9	of	of	IN	_	12	case
10	renal	renal	JJ	_	12	amod
11	tubular	tubular	JJ	_	12	amod
12	secretion	secretion	NN	_	8	nmod
13	.	.	.	_	8	punct

1	drug1	drug1	NN	_	3	compound
2	pharmacokinetic	pharmacokinetic	JJ	_	3	amod
3	parameters	parameter	NNS	_	9	nsubj
4	without	without	IN	_	7	case
5	and	and	CC	_	4	cc
6	with	with	IN	_	4	conj
7	drug2	drug2	NN	_	3	nmod
8	were	be	VBD	_	9	cop
9	comparable	comparable	JJ	_	0	ROOT
10	.	.	.	_	9	punct

1	This	this	DT	_	2	nsubj
2	indicates	indicate	VBZ	_	0	ROOT
3	that	that	IN	_	7	mark
4	drug1	drug1	NN	_	7	nsubj
5	does	do	VBZ	_	7	aux
6	not	not	RB	_	7	neg
7	undergo	undergo	VB	_	2	ccomp
8	renal	renal	JJ	_	10	amod
9	tubular	tubular	JJ	_	10	amod
10	secretion	secretion	NN	_	7	dobj
11	by	by	IN	_	13	case
12	the	the	DT	_	13	det
13	pathway	pathway	NN	_	7	nmod
14	that	that	WDT	_	16	nsubjpass
15	is	be	VBZ	_	16	auxpass
16	blocked	block	VBN	_	13	acl:relcl
17	by	by	IN	_	18	case
18	drug2	drug2	NN	_	16	nmod
19	.	.	.	_	2	punct

1	Drug/Laboratory	Drug/Laboratory	NNP	_	3	compound
2	Tests	Tests	NNP	_	3	compound
3	Interactions	interaction	NNS	_	36	nsubjpass
4	Because	because	IN	_	9	mark
5	false	false	JJ	_	7	amod
6	positive	positive	JJ	_	7	amod
7	readings	reading	NNS	_	9	nsubjpass
8	were	be	VBD	_	9	auxpass
9	reported	report	VBN	_	36	advcl
10	with	with	IN	_	16	case
11	the	the	DT	_	16	det
12	Ames	Ames	NNP	_	16	compound
13	N-Multistix	N-Multistix	NNP	_	16	compound
14	SG	SG	NNP	_	16	compound
15	dipstick	dipstick	NN	_	16	compound
16	test	test	NN	_	9	nmod
17	for	for	IN	_	19	case
18	urinary	urinary	JJ	_	19	amod
19	protein	protein	NN	_	16	nmod
20	when	when	WRB	_	23	advmod
21	drug1	drug1	NN	_	23	nsubjpass
22	was	be	VBD	_	23	auxpass
23	added	add	VBN	_	9	advcl
24	to	to	TO	_	26	case
25	other	other	JJ	_	26	amod
26	drug2	drug2	NN	_	23	nmod
27	,	,	,	_	36	punct
28	the	the	DT	_	34	det
29	more	more	RBR	_	30	advmod
30	specific	specific	JJ	_	34	amod
31	sulfosalicylic	sulfosalicylic	JJ	_	34	amod
32	acid	acid	NN	_	34	compound
33	precipitation	precipitation	NN	_	34	compound
34	procedure	procedure	NN	_	36	nsubjpass
35	is	be	VBZ	_	36	auxpass
36	recommended	recommend	VBN	_	0	ROOT
37	to	to	TO	_	38	mark
38	determine	determine	VB	_	36	xcomp
39	the	the	DT	_	40	det
40	presence	presence	NN	_	38	dobj
41	of	of	IN	_	43	case
42	urine	urine	NN	_	43	compound
43	protein	protein	NN	_	40	nmod

1	.	.	.	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	accentuate	accentuate	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	electrolyte	electrolyte	NN	_	6	compound
6	loss	loss	NN	_	3	dobj
7	associated	associate	VBN	_	6	acl
8	with	with	IN	_	10	case
9	drug2	drug2	NN	_	10	compound
10	therapy	therapy	NN	_	7	nmod
11	.	.	.	_	3	punct

1	drug1	drug1	NN	_	2	compound
2	Supplements	supplement	NNS	_	0	ROOT
3	/	/	:	_	2	punct
4	drug2	drug2	NN	_	2	dep

1	Products	Products	NNPS	_	18	nsubj
2	containing	contain	VBG	_	1	acl
3	drug1	drug1	NN	_	2	dobj
4	and	and	CC	_	3	cc
5	other	other	JJ	_	7	amod
6	multivalent	multivalent	JJ	_	7	amod
7	cations	cation	NNS	_	3	conj
8	-LRB-	-lrb-	-LRB-	_	11	punct
9	such	such	JJ	_	11	case
10	as	as	IN	_	9	mwe
11	drug2	drug2	NN	_	7	nmod
12	,	,	,	_	11	punct
13	drug3	drug3	NN	_	11	appos
14	,	,	,	_	11	punct
15	drug4	drug4	NN	_	11	appos
16	-RRB-	-rrb-	-RRB-	_	11	punct
17	are	be	VBP	_	18	cop
18	likely	likely	JJ	_	0	ROOT
19	to	to	TO	_	20	mark
20	interfere	interfere	VB	_	18	xcomp
21	with	with	IN	_	22	case
22	absorption	absorption	NN	_	20	nmod
23	of	of	IN	_	24	case
24	drug5	drug5	NN	_	22	nmod
25	.	.	.	_	18	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	taken	take	VBN	_	0	ROOT
5	at	at	IN	_	6	case
6	least	least	JJS	_	7	nmod:npmod
7	60	60	CD	_	8	nummod
8	minutes	minute	NNS	_	4	nmod:tmod
9	before	before	IN	_	12	case
10	any	any	DT	_	12	det
11	oral	oral	JJ	_	12	amod
12	medications	medication	NNS	_	4	nmod
13	containing	contain	VBG	_	12	acl
14	multivalent	multivalent	JJ	_	15	amod
15	cations	cation	NNS	_	13	dobj
16	-LRB-	-lrb-	-LRB-	_	18	punct
17	including	include	VBG	_	18	case
18	drug2	drug2	NN	_	15	nmod
19	,	,	,	_	18	punct
20	supplements	supplement	NNS	_	18	conj
21	or	or	CC	_	18	cc
22	drug3	drug3	NN	_	18	conj
23	-RRB-	-rrb-	-RRB-	_	18	punct
24	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	drug3	drug3	NN	_	3	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct

1	Of	of	IN	_	4	case
2	over	over	IN	_	3	advmod
3	3500	3500	CD	_	4	nummod
4	patients	patient	NNS	_	17	nmod
5	enrolled	enrol	VBN	_	4	acl
6	in	in	IN	_	10	case
7	the	the	DT	_	10	det
8	drug1	drug1	NN	_	10	compound
9	osteoporosis	osteoporosis	NN	_	10	compound
10	Treatment	treatment	NN	_	5	nmod
11	and	and	CC	_	10	cc
12	Prevention	Prevention	NNP	_	13	compound
13	Studies	Studies	NNPS	_	10	conj
14	,	,	,	_	17	punct
15	15	15	CD	_	16	nummod
16	%	%	NN	_	17	nsubj
17	used	use	VBN	_	0	ROOT
18	anti-peptic	anti-peptic	JJ	_	19	amod
19	agents	agent	NNS	_	17	dobj
20	-LRB-	-lrb-	-LRB-	_	22	punct
21	primarily	primarily	RB	_	22	advmod
22	drug2	drug2	NN	_	19	dep
23	and	and	CC	_	22	cc
24	drug3	drug3	NN	_	22	conj
25	-RRB-	-rrb-	-RRB-	_	22	punct
26	.	.	.	_	17	punct

1	Among	among	IN	_	3	case
2	these	these	DT	_	3	det
3	patients	patient	NNS	_	19	nmod
4	,	,	,	_	19	punct
5	the	the	DT	_	6	det
6	incidence	incidence	NN	_	19	nsubj
7	of	of	IN	_	11	case
8	upper	upper	JJ	_	11	amod
9	gastrointestinal	gastrointestinal	JJ	_	11	amod
10	adverse	adverse	JJ	_	11	amod
11	experiences	experience	NNS	_	6	nmod
12	in	in	IN	_	14	case
13	the	the	DT	_	14	det
14	patients	patient	NNS	_	11	nmod
15	treated	treat	VBN	_	14	acl
16	with	with	IN	_	17	case
17	drug1	drug1	NN	_	15	nmod
18	was	be	VBD	_	19	cop
19	similar	similar	JJ	_	0	ROOT
20	to	to	TO	_	21	case
21	that	that	DT	_	19	nmod
22	in	in	IN	_	24	case
23	placebo-treated	placebo-treated	JJ	_	24	amod
24	patients	patient	NNS	_	21	nmod
25	.	.	.	_	19	punct

1	Similarly	similarly	RB	_	0	ROOT
2	,	,	,	_	1	punct
3	of	of	IN	_	6	case
4	over	over	IN	_	5	advmod
5	1600	1600	CD	_	6	nummod
6	patients	patient	NNS	_	2	root
7	enrolled	enrol	VBN	_	6	acl
8	in	in	IN	_	10	case
9	a	a	DT	_	10	det
10	study	study	NN	_	7	nmod
11	comparing	compare	VBG	_	10	acl
12	once-monthly	once-monthly	JJ	_	11	dobj
13	with	with	IN	_	16	case
14	daily	daily	JJ	_	16	amod
15	dosing	dosing	NN	_	16	compound
16	regimens	regimen	NNS	_	12	nmod
17	of	of	IN	_	18	case
18	drug1	drug1	NN	_	16	nmod
19	,	,	,	_	6	punct
20	14	14	CD	_	21	nummod
21	%	%	NN	_	19	root
22	of	of	IN	_	23	case
23	patients	patient	NNS	_	21	nmod
24	used	use	VBN	_	26	amod
25	anti-peptic	anti-peptic	JJ	_	26	amod
26	agents	agent	NNS	_	23	dep
27	.	.	.	_	21	punct

1	Among	among	IN	_	3	case
2	these	these	DT	_	3	det
3	patients	patient	NNS	_	23	nmod
4	,	,	,	_	23	punct
5	the	the	DT	_	6	det
6	incidence	incidence	NN	_	23	nsubj
7	of	of	IN	_	11	case
8	upper	upper	JJ	_	11	amod
9	gastrointestinal	gastrointestinal	JJ	_	11	amod
10	adverse	adverse	JJ	_	11	amod
11	experiences	experience	NNS	_	6	nmod
12	in	in	IN	_	14	case
13	the	the	DT	_	14	det
14	patients	patient	NNS	_	11	nmod
15	treated	treat	VBN	_	14	acl
16	with	with	IN	_	19	case
17	drug1	drug1	NN	_	19	compound
18	150	150	CD	_	19	nummod
19	mg	mg	NN	_	15	nmod
20	once	once	RB	_	21	advmod
21	monthly	monthly	JJ	_	23	advmod
22	was	be	VBD	_	23	cop
23	similar	similar	JJ	_	0	ROOT
24	to	to	TO	_	25	case
25	that	that	DT	_	23	nmod
26	in	in	IN	_	27	case
27	patients	patient	NNS	_	25	nmod
28	treated	treat	VBN	_	27	acl
29	with	with	IN	_	32	case
30	drug2	drug2	NN	_	32	compound
31	2.5	2.5	CD	_	32	nummod
32	mg	mg	NN	_	28	nmod
33	once	once	RB	_	34	advmod
34	daily	daily	RB	_	28	advmod
35	.	.	.	_	23	punct

1	drug1	drug1	NN	_	4	compound
2	/	/	:	_	4	punct
3	drug2	drug2	NN	_	4	compound
4	s	s	NNS	_	0	ROOT
5	-LRB-	-lrb-	-LRB-	_	6	punct
6	drug3	drug3	NN	_	4	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct

1	In	in	IN	_	8	case
2	the	the	DT	_	8	det
3	large	large	JJ	_	8	amod
4	,	,	,	_	8	punct
5	placebo-controlled	placebo-controlled	JJ	_	8	amod
6	osteoporosis	osteoporosis	NN	_	8	compound
7	Treatment	treatment	NN	_	8	compound
8	Study	study	NN	_	14	nmod
9	,	,	,	_	14	punct
10	drug1	drug1	NN	_	14	nsubjpass
11	and	and	CC	_	10	cc
12	drug2	drug2	NN	_	10	conj
13	were	be	VBD	_	14	auxpass
14	taken	take	VBN	_	0	ROOT
15	by	by	IN	_	17	case
16	62	62	CD	_	17	nummod
17	%	%	NN	_	14	nmod
18	of	of	IN	_	21	case
19	the	the	DT	_	21	det
20	2946	2946	CD	_	21	nummod
21	patients	patient	NNS	_	17	nmod
22	.	.	.	_	14	punct

1	Among	among	IN	_	2	case
2	drug1	drug1	NN	_	27	nmod
3	or	or	CC	_	2	cc
4	drug2	drug2	NN	_	5	compound
5	users	user	NNS	_	2	conj
6	,	,	,	_	27	punct
7	the	the	DT	_	8	det
8	incidence	incidence	NN	_	27	nsubj
9	of	of	IN	_	13	case
10	upper	upper	JJ	_	13	amod
11	gastrointestinal	gastrointestinal	JJ	_	13	amod
12	adverse	adverse	JJ	_	13	amod
13	events	event	NNS	_	8	nmod
14	in	in	IN	_	15	case
15	patients	patient	NNS	_	13	nmod
16	treated	treat	VBN	_	15	acl
17	with	with	IN	_	20	case
18	drug3	drug3	NN	_	20	compound
19	2.5	2.5	CD	_	20	nummod
20	mg	mg	NN	_	16	nmod
21	daily	daily	JJ	_	20	amod
22	-LRB-	-lrb-	-LRB-	_	24	punct
23	28.9	28.9	CD	_	24	nummod
24	%	%	NN	_	20	appos
25	-RRB-	-rrb-	-RRB-	_	24	punct
26	was	be	VBD	_	27	cop
27	similar	similar	JJ	_	0	ROOT
28	to	to	TO	_	29	case
29	that	that	DT	_	27	nmod
30	in	in	IN	_	32	case
31	placebo-treated	placebo-treated	JJ	_	32	amod
32	patients	patient	NNS	_	29	nmod
33	-LRB-	-lrb-	-LRB-	_	35	punct
34	30.7	30.7	CD	_	35	nummod
35	%	%	NN	_	32	appos
36	-RRB-	-rrb-	-RRB-	_	35	punct
37	.	.	.	_	27	punct

1	Similarly	similarly	RB	_	14	advmod
2	,	,	,	_	14	punct
3	in	in	IN	_	8	case
4	the	the	DT	_	8	det
5	1-year	1-year	JJ	_	8	amod
6	monthly	monthly	JJ	_	8	amod
7	comparison	comparison	NN	_	8	compound
8	study	study	NN	_	14	nmod
9	,	,	,	_	14	punct
10	drug1	drug1	NN	_	14	nsubjpass
11	and	and	CC	_	10	cc
12	drug2	drug2	NN	_	10	conj
13	were	be	VBD	_	14	auxpass
14	taken	take	VBN	_	0	ROOT
15	by	by	IN	_	17	case
16	39	39	CD	_	17	nummod
17	%	%	NN	_	14	nmod
18	of	of	IN	_	21	case
19	the	the	DT	_	21	det
20	1602	1602	CD	_	21	nummod
21	patients	patient	NNS	_	17	nmod
22	.	.	.	_	14	punct

1	The	the	DT	_	2	det
2	incidence	incidence	NN	_	15	nsubj
3	of	of	IN	_	6	case
4	upper	upper	JJ	_	6	amod
5	gastrointestinal	gastrointestinal	JJ	_	6	amod
6	events	event	NNS	_	2	nmod
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	concomitantly	concomitantly	RB	_	10	advmod
10	taking	take	VBG	_	8	acl
11	drug1	drug1	NN	_	10	dobj
12	or	or	CC	_	11	cc
13	drug2	drug2	NN	_	11	conj
14	was	be	VBD	_	15	cop
15	similar	similar	JJ	_	0	ROOT
16	in	in	IN	_	17	case
17	patients	patient	NNS	_	15	nmod
18	taking	take	VBG	_	17	acl
19	drug3	drug3	NN	_	18	dobj
20	2.5	2.5	CD	_	21	nummod
21	mg	mg	NN	_	22	nmod:npmod
22	daily	daily	JJ	_	19	amod
23	-LRB-	-lrb-	-LRB-	_	25	punct
24	21.7	21.7	CD	_	25	nummod
25	%	%	NN	_	15	dep
26	-RRB-	-rrb-	-RRB-	_	25	punct
27	and	and	CC	_	15	cc
28	150	150	CD	_	29	nummod
29	mg	mg	NN	_	15	conj
30	once	once	RB	_	31	advmod
31	monthly	monthly	JJ	_	29	amod
32	-LRB-	-lrb-	-LRB-	_	34	punct
33	22.0	22.0	CD	_	34	nummod
34	%	%	NN	_	31	dep
35	-RRB-	-rrb-	-RRB-	_	34	punct
36	.	.	.	_	15	punct

1	However	however	RB	_	6	advmod
2	,	,	,	_	6	punct
3	since	since	IN	_	4	case
4	drug1	drug1	NN	_	6	nmod
5	,	,	,	_	6	punct
6	drug2	drug2	NN	_	20	ccomp
7	,	,	,	_	6	punct
8	and	and	CC	_	6	cc
9	drug3	drug3	NN	_	12	nsubjpass
10	are	be	VBP	_	12	auxpass
11	all	all	DT	_	12	dep
12	associated	associate	VBN	_	6	conj
13	with	with	IN	_	15	case
14	gastrointestinal	gastrointestinal	JJ	_	15	amod
15	irritation	irritation	NN	_	12	nmod
16	,	,	,	_	20	punct
17	caution	caution	NN	_	20	nsubjpass
18	should	should	MD	_	20	aux
19	be	be	VB	_	20	auxpass
20	exercised	exercise	VBN	_	0	ROOT
21	in	in	IN	_	24	case
22	the	the	DT	_	24	det
23	concomitant	concomitant	JJ	_	24	amod
24	use	use	NN	_	20	nmod
25	of	of	IN	_	26	case
26	drug4	drug4	NN	_	24	nmod
27	or	or	CC	_	26	cc
28	drug5	drug5	NN	_	26	conj
29	with	with	IN	_	30	case
30	drug6	drug6	NN	_	24	nmod
31	.	.	.	_	20	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	3	amod
2	Test	test	NN	_	3	compound
3	Interactions	interaction	NNS	_	0	ROOT

1	drug1	drug1	NN	_	3	nsubjpass
2	are	be	VBP	_	3	auxpass
3	known	know	VBN	_	0	ROOT
4	to	to	TO	_	5	mark
5	interfere	interfere	VB	_	3	xcomp
6	with	with	IN	_	8	case
7	the	the	DT	_	8	det
8	use	use	NN	_	5	nmod
9	of	of	IN	_	11	case
10	bone-imaging	bone-imaging	JJ	_	11	amod
11	agents	agent	NNS	_	8	nmod
12	.	.	.	_	3	punct

1	Specific	specific	JJ	_	2	amod
2	studies	study	NNS	_	8	nsubjpass
3	with	with	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	have	have	VBP	_	8	aux
6	not	not	RB	_	8	neg
7	been	be	VBN	_	8	auxpass
8	performed	perform	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	Monoamine	Monoamine	NNP	_	3	compound
2	Oxidase	Oxidase	NNP	_	3	compound
3	Inhibition	inhibition	NN	_	0	ROOT
4	:	:	:	_	3	punct
5	drug1	drug1	NN	_	11	nsubj
6	is	be	VBZ	_	11	cop
7	a	a	DT	_	11	det
8	reversible	reversible	JJ	_	11	amod
9	,	,	,	_	8	punct
10	nonselective	nonselective	JJ	_	8	dep
11	inhibitor	inhibitor	NN	_	3	dep
12	of	of	IN	_	14	case
13	monoamine	monoamine	NN	_	14	compound
14	oxidase	oxidase	NN	_	11	nmod
15	.	.	.	_	3	punct

1	Therefore	therefore	RB	_	4	advmod
2	,	,	,	_	4	punct
3	drug1	drug1	NN	_	4	nsubj
4	has	have	VBZ	_	0	ROOT
5	the	the	DT	_	6	det
6	potential	potential	NN	_	4	dobj
7	for	for	IN	_	8	case
8	interaction	interaction	NN	_	6	nmod
9	with	with	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	drug3	drug3	NN	_	10	conj
13	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Some	some	DT	_	4	det
4	individuals	individual	NNS	_	8	nsubj
5	receiving	receive	VBG	_	4	acl
6	drug2	drug2	NN	_	5	dobj
7	may	may	MD	_	8	aux
8	experience	experience	VB	_	1	appos
9	a	a	DT	_	11	det
10	reversible	reversible	JJ	_	11	amod
11	enhancement	enhancement	NN	_	8	dobj
12	of	of	IN	_	15	case
13	the	the	DT	_	15	det
14	pressor	pressor	NN	_	15	compound
15	response	response	NN	_	11	nmod
16	to	to	TO	_	18	case
17	indirect-acting	indirect-acting	JJ	_	18	amod
18	drug3	drug3	NN	_	15	nmod
19	,	,	,	_	18	punct
20	drug4	drug4	NN	_	18	conj
21	or	or	CC	_	18	cc
22	drug5	drug5	NN	_	18	conj
23	.	.	.	_	8	punct

1	Commonly	commonly	RB	_	2	advmod
2	used	use	VBN	_	3	amod
3	drugs	drug	NNS	_	12	nsubjpass
4	such	such	JJ	_	6	case
5	as	as	IN	_	4	mwe
6	drug1	drug1	NN	_	3	nmod
7	and	and	CC	_	6	cc
8	drug2	drug2	NN	_	6	conj
9	have	have	VBP	_	12	aux
10	been	be	VBN	_	12	auxpass
11	specifically	specifically	RB	_	12	advmod
12	studied	study	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	Initial	initial	JJ	_	2	amod
2	doses	dose	NNS	_	14	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	,	,	,	_	2	punct
6	such	such	JJ	_	8	case
7	as	as	IN	_	6	mwe
8	drug2	drug2	NN	_	2	nmod
9	or	or	CC	_	8	cc
10	drug3	drug3	NN	_	8	conj
11	,	,	,	_	2	punct
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	reduced	reduce	VBN	_	0	ROOT
15	and	and	CC	_	14	cc
16	titrated	titrate	VBN	_	14	conj
17	to	to	TO	_	18	mark
18	achieve	achieve	VB	_	14	xcomp
19	the	the	DT	_	21	det
20	desired	desire	VBN	_	21	amod
21	response	response	NN	_	18	dobj
22	.	.	.	_	14	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Co-administration	co-administration	NN	_	10	nsubjpass
4	of	of	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug3	drug3	NN	_	5	conj
8	was	be	VBD	_	10	auxpass
9	not	not	RB	_	10	neg
10	associated	associate	VBN	_	1	appos
11	with	with	IN	_	13	case
12	serotonin	serotonin	NN	_	13	compound
13	syndrome	syndrome	NN	_	10	nmod
14	in	in	IN	_	15	case
15	Phase	phase	NN	_	13	nmod
16	1	1	CD	_	15	nummod
17	,	,	,	_	15	punct
18	2	2	CD	_	15	nummod
19	or	or	CC	_	15	cc
20	3	3	CD	_	21	nummod
21	studies	study	NNS	_	15	conj
22	.	.	.	_	1	punct

1	Spontaneous	spontaneous	JJ	_	2	amod
2	reports	report	NNS	_	25	nsubjpass
3	of	of	IN	_	5	case
4	serotonin	serotonin	NN	_	5	compound
5	syndrome	syndrome	NN	_	2	nmod
6	associated	associate	VBN	_	2	acl
7	with	with	IN	_	8	case
8	co-administration	co-administration	NN	_	6	nmod
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	drug2	drug2	NN	_	10	conj
13	,	,	,	_	8	punct
14	including	include	VBG	_	15	case
15	drug3	drug3	NN	_	8	nmod
16	such	such	JJ	_	18	case
17	as	as	IN	_	16	mwe
18	drug4	drug4	NN	_	15	nmod
19	-LRB-	-lrb-	-LRB-	_	20	punct
20	drug5	drug5	NN	_	18	appos
21	-RRB-	-rrb-	-RRB-	_	20	punct
22	,	,	,	_	2	punct
23	have	have	VBP	_	25	aux
24	been	be	VBN	_	25	auxpass
25	reported	report	VBN	_	0	ROOT
26	.	.	.	_	25	punct

1	Patients	patient	NNS	_	13	nsubjpass
2	who	who	WP	_	4	nsubjpass
3	are	be	VBP	_	4	auxpass
4	treated	treat	VBN	_	1	acl:relcl
5	with	with	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	concomitant	concomitant	JJ	_	9	amod
9	drug2	drug2	NN	_	6	conj
10	should	should	MD	_	13	aux
11	be	be	VB	_	13	auxpass
12	closely	closely	RB	_	13	advmod
13	observed	observe	VBN	_	0	ROOT
14	for	for	IN	_	15	case
15	signs	sign	NNS	_	13	nmod
16	and	and	CC	_	15	cc
17	symptoms	symptom	NNS	_	15	conj
18	of	of	IN	_	20	case
19	serotonin	serotonin	NN	_	20	compound
20	syndrome	syndrome	NN	_	15	nmod
21	-LRB-	-lrb-	-LRB-	_	25	punct
22	e.g.	e.g.	FW	_	25	dep
23	,	,	,	_	25	punct
24	cognitive	cognitive	JJ	_	25	amod
25	dysfunction	dysfunction	NN	_	15	dep
26	,	,	,	_	25	punct
27	hyperpyrexia	hyperpyrexia	NN	_	25	conj
28	,	,	,	_	25	punct
29	hyperreflexia	hyperreflexia	NN	_	25	conj
30	,	,	,	_	25	punct
31	incoordination	incoordination	NN	_	25	appos
32	-RRB-	-rrb-	-RRB-	_	25	punct
33	.	.	.	_	13	punct

1	If	if	IN	_	6	mark
2	any	any	DT	_	3	det
3	signs	sign	NNS	_	6	nsubj
4	or	or	CC	_	3	cc
5	symptoms	symptom	NNS	_	3	conj
6	occur	occur	VBP	_	0	ROOT
7	physicians	physician	NNS	_	9	nsubj
8	should	should	MD	_	9	aux
9	consider	consider	VB	_	6	ccomp
10	discontinuation	discontinuation	NN	_	9	dobj
11	of	of	IN	_	13	case
12	either	either	DT	_	13	cc:preconj
13	one	one	CD	_	10	nmod
14	or	or	CC	_	13	cc
15	both	both	DT	_	16	det
16	agents	agent	NNS	_	13	conj
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	drug1	drug1	NN	_	16	dep
19	or	or	CC	_	18	cc
20	concomitant	concomitant	JJ	_	21	amod
21	drug2	drug2	NN	_	18	conj
22	-RRB-	-rrb-	-RRB-	_	18	punct
23	.	.	.	_	6	punct

1	Drug-Laboratory	drug-laboratory	JJ	_	3	amod
2	Test	test	NN	_	3	compound
3	Interactions	interaction	NNS	_	0	ROOT
4	There	there	EX	_	5	expl
5	are	be	VBP	_	3	acl:relcl
6	no	no	DT	_	10	neg
7	reported	report	VBN	_	10	amod
8	drug-laboratory	drug-laboratory	JJ	_	10	amod
9	test	test	NN	_	10	compound
10	interactions	interaction	NNS	_	5	nsubj
11	.	.	.	_	3	punct

1	Increases	increase	NNS	_	7	nsubjpass
2	in	in	IN	_	4	case
3	prothrombin	prothrombin	NN	_	4	compound
4	time	time	NN	_	1	nmod
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	noted	note	VBN	_	0	ROOT
8	in	in	IN	_	9	case
9	patients	patient	NNS	_	7	nmod
10	receiving	receive	VBG	_	9	acl
11	long	long	JJ	_	15	amod
12	-	-	:	_	15	punct
13	term	term	NN	_	15	compound
14	drug1	drug1	NN	_	15	compound
15	therapy	therapy	NN	_	10	dobj
16	after	after	IN	_	19	mark
17	drug2	drug2	NN	_	19	nsubjpass
18	was	be	VBD	_	19	auxpass
19	initiated	initiate	VBN	_	10	advcl
20	.	.	.	_	7	punct

1	Therefore	therefore	RB	_	9	advmod
2	,	,	,	_	9	punct
3	close	close	JJ	_	4	amod
4	monitoring	monitoring	NN	_	9	nsubjpass
5	of	of	IN	_	7	case
6	prothrombin	prothrombin	NN	_	7	compound
7	time	time	NN	_	4	nmod
8	is	be	VBZ	_	9	auxpass
9	recommended	recommend	VBN	_	0	ROOT
10	and	and	CC	_	9	cc
11	adjustment	adjustment	NN	_	18	nsubj
12	of	of	IN	_	15	case
13	the	the	DT	_	15	det
14	drug1	drug1	NN	_	15	compound
15	dose	dose	NN	_	11	nmod
16	may	may	MD	_	18	aux
17	be	be	VB	_	18	cop
18	necessary	necessary	JJ	_	9	conj
19	when	when	WRB	_	23	advmod
20	drug2	drug2	NN	_	21	compound
21	Capsules	capsule	NNS	_	23	nsubjpass
22	are	be	VBP	_	23	auxpass
23	administered	administer	VBN	_	18	advcl
24	concomitantly	concomitantly	RB	_	23	advmod
25	with	with	IN	_	26	case
26	drug3	drug3	NN	_	23	nmod
27	.	.	.	_	9	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	decrease	decrease	VB	_	1	appos
6	the	the	DT	_	7	det
7	effects	effect	NNS	_	5	dobj
8	of	of	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	,	,	,	_	9	punct
11	drug4	drug4	NN	_	9	conj
12	,	,	,	_	9	punct
13	and	and	CC	_	9	cc
14	drug5	drug5	NN	_	9	conj
15	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Has	have	VBZ	_	1	dep
4	a	a	DT	_	6	det
5	synergistic	synergistic	JJ	_	6	amod
6	effect	effect	NN	_	3	dobj
7	with	with	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	in	in	IN	_	10	mark
10	causing	cause	VBG	_	3	advcl
11	gastrointestinal	gastrointestinal	JJ	_	12	amod
12	bleeding	bleeding	NN	_	10	dobj
13	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concomitant	concomitant	JJ	_	4	amod
4	administration	administration	NN	_	8	nsubj
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	may	may	MD	_	8	aux
8	increase	increase	VB	_	1	dep
9	the	the	DT	_	10	det
10	risk	risk	NN	_	8	dobj
11	of	of	IN	_	13	case
12	gastrointestinal	gastrointestinal	JJ	_	13	amod
13	ulceration	ulceration	NN	_	10	nmod
14	and	and	CC	_	8	cc
15	may	may	MD	_	16	aux
16	reduce	reduce	VB	_	8	conj
17	serum	serum	NN	_	19	compound
18	salicylate	salicylate	NN	_	19	compound
19	levels	level	NNS	_	16	dobj
20	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	drug2	drug2	NN	_	1	dep
4	,	,	,	_	3	punct
5	drug3	drug3	NN	_	3	conj
6	,	,	,	_	3	punct
7	and	and	CC	_	3	cc
8	possibly	possibly	RB	_	9	advmod
9	drug4	drug4	NN	_	3	conj
10	-RRB-	-rrb-	-RRB-	_	3	punct
11	:	:	:	_	1	punct
12	Concomitant	concomitant	JJ	_	13	amod
13	administration	administration	NN	_	17	nsubj
14	with	with	IN	_	15	case
15	drug5	drug5	NN	_	13	nmod
16	may	may	MD	_	17	aux
17	increase	increase	VB	_	1	dep
18	the	the	DT	_	19	det
19	risk	risk	NN	_	17	dobj
20	of	of	IN	_	22	case
21	gastrointestinal	gastrointestinal	JJ	_	22	amod
22	ulceration	ulceration	NN	_	19	nmod
23	.	.	.	_	1	punct

1	drug1	drug1	NN	_	2	compound
2	Agents	agent	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	drug2	drug2	NN	_	6	nsubjpass
5	is	be	VBZ	_	6	auxpass
6	contraindicated	contraindicate	VBN	_	2	dep
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	who	who	WP	_	11	nsubj
10	are	be	VBP	_	11	cop
11	hypersensitive	hypersensitive	JJ	_	8	acl:relcl
12	to	to	TO	_	13	mark
13	drug3	drug3	VB	_	11	xcomp
14	agents	agent	NNS	_	13	dobj
15	.	.	.	_	2	punct

1	Urinary	urinary	JJ	_	2	amod
2	Alkalinizers	alkalinizer	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	Decrease	decrease	NN	_	6	compound
5	drug1	drug1	NN	_	6	compound
6	effectiveness	effectiveness	NN	_	2	dep
7	by	by	IN	_	8	mark
8	increasing	increase	VBG	_	6	acl
9	the	the	DT	_	10	det
10	rate	rate	NN	_	8	dobj
11	of	of	IN	_	14	case
12	drug2	drug2	NN	_	14	compound
13	renal	renal	JJ	_	14	amod
14	excretion	excretion	NN	_	10	nmod
15	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Decreases	decrease	VBZ	_	1	dep
4	drug2	drug2	NN	_	5	compound
5	effectiveness	effectiveness	NN	_	3	dobj
6	by	by	IN	_	8	case
7	enzyme	enzyme	NN	_	8	compound
8	induction	induction	NN	_	3	nmod
9	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Serum	serum	NN	_	5	compound
4	drug2	drug2	NN	_	5	compound
5	levels	level	NNS	_	8	nsubjpass
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	increased	increase	VBN	_	1	parataxis
9	by	by	IN	_	10	case
10	drug3	drug3	NN	_	8	nmod
11	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	May	May	NNP	_	4	nsubj
4	decrease	decrease	VB	_	1	dep
5	drug2	drug2	NN	_	7	compound
6	anti-inflammatory	anti-inflammatory	JJ	_	7	amod
7	action	action	NN	_	4	dobj
8	by	by	IN	_	9	mark
9	competing	compete	VBG	_	4	advcl
10	for	for	IN	_	13	case
11	the	the	DT	_	13	det
12	same	same	JJ	_	13	amod
13	receptors	receptor	NNS	_	9	nmod
14	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Enteric	enteric	JJ	_	5	amod
4	Coated	coated	JJ	_	5	amod
5	drug2	drug2	NN	_	9	nsubjpass
6	should	should	MD	_	9	aux
7	not	not	RB	_	9	neg
8	be	be	VB	_	9	auxpass
9	given	give	VBN	_	1	dep
10	concurrently	concurrently	RB	_	9	advmod
11	with	with	IN	_	12	case
12	drug3	drug3	NN	_	9	nmod
13	,	,	,	_	9	punct
14	since	since	IN	_	16	case
15	an	a	DT	_	16	det
16	increase	increase	NN	_	9	nmod
17	in	in	IN	_	19	case
18	the	the	DT	_	19	det
19	pH	ph	NN	_	16	nmod
20	of	of	IN	_	22	case
21	the	the	DT	_	22	det
22	stomach	stomach	NN	_	19	nmod
23	may	may	MD	_	24	aux
24	effect	effect	VB	_	9	dep
25	the	the	DT	_	27	det
26	enteric	enteric	JJ	_	27	amod
27	coating	coating	NN	_	24	dobj
28	of	of	IN	_	30	case
29	the	the	DT	_	30	det
30	tablets	tablet	NNS	_	27	nmod
31	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	use	use	NN	_	13	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	FOR	for	IN	_	6	case
6	INJECTION	injection	NN	_	2	nmod
7	in	in	IN	_	8	case
8	combination	combination	NN	_	2	nmod
9	with	with	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	is	be	VBZ	_	13	auxpass
12	not	not	RB	_	13	neg
13	recommended	recommend	VBN	_	0	ROOT
14	due	due	JJ	_	17	case
15	to	to	TO	_	14	mwe
16	the	the	DT	_	17	det
17	risk	risk	NN	_	13	nmod
18	of	of	IN	_	21	case
19	severe	severe	JJ	_	21	amod
20	pulmonary	pulmonary	JJ	_	21	amod
21	toxicity	toxicity	NN	_	17	nmod
22	.	.	.	_	13	punct

1	No	no	DT	_	5	neg
2	clinically	clinically	RB	_	3	advmod
3	relevant	relevant	JJ	_	5	amod
4	drug-drug	drug-drug	JJ	_	5	amod
5	interactions	interaction	NNS	_	8	nsubjpass
6	have	have	VBP	_	8	aux
7	been	be	VBN	_	8	auxpass
8	observed	observe	VBN	_	0	ROOT
9	with	with	IN	_	10	case
10	drugs	drug	NNS	_	8	nmod
11	likely	likely	JJ	_	10	amod
12	to	to	TO	_	14	mark
13	be	be	VB	_	14	auxpass
14	co-administered	co-administer	VBN	_	11	xcomp
15	with	with	IN	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	.	.	.	_	8	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	interact	interact	VB	_	0	ROOT
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	,	,	,	_	5	punct
7	drug3	drug3	NN	_	5	conj
8	,	,	,	_	5	punct
9	drug4	drug4	NN	_	5	conj
10	,	,	,	_	5	punct
11	drug5	drug5	NN	_	5	conj
12	,	,	,	_	5	punct
13	drug6	drug6	NN	_	14	compound
14	supplements	supplement	NNS	_	5	conj
15	,	,	,	_	5	punct
16	drug7	drug7	NN	_	5	conj
17	,	,	,	_	5	punct
18	drug8	drug8	NN	_	5	conj
19	,	,	,	_	5	punct
20	drug9	drug9	NN	_	5	conj
21	,	,	,	_	5	punct
22	drug10	drug10	NN	_	5	conj
23	,	,	,	_	5	punct
24	drug11	drug11	NN	_	5	conj
25	,	,	,	_	5	punct
26	drug12	drug12	NN	_	5	conj
27	,	,	,	_	5	punct
28	drug13	drug13	NN	_	5	conj
29	,	,	,	_	5	punct
30	and	and	CC	_	5	cc
31	drug14	drug14	NN	_	5	conj
32	.	.	.	_	3	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	3	amod
2	Test	test	NN	_	3	compound
3	Interactions	interaction	NNS	_	0	ROOT
4	:	:	:	_	3	punct
5	A	a	DT	_	7	det
6	false-positive	false-positive	JJ	_	7	amod
7	reaction	reaction	NN	_	14	nsubj
8	for	for	IN	_	9	case
9	glucose	glucose	NN	_	7	nmod
10	in	in	IN	_	12	case
11	the	the	DT	_	12	det
12	urine	urine	NN	_	9	nmod
13	may	may	MD	_	14	aux
14	occur	occur	VB	_	3	appos
15	with	with	IN	_	18	case
16	copper	copper	NN	_	18	compound
17	reduction	reduction	NN	_	18	compound
18	tests	test	NNS	_	14	nmod
19	-LRB-	-lrb-	-LRB-	_	21	punct
20	Benedict	Benedict	NNP	_	21	compound
21	s	s	NNS	_	18	dep
22	or	or	CC	_	21	cc
23	Fehling	fehling	NN	_	25	compound
24	s	s	NNS	_	25	compound
25	solution	solution	NN	_	21	conj
26	or	or	CC	_	21	cc
27	with	with	IN	_	29	case
28	Clinitest	Clinitest	NNP	_	29	compound
29	tablets	tablet	NNS	_	21	conj
30	-RRB-	-rrb-	-RRB-	_	21	punct
31	but	but	CC	_	18	cc
32	not	not	RB	_	35	neg
33	with	with	IN	_	35	case
34	enzyme-based	enzyme-based	JJ	_	35	amod
35	tests	test	NNS	_	18	conj
36	for	for	IN	_	37	case
37	glycosuria	glycosuria	NN	_	35	nmod
38	.	.	.	_	3	punct

1	As	as	IN	_	6	mark
2	a	a	DT	_	4	det
3	false-negative	false-negative	JJ	_	4	amod
4	result	result	NN	_	6	nsubj
5	may	may	MD	_	6	aux
6	occur	occur	VB	_	14	advcl
7	in	in	IN	_	10	case
8	the	the	DT	_	10	det
9	ferricyanide	ferricyanide	JJ	_	10	amod
10	test	test	NN	_	6	nmod
11	,	,	,	_	14	punct
12	it	it	PRP	_	14	nsubjpass
13	is	be	VBZ	_	14	auxpass
14	recommended	recommend	VBN	_	0	ROOT
15	that	that	IN	_	24	mark
16	either	either	CC	_	19	cc:preconj
17	the	the	DT	_	19	det
18	glucose	glucose	NN	_	19	compound
19	oxidase	oxidase	NN	_	24	nsubjpass
20	or	or	CC	_	19	cc
21	hexokinase	hexokinase	NN	_	22	compound
22	method	method	NN	_	19	conj
23	be	be	VB	_	24	auxpass
24	used	use	VBN	_	14	ccomp
25	to	to	TO	_	26	mark
26	determine	determine	VB	_	24	xcomp
27	blood	blood	NN	_	30	compound
28	plasma	plasma	NN	_	30	compound
29	glucose	glucose	NN	_	30	compound
30	levels	level	NNS	_	26	dobj
31	in	in	IN	_	32	case
32	patients	patient	NNS	_	30	nmod
33	receiving	receive	VBG	_	32	acl
34	drug1	drug1	NN	_	33	dobj
35	.	.	.	_	14	punct

1	drug1	drug1	NN	_	4	nsubj
2	does	do	VBZ	_	4	aux
3	not	not	RB	_	4	neg
4	interfere	interfere	VB	_	0	ROOT
5	with	with	IN	_	7	case
6	the	the	DT	_	7	det
7	assay	assay	NN	_	4	nmod
8	of	of	IN	_	9	case
9	serum	serum	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	urine	urine	NN	_	12	compound
12	creatinine	creatinine	NN	_	9	conj
13	by	by	IN	_	17	case
14	the	the	DT	_	17	det
15	alkaline	alkaline	NN	_	17	compound
16	picrate	picrate	NN	_	17	compound
17	method	method	NN	_	7	nmod
18	.	.	.	_	4	punct

1	drug1	drug1	NN	_	2	nsubj
2	prolong	prolong	VB	_	0	ROOT
3	and	and	CC	_	2	cc
4	intensify	intensify	VB	_	2	conj
5	the	the	DT	_	6	det
6	effects	effect	NNS	_	2	dobj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	.	.	.	_	2	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	use	use	NN	_	16	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	2	nmod
7	,	,	,	_	6	punct
8	drug3	drug3	NN	_	6	conj
9	,	,	,	_	6	punct
10	drug4	drug4	NN	_	6	conj
11	,	,	,	_	6	punct
12	or	or	CC	_	6	cc
13	other	other	JJ	_	14	amod
14	drug5	drug5	NN	_	6	conj
15	may	may	MD	_	16	aux
16	have	have	VB	_	0	ROOT
17	an	a	DT	_	19	det
18	additive	additive	JJ	_	19	amod
19	effect	effect	NN	_	16	dobj
20	.	.	.	_	16	punct

1	When	when	WRB	_	4	advmod
2	drug1	drug1	NN	_	4	nsubjpass
3	are	be	VBP	_	4	auxpass
4	given	give	VBN	_	18	advcl
5	to	to	TO	_	6	case
6	patients	patient	NNS	_	4	nmod
7	receiving	receive	VBG	_	6	acl
8	drug2	drug2	NN	_	7	dobj
9	,	,	,	_	18	punct
10	hypertensive	hypertensive	JJ	_	11	amod
11	reactions	reaction	NNS	_	18	nsubj
12	,	,	,	_	11	punct
13	including	include	VBG	_	15	case
14	hypertensive	hypertensive	JJ	_	15	amod
15	crises	crisis	NNS	_	11	nmod
16	,	,	,	_	11	punct
17	may	may	MD	_	18	aux
18	occur	occur	VB	_	0	ROOT
19	.	.	.	_	18	punct

1	The	the	DT	_	3	det
2	antihypertensive	antihypertensive	JJ	_	3	amod
3	effects	effect	NNS	_	15	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	,	,	,	_	5	punct
7	drug2	drug2	NN	_	5	conj
8	,	,	,	_	5	punct
9	drug3	drug3	NN	_	5	conj
10	,	,	,	_	5	punct
11	and	and	CC	_	5	cc
12	drug4	drug4	NN	_	5	conj
13	may	may	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	reduced	reduce	VBN	_	0	ROOT
16	by	by	IN	_	17	case
17	drug5	drug5	NN	_	15	nmod
18	.	.	.	_	15	punct

1	drug1	drug1	NN	_	4	nsubj
2	may	may	MD	_	4	aux
3	also	also	RB	_	4	advmod
4	interact	interact	VB	_	0	ROOT
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	.	.	.	_	4	punct

1	Increased	increase	VBN	_	4	amod
2	ectopic	ectopic	JJ	_	4	amod
3	pacemaker	pacemaker	NN	_	4	compound
4	activity	activity	NN	_	6	nsubj
5	can	can	MD	_	6	aux
6	occur	occur	VB	_	0	ROOT
7	when	when	WRB	_	10	advmod
8	drug1	drug1	NN	_	10	nsubjpass
9	is	be	VBZ	_	10	auxpass
10	used	use	VBN	_	6	advcl
11	concomitantly	concomitantly	RB	_	10	advmod
12	with	with	IN	_	13	case
13	drug2	drug2	NN	_	10	nmod
14	.	.	.	_	6	punct

1	drug1	drug1	NN	_	2	nsubj
2	increase	increase	VBP	_	0	ROOT
3	the	the	DT	_	4	det
4	rate	rate	NN	_	2	dobj
5	of	of	IN	_	6	case
6	absorption	absorption	NN	_	4	nmod
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	,	,	,	_	2	punct
10	while	while	IN	_	12	mark
11	drug3	drug3	NN	_	12	nsubj
12	decreases	decrease	VBZ	_	2	advcl
13	it	it	PRP	_	12	dobj
14	.	.	.	_	2	punct

1	Co-administration	co-administration	NN	_	11	nsubjpass
2	with	with	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	such	such	JJ	_	6	case
5	as	as	IN	_	4	mwe
6	drug2	drug2	NN	_	3	nmod
7	or	or	CC	_	6	cc
8	drug3	drug3	NN	_	6	conj
9	is	be	VBZ	_	11	auxpass
10	not	not	RB	_	11	neg
11	recommended	recommend	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	drug1	drug1	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	,	,	,	_	1	punct
5	drug3	drug3	NN	_	1	conj
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	consider	consider	VB	_	5	dep
8	drug4	drug4	NN	_	10	compound
9	dose	dose	NN	_	10	compound
10	reduction	reduction	NN	_	7	dobj
11	-RRB-	-rrb-	-RRB-	_	7	punct
12	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	,	,	,	_	1	punct
5	drug3	drug3	NN	_	1	conj
6	,	,	,	_	1	punct
7	drug4	drug4	NN	_	1	conj
8	,	,	,	_	1	punct
9	drug5	drug5	NN	_	1	conj
10	-LRB-	-lrb-	-LRB-	_	12	punct
11	exercise	exercise	NN	_	12	compound
12	caution	caution	NN	_	9	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	.	.	.	_	1	punct

1	drug1	drug1	NN	_	6	nsubj
2	are	be	VBP	_	6	cop
3	a	a	DT	_	6	det
4	major	major	JJ	_	6	amod
5	contributing	contributing	JJ	_	6	amod
6	factor	factor	NN	_	0	ROOT
7	to	to	TO	_	9	case
8	drug2	drug2	NN	_	9	compound
9	toxicity	toxicity	NN	_	6	nmod
10	.	.	.	_	6	punct

1	drug1	drug1	NN	_	13	nsubj
2	,	,	,	_	1	punct
3	particularly	particularly	RB	_	5	advmod
4	if	if	IN	_	5	mark
5	administered	administer	VBN	_	1	acl
6	rapidly	rapidly	RB	_	5	advmod
7	by	by	IN	_	10	case
8	the	the	DT	_	10	det
9	intravenous	intravenous	JJ	_	10	amod
10	route	route	NN	_	5	nmod
11	,	,	,	_	1	punct
12	may	may	MD	_	13	aux
13	produce	produce	VB	_	0	ROOT
14	serious	serious	JJ	_	15	amod
15	arrhythmias	arrhythmia	NNS	_	13	dobj
16	in	in	IN	_	18	case
17	digitalized	digitalized	JJ	_	18	amod
18	patients	patient	NNS	_	13	nmod
19	.	.	.	_	13	punct

1	drug1	drug1	NN	_	17	nsubj
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	,	,	,	_	1	punct
5	drug3	drug3	NN	_	1	conj
6	,	,	,	_	1	punct
7	drug4	drug4	NN	_	1	conj
8	,	,	,	_	1	punct
9	drug5	drug5	NN	_	1	conj
10	,	,	,	_	1	punct
11	drug6	drug6	NN	_	1	conj
12	,	,	,	_	1	punct
13	drug7	drug7	NN	_	1	conj
14	,	,	,	_	1	punct
15	and	and	CC	_	1	cc
16	drug8	drug8	NN	_	1	conj
17	raise	raise	VBP	_	0	ROOT
18	the	the	DT	_	21	det
19	serum	serum	NN	_	21	compound
20	drug9	drug9	NN	_	21	compound
21	concentration	concentration	NN	_	17	dobj
22	due	due	JJ	_	25	case
23	to	to	TO	_	22	mwe
24	a	a	DT	_	25	det
25	reduction	reduction	NN	_	17	nmod
26	in	in	IN	_	27	case
27	clearance	clearance	NN	_	25	nmod
28	and/or	and/or	CC	_	27	cc
29	in	in	IN	_	30	case
30	volume	volume	NN	_	27	conj
31	of	of	IN	_	32	case
32	distribution	distribution	NN	_	30	nmod
33	of	of	IN	_	35	case
34	the	the	DT	_	35	det
35	drug	drug	NN	_	32	nmod
36	,	,	,	_	17	punct
37	with	with	IN	_	39	case
38	the	the	DT	_	39	det
39	implication	implication	NN	_	17	nmod
40	that	that	IN	_	44	mark
41	drug10	drug10	NN	_	42	compound
42	intoxication	intoxication	NN	_	44	nsubj
43	may	may	MD	_	44	aux
44	result	result	VB	_	39	ccomp
45	.	.	.	_	17	punct

1	drug1	drug1	NN	_	13	nsubj
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	-LRB-	-lrb-	-LRB-	_	8	punct
5	and	and	CC	_	8	cc
6	possibly	possibly	RB	_	8	advmod
7	other	other	JJ	_	8	amod
8	drug3	drug3	NN	_	1	appos
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	and	and	CC	_	1	cc
11	drug4	drug4	NN	_	1	conj
12	may	may	MD	_	13	aux
13	increase	increase	VB	_	0	ROOT
14	drug5	drug5	NN	_	15	compound
15	absorption	absorption	NN	_	13	dobj
16	in	in	IN	_	17	case
17	patients	patient	NNS	_	13	nmod
18	who	who	WP	_	19	nsubj
19	inactivate	inactivate	VBP	_	17	acl:relcl
20	drug6	drug6	NN	_	19	dobj
21	by	by	IN	_	23	case
22	bacterial	bacterial	JJ	_	23	amod
23	metabolism	metabolism	NN	_	19	nmod
24	in	in	IN	_	27	case
25	the	the	DT	_	27	det
26	lower	lower	JJR	_	27	amod
27	intestine	intestine	NN	_	19	nmod
28	,	,	,	_	13	punct
29	so	so	RB	_	34	mark
30	that	that	IN	_	29	mwe
31	drug7	drug7	NN	_	32	compound
32	intoxication	intoxication	NN	_	34	nsubj
33	may	may	MD	_	34	aux
34	result	result	VB	_	13	advcl
35	.	.	.	_	13	punct

1	The	the	DT	_	2	det
2	risk	risk	NN	_	8	nsubjpass
3	of	of	IN	_	5	case
4	this	this	DT	_	5	det
5	interaction	interaction	NN	_	2	nmod
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	reduced	reduce	VBN	_	0	ROOT
9	if	if	IN	_	12	mark
10	drug1	drug1	NN	_	12	nsubjpass
11	is	be	VBZ	_	12	auxpass
12	given	give	VBN	_	8	advcl
13	as	as	IN	_	14	case
14	capsules	capsule	NNS	_	12	nmod
15	.	.	.	_	8	punct

1	drug1	drug1	NN	_	11	nsubj
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	,	,	,	_	1	punct
5	by	by	IN	_	6	mark
6	decreasing	decrease	VBG	_	1	acl
7	gut	gut	NN	_	8	compound
8	motility	motility	NN	_	6	dobj
9	,	,	,	_	1	punct
10	may	may	MD	_	11	aux
11	increase	increase	VB	_	0	ROOT
12	drug3	drug3	NN	_	13	compound
13	absorption	absorption	NN	_	11	dobj
14	.	.	.	_	11	punct

1	drug1	drug1	NN	_	20	nsubj
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	5	compound
4	-	-	:	_	5	punct
5	pectin	pectin	NN	_	1	appos
6	,	,	,	_	5	punct
7	drug3	drug3	NN	_	5	conj
8	,	,	,	_	5	punct
9	drug4	drug4	NN	_	5	conj
10	,	,	,	_	5	punct
11	drug5	drug5	NN	_	5	conj
12	,	,	,	_	5	punct
13	certain	certain	JJ	_	15	amod
14	anticancer	anticancer	JJ	_	15	amod
15	drugs	drug	NNS	_	5	conj
16	,	,	,	_	5	punct
17	and	and	CC	_	5	cc
18	drug6	drug6	NN	_	5	conj
19	may	may	MD	_	20	aux
20	interfere	interfere	VB	_	0	ROOT
21	with	with	IN	_	24	case
22	intestinal	intestinal	JJ	_	24	amod
23	drug7	drug7	NN	_	24	compound
24	absorption	absorption	NN	_	20	nmod
25	,	,	,	_	20	punct
26	resulting	result	VBG	_	20	advcl
27	in	in	IN	_	31	case
28	unexpectedly	unexpectedly	RB	_	29	advmod
29	low	low	JJ	_	31	amod
30	serum	serum	NN	_	31	compound
31	concentrations	concentration	NNS	_	26	nmod
32	.	.	.	_	20	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	decrease	decrease	VB	_	0	ROOT
4	serum	serum	NN	_	6	compound
5	drug2	drug2	NN	_	6	compound
6	concentration	concentration	NN	_	3	dobj
7	,	,	,	_	3	punct
8	especially	especially	RB	_	10	advmod
9	in	in	IN	_	10	case
10	patients	patient	NNS	_	3	nmod
11	with	with	IN	_	13	case
12	renal	renal	JJ	_	13	amod
13	dysfunction	dysfunction	NN	_	10	nmod
14	,	,	,	_	3	punct
15	by	by	IN	_	16	mark
16	increasing	increase	VBG	_	3	advcl
17	the	the	DT	_	19	det
18	non-renal	non-renal	JJ	_	19	amod
19	clearance	clearance	NN	_	16	dobj
20	of	of	IN	_	21	case
21	drug3	drug3	NN	_	19	nmod
22	.	.	.	_	3	punct

1	There	there	EX	_	5	expl
2	have	have	VBP	_	5	aux
3	been	be	VBN	_	5	cop
4	inconsistent	inconsistent	JJ	_	5	amod
5	reports	report	NNS	_	0	ROOT
6	regarding	regard	VBG	_	8	case
7	the	the	DT	_	8	det
8	effects	effect	NNS	_	5	nmod
9	of	of	IN	_	11	case
10	other	other	JJ	_	11	amod
11	drugs	drug	NNS	_	8	nmod
12	-LRB-	-lrb-	-LRB-	_	15	punct
13	e.g.	e.g.	FW	_	15	dep
14	,	,	,	_	15	punct
15	drug1	drug1	NN	_	11	dep
16	,	,	,	_	15	punct
17	drug2	drug2	NN	_	15	appos
18	-RRB-	-rrb-	-RRB-	_	15	punct
19	on	on	IN	_	22	case
20	serum	serum	NN	_	22	compound
21	drug3	drug3	NN	_	22	compound
22	concentration	concentration	NN	_	8	nmod
23	.	.	.	_	5	punct

1	drug1	drug1	NN	_	2	compound
2	administration	administration	NN	_	10	nsubj
3	to	to	TO	_	8	case
4	a	a	DT	_	8	det
5	digitalized	digitalized	JJ	_	8	amod
6	,	,	,	_	8	punct
7	hypothyroid	hypothyroid	JJ	_	8	amod
8	patient	patient	NN	_	2	nmod
9	may	may	MD	_	10	aux
10	increase	increase	VB	_	0	ROOT
11	the	the	DT	_	13	det
12	dose	dose	NN	_	13	compound
13	requirement	requirement	NN	_	10	dobj
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	.	.	.	_	10	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	use	use	NN	_	7	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	increases	increase	VBZ	_	0	ROOT
8	the	the	DT	_	9	det
9	risk	risk	NN	_	7	dobj
10	of	of	IN	_	12	case
11	cardiac	cardiac	JJ	_	12	amod
12	arrhythmias	arrhythmia	NNS	_	9	nmod
13	.	.	.	_	7	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	cause	cause	VB	_	0	ROOT
4	a	a	DT	_	6	det
5	sudden	sudden	JJ	_	6	amod
6	extrusion	extrusion	NN	_	3	dobj
7	of	of	IN	_	8	case
8	potassium	potassium	NN	_	6	nmod
9	from	from	IN	_	11	case
10	muscle	muscle	NN	_	11	compound
11	cells	cell	NNS	_	6	nmod
12	,	,	,	_	3	punct
13	and	and	CC	_	3	cc
14	may	may	MD	_	16	aux
15	thereby	thereby	RB	_	16	advmod
16	cause	cause	VB	_	3	conj
17	arrhythmias	arrhythmia	NNS	_	16	dobj
18	in	in	IN	_	20	case
19	digitalized	digitalized	JJ	_	20	amod
20	patients	patient	NNS	_	17	nmod
21	.	.	.	_	3	punct

1	Although	although	IN	_	9	mark
2	drug1	drug1	NN	_	9	nsubj
3	or	or	CC	_	2	cc
4	drug2	drug2	NN	_	2	conj
5	and	and	CC	_	2	cc
6	drug3	drug3	NN	_	2	conj
7	may	may	MD	_	9	aux
8	be	be	VB	_	9	cop
9	useful	useful	JJ	_	25	advcl
10	in	in	IN	_	11	case
11	combination	combination	NN	_	9	nmod
12	to	to	TO	_	13	mark
13	control	control	VB	_	11	acl
14	atrial	atrial	JJ	_	15	amod
15	fibrillation	fibrillation	NN	_	13	dobj
16	,	,	,	_	25	punct
17	their	they	PRP$	_	19	nmod:poss
18	additive	additive	JJ	_	19	amod
19	effects	effect	NNS	_	25	nsubj
20	on	on	IN	_	23	case
21	AV	av	NN	_	23	compound
22	node	node	NN	_	23	compound
23	conduction	conduction	NN	_	19	nmod
24	can	can	MD	_	25	aux
25	result	result	VB	_	0	ROOT
26	in	in	IN	_	31	case
27	advanced	advanced	JJ	_	31	amod
28	or	or	CC	_	27	cc
29	complete	complete	JJ	_	27	conj
30	heart	heart	NN	_	31	compound
31	block	block	NN	_	25	nmod
32	.	.	.	_	25	punct

1	Due	due	JJ	_	5	case
2	to	to	TO	_	1	mwe
3	the	the	DT	_	5	det
4	considerable	considerable	JJ	_	5	amod
5	variability	variability	NN	_	16	nmod
6	of	of	IN	_	8	case
7	these	these	DT	_	8	det
8	interactions	interaction	NNS	_	5	nmod
9	,	,	,	_	16	punct
10	the	the	DT	_	11	det
11	dosage	dosage	NN	_	16	nsubjpass
12	of	of	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	should	should	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	individualized	individualize	VBN	_	0	ROOT
17	when	when	WRB	_	19	advmod
18	patients	patient	NNS	_	19	nsubj
19	receive	receive	VBP	_	16	advcl
20	these	these	DT	_	21	det
21	medications	medication	NNS	_	19	dobj
22	concurrently	concurrently	RB	_	19	advmod
23	.	.	.	_	16	punct

1	Furthermore	furthermore	RB	_	6	advmod
2	,	,	,	_	6	punct
3	caution	caution	NN	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	exercised	exercise	VBN	_	33	csubj
7	when	when	WRB	_	8	advmod
8	combining	combine	VBG	_	6	advcl
9	drug1	drug1	NN	_	8	dobj
10	with	with	IN	_	12	case
11	any	any	DT	_	12	det
12	drug	drug	NN	_	8	nmod
13	that	that	WDT	_	15	nsubj
14	may	may	MD	_	15	aux
15	cause	cause	VB	_	12	acl:relcl
16	a	a	DT	_	18	det
17	significant	significant	JJ	_	18	amod
18	deterioration	deterioration	NN	_	15	dobj
19	in	in	IN	_	21	case
20	renal	renal	JJ	_	21	amod
21	function	function	NN	_	18	nmod
22	,	,	,	_	6	punct
23	since	since	IN	_	25	case
24	a	a	DT	_	25	det
25	decline	decline	NN	_	6	nmod
26	in	in	IN	_	28	case
27	glomerular	glomerular	JJ	_	28	amod
28	filtration	filtration	NN	_	25	nmod
29	or	or	CC	_	28	cc
30	tubular	tubular	JJ	_	31	amod
31	secretion	secretion	NN	_	28	conj
32	may	may	MD	_	33	aux
33	impair	impair	VB	_	0	ROOT
34	the	the	DT	_	35	det
35	excretion	excretion	NN	_	33	dobj
36	of	of	IN	_	37	case
37	drug2	drug2	NN	_	35	nmod
38	.	.	.	_	33	punct

1	Drug	drug	NN	_	2	compound
2	interactions	interaction	NNS	_	10	nsubjpass
3	with	with	IN	_	6	case
4	drug1	drug1	NN	_	6	compound
5	tablets	tablet	NNS	_	6	compound
6	USP	USP	NNP	_	2	nmod
7	have	have	VBP	_	10	aux
8	not	not	RB	_	10	neg
9	been	be	VBN	_	10	auxpass
10	documented	document	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	Administration	administration	NN	_	15	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	to	to	TO	_	6	case
5	hypoparathyroid	hypoparathyroid	JJ	_	6	amod
6	patients	patient	NNS	_	1	nmod
7	who	who	WP	_	11	nsubjpass
8	are	be	VBP	_	11	aux
9	concurrently	concurrently	RB	_	11	advmod
10	being	be	VBG	_	11	auxpass
11	treated	treat	VBN	_	6	acl:relcl
12	with	with	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	may	may	MD	_	15	aux
15	cause	cause	VB	_	0	ROOT
16	hypercalcemia	hypercalcemia	NN	_	15	dobj
17	.	.	.	_	15	punct

1	drug1	drug1	NN	_	8	nsubjpass
2	,	,	,	_	1	punct
3	a	a	DT	_	4	det
4	drug2	drug2	NN	_	1	appos
5	,	,	,	_	1	punct
6	has	have	VBZ	_	8	aux
7	been	be	VBN	_	8	auxpass
8	reported	report	VBN	_	0	ROOT
9	to	to	TO	_	10	mark
10	inactivate	inactivate	VB	_	8	xcomp
11	the	the	DT	_	13	det
12	antifungal	antifungal	JJ	_	13	amod
13	activity	activity	NN	_	10	dobj
14	of	of	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	by	by	IN	_	18	case
17	competitive	competitive	JJ	_	18	amod
18	inhibition	inhibition	NN	_	10	nmod
19	.	.	.	_	8	punct

1	Drugs	drug	NNS	_	7	nsubj
2	which	which	WDT	_	3	nsubj
3	impair	impair	VBP	_	1	acl:relcl
4	glomerular	glomerular	JJ	_	5	amod
5	filtration	filtration	NN	_	3	dobj
6	may	may	MD	_	7	aux
7	prolong	prolong	VB	_	0	ROOT
8	the	the	DT	_	10	det
9	biological	biological	JJ	_	10	amod
10	half-life	half-life	NN	_	7	dobj
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	.	.	.	_	7	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	3	amod
2	Test	test	NN	_	3	compound
3	Interactions	interaction	NNS	_	0	ROOT
4	:	:	:	_	3	punct
5	Measurement	measurement	NN	_	12	nsubjpass
6	of	of	IN	_	9	case
7	serum	serum	NN	_	9	compound
8	creatinine	creatinine	NN	_	9	compound
9	levels	level	NNS	_	5	nmod
10	should	should	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	determined	determine	VBN	_	3	dep
13	by	by	IN	_	16	case
14	the	the	DT	_	16	det
15	Jaffe	Jaffe	NNP	_	16	compound
16	reaction	reaction	NN	_	12	nmod
17	,	,	,	_	12	punct
18	since	since	IN	_	22	mark
19	drug1	drug1	NN	_	22	nsubj
20	does	do	VBZ	_	22	aux
21	not	not	RB	_	22	neg
22	interfere	interfere	VB	_	12	advcl
23	with	with	IN	_	25	case
24	the	the	DT	_	25	det
25	determination	determination	NN	_	22	nmod
26	of	of	IN	_	28	case
27	creatinine	creatinine	NN	_	28	compound
28	values	value	NNS	_	25	nmod
29	by	by	IN	_	31	case
30	this	this	DT	_	31	det
31	method	method	NN	_	25	nmod
32	.	.	.	_	3	punct

1	Most	most	JJS	_	3	amod
2	automated	automated	JJ	_	3	amod
3	equipment	equipment	NN	_	8	nsubj
4	for	for	IN	_	5	case
5	measurement	measurement	NN	_	3	nmod
6	of	of	IN	_	7	case
7	creatinine	creatinine	NN	_	5	nmod
8	makes	make	VBZ	_	0	ROOT
9	use	use	NN	_	8	dobj
10	of	of	IN	_	13	case
11	the	the	DT	_	13	det
12	Jaffe	Jaffe	NNP	_	13	compound
13	reaction	reaction	NN	_	9	nmod
14	.	.	.	_	8	punct

1	-	-	:	_	4	punct
2	drug1	drug1	NN	_	4	nsubj
3	may	may	MD	_	4	aux
4	enhance	enhance	VB	_	0	ROOT
5	the	the	DT	_	8	det
6	CNS	cns	NN	_	8	compound
7	depressive	depressive	JJ	_	8	amod
8	effects	effect	NNS	_	4	dobj
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	,	,	,	_	10	punct
12	drug3	drug3	NN	_	10	conj
13	and	and	CC	_	10	cc
14	other	other	JJ	_	15	amod
15	drug4	drug4	NN	_	10	conj

1	.	.	.	_	0	ROOT

1	-	-	:	_	4	punct
2	drug1	drug1	NN	_	4	nsubj
3	may	may	MD	_	4	aux
4	enhance	enhance	VB	_	0	ROOT
5	the	the	DT	_	6	det
6	effects	effect	NNS	_	4	dobj
7	of	of	IN	_	9	case
8	drug2	drug2	NN	_	9	compound
9	therapy	therapy	NN	_	6	nmod

1	.	.	.	_	0	ROOT

1	-	-	:	_	7	punct
2	Concomitant	concomitant	JJ	_	3	amod
3	use	use	NN	_	7	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	may	may	MD	_	7	aux
7	reduce	reduce	VB	_	0	ROOT
8	the	the	DT	_	9	det
9	efficacy	efficacy	NN	_	7	dobj
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	.	.	.	_	7	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	8	nsubj
4	of	of	IN	_	7	case
5	human	human	JJ	_	7	amod
6	CYP	cyp	NN	_	7	compound
7	enzymes	enzyme	NNS	_	3	nmod
8	showed	show	VBD	_	0	ROOT
9	that	that	IN	_	11	mark
10	drug1	drug1	NN	_	11	nsubj
11	inhibited	inhibit	VBD	_	8	ccomp
12	the	the	DT	_	15	det
13	CYP	cyp	NN	_	15	compound
14	enzymes	enzyme	NNS	_	15	compound
15	1A2	1a2	NN	_	11	dobj
16	,	,	,	_	15	punct
17	2A6	2a6	NN	_	15	conj
18	,	,	,	_	15	punct
19	2C9	2c9	NN	_	15	conj
20	,	,	,	_	15	punct
21	2C19	2c19	NN	_	15	conj
22	,	,	,	_	15	punct
23	2D6	2d6	NN	_	15	conj
24	,	,	,	_	15	punct
25	2E1	2e1	NN	_	15	conj
26	and	and	CC	_	15	cc
27	3A	3a	NN	_	15	conj
28	only	only	RB	_	32	advmod
29	at	at	IN	_	32	case
30	very	very	RB	_	31	advmod
31	high	high	JJ	_	32	amod
32	concentrations	concentration	NNS	_	11	nmod
33	-LRB-	-lrb-	-LRB-	_	34	punct
34	IC50	ic50	NN	_	32	dep
35	from	from	IN	_	36	case
36	200	200	CD	_	34	nmod
37	to	to	TO	_	40	case
38	over	over	IN	_	39	advmod
39	1000	1000	CD	_	40	nummod
40	uM	um	NN	_	34	nmod
41	;	;	:	_	8	punct

1	an	a	DT	_	5	det
2	oral	oral	JJ	_	5	amod
3	200	200	CD	_	4	compound
4	mg	mg	NN	_	5	amod
5	dose	dose	NN	_	6	nsubj
6	achieves	achieve	VBZ	_	0	ROOT
7	a	a	DT	_	9	det
8	highest	highest	JJS	_	9	amod
9	level	level	NN	_	6	dobj
10	of	of	IN	_	13	case
11	approximately	approximately	RB	_	12	advmod
12	5	5	CD	_	13	nummod
13	uM	um	NN	_	9	nmod
14	in	in	IN	_	15	case
15	people	people	NNS	_	9	nmod
16	-RRB-	-rrb-	-RRB-	_	6	punct
17	;	;	:	_	6	punct

1	these	these	DT	_	2	det
2	enzymes	enzyme	NNS	_	7	nsubjpass
3	would	would	MD	_	7	aux
4	therefore	therefore	RB	_	7	advmod
5	not	not	RB	_	7	neg
6	be	be	VB	_	7	auxpass
7	expected	expect	VBN	_	0	ROOT
8	to	to	TO	_	10	mark
9	be	be	VB	_	10	auxpass
10	inhibited	inhibit	VBN	_	7	xcomp
11	in	in	IN	_	13	case
12	clinical	clinical	JJ	_	13	amod
13	use	use	NN	_	10	nmod
14	.	.	.	_	7	punct

1	Protein	protein	NN	_	2	compound
2	Binding	binding	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	drug1	drug1	NN	_	8	nsubj
5	is	be	VBZ	_	8	cop
6	highly	highly	RB	_	8	advmod
7	protein	protein	NN	_	8	nmod:npmod
8	bound	bind	VBD	_	2	dep
9	-LRB-	-lrb-	-LRB-	_	11	punct
10	98	98	CD	_	11	nummod
11	%	%	NN	_	8	dep
12	-RRB-	-rrb-	-RRB-	_	11	punct
13	.	.	.	_	2	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	5	nsubj
4	have	have	VBP	_	5	aux
5	shown	show	VBN	_	0	ROOT
6	no	no	DT	_	8	neg
7	binding	binding	NN	_	8	compound
8	displacement	displacement	NN	_	5	dobj
9	between	between	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	other	other	JJ	_	15	amod
13	highly	highly	RB	_	14	advmod
14	bound	bind	VBN	_	15	amod
15	drugs	drug	NNS	_	10	conj
16	,	,	,	_	15	punct
17	such	such	JJ	_	19	case
18	as	as	IN	_	17	mwe
19	drug2	drug2	NN	_	15	nmod
20	,	,	,	_	19	punct
21	drug3	drug3	NN	_	19	conj
22	,	,	,	_	19	punct
23	drug4	drug4	NN	_	19	conj
24	,	,	,	_	19	punct
25	and	and	CC	_	19	cc
26	drug5	drug5	NN	_	19	conj
27	.	.	.	_	5	punct

1	Drugs	drug	NNS	_	0	ROOT
2	Metabolized	metabolize	VBN	_	1	acl
3	by	by	IN	_	4	case
4	Catechol-O-methyltransferase	catechol-o-methyltransferase	NN	_	2	nmod
5	-LRB-	-lrb-	-LRB-	_	6	punct
6	COMT	comt	NN	_	4	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	:	:	:	_	1	punct
9	Hormone	hormone	NN	_	10	compound
10	levels	level	NNS	_	1	dep
11	:	:	:	_	10	punct
12	drug1	drug1	NN	_	14	nsubjpass
13	is	be	VBZ	_	14	auxpass
14	known	know	VBN	_	10	dep
15	to	to	TO	_	16	mark
16	depress	depress	VB	_	14	xcomp
17	prolactin	prolactin	NN	_	18	compound
18	secretion	secretion	NN	_	16	dobj
19	and	and	CC	_	18	cc
20	increase	increase	NN	_	23	compound
21	growth	growth	NN	_	23	compound
22	hormone	hormone	NN	_	23	compound
23	levels	level	NNS	_	18	conj
24	.	.	.	_	1	punct

1	Treatment	treatment	NN	_	4	nsubj
2	with	with	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	coadministered	coadminister	VBN	_	0	ROOT
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	/	/	:	_	4	punct
8	drug3	drug3	NN	_	11	nsubj
9	does	do	VBZ	_	11	aux
10	not	not	RB	_	11	neg
11	change	change	VB	_	4	parataxis
12	these	these	DT	_	13	det
13	effects	effect	NNS	_	11	dobj
14	.	.	.	_	4	punct

1	No	no	DT	_	2	neg
2	interaction	interaction	NN	_	4	nsubjpass
3	was	be	VBD	_	4	auxpass
4	noted	note	VBN	_	0	ROOT
5	with	with	IN	_	8	case
6	the	the	DT	_	8	det
7	drug1	drug1	NN	_	8	compound
8	drug2	drug2	NN	_	4	nmod
9	in	in	IN	_	13	case
10	two	two	CD	_	13	nummod
11	multiple-dose	multiple-dose	JJ	_	13	amod
12	interaction	interaction	NN	_	13	compound
13	studies	study	NNS	_	8	nmod
14	when	when	WRB	_	17	advmod
15	drug3	drug3	NN	_	17	nsubjpass
16	was	be	VBD	_	17	auxpass
17	coadministered	coadminister	VBN	_	4	advcl
18	with	with	IN	_	22	case
19	a	a	DT	_	22	det
20	drug4	drug4	NN	_	22	compound
21	/	/	:	_	22	punct
22	drug5	drug5	NN	_	17	nmod
23	-LRB-	-lrb-	-LRB-	_	24	punct
24	n	n	NN	_	22	dep
25	=	=	JJ	_	24	amod
26	29	29	CD	_	25	dep
27	-RRB-	-rrb-	-RRB-	_	24	punct
28	.	.	.	_	4	punct

1	More	more	JJR	_	3	advmod
2	than	than	IN	_	1	mwe
3	600	600	CD	_	6	nummod
4	Parkinsons	Parkinsons	NNPS	_	6	compound
5	disease	disease	NN	_	6	compound
6	patients	patient	NNS	_	11	nsubj
7	in	in	IN	_	9	case
8	clinical	clinical	JJ	_	9	amod
9	trials	trial	NNS	_	6	nmod
10	have	have	VBP	_	11	aux
11	used	use	VBN	_	0	ROOT
12	drug1	drug1	NN	_	11	dobj
13	in	in	IN	_	14	case
14	combination	combination	NN	_	11	nmod
15	with	with	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	and	and	CC	_	16	cc
18	drug3	drug3	NN	_	16	conj
19	/	/	:	_	16	punct
20	drug4	drug4	NN	_	16	dep
21	.	.	.	_	11	punct

1	As	as	IN	_	8	mark
2	most	most	JJS	_	4	amod
3	drug1	drug1	NN	_	4	compound
4	excretion	excretion	NN	_	8	nsubj
5	is	be	VBZ	_	8	cop
6	via	via	IN	_	8	case
7	the	the	DT	_	8	det
8	bile	bile	NN	_	13	advcl
9	,	,	,	_	13	punct
10	caution	caution	NN	_	13	nsubjpass
11	should	should	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	exercised	exercise	VBN	_	0	ROOT
14	when	when	WRB	_	29	advmod
15	drugs	drug	NNS	_	29	nsubjpass
16	known	know	VBN	_	15	acl
17	to	to	TO	_	18	mark
18	interfere	interfere	VB	_	16	xcomp
19	with	with	IN	_	21	case
20	biliary	biliary	JJ	_	21	amod
21	excretion	excretion	NN	_	18	nmod
22	,	,	,	_	21	punct
23	glucuronidation	glucuronidation	NN	_	21	conj
24	,	,	,	_	21	punct
25	and	and	CC	_	21	cc
26	intestinal	intestinal	JJ	_	27	amod
27	beta-glucuronidase	beta-glucuronidase	NN	_	21	conj
28	are	be	VBP	_	29	auxpass
29	given	give	VBN	_	13	advcl
30	concurrently	concurrently	RB	_	29	advmod
31	with	with	IN	_	32	case
32	drug2	drug2	NN	_	29	nmod
33	.	.	.	_	13	punct

1	These	these	DT	_	2	nsubj
2	include	include	VBP	_	0	ROOT
3	drug1	drug1	NN	_	2	dobj
4	,	,	,	_	3	punct
5	drug2	drug2	NN	_	3	conj
6	,	,	,	_	3	punct
7	and	and	CC	_	3	cc
8	some	some	DT	_	9	det
9	drug3	drug3	NN	_	3	conj
10	-LRB-	-lrb-	-LRB-	_	9	punct
11	e.g.	e.g.	FW	_	10	root
12	drug4	drug4	FW	_	11	dep
13	,	,	,	_	12	punct
14	rifamipicin	rifamipicin	NN	_	12	conj
15	,	,	,	_	12	punct
16	drug5	drug5	NN	_	12	conj
17	and	and	CC	_	12	cc
18	drug6	drug6	NN	_	12	conj
19	-RRB-	-rrb-	-RRB-	_	11	punct
20	.	.	.	_	11	punct

1	No	no	DT	_	2	neg
2	interaction	interaction	NN	_	8	nsubjpass
3	with	with	IN	_	6	case
4	the	the	DT	_	6	det
5	drug1	drug1	NN	_	6	compound
6	drug2	drug2	NN	_	2	nmod
7	was	be	VBD	_	8	auxpass
8	shown	show	VBN	_	0	ROOT
9	in	in	IN	_	12	case
10	a	a	DT	_	12	det
11	single-dose	single-dose	JJ	_	12	amod
12	study	study	NN	_	8	nmod
13	with	with	IN	_	14	case
14	drug3	drug3	NN	_	12	nmod
15	without	without	IN	_	19	case
16	coadministered	coadminister	VBN	_	19	amod
17	drug4	drug4	NN	_	19	compound
18	/	/	:	_	19	punct
19	drug5	drug5	NN	_	8	nmod
20	.	.	.	_	8	punct

1	Co-treatment	co-treatment	NN	_	8	nsubj
2	with	with	IN	_	7	case
3	the	the	DT	_	7	det
4	potent	potent	JJ	_	7	amod
5	CYP3A4	cyp3a4	NN	_	7	compound
6	inhibitor	inhibitor	NN	_	7	compound
7	drug1	drug1	NN	_	1	nmod
8	increases	increase	VBZ	_	0	ROOT
9	drug2	drug2	NN	_	10	compound
10	AUC	auc	NN	_	8	dobj
11	by	by	IN	_	12	case
12	2/3	2/3	CD	_	8	nmod
13	.	.	.	_	8	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	when	when	WRB	_	6	advmod
6	administering	administer	VBG	_	4	advcl
7	or	or	CC	_	6	cc
8	taking	take	VBG	_	6	conj
9	drug1	drug1	NN	_	6	dobj
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	other	other	JJ	_	16	amod
14	strong	strong	JJ	_	16	amod
15	CYP3A4	cyp3a4	NN	_	16	compound
16	inhibitors	inhibitor	NNS	_	11	conj
17	such	such	JJ	_	22	nmod
18	as	as	IN	_	17	mwe
19	,	,	,	_	22	punct
20	but	but	CC	_	22	cc
21	not	not	RB	_	22	neg
22	limited	limit	VBN	_	16	acl
23	to	to	TO	_	22	dep
24	,	,	,	_	23	punct
25	drug3	drug3	NN	_	24	root
26	,	,	,	_	25	punct
27	drug4	drug4	NN	_	26	root
28	,	,	,	_	27	punct
29	drug5	drug5	NN	_	28	root
30	,	,	,	_	29	punct
31	drug6	drug6	NN	_	30	root
32	,	,	,	_	31	punct
33	drug7	drug7	NN	_	32	root
34	,	,	,	_	33	punct
35	drug8	drug8	NN	_	34	root
36	,	,	,	_	35	punct
37	drug9	drug9	NN	_	36	root
38	,	,	,	_	37	punct
39	drug10	drug10	NN	_	38	root
40	,	,	,	_	39	punct
41	drug11	drug11	NN	_	40	root
42	,	,	,	_	41	punct
43	drug12	drug12	NN	_	42	root
44	-LRB-	-lrb-	-LRB-	_	45	punct
45	drug13	drug13	NN	_	43	appos
46	-RRB-	-rrb-	-RRB-	_	45	punct
47	,	,	,	_	43	punct
48	and	and	CC	_	43	cc
49	drug14	drug14	NN	_	43	conj
50	.	.	.	_	43	punct

1	Pre-treatment	pre-treatment	NN	_	7	nsubj
2	with	with	IN	_	6	case
3	the	the	DT	_	6	det
4	CYP3A4	cyp3a4	NN	_	6	compound
5	inducer	inducer	NN	_	6	compound
6	drug1	drug1	NN	_	1	nmod
7	decreased	decrease	VBD	_	0	ROOT
8	drug2	drug2	NN	_	9	compound
9	AUC	auc	NN	_	7	dobj
10	by	by	IN	_	12	case
11	about	about	IN	_	12	advmod
12	2/3	2/3	CD	_	7	nmod
13	.	.	.	_	7	punct

1	Alternate	alternate	JJ	_	2	amod
2	treatments	treatment	NNS	_	9	nsubjpass
3	lacking	lack	VBG	_	2	acl
4	CYP3A4	cyp3a4	NN	_	6	compound
5	inducing	inducing	NN	_	6	compound
6	activity	activity	NN	_	3	dobj
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	considered	consider	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	If	if	IN	_	6	mark
2	an	a	DT	_	4	det
3	alternative	alternative	JJ	_	4	amod
4	treatment	treatment	NN	_	6	nsubj
5	is	be	VBZ	_	6	cop
6	unavailable	unavailable	JJ	_	17	advcl
7	,	,	,	_	17	punct
8	a	a	DT	_	10	det
9	drug1	drug1	NN	_	10	compound
10	dose	dose	NN	_	17	nsubjpass
11	greater	greater	JJR	_	10	amod
12	than	than	IN	_	14	case
13	150	150	CD	_	14	nummod
14	mg	mg	NN	_	11	nmod
15	should	should	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	considered	consider	VBN	_	0	ROOT
18	for	for	IN	_	20	case
19	NSCLC	nsclc	NN	_	20	compound
20	patients	patient	NNS	_	17	nmod
21	,	,	,	_	17	punct
22	and	and	CC	_	17	cc
23	greater	greater	JJR	_	25	advmod
24	than	than	IN	_	25	advmod
25	100	100	CD	_	26	nummod
26	mg	mg	NN	_	17	conj
27	considered	consider	VBN	_	26	acl
28	for	for	IN	_	31	case
29	pancreatic	pancreatic	JJ	_	31	amod
30	cancer	cancer	NN	_	31	compound
31	patients	patient	NNS	_	27	nmod
32	.	.	.	_	17	punct

1	If	if	IN	_	6	mark
2	the	the	DT	_	4	det
3	drug1	drug1	NN	_	4	compound
4	dose	dose	NN	_	6	nsubjpass
5	is	be	VBZ	_	6	auxpass
6	adjusted	adjust	VBN	_	12	advcl
7	upward	upward	RB	_	6	advmod
8	,	,	,	_	12	punct
9	the	the	DT	_	10	det
10	dose	dose	NN	_	12	nsubj
11	will	will	MD	_	12	aux
12	need	need	VB	_	0	ROOT
13	to	to	TO	_	15	mark
14	be	be	VB	_	15	auxpass
15	reduced	reduce	VBN	_	12	xcomp
16	upon	upon	IN	_	17	case
17	discontinuation	discontinuation	NN	_	15	nmod
18	of	of	IN	_	19	case
19	drug2	drug2	NN	_	17	nmod
20	or	or	CC	_	19	cc
21	other	other	JJ	_	22	amod
22	inducers	inducer	NNS	_	19	conj
23	.	.	.	_	12	punct

1	Other	other	JJ	_	3	amod
2	CYP3A4	cyp3a4	NN	_	3	compound
3	inducers	inducer	NNS	_	4	nsubj
4	include	include	VBP	_	0	ROOT
5	,	,	,	_	4	punct
6	but	but	CC	_	4	cc
7	are	be	VBP	_	9	auxpass
8	not	not	RB	_	9	neg
9	limited	limit	VBN	_	4	conj
10	to	to	TO	_	9	dep
11	,	,	,	_	10	punct
12	drug1	drug1	NN	_	11	root
13	,	,	,	_	12	punct
14	drug2	drug2	NN	_	13	root
15	,	,	,	_	14	punct
16	drug3	drug3	NN	_	15	root
17	,	,	,	_	16	punct
18	drug4	drug4	NN	_	17	root
19	,	,	,	_	18	punct
20	drug5	drug5	NN	_	18	conj
21	and	and	CC	_	18	cc
22	St.	St.	NNP	_	24	compound
23	Johns	Johns	NNP	_	24	compound
24	Wort	Wort	NNP	_	18	conj
25	.	.	.	_	18	punct

1	Hepatotoxicity	hepatotoxicity	NN	_	3	compound
2	Asymptomatic	asymptomatic	JJ	_	3	amod
3	increases	increase	NNS	_	9	nsubjpass
4	in	in	IN	_	6	case
5	liver	liver	NN	_	6	compound
6	transaminases	transaminase	NNS	_	3	nmod
7	have	have	VBP	_	9	aux
8	been	be	VBN	_	9	auxpass
9	observed	observe	VBN	_	0	ROOT
10	in	in	IN	_	13	case
11	drug1	drug1	NN	_	13	compound
12	treated	treated	JJ	_	13	amod
13	patients	patient	NNS	_	9	nmod
14	;	;	:	_	9	punct

1	therefore	therefore	RB	_	18	advmod
2	,	,	,	_	18	punct
3	periodic	periodic	JJ	_	6	amod
4	liver	liver	NN	_	6	compound
5	function	function	NN	_	6	compound
6	testing	testing	NN	_	18	nsubjpass
7	-LRB-	-lrb-	-LRB-	_	8	punct
8	transaminases	transaminase	NNS	_	6	dep
9	,	,	,	_	8	punct
10	bilirubin	bilirubin	NN	_	8	conj
11	,	,	,	_	8	punct
12	and	and	CC	_	8	cc
13	alkaline	alkaline	NN	_	14	compound
14	phosphatase	phosphatase	NN	_	8	conj
15	-RRB-	-rrb-	-RRB-	_	8	punct
16	should	should	MD	_	18	aux
17	be	be	VB	_	18	auxpass
18	considered	consider	VBN	_	0	ROOT
19	.	.	.	_	18	punct

1	Dose	dose	NN	_	2	compound
2	reduction	reduction	NN	_	9	nsubjpass
3	or	or	CC	_	2	cc
4	interruption	interruption	NN	_	2	conj
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	2	nmod
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	considered	consider	VBN	_	0	ROOT
10	if	if	IN	_	16	mark
11	changes	change	NNS	_	16	nsubj
12	in	in	IN	_	14	case
13	liver	liver	NN	_	14	compound
14	function	function	NN	_	11	nmod
15	are	be	VBP	_	16	cop
16	severe	severe	JJ	_	9	advcl
17	.	.	.	_	9	punct

1	Patients	patient	NNS	_	11	nmod
2	with	with	IN	_	4	case
3	Hepatic	hepatic	JJ	_	4	amod
4	Impairment	impairment	NN	_	1	nmod
5	In	in	FW	_	6	compound
6	vitro	vitro	FW	_	7	advmod
7	and	and	CC	_	11	cc
8	in	in	FW	_	10	amod
9	vivo	vivo	FW	_	8	dep
10	evidence	evidence	NN	_	11	nsubj
11	suggest	suggest	VBP	_	0	ROOT
12	that	that	IN	_	15	mark
13	drug1	drug1	NN	_	15	nsubjpass
14	is	be	VBZ	_	15	auxpass
15	cleared	clear	VBN	_	11	ccomp
16	primarily	primarily	RB	_	15	advmod
17	by	by	IN	_	19	case
18	the	the	DT	_	19	det
19	liver	liver	NN	_	15	nmod
20	.	.	.	_	11	punct

1	Therefore	therefore	RB	_	7	advmod
2	,	,	,	_	7	punct
3	drug1	drug1	NN	_	4	compound
4	exposure	exposure	NN	_	7	nsubjpass
5	may	may	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	increased	increase	VBN	_	0	ROOT
8	in	in	IN	_	9	case
9	patients	patient	NNS	_	7	nmod
10	with	with	IN	_	12	case
11	hepatic	hepatic	JJ	_	12	amod
12	dysfunction	dysfunction	NN	_	9	nmod
13	.	.	.	_	7	punct

1	Elevated	elevated	JJ	_	4	amod
2	International	International	NNP	_	4	compound
3	Normalized	Normalized	NNP	_	4	compound
4	Ratio	Ratio	NNP	_	28	nsubjpass
5	and	and	CC	_	4	cc
6	Potential	potential	JJ	_	10	amod
7	Bleeding	Bleeding	NNP	_	10	compound
8	International	International	NNP	_	10	compound
9	Normalized	Normalized	NNP	_	10	compound
10	Ratio	Ratio	NNP	_	4	conj
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	INR	INR	NNP	_	10	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	elevations	elevation	NNS	_	4	dep
15	and	and	CC	_	4	cc
16	infrequent	infrequent	JJ	_	17	amod
17	reports	report	NNS	_	4	conj
18	of	of	IN	_	20	case
19	bleeding	bleed	VBG	_	20	amod
20	events	event	NNS	_	17	nmod
21	including	include	VBG	_	25	case
22	gastrointestinal	gastrointestinal	JJ	_	25	amod
23	and	and	CC	_	22	cc
24	non-gastrointestinal	non-gastrointestinal	JJ	_	22	conj
25	bleedings	bleeding	NNS	_	20	nmod
26	have	have	VBP	_	28	aux
27	been	be	VBN	_	28	auxpass
28	reported	report	VBN	_	0	ROOT
29	in	in	IN	_	31	case
30	clinical	clinical	JJ	_	31	amod
31	studies	study	NNS	_	28	nmod
32	,	,	,	_	28	punct
33	some	some	DT	_	28	dobj
34	associated	associate	VBN	_	33	acl
35	with	with	IN	_	38	case
36	concomitant	concomitant	JJ	_	38	amod
37	drug1	drug1	NN	_	38	compound
38	administration	administration	NN	_	34	nmod
39	.	.	.	_	28	punct

1	Patients	patient	NNS	_	9	nsubjpass
2	taking	take	VBG	_	1	acl
3	drug1	drug1	NN	_	2	dobj
4	or	or	CC	_	3	cc
5	other	other	JJ	_	6	amod
6	drug2	drug2	NN	_	3	conj
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	monitored	monitor	VBN	_	0	ROOT
10	regularly	regularly	RB	_	9	advmod
11	for	for	IN	_	12	case
12	changes	change	NNS	_	9	nmod
13	in	in	IN	_	15	case
14	prothrombin	prothrombin	NN	_	15	compound
15	time	time	NN	_	12	nmod
16	or	or	CC	_	15	cc
17	INR	inr	NN	_	15	conj

1	.	.	.	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	decrease	decrease	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	effectiveness	effectiveness	NN	_	3	dobj
6	of	of	IN	_	8	case
7	oral	oral	JJ	_	8	amod
8	drug2	drug2	NN	_	5	nmod
9	,	,	,	_	8	punct
10	certain	certain	JJ	_	11	amod
11	drug3	drug3	NN	_	8	conj
12	,	,	,	_	8	punct
13	drug4	drug4	NN	_	8	conj
14	,	,	,	_	8	punct
15	drug5	drug5	NN	_	8	conj
16	,	,	,	_	8	punct
17	drug6	drug6	NN	_	8	conj
18	,	,	,	_	8	punct
19	drug7	drug7	NN	_	8	conj
20	,	,	,	_	8	punct
21	and	and	CC	_	8	cc
22	drug8	drug8	NN	_	8	conj
23	.	.	.	_	3	punct

1	drug1	drug1	NN	_	5	nsubj
2	is	be	VBZ	_	5	cop
3	a	a	DT	_	5	det
4	potent	potent	JJ	_	5	amod
5	inhibitor	inhibitor	NN	_	0	ROOT
6	of	of	IN	_	12	case
7	the	the	DT	_	12	det
8	cytochrome	cytochrome	NN	_	12	compound
9	P450	p450	NN	_	12	compound
10	3A4	3a4	NN	_	12	compound
11	enzyme	enzyme	NN	_	12	compound
12	system	system	NN	_	5	nmod
13	.	.	.	_	5	punct

1	Coadministration	coadministration	NN	_	17	nsubj
2	of	of	IN	_	4	case
3	drug1	drug1	NN	_	4	compound
4	Tablets	tablet	NNS	_	1	nmod
5	and	and	CC	_	4	cc
6	drugs	drug	NNS	_	4	conj
7	primarily	primarily	RB	_	8	advmod
8	metabolized	metabolize	VBN	_	1	acl
9	by	by	IN	_	15	case
10	the	the	DT	_	15	det
11	cytochrome	cytochrome	NN	_	15	compound
12	P450	p450	NN	_	15	compound
13	3A4	3a4	NN	_	15	compound
14	enzyme	enzyme	NN	_	15	compound
15	system	system	NN	_	8	nmod
16	may	may	MD	_	17	aux
17	result	result	VB	_	0	ROOT
18	in	in	IN	_	21	case
19	increased	increase	VBN	_	21	amod
20	plasma	plasma	NN	_	21	compound
21	concentrations	concentration	NNS	_	17	nmod
22	of	of	IN	_	24	case
23	the	the	DT	_	24	det
24	drugs	drug	NNS	_	21	nmod
25	that	that	WDT	_	27	nsubj
26	could	could	MD	_	27	aux
27	increase	increase	VB	_	24	acl:relcl
28	or	or	CC	_	27	cc
29	prolong	prolong	VB	_	27	conj
30	both	both	DT	_	31	cc:preconj
31	therapeutic	therapeutic	JJ	_	34	amod
32	and	and	CC	_	31	cc
33	adverse	adverse	JJ	_	31	conj
34	effects	effect	NNS	_	27	dobj
35	.	.	.	_	17	punct

1	Therefore	therefore	RB	_	12	advmod
2	,	,	,	_	12	punct
3	unless	unless	IN	_	5	mark
4	otherwise	otherwise	RB	_	5	advmod
5	specified	specify	VBN	_	12	advcl
6	,	,	,	_	12	punct
7	appropriate	appropriate	JJ	_	9	amod
8	dosage	dosage	NN	_	9	compound
9	adjustments	adjustment	NNS	_	12	nsubj
10	may	may	MD	_	12	aux
11	be	be	VB	_	12	cop
12	necessary	necessary	JJ	_	0	ROOT
13	.	.	.	_	12	punct

1	The	the	DT	_	4	det
2	following	follow	VBG	_	4	amod
3	drug	drug	NN	_	4	compound
4	interactions	interaction	NNS	_	7	nsubjpass
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	identified	identify	VBN	_	0	ROOT
8	involving	involve	VBG	_	7	xcomp
9	drug1	drug1	NN	_	10	compound
10	Tablets	tablet	NNS	_	8	dobj
11	and	and	CC	_	10	cc
12	other	other	JJ	_	13	amod
13	drugs	drug	NNS	_	10	conj
14	metabolized	metabolize	VBN	_	10	acl
15	by	by	IN	_	21	case
16	the	the	DT	_	21	det
17	cytochrome	cytochrome	NN	_	21	compound
18	P450	p450	NN	_	21	compound
19	3A4	3a4	NN	_	21	compound
20	enzyme	enzyme	NN	_	21	compound
21	system	system	NN	_	14	nmod
22	:	:	:	_	7	punct
23	drug2	drug2	NN	_	24	compound
24	tablets	tablet	NNS	_	25	nsubj
25	inhibit	inhibit	VBP	_	7	parataxis
26	the	the	DT	_	27	det
27	metabolism	metabolism	NN	_	25	dobj
28	of	of	IN	_	29	case
29	drug3	drug3	NN	_	27	nmod
30	,	,	,	_	25	punct
31	resulting	result	VBG	_	25	advcl
32	in	in	IN	_	36	case
33	an	a	DT	_	36	det
34	increased	increase	VBN	_	36	amod
35	plasma	plasma	NN	_	36	compound
36	concentration	concentration	NN	_	31	nmod
37	of	of	IN	_	38	case
38	drug4	drug4	NN	_	36	nmod
39	and	and	CC	_	36	cc
40	a	a	DT	_	41	det
41	delay	delay	NN	_	36	conj
42	in	in	IN	_	44	case
43	the	the	DT	_	44	det
44	elimination	elimination	NN	_	41	nmod
45	of	of	IN	_	48	case
46	its	its	PRP$	_	48	nmod:poss
47	acid	acid	NN	_	48	compound
48	metabolite	metabolite	NN	_	44	nmod
49	.	.	.	_	7	punct

1	The	the	DT	_	4	det
2	increased	increase	VBN	_	4	amod
3	plasma	plasma	NN	_	4	compound
4	concentration	concentration	NN	_	11	nsubj
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	or	or	CC	_	6	cc
8	its	its	PRP$	_	9	nmod:poss
9	metabolite	metabolite	NN	_	6	conj
10	may	may	MD	_	11	aux
11	result	result	VB	_	0	ROOT
12	in	in	IN	_	15	case
13	prolonged	prolonged	JJ	_	15	amod
14	QT	qt	NN	_	15	compound
15	intervals	interval	NNS	_	11	nmod
16	.	.	.	_	11	punct

1	Pharmacokinetic	pharmacokinetic	JJ	_	2	amod
2	data	datum	NNS	_	3	nsubj
3	indicate	indicate	VBP	_	0	ROOT
4	that	that	IN	_	7	mark
5	oral	oral	JJ	_	6	amod
6	drug1	drug1	NN	_	7	nsubj
7	inhibits	inhibit	VBZ	_	3	ccomp
8	the	the	DT	_	9	det
9	metabolism	metabolism	NN	_	7	dobj
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	,	,	,	_	7	punct
13	resulting	result	VBG	_	7	advcl
14	in	in	IN	_	17	case
15	elevated	elevated	JJ	_	17	amod
16	plasma	plasma	NN	_	17	compound
17	levels	level	NNS	_	13	nmod
18	of	of	IN	_	19	case
19	drug3	drug3	NN	_	17	nmod
20	and	and	CC	_	19	cc
21	its	its	PRP$	_	24	nmod:poss
22	active	active	JJ	_	24	amod
23	metabolite	metabolite	NN	_	24	compound
24	drug4	drug4	NN	_	19	conj
25	which	which	WDT	_	27	nsubj
26	may	may	MD	_	27	aux
27	prolong	prolong	VB	_	24	acl:relcl
28	QT	QT	NNP	_	29	compound
29	intervals	interval	NNS	_	27	dobj
30	.	.	.	_	3	punct

1	Coadministration	coadministration	NN	_	9	nsubjpass
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	6	case
5	drug2	drug2	NN	_	6	compound
6	tablets	tablet	NNS	_	1	nmod
7	is	be	VBZ	_	9	auxpass
8	therefore	therefore	RB	_	9	advmod
9	contraindicated	contraindicate	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	Human	human	JJ	_	3	amod
2	pharmacokinetics	pharmacokinetic	NNS	_	3	compound
3	data	datum	NNS	_	4	nsubj
4	indicate	indicate	VBP	_	0	ROOT
5	that	that	IN	_	9	mark
6	oral	oral	JJ	_	7	amod
7	drug1	drug1	NN	_	9	nsubj
8	potently	potently	RB	_	9	advmod
9	inhibits	inhibit	VBZ	_	4	ccomp
10	the	the	DT	_	11	det
11	metabolism	metabolism	NN	_	9	dobj
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	resulting	result	VBG	_	11	acl
15	in	in	IN	_	19	case
16	a	a	DT	_	19	det
17	mean	mean	NN	_	19	compound
18	eight-fold	eight-fold	JJ	_	19	amod
19	increase	increase	NN	_	14	nmod
20	in	in	IN	_	21	case
21	AUC	auc	NN	_	19	nmod
22	of	of	IN	_	23	case
23	drug3	drug3	NN	_	21	nmod
24	.	.	.	_	4	punct

1	Data	datum	NNS	_	2	nsubj
2	suggest	suggest	VBP	_	0	ROOT
3	that	that	IN	_	11	mark
4	coadministration	coadministration	NN	_	11	nsubj
5	of	of	IN	_	7	case
6	oral	oral	JJ	_	7	amod
7	drug1	drug1	NN	_	4	nmod
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	can	can	MD	_	11	aux
11	result	result	VB	_	2	ccomp
12	in	in	IN	_	13	case
13	prolongation	prolongation	NN	_	11	nmod
14	of	of	IN	_	17	case
15	the	the	DT	_	17	det
16	QT	QT	NNP	_	17	compound
17	interval	interval	NN	_	13	nmod
18	on	on	IN	_	20	case
19	the	the	DT	_	20	det
20	ECG	ecg	NN	_	17	nmod
21	.	.	.	_	2	punct

1	Therefore	therefore	RB	_	10	advmod
2	concomitant	concomitant	JJ	_	3	amod
3	administration	administration	NN	_	10	nsubjpass
4	of	of	IN	_	6	case
5	drug1	drug1	NN	_	6	compound
6	tablets	tablet	NNS	_	3	nmod
7	with	with	IN	_	8	case
8	drug2	drug2	NN	_	3	nmod
9	is	be	VBZ	_	10	auxpass
10	contraindicated	contraindicate	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	drug1	drug1	NN	_	2	compound
2	tablets	tablet	NNS	_	4	nsubj
3	may	may	MD	_	4	aux
4	alter	alter	VB	_	0	ROOT
5	the	the	DT	_	6	det
6	metabolism	metabolism	NN	_	4	dobj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	,	,	,	_	8	punct
10	drug3	drug3	NN	_	8	conj
11	,	,	,	_	8	punct
12	and	and	CC	_	8	cc
13	drug4	drug4	NN	_	8	conj
14	,	,	,	_	4	punct
15	resulting	result	VBG	_	4	advcl
16	in	in	IN	_	19	case
17	elevated	elevated	JJ	_	19	amod
18	plasma	plasma	NN	_	19	compound
19	concentrations	concentration	NNS	_	15	nmod
20	of	of	IN	_	23	case
21	the	the	DT	_	23	det
22	latter	latter	JJ	_	23	amod
23	drugs	drug	NNS	_	19	nmod
24	.	.	.	_	4	punct

1	Dosage	dosage	NN	_	2	compound
2	adjustment	adjustment	NN	_	5	nsubjpass
3	may	may	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	required	require	VBN	_	0	ROOT
6	if	if	IN	_	14	mark
7	drug1	drug1	NN	_	14	nsubjpass
8	,	,	,	_	7	punct
9	drug2	drug2	NN	_	7	conj
10	,	,	,	_	7	punct
11	or	or	CC	_	7	cc
12	drug3	drug3	NN	_	7	conj
13	are	be	VBP	_	14	auxpass
14	given	give	VBN	_	5	advcl
15	concomitantly	concomitantly	RB	_	14	advmod
16	with	with	IN	_	18	case
17	drug4	drug4	NN	_	18	compound
18	Tablets	tablet	NNS	_	14	nmod
19	.	.	.	_	5	punct

1	Coadministration	coadministration	NN	_	10	nsubj
2	of	of	IN	_	4	case
3	drug1	drug1	NN	_	4	compound
4	Tablets	tablet	NNS	_	1	nmod
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	1	nmod
7	or	or	CC	_	6	cc
8	drug3	drug3	NN	_	6	conj
9	has	have	VBZ	_	10	aux
10	resulted	result	VBN	_	0	ROOT
11	in	in	IN	_	14	case
12	elevated	elevated	JJ	_	14	amod
13	plasma	plasma	NN	_	14	compound
14	concentrations	concentration	NNS	_	10	nmod
15	of	of	IN	_	19	case
16	the	the	DT	_	19	det
17	latter	latter	JJ	_	19	amod
18	two	two	CD	_	19	nummod
19	drugs	drug	NNS	_	14	nmod
20	.	.	.	_	10	punct

1	This	this	DT	_	3	nsubj
2	may	may	MD	_	3	aux
3	potentiate	potentiate	VB	_	0	ROOT
4	and	and	CC	_	3	cc
5	prolong	prolong	VB	_	3	conj
6	hypnotic	hypnotic	JJ	_	9	amod
7	and	and	CC	_	6	cc
8	sedative	sedative	JJ	_	6	conj
9	effects	effect	NNS	_	3	dobj
10	,	,	,	_	9	punct
11	especially	especially	RB	_	14	advmod
12	with	with	IN	_	14	case
13	repeated	repeat	VBN	_	14	amod
14	dosing	dosing	NN	_	9	nmod
15	or	or	CC	_	14	cc
16	chronic	chronic	JJ	_	17	amod
17	administration	administration	NN	_	14	conj
18	of	of	IN	_	20	case
19	these	these	DT	_	20	det
20	agents	agent	NNS	_	14	nmod
21	.	.	.	_	3	punct

1	These	these	DT	_	2	det
2	agents	agent	NNS	_	6	nsubjpass
3	should	should	MD	_	6	aux
4	not	not	RB	_	6	neg
5	be	be	VB	_	6	auxpass
6	used	use	VBN	_	0	ROOT
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	treated	treat	VBN	_	8	acl
10	with	with	IN	_	12	case
11	drug1	drug1	NN	_	12	compound
12	Tablets	tablet	NNS	_	9	nmod
13	.	.	.	_	6	punct

1	If	if	IN	_	4	mark
2	drug1	drug1	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	administered	administer	VBN	_	10	advcl
5	parenterally	parenterally	RB	_	4	advmod
6	,	,	,	_	10	punct
7	special	special	JJ	_	8	amod
8	precaution	precaution	NN	_	10	nsubjpass
9	is	be	VBZ	_	10	auxpass
10	required	require	VBN	_	0	ROOT
11	since	since	IN	_	17	mark
12	the	the	DT	_	14	det
13	sedative	sedative	JJ	_	14	amod
14	effect	effect	NN	_	17	nsubjpass
15	may	may	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	prolonged	prolong	VBN	_	10	advcl
18	.	.	.	_	10	punct

1	Rare	rare	JJ	_	2	amod
2	cases	case	NNS	_	11	nsubjpass
3	of	of	IN	_	6	case
4	elevated	elevated	JJ	_	6	amod
5	plasma	plasma	NN	_	6	compound
6	concentrations	concentration	NNS	_	2	nmod
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	have	have	VBP	_	11	aux
10	been	be	VBN	_	11	auxpass
11	reported	report	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	It	it	PRP	_	4	nsubj
2	is	be	VBZ	_	4	cop
3	not	not	RB	_	4	neg
4	clear	clear	JJ	_	0	ROOT
5	whether	whether	IN	_	8	mark
6	this	this	DT	_	8	nsubj
7	was	be	VBD	_	8	cop
8	due	due	JJ	_	4	ccomp
9	to	to	TO	_	11	case
10	the	the	DT	_	11	det
11	combination	combination	NN	_	8	nmod
12	of	of	IN	_	13	case
13	therapy	therapy	NN	_	11	nmod
14	.	.	.	_	4	punct

1	It	it	PRP	_	6	nsubj
2	is	be	VBZ	_	6	cop
3	,	,	,	_	6	punct
4	therefore	therefore	RB	_	6	advmod
5	,	,	,	_	6	punct
6	advisable	advisable	JJ	_	0	ROOT
7	to	to	TO	_	8	mark
8	monitor	monitor	VB	_	6	xcomp
9	drug1	drug1	NN	_	10	compound
10	concentrations	concentration	NNS	_	8	dobj
11	in	in	IN	_	12	case
12	patients	patient	NNS	_	10	nmod
13	receiving	receive	VBG	_	12	acl
14	drug2	drug2	NN	_	13	dobj
15	.	.	.	_	6	punct

1	When	when	WRB	_	2	advmod
2	taken	take	VBN	_	9	advcl
3	orally	orally	RB	_	2	advmod
4	,	,	,	_	9	punct
5	drug1	drug1	NN	_	9	nsubj
6	like	like	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	may	may	MD	_	9	aux
9	enhance	enhance	VB	_	0	ROOT
10	the	the	DT	_	12	det
11	anticoagulant	anticoagulant	JJ	_	12	amod
12	effect	effect	NN	_	9	dobj
13	of	of	IN	_	14	case
14	drug3	drug3	NN	_	12	nmod
15	-	-	:	_	12	punct
16	like	like	IN	_	17	case
17	drugs	drug	NNS	_	12	nmod
18	.	.	.	_	9	punct

1	In	in	IN	_	3	case
2	simultaneous	simultaneous	JJ	_	3	amod
3	treatment	treatment	NN	_	15	nmod
4	with	with	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	,	,	,	_	15	punct
9	the	the	DT	_	11	det
10	anticoagulant	anticoagulant	JJ	_	11	amod
11	effect	effect	NN	_	15	nsubjpass
12	should	should	MD	_	15	aux
13	be	be	VB	_	15	auxpass
14	carefully	carefully	RB	_	15	advmod
15	titrated	titrate	VBN	_	0	ROOT
16	and	and	CC	_	15	cc
17	monitored	monitor	VBN	_	15	conj
18	.	.	.	_	15	punct

1	Because	because	IN	_	6	mark
2	severe	severe	JJ	_	3	amod
3	hypoglycemia	hypoglycemia	NN	_	6	nsubjpass
4	has	have	VBZ	_	6	aux
5	been	be	VBN	_	6	auxpass
6	reported	report	VBN	_	42	advcl
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	concomitantly	concomitantly	RB	_	10	advmod
10	receiving	receive	VBG	_	8	acl
11	oral	oral	JJ	_	12	amod
12	drug1	drug1	NN	_	10	dobj
13	-LRB-	-lrb-	-LRB-	_	15	punct
14	an	a	DT	_	15	det
15	drug2	drug2	NN	_	12	appos
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	and	and	CC	_	12	cc
18	oral	oral	JJ	_	19	amod
19	drug3	drug3	NN	_	12	conj
20	,	,	,	_	42	punct
21	such	such	PDT	_	24	amod
22	a	a	DT	_	24	det
23	potential	potential	JJ	_	24	amod
24	interaction	interaction	NN	_	42	nsubjpass
25	involving	involve	VBG	_	24	acl
26	the	the	DT	_	28	det
27	latter	latter	JJ	_	28	amod
28	agents	agent	NNS	_	25	dobj
29	when	when	WRB	_	30	advmod
30	used	use	VBN	_	25	advcl
31	concomitantly	concomitantly	RB	_	30	advmod
32	with	with	IN	_	34	case
33	drug4	drug4	NN	_	34	compound
34	tablets	tablet	NNS	_	30	nmod
35	-LRB-	-lrb-	-LRB-	_	37	punct
36	an	a	DT	_	37	det
37	drug5	drug5	NN	_	34	appos
38	-RRB-	-rrb-	-RRB-	_	37	punct
39	can	can	MD	_	42	aux
40	not	not	RB	_	42	neg
41	be	be	VB	_	42	auxpass
42	ruled	rule	VBN	_	0	ROOT
43	out	out	RP	_	42	compound:prt
44	.	.	.	_	42	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	9	nsubj
3	of	of	IN	_	5	case
4	drug1	drug1	NN	_	5	compound
5	tablets	tablet	NNS	_	2	nmod
6	with	with	IN	_	7	case
7	drug2	drug2	NN	_	2	nmod
8	may	may	MD	_	9	aux
9	alter	alter	VB	_	0	ROOT
10	the	the	DT	_	11	det
11	metabolism	metabolism	NN	_	9	dobj
12	of	of	IN	_	13	case
13	one	one	CD	_	11	nmod
14	or	or	CC	_	13	cc
15	both	both	DT	_	13	conj
16	of	of	IN	_	18	case
17	the	the	DT	_	18	det
18	drugs	drug	NNS	_	13	nmod
19	.	.	.	_	9	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	suggested	suggest	VBN	_	0	ROOT
4	to	to	TO	_	5	mark
5	monitor	monitor	VB	_	3	xcomp
6	both	both	DT	_	7	cc:preconj
7	drug1	drug1	NN	_	5	dobj
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	.	.	.	_	3	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	8	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	7	case
6	drug2	drug2	NN	_	7	compound
7	tablets	tablet	NNS	_	2	nmod
8	reduces	reduce	VBZ	_	0	ROOT
9	the	the	DT	_	11	det
10	blood	blood	NN	_	11	compound
11	levels	level	NNS	_	8	dobj
12	of	of	IN	_	14	case
13	the	the	DT	_	14	det
14	latter	latter	JJ	_	11	nmod
15	.	.	.	_	8	punct

1	drug1	drug1	NN	_	7	nsubjpass
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	drug2	drug2	NN	_	1	appos
4	-RRB-	-rrb-	-RRB-	_	3	punct
5	is	be	VBZ	_	7	auxpass
6	also	also	RB	_	7	advmod
7	reported	report	VBN	_	0	ROOT
8	to	to	TO	_	9	mark
9	affect	affect	VB	_	7	xcomp
10	drug3	drug3	NN	_	11	compound
11	concentrations	concentration	NNS	_	9	dobj
12	adversely	adversely	RB	_	9	advmod
13	.	.	.	_	7	punct

1	These	these	DT	_	2	det
2	drugs	drug	NNS	_	6	nsubjpass
3	should	should	MD	_	6	aux
4	not	not	RB	_	6	neg
5	be	be	VB	_	6	auxpass
6	given	give	VBN	_	0	ROOT
7	concomitantly	concomitantly	RB	_	6	advmod
8	.	.	.	_	6	punct

1	After	after	IN	_	3	case
2	the	the	DT	_	3	det
3	coadministration	coadministration	NN	_	28	nmod
4	of	of	IN	_	6	case
5	200	200	CD	_	6	nummod
6	mg	mg	NN	_	3	nmod
7	oral	oral	JJ	_	8	amod
8	drug1	drug1	NN	_	6	dep
9	twice	twice	RB	_	10	advmod
10	daily	daily	RB	_	3	advmod
11	and	and	CC	_	3	cc
12	one	one	CD	_	15	nummod
13	20	20	CD	_	14	compound
14	mg	mg	NN	_	15	amod
15	dose	dose	NN	_	3	conj
16	of	of	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	to	to	TO	_	20	case
19	11	11	CD	_	20	nummod
20	subjects	subject	NNS	_	15	nmod
21	,	,	,	_	28	punct
22	the	the	DT	_	23	det
23	AUC	auc	NN	_	28	nsubj
24	and	and	CC	_	23	cc
25	Cmax	cmax	NN	_	23	conj
26	of	of	IN	_	27	case
27	drug3	drug3	NN	_	23	nmod
28	averaged	average	VBD	_	0	ROOT
29	302	302	CD	_	30	nummod
30	%	%	NN	_	28	dobj
31	-LRB-	-lrb-	-LRB-	_	33	punct
32	142	142	CD	_	33	nummod
33	S.D.	s.d.	NN	_	30	appos
34	-RRB-	-rrb-	-RRB-	_	33	punct
35	and	and	CC	_	30	cc
36	251	251	CD	_	37	nummod
37	%	%	NN	_	30	conj
38	-LRB-	-lrb-	-LRB-	_	40	punct
39	68	68	CD	_	40	nummod
40	S.D.	s.d.	NN	_	37	appos
41	-RRB-	-rrb-	-RRB-	_	40	punct
42	,	,	,	_	30	punct
43	respectively	respectively	RB	_	30	advmod
44	,	,	,	_	30	punct
45	of	of	IN	_	46	case
46	those	those	DT	_	30	nmod
47	obtained	obtain	VBN	_	46	acl
48	after	after	IN	_	49	case
49	co-treatment	co-treatment	NN	_	47	nmod
50	with	with	IN	_	51	case
51	placebo	placebo	NN	_	49	nmod
52	.	.	.	_	28	punct

1	The	the	DT	_	2	det
2	AUC	auc	NN	_	12	nsubj
3	and	and	CC	_	2	cc
4	Cmax	cmax	NN	_	2	conj
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	2	nmod
7	,	,	,	_	6	punct
8	an	a	DT	_	10	det
9	active	active	JJ	_	10	amod
10	metabolite	metabolite	NN	_	6	appos
11	,	,	,	_	6	punct
12	averaged	average	VBD	_	0	ROOT
13	155	155	CD	_	14	nummod
14	%	%	NN	_	12	dobj
15	-LRB-	-lrb-	-LRB-	_	17	punct
16	27	27	CD	_	17	nummod
17	S.D.	s.d.	NN	_	14	appos
18	-RRB-	-rrb-	-RRB-	_	17	punct
19	and	and	CC	_	14	cc
20	141	141	CD	_	21	nummod
21	%	%	NN	_	14	conj
22	-LRB-	-lrb-	-LRB-	_	24	punct
23	35	35	CD	_	24	nummod
24	S.D.	s.d.	NN	_	21	appos
25	-RRB-	-rrb-	-RRB-	_	24	punct
26	,	,	,	_	12	punct
27	respectively	respectively	RB	_	12	advmod
28	.	.	.	_	12	punct

1	However	however	RB	_	7	advmod
2	,	,	,	_	7	punct
3	no	no	DT	_	5	neg
4	related	related	JJ	_	5	amod
5	changes	change	NNS	_	7	nsubjpass
6	were	be	VBD	_	7	auxpass
7	noted	note	VBN	_	0	ROOT
8	in	in	IN	_	10	case
9	the	the	DT	_	10	det
10	QT0	qt0	NN	_	7	nmod
11	on	on	IN	_	12	case
12	ECG	ecg	NN	_	10	nmod
13	taken	take	VBN	_	12	acl
14	at	at	IN	_	15	case
15	2	2	CD	_	13	nmod
16	,	,	,	_	15	punct
17	6	6	CD	_	15	conj
18	,	,	,	_	15	punct
19	and	and	CC	_	15	cc
20	24	24	CD	_	15	conj
21	hours	hour	NNS	_	15	dep
22	after	after	IN	_	24	case
23	the	the	DT	_	24	det
24	coadministration	coadministration	NN	_	7	nmod
25	.	.	.	_	7	punct

1	Also	also	RB	_	4	advmod
2	,	,	,	_	4	punct
3	there	there	EX	_	4	expl
4	were	be	VBD	_	0	ROOT
5	no	no	DT	_	8	neg
6	clinically	clinically	RB	_	7	advmod
7	significant	significant	JJ	_	8	amod
8	differences	difference	NNS	_	4	nsubj
9	in	in	IN	_	11	case
10	adverse	adverse	JJ	_	11	amod
11	events	event	NNS	_	8	nmod
12	when	when	WRB	_	15	advmod
13	drug1	drug1	NN	_	15	nsubjpass
14	was	be	VBD	_	15	auxpass
15	administered	administer	VBN	_	8	acl:relcl
16	with	with	IN	_	19	nmod
17	or	or	CC	_	16	cc
18	without	without	IN	_	16	conj
19	drug2	drug2	NN	_	15	nmod
20	.	.	.	_	4	punct

1	Rare	rare	JJ	_	2	amod
2	cases	case	NNS	_	11	nsubjpass
3	of	of	IN	_	6	case
4	a	a	DT	_	6	det
5	disulfiram-like	disulfiram-like	JJ	_	6	amod
6	reaction	reaction	NN	_	2	nmod
7	to	to	TO	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	have	have	VBP	_	11	aux
10	been	be	VBN	_	11	auxpass
11	reported	report	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	These	these	DT	_	2	det
2	experiences	experience	NNS	_	5	nsubjpass
3	have	have	VBP	_	5	aux
4	been	be	VBN	_	5	auxpass
5	characterized	characterize	VBN	_	0	ROOT
6	by	by	IN	_	7	case
7	flushing	flushing	NN	_	5	nmod
8	,	,	,	_	7	punct
9	rash	rash	NN	_	7	conj
10	,	,	,	_	7	punct
11	peripheral	peripheral	JJ	_	12	amod
12	edema	edema	NN	_	7	conj
13	,	,	,	_	7	punct
14	nausea	nausea	NN	_	7	conj
15	,	,	,	_	7	punct
16	and	and	CC	_	7	cc
17	headache	headache	NN	_	7	conj
18	.	.	.	_	5	punct

1	Symptoms	symptom	NNS	_	2	nsubj
2	resolved	resolve	VBN	_	0	ROOT
3	within	within	IN	_	6	case
4	a	a	DT	_	6	det
5	few	few	JJ	_	6	amod
6	hours	hour	NNS	_	2	nmod
7	.	.	.	_	2	punct

1	The	the	DT	_	3	det
2	daily	daily	JJ	_	3	amod
3	dose	dose	NN	_	8	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	should	should	MD	_	8	aux
7	not	not	RB	_	8	neg
8	exceed	exceed	VB	_	0	ROOT
9	7.5	7.5	CD	_	10	nummod
10	mg	mg	NN	_	8	dobj
11	when	when	WRB	_	12	advmod
12	coadministered	coadminister	VBN	_	8	advcl
13	with	with	IN	_	16	case
14	potent	potent	JJ	_	16	amod
15	CYP3A4	cyp3a4	NN	_	16	compound
16	inhibitors	inhibitor	NNS	_	12	nmod
17	-LRB-	-lrb-	-LRB-	_	20	punct
18	e.g.	e.g.	FW	_	20	dep
19	,	,	,	_	20	punct
20	drug2	drug2	NN	_	16	dep
21	,	,	,	_	20	punct
22	drug3	drug3	NN	_	20	conj
23	,	,	,	_	20	punct
24	drug4	drug4	NN	_	20	conj
25	,	,	,	_	20	punct
26	drug5	drug5	NN	_	20	conj
27	,	,	,	_	20	punct
28	drug6	drug6	NN	_	20	conj
29	and	and	CC	_	20	cc
30	nefazadone	nefazadone	NN	_	20	conj
31	-RRB-	-rrb-	-RRB-	_	20	punct
32	.	.	.	_	8	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	taken	take	VBN	_	0	ROOT
5	when	when	WRB	_	8	advmod
6	drug1	drug1	NN	_	8	nsubjpass
7	is	be	VBZ	_	8	auxpass
8	used	use	VBN	_	4	advcl
9	concomitantly	concomitantly	RB	_	8	advmod
10	with	with	IN	_	11	case
11	medications	medication	NNS	_	8	nmod
12	that	that	WDT	_	15	nsubjpass
13	are	be	VBP	_	15	auxpass
14	predominantly	predominantly	RB	_	15	advmod
15	metabolized	metabolize	VBN	_	11	acl:relcl
16	by	by	IN	_	17	case
17	CYP2D6	cyp2d6	NN	_	15	nmod
18	and	and	CC	_	15	cc
19	which	which	WDT	_	20	nsubj
20	have	have	VBP	_	15	conj
21	a	a	DT	_	24	det
22	narrow	narrow	JJ	_	24	amod
23	therapeutic	therapeutic	JJ	_	24	amod
24	window	window	NN	_	20	dobj
25	,	,	,	_	24	punct
26	such	such	JJ	_	28	case
27	as	as	IN	_	26	mwe
28	drug2	drug2	NN	_	24	nmod
29	,	,	,	_	28	punct
30	drug3	drug3	NN	_	28	conj
31	and	and	CC	_	28	cc
32	drug4	drug4	NN	_	28	conj
33	-LRB-	-lrb-	-LRB-	_	34	punct
34	see	see	VB	_	20	parataxis
35	CLINICAL	CLINICAL	NNP	_	36	compound
36	PHARMACOLOGY	PHARMACOLOGY	NNP	_	34	dobj
37	-RRB-	-rrb-	-RRB-	_	34	punct
38	.	.	.	_	4	punct

1	The	the	DT	_	3	det
2	concomitant	concomitant	JJ	_	3	amod
3	use	use	NN	_	10	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	with	with	IN	_	8	case
7	other	other	JJ	_	8	amod
8	drug2	drug2	NN	_	3	nmod
9	may	may	MD	_	10	aux
10	increase	increase	VB	_	0	ROOT
11	the	the	DT	_	12	det
12	frequency	frequency	NN	_	10	dobj
13	and/or	and/or	CC	_	12	cc
14	severity	severity	NN	_	12	conj
15	of	of	IN	_	17	case
16	dry	dry	JJ	_	17	amod
17	mouth	mouth	NN	_	12	nmod
18	,	,	,	_	17	punct
19	constipation	constipation	NN	_	17	appos
20	,	,	,	_	17	punct
21	blurred	blur	VBD	_	10	dep
22	vision	vision	NN	_	21	dobj
23	and	and	CC	_	22	cc
24	other	other	JJ	_	27	amod
25	anticholinergic	anticholinergic	JJ	_	27	amod
26	pharmacological	pharmacological	JJ	_	27	amod
27	effects	effect	NNS	_	22	conj
28	.	.	.	_	10	punct

1	drug1	drug1	NN	_	4	nsubj
2	may	may	MD	_	4	aux
3	potentially	potentially	RB	_	4	advmod
4	alter	alter	VB	_	0	ROOT
5	the	the	DT	_	6	det
6	absorption	absorption	NN	_	4	dobj
7	of	of	IN	_	11	case
8	some	some	DT	_	11	det
9	concomitantly	concomitantly	RB	_	10	advmod
10	administered	administer	VBN	_	11	amod
11	drugs	drug	NNS	_	6	nmod
12	due	due	JJ	_	14	case
13	to	to	TO	_	12	mwe
14	effects	effect	NNS	_	6	nmod
15	on	on	IN	_	17	case
16	gastrointestinal	gastrointestinal	JJ	_	17	amod
17	motility	motility	NN	_	14	nmod
18	.	.	.	_	4	punct

1	Drug	Drug	NNP	_	5	compound
2	Laboratory	Laboratory	NNP	_	5	compound
3	Test	Test	NNP	_	5	compound
4	Interactions	interaction	NNS	_	5	compound
5	Interactions	interaction	NNS	_	14	nsubjpass
6	between	between	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	laboratory	laboratory	NN	_	10	compound
10	tests	test	NNS	_	7	conj
11	have	have	VBP	_	14	aux
12	not	not	RB	_	14	neg
13	been	be	VBN	_	14	auxpass
14	studied	study	VBN	_	0	ROOT
15	.	.	.	_	14	punct

1	In	in	FW	_	5	amod
2	vitro	vitro	FW	_	1	dep
3	drug	drug	NN	_	5	compound
4	metabolism	metabolism	NN	_	5	compound
5	studies	study	NNS	_	6	nsubj
6	indicate	indicate	VBP	_	0	ROOT
7	that	that	IN	_	11	mark
8	drug1	drug1	NN	_	11	nsubjpass
9	is	be	VBZ	_	11	auxpass
10	predominantly	predominantly	RB	_	11	advmod
11	metabolized	metabolize	VBN	_	6	ccomp
12	by	by	IN	_	17	case
13	the	the	DT	_	17	det
14	cytochrome	cytochrome	NN	_	17	compound
15	P450	p450	NN	_	17	compound
16	isozyme	isozyme	NN	_	17	compound
17	CYP2C9	cyp2c9	NN	_	11	nmod
18	-LRB-	-lrb-	-LRB-	_	20	punct
19	70	70	CD	_	20	nummod
20	%	%	NN	_	17	appos
21	-RRB-	-rrb-	-RRB-	_	20	punct
22	and	and	CC	_	17	cc
23	to	to	TO	_	27	case
24	a	a	DT	_	27	det
25	lesser	lesser	JJR	_	27	amod
26	extent	extent	NN	_	27	compound
27	CYP3A4	cyp3a4	NN	_	17	conj
28	-LRB-	-lrb-	-LRB-	_	30	punct
29	30	30	CD	_	30	nummod
30	%	%	NN	_	27	appos
31	-RRB-	-rrb-	-RRB-	_	30	punct
32	.	.	.	_	6	punct

1	drug1	drug1	NN	_	5	nsubj
2	is	be	VBZ	_	5	cop
3	a	a	DT	_	5	det
4	potential	potential	JJ	_	5	amod
5	inhibitor	inhibitor	NN	_	0	ROOT
6	of	of	IN	_	9	case
7	the	the	DT	_	9	det
8	CYP2C9	cyp2c9	NN	_	9	compound
9	isoenzyme	isoenzyme	NN	_	5	nmod
10	in	in	FW	_	11	compound
11	vivo	vivo	FW	_	5	advmod
12	as	as	IN	_	13	mark
13	indicated	indicate	VBN	_	5	advcl
14	by	by	IN	_	16	case
15	its	its	PRP$	_	16	nmod:poss
16	ability	ability	NN	_	13	nmod
17	to	to	TO	_	18	mark
18	inhibit	inhibit	VB	_	16	acl
19	the	the	DT	_	22	det
20	in	in	FW	_	22	amod
21	vitro	vitro	FW	_	20	dep
22	metabolism	metabolism	NN	_	18	dobj
23	of	of	IN	_	24	case
24	drug2	drug2	NN	_	22	nmod
25	.	.	.	_	5	punct

1	Inhibition	inhibition	NN	_	8	nsubjpass
2	of	of	IN	_	5	case
3	CYP3A4	cyp3a4	NN	_	5	compound
4	metabolic	metabolic	JJ	_	5	amod
5	reactions	reaction	NNS	_	1	nmod
6	was	be	VBD	_	8	auxpass
7	not	not	RB	_	8	neg
8	detected	detect	VBN	_	0	ROOT
9	in	in	IN	_	12	case
10	in	in	FW	_	12	amod
11	vitro	vitro	FW	_	10	dep
12	experiments	experiment	NNS	_	8	nmod
13	.	.	.	_	8	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	9	case
4	a	a	DT	_	9	det
5	randomized	randomize	VBN	_	9	amod
6	,	,	,	_	9	punct
7	multiple-dose	multiple-dose	JJ	_	9	amod
8	crossover	crossover	NN	_	9	compound
9	study	study	NN	_	17	nmod
10	,	,	,	_	17	punct
11	patients	patient	NNS	_	17	nsubjpass
12	with	with	IN	_	15	case
13	Type	type	NN	_	15	compound
14	2	2	CD	_	15	nummod
15	diabetes	diabetes	NNS	_	11	nmod
16	were	be	VBD	_	17	auxpass
17	administered	administer	VBN	_	1	appos
18	120	120	CD	_	20	nummod
19	mg	mg	NN	_	20	compound
20	drug2	drug2	NN	_	17	dobj
21	three	three	CD	_	22	nummod
22	times	time	NNS	_	17	nmod:tmod
23	a	a	DT	_	24	det
24	day	day	NN	_	22	nmod:npmod
25	before	before	IN	_	26	case
26	meals	meal	NNS	_	17	nmod
27	for	for	IN	_	29	case
28	1	1	CD	_	29	nummod
29	day	day	NN	_	26	nmod
30	in	in	IN	_	31	case
31	combination	combination	NN	_	26	nmod
32	with	with	IN	_	35	case
33	drug3	drug3	NN	_	35	compound
34	10	10	CD	_	35	nummod
35	mg	mg	NN	_	31	nmod
36	daily	daily	RB	_	35	advmod
37	.	.	.	_	1	punct

1	There	there	EX	_	2	expl
2	were	be	VBD	_	0	ROOT
3	no	no	DT	_	6	neg
4	clinically	clinically	RB	_	5	advmod
5	relevant	relevant	JJ	_	6	amod
6	alterations	alteration	NNS	_	2	nsubj
7	in	in	IN	_	9	case
8	the	the	DT	_	9	det
9	pharmacokinetics	pharmacokinetic	NNS	_	2	nmod
10	of	of	IN	_	12	case
11	either	either	CC	_	12	det
12	agent	agent	NN	_	9	nmod
13	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	When	when	WRB	_	13	advmod
4	drug2	drug2	NN	_	6	compound
5	120	120	CD	_	6	nummod
6	mg	mg	NN	_	13	nsubjpass
7	three	three	CD	_	8	nummod
8	times	time	NNS	_	13	dep
9	daily	daily	RB	_	8	advmod
10	before	before	IN	_	13	mark
11	meals	meal	NNS	_	13	nsubjpass
12	was	be	VBD	_	13	auxpass
13	administered	administer	VBN	_	31	advcl
14	in	in	IN	_	15	case
15	combination	combination	NN	_	13	nmod
16	with	with	IN	_	19	case
17	drug3	drug3	NN	_	19	compound
18	500	500	CD	_	19	nummod
19	mg	mg	NN	_	15	nmod
20	three	three	CD	_	21	compound
21	times	time	NNS	_	22	nummod
22	daily	daily	JJ	_	19	amod
23	to	to	TO	_	24	case
24	patients	patient	NNS	_	22	nmod
25	with	with	IN	_	26	case
26	Type	type	NN	_	24	nmod
27	2	2	CD	_	26	nummod
28	diabetes	diabetes	NN	_	26	dep
29	,	,	,	_	31	punct
30	there	there	EX	_	31	expl
31	were	be	VBD	_	1	dep
32	no	no	DT	_	35	neg
33	clinically	clinically	RB	_	34	advmod
34	relevant	relevant	JJ	_	35	amod
35	changes	change	NNS	_	31	nsubj
36	in	in	IN	_	38	case
37	the	the	DT	_	38	det
38	pharmacokinetics	pharmacokinetic	NNS	_	35	nmod
39	of	of	IN	_	41	case
40	either	either	CC	_	41	det
41	agent	agent	NN	_	38	nmod
42	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	When	when	WRB	_	10	advmod
4	drug2	drug2	NN	_	6	compound
5	120	120	CD	_	6	nummod
6	mg	mg	NN	_	10	nsubjpass
7	before	before	IN	_	8	case
8	meals	meal	NNS	_	6	nmod
9	was	be	VBD	_	10	auxpass
10	administered	administer	VBN	_	25	advcl
11	in	in	IN	_	12	case
12	combination	combination	NN	_	10	nmod
13	with	with	IN	_	17	case
14	a	a	DT	_	17	det
15	single	single	JJ	_	17	amod
16	1-mg	1-mg	JJ	_	17	amod
17	dose	dose	NN	_	12	nmod
18	of	of	IN	_	19	case
19	drug3	drug3	NN	_	17	nmod
20	to	to	TO	_	22	case
21	healthy	healthy	JJ	_	22	amod
22	volunteers	volunteer	NNS	_	17	nmod
23	,	,	,	_	25	punct
24	there	there	EX	_	25	expl
25	were	be	VBD	_	1	dep
26	no	no	DT	_	29	neg
27	clinically	clinically	RB	_	28	advmod
28	relevant	relevant	JJ	_	29	amod
29	changes	change	NNS	_	25	nsubj
30	in	in	IN	_	32	case
31	the	the	DT	_	32	det
32	pharmacokinetics	pharmacokinetic	NNS	_	29	nmod
33	of	of	IN	_	35	case
34	either	either	CC	_	35	det
35	agent	agent	NN	_	32	nmod
36	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	When	when	WRB	_	7	advmod
4	healthy	healthy	JJ	_	5	amod
5	subjects	subject	NNS	_	7	nsubjpass
6	were	be	VBD	_	7	auxpass
7	administered	administer	VBN	_	34	advcl
8	drug2	drug2	NN	_	10	compound
9	120	120	CD	_	10	nummod
10	mg	mg	NN	_	7	dobj
11	three	three	CD	_	12	nummod
12	times	time	NNS	_	7	nmod:npmod
13	daily	daily	RB	_	12	advmod
14	before	before	IN	_	15	case
15	meals	meal	NNS	_	12	nmod
16	for	for	IN	_	18	case
17	four	four	CD	_	18	nummod
18	days	day	NNS	_	7	nmod
19	in	in	IN	_	20	case
20	combination	combination	NN	_	7	nmod
21	with	with	IN	_	24	case
22	a	a	DT	_	24	det
23	single	single	JJ	_	24	amod
24	dose	dose	NN	_	20	nmod
25	of	of	IN	_	26	case
26	drug3	drug3	NN	_	24	nmod
27	30	30	CD	_	28	nummod
28	mg	mg	NN	_	26	dep
29	on	on	IN	_	30	case
30	day	day	NN	_	20	nmod
31	2	2	CD	_	30	nummod
32	,	,	,	_	34	punct
33	there	there	EX	_	34	expl
34	were	be	VBD	_	1	dep
35	no	no	DT	_	36	neg
36	alterations	alteration	NNS	_	34	nsubj
37	in	in	IN	_	39	case
38	the	the	DT	_	39	det
39	pharmacokinetics	pharmacokinetic	NNS	_	36	nmod
40	of	of	IN	_	42	case
41	either	either	CC	_	42	det
42	agent	agent	NN	_	39	nmod
43	.	.	.	_	1	punct

1	Prothrombin	Prothrombin	NNP	_	2	compound
2	time	time	NN	_	5	nsubjpass
3	was	be	VBD	_	5	auxpass
4	not	not	RB	_	5	neg
5	affected	affect	VBN	_	0	ROOT
6	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Administration	administration	NN	_	25	nsubj
4	of	of	IN	_	5	case
5	morning	morning	NN	_	3	nmod
6	and	and	CC	_	3	cc
7	lunch	lunch	NN	_	8	compound
8	doses	dose	NNS	_	3	conj
9	of	of	IN	_	12	case
10	drug2	drug2	NN	_	12	compound
11	120	120	CD	_	12	nummod
12	mg	mg	NN	_	8	nmod
13	in	in	IN	_	14	case
14	combination	combination	NN	_	3	nmod
15	with	with	IN	_	19	case
16	a	a	DT	_	19	det
17	single	single	JJ	_	19	amod
18	75-mg	75-mg	JJ	_	19	amod
19	dose	dose	NN	_	14	nmod
20	of	of	IN	_	21	case
21	drug3	drug3	NN	_	19	nmod
22	in	in	IN	_	24	case
23	healthy	healthy	JJ	_	24	amod
24	volunteers	volunteer	NNS	_	19	nmod
25	resulted	result	VBD	_	1	appos
26	in	in	IN	_	29	case
27	no	no	DT	_	29	neg
28	significant	significant	JJ	_	29	amod
29	changes	change	NNS	_	25	nmod
30	to	to	TO	_	32	case
31	the	the	DT	_	32	det
32	pharmacokinetics	pharmacokinetic	NNS	_	29	nmod
33	of	of	IN	_	35	case
34	either	either	CC	_	35	det
35	agent	agent	NN	_	32	nmod
36	.	.	.	_	1	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	highly	highly	RB	_	4	advmod
4	bound	bind	VBN	_	0	ROOT
5	to	to	TO	_	7	case
6	plasma	plasma	NN	_	7	compound
7	proteins	protein	NNS	_	4	nmod
8	-LRB-	-lrb-	-LRB-	_	10	punct
9	98	98	CD	_	10	nummod
10	%	%	NN	_	7	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	,	,	,	_	7	punct
13	mainly	mainly	RB	_	14	advmod
14	albumin	albumin	NN	_	7	appos
15	.	.	.	_	4	punct

1	In	in	FW	_	4	amod
2	vitro	vitro	FW	_	1	dep
3	displacement	displacement	NN	_	4	compound
4	studies	study	NNS	_	33	nsubj
5	with	with	IN	_	8	case
6	highly	highly	RB	_	7	advmod
7	protein-bound	protein-bound	JJ	_	8	amod
8	drugs	drug	NNS	_	4	nmod
9	such	such	JJ	_	11	case
10	as	as	IN	_	9	mwe
11	drug1	drug1	NN	_	8	nmod
12	,	,	,	_	11	punct
13	drug2	drug2	NN	_	11	conj
14	,	,	,	_	11	punct
15	drug3	drug3	NN	_	11	conj
16	,	,	,	_	11	punct
17	drug4	drug4	NN	_	11	conj
18	,	,	,	_	11	punct
19	drug5	drug5	NN	_	11	conj
20	,	,	,	_	11	punct
21	drug6	drug6	NN	_	11	conj
22	,	,	,	_	11	punct
23	drug7	drug7	NN	_	11	conj
24	,	,	,	_	11	punct
25	drug8	drug8	NN	_	11	conj
26	,	,	,	_	11	punct
27	drug9	drug9	NN	_	11	conj
28	,	,	,	_	11	punct
29	drug10	drug10	NN	_	11	conj
30	,	,	,	_	11	punct
31	and	and	CC	_	11	cc
32	drug11	drug11	NN	_	11	conj
33	showed	show	VBD	_	0	ROOT
34	no	no	DT	_	35	neg
35	influence	influence	NN	_	33	dobj
36	on	on	IN	_	38	case
37	the	the	DT	_	38	det
38	extent	extent	NN	_	35	nmod
39	of	of	IN	_	42	case
40	drug12	drug12	NN	_	42	compound
41	protein	protein	NN	_	42	compound
42	binding	binding	NN	_	38	nmod
43	.	.	.	_	33	punct

1	Similarly	similarly	RB	_	4	advmod
2	,	,	,	_	4	punct
3	drug1	drug1	NN	_	4	nsubj
4	had	have	VBD	_	0	ROOT
5	no	no	DT	_	6	neg
6	influence	influence	NN	_	4	dobj
7	on	on	IN	_	10	case
8	the	the	DT	_	10	det
9	serum	serum	NN	_	10	compound
10	protein	protein	NN	_	6	nmod
11	binding	binding	NN	_	10	acl
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	,	,	,	_	13	punct
15	drug3	drug3	NN	_	13	conj
16	,	,	,	_	13	punct
17	drug4	drug4	NN	_	13	conj
18	,	,	,	_	13	punct
19	drug5	drug5	NN	_	13	conj
20	,	,	,	_	13	punct
21	drug6	drug6	NN	_	13	conj
22	,	,	,	_	13	punct
23	drug7	drug7	NN	_	13	conj
24	,	,	,	_	13	punct
25	and	and	CC	_	13	cc
26	drug8	drug8	NN	_	13	conj
27	in	in	FW	_	28	compound
28	vitro	vitro	FW	_	11	advmod
29	.	.	.	_	4	punct

1	However	however	RB	_	9	advmod
2	,	,	,	_	9	punct
3	prudent	prudent	JJ	_	4	amod
4	evaluation	evaluation	NN	_	9	nsubjpass
5	of	of	IN	_	7	case
6	individual	individual	JJ	_	7	amod
7	cases	case	NNS	_	4	nmod
8	is	be	VBZ	_	9	auxpass
9	warranted	warrant	VBN	_	0	ROOT
10	in	in	IN	_	13	case
11	the	the	DT	_	13	det
12	clinical	clinical	JJ	_	13	amod
13	setting	setting	NN	_	9	nmod
14	.	.	.	_	9	punct

1	Certain	certain	JJ	_	2	amod
2	drugs	drug	NNS	_	17	nsubj
3	,	,	,	_	2	punct
4	including	include	VBG	_	5	case
5	drug1	drug1	NN	_	2	nmod
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	drug2	drug2	NN	_	5	appos
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	,	,	,	_	5	punct
10	drug3	drug3	NN	_	5	conj
11	,	,	,	_	5	punct
12	drug4	drug4	NN	_	5	conj
13	,	,	,	_	5	punct
14	and	and	CC	_	5	cc
15	drug5	drug5	NN	_	5	conj
16	may	may	MD	_	17	aux
17	potentiate	potentiate	VB	_	0	ROOT
18	the	the	DT	_	20	det
19	hypoglycemic	hypoglycemic	JJ	_	20	amod
20	action	action	NN	_	17	dobj
21	of	of	IN	_	22	case
22	drug6	drug6	NN	_	20	nmod
23	and	and	CC	_	22	cc
24	other	other	JJ	_	26	amod
25	oral	oral	JJ	_	26	amod
26	drug7	drug7	NN	_	22	conj
27	.	.	.	_	17	punct

1	Certain	certain	JJ	_	2	amod
2	drugs	drug	NNS	_	13	nsubj
3	including	include	VBG	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	,	,	,	_	4	punct
6	drug2	drug2	NN	_	4	conj
7	,	,	,	_	4	punct
8	drug3	drug3	NN	_	4	conj
9	,	,	,	_	4	punct
10	and	and	CC	_	4	cc
11	drug4	drug4	NN	_	4	conj
12	may	may	MD	_	13	aux
13	reduce	reduce	VB	_	0	ROOT
14	the	the	DT	_	16	det
15	hypoglycemic	hypoglycemic	JJ	_	16	amod
16	action	action	NN	_	13	dobj
17	of	of	IN	_	18	case
18	drug5	drug5	NN	_	16	nmod
19	and	and	CC	_	18	cc
20	other	other	JJ	_	22	amod
21	oral	oral	JJ	_	22	amod
22	drug6	drug6	NN	_	18	conj
23	.	.	.	_	13	punct

1	When	when	WRB	_	5	advmod
2	these	these	DT	_	3	det
3	drugs	drug	NNS	_	5	nsubjpass
4	are	be	VBP	_	5	auxpass
5	administered	administer	VBN	_	0	ROOT
6	to	to	TO	_	18	mark
7	or	or	CC	_	6	cc
8	withdrawn	withdraw	VBN	_	6	conj
9	from	from	IN	_	10	case
10	patients	patient	NNS	_	18	nmod
11	receiving	receive	VBG	_	10	acl
12	drug1	drug1	NN	_	11	dobj
13	,	,	,	_	18	punct
14	the	the	DT	_	15	det
15	patient	patient	NN	_	18	nsubjpass
16	should	should	MD	_	18	aux
17	be	be	VB	_	18	auxpass
18	observed	observe	VBN	_	5	advcl
19	closely	closely	RB	_	18	advmod
20	for	for	IN	_	21	case
21	changes	change	NNS	_	18	nmod
22	in	in	IN	_	24	case
23	glycemic	glycemic	JJ	_	24	amod
24	control	control	NN	_	21	nmod
25	.	.	.	_	5	punct

1	Additive	additive	JJ	_	3	amod
2	depressant	depressant	NN	_	3	compound
3	effect	effect	NN	_	0	ROOT
4	when	when	WRB	_	5	advmod
5	used	use	VBN	_	3	acl:relcl
6	with	with	IN	_	8	case
7	general	general	JJ	_	8	amod
8	drug1	drug1	NN	_	5	nmod
9	,	,	,	_	8	punct
10	drug2	drug2	NN	_	8	conj
11	,	,	,	_	8	punct
12	drug3	drug3	NN	_	8	conj
13	,	,	,	_	8	punct
14	drug4	drug4	NN	_	8	conj
15	,	,	,	_	8	punct
16	drug5	drug5	NN	_	8	conj
17	,	,	,	_	8	punct
18	and	and	CC	_	8	cc
19	other	other	JJ	_	20	amod
20	drug6	drug6	NN	_	8	conj
21	.	.	.	_	3	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	mixing	mix	VBG	_	13	nsubj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	with	with	IN	_	9	case
8	an	a	DT	_	9	det
9	drug3	drug3	NN	_	4	nmod
10	in	in	FW	_	11	compound
11	vitro	vitro	FW	_	9	advmod
12	can	can	MD	_	13	aux
13	result	result	VB	_	1	dep
14	in	in	IN	_	16	case
15	substantial	substantial	JJ	_	16	amod
16	inactivation	inactivation	NN	_	13	nmod
17	of	of	IN	_	19	case
18	the	the	DT	_	19	det
19	drug4	drug4	NN	_	16	nmod
20	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	When	when	WRB	_	4	advmod
4	used	use	VBN	_	13	advcl
5	in	in	IN	_	8	case
6	the	the	DT	_	8	det
7	perioperative	perioperative	JJ	_	8	amod
8	period	period	NN	_	4	nmod
9	,	,	,	_	13	punct
10	drug2	drug2	NN	_	13	nsubjpass
11	has	have	VBZ	_	13	aux
12	been	be	VBN	_	13	auxpass
13	implicated	implicate	VBN	_	1	dep
14	in	in	IN	_	16	case
15	the	the	DT	_	16	det
16	prolongation	prolongation	NN	_	13	nmod
17	of	of	IN	_	20	case
18	the	the	DT	_	20	det
19	neuromuscular	neuromuscular	JJ	_	20	amod
20	blockade	blockade	NN	_	16	nmod
21	of	of	IN	_	22	case
22	drug3	drug3	NN	_	20	nmod
23	.	.	.	_	1	punct

1	Caution	caution	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	indicated	indicate	VBN	_	0	ROOT
4	when	when	WRB	_	7	advmod
5	drug1	drug1	NN	_	7	nsubjpass
6	is	be	VBZ	_	7	auxpass
7	used	use	VBN	_	3	advcl
8	perioperatively	perioperatively	RB	_	7	advmod
9	.	.	.	_	3	punct

1	In	in	IN	_	5	case
2	one	one	CD	_	5	nummod
3	controlled	controlled	JJ	_	5	amod
4	clinical	clinical	JJ	_	5	amod
5	study	study	NN	_	14	nmod
6	,	,	,	_	14	punct
7	the	the	DT	_	8	det
8	ureidopenicillins	ureidopenicillin	NNS	_	14	nsubjpass
9	,	,	,	_	8	punct
10	including	include	VBG	_	11	case
11	drug1	drug1	NN	_	8	nmod
12	,	,	,	_	8	punct
13	were	be	VBD	_	14	auxpass
14	reported	report	VBN	_	0	ROOT
15	to	to	TO	_	16	mark
16	prolong	prolong	VB	_	14	xcomp
17	the	the	DT	_	18	det
18	action	action	NN	_	16	dobj
19	of	of	IN	_	20	case
20	drug2	drug2	NN	_	18	nmod
21	.	.	.	_	14	punct

1	Due	due	JJ	_	5	case
2	to	to	TO	_	1	mwe
3	their	they	PRP$	_	5	nmod:poss
4	similar	similar	JJ	_	5	amod
5	mechanism	mechanism	NN	_	11	nmod
6	of	of	IN	_	7	case
7	action	action	NN	_	5	nmod
8	,	,	,	_	11	punct
9	it	it	PRP	_	11	nsubjpass
10	is	be	VBZ	_	11	auxpass
11	expected	expect	VBN	_	0	ROOT
12	that	that	IN	_	24	mark
13	the	the	DT	_	15	det
14	neuromuscular	neuromuscular	JJ	_	15	amod
15	blockade	blockade	NN	_	24	nsubjpass
16	produced	produce	VBN	_	15	acl
17	by	by	IN	_	18	case
18	any	any	DT	_	16	nmod
19	of	of	IN	_	21	case
20	the	the	DT	_	21	det
21	drug1	drug1	NN	_	18	nmod
22	could	could	MD	_	24	aux
23	be	be	VB	_	24	auxpass
24	prolonged	prolong	VBN	_	11	ccomp
25	in	in	IN	_	27	case
26	the	the	DT	_	27	det
27	presence	presence	NN	_	24	nmod
28	of	of	IN	_	29	case
29	drug2	drug2	NN	_	27	nmod
30	.	.	.	_	11	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	5	det
4	oral	oral	JJ	_	5	amod
5	combination	combination	NN	_	13	nsubj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	before	before	IN	_	10	case
9	intramuscular	intramuscular	JJ	_	10	amod
10	injection	injection	NN	_	5	nmod
11	of	of	IN	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	produces	produce	VBZ	_	1	appos
14	an	a	DT	_	15	det
15	increase	increase	NN	_	13	dobj
16	in	in	IN	_	20	case
17	drug4	drug4	NN	_	20	compound
18	peak	peak	JJ	_	20	amod
19	serum	serum	NN	_	20	compound
20	level	level	NN	_	15	nmod
21	of	of	IN	_	24	case
22	about	about	IN	_	23	advmod
23	30	30	CD	_	24	nummod
24	%	%	NN	_	20	nmod
25	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Coagulation	coagulation	NN	_	4	compound
4	parameters	parameter	NNS	_	7	nsubjpass
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	tested	test	VBN	_	1	dep
8	more	more	RBR	_	9	advmod
9	frequently	frequently	RB	_	7	advmod
10	and	and	CC	_	7	cc
11	monitored	monitor	VBD	_	7	conj
12	regularly	regularly	RB	_	11	advmod
13	during	during	IN	_	15	case
14	simultaneous	simultaneous	JJ	_	15	amod
15	administration	administration	NN	_	11	nmod
16	of	of	IN	_	18	case
17	high	high	JJ	_	18	amod
18	doses	dose	NNS	_	15	nmod
19	of	of	IN	_	20	case
20	drug2	drug2	NN	_	18	nmod
21	,	,	,	_	7	punct
22	oral	oral	JJ	_	23	amod
23	drug3	drug3	NN	_	7	conj
24	,	,	,	_	7	punct
25	or	or	CC	_	7	cc
26	other	other	JJ	_	27	amod
27	drugs	drug	NNS	_	7	conj
28	that	that	WDT	_	30	nsubj
29	may	may	MD	_	30	aux
30	affect	affect	VB	_	27	acl:relcl
31	the	the	DT	_	34	det
32	blood	blood	NN	_	34	compound
33	coagulation	coagulation	NN	_	34	compound
34	system	system	NN	_	30	dobj
35	or	or	CC	_	34	cc
36	the	the	DT	_	38	det
37	thrombocyte	thrombocyte	NN	_	38	compound
38	function	function	NN	_	34	conj
39	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	reduce	reduce	VB	_	1	dep
6	the	the	DT	_	7	det
7	excretion	excretion	NN	_	5	dobj
8	of	of	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	.	.	.	_	5	punct

1	Therefore	therefore	RB	_	9	advmod
2	,	,	,	_	9	punct
3	serum	serum	NN	_	4	compound
4	levels	level	NNS	_	9	nsubjpass
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	monitored	monitor	VBN	_	0	ROOT
10	in	in	IN	_	11	case
11	patients	patient	NNS	_	9	nmod
12	to	to	TO	_	13	mark
13	avoid	avoid	VB	_	11	acl
14	drug	drug	NN	_	15	compound
15	toxicity	toxicity	NN	_	13	dobj
16	.	.	.	_	9	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	3	amod
2	Test	test	NN	_	3	compound
3	Interactions	interaction	NNS	_	14	nsubj
4	As	as	IN	_	7	case
5	with	with	IN	_	7	case
6	other	other	JJ	_	7	amod
7	drug1	drug1	NN	_	14	nmod
8	,	,	,	_	14	punct
9	the	the	DT	_	10	det
10	administration	administration	NN	_	14	nsubj
11	of	of	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	may	may	MD	_	14	aux
14	result	result	VB	_	0	ROOT
15	in	in	IN	_	18	case
16	a	a	DT	_	18	det
17	false-positive	false-positive	JJ	_	18	amod
18	reaction	reaction	NN	_	14	nmod
19	for	for	IN	_	20	case
20	glucose	glucose	NN	_	18	nmod
21	in	in	IN	_	23	case
22	the	the	DT	_	23	det
23	urine	urine	NN	_	20	nmod
24	using	use	VBG	_	14	xcomp
25	a	a	DT	_	27	det
26	copper-reduction	copper-reduction	NN	_	27	compound
27	method	method	NN	_	24	dobj
28	.	.	.	_	14	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	recommended	recommend	VBN	_	0	ROOT
4	that	that	IN	_	14	mark
5	glucose	glucose	NN	_	6	compound
6	tests	test	NNS	_	14	nsubjpass
7	based	base	VBN	_	12	case
8	on	on	IN	_	12	case
9	enzymatic	enzymatic	JJ	_	12	amod
10	glucose	glucose	NN	_	12	compound
11	oxidase	oxidase	NN	_	12	compound
12	reactions	reaction	NNS	_	6	nmod
13	be	be	VB	_	14	auxpass
14	used	use	VBN	_	3	ccomp
15	.	.	.	_	3	punct

1	There	there	EX	_	4	expl
2	have	have	VBP	_	4	aux
3	been	be	VBN	_	4	cop
4	reports	report	NNS	_	0	ROOT
5	of	of	IN	_	8	case
6	positive	positive	JJ	_	8	amod
7	test	test	NN	_	8	compound
8	results	result	NNS	_	4	nmod
9	using	use	VBG	_	4	acl
10	the	the	DT	_	16	det
11	Bio-Rad	Bio-Rad	NNP	_	16	compound
12	Laboratories	Laboratories	NNPS	_	16	compound
13	Platelia	Platelia	NNP	_	16	compound
14	Aspergillus	Aspergillus	NNPS	_	16	compound
15	EIA	eia	NN	_	16	compound
16	test	test	NN	_	9	dobj
17	in	in	IN	_	18	case
18	patients	patient	NNS	_	16	nmod
19	receiving	receive	VBG	_	18	acl
20	drug1	drug1	NN	_	19	dobj
21	/	/	:	_	4	punct
22	drug2	drug2	NN	_	23	compound
23	injection	injection	NN	_	4	dep
24	who	who	WP	_	27	nsubjpass
25	were	be	VBD	_	27	auxpass
26	subsequently	subsequently	RB	_	27	advmod
27	found	find	VBN	_	23	acl:relcl
28	to	to	TO	_	30	mark
29	be	be	VB	_	30	cop
30	free	free	JJ	_	27	xcomp
31	of	of	IN	_	33	case
32	Aspergillus	aspergillus	JJ	_	33	amod
33	infection	infection	NN	_	30	nmod
34	.	.	.	_	4	punct

1	Cross-reactions	cross-reaction	NNS	_	17	nsubjpass
2	with	with	IN	_	4	case
3	non-Aspergillus	non-aspergillus	JJ	_	4	amod
4	polysaccharides	polysaccharide	NNS	_	1	nmod
5	and	and	CC	_	4	cc
6	polyfuranoses	polyfuranose	NNS	_	4	conj
7	with	with	IN	_	14	case
8	the	the	DT	_	14	det
9	Bio-Rad	Bio-Rad	NNP	_	14	compound
10	Laboratories	Laboratories	NNPS	_	14	compound
11	Platelia	Platelia	NNP	_	14	compound
12	Aspergillus	Aspergillus	NNPS	_	14	compound
13	EIA	eia	NN	_	14	compound
14	test	test	NN	_	1	nmod
15	have	have	VBP	_	17	aux
16	been	be	VBN	_	17	auxpass
17	reported	report	VBN	_	0	ROOT
18	.	.	.	_	17	punct

1	Therefore	therefore	RB	_	5	advmod
2	,	,	,	_	5	punct
3	positive	positive	JJ	_	4	amod
4	test	test	NN	_	5	nsubj
5	results	result	VBZ	_	0	ROOT
6	in	in	IN	_	7	case
7	patients	patient	NNS	_	5	nmod
8	receiving	receive	VBG	_	7	acl
9	drug1	drug1	NN	_	8	dobj
10	should	should	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	interpreted	interpret	VBN	_	5	dep
13	cautiously	cautiously	RB	_	12	advmod
14	and	and	CC	_	12	cc
15	confirmed	confirm	VBN	_	12	conj
16	by	by	IN	_	19	case
17	other	other	JJ	_	19	amod
18	diagnostic	diagnostic	JJ	_	19	amod
19	methods	method	NNS	_	15	nmod
20	.	.	.	_	5	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	recommended	recommend	VBN	_	0	ROOT
4	that	that	IN	_	8	mark
5	drug1	drug1	NN	_	8	nsubjpass
6	not	not	RB	_	8	neg
7	be	be	VB	_	8	auxpass
8	used	use	VBN	_	3	ccomp
9	concomitantly	concomitantly	RB	_	8	advmod
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	8	nmod
12	Because	because	IN	_	27	mark
13	the	the	DT	_	14	det
14	effects	effect	NNS	_	27	nsubjpass
15	of	of	IN	_	17	case
16	concomitant	concomitant	JJ	_	17	amod
17	administration	administration	NN	_	14	nmod
18	of	of	IN	_	19	case
19	drug3	drug3	NN	_	17	nmod
20	with	with	IN	_	23	case
21	most	most	JJS	_	23	amod
22	other	other	JJ	_	23	amod
23	drug4	drug4	NN	_	14	nmod
24	have	have	VBP	_	27	aux
25	not	not	RB	_	27	neg
26	been	be	VBN	_	27	auxpass
27	studied	study	VBN	_	40	advcl
28	,	,	,	_	40	punct
29	the	the	DT	_	31	det
30	concomitant	concomitant	JJ	_	31	amod
31	use	use	NN	_	40	nsubjpass
32	of	of	IN	_	33	case
33	drug5	drug5	NN	_	31	nmod
34	with	with	IN	_	37	case
35	other	other	JJ	_	37	amod
36	CNS-active	cns-active	JJ	_	37	amod
37	drugs	drug	NNS	_	31	nmod
38	should	should	MD	_	40	aux
39	be	be	VB	_	40	auxpass
40	approached	approach	VBN	_	8	dep
41	with	with	IN	_	42	case
42	caution	caution	NN	_	40	nmod
43	.	.	.	_	3	punct

1	There	there	EX	_	2	expl
2	is	be	VBZ	_	0	ROOT
3	one	one	CD	_	4	nummod
4	report	report	NN	_	2	nsubj
5	suggesting	suggest	VBG	_	4	acl
6	that	that	IN	_	19	mark
7	the	the	DT	_	9	det
8	concomitant	concomitant	JJ	_	9	amod
9	use	use	NN	_	19	nsubj
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	-LRB-	-lrb-	-LRB-	_	13	punct
13	drug2	drug2	NN	_	11	appos
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	and	and	CC	_	11	cc
16	drug3	drug3	NN	_	11	conj
17	may	may	MD	_	19	aux
18	have	have	VB	_	19	aux
19	caused	cause	VBN	_	5	ccomp
20	3	3	LS	_	19	dobj
21	-	-	:	_	20	punct
22	to	to	TO	_	24	case
23	6-fold	6-fold	RB	_	24	advmod
24	elevations	elevation	NNS	_	20	nmod
25	on	on	IN	_	28	case
26	SGPT	sgpt	NN	_	28	compound
27	-LRB-	-lrb-	-LRB-	_	28	punct
28	ALT	alt	NN	_	24	nmod
29	-RRB-	-rrb-	-RRB-	_	24	punct
30	in	in	IN	_	33	case
31	a	a	DT	_	33	det
32	few	few	JJ	_	33	amod
33	patients	patient	NNS	_	24	nmod
34	.	.	.	_	2	punct

1	In	in	IN	_	4	case
2	a	a	DT	_	4	det
3	similar	similar	JJ	_	4	amod
4	study	study	NN	_	19	nmod
5	,	,	,	_	19	punct
6	attempting	attempt	VBG	_	19	advcl
7	to	to	TO	_	8	mark
8	replicate	replicate	VB	_	6	xcomp
9	this	this	DT	_	10	det
10	finding	finding	NN	_	8	dobj
11	,	,	,	_	19	punct
12	no	no	DT	_	14	neg
13	interactive	interactive	JJ	_	14	amod
14	effect	effect	NN	_	19	nsubjpass
15	on	on	IN	_	17	case
16	hepatic	hepatic	JJ	_	17	amod
17	transaminases	transaminase	NNS	_	14	nmod
18	was	be	VBD	_	19	auxpass
19	identified	identify	VBN	_	0	ROOT
20	.	.	.	_	19	punct

1	In	in	IN	_	3	case
2	a	a	DT	_	3	det
3	study	study	NN	_	14	nmod
4	in	in	IN	_	6	case
5	normal	normal	JJ	_	6	amod
6	volunteers	volunteer	NNS	_	3	nmod
7	,	,	,	_	14	punct
8	concomitant	concomitant	JJ	_	9	amod
9	administration	administration	NN	_	14	nsubj
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	drug2	drug2	NN	_	11	conj
14	resulted	result	VBD	_	0	ROOT
15	in	in	IN	_	19	case
16	increased	increase	VBN	_	19	amod
17	serum	serum	NN	_	19	compound
18	drug3	drug3	NN	_	19	compound
19	concentrations	concentration	NNS	_	14	nmod
20	.	.	.	_	14	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	significance	significance	NN	_	9	nsubj
4	of	of	IN	_	6	case
5	this	this	DT	_	6	det
6	finding	finding	NN	_	3	nmod
7	is	be	VBZ	_	9	cop
8	not	not	RB	_	9	neg
9	clear	clear	JJ	_	0	ROOT
10	.	.	.	_	9	punct

1	In	in	FW	_	2	compound
2	vitro	vitro	FW	_	7	advmod
3	,	,	,	_	7	punct
4	drug1	drug1	NN	_	7	nsubj
5	does	do	VBZ	_	7	aux
6	not	not	RB	_	7	neg
7	displace	displace	VB	_	0	ROOT
8	tightly	tightly	RB	_	9	advmod
9	bound	bind	VBN	_	10	amod
10	drugs	drug	NNS	_	7	dobj
11	like	like	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	,	,	,	_	12	punct
14	drug3	drug3	NN	_	12	conj
15	,	,	,	_	12	punct
16	and	and	CC	_	12	cc
17	drug4	drug4	NN	_	12	conj
18	from	from	IN	_	20	case
19	serum	serum	NN	_	20	compound
20	proteins	protein	NNS	_	17	nmod
21	.	.	.	_	7	punct

1	However	however	RB	_	7	advmod
2	,	,	,	_	7	punct
3	there	there	EX	_	7	expl
4	has	have	VBZ	_	7	aux
5	been	be	VBN	_	7	cop
6	one	one	CD	_	7	nummod
7	report	report	NN	_	0	ROOT
8	of	of	IN	_	11	case
9	prolonged	prolonged	JJ	_	11	amod
10	prothrombin	prothrombin	NN	_	11	compound
11	time	time	NN	_	7	nmod
12	when	when	WRB	_	15	advmod
13	drug1	drug1	NN	_	15	nsubjpass
14	was	be	VBD	_	15	auxpass
15	added	add	VBN	_	7	advcl
16	to	to	TO	_	18	case
17	the	the	DT	_	18	det
18	regimen	regimen	NN	_	15	nmod
19	of	of	IN	_	21	case
20	a	a	DT	_	21	det
21	patient	patient	NN	_	18	nmod
22	treated	treat	VBN	_	21	acl
23	with	with	IN	_	24	case
24	drug2	drug2	NN	_	22	nmod
25	.	.	.	_	7	punct

1	The	the	DT	_	2	det
2	patient	patient	NN	_	6	nsubj
3	was	be	VBD	_	6	aux
4	also	also	RB	_	6	advmod
5	chronically	chronically	RB	_	6	advmod
6	receiving	receive	VBG	_	0	ROOT
7	drug1	drug1	NN	_	6	dobj
8	,	,	,	_	7	punct
9	drug2	drug2	NN	_	7	conj
10	,	,	,	_	7	punct
11	drug3	drug3	NN	_	7	conj
12	,	,	,	_	7	punct
13	and	and	CC	_	7	cc
14	drug4	drug4	NN	_	7	conj
15	.	.	.	_	6	punct

1	In	in	FW	_	2	compound
2	vitro	vitro	FW	_	6	advmod
3	,	,	,	_	6	punct
4	drug1	drug1	NN	_	6	nsubj
5	may	may	MD	_	6	aux
6	displace	displace	VB	_	0	ROOT
7	less	less	JJR	_	9	advmod
8	firmly	firmly	RB	_	9	advmod
9	bound	bind	VBN	_	6	dep
10	drugs	drug	NNS	_	9	dobj
11	like	like	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	.	.	.	_	6	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	significance	significance	NN	_	8	nsubj
4	of	of	IN	_	6	case
5	this	this	DT	_	6	det
6	property	property	NN	_	3	nmod
7	is	be	VBZ	_	8	cop
8	unknown	unknown	JJ	_	0	ROOT
9	.	.	.	_	8	punct

1	drug1	drug1	NN	_	24	nsubj
2	in	in	IN	_	3	case
3	combination	combination	NN	_	1	nmod
4	with	with	IN	_	6	case
5	other	other	JJ	_	6	amod
6	drug2	drug2	NN	_	3	nmod
7	,	,	,	_	6	punct
8	general	general	JJ	_	9	amod
9	drug3	drug3	NN	_	6	conj
10	,	,	,	_	6	punct
11	drug4	drug4	NN	_	6	conj
12	,	,	,	_	6	punct
13	drug5	drug5	NN	_	6	conj
14	,	,	,	_	6	punct
15	drug6	drug6	NN	_	6	conj
16	,	,	,	_	6	punct
17	or	or	CC	_	6	cc
18	other	other	JJ	_	19	amod
19	drug7	drug7	NN	_	6	conj
20	-LRB-	-lrb-	-LRB-	_	22	punct
21	including	include	VBG	_	22	case
22	drug8	drug8	NN	_	19	nmod
23	-RRB-	-rrb-	-RRB-	_	22	punct
24	has	have	VBZ	_	0	ROOT
25	additive	additive	JJ	_	27	amod
26	depressant	depressant	NN	_	27	compound
27	effects	effect	NNS	_	24	dobj
28	.	.	.	_	24	punct

1	When	when	WRB	_	2	advmod
2	s.c.	s.c.	NN	_	0	ROOT

1	combination	combination	NN	_	2	compound
2	therapy	therapy	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	contemplated	contemplate	VBN	_	0	ROOT
5	,	,	,	_	4	punct
6	the	the	DT	_	7	det
7	dosage	dosage	NN	_	15	nsubjpass
8	of	of	IN	_	9	case
9	one	one	CD	_	7	nmod
10	or	or	CC	_	9	cc
11	both	both	DT	_	12	det
12	agents	agent	NNS	_	9	conj
13	should	should	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	reduced	reduce	VBN	_	4	ccomp
16	.	.	.	_	4	punct

1	The	the	DT	_	3	det
2	vasodilating	vasodilating	JJ	_	3	amod
3	effects	effect	NNS	_	8	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	cop
8	additive	additive	JJ	_	0	ROOT
9	with	with	IN	_	10	case
10	those	those	DT	_	8	nmod
11	of	of	IN	_	13	case
12	other	other	JJ	_	13	amod
13	drug2	drug2	NN	_	10	nmod
14	.	.	.	_	8	punct

1	drug1	drug1	NN	_	8	nsubjpass
2	,	,	,	_	8	punct
3	in	in	IN	_	4	case
4	particular	particular	JJ	_	8	nmod
5	,	,	,	_	8	punct
6	has	have	VBZ	_	8	aux
7	been	be	VBN	_	8	auxpass
8	found	find	VBN	_	0	ROOT
9	to	to	TO	_	10	mark
10	exhibit	exhibit	VB	_	8	xcomp
11	additive	additive	JJ	_	12	amod
12	effects	effect	NNS	_	10	dobj
13	of	of	IN	_	15	case
14	this	this	DT	_	15	det
15	variety	variety	NN	_	12	nmod
16	.	.	.	_	8	punct

1	Drug	drug	NN	_	2	compound
2	Interaction	interaction	NN	_	10	nsubjpass
3	with	with	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	7	compound
7	drug3	drug3	NN	_	4	conj
8	has	have	VBZ	_	10	aux
9	been	be	VBN	_	10	auxpass
10	shown	show	VBN	_	0	ROOT
11	to	to	TO	_	12	mark
12	exhibit	exhibit	VB	_	10	xcomp
13	minimal	minimal	JJ	_	19	amod
14	-LRB-	-lrb-	-LRB-	_	17	punct
15	ca.	ca.	FW	_	17	dep
16	5	5	CD	_	17	nummod
17	%	%	NN	_	13	dep
18	-RRB-	-rrb-	-RRB-	_	17	punct
19	metabolism	metabolism	NN	_	12	dobj
20	.	.	.	_	10	punct

1	However	however	RB	_	12	advmod
2	,	,	,	_	12	punct
3	co	co	NN	_	4	compound
4	administration	administration	NN	_	12	nsubj
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	with	with	IN	_	9	case
8	either	either	CC	_	9	cc:preconj
9	drug2	drug2	NN	_	4	nmod
10	or	or	CC	_	9	cc
11	drug3	drug3	NN	_	9	conj
12	led	lead	VBD	_	0	ROOT
13	to	to	TO	_	16	case
14	increased	increase	VBN	_	16	amod
15	plasma	plasma	NN	_	16	compound
16	concentrations	concentration	NNS	_	12	nmod
17	of	of	IN	_	18	case
18	drug4	drug4	NN	_	16	nmod
19	.	.	.	_	12	punct

1	drug1	drug1	NN	_	2	nsubj
2	had	have	VBD	_	0	ROOT
3	no	no	DT	_	4	neg
4	effect	effect	NN	_	2	dobj
5	on	on	IN	_	7	case
6	the	the	DT	_	7	det
7	pharmacokinetics	pharmacokinetic	NNS	_	2	nmod
8	of	of	IN	_	10	case
9	either	either	CC	_	10	cc:preconj
10	drug2	drug2	NN	_	7	nmod
11	or	or	CC	_	10	cc
12	drug3	drug3	NN	_	10	conj
13	.	.	.	_	2	punct

1	In	in	IN	_	4	case
2	2	2	CD	_	4	nummod
3	separate	separate	JJ	_	4	amod
4	studies	study	NNS	_	19	nmod
5	,	,	,	_	19	punct
6	drug1	drug1	NN	_	8	compound
7	120	120	CD	_	8	nummod
8	mg	mg	NN	_	19	nsubjpass
9	twice	twice	RB	_	10	advmod
10	daily	daily	RB	_	8	advmod
11	-LRB-	-lrb-	-LRB-	_	16	punct
12	240	240	CD	_	16	nummod
13	mg	mg	NN	_	16	compound
14	total	total	JJ	_	16	amod
15	daily	daily	JJ	_	16	amod
16	dose	dose	NN	_	8	appos
17	-RRB-	-rrb-	-RRB-	_	16	punct
18	was	be	VBD	_	19	auxpass
19	co-administered	co-administer	VBN	_	0	ROOT
20	with	with	IN	_	24	case
21	either	either	CC	_	24	det
22	drug2	drug2	NN	_	24	compound
23	500	500	CD	_	24	nummod
24	mg	mg	NN	_	19	nmod
25	every	every	DT	_	27	det
26	8	8	CD	_	27	nummod
27	hours	hour	NNS	_	19	dobj
28	or	or	CC	_	27	cc
29	drug3	drug3	NN	_	31	compound
30	400	400	CD	_	31	nummod
31	mg	mg	NN	_	27	conj
32	once	once	RB	_	33	advmod
33	daily	daily	RB	_	27	advmod
34	under	under	IN	_	36	case
35	steady-state	steady-state	JJ	_	36	amod
36	conditions	condition	NNS	_	27	nmod
37	to	to	TO	_	39	case
38	healthy	healthy	JJ	_	39	amod
39	volunteers	volunteer	NNS	_	27	nmod
40	-LRB-	-lrb-	-LRB-	_	41	punct
41	n	n	NN	_	27	dep
42	=	=	JJ	_	41	amod
43	24	24	CD	_	42	dep
44	,	,	,	_	41	punct
45	each	each	DT	_	46	det
46	study	study	NN	_	41	appos
47	-RRB-	-rrb-	-RRB-	_	41	punct
48	.	.	.	_	19	punct

1	No	no	DT	_	2	neg
2	differences	difference	NNS	_	10	nsubjpass
3	in	in	IN	_	5	case
4	adverse	adverse	JJ	_	5	amod
5	events	event	NNS	_	2	nmod
6	or	or	CC	_	5	cc
7	QTc	qtc	NN	_	8	compound
8	interval	interval	NN	_	5	conj
9	were	be	VBD	_	10	auxpass
10	observed	observe	VBN	_	0	ROOT
11	when	when	WRB	_	14	advmod
12	subjects	subject	NNS	_	14	nsubjpass
13	were	be	VBD	_	14	auxpass
14	administered	administer	VBN	_	10	advcl
15	drug1	drug1	NN	_	14	dobj
16	alone	alone	RB	_	15	advmod
17	or	or	CC	_	15	cc
18	in	in	IN	_	19	case
19	combination	combination	NN	_	15	conj
20	with	with	IN	_	22	case
21	either	either	CC	_	22	cc:preconj
22	drug2	drug2	NN	_	19	nmod
23	or	or	CC	_	22	cc
24	drug3	drug3	NN	_	22	conj
25	.	.	.	_	10	punct

1	The	the	DT	_	2	det
2	findings	finding	NNS	_	7	nsubjpass
3	of	of	IN	_	5	case
4	these	these	DT	_	5	det
5	studies	study	NNS	_	2	nmod
6	are	be	VBP	_	7	auxpass
7	summarized	summarize	VBN	_	0	ROOT
8	in	in	IN	_	11	case
9	the	the	DT	_	11	det
10	following	follow	VBG	_	11	amod
11	table	table	NN	_	7	nmod
12	:	:	:	_	7	punct
13	Effects	effect	NNS	_	7	dep
14	on	on	IN	_	17	case
15	steady-state	steady-state	JJ	_	17	amod
16	drug1	drug1	NN	_	17	compound
17	pharmacokinetics	pharmacokinetic	NNS	_	13	nmod
18	after	after	IN	_	20	case
19	7	7	CD	_	20	nummod
20	days	day	NNS	_	13	nmod
21	of	of	IN	_	22	case
22	co-administration	co-administration	NN	_	20	nmod
23	with	with	IN	_	26	case
24	drug2	drug2	NN	_	26	compound
25	120	120	CD	_	26	nummod
26	mg	mg	NN	_	22	nmod
27	every	every	DT	_	29	det
28	12	12	CD	_	29	nummod
29	hours	hour	NNS	_	20	dep
30	-LRB-	-lrb-	-LRB-	_	32	punct
31	two	two	CD	_	32	nummod
32	times	time	NNS	_	29	dep
33	the	the	DT	_	37	det
34	recommended	recommend	VBN	_	37	amod
35	twice	twice	RB	_	37	advmod
36	daily	daily	RB	_	37	advmod
37	dose	dose	NN	_	32	dep
38	-RRB-	-rrb-	-RRB-	_	32	punct
39	in	in	IN	_	41	case
40	healthy	healthy	JJ	_	41	amod
41	volunteers	volunteer	NNS	_	29	nmod
42	-LRB-	-lrb-	-LRB-	_	43	punct
43	n	n	NN	_	29	dep
44	=	=	JJ	_	43	amod
45	24	24	CD	_	44	dep
46	-RRB-	-rrb-	-RRB-	_	43	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	Drug	drug	NN	_	0	ROOT

1	cmaxSS	cmaxss	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	5	punct
3	Peak	peak	JJ	_	5	amod
4	plasma	plasma	NN	_	5	compound
5	concentration	concentration	NN	_	1	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct

1	AUCss	aucss	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	0-12h	0-12h	NN	_	1	appos
4	-RRB-	-rrb-	-RRB-	_	3	punct
5	-LRB-	-lrb-	-LRB-	_	6	punct
6	Extent	extent	NN	_	1	dep
7	of	of	IN	_	9	case
8	systemic	systemic	JJ	_	9	amod
9	exposure	exposure	NN	_	6	nmod
10	-RRB-	-rrb-	-RRB-	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	4	punct
3	500	500	CD	_	4	nummod
4	mg	mg	NN	_	1	dep
5	every	every	DT	_	7	det
6	8	8	CD	_	7	nummod
7	hrs	hr	NNS	_	4	dep
8	-RRB-	-rrb-	-RRB-	_	4	punct

1	+82	+82	CD	_	2	nummod
2	%	%	NN	_	0	ROOT

1	+109	+109	CD	_	2	nummod
2	%	%	NN	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	4	punct
3	400	400	CD	_	4	nummod
4	mg	mg	NN	_	1	dep
5	once	once	RB	_	6	advmod
6	daily	daily	JJ	_	4	amod
7	-RRB-	-rrb-	-RRB-	_	4	punct

1	+135	+135	CD	_	2	nummod
2	%	%	NN	_	0	ROOT

1	+164	+164	CD	_	2	nummod
2	%	%	NN	_	0	ROOT

1	The	the	DT	_	2	det
2	changes	change	NNS	_	9	nsubj
3	in	in	IN	_	5	case
4	plasma	plasma	NN	_	5	compound
5	levels	level	NNS	_	2	nmod
6	were	be	VBD	_	9	cop
7	within	within	IN	_	9	case
8	the	the	DT	_	9	det
9	range	range	NN	_	0	ROOT
10	of	of	IN	_	12	case
11	plasma	plasma	NN	_	12	compound
12	levels	level	NNS	_	9	nmod
13	achieved	achieve	VBN	_	12	acl
14	in	in	IN	_	19	case
15	adequate	adequate	JJ	_	19	amod
16	and	and	CC	_	15	cc
17	well-controlled	well-controlled	JJ	_	15	conj
18	clinical	clinical	JJ	_	19	amod
19	trials	trial	NNS	_	13	nmod
20	.	.	.	_	9	punct

1	The	the	DT	_	2	det
2	mechanism	mechanism	NN	_	8	nsubjpass
3	of	of	IN	_	5	case
4	these	these	DT	_	5	det
5	interactions	interaction	NNS	_	2	nmod
6	has	have	VBZ	_	8	aux
7	been	be	VBN	_	8	auxpass
8	evaluated	evaluate	VBN	_	0	ROOT
9	in	in	IN	_	11	case
10	in	in	FW	_	11	compound
11	vitro	vitro	FW	_	16	advmod
12	,	,	,	_	16	punct
13	in	in	FW	_	14	compound
14	situ	situ	FW	_	16	advmod
15	,	,	,	_	16	punct
16	and	and	CC	_	8	advmod
17	in	in	FW	_	20	amod
18	vivo	vivo	FW	_	17	dep
19	animal	animal	NN	_	20	compound
20	models	model	NNS	_	16	conj
21	.	.	.	_	8	punct

1	These	these	DT	_	2	det
2	studies	study	NNS	_	3	nsubj
3	indicate	indicate	VBP	_	0	ROOT
4	that	that	IN	_	9	mark
5	drug1	drug1	NN	_	9	nsubj
6	or	or	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	co-administration	co-administration	NN	_	5	dep
9	enhances	enhance	VBZ	_	3	ccomp
10	drug3	drug3	NN	_	12	compound
11	gastrointestinal	gastrointestinal	JJ	_	12	amod
12	absorption	absorption	NN	_	9	dobj
13	.	.	.	_	3	punct

1	This	this	DT	_	3	det
2	observed	observe	VBN	_	3	amod
3	increase	increase	NN	_	14	nsubj
4	in	in	IN	_	6	case
5	the	the	DT	_	6	det
6	bioavailability	bioavailability	NN	_	3	nmod
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	may	may	MD	_	14	aux
10	be	be	VB	_	14	cop
11	due	due	JJ	_	14	case
12	to	to	TO	_	11	mwe
13	transport-related	transport-related	JJ	_	14	amod
14	effects	effect	NNS	_	0	ROOT
15	,	,	,	_	14	punct
16	such	such	JJ	_	18	case
17	as	as	IN	_	16	mwe
18	p-glycoprotein	p-glycoprotein	NN	_	14	nmod
19	.	.	.	_	14	punct
20	in	in	FW	_	23	amod
21	vivo	vivo	FW	_	20	dep
22	animal	animal	NN	_	23	compound
23	studies	study	NNS	_	25	nsubj
24	also	also	RB	_	25	advmod
25	suggest	suggest	VBP	_	14	parataxis
26	that	that	IN	_	34	mark
27	in	in	IN	_	28	case
28	addition	addition	NN	_	34	nmod
29	to	to	TO	_	30	mark
30	enhancing	enhance	VBG	_	28	acl
31	absorption	absorption	NN	_	30	dobj
32	,	,	,	_	34	punct
33	drug2	drug2	NN	_	34	nsubj
34	decreases	decrease	VBZ	_	25	ccomp
35	drug3	drug3	NN	_	37	compound
36	gastrointestinal	gastrointestinal	JJ	_	37	amod
37	secretion	secretion	NN	_	34	dobj
38	,	,	,	_	34	punct
39	while	while	IN	_	43	mark
40	drug4	drug4	NN	_	43	nsubj
41	may	may	MD	_	43	aux
42	also	also	RB	_	43	advmod
43	decrease	decrease	VB	_	34	advcl
44	biliary	biliary	JJ	_	45	amod
45	excretion	excretion	NN	_	43	dobj
46	.	.	.	_	14	punct

1	Drug	drug	NN	_	2	compound
2	Interactions	interaction	NNS	_	31	nsubj
3	with	with	IN	_	5	case
4	drug1	drug1	NN	_	5	compound
5	Administration	administration	NN	_	2	nmod
6	of	of	IN	_	8	case
7	120	120	CD	_	8	nummod
8	mg	mg	NN	_	5	nmod
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	-LRB-	-lrb-	-LRB-	_	16	punct
12	2	2	CD	_	15	dep
13	x	x	CC	_	12	cc
14	60	60	CD	_	12	conj
15	mg	mg	NN	_	16	dep
16	capsule	capsule	NN	_	8	appos
17	-RRB-	-rrb-	-RRB-	_	16	punct
18	within	within	IN	_	20	case
19	15	15	CD	_	20	nummod
20	minutes	minute	NNS	_	2	nmod
21	of	of	IN	_	23	case
22	an	a	DT	_	23	det
23	drug3	drug3	NN	_	20	nmod
24	and	and	CC	_	23	cc
25	drug4	drug4	NN	_	23	conj
26	containing	contain	VBG	_	23	acl
27	drug5	drug5	NN	_	26	dobj
28	-LRB-	-lrb-	-LRB-	_	29	punct
29	drug6	drug6	NN	_	27	appos
30	-RRB-	-rrb-	-RRB-	_	29	punct
31	decreased	decrease	VBD	_	0	ROOT
32	drug7	drug7	NN	_	33	compound
33	AUC	auc	NN	_	31	dobj
34	by	by	IN	_	36	case
35	41	41	CD	_	36	nummod
36	%	%	NN	_	31	nmod
37	and	and	CC	_	31	cc
38	cmax	cmax	NN	_	31	conj
39	by	by	IN	_	41	case
40	43	43	CD	_	41	nummod
41	%	%	NN	_	38	nmod
42	.	.	.	_	31	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	should	should	MD	_	5	aux
3	not	not	RB	_	5	neg
4	be	be	VB	_	5	auxpass
5	taken	take	VBN	_	0	ROOT
6	closely	closely	RB	_	5	advmod
7	in	in	IN	_	8	case
8	time	time	NN	_	5	nmod
9	with	with	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	drug3	drug3	NN	_	10	conj
13	containing	contain	VBG	_	10	acl
14	drug4	drug4	NN	_	13	dobj
15	.	.	.	_	5	punct

1	Interactions	interaction	NNS	_	15	nsubj
2	with	with	IN	_	6	case
3	Fruit	Fruit	NNP	_	6	compound
4	Juices	Juices	NNP	_	6	compound
5	Fruit	Fruit	NNP	_	6	compound
6	juices	juice	NNS	_	1	nmod
7	such	such	JJ	_	9	case
8	as	as	IN	_	7	mwe
9	grapefruit	grapefruit	NN	_	6	nmod
10	,	,	,	_	9	punct
11	orange	orange	NN	_	9	conj
12	and	and	CC	_	9	cc
13	apple	apple	NN	_	9	conj
14	may	may	MD	_	15	aux
15	reduce	reduce	VB	_	0	ROOT
16	the	the	DT	_	17	det
17	bioavailability	bioavailability	NN	_	15	dobj
18	and	and	CC	_	17	cc
19	exposure	exposure	NN	_	17	conj
20	of	of	IN	_	21	case
21	drug1	drug1	NN	_	17	nmod
22	.	.	.	_	15	punct

1	This	this	DT	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	based	base	VBN	_	0	ROOT
4	on	on	IN	_	6	case
5	the	the	DT	_	6	det
6	results	result	NNS	_	3	nmod
7	from	from	IN	_	10	case
8	3	3	CD	_	10	nummod
9	clinical	clinical	JJ	_	10	amod
10	studies	study	NNS	_	6	nmod
11	using	use	VBG	_	10	acl
12	drug1	drug1	NN	_	11	dobj
13	induced	induce	VBD	_	15	amod
14	skin	skin	NN	_	15	compound
15	wheals	wheal	NNS	_	3	dobj
16	and	and	CC	_	15	cc
17	flares	flare	NNS	_	15	conj
18	coupled	couple	VBN	_	15	acl
19	with	with	IN	_	22	case
20	population	population	NN	_	22	compound
21	pharmacokinetic	pharmacokinetic	JJ	_	22	amod
22	analysis	analysis	NN	_	18	nmod
23	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	size	size	NN	_	9	nsubj
3	of	of	IN	_	4	case
4	wheal	wheal	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	flare	flare	NN	_	4	conj
7	were	be	VBD	_	9	cop
8	significantly	significantly	RB	_	9	advmod
9	larger	larger	JJR	_	0	ROOT
10	when	when	WRB	_	13	advmod
11	drug1	drug1	NN	_	13	nsubjpass
12	was	be	VBD	_	13	auxpass
13	administered	administer	VBN	_	9	advcl
14	with	with	IN	_	16	case
15	either	either	CC	_	16	cc:preconj
16	grapefruit	grapefruit	NN	_	13	nmod
17	or	or	CC	_	16	cc
18	orange	orange	JJ	_	19	amod
19	juices	juice	NNS	_	16	conj
20	compared	compare	VBN	_	22	case
21	to	to	TO	_	22	case
22	water	water	NN	_	13	advcl
23	.	.	.	_	9	punct

1	Based	base	VBN	_	5	case
2	on	on	IN	_	5	case
3	the	the	DT	_	5	det
4	literature	literature	NN	_	5	compound
5	reports	report	NNS	_	12	advcl
6	,	,	,	_	12	punct
7	the	the	DT	_	9	det
8	same	same	JJ	_	9	amod
9	effects	effect	NNS	_	12	nsubjpass
10	may	may	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	extrapolated	extrapolate	VBN	_	0	ROOT
13	to	to	TO	_	16	case
14	other	other	JJ	_	16	amod
15	fruit	fruit	NN	_	16	compound
16	juices	juice	NNS	_	12	nmod
17	such	such	JJ	_	20	case
18	as	as	IN	_	17	mwe
19	apple	apple	NN	_	20	compound
20	juice	juice	NN	_	16	nmod
21	.	.	.	_	12	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	significance	significance	NN	_	8	nsubj
4	of	of	IN	_	6	case
5	these	these	DT	_	6	det
6	observations	observation	NNS	_	3	nmod
7	is	be	VBZ	_	8	cop
8	unknown	unknown	JJ	_	0	ROOT
9	.	.	.	_	8	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	33	nmod
3	,	,	,	_	33	punct
4	based	base	VBN	_	9	case
5	on	on	IN	_	9	case
6	the	the	DT	_	9	det
7	population	population	NN	_	9	compound
8	pharmacokinetics	pharmacokinetic	NNS	_	9	compound
9	analysis	analysis	NN	_	33	advcl
10	of	of	IN	_	13	case
11	the	the	DT	_	13	det
12	combined	combined	JJ	_	13	amod
13	data	datum	NNS	_	9	nmod
14	from	from	IN	_	15	case
15	grapefruit	grapefruit	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	orange	orange	JJ	_	19	amod
18	juices	juice	NNS	_	19	compound
19	studies	study	NNS	_	15	conj
20	with	with	IN	_	22	case
21	the	the	DT	_	22	det
22	data	datum	NNS	_	9	nmod
23	from	from	IN	_	26	case
24	a	a	DT	_	26	det
25	bioequivalence	bioequivalence	NN	_	26	compound
26	study	study	NN	_	22	nmod
27	,	,	,	_	33	punct
28	the	the	DT	_	29	det
29	bioavailability	bioavailability	NN	_	33	nsubjpass
30	of	of	IN	_	31	case
31	drug1	drug1	NN	_	29	nmod
32	was	be	VBD	_	33	auxpass
33	reduced	reduce	VBN	_	0	ROOT
34	by	by	IN	_	36	case
35	36	36	CD	_	36	nummod
36	%	%	NN	_	33	nmod
37	.	.	.	_	33	punct

1	Therefore	therefore	RB	_	12	advmod
2	,	,	,	_	12	punct
3	to	to	TO	_	4	mark
4	maximize	maximize	VB	_	12	advcl
5	the	the	DT	_	6	det
6	effects	effect	NNS	_	4	dobj
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	,	,	,	_	12	punct
10	it	it	PRP	_	12	nsubjpass
11	is	be	VBZ	_	12	auxpass
12	recommended	recommend	VBN	_	0	ROOT
13	that	that	IN	_	17	mark
14	drug2	drug2	NN	_	17	nsubjpass
15	should	should	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	taken	take	VBN	_	12	ccomp
18	with	with	IN	_	19	case
19	water	water	NN	_	17	nmod

1	.	.	.	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	No	no	DT	_	3	neg
2	formal	formal	JJ	_	3	amod
3	studies	study	NNS	_	12	nsubjpass
4	to	to	TO	_	5	mark
5	evaluate	evaluate	VB	_	3	acl
6	drug	drug	NN	_	7	compound
7	interactions	interaction	NNS	_	5	dobj
8	with	with	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	have	have	VBP	_	12	aux
11	been	be	VBN	_	12	auxpass
12	conducted	conduct	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	drug1	drug1	NN	_	3	compound
2	oxidative	oxidative	JJ	_	3	amod
3	metabolites	metabolite	NNS	_	4	nsubj
4	appear	appear	VBP	_	0	ROOT
5	to	to	TO	_	7	mark
6	be	be	VB	_	7	auxpass
7	formed	form	VBN	_	4	xcomp
8	by	by	IN	_	11	case
9	cytochrome	cytochrome	NN	_	11	compound
10	P450	p450	NN	_	11	compound
11	3A4	3a4	NN	_	7	nmod
12	.	.	.	_	4	punct

1	On	on	IN	_	3	case
2	the	the	DT	_	3	det
3	basis	basis	NN	_	34	nmod
4	of	of	IN	_	6	case
5	the	the	DT	_	6	det
6	metabolism	metabolism	NN	_	3	nmod
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	by	by	IN	_	12	case
10	cytochrome	cytochrome	NN	_	12	compound
11	P450	p450	NN	_	12	compound
12	3A4	3a4	NN	_	6	nmod
13	,	,	,	_	12	punct
14	drug2	drug2	NN	_	12	conj
15	,	,	,	_	12	punct
16	drug3	drug3	NN	_	12	conj
17	,	,	,	_	12	punct
18	drug4	drug4	NN	_	12	conj
19	,	,	,	_	12	punct
20	drug5	drug5	NN	_	12	conj
21	,	,	,	_	12	punct
22	grapefruit	grapefruit	NN	_	23	compound
23	juice	juice	NN	_	12	conj
24	,	,	,	_	12	punct
25	and	and	CC	_	12	cc
26	other	other	JJ	_	27	amod
27	inhibitors	inhibitor	NNS	_	12	conj
28	of	of	IN	_	31	case
29	cytochrome	cytochrome	NN	_	31	compound
30	P450	p450	NN	_	31	compound
31	3A4	3a4	NN	_	27	nmod
32	would	would	MD	_	34	aux
33	be	be	VB	_	34	auxpass
34	expected	expect	VBN	_	0	ROOT
35	to	to	TO	_	36	mark
36	lead	lead	VB	_	34	xcomp
37	to	to	TO	_	39	case
38	an	a	DT	_	39	det
39	increase	increase	NN	_	36	nmod
40	in	in	IN	_	43	case
41	plasma	plasma	NN	_	43	compound
42	drug6	drug6	NN	_	43	compound
43	concentrations	concentration	NNS	_	39	nmod
44	.	.	.	_	34	punct

1	Furthermore	furthermore	RB	_	17	advmod
2	,	,	,	_	17	punct
3	drug1	drug1	NN	_	17	nmod:tmod
4	,	,	,	_	17	punct
5	drug2	drug2	NN	_	17	nsubj
6	,	,	,	_	5	punct
7	drug3	drug3	NN	_	5	conj
8	,	,	,	_	5	punct
9	and	and	CC	_	5	cc
10	other	other	JJ	_	11	amod
11	inducers	inducer	NNS	_	5	conj
12	of	of	IN	_	15	case
13	cytochrome	cytochrome	NN	_	15	compound
14	P450	p450	NN	_	15	compound
15	3A4	3a4	NN	_	11	nmod
16	may	may	MD	_	17	aux
17	cause	cause	VB	_	0	ROOT
18	a	a	DT	_	19	det
19	reduction	reduction	NN	_	17	dobj
20	in	in	IN	_	23	case
21	plasma	plasma	NN	_	23	compound
22	drug4	drug4	NN	_	23	compound
23	concentrations	concentration	NNS	_	19	nmod
24	.	.	.	_	17	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	8	nsubj
3	of	of	IN	_	5	case
4	drug1	drug1	NN	_	5	compound
5	capsules	capsule	NNS	_	2	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	resulted	result	VBD	_	0	ROOT
9	in	in	IN	_	11	case
10	substantial	substantial	JJ	_	11	amod
11	increases	increase	NNS	_	8	nmod
12	in	in	IN	_	14	case
13	plasma	plasma	NN	_	14	compound
14	concentrations	concentration	NNS	_	11	nmod
15	of	of	IN	_	16	case
16	drug3	drug3	NN	_	14	nmod
17	,	,	,	_	11	punct
18	probably	probably	RB	_	22	advmod
19	at	at	IN	_	21	advmod
20	least	least	JJS	_	19	mwe
21	partially	partially	RB	_	22	advmod
22	related	related	JJ	_	11	amod
23	to	to	TO	_	27	case
24	cytochrome	cytochrome	NN	_	27	compound
25	P450	p450	NN	_	27	compound
26	3A4	3a4	NN	_	27	compound
27	inhibition	inhibition	NN	_	22	nmod
28	by	by	IN	_	29	case
29	drug4	drug4	NN	_	27	nmod
30	.	.	.	_	8	punct

1	Under	under	IN	_	3	case
2	similar	similar	JJ	_	3	amod
3	conditions	condition	NNS	_	9	nmod
4	,	,	,	_	9	punct
5	drug1	drug1	NN	_	6	compound
6	concentrations	concentration	NNS	_	9	nsubjpass
7	were	be	VBD	_	9	auxpass
8	not	not	RB	_	9	neg
9	affected	affect	VBN	_	0	ROOT
10	by	by	IN	_	13	case
11	concomitant	concomitant	JJ	_	13	amod
12	drug2	drug2	NN	_	13	compound
13	administration	administration	NN	_	9	nmod
14	.	.	.	_	9	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	10	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	7	case
6	drug2	drug2	NN	_	7	compound
7	capsules	capsule	NNS	_	2	nmod
8	is	be	VBZ	_	10	auxpass
9	not	not	RB	_	10	neg
10	recommended	recommend	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	6	case
4	controlled	controlled	JJ	_	6	amod
5	clinical	clinical	JJ	_	6	amod
6	studies	study	NNS	_	12	nmod
7	,	,	,	_	12	punct
8	drug2	drug2	NN	_	12	nsubjpass
9	have	have	VBP	_	12	aux
10	been	be	VBN	_	12	auxpass
11	frequently	frequently	RB	_	12	advmod
12	administered	administer	VBN	_	1	appos
13	concomitantly	concomitantly	RB	_	12	advmod
14	with	with	IN	_	15	case
15	drug3	drug3	NN	_	12	nmod
16	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	combination	combination	NN	_	5	nsubjpass
3	is	be	VBZ	_	5	auxpass
4	well	well	RB	_	5	advmod
5	tolerated	tolerate	VBN	_	0	ROOT
6	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	nsubj
4	increases	increase	VBZ	_	1	appos
5	drug3	drug3	NN	_	7	compound
6	plasma	plasma	NN	_	7	compound
7	levels	level	NNS	_	4	dobj
8	.	.	.	_	1	punct

1	Patients	patient	NNS	_	10	nsubjpass
2	receiving	receive	VBG	_	1	acl
3	the	the	DT	_	5	det
4	two	two	CD	_	5	nummod
5	drugs	drug	NNS	_	2	dobj
6	concomitantly	concomitantly	RB	_	10	advmod
7	should	should	MD	_	10	aux
8	be	be	VB	_	10	auxpass
9	carefully	carefully	RB	_	10	advmod
10	monitored	monitor	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Some	some	DT	_	4	det
4	drug2	drug2	NN	_	6	nsubj
5	may	may	MD	_	6	aux
6	increase	increase	VB	_	1	appos
7	the	the	DT	_	8	det
8	concentration	concentration	NN	_	6	dobj
9	of	of	IN	_	10	case
10	drug3	drug3	NN	_	8	nmod
11	in	in	IN	_	13	case
12	the	the	DT	_	13	det
13	blood	blood	NN	_	8	nmod
14	.	.	.	_	1	punct

1	drug1	drug1	NN	_	5	nsubj
2	usually	usually	RB	_	5	advmod
3	does	do	VBZ	_	5	aux
4	not	not	RB	_	5	neg
5	alter	alter	VB	_	0	ROOT
6	the	the	DT	_	8	det
7	plasma	plasma	NN	_	8	compound
8	levels	level	NNS	_	5	dobj
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	,	,	,	_	5	punct
12	however	however	RB	_	5	advmod
13	,	,	,	_	5	punct
14	serum	serum	NN	_	16	compound
15	drug3	drug3	NN	_	16	compound
16	levels	level	NNS	_	19	nsubjpass
17	should	should	MD	_	19	aux
18	be	be	VB	_	19	auxpass
19	evaluated	evaluate	VBN	_	26	csubjpass
20	after	after	IN	_	22	case
21	concomitant	concomitant	JJ	_	22	amod
22	therapy	therapy	NN	_	19	nmod
23	with	with	IN	_	24	case
24	drug4	drug4	NN	_	22	nmod
25	is	be	VBZ	_	26	auxpass
26	initiated	initiate	VBN	_	5	parataxis
27	.	.	.	_	5	punct

1	drug1	drug1	NN	_	3	compound
2	*	*	SYM	_	3	dep
3	Coadministration	Coadministration	NNP	_	6	nsubj
4	of	of	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	had	have	VBD	_	0	ROOT
7	no	no	DT	_	8	neg
8	effect	effect	NN	_	6	dobj
9	on	on	IN	_	11	case
10	drug3	drug3	NN	_	11	compound
11	absorption	absorption	NN	_	6	nmod
12	.	.	.	_	6	punct

1	Even	even	RB	_	7	advmod
2	though	though	IN	_	7	mark
3	such	such	JJ	_	4	amod
4	interactions	interaction	NNS	_	7	nsubjpass
5	were	be	VBD	_	7	auxpass
6	not	not	RB	_	7	neg
7	seen	see	VBN	_	22	csubjpass
8	during	during	IN	_	10	case
9	clinical	clinical	JJ	_	10	amod
10	studies	study	NNS	_	7	nmod
11	with	with	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	,	,	,	_	12	punct
14	an	a	DT	_	16	det
15	increased	increase	VBN	_	16	amod
16	volume	volume	NN	_	12	appos
17	of	of	IN	_	19	case
18	circulating	circulate	VBG	_	19	amod
19	fluids	fluid	NNS	_	16	nmod
20	might	might	MD	_	22	aux
21	be	be	VB	_	22	auxpass
22	required	require	VBN	_	0	ROOT
23	if	if	IN	_	27	mark
24	such	such	PDT	_	26	det:predet
25	an	a	DT	_	26	det
26	interaction	interaction	NN	_	27	nsubj
27	were	be	VBD	_	22	advcl
28	to	to	TO	_	29	mark
29	occur	occur	VB	_	27	xcomp
30	.	.	.	_	22	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concomitant	concomitant	JJ	_	4	amod
4	administration	administration	NN	_	1	dep
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	drug3	drug3	NN	_	6	conj
9	levels	level	NNS	_	6	dep
10	.	.	.	_	1	punct

1	Plasma	plasma	NN	_	2	compound
2	concentrations	concentration	NNS	_	9	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	should	should	MD	_	9	aux
6	therefore	therefore	RB	_	9	advmod
7	be	be	VB	_	9	auxpass
8	closely	closely	RB	_	9	advmod
9	monitored	monitor	VBN	_	0	ROOT
10	,	,	,	_	9	punct
11	and	and	CC	_	9	cc
12	its	its	PRP$	_	13	nmod:poss
13	dosage	dosage	NN	_	14	nsubj
14	reduced	reduce	VBD	_	9	conj
15	accordingly	accordingly	RB	_	14	advmod
16	,	,	,	_	14	punct
17	in	in	IN	_	18	case
18	patients	patient	NNS	_	14	nmod
19	treated	treat	VBN	_	18	acl
20	with	with	IN	_	21	case
21	drug2	drug2	NN	_	19	nmod
22	.	.	.	_	9	punct

1	When	when	WRB	_	18	advmod
2	therapeutic	therapeutic	JJ	_	3	amod
3	concentrations	concentration	NNS	_	18	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	,	,	,	_	5	punct
7	drug2	drug2	NN	_	5	conj
8	,	,	,	_	5	punct
9	drug3	drug3	NN	_	5	conj
10	,	,	,	_	5	punct
11	drug4	drug4	NN	_	5	conj
12	,	,	,	_	5	punct
13	drug5	drug5	NN	_	5	conj
14	,	,	,	_	5	punct
15	or	or	CC	_	5	cc
16	drug6	drug6	NN	_	5	conj
17	were	be	VBD	_	18	auxpass
18	added	add	VBN	_	35	advcl
19	to	to	TO	_	21	case
20	human	human	JJ	_	21	amod
21	plasma	plasma	NN	_	18	nmod
22	-LRB-	-lrb-	-LRB-	_	24	punct
23	in	in	FW	_	24	compound
24	vitro	vitro	FW	_	21	dep
25	-RRB-	-rrb-	-RRB-	_	24	punct
26	,	,	,	_	35	punct
27	the	the	DT	_	30	det
28	plasma	plasma	NN	_	30	compound
29	protein	protein	NN	_	30	compound
30	binding	binding	NN	_	35	nsubjpass
31	of	of	IN	_	32	case
32	drug7	drug7	NN	_	30	nmod
33	was	be	VBD	_	35	auxpass
34	not	not	RB	_	35	neg
35	altered	alter	VBN	_	0	ROOT
36	.	.	.	_	35	punct

1	Drugs	drug	NNS	_	11	nsubj
2	which	which	WDT	_	4	nsubj
3	may	may	MD	_	4	aux
4	enhance	enhance	VB	_	1	acl:relcl
5	the	the	DT	_	8	det
6	neuromuscular	neuromuscular	JJ	_	8	amod
7	blocking	block	VBG	_	8	amod
8	action	action	NN	_	4	dobj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	include	include	VBP	_	0	ROOT
12	:	:	:	_	11	punct
13	drug2	drug2	NN	_	11	dep
14	;	;	:	_	13	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	certain	certain	JJ	_	2	amod
2	drug1	drug1	NN	_	0	ROOT
3	,	,	,	_	2	punct
4	especially	especially	RB	_	6	advmod
5	the	the	DT	_	6	det
6	drug2	drug2	NN	_	2	appos
7	and	and	CC	_	6	cc
8	drug3	drug3	NN	_	6	conj
9	;	;	:	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	drug1	drug1	NN	_	2	compound
2	salts	salt	NNS	_	0	ROOT
3	;	;	:	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	;	;	:	_	1	punct

1	Drugs	drug	NNS	_	11	nsubj
2	which	which	WDT	_	4	nsubj
3	may	may	MD	_	4	aux
4	enhance	enhance	VB	_	1	acl:relcl
5	the	the	DT	_	8	det
6	neuromuscular	neuromuscular	JJ	_	8	amod
7	blocking	block	VBG	_	8	amod
8	action	action	NN	_	4	dobj
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	include	include	VBP	_	0	ROOT
12	:	:	:	_	11	punct
13	drug2	drug2	NN	_	11	dep
14	;	;	:	_	13	punct
15	drug3	drug3	NN	_	13	conj
16	;	;	:	_	13	punct
17	drug4	drug4	NN	_	13	conj
18	;	;	:	_	13	punct
19	certain	certain	JJ	_	20	amod
20	drug5	drug5	NN	_	13	conj
21	,	,	,	_	20	punct
22	especially	especially	RB	_	24	advmod
23	the	the	DT	_	24	det
24	drug6	drug6	NN	_	20	appos
25	and	and	CC	_	24	cc
26	drug7	drug7	NN	_	24	conj
27	;	;	:	_	13	punct
28	drug8	drug8	NN	_	13	conj
29	;	;	:	_	13	punct
30	drug9	drug9	NN	_	31	compound
31	salts	salt	NNS	_	13	conj
32	;	;	:	_	13	punct
33	drug10	drug10	NN	_	13	conj
34	;	;	:	_	13	punct
35	and	and	CC	_	13	cc
36	drug11	drug11	NN	_	13	conj
37	.	.	.	_	11	punct

1	If	if	IN	_	5	mark
2	other	other	JJ	_	3	amod
3	drug1	drug1	NN	_	5	nsubjpass
4	are	be	VBP	_	5	auxpass
5	used	use	VBN	_	21	advcl
6	during	during	IN	_	9	case
7	the	the	DT	_	9	det
8	same	same	JJ	_	9	amod
9	procedure	procedure	NN	_	5	nmod
10	,	,	,	_	21	punct
11	the	the	DT	_	12	det
12	possibility	possibility	NN	_	21	nsubjpass
13	of	of	IN	_	18	case
14	a	a	DT	_	18	det
15	synergistic	synergistic	JJ	_	18	amod
16	or	or	CC	_	15	cc
17	antagonist	antagonist	NN	_	15	conj
18	effect	effect	NN	_	12	nmod
19	should	should	MD	_	21	aux
20	be	be	VB	_	21	auxpass
21	considered	consider	VBN	_	0	ROOT
22	.	.	.	_	21	punct

1	The	the	DT	_	3	det
2	prior	prior	JJ	_	3	amod
3	administration	administration	NN	_	8	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	does	do	VBZ	_	8	aux
7	not	not	RB	_	8	neg
8	enhance	enhance	VB	_	0	ROOT
9	the	the	DT	_	10	det
10	duration	duration	NN	_	8	dobj
11	,	,	,	_	8	punct
12	but	but	CC	_	8	cc
13	quickens	quicken	VBZ	_	8	conj
14	the	the	DT	_	15	det
15	onset	onset	NN	_	13	dobj
16	and	and	CC	_	13	cc
17	may	may	MD	_	18	aux
18	increase	increase	VB	_	13	conj
19	the	the	DT	_	20	det
20	depth	depth	NN	_	18	dobj
21	,	,	,	_	20	punct
22	of	of	IN	_	24	case
23	neuromuscular	neuromuscular	JJ	_	24	amod
24	block	block	NN	_	20	nmod
25	induced	induce	VBN	_	24	acl
26	by	by	IN	_	27	case
27	drug2	drug2	NN	_	25	nmod
28	.	.	.	_	8	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	should	should	MD	_	5	aux
3	not	not	RB	_	5	neg
4	be	be	VB	_	5	auxpass
5	administered	administer	VBN	_	0	ROOT
6	until	until	IN	_	10	mark
7	a	a	DT	_	8	det
8	patient	patient	NN	_	10	nsubj
9	has	have	VBZ	_	10	aux
10	recovered	recover	VBN	_	5	advcl
11	from	from	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	-	-	:	_	5	punct
14	induced	induce	VBN	_	16	amod
15	neuromuscular	neuromuscular	JJ	_	16	amod
16	block	block	NN	_	5	dep
17	.	.	.	_	5	punct

1	No	no	DT	_	3	neg
2	formal	formal	JJ	_	3	amod
3	assessments	assessment	NNS	_	15	nsubjpass
4	of	of	IN	_	7	case
5	pharmacokinetic	pharmacokinetic	JJ	_	7	amod
6	drug-drug	drug-drug	NN	_	7	compound
7	interactions	interaction	NNS	_	3	nmod
8	between	between	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	other	other	JJ	_	12	amod
12	agents	agent	NNS	_	9	conj
13	have	have	VBP	_	15	aux
14	been	be	VBN	_	15	auxpass
15	conducted	conduct	VBN	_	0	ROOT
16	.	.	.	_	15	punct

1	Caution	caution	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	advised	advise	VBN	_	0	ROOT
4	when	when	WRB	_	7	advmod
5	drug1	drug1	NN	_	7	nsubjpass
6	is	be	VBZ	_	7	auxpass
7	coadministered	coadminister	VBN	_	3	advcl
8	with	with	IN	_	10	case
9	other	other	JJ	_	10	amod
10	medications	medication	NNS	_	7	nmod
11	that	that	WDT	_	13	nsubj
12	can	can	MD	_	13	aux
13	prolong	prolong	VB	_	10	acl:relcl
14	the	the	DT	_	16	det
15	QT	QT	NNP	_	16	compound
16	interval	interval	NN	_	13	dobj
17	-LRB-	-lrb-	-LRB-	_	20	punct
18	e.g.	e.g.	FW	_	20	dep
19	certain	certain	JJ	_	20	amod
20	drug2	drug2	NN	_	16	dep
21	or	or	CC	_	20	cc
22	drug3	drug3	NN	_	20	conj
23	-RRB-	-rrb-	-RRB-	_	20	punct
24	or	or	CC	_	13	cc
25	lead	lead	VB	_	13	conj
26	to	to	TO	_	28	case
27	electrolyte	electrolyte	NN	_	28	compound
28	abnormalities	abnormality	NNS	_	25	nmod
29	-LRB-	-lrb-	-LRB-	_	32	punct
30	such	such	JJ	_	32	case
31	as	as	IN	_	30	mwe
32	drug4	drug4	NN	_	28	nmod
33	or	or	CC	_	32	cc
34	drug5	drug5	NN	_	32	conj
35	-RRB-	-rrb-	-RRB-	_	32	punct
36	.	.	.	_	3	punct

1	drug1	drug1	NN	_	2	nsubj
2	interferes	interfere	VBZ	_	0	ROOT
3	with	with	IN	_	5	case
4	the	the	DT	_	5	det
5	absorption	absorption	NN	_	2	nmod
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	,	,	,	_	5	punct
9	including	include	VBG	_	10	case
10	drug3	drug3	NN	_	5	nmod
11	.	.	.	_	2	punct

1	Administration	administration	NN	_	15	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	to	to	TO	_	6	case
5	hypoparathyroid	hypoparathyroid	JJ	_	6	amod
6	patients	patient	NNS	_	1	nmod
7	who	who	WP	_	11	nsubjpass
8	are	be	VBP	_	11	aux
9	concurrently	concurrently	RB	_	11	advmod
10	being	be	VBG	_	11	auxpass
11	treated	treat	VBN	_	6	acl:relcl
12	with	with	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	may	may	MD	_	15	aux
15	cause	cause	VB	_	0	ROOT
16	hypercalcemia	hypercalcemia	NN	_	15	dobj
17	.	.	.	_	15	punct

1	drug1	drug1	NN	_	5	compound
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	CNS	cns	NN	_	1	appos
4	-RRB-	-rrb-	-RRB-	_	3	punct
5	drugs	drug	NNS	_	0	ROOT
6	including	include	VBG	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	,	,	,	_	7	punct
9	drug3	drug3	NN	_	7	conj
10	,	,	,	_	7	punct
11	drug4	drug4	NN	_	7	conj
12	,	,	,	_	7	punct
13	drug5	drug5	NN	_	7	conj
14	,	,	,	_	7	punct
15	blood	blood	NN	_	17	compound
16	pressure	pressure	NN	_	17	compound
17	medications	medication	NNS	_	7	conj
18	-LRB-	-lrb-	-LRB-	_	19	punct
19	drug6	drug6	NN	_	17	dep
20	,	,	,	_	19	punct
21	drug7	drug7	NN	_	19	appos
22	,	,	,	_	19	punct
23	drug8	drug8	NN	_	19	appos
24	-RRB-	-rrb-	-RRB-	_	19	punct
25	,	,	,	_	7	punct
26	motion	motion	NN	_	28	compound
27	sickness	sickness	NN	_	28	compound
28	medications	medication	NNS	_	7	conj
29	,	,	,	_	7	punct
30	drug9	drug9	NN	_	7	conj
31	,	,	,	_	7	punct
32	drug10	drug10	NN	_	7	conj
33	,	,	,	_	7	punct
34	drug11	drug11	NN	_	7	conj
35	,	,	,	_	7	punct
36	sleeping	sleep	VBG	_	37	amod
37	pills	pill	NNS	_	7	conj
38	and	and	CC	_	7	cc
39	drug12	drug12	NN	_	7	conj

1	Although	although	IN	_	9	mark
2	no	no	DT	_	6	neg
3	clinical	clinical	JJ	_	6	amod
4	drug-drug	drug-drug	JJ	_	6	amod
5	interaction	interaction	NN	_	6	compound
6	studies	study	NNS	_	9	nsubjpass
7	have	have	VBP	_	9	aux
8	been	be	VBN	_	9	auxpass
9	conducted	conduct	VBN	_	28	advcl
10	to	to	TO	_	11	case
11	date	date	NN	_	9	nmod
12	,	,	,	_	28	punct
13	on	on	IN	_	15	case
14	the	the	DT	_	15	det
15	basis	basis	NN	_	28	nmod
16	of	of	IN	_	20	case
17	the	the	DT	_	20	det
18	in	in	FW	_	20	amod
19	vitro	vitro	FW	_	18	dep
20	studies	study	NNS	_	15	nmod
21	,	,	,	_	28	punct
22	cytochrome	cytochrome	NN	_	24	compound
23	p450	p450	NN	_	24	compound
24	inhibitors	inhibitor	NNS	_	28	nsubj
25	and	and	CC	_	24	cc
26	inducers	inducer	NNS	_	24	conj
27	are	be	VBP	_	28	cop
28	unlikely	unlikely	JJ	_	0	ROOT
29	to	to	TO	_	30	mark
30	affect	affect	VB	_	28	xcomp
31	the	the	DT	_	32	det
32	metabolism	metabolism	NN	_	30	dobj
33	of	of	IN	_	34	case
34	drug1	drug1	NN	_	32	nmod
35	.	.	.	_	28	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	15	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	on	on	IN	_	7	case
6	the	the	DT	_	7	det
7	metabolism	metabolism	NN	_	2	nmod
8	of	of	IN	_	11	case
9	cytochrome	cytochrome	NN	_	11	compound
10	p450	p450	NN	_	11	compound
11	substrates	substrate	NNS	_	7	nmod
12	has	have	VBZ	_	15	aux
13	not	not	RB	_	15	neg
14	been	be	VBN	_	15	auxpass
15	studied	study	VBN	_	0	ROOT
16	.	.	.	_	15	punct

1	Drug/Laboratory	Drug/Laboratory	NNP	_	3	compound
2	Tests	Tests	NNP	_	3	compound
3	Interactions	interaction	NNS	_	0	ROOT
4	There	there	EX	_	5	expl
5	are	be	VBP	_	3	acl:relcl
6	no	no	DT	_	10	neg
7	known	known	JJ	_	10	amod
8	clinically	clinically	RB	_	9	advmod
9	significant	significant	JJ	_	10	amod
10	interactions	interaction	NNS	_	5	nsubj
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	with	with	IN	_	15	case
14	other	other	JJ	_	15	amod
15	medications	medication	NNS	_	10	nmod
16	or	or	CC	_	15	cc
17	laboratory	laboratory	NN	_	18	compound
18	tests	test	NNS	_	15	conj
19	.	.	.	_	3	punct

1	No	no	DT	_	6	neg
2	formal	formal	JJ	_	6	amod
3	drug/laboratory	drug/laboratory	JJ	_	6	amod
4	test	test	NN	_	6	compound
5	interaction	interaction	NN	_	6	compound
6	studies	study	NNS	_	9	nsubjpass
7	have	have	VBP	_	9	aux
8	been	be	VBN	_	9	auxpass
9	conducted	conduct	VBN	_	0	ROOT
10	with	with	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	.	.	.	_	9	punct

1	Unless	unless	IN	_	3	mark
2	really	really	RB	_	3	advmod
3	needed	need	VBN	_	15	advcl
4	,	,	,	_	15	punct
5	agents	agent	NNS	_	15	nsubjpass
6	which	which	WDT	_	8	nsubj
7	may	may	MD	_	8	aux
8	enhance	enhance	VB	_	5	acl:relcl
9	the	the	DT	_	10	det
10	risk	risk	NN	_	8	dobj
11	of	of	IN	_	12	case
12	hemorrhage	hemorrhage	NN	_	10	nmod
13	should	should	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	discontinued	discontinue	VBN	_	0	ROOT
16	prior	prior	RB	_	15	advmod
17	to	to	TO	_	18	case
18	initiation	initiation	NN	_	16	nmod
19	of	of	IN	_	22	case
20	drug1	drug1	NN	_	22	compound
21	Injection	injection	NN	_	22	compound
22	therapy	therapy	NN	_	18	nmod
23	.	.	.	_	15	punct

1	These	these	DT	_	2	det
2	agents	agent	NNS	_	3	nsubj
3	include	include	VBP	_	0	ROOT
4	medications	medication	NNS	_	3	dobj
5	such	such	JJ	_	8	case
6	as	as	IN	_	5	mwe
7	:	:	:	_	8	punct
8	drug1	drug1	NN	_	4	nmod
9	,	,	,	_	8	punct
10	drug2	drug2	NN	_	8	appos
11	including	include	VBG	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	,	,	,	_	12	punct
14	sali-cylates	sali-cylate	NNS	_	12	conj
15	,	,	,	_	12	punct
16	drug4	drug4	NN	_	12	conj
17	-LRB-	-lrb-	-LRB-	_	19	punct
18	including	include	VBG	_	19	case
19	drug5	drug5	NN	_	16	nmod
20	-RRB-	-rrb-	-RRB-	_	19	punct
21	,	,	,	_	12	punct
22	drug6	drug6	NN	_	12	conj
23	,	,	,	_	12	punct
24	or	or	CC	_	12	cc
25	drug7	drug7	NN	_	12	conj
26	.	.	.	_	3	punct

1	If	if	IN	_	4	mark
2	co-administration	co-administration	NN	_	4	nsubj
3	is	be	VBZ	_	4	cop
4	essential	essential	JJ	_	6	advcl
5	,	,	,	_	6	punct
6	conduct	conduct	VB	_	0	ROOT
7	close	close	JJ	_	11	amod
8	clinical	clinical	JJ	_	11	amod
9	and	and	CC	_	8	cc
10	laboratory	laboratory	JJ	_	8	conj
11	monitoring	monitoring	NN	_	6	dobj

1	.	.	.	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	No	no	DT	_	2	neg
2	interactions	interaction	NNS	_	5	nsubjpass
3	have	have	VBP	_	5	aux
4	been	be	VBN	_	5	auxpass
5	observed	observe	VBN	_	0	ROOT
6	between	between	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	,	,	,	_	7	punct
11	drug3	drug3	NN	_	7	conj
12	,	,	,	_	7	punct
13	drug4	drug4	NN	_	7	conj
14	,	,	,	_	7	punct
15	drug5	drug5	NN	_	7	conj
16	,	,	,	_	7	punct
17	drug6	drug6	NN	_	7	conj
18	,	,	,	_	7	punct
19	and	and	CC	_	7	cc
20	drug7	drug7	NN	_	7	conj
21	.	.	.	_	5	punct

1	drug1	drug1	NN	_	4	nsubj
2	does	do	VBZ	_	4	aux
3	not	not	RB	_	4	neg
4	inhibit	inhibit	VB	_	0	ROOT
5	the	the	DT	_	10	det
6	cytochrome	cytochrome	NN	_	10	compound
7	P-450-linked	p-450-linked	JJ	_	10	amod
8	drug-metabolizing	drug-metabolizing	JJ	_	10	amod
9	enzyme	enzyme	NN	_	10	compound
10	system	system	NN	_	4	dobj
11	;	;	:	_	4	punct

1	therefore	therefore	RB	_	13	advmod
2	,	,	,	_	13	punct
3	drug	drug	NN	_	4	compound
4	interactions	interaction	NNS	_	13	nsubjpass
5	mediated	mediate	VBN	_	4	acl
6	by	by	IN	_	7	case
7	inhibition	inhibition	NN	_	5	nmod
8	of	of	IN	_	10	case
9	hepatic	hepatic	JJ	_	10	amod
10	metabolism	metabolism	NN	_	7	nmod
11	are	be	VBP	_	13	auxpass
12	not	not	RB	_	13	neg
13	expected	expect	VBN	_	0	ROOT
14	to	to	TO	_	15	mark
15	occur	occur	VB	_	13	xcomp
16	.	.	.	_	13	punct

1	In	in	IN	_	2	case
2	patients	patient	NNS	_	15	nmod
3	given	give	VBN	_	6	case
4	very	very	RB	_	5	advmod
5	high	high	JJ	_	6	amod
6	doses	dose	NNS	_	2	nmod
7	-LRB-	-lrb-	-LRB-	_	9	punct
8	3900	3900	CD	_	9	nummod
9	mg	mg	NN	_	6	appos
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	6	nmod
13	daily	daily	RB	_	2	advmod
14	,	,	,	_	15	punct
15	increases	increase	VBZ	_	0	ROOT
16	in	in	IN	_	19	case
17	serum	serum	NN	_	19	compound
18	drug2	drug2	NN	_	19	compound
19	levels	level	NNS	_	15	nmod
20	were	be	VBD	_	21	auxpass
21	seen	see	VBN	_	15	dep
22	when	when	WRB	_	30	advmod
23	drug3	drug3	NN	_	30	nsubjpass
24	,	,	,	_	23	punct
25	150	150	CD	_	26	compound
26	mg	mg	NN	_	27	amod
27	b.i.d.	b.i.d.	NN	_	23	appos
28	,	,	,	_	23	punct
29	was	be	VBD	_	30	auxpass
30	administered	administer	VBN	_	21	advcl
31	concurrently	concurrently	RB	_	30	advmod
32	.	.	.	_	15	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	should	should	MD	_	5	aux
3	not	not	RB	_	5	neg
4	be	be	VB	_	5	auxpass
5	combined	combine	VBN	_	0	ROOT
6	with	with	IN	_	8	case
7	other	other	JJ	_	8	amod
8	drug2	drug2	NN	_	5	nmod
9	.	.	.	_	5	punct

1	Patients	patient	NNS	_	15	nsubjpass
2	receiving	receive	VBG	_	1	acl
3	catecholamine-depleting	catecholamine-depleting	JJ	_	4	amod
4	drugs	drug	NNS	_	2	dobj
5	,	,	,	_	1	punct
6	such	such	JJ	_	8	case
7	as	as	IN	_	6	mwe
8	drug1	drug1	NN	_	1	nmod
9	or	or	CC	_	8	cc
10	drug2	drug2	NN	_	8	conj
11	,	,	,	_	1	punct
12	should	should	MD	_	15	aux
13	be	be	VB	_	15	auxpass
14	closely	closely	RB	_	15	advmod
15	monitored	monitor	VBN	_	0	ROOT
16	,	,	,	_	15	punct
17	because	because	IN	_	26	mark
18	the	the	DT	_	22	det
19	added	add	VBN	_	22	amod
20	beta-adrenergic	beta-adrenergic	JJ	_	22	amod
21	blocking	block	VBG	_	22	amod
22	action	action	NN	_	26	nsubj
23	of	of	IN	_	24	case
24	drug3	drug3	NN	_	22	nmod
25	may	may	MD	_	26	aux
26	produce	produce	VB	_	15	advcl
27	excessive	excessive	JJ	_	28	amod
28	reduction	reduction	NN	_	26	dobj
29	of	of	IN	_	31	case
30	sympathetic	sympathetic	JJ	_	31	amod
31	activity	activity	NN	_	28	nmod
32	.	.	.	_	15	punct

1	In	in	IN	_	2	case
2	patients	patient	NNS	_	18	nmod
3	receiving	receive	VBG	_	2	acl
4	concurrent	concurrent	JJ	_	5	amod
5	therapy	therapy	NN	_	3	dobj
6	with	with	IN	_	7	case
7	drug1	drug1	NN	_	3	nmod
8	,	,	,	_	18	punct
9	if	if	IN	_	11	mark
10	therapy	therapy	NN	_	11	nsubj
11	is	be	VBZ	_	18	advcl
12	to	to	TO	_	14	mark
13	be	be	VB	_	14	auxpass
14	discontinued	discontinue	VBN	_	11	xcomp
15	,	,	,	_	18	punct
16	it	it	PRP	_	18	nsubjpass
17	is	be	VBZ	_	18	auxpass
18	suggested	suggest	VBN	_	0	ROOT
19	that	that	IN	_	22	mark
20	drug2	drug2	NN	_	22	nsubjpass
21	be	be	VB	_	22	auxpass
22	discontinued	discontinue	VBN	_	18	ccomp
23	for	for	IN	_	25	case
24	several	several	JJ	_	25	amod
25	days	day	NNS	_	22	nmod
26	before	before	IN	_	28	case
27	the	the	DT	_	28	det
28	withdrawal	withdrawal	NN	_	22	nmod
29	of	of	IN	_	30	case
30	drug3	drug3	NN	_	28	nmod
31	.	.	.	_	18	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	with	with	IN	_	6	case
6	care	care	NN	_	4	nmod
7	when	when	WRB	_	43	advmod
8	drug2	drug2	NN	_	43	nsubjpass
9	or	or	CC	_	8	cc
10	inhibitors	inhibitor	NNS	_	8	conj
11	of	of	IN	_	13	case
12	AV	av	NN	_	13	compound
13	conduction	conduction	NN	_	8	nmod
14	,	,	,	_	8	punct
15	such	such	JJ	_	18	case
16	as	as	IN	_	15	mwe
17	certain	certain	JJ	_	18	amod
18	drug3	drug3	NN	_	8	nmod
19	-LRB-	-lrb-	-LRB-	_	32	punct
20	particularly	particularly	RB	_	32	advmod
21	of	of	IN	_	32	case
22	the	the	DT	_	32	det
23	drug4	drug4	NN	_	32	compound
24	-LSB-	-lsb-	-LRB-	_	25	punct
25	drug5	drug5	NN	_	23	appos
26	-RSB-	-rsb-	-RRB-	_	25	punct
27	and	and	CC	_	23	cc
28	drug6	drug6	NN	_	23	conj
29	-LSB-	-lsb-	-LRB-	_	30	punct
30	drug7	drug7	NN	_	28	appos
31	-RSB-	-rsb-	-RRB-	_	30	punct
32	classes	class	NNS	_	18	appos
33	-RRB-	-rrb-	-RRB-	_	32	punct
34	,	,	,	_	18	punct
35	or	or	CC	_	18	cc
36	drug8	drug8	NN	_	18	conj
37	,	,	,	_	18	punct
38	such	such	JJ	_	40	case
39	as	as	IN	_	38	mwe
40	drug9	drug9	NN	_	18	nmod
41	,	,	,	_	18	punct
42	are	be	VBP	_	43	auxpass
43	used	use	VBN	_	4	advcl
44	concurrently	concurrently	RB	_	43	advmod
45	.	.	.	_	4	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	use	use	NN	_	5	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	increases	increase	VBZ	_	0	ROOT
6	the	the	DT	_	8	det
7	metabolic	metabolic	JJ	_	8	amod
8	clearance	clearance	NN	_	5	dobj
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	,	,	,	_	5	punct
12	resulting	result	VBG	_	5	advcl
13	in	in	IN	_	17	case
14	a	a	DT	_	17	det
15	shortened	shorten	VBN	_	17	amod
16	elimination	elimination	NN	_	17	compound
17	half-life	half-life	NN	_	12	nmod
18	of	of	IN	_	19	case
19	drug3	drug3	NN	_	17	nmod
20	.	.	.	_	5	punct

1	However	however	RB	_	9	advmod
2	,	,	,	_	9	punct
3	initial	initial	JJ	_	5	amod
4	dose	dose	NN	_	5	compound
5	modification	modification	NN	_	9	nsubj
6	is	be	VBZ	_	9	cop
7	generally	generally	RB	_	9	advmod
8	not	not	RB	_	9	neg
9	necessary	necessary	JJ	_	0	ROOT
10	.	.	.	_	9	punct

1	Pharmacokinetic	pharmacokinetic	JJ	_	2	amod
2	studies	study	NNS	_	3	nsubj
3	document	document	VBP	_	0	ROOT
4	no	no	DT	_	7	neg
5	clinically	clinically	RB	_	6	advmod
6	relevant	relevant	JJ	_	7	amod
7	interactions	interaction	NNS	_	3	dobj
8	with	with	IN	_	10	case
9	other	other	JJ	_	10	amod
10	agents	agent	NNS	_	7	nmod
11	given	give	VBN	_	10	acl
12	concomitantly	concomitantly	RB	_	11	advmod
13	,	,	,	_	10	punct
14	including	include	VBG	_	15	case
15	drug1	drug1	NN	_	10	nmod
16	,	,	,	_	15	punct
17	drug2	drug2	NN	_	15	conj
18	,	,	,	_	15	punct
19	and	and	CC	_	15	cc
20	drug3	drug3	NN	_	15	conj
21	.	.	.	_	3	punct

1	There	there	EX	_	2	expl
2	was	be	VBD	_	0	ROOT
3	no	no	DT	_	4	neg
4	effect	effect	NN	_	2	nsubj
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	on	on	IN	_	9	case
8	prothrombin	prothrombin	NN	_	9	compound
9	time	time	NN	_	4	nmod
10	in	in	IN	_	11	case
11	patients	patient	NNS	_	9	nmod
12	on	on	IN	_	14	case
13	stable	stable	JJ	_	14	amod
14	doses	dose	NNS	_	11	nmod
15	of	of	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	.	.	.	_	2	punct

1	Risk	risk	NN	_	0	ROOT
2	of	of	IN	_	4	case
3	Anaphylactic	Anaphylactic	NNP	_	4	compound
4	Reaction	Reaction	NNP	_	1	nmod
5	:	:	:	_	1	punct
6	While	while	IN	_	7	mark
7	taking	take	VBG	_	26	advcl
8	drug1	drug1	NN	_	7	dobj
9	,	,	,	_	26	punct
10	patients	patient	NNS	_	26	nsubj
11	with	with	IN	_	13	case
12	a	a	DT	_	13	det
13	history	history	NN	_	10	nmod
14	of	of	IN	_	17	case
15	severe	severe	JJ	_	17	amod
16	anaphylactic	anaphylactic	JJ	_	17	amod
17	reaction	reaction	NN	_	13	nmod
18	to	to	TO	_	20	case
19	a	a	DT	_	20	det
20	variety	variety	NN	_	17	nmod
21	of	of	IN	_	22	case
22	allergens	allergen	NNS	_	20	nmod
23	may	may	MD	_	26	aux
24	be	be	VB	_	26	cop
25	more	more	RBR	_	26	advmod
26	reactive	reactive	JJ	_	1	dep
27	to	to	TO	_	29	case
28	repeated	repeat	VBN	_	29	amod
29	challenge	challenge	NN	_	26	nmod
30	,	,	,	_	26	punct
31	either	either	CC	_	32	cc:preconj
32	accidental	accidental	JJ	_	26	dep
33	,	,	,	_	32	punct
34	diagnostic	diagnostic	JJ	_	32	conj
35	,	,	,	_	32	punct
36	or	or	CC	_	32	cc
37	therapeutic	therapeutic	JJ	_	32	conj
38	.	.	.	_	1	punct

1	Such	such	JJ	_	2	amod
2	patients	patient	NNS	_	5	nsubj
3	may	may	MD	_	5	aux
4	be	be	VB	_	5	cop
5	unresponsive	unresponsive	JJ	_	0	ROOT
6	to	to	TO	_	9	case
7	the	the	DT	_	9	det
8	usual	usual	JJ	_	9	amod
9	doses	dose	NNS	_	5	nmod
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	used	use	VBN	_	9	acl
13	to	to	TO	_	14	mark
14	treat	treat	VB	_	12	xcomp
15	allergic	allergic	JJ	_	16	amod
16	reactions	reaction	NNS	_	14	dobj
17	.	.	.	_	5	punct

1	Hypertensive	hypertensive	JJ	_	2	amod
2	crises	crisis	NNS	_	4	nsubj
3	have	have	VBP	_	4	aux
4	resulted	result	VBN	_	0	ROOT
5	when	when	WRB	_	9	advmod
6	drug1	drug1	NN	_	9	nsubjpass
7	have	have	VBP	_	9	aux
8	been	be	VBN	_	9	auxpass
9	used	use	VBN	_	4	advcl
10	concomitantly	concomitantly	RB	_	12	advmod
11	within14	within14	CD	_	12	nummod
12	days	day	NNS	_	9	nmod:tmod
13	following	follow	VBG	_	14	case
14	use	use	NN	_	9	nmod
15	of	of	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	.	.	.	_	4	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	should	should	MD	_	5	aux
3	not	not	RB	_	5	neg
4	be	be	VB	_	5	auxpass
5	used	use	VBN	_	0	ROOT
6	concomitantly	concomitantly	RB	_	5	advmod
7	with	with	IN	_	9	case
8	other	other	JJ	_	9	amod
9	drug2	drug2	NN	_	5	nmod
10	.	.	.	_	5	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	decrease	decrease	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	hypotensive	hypotensive	JJ	_	6	amod
6	effect	effect	NN	_	3	dobj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	.	.	.	_	3	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	enhance	enhance	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	effects	effect	NNS	_	3	dobj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	.	.	.	_	3	punct

1	Urinary	urinary	JJ	_	3	amod
2	alkalinizing	alkalinizing	JJ	_	3	amod
3	agents	agent	NNS	_	4	nsubj
4	increase	increase	VBP	_	0	ROOT
5	blood	blood	NN	_	6	compound
6	levels	level	NNS	_	4	dobj
7	and	and	CC	_	4	cc
8	decrease	decrease	VB	_	4	conj
9	excretion	excretion	NN	_	8	dobj
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	.	.	.	_	4	punct

1	drug1	drug1	NN	_	2	compound
2	agents	agent	NNS	_	3	nsubj
3	decrease	decrease	VBP	_	0	ROOT
4	blood	blood	NN	_	5	compound
5	levels	level	NNS	_	3	dobj
6	and	and	CC	_	3	cc
7	increase	increase	VB	_	3	conj
8	excretion	excretion	NN	_	7	dobj
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	.	.	.	_	3	punct

1	drug1	drug1	NN	_	7	nsubjpass
2	-	-	:	_	7	punct
3	containing	contain	VBG	_	7	csubjpass
4	drugs	drug	NNS	_	3	dobj
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	reported	report	VBN	_	0	ROOT
8	to	to	TO	_	9	mark
9	cause	cause	VB	_	7	xcomp
10	prolonged	prolonged	JJ	_	12	amod
11	vasospastic	vasospastic	JJ	_	12	amod
12	reactions	reaction	NNS	_	9	dobj
13	.	.	.	_	7	punct

1	Because	because	IN	_	3	mark
2	there	there	EX	_	3	expl
3	is	be	VBZ	_	0	ROOT
4	a	a	DT	_	6	det
5	theoretical	theoretical	JJ	_	6	amod
6	basis	basis	NN	_	3	nsubj
7	that	that	IN	_	12	mark
8	these	these	DT	_	9	det
9	effects	effect	NNS	_	12	nsubj
10	may	may	MD	_	12	aux
11	be	be	VB	_	12	cop
12	additive	additive	JJ	_	6	ccomp
13	,	,	,	_	12	punct
14	use	use	NN	_	33	nsubjpass
15	of	of	IN	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	-	-	:	_	14	punct
18	containing	contain	VBG	_	14	dep
19	or	or	CC	_	18	cc
20	drug2	drug2	NN	_	18	conj
21	-LRB-	-lrb-	-LRB-	_	23	punct
22	like	like	IN	_	23	case
23	drug3	drug3	NN	_	18	nmod
24	or	or	CC	_	23	cc
25	drug4	drug4	NN	_	23	conj
26	-RRB-	-rrb-	-RRB-	_	23	punct
27	and	and	CC	_	18	cc
28	drug5	drug5	NN	_	18	conj
29	within	within	IN	_	31	case
30	24	24	CD	_	31	nummod
31	hours	hour	NNS	_	28	nmod
32	is	be	VBZ	_	33	auxpass
33	contraindicated	contraindicate	VBN	_	12	parataxis
34	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	administration	administration	NN	_	11	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	7	case
6	other	other	JJ	_	7	amod
7	drug2	drug2	NN	_	2	nmod
8	has	have	VBZ	_	11	aux
9	not	not	RB	_	11	neg
10	been	be	VBN	_	11	auxpass
11	evaluated	evaluate	VBN	_	0	ROOT
12	in	in	IN	_	14	case
13	migraine	migraine	NN	_	14	compound
14	patients	patient	NNS	_	11	nmod
15	.	.	.	_	11	punct

1	Because	because	IN	_	7	mark
2	their	they	PRP$	_	4	nmod:poss
3	vasospastic	vasospastic	JJ	_	4	amod
4	effects	effect	NNS	_	7	nsubj
5	may	may	MD	_	7	aux
6	be	be	VB	_	7	cop
7	additive	additive	JJ	_	23	advcl
8	,	,	,	_	23	punct
9	coadministration	coadministration	NN	_	23	nsubjpass
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	other	other	JJ	_	14	amod
14	drug2	drug2	NN	_	11	conj
15	within	within	IN	_	17	case
16	24	24	CD	_	17	nummod
17	hours	hour	NNS	_	9	nmod
18	of	of	IN	_	20	case
19	each	each	DT	_	20	det
20	other	other	JJ	_	17	nmod
21	is	be	VBZ	_	23	auxpass
22	not	not	RB	_	23	neg
23	recommended	recommend	VBN	_	0	ROOT
24	.	.	.	_	23	punct

1	drug1	drug1	NN	_	18	nsubjpass
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	drug2	drug2	NN	_	1	appos
4	-RRB-	-rrb-	-RRB-	_	3	punct
5	-LRB-	-lrb-	-LRB-	_	8	punct
6	e.g.	e.g.	FW	_	8	dep
7	,	,	,	_	8	punct
8	drug3	drug3	NN	_	1	dep
9	,	,	,	_	8	punct
10	drug4	drug4	NN	_	8	conj
11	,	,	,	_	8	punct
12	drug5	drug5	NN	_	8	conj
13	,	,	,	_	8	punct
14	drug6	drug6	NN	_	8	appos
15	-RRB-	-rrb-	-RRB-	_	8	punct
16	have	have	VBP	_	18	aux
17	been	be	VBN	_	18	auxpass
18	reported	report	VBN	_	0	ROOT
19	,	,	,	_	18	punct
20	rarely	rarely	RB	_	18	advmod
21	,	,	,	_	18	punct
22	to	to	TO	_	23	mark
23	cause	cause	VB	_	18	xcomp
24	weakness	weakness	NN	_	23	dobj
25	,	,	,	_	24	punct
26	hyperreflexia	hyperreflexia	NN	_	24	conj
27	,	,	,	_	24	punct
28	and	and	CC	_	24	cc
29	incoordination	incoordination	NN	_	24	conj
30	when	when	WRB	_	31	advmod
31	coadministered	coadminister	VBN	_	23	advcl
32	with	with	IN	_	34	case
33	5-HTv	5-htv	NN	_	34	compound
34	agonists	agonist	NNS	_	31	nmod
35	.	.	.	_	18	punct

1	If	if	IN	_	11	mark
2	concomitant	concomitant	JJ	_	3	amod
3	treatment	treatment	NN	_	11	nsubjpass
4	with	with	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	an	a	DT	_	8	det
8	drug2	drug2	NN	_	5	conj
9	is	be	VBZ	_	11	auxpass
10	clinically	clinically	RB	_	11	advmod
11	warranted	warrant	VBN	_	19	advcl
12	,	,	,	_	19	punct
13	appropriate	appropriate	JJ	_	14	amod
14	observation	observation	NN	_	19	nsubjpass
15	of	of	IN	_	17	case
16	the	the	DT	_	17	det
17	patient	patient	NN	_	14	nmod
18	is	be	VBZ	_	19	auxpass
19	advised	advise	VBN	_	0	ROOT
20	.	.	.	_	19	punct

1	Drug	drug	NN	_	6	dep
2	/	/	:	_	6	punct
3	Laboratory	Laboratory	NNP	_	5	compound
4	Test	Test	NNP	_	5	compound
5	Interactions	interaction	NNS	_	6	nsubj
6	drug1	drug1	VBP	_	0	ROOT
7	Tablets	tablet	NNS	_	10	nsubjpass
8	are	be	VBP	_	10	auxpass
9	not	not	RB	_	10	neg
10	known	know	VBN	_	6	ccomp
11	to	to	TO	_	12	mark
12	interfere	interfere	VB	_	10	xcomp
13	with	with	IN	_	18	case
14	commonly	commonly	RB	_	15	advmod
15	employed	employ	VBN	_	18	amod
16	clinical	clinical	JJ	_	18	amod
17	laboratory	laboratory	NN	_	18	compound
18	tests	test	NNS	_	12	nmod
19	.	.	.	_	6	punct

1	The	the	DT	_	3	det
2	vasodilating	vasodilating	JJ	_	3	amod
3	effects	effect	NNS	_	8	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	cop
8	additive	additive	JJ	_	0	ROOT
9	with	with	IN	_	10	case
10	those	those	DT	_	8	nmod
11	of	of	IN	_	13	case
12	other	other	JJ	_	13	amod
13	drug2	drug2	NN	_	10	nmod
14	.	.	.	_	8	punct

1	drug1	drug1	NN	_	8	nsubjpass
2	,	,	,	_	8	punct
3	in	in	IN	_	4	case
4	particular	particular	JJ	_	8	nmod
5	,	,	,	_	8	punct
6	has	have	VBZ	_	8	aux
7	been	be	VBN	_	8	auxpass
8	found	find	VBN	_	0	ROOT
9	to	to	TO	_	10	mark
10	exhibit	exhibit	VB	_	8	xcomp
11	additive	additive	JJ	_	12	amod
12	effects	effect	NNS	_	10	dobj
13	of	of	IN	_	15	case
14	this	this	DT	_	15	det
15	variety	variety	NN	_	12	nmod
16	.	.	.	_	8	punct

1	Marked	marked	JJ	_	4	amod
2	symptomatic	symptomatic	JJ	_	4	amod
3	orthostatic	orthostatic	JJ	_	4	amod
4	hypotension	hypotension	NN	_	7	nsubjpass
5	has	have	VBZ	_	7	aux
6	been	be	VBN	_	7	auxpass
7	reported	report	VBN	_	0	ROOT
8	when	when	WRB	_	13	advmod
9	drug1	drug1	NN	_	13	nsubjpass
10	and	and	CC	_	9	cc
11	drug2	drug2	NN	_	9	conj
12	were	be	VBD	_	13	auxpass
13	used	use	VBN	_	7	advcl
14	in	in	IN	_	15	case
15	combination	combination	NN	_	13	nmod
16	.	.	.	_	7	punct

1	Dose	dose	NN	_	2	compound
2	adjustments	adjustment	NNS	_	10	nsubj
3	of	of	IN	_	5	case
4	either	either	CC	_	5	det
5	class	class	NN	_	2	nmod
6	of	of	IN	_	7	case
7	agents	agent	NNS	_	5	nmod
8	may	may	MD	_	10	aux
9	be	be	VB	_	10	cop
10	necessary	necessary	JJ	_	0	ROOT
11	.	.	.	_	10	punct

1	The	the	DT	_	2	det
2	risks	risk	NNS	_	15	nsubjpass
3	of	of	IN	_	4	mark
4	using	use	VBG	_	2	acl
5	drug1	drug1	NN	_	4	dobj
6	in	in	IN	_	7	case
7	combination	combination	NN	_	4	nmod
8	with	with	IN	_	10	case
9	other	other	JJ	_	10	amod
10	drugs	drug	NNS	_	7	nmod
11	have	have	VBP	_	15	aux
12	not	not	RB	_	15	neg
13	been	be	VBN	_	15	auxpass
14	systematically	systematically	RB	_	15	advmod
15	evaluated	evaluate	VBN	_	0	ROOT
16	.	.	.	_	15	punct

1	Pharmacodynamic-related	pharmacodynamic-related	JJ	_	2	amod
2	Interactions	interaction	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	The	the	DT	_	5	det
5	mechanism	mechanism	NN	_	8	nsubj
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	induced	induce	VBD	_	11	csubj
9	agranulocytosis	agranulocytosis	NN	_	8	dobj
10	is	be	VBZ	_	11	cop
11	unknown	unknown	JJ	_	2	dep
12	;	;	:	_	2	punct

1	nonetheless	nonetheless	RB	_	0	ROOT
2	,	,	,	_	1	punct
3	the	the	DT	_	4	det
4	possibility	possibility	NN	_	2	root
5	that	that	IN	_	9	mark
6	causative	causative	JJ	_	7	amod
7	factors	factor	NNS	_	9	nsubj
8	may	may	MD	_	9	aux
9	interact	interact	VB	_	4	ccomp
10	synergistically	synergistically	RB	_	9	advmod
11	to	to	TO	_	12	mark
12	increase	increase	VB	_	9	xcomp
13	the	the	DT	_	14	det
14	risk	risk	NN	_	12	dobj
15	and/or	and/or	CC	_	14	cc
16	severity	severity	NN	_	14	conj
17	of	of	IN	_	22	case
18	bone	bone	NN	_	22	compound
19	marrow	marrow	NN	_	22	compound
20	suppression	suppression	NN	_	22	compound
21	warrants	warrant	NNS	_	22	compound
22	consideration	consideration	NN	_	14	nmod
23	.	.	.	_	4	punct

1	Therefore	therefore	RB	_	7	advmod
2	,	,	,	_	7	punct
3	drug1	drug1	NN	_	7	nsubjpass
4	should	should	MD	_	7	aux
5	not	not	RB	_	7	neg
6	be	be	VB	_	7	auxpass
7	used	use	VBN	_	0	ROOT
8	with	with	IN	_	10	case
9	other	other	JJ	_	10	amod
10	agents	agent	NNS	_	7	nmod
11	having	have	VBG	_	10	acl
12	a	a	DT	_	14	det
13	well-known	well-known	JJ	_	14	amod
14	potential	potential	NN	_	11	dobj
15	to	to	TO	_	16	mark
16	suppress	suppress	VB	_	14	acl
17	bone	bone	NN	_	19	compound
18	marrow	marrow	NN	_	19	compound
19	function	function	NN	_	16	dobj
20	.	.	.	_	7	punct

1	Given	give	VBN	_	5	case
2	the	the	DT	_	5	det
3	primary	primary	JJ	_	5	amod
4	CNS	cns	NN	_	5	compound
5	effects	effect	NNS	_	11	nmod
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	,	,	,	_	11	punct
9	caution	caution	NN	_	11	nsubjpass
10	is	be	VBZ	_	11	auxpass
11	advised	advise	VBN	_	0	ROOT
12	in	in	IN	_	13	mark
13	using	use	VBG	_	11	advcl
14	it	it	PRP	_	13	dobj
15	concomitantly	concomitantly	RB	_	13	advmod
16	with	with	IN	_	19	case
17	other	other	JJ	_	19	amod
18	CNS-active	cns-active	JJ	_	19	amod
19	drugs	drug	NNS	_	13	nmod
20	or	or	CC	_	19	cc
21	drug2	drug2	NN	_	19	conj
22	.	.	.	_	11	punct

1	Orthostatic	orthostatic	JJ	_	2	amod
2	hypotension	hypotension	NN	_	22	nsubjpass
3	in	in	IN	_	4	case
4	patients	patient	NNS	_	2	nmod
5	taking	take	VBG	_	4	acl
6	drug1	drug1	NN	_	5	dobj
7	can	can	MD	_	22	aux
8	,	,	,	_	22	punct
9	in	in	IN	_	11	case
10	rare	rare	JJ	_	11	amod
11	cases	case	NNS	_	22	nmod
12	-LRB-	-lrb-	-LRB-	_	15	punct
13	approximately	approximately	RB	_	14	advmod
14	1	1	CD	_	15	nummod
15	case	case	NN	_	11	dep
16	per	per	IN	_	18	case
17	3,000	3,000	CD	_	18	nummod
18	patients	patient	NNS	_	15	nmod
19	-RRB-	-rrb-	-RRB-	_	15	punct
20	,	,	,	_	22	punct
21	be	be	VB	_	22	auxpass
22	accompanied	accompany	VBN	_	0	ROOT
23	by	by	IN	_	25	case
24	profound	profound	JJ	_	25	amod
25	collapse	collapse	NN	_	22	nmod
26	and	and	CC	_	25	cc
27	respiratory	respiratory	JJ	_	30	amod
28	and/or	and/or	CC	_	27	cc
29	cardiac	cardiac	JJ	_	27	conj
30	arrest	arrest	NN	_	25	conj
31	.	.	.	_	22	punct

1	Some	some	DT	_	12	nsubj
2	of	of	IN	_	4	case
3	the	the	DT	_	4	det
4	cases	case	NNS	_	1	nmod
5	of	of	IN	_	8	case
6	collapse/respiratory	collapse/respiratory	JJ	_	8	amod
7	arrest/cardiac	arrest/cardiac	JJ	_	8	amod
8	arrest	arrest	NN	_	4	nmod
9	during	during	IN	_	11	case
10	initial	initial	JJ	_	11	amod
11	treatment	treatment	NN	_	1	nmod
12	occurred	occur	VBD	_	0	ROOT
13	in	in	IN	_	14	case
14	patients	patient	NNS	_	12	nmod
15	who	who	WP	_	18	nsubjpass
16	were	be	VBD	_	18	aux
17	being	be	VBG	_	18	auxpass
18	administered	administer	VBN	_	14	acl:relcl
19	drug1	drug1	NN	_	18	dobj
20	;	;	:	_	12	punct

1	similar	similar	JJ	_	2	amod
2	events	event	NNS	_	5	nsubjpass
3	have	have	VBP	_	5	aux
4	been	be	VBN	_	5	auxpass
5	reported	report	VBN	_	0	ROOT
6	in	in	IN	_	7	case
7	patients	patient	NNS	_	5	nmod
8	taking	take	VBG	_	7	acl
9	other	other	JJ	_	10	amod
10	drug1	drug1	NN	_	8	dobj
11	or	or	CC	_	10	cc
12	even	even	RB	_	13	advmod
13	drug2	drug2	NN	_	10	conj
14	by	by	IN	_	15	case
15	itself	itself	PRP	_	8	nmod
16	.	.	.	_	5	punct

1	Although	although	IN	_	6	mark
2	it	it	PRP	_	6	nsubjpass
3	has	have	VBZ	_	6	aux
4	not	not	RB	_	6	neg
5	been	be	VBN	_	6	auxpass
6	established	establish	VBN	_	22	advcl
7	that	that	IN	_	9	mark
8	there	there	EX	_	9	expl
9	is	be	VBZ	_	6	ccomp
10	an	a	DT	_	11	det
11	interaction	interaction	NN	_	9	nsubj
12	between	between	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	and	and	CC	_	13	cc
15	drug2	drug2	NN	_	13	conj
16	or	or	CC	_	13	cc
17	other	other	JJ	_	18	amod
18	drug3	drug3	NN	_	13	conj
19	,	,	,	_	22	punct
20	caution	caution	NN	_	22	nsubjpass
21	is	be	VBZ	_	22	auxpass
22	advised	advise	VBN	_	0	ROOT
23	when	when	WRB	_	26	advmod
24	drug4	drug4	NN	_	26	nsubjpass
25	is	be	VBZ	_	26	auxpass
26	initiated	initiate	VBN	_	22	advcl
27	in	in	IN	_	28	case
28	patients	patient	NNS	_	26	nmod
29	taking	take	VBG	_	28	acl
30	a	a	DT	_	31	det
31	drug5	drug5	NN	_	29	dobj
32	or	or	CC	_	31	cc
33	any	any	DT	_	35	det
34	other	other	JJ	_	35	amod
35	drug6	drug6	NN	_	31	conj
36	.	.	.	_	22	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	potentiate	potentiate	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	hypotensive	hypotensive	JJ	_	6	amod
6	effects	effect	NNS	_	3	dobj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	the	the	DT	_	12	det
11	anticholinergic	anticholinergic	JJ	_	12	amod
12	effects	effect	NNS	_	8	conj
13	of	of	IN	_	17	case
14	drug3	drug3	NN	_	17	compound
15	-	-	:	_	17	punct
16	type	type	NN	_	17	compound
17	drugs	drug	NNS	_	12	nmod
18	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	administration	administration	NN	_	7	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	avoided	avoid	VBN	_	0	ROOT
8	in	in	IN	_	10	case
9	the	the	DT	_	10	det
10	treatment	treatment	NN	_	7	nmod
11	of	of	IN	_	12	case
12	drug	drug	NN	_	10	nmod
13	induced	induce	VBD	_	14	amod
14	hypotension	hypotension	NN	_	7	dobj
15	because	because	IN	_	21	case
16	of	of	IN	_	15	mwe
17	a	a	DT	_	21	det
18	possible	possible	JJ	_	21	amod
19	reverse	reverse	JJ	_	21	amod
20	drug2	drug2	NN	_	21	compound
21	effect	effect	NN	_	7	nmod
22	.	.	.	_	7	punct

1	Pharmacokinetic-related	pharmacokinetic-related	JJ	_	2	amod
2	Interactions	interaction	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	drug1	drug1	NN	_	7	nsubj
5	is	be	VBZ	_	7	cop
6	a	a	DT	_	7	det
7	substrate	substrate	NN	_	2	dep
8	for	for	IN	_	12	case
9	many	many	JJ	_	12	amod
10	CYP	cyp	NN	_	12	compound
11	450	450	CD	_	12	nummod
12	isozymes	isozyme	NNS	_	7	nmod
13	,	,	,	_	7	punct
14	in	in	IN	_	16	case
15	particular	particular	JJ	_	16	amod
16	1A2	1a2	NN	_	7	nmod
17	,	,	,	_	16	punct
18	2D6	2d6	NN	_	16	conj
19	,	,	,	_	16	punct
20	and	and	CC	_	16	cc
21	3A4	3a4	NN	_	16	conj
22	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	risk	risk	NN	_	16	nsubjpass
3	of	of	IN	_	5	case
4	metabolic	metabolic	JJ	_	5	amod
5	interactions	interaction	NNS	_	2	nmod
6	caused	cause	VBN	_	5	acl
7	by	by	IN	_	9	case
8	an	a	DT	_	9	det
9	effect	effect	NN	_	6	nmod
10	on	on	IN	_	13	case
11	an	a	DT	_	13	det
12	individual	individual	JJ	_	13	amod
13	isoform	isoform	NN	_	9	nmod
14	is	be	VBZ	_	16	auxpass
15	therefore	therefore	RB	_	16	advmod
16	minimized	minimize	VBN	_	0	ROOT
17	.	.	.	_	16	punct

1	Nevertheless	nevertheless	RB	_	6	advmod
2	,	,	,	_	6	punct
3	caution	caution	NN	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	used	use	VBN	_	0	ROOT
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	receiving	receive	VBG	_	8	acl
10	concomitant	concomitant	JJ	_	11	amod
11	treatment	treatment	NN	_	9	dobj
12	with	with	IN	_	14	case
13	other	other	JJ	_	14	amod
14	drugs	drug	NNS	_	9	nmod
15	that	that	WDT	_	18	nsubj
16	are	be	VBP	_	18	cop
17	either	either	DT	_	18	cc:preconj
18	inhibitors	inhibitor	NNS	_	14	acl:relcl
19	or	or	CC	_	18	cc
20	inducers	inducer	NNS	_	18	conj
21	of	of	IN	_	23	case
22	these	these	DT	_	23	det
23	enzymes	enzyme	NNS	_	18	nmod
24	.	.	.	_	6	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	12	nsubj
3	of	of	IN	_	4	case
4	drugs	drug	NNS	_	2	nmod
5	known	know	VBN	_	4	acl
6	to	to	TO	_	7	mark
7	induce	induce	VB	_	5	xcomp
8	cytochrome	cytochrome	NN	_	10	compound
9	P450	p450	NN	_	10	compound
10	enzymes	enzyme	NNS	_	7	dobj
11	may	may	MD	_	12	aux
12	decrease	decrease	VB	_	0	ROOT
13	the	the	DT	_	15	det
14	plasma	plasma	NN	_	15	compound
15	levels	level	NNS	_	12	dobj
16	of	of	IN	_	17	case
17	drug1	drug1	NN	_	15	nmod
18	.	.	.	_	12	punct

1	drug1	drug1	NN	_	8	nsubj
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	,	,	,	_	1	punct
5	and	and	CC	_	1	cc
6	drug3	drug3	NN	_	1	conj
7	may	may	MD	_	8	aux
8	decrease	decrease	VB	_	0	ROOT
9	drug4	drug4	NN	_	11	compound
10	plasma	plasma	NN	_	11	compound
11	levels	level	NNS	_	8	dobj
12	,	,	,	_	8	punct
13	resulting	result	VBG	_	8	advcl
14	in	in	IN	_	16	case
15	a	a	DT	_	16	det
16	decrease	decrease	NN	_	13	nmod
17	in	in	IN	_	18	case
18	effectiveness	effectiveness	NN	_	16	nmod
19	of	of	IN	_	24	case
20	a	a	DT	_	24	det
21	previously	previously	RB	_	22	advmod
22	effective	effective	JJ	_	24	amod
23	drug5	drug5	NN	_	24	compound
24	dose	dose	NN	_	18	nmod
25	.	.	.	_	8	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	15	nsubj
3	of	of	IN	_	4	case
4	drugs	drug	NNS	_	2	nmod
5	known	know	VBN	_	4	acl
6	to	to	TO	_	7	mark
7	inhibit	inhibit	VB	_	5	xcomp
8	the	the	DT	_	9	det
9	activity	activity	NN	_	7	dobj
10	of	of	IN	_	13	case
11	cytochrome	cytochrome	NN	_	13	compound
12	P450	p450	NN	_	13	compound
13	isozymes	isozyme	NNS	_	9	nmod
14	may	may	MD	_	15	aux
15	increase	increase	VB	_	0	ROOT
16	the	the	DT	_	18	det
17	plasma	plasma	NN	_	18	compound
18	levels	level	NNS	_	15	dobj
19	of	of	IN	_	20	case
20	drug1	drug1	NN	_	18	nmod
21	.	.	.	_	15	punct

1	drug1	drug1	NN	_	8	nsubj
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	,	,	,	_	1	punct
5	and	and	CC	_	1	cc
6	drug3	drug3	NN	_	1	conj
7	may	may	MD	_	8	aux
8	increase	increase	VB	_	0	ROOT
9	plasma	plasma	NN	_	10	compound
10	levels	level	NNS	_	8	dobj
11	of	of	IN	_	12	case
12	drug4	drug4	NN	_	10	nmod
13	,	,	,	_	8	punct
14	potentially	potentially	RB	_	15	advmod
15	resulting	result	VBG	_	8	advcl
16	in	in	IN	_	18	case
17	adverse	adverse	JJ	_	18	amod
18	effects	effect	NNS	_	15	nmod
19	.	.	.	_	8	punct

1	Although	although	IN	_	10	mark
2	concomitant	concomitant	JJ	_	3	amod
3	use	use	NN	_	10	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	is	be	VBZ	_	10	auxpass
9	not	not	RB	_	10	neg
10	recommended	recommend	VBN	_	15	advcl
11	,	,	,	_	15	punct
12	it	it	PRP	_	15	nsubjpass
13	should	should	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	noted	note	VBN	_	0	ROOT
16	that	that	IN	_	23	mark
17	discontinuation	discontinuation	NN	_	23	nsubj
18	of	of	IN	_	21	case
19	concomitant	concomitant	JJ	_	21	amod
20	drug3	drug3	NN	_	21	compound
21	administration	administration	NN	_	17	nmod
22	may	may	MD	_	23	aux
23	result	result	VB	_	15	ccomp
24	in	in	IN	_	26	case
25	an	a	DT	_	26	det
26	increase	increase	NN	_	23	nmod
27	in	in	IN	_	30	case
28	drug4	drug4	NN	_	30	compound
29	plasma	plasma	NN	_	30	compound
30	levels	level	NNS	_	26	nmod
31	.	.	.	_	15	punct

1	In	in	IN	_	3	case
2	a	a	DT	_	3	det
3	study	study	NN	_	19	nmod
4	of	of	IN	_	6	case
5	schizophrenic	schizophrenic	JJ	_	6	amod
6	patients	patient	NNS	_	3	nmod
7	who	who	WP	_	8	nsubj
8	received	receive	VBD	_	6	acl:relcl
9	drug1	drug1	NN	_	8	dobj
10	under	under	IN	_	13	case
11	steady	steady	JJ	_	13	amod
12	state	state	NN	_	13	compound
13	conditions	condition	NNS	_	8	nmod
14	,	,	,	_	13	punct
15	drug2	drug2	NN	_	13	conj
16	or	or	CC	_	13	cc
17	drug3	drug3	NN	_	13	conj
18	was	be	VBD	_	19	auxpass
19	added	add	VBN	_	0	ROOT
20	in	in	IN	_	24	case
21	16	16	CD	_	24	nummod
22	and	and	CC	_	21	cc
23	14	14	CD	_	21	conj
24	patients	patient	NNS	_	19	nmod
25	,	,	,	_	19	punct
26	respectively	respectively	RB	_	19	advmod
27	.	.	.	_	19	punct

1	After	after	IN	_	3	case
2	14	14	CD	_	3	nummod
3	days	day	NNS	_	7	nmod
4	of	of	IN	_	5	case
5	co-administration	co-administration	NN	_	3	nmod
6	,	,	,	_	7	punct
7	mean	mean	VB	_	0	ROOT
8	trough	trough	NN	_	9	compound
9	concentrations	concentration	NNS	_	21	nsubj
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	its	its	PRP$	_	14	nmod:poss
14	metabolites	metabolite	NNS	_	11	conj
15	,	,	,	_	14	punct
16	drug2	drug2	NN	_	14	appos
17	and	and	CC	_	16	cc
18	drug3	drug3	NN	_	16	conj
19	,	,	,	_	14	punct
20	were	be	VBD	_	21	aux
21	elevated	elevated	JJ	_	7	ccomp
22	with	with	IN	_	23	case
23	drug4	drug4	NN	_	21	nmod
24	by	by	IN	_	26	case
25	about	about	IN	_	26	amod
26	three-fold	three-fold	JJ	_	21	nmod
27	compared	compare	VBN	_	30	case
28	to	to	TO	_	30	case
29	baseline	baseline	NN	_	30	compound
30	concentrations	concentration	NNS	_	26	advcl
31	.	.	.	_	7	punct

1	drug1	drug1	NN	_	2	nsubj
2	produced	produce	VBD	_	0	ROOT
3	only	only	RB	_	5	advmod
4	minor	minor	JJ	_	5	amod
5	changes	change	NNS	_	2	dobj
6	in	in	IN	_	8	case
7	the	the	DT	_	8	det
8	levels	level	NNS	_	5	nmod
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	its	its	PRP$	_	13	nmod:poss
13	metabolites	metabolite	NNS	_	10	conj
14	.	.	.	_	2	punct

1	However	however	RB	_	6	advmod
2	,	,	,	_	6	punct
3	other	other	JJ	_	5	amod
4	published	publish	VBN	_	5	amod
5	reports	report	NNS	_	6	nsubj
6	describe	describe	VBP	_	0	ROOT
7	modest	modest	JJ	_	8	amod
8	elevations	elevation	NNS	_	6	dobj
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	less	less	JJR	_	8	dep
11	than	than	IN	_	12	case
12	two-fold	two-fold	JJ	_	10	nmod
13	-RRB-	-rrb-	-RRB-	_	10	punct
14	of	of	IN	_	15	case
15	drug1	drug1	NN	_	8	nmod
16	and	and	CC	_	15	cc
17	metabolite	metabolite	NN	_	15	conj
18	concentrations	concentration	NNS	_	15	dep
19	when	when	WRB	_	22	advmod
20	drug2	drug2	NN	_	22	nsubjpass
21	was	be	VBD	_	22	auxpass
22	taken	take	VBN	_	6	advcl
23	with	with	IN	_	24	case
24	drug3	drug3	NN	_	22	nmod
25	,	,	,	_	24	punct
26	drug4	drug4	NN	_	24	conj
27	,	,	,	_	24	punct
28	and	and	CC	_	24	cc
29	drug5	drug5	NN	_	24	conj
30	.	.	.	_	6	punct

1	Therefore	therefore	RB	_	8	advmod
2	,	,	,	_	8	punct
3	such	such	JJ	_	5	amod
4	combined	combined	JJ	_	5	amod
5	treatment	treatment	NN	_	8	nsubjpass
6	should	should	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	approached	approach	VBN	_	0	ROOT
9	with	with	IN	_	10	case
10	caution	caution	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	patients	patient	NNS	_	10	conj
13	should	should	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	monitored	monitor	VBN	_	8	dep
16	closely	closely	RB	_	15	advmod
17	when	when	WRB	_	20	advmod
18	drug1	drug1	NN	_	20	nsubjpass
19	is	be	VBZ	_	20	auxpass
20	combined	combine	VBN	_	15	advcl
21	with	with	IN	_	23	case
22	these	these	DT	_	23	det
23	drugs	drug	NNS	_	20	nmod
24	,	,	,	_	15	punct
25	particularly	particularly	RB	_	27	advmod
26	with	with	IN	_	27	case
27	drug2	drug2	NN	_	15	nmod
28	.	.	.	_	8	punct

1	A	a	DT	_	4	det
2	reduced	reduce	VBN	_	4	amod
3	drug1	drug1	NN	_	4	compound
4	dose	dose	NN	_	7	nsubjpass
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	considered	consider	VBN	_	0	ROOT
8	.	.	.	_	7	punct

1	A	a	DT	_	2	det
2	subset	subset	NN	_	13	nsubj
3	-LRB-	-lrb-	-LRB-	_	5	punct
4	3	3	CD	_	5	nummod
5	%	%	NN	_	2	dep
6	-10	-10	CD	_	7	nummod
7	%	%	NN	_	5	dep
8	-RRB-	-rrb-	-RRB-	_	5	punct
9	of	of	IN	_	11	case
10	the	the	DT	_	11	det
11	population	population	NN	_	2	nmod
12	has	have	VBZ	_	13	aux
13	reduced	reduce	VBN	_	0	ROOT
14	activity	activity	NN	_	13	dobj
15	of	of	IN	_	17	case
16	certain	certain	JJ	_	17	amod
17	drug	drug	NN	_	14	nmod
18	metabolizing	metabolize	VBG	_	19	amod
19	enzymes	enzyme	NNS	_	17	dep
20	such	such	JJ	_	27	case
21	as	as	IN	_	20	mwe
22	the	the	DT	_	27	det
23	cytochrome	cytochrome	NN	_	27	compound
24	P450	p450	NN	_	27	compound
25	isozyme	isozyme	NN	_	27	compound
26	P450	p450	NN	_	27	compound
27	2D6	2d6	NN	_	19	nmod
28	.	.	.	_	13	punct

1	Such	such	JJ	_	2	amod
2	individuals	individual	NNS	_	4	nsubjpass
3	are	be	VBP	_	4	auxpass
4	referred	refer	VBN	_	0	ROOT
5	to	to	TO	_	8	case
6	as	as	IN	_	8	case
7	poor	poor	JJ	_	8	amod
8	metabolizers	metabolizer	NNS	_	4	nmod
9	of	of	IN	_	10	case
10	drugs	drug	NNS	_	8	nmod
11	such	such	JJ	_	13	case
12	as	as	IN	_	11	mwe
13	drug1	drug1	NN	_	10	nmod
14	,	,	,	_	13	punct
15	drug2	drug2	NN	_	13	conj
16	,	,	,	_	13	punct
17	the	the	DT	_	18	det
18	drug3	drug3	NN	_	13	conj
19	,	,	,	_	13	punct
20	and	and	CC	_	13	cc
21	drug4	drug4	NN	_	13	conj
22	.	.	.	_	4	punct

1	These	these	DT	_	2	det
2	individuals	individual	NNS	_	4	nsubj
3	may	may	MD	_	4	aux
4	develop	develop	VB	_	0	ROOT
5	higher	higher	JJR	_	9	amod
6	than	than	IN	_	7	dep
7	expected	expect	VBN	_	9	amod
8	plasma	plasma	NN	_	9	compound
9	concentrations	concentration	NNS	_	4	dobj
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	when	when	WRB	_	13	advmod
13	given	give	VBN	_	4	advcl
14	usual	usual	JJ	_	15	amod
15	doses	dose	NNS	_	13	dobj
16	.	.	.	_	4	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	26	nmod
3	,	,	,	_	26	punct
4	certain	certain	JJ	_	5	amod
5	drugs	drug	NNS	_	26	nsubj
6	that	that	WDT	_	8	nsubjpass
7	are	be	VBP	_	8	auxpass
8	metabolized	metabolize	VBN	_	5	acl:relcl
9	by	by	IN	_	11	case
10	this	this	DT	_	11	det
11	isozyme	isozyme	NN	_	8	nmod
12	,	,	,	_	5	punct
13	including	include	VBG	_	15	case
14	many	many	JJ	_	15	amod
15	drug1	drug1	NN	_	5	nmod
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	drug2	drug2	NN	_	15	dep
18	,	,	,	_	17	punct
19	drug3	drug3	NN	_	17	conj
20	,	,	,	_	17	punct
21	and	and	CC	_	17	cc
22	others	other	NNS	_	17	conj
23	-RRB-	-rrb-	-RRB-	_	17	punct
24	,	,	,	_	5	punct
25	may	may	MD	_	26	aux
26	inhibit	inhibit	VB	_	0	ROOT
27	the	the	DT	_	28	det
28	activity	activity	NN	_	26	dobj
29	of	of	IN	_	31	case
30	this	this	DT	_	31	det
31	isozyme	isozyme	NN	_	28	nmod
32	,	,	,	_	26	punct
33	and	and	CC	_	26	cc
34	thus	thus	RB	_	36	advmod
35	may	may	MD	_	36	aux
36	make	make	VB	_	26	conj
37	normal	normal	JJ	_	38	amod
38	metabolizers	metabolizer	NNS	_	39	nsubj
39	resemble	resemble	VBP	_	36	ccomp
40	poor	poor	JJ	_	41	amod
41	metabolizers	metabolizer	NNS	_	39	dobj
42	with	with	IN	_	43	case
43	regard	regard	NN	_	39	nmod
44	to	to	TO	_	46	case
45	concomitant	concomitant	JJ	_	46	amod
46	therapy	therapy	NN	_	43	nmod
47	with	with	IN	_	49	case
48	other	other	JJ	_	49	amod
49	drugs	drug	NNS	_	46	nmod
50	metabolized	metabolize	VBN	_	49	acl
51	by	by	IN	_	54	case
52	this	this	DT	_	54	det
53	enzyme	enzyme	NN	_	54	compound
54	system	system	NN	_	50	nmod
55	,	,	,	_	39	punct
56	leading	lead	VBG	_	39	xcomp
57	to	to	TO	_	59	case
58	drug	drug	NN	_	59	compound
59	interaction	interaction	NN	_	56	nmod
60	.	.	.	_	26	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	use	use	NN	_	14	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	7	case
6	other	other	JJ	_	7	amod
7	drugs	drug	NNS	_	2	nmod
8	metabolized	metabolize	VBN	_	7	acl
9	by	by	IN	_	12	case
10	cytochrome	cytochrome	NN	_	12	compound
11	P450	p450	NN	_	12	compound
12	2D6	2d6	NN	_	8	nmod
13	may	may	MD	_	14	aux
14	require	require	VB	_	0	ROOT
15	lower	lower	JJR	_	16	amod
16	doses	dose	NNS	_	14	dobj
17	than	than	IN	_	19	mark
18	usually	usually	RB	_	19	advmod
19	prescribed	prescribe	VBN	_	16	dep
20	for	for	IN	_	22	case
21	either	either	CC	_	22	cc:preconj
22	drug2	drug2	NN	_	19	nmod
23	or	or	CC	_	22	cc
24	the	the	DT	_	26	det
25	other	other	JJ	_	26	amod
26	drug	drug	NN	_	22	conj
27	.	.	.	_	14	punct

1	Therefore	therefore	RB	_	48	advmod
2	,	,	,	_	48	punct
3	co-administration	co-administration	NN	_	48	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	with	with	IN	_	8	case
7	other	other	JJ	_	8	amod
8	drugs	drug	NNS	_	3	nmod
9	that	that	WDT	_	11	nsubjpass
10	are	be	VBP	_	11	auxpass
11	metabolized	metabolize	VBN	_	8	acl:relcl
12	by	by	IN	_	14	case
13	this	this	DT	_	14	det
14	isozyme	isozyme	NN	_	11	nmod
15	,	,	,	_	8	punct
16	including	include	VBG	_	17	case
17	drug2	drug2	NN	_	8	nmod
18	,	,	,	_	17	punct
19	drug3	drug3	NN	_	17	conj
20	,	,	,	_	17	punct
21	drug4	drug4	NN	_	17	conj
22	,	,	,	_	17	punct
23	and	and	CC	_	17	cc
24	drug5	drug5	NN	_	17	conj
25	-LRB-	-lrb-	-LRB-	_	28	punct
26	e.g.	e.g.	FW	_	28	dep
27	,	,	,	_	28	punct
28	drug6	drug6	NN	_	24	dep
29	,	,	,	_	28	punct
30	drug7	drug7	NN	_	28	conj
31	and	and	CC	_	28	cc
32	drug8	drug8	NN	_	28	conj
33	-RRB-	-rrb-	-RRB-	_	28	punct
34	,	,	,	_	8	punct
35	or	or	CC	_	8	cc
36	that	that	IN	_	37	nsubj
37	inhibit	inhibit	VBP	_	8	conj
38	this	this	DT	_	39	det
39	enzyme	enzyme	NN	_	37	dobj
40	-LRB-	-lrb-	-LRB-	_	43	punct
41	e.g.	e.g.	FW	_	43	dep
42	,	,	,	_	43	punct
43	drug9	drug9	NN	_	37	dep
44	-RRB-	-rrb-	-RRB-	_	43	punct
45	,	,	,	_	3	punct
46	should	should	MD	_	48	aux
47	be	be	VB	_	48	auxpass
48	approached	approach	VBN	_	0	ROOT
49	with	with	IN	_	50	case
50	caution	caution	NN	_	48	nmod
51	.	.	.	_	48	punct

1	Milk	milk	NN	_	14	nsubj
2	,	,	,	_	1	punct
3	milk	milk	NN	_	4	compound
4	products	product	NNS	_	1	conj
5	,	,	,	_	1	punct
6	and	and	CC	_	1	cc
7	drug1	drug1	NN	_	1	conj
8	-	-	:	_	1	punct
9	rich	rich	JJ	_	10	amod
10	foods	food	NNS	_	1	dep
11	or	or	CC	_	10	cc
12	drugs	drug	NNS	_	10	conj
13	may	may	MD	_	14	aux
14	impair	impair	VB	_	0	ROOT
15	the	the	DT	_	16	det
16	absorption	absorption	NN	_	14	dobj
17	of	of	IN	_	18	case
18	drug2	drug2	NN	_	16	nmod
19	.	.	.	_	14	punct

1	Do	do	VB	_	3	aux
2	not	not	RB	_	3	neg
3	take	take	VB	_	0	ROOT
4	this	this	DT	_	5	det
5	medicine	medicine	NN	_	3	dobj
6	with	with	IN	_	7	case
7	thioridizine	thioridizine	NN	_	3	nmod
8	,	,	,	_	3	punct
9	or	or	CC	_	3	cc
10	within	within	IN	_	12	case
11	5	5	CD	_	12	nummod
12	weeks	week	NNS	_	3	conj
13	of	of	IN	_	14	mark
14	taking	take	VBG	_	12	acl
15	drug1	drug1	NN	_	14	dobj
16	.	.	.	_	3	punct

1	Talk	talk	NN	_	0	ROOT
2	to	to	TO	_	4	case
3	your	you	PRP$	_	4	nmod:poss
4	doctor	doctor	NN	_	1	nmod
5	if	if	IN	_	8	mark
6	you	you	PRP	_	8	nsubj
7	are	be	VBP	_	8	aux
8	taking	take	VBG	_	1	advcl
9	certain	certain	JJ	_	10	amod
10	drug1	drug1	NN	_	8	dobj
11	such	such	JJ	_	13	case
12	as	as	IN	_	11	mwe
13	drug2	drug2	NN	_	10	nmod
14	,	,	,	_	13	punct
15	drug3	drug3	NN	_	13	conj
16	or	or	CC	_	13	cc
17	drug4	drug4	NN	_	13	conj
18	.	.	.	_	1	punct

1	This	this	DT	_	2	det
2	medicine	medicine	NN	_	6	nsubjpass
3	should	should	MD	_	6	aux
4	not	not	RB	_	6	neg
5	be	be	VB	_	6	auxpass
6	taken	take	VBN	_	0	ROOT
7	with	with	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	.	.	.	_	6	punct

1	Caution	caution	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	exercised	exercise	VBN	_	0	ROOT
5	when	when	WRB	_	6	advmod
6	taking	take	VBG	_	4	advcl
7	this	this	DT	_	8	det
8	medicine	medicine	NN	_	6	dobj
9	certain	certain	JJ	_	10	amod
10	drug1	drug1	NN	_	6	dobj
11	,	,	,	_	10	punct
12	such	such	JJ	_	14	case
13	as	as	IN	_	12	mwe
14	drug2	drug2	NN	_	10	nmod
15	,	,	,	_	14	punct
16	drug3	drug3	NN	_	14	conj
17	,	,	,	_	14	punct
18	or	or	CC	_	14	cc
19	drug4	drug4	NN	_	14	conj
20	.	.	.	_	4	punct

1	This	this	DT	_	2	det
2	medicine	medicine	NN	_	6	nsubjpass
3	should	should	MD	_	6	aux
4	not	not	RB	_	6	neg
5	be	be	VB	_	6	auxpass
6	taken	take	VBN	_	0	ROOT
7	with	with	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	.	.	.	_	6	punct

1	If	if	IN	_	3	mark
2	you	you	PRP	_	3	nsubj
3	think	think	VBP	_	0	ROOT
4	you	you	PRP	_	6	nsubj
5	are	be	VBP	_	6	aux
6	taking	take	VBG	_	3	ccomp
7	an	a	DT	_	9	det
8	drug1	drug1	NN	_	9	compound
9	talk	talk	NN	_	6	dobj
10	to	to	TO	_	12	case
11	your	you	PRP$	_	12	nmod:poss
12	doctor	doctor	NN	_	9	nmod
13	or	or	CC	_	12	cc
14	pharmacist	pharmacist	NN	_	12	conj
15	.	.	.	_	3	punct

1	Do	do	VB	_	3	aux
2	not	not	RB	_	3	neg
3	take	take	VB	_	0	ROOT
4	this	this	DT	_	5	det
5	medicine	medicine	NN	_	3	dobj
6	with	with	IN	_	9	case
7	St.	St.	NNP	_	9	compound
8	Johns	Johns	NNP	_	9	compound
9	Wort	Wort	NNP	_	3	nmod
10	because	because	IN	_	14	case
11	of	of	IN	_	10	mwe
12	the	the	DT	_	14	det
13	additive	additive	JJ	_	14	amod
14	effects	effect	NNS	_	3	nmod
15	of	of	IN	_	16	case
16	sertonin	sertonin	NN	_	14	nmod
17	.	.	.	_	3	punct

1	This	this	DT	_	2	det
2	medication	medication	NN	_	6	nsubjpass
3	should	should	MD	_	6	aux
4	not	not	RB	_	6	neg
5	be	be	VB	_	6	auxpass
6	taken	take	VBN	_	0	ROOT
7	with	with	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	.	.	.	_	6	punct

1	Your	you	PRP$	_	2	nmod:poss
2	doctor	doctor	NN	_	6	nsubj
3	or	or	CC	_	2	cc
4	pharmacist	pharmacist	NN	_	2	conj
5	can	can	MD	_	6	aux
6	give	give	VB	_	0	ROOT
7	you	you	PRP	_	6	iobj
8	more	more	JJR	_	9	amod
9	information	information	NN	_	6	dobj
10	on	on	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	.	.	.	_	6	punct

1	Wait	wait	VB	_	0	ROOT
2	5	5	CD	_	3	nummod
3	weeks	week	NNS	_	1	nmod
4	after	after	IN	_	3	mark
5	stopping	stop	VBG	_	3	dep
6	drug1	drug1	NN	_	5	dobj
7	before	before	IN	_	8	mark
8	starting	start	VBG	_	5	advcl
9	a	a	DT	_	10	det
10	drug2	drug2	NN	_	8	dobj
11	.	.	.	_	1	punct

1	Wait	wait	VB	_	0	ROOT
2	2	2	CD	_	3	nummod
3	weeks	week	NNS	_	1	nmod
4	after	after	IN	_	3	mark
5	stopping	stop	VBG	_	3	dep
6	an	a	DT	_	7	det
7	drug1	drug1	NN	_	5	dobj
8	before	before	IN	_	9	mark
9	starting	start	VBG	_	5	advcl
10	drug2	drug2	NN	_	9	dobj
11	.	.	.	_	1	punct

1	If	if	IN	_	4	mark
2	you	you	PRP	_	4	nsubj
3	are	be	VBP	_	4	aux
4	taking	take	VBG	_	0	ROOT
5	medications	medication	NNS	_	4	dobj
6	for	for	IN	_	7	case
7	migraines	migraine	NNS	_	4	nmod
8	such	such	JJ	_	10	case
9	as	as	IN	_	8	mwe
10	drug1	drug1	NN	_	7	nmod
11	,	,	,	_	4	punct
12	talk	talk	NN	_	11	root
13	to	to	TO	_	15	case
14	your	you	PRP$	_	15	nmod:poss
15	doctor	doctor	NN	_	12	nmod
16	before	before	IN	_	17	mark
17	starting	start	VBG	_	12	acl
18	this	this	DT	_	19	det
19	medicine	medicine	NN	_	17	dobj
20	.	.	.	_	12	punct

1	If	if	IN	_	4	mark
2	you	you	PRP	_	4	nsubj
3	are	be	VBP	_	4	aux
4	taking	take	VBG	_	0	ROOT
5	a	a	DT	_	6	det
6	drug1	drug1	NN	_	4	dobj
7	,	,	,	_	4	punct
8	talk	talk	NN	_	7	root
9	to	to	TO	_	11	case
10	your	you	PRP$	_	11	nmod:poss
11	doctor	doctor	NN	_	8	nmod
12	before	before	IN	_	13	mark
13	taking	take	VBG	_	8	acl
14	this	this	DT	_	15	det
15	medicine	medicine	NN	_	13	dobj
16	.	.	.	_	8	punct

1	St.	St.	NNP	_	4	compound
2	John	John	NNP	_	4	compound
3	s	be	VBZ	_	4	compound
4	Wort	Wort	NNP	_	7	nsubjpass
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	avoided	avoid	VBN	_	0	ROOT
8	while	while	IN	_	9	mark
9	taking	take	VBG	_	7	advcl
10	this	this	DT	_	11	det
11	medicine	medicine	NN	_	9	dobj
12	due	due	JJ	_	16	case
13	to	to	TO	_	12	mwe
14	the	the	DT	_	16	det
15	additive	additive	JJ	_	16	amod
16	effects	effect	NNS	_	9	nmod
17	of	of	IN	_	18	case
18	serotonin	serotonin	NN	_	16	nmod
19	.	.	.	_	7	punct

1	Tell	tell	VB	_	0	ROOT
2	your	you	PRP$	_	3	nmod:poss
3	doctor	doctor	NN	_	1	dobj
4	if	if	IN	_	7	mark
5	you	you	PRP	_	7	nsubj
6	are	be	VBP	_	7	aux
7	taking	take	VBG	_	1	advcl
8	any	any	DT	_	7	dobj
9	of	of	IN	_	12	case
10	the	the	DT	_	12	det
11	following	follow	VBG	_	12	amod
12	drugs	drug	NNS	_	8	nmod
13	:	:	:	_	1	punct
14	drug1	drug1	NN	_	15	compound
15	s	s	NNS	_	1	dep
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	drug2	drug2	NN	_	15	appos
18	-RRB-	-rrb-	-RRB-	_	17	punct
19	other	other	JJ	_	23	amod
20	drug3	drug3	NN	_	23	compound
21	drug4	drug4	NN	_	23	compound
22	drug5	drug5	NN	_	23	compound
23	drug6	drug6	NN	_	15	dep
24	-LRB-	-lrb-	-LRB-	_	25	punct
25	drug7	drug7	NN	_	23	appos
26	-RRB-	-rrb-	-RRB-	_	25	punct
27	drug8	drug8	NN	_	32	compound
28	-LRB-	-lrb-	-LRB-	_	29	punct
29	drug9	drug9	NN	_	27	appos
30	-RRB-	-rrb-	-RRB-	_	29	punct
31	drug10	drug10	NN	_	32	compound
32	drug11	drug11	NN	_	23	dep
33	-LRB-	-lrb-	-LRB-	_	34	punct
34	drug12	drug12	NN	_	32	appos
35	-RRB-	-rrb-	-RRB-	_	34	punct
36	intraconazole	intraconazole	NN	_	40	compound
37	-LRB-	-lrb-	-LRB-	_	38	punct
38	drug13	drug13	NN	_	36	appos
39	-RRB-	-rrb-	-RRB-	_	38	punct
40	drug14	drug14	NN	_	23	dep
41	-LRB-	-lrb-	-LRB-	_	42	punct
42	drug15	drug15	NN	_	40	appos
43	-RRB-	-rrb-	-RRB-	_	42	punct
44	drug16	drug16	NN	_	49	compound
45	drug17	drug17	NN	_	49	compound
46	drug18	drug18	NN	_	49	compound
47	birth	birth	NN	_	49	compound
48	control	control	NN	_	49	compound
49	pills	pill	NNS	_	23	dep
50	sleeping	sleep	VBG	_	49	acl
51	pills	pill	NNS	_	53	compound
52	thyroid	thyroid	NN	_	53	compound
53	medications	medication	NNS	_	50	dobj

1	Increases	increase	NNS	_	6	nsubj
2	in	in	IN	_	4	case
3	serum	serum	NN	_	4	compound
4	creatinine	creatinine	NN	_	1	nmod
5	have	have	VBP	_	6	aux
6	occurred	occur	VBN	_	0	ROOT
7	when	when	WRB	_	10	advmod
8	drug1	drug1	NN	_	10	nsubjpass
9	was	be	VBD	_	10	auxpass
10	given	give	VBN	_	6	advcl
11	alone	alone	RB	_	10	advmod
12	.	.	.	_	6	punct

1	If	if	IN	_	7	mark
2	drug1	drug1	NN	_	7	nsubjpass
3	and	and	CC	_	2	cc
4	an	a	DT	_	5	det
5	drug2	drug2	NN	_	2	conj
6	are	be	VBP	_	7	auxpass
7	used	use	VBN	_	15	advcl
8	concomitantly	concomitantly	RB	_	7	advmod
9	,	,	,	_	15	punct
10	renal	renal	JJ	_	11	amod
11	function	function	NN	_	15	nsubjpass
12	should	should	MD	_	15	aux
13	be	be	VB	_	15	auxpass
14	carefully	carefully	RB	_	15	advmod
15	monitored	monitor	VBN	_	0	ROOT
16	,	,	,	_	15	punct
17	because	because	IN	_	21	mark
18	nephrotoxicity	nephrotoxicity	NN	_	21	nsubjpass
19	may	may	MD	_	21	aux
20	be	be	VB	_	21	auxpass
21	potentiated	potentiate	VBN	_	15	advcl
22	.	.	.	_	15	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	3	amod
2	Test	test	NN	_	3	compound
3	Interactions	interaction	NNS	_	0	ROOT
4	:	:	:	_	3	punct
5	The	the	DT	_	6	det
6	administration	administration	NN	_	10	nsubj
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	may	may	MD	_	10	aux
10	result	result	VB	_	3	appos
11	in	in	IN	_	15	case
12	a	a	DT	_	15	det
13	false	false	JJ	_	15	amod
14	positive	positive	JJ	_	15	amod
15	reaction	reaction	NN	_	10	nmod
16	for	for	IN	_	17	case
17	glucose	glucose	NN	_	15	nmod
18	in	in	IN	_	20	case
19	the	the	DT	_	20	det
20	urine	urine	NN	_	17	nmod
21	using	use	VBG	_	15	acl
22	Clinitest	Clinitest	NNP	_	21	dobj
23	,	,	,	_	22	punct
24	Benedicts	Benedicts	NNP	_	25	compound
25	solution	solution	NN	_	22	conj
26	,	,	,	_	22	punct
27	or	or	CC	_	22	cc
28	Fehlings	Fehlings	NNP	_	29	compound
29	solution	solution	NN	_	22	conj
30	.	.	.	_	3	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	recommended	recommend	VBN	_	0	ROOT
4	that	that	IN	_	13	mark
5	glucose	glucose	NN	_	6	compound
6	tests	test	NNS	_	13	nsubjpass
7	based	base	VBN	_	11	case
8	on	on	IN	_	11	case
9	enzymatic	enzymatic	JJ	_	11	amod
10	glucose	glucose	NN	_	11	compound
11	oxidase	oxidase	NN	_	6	nmod
12	be	be	VB	_	13	auxpass
13	used	use	VBN	_	3	ccomp
14	.	.	.	_	3	punct

1	As	as	IN	_	4	case
2	with	with	IN	_	4	case
3	other	other	JJ	_	4	amod
4	drug1	drug1	NN	_	11	nmod
5	,	,	,	_	11	punct
6	high	high	JJ	_	7	amod
7	concentrations	concentration	NNS	_	11	nsubj
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	may	may	MD	_	11	aux
11	interfere	interfere	VB	_	32	ccomp
12	with	with	IN	_	13	case
13	measurement	measurement	NN	_	11	nmod
14	of	of	IN	_	15	case
15	serum	serum	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	urine	urine	NN	_	15	conj
18	creatinine	creatinine	NN	_	19	compound
19	levels	level	NNS	_	15	dep
20	by	by	IN	_	22	case
21	Jaffe	Jaffe	NNP	_	22	compound
22	reaction	reaction	NN	_	13	nmod
23	and	and	CC	_	11	cc
24	produce	produce	VBP	_	11	conj
25	false	false	JJ	_	26	amod
26	increases	increase	NNS	_	24	dobj
27	in	in	IN	_	29	case
28	the	the	DT	_	29	det
29	levels	level	NNS	_	26	nmod
30	of	of	IN	_	31	case
31	creatinine	creatinine	NN	_	29	nmod
32	reported	report	VBD	_	0	ROOT
33	.	.	.	_	32	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	interact	interact	VB	_	0	ROOT
4	with	with	IN	_	7	case
5	the	the	DT	_	7	det
6	following	follow	VBG	_	7	amod
7	medications	medication	NNS	_	3	nmod
8	:	:	:	_	7	punct
9	drug2	drug2	NN	_	7	dep
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	drug3	drug3	NN	_	9	appos
12	-RRB-	-rrb-	-RRB-	_	11	punct
13	,	,	,	_	9	punct
14	drug4	drug4	NN	_	9	appos
15	such	such	JJ	_	17	case
16	as	as	IN	_	15	mwe
17	drug5	drug5	NN	_	14	nmod
18	and	and	CC	_	17	cc
19	drug6	drug6	NN	_	17	conj
20	,	,	,	_	17	punct
21	drug7	drug7	NN	_	17	conj
22	-LRB-	-lrb-	-LRB-	_	23	punct
23	drug8	drug8	NN	_	21	dep
24	,	,	,	_	23	punct
25	drug9	drug9	NN	_	23	conj
26	,	,	,	_	23	punct
27	drug10	drug10	NN	_	23	conj
28	,	,	,	_	23	punct
29	drug11	drug11	NN	_	23	conj
30	,	,	,	_	23	punct
31	drug12	drug12	NN	_	23	conj
32	,	,	,	_	23	punct
33	drug13	drug13	NN	_	23	appos
34	-RRB-	-rrb-	-RRB-	_	23	punct
35	,	,	,	_	17	punct
36	drug14	drug14	NN	_	17	conj
37	-LRB-	-lrb-	-LRB-	_	38	punct
38	drug15	drug15	NN	_	36	dep
39	,	,	,	_	38	punct
40	drug16	drug16	NN	_	38	appos
41	,	,	,	_	38	punct
42	drug17	drug17	NN	_	38	appos
43	-RRB-	-rrb-	-RRB-	_	38	punct
44	,	,	,	_	17	punct
45	drug18	drug18	NN	_	17	conj
46	-LRB-	-lrb-	-LRB-	_	47	punct
47	drug19	drug19	NN	_	45	appos
48	-RRB-	-rrb-	-RRB-	_	47	punct
49	,	,	,	_	17	punct
50	drug20	drug20	NN	_	17	conj
51	-LRB-	-lrb-	-LRB-	_	52	punct
52	drug21	drug21	NN	_	50	appos
53	-RRB-	-rrb-	-RRB-	_	52	punct
54	,	,	,	_	17	punct
55	drug22	drug22	NN	_	17	conj
56	-LRB-	-lrb-	-LRB-	_	57	punct
57	drug23	drug23	NN	_	55	dep
58	,	,	,	_	57	punct
59	drug24	drug24	NN	_	57	appos
60	-RRB-	-rrb-	-RRB-	_	57	punct
61	,	,	,	_	17	punct
62	HIV	hiv	NN	_	63	compound
63	drugs	drug	NNS	_	17	conj
64	classified	classify	VBN	_	63	acl
65	as	as	IN	_	66	case
66	drug25	drug25	NN	_	64	nmod
67	-LRB-	-lrb-	-LRB-	_	68	punct
68	drug26	drug26	NN	_	66	dep
69	,	,	,	_	68	punct
70	drug27	drug27	NN	_	68	conj
71	,	,	,	_	68	punct
72	drug28	drug28	NN	_	68	conj
73	,	,	,	_	68	punct
74	drug29	drug29	NN	_	68	conj
75	,	,	,	_	68	punct
76	drug30	drug30	NN	_	68	conj
77	,	,	,	_	68	punct
78	drug31	drug31	NN	_	68	conj
79	,	,	,	_	68	punct
80	drug32	drug32	NN	_	68	appos
81	-RRB-	-rrb-	-RRB-	_	68	punct
82	,	,	,	_	66	punct
83	drug33	drug33	NN	_	66	conj
84	-LRB-	-lrb-	-LRB-	_	85	punct
85	drug34	drug34	NN	_	83	dep
86	,	,	,	_	85	punct
87	drug35	drug35	NN	_	85	appos
88	,	,	,	_	85	punct
89	drug36	drug36	NN	_	85	appos
90	-RRB-	-rrb-	-RRB-	_	85	punct
91	,	,	,	_	66	punct
92	drug37	drug37	NN	_	66	conj
93	,	,	,	_	66	punct
94	drug38	drug38	NN	_	66	conj
95	-LRB-	-lrb-	-LRB-	_	96	punct
96	drug39	drug39	NN	_	94	appos
97	-RRB-	-rrb-	-RRB-	_	96	punct
98	,	,	,	_	66	punct
99	drug40	drug40	NN	_	66	conj
100	-LRB-	-lrb-	-LRB-	_	101	punct
101	drug41	drug41	NN	_	99	appos
102	-RRB-	-rrb-	-RRB-	_	101	punct
103	,	,	,	_	66	punct
104	St.	St.	NNP	_	106	compound
105	Johns	Johns	NNP	_	106	compound
106	wort	wort	NN	_	66	conj
107	,	,	,	_	66	punct
108	drug42	drug42	NN	_	66	conj
109	,	,	,	_	66	punct
110	drug43	drug43	NN	_	66	conj
111	-LRB-	-lrb-	-LRB-	_	112	punct
112	drug44	drug44	NN	_	110	appos
113	-RRB-	-rrb-	-RRB-	_	112	punct
114	,	,	,	_	66	punct
115	and	and	CC	_	66	cc
116	drug45	drug45	NN	_	66	conj
117	.	.	.	_	3	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Substrate	substrate	NN	_	1	dep
4	of	of	IN	_	5	case
5	CYP3A4	cyp3a4	NN	_	3	nmod
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	major	major	JJ	_	5	dep
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	,	,	,	_	5	punct
10	3A5-7	3a5-7	NN	_	5	appos
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	minor	minor	JJ	_	10	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	;	;	:	_	1	punct

1	Inhibits	inhibit	VBZ	_	0	ROOT
2	CYP1A2	cyp1a2	NN	_	1	dobj
3	-LRB-	-lrb-	-LRB-	_	4	punct
4	weak	weak	JJ	_	2	dep
5	-RRB-	-rrb-	-RRB-	_	4	punct
6	,	,	,	_	2	punct
7	2B6	2b6	NN	_	2	conj
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	weak	weak	JJ	_	7	dep
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	,	,	,	_	2	punct
12	2C19	2c19	NN	_	2	conj
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	weak	weak	JJ	_	12	dep
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	,	,	,	_	2	punct
17	3A4	3a4	NN	_	2	conj
18	-LRB-	-lrb-	-LRB-	_	19	punct
19	weak	weak	JJ	_	17	dep
20	-RRB-	-rrb-	-RRB-	_	19	punct
21	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	May	May	NNP	_	6	compound
4	increase	increase	NN	_	6	compound
5	plasma	plasma	NN	_	6	compound
6	concentration	concentration	NN	_	1	dep
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	,	,	,	_	6	punct
10	possibly	possibly	RB	_	12	advmod
11	by	by	IN	_	12	mark
12	inhibiting	inhibit	VBG	_	6	acl
13	conjugation	conjugation	NN	_	12	dobj
14	.	.	.	_	1	punct

1	Combination	combination	NN	_	2	compound
2	drug1	drug1	NN	_	5	nsubj
3	may	may	MD	_	5	aux
4	also	also	RB	_	5	advmod
5	decrease	decrease	VB	_	0	ROOT
6	the	the	DT	_	8	det
7	plasma	plasma	NN	_	8	compound
8	concentration	concentration	NN	_	5	dobj
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Interferes	interfere	NNS	_	1	dep
4	with	with	IN	_	7	case
5	the	the	DT	_	7	det
6	contraceptive	contraceptive	JJ	_	7	amod
7	effect	effect	NN	_	3	nmod
8	of	of	IN	_	10	case
9	microdosed	microdosed	JJ	_	10	amod
10	drug2	drug2	NN	_	7	nmod
11	-	-	:	_	10	punct
12	containing	contain	VBG	_	10	acl
13	minipill	minipill	NN	_	14	compound
14	preparations	preparation	NNS	_	12	dobj
15	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	14	nsubj
3	on	on	IN	_	5	case
4	other	other	JJ	_	5	amod
5	drug1	drug1	NN	_	2	nmod
6	-LRB-	-lrb-	-LRB-	_	9	punct
7	eg	eg	FW	_	9	dep
8	,	,	,	_	9	punct
9	implants	implant	NNS	_	5	dep
10	,	,	,	_	9	punct
11	injectables	injectable	NNS	_	9	appos
12	-RRB-	-rrb-	-RRB-	_	9	punct
13	is	be	VBZ	_	14	cop
14	unknown	unknown	JJ	_	0	ROOT
15	.	.	.	_	14	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	May	May	NNP	_	6	compound
4	increase	increase	NN	_	6	compound
5	CYP	cyp	NN	_	6	compound
6	metabolism	metabolism	NN	_	1	dep
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	leading	lead	VBG	_	8	acl
10	to	to	TO	_	12	case
11	possible	possible	JJ	_	12	amod
12	decrease	decrease	NN	_	9	nmod
13	in	in	IN	_	15	case
14	contraceptive	contraceptive	JJ	_	15	amod
15	effectiveness	effectiveness	NN	_	12	nmod
16	.	.	.	_	1	punct

1	Use	use	NN	_	6	nsubjpass
2	of	of	IN	_	4	case
3	a	a	DT	_	4	det
4	drug1	drug1	NN	_	1	nmod
5	is	be	VBZ	_	6	auxpass
6	recommended	recommend	VBN	_	0	ROOT
7	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	drug2	drug2	NN	_	1	dep
4	,	,	,	_	3	punct
5	drug3	drug3	NN	_	3	appos
6	-RRB-	-rrb-	-RRB-	_	3	punct
7	:	:	:	_	1	punct
8	Pregnancy	pregnancy	NN	_	11	nsubjpass
9	has	have	VBZ	_	11	aux
10	been	be	VBN	_	11	auxpass
11	reported	report	VBN	_	1	dep
12	following	follow	VBG	_	14	case
13	concomitant	concomitant	JJ	_	14	amod
14	use	use	NN	_	11	nmod
15	,	,	,	_	11	punct
16	however	however	RB	_	11	advmod
17	,	,	,	_	11	punct
18	pharmacokinetic	pharmacokinetic	JJ	_	19	amod
19	studies	study	NNS	_	22	nsubj
20	have	have	VBP	_	22	aux
21	not	not	RB	_	22	neg
22	shown	show	VBN	_	11	dep
23	consistent	consistent	JJ	_	24	amod
24	effects	effect	NNS	_	22	dobj
25	with	with	IN	_	27	case
26	these	these	DT	_	27	det
27	drug4	drug4	NN	_	24	nmod
28	on	on	IN	_	30	case
29	plasma	plasma	NN	_	30	compound
30	concentrations	concentration	NNS	_	24	nmod
31	of	of	IN	_	32	case
32	drug5	drug5	NN	_	30	nmod
33	.	.	.	_	1	punct

1	Use	use	NN	_	6	nsubjpass
2	of	of	IN	_	4	case
3	a	a	DT	_	4	det
4	drug1	drug1	NN	_	1	nmod
5	is	be	VBZ	_	6	auxpass
6	recommended	recommend	VBN	_	0	ROOT
7	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Combination	combination	NN	_	4	compound
4	drug2	drug2	NN	_	6	nsubj
5	may	may	MD	_	6	aux
6	increase	increase	VB	_	1	dep
7	or	or	CC	_	6	cc
8	decrease	decrease	VB	_	6	conj
9	the	the	DT	_	10	det
10	effects	effect	NNS	_	6	dobj
11	of	of	IN	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	.	.	.	_	6	punct

1	Combination	combination	NN	_	2	compound
2	drug1	drug1	NN	_	5	nsubj
3	may	may	MD	_	5	aux
4	also	also	RB	_	5	advmod
5	increase	increase	VB	_	0	ROOT
6	risk	risk	NN	_	5	dobj
7	of	of	IN	_	9	case
8	thromboembolic	thromboembolic	JJ	_	9	amod
9	disorders	disorder	NNS	_	6	nmod
10	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	drug2	drug2	NN	_	1	dep
4	,	,	,	_	3	punct
5	drug3	drug3	NN	_	3	conj
6	,	,	,	_	3	punct
7	drug4	drug4	NN	_	3	conj
8	,	,	,	_	3	punct
9	drug5	drug5	NN	_	3	conj
10	,	,	,	_	3	punct
11	drug6	drug6	NN	_	3	appos
12	-RRB-	-rrb-	-RRB-	_	3	punct
13	:	:	:	_	1	punct
14	Increase	increase	VB	_	1	dep
15	the	the	DT	_	16	det
16	metabolism	metabolism	NN	_	14	dobj
17	of	of	IN	_	18	case
18	drug7	drug7	NN	_	16	nmod
19	and/or	and/or	CC	_	18	cc
20	some	some	DT	_	21	det
21	drug8	drug8	NN	_	18	conj
22	,	,	,	_	14	punct
23	leading	lead	VBG	_	14	advcl
24	to	to	TO	_	26	case
25	possible	possible	JJ	_	26	amod
26	decrease	decrease	NN	_	23	nmod
27	in	in	IN	_	29	case
28	contraceptive	contraceptive	JJ	_	29	amod
29	effectiveness	effectiveness	NN	_	26	nmod
30	.	.	.	_	1	punct

1	Use	use	NN	_	6	nsubjpass
2	of	of	IN	_	4	case
3	a	a	DT	_	4	det
4	drug1	drug1	NN	_	1	nmod
5	is	be	VBZ	_	6	auxpass
6	recommended	recommend	VBN	_	0	ROOT
7	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Doses	dose	NNS	_	13	nsubjpass
4	of	of	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	drug3	drug3	NN	_	5	appos
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	1	1	CD	_	10	nummod
10	g/day	g/day	NN	_	5	dep
11	have	have	VBP	_	13	aux
12	been	be	VBN	_	13	auxpass
13	reported	report	VBN	_	1	appos
14	to	to	TO	_	15	mark
15	increase	increase	VB	_	13	xcomp
16	plasma	plasma	NN	_	17	compound
17	concentration	concentration	NN	_	15	dobj
18	of	of	IN	_	19	case
19	drug4	drug4	NN	_	17	nmod
20	by	by	IN	_	21	case
21	~	~	NN	_	15	nmod
22	47	47	CD	_	23	nummod
23	%	%	NN	_	21	dep
24	,	,	,	_	15	punct
25	possibly	possibly	RB	_	27	advmod
26	by	by	IN	_	27	mark
27	inhibiting	inhibit	VBG	_	15	advcl
28	conjugation	conjugation	NN	_	27	dobj
29	;	;	:	_	1	punct

1	clinical	clinical	JJ	_	2	amod
2	implications	implication	NNS	_	4	nsubj
3	are	be	VBP	_	4	cop
4	unclear	unclear	JJ	_	0	ROOT
5	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	nsubj
4	increases	increase	VBZ	_	1	appos
5	the	the	DT	_	6	det
6	AUC	auc	NN	_	4	dobj
7	for	for	IN	_	8	case
8	drug3	drug3	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	drug4	drug4	NN	_	8	conj
11	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Combination	combination	NN	_	4	compound
4	drug2	drug2	NN	_	6	nsubj
5	may	may	MD	_	6	aux
6	decrease	decrease	VB	_	1	dep
7	the	the	DT	_	8	det
8	clearance	clearance	NN	_	6	dobj
9	of	of	IN	_	11	case
10	some	some	DT	_	11	det
11	drug3	drug3	NN	_	8	nmod
12	-LRB-	-lrb-	-LRB-	_	13	punct
13	drug4	drug4	NN	_	11	dep
14	,	,	,	_	13	punct
15	drug5	drug5	NN	_	13	appos
16	,	,	,	_	13	punct
17	drug6	drug6	NN	_	13	appos
18	-RRB-	-rrb-	-RRB-	_	13	punct
19	and	and	CC	_	6	cc
20	increase	increase	VB	_	6	conj
21	the	the	DT	_	22	det
22	clearance	clearance	NN	_	20	dobj
23	of	of	IN	_	24	case
24	others	other	NNS	_	22	nmod
25	-LRB-	-lrb-	-LRB-	_	26	punct
26	drug7	drug7	NN	_	24	dep
27	,	,	,	_	26	punct
28	drug8	drug8	NN	_	26	appos
29	,	,	,	_	26	punct
30	drug9	drug9	NN	_	26	appos
31	-RRB-	-rrb-	-RRB-	_	26	punct
32	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Combination	combination	NN	_	4	compound
4	drug2	drug2	NN	_	6	nsubj
5	may	may	MD	_	6	aux
6	increase	increase	VB	_	1	parataxis
7	the	the	DT	_	8	det
8	clearance	clearance	NN	_	6	dobj
9	of	of	IN	_	10	case
10	drug3	drug3	NN	_	8	nmod
11	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Combination	combination	NN	_	4	compound
4	drug2	drug2	NN	_	6	nsubj
5	may	may	MD	_	6	aux
6	inhibit	inhibit	VB	_	1	dep
7	the	the	DT	_	8	det
8	metabolism	metabolism	NN	_	6	dobj
9	of	of	IN	_	10	case
10	drug3	drug3	NN	_	8	nmod
11	,	,	,	_	6	punct
12	leading	lead	VBG	_	6	advcl
13	to	to	TO	_	16	case
14	increased	increase	VBN	_	16	amod
15	plasma	plasma	NN	_	16	compound
16	concentrations	concentration	NNS	_	12	nmod
17	;	;	:	_	6	punct

1	monitor	monitor	NN	_	3	compound
2	drug1	drug1	NN	_	3	compound
3	levels	level	NNS	_	0	ROOT
4	.	.	.	_	3	punct

1	CYP3A4	cyp3a4	NN	_	2	compound
2	inducers	inducer	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	CYP3A4	cyp3a4	NN	_	5	compound
5	inducers	inducer	NNS	_	7	nsubj
6	may	may	MD	_	7	aux
7	decrease	decrease	VB	_	2	dep
8	the	the	DT	_	9	det
9	levels/effects	levels/effects	NNS	_	7	dobj
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	.	.	.	_	2	punct

1	Example	example	NN	_	2	compound
2	inducers	inducer	NNS	_	3	nsubj
3	include	include	VBP	_	0	ROOT
4	drug1	drug1	NN	_	3	dobj
5	,	,	,	_	4	punct
6	drug2	drug2	NN	_	4	conj
7	,	,	,	_	4	punct
8	drug3	drug3	NN	_	4	conj
9	,	,	,	_	4	punct
10	drug4	drug4	NN	_	4	conj
11	,	,	,	_	4	punct
12	drug5	drug5	NN	_	4	conj
13	,	,	,	_	4	punct
14	drug6	drug6	NN	_	4	conj
15	,	,	,	_	4	punct
16	and	and	CC	_	4	cc
17	drug7	drug7	NN	_	4	conj
18	.	.	.	_	3	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	induce	induce	VB	_	1	appos
6	the	the	DT	_	7	det
7	metabolism	metabolism	NN	_	5	dobj
8	of	of	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	causing	cause	VBG	_	7	acl
11	menstrual	menstrual	JJ	_	12	amod
12	changes	change	NNS	_	10	dobj
13	;	;	:	_	1	punct

1	pregnancies	pregnancy	NNS	_	4	nsubjpass
2	have	have	VBP	_	4	aux
3	been	be	VBN	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	.	.	.	_	4	punct

1	Use	use	NN	_	8	nsubjpass
2	of	of	IN	_	4	case
3	barrier	barrier	NN	_	4	compound
4	form	form	NN	_	1	nmod
5	of	of	IN	_	6	case
6	contraception	contraception	NN	_	4	nmod
7	is	be	VBZ	_	8	auxpass
8	suggested	suggest	VBN	_	0	ROOT
9	while	while	IN	_	12	mark
10	on	on	IN	_	12	case
11	drug1	drug1	NN	_	12	compound
12	therapy	therapy	NN	_	8	advcl
13	.	.	.	_	8	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Combination	combination	NN	_	4	compound
4	drug2	drug2	NN	_	6	nsubj
5	may	may	MD	_	6	aux
6	increase	increase	VB	_	1	parataxis
7	the	the	DT	_	8	det
8	clearance	clearance	NN	_	6	dobj
9	of	of	IN	_	10	case
10	drug3	drug3	NN	_	8	nmod
11	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	drug2	drug2	NN	_	1	appos
4	-RRB-	-rrb-	-RRB-	_	3	punct
5	:	:	:	_	1	punct
6	drug3	drug3	NN	_	8	nsubj
7	may	may	MD	_	8	aux
8	decrease	decrease	VB	_	1	dep
9	plasma	plasma	NN	_	10	compound
10	levels	level	NNS	_	8	dobj
11	of	of	IN	_	12	case
12	drug4	drug4	NN	_	10	nmod
13	;	;	:	_	8	punct

1	use	use	NN	_	6	nsubjpass
2	of	of	IN	_	4	case
3	a	a	DT	_	4	det
4	drug1	drug1	NN	_	1	nmod
5	is	be	VBZ	_	6	auxpass
6	recommended	recommend	VBN	_	0	ROOT
7	.	.	.	_	6	punct

1	No	no	DT	_	2	neg
2	data	datum	NNS	_	0	ROOT
3	for	for	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	;	;	:	_	2	punct

1	incomplete	incomplete	JJ	_	2	amod
2	data	datum	NNS	_	0	ROOT
3	for	for	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	inhibit	inhibit	VB	_	1	dep
6	the	the	DT	_	7	det
7	metabolism	metabolism	NN	_	5	dobj
8	of	of	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	,	,	,	_	5	punct
11	leading	lead	VBG	_	5	advcl
12	to	to	TO	_	15	case
13	increased	increase	VBN	_	15	amod
14	plasma	plasma	NN	_	15	compound
15	concentrations	concentration	NNS	_	11	nmod
16	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	13	nsubjpass
4	,	,	,	_	3	punct
5	drug3	drug3	NN	_	3	conj
6	,	,	,	_	3	punct
7	drug4	drug4	NN	_	3	conj
8	,	,	,	_	3	punct
9	and	and	CC	_	3	cc
10	drug5	drug5	NN	_	3	conj
11	have	have	VBP	_	13	aux
12	been	be	VBN	_	13	auxpass
13	shown	show	VBN	_	1	appos
14	to	to	TO	_	15	mark
15	decrease	decrease	VB	_	13	xcomp
16	plasma	plasma	NN	_	17	compound
17	levels	level	NNS	_	15	dobj
18	of	of	IN	_	19	case
19	drug6	drug6	NN	_	17	nmod
20	;	;	:	_	1	punct

1	use	use	NN	_	6	nsubjpass
2	of	of	IN	_	4	case
3	a	a	DT	_	4	det
4	drug1	drug1	NN	_	1	nmod
5	is	be	VBZ	_	6	auxpass
6	recommended	recommend	VBN	_	0	ROOT
7	.	.	.	_	6	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	shown	show	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	increase	increase	VB	_	4	xcomp
7	plasma	plasma	NN	_	8	compound
8	levels	level	NNS	_	6	dobj
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	.	.	.	_	4	punct

1	No	no	DT	_	2	neg
2	data	datum	NNS	_	0	ROOT
3	for	for	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	nsubj
4	increases	increase	VBZ	_	1	dep
5	the	the	DT	_	6	det
6	metabolism	metabolism	NN	_	4	dobj
7	of	of	IN	_	8	case
8	drug3	drug3	NN	_	6	nmod
9	and	and	CC	_	6	cc
10	some	some	DT	_	15	det
11	drug4	drug4	NN	_	15	compound
12	-LRB-	-lrb-	-LRB-	_	13	punct
13	drug5	drug5	NN	_	11	appos
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	resulting	result	VBG	_	6	conj
16	in	in	IN	_	19	case
17	decreased	decrease	VBN	_	19	amod
18	contraceptive	contraceptive	JJ	_	19	amod
19	effectiveness	effectiveness	NN	_	15	nmod
20	and	and	CC	_	4	cc
21	increased	increase	VBD	_	23	amod
22	menstrual	menstrual	JJ	_	23	amod
23	irregularities	irregularity	NNS	_	4	conj
24	.	.	.	_	1	punct

1	Use	use	NN	_	6	nsubjpass
2	of	of	IN	_	4	case
3	a	a	DT	_	4	det
4	drug1	drug1	NN	_	1	nmod
5	is	be	VBZ	_	6	auxpass
6	recommended	recommend	VBN	_	0	ROOT
7	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Combination	combination	NN	_	4	compound
4	drug2	drug2	NN	_	6	nsubj
5	may	may	MD	_	6	aux
6	increase	increase	VB	_	1	parataxis
7	the	the	DT	_	8	det
8	clearance	clearance	NN	_	6	dobj
9	of	of	IN	_	10	case
10	drug3	drug3	NN	_	8	nmod
11	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	increase	increase	VB	_	1	dep
6	the	the	DT	_	8	det
7	serum	serum	NN	_	8	compound
8	concentration	concentration	NN	_	5	dobj
9	of	of	IN	_	10	case
10	drug3	drug3	NN	_	8	nmod
11	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	inhibit	inhibit	VB	_	1	dep
6	the	the	DT	_	7	det
7	metabolism	metabolism	NN	_	5	dobj
8	of	of	IN	_	9	case
9	drug3	drug3	NN	_	7	nmod
10	,	,	,	_	5	punct
11	leading	lead	VBG	_	5	advcl
12	to	to	TO	_	15	case
13	increased	increase	VBN	_	15	amod
14	plasma	plasma	NN	_	15	compound
15	concentrations	concentration	NNS	_	11	nmod
16	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	drug2	drug2	NN	_	1	dep
4	,	,	,	_	3	punct
5	drug3	drug3	NN	_	3	appos
6	,	,	,	_	3	punct
7	drug4	drug4	NN	_	3	appos
8	-RRB-	-rrb-	-RRB-	_	3	punct
9	:	:	:	_	1	punct
10	Metabolism	metabolism	NN	_	13	nsubjpass
11	may	may	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	inhibited	inhibit	VBN	_	1	dep
14	by	by	IN	_	15	case
15	drug5	drug5	NN	_	13	nmod
16	,	,	,	_	13	punct
17	increasing	increase	VBG	_	13	xcomp
18	plasma	plasma	NN	_	19	compound
19	levels	level	NNS	_	17	dobj
20	of	of	IN	_	21	case
21	drug6	drug6	NN	_	19	nmod
22	;	;	:	_	1	punct

1	use	use	NN	_	2	compound
2	caution	caution	NN	_	0	ROOT
3	.	.	.	_	2	punct

1	drug1	drug1	NN	_	11	compound
2	/	/	:	_	3	punct
3	NUTRITION	NUTRITION	NNP	_	11	dep
4	/	/	:	_	3	punct
5	HERB	HERB	NNP	_	6	compound
6	INTERACTIONS	INTERACTIONS	NNPS	_	3	dep
7	:	:	:	_	3	punct
8	Food	Food	NNP	_	3	dep
9	:	:	:	_	3	punct
10	CNS	cns	NN	_	11	compound
11	effects	effect	NNS	_	16	nsubjpass
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	may	may	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	enhanced	enhance	VBN	_	0	ROOT
17	if	if	IN	_	20	mark
18	drug3	drug3	NN	_	20	nsubjpass
19	are	be	VBP	_	20	auxpass
20	used	use	VBN	_	16	advcl
21	concurrently	concurrently	RB	_	20	advmod
22	with	with	IN	_	23	case
23	drug4	drug4	NN	_	20	nmod
24	.	.	.	_	16	punct

1	Grapefruit	grapefruit	NN	_	2	compound
2	juice	juice	NN	_	3	nsubj
3	increases	increase	VBZ	_	0	ROOT
4	drug1	drug1	NN	_	5	compound
5	concentrations	concentration	NNS	_	3	dobj
6	and	and	CC	_	3	cc
7	would	would	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	expected	expect	VBN	_	3	conj
10	to	to	TO	_	11	mark
11	increase	increase	VB	_	9	xcomp
12	drug2	drug2	NN	_	14	compound
13	serum	serum	NN	_	14	compound
14	levels	level	NNS	_	11	dobj
15	as	as	RB	_	16	case
16	well	well	RB	_	11	advmod
17	;	;	:	_	3	punct

1	clinical	clinical	JJ	_	2	amod
2	implications	implication	NNS	_	4	nsubj
3	are	be	VBP	_	4	cop
4	unclear	unclear	JJ	_	0	ROOT
5	.	.	.	_	4	punct

1	Herb/Nutraceutical	Herb/Nutraceutical	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	St	St	NNP	_	5	compound
4	Johns	Johns	NNP	_	5	compound
5	wort	wort	NN	_	7	nsubj
6	may	may	MD	_	7	aux
7	decrease	decrease	VB	_	1	dep
8	the	the	DT	_	9	det
9	effectiveness	effectiveness	NN	_	7	dobj
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	by	by	IN	_	13	mark
13	inducing	induce	VBG	_	7	advcl
14	hepatic	hepatic	JJ	_	15	amod
15	enzymes	enzyme	NNS	_	13	dobj
16	.	.	.	_	1	punct

1	Avoid	avoid	VB	_	0	ROOT
2	dong	dong	FW	_	3	compound
3	quai	quai	FW	_	1	dobj
4	and	and	CC	_	3	cc
5	black	black	JJ	_	6	amod
6	cohosh	cohosh	NN	_	3	conj
7	-LRB-	-lrb-	-LRB-	_	8	punct
8	have	have	VB	_	1	parataxis
9	estrogen	estrogen	NN	_	10	compound
10	activity	activity	NN	_	8	dobj
11	-RRB-	-rrb-	-RRB-	_	8	punct
12	.	.	.	_	1	punct

1	Avoid	avoid	VB	_	0	ROOT
2	saw	saw	NN	_	3	compound
3	palmetto	palmetto	NN	_	1	dobj
4	,	,	,	_	3	punct
5	red	red	JJ	_	6	amod
6	clover	clover	NN	_	3	conj
7	,	,	,	_	3	punct
8	ginseng	ginseng	NN	_	3	conj
9	.	.	.	_	1	punct

1	No	no	DT	_	4	neg
2	drug	drug	NN	_	4	compound
3	interaction	interaction	NN	_	4	compound
4	studies	study	NNS	_	7	nsubjpass
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	conducted	conduct	VBN	_	0	ROOT
8	for	for	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	,	,	,	_	7	punct
11	however	however	RB	_	22	advmod
12	the	the	DT	_	13	det
13	use	use	NN	_	22	nsubj
14	of	of	IN	_	17	case
15	orally	orally	RB	_	16	advmod
16	administered	administer	VBN	_	17	amod
17	drug2	drug2	NN	_	13	nmod
18	could	could	MD	_	22	aux
19	,	,	,	_	22	punct
20	theoretically	theoretically	RB	_	22	advmod
21	,	,	,	_	22	punct
22	interfere	interfere	VBP	_	7	parataxis
23	with	with	IN	_	25	case
24	the	the	DT	_	25	det
25	release	release	NN	_	22	nmod
26	of	of	IN	_	27	case
27	drug3	drug3	NN	_	25	nmod
28	in	in	IN	_	30	case
29	the	the	DT	_	30	det
30	colon	colon	NN	_	25	nmod
31	.	.	.	_	7	punct

1	The	the	DT	_	3	det
2	pharmacokinetic	pharmacokinetic	JJ	_	3	amod
3	interactions	interaction	NNS	_	9	nsubj
4	listed	list	VBN	_	3	acl
5	below	below	RB	_	4	advmod
6	are	be	VBP	_	9	cop
7	potentially	potentially	RB	_	9	advmod
8	clinically	clinically	RB	_	9	advmod
9	important	important	JJ	_	0	ROOT
10	.	.	.	_	9	punct

1	Drugs	drug	NNS	_	14	nsubj
2	that	that	WDT	_	3	nsubj
3	induce	induce	VBP	_	1	acl:relcl
4	hepatic	hepatic	JJ	_	5	amod
5	enzymes	enzyme	NNS	_	3	dobj
6	such	such	JJ	_	8	case
7	as	as	IN	_	6	mwe
8	drug1	drug1	NN	_	5	nmod
9	,	,	,	_	8	punct
10	drug2	drug2	NN	_	8	conj
11	and	and	CC	_	8	cc
12	drug3	drug3	NN	_	8	conj
13	may	may	MD	_	14	aux
14	increase	increase	VB	_	0	ROOT
15	the	the	DT	_	16	det
16	clearance	clearance	NN	_	14	dobj
17	of	of	IN	_	18	case
18	drug4	drug4	NN	_	16	nmod
19	and	and	CC	_	14	cc
20	may	may	MD	_	21	aux
21	require	require	VB	_	14	conj
22	increases	increase	NNS	_	21	dobj
23	in	in	IN	_	25	case
24	drug5	drug5	NN	_	25	compound
25	dose	dose	NN	_	22	nmod
26	to	to	TO	_	27	mark
27	achieve	achieve	VB	_	21	xcomp
28	the	the	DT	_	30	det
29	desired	desire	VBN	_	30	amod
30	response	response	NN	_	27	dobj
31	.	.	.	_	14	punct

1	Drugs	drug	NNS	_	8	nsubj
2	such	such	JJ	_	4	case
3	as	as	IN	_	2	mwe
4	drug1	drug1	NN	_	1	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	may	may	MD	_	8	aux
8	inhibit	inhibit	VB	_	0	ROOT
9	the	the	DT	_	10	det
10	metabolism	metabolism	NN	_	8	dobj
11	of	of	IN	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	and	and	CC	_	8	cc
14	thus	thus	RB	_	15	advmod
15	decrease	decrease	VB	_	8	conj
16	their	they	PRP$	_	17	nmod:poss
17	clearance	clearance	NN	_	15	dobj
18	.	.	.	_	8	punct

1	Therefore	therefore	RB	_	9	advmod
2	,	,	,	_	9	punct
3	the	the	DT	_	4	det
4	dose	dose	NN	_	9	nsubjpass
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	titrated	titrate	VBN	_	0	ROOT
10	to	to	TO	_	11	mark
11	avoid	avoid	VB	_	9	xcomp
12	steroid	steroid	NN	_	13	compound
13	toxicity	toxicity	NN	_	11	dobj
14	.	.	.	_	9	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	increase	increase	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	clearance	clearance	NN	_	3	dobj
6	of	of	IN	_	10	case
7	chronic	chronic	JJ	_	10	amod
8	high	high	JJ	_	10	amod
9	dose	dose	NN	_	10	compound
10	drug2	drug2	NN	_	5	nmod
11	.	.	.	_	3	punct

1	This	this	DT	_	3	nsubj
2	could	could	MD	_	3	aux
3	lead	lead	VB	_	0	ROOT
4	to	to	TO	_	8	case
5	decreased	decrease	VBN	_	8	amod
6	drug1	drug1	NN	_	8	compound
7	serum	serum	NN	_	8	compound
8	levels	level	NNS	_	3	nmod
9	or	or	CC	_	3	cc
10	increase	increase	VB	_	3	conj
11	the	the	DT	_	12	det
12	risk	risk	NN	_	10	dobj
13	of	of	IN	_	15	case
14	drug2	drug2	NN	_	15	compound
15	toxicity	toxicity	NN	_	12	nmod
16	when	when	WRB	_	19	advmod
17	drug3	drug3	NN	_	19	nsubjpass
18	is	be	VBZ	_	19	auxpass
19	withdrawn	withdraw	VBN	_	10	advcl
20	.	.	.	_	3	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	cautiously	cautiously	RB	_	4	advmod
6	in	in	IN	_	7	case
7	conjunction	conjunction	NN	_	4	nmod
8	with	with	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	in	in	IN	_	11	case
11	patients	patient	NNS	_	9	nmod
12	suffering	suffer	VBG	_	11	acl
13	from	from	IN	_	14	case
14	hypopro-thrombinemia	hypopro-thrombinemia	JJ	_	12	nmod
15	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	9	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	on	on	IN	_	7	case
6	oral	oral	JJ	_	7	amod
7	drug2	drug2	NN	_	2	nmod
8	is	be	VBZ	_	9	cop
9	variable	variable	JJ	_	0	ROOT
10	.	.	.	_	9	punct

1	There	there	EX	_	2	expl
2	are	be	VBP	_	0	ROOT
3	reports	report	NNS	_	2	nsubj
4	of	of	IN	_	10	case
5	enhanced	enhance	VBN	_	10	amod
6	as	as	RB	_	5	cc
7	well	well	RB	_	6	mwe
8	as	as	IN	_	6	mwe
9	diminished	diminished	JJ	_	5	conj
10	effects	effect	NNS	_	3	nmod
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	when	when	WRB	_	14	advmod
14	given	give	VBN	_	2	advcl
15	concurrently	concurrently	RB	_	14	advmod
16	with	with	IN	_	17	case
17	drug2	drug2	NN	_	14	nmod
18	.	.	.	_	2	punct

1	Therefore	therefore	RB	_	7	advmod
2	,	,	,	_	7	punct
3	coagulation	coagulation	NN	_	4	compound
4	indices	index	NNS	_	7	nsubjpass
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	monitored	monitor	VBN	_	0	ROOT
8	to	to	TO	_	9	mark
9	maintain	maintain	VB	_	7	xcomp
10	the	the	DT	_	13	det
11	desired	desire	VBN	_	13	amod
12	anticoagulant	anticoagulant	JJ	_	13	amod
13	effect	effect	NN	_	9	dobj
14	.	.	.	_	7	punct

1	Drug	drug	NN	_	2	compound
2	Interactions	interaction	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	a.	a.	VB	_	2	dep
5	Drugs	drug	NNS	_	8	compound
6	Enhancing	enhancing	NN	_	8	compound
7	drug1	drug1	NN	_	8	compound
8	Effect	effect	NN	_	4	dobj
9	:	:	:	_	4	punct
10	Oral	oral	JJ	_	11	amod
11	drug2	drug2	NN	_	4	dep
12	:	:	:	_	11	punct
13	drug3	drug3	NN	_	15	nsubj
14	may	may	MD	_	15	aux
15	prolong	prolong	VB	_	11	dep
16	the	the	DT	_	19	det
17	one-stage	one-stage	JJ	_	19	amod
18	prothrombin	prothrombin	NN	_	19	compound
19	time	time	NN	_	15	dobj
20	.	.	.	_	2	punct

1	Therefore	therefore	RB	_	0	ROOT
2	,	,	,	_	1	punct
3	when	when	WRB	_	6	advmod
4	drug1	drug1	NN	_	6	nsubjpass
5	is	be	VBZ	_	6	auxpass
6	given	give	VBN	_	2	root
7	with	with	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	or	or	CC	_	8	cc
10	drug3	drug3	NN	_	8	conj
11	,	,	,	_	6	punct
12	a	a	DT	_	13	det
13	period	period	NN	_	11	root
14	of	of	IN	_	18	case
15	at	at	IN	_	16	case
16	least	least	JJS	_	17	nmod:npmod
17	5	5	CD	_	18	nummod
18	hours	hour	NNS	_	13	nmod
19	after	after	IN	_	23	case
20	the	the	DT	_	23	det
21	last	last	JJ	_	23	amod
22	intravenous	intravenous	JJ	_	23	amod
23	dose	dose	NN	_	13	nmod
24	or	or	CC	_	23	cc
25	24	24	CD	_	26	nummod
26	hours	hour	NNS	_	23	conj
27	after	after	IN	_	33	mark
28	the	the	DT	_	31	det
29	last	last	JJ	_	31	amod
30	subcutaneous	subcutaneous	JJ	_	31	amod
31	dose	dose	NN	_	33	nsubj
32	should	should	MD	_	33	aux
33	elapse	elapse	VB	_	13	acl
34	before	before	IN	_	37	mark
35	blood	blood	NN	_	37	nsubjpass
36	is	be	VBZ	_	37	auxpass
37	drawn	draw	VBN	_	33	advcl
38	if	if	IN	_	43	mark
39	a	a	DT	_	42	det
40	valid	valid	JJ	_	42	amod
41	prothrombin	prothrombin	NN	_	42	compound
42	time	time	NN	_	43	nsubj
43	is	be	VBZ	_	37	advcl
44	to	to	TO	_	46	mark
45	be	be	VB	_	46	auxpass
46	obtained	obtain	VBN	_	43	xcomp
47	.	.	.	_	13	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Drugs	drug	NNS	_	36	nsubj
4	such	such	JJ	_	6	case
5	as	as	IN	_	4	mwe
6	drug2	drug2	NN	_	3	nmod
7	,	,	,	_	6	punct
8	drug3	drug3	NN	_	6	conj
9	,	,	,	_	6	punct
10	drug4	drug4	NN	_	6	conj
11	,	,	,	_	6	punct
12	drug5	drug5	NN	_	6	conj
13	,	,	,	_	6	punct
14	drug6	drug6	NN	_	6	conj
15	,	,	,	_	6	punct
16	drug7	drug7	NN	_	6	conj
17	,	,	,	_	6	punct
18	drug8	drug8	NN	_	6	conj
19	and	and	CC	_	6	cc
20	others	other	NNS	_	6	conj
21	that	that	WDT	_	22	nsubj
22	interfere	interfere	VBP	_	3	acl:relcl
23	with	with	IN	_	25	case
24	platelet-aggregation	platelet-aggregation	JJ	_	25	amod
25	reactions	reaction	NNS	_	22	nmod
26	-LRB-	-lrb-	-LRB-	_	30	punct
27	the	the	DT	_	30	det
28	main	main	JJ	_	30	amod
29	hemostatic	hemostatic	JJ	_	30	amod
30	defense	defense	NN	_	25	dep
31	of	of	IN	_	33	case
32	heparinized	heparinized	JJ	_	33	amod
33	patients	patient	NNS	_	30	nmod
34	-RRB-	-rrb-	-RRB-	_	30	punct
35	may	may	MD	_	36	aux
36	induce	induce	VB	_	1	appos
37	bleeding	bleeding	NN	_	36	dobj
38	and	and	CC	_	36	cc
39	should	should	MD	_	41	aux
40	be	be	VB	_	41	auxpass
41	used	use	VBN	_	36	conj
42	with	with	IN	_	43	case
43	caution	caution	NN	_	41	nmod
44	in	in	IN	_	45	case
45	patients	patient	NNS	_	43	nmod
46	receiving	receive	VBG	_	45	acl
47	drug9	drug9	NN	_	46	dobj
48	.	.	.	_	1	punct

1	The	the	DT	_	3	det
2	anticoagulant	anticoagulant	JJ	_	3	amod
3	effect	effect	NN	_	7	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	is	be	VBZ	_	7	auxpass
7	enhanced	enhance	VBN	_	0	ROOT
8	by	by	IN	_	10	case
9	concurrent	concurrent	JJ	_	10	amod
10	treatment	treatment	NN	_	7	nmod
11	with	with	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	-LRB-	-lrb-	-LRB-	_	14	punct
14	human	human	JJ	_	12	dep
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	in	in	IN	_	17	case
17	patients	patient	NNS	_	10	nmod
18	with	with	IN	_	22	case
19	hereditary	hereditary	JJ	_	22	amod
20	antithrombin	antithrombin	NN	_	22	compound
21	III	iii	CD	_	22	nummod
22	deficiency	deficiency	NN	_	17	nmod
23	.	.	.	_	7	punct

1	Thus	thus	RB	_	8	advmod
2	in	in	IN	_	5	mark
3	order	order	NN	_	2	mwe
4	to	to	TO	_	5	mark
5	avoid	avoid	VB	_	8	advcl
6	bleeding	bleeding	NN	_	5	dobj
7	,	,	,	_	8	punct
8	reduced	reduce	VBD	_	13	csubjpass
9	dosage	dosage	NN	_	8	dobj
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	is	be	VBZ	_	13	auxpass
13	recommended	recommend	VBN	_	0	ROOT
14	during	during	IN	_	15	case
15	treatment	treatment	NN	_	13	nmod
16	with	with	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	-LRB-	-lrb-	-LRB-	_	19	punct
19	human	human	JJ	_	17	dep
20	-RRB-	-rrb-	-RRB-	_	19	punct
21	.	.	.	_	13	punct

1	b.	b.	NN	_	0	ROOT

1	Drugs	drug	NNS	_	0	ROOT
2	Decreasing	decrease	VBG	_	1	acl
3	drug1	drug1	NN	_	4	compound
4	Effect	effect	NN	_	2	dobj
5	:	:	:	_	1	punct
6	drug2	drug2	NN	_	16	nsubj
7	,	,	,	_	6	punct
8	drug3	drug3	NN	_	6	conj
9	,	,	,	_	6	punct
10	drug4	drug4	NN	_	6	conj
11	,	,	,	_	6	punct
12	or	or	CC	_	6	cc
13	drug5	drug5	NN	_	6	conj
14	may	may	MD	_	16	aux
15	partially	partially	RB	_	16	advmod
16	counteract	counteract	VB	_	1	dep
17	the	the	DT	_	19	det
18	anticoagulant	anticoagulant	JJ	_	19	amod
19	action	action	NN	_	16	dobj
20	of	of	IN	_	21	case
21	drug6	drug6	NN	_	19	nmod
22	.	.	.	_	16	punct

1	drug1	drug1	NN	_	2	compound
2	Injection	injection	NN	_	6	nsubjpass
3	should	should	MD	_	6	aux
4	not	not	RB	_	6	neg
5	be	be	VB	_	6	auxpass
6	mixed	mix	VBN	_	0	ROOT
7	with	with	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	,	,	,	_	8	punct
10	drug3	drug3	NN	_	8	conj
11	,	,	,	_	8	punct
12	drug4	drug4	NN	_	8	conj
13	,	,	,	_	8	punct
14	or	or	CC	_	8	cc
15	drug5	drug5	NN	_	8	conj
16	,	,	,	_	6	punct
17	since	since	IN	_	21	mark
18	it	it	PRP	_	21	nsubjpass
19	has	have	VBZ	_	21	aux
20	been	be	VBN	_	21	auxpass
21	reported	report	VBN	_	6	advcl
22	that	that	IN	_	26	mark
23	these	these	DT	_	24	det
24	drugs	drug	NNS	_	26	nsubj
25	are	be	VBP	_	26	cop
26	incompatible	incompatible	JJ	_	21	ccomp
27	with	with	IN	_	28	case
28	drug6	drug6	NN	_	26	nmod
29	and	and	CC	_	28	cc
30	a	a	DT	_	31	det
31	precipitate	precipitate	NN	_	28	conj
32	may	may	MD	_	33	aux
33	form	form	VB	_	26	dep
34	.	.	.	_	6	punct

1	Drug	drug	NN	_	6	compound
2	/	/	:	_	6	punct
3	Laboratory	Laboratory	NNP	_	6	compound
4	Tests	Tests	NNP	_	6	compound
5	Interactions	interaction	NNS	_	6	compound
6	Hyperaminotransferasemia	Hyperaminotransferasemia	NNP	_	0	ROOT
7	:	:	:	_	6	punct
8	Significant	significant	JJ	_	9	amod
9	elevations	elevation	NNS	_	6	dep
10	of	of	IN	_	11	case
11	aminotransferase	aminotransferase	NN	_	9	nmod
12	-LRB-	-lrb-	-LRB-	_	13	punct
13	SGOT	sgot	NN	_	11	dep
14	-LSB-	-lsb-	-LRB-	_	15	punct
15	S-AST	s-ast	NN	_	13	appos
16	-RSB-	-rsb-	-RRB-	_	15	punct
17	and	and	CC	_	13	cc
18	SGPT	sgpt	NN	_	13	conj
19	-LSB-	-lsb-	-LRB-	_	20	punct
20	S-ALT	s-alt	NN	_	18	appos
21	-RSB-	-rsb-	-RRB-	_	20	punct
22	-RRB-	-rrb-	-RRB-	_	13	punct
23	levels	level	NNS	_	25	nsubj
24	have	have	VBP	_	25	aux
25	occurred	occur	VBN	_	9	acl:relcl
26	in	in	IN	_	29	case
27	a	a	DT	_	29	det
28	high	high	JJ	_	29	amod
29	percentage	percentage	NN	_	25	nmod
30	of	of	IN	_	31	case
31	patients	patient	NNS	_	29	nmod
32	-LRB-	-lrb-	-LRB-	_	35	punct
33	and	and	CC	_	35	cc
34	healthy	healthy	JJ	_	35	amod
35	subjects	subject	NNS	_	25	dep
36	-RRB-	-rrb-	-RRB-	_	35	punct
37	who	who	WP	_	39	nsubj
38	have	have	VBP	_	39	aux
39	received	receive	VBN	_	35	acl:relcl
40	drug1	drug1	NN	_	39	dobj
41	.	.	.	_	6	punct

1	Since	since	IN	_	5	mark
2	aminotransferase	aminotransferase	NN	_	3	compound
3	determinations	determination	NNS	_	5	nsubj
4	are	be	VBP	_	5	cop
5	important	important	JJ	_	20	advcl
6	in	in	IN	_	9	case
7	the	the	DT	_	9	det
8	differential	differential	JJ	_	9	amod
9	diagnosis	diagnosis	NN	_	5	nmod
10	of	of	IN	_	12	case
11	myocardial	myocardial	JJ	_	12	amod
12	infarction	infarction	NN	_	9	nmod
13	,	,	,	_	12	punct
14	liver	liver	NN	_	15	compound
15	disease	disease	NN	_	12	conj
16	and	and	CC	_	12	cc
17	pulmonary	pulmonary	JJ	_	18	amod
18	emboli	embolus	NNS	_	12	conj
19	,	,	,	_	20	punct
20	rises	rise	VBZ	_	0	ROOT
21	that	that	IN	_	24	nsubjpass
22	might	might	MD	_	24	aux
23	be	be	VB	_	24	auxpass
24	caused	cause	VBN	_	20	ccomp
25	by	by	IN	_	26	case
26	drugs	drug	NNS	_	24	nmod
27	-LRB-	-lrb-	-LRB-	_	28	punct
28	drug1	drug1	NN	_	26	appos
29	-RRB-	-rrb-	-RRB-	_	28	punct
30	should	should	MD	_	32	aux
31	be	be	VB	_	32	auxpass
32	interpreted	interpret	VBN	_	24	xcomp
33	with	with	IN	_	34	case
34	caution	caution	NN	_	32	nmod
35	.	.	.	_	20	punct

1	The	the	DT	_	3	det
2	following	follow	VBG	_	3	amod
3	drugs	drug	NNS	_	6	nsubjpass
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	auxpass
6	coadministered	coadminister	VBN	_	0	ROOT
7	with	with	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	and	and	CC	_	6	cc
10	have	have	VBP	_	12	aux
11	not	not	RB	_	12	neg
12	altered	alter	VBN	_	6	conj
13	its	its	PRP$	_	14	nmod:poss
14	pharmacokinetics	pharmacokinetic	NNS	_	12	dobj
15	:	:	:	_	14	punct
16	drug2	drug2	NN	_	14	dep
17	,	,	,	_	16	punct
18	drug3	drug3	NN	_	16	conj
19	,	,	,	_	16	punct
20	drug4	drug4	NN	_	16	conj
21	,	,	,	_	16	punct
22	and	and	CC	_	16	cc
23	drug5	drug5	NN	_	16	conj
24	.	.	.	_	6	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	12	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	9	case
6	the	the	DT	_	9	det
7	oral	oral	JJ	_	9	amod
8	drug2	drug2	NN	_	9	compound
9	drug3	drug3	NN	_	2	nmod
10	has	have	VBZ	_	12	aux
11	been	be	VBN	_	12	auxpass
12	shown	show	VBN	_	0	ROOT
13	not	not	RB	_	15	neg
14	to	to	TO	_	15	mark
15	potentiate	potentiate	VB	_	12	xcomp
16	the	the	DT	_	18	det
17	anticoagulant	anticoagulant	JJ	_	18	amod
18	effect	effect	NN	_	15	dobj
19	of	of	IN	_	20	case
20	drug4	drug4	NN	_	18	nmod
21	.	.	.	_	12	punct

1	Catecholamine-depleting	catecholamine-depleting	JJ	_	2	amod
2	drugs	drug	NNS	_	9	nsubj
3	-LRB-	-lrb-	-LRB-	_	6	punct
4	e.g.	e.g.	FW	_	6	dep
5	,	,	,	_	6	punct
6	drug1	drug1	NN	_	2	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	may	may	MD	_	9	aux
9	have	have	VB	_	0	ROOT
10	an	a	DT	_	12	det
11	additive	additive	JJ	_	12	amod
12	effect	effect	NN	_	9	dobj
13	when	when	WRB	_	14	advmod
14	given	give	VBN	_	9	advcl
15	with	with	IN	_	17	case
16	drug2	drug2	NN	_	17	compound
17	agents	agent	NNS	_	14	nmod
18	.	.	.	_	9	punct

1	Patients	patient	NNS	_	14	nsubjpass
2	treated	treat	VBN	_	1	acl
3	with	with	IN	_	5	case
4	a	a	DT	_	5	det
5	drug1	drug1	NN	_	2	nmod
6	plus	plus	CC	_	5	cc
7	a	a	DT	_	9	det
8	catecholamine	catecholamine	NN	_	9	compound
9	depletor	depletor	NN	_	5	conj
10	should	should	MD	_	14	aux
11	therefore	therefore	RB	_	14	advmod
12	be	be	VB	_	14	auxpass
13	closely	closely	RB	_	14	advmod
14	observed	observe	VBN	_	0	ROOT
15	for	for	IN	_	16	case
16	evidence	evidence	NN	_	14	nmod
17	of	of	IN	_	18	case
18	hypotension	hypotension	NN	_	16	nmod
19	or	or	CC	_	18	cc
20	marked	marked	JJ	_	21	amod
21	bradycardia	bradycardia	NN	_	18	conj
22	,	,	,	_	16	punct
23	which	which	WDT	_	25	nsubj
24	may	may	MD	_	25	aux
25	produce	produce	VB	_	16	acl:relcl
26	vertigo	vertigo	NN	_	25	dobj
27	,	,	,	_	26	punct
28	syncope	syncope	NN	_	26	conj
29	,	,	,	_	26	punct
30	or	or	CC	_	26	cc
31	postural	postural	JJ	_	32	amod
32	hypotension	hypotension	NN	_	26	conj
33	.	.	.	_	14	punct

1	Should	should	MD	_	4	aux
2	it	it	PRP	_	4	nsubjpass
3	be	be	VB	_	4	auxpass
4	decided	decide	VBN	_	20	advcl
5	to	to	TO	_	6	mark
6	discontinue	discontinue	VB	_	4	xcomp
7	therapy	therapy	NN	_	6	dobj
8	in	in	IN	_	9	case
9	patients	patient	NNS	_	7	nmod
10	receiving	receive	VBG	_	9	acl
11	drug1	drug1	NN	_	10	dobj
12	and	and	CC	_	11	cc
13	drug2	drug2	NN	_	11	conj
14	concurrently	concurrently	RB	_	6	advmod
15	,	,	,	_	20	punct
16	the	the	DT	_	17	det
17	drug3	drug3	NN	_	20	nsubjpass
18	should	should	MD	_	20	aux
19	be	be	VB	_	20	auxpass
20	discontinued	discontinue	VBN	_	0	ROOT
21	slowly	slowly	RB	_	20	advmod
22	over	over	IN	_	24	case
23	several	several	JJ	_	24	amod
24	days	day	NNS	_	20	nmod
25	before	before	IN	_	28	case
26	the	the	DT	_	28	det
27	gradual	gradual	JJ	_	28	amod
28	withdrawal	withdrawal	NN	_	20	nmod
29	of	of	IN	_	30	case
30	drug4	drug4	NN	_	28	nmod
31	.	.	.	_	20	punct

1	Literature	literature	NN	_	2	compound
2	reports	report	NNS	_	3	nsubj
3	suggest	suggest	VBP	_	0	ROOT
4	that	that	IN	_	9	mark
5	oral	oral	JJ	_	6	amod
6	drug1	drug1	NN	_	9	nsubjpass
7	may	may	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	used	use	VBN	_	3	ccomp
10	in	in	IN	_	11	case
11	combination	combination	NN	_	9	nmod
12	with	with	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	when	when	WRB	_	18	advmod
15	heart	heart	NN	_	16	compound
16	function	function	NN	_	18	nsubj
17	is	be	VBZ	_	18	cop
18	normal	normal	JJ	_	9	advcl
19	,	,	,	_	9	punct
20	but	but	CC	_	9	cc
21	should	should	MD	_	23	aux
22	be	be	VB	_	23	auxpass
23	avoided	avoid	VBN	_	9	conj
24	in	in	IN	_	25	case
25	patients	patient	NNS	_	23	nmod
26	with	with	IN	_	29	case
27	impaired	impaired	JJ	_	29	amod
28	cardiac	cardiac	JJ	_	29	amod
29	function	function	NN	_	25	nmod
30	.	.	.	_	3	punct

1	Hypotension	hypotension	NN	_	13	nmod:tmod
2	,	,	,	_	13	punct
3	AV	av	NN	_	5	compound
4	conduction	conduction	NN	_	5	compound
5	disturbances	disturbance	NNS	_	13	nsubjpass
6	,	,	,	_	5	punct
7	and	and	CC	_	5	cc
8	left	leave	VBD	_	5	conj
9	ventricular	ventricular	JJ	_	10	amod
10	failure	failure	NN	_	8	dobj
11	have	have	VBP	_	13	aux
12	been	be	VBN	_	13	auxpass
13	reported	report	VBN	_	0	ROOT
14	in	in	IN	_	16	case
15	some	some	DT	_	16	det
16	patients	patient	NNS	_	13	nmod
17	receiving	receive	VBG	_	16	acl
18	drug1	drug1	NN	_	17	dobj
19	when	when	WRB	_	24	advmod
20	an	a	DT	_	22	det
21	oral	oral	JJ	_	22	amod
22	drug2	drug2	NN	_	24	nsubjpass
23	was	be	VBD	_	24	auxpass
24	added	add	VBN	_	17	advcl
25	to	to	TO	_	28	case
26	the	the	DT	_	28	det
27	treatment	treatment	NN	_	28	compound
28	regimen	regimen	NN	_	24	nmod
29	.	.	.	_	13	punct

1	Hypotension	hypotension	NN	_	4	nsubj
2	was	be	VBD	_	4	cop
3	more	more	RBR	_	4	advmod
4	likely	likely	JJ	_	0	ROOT
5	to	to	TO	_	6	mark
6	occur	occur	VB	_	4	xcomp
7	if	if	IN	_	12	mark
8	the	the	DT	_	9	det
9	drug1	drug1	NN	_	12	nsubj
10	were	be	VBD	_	12	cop
11	a	a	DT	_	12	det
12	drug2	drug2	NN	_	6	advcl
13	,	,	,	_	12	punct
14	e.g.	e.g.	FW	_	12	conj
15	,	,	,	_	12	punct
16	drug3	drug3	NN	_	12	conj
17	,	,	,	_	12	punct
18	while	while	IN	_	34	mark
19	left	leave	VBN	_	21	amod
20	ventricular	ventricular	JJ	_	21	amod
21	failure	failure	NN	_	34	nsubj
22	and	and	CC	_	21	cc
23	AV	av	NN	_	25	compound
24	conduction	conduction	NN	_	25	compound
25	disturbances	disturbance	NNS	_	21	conj
26	,	,	,	_	21	punct
27	including	include	VBG	_	30	case
28	complete	complete	JJ	_	30	amod
29	heart	heart	NN	_	30	compound
30	block	block	NN	_	21	nmod
31	,	,	,	_	21	punct
32	were	be	VBD	_	34	cop
33	more	more	RBR	_	34	advmod
34	likely	likely	JJ	_	12	advcl
35	to	to	TO	_	36	mark
36	occur	occur	VB	_	34	xcomp
37	with	with	IN	_	39	case
38	either	either	CC	_	39	cc:preconj
39	drug4	drug4	NN	_	36	nmod
40	or	or	CC	_	39	cc
41	drug5	drug5	NN	_	39	conj
42	.	.	.	_	4	punct

1	Risk	risk	NN	_	0	ROOT
2	of	of	IN	_	4	case
3	Anaphylactic	Anaphylactic	NNP	_	4	compound
4	Reaction	Reaction	NNP	_	1	nmod
5	:	:	:	_	1	punct
6	Although	although	IN	_	9	mark
7	it	it	PRP	_	9	nsubjpass
8	is	be	VBZ	_	9	auxpass
9	known	know	VBN	_	32	advcl
10	that	that	IN	_	16	mark
11	patients	patient	NNS	_	16	nsubj
12	on	on	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	may	may	MD	_	16	aux
15	be	be	VB	_	16	cop
16	refractory	refractory	JJ	_	9	ccomp
17	to	to	TO	_	18	mark
18	drug2	drug2	VB	_	16	xcomp
19	in	in	IN	_	21	case
20	the	the	DT	_	21	det
21	treatment	treatment	NN	_	18	nmod
22	of	of	IN	_	24	case
23	anaphylactic	anaphylactic	JJ	_	24	amod
24	shock	shock	NN	_	21	nmod
25	,	,	,	_	32	punct
26	drug3	drug3	NN	_	32	nsubj
27	can	can	MD	_	32	aux
28	,	,	,	_	32	punct
29	in	in	IN	_	30	case
30	addition	addition	NN	_	32	nmod
31	,	,	,	_	32	punct
32	interfere	interfere	VBP	_	1	parataxis
33	with	with	IN	_	35	case
34	the	the	DT	_	35	det
35	modulation	modulation	NN	_	32	nmod
36	of	of	IN	_	38	case
37	allergic	allergic	JJ	_	38	amod
38	reaction	reaction	NN	_	35	nmod
39	and	and	CC	_	32	cc
40	lead	lead	VB	_	32	conj
41	to	to	TO	_	44	case
42	an	a	DT	_	44	det
43	increased	increase	VBN	_	44	amod
44	severity	severity	NN	_	40	nmod
45	and/or	and/or	CC	_	44	cc
46	frequency	frequency	NN	_	44	conj
47	of	of	IN	_	48	case
48	attacks	attack	NNS	_	44	nmod
49	.	.	.	_	1	punct

1	Severe	severe	JJ	_	3	amod
2	allergic	allergic	JJ	_	3	amod
3	reactions	reaction	NNS	_	8	nsubjpass
4	including	include	VBG	_	5	case
5	anaphylaxis	anaphylaxis	NN	_	3	nmod
6	have	have	VBP	_	8	aux
7	been	be	VBN	_	8	auxpass
8	reported	report	VBN	_	0	ROOT
9	in	in	IN	_	10	case
10	patients	patient	NNS	_	8	nmod
11	exposed	expose	VBN	_	10	acl
12	to	to	TO	_	14	case
13	a	a	DT	_	14	det
14	variety	variety	NN	_	11	nmod
15	of	of	IN	_	16	case
16	allergens	allergen	NNS	_	14	nmod
17	either	either	CC	_	20	cc:preconj
18	by	by	IN	_	20	case
19	repeated	repeat	VBN	_	20	amod
20	challenge	challenge	NN	_	10	nmod
21	,	,	,	_	20	punct
22	or	or	CC	_	20	cc
23	accidental	accidental	JJ	_	24	amod
24	contact	contact	NN	_	20	conj
25	,	,	,	_	8	punct
26	and	and	CC	_	8	cc
27	with	with	IN	_	31	case
28	diagnostic	diagnostic	JJ	_	31	amod
29	or	or	CC	_	28	cc
30	therapeutic	therapeutic	JJ	_	28	conj
31	agents	agent	NNS	_	8	conj
32	while	while	IN	_	33	mark
33	receiving	receive	VBG	_	31	acl
34	drug1	drug1	NN	_	33	dobj
35	.	.	.	_	8	punct

1	Such	such	JJ	_	2	amod
2	patients	patient	NNS	_	5	nsubj
3	may	may	MD	_	5	aux
4	be	be	VB	_	5	cop
5	unresponsive	unresponsive	JJ	_	0	ROOT
6	to	to	TO	_	9	case
7	the	the	DT	_	9	det
8	usual	usual	JJ	_	9	amod
9	doses	dose	NNS	_	5	nmod
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	used	use	VBN	_	9	acl
13	to	to	TO	_	14	mark
14	treat	treat	VB	_	12	xcomp
15	allergic	allergic	JJ	_	16	amod
16	reaction	reaction	NN	_	14	dobj
17	.	.	.	_	5	punct

1	-RRB-	-rrb-	-RRB-	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	Clinical	clinical	JJ	_	2	amod
2	Laboratory	laboratory	NN	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	increased	increase	VBN	_	2	amod
2	creatine	creatine	NN	_	0	ROOT

1	positive	positive	JJ	_	2	amod
2	antinuclear	antinuclear	JJ	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	phosphokinase	phosphokinase	NN	_	0	ROOT

1	antibody	antibody	NN	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	increased	increase	VBN	_	2	amod
2	bilirubin	bilirubin	NN	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	increased	increase	VBN	_	2	amod
2	liver	liver	NN	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	transaminases	transaminase	NNS	_	3	compound
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	AST	AST	NNP	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	-LRB-	-lrb-	-LRB-	_	2	punct
2	SGOT	sgot	NN	_	0	ROOT
3	-RRB-	-rrb-	-RRB-	_	2	punct
4	,	,	,	_	2	punct
5	ALT	alt	NN	_	4	root
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	SGPT	sgpt	NN	_	5	appos
8	-RRB-	-rrb-	-RRB-	_	7	punct

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	increased	increase	VBN	_	2	amod
2	alkaline	alkaline	NN	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	phophatase	phophatase	NN	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	Hematopoietic	hematopoietic	JJ	_	0	ROOT

1	anemia	anemia	NN	_	0	ROOT

1	thrombocytopenia	thrombocytopenia	NN	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	leukopenia	leukopenia	NN	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	bone	bone	NN	_	3	compound
2	marrow	marrow	NN	_	3	compound
3	hypoplasia	hypoplasia	NN	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	eosinophilia	eosinophilia	NN	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	Immunologic	immunologic	JJ	_	0	ROOT

1	angioedema	angioedema	NN	_	0	ROOT

1	anaphylaxis	anaphylaxis	NN	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	laryngeal	laryngeal	JJ	_	2	amod
2	edema	edema	NN	_	0	ROOT

1	Lupus-like	lupus-like	JJ	_	2	amod
2	syndrome	syndrome	NN	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	urticaria	urticaria	NN	_	0	ROOT

1	vasculitis	vasculitis	NN	_	0	ROOT

1	Integumentary	integumentary	JJ	_	0	ROOT

1	exfoliative	exfoliative	JJ	_	2	amod
2	dermatitis	dermatitis	NN	_	0	ROOT

1	alopecia	alopecia	NN	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	rash	rash	NN	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	dermatitis	dermatitis	NN	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	pruritus	pruritus	NN	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	No	no	DT	_	4	neg
2	formal	formal	JJ	_	4	amod
3	interaction	interaction	NN	_	4	compound
4	studies	study	NNS	_	7	nsubjpass
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	performed	perform	VBN	_	0	ROOT
8	.	.	.	_	7	punct

1	The	the	DT	_	2	det
2	duration	duration	NN	_	13	nsubj
3	of	of	IN	_	5	case
4	the	the	DT	_	5	det
5	period	period	NN	_	2	nmod
6	following	follow	VBG	_	7	case
7	treatment	treatment	NN	_	2	nmod
8	with	with	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	before	before	IN	_	11	case
11	one	one	CD	_	7	nmod
12	should	should	MD	_	13	aux
13	consider	consider	VB	_	21	csubjpass
14	starting	start	VBG	_	13	xcomp
15	other	other	JJ	_	17	amod
16	drug2	drug2	NN	_	17	compound
17	therapy	therapy	NN	_	14	dobj
18	has	have	VBZ	_	21	aux
19	not	not	RB	_	21	neg
20	been	be	VBN	_	21	auxpass
21	evaluated	evaluate	VBN	_	0	ROOT
22	.	.	.	_	21	punct

1	Carcinogenesis	carcinogenesis	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	Mutagenesis	mutagenesis	NN	_	1	conj
4	,	,	,	_	1	punct
5	and	and	CC	_	1	cc
6	Fertility	fertility	NN	_	1	conj

1	In	in	IN	_	5	case
2	a	a	DT	_	5	det
3	chronic	chronic	JJ	_	5	amod
4	toxicity	toxicity	NN	_	5	compound
5	study	study	NN	_	10	nmod
6	,	,	,	_	10	punct
7	cynomolgus	cynomolgus	NN	_	8	compound
8	monkeys	monkey	NNS	_	10	nsubjpass
9	were	be	VBD	_	10	auxpass
10	dosed	dose	VBN	_	0	ROOT
11	weekly	weekly	RB	_	10	advmod
12	for	for	IN	_	14	case
13	52	52	CD	_	14	nummod
14	weeks	week	NNS	_	10	nmod
15	with	with	IN	_	17	case
16	intravenous	intravenous	JJ	_	17	amod
17	drug1	drug1	NN	_	10	nmod
18	at	at	IN	_	20	case
19	1	1	CD	_	20	nummod
20	mg/kg/dose	mg/kg/dose	NN	_	17	nmod
21	or	or	CC	_	20	cc
22	20	20	CD	_	23	nummod
23	mg/kg/dose	mg/kg/dose	NN	_	20	conj
24	.	.	.	_	10	punct

1	One	one	CD	_	2	nummod
2	animal	animal	NN	_	8	nsubj
3	in	in	IN	_	7	case
4	the	the	DT	_	7	det
5	high	high	JJ	_	7	amod
6	dose	dose	NN	_	7	compound
7	group	group	NN	_	2	nmod
8	developed	develop	VBD	_	0	ROOT
9	a	a	DT	_	11	det
10	B-cell	b-cell	NN	_	11	compound
11	lymphoma	lymphoma	NN	_	8	dobj
12	that	that	WDT	_	14	nsubjpass
13	was	be	VBD	_	14	auxpass
14	detected	detect	VBN	_	11	acl:relcl
15	after	after	IN	_	17	case
16	28	28	CD	_	17	nummod
17	weeks	week	NNS	_	14	nmod
18	of	of	IN	_	19	case
19	dosing	dosing	NN	_	17	nmod
20	.	.	.	_	8	punct

1	Additional	additional	JJ	_	2	amod
2	animals	animal	NNS	_	7	nsubj
3	in	in	IN	_	6	case
4	both	both	DT	_	6	det
5	dose	dose	NN	_	6	compound
6	groups	group	NNS	_	2	nmod
7	developed	develop	VBD	_	0	ROOT
8	B-cell	b-cell	NN	_	9	compound
9	hyperplasia	hyperplasia	NN	_	7	dobj
10	of	of	IN	_	15	case
11	the	the	DT	_	15	det
12	spleen	spleen	NN	_	15	compound
13	and	and	CC	_	12	cc
14	lymph	lymph	NN	_	12	conj
15	nodes	node	NNS	_	9	nmod
16	.	.	.	_	7	punct

1	All	all	DT	_	2	det
2	animals	animal	NNS	_	7	nsubj
3	in	in	IN	_	5	case
4	the	the	DT	_	5	det
5	study	study	NN	_	2	nmod
6	were	be	VBD	_	7	cop
7	positive	positive	JJ	_	0	ROOT
8	for	for	IN	_	13	case
9	an	a	DT	_	13	det
10	endemic	endemic	JJ	_	13	amod
11	primate	primate	JJ	_	13	amod
12	gammaherpes	gammaherpe	NNS	_	13	compound
13	virus	virus	NN	_	7	nmod
14	also	also	RB	_	15	advmod
15	known	know	VBN	_	13	acl
16	as	as	IN	_	17	case
17	lymphocryptovirus	lymphocryptovirus	NN	_	15	nmod
18	-LRB-	-lrb-	-LRB-	_	19	punct
19	LCV	lcv	NN	_	17	appos
20	-RRB-	-rrb-	-RRB-	_	19	punct
21	.	.	.	_	7	punct

1	Latent	latent	JJ	_	3	amod
2	LCV	lcv	NN	_	3	compound
3	infection	infection	NN	_	6	nsubj
4	is	be	VBZ	_	6	cop
5	generally	generally	RB	_	6	advmod
6	asymptomatic	asymptomatic	JJ	_	0	ROOT
7	,	,	,	_	6	punct
8	but	but	CC	_	6	cc
9	can	can	MD	_	10	aux
10	lead	lead	VB	_	6	conj
11	to	to	TO	_	13	case
12	B-cell	b-cell	NN	_	13	compound
13	lymphomas	lymphoma	NNS	_	10	nmod
14	when	when	WRB	_	18	advmod
15	animals	animal	NNS	_	18	nsubjpass
16	are	be	VBP	_	18	auxpass
17	immune	immune	JJ	_	18	advmod
18	suppressed	suppress	VBN	_	10	advcl
19	.	.	.	_	6	punct

1	In	in	IN	_	4	case
2	a	a	DT	_	4	det
3	separate	separate	JJ	_	4	amod
4	study	study	NN	_	7	nmod
5	,	,	,	_	7	punct
6	baboons	baboon	NNS	_	7	nsubj
7	given	give	VBN	_	0	ROOT
8	3	3	CD	_	9	nummod
9	doses	dose	NNS	_	7	dobj
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	at	at	IN	_	14	case
13	1	1	CD	_	14	nummod
14	mg/kg	mg/kg	NN	_	19	nmod
15	every	every	DT	_	17	det
16	8	8	CD	_	17	nummod
17	weeks	week	NNS	_	19	nsubjpass
18	were	be	VBD	_	19	auxpass
19	found	find	VBN	_	7	advcl
20	to	to	TO	_	21	mark
21	have	have	VB	_	19	xcomp
22	centroblast	centroblast	NN	_	23	compound
23	proliferation	proliferation	NN	_	21	dobj
24	in	in	IN	_	27	case
25	B-cell	b-cell	NN	_	27	compound
26	dependent	dependent	JJ	_	27	amod
27	areas	area	NNS	_	23	nmod
28	in	in	IN	_	31	case
29	the	the	DT	_	31	det
30	germinal	germinal	JJ	_	31	amod
31	centers	center	NNS	_	21	nmod
32	of	of	IN	_	34	case
33	the	the	DT	_	34	det
34	spleen	spleen	NN	_	31	nmod
35	following	follow	VBG	_	39	case
36	a	a	DT	_	39	det
37	116-day	116-day	JJ	_	39	amod
38	washout	washout	NN	_	39	compound
39	period	period	NN	_	21	nmod
40	.	.	.	_	7	punct

1	The	the	DT	_	2	det
2	role	role	NN	_	25	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	in	in	IN	_	7	case
6	the	the	DT	_	7	det
7	development	development	NN	_	2	nmod
8	of	of	IN	_	11	case
9	the	the	DT	_	11	det
10	lymphoid	lymphoid	JJ	_	11	amod
11	malignancy	malignancy	NN	_	7	nmod
12	and	and	CC	_	7	cc
13	the	the	DT	_	14	det
14	hyperplasia	hyperplasia	NN	_	7	conj
15	observed	observe	VBN	_	14	acl
16	in	in	IN	_	18	case
17	non-human	non-human	JJ	_	18	amod
18	primates	primate	NNS	_	15	nmod
19	and	and	CC	_	2	cc
20	the	the	DT	_	21	det
21	relevance	relevance	NN	_	2	conj
22	to	to	TO	_	23	case
23	humans	human	NNS	_	21	nmod
24	is	be	VBZ	_	25	cop
25	unknown	unknown	JJ	_	0	ROOT
26	.	.	.	_	25	punct

1	Immunodeficiency-associated	immunodeficiency-associated	JJ	_	3	amod
2	lymphocyte	lymphocyte	NN	_	3	compound
3	disorders	disorder	NNS	_	15	nsubj
4	-LRB-	-lrb-	-LRB-	_	6	punct
5	plasmacytic	plasmacytic	JJ	_	6	amod
6	hyperplasia	hyperplasia	NN	_	3	dep
7	,	,	,	_	6	punct
8	polymorphic	polymorphic	JJ	_	9	amod
9	proliferation	proliferation	NN	_	6	conj
10	,	,	,	_	6	punct
11	and	and	CC	_	6	cc
12	B-cell	b-cell	NN	_	13	compound
13	lymphomas	lymphoma	NNS	_	6	conj
14	-RRB-	-rrb-	-RRB-	_	6	punct
15	occur	occur	VBP	_	0	ROOT
16	in	in	IN	_	17	case
17	patients	patient	NNS	_	15	nmod
18	who	who	WP	_	19	nsubj
19	have	have	VBP	_	17	acl:relcl
20	congenital	congenital	JJ	_	23	amod
21	or	or	CC	_	20	cc
22	acquired	acquire	VBN	_	20	conj
23	immunodeficiencies	immunodeficiency	NNS	_	19	dobj
24	including	include	VBG	_	25	case
25	those	those	DT	_	23	nmod
26	resulting	result	VBG	_	25	acl
27	from	from	IN	_	29	case
28	drug1	drug1	NN	_	29	compound
29	therapy	therapy	NN	_	26	nmod
30	.	.	.	_	15	punct

1	No	no	DT	_	2	neg
2	carcinogenicity	carcinogenicity	NN	_	7	nsubjpass
3	or	or	CC	_	2	cc
4	fertility	fertility	NN	_	2	conj
5	studies	study	NNS	_	2	dep
6	were	be	VBD	_	7	auxpass
7	conducted	conduct	VBN	_	0	ROOT
8	.	.	.	_	7	punct

1	Mutagenicity	mutagenicity	NN	_	2	compound
2	studies	study	NNS	_	4	nsubjpass
3	were	be	VBD	_	4	auxpass
4	conducted	conduct	VBN	_	0	ROOT
5	in	in	FW	_	6	compound
6	vitro	vitro	FW	_	7	advmod
7	and	and	CC	_	4	advmod
8	in	in	FW	_	9	compound
9	vivo	vivo	FW	_	7	advmod
10	;	;	:	_	4	punct

1	no	no	DT	_	2	neg
2	evidence	evidence	NN	_	6	nsubjpass
3	of	of	IN	_	4	case
4	mutagenicity	mutagenicity	NN	_	2	nmod
5	was	be	VBD	_	6	auxpass
6	observed	observe	VBN	_	0	ROOT
7	.	.	.	_	6	punct

1	Pregnancy	pregnancy	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	4	punct
3	Category	category	NN	_	4	compound
4	B	b	NN	_	1	appos
5	-RRB-	-rrb-	-RRB-	_	4	punct

1	Women	woman	NNS	_	5	nsubj
2	of	of	IN	_	4	case
3	childbearing	childbearing	JJ	_	4	amod
4	potential	potential	JJ	_	1	nmod
5	make	make	VB	_	0	ROOT
6	up	up	RP	_	5	compound:prt
7	a	a	DT	_	9	det
8	considerable	considerable	JJ	_	9	amod
9	segment	segment	NN	_	5	dobj
10	of	of	IN	_	13	case
11	the	the	DT	_	13	det
12	patient	patient	NN	_	13	compound
13	population	population	NN	_	9	nmod
14	affected	affect	VBN	_	13	acl
15	by	by	IN	_	16	case
16	psoriasis	psoriasis	NN	_	14	nmod
17	.	.	.	_	5	punct

1	Since	since	IN	_	19	mark
2	the	the	DT	_	3	det
3	effect	effect	NN	_	19	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	on	on	IN	_	7	case
7	pregnancy	pregnancy	NN	_	3	nmod
8	and	and	CC	_	7	cc
9	fetal	fetal	JJ	_	10	amod
10	development	development	NN	_	7	conj
11	,	,	,	_	7	punct
12	including	include	VBG	_	15	case
13	immune	immune	JJ	_	15	amod
14	system	system	NN	_	15	compound
15	development	development	NN	_	7	nmod
16	,	,	,	_	7	punct
17	is	be	VBZ	_	19	auxpass
18	not	not	RB	_	19	neg
19	known	know	VBN	_	25	advcl
20	,	,	,	_	25	punct
21	health	health	NN	_	23	compound
22	care	care	NN	_	23	compound
23	providers	provider	NNS	_	25	nsubjpass
24	are	be	VBP	_	25	auxpass
25	encouraged	encourage	VBN	_	0	ROOT
26	to	to	TO	_	27	mark
27	enroll	enroll	VB	_	25	xcomp
28	patients	patient	NNS	_	27	dobj
29	currently	currently	RB	_	30	advmod
30	taking	take	VBG	_	27	xcomp
31	drug2	drug2	NN	_	30	dobj
32	who	who	WP	_	33	nsubj
33	become	become	VBP	_	31	acl:relcl
34	pregnant	pregnant	JJ	_	33	xcomp
35	into	into	IN	_	39	case
36	the	the	DT	_	39	det
37	Biogen	Biogen	NNP	_	39	compound
38	Pregnancy	Pregnancy	NNP	_	39	compound
39	Registry	Registry	NNP	_	33	nmod
40	by	by	IN	_	41	mark
41	calling	call	VBG	_	33	advcl
42	1-866	1-866	CD	_	44	nummod
43	-	-	:	_	44	punct
44	drug3	drug3	NN	_	41	dobj
45	-LRB-	-lrb-	-LRB-	_	46	punct
46	1-866-263-8483	1-866-263-8483	CD	_	44	appos
47	-RRB-	-rrb-	-RRB-	_	46	punct
48	.	.	.	_	25	punct

1	Reproductive	Reproductive	NNP	_	3	compound
2	toxicology	toxicology	NN	_	3	compound
3	studies	study	NNS	_	6	nsubjpass
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	auxpass
6	performed	perform	VBN	_	0	ROOT
7	in	in	IN	_	9	case
8	cynomolgus	cynomolgus	NN	_	9	compound
9	monkeys	monkey	NNS	_	6	nmod
10	at	at	IN	_	11	case
11	doses	dose	NNS	_	6	nmod
12	up	up	RB	_	14	advmod
13	to	to	TO	_	14	dep
14	5	5	CD	_	15	nummod
15	mg/kg/week	mg/kg/week	NN	_	11	dep
16	-LRB-	-lrb-	-LRB-	_	22	punct
17	about	about	IN	_	19	advmod
18	62	62	CD	_	19	compound
19	times	time	NNS	_	22	nummod
20	the	the	DT	_	22	det
21	human	human	JJ	_	22	amod
22	dose	dose	NN	_	15	appos
23	based	base	VBN	_	26	case
24	on	on	IN	_	26	case
25	body	body	NN	_	26	compound
26	weight	weight	NN	_	22	nmod
27	-RRB-	-rrb-	-RRB-	_	22	punct
28	and	and	CC	_	6	cc
29	have	have	VBP	_	30	aux
30	revealed	reveal	VBN	_	6	conj
31	no	no	DT	_	32	neg
32	evidence	evidence	NN	_	30	dobj
33	of	of	IN	_	35	case
34	impaired	impaired	JJ	_	35	amod
35	fertility	fertility	NN	_	32	nmod
36	or	or	CC	_	35	cc
37	harm	harm	NN	_	35	conj
38	to	to	TO	_	40	case
39	the	the	DT	_	40	det
40	fetus	fetus	NN	_	32	nmod
41	due	due	JJ	_	43	case
42	to	to	TO	_	41	mwe
43	drug1	drug1	NN	_	40	nmod
44	.	.	.	_	6	punct

1	No	no	DT	_	2	neg
2	abortifacient	abortifacient	NN	_	7	nsubjpass
3	or	or	CC	_	2	cc
4	teratogenic	teratogenic	JJ	_	2	conj
5	effects	effect	NNS	_	2	dep
6	were	be	VBD	_	7	auxpass
7	observed	observe	VBN	_	0	ROOT
8	in	in	IN	_	10	case
9	cynomolgus	cynomolgus	NN	_	10	compound
10	monkeys	monkey	NNS	_	7	nmod
11	following	follow	VBG	_	14	case
12	intravenous	intravenous	JJ	_	14	amod
13	bolus	bolus	NN	_	14	compound
14	injections	injection	NNS	_	7	nmod
15	of	of	IN	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	administered	administer	VBN	_	16	acl
18	weekly	weekly	RB	_	17	advmod
19	during	during	IN	_	21	case
20	the	the	DT	_	21	det
21	period	period	NN	_	17	nmod
22	of	of	IN	_	23	case
23	organogenesis	organogenesis	NN	_	21	nmod
24	to	to	TO	_	25	case
25	gestation	gestation	NN	_	21	nmod
26	.	.	.	_	7	punct

1	drug1	drug1	NN	_	2	nsubj
2	underwent	undergo	VBD	_	0	ROOT
3	trans-placental	trans-placental	JJ	_	4	amod
4	passage	passage	NN	_	2	dobj
5	and	and	CC	_	2	cc
6	produced	produce	VBN	_	2	conj
7	in	in	IN	_	9	case
8	utero	utero	NN	_	9	compound
9	exposure	exposure	NN	_	6	nmod
10	in	in	IN	_	13	case
11	the	the	DT	_	13	det
12	developing	develop	VBG	_	13	amod
13	monkeys	monkey	NNS	_	9	nmod
14	.	.	.	_	2	punct

1	In	in	IN	_	2	case
2	utero	utero	NN	_	13	nmod
3	,	,	,	_	13	punct
4	serum	serum	NN	_	5	compound
5	levels	level	NNS	_	13	nsubj
6	of	of	IN	_	7	case
7	exposure	exposure	NN	_	5	nmod
8	in	in	IN	_	10	case
9	these	these	DT	_	10	det
10	monkeys	monkey	NNS	_	7	nmod
11	were	be	VBD	_	13	cop
12	23	23	CD	_	13	nummod
13	%	%	NN	_	0	ROOT
14	of	of	IN	_	17	case
15	maternal	maternal	JJ	_	17	amod
16	serum	serum	NN	_	17	compound
17	levels	level	NNS	_	13	nmod
18	.	.	.	_	13	punct

1	No	no	DT	_	2	neg
2	evidence	evidence	NN	_	14	nsubjpass
3	of	of	IN	_	5	case
4	fetal	fetal	JJ	_	5	amod
5	toxicity	toxicity	NN	_	2	nmod
6	including	include	VBG	_	8	case
7	adverse	adverse	JJ	_	8	amod
8	effects	effect	NNS	_	5	nmod
9	on	on	IN	_	12	case
10	immune	immune	JJ	_	12	amod
11	system	system	NN	_	12	compound
12	development	development	NN	_	8	nmod
13	was	be	VBD	_	14	auxpass
14	observed	observe	VBN	_	0	ROOT
15	in	in	IN	_	16	case
16	any	any	DT	_	14	nmod
17	of	of	IN	_	19	case
18	these	these	DT	_	19	det
19	animals	animal	NNS	_	16	nmod
20	.	.	.	_	14	punct

1	Animal	animal	NN	_	3	compound
2	reproduction	reproduction	NN	_	3	compound
3	studies	study	NNS	_	10	nsubj
4	,	,	,	_	10	punct
5	however	however	RB	_	10	advmod
6	,	,	,	_	10	punct
7	are	be	VBP	_	10	cop
8	not	not	RB	_	10	neg
9	always	always	RB	_	10	advmod
10	predictive	predictive	JJ	_	0	ROOT
11	of	of	IN	_	13	case
12	human	human	JJ	_	13	amod
13	response	response	NN	_	10	nmod
14	and	and	CC	_	10	cc
15	there	there	EX	_	16	expl
16	are	be	VBP	_	10	conj
17	no	no	DT	_	21	neg
18	adequate	adequate	JJ	_	21	amod
19	and	and	CC	_	18	cc
20	well-controlled	well-controlled	JJ	_	18	conj
21	studies	study	NNS	_	16	nsubj
22	in	in	IN	_	24	case
23	pregnant	pregnant	JJ	_	24	amod
24	women	woman	NNS	_	21	nmod
25	.	.	.	_	10	punct

1	Because	because	IN	_	19	mark
2	the	the	DT	_	3	det
3	risk	risk	NN	_	19	nsubj
4	to	to	TO	_	6	case
5	the	the	DT	_	6	det
6	development	development	NN	_	3	nmod
7	of	of	IN	_	11	case
8	the	the	DT	_	11	det
9	fetal	fetal	JJ	_	11	amod
10	immune	immune	JJ	_	11	amod
11	system	system	NN	_	6	nmod
12	and	and	CC	_	6	cc
13	postnatal	postnatal	JJ	_	15	amod
14	immune	immune	JJ	_	15	amod
15	function	function	NN	_	6	conj
16	in	in	IN	_	17	case
17	humans	human	NNS	_	15	nmod
18	is	be	VBZ	_	19	cop
19	unknown	unknown	JJ	_	24	advcl
20	,	,	,	_	24	punct
21	drug1	drug1	NN	_	24	nsubjpass
22	should	should	MD	_	24	aux
23	be	be	VB	_	24	auxpass
24	used	use	VBN	_	0	ROOT
25	during	during	IN	_	26	case
26	pregnancy	pregnancy	NN	_	24	nmod
27	only	only	RB	_	30	advmod
28	if	if	IN	_	30	mark
29	clearly	clearly	RB	_	30	advmod
30	needed	need	VBN	_	24	advcl
31	.	.	.	_	24	punct

1	If	if	IN	_	3	mark
2	pregnancy	pregnancy	NN	_	3	nsubj
3	occurs	occur	VBZ	_	15	advcl
4	while	while	IN	_	5	mark
5	taking	take	VBG	_	3	advcl
6	drug1	drug1	NN	_	5	dobj
7	,	,	,	_	15	punct
8	continued	continue	VBD	_	9	amod
9	use	use	NN	_	15	nsubjpass
10	of	of	IN	_	12	case
11	the	the	DT	_	12	det
12	drug	drug	NN	_	9	nmod
13	should	should	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	assessed	assess	VBN	_	0	ROOT
16	.	.	.	_	15	punct

1	Nursing	Nursing	NNP	_	2	compound
2	Mothers	mother	NNS	_	0	ROOT

1	It	it	PRP	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	not	not	RB	_	4	neg
4	known	know	VBN	_	0	ROOT
5	whether	whether	IN	_	8	mark
6	drug1	drug1	NN	_	8	nsubjpass
7	is	be	VBZ	_	8	auxpass
8	excreted	excrete	VBN	_	4	ccomp
9	in	in	IN	_	11	case
10	human	human	JJ	_	11	amod
11	milk	milk	NN	_	8	nmod
12	.	.	.	_	4	punct

1	Because	because	IN	_	5	mark
2	many	many	JJ	_	3	amod
3	drugs	drug	NNS	_	5	nsubjpass
4	are	be	VBP	_	5	auxpass
5	excreted	excrete	VBN	_	0	ROOT
6	in	in	IN	_	8	case
7	human	human	JJ	_	8	amod
8	milk	milk	NN	_	5	nmod
9	,	,	,	_	5	punct
10	and	and	CC	_	5	cc
11	because	because	IN	_	13	mark
12	there	there	EX	_	13	expl
13	exists	exist	VBZ	_	30	advcl
14	the	the	DT	_	15	det
15	potential	potential	NN	_	13	dobj
16	for	for	IN	_	19	case
17	serious	serious	JJ	_	19	amod
18	adverse	adverse	JJ	_	19	amod
19	reactions	reaction	NNS	_	15	nmod
20	in	in	IN	_	22	case
21	nursing	nursing	NN	_	22	compound
22	infants	infant	NNS	_	19	nmod
23	from	from	IN	_	24	case
24	drug1	drug1	NN	_	22	nmod
25	,	,	,	_	30	punct
26	a	a	DT	_	27	det
27	decision	decision	NN	_	30	nsubjpass
28	should	should	MD	_	30	aux
29	be	be	VB	_	30	auxpass
30	made	make	VBN	_	5	conj
31	whether	whether	IN	_	33	mark
32	to	to	TO	_	33	mark
33	discontinue	discontinue	VB	_	30	ccomp
34	nursing	nursing	NN	_	33	dobj
35	while	while	IN	_	36	mark
36	taking	take	VBG	_	33	advcl
37	the	the	DT	_	38	det
38	drug	drug	NN	_	36	dobj
39	or	or	CC	_	36	cc
40	to	to	TO	_	41	mark
41	discontinue	discontinue	VB	_	36	conj
42	the	the	DT	_	43	det
43	use	use	NN	_	41	dobj
44	of	of	IN	_	46	case
45	the	the	DT	_	46	det
46	drug	drug	NN	_	43	nmod
47	,	,	,	_	33	punct
48	taking	take	VBG	_	33	xcomp
49	into	into	IN	_	50	case
50	account	account	NN	_	48	nmod
51	the	the	DT	_	52	det
52	importance	importance	NN	_	48	dobj
53	of	of	IN	_	55	case
54	the	the	DT	_	55	det
55	drug	drug	NN	_	52	nmod
56	to	to	TO	_	58	case
57	the	the	DT	_	58	det
58	mother	mother	NN	_	52	nmod
59	.	.	.	_	5	punct

1	Geriatric	Geriatric	NNP	_	2	compound
2	Use	Use	NNP	_	0	ROOT

1	Of	of	IN	_	4	case
2	the	the	DT	_	4	det
3	1357	1357	CD	_	4	nummod
4	patients	patient	NNS	_	17	nmod
5	who	who	WP	_	6	nsubj
6	received	receive	VBD	_	4	acl:relcl
7	drug1	drug1	NN	_	6	dobj
8	in	in	IN	_	10	case
9	clinical	clinical	JJ	_	10	amod
10	trials	trial	NNS	_	6	nmod
11	,	,	,	_	17	punct
12	a	a	DT	_	13	det
13	total	total	NN	_	17	nsubj
14	of	of	IN	_	16	case
15	100	100	CD	_	16	nummod
16	patients	patient	NNS	_	13	nmod
17	were	be	VBD	_	0	ROOT

1	65	65	CD	_	2	nummod
2	years	year	NNS	_	0	ROOT
3	of	of	IN	_	4	case
4	age	age	NN	_	2	nmod
5	and	and	CC	_	2	cc
6	13	13	CD	_	7	nummod
7	patients	patient	NNS	_	2	conj
8	were	be	VBD	_	2	dep

1	75	75	CD	_	2	nummod
2	years	year	NNS	_	0	ROOT
3	of	of	IN	_	4	case
4	age	age	NN	_	2	nmod
5	.	.	.	_	2	punct

1	No	no	DT	_	2	neg
2	differences	difference	NNS	_	8	nsubjpass
3	in	in	IN	_	4	case
4	safety	safety	NN	_	2	nmod
5	or	or	CC	_	4	cc
6	efficacy	efficacy	NN	_	4	conj
7	were	be	VBD	_	8	auxpass
8	observed	observe	VBN	_	0	ROOT
9	between	between	IN	_	10	case
10	older	older	JJR	_	8	nmod
11	and	and	CC	_	10	cc
12	younger	younger	JJR	_	10	conj
13	patients	patient	NNS	_	10	dep
14	,	,	,	_	8	punct
15	but	but	CC	_	8	cc
16	there	there	EX	_	17	expl
17	were	be	VBD	_	8	conj
18	not	not	RB	_	17	neg
19	sufficient	sufficient	JJ	_	20	amod
20	data	datum	NNS	_	17	nsubj
21	to	to	TO	_	22	mark
22	exclude	exclude	VB	_	20	acl
23	important	important	JJ	_	24	amod
24	differences	difference	NNS	_	22	dobj
25	.	.	.	_	8	punct

1	Because	because	IN	_	10	mark
2	the	the	DT	_	3	det
3	incidence	incidence	NN	_	10	nsubj
4	of	of	IN	_	5	case
5	infections	infection	NNS	_	3	nmod
6	and	and	CC	_	5	cc
7	certain	certain	JJ	_	8	amod
8	malignancies	malignancy	NNS	_	5	conj
9	is	be	VBZ	_	10	cop
10	higher	higher	JJR	_	22	advcl
11	in	in	IN	_	14	case
12	the	the	DT	_	14	det
13	elderly	elderly	JJ	_	14	amod
14	population	population	NN	_	10	nmod
15	,	,	,	_	22	punct
16	in	in	IN	_	17	case
17	general	general	JJ	_	22	nmod
18	,	,	,	_	22	punct
19	caution	caution	NN	_	22	nsubjpass
20	should	should	MD	_	22	aux
21	be	be	VB	_	22	auxpass
22	used	use	VBN	_	0	ROOT
23	in	in	IN	_	24	mark
24	treating	treat	VBG	_	22	advcl
25	the	the	DT	_	26	det
26	elderly	elderly	JJ	_	24	dobj
27	.	.	.	_	22	punct

1	Pediatric	Pediatric	NNP	_	2	compound
2	Use	Use	NNP	_	0	ROOT

1	The	the	DT	_	2	det
2	safety	safety	NN	_	13	nsubjpass
3	and	and	CC	_	2	cc
4	efficacy	efficacy	NN	_	2	conj
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	2	nmod
7	in	in	IN	_	9	case
8	pediatric	pediatric	JJ	_	9	amod
9	patients	patient	NNS	_	2	nmod
10	have	have	VBP	_	13	aux
11	not	not	RB	_	13	neg
12	been	be	VBN	_	13	auxpass
13	studied	study	VBN	_	0	ROOT
14	.	.	.	_	13	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	not	not	RB	_	4	neg
4	indicated	indicate	VBN	_	0	ROOT
5	for	for	IN	_	7	case
6	pediatric	pediatric	JJ	_	7	amod
7	patients	patient	NNS	_	4	nmod
8	.	.	.	_	4	punct

1	drug1	drug1	NN	_	2	nsubj
2	prolong	prolong	VB	_	0	ROOT
3	and	and	CC	_	2	cc
4	intensify	intensify	VB	_	2	conj
5	the	the	DT	_	7	det
6	anticholinergic	anticholinergic	JJ	_	7	amod
7	effects	effect	NNS	_	2	dobj
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	.	.	.	_	2	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	have	have	VB	_	0	ROOT
4	additive	additive	JJ	_	5	amod
5	effects	effect	NNS	_	3	dobj
6	with	with	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	other	other	JJ	_	10	amod
10	drug3	drug3	NN	_	7	conj
11	,	,	,	_	10	punct
12	e.g.	e.g.	FW	_	14	dep
13	,	,	,	_	14	punct
14	drug4	drug4	NN	_	10	nmod
15	,	,	,	_	14	punct
16	drug5	drug5	NN	_	14	conj
17	,	,	,	_	14	punct
18	drug6	drug6	NN	_	14	conj
19	,	,	,	_	14	punct
20	drug7	drug7	NN	_	14	conj
21	.	.	.	_	3	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	6	nsubjpass
4	has	have	VBZ	_	6	aux
5	been	be	VBN	_	6	auxpass
6	studied	study	VBN	_	1	appos
7	in	in	IN	_	10	case
8	rheumatoid	rheumatoid	JJ	_	10	amod
9	arthritis	arthritis	NN	_	10	compound
10	patients	patient	NNS	_	6	nmod
11	taking	take	VBG	_	10	acl
12	concomitant	concomitant	JJ	_	13	amod
13	drug3	drug3	NN	_	11	dobj
14	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	data	datum	NNS	_	5	nsubj
3	do	do	VBP	_	5	aux
4	not	not	RB	_	5	neg
5	suggest	suggest	VB	_	0	ROOT
6	the	the	DT	_	7	det
7	need	need	NN	_	5	dobj
8	for	for	IN	_	10	case
9	dose	dose	NN	_	10	compound
10	adjustment	adjustment	NN	_	7	nmod
11	of	of	IN	_	13	case
12	either	either	CC	_	13	cc:preconj
13	drug1	drug1	NN	_	10	nmod
14	or	or	CC	_	13	cc
15	drug2	drug2	NN	_	13	conj
16	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concurrent	concurrent	JJ	_	4	amod
4	administration	administration	NN	_	16	nsubjpass
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	-LRB-	-lrb-	-LRB-	_	9	punct
8	an	a	DT	_	9	det
9	drug3	drug3	NN	_	6	appos
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	and	and	CC	_	6	cc
12	another	another	DT	_	13	det
13	drug4	drug4	NN	_	6	conj
14	has	have	VBZ	_	16	aux
15	been	be	VBN	_	16	auxpass
16	associated	associate	VBN	_	1	appos
17	with	with	IN	_	20	case
18	an	a	DT	_	20	det
19	increased	increase	VBN	_	20	amod
20	risk	risk	NN	_	16	nmod
21	of	of	IN	_	23	case
22	serious	serious	JJ	_	23	amod
23	infections	infection	NNS	_	20	nmod
24	,	,	,	_	20	punct
25	an	a	DT	_	27	det
26	increased	increase	VBN	_	27	amod
27	risk	risk	NN	_	20	conj
28	of	of	IN	_	29	case
29	neutropenia	neutropenia	NN	_	27	nmod
30	and	and	CC	_	20	cc
31	no	no	DT	_	33	neg
32	additional	additional	JJ	_	33	amod
33	benefit	benefit	NN	_	20	conj
34	compared	compare	VBN	_	38	case
35	to	to	TO	_	38	case
36	these	these	DT	_	38	det
37	medicinal	medicinal	JJ	_	38	amod
38	products	product	NNS	_	20	acl
39	alone	alone	RB	_	38	advmod
40	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	safety	safety	NN	_	15	nsubjpass
3	and	and	CC	_	2	cc
4	efficacy	efficacy	NN	_	2	conj
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	2	nmod
7	used	use	VBN	_	6	acl
8	in	in	IN	_	9	case
9	combination	combination	NN	_	7	nmod
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	has	have	VBZ	_	15	aux
13	not	not	RB	_	15	neg
14	been	be	VBN	_	15	auxpass
15	studied	study	VBN	_	0	ROOT
16	.	.	.	_	15	punct

1	Therefore	therefore	RB	_	16	advmod
2	the	the	DT	_	16	dep
3	,	,	,	_	16	punct
4	combination	combination	NN	_	16	nsubj
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	with	with	IN	_	9	case
8	other	other	JJ	_	9	amod
9	drug2	drug2	NN	_	4	nmod
10	,	,	,	_	9	punct
11	including	include	VBG	_	12	case
12	drug3	drug3	NN	_	9	nmod
13	,	,	,	_	9	punct
14	may	may	MD	_	16	aux
15	also	also	RB	_	16	advmod
16	result	result	VB	_	0	ROOT
17	i	i	FW	_	20	compound
18	n	n	NN	_	20	compound
19	similar	similar	JJ	_	20	amod
20	toxicities	toxicity	NNS	_	16	dobj
21	.	.	.	_	16	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	use	use	NN	_	14	nsubj
3	with	with	IN	_	5	case
4	other	other	JJ	_	5	amod
5	drug1	drug1	NN	_	2	nmod
6	-	-	:	_	5	punct
7	containing	contain	VBG	_	5	acl
8	medicines	medicine	NNS	_	7	dobj
9	-LRB-	-lrb-	-LRB-	_	11	punct
10	including	include	VBG	_	11	case
11	drug2	drug2	NN	_	8	nmod
12	-RRB-	-rrb-	-RRB-	_	11	punct
13	may	may	MD	_	14	aux
14	cause	cause	VB	_	0	ROOT
15	too	too	RB	_	16	advmod
16	much	much	JJ	_	17	amod
17	drug3	drug3	NN	_	14	dobj
18	in	in	IN	_	20	case
19	the	the	DT	_	20	det
20	blood	blood	NN	_	17	nmod
21	or	or	CC	_	20	cc
22	urine	urine	NN	_	20	conj
23	,	,	,	_	17	punct
24	which	which	WDT	_	26	nsubj
25	may	may	MD	_	26	aux
26	increase	increase	VB	_	17	acl:relcl
27	the	the	DT	_	28	det
28	chance	chance	NN	_	26	dobj
29	of	of	IN	_	31	case
30	side	side	JJ	_	31	amod
31	effects	effect	NNS	_	28	nmod
32	.	.	.	_	14	punct

1	Using	use	VBG	_	10	csubj
2	drug1	drug1	NN	_	1	dobj
3	with	with	IN	_	4	case
4	drug2	drug2	NN	_	1	nmod
5	-LRB-	-lrb-	-LRB-	_	7	punct
6	heart	heart	NN	_	7	compound
7	medicine	medicine	NN	_	4	appos
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	may	may	MD	_	10	aux
10	cause	cause	VB	_	0	ROOT
11	hypercalcemia	hypercalcemia	NN	_	10	dobj
12	-LRB-	-lrb-	-LRB-	_	15	punct
13	too	too	RB	_	14	advmod
14	much	much	JJ	_	15	amod
15	drug3	drug3	NN	_	11	dep
16	in	in	IN	_	18	case
17	the	the	DT	_	18	det
18	blood	blood	NN	_	15	nmod
19	-RRB-	-rrb-	-RRB-	_	15	punct
20	,	,	,	_	11	punct
21	which	which	WDT	_	23	nsubj
22	could	could	MD	_	23	aux
23	increase	increase	VB	_	11	acl:relcl
24	the	the	DT	_	25	det
25	chance	chance	NN	_	23	dobj
26	of	of	IN	_	27	mark
27	developing	develop	VBG	_	25	acl
28	an	a	DT	_	30	det
29	irregular	irregular	JJ	_	30	amod
30	heartbeat	heartbeat	NN	_	27	dobj
31	.	.	.	_	10	punct

1	Tablet	Tablet	NNP	_	0	ROOT
2	If	if	IN	_	9	mark
3	a	a	DT	_	4	det
4	patient	patient	NN	_	9	nsubj
5	receiving	receive	VBG	_	4	acl
6	drug1	drug1	NN	_	5	dobj
7	is	be	VBZ	_	9	aux
8	also	also	RB	_	9	advmod
9	taking	take	VBG	_	1	advcl
10	drug2	drug2	NN	_	9	dobj
11	,	,	,	_	1	punct
12	the	the	DT	_	13	det
13	effect	effect	NN	_	18	nsubjpass
14	of	of	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	may	may	MD	_	18	aux
17	be	be	VB	_	18	auxpass
18	reduced	reduce	VBN	_	1	acl:relcl
19	,	,	,	_	18	punct
20	thus	thus	RB	_	21	advmod
21	necessitating	necessitate	VBG	_	18	xcomp
22	an	a	DT	_	23	det
23	increase	increase	NN	_	21	dobj
24	in	in	IN	_	25	case
25	dosage	dosage	NN	_	23	nmod
26	.	.	.	_	1	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	enhance	enhance	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	CNS-depressive	cns-depressive	JJ	_	6	amod
6	effects	effect	NNS	_	3	dobj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	,	,	,	_	8	punct
10	drug3	drug3	NN	_	8	conj
11	or	or	CC	_	8	cc
12	other	other	JJ	_	13	amod
13	drug4	drug4	NN	_	8	conj
14	.	.	.	_	3	punct

1	drug1	drug1	NN	_	6	nsubj
2	in	in	IN	_	3	case
3	combination	combination	NN	_	1	nmod
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	enhances	enhance	VBZ	_	0	ROOT
7	the	the	DT	_	8	det
8	manifestation	manifestation	NN	_	6	dobj
9	of	of	IN	_	11	case
10	corneal	corneal	NN	_	11	compound
11	lesions	lesion	NNS	_	8	nmod
12	in	in	IN	_	13	case
13	rats	rat	NNS	_	18	nmod
14	Epidural	epidural	JJ	_	16	amod
15	Injection	injection	NN	_	16	compound
16	drug3	drug3	NN	_	18	nsubj
17	may	may	MD	_	18	aux
18	potentiate	potentiate	VB	_	8	acl:relcl
19	the	the	DT	_	21	det
20	CNS-depressive	cns-depressive	JJ	_	21	amod
21	effect	effect	NN	_	18	dobj
22	of	of	IN	_	23	case
23	drug4	drug4	NN	_	21	nmod
24	,	,	,	_	23	punct
25	drug5	drug5	NN	_	23	conj
26	or	or	CC	_	23	cc
27	other	other	JJ	_	28	amod
28	drug6	drug6	NN	_	23	conj
29	.	.	.	_	6	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	potentiate	potentiate	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	hypotensive	hypotensive	JJ	_	6	amod
6	effects	effect	NNS	_	3	dobj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	.	.	.	_	3	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	antagonize	antagonize	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	hypotensive	hypotensive	JJ	_	6	amod
6	effects	effect	NNS	_	3	dobj
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	effects	effect	NNS	_	12	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	on	on	IN	_	9	case
6	drug2	drug2	NN	_	9	compound
7	s	s	NNS	_	9	compound
8	analgesic	analgesic	JJ	_	9	amod
9	actions	action	NNS	_	2	nmod
10	are	be	VBP	_	12	auxpass
11	not	not	RB	_	12	neg
12	known	know	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	exacerbate	exacerbate	VB	_	0	ROOT
4	the	the	DT	_	6	det
5	hypertensive	hypertensive	JJ	_	6	amod
6	response	response	NN	_	3	dobj
7	seen	see	VBN	_	6	acl
8	with	with	IN	_	10	case
9	drug2	drug2	NN	_	10	compound
10	withdrawl	withdrawl	NN	_	7	nmod
11	.	.	.	_	3	punct

1	Also	also	RB	_	19	advmod
2	,	,	,	_	19	punct
3	due	due	JJ	_	6	case
4	to	to	TO	_	3	mwe
5	the	the	DT	_	6	det
6	potential	potential	NN	_	19	nmod
7	for	for	IN	_	9	case
8	additive	additive	JJ	_	9	amod
9	effects	effect	NNS	_	6	nmod
10	such	such	JJ	_	12	case
11	as	as	IN	_	10	mwe
12	bradycardia	bradycardia	NN	_	9	nmod
13	and	and	CC	_	12	cc
14	AV	av	NN	_	15	compound
15	block	block	NN	_	12	conj
16	,	,	,	_	19	punct
17	caution	caution	NN	_	19	nsubjpass
18	is	be	VBZ	_	19	auxpass
19	warranted	warrant	VBN	_	0	ROOT
20	in	in	IN	_	21	case
21	patients	patient	NNS	_	19	nmod
22	receiving	receive	VBG	_	21	acl
23	drug1	drug1	NN	_	22	dobj
24	with	with	IN	_	25	case
25	agents	agent	NNS	_	22	nmod
26	known	know	VBN	_	25	acl
27	to	to	TO	_	28	mark
28	affect	affect	VB	_	26	xcomp
29	sinus	sinus	NN	_	31	compound
30	node	node	NN	_	31	compound
31	function	function	NN	_	28	dobj
32	or	or	CC	_	31	cc
33	AV	av	NN	_	35	compound
34	nodal	nodal	JJ	_	35	amod
35	conduction	conduction	NN	_	31	conj
36	-LRB-	-lrb-	-LRB-	_	39	punct
37	e.g.	e.g.	FW	_	39	dep
38	,	,	,	_	39	punct
39	drug2	drug2	NN	_	35	dep
40	,	,	,	_	39	punct
41	drug3	drug3	NN	_	39	conj
42	,	,	,	_	39	punct
43	and	and	CC	_	39	cc
44	drug4	drug4	NN	_	39	conj
45	.	.	.	_	39	punct
46	-RRB-	-rrb-	-RRB-	_	39	punct

1	There	there	EX	_	2	expl
2	is	be	VBZ	_	0	ROOT
3	one	one	CD	_	5	nummod
4	reported	report	VBD	_	5	amod
5	case	case	NN	_	2	nsubj
6	of	of	IN	_	8	case
7	a	a	DT	_	8	det
8	patient	patient	NN	_	5	nmod
9	with	with	IN	_	11	case
10	acute	acute	JJ	_	11	amod
11	delirium	delirium	NN	_	8	nmod
12	associated	associate	VBN	_	11	acl
13	with	with	IN	_	16	case
14	the	the	DT	_	16	det
15	simultaneous	simultaneous	JJ	_	16	amod
16	use	use	NN	_	12	nmod
17	of	of	IN	_	18	case
18	drug1	drug1	NN	_	16	nmod
19	and	and	CC	_	18	cc
20	oral	oral	JJ	_	21	amod
21	drug2	drug2	NN	_	18	conj
22	.	.	.	_	2	punct

1	Symptoms	symptom	NNS	_	0	ROOT
2	resolved	resolve	VBN	_	1	acl
3	when	when	WRB	_	6	advmod
4	drug1	drug1	NN	_	6	nsubjpass
5	was	be	VBD	_	6	auxpass
6	withdrawn	withdraw	VBN	_	2	advcl
7	and	and	CC	_	6	cc
8	recurred	recur	VBN	_	6	conj
9	when	when	WRB	_	13	advmod
10	the	the	DT	_	11	det
11	patient	patient	NN	_	13	nsubjpass
12	was	be	VBD	_	13	auxpass
13	rechallenged	rechallenge	VBN	_	6	advcl
14	with	with	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	.	.	.	_	1	punct

1	Epidural	epidural	JJ	_	2	amod
2	drug1	drug1	NN	_	4	nsubj
3	may	may	MD	_	4	aux
4	prolong	prolong	VB	_	0	ROOT
5	the	the	DT	_	6	det
6	duration	duration	NN	_	4	dobj
7	of	of	IN	_	9	case
8	pharmacologic	pharmacologic	JJ	_	9	amod
9	effects	effect	NNS	_	6	nmod
10	of	of	IN	_	13	case
11	epidural	epidural	JJ	_	13	amod
12	local	local	JJ	_	13	amod
13	drug2	drug2	NN	_	9	nmod
14	,	,	,	_	13	punct
15	including	include	VBG	_	17	case
16	both	both	DT	_	17	cc:preconj
17	sensory	sensory	JJ	_	13	nmod
18	and	and	CC	_	17	cc
19	motor	motor	NN	_	20	compound
20	blockade	blockade	NN	_	17	conj
21	.	.	.	_	4	punct

1	No	no	DT	_	2	neg
2	evidence	evidence	NN	_	11	nsubjpass
3	of	of	IN	_	4	case
4	interaction	interaction	NN	_	2	nmod
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	with	with	IN	_	9	case
8	other	other	JJ	_	9	amod
9	drugs	drug	NNS	_	4	nmod
10	was	be	VBD	_	11	auxpass
11	observed	observe	VBN	_	0	ROOT
12	in	in	IN	_	14	case
13	the	the	DT	_	14	det
14	course	course	NN	_	11	nmod
15	of	of	IN	_	17	case
16	clinical	clinical	JJ	_	17	amod
17	trials	trial	NNS	_	14	nmod
18	.	.	.	_	11	punct

1	drug1	drug1	NN	_	8	compound
2	-LRB-	-lrb-	-LRB-	_	5	punct
3	drug2	drug2	NN	_	5	compound
4	ophthalmic	ophthalmic	JJ	_	5	amod
5	suspension	suspension	NN	_	1	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	1	1	CD	_	8	nummod
8	%	%	NN	_	9	nsubj
9	contains	contain	VBZ	_	0	ROOT
10	a	a	DT	_	11	det
11	drug3	drug3	NN	_	9	dobj
12	.	.	.	_	9	punct

1	Acid-base	acid-base	NN	_	4	compound
2	and	and	CC	_	1	cc
3	electrolyte	electrolyte	NN	_	1	conj
4	alterations	alteration	NNS	_	7	nsubjpass
5	were	be	VBD	_	7	auxpass
6	not	not	RB	_	7	neg
7	reported	report	VBN	_	0	ROOT
8	in	in	IN	_	11	case
9	the	the	DT	_	11	det
10	clinical	clinical	JJ	_	11	amod
11	trials	trial	NNS	_	7	nmod
12	with	with	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	.	.	.	_	7	punct

1	However	however	RB	_	16	advmod
2	,	,	,	_	16	punct
3	in	in	IN	_	4	case
4	patients	patient	NNS	_	16	nmod
5	treated	treat	VBN	_	4	acl
6	with	with	IN	_	8	case
7	oral	oral	JJ	_	8	amod
8	drug1	drug1	NN	_	5	nmod
9	,	,	,	_	16	punct
10	rare	rare	JJ	_	11	amod
11	instances	instance	NNS	_	16	nsubj
12	of	of	IN	_	14	case
13	drug	drug	NN	_	14	compound
14	interactions	interaction	NNS	_	11	nmod
15	have	have	VBP	_	16	aux
16	occurred	occur	VBN	_	0	ROOT
17	with	with	IN	_	20	case
18	high-dose	high-dose	JJ	_	20	amod
19	drug2	drug2	NN	_	20	compound
20	therapy	therapy	NN	_	16	nmod
21	.	.	.	_	16	punct

1	Therefore	therefore	RB	_	11	advmod
2	,	,	,	_	11	punct
3	the	the	DT	_	4	det
4	potential	potential	NN	_	11	nsubjpass
5	for	for	IN	_	8	case
6	such	such	JJ	_	8	amod
7	drug	drug	NN	_	8	compound
8	interaction	interaction	NN	_	4	nmod
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	considered	consider	VBN	_	0	ROOT
12	in	in	IN	_	13	case
13	patients	patient	NNS	_	11	nmod
14	receiving	receive	VBG	_	13	acl
15	drug1	drug1	NN	_	22	compound
16	-LRB-	-lrb-	-LRB-	_	19	punct
17	drug2	drug2	NN	_	19	compound
18	ophthalmic	ophthalmic	JJ	_	19	amod
19	suspension	suspension	NN	_	15	appos
20	-RRB-	-rrb-	-RRB-	_	19	punct
21	1	1	CD	_	22	nummod
22	%	%	NN	_	14	dobj
23	.	.	.	_	11	punct

1	Certain	certain	JJ	_	2	amod
2	drug1	drug1	NN	_	11	nsubj
3	,	,	,	_	2	punct
4	especially	especially	RB	_	5	advmod
5	drug2	drug2	NN	_	2	appos
6	,	,	,	_	5	punct
7	drug3	drug3	NN	_	5	conj
8	and	and	CC	_	5	cc
9	drug4	drug4	NN	_	5	conj
10	,	,	,	_	2	punct
11	have	have	VBP	_	0	ROOT
12	a	a	DT	_	18	det
13	mild	mild	JJ	_	18	amod
14	but	but	CC	_	13	cc
15	definite	definite	JJ	_	13	conj
16	nondepolarizing	nondepolarizing	JJ	_	18	amod
17	blocking	block	VBG	_	18	compound
18	action	action	NN	_	11	dobj
19	which	which	WDT	_	21	nsubj
20	may	may	MD	_	21	aux
21	accentuate	accentuate	VB	_	18	acl:relcl
22	neuromuscular	neuromuscular	JJ	_	23	amod
23	block	block	NN	_	21	dobj
24	.	.	.	_	11	punct

1	These	these	DT	_	2	det
2	drug1	drug1	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	used	use	VBN	_	0	ROOT
6	in	in	IN	_	9	case
7	the	the	DT	_	9	det
8	myasthenic	myasthenic	JJ	_	9	amod
9	patient	patient	NN	_	5	nmod
10	only	only	RB	_	11	advmod
11	where	where	WRB	_	13	advmod
12	definitely	definitely	RB	_	13	advmod
13	indicated	indicate	VBN	_	9	acl:relcl
14	,	,	,	_	5	punct
15	and	and	CC	_	5	cc
16	then	then	RB	_	18	advmod
17	careful	careful	JJ	_	18	amod
18	adjustment	adjustment	NN	_	21	nsubjpass
19	should	should	MD	_	21	aux
20	be	be	VB	_	21	auxpass
21	made	make	VBN	_	5	conj
22	of	of	IN	_	25	case
23	adjunctive	adjunctive	JJ	_	25	amod
24	drug2	drug2	NN	_	25	compound
25	dosage	dosage	NN	_	21	nmod
26	.	.	.	_	5	punct

1	Local	local	JJ	_	18	nsubjpass
2	and	and	CC	_	1	cc
3	some	some	DT	_	5	det
4	general	general	JJ	_	5	amod
5	drug1	drug1	NN	_	1	conj
6	,	,	,	_	5	punct
7	drug2	drug2	NN	_	5	conj
8	and	and	CC	_	5	cc
9	other	other	JJ	_	10	amod
10	drugs	drug	NNS	_	5	conj
11	that	that	WDT	_	12	nsubj
12	interfere	interfere	VBP	_	10	acl:relcl
13	with	with	IN	_	15	case
14	neuromuscular	neuromuscular	JJ	_	15	amod
15	transmission	transmission	NN	_	12	nmod
16	should	should	MD	_	18	aux
17	be	be	VB	_	18	auxpass
18	used	use	VBN	_	0	ROOT
19	cautiously	cautiously	RB	_	18	advmod
20	,	,	,	_	18	punct
21	if	if	IN	_	23	mark
22	at	at	IN	_	23	case
23	all	all	DT	_	18	advcl
24	,	,	,	_	23	punct
25	in	in	IN	_	26	case
26	patients	patient	NNS	_	24	root
27	with	with	IN	_	29	case
28	myasthenia	myasthenia	NN	_	29	compound
29	gravis	gravis	NN	_	26	nmod
30	;	;	:	_	26	punct

1	the	the	DT	_	2	det
2	dose	dose	NN	_	6	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	may	may	MD	_	6	aux
6	have	have	VB	_	0	ROOT
7	to	to	TO	_	9	mark
8	be	be	VB	_	9	auxpass
9	increased	increase	VBN	_	6	xcomp
10	accordingly	accordingly	RB	_	9	advmod
11	.	.	.	_	6	punct

1	The	the	DT	_	4	det
2	following	follow	VBG	_	4	amod
3	drug	drug	NN	_	4	compound
4	interactions	interaction	NNS	_	6	nsubjpass
5	were	be	VBD	_	6	auxpass
6	studied	study	VBN	_	0	ROOT
7	with	with	IN	_	9	case
8	drug1	drug1	NN	_	9	compound
9	doses	dose	NNS	_	6	nmod
10	of	of	IN	_	12	case
11	200	200	CD	_	12	nummod
12	mg/day	mg/day	NN	_	9	nmod
13	.	.	.	_	6	punct

1	The	the	DT	_	2	det
2	possibility	possibility	NN	_	8	nsubjpass
3	of	of	IN	_	5	case
4	increased	increase	VBN	_	5	amod
5	interaction	interaction	NN	_	2	nmod
6	should	should	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	kept	keep	VBN	_	0	ROOT
9	in	in	IN	_	10	case
10	mind	mind	NN	_	8	nmod
11	when	when	WRB	_	30	advmod
12	drug1	drug1	NN	_	13	compound
13	doses	dose	NNS	_	30	nsubjpass
14	greater	greater	JJR	_	13	amod
15	than	than	IN	_	17	case
16	50	50	CD	_	17	nummod
17	mg	mg	NN	_	14	nmod
18	as	as	IN	_	21	case
19	a	a	DT	_	21	det
20	single	single	JJ	_	21	amod
21	dose	dose	NN	_	13	nmod
22	or	or	CC	_	21	cc
23	200	200	CD	_	24	nummod
24	mg	mg	NN	_	21	conj
25	of	of	IN	_	26	case
26	drug2	drug2	NN	_	21	nmod
27	per	per	IN	_	28	case
28	day	day	NN	_	26	nmod
29	are	be	VBP	_	30	auxpass
30	used	use	VBN	_	8	advcl
31	concomitantly	concomitantly	RB	_	30	advmod
32	with	with	IN	_	35	case
33	highly	highly	RB	_	34	advmod
34	bound	bind	VBN	_	35	amod
35	drugs	drug	NNS	_	30	nmod
36	.	.	.	_	8	punct

1	1	1	LS	_	0	ROOT
2	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concomitant	concomitant	JJ	_	4	amod
4	administration	administration	NN	_	11	nsubj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	drug3	drug3	NN	_	6	conj
9	does	do	VBZ	_	11	aux
10	not	not	RB	_	11	neg
11	interfere	interfere	VB	_	1	dep
12	with	with	IN	_	14	case
13	the	the	DT	_	14	det
14	rate	rate	NN	_	11	nmod
15	or	or	CC	_	14	cc
16	extent	extent	NN	_	14	conj
17	of	of	IN	_	19	case
18	the	the	DT	_	19	det
19	absorption	absorption	NN	_	14	nmod
20	of	of	IN	_	21	case
21	drug4	drug4	NN	_	19	nmod
22	administered	administer	VBN	_	21	acl
23	as	as	IN	_	24	case
24	drug5	drug5	NN	_	22	nmod
25	.	.	.	_	1	punct

1	2	2	LS	_	0	ROOT
2	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	6	nsubj
4	does	do	VBZ	_	6	aux
5	not	not	RB	_	6	neg
6	alter	alter	VB	_	1	dep
7	drug3	drug3	NN	_	8	compound
8	absorption	absorption	NN	_	6	dobj
9	;	;	:	_	6	punct

1	however	however	RB	_	15	advmod
2	,	,	,	_	15	punct
3	in	in	IN	_	5	case
4	a	a	DT	_	5	det
5	study	study	NN	_	15	nmod
6	of	of	IN	_	9	case
7	12	12	CD	_	9	nummod
8	normal	normal	JJ	_	9	amod
9	subjects	subject	NNS	_	5	nmod
10	,	,	,	_	15	punct
11	concurrent	concurrent	JJ	_	12	amod
12	administration	administration	NN	_	15	nsubj
13	of	of	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	decreased	decrease	VBD	_	0	ROOT
16	drug2	drug2	NN	_	18	compound
17	protein	protein	NN	_	18	compound
18	binding	binding	NN	_	15	dobj
19	and	and	CC	_	15	cc
20	increased	increase	VBD	_	23	amod
21	drug3	drug3	NN	_	23	compound
22	plasma	plasma	NN	_	23	compound
23	clearance	clearance	NN	_	15	conj
24	from	from	IN	_	26	case
25	0.07	0.07	CD	_	26	nummod
26	L/kg/h	l/kg/h	NN	_	23	nmod
27	without	without	IN	_	28	case
28	drug4	drug4	NN	_	23	nmod
29	to	to	TO	_	31	case
30	0.11	0.11	CD	_	31	nummod
31	L/kg/h	l/kg/h	NN	_	28	nmod
32	with	with	IN	_	33	case
33	drug5	drug5	NN	_	31	nmod
34	.	.	.	_	15	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	significance	significance	NN	_	11	nsubjpass
4	of	of	IN	_	6	case
5	these	these	DT	_	6	det
6	changes	change	NNS	_	3	nmod
7	has	have	VBZ	_	11	aux
8	not	not	RB	_	11	neg
9	been	be	VBN	_	11	auxpass
10	adequately	adequately	RB	_	11	advmod
11	studied	study	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	Therefore	therefore	RB	_	11	advmod
2	,	,	,	_	11	punct
3	concurrent	concurrent	JJ	_	4	amod
4	use	use	NN	_	11	nsubjpass
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	drug2	drug2	NN	_	6	conj
9	is	be	VBZ	_	11	auxpass
10	not	not	RB	_	11	neg
11	recommended	recommend	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	3	3	LS	_	0	ROOT
2	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	10	nsubj
4	,	,	,	_	3	punct
5	given	give	VBN	_	3	acl
6	concomitantly	concomitantly	RB	_	5	advmod
7	with	with	IN	_	8	case
8	drug3	drug3	NN	_	5	nmod
9	,	,	,	_	3	punct
10	produces	produce	VBZ	_	1	dep
11	a	a	DT	_	12	det
12	reduction	reduction	NN	_	10	dobj
13	in	in	IN	_	15	case
14	urinary	urinary	JJ	_	15	amod
15	potassium	potassium	NN	_	12	nmod
16	and	and	CC	_	15	cc
17	chloride	chloride	NN	_	18	compound
18	excretion	excretion	NN	_	15	conj
19	compared	compare	VBN	_	12	acl
20	to	to	TO	_	21	case
21	drug4	drug4	NN	_	19	nmod
22	alone	alone	RB	_	21	advmod
23	.	.	.	_	10	punct

1	Patients	patient	NNS	_	8	nsubj
2	taking	take	VBG	_	1	acl
3	drug1	drug1	NN	_	2	dobj
4	are	be	VBP	_	8	cop
5	at	at	IN	_	8	case
6	a	a	DT	_	8	det
7	greater	greater	JJR	_	8	amod
8	risk	risk	NN	_	0	ROOT
9	of	of	IN	_	10	mark
10	developing	develop	VBG	_	8	acl
11	renal	renal	JJ	_	12	amod
12	failure	failure	NN	_	10	dobj
13	secondary	secondary	JJ	_	12	amod
14	to	to	TO	_	16	case
15	a	a	DT	_	16	det
16	decrease	decrease	NN	_	13	nmod
17	in	in	IN	_	20	case
18	renal	renal	JJ	_	20	amod
19	blood	blood	NN	_	20	compound
20	flow	flow	NN	_	16	nmod
21	caused	cause	VBN	_	20	acl
22	by	by	IN	_	24	case
23	prostaglandin	prostaglandin	NN	_	24	compound
24	inhibition	inhibition	NN	_	21	nmod
25	.	.	.	_	8	punct

1	4	4	LS	_	0	ROOT
2	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	5	case
4	a	a	DT	_	5	det
5	study	study	NN	_	24	nmod
6	in	in	IN	_	8	case
7	12	12	CD	_	8	nummod
8	patients	patient	NNS	_	5	nmod
9	with	with	IN	_	12	case
10	congestive	congestive	JJ	_	12	amod
11	heart	heart	NN	_	12	compound
12	failure	failure	NN	_	8	nmod
13	where	where	WRB	_	19	advmod
14	drug2	drug2	NN	_	19	nsubjpass
15	and	and	CC	_	14	cc
16	drug3	drug3	NN	_	14	conj
17	were	be	VBD	_	19	auxpass
18	concomitantly	concomitantly	RB	_	19	advmod
19	administered	administer	VBN	_	12	acl:relcl
20	,	,	,	_	24	punct
21	drug4	drug4	NN	_	24	nsubj
22	did	do	VBD	_	24	aux
23	not	not	RB	_	24	neg
24	alter	alter	VB	_	1	appos
25	the	the	DT	_	27	det
26	serum	serum	NN	_	27	compound
27	levels	level	NNS	_	24	dobj
28	of	of	IN	_	29	case
29	drug5	drug5	NN	_	27	nmod
30	.	.	.	_	1	punct

1	5	5	CD	_	0	ROOT
2	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	7	case
4	a	a	DT	_	7	det
5	short-term	short-term	JJ	_	7	amod
6	controlled	controlled	JJ	_	7	amod
7	study	study	NN	_	17	nmod
8	in	in	IN	_	11	case
9	14	14	CD	_	11	nummod
10	normal	normal	JJ	_	11	amod
11	volunteers	volunteer	NNS	_	7	nmod
12	,	,	,	_	17	punct
13	drug2	drug2	NN	_	17	nsubj
14	did	do	VBD	_	17	aux
15	not	not	RB	_	17	neg
16	significantly	significantly	RB	_	17	advmod
17	interfere	interfere	VB	_	1	appos
18	with	with	IN	_	20	case
19	the	the	DT	_	20	det
20	effect	effect	NN	_	17	nmod
21	of	of	IN	_	22	case
22	drug3	drug3	NN	_	20	nmod
23	on	on	IN	_	25	case
24	prothrombin	prothrombin	NN	_	25	compound
25	time	time	NN	_	20	nmod
26	.	.	.	_	1	punct

1	Bleeding	bleed	VBG	_	10	csubj
2	from	from	IN	_	4	case
3	a	a	DT	_	4	det
4	number	number	NN	_	1	nmod
5	of	of	IN	_	6	case
6	sites	site	NNS	_	4	nmod
7	may	may	MD	_	10	aux
8	be	be	VB	_	10	cop
9	a	a	DT	_	10	det
10	complication	complication	NN	_	0	ROOT
11	of	of	IN	_	13	case
12	drug1	drug1	NN	_	13	compound
13	treatment	treatment	NN	_	10	nmod
14	and	and	CC	_	13	cc
15	GI	gi	NN	_	13	conj
16	bleeding	bleed	VBG	_	15	acl
17	a	a	DT	_	18	det
18	complication	complication	NN	_	16	dobj
19	of	of	IN	_	21	case
20	drug2	drug2	NN	_	21	compound
21	treatment	treatment	NN	_	18	nmod
22	.	.	.	_	10	punct

1	Because	because	IN	_	3	mark
2	prostaglandina	prostaglandina	NNS	_	3	nsubj
3	play	play	VBP	_	0	ROOT
4	an	a	DT	_	6	det
5	important	important	JJ	_	6	amod
6	role	role	NN	_	3	dobj
7	in	in	IN	_	8	case
8	hemostasis	hemostasis	NN	_	3	nmod
9	and	and	CC	_	8	cc
10	drug1	drug1	NN	_	8	conj
11	has	have	VBZ	_	3	dep
12	an	a	DT	_	13	det
13	effect	effect	NN	_	11	dobj
14	on	on	IN	_	16	case
15	platelet	platelet	NN	_	16	compound
16	function	function	NN	_	11	nmod
17	as	as	RB	_	18	case
18	well	well	RB	_	11	advmod
19	,	,	,	_	11	punct
20	concurent	concurent	JJ	_	21	amod
21	therapy	therapy	NN	_	26	nsubj
22	with	with	IN	_	23	case
23	drug2	drug2	NN	_	21	nmod
24	and	and	CC	_	23	cc
25	drug3	drug3	NN	_	23	conj
26	requires	require	VBZ	_	11	parataxis
27	close	close	JJ	_	28	amod
28	monitoring	monitoring	NN	_	26	dobj
29	of	of	IN	_	30	case
30	patients	patient	NNS	_	28	nmod
31	on	on	IN	_	33	case
32	both	both	DT	_	33	det
33	drugs	drug	NNS	_	30	nmod
34	.	.	.	_	3	punct

1	6	6	CD	_	0	ROOT
2	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	nsubj
4	increases	increase	VBZ	_	1	dep
5	both	both	CC	_	6	cc:preconj
6	free	free	JJ	_	9	amod
7	and	and	CC	_	6	cc
8	bound	bind	VBD	_	6	conj
9	drug3	drug3	NN	_	4	dobj
10	by	by	IN	_	11	mark
11	reducing	reduce	VBG	_	4	advcl
12	the	the	DT	_	14	det
13	plasma	plasma	NN	_	14	compound
14	clearance	clearance	NN	_	11	dobj
15	of	of	IN	_	16	case
16	drug4	drug4	NN	_	14	nmod
17	to	to	TO	_	19	case
18	about	about	IN	_	19	amod
19	one-third	one-third	NN	_	11	nmod
20	,	,	,	_	4	punct
21	as	as	RB	_	4	cc
22	well	well	RB	_	21	mwe
23	as	as	IN	_	21	mwe
24	decreasing	decrease	VBG	_	4	conj
25	its	its	PRP$	_	27	nmod:poss
26	protein	protein	NN	_	27	compound
27	binding	binding	NN	_	24	dobj
28	.	.	.	_	1	punct

1	Therefore	therefore	RB	_	11	advmod
2	,	,	,	_	11	punct
3	the	the	DT	_	4	det
4	combination	combination	NN	_	11	nsubjpass
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	drug2	drug2	NN	_	6	conj
9	is	be	VBZ	_	11	auxpass
10	not	not	RB	_	11	neg
11	recommended	recommend	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	7	7	CD	_	0	ROOT
2	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	10	nsubj
4	,	,	,	_	3	punct
5	like	like	IN	_	7	case
6	other	other	JJ	_	7	amod
7	drug3	drug3	NN	_	3	nmod
8	,	,	,	_	3	punct
9	may	may	MD	_	10	aux
10	cause	cause	VB	_	1	dep
11	changes	change	NNS	_	10	dobj
12	in	in	IN	_	14	case
13	the	the	DT	_	14	det
14	elimination	elimination	NN	_	11	nmod
15	of	of	IN	_	16	case
16	drug4	drug4	NN	_	14	nmod
17	leading	lead	VBG	_	16	acl
18	to	to	TO	_	21	case
19	elevated	elevated	JJ	_	21	amod
20	serum	serum	NN	_	21	compound
21	levels	level	NNS	_	17	nmod
22	of	of	IN	_	24	case
23	the	the	DT	_	24	det
24	drug	drug	NN	_	21	nmod
25	and	and	CC	_	10	cc
26	increased	increase	VBD	_	27	amod
27	toxicity	toxicity	NN	_	10	conj
28	.	.	.	_	10	punct

1	8	8	CD	_	0	ROOT
2	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	6	nsubjpass
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	auxpass
6	reported	report	VBN	_	1	appos
7	to	to	TO	_	8	mark
8	increase	increase	VB	_	6	xcomp
9	steadystate	steadystate	JJ	_	12	amod
10	plasma	plasma	NN	_	12	compound
11	drug3	drug3	NN	_	12	compound
12	levels	level	NNS	_	8	dobj
13	.	.	.	_	1	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	recommended	recommend	VBN	_	0	ROOT
4	that	that	IN	_	9	mark
5	plasma	plasma	NN	_	7	compound
6	drug1	drug1	NN	_	7	compound
7	levels	level	NNS	_	9	nsubjpass
8	be	be	VB	_	9	auxpass
9	monitored	monitor	VBN	_	3	ccomp
10	when	when	WRB	_	13	advmod
11	drug2	drug2	NN	_	13	nsubjpass
12	is	be	VBZ	_	13	auxpass
13	coadministered	coadminister	VBN	_	9	advcl
14	with	with	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	.	.	.	_	3	punct

1	DRUG/LABORATORY	drug/laboratory	NN	_	3	compound
2	TEST	test	NN	_	3	compound
3	INTERACTIONS	interaction	NNS	_	0	ROOT
4	:	:	:	_	3	punct
5	EFFECT	effect	NN	_	10	nsubj
6	ON	on	IN	_	9	case
7	BLOOD	blood	NN	_	9	compound
8	COAGULATION	coagulation	NN	_	9	compound
9	drug1	drug1	NN	_	5	nmod
10	decreases	decrease	VBZ	_	3	dep
11	platelet	platelet	NN	_	12	compound
12	adhesion	adhesion	NN	_	10	dobj
13	and	and	CC	_	12	cc
14	aggregation	aggregation	NN	_	12	conj
15	.	.	.	_	3	punct

1	Therefore	therefore	RB	_	5	advmod
2	,	,	,	_	5	punct
3	it	it	PRP	_	5	nsubj
4	can	can	MD	_	5	aux
5	prolong	prolong	VB	_	0	ROOT
6	bleeding	bleeding	JJ	_	7	amod
7	time	time	NN	_	5	dobj
8	by	by	IN	_	13	case
9	approximately	approximately	RB	_	12	advmod
10	3	3	CD	_	12	compound
11	to	to	TO	_	12	dep
12	4	4	CD	_	13	nummod
13	minutes	minute	NNS	_	5	nmod
14	from	from	IN	_	16	case
15	baseline	baseline	NN	_	16	compound
16	values	value	NNS	_	5	nmod
17	.	.	.	_	5	punct

1	There	there	EX	_	2	expl
2	is	be	VBZ	_	0	ROOT
3	no	no	DT	_	5	neg
4	significant	significant	JJ	_	5	amod
5	change	change	NN	_	2	nsubj
6	in	in	IN	_	8	case
7	platelet	platelet	NN	_	8	compound
8	count	count	NN	_	5	nmod
9	,	,	,	_	8	punct
10	prothrombin	prothrombin	NN	_	11	compound
11	time	time	NN	_	8	conj
12	,	,	,	_	8	punct
13	partial	partial	JJ	_	15	amod
14	thromboplastin	thromboplastin	NN	_	15	compound
15	time	time	NN	_	8	conj
16	,	,	,	_	8	punct
17	or	or	CC	_	8	cc
18	thrombin	thrombin	NN	_	19	compound
19	time	time	NN	_	8	conj
20	.	.	.	_	2	punct

1	Because	because	IN	_	5	mark
2	drug1	drug1	NN	_	5	nsubjpass
3	have	have	VBP	_	5	aux
4	been	be	VBN	_	5	auxpass
5	shown	show	VBN	_	19	advcl
6	to	to	TO	_	7	mark
7	depress	depress	VB	_	5	xcomp
8	plasma	plasma	NN	_	10	compound
9	prothrombin	prothrombin	NN	_	10	compound
10	activity	activity	NN	_	7	dobj
11	,	,	,	_	19	punct
12	patients	patient	NNS	_	19	nsubj
13	who	who	WP	_	17	nsubj
14	are	be	VBP	_	17	cop
15	on	on	IN	_	17	case
16	drug2	drug2	NN	_	17	compound
17	therapy	therapy	NN	_	12	acl:relcl
18	may	may	MD	_	19	aux
19	require	require	VB	_	0	ROOT
20	downward	downward	JJ	_	21	amod
21	adjustment	adjustment	NN	_	19	dobj
22	of	of	IN	_	25	case
23	their	they	PRP$	_	25	nmod:poss
24	drug3	drug3	NN	_	25	compound
25	dosage	dosage	NN	_	21	nmod
26	.	.	.	_	19	punct

1	Since	since	IN	_	5	mark
2	bacteriostatic	bacteriostatic	JJ	_	3	amod
3	drugs	drug	NNS	_	5	nsubj
4	may	may	MD	_	5	aux
5	interfere	interfere	VB	_	15	advcl
6	with	with	IN	_	9	case
7	the	the	DT	_	9	det
8	bactericidal	bactericidal	JJ	_	9	amod
9	action	action	NN	_	5	nmod
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	,	,	,	_	15	punct
13	it	it	PRP	_	15	nsubj
14	is	be	VBZ	_	15	cop
15	advisable	advisable	JJ	_	0	ROOT
16	to	to	TO	_	17	mark
17	avoid	avoid	VB	_	15	xcomp
18	giving	give	VBG	_	17	xcomp
19	drug2	drug2	NN	_	18	dobj
20	in	in	IN	_	21	case
21	conjunction	conjunction	NN	_	18	nmod
22	with	with	IN	_	23	case
23	drug3	drug3	NN	_	21	nmod
24	.	.	.	_	15	punct

1	Absorption	absorption	NN	_	5	nsubjpass
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	is	be	VBZ	_	5	auxpass
5	impaired	impair	VBN	_	0	ROOT
6	by	by	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	containing	contain	VBG	_	7	acl
9	drug3	drug3	NN	_	8	dobj
10	,	,	,	_	9	punct
11	drug4	drug4	NN	_	9	conj
12	,	,	,	_	9	punct
13	or	or	CC	_	9	cc
14	drug5	drug5	NN	_	9	conj
15	,	,	,	_	5	punct
16	and	and	CC	_	5	cc
17	drug6	drug6	NN	_	5	conj
18	-	-	:	_	17	punct
19	containing	contain	VBG	_	17	acl
20	preparations	preparation	NNS	_	19	dobj
21	.	.	.	_	5	punct

1	Absorption	absorption	NN	_	5	nsubjpass
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	is	be	VBZ	_	5	auxpass
5	impaired	impair	VBN	_	0	ROOT
6	by	by	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	.	.	.	_	5	punct

1	drug1	drug1	NN	_	7	nsubj
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	,	,	,	_	1	punct
5	and	and	CC	_	1	cc
6	drug3	drug3	NN	_	1	conj
7	decrease	decrease	VBP	_	0	ROOT
8	the	the	DT	_	9	det
9	half-life	half-life	NN	_	7	dobj
10	of	of	IN	_	11	case
11	drug4	drug4	NN	_	9	nmod
12	.	.	.	_	7	punct

1	The	the	DT	_	3	det
2	concurrent	concurrent	JJ	_	3	amod
3	use	use	NN	_	13	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	drug3	drug3	NN	_	7	appos
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	has	have	VBZ	_	13	aux
12	been	be	VBN	_	13	auxpass
13	reported	report	VBN	_	0	ROOT
14	to	to	TO	_	15	mark
15	result	result	VB	_	13	xcomp
16	in	in	IN	_	19	case
17	fatal	fatal	JJ	_	19	amod
18	renal	renal	JJ	_	19	amod
19	toxicity	toxicity	NN	_	15	nmod
20	.	.	.	_	13	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	use	use	NN	_	6	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	may	may	MD	_	6	aux
6	render	render	VB	_	0	ROOT
7	oral	oral	JJ	_	8	amod
8	drug2	drug2	NN	_	10	nsubj
9	less	less	RBR	_	10	advmod
10	effective	effective	JJ	_	6	xcomp
11	.	.	.	_	6	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	3	amod
2	Test	test	NN	_	3	compound
3	Interactions	interaction	NNS	_	0	ROOT
4	False	false	JJ	_	5	amod
5	elevations	elevation	NNS	_	11	nsubj
6	of	of	IN	_	9	case
7	urinary	urinary	JJ	_	9	amod
8	catecholamine	catecholamine	NN	_	9	compound
9	levels	level	NNS	_	5	nmod
10	may	may	MD	_	11	aux
11	occur	occur	VB	_	3	acl:relcl
12	due	due	JJ	_	14	case
13	to	to	TO	_	12	mwe
14	interference	interference	NN	_	11	nmod
15	with	with	IN	_	18	case
16	the	the	DT	_	18	det
17	fluorescence	fluorescence	NN	_	18	compound
18	test	test	NN	_	14	nmod
19	.	.	.	_	3	punct

1	General	General	NNP	_	6	compound
2	No	No	NNP	_	6	compound
3	clinical	clinical	JJ	_	6	amod
4	drug	drug	NN	_	6	compound
5	interaction	interaction	NN	_	6	compound
6	studies	study	NNS	_	8	nsubjpass
7	were	be	VBD	_	8	auxpass
8	performed	perform	VBN	_	0	ROOT
9	.	.	.	_	8	punct

1	No	no	DT	_	2	neg
2	evaluation	evaluation	NN	_	13	nsubjpass
3	of	of	IN	_	6	case
4	drug1	drug1	NN	_	6	compound
5	s	s	NNS	_	6	compound
6	effects	effect	NNS	_	2	nmod
7	on	on	IN	_	11	case
8	the	the	DT	_	11	det
9	cytochrome	cytochrome	NN	_	11	compound
10	P450	p450	NN	_	11	compound
11	system	system	NN	_	6	nmod
12	was	be	VBD	_	13	auxpass
13	conducted	conduct	VBN	_	0	ROOT
14	.	.	.	_	13	punct

1	As	as	IN	_	4	case
2	with	with	IN	_	4	case
3	other	other	JJ	_	4	amod
4	drug1	drug1	NN	_	13	nmod
5	,	,	,	_	13	punct
6	blood	blood	NN	_	7	compound
7	concentrations	concentration	NNS	_	13	nsubjpass
8	of	of	IN	_	10	case
9	dialyzable	dialyzable	JJ	_	10	amod
10	drugs	drug	NNS	_	7	nmod
11	may	may	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	reduced	reduce	VBN	_	0	ROOT
14	by	by	IN	_	15	case
15	dialysis	dialysis	NN	_	13	nmod
16	.	.	.	_	13	punct

1	Dosage	dosage	NN	_	2	compound
2	adjustment	adjustment	NN	_	8	nsubj
3	of	of	IN	_	5	case
4	concomitant	concomitant	JJ	_	5	amod
5	medications	medication	NNS	_	2	nmod
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	cop
8	necessary	necessary	JJ	_	0	ROOT
9	.	.	.	_	8	punct

1	In	in	IN	_	2	case
2	patients	patient	NNS	_	22	nmod
3	using	use	VBG	_	2	acl
4	drug1	drug1	NN	_	3	dobj
5	-LRB-	-lrb-	-LRB-	_	6	punct
6	drug2	drug2	NN	_	4	dep
7	and	and	CC	_	6	cc
8	others	other	NNS	_	6	conj
9	-RRB-	-rrb-	-RRB-	_	6	punct
10	,	,	,	_	22	punct
11	plasma	plasma	NN	_	12	compound
12	levels	level	NNS	_	22	nsubjpass
13	of	of	IN	_	14	case
14	calcium	calcium	NN	_	12	nmod
15	,	,	,	_	14	punct
16	potassium	potassium	NN	_	14	conj
17	and	and	CC	_	14	cc
18	magnesium	magnesium	NN	_	14	conj
19	must	must	MD	_	22	aux
20	be	be	VB	_	22	auxpass
21	carefully	carefully	RB	_	22	advmod
22	monitored	monitor	VBN	_	0	ROOT
23	.	.	.	_	22	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	A	a	DT	_	5	det
4	clinical	clinical	JJ	_	5	amod
5	study	study	NN	_	11	nsubj
6	in	in	IN	_	10	case
7	6	6	CD	_	10	nummod
8	insulin-dependent	insulin-dependent	JJ	_	10	amod
9	diabetic	diabetic	JJ	_	10	amod
10	patients	patient	NNS	_	5	nmod
11	demonstrated	demonstrate	VBD	_	1	dep
12	no	no	DT	_	13	neg
13	effect	effect	NN	_	11	dobj
14	of	of	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	on	on	IN	_	18	case
17	drug3	drug3	NN	_	18	compound
18	absorption	absorption	NN	_	13	nmod
19	from	from	IN	_	22	case
20	the	the	DT	_	22	det
21	peritoneal	peritoneal	JJ	_	22	amod
22	cavity	cavity	NN	_	18	nmod
23	or	or	CC	_	22	cc
24	on	on	IN	_	27	case
25	drug4	drug4	NN	_	27	compound
26	s	s	NNS	_	27	compound
27	ability	ability	NN	_	22	conj
28	to	to	TO	_	29	mark
29	control	control	VB	_	27	acl
30	blood	blood	NN	_	31	compound
31	glucose	glucose	NN	_	29	dobj
32	when	when	WRB	_	35	advmod
33	drug5	drug5	NN	_	35	nsubjpass
34	was	be	VBD	_	35	auxpass
35	administered	administer	VBN	_	29	advcl
36	intraperitoneally	intraperitoneally	RB	_	35	advmod
37	with	with	IN	_	38	case
38	drug6	drug6	NN	_	35	nmod
39	.	.	.	_	1	punct

1	However	however	RB	_	10	advmod
2	,	,	,	_	10	punct
3	appropriate	appropriate	JJ	_	4	amod
4	monitoring	monitoring	NN	_	10	nsubjpass
5	of	of	IN	_	7	case
6	blood	blood	NN	_	7	compound
7	glucose	glucose	NN	_	4	nmod
8	should	should	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	performed	perform	VBN	_	0	ROOT
11	when	when	WRB	_	12	advmod
12	initiating	initiate	VBG	_	10	advcl
13	drug1	drug1	NN	_	12	dobj
14	in	in	IN	_	16	case
15	diabetic	diabetic	JJ	_	16	amod
16	patients	patient	NNS	_	12	nmod
17	and	and	CC	_	16	cc
18	drug2	drug2	NN	_	19	compound
19	dosage	dosage	NN	_	16	conj
20	should	should	MD	_	22	aux
21	be	be	VB	_	22	auxpass
22	adjusted	adjust	VBN	_	10	dep
23	if	if	IN	_	24	mark
24	needed	need	VBN	_	22	advcl
25	.	.	.	_	10	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	No	no	DT	_	7	neg
4	human	human	JJ	_	7	amod
5	drug	drug	NN	_	7	compound
6	interaction	interaction	NN	_	7	compound
7	studies	study	NNS	_	11	nsubjpass
8	with	with	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	were	be	VBD	_	11	auxpass
11	conducted	conduct	VBN	_	1	dep
12	.	.	.	_	11	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	4	nsubj
4	demonstrated	demonstrate	VBD	_	0	ROOT
5	no	no	DT	_	6	neg
6	evidence	evidence	NN	_	4	dobj
7	of	of	IN	_	8	case
8	incompatibility	incompatibility	NN	_	6	nmod
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	with	with	IN	_	12	case
12	drug2	drug2	NN	_	8	nmod
13	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	No	no	DT	_	7	neg
4	human	human	JJ	_	7	amod
5	drug	drug	NN	_	7	compound
6	interaction	interaction	NN	_	7	compound
7	studies	study	NNS	_	11	nsubjpass
8	with	with	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	were	be	VBD	_	11	auxpass
11	conducted	conduct	VBN	_	1	dep
12	.	.	.	_	11	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	29	nsubj
4	evaluating	evaluate	VBG	_	3	acl
5	the	the	DT	_	8	det
6	minimum	minimum	JJ	_	8	amod
7	inhibitory	inhibitory	JJ	_	8	amod
8	concentration	concentration	NN	_	4	dobj
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	MIC	mic	NN	_	8	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	of	of	IN	_	13	case
13	drug1	drug1	NN	_	8	nmod
14	,	,	,	_	13	punct
15	drug2	drug2	NN	_	13	conj
16	,	,	,	_	13	punct
17	drug3	drug3	NN	_	13	conj
18	,	,	,	_	13	punct
19	drug4	drug4	NN	_	13	conj
20	/	/	:	_	13	punct
21	flucoxacillin	flucoxacillin	NN	_	13	dep
22	,	,	,	_	21	punct
23	drug5	drug5	NN	_	21	conj
24	,	,	,	_	21	punct
25	drug6	drug6	NN	_	21	conj
26	,	,	,	_	21	punct
27	and	and	CC	_	21	cc
28	drug7	drug7	NN	_	21	conj
29	demonstrated	demonstrate	VBD	_	0	ROOT
30	no	no	DT	_	31	neg
31	evidence	evidence	NN	_	29	dobj
32	of	of	IN	_	33	case
33	incompatibility	incompatibility	NN	_	31	nmod
34	of	of	IN	_	36	case
35	these	these	DT	_	36	det
36	drug8	drug8	NN	_	33	nmod
37	with	with	IN	_	38	case
38	drug9	drug9	NN	_	33	nmod
39	.	.	.	_	29	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	8	amod
2	Test	test	NN	_	8	compound
3	Interactions	interaction	NNS	_	8	compound
4	Blood	blood	NN	_	8	compound
5	Glucose	glucose	NN	_	8	compound
6	Blood	blood	NN	_	8	compound
7	glucose	glucose	NN	_	8	compound
8	measurement	measurement	NN	_	11	nsubjpass
9	must	must	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	done	do	VBN	_	0	ROOT
12	with	with	IN	_	15	case
13	a	a	DT	_	15	det
14	glucose-specific	glucose-specific	JJ	_	15	amod
15	method	method	NN	_	11	nmod
16	to	to	TO	_	17	mark
17	prevent	prevent	VB	_	15	acl
18	maltose	maltose	NN	_	19	compound
19	interference	interference	NN	_	17	dobj
20	with	with	IN	_	22	case
21	test	test	NN	_	22	compound
22	results	result	NNS	_	17	nmod
23	.	.	.	_	11	punct

1	Since	since	IN	_	8	mark
2	falsely	falsely	RB	_	3	advmod
3	elevated	elevated	JJ	_	5	amod
4	glucose	glucose	NN	_	5	compound
5	levels	level	NNS	_	8	nsubjpass
6	have	have	VBP	_	8	aux
7	been	be	VBN	_	8	auxpass
8	observed	observe	VBN	_	0	ROOT
9	with	with	IN	_	13	case
10	blood	blood	NN	_	13	compound
11	glucose	glucose	NN	_	13	compound
12	monitoring	monitoring	NN	_	13	compound
13	devices	device	NNS	_	8	nmod
14	and	and	CC	_	13	cc
15	test	test	NN	_	16	compound
16	strips	strip	NNS	_	13	conj
17	that	that	WDT	_	18	nsubj
18	use	use	VBP	_	13	acl:relcl
19	glucose	glucose	NN	_	21	compound
20	dehydrogenase	dehydrogenase	NN	_	21	compound
21	pyrroloquinolinequinone	pyrroloquinolinequinone	NN	_	18	dobj
22	-LRB-	-lrb-	-LRB-	_	24	punct
23	GDH	gdh	NN	_	24	compound
24	PQQ	pqq	NN	_	21	appos
25	-RRB-	-rrb-	-RRB-	_	24	punct
26	-	-	:	_	21	punct
27	based	base	VBN	_	28	amod
28	methods	method	NNS	_	36	nsubjpass
29	,	,	,	_	28	punct
30	GDH	gdh	NN	_	32	compound
31	PQQ-based	pqq-based	JJ	_	32	amod
32	methods	method	NNS	_	28	appos
33	should	should	MD	_	36	aux
34	not	not	RB	_	36	neg
35	be	be	VB	_	36	auxpass
36	used	use	VBN	_	21	acl:relcl
37	to	to	TO	_	38	mark
38	measure	measure	VB	_	36	xcomp
39	glucose	glucose	NN	_	40	compound
40	levels	level	NNS	_	38	dobj
41	in	in	IN	_	42	case
42	patients	patient	NNS	_	40	nmod
43	administered	administer	VBN	_	44	amod
44	drug1	drug1	NN	_	42	dep
45	.	.	.	_	8	punct
46	.	.	.	_	8	punct

1	Serum	serum	NN	_	2	compound
2	Amylase	amylase	NN	_	12	nsubjpass
3	An	a	DT	_	5	det
4	apparent	apparent	JJ	_	5	amod
5	decrease	decrease	NN	_	2	dep
6	in	in	IN	_	9	case
7	serum	serum	NN	_	9	compound
8	amylase	amylase	NN	_	9	compound
9	activity	activity	NN	_	5	nmod
10	has	have	VBZ	_	12	aux
11	been	be	VBN	_	12	auxpass
12	observed	observe	VBN	_	0	ROOT
13	in	in	IN	_	14	case
14	patients	patient	NNS	_	12	nmod
15	administered	administer	VBN	_	16	amod
16	drug1	drug1	NN	_	14	dep
17	.	.	.	_	12	punct

1	Preliminary	preliminary	JJ	_	2	amod
2	investigations	investigation	NNS	_	3	nsubj
3	indicate	indicate	VBP	_	0	ROOT
4	that	that	IN	_	9	mark
5	drug1	drug1	NN	_	9	nsubj
6	and	and	CC	_	5	cc
7	its	its	PRP$	_	8	nmod:poss
8	metabolites	metabolite	NNS	_	5	conj
9	interfere	interfere	VBP	_	3	ccomp
10	with	with	IN	_	13	case
11	enzymatic-based	enzymatic-based	JJ	_	13	amod
12	amylase	amylase	NN	_	13	compound
13	assays	assay	NNS	_	9	nmod
14	,	,	,	_	9	punct
15	resulting	result	VBG	_	9	advcl
16	in	in	IN	_	19	case
17	inaccurately	inaccurately	RB	_	18	advmod
18	low	low	JJ	_	19	amod
19	values	value	NNS	_	15	nmod
20	.	.	.	_	3	punct

1	This	this	DT	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	taken	take	VBN	_	0	ROOT
5	into	into	IN	_	6	case
6	account	account	NN	_	4	nmod
7	when	when	WRB	_	8	advmod
8	evaluating	evaluate	VBG	_	4	advcl
9	serum	serum	NN	_	11	compound
10	amylase	amylase	NN	_	11	compound
11	levels	level	NNS	_	8	dobj
12	for	for	IN	_	13	case
13	diagnosis	diagnosis	NN	_	11	nmod
14	or	or	CC	_	13	cc
15	monitoring	monitoring	NN	_	13	conj
16	of	of	IN	_	17	case
17	pancreatitis	pancreatitis	NN	_	13	nmod
18	in	in	IN	_	19	case
19	patients	patient	NNS	_	8	nmod
20	using	use	VBG	_	19	acl
21	drug1	drug1	NN	_	20	dobj
22	.	.	.	_	4	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	with	with	IN	_	6	case
6	caution	caution	NN	_	4	nmod
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	who	who	WP	_	11	nsubj
10	are	be	VBP	_	11	aux
11	receiving	receive	VBG	_	8	acl:relcl
12	a	a	DT	_	13	det
13	drug2	drug2	NN	_	11	dobj
14	orally	orally	RB	_	11	advmod
15	because	because	IN	_	18	case
16	of	of	IN	_	15	mwe
17	the	the	DT	_	18	det
18	potential	potential	NN	_	11	nmod
19	for	for	IN	_	21	case
20	additive	additive	JJ	_	21	amod
21	effects	effect	NNS	_	18	nmod
22	on	on	IN	_	24	case
23	systemic	systemic	JJ	_	24	amod
24	beta-blockade	beta-blockade	NN	_	21	nmod
25	.	.	.	_	4	punct

1	Close	close	JJ	_	2	amod
2	observation	observation	NN	_	7	nsubjpass
3	of	of	IN	_	5	case
4	the	the	DT	_	5	det
5	patient	patient	NN	_	2	nmod
6	is	be	VBZ	_	7	auxpass
7	recommended	recommend	VBN	_	0	ROOT
8	when	when	WRB	_	12	advmod
9	a	a	DT	_	10	det
10	drug1	drug1	NN	_	12	nsubjpass
11	is	be	VBZ	_	12	auxpass
12	administered	administer	VBN	_	7	advcl
13	to	to	TO	_	14	case
14	patients	patient	NNS	_	12	nmod
15	receiving	receive	VBG	_	14	acl
16	catecholamine-depleting	catecholamine-depleting	JJ	_	17	amod
17	drugs	drug	NNS	_	15	dobj
18	such	such	JJ	_	20	case
19	as	as	IN	_	18	mwe
20	drug2	drug2	NN	_	17	nmod
21	,	,	,	_	7	punct
22	because	because	IN	_	26	case
23	of	of	IN	_	22	mwe
24	possible	possible	JJ	_	26	amod
25	additive	additive	JJ	_	26	amod
26	effects	effect	NNS	_	7	nmod
27	and	and	CC	_	26	cc
28	the	the	DT	_	29	det
29	production	production	NN	_	26	conj
30	of	of	IN	_	31	case
31	hypotension	hypotension	NN	_	29	nmod
32	and/or	and/or	CC	_	31	cc
33	marked	marked	JJ	_	34	amod
34	bradycardia	bradycardia	NN	_	31	conj
35	,	,	,	_	29	punct
36	which	which	WDT	_	38	nsubj
37	may	may	MD	_	38	aux
38	produce	produce	VB	_	29	acl:relcl
39	vertigo	vertigo	NN	_	38	dobj
40	,	,	,	_	39	punct
41	syncope	syncope	NN	_	39	conj
42	,	,	,	_	39	punct
43	or	or	CC	_	39	cc
44	postural	postural	JJ	_	45	amod
45	hypotension	hypotension	NN	_	39	conj
46	.	.	.	_	7	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	increase	increase	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	plasma-level	plasma-level	NN	_	3	dobj
6	of	of	IN	_	9	case
7	concomitantly	concomitantly	RB	_	8	advmod
8	given	give	VBN	_	9	amod
9	drug2	drug2	NN	_	5	nmod
10	.	.	.	_	3	punct

1	In	in	IN	_	4	mark
2	order	order	NN	_	1	mwe
3	to	to	TO	_	4	mark
4	avoid	avoid	VB	_	13	advcl
5	drug1	drug1	NN	_	6	compound
6	intoxication	intoxication	NN	_	4	dobj
7	,	,	,	_	13	punct
8	drug2	drug2	NN	_	10	compound
9	plasma	plasma	NN	_	10	compound
10	levels	level	NNS	_	13	nsubjpass
11	should	should	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	monitored	monitor	VBN	_	0	ROOT
14	closely	closely	RB	_	13	advmod
15	.	.	.	_	13	punct

1	If	if	IN	_	4	mark
2	drug1	drug1	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	given	give	VBN	_	14	advcl
5	concomitantly	concomitantly	RB	_	4	advmod
6	with	with	IN	_	7	case
7	drug2	drug2	NN	_	4	nmod
8	,	,	,	_	14	punct
9	the	the	DT	_	11	det
10	drug3	drug3	NN	_	11	compound
11	dose	dose	NN	_	14	nsubjpass
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	reduced	reduce	VBN	_	0	ROOT
15	-LRB-	-lrb-	-LRB-	_	17	punct
16	by	by	IN	_	17	case
17	approx	approx	RB	_	14	dep
18	.	.	.	_	17	punct
19	50	50	CD	_	20	nummod
20	%	%	NN	_	17	dep
21	-RRB-	-rrb-	-RRB-	_	17	punct
22	,	,	,	_	14	punct
23	because	because	IN	_	25	mark
24	drug4	drug4	NN	_	25	nsubj
25	amplifies	amplify	VBZ	_	14	advcl
26	the	the	DT	_	28	det
27	therapeutic	therapeutic	JJ	_	28	amod
28	actions	action	NNS	_	25	dobj
29	and	and	CC	_	28	cc
30	side-effects	side-effect	NNS	_	28	conj
31	of	of	IN	_	32	case
32	drug5	drug5	NN	_	28	nmod
33	massively	massively	RB	_	32	advmod
34	.	.	.	_	14	punct

1	Avoid	avoid	VB	_	0	ROOT
2	the	the	DT	_	4	det
3	concomitant	concomitant	JJ	_	4	amod
4	use	use	NN	_	1	dobj
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	drug2	drug2	NN	_	6	conj
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	drug3	drug3	NN	_	8	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	.	.	.	_	1	punct

1	Massive	massive	JJ	_	2	amod
2	seizures	seizure	NNS	_	5	nsubjpass
3	may	may	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	encountered	encounter	VBN	_	0	ROOT
6	with	with	IN	_	8	case
7	this	this	DT	_	8	det
8	combination	combination	NN	_	5	nmod
9	.	.	.	_	5	punct

1	Consider	consider	VB	_	0	ROOT
2	additive	additive	JJ	_	4	amod
3	sedative	sedative	JJ	_	4	amod
4	effects	effect	NNS	_	1	dobj
5	and	and	CC	_	4	cc
6	confusional	confusional	JJ	_	7	amod
7	states	state	NNS	_	4	conj
8	to	to	TO	_	9	mark
9	emerge	emerge	VB	_	1	xcomp
10	,	,	,	_	9	punct
11	if	if	IN	_	14	mark
12	drug1	drug1	NN	_	14	nsubjpass
13	is	be	VBZ	_	14	auxpass
14	given	give	VBN	_	9	advcl
15	with	with	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	or	or	CC	_	16	cc
18	drug3	drug3	NN	_	16	conj
19	.	.	.	_	1	punct

1	Choose	choose	VB	_	0	ROOT
2	particular	particular	JJ	_	4	amod
3	low	low	JJ	_	4	amod
4	doses	dose	NNS	_	1	dobj
5	of	of	IN	_	7	case
6	these	these	DT	_	7	det
7	drugs	drug	NNS	_	4	nmod
8	.	.	.	_	1	punct

1	Exert	exert	VB	_	0	ROOT
2	particular	particular	JJ	_	3	amod
3	caution	caution	NN	_	1	dobj
4	in	in	IN	_	5	mark
5	combining	combine	VBG	_	1	advcl
6	drug1	drug1	NN	_	5	dobj
7	with	with	IN	_	9	case
8	other	other	JJ	_	9	amod
9	drug2	drug2	NN	_	5	nmod
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	drug3	drug3	NN	_	9	dep
12	and	and	CC	_	11	cc
13	drug4	drug4	NN	_	11	conj
14	-RRB-	-rrb-	-RRB-	_	11	punct
15	:	:	:	_	1	punct
16	Particularly	particularly	RB	_	18	advmod
17	the	the	DT	_	18	det
18	elderly	elderly	JJ	_	20	nsubj
19	may	may	MD	_	20	aux
20	develop	develop	VB	_	1	parataxis
21	delirium	delirium	NN	_	20	dobj
22	,	,	,	_	21	punct
23	high	high	JJ	_	24	amod
24	fever	fever	NN	_	21	conj
25	,	,	,	_	21	punct
26	severe	severe	JJ	_	27	amod
27	obstipation	obstipation	NN	_	21	conj
28	,	,	,	_	21	punct
29	even	even	RB	_	30	advmod
30	ileus	ileus	NN	_	21	conj
31	and	and	CC	_	21	cc
32	glaucoma	glaucoma	NN	_	21	conj
33	.	.	.	_	1	punct

1	There	there	EX	_	5	expl
2	have	have	VBP	_	5	aux
3	been	be	VBN	_	5	cop
4	rare	rare	JJ	_	5	amod
5	reports	report	NNS	_	0	ROOT
6	of	of	IN	_	9	case
7	significant	significant	JJ	_	9	amod
8	respiratory	respiratory	JJ	_	9	amod
9	depression	depression	NN	_	5	nmod
10	,	,	,	_	9	punct
11	stupor	stupor	NN	_	9	conj
12	and/or	and/or	CC	_	9	cc
13	hypotension	hypotension	NN	_	9	conj
14	with	with	IN	_	17	case
15	the	the	DT	_	17	det
16	concomitant	concomitant	JJ	_	17	amod
17	use	use	NN	_	5	nmod
18	of	of	IN	_	19	case
19	drug1	drug1	NN	_	17	nmod
20	and	and	CC	_	19	cc
21	drug2	drug2	NN	_	19	conj
22	.	.	.	_	5	punct

1	The	the	DT	_	2	det
2	risk	risk	NN	_	15	nsubjpass
3	of	of	IN	_	4	mark
4	using	use	VBG	_	2	acl
5	drug1	drug1	NN	_	4	dobj
6	in	in	IN	_	7	case
7	combination	combination	NN	_	4	nmod
8	with	with	IN	_	10	case
9	CNS-active	cns-active	JJ	_	10	amod
10	drugs	drug	NNS	_	7	nmod
11	has	have	VBZ	_	15	aux
12	not	not	RB	_	15	neg
13	been	be	VBN	_	15	auxpass
14	systematically	systematically	RB	_	15	advmod
15	evaluated	evaluate	VBN	_	0	ROOT
16	.	.	.	_	15	punct

1	Therefore	therefore	RB	_	5	advmod
2	,	,	,	_	5	punct
3	caution	caution	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	advised	advise	VBN	_	0	ROOT
6	if	if	IN	_	16	mark
7	the	the	DT	_	9	det
8	concomitant	concomitant	JJ	_	9	amod
9	administration	administration	NN	_	16	nsubjpass
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	CNS-active	cns-active	JJ	_	14	amod
14	drugs	drug	NNS	_	11	conj
15	is	be	VBZ	_	16	auxpass
16	required	require	VBN	_	5	advcl
17	.	.	.	_	5	punct

1	No	no	DT	_	5	neg
2	pharmacokinetic	pharmacokinetic	JJ	_	5	amod
3	drug-drug	drug-drug	NN	_	5	compound
4	interaction	interaction	NN	_	5	compound
5	studies	study	NNS	_	7	nsubjpass
6	were	be	VBD	_	7	auxpass
7	conducted	conduct	VBN	_	0	ROOT
8	with	with	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	-LRB-	-lrb-	-LRB-	_	12	punct
11	drug2	drug2	NN	_	12	compound
12	USP	usp	NN	_	9	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	Tablets	tablet	NNS	_	9	dep
15	.	.	.	_	7	punct

1	The	the	DT	_	3	det
2	following	follow	VBG	_	3	amod
3	information	information	NN	_	5	nsubjpass
4	was	be	VBD	_	5	auxpass
5	obtained	obtain	VBN	_	0	ROOT
6	from	from	IN	_	8	case
7	the	the	DT	_	8	det
8	literature	literature	NN	_	5	nmod
9	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	6	nsubjpass
4	has	have	VBZ	_	6	aux
5	been	be	VBN	_	6	auxpass
6	reported	report	VBN	_	1	appos
7	to	to	TO	_	8	mark
8	increase	increase	VB	_	6	xcomp
9	the	the	DT	_	11	det
10	plasma	plasma	NN	_	11	compound
11	levels	level	NNS	_	8	dobj
12	and	and	CC	_	11	cc
13	cardiovascular	cardiovascular	JJ	_	14	amod
14	effects	effect	NNS	_	11	conj
15	of	of	IN	_	16	case
16	drug3	drug3	NN	_	11	nmod
17	.	.	.	_	1	punct

1	Adjustment	Adjustment	NNP	_	7	nsubj
2	of	of	IN	_	4	case
3	drug1	drug1	NN	_	4	compound
4	dosage	dosage	NN	_	1	nmod
5	may	may	MD	_	7	aux
6	be	be	VB	_	7	cop
7	necessary	necessary	JJ	_	0	ROOT
8	.	.	.	_	7	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	counteract	counteract	VB	_	1	dep
6	the	the	DT	_	8	det
7	anticholinesterase	anticholinesterase	NN	_	8	compound
8	effect	effect	NN	_	5	dobj
9	of	of	IN	_	10	case
10	drug3	drug3	NN	_	8	nmod
11	,	,	,	_	5	punct
12	thereby	thereby	RB	_	14	advmod
13	potentially	potentially	RB	_	14	advmod
14	aggravating	aggravating	JJ	_	16	amod
15	myasthenia	myasthenia	NN	_	16	compound
16	gravis	gravis	NN	_	5	dobj
17	.	.	.	_	1	punct

1	If	if	IN	_	9	mark
2	drug1	drug1	NN	_	9	nsubjpass
3	or	or	CC	_	2	cc
4	other	other	JJ	_	7	amod
5	hepatic	hepatic	JJ	_	7	amod
6	enzyme	enzyme	NN	_	7	compound
7	inducers	inducer	NNS	_	2	conj
8	are	be	VBP	_	9	auxpass
9	taken	take	VBN	_	22	advcl
10	concurrently	concurrently	RB	_	9	advmod
11	with	with	IN	_	12	case
12	drug2	drug2	NN	_	9	nmod
13	or	or	CC	_	12	cc
14	drug3	drug3	NN	_	12	conj
15	,	,	,	_	22	punct
16	lower	lower	JJR	_	18	amod
17	plasma	plasma	NN	_	18	compound
18	levels	level	NNS	_	22	nsubj
19	of	of	IN	_	20	case
20	drug4	drug4	NN	_	18	nmod
21	may	may	MD	_	22	aux
22	occur	occur	VB	_	0	ROOT
23	.	.	.	_	22	punct

1	Monitoring	monitoring	NN	_	7	nsubjpass
2	of	of	IN	_	5	case
3	drug1	drug1	NN	_	5	compound
4	plasma	plasma	NN	_	5	compound
5	levels	level	NNS	_	1	nmod
6	is	be	VBZ	_	7	auxpass
7	recommended	recommend	VBN	_	0	ROOT
8	in	in	IN	_	11	case
9	such	such	JJ	_	11	amod
10	concurrent	concurrent	JJ	_	11	amod
11	use	use	NN	_	7	nmod
12	to	to	TO	_	13	mark
13	avoid	avoid	VB	_	11	acl
14	ineffective	ineffective	JJ	_	15	amod
15	therapy	therapy	NN	_	13	dobj
16	.	.	.	_	7	punct

1	Other	other	JJ	_	2	amod
2	drug1	drug1	NN	_	17	nsubjpass
3	-LRB-	-lrb-	-LRB-	_	6	punct
4	eg	eg	FW	_	6	compound
5	,	,	,	_	6	punct
6	drug2	drug2	NN	_	2	dep
7	,	,	,	_	6	punct
8	drug3	drug3	NN	_	6	conj
9	,	,	,	_	6	punct
10	drug4	drug4	NN	_	6	conj
11	,	,	,	_	6	punct
12	drug5	drug5	NN	_	6	appos
13	-RRB-	-rrb-	-RRB-	_	6	punct
14	have	have	VBP	_	17	aux
15	occasionally	occasionally	RB	_	17	advmod
16	been	be	VBN	_	17	auxpass
17	used	use	VBN	_	0	ROOT
18	concurrently	concurrently	RB	_	17	advmod
19	with	with	IN	_	20	case
20	drug6	drug6	NN	_	17	nmod
21	.	.	.	_	17	punct

1	Excessive	excessive	JJ	_	2	amod
2	widening	widening	NN	_	14	nsubj
3	of	of	IN	_	6	case
4	the	the	DT	_	6	det
5	QRS	QRS	NNP	_	6	compound
6	complex	complex	NN	_	2	nmod
7	and/or	and/or	CC	_	2	cc
8	prolongation	prolongation	NN	_	2	conj
9	of	of	IN	_	12	case
10	the	the	DT	_	12	det
11	Q-T	q-t	JJ	_	12	amod
12	interval	interval	NN	_	8	nmod
13	may	may	MD	_	14	aux
14	occur	occur	VB	_	0	ROOT
15	in	in	IN	_	17	case
16	these	these	DT	_	17	det
17	situations	situation	NNS	_	14	nmod
18	.	.	.	_	14	punct

1	In	in	IN	_	3	case
2	healthy	healthy	JJ	_	3	amod
3	subjects	subject	NNS	_	10	nmod
4	,	,	,	_	10	punct
5	no	no	DT	_	8	neg
6	significant	significant	JJ	_	8	amod
7	drug-drug	drug-drug	JJ	_	8	amod
8	interaction	interaction	NN	_	10	nsubjpass
9	was	be	VBD	_	10	auxpass
10	observed	observe	VBN	_	0	ROOT
11	when	when	WRB	_	14	advmod
12	drug1	drug1	NN	_	14	nsubjpass
13	was	be	VBD	_	14	auxpass
14	coadministered	coadminister	VBN	_	10	advcl
15	with	with	IN	_	17	case
16	either	either	CC	_	17	cc:preconj
17	drug2	drug2	NN	_	14	nmod
18	or	or	CC	_	17	cc
19	drug3	drug3	NN	_	17	conj
20	.	.	.	_	10	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	7	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	resulted	result	VBD	_	0	ROOT
8	in	in	IN	_	10	case
9	slight	slight	JJ	_	10	amod
10	increases	increase	NNS	_	7	nmod
11	in	in	IN	_	14	case
12	plasma	plasma	NN	_	14	compound
13	drug3	drug3	NN	_	14	compound
14	levels	level	NNS	_	10	nmod
15	and	and	CC	_	14	cc
16	slight	slight	JJ	_	17	amod
17	decreases	decrease	NNS	_	14	conj
18	in	in	IN	_	21	case
19	plasma	plasma	NN	_	21	compound
20	drug4	drug4	NN	_	21	compound
21	levels	level	NNS	_	10	nmod
22	.	.	.	_	7	punct

1	drug1	drug1	NN	_	4	nsubj
2	does	do	VBZ	_	4	aux
3	not	not	RB	_	4	neg
4	increase	increase	VB	_	0	ROOT
5	serum	serum	NN	_	7	compound
6	drug2	drug2	NN	_	7	compound
7	levels	level	NNS	_	4	dobj
8	.	.	.	_	4	punct

1	Patients	patient	NNS	_	8	nsubj
2	taking	take	VBG	_	1	acl
3	drug1	drug1	NN	_	2	dobj
4	and	and	CC	_	3	cc
5	drug2	drug2	NN	_	3	conj
6	concomitantly	concomitantly	RB	_	8	advmod
7	may	may	MD	_	8	aux
8	develop	develop	VB	_	0	ROOT
9	increased	increase	VBN	_	11	amod
10	serum	serum	NN	_	11	compound
11	concentrations	concentration	NNS	_	8	dobj
12	of	of	IN	_	13	case
13	drug3	drug3	NN	_	11	nmod
14	resulting	result	VBG	_	11	acl
15	in	in	IN	_	17	case
16	excessive	excessive	JJ	_	17	amod
17	widening	widening	NN	_	14	nmod
18	of	of	IN	_	21	case
19	the	the	DT	_	21	det
20	QRS	QRS	NNP	_	21	compound
21	complex	complex	NN	_	17	nmod
22	and/or	and/or	CC	_	17	cc
23	prolongation	prolongation	NN	_	17	conj
24	of	of	IN	_	27	case
25	the	the	DT	_	27	det
26	Q-T	q-t	JJ	_	27	amod
27	interval	interval	NN	_	23	nmod
28	.	.	.	_	8	punct

1	Patients	patient	NNS	_	12	nsubjpass
2	taking	take	VBG	_	1	acl
3	drug1	drug1	NN	_	7	compound
4	and	and	CC	_	3	cc
5	hepatic	hepatic	JJ	_	3	conj
6	enzyme	enzyme	NN	_	7	compound
7	inhibitors	inhibitor	NNS	_	2	dobj
8	concomitantly	concomitantly	RB	_	12	advmod
9	should	should	MD	_	12	aux
10	be	be	VB	_	12	auxpass
11	closely	closely	RB	_	12	advmod
12	monitored	monitor	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	Until	until	IN	_	2	case
2	data	datum	NNS	_	11	nsubjpass
3	on	on	IN	_	5	case
4	possible	possible	JJ	_	5	amod
5	interactions	interaction	NNS	_	2	nmod
6	between	between	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	are	be	VBP	_	11	auxpass
11	obtained	obtain	VBN	_	0	ROOT
12	,	,	,	_	11	punct
13	drug3	drug3	NN	_	17	nsubjpass
14	should	should	MD	_	17	aux
15	not	not	RB	_	17	neg
16	be	be	VB	_	17	auxpass
17	administered	administer	VBN	_	11	ccomp
18	within	within	IN	_	20	case
19	48	48	CD	_	20	nummod
20	hours	hour	NNS	_	17	nmod
21	before	before	IN	_	20	advmod
22	or	or	CC	_	21	cc
23	24	24	CD	_	24	nummod
24	hours	hour	NNS	_	21	conj
25	after	after	IN	_	27	case
26	drug4	drug4	NN	_	27	compound
27	administration	administration	NN	_	21	nmod
28	.	.	.	_	11	punct

1	The	the	DT	_	2	det
2	potential	potential	NN	_	15	nsubjpass
3	for	for	IN	_	5	case
4	increased	increase	VBN	_	5	amod
5	sedation	sedation	NN	_	2	nmod
6	when	when	WRB	_	9	advmod
7	drug1	drug1	NN	_	9	nsubjpass
8	is	be	VBZ	_	9	auxpass
9	given	give	VBN	_	2	acl:relcl
10	with	with	IN	_	12	case
11	other	other	JJ	_	12	amod
12	drug2	drug2	NN	_	9	nmod
13	should	should	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	appreciated	appreciate	VBN	_	0	ROOT
16	.	.	.	_	15	punct

1	The	the	DT	_	2	det
2	administration	administration	NN	_	23	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	concomitantly	concomitantly	RB	_	10	advmod
6	with	with	IN	_	10	case
7	known	known	JJ	_	10	amod
8	microsomal	microsomal	JJ	_	10	amod
9	enzyme	enzyme	NN	_	10	compound
10	inducer	inducer	NN	_	2	nmod
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	drug2	drug2	NN	_	10	dep
13	or	or	CC	_	12	cc
14	drug3	drug3	NN	_	12	conj
15	-RRB-	-rrb-	-RRB-	_	12	punct
16	to	to	TO	_	18	case
17	two	two	CD	_	18	nummod
18	patients	patient	NNS	_	10	nmod
19	with	with	IN	_	21	case
20	renal	renal	JJ	_	21	amod
21	impairment	impairment	NN	_	18	nmod
22	reportedly	reportedly	RB	_	23	advmod
23	resulted	result	VBD	_	0	ROOT
24	in	in	IN	_	26	case
25	significant	significant	JJ	_	26	amod
26	reductions	reduction	NNS	_	23	nmod
27	in	in	IN	_	29	case
28	elimination	elimination	NN	_	29	compound
29	half-life	half-life	NN	_	26	nmod
30	and	and	CC	_	29	cc
31	plasma	plasma	NN	_	32	compound
32	concentration	concentration	NN	_	29	conj
33	.	.	.	_	23	punct

1	In	in	IN	_	3	case
2	such	such	JJ	_	3	amod
3	cases	case	NNS	_	12	nmod
4	,	,	,	_	12	punct
5	therefore	therefore	RB	_	12	advmod
6	,	,	,	_	12	punct
7	more	more	JJR	_	9	amod
8	frequent	frequent	JJ	_	9	amod
9	dosing	dosing	NN	_	12	nsubjpass
10	may	may	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	required	require	VBN	_	0	ROOT
13	to	to	TO	_	14	mark
14	achieve	achieve	VB	_	12	xcomp
15	or	or	CC	_	14	cc
16	maintain	maintain	VB	_	14	conj
17	the	the	DT	_	20	det
18	desired	desire	VBN	_	20	amod
19	hypotensive	hypotensive	NN	_	20	compound
20	response	response	NN	_	14	dobj
21	.	.	.	_	12	punct

1	Further	further	RB	_	20	advmod
2	,	,	,	_	20	punct
3	if	if	IN	_	5	mark
4	drug1	drug1	NN	_	5	nsubj
5	is	be	VBZ	_	20	advcl
6	to	to	TO	_	8	mark
7	be	be	VB	_	8	auxpass
8	discontinued	discontinue	VBN	_	5	xcomp
9	in	in	IN	_	11	case
10	such	such	JJ	_	11	amod
11	patients	patient	NNS	_	8	nmod
12	,	,	,	_	20	punct
13	careful	careful	JJ	_	14	amod
14	tapering	taper	VBG	_	20	nsubj
15	of	of	IN	_	17	case
16	the	the	DT	_	17	det
17	dosage	dosage	NN	_	14	nmod
18	may	may	MD	_	20	aux
19	be	be	VB	_	20	cop
20	necessary	necessary	JJ	_	0	ROOT
21	in	in	IN	_	24	mark
22	order	order	NN	_	21	mwe
23	to	to	TO	_	24	mark
24	avoid	avoid	VB	_	20	advcl
25	rebound	rebound	NN	_	26	compound
26	phenomena	phenomenon	NNS	_	24	dobj
27	.	.	.	_	20	punct

1	drug1	drug1	NN	_	2	nsubj
2	decrease	decrease	VB	_	0	ROOT
3	the	the	DT	_	5	det
4	hypotensive	hypotensive	JJ	_	5	amod
5	effect	effect	NN	_	2	dobj
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	.	.	.	_	2	punct

1	drug1	drug1	NN	_	10	nsubj
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	drug2	drug2	NN	_	1	dep
4	,	,	,	_	3	punct
5	porpranolol	porpranolol	NN	_	3	appos
6	,	,	,	_	3	punct
7	drug3	drug3	NN	_	3	appos
8	-RRB-	-rrb-	-RRB-	_	3	punct
9	may	may	MD	_	10	aux
10	exacerbate	exacerbate	VB	_	0	ROOT
11	rebound	rebind	VB	_	10	ccomp
12	hypertension	hypertension	NN	_	11	dobj
13	when	when	WRB	_	16	advmod
14	drug4	drug4	NN	_	16	nsubjpass
15	is	be	VBZ	_	16	auxpass
16	withdrawn	withdraw	VBN	_	11	advcl
17	.	.	.	_	10	punct

1	The	the	DT	_	2	det
2	drug1	drug1	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	withdrawn	withdraw	VBN	_	0	ROOT
6	first	first	RB	_	5	advmod
7	.	.	.	_	5	punct

1	The	the	DT	_	3	det
2	gradual	gradual	JJ	_	3	amod
3	withdrawal	withdrawal	NN	_	11	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	or	or	CC	_	5	cc
7	a	a	DT	_	8	det
8	drug2	drug2	NN	_	5	conj
9	could	could	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	substituted	substitute	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Ten	ten	CD	_	4	nummod
4	patients	patient	NNS	_	12	nsubjpass
5	who	who	WP	_	7	nsubjpass
6	were	be	VBD	_	7	auxpass
7	stabilized	stabilize	VBN	_	4	acl:relcl
8	on	on	IN	_	10	case
9	oral	oral	JJ	_	10	amod
10	drug2	drug2	NN	_	7	nmod
11	were	be	VBD	_	12	auxpass
12	given	give	VBN	_	1	dep
13	drug3	drug3	NN	_	12	dobj
14	,	,	,	_	13	punct
15	1-2	1-2	CD	_	16	nummod
16	mg/day	mg/day	NN	_	13	appos
17	,	,	,	_	13	punct
18	for	for	IN	_	20	case
19	4	4	CD	_	20	nummod
20	weeks	week	NNS	_	12	nmod
21	.	.	.	_	1	punct

1	No	no	DT	_	2	neg
2	changes	change	NNS	_	4	nsubjpass
3	were	be	VBD	_	4	auxpass
4	observed	observe	VBN	_	0	ROOT
5	in	in	IN	_	7	case
6	the	the	DT	_	7	det
7	degree	degree	NN	_	4	nmod
8	of	of	IN	_	9	case
9	anticoagulation	anticoagulation	NN	_	7	nmod
10	.	.	.	_	4	punct

1	In	in	IN	_	4	case
2	several	several	JJ	_	4	amod
3	well-controlled	well-controlled	JJ	_	4	amod
4	studies	study	NNS	_	8	nmod
5	,	,	,	_	8	punct
6	drug1	drug1	NN	_	8	nsubjpass
7	was	be	VBD	_	8	auxpass
8	administered	administer	VBN	_	0	ROOT
9	together	together	RB	_	8	advmod
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	8	nmod
12	with	with	IN	_	15	case
13	no	no	DT	_	15	neg
14	drug	drug	NN	_	15	compound
15	interactions	interaction	NNS	_	11	nmod
16	reported	report	VBD	_	15	acl
17	.	.	.	_	8	punct

1	In	in	IN	_	5	case
2	the	the	DT	_	5	det
3	long-term	long-term	JJ	_	5	amod
4	safety	safety	NN	_	5	compound
5	studies	study	NNS	_	9	nmod
6	,	,	,	_	9	punct
7	drug1	drug1	NN	_	9	nsubjpass
8	was	be	VBD	_	9	auxpass
9	given	give	VBN	_	0	ROOT
10	concomitantly	concomitantly	RB	_	9	advmod
11	with	with	IN	_	13	case
12	many	many	JJ	_	13	amod
13	drugs	drug	NNS	_	9	nmod
14	without	without	IN	_	15	case
15	evidence	evidence	NN	_	9	nmod
16	of	of	IN	_	18	case
17	any	any	DT	_	18	det
18	interactions	interaction	NNS	_	15	nmod
19	.	.	.	_	9	punct

1	The	the	DT	_	3	det
2	principal	principal	JJ	_	3	amod
3	drugs	drug	NNS	_	14	nsubj
4	given	give	VBN	_	3	acl
5	-LRB-	-lrb-	-LRB-	_	6	punct
6	number	number	NN	_	4	dep
7	of	of	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	in	in	IN	_	10	case
10	parentheses	parenthesis	NNS	_	8	nmod
11	-RRB-	-rrb-	-RRB-	_	6	punct
12	were	be	VBD	_	14	cop
13	:	:	:	_	14	punct
14	drug1	drug1	NN	_	0	ROOT
15	-LRB-	-lrb-	-LRB-	_	16	punct
16	115	115	CD	_	14	appos
17	-RRB-	-rrb-	-RRB-	_	16	punct
18	,	,	,	_	14	punct
19	drug2	drug2	NN	_	14	appos
20	and	and	CC	_	19	cc
21	drug3	drug3	NN	_	19	conj
22	-LRB-	-lrb-	-LRB-	_	23	punct
23	103	103	CD	_	21	appos
24	-RRB-	-rrb-	-RRB-	_	23	punct
25	,	,	,	_	14	punct
26	drug4	drug4	NN	_	14	conj
27	-LRB-	-lrb-	-LRB-	_	28	punct
28	52	52	CD	_	26	appos
29	-RRB-	-rrb-	-RRB-	_	28	punct
30	,	,	,	_	14	punct
31	oral	oral	JJ	_	32	amod
32	drug5	drug5	NN	_	14	conj
33	-LRB-	-lrb-	-LRB-	_	34	punct
34	45	45	CD	_	32	appos
35	-RRB-	-rrb-	-RRB-	_	34	punct
36	,	,	,	_	14	punct
37	cough	cough	NN	_	14	conj
38	and	and	CC	_	14	cc
39	cold	cold	JJ	_	40	amod
40	preparations	preparation	NNS	_	14	conj
41	-LRB-	-lrb-	-LRB-	_	42	punct
42	45	45	CD	_	40	appos
43	-RRB-	-rrb-	-RRB-	_	42	punct
44	,	,	,	_	14	punct
45	drug6	drug6	NN	_	14	conj
46	-LRB-	-lrb-	-LRB-	_	47	punct
47	38	38	CD	_	45	appos
48	-RRB-	-rrb-	-RRB-	_	47	punct
49	,	,	,	_	14	punct
50	drug7	drug7	NN	_	14	conj
51	-LRB-	-lrb-	-LRB-	_	52	punct
52	29	29	CD	_	50	appos
53	-RRB-	-rrb-	-RRB-	_	52	punct
54	,	,	,	_	14	punct
55	drug8	drug8	NN	_	14	conj
56	-LRB-	-lrb-	-LRB-	_	57	punct
57	24	24	CD	_	55	appos
58	-RRB-	-rrb-	-RRB-	_	57	punct
59	,	,	,	_	14	punct
60	oral	oral	JJ	_	61	amod
61	drug9	drug9	NN	_	14	conj
62	-LRB-	-lrb-	-LRB-	_	63	punct
63	18	18	CD	_	61	appos
64	-RRB-	-rrb-	-RRB-	_	63	punct
65	,	,	,	_	14	punct
66	drug10	drug10	NN	_	14	conj
67	-LRB-	-lrb-	-LRB-	_	68	punct
68	13	13	CD	_	66	appos
69	-RRB-	-rrb-	-RRB-	_	68	punct
70	,	,	,	_	14	punct
71	drug11	drug11	NN	_	14	conj
72	-LRB-	-lrb-	-LRB-	_	73	punct
73	10	10	CD	_	71	appos
74	-RRB-	-rrb-	-RRB-	_	73	punct
75	,	,	,	_	14	punct
76	and	and	CC	_	14	cc
77	drug12	drug12	NN	_	14	conj
78	-LRB-	-lrb-	-LRB-	_	79	punct
79	10	10	CD	_	77	appos
80	-RRB-	-rrb-	-RRB-	_	79	punct
81	.	.	.	_	14	punct

1	Laboratory	Laboratory	NNP	_	2	compound
2	Test	Test	NNP	_	14	nsubjpass
3	In	in	IN	_	5	case
4	clinical	clinical	JJ	_	5	amod
5	trials	trial	NNS	_	2	nmod
6	,	,	,	_	2	punct
7	no	no	DT	_	12	neg
8	clinically	clinically	RB	_	9	advmod
9	relevant	relevant	JJ	_	12	amod
10	laboratory	laboratory	NN	_	12	compound
11	test	test	NN	_	12	compound
12	abnormalities	abnormality	NNS	_	2	appos
13	were	be	VBD	_	14	auxpass
14	identified	identify	VBN	_	0	ROOT
15	as	as	IN	_	17	case
16	causally	causally	RB	_	17	advmod
17	related	related	JJ	_	14	nmod
18	to	to	TO	_	19	case
19	drug	drug	NN	_	17	nmod
20	during	during	IN	_	22	case
21	short-term	short-term	JJ	_	22	amod
22	treatment	treatment	NN	_	17	nmod
23	with	with	IN	_	24	case
24	drug1	drug1	NN	_	22	nmod
25	.	.	.	_	14	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	3	amod
2	Test	test	NN	_	3	compound
3	Interactions	interaction	NNS	_	0	ROOT
4	No	no	DT	_	7	neg
5	laboratory	laboratory	NN	_	7	compound
6	test	test	NN	_	7	compound
7	abnormalities	abnormality	NNS	_	16	nsubjpass
8	related	relate	VBN	_	7	acl
9	to	to	TO	_	11	case
10	the	the	DT	_	11	det
11	use	use	NN	_	8	nmod
12	of	of	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	have	have	VBP	_	16	aux
15	been	be	VBN	_	16	auxpass
16	identified	identify	VBN	_	3	acl:relcl
17	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	interaction	interaction	NN	_	14	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	10	case
6	other	other	JJ	_	10	amod
7	cardioactive	cardioactive	JJ	_	10	amod
8	or	or	CC	_	7	cc
9	cerebroactive	cerebroactive	JJ	_	7	conj
10	drugs	drug	NNS	_	2	nmod
11	has	have	VBZ	_	14	aux
12	not	not	RB	_	14	neg
13	been	be	VBN	_	14	auxpass
14	studied	study	VBN	_	0	ROOT
15	.	.	.	_	14	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	26	nmod
3	to	to	TO	_	4	case
4	bleeding	bleeding	NN	_	2	nmod
5	associated	associate	VBN	_	4	acl
6	with	with	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	,	,	,	_	7	punct
11	drugs	drug	NNS	_	7	conj
12	that	that	WDT	_	13	nsubj
13	alter	alter	VBP	_	11	acl:relcl
14	platelet	platelet	NN	_	15	compound
15	function	function	NN	_	13	dobj
16	-LRB-	-lrb-	-LRB-	_	19	punct
17	such	such	JJ	_	19	case
18	as	as	IN	_	17	mwe
19	drug3	drug3	NN	_	11	nmod
20	,	,	,	_	19	punct
21	drug4	drug4	NN	_	19	conj
22	and	and	CC	_	19	cc
23	drug5	drug5	NN	_	19	conj
24	-RRB-	-rrb-	-RRB-	_	19	punct
25	may	may	MD	_	26	aux
26	increase	increase	VB	_	0	ROOT
27	the	the	DT	_	28	det
28	risk	risk	NN	_	26	dobj
29	of	of	IN	_	30	case
30	bleeding	bleed	VBG	_	28	nmod
31	if	if	IN	_	32	mark
32	administered	administer	VBN	_	26	advcl
33	prior	prior	RB	_	32	advmod
34	to	to	TO	_	41	nmod
35	,	,	,	_	41	punct
36	during	during	IN	_	41	conj
37	,	,	,	_	41	punct
38	or	or	CC	_	41	cc
39	after	after	IN	_	41	conj
40	drug6	drug6	NN	_	41	compound
41	therapy	therapy	NN	_	32	nmod
42	.	.	.	_	26	punct

1	Use	use	NN	_	9	nsubjpass
2	of	of	IN	_	4	case
3	drug1	drug1	NN	_	4	compound
4	drug2	drug2	NN	_	1	nmod
5	and	and	CC	_	4	cc
6	drug3	drug3	NN	_	4	conj
7	have	have	VBP	_	9	aux
8	been	be	VBN	_	9	auxpass
9	administered	administer	VBN	_	0	ROOT
10	concomitantly	concomitantly	RB	_	9	advmod
11	with	with	IN	_	14	case
12	and	and	CC	_	11	cc
13	following	follow	VBG	_	11	conj
14	infusions	infusion	NNS	_	9	nmod
15	of	of	IN	_	16	case
16	drug4	drug4	NN	_	14	nmod
17	in	in	IN	_	19	case
18	the	the	DT	_	19	det
19	management	management	NN	_	14	nmod
20	of	of	IN	_	23	case
21	acute	acute	JJ	_	23	amod
22	myocardial	myocardial	JJ	_	23	amod
23	infarction	infarction	NN	_	19	nmod
24	or	or	CC	_	23	cc
25	pulmonary	pulmonary	JJ	_	26	amod
26	embolism	embolism	NN	_	23	conj
27	.	.	.	_	9	punct

1	Because	because	IN	_	9	mark
2	drug1	drug1	NN	_	9	nsubj
3	,	,	,	_	2	punct
4	drug2	drug2	NN	_	2	conj
5	,	,	,	_	2	punct
6	or	or	CC	_	2	cc
7	drug3	drug3	NN	_	2	conj
8	may	may	MD	_	9	aux
9	cause	cause	VB	_	18	advcl
10	bleeding	bleeding	JJ	_	11	amod
11	complications	complication	NNS	_	9	dobj
12	,	,	,	_	18	punct
13	careful	careful	JJ	_	14	amod
14	monitoring	monitoring	NN	_	18	nsubjpass
15	for	for	IN	_	16	case
16	bleeding	bleeding	NN	_	14	nmod
17	is	be	VBZ	_	18	auxpass
18	advised	advise	VBN	_	0	ROOT
19	,	,	,	_	18	punct
20	especially	especially	RB	_	24	advmod
21	at	at	IN	_	24	case
22	arterial	arterial	JJ	_	24	amod
23	puncture	puncture	NN	_	24	compound
24	sites	site	NNS	_	18	nmod
25	.	.	.	_	18	punct

1	The	the	DT	_	3	det
2	concomitant	concomitant	JJ	_	3	amod
3	use	use	NN	_	17	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	or	or	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	during	during	IN	_	12	case
9	the	the	DT	_	12	det
10	first	first	JJ	_	12	amod
11	24	24	CD	_	12	nummod
12	hours	hour	NNS	_	3	nmod
13	following	follow	VBG	_	15	case
14	symptom	symptom	NN	_	15	compound
15	onset	onset	NN	_	12	nmod
16	were	be	VBD	_	17	auxpass
17	prohibited	prohibit	VBN	_	0	ROOT
18	in	in	IN	_	23	case
19	The	the	DT	_	23	det
20	NINDS	ninds	NN	_	23	compound
21	t-PA	t-pa	NN	_	23	compound
22	Stroke	Stroke	NNP	_	23	compound
23	Trial	Trial	NNP	_	17	nmod
24	.	.	.	_	17	punct

1	The	the	DT	_	2	det
2	safety	safety	NN	_	17	nsubj
3	of	of	IN	_	6	case
4	such	such	JJ	_	6	amod
5	concomitant	concomitant	JJ	_	6	amod
6	use	use	NN	_	2	nmod
7	with	with	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	for	for	IN	_	11	case
10	the	the	DT	_	11	det
11	management	management	NN	_	6	nmod
12	of	of	IN	_	15	case
13	acute	acute	JJ	_	15	amod
14	ischemic	ischemic	JJ	_	15	amod
15	stroke	stroke	NN	_	11	nmod
16	is	be	VBZ	_	17	cop
17	unknown	unknown	JJ	_	0	ROOT
18	.	.	.	_	17	punct

1	Drug-Drug	Drug-Drug	NNP	_	2	compound
2	Interactions	interaction	NNS	_	14	nsubjpass
3	Given	give	VBN	_	7	case
4	the	the	DT	_	7	det
5	primary	primary	JJ	_	7	amod
6	CNS	cns	NN	_	7	compound
7	effects	effect	NNS	_	2	nmod
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	,	,	,	_	2	punct
11	caution	caution	NN	_	2	appos
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	used	use	VBN	_	0	ROOT
15	when	when	WRB	_	18	advmod
16	drug2	drug2	NN	_	18	nsubjpass
17	is	be	VBZ	_	18	auxpass
18	taken	take	VBN	_	14	advcl
19	in	in	IN	_	20	case
20	combination	combination	NN	_	18	nmod
21	with	with	IN	_	23	case
22	other	other	JJ	_	23	amod
23	drug3	drug3	NN	_	20	nmod
24	and	and	CC	_	23	cc
25	drug4	drug4	NN	_	23	conj
26	.	.	.	_	14	punct

1	Due	due	JJ	_	3	case
2	to	to	TO	_	1	mwe
3	its	its	PRP$	_	0	ROOT

1	1	1	LS	_	8	dep
2	-	-	:	_	1	punct
3	adrenergic	adrenergic	JJ	_	5	amod
4	receptor	receptor	NN	_	5	compound
5	antagonism	antagonism	NN	_	8	nsubj
6	,	,	,	_	5	punct
7	drug1	drug1	NN	_	5	appos
8	has	have	VBZ	_	0	ROOT
9	the	the	DT	_	10	det
10	potential	potential	JJ	_	8	dobj
11	to	to	TO	_	12	mark
12	enhance	enhance	VB	_	10	acl
13	the	the	DT	_	14	det
14	effect	effect	NN	_	12	dobj
15	of	of	IN	_	17	case
16	certain	certain	JJ	_	17	amod
17	drug2	drug2	NN	_	14	nmod
18	.	.	.	_	8	punct

1	Potential	potential	JJ	_	12	nsubj
2	for	for	IN	_	6	mark
3	Other	other	JJ	_	4	amod
4	Drugs	drug	NNS	_	6	nsubj
5	to	to	TO	_	6	mark
6	Affect	affect	VB	_	1	advcl
7	drug1	drug1	NN	_	8	compound
8	drug2	drug2	NN	_	6	dobj
9	is	be	VBZ	_	12	cop
10	not	not	RB	_	12	neg
11	a	a	DT	_	12	det
12	substrate	substrate	NN	_	0	ROOT
13	of	of	IN	_	14	case
14	CYP1A1	cyp1a1	NN	_	12	nmod
15	,	,	,	_	14	punct
16	CYP1A2	cyp1a2	NN	_	14	conj
17	,	,	,	_	14	punct
18	CYP2A6	cyp2a6	NN	_	14	conj
19	,	,	,	_	14	punct
20	CYP2B6	cyp2b6	NN	_	14	conj
21	,	,	,	_	14	punct
22	CYP2C8	cyp2c8	NN	_	14	conj
23	,	,	,	_	14	punct
24	CYP2C9	cyp2c9	NN	_	14	conj
25	,	,	,	_	14	punct
26	CYP2C19	cyp2c19	NN	_	14	conj
27	,	,	,	_	14	punct
28	or	or	CC	_	14	cc
29	CYP2E1	cyp2e1	NN	_	30	compound
30	enzymes	enzyme	NNS	_	14	conj
31	.	.	.	_	12	punct

1	drug1	drug1	NN	_	5	nsubj
2	also	also	RB	_	5	advmod
3	does	do	VBZ	_	5	aux
4	not	not	RB	_	5	neg
5	undergo	undergo	VB	_	0	ROOT
6	direct	direct	JJ	_	7	amod
7	glucuronidation	glucuronidation	NN	_	5	dobj
8	.	.	.	_	5	punct

1	This	this	DT	_	2	nsubj
2	suggests	suggest	VBZ	_	0	ROOT
3	that	that	IN	_	24	mark
4	an	a	DT	_	5	det
5	interaction	interaction	NN	_	24	nsubj
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	with	with	IN	_	9	case
9	inhibitors	inhibitor	NNS	_	5	nmod
10	or	or	CC	_	9	cc
11	inducers	inducer	NNS	_	9	conj
12	of	of	IN	_	14	case
13	these	these	DT	_	14	det
14	enzymes	enzyme	NNS	_	9	nmod
15	,	,	,	_	14	punct
16	or	or	CC	_	14	cc
17	other	other	JJ	_	18	amod
18	factors	factor	NNS	_	14	conj
19	,	,	,	_	5	punct
20	like	like	IN	_	21	case
21	smoking	smoking	NN	_	5	nmod
22	,	,	,	_	5	punct
23	is	be	VBZ	_	24	cop
24	unlikely	unlikely	JJ	_	2	ccomp
25	.	.	.	_	2	punct

1	Both	both	DT	_	2	cc:preconj
2	CYP3A4	cyp3a4	NN	_	6	nsubj
3	and	and	CC	_	2	cc
4	CYP2D6	cyp2d6	NN	_	2	conj
5	are	be	VBP	_	6	cop
6	responsible	responsible	JJ	_	0	ROOT
7	for	for	IN	_	9	case
8	drug1	drug1	NN	_	9	compound
9	metabolism	metabolism	NN	_	6	nmod
10	.	.	.	_	6	punct

1	Agents	agent	NNS	_	11	nsubj
2	that	that	WDT	_	3	nsubj
3	induce	induce	VBP	_	1	acl:relcl
4	CYP3A4	cyp3a4	NN	_	3	dobj
5	-LRB-	-lrb-	-LRB-	_	6	punct
6	eg	eg	FW	_	1	dep
7	,	,	,	_	6	punct
8	drug1	drug1	NN	_	6	appos
9	-RRB-	-rrb-	-RRB-	_	6	punct
10	could	could	MD	_	11	aux
11	cause	cause	VB	_	0	ROOT
12	an	a	DT	_	13	det
13	increase	increase	NN	_	11	dobj
14	in	in	IN	_	16	case
15	drug2	drug2	NN	_	16	compound
16	clearance	clearance	NN	_	13	nmod
17	and	and	CC	_	16	cc
18	lower	lower	JJR	_	20	amod
19	blood	blood	NN	_	20	compound
20	levels	level	NNS	_	16	conj
21	.	.	.	_	11	punct

1	Inhibitors	inhibitor	NNS	_	22	nsubj
2	of	of	IN	_	3	case
3	CYP3A4	cyp3a4	NN	_	1	nmod
4	-LRB-	-lrb-	-LRB-	_	7	punct
5	eg	eg	FW	_	7	dep
6	,	,	,	_	7	punct
7	drug1	drug1	NN	_	3	appos
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	or	or	CC	_	3	cc
10	CYP2D6	cyp2d6	NN	_	3	conj
11	-LRB-	-lrb-	-LRB-	_	14	punct
12	eg	eg	FW	_	14	compound
13	,	,	,	_	14	punct
14	drug2	drug2	NN	_	10	dep
15	,	,	,	_	14	punct
16	drug3	drug3	NN	_	14	conj
17	,	,	,	_	14	punct
18	or	or	CC	_	14	cc
19	drug4	drug4	NN	_	14	conj
20	-RRB-	-rrb-	-RRB-	_	14	punct
21	can	can	MD	_	22	aux
22	inhibit	inhibit	VB	_	0	ROOT
23	drug5	drug5	NN	_	24	compound
24	elimination	elimination	NN	_	22	dobj
25	and	and	CC	_	22	cc
26	cause	cause	VB	_	22	conj
27	increased	increase	VBN	_	29	amod
28	blood	blood	NN	_	29	compound
29	levels	level	NNS	_	26	dobj
30	.	.	.	_	22	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Coadministration	coadministration	NN	_	20	nsubj
4	of	of	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	-LRB-	-lrb-	-LRB-	_	8	punct
7	200	200	CD	_	8	nummod
8	mg/day	mg/day	NN	_	5	dep
9	for	for	IN	_	11	case
10	14	14	CD	_	11	nummod
11	days	day	NNS	_	8	nmod
12	-RRB-	-rrb-	-RRB-	_	8	punct
13	with	with	IN	_	17	case
14	a	a	DT	_	17	det
15	15-mg	15-mg	JJ	_	17	amod
16	single	single	JJ	_	17	amod
17	dose	dose	NN	_	3	nmod
18	of	of	IN	_	19	case
19	drug3	drug3	NN	_	17	nmod
20	increased	increase	VBD	_	1	appos
21	the	the	DT	_	22	det
22	AUC	auc	NN	_	20	dobj
23	of	of	IN	_	24	case
24	drug4	drug4	NN	_	22	nmod
25	and	and	CC	_	22	cc
26	its	its	PRP$	_	28	nmod:poss
27	active	active	JJ	_	28	amod
28	metabolite	metabolite	NN	_	22	conj
29	by	by	IN	_	31	case
30	63	63	CD	_	31	nummod
31	%	%	NN	_	28	nmod
32	and	and	CC	_	31	cc
33	77	77	CD	_	34	nummod
34	%	%	NN	_	31	conj
35	,	,	,	_	20	punct
36	respectively	respectively	RB	_	20	advmod
37	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	15	nsubjpass
3	of	of	IN	_	7	case
4	a	a	DT	_	7	det
5	higher	higher	JJR	_	7	amod
6	drug1	drug1	NN	_	7	compound
7	dose	dose	NN	_	2	nmod
8	-LRB-	-lrb-	-LRB-	_	10	punct
9	400	400	CD	_	10	nummod
10	mg/day	mg/day	NN	_	7	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	has	have	VBZ	_	15	aux
13	not	not	RB	_	15	neg
14	been	be	VBN	_	15	auxpass
15	studied	study	VBN	_	0	ROOT
16	.	.	.	_	15	punct

1	When	when	WRB	_	8	advmod
2	concomitant	concomitant	JJ	_	3	amod
3	administration	administration	NN	_	8	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	with	with	IN	_	7	case
7	drug2	drug2	NN	_	3	nmod
8	occurs	occur	VBZ	_	14	advcl
9	,	,	,	_	14	punct
10	drug3	drug3	NN	_	11	compound
11	dose	dose	NN	_	14	nsubjpass
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	reduced	reduce	VBN	_	0	ROOT
15	to	to	TO	_	16	case
16	one-half	one-half	NN	_	14	nmod
17	of	of	IN	_	20	case
18	its	its	PRP$	_	20	nmod:poss
19	normal	normal	JJ	_	20	amod
20	dose	dose	NN	_	16	nmod
21	.	.	.	_	14	punct

1	Other	other	JJ	_	3	amod
2	strong	strong	JJ	_	3	amod
3	inhibitors	inhibitor	NNS	_	11	nsubjpass
4	of	of	IN	_	5	case
5	CYP3A4	cyp3a4	NN	_	3	nmod
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	drug1	drug1	NN	_	5	appos
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	would	would	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	expected	expect	VBN	_	0	ROOT
12	to	to	TO	_	13	mark
13	have	have	VB	_	11	xcomp
14	similar	similar	JJ	_	15	amod
15	effects	effect	NNS	_	13	dobj
16	and	and	CC	_	11	cc
17	need	need	VBP	_	11	conj
18	similar	similar	JJ	_	20	amod
19	dose	dose	NN	_	20	compound
20	reductions	reduction	NNS	_	17	dobj
21	;	;	:	_	11	punct

1	weaker	weaker	JJR	_	2	amod
2	inhibitors	inhibitor	NNS	_	12	nsubjpass
3	-LRB-	-lrb-	-LRB-	_	4	punct
4	drug1	drug1	NN	_	2	dep
5	,	,	,	_	4	punct
6	grapefruit	grapefruit	NN	_	7	compound
7	juice	juice	NN	_	4	appos
8	-RRB-	-rrb-	-RRB-	_	4	punct
9	have	have	VBP	_	12	aux
10	not	not	RB	_	12	neg
11	been	be	VBN	_	12	auxpass
12	studied	study	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	When	when	WRB	_	6	advmod
2	the	the	DT	_	4	det
3	CYP3A4	cyp3a4	NN	_	4	compound
4	inhibitor	inhibitor	NN	_	6	nsubjpass
5	is	be	VBZ	_	6	auxpass
6	withdrawn	withdraw	VBN	_	17	advcl
7	from	from	IN	_	10	case
8	the	the	DT	_	10	det
9	combination	combination	NN	_	10	compound
10	therapy	therapy	NN	_	6	nmod
11	,	,	,	_	17	punct
12	drug1	drug1	NN	_	13	compound
13	dose	dose	NN	_	17	nsubjpass
14	should	should	MD	_	17	aux
15	then	then	RB	_	17	advmod
16	be	be	VB	_	17	auxpass
17	increased	increase	VBN	_	0	ROOT
18	.	.	.	_	17	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Coadministration	coadministration	NN	_	27	nsubj
4	of	of	IN	_	8	case
5	a	a	DT	_	8	det
6	10-mg	10-mg	JJ	_	8	amod
7	single	single	JJ	_	8	amod
8	dose	dose	NN	_	3	nmod
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	with	with	IN	_	12	case
12	drug3	drug3	NN	_	3	nmod
13	-LRB-	-lrb-	-LRB-	_	15	punct
14	166	166	CD	_	15	nummod
15	mg/day	mg/day	NN	_	12	dep
16	for	for	IN	_	18	case
17	13	13	CD	_	18	nummod
18	days	day	NNS	_	15	nmod
19	-RRB-	-rrb-	-RRB-	_	15	punct
20	,	,	,	_	12	punct
21	a	a	DT	_	23	det
22	potent	potent	JJ	_	23	amod
23	inhibitor	inhibitor	NN	_	12	appos
24	of	of	IN	_	25	case
25	CYP2D6	cyp2d6	NN	_	23	nmod
26	,	,	,	_	12	punct
27	increased	increase	VBD	_	1	appos
28	the	the	DT	_	29	det
29	AUC	auc	NN	_	27	dobj
30	of	of	IN	_	31	case
31	drug4	drug4	NN	_	29	nmod
32	by	by	IN	_	34	case
33	112	112	CD	_	34	nummod
34	%	%	NN	_	27	nmod
35	but	but	CC	_	27	cc
36	decreased	decrease	VBD	_	27	conj
37	the	the	DT	_	38	det
38	AUC	auc	NN	_	36	dobj
39	of	of	IN	_	42	case
40	its	its	PRP$	_	42	nmod:poss
41	active	active	JJ	_	42	amod
42	metabolite	metabolite	NN	_	38	nmod
43	,	,	,	_	42	punct
44	drug5	drug5	NN	_	42	appos
45	,	,	,	_	42	punct
46	by	by	IN	_	48	case
47	35	35	CD	_	48	nummod
48	%	%	NN	_	36	nmod
49	.	.	.	_	1	punct

1	drug1	drug1	NN	_	2	compound
2	dose	dose	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	reduced	reduce	VBN	_	0	ROOT
6	to	to	TO	_	7	case
7	one-half	one-half	NN	_	5	nmod
8	of	of	IN	_	11	case
9	its	its	PRP$	_	11	nmod:poss
10	normal	normal	JJ	_	11	amod
11	dose	dose	NN	_	7	nmod
12	when	when	WRB	_	19	advmod
13	concomitant	concomitant	JJ	_	14	amod
14	administration	administration	NN	_	19	nsubj
15	of	of	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	with	with	IN	_	18	case
18	drug3	drug3	NN	_	14	nmod
19	occurs	occur	VBZ	_	5	advcl
20	.	.	.	_	5	punct

1	Other	other	JJ	_	3	amod
2	significant	significant	JJ	_	3	amod
3	inhibitors	inhibitor	NNS	_	15	nsubjpass
4	of	of	IN	_	5	case
5	CYP2D6	cyp2d6	NN	_	3	nmod
6	,	,	,	_	3	punct
7	such	such	JJ	_	9	case
8	as	as	IN	_	7	mwe
9	drug1	drug1	NN	_	3	nmod
10	or	or	CC	_	9	cc
11	drug2	drug2	NN	_	9	conj
12	,	,	,	_	3	punct
13	would	would	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	expected	expect	VBN	_	0	ROOT
16	to	to	TO	_	17	mark
17	have	have	VB	_	15	xcomp
18	similar	similar	JJ	_	19	amod
19	effects	effect	NNS	_	17	dobj
20	and	and	CC	_	15	cc
21	,	,	,	_	15	punct
22	therefore	therefore	RB	_	26	advmod
23	,	,	,	_	26	punct
24	should	should	MD	_	26	aux
25	be	be	VB	_	26	auxpass
26	accompanied	accompany	VBN	_	15	conj
27	by	by	IN	_	30	case
28	similar	similar	JJ	_	30	amod
29	dose	dose	NN	_	30	compound
30	reductions	reduction	NNS	_	26	nmod
31	.	.	.	_	15	punct

1	When	when	WRB	_	6	advmod
2	the	the	DT	_	4	det
3	CYP2D6	cyp2d6	NN	_	4	compound
4	inhibitor	inhibitor	NN	_	6	nsubjpass
5	is	be	VBZ	_	6	auxpass
6	withdrawn	withdraw	VBN	_	17	advcl
7	from	from	IN	_	10	case
8	the	the	DT	_	10	det
9	combination	combination	NN	_	10	compound
10	therapy	therapy	NN	_	6	nmod
11	,	,	,	_	17	punct
12	drug1	drug1	NN	_	13	compound
13	dose	dose	NN	_	17	nsubjpass
14	should	should	MD	_	17	aux
15	then	then	RB	_	17	advmod
16	be	be	VB	_	17	auxpass
17	increased	increase	VBN	_	0	ROOT
18	.	.	.	_	17	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Coadministration	coadministration	NN	_	24	nsubj
4	of	of	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	-LRB-	-lrb-	-LRB-	_	9	punct
7	200	200	CD	_	8	compound
8	mg	mg	NN	_	9	amod
9	BID	BID	NNP	_	5	appos
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	,	,	,	_	5	punct
12	a	a	DT	_	15	det
13	potent	potent	JJ	_	15	amod
14	CYP3A4	cyp3a4	NN	_	15	compound
15	inducer	inducer	NN	_	5	appos
16	,	,	,	_	5	punct
17	with	with	IN	_	18	case
18	drug3	drug3	NN	_	3	nmod
19	-LRB-	-lrb-	-LRB-	_	22	punct
20	30	30	CD	_	21	compound
21	mg	mg	NN	_	22	amod
22	QD	qd	NN	_	18	appos
23	-RRB-	-rrb-	-RRB-	_	22	punct
24	resulted	result	VBD	_	1	appos
25	in	in	IN	_	30	case
26	an	a	DT	_	30	det
27	approximate	approximate	JJ	_	30	amod
28	70	70	CD	_	29	compound
29	%	%	NN	_	30	amod
30	decrease	decrease	NN	_	24	nmod
31	in	in	IN	_	35	case
32	Cmax	cmax	NN	_	35	compound
33	and	and	CC	_	32	cc
34	AUC	auc	NN	_	32	conj
35	values	value	NNS	_	30	nmod
36	of	of	IN	_	38	case
37	both	both	DT	_	38	cc:preconj
38	drug4	drug4	NN	_	35	nmod
39	and	and	CC	_	38	cc
40	its	its	PRP$	_	42	nmod:poss
41	active	active	JJ	_	42	amod
42	metabolite	metabolite	NN	_	38	conj
43	,	,	,	_	42	punct
44	drug5	drug5	NN	_	42	appos
45	.	.	.	_	1	punct

1	When	when	WRB	_	4	advmod
2	drug1	drug1	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	added	add	VBN	_	13	advcl
5	to	to	TO	_	7	case
6	drug2	drug2	NN	_	7	compound
7	therapy	therapy	NN	_	4	nmod
8	,	,	,	_	13	punct
9	drug3	drug3	NN	_	10	compound
10	dose	dose	NN	_	13	nsubjpass
11	should	should	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	doubled	double	VBN	_	0	ROOT
14	.	.	.	_	13	punct

1	Additional	additional	JJ	_	3	amod
2	dose	dose	NN	_	3	compound
3	increases	increase	NNS	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	based	base	VBN	_	0	ROOT
7	on	on	IN	_	9	case
8	clinical	clinical	JJ	_	9	amod
9	evaluation	evaluation	NN	_	6	nmod
10	.	.	.	_	6	punct

1	When	when	WRB	_	4	advmod
2	drug1	drug1	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	withdrawn	withdraw	VBN	_	15	advcl
5	from	from	IN	_	8	case
6	the	the	DT	_	8	det
7	combination	combination	NN	_	8	compound
8	therapy	therapy	NN	_	4	nmod
9	,	,	,	_	15	punct
10	drug2	drug2	NN	_	11	compound
11	dose	dose	NN	_	15	nsubjpass
12	should	should	MD	_	15	aux
13	then	then	RB	_	15	advmod
14	be	be	VB	_	15	auxpass
15	reduced	reduce	VBN	_	0	ROOT
16	.	.	.	_	15	punct

1	No	no	DT	_	4	neg
2	clinically	clinically	RB	_	3	advmod
3	significant	significant	JJ	_	4	amod
4	effect	effect	NN	_	13	nsubjpass
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	,	,	,	_	6	punct
8	drug2	drug2	NN	_	6	conj
9	,	,	,	_	6	punct
10	or	or	CC	_	6	cc
11	drug3	drug3	NN	_	6	conj
12	was	be	VBD	_	13	auxpass
13	seen	see	VBN	_	0	ROOT
14	on	on	IN	_	16	case
15	the	the	DT	_	16	det
16	pharmacokinetics	pharmacokinetic	NNS	_	13	nmod
17	of	of	IN	_	18	case
18	drug4	drug4	NN	_	16	nmod
19	-LRB-	-lrb-	-LRB-	_	20	punct
20	see	see	VB	_	13	parataxis
21	CLINICAL	CLINICAL	NNP	_	22	compound
22	PHARMACOLOGY	PHARMACOLOGY	NNP	_	20	dobj
23	:	:	:	_	22	punct
24	Drug	drug	NN	_	27	compound
25	-	-	:	_	27	punct
26	Drug	drug	NN	_	27	compound
27	Interactions	interaction	NNS	_	22	dep
28	-RRB-	-rrb-	-RRB-	_	20	punct
29	.	.	.	_	13	punct

1	Potential	potential	JJ	_	10	nsubj
2	for	for	IN	_	5	mark
3	drug1	drug1	NN	_	5	nsubj
4	to	to	TO	_	5	mark
5	Affect	affect	VB	_	1	advcl
6	Other	other	JJ	_	8	amod
7	Drugs	drug	NNS	_	8	compound
8	drug2	drug2	NN	_	5	dobj
9	is	be	VBZ	_	10	cop
10	unlikely	unlikely	JJ	_	0	ROOT
11	to	to	TO	_	12	mark
12	cause	cause	VB	_	10	xcomp
13	clinically	clinically	RB	_	14	advmod
14	important	important	JJ	_	16	amod
15	pharmacokinetic	pharmacokinetic	JJ	_	16	amod
16	interactions	interaction	NNS	_	12	dobj
17	with	with	IN	_	18	case
18	drugs	drug	NNS	_	16	nmod
19	metabolized	metabolize	VBN	_	18	acl
20	by	by	IN	_	23	case
21	cytochrome	cytochrome	NN	_	23	compound
22	P450	p450	NN	_	23	compound
23	enzymes	enzyme	NNS	_	19	nmod
24	.	.	.	_	10	punct

1	In	in	IN	_	4	case
2	in	in	FW	_	4	amod
3	vivo	vivo	FW	_	2	dep
4	studies	study	NNS	_	0	ROOT
5	,	,	,	_	4	punct
6	10	10	CD	_	5	root
7	-	-	:	_	10	punct
8	to	to	TO	_	10	case
9	30-mg/day	30-mg/day	JJ	_	10	amod
10	doses	dose	NNS	_	6	dep
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	had	have	VBD	_	10	acl
14	no	no	DT	_	16	neg
15	significant	significant	JJ	_	16	amod
16	effect	effect	NN	_	13	dobj
17	on	on	IN	_	18	case
18	metabolism	metabolism	NN	_	13	nmod
19	by	by	IN	_	20	case
20	CYP2D6	cyp2d6	NN	_	18	nmod
21	-LRB-	-lrb-	-LRB-	_	22	punct
22	drug2	drug2	NN	_	20	appos
23	-RRB-	-rrb-	-RRB-	_	22	punct
24	,	,	,	_	20	punct
25	CYP2C9	cyp2c9	NN	_	20	conj
26	-LRB-	-lrb-	-LRB-	_	27	punct
27	drug3	drug3	NN	_	25	appos
28	-RRB-	-rrb-	-RRB-	_	27	punct
29	,	,	,	_	20	punct
30	CYP2C19	cyp2c19	NN	_	20	conj
31	-LRB-	-lrb-	-LRB-	_	32	punct
32	drug4	drug4	NN	_	30	dep
33	,	,	,	_	32	punct
34	drug5	drug5	NN	_	32	appos
35	-RRB-	-rrb-	-RRB-	_	32	punct
36	,	,	,	_	20	punct
37	and	and	CC	_	20	cc
38	CYP3A4	cyp3a4	NN	_	42	compound
39	-LRB-	-lrb-	-LRB-	_	40	punct
40	drug6	drug6	NN	_	38	appos
41	-RRB-	-rrb-	-RRB-	_	40	punct
42	substrates	substrate	NNS	_	20	conj
43	.	.	.	_	6	punct

1	Additionally	additionally	RB	_	8	advmod
2	,	,	,	_	8	punct
3	drug1	drug1	NN	_	8	nsubj
4	and	and	CC	_	3	cc
5	drug2	drug2	NN	_	3	conj
6	did	do	VBD	_	8	aux
7	not	not	RB	_	8	neg
8	show	show	VB	_	0	ROOT
9	potential	potential	JJ	_	8	xcomp
10	for	for	IN	_	11	mark
11	altering	alter	VBG	_	9	advcl
12	CYP1A2-mediated	cyp1a2-mediated	JJ	_	13	amod
13	metabolism	metabolism	NN	_	11	dobj
14	in	in	FW	_	15	compound
15	vitro	vitro	FW	_	11	advmod
16	.	.	.	_	8	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	There	there	EX	_	4	expl
4	was	be	VBD	_	1	dep
5	no	no	DT	_	7	neg
6	significant	significant	JJ	_	7	amod
7	difference	difference	NN	_	4	nsubj
8	between	between	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	coadministered	coadminister	VBN	_	9	acl
11	with	with	IN	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	and	and	CC	_	12	cc
14	placebo	placebo	NN	_	12	conj
15	coadministered	coadminister	VBN	_	12	acl
16	with	with	IN	_	17	case
17	drug4	drug4	NN	_	15	nmod
18	on	on	IN	_	19	case
19	performance	performance	NN	_	15	nmod
20	of	of	IN	_	23	case
21	gross	gross	JJ	_	23	amod
22	motor	motor	NN	_	23	compound
23	skills	skill	NNS	_	19	nmod
24	or	or	CC	_	23	cc
25	stimulus	stimulus	NN	_	26	compound
26	response	response	NN	_	23	conj
27	in	in	IN	_	29	case
28	healthy	healthy	JJ	_	29	amod
29	subjects	subject	NNS	_	19	nmod
30	.	.	.	_	1	punct

1	As	as	IN	_	5	case
2	with	with	IN	_	5	case
3	most	most	JJS	_	5	amod
4	psychoactive	psychoactive	JJ	_	5	amod
5	medications	medication	NNS	_	10	nmod
6	,	,	,	_	10	punct
7	patients	patient	NNS	_	10	nsubjpass
8	should	should	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	advised	advise	VBN	_	0	ROOT
11	to	to	TO	_	12	mark
12	avoid	avoid	VB	_	10	xcomp
13	drug1	drug1	NN	_	12	dobj
14	while	while	IN	_	15	mark
15	taking	take	VBG	_	12	advcl
16	drug2	drug2	NN	_	15	dobj

1	.	.	.	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	The	the	DT	_	3	det
2	concurrent	concurrent	JJ	_	3	amod
3	use	use	NN	_	26	nsubj
4	of	of	IN	_	6	case
5	drug1	drug1	NN	_	6	compound
6	Injection	injection	NN	_	3	nmod
7	with	with	IN	_	9	case
8	other	other	JJ	_	9	amod
9	drug2	drug2	NN	_	3	nmod
10	or	or	CC	_	9	cc
11	medications	medication	NNS	_	9	conj
12	with	with	IN	_	14	case
13	anticholinergic	anticholinergic	JJ	_	14	amod
14	activity	activity	NN	_	3	nmod
15	,	,	,	_	14	punct
16	such	such	JJ	_	18	case
17	as	as	IN	_	16	mwe
18	drug3	drug3	NN	_	14	nmod
19	,	,	,	_	18	punct
20	drug4	drug4	NN	_	18	conj
21	,	,	,	_	18	punct
22	or	or	CC	_	18	cc
23	drug5	drug5	NN	_	18	conj
24	,	,	,	_	3	punct
25	may	may	MD	_	26	aux
26	intensify	intensify	VB	_	0	ROOT
27	the	the	DT	_	29	det
28	antimuscarinic	antimuscarinic	JJ	_	29	amod
29	effects	effect	NNS	_	26	dobj
30	and	and	CC	_	26	cc
31	may	may	MD	_	32	aux
32	result	result	VB	_	26	conj
33	in	in	IN	_	35	case
34	an	a	DT	_	35	det
35	increase	increase	NN	_	32	nmod
36	in	in	IN	_	39	case
37	anticholinergic	anticholinergic	JJ	_	39	amod
38	side	side	JJ	_	39	amod
39	effects	effect	NNS	_	35	nmod
40	.	.	.	_	26	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	13	nsubj
3	of	of	IN	_	5	case
4	drug1	drug1	NN	_	5	compound
5	Injection	injection	NN	_	2	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	in	in	IN	_	11	case
9	a	a	DT	_	11	det
10	wax	wax	NN	_	11	compound
11	matrix	matrix	NN	_	2	nmod
12	may	may	MD	_	13	aux
13	increase	increase	VB	_	0	ROOT
14	the	the	DT	_	15	det
15	severity	severity	NN	_	13	dobj
16	of	of	IN	_	20	case
17	potassium	potassium	NN	_	20	compound
18	chloride-induced	chloride-induced	JJ	_	20	amod
19	gastrointestinal	gastrointestinal	JJ	_	20	amod
20	lesions	lesion	NNS	_	15	nmod
21	as	as	IN	_	23	case
22	a	a	DT	_	23	det
23	result	result	NN	_	13	nmod
24	of	of	IN	_	29	case
25	a	a	DT	_	29	det
26	slower	slower	JJR	_	29	amod
27	gastrointestinal	gastrointestinal	JJ	_	29	amod
28	transit	transit	NN	_	29	compound
29	time	time	NN	_	23	nmod
30	.	.	.	_	13	punct

1	A	a	DT	_	4	det
2	possible	possible	JJ	_	4	amod
3	drug	drug	NN	_	4	compound
4	interaction	interaction	NN	_	12	nsubjpass
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	intravenous	intravenous	JJ	_	9	amod
9	drug2	drug2	NN	_	6	conj
10	has	have	VBZ	_	12	aux
11	been	be	VBN	_	12	auxpass
12	described	describe	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	treatment	treatment	NN	_	17	nsubj
3	of	of	IN	_	5	case
4	four	four	CD	_	5	nummod
5	patients	patient	NNS	_	2	nmod
6	in	in	IN	_	9	case
7	the	the	DT	_	9	det
8	United	United	NNP	_	9	compound
9	Kingdom	Kingdom	NNP	_	5	nmod
10	with	with	IN	_	11	case
11	drug1	drug1	NN	_	5	nmod
12	and	and	CC	_	11	cc
13	intravenous	intravenous	JJ	_	14	amod
14	drug2	drug2	NN	_	11	conj
15	may	may	MD	_	17	aux
16	have	have	VB	_	17	aux
17	caused	cause	VBN	_	0	ROOT
18	hypocalcemia	hypocalcemia	NN	_	17	dobj
19	;	;	:	_	17	punct

1	one	one	CD	_	2	nummod
2	patient	patient	NN	_	3	nsubj
3	died	die	VBD	_	0	ROOT
4	with	with	IN	_	6	case
5	severe	severe	JJ	_	6	amod
6	hypocalcemia	hypocalcemia	NN	_	3	nmod
7	.	.	.	_	3	punct

1	Toxicity	toxicity	NN	_	12	nsubjpass
2	associated	associate	VBN	_	1	acl
3	with	with	IN	_	5	case
4	concomitant	concomitant	JJ	_	5	amod
5	use	use	NN	_	2	nmod
6	of	of	IN	_	8	case
7	aerosolized	aerosolized	JJ	_	8	amod
8	drug1	drug1	NN	_	5	nmod
9	has	have	VBZ	_	12	aux
10	not	not	RB	_	12	neg
11	been	be	VBN	_	12	auxpass
12	reported	report	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	Because	because	IN	_	5	case
2	of	of	IN	_	1	mwe
3	drug1	drug1	NN	_	5	compound
4	s	s	NNS	_	5	compound
5	tendency	tendency	NN	_	17	nmod
6	to	to	TO	_	7	mark
7	cause	cause	VB	_	5	acl
8	renal	renal	JJ	_	9	amod
9	impairment	impairment	NN	_	7	dobj
10	,	,	,	_	17	punct
11	the	the	DT	_	12	det
12	use	use	NN	_	17	nsubjpass
13	of	of	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	should	should	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	avoided	avoid	VBN	_	0	ROOT
18	in	in	IN	_	19	case
19	combination	combination	NN	_	17	nmod
20	with	with	IN	_	23	case
21	potentially	potentially	RB	_	22	advmod
22	nephrotoxic	nephrotoxic	JJ	_	23	amod
23	drugs	drug	NNS	_	19	nmod
24	such	such	JJ	_	26	case
25	as	as	IN	_	24	mwe
26	drug3	drug3	NN	_	23	nmod
27	,	,	,	_	26	punct
28	drug4	drug4	NN	_	26	conj
29	and	and	CC	_	26	cc
30	intravenous	intravenous	JJ	_	31	amod
31	drug5	drug5	NN	_	26	conj
32	unless	unless	IN	_	36	mark
33	the	the	DT	_	35	det
34	potential	potential	JJ	_	35	amod
35	benefits	benefit	NNS	_	36	nsubj
36	outweigh	outweigh	VBP	_	17	advcl
37	the	the	DT	_	38	det
38	risks	risk	NNS	_	36	dobj
39	to	to	TO	_	41	case
40	the	the	DT	_	41	det
41	patient	patient	NN	_	36	nmod
42	.	.	.	_	17	punct

1	Since	since	IN	_	3	mark
2	drug1	drug1	NN	_	3	nsubj
3	decreases	decrease	VBZ	_	0	ROOT
4	serum	serum	NN	_	5	compound
5	concentrations	concentration	NNS	_	3	dobj
6	of	of	IN	_	8	case
7	ionized	ionize	VBN	_	8	amod
8	calcium	calcium	NN	_	5	nmod
9	,	,	,	_	8	punct
10	concurrent	concurrent	JJ	_	11	amod
11	treatment	treatment	NN	_	8	appos
12	with	with	IN	_	14	case
13	other	other	JJ	_	14	amod
14	drugs	drug	NNS	_	11	nmod
15	known	know	VBN	_	14	acl
16	to	to	TO	_	17	mark
17	influence	influence	VB	_	15	xcomp
18	serum	serum	NN	_	20	compound
19	calcium	calcium	NN	_	20	compound
20	concentrations	concentration	NNS	_	17	dobj
21	should	should	MD	_	23	aux
22	be	be	VB	_	23	auxpass
23	used	use	VBN	_	3	ccomp
24	with	with	IN	_	26	case
25	particular	particular	JJ	_	26	amod
26	caution	caution	NN	_	23	nmod
27	.	.	.	_	3	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	pharmacokinetics	pharmacokinetic	NNS	_	11	nsubjpass
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	drug3	drug3	NN	_	6	conj
9	were	be	VBD	_	11	auxpass
10	not	not	RB	_	11	neg
11	altered	alter	VBN	_	1	dep
12	in	in	IN	_	14	case
13	13	13	CD	_	14	nummod
14	patients	patient	NNS	_	11	nmod
15	receiving	receive	VBG	_	14	acl
16	either	either	CC	_	18	cc:preconj
17	concomitant	concomitant	JJ	_	18	amod
18	therapy	therapy	NN	_	15	dobj
19	or	or	CC	_	18	cc
20	daily	daily	JJ	_	22	amod
21	alternating	alternate	VBG	_	22	amod
22	therapy	therapy	NN	_	18	conj
23	for	for	IN	_	24	case
24	maintenance	maintenance	NN	_	11	nmod
25	of	of	IN	_	27	case
26	CMV	cmv	NN	_	27	compound
27	disease	disease	NN	_	24	nmod
28	.	.	.	_	11	punct

1	and/or	and/or	CC	_	5	cc
2	Drug/Laboratory	drug/laboratory	JJ	_	4	amod
3	Test	test	NN	_	4	compound
4	Interactions	interaction	NNS	_	5	nsubj
5	See	see	VB	_	0	ROOT
6	CLINICAL	CLINICAL	NNP	_	7	compound
7	PHARMACOLOGY	PHARMACOLOGY	NNP	_	5	dobj
8	,	,	,	_	7	punct
9	Pharmacokinetics	Pharmacokinetics	NNP	_	7	conj
10	and	and	CC	_	7	cc
11	Drug	Drug	NNP	_	12	compound
12	Interactions	interaction	NNS	_	7	conj
13	.	.	.	_	5	punct

1	Effect	effect	NN	_	0	ROOT
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	on	on	IN	_	6	case
5	other	other	JJ	_	6	amod
6	drugs	drug	NNS	_	1	nmod
7	:	:	:	_	1	punct
8	Drugs	drug	NNS	_	1	dep
9	metabolized	metabolize	VBN	_	8	acl
10	by	by	IN	_	13	case
11	cytochrome	cytochrome	NN	_	13	compound
12	P450	p450	NN	_	13	compound
13	2D6	2d6	NN	_	9	nmod
14	-LRB-	-lrb-	-LRB-	_	15	punct
15	CYP2D6	cyp2d6	NN	_	13	appos
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	:	:	:	_	8	punct
18	drug2	drug2	NN	_	24	nsubj
19	is	be	VBZ	_	24	cop
20	a	a	DT	_	24	det
21	strong	strong	JJ	_	24	amod
22	in	in	FW	_	24	amod
23	vitro	vitro	FW	_	22	dep
24	inhibitor	inhibitor	NN	_	8	dep
25	of	of	IN	_	26	case
26	CYP2D6	cyp2d6	NN	_	24	nmod
27	.	.	.	_	1	punct

1	Therefore	therefore	RB	_	0	ROOT
2	,	,	,	_	1	punct
3	dose	dose	NN	_	4	compound
4	adjustments	adjustment	NNS	_	2	root
5	of	of	IN	_	7	case
6	concomitant	concomitant	JJ	_	7	amod
7	medications	medication	NNS	_	4	nmod
8	that	that	WDT	_	11	nsubjpass
9	are	be	VBP	_	11	auxpass
10	predominantly	predominantly	RB	_	11	advmod
11	metabolized	metabolize	VBN	_	7	acl:relcl
12	by	by	IN	_	13	case
13	CYP2D6	cyp2d6	NN	_	11	nmod
14	and	and	CC	_	11	cc
15	have	have	VBP	_	34	aux
16	a	a	DT	_	19	det
17	narrow	narrow	JJ	_	19	amod
18	therapeutic	therapeutic	JJ	_	19	amod
19	index	index	NN	_	34	nsubjpass
20	-LRB-	-lrb-	-LRB-	_	23	punct
21	e.g.	e.g.	FW	_	23	dep
22	,	,	,	_	23	punct
23	drug1	drug1	NN	_	19	dep
24	,	,	,	_	23	punct
25	drug2	drug2	NN	_	23	conj
26	,	,	,	_	23	punct
27	drug3	drug3	NN	_	23	conj
28	and	and	CC	_	23	cc
29	most	most	RBS	_	30	advmod
30	drug4	drug4	JJ	_	23	conj
31	-RRB-	-rrb-	-RRB-	_	23	punct
32	may	may	MD	_	34	aux
33	be	be	VB	_	34	auxpass
34	required	require	VBN	_	11	conj
35	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concurrent	concurrent	JJ	_	4	amod
4	administration	administration	NN	_	16	nsubj
5	of	of	IN	_	7	case
6	25	25	CD	_	7	nummod
7	mg	mg	NN	_	4	nmod
8	or	or	CC	_	7	cc
9	100	100	CD	_	10	compound
10	mg	mg	NN	_	11	amod
11	drug2	drug2	NN	_	7	conj
12	with	with	IN	_	15	case
13	50	50	CD	_	14	compound
14	mg	mg	NN	_	15	amod
15	drug3	drug3	NN	_	4	nmod
16	increased	increase	VBD	_	1	dep
17	drug4	drug4	NN	_	18	compound
18	exposure	exposure	NN	_	16	dobj
19	and	and	CC	_	18	cc
20	drug5	drug5	NN	_	25	compound
21	-LRB-	-lrb-	-LRB-	_	23	punct
22	active	active	JJ	_	23	amod
23	metabolite	metabolite	NN	_	20	appos
24	-RRB-	-rrb-	-RRB-	_	23	punct
25	exposure	exposure	NN	_	18	conj
26	by	by	IN	_	29	case
27	approximately	approximately	RB	_	28	advmod
28	20	20	CD	_	29	nummod
29	%	%	NN	_	16	nmod
30	in	in	IN	_	33	case
31	CYP2D6	cyp2d6	NN	_	33	compound
32	extensive	extensive	JJ	_	33	amod
33	metabolizers	metabolizer	NNS	_	16	nmod
34	.	.	.	_	1	punct

1	Effect	effect	NN	_	0	ROOT
2	of	of	IN	_	4	case
3	other	other	JJ	_	4	amod
4	drugs	drug	NNS	_	1	nmod
5	on	on	IN	_	6	case
6	drug1	drug1	NN	_	1	nmod
7	:	:	:	_	1	punct
8	drug2	drug2	NN	_	10	nsubjpass
9	is	be	VBZ	_	10	auxpass
10	metabolized	metabolize	VBN	_	1	dep
11	by	by	IN	_	15	case
12	multiple	multiple	JJ	_	15	amod
13	cytochrome	cytochrome	NN	_	15	compound
14	P450	p450	NN	_	15	compound
15	enzymes	enzyme	NNS	_	10	nmod
16	,	,	,	_	15	punct
17	primarily	primarily	RB	_	18	advmod
18	CYP3A4	cyp3a4	NN	_	15	appos
19	,	,	,	_	18	punct
20	CYP2D6	cyp2d6	NN	_	18	conj
21	,	,	,	_	18	punct
22	and	and	CC	_	18	cc
23	CYP1A2	cyp1a2	NN	_	18	conj
24	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	metabolized	metabolize	VBN	_	1	appos
6	in	in	IN	_	7	case
7	part	part	NN	_	5	nmod
8	by	by	IN	_	9	case
9	CYP3A4	cyp3a4	NN	_	7	nmod
10	.	.	.	_	1	punct

1	Co-administration	co-administration	NN	_	11	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	,	,	,	_	3	punct
5	a	a	DT	_	7	det
6	strong	strong	JJ	_	7	amod
7	inhibitor	inhibitor	NN	_	3	appos
8	of	of	IN	_	9	case
9	CYP3A4	cyp3a4	NN	_	7	nmod
10	,	,	,	_	3	punct
11	increased	increase	VBD	_	0	ROOT
12	drug2	drug2	NN	_	13	compound
13	exposure	exposure	NN	_	11	dobj
14	following	follow	VBG	_	19	case
15	a	a	DT	_	19	det
16	single	single	JJ	_	19	amod
17	90	90	CD	_	18	compound
18	mg	mg	NN	_	19	amod
19	dose	dose	NN	_	11	nmod
20	of	of	IN	_	21	case
21	drug3	drug3	NN	_	19	nmod
22	by	by	IN	_	24	case
23	2.3	2.3	CD	_	24	nummod
24	fold	fold	NN	_	11	nmod
25	.	.	.	_	11	punct

1	Dose	dose	NN	_	2	compound
2	adjustment	adjustment	NN	_	7	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	may	may	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	required	require	VBN	_	0	ROOT
8	and	and	CC	_	7	cc
9	PTH	pth	NN	_	13	compound
10	and	and	CC	_	9	cc
11	serum	serum	NN	_	9	conj
12	calcium	calcium	NN	_	13	compound
13	concentrations	concentration	NNS	_	17	nsubjpass
14	should	should	MD	_	17	aux
15	be	be	VB	_	17	auxpass
16	closely	closely	RB	_	17	advmod
17	monitored	monitor	VBN	_	7	conj
18	if	if	IN	_	21	mark
19	a	a	DT	_	20	det
20	patient	patient	NN	_	21	nsubj
21	initiates	initiate	VBZ	_	17	advcl
22	or	or	CC	_	21	cc
23	discontinues	discontinue	VBZ	_	21	conj
24	therapy	therapy	NN	_	21	dobj
25	with	with	IN	_	29	case
26	a	a	DT	_	29	det
27	strong	strong	JJ	_	29	amod
28	CYP3A4	cyp3a4	NN	_	29	compound
29	inhibitor	inhibitor	NN	_	24	nmod
30	-LRB-	-lrb-	-LRB-	_	33	punct
31	e.g.	e.g.	FW	_	33	dep
32	,	,	,	_	33	punct
33	drug2	drug2	NN	_	29	dep
34	,	,	,	_	33	punct
35	drug3	drug3	NN	_	33	conj
36	,	,	,	_	33	punct
37	drug4	drug4	NN	_	33	appos
38	;	;	:	_	33	punct

1	see	see	VB	_	0	ROOT
2	DOSAGE	DOSAGE	NNP	_	1	dobj
3	AND	and	CC	_	2	cc
4	ADMINISTRATION	ADMINISTRATION	NNP	_	2	conj
5	-RRB-	-rrb-	-RRB-	_	1	punct
6	.	.	.	_	1	punct

1	Special	special	JJ	_	2	amod
2	care	care	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	required	require	VBN	_	0	ROOT
5	if	if	IN	_	9	mark
6	this	this	DT	_	7	det
7	drug	drug	NN	_	9	nsubjpass
8	is	be	VBZ	_	9	auxpass
9	given	give	VBN	_	4	advcl
10	to	to	TO	_	11	case
11	patients	patient	NNS	_	9	nmod
12	receiving	receive	VBG	_	11	acl
13	drug1	drug1	NN	_	12	dobj
14	because	because	IN	_	22	mark
15	a	a	DT	_	17	det
16	critical	critical	JJ	_	17	amod
17	fall	fall	NN	_	22	nsubj
18	in	in	IN	_	20	case
19	blood	blood	NN	_	20	compound
20	pressure	pressure	NN	_	17	nmod
21	may	may	MD	_	22	aux
22	occur	occur	VB	_	9	advcl
23	.	.	.	_	4	punct

1	Usually	usually	RB	_	6	advmod
2	,	,	,	_	6	punct
3	severe	severe	JJ	_	5	amod
4	abdominal	abdominal	JJ	_	5	amod
5	symptoms	symptom	NNS	_	6	nsubj
6	appear	appear	VBP	_	0	ROOT
7	before	before	IN	_	9	mark
8	there	there	EX	_	9	expl
9	is	be	VBZ	_	6	advcl
10	such	such	JJ	_	12	amod
11	a	a	DT	_	12	det
12	fall	fall	NN	_	9	nsubj
13	in	in	IN	_	16	case
14	the	the	DT	_	16	det
15	blood	blood	NN	_	16	compound
16	pressure	pressure	NN	_	12	nmod
17	.	.	.	_	6	punct

1	drug1	drug1	NN	_	4	nsubj
2	are	be	VBP	_	4	cop
3	strong	strong	JJ	_	4	amod
4	drug2	drug2	NN	_	0	ROOT
5	,	,	,	_	4	punct
6	but	but	CC	_	4	cc
7	regular	regular	JJ	_	8	amod
8	users	user	NNS	_	9	nsubj
9	develop	develop	VB	_	4	conj
10	physiological	physiological	JJ	_	11	amod
11	tolerance	tolerance	NN	_	9	dobj
12	allowing	allow	VBG	_	11	acl
13	gradually	gradually	RB	_	14	advmod
14	increased	increase	VBN	_	15	amod
15	dosages	dosage	NNS	_	12	dobj
16	.	.	.	_	4	punct

1	In	in	IN	_	2	case
2	combination	combination	NN	_	10	nmod
3	with	with	IN	_	5	case
4	other	other	JJ	_	5	amod
5	drug1	drug1	NN	_	2	nmod
6	,	,	,	_	10	punct
7	drug2	drug2	NN	_	10	nsubj
8	may	may	MD	_	10	aux
9	still	still	RB	_	10	advmod
10	kill	kill	VB	_	0	ROOT
11	even	even	RB	_	13	advmod
12	experienced	experienced	JJ	_	13	amod
13	users	user	NNS	_	10	dobj
14	,	,	,	_	10	punct
15	particularly	particularly	RB	_	23	advmod
16	if	if	IN	_	23	mark
17	their	they	PRP$	_	18	nmod:poss
18	tolerance	tolerance	NN	_	23	nsubj
19	to	to	TO	_	21	case
20	the	the	DT	_	21	det
21	drug	drug	NN	_	18	nmod
22	has	have	VBZ	_	23	aux
23	reduced	reduce	VBN	_	10	advcl
24	or	or	CC	_	23	cc
25	the	the	DT	_	26	det
26	strength	strength	NN	_	32	nsubj
27	of	of	IN	_	30	case
28	their	they	PRP$	_	30	nmod:poss
29	usual	usual	JJ	_	30	amod
30	dose	dose	NN	_	26	nmod
31	has	have	VBZ	_	32	aux
32	increased	increase	VBN	_	23	conj
33	.	.	.	_	10	punct

1	Toxicology	toxicology	NN	_	2	compound
2	studies	study	NNS	_	8	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	-	-	:	_	4	punct
6	related	related	JJ	_	7	amod
7	deaths	death	NNS	_	4	dep
8	reveal	reveal	VBP	_	0	ROOT
9	frequent	frequent	JJ	_	10	amod
10	involvement	involvement	NN	_	8	dobj
11	of	of	IN	_	13	case
12	other	other	JJ	_	13	amod
13	drug2	drug2	NN	_	10	nmod
14	,	,	,	_	13	punct
15	including	include	VBG	_	16	case
16	drug3	drug3	NN	_	13	nmod
17	,	,	,	_	16	punct
18	drug4	drug4	NN	_	16	appos
19	such	such	JJ	_	21	case
20	as	as	IN	_	19	mwe
21	drug5	drug5	NN	_	18	nmod
22	-LRB-	-lrb-	-LRB-	_	23	punct
23	drug6	drug6	NN	_	21	appos
24	-RRB-	-rrb-	-RRB-	_	23	punct
25	,	,	,	_	21	punct
26	and	and	CC	_	21	cc
27	,	,	,	_	21	punct
28	to	to	TO	_	31	case
29	a	a	DT	_	31	det
30	rising	rise	VBG	_	31	amod
31	degree	degree	NN	_	21	conj
32	,	,	,	_	21	punct
33	drug7	drug7	NN	_	21	conj
34	.	.	.	_	8	punct

1	Ironically	ironically	RB	_	6	advmod
2	,	,	,	_	6	punct
3	drug1	drug1	NN	_	6	nsubjpass
4	are	be	VBP	_	6	auxpass
5	often	often	RB	_	6	advmod
6	used	use	VBN	_	0	ROOT
7	in	in	IN	_	9	case
8	the	the	DT	_	9	det
9	treatment	treatment	NN	_	6	nmod
10	of	of	IN	_	12	case
11	drug2	drug2	NN	_	12	compound
12	addiction	addiction	NN	_	9	nmod
13	while	while	IN	_	15	mark
14	they	they	PRP	_	15	nsubj
15	cause	cause	VBP	_	6	advcl
16	much	much	RB	_	17	advmod
17	more	more	RBR	_	20	amod
18	severe	severe	JJ	_	20	amod
19	withdrawal	withdrawal	NN	_	20	compound
20	symptoms	symptom	NNS	_	15	dobj
21	.	.	.	_	6	punct

1	drug1	drug1	NN	_	3	nsubj
2	sometimes	sometimes	RB	_	3	advmod
3	proves	prove	VBZ	_	0	ROOT
4	to	to	TO	_	6	mark
5	be	be	VB	_	6	cop
6	fatal	fatal	JJ	_	3	xcomp
7	when	when	WRB	_	8	advmod
8	used	use	VBN	_	3	advcl
9	in	in	IN	_	10	case
10	combination	combination	NN	_	8	nmod
11	with	with	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	.	.	.	_	3	punct

1	The	the	DT	_	2	det
2	physician	physician	NN	_	5	nsubj
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	cop
5	alert	alert	JJ	_	0	ROOT
6	for	for	IN	_	10	case
7	possible	possible	JJ	_	10	amod
8	combined	combine	VBN	_	10	amod
9	drug	drug	NN	_	10	compound
10	actions	action	NNS	_	5	nmod
11	,	,	,	_	10	punct
12	desirable	desirable	JJ	_	10	amod
13	or	or	CC	_	12	cc
14	undesirable	undesirable	JJ	_	12	conj
15	,	,	,	_	10	punct
16	involving	involve	VBG	_	10	acl
17	drug1	drug1	NN	_	16	dobj
18	even	even	RB	_	23	advmod
19	though	though	IN	_	23	mark
20	drug2	drug2	NN	_	23	nsubjpass
21	has	have	VBZ	_	23	aux
22	been	be	VBN	_	23	auxpass
23	used	use	VBN	_	16	advcl
24	successfully	successfully	RB	_	25	advmod
25	concurrently	concurrently	RB	_	23	advmod
26	with	with	IN	_	28	case
27	other	other	JJ	_	28	amod
28	drugs	drug	NNS	_	23	nmod
29	,	,	,	_	28	punct
30	including	include	VBG	_	33	case
31	other	other	JJ	_	33	amod
32	cytotoxic	cytotoxic	JJ	_	33	amod
33	drugs	drug	NNS	_	28	nmod
34	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	6	case
4	three	three	CD	_	6	nummod
5	pharmacokinetic	pharmacokinetic	JJ	_	6	amod
6	studies	study	NNS	_	21	nmod
7	including	include	VBG	_	12	case
8	46	46	CD	_	12	nummod
9	normal	normal	JJ	_	12	amod
10	,	,	,	_	12	punct
11	healthy	healthy	JJ	_	12	amod
12	subjects	subject	NNS	_	6	nmod
13	,	,	,	_	12	punct
14	drug2	drug2	NN	_	15	compound
15	clearance	clearance	NN	_	12	conj
16	and	and	CC	_	12	cc
17	concentration	concentration	NN	_	12	conj
18	were	be	VBD	_	21	auxpass
19	not	not	RB	_	21	neg
20	significantly	significantly	RB	_	21	advmod
21	altered	alter	VBN	_	1	appos
22	by	by	IN	_	24	case
23	the	the	DT	_	24	det
24	addition	addition	NN	_	21	nmod
25	of	of	IN	_	26	case
26	drug3	drug3	NN	_	24	nmod
27	.	.	.	_	1	punct

1	In	in	IN	_	3	case
2	clinical	clinical	JJ	_	3	amod
3	studies	study	NNS	_	0	ROOT
4	where	where	WRB	_	10	advmod
5	patients	patient	NNS	_	10	nsubj
6	were	be	VBD	_	10	cop
7	on	on	IN	_	10	case
8	chronic	chronic	JJ	_	10	amod
9	drug1	drug1	NN	_	10	compound
10	therapy	therapy	NN	_	3	acl:relcl
11	,	,	,	_	10	punct
12	drug2	drug2	NN	_	13	nsubj
13	had	have	VBD	_	10	acl:relcl
14	no	no	DT	_	16	neg
15	measurable	measurable	JJ	_	16	amod
16	effect	effect	NN	_	13	dobj
17	on	on	IN	_	20	case
18	the	the	DT	_	20	det
19	mean	mean	JJ	_	20	amod
20	distribution	distribution	NN	_	13	nmod
21	of	of	IN	_	23	case
22	drug3	drug3	NN	_	23	compound
23	concentrations	concentration	NNS	_	20	nmod
24	or	or	CC	_	20	cc
25	the	the	DT	_	27	det
26	mean	mean	NN	_	27	compound
27	estimates	estimate	NNS	_	20	conj
28	of	of	IN	_	30	case
29	drug4	drug4	NN	_	30	compound
30	clearance	clearance	NN	_	27	nmod
31	.	.	.	_	3	punct

1	Though	though	IN	_	5	mark
2	individual	individual	JJ	_	4	amod
3	drug1	drug1	NN	_	4	compound
4	levels	level	NNS	_	5	nsubj
5	fluctuated	fluctuate	VBD	_	8	advcl
6	,	,	,	_	8	punct
7	there	there	EX	_	8	expl
8	were	be	VBD	_	0	ROOT
9	no	no	DT	_	12	neg
10	clinically	clinically	RB	_	11	advmod
11	significant	significant	JJ	_	12	amod
12	symptoms	symptom	NNS	_	8	nsubj
13	of	of	IN	_	15	case
14	drug	drug	NN	_	15	compound
15	inter-action	inter-action	NN	_	12	nmod
16	.	.	.	_	8	punct

1	drug1	drug1	NN	_	0	ROOT
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	:	:	:	_	1	punct
5	drug3	drug3	NN	_	39	nsubj
6	and	and	CC	_	5	cc
7	drug4	drug4	NN	_	5	conj
8	containing	contain	VBG	_	5	acl
9	drug5	drug5	NN	_	8	dobj
10	or	or	CC	_	9	cc
11	drug6	drug6	NN	_	9	conj
12	,	,	,	_	5	punct
13	as	as	RB	_	5	cc
14	well	well	RB	_	13	mwe
15	as	as	IN	_	13	mwe
16	formulations	formulation	NNS	_	5	conj
17	containing	contain	VBG	_	16	acl
18	divalent	divalent	JJ	_	21	amod
19	and	and	CC	_	18	cc
20	trivalent	trivalent	JJ	_	18	conj
21	cations	cation	NNS	_	17	dobj
22	such	such	JJ	_	24	case
23	as	as	IN	_	22	mwe
24	drug7	drug7	NN	_	21	nmod
25	-LRB-	-lrb-	-LRB-	_	26	punct
26	drug8	drug8	NN	_	24	appos
27	-RRB-	-rrb-	-RRB-	_	26	punct
28	,	,	,	_	24	punct
29	chewable/buffered	chewable/buffered	JJ	_	30	amod
30	tablets	tablet	NNS	_	24	conj
31	or	or	CC	_	24	cc
32	the	the	DT	_	34	det
33	pediatric	pediatric	JJ	_	34	amod
34	powder	powder	NN	_	24	conj
35	for	for	IN	_	37	case
36	oral	oral	JJ	_	37	amod
37	solution	solution	NN	_	34	nmod
38	can	can	MD	_	39	aux
39	form	form	VB	_	1	parataxis
40	chelation	chelation	NN	_	41	compound
41	complexes	complex	NNS	_	39	dobj
42	with	with	IN	_	43	case
43	drug9	drug9	NN	_	39	nmod
44	and	and	CC	_	39	cc
45	interfere	interfere	VB	_	39	conj
46	with	with	IN	_	48	case
47	its	its	PRP$	_	48	nmod:poss
48	bioavailability	bioavailability	NN	_	45	nmod
49	.	.	.	_	1	punct

1	drug1	drug1	NN	_	2	nsubj
2	administered	administer	VBN	_	7	csubj
3	2	2	CD	_	4	nummod
4	hours	hour	NNS	_	2	nmod
5	before	before	IN	_	4	case
6	drug2	drug2	NN	_	4	dep
7	resulted	result	VBD	_	0	ROOT
8	in	in	IN	_	11	case
9	a	a	DT	_	11	det
10	slower	slower	JJR	_	11	amod
11	absorption	absorption	NN	_	7	nmod
12	-LRB-	-lrb-	-LRB-	_	15	punct
13	mean	mean	NN	_	15	compound
14	C	c	NN	_	15	compound
15	max	max	NN	_	11	dep
16	decreased	decrease	VBN	_	15	acl
17	by	by	IN	_	19	case
18	30	30	CD	_	19	nummod
19	%	%	NN	_	16	nmod
20	and	and	CC	_	15	cc
21	mean	mean	VB	_	15	conj
22	T	t	NN	_	23	compound
23	max	max	NN	_	24	nsubj
24	increased	increase	VBN	_	21	ccomp
25	by	by	IN	_	27	case
26	1	1	CD	_	27	nummod
27	hour	hour	NN	_	24	nmod
28	-RRB-	-rrb-	-RRB-	_	15	punct
29	and	and	CC	_	11	cc
30	a	a	DT	_	32	det
31	lesser	lesser	JJR	_	32	amod
32	extent	extent	NN	_	11	conj
33	of	of	IN	_	34	case
34	absorption	absorption	NN	_	32	nmod
35	-LRB-	-lrb-	-LRB-	_	37	punct
36	mean	mean	NN	_	37	compound
37	AUC	auc	NN	_	32	dep
38	decreased	decrease	VBN	_	37	acl
39	by	by	IN	_	42	case
40	approximately	approximately	RB	_	41	advmod
41	25	25	CD	_	42	nummod
42	%	%	NN	_	38	nmod
43	-RRB-	-rrb-	-RRB-	_	37	punct
44	.	.	.	_	7	punct

1	drug1	drug1	NN	_	9	nsubj
2	-	-	:	_	1	punct
3	and	and	CC	_	1	cc
4	drug2	drug2	NN	_	1	conj
5	-	-	:	_	1	punct
6	containing	contain	VBG	_	1	acl
7	drug3	drug3	NN	_	6	dobj
8	,	,	,	_	1	punct
9	administered	administer	VBN	_	0	ROOT
10	concomitantly	concomitantly	RB	_	9	advmod
11	with	with	IN	_	12	case
12	drug4	drug4	NN	_	9	nmod
13	,	,	,	_	9	punct
14	significantly	significantly	RB	_	15	advmod
15	decreased	decrease	VBD	_	9	dep
16	the	the	DT	_	17	det
17	bioavailability	bioavailability	NN	_	15	dobj
18	-LRB-	-lrb-	-LRB-	_	20	punct
19	48	48	CD	_	20	nummod
20	%	%	NN	_	17	appos
21	-RRB-	-rrb-	-RRB-	_	20	punct
22	of	of	IN	_	23	case
23	drug5	drug5	NN	_	17	nmod
24	.	.	.	_	9	punct

1	Separating	separate	VBG	_	8	csubj
2	the	the	DT	_	3	det
3	doses	dose	NNS	_	1	dobj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	minimizes	minimize	VBZ	_	0	ROOT
9	this	this	DT	_	10	det
10	decrease	decrease	NN	_	8	dobj
11	in	in	IN	_	12	case
12	bioavailability	bioavailability	NN	_	10	nmod
13	;	;	:	_	8	punct

1	therefore	therefore	RB	_	8	advmod
2	,	,	,	_	8	punct
3	administration	administration	NN	_	8	nsubj
4	of	of	IN	_	6	case
5	these	these	DT	_	6	det
6	agents	agent	NNS	_	3	nmod
7	should	should	MD	_	8	aux
8	precede	precede	VB	_	0	ROOT
9	drug1	drug1	NN	_	10	compound
10	dosing	dosing	NN	_	8	dobj
11	by	by	IN	_	13	case
12	4	4	CD	_	13	nummod
13	hours	hour	NNS	_	8	nmod
14	or	or	CC	_	8	cc
15	follow	follow	VB	_	8	conj
16	drug2	drug2	NN	_	17	compound
17	dosing	dosing	NN	_	15	dobj
18	by	by	IN	_	22	case
19	at	at	IN	_	20	case
20	least	least	JJS	_	21	nmod:npmod
21	2	2	CD	_	22	nummod
22	hours	hour	NNS	_	15	nmod
23	.	.	.	_	8	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Two	two	CD	_	4	compound
4	hundred	hundred	CD	_	5	nummod
5	mg	mg	NN	_	20	nsubjpass
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	equivalent	equivalent	JJ	_	5	dep
10	to	to	TO	_	14	case
11	1	1	CD	_	13	compound
12	to	to	TO	_	13	dep
13	3	3	CD	_	14	nummod
14	cups	cup	NNS	_	9	nmod
15	of	of	IN	_	17	case
16	American	american	JJ	_	17	amod
17	coffee	coffee	NN	_	14	nmod
18	-RRB-	-rrb-	-RRB-	_	9	punct
19	was	be	VBD	_	20	auxpass
20	administered	administer	VBN	_	1	dep
21	to	to	TO	_	26	case
22	16	16	CD	_	26	nummod
23	normal	normal	JJ	_	26	amod
24	,	,	,	_	26	punct
25	healthy	healthy	JJ	_	26	amod
26	volunteers	volunteer	NNS	_	20	nmod
27	who	who	WP	_	29	nsubj
28	had	have	VBD	_	29	aux
29	achieved	achieve	VBN	_	26	acl:relcl
30	steady-state	steady-state	JJ	_	32	amod
31	blood	blood	NN	_	32	compound
32	concentrations	concentration	NNS	_	29	dobj
33	of	of	IN	_	34	case
34	drug3	drug3	NN	_	32	nmod
35	after	after	IN	_	37	mark
36	being	be	VBG	_	37	auxpass
37	dosed	dose	VBN	_	29	advcl
38	at	at	IN	_	41	case
39	400	400	CD	_	41	nummod
40	mg	mg	NN	_	41	compound
41	qd	qd	NN	_	37	nmod
42	.	.	.	_	1	punct

1	This	this	DT	_	4	nsubj
2	did	do	VBD	_	4	aux
3	not	not	RB	_	4	neg
4	result	result	VB	_	0	ROOT
5	in	in	IN	_	11	case
6	any	any	DT	_	11	det
7	statistically	statistically	RB	_	8	advmod
8	or	or	CC	_	10	advmod
9	clinically	clinically	RB	_	8	advmod
10	relevant	relevant	JJ	_	11	amod
11	changes	change	NNS	_	4	nmod
12	in	in	IN	_	15	case
13	the	the	DT	_	15	det
14	pharmacokinetic	pharmacokinetic	JJ	_	15	amod
15	parameters	parameter	NNS	_	11	nmod
16	of	of	IN	_	18	case
17	either	either	CC	_	18	cc:preconj
18	drug1	drug1	NN	_	15	nmod
19	or	or	CC	_	18	cc
20	its	its	PRP$	_	22	nmod:poss
21	major	major	JJ	_	22	amod
22	metabolite	metabolite	NN	_	18	conj
23	,	,	,	_	22	punct
24	drug2	drug2	NN	_	22	appos
25	.	.	.	_	4	punct

1	No	no	DT	_	2	neg
2	data	datum	NNS	_	4	nsubj
3	are	be	VBP	_	4	cop
4	available	available	JJ	_	0	ROOT
5	on	on	IN	_	7	case
6	potential	potential	JJ	_	7	amod
7	interactions	interaction	NNS	_	4	nmod
8	in	in	IN	_	9	case
9	individuals	individual	NNS	_	7	nmod
10	who	who	WP	_	11	nsubj
11	consume	consume	VBP	_	9	acl:relcl
12	greater	greater	JJR	_	14	advmod
13	than	than	IN	_	14	advmod
14	200	200	CD	_	15	nummod
15	mg	mg	NN	_	11	dobj
16	of	of	IN	_	17	case
17	drug1	drug1	NN	_	15	nmod
18	per	per	IN	_	19	case
19	day	day	NN	_	11	nmod
20	or	or	CC	_	19	cc
21	in	in	IN	_	22	case
22	those	those	DT	_	19	conj
23	,	,	,	_	9	punct
24	such	such	JJ	_	28	case
25	as	as	IN	_	24	mwe
26	the	the	DT	_	28	det
27	geriatric	geriatric	JJ	_	28	amod
28	population	population	NN	_	9	nmod
29	,	,	,	_	28	punct
30	who	who	WP	_	33	nsubjpass
31	are	be	VBP	_	33	auxpass
32	generally	generally	RB	_	33	advmod
33	believed	believe	VBN	_	28	acl:relcl
34	to	to	TO	_	37	mark
35	be	be	VB	_	37	cop
36	more	more	RBR	_	37	advmod
37	susceptible	susceptible	JJ	_	33	xcomp
38	to	to	TO	_	40	case
39	the	the	DT	_	40	det
40	development	development	NN	_	37	nmod
41	of	of	IN	_	45	case
42	drug-induced	drug-induced	JJ	_	45	amod
43	CNS-related	cns-related	JJ	_	45	amod
44	adverse	adverse	JJ	_	45	amod
45	effects	effect	NNS	_	40	nmod
46	.	.	.	_	4	punct

1	Other	other	JJ	_	2	amod
2	drug1	drug1	NN	_	4	nsubj
3	have	have	VBP	_	4	aux
4	demonstrated	demonstrate	VBN	_	0	ROOT
5	moderate	moderate	JJ	_	4	xcomp
6	to	to	TO	_	8	case
7	marked	marked	JJ	_	8	amod
8	interference	interference	NN	_	5	nmod
9	with	with	IN	_	11	case
10	the	the	DT	_	11	det
11	metabolism	metabolism	NN	_	8	nmod
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	,	,	,	_	4	punct
15	resulting	result	VBG	_	4	xcomp
16	in	in	IN	_	19	case
17	a	a	DT	_	19	det
18	reduced	reduce	VBN	_	19	amod
19	clearance	clearance	NN	_	15	nmod
20	,	,	,	_	19	punct
21	a	a	DT	_	22	det
22	prolongation	prolongation	NN	_	19	conj
23	of	of	IN	_	25	case
24	plasma	plasma	NN	_	25	compound
25	half-life	half-life	NN	_	22	nmod
26	,	,	,	_	19	punct
27	and	and	CC	_	19	cc
28	an	a	DT	_	29	det
29	increase	increase	NN	_	19	conj
30	in	in	IN	_	31	case
31	symptoms	symptom	NNS	_	29	nmod
32	that	that	WDT	_	33	nsubj
33	accompany	accompany	VBP	_	31	acl:relcl
34	high	high	JJ	_	35	amod
35	levels	level	NNS	_	33	dobj
36	of	of	IN	_	37	case
37	drug3	drug3	NN	_	35	nmod
38	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	6	nsubjpass
4	has	have	VBZ	_	6	aux
5	been	be	VBN	_	6	auxpass
6	demonstrated	demonstrate	VBN	_	1	dep
7	to	to	TO	_	8	mark
8	interfere	interfere	VB	_	6	xcomp
9	with	with	IN	_	11	case
10	the	the	DT	_	11	det
11	elimination	elimination	NN	_	8	nmod
12	of	of	IN	_	14	case
13	other	other	JJ	_	14	amod
14	drug3	drug3	NN	_	11	nmod
15	.	.	.	_	1	punct

1	This	this	DT	_	2	det
2	interference	interference	NN	_	4	nsubj
3	has	have	VBZ	_	4	aux
4	resulted	result	VBN	_	0	ROOT
5	in	in	IN	_	7	case
6	significant	significant	JJ	_	7	amod
7	increases	increase	NNS	_	4	nmod
8	in	in	IN	_	9	case
9	half-life	half-life	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	AUC	auc	NN	_	9	conj
12	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	interaction	interaction	NN	_	10	nsubjpass
3	between	between	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	has	have	VBZ	_	10	aux
8	not	not	RB	_	10	neg
9	been	be	VBN	_	10	auxpass
10	studied	study	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Elevated	elevated	JJ	_	5	amod
4	serum	serum	NN	_	5	compound
5	levels	level	NNS	_	10	nsubjpass
6	of	of	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	have	have	VBP	_	10	aux
9	been	be	VBN	_	10	auxpass
10	reported	report	VBN	_	1	appos
11	with	with	IN	_	13	case
12	concomitant	concomitant	JJ	_	13	amod
13	use	use	NN	_	10	nmod
14	of	of	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	with	with	IN	_	18	case
17	other	other	JJ	_	18	amod
18	members	member	NNS	_	13	nmod
19	of	of	IN	_	21	case
20	the	the	DT	_	21	det
21	drug4	drug4	NN	_	18	nmod
22	.	.	.	_	1	punct

1	Interaction	interaction	NN	_	9	nsubjpass
2	between	between	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	drug2	drug2	NN	_	3	conj
6	has	have	VBZ	_	9	aux
7	not	not	RB	_	9	neg
8	been	be	VBN	_	9	auxpass
9	studied	study	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	No	no	DT	_	6	neg
4	clinically	clinically	RB	_	5	advmod
5	significant	significant	JJ	_	6	amod
6	changes	change	NNS	_	21	nsubjpass
7	in	in	IN	_	9	case
8	drug2	drug2	NN	_	9	compound
9	pharmacokinetics	pharmacokinetic	NNS	_	6	nmod
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	AUC	auc	NN	_	9	dep
12	,	,	,	_	11	punct
13	C	c	NN	_	14	compound
14	max	max	NN	_	11	conj
15	,	,	,	_	11	punct
16	or	or	CC	_	11	cc
17	T	t	NN	_	18	compound
18	max	max	NN	_	11	conj
19	-RRB-	-rrb-	-RRB-	_	11	punct
20	were	be	VBD	_	21	auxpass
21	observed	observe	VBN	_	1	appos
22	when	when	WRB	_	31	advmod
23	a	a	DT	_	25	det
24	single	single	JJ	_	25	amod
25	dose	dose	NN	_	31	nsubjpass
26	of	of	IN	_	29	case
27	drug3	drug3	NN	_	29	compound
28	400	400	CD	_	29	nummod
29	mg	mg	NN	_	25	nmod
30	was	be	VBD	_	31	auxpass
31	given	give	VBN	_	21	advcl
32	after	after	IN	_	34	case
33	multiple	multiple	JJ	_	34	amod
34	doses	dose	NNS	_	31	nmod
35	of	of	IN	_	36	case
36	drug4	drug4	NN	_	34	nmod
37	-LRB-	-lrb-	-LRB-	_	40	punct
38	20	20	CD	_	39	compound
39	mg	mg	NN	_	40	amod
40	qd	qd	NN	_	36	appos
41	-RRB-	-rrb-	-RRB-	_	40	punct
42	in	in	IN	_	45	case
43	13	13	CD	_	45	nummod
44	healthy	healthy	JJ	_	45	amod
45	volunteers	volunteer	NNS	_	31	nmod
46	.	.	.	_	1	punct

1	Changes	change	NNS	_	7	nsubjpass
2	in	in	IN	_	4	case
3	drug1	drug1	NN	_	4	compound
4	pharmacokinetics	pharmacokinetic	NNS	_	1	nmod
5	were	be	VBD	_	7	auxpass
6	not	not	RB	_	7	neg
7	studied	study	VBN	_	0	ROOT
8	.	.	.	_	7	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	No	no	DT	_	5	neg
4	significant	significant	JJ	_	5	amod
5	differences	difference	NNS	_	7	nsubjpass
6	were	be	VBD	_	7	auxpass
7	observed	observe	VBN	_	1	dep
8	in	in	IN	_	11	case
9	mean	mean	JJ	_	11	amod
10	drug2	drug2	NN	_	11	compound
11	AUC	auc	NN	_	7	nmod
12	,	,	,	_	11	punct
13	C	c	NN	_	14	compound
14	max	max	NN	_	11	conj
15	,	,	,	_	11	punct
16	C	c	NN	_	17	compound
17	min	min	NN	_	11	conj
18	or	or	CC	_	11	cc
19	T	t	NN	_	20	compound
20	max	max	NN	_	11	conj
21	-LRB-	-lrb-	-LRB-	_	25	punct
22	although	although	IN	_	25	mark
23	C	c	NN	_	24	compound
24	max	max	NN	_	25	nsubj
25	increased	increase	VBN	_	20	dep
26	by	by	IN	_	28	case
27	11	11	CD	_	28	nummod
28	%	%	NN	_	25	nmod
29	-RRB-	-rrb-	-RRB-	_	25	punct
30	when	when	WRB	_	31	advmod
31	extended	extend	VBN	_	7	advcl
32	drug3	drug3	NN	_	33	compound
33	capsules	capsule	NNS	_	40	nsubjpass
34	-LRB-	-lrb-	-LRB-	_	37	punct
35	100	100	CD	_	37	nummod
36	mg	mg	NN	_	37	compound
37	tid	tid	NN	_	33	appos
38	-RRB-	-rrb-	-RRB-	_	37	punct
39	were	be	VBD	_	40	auxpass
40	coadministered	coadminister	VBN	_	31	ccomp
41	with	with	IN	_	42	case
42	drug4	drug4	NN	_	40	nmod
43	-LRB-	-lrb-	-LRB-	_	46	punct
44	400	400	CD	_	46	nummod
45	mg	mg	NN	_	46	compound
46	qd	qd	NN	_	42	appos
47	-RRB-	-rrb-	-RRB-	_	46	punct
48	for	for	IN	_	50	case
49	five	five	CD	_	50	nummod
50	days	day	NNS	_	40	nmod
51	in	in	IN	_	54	case
52	15	15	CD	_	54	nummod
53	healthy	healthy	JJ	_	54	amod
54	males	male	NNS	_	50	nmod
55	.	.	.	_	7	punct

1	drug1	drug1	NN	_	3	nsubj
2	is	be	VBZ	_	3	cop
3	unlikely	unlikely	JJ	_	0	ROOT
4	to	to	TO	_	5	mark
5	have	have	VB	_	3	xcomp
6	a	a	DT	_	8	det
7	significant	significant	JJ	_	8	amod
8	effect	effect	NN	_	5	dobj
9	on	on	IN	_	11	case
10	drug2	drug2	NN	_	11	compound
11	metabolism	metabolism	NN	_	5	nmod
12	.	.	.	_	3	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	nsubj
4	slows	slow	VBZ	_	1	appos
5	the	the	DT	_	7	det
6	renal	renal	JJ	_	7	amod
7	elimination	elimination	NN	_	4	dobj
8	of	of	IN	_	9	case
9	lome-floxacin	lome-floxacin	NN	_	7	nmod
10	.	.	.	_	1	punct

1	An	a	DT	_	2	det
2	increase	increase	NN	_	31	nsubjpass
3	of	of	IN	_	5	case
4	63	63	CD	_	5	nummod
5	%	%	NN	_	2	nmod
6	in	in	IN	_	9	case
7	the	the	DT	_	9	det
8	mean	mean	NN	_	9	compound
9	AUC	auc	NN	_	2	nmod
10	and	and	CC	_	9	cc
11	increases	increase	NNS	_	9	conj
12	of	of	IN	_	14	case
13	50	50	CD	_	14	nummod
14	%	%	NN	_	9	nmod
15	and	and	CC	_	14	cc
16	4	4	CD	_	17	nummod
17	%	%	NN	_	14	conj
18	,	,	,	_	2	punct
19	respectively	respectively	RB	_	2	advmod
20	,	,	,	_	2	punct
21	in	in	IN	_	25	case
22	the	the	DT	_	25	det
23	mean	mean	JJ	_	25	amod
24	T	t	NN	_	25	compound
25	max	max	NN	_	2	nmod
26	and	and	CC	_	25	cc
27	mean	mean	VB	_	29	amod
28	C	c	NN	_	29	compound
29	max	max	NN	_	25	conj
30	were	be	VBD	_	31	auxpass
31	noted	note	VBN	_	0	ROOT
32	in	in	IN	_	34	case
33	1	1	CD	_	34	nummod
34	study	study	NN	_	31	nmod
35	of	of	IN	_	37	case
36	6	6	CD	_	37	nummod
37	individuals	individual	NNS	_	34	nmod
38	.	.	.	_	31	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	No	no	DT	_	6	neg
4	clinically	clinically	RB	_	5	advmod
5	significant	significant	JJ	_	6	amod
6	changes	change	NNS	_	7	nsubj
7	occurred	occur	VBD	_	1	dep
8	in	in	IN	_	10	case
9	heart	heart	NN	_	10	compound
10	rate	rate	NN	_	7	nmod
11	or	or	CC	_	7	cc
12	corrected	correct	VBN	_	14	amod
13	QT	qt	NN	_	14	compound
14	intervals	interval	NNS	_	7	conj
15	,	,	,	_	7	punct
16	or	or	CC	_	7	cc
17	in	in	IN	_	19	case
18	drug2	drug2	NN	_	19	compound
19	metabolite	metabolite	NN	_	7	conj
20	or	or	CC	_	19	cc
21	drug3	drug3	NN	_	22	compound
22	pharmacokinetics	pharmacokinetic	NNS	_	19	conj
23	,	,	,	_	7	punct
24	during	during	IN	_	26	case
25	concurrent	concurrent	JJ	_	26	amod
26	administration	administration	NN	_	7	nmod
27	of	of	IN	_	28	case
28	drug4	drug4	NN	_	26	nmod
29	and	and	CC	_	28	cc
30	drug5	drug5	NN	_	28	conj
31	at	at	IN	_	32	case
32	steady-state	steady-state	JJ	_	26	nmod
33	in	in	IN	_	36	case
34	28	28	CD	_	36	nummod
35	healthy	healthy	JJ	_	36	amod
36	males	male	NNS	_	32	nmod
37	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	enhance	enhance	VB	_	1	appos
6	the	the	DT	_	7	det
7	effects	effect	NNS	_	5	dobj
8	of	of	IN	_	11	case
9	the	the	DT	_	11	det
10	oral	oral	JJ	_	11	amod
11	drug3	drug3	NN	_	7	nmod
12	,	,	,	_	11	punct
13	drug4	drug4	NN	_	11	conj
14	,	,	,	_	11	punct
15	or	or	CC	_	11	cc
16	its	its	PRP$	_	17	nmod:poss
17	derivatives	derivative	NNS	_	11	conj
18	.	.	.	_	1	punct

1	When	when	WRB	_	5	advmod
2	these	these	DT	_	3	det
3	products	product	NNS	_	5	nsubjpass
4	are	be	VBP	_	5	auxpass
5	administered	administer	VBN	_	16	advcl
6	concomitantly	concomitantly	RB	_	5	advmod
7	,	,	,	_	16	punct
8	prothrombin	prothrombin	NN	_	16	nsubjpass
9	or	or	CC	_	8	cc
10	other	other	JJ	_	13	amod
11	suitable	suitable	JJ	_	13	amod
12	coagulation	coagulation	NN	_	13	compound
13	tests	test	NNS	_	8	conj
14	should	should	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	monitored	monitor	VBN	_	0	ROOT
17	closely	closely	RB	_	16	advmod
18	.	.	.	_	16	punct

1	However	however	RB	_	18	advmod
2	,	,	,	_	18	punct
3	no	no	DT	_	4	neg
4	clinically	clinically	RB	_	18	nsubjpass
5	or	or	CC	_	4	cc
6	statistically	statistically	RB	_	4	conj
7	significant	significant	JJ	_	8	amod
8	differences	difference	NNS	_	4	dep
9	in	in	IN	_	12	case
10	prothrombin	prothrombin	NN	_	12	compound
11	time	time	NN	_	12	compound
12	ratio	ratio	NN	_	4	nmod
13	or	or	CC	_	12	cc
14	drug1	drug1	NN	_	16	compound
15	enantiomer	enantiomer	NN	_	16	compound
16	pharmacokinetics	pharmacokinetic	NNS	_	12	conj
17	were	be	VBD	_	18	auxpass
18	observed	observe	VBN	_	0	ROOT
19	in	in	IN	_	22	case
20	a	a	DT	_	22	det
21	small	small	JJ	_	22	amod
22	study	study	NN	_	18	nmod
23	of	of	IN	_	26	case
24	7	7	CD	_	26	nummod
25	healthy	healthy	JJ	_	26	amod
26	males	male	NNS	_	22	nmod
27	who	who	WP	_	28	nsubj
28	received	receive	VBD	_	26	acl:relcl
29	both	both	DT	_	30	cc:preconj
30	drug2	drug2	NN	_	28	dobj
31	and	and	CC	_	30	cc
32	drug3	drug3	NN	_	30	conj
33	under	under	IN	_	35	case
34	steady-state	steady-state	JJ	_	35	amod
35	conditions	condition	NNS	_	28	nmod
36	.	.	.	_	18	punct

1	drug1	drug1	NN	_	7	nsubj
2	,	,	,	_	1	punct
3	a	a	DT	_	4	det
4	drug2	drug2	NN	_	1	appos
5	,	,	,	_	1	punct
6	may	may	MD	_	7	aux
7	antagonize	antagonize	VB	_	21	csubjpass
8	the	the	DT	_	10	det
9	bactercidal	bactercidal	JJ	_	10	amod
10	effect	effect	NN	_	7	dobj
11	of	of	IN	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	and	and	CC	_	12	cc
14	concurrent	concurrent	JJ	_	15	amod
15	use	use	NN	_	12	conj
16	of	of	IN	_	18	case
17	these	these	DT	_	18	det
18	drugs	drug	NNS	_	12	nmod
19	should	should	MD	_	21	aux
20	be	be	VB	_	21	auxpass
21	avoided	avoid	VBN	_	0	ROOT
22	.	.	.	_	21	punct

1	Prolonged	prolonged	JJ	_	3	amod
2	recovery	recovery	NN	_	3	compound
3	time	time	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	occur	occur	VB	_	0	ROOT
6	if	if	IN	_	11	mark
7	drug1	drug1	NN	_	11	nsubjpass
8	and/or	and/or	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	are	be	VBP	_	11	auxpass
11	used	use	VBN	_	5	advcl
12	concurrently	concurrently	RB	_	11	advmod
13	with	with	IN	_	14	case
14	drug3	drug3	NN	_	11	nmod
15	.	.	.	_	5	punct

1	drug1	drug1	NN	_	4	nsubj
2	is	be	VBZ	_	4	cop
3	clinically	clinically	RB	_	4	advmod
4	compatible	compatible	JJ	_	0	ROOT
5	with	with	IN	_	12	case
6	the	the	DT	_	12	det
7	commonly	commonly	RB	_	8	advmod
8	used	use	VBN	_	12	amod
9	general	general	JJ	_	12	amod
10	and	and	CC	_	9	cc
11	local	local	JJ	_	9	conj
12	drug2	drug2	NN	_	4	nmod
13	when	when	WRB	_	19	advmod
14	an	a	DT	_	17	det
15	adequate	adequate	JJ	_	17	amod
16	respiratory	respiratory	JJ	_	17	amod
17	exchange	exchange	NN	_	19	nsubjpass
18	is	be	VBZ	_	19	auxpass
19	maintained	maintain	VBN	_	4	advcl
20	.	.	.	_	4	punct

1	No	no	DT	_	5	neg
2	formal	formal	JJ	_	5	amod
3	drug/drug	drug/drug	NN	_	5	compound
4	interaction	interaction	NN	_	5	compound
5	studies	study	NNS	_	9	nsubjpass
6	with	with	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	were	be	VBD	_	9	auxpass
9	performed	perform	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	Cytochrome	cytochrome	NN	_	2	compound
2	P-450	p-450	NN	_	5	nsubjpass
3	is	be	VBZ	_	5	auxpass
4	not	not	RB	_	5	neg
5	known	know	VBN	_	0	ROOT
6	to	to	TO	_	8	mark
7	be	be	VB	_	8	auxpass
8	involved	involve	VBN	_	5	xcomp
9	in	in	IN	_	11	case
10	the	the	DT	_	11	det
11	metabolism	metabolism	NN	_	8	nmod
12	of	of	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	.	.	.	_	5	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	highly	highly	RB	_	4	advmod
4	bound	bind	VBN	_	0	ROOT
5	to	to	TO	_	7	case
6	plasma	plasma	NN	_	7	compound
7	proteins	protein	NNS	_	4	nmod
8	-LRB-	-lrb-	-LRB-	_	12	punct
9	96	96	CD	_	11	compound
10	to	to	TO	_	11	dep
11	99	99	CD	_	12	nummod
12	%	%	NN	_	7	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	.	.	.	_	4	punct

1	Laboratory	laboratory	NN	_	3	compound
2	Tests	test	NNS	_	3	compound
3	Response	response	NN	_	8	nsubjpass
4	to	to	TO	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	should	should	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	monitored	monitor	VBN	_	0	ROOT
9	by	by	IN	_	10	mark
10	measuring	measure	VBG	_	8	advcl
11	serum	serum	NN	_	14	compound
12	total	total	JJ	_	14	amod
13	drug2	drug2	NN	_	14	compound
14	concentrations	concentration	NNS	_	10	dobj
15	just	just	RB	_	16	advmod
16	prior	prior	RB	_	10	advmod
17	to	to	TO	_	18	case
18	administration	administration	NN	_	16	nmod
19	on	on	IN	_	20	case
20	Day	day	NN	_	10	nmod
21	29	29	CD	_	20	nummod
22	and	and	CC	_	10	cc
23	every	every	DT	_	25	det
24	8	8	CD	_	25	nummod
25	weeks	week	NNS	_	26	nmod:npmod
26	thereafter	thereafter	RB	_	10	conj
27	.	.	.	_	8	punct

1	Serum	serum	NN	_	3	compound
2	transaminase	transaminase	NN	_	3	compound
3	levels	level	NNS	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	obtained	obtain	VBN	_	0	ROOT
7	before	before	IN	_	8	mark
8	starting	start	VBG	_	6	advcl
9	treatment	treatment	NN	_	8	dobj
10	with	with	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	and	and	CC	_	9	cc
13	periodically	periodically	RB	_	15	advmod
14	during	during	IN	_	15	case
15	treatment	treatment	NN	_	9	conj
16	.	.	.	_	6	punct

1	Periodic	periodic	JJ	_	2	amod
2	measurement	measurement	NN	_	10	nsubjpass
3	of	of	IN	_	6	case
4	serum	serum	NN	_	6	compound
5	PSA	psa	NN	_	6	compound
6	levels	level	NNS	_	2	nmod
7	may	may	MD	_	10	aux
8	also	also	RB	_	10	advmod
9	be	be	VB	_	10	auxpass
10	considered	consider	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	The	the	DT	_	3	det
2	renal	renal	JJ	_	3	amod
3	effects	effect	NNS	_	9	nsubjpass
4	of	of	IN	_	6	case
5	nephrotoxic	nephrotoxic	JJ	_	6	amod
6	compounds	compound	NNS	_	3	nmod
7	may	may	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	potentiated	potentiate	VBN	_	0	ROOT
10	by	by	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	.	.	.	_	9	punct

1	Many	many	JJ	_	3	amod
2	other	other	JJ	_	3	amod
3	medicines	medicine	NNS	_	5	nsubj
4	may	may	MD	_	5	aux
5	increase	increase	VB	_	0	ROOT
6	or	or	CC	_	5	cc
7	decrease	decrease	VB	_	5	conj
8	the	the	DT	_	9	det
9	effects	effect	NNS	_	5	dobj
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	or	or	CC	_	5	cc
13	affect	affect	VB	_	5	conj
14	your	you	PRP$	_	15	nmod:poss
15	condition	condition	NN	_	13	dobj
16	.	.	.	_	5	punct

1	Before	before	IN	_	2	mark
2	taking	take	VBG	_	5	advcl
3	drug1	drug1	NN	_	2	dobj
4	,	,	,	_	5	punct
5	tell	tell	VB	_	0	ROOT
6	your	you	PRP$	_	7	nmod:poss
7	doctor	doctor	NN	_	5	dobj
8	if	if	IN	_	11	mark
9	you	you	PRP	_	11	nsubj
10	are	be	VBP	_	11	aux
11	taking	take	VBG	_	5	advcl
12	any	any	DT	_	11	dobj
13	of	of	IN	_	16	case
14	the	the	DT	_	16	det
15	following	follow	VBG	_	16	amod
16	medicines	medicine	NNS	_	12	nmod
17	:	:	:	_	11	punct
18	-	-	:	_	11	punct
19	drug2	drug2	NN	_	11	dobj
20	or	or	CC	_	19	cc
21	another	another	DT	_	22	det
22	drug3	drug3	NN	_	19	conj
23	such	such	JJ	_	25	case
24	as	as	IN	_	23	mwe
25	drug4	drug4	NN	_	22	nmod
26	-LRB-	-lrb-	-LRB-	_	27	punct
27	drug5	drug5	NN	_	25	appos
28	-RRB-	-rrb-	-RRB-	_	27	punct
29	,	,	,	_	25	punct
30	drug6	drug6	NN	_	25	conj
31	-LRB-	-lrb-	-LRB-	_	32	punct
32	drug7	drug7	NN	_	30	dep
33	,	,	,	_	32	punct
34	others	other	NNS	_	32	appos
35	-RRB-	-rrb-	-RRB-	_	32	punct
36	,	,	,	_	25	punct
37	drug8	drug8	NN	_	25	conj
38	-LRB-	-lrb-	-LRB-	_	39	punct
39	drug9	drug9	NN	_	37	appos
40	-RRB-	-rrb-	-RRB-	_	39	punct
41	,	,	,	_	25	punct
42	drug10	drug10	NN	_	25	conj
43	-LRB-	-lrb-	-LRB-	_	44	punct
44	drug11	drug11	NN	_	42	appos
45	-RRB-	-rrb-	-RRB-	_	44	punct
46	,	,	,	_	25	punct
47	or	or	CC	_	25	cc
48	drug12	drug12	NN	_	25	conj
49	-LRB-	-lrb-	-LRB-	_	50	punct
50	drug13	drug13	NN	_	48	appos
51	-RRB-	-rrb-	-RRB-	_	50	punct
52	;	;	:	_	5	punct

1	-	-	:	_	0	ROOT
2	a	a	DT	_	1	root
3	drug1	drug1	NN	_	2	root
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	drug2	drug2	NN	_	3	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	such	such	JJ	_	9	case
8	as	as	IN	_	7	mwe
9	drug3	drug3	NN	_	3	nmod
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	drug4	drug4	NN	_	9	dep
12	,	,	,	_	11	punct
13	drug5	drug5	NN	_	11	conj
14	,	,	,	_	11	punct
15	drug6	drug6	NN	_	11	conj
16	,	,	,	_	11	punct
17	others	other	NNS	_	11	appos
18	-RRB-	-rrb-	-RRB-	_	11	punct
19	,	,	,	_	9	punct
20	drug7	drug7	NN	_	9	conj
21	-LRB-	-lrb-	-LRB-	_	22	punct
22	drug8	drug8	NN	_	20	dep
23	,	,	,	_	22	punct
24	drug9	drug9	NN	_	22	appos
25	,	,	,	_	22	punct
26	drug10	drug10	NN	_	22	appos
27	-RRB-	-rrb-	-RRB-	_	22	punct
28	,	,	,	_	9	punct
29	drug11	drug11	NN	_	9	conj
30	-LRB-	-lrb-	-LRB-	_	31	punct
31	drug12	drug12	NN	_	29	dep
32	,	,	,	_	31	punct
33	drug13	drug13	NN	_	31	appos
34	-RRB-	-rrb-	-RRB-	_	31	punct
35	,	,	,	_	9	punct
36	drug14	drug14	NN	_	9	conj
37	-LRB-	-lrb-	-LRB-	_	38	punct
38	drug15	drug15	NN	_	36	appos
39	-RRB-	-rrb-	-RRB-	_	38	punct
40	,	,	,	_	9	punct
41	drug16	drug16	NN	_	9	conj
42	-LRB-	-lrb-	-LRB-	_	43	punct
43	drug17	drug17	NN	_	41	appos
44	-RRB-	-rrb-	-RRB-	_	43	punct
45	,	,	,	_	9	punct
46	drug18	drug18	NN	_	9	conj
47	-LRB-	-lrb-	-LRB-	_	48	punct
48	drug19	drug19	NN	_	46	appos
49	-RRB-	-rrb-	-RRB-	_	48	punct
50	,	,	,	_	9	punct
51	drug20	drug20	NN	_	9	conj
52	-LRB-	-lrb-	-LRB-	_	53	punct
53	drug21	drug21	NN	_	51	appos
54	-RRB-	-rrb-	-RRB-	_	53	punct
55	,	,	,	_	9	punct
56	and	and	CC	_	9	cc
57	drug22	drug22	NN	_	9	conj
58	-LRB-	-lrb-	-LRB-	_	59	punct
59	drug23	drug23	NN	_	57	dep
60	,	,	,	_	59	punct
61	drug24	drug24	NN	_	59	appos
62	,	,	,	_	59	punct
63	drug25	drug25	NN	_	59	appos
64	-RRB-	-rrb-	-RRB-	_	59	punct
65	;	;	:	_	3	punct

1	-	-	:	_	0	ROOT
2	a	a	DT	_	4	det
3	sulfa-based	sulfa-based	JJ	_	4	amod
4	drug	drug	NN	_	1	root
5	such	such	JJ	_	7	case
6	as	as	IN	_	5	mwe
7	drug1	drug1	NN	_	4	nmod
8	-	-	:	_	7	punct
9	drug2	drug2	NN	_	7	dep
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	drug3	drug3	NN	_	9	dep
12	,	,	,	_	11	punct
13	drug4	drug4	NN	_	11	appos
14	-RRB-	-rrb-	-RRB-	_	11	punct
15	,	,	,	_	7	punct
16	drug5	drug5	NN	_	7	conj
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	drug6	drug6	NN	_	16	appos
19	-RRB-	-rrb-	-RRB-	_	18	punct
20	,	,	,	_	7	punct
21	or	or	CC	_	7	cc
22	drug7	drug7	NN	_	7	conj
23	-LRB-	-lrb-	-LRB-	_	24	punct
24	drug8	drug8	NN	_	22	appos
25	-RRB-	-rrb-	-RRB-	_	24	punct
26	;	;	:	_	4	punct

1	-	-	:	_	0	ROOT
2	a	a	DT	_	1	root
3	drug1	drug1	NN	_	2	root
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	drug2	drug2	NN	_	3	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	such	such	JJ	_	9	case
8	as	as	IN	_	7	mwe
9	drug3	drug3	NN	_	3	nmod
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	drug4	drug4	NN	_	9	appos
12	-RRB-	-rrb-	-RRB-	_	11	punct
13	,	,	,	_	9	punct
14	drug5	drug5	NN	_	9	conj
15	-LRB-	-lrb-	-LRB-	_	16	punct
16	drug6	drug6	NN	_	14	appos
17	-RRB-	-rrb-	-RRB-	_	16	punct
18	,	,	,	_	9	punct
19	or	or	CC	_	9	cc
20	drug7	drug7	NN	_	9	conj
21	-LRB-	-lrb-	-LRB-	_	22	punct
22	drug8	drug8	NN	_	20	appos
23	-RRB-	-rrb-	-RRB-	_	22	punct
24	;	;	:	_	3	punct

1	-	-	:	_	0	ROOT
2	a	a	DT	_	3	det
3	drug1	drug1	NN	_	1	root
4	such	such	JJ	_	6	case
5	as	as	IN	_	4	mwe
6	drug2	drug2	NN	_	3	nmod
7	-LRB-	-lrb-	-LRB-	_	8	punct
8	drug3	drug3	NN	_	6	appos
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	,	,	,	_	6	punct
11	drug4	drug4	NN	_	6	conj
12	-LRB-	-lrb-	-LRB-	_	13	punct
13	drug5	drug5	NN	_	11	appos
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	,	,	,	_	6	punct
16	drug6	drug6	NN	_	6	conj
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	drug7	drug7	NN	_	16	appos
19	-RRB-	-rrb-	-RRB-	_	18	punct
20	,	,	,	_	6	punct
21	drug8	drug8	NN	_	6	conj
22	-LRB-	-lrb-	-LRB-	_	23	punct
23	drug9	drug9	NN	_	21	appos
24	-RRB-	-rrb-	-RRB-	_	23	punct
25	,	,	,	_	6	punct
26	and	and	CC	_	6	cc
27	others	other	NNS	_	6	conj
28	;	;	:	_	3	punct

1	-	-	:	_	6	punct
2	a	a	DT	_	6	det
3	drug1	drug1	NN	_	6	compound
4	-LRB-	-lrb-	-LRB-	_	6	punct
5	water	water	NN	_	6	compound
6	pill	pill	NN	_	0	ROOT
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	such	such	JJ	_	10	case
9	as	as	IN	_	8	mwe
10	drug2	drug2	NN	_	6	nmod
11	-LRB-	-lrb-	-LRB-	_	12	punct
12	drug3	drug3	NN	_	10	dep
13	,	,	,	_	12	punct
14	drug4	drug4	NN	_	12	appos
15	-RRB-	-rrb-	-RRB-	_	12	punct
16	,	,	,	_	10	punct
17	drug5	drug5	NN	_	10	conj
18	-LRB-	-lrb-	-LRB-	_	19	punct
19	drug6	drug6	NN	_	17	appos
20	-RRB-	-rrb-	-RRB-	_	19	punct
21	,	,	,	_	10	punct
22	and	and	CC	_	10	cc
23	others	other	NNS	_	10	conj
24	;	;	:	_	6	punct

1	-	-	:	_	0	ROOT
2	a	a	DT	_	3	det
3	drug1	drug1	NN	_	1	root
4	such	such	JJ	_	6	case
5	as	as	IN	_	4	mwe
6	drug2	drug2	NN	_	3	nmod
7	-LRB-	-lrb-	-LRB-	_	8	punct
8	drug3	drug3	NN	_	6	dep
9	,	,	,	_	8	punct
10	drug4	drug4	NN	_	8	appos
11	,	,	,	_	8	punct
12	others	other	NNS	_	8	appos
13	-RRB-	-rrb-	-RRB-	_	8	punct
14	,	,	,	_	6	punct
15	drug5	drug5	NN	_	6	conj
16	-LRB-	-lrb-	-LRB-	_	17	punct
17	drug6	drug6	NN	_	15	dep
18	,	,	,	_	17	punct
19	others	other	NNS	_	17	appos
20	-RRB-	-rrb-	-RRB-	_	17	punct
21	,	,	,	_	6	punct
22	drug7	drug7	NN	_	6	conj
23	-LRB-	-lrb-	-LRB-	_	24	punct
24	drug8	drug8	NN	_	22	dep
25	,	,	,	_	24	punct
26	drug9	drug9	NN	_	24	appos
27	,	,	,	_	24	punct
28	others	other	NNS	_	24	appos
29	-RRB-	-rrb-	-RRB-	_	24	punct
30	,	,	,	_	6	punct
31	and	and	CC	_	6	cc
32	others	other	NNS	_	6	conj
33	;	;	:	_	3	punct

1	-	-	:	_	0	ROOT
2	a	a	DT	_	3	det
3	drug1	drug1	NN	_	1	root
4	such	such	JJ	_	6	case
5	as	as	IN	_	4	mwe
6	drug2	drug2	NN	_	3	nmod
7	-LRB-	-lrb-	-LRB-	_	8	punct
8	drug3	drug3	NN	_	6	appos
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	,	,	,	_	6	punct
11	drug4	drug4	NN	_	6	conj
12	-LRB-	-lrb-	-LRB-	_	13	punct
13	drug5	drug5	NN	_	11	dep
14	,	,	,	_	13	punct
15	drug6	drug6	NN	_	13	appos
16	-RRB-	-rrb-	-RRB-	_	13	punct
17	,	,	,	_	6	punct
18	drug7	drug7	NN	_	6	conj
19	-LRB-	-lrb-	-LRB-	_	20	punct
20	drug8	drug8	NN	_	18	appos
21	-RRB-	-rrb-	-RRB-	_	20	punct
22	,	,	,	_	6	punct
23	drug9	drug9	NN	_	6	conj
24	-LRB-	-lrb-	-LRB-	_	25	punct
25	drug10	drug10	NN	_	23	appos
26	-RRB-	-rrb-	-RRB-	_	25	punct
27	,	,	,	_	6	punct
28	and	and	CC	_	6	cc
29	others	other	NNS	_	6	conj
30	;	;	:	_	3	punct

1	-	-	:	_	0	ROOT
2	drug1	drug1	NN	_	1	root
3	-LRB-	-lrb-	-LRB-	_	4	punct
4	drug2	drug2	NN	_	2	appos
5	-RRB-	-rrb-	-RRB-	_	4	punct
6	;	;	:	_	2	punct

1	-	-	:	_	0	ROOT
2	drug1	drug1	NN	_	1	root
3	-LRB-	-lrb-	-LRB-	_	4	punct
4	drug2	drug2	NN	_	2	appos
5	-RRB-	-rrb-	-RRB-	_	4	punct
6	;	;	:	_	2	punct

1	-	-	:	_	0	ROOT
2	drug1	drug1	NN	_	1	root
3	-LRB-	-lrb-	-LRB-	_	4	punct
4	drug2	drug2	NN	_	2	dep
5	,	,	,	_	4	punct
6	drug3	drug3	NN	_	4	appos
7	-RRB-	-rrb-	-RRB-	_	4	punct
8	;	;	:	_	2	punct

1	or	or	CC	_	4	cc
2	-	-	:	_	4	punct
3	over-the-counter	over-the-counter	JJ	_	4	amod
4	cough	cough	NN	_	0	ROOT
5	,	,	,	_	4	punct
6	cold	cold	JJ	_	4	amod
7	,	,	,	_	4	punct
8	allergy	allergy	NN	_	4	conj
9	,	,	,	_	4	punct
10	or	or	CC	_	4	cc
11	weight	weight	NN	_	13	compound
12	loss	loss	NN	_	13	compound
13	medications	medication	NNS	_	4	conj
14	.	.	.	_	4	punct

1	You	you	PRP	_	3	nsubj
2	may	may	MD	_	3	aux
3	require	require	VB	_	0	ROOT
4	a	a	DT	_	6	det
5	dosage	dosage	NN	_	6	compound
6	adjustment	adjustment	NN	_	3	dobj
7	or	or	CC	_	6	cc
8	special	special	JJ	_	9	amod
9	monitoring	monitoring	NN	_	6	conj
10	if	if	IN	_	13	mark
11	you	you	PRP	_	13	nsubj
12	are	be	VBP	_	13	aux
13	taking	take	VBG	_	3	advcl
14	any	any	DT	_	13	dobj
15	of	of	IN	_	17	case
16	the	the	DT	_	17	det
17	medicines	medicine	NNS	_	14	nmod
18	listed	list	VBN	_	17	acl
19	above	above	RB	_	18	advmod
20	.	.	.	_	3	punct

1	Drugs	drug	NNS	_	9	nsubj
2	other	other	JJ	_	1	amod
3	than	than	IN	_	4	case
4	those	those	DT	_	2	nmod
5	listed	list	VBN	_	4	acl
6	here	here	RB	_	5	advmod
7	may	may	MD	_	9	aux
8	also	also	RB	_	9	advmod
9	interact	interact	VB	_	0	ROOT
10	with	with	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	or	or	CC	_	9	cc
13	affect	affect	VB	_	9	conj
14	your	you	PRP$	_	15	nmod:poss
15	condition	condition	NN	_	13	dobj
16	.	.	.	_	9	punct

1	Talk	talk	NN	_	0	ROOT
2	to	to	TO	_	4	case
3	your	you	PRP$	_	4	nmod:poss
4	doctor	doctor	NN	_	1	nmod
5	and	and	CC	_	4	cc
6	pharmacist	pharmacist	NN	_	4	conj
7	before	before	IN	_	8	mark
8	taking	take	VBG	_	1	acl
9	any	any	DT	_	10	det
10	prescription	prescription	NN	_	8	dobj
11	or	or	CC	_	10	cc
12	over-the-counter	over-the-counter	JJ	_	13	amod
13	medicines	medicine	NNS	_	10	conj
14	,	,	,	_	10	punct
15	including	include	VBG	_	17	case
16	herbal	herbal	JJ	_	17	amod
17	products	product	NNS	_	10	nmod
18	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	6	case
4	a	a	DT	_	6	det
5	prospective	prospective	JJ	_	6	amod
6	study	study	NN	_	14	nmod
7	involving	involve	VBG	_	6	acl
8	six-healthy-male	six-healthy-male	JJ	_	9	amod
9	volunteers	volunteer	NNS	_	7	dobj
10	,	,	,	_	14	punct
11	drug2	drug2	NN	_	14	nsubj
12	did	do	VBD	_	14	aux
13	not	not	RB	_	14	neg
14	affect	affect	VB	_	1	appos
15	the	the	DT	_	16	det
16	metabolism	metabolism	NN	_	14	dobj
17	of	of	IN	_	18	case
18	drug3	drug3	NN	_	16	nmod
19	.	.	.	_	1	punct

1	These	these	DT	_	3	det
2	six	six	CD	_	3	nummod
3	volunteers	volunteer	NNS	_	4	nsubj
4	received	receive	VBD	_	0	ROOT
5	drug1	drug1	NN	_	4	dobj
6	alone	alone	RB	_	5	advmod
7	-LRB-	-lrb-	-LRB-	_	9	punct
8	60	60	CD	_	9	nummod
9	mg	mg	NN	_	5	appos
10	twice	twice	RB	_	11	advmod
11	daily	daily	RB	_	9	advmod
12	-RRB-	-rrb-	-RRB-	_	9	punct
13	for	for	IN	_	15	case
14	8	8	CD	_	15	nummod
15	days	day	NNS	_	4	nmod
16	,	,	,	_	4	punct
17	followed	follow	VBN	_	4	dep
18	by	by	IN	_	19	case
19	drug2	drug2	NN	_	17	nmod
20	in	in	IN	_	21	case
21	combination	combination	NN	_	19	nmod
22	with	with	IN	_	23	case
23	drug3	drug3	NN	_	21	nmod
24	-LRB-	-lrb-	-LRB-	_	26	punct
25	500	500	CD	_	26	nummod
26	mg	mg	NN	_	23	appos
27	once	once	RB	_	28	advmod
28	daily	daily	JJ	_	26	amod
29	-RRB-	-rrb-	-RRB-	_	26	punct
30	for	for	IN	_	32	case
31	10	10	CD	_	32	nummod
32	days	day	NNS	_	17	nmod
33	.	.	.	_	4	punct

1	-LRB-	-lrb-	-LRB-	_	6	punct
2	Both	both	CC	_	3	det
3	drugs	drug	NNS	_	6	nsubjpass
4	were	be	VBD	_	6	auxpass
5	thus	thus	RB	_	6	advmod
6	dosed	dose	VBN	_	0	ROOT
7	to	to	TO	_	9	case
8	steady	steady	JJ	_	9	amod
9	state	state	NN	_	6	nmod
10	.	.	.	_	6	punct
11	-RRB-	-rrb-	-RRB-	_	6	punct

1	The	the	DT	_	2	det
2	pharmacokinetics	pharmacokinetic	NNS	_	16	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	its	its	PRP$	_	8	nmod:poss
7	acid	acid	NN	_	8	compound
8	metabolite	metabolite	NN	_	4	conj
9	and	and	CC	_	2	cc
10	the	the	DT	_	14	det
11	electrocardiographic	electrocardiographic	JJ	_	14	amod
12	QT	qt	NN	_	14	compound
13	c	c	NN	_	14	compound
14	interval	interval	NN	_	2	conj
15	were	be	VBD	_	16	auxpass
16	measured	measure	VBN	_	0	ROOT
17	during	during	IN	_	19	case
18	both	both	DT	_	19	det
19	periods	period	NNS	_	16	nmod
20	:	:	:	_	16	punct
21	with	with	IN	_	22	case
22	drug2	drug2	NN	_	16	nmod
23	alone	alone	RB	_	22	advmod
24	,	,	,	_	22	punct
25	and	and	CC	_	22	cc
26	with	with	IN	_	27	case
27	drug3	drug3	NN	_	22	conj
28	plus	plus	CC	_	27	cc
29	drug4	drug4	NN	_	27	conj
30	.	.	.	_	16	punct

1	In	in	IN	_	3	case
2	five	five	CD	_	3	nummod
3	men	man	NNS	_	8	nmod
4	,	,	,	_	8	punct
5	drug1	drug1	NN	_	6	compound
6	levels	level	NNS	_	8	nsubj
7	were	be	VBD	_	8	cop
8	undetectable	undetectable	JJ	_	0	ROOT
9	-LRB-	-lrb-	-LRB-	_	11	punct
10	5	5	CD	_	11	nummod
11	ng/mL	ng/ml	NN	_	8	dep
12	-RRB-	-rrb-	-RRB-	_	11	punct
13	throughout	throughout	IN	_	15	case
14	the	the	DT	_	15	det
15	study	study	NN	_	8	nmod
16	;	;	:	_	8	punct

1	in	in	IN	_	3	case
2	one	one	CD	_	3	nummod
3	man	man	NN	_	12	nmod
4	,	,	,	_	12	punct
5	the	the	DT	_	7	det
6	C	c	NN	_	7	compound
7	max	max	NN	_	12	nsubj
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	was	be	VBD	_	12	cop
11	8.1	8.1	CD	_	12	nummod
12	ng/mL	ng/ml	NN	_	0	ROOT
13	with	with	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	alone	alone	RB	_	14	advmod
16	and	and	CC	_	14	cc
17	7.2	7.2	CD	_	18	nummod
18	ng/mL	ng/ml	NN	_	14	conj
19	with	with	IN	_	20	case
20	drug3	drug3	NN	_	18	nmod
21	plus	plus	CC	_	20	cc
22	drug4	drug4	NN	_	20	conj
23	.	.	.	_	12	punct

1	The	the	DT	_	4	det
2	mean	mean	NN	_	4	compound
3	C	c	NN	_	4	compound
4	max	max	NN	_	20	nsubjpass
5	,	,	,	_	4	punct
6	T	t	NN	_	7	compound
7	max	max	NN	_	4	conj
8	,	,	,	_	4	punct
9	and	and	CC	_	4	cc
10	AUC	auc	NN	_	4	conj
11	of	of	IN	_	14	case
12	the	the	DT	_	14	det
13	acid	acid	NN	_	14	compound
14	metabolite	metabolite	NN	_	10	nmod
15	of	of	IN	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	were	be	VBD	_	20	auxpass
18	not	not	RB	_	20	neg
19	significantly	significantly	RB	_	20	advmod
20	changed	change	VBD	_	0	ROOT
21	.	.	.	_	20	punct

1	The	the	DT	_	5	det
2	mean	mean	NN	_	5	compound
3	QT	qt	NN	_	5	compound
4	c	c	NN	_	5	compound
5	interval	interval	NN	_	10	nsubj
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	msec	msec	NN	_	5	appos
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	was	be	VBD	_	10	cop
10	369	369	CD	_	0	ROOT
11	with	with	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	alone	alone	RB	_	12	advmod
14	and	and	CC	_	10	cc
15	367	367	CD	_	10	conj
16	with	with	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	plus	plus	CC	_	17	cc
19	drug3	drug3	NN	_	17	conj
20	.	.	.	_	10	punct

1	Also	also	RB	_	6	advmod
2	,	,	,	_	6	punct
3	in	in	FW	_	5	amod
4	vitro	vitro	FW	_	3	dep
5	experiments	experiment	NNS	_	6	nsubj
6	demonstrated	demonstrate	VBD	_	0	ROOT
7	a	a	DT	_	8	det
8	lack	lack	NN	_	6	dobj
9	of	of	IN	_	10	case
10	interaction	interaction	NN	_	8	nmod
11	between	between	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	and	and	CC	_	12	cc
14	drug2	drug2	NN	_	12	conj
15	.	.	.	_	6	punct

1	Thus	thus	RB	_	12	advmod
2	,	,	,	_	12	punct
3	the	the	DT	_	4	det
4	interaction	interaction	NN	_	12	nsubjpass
5	observed	observe	VBN	_	4	acl
6	between	between	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	and	and	CC	_	7	cc
9	drug2	drug2	NN	_	7	conj
10	is	be	VBZ	_	12	auxpass
11	not	not	RB	_	12	neg
12	expected	expect	VBN	_	0	ROOT
13	for	for	IN	_	14	case
14	drug3	drug3	NN	_	12	nmod
15	.	.	.	_	12	punct

1	Serious	serious	JJ	_	3	amod
2	cardiac	cardiac	JJ	_	3	amod
3	dysrhythmias	dysrhythmia	NNS	_	11	nsubj
4	,	,	,	_	3	punct
5	some	some	DT	_	3	appos
6	resulting	result	VBG	_	5	acl
7	in	in	IN	_	8	case
8	death	death	NN	_	6	nmod
9	,	,	,	_	3	punct
10	have	have	VBP	_	11	aux
11	occurred	occur	VBN	_	0	ROOT
12	in	in	IN	_	13	case
13	patients	patient	NNS	_	11	nmod
14	receiving	receive	VBG	_	13	acl
15	drug1	drug1	NN	_	14	dobj
16	concomitantly	concomitantly	RB	_	14	advmod
17	with	with	IN	_	19	case
18	other	other	JJ	_	19	amod
19	drug2	drug2	NN	_	14	nmod
20	.	.	.	_	11	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	7	nmod
3	,	,	,	_	7	punct
4	most	most	JJS	_	5	amod
5	drug1	drug1	NNS	_	7	nsubjpass
6	are	be	VBP	_	7	auxpass
7	contraindicated	contraindicate	VBN	_	0	ROOT
8	in	in	IN	_	9	case
9	patients	patient	NNS	_	7	nmod
10	receiving	receive	VBG	_	9	acl
11	drug2	drug2	NN	_	12	compound
12	therapy	therapy	NN	_	10	dobj
13	who	who	WP	_	14	nsubj
14	have	have	VBP	_	12	acl:relcl
15	pre-existing	pre-existing	JJ	_	17	amod
16	cardiac	cardiac	JJ	_	17	amod
17	abnormalities	abnormality	NNS	_	14	dobj
18	-LRB-	-lrb-	-LRB-	_	19	punct
19	arrhythmia	arrhythmia	NN	_	17	appos
20	,	,	,	_	19	punct
21	bradycardia	bradycardia	NN	_	19	conj
22	,	,	,	_	19	punct
23	QT	qt	NN	_	26	compound
24	c	c	NN	_	26	compound
25	interval	interval	NN	_	26	compound
26	prolongation	prolongation	NN	_	19	conj
27	,	,	,	_	19	punct
28	ischemic	ischemic	JJ	_	30	amod
29	heart	heart	NN	_	30	compound
30	disease	disease	NN	_	19	conj
31	,	,	,	_	19	punct
32	congestive	congestive	JJ	_	34	amod
33	heart	heart	NN	_	34	compound
34	failure	failure	NN	_	19	conj
35	,	,	,	_	19	punct
36	etc.	etc.	FW	_	19	dep
37	-RRB-	-rrb-	-RRB-	_	19	punct
38	or	or	CC	_	17	cc
39	electrolyte	electrolyte	NN	_	40	compound
40	disturbances	disturbance	NNS	_	17	conj
41	.	.	.	_	7	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Following	follow	VBG	_	4	case
4	co-administration	co-administration	NN	_	1	nmod
5	of	of	IN	_	9	case
6	two	two	CD	_	9	nummod
7	250-mg	250-mg	JJ	_	9	amod
8	drug2	drug2	NN	_	9	compound
9	tablets	tablet	NNS	_	4	nmod
10	administered	administer	VBN	_	9	acl
11	once	once	RB	_	12	advmod
12	daily	daily	RB	_	10	advmod
13	with	with	IN	_	16	case
14	200-mg	200-mg	JJ	_	16	amod
15	drug3	drug3	NN	_	16	compound
16	tablets	tablet	NNS	_	10	nmod
17	administered	administer	VBN	_	16	acl
18	twice	twice	RB	_	19	advmod
19	daily	daily	RB	_	17	advmod
20	for	for	IN	_	22	case
21	10	10	CD	_	22	nummod
22	days	day	NNS	_	17	nmod
23	to	to	TO	_	26	case
24	14	14	CD	_	26	nummod
25	healthy	healthy	JJ	_	26	amod
26	subjects	subject	NNS	_	17	nmod
27	,	,	,	_	4	punct
28	the	the	DT	_	31	det
29	steady-state	steady-state	JJ	_	31	amod
30	plasma	plasma	NN	_	31	compound
31	concentration	concentration	NN	_	37	nsubjpass
32	of	of	IN	_	33	case
33	drug4	drug4	NN	_	31	nmod
34	was	be	VBD	_	37	auxpass
35	not	not	RB	_	37	neg
36	significantly	significantly	RB	_	37	advmod
37	altered	alter	VBN	_	4	acl:relcl
38	.	.	.	_	1	punct

1	In	in	IN	_	2	case
2	general	general	JJ	_	17	nmod
3	,	,	,	_	17	punct
4	most	most	JJS	_	5	amod
5	patients	patient	NNS	_	17	nsubj
6	treated	treat	VBN	_	5	acl
7	with	with	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	who	who	WP	_	11	nsubj
10	are	be	VBP	_	11	aux
11	receiving	receive	VBG	_	8	acl:relcl
12	concomitant	concomitant	JJ	_	14	amod
13	drug2	drug2	NN	_	14	compound
14	therapy	therapy	NN	_	11	dobj
15	may	may	MD	_	17	aux
16	not	not	RB	_	17	neg
17	require	require	VB	_	0	ROOT
18	empiric	empiric	JJ	_	19	amod
19	adjustment	adjustment	NN	_	17	dobj
20	of	of	IN	_	22	case
21	drug3	drug3	NN	_	22	compound
22	dosage	dosage	NN	_	19	nmod
23	or	or	CC	_	22	cc
24	monitoring	monitoring	NN	_	22	conj
25	of	of	IN	_	28	case
26	drug4	drug4	NN	_	28	compound
27	plasma	plasma	NN	_	28	compound
28	concentrations	concentration	NNS	_	24	nmod
29	.	.	.	_	17	punct

1	However	however	RB	_	8	advmod
2	,	,	,	_	8	punct
3	drug1	drug1	NN	_	5	compound
4	plasma	plasma	NN	_	5	compound
5	concentrations	concentration	NNS	_	8	nsubjpass
6	should	should	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	monitored	monitor	VBN	_	0	ROOT
9	,	,	,	_	8	punct
10	with	with	IN	_	12	case
11	dosage	dosage	NN	_	12	compound
12	adjustment	adjustment	NN	_	8	nmod
13	as	as	IN	_	14	case
14	appropriate	appropriate	JJ	_	12	acl
15	,	,	,	_	8	punct
16	in	in	IN	_	17	case
17	patients	patient	NNS	_	8	nmod
18	whose	whose	WP$	_	20	nmod:poss
19	pulmonary	pulmonary	JJ	_	20	amod
20	disease	disease	NN	_	21	nsubj
21	requires	require	VBZ	_	17	acl:relcl
22	maintaining	maintain	VBG	_	21	xcomp
23	a	a	DT	_	27	det
24	given	give	VBN	_	27	amod
25	drug2	drug2	NN	_	27	compound
26	plasma	plasma	NN	_	27	compound
27	concentration	concentration	NN	_	22	dobj
28	for	for	IN	_	31	case
29	optimal	optimal	JJ	_	31	amod
30	pulmonary	pulmonary	JJ	_	31	amod
31	function	function	NN	_	27	nmod
32	or	or	CC	_	31	cc
33	in	in	IN	_	34	case
34	patients	patient	NNS	_	31	conj
35	with	with	IN	_	37	case
36	drug3	drug3	NN	_	37	compound
37	concentrations	concentration	NNS	_	34	nmod
38	at	at	IN	_	41	case
39	the	the	DT	_	41	det
40	higher	higher	JJR	_	41	amod
41	end	end	NN	_	34	nmod
42	of	of	IN	_	45	case
43	the	the	DT	_	45	det
44	therapeutic	therapeutic	JJ	_	45	amod
45	range	range	NN	_	41	nmod
46	.	.	.	_	8	punct

1	drug1	drug1	NN	_	0	ROOT
2	or	or	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	:	:	:	_	1	punct
5	When	when	WRB	_	8	advmod
6	drug3	drug3	NN	_	8	nsubjpass
7	is	be	VBZ	_	8	auxpass
8	administered	administer	VBN	_	21	advcl
9	immediately	immediately	RB	_	8	advmod
10	following	follow	VBG	_	11	case
11	drug4	drug4	NN	_	8	nmod
12	or	or	CC	_	11	cc
13	drug5	drug5	NN	_	11	conj
14	,	,	,	_	21	punct
15	the	the	DT	_	16	det
16	absorption	absorption	NN	_	21	nsubjpass
17	of	of	IN	_	18	case
18	drug6	drug6	NN	_	16	nmod
19	is	be	VBZ	_	21	auxpass
20	slightly	slightly	RB	_	21	advmod
21	enhanced	enhance	VBN	_	1	dep
22	.	.	.	_	1	punct

1	The	the	DT	_	4	det
2	following	follow	VBG	_	4	amod
3	drug	drug	NN	_	4	compound
4	interactions	interaction	NNS	_	7	nsubjpass
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	reported	report	VBN	_	0	ROOT
8	with	with	IN	_	10	case
9	drug1	drug1	NN	_	10	compound
10	products	product	NNS	_	7	nmod
11	.	.	.	_	7	punct

1	It	it	PRP	_	5	nsubjpass
2	is	be	VBZ	_	5	auxpass
3	presently	presently	RB	_	5	advmod
4	not	not	RB	_	5	neg
5	known	know	VBN	_	0	ROOT
6	whether	whether	IN	_	11	mark
7	these	these	DT	_	10	det
8	same	same	JJ	_	10	amod
9	drug	drug	NN	_	10	compound
10	interactions	interaction	NNS	_	11	nsubj
11	occur	occur	VBP	_	5	ccomp
12	with	with	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	.	.	.	_	5	punct

1	Until	until	IN	_	5	mark
2	further	further	JJ	_	3	amod
3	data	datum	NNS	_	5	nsubj
4	are	be	VBP	_	5	cop
5	available	available	JJ	_	19	advcl
6	regarding	regard	VBG	_	9	case
7	the	the	DT	_	9	det
8	potential	potential	JJ	_	9	amod
9	interaction	interaction	NN	_	5	nmod
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	with	with	IN	_	14	case
13	these	these	DT	_	14	det
14	compounds	compound	NNS	_	9	nmod
15	,	,	,	_	19	punct
16	caution	caution	NN	_	19	nsubjpass
17	should	should	MD	_	19	aux
18	be	be	VB	_	19	auxpass
19	used	use	VBN	_	0	ROOT
20	during	during	IN	_	21	case
21	coadministration	coadministration	NN	_	19	nmod
22	.	.	.	_	19	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	6	nsubjpass
4	has	have	VBZ	_	6	aux
5	been	be	VBN	_	6	auxpass
6	reported	report	VBN	_	1	dep
7	to	to	TO	_	8	mark
8	decrease	decrease	VB	_	6	xcomp
9	the	the	DT	_	10	det
10	clearance	clearance	NN	_	8	dobj
11	of	of	IN	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	and	and	CC	_	6	cc
14	,	,	,	_	6	punct
15	thus	thus	RB	_	6	advmod
16	,	,	,	_	6	punct
17	may	may	MD	_	18	aux
18	increase	increase	VB	_	6	ccomp
19	the	the	DT	_	21	det
20	pharmacologic	pharmacologic	JJ	_	21	amod
21	effect	effect	NN	_	18	dobj
22	of	of	IN	_	23	case
23	drug4	drug4	NN	_	21	nmod
24	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concomitant	concomitant	JJ	_	4	amod
4	administration	administration	NN	_	11	nsubjpass
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	and	and	CC	_	4	cc
8	drug3	drug3	NN	_	4	conj
9	has	have	VBZ	_	11	aux
10	been	be	VBN	_	11	auxpass
11	reported	report	VBN	_	1	appos
12	to	to	TO	_	13	mark
13	result	result	VB	_	11	xcomp
14	in	in	IN	_	18	case
15	elevated	elevated	JJ	_	18	amod
16	drug4	drug4	NN	_	18	compound
17	serum	serum	NN	_	18	compound
18	levels	level	NNS	_	13	nmod
19	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	There	there	EX	_	6	expl
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	cop
6	reports	report	NNS	_	1	appos
7	of	of	IN	_	10	case
8	increased	increase	VBN	_	10	amod
9	anticoagulant	anticoagulant	JJ	_	10	amod
10	effects	effect	NNS	_	6	nmod
11	when	when	WRB	_	17	advmod
12	drug2	drug2	NN	_	17	nsubjpass
13	and	and	CC	_	12	cc
14	oral	oral	JJ	_	12	conj
15	drug3	drug3	NN	_	12	dep
16	were	be	VBD	_	17	auxpass
17	used	use	VBN	_	6	advcl
18	concomitantly	concomitantly	RB	_	17	advmod
19	.	.	.	_	1	punct

1	Increased	increase	VBN	_	3	amod
2	anticoagulation	anticoagulation	JJ	_	3	amod
3	effects	effect	NNS	_	14	nsubj
4	due	due	JJ	_	3	amod
5	to	to	TO	_	8	case
6	a	a	DT	_	8	det
7	drug	drug	NN	_	8	compound
8	interaction	interaction	NN	_	4	nmod
9	with	with	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	may	may	MD	_	14	aux
12	be	be	VB	_	14	cop
13	more	more	RBR	_	14	advmod
14	pronounced	pronounced	JJ	_	0	ROOT
15	in	in	IN	_	17	case
16	the	the	DT	_	17	det
17	elderly	elderly	JJ	_	14	nmod
18	.	.	.	_	14	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concurrent	concurrent	JJ	_	4	amod
4	use	use	NN	_	13	nsubjpass
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	drug3	drug3	NN	_	6	conj
9	or	or	CC	_	4	cc
10	drug4	drug4	NN	_	4	conj
11	has	have	VBZ	_	13	aux
12	been	be	VBN	_	13	auxpass
13	associated	associate	VBN	_	1	appos
14	in	in	IN	_	16	case
15	some	some	DT	_	16	det
16	patients	patient	NNS	_	13	nmod
17	with	with	IN	_	20	case
18	acute	acute	JJ	_	20	amod
19	ergot	ergot	NN	_	20	compound
20	toxicity	toxicity	NN	_	16	nmod
21	characterized	characterize	VBN	_	20	acl
22	by	by	IN	_	25	case
23	severe	severe	JJ	_	25	amod
24	peripheral	peripheral	JJ	_	25	amod
25	vasospasm	vasospasm	NN	_	21	nmod
26	and	and	CC	_	25	cc
27	dysesthesia	dysesthesia	NN	_	25	conj
28	.	.	.	_	1	punct

1	Other	other	JJ	_	4	amod
2	drugs	drug	NNS	_	4	compound
3	Drug	drug	NN	_	4	compound
4	interactions	interaction	NNS	_	7	nsubjpass
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	reported	report	VBN	_	0	ROOT
8	with	with	IN	_	10	case
9	concomitant	concomitant	JJ	_	10	amod
10	administration	administration	NN	_	7	nmod
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	and	and	CC	_	12	cc
14	other	other	JJ	_	15	amod
15	medications	medication	NNS	_	12	conj
16	,	,	,	_	10	punct
17	including	include	VBG	_	18	case
18	drug2	drug2	NN	_	10	nmod
19	,	,	,	_	18	punct
20	drug3	drug3	NN	_	18	conj
21	,	,	,	_	18	punct
22	drug4	drug4	NN	_	18	conj
23	,	,	,	_	18	punct
24	drug5	drug5	NN	_	18	conj
25	,	,	,	_	18	punct
26	drug6	drug6	NN	_	18	conj
27	,	,	,	_	18	punct
28	drug7	drug7	NN	_	18	conj
29	,	,	,	_	18	punct
30	drug8	drug8	NN	_	18	conj
31	,	,	,	_	18	punct
32	drug9	drug9	NN	_	18	conj
33	,	,	,	_	18	punct
34	drug10	drug10	NN	_	18	conj
35	,	,	,	_	18	punct
36	and	and	CC	_	18	cc
37	drug11	drug11	NN	_	18	conj
38	.	.	.	_	7	punct

1	Injection	injection	NN	_	0	ROOT
2	There	there	EX	_	3	expl
3	is	be	VBZ	_	1	ccomp
4	inadequate	inadequate	JJ	_	6	amod
5	systematic	systematic	JJ	_	6	amod
6	experience	experience	NN	_	3	nsubj
7	with	with	IN	_	9	case
8	the	the	DT	_	9	det
9	use	use	NN	_	6	nmod
10	of	of	IN	_	12	case
11	drug1	drug1	NN	_	12	compound
12	injection	injection	NN	_	9	nmod
13	in	in	IN	_	14	case
14	combination	combination	NN	_	9	nmod
15	with	with	IN	_	17	case
16	other	other	JJ	_	17	amod
17	medications	medication	NNS	_	14	nmod
18	to	to	TO	_	19	mark
19	predict	predict	VB	_	6	acl
20	specific	specific	JJ	_	22	amod
21	drug-drug	drug-drug	JJ	_	22	amod
22	interactions	interaction	NNS	_	19	dobj
23	.	.	.	_	1	punct

1	Interactions	interaction	NNS	_	2	nsubj
2	attributed	attribute	VBD	_	0	ROOT
3	to	to	TO	_	6	case
4	the	the	DT	_	6	det
5	combined	combine	VBN	_	6	amod
6	use	use	NN	_	2	nmod
7	of	of	IN	_	9	case
8	drug1	drug1	NN	_	9	compound
9	injection	injection	NN	_	6	nmod
10	and	and	CC	_	9	cc
11	epidural	epidural	JJ	_	12	amod
12	drug2	drug2	NN	_	9	conj
13	include	include	VBP	_	2	dep
14	hypotension	hypotension	NN	_	13	dobj
15	and	and	CC	_	14	cc
16	dyspnea	dyspnea	NN	_	14	conj
17	.	.	.	_	2	punct

1	SIDE	SIDE	NNP	_	2	compound
2	EFFECTS	EFFECTS	NNP	_	17	nsubj
3	-LRB-	-lrb-	-LRB-	_	4	punct
4	drug1	drug1	NN	_	2	appos
5	-RRB-	-rrb-	-RRB-	_	4	punct
6	The	the	DT	_	10	det
7	most	most	RBS	_	8	advmod
8	common	common	JJ	_	10	amod
9	adverse	adverse	JJ	_	10	amod
10	reaction	reaction	NN	_	2	dep
11	during	during	IN	_	12	case
12	treatment	treatment	NN	_	10	nmod
13	with	with	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	is	be	VBZ	_	17	cop
16	transient	transient	JJ	_	17	amod
17	drowsiness	drowsiness	NN	_	0	ROOT
18	-LRB-	-lrb-	-LRB-	_	20	punct
19	10-63	10-63	CD	_	20	nummod
20	%	%	NN	_	17	appos
21	-RRB-	-rrb-	-RRB-	_	20	punct
22	.	.	.	_	17	punct

1	In	in	IN	_	4	case
2	one	one	CD	_	4	nummod
3	controlled	controlled	JJ	_	4	amod
4	study	study	NN	_	12	nmod
5	of	of	IN	_	7	case
6	175	175	CD	_	7	nummod
7	patients	patient	NNS	_	4	nmod
8	,	,	,	_	12	punct
9	transient	transient	JJ	_	10	amod
10	drowsiness	drowsiness	NN	_	12	nsubjpass
11	was	be	VBD	_	12	auxpass
12	observed	observe	VBN	_	0	ROOT
13	in	in	IN	_	15	case
14	63	63	CD	_	15	nummod
15	%	%	NN	_	12	nmod
16	of	of	IN	_	17	case
17	those	those	DT	_	15	nmod
18	receiving	receive	VBG	_	17	acl
19	drug1	drug1	NN	_	20	compound
20	tablets	tablet	NNS	_	18	dobj
21	compared	compare	VBN	_	24	case
22	to	to	TO	_	24	case
23	36	36	CD	_	24	nummod
24	%	%	NN	_	12	advcl
25	of	of	IN	_	26	case
26	those	those	DT	_	24	nmod
27	in	in	IN	_	30	case
28	the	the	DT	_	30	det
29	placebo	placebo	NN	_	30	compound
30	group	group	NN	_	26	nmod
31	.	.	.	_	12	punct

1	Other	other	JJ	_	4	amod
2	common	common	JJ	_	4	amod
3	adverse	adverse	JJ	_	4	amod
4	reactions	reaction	NNS	_	6	nsubj
5	are	be	VBP	_	6	cop
6	dizziness	dizziness	NN	_	0	ROOT
7	-LRB-	-lrb-	-LRB-	_	9	punct
8	5-15	5-15	CD	_	9	nummod
9	%	%	NN	_	6	appos
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	,	,	,	_	6	punct
12	weakness	weakness	NN	_	6	appos
13	-LRB-	-lrb-	-LRB-	_	15	punct
14	5-15	5-15	CD	_	15	nummod
15	%	%	NN	_	12	appos
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	and	and	CC	_	12	cc
18	fatigue	fatigue	NN	_	12	conj
19	-LRB-	-lrb-	-LRB-	_	21	punct
20	2-4	2-4	CD	_	21	nummod
21	%	%	NN	_	18	appos
22	-RRB-	-rrb-	-RRB-	_	21	punct
23	.	.	.	_	6	punct

1	Others	other	NNS	_	2	nsubj
2	reported	report	VBD	_	0	ROOT
3	:	:	:	_	2	punct
4	Neuropsychiatric	Neuropsychiatric	NNP	_	2	dep
5	:	:	:	_	4	punct
6	Confusion	confusion	NN	_	4	dep
7	-LRB-	-lrb-	-LRB-	_	9	punct
8	1-11	1-11	CD	_	9	nummod
9	%	%	NN	_	6	appos
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	,	,	,	_	6	punct
12	headache	headache	NN	_	6	conj
13	-LRB-	-lrb-	-LRB-	_	15	punct
14	4-8	4-8	CD	_	15	nummod
15	%	%	NN	_	12	appos
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	,	,	,	_	6	punct
18	insomnia	insomnia	NN	_	6	conj
19	-LRB-	-lrb-	-LRB-	_	21	punct
20	2-7	2-7	CD	_	21	nummod
21	%	%	NN	_	18	appos
22	-RRB-	-rrb-	-RRB-	_	21	punct
23	;	;	:	_	2	punct

1	and	and	CC	_	20	cc
2	,	,	,	_	20	punct
3	rarely	rarely	RB	_	20	advmod
4	,	,	,	_	20	punct
5	euphoria	euphoria	NN	_	20	dep
6	,	,	,	_	20	punct
7	excitement	excitement	NN	_	20	nsubj
8	,	,	,	_	20	punct
9	depression	depression	NN	_	20	dep
10	,	,	,	_	20	punct
11	hallucinations	hallucination	NNS	_	20	nsubj
12	,	,	,	_	11	punct
13	paresthesia	paresthesia	NN	_	11	conj
14	,	,	,	_	11	punct
15	muscle	muscle	NN	_	16	compound
16	pain	pain	NN	_	11	conj
17	,	,	,	_	11	punct
18	tinnitus	tinnitus	NN	_	11	conj
19	,	,	,	_	11	punct
20	slurred	slur	VBD	_	0	ROOT
21	speech	speech	NN	_	34	nsubj
22	,	,	,	_	21	punct
23	coordination	coordination	NN	_	24	compound
24	disorder	disorder	NN	_	21	conj
25	,	,	,	_	21	punct
26	tremor	tremor	NN	_	21	conj
27	,	,	,	_	21	punct
28	rigidity	rigidity	NN	_	21	conj
29	,	,	,	_	21	punct
30	dystonia	dystonia	NN	_	21	conj
31	,	,	,	_	21	punct
32	ataxia	ataxia	NN	_	21	conj
33	,	,	,	_	21	punct
34	blurred	blur	VBD	_	20	ccomp
35	vision	vision	NN	_	34	dobj
36	,	,	,	_	35	punct
37	nystagmus	nystagmus	NN	_	35	conj
38	,	,	,	_	35	punct
39	strabismus	strabismus	NN	_	35	conj
40	,	,	,	_	35	punct
41	miosis	miosis	NN	_	35	conj
42	,	,	,	_	35	punct
43	mydriasis	mydriasis	NN	_	35	conj
44	,	,	,	_	35	punct
45	diplopia	diplopia	NN	_	35	conj
46	,	,	,	_	35	punct
47	dysarthria	dysarthria	NN	_	35	conj
48	,	,	,	_	35	punct
49	epileptic	epileptic	JJ	_	50	amod
50	seizure	seizure	NN	_	35	conj
51	.	.	.	_	20	punct

1	Cardiovascular	Cardiovascular	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	Hypotension	hypotension	NN	_	1	dep
4	-LRB-	-lrb-	-LRB-	_	6	punct
5	0-9	0-9	CD	_	6	nummod
6	%	%	NN	_	3	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	.	.	.	_	1	punct

1	Rare	rare	JJ	_	2	amod
2	instances	instance	NNS	_	0	ROOT
3	of	of	IN	_	4	case
4	dyspnea	dyspnea	NN	_	2	nmod
5	,	,	,	_	4	punct
6	palpitation	palpitation	NN	_	4	conj
7	,	,	,	_	4	punct
8	chest	chest	NN	_	9	compound
9	pain	pain	NN	_	4	conj
10	,	,	,	_	4	punct
11	syncope	syncope	NN	_	4	conj
12	.	.	.	_	2	punct

1	Gastrointestinal	gastrointestinal	JJ	_	0	ROOT
2	:	:	:	_	1	punct
3	Nausea	nausea	NN	_	1	dep
4	-LRB-	-lrb-	-LRB-	_	6	punct
5	4-12	4-12	CD	_	6	nummod
6	%	%	NN	_	3	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	,	,	,	_	3	punct
9	constipation	constipation	NN	_	3	appos
10	-LRB-	-lrb-	-LRB-	_	12	punct
11	2-6	2-6	CD	_	12	nummod
12	%	%	NN	_	9	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	;	;	:	_	1	punct

1	and	and	CC	_	10	cc
2	,	,	,	_	10	punct
3	rarely	rarely	RB	_	10	advmod
4	,	,	,	_	10	punct
5	dry	dry	JJ	_	6	amod
6	mouth	mouth	NN	_	10	nsubj
7	,	,	,	_	6	punct
8	anorexia	anorexia	NN	_	6	appos
9	,	,	,	_	6	punct
10	taste	taste	VBP	_	0	ROOT
11	disorder	disorder	NN	_	10	dobj
12	,	,	,	_	11	punct
13	abdominal	abdominal	JJ	_	14	amod
14	pain	pain	NN	_	11	conj
15	,	,	,	_	11	punct
16	vomiting	vomit	VBG	_	11	conj
17	,	,	,	_	11	punct
18	diarrhea	diarrhea	NN	_	11	conj
19	,	,	,	_	11	punct
20	and	and	CC	_	11	cc
21	positive	positive	JJ	_	22	amod
22	test	test	NN	_	11	conj
23	for	for	IN	_	25	case
24	occult	occult	VBN	_	25	amod
25	blood	blood	NN	_	22	nmod
26	in	in	IN	_	27	case
27	stool	stool	NN	_	22	nmod
28	.	.	.	_	10	punct

1	Genitourinary	Genitourinary	NNP	_	0	ROOT
2	:	:	:	_	1	punct
3	Urinary	urinary	JJ	_	4	amod
4	frequency	frequency	NN	_	1	dep
5	-LRB-	-lrb-	-LRB-	_	7	punct
6	2-6	2-6	CD	_	7	nummod
7	%	%	NN	_	4	appos
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	;	;	:	_	1	punct

1	and	and	CC	_	8	cc
2	,	,	,	_	8	punct
3	rarely	rarely	RB	_	8	advmod
4	,	,	,	_	8	punct
5	enuresis	enuresis	NN	_	8	dep
6	,	,	,	_	8	punct
7	urinary	urinary	JJ	_	8	amod
8	retention	retention	NN	_	0	ROOT
9	,	,	,	_	8	punct
10	dysuria	dysuria	NN	_	8	conj
11	,	,	,	_	8	punct
12	impotence	impotence	NN	_	8	conj
13	,	,	,	_	8	punct
14	inability	inability	NN	_	8	appos
15	to	to	TO	_	16	mark
16	ejaculate	ejaculate	VB	_	14	acl
17	,	,	,	_	16	punct
18	nocturia	nocturia	NN	_	16	conj
19	,	,	,	_	16	punct
20	hematuria	hematuria	NN	_	16	conj
21	.	.	.	_	8	punct

1	Other	other	JJ	_	0	ROOT
2	:	:	:	_	1	punct
3	Instances	instance	NNS	_	1	dep
4	of	of	IN	_	5	case
5	rash	rash	NN	_	3	nmod
6	,	,	,	_	5	punct
7	pruritus	pruritus	NN	_	5	conj
8	,	,	,	_	5	punct
9	ankle	ankle	NN	_	10	compound
10	edema	edema	NN	_	5	conj
11	,	,	,	_	5	punct
12	excessive	excessive	JJ	_	13	amod
13	perspiration	perspiration	NN	_	5	conj
14	,	,	,	_	5	punct
15	weight	weight	NN	_	16	compound
16	gain	gain	NN	_	5	conj
17	,	,	,	_	5	punct
18	nasal	nasal	JJ	_	19	amod
19	congestion	congestion	NN	_	5	conj
20	.	.	.	_	1	punct

1	Some	some	DT	_	10	nsubj
2	of	of	IN	_	7	case
3	the	the	DT	_	7	det
4	CNS	cns	NN	_	7	compound
5	and	and	CC	_	4	cc
6	genitourinary	genitourinary	JJ	_	4	conj
7	symptoms	symptom	NNS	_	1	nmod
8	may	may	MD	_	10	aux
9	be	be	VB	_	10	cop
10	related	relate	VBN	_	0	ROOT
11	to	to	TO	_	14	case
12	the	the	DT	_	14	det
13	underlying	underlie	VBG	_	14	amod
14	disease	disease	NN	_	10	nmod
15	rather	rather	RB	_	14	cc
16	than	than	IN	_	15	mwe
17	to	to	TO	_	19	case
18	drug	drug	NN	_	19	compound
19	therapy	therapy	NN	_	14	conj
20	.	.	.	_	10	punct

1	The	the	DT	_	4	det
2	following	follow	VBG	_	4	amod
3	laboratory	laboratory	NN	_	4	compound
4	tests	test	NNS	_	7	nsubjpass
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	found	find	VBN	_	0	ROOT
8	to	to	TO	_	10	mark
9	be	be	VB	_	10	cop
10	abnormal	abnormal	JJ	_	7	xcomp
11	in	in	IN	_	14	case
12	a	a	DT	_	14	det
13	few	few	JJ	_	14	amod
14	patients	patient	NNS	_	10	nmod
15	receiving	receive	VBG	_	14	acl
16	drug1	drug1	NN	_	15	dobj
17	:	:	:	_	10	punct
18	increased	increase	VBN	_	19	amod
19	SGOT	SGOT	NNP	_	10	dep
20	,	,	,	_	19	punct
21	elevated	elevated	JJ	_	23	amod
22	alkaline	alkaline	NN	_	23	compound
23	phosphatase	phosphatase	NN	_	19	conj
24	,	,	,	_	19	punct
25	and	and	CC	_	19	cc
26	elevation	elevation	NN	_	19	conj
27	of	of	IN	_	29	case
28	blood	blood	NN	_	29	compound
29	sugar	sugar	NN	_	26	nmod
30	.	.	.	_	7	punct

1	The	the	DT	_	4	det
2	adverse	adverse	JJ	_	4	amod
3	experience	experience	NN	_	4	compound
4	profile	profile	NN	_	9	nsubj
5	seen	see	VBN	_	4	acl
6	with	with	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	was	be	VBD	_	9	cop
9	similar	similar	JJ	_	0	ROOT
10	to	to	TO	_	11	case
11	that	that	DT	_	9	nmod
12	seen	see	VBN	_	11	acl
13	with	with	IN	_	15	case
14	drug2	drug2	NN	_	15	compound
15	tablets	tablet	NNS	_	12	nmod
16	.	.	.	_	9	punct

1	drug1	drug1	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	,	,	,	_	1	punct
5	drug3	drug3	NN	_	1	conj
6	,	,	,	_	1	punct
7	drug4	drug4	NN	_	1	conj
8	,	,	,	_	1	punct
9	drug5	drug5	NN	_	1	conj
10	.	.	.	_	1	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	shown	show	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	have	have	VB	_	4	xcomp
7	no	no	DT	_	8	neg
8	effect	effect	NN	_	6	dobj
9	on	on	IN	_	11	case
10	the	the	DT	_	11	det
11	pharmacokinetics	pharmacokinetic	NNS	_	6	nmod
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	and	and	CC	_	13	cc
15	the	the	DT	_	16	det
16	pharmacodynamics	pharmacodynamic	NNS	_	13	conj
17	of	of	IN	_	18	case
18	drug3	drug3	NN	_	16	nmod
19	and	and	CC	_	18	cc
20	drug4	drug4	NN	_	18	conj
21	.	.	.	_	4	punct

1	Thus	thus	RB	_	6	advmod
2	no	no	DT	_	4	neg
3	dosing	dosing	NN	_	4	compound
4	adjustments	adjustment	NNS	_	6	nsubj
5	are	be	VBP	_	6	cop
6	necessary	necessary	JJ	_	0	ROOT
7	during	during	IN	_	9	case
8	concomitant	concomitant	JJ	_	9	amod
9	use	use	NN	_	6	nmod
10	with	with	IN	_	12	case
11	these	these	DT	_	12	det
12	agents	agent	NNS	_	9	nmod
13	.	.	.	_	6	punct

1	Because	because	IN	_	5	mark
2	drug1	drug1	NN	_	5	nsubjpass
3	is	be	VBZ	_	5	auxpass
4	not	not	RB	_	5	neg
5	metabolized	metabolize	VBN	_	19	advcl
6	by	by	IN	_	10	case
7	the	the	DT	_	10	det
8	cytochrome	cytochrome	NN	_	10	compound
9	P450	p450	NN	_	10	compound
10	system	system	NN	_	5	nmod
11	,	,	,	_	19	punct
12	inhibitors	inhibitor	NNS	_	19	nsubjpass
13	of	of	IN	_	15	case
14	CYP450	cyp450	NN	_	15	compound
15	enzyme	enzyme	NN	_	12	nmod
16	would	would	MD	_	19	aux
17	not	not	RB	_	19	neg
18	be	be	VB	_	19	auxpass
19	expected	expect	VBN	_	0	ROOT
20	to	to	TO	_	21	mark
21	affect	affect	VB	_	19	xcomp
22	its	its	PRP$	_	23	nmod:poss
23	metabolism	metabolism	NN	_	21	dobj
24	,	,	,	_	19	punct
25	and	and	CC	_	19	cc
26	drug2	drug2	NN	_	41	nsubjpass
27	and	and	CC	_	26	cc
28	drug3	drug3	NN	_	26	conj
29	,	,	,	_	26	punct
30	potent	potent	JJ	_	31	amod
31	inhibitors	inhibitor	NNS	_	26	appos
32	of	of	IN	_	33	case
33	CYP3A	cyp3a	NN	_	31	nmod
34	and	and	CC	_	33	cc
35	2C9	2c9	NN	_	33	conj
36	,	,	,	_	26	punct
37	respectively	respectively	RB	_	26	advmod
38	,	,	,	_	26	punct
39	have	have	VBP	_	41	aux
40	been	be	VBN	_	41	auxpass
41	shown	show	VBN	_	19	conj
42	to	to	TO	_	43	mark
43	have	have	VB	_	41	xcomp
44	no	no	DT	_	45	neg
45	effect	effect	NN	_	43	dobj
46	on	on	IN	_	48	case
47	drug4	drug4	NN	_	48	compound
48	pharmacokinetics	pharmacokinetic	NNS	_	43	nmod
49	.	.	.	_	19	punct

1	drug1	drug1	NN	_	3	nsubj
2	also	also	RB	_	3	advmod
3	has	have	VBZ	_	0	ROOT
4	no	no	DT	_	5	neg
5	effect	effect	NN	_	3	dobj
6	on	on	IN	_	8	case
7	drug2	drug2	NN	_	8	compound
8	pharmacokinetics	pharmacokinetic	NNS	_	3	nmod
9	.	.	.	_	3	punct

1	drug1	drug1	NN	_	13	compound
2	-LRB-	-lrb-	-LRB-	_	7	punct
3	up	up	RB	_	5	advmod
4	to	to	TO	_	5	dep
5	400	400	CD	_	7	nummod
6	mg	mg	NN	_	7	compound
7	b.i.d.	b.i.d.	NN	_	1	dep
8	or	or	CC	_	7	cc
9	800	800	CD	_	10	compound
10	mg	mg	NN	_	11	amod
11	q.d.	q.d.	NN	_	7	conj
12	-RRB-	-rrb-	-RRB-	_	7	punct
13	doses	dose	NNS	_	17	nsubjpass
14	have	have	VBP	_	17	aux
15	been	be	VBN	_	17	auxpass
16	safely	safely	RB	_	17	advmod
17	used	use	VBN	_	0	ROOT
18	concomitantly	concomitantly	RB	_	17	advmod
19	with	with	IN	_	17	nmod
20	a	a	DT	_	19	dep
21	drug2	drug2	NN	_	20	dep
22	-LRB-	-lrb-	-LRB-	_	23	punct
23	drug3	drug3	NN	_	21	appos
24	-RRB-	-rrb-	-RRB-	_	23	punct
25	.	.	.	_	17	punct

1	drug1	drug1	NN	_	2	compound
2	doses	dose	NNS	_	12	nsubjpass
3	of	of	IN	_	8	case
4	up	up	RB	_	6	dep
5	to	to	TO	_	4	mwe
6	300	300	CD	_	8	nummod
7	mg	mg	NN	_	8	compound
8	b.i.d.	b.i.d.	NN	_	2	nmod
9	have	have	VBP	_	12	aux
10	been	be	VBN	_	12	auxpass
11	safely	safely	RB	_	12	advmod
12	used	use	VBN	_	0	ROOT
13	concomitantly	concomitantly	RB	_	12	advmod
14	with	with	IN	_	16	case
15	sustained-release	sustained-release	JJ	_	16	amod
16	drug2	drug2	NN	_	12	nmod
17	-LRB-	-lrb-	-LRB-	_	19	punct
18	sustained-release	sustained-release	JJ	_	19	amod
19	drug3	drug3	NN	_	16	appos
20	-RRB-	-rrb-	-RRB-	_	19	punct
21	with	with	IN	_	26	case
22	no	no	DT	_	26	neg
23	clinically	clinically	RB	_	24	advmod
24	significant	significant	JJ	_	26	amod
25	adverse	adverse	JJ	_	26	amod
26	interactions	interaction	NNS	_	12	nmod
27	.	.	.	_	12	punct

1	When	when	WRB	_	2	advmod
2	administered	administer	VBN	_	9	advcl
3	concurrently	concurrently	RB	_	2	advmod
4	,	,	,	_	9	punct
5	the	the	DT	_	7	det
6	following	follow	VBG	_	7	amod
7	drugs	drug	NNS	_	9	nsubj
8	may	may	MD	_	9	aux
9	interact	interact	VB	_	0	ROOT
10	with	with	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	.	.	.	_	9	punct

1	drug1	drug1	NN	_	14	nsubj
2	or	or	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	drug3	drug3	NN	_	1	dep
6	and	and	CC	_	5	cc
7	related	related	JJ	_	8	amod
8	drugs	drug	NNS	_	5	conj
9	,	,	,	_	5	punct
10	drug4	drug4	NN	_	5	conj
11	and	and	CC	_	5	cc
12	drug5	drug5	NN	_	5	conj
13	-RRB-	-rrb-	-RRB-	_	5	punct
14	enhanced	enhance	VBD	_	0	ROOT
15	hypokalemia	hypokalemia	NN	_	14	dobj
16	.	.	.	_	14	punct

1	Check	check	VB	_	0	ROOT
2	serum	serum	NN	_	4	compound
3	potassium	potassium	NN	_	4	compound
4	levels	level	NNS	_	1	dobj
5	at	at	IN	_	7	case
6	frequent	frequent	JJ	_	7	amod
7	intervals	interval	NNS	_	1	nmod
8	;	;	:	_	1	punct

1	use	use	NN	_	0	ROOT
2	drug1	drug1	NN	_	3	compound
3	supplements	supplement	NNS	_	1	dobj
4	if	if	IN	_	5	mark
5	necessary	necessary	JJ	_	1	advcl
6	.	.	.	_	1	punct

1	drug1	drug1	NN	_	2	nsubj
2	enhanced	enhance	VBD	_	0	ROOT
3	possibility	possibility	NN	_	2	dobj
4	of	of	IN	_	5	case
5	arrhythmias	arrhythmia	NNS	_	3	nmod
6	or	or	CC	_	5	cc
7	drug2	drug2	NN	_	8	compound
8	toxicity	toxicity	NN	_	5	conj
9	associated	associate	VBN	_	5	acl
10	with	with	IN	_	11	case
11	hypokalemia	hypokalemia	NN	_	9	nmod
12	.	.	.	_	2	punct

1	Monitor	Monitor	NNP	_	4	compound
2	serum	serum	NN	_	4	compound
3	potassium	potassium	NN	_	4	compound
4	levels	level	NNS	_	0	ROOT
5	;	;	:	_	4	punct

1	use	use	NN	_	0	ROOT
2	drug1	drug1	NN	_	3	compound
3	supplements	supplement	NNS	_	1	dobj
4	if	if	IN	_	5	mark
5	necessary	necessary	JJ	_	1	advcl
6	.	.	.	_	1	punct

1	Oral	oral	JJ	_	2	amod
2	drug1	drug1	NN	_	3	nsubj
3	decreased	decrease	VBD	_	0	ROOT
4	prothrombin	prothrombin	NN	_	6	compound
5	time	time	NN	_	6	compound
6	response	response	NN	_	3	dobj
7	.	.	.	_	3	punct

1	Monitor	Monitor	NNP	_	3	compound
2	prothrombin	prothrombin	NN	_	3	compound
3	levels	level	NNS	_	0	ROOT
4	and	and	CC	_	3	cc
5	adjust	adjust	VBP	_	3	conj
6	drug1	drug1	NN	_	7	compound
7	dosage	dosage	NN	_	5	dobj
8	accordingly	accordingly	RB	_	3	advmod
9	.	.	.	_	3	punct

1	drug1	drug1	NN	_	8	nsubj
2	-LRB-	-lrb-	-LRB-	_	4	punct
3	oral	oral	JJ	_	4	amod
4	agents	agent	NNS	_	1	dep
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	-RRB-	-rrb-	-RRB-	_	4	punct
8	diminished	diminish	VBD	_	0	ROOT
9	antidiabetic	antidiabetic	JJ	_	10	amod
10	effect	effect	NN	_	8	dobj
11	.	.	.	_	8	punct

1	Monitor	Monitor	NNP	_	0	ROOT
2	for	for	IN	_	3	case
3	symptoms	symptom	NNS	_	1	nmod
4	of	of	IN	_	5	case
5	hyperglycemia	hyperglycemia	NN	_	3	nmod
6	;	;	:	_	1	punct

1	adjust	adjust	VBP	_	0	ROOT
2	dosage	dosage	NN	_	1	dobj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	upward	upward	RB	_	1	advmod
6	if	if	IN	_	7	mark
7	necessary	necessary	JJ	_	1	advcl
8	.	.	.	_	1	punct

1	drug1	drug1	NN	_	2	nsubj
2	increased	increase	VBD	_	0	ROOT
3	ulcerogenic	ulcerogenic	JJ	_	4	amod
4	effect	effect	NN	_	2	dobj
5	;	;	:	_	2	punct

1	decreased	decrease	VBN	_	3	amod
2	pharmacologic	pharmacologic	JJ	_	3	amod
3	effect	effect	NN	_	0	ROOT
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	.	.	.	_	3	punct

1	Rarely	rarely	RB	_	3	advmod
2	drug1	drug1	NN	_	3	compound
3	toxicity	toxicity	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	occur	occur	VB	_	0	ROOT
6	in	in	IN	_	7	case
7	patients	patient	NNS	_	5	nmod
8	who	who	WP	_	9	nsubj
9	discontinue	discontinue	VBP	_	7	acl:relcl
10	drug2	drug2	NN	_	9	dobj
11	after	after	IN	_	15	case
12	concurrent	concurrent	JJ	_	15	amod
13	high-dose	high-dose	JJ	_	15	amod
14	drug3	drug3	NN	_	15	compound
15	therapy	therapy	NN	_	9	nmod
16	.	.	.	_	5	punct

1	Monitor	Monitor	NNP	_	3	compound
2	drug1	drug1	NN	_	3	compound
3	levels	level	NNS	_	0	ROOT
4	or	or	CC	_	3	cc
5	the	the	DT	_	7	det
6	therapeutic	therapeutic	JJ	_	7	amod
7	effect	effect	NN	_	3	conj
8	for	for	IN	_	9	case
9	which	which	WDT	_	12	nmod
10	drug2	drug2	NN	_	12	nsubjpass
11	is	be	VBZ	_	12	auxpass
12	given	give	VBN	_	7	acl:relcl
13	;	;	:	_	3	punct

1	adjust	adjust	VBP	_	0	ROOT
2	drug1	drug1	NN	_	3	compound
3	dosage	dosage	NN	_	1	dobj
4	accordingly	accordingly	RB	_	8	advmod
5	if	if	IN	_	8	mark
6	effect	effect	NN	_	8	nsubjpass
7	is	be	VBZ	_	8	auxpass
8	altered	alter	VBN	_	1	advcl
9	.	.	.	_	1	punct

1	drug1	drug1	NN	_	7	nsubj
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	,	,	,	_	1	punct
5	or	or	CC	_	1	cc
6	drug3	drug3	NN	_	1	conj
7	increased	increase	VBD	_	0	ROOT
8	metabolic	metabolic	JJ	_	9	amod
9	clearance	clearance	NN	_	7	dobj
10	of	of	IN	_	11	case
11	drug4	drug4	NN	_	9	nmod
12	because	because	IN	_	15	case
13	of	of	IN	_	12	mwe
14	the	the	DT	_	15	det
15	induction	induction	NN	_	7	nmod
16	of	of	IN	_	18	case
17	hepatic	hepatic	JJ	_	18	amod
18	enzymes	enzyme	NNS	_	15	nmod
19	.	.	.	_	7	punct

1	Observe	observe	VB	_	0	ROOT
2	the	the	DT	_	3	det
3	patient	patient	NN	_	1	dobj
4	for	for	IN	_	7	case
5	possible	possible	JJ	_	7	amod
6	diminished	diminished	JJ	_	7	amod
7	effect	effect	NN	_	3	nmod
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	and	and	CC	_	1	cc
11	increase	increase	VB	_	1	conj
12	the	the	DT	_	14	det
13	drug2	drug2	NN	_	14	compound
14	dosage	dosage	NN	_	11	dobj
15	accordingly	accordingly	RB	_	11	advmod
16	.	.	.	_	1	punct

1	drug1	drug1	NN	_	19	nsubj
2	-LRB-	-lrb-	-LRB-	_	6	punct
3	particularly	particularly	RB	_	4	advmod
4	C-17	c-17	JJ	_	6	amod
5	alkylated	alkylate	VBN	_	6	amod
6	drug2	drug2	NN	_	1	dep
7	such	such	JJ	_	9	case
8	as	as	IN	_	7	mwe
9	drug3	drug3	NN	_	6	nmod
10	,	,	,	_	9	punct
11	drug4	drug4	NN	_	9	conj
12	,	,	,	_	9	punct
13	drug5	drug5	NN	_	9	conj
14	,	,	,	_	9	punct
15	and	and	CC	_	9	cc
16	similar	similar	JJ	_	17	amod
17	compounds	compound	NNS	_	9	conj
18	-RRB-	-rrb-	-RRB-	_	6	punct
19	enhanced	enhance	VBD	_	0	ROOT
20	tendency	tendency	NN	_	19	dobj
21	toward	toward	IN	_	22	case
22	edema	edema	NN	_	20	nmod
23	.	.	.	_	19	punct

1	Use	Use	NNP	_	2	compound
2	caution	caution	NN	_	0	ROOT
3	when	when	WRB	_	4	advmod
4	giving	give	VBG	_	2	advcl
5	these	these	DT	_	6	det
6	drugs	drug	NNS	_	4	dobj
7	together	together	RB	_	4	advmod
8	,	,	,	_	4	punct
9	especially	especially	RB	_	11	advmod
10	in	in	IN	_	11	case
11	patients	patient	NNS	_	4	nmod
12	with	with	IN	_	13	case
13	hepatic	hepatic	JJ	_	11	nmod
14	or	or	CC	_	13	cc
15	cardiac	cardiac	JJ	_	13	conj
16	disease	disease	NN	_	13	dep
17	.	.	.	_	2	punct

1	drug1	drug1	NN	_	3	compound
2	neurological	neurological	JJ	_	3	amod
3	complications	complication	NNS	_	0	ROOT
4	and	and	CC	_	3	cc
5	lack	lack	NN	_	3	conj
6	of	of	IN	_	8	case
7	antibody	antibody	NN	_	8	compound
8	response	response	NN	_	5	nmod
9	.	.	.	_	3	punct

1	drug1	drug1	NN	_	2	nsubj
2	increased	increase	VBD	_	0	ROOT
3	levels	level	NNS	_	2	dobj
4	of	of	IN	_	6	case
5	corticosteroid-binding	corticosteroid-binding	JJ	_	6	amod
6	globulin	globulin	NN	_	3	nmod
7	,	,	,	_	2	punct
8	thereby	thereby	RB	_	9	advmod
9	increasing	increase	VBG	_	2	advcl
10	the	the	DT	_	15	det
11	bound	bind	VBN	_	15	amod
12	-LRB-	-lrb-	-LRB-	_	13	punct
13	inactive	inactive	JJ	_	11	dep
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	fraction	fraction	NN	_	9	dobj
16	;	;	:	_	2	punct

1	this	this	DT	_	2	det
2	effect	effect	NN	_	6	nsubjpass
3	is	be	VBZ	_	6	auxpass
4	at	at	IN	_	6	advmod
5	least	least	JJS	_	4	mwe
6	balanced	balance	VBN	_	0	ROOT
7	by	by	IN	_	9	case
8	decreased	decrease	VBN	_	9	amod
9	metabolism	metabolism	NN	_	6	nmod
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	.	.	.	_	6	punct

1	When	when	WRB	_	5	advmod
2	drug1	drug1	NN	_	3	compound
3	therapy	therapy	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	initiated	initiate	VBN	_	14	advcl
6	,	,	,	_	14	punct
7	a	a	DT	_	8	det
8	reduction	reduction	NN	_	14	nsubjpass
9	in	in	IN	_	11	case
10	drug2	drug2	NN	_	11	compound
11	dosage	dosage	NN	_	8	nmod
12	may	may	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	required	require	VBN	_	0	ROOT
15	,	,	,	_	14	punct
16	and	and	CC	_	14	cc
17	increased	increase	VBD	_	18	amod
18	amounts	amount	NNS	_	21	nsubjpass
19	may	may	MD	_	21	aux
20	be	be	VB	_	21	auxpass
21	required	require	VBN	_	14	conj
22	when	when	WRB	_	25	advmod
23	drug3	drug3	NN	_	25	nsubjpass
24	is	be	VBZ	_	25	auxpass
25	terminated	terminate	VBN	_	21	advcl
26	.	.	.	_	14	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	4	amod
2	Test	test	NN	_	4	compound
3	Interactions	interaction	NNS	_	4	compound
4	drug1	drug1	NN	_	6	nsubj
5	may	may	MD	_	6	aux
6	affect	affect	VB	_	0	ROOT
7	the	the	DT	_	9	det
8	nitrobluetetrazolium	nitrobluetetrazolium	JJ	_	9	amod
9	test	test	NN	_	6	dobj
10	for	for	IN	_	12	case
11	bacterial	bacterial	JJ	_	12	amod
12	infection	infection	NN	_	9	nmod
13	and	and	CC	_	6	cc
14	produce	produce	VBP	_	6	conj
15	false-negative	false-negative	JJ	_	16	amod
16	results	result	NNS	_	14	dobj

1	.	.	.	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	A	a	DT	_	2	det
2	number	number	NN	_	5	nsubj
3	of	of	IN	_	4	case
4	substances	substance	NNS	_	2	nmod
5	affect	affect	VBP	_	0	ROOT
6	glucose	glucose	NN	_	7	compound
7	metabolism	metabolism	NN	_	5	dobj
8	and	and	CC	_	5	cc
9	may	may	MD	_	10	aux
10	require	require	VB	_	5	conj
11	drug1	drug1	NN	_	13	compound
12	dose	dose	NN	_	13	compound
13	adjustment	adjustment	NN	_	10	dobj
14	and	and	CC	_	13	cc
15	particularly	particularly	RB	_	16	advmod
16	close	close	JJ	_	17	amod
17	monitoring	monitoring	NN	_	13	conj
18	.	.	.	_	5	punct

1	The	the	DT	_	2	det
2	following	follow	VBG	_	4	nsubj
3	are	be	VBP	_	4	cop
4	examples	example	NNS	_	0	ROOT
5	of	of	IN	_	6	case
6	substances	substance	NNS	_	4	nmod
7	that	that	WDT	_	9	nsubj
8	may	may	MD	_	9	aux
9	increase	increase	VB	_	4	acl:relcl
10	the	the	DT	_	12	det
11	blood-glucose-lowering	blood-glucose-lowering	NN	_	12	compound
12	effect	effect	NN	_	9	dobj
13	and	and	CC	_	12	cc
14	susceptibility	susceptibility	NN	_	12	conj
15	to	to	TO	_	16	case
16	hypoglycemia	hypoglycemia	NN	_	14	nmod
17	:	:	:	_	4	punct
18	oral	oral	JJ	_	20	amod
19	antidiabetes	antidiabete	NNS	_	20	compound
20	products	product	NNS	_	4	dep
21	,	,	,	_	20	punct
22	drug1	drug1	NN	_	20	conj
23	,	,	,	_	20	punct
24	drug2	drug2	NN	_	20	conj
25	,	,	,	_	20	punct
26	drug3	drug3	NN	_	20	conj
27	,	,	,	_	20	punct
28	drug4	drug4	NN	_	20	conj
29	,	,	,	_	20	punct
30	drug5	drug5	NN	_	20	conj
31	,	,	,	_	20	punct
32	drug6	drug6	NN	_	20	conj
33	,	,	,	_	20	punct
34	drug7	drug7	NN	_	20	conj
35	,	,	,	_	20	punct
36	drug8	drug8	NN	_	20	conj
37	-LRB-	-lrb-	-LRB-	_	40	punct
38	e.g.	e.g.	FW	_	40	dep
39	,	,	,	_	40	punct
40	drug9	drug9	NN	_	36	appos
41	-RRB-	-rrb-	-RRB-	_	40	punct
42	,	,	,	_	20	punct
43	drug10	drug10	NN	_	20	appos
44	.	.	.	_	4	punct

1	The	the	DT	_	2	det
2	following	follow	VBG	_	4	nsubj
3	are	be	VBP	_	4	cop
4	examples	example	NNS	_	0	ROOT
5	of	of	IN	_	6	case
6	substances	substance	NNS	_	4	nmod
7	that	that	WDT	_	9	nsubj
8	may	may	MD	_	9	aux
9	reduce	reduce	VB	_	6	acl:relcl
10	the	the	DT	_	12	det
11	blood-glucose-lowering	blood-glucose-lowering	NN	_	12	compound
12	effect	effect	NN	_	9	dobj
13	of	of	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	:	:	:	_	4	punct
16	drug2	drug2	NN	_	4	dep
17	,	,	,	_	16	punct
18	drug3	drug3	NN	_	16	conj
19	,	,	,	_	16	punct
20	drug4	drug4	NN	_	16	conj
21	,	,	,	_	16	punct
22	drug5	drug5	NN	_	16	conj
23	-LRB-	-lrb-	-LRB-	_	26	punct
24	e.g.	e.g.	FW	_	26	dep
25	,	,	,	_	26	punct
26	drug6	drug6	NN	_	22	dep
27	,	,	,	_	26	punct
28	drug7	drug7	NN	_	26	appos
29	,	,	,	_	26	punct
30	drug8	drug8	NN	_	26	appos
31	-RRB-	-rrb-	-RRB-	_	26	punct
32	,	,	,	_	16	punct
33	drug9	drug9	NN	_	16	conj
34	,	,	,	_	16	punct
35	drug10	drug10	NN	_	16	conj
36	,	,	,	_	16	punct
37	drug11	drug11	NN	_	16	conj
38	,	,	,	_	16	punct
39	drug12	drug12	NN	_	16	conj
40	,	,	,	_	16	punct
41	drug13	drug13	NN	_	16	conj
42	,	,	,	_	16	punct
43	drug14	drug14	NN	_	16	conj
44	-LRB-	-lrb-	-LRB-	_	49	punct
45	e.g.	e.g.	FW	_	49	advmod
46	,	,	,	_	49	punct
47	in	in	IN	_	49	case
48	oral	oral	JJ	_	49	amod
49	drug15	drug15	NN	_	43	appos
50	-RRB-	-rrb-	-RRB-	_	49	punct
51	.	.	.	_	4	punct

1	drug1	drug1	NN	_	12	nsubj
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	,	,	,	_	1	punct
5	drug3	drug3	NN	_	6	compound
6	salts	salt	NNS	_	1	conj
7	,	,	,	_	1	punct
8	and	and	CC	_	1	cc
9	drug4	drug4	NN	_	1	conj
10	may	may	MD	_	12	aux
11	either	either	RB	_	12	advmod
12	potentiate	potentiate	VB	_	0	ROOT
13	or	or	CC	_	12	cc
14	weaken	weaken	VB	_	12	conj
15	the	the	DT	_	17	det
16	blood-glucose-lowering	blood-glucose-lowering	NN	_	17	compound
17	effect	effect	NN	_	12	dobj
18	of	of	IN	_	19	case
19	drug5	drug5	NN	_	17	nmod
20	.	.	.	_	12	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	cause	cause	VB	_	0	ROOT
4	hypoglycemia	hypoglycemia	NN	_	3	dobj
5	,	,	,	_	4	punct
6	which	which	WDT	_	10	nsubjpass
7	may	may	MD	_	10	aux
8	sometimes	sometimes	RB	_	10	advmod
9	be	be	VB	_	10	auxpass
10	followed	follow	VBN	_	4	acl:relcl
11	by	by	IN	_	12	case
12	hyperglycemia	hyperglycemia	NN	_	10	nmod
13	.	.	.	_	3	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	28	nmod
3	,	,	,	_	28	punct
4	under	under	IN	_	6	case
5	the	the	DT	_	6	det
6	influence	influence	NN	_	28	nmod
7	of	of	IN	_	10	case
8	sympatholytic	sympatholytic	JJ	_	10	amod
9	medicinal	medicinal	JJ	_	10	amod
10	products	product	NNS	_	6	nmod
11	such	such	JJ	_	13	case
12	as	as	IN	_	11	mwe
13	drug1	drug1	NN	_	10	nmod
14	,	,	,	_	13	punct
15	drug2	drug2	NN	_	13	conj
16	,	,	,	_	13	punct
17	drug3	drug3	NN	_	13	conj
18	,	,	,	_	13	punct
19	and	and	CC	_	13	cc
20	drug4	drug4	NN	_	13	conj
21	,	,	,	_	28	punct
22	the	the	DT	_	23	det
23	signs	sign	NNS	_	28	nsubjpass
24	of	of	IN	_	25	case
25	hypoglycemia	hypoglycemia	NN	_	23	nmod
26	may	may	MD	_	28	aux
27	be	be	VB	_	28	auxpass
28	reduced	reduce	VBN	_	0	ROOT
29	or	or	CC	_	28	cc
30	absent	absent	JJ	_	28	conj
31	.	.	.	_	28	punct

1	drug1	drug1	NN	_	0	ROOT
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	-	-	:	_	1	punct
5	drug3	drug3	NN	_	7	nsubj
6	may	may	MD	_	7	aux
7	decrease	decrease	VB	_	1	dep
8	hepatic	hepatic	JJ	_	9	amod
9	toxicity	toxicity	NN	_	7	dobj
10	in	in	IN	_	11	case
11	those	those	DT	_	7	nmod
12	with	with	IN	_	14	case
13	drug4	drug4	NN	_	14	compound
14	overdosage	overdosage	NN	_	11	nmod
15	or	or	CC	_	14	cc
16	in	in	IN	_	17	case
17	those	those	DT	_	14	conj
18	taking	take	VBG	_	17	acl
19	drug5	drug5	NN	_	18	dobj
20	.	.	.	_	1	punct

1	Theoretically	theoretically	RB	_	5	advmod
2	,	,	,	_	5	punct
3	it	it	PRP	_	5	nsubj
4	may	may	MD	_	5	aux
5	decrease	decrease	VB	_	0	ROOT
6	hepatic	hepatic	JJ	_	7	amod
7	toxicity	toxicity	NN	_	5	dobj
8	in	in	IN	_	10	case
9	the	the	DT	_	10	det
10	case	case	NN	_	5	nmod
11	of	of	IN	_	15	case
12	other	other	JJ	_	15	amod
13	potential	potential	JJ	_	15	amod
14	hepatotoxic	hepatotoxic	JJ	_	15	amod
15	drugs	drug	NNS	_	10	nmod
16	,	,	,	_	5	punct
17	as	as	RB	_	5	advmod
18	well	well	RB	_	17	mwe
19	.	.	.	_	5	punct

1	drug1	drug1	NN	_	5	dep
2	-	-	:	_	5	punct
3	drug2	drug2	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	protect	protect	VB	_	0	ROOT
6	against	against	IN	_	9	case
7	the	the	DT	_	9	det
8	ototoxic	ototoxic	JJ	_	9	amod
9	effects	effect	NNS	_	5	nmod
10	of	of	IN	_	11	case
11	drug3	drug3	NN	_	9	nmod
12	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Administration	administration	NN	_	16	nsubj
4	of	of	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	to	to	TO	_	7	case
7	volunteers	volunteer	NNS	_	3	nmod
8	under	under	IN	_	10	case
9	fasting	fasting	NN	_	10	compound
10	conditions	condition	NNS	_	3	nmod
11	,	,	,	_	3	punct
12	or	or	CC	_	3	cc
13	with	with	IN	_	15	case
14	drug3	drug3	NN	_	15	compound
15	suspension	suspension	NN	_	3	conj
16	yielded	yield	VBD	_	1	dep
17	similar	similar	JJ	_	21	amod
18	serum	serum	NN	_	21	compound
19	drug4	drug4	NN	_	21	compound
20	time	time	NN	_	21	compound
21	profiles	profile	NNS	_	16	dobj
22	in	in	IN	_	24	case
23	young	young	JJ	_	24	amod
24	subjects	subject	NNS	_	16	nmod
25	-LRB-	-lrb-	-LRB-	_	26	punct
26	n	n	NN	_	16	dep
27	=	=	JJ	_	26	amod
28	12	12	CD	_	27	dep
29	-RRB-	-rrb-	-RRB-	_	26	punct
30	.	.	.	_	1	punct

1	In	in	IN	_	3	case
2	geriatric	geriatric	JJ	_	3	amod
3	subjects	subject	NNS	_	10	nmod
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	n	n	NN	_	3	dep
6	=	=	JJ	_	5	amod
7	7	7	CD	_	6	dep
8	-RRB-	-rrb-	-RRB-	_	5	punct
9	there	there	EX	_	10	expl
10	was	be	VBD	_	0	ROOT
11	a	a	DT	_	12	det
12	reduction	reduction	NN	_	10	nsubj
13	in	in	IN	_	15	case
14	the	the	DT	_	15	det
15	rate	rate	NN	_	12	nmod
16	but	but	CC	_	17	cc
17	not	not	RB	_	15	cc
18	the	the	DT	_	19	det
19	extent	extent	NN	_	15	conj
20	of	of	IN	_	22	case
21	drug1	drug1	NN	_	22	compound
22	absorption	absorption	NN	_	15	nmod
23	.	.	.	_	10	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	10	nsubjpass
4	like	like	IN	_	6	case
5	other	other	JJ	_	6	amod
6	drug3	drug3	NN	_	3	nmod
7	,	,	,	_	3	punct
8	has	have	VBZ	_	10	aux
9	been	be	VBN	_	10	auxpass
10	shown	show	VBN	_	26	csubjpass
11	to	to	TO	_	12	mark
12	affect	affect	VB	_	10	xcomp
13	bleeding	bleed	VBG	_	12	dobj
14	parameters	parameter	NNS	_	13	dobj
15	in	in	IN	_	16	case
16	patients	patient	NNS	_	13	nmod
17	receiving	receive	VBG	_	16	acl
18	drug4	drug4	NN	_	17	dobj
19	,	,	,	_	13	punct
20	and	and	CC	_	13	cc
21	serious	serious	JJ	_	23	amod
22	clinical	clinical	JJ	_	23	amod
23	bleeding	bleeding	NN	_	13	conj
24	has	have	VBZ	_	26	aux
25	been	be	VBN	_	26	auxpass
26	reported	report	VBN	_	1	dep
27	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	physician	physician	NN	_	5	nsubj
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	cop
5	cautious	cautious	JJ	_	0	ROOT
6	when	when	WRB	_	7	advmod
7	administering	administer	VBG	_	5	advcl
8	drug1	drug1	NN	_	7	dobj
9	to	to	TO	_	10	case
10	patients	patient	NNS	_	7	nmod
11	taking	take	VBG	_	10	acl
12	drug2	drug2	NN	_	11	dobj
13	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concurrent	concurrent	JJ	_	4	amod
4	administration	administration	NN	_	9	nsubj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	drug3	drug3	NN	_	6	conj
9	resulted	result	VBD	_	1	appos
10	in	in	IN	_	16	case
11	50	50	CD	_	12	compound
12	%	%	NN	_	16	amod
13	lower	lower	JJR	_	16	amod
14	serum	serum	NN	_	16	compound
15	drug4	drug4	NN	_	16	compound
16	concentrations	concentration	NNS	_	9	nmod
17	.	.	.	_	1	punct

1	This	this	DT	_	2	det
2	effect	effect	NN	_	20	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	-LRB-	-lrb-	-LRB-	_	8	punct
6	which	which	WDT	_	8	nsubj
7	also	also	RB	_	8	advmod
8	lowers	lower	VBZ	_	4	dep
9	serum	serum	NN	_	10	compound
10	concentrations	concentration	NNS	_	8	dobj
11	of	of	IN	_	13	case
12	other	other	JJ	_	13	amod
13	drug2	drug2	NN	_	10	nmod
14	given	give	VBN	_	8	dep
15	with	with	IN	_	16	case
16	it	it	PRP	_	14	nmod
17	-RRB-	-rrb-	-RRB-	_	8	punct
18	has	have	VBZ	_	20	aux
19	been	be	VBN	_	20	auxpass
20	demonstrated	demonstrate	VBN	_	0	ROOT
21	in	in	IN	_	22	case
22	patients	patient	NNS	_	20	nmod
23	with	with	IN	_	25	case
24	rheumatoid	rheumatoid	JJ	_	25	amod
25	arthritis	arthritis	NN	_	22	nmod
26	-LRB-	-lrb-	-LRB-	_	27	punct
27	n	n	NN	_	25	dep
28	=	=	JJ	_	27	amod
29	15	15	CD	_	28	dep
30	-RRB-	-rrb-	-RRB-	_	27	punct
31	as	as	RB	_	22	cc
32	well	well	RB	_	31	mwe
33	as	as	IN	_	31	mwe
34	normal	normal	JJ	_	35	amod
35	volunteers	volunteer	NNS	_	22	conj
36	-LRB-	-lrb-	-LRB-	_	37	punct
37	n	n	NN	_	35	dep
38	=	=	JJ	_	37	amod
39	16	16	CD	_	38	dep
40	-RRB-	-rrb-	-RRB-	_	37	punct
41	.	.	.	_	20	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	use	use	NN	_	10	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	is	be	VBZ	_	10	auxpass
8	therefore	therefore	RB	_	10	advmod
9	not	not	RB	_	10	neg
10	recommended	recommend	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	effect	effect	NN	_	16	nsubjpass
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	on	on	IN	_	10	case
8	blood	blood	NN	_	10	compound
9	pressure	pressure	NN	_	10	compound
10	response	response	NN	_	4	nmod
11	to	to	TO	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	and	and	CC	_	12	cc
14	drug4	drug4	NN	_	12	conj
15	was	be	VBD	_	16	auxpass
16	evaluated	evaluate	VBN	_	1	appos
17	in	in	IN	_	18	case
18	men	man	NNS	_	16	nmod
19	with	with	IN	_	22	case
20	mild	mild	JJ	_	22	amod
21	uncomplicated	uncomplicated	JJ	_	22	amod
22	hypertension	hypertension	NN	_	18	nmod
23	-LRB-	-lrb-	-LRB-	_	24	punct
24	n	n	NN	_	22	dep
25	=	=	JJ	_	24	amod
26	10	10	CD	_	25	dep
27	-RRB-	-rrb-	-RRB-	_	24	punct
28	.	.	.	_	1	punct

1	drug1	drug1	NN	_	2	compound
2	pretreatment	pretreatment	NN	_	3	nsubj
3	attenuated	attenuate	VBD	_	0	ROOT
4	the	the	DT	_	6	det
5	hypotensive	hypotensive	JJ	_	6	amod
6	effect	effect	NN	_	3	dobj
7	of	of	IN	_	10	case
8	a	a	DT	_	10	det
9	single	single	JJ	_	10	amod
10	dose	dose	NN	_	6	nmod
11	of	of	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	but	but	CC	_	14	cc
14	not	not	RB	_	12	cc
15	drug3	drug3	NN	_	12	conj
16	.	.	.	_	3	punct

1	drug1	drug1	NN	_	4	nsubj
2	did	do	VBD	_	4	aux
3	not	not	RB	_	4	neg
4	appear	appear	VB	_	0	ROOT
5	to	to	TO	_	6	mark
6	affect	affect	VB	_	4	xcomp
7	the	the	DT	_	9	det
8	beta-blocker-mediated	beta-blocker-mediated	JJ	_	9	amod
9	reduction	reduction	NN	_	6	dobj
10	in	in	IN	_	12	case
11	heart	heart	NN	_	12	compound
12	rate	rate	NN	_	9	nmod
13	.	.	.	_	4	punct

1	drug1	drug1	NN	_	4	nsubj
2	did	do	VBD	_	4	aux
3	not	not	RB	_	4	neg
4	affect	affect	VB	_	0	ROOT
5	the	the	DT	_	7	det
6	pharmacokinetic	pharmacokinetic	JJ	_	7	amod
7	profile	profile	NN	_	4	dobj
8	of	of	IN	_	10	case
9	either	either	CC	_	10	det
10	drug	drug	NN	_	7	nmod
11	,	,	,	_	4	punct
12	and	and	CC	_	4	cc
13	the	the	DT	_	14	det
14	mechanism	mechanism	NN	_	25	nsubj
15	under	under	IN	_	16	mark
16	lying	lie	VBG	_	14	acl
17	the	the	DT	_	18	det
18	interference	interference	NN	_	16	dobj
19	with	with	IN	_	23	case
20	drug2	drug2	NN	_	23	compound
21	s	s	NNS	_	23	compound
22	hypotensive	hypotensive	JJ	_	23	amod
23	effect	effect	NN	_	18	nmod
24	is	be	VBZ	_	25	cop
25	unknown	unknown	JJ	_	4	conj
26	.	.	.	_	4	punct

1	Patients	patient	NNS	_	10	nsubjpass
2	taking	take	VBG	_	1	acl
3	both	both	CC	_	4	cc:preconj
4	drug1	drug1	NN	_	2	dobj
5	and	and	CC	_	4	cc
6	a	a	DT	_	7	det
7	drug2	drug2	NN	_	4	conj
8	should	should	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	monitored	monitor	VBN	_	0	ROOT
11	to	to	TO	_	12	mark
12	ensure	ensure	VB	_	10	xcomp
13	that	that	IN	_	19	mark
14	a	a	DT	_	17	det
15	satisfactory	satisfactory	JJ	_	17	amod
16	hypotensive	hypotensive	JJ	_	17	amod
17	effect	effect	NN	_	19	nsubjpass
18	is	be	VBZ	_	19	auxpass
19	achieved	achieve	VBN	_	12	ccomp
20	.	.	.	_	10	punct

1	drug1	drug1	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	appos
4	:	:	:	_	1	punct
5	In	in	IN	_	7	case
6	normal	normal	JJ	_	7	amod
7	volunteers	volunteer	NNS	_	21	nmod
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	n	n	NN	_	7	dep
10	=	=	JJ	_	9	amod
11	9	9	CD	_	10	dep
12	-RRB-	-rrb-	-RRB-	_	9	punct
13	,	,	,	_	7	punct
14	pretreatment	pretreatment	NN	_	7	appos
15	with	with	IN	_	16	case
16	drug3	drug3	NN	_	14	nmod
17	or	or	CC	_	16	cc
18	drug4	drug4	NN	_	16	conj
19	did	do	VBD	_	21	aux
20	not	not	RB	_	21	neg
21	affect	affect	VB	_	1	dep
22	drug5	drug5	NN	_	23	compound
23	pharmacokinetics	pharmacokinetic	NNS	_	21	dobj
24	except	except	IN	_	46	mark
25	that	that	IN	_	46	mark
26	a	a	DT	_	35	det
27	small	small	JJ	_	35	amod
28	-LRB-	-lrb-	-LRB-	_	30	punct
29	13	13	CD	_	30	nummod
30	%	%	NN	_	27	dep
31	-RRB-	-rrb-	-RRB-	_	30	punct
32	but	but	CC	_	27	cc
33	statistically	statistically	RB	_	34	advmod
34	significant	significant	JJ	_	27	conj
35	increase	increase	NN	_	46	nsubj
36	in	in	IN	_	38	case
37	the	the	DT	_	38	det
38	area	area	NN	_	35	nmod
39	under	under	IN	_	43	case
40	the	the	DT	_	43	det
41	serum	serum	NN	_	43	compound
42	concentration	concentration	NN	_	43	compound
43	curve	curve	NN	_	35	nmod
44	of	of	IN	_	45	case
45	drug6	drug6	NN	_	43	nmod
46	resulted	result	VBD	_	21	advcl
47	with	with	IN	_	48	case
48	drug7	drug7	NN	_	46	nmod
49	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Studies	study	NNS	_	21	nsubj
4	of	of	IN	_	6	case
5	concomitant	concomitant	JJ	_	6	amod
6	administration	administration	NN	_	3	nmod
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	drug3	drug3	NN	_	8	conj
11	to	to	TO	_	13	case
12	healthy	healthy	JJ	_	13	amod
13	men	man	NNS	_	3	nmod
14	-LRB-	-lrb-	-LRB-	_	15	punct
15	n	n	NN	_	13	dep
16	=	=	JJ	_	15	amod
17	14	14	CD	_	16	dep
18	-RRB-	-rrb-	-RRB-	_	15	punct
19	did	do	VBD	_	21	aux
20	not	not	RB	_	21	neg
21	show	show	VB	_	1	dep
22	a	a	DT	_	23	det
23	change	change	NN	_	21	dobj
24	in	in	IN	_	29	case
25	the	the	DT	_	29	det
26	steady	steady	JJ	_	29	amod
27	state	state	NN	_	29	compound
28	serum	serum	NN	_	29	compound
29	levels	level	NNS	_	23	nmod
30	of	of	IN	_	32	case
31	either	either	CC	_	32	det
32	drug	drug	NN	_	29	nmod
33	.	.	.	_	21	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Studies	study	NNS	_	8	nsubj
4	in	in	IN	_	6	case
5	normal	normal	JJ	_	6	amod
6	volunteers	volunteer	NNS	_	3	nmod
7	have	have	VBP	_	8	aux
8	shown	show	VBN	_	1	appos
9	that	that	IN	_	16	mark
10	drug2	drug2	NN	_	16	nsubj
11	like	like	IN	_	13	case
12	other	other	JJ	_	13	amod
13	drug3	drug3	NN	_	10	nmod
14	,	,	,	_	16	punct
15	can	can	MD	_	16	aux
16	interfere	interfere	VB	_	8	ccomp
17	with	with	IN	_	19	case
18	the	the	DT	_	19	det
19	effects	effect	NNS	_	16	nmod
20	of	of	IN	_	21	case
21	drug4	drug4	NN	_	19	nmod
22	.	.	.	_	1	punct

1	Although	although	IN	_	4	mark
2	results	result	NNS	_	4	nsubj
3	have	have	VBP	_	4	aux
4	varied	vary	VBN	_	13	advcl
5	from	from	IN	_	6	case
6	study	study	NN	_	4	nmod
7	to	to	TO	_	8	mark
8	study	study	VB	_	6	acl
9	,	,	,	_	13	punct
10	effects	effect	NNS	_	13	nsubjpass
11	have	have	VBP	_	13	aux
12	been	be	VBN	_	13	auxpass
13	shown	show	VBN	_	0	ROOT
14	on	on	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	-	-	:	_	15	punct
17	stimulated	stimulate	VBN	_	18	amod
18	diuresis	diuresis	NN	_	15	dep
19	,	,	,	_	18	punct
20	natriuresis	natriuresis	NN	_	18	conj
21	,	,	,	_	18	punct
22	and	and	CC	_	18	cc
23	kaliuresis	kaliuresis	NN	_	18	conj
24	.	.	.	_	13	punct

1	Other	other	JJ	_	2	amod
2	drug1	drug1	NN	_	9	nsubjpass
3	that	that	WDT	_	4	nsubj
4	inhibit	inhibit	VBP	_	2	acl:relcl
5	prostaglandin	prostaglandin	NN	_	6	compound
6	synthesis	synthesis	NN	_	4	dobj
7	have	have	VBP	_	9	aux
8	been	be	VBN	_	9	auxpass
9	shown	show	VBN	_	0	ROOT
10	to	to	TO	_	11	mark
11	interfere	interfere	VB	_	9	xcomp
12	with	with	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	in	in	IN	_	16	case
15	some	some	DT	_	16	det
16	studies	study	NNS	_	11	nmod
17	and	and	CC	_	16	cc
18	with	with	IN	_	19	case
19	drug3	drug3	NN	_	16	conj
20	.	.	.	_	9	punct

1	Patients	patient	NNS	_	11	nsubjpass
2	receiving	receive	VBG	_	1	acl
3	drug1	drug1	NN	_	2	dobj
4	and	and	CC	_	3	cc
5	drug2	drug2	NN	_	3	conj
6	or	or	CC	_	3	cc
7	other	other	JJ	_	8	amod
8	drug3	drug3	NN	_	3	conj
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	observed	observe	VBN	_	0	ROOT
12	closely	closely	RB	_	11	advmod
13	to	to	TO	_	14	mark
14	determine	determine	VB	_	11	xcomp
15	if	if	IN	_	20	mark
16	the	the	DT	_	18	det
17	desired	desire	VBN	_	18	amod
18	effect	effect	NN	_	20	nsubjpass
19	is	be	VBZ	_	20	auxpass
20	obtained	obtain	VBN	_	14	advcl
21	.	.	.	_	11	punct

1	Oral	oral	JJ	_	2	amod
2	drug1	drug1	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	In	in	IN	_	6	case
5	one	one	CD	_	6	nummod
6	study	study	NN	_	10	nmod
7	,	,	,	_	10	punct
8	drug2	drug2	NN	_	10	nsubjpass
9	was	be	VBD	_	10	auxpass
10	given	give	VBN	_	2	dep
11	to	to	TO	_	13	case
12	adult	adult	JJ	_	13	amod
13	diabetics	diabetic	NNS	_	10	nmod
14	who	who	WP	_	17	nsubj
15	were	be	VBD	_	17	aux
16	already	already	RB	_	17	advmod
17	receiving	receive	VBG	_	13	acl:relcl
18	drug3	drug3	NN	_	17	dobj
19	-LRB-	-lrb-	-LRB-	_	21	punct
20	n	n	NN	_	21	nsubj
21	=	=	JJ	_	10	parataxis
22	4	4	CD	_	21	dobj
23	-RRB-	-rrb-	-RRB-	_	21	punct
24	,	,	,	_	10	punct
25	drug4	drug4	NN	_	31	compound
26	-LRB-	-lrb-	-LRB-	_	27	punct
27	n	n	NN	_	25	dep
28	=	=	JJ	_	27	amod
29	2	2	CD	_	28	dep
30	-RRB-	-rrb-	-RRB-	_	27	punct
31	drug5	drug5	NN	_	10	dobj
32	with	with	IN	_	33	case
33	drug6	drug6	NN	_	31	nmod
34	-LRB-	-lrb-	-LRB-	_	35	punct
35	n	n	NN	_	31	dep
36	=	=	JJ	_	35	amod
37	3	3	CD	_	36	dep
38	-RRB-	-rrb-	-RRB-	_	35	punct
39	or	or	CC	_	31	cc
40	drug7	drug7	NN	_	31	conj
41	with	with	IN	_	42	case
42	drug8	drug8	NN	_	40	nmod
43	-LRB-	-lrb-	-LRB-	_	44	punct
44	n	n	NN	_	42	dep
45	=	=	JJ	_	44	amod
46	6	6	CD	_	45	dep
47	-RRB-	-rrb-	-RRB-	_	44	punct
48	.	.	.	_	2	punct

1	Although	although	IN	_	3	mark
2	there	there	EX	_	3	expl
3	was	be	VBD	_	20	advcl
4	a	a	DT	_	6	det
5	slight	slight	JJ	_	6	amod
6	reduction	reduction	NN	_	3	nsubj
7	in	in	IN	_	10	case
8	blood	blood	NN	_	10	compound
9	sugar	sugar	NN	_	10	compound
10	concentrations	concentration	NNS	_	6	nmod
11	during	during	IN	_	13	case
12	concomitant	concomitant	JJ	_	13	amod
13	administration	administration	NN	_	6	nmod
14	of	of	IN	_	15	case
15	drug1	drug1	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	drug2	drug2	NN	_	15	conj
18	,	,	,	_	20	punct
19	there	there	EX	_	20	expl
20	were	be	VBD	_	0	ROOT
21	no	no	DT	_	22	neg
22	signs	sign	NNS	_	20	nsubj
23	or	or	CC	_	22	cc
24	symptoms	symptom	NNS	_	22	conj
25	of	of	IN	_	26	case
26	hypoglycemia	hypoglycemia	NN	_	22	nmod
27	.	.	.	_	20	punct

1	drug1	drug1	NN	_	0	ROOT
2	-	-	:	_	1	punct
3	including	include	VBG	_	4	case
4	drug2	drug2	NN	_	1	nmod
5	,	,	,	_	4	punct
6	drug3	drug3	NN	_	4	conj
7	and	and	CC	_	4	cc
8	drug4	drug4	NN	_	9	compound
9	HC1	hc1	NN	_	4	conj
10	.	.	.	_	1	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	use	use	NN	_	8	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	may	may	MD	_	8	aux
8	cause	cause	VB	_	0	ROOT
9	hypertension	hypertension	NN	_	8	dobj
10	.	.	.	_	8	punct

1	drug1	drug1	NN	_	9	nsubj
2	-	-	:	_	1	punct
3	drug2	drug2	NN	_	1	dep
4	and	and	CC	_	3	cc
5	the	the	DT	_	7	det
6	drug3	drug3	NN	_	7	compound
7	drug4	drug4	NN	_	3	conj
8	may	may	MD	_	9	aux
9	have	have	VB	_	0	ROOT
10	synergistic	synergistic	JJ	_	12	amod
11	antidepressant	antidepressant	JJ	_	12	amod
12	activity	activity	NN	_	9	dobj
13	if	if	IN	_	14	mark
14	used	use	VBN	_	9	advcl
15	concomitantly	concomitantly	RB	_	14	advmod
16	.	.	.	_	9	punct

1	drug1	drug1	NN	_	3	compound
2	-	-	:	_	3	punct
3	drug2	drug2	NN	_	5	nsubj
4	may	may	MD	_	5	aux
5	potentiate	potentiate	VB	_	0	ROOT
6	the	the	DT	_	10	det
7	tardive	tardive	JJ	_	10	amod
8	dyskinesia	dyskinesia	NN	_	10	compound
9	side	side	NN	_	10	amod
10	reactions	reaction	NNS	_	5	dobj
11	of	of	IN	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	if	if	IN	_	14	mark
14	used	use	VBN	_	5	advcl
15	concomitantly	concomitantly	RB	_	14	advmod
16	with	with	IN	_	17	case
17	them	they	PRP	_	14	nmod
18	.	.	.	_	5	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	shown	show	VBN	_	0	ROOT
5	in	in	FW	_	6	compound
6	vivo	vivo	FW	_	4	advmod
7	to	to	TO	_	8	mark
8	induce	induce	VB	_	4	xcomp
9	CYP3A4	cyp3a4	NN	_	8	dobj
10	.	.	.	_	4	punct

1	Other	other	JJ	_	2	amod
2	compounds	compound	NNS	_	10	nsubj
3	that	that	WDT	_	5	nsubj
4	are	be	VBP	_	5	cop
5	substrates	substrate	NNS	_	2	acl:relcl
6	of	of	IN	_	7	case
7	CYP3A4	cyp3a4	NN	_	5	nmod
8	may	may	MD	_	10	aux
9	have	have	VB	_	10	aux
10	decreased	decrease	VBN	_	0	ROOT
11	plasma	plasma	NN	_	12	compound
12	concentrations	concentration	NNS	_	10	dobj
13	when	when	WRB	_	14	advmod
14	coadministered	coadminister	VBN	_	10	advcl
15	with	with	IN	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	drug2	drug2	NN	_	16	appos
19	-RRB-	-rrb-	-RRB-	_	18	punct
20	.	.	.	_	10	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	5	nsubj
4	have	have	VBP	_	5	aux
5	demonstrated	demonstrate	VBN	_	0	ROOT
6	that	that	IN	_	8	mark
7	drug1	drug1	NN	_	8	nsubj
8	inhibits	inhibit	VBZ	_	5	ccomp
9	2C9	2c9	NN	_	8	dobj
10	,	,	,	_	9	punct
11	2C19	2c19	NN	_	9	conj
12	,	,	,	_	9	punct
13	and	and	CC	_	9	cc
14	3A4	3a4	NN	_	15	compound
15	isozymes	isozyme	NNS	_	9	conj
16	in	in	IN	_	18	case
17	the	the	DT	_	18	det
18	range	range	NN	_	8	nmod
19	of	of	IN	_	23	case
20	observed	observe	VBN	_	23	amod
21	drug2	drug2	NN	_	23	compound
22	plasma	plasma	NN	_	23	compound
23	concentrations	concentration	NNS	_	18	nmod
24	.	.	.	_	5	punct

1	Coadministration	coadministration	NN	_	12	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	5	case
5	drugs	drug	NNS	_	1	nmod
6	primarily	primarily	RB	_	7	advmod
7	metabolized	metabolize	VBN	_	5	acl
8	by	by	IN	_	10	case
9	these	these	DT	_	10	det
10	isozymes	isozyme	NNS	_	7	nmod
11	may	may	MD	_	12	aux
12	result	result	VB	_	0	ROOT
13	in	in	IN	_	16	case
14	altered	altered	JJ	_	16	amod
15	plasma	plasma	NN	_	16	compound
16	concentrations	concentration	NNS	_	12	nmod
17	of	of	IN	_	20	case
18	the	the	DT	_	20	det
19	coadministered	coadminister	VBN	_	20	amod
20	drug	drug	NN	_	16	nmod
21	.	.	.	_	12	punct

1	Therefore	therefore	RB	_	8	advmod
2	,	,	,	_	8	punct
3	appropriate	appropriate	JJ	_	5	amod
4	dose	dose	NN	_	5	compound
5	adjustments	adjustment	NNS	_	8	nsubj
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	cop
8	necessary	necessary	JJ	_	0	ROOT
9	for	for	IN	_	11	case
10	these	these	DT	_	11	det
11	drugs	drug	NNS	_	8	nmod
12	.	.	.	_	8	punct

1	Drugs	drug	NNS	_	17	nsubjpass
2	which	which	WDT	_	3	nsubj
3	induce	induce	VBP	_	1	acl:relcl
4	CYP3A4	cyp3a4	NN	_	5	compound
5	activity	activity	NN	_	3	dobj
6	-LRB-	-lrb-	-LRB-	_	9	punct
7	eg	eg	FW	_	9	compound
8	,	,	,	_	9	punct
9	drug1	drug1	NN	_	1	dep
10	,	,	,	_	9	punct
11	drug2	drug2	NN	_	9	appos
12	,	,	,	_	9	punct
13	drug3	drug3	NN	_	9	appos
14	-RRB-	-rrb-	-RRB-	_	9	punct
15	would	would	MD	_	17	aux
16	be	be	VB	_	17	auxpass
17	expected	expect	VBN	_	0	ROOT
18	to	to	TO	_	19	mark
19	increase	increase	VB	_	17	xcomp
20	the	the	DT	_	21	det
21	clearance	clearance	NN	_	19	dobj
22	of	of	IN	_	23	case
23	drug4	drug4	NN	_	21	nmod
24	resulting	result	VBG	_	23	acl
25	in	in	IN	_	28	case
26	lowered	lowered	JJ	_	28	amod
27	plasma	plasma	NN	_	28	compound
28	concentrations	concentration	NNS	_	24	nmod
29	.	.	.	_	17	punct

1	Drug	drug	NN	_	2	compound
2	interactions	interaction	NNS	_	6	nsubjpass
3	with	with	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	are	be	VBP	_	6	auxpass
6	summarized	summarize	VBN	_	0	ROOT
7	in	in	IN	_	8	case
8	Table	Table	NNP	_	6	nmod
9	5	5	CD	_	8	nummod
10	.	.	.	_	6	punct

1	Table	Table	NNP	_	2	compound
2	5a	5a	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	Drugs	drug	NNS	_	2	dep
5	That	that	WDT	_	9	nsubj
6	Should	should	MD	_	9	aux
7	Not	not	RB	_	9	neg
8	Be	be	VB	_	9	cop
9	Coadministered	coadministered	JJ	_	4	acl:relcl
10	With	with	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod

1	Drug	drug	NN	_	2	compound
2	Class	class	NN	_	0	ROOT

1	Drugs	drug	NNS	_	0	ROOT
2	Within	within	IN	_	3	case
3	Class	Class	NNP	_	1	nmod
4	Not	not	RB	_	7	neg
5	To	to	TO	_	7	mark
6	Be	be	VB	_	7	cop
7	Coadministered	coadministered	JJ	_	1	acl
8	With	with	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	6	compound
4	GI	gi	NN	_	6	compound
5	Motility	motility	NN	_	6	compound
6	Agents	agent	NNS	_	7	nsubj
7	drug3	drug3	VBP	_	1	appos
8	drug4	drug4	NN	_	7	dobj

1	drug1	drug1	NN	_	2	compound
2	drug2	drug2	NN	_	8	nsubj
3	,	,	,	_	2	punct
4	drug3	drug3	NN	_	7	compound
5	drug4	drug4	NN	_	7	compound
6	ergot	ergot	NN	_	7	compound
7	derivatives	derivative	NNS	_	2	appos
8	drug5	drug5	VBP	_	0	ROOT

1	Established	establish	VBN	_	3	amod
2	Drug	drug	NN	_	3	compound
3	Interactions	interaction	NNS	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	Drug	drug	NN	_	2	nsubj
2	Name	name	VB	_	0	ROOT

1	Effect	effect	NN	_	0	ROOT

1	Clinical	clinical	JJ	_	2	amod
2	Comment	comment	NN	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT

1	When	when	WRB	_	2	advmod
2	coadministered	coadminister	VBN	_	16	advcl
3	with	with	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	in	in	IN	_	7	case
6	treatment-naive	treatment-naive	JJ	_	7	amod
7	patients	patient	NNS	_	2	nmod
8	,	,	,	_	16	punct
9	the	the	DT	_	11	det
10	recommended	recommend	VBN	_	11	amod
11	dose	dose	NN	_	16	nsubj
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	is	be	VBZ	_	16	cop
15	300	300	CD	_	16	nummod
16	mg	mg	NN	_	0	ROOT
17	with	with	IN	_	20	case
18	drug3	drug3	NN	_	20	compound
19	100	100	CD	_	20	nummod
20	mg	mg	NN	_	16	nmod
21	and	and	CC	_	20	cc
22	drug4	drug4	NN	_	24	compound
23	600	600	CD	_	24	nummod
24	mg	mg	NN	_	20	conj
25	-LRB-	-lrb-	-LRB-	_	28	punct
26	all	all	DT	_	28	dep
27	once	once	RB	_	28	advmod
28	daily	daily	JJ	_	20	dep
29	-RRB-	-rrb-	-RRB-	_	28	punct
30	.	.	.	_	16	punct

1	Dosing	dosing	NN	_	2	compound
2	recommendations	recommendation	NNS	_	13	nsubjpass
3	for	for	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	and	and	CC	_	4	cc
6	drug2	drug2	NN	_	4	conj
7	in	in	IN	_	9	case
8	treatment-experienced	treatment-experienced	JJ	_	9	amod
9	patients	patient	NNS	_	2	nmod
10	have	have	VBP	_	13	aux
11	not	not	RB	_	13	neg
12	been	be	VBN	_	13	auxpass
13	established	establish	VBN	_	0	ROOT
14	.	.	.	_	13	punct

1	Established	establish	VBN	_	3	amod
2	Drug	drug	NN	_	3	compound
3	Interactions	interaction	NNS	_	0	ROOT
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	continued	continue	VBN	_	3	dep
6	-RRB-	-rrb-	-RRB-	_	5	punct

1	Drug	drug	NN	_	2	nsubj
2	Name	name	VB	_	0	ROOT

1	Effect	effect	NN	_	0	ROOT

1	Clinical	clinical	JJ	_	2	amod
2	Comment	comment	NN	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	2	compound
2	concentration	concentration	NN	_	0	ROOT

1	Plasma	plasma	NN	_	2	compound
2	concentrations	concentration	NNS	_	0	ROOT
3	decreased	decrease	VBN	_	2	acl
4	by	by	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	;	;	:	_	2	punct

1	clinical	clinical	JJ	_	3	amod
2	significance	significance	NN	_	3	compound
3	unknown	unknown	NN	_	0	ROOT
4	.	.	.	_	3	punct

1	In	in	IN	_	3	case
2	uninfected	uninfected	JJ	_	3	amod
3	volunteers	volunteer	NNS	_	7	nmod
4	,	,	,	_	7	punct
5	46	46	CD	_	6	nummod
6	%	%	NN	_	7	nsubj
7	developed	develop	VBD	_	0	ROOT
8	rash	rash	NN	_	7	dobj
9	while	while	IN	_	10	mark
10	receiving	receive	VBG	_	7	advcl
11	drug1	drug1	NN	_	10	dobj
12	and	and	CC	_	11	cc
13	drug2	drug2	NN	_	11	conj
14	.	.	.	_	7	punct

1	No	no	DT	_	3	neg
2	dose	dose	NN	_	3	compound
3	adjustment	adjustment	NN	_	7	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	is	be	VBZ	_	7	auxpass
7	recommended	recommend	VBN	_	0	ROOT
8	when	when	WRB	_	9	advmod
9	given	give	VBN	_	7	advcl
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	.	.	.	_	7	punct

1	Alternatives	Alternatives	NNP	_	11	nsubjpass
2	to	to	TO	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	,	,	,	_	1	punct
5	such	such	JJ	_	7	case
6	as	as	IN	_	5	mwe
7	drug2	drug2	NN	_	1	nmod
8	,	,	,	_	1	punct
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	considered	consider	VBN	_	0	ROOT
12	.	.	.	_	11	punct

1	Other	other	JJ	_	2	amod
2	drug1	drug1	NN	_	11	nsubjpass
3	,	,	,	_	2	punct
4	such	such	JJ	_	6	case
5	as	as	IN	_	4	mwe
6	drug2	drug2	NN	_	2	nmod
7	,	,	,	_	2	punct
8	have	have	VBP	_	11	aux
9	not	not	RB	_	11	neg
10	been	be	VBN	_	11	auxpass
11	studied	study	VBN	_	0	ROOT
12	in	in	IN	_	13	case
13	combination	combination	NN	_	11	nmod
14	with	with	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	.	.	.	_	11	punct

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	14-OH	14-oh	JJ	_	3	amod
2	metabolite	metabolite	NN	_	3	compound
3	concentration	concentration	NN	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	2	compound
2	concentration	concentration	NN	_	0	ROOT

1	The	the	DT	_	3	det
2	optimal	optimal	JJ	_	3	amod
3	dose	dose	NN	_	16	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	,	,	,	_	3	punct
7	when	when	WRB	_	8	advmod
8	given	give	VBN	_	3	acl:relcl
9	in	in	IN	_	10	case
10	combination	combination	NN	_	8	nmod
11	with	with	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	,	,	,	_	3	punct
14	is	be	VBZ	_	16	auxpass
15	not	not	RB	_	16	neg
16	known	know	VBN	_	0	ROOT
17	.	.	.	_	16	punct

1	Increasing	increase	VBG	_	0	ROOT
2	the	the	DT	_	4	det
3	drug1	drug1	NN	_	4	compound
4	dose	dose	NN	_	1	dobj
5	to	to	TO	_	7	case
6	1000	1000	CD	_	7	nummod
7	mg	mg	NN	_	1	nmod
8	every	every	DT	_	10	det
9	8	8	CD	_	10	nummod
10	hours	hour	NNS	_	13	nsubj
11	does	do	VBZ	_	13	aux
12	not	not	RB	_	13	neg
13	compensate	compensate	VB	_	1	dep
14	for	for	IN	_	18	case
15	the	the	DT	_	18	det
16	increased	increase	VBN	_	18	amod
17	drug2	drug2	NN	_	18	compound
18	metabolism	metabolism	NN	_	13	nmod
19	due	due	JJ	_	21	case
20	to	to	TO	_	19	mwe
21	drug3	drug3	NN	_	18	nmod
22	.	.	.	_	1	punct

1	When	when	WRB	_	15	advmod
2	drug1	drug1	NN	_	15	nsubjpass
3	at	at	IN	_	6	case
4	an	a	DT	_	6	det
5	increased	increase	VBN	_	6	amod
6	dose	dose	NN	_	2	nmod
7	-LRB-	-lrb-	-LRB-	_	9	punct
8	1000	1000	CD	_	9	nummod
9	mg	mg	NN	_	6	dep
10	every	every	DT	_	12	det
11	8	8	CD	_	12	nummod
12	hours	hour	NNS	_	9	dep
13	-RRB-	-rrb-	-RRB-	_	9	punct
14	was	be	VBD	_	15	auxpass
15	given	give	VBN	_	31	advcl
16	with	with	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	-LRB-	-lrb-	-LRB-	_	20	punct
19	600	600	CD	_	20	nummod
20	mg	mg	NN	_	17	dep
21	once	once	RB	_	22	advmod
22	daily	daily	JJ	_	20	amod
23	-RRB-	-rrb-	-RRB-	_	20	punct
24	,	,	,	_	31	punct
25	the	the	DT	_	27	det
26	drug3	drug3	NN	_	27	compound
27	AUC	auc	NN	_	31	nsubjpass
28	and	and	CC	_	27	cc
29	Cmin	cmin	NN	_	27	conj
30	were	be	VBD	_	31	auxpass
31	decreased	decrease	VBN	_	0	ROOT
32	on	on	IN	_	33	case
33	average	average	NN	_	31	nmod
34	by	by	IN	_	36	case
35	33-46	33-46	CD	_	36	nummod
36	%	%	NN	_	31	nmod
37	and	and	CC	_	31	cc
38	39-57	39-57	CD	_	39	nummod
39	%	%	NN	_	31	conj
40	,	,	,	_	39	punct
41	respectively	respectively	RB	_	39	advmod
42	,	,	,	_	39	punct
43	compared	compare	VBN	_	39	acl
44	to	to	TO	_	43	nmod
45	when	when	WRB	_	55	advmod
46	drug4	drug4	NN	_	55	nsubjpass
47	-LRB-	-lrb-	-LRB-	_	49	punct
48	800	800	CD	_	49	nummod
49	mg	mg	NN	_	46	appos
50	every	every	DT	_	52	det
51	8	8	CD	_	52	nummod
52	hours	hour	NNS	_	49	dep
53	-RRB-	-rrb-	-RRB-	_	49	punct
54	was	be	VBD	_	55	auxpass
55	given	give	VBN	_	44	advcl
56	alone	alone	RB	_	55	advmod
57	.	.	.	_	31	punct

1	drug1	drug1	NN	_	0	ROOT
2	/	/	:	_	1	punct
3	drug2	drug2	NN	_	1	dep

1	drug1	drug1	NN	_	2	compound
2	concentration	concentration	NN	_	0	ROOT

1	A	a	DT	_	3	det
2	dose	dose	NN	_	3	compound
3	increase	increase	NN	_	24	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	/	/	:	_	3	punct
7	drug2	drug2	NN	_	3	dep
8	to	to	TO	_	10	case
9	533/133	533/133	CD	_	10	nummod
10	mg	mg	NN	_	7	nmod
11	-LRB-	-lrb-	-LRB-	_	13	punct
12	4	4	CD	_	13	nummod
13	capsules	capsule	NNS	_	10	dep
14	or	or	CC	_	13	cc
15	6.5	6.5	CD	_	16	nummod
16	mL	ml	NN	_	13	conj
17	-RRB-	-rrb-	-RRB-	_	13	punct
18	twice	twice	RB	_	19	advmod
19	daily	daily	JJ	_	20	advmod
20	taken	take	VBN	_	7	acl
21	with	with	IN	_	22	case
22	food	food	NN	_	20	nmod
23	is	be	VBZ	_	24	auxpass
24	recommended	recommend	VBN	_	0	ROOT
25	when	when	WRB	_	26	advmod
26	used	use	VBN	_	24	advcl
27	in	in	IN	_	28	case
28	combination	combination	NN	_	26	nmod
29	with	with	IN	_	30	case
30	drug3	drug3	NN	_	28	nmod
31	.	.	.	_	24	punct

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	2	compound
2	concentration	concentration	NN	_	0	ROOT

1	Coadministration	Coadministration	NNP	_	12	nsubj
2	in	in	IN	_	4	case
3	HIV-infected	hiv-infected	JJ	_	4	amod
4	individuals	individual	NNS	_	1	nmod
5	with	with	IN	_	7	case
6	a	a	DT	_	7	det
7	history	history	NN	_	4	nmod
8	of	of	IN	_	11	case
9	injection	injection	NN	_	11	compound
10	drug	drug	NN	_	11	compound
11	use	use	NN	_	7	nmod
12	resulted	result	VBD	_	0	ROOT
13	in	in	IN	_	16	case
14	decreased	decrease	VBN	_	16	amod
15	plasma	plasma	NN	_	16	compound
16	levels	level	NNS	_	12	nmod
17	of	of	IN	_	18	case
18	drug1	drug1	NN	_	16	nmod
19	and	and	CC	_	18	cc
20	signs	sign	NNS	_	18	conj
21	of	of	IN	_	23	case
22	drug2	drug2	NN	_	23	compound
23	withdrawal	withdrawal	NN	_	18	nmod
24	.	.	.	_	12	punct

1	drug1	drug1	NN	_	2	compound
2	dose	dose	NN	_	4	nsubjpass
3	was	be	VBD	_	4	auxpass
4	increased	increase	VBN	_	0	ROOT
5	by	by	IN	_	7	case
6	a	a	DT	_	7	det
7	mean	mean	NN	_	4	nmod
8	of	of	IN	_	10	case
9	22	22	CD	_	10	nummod
10	%	%	NN	_	7	nmod
11	to	to	TO	_	12	mark
12	alleviate	alleviate	VB	_	7	acl
13	withdrawal	withdrawal	NN	_	14	compound
14	symptoms	symptom	NNS	_	12	dobj
15	.	.	.	_	4	punct

1	Patients	patient	NNS	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	monitored	monitor	VBN	_	0	ROOT
5	for	for	IN	_	6	case
6	signs	sign	NNS	_	4	nmod
7	of	of	IN	_	8	case
8	withdrawal	withdrawal	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	their	they	PRP$	_	12	nmod:poss
11	drug1	drug1	NN	_	12	compound
12	dose	dose	NN	_	8	conj
13	increased	increase	VBD	_	4	xcomp
14	as	as	IN	_	15	mark
15	required	require	VBN	_	13	advcl
16	to	to	TO	_	17	mark
17	alleviate	alleviate	VB	_	15	xcomp
18	withdrawal	withdrawal	NN	_	19	compound
19	symptoms	symptom	NNS	_	17	dobj
20	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	2	compound
2	concentration	concentration	NN	_	0	ROOT

1	Plasma	plasma	NN	_	2	compound
2	concentrations	concentration	NNS	_	0	ROOT
3	increased	increase	VBN	_	2	acl
4	by	by	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	drug2	drug2	NN	_	5	appos
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	;	;	:	_	2	punct

1	clinical	clinical	JJ	_	3	amod
2	significance	significance	NN	_	3	compound
3	unknown	unknown	NN	_	0	ROOT
4	.	.	.	_	3	punct

1	Because	because	IN	_	14	mark
2	the	the	DT	_	4	det
3	potential	potential	JJ	_	4	amod
4	interaction	interaction	NN	_	14	nsubjpass
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	with	with	IN	_	9	case
8	oral	oral	JJ	_	9	amod
9	drug2	drug2	NN	_	4	nmod
10	has	have	VBZ	_	14	aux
11	not	not	RB	_	14	neg
12	been	be	VBN	_	14	auxpass
13	fully	fully	RB	_	14	advmod
14	characterized	characterize	VBN	_	24	advcl
15	,	,	,	_	24	punct
16	a	a	DT	_	18	det
17	reliable	reliable	JJ	_	18	amod
18	method	method	NN	_	24	nsubjpass
19	of	of	IN	_	21	case
20	barrier	barrier	NN	_	21	compound
21	contraception	contraception	NN	_	18	nmod
22	should	should	MD	_	24	aux
23	be	be	VB	_	24	auxpass
24	used	use	VBN	_	0	ROOT
25	in	in	IN	_	26	case
26	addition	addition	NN	_	24	nmod
27	to	to	TO	_	29	case
28	oral	oral	JJ	_	29	amod
29	drug3	drug3	NN	_	26	nmod
30	.	.	.	_	24	punct

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	2	compound
2	concentration	concentration	NN	_	0	ROOT

1	Increase	increase	NN	_	3	compound
2	daily	daily	RB	_	3	advmod
3	dose	dose	NN	_	0	ROOT
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	by	by	IN	_	8	case
7	50	50	CD	_	8	nummod
8	%	%	NN	_	3	nmod
9	.	.	.	_	3	punct

1	Consider	consider	VB	_	0	ROOT
2	doubling	double	VBG	_	1	xcomp
3	the	the	DT	_	5	det
4	drug1	drug1	NN	_	5	compound
5	dose	dose	NN	_	2	dobj
6	in	in	IN	_	7	case
7	regimens	regimen	NNS	_	2	nmod
8	where	where	WRB	_	11	advmod
9	drug2	drug2	NN	_	11	nsubjpass
10	is	be	VBZ	_	11	auxpass
11	given	give	VBN	_	7	acl:relcl
12	2	2	CD	_	15	compound
13	or	or	CC	_	12	cc
14	3	3	CD	_	12	conj
15	times	time	NNS	_	11	nmod:tmod
16	a	a	DT	_	17	det
17	week	week	NN	_	15	nmod:npmod
18	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	2	compound
2	concentration	concentration	NN	_	0	ROOT

1	Clinical	clinical	JJ	_	2	amod
2	significance	significance	NN	_	0	ROOT
3	of	of	IN	_	6	case
4	reduced	reduce	VBN	_	6	amod
5	drug1	drug1	NN	_	6	compound
6	concentrations	concentration	NNS	_	2	nmod
7	unknown	unknown	JJ	_	6	amod
8	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	2	compound
2	concentration	concentration	NN	_	0	ROOT

1	Combination	combination	NN	_	3	nsubjpass
2	was	be	VBD	_	3	auxpass
3	associated	associate	VBN	_	0	ROOT
4	with	with	IN	_	7	case
5	a	a	DT	_	7	det
6	higher	higher	JJR	_	7	amod
7	frequency	frequency	NN	_	3	nmod
8	of	of	IN	_	11	case
9	adverse	adverse	JJ	_	11	amod
10	clinical	clinical	JJ	_	11	amod
11	experiences	experience	NNS	_	7	nmod
12	-LRB-	-lrb-	-LRB-	_	15	punct
13	eg	eg	FW	_	15	compound
14	,	,	,	_	15	punct
15	dizziness	dizziness	NN	_	11	dep
16	,	,	,	_	15	punct
17	nausea	nausea	NN	_	15	appos
18	,	,	,	_	15	punct
19	paresthesia	paresthesia	NN	_	15	appos
20	-RRB-	-rrb-	-RRB-	_	15	punct
21	and	and	CC	_	11	cc
22	laboratory	laboratory	NN	_	23	compound
23	abnormalities	abnormality	NNS	_	11	conj
24	-LRB-	-lrb-	-LRB-	_	27	punct
25	elevated	elevated	JJ	_	27	amod
26	liver	liver	NN	_	27	compound
27	enzymes	enzyme	NNS	_	23	appos
28	-RRB-	-rrb-	-RRB-	_	27	punct
29	.	.	.	_	3	punct

1	Monitoring	monitoring	NN	_	6	nsubjpass
2	of	of	IN	_	4	case
3	liver	liver	NN	_	4	compound
4	enzymes	enzyme	NNS	_	1	nmod
5	is	be	VBZ	_	6	auxpass
6	recommended	recommend	VBN	_	0	ROOT
7	when	when	WRB	_	10	advmod
8	drug1	drug1	NN	_	10	nsubjpass
9	is	be	VBZ	_	10	auxpass
10	used	use	VBN	_	6	advcl
11	in	in	IN	_	12	case
12	combination	combination	NN	_	10	nmod
13	with	with	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	.	.	.	_	6	punct

1	drug1	drug1	NN	_	2	compound
2	concentration	concentration	NN	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	2	compound
2	concentration	concentration	NN	_	0	ROOT

1	Should	should	MD	_	4	aux
2	not	not	RB	_	4	neg
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	as	as	IN	_	7	case
6	sole	sole	JJ	_	7	amod
7	drug1	drug1	NN	_	4	nmod
8	in	in	IN	_	9	case
9	combination	combination	NN	_	4	nmod
10	with	with	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT

1	drug1	drug1	NN	_	2	compound
2	concentration	concentration	NN	_	0	ROOT

1	Increases	increase	NNS	_	7	nsubjpass
2	in	in	IN	_	4	case
3	drug1	drug1	NN	_	4	compound
4	dose	dose	NN	_	1	nmod
5	should	should	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	guided	guide	VBN	_	0	ROOT
8	by	by	IN	_	10	case
9	clinical	clinical	JJ	_	10	amod
10	response	response	NN	_	7	nmod
11	.	.	.	_	7	punct

1	Other	other	JJ	_	5	amod
2	Potentially	potentially	RB	_	4	advmod
3	Clinically	clinically	RB	_	4	advmod
4	Significant	significant	JJ	_	5	amod
5	Drug	drug	NN	_	0	ROOT
6	or	or	CC	_	5	cc
7	Herbal	Herbal	NNP	_	9	compound
8	Product	Product	NNP	_	9	compound
9	Interactions	interaction	NNS	_	5	conj
10	With	with	IN	_	11	case
11	SUSTIVAb	sustivab	NN	_	5	nmod

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	1	dep

1	Plasma	plasma	NN	_	2	compound
2	concentrations	concentration	NNS	_	6	nsubj
3	and	and	CC	_	2	cc
4	effects	effect	NNS	_	2	conj
5	potentially	potentially	RB	_	6	advmod
6	increased	increase	VBD	_	0	ROOT
7	or	or	CC	_	6	cc
8	decreased	decrease	VBN	_	6	conj
9	by	by	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	5	compound
4	drug3	drug3	NN	_	5	compound
5	drug4	drug4	NN	_	1	dep

1	Potential	potential	JJ	_	0	ROOT
2	for	for	IN	_	3	case
3	reduction	reduction	NN	_	1	nmod
4	in	in	IN	_	9	case
5	drug1	drug1	NN	_	9	compound
6	and/or	and/or	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	plasma	plasma	NN	_	9	compound
9	levels	level	NNS	_	3	nmod
10	;	;	:	_	1	punct

1	periodic	periodic	JJ	_	2	amod
2	monitoring	monitoring	NN	_	9	nsubjpass
3	of	of	IN	_	6	case
4	drug1	drug1	NN	_	6	compound
5	plasma	plasma	NN	_	6	compound
6	levels	level	NNS	_	2	nmod
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	conducted	conduct	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	4	compound
4	drug3	drug3	NN	_	1	dep

1	Drug	drug	NN	_	3	compound
2	interaction	interaction	NN	_	3	compound
3	studies	study	NNS	_	14	nsubjpass
4	with	with	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	these	these	DT	_	8	det
8	drug2	drug2	NN	_	5	conj
9	and	and	CC	_	5	cc
10	drug3	drug3	NN	_	5	conj
11	have	have	VBP	_	14	aux
12	not	not	RB	_	14	neg
13	been	be	VBN	_	14	auxpass
14	conducted	conduct	VBN	_	0	ROOT
15	.	.	.	_	14	punct

1	drug1	drug1	NN	_	2	nsubj
2	has	have	VBZ	_	0	ROOT
3	the	the	DT	_	4	det
4	potential	potential	JJ	_	2	dobj
5	to	to	TO	_	6	mark
6	decrease	decrease	VB	_	4	acl
7	plasma	plasma	NN	_	8	compound
8	concentrations	concentration	NNS	_	6	dobj
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	drug3	drug3	NN	_	10	conj
13	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	drug2	drug2	NN	_	6	compound
4	/	/	:	_	6	punct
5	drug3	drug3	NN	_	6	compound
6	combination	combination	NN	_	1	dep

1	No	no	DT	_	3	neg
2	pharmacokinetic	pharmacokinetic	JJ	_	3	amod
3	data	datum	NNS	_	5	nsubj
4	are	be	VBP	_	5	cop
5	available	available	JJ	_	0	ROOT
6	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT

1	SUSTIVAhas	sustivaha	NNS	_	0	ROOT
2	the	the	DT	_	3	det
3	potential	potential	JJ	_	1	dobj
4	to	to	TO	_	5	mark
5	decrease	decrease	VB	_	3	acl
6	serum	serum	NN	_	7	compound
7	concentrations	concentration	NNS	_	5	dobj
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT

1	No	no	DT	_	2	neg
2	studies	study	NNS	_	5	nsubjpass
3	have	have	VBP	_	5	aux
4	been	be	VBN	_	5	auxpass
5	performed	perform	VBN	_	0	ROOT
6	with	with	IN	_	8	case
7	other	other	JJ	_	8	amod
8	drug1	drug1	NN	_	5	nmod
9	.	.	.	_	5	punct

1	St.	St.	NNP	_	4	compound
2	John	John	NNP	_	4	compound
3	s	be	VBZ	_	4	compound
4	wort	wort	NN	_	0	ROOT
5	-LRB-	-lrb-	-LRB-	_	7	punct
6	Hypericum	hypericum	NN	_	7	compound
7	perforatum	perforatum	NN	_	4	appos
8	-RRB-	-rrb-	-RRB-	_	7	punct

1	Expected	expect	VBN	_	0	ROOT
2	to	to	TO	_	4	mark
3	substantially	substantially	RB	_	4	advmod
4	decrease	decrease	VB	_	1	xcomp
5	plasma	plasma	NN	_	6	compound
6	levels	level	NNS	_	4	dobj
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	;	;	:	_	1	punct
10	has	have	VBZ	_	13	aux
11	not	not	RB	_	13	neg
12	been	be	VBN	_	13	auxpass
13	studied	study	VBN	_	1	parataxis
14	in	in	IN	_	15	case
15	combination	combination	NN	_	13	nmod
16	with	with	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	.	.	.	_	1	punct

1	a	a	DT	_	3	det
2	See	See	NNP	_	3	compound
3	Tables	Tables	NNP	_	0	ROOT
4	1	1	CD	_	3	nummod
5	and	and	CC	_	3	cc
6	2	2	CD	_	3	conj
7	.	.	.	_	3	punct

1	b	b	NN	_	3	compound
2	This	this	DT	_	3	det
3	table	table	NN	_	6	nsubj
4	is	be	VBZ	_	6	cop
5	not	not	RB	_	6	neg
6	all-inclusive	all-inclusive	JJ	_	0	ROOT
7	.	.	.	_	6	punct

1	Other	other	JJ	_	2	amod
2	Drugs	drug	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	Based	base	VBN	_	7	case
5	on	on	IN	_	7	case
6	the	the	DT	_	7	det
7	results	result	NNS	_	2	nmod
8	of	of	IN	_	11	case
9	drug	drug	NN	_	11	compound
10	interaction	interaction	NN	_	11	compound
11	studies	study	NNS	_	7	nmod
12	,	,	,	_	7	punct
13	no	no	DT	_	15	neg
14	dosage	dosage	NN	_	15	compound
15	adjustment	adjustment	NN	_	17	nsubjpass
16	is	be	VBZ	_	17	auxpass
17	recommended	recommend	VBN	_	7	acl:relcl
18	when	when	WRB	_	24	advmod
19	drug1	drug1	NN	_	24	nsubjpass
20	-LRB-	-lrb-	-LRB-	_	21	punct
21	drug2	drug2	NN	_	19	appos
22	-RRB-	-rrb-	-RRB-	_	21	punct
23	is	be	VBZ	_	24	auxpass
24	given	give	VBN	_	17	advcl
25	with	with	IN	_	27	case
26	the	the	DT	_	27	det
27	following	following	NN	_	24	nmod
28	:	:	:	_	7	punct
29	drug3	drug3	NN	_	7	dep
30	,	,	,	_	29	punct
31	drug4	drug4	NN	_	29	conj
32	,	,	,	_	29	punct
33	drug5	drug5	NN	_	29	conj
34	,	,	,	_	29	punct
35	drug6	drug6	NN	_	29	conj
36	,	,	,	_	29	punct
37	drug7	drug7	NN	_	29	conj
38	,	,	,	_	29	punct
39	drug8	drug8	NN	_	29	conj
40	,	,	,	_	29	punct
41	drug9	drug9	NN	_	29	conj
42	,	,	,	_	29	punct
43	drug10	drug10	NN	_	29	conj
44	,	,	,	_	29	punct
45	drug11	drug11	NN	_	29	conj
46	,	,	,	_	29	punct
47	and	and	CC	_	29	cc
48	drug12	drug12	NN	_	29	conj
49	.	.	.	_	2	punct

1	Specific	specific	JJ	_	4	amod
2	drug	drug	NN	_	4	compound
3	interaction	interaction	NN	_	4	compound
4	studies	study	NNS	_	8	nsubjpass
5	have	have	VBP	_	8	aux
6	not	not	RB	_	8	neg
7	been	be	VBN	_	8	auxpass
8	performed	perform	VBN	_	0	ROOT
9	with	with	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	drug2	drug2	NN	_	10	conj
13	other	other	JJ	_	10	amod
14	than	than	IN	_	15	case
15	drug3	drug3	NN	_	13	nmod
16	and	and	CC	_	15	cc
17	drug4	drug4	NN	_	15	conj
18	.	.	.	_	8	punct

1	Clinically	clinically	RB	_	3	advmod
2	significant	significant	JJ	_	3	amod
3	interactions	interaction	NNS	_	7	nsubjpass
4	would	would	MD	_	7	aux
5	not	not	RB	_	7	neg
6	be	be	VB	_	7	auxpass
7	expected	expect	VBN	_	0	ROOT
8	since	since	IN	_	12	mark
9	the	the	DT	_	10	det
10	drug1	drug1	NN	_	12	nsubjpass
11	are	be	VBP	_	12	auxpass
12	metabolized	metabolize	VBN	_	7	advcl
13	via	via	IN	_	16	case
14	a	a	DT	_	16	det
15	different	different	JJ	_	16	amod
16	route	route	NN	_	12	nmod
17	than	than	IN	_	18	case
18	drug2	drug2	NN	_	16	nmod
19	and	and	CC	_	7	cc
20	would	would	MD	_	22	aux
21	be	be	VB	_	22	cop
22	unlikely	unlikely	JJ	_	7	conj
23	to	to	TO	_	24	mark
24	compete	compete	VB	_	22	xcomp
25	for	for	IN	_	29	case
26	the	the	DT	_	29	det
27	same	same	JJ	_	29	amod
28	metabolic	metabolic	JJ	_	29	amod
29	enzymes	enzyme	NNS	_	24	nmod
30	and	and	CC	_	29	cc
31	elimination	elimination	NN	_	32	compound
32	pathways	pathway	NNS	_	29	conj
33	.	.	.	_	7	punct

1	Formal	formal	JJ	_	4	amod
2	drug	drug	NN	_	4	compound
3	interaction	interaction	NN	_	4	compound
4	studies	study	NNS	_	10	nsubjpass
5	with	with	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	have	have	VBP	_	10	aux
8	not	not	RB	_	10	neg
9	been	be	VBN	_	10	auxpass
10	conducted	conduct	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	administered	administer	VBN	_	0	ROOT
5	to	to	TO	_	6	case
6	patients	patient	NNS	_	4	nmod
7	with	with	IN	_	10	case
8	ischemic	ischemic	JJ	_	10	amod
9	heart	heart	NN	_	10	compound
10	disease	disease	NN	_	6	nmod
11	treated	treat	VBN	_	10	acl
12	concomitantly	concomitantly	RB	_	11	advmod
13	with	with	IN	_	16	case
14	a	a	DT	_	16	det
15	broad	broad	JJ	_	16	amod
16	range	range	NN	_	11	nmod
17	of	of	IN	_	18	case
18	medications	medication	NNS	_	16	nmod
19	used	use	VBN	_	18	acl
20	in	in	IN	_	22	case
21	the	the	DT	_	22	det
22	treatment	treatment	NN	_	19	nmod
23	of	of	IN	_	26	case
24	angina	angina	NN	_	26	compound
25	myocardial	myocardial	JJ	_	26	amod
26	infarction	infarction	NN	_	22	nmod
27	and	and	CC	_	26	cc
28	hypertension	hypertension	NN	_	26	conj
29	.	.	.	_	4	punct

1	These	these	DT	_	2	det
2	medications	medication	NNS	_	4	nsubj
3	have	have	VBP	_	4	aux
4	included	include	VBN	_	0	ROOT
5	drug1	drug1	NN	_	18	compound
6	,	,	,	_	5	punct
7	drug2	drug2	NN	_	5	conj
8	,	,	,	_	5	punct
9	drug3	drug3	NN	_	5	conj
10	,	,	,	_	5	punct
11	drug4	drug4	NN	_	5	conj
12	,	,	,	_	5	punct
13	drug5	drug5	NN	_	5	conj
14	,	,	,	_	5	punct
15	intravenous	intravenous	JJ	_	5	conj
16	and	and	CC	_	5	cc
17	oral	oral	JJ	_	5	conj
18	drug6	drug6	NN	_	4	dobj
19	,	,	,	_	18	punct
20	drug7	drug7	NN	_	18	conj
21	,	,	,	_	18	punct
22	and	and	CC	_	18	cc
23	drug8	drug8	NN	_	18	conj
24	.	.	.	_	4	punct

1	drug1	drug1	NN	_	11	nsubjpass
2	,	,	,	_	1	punct
3	other	other	JJ	_	4	amod
4	drug2	drug2	NN	_	1	conj
5	,	,	,	_	1	punct
6	drug3	drug3	NN	_	1	conj
7	,	,	,	_	1	punct
8	and	and	CC	_	1	cc
9	drug4	drug4	NN	_	1	conj
10	are	be	VBP	_	11	auxpass
11	associated	associate	VBN	_	0	ROOT
12	with	with	IN	_	14	case
13	an	a	DT	_	14	det
14	increase	increase	NN	_	11	nmod
15	in	in	IN	_	16	case
16	bleeding	bleeding	NN	_	14	nmod
17	.	.	.	_	11	punct

1	Patients	patient	NNS	_	6	nsubj
2	with	with	IN	_	4	case
3	HACA	haca	NN	_	4	compound
4	titers	titer	NNS	_	1	nmod
5	may	may	MD	_	6	aux
6	have	have	VB	_	0	ROOT
7	allergic	allergic	JJ	_	10	amod
8	or	or	CC	_	7	cc
9	hypersensitivity	hypersensitivity	NN	_	7	conj
10	reactions	reaction	NNS	_	6	dobj
11	when	when	WRB	_	12	advmod
12	treated	treat	VBN	_	6	advcl
13	with	with	IN	_	15	case
14	other	other	JJ	_	15	amod
15	drug1	drug1	NN	_	12	nmod
16	or	or	CC	_	15	cc
17	drug2	drug2	NN	_	15	conj
18	.	.	.	_	6	punct

1	Effects	effect	NNS	_	14	advcl
2	of	of	IN	_	4	case
3	Other	other	JJ	_	4	amod
4	Drugs	drug	NNS	_	1	nmod
5	on	on	IN	_	6	case
6	drug1	drug1	NN	_	1	nmod
7	Based	base	VBN	_	6	acl
8	on	on	IN	_	10	case
9	in-vitro	in-vitro	FW	_	10	compound
10	studies	study	NNS	_	7	nmod
11	,	,	,	_	14	punct
12	drug2	drug2	NN	_	14	nsubjpass
13	is	be	VBZ	_	14	auxpass
14	metabolized	metabolize	VBN	_	0	ROOT
15	by	by	IN	_	17	case
16	CYP	cyp	NN	_	17	compound
17	3A4	3a4	NN	_	14	nmod
18	.	.	.	_	14	punct

1	Co-administration	co-administration	NN	_	26	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	,	,	,	_	3	punct
5	drug2	drug2	NN	_	3	conj
6	,	,	,	_	3	punct
7	drug3	drug3	NN	_	3	conj
8	,	,	,	_	3	punct
9	drug4	drug4	NN	_	3	conj
10	,	,	,	_	3	punct
11	drug5	drug5	NN	_	3	conj
12	,	,	,	_	3	punct
13	drug6	drug6	NN	_	3	conj
14	,	,	,	_	3	punct
15	drug7	drug7	NN	_	3	conj
16	,	,	,	_	3	punct
17	drug8	drug8	NN	_	3	conj
18	,	,	,	_	3	punct
19	drug9	drug9	NN	_	3	conj
20	,	,	,	_	3	punct
21	drug10	drug10	NN	_	3	conj
22	and	and	CC	_	3	cc
23	drug11	drug11	NN	_	3	conj
24	did	do	VBD	_	26	aux
25	not	not	RB	_	26	neg
26	result	result	VB	_	0	ROOT
27	in	in	IN	_	30	case
28	clinically	clinically	RB	_	29	advmod
29	significant	significant	JJ	_	30	amod
30	increases	increase	NNS	_	26	nmod
31	in	in	IN	_	33	case
32	drug12	drug12	NN	_	33	compound
33	exposure	exposure	NN	_	30	nmod
34	.	.	.	_	26	punct

1	Co-administration	co-administration	NN	_	4	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	reduced	reduce	VBD	_	0	ROOT
5	drug2	drug2	NN	_	6	compound
6	Cmax	cmax	NN	_	4	dobj
7	up	up	IN	_	9	advmod
8	to	to	TO	_	9	dep
9	50	50	CD	_	10	nummod
10	%	%	NN	_	4	nmod:npmod
11	after	after	IN	_	13	case
12	multiple	multiple	JJ	_	13	amod
13	dosing	dosing	NN	_	10	nmod
14	.	.	.	_	4	punct

1	Co-administration	co-administration	NN	_	4	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	resulted	result	VBD	_	0	ROOT
5	in	in	IN	_	10	case
6	about	about	IN	_	10	amod
7	a	a	DT	_	10	det
8	50	50	CD	_	9	compound
9	%	%	NN	_	10	amod
10	increase	increase	NN	_	4	nmod
11	in	in	IN	_	13	case
12	drug2	drug2	NN	_	13	compound
13	Cmax	cmax	NN	_	10	nmod
14	and	and	CC	_	13	cc
15	AUC	auc	NN	_	13	conj
16	after	after	IN	_	18	case
17	multiple	multiple	JJ	_	18	amod
18	dosing	dosing	NN	_	10	nmod
19	.	.	.	_	4	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Co-administration	co-administration	NN	_	11	nsubj
4	of	of	IN	_	8	case
5	200	200	CD	_	6	compound
6	mg	mg	NN	_	8	amod
7	twice-daily	twice-daily	JJ	_	8	amod
8	drug2	drug2	NN	_	3	nmod
9	with	with	IN	_	10	case
10	drug3	drug3	NN	_	3	nmod
11	resulted	result	VBD	_	1	appos
12	in	in	IN	_	17	case
13	an	a	DT	_	17	det
14	approximate	approximate	JJ	_	17	amod
15	80	80	CD	_	16	compound
16	%	%	NN	_	17	amod
17	increase	increase	NN	_	11	nmod
18	in	in	IN	_	20	case
19	plasma	plasma	NN	_	20	compound
20	levels	level	NNS	_	17	nmod
21	of	of	IN	_	22	case
22	drug4	drug4	NN	_	20	nmod
23	.	.	.	_	1	punct

1	A	a	DT	_	5	det
2	400	400	CD	_	3	compound
3	mg	mg	NN	_	5	amod
4	once-daily	once-daily	JJ	_	5	amod
5	dose	dose	NN	_	8	nsubjpass
6	was	be	VBD	_	8	auxpass
7	not	not	RB	_	8	neg
8	studied	study	VBN	_	0	ROOT
9	but	but	CC	_	8	cc
10	would	would	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	expected	expect	VBN	_	8	conj
13	to	to	TO	_	14	mark
14	increase	increase	VB	_	12	xcomp
15	drug1	drug1	NN	_	17	compound
16	blood	blood	NN	_	17	compound
17	levels	level	NNS	_	14	dobj
18	further	further	RB	_	14	advmod
19	.	.	.	_	8	punct

1	Effects	effect	NNS	_	10	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	on	on	IN	_	7	case
5	Other	other	JJ	_	7	amod
6	Drugs	drug	NNS	_	7	compound
7	drug2	drug2	NN	_	1	nmod
8	does	do	VBZ	_	10	aux
9	not	not	RB	_	10	neg
10	inhibit	inhibit	VB	_	0	ROOT
11	the	the	DT	_	13	det
12	CYP450	cyp450	NN	_	13	compound
13	isoenzymes	isoenzyme	NNS	_	10	dobj
14	-LRB-	-lrb-	-LRB-	_	15	punct
15	CYP1A2	cyp1a2	NN	_	13	dep
16	,	,	,	_	15	punct
17	2C8	2c8	NN	_	15	conj
18	,	,	,	_	15	punct
19	2C9	2c9	NN	_	15	conj
20	,	,	,	_	15	punct
21	2C19	2c19	NN	_	15	conj
22	,	,	,	_	15	punct
23	2D6	2d6	NN	_	15	conj
24	,	,	,	_	15	punct
25	2E1	2e1	NN	_	15	conj
26	,	,	,	_	15	punct
27	and	and	CC	_	15	cc
28	CYP	cyp	NN	_	29	compound
29	3A	3a	NN	_	15	conj
30	-RRB-	-rrb-	-RRB-	_	15	punct
31	or	or	CC	_	10	cc
32	induce	induce	VB	_	10	conj
33	CYP	cyp	NN	_	34	compound
34	3A4	3a4	NN	_	32	dobj
35	.	.	.	_	10	punct

1	Co-administration	co-administration	NN	_	7	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	did	do	VBD	_	7	aux
5	not	not	RB	_	7	neg
6	significantly	significantly	RB	_	7	advmod
7	affect	affect	VB	_	0	ROOT
8	the	the	DT	_	9	det
9	pharmacokinetics	pharmacokinetic	NNS	_	7	dobj
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	,	,	,	_	11	punct
13	drug3	drug3	NN	_	11	conj
14	,	,	,	_	11	punct
15	drug4	drug4	NN	_	11	conj
16	,	,	,	_	11	punct
17	drug5	drug5	NN	_	11	conj
18	,	,	,	_	11	punct
19	drug6	drug6	NN	_	11	conj
20	,	,	,	_	11	punct
21	drug7	drug7	NN	_	11	conj
22	,	,	,	_	11	punct
23	drug8	drug8	NN	_	11	conj
24	,	,	,	_	11	punct
25	drug9	drug9	NN	_	11	conj
26	,	,	,	_	11	punct
27	drug10	drug10	NN	_	11	conj
28	or	or	CC	_	11	cc
29	drug11	drug11	NN	_	11	conj
30	.	.	.	_	7	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	effects	effect	NNS	_	13	nsubjpass
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	on	on	IN	_	9	case
8	drug3	drug3	NN	_	9	compound
9	pharmacokinetics	pharmacokinetic	NNS	_	4	nmod
10	have	have	VBP	_	13	aux
11	not	not	RB	_	13	neg
12	been	be	VBN	_	13	auxpass
13	evaluated	evaluate	VBN	_	1	appos
14	in	in	IN	_	18	case
15	a	a	DT	_	18	det
16	well-controlled	well-controlled	JJ	_	18	amod
17	clinical	clinical	JJ	_	18	amod
18	trial	trial	NN	_	13	nmod
19	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	When	when	WRB	_	6	advmod
4	drug2	drug2	NN	_	6	nsubjpass
5	was	be	VBD	_	6	auxpass
6	co-administered	co-administer	VBN	_	17	advcl
7	with	with	IN	_	8	case
8	drug3	drug3	NN	_	6	nmod
9	,	,	,	_	17	punct
10	the	the	DT	_	11	det
11	AUC	auc	NN	_	17	nsubjpass
12	and	and	CC	_	11	cc
13	Cmax	cmax	NN	_	11	conj
14	of	of	IN	_	15	case
15	drug4	drug4	NN	_	11	nmod
16	were	be	VBD	_	17	auxpass
17	reduced	reduce	VBN	_	1	dep
18	by	by	IN	_	21	case
19	about	about	IN	_	20	advmod
20	30	30	CD	_	21	nummod
21	%	%	NN	_	17	nmod
22	and	and	CC	_	17	cc
23	50	50	CD	_	24	nummod
24	%	%	NN	_	17	conj
25	,	,	,	_	17	punct
26	respectively	respectively	RB	_	17	advmod
27	.	.	.	_	1	punct

1	No	no	DT	_	5	neg
2	formal	formal	JJ	_	5	amod
3	drug	drug	NN	_	5	compound
4	interaction	interaction	NN	_	5	compound
5	studies	study	NNS	_	10	nsubjpass
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	have	have	VBP	_	10	aux
9	been	be	VBN	_	10	auxpass
10	performed	perform	VBN	_	0	ROOT
11	.	.	.	_	10	punct

1	CYP450	cyp450	NN	_	4	compound
2	Metabolized	metabolize	VBN	_	4	amod
3	Drugs	drug	NNS	_	4	compound
4	Results	result	NNS	_	12	nsubj
5	from	from	IN	_	7	case
6	in	in	FW	_	7	compound
7	vitro	vitro	FW	_	4	nmod
8	and	and	CC	_	7	cc
9	in	in	FW	_	7	conj
10	vivo	vivo	FW	_	9	dep
11	studies	study	NNS	_	7	dep
12	suggest	suggest	VBP	_	0	ROOT
13	that	that	IN	_	16	mark
14	drug1	drug1	NN	_	16	nsubj
15	is	be	VBZ	_	16	cop
16	unlikely	unlikely	JJ	_	12	ccomp
17	to	to	TO	_	18	mark
18	have	have	VB	_	16	xcomp
19	significant	significant	JJ	_	21	amod
20	drug	drug	NN	_	21	compound
21	interactions	interaction	NNS	_	18	dobj
22	with	with	IN	_	25	case
23	concomitantly	concomitantly	RB	_	24	advmod
24	administered	administer	VBN	_	25	amod
25	drugs	drug	NNS	_	21	nmod
26	metabolized	metabolize	VBN	_	25	acl
27	by	by	IN	_	29	case
28	CYP450	cyp450	NN	_	29	compound
29	enzymes	enzyme	NNS	_	26	nmod
30	.	.	.	_	12	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	No	no	DT	_	5	neg
4	drug	drug	NN	_	5	compound
5	interactions	interaction	NNS	_	11	nsubjpass
6	with	with	IN	_	8	case
7	other	other	JJ	_	8	amod
8	drug2	drug2	NN	_	5	nmod
9	have	have	VBP	_	11	aux
10	been	be	VBN	_	11	auxpass
11	identified	identify	VBN	_	1	appos
12	that	that	WDT	_	14	nsubj
13	would	would	MD	_	14	aux
14	warrant	warrant	VB	_	11	ccomp
15	alteration	alteration	NN	_	14	dobj
16	of	of	IN	_	20	case
17	either	either	CC	_	20	cc:preconj
18	the	the	DT	_	20	det
19	drug3	drug3	NN	_	20	compound
20	dose	dose	NN	_	15	nmod
21	or	or	CC	_	20	cc
22	the	the	DT	_	23	det
23	dose	dose	NN	_	20	conj
24	of	of	IN	_	27	case
25	the	the	DT	_	27	det
26	other	other	JJ	_	27	amod
27	drug4	drug4	NN	_	23	nmod
28	.	.	.	_	1	punct

1	Certain	certain	JJ	_	2	amod
2	drugs	drug	NNS	_	3	nsubj
3	tend	tend	VBP	_	0	ROOT
4	to	to	TO	_	5	mark
5	produce	produce	VB	_	3	xcomp
6	hyperglycemia	hyperglycemia	NN	_	5	dobj
7	and	and	CC	_	3	cc
8	may	may	MD	_	9	aux
9	lead	lead	VB	_	3	conj
10	to	to	TO	_	11	case
11	loss	loss	NN	_	9	nmod
12	of	of	IN	_	15	case
13	blood	blood	NN	_	15	compound
14	glucose	glucose	NN	_	15	compound
15	control	control	NN	_	11	nmod
16	.	.	.	_	3	punct

1	These	these	DT	_	2	det
2	drugs	drug	NNS	_	3	nsubj
3	include	include	VBP	_	0	ROOT
4	the	the	DT	_	5	det
5	drug1	drug1	NN	_	3	dobj
6	and	and	CC	_	5	cc
7	other	other	JJ	_	8	amod
8	drug2	drug2	NN	_	5	conj
9	,	,	,	_	8	punct
10	drug3	drug3	NN	_	8	conj
11	,	,	,	_	8	punct
12	drug4	drug4	NN	_	8	conj
13	,	,	,	_	8	punct
14	drug5	drug5	NN	_	8	conj
15	,	,	,	_	8	punct
16	drug6	drug6	NN	_	8	conj
17	,	,	,	_	8	punct
18	oral	oral	JJ	_	19	amod
19	drug7	drug7	NN	_	8	conj
20	,	,	,	_	8	punct
21	drug8	drug8	NN	_	8	conj
22	,	,	,	_	8	punct
23	drug9	drug9	NN	_	8	conj
24	,	,	,	_	8	punct
25	drug10	drug10	NN	_	8	conj
26	,	,	,	_	8	punct
27	drug11	drug11	NN	_	8	conj
28	,	,	,	_	8	punct
29	and	and	CC	_	8	cc
30	drug12	drug12	NN	_	8	conj
31	.	.	.	_	3	punct

1	When	when	WRB	_	5	advmod
2	such	such	JJ	_	3	amod
3	drugs	drug	NNS	_	5	nsubjpass
4	are	be	VBP	_	5	auxpass
5	administered	administer	VBN	_	17	advcl
6	to	to	TO	_	8	case
7	a	a	DT	_	8	det
8	patient	patient	NN	_	5	nmod
9	receiving	receive	VBG	_	8	acl
10	drug1	drug1	NN	_	9	dobj
11	,	,	,	_	17	punct
12	the	the	DT	_	13	det
13	patient	patient	NN	_	17	nsubjpass
14	should	should	MD	_	17	aux
15	be	be	VB	_	17	auxpass
16	closely	closely	RB	_	17	advmod
17	observed	observe	VBN	_	0	ROOT
18	for	for	IN	_	19	case
19	loss	loss	NN	_	17	nmod
20	of	of	IN	_	23	case
21	blood	blood	NN	_	23	compound
22	glucose	glucose	NN	_	23	compound
23	control	control	NN	_	19	nmod
24	.	.	.	_	17	punct

1	When	when	WRB	_	5	advmod
2	such	such	JJ	_	3	amod
3	drugs	drug	NNS	_	5	nsubjpass
4	are	be	VBP	_	5	auxpass
5	withdrawn	withdraw	VBN	_	20	advcl
6	from	from	IN	_	7	case
7	patients	patient	NNS	_	5	nmod
8	receiving	receive	VBG	_	7	acl
9	drug1	drug1	NN	_	8	dobj
10	in	in	IN	_	11	case
11	combination	combination	NN	_	8	nmod
12	with	with	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	or	or	CC	_	13	cc
15	drug3	drug3	NN	_	13	conj
16	,	,	,	_	20	punct
17	patients	patient	NNS	_	20	nsubjpass
18	should	should	MD	_	20	aux
19	be	be	VB	_	20	auxpass
20	observed	observe	VBN	_	0	ROOT
21	closely	closely	RB	_	20	advmod
22	for	for	IN	_	24	case
23	any	any	DT	_	24	det
24	evidence	evidence	NN	_	20	nmod
25	of	of	IN	_	26	case
26	hypoglycemia	hypoglycemia	NN	_	24	nmod
27	.	.	.	_	20	punct

1	drug1	drug1	NN	_	22	nsubj
2	-LRB-	-lrb-	-LRB-	_	4	punct
3	e.	e.	FW	_	4	compound
4	g.	g.	FW	_	1	dep
5	,	,	,	_	4	punct
6	drug2	drug2	NN	_	4	appos
7	-RRB-	-rrb-	-RRB-	_	4	punct
8	and	and	CC	_	1	cc
9	drug3	drug3	NN	_	1	conj
10	containing	contain	VBG	_	9	acl
11	carbohydrate-splitting	carbohydrate-splitting	JJ	_	12	amod
12	enzymes	enzyme	NNS	_	10	dobj
13	-LRB-	-lrb-	-LRB-	_	15	punct
14	e.	e.	FW	_	15	compound
15	g.	g.	FW	_	12	dep
16	,	,	,	_	15	punct
17	drug4	drug4	NN	_	15	appos
18	,	,	,	_	15	punct
19	drug5	drug5	NN	_	15	appos
20	-RRB-	-rrb-	-RRB-	_	15	punct
21	may	may	MD	_	22	aux
22	reduce	reduce	VB	_	0	ROOT
23	the	the	DT	_	24	det
24	effect	effect	NN	_	22	dobj
25	of	of	IN	_	26	case
26	drug6	drug6	NN	_	24	nmod
27	and	and	CC	_	22	cc
28	should	should	MD	_	31	aux
29	not	not	RB	_	31	neg
30	be	be	VB	_	31	auxpass
31	taken	take	VBN	_	22	conj
32	concomitantly	concomitantly	RB	_	31	advmod
33	.	.	.	_	22	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	shown	show	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	change	change	VB	_	4	xcomp
7	the	the	DT	_	9	det
8	bioavailabillty	bioavailabillty	NN	_	9	compound
9	drug2	drug2	NN	_	6	dobj
10	when	when	WRB	_	13	advmod
11	they	they	PRP	_	13	nsubj
12	are	be	VBP	_	13	cop
13	co-administered	co-administered	JJ	_	6	advcl
14	,	,	,	_	6	punct
15	which	which	WDT	_	17	nsubj
16	may	may	MD	_	17	aux
17	require	require	VB	_	6	dep
18	drug3	drug3	NN	_	20	compound
19	dose	dose	NN	_	20	compound
20	adjustment	adjustment	NN	_	17	dobj
21	.	.	.	_	4	punct

1	Studies	study	NNS	_	6	nsubj
2	in	in	IN	_	4	case
3	healthy	healthy	JJ	_	4	amod
4	volunteers	volunteer	NNS	_	1	nmod
5	have	have	VBP	_	6	aux
6	shown	show	VBN	_	0	ROOT
7	that	that	IN	_	9	mark
8	drug1	drug1	NN	_	9	nsubj
9	has	have	VBZ	_	6	ccomp
10	no	no	DT	_	11	neg
11	effect	effect	NN	_	9	dobj
12	on	on	IN	_	15	case
13	either	either	CC	_	15	cc:preconj
14	the	the	DT	_	15	det
15	pharmacokinetics	pharmacokinetic	NNS	_	9	nmod
16	or	or	CC	_	15	cc
17	pharmacodynamics	pharmacodynamic	NNS	_	15	conj
18	of	of	IN	_	19	case
19	drug2	drug2	NN	_	15	nmod
20	,	,	,	_	19	punct
21	drug3	drug3	NN	_	19	conj
22	,	,	,	_	19	punct
23	drug4	drug4	NN	_	19	conj
24	,	,	,	_	19	punct
25	or	or	CC	_	19	cc
26	drug5	drug5	NN	_	19	conj
27	.	.	.	_	6	punct

1	drug1	drug1	NN	_	4	nsubj
2	did	do	VBD	_	4	aux
3	not	not	RB	_	4	neg
4	interfere	interfere	VB	_	0	ROOT
5	with	with	IN	_	7	case
6	the	the	DT	_	7	det
7	absorption	absorption	NN	_	4	nmod
8	or	or	CC	_	7	cc
9	disposition	disposition	NN	_	7	conj
10	of	of	IN	_	13	case
11	the	the	DT	_	13	det
12	drug2	drug2	NN	_	13	compound
13	drug3	drug3	NN	_	7	nmod
14	in	in	IN	_	16	case
15	diabetic	diabetic	JJ	_	16	amod
16	patients	patient	NNS	_	7	nmod
17	.	.	.	_	4	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	affect	affect	VB	_	0	ROOT
4	drug2	drug2	NN	_	5	compound
5	bioavailabillty	bioavailabillty	NN	_	3	dobj
6	and	and	CC	_	3	cc
7	may	may	MD	_	8	aux
8	require	require	VB	_	3	conj
9	dose	dose	NN	_	10	compound
10	adjustment	adjustment	NN	_	8	dobj
11	of	of	IN	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	by	by	IN	_	15	case
14	16	16	CD	_	15	nummod
15	%	%	NN	_	8	nmod
16	-LRB-	-lrb-	-LRB-	_	20	punct
17	90	90	CD	_	18	compound
18	%	%	NN	_	20	amod
19	confidence	confidence	NN	_	20	compound
20	interval	interval	NN	_	15	dep
21	:	:	:	_	20	punct
22	8-23	8-23	CD	_	23	nummod
23	%	%	NN	_	20	dep
24	-RRB-	-rrb-	-RRB-	_	20	punct
25	,	,	,	_	3	punct
26	decrease	decrease	NN	_	30	compound
27	mean	mean	NN	_	30	compound
28	C	c	NN	_	30	compound
29	max	max	NN	_	30	compound
30	drug4	drug4	NN	_	25	root
31	by	by	IN	_	33	case
32	26	26	CD	_	33	nummod
33	%	%	NN	_	30	nmod
34	-LRB-	-lrb-	-LRB-	_	38	punct
35	90	90	CD	_	36	compound
36	%	%	NN	_	38	amod
37	confidence	confidence	NN	_	38	compound
38	interval	interval	NN	_	33	dep
39	:	:	:	_	38	punct
40	16-34	16-34	CD	_	41	nummod
41	%	%	NN	_	38	dep
42	-RRB-	-rrb-	-RRB-	_	38	punct
43	and	and	CC	_	30	cc
44	decrease	decrease	VB	_	30	conj
45	mean	mean	JJ	_	47	amod
46	trough	trough	NN	_	47	compound
47	concentrations	concentration	NNS	_	44	dobj
48	of	of	IN	_	49	case
49	drug5	drug5	NN	_	47	nmod
50	by	by	IN	_	52	case
51	9	9	CD	_	52	nummod
52	%	%	NN	_	44	nmod
53	-LRB-	-lrb-	-LRB-	_	57	punct
54	90	90	CD	_	55	compound
55	%	%	NN	_	57	amod
56	confidence	confidence	NN	_	57	compound
57	limit	limit	NN	_	52	dep
58	:	:	:	_	57	punct
59	19	19	CD	_	60	compound
60	%	%	NN	_	61	amod
61	decrease	decrease	NN	_	57	dep
62	to	to	TO	_	64	dep
63	2	2	CD	_	64	compound
64	%	%	NN	_	61	nmod
65	increase	increase	NN	_	64	dep
66	-RRB-	-rrb-	-RRB-	_	57	punct
67	.	.	.	_	30	punct

1	The	the	DT	_	2	det
2	amount	amount	NN	_	5	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	absorbed	absorb	VBN	_	10	csubj
6	while	while	IN	_	7	mark
7	taking	take	VBG	_	5	advcl
8	drug2	drug2	NN	_	7	dobj
9	was	be	VBD	_	10	cop
10	bioequivalent	bioequivalent	JJ	_	0	ROOT
11	to	to	TO	_	13	case
12	the	the	DT	_	13	det
13	amount	amount	NN	_	10	nmod
14	absorbed	absorb	VBN	_	13	acl
15	when	when	WRB	_	16	advmod
16	taking	take	VBG	_	14	advcl
17	placebo	placebo	NN	_	16	dobj
18	,	,	,	_	10	punct
19	as	as	IN	_	20	mark
20	indicated	indicate	VBN	_	10	advcl
21	by	by	IN	_	25	case
22	the	the	DT	_	25	det
23	plasma	plasma	NN	_	25	compound
24	AUC	auc	NN	_	25	compound
25	values	value	NNS	_	20	nmod
26	.	.	.	_	10	punct

1	However	however	RB	_	10	advmod
2	,	,	,	_	10	punct
3	the	the	DT	_	6	det
4	peak	peak	NN	_	6	compound
5	plasma	plasma	NN	_	6	compound
6	level	level	NN	_	10	nsubjpass
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	was	be	VBD	_	10	auxpass
10	reduced	reduce	VBN	_	0	ROOT
11	by	by	IN	_	14	case
12	approximately	approximately	RB	_	13	advmod
13	20	20	CD	_	14	nummod
14	%	%	NN	_	10	nmod
15	when	when	WRB	_	16	advmod
16	taking	take	VBG	_	10	advcl
17	drug2	drug2	NN	_	16	dobj
18	due	due	JJ	_	22	case
19	to	to	TO	_	18	mwe
20	a	a	DT	_	22	det
21	slight	slight	JJ	_	22	amod
22	delay	delay	NN	_	16	nmod
23	in	in	IN	_	25	case
24	the	the	DT	_	25	det
25	absorption	absorption	NN	_	22	nmod
26	of	of	IN	_	27	case
27	drug3	drug3	NN	_	25	nmod
28	.	.	.	_	10	punct

1	There	there	EX	_	2	expl
2	is	be	VBZ	_	0	ROOT
3	little	little	JJ	_	2	nsubj
4	if	if	IN	_	3	dep
5	any	any	DT	_	8	det
6	clinically	clinically	RB	_	7	advmod
7	significant	significant	JJ	_	8	amod
8	interaction	interaction	NN	_	4	dep
9	between	between	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	drug2	drug2	NN	_	10	conj
13	.	.	.	_	2	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	interact	interact	VB	_	0	ROOT
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	-LRB-	-lrb-	-LRB-	_	9	punct
7	e.g.	e.g.	FW	_	9	dep
8	,	,	,	_	9	punct
9	drug3	drug3	NN	_	5	appos
10	-RRB-	-rrb-	-RRB-	_	9	punct
11	,	,	,	_	5	punct
12	drug4	drug4	NN	_	5	conj
13	-LRB-	-lrb-	-LRB-	_	16	punct
14	e.g.	e.g.	FW	_	16	dep
15	,	,	,	_	16	punct
16	drug5	drug5	NN	_	12	dep
17	-RRB-	-rrb-	-RRB-	_	16	punct
18	,	,	,	_	5	punct
19	local	local	JJ	_	20	amod
20	drug6	drug6	NN	_	5	conj
21	-LRB-	-lrb-	-LRB-	_	24	punct
22	e.g.	e.g.	FW	_	24	dep
23	,	,	,	_	24	punct
24	drug7	drug7	NN	_	20	dep
25	and	and	CC	_	24	cc
26	drug8	drug8	NN	_	24	conj
27	-RRB-	-rrb-	-RRB-	_	24	punct
28	,	,	,	_	5	punct
29	drug9	drug9	NN	_	5	conj
30	-LRB-	-lrb-	-LRB-	_	31	punct
31	drug10	drug10	NN	_	29	appos
32	-RRB-	-rrb-	-RRB-	_	31	punct
33	-	-	:	_	5	punct
34	containing	contain	VBG	_	5	acl
35	preparations	preparation	NNS	_	34	dobj
36	-LRB-	-lrb-	-LRB-	_	39	punct
37	e.g.	e.g.	FW	_	39	dep
38	,	,	,	_	39	punct
39	sunscreens	sunscreen	NNS	_	35	dep
40	and	and	CC	_	39	cc
41	some	some	DT	_	42	det
42	drug11	drug11	NN	_	39	conj
43	-RRB-	-rrb-	-RRB-	_	39	punct
44	,	,	,	_	35	punct
45	drug12	drug12	NN	_	35	conj
46	-LRB-	-lrb-	-LRB-	_	49	punct
47	e.g.	e.g.	FW	_	49	dep
48	,	,	,	_	49	punct
49	drug13	drug13	NN	_	45	appos
50	-RRB-	-rrb-	-RRB-	_	49	punct
51	,	,	,	_	35	punct
52	drug14	drug14	NN	_	35	conj
53	-LRB-	-lrb-	-LRB-	_	55	punct
54	sulfa	sulfa	NN	_	55	compound
55	medicines	medicine	NNS	_	52	appos
56	-RRB-	-rrb-	-RRB-	_	55	punct
57	,	,	,	_	35	punct
58	drug15	drug15	NN	_	60	compound
59	-LRB-	-lrb-	-LRB-	_	60	punct
60	use	use	NN	_	35	conj
61	of	of	IN	_	63	case
62	these	these	DT	_	63	det
63	medicines	medicine	NNS	_	60	nmod
64	during	during	IN	_	67	case
65	the	the	DT	_	67	det
66	test	test	NN	_	67	compound
67	period	period	NN	_	60	nmod
68	will	will	MD	_	69	aux
69	affect	affect	VB	_	3	dep
70	the	the	DT	_	71	det
71	test	test	NN	_	72	nsubj
72	results	result	VBZ	_	69	ccomp
73	-RRB-	-rrb-	-RRB-	_	69	punct
74	,	,	,	_	69	punct
75	and	and	CC	_	69	cc
76	pancreatic	pancreatic	JJ	_	77	amod
77	supplements	supplement	NNS	_	69	conj
78	-LRB-	-lrb-	-LRB-	_	79	punct
79	use	use	NN	_	84	nsubj
80	of	of	IN	_	82	case
81	pancreatic	pancreatic	JJ	_	82	amod
82	supplements	supplement	NNS	_	79	nmod
83	may	may	MD	_	84	aux
84	give	give	VB	_	77	acl:relcl
85	false	false	JJ	_	87	amod
86	test	test	NN	_	87	compound
87	results	result	NNS	_	84	dobj
88	-RRB-	-rrb-	-RRB-	_	3	punct
89	.	.	.	_	3	punct

1	Known	know	VBN	_	3	amod
2	drug	drug	NN	_	3	compound
3	interactions	interaction	NNS	_	4	nsubj
4	include	include	VBP	_	0	ROOT
5	drug1	drug1	NN	_	4	dobj
6	,	,	,	_	5	punct
7	drug2	drug2	NN	_	5	conj
8	,	,	,	_	5	punct
9	and	and	CC	_	5	cc
10	drug3	drug3	NN	_	5	conj
11	.	.	.	_	4	punct

1	drug1	drug1	NN	_	5	nsubj
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	may	may	MD	_	5	aux
5	interact	interact	VB	_	16	ccomp
6	with	with	IN	_	7	case
7	drug3	drug3	NN	_	5	nmod
8	In	in	IN	_	9	case
9	studies	study	NNS	_	5	nmod
10	with	with	IN	_	12	case
11	male	male	JJ	_	12	amod
12	rats	rat	NNS	_	9	nmod
13	,	,	,	_	16	punct
14	drug4	drug4	NN	_	16	nsubjpass
15	was	be	VBD	_	16	auxpass
16	found	find	VBN	_	0	ROOT
17	to	to	TO	_	18	mark
18	inhibit	inhibit	VB	_	16	xcomp
19	the	the	DT	_	23	det
20	hepatic	hepatic	JJ	_	23	amod
21	microsomal	microsomal	JJ	_	23	amod
22	enzyme	enzyme	NN	_	23	compound
23	system	system	NN	_	18	dobj
24	at	at	IN	_	26	case
25	a	a	DT	_	26	det
26	dose	dose	NN	_	18	nmod
27	of	of	IN	_	29	case
28	2	2	CD	_	29	nummod
29	mg/kg/day	mg/kg/day	NN	_	26	nmod
30	.	.	.	_	16	punct

1	Therefore	therefore	RB	_	4	advmod
2	,	,	,	_	4	punct
3	drug1	drug1	NN	_	4	nsubj
4	has	have	VBZ	_	0	ROOT
5	the	the	DT	_	6	det
6	potential	potential	JJ	_	4	dobj
7	to	to	TO	_	8	mark
8	prolong	prolong	VB	_	6	acl
9	the	the	DT	_	11	det
10	biological	biological	JJ	_	11	amod
11	half-lives	half-life	NNS	_	8	dobj
12	of	of	IN	_	13	case
13	drugs	drug	NNS	_	11	nmod
14	for	for	IN	_	15	case
15	which	which	WDT	_	21	nmod
16	the	the	DT	_	17	det
17	rate	rate	NN	_	21	nsubj
18	of	of	IN	_	19	case
19	elimination	elimination	NN	_	17	nmod
20	is	be	VBZ	_	21	cop
21	dependent	dependent	JJ	_	13	acl:relcl
22	on	on	IN	_	25	case
23	the	the	DT	_	25	det
24	microsomal	microsomal	JJ	_	25	amod
25	drug	drug	NN	_	21	nmod
26	metabolizing	metabolize	VBG	_	28	amod
27	enzyme	enzyme	NN	_	28	compound
28	system	system	NN	_	25	dep
29	.	.	.	_	4	punct

1	Interacts	interact	NNS	_	0	ROOT
2	with	with	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod

1	No	no	DT	_	5	neg
2	formal	formal	JJ	_	5	amod
3	drug	drug	NN	_	5	compound
4	interaction	interaction	NN	_	5	compound
5	studies	study	NNS	_	8	nsubjpass
6	have	have	VBP	_	8	aux
7	been	be	VBN	_	8	auxpass
8	performed	perform	VBN	_	0	ROOT
9	with	with	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	.	.	.	_	8	punct

1	May	May	NNP	_	2	nsubj
2	interact	interact	VBP	_	0	ROOT
3	with	with	IN	_	5	case
4	the	the	DT	_	5	det
5	following	following	NN	_	2	nmod
6	:	:	:	_	2	punct
7	drug1	drug1	NN	_	2	dep
8	-LRB-	-lrb-	-LRB-	_	12	punct
9	these	these	DT	_	10	det
10	medicines	medicine	NNS	_	12	nsubj
11	may	may	MD	_	12	aux
12	make	make	VB	_	7	dep
13	your	you	PRP$	_	14	nmod:poss
14	condition	condition	NN	_	15	nsubj
15	worse	worse	JJR	_	12	xcomp
16	and	and	CC	_	12	cc
17	prevent	prevent	VB	_	12	conj
18	the	the	DT	_	19	det
19	drug2	drug2	NN	_	17	dobj
20	from	from	IN	_	21	mark
21	working	work	VBG	_	17	advcl
22	properly	properly	RB	_	21	advmod
23	-RRB-	-rrb-	-RRB-	_	12	punct
24	and	and	CC	_	7	cc
25	drug3	drug3	NN	_	7	conj
26	,	,	,	_	25	punct
27	drug4	drug4	NN	_	25	conj
28	,	,	,	_	25	punct
29	drug5	drug5	NN	_	25	conj
30	,	,	,	_	25	punct
31	and	and	CC	_	25	cc
32	drug6	drug6	NN	_	25	conj
33	-LRB-	-lrb-	-LRB-	_	37	punct
34	these	these	DT	_	35	det
35	medicines	medicine	NNS	_	37	nsubj
36	may	may	MD	_	37	aux
37	increase	increase	VB	_	25	dep
38	the	the	DT	_	39	det
39	risk	risk	NN	_	37	dobj
40	of	of	IN	_	42	case
41	heart	heart	NN	_	42	compound
42	problems	problem	NNS	_	39	nmod
43	-RRB-	-rrb-	-RRB-	_	37	punct
44	.	.	.	_	2	punct

1	Interactions	interaction	NNS	_	0	ROOT
2	for	for	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	-LRB-	-lrb-	-LRB-	_	5	punct
5	drug2	drug2	NN	_	3	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	:	:	:	_	1	punct
8	drug3	drug3	NN	_	9	compound
9	Therapy	therapy	NN	_	1	dep
10	:	:	:	_	9	punct
11	drug4	drug4	NN	_	13	nsubj
12	may	may	MD	_	13	aux
13	potentiate	potentiate	VB	_	9	dep
14	the	the	DT	_	15	det
15	effects	effect	NNS	_	13	dobj
16	of	of	IN	_	17	case
17	drug5	drug5	NN	_	15	nmod
18	and	and	CC	_	17	cc
19	vasoactive	vasoactive	JJ	_	20	amod
20	drugs	drug	NNS	_	17	conj
21	resulting	result	VBG	_	15	acl
22	in	in	IN	_	24	case
23	postural	postural	JJ	_	24	amod
24	hypotension	hypotension	NN	_	21	nmod
25	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concomitant	concomitant	JJ	_	4	amod
4	drug2	drug2	NN	_	6	nsubj
5	may	may	MD	_	6	aux
6	decrease	decrease	VB	_	1	dep
7	the	the	DT	_	9	det
8	metabolic	metabolic	JJ	_	9	amod
9	clearance	clearance	NN	_	6	dobj
10	of	of	IN	_	11	case
11	drug3	drug3	NN	_	9	nmod
12	.	.	.	_	1	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	relevance	relevance	NN	_	8	nsubj
4	of	of	IN	_	6	case
5	this	this	DT	_	6	det
6	finding	finding	NN	_	3	nmod
7	is	be	VBZ	_	8	cop
8	unclear	unclear	JJ	_	0	ROOT
9	.	.	.	_	8	punct

1	Other	other	JJ	_	0	ROOT
2	:	:	:	_	1	punct
3	Concomitant	concomitant	JJ	_	4	amod
4	drug1	drug1	NN	_	9	nsubj
5	or	or	CC	_	4	cc
6	hot	hot	JJ	_	7	amod
7	drinks	drink	NNS	_	4	conj
8	may	may	MD	_	9	aux
9	increase	increase	VB	_	1	parataxis
10	the	the	DT	_	12	det
11	side	side	JJ	_	12	amod
12	effects	effect	NNS	_	9	dobj
13	of	of	IN	_	14	case
14	flushing	flushing	NN	_	12	nmod
15	and	and	CC	_	14	cc
16	pruritus	pruritus	NN	_	14	conj
17	and	and	CC	_	9	cc
18	should	should	MD	_	20	aux
19	be	be	VB	_	20	auxpass
20	avoided	avoid	VBN	_	9	conj
21	at	at	IN	_	23	case
22	the	the	DT	_	23	det
23	time	time	NN	_	20	nmod
24	of	of	IN	_	26	case
25	drug	drug	NN	_	26	compound
26	ingestion	ingestion	NN	_	23	nmod
27	.	.	.	_	1	punct

1	The	the	DT	_	3	det
2	following	follow	VBG	_	3	amod
3	agents	agent	NNS	_	5	nsubj
4	may	may	MD	_	5	aux
5	increase	increase	VB	_	0	ROOT
6	certain	certain	JJ	_	7	amod
7	actions	action	NNS	_	5	dobj
8	or	or	CC	_	7	cc
9	side	side	JJ	_	10	amod
10	effects	effect	NNS	_	7	conj
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	.	.	.	_	5	punct
14	drug2	drug2	NN	_	15	compound
15	drug3	drug3	NN	_	5	dep
16	of	of	IN	_	17	case
17	class	class	NN	_	15	nmod
18	-LRB-	-lrb-	-LRB-	_	20	punct
19	e.g.	e.g.	FW	_	20	dep
20	drug4	drug4	NN	_	17	appos
21	-RRB-	-rrb-	-RRB-	_	20	punct
22	,	,	,	_	17	punct
23	drug5	drug5	NN	_	24	compound
24	drug6	drug6	NN	_	17	appos
25	-LRB-	-lrb-	-LRB-	_	27	punct
26	e.g.	e.g.	FW	_	27	dep
27	drug7	drug7	FW	_	24	dep
28	-RRB-	-rrb-	-RRB-	_	27	punct
29	,	,	,	_	17	punct
30	drug8	drug8	NN	_	17	appos
31	.	.	.	_	5	punct

1	drug1	drug1	NN	_	0	ROOT
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	-LRB-	-lrb-	-LRB-	_	7	punct
5	e.g.	e.g.	FW	_	7	dep
6	,	,	,	_	7	punct
7	drug3	drug3	NN	_	3	dep
8	-RRB-	-rrb-	-RRB-	_	7	punct
9	,	,	,	_	1	punct
10	drug4	drug4	NN	_	1	conj
11	and	and	CC	_	1	cc
12	drug5	drug5	NN	_	1	conj
13	,	,	,	_	1	punct
14	drug6	drug6	NN	_	1	conj
15	,	,	,	_	1	punct
16	drug7	drug7	NN	_	1	conj
17	,	,	,	_	1	punct
18	and	and	CC	_	1	cc
19	other	other	JJ	_	20	amod
20	drugs	drug	NNS	_	21	nsubj
21	having	have	VBG	_	1	conj
22	anticholinergic	anticholinergic	JJ	_	23	amod
23	activity	activity	NN	_	21	dobj
24	.	.	.	_	1	punct

1	drug1	drug1	NN	_	2	nsubj
2	antagonize	antagonize	VBP	_	0	ROOT
3	the	the	DT	_	4	det
4	effects	effect	NNS	_	2	dobj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	.	.	.	_	2	punct

1	drug1	drug1	NN	_	11	nsubj
2	in	in	IN	_	4	case
3	the	the	DT	_	4	det
4	presence	presence	NN	_	1	nmod
5	of	of	IN	_	8	case
6	increased	increase	VBN	_	8	amod
7	intraocular	intraocular	JJ	_	8	amod
8	pressure	pressure	NN	_	4	nmod
9	may	may	MD	_	11	aux
10	be	be	VB	_	11	cop
11	hazardous	hazardous	JJ	_	0	ROOT
12	when	when	WRB	_	13	advmod
13	taken	take	VBN	_	11	advcl
14	concurrently	concurrently	RB	_	13	advmod
15	with	with	IN	_	16	case
16	agents	agent	NNS	_	13	nmod
17	such	such	JJ	_	20	case
18	as	as	IN	_	17	mwe
19	corti	corti	NN	_	20	compound
20	costeroids	costeroid	NNS	_	16	nmod
21	.	.	.	_	11	punct
22	.	.	.	_	11	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	affect	affect	VB	_	0	ROOT
4	gastrointestinal	gastrointestinal	JJ	_	5	amod
5	absorption	absorption	NN	_	3	dobj
6	of	of	IN	_	8	case
7	various	various	JJ	_	8	amod
8	drugs	drug	NNS	_	5	nmod
9	,	,	,	_	8	punct
10	such	such	JJ	_	13	mark
11	as	as	IN	_	10	mwe
12	slowly	slowly	RB	_	13	advmod
13	dissolving	dissolve	VBG	_	8	acl
14	dosage	dosage	JJ	_	15	amod
15	forms	form	NNS	_	13	dobj
16	of	of	IN	_	17	case
17	drug2	drug2	NN	_	15	nmod
18	;	;	:	_	3	punct

1	increased	increase	VBN	_	4	amod
2	serum	serum	NN	_	4	compound
3	drug1	drug1	NN	_	4	compound
4	concentrations	concentration	NNS	_	6	nsubj
5	may	may	MD	_	6	aux
6	result	result	VB	_	0	ROOT
7	.	.	.	_	6	punct

1	drug1	drug1	NN	_	3	nsubj
2	may	may	MD	_	3	aux
3	antagonize	antagonize	VB	_	0	ROOT
4	the	the	DT	_	5	det
5	effects	effect	NNS	_	3	dobj
6	of	of	IN	_	8	case
7	the	the	DT	_	8	det
8	drugs	drug	NNS	_	5	nmod
9	that	that	WDT	_	10	nsubj
10	alter	alter	VBP	_	8	acl:relcl
11	gastrointestinal	gastrointestinal	JJ	_	12	amod
12	motility	motility	NN	_	10	dobj
13	,	,	,	_	12	punct
14	such	such	JJ	_	16	case
15	as	as	IN	_	14	mwe
16	drug2	drug2	NN	_	12	nmod
17	.	.	.	_	3	punct

1	Because	because	IN	_	4	mark
2	drug1	drug1	NN	_	4	nsubj
3	may	may	MD	_	4	aux
4	interfere	interfere	VB	_	18	advcl
5	with	with	IN	_	7	case
6	the	the	DT	_	7	det
7	absorption	absorption	NN	_	4	nmod
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	,	,	,	_	18	punct
11	simultaneous	simultaneous	JJ	_	12	amod
12	use	use	NN	_	18	nsubjpass
13	of	of	IN	_	15	case
14	these	these	DT	_	15	det
15	drugs	drug	NNS	_	12	nmod
16	should	should	MD	_	18	aux
17	be	be	VB	_	18	auxpass
18	avoided	avoid	VBN	_	0	ROOT
19	.	.	.	_	18	punct

1	The	the	DT	_	3	det
2	inhibiting	inhibiting	JJ	_	3	amod
3	effects	effect	NNS	_	12	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	on	on	IN	_	10	case
7	gastric	gastric	JJ	_	10	amod
8	hydrochloric	hydrochloric	JJ	_	10	amod
9	acid	acid	NN	_	10	compound
10	secretion	secretion	NN	_	3	nmod
11	are	be	VBP	_	12	auxpass
12	antagonized	antagonize	VBN	_	0	ROOT
13	by	by	IN	_	14	case
14	agents	agent	NNS	_	12	nmod
15	used	use	VBN	_	14	acl
16	to	to	TO	_	17	mark
17	treat	treat	VB	_	15	xcomp
18	achlorhydria	achlorhydria	NN	_	17	dobj
19	and	and	CC	_	18	cc
20	those	those	DT	_	18	conj
21	used	use	VBN	_	20	acl
22	to	to	TO	_	23	mark
23	test	test	VB	_	21	xcomp
24	gastric	gastric	JJ	_	25	amod
25	secretion	secretion	NN	_	23	dobj
26	.	.	.	_	12	punct

1	No	no	DT	_	3	neg
2	dose	dose	NN	_	3	compound
3	adjustment	adjustment	NN	_	5	nsubj
4	is	be	VBZ	_	5	cop
5	necessary	necessary	JJ	_	0	ROOT
6	when	when	WRB	_	9	advmod
7	drug1	drug1	NN	_	9	nsubjpass
8	is	be	VBZ	_	9	auxpass
9	added	add	VBN	_	5	advcl
10	to	to	TO	_	12	case
11	triple-immunosuppression	triple-immunosuppression	JJ	_	12	amod
12	regimens	regimen	NNS	_	9	nmod
13	including	include	VBG	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	,	,	,	_	14	punct
16	drug3	drug3	NN	_	14	conj
17	,	,	,	_	14	punct
18	and	and	CC	_	14	cc
19	either	either	CC	_	20	cc:preconj
20	drug4	drug4	NN	_	14	conj
21	or	or	CC	_	20	cc
22	drug5	drug5	NN	_	20	conj
23	.	.	.	_	5	punct

1	Three	three	CD	_	3	nummod
2	clinical	clinical	JJ	_	3	amod
3	trials	trial	NNS	_	5	nsubj
4	have	have	VBP	_	5	aux
5	investigated	investigate	VBN	_	0	ROOT
6	drug1	drug1	NN	_	7	compound
7	use	use	NN	_	5	dobj
8	in	in	IN	_	9	case
9	combination	combination	NN	_	5	nmod
10	with	with	IN	_	12	case
11	triple-therapy	triple-therapy	JJ	_	12	amod
12	regimens	regimen	NNS	_	9	nmod
13	.	.	.	_	5	punct

1	Pharmacokinetics	pharmacokinetic	NNS	_	3	nsubjpass
2	were	be	VBD	_	3	auxpass
3	assessed	assess	VBN	_	0	ROOT
4	in	in	IN	_	5	case
5	two	two	CD	_	3	nmod
6	of	of	IN	_	8	case
7	these	these	DT	_	8	det
8	trials	trial	NNS	_	5	nmod
9	.	.	.	_	3	punct

1	Total	total	JJ	_	3	amod
2	body	body	NN	_	3	compound
3	clearance	clearance	NN	_	7	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	was	be	VBD	_	7	auxpass
7	reduced	reduce	VBN	_	0	ROOT
8	by	by	IN	_	12	case
9	an	a	DT	_	12	det
10	average	average	JJ	_	12	amod
11	22	22	CD	_	12	nummod
12	%	%	NN	_	7	nmod
13	and	and	CC	_	12	cc
14	51	51	CD	_	15	nummod
15	%	%	NN	_	12	conj
16	when	when	WRB	_	24	advmod
17	drug2	drug2	NN	_	24	nsubjpass
18	and	and	CC	_	17	cc
19	drug3	drug3	NN	_	17	conj
20	,	,	,	_	17	punct
21	respectively	respectively	RB	_	17	advmod
22	,	,	,	_	17	punct
23	were	be	VBD	_	24	auxpass
24	added	add	VBN	_	7	advcl
25	to	to	TO	_	27	case
26	a	a	DT	_	27	det
27	regimen	regimen	NN	_	24	nmod
28	consisting	consist	VBG	_	27	acl
29	of	of	IN	_	30	case
30	drug4	drug4	NN	_	28	nmod
31	,	,	,	_	30	punct
32	USP	usp	NN	_	30	conj
33	-LRB-	-lrb-	-LRB-	_	34	punct
34	MODIFIED	modify	VBN	_	32	dep
35	-RRB-	-rrb-	-RRB-	_	34	punct
36	and	and	CC	_	30	cc
37	drug5	drug5	NN	_	30	conj
38	.	.	.	_	7	punct

1	Nonetheless	nonetheless	RB	_	27	advmod
2	,	,	,	_	27	punct
3	the	the	DT	_	4	det
4	range	range	NN	_	27	nsubj
5	of	of	IN	_	9	case
6	individual	individual	JJ	_	9	amod
7	drug1	drug1	NN	_	9	compound
8	clearance	clearance	NN	_	9	compound
9	values	value	NNS	_	4	nmod
10	in	in	IN	_	14	case
11	the	the	DT	_	14	dep
12	presence	presence	NN	_	14	dep
13	of	of	IN	_	14	case
14	drug2	drug2	NN	_	4	nmod
15	-LRB-	-lrb-	-LRB-	_	17	punct
16	12-57	12-57	CD	_	17	nummod
17	mL/h	ml/h	NN	_	14	appos
18	-RRB-	-rrb-	-RRB-	_	17	punct
19	or	or	CC	_	14	cc
20	drug3	drug3	NN	_	14	conj
21	-LRB-	-lrb-	-LRB-	_	23	punct
22	7-54	7-54	CD	_	23	nummod
23	mL/h	ml/h	NN	_	20	appos
24	-RRB-	-rrb-	-RRB-	_	23	punct
25	did	do	VBD	_	27	aux
26	not	not	RB	_	27	neg
27	extend	extend	VB	_	0	ROOT
28	outside	outside	IN	_	30	case
29	the	the	DT	_	30	det
30	range	range	NN	_	27	nmod
31	observed	observe	VBN	_	30	acl
32	with	with	IN	_	34	case
33	dual	dual	JJ	_	34	amod
34	therapy	therapy	NN	_	31	nmod
35	-LRB-	-lrb-	-LRB-	_	37	punct
36	10-78	10-78	CD	_	37	nummod
37	mL/h	ml/h	NN	_	34	appos
38	-RRB-	-rrb-	-RRB-	_	37	punct
39	.	.	.	_	27	punct

1	The	the	DT	_	3	det
2	following	follow	VBG	_	3	amod
3	medications	medication	NNS	_	6	nsubjpass
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	auxpass
6	administered	administer	VBN	_	0	ROOT
7	in	in	IN	_	9	case
8	clinical	clinical	JJ	_	9	amod
9	trials	trial	NNS	_	6	nmod
10	with	with	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	with	with	IN	_	14	case
13	no	no	DT	_	14	neg
14	increase	increase	NN	_	6	nmod
15	in	in	IN	_	17	case
16	adverse	adverse	JJ	_	17	amod
17	reactions	reaction	NNS	_	14	nmod
18	:	:	:	_	6	punct
19	ATG/ALG	atg/alg	NN	_	6	dep
20	,	,	,	_	19	punct
21	drug2	drug2	NN	_	19	conj
22	,	,	,	_	19	punct
23	drug3	drug3	NN	_	19	conj
24	,	,	,	_	19	punct
25	drug4	drug4	NN	_	19	conj
26	,	,	,	_	19	punct
27	drug5	drug5	NN	_	19	conj
28	,	,	,	_	19	punct
29	and	and	CC	_	19	cc
30	drug6	drug6	NN	_	19	conj
31	.	.	.	_	6	punct

1	drug1	drug1	NN	_	6	compound
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	drug2	drug2	NN	_	1	appos
4	-RRB-	-rrb-	-RRB-	_	3	punct
5	blood	blood	NN	_	6	compound
6	levels	level	NNS	_	9	nsubjpass
7	may	may	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	increased	increase	VBN	_	0	ROOT
10	and	and	CC	_	9	cc
11	prolonged	prolong	VBN	_	9	conj
12	by	by	IN	_	14	case
13	concurrent	concurrent	JJ	_	14	amod
14	administration	administration	NN	_	11	nmod
15	of	of	IN	_	16	case
16	drug3	drug3	NN	_	14	nmod
17	.	.	.	_	9	punct

1	Drug	drug	NN	_	2	compound
2	Interactions	interaction	NNS	_	0	ROOT
3	with	with	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	:	:	:	_	2	punct
6	Concomitant	concomitant	JJ	_	7	amod
7	use	use	NN	_	14	nsubjpass
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	with	with	IN	_	11	case
11	drug3	drug3	NN	_	7	nmod
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	avoided	avoid	VBN	_	2	dep
15	.	.	.	_	2	punct

1	If	if	IN	_	5	mark
2	the	the	DT	_	3	det
3	drugs	drug	NNS	_	5	nsubjpass
4	are	be	VBP	_	5	auxpass
5	used	use	VBN	_	11	advcl
6	together	together	RB	_	5	advmod
7	,	,	,	_	11	punct
8	caution	caution	NN	_	11	nsubjpass
9	should	should	MD	_	11	aux
10	be	be	VB	_	11	auxpass
11	exercised	exercise	VBN	_	0	ROOT
12	because	because	IN	_	16	mark
13	unexpected	unexpected	JJ	_	14	amod
14	hypotension	hypotension	NN	_	16	nsubj
15	could	could	MD	_	16	aux
16	result	result	VB	_	11	advcl
17	from	from	IN	_	19	case
18	beta-blocker	beta-blocker	NN	_	19	compound
19	inhibition	inhibition	NN	_	16	nmod
20	of	of	IN	_	24	case
21	the	the	DT	_	24	det
22	sympathetic	sympathetic	JJ	_	24	amod
23	reflex	reflex	JJ	_	24	amod
24	response	response	NN	_	19	nmod
25	to	to	TO	_	26	case
26	drug1	drug1	NN	_	24	nmod
27	.	.	.	_	11	punct

1	Drug	drug	NN	_	2	compound
2	Interactions	interaction	NNS	_	0	ROOT
3	,	,	,	_	2	punct
4	General	General	NNP	_	2	appos
5	:	:	:	_	2	punct
6	Although	although	IN	_	13	mark
7	there	there	EX	_	13	expl
8	have	have	VBP	_	13	aux
9	been	be	VBN	_	13	cop
10	no	no	DT	_	13	neg
11	formal	formal	JJ	_	13	amod
12	interaction	interaction	NN	_	13	compound
13	studies	study	NNS	_	19	advcl
14	,	,	,	_	19	punct
15	intravenous	intravenous	JJ	_	16	amod
16	drug1	drug1	NN	_	19	nsubjpass
17	has	have	VBZ	_	19	aux
18	been	be	VBN	_	19	auxpass
19	administered	administer	VBN	_	2	dep
20	safely	safely	RB	_	19	advmod
21	with	with	IN	_	22	case
22	drugs	drug	NNS	_	19	nmod
23	such	such	JJ	_	25	case
24	as	as	IN	_	23	mwe
25	drug2	drug2	NN	_	22	nmod
26	and	and	CC	_	25	cc
27	sublingual	sublingual	JJ	_	28	amod
28	drug3	drug3	NN	_	25	conj
29	.	.	.	_	2	punct

1	There	there	EX	_	2	expl
2	is	be	VBZ	_	0	ROOT
3	limited	limited	JJ	_	4	amod
4	experience	experience	NN	_	2	nsubj
5	with	with	IN	_	7	case
6	concomitant	concomitant	JJ	_	7	amod
7	drug1	drug1	NN	_	4	nmod
8	such	such	JJ	_	10	case
9	as	as	IN	_	8	mwe
10	drug2	drug2	NN	_	7	nmod
11	,	,	,	_	10	punct
12	drug3	drug3	NN	_	10	conj
13	,	,	,	_	10	punct
14	drug4	drug4	NN	_	10	conj
15	,	,	,	_	10	punct
16	and	and	CC	_	10	cc
17	drug5	drug5	NN	_	10	conj
18	-LRB-	-lrb-	-LRB-	_	20	punct
19	both	both	DT	_	20	det
20	drug6	drug6	NN	_	17	dep
21	-	-	:	_	20	punct
22	like	like	IN	_	20	dep
23	and	and	CC	_	22	cc
24	loop	loop	NN	_	22	conj
25	-RRB-	-rrb-	-RRB-	_	20	punct
26	.	.	.	_	2	punct

1	No	no	DT	_	4	neg
2	significant	significant	JJ	_	4	amod
3	drug	drug	NN	_	4	compound
4	interactions	interaction	NNS	_	7	nsubjpass
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	reported	report	VBN	_	0	ROOT
8	in	in	IN	_	9	case
9	studies	study	NNS	_	7	nmod
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	given	give	VBN	_	11	acl
13	with	with	IN	_	15	case
14	other	other	JJ	_	15	amod
15	drugs	drug	NNS	_	12	nmod
16	such	such	JJ	_	18	case
17	as	as	IN	_	16	mwe
18	drug2	drug2	NN	_	15	nmod
19	,	,	,	_	18	punct
20	drug3	drug3	NN	_	18	conj
21	,	,	,	_	18	punct
22	drug4	drug4	NN	_	18	conj
23	,	,	,	_	18	punct
24	drug5	drug5	NN	_	18	conj
25	,	,	,	_	18	punct
26	drug6	drug6	NN	_	18	conj
27	,	,	,	_	18	punct
28	and	and	CC	_	18	cc
29	oral	oral	JJ	_	30	amod
30	drug7	drug7	NN	_	18	conj
31	in	in	IN	_	33	case
32	healthy	healthy	JJ	_	33	amod
33	volunteers	volunteer	NNS	_	15	nmod
34	,	,	,	_	11	punct
35	or	or	CC	_	11	cc
36	given	give	VBN	_	11	conj
37	with	with	IN	_	38	case
38	drug8	drug8	NN	_	36	nmod
39	to	to	TO	_	40	case
40	patients	patient	NNS	_	38	nmod
41	with	with	IN	_	43	case
42	heart	heart	NN	_	43	compound
43	failure	failure	NN	_	40	nmod
44	-LRB-	-lrb-	-LRB-	_	46	punct
45	NYHA	nyha	NN	_	46	compound
46	class	class	NN	_	43	dep
47	II	ii	CD	_	46	nummod
48	and	and	CC	_	46	cc
49	III	iii	CD	_	46	conj
50	-RRB-	-rrb-	-RRB-	_	46	punct
51	.	.	.	_	7	punct

1	Because	because	IN	_	6	mark
2	drug1	drug1	NN	_	6	nsubjpass
3	is	be	VBZ	_	6	auxpass
4	not	not	RB	_	6	neg
5	significantly	significantly	RB	_	6	advmod
6	metabolized	metabolize	VBN	_	37	advcl
7	by	by	IN	_	11	case
8	the	the	DT	_	11	det
9	cytochrome	cytochrome	NN	_	11	compound
10	P450	p450	NN	_	11	compound
11	system	system	NN	_	6	nmod
12	and	and	CC	_	11	cc
13	at	at	IN	_	15	case
14	therapeutic	therapeutic	JJ	_	15	amod
15	concentrations	concentration	NNS	_	11	conj
16	has	have	VBZ	_	37	aux
17	no	no	DT	_	18	neg
18	effects	effect	NNS	_	16	dobj
19	on	on	IN	_	21	case
20	P450	p450	NN	_	21	compound
21	enzymes	enzyme	NNS	_	16	nmod
22	,	,	,	_	16	punct
23	interactions	interaction	NNS	_	37	nsubjpass
24	with	with	IN	_	25	case
25	drugs	drug	NNS	_	23	nmod
26	that	that	WDT	_	27	nsubj
27	inhibit	inhibit	VBP	_	25	acl:relcl
28	or	or	CC	_	27	cc
29	are	be	VBP	_	30	auxpass
30	metabolized	metabolize	VBN	_	27	conj
31	by	by	IN	_	33	case
32	those	those	DT	_	33	det
33	enzymes	enzyme	NNS	_	27	nmod
34	would	would	MD	_	37	aux
35	not	not	RB	_	37	neg
36	be	be	VB	_	37	auxpass
37	expected	expect	VBN	_	0	ROOT
38	.	.	.	_	37	punct

1	drug1	drug1	NN	_	3	compound
2	Reversible	reversible	JJ	_	3	amod
3	increases	increase	NNS	_	12	nsubjpass
4	in	in	IN	_	7	case
5	serum	serum	NN	_	7	compound
6	drug2	drug2	NN	_	7	compound
7	concentrations	concentration	NNS	_	3	nmod
8	and	and	CC	_	7	cc
9	toxicity	toxicity	NN	_	7	conj
10	have	have	VBP	_	12	aux
11	been	be	VBN	_	12	auxpass
12	reported	report	VBN	_	0	ROOT
13	during	during	IN	_	15	case
14	concomitant	concomitant	JJ	_	15	amod
15	administration	administration	NN	_	12	nmod
16	of	of	IN	_	17	case
17	drug3	drug3	NN	_	15	nmod
18	with	with	IN	_	19	case
19	drug4	drug4	NN	_	15	nmod
20	,	,	,	_	12	punct
21	and	and	CC	_	12	cc
22	with	with	IN	_	24	case
23	some	some	DT	_	24	det
24	drug5	drug5	NN	_	12	conj
25	.	.	.	_	12	punct

1	An	a	DT	_	2	det
2	increase	increase	NN	_	9	nsubjpass
3	in	in	IN	_	6	case
4	serum	serum	NN	_	6	compound
5	drug1	drug1	NN	_	6	compound
6	concentration	concentration	NN	_	2	nmod
7	has	have	VBZ	_	9	aux
8	been	be	VBN	_	9	auxpass
9	reported	report	VBN	_	0	ROOT
10	during	during	IN	_	12	case
11	concomitant	concomitant	JJ	_	12	amod
12	administration	administration	NN	_	9	nmod
13	of	of	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	with	with	IN	_	16	case
16	drug3	drug3	NN	_	12	nmod
17	,	,	,	_	9	punct
18	so	so	RB	_	19	advmod
19	careful	careful	JJ	_	20	amod
20	monitoring	monitoring	NN	_	26	nsubjpass
21	of	of	IN	_	24	case
22	serum	serum	NN	_	24	compound
23	drug4	drug4	NN	_	24	compound
24	levels	level	NNS	_	20	nmod
25	is	be	VBZ	_	26	auxpass
26	recommended	recommend	VBN	_	9	ccomp
27	during	during	IN	_	29	case
28	concomitant	concomitant	JJ	_	29	amod
29	use	use	NN	_	26	nmod
30	.	.	.	_	9	punct

1	Potential	potential	JJ	_	0	ROOT
2	for	for	IN	_	6	mark
3	Other	other	JJ	_	4	amod
4	Drugs	drug	NNS	_	6	nsubj
5	to	to	TO	_	6	mark
6	Affect	affect	VB	_	1	advcl
7	drug1	drug1	NN	_	6	dobj
8	:	:	:	_	1	punct
9	Both	both	CC	_	10	cc:preconj
10	CYP1A2	cyp1a2	NN	_	14	nsubj
11	and	and	CC	_	10	cc
12	CYP2D6	cyp2d6	NN	_	10	conj
13	are	be	VBP	_	14	cop
14	responsible	responsible	JJ	_	1	parataxis
15	for	for	IN	_	17	case
16	drug2	drug2	NN	_	17	compound
17	metabolism	metabolism	NN	_	14	nmod
18	.	.	.	_	14	punct

1	Inhibitors	inhibitor	NNS	_	0	ROOT
2	of	of	IN	_	3	case
3	CYP1A2	cyp1a2	NN	_	1	nmod
4	:	:	:	_	1	punct
5	Concomitant	concomitant	JJ	_	6	amod
6	use	use	NN	_	17	nsubj
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	with	with	IN	_	10	case
10	drug2	drug2	NN	_	6	nmod
11	,	,	,	_	10	punct
12	an	a	DT	_	13	det
13	inhibitor	inhibitor	NN	_	10	appos
14	of	of	IN	_	15	case
15	CYP1A2	cyp1a2	NN	_	13	nmod
16	,	,	,	_	6	punct
17	results	result	VBZ	_	1	dep
18	in	in	IN	_	22	case
19	approximately	approximately	RB	_	22	advmod
20	a	a	DT	_	22	det
21	6-fold	6-fold	RB	_	22	amod
22	increase	increase	NN	_	17	nmod
23	in	in	IN	_	24	case
24	AUC	auc	NN	_	22	nmod
25	and	and	CC	_	22	cc
26	about	about	IN	_	29	case
27	a	a	DT	_	29	det
28	2.5-fold	2.5-fold	JJ	_	29	amod
29	increase	increase	NN	_	22	conj
30	in	in	IN	_	31	case
31	Cmax	cmax	NN	_	29	nmod
32	of	of	IN	_	33	case
33	drug3	drug3	NN	_	31	nmod
34	.	.	.	_	1	punct

1	Some	some	DT	_	2	det
2	drug1	drug1	NN	_	5	nsubjpass
3	would	would	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	expected	expect	VBN	_	0	ROOT
6	to	to	TO	_	7	mark
7	have	have	VB	_	5	xcomp
8	similar	similar	JJ	_	9	amod
9	effects	effect	NNS	_	7	dobj
10	and	and	CC	_	5	cc
11	these	these	DT	_	12	det
12	combinations	combination	NNS	_	15	nsubjpass
13	should	should	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	avoided	avoid	VBN	_	5	conj
16	.	.	.	_	5	punct

1	Inhibitors	inhibitor	NNS	_	0	ROOT
2	of	of	IN	_	3	case
3	CYP2D6	cyp2d6	NN	_	1	nmod
4	:	:	:	_	1	punct
5	Because	because	IN	_	8	mark
6	CYP2D6	cyp2d6	NN	_	8	nsubjpass
7	is	be	VBZ	_	8	auxpass
8	involved	involve	VBN	_	23	advcl
9	in	in	IN	_	11	case
10	drug1	drug1	NN	_	11	compound
11	metabolism	metabolism	NN	_	8	nmod
12	,	,	,	_	23	punct
13	concomitant	concomitant	JJ	_	14	amod
14	use	use	NN	_	23	nsubj
15	of	of	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	with	with	IN	_	19	case
18	potent	potent	JJ	_	19	amod
19	inhibitors	inhibitor	NNS	_	14	nmod
20	of	of	IN	_	21	case
21	CYP2D6	cyp2d6	NN	_	19	nmod
22	may	may	MD	_	23	aux
23	result	result	VB	_	1	dep
24	in	in	IN	_	26	case
25	higher	higher	JJR	_	26	amod
26	concentrations	concentration	NNS	_	23	nmod
27	of	of	IN	_	28	case
28	drug3	drug3	NN	_	26	nmod
29	.	.	.	_	23	punct

1	drug1	drug1	NN	_	7	nsubj
2	-LRB-	-lrb-	-LRB-	_	5	punct
3	20	20	CD	_	4	compound
4	mg	mg	NN	_	5	amod
5	QD	qd	NN	_	1	appos
6	-RRB-	-rrb-	-RRB-	_	5	punct
7	increased	increase	VBD	_	0	ROOT
8	the	the	DT	_	9	det
9	concentration	concentration	NN	_	7	dobj
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	-LRB-	-lrb-	-LRB-	_	15	punct
13	40	40	CD	_	14	compound
14	mg	mg	NN	_	15	amod
15	QD	qd	NN	_	11	appos
16	-RRB-	-rrb-	-RRB-	_	15	punct
17	by	by	IN	_	20	case
18	about	about	RB	_	19	advmod
19	60	60	CD	_	20	nummod
20	%	%	NN	_	7	nmod
21	,	,	,	_	7	punct
22	and	and	CC	_	7	cc
23	greater	greater	JJR	_	24	amod
24	degrees	degree	NNS	_	28	nsubjpass
25	of	of	IN	_	26	case
26	inhibition	inhibition	NN	_	24	nmod
27	are	be	VBP	_	28	auxpass
28	expected	expect	VBN	_	7	conj
29	with	with	IN	_	31	case
30	higher	higher	JJR	_	31	amod
31	doses	dose	NNS	_	28	nmod
32	of	of	IN	_	33	case
33	drug3	drug3	NN	_	31	nmod
34	.	.	.	_	7	punct

1	Similar	similar	JJ	_	2	amod
2	effects	effect	NNS	_	5	nsubjpass
3	would	would	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	expected	expect	VBN	_	0	ROOT
6	with	with	IN	_	10	case
7	other	other	JJ	_	10	amod
8	potent	potent	JJ	_	10	amod
9	CYP2D6	cyp2d6	NN	_	10	compound
10	inhibitors	inhibitor	NNS	_	5	nmod
11	-LRB-	-lrb-	-LRB-	_	14	punct
12	e.g.	e.g.	FW	_	14	dep
13	,	,	,	_	14	punct
14	drug1	drug1	NN	_	10	dep
15	,	,	,	_	14	punct
16	drug2	drug2	NN	_	14	appos
17	-RRB-	-rrb-	-RRB-	_	14	punct
18	.	.	.	_	5	punct

1	Potential	potential	JJ	_	0	ROOT
2	for	for	IN	_	5	mark
3	drug1	drug1	NN	_	5	nsubj
4	to	to	TO	_	5	mark
5	Affect	affect	VB	_	1	advcl
6	Other	other	JJ	_	7	amod
7	Drugs	drug	NNS	_	5	dobj
8	:	:	:	_	1	punct
9	Drugs	drug	NNS	_	1	dep
10	Metabolized	metabolize	VBN	_	9	acl
11	by	by	IN	_	12	case
12	CYP1A2	cyp1a2	NN	_	10	nmod
13	:	:	:	_	9	punct
14	In	in	FW	_	18	amod
15	vitro	vitro	FW	_	14	dep
16	drug	drug	NN	_	18	compound
17	interaction	interaction	NN	_	18	compound
18	studies	study	NNS	_	19	nsubj
19	demonstrate	demonstrate	VBP	_	9	dep
20	that	that	IN	_	24	mark
21	drug2	drug2	NN	_	24	nsubj
22	does	do	VBZ	_	24	aux
23	not	not	RB	_	24	neg
24	induce	induce	VB	_	19	ccomp
25	CYP1A2	cyp1a2	NN	_	26	compound
26	activity	activity	NN	_	24	dobj
27	,	,	,	_	19	punct
28	and	and	CC	_	19	cc
29	it	it	PRP	_	31	nsubj
30	is	be	VBZ	_	31	cop
31	unlikely	unlikely	JJ	_	19	conj
32	to	to	TO	_	33	mark
33	have	have	VB	_	31	xcomp
34	a	a	DT	_	37	det
35	clinically	clinically	RB	_	36	advmod
36	significant	significant	JJ	_	37	amod
37	effect	effect	NN	_	33	dobj
38	on	on	IN	_	40	case
39	the	the	DT	_	40	det
40	metabolism	metabolism	NN	_	33	nmod
41	of	of	IN	_	43	case
42	CYP1A2	cyp1a2	NN	_	43	compound
43	substrates	substrate	NNS	_	40	nmod
44	.	.	.	_	1	punct

1	Drugs	drug	NNS	_	0	ROOT
2	Metabolized	metabolize	VBN	_	1	acl
3	by	by	IN	_	4	case
4	CYP2D6	cyp2d6	NN	_	2	nmod
5	:	:	:	_	1	punct
6	drug1	drug1	NN	_	10	nsubj
7	is	be	VBZ	_	10	cop
8	a	a	DT	_	10	det
9	moderate	moderate	JJ	_	10	amod
10	inhibitor	inhibitor	NN	_	1	dep
11	of	of	IN	_	12	case
12	CYP2D6	cyp2d6	NN	_	10	nmod
13	.	.	.	_	1	punct

1	When	when	WRB	_	4	advmod
2	drug1	drug1	NN	_	4	nsubjpass
3	was	be	VBD	_	4	auxpass
4	administered	administer	VBN	_	0	ROOT
5	-LRB-	-lrb-	-LRB-	_	8	punct
6	at	at	IN	_	8	case
7	a	a	DT	_	8	det
8	dose	dose	NN	_	4	nmod
9	of	of	IN	_	12	case
10	60	60	CD	_	12	nummod
11	mg	mg	NN	_	12	compound
12	BID	BID	NNP	_	8	nmod
13	-RRB-	-rrb-	-RRB-	_	8	punct
14	in	in	IN	_	15	case
15	conjunction	conjunction	NN	_	4	nmod
16	with	with	IN	_	20	case
17	a	a	DT	_	20	det
18	single	single	JJ	_	20	amod
19	50-mg	50-mg	JJ	_	20	amod
20	dose	dose	NN	_	15	nmod
21	of	of	IN	_	22	case
22	drug2	drug2	NN	_	20	nmod
23	,	,	,	_	20	punct
24	a	a	DT	_	26	det
25	CYP2D6	cyp2d6	NN	_	26	compound
26	substrate	substrate	NN	_	20	appos
27	,	,	,	_	20	punct
28	the	the	DT	_	29	det
29	AUC	auc	NN	_	32	nsubj
30	of	of	IN	_	31	case
31	drug3	drug3	NN	_	29	nmod
32	increased	increase	VBD	_	20	acl:relcl
33	3-fold	3-fold	RB	_	32	advmod
34	.	.	.	_	4	punct

1	Therefore	therefore	RB	_	56	advmod
2	,	,	,	_	56	punct
3	co-administration	co-administration	NN	_	56	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	with	with	IN	_	8	case
7	other	other	JJ	_	8	amod
8	drugs	drug	NNS	_	3	nmod
9	that	that	WDT	_	12	nsubjpass
10	are	be	VBP	_	12	auxpass
11	extensively	extensively	RB	_	12	advmod
12	metabolized	metabolize	VBN	_	8	acl:relcl
13	by	by	IN	_	15	case
14	this	this	DT	_	15	det
15	isozyme	isozyme	NN	_	12	nmod
16	and	and	CC	_	12	cc
17	which	which	WDT	_	18	nsubj
18	have	have	VBP	_	12	conj
19	a	a	DT	_	22	det
20	narrow	narrow	JJ	_	22	amod
21	therapeutic	therapeutic	JJ	_	22	amod
22	index	index	NN	_	18	dobj
23	,	,	,	_	22	punct
24	including	include	VBG	_	26	case
25	certain	certain	JJ	_	26	amod
26	drug2	drug2	NN	_	22	nmod
27	-LRB-	-lrb-	-LRB-	_	28	punct
28	drug3	drug3	NN	_	26	dep
29	-LSB-	-lsb-	-LRB-	_	30	punct
30	drug4	drug4	NN	_	28	appos
31	-RSB-	-rsb-	-RRB-	_	30	punct
32	,	,	,	_	28	punct
33	such	such	JJ	_	35	case
34	as	as	IN	_	33	mwe
35	drug5	drug5	NN	_	28	nmod
36	,	,	,	_	35	punct
37	drug6	drug6	NN	_	35	conj
38	,	,	,	_	35	punct
39	and	and	CC	_	35	cc
40	drug7	drug7	NN	_	35	conj
41	-RRB-	-rrb-	-RRB-	_	28	punct
42	,	,	,	_	26	punct
43	drug8	drug8	NN	_	26	conj
44	and	and	CC	_	26	cc
45	drug9	drug9	NN	_	26	conj
46	-LRB-	-lrb-	-LRB-	_	49	punct
47	e.g.	e.g.	FW	_	49	dep
48	,	,	,	_	49	punct
49	drug10	drug10	NN	_	45	dep
50	,	,	,	_	49	punct
51	drug11	drug11	NN	_	49	appos
52	-RRB-	-rrb-	-RRB-	_	49	punct
53	,	,	,	_	3	punct
54	should	should	MD	_	56	aux
55	be	be	VB	_	56	auxpass
56	approached	approach	VBN	_	0	ROOT
57	with	with	IN	_	58	case
58	caution	caution	NN	_	56	nmod
59	.	.	.	_	56	punct

1	Plasma	plasma	NN	_	3	compound
2	drug1	drug1	NN	_	3	compound
3	concentrations	concentration	NNS	_	5	nsubj
4	may	may	MD	_	5	aux
5	need	need	VB	_	0	ROOT
6	to	to	TO	_	8	mark
7	be	be	VB	_	8	auxpass
8	monitored	monitor	VBN	_	5	xcomp
9	and	and	CC	_	8	cc
10	the	the	DT	_	11	det
11	dose	dose	NN	_	16	nsubj
12	of	of	IN	_	14	case
13	the	the	DT	_	14	det
14	drug2	drug2	NN	_	11	nmod
15	may	may	MD	_	16	aux
16	need	need	VB	_	8	conj
17	to	to	TO	_	19	mark
18	be	be	VB	_	19	auxpass
19	reduced	reduce	VBN	_	16	xcomp
20	if	if	IN	_	24	mark
21	a	a	DT	_	22	det
22	drug3	drug3	NN	_	24	nsubjpass
23	is	be	VBZ	_	24	auxpass
24	co-administered	co-administer	VBN	_	19	advcl
25	with	with	IN	_	26	case
26	drug4	drug4	NN	_	24	nmod
27	.	.	.	_	5	punct

1	Because	because	IN	_	4	case
2	of	of	IN	_	1	mwe
3	the	the	DT	_	4	det
4	risk	risk	NN	_	27	nmod
5	of	of	IN	_	8	case
6	serious	serious	JJ	_	8	amod
7	ventricular	ventricular	JJ	_	8	amod
8	arrhythmias	arrhythmia	NNS	_	4	nmod
9	and	and	CC	_	8	cc
10	sudden	sudden	JJ	_	11	amod
11	death	death	NN	_	8	conj
12	potentially	potentially	RB	_	13	advmod
13	associated	associate	VBN	_	8	acl
14	with	with	IN	_	17	case
15	elevated	elevated	JJ	_	17	amod
16	plasma	plasma	NN	_	17	compound
17	levels	level	NNS	_	13	nmod
18	of	of	IN	_	19	case
19	drug1	drug1	NN	_	17	nmod
20	,	,	,	_	19	punct
21	drug2	drug2	NN	_	19	conj
22	and	and	CC	_	19	cc
23	drug3	drug3	NN	_	19	conj
24	should	should	MD	_	27	aux
25	not	not	RB	_	27	neg
26	be	be	VB	_	27	auxpass
27	co-administered	co-administer	VBN	_	0	ROOT
28	.	.	.	_	27	punct

1	Drugs	drug	NNS	_	0	ROOT
2	Metabolized	metabolize	VBN	_	1	acl
3	by	by	IN	_	4	case
4	CYP3A	cyp3a	NN	_	2	nmod
5	:	:	:	_	1	punct
6	Results	result	NNS	_	11	nsubj
7	of	of	IN	_	10	case
8	in	in	FW	_	10	amod
9	vitro	vitro	FW	_	8	dep
10	studies	study	NNS	_	6	nmod
11	demonstrate	demonstrate	VBP	_	1	dep
12	that	that	IN	_	16	mark
13	drug1	drug1	NN	_	16	nsubj
14	does	do	VBZ	_	16	aux
15	not	not	RB	_	16	neg
16	inhibit	inhibit	VB	_	11	ccomp
17	or	or	CC	_	16	cc
18	induce	induce	VB	_	16	conj
19	CYP3A	cyp3a	NN	_	20	compound
20	activity	activity	NN	_	16	dobj
21	.	.	.	_	1	punct

1	drug1	drug1	NN	_	2	compound
2	May	May	NNP	_	3	nsubj
3	Have	have	VBP	_	0	ROOT
4	a	a	DT	_	7	det
5	Clinically	clinically	RB	_	6	advmod
6	Important	important	JJ	_	7	amod
7	Interaction	interaction	NN	_	3	dobj
8	with	with	IN	_	12	case
9	the	the	DT	_	12	det
10	Following	follow	VBG	_	12	amod
11	Other	other	JJ	_	12	amod
12	Drugs	drug	NNS	_	7	nmod
13	:	:	:	_	7	punct
14	drug2	drug2	NN	_	7	dep
15	:	:	:	_	14	punct
16	When	when	WRB	_	21	advmod
17	drug3	drug3	NN	_	21	nsubjpass
18	and	and	CC	_	17	cc
19	drug4	drug4	NN	_	17	conj
20	were	be	VBD	_	21	auxpass
21	administered	administer	VBN	_	37	advcl
22	several	several	JJ	_	23	amod
23	hours	hour	NNS	_	32	dep
24	apart	apart	RB	_	25	advmod
25	so	so	RB	_	32	mark
26	that	that	IN	_	25	mwe
27	peak	peak	JJ	_	28	amod
28	concentrations	concentration	NNS	_	32	nsubj
29	of	of	IN	_	30	case
30	each	each	DT	_	28	nmod
31	would	would	MD	_	32	aux
32	coincide	coincide	VB	_	21	advcl
33	,	,	,	_	37	punct
34	drug5	drug5	NN	_	37	nsubj
35	did	do	VBD	_	37	aux
36	not	not	RB	_	37	neg
37	increase	increase	VB	_	14	dep
38	the	the	DT	_	39	det
39	impairment	impairment	NN	_	37	dobj
40	of	of	IN	_	44	case
41	mental	mental	JJ	_	44	amod
42	and	and	CC	_	41	cc
43	motor	motor	NN	_	41	conj
44	skills	skill	NNS	_	39	nmod
45	caused	cause	VBN	_	44	acl
46	by	by	IN	_	47	case
47	drug6	drug6	NN	_	45	nmod
48	.	.	.	_	3	punct

1	In	in	IN	_	6	case
2	the	the	DT	_	6	det
3	drug1	drug1	NN	_	6	compound
4	clinical	clinical	JJ	_	6	amod
5	trials	trial	NNS	_	6	compound
6	database	database	NN	_	0	ROOT
7	,	,	,	_	6	punct
8	three	three	CD	_	9	nummod
9	drug2	drug2	NN	_	7	root
10	-	-	:	_	9	punct
11	treated	treated	JJ	_	12	amod
12	patients	patient	NNS	_	13	nsubj
13	had	have	VBD	_	9	dep
14	liver	liver	NN	_	15	compound
15	injury	injury	NN	_	13	dobj
16	as	as	IN	_	17	mark
17	manifested	manifest	VBN	_	13	advcl
18	by	by	IN	_	19	case
19	ALT	ALT	NNP	_	17	nmod
20	and	and	CC	_	19	cc
21	total	total	JJ	_	23	amod
22	bilirubin	bilirubin	NN	_	23	compound
23	elevations	elevation	NNS	_	19	conj
24	,	,	,	_	13	punct
25	with	with	IN	_	26	case
26	evidence	evidence	NN	_	13	nmod
27	of	of	IN	_	28	case
28	obstruction	obstruction	NN	_	26	nmod
29	.	.	.	_	9	punct

1	Substantial	substantial	JJ	_	4	amod
2	intercurrent	intercurrent	JJ	_	4	amod
3	drug1	drug1	NN	_	4	compound
4	use	use	NN	_	6	nsubj
5	was	be	VBD	_	6	cop
6	present	present	JJ	_	0	ROOT
7	in	in	IN	_	8	case
8	each	each	DT	_	6	nmod
9	of	of	IN	_	11	case
10	these	these	DT	_	11	det
11	cases	case	NNS	_	8	nmod
12	,	,	,	_	6	punct
13	and	and	CC	_	6	cc
14	this	this	DT	_	17	nsubj
15	may	may	MD	_	17	aux
16	have	have	VB	_	17	aux
17	contributed	contribute	VBN	_	6	conj
18	to	to	TO	_	20	case
19	the	the	DT	_	20	det
20	abnormalities	abnormality	NNS	_	17	nmod
21	seen	see	VBN	_	20	acl
22	.	.	.	_	6	punct

1	CNS	cns	NN	_	3	compound
2	Acting	acting	NN	_	3	compound
3	Drugs	drug	NNS	_	0	ROOT
4	:	:	:	_	3	punct
5	Given	give	VBN	_	9	case
6	the	the	DT	_	9	det
7	primary	primary	JJ	_	9	amod
8	CNS	cns	NN	_	9	compound
9	effects	effect	NNS	_	16	nmod
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	,	,	,	_	16	punct
13	it	it	PRP	_	16	nsubjpass
14	should	should	MD	_	16	aux
15	be	be	VB	_	16	auxpass
16	used	use	VBN	_	3	dep
17	with	with	IN	_	18	case
18	caution	caution	NN	_	16	nmod
19	when	when	WRB	_	22	advmod
20	it	it	PRP	_	22	nsubjpass
21	is	be	VBZ	_	22	auxpass
22	taken	take	VBN	_	16	advcl
23	in	in	IN	_	24	case
24	combination	combination	NN	_	22	nmod
25	with	with	IN	_	32	case
26	or	or	CC	_	25	cc
27	substituted	substitute	VBN	_	25	conj
28	for	for	IN	_	32	case
29	other	other	JJ	_	32	amod
30	centrally	centrally	RB	_	31	advmod
31	acting	act	VBG	_	32	amod
32	drugs	drug	NNS	_	24	nmod
33	,	,	,	_	32	punct
34	including	include	VBG	_	35	case
35	those	those	DT	_	32	nmod
36	with	with	IN	_	39	case
37	a	a	DT	_	39	det
38	similar	similar	JJ	_	39	amod
39	mechanism	mechanism	NN	_	35	nmod
40	of	of	IN	_	41	case
41	action	action	NN	_	39	nmod
42	.	.	.	_	3	punct

1	Potential	potential	JJ	_	0	ROOT
2	for	for	IN	_	3	case
3	Interaction	interaction	NN	_	1	nmod
4	with	with	IN	_	5	case
5	Drugs	drug	NNS	_	3	nmod
6	that	that	WDT	_	7	nsubj
7	Affect	affect	VBP	_	5	acl:relcl
8	Gastric	gastric	JJ	_	9	amod
9	Acidity	acidity	NN	_	7	dobj
10	:	:	:	_	1	punct
11	drug1	drug1	NN	_	12	nsubj
12	has	have	VBZ	_	1	parataxis
13	an	a	DT	_	15	det
14	enteric	enteric	JJ	_	15	amod
15	coating	coating	NN	_	12	dobj
16	that	that	WDT	_	17	nsubj
17	resists	resist	VBZ	_	15	acl:relcl
18	dissolution	dissolution	NN	_	17	dobj
19	until	until	IN	_	20	mark
20	reaching	reach	VBG	_	17	advcl
21	a	a	DT	_	22	det
22	segment	segment	NN	_	20	dobj
23	of	of	IN	_	26	case
24	the	the	DT	_	26	det
25	gastrointestinal	gastrointestinal	JJ	_	26	amod
26	tract	tract	NN	_	22	nmod
27	where	where	WRB	_	30	advmod
28	the	the	DT	_	29	det
29	pH	ph	NN	_	30	nsubj
30	exceeds	exceed	VBZ	_	26	acl:relcl
31	5.5	5.5	CD	_	30	dobj
32	.	.	.	_	1	punct

1	In	in	IN	_	4	case
2	extremely	extremely	RB	_	3	advmod
3	acidic	acidic	JJ	_	4	amod
4	conditions	condition	NNS	_	15	nmod
5	,	,	,	_	15	punct
6	drug1	drug1	NN	_	15	nsubj
7	,	,	,	_	6	punct
8	unprotected	unprotected	JJ	_	6	amod
9	by	by	IN	_	12	case
10	the	the	DT	_	12	det
11	enteric	enteric	JJ	_	12	amod
12	coating	coating	NN	_	8	nmod
13	,	,	,	_	6	punct
14	may	may	MD	_	15	aux
15	undergo	undergo	VB	_	0	ROOT
16	hydrolysis	hydrolysis	NN	_	15	dobj
17	to	to	TO	_	18	mark
18	form	form	VB	_	15	advcl
19	naphthol	naphthol	NN	_	18	dobj
20	.	.	.	_	15	punct

1	Caution	caution	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	advised	advise	VBN	_	0	ROOT
4	in	in	IN	_	5	mark
5	using	use	VBG	_	3	advcl
6	drug1	drug1	NN	_	5	dobj
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	with	with	IN	_	10	case
10	conditions	condition	NNS	_	8	nmod
11	that	that	WDT	_	13	nsubj
12	may	may	MD	_	13	aux
13	slow	slow	VB	_	8	acl:relcl
14	gastric	gastric	JJ	_	15	amod
15	emptying	emptying	NN	_	13	dobj
16	-LRB-	-lrb-	-LRB-	_	20	punct
17	e.g.	e.g.	FW	_	20	dep
18	,	,	,	_	20	punct
19	some	some	DT	_	20	det
20	diabetics	diabetic	NNS	_	3	dep
21	-RRB-	-rrb-	-RRB-	_	20	punct
22	.	.	.	_	3	punct

1	Drugs	drug	NNS	_	8	nsubj
2	that	that	WDT	_	3	nsubj
3	raise	raise	VBP	_	1	acl:relcl
4	the	the	DT	_	6	det
5	gastrointestinal	gastrointestinal	JJ	_	6	amod
6	pH	ph	NN	_	3	dobj
7	may	may	MD	_	8	aux
8	lead	lead	VB	_	0	ROOT
9	to	to	TO	_	12	case
10	an	a	DT	_	12	det
11	earlier	earlier	JJR	_	12	amod
12	release	release	NN	_	8	nmod
13	of	of	IN	_	14	case
14	drug1	drug1	NN	_	12	nmod
15	.	.	.	_	8	punct

1	However	however	RB	_	23	advmod
2	,	,	,	_	23	punct
3	co-administration	co-administration	NN	_	23	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	with	with	IN	_	7	case
7	drug2	drug2	NN	_	3	nmod
8	-	-	:	_	7	punct
9	and	and	CC	_	7	cc
10	drug3	drug3	NN	_	7	conj
11	-	-	:	_	7	punct
12	containing	contain	VBG	_	7	acl
13	drug4	drug4	NN	_	12	dobj
14	-LRB-	-lrb-	-LRB-	_	16	punct
15	51	51	CD	_	16	nummod
16	mEq	meq	NN	_	13	appos
17	-RRB-	-rrb-	-RRB-	_	16	punct
18	or	or	CC	_	13	cc
19	drug5	drug5	NN	_	13	conj
20	with	with	IN	_	21	case
21	drug6	drug6	NN	_	19	nmod
22	,	,	,	_	23	punct
23	had	have	VBD	_	0	ROOT
24	no	no	DT	_	26	neg
25	significant	significant	JJ	_	26	amod
26	effect	effect	NN	_	23	dobj
27	on	on	IN	_	29	case
28	the	the	DT	_	29	det
29	rate	rate	NN	_	23	nmod
30	or	or	CC	_	29	cc
31	extent	extent	NN	_	29	conj
32	of	of	IN	_	34	case
33	drug7	drug7	NN	_	34	compound
34	absorption	absorption	NN	_	29	nmod
35	after	after	IN	_	36	case
36	administration	administration	NN	_	23	nmod
37	of	of	IN	_	41	case
38	a	a	DT	_	41	det
39	40-mg	40-mg	JJ	_	41	amod
40	oral	oral	JJ	_	41	amod
41	dose	dose	NN	_	36	nmod
42	.	.	.	_	23	punct

1	It	it	PRP	_	3	nsubj
2	is	be	VBZ	_	3	cop
3	unknown	unknown	JJ	_	0	ROOT
4	whether	whether	IN	_	10	mark
5	the	the	DT	_	7	det
6	concomitant	concomitant	JJ	_	7	amod
7	administration	administration	NN	_	10	nsubj
8	of	of	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	affects	affect	VBZ	_	3	ccomp
11	drug2	drug2	NN	_	12	compound
12	absorption	absorption	NN	_	10	dobj
13	.	.	.	_	3	punct

1	In	in	IN	_	2	case
2	studies	study	NNS	_	8	nmod
3	in	in	IN	_	5	case
4	normal	normal	JJ	_	5	amod
5	volunteers	volunteer	NNS	_	2	nmod
6	,	,	,	_	8	punct
7	there	there	EX	_	8	expl
8	was	be	VBD	_	0	ROOT
9	no	no	DT	_	11	neg
10	pharmacodynamic	pharmacodynamic	JJ	_	11	amod
11	interaction	interaction	NN	_	8	nsubj
12	between	between	IN	_	14	case
13	intravenous	intravenous	JJ	_	14	amod
14	drug1	drug1	NN	_	11	nmod
15	and	and	CC	_	14	cc
16	either	either	CC	_	17	cc:preconj
17	drug2	drug2	NN	_	14	conj
18	,	,	,	_	17	punct
19	drug3	drug3	NN	_	17	conj
20	,	,	,	_	17	punct
21	or	or	CC	_	17	cc
22	drug4	drug4	NN	_	17	conj
23	.	.	.	_	8	punct

1	However	however	RB	_	4	advmod
2	,	,	,	_	4	punct
3	drug1	drug1	NN	_	4	nsubj
4	has	have	VBZ	_	0	ROOT
5	the	the	DT	_	6	det
6	potential	potential	JJ	_	4	dobj
7	to	to	TO	_	8	mark
8	increase	increase	VB	_	6	acl
9	the	the	DT	_	11	det
10	hypotensive	hypotensive	JJ	_	11	amod
11	effect	effect	NN	_	8	dobj
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	and	and	CC	_	13	cc
15	drug3	drug3	NN	_	13	conj
16	.	.	.	_	4	punct

1	Since	since	IN	_	3	mark
2	drug1	drug1	NN	_	3	nsubj
3	inhibits	inhibit	VBZ	_	8	advcl
4	platelet	platelet	NN	_	5	compound
5	function	function	NN	_	3	dobj
6	,	,	,	_	8	punct
7	there	there	EX	_	8	expl
8	is	be	VBZ	_	0	ROOT
9	a	a	DT	_	10	det
10	potential	potential	NN	_	8	nsubj
11	for	for	IN	_	13	case
12	increased	increase	VBN	_	13	amod
13	risk	risk	NN	_	10	nmod
14	of	of	IN	_	15	case
15	bleeding	bleeding	NN	_	13	nmod
16	,	,	,	_	10	punct
17	particularly	particularly	RB	_	19	advmod
18	in	in	IN	_	19	case
19	patients	patient	NNS	_	10	nmod
20	maintained	maintain	VBN	_	19	acl
21	on	on	IN	_	22	case
22	drug2	drug2	NN	_	20	nmod
23	.	.	.	_	8	punct

1	During	during	IN	_	3	case
2	clinical	clinical	JJ	_	3	amod
3	trials	trial	NNS	_	7	nmod
4	,	,	,	_	7	punct
5	drug1	drug1	NN	_	7	nsubjpass
6	was	be	VBD	_	7	auxpass
7	used	use	VBN	_	0	ROOT
8	concurrently	concurrently	RB	_	7	advmod
9	with	with	IN	_	10	case
10	drug2	drug2	NN	_	7	nmod
11	,	,	,	_	10	punct
12	drug3	drug3	NN	_	10	conj
13	,	,	,	_	10	punct
14	drug4	drug4	NN	_	10	conj
15	,	,	,	_	10	punct
16	drug5	drug5	NN	_	10	conj
17	,	,	,	_	10	punct
18	drug6	drug6	NN	_	10	conj
19	,	,	,	_	10	punct
20	drug7	drug7	NN	_	10	conj
21	,	,	,	_	10	punct
22	drug8	drug8	NN	_	10	conj
23	,	,	,	_	10	punct
24	drug9	drug9	NN	_	10	conj
25	,	,	,	_	10	punct
26	and	and	CC	_	10	cc
27	other	other	JJ	_	28	amod
28	medications	medication	NNS	_	10	conj
29	.	.	.	_	7	punct

1	Intravenous	intravenous	JJ	_	2	amod
2	infusion	infusion	NN	_	5	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	had	have	VBD	_	0	ROOT
6	no	no	DT	_	7	neg
7	effect	effect	NN	_	5	dobj
8	on	on	IN	_	10	case
9	the	the	DT	_	10	det
10	pharmacokinetics	pharmacokinetic	NNS	_	5	nmod
11	of	of	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	.	.	.	_	5	punct

1	drug1	drug1	NN	_	4	nsubj
2	did	do	VBD	_	4	aux
3	not	not	RB	_	4	neg
4	alter	alter	VB	_	0	ROOT
5	the	the	DT	_	6	det
6	clearance	clearance	NN	_	4	dobj
7	-LRB-	-lrb-	-LRB-	_	8	punct
8	pharmacokinetics	pharmacokinetic	NNS	_	6	appos
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	6	nmod
12	.	.	.	_	4	punct

1	Although	although	IN	_	7	mark
2	clinical	clinical	JJ	_	3	amod
3	studies	study	NNS	_	7	nsubjpass
4	have	have	VBP	_	7	aux
5	not	not	RB	_	7	neg
6	been	be	VBN	_	7	auxpass
7	conducted	conduct	VBN	_	14	advcl
8	,	,	,	_	14	punct
9	in	in	FW	_	11	amod
10	vitro	vitro	FW	_	9	dep
11	studies	study	NNS	_	14	nsubj
12	of	of	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	indicate	indicate	VBP	_	0	ROOT
15	that	that	IN	_	26	mark
16	no	no	DT	_	18	neg
17	relevant	relevant	JJ	_	18	amod
18	inhibition	inhibition	NN	_	26	nsubjpass
19	of	of	IN	_	23	case
20	cytochrome	cytochrome	NN	_	23	compound
21	P450	p450	NN	_	23	compound
22	drug	drug	NN	_	23	compound
23	metabolism	metabolism	NN	_	18	nmod
24	would	would	MD	_	26	aux
25	be	be	VB	_	26	auxpass
26	expected	expect	VBN	_	14	ccomp
27	.	.	.	_	14	punct

1	Oral	oral	JJ	_	4	amod
2	drug1	drug1	NN	_	4	compound
3	Multiple	multiple	JJ	_	4	amod
4	doses	dose	NNS	_	7	nsubj
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	had	have	VBD	_	0	ROOT
8	no	no	DT	_	9	neg
9	effect	effect	NN	_	7	dobj
10	on	on	IN	_	12	case
11	the	the	DT	_	12	det
12	pharmacokinetics	pharmacokinetic	NNS	_	7	nmod
13	of	of	IN	_	14	case
14	drug3	drug3	NN	_	12	nmod
15	,	,	,	_	7	punct
16	the	the	DT	_	18	det
17	estrogenic	estrogenic	JJ	_	18	amod
18	component	component	NN	_	15	root
19	in	in	IN	_	22	case
20	most	most	JJS	_	22	amod
21	oral	oral	JJ	_	22	amod
22	drug4	drug4	NN	_	18	nmod
23	.	.	.	_	18	punct

1	Although	although	IN	_	7	mark
2	the	the	DT	_	4	det
3	clinical	clinical	JJ	_	4	amod
4	significance	significance	NN	_	7	nsubjpass
5	is	be	VBZ	_	7	auxpass
6	not	not	RB	_	7	neg
7	known	know	VBN	_	12	advcl
8	,	,	,	_	12	punct
9	it	it	PRP	_	12	nsubjpass
10	is	be	VBZ	_	12	auxpass
11	not	not	RB	_	12	neg
12	recommended	recommend	VBN	_	0	ROOT
13	that	that	IN	_	16	mark
14	drug1	drug1	NN	_	16	nsubjpass
15	be	be	VB	_	16	auxpass
16	taken	take	VBN	_	12	ccomp
17	concomitantly	concomitantly	RB	_	16	advmod
18	with	with	IN	_	19	case
19	drug2	drug2	NN	_	16	nmod
20	.	.	.	_	12	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Co-administration	co-administration	NN	_	16	nsubj
4	of	of	IN	_	7	case
5	a	a	DT	_	7	det
6	single	single	JJ	_	7	amod
7	dose	dose	NN	_	3	nmod
8	of	of	IN	_	11	case
9	intravenously	intravenously	RB	_	10	advmod
10	administered	administer	VBN	_	11	amod
11	drug2	drug2	NN	_	7	nmod
12	-LRB-	-lrb-	-LRB-	_	14	punct
13	20	20	CD	_	14	nummod
14	mg	mg	NN	_	11	appos
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	reduced	reduce	VBD	_	1	appos
17	the	the	DT	_	19	det
18	oral	oral	JJ	_	19	amod
19	absorption	absorption	NN	_	16	dobj
20	of	of	IN	_	25	case
21	a	a	DT	_	25	det
22	single	single	JJ	_	25	amod
23	400	400	CD	_	25	nummod
24	mg	mg	NN	_	25	compound
25	dose	dose	NN	_	19	nmod
26	of	of	IN	_	27	case
27	drug3	drug3	NN	_	25	nmod
28	administered	administer	VBN	_	25	acl
29	following	follow	VBG	_	31	case
30	a	a	DT	_	31	det
31	meal	meal	NN	_	28	nmod
32	,	,	,	_	16	punct
33	as	as	IN	_	34	mark
34	evidenced	evidence	VBN	_	16	advcl
35	by	by	IN	_	39	case
36	a	a	DT	_	39	det
37	27	27	CD	_	38	compound
38	%	%	NN	_	39	amod
39	decrease	decrease	NN	_	34	nmod
40	in	in	IN	_	42	case
41	mean	mean	JJ	_	42	amod
42	Cmax	cmax	NN	_	39	nmod
43	and	and	CC	_	39	cc
44	a	a	DT	_	47	det
45	22	22	CD	_	46	compound
46	%	%	NN	_	47	amod
47	decrease	decrease	NN	_	39	conj
48	in	in	IN	_	50	case
49	mean	mean	JJ	_	50	amod
50	AUC	auc	NN	_	47	nmod
51	.	.	.	_	1	punct

1	Although	although	IN	_	7	mark
2	the	the	DT	_	4	det
3	clinical	clinical	JJ	_	4	amod
4	significance	significance	NN	_	7	nsubjpass
5	is	be	VBZ	_	7	auxpass
6	not	not	RB	_	7	neg
7	known	know	VBN	_	12	advcl
8	,	,	,	_	12	punct
9	it	it	PRP	_	12	nsubjpass
10	is	be	VBZ	_	12	auxpass
11	not	not	RB	_	12	neg
12	recommended	recommend	VBN	_	0	ROOT
13	that	that	IN	_	16	mark
14	drug1	drug1	NN	_	16	nsubjpass
15	be	be	VB	_	16	auxpass
16	taken	take	VBN	_	12	ccomp
17	concomitantly	concomitantly	RB	_	16	advmod
18	with	with	IN	_	19	case
19	drug2	drug2	NN	_	16	nmod
20	.	.	.	_	12	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	As	as	IN	_	6	case
4	with	with	IN	_	6	case
5	other	other	JJ	_	6	amod
6	drug2	drug2	NN	_	13	nmod
7	,	,	,	_	6	punct
8	co-administration	co-administration	NN	_	6	appos
9	of	of	IN	_	10	case
10	drug3	drug3	NN	_	8	nmod
11	with	with	IN	_	12	case
12	drug4	drug4	NN	_	8	nmod
13	resulted	result	VBD	_	1	dep
14	in	in	IN	_	16	case
15	an	a	DT	_	16	det
16	increase	increase	NN	_	13	nmod
17	in	in	IN	_	20	case
18	the	the	DT	_	20	det
19	plasma	plasma	NN	_	20	compound
20	exposure	exposure	NN	_	16	nmod
21	of	of	IN	_	22	case
22	drug5	drug5	NN	_	20	nmod
23	,	,	,	_	13	punct
24	with	with	IN	_	28	case
25	a	a	DT	_	28	det
26	49	49	CD	_	27	compound
27	%	%	NN	_	28	amod
28	increase	increase	NN	_	13	nmod
29	in	in	IN	_	31	case
30	mean	mean	NN	_	31	compound
31	Cmax	cmax	NN	_	28	nmod
32	,	,	,	_	28	punct
33	a	a	DT	_	36	det
34	122	122	CD	_	35	compound
35	%	%	NN	_	36	amod
36	increase	increase	NN	_	28	conj
37	in	in	IN	_	39	case
38	mean	mean	JJ	_	39	amod
39	AUC	auc	NN	_	36	nmod
40	,	,	,	_	28	punct
41	and	and	CC	_	28	cc
42	a	a	DT	_	45	det
43	53	53	CD	_	44	compound
44	%	%	NN	_	45	amod
45	increase	increase	NN	_	28	conj
46	in	in	IN	_	47	case
47	half-life	half-life	NN	_	45	nmod
48	.	.	.	_	1	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	4	amod
2	Test	test	NN	_	4	compound
3	Interactions	interaction	NNS	_	4	compound
4	drug1	drug1	NN	_	6	nsubjpass
5	are	be	VBP	_	6	auxpass
6	known	know	VBN	_	0	ROOT
7	to	to	TO	_	9	mark
8	occasionally	occasionally	RB	_	9	advmod
9	induce	induce	VB	_	6	xcomp
10	a	a	DT	_	14	det
11	positive	positive	JJ	_	14	amod
12	direct	direct	JJ	_	14	amod
13	Coombs	coomb	NNS	_	14	compound
14	test	test	NN	_	9	dobj
15	.	.	.	_	6	punct

1	A	a	DT	_	3	det
2	false-positive	false-positive	JJ	_	3	amod
3	reaction	reaction	NN	_	10	nsubj
4	for	for	IN	_	5	case
5	glucose	glucose	NN	_	3	nmod
6	in	in	IN	_	8	case
7	the	the	DT	_	8	det
8	urine	urine	NN	_	5	nmod
9	may	may	MD	_	10	aux
10	occur	occur	VB	_	0	ROOT
11	with	with	IN	_	14	case
12	copper	copper	NN	_	14	compound
13	reduction	reduction	NN	_	14	compound
14	tests	test	NNS	_	10	nmod
15	-LRB-	-lrb-	-LRB-	_	16	punct
16	Benedicts	benedict	NNS	_	14	dep
17	or	or	CC	_	16	cc
18	Fehlings	fehling	NNS	_	19	compound
19	solution	solution	NN	_	16	conj
20	or	or	CC	_	16	cc
21	with	with	IN	_	23	case
22	CLINITEST	clinitest	NN	_	23	compound
23	tablets	tablet	NNS	_	16	conj
24	-RRB-	-rrb-	-RRB-	_	16	punct
25	,	,	,	_	14	punct
26	but	but	CC	_	14	cc
27	not	not	RB	_	30	neg
28	with	with	IN	_	30	case
29	enzyme-based	enzyme-based	JJ	_	30	amod
30	tests	test	NNS	_	14	conj
31	for	for	IN	_	32	case
32	glycosuria	glycosuria	NN	_	30	nmod
33	-LRB-	-lrb-	-LRB-	_	36	punct
34	e.g.	e.g.	FW	_	36	dep
35	,	,	,	_	36	punct
36	CLINISTIX	clinistix	NN	_	30	dep
37	,	,	,	_	36	punct
38	TES-TAPE	tes-tape	NN	_	36	appos
39	-RRB-	-rrb-	-RRB-	_	36	punct
40	.	.	.	_	10	punct

1	As	as	IN	_	6	mark
2	a	a	DT	_	4	det
3	false-negative	false-negative	JJ	_	4	amod
4	result	result	NN	_	6	nsubj
5	may	may	MD	_	6	aux
6	occur	occur	VB	_	14	advcl
7	in	in	IN	_	10	case
8	the	the	DT	_	10	det
9	ferricyanide	ferricyanide	JJ	_	10	amod
10	test	test	NN	_	6	nmod
11	,	,	,	_	14	punct
12	it	it	PRP	_	14	nsubjpass
13	is	be	VBZ	_	14	auxpass
14	recommended	recommend	VBN	_	0	ROOT
15	that	that	IN	_	24	mark
16	either	either	CC	_	19	cc:preconj
17	the	the	DT	_	19	det
18	glucose	glucose	NN	_	19	compound
19	oxidase	oxidase	NN	_	24	nsubjpass
20	or	or	CC	_	19	cc
21	hexokinase	hexokinase	NN	_	22	compound
22	method	method	NN	_	19	conj
23	be	be	VB	_	24	auxpass
24	used	use	VBN	_	14	ccomp
25	to	to	TO	_	26	mark
26	determine	determine	VB	_	24	xcomp
27	blood/plasma	blood/plasma	NN	_	29	compound
28	glucose	glucose	NN	_	29	compound
29	levels	level	NNS	_	26	dobj
30	in	in	IN	_	31	case
31	patients	patient	NNS	_	29	nmod
32	receiving	receive	VBG	_	31	acl
33	drug1	drug1	NN	_	32	dobj
34	.	.	.	_	14	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	studied	study	VBN	_	0	ROOT
5	in	in	IN	_	10	case
6	several	several	JJ	_	10	amod
7	human	human	JJ	_	10	amod
8	drug	drug	NN	_	10	compound
9	interaction	interaction	NN	_	10	compound
10	studies	study	NNS	_	4	nmod
11	in	in	IN	_	12	case
12	which	which	WDT	_	15	nmod
13	it	it	PRP	_	15	nsubjpass
14	was	be	VBD	_	15	auxpass
15	administered	administer	VBN	_	10	acl:relcl
16	with	with	IN	_	18	case
17	a	a	DT	_	18	det
18	meal	meal	NN	_	15	nmod
19	and	and	CC	_	18	cc
20	the	the	DT	_	22	det
21	test	test	NN	_	22	compound
22	drug	drug	NN	_	18	conj
23	.	.	.	_	4	punct

1	drug1	drug1	NN	_	3	nsubjpass
2	was	be	VBD	_	3	auxpass
3	found	find	VBN	_	0	ROOT
4	to	to	TO	_	5	mark
5	have	have	VB	_	3	xcomp
6	no	no	DT	_	8	neg
7	significant	significant	JJ	_	8	amod
8	effect	effect	NN	_	5	dobj
9	on	on	IN	_	11	case
10	the	the	DT	_	11	det
11	bioavailability	bioavailability	NN	_	5	nmod
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	,	,	,	_	13	punct
15	drug3	drug3	NN	_	13	conj
16	,	,	,	_	13	punct
17	drug4	drug4	NN	_	13	conj
18	,	,	,	_	13	punct
19	drug5	drug5	NN	_	13	conj
20	,	,	,	_	13	punct
21	drug6	drug6	NN	_	13	conj
22	,	,	,	_	13	punct
23	and	and	CC	_	13	cc
24	drug7	drug7	NN	_	13	conj
25	.	.	.	_	3	punct

1	drug1	drug1	NN	_	2	nsubj
2	decreased	decrease	VBD	_	0	ROOT
3	the	the	DT	_	4	det
4	Cmax	cmax	NN	_	2	dobj
5	and	and	CC	_	4	cc
6	AUC	auc	NN	_	4	conj
7	of	of	IN	_	9	case
8	sustained-release	sustained-release	JJ	_	9	amod
9	drug2	drug2	NN	_	4	nmod
10	-LRB-	-lrb-	-LRB-	_	11	punct
11	drug3	drug3	NN	_	9	appos
12	-RRB-	-rrb-	-RRB-	_	11	punct
13	by	by	IN	_	16	case
14	approximately	approximately	RB	_	15	advmod
15	31	31	CD	_	16	nummod
16	%	%	NN	_	2	nmod
17	and	and	CC	_	16	cc
18	11	11	CD	_	19	nummod
19	%	%	NN	_	16	conj
20	,	,	,	_	2	punct
21	respectively	respectively	RB	_	2	advmod
22	.	.	.	_	2	punct

1	Since	since	IN	_	3	mark
2	there	there	EX	_	3	expl
3	is	be	VBZ	_	22	advcl
4	a	a	DT	_	6	det
5	high	high	JJ	_	6	amod
6	degree	degree	NN	_	3	nsubj
7	of	of	IN	_	8	case
8	variability	variability	NN	_	6	nmod
9	in	in	IN	_	11	case
10	the	the	DT	_	11	det
11	bioavailability	bioavailability	NN	_	3	nmod
12	of	of	IN	_	13	case
13	drug1	drug1	NN	_	11	nmod
14	,	,	,	_	22	punct
15	the	the	DT	_	17	det
16	clinical	clinical	JJ	_	17	amod
17	significance	significance	NN	_	22	nsubj
18	of	of	IN	_	20	case
19	this	this	DT	_	20	det
20	finding	finding	NN	_	17	nmod
21	is	be	VBZ	_	22	cop
22	unclear	unclear	JJ	_	0	ROOT
23	.	.	.	_	22	punct

1	In	in	IN	_	3	case
2	clinical	clinical	JJ	_	3	amod
3	studies	study	NNS	_	17	nmod
4	,	,	,	_	17	punct
5	coadministration	coadministration	NN	_	17	nsubj
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	with	with	IN	_	9	case
9	drug2	drug2	NN	_	5	nmod
10	,	,	,	_	9	punct
11	drug3	drug3	NN	_	9	conj
12	,	,	,	_	9	punct
13	or	or	CC	_	9	cc
14	drug4	drug4	NN	_	9	conj
15	did	do	VBD	_	17	aux
16	not	not	RB	_	17	neg
17	interfere	interfere	VB	_	0	ROOT
18	with	with	IN	_	21	case
19	the	the	DT	_	21	det
20	lipid-lowering	lipid-lowering	JJ	_	21	amod
21	activity	activity	NN	_	17	nmod
22	of	of	IN	_	24	case
23	the	the	DT	_	24	det
24	drug5	drug5	NN	_	21	nmod
25	.	.	.	_	17	punct

1	Other	other	JJ	_	2	amod
2	drugs	drug	NNS	_	6	nsubjpass
3	have	have	VBP	_	6	aux
4	not	not	RB	_	6	neg
5	been	be	VBN	_	6	auxpass
6	studied	study	VBN	_	0	ROOT
7	.	.	.	_	6	punct

1	When	when	WRB	_	2	advmod
2	administering	administer	VBG	_	24	advcl
3	other	other	JJ	_	4	amod
4	drugs	drug	NNS	_	2	dobj
5	for	for	IN	_	6	case
6	which	which	WDT	_	12	nmod
7	alterations	alteration	NNS	_	12	nsubj
8	in	in	IN	_	10	case
9	blood	blood	NN	_	10	compound
10	levels	level	NNS	_	7	nmod
11	could	could	MD	_	12	aux
12	have	have	VB	_	4	acl:relcl
13	a	a	DT	_	16	det
14	clinically	clinically	RB	_	15	advmod
15	significant	significant	JJ	_	16	amod
16	effect	effect	NN	_	12	dobj
17	on	on	IN	_	18	case
18	safety	safety	NN	_	12	nmod
19	or	or	CC	_	18	cc
20	efficacy	efficacy	NN	_	18	conj
21	,	,	,	_	24	punct
22	physicians	physician	NNS	_	24	nsubj
23	should	should	MD	_	24	aux
24	consider	consider	VB	_	0	ROOT
25	monitoring	monitor	VBG	_	24	xcomp
26	drug	drug	NN	_	27	compound
27	levels	level	NNS	_	25	dobj
28	or	or	CC	_	27	cc
29	effects	effect	NNS	_	27	conj
30	.	.	.	_	24	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	administered	administer	VBN	_	0	ROOT
5	with	with	IN	_	6	case
6	caution	caution	NN	_	4	nmod
7	to	to	TO	_	8	case
8	patients	patient	NNS	_	6	nmod
9	who	who	WP	_	11	nsubj
10	are	be	VBP	_	11	aux
11	taking	take	VBG	_	8	acl:relcl
12	other	other	JJ	_	13	amod
13	drug2	drug2	NN	_	11	dobj
14	or	or	CC	_	13	cc
15	drug3	drug3	NN	_	13	conj
16	,	,	,	_	13	punct
17	including	include	VBG	_	18	case
18	drug4	drug4	NN	_	13	nmod
19	,	,	,	_	18	punct
20	drug5	drug5	NN	_	18	conj
21	and	and	CC	_	18	cc
22	drug6	drug6	NN	_	18	conj
23	,	,	,	_	18	punct
24	or	or	CC	_	18	cc
25	to	to	TO	_	26	case
26	those	those	DT	_	18	conj
27	with	with	IN	_	29	case
28	a	a	DT	_	29	det
29	history	history	NN	_	26	nmod
30	of	of	IN	_	32	case
31	psychiatric	psychiatric	JJ	_	32	amod
32	disorder	disorder	NN	_	29	nmod
33	-LRB-	-lrb-	-LRB-	_	36	punct
34	including	include	VBG	_	36	case
35	manic-depressive	manic-depressive	NN	_	36	compound
36	illness	illness	NN	_	29	nmod
37	and	and	CC	_	36	cc
38	schizophrenia	schizophrenia	NN	_	36	conj
39	-RRB-	-rrb-	-RRB-	_	36	punct
40	.	.	.	_	4	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	shown	show	VBN	_	0	ROOT
5	to	to	TO	_	6	mark
6	have	have	VB	_	4	xcomp
7	an	a	DT	_	11	det
8	additive	additive	JJ	_	11	amod
9	CNS	cns	NN	_	11	compound
10	depressant	depressant	NN	_	11	compound
11	effect	effect	NN	_	6	dobj
12	when	when	WRB	_	13	advmod
13	given	give	VBN	_	6	advcl
14	with	with	IN	_	16	case
15	either	either	CC	_	16	cc:preconj
16	drug2	drug2	NN	_	13	nmod
17	,	,	,	_	16	punct
18	drug3	drug3	NN	_	16	conj
19	,	,	,	_	16	punct
20	drug4	drug4	NN	_	16	conj
21	or	or	CC	_	16	cc
22	drug5	drug5	NN	_	16	conj
23	.	.	.	_	4	punct

1	Drug	Drug	NNP	_	4	compound
2	Laboratory	Laboratory	NNP	_	4	compound
3	Test	Test	NNP	_	4	compound
4	Interactions	interaction	NNS	_	0	ROOT
5	:	:	:	_	4	punct
6	Prolongation	prolongation	NN	_	14	nsubjpass
7	of	of	IN	_	11	case
8	the	the	DT	_	11	det
9	template	template	NN	_	11	compound
10	bleeding	bleeding	NN	_	11	compound
11	time	time	NN	_	6	nmod
12	has	have	VBZ	_	14	aux
13	been	be	VBN	_	14	auxpass
14	reported	report	VBN	_	4	dep
15	during	during	IN	_	18	case
16	continuous	continuous	JJ	_	18	amod
17	intravenous	intravenous	JJ	_	18	amod
18	infusion	infusion	NN	_	14	nmod
19	of	of	IN	_	20	case
20	drug1	drug1	NN	_	18	nmod
21	at	at	IN	_	22	case
22	dosages	dosage	NNS	_	18	nmod
23	exceeding	exceed	VBG	_	22	acl
24	24	24	CD	_	25	nummod
25	g/day	g/day	NN	_	23	dobj
26	.	.	.	_	4	punct

1	Platelet	platelet	NN	_	3	compound
2	function	function	NN	_	3	compound
3	studies	study	NNS	_	9	nsubj
4	in	in	IN	_	6	case
5	these	these	DT	_	6	det
6	patients	patient	NNS	_	3	nmod
7	have	have	VBP	_	9	aux
8	not	not	RB	_	9	neg
9	demonstrated	demonstrate	VBN	_	0	ROOT
10	any	any	DT	_	13	det
11	significant	significant	JJ	_	13	amod
12	platelet	platelet	NN	_	13	compound
13	dysfunction	dysfunction	NN	_	9	dobj
14	.	.	.	_	9	punct

1	However	however	RB	_	7	advmod
2	,	,	,	_	7	punct
3	in	in	FW	_	5	amod
4	vitro	vitro	FW	_	3	dep
5	studies	study	NNS	_	7	nsubj
6	have	have	VBP	_	7	aux
7	shown	show	VBN	_	0	ROOT
8	that	that	IN	_	22	mark
9	at	at	IN	_	11	case
10	high	high	JJ	_	11	amod
11	concentrations	concentration	NNS	_	22	nmod
12	-LRB-	-lrb-	-LRB-	_	14	punct
13	7.4	7.4	CD	_	14	nummod
14	mMol/L	mmol/l	NN	_	11	dep
15	or	or	CC	_	14	cc
16	0.97	0.97	CD	_	17	nummod
17	mg/mL	mg/ml	NN	_	14	conj
18	and	and	CC	_	14	cc
19	greater	greater	JJR	_	14	conj
20	-RRB-	-rrb-	-RRB-	_	14	punct
21	drug1	drug1	NN	_	22	nsubj
22	inhibits	inhibit	VBZ	_	7	ccomp
23	ADP	adp	NN	_	27	compound
24	and	and	CC	_	23	cc
25	collagen-induced	collagen-induced	JJ	_	23	conj
26	platelet	platelet	NN	_	27	compound
27	aggregation	aggregation	NN	_	22	dobj
28	,	,	,	_	22	punct
29	the	the	DT	_	30	det
30	release	release	NN	_	22	conj
31	of	of	IN	_	32	case
32	ATP	atp	NN	_	30	nmod
33	and	and	CC	_	32	cc
34	serotonin	serotonin	NN	_	32	conj
35	,	,	,	_	22	punct
36	and	and	CC	_	22	cc
37	the	the	DT	_	38	det
38	binding	binding	NN	_	22	conj
39	of	of	IN	_	40	case
40	fibrinogen	fibrinogen	NN	_	38	nmod
41	to	to	TO	_	43	case
42	the	the	DT	_	43	det
43	platelets	platelet	NNS	_	38	nmod
44	in	in	IN	_	47	case
45	a	a	DT	_	47	det
46	concentration-response	concentration-response	JJ	_	47	amod
47	manner	manner	NN	_	38	nmod
48	.	.	.	_	7	punct

1	Following	follow	VBG	_	5	case
2	a	a	DT	_	5	det
3	10	10	CD	_	4	compound
4	g	g	NN	_	5	amod
5	bolus	bolus	NN	_	21	nmod
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	,	,	,	_	21	punct
9	transient	transient	JJ	_	12	amod
10	peak	peak	NN	_	12	compound
11	plasma	plasma	NN	_	12	compound
12	concentrations	concentration	NNS	_	21	nsubjpass
13	of	of	IN	_	15	case
14	4.6	4.6	CD	_	15	nummod
15	mMol/L	mmol/l	NN	_	12	nmod
16	or	or	CC	_	15	cc
17	0.60	0.60	CD	_	18	nummod
18	mg/mL	mg/ml	NN	_	15	conj
19	have	have	VBP	_	21	aux
20	been	be	VBN	_	21	auxpass
21	obtained	obtain	VBN	_	0	ROOT
22	.	.	.	_	21	punct

1	The	the	DT	_	2	det
2	concentration	concentration	NN	_	13	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	necessary	necessary	JJ	_	2	amod
6	to	to	TO	_	7	mark
7	maintain	maintain	VB	_	5	xcomp
8	inhibition	inhibition	NN	_	7	dobj
9	of	of	IN	_	10	case
10	fibrinolysis	fibrinolysis	NN	_	8	nmod
11	is	be	VBZ	_	13	cop
12	0.99	0.99	CD	_	13	nummod
13	mMol/L	mmol/l	NN	_	0	ROOT
14	or	or	CC	_	13	cc
15	0.13	0.13	CD	_	16	nummod
16	mg/mL	mg/ml	NN	_	13	conj
17	.	.	.	_	13	punct

1	Administration	administration	NN	_	7	nsubj
2	of	of	IN	_	6	case
3	a	a	DT	_	6	det
4	5	5	CD	_	5	compound
5	g	g	NN	_	6	amod
6	bolus	bolus	NN	_	1	nmod
7	followed	follow	VBN	_	0	ROOT
8	by	by	IN	_	12	case
9	1	1	CD	_	11	compound
10	to	to	TO	_	11	dep
11	1.25	1.25	CD	_	12	nummod
12	g/hr	g/hr	NN	_	7	nmod
13	should	should	MD	_	14	aux
14	achieve	achieve	VB	_	7	ccomp
15	and	and	CC	_	14	cc
16	sustain	sustain	VB	_	14	conj
17	plasma	plasma	NN	_	18	compound
18	levels	level	NNS	_	14	dobj
19	of	of	IN	_	21	case
20	0.13	0.13	CD	_	21	nummod
21	mg/mL	mg/ml	NN	_	18	nmod
22	.	.	.	_	7	punct

1	Thus	thus	RB	_	19	advmod
2	,	,	,	_	19	punct
3	concentrations	concentration	NNS	_	19	nsubj
4	which	which	WDT	_	7	nsubjpass
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	obtained	obtain	VBN	_	3	acl:relcl
8	in	in	FW	_	9	compound
9	vivo	vivo	FW	_	7	advmod
10	clinically	clinically	RB	_	12	advmod
11	in	in	IN	_	12	case
12	patients	patient	NNS	_	7	nmod
13	with	with	IN	_	16	case
14	normal	normal	JJ	_	16	amod
15	renal	renal	JJ	_	16	amod
16	function	function	NN	_	12	nmod
17	are	be	VBP	_	19	cop
18	considerably	considerably	RB	_	19	advmod
19	lower	lower	JJR	_	0	ROOT
20	than	than	IN	_	24	case
21	the	the	DT	_	24	det
22	in	in	FW	_	24	amod
23	vitro	vitro	FW	_	22	dep
24	concentrations	concentration	NNS	_	19	nmod
25	found	find	VBN	_	24	acl
26	to	to	TO	_	27	mark
27	induce	induce	VB	_	25	xcomp
28	abnormalities	abnormality	NNS	_	27	dobj
29	in	in	IN	_	32	case
30	platelet	platelet	NN	_	32	compound
31	function	function	NN	_	32	compound
32	tests	test	NNS	_	28	nmod
33	.	.	.	_	19	punct

1	However	however	RB	_	9	advmod
2	,	,	,	_	9	punct
3	higher	higher	JJR	_	5	amod
4	plasma	plasma	NN	_	5	compound
5	concentrations	concentration	NNS	_	9	nsubj
6	of	of	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	may	may	MD	_	9	aux
9	occur	occur	VB	_	0	ROOT
10	in	in	IN	_	11	case
11	patients	patient	NNS	_	9	nmod
12	with	with	IN	_	15	case
13	severe	severe	JJ	_	15	amod
14	renal	renal	JJ	_	15	amod
15	failure	failure	NN	_	11	nmod
16	.	.	.	_	9	punct

1	Certain	certain	JJ	_	2	amod
2	drug1	drug1	NN	_	0	ROOT
3	,	,	,	_	2	punct
4	drug2	drug2	NN	_	2	conj
5	,	,	,	_	2	punct
6	drug3	drug3	NN	_	2	conj
7	,	,	,	_	2	punct
8	drug4	drug4	NN	_	2	conj
9	,	,	,	_	2	punct
10	drug5	drug5	NN	_	2	conj
11	,	,	,	_	2	punct
12	and	and	CC	_	2	cc
13	drug6	drug6	NN	_	2	conj
14	.	.	.	_	2	punct

1	No	no	DT	_	2	neg
2	information	information	NN	_	0	ROOT
3	available	available	JJ	_	2	amod

1	.	.	.	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	Increased	increase	VBN	_	2	amod
2	nephrotoxicity	nephrotoxicity	NN	_	5	nsubjpass
3	has	have	VBZ	_	5	aux
4	been	be	VBN	_	5	auxpass
5	reported	report	VBN	_	0	ROOT
6	following	follow	VBG	_	8	case
7	concomitant	concomitant	JJ	_	8	amod
8	administration	administration	NN	_	5	nmod
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	drug2	drug2	NN	_	10	conj
13	.	.	.	_	5	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	3	amod
2	Test	test	NN	_	3	compound
3	Interactions	interaction	NNS	_	17	nsubj
4	As	as	IN	_	6	case
5	with	with	IN	_	6	case
6	drug1	drug1	NN	_	3	nmod
7	,	,	,	_	6	punct
8	high	high	JJ	_	9	amod
9	concentrations	concentration	NNS	_	6	appos
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	-LRB-	-lrb-	-LRB-	_	14	punct
13	100	100	CD	_	14	nummod
14	micrograms/mL	micrograms/ml	NNS	_	11	appos
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	may	may	MD	_	17	aux
17	interfere	interfere	VB	_	0	ROOT
18	with	with	IN	_	19	case
19	measurement	measurement	NN	_	17	nmod
20	of	of	IN	_	21	case
21	serum	serum	NN	_	19	nmod
22	and	and	CC	_	21	cc
23	urine	urine	NN	_	21	conj
24	creatinine	creatinine	NN	_	25	compound
25	levels	level	NNS	_	21	dep
26	by	by	IN	_	29	case
27	the	the	DT	_	29	det
28	Jaff	Jaff	NNP	_	29	compound
29	reaction	reaction	NN	_	19	nmod
30	,	,	,	_	17	punct
31	and	and	CC	_	17	cc
32	produce	produce	VBP	_	17	conj
33	false	false	JJ	_	34	amod
34	increases	increase	NNS	_	32	dobj
35	of	of	IN	_	37	case
36	modest	modest	JJ	_	37	amod
37	degree	degree	NN	_	34	nmod
38	in	in	IN	_	40	case
39	the	the	DT	_	40	det
40	levels	level	NNS	_	32	nmod
41	of	of	IN	_	42	case
42	creatinine	creatinine	NN	_	40	nmod
43	reported	report	VBD	_	40	acl
44	.	.	.	_	17	punct

1	Serum	serum	NN	_	2	compound
2	samples	sample	NNS	_	11	nsubjpass
3	from	from	IN	_	4	case
4	patients	patient	NNS	_	2	nmod
5	treated	treat	VBN	_	4	acl
6	with	with	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	should	should	MD	_	11	aux
9	not	not	RB	_	11	neg
10	be	be	VB	_	11	auxpass
11	analyzed	analyze	VBN	_	0	ROOT
12	for	for	IN	_	13	case
13	creatinine	creatinine	NN	_	11	nmod
14	if	if	IN	_	15	mark
15	withdrawn	withdraw	VBN	_	11	advcl
16	within	within	IN	_	18	case
17	2	2	CD	_	18	nummod
18	hours	hour	NNS	_	15	nmod
19	of	of	IN	_	21	case
20	drug	drug	NN	_	21	compound
21	administration	administration	NN	_	18	nmod
22	.	.	.	_	11	punct

1	High	high	JJ	_	2	amod
2	concentrations	concentration	NNS	_	9	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	in	in	IN	_	7	case
6	the	the	DT	_	7	det
7	urine	urine	NN	_	2	nmod
8	may	may	MD	_	9	aux
9	interfere	interfere	VB	_	0	ROOT
10	with	with	IN	_	11	case
11	measurement	measurement	NN	_	9	nmod
12	of	of	IN	_	14	case
13	urinary	urinary	JJ	_	14	amod
14	17-hydroxy-corticosteroids	17-hydroxy-corticosteroid	NNS	_	11	nmod
15	by	by	IN	_	18	case
16	the	the	DT	_	18	det
17	Porter-Silber	Porter-Silber	NNP	_	18	compound
18	reaction	reaction	NN	_	9	nmod
19	,	,	,	_	9	punct
20	and	and	CC	_	9	cc
21	produce	produce	VBP	_	9	conj
22	false	false	JJ	_	23	amod
23	increases	increase	NNS	_	21	dobj
24	of	of	IN	_	26	case
25	modest	modest	JJ	_	26	amod
26	degree	degree	NN	_	23	nmod
27	in	in	IN	_	29	case
28	the	the	DT	_	29	det
29	levels	level	NNS	_	21	nmod
30	reported	report	VBD	_	29	acl
31	.	.	.	_	9	punct

1	A	a	DT	_	3	det
2	false-positive	false-positive	JJ	_	3	amod
3	reaction	reaction	NN	_	10	nsubj
4	for	for	IN	_	5	case
5	glucose	glucose	NN	_	3	nmod
6	in	in	IN	_	8	case
7	the	the	DT	_	8	det
8	urine	urine	NN	_	5	nmod
9	may	may	MD	_	10	aux
10	occur	occur	VB	_	0	ROOT
11	.	.	.	_	10	punct

1	This	this	DT	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	observed	observe	VBN	_	0	ROOT
5	with	with	IN	_	8	case
6	CLINITEST	clinitest	NN	_	8	compound
7	reagent	reagent	NN	_	8	compound
8	tablets	tablet	NNS	_	4	nmod

1	.	.	.	_	0	ROOT

1	Registered	Registered	NNP	_	2	compound
2	trademark	trademark	NN	_	0	ROOT
3	of	of	IN	_	5	case
4	Ames	Ames	NNP	_	5	compound
5	Company	Company	NNP	_	2	nmod
6	,	,	,	_	5	punct
7	Division	Division	NNP	_	5	appos
8	of	of	IN	_	10	case
9	Miles	Miles	NNP	_	10	compound
10	Laboratories	Laboratories	NNPS	_	7	nmod
11	,	,	,	_	10	punct
12	Inc.	Inc.	NNP	_	10	appos
13	.	.	.	_	2	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	3	amod
2	Test	test	NN	_	3	compound
3	Interactions	interaction	NNS	_	0	ROOT
4	Positive	positive	JJ	_	7	amod
5	direct	direct	JJ	_	7	amod
6	Coombs	Coombs	NNP	_	7	compound
7	tests	test	NNS	_	10	nsubjpass
8	have	have	VBP	_	10	aux
9	been	be	VBN	_	10	auxpass
10	reported	report	VBN	_	3	acl:relcl
11	during	during	IN	_	12	case
12	treatment	treatment	NN	_	10	nmod
13	with	with	IN	_	15	case
14	the	the	DT	_	15	det
15	drug1	drug1	NN	_	12	nmod
16	.	.	.	_	3	punct

1	In	in	IN	_	3	case
2	hematologic	hematologic	JJ	_	3	amod
3	studies	study	NNS	_	35	nmod
4	or	or	CC	_	3	cc
5	in	in	IN	_	8	case
6	transfusion	transfusion	NN	_	8	compound
7	cross-matching	cross-matching	NN	_	8	compound
8	procedures	procedure	NNS	_	3	conj
9	when	when	WRB	_	13	advmod
10	anti-globulin	anti-globulin	JJ	_	11	amod
11	tests	test	NNS	_	13	nsubjpass
12	are	be	VBP	_	13	auxpass
13	performed	perform	VBN	_	8	acl:relcl
14	on	on	IN	_	17	case
15	the	the	DT	_	17	det
16	minor	minor	JJ	_	17	amod
17	side	side	NN	_	13	nmod
18	or	or	CC	_	17	cc
19	in	in	IN	_	21	case
20	Coombs	Coombs	NNP	_	21	compound
21	testing	testing	NN	_	17	conj
22	of	of	IN	_	23	case
23	newborns	newborn	NNS	_	21	nmod
24	whose	whose	WP$	_	25	nmod:poss
25	mothers	mother	NNS	_	27	nsubj
26	have	have	VBP	_	27	aux
27	received	receive	VBN	_	23	acl:relcl
28	drug1	drug1	NN	_	27	dobj
29	before	before	IN	_	30	case
30	parturition	parturition	NN	_	27	nmod
31	,	,	,	_	35	punct
32	it	it	PRP	_	35	nsubjpass
33	should	should	MD	_	35	aux
34	be	be	VB	_	35	auxpass
35	recognized	recognize	VBN	_	0	ROOT
36	that	that	IN	_	46	mark
37	a	a	DT	_	40	det
38	positive	positive	JJ	_	40	amod
39	Coombs	Coombs	NNP	_	40	compound
40	test	test	NN	_	46	nsubj
41	may	may	MD	_	46	aux
42	be	be	VB	_	46	cop
43	due	due	JJ	_	46	case
44	to	to	TO	_	43	mwe
45	the	the	DT	_	46	det
46	drug	drug	NN	_	35	ccomp
47	.	.	.	_	35	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	4	amod
2	Test	test	NN	_	4	compound
3	Interactions	interaction	NNS	_	4	compound
4	None	none	NN	_	0	ROOT
5	known	know	VBN	_	4	acl
6	.	.	.	_	4	punct

1	Drug-Drug	Drug-Drug	NNP	_	3	compound
2	Interactions	interaction	NNS	_	3	compound
3	drug1	drug1	NN	_	0	ROOT
4	:	:	:	_	3	punct
5	Concomitant	concomitant	JJ	_	6	amod
6	use	use	NN	_	10	nsubjpass
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	is	be	VBZ	_	10	auxpass
10	contraindicated	contraindicate	VBN	_	3	dep
11	.	.	.	_	3	punct

1	drug1	drug1	NN	_	25	nsubjpass
2	at	at	IN	_	5	case
3	400	400	CD	_	5	nummod
4	mg	mg	NN	_	5	compound
5	BID	BID	NNP	_	1	nmod
6	-LRB-	-lrb-	-LRB-	_	10	punct
7	the	the	DT	_	10	det
8	usual	usual	JJ	_	10	amod
9	prescription	prescription	NN	_	10	compound
10	dose	dose	NN	_	5	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	co-administered	co-administered	JJ	_	1	amod
13	with	with	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	-LRB-	-lrb-	-LRB-	_	18	punct
16	500	500	CD	_	18	nummod
17	mcg	mcg	NN	_	18	compound
18	BID	BID	NNP	_	14	appos
19	-RRB-	-rrb-	-RRB-	_	18	punct
20	for	for	IN	_	22	case
21	7	7	CD	_	22	nummod
22	days	day	NNS	_	12	nmod
23	has	have	VBZ	_	25	aux
24	been	be	VBN	_	25	auxpass
25	shown	show	VBN	_	0	ROOT
26	to	to	TO	_	27	mark
27	increase	increase	VB	_	25	xcomp
28	drug3	drug3	NN	_	30	compound
29	plasma	plasma	NN	_	30	compound
30	levels	level	NNS	_	27	dobj
31	by	by	IN	_	33	case
32	58	58	CD	_	33	nummod
33	%	%	NN	_	27	nmod
34	.	.	.	_	25	punct

1	drug1	drug1	NN	_	12	nsubj
2	at	at	IN	_	3	case
3	doses	dose	NNS	_	1	nmod
4	of	of	IN	_	7	case
5	100	100	CD	_	7	nummod
6	mg	mg	NN	_	7	compound
7	BID	BID	NNP	_	3	nmod
8	-LRB-	-lrb-	-LRB-	_	10	punct
9	OTC	OTC	NNP	_	10	compound
10	dose	dose	NN	_	7	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	resulted	result	VBD	_	0	ROOT
13	in	in	IN	_	17	case
14	a	a	DT	_	17	det
15	13	13	CD	_	16	compound
16	%	%	NN	_	17	amod
17	increase	increase	NN	_	12	nmod
18	in	in	IN	_	21	case
19	drug2	drug2	NN	_	21	compound
20	plasma	plasma	NN	_	21	compound
21	levels	level	NNS	_	17	nmod
22	-LRB-	-lrb-	-LRB-	_	24	punct
23	500	500	CD	_	24	nummod
24	mcg	mcg	NN	_	17	dep
25	single	single	JJ	_	26	amod
26	dose	dose	NN	_	24	dep
27	-RRB-	-rrb-	-RRB-	_	24	punct
28	.	.	.	_	12	punct

1	No	no	DT	_	2	neg
2	studies	study	NNS	_	5	nsubjpass
3	have	have	VBP	_	5	aux
4	been	be	VBN	_	5	auxpass
5	conducted	conduct	VBN	_	0	ROOT
6	at	at	IN	_	8	case
7	intermediate	intermediate	JJ	_	8	amod
8	doses	dose	NNS	_	5	nmod
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	.	.	.	_	5	punct

1	If	if	IN	_	4	mark
2	a	a	DT	_	3	det
3	patient	patient	NN	_	4	nsubj
4	requires	require	VBZ	_	12	advcl
5	drug1	drug1	NN	_	8	compound
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	therapy	therapy	NN	_	4	dobj
9	,	,	,	_	12	punct
10	it	it	PRP	_	12	nsubjpass
11	is	be	VBZ	_	12	auxpass
12	suggested	suggest	VBN	_	0	ROOT
13	that	that	IN	_	27	mark
14	drug3	drug3	NN	_	27	nsubjpass
15	,	,	,	_	14	punct
16	drug4	drug4	NN	_	14	conj
17	,	,	,	_	14	punct
18	or	or	CC	_	14	cc
19	drug5	drug5	NN	_	14	conj
20	-LRB-	-lrb-	-LRB-	_	21	punct
21	drug6	drug6	NN	_	19	dep
22	and	and	CC	_	21	cc
23	drug7	drug7	NN	_	24	compound
24	s	s	NNS	_	21	conj
25	-RRB-	-rrb-	-RRB-	_	21	punct
26	be	be	VB	_	27	auxpass
27	used	use	VBN	_	12	ccomp
28	as	as	IN	_	29	case
29	alternatives	alternative	NNS	_	27	nmod
30	to	to	TO	_	31	case
31	drug8	drug8	NN	_	29	nmod
32	,	,	,	_	27	punct
33	as	as	IN	_	36	mark
34	these	these	DT	_	35	det
35	agents	agent	NNS	_	36	nsubj
36	have	have	VBP	_	27	advcl
37	no	no	DT	_	38	neg
38	effect	effect	NN	_	36	dobj
39	on	on	IN	_	42	case
40	the	the	DT	_	42	det
41	pharmacokinetic	pharmacokinetic	JJ	_	42	amod
42	profile	profile	NN	_	36	nmod
43	of	of	IN	_	44	case
44	drug9	drug9	NN	_	42	nmod
45	.	.	.	_	12	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concomitant	concomitant	JJ	_	4	amod
4	use	use	NN	_	8	nsubjpass
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	is	be	VBZ	_	8	auxpass
8	contraindicated	contraindicate	VBN	_	1	dep
9	.	.	.	_	1	punct

1	Co-administration	co-administration	NN	_	6	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	1	nmod
6	resulted	result	VBD	_	0	ROOT
7	in	in	IN	_	8	case
8	increases	increase	NNS	_	6	nmod
9	in	in	IN	_	13	case
10	drug3	drug3	NN	_	13	compound
11	peak	peak	NN	_	13	compound
12	plasma	plasma	NN	_	13	compound
13	levels	level	NNS	_	8	nmod
14	of	of	IN	_	16	case
15	42	42	CD	_	16	nummod
16	%	%	NN	_	13	nmod
17	,	,	,	_	6	punct
18	although	although	IN	_	26	mark
19	overall	overall	JJ	_	20	amod
20	exposure	exposure	NN	_	26	nsubjpass
21	to	to	TO	_	22	case
22	drug4	drug4	NN	_	20	nmod
23	was	be	VBD	_	26	auxpass
24	not	not	RB	_	26	neg
25	significantly	significantly	RB	_	26	advmod
26	increased	increase	VBN	_	6	advcl
27	.	.	.	_	6	punct

1	In	in	IN	_	3	case
2	an	a	DT	_	3	det
3	analysis	analysis	NN	_	21	nmod
4	of	of	IN	_	7	case
5	the	the	DT	_	7	det
6	supraventricular	supraventricular	JJ	_	7	amod
7	arrhythmia	arrhythmia	NN	_	3	nmod
8	and	and	CC	_	7	cc
9	DIAMOND	diamond	NN	_	11	compound
10	patient	patient	NN	_	11	compound
11	populations	population	NNS	_	7	conj
12	,	,	,	_	21	punct
13	the	the	DT	_	15	det
14	concomitant	concomitant	JJ	_	15	amod
15	administration	administration	NN	_	21	nsubjpass
16	of	of	IN	_	17	case
17	drug1	drug1	NN	_	15	nmod
18	with	with	IN	_	19	case
19	drug2	drug2	NN	_	15	nmod
20	was	be	VBD	_	21	auxpass
21	associated	associate	VBN	_	0	ROOT
22	with	with	IN	_	25	case
23	a	a	DT	_	25	det
24	higher	higher	JJR	_	25	amod
25	occurrence	occurrence	NN	_	21	nmod
26	of	of	IN	_	29	case
27	torsade	torsade	FW	_	29	compound
28	de	de	FW	_	29	compound
29	pointes	pointes	FW	_	25	nmod
30	.	.	.	_	21	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Concomitant	concomitant	JJ	_	4	amod
4	use	use	NN	_	8	nsubjpass
5	of	of	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	is	be	VBZ	_	8	auxpass
8	contraindicated	contraindicate	VBN	_	1	dep
9	.	.	.	_	1	punct

1	drug1	drug1	NN	_	26	nsubjpass
2	at	at	IN	_	4	case
3	400	400	CD	_	4	nummod
4	mg	mg	NN	_	1	nmod
5	daily	daily	JJ	_	4	amod
6	-LRB-	-lrb-	-LRB-	_	9	punct
7	the	the	DT	_	8	det
8	maximum	maximum	NN	_	9	nsubj
9	approved	approve	VBD	_	4	dep
10	prescription	prescription	NN	_	11	compound
11	dose	dose	NN	_	9	dobj
12	-RRB-	-rrb-	-RRB-	_	9	punct
13	co-administered	co-administered	JJ	_	1	amod
14	with	with	IN	_	15	case
15	drug2	drug2	NN	_	13	nmod
16	-LRB-	-lrb-	-LRB-	_	19	punct
17	500	500	CD	_	19	nummod
18	mcg	mcg	NN	_	19	compound
19	BID	BID	NNP	_	15	appos
20	-RRB-	-rrb-	-RRB-	_	19	punct
21	for	for	IN	_	23	case
22	7	7	CD	_	23	nummod
23	days	day	NNS	_	13	nmod
24	has	have	VBZ	_	26	aux
25	been	be	VBN	_	26	auxpass
26	shown	show	VBN	_	0	ROOT
27	to	to	TO	_	28	mark
28	increase	increase	VB	_	26	xcomp
29	drug3	drug3	NN	_	30	compound
30	Cmax	cmax	NN	_	28	dobj
31	by	by	IN	_	33	case
32	53	53	CD	_	33	nummod
33	%	%	NN	_	28	nmod
34	in	in	IN	_	35	case
35	males	male	NNS	_	28	nmod
36	and	and	CC	_	28	cc
37	97	97	CD	_	38	nummod
38	%	%	NN	_	28	conj
39	in	in	IN	_	40	case
40	females	female	NNS	_	38	nmod
41	,	,	,	_	26	punct
42	and	and	CC	_	26	cc
43	AUC	auc	NN	_	26	conj
44	by	by	IN	_	46	case
45	41	41	CD	_	46	nummod
46	%	%	NN	_	43	nmod
47	in	in	IN	_	48	case
48	males	male	NNS	_	46	nmod
49	and	and	CC	_	46	cc
50	69	69	CD	_	51	nummod
51	%	%	NN	_	46	conj
52	in	in	IN	_	53	case
53	females	female	NNS	_	51	nmod
54	.	.	.	_	26	punct

1	drug1	drug1	NN	_	0	ROOT
2	Alone	alone	RB	_	3	advmod
3	or	or	CC	_	1	advmod
4	in	in	IN	_	5	case
5	Combination	combination	NN	_	3	conj
6	with	with	IN	_	7	case
7	drug2	drug2	NN	_	5	nmod
8	:	:	:	_	1	punct
9	Concomitant	concomitant	JJ	_	10	amod
10	use	use	NN	_	20	nsubjpass
11	of	of	IN	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	alone	alone	RB	_	12	advmod
14	or	or	CC	_	12	cc
15	in	in	IN	_	16	case
16	combination	combination	NN	_	12	conj
17	with	with	IN	_	18	case
18	drug4	drug4	NN	_	16	nmod
19	is	be	VBZ	_	20	auxpass
20	contraindicated	contraindicate	VBN	_	1	dep
21	.	.	.	_	20	punct

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	drug2	drug2	NN	_	1	appos
4	-RRB-	-rrb-	-RRB-	_	3	punct
5	Alone	alone	RB	_	6	advmod
6	or	or	CC	_	1	advmod
7	in	in	IN	_	8	case
8	Combination	combination	NN	_	6	conj
9	with	with	IN	_	10	case
10	drug3	drug3	NN	_	8	nmod
11	:	:	:	_	1	punct
12	Concomitant	concomitant	JJ	_	13	amod
13	use	use	NN	_	23	nsubjpass
14	of	of	IN	_	15	case
15	drug4	drug4	NN	_	13	nmod
16	alone	alone	RB	_	15	advmod
17	or	or	CC	_	15	cc
18	in	in	IN	_	19	case
19	combination	combination	NN	_	15	conj
20	with	with	IN	_	21	case
21	drug5	drug5	NN	_	19	nmod
22	is	be	VBZ	_	23	auxpass
23	contraindicated	contraindicate	VBN	_	1	dep
24	.	.	.	_	23	punct

1	drug1	drug1	NN	_	4	compound
2	50	50	CD	_	3	compound
3	mg	mg	NN	_	4	amod
4	QD	qd	NN	_	13	nsubjpass
5	or	or	CC	_	4	cc
6	drug2	drug2	NN	_	11	compound
7	/	/	:	_	11	punct
8	drug3	drug3	NN	_	11	compound
9	50/100	50/100	CD	_	11	nummod
10	mg	mg	NN	_	11	compound
11	QD	qd	NN	_	4	conj
12	was	be	VBD	_	13	auxpass
13	co-administered	co-administer	VBN	_	0	ROOT
14	with	with	IN	_	15	case
15	drug4	drug4	NN	_	13	nmod
16	-LRB-	-lrb-	-LRB-	_	19	punct
17	500	500	CD	_	19	nummod
18	mcg	mcg	NN	_	19	compound
19	BID	BID	NNP	_	15	appos
20	-RRB-	-rrb-	-RRB-	_	19	punct
21	for	for	IN	_	23	case
22	5	5	CD	_	23	nummod
23	days	day	NNS	_	13	nmod
24	-LRB-	-lrb-	-LRB-	_	27	punct
25	following	follow	VBG	_	27	case
26	2	2	CD	_	27	nummod
27	days	day	NNS	_	23	nmod
28	of	of	IN	_	30	case
29	drug5	drug5	NN	_	30	compound
30	use	use	NN	_	27	nmod
31	at	at	IN	_	33	case
32	half	half	NN	_	33	amod
33	dose	dose	NN	_	30	nmod
34	-RRB-	-rrb-	-RRB-	_	27	punct
35	.	.	.	_	13	punct

1	In	in	IN	_	2	case
2	patients	patient	NNS	_	9	nmod
3	receiving	receive	VBG	_	2	acl
4	drug1	drug1	NN	_	3	dobj
5	alone	alone	RB	_	3	advmod
6	,	,	,	_	9	punct
7	drug2	drug2	NN	_	8	compound
8	AUC	auc	NN	_	9	nsubj
9	increased	increase	VBN	_	0	ROOT
10	by	by	IN	_	12	case
11	27	27	CD	_	12	nummod
12	%	%	NN	_	9	nmod
13	and	and	CC	_	9	cc
14	Cmax	cmax	NN	_	9	conj
15	by	by	IN	_	17	case
16	21	21	CD	_	17	nummod
17	%	%	NN	_	14	nmod
18	.	.	.	_	9	punct

1	However	however	RB	_	6	advmod
2	,	,	,	_	6	punct
3	the	the	DT	_	5	det
4	pharmacodynamic	pharmacodynamic	JJ	_	5	amod
5	effect	effect	NN	_	6	nsubj
6	increased	increase	VBN	_	0	ROOT
7	by	by	IN	_	9	case
8	197	197	CD	_	9	nummod
9	%	%	NN	_	6	nmod
10	-LRB-	-lrb-	-LRB-	_	12	punct
11	QTc	qtc	NN	_	12	compound
12	increase	increase	NN	_	9	dep
13	over	over	IN	_	14	case
14	time	time	NN	_	12	nmod
15	-RRB-	-rrb-	-RRB-	_	12	punct
16	and	and	CC	_	6	cc
17	by	by	IN	_	19	case
18	95	95	CD	_	19	nummod
19	%	%	NN	_	6	conj
20	-LRB-	-lrb-	-LRB-	_	23	punct
21	maximum	maximum	NN	_	23	compound
22	QTc	qtc	NN	_	23	compound
23	increase	increase	NN	_	19	appos
24	-RRB-	-rrb-	-RRB-	_	23	punct
25	.	.	.	_	6	punct

1	However	however	RB	_	6	advmod
2	,	,	,	_	6	punct
3	the	the	DT	_	5	det
4	pharmacodynamic	pharmacodynamic	JJ	_	5	amod
5	effect	effect	NN	_	6	nsubj
6	increased	increase	VBN	_	0	ROOT
7	by	by	IN	_	9	case
8	190	190	CD	_	9	nummod
9	%	%	NN	_	6	nmod
10	-LRB-	-lrb-	-LRB-	_	12	punct
11	QTc	qtc	NN	_	12	compound
12	increase	increase	NN	_	9	dep
13	over	over	IN	_	14	case
14	time	time	NN	_	12	nmod
15	-RRB-	-rrb-	-RRB-	_	12	punct
16	and	and	CC	_	6	cc
17	by	by	IN	_	19	case
18	84	84	CD	_	19	nummod
19	%	%	NN	_	6	conj
20	-LRB-	-lrb-	-LRB-	_	23	punct
21	Maximum	Maximum	NNP	_	23	compound
22	QTc	QTc	NNP	_	23	compound
23	increase	increase	NN	_	19	appos
24	-RRB-	-rrb-	-RRB-	_	23	punct
25	.	.	.	_	6	punct

1	The	the	DT	_	3	det
2	pharmacodynamic	pharmacodynamic	JJ	_	3	amod
3	effects	effect	NNS	_	6	nsubjpass
4	can	can	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	explained	explain	VBN	_	0	ROOT
7	by	by	IN	_	9	case
8	a	a	DT	_	9	det
9	combination	combination	NN	_	6	nmod
10	of	of	IN	_	12	case
11	the	the	DT	_	12	det
12	increase	increase	NN	_	9	nmod
13	in	in	IN	_	15	case
14	drug1	drug1	NN	_	15	compound
15	exposure	exposure	NN	_	12	nmod
16	and	and	CC	_	12	cc
17	the	the	DT	_	18	det
18	reductions	reduction	NNS	_	12	conj
19	in	in	IN	_	21	case
20	serum	serum	NN	_	21	compound
21	potassium	potassium	NN	_	18	nmod
22	.	.	.	_	6	punct

1	In	in	IN	_	4	case
2	the	the	DT	_	4	det
3	DIAMOND	diamond	NN	_	4	compound
4	trials	trial	NNS	_	9	nmod
5	,	,	,	_	9	punct
6	1252	1252	CD	_	7	nummod
7	patients	patient	NNS	_	9	nsubjpass
8	were	be	VBD	_	9	auxpass
9	treated	treat	VBN	_	0	ROOT
10	with	with	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	drug2	drug2	NN	_	11	conj
14	concomitantly	concomitantly	RB	_	18	advmod
15	of	of	IN	_	16	case
16	whom	whom	WP	_	18	nmod
17	493	493	CD	_	18	nsubj
18	died	die	VBD	_	11	acl
19	compared	compare	VBN	_	22	case
20	to	to	TO	_	22	case
21	508	508	CD	_	22	nummod
22	deaths	death	NNS	_	18	advcl
23	among	among	IN	_	26	case
24	the	the	DT	_	26	det
25	1248	1248	CD	_	26	nummod
26	patients	patient	NNS	_	22	nmod
27	receiving	receive	VBG	_	26	acl
28	placebo	placebo	NN	_	27	dobj
29	and	and	CC	_	28	cc
30	drug3	drug3	NN	_	28	conj
31	.	.	.	_	9	punct

1	Of	of	IN	_	4	case
2	the	the	DT	_	4	det
3	229	229	CD	_	4	nummod
4	patients	patient	NNS	_	22	nmod
5	who	who	WP	_	6	nsubj
6	had	have	VBD	_	4	acl:relcl
7	drug1	drug1	NN	_	6	dobj
8	added	add	VBD	_	4	acl
9	to	to	TO	_	12	case
10	their	they	PRP$	_	12	nmod:poss
11	concomitant	concomitant	JJ	_	12	amod
12	medications	medication	NNS	_	8	nmod
13	in	in	IN	_	16	case
14	the	the	DT	_	16	det
15	DIAMOND	diamond	NN	_	16	compound
16	trials	trial	NNS	_	12	nmod
17	,	,	,	_	22	punct
18	the	the	DT	_	19	det
19	patients	patient	NNS	_	22	nsubj
20	on	on	IN	_	21	case
21	drug2	drug2	NN	_	19	nmod
22	had	have	VBD	_	0	ROOT
23	a	a	DT	_	27	det
24	non-significantly	non-significantly	JJ	_	27	amod
25	reduced	reduce	VBN	_	27	amod
26	relative	relative	JJ	_	27	amod
27	risk	risk	NN	_	22	dobj
28	for	for	IN	_	29	case
29	death	death	NN	_	27	nmod
30	of	of	IN	_	31	case
31	0.68	0.68	CD	_	29	nmod
32	-LRB-	-lrb-	-LRB-	_	35	punct
33	95	95	CD	_	34	compound
34	%	%	NN	_	35	amod
35	CI	ci	NN	_	27	appos
36	0.376	0.376	CD	_	35	nummod
37	,	,	,	_	35	punct
38	1.230	1.230	CD	_	35	nummod
39	-RRB-	-rrb-	-RRB-	_	35	punct
40	.	.	.	_	22	punct

1	Potential	potential	JJ	_	4	amod
2	Drug	drug	NN	_	4	compound
3	Interactions	interaction	NNS	_	4	compound
4	drug1	drug1	NN	_	6	nsubjpass
5	is	be	VBZ	_	6	auxpass
6	eliminated	eliminate	VBN	_	0	ROOT
7	in	in	IN	_	9	case
8	the	the	DT	_	9	det
9	kidney	kidney	NN	_	6	nmod
10	by	by	IN	_	12	case
11	cationic	cationic	JJ	_	12	amod
12	secretion	secretion	NN	_	6	nmod
13	.	.	.	_	6	punct

1	Inhibitors	inhibitor	NNS	_	7	nsubjpass
2	of	of	IN	_	5	case
3	renal	renal	JJ	_	5	amod
4	cationic	cationic	JJ	_	5	amod
5	secretion	secretion	NN	_	1	nmod
6	are	be	VBP	_	7	auxpass
7	contraindicated	contraindicate	VBN	_	0	ROOT
8	with	with	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	.	.	.	_	7	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	23	nmod
3	,	,	,	_	23	punct
4	drugs	drug	NNS	_	23	nsubjpass
5	that	that	WDT	_	8	nsubjpass
6	are	be	VBP	_	8	auxpass
7	actively	actively	RB	_	8	advmod
8	secreted	secrete	VBN	_	4	acl:relcl
9	via	via	IN	_	11	case
10	this	this	DT	_	11	det
11	route	route	NN	_	8	nmod
12	-LRB-	-lrb-	-LRB-	_	15	punct
13	e.g.	e.g.	FW	_	15	dep
14	,	,	,	_	15	punct
15	drug1	drug1	NN	_	4	dep
16	,	,	,	_	15	punct
17	drug2	drug2	NN	_	15	conj
18	and	and	CC	_	15	cc
19	drug3	drug3	NN	_	15	conj
20	-RRB-	-rrb-	-RRB-	_	15	punct
21	should	should	MD	_	23	aux
22	be	be	VB	_	23	auxpass
23	co-administered	co-administer	VBN	_	0	ROOT
24	with	with	IN	_	25	case
25	care	care	NN	_	23	nmod
26	as	as	IN	_	29	mark
27	they	they	PRP	_	29	nsubj
28	might	might	MD	_	29	aux
29	increase	increase	VB	_	23	advcl
30	drug4	drug4	NN	_	31	compound
31	levels	level	NNS	_	29	dobj
32	.	.	.	_	23	punct

1	drug1	drug1	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	metabolized	metabolize	VBN	_	0	ROOT
4	to	to	TO	_	7	case
5	a	a	DT	_	7	det
6	small	small	JJ	_	7	amod
7	extent	extent	NN	_	3	nmod
8	by	by	IN	_	11	case
9	the	the	DT	_	11	det
10	CYP3A4	cyp3a4	NN	_	11	compound
11	isoenzyme	isoenzyme	NN	_	3	nmod
12	of	of	IN	_	16	case
13	the	the	DT	_	16	det
14	cytochrome	cytochrome	NN	_	16	compound
15	P450	p450	NN	_	16	compound
16	system	system	NN	_	11	nmod
17	.	.	.	_	3	punct

1	Inhibitors	inhibitor	NNS	_	7	nsubj
2	of	of	IN	_	5	case
3	the	the	DT	_	5	det
4	CYP3A4	cyp3a4	NN	_	5	compound
5	isoenzyme	isoenzyme	NN	_	1	nmod
6	could	could	MD	_	7	aux
7	increase	increase	VB	_	0	ROOT
8	systemic	systemic	JJ	_	10	amod
9	drug1	drug1	NN	_	10	compound
10	exposure	exposure	NN	_	7	dobj
11	.	.	.	_	7	punct

1	Inhibitors	inhibitor	NNS	_	36	nsubjpass
2	of	of	IN	_	4	case
3	this	this	DT	_	4	det
4	isoenzyme	isoenzyme	NN	_	1	nmod
5	-LRB-	-lrb-	-LRB-	_	8	punct
6	e.g.	e.g.	FW	_	8	dep
7	,	,	,	_	8	punct
8	drug1	drug1	NN	_	4	dep
9	,	,	,	_	8	punct
10	drug2	drug2	NN	_	8	conj
11	,	,	,	_	8	punct
12	drug3	drug3	NN	_	8	conj
13	,	,	,	_	8	punct
14	drug4	drug4	NN	_	8	conj
15	,	,	,	_	8	punct
16	drug5	drug5	NN	_	8	conj
17	,	,	,	_	8	punct
18	drug6	drug6	NN	_	8	conj
19	,	,	,	_	8	punct
20	drug7	drug7	NN	_	8	conj
21	,	,	,	_	8	punct
22	grapefruit	grapefruit	NN	_	23	compound
23	juice	juice	NN	_	8	conj
24	,	,	,	_	8	punct
25	drug8	drug8	NN	_	8	conj
26	,	,	,	_	8	punct
27	drug9	drug9	NN	_	8	conj
28	,	,	,	_	8	punct
29	drug10	drug10	NN	_	8	conj
30	,	,	,	_	8	punct
31	drug11	drug11	NN	_	8	appos
32	-RRB-	-rrb-	-RRB-	_	8	punct
33	should	should	MD	_	36	aux
34	be	be	VB	_	36	auxpass
35	cautiously	cautiously	RB	_	36	advmod
36	coadministered	coadminister	VBN	_	0	ROOT
37	with	with	IN	_	38	case
38	drug12	drug12	NN	_	36	nmod
39	as	as	IN	_	43	mark
40	they	they	PRP	_	43	nsubj
41	can	can	MD	_	43	aux
42	potentially	potentially	RB	_	43	advmod
43	increase	increase	VB	_	36	advcl
44	drug13	drug13	NN	_	45	compound
45	levels	level	NNS	_	43	dobj
46	.	.	.	_	36	punct

1	drug1	drug1	NN	_	5	nsubj
2	is	be	VBZ	_	5	cop
3	not	not	RB	_	5	neg
4	an	a	DT	_	5	det
5	inhibitor	inhibitor	NN	_	0	ROOT
6	of	of	IN	_	7	case
7	CYP3A4	cyp3a4	NN	_	5	nmod
8	nor	nor	CC	_	7	cc
9	of	of	IN	_	13	case
10	other	other	JJ	_	13	amod
11	cytochrome	cytochrome	NN	_	13	compound
12	P450	p450	NN	_	13	compound
13	isoenzymes	isoenzyme	NNS	_	7	conj
14	-LRB-	-lrb-	-LRB-	_	17	punct
15	e.g.	e.g.	FW	_	17	dep
16	,	,	,	_	17	punct
17	CYP2C9	cyp2c9	NN	_	13	dep
18	,	,	,	_	17	punct
19	CYP2D6	cyp2d6	NN	_	17	appos
20	-RRB-	-rrb-	-RRB-	_	17	punct
21	and	and	CC	_	5	cc
22	is	be	VBZ	_	24	auxpass
23	not	not	RB	_	24	neg
24	expected	expect	VBN	_	5	conj
25	to	to	TO	_	26	mark
26	increase	increase	VB	_	24	xcomp
27	levels	level	NNS	_	26	dobj
28	of	of	IN	_	29	case
29	drugs	drug	NNS	_	27	nmod
30	metabolized	metabolize	VBN	_	29	acl
31	by	by	IN	_	32	case
32	CYP3A4	cyp3a4	NN	_	30	nmod
33	.	.	.	_	5	punct

1	Other	other	JJ	_	5	amod
2	Drug	drug	NN	_	5	compound
3	Interaction	interaction	NN	_	5	compound
4	Information	information	NN	_	5	compound
5	drug1	drug1	NN	_	0	ROOT
6	:	:	:	_	5	punct
7	Studies	study	NNS	_	12	nsubj
8	in	in	IN	_	10	case
9	healthy	healthy	JJ	_	10	amod
10	volunteers	volunteer	NNS	_	7	nmod
11	have	have	VBP	_	12	aux
12	shown	show	VBN	_	5	dep
13	that	that	IN	_	17	mark
14	drug2	drug2	NN	_	17	nsubj
15	does	do	VBZ	_	17	aux
16	not	not	RB	_	17	neg
17	affect	affect	VB	_	12	ccomp
18	the	the	DT	_	19	det
19	pharmacokinetics	pharmacokinetic	NNS	_	17	dobj
20	of	of	IN	_	21	case
21	drug3	drug3	NN	_	19	nmod
22	.	.	.	_	5	punct

1	In	in	IN	_	2	case
2	patients	patient	NNS	_	12	nmod
3	,	,	,	_	12	punct
4	the	the	DT	_	6	det
5	concomitant	concomitant	JJ	_	6	amod
6	administration	administration	NN	_	12	nsubjpass
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	with	with	IN	_	10	case
10	drug2	drug2	NN	_	6	nmod
11	was	be	VBD	_	12	auxpass
12	associated	associate	VBN	_	0	ROOT
13	with	with	IN	_	16	case
14	a	a	DT	_	16	det
15	higher	higher	JJR	_	16	amod
16	occurrence	occurrence	NN	_	12	nmod
17	of	of	IN	_	20	case
18	torsade	torsade	FW	_	20	compound
19	de	de	FW	_	20	compound
20	pointes	pointes	FW	_	16	nmod
21	.	.	.	_	12	punct

1	It	it	PRP	_	4	nsubj
2	is	be	VBZ	_	4	cop
3	not	not	RB	_	4	neg
4	clear	clear	JJ	_	0	ROOT
5	whether	whether	IN	_	7	mark
6	this	this	DT	_	7	nsubj
7	represents	represent	VBZ	_	4	ccomp
8	an	a	DT	_	9	det
9	interaction	interaction	NN	_	7	dobj
10	with	with	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	or	or	CC	_	11	cc
13	the	the	DT	_	14	det
14	presence	presence	NN	_	11	conj
15	of	of	IN	_	20	case
16	more	more	RBR	_	17	advmod
17	severe	severe	JJ	_	20	amod
18	structural	structural	JJ	_	20	amod
19	heart	heart	NN	_	20	compound
20	disease	disease	NN	_	14	nmod
21	in	in	IN	_	22	case
22	patients	patient	NNS	_	9	nmod
23	on	on	IN	_	24	case
24	drug2	drug2	NN	_	22	nmod
25	;	;	:	_	4	punct

1	structural	structural	JJ	_	3	amod
2	heart	heart	NN	_	3	compound
3	disease	disease	NN	_	8	nsubj
4	is	be	VBZ	_	8	cop
5	a	a	DT	_	8	det
6	known	known	JJ	_	8	amod
7	risk	risk	NN	_	8	compound
8	factor	factor	NN	_	0	ROOT
9	for	for	IN	_	10	case
10	arrhythmia	arrhythmia	NN	_	8	nmod
11	.	.	.	_	8	punct

1	No	no	DT	_	2	neg
2	increase	increase	NN	_	6	nsubjpass
3	in	in	IN	_	4	case
4	mortality	mortality	NN	_	2	nmod
5	was	be	VBD	_	6	auxpass
6	observed	observe	VBN	_	0	ROOT
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	taking	take	VBG	_	8	acl
10	drug1	drug1	NN	_	9	dobj
11	as	as	IN	_	13	case
12	concomitant	concomitant	JJ	_	13	amod
13	medication	medication	NN	_	9	nmod
14	.	.	.	_	6	punct

1	Other	other	JJ	_	2	amod
2	Drugs	drug	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	In	in	IN	_	6	case
5	healthy	healthy	JJ	_	6	amod
6	volunteers	volunteer	NNS	_	42	nmod
7	,	,	,	_	6	punct
8	drug1	drug1	NN	_	6	conj
9	,	,	,	_	6	punct
10	drug2	drug2	NN	_	6	conj
11	,	,	,	_	6	punct
12	drug3	drug3	NN	_	6	conj
13	,	,	,	_	6	punct
14	drug4	drug4	NN	_	6	conj
15	,	,	,	_	6	punct
16	drug5	drug5	NN	_	6	conj
17	,	,	,	_	6	punct
18	hormone	hormone	NN	_	20	compound
19	replacement	replacement	NN	_	20	compound
20	therapy	therapy	NN	_	6	conj
21	-LRB-	-lrb-	-LRB-	_	23	punct
22	a	a	DT	_	23	det
23	combination	combination	NN	_	20	dep
24	of	of	IN	_	26	case
25	conjugated	conjugate	VBN	_	26	amod
26	drug6	drug6	NN	_	23	nmod
27	and	and	CC	_	26	cc
28	drug7	drug7	NN	_	26	conj
29	-RRB-	-rrb-	-RRB-	_	23	punct
30	,	,	,	_	6	punct
31	drug8	drug8	NN	_	6	conj
32	-LRB-	-lrb-	-LRB-	_	33	punct
33	drug9	drug9	NN	_	31	dep
34	and	and	CC	_	33	cc
35	drug10	drug10	NN	_	36	compound
36	s	s	NNS	_	33	conj
37	-RRB-	-rrb-	-RRB-	_	33	punct
38	and	and	CC	_	6	cc
39	drug11	drug11	NN	_	6	conj
40	did	do	VBD	_	42	aux
41	not	not	RB	_	42	neg
42	affect	affect	VB	_	2	dep
43	the	the	DT	_	44	det
44	pharmacokinetics	pharmacokinetic	NNS	_	42	dobj
45	of	of	IN	_	46	case
46	drug12	drug12	NN	_	44	nmod
47	.	.	.	_	2	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	9	nmod
3	,	,	,	_	9	punct
4	studies	study	NNS	_	9	nsubj
5	in	in	IN	_	7	case
6	healthy	healthy	JJ	_	7	amod
7	volunteers	volunteer	NNS	_	4	nmod
8	have	have	VBP	_	9	aux
9	shown	show	VBN	_	0	ROOT
10	that	that	IN	_	14	mark
11	drug1	drug1	NN	_	14	nsubj
12	does	do	VBZ	_	14	aux
13	not	not	RB	_	14	neg
14	affect	affect	VB	_	9	ccomp
15	the	the	DT	_	16	det
16	pharmacokinetics	pharmacokinetic	NNS	_	14	dobj
17	or	or	CC	_	16	cc
18	pharmacodynamics	pharmacodynamic	NNS	_	16	conj
19	of	of	IN	_	20	case
20	drug2	drug2	NN	_	16	nmod
21	,	,	,	_	16	punct
22	or	or	CC	_	16	cc
23	the	the	DT	_	24	det
24	pharmacokinetics	pharmacokinetic	NNS	_	16	conj
25	of	of	IN	_	26	case
26	drug3	drug3	NN	_	24	nmod
27	-LRB-	-lrb-	-LRB-	_	29	punct
28	40	40	CD	_	29	nummod
29	mg	mg	NN	_	26	appos
30	twice	twice	RB	_	31	advmod
31	daily	daily	RB	_	29	advmod
32	-RRB-	-rrb-	-RRB-	_	29	punct
33	,	,	,	_	26	punct
34	drug4	drug4	NN	_	26	conj
35	,	,	,	_	26	punct
36	drug5	drug5	NN	_	26	conj
37	,	,	,	_	26	punct
38	or	or	CC	_	26	cc
39	oral	oral	JJ	_	40	amod
40	drug6	drug6	NN	_	26	conj
41	.	.	.	_	9	punct

1	Population	Population	NNP	_	3	compound
2	pharmacokinetic	pharmacokinetic	JJ	_	3	amod
3	analyses	analysis	NNS	_	5	nsubjpass
4	were	be	VBD	_	5	auxpass
5	conducted	conduct	VBN	_	0	ROOT
6	on	on	IN	_	9	case
7	plasma	plasma	NN	_	9	compound
8	concentration	concentration	NN	_	9	compound
9	data	datum	NNS	_	5	nmod
10	from	from	IN	_	12	case
11	1445	1445	CD	_	12	nummod
12	patients	patient	NNS	_	9	nmod
13	in	in	IN	_	15	case
14	clinical	clinical	JJ	_	15	amod
15	trials	trial	NNS	_	12	nmod
16	to	to	TO	_	17	mark
17	examine	examine	VB	_	5	xcomp
18	the	the	DT	_	19	det
19	effects	effect	NNS	_	17	dobj
20	of	of	IN	_	22	case
21	concomitant	concomitant	JJ	_	22	amod
22	medications	medication	NNS	_	19	nmod
23	on	on	IN	_	24	case
24	clearance	clearance	NN	_	19	nmod
25	or	or	CC	_	24	cc
26	volume	volume	NN	_	24	conj
27	of	of	IN	_	28	case
28	distribution	distribution	NN	_	24	nmod
29	of	of	IN	_	30	case
30	drug1	drug1	NN	_	28	nmod
31	.	.	.	_	5	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	medications	medication	NNS	_	4	nsubjpass
3	were	be	VBD	_	4	auxpass
4	grouped	group	VBN	_	0	ROOT
5	as	as	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	,	,	,	_	6	punct
8	oral	oral	JJ	_	9	amod
9	drug2	drug2	NN	_	6	conj
10	,	,	,	_	6	punct
11	drug3	drug3	NN	_	6	conj
12	,	,	,	_	6	punct
13	drug4	drug4	NN	_	6	conj
14	,	,	,	_	6	punct
15	drug5	drug5	NN	_	6	conj
16	,	,	,	_	6	punct
17	inducers	inducer	NNS	_	6	conj
18	of	of	IN	_	19	case
19	CYP3A4	cyp3a4	NN	_	17	nmod
20	,	,	,	_	19	punct
21	substrates	substrate	NNS	_	19	conj
22	and	and	CC	_	19	cc
23	inhibitors	inhibitor	NNS	_	19	conj
24	of	of	IN	_	25	case
25	CYP3A4	cyp3a4	NN	_	23	nmod
26	,	,	,	_	25	punct
27	substrates	substrate	NNS	_	25	conj
28	and	and	CC	_	25	cc
29	inhibitors	inhibitor	NNS	_	25	conj
30	of	of	IN	_	31	case
31	P-glycoprotein	p-glycoprotein	NN	_	29	nmod
32	,	,	,	_	31	punct
33	drug6	drug6	NN	_	31	conj
34	,	,	,	_	31	punct
35	drug7	drug7	NN	_	31	conj
36	,	,	,	_	31	punct
37	drug8	drug8	NN	_	31	conj
38	,	,	,	_	31	punct
39	drug9	drug9	NN	_	31	conj
40	,	,	,	_	31	punct
41	drug10	drug10	NN	_	31	conj
42	,	,	,	_	31	punct
43	substrates	substrate	NNS	_	31	conj
44	and	and	CC	_	31	cc
45	inhibitors	inhibitor	NNS	_	31	conj
46	of	of	IN	_	50	case
47	tubular	tubular	JJ	_	50	amod
48	organic	organic	JJ	_	50	amod
49	cation	cation	NN	_	50	compound
50	transport	transport	NN	_	31	nmod
51	,	,	,	_	6	punct
52	and	and	CC	_	6	cc
53	QTc-prolonging	qtc-prolonging	JJ	_	54	amod
54	drugs	drug	NNS	_	6	conj
55	.	.	.	_	4	punct

1	Differences	difference	NNS	_	0	ROOT
2	in	in	IN	_	3	case
3	clearance	clearance	NN	_	1	nmod
4	between	between	IN	_	5	case
5	patients	patient	NNS	_	3	nmod
6	on	on	IN	_	8	case
7	these	these	DT	_	8	det
8	medications	medication	NNS	_	5	nmod
9	-LRB-	-lrb-	-LRB-	_	12	punct
10	at	at	IN	_	12	case
11	any	any	DT	_	12	det
12	occasion	occasion	NN	_	1	nmod
13	in	in	IN	_	15	case
14	the	the	DT	_	15	det
15	study	study	NN	_	12	nmod
16	-RRB-	-rrb-	-RRB-	_	12	punct
17	and	and	CC	_	1	cc
18	those	those	DT	_	1	conj
19	off	off	IN	_	20	case
20	medications	medication	NNS	_	18	nmod
21	varied	vary	VBD	_	20	acl
22	between	between	IN	_	24	case
23	-16	-16	CD	_	24	nummod
24	%	%	NN	_	21	nmod
25	and	and	CC	_	24	cc
26	+3	+3	CD	_	27	nummod
27	%	%	NN	_	24	conj
28	.	.	.	_	1	punct

1	The	the	DT	_	3	det
2	mean	mean	NN	_	3	compound
3	clearances	clearance	NNS	_	8	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	were	be	VBD	_	8	cop
7	16	16	CD	_	8	nummod
8	%	%	NN	_	0	ROOT
9	and	and	CC	_	8	cc
10	15	15	CD	_	11	nummod
11	%	%	NN	_	8	conj
12	lower	lower	JJR	_	8	amod
13	in	in	IN	_	14	case
14	patients	patient	NNS	_	12	nmod
15	on	on	IN	_	16	case
16	drug2	drug2	NN	_	14	nmod
17	and	and	CC	_	16	cc
18	inhibitors	inhibitor	NNS	_	16	conj
19	of	of	IN	_	23	case
20	tubular	tubular	JJ	_	23	amod
21	organic	organic	JJ	_	23	amod
22	cation	cation	NN	_	23	compound
23	transport	transport	NN	_	16	nmod
24	,	,	,	_	8	punct
25	respectively	respectively	RB	_	8	advmod
26	.	.	.	_	8	punct

1	The	the	DT	_	3	det
2	CNS	cns	NN	_	3	compound
3	effects	effect	NNS	_	8	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	may	may	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	enhanced	enhance	VBN	_	0	ROOT
9	by	by	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	.	.	.	_	8	punct

1	drug1	drug1	NN	_	7	nsubj
2	,	,	,	_	1	punct
3	drug2	drug2	NN	_	1	conj
4	and	and	CC	_	1	cc
5	drug3	drug3	NN	_	1	conj
6	may	may	MD	_	7	aux
7	enhance	enhance	VB	_	0	ROOT
8	the	the	DT	_	9	det
9	effects	effect	NNS	_	7	dobj
10	of	of	IN	_	14	case
11	:	:	:	_	14	punct
12	other	other	JJ	_	14	amod
13	drug4	drug4	NN	_	14	compound
14	s	s	NNS	_	9	nmod
15	,	,	,	_	14	punct
16	drug5	drug5	NN	_	14	conj
17	,	,	,	_	14	punct
18	general	general	JJ	_	19	amod
19	drug6	drug6	NN	_	14	conj
20	,	,	,	_	14	punct
21	drug7	drug7	NN	_	14	conj
22	such	such	JJ	_	24	case
23	as	as	IN	_	22	mwe
24	drug8	drug8	NN	_	21	nmod
25	,	,	,	_	24	punct
26	drug9	drug9	NN	_	24	conj
27	,	,	,	_	24	punct
28	or	or	CC	_	24	cc
29	other	other	JJ	_	30	amod
30	drug10	drug10	NN	_	24	conj
31	,	,	,	_	14	punct
32	causing	cause	VBG	_	14	acl
33	increased	increase	VBN	_	35	amod
34	CNS	cns	NN	_	35	compound
35	depression	depression	NN	_	32	dobj
36	.	.	.	_	7	punct

1	Drug/Laboratory	drug/laboratory	JJ	_	4	amod
2	Test	test	NN	_	4	compound
3	Interactions	interaction	NNS	_	4	compound
4	drug1	drug1	NN	_	6	nsubj
5	may	may	MD	_	6	aux
6	produce	produce	VB	_	0	ROOT
7	false-positive	false-positive	JJ	_	8	amod
8	test	test	NN	_	9	nsubj
9	results	result	VBZ	_	6	ccomp
10	for	for	IN	_	13	case
11	urinary	urinary	JJ	_	13	amod
12	5-hydroxyindoleacetic	5-hydroxyindoleacetic	JJ	_	13	amod
13	acid	acid	NN	_	9	nmod
14	.	.	.	_	6	punct

1	Use	use	NN	_	5	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	may	may	MD	_	5	aux
5	cause	cause	VB	_	0	ROOT
6	an	a	DT	_	8	det
7	excessive	excessive	JJ	_	8	amod
8	increase	increase	NN	_	5	dobj
9	in	in	IN	_	11	case
10	blood	blood	NN	_	11	compound
11	pressure	pressure	NN	_	8	nmod
12	and	and	CC	_	11	cc
13	heart	heart	NN	_	14	compound
14	stimulation	stimulation	NN	_	11	conj
15	.	.	.	_	5	punct

1	If	if	IN	_	5	mark
2	you	you	PRP	_	5	nsubj
3	are	be	VBP	_	5	aux
4	also	also	RB	_	5	advmod
5	using	use	VBG	_	10	advcl
6	a	a	DT	_	8	det
7	drug1	drug1	NN	_	8	compound
8	inhaler	inhaler	NN	_	5	dobj
9	,	,	,	_	10	punct
10	take	take	VB	_	0	ROOT
11	drug2	drug2	NN	_	12	compound
12	first	first	JJ	_	10	dobj
13	and	and	CC	_	10	cc
14	then	then	RB	_	15	advmod
15	wait	wait	VB	_	10	conj
16	about	about	RB	_	17	advmod
17	15	15	CD	_	18	nummod
18	minutes	minute	NNS	_	15	dobj
19	before	before	IN	_	20	mark
20	using	use	VBG	_	15	advcl
21	the	the	DT	_	23	det
22	drug3	drug3	NN	_	23	compound
23	inhaler	inhaler	NN	_	20	dobj
24	.	.	.	_	10	punct

1	This	this	DT	_	2	nsubj
2	allows	allow	VBZ	_	0	ROOT
3	drug1	drug1	NN	_	2	dobj
4	to	to	TO	_	5	mark
5	open	open	VB	_	2	xcomp
6	air	air	NN	_	7	compound
7	passages	passage	NNS	_	5	dobj
8	,	,	,	_	5	punct
9	increasing	increase	VBG	_	5	advcl
10	the	the	DT	_	11	det
11	effectiveness	effectiveness	NN	_	9	dobj
12	of	of	IN	_	14	case
13	the	the	DT	_	14	det
14	drug2	drug2	NN	_	11	nmod
15	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Patients	patient	NNS	_	19	nsubj
4	on	on	IN	_	5	case
5	drug2	drug2	NN	_	3	nmod
6	,	,	,	_	3	punct
7	especially	especially	RB	_	8	advmod
8	those	those	DT	_	3	appos
9	in	in	IN	_	10	case
10	whom	whom	WP	_	15	nmod
11	diuretic	diuretic	JJ	_	12	amod
12	therapy	therapy	NN	_	15	nsubjpass
13	was	be	VBD	_	15	auxpass
14	recently	recently	RB	_	15	advmod
15	instituted	institute	VBN	_	8	acl:relcl
16	,	,	,	_	3	punct
17	may	may	MD	_	19	aux
18	occasionally	occasionally	RB	_	19	advmod
19	experience	experience	VB	_	1	dep
20	an	a	DT	_	22	det
21	excessive	excessive	JJ	_	22	amod
22	reduction	reduction	NN	_	19	dobj
23	of	of	IN	_	25	case
24	blood	blood	NN	_	25	compound
25	pressure	pressure	NN	_	22	nmod
26	after	after	IN	_	27	case
27	initiation	initiation	NN	_	19	nmod
28	of	of	IN	_	29	case
29	therapy	therapy	NN	_	27	nmod
30	with	with	IN	_	31	case
31	drug3	drug3	NN	_	27	nmod
32	.	.	.	_	19	punct

1	The	the	DT	_	2	det
2	possibility	possibility	NN	_	10	nsubjpass
3	of	of	IN	_	5	case
4	hypotensive	hypotensive	JJ	_	5	amod
5	effects	effect	NNS	_	2	nmod
6	with	with	IN	_	7	case
7	drug1	drug1	NN	_	5	nmod
8	can	can	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	minimized	minimize	VBN	_	0	ROOT
11	by	by	IN	_	13	mark
12	either	either	CC	_	13	cc:preconj
13	discontinuing	discontinue	VBG	_	10	advcl
14	the	the	DT	_	15	det
15	drug2	drug2	NN	_	13	dobj
16	or	or	CC	_	13	cc
17	increasing	increase	VBG	_	13	conj
18	the	the	DT	_	20	det
19	salt	salt	NN	_	20	compound
20	intake	intake	NN	_	17	dobj
21	prior	prior	RB	_	17	advmod
22	to	to	TO	_	23	case
23	initiation	initiation	NN	_	21	nmod
24	of	of	IN	_	25	case
25	treatment	treatment	NN	_	23	nmod
26	with	with	IN	_	27	case
27	drug3	drug3	NN	_	25	nmod
28	.	.	.	_	10	punct

1	If	if	IN	_	5	mark
2	this	this	DT	_	5	nsubj
3	is	be	VBZ	_	5	cop
4	not	not	RB	_	5	neg
5	possible	possible	JJ	_	12	advcl
6	,	,	,	_	12	punct
7	the	the	DT	_	9	det
8	starting	start	VBG	_	9	amod
9	dose	dose	NN	_	12	nsubjpass
10	should	should	MD	_	12	aux
11	be	be	VB	_	12	auxpass
12	reduced	reduce	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	drug1	drug1	NN	_	2	compound
2	Supplements	supplement	NNS	_	7	nsubj
3	and	and	CC	_	2	cc
4	drug2	drug2	NN	_	5	compound
5	Lotensin	lotensin	NN	_	2	conj
6	can	can	MD	_	7	aux
7	attenuate	attenuate	VB	_	0	ROOT
8	potassium	potassium	NN	_	9	compound
9	loss	loss	NN	_	7	dobj
10	caused	cause	VBN	_	9	acl
11	by	by	IN	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	.	.	.	_	7	punct

1	drug1	drug1	NN	_	14	compound
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	drug2	drug2	NN	_	1	dep
4	,	,	,	_	3	punct
5	drug3	drug3	NN	_	3	conj
6	,	,	,	_	3	punct
7	drug4	drug4	NN	_	3	conj
8	,	,	,	_	3	punct
9	and	and	CC	_	3	cc
10	others	other	NNS	_	3	conj
11	-RRB-	-rrb-	-RRB-	_	3	punct
12	or	or	CC	_	1	cc
13	drug5	drug5	NN	_	1	conj
14	supplements	supplement	NNS	_	16	nsubj
15	can	can	MD	_	16	aux
16	increase	increase	VB	_	0	ROOT
17	the	the	DT	_	18	det
18	risk	risk	NN	_	16	dobj
19	of	of	IN	_	20	case
20	hyperkalemia	hyperkalemia	NN	_	18	nmod
21	.	.	.	_	16	punct

1	Therefore	therefore	RB	_	15	advmod
2	,	,	,	_	15	punct
3	if	if	IN	_	10	mark
4	concomitant	concomitant	JJ	_	5	amod
5	use	use	NN	_	10	nsubjpass
6	of	of	IN	_	8	case
7	such	such	JJ	_	8	amod
8	agents	agent	NNS	_	5	nmod
9	is	be	VBZ	_	10	auxpass
10	indicated	indicate	VBN	_	15	advcl
11	,	,	,	_	15	punct
12	they	they	PRP	_	15	nsubjpass
13	should	should	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	given	give	VBN	_	0	ROOT
16	with	with	IN	_	17	case
17	caution	caution	NN	_	15	nmod
18	,	,	,	_	15	punct
19	and	and	CC	_	15	cc
20	the	the	DT	_	21	det
21	patient	patient	NN	_	24	nmod:poss
22	's	's	POS	_	21	case
23	serum	serum	NN	_	24	compound
24	potassium	potassium	NN	_	27	nsubjpass
25	should	should	MD	_	27	aux
26	be	be	VB	_	27	auxpass
27	monitored	monitor	VBN	_	15	conj
28	frequently	frequently	RB	_	27	advmod
29	.	.	.	_	15	punct

1	Oral	oral	JJ	_	4	amod
2	drug1	drug1	NN	_	4	compound
3	Interaction	interaction	NN	_	4	compound
4	studies	study	NNS	_	9	nsubj
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	drug3	drug3	NN	_	6	conj
9	failed	fail	VBD	_	0	ROOT
10	to	to	TO	_	11	mark
11	identify	identify	VB	_	9	xcomp
12	any	any	DT	_	15	det
13	clinically	clinically	RB	_	14	advmod
14	important	important	JJ	_	15	amod
15	effects	effect	NNS	_	11	dobj
16	on	on	IN	_	19	case
17	the	the	DT	_	19	det
18	serum	serum	NN	_	19	compound
19	concentrations	concentration	NNS	_	15	nmod
20	or	or	CC	_	19	cc
21	clinical	clinical	JJ	_	22	amod
22	effects	effect	NNS	_	19	conj
23	of	of	IN	_	25	case
24	these	these	DT	_	25	det
25	drug4	drug4	NN	_	19	nmod
26	.	.	.	_	9	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	Increased	increase	VBN	_	6	amod
4	serum	serum	NN	_	6	compound
5	drug2	drug2	NN	_	6	compound
6	levels	level	NNS	_	14	nsubjpass
7	and	and	CC	_	6	cc
8	symptoms	symptom	NNS	_	6	conj
9	of	of	IN	_	11	case
10	drug3	drug3	NN	_	11	compound
11	toxicity	toxicity	NN	_	8	nmod
12	have	have	VBP	_	14	aux
13	been	be	VBN	_	14	auxpass
14	reported	report	VBN	_	1	appos
15	in	in	IN	_	16	case
16	patients	patient	NNS	_	14	nmod
17	receiving	receive	VBG	_	16	acl
18	drug4	drug4	NN	_	17	dobj
19	during	during	IN	_	20	case
20	therapy	therapy	NN	_	17	nmod
21	with	with	IN	_	22	case
22	drug5	drug5	NN	_	20	nmod
23	.	.	.	_	1	punct

1	These	these	DT	_	2	det
2	drugs	drug	NNS	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	coadministered	coadminister	VBN	_	0	ROOT
6	with	with	IN	_	7	case
7	caution	caution	NN	_	5	nmod
8	,	,	,	_	5	punct
9	and	and	CC	_	5	cc
10	frequent	frequent	JJ	_	11	amod
11	monitoring	monitoring	NN	_	17	nsubjpass
12	of	of	IN	_	15	case
13	serum	serum	NN	_	15	compound
14	drug1	drug1	NN	_	15	compound
15	levels	level	NNS	_	11	nmod
16	is	be	VBZ	_	17	auxpass
17	recommended	recommend	VBN	_	5	conj
18	.	.	.	_	5	punct

1	If	if	IN	_	6	mark
2	a	a	DT	_	3	det
3	drug1	drug1	NN	_	6	nsubjpass
4	is	be	VBZ	_	6	auxpass
5	also	also	RB	_	6	advmod
6	used	use	VBN	_	15	advcl
7	,	,	,	_	15	punct
8	the	the	DT	_	9	det
9	risk	risk	NN	_	15	nsubjpass
10	of	of	IN	_	12	case
11	drug2	drug2	NN	_	12	compound
12	toxicity	toxicity	NN	_	9	nmod
13	may	may	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	increased	increase	VBN	_	0	ROOT
16	.	.	.	_	15	punct

1	Other	other	JJ	_	6	amod
2	No	no	DT	_	6	neg
3	clinically	clinically	RB	_	4	advmod
4	important	important	JJ	_	6	amod
5	pharmacokinetic	pharmacokinetic	JJ	_	6	amod
6	interactions	interaction	NNS	_	7	nsubj
7	occurred	occur	VBD	_	0	ROOT
8	when	when	WRB	_	11	advmod
9	drug1	drug1	NN	_	11	nsubjpass
10	was	be	VBD	_	11	auxpass
11	administered	administer	VBN	_	7	advcl
12	concomitantly	concomitantly	RB	_	11	advmod
13	with	with	IN	_	14	case
14	drug2	drug2	NN	_	11	nmod
15	,	,	,	_	14	punct
16	drug3	drug3	NN	_	14	conj
17	,	,	,	_	14	punct
18	drug4	drug4	NN	_	14	conj
19	,	,	,	_	14	punct
20	drug5	drug5	NN	_	14	conj
21	,	,	,	_	14	punct
22	drug6	drug6	NN	_	14	conj
23	,	,	,	_	14	punct
24	drug7	drug7	NN	_	14	conj
25	,	,	,	_	14	punct
26	drug8	drug8	NN	_	14	conj
27	,	,	,	_	14	punct
28	or	or	CC	_	14	cc
29	drug9	drug9	NN	_	14	conj
30	.	.	.	_	7	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	has	have	VBZ	_	4	aux
3	been	be	VBN	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	concomitantly	concomitantly	RB	_	4	advmod
6	with	with	IN	_	7	case
7	drug2	drug2	NN	_	4	nmod
8	,	,	,	_	7	punct
9	drug3	drug3	NN	_	7	conj
10	,	,	,	_	7	punct
11	drug4	drug4	NN	_	7	conj
12	,	,	,	_	7	punct
13	drug5	drug5	NN	_	7	conj
14	,	,	,	_	7	punct
15	and	and	CC	_	7	cc
16	drug6	drug6	NN	_	7	conj
17	,	,	,	_	4	punct
18	without	without	IN	_	19	case
19	evidence	evidence	NN	_	4	nmod
20	of	of	IN	_	24	case
21	clinically	clinically	RB	_	22	advmod
22	important	important	JJ	_	24	amod
23	adverse	adverse	JJ	_	24	amod
24	interactions	interaction	NNS	_	19	nmod
25	.	.	.	_	4	punct

1	drug1	drug1	NN	_	8	nsubj
2	,	,	,	_	8	punct
3	like	like	IN	_	5	case
4	other	other	JJ	_	5	amod
5	drug2	drug2	NN	_	8	nmod
6	,	,	,	_	8	punct
7	has	have	VBZ	_	8	aux
8	had	have	VBN	_	0	ROOT
9	less	less	JJR	_	8	dobj
10	than	than	IN	_	12	case
11	additive	additive	JJ	_	12	amod
12	effects	effect	NNS	_	9	nmod
13	with	with	IN	_	14	case
14	drug3	drug3	NN	_	12	nmod
15	,	,	,	_	8	punct
16	presumably	presumably	RB	_	20	advmod
17	because	because	IN	_	20	mark
18	both	both	DT	_	19	det
19	drugs	drug	NNS	_	20	nsubj
20	lower	lower	JJR	_	8	advcl
21	blood	blood	NN	_	22	compound
22	pressure	pressure	NN	_	20	dobj
23	by	by	IN	_	24	mark
24	inhibiting	inhibit	VBG	_	20	advcl
25	parts	part	NNS	_	24	dobj
26	of	of	IN	_	29	case
27	the	the	DT	_	29	det
28	renin-angiotensin	renin-angiotensin	JJ	_	29	amod
29	system	system	NN	_	25	nmod

1	.	.	.	_	0	ROOT

1	fucking	fuck	VBG	_	0	ROOT
2	empty	empty	JJ	_	3	amod
3	sentence	sentence	NN	_	1	dobj

1	Elevated	elevated	JJ	_	3	amod
2	plasma	plasma	NN	_	3	compound
3	levels	level	NNS	_	8	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	have	have	VBP	_	8	aux
7	been	be	VBN	_	8	auxpass
8	reported	report	VBN	_	0	ROOT
9	with	with	IN	_	11	case
10	concomitant	concomitant	JJ	_	11	amod
11	use	use	NN	_	8	nmod
12	of	of	IN	_	14	case
13	some	some	DT	_	14	det
14	drug2	drug2	NN	_	11	nmod
15	.	.	.	_	8	punct

1	There	there	EX	_	4	expl
2	have	have	VBP	_	4	aux
3	been	be	VBN	_	4	cop
4	reports	report	NNS	_	0	ROOT
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	-	-	:	_	6	punct
8	related	related	JJ	_	9	amod
9	side-effects	side-effect	NNS	_	6	dep
10	in	in	IN	_	11	case
11	patients	patient	NNS	_	9	nmod
12	on	on	IN	_	14	case
13	concomitant	concomitant	JJ	_	14	amod
14	drug2	drug2	NN	_	11	nmod
15	-	-	:	_	14	punct
16	drug3	drug3	NN	_	17	compound
17	therapy	therapy	NN	_	14	dep
18	.	.	.	_	4	punct

1	Therefore	therefore	RB	_	10	advmod
2	,	,	,	_	10	punct
3	monitoring	monitoring	NN	_	10	nsubjpass
4	of	of	IN	_	7	case
5	drug1	drug1	NN	_	7	compound
6	plasma	plasma	NN	_	7	compound
7	levels	level	NNS	_	3	nmod
8	should	should	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	considered	consider	VBN	_	0	ROOT
11	and	and	CC	_	10	cc
12	dosage	dosage	NN	_	10	conj
13	of	of	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	adjusted	adjust	VBN	_	12	acl
16	as	as	IN	_	17	mark
17	required	require	VBN	_	15	advcl
18	.	.	.	_	10	punct

1	drug1	drug1	NN	_	5	nsubjpass
2	have	have	VBP	_	5	aux
3	also	also	RB	_	5	advmod
4	been	be	VBN	_	5	auxpass
5	shown	show	VBN	_	0	ROOT
6	to	to	TO	_	7	mark
7	interfere	interfere	VB	_	5	xcomp
8	with	with	IN	_	10	case
9	the	the	DT	_	10	det
10	metabolism	metabolism	NN	_	7	nmod
11	of	of	IN	_	12	case
12	drug2	drug2	NN	_	10	nmod
13	.	.	.	_	5	punct

1	This	this	DT	_	3	nsubj
2	may	may	MD	_	3	aux
3	lead	lead	VB	_	0	ROOT
4	to	to	TO	_	6	case
5	reduced	reduce	VBN	_	6	amod
6	clearance	clearance	NN	_	3	nmod
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	and	and	CC	_	6	cc
10	a	a	DT	_	11	det
11	prolongation	prolongation	NN	_	6	conj
12	of	of	IN	_	15	case
13	its	its	PRP$	_	15	nmod:poss
14	plasma	plasma	NN	_	15	compound
15	half-life	half-life	NN	_	11	nmod
16	.	.	.	_	3	punct

1	Although	although	IN	_	7	mark
2	this	this	DT	_	3	det
3	interaction	interaction	NN	_	7	nsubjpass
4	has	have	VBZ	_	7	aux
5	not	not	RB	_	7	neg
6	been	be	VBN	_	7	auxpass
7	reported	report	VBN	_	14	advcl
8	with	with	IN	_	9	case
9	drug1	drug1	NN	_	7	nmod
10	,	,	,	_	14	punct
11	caution	caution	NN	_	14	nsubjpass
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	exercised	exercise	VBN	_	0	ROOT
15	when	when	WRB	_	18	advmod
16	drug2	drug2	NN	_	18	nsubjpass
17	is	be	VBZ	_	18	auxpass
18	given	give	VBN	_	14	advcl
19	concomitantly	concomitantly	RB	_	18	advmod
20	with	with	IN	_	21	case
21	drug3	drug3	NN	_	18	nmod
22	-	-	:	_	18	punct
23	containing	contain	VBG	_	18	advcl
24	products	product	NNS	_	23	dobj
25	.	.	.	_	14	punct

1	drug1	drug1	NN	_	5	nsubj
2	or	or	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	substantially	substantially	RB	_	5	advmod
5	interfere	interfere	VBP	_	0	ROOT
6	with	with	IN	_	8	case
7	the	the	DT	_	8	det
8	absorption	absorption	NN	_	5	nmod
9	of	of	IN	_	11	case
10	some	some	DT	_	11	det
11	drug3	drug3	NN	_	8	nmod
12	,	,	,	_	5	punct
13	resulting	result	VBG	_	5	advcl
14	in	in	IN	_	17	case
15	low	low	JJ	_	17	amod
16	urine	urine	NN	_	17	compound
17	levels	level	NNS	_	13	nmod
18	.	.	.	_	5	punct

1	Also	also	RB	_	21	advmod
2	,	,	,	_	21	punct
3	concomitant	concomitant	JJ	_	4	amod
4	administration	administration	NN	_	21	nsubj
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	with	with	IN	_	8	case
8	products	product	NNS	_	4	nmod
9	containing	contain	VBG	_	8	acl
10	drug2	drug2	NN	_	9	dobj
11	,	,	,	_	10	punct
12	drug3	drug3	NN	_	10	appos
13	containing	contain	VBG	_	12	acl
14	drug4	drug4	NN	_	13	dobj
15	,	,	,	_	14	punct
16	or	or	CC	_	14	cc
17	drug5	drug5	NN	_	14	conj
18	-LRB-	-lrb-	-LRB-	_	19	punct
19	drug6	drug6	NN	_	17	appos
20	-RRB-	-rrb-	-RRB-	_	19	punct
21	chewable/buffered	chewable/buffered	VBD	_	31	csubj
22	tablets	tablet	NNS	_	21	dobj
23	or	or	CC	_	22	cc
24	the	the	DT	_	26	det
25	pediatric	pediatric	JJ	_	26	amod
26	powder	powder	NN	_	22	conj
27	for	for	IN	_	29	case
28	oral	oral	JJ	_	29	amod
29	solution	solution	NN	_	21	nmod
30	may	may	MD	_	31	aux
31	result	result	VB	_	0	ROOT
32	in	in	IN	_	35	case
33	low	low	JJ	_	35	amod
34	urine	urine	NN	_	35	compound
35	levels	level	NNS	_	31	nmod
36	.	.	.	_	31	punct

1	drug1	drug1	NN	_	7	nsubj
2	,	,	,	_	1	punct
3	including	include	VBG	_	4	case
4	drug2	drug2	NN	_	1	nmod
5	,	,	,	_	1	punct
6	may	may	MD	_	7	aux
7	enhance	enhance	VB	_	0	ROOT
8	the	the	DT	_	9	det
9	effects	effect	NNS	_	7	dobj
10	of	of	IN	_	12	case
11	oral	oral	JJ	_	12	amod
12	drug3	drug3	NN	_	9	nmod
13	,	,	,	_	12	punct
14	such	such	JJ	_	16	case
15	as	as	IN	_	14	mwe
16	drug4	drug4	NN	_	12	nmod
17	or	or	CC	_	16	cc
18	its	its	PRP$	_	19	nmod:poss
19	derivatives	derivative	NNS	_	16	conj
20	.	.	.	_	7	punct

1	When	when	WRB	_	5	advmod
2	these	these	DT	_	3	det
3	products	product	NNS	_	5	nsubjpass
4	are	be	VBP	_	5	auxpass
5	administered	administer	VBN	_	18	advcl
6	concomitantly	concomitantly	RB	_	5	advmod
7	,	,	,	_	18	punct
8	prothrombin	prothrombin	NN	_	9	compound
9	time	time	NN	_	18	nsubjpass
10	or	or	CC	_	9	cc
11	other	other	JJ	_	14	amod
12	suitable	suitable	JJ	_	14	amod
13	coagulation	coagulation	NN	_	14	compound
14	tests	test	NNS	_	9	conj
15	should	should	MD	_	18	aux
16	be	be	VB	_	18	auxpass
17	closely	closely	RB	_	18	advmod
18	monitored	monitor	VBN	_	0	ROOT
19	.	.	.	_	18	punct

1	Seizures	seizure	NNS	_	4	nsubjpass
2	have	have	VBP	_	4	aux
3	been	be	VBN	_	4	auxpass
4	reported	report	VBN	_	0	ROOT
5	in	in	IN	_	6	case
6	patients	patient	NNS	_	4	nmod
7	taking	take	VBG	_	6	acl
8	another	another	DT	_	9	det
9	drug1	drug1	NN	_	7	dobj
10	and	and	CC	_	6	cc
11	the	the	DT	_	13	det
12	drug2	drug2	NN	_	13	compound
13	drug3	drug3	NN	_	6	conj
14	concurrently	concurrently	RB	_	13	advmod
15	.	.	.	_	4	punct

1	Animal	animal	NN	_	2	compound
2	studies	study	NNS	_	4	nsubj
3	also	also	RB	_	4	advmod
4	suggest	suggest	VBP	_	0	ROOT
5	an	a	DT	_	7	det
6	increased	increase	VBN	_	7	amod
7	potential	potential	NN	_	4	dobj
8	for	for	IN	_	9	case
9	seizures	seizure	NNS	_	7	nmod
10	when	when	WRB	_	15	advmod
11	these	these	DT	_	13	det
12	2	2	CD	_	13	nummod
13	drugs	drug	NNS	_	15	nsubjpass
14	are	be	VBP	_	15	auxpass
15	given	give	VBN	_	7	acl:relcl
16	concomitantly	concomitantly	RB	_	15	advmod
17	.	.	.	_	4	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	is	be	VBZ	_	4	auxpass
3	not	not	RB	_	4	neg
4	approved	approve	VBN	_	0	ROOT
5	in	in	IN	_	8	case
6	the	the	DT	_	8	det
7	United	United	NNP	_	8	compound
8	States	States	NNPS	_	4	nmod
9	at	at	IN	_	11	case
10	this	this	DT	_	11	det
11	time	time	NN	_	4	nmod
12	.	.	.	_	4	punct

1	Physicians	Physicians	NNP	_	3	nsubjpass
2	are	be	VBP	_	3	auxpass
3	provided	provide	VBN	_	0	ROOT
4	this	this	DT	_	5	det
5	information	information	NN	_	3	dobj
6	to	to	TO	_	7	mark
7	increase	increase	VB	_	3	xcomp
8	awareness	awareness	NN	_	7	dobj
9	of	of	IN	_	11	case
10	the	the	DT	_	11	det
11	potential	potential	NN	_	8	nmod
12	for	for	IN	_	14	case
13	serious	serious	JJ	_	14	amod
14	interactions	interaction	NNS	_	11	nmod
15	when	when	WRB	_	21	advmod
16	drug1	drug1	NN	_	21	nsubjpass
17	and	and	CC	_	16	cc
18	certain	certain	JJ	_	19	amod
19	drug2	drug2	NN	_	16	conj
20	are	be	VBP	_	21	auxpass
21	administered	administer	VBN	_	7	advcl
22	concomitantly	concomitantly	RB	_	21	advmod
23	.	.	.	_	3	punct

1	Elevated	elevated	JJ	_	4	amod
2	drug1	drug1	NN	_	4	compound
3	serum	serum	NN	_	4	compound
4	levels	level	NNS	_	7	nsubjpass
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	reported	report	VBN	_	0	ROOT
8	with	with	IN	_	11	case
9	the	the	DT	_	11	det
10	concomitant	concomitant	JJ	_	11	amod
11	use	use	NN	_	7	nmod
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	and	and	CC	_	13	cc
15	drug3	drug3	NN	_	13	conj
16	.	.	.	_	7	punct

1	Special	special	JJ	_	2	amod
2	consideration	consideration	NN	_	5	nsubjpass
3	should	should	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	given	give	VBN	_	0	ROOT
6	to	to	TO	_	8	case
7	the	the	DT	_	8	det
8	administration	administration	NN	_	5	nmod
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	in	in	IN	_	12	case
12	patients	patient	NNS	_	5	nmod
13	receiving	receive	VBG	_	12	acl
14	drug2	drug2	NN	_	13	dobj
15	or	or	CC	_	14	cc
16	other	other	JJ	_	17	amod
17	drugs	drug	NNS	_	14	conj
18	that	that	WDT	_	20	nsubj
19	could	could	MD	_	20	aux
20	cause	cause	VB	_	14	acl:relcl
21	or	or	CC	_	20	cc
22	potentiate	potentiate	VB	_	20	conj
23	hypotension	hypotension	NN	_	20	dobj
24	.	.	.	_	5	punct

1	The	the	DT	_	2	det
2	administration	administration	NN	_	17	nsubj
3	of	of	IN	_	5	case
4	local	local	JJ	_	5	amod
5	drug1	drug1	NN	_	2	nmod
6	containing	contain	VBG	_	5	acl
7	drug2	drug2	NN	_	6	dobj
8	or	or	CC	_	7	cc
9	drug3	drug3	NN	_	7	conj
10	to	to	TO	_	11	case
11	patients	patient	NNS	_	6	nmod
12	receiving	receive	VBG	_	11	acl
13	drug4	drug4	NN	_	12	dobj
14	or	or	CC	_	13	cc
15	drug5	drug5	NN	_	13	conj
16	may	may	MD	_	17	aux
17	produce	produce	VB	_	0	ROOT
18	severe	severe	JJ	_	21	amod
19	,	,	,	_	21	punct
20	prolonged	prolonged	JJ	_	21	amod
21	hypertension	hypertension	NN	_	17	dobj
22	.	.	.	_	17	punct

1	drug1	drug1	NN	_	5	nsubj
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	may	may	MD	_	5	aux
5	reduce	reduce	VB	_	0	ROOT
6	or	or	CC	_	5	cc
7	reverse	reverse	VB	_	5	conj
8	the	the	DT	_	10	det
9	pressor	pressor	NN	_	10	compound
10	effect	effect	NN	_	5	dobj
11	of	of	IN	_	12	case
12	drug3	drug3	NN	_	10	nmod
13	.	.	.	_	5	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	use	use	NN	_	9	nsubjpass
3	of	of	IN	_	5	case
4	these	these	DT	_	5	det
5	agents	agent	NNS	_	2	nmod
6	should	should	MD	_	9	aux
7	generally	generally	RB	_	9	advmod
8	be	be	VB	_	9	auxpass
9	avoided	avoid	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	In	in	IN	_	2	case
2	situations	situation	NNS	_	13	nmod
3	when	when	WRB	_	7	advmod
4	concurrent	concurrent	JJ	_	5	amod
5	therapy	therapy	NN	_	7	nsubj
6	is	be	VBZ	_	7	cop
7	necessary	necessary	JJ	_	2	acl:relcl
8	,	,	,	_	13	punct
9	careful	careful	JJ	_	11	amod
10	patient	patient	NN	_	11	compound
11	monitoring	monitoring	NN	_	13	nsubj
12	is	be	VBZ	_	13	cop
13	essential	essential	JJ	_	0	ROOT
14	.	.	.	_	13	punct

1	Concurrent	concurrent	JJ	_	2	amod
2	administration	administration	NN	_	19	nsubj
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	-LRB-	-lrb-	-LRB-	_	8	punct
6	for	for	IN	_	8	case
7	the	the	DT	_	8	det
8	treatment	treatment	NN	_	2	nmod
9	of	of	IN	_	10	case
10	hypotension	hypotension	NN	_	8	nmod
11	related	related	JJ	_	10	amod
12	to	to	TO	_	14	case
13	obstetric	obstetric	JJ	_	14	amod
14	blocks	block	NNS	_	11	nmod
15	-RRB-	-rrb-	-RRB-	_	8	punct
16	and	and	CC	_	2	cc
17	drug2	drug2	NN	_	2	conj
18	may	may	MD	_	19	aux
19	cause	cause	VB	_	0	ROOT
20	severe	severe	JJ	_	26	amod
21	,	,	,	_	20	punct
22	persistent	persistent	JJ	_	23	amod
23	hypertension	hypertension	NN	_	20	conj
24	or	or	CC	_	20	cc
25	cerebrovascular	cerebrovascular	JJ	_	20	conj
26	accidents	accident	NNS	_	19	dobj
27	.	.	.	_	19	punct

1	Due	due	JJ	_	14	nsubjpass
2	to	to	TO	_	4	case
3	the	the	DT	_	4	det
4	potential	potential	NN	_	1	nmod
5	for	for	IN	_	7	case
6	additive	additive	JJ	_	7	amod
7	effects	effect	NNS	_	4	nmod
8	,	,	,	_	7	punct
9	caution	caution	NN	_	7	conj
10	and	and	CC	_	7	cc
11	careful	careful	JJ	_	12	amod
12	titration	titration	NN	_	7	conj
13	are	be	VBP	_	14	auxpass
14	warranted	warrant	VBN	_	0	ROOT
15	in	in	IN	_	16	case
16	patients	patient	NNS	_	14	nmod
17	receiving	receive	VBG	_	16	acl
18	drug1	drug1	NN	_	17	dobj
19	concomitantly	concomitantly	RB	_	17	advmod
20	with	with	IN	_	22	case
21	other	other	JJ	_	22	amod
22	agents	agent	NNS	_	17	nmod
23	known	know	VBN	_	22	acl
24	to	to	TO	_	25	mark
25	affect	affect	VB	_	23	xcomp
26	cardiac	cardiac	JJ	_	27	amod
27	contractility	contractility	NN	_	25	dobj
28	and/or	and/or	CC	_	27	cc
29	conduction	conduction	NN	_	27	conj
30	.	.	.	_	14	punct

1	Pharmacologic	pharmacologic	JJ	_	2	amod
2	studies	study	NNS	_	3	nsubj
3	indicate	indicate	VBP	_	0	ROOT
4	that	that	IN	_	9	mark
5	there	there	EX	_	9	expl
6	may	may	MD	_	9	aux
7	be	be	VB	_	9	cop
8	additive	additive	JJ	_	9	amod
9	effects	effect	NNS	_	3	ccomp
10	in	in	IN	_	11	mark
11	prolonging	prolong	VBG	_	9	advcl
12	AV	av	NN	_	13	compound
13	conduction	conduction	NN	_	11	dobj
14	when	when	WRB	_	15	advmod
15	using	use	VBG	_	11	advcl
16	drug1	drug1	NN	_	15	dobj
17	or	or	CC	_	16	cc
18	drug2	drug2	NN	_	16	conj
19	concomitantly	concomitantly	RB	_	21	advmod
20	with	with	IN	_	21	case
21	drug3	drug3	NN	_	15	nmod
22	.	.	.	_	3	punct

1	As	as	IN	_	4	case
2	with	with	IN	_	4	case
3	all	all	DT	_	4	det
4	drugs	drug	NNS	_	9	nmod
5	,	,	,	_	9	punct
6	care	care	NN	_	9	nsubjpass
7	should	should	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	exercised	exercise	VBN	_	0	ROOT
10	when	when	WRB	_	11	advmod
11	treating	treat	VBG	_	9	advcl
12	patients	patient	NNS	_	11	dobj
13	with	with	IN	_	15	case
14	multiple	multiple	JJ	_	15	amod
15	medications	medication	NNS	_	12	nmod
16	.	.	.	_	9	punct

1	drug1	drug1	NN	_	5	nsubj
2	is	be	VBZ	_	5	cop
3	both	both	CC	_	5	cc:preconj
4	a	a	DT	_	5	det
5	substrate	substrate	NN	_	0	ROOT
6	and	and	CC	_	5	cc
7	an	a	DT	_	8	det
8	inhibitor	inhibitor	NN	_	5	conj
9	of	of	IN	_	15	case
10	the	the	DT	_	15	det
11	cytochrome	cytochrome	NN	_	15	compound
12	P-450	p-450	NN	_	15	compound
13	3A4	3a4	NN	_	15	compound
14	enzyme	enzyme	NN	_	15	compound
15	system	system	NN	_	8	nmod
16	.	.	.	_	5	punct

1	Other	other	JJ	_	2	amod
2	drugs	drug	NNS	_	17	nsubj
3	that	that	WDT	_	6	nsubj
4	are	be	VBP	_	6	cop
5	specific	specific	JJ	_	6	amod
6	substrates	substrate	NNS	_	2	acl:relcl
7	,	,	,	_	2	punct
8	inhibitors	inhibitor	NNS	_	2	conj
9	,	,	,	_	2	punct
10	or	or	CC	_	2	cc
11	inducers	inducer	NNS	_	2	conj
12	of	of	IN	_	15	case
13	the	the	DT	_	15	det
14	enzyme	enzyme	NN	_	15	compound
15	system	system	NN	_	11	nmod
16	may	may	MD	_	17	aux
17	have	have	VB	_	0	ROOT
18	a	a	DT	_	20	det
19	significant	significant	JJ	_	20	amod
20	impact	impact	NN	_	17	dobj
21	on	on	IN	_	27	case
22	the	the	DT	_	27	det
23	efficacy	efficacy	NN	_	27	compound
24	and	and	CC	_	23	cc
25	side	side	NN	_	23	conj
26	effect	effect	NN	_	27	compound
27	profile	profile	NN	_	20	nmod
28	of	of	IN	_	29	case
29	drug1	drug1	NN	_	27	nmod
30	.	.	.	_	17	punct

1	Patients	patient	NNS	_	21	nsubj
2	taking	take	VBG	_	1	acl
3	other	other	JJ	_	4	amod
4	drugs	drug	NNS	_	2	dobj
5	that	that	WDT	_	7	nsubj
6	are	be	VBP	_	7	cop
7	substrates	substrate	NNS	_	4	acl:relcl
8	of	of	IN	_	10	case
9	CYP450	cyp450	NN	_	10	compound
10	3A4	3a4	NN	_	7	nmod
11	,	,	,	_	1	punct
12	especially	especially	RB	_	13	advmod
13	patients	patient	NNS	_	1	appos
14	with	with	IN	_	18	case
15	renal	renal	JJ	_	18	amod
16	and/or	and/or	CC	_	15	cc
17	hepatic	hepatic	JJ	_	15	conj
18	impairment	impairment	NN	_	13	nmod
19	,	,	,	_	1	punct
20	may	may	MD	_	21	aux
21	require	require	VB	_	0	ROOT
22	dosage	dosage	NN	_	23	compound
23	adjustment	adjustment	NN	_	21	dobj
24	when	when	WRB	_	25	advmod
25	starting	start	VBG	_	21	advcl
26	or	or	CC	_	25	cc
27	stopping	stop	VBG	_	25	conj
28	concomitantly	concomitantly	RB	_	29	advmod
29	administered	administer	VBN	_	30	amod
30	drug1	drug1	NN	_	25	dobj
31	in	in	IN	_	34	mark
32	order	order	NN	_	31	mwe
33	to	to	TO	_	34	mark
34	maintain	maintain	VB	_	30	acl
35	optimum	optimum	JJ	_	38	amod
36	therapeutic	therapeutic	JJ	_	38	amod
37	blood	blood	NN	_	38	compound
38	levels	level	NNS	_	34	dobj
39	.	.	.	_	21	punct

1	drug1	drug1	NN	_	0	ROOT

1	Controlled	control	VBN	_	5	amod
2	and	and	CC	_	1	cc
3	uncontrolled	uncontrolled	JJ	_	1	conj
4	domestic	domestic	JJ	_	5	amod
5	studies	study	NNS	_	6	nsubj
6	suggest	suggest	VBP	_	0	ROOT
7	that	that	IN	_	17	mark
8	concomitant	concomitant	JJ	_	9	amod
9	use	use	NN	_	17	nsubjpass
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	and	and	CC	_	11	cc
13	drug2	drug2	NN	_	11	conj
14	is	be	VBZ	_	17	auxpass
15	usually	usually	RB	_	17	advmod
16	well	well	RB	_	17	advmod
17	tolerated	tolerate	VBD	_	6	ccomp
18	,	,	,	_	17	punct
19	but	but	CC	_	17	cc
20	available	available	JJ	_	21	amod
21	data	datum	NNS	_	24	nsubj
22	are	be	VBP	_	24	cop
23	not	not	RB	_	24	neg
24	sufficient	sufficient	JJ	_	17	conj
25	to	to	TO	_	26	mark
26	predict	predict	VB	_	24	xcomp
27	the	the	DT	_	28	det
28	effects	effect	NNS	_	26	dobj
29	of	of	IN	_	31	case
30	concomitant	concomitant	JJ	_	31	amod
31	treatment	treatment	NN	_	28	nmod
32	in	in	IN	_	33	case
33	patients	patient	NNS	_	31	nmod
34	with	with	IN	_	37	case
35	left	left	JJ	_	37	amod
36	ventricular	ventricular	JJ	_	37	amod
37	dysfunction	dysfunction	NN	_	33	nmod
38	or	or	CC	_	37	cc
39	cardiac	cardiac	JJ	_	41	amod
40	conduction	conduction	NN	_	41	compound
41	abnormalities	abnormality	NNS	_	37	conj
42	.	.	.	_	6	punct

1	Administration	administration	NN	_	11	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	concomitantly	concomitantly	RB	_	6	advmod
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	1	nmod
7	in	in	IN	_	10	case
8	five	five	CD	_	10	nummod
9	normal	normal	JJ	_	10	amod
10	volunteers	volunteer	NNS	_	6	nmod
11	resulted	result	VBD	_	24	csubjpass
12	in	in	IN	_	15	case
13	increased	increase	VBN	_	15	amod
14	drug3	drug3	NN	_	15	compound
15	levels	level	NNS	_	11	nmod
16	in	in	IN	_	18	case
17	all	all	DT	_	18	det
18	subjects	subject	NNS	_	15	nmod
19	and	and	CC	_	18	cc
20	bioavailability	bioavailability	NN	_	18	conj
21	of	of	IN	_	22	case
22	drug4	drug4	NN	_	20	nmod
23	was	be	VBD	_	24	auxpass
24	increased	increase	VBN	_	0	ROOT
25	approximately	approximately	RB	_	26	advmod
26	50	50	CD	_	27	nummod
27	%	%	NN	_	24	dobj
28	.	.	.	_	24	punct

1	In	in	FW	_	2	compound
2	vitro	vitro	FW	_	5	advmod
3	,	,	,	_	5	punct
4	drug1	drug1	NN	_	5	nsubj
5	appears	appear	VBZ	_	0	ROOT
6	to	to	TO	_	8	mark
7	be	be	VB	_	8	auxpass
8	displaced	displace	VBN	_	5	xcomp
9	from	from	IN	_	12	case
10	its	its	PRP$	_	12	nmod:poss
11	binding	binding	NN	_	12	compound
12	sites	site	NNS	_	8	nmod
13	by	by	IN	_	14	case
14	drug2	drug2	NN	_	8	nmod
15	.	.	.	_	5	punct

1	If	if	IN	_	5	mark
2	combination	combination	NN	_	3	compound
3	therapy	therapy	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	initiated	initiate	VBN	_	21	advcl
6	or	or	CC	_	5	cc
7	withdrawn	withdraw	VBN	_	5	conj
8	in	in	IN	_	9	case
9	conjunction	conjunction	NN	_	5	nmod
10	with	with	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	,	,	,	_	11	punct
13	an	a	DT	_	14	det
14	adjustment	adjustment	NN	_	11	appos
15	in	in	IN	_	18	case
16	the	the	DT	_	18	det
17	drug2	drug2	NN	_	18	compound
18	dose	dose	NN	_	14	nmod
19	may	may	MD	_	21	aux
20	be	be	VB	_	21	auxpass
21	warranted	warrant	VBN	_	0	ROOT
22	.	.	.	_	21	punct

1	drug1	drug1	NN	_	0	ROOT

1	A	a	DT	_	2	det
2	study	study	NN	_	8	nsubj
3	in	in	IN	_	6	case
4	six	six	CD	_	6	nummod
5	healthy	healthy	JJ	_	6	amod
6	volunteers	volunteer	NNS	_	2	nmod
7	has	have	VBZ	_	8	aux
8	shown	show	VBN	_	0	ROOT
9	a	a	DT	_	11	det
10	significant	significant	JJ	_	11	amod
11	increase	increase	NN	_	8	dobj
12	in	in	IN	_	16	case
13	peak	peak	JJ	_	16	amod
14	drug1	drug1	NN	_	16	compound
15	plasma	plasma	NN	_	16	compound
16	levels	level	NNS	_	11	nmod
17	-LRB-	-lrb-	-LRB-	_	19	punct
18	58	58	CD	_	19	nummod
19	%	%	NN	_	11	dep
20	-RRB-	-rrb-	-RRB-	_	19	punct
21	and	and	CC	_	11	cc
22	AUC	auc	NN	_	11	conj
23	-LRB-	-lrb-	-LRB-	_	25	punct
24	53	53	CD	_	25	nummod
25	%	%	NN	_	22	appos
26	-RRB-	-rrb-	-RRB-	_	25	punct
27	after	after	IN	_	30	case
28	a	a	DT	_	30	det
29	1-week	1-week	JJ	_	30	amod
30	course	course	NN	_	11	nmod
31	of	of	IN	_	34	case
32	drug2	drug2	NN	_	34	compound
33	1200	1200	CD	_	34	nummod
34	mg/day	mg/day	NN	_	30	nmod
35	and	and	CC	_	11	cc
36	a	a	DT	_	38	det
37	single	single	JJ	_	38	amod
38	dose	dose	NN	_	11	conj
39	of	of	IN	_	40	case
40	drug3	drug3	NN	_	38	nmod
41	60mg	60mg	CD	_	40	nummod
42	.	.	.	_	8	punct

1	drug1	drug1	NN	_	2	nsubj
2	produced	produce	VBD	_	0	ROOT
3	smaller	smaller	JJR	_	6	amod
4	,	,	,	_	6	punct
5	nonsignificant	nonsignificant	JJ	_	6	amod
6	increases	increase	NNS	_	2	dobj
7	.	.	.	_	2	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	5	nsubjpass
3	may	may	MD	_	5	aux
4	be	be	VB	_	5	auxpass
5	mediated	mediate	VBN	_	0	ROOT
6	by	by	IN	_	8	case
7	drug1	drug1	NN	_	8	compound
8	s	s	NNS	_	5	nmod
9	known	know	VBN	_	10	amod
10	inhibition	inhibition	NN	_	8	dep
11	of	of	IN	_	14	case
12	hepatic	hepatic	JJ	_	14	amod
13	cytochrome	cytochrome	NN	_	14	compound
14	P-450	p-450	NN	_	10	nmod
15	,	,	,	_	8	punct
16	the	the	DT	_	18	det
17	enzyme	enzyme	NN	_	18	compound
18	system	system	NN	_	8	appos
19	responsible	responsible	JJ	_	18	amod
20	for	for	IN	_	23	case
21	the	the	DT	_	23	det
22	first-pass	first-pass	JJ	_	23	amod
23	metabolism	metabolism	NN	_	19	nmod
24	of	of	IN	_	25	case
25	drug2	drug2	NN	_	23	nmod
26	.	.	.	_	5	punct

1	Patients	patient	NNS	_	9	nsubjpass
2	currently	currently	RB	_	3	advmod
3	receiving	receive	VBG	_	1	acl
4	drug1	drug1	NN	_	5	compound
5	therapy	therapy	NN	_	3	dobj
6	should	should	MD	_	9	aux
7	be	be	VB	_	9	auxpass
8	carefully	carefully	RB	_	9	advmod
9	monitored	monitor	VBN	_	0	ROOT
10	for	for	IN	_	12	case
11	a	a	DT	_	12	det
12	change	change	NN	_	9	nmod
13	in	in	IN	_	15	case
14	pharmacological	pharmacological	JJ	_	15	amod
15	effect	effect	NN	_	12	nmod
16	when	when	WRB	_	17	advmod
17	initiating	initiate	VBG	_	9	advcl
18	and	and	CC	_	17	cc
19	discontinuing	discontinue	VBG	_	17	conj
20	therapy	therapy	NN	_	19	dobj
21	with	with	IN	_	22	case
22	drug2	drug2	NN	_	19	nmod
23	.	.	.	_	9	punct

1	An	a	DT	_	2	det
2	adjustment	adjustment	NN	_	9	nsubjpass
3	in	in	IN	_	6	case
4	the	the	DT	_	6	det
5	drug1	drug1	NN	_	6	compound
6	dose	dose	NN	_	2	nmod
7	may	may	MD	_	9	aux
8	be	be	VB	_	9	auxpass
9	warranted	warrant	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	drug1	drug1	NN	_	0	ROOT

1	Administration	administration	NN	_	11	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	1	nmod
6	in	in	IN	_	10	case
7	24	24	CD	_	10	nummod
8	healthy	healthy	JJ	_	10	amod
9	male	male	JJ	_	10	amod
10	subjects	subject	NNS	_	1	nmod
11	increased	increase	VBN	_	0	ROOT
12	plasma	plasma	NN	_	14	compound
13	drug3	drug3	NN	_	14	compound
14	concentrations	concentration	NNS	_	11	dobj
15	approximately	approximately	RB	_	16	advmod
16	20	20	CD	_	17	nummod
17	%	%	NN	_	11	nmod:npmod
18	.	.	.	_	11	punct

1	Another	another	DT	_	2	det
2	investigator	investigator	NN	_	3	nsubj
3	found	find	VBD	_	0	ROOT
4	no	no	DT	_	5	neg
5	increase	increase	NN	_	3	dobj
6	in	in	IN	_	8	case
7	drug1	drug1	NN	_	8	compound
8	levels	level	NNS	_	5	nmod
9	in	in	IN	_	11	case
10	12	12	CD	_	11	nummod
11	patients	patient	NNS	_	3	nmod
12	with	with	IN	_	15	case
13	coronary	coronary	JJ	_	15	amod
14	artery	artery	NN	_	15	compound
15	disease	disease	NN	_	11	nmod
16	.	.	.	_	3	punct

1	Since	since	IN	_	6	mark
2	there	there	EX	_	6	expl
3	have	have	VBP	_	6	aux
4	been	be	VBN	_	6	cop
5	conflicting	conflicting	JJ	_	6	amod
6	results	result	NNS	_	16	advcl
7	regarding	regard	VBG	_	9	case
8	the	the	DT	_	9	det
9	effect	effect	NN	_	6	nmod
10	of	of	IN	_	12	case
11	drug1	drug1	NN	_	12	compound
12	levels	level	NNS	_	9	nmod
13	,	,	,	_	16	punct
14	it	it	PRP	_	16	nsubjpass
15	is	be	VBZ	_	16	auxpass
16	recommended	recommend	VBN	_	0	ROOT
17	that	that	IN	_	21	mark
18	drug2	drug2	NN	_	19	compound
19	levels	level	NNS	_	21	nsubjpass
20	be	be	VB	_	21	auxpass
21	monitored	monitor	VBN	_	16	ccomp
22	when	when	WRB	_	23	advmod
23	initiating	initiate	VBG	_	21	advcl
24	,	,	,	_	23	punct
25	adjusting	adjust	VBG	_	23	conj
26	,	,	,	_	23	punct
27	and	and	CC	_	23	cc
28	discontinuing	discontinue	VBG	_	23	conj
29	drug3	drug3	NN	_	30	compound
30	therapy	therapy	NN	_	28	dobj
31	to	to	TO	_	32	mark
32	avoid	avoid	VB	_	28	xcomp
33	possible	possible	JJ	_	32	xcomp
34	over	over	IN	_	37	case
35	-	-	:	_	37	punct
36	or	or	CC	_	37	cc
37	under-digitalization	under-digitalization	NN	_	33	nmod
38	.	.	.	_	16	punct

1	drug1	drug1	NN	_	0	ROOT

1	The	the	DT	_	2	det
2	depression	depression	NN	_	22	nsubjpass
3	of	of	IN	_	5	case
4	cardiac	cardiac	JJ	_	5	amod
5	contractility	contractility	NN	_	2	nmod
6	,	,	,	_	5	punct
7	conductivity	conductivity	NN	_	5	conj
8	,	,	,	_	5	punct
9	and	and	CC	_	5	cc
10	automaticity	automaticity	NN	_	5	conj
11	as	as	RB	_	5	cc
12	well	well	RB	_	11	mwe
13	as	as	IN	_	11	mwe
14	the	the	DT	_	16	det
15	vascular	vascular	JJ	_	16	amod
16	dilation	dilation	NN	_	5	conj
17	associated	associate	VBN	_	16	acl
18	with	with	IN	_	19	case
19	drug1	drug1	NN	_	17	nmod
20	may	may	MD	_	22	aux
21	be	be	VB	_	22	auxpass
22	potentiated	potentiate	VBN	_	0	ROOT
23	by	by	IN	_	24	case
24	drug2	drug2	NN	_	22	nmod
25	.	.	.	_	22	punct

1	When	when	WRB	_	2	advmod
2	used	use	VBN	_	10	advcl
3	concomitantly	concomitantly	RB	_	2	advmod
4	,	,	,	_	10	punct
5	drug1	drug1	NN	_	10	nsubjpass
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	should	should	MD	_	10	aux
9	be	be	VB	_	10	auxpass
10	titrated	titrate	VBN	_	0	ROOT
11	carefully	carefully	RB	_	10	advmod
12	.	.	.	_	10	punct

1	drug1	drug1	NN	_	0	ROOT

1	A	a	DT	_	3	det
2	pharmacokinetic	pharmacokinetic	JJ	_	3	amod
3	interaction	interaction	NN	_	10	nsubjpass
4	between	between	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	drug2	drug2	NN	_	5	conj
8	has	have	VBZ	_	10	aux
9	been	be	VBN	_	10	auxpass
10	observed	observe	VBN	_	0	ROOT
11	during	during	IN	_	12	case
12	studies	study	NNS	_	10	nmod
13	involving	involve	VBG	_	12	acl
14	renal	renal	JJ	_	18	amod
15	and	and	CC	_	14	cc
16	cardiac	cardiac	JJ	_	14	conj
17	transplant	transplant	NN	_	18	compound
18	patients	patient	NNS	_	13	dobj
19	.	.	.	_	10	punct

1	In	in	IN	_	6	case
2	renal	renal	JJ	_	6	amod
3	and	and	CC	_	2	cc
4	cardiac	cardiac	JJ	_	2	conj
5	transplant	transplant	NN	_	6	compound
6	recipients	recipient	NNS	_	21	nmod
7	,	,	,	_	21	punct
8	a	a	DT	_	9	det
9	reduction	reduction	NN	_	21	nsubj
10	of	of	IN	_	12	case
11	drug1	drug1	NN	_	12	compound
12	dose	dose	NN	_	9	nmod
13	ranging	range	VBG	_	9	acl
14	from	from	IN	_	16	case
15	15	15	CD	_	16	nummod
16	%	%	NN	_	13	nmod
17	to	to	TO	_	19	case
18	48	48	CD	_	19	nummod
19	%	%	NN	_	16	nmod
20	was	be	VBD	_	21	cop
21	necessary	necessary	JJ	_	0	ROOT
22	to	to	TO	_	23	mark
23	maintain	maintain	VB	_	21	xcomp
24	drug2	drug2	NN	_	26	compound
25	trough	trough	NN	_	26	compound
26	concentrations	concentration	NNS	_	23	dobj
27	similar	similar	JJ	_	26	amod
28	to	to	TO	_	29	case
29	those	those	DT	_	27	nmod
30	seen	see	VBN	_	29	acl
31	prior	prior	JJ	_	30	xcomp
32	to	to	TO	_	34	case
33	the	the	DT	_	34	det
34	addition	addition	NN	_	31	nmod
35	of	of	IN	_	36	case
36	drug3	drug3	NN	_	34	nmod
37	.	.	.	_	21	punct

1	If	if	IN	_	4	mark
2	these	these	DT	_	3	det
3	agents	agent	NNS	_	4	nsubj
4	are	be	VBP	_	14	advcl
5	to	to	TO	_	7	mark
6	be	be	VB	_	7	auxpass
7	administered	administer	VBN	_	4	xcomp
8	concurrently	concurrently	RB	_	7	advmod
9	,	,	,	_	14	punct
10	drug1	drug1	NN	_	11	compound
11	concentrations	concentration	NNS	_	14	nsubjpass
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	monitored	monitor	VBN	_	0	ROOT
15	,	,	,	_	14	punct
16	especially	especially	RB	_	17	advmod
17	when	when	WRB	_	21	advmod
18	drug2	drug2	NN	_	19	compound
19	therapy	therapy	NN	_	21	nsubjpass
20	is	be	VBZ	_	21	auxpass
21	initiated	initiate	VBN	_	14	advcl
22	,	,	,	_	21	punct
23	adjusted	adjust	VBN	_	21	conj
24	,	,	,	_	21	punct
25	or	or	CC	_	21	cc
26	discontinued	discontinue	VBN	_	21	conj
27	.	.	.	_	14	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	12	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	on	on	IN	_	8	case
6	drug2	drug2	NN	_	8	compound
7	plasma	plasma	NN	_	8	compound
8	concentrations	concentration	NNS	_	2	nmod
9	has	have	VBZ	_	12	aux
10	not	not	RB	_	12	neg
11	been	be	VBN	_	12	auxpass
12	evaluated	evaluate	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	drug1	drug1	NN	_	0	ROOT

1	Concomitant	concomitant	JJ	_	2	amod
2	administration	administration	NN	_	9	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	with	with	IN	_	6	case
6	drug2	drug2	NN	_	2	nmod
7	has	have	VBZ	_	9	aux
8	been	be	VBN	_	9	auxpass
9	reported	report	VBN	_	0	ROOT
10	to	to	TO	_	11	mark
11	result	result	VB	_	9	xcomp
12	in	in	IN	_	15	case
13	elevated	elevated	JJ	_	15	amod
14	serum	serum	NN	_	15	compound
15	levels	level	NNS	_	11	nmod
16	of	of	IN	_	17	case
17	drug3	drug3	NN	_	15	nmod
18	-LRB-	-lrb-	-LRB-	_	24	punct
19	40	40	CD	_	23	compound
20	%	%	NN	_	23	dep
21	to	to	TO	_	23	dep
22	72	72	CD	_	23	compound
23	%	%	NN	_	24	nummod
24	increase	increase	NN	_	17	appos
25	-RRB-	-rrb-	-RRB-	_	24	punct
26	,	,	,	_	11	punct
27	resulting	result	VBG	_	11	advcl
28	in	in	IN	_	29	case
29	toxicity	toxicity	NN	_	27	nmod
30	in	in	IN	_	32	case
31	some	some	DT	_	32	det
32	cases	case	NNS	_	27	nmod
33	.	.	.	_	9	punct

1	Patients	patient	NNS	_	8	nsubjpass
2	receiving	receive	VBG	_	1	acl
3	these	these	DT	_	4	det
4	drugs	drug	NNS	_	2	dobj
5	concurrently	concurrently	RB	_	8	advmod
6	should	should	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	monitored	monitor	VBN	_	0	ROOT
9	for	for	IN	_	13	case
10	a	a	DT	_	13	det
11	potential	potential	JJ	_	13	amod
12	drug	drug	NN	_	13	compound
13	interaction	interaction	NN	_	8	nmod
14	.	.	.	_	8	punct

1	drug1	drug1	NN	_	0	ROOT

1	Studies	study	NNS	_	2	nsubj
2	showed	show	VBD	_	0	ROOT
3	that	that	IN	_	5	mark
4	drug1	drug1	NN	_	5	nsubj
5	increased	increase	VBD	_	2	ccomp
6	the	the	DT	_	7	det
7	AUC	auc	NN	_	5	dobj
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	and	and	CC	_	9	cc
11	drug3	drug3	NN	_	9	conj
12	by	by	IN	_	14	case
13	3-4	3-4	CD	_	14	nummod
14	fold	fold	NN	_	5	nmod
15	and	and	CC	_	5	cc
16	the	the	DT	_	17	det
17	Cmax	cmax	NN	_	5	conj
18	by	by	IN	_	19	case
19	2-fold	2-fold	RB	_	17	nmod
20	,	,	,	_	17	punct
21	compared	compare	VBN	_	23	case
22	to	to	TO	_	23	case
23	placebo	placebo	NN	_	17	nmod
24	.	.	.	_	2	punct

1	The	the	DT	_	4	det
2	elimination	elimination	NN	_	4	compound
3	half	half	NN	_	4	amod
4	life	life	NN	_	10	nsubj
5	of	of	IN	_	6	case
6	drug1	drug1	NN	_	4	nmod
7	and	and	CC	_	6	cc
8	drug2	drug2	NN	_	6	conj
9	also	also	RB	_	10	advmod
10	increased	increase	VBD	_	0	ROOT
11	-LRB-	-lrb-	-LRB-	_	14	punct
12	1.5-2	1.5-2	CD	_	13	compound
13	.5	.5	CD	_	14	nummod
14	fold	fold	NN	_	10	dep
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	during	during	IN	_	17	case
17	coadministration	coadministration	NN	_	10	nmod
18	with	with	IN	_	19	case
19	drug3	drug3	NN	_	17	nmod
20	.	.	.	_	10	punct

1	These	these	DT	_	3	det
2	pharmacokinetic	pharmacokinetic	JJ	_	3	amod
3	effects	effect	NNS	_	9	nsubj
4	seen	see	VBN	_	3	acl
5	during	during	IN	_	7	case
6	drug1	drug1	NN	_	7	compound
7	coadministration	coadministration	NN	_	4	nmod
8	can	can	MD	_	9	aux
9	result	result	VB	_	0	ROOT
10	in	in	IN	_	13	case
11	increased	increase	VBN	_	13	amod
12	clinical	clinical	JJ	_	13	amod
13	effects	effect	NNS	_	9	nmod
14	-LRB-	-lrb-	-LRB-	_	18	punct
15	e.g.	e.g.	FW	_	18	dep
16	,	,	,	_	18	punct
17	prolonged	prolonged	JJ	_	18	amod
18	sodation	sodation	NN	_	13	dep
19	-RRB-	-rrb-	-RRB-	_	18	punct
20	of	of	IN	_	22	case
21	both	both	DT	_	22	cc:preconj
22	drug2	drug2	NN	_	13	nmod
23	and	and	CC	_	22	cc
24	drug3	drug3	NN	_	22	conj
25	.	.	.	_	9	punct

1	drug1	drug1	NN	_	0	ROOT

1	In	in	IN	_	4	case
2	a	a	DT	_	4	det
3	ten-subject	ten-subject	JJ	_	4	amod
4	study	study	NN	_	16	nmod
5	,	,	,	_	16	punct
6	coadministration	coadministration	NN	_	16	nsubj
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	-LRB-	-lrb-	-LRB-	_	12	punct
10	120	120	CD	_	12	nummod
11	mg	mg	NN	_	12	compound
12	bid	bid	NN	_	8	appos
13	-RRB-	-rrb-	-RRB-	_	12	punct
14	with	with	IN	_	15	case
15	drug2	drug2	NN	_	6	nmod
16	resulted	result	VBD	_	0	ROOT
17	in	in	IN	_	21	case
18	a	a	DT	_	21	det
19	3-4	3-4	CD	_	20	compound
20	times	time	NNS	_	21	nummod
21	increase	increase	VBP	_	16	nmod
22	in	in	IN	_	25	case
23	mean	mean	JJ	_	25	amod
24	drug3	drug3	NN	_	25	compound
25	AUC	auc	NN	_	21	nmod
26	and	and	CC	_	25	cc
27	Cmax	cmax	NN	_	25	conj
28	vs.	vs.	CC	_	25	cc
29	drug4	drug4	NN	_	25	conj
30	alone	alone	RB	_	29	advmod
31	;	;	:	_	16	punct

1	no	no	DT	_	2	neg
2	change	change	NN	_	9	nsubjpass
3	in	in	IN	_	5	case
4	drug1	drug1	NN	_	5	compound
5	AUC	auc	NN	_	2	nmod
6	and	and	CC	_	5	cc
7	Cmax	cmax	NN	_	5	conj
8	was	be	VBD	_	9	auxpass
9	observed	observe	VBN	_	0	ROOT
10	during	during	IN	_	12	case
11	drug2	drug2	NN	_	12	compound
12	coadministration	coadministration	NN	_	9	nmod
13	.	.	.	_	9	punct

1	drug1	drug1	NN	_	3	compound
2	plasma	plasma	NN	_	3	compound
3	levels	level	NNS	_	7	nsubjpass
4	were	be	VBD	_	7	auxpass
5	not	not	RB	_	7	neg
6	significantly	significantly	RB	_	7	advmod
7	affected	affect	VBN	_	0	ROOT
8	by	by	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	or	or	CC	_	9	cc
11	drug3	drug3	NN	_	9	conj
12	.	.	.	_	7	punct

1	drug1	drug1	NN	_	0	ROOT

1	Coadministration	coadministration	NN	_	6	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	1	nmod
6	lowered	lower	VBD	_	0	ROOT
7	the	the	DT	_	10	det
8	drug3	drug3	NN	_	10	compound
9	plasma	plasma	NN	_	10	compound
10	concentrations	concentration	NNS	_	6	dobj
11	to	to	TO	_	13	case
12	undetectable	undetectable	JJ	_	13	amod
13	levels	level	NNS	_	6	nmod
14	.	.	.	_	6	punct

1	Coadministration	coadministration	NN	_	13	nsubjpass
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	with	with	IN	_	5	case
5	drug2	drug2	NN	_	1	nmod
6	or	or	CC	_	5	cc
7	any	any	DT	_	10	det
8	known	known	JJ	_	10	amod
9	CYP3A4	cyp3a4	NN	_	10	compound
10	inducer	inducer	NN	_	5	conj
11	should	should	MD	_	13	aux
12	be	be	VB	_	13	auxpass
13	avoided	avoid	VBN	_	0	ROOT
14	when	when	WRB	_	15	advmod
15	possible	possible	JJ	_	13	advcl
16	,	,	,	_	13	punct
17	and	and	CC	_	13	cc
18	alternative	alternative	JJ	_	19	amod
19	therapy	therapy	NN	_	13	conj
20	considered	consider	VBN	_	19	acl
21	.	.	.	_	13	punct

1	drug1	drug1	NN	_	2	compound
2	drug2	drug2	NN	_	4	nsubj
3	may	may	MD	_	4	aux
4	delay	delay	VB	_	0	ROOT
5	or	or	CC	_	4	cc
6	reduce	reduce	VB	_	4	conj
7	the	the	DT	_	8	det
8	absorption	absorption	NN	_	4	dobj
9	of	of	IN	_	12	case
10	concomitant	concomitant	JJ	_	12	amod
11	oral	oral	JJ	_	12	amod
12	medication	medication	NN	_	8	nmod
13	such	such	JJ	_	15	case
14	as	as	IN	_	13	mwe
15	drug3	drug3	NN	_	12	nmod
16	,	,	,	_	15	punct
17	drug4	drug4	NN	_	15	conj
18	,	,	,	_	15	punct
19	drug5	drug5	NN	_	15	conj
20	-LRB-	-lrb-	-LRB-	_	21	punct
21	acidic	acidic	JJ	_	19	dep
22	-RRB-	-rrb-	-RRB-	_	21	punct
23	or	or	CC	_	15	cc
24	drug6	drug6	NN	_	15	conj
25	-LRB-	-lrb-	-LRB-	_	26	punct
26	basic	basic	JJ	_	24	appos
27	-RRB-	-rrb-	-RRB-	_	26	punct
28	,	,	,	_	4	punct
29	as	as	RB	_	4	cc
30	well	well	RB	_	29	mwe
31	as	as	IN	_	29	mwe
32	drug7	drug7	NN	_	33	compound
33	drug8	drug8	NN	_	4	conj
34	,	,	,	_	33	punct
35	drug9	drug9	NN	_	33	conj
36	,	,	,	_	33	punct
37	thyroid	thyroid	NN	_	33	conj
38	and	and	CC	_	33	cc
39	drug10	drug10	NN	_	40	compound
40	preparations	preparation	NNS	_	33	conj
41	,	,	,	_	33	punct
42	drug11	drug11	NN	_	33	conj
43	and	and	CC	_	33	cc
44	drug12	drug12	NN	_	33	conj
45	,	,	,	_	33	punct
46	and	and	CC	_	33	cc
47	drug13	drug13	NN	_	33	conj
48	.	.	.	_	4	punct

1	Interference	interference	NN	_	11	nsubjpass
2	with	with	IN	_	4	case
3	the	the	DT	_	4	det
4	absorption	absorption	NN	_	1	nmod
5	of	of	IN	_	8	case
6	oral	oral	JJ	_	8	amod
7	drug1	drug1	NN	_	8	compound
8	supplements	supplement	NNS	_	4	nmod
9	has	have	VBZ	_	11	aux
10	been	be	VBN	_	11	auxpass
11	observed	observe	VBN	_	0	ROOT
12	with	with	IN	_	17	case
13	another	another	DT	_	17	det
14	positively-charged	positively-charged	JJ	_	17	amod
15	bile	bile	NN	_	17	compound
16	acid	acid	NN	_	17	compound
17	sequestrant	sequestrant	NN	_	11	nmod
18	.	.	.	_	11	punct

1	drug1	drug1	NN	_	2	compound
2	drug2	drug2	NN	_	4	nsubj
3	may	may	MD	_	4	aux
4	interfere	interfere	VB	_	0	ROOT
5	with	with	IN	_	7	case
6	the	the	DT	_	7	det
7	pharmacokinetics	pharmacokinetic	NNS	_	4	nmod
8	of	of	IN	_	9	case
9	drugs	drug	NNS	_	7	nmod
10	that	that	WDT	_	11	nsubj
11	undergo	undergo	VBP	_	9	acl:relcl
12	enterohepatic	enterohepatic	JJ	_	13	amod
13	circulation	circulation	NN	_	11	dobj
14	,	,	,	_	4	punct
15	The	the	DT	_	16	det
16	discontinuance	discontinuance	NN	_	21	nsubj
17	of	of	IN	_	19	case
18	drug3	drug3	NN	_	19	compound
19	drug4	drug4	NN	_	16	nmod
20	could	could	MD	_	21	aux
21	pose	pose	VB	_	4	ccomp
22	a	a	DT	_	23	det
23	hazard	hazard	NN	_	21	dobj
24	to	to	TO	_	25	case
25	health	health	NN	_	21	nmod
26	if	if	IN	_	36	mark
27	a	a	DT	_	30	det
28	potentially	potentially	RB	_	29	advmod
29	toxic	toxic	JJ	_	30	amod
30	drug	drug	NN	_	36	nsubjpass
31	such	such	JJ	_	33	case
32	as	as	IN	_	31	mwe
33	drug5	drug5	NN	_	30	nmod
34	has	have	VBZ	_	36	aux
35	been	be	VBN	_	36	auxpass
36	filtrated	filtrate	VBN	_	21	advcl
37	to	to	TO	_	40	case
38	a	a	DT	_	40	det
39	maintenance	maintenance	NN	_	40	compound
40	level	level	NN	_	36	nmod
41	while	while	IN	_	45	mark
42	the	the	DT	_	43	det
43	patient	patient	NN	_	45	nsubj
44	was	be	VBD	_	45	aux
45	taking	take	VBG	_	36	advcl
46	drug6	drug6	JJ	_	47	amod
47	drug7	drug7	NN	_	45	dobj
48	.	.	.	_	4	punct

1	Because	because	IN	_	3	mark
2	drug1	drug1	NN	_	3	nsubj
3	binds	bind	VBZ	_	10	advcl
4	bile	bile	NN	_	5	compound
5	acids	acid	NNS	_	3	dobj
6	,	,	,	_	10	punct
7	drug2	drug2	NN	_	8	compound
8	drug3	drug3	NN	_	10	nsubj
9	may	may	MD	_	10	aux
10	interfere	interfere	VB	_	0	ROOT
11	with	with	IN	_	14	case
12	normal	normal	JJ	_	14	amod
13	fat	fat	JJ	_	14	amod
14	digestion	digestion	NN	_	10	nmod
15	and	and	CC	_	14	cc
16	absorption	absorption	NN	_	14	conj
17	and	and	CC	_	10	cc
18	thus	thus	RB	_	20	advmod
19	may	may	MD	_	20	aux
20	prevent	prevent	VB	_	10	conj
21	absorption	absorption	NN	_	20	dobj
22	of	of	IN	_	23	case
23	drug4	drug4	NN	_	21	nmod
24	such	such	JJ	_	26	case
25	as	as	IN	_	24	mwe
26	A	a	DT	_	23	nmod
27	,	,	,	_	26	punct
28	D	d	NN	_	26	conj
29	,	,	,	_	26	punct
30	E	e	NN	_	26	conj
31	,	,	,	_	26	punct
32	and	and	CC	_	26	cc
33	K	k	NN	_	26	conj
34	.	.	.	_	10	punct

1	When	when	WRB	_	5	advmod
2	drug1	drug1	NN	_	3	compound
3	drug2	drug2	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	given	give	VBN	_	25	advcl
6	for	for	IN	_	8	case
7	long	long	JJ	_	8	amod
8	periods	period	NNS	_	5	nmod
9	of	of	IN	_	10	case
10	time	time	NN	_	8	nmod
11	,	,	,	_	25	punct
12	concomitant	concomitant	JJ	_	13	amod
13	supplementation	supplementation	NN	_	25	nsubjpass
14	with	with	IN	_	20	case
15	water-miscible	water-miscible	JJ	_	20	amod
16	-LRB-	-lrb-	-LRB-	_	18	punct
17	or	or	CC	_	18	cc
18	parenteral	parenteral	JJ	_	15	dep
19	-RRB-	-rrb-	-RRB-	_	18	punct
20	forms	form	NNS	_	13	nmod
21	of	of	IN	_	22	case
22	drug3	drug3	NN	_	20	nmod
23	should	should	MD	_	25	aux
24	be	be	VB	_	25	auxpass
25	considered	consider	VBN	_	0	ROOT
26	.	.	.	_	25	punct

1	SINCE	since	IN	_	8	mark
2	drug1	drug1	NN	_	7	compound
3	drug2	drug2	NN	_	7	compound
4	MAY	MAY	NNP	_	7	compound
5	BIND	BIND	NNP	_	7	compound
6	OTHER	other	JJ	_	7	amod
7	DRUGS	drug	NNS	_	8	nsubj
8	GIVEN	give	VBP	_	12	advcl
9	CONCURRENTLY	concurrently	RB	_	8	advmod
10	,	,	,	_	12	punct
11	IT	it	PRP	_	12	nsubj
12	IS	be	VBZ	_	0	ROOT
13	RECOMMENDED	RECOMMENDED	NNP	_	15	compound
14	THAT	that	WDT	_	15	amod
15	PATIENTS	patient	NNS	_	16	nsubj
16	TAKE	take	VBP	_	12	ccomp
17	OTHER	other	JJ	_	18	amod
18	DRUGS	drug	NNS	_	16	dobj
19	AT	at	IN	_	22	case
20	LEAST	least	NN	_	22	compound
21	1	1	CD	_	22	nummod
22	HOUR	hour	NN	_	18	nmod
23	BEFORE	before	IN	_	16	dep
24	OR	or	NN	_	28	compound
25	4	4	CD	_	27	compound
26	TO	to	TO	_	27	dep
27	6	6	CD	_	28	nummod
28	HOURS	hour	NNS	_	23	dobj
29	AFTER	after	IN	_	31	case
30	drug3	drug3	NN	_	31	compound
31	drug4	drug4	NN	_	28	nmod
32	-LRB-	-lrb-	-LRB-	_	33	punct
33	OR	or	NN	_	31	dep
34	AT	at	IN	_	40	case
35	AS	as	JJ	_	40	amod
36	GREAT	great	JJ	_	40	amod
37	AN	a	DT	_	40	det
38	INTERVAL	INTERVAL	NNP	_	40	compound
39	AS	AS	NNP	_	40	compound
40	POSSIBLE	possible	NN	_	33	nmod
41	-RRB-	-rrb-	-RRB-	_	33	punct
42	TO	to	TO	_	43	mark
43	AVOID	avoid	VB	_	28	acl
44	IMPEDING	IMPEDING	NNP	_	46	compound
45	THEIR	THEIR	NNP	_	46	compound
46	ABSORPTION	ABSORPTION	NNP	_	43	dobj
47	.	.	.	_	12	punct

1	CYP3A4	cyp3a4	NN	_	2	compound
2	Interactions	interaction	NNS	_	0	ROOT

1	drug1	drug1	NN	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	metabolized	metabolize	VBN	_	0	ROOT
4	by	by	IN	_	5	case
5	CYP3A4	cyp3a4	NN	_	3	nmod
6	but	but	CC	_	3	cc
7	has	have	VBZ	_	3	conj
8	no	no	DT	_	11	neg
9	CYP3A4	cyp3a4	NN	_	11	compound
10	inhibitory	inhibitory	JJ	_	11	amod
11	activity	activity	NN	_	7	dobj
12	;	;	:	_	3	punct

1	therefore	therefore	RB	_	5	advmod
2	it	it	PRP	_	5	nsubjpass
3	is	be	VBZ	_	5	auxpass
4	not	not	RB	_	5	neg
5	expected	expect	VBN	_	0	ROOT
6	to	to	TO	_	7	mark
7	affect	affect	VB	_	5	xcomp
8	the	the	DT	_	10	det
9	plasma	plasma	NN	_	10	compound
10	concentrations	concentration	NNS	_	7	dobj
11	of	of	IN	_	13	case
12	other	other	JJ	_	13	amod
13	drugs	drug	NNS	_	10	nmod
14	metabolized	metabolize	VBN	_	13	acl
15	by	by	IN	_	16	case
16	CYP3A4	cyp3a4	NN	_	14	nmod
17	.	.	.	_	5	punct

1	Potent	potent	JJ	_	2	amod
2	inhibitors	inhibitor	NNS	_	8	nsubj
3	of	of	IN	_	4	case
4	CYP3A4	cyp3a4	NN	_	2	nmod
5	-LRB-	-lrb-	-LRB-	_	6	punct
6	below	below	IN	_	4	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	increase	increase	VBP	_	0	ROOT
9	the	the	DT	_	10	det
10	risk	risk	NN	_	8	dobj
11	of	of	IN	_	12	case
12	myopathy	myopathy	NN	_	10	nmod
13	by	by	IN	_	14	mark
14	reducing	reduce	VBG	_	8	advcl
15	the	the	DT	_	16	det
16	elimination	elimination	NN	_	14	dobj
17	of	of	IN	_	18	case
18	drug1	drug1	NN	_	16	nmod
19	.	.	.	_	8	punct

1	Pharmacokinetics	pharmacokinetic	NNS	_	0	ROOT
2	.	.	.	_	1	punct

1	drug1	drug1	NN	_	10	compound
2	drug2	drug2	NN	_	10	compound
3	drug3	drug3	NN	_	10	compound
4	drug4	drug4	NN	_	10	compound
5	drug5	drug5	NN	_	10	compound
6	drug6	drug6	NN	_	10	compound
7	drug7	drug7	NN	_	10	compound
8	drug8	drug8	NN	_	10	compound
9	Large	large	JJ	_	10	amod
10	quantities	quantity	NNS	_	0	ROOT
11	of	of	IN	_	13	case
12	grapefruit	grapefruit	NN	_	13	compound
13	juice	juice	NN	_	10	nmod
14	-LRB-	-lrb-	-LRB-	_	16	punct
15	1	1	CD	_	16	nummod
16	quart	quart	NN	_	13	dep
17	daily	daily	JJ	_	16	amod
18	-RRB-	-rrb-	-RRB-	_	16	punct

1	Interactions	interaction	NNS	_	0	ROOT
2	with	with	IN	_	4	case
3	lipid-lowering	lipid-lowering	JJ	_	4	amod
4	drugs	drug	NNS	_	1	nmod
5	that	that	WDT	_	7	nsubj
6	can	can	MD	_	7	aux
7	cause	cause	VB	_	1	acl:relcl
8	myopathy	myopathy	NN	_	7	dobj
9	when	when	WRB	_	10	advmod
10	given	give	VBN	_	7	advcl
11	alone	alone	RB	_	10	advmod
12	.	.	.	_	1	punct

1	The	the	DT	_	2	det
2	risk	risk	NN	_	7	nsubjpass
3	of	of	IN	_	4	case
4	myopathy	myopathy	NN	_	2	nmod
5	is	be	VBZ	_	7	auxpass
6	also	also	RB	_	7	advmod
7	increased	increase	VBN	_	0	ROOT
8	by	by	IN	_	12	case
9	the	the	DT	_	12	det
10	following	follow	VBG	_	12	amod
11	lipid-lowering	lipid-lowering	JJ	_	12	amod
12	drugs	drug	NNS	_	7	nmod
13	that	that	WDT	_	18	nsubj
14	are	be	VBP	_	18	cop
15	not	not	RB	_	18	neg
16	potent	potent	JJ	_	18	amod
17	CYP3A4	cyp3a4	NN	_	18	compound
18	inhibitors	inhibitor	NNS	_	12	acl:relcl
19	,	,	,	_	7	punct
20	but	but	CC	_	7	cc
21	which	which	WDT	_	23	nsubj
22	can	can	MD	_	23	aux
23	cause	cause	VB	_	7	conj
24	myopathy	myopathy	NN	_	23	dobj
25	when	when	WRB	_	26	advmod
26	given	give	VBN	_	23	advcl
27	alone	alone	RB	_	26	advmod
28	.	.	.	_	7	punct

1	See	see	VB	_	0	ROOT
2	WARNINGS	WARNINGS	NNP	_	1	dobj
3	,	,	,	_	2	punct
4	Myopathy/Rhabdomyolysis	Myopathy/Rhabdomyolysis	NNP	_	2	appos
5	.	.	.	_	1	punct

1	drug1	drug1	NN	_	4	compound
2	Other	other	JJ	_	4	amod
3	drug2	drug2	NN	_	4	compound
4	drug3	drug3	NN	_	0	ROOT
5	-LRB-	-lrb-	-LRB-	_	6	punct
6	drug4	drug4	NN	_	4	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	=	=	JJ	_	4	dep
10	1	1	CD	_	11	nummod
11	g/day	g/day	NN	_	9	dobj
12	-RRB-	-rrb-	-RRB-	_	9	punct

1	Other	other	JJ	_	3	amod
2	drug	drug	NN	_	3	compound
3	interactions	interaction	NNS	_	0	ROOT

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	The	the	DT	_	4	det
4	risk	risk	NN	_	8	nsubjpass
5	of	of	IN	_	6	case
6	myopathy/rhabdomyolysis	myopathy/rhabdomyolysis	NN	_	4	nmod
7	is	be	VBZ	_	8	auxpass
8	increased	increase	VBN	_	1	dep
9	by	by	IN	_	11	case
10	concomitant	concomitant	JJ	_	11	amod
11	administration	administration	NN	_	8	nmod
12	of	of	IN	_	13	case
13	drug2	drug2	NN	_	11	nmod
14	particularly	particularly	RB	_	17	advmod
15	with	with	IN	_	17	case
16	higher	higher	JJR	_	17	amod
17	doses	dose	NNS	_	11	nmod
18	of	of	IN	_	19	case
19	drug3	drug3	NN	_	17	nmod
20	-LRB-	-lrb-	-LRB-	_	21	punct
21	see	see	VB	_	8	parataxis
22	WARNINGS	warning	NNS	_	21	dobj
23	,	,	,	_	22	punct
24	Myopathy/Rhabdomyolysis	myopathy/rhabdomyolysis	NN	_	22	appos
25	-RRB-	-rrb-	-RRB-	_	21	punct
26	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	or	or	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	:	:	:	_	1	punct
5	The	the	DT	_	6	det
6	risk	risk	NN	_	10	nsubjpass
7	of	of	IN	_	8	case
8	myopathy/rhabdomyolysis	myopathy/rhabdomyolysis	NN	_	6	nmod
9	is	be	VBZ	_	10	auxpass
10	increased	increase	VBN	_	1	dep
11	when	when	WRB	_	17	advmod
12	either	either	CC	_	13	cc:preconj
13	drug3	drug3	NN	_	17	nsubjpass
14	or	or	CC	_	13	cc
15	drug4	drug4	NN	_	13	conj
16	is	be	VBZ	_	17	auxpass
17	used	use	VBN	_	10	advcl
18	concomitantly	concomitantly	RB	_	17	advmod
19	with	with	IN	_	23	case
20	a	a	DT	_	23	det
21	closely	closely	RB	_	22	advmod
22	related	related	JJ	_	23	amod
23	member	member	NN	_	17	nmod
24	of	of	IN	_	26	case
25	the	the	DT	_	26	det
26	drug5	drug5	NN	_	23	nmod
27	-LRB-	-lrb-	-LRB-	_	28	punct
28	see	see	VB	_	10	parataxis
29	WARNINGS	warning	NNS	_	28	dobj
30	,	,	,	_	29	punct
31	Myopathy/Rhabdomyolysis	myopathy/rhabdomyolysis	NN	_	29	appos
32	-RRB-	-rrb-	-RRB-	_	28	punct
33	.	.	.	_	10	punct

1	drug1	drug1	NN	_	2	compound
2	s	s	NNS	_	0	ROOT
3	:	:	:	_	2	punct
4	In	in	IN	_	8	case
5	a	a	DT	_	8	det
6	small	small	JJ	_	8	amod
7	clinical	clinical	JJ	_	8	amod
8	trial	trial	NN	_	25	nmod
9	in	in	IN	_	10	case
10	which	which	WDT	_	13	nmod
11	drug2	drug2	NN	_	13	nsubjpass
12	was	be	VBD	_	13	auxpass
13	administered	administer	VBN	_	8	acl:relcl
14	to	to	TO	_	15	mark
15	drug3	drug3	VB	_	13	xcomp
16	treated	treated	JJ	_	17	amod
17	patients	patient	NNS	_	15	dobj
18	,	,	,	_	25	punct
19	no	no	DT	_	20	neg
20	effect	effect	NN	_	25	nsubjpass
21	on	on	IN	_	23	case
22	prothrombin	prothrombin	NN	_	23	compound
23	time	time	NN	_	20	nmod
24	was	be	VBD	_	25	auxpass
25	detected	detect	VBN	_	2	appos
26	.	.	.	_	2	punct

1	However	however	RB	_	7	advmod
2	,	,	,	_	7	punct
3	another	another	DT	_	4	det
4	drug1	drug1	NN	_	7	nsubjpass
5	has	have	VBZ	_	7	aux
6	been	be	VBN	_	7	auxpass
7	found	find	VBN	_	0	ROOT
8	to	to	TO	_	9	mark
9	produce	produce	VB	_	7	xcomp
10	a	a	DT	_	14	det
11	less	less	JJR	_	14	advmod
12	than	than	IN	_	14	case
13	two-second	two-second	JJ	_	14	amod
14	increase	increase	NN	_	9	dobj
15	in	in	IN	_	17	case
16	prothrombin	prothrombin	NN	_	17	compound
17	time	time	NN	_	14	nmod
18	in	in	IN	_	20	case
19	healthy	healthy	JJ	_	20	amod
20	volunteers	volunteer	NNS	_	14	nmod
21	receiving	receive	VBG	_	20	acl
22	low	low	JJ	_	23	amod
23	doses	dose	NNS	_	21	dobj
24	of	of	IN	_	25	case
25	drug2	drug2	NN	_	23	nmod
26	.	.	.	_	7	punct

1	Also	also	RB	_	10	advmod
2	,	,	,	_	10	punct
3	bleeding	bleed	VBG	_	10	nsubjpass
4	and/or	and/or	CC	_	3	cc
5	increased	increase	VBN	_	7	amod
6	prothrombin	prothrombin	NN	_	7	compound
7	time	time	NN	_	3	conj
8	have	have	VBP	_	10	aux
9	been	be	VBN	_	10	auxpass
10	reported	report	VBN	_	0	ROOT
11	in	in	IN	_	14	case
12	a	a	DT	_	14	det
13	few	few	JJ	_	14	amod
14	patients	patient	NNS	_	10	nmod
15	taking	take	VBG	_	14	acl
16	drug1	drug1	NN	_	17	compound
17	s	s	NNS	_	15	dobj
18	concomitantly	concomitantly	RB	_	15	advmod
19	with	with	IN	_	20	case
20	drug2	drug2	NN	_	15	nmod
21	.	.	.	_	10	punct

1	It	it	PRP	_	3	nsubjpass
2	is	be	VBZ	_	3	auxpass
3	recommended	recommend	VBN	_	0	ROOT
4	that	that	IN	_	13	mark
5	in	in	IN	_	6	case
6	patients	patient	NNS	_	13	nmod
7	taking	take	VBG	_	6	acl
8	drug1	drug1	NN	_	7	dobj
9	,	,	,	_	13	punct
10	prothrombin	prothrombin	NN	_	11	compound
11	time	time	NN	_	13	nsubjpass
12	be	be	VB	_	13	auxpass
13	determined	determine	VBN	_	3	ccomp
14	before	before	IN	_	15	mark
15	starting	start	VBG	_	13	advcl
16	drug2	drug2	NN	_	15	dobj
17	and	and	CC	_	16	cc
18	frequently	frequently	RB	_	16	conj
19	enough	enough	RB	_	22	advmod
20	during	during	IN	_	22	case
21	early	early	JJ	_	22	amod
22	therapy	therapy	NN	_	16	nmod
23	to	to	TO	_	24	mark
24	insure	insure	VB	_	15	advcl
25	that	that	IN	_	32	mark
26	no	no	DT	_	28	neg
27	significant	significant	JJ	_	28	amod
28	alteration	alteration	NN	_	32	nsubj
29	of	of	IN	_	31	case
30	prothrombin	prothrombin	NN	_	31	compound
31	time	time	NN	_	28	nmod
32	occurs	occur	VBZ	_	24	ccomp
33	.	.	.	_	3	punct

1	Once	once	RB	_	8	advmod
2	a	a	DT	_	5	det
3	stable	stable	JJ	_	5	amod
4	prothrombin	prothrombin	NN	_	5	compound
5	time	time	NN	_	8	nsubjpass
6	has	have	VBZ	_	8	aux
7	been	be	VBN	_	8	auxpass
8	documented	document	VBN	_	14	advcl
9	,	,	,	_	14	punct
10	prothrombin	prothrombin	NN	_	11	compound
11	times	time	NNS	_	14	nsubjpass
12	can	can	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	monitored	monitor	VBN	_	0	ROOT
15	at	at	IN	_	17	case
16	the	the	DT	_	17	det
17	intervals	interval	NNS	_	14	nmod
18	usually	usually	RB	_	19	advmod
19	recommended	recommend	VBN	_	17	acl
20	for	for	IN	_	21	case
21	patients	patient	NNS	_	19	nmod
22	on	on	IN	_	23	case
23	drug1	drug1	NN	_	21	nmod
24	.	.	.	_	14	punct

1	If	if	IN	_	7	mark
2	the	the	DT	_	3	det
3	dose	dose	NN	_	7	nsubjpass
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	is	be	VBZ	_	7	auxpass
7	changed	change	VBN	_	14	advcl
8	,	,	,	_	14	punct
9	the	the	DT	_	11	det
10	same	same	JJ	_	11	amod
11	procedure	procedure	NN	_	14	nsubjpass
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	repeated	repeat	VBN	_	0	ROOT
15	.	.	.	_	14	punct

1	drug1	drug1	NN	_	2	compound
2	therapy	therapy	NN	_	6	nsubjpass
3	has	have	VBZ	_	6	aux
4	not	not	RB	_	6	neg
5	been	be	VBN	_	6	auxpass
6	associated	associate	VBN	_	0	ROOT
7	with	with	IN	_	8	case
8	bleeding	bleeding	NN	_	6	nmod
9	or	or	CC	_	8	cc
10	with	with	IN	_	11	case
11	changes	change	NNS	_	8	conj
12	in	in	IN	_	14	case
13	prothrombin	prothrombin	NN	_	14	compound
14	time	time	NN	_	11	nmod
15	in	in	IN	_	16	case
16	patients	patient	NNS	_	14	nmod
17	not	not	RB	_	18	neg
18	taking	take	VBG	_	16	acl
19	drug2	drug2	NN	_	18	dobj
20	.	.	.	_	6	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	5	case
4	normal	normal	JJ	_	5	amod
5	volunteers	volunteer	NNS	_	8	nmod
6	,	,	,	_	8	punct
7	there	there	EX	_	8	expl
8	was	be	VBD	_	1	dep
9	no	no	DT	_	15	neg
10	clinically	clinically	RB	_	11	advmod
11	significant	significant	JJ	_	15	amod
12	pharmacokinetic	pharmacokinetic	JJ	_	15	amod
13	or	or	CC	_	12	cc
14	pharmacodynamic	pharmacodynamic	JJ	_	12	conj
15	interaction	interaction	NN	_	8	nsubj
16	with	with	IN	_	18	case
17	concomitant	concomitant	JJ	_	18	amod
18	administration	administration	NN	_	15	nmod
19	of	of	IN	_	21	case
20	single	single	JJ	_	21	amod
21	doses	dose	NNS	_	18	nmod
22	of	of	IN	_	23	case
23	drug2	drug2	NN	_	21	nmod
24	and	and	CC	_	23	cc
25	drug3	drug3	NN	_	23	conj
26	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	4	case
4	patients	patient	NNS	_	14	nmod
5	with	with	IN	_	6	case
6	hypercholesterolemia	hypercholesterolemia	NN	_	4	nmod
7	,	,	,	_	4	punct
8	concomitant	concomitant	JJ	_	9	amod
9	administration	administration	NN	_	4	conj
10	of	of	IN	_	11	case
11	drug2	drug2	NN	_	9	nmod
12	and	and	CC	_	4	cc
13	drug3	drug3	NN	_	4	conj
14	resulted	result	VBD	_	1	appos
15	in	in	IN	_	17	case
16	no	no	DT	_	17	neg
17	effect	effect	NN	_	14	nmod
18	on	on	IN	_	21	case
19	drug4	drug4	NN	_	21	compound
20	plasma	plasma	NN	_	21	compound
21	concentrations	concentration	NNS	_	17	nmod
22	.	.	.	_	1	punct

1	Oral	oral	JJ	_	2	amod
2	drug1	drug1	NN	_	0	ROOT
3	:	:	:	_	2	punct
4	In	in	IN	_	6	case
5	pharmacokinetic	pharmacokinetic	JJ	_	6	amod
6	studies	study	NNS	_	17	nmod
7	of	of	IN	_	8	case
8	drug2	drug2	NN	_	6	nmod
9	in	in	IN	_	14	case
10	hypercholesterolemic	hypercholesterolemic	JJ	_	14	amod
11	noninsulin	noninsulin	NN	_	12	nmod:npmod
12	dependent	dependent	JJ	_	14	amod
13	diabetic	diabetic	JJ	_	14	amod
14	patients	patient	NNS	_	8	nmod
15	,	,	,	_	17	punct
16	there	there	EX	_	17	expl
17	was	be	VBD	_	2	dep
18	no	no	DT	_	20	neg
19	drug	drug	NN	_	20	compound
20	interaction	interaction	NN	_	17	nsubj
21	with	with	IN	_	22	case
22	drug3	drug3	NN	_	20	nmod
23	or	or	CC	_	22	cc
24	with	with	IN	_	25	case
25	drug4	drug4	NN	_	22	conj

1	CNS	cns	NN	_	2	compound
2	Drugs	drug	NNS	_	0	ROOT
3	-	-	:	_	2	punct
4	Given	give	VBN	_	8	case
5	the	the	DT	_	8	det
6	primary	primary	JJ	_	8	amod
7	CNS	cns	NN	_	8	compound
8	effects	effect	NNS	_	15	nmod
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	,	,	,	_	15	punct
12	caution	caution	NN	_	15	nsubjpass
13	should	should	MD	_	15	aux
14	be	be	VB	_	15	auxpass
15	used	use	VBN	_	2	dep
16	when	when	WRB	_	19	advmod
17	it	it	PRP	_	19	nsubjpass
18	is	be	VBZ	_	19	auxpass
19	taken	take	VBN	_	15	advcl
20	in	in	IN	_	21	case
21	combination	combination	NN	_	19	nmod
22	with	with	IN	_	26	case
23	other	other	JJ	_	26	amod
24	centrally	centrally	RB	_	25	advmod
25	acting	act	VBG	_	26	amod
26	drugs	drug	NNS	_	21	nmod
27	.	.	.	_	2	punct

1	drug1	drug1	NN	_	0	ROOT
2	-	-	:	_	1	punct
3	Although	although	IN	_	7	mark
4	drug2	drug2	NN	_	7	nsubj
5	did	do	VBD	_	7	aux
6	not	not	RB	_	7	neg
7	potentiate	potentiate	VB	_	35	advcl
8	the	the	DT	_	12	det
9	cognitive	cognitive	JJ	_	12	amod
10	and	and	CC	_	9	cc
11	motor	motor	NN	_	9	conj
12	effects	effect	NNS	_	7	dobj
13	of	of	IN	_	14	case
14	drug3	drug3	NN	_	12	nmod
15	in	in	IN	_	18	case
16	a	a	DT	_	18	det
17	clinical	clinical	JJ	_	18	amod
18	trial	trial	NN	_	7	nmod
19	,	,	,	_	7	punct
20	as	as	IN	_	23	case
21	with	with	IN	_	23	case
22	other	other	JJ	_	23	amod
23	drug4	drug4	NN	_	7	nmod
24	,	,	,	_	7	punct
25	the	the	DT	_	26	det
26	use	use	NN	_	35	nsubjpass
27	of	of	IN	_	28	case
28	drug5	drug5	NN	_	26	nmod
29	by	by	IN	_	30	case
30	patients	patient	NNS	_	26	nmod
31	taking	take	VBG	_	30	acl
32	drug6	drug6	NN	_	31	dobj
33	is	be	VBZ	_	35	auxpass
34	not	not	RB	_	35	neg
35	recommended	recommend	VBN	_	1	dep
36	.	.	.	_	1	punct

1	drug1	drug1	NN	_	0	ROOT
2	-LRB-	-lrb-	-LRB-	_	3	punct
3	drug2	drug2	NN	_	1	appos
4	-RRB-	-rrb-	-RRB-	_	3	punct

1	Drugs	drug	NNS	_	0	ROOT
2	That	that	WDT	_	3	nsubj
3	Interfere	interfere	VBP	_	1	acl:relcl
4	With	with	IN	_	5	case
5	Hemostasis	hemostasis	NN	_	3	nmod
6	-LRB-	-lrb-	-LRB-	_	7	punct
7	drug1	drug1	NN	_	5	appos
8	,	,	,	_	7	punct
9	drug2	drug2	NN	_	7	conj
10	,	,	,	_	7	punct
11	drug3	drug3	NN	_	7	conj
12	,	,	,	_	7	punct
13	etc.	etc.	FW	_	7	dep
14	-RRB-	-rrb-	-RRB-	_	7	punct

1	Serotonin	serotonin	NN	_	2	compound
2	release	release	NN	_	5	nsubj
3	by	by	IN	_	4	case
4	platelets	platelet	NNS	_	2	nmod
5	plays	play	VBZ	_	0	ROOT
6	an	a	DT	_	8	det
7	important	important	JJ	_	8	amod
8	role	role	NN	_	5	dobj
9	in	in	IN	_	10	case
10	hemostasis	hemostasis	NN	_	5	nmod
11	.	.	.	_	5	punct

1	Epidemiological	epidemiological	JJ	_	2	amod
2	studies	study	NNS	_	32	nsubj
3	of	of	IN	_	8	case
4	the	the	DT	_	8	det
5	case-control	case-control	JJ	_	8	amod
6	and	and	CC	_	5	cc
7	cohort	cohort	NN	_	5	conj
8	design	design	NN	_	2	nmod
9	that	that	WDT	_	11	nsubj
10	have	have	VBP	_	11	aux
11	demonstrated	demonstrate	VBN	_	8	acl:relcl
12	an	a	DT	_	13	det
13	association	association	NN	_	11	dobj
14	between	between	IN	_	15	case
15	use	use	NN	_	13	nmod
16	of	of	IN	_	17	case
17	drug1	drug1	NN	_	15	nmod
18	that	that	WDT	_	19	nsubj
19	interfere	interfere	VBP	_	13	acl:relcl
20	with	with	IN	_	22	case
21	serotonin	serotonin	NN	_	22	compound
22	reuptake	reuptake	NN	_	19	nmod
23	and	and	CC	_	22	cc
24	the	the	DT	_	25	det
25	occurrence	occurrence	NN	_	22	conj
26	of	of	IN	_	29	case
27	upper	upper	JJ	_	29	amod
28	gastrointestinal	gastrointestinal	JJ	_	29	amod
29	bleeding	bleeding	NN	_	25	nmod
30	have	have	VBP	_	32	aux
31	also	also	RB	_	32	advmod
32	shown	show	VBN	_	0	ROOT
33	that	that	IN	_	41	mark
34	concurrent	concurrent	JJ	_	35	amod
35	use	use	NN	_	41	nsubj
36	of	of	IN	_	38	case
37	an	a	DT	_	38	det
38	drug2	drug2	NN	_	35	nmod
39	or	or	CC	_	38	cc
40	drug3	drug3	NN	_	38	conj
41	potentiated	potentiate	VBD	_	32	ccomp
42	the	the	DT	_	43	det
43	risk	risk	NN	_	41	dobj
44	of	of	IN	_	45	case
45	bleeding	bleeding	NN	_	43	nmod
46	.	.	.	_	32	punct

1	Thus	thus	RB	_	6	advmod
2	,	,	,	_	6	punct
3	patients	patient	NNS	_	6	nsubjpass
4	should	should	MD	_	6	aux
5	be	be	VB	_	6	auxpass
6	cautioned	caution	VBN	_	0	ROOT
7	about	about	IN	_	9	case
8	the	the	DT	_	9	det
9	use	use	NN	_	6	nmod
10	of	of	IN	_	12	case
11	such	such	JJ	_	12	amod
12	drugs	drug	NNS	_	9	nmod
13	concurrently	concurrently	RB	_	15	advmod
14	with	with	IN	_	15	case
15	drug1	drug1	NN	_	12	nmod
16	.	.	.	_	6	punct

1	drug1	drug1	NN	_	25	dep
2	-	-	:	_	4	punct
3	In	in	IN	_	4	case
4	subjects	subject	NNS	_	25	dep
5	who	who	WP	_	7	nsubj
6	had	have	VBD	_	7	aux
7	received	receive	VBN	_	4	acl:relcl
8	21	21	CD	_	9	nummod
9	days	day	NNS	_	7	nmod:tmod
10	of	of	IN	_	14	case
11	40	40	CD	_	14	nummod
12	mg/day	mg/day	NN	_	14	compound
13	racemic	racemic	JJ	_	14	amod
14	drug2	drug2	NN	_	9	nmod
15	,	,	,	_	4	punct
16	combined	combine	VBN	_	17	amod
17	administration	administration	NN	_	25	nsubj
18	of	of	IN	_	21	case
19	400	400	CD	_	21	nummod
20	mg/day	mg/day	NN	_	21	compound
21	drug3	drug3	NN	_	17	nmod
22	for	for	IN	_	24	case
23	8	8	CD	_	24	nummod
24	days	day	NNS	_	17	nmod
25	resulted	result	VBD	_	0	ROOT
26	in	in	IN	_	28	case
27	an	a	DT	_	28	det
28	increase	increase	NN	_	25	nmod
29	in	in	IN	_	31	case
30	drug4	drug4	NN	_	31	compound
31	AUC	auc	NN	_	28	nmod
32	and	and	CC	_	31	cc
33	Cmax	cmax	NN	_	31	conj
34	of	of	IN	_	36	case
35	43	43	CD	_	36	nummod
36	%	%	NN	_	28	nmod
37	and	and	CC	_	36	cc
38	39	39	CD	_	39	nummod
39	%	%	NN	_	36	conj
40	,	,	,	_	28	punct
41	respectively	respectively	RB	_	28	advmod
42	.	.	.	_	25	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	significance	significance	NN	_	8	nsubj
4	of	of	IN	_	6	case
5	these	these	DT	_	6	det
6	findings	finding	NNS	_	3	nmod
7	is	be	VBZ	_	8	cop
8	unknown	unknown	JJ	_	0	ROOT
9	.	.	.	_	8	punct

1	drug1	drug1	NN	_	32	dep
2	-	-	:	_	4	punct
3	In	in	IN	_	4	case
4	subjects	subject	NNS	_	32	dep
5	who	who	WP	_	7	nsubj
6	had	have	VBD	_	7	aux
7	received	receive	VBN	_	4	acl:relcl
8	21	21	CD	_	9	nummod
9	days	day	NNS	_	7	nmod:tmod
10	of	of	IN	_	14	case
11	40	40	CD	_	14	nummod
12	mg/day	mg/day	NN	_	14	compound
13	racemic	racemic	JJ	_	14	amod
14	drug2	drug2	NN	_	9	nmod
15	,	,	,	_	4	punct
16	combined	combine	VBN	_	17	amod
17	administration	administration	NN	_	32	nsubj
18	of	of	IN	_	19	case
19	drug3	drug3	NN	_	17	nmod
20	and	and	CC	_	19	cc
21	drug4	drug4	NN	_	19	conj
22	-LRB-	-lrb-	-LRB-	_	24	punct
23	single	single	JJ	_	24	amod
24	dose	dose	NN	_	17	dep
25	of	of	IN	_	27	case
26	1	1	CD	_	27	nummod
27	mg	mg	NN	_	24	nmod
28	-RRB-	-rrb-	-RRB-	_	24	punct
29	did	do	VBD	_	32	aux
30	not	not	RB	_	32	neg
31	significantly	significantly	RB	_	32	advmod
32	affect	affect	VB	_	0	ROOT
33	the	the	DT	_	34	det
34	pharmacokinetics	pharmacokinetic	NNS	_	32	dobj
35	of	of	IN	_	37	case
36	either	either	CC	_	37	cc:preconj
37	drug5	drug5	NN	_	34	nmod
38	or	or	CC	_	37	cc
39	drug6	drug6	NN	_	37	conj
40	.	.	.	_	32	punct

1	drug1	drug1	NN	_	23	nsubj
2	-	-	:	_	1	punct
3	Coadministration	coadministration	NN	_	1	dep
4	of	of	IN	_	6	case
5	racemic	racemic	JJ	_	6	amod
6	drug2	drug2	NN	_	3	nmod
7	-LRB-	-lrb-	-LRB-	_	9	punct
8	40	40	CD	_	9	nummod
9	mg/day	mg/day	NN	_	6	dep
10	for	for	IN	_	12	case
11	10	10	CD	_	12	nummod
12	days	day	NNS	_	9	nmod
13	-RRB-	-rrb-	-RRB-	_	9	punct
14	and	and	CC	_	6	cc
15	drug3	drug3	NN	_	18	compound
16	-LRB-	-lrb-	-LRB-	_	18	punct
17	30	30	CD	_	18	nummod
18	mmol/day	mmol/day	NN	_	6	conj
19	for	for	IN	_	21	case
20	5	5	CD	_	21	nummod
21	days	day	NNS	_	18	nmod
22	-RRB-	-rrb-	-RRB-	_	18	punct
23	had	have	VBD	_	0	ROOT
24	no	no	DT	_	26	neg
25	significant	significant	JJ	_	26	amod
26	effect	effect	NN	_	23	dobj
27	on	on	IN	_	29	case
28	the	the	DT	_	29	det
29	pharmacokinetics	pharmacokinetic	NNS	_	23	nmod
30	of	of	IN	_	31	case
31	drug4	drug4	NN	_	29	nmod
32	or	or	CC	_	31	cc
33	drug5	drug5	NN	_	31	conj
34	.	.	.	_	23	punct

1	Nevertheless	nevertheless	RB	_	8	advmod
2	,	,	,	_	8	punct
3	plasma	plasma	NN	_	5	compound
4	drug1	drug1	NN	_	5	compound
5	levels	level	NNS	_	8	nsubjpass
6	should	should	MD	_	8	aux
7	be	be	VB	_	8	auxpass
8	monitored	monitor	VBN	_	0	ROOT
9	with	with	IN	_	11	case
10	appropriate	appropriate	JJ	_	11	amod
11	adjustment	adjustment	NN	_	8	nmod
12	to	to	TO	_	15	case
13	the	the	DT	_	15	det
14	drug2	drug2	NN	_	15	compound
15	dose	dose	NN	_	11	nmod
16	in	in	IN	_	17	case
17	accordance	accordance	NN	_	11	nmod
18	with	with	IN	_	21	case
19	standard	standard	JJ	_	21	amod
20	clinical	clinical	JJ	_	21	amod
21	practice	practice	NN	_	17	nmod
22	.	.	.	_	8	punct

1	Because	because	IN	_	4	mark
2	drug1	drug1	NN	_	4	nsubj
3	may	may	MD	_	4	aux
4	enhance	enhance	VB	_	14	advcl
5	the	the	DT	_	7	det
6	serotonergic	serotonergic	JJ	_	7	amod
7	effects	effect	NNS	_	4	dobj
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	,	,	,	_	14	punct
11	caution	caution	NN	_	14	nsubjpass
12	should	should	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	exercised	exercise	VBN	_	0	ROOT
15	when	when	WRB	_	20	advmod
16	drug3	drug3	NN	_	20	nsubjpass
17	and	and	CC	_	16	cc
18	drug4	drug4	NN	_	16	conj
19	are	be	VBP	_	20	auxpass
20	coadministered	coadminister	VBN	_	14	advcl
21	.	.	.	_	14	punct

1	drug1	drug1	NN	_	30	nsubjpass
2	and	and	CC	_	1	cc
3	drug2	drug2	NN	_	1	conj
4	-	-	:	_	1	punct
5	In	in	IN	_	8	case
6	a	a	DT	_	8	det
7	controlled	controlled	JJ	_	8	amod
8	study	study	NN	_	30	nmod
9	,	,	,	_	8	punct
10	a	a	DT	_	12	det
11	single	single	JJ	_	12	amod
12	dose	dose	NN	_	8	appos
13	of	of	IN	_	16	case
14	drug3	drug3	NN	_	16	compound
15	2	2	CD	_	16	nummod
16	mg	mg	NN	_	12	nmod
17	co-administered	co-administer	VBN	_	12	acl
18	with	with	IN	_	22	case
19	racemic	racemic	JJ	_	22	amod
20	drug4	drug4	NN	_	22	compound
21	40	40	CD	_	22	nummod
22	mg	mg	NN	_	17	nmod
23	given	give	VBN	_	22	acl
24	once	once	RB	_	25	advmod
25	daily	daily	RB	_	23	advmod
26	for	for	IN	_	28	case
27	11	11	CD	_	28	nummod
28	days	day	NNS	_	23	nmod
29	was	be	VBD	_	30	auxpass
30	associated	associate	VBN	_	0	ROOT
31	with	with	IN	_	34	case
32	a	a	DT	_	34	det
33	mean	mean	JJ	_	34	amod
34	increase	increase	NN	_	30	nmod
35	in	in	IN	_	37	case
36	QTc	qtc	NN	_	37	compound
37	values	value	NNS	_	34	nmod
38	of	of	IN	_	41	case
39	approximately	approximately	RB	_	40	advmod
40	10	10	CD	_	41	nummod
41	msec	msec	NN	_	37	nmod
42	compared	compare	VBN	_	34	acl
43	to	to	TO	_	44	case
44	drug5	drug5	VB	_	42	nmod
45	given	give	VBN	_	44	acl
46	alone	alone	RB	_	45	advmod
47	.	.	.	_	30	punct

1	Racemic	racemic	JJ	_	2	amod
2	drug1	drug1	NN	_	5	nsubj
3	did	do	VBD	_	5	aux
4	not	not	RB	_	5	neg
5	alter	alter	VB	_	0	ROOT
6	the	the	DT	_	8	det
7	mean	mean	NN	_	8	compound
8	AUC	auc	NN	_	5	dobj
9	or	or	CC	_	8	cc
10	Cmax	cmax	NN	_	8	conj
11	of	of	IN	_	12	case
12	drug2	drug2	NN	_	8	nmod
13	.	.	.	_	5	punct

1	The	the	DT	_	2	det
2	mechanism	mechanism	NN	_	9	nsubjpass
3	of	of	IN	_	6	case
4	this	this	DT	_	6	det
5	pharmacodynamic	pharmacodynamic	JJ	_	6	amod
6	interaction	interaction	NN	_	2	nmod
7	is	be	VBZ	_	9	auxpass
8	not	not	RB	_	9	neg
9	known	know	VBN	_	0	ROOT
10	.	.	.	_	9	punct

1	drug1	drug1	NN	_	6	dep
2	-	-	:	_	6	punct
3	There	there	EX	_	6	expl
4	have	have	VBP	_	6	aux
5	been	be	VBN	_	6	cop
6	rare	rare	JJ	_	8	amod
7	postmarketing	postmarket	VBG	_	8	amod
8	reports	report	NNS	_	0	ROOT
9	describing	describe	VBG	_	8	acl
10	patients	patient	NNS	_	9	dobj
11	with	with	IN	_	12	case
12	weakness	weakness	NN	_	10	nmod
13	,	,	,	_	12	punct
14	hyperreflexia	hyperreflexia	NN	_	12	conj
15	,	,	,	_	12	punct
16	and	and	CC	_	12	cc
17	incoordination	incoordination	NN	_	12	conj
18	following	follow	VBG	_	20	case
19	the	the	DT	_	20	det
20	use	use	NN	_	8	nmod
21	of	of	IN	_	20	acl
22	a	a	DT	_	21	dep
23	drug2	drug2	NN	_	22	dep
24	-LRB-	-lrb-	-LRB-	_	25	punct
25	drug3	drug3	NN	_	23	appos
26	-RRB-	-rrb-	-RRB-	_	25	punct
27	and	and	CC	_	23	cc
28	drug4	drug4	NN	_	23	conj
29	.	.	.	_	8	punct

1	If	if	IN	_	26	mark
2	concomitant	concomitant	JJ	_	3	amod
3	treatment	treatment	NN	_	26	nsubjpass
4	with	with	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	and	and	CC	_	5	cc
7	an	a	DT	_	8	det
8	drug2	drug2	NN	_	5	conj
9	-LRB-	-lrb-	-LRB-	_	12	punct
10	e.g.	e.g.	FW	_	12	dep
11	,	,	,	_	12	punct
12	drug3	drug3	NN	_	8	dep
13	,	,	,	_	12	punct
14	drug4	drug4	NN	_	12	conj
15	,	,	,	_	12	punct
16	drug5	drug5	NN	_	12	conj
17	,	,	,	_	12	punct
18	drug6	drug6	NN	_	12	conj
19	,	,	,	_	12	punct
20	drug7	drug7	NN	_	12	conj
21	,	,	,	_	12	punct
22	drug8	drug8	NN	_	12	appos
23	-RRB-	-rrb-	-RRB-	_	12	punct
24	is	be	VBZ	_	26	auxpass
25	clinically	clinically	RB	_	26	advmod
26	warranted	warrant	VBN	_	34	advcl
27	,	,	,	_	34	punct
28	appropriate	appropriate	JJ	_	29	amod
29	observation	observation	NN	_	34	nsubjpass
30	of	of	IN	_	32	case
31	the	the	DT	_	32	det
32	patient	patient	NN	_	29	nmod
33	is	be	VBZ	_	34	auxpass
34	advised	advise	VBN	_	0	ROOT
35	.	.	.	_	34	punct

1	drug1	drug1	NN	_	4	compound
2	-	-	:	_	4	punct
3	Combined	combine	VBN	_	4	amod
4	administration	administration	NN	_	29	nsubj
5	of	of	IN	_	7	case
6	racemic	racemic	JJ	_	7	amod
7	drug2	drug2	NN	_	4	nmod
8	-LRB-	-lrb-	-LRB-	_	10	punct
9	40	40	CD	_	10	nummod
10	mg/day	mg/day	NN	_	7	dep
11	for	for	IN	_	13	case
12	21	21	CD	_	13	nummod
13	days	day	NNS	_	10	nmod
14	-RRB-	-rrb-	-RRB-	_	10	punct
15	and	and	CC	_	7	cc
16	the	the	DT	_	19	det
17	CYP1A2	cyp1a2	NN	_	19	compound
18	substrate	substrate	NN	_	19	compound
19	drug3	drug3	NN	_	7	conj
20	-LRB-	-lrb-	-LRB-	_	22	punct
21	single	single	JJ	_	22	amod
22	dose	dose	NN	_	19	dep
23	of	of	IN	_	25	case
24	300	300	CD	_	25	nummod
25	mg	mg	NN	_	22	nmod
26	-RRB-	-rrb-	-RRB-	_	22	punct
27	did	do	VBD	_	29	aux
28	not	not	RB	_	29	neg
29	affect	affect	VB	_	0	ROOT
30	the	the	DT	_	31	det
31	pharmacokinetics	pharmacokinetic	NNS	_	29	dobj
32	of	of	IN	_	33	case
33	drug4	drug4	NN	_	31	nmod
34	.	.	.	_	29	punct

1	The	the	DT	_	2	det
2	effect	effect	NN	_	12	nsubjpass
3	of	of	IN	_	4	case
4	drug1	drug1	NN	_	2	nmod
5	on	on	IN	_	7	case
6	the	the	DT	_	7	det
7	pharmacokinetics	pharmacokinetic	NNS	_	2	nmod
8	of	of	IN	_	9	case
9	drug2	drug2	NN	_	7	nmod
10	was	be	VBD	_	12	auxpass
11	not	not	RB	_	12	neg
12	evaluated	evaluate	VBN	_	0	ROOT
13	.	.	.	_	12	punct

1	drug1	drug1	NN	_	14	nsubj
2	-	-	:	_	1	punct
3	Administration	administration	NN	_	1	dep
4	of	of	IN	_	8	case
5	40	40	CD	_	8	nummod
6	mg/day	mg/day	NN	_	8	compound
7	racemic	racemic	JJ	_	8	amod
8	drug2	drug2	NN	_	3	nmod
9	for	for	IN	_	11	case
10	21	21	CD	_	11	nummod
11	days	day	NNS	_	3	nmod
12	did	do	VBD	_	14	aux
13	not	not	RB	_	14	neg
14	affect	affect	VB	_	0	ROOT
15	the	the	DT	_	16	det
16	pharmacokinetics	pharmacokinetic	NNS	_	14	dobj
17	of	of	IN	_	18	case
18	drug3	drug3	NN	_	16	nmod
19	,	,	,	_	18	punct
20	a	a	DT	_	22	det
21	CYP3A4	cyp3a4	NN	_	22	compound
22	substrate	substrate	NN	_	18	appos
23	.	.	.	_	14	punct

1	Prothrombin	Prothrombin	NNP	_	2	compound
2	time	time	NN	_	4	nsubjpass
3	was	be	VBD	_	4	auxpass
4	increased	increase	VBN	_	0	ROOT
5	by	by	IN	_	7	case
6	5	5	CD	_	7	nummod
7	%	%	NN	_	4	nmod
8	,	,	,	_	4	punct
9	the	the	DT	_	11	det
10	clinical	clinical	JJ	_	11	amod
11	significance	significance	NN	_	15	nsubj
12	of	of	IN	_	13	case
13	which	which	WDT	_	11	nmod
14	is	be	VBZ	_	15	cop
15	unknown	unknown	JJ	_	4	ccomp
16	.	.	.	_	4	punct

1	drug1	drug1	NN	_	4	compound
2	-	-	:	_	4	punct
3	Combined	combine	VBN	_	4	amod
4	administration	administration	NN	_	29	nsubj
5	of	of	IN	_	7	case
6	racemic	racemic	JJ	_	7	amod
7	drug2	drug2	NN	_	4	nmod
8	-LRB-	-lrb-	-LRB-	_	10	punct
9	40	40	CD	_	10	nummod
10	mg/day	mg/day	NN	_	7	dep
11	for	for	IN	_	13	case
12	14	14	CD	_	13	nummod
13	days	day	NNS	_	10	nmod
14	-RRB-	-rrb-	-RRB-	_	10	punct
15	and	and	CC	_	7	cc
16	drug3	drug3	NN	_	7	conj
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	titrated	titrate	VBN	_	16	dep
19	to	to	TO	_	21	case
20	400	400	CD	_	21	nummod
21	mg/day	mg/day	NN	_	18	nmod
22	for	for	IN	_	24	case
23	35	35	CD	_	24	nummod
24	days	day	NNS	_	18	nmod
25	-RRB-	-rrb-	-RRB-	_	18	punct
26	did	do	VBD	_	29	aux
27	not	not	RB	_	29	neg
28	significantly	significantly	RB	_	29	advmod
29	affect	affect	VB	_	0	ROOT
30	the	the	DT	_	31	det
31	pharmacokinetics	pharmacokinetic	NNS	_	29	dobj
32	of	of	IN	_	33	case
33	drug4	drug4	NN	_	31	nmod
34	,	,	,	_	33	punct
35	a	a	DT	_	37	det
36	CYP3A4	cyp3a4	NN	_	37	compound
37	substrate	substrate	NN	_	33	appos
38	.	.	.	_	29	punct

1	Although	although	IN	_	7	mark
2	trough	trough	NN	_	5	compound
3	drug1	drug1	NN	_	5	compound
4	plasma	plasma	NN	_	5	compound
5	levels	level	NNS	_	7	nsubjpass
6	were	be	VBD	_	7	auxpass
7	unaffected	unaffected	JJ	_	28	advcl
8	,	,	,	_	28	punct
9	given	give	VBN	_	12	case
10	the	the	DT	_	12	det
11	enzyme-inducing	enzyme-inducing	JJ	_	12	amod
12	properties	property	NNS	_	28	nmod
13	of	of	IN	_	14	case
14	drug2	drug2	NN	_	12	nmod
15	,	,	,	_	28	punct
16	the	the	DT	_	17	det
17	possibility	possibility	NN	_	28	nsubjpass
18	that	that	IN	_	21	mark
19	drug3	drug3	NN	_	21	nsubj
20	might	might	MD	_	21	aux
21	increase	increase	VB	_	17	ccomp
22	the	the	DT	_	23	det
23	clearance	clearance	NN	_	21	dobj
24	of	of	IN	_	25	case
25	drug4	drug4	NN	_	23	nmod
26	should	should	MD	_	28	aux
27	be	be	VB	_	28	auxpass
28	considered	consider	VBN	_	0	ROOT
29	if	if	IN	_	34	mark
30	the	the	DT	_	32	det
31	two	two	CD	_	32	nummod
32	drugs	drug	NNS	_	34	nsubjpass
33	are	be	VBP	_	34	auxpass
34	coadministered	coadminister	VBN	_	28	advcl
35	.	.	.	_	28	punct

1	drug1	drug1	NN	_	4	compound
2	-	-	:	_	4	punct
3	Combined	combine	VBN	_	4	amod
4	administration	administration	NN	_	32	nsubj
5	of	of	IN	_	7	case
6	racemic	racemic	JJ	_	7	amod
7	drug2	drug2	NN	_	4	nmod
8	-LRB-	-lrb-	-LRB-	_	9	punct
9	titrated	titrate	VBN	_	4	dep
10	to	to	TO	_	12	case
11	40	40	CD	_	12	nummod
12	mg/day	mg/day	NN	_	9	nmod
13	for	for	IN	_	15	case
14	28	28	CD	_	15	nummod
15	days	day	NNS	_	9	nmod
16	-RRB-	-rrb-	-RRB-	_	9	punct
17	and	and	CC	_	4	cc
18	the	the	DT	_	21	det
19	CYP3A4	cyp3a4	NN	_	21	compound
20	substrate	substrate	NN	_	21	compound
21	drug3	drug3	NN	_	4	conj
22	-LRB-	-lrb-	-LRB-	_	24	punct
23	single	single	JJ	_	24	amod
24	dose	dose	NN	_	21	dep
25	of	of	IN	_	27	case
26	0.25	0.25	CD	_	27	nummod
27	mg	mg	NN	_	24	nmod
28	-RRB-	-rrb-	-RRB-	_	24	punct
29	did	do	VBD	_	32	aux
30	not	not	RB	_	32	neg
31	significantly	significantly	RB	_	32	advmod
32	affect	affect	VB	_	0	ROOT
33	the	the	DT	_	34	det
34	pharmacokinetics	pharmacokinetic	NNS	_	32	dobj
35	of	of	IN	_	37	case
36	either	either	CC	_	37	cc:preconj
37	drug4	drug4	NN	_	34	nmod
38	or	or	CC	_	37	cc
39	drug5	drug5	NN	_	37	conj
40	.	.	.	_	32	punct

1	drug1	drug1	NN	_	4	compound
2	-	-	:	_	4	punct
3	Combined	combine	VBN	_	4	amod
4	administration	administration	NN	_	18	nsubj
5	of	of	IN	_	7	case
6	racemic	racemic	JJ	_	7	amod
7	drug2	drug2	NN	_	4	nmod
8	-LRB-	-lrb-	-LRB-	_	10	punct
9	40	40	CD	_	10	nummod
10	mg	mg	NN	_	7	appos
11	-RRB-	-rrb-	-RRB-	_	10	punct
12	and	and	CC	_	7	cc
13	drug3	drug3	NN	_	7	conj
14	-LRB-	-lrb-	-LRB-	_	16	punct
15	200	200	CD	_	16	nummod
16	mg	mg	NN	_	13	appos
17	-RRB-	-rrb-	-RRB-	_	16	punct
18	decreased	decrease	VBD	_	0	ROOT
19	the	the	DT	_	20	det
20	Cmax	cmax	NN	_	18	dobj
21	and	and	CC	_	20	cc
22	AUC	auc	NN	_	20	conj
23	of	of	IN	_	24	case
24	drug4	drug4	NN	_	20	nmod
25	by	by	IN	_	27	case
26	21	21	CD	_	27	nummod
27	%	%	NN	_	18	nmod
28	and	and	CC	_	18	cc
29	10	10	CD	_	30	nummod
30	%	%	NN	_	18	conj
31	,	,	,	_	18	punct
32	respectively	respectively	RB	_	18	advmod
33	,	,	,	_	18	punct
34	and	and	CC	_	18	cc
35	did	do	VBD	_	38	aux
36	not	not	RB	_	38	neg
37	significantly	significantly	RB	_	38	advmod
38	affect	affect	VB	_	18	conj
39	the	the	DT	_	40	det
40	pharmacokinetics	pharmacokinetic	NNS	_	38	dobj
41	of	of	IN	_	42	case
42	drug5	drug5	NN	_	40	nmod
43	.	.	.	_	18	punct

1	drug1	drug1	NN	_	4	compound
2	-	-	:	_	4	punct
3	Combined	combine	VBN	_	4	amod
4	administration	administration	NN	_	0	ROOT
5	of	of	IN	_	8	case
6	a	a	DT	_	8	det
7	single	single	JJ	_	8	amod
8	dose	dose	NN	_	4	nmod
9	of	of	IN	_	10	case
10	drug2	drug2	NN	_	8	nmod
11	-LRB-	-lrb-	-LRB-	_	13	punct
12	600	600	CD	_	13	nummod
13	mg	mg	NN	_	8	appos
14	-RRB-	-rrb-	-RRB-	_	13	punct
15	,	,	,	_	4	punct
16	both	both	CC	_	19	cc:preconj
17	a	a	DT	_	19	det
18	CYP3A4	cyp3a4	NN	_	19	compound
19	substrate	substrate	NN	_	35	nsubj
20	and	and	CC	_	19	cc
21	a	a	DT	_	23	det
22	potent	potent	JJ	_	23	amod
23	inhibitor	inhibitor	NN	_	19	conj
24	of	of	IN	_	25	case
25	CYP3A4	cyp3a4	NN	_	23	nmod
26	,	,	,	_	19	punct
27	and	and	CC	_	19	cc
28	drug3	drug3	NN	_	19	conj
29	-LRB-	-lrb-	-LRB-	_	31	punct
30	20	20	CD	_	31	nummod
31	mg	mg	NN	_	28	appos
32	-RRB-	-rrb-	-RRB-	_	31	punct
33	did	do	VBD	_	35	aux
34	not	not	RB	_	35	neg
35	affect	affect	VB	_	4	acl:relcl
36	the	the	DT	_	37	det
37	pharmacokinetics	pharmacokinetic	NNS	_	35	dobj
38	of	of	IN	_	40	case
39	either	either	CC	_	40	cc:preconj
40	drug4	drug4	NN	_	37	nmod
41	or	or	CC	_	40	cc
42	drug5	drug5	NN	_	40	conj
43	.	.	.	_	4	punct

1	CYP3A4	cyp3a4	NN	_	5	compound
2	and	and	CC	_	1	cc
3	-2	-2	CD	_	1	conj
4	C19	c19	NN	_	5	compound
5	Inhibitors	inhibitor	NNS	_	10	nsubj
6	-	-	:	_	5	punct
7	In	in	FW	_	5	dep
8	vitro	vitro	FW	_	7	dep
9	studies	study	NNS	_	5	dep
10	indicated	indicate	VBD	_	0	ROOT
11	that	that	IN	_	19	mark
12	CYP3A4	cyp3a4	NN	_	19	nsubj
13	and	and	CC	_	12	cc
14	-2	-2	CD	_	15	nummod
15	C19	c19	NN	_	12	conj
16	are	be	VBP	_	19	cop
17	the	the	DT	_	19	det
18	primary	primary	JJ	_	19	amod
19	enzymes	enzyme	NNS	_	10	ccomp
20	involved	involve	VBN	_	19	acl
21	in	in	IN	_	23	case
22	the	the	DT	_	23	det
23	metabolism	metabolism	NN	_	20	nmod
24	of	of	IN	_	25	case
25	drug1	drug1	NN	_	23	nmod
26	.	.	.	_	10	punct

1	However	however	RB	_	26	advmod
2	,	,	,	_	26	punct
3	coadministration	coadministration	NN	_	26	nsubj
4	of	of	IN	_	5	case
5	drug1	drug1	NN	_	3	nmod
6	-LRB-	-lrb-	-LRB-	_	8	punct
7	20	20	CD	_	8	nummod
8	mg	mg	NN	_	5	appos
9	-RRB-	-rrb-	-RRB-	_	8	punct
10	and	and	CC	_	5	cc
11	drug2	drug2	NN	_	5	conj
12	-LRB-	-lrb-	-LRB-	_	14	punct
13	600	600	CD	_	14	nummod
14	mg	mg	NN	_	11	appos
15	-RRB-	-rrb-	-RRB-	_	14	punct
16	,	,	,	_	5	punct
17	a	a	DT	_	19	det
18	potent	potent	JJ	_	19	amod
19	inhibitor	inhibitor	NN	_	5	appos
20	of	of	IN	_	21	case
21	CYP3A4	cyp3a4	NN	_	19	nmod
22	,	,	,	_	5	punct
23	did	do	VBD	_	26	aux
24	not	not	RB	_	26	neg
25	significantly	significantly	RB	_	26	advmod
26	affect	affect	VB	_	0	ROOT
27	the	the	DT	_	28	det
28	pharmacokinetics	pharmacokinetic	NNS	_	26	dobj
29	of	of	IN	_	30	case
30	drug3	drug3	NN	_	28	nmod
31	.	.	.	_	26	punct

1	Because	because	IN	_	4	mark
2	drug1	drug1	NN	_	4	nsubjpass
3	is	be	VBZ	_	4	auxpass
4	metabolized	metabolize	VBN	_	18	advcl
5	by	by	IN	_	8	case
6	multiple	multiple	JJ	_	8	amod
7	enzyme	enzyme	NN	_	8	compound
8	systems	system	NNS	_	4	nmod
9	,	,	,	_	18	punct
10	inhibition	inhibition	NN	_	18	nsubj
11	of	of	IN	_	14	case
12	a	a	DT	_	14	det
13	single	single	JJ	_	14	amod
14	enzyme	enzyme	NN	_	10	nmod
15	may	may	MD	_	18	aux
16	not	not	RB	_	18	neg
17	appreciably	appreciably	RB	_	18	advmod
18	decrease	decrease	VB	_	0	ROOT
19	drug2	drug2	NN	_	20	compound
20	clearance	clearance	NN	_	18	dobj
21	.	.	.	_	18	punct

1	Drugs	drug	NNS	_	0	ROOT
2	Metabolized	metabolize	VBN	_	1	acl
3	by	by	IN	_	5	case
4	Cytochrome	cytochrome	NN	_	5	compound
5	P4502D6	p4502d6	NN	_	2	nmod
6	-	-	:	_	1	punct
7	In	in	FW	_	9	amod
8	vitro	vitro	FW	_	7	dep
9	studies	study	NNS	_	12	nsubj
10	did	do	VBD	_	12	aux
11	not	not	RB	_	12	neg
12	reveal	reveal	VB	_	1	dep
13	an	a	DT	_	15	det
14	inhibitory	inhibitory	JJ	_	15	amod
15	effect	effect	NN	_	12	dobj
16	of	of	IN	_	17	case
17	drug1	drug1	NN	_	15	nmod
18	on	on	IN	_	19	case
19	CYP2D6	cyp2d6	NN	_	15	nmod
20	.	.	.	_	1	punct

1	In	in	IN	_	2	case
2	addition	addition	NN	_	13	nmod
3	,	,	,	_	13	punct
4	steady	steady	JJ	_	6	amod
5	state	state	NN	_	6	compound
6	levels	level	NNS	_	13	nsubj
7	of	of	IN	_	9	case
8	racemic	racemic	JJ	_	9	amod
9	drug1	drug1	NN	_	6	nmod
10	were	be	VBD	_	13	cop
11	not	not	RB	_	13	neg
12	significantly	significantly	RB	_	13	advmod
13	different	different	JJ	_	0	ROOT
14	in	in	IN	_	16	case
15	poor	poor	JJ	_	16	amod
16	metabolizers	metabolizer	NNS	_	13	nmod
17	and	and	CC	_	16	cc
18	extensive	extensive	JJ	_	20	amod
19	CYP2D6	cyp2d6	NN	_	20	compound
20	metabolizers	metabolizer	NNS	_	16	conj
21	after	after	IN	_	23	case
22	multiple-dose	multiple-dose	JJ	_	23	amod
23	administration	administration	NN	_	13	nmod
24	of	of	IN	_	25	case
25	drug2	drug2	NN	_	23	nmod
26	,	,	,	_	13	punct
27	suggesting	suggest	VBG	_	13	advcl
28	that	that	IN	_	42	mark
29	coadministration	coadministration	NN	_	42	nsubj
30	,	,	,	_	29	punct
31	with	with	IN	_	32	case
32	drug3	drug3	NN	_	29	nmod
33	,	,	,	_	29	punct
34	of	of	IN	_	36	case
35	a	a	DT	_	36	det
36	drug	drug	NN	_	29	nmod
37	that	that	WDT	_	38	nsubj
38	inhibits	inhibit	VBZ	_	36	acl:relcl
39	CYP2D6	cyp2d6	NN	_	38	dobj
40	,	,	,	_	29	punct
41	is	be	VBZ	_	42	cop
42	unlikely	unlikely	JJ	_	27	ccomp
43	to	to	TO	_	44	mark
44	have	have	VB	_	42	xcomp
45	clinically	clinically	RB	_	46	advmod
46	significant	significant	JJ	_	47	amod
47	effects	effect	NNS	_	44	dobj
48	on	on	IN	_	50	case
49	drug4	drug4	NN	_	50	compound
50	metabolism	metabolism	NN	_	44	nmod
51	.	.	.	_	13	punct

1	However	however	RB	_	4	advmod
2	,	,	,	_	4	punct
3	there	there	EX	_	4	expl
4	are	be	VBP	_	0	ROOT
5	limited	limited	JJ	_	8	amod
6	in	in	FW	_	8	amod
7	vivo	vivo	FW	_	6	dep
8	data	datum	NNS	_	4	nsubj
9	suggesting	suggest	VBG	_	8	acl
10	a	a	DT	_	14	det
11	modest	modest	JJ	_	14	amod
12	CYP2D6	cyp2d6	NN	_	14	compound
13	inhibitory	inhibitory	JJ	_	14	amod
14	effect	effect	NN	_	9	dobj
15	for	for	IN	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	,	,	,	_	16	punct
18	i.e.	i.e.	FW	_	47	advmod
19	,	,	,	_	47	punct
20	coadministration	coadministration	NN	_	47	nsubj
21	of	of	IN	_	22	case
22	drug2	drug2	NN	_	20	nmod
23	-LRB-	-lrb-	-LRB-	_	25	punct
24	20	20	CD	_	25	nummod
25	mg/day	mg/day	NN	_	22	dep
26	for	for	IN	_	28	case
27	21	21	CD	_	28	nummod
28	days	day	NNS	_	25	nmod
29	-RRB-	-rrb-	-RRB-	_	25	punct
30	with	with	IN	_	33	case
31	the	the	DT	_	33	det
32	drug3	drug3	NN	_	33	compound
33	drug4	drug4	NN	_	20	nmod
34	-LRB-	-lrb-	-LRB-	_	36	punct
35	single	single	JJ	_	36	amod
36	dose	dose	NN	_	33	dep
37	of	of	IN	_	39	case
38	50	50	CD	_	39	nummod
39	mg	mg	NN	_	36	nmod
40	-RRB-	-rrb-	-RRB-	_	36	punct
41	,	,	,	_	33	punct
42	a	a	DT	_	43	det
43	substrate	substrate	NN	_	33	appos
44	for	for	IN	_	45	case
45	CYP2D6	cyp2d6	NN	_	43	nmod
46	,	,	,	_	33	punct
47	resulted	result	VBD	_	16	acl
48	in	in	IN	_	52	case
49	a	a	DT	_	52	det
50	40	40	CD	_	51	compound
51	%	%	NN	_	52	amod
52	increase	increase	NN	_	47	nmod
53	in	in	IN	_	54	case
54	Cmax	Cmax	NNP	_	52	nmod
55	and	and	CC	_	52	cc
56	a	a	DT	_	59	det
57	100	100	CD	_	58	compound
58	%	%	NN	_	59	amod
59	increase	increase	NN	_	52	conj
60	in	in	IN	_	61	case
61	AUC	auc	NN	_	59	nmod
62	of	of	IN	_	63	case
63	drug5	drug5	NN	_	61	nmod
64	.	.	.	_	4	punct

1	The	the	DT	_	3	det
2	clinical	clinical	JJ	_	3	amod
3	significance	significance	NN	_	8	nsubj
4	of	of	IN	_	6	case
5	this	this	DT	_	6	det
6	finding	finding	NN	_	3	nmod
7	is	be	VBZ	_	8	cop
8	unknown	unknown	JJ	_	0	ROOT
9	.	.	.	_	8	punct

1	Nevertheless	nevertheless	RB	_	5	advmod
2	,	,	,	_	5	punct
3	caution	caution	NN	_	5	nsubjpass
4	is	be	VBZ	_	5	auxpass
5	indicated	indicate	VBN	_	0	ROOT
6	in	in	IN	_	8	case
7	the	the	DT	_	8	det
8	coadministration	coadministration	NN	_	5	nmod
9	of	of	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	and	and	CC	_	10	cc
12	drugs	drug	NNS	_	10	conj
13	metabolized	metabolize	VBN	_	10	acl
14	by	by	IN	_	15	case
15	CYP2D6	cyp2d6	NN	_	13	nmod
16	.	.	.	_	5	punct

1	drug1	drug1	NN	_	14	nsubj
2	-	-	:	_	1	punct
3	Administration	administration	NN	_	1	dep
4	of	of	IN	_	7	case
5	20	20	CD	_	7	nummod
6	mg/day	mg/day	NN	_	7	compound
7	drug2	drug2	NN	_	3	nmod
8	for	for	IN	_	10	case
9	21	21	CD	_	10	nummod
10	days	day	NNS	_	3	nmod
11	in	in	IN	_	13	case
12	healthy	healthy	JJ	_	13	amod
13	volunteers	volunteer	NNS	_	10	nmod
14	resulted	result	VBD	_	0	ROOT
15	in	in	IN	_	19	case
16	a	a	DT	_	19	det
17	50	50	CD	_	18	compound
18	%	%	NN	_	19	amod
19	increase	increase	NN	_	14	nmod
20	in	in	IN	_	21	case
21	Cmax	Cmax	NNP	_	19	nmod
22	and	and	CC	_	19	cc
23	82	82	CD	_	24	compound
24	%	%	NN	_	25	amod
25	increase	increase	NN	_	19	conj
26	in	in	IN	_	27	case
27	AUC	auc	NN	_	25	nmod
28	of	of	IN	_	31	case
29	the	the	DT	_	31	det
30	drug3	drug3	NN	_	31	compound
31	drug4	drug4	NN	_	27	nmod
32	-LRB-	-lrb-	-LRB-	_	33	punct
33	given	give	VBN	_	19	dep
34	in	in	IN	_	37	case
35	a	a	DT	_	37	det
36	single	single	JJ	_	37	amod
37	dose	dose	NN	_	33	nmod
38	of	of	IN	_	40	case
39	100	100	CD	_	40	nummod
40	mg	mg	NN	_	37	nmod
41	-RRB-	-rrb-	-RRB-	_	33	punct
42	.	.	.	_	14	punct

1	Increased	increase	VBN	_	4	amod
2	drug1	drug1	NN	_	4	compound
3	plasma	plasma	NN	_	4	compound
4	levels	level	NNS	_	7	nsubjpass
5	have	have	VBP	_	7	aux
6	been	be	VBN	_	7	auxpass
7	associated	associate	VBN	_	0	ROOT
8	with	with	IN	_	10	case
9	decreased	decrease	VBN	_	10	amod
10	cardioselectivity	cardioselectivity	NN	_	7	nmod
11	.	.	.	_	7	punct

1	Coadministration	coadministration	NN	_	6	nsubj
2	of	of	IN	_	3	case
3	drug1	drug1	NN	_	1	nmod
4	and	and	CC	_	3	cc
5	drug2	drug2	NN	_	3	conj
6	had	have	VBD	_	0	ROOT
7	no	no	DT	_	10	neg
8	clinically	clinically	RB	_	9	advmod
9	significant	significant	JJ	_	10	amod
10	effects	effect	NNS	_	6	dobj
11	on	on	IN	_	13	case
12	blood	blood	NN	_	13	compound
13	pressure	pressure	NN	_	6	nmod
14	or	or	CC	_	13	cc
15	heart	heart	NN	_	16	compound
16	rate	rate	NN	_	13	conj
17	.	.	.	_	6	punct

1	Electroconvulsive	electroconvulsive	JJ	_	2	amod
2	Therapy	therapy	NN	_	0	ROOT
3	-LRB-	-lrb-	-LRB-	_	4	punct
4	ECT	ect	NN	_	2	appos
5	-RRB-	-rrb-	-RRB-	_	4	punct
6	-	-	:	_	2	punct
7	There	there	EX	_	8	expl
8	are	be	VBP	_	2	dep
9	no	no	DT	_	11	neg
10	clinical	clinical	JJ	_	11	amod
11	studies	study	NNS	_	8	nsubj
12	of	of	IN	_	15	case
13	the	the	DT	_	15	det
14	combined	combine	VBN	_	15	amod
15	use	use	NN	_	11	nmod
16	of	of	IN	_	17	case
17	ECT	ECT	NNP	_	15	nmod
18	and	and	CC	_	17	cc
19	drug1	drug1	NN	_	17	conj
20	.	.	.	_	2	punct

1	Concomitant	concomitant	JJ	_	2	amod
2	Administration	administration	NN	_	27	nsubjpass
3	with	with	IN	_	6	case
4	Racemic	racemic	JJ	_	6	amod
5	drug1	drug1	NN	_	6	compound
6	drug2	drug2	NN	_	2	nmod
7	-	-	:	_	27	punct
8	Since	since	IN	_	13	mark
9	drug3	drug3	NN	_	13	nsubj
10	is	be	VBZ	_	13	cop
11	the	the	DT	_	13	det
12	active	active	JJ	_	13	amod
13	isomer	isomer	NN	_	27	advcl
14	of	of	IN	_	16	case
15	racemic	racemic	JJ	_	16	amod
16	drug4	drug4	NN	_	13	nmod
17	-LRB-	-lrb-	-LRB-	_	18	punct
18	drug5	drug5	NN	_	16	appos
19	-RRB-	-rrb-	-RRB-	_	18	punct
20	,	,	,	_	27	punct
21	the	the	DT	_	23	det
22	two	two	CD	_	23	nummod
23	agents	agent	NNS	_	27	nsubjpass
24	should	should	MD	_	27	aux
25	not	not	RB	_	27	neg
26	be	be	VB	_	27	auxpass
27	coadministered	coadminister	VBN	_	0	ROOT
28	.	.	.	_	27	punct

1	drug1	drug1	NN	_	4	nsubj
2	does	do	VBZ	_	4	aux
3	not	not	RB	_	4	neg
4	exhibit	exhibit	VB	_	0	ROOT
5	binding	bind	VBG	_	4	dobj
6	to	to	TO	_	8	case
7	plasma	plasma	NN	_	8	compound
8	proteins	protein	NNS	_	5	nmod
9	-LRB-	-lrb-	-LRB-	_	10	punct
10	other	other	JJ	_	8	dep
11	than	than	IN	_	12	case
12	thrombin	thrombin	NN	_	10	nmod
13	-RRB-	-rrb-	-RRB-	_	10	punct
14	or	or	CC	_	8	cc
15	red	red	JJ	_	17	amod
16	blood	blood	NN	_	17	compound
17	cells	cell	NNS	_	8	conj
18	.	.	.	_	4	punct

1	In	in	IN	_	3	case
2	clinical	clinical	JJ	_	3	amod
3	trials	trial	NNS	_	23	nmod
4	in	in	IN	_	5	case
5	patients	patient	NNS	_	3	nmod
6	undergoing	undergo	VBG	_	5	acl
7	PTCA/PCI	ptca/pci	NN	_	6	dobj
8	,	,	,	_	23	punct
9	co-administration	co-administration	NN	_	23	nsubjpass
10	of	of	IN	_	11	case
11	drug1	drug1	NN	_	9	nmod
12	with	with	IN	_	13	case
13	drug2	drug2	NN	_	9	nmod
14	,	,	,	_	13	punct
15	drug3	drug3	NN	_	13	conj
16	,	,	,	_	13	punct
17	drug4	drug4	NN	_	13	conj
18	or	or	CC	_	13	cc
19	glycoprotein	glycoprotein	NN	_	21	compound
20	IIb/IIIa	iib/iiia	NN	_	21	compound
21	inhibitors	inhibitor	NNS	_	13	conj
22	was	be	VBD	_	23	auxpass
23	associated	associate	VBN	_	0	ROOT
24	with	with	IN	_	26	case
25	increased	increase	VBN	_	26	amod
26	risks	risk	NNS	_	23	nmod
27	of	of	IN	_	30	case
28	major	major	JJ	_	30	amod
29	bleeding	bleeding	JJ	_	30	amod
30	events	event	NNS	_	26	nmod
31	compared	compare	VBN	_	33	case
32	to	to	TO	_	33	case
33	patients	patient	NNS	_	30	nmod
34	not	not	RB	_	35	neg
35	receiving	receive	VBG	_	33	acl
36	these	these	DT	_	38	det
37	concomitant	concomitant	JJ	_	38	amod
38	medications	medication	NNS	_	35	dobj
39	.	.	.	_	23	punct

1	There	there	EX	_	2	expl
2	is	be	VBZ	_	0	ROOT
3	no	no	DT	_	4	neg
4	experience	experience	NN	_	2	nsubj
5	with	with	IN	_	6	case
6	co-administration	co-administration	NN	_	4	nmod
7	of	of	IN	_	8	case
8	drug1	drug1	NN	_	6	nmod
9	and	and	CC	_	8	cc
10	plasma	plasma	NN	_	11	compound
11	expanders	expander	NNS	_	8	conj
12	such	such	JJ	_	14	case
13	as	as	IN	_	12	mwe
14	drug2	drug2	NN	_	8	nmod
15	.	.	.	_	2	punct

1	drug1	drug1	NN	_	4	nsubjpass
2	should	should	MD	_	4	aux
3	be	be	VB	_	4	auxpass
4	used	use	VBN	_	0	ROOT
5	with	with	IN	_	6	case
6	caution	caution	NN	_	4	nmod
7	in	in	IN	_	8	case
8	patients	patient	NNS	_	6	nmod
9	with	with	IN	_	11	case
10	disease	disease	NN	_	11	compound
11	states	state	NNS	_	8	nmod
12	associated	associate	VBN	_	11	acl
13	with	with	IN	_	16	case
14	an	a	DT	_	16	det
15	increased	increase	VBN	_	16	amod
16	risk	risk	NN	_	12	nmod
17	of	of	IN	_	18	case
18	bleeding	bleeding	NN	_	16	nmod
19	.	.	.	_	4	punct

1	Immunogenicity/Re-exposure	immunogenicity/re-exposure	NN	_	0	ROOT
2	:	:	:	_	1	punct
3	In	in	IN	_	6	case
4	in	in	FW	_	6	amod
5	vitro	vitro	FW	_	4	dep
6	studies	study	NNS	_	9	nmod
7	,	,	,	_	9	punct
8	drug1	drug1	NN	_	9	nsubj
9	exhibited	exhibit	VBD	_	1	appos
10	no	no	DT	_	13	neg
11	platelet	platelet	NN	_	13	compound
12	aggregation	aggregation	NN	_	13	compound
13	response	response	NN	_	9	dobj
14	against	against	IN	_	15	case
15	sera	serum	NNS	_	13	nmod
16	from	from	IN	_	17	case
17	patients	patient	NNS	_	15	nmod
18	with	with	IN	_	20	case
19	a	a	DT	_	20	det
20	history	history	NN	_	17	nmod
21	of	of	IN	_	22	case
22	HIT/HITTS	hit/hitts	NN	_	20	nmod
23	.	.	.	_	1	punct

1	Among	among	IN	_	3	case
2	494	494	CD	_	3	nummod
3	subjects	subject	NNS	_	0	ROOT
4	who	who	WP	_	5	nsubj
5	received	receive	VBD	_	3	acl:relcl
6	drug1	drug1	NN	_	5	dobj
7	in	in	IN	_	9	case
8	clinical	clinical	JJ	_	9	amod
9	trials	trial	NNS	_	5	nmod
10	and	and	CC	_	5	cc
11	were	be	VBD	_	12	auxpass
12	tested	test	VBN	_	5	conj
13	for	for	IN	_	14	case
14	antibodies	antibody	NNS	_	12	nmod
15	,	,	,	_	14	punct
16	2	2	CD	_	17	nummod
17	subjects	subject	NNS	_	18	nsubj
18	had	have	VBD	_	14	acl:relcl
19	treatment-emergent	treatment-emergent	JJ	_	23	amod
20	positive	positive	JJ	_	23	amod
21	drug2	drug2	NN	_	23	compound
22	antibody	antibody	NN	_	23	compound
23	tests	test	NNS	_	18	dobj
24	.	.	.	_	3	punct

1	Neither	neither	DT	_	2	det
2	subject	subject	JJ	_	3	nsubj
3	demonstrated	demonstrate	VBD	_	0	ROOT
4	clinical	clinical	JJ	_	5	amod
5	evidence	evidence	NN	_	16	nsubjpass
6	of	of	IN	_	10	case
7	allergic	allergic	JJ	_	10	amod
8	or	or	CC	_	7	cc
9	anaphylactic	anaphylactic	JJ	_	7	conj
10	reactions	reaction	NNS	_	5	nmod
11	and	and	CC	_	10	cc
12	repeat	repeat	NN	_	13	compound
13	testing	testing	NN	_	10	conj
14	was	be	VBD	_	16	auxpass
15	not	not	RB	_	16	neg
16	performed	perform	VBN	_	3	ccomp
17	.	.	.	_	3	punct

1	Nine	nine	CD	_	3	nummod
2	additional	additional	JJ	_	3	amod
3	patients	patient	NNS	_	10	nsubj
4	who	who	WP	_	5	nsubj
5	had	have	VBD	_	3	acl:relcl
6	initial	initial	JJ	_	8	amod
7	positive	positive	JJ	_	8	amod
8	tests	test	NNS	_	5	dobj
9	were	be	VBD	_	10	cop
10	negative	negative	JJ	_	0	ROOT
11	on	on	IN	_	13	case
12	repeat	repeat	NN	_	13	compound
13	testing	testing	NN	_	10	nmod
14	.	.	.	_	10	punct

1	Drug	drug	NN	_	5	compound
2	/	/	:	_	5	punct
3	Laboratory	Laboratory	NNP	_	5	compound
4	Test	Test	NNP	_	5	compound
5	Interactions	interaction	NNS	_	14	nsubjpass
6	Certain	certain	JJ	_	7	amod
7	endocrine	endocrine	NN	_	5	dep
8	and	and	CC	_	7	cc
9	liver	liver	NN	_	11	compound
10	function	function	NN	_	11	compound
11	tests	test	NNS	_	7	conj
12	may	may	MD	_	14	aux
13	be	be	VB	_	14	auxpass
14	affected	affect	VBN	_	0	ROOT
15	by	by	IN	_	16	case
16	drug1	drug1	NN	_	14	nmod
17	-	-	:	_	16	punct
18	containing	contain	VBG	_	16	acl
19	oral	oral	JJ	_	20	amod
20	drug2	drug2	NN	_	18	dobj
21	.	.	.	_	14	punct

1	The	the	DT	_	4	det
2	following	follow	VBG	_	4	amod
3	similar	similar	JJ	_	4	amod
4	changes	change	NNS	_	7	nsubjpass
5	may	may	MD	_	7	aux
6	be	be	VB	_	7	auxpass
7	expected	expect	VBN	_	0	ROOT
8	with	with	IN	_	10	case
9	larger	larger	JJR	_	10	amod
10	doses	dose	NNS	_	7	nmod
11	of	of	IN	_	12	case
12	drug1	drug1	NN	_	10	nmod
13	:	:	:	_	7	punct
14	-	-	:	_	7	punct
15	Increased	increase	VBN	_	17	amod
16	sulfobromophthalein	sulfobromophthalein	NN	_	17	compound
17	retention	retention	NN	_	7	dep

1	.	.	.	_	0	ROOT

1	-	-	:	_	0	ROOT
2	Increased	increase	VBN	_	3	amod
3	prothrombin	prothrombin	NN	_	1	root
4	and	and	CC	_	3	cc
5	factors	factor	NNS	_	3	conj
6	VII	VII	NNP	_	5	dep
7	,	,	,	_	6	punct
8	VIII	VIII	NNP	_	6	conj
9	,	,	,	_	6	punct
10	IX	ix	CD	_	6	conj
11	,	,	,	_	6	punct
12	and	and	CC	_	6	cc
13	X	x	NN	_	6	conj
14	;	;	:	_	3	punct

1	decreased	decrease	VBN	_	2	amod
2	drug1	drug1	NN	_	0	ROOT
3	;	;	:	_	2	punct

1	increased	increase	VBN	_	4	amod
2	norepinephrine-induced	norepinephrine-induced	JJ	_	4	amod
3	platelet	platelet	NN	_	4	compound
4	aggregability	aggregability	NN	_	0	ROOT

1	.	.	.	_	0	ROOT

1	-	-	:	_	0	ROOT
2	Increased	increase	VBN	_	4	amod
3	thyroid-binding	thyroid-binding	JJ	_	4	amod
4	globulin	globulin	NN	_	1	root
5	-LRB-	-lrb-	-LRB-	_	6	punct
6	TBG	tbg	NN	_	4	appos
7	-RRB-	-rrb-	-RRB-	_	6	punct
8	leading	lead	VBG	_	4	acl
9	to	to	TO	_	14	case
10	in-creased	in-creased	JJ	_	14	amod
11	circulating	circulate	VBG	_	14	amod
12	total	total	JJ	_	14	amod
13	thyroid	thyroid	NN	_	14	compound
14	hormone	hormone	NN	_	8	nmod
15	;	;	:	_	4	punct

1	as	as	IN	_	2	mark
2	measured	measure	VBN	_	0	ROOT
3	by	by	IN	_	4	case
4	PBI	pbi	NN	_	2	nmod
5	,	,	,	_	4	punct
6	T4	t4	NN	_	4	appos
7	by	by	IN	_	8	case
8	column	column	NN	_	6	nmod
9	,	,	,	_	8	punct
10	or	or	CC	_	8	cc
11	T4	t4	NN	_	8	conj
12	by	by	IN	_	13	case
13	radioimmunoassay	radioimmunoassay	NN	_	11	nmod
14	.	.	.	_	2	punct

1	Free	Free	NNP	_	4	compound
2	T3	t3	NN	_	4	compound
3	resin	resin	NN	_	4	compound
4	uptake	uptake	NN	_	6	nsubjpass
5	is	be	VBZ	_	6	auxpass
6	decreased	decrease	VBN	_	0	ROOT
7	,	,	,	_	6	punct
8	reflecting	reflect	VBG	_	6	xcomp
9	the	the	DT	_	11	det
10	elevated	elevated	JJ	_	11	amod
11	TBG	tbg	NN	_	8	dobj
12	;	;	:	_	6	punct

1	free	free	JJ	_	3	amod
2	T4	t4	NN	_	3	compound
3	concentration	concentration	NN	_	5	nsubj
4	is	be	VBZ	_	5	cop
5	unaltered	unaltered	JJ	_	0	ROOT

1	.	.	.	_	0	ROOT

1	-	-	:	_	4	punct
2	Impaired	impaired	JJ	_	4	amod
3	glucose	glucose	NN	_	4	compound
4	tolerance	tolerance	NN	_	0	ROOT

1	.	.	.	_	0	ROOT

1	-	-	:	_	4	punct
2	Decreased	decrease	VBN	_	4	amod
3	pregnanediol	pregnanediol	NN	_	4	compound
4	excretion	excretion	NN	_	0	ROOT

1	.	.	.	_	0	ROOT

1	-	-	:	_	0	ROOT
2	Reduced	reduce	VBN	_	3	amod
3	response	response	NN	_	1	root
4	to	to	TO	_	6	case
5	metyrapone	metyrapone	NN	_	6	compound
6	test	test	NN	_	3	nmod

1	.	.	.	_	0	ROOT

1	-	-	:	_	4	punct
2	Reduced	reduce	VBN	_	3	amod
3	serum	serum	NN	_	4	nsubj
4	folate	folate	VBP	_	0	ROOT
5	concentration	concentration	NN	_	4	dobj

1	.	.	.	_	0	ROOT

1	-	-	:	_	0	ROOT
2	Increased	increase	VBN	_	4	amod
3	serum	serum	NN	_	4	compound
4	triglyceride	triglyceride	NN	_	1	root
5	and	and	CC	_	4	cc
6	phospholipid	phospholipid	JJ	_	7	amod
7	concentration	concentration	NN	_	4	conj
8	.	.	.	_	4	punct

1	No	no	DT	_	5	neg
2	formal	formal	JJ	_	5	amod
3	drug	drug	NN	_	5	compound
4	interaction	interaction	NN	_	5	compound
5	studies	study	NNS	_	8	nsubjpass
6	have	have	VBP	_	8	aux
7	been	be	VBN	_	8	auxpass
8	conducted	conduct	VBN	_	0	ROOT
9	with	with	IN	_	10	case
10	drug1	drug1	NN	_	8	nmod
11	.	.	.	_	8	punct

1	In	in	FW	_	3	amod
2	vitro	vitro	FW	_	1	dep
3	studies	study	NNS	_	8	nsubj
4	with	with	IN	_	7	case
5	human	human	JJ	_	7	amod
6	liver	liver	NN	_	7	compound
7	microsomes	microsome	NNS	_	3	nmod
8	indicate	indicate	VBP	_	0	ROOT
9	that	that	IN	_	14	mark
10	drug1	drug1	NN	_	14	nsubj
11	is	be	VBZ	_	14	cop
12	primarily	primarily	RB	_	14	advmod
13	a	a	DT	_	14	det
14	substrate	substrate	NN	_	8	ccomp
15	for	for	IN	_	18	case
16	cytochrome	cytochrome	NN	_	18	compound
17	P450	p450	NN	_	18	compound
18	3A4	3a4	NN	_	14	nmod
19	,	,	,	_	18	punct
20	2C19	2c19	NN	_	18	conj
21	,	,	,	_	18	punct
22	and	and	CC	_	18	cc
23	1A2	1a2	NN	_	18	conj
24	.	.	.	_	8	punct

1	Patients	patient	NNS	_	21	nsubjpass
2	who	who	WP	_	5	nsubj
3	are	be	VBP	_	5	aux
4	concomitantly	concomitantly	RB	_	5	advmod
5	receiving	receive	VBG	_	1	acl:relcl
6	drug1	drug1	NN	_	5	dobj
7	and	and	CC	_	6	cc
8	drugs	drug	NNS	_	6	conj
9	that	that	WDT	_	11	nsubj
10	are	be	VBP	_	11	cop
11	inhibitors	inhibitor	NNS	_	6	acl:relcl
12	or	or	CC	_	11	cc
13	inducers	inducer	NNS	_	11	conj
14	of	of	IN	_	17	case
15	cytochrome	cytochrome	NN	_	17	compound
16	P450	p450	NN	_	17	compound
17	3A4	3a4	NN	_	11	nmod
18	should	should	MD	_	21	aux
19	be	be	VB	_	21	auxpass
20	closely	closely	RB	_	21	advmod
21	monitored	monitor	VBN	_	0	ROOT
22	for	for	IN	_	24	case
23	either	either	CC	_	24	cc:preconj
24	toxicities	toxicity	NNS	_	21	nmod
25	or	or	CC	_	24	cc
26	reduced	reduce	VBN	_	27	amod
27	efficacy	efficacy	NN	_	24	conj
28	.	.	.	_	21	punct

1	During	during	IN	_	3	case
2	clinical	clinical	JJ	_	3	amod
3	trials	trial	NNS	_	9	nmod
4	,	,	,	_	9	punct
5	hypoglycemia	hypoglycemia	NN	_	9	nsubjpass
6	and	and	CC	_	5	cc
7	hyperglycemia	hyperglycemia	NN	_	5	conj
8	were	be	VBD	_	9	auxpass
9	reported	report	VBN	_	0	ROOT
10	in	in	IN	_	12	case
11	diabetic	diabetic	JJ	_	12	amod
12	patients	patient	NNS	_	9	nmod
13	receiving	receive	VBG	_	12	acl
14	oral	oral	JJ	_	15	amod
15	drug1	drug1	NN	_	13	dobj
16	.	.	.	_	9	punct

1	Patients	patient	NNS	_	9	nsubj
2	on	on	IN	_	4	case
3	oral	oral	JJ	_	4	amod
4	drug1	drug1	NN	_	1	nmod
5	receiving	receive	VBG	_	4	acl
6	drug2	drug2	NN	_	7	compound
7	treatment	treatment	NN	_	5	dobj
8	may	may	MD	_	9	aux
9	require	require	VB	_	0	ROOT
10	close	close	JJ	_	11	amod
11	monitoring	monitoring	NN	_	9	dobj
12	of	of	IN	_	16	case
13	their	they	PRP$	_	16	nmod:poss
14	blood	blood	NN	_	16	compound
15	glucose	glucose	NN	_	16	compound
16	levels	level	NNS	_	11	nmod
17	and	and	CC	_	11	cc
18	adjustment	adjustment	NN	_	11	conj
19	of	of	IN	_	21	case
20	the	the	DT	_	21	det
21	dose	dose	NN	_	18	nmod
22	of	of	IN	_	24	case
23	their	they	PRP$	_	24	nmod:poss
24	drug3	drug3	NN	_	21	nmod
25	.	.	.	_	9	punct

1	Drug	Drug	NNP	_	5	compound
2	Laboratory	Laboratory	NNP	_	5	compound
3	Test	Test	NNP	_	5	compound
4	Interactions	interaction	NNS	_	5	compound
5	None	none	NN	_	6	nsubj
6	known	know	VBN	_	0	ROOT
7	.	.	.	_	6	punct

